FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yu, YJ
   Wu, JK
   Li, J
   Liu, YZ
   Zheng, XY
   Du, MZ
   Zhou, LM
   Yang, YJ
   Luo, SY
   Hu, WJ
   Li, L
   Yao, WM
   Liu, YY
AF Yu, Yongjie
   Wu, Jingkai
   Li, Jin
   Liu, Yanzhi
   Zheng, Xiaoyan
   Du, Mingzhu
   Zhou, Limin
   Yang, Yajun
   Luo, Shiying
   Hu, Wenjia
   Li, Lin
   Yao, Weimin
   Liu, Yuyu
TI Cycloastragenol prevents age related bone loss: Evidence in
   D galactose treated and aged rats
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Cycloastragenol; Aging; Osteoporosis; Osteoactivin
ID FORMATION IN VIVO; OSTEOBLAST DIFFERENTIATION; ENHANCES BONE;
   OSTEOPOROSIS; METABOLISM; ACTIVATION; RESORPTION; TOXICITY; MUTATION;
   DISEASE
AB Background and aims: Aging induced bone loss is a multifactorial, age related, and progressive phenomenon among the general population and may further progress to osteoporosis and increase the risk of fractures. Cycloastragenol (CAG), currently the only compound reported that activates human telomerase, is thought to be able to alleviate or delay the symptoms of aging and chronic diseases. Previous research has suggested that CAG may have the potential to alleviate age related bone loss. However, to date, no research has specifically focused on this aspect. In this study, we aimed to investigate whether CAG could prevent senile osteoporosis, and further reveal its underlying mechanism.
   Methods: CAG treatment was administrated into two bone loss rat models (D galactose administration and aging) for 20 weeks and 33 weeks, respectively. Serum biomarkers analyses, bone biomechanical tests, microcomputed tomography assessment, and bone histomorphometry analyses were performed on the bone samples collected at the endpoint, to determine whether CAG could prevent or alleviate age related bone loss. Proteomic analysis was performed to reveal the changes in protein profiles of the bones, and western blot was used to further verify the identity of the key proteins. The viability, osteoblastic differentiation, and mineralization of MC3T3 E1 cells were also evaluated after CAG treatment in vitro.
   Results: The results suggest that CAG treatment improves bone formation, reduces osteoclast number, alleviates the degradation of bone microstructure, and enhances bone biomechanical properties in both n galactose  and aging induced bone loss models. CAG treatment promotes viability, osteoblastic differentiation, and mineralization in MC3T3 E1 cells. Proteomic and western blot analyses revealed that CAG treatment increases osteoactivin (OA) expression to alleviate bone loss.
   Conclusion: The results revealed that CAG alleviates age related bone loss and improves bone microstructure and biomechanical properties. This may due to CAG induced increase in OA expression. In addition, the results support preclinical investigations of CAG as a potential therapeutic medicine for the treatment of senile osteoporosis.
C1 [Yu, Yongjie; Wu, Jingkai; Li, Jin; Zheng, Xiaoyan; Du, Mingzhu; Zhou, Limin; Yang, Yajun; Luo, Shiying; Liu, Yuyu] Guangdong Med Univ, Dept Pharmacol, Zhanjiang 524023, Guangdong, Peoples R China.
   [Liu, Yanzhi] Guangdong Med Univ, Marine Med Res Inst, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang 524023, Guangdong, Peoples R China.
   [Liu, Yanzhi] Chinese Acad Sci, Translat Med R&D Ctr, Inst Biomed & Hlth Engn, Shenzhen Inst Adv Technol, Shenzhen 518000, Peoples R China.
   [Hu, Wenjia] Guangdong Med Univ, Inst Biochem & Mol Biol, Zhanjiang 524023, Guangdong, Peoples R China.
   [Li, Lin] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou Key Lab Drug Res Emerging Virus Prevent, Guangzhou 510515, Guangdong, Peoples R China.
   [Yao, Weimin] Guangdong Med Univ, Dept Resp Med, Affiliated Hosp, Zhanjiang 524000, Guangdong, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University; Chinese
   Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS;
   Guangdong Medical University; Southern Medical University   China;
   Guangdong Medical University
RP Liu, YY (通讯作者)，Guangdong Med Univ, Dept Pharmacol, Zhanjiang 524023, Guangdong, Peoples R China.; Yao, WM (通讯作者)，Guangdong Med Univ, Dept Resp Med, Affiliated Hosp, Zhanjiang 524000, Guangdong, Peoples R China.
EM 490296443@qq.com; liuyuyu77@163.com
RI Liu, Yanzhi/P 6387 2014
OI Yao, Weimin/0000 0002 8722 6453; Hu, Wenjia/0000 0001 6738 7535
FU National Natural Science Foundation of China [81703584]; Guangdong
   Province Natural Science Foundation of China [2017A030310614]; China
   Postdoctoral Science Foundation [2018M633192]; Scientific Research
   Foundation for PhD of Guangdong Medical University [B2017030]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81703584), Guangdong Province Natural Science Foundation of
   China (No.2017A030310614), China Postdoctoral Science Foundation
   (2018M633192), and the Scientific Research Foundation for PhD of
   Guangdong Medical University (No: B2017030).
CR Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Abdelmagid SM, 2014, AM J PATHOL, V184, P697, DOI 10.1016/j.ajpath.2013.11.031
   [Anonymous], 2018, 2018 INT C CYB CW, DOI DOI 10.1109/CW.2018.00015
   [Anonymous], 2018, EXP THER MED, DOI DOI 10.3892/ETM.2018.6501
   Azman KF, 2019, BIOGERONTOLOGY, V20, P763, DOI 10.1007/s10522 019 09837 y
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Baum E, 2008, DTSCH ARZTEBL INT, V105, P573, DOI 10.3238/arztebl.2008.0573
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Bijlsma AY, 2012, AGEING RES REV, V11, P320, DOI 10.1016/j.arr.2012.01.001
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Cui L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034647
   Farr JN, 2019, BONE, V121, P121, DOI 10.1016/j.bone.2019.01.015
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Frara N, 2016, J CELL PHYSIOL, V231, P72, DOI 10.1002/jcp.25020
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Gu M, 2017, PHARMACOL RES, V121, P22, DOI 10.1016/j.phrs.2017.04.021
   Hu XF, 2013, J CELL BIOCHEM, V114, P2729, DOI 10.1002/jcb.24621
   Hung YT, 2014, CHINESE J PHYSIOL, V57, P121, DOI 10.4077/CJP.2014.BAC199
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Lin SE, 2014, CALCIFIED TISSUE INT, V95, P362, DOI 10.1007/s00223 014 9899 7
   Liu YZ, 2016, DRUG DES DEV THER, V10, P2535, DOI 10.2147/DDDT.S110125
   Long JG, 2007, BIOGERONTOLOGY, V8, P373, DOI 10.1007/s10522 007 9081 y
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   Pignolo RJ, 2008, AGING CELL, V7, P23, DOI 10.1111/j.1474 9726.2007.00350.x
   Pignolo RJ, 2019, CURR OSTEOPOROS REP, V17, P70, DOI 10.1007/s11914 019 00504 2
   Saeed H, 2011, J BONE MINER RES, V26, P1494, DOI 10.1002/jbmr.349
   Salvador L, 2016, REJUV RES, V19, P478, DOI 10.1089/rej.2015.1793
   SAVILLE PD, 1968, LANCET, V1, P535
   Sun CH, 2017, IMMUNOPHARM IMMUNOT, V39, P131, DOI 10.1080/08923973.2017.1300170
   Szabo NJ, 2014, FOOD CHEM TOXICOL, V64, P322, DOI 10.1016/j.fct.2013.11.041
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V450, P306, DOI 10.1016/j.bbrc.2014.05.117
   Wang YX, 2019, BRIT J PHARMACOL, V176, P282, DOI 10.1111/bph.14515
   Wiley CD, 2016, CELL METAB, V23, P1013, DOI 10.1016/j.cmet.2016.05.010
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Yang YJ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1092746
   Zhao Y, 2015, J ETHNOPHARMACOL, V169, P210, DOI 10.1016/j.jep.2015.04.030
   Zheng YY, 2017, EXP THER MED, V14, P2845, DOI 10.3892/etm.2017.4915
NR 43
TC 27
Z9 29
U1 7
U2 35
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD AUG
PY 2020
VL 128
AR 110304
DI 10.1016/j.biopha.2020.110304
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA ND2MV
UT WOS:000561740200011
PM 32497865
OA gold
DA 2025 08 17
ER

PT J
AU Miron, RJ
   Bosshardt, DD
   Gemperli, AC
   Dard, M
   Buser, D
   Gruber, R
   Sculean, A
AF Miron, Richard J.
   Bosshardt, Dieter D.
   Gemperli, Anja C.
   Dard, Michel
   Buser, Daniel
   Gruber, Reinhard
   Sculean, Anton
TI In vitro characterization of a synthetic calcium phosphate bone graft on
   periodontal ligament cell and osteoblast behavior and its combination
   with an enamel matrix derivative
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Enamel matrix derivative (EMD); Emdogain; Allograft; Blood proteins;
   Protein adsorption; Bone grafting materials
ID FREEZE DRIED BONE; GUIDED TISSUE REGENERATION; CONTROLLED
   CLINICAL TRIAL; AUTOGENOUS BONE; OSSEOUS DEFECTS; HISTOLOGIC EVALUATION;
   INTRABONY DEFECTS; ALLOGRAFT; HUMANS; PROTEINS
AB Recent studies suggest that a combination of enamel matrix derivative (EMD) with grafting material may improve periodontal wound healing/regeneration. Newly developed calcium phosphate (CaP) ceramics have been demonstrated a viable synthetic replacement option for bone grafting filler materials.
   This study aims to test the ability for EMD to adsorb to the surface of CaP particles and to determine the effect of EMD on downstream cellular pathways such as adhesion, proliferation, and differentiation of primary human osteoblasts and periodontal ligament (PDL) cells.
   EMD was adsorbed onto CaP particles and analyzed for protein adsorption patterns via scanning electron microscopy and high resolution immunocytochemistry with an anti EMD antibody. Cell attachment and cell proliferation were quantified using CellTiter 96 One Solution Cell Assay (MTS). Cell differentiation was analyzed using real time PCR for genes encoding Runx2, alkaline phosphatase, osteocalcin, and collagen1 alpha 1, and mineralization was assessed using alizarin red staining.
   Analysis of cell attachment revealed significantly higher number of cells attached to EMD adsorbed CaP particles when compared to control and blood adsorbed samples. EMD also significantly increased cell proliferation at 3 and 5 days post seeding. Moreover, there were significantly higher mRNA levels of osteoblast differentiation markers including collagen1 alpha 1, alkaline phosphatase, and osteocalcin in osteoblasts and PDL cells cultured on EMD adsorbed CaP particles at various time points.
   The present study suggests that the addition of EMD to CaP grafting particles may influence periodontal regeneration by stimulating PDL cell and osteoblast attachment, proliferation, and differentiation. Future in vivo and clinical studies are required to confirm these findings.
   The combination of EMD and CaP may represent an option for regenerative periodontal therapy in advanced intrabony defects.
C1 [Miron, Richard J.; Bosshardt, Dieter D.; Gruber, Reinhard; Sculean, Anton] Univ Bern, Dept Periodontol, Sch Dent Med, CH 3010 Bern, Switzerland.
   [Miron, Richard J.; Bosshardt, Dieter D.; Buser, Daniel; Gruber, Reinhard] Univ Bern, Sch Dent Med, Dept Oral Surg & Stomatol, CH 3010 Bern, Switzerland.
   [Gemperli, Anja C.; Dard, Michel] Inst Straumann AG, Basel, Switzerland.
C3 University of Bern; University of Bern; Institut Straumann AG
RP Sculean, A (通讯作者)，Univ Bern, Dept Periodontol, Sch Dent Med, Freiburgstr 7, CH 3010 Bern, Switzerland.
EM anton.sculean@zmk.unibe.ch
RI ; Bosshardt, Dieter/C 9442 2012; Miron, Richard/J 4995 2012; Buser,
   Daniel/D 3971 2011; Gruber, Reinhard/A 8053 2012
OI Gruber, Reinhard/0000 0001 5400 9009; 
FU Department of Periodontology at the University of Bern; Institut
   Straumann AG (Basel, Switzerland)
FX The authors gratefully acknowledge the Robert K. Schenk Laboratory of
   Oral Histology, School of Dental Medicine at the University of Bern,
   most notably Thuy Tran Nguyen and Monika Aeberhard for their
   considerable time and valuable insights into the project design. This
   work was funded by the Department of Periodontology at the University of
   Bern and Institut Straumann AG (Basel, Switzerland).
CR Aspriello SD, 2011, CLIN ORAL INVEST, V15, P225, DOI 10.1007/s00784 009 0369 y
   Bosshardt DD, 2008, J CLIN PERIODONTOL, V35, P87, DOI 10.1111/j.1600 051X.2008.01264.x
   Boyan BD, 2000, J PERIODONTOL, V71, P1278, DOI 10.1902/jop.2000.71.8.1278
   Browaeys H, 2007, CLIN IMPLANT DENT R, V9, P166, DOI 10.1111/j.1708 8208.2007.00050.x
   Cochran DL, 2003, J PERIODONTOL, V74, P1269, DOI 10.1902/jop.2003.74.9.1269
   Dean DD, 2002, CELLS TISSUES ORGANS, V171, P117, DOI 10.1159/000063705
   Fellah BH, 2008, BIOMATERIALS, V29, P1177, DOI 10.1016/j.biomaterials.2007.11.034
   Gestrelius S, 1997, J CLIN PERIODONTOL, V24, P678, DOI 10.1111/j.1600 051X.1997.tb00249.x
   Guida L, 2007, J PERIODONTOL, V78, P231, DOI 10.1902/jop.2007.060142
   Gurinsky BS, 2004, J PERIODONTOL, V75, P1309, DOI 10.1902/jop.2004.75.10.1309
   Hoidal MJ, 2008, J PERIODONTOL, V79, P2273, DOI [10.1902/jop.2008.080259, 10.1902/jop.2008.080259 ]
   Horváth A, 2013, CLIN ORAL INVEST, V17, P423, DOI 10.1007/s00784 012 0739 8
   Huang HL, 2013, CLIN ORAL INVEST, V17, P535, DOI 10.1007/s00784 012 0725 1
   Intini G, 2008, J PERIODONTOL, V79, P1217, DOI [10.1902/jop.2008.070435, 10.1902/jop.2008.070435 ]
   Jensen T, 2012, CLIN ORAL IMPLAN RES, V23, P263, DOI 10.1111/j.1600 0501.2011.02168.x
   Kühl S, 2013, CLIN ORAL INVEST, V17, P543, DOI 10.1007/s00784 012 0732 2
   Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260
   Miron RJ, 2011, J DENT RES, V90, P1428, DOI 10.1177/0022034511422718
   Miron RJ, 2013, CLIN IMPLANT DENT R, V15, P481, DOI 10.1111/j.1708 8208.2012.00440.x
   Miron RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023375
   Miron RJ, 2010, BIOMATERIALS, V31, P449, DOI 10.1016/j.biomaterials.2009.09.075
   Miron RJ, 2012, J PERIODONTOL, DOI [10.1902/jop.2011.110480, DOI 10.1902/J0P.2011.110480]
   Nauth A, 2011, INJURY, V42, P574, DOI 10.1016/j.injury.2011.03.034
   Pietruska M, 2012, CLIN ORAL INVEST, V16, P1191, DOI 10.1007/s00784 011 0611 2
   Polimeni G, 2004, J CLIN PERIODONTOL, V31, P730, DOI 10.1111/j.1600 051X.2004.00543.x
   Rickert D, 2012, INT J ORAL MAX SURG, V41, P160, DOI 10.1016/j.ijom.2011.10.001
   Rosen PS, 2002, J PERIODONTOL, V73, P942, DOI 10.1902/jop.2002.73.8.942
   Sculean A, 2005, INT J PERIODONT REST, V25, P139
   Sculean A, 2008, J PERIODONTOL, V79, P1991, DOI [10.1902/jop.2008.080009, 10.1902/jop.2008.080009 ]
   Sculean A, 2011, CLIN ADV PERIODONTIC, V1, P101, DOI 10.1902/cap.2011.110047
   Siciliano VI, 2011, J PERIODONTOL, V82, P62, DOI 10.1902/jop.2010.100144
   Suzuki S, 2005, J DENT RES, V84, P510, DOI 10.1177/154405910508400605
   van Hout WMMT, 2011, CLIN ORAL INVEST, V15, P297, DOI 10.1007/s00784 011 0547 6
   Velasquez Plata D, 2002, J PERIODONTOL, V73, P433, DOI 10.1902/jop.2002.73.4.433
   Yamamoto S, 2007, INT J PERIODONT REST, V27, P471
   Yilmaz S, 2010, J CLIN PERIODONTOL, V37, P544, DOI 10.1111/j.1600 051X.2010.01567.x
   Yuan HP, 1998, J MATER SCI MATER M, V9, P723, DOI 10.1023/A:1008950902047
   Yuan HP, 2006, TISSUE ENG, V12, P1607, DOI 10.1089/ten.2006.12.1607
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zucchelli G, 2003, J PERIODONTOL, V74, P1725, DOI 10.1902/jop.2003.74.12.1725
NR 40
TC 20
Z9 20
U1 2
U2 17
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD MAR
PY 2014
VL 18
IS 2
BP 443
EP 451
DI 10.1007/s00784 013 0977 4
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AC2GL
UT WOS:000332317500014
PM 23620149
DA 2025 08 17
ER

PT J
AU Lovy, AJ
   Koehler, SM
   Keswani, A
   Joseph, D
   Hasija, R
   Ghillani, R
AF Lovy, A. J.
   Koehler, S. M.
   Keswani, A.
   Joseph, D.
   Hasija, R.
   Ghillani, R.
TI Atypical femur fracture during bisphosphonate drug holiday: a case
   series
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Atypical femur fractures; Bisphosphonates; Drug holiday; Osteoporosis
ID POSTMENOPAUSAL OSTEOPOROSIS; POWER FUNCTION; ALENDRONATE; RISK; WOMEN;
   SIMILARITIES; MICRODAMAGE; RISEDRONATE; MECHANISMS; EXTENSION
AB Recent studies have noted an increased risk of low energy subtrochanteric and femoral shaft fractures termed "atypical femur fractures" (AFFs) associated with long term bisphosphonate use. As such, many clinicians have begun recommending a "drug holiday" to reduce the risks associated with long term bisphosphonate use. We present two cases of AFFs occurring during a 4 year or greater drug holiday following long term bisphosphonate use. These findings highlight the need to reevaluate optimal bisphosphonate therapy duration, dosage, as well as initiation and duration of a drug holiday with continued monitoring in the prevention of AFFs.
C1 [Lovy, A. J.; Koehler, S. M.; Keswani, A.; Joseph, D.; Ghillani, R.] Mt Sinai Hosp, Dept Orthopaed Surg, New York, NY 10029 USA.
   [Joseph, D.; Hasija, R.; Ghillani, R.] Elmhurst Hosp Ctr, Dept Orthopaed Surg, Queens, NY 11373 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Lovy, AJ (通讯作者)，Mt Sinai Hosp, Dept Orthopaed Surg, 5 East 98th St,9th Floor, New York, NY 10029 USA.
EM andrew.lovy@mountsinai.org
RI ; Koehler, Steven/AAI 1353 2019
OI Lovy, Andrew/0000 0002 7874 1947; 
CR Abrahamsen B, 2010, J CLIN ENDOCR METAB, V95, P5258, DOI 10.1210/jc.2010 1571
   Allen MR, 2007, J BONE MINER RES, V22, P1759, DOI 10.1359/JBMR.070720
   Ananchenko G, 2013, PROF DRUG SUB EXCIP
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2007, BONE, V40, pS26, DOI 10.1016/j.bone.2007.03.003
   Boskey AL, 2009, OSTEOPOROSIS INT, V20, P793, DOI 10.1007/s00198 008 0725 9
   Brennan O, 2011, J ORTHOP RES, V29, P419, DOI 10.1002/jor.21229
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Diab DL, 2013, THER ADV MUSCULOSKEL, V5, P107, DOI 10.1177/1759720X13477714
   Donnelly E, 2012, J BONE MINER RES, V27, P672, DOI 10.1002/jbmr.560
   Eriksen EF, 2014, BONE, V58, P126, DOI 10.1016/j.bone.2013.09.023
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Giusti A, 2011, BONE, V48, P966, DOI 10.1016/j.bone.2010.12.033
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   MARSHALL JH, 1964, J THEOR BIOL, V6, P386, DOI 10.1016/0022 5193(64)90055 4
   MARSHALL JH, 1968, NATURE, V217, P742, DOI 10.1038/217742a0
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schwartz AV, 2010, J BONE MINER RES, V25, P976, DOI 10.1002/jbmr.11
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Siris ES, 2011, J BONE MINER RES, V26, P3, DOI 10.1002/jbmr.189
   Teo BJX, 2014, BONE JOINT J, V96B, P658, DOI 10.1302/0301 620X.96B5.32887
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
NR 32
TC 8
Z9 8
U1 2
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2015
VL 26
IS 6
BP 1755
EP 1758
DI 10.1007/s00198 015 3063 8
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CK6AV
UT WOS:000356311100011
PM 25832177
DA 2025 08 17
ER

PT J
AU Journé, F
   Magné, N
   Chaboteaux, C
   Kinnaert, E
   Bauss, F
   Body, JJ
AF Journe, Fabrice
   Magne, Nicolas
   Chaboteaux, Carole
   Kinnaert, Eric
   Bauss, Frieder
   Body, Jean Jacques
TI Sequence  and concentration dependent effects of acute and long term
   exposure to the bisphosphonate ibandronate in combination with single
   and multiple fractions of ionising radiation doses in human breast
   cancer cell lines
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE bisphosphonate; bone metastases; breast cancer cells; ibandronate;
   ionising radiation
ID METASTATIC BONE DISEASE; QUALITY OF LIFE; PROSTATE CANCER; RADIOTHERAPY;
   PALLIATION; PAIN; MECHANISMS; THERAPY
AB Both bisphosphonates and radiotherapy are highly effective for the management of bone metastases. Our in vitro study examined the cytotoxic effects resulting from combinations of ibandronate and ionising radiations (RX) in various sequences on breast cancer cells. Single radiation doses were given before, at halftime of, or after acute ibandronate incubation (48 h). Single or fractionated radiation doses were applied at the end of chronic ibandronate incubation (5 weeks). Combination of acute ibandronate exposure and single radiation doses led to synergistic cytotoxic effects in MDA MB 231 cell line, but only with low ibandronate concentrations in MCF 7 cell line. In both cell lines, synergy was more marked when ibandronate followed RX. After long term ibandronate exposure, only high single radiation doses induced synergistic effects in MDA MB 231 cell line. Synergy was only detected with low ibandronate concentrations in MCF 7 cell line. In both cell lines, fractionated radiation doses exerted similar effects. The combination of ibandronate with radiation can exert synergistic effects on the inhibition of breast cancer cells growth, depending on cell line, drug sequence and dosage. Our data might provide a rationale for associating bisphosphonates and radiotherapy for the treatment of bone metastases from breast cancer.
C1 Univ Libre Bruxelles, Ctr Tumeurs, Inst Jules Bordet, Dept Internal Med, B 1000 Brussels, Belgium.
   Univ Libre Bruxelles, Ctr Tumeurs, Dept Radiotherapy, Inst Jules Bordet, Brussels, Belgium.
   Univ Libre Bruxelles, LOCE, Inst Jules Bordet, Ctr Tumeurs, Brussels, Belgium.
   Roche Diagnost GmbH, Pharma Res Penzberg, Penzberg, Germany.
C3 Universite Libre de Bruxelles; Institut Jules Bordet; Institut Jules
   Bordet; Universite Libre de Bruxelles; Institut Jules Bordet; Universite
   Libre de Bruxelles; Roche Holding; Roche Holding Germany
RP Body, JJ (通讯作者)，Univ Libre Bruxelles, Ctr Tumeurs, Inst Jules Bordet, Dept Internal Med, 1 Rue Heger Bordet, B 1000 Brussels, Belgium.
EM jj.body@bordet.be
RI Body, Jean Jacques/G 9785 2015
OI JOURNE, Fabrice/0000 0001 5051 231X
CR Algur E, 2005, INT J RADIAT ONCOL, V61, P535, DOI 10.1016/j.ijrobp.2004.09.065
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bauss F, 2005, ANTI CANCER DRUG, V16, P107, DOI 10.1097/00001813 200502000 00001
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bernhard EJ, 1998, CANCER RES, V58, P1754
   BERNING D, 2005, P EUR SOC THER RADIO, pS388
   Body JJ, 2005, TEXTBOOK OF BONE METASTASES, P291
   Body Jean Jaques, 1997, Current Opinion in Oncology, V9, P332, DOI 10.1097/00001622 199709040 00005
   Body JJ, 2004, SEMIN NEPHROL, V24, P48, DOI 10.1053/j.semnephrol.2003.08.015
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Body JJ, 2003, CANCER, V97, P859, DOI 10.1002/cncr.11139
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   BODY JJ, 1992, BONE, V13, pS57, DOI 10.1016/S8756 3282(09)80011 2
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Busch M, 1998, Eur J Med Res, V3, P427
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS32, DOI 10.1097/00000421 200212001 00006
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hoskin PJ, 2003, CANCER TREAT REV, V29, P321, DOI 10.1016/S0305 7372(03)00013 6
   Journe F, 2004, BRIT J CANCER, V91, P1703, DOI 10.1038/sj.bjc.6602181
   KANO Y, 1988, CANCER RES, V48, P351
   Kouloulias V, 2003, INT J RADIAT ONCOL, V57, P143, DOI 10.1016/S0360 3016(03)00525 X
   Krempien R, 2003, CANCER, V98, P1318, DOI 10.1002/cncr.11646
   Li L, 2001, INT J RADIAT ONCOL, V49, P1157, DOI 10.1016/S0360 3016(00)01524 8
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Mancini I, 2004, J CLIN ONCOL, V22, P3587, DOI 10.1200/JCO.2004.07.054
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Neudert M, 2003, INT J CANCER, V107, P468, DOI 10.1002/ijc.11397
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85
   Sze WM, 2003, CLIN ONCOL UK, V15, P345, DOI 10.1016/S0936 6555(03)00113 4
   Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360 3016(02)04147 0
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 39
TC 10
Z9 10
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD APR
PY 2006
VL 23
IS 2
BP 135
EP 147
DI 10.1007/s10585 006 9025 y
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 087CU
UT WOS:000240720900005
PM 16912915
DA 2025 08 17
ER

PT J
AU Fleissig, Y
   Regev, E
   Lehman, H
AF Fleissig, Yoram
   Regev, Eran
   Lehman, Hadas
TI Sunitinib related osteonecrosis of jaw: a case report
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID RENAL CELL CARCINOMA; BISPHOSPHONATE; PATIENT
AB A 58 year old woman presented to the Oral and Maxillofacial Surgery Clinic experiencing severe limited mouth opening and exposed bone in the socket of the right mandibular third molar 8 months following the extraction of the tooth. The patient had been treated during the year before her presentation with sunitinib, an antiangiogenic drug, for renal cell carcinoma. The clinical, radiographic, and histologic picture of a chronic nonhealing extraction socket was consistent with osteonecrosis of the jaw (ONJ), although she had never been treated with bisphosphonates or corticosteroids. The treatment with sunitinib was discontinued and the patient was treated with antibiotics and physiotherapy for 12 weeks with complete recovery. Sunitinib may cause osteonecrosis of the jaw after oral surgical interventions with no previous exposure to bisphosphonates. The pathogenesis may be related to its antiangiogenic mechanism and impaired wound healing. Full recovery may require long term cessation of the insulting drug combined with prolonged antibiotic treatment. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:e1 e3)
C1 [Fleissig, Yoram; Regev, Eran; Lehman, Hadas] Hadassah Hebrew Univ, Med Ctr, Dept Oral & Maxillofacial Surg, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Fleissig, Y (通讯作者)，Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral & Maxillofacial Surg, IL 91129 Jerusalem, Israel.
EM yoram77@gmail.com
OI Fleissig, Yoram/0000 0003 1748 0023
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Bozas G, 2010, ONKOLOGIE, V33, P321, DOI 10.1159/000313680
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Cordon CR, 2009, ANN PLAS SURG, V62, P707, DOI 10.1097/SAP.0b013e3181828141
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406
   MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278 2391(83)90294 X
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Oudard S, 2011, CANCER TREAT REV, V37, P178, DOI 10.1016/j.ctrv.2010.08.005
   Patyna S, 2006, MOL CANCER THER, V5, P1774, DOI 10.1158/1535 7163.MCT 05 0333
   Salort Llorca C, 2011, MED ORAL PATOL ORAL, V16, pE137, DOI 10.4317/medoral.16.e137
   Sung Eric C, 2002, Spec Care Dentist, V22, P142, DOI 10.1111/j.1754 4505.2002.tb01178.x
NR 17
TC 91
Z9 98
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 2212 4403
EI 1528 395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD MAR
PY 2012
VL 113
IS 3
BP E1
EP E3
DI 10.1016/j.tripleo.2011.06.023
PG 3
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 899BC
UT WOS:000300785900001
PM 22676833
DA 2025 08 17
ER

PT J
AU Pagani, S
   Fini, M
   Giavaresi, G
   Salamanna, F
   Borsari, V
AF Pagani, Stefania
   Fini, Milena
   Giavaresi, Gianluca
   Salamanna, Francesca
   Borsari, Veronica
TI The active role of osteoporosis in the interaction between osteoblasts
   and bone metastases
SO BONE
LA English
DT Article
DE Breast cancer cells; Metastasis; Osteoporosis; Osteoblasts
ID BREAST CANCER; IN VITRO; CELLS; BIOLOGY; VIVO; OSTEOCLASTOGENESIS;
   MICROENVIRONMENT; DIFFERENTIATION; CONTRIBUTOR; RESORPTION
AB Introduction: To minimize the severity of bone metastases and to delay their onset, it is important to analyze the underlying biological mechanisms. The present study focused on the link between OP and metastatic cells, with particular attention to osteoblast behavior.
   Methods: Osteoblasts COB) were isolated from the trabecular bone of iliac crest of healthy (SHAM) and ovariectomized (OVX) adult female rats and co cultured with MRMT 1 rat breast carcinoma cells as conditioned medium (CM) or alone (CTR) for 24 h, 7 and 14 days and tested for cell viability, morphology and synthetic activity, i.e. C terminal procollagen type I, alkaline phosphatase, osteoprotegerin, receptor activator for nuclear factor KB ligand and interleukin 8.
   Results: Osteoblast morphology showed a reduced organization in the OVX group, in particular in the CM condition. Conversely, the analysis of cell viability revealed significantly higher values in the OVXCM group with respect to the SHAM(CM) group at all experimental times, whereas the OVXCTR group had significantly lower values at 7 and 14 days in comparison to those of the SHAM group. ALP release was significantly lower in the CM condition than that of CTR at all timepoints, and so was procollagen type I at 7 and 14 days. The RANKL/OPG ratio showed significantly higher values in OVX osteoblasts in comparison with those of the SHAM group, both in CTR and in CM conditions at each experimental time. Finally, OVXCM showed significantly higher values of IL 8 than those of SHAW(CM), at 7 and 14 days.
   Conclusions: The results clearly indicate an influence of the metastatic cells on the osteoblastic physiology at different levels: morphology, viability, release of typical proteins, and also IL 8 as a proinflammatory cytokine, especially marked by osteoporosis. Further investigations might highlight the relationship between osteoblasts and breast cancer cells, which might be useful to improve common drugs used against osteoporosis and bone metastases, by enhancing the bone deposition/tumor progression ratio. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Pagani, Stefania; Fini, Milena; Giavaresi, Gianluca] Rizzoli Orthopaed Inst, Lab Preclin & Surg Studies, I 40136 Bologna, Italy.
   [Pagani, Stefania; Fini, Milena; Giavaresi, Gianluca; Salamanna, Francesca; Borsari, Veronica] Rizzoli Orthopaed Inst, Dept RIT Rizzoli, Lab Biocompatibil Technol Innovat & Adv Therapies, I 40136 Bologna, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli
RP Pagani, S (通讯作者)，Rizzoli Orthopaed Inst, Lab Preclin & Surg Studies, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM stefania.pagani@ior.it
RI Fini, Milena/J 4808 2016; Borsari, Veronica/AAC 9501 2021; Salamanna,
   Francesca/J 6032 2016; Giavaresi, Gianluca/J 5583 2016; Pagani,
   Stefania/C 7151 2019
OI Salamanna, Francesca/0000 0001 7402 4054; Pagani,
   Stefania/0000 0002 4055 3828; Giavaresi, Gianluca/0000 0001 7843 5969;
   Fini, Milena/0000 0002 3732 3570; Borsari, Veronica/0000 0002 6327 4653
FU Project: "Tumor microenvironment: potential role of osteoporosis in the
   development of bone metastases. In vitro and in vivo studies"
FX This research was supported by the Project: "Tumor microenvironment:
   potential role of osteoporosis in the development of bone metastases. In
   vitro and in vivo studies". Programma di ricerca Regione Universita
   2010 2012 Area 1 "Bando Giovani Ricercatori".
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bussard KM, 2010, J CELL BIOCHEM, V111, P1138, DOI 10.1002/jcb.22799
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Curtin P, 2012, BIOMATERIALS, V33, P1065, DOI 10.1016/j.biomaterials.2011.10.046
   Das S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034374
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS129, DOI 10.1007/s00198 005 1859 7
   Feller L, 2011, CANCER CELL INT, V11, DOI 10.1186/1475 2867 11 24
   Fili S, 2009, CANCER LETT, V283, P10, DOI 10.1016/j.canlet.2009.01.011
   Fini Milena, 2010, Front Biosci (Schol Ed), V2, P468
   Greenfield EM, 1999, LIFE SCI, V65, P1087, DOI 10.1016/S0024 3205(99)00156 3
   Gregory LS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068103
   Hwang YS, 2012, ORAL ONCOL, V48, P40, DOI 10.1016/j.oraloncology.2011.08.022
   Kinder M, 2008, EXP CELL RES, V314, P173, DOI 10.1016/j.yexcr.2007.09.021
   Kovacic N, 2010, LAB INVEST, V90, P402, DOI 10.1038/labinvest.2009.144
   Krawetz R, 2009, EXP CELL RES, V315, P2333, DOI 10.1016/j.yexcr.2009.04.026
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Mastro AM, 2004, J CELL BIOCHEM, V91, P265, DOI 10.1002/jcb.10746
   Mercer RR, 2004, CLIN EXP METASTAS, V21, P427, DOI 10.1007/s10585 004 1867 6
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Roato I, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/315024
   Salamanna F, 2013, ACTA HISTOCHEM, V115, P76, DOI 10.1016/j.acthis.2012.05.005
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Syed Farhan A, 2011, Curr Osteoporos Rep, V9, P219, DOI 10.1007/s11914 011 0074 z
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Wu YP, 2010, MED HYPOTHESES, V75, P514, DOI 10.1016/j.mehy.2010.07.010
   Zhu Guo Ying, 2009, Ai Zheng, V28, P449
NR 32
TC 19
Z9 20
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2015
VL 79
BP 176
EP 182
DI 10.1016/j.bone.2015.06.002
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CO9QF
UT WOS:000359509700024
PM 26057367
DA 2025 08 17
ER

PT J
AU Lee, WY
   Oh, KW
   Rhee, EJ
   Jung, CH
   Kim, SW
   Yun, EJ
   Tae, HJ
   Baek, KH
   Kang, MI
   Choi, MG
   Yoo, HJ
   Park, SW
AF Lee, WY
   Oh, KW
   Rhee, EJ
   Jung, CH
   Kim, SW
   Yun, EJ
   Tae, HJ
   Baek, KH
   Kang, MI
   Choi, MG
   Yoo, HJ
   Park, SW
TI Relationship between subclinical thyroid dysfunction and femoral neck
   bone mineral density in women
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE subclinical thyroid dysfunction; subclinical hyperthyroidism;
   subclinical hypothyroidism; thyroid stimulating hormone; bone mineral
   density; women
ID FORMER HYPERTHYROID PATIENTS; L THYROXINE THERAPY; BODY COMPOSITION;
   POSTMENOPAUSAL WOMEN; CALCIUM HOMEOSTASIS; TURNOVER; MASS; RISK;
   HYPOTHYROIDISM; METAANALYSIS
AB Background. Osteoporosis associated with thyroid dysfunction has been traditionally viewed as a secondary consequence of altered thyroid function, but there was recently a report about the direct effects of thyroid stimulating hormone (TSH) on bone remodeling, which was mediated via the TSH receptor found on osteoblast and osteoclast precursor cells. Endogenous subclinical thyroid dysfunction seems to be an appropriate model to examine the direct effect of TSH on bone metabolism while ruling out the direct effect of thyroid hormone on bone metabolism. Thus, we aimed to investigate the relationship between subclinical thyroid dysfunction and bone mineral metabolism in women.
   Methods. We enrolled 413 women (mean age: 52.2 +/  6.6 years) in our study. Serum levels of TSH, free T 4 and the biochemical markers of bone turnover were measured by the standard methods. BMD at the lumbar spine and femoral neck were measured by dual energy X ray absorptiometry.
   Results. Femoral neck BMD was significantly reduced both in the subclinical hyperthyroid group and in the subclinical hypothyroid group as compared with the euthyroid group (one way ANOVA, p <0.001; post hoc analysis, p = 0.041, p = 0.033). In contrast to the femoral neck BMD, the lumbar spine BMD showed no difference between the two groups. Additionally, serum calcium and alkaline phosphatase levels, urine deoxypyridinoline levels, and urine calcium to creatinine ratio showed no differences between the two groups.
   Conclusions. Women having subclinical hyperthyroidism and women with subclinical hypothyroidsm have reduced femoral neck BMD. Additional studies are required to elucidate the mechanism for this finding. (C) 2006 IMSS. Published by Elsevier Inc.
C1 Sungkyunkwan Univ, Sch Med, Dept Internal Med, Seoul, South Korea.
   Hallym Univ, Dept Radiol, Chunchon, South Korea.
   Hallym Univ, Dept Internal Med, Chunchon, South Korea.
   Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Hallym University; Hallym University;
   Catholic University of Korea
RP Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Endocrinol & Metab, 896 Pyungchon Dong, Anyang, Kyungki Do, South Korea.
EM okwendo@yahoo.co.kr
RI ; LEE, WON YOUNG/C 7249 2018; Jung, Chan Hee/AAV 3164 2020; Rhee,
   Eun Jung/M 9294 2015
OI Jung, Chan Hee/0000 0001 8988 0187; LEE, WON YOUNG/0000 0002 1082 7592;
   Rhee, Eun Jung/0000 0002 6108 7758
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   ALLAIN TJ, 1995, BONE, V16, P505, DOI 10.1016/8756 3282(95)00074 N
   Bertoli A, 2002, HORM RES, V57, P79, DOI 10.1159/000057956
   COINDRE JM, 1986, ARCH INTERN MED, V146, P48, DOI 10.1001/archinte.146.1.48
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Engler H, 1999, CLIN CHIM ACTA, V289, P159, DOI 10.1016/S0009 8981(99)00173 4
   Faber J, 1998, CLIN ENDOCRINOL, V48, P285
   FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350
   FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365 2265.1993.tb02403.x
   Kumeda Y, 2000, J CLIN ENDOCR METAB, V85, P4157, DOI 10.1210/jc.85.11.4157
   Langdahl BL, 1996, THYROID, V6, P161
   Langdahl BL, 1996, THYROID, V6, P169
   Langdahl BL, 1996, EUR J ENDOCRINOL, V134, P702, DOI 10.1530/eje.0.1340702
   LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem 70 3 766
   LEHMKE J, 1992, CLIN ENDOCRINOL, V36, P511, DOI 10.1111/j.1365 2265.1992.tb02254.x
   Milne M, 1998, ENDOCRINOLOGY, V139, P2527, DOI 10.1210/en.139.5.2527
   MOSEKILDE L, 1978, ACTA PATH MICRO IM A, V86, P56
   MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889 8529(18)30338 4
   MUDDE AH, 1994, CLIN ENDOCRINOL, V41, P421, DOI 10.1111/j.1365 2265.1994.tb02571.x
   MUDDE AH, 1992, CLIN ENDOCRINOL, V37, P35, DOI 10.1111/j.1365 2265.1992.tb02280.x
   ONGPHIPHADHANAKUL B, 1992, J BONE MINER RES, V7, P1227
   PAUL TL, 1988, JAMA J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137
   Suwanwalaikorn S, 1997, AM J PHYSIOL ENDOC M, V272, pE212, DOI 10.1152/ajpendo.1997.272.2.E212
   Suwanwalaikorn S, 1996, EUR J ENDOCRINOL, V134, P655, DOI 10.1530/eje.0.1340655
   Tsai K S, 1991, J Formos Med Assoc, V90, P250
   Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278
   Vestergaard P, 2000, THYROID, V10, P341, DOI 10.1089/thy.2000.10.341
   Vestergaard P, 2002, THYROID, V12, P411, DOI 10.1089/105072502760043503
   WEJDA B, 1995, J INTERN MED, V237, P241, DOI 10.1111/j.1365 2796.1995.tb01172.x
   YEO PPB, 1976, AUST NZ J MED, V6, P311, DOI 10.1111/imj.1976.6.4.311
NR 30
TC 52
Z9 67
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0188 4409
EI 1873 5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD MAY
PY 2006
VL 37
IS 4
BP 511
EP 516
DI 10.1016/j.arcmed.2005.09.009
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 037JK
UT WOS:000237142700015
PM 16624651
DA 2025 08 17
ER

PT J
AU Maekawa, K
   Ishizawa, M
   Ikawa, T
   Sajiki, H
   Matsumoto, T
   Tokiwa, H
   Makishima, M
   Yamada, S
AF Maekawa, Kazuki
   Ishizawa, Michiyasu
   Ikawa, Takashi
   Sajiki, Hironao
   Matsumoto, Taro
   Tokiwa, Hiroaki
   Makishima, Makoto
   Yamada, Sachiko
TI Syntheses of 25 Adamantyl 25 alkyl 2 methylidene 1α,25 dihydroxyvitamin
   D3 Derivatives with Structure Function Studies of
   Antagonistic and Agonistic Active Vitamin D Analogs
SO BIOMOLECULES
LA English
DT Article
DE vitamin D; nuclear receptor; osteoblast differentiation; cell
   selectivity
ID D RECEPTOR; 1,25 DIHYDROXYVITAMIN D 3; PARATHYROID HORMONE;
   CRYSTAL STRUCTURES; HUMAN SKIN; CALCIUM; DIFFERENTIATION; CELLS;
   IDENTIFICATION; ELDECALCITOL
AB The active form of vitamin D 3, 1 & alpha;,25 dihydroxyvitamin D 3 [1,25(OH)(2)D 3], is a major regulator of calcium homeostasis through activation of the vitamin D receptor (VDR). We have previously synthesized vitamin D derivatives with large adamantane (AD) rings at position 24, 25, or 26 of the side chain to study VDR agonist and/or antagonist properties. One of them ADTK1, with an AD ring and 23,24 triple bond shows a high VDR affinity and cell selective VDR activity. In this study, we synthesized novel vitamin D derivatives (ADKM1 6) with an alkyl group substituted at position 25 of ADTK1 to develop more cell selective VDR ligands. ADKM2, ADKM4, and ADKM6 had VDR transcriptional activity comparable to 1,25(OH)(2)D 3 and ADTK1, although their VDR affinities were weaker. Interestingly, ADKM2 has selective VDR activity in kidney  and skin derived cells a unique phenotype that differs from ADTK1. Furthermore, ADKM2, ADKM4, and ADKM6 induced osteoblast differentiation in human dedifferentiated fat cells more effectively than ADTK1. The development of vitamin D derivatives with bulky modifications such as AD at position 24, 25, or 26 of the side chain is useful for increased stability and tissue selectivity in VDR targeting therapy.
C1 [Maekawa, Kazuki] Rikkyo Univ, Fac Sci, Dept Chem, Toshima, Tokyo 1718501, Japan.
   [Ishizawa, Michiyasu; Makishima, Makoto; Yamada, Sachiko] Nihon Univ Sch Med, Dept Biomed Sci, Div Biochem, Tokyo, Tokyo 1738610, Japan.
   [Ikawa, Takashi; Sajiki, Hironao; Tokiwa, Hiroaki] Gifu Pharmaceut Univ, Lab Organ Chem, 1 25 4 Daigaku Nishi, Gifu 5011196, Japan.
   [Matsumoto, Taro] Nihon Univ, Div Cell Regenerat & Transplantat, Dept Funct Morphol, Tokyo 1738610, Japan.
C3 Rikkyo University; Nihon University; Gifu Pharmaceutical University;
   Nihon University
RP Makishima, M; Yamada, S (通讯作者)，Nihon Univ Sch Med, Dept Biomed Sci, Div Biochem, Tokyo, Tokyo 1738610, Japan.; Tokiwa, H (通讯作者)，Gifu Pharmaceut Univ, Lab Organ Chem, 1 25 4 Daigaku Nishi, Gifu 5011196, Japan.
EM kkazukki@gmail.com; ishizawa.michiyasu@nihon u.ac.jp;
   kawa ta@gifu pu.ac.jp; sajiki@gifu pu.ac.jp;
   matsumoto.taro@nihon u.ac.jp; tokiwa hi@gifu pu.ac.jp;
   makishima.makoto@nihon u.ac.jp; yamada.sachiko@coral.plala.or.jp
FU MEXT by Ministry of Education, Culture, Sports, Science and Technology
   in Japan [S1411018]; Nihon University President Grant Initiative; Nihon
   University
FX This research was partly supported by the MEXT supported Program for the
   Strategic Research Foundation at Private Universities (S1411018) by the
   Ministry of Education, Culture, Sports, Science and Technology in Japan,
   by the Nihon University President Grant Initiative (2018 2020), and by
   the Research Grant from the Chairperson and the President of Nihon
   University (2021 2022) by the Nihon University.
CR [Anonymous], 2016, Molecular Operating Environment (MOE)
   Arulmozhiraja S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166275
   Belorusova AY, 2020, J MED CHEM, V63, P9457, DOI 10.1021/acs.jmedchem.0c00656
   Bernholdt DE, 1996, CHEM PHYS LETT, V250, P477, DOI 10.1016/0009 2614(96)00054 1
   Berridge MJ, 2017, J PHYSIOL LONDON, V595, P6825, DOI 10.1113/JP274887
   Bislev LS, 2019, CALCIFIED TISSUE INT, V104, P160, DOI [10.1007/s00223 018 0481 6, 10.1007/s00223 018 ]
   Boonen S, 2006, J INTERN MED, V259, P539, DOI 10.1111/j.1365 2796.2006.01655.x
   Caricato M., 2016, Gaussian 09
   Choi M, 2003, CHEM BIOL, V10, P261, DOI 10.1016/S1074 5521(03)00050 4
   De Kok I J, 2006, J Oral Implantol, V32, P103, DOI 10.1563/760.1
   DELANO WL, 2002, PYMOL
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153
   Endo M, 2006, J PHARMACOL SCI, V100, P519, DOI 10.1254/jphs.CPJ06004X
   Endo Y, 2017, BIOL PHARM BULL, V40, P739, DOI 10.1248/bpb.b16 01020
   FEYEREISEN M, 1993, CHEM PHYS LETT, V208, P359, DOI 10.1016/0009 2614(93)87156 W
   Fuggle NR, 2020, AGING CLIN EXP RES, V32, P547, DOI 10.1007/s40520 020 01515 1
   Gallagher JC, 2013, ENDOCRIN METAB CLIN, V42, P319, DOI 10.1016/j.ecl.2013.02.004
   HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523
   HOLICK MF, 1971, BIOCHEMISTRY US, V10, P2799
   HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Igarashi M, 2007, ARCH BIOCHEM BIOPHYS, V460, P240, DOI 10.1016/j.abb.2006.11.026
   Inaba Y, 2007, MOL PHARMACOL, V71, P1298, DOI 10.1124/mol.106.032318
   Ishikawa T, 2009, J COMPUT CHEM, V30, P2594, DOI 10.1002/jcc.21265
   Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193
   Joosten RP, 2014, IUCRJ, V1, P213, DOI 10.1107/S2052252514009324
   Kakuda S, 2010, ACTA CRYSTALLOGR D, V66, P918, DOI 10.1107/S0907444910020810
   Kaneko E, 2003, J BIOL CHEM, V278, P36091, DOI 10.1074/jbc.M304153200
   Kaneko K, 2022, INTERNAL MED, V61, P2405, DOI 10.2169/internalmedicine.8560 21
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kitaura K, 1999, CHEM PHYS LETT, V312, P319, DOI 10.1016/S0009 2614(99)00937 9
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   KREAM BE, 1977, SCIENCE, V197, P1086, DOI 10.1126/science.887939
   KREAM BE, 1977, J BIOL CHEM, V252, P4501
   Kudo T, 2014, J MED CHEM, V57, P4073, DOI 10.1021/jm401989c
   Labute P, 2009, PROTEINS, V75, P187, DOI 10.1002/prot.22234
   Lee SM, 2015, J BIOL CHEM, V290, P18199, DOI 10.1074/jbc.M115.665794
   Levi B, 2012, P NATL ACAD SCI USA, V109, P20379, DOI 10.1073/pnas.1218052109
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   Matsumoto T, 2012, DRUG TODAY, V48, P189, DOI 10.1358/dot.2012.48.3.1745223
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304
   Matsumoto T, 2020, J BONE MINER METAB, V38, P522, DOI 10.1007/s00774 020 01091 4
   Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392
   Mochizuki Y., 2021, Recent Advances of the Fragment Molecular Orbital Method, DOI DOI 10.1007/978 981 15 7929 5
   Nakabayashi M, 2008, J MED CHEM, V51, P5320, DOI 10.1021/jm8004477
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   Otero R, 2018, J MED CHEM, V61, P6658, DOI 10.1021/acs.jmedchem.8b00427
   Otero R, 2016, CHEM SCI, V7, P1033, DOI 10.1039/c5sc03084f
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Pymolwiki, RMSDBY RESIDUE
   Ryan ZC, 2016, J BIOL CHEM, V291, P1514, DOI 10.1074/jbc.M115.684399
   Sanford M, 2011, DRUGS, V71, P1755, DOI 10.2165/11206790 000000000 00000
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   SHIINA Y, 1983, ARCH BIOCHEM BIOPHYS, V220, P90, DOI 10.1016/0003 9861(83)90390 9
   SHIMIZU M, 1990, J CHEM SOC CHEM COMM, P1416, DOI 10.1039/c39900001416
   SHIMIZU M, 1991, ANAL BIOCHEM, V194, P77, DOI 10.1016/0003 2697(91)90153 K
   SHIMIZU M, 1992, ANAL BIOCHEM, V204, P258, DOI 10.1016/0003 2697(92)90236 Z
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   TAM SP, 1988, J LIPID RES, V29, P1637
   TAVANGAR K, 1990, ANAL BIOCHEM, V186, P60, DOI 10.1016/0003 2697(90)90572 Q
   Tocchini Valentini G, 2004, J MED CHEM, V47, P1956, DOI 10.1021/jm0310582
   Väisänen S, 2002, J MOL BIOL, V315, P229, DOI 10.1006/jmbi.2001.5225
   Watarai Y, 2015, J MED CHEM, V58, P9510, DOI 10.1021/acs.jmedchem.5b00792
   Williams RJP, 1998, BBA MOL CELL RES, V1448, P153, DOI 10.1016/S0167 4889(98)00139 6
   YAMADA S, 1978, ANAL BIOCHEM, V85, P34, DOI 10.1016/0003 2697(78)90270 1
   YAMADA S, 1979, CHEM PHARM BULL, V27, P3196
   YAMADA S, 1979, TETRAHEDRON LETT, P1859
   Yamagishi K, 2006, CHEM PHYS LETT, V420, P465, DOI 10.1016/j.cplett.2005.12.078
   Yamagishi K, 2010, J STEROID BIOCHEM, V121, P63, DOI 10.1016/j.jsbmb.2010.03.028
   Yamamoto K, 2006, J MED CHEM, V49, P1313, DOI 10.1021/jm050795q
   Yoshimoto N., 2007, THESIS TOKYO MED DEN
NR 72
TC 2
Z9 2
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD JUL
PY 2023
VL 13
IS 7
AR 1082
DI 10.3390/biom13071082
PG 22
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA N6JH4
UT WOS:001038046300001
PM 37509118
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pan, HH
   Li, X
   Wang, JR
   Zhang, KB
   Yang, H
   Li, ZM
   Zheng, ZM
   Liu, H
AF Pan, Hehai
   Li, Xiang
   Wang, Jianru
   Zhang, Kuibo
   Yang, Hao
   Li, Zemin
   Zheng, Zhaomin
   Liu, Hui
TI LIM Mineralization Protein 1 Enhances Bone Morphogenetic
   Protein 2 Mediated Osteogenesis Through Activation of ERK1/2 MAPK
   Pathway and Upregulation of Runx2 Transactivity
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE LMP 1; BMP 2; RUNX2; ERK1; 2; OSTEOGENESIS
ID NF KAPPA B; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR;
   GENE THERAPY; C2C12 CELLS; IN VITRO; LMP 1; INDUCTION; BINDING;
   RESPONSIVENESS
AB LIM mineralization protein 1 (LMP 1) is an intracellular regulator of bone formation. Upregulation of bone morphogenetic proteins (BMPs) and stabilization of BMP/Smad signaling have been proven to be the key mechanisms through which LMP 1 enhances osteogenesis. However, how LMP 1 regulates BMPs expression and related bone formation remains unclear. In this study, a LMP 1 induced osteogenesis cell model was used to study the molecular action of LMP 1 on BMP 2 expression and bone formation. The results show that overexpression of LMP 1 significantly increases, whereas downregulation of endogenous LMP 1 decreases BMP 2 expression and bone formation. Antagonism of BMP 2 with noggin or short hairpin BMP 2 significantly attenuates the osteoinductive effect of LMP 1, suggesting that the osteoinductive effect of LMP 1 is mediated by BMP 2. LMP 1 regulation of BMP 2 is found to occur at the transcription level using a luciferase reporter assay with a reporter construct containing a BMP 2 promoter. A promoter deletion assay reveals that  1000/ 500 bp is the key regulated region by LMP 1. A Runx2 binding site is then located at  934/ 920 bp and confirmed by luciferase assay using a reporter construct containing repeats of this Runx2 binding site and the site directed mutagenesis analysis. Overexpression of LMP 1 significantly increases Runx2 expression. Downregulation of Runx2 expression significantly decreases BMP 2 promoter activity and BMP 2 expression. A ChIP assay demonstrates that LMP 1 increases the interaction between Runx2 and BMP 2 promoter. A luciferase reporter assay using the OSE2 promoter containing a Runx2 binding site confirms that Runx2 transactivity can be upregulated by LMP 1. Moreover, inhibiting the activation of different pathways with specific pathway inhibitors reveals that ERK1/2 MAPK activation is essential for LMP 1 induced upregulation of Runx2 transactivity and subsequent BMP 2 expression. In conclusion, our novel findings describe a positive regulatory effect of LMP 1 on BMP 2 expression and BMP 2 mediated osteogenesis. This effect occurs through activation of ERK1/2 pathway and subsequent upregulation of Runx2 transactivity. (c) 2015 American Society for Bone and Mineral Research.
C1 [Pan, Hehai; Li, Xiang; Wang, Jianru; Yang, Hao; Li, Zemin; Zheng, Zhaomin; Liu, Hui] Sun Yat Sen Univ, Dept Spine Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhang, Kuibo] Sun Yat Sen Univ, Dept Orthoped, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Liu, H (通讯作者)，Sun Yat Sen Univ, Dept Spine Surg, Affiliated Hosp 1, 58,Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.
EM zhengzm1@163.com; liuhui58@mail.sysu.edu.cn
OI Li, Xiang/0000 0002 4869 7041
FU National Natural Science Foundation of China [81071511, 81101384];
   Natural Science Foundation of Guangdong province [S2013010015397]
FX This work was supported by the National Natural Science Foundation of
   China (grant no. 81071511, 81101384) and the Natural Science Foundation
   of Guangdong province (grant no. S2013010015397). Approval of the
   institutional review board at our hospital was obtained before the
   current study.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092 8674(93)90680 O
   Boden SD, 1998, SPINE, V23, P2486, DOI 10.1097/00007632 199812010 00003
   Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125
   Brusin Joyce Helena, 2008, Radiol Technol, V79, P535
   Carbonare LD, 2012, STEM CELL REV REP, V8, P891, DOI 10.1007/s12015 011 9337 4
   Chen HY, 2014, J BONE MINER RES, V29, P2653, DOI 10.1002/jbmr.2287
   Chrastil J, 2013, SPINE, V38, pE1020, DOI 10.1097/BRS.0b013e3182982f8e
   Cohen MM, 2009, AM J MED GENET A, V149A, P2629, DOI 10.1002/ajmg.a.33021
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fei QM, 2007, ACTA BIOCH BIOPH SIN, V39, P693, DOI 10.1111/j.1745 7270.2007.00333.x
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Gregory KE, 2005, J BIOL CHEM, V280, P27970, DOI 10.1074/jbc.M504270200
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Liu H, 2011, J BONE MINER RES, V26, P1122, DOI 10.1002/jbmr.296
   Liu H, 2010, BONE, V46, P1328, DOI 10.1016/j.bone.2009.11.017
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu YS, 2002, J BONE MINER RES, V17, P406, DOI 10.1359/jbmr.2002.17.3.406
   LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623 200306000 00007
   Miyazaki M, 2009, EUR SPINE J, V18, P783, DOI 10.1007/s00586 009 0924 x
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Raizman NM, 2009, J AM ACAD ORTHOP SUR, V17, P494, DOI 10.5435/00124635 200908000 00003
   REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959 437X(94)90141 O
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Sangadala S, 2006, J BIOL CHEM, V281, P17212, DOI 10.1074/jbc.M511013200
   Sangadala S, 2014, MOL CELL BIOCHEM, V385, P145, DOI 10.1007/s11010 013 1823 3
   Shimer AL, 2009, INJURY, V40, P32
   Strohbach CA, 2008, CALCIFIED TISSUE INT, V83, P202, DOI 10.1007/s00223 008 9163 0
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Urist MR, 2002, CLIN ORTHOP RELAT R, P5
   URIST MR, 1973, P NATL ACAD SCI USA, V70, P3511, DOI 10.1073/pnas.70.12.3511
   Viggeswarapu M, 2001, J BONE JOINT SURG AM, V83A, P364, DOI 10.2106/00004623 200103000 00008
   Wang JR, 2013, ARTHRITIS RHEUM US, V65, P832, DOI 10.1002/art.37819
   Wang XJ, 2011, STOCH ANAL APPL, V29, P1, DOI 10.1080/07362994.2010.515484
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yoon ST, 2004, SPINE, V29, P2603, DOI 10.1097/01.brs.0000146103.94600.85
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Zerega B, 1999, J BONE MINER RES, V14, P1281, DOI 10.1359/jbmr.1999.14.8.1281
   Zhang W, 2014, J BONE MINER RES, V29, P1232, DOI 10.1002/jbmr.2116
   ZHOU H, 1995, BONE, V17, pS443, DOI 10.1016/8756 3282(95)00324 7
NR 47
TC 22
Z9 26
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2015
VL 30
IS 8
BP 1523
EP 1535
DI 10.1002/jbmr.2481
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CN1JL
UT WOS:000358175500019
PM 25677945
OA Bronze
DA 2025 08 17
ER

PT J
AU Ling, ZM
   Crane, J
   Hu, H
   Chen, Y
   Wan, M
   Ni, SF
   Demehri, S
   Mohajer, B
   Peng, XS
   Zou, XN
   Cao, X
AF Ling, Zemin
   Crane, Janet
   Hu, Hao
   Chen, Yan
   Wan, Mei
   Ni, Shuangfei
   Demehri, Shadpour
   Mohajer, Bahram
   Peng, Xinsheng
   Zou, Xuenong
   Cao, Xu
TI Parathyroid hormone treatment partially reverses endplate remodeling and
   attenuates low back pain in animal models of spine degeneration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID GROWTH FACTOR I; INTERVERTEBRAL DISC DEGENERATION; PGE(2) PRODUCTION;
   RHESUS MONKEYS; MODIC CHANGES; ANGIOGENESIS; STRESS; CELLS;
   CLASSIFICATION; INNERVATION
AB Low back pain (LBP) is one of the most prevalent diseases affecting quality of life, with no disease modifying therapy. During aging and spinal degeneration, the balance between the normal endplate (EP) bilayers of cartilage and bone shifts to more bone. The aged/degenerated bony EP has increased porosity because of osteoclastic remodeling activity and may be a source of LBP due to aberrant sensory innervation within the pores. We used two mouse models of spinal degeneration to show that parathyroid hormone (PTH) treatment induced osteogenesis and angiogenesis and reduced the porosity of bony EPs. PTH increased the cartilaginous volume and improved the mechanical properties of EPs, which was accompanied by a reduction of the inflammatory factors cyclooxygenase 2 and prostaglandin E2. PTH treatment furthermore partially reversed the innervation of porous EPs and reversed LBP related behaviors. Conditional knockout of PTH 1 receptors in the nucleus pulposus (NP) did not abolish the treatment effects of PTH, suggesting that the NP is not the primary source of LBP in our mouse models. Last, we showed that aged rhesus macaques with spontaneous spinal degeneration also had decreased EP porosity and sensory innervation when treated with PTH, demonstrating a similar mechanism of PTH action on EP sclerosis between mice and macaques. In summary, our results suggest that PTH treatment could partially reverse EP restructuring during spinal regeneration and support further investigation into this potentially disease modifying treatment strategy for LBP.
C1 [Ling, Zemin; Crane, Janet; Wan, Mei; Ni, Shuangfei; Cao, Xu] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.
   [Ling, Zemin; Hu, Hao; Chen, Yan; Peng, Xinsheng; Zou, Xuenong] Sun Yat sen Univ, Affiliated Hosp 1, Dept Spinal Surg, Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 51008, Peoples R China.
   [Crane, Janet] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
   [Demehri, Shadpour; Mohajer, Bahram] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Sun Yat Sen University; Johns Hopkins
   University; Johns Hopkins University
RP Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.; Zou, XN (通讯作者)，Sun Yat sen Univ, Affiliated Hosp 1, Dept Spinal Surg, Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 51008, Peoples R China.
EM xcao11@jhmi.edu; zouxuen@mail.sysu.edu.cn
RI ; peng, Xinsheng/Q 9115 2019; HU, Hao/H 7813 2018; D'Este,
   Matteo/AAB 2835 2022; Ling, Zemin/ABF 3060 2021; Mohajer,
   Bahram/I 9529 2019; Crane, Janet/LNP 7603 2024
OI Hu, Hao/0000 0002 1127 0589; Ling, Zemin/0000 0002 2742 6429; 
FU FOX Gift; Necrosis Fund from the Johns Hopkins Department of Orthopaedic
   Surgery
FX This work is supported by FOX Gift and Necrosis Fund from the Johns
   Hopkins Department of Orthopaedic Surgery(X.C.).
CR AOKI J, 1987, RADIOLOGY, V164, P411, DOI 10.1148/radiology.164.2.3602378
   Bakker AD, 2003, AM J PHYSIOL ENDOC M, V285, pE608, DOI 10.1152/ajpendo.00501.2002
   Bedore J, 2013, ARTHRITIS RHEUM US, V65, P2634, DOI 10.1002/art.38075
   BERNICK S, 1982, SPINE, V7, P97, DOI 10.1097/00007632 198203000 00002
   Bian Q, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.8
   Bian Q, 2016, SCI REP UK, V6, DOI 10.1038/srep27093
   Binch ALA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0416 1
   Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632 200212010 00002
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Chen H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08097 7
   Chou R, 2007, ANN INTERN MED, V147, P505, DOI 10.7326/0003 4819 147 7 200710020 00008
   Clark S, 2018, LANCET, V391, P2302, DOI 10.1016/S0140 6736(18)30725 6
   Coetzee M, 2005, PROSTAG LEUKOTR ESS, V73, P423, DOI 10.1016/j.plefa.2005.08.005
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Dudli S, 2018, J MECH BEHAV BIOMED, V80, P104, DOI 10.1016/j.jmbbm.2018.01.019
   Duncan AE, 2012, SPINE, V37, P915, DOI 10.1097/BRS.0b013e31823ab7fc
   Eastman K, 2021, OSTEOPOROSIS INT, V32, P1531, DOI 10.1007/s00198 021 05847 0
   Fields Aaron J, 2018, Curr Mol Biol Rep, V4, P151, DOI 10.1007/s40610 018 0105 y
   Fields AJ, 2014, SPINE J, V14, P513, DOI 10.1016/j.spinee.2013.06.075
   Gruber HE, 2007, SPINE, V32, P2529, DOI 10.1097/BRS.0b013e318158cd69
   Grunhagen T, 2011, ORTHOP CLIN N AM, V42, P465, DOI 10.1016/j.ocl.2011.07.010
   Hulme PA, 2007, BONE, V41, P946, DOI 10.1016/j.bone.2007.08.019
   Järvinen J, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0540 3
   Jensen TS, 2008, EUR SPINE J, V17, P1407, DOI 10.1007/s00586 008 0770 2
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Langrana Noshir A, 2006, Spine J, V6, P267, DOI 10.1016/j.spinee.2005.09.008
   Lee JM, 2011, J ORTHOP RES, V29, P265, DOI 10.1002/jor.21210
   Levin DA, 2007, SPINE, V32, P2905, DOI 10.1097/BRS.0b013e31815b84ae
   Ling ZM, 2020, J ORTHOP TRANSL, V24, P23, DOI 10.1016/j.jot.2020.04.004
   Lotz JC, 2013, GLOB SPINE J, V3, P153, DOI 10.1055/s 0033 1347298
   Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632 200002150 00016
   Luoma K, 2016, EUR SPINE J, V25, P2873, DOI 10.1007/s00586 016 4715 x
   Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140 6736(16)30970 9
   Martin BI, 2008, JAMA J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656
   McCann MR, 2012, DIS MODEL MECH, V5, P73, DOI 10.1242/dmm.008128
   McGorry RW, 2000, SPINE, V25, P834, DOI 10.1097/00007632 200004010 00012
   MIZRAHI J, 1993, SPINE, V18, P2088, DOI 10.1097/00007632 199310001 00028
   Moore RJ, 2000, EUR SPINE J, V9, P92, DOI 10.1007/s005860050217
   Nevitt MC, 2006, OSTEOPOROSIS INT, V17, P273, DOI 10.1007/s00198 005 2013 2
   Ni SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13476 9
   Ohtori S, 2006, SPINE, V31, P1026, DOI 10.1097/01.brs.0000215027.87102.7c
   Ohtori S, 2015, SPINE J, V15, P1347, DOI 10.1016/j.spinee.2013.07.490
   Paesold G, 2007, EUR SPINE J, V16, P447, DOI 10.1007/s00586 006 0220 y
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632 200109010 00011
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Rahme R, 2008, AM J NEURORADIOL, V29, P838, DOI 10.3174/ajnr.A0925
   Raj P Prithvi, 2008, Pain Pract, V8, P18, DOI 10.1111/j.1533 2500.2007.00171.x
   Rodriguez AG, 2012, J ORTHOP RES, V30, P280, DOI 10.1002/jor.21513
   Rubin DI, 2007, NEUROL CLIN, V25, P353, DOI 10.1016/j.ncl.2007.01.004
   Samartzis D, 2017, SCOLIOSIS SPINAL DIS, V12, DOI 10.1186/s13013 016 0108 5
   Sampson ER, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002214
   Saukkonen J, 2020, SPINE, V45, P1360, DOI 10.1097/BRS.0000000000003529
   Sun Q, 2021, ELIFE, V10, DOI 10.7554/eLife.66532
   Taher F, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/970752
   Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Wang Y, 2012, SPINE, V37, P1490, DOI 10.1097/BRS.0b013e3182608ac4
   WATSON P, 1995, BONE, V16, P357, DOI 10.1016/8756 3282(94)00051 4
   Wei F, 2015, SPINE, V40, pE199, DOI 10.1097/BRS.0000000000000736
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Zhao FD, 2009, BONE, V44, P372, DOI 10.1016/j.bone.2008.10.048
   Zheng LW, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0022 y
   Zhong R, 2016, EUR SPINE J, V25, P2705, DOI 10.1007/s00586 016 4593 2
   Zhou ZY, 2013, RADIOLOGY, V268, P492, DOI 10.1148/radiol.13120874
NR 67
TC 13
Z9 14
U1 4
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD NOV 15
PY 2023
VL 15
IS 722
AR eadg8982
DI 10.1126/scitranslmed.adg8982
PG 15
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AR7T2
UT WOS:001120258900001
PM 37967203
DA 2025 08 17
ER

PT J
AU Cai, YY
   Liu, YT
   Culhane, KJ
   DeVree, BT
   Yang, Y
   Sunahara, RK
   Yan, ECY
AF Cai, Yingying
   Liu, Yuting
   Culhane, Kelly J.
   DeVree, Brian T.
   Yang, Yang
   Sunahara, Roger K.
   Yan, Elsa C. Y.
TI Purification of family B G protein coupled receptors using nanodiscs:
   Application to human glucagon like peptide 1 receptor
SO PLOS ONE
LA English
DT Article
ID PHOSPHOLIPID BILAYER NANODISCS; HIGH LEVEL EXPRESSION; LIGAND BINDING;
   GLP 1 RECEPTOR; PARATHYROID HORMONE; CRYSTAL STRUCTURE; SECRETIN FAMILY;
   IN VITRO; RHODOPSIN; ACTIVATION
AB Family B G protein coupled receptors (GPCRs) play vital roles in hormone regulated homeostasis. They are drug targets for metabolic diseases, including type 2 diabetes and osteoporosis. Despite their importance, the signaling mechanisms for family B GPCRs at the molecular level remain largely unexplored due to the challenges in purification of functional receptors in sufficient amount for biophysical characterization. Here, we purified the family B GPCR human glucagon like peptide 1 (GLP 1) receptor (GLP1R), whose agonists, e.g. exendin 4, are used for the treatment of type 2 diabetes mellitus. The receptor was expressed in HEK293S GnTl  cells using our recently developed protocol. The protocol incorporates the receptor into the native like lipid environment of reconstituted high density lipoprotein (rHDL) particles, also known as nanodiscs, immediately after the membrane solubilization step followed by chromatographic purification, minimizing detergent contact with the target receptor to reduce denaturation and prolonging stabilization of receptor in lipid bilayers without extra steps of reconstitution. This method yielded purified GLP1R in nanodiscs that could bind to GLP 1 and exendin 4 and activate G(s) protein. This nanodisc purification method can potentially be a general strategy to routinely obtain purified family B GPCRs in the 10s of microgram amounts useful for spectroscopic analysis of receptor functions and activation mechanisms.
C1 [Cai, Yingying; Liu, Yuting; Yan, Elsa C. Y.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [Culhane, Kelly J.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA.
   [DeVree, Brian T.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
   [Yang, Yang] Yale Univ, Nanobiol Inst, New Haven, CT USA.
   [Yang, Yang] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.
   [Sunahara, Roger K.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
C3 Yale University; Yale University; University of Michigan System;
   University of Michigan; Yale University; Yale University; University of
   California System; University of California San Diego
RP Yan, ECY (通讯作者)，Yale Univ, Dept Chem, New Haven, CT 06520 USA.
EM elsa.yan@yale.edu
RI ; DeVree, Brian/F 6205 2011; Sunahara, Roger/AAJ 8667 2020
OI Sunahara, Roger K./0000 0003 1702 8619; Yan, Elsa/0000 0002 3583 1627;
   DeVree, Brian/0000 0003 0582 8125; Culhane, Kelly/0000 0001 8075 4782
FU Yale Setup fund; National Institute of Health Biophysics Training Grant
   [T32 GM008283 27]; National Institute of General Medical Sciences
   [R01 GM083118, R01 GM068603]; Molecular Biophysics Training Grant
   [T32GM008270]; National Institute of Health Director's New Innovator
   Award [DP2 GM114830]; NIH Biophysics Training Grant [T32 GM008283 27];
   NIH Director's New Innovator Award [DP2 GM114830]
FX The work was partially supported by the Yale Setup fund (to EY), the
   National Institute of Health Biophysics Training Grant T32 GM008283 27
   (to KC), the National Institute of General Medical Sciences Grants
   R01 GM083118 and R01 GM068603 (to RKS), Molecular Biophysics Training
   Grant T32GM008270 (to BTD) and the National Institute of Health
   Director's New Innovator Award DP2 GM114830 (to support YY and to
   maintain the TEM facility). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.We thank Prof. Victor S. Batista for providing the schematic
   figure of a receptor incorporated nanodisc. We also thank Prof.
   Chenxiang Lin for the access to the transmission electron spectroscope
   facility. The work was partially supported by the Yale Setup fund (to
   EY), the NIH Biophysics Training Grant T32 GM008283 27 (to KC), the
   National Institute of General Medical Sciences Grants RO1 GM083118 and
   RO1 GM068603 (to RKS), Molecular Biophysics Training Grant T32GM008270
   (to BTD) and the NIH Director's New Innovator Award DP2 GM114830 (to
   support YY and to maintain the TEM facility).
CR Aaboe K, 2008, DIABETES OBES METAB, V10, P994, DOI 10.1111/j.1463 1326.2008.00853.x
   Al Sabah S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106890
   Banerjee S, 2008, J MOL BIOL, V377, P1067, DOI 10.1016/j.jmb.2008.01.066
   Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k
   Bayburt TH, 2011, J BIOL CHEM, V286, P1420, DOI 10.1074/jbc.M110.151043
   Bradley SJ, 2016, ANNU REV PHARMACOL, V56, P535, DOI 10.1146/annurev pharmtox 011613 140012
   Breivogel CS, 1998, J BIOL CHEM, V273, P16865, DOI 10.1074/jbc.273.27.16865
   BROWN PJ, 1993, J BIOL CHEM, V268, P6668
   Bueno AB, 2016, J BIOL CHEM, V291, P10700, DOI 10.1074/jbc.M115.696039
   Buteau J, 2008, DIABETES METAB, V34, pS73, DOI 10.1016/S1262 3636(08)73398 6
   Chini B, 2009, J MOL ENDOCRINOL, V42, P371, DOI 10.1677/JME 08 0114
   Christ E, 2010, ENDOCRIN METAB CLIN, V39, P791, DOI 10.1016/j.ecl.2010.09.003
   Chung KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054942
   Corin K, 2011, SCI REP UK, V1, DOI 10.1038/srep00172
   Culhane KJ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00264
   Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574
   Denisov IG, 2016, NAT STRUCT MOL BIOL, V23, P481, DOI 10.1038/nsmb.3195
   Deupi X, 2007, ADV PROTEIN CHEM, V74, P137, DOI 10.1016/S0065 3231(07)74004 4
   Donnelly D, 2012, BRIT J PHARMACOL, V166, P27, DOI 10.1111/j.1476 5381.2011.01687.x
   Drew D, 2006, NAT METHODS, V3, P303, DOI 10.1038/nmeth0406 303
   Escribá PV, 2007, BBA BIOMEMBRANES, V1768, P836, DOI 10.1016/j.bbamem.2006.09.001
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Glück JM, 2009, J AM CHEM SOC, V131, P12060, DOI 10.1021/ja904897p
   GOKE R, 1993, J BIOL CHEM, V268, P19650
   GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258
   GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014 5793(95)01070 U
   Grunbeck A, 2013, METHOD ENZYMOL, V520, P307, DOI 10.1016/B978 0 12 391861 1.00014 9
   Gutzwiller JP, 1999, GUT, V44, P81, DOI 10.1136/gut.44.1.81
   Harikumar KG, 2012, P NATL ACAD SCI USA, V109, P18607, DOI 10.1073/pnas.1205227109
   Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005
   Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359 6446(05)03370 2
   Hollenstein K, 2014, TRENDS PHARMACOL SCI, V35, P12, DOI 10.1016/j.tips.2013.11.001
   Hollenstein K, 2013, NATURE, V499, P438, DOI 10.1038/nature12357
   Huber T, 2013, METHOD ENZYMOL, V520, P281, DOI 10.1016/B978 0 12 391861 1.00013 7
   Kieffer TJ, 1996, ENDOCRINOLOGY, V137, P5119, DOI 10.1210/en.137.11.5119
   Kim H, 2009, BIOCHEMISTRY US, V48, P10976, DOI 10.1021/bi901291c
   Kumari P, 2015, TRENDS MOL MED, V21, P687, DOI 10.1016/j.molmed.2015.09.002
   Lagerström MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518
   Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320
   LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024 3205(93)90301 I
   Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504
   Liu YT, 2015, CHEM COMMUN, V51, P6157, DOI 10.1039/c5cc00301f
   Mak PJ, 2011, J AM CHEM SOC, V133, P1357, DOI 10.1021/ja105869p
   Mann RJ, 2010, BRIT J PHARMACOL, V160, P1973, DOI 10.1111/j.1476 5381.2010.00834.x
   MENDEL D, 1995, ANNU REV BIOPH BIOM, V24, P435, DOI 10.1146/annurev.biophys.24.1.435
   Mitra N, 2013, ACS CHEM BIOL, V8, P617, DOI 10.1021/cb300466n
   Mooney V, 2015, J AM CHEM SOC, V137, P307, DOI 10.1021/ja510553f
   Nadkarni P, 2014, PROG MOL BIOL TRANSL, V121, P23, DOI 10.1016/B978 0 12 800101 1.00002 8
   Naganathan S, 2013, BIOCHEMISTRY US, V52, P1028, DOI 10.1021/bi301292h
   Nath A, 2007, BIOCHEMISTRY US, V46, P2059, DOI 10.1021/bi602371n
   Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229
   Ohtaki T, 1998, J BIOL CHEM, V273, P15464, DOI 10.1074/jbc.273.25.15464
   OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874
   Pal K, 2012, ACTA PHARMACOL SIN, V33, P300, DOI 10.1038/aps.2011.170
   Park M, 2015, CHEM BIOL, V22, P1431, DOI 10.1016/j.chembiol.2015.09.014
   Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165 6147(03)00160 3
   Poyner DR, 2012, BRIT J PHARMACOL, V166, P1, DOI 10.1111/j.1476 5381.2011.01810.x
   Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361
   Rath A, 2013, ANAL BIOCHEM, V434, P67, DOI 10.1016/j.ab.2012.11.007
   Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199
   Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299
   Ren H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004509
   Runge S, 2008, J BIOL CHEM, V283, P11340, DOI 10.1074/jbc.M708740200
   Runge S, 2007, BIOCHEMISTRY US, V46, P5830, DOI 10.1021/bi062309m
   Salon JA, 2011, PHARMACOL REV, V63, P901, DOI 10.1124/pr.110.003350
   Schmied WH, 2014, J AM CHEM SOC, V136, P15577, DOI 10.1021/ja5069728
   Schröder Tittmann K, 2010, BIOCHEMISTRY US, V49, P7956, DOI 10.1021/bi101159s
   Serebryany E, 2012, BBA BIOMEMBRANES, V1818, P225, DOI 10.1016/j.bbamem.2011.07.047
   Shimada M, 2002, J BIOL CHEM, V277, P31774, DOI 10.1074/jbc.M204166200
   Singh Awadhesh Kumar, 2015, Indian J Endocrinol Metab, V19, P182, DOI 10.4103/2230 8210.146881
   Siu FY, 2013, NATURE, V499, P444, DOI 10.1038/nature12393
   Soubias O, 2012, BBA BIOMEMBRANES, V1818, P234, DOI 10.1016/j.bbamem.2011.08.034
   Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291
   Syme CA, 2006, MOL ENDOCRINOL, V20, P3400, DOI 10.1210/me.2006 0178
   Szekeres PG, 1997, J PHARMACOL EXP THER, V283, P1276
   THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678
   THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641
   Tian H, 2014, CHEMBIOCHEM, V15, P1820, DOI 10.1002/cbic.201402193
   TIAN WN, 1994, MOL PHARMACOL, V45, P524
   Tsukamoto H, 2011, BIOCHEMISTRY US, V50, P5086, DOI 10.1021/bi200391a
   Underwood CR, 2010, J BIOL CHEM, V285, P723, DOI 10.1074/jbc.M109.033829
   Valentin Hansen L, 2014, J BIOL CHEM, V289, P18045, DOI 10.1074/jbc.M113.527085
   Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896
   Wang L, 2006, ANNU REV BIOPH BIOM, V35, P225, DOI 10.1146/annurev.biophys.35.101105.121507
   Wang X., 2015, INT J ENDOCRINOL, V2015
   Willard Francis S, 2012, Exp Diabetes Res, V2012, P709893, DOI 10.1155/2012/709893
   Yamamoto K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/315848
   Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200
   Zhao LH, 2016, J BIOL CHEM, V291, P15119, DOI 10.1074/jbc.M116.726620
   Zocher M, 2012, ACS NANO, V6, P961, DOI 10.1021/nn204624p
NR 90
TC 19
Z9 21
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2017
VL 12
IS 6
AR e0179568
DI 10.1371/journal.pone.0179568
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EX5IQ
UT WOS:000403274700042
PM 28609478
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Park, SJ
   Bae, HS
   Park, JC
AF Park, Su Jin
   Bae, Hyun Sook
   Park, Joo Cheol
TI Osteogenic differentiation and gene expression profile of human dental
   follicle cells induced by human dental pulp cells
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE Dental follicle cell; Dental pulp cell; Osteogenic differentiation;
   Microarray; Induction
ID STEM CELLS; BONE FORMATION; TRANSCRIPTION FACTOR; ENAMEL MATRIX;
   IN VITRO; OSTEOBLAST DIFFERENTIATION; TOOTH REGENERATION; CONDITIONED
   MEDIUM; TEETH; PATHWAY
AB Dental follicle cells (DFCs) differentiate into cementoblasts or osteoblasts under appropriate triggering. However, the mechanism(s) for osteogenic differentiation of DFCs are still unclear. The purpose of this study was to examine the effects of dental papilla derived human dental pulp cells (hDPCs) on osteogenic differentiation of human DFCs (hDFCs) in vitro and in vivo and to compare gene expression in hDFCs in the presence or absence of hDPCs. To evaluate the osteogenic differentiation of hDFCs induced by hDPCs, hDFCs were cultured in osteogenic medium with or without hDPCs conditioned medium (CM) in vitro and the cells transplanted into the subcutaneous tissue of immunodeficient mice in vivo. The hDPCs CM enhanced alkaline phosphatase promoter activity of hDFCs in osteogenic culture. The expression of several osteoblast marker genes was increased in hDFCs treated with hDPCs CM compared to hDFCs in normal medium. The hDFCs induced by hDPCs CM also produced more calcified nodules than hDFCs in normal medium. In transplantation experiments, hDPCs CM promoted the osteogenic induction and bone formation of hDFCs. Microarray analysis and quantitative real time PCR showed that osteogenesis related genes including WNT2, VCAN, OSR2, FOSB, and POSTN in hDFCs were significantly upregulated after induction by hDPCs CM compared to hDFCs in normal medium. These findings indicate that hDPCs could increase the expression of osteogenic genes in hDFCs and stimulate their osteogenesis and could be a cellular resource for bone regeneration therapy when induced by hDPCs derived factors.
C1 [Park, Su Jin; Park, Joo Cheol] Seoul Natl Univ, Dept Oral Histol Dev Biol, Seoul 110744, South Korea.
   [Park, Su Jin; Park, Joo Cheol] Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul 110744, South Korea.
   [Park, Su Jin; Bae, Hyun Sook] Namseoul Univ, Dept Dent Hyg, Cheonan 331707, Chungcheongnam, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Namseoul University
RP Park, JC (通讯作者)，Seoul Natl Univ, Dept Oral Histol Dev Biol, 101 Daehagro, Seoul 110744, South Korea.
EM jcapark@snu.ac.kr
RI Su JIN, Park/HJO 8762 2023; Park, Joo Cheol/D 6437 2012
FU Namseoul University; National Research Foundation of Korea
   [NRF 2013M3A9B2076480, NRF 2013037491]
FX This work was supported by Namseoul University and by National Research
   Foundation of Korea (NRF 2013M3A9B2076480 and NRF 2013037491).
CR Aonuma H, 2012, CELL TISSUE RES, V350, P317, DOI 10.1007/s00441 012 1477 6
   Bai YD, 2010, CELL TISSUE RES, V342, P221, DOI 10.1007/s00441 010 1046 9
   Batouli S, 2003, J DENT RES, V82, P976, DOI 10.1177/154405910308201208
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Cantinieaux D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069515
   Cate ART, 1997, PERIODONTOL 2000, V13, P9, DOI 10.1111/j.1600 0757.1997.tb00093.x
   Choung HW, 2013, J MOL HISTOL, V44, P715, DOI 10.1007/s10735 013 9513 8
   Darby I, 2011, AUST DENT J, V56, P107, DOI 10.1111/j.1834 7819.2010.01301.x
   Dowling P, 2011, PROTEOMICS, V11, P794, DOI 10.1002/pmic.201000530
   Felthaus O, 2014, CELL TISSUE RES, V357, P695, DOI 10.1007/s00441 014 1891 z
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hakki SS, 2001, J PERIODONTOL, V72, P679, DOI 10.1902/jop.2001.72.5.679
   Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600 051X.1997.tb00247.x
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Inukai T, 2013, BIOCHEM BIOPH RES CO, V430, P763, DOI 10.1016/j.bbrc.2012.11.074
   Jung HS, 2011, J MOL HISTOL, V42, P227, DOI 10.1007/s10735 011 9327 5
   Kawai S, 2007, J BONE MINER RES, V22, P1362, DOI 10.1359/JBMR.070602
   Kémoun P, 2007, CELL TISSUE RES, V329, P283, DOI 10.1007/s00441 007 0397 3
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Kruzynska Frejtag A, 2004, DEV DYNAM, V229, P857, DOI 10.1002/dvdy.10453
   Lan Y, 2004, DEVELOPMENT, V131, P3207, DOI 10.1242/dev.01175
   Li LF, 2013, BIOMATERIALS, V34, P78, DOI 10.1016/j.biomaterials.2012.09.042
   Lim JM, 2011, ANN NY ACAD SCI, V1229, P89, DOI 10.1111/j.1749 6632.2011.06093.x
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Morsczeck C, 2005, MATRIX BIOL, V24, P155, DOI 10.1016/j.matbio.2004.12.004
   Morsczeck C, 2008, CLIN ORAL INVEST, V12, P113, DOI 10.1007/s00784 007 0170 8
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Osugi M, 2012, TISSUE ENG PT A, V18, P1479, DOI [10.1089/ten.tea.2011.0325, 10.1089/ten.TEA.2011.0325]
   Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Ratka Krüger P, 2000, J CLIN PERIODONTOL, V27, P120, DOI 10.1034/j.1600 051x.2000.027002120.x
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Snead ML, 2008, J DENT EDUC, V72, P903
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Takahashi K, 2013, ARCH ORAL BIOL, V58, P690, DOI 10.1016/j.archoralbio.2012.10.018
   Takeda T, 2008, J DENT RES, V87, P676, DOI 10.1177/154405910808700716
   Tziafas D, 2010, J ENDODONT, V36, P781, DOI 10.1016/j.joen.2010.02.006
   Villar Cristina C, 2010, Dent Clin North Am, V54, P73, DOI 10.1016/j.cden.2009.08.011
   Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955 0674(02)00375 7
   Wu J, 2008, BIOL CELL, V100, P291, DOI 10.1042/BC20070092
   Xu T, 2014, J MOL HISTOL, V45, P11, DOI 10.1007/s10735 013 9533 4
   YAMAMURA T, 1985, J DENT RES, V64, P530, DOI 10.1177/002203458506400406
   Yang YL, 2014, BONE, V63, P158, DOI 10.1016/j.bone.2014.03.006
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318
   Zhang ZY, 2009, SCIENCE, V323, P1232, DOI 10.1126/science.1167418
   Zhang ZY, 2003, MECH DEVELOP, V120, P1469, DOI 10.1016/j.mod.2003.09.002
   Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 53
TC 13
Z9 13
U1 1
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567 2379
EI 1567 2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD FEB
PY 2015
VL 46
IS 1
BP 93
EP 106
DI 10.1007/s10735 014 9604 1
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AZ7WI
UT WOS:000348425400009
PM 25520056
DA 2025 08 17
ER

PT J
AU Jing, Y
   Zhou, J
   Guo, FH
   Yu, L
   Ren, XM
   Yin, XS
AF Jing, Yue
   Zhou, Jian
   Guo, Fenghua
   Yu, Lin
   Ren, Xiaomeng
   Yin, Xiushan
TI Betaine regulates adipogenic and osteogenic differentiation of hAD MSCs
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Betaine; hAD MSCs; RNA seq; Osteogenic differentiation; Adipogenic
   differentiation
ID MESENCHYMAL STEM CELLS; ELEVATED S ADENOSYLHOMOCYSTEINE; MARROW STROMAL
   CELLS; UP REGULATION; OSTEOBLAST; OBESITY; ROLES; PDE3B
AB BackgroundWith an ageing population, the incidence of bone loss and obesity are increasing. Numerous studies emphasized the multidirectional differentiation ability of mesenchymal stem cells (MSCs), and reported betaine modulated the osteogenic differentiation and adipogenic differentiation of MSCs in vitro. We wondered how betaine affected the differentiation of hAD MSCs and hUC MSCs.Methods and resultsALP staining and alizarin red S (ARS) staining were proved 10 mM betaine significantly increased the number of ALP positive cells and plaque calcified extracellular matrices, accompanying by the up regulation of OPN, Runx 2 and OCN. Oil red O staining demonstrated the number and size of lipid droplets were reduced, the expression of adipogenic master genes such as PPAR gamma, CEBP alpha and FASN were down regulated simultaneously. For further investigating the mechanism of betaine on hAD MSCs, RNA seq was performed in none differentiation medium. The Gene Ontology (GO) analysis showed fat cell differentiation and bone mineralization function terms were enriched, and KEGG showed PI3K Akt signaling pathway, cytokine cytokine receptor interaction and ECM receptor interaction pathways were enriched in betaine treated hAD MSCs, demonstrated betaine had a positive inducing effect on osteogenic of hAD MSCs in the non differentiation medium in vitro, which is opposite to the effect on adipogenic differentiation.ConclusionsOur study demonstrated that betaine promoted osteogenic and compromised adipogenic differentiation of hUC MSCs and hAD MSCs upon low concentration administration. PI3K Akt signaling pathway, cytokine cytokine receptor interaction and ECM receptor interaction were significantly enriched under betaine treated. We showed hAD MSCs were more sensitive to betaine stimulation and have a better differentiation ability than hUC MSCs. Our results contributed to the exploration of betaine as an aiding agent for MSCs therapy.
C1 [Jing, Yue; Yu, Lin; Ren, Xiaomeng; Yin, Xiushan] Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Appl Biol Lab, Shenyang, Liaoning, Peoples R China.
   [Zhou, Jian] Gannan Med Univ, Coll Pharmaceut Sci, Ganzhou, Jiangxi, Peoples R China.
   [Guo, Fenghua] Jiangsu Pulu Rui Med Technol Co Ltd, Xuzhou, Jiangsu, Peoples R China.
C3 Shenyang University of Chemical Technology; Gannan Medical University
RP Yin, XS (通讯作者)，Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Appl Biol Lab, Shenyang, Liaoning, Peoples R China.
EM 1798998684@qq.com; 3466640853@qq.com; guofenghua0822@gmail.com;
   50412194@qq.com; renxm@syuct.edu.cn; xiushanyin@me.com
FU Liaoning Revitalization Talents Program [XLYC2002027]; Department of
   Education of Liaoning Province [LQ2020022]
FX This work was supported by Liaoning Revitalization Talents Program
   (XLYC2002027), Programs from the Department of Education of Liaoning
   Province (LQ2020022). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Alshammari GM, 2019, SAUDI J BIOL SCI, V26, P744, DOI 10.1016/j.sjbs.2018.10.002
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301 472X(00)00160 0
   Barak AJ, 2003, J NUTR, V133, P2845, DOI 10.1093/jn/133.9.2845
   Biver E, 2012, BIOCHEM BIOPH RES CO, V427, P737, DOI 10.1016/j.bbrc.2012.09.129
   Carow B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00058
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Chi Ying, 2014, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V22, P588, DOI 10.7534/j.issn.1009 2137.2014.03.003
   DiPilato LM, 2015, MOL CELL BIOL, V35, P2752, DOI 10.1128/MCB.00422 15
   Furukawa S., 2004, Journal of Clinical Investigation, V114, P1752, DOI 10.1172/JCI21625
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Higuchi M, 2013, STEM CELLS DEV, V22, P878, DOI 10.1089/scd.2012.0306
   Hoshiba T, 2012, BIOMATERIALS, V33, P2025, DOI 10.1016/j.biomaterials.2011.11.061
   Jaber H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85917 9
   Joselit Y, 2018, NUTR DIABETES, V8, DOI 10.1038/s41387 018 0035 z
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kharbanda KK, 2005, BIOCHEM PHARMACOL, V70, P1883, DOI 10.1016/j.bcp.2005.09.021
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   Kornsuthisopon C, 2022, BDJ OPEN, V8, DOI 10.1038/s41405 022 00123 7
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Li LR, 2016, SCI REP UK, V6, DOI 10.1038/srep37894
   Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395
   Matas J, 2019, STEM CELL TRANSL MED, V8, P215, DOI 10.1002/sctm.18 0053
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Page McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Schäffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006 0589
   Shaik S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48089 1
   Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581 018 0023 5
   Szkudelska K, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.112946
   Takeuchi S, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00132 4
   Villa I, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1233 5
   Yang QH, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109486
   Yi X, 2019, J CELL PHYSIOL, V234, P20217, DOI 10.1002/jcp.28621
   Yu WH, 2008, MOL CELL BIOCHEM, V310, P11, DOI 10.1007/s11010 007 9661 9
   Zhang C, 2022, GENOM PROTEOM BIOINF, V20, P70, DOI 10.1016/j.gpb.2022.01.005
   Zmuda Trzebiatowska E, 2006, CELL SIGNAL, V18, P382, DOI 10.1016/j.cellsig.2005.05.007
NR 40
TC 9
Z9 9
U1 4
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUN
PY 2023
VL 50
IS 6
BP 5081
EP 5089
DI 10.1007/s11033 023 08404 6
EA APR 2023
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA Q8CB3
UT WOS:000979778900002
PM 37101008
DA 2025 08 17
ER

PT J
AU Tsoumpra, MK
   Muniz, JR
   Barnett, BL
   Kwaasi, AA
   Pilka, ES
   Kavanagh, KL
   Evdokimov, A
   Walter, RL
   Von Delft, F
   Ebetino, FH
   Oppermann, U
   Russell, RGG
   Dunford, JE
AF Tsoumpra, Maria K.
   Muniz, Joao R.
   Barnett, Bobby L.
   Kwaasi, Aaron A.
   Pilka, Ewa S.
   Kavanagh, Kathryn L.
   Evdokimov, Artem
   Walter, Richard L.
   Von Delft, Frank
   Ebetino, Frank H.
   Oppermann, Udo
   Russell, R. Graham G.
   Dunford, James E.
TI The inhibition of human farnesyl pyrophosphate synthase by
   nitrogen containing bisphosphonates. Elucidating the role of active site
   threonine 201 and tyrosine 204 residues using enzyme mutants
SO BONE
LA English
DT Article
DE Bisphosphonate; Farnesyl pyrophosphate synthase; Inhibition mechanism;
   Drug binding; Substrate binding; Active site mutant
ID TRYPANOSOMA CRUZI HEXOKINASE; IN VIVO; ISOPRENOID BIOSYNTHESIS;
   DIPHOSPHATE SYNTHASE; STRUCTURAL BASIS; BONE RESORPTION; MECHANISM;
   ANALOGS; DRUGS; VITRO
AB Farnesyl pyrophosphate synthase (FPPS) is the major molecular target of nitrogen containing bisphosphonates (N Bps), used clinically as bone resorption inhibitors. We investigated the role of threonine 201 (Thr201) and tyrosine 204 (Tyr204) residues in substrate binding, catalysis and inhibition by N BPs, employing kinetic and crystallographic studies of mutated FPPS proteins.
   Mutants of Thr201 illustrated the importance of the methyl group in aiding the formation of the Isopentenyl pyrophosphate (IPP) binding site, while Tyr204 mutations revealed the unknown role of this residue in both catalysis and IPP binding. The interaction between Thr201 and the side chain nitrogen of N BP was shown to be important for tight binding inhibition by zoledronate (ZOL) and risedronate (RIS), although RIS was also still capable of interacting with the main chain carbonyl of Lys200. The interaction of RIS with the phenyl ring of Tyr204 proved essential for the maintenance of the isomerized enzyme inhibitor complex. Studies with conformationally restricted analogues of RIS reaffirmed the importance of Thr201 in the formation of hydrogen bonds with N BPs.
   In conclusion we have identified new features of FPPS inhibition by N Bps and revealed unknown roles of the active site residues in catalysis and substrate binding. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Tsoumpra, Maria K.; Kwaasi, Aaron A.; Oppermann, Udo; Russell, R. Graham G.; Dunford, James E.] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.
   [Tsoumpra, Maria K.; Muniz, Joao R.; Pilka, Ewa S.; Kavanagh, Kathryn L.; Von Delft, Frank; Ebetino, Frank H.; Oppermann, Udo; Dunford, James E.] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England.
   [Barnett, Bobby L.] Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA.
   [Ebetino, Frank H.] Univ Rochester, Dept Chem, Rochester, NY 14627 USA.
   [Russell, R. Graham G.] Univ Sheffield, Mellanby Ctr Bone Res, Sch Med, Sheffield S10 2RX, S Yorkshire, England.
   [Evdokimov, Artem] Monsanto Co, St Louis, MO USA.
   [Walter, Richard L.] Shamrock Struct, Woodridge, IL USA.
   [Muniz, Joao R.] Univ Sao Paulo, Inst Fis Sao Carlos, Sao Carlos, SP, Brazil.
C3 University of Oxford; University of Oxford; University System of Ohio;
   University of Cincinnati; University of Rochester; University of
   Sheffield; Monsanto; Universidade de Sao Paulo
RP Dunford, JE (通讯作者)，Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.
EM james.dunford@ndorms.ox.ac.uk
RI ; Russell, R/JEF 5877 2023; Russell, Robert Graham G/JEF 5877 2023;
   Muniz, Joao/B 7782 2016
OI Dunford, James/0000 0002 9932 4042; von Delft,
   Frank/0000 0003 0378 0017; Russell, Robert Graham G/0000 0002 4136 1828;
   Muniz, Joao/0000 0003 2731 3966
FU Oxford NIHR Biomedical Research Unit; Arthritis Research UK [20522];
   Rosetrees Trust; Medical Research Council; BBSRC; Abbvie; Bayer
   Healthcare; Boehringer Ingelheim; Canadian Institutes for Health
   Research; Canadian Foundation for Innovation; Eli Lilly and Company;
   Genome Canada; GlaxoSmithKline; Ontario Ministry of Economic Development
   and Innovation; Janssen; Novartis Research Foundation; Pfizer; Takeda;
   Wellcome Trust [092809/Z/10/Z]; Alliance for better Bone Health; Procter
   AMP; Gamble Pharmaceuticals; Sanofi Aventis; MRC [MC_PC_12020] Funding
   Source: UKRI; Medical Research Council [MC_PC_12020] Funding Source:
   researchfish; Rosetrees [M289 F1, M289] Funding Source: researchfish;
   Versus Arthritis [20522] Funding Source: researchfish
FX Research was supported through funding from the Oxford NIHR Biomedical
   Research Unit, Arthritis Research UK (program grant 20522), the
   Rosetrees Trust, Medical Research Council and BBSRC. The Structural
   Genomics Consortium is a registered charity (number 1097737) that
   receives funds from Abbvie, Bayer Healthcare, Boehringer Ingelheim, the
   Canadian Institutes for Health Research, the Canadian Foundation for
   Innovation, Eli Lilly and Company, Genome Canada, GlaxoSmithKline, the
   Ontario Ministry of Economic Development and Innovation, Janssen, the
   Novartis Research Foundation, Pfizer, Takeda, and the Wellcome Trust
   [092809/Z/10/Z]. We thank the Alliance for better Bone Health (Procter &
   Gamble Pharmaceuticals and Sanofi Aventis) for financial support of this
   work through an unrestricted educational grant.
CR Artz JD, 2011, J BIOL CHEM, V286, P3315, DOI 10.1074/jbc.M109.027235
   BROCKLEHURST K, 1994, PROTEIN ENG, V7, P291, DOI 10.1093/protein/7.3.291
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Hounslow AM, 2008, J MED CHEM, V51, P4170, DOI 10.1021/jm7015792
   Hudock MP, 2006, J MED CHEM, V49, P215, DOI 10.1021/jm0582625
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Sanchez VM, 2006, J PHYS CHEM B, V110, P18052, DOI 10.1021/jp063099q
   POULTER CD, 1976, BIOCHEMISTRY US, V15, P1079, DOI 10.1021/bi00650a019
   POULTER CD, 1978, J BIOL CHEM, V253, P7227
   Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sanz Rodríguez CE, 2007, J BIOL CHEM, V282, P12377, DOI 10.1074/jbc.M607286200
   Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786
   Williams J W, 1979, Methods Enzymol, V63, P437
   Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929 931.2002
   ZOGRAPHOS SE, 1995, BIOCHEM J, V310, P565, DOI 10.1042/bj3100565
NR 38
TC 44
Z9 51
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2015
VL 81
BP 478
EP 486
DI 10.1016/j.bone.2015.08.020
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CX0FR
UT WOS:000365372800058
PM 26318908
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lu, Q
   Jiang, C
   Hou, JL
   Qian, H
   Chu, FF
   Zhang, WQ
   Ye, MK
   Chen, ZY
   Liu, J
   Yao, HB
   Zhang, JF
   Xu, JK
   Wang, T
   Fan, SW
   Wang, QQ
AF Lu, Qian
   Jiang, Chao
   Hou, Jialong
   Qian, Hao
   Chu, Feifan
   Zhang, Weiqi
   Ye, Mengke
   Chen, Ziyi
   Liu, Jian
   Yao, Hanbing
   Zhang, Jianfeng
   Xu, Jiake
   Wang, Te
   Fan, Shunwu
   Wang, Qingqing
TI Patchouli Alcohol Modulates the Pregnancy X Receptor/Toll like Receptor
   4/Nuclear Factor Kappa B Axis to Suppress Osteoclastogenesis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE PXR; patchouli alcohol; receptor activator for nuclear factor kappa B
   ligand; osteoclast; osteoporosis; nuclear factor kappa B
ID INDUCED BONE LOSS; ACTIVATION; OSTEOPOROSIS; EXPRESSION;
   LIPOPOLYSACCHARIDE; INFLAMMATION; CLONING; MODEL
AB The incidence of osteoporosis, which is primarily characterized by plethoric osteoclast (OC) formation and severe bone loss, has increased in recent years. Millions of people worldwide, especially postmenopausal women, suffer from osteoporosis. The drugs commonly used to treat osteoporosis still exist many disadvantages, but natural extracts provide options for the treatment of osteoporosis. Therefore, the identification of cost effective natural compounds is important. Patchouli alcohol (PA), a natural compound extracted from Pogostemon cablin that exerts anti inflammatory effects, is used as a treatment for gastroenteritis. However, no research on the use of Patchouli alcohol in osteoporosis has been reported. We found that PA dose dependently inhibited the receptor activator of nuclear factor kappa B ligand (RANKL) induced formation and function of OCs without cytotoxicity. Furthermore, these inhibitory effects were reflected in the significant effect of PA on the NF kappa B signaling pathway, as PA suppressed the transcription factors NFATc1 and c Fos. We also determined that PA activated expression of the nuclear receptor pregnane X receptor (PXR) and promoted the PXR/Toll like receptor 4 (TLR4) axis to inhibit the nuclear import of NF kappa B (p50 and p65). Additionally, PA exerted therapeutic effects against osteoporosis in ovariectomized (OVX) mice, supporting the use of PA as a treatment for osteoporosis in the future.
C1 [Lu, Qian; Jiang, Chao; Zhang, Jianfeng; Xu, Jiake; Wang, Te; Fan, Shunwu; Wang, Qingqing] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China.
   [Hou, Jialong; Qian, Hao; Chu, Feifan; Zhang, Weiqi; Ye, Mengke; Chen, Ziyi; Liu, Jian; Yao, Hanbing; Wang, Te] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Lu, Qian] Huzhou Cent Hosp, Dept Orthopaed, Huzhou, Peoples R China.
C3 Zhejiang University; Wenzhou Medical University; University of Western
   Australia; Huzhou University
RP Wang, T; Fan, SW; Wang, QQ (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China.; Wang, T (通讯作者)，Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China.
EM 289726269@qq.com; 0099203@zju.edu.cn; wangqingqing@zju.edu.cn
RI Wang, Qingqing/E 7972 2014; lu, qian/IUN 7445 2023; Chen,
   Ziyi/CAH 5334 2022
OI Xu, Jiake/0000 0003 2021 8309; 
FU Natural Science Foundation of the Zhejiang Province of China
   [LQ21H060009]; Medical Health Science and Technology Project of the
   Zhejiang Provincial Health Commission [2021436226]; Public Projects of
   Zhejiang Province [LGF19H060013]
FX This study was supported by grants from the Natural Science Foundation
   of the Zhejiang Province of China (LQ21H060009), the Medical Health
   Science and Technology Project of the Zhejiang Provincial Health
   Commission (2021436226) and the Public Projects of Zhejiang Province
   (LGF19H060013).
CR Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Bagamasbad P, 2011, GEN COMP ENDOCR, V170, P3, DOI 10.1016/j.ygcen.2010.03.013
   Bailey I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016703
   Chai SC, 2020, MED RES REV, V40, P1061, DOI 10.1002/med.21648
   Chen F, 2006, CELL DEATH DIFFER, V13, P1835, DOI 10.1038/sj.cdd.4402014
   Deng SQ, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.7636
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   GALLAGHER JC, 1990, BONE MINER, V9, P215, DOI 10.1016/0169 6009(90)90039 I
   Guo JC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00693
   He LG, 2016, EUR J PHARMACOL, V779, P66, DOI 10.1016/j.ejphar.2016.03.014
   Huang KZ, 2018, PEDIATR RES, V83, P1031, DOI 10.1038/pr.2018.14
   Jeong JB, 2013, FOOD CHEM TOXICOL, V55, P229, DOI 10.1016/j.fct.2012.12.062
   Chen JR, 2021, CHIN MED UK, V16, DOI 10.1186/s13020 020 00413 y
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092 8674(02)00827 9
   LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706
   Lawrence Toby, 2009, Cold Spring Harb Perspect Biol, V1, pa001651, DOI 10.1101/cshperspect.a001651
   Leong W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01229
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Li YL, 2019, METALLOMICS, V11, P936, DOI 10.1039/c8mt00361k
   Lian DW, 2019, PHYTOMEDICINE, V65, DOI 10.1016/j.phymed.2019.153097
   Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu C, 2020, CURR STEM CELL RES T, V15, P579, DOI 10.2174/1574888X14666191107103755
   Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704
   Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev biophys 083012 130338
   Okamura M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9102296
   Oladimeji Peter O, 2018, Mol Pharmacol, V93, P119, DOI 10.1124/mol.117.110155
   Qiu ZJ, 2016, SCI REP UK, V6, DOI 10.1038/srep31936
   Roberts BC, 2019, BONE, V127, P260, DOI 10.1016/j.bone.2019.06.024
   Sato N, 2004, J EXP MED, V200, P601, DOI 10.1084/jem.20040689
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shao YY, 2021, INFLAMMATION, V44, P645, DOI 10.1007/s10753 020 01364 0
   Smutny T, 2021, ARCH TOXICOL, V95, P11, DOI 10.1007/s00204 020 02916 x
   Smutny T, 2020, ACTA PHARMACOL SIN B, V10, P136, DOI 10.1016/j.apsb.2019.09.010
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Ve T, 2017, NAT STRUCT MOL BIOL, V24, P743, DOI 10.1038/nsmb.3444
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827
   Xu FF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169578
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Xu YF, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00122 17, 10.1128/aac.00122 17]
   Zhang GH, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112302
   Zhao YG, 2020, ACTA PHARMACOL SIN B, V10, P1966, DOI 10.1016/j.apsb.2020.07.019
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhou TR, 2018, WORLD J GASTROENTERO, V24, P693, DOI 10.3748/wjg.v24.i6.693
   Zhou XQ, 2016, SCI REP UK, V6, DOI 10.1038/srep27876
NR 54
TC 8
Z9 9
U1 0
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 8
PY 2021
VL 12
AR 684976
DI 10.3389/fphar.2021.684976
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SY4ER
UT WOS:000665843500001
PM 34177594
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bergholt, NL
   Demirel, A
   Pedersen, M
   Ding, M
   Kragstrup, TW
   Andersen, T
   Deleuran, BW
   Foldager, CB
AF Bergholt, Natasja Leth
   Demirel, Ari
   Pedersen, Michael
   Ding, Ming
   Kragstrup, Tue Wenzel
   Andersen, Thomas
   Deleuran, Bent Winding
   Foldager, Casper Bindzus
TI Intermittent Hypoxic Therapy Inhibits Allogenic Bone Graft Resorption by
   Inhibition of Osteoclastogenesis in a Mouse Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE intermittent hypoxic therapy; bone; spine
ID TGF BETA; CELLS; DIFFERENTIATION; ACTIVATION; EXPRESSION; BINDING;
   MECHANISMS; BETAGLYCAN; INDUCTION; OUTCOMES
AB Systemic Intermittent Hypoxic Therapy (IHT) relies on the adaptive response to hypoxic stress. We investigated allogenic bone graft resorption in the lumbar spine in 48 mice. The mice were exposed to IHT for 1 week before surgery or 1 week after surgery and compared with controls after 1 and 4 weeks. Complete graft resorption was observed in 33 36% of the animals in the control group, but none in the preoperative IHT group. Increased bone graft volume was demonstrated by micro computed tomography in the preoperative IHT group after 1 week (p = 0.03) while a non significant difference was observed after 4 weeks (p = 0.12). There were no significant differences in the postoperative IHT group. Increased concentration of immune cells was localized in the graft area, and more positive tartrate resistant acid phosphatase (TRAP) staining was found in controls compared with IHT allogenic bone grafts. Systemic IHT resulted in a significant increase of the major osteoclast inhibitor osteoprotegerin as well as osteogenic and angiogenic regulators Tgfbr3, Fst3l, Wisp1, and Vegfd. Inflammatory cytokines and receptor activator of nuclear factor kappa B ligand (RANKL) stimulators IL 6, IL 17a, IL 17f, and IL 23r increased after 1 and 4 weeks, and serum RANKL expression remained constant while Ccl3 and Ccl5 decreased. We conclude that the adaptive response to IHT activates numerous pathways leading to inhibition of osteoclastic activity and inhibition of allogenic bone graft resorption.
C1 [Bergholt, Natasja Leth; Demirel, Ari; Foldager, Casper Bindzus] Aarhus Univ Hosp, Orthopaed Res Lab, DK 8200 Aarhus, Denmark.
   [Pedersen, Michael; Foldager, Casper Bindzus] Aarhus Univ, Comparat Med Lab, DK 8200 Aarhus, Denmark.
   [Ding, Ming] Odense Univ Hosp, Dept Orthopaed Surg & Traumatol, DK 5000 Odense, Denmark.
   [Ding, Ming] Univ Southern Denmark, DK 5000 Odense, Denmark.
   [Kragstrup, Tue Wenzel; Andersen, Thomas; Deleuran, Bent Winding] Aarhus Univ, Dept Biomed, DK 8000 Aarhus, Denmark.
   [Kragstrup, Tue Wenzel] Aarhus Univ Hosp, Dept Rheumatol, DK 8200 Aarhus, Denmark.
C3 Aarhus University; Aarhus University; University of Southern Denmark;
   Odense University Hospital; University of Southern Denmark; Aarhus
   University; Aarhus University
RP Foldager, CB (通讯作者)，Aarhus Univ Hosp, Orthopaed Res Lab, DK 8200 Aarhus, Denmark.; Foldager, CB (通讯作者)，Aarhus Univ, Comparat Med Lab, DK 8200 Aarhus, Denmark.
EM natasja.leth@gmail.com; ari.demirel@hotmail.com; michael@clin.au.dk;
   Ming.Ding@rsyd.dk; thomas.andersen@midt.rm.dk;
   thomas.andersen@midt.rm.dk; bd@biomed.au.dk; foldager@clin.au.dk
OI Deleuran, Bent/0000 0002 7079 1587; Kragstrup, Tue
   Wenzel/0000 0002 6439 397X; Pedersen, Michael/0000 0002 1146 0382; Ding,
   Ming/0000 0002 6610 8079
CR Bergholt NL, 2019, HIGH ALT MED BIOL, V20, P221, DOI 10.1089/ham.2018.0113
   Blakytny R, 2004, J CELL PHYSIOL, V199, P67, DOI 10.1002/jcp.10454
   Braun J, 2017, ANN RHEUM DIS, V76, P1070, DOI 10.1136/annrheumdis 2016 209730
   Cahill E, 2012, EXP PHYSIOL, V97, P796, DOI 10.1113/expphysiol.2012.065474
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Croes M, 2016, BONE, V84, P262, DOI 10.1016/j.bone.2016.01.010
   DALLAS SL, 1994, J BIOL CHEM, V269, P6815
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727
   Ding M, 2010, ACTA ORTHOP, V81, P5, DOI 10.3109/17453671003619037
   Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295
   Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Fu R, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935 014 0132 6
   Fuhrmann DC, 2017, REDOX BIOL, V12, P208, DOI 10.1016/j.redox.2017.02.012
   Good SR, 2009, J IMMUNOL, V183, P3839, DOI 10.4049/jimmunol.0901411
   Ha KY, 2009, SPINE, V34, P1663, DOI 10.1097/BRS.0b013e3181aacab5
   Hill CR, 2015, DEV DYNAM, V244, P122, DOI 10.1002/dvdy.24225
   Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097 2765(01)00332 X
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Jakobsen T, 2007, CLIN ORTHOP RELAT R, P195, DOI 10.1097/BLO.0b013e31813c6696
   Jespersen AB, 2019, SPINE, V44, P157, DOI 10.1097/BRS.0000000000002791
   Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092 8674(91)90073 8
   LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557
   LORENZ M, 1991, SPINE, V16, pS455, DOI 10.1097/00007632 199108001 00029
   Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424
   Maeda A, 2015, J BIOL CHEM, V290, P14004, DOI 10.1074/jbc.M114.628818
   Michiels C, 2004, AM J PATHOL, V164, P1875, DOI 10.1016/S0002 9440(10)63747 9
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Nam J, 2015, BONE, V78, P62, DOI 10.1016/j.bone.2015.04.038
   Navarrete Opazo A, 2014, AM J PHYSIOL REG I, V307, pR1181, DOI 10.1152/ajpregu.00208.2014
   Orlandini M, 2006, J BIOL CHEM, V281, P17961, DOI 10.1074/jbc.M600413200
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00425
   Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720
   Rifas L, 2006, J CELL BIOCHEM, V98, P706, DOI 10.1002/jcb.20933
   Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354
   Stray Gundersen J, 2001, J APPL PHYSIOL, V91, P1113, DOI 10.1152/jappl.2001.91.3.1113
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Worthington JJ, 2012, IMMUNOBIOLOGY, V217, P1259, DOI 10.1016/j.imbio.2012.06.009
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P9, DOI 10.1159/000351895
   Xiong DH, 2009, AM J HUM GENET, V84, P388, DOI 10.1016/j.ajhg.2009.01.025
   Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
NR 48
TC 4
Z9 4
U1 0
U2 4
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2022
VL 23
IS 1
AR 323
DI 10.3390/ijms23010323
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YT1GS
UT WOS:000751116600001
PM 35008749
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dmitrzak Weglarz, M
   Szczepankiewicz, A
   Rybakowski, J
   Kapelski, P
   Bilska, K
   Skibinska, M
   Reszka, E
   Lesicka, M
   Jablonska, E
   Wieczorek, E
   Bukowska Olech, E
   Pawlak, J
AF Dmitrzak Weglarz, Monika
   Szczepankiewicz, Aleksandra
   Rybakowski, Janusz
   Kapelski, Pawel
   Bilska, Karolina
   Skibinska, Maria
   Reszka, Edyta
   Lesicka, Monika
   Jablonska, Ewa
   Wieczorek, Edyta
   Bukowska Olech, Ewelina
   Pawlak, Joanna
TI Transcriptomic profiling as biological markers of depression   A pilot
   study in unipolar and bipolar women
SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Transcriptomic profiles; ontology and pathway analysis; depression
   episode; unipolar disorder; bipolar disorder
ID GENE EXPRESSION; LIPID PROFILE; DISORDER; NEUROTROPHINS; RELIABILITY;
   OXYTOCIN; ILLNESS
AB Objectives A significant challenge in psychiatry is the differential diagnosis of depressive episodes in the course of mood disorders. Gene expression profiling may provide an opportunity for such distinguishment.
   Methods We studied differentially expressed genes in women with a depressive episode in the course of unipolar depression (UD) (n=24) and bipolar disorder types I (BDI) (n=13) and II (BDII) (n=19), and healthy controls (n=15).
   Results Different types of depression varied in the number and type of up or down regulated genes. The pathway analysis showed: in UD, up regulated rheumatoid arthritis pathway (including ITGB2, CXCL8, TEK, TLR4 genes), and down regulated taste transduction pathway (TAS2R10, TAS2R46, TAS2R14, TAS2R43, TAS2R45, TAS2R19, TAS2R13, TAS2R20, GNG13); in BDI, eight down regulated pathways: glutamatergic synapse, retrograde endocannabinoid signalling, axon guidance, calcium signalling, nicotine addiction, PI3K Akt signalling, drug metabolism   cytochrome P450, and morphine addiction; in BDII, up regulated osteoclast differentiation and Notch signalling pathway, and down regulated type I diabetes mellitus pathway. Distinct expression markers analysis uncovered the unique for UD, up regulated bladder cancer pathway (HBEGF and CXCL8 genes).
   Conclusions This pilot study suggests a probability of differentiating depression in the course of UD, BDI, and II, based on transcriptomic profiling.
C1 [Dmitrzak Weglarz, Monika; Kapelski, Pawel; Bilska, Karolina; Skibinska, Maria; Pawlak, Joanna] Poznan Univ Med Sci, Dept Psychiat Genet, Poznan, Poland.
   [Szczepankiewicz, Aleksandra] Poznan Univ Med Sci, Dept Pediat Pulmonol, Lab Mol & Cell Biol, Allergy & Clin Immunol, Poznan, Poland.
   [Rybakowski, Janusz] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland.
   [Reszka, Edyta; Lesicka, Monika; Jablonska, Ewa; Wieczorek, Edyta] Nofer Inst Occupat Med, Dept Mol Genet & Epigenet, Lodz, Poland.
   [Bukowska Olech, Ewelina] Poznan Univ Med Sci, Dept Med Genet, Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences; Poznan University of Medical Sciences; Nofer Institute of
   Occupational Medicine; Poznan University of Medical Sciences
RP Dmitrzak Weglarz, M (通讯作者)，Poznan Univ Med Sci, Dept Psychiat Genet, Poznan, Poland.
EM mweglarz@ump.edu.pl
RI ; Reszka, Edyta/F 6008 2010; Lesicka, Monika/G 7673 2015;
   Dmitrzak Weglarz, Monika/C 6674 2011; Bukowska Olech,
   Ewelina/H 7693 2017; Jablonska, Ewa/F 6005 2010; Kasperczyk,
   Edyta/F 7057 2010; Skibinska, Maria/C 5989 2011
OI Skibinska, Maria/0000 0002 5634 1061; Reszka, Edyta/0000 0003 2153 4864;
   Rybakowski, Janusz/0000 0003 0577 0381; Lesicka,
   Monika/0000 0003 2095 8681; Bilska, Karolina/0000 0001 6777 5829;
   Jablonska, Ewa/0000 0002 3946 3964; Kasperczyk,
   Edyta/0000 0002 4390 2042; Kapelski, Pawel/0000 0002 7766 4986;
   Dmitrzak Weglarz, Monika/0000 0002 0493 8325; Bukowska Olech,
   Ewelina/0000 0003 0509 1696
FU National Science Centre, Poland [2016/23/B/NZ5/02634]
FX This work was supported by the National Science Centre, Poland under
   Grant 2016/23/B/NZ5/02634.
CR al Haddad BJS, 2019, AM J OBSTET GYNECOL, V221, P549, DOI 10.1016/j.ajog.2019.06.013
   [Anonymous], 2019, Hogrefe
   Bachmanov AA, 2014, CURR PHARM DESIGN, V20, P2669, DOI 10.2174/13816128113199990566
   Bagot RC, 2016, NEURON, V90, P969, DOI 10.1016/j.neuron.2016.04.015
   Bartkiene E, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2097415
   Bruce Travis O, 2008, Curr Psychiatry Rep, V10, P258, DOI 10.1007/s11920 008 0042 1
   Capuzzi E, 2018, PSYCHIAT RES, V270, P611, DOI 10.1016/j.psychres.2018.10.050
   Cheng C, 2007, BIOINFORMATION, V1, P436, DOI 10.6026/97320630001436
   Cichon S, 2009, AM J PSYCHIAT, V166, P540, DOI 10.1176/appi.ajp.2008.08091354
   Coclami T., 2011, Eastern Mediterranean Health Journal, V17, P777
   Cossart P, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016972
   Dalman MR, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 S2 S11
   Dmitrzak Weglarz MP, 2015, MOL BIOL REP, V42, P277, DOI 10.1007/s11033 014 3770 9
   Eyre HA, 2016, PROG NEURO PSYCHOPH, V68, P1, DOI 10.1016/j.pnpbp.2016.02.006
   Fernandes BS, 2016, LANCET PSYCHIAT, V3, P1147, DOI 10.1016/S2215 0366(16)30370 4
   Gautam A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225137
   Goldsmith DR, 2016, MOL PSYCHIATR, V21, P1696, DOI 10.1038/mp.2016.3
   Hakulinen C, 2019, DEPRESS ANXIETY, V36, P1080, DOI 10.1002/da.22956
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Henry C, 2010, CURR PSYCHIAT REP, V12, P505, DOI 10.1007/s11920 010 0156 0
   Horwitz T, 2019, MOL PSYCHIATR, V24, P378, DOI 10.1038/s41380 018 0055 z
   Hoseth EZ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23703 w
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962
   Kawasaki M, 2009, CLIN EXP RHEUMATOL, V27, P260
   Kessing LV, 2004, J PSYCHIATR RES, V38, P395, DOI 10.1016/j.jpsychires.2003.12.001
   King S, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00066
   Kirsch P, 2015, DIALOGUES CLIN NEURO, V17, P463
   Knüppel A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05649 7
   Konttinen H, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966 019 0791 8
   Labonté B, 2017, NAT MED, V23, P1102, DOI 10.1038/nm.4386
   Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924 9338(97)83296 8
   Li XH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07928 9
   Lien YJ, 2017, PSYCHIAT RES, V258, P402, DOI 10.1016/j.psychres.2017.08.080
   Liew CC, 2006, J LAB CLIN MED, V147, P126, DOI 10.1016/j.lab.2005.10.005
   MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764
   Memon AA, 2017, PSYCHIAT RES, V254, P311, DOI 10.1016/j.psychres.2017.05.012
   Misrani Afzal, 2017, Shengli Xuebao, V69, P196, DOI 10.13294/j.aps.2016.0105
   Miyata S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150262
   Nasrallah Henry A, 2015, J Clin Psychiatry, V76, pe1328, DOI 10.4088/JCP.14016tx2c
   Pan DQ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28509 4
   Perez J, 1999, ARCH GEN PSYCHIAT, V56, P248, DOI 10.1001/archpsyc.56.3.248
   Pham H, 2019, UROL ONCOL SEMIN ORI, V37, P97, DOI 10.1016/j.urolonc.2018.12.006
   Reszka E., 2015, J CLIN RES BIOETH, V6, P218
   Rowland T, 2018, BRIT J PSYCHIAT, V213, P514, DOI 10.1192/bjp.2018.144
   Royall DR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175790
   Rui P, 2018, PSYCHIAT RES, V266, P111, DOI 10.1016/j.psychres.2018.05.059
   Rybakowski JK, 2012, EUR PSYCHIAT, V27, P577, DOI 10.1016/j.eurpsy.2010.12.001
   Rybakowski JK, 2007, PSYCHOPATHOLOGY, V40, P153, DOI 10.1159/000100004
   Rybakowski JK, 2018, BIPOLAR DISORD, V20, P391, DOI 10.1111/bdi.12608
   Rybakowski JK, 2012, J AFFECT DISORDERS, V136, pE13, DOI 10.1016/j.jad.2011.05.005
   Sagar R, 2017, INDIAN J MED RES, V145, P7, DOI 10.4103/ijmr.IJMR_1386_16
   Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471 2199 7 3
   Scola G, 2015, PROG NEURO PSYCHOPH, V56, P122, DOI 10.1016/j.pnpbp.2014.08.013
   Seney ML, 2018, BIOL PSYCHIAT, V84, P18, DOI 10.1016/j.biopsych.2018.01.017
   Vallerand IA, 2019, CURR OPIN RHEUMATOL, V31, P279, DOI 10.1097/BOR.0000000000000597
   Vartolomei L, 2020, EUR UROL FOCUS, V6, P1158, DOI 10.1016/j.euf.2019.10.008
   Vartolomei L, 2018, BLADDER CANCER, V4, P319, DOI 10.3233/BLC 180181
   Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748
   Willner P, 2019, BEHAV PHARMACOL, V30, P239, DOI 10.1097/FBP.0000000000000431
NR 60
TC 17
Z9 17
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1562 2975
EI 1814 1412
J9 WORLD J BIOL PSYCHIA
JI World J. Biol. Psychiatry
PD NOV 26
PY 2021
VL 22
IS 10
BP 744
EP 756
DI 10.1080/15622975.2021.1907715
PG 13
WC Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA XV3OR
UT WOS:000734855900001
PM 33821765
DA 2025 08 17
ER

PT J
AU Liapis, V
   Labrinidis, A
   Zinonos, I
   Hay, S
   Ponomarev, V
   Panagopoulos, V
   DeNichilo, M
   Ingman, W
   Atkins, GJ
   Findlay, DM
   Zannettino, ACW
   Evdokiou, A
AF Liapis, Vasilios
   Labrinidis, Agatha
   Zinonos, Irene
   Hay, Shelley
   Ponomarev, Vladimir
   Panagopoulos, Vasilios
   DeNichilo, Mark
   Ingman, Wendy
   Atkins, Gerald J.
   Findlay, David M.
   Zannettino, Andrew C. W.
   Evdokiou, Andreas
TI Hypoxia activated pro drug TH 302 exhibits potent tumor suppressive
   activity and cooperates with chemotherapy against osteosarcoma
SO CANCER LETTERS
LA English
DT Article
DE Hypoxia; TH 302; Osteosarcoma; Metastasis; Chemotherapy
ID PRODRUG TH 302; IN VIVO; CANCER; EXPRESSION; BONE; PHARMACOKINETICS;
   COMBINATION; MECHANISMS; METASTASES; APOPTOSIS
AB Tumor hypoxia is a major cause of treatment failure for a variety of malignancies. However, tumor hypoxia also offers treatment opportunities, exemplified by the development compounds that target hypoxic regions within tumors. TH 302 is a pro drug created by the conjugation of 2 nitroimidazole to bromoisophosphoramide (Br IPM). When TH 302 is delivered to regions of hypoxia, Br IPM, the DNA cross linking toxin, is released. In this study we assessed the cytotoxic activity of TH 302 against osteosarcoma cells in vitro and evaluated its anticancer efficacy as a single agent, and in combination with doxorubicin, in an orthotopic mouse model of human osteosarcoma (OS). In vitro, TH 302 was potently cytotoxic to osteosarcoma cells selectively under hypoxic conditions, whereas primary normal human osteoblasts were protected. Animals transplanted with OS cells directly into their tibiae and left untreated developed mixed osteolytic/osteosclerotic bone lesions and subsequently developed lung metastases. TH 302 reduced tumor burden in bone and cooperated with doxorubicin to protect bone from osteosarcoma induced bone destruction, while it also reduced lung metastases. TH 302 may therefore be an attractive therapeutic agent with strong activity as a single agent and in combination with chemotherapy against OS. Crown Copyright (c) 2014 Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Liapis, Vasilios; Labrinidis, Agatha; Zinonos, Irene; Hay, Shelley; Panagopoulos, Vasilios; DeNichilo, Mark; Evdokiou, Andreas] Univ Adelaide Woodville, Basil Hetzel Inst, Breast Canc Res Unit, Discipline Surg, Woodville, SA, Australia.
   [Liapis, Vasilios; Labrinidis, Agatha; Zinonos, Irene; Hay, Shelley; Panagopoulos, Vasilios; DeNichilo, Mark; Evdokiou, Andreas] Univ Adelaide Woodville, Ctr Personalised Canc Med, Woodville, SA, Australia.
   [Ponomarev, Vladimir] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA.
   [Ingman, Wendy] Univ Adelaide, Basil Hetzel Inst, Breast Biol Canc Unit, Discipline Surg, Adelaide, SA, Australia.
   [Atkins, Gerald J.; Findlay, David M.] Univ Adelaide, Discipline Orthopaed & Trauma, Adelaide, SA, Australia.
   [Zannettino, Andrew C. W.] Univ Adelaide, Fac Hlth Sci, Sch Med Sci, Myeloma Res Lab Canc Theme,SAHMRI, Adelaide, SA, Australia.
C3 Basil Hetzel Institute; Memorial Sloan Kettering Cancer Center; Basil
   Hetzel Institute; University of Adelaide; University of Adelaide;
   University of Adelaide; South Australian Health & Medical Research
   Institute (SAHMRI)
RP Evdokiou, A (通讯作者)，Univ Adelaide Woodville, Basil Hetzel Inst, Breast Canc Res Unit, Discipline Surg, Woodville, SA, Australia.
EM andreas.evdokiou@adelaide.edu.au
RI ; Liapis, Vasilios/B 2808 2016; liapis, vasilios/B 2808 2016; Ponomarev,
   Vladimir/G 1608 2013
OI Zannettino, Andrew/0000 0002 6646 6167; Liapis,
   Vasilios/0000 0002 2354 3521; Atkins, Gerald/0000 0002 3123 9861;
   Labrinidis, Agatha/0009 0000 3897 3084; Panagopoulos,
   Vasilios/0000 0002 6879 1262; Ingman, Wendy/0000 0003 3116 2902;
   Ponomarev, Vladimir/0000 0002 9119 9128
FU National Health and Medical Research Council (NHMRC) of Australia
   [627015]; Hospital Research Foundation, Adelaide, South Australia;
   National Breast Cancer Foundation; Australian Breast Cancer Research
FX This work was supported by grants from the National Health and Medical
   Research Council (NHMRC) of Australia ID# 627015, the Hospital Research
   Foundation, Adelaide, South Australia, (N/A.) the National Breast Cancer
   Foundation and the Australian Breast Cancer Research. The funders had no
   role in study design, data collection and analysis, decision to publish
   or preparation of the manuscript. We wish to thank Adelaide Microscopy
   at the University of Adelaide for technical assistance in
   bioluminescence imaging and Micro CT.
CR Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Brahimi Horn MC, 2007, J MOL MED JMM, V85, P1301, DOI 10.1007/s00109 007 0281 3
   Campanacci M., 1999, BONE SOFT TISSUE TUM
   Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582 4934.2011.01258.x
   Chan HSL, 1997, J NATL CANCER I, V89, P1706, DOI 10.1093/jnci/89.22.1706
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Duan JX, 2008, J MED CHEM, V51, P2412, DOI 10.1021/jm701028q
   Ganjoo KN, 2011, ONCOLOGY BASEL, V80, P50, DOI 10.1159/000327739
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Goltzman David, 2000, Cancer, V88, P2903, DOI 10.1002/1097 0142(20000615)88:12+<2903::AID CNCR4>3.0.CO;2 G
   Guise C.P., 2013, AI ZHENG, V33, P80
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   Hu JS, 2013, MOL CANCER THER, V12, P1763, DOI 10.1158/1535 7163.MCT 13 0123
   Hu JS, 2010, BLOOD, V116, P1524, DOI 10.1182/blood 2010 02 269126
   Labrinidis A, 2009, CLIN EXP METASTAS, V26, P872
   LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302
   LINK MP, 1991, CLIN ORTHOP RELAT R, P8
   Liu Q, 2012, CANCER CHEMOTH PHARM, V69, P1487, DOI 10.1007/s00280 012 1852 8
   Mirandola P, 2006, INT J ONCOL, V28, P127
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pringle J. A. S., 1999, PATHOLOGY BONE JOINT
   Saeter G, 1997, ACTA ORTHOP SCAND, V68, P120, DOI 10.1080/17453674.1997.11744716
   Saggar JK, 2014, INT J CANCER, V134, P2726, DOI 10.1002/ijc.28595
   Sun JD, 2012, CLIN CANCER RES, V18, P758, DOI 10.1158/1078 0432.CCR 11 1980
   Tamm I, 2000, CLIN CANCER RES, V6, P1796
   TAUBE T, 1994, BONE, V15, P161, DOI 10.1016/8756 3282(94)90703 X
   Weiss GJ, 2011, CLIN CANCER RES, V17, P2997, DOI 10.1158/1078 0432.CCR 10 3425
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Zannettino ACW, 1996, J IMMUNOL, V156, P611
   Zinonos I, 2011, J BONE MINER RES, V26, P630, DOI 10.1002/jbmr.244
   Zinonos I, 2009, MOL CANCER THER, V8, P2969, DOI 10.1158/1535 7163.MCT 09 0745
NR 32
TC 39
Z9 42
U1 0
U2 31
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD FEB 1
PY 2015
VL 357
IS 1
BP 160
EP 169
DI 10.1016/j.canlet.2014.11.020
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AZ2TB
UT WOS:000348084100016
PM 25444931
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Farr, JN
   Saul, D
   Doolittle, ML
   Kaur, J
   Rowsey, JL
   Vos, SJ
   Froemming, MN
   Lagnado, AB
   Zhu, Y
   Weivoda, M
   Ikeno, Y
   Pignolo, RJ
   Niedernhofer, LJ
   Robbins, PD
   Jurk, D
   Passos, JF
   LeBrasseur, NK
   Tchkonia, T
   Kirkland, JL
   Monroe, DG
   Khosla, S
AF Farr, Joshua N.
   Saul, Dominik
   Doolittle, Madison L.
   Kaur, Japneet
   Rowsey, Jennifer L.
   Vos, Stephanie J.
   Froemming, Mitchell N.
   Lagnado, Anthony B.
   Zhu, Yi
   Weivoda, Megan
   Ikeno, Yuji
   Pignolo, Robert J.
   Niedernhofer, Laura J.
   Robbins, Paul D.
   Jurk, Diana
   Passos, Joao F.
   LeBrasseur, Nathan K.
   Tchkonia, Tamara
   Kirkland, James L.
   Monroe, David G.
   Khosla, Sundeep
TI Local senolysis in aged mice only partially replicates the benefits of
   systemic senolysis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID FACTOR BINDING PROTEIN 5; CELLULAR SENESCENCE; CELLS; OSTEOCYTE; P16;
   APOPTOSIS
AB Clearance of senescent cells (SnCs) can prevent several age related pathologies, including bone loss. However, the local versus systemic roles of SnCs in mediating tissue dysfunction remain unclear. Thus, we developed a mouse model (p16 LOX ATTAC) that allowed for inducible SnC elimination (senolysis) in a cell specific manner and compared the effects of local versus systemic senolysis during aging using bone as a prototype tissue. Specific removal of Sn osteocytes prevented age related bone loss at the spine, but not the femur, by improving bone formation without affecting osteoclasts or marrow adipocytes. By contrast, systemic senolysis prevented bone loss at the spine and femur and not only improved bone formation, but also reduced osteoclast and marrow adipocyte numbers. Transplantation of SnCs into the peritoneal cavity of young mice caused bone loss and also induced senescence in distant host osteocytes. Collectively, our findings provide proof of concept evidence that local senolysis has health benefits in the context of aging, but, importantly, that local senolysis only partially replicates the benefits of systemic senolysis. Furthermore, we establish that SnCs, through their senescence associated secretory phenotype (SASP), lead to senescence in distant cells. Therefore, our study indicates that optimizing senolytic drugs may require systemic instead of local SnC targeting to extend healthy aging.
C1 [Farr, Joshua N.; Saul, Dominik; Doolittle, Madison L.; Kaur, Japneet; Rowsey, Jennifer L.; Vos, Stephanie J.; Froemming, Mitchell N.; Lagnado, Anthony B.; Zhu, Yi; Pignolo, Robert J.; Jurk, Diana; Passos, Joao F.; LeBrasseur, Nathan K.; Monroe, David G.; Khosla, Sundeep] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Coll Med, Rochester, MN USA.
   [Farr, Joshua N.; Saul, Dominik; Doolittle, Madison L.; Kaur, Japneet; Rowsey, Jennifer L.; Vos, Stephanie J.; Froemming, Mitchell N.; Monroe, David G.; Khosla, Sundeep] Mayo Clin, Div Endocrinol, Coll Med, Rochester, MN USA.
   [Farr, Joshua N.; Lagnado, Anthony B.; Zhu, Yi; Pignolo, Robert J.; Jurk, Diana; Passos, Joao F.; LeBrasseur, Nathan K.; Tchkonia, Tamara; Kirkland, James L.; Khosla, Sundeep] Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, Rochester, MN USA.
   [Weivoda, Megan] Mayo Clin, Dept Hematol, Coll Med, Rochester, MN USA.
   [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol & Lab Med, San Antonio, TX USA.
   [Pignolo, Robert J.] Mayo Clin, Dept Med, Coll Med, Rochester, MN USA.
   [Niedernhofer, Laura J.; Robbins, Paul D.] Univ Minnesota, Inst Biol Aging & Metab, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA.
   [LeBrasseur, Nathan K.] Mayo Clin, Dept Phys Med & Rehabil, Coll Med, Rochester, MN USA.
   [Farr, Joshua N.; Khosla, Sundeep] Mayo Clin, Coll Med, Guggenheim 7,200 First St SW, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Texas
   System; University of Texas Health Science Center at San Antonio; Mayo
   Clinic; University of Minnesota System; University of Minnesota Twin
   Cities; Mayo Clinic; Mayo Clinic
RP Farr, JN; Khosla, S (通讯作者)，Mayo Clin, Robert & Arlene Kogod Ctr Aging, Coll Med, Rochester, MN USA.; Farr, JN; Khosla, S (通讯作者)，Mayo Clin, Div Endocrinol, Coll Med, Rochester, MN USA.; Farr, JN; Khosla, S (通讯作者)，Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, Rochester, MN USA.; Farr, JN; Khosla, S (通讯作者)，Mayo Clin, Coll Med, Guggenheim 7,200 First St SW, Rochester, MN 55905 USA.
EM farr.joshua@mayo.edu; khosla.sundeep@mayo.edu
RI ; Farr, Joshua/B 3355 2011; Kirkland, James/F 9159 2016; Passos,
   Joao/LTF 6572 2024; LeBrasseur, Nathan/HGD 6434 2022; Khosla,
   Sundeep/AAE 6170 2020; Niedernhofer, Laura/LTD 0324 2024; Saul,
   Dominik/K 7355 2019; Doolittle, Madison/AAB 3047 2022; Zhu,
   Yi/ABW 1434 2022; KAUR, JAPNEET/JFT 0765 2023
OI Farr, Joshua/0000 0002 3179 6414; Rowsey, Jennifer/0009 0005 0677 7907;
   Passos, Joao/0000 0001 8765 1890; Jurk, Diana/0000 0003 4486 0857;
   Doolittle, Madison/0000 0003 0912 0095; Saul,
   Dominik/0000 0002 0673 3710; Zhu, Yi/0000 0002 3876 3156; 
FU NIH [AG062413, R01 DK128552, R01 AG076515, R01 AG063707, R01 AG068048,
   R37 AG013925, 1UG3CA26810, R01AG063543, U19AG056278]; Connor Group;
   Noaber Foundation
FX We gratefully acknowledge funding from the NIH: AG062413 (to SK, JNF,
   NKL, JLK, and TT) , R01 DK128552 (to JNF) , R01 AG076515 (to SK and DGM)
   , R01 AG063707 (to DGM) , R01 AG068048 (to JFP) , R37 AG013925 (to JLK
   and TT) , 1UG3CA26810 (to JFP) , R01AG063543 (to LJN) , U19AG056278 (to
   PDR and LJN) . We also acknowledge funding from the Connor Group (to JLK
   and TT) , Robert J. and Theresa W. Ryan (to JLK and TT) , and the Noaber
   Foundation (to JLK and TT) . We would like to thank the Stanford
   Transgenic, Knockout, and Tumor Model Center for inserting the
   p16 LOX ATTAC transgene into C57BL/6 mice. JLK, TT, J.M. van Deursen
   (Mayo Clinic) , and D.J. Baker (Mayo Clinic) designed the strategy for
   and developed the INK ATTAC mice.
CR Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742
   Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chandra A, 2022, AGING CELL, V21, DOI 10.1111/acel.13602
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 128
   Eckhardt BA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135236
   Ewald JA, 2010, JNCI J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Farr JN, 2020, CURR OSTEOPOROS REP, V18, P559, DOI 10.1007/s11914 020 00619 x
   Farr JN, 2019, BONE, V121, P121, DOI 10.1016/j.bone.2019.01.015
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Garcia Sifuentes Y, 2021, ELIFE, V10, DOI [10.7554/eLife.70817, 10.7554/eLife.70817.sa1, 10.7554/eLife.70817.sa2]
   Goldman DP, 2013, HEALTH AFFAIR, V32, P1698, DOI 10.1377/hlthaff.2013.0052
   Hernandez Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033
   Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708
   Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 488
   Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040
   Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039
   Khosla S, 2020, NAT REV ENDOCRINOL, V16, P263, DOI 10.1038/s41574 020 0335 y
   Kim KS, 2007, MOL BIOL CELL, V18, P4543, DOI 10.1091/mbc.E07 03 0280
   Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013
   Kirkland JL, 2013, EXP GERONTOL, V48, P1, DOI 10.1016/j.exger.2012.11.014
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Lagnado A, 2021, EMBO J, V40, DOI 10.15252/embj.2020106048
   Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860
   Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474 9726.2012.00795.x
   Nelsons G, 2018, MECH AGEING DEV, V170, P30, DOI 10.1016/j.mad.2017.08.005
   Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262
   Partridge L, 2018, NATURE, V561, P45, DOI 10.1038/s41586 018 0457 8
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Salih DAM, 2005, ENDOCRINOLOGY, V146, P931, DOI 10.1210/en.2004 0816
   Saul D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32552 1
   Saul D, 2021, ELIFE, V10, DOI [10.7554/eLife.69958, 10.7554/eLife.69958.sa1, 10.7554/eLife.69958.sa2]
   Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080
   Sfeir JG, 2022, MAYO CLIN PROC, V97, P1194, DOI 10.1016/j.mayocp.2022.03.011
   Sierra F, 2017, GEROSCIENCE, V39, P1, DOI 10.1007/s11357 016 9954 6
   St Sauver JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen 2014 006413
   Sturmlechner I, 2021, SCIENCE, V374, DOI 10.1126/science.abb3420
   Tasic B, 2011, P NATL ACAD SCI USA, V108, P7902, DOI 10.1073/pnas.1019507108
   Tiede Lewis LM, 2017, AGING US, V9, P2187, DOI 10.18632/aging.101308
   Tsai CA, 2009, BIOINFORMATICS, V25, P897, DOI 10.1093/bioinformatics/btp098
   van Tol AF, 2020, P NATL ACAD SCI USA, V117, P32251, DOI 10.1073/pnas.2011504117
   Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591 018 0092 9
   Xu M, 2017, J GERONTOL A BIOL, V72, P780, DOI 10.1093/gerona/glw154
   Xu M, 2015, ELIFE, V4, DOI 10.7554/eLife.12997
   Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 54
TC 38
Z9 39
U1 3
U2 12
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR 17
PY 2023
VL 133
IS 8
AR e162519
DI 10.1172/JCI162519
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA G5QL2
UT WOS:000989698800005
PM 36809340
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kato, T
   Khanh, VC
   Sato, K
   Kimura, K
   Yamashita, T
   Sugaya, H
   Yoshioka, T
   Mishima, H
   Ohneda, O
AF Kato, Toshiki
   Khanh, Vuong Cat
   Sato, Kazutoshi
   Kimura, Kenichi
   Yamashita, Toshiharu
   Sugaya, Hisashi
   Yoshioka, Tomokazu
   Mishima, Hajime
   Ohneda, Osamu
TI Elevated Expression of Dkk 1 by Glucocorticoid Treatment Impairs Bone
   Regenerative Capacity of Adipose Tissue Derived Mesenchymal Stem Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE stem cell therapy; steroid; osteogenesis; Dkk 1
ID CORTICOSTEROID INDUCED OSTEONECROSIS; ALKALINE PHOSPHATASE ACTIVITY;
   FEMORAL HEAD; OSTEOGENIC DIFFERENTIATION; STROMAL CELLS; NONTRAUMATIC
   OSTEONECROSIS; FOLLOW UP; DEXAMETHASONE; OSTEOBLASTS; ACTIVATION
AB Glucocorticoids are steroid hormones used as anti inflammatory treatments. However, this strong immunomodulation causes undesirable side effects that impair bones, such as osteoporosis. Glucocorticoid therapy is a major risk factor for developing steroid induced osteonecrosis of the femur head (ONFH). Since ONFH is incurable, therapy with mesenchymal stem cells (MSCs) that can differentiate into osteoblasts are a first line choice. Bone marrow derived MSCs (BM MSCs) are often used as a source of stem cell therapy for ONFH, but their proliferative activity is impaired after steroid treatment. Adipose tissue derived MSCs (AT MSCs) may be an attractive alternative source; however, it is unknown whether AT MSCs from steroid induced ONFH (sAT MSCs) have the same differentiation ability as BM MSCs or normal AT MSCs (nAT MSCs). In this study, we demonstrate that nAT MSCs chronically exposed to glucocorticoids show lower alkaline phosphatase activity leading to reduced osteogenic differentiation ability. This impaired osteogenesis is mediated by high expression of Dickkopf1 (Dkk 1) that inhibits wnt/ catenin signaling. Increased Dkk 1 also causes impaired osteogenesis along with reductions in bone regenerative capacity in sAT MSCs. Of note, plasma Dkk 1 levels are elevated in steroid induced ONFH patients. Collectively, our findings suggest that glucocorticoid induced expression of Dkk 1 could be a key factor in modulating the differentiation ability of MSCs used for ONFH and other stem cell therapies.
C1 [Kato, Toshiki; Khanh, Vuong Cat; Sato, Kazutoshi; Kimura, Kenichi; Yamashita, Toshiharu; Ohneda, Osamu] Univ Tsukuba, Grad Sch Comprehens Human Sci, Lab Regenerat Med & Stem Cell Biol, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
   [Kato, Toshiki] Univ Tsukuba, Sch Integrat Global Majors, Tsukuba, Ibaraki, Japan.
   [Sugaya, Hisashi; Yoshioka, Tomokazu; Mishima, Hajime] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Orthoped Surg, Tsukuba, Ibaraki, Japan.
   [Sugaya, Hisashi; Yoshioka, Tomokazu] Univ Tsukuba, Fac Med, Dept Orthoped Surg, Div Regenerat Med Musculoskeletal Syst, Tsukuba, Ibaraki, Japan.
C3 University of Tsukuba; University of Tsukuba; University of Tsukuba;
   University of Tsukuba
RP Ohneda, O (通讯作者)，Univ Tsukuba, Grad Sch Comprehens Human Sci, Lab Regenerat Med & Stem Cell Biol, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
EM oohneda@md.tsukuba.ac.jp
OI Vuong, Cat Khanh/0000 0002 9252 181X; Kimura,
   Kenichi/0000 0002 0363 8865; Kato, Toshiki/0000 0003 1871 8064
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   (MEXT); Grants in Aid for Scientific Research [15K06823] Funding Source:
   KAKEN
FX The authors thank the Japanese Ministry of Education, Culture, Sports,
   Science, and Technology (MEXT) for their support. We thank Ms. Chizuko
   Fujisawa for excellent work on the colony formation assay. We thank Dr.
   Bryan Mathis, Medical English Communication Center, University of
   Tsukuba, for proofreading.
CR Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557
   Butler JS, 2011, J ORTHOP RES, V29, P414, DOI 10.1002/jor.21260
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Cox G, 2010, J BONE JOINT SURG BR, V92B, P329, DOI 10.1302/0301 620X.92B3.22787
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   FISHER DE, 1971, J BONE JOINT SURG AM, VA 53, P859, DOI 10.2106/00004623 197153050 00002
   Fukushima W, 2010, CLIN ORTHOP RELAT R, V468, P2715, DOI 10.1007/s11999 010 1292 x
   Gangji V, 2011, BONE, V49, P1005, DOI 10.1016/j.bone.2011.07.032
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hardy Rowan, 2011, Front Endocrinol (Lausanne), V2, P24, DOI 10.3389/fendo.2011.00024
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79
   Hernigou P, 1999, J BONE JOINT SURG BR, V81B, P349, DOI 10.1302/0301 620X.81B2.8818
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Honsawek S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 257
   Houdek MT, 2016, J ARTHROPLASTY, V31, P893, DOI 10.1016/j.arth.2015.08.017
   Jones LC, 2004, CURR OPIN RHEUMATOL, V16, P443, DOI 10.1097/01.moo.0000127829.34643.fd
   Kajiyama S, 2015, J BIOMED MATER RES A, V103, P2807, DOI 10.1002/jbm.a.35396
   Kato T, 2017, BIOCHEM BIOPH RES CO, V493, P1010, DOI 10.1016/j.bbrc.2017.09.100
   Kimura K, 2014, STEM CELLS DEV, V23, P488, DOI 10.1089/scd.2013.0307
   Ko E, 2016, ACS APPL MATER INTER, V8, P22819, DOI 10.1021/acsami.6b05358
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee JS, 2006, J ORTHOP RES, V24, P604, DOI 10.1002/jor.20078
   Li HW, 2007, BIOCHEM BIOPH RES CO, V356, P836, DOI 10.1016/j.bbrc.2007.02.165
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mostafa NZ, 2012, CONNECT TISSUE RES, V53, P117, DOI 10.3109/03008207.2011.611601
   Mukhopadhyay M, 2011, INDIAN J CLIN BIOCHE, V26, P274, DOI 10.1007/s12291 011 0143 1
   Muljacic A, 2013, COLLEGIUM ANTROPOL, V37, P1275
   Nagano M, 2010, STEM CELLS DEV, V19, P1195, DOI 10.1089/scd.2009.0447
   Trinh NT, 2016, STEM CELLS DEV, V25, P760, DOI 10.1089/scd.2015.0335
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Sanderson M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135358
   Sato K, 2015, IN VITRO CELL DEV AN, V51, P515, DOI 10.1007/s11626 014 9860 0
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   SCHLEIMER RP, 1993, EUR J CLIN PHARMACOL, V45, pS3, DOI 10.1007/BF01844196
   Sen RK, 2012, J ARTHROPLASTY, V27, P679, DOI 10.1016/j.arth.2011.08.008
   Serena C, 2016, STEM CELLS, V34, P2559, DOI 10.1002/stem.2429
   Shao XR, 2017, NANOMED NANOTECHNOL, V13, P1809, DOI 10.1016/j.nano.2017.02.011
   Shao XR, 2017, SMALL, V13, DOI 10.1002/smll.201602770
   Stucki U, 2001, CLIN ORAL IMPLAN RES, V12, P121, DOI 10.1034/j.1600 0501.2001.012002121.x
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tran TC, 2011, J CELL PHYSIOL, V226, P224, DOI 10.1002/jcp.22329
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   URBANIAK JR, 1995, J BONE JOINT SURG AM, V77A, P681, DOI 10.2106/00004623 199505000 00004
   Khanh VC, 2017, STEM CELLS DEV, V26, P948, DOI 10.1089/scd.2016.0326
   Wang BL, 2008, ORTHOPEDICS, V31, P444, DOI 10.3928/01477447 20080501 33
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Wu LA, 2016, J CELL PHYSIOL, V231, P1189, DOI 10.1002/jcp.25266
   Wyles CC, 2015, CLIN ORTHOP RELAT R, V473, P3080, DOI 10.1007/s11999 015 4385 8
   Xie Q, 2016, BIOMATERIALS, V75, P279, DOI 10.1016/j.biomaterials.2015.10.042
   Yamanaka S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102311
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yoshioka T, 2011, INT ORTHOP, V35, P823, DOI 10.1007/s00264 010 1048 y
NR 69
TC 21
Z9 22
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JAN
PY 2018
VL 27
IS 2
BP 85
EP 99
DI 10.1089/scd.2017.0199
PG 15
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA FS6LO
UT WOS:000419909100002
PM 29084466
DA 2025 08 17
ER

PT J
AU Konishi, Y
   Okunishi, A
   Sugihara, F
   Nakamura, T
   Akazawa, K
   Minoshima, M
   Kikuchi, K
AF Konishi, Yuki
   Okunishi, Atsuya
   Sugihara, Fuminori
   Nakamura, Tatsuya
   Akazawa, Kazuki
   Minoshima, Masafumi
   Kikuchi, Kazuya
TI Development of Off On Switching <SUP>19</SUP>F MRI Probes for Cathepsin
   K Activity Detection
SO BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN
LA English
DT Article
DE F 19 MRI; Cathepsin K; Paramagnetic relaxation enhancement (PRE) effect
ID NANOPARTICLES
AB Cathepsin K is a protease expressed in osteoclasts that degrades bone tissue, such as type I collagen fibers. Over expression of cathepsin K is involved in osteoporosis, rheumatoid arthritis, and bone metastasis. Therefore, detecting cathepsin K activity is important for understanding the mechanism of these diseases and developing new drugs. However, current chemical probes cannot be employed for the detection of cathepsin K activity in animal deep tissue. In this study, we developed novel F 19 magnetic resonance imaging (MRI) probes (FLAME (Gd X), X = Acp, Deg, Deg2) to detect cathepsin K. In FLAME (Gd X), the Gd3+ complex was modified on the surface of perfluorocarbon encapsulated silica nanoparticles through cathepsin K substrate and three different hydrophobic/ hydrophilic linkers. The F 19 NMR signal intensities of these probes were suppressed by the paramagnetic relaxation enhancement (PRE) effect of the Gd3+ complexes. The F 19 MRI signal intensities of FLAME Gd Acp and FLAME Gd Deg specifically increased with the substrate cleavage by cathepsin K. The F 19 MRI probes based on the PRE effect can be applied to the in vivo detection of cathepsin K activity.
C1 [Konishi, Yuki; Okunishi, Atsuya; Nakamura, Tatsuya; Akazawa, Kazuki; Minoshima, Masafumi; Kikuchi, Kazuya] Osaka Univ, Grad Sch Engn, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Sugihara, Fuminori] Res Inst Microbial Dis, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Sugihara, Fuminori; Kikuchi, Kazuya] Osaka Univ, Immunol Frontier Res Ctr, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Kikuchi, Kazuya] Osaka Univ, Quantum Informat & Quantum Biol Div, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 University of Osaka; University of Osaka; University of Osaka
RP Kikuchi, K (通讯作者)，Osaka Univ, Grad Sch Engn, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.; Kikuchi, K (通讯作者)，Osaka Univ, Immunol Frontier Res Ctr, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.; Kikuchi, K (通讯作者)，Osaka Univ, Quantum Informat & Quantum Biol Div, 2 1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM kkikuchi@mis.eng.osaka u.ac.jp
RI Namkoong, Ho/I 8982 2018
FU JSPS KAKENHI [JP17H06409, JP18H039351, JP19K22255, JP25220207,
   20K05747]; AMED [18he0902005h0004, 18fm0208018h0002]; Takeda Science
   Foundation; Naito Foundation; JSPS A3 Foresight Program; JSPS
   CORE to CORE Program "Asian Chemical Biology Initiative"; Japan
   (JSPS) UK (RSC) Research Cooperative Program [JPJSBP120195705]; JSPS ISF
   Joint Research Program [JPJSBP120218404]; Grants in Aid for Scientific
   Research [20K05747, 21H00401, 21H04706] Funding Source: KAKEN
FX This research was supported by JSPS KAKENHI (Grant numbers: JP17H06409
   "Frontier Research on Chemical Communications," JP18H039351, JP19K22255,
   JP25220207 to K. K.; 20K05747 to M. M.), AMED (18he0902005h0004,
   18fm0208018h0002 to K. K.); Takeda Science Foundation (to K. K.); the
   Naito Foundation (to M. M.); JSPS A3 Foresight Program; JSPS
   CORE to CORE Program "Asian Chemical Biology Initiative"; Japan
   (JSPS) UK (RSC) Research Cooperative Program (JPJSBP120195705 to K. K.),
   and JSPS ISF Joint Research Program (JPJSBP120218404 to K. K.).
CR Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121
   Akazawa K, 2018, CHEM COMMUN, V54, P11785, DOI 10.1039/c8cc05381b
   Akazawa K, 2018, BIOCONJUGATE CHEM, V29, P1720, DOI 10.1021/acs.bioconjchem.8b00167
   Clore GM, 2009, CHEM REV, V109, P4108, DOI 10.1021/cr900033p
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   i N. Takahash, 1988, ENDOCRINOLOGY ENDOCRINOLOGY, V122, P1373
   ie D. X, 2020, ANGEW CHEM INT EDIT, V59
   Kozloff KM, 2009, BONE, V44, P190, DOI 10.1016/j.bone.2008.10.036
   Lecaille F, 2003, BIOCHEM J, V375, P307, DOI 10.1042/BJ20030468
   Matsushita H, 2014, ANGEW CHEM INT EDIT, V53, P1008, DOI 10.1002/anie.201308500
   Mizukami S, 2009, ANGEW CHEM INT EDIT, V48, P3641, DOI 10.1002/anie.200806328
   Nakamura T, 2015, ANGEW CHEM INT EDIT, V54, P1007, DOI 10.1002/anie.201409365
   Pa lermo C., 2008, TRENDS PHARMACOL SCI, V29, P22
   Re iser J., 2010, J C LIN INVEST J C LIN INVEST, V120, P3421
   Yuan Y, 2015, ACS NANO, V9, P761, DOI 10.1021/nn5062657
   Yue XY, 2014, MOL PHARMACEUT, V11, P4208, DOI 10.1021/mp500443x
NR 16
TC 8
Z9 8
U1 3
U2 32
PU CHEMICAL SOC JAPAN
PI TOKYO
PA 1 5 KANDA SURUGADAI CHIYODA KU, TOKYO, 101 8307, JAPAN
SN 0009 2673
EI 1348 0634
J9 B CHEM SOC JPN
JI Bull. Chem. Soc. Jpn.
PD JUN
PY 2021
VL 94
IS 6
BP 1690
EP 1694
DI 10.1246/bcsj.20210099
PG 5
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA TF0RF
UT WOS:000670417800002
DA 2025 08 17
ER

PT J
AU Guo, SH
   Zhang, Z
   Cao, LL
   Wu, T
   Li, BL
   Cui, YC
AF Guo, Shenghua
   Zhang, Zhi
   Cao, Lulu
   Wu, Tao
   Li, Binglun
   Cui, Yanchao
TI Nanocomposites containing ZnO TiO2 Chitosan and berbamine
   promote osteoblast differentiation, proliferation, and calcium
   mineralization in MG63 osteoblasts
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE Osteoporosis; Osteoblast; Calcium; MG 63 cells; ZnO TiO2  Chitosan;
   Berbamine; nanocomposites; Osteocalcin
ID NANOPARTICLES; OSTEOPOROSIS
AB Recently, biomedical research has focused on bio nanocomposites that are capable of regeneration of tissues, as well as treating osteomyelitis, osteosarcoma, and other diseases with therapeutic medications. A novel osteo conductive nanocomposite will be synthesized and used to enhance the mineralization of injured bone tissues, as well as their antimicrobial properties. The unique structural characteristics of ZnO TiO2 Chitosan berbamine nanocomposites have been described by UV Vis, PL, FTIR, XRD, FESEM, and HR TEM experiments, while antimicrobial activity against pathogenic microorganisms has been evaluated by the agar well diffusion method. MTT assays and levels of ALP enzymes were used to test nanocomposites on osteosarcoma cell lines (MG 63) and to assess the osteosarcoma cell line's physical characteristics, bioactivity, and calcium deposition by staining with Alizarin Red S. In addition to showing significant Zones of Inhibition (ZOI) against bacterial and fungal strains, structural characterization revealed the antimicrobial properties of ZnO TiO2 Chitosan berbamine composites. According to research conducted on osteoblast like MG 63 cells grown on ZnO TiO2 Chitosan berbamine composites, the composites do not cause toxicity and significantly increase osteoblast proliferation, ALP activity, calcium deposition, and bone growth, making ZnO TiO2 Chitosan berbamine a potential therapy for bone related diseases. Understanding the druggable mechanism of ZnO TiO2 Chitosan berbamine will require further studies in the future, including in vivo testing and clinical trials.
C1 [Guo, Shenghua] Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian, Peoples R China.
   [Zhang, Zhi] Xi An Jiao Tong Univ, Dept Orthopaed, Affiliated Hosp 1, Xian, Peoples R China.
   [Cao, Lulu; Wu, Tao; Li, Binglun; Cui, Yanchao] Xi An Jiao Tong Univ, Dept Rehabil Med, Affiliated Hosp 1, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Cui, YC (通讯作者)，Xi An Jiao Tong Univ, Dept Rehabil Med, Affiliated Hosp 1, Xian, Peoples R China.
EM hermes121@stu.xjtu.edu.cn
RI Wu, Tongsuo/AGW 5564 2022
OI Cui, Yanchao/0000 0002 5940 2886
FU Department of Rehabilitation Medicine; First Affiliated Hospital of Xian
   Jiaotong University
FX Grant support from the Department of Rehabilitation Medicine, The First
   Affiliated Hospital of Xian Jiaotong University.
CR Adnan MM, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10101129
   Alloisio G, 2021, CELLS BASEL, V10, DOI 10.3390/cells10092383
   Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w
   Belwal T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00041
   Branca C, 2018, J COLLOID INTERF SCI, V517, P221, DOI 10.1016/j.jcis.2018.02.004
   Cawthon PM, 2011, CLIN ORTHOP RELAT R, V469, P1900, DOI 10.1007/s11999 011 1780 7
   Chen L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153120
   Chen P, 2017, CELL PHYSIOL BIOCHEM, V43, P1939, DOI 10.1159/000484118
   El Zahar KM, 2022, MOLECULES, V27, DOI 10.3390/molecules27186114
   Elderdery AY, 2022, BIOINORG CHEM APPL, V2022, DOI 10.1155/2022/9602725
   Hagar MN, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01621 0
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Hu Z, 2012, POLIMEROS, V22, P422, DOI 10.1590/S0104 14282012005000073
   IBM Corp, 2011, IBM SPSS Statistics for Windows, Version 20.0.
   Inchingolo F, 2022, MATERIALS, V15, DOI 10.3390/ma15031120
   Jafary F, 2017, INT J TRANSPLANT MED, V8, P195
   Karthikeyan C, 2020, CARBOHYD POLYM, V249, DOI 10.1016/j.carbpol.2020.116825
   Kaur K, 2019, ACS OMEGA, V4, P1504, DOI 10.1021/acsomega.8b03272
   Kazemipoor M, 2021, CLIN EXP DENT RES, V7, P601, DOI 10.1002/cre2.379
   Khinda R, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19052999
   Kibasomba PM, 2018, RESULTS PHYS, V9, P628, DOI 10.1016/j.rinp.2018.03.008
   Klink MJ, 2022, MOLECULES, V27, DOI 10.3390/molecules27113532
   Liu LL, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5517143
   Lopes D, 2018, BIOMATERIALS, V185, P240, DOI 10.1016/j.biomaterials.2018.09.028
   Mielcarek Christine, 2022, Methods Mol Biol, V2525, P35, DOI 10.1007/978 1 0716 2473 9_4
   Munguti L, 2021, MAT SCI SEMICON PROC, V128, DOI 10.1016/j.mssp.2021.105786
   Mura P, 2022, MAR DRUGS, V20, DOI 10.3390/md20050335
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Musson DS, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1089 x
   Poornaprakash B, 2020, CERAM INT, V46, P2931, DOI 10.1016/j.ceramint.2019.09.289
   Price P A, 1989, Connect Tissue Res, V21, P51, DOI 10.3109/03008208909049995
   Pujari Palmer M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163530
   Raghavanpillai Sabu Kuzhunellil, 2022, J Exp Pharmacol, V14, P17, DOI 10.2147/JEP.S339383
   Rajendar V, 2014, SUPERLATTICE MICROST, V75, P551, DOI 10.1016/j.spmi.2014.07.049
   Rilda Y., 2019, IOP C SER EARTH ENV, P217
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sekaran S, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111564
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Sun JY, 2009, ACTA BIOMATER, V5, P1284, DOI 10.1016/j.actbio.2008.10.011
   Tu KN., 2018, Options, V43, P92
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   Wehner C, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01089 4
   Yao BD, 2000, J PHYS CONDENS MAT, V12, P6265, DOI 10.1088/0953 8984/12/28/322
   Kuen CY, 2022, MOLECULES, V27, DOI 10.3390/molecules27020473
   Zhang SQ, 2021, SAUDI J BIOL SCI, V28, P4908, DOI 10.1016/j.sjbs.2021.07.019
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 47
TC 11
Z9 11
U1 2
U2 19
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1359 5113
EI 1873 3298
J9 PROCESS BIOCHEM
JI Process Biochem.
PD JAN
PY 2023
VL 124
BP 63
EP 70
DI 10.1016/j.procbio.2022.11.004
EA NOV 2022
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA 7S6FR
UT WOS:000910848100001
DA 2025 08 17
ER

PT J
AU Gevorgyan, A
   Sukhu, B
   Alman, BA
   Bristow, RG
   Pang, CY
   Forrest, CR
AF Gevorgyan, Artur
   Sukhu, Balram
   Alman, Benjamin A.
   Bristow, Robert G.
   Pang, Cho Y.
   Forrest, Christopher R.
TI Radiation effects and radioprotection in MC3T3 E1 mouse calvarial
   osteoblastic cells
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID BONE GROWTH INHIBITION; MICROVASCULAR ENDOTHELIAL CELLS; IN VITRO;
   INDUCED DAMAGE; IONIZING RADIATION; PLATE IRRADIATION; AMIFOSTINE;
   DIFFERENTIATION; PROLIFERATION; PHYSIS
AB Background: Little is known about the mechanisms and treatment of radiation induced inhibition of craniofacial bone growth. In an earlier study, the radioprotector amifostine (WR 2721) administered to rabbits before irradiation radio protected cultured orbitozygomatic complex periosteal osteoblast like cells. This study assessed the effects of amifostine and its active metabolite on the radiation survival, function, and phenotype of mouse calvarial osteoblast like cells in a cell culture model.
   Methods: MC3T3 E1 newborn mouse calvarial osteoblast like cells underwent gamma radiation (0 to 10 Gy) in the presence or absence of either WR 2721 or WR 1065, its active metabolite (10( 7) to 10( 3) M). The effects of radiation with and without drugs were assessed using endpoints of colony forming ability, cell viability, alkaline phosphatase activity, and expression of osteoblastic phenotype genes (alkaline phosphatase, collagen type 1, osteocalcin, and osteopontin). All experiments were replicated at least in triplicate.
   Results: Irradiation resulted in a dose dependent inhibition of clonogenic cell survival. Pretreatment with WR 1065, but not WR 2721, resulted in a significant improvement of ostcoblast like cell survival. Specifically, maximum radioprotection was observed with 10( 4) M WR 1065 at a clinically relevant 2 Gy dose of irradiation. No significant radioprotection was observed at the lower (5 x 10( 7) M) concentration of WR 1065. Furthermore, radiation seemed to suppress the expression of osteoblastic phenotype related genes in a dose dependent manner.
   Conclusions: This study reveals improved survival after irradiation in osteoblast like cells treated with WR 1065 in vitro and corroborates previous findings from animal models. Further studies using this agent and similar drugs are important for devising strategies to prevent radiation induced inhibition of craniofacial bone growth.
C1 Hosp Sick Children, Ctr Craniofacial Care & Res, Div Plast Surg, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada.
   Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   Univ Toronto, Dept Surg, Toronto, ON, Canada.
   Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
   Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada.
   Univ Hlth Network, Princess Margaret Hosp, Toronto, ON, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; Hospital for Sick Children (SickKids); University of
   Toronto; Hospital for Sick Children (SickKids); University of Toronto;
   Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute;
   University of Toronto; University of Toronto; University of Toronto;
   University of Toronto; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre
RP Forrest, CR (通讯作者)，Hosp Sick Children, Ctr Craniofacial Care & Res, Div Plast Surg, 555 Univ Ave,Room 5430, Toronto, ON M5G 1X8, Canada.
EM christopher.forrest@sickkids.ca
RI bristow, robert/NES 3364 2025
OI Bristow, Robert/0000 0002 8553 9544
FU Plastic Surgery Educational Foundation; Maxillofacial Surgeons
   Foundation of the American Society of Maxillofacial Surgeons
FX This study was supported by a Plastic Surgery Educational Foundation
   research grant and a Bernd Spiessl research grant from the Maxillofacial
   Surgeons Foundation of the American Society of Maxillofacial Surgeons.
   Artur Gevorgyan is a recipient of the Lyndon Peer Research Fellowship of
   the Plastic Surgery Educational Foundation. Robert G. Bristow is a
   Canadian Cancer Society research scientist. Amifostine was kindly
   provided by Dr. Bill Ellis of Walter Reed Army Institute of Research
   (Washington, D.C.). WR 1065 was provided by Dr. Robert Schultz of the
   National Cancer Institute (Bethesda, Md.). The authors thank Farid
   Jalali and Carla Coackley of the Ontario Cancer Center and Princess
   Margaret Hospital for their technical expertise and advice.
CR Bonner HS, 2002, J CLIN PHARMACOL, V42, P166, DOI 10.1177/00912700222011201
   Bristow R.G., 2004, BASIC SCI ONCOLOGY, P261
   BRISTOW RG, 1994, ONCOGENE, V9, P1527
   BRISTOW RG, 1990, INT J RADIAT ONCOL, V18, P331, DOI 10.1016/0360 3016(90)90098 5
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   COHEN SR, 1990, PLAST RECONSTR SURG, V86, P229, DOI 10.1097/00006534 199008000 00004
   Damron TA, 2006, RADIAT RES, V165, P350, DOI 10.1667/RR3504.1
   Damron TA, 2004, CLIN ORTHOP RELAT R, P110, DOI 10.1097/01.blo.0000131247.18112.0f
   Damron TA, 2004, INT J RADIAT BIOL, V80, P217, DOI 10.1080/09553000410001669524
   Damron TA, 2004, J HISTOCHEM CYTOCHEM, V52, P157, DOI 10.1177/002215540405200203
   Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623 200307000 00017
   Damron TA, 2001, INT J RADIAT ONCOL, V50, P479, DOI 10.1016/S0360 3016(01)01532 2
   Damron TA, 2000, INT J CANCER, V90, P73, DOI 10.1002/(SICI)1097 0215(20000420)90:2<73::AID IJC3>3.3.CO;2 5
   Damron TA, 2000, INT J RADIAT ONCOL, V47, P1067, DOI 10.1016/S0360 3016(00)00511 3
   Dare A, 1997, J DENT RES, V76, P658, DOI 10.1177/00220345970760020601
   Denys D, 1998, INT J PEDIATR OTORHI, V45, P7, DOI 10.1016/S0165 5876(98)00028 7
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Faulhaber O, 2005, APPLICATION OF APOPTOSIS TO CANCER TREATMENT, P293, DOI 10.1007/1 4020 3302 8_13
   Forrest CR, 2002, PLAST RECONSTR SURG, V109, P1311, DOI 10.1097/00006534 200204010 00015
   Fouladi M, 2001, CANCER, V92, P914, DOI 10.1002/1097 0142(20010815)92:4<914::AID CNCR1401>3.0.CO;2 S
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   Gevorgyan A, 2007, J CRANIOFAC SURG, V18, P1044, DOI 10.1097/scs.0b013e31814c916f
   Gevorgyan AM, 2008, PLAST RECONSTR SURG, V121, P763, DOI 10.1097/01.prs.0000299908.66658.82
   GRDINA DJ, 1985, CARCINOGENESIS, V6, P929, DOI 10.1093/carcin/6.6.929
   Grdina DJ, 2002, ONCOLOGY BASEL, V63, P2, DOI 10.1159/000067146
   GUYURON B, 1983, ANN PLAS SURG, V11, P423, DOI 10.1097/00000637 198311000 00010
   Jackson IT, 1996, PLAST RECONSTR SURG, V98, P1169, DOI 10.1097/00006534 199612000 00007
   Khodarev NN, 2004, INT J RADIAT ONCOL, V60, P553, DOI 10.1016/j.ijrobp.2004.04.060
   La Scala GC, 2005, PLAST RECONSTR SURG, V115, P1973, DOI 10.1097/01.PRS.0000163322.22436.3B
   Margulies Bryan, 2003, Am J Clin Oncol, V26, pe106, DOI 10.1097/00000421 200308000 00032
   Matsumura S, 1998, RADIAT RES, V149, P463, DOI 10.2307/3579786
   Matsumura S, 1996, CALCIFIED TISSUE INT, V59, P307, DOI 10.1007/s002239900129
   Mooteri SN, 1996, RADIAT RES, V145, P217, DOI 10.2307/3579177
   Murley JS, 2006, FREE RADICAL BIO MED, V40, P1004, DOI 10.1016/j.freeradbiomed.2005.10.060
   O'Donovan DA, 2001, J CRANIOFAC SURG, V12, P533, DOI 10.1097/00001665 200111000 00006
   Paulino AC, 2000, INT J RADIAT ONCOL, V48, P1489, DOI 10.1016/S0360 3016(00)00799 9
   Peterson WJ, 2004, CELL PROLIFERAT, V37, P325, DOI 10.1111/j.1365 2184.2004.00316.x
   Poggi MM, 2001, CURR PROB CANCER, V25, P334, DOI 10.1067/mcn.2001.120122
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rubin DB, 1996, RADIAT RES, V145, P210, DOI 10.2307/3579176
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Souid AK, 1999, CANCER CHEMOTH PHARM, V44, P498, DOI 10.1007/s002800051124
   Spadaro JA, 2005, INT J RADIAT BIOL, V81, P759, DOI 10.1080/09553000500495710
   Spadaro JA, 2003, J PEDIATR ORTHOPED, V23, P35, DOI 10.1097/00004694 200301000 00007
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sweeney T.R., 1979, A survey of compounds from the antiradiation drug development program of the U.S. Army Medical Research and Development Command
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   TAKAHASHI S, 1994, J BONE JOINT SURG AM, V76A, P722, DOI 10.2106/00004623 199405000 00014
   Tamurian RM, 1999, J ORTHOPAED RES, V17, P286, DOI 10.1002/jor.1100170219
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Zhao Y, 2005, BIOL PHARM BULL, V28, P1371, DOI 10.1248/bpb.28.1371
NR 52
TC 15
Z9 16
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0032 1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD OCT
PY 2008
VL 122
IS 4
BP 1025
EP 1035
DI 10.1097/PRS.0b013e3181845931
PG 11
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 356XU
UT WOS:000259811700004
PM 18827633
DA 2025 08 17
ER

PT J
AU Wu, C
   Wang, NN
   Xu, PC
   Wang, XP
   Shou, D
   Zhu, Y
AF Wu, Can
   Wang, Nani
   Xu, Pingcui
   Wang, Xuping
   Shou, Dan
   Zhu, Yan
TI Preparation and application of polyvinyl alcohol decorated cell membrane
   chromatography for screening anti osteoporosis components from Liuwei
   Dihuang decoction containing serum
SO JOURNAL OF SEPARATION SCIENCE
LA English
DT Article
DE osteoblast cell membrane chromatography; polyvinyl alcohol decorated;
   metabolites; rat serum; traditional Chinese medicine
ID FLIGHT MASS SPECTROMETRY; DIABETIC OSTEOPOROSIS; LIQUID CHROMATOGRAPHY;
   POLY(VINYL ALCOHOL); BIOACTIVE COMPOUNDS; ACTIVE COMPONENTS; AFFINITY;
   PHASE; STREPTOZOTOCIN; SILICA
AB Cell membrane chromatography is a powerful tool for screening active components from complex matrices. New cell membrane carriers need to be developed to increase the coverage of cell membranes on the surface of stationary phases, thereby improving cell membrane chromatographic retention. In this work, we prepared polyvinyl alcohol poly dimethyl diallyl ammonium chloride modified silica gel as a cell membrane carrier. Osteoblast cell was used as cell membrane source, which was widely used to evaluate the osteogenic activity of drugs. The new cell membrane chromatographic stationary phase was used to screen anti osteoporosis components in Liuwei Dihuang decoction containing serum. The chemical structures of the new modified materials were characterized by scanning electronic microscopy, Fourier transform infrared spectroscopy, and elemental analysis characterization. Compared with the common cell membrane column, the cell membrane coverage of this modified material was increased by 30%, and thus provided a stronger retention effect in positive drugs. Nineteen metabolites in rat serum samples were retained on the cell membrane chromatography and identified by ultra high performance liquid chromatography/time of flight mass spectrometry. Among those, four components (morroniside, catalpol, loganin, and acteoside) were selected for in vitro pharmacodynamics validation. They significantly increased the osteoblast proliferation. The new modified material was successfully applied to screen anti osteoporosis components from Liuwei Dihuang Decoction containing serum.
C1 [Wu, Can; Zhu, Yan] Zhejiang Univ, Dept Chem, 145 Tianmushan Rd, Hangzhou 310007, Zhejiang, Peoples R China.
   [Wang, Nani; Xu, Pingcui; Wang, Xuping; Shou, Dan] Zhejiang Acad Tradit Chinese Med, Dept Med, 132 Tianmushan Rd, Hangzhou 310007, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Zhu, Y (通讯作者)，Zhejiang Univ, Dept Chem, 145 Tianmushan Rd, Hangzhou 310007, Zhejiang, Peoples R China.; Wang, NN (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, 132 Tianmushan Rd, Hangzhou 310007, Zhejiang, Peoples R China.
EM wnn8511@163.com; zhuyan@zju.edu.cn
RI ; Zhu, Yan/A 1548 2017
OI Shou, Dan/0000 0003 3465 4072; Wang, Nani/0000 0003 0748 0222
FU National Natural Science Foundation of China [81973447, 21974121]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81973447, 21974121
CR Baerts L, 2015, PHARMACOL RES, V100, P336, DOI 10.1016/j.phrs.2015.08.023
   Bu YS, 2018, CHEM COMMUN, V54, P13427, DOI 10.1039/c8cc08530g
   Chen XF, 2014, ANAL CHEM, V86, P4748, DOI 10.1021/ac500287e
   Chen XF, 2012, J CHROMATOGR A, V1242, P67, DOI 10.1016/j.chroma.2012.04.034
   Choi C, 2012, MENOPAUSE, V19, P1043, DOI 10.1097/gme.0b013e31824b1cc5
   Ding X, 2016, ANAL CHEM, V88, P12081, DOI 10.1021/acs.analchem.6b02709
   Fei YR, 2007, MICRON, V38, P637, DOI 10.1016/j.micron.2006.09.003
   Figueiredo KCS, 2009, J APPL POLYM SCI, V111, P3074, DOI 10.1002/app.29263
   Gray MJ, 2004, J CHROMATOGR A, V1041, P101, DOI 10.1016/j.chroma.2004.04.039
   Han JQ, 2014, CARBOHYD POLYM, V102, P306, DOI 10.1016/j.carbpol.2013.11.045
   He HB, 2007, J PHARM PHARMACOL, V59, P1297, DOI 10.1211/jpp.59.9.0015
   Hu Q, 2019, ANAL CHEM, V91, P13062, DOI 10.1021/acs.analchem.9b03268
   Hu Q, 2019, CHEM ENG J, V364, P269, DOI 10.1016/j.cej.2019.01.171
   Ji SL, 2015, ANALYST, V140, P6250, DOI 10.1039/c5an01159k
   Kasai K, 2014, P JPN ACAD B PHYS, V90, P215, DOI 10.2183/pjab.90.215
   Liu JP, 2013, J ETHNOPHARMACOL, V150, P371, DOI 10.1016/j.jep.2013.09.003
   Ma WN, 2017, J CHROMATOGR A, V1503, P12, DOI 10.1016/j.chroma.2017.04.053
   Miyazaki T, 2010, POLYMER, V51, P5539, DOI 10.1016/j.polymer.2010.09.048
   Muhammad S, 2017, J SEP SCI, V40, P299, DOI 10.1002/jssc.201600773
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Stoll DR, 2007, J CHROMATOGR A, V1168, P3, DOI 10.1016/j.chroma.2007.08.054
   Wang N, 2017, J SEP SCI, V40, P4311, DOI 10.1002/jssc.201700688
   Wei F, 2017, J PHARMACEUT BIOMED, V136, P134, DOI 10.1016/j.jpba.2017.01.005
   Wei F, 2017, J CHROMATOGR B, V1040, P273, DOI 10.1016/j.jchromb.2016.11.002
   Wu C, 2019, ANAL METHODS UK, V11, P3590, DOI 10.1039/c9ay00992b
   Xu Q, 2007, CLIN EXP PHARMACOL P, V34, P624, DOI 10.1111/j.1440 1681.2007.04619.x
   Zhou WX, 2016, PHARMACOL THERAPEUT, V162, P170, DOI 10.1016/j.pharmthera.2016.02.004
NR 28
TC 17
Z9 20
U1 10
U2 80
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1615 9306
EI 1615 9314
J9 J SEP SCI
JI J. Sep. Sci.
PD JUN
PY 2020
VL 43
IS 11
BP 2105
EP 2114
DI 10.1002/jssc.201901203
EA MAR 2020
PG 10
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA LT3JR
UT WOS:000522053200001
PM 32135026
DA 2025 08 17
ER

PT J
AU Xue, S
   Xu, YM
   Xu, SL
   Zhong, YM
   Ruan, GF
   Ma, JZ
   Hu, Y
   Ding, CH
   Sang, WL
AF Xue, Song
   Xu, Yiming
   Xu, Shenglin
   Zhong, Yiming
   Ruan, Guangfeng
   Ma, Jinzhong
   Hu, Yong
   Ding, Changhai
   Sang, Weilin
TI Mitophagy impairment mediates the pathogenesis of CoCrMo
   particle induced osteolysis via NLRP3/caspase 1/GSDMD dependent
   pyroptosis in macrophages
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE CoCrMo; Osteoclastogenesis; Mitophagy; Reactive oxygen species;
   Pyroptosis
ID INDUCED BONE LOSS; NLRP3 INFLAMMASOME; IN VITRO; ACTIVATION; APOPTOSIS;
   CELLS; SALIDROSIDE; OSTEOBLAST; STRESS; TARGET
AB Wear particles derived from implant surfaces are the important factors causing periprosthetic osteolysis (PPO), which is the main reason for total joint revision. To date, the specific pathogenesis of PPO remains largely unknown, and developing new therapeutic strategies is urgently necessary. Our study indicated the most clinically common cobalt chromium molybdenum (CoCrMo) wear particles (CoPs) activated macrophages and further accelerated osteoclastogenesis. Subsequently, we put emphasis on the pathologic change in macrophages after CoPs stimulation. Meaningfully, high concentration CoPs induced reactive oxygen species (ROS) accumulation in macrophages and activated NOD like receptor pyrin domain containing 3 (NLRP3) dependent pyroptosis, promoting the release of cytokines such as IL 18, IL 1 beta and HMGB1, and subsequent formation of extracellular inflammatory microenvironment, which is crucial for osteoclastogenesis. More interestingly, transmission electron microscopy and flow cytometry results revealed that there were accumulation of endamaged mitochondria in high concentration CoP challenged macrophages, which accelerated intracellular ROS accumulation and mediated NLRP3 dependent pyroptosis. Mechanismly, high concentration CoPs induced macrophage mitophagy impairment and the loss of mitochondrial membrane potential via inhibiting PINK1/Parkin signalling pathway. Furthermore, by subcutaneous injection of salidroside and/or CY 09 in situ significantly delayed CoP induced mice calvaria osteolysis. Collectively, this study demonstrates a novel mechanism underlying the pathogenesis of PPO and provides a potential therapy avenue.
C1 [Xue, Song; Ding, Changhai] Anhui Med Univ, Arthrit Res Inst, Dept Rheumatol & Immunol, Affiliated Hosp 1, Hefei, Peoples R China.
   [Xu, Yiming; Zhong, Yiming; Ma, Jinzhong; Sang, Weilin] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai, Peoples R China.
   [Xu, Shenglin; Hu, Yong] Anhui Med Univ, Dept Orthoped, Affiliated Hosp 1, Hefei, Peoples R China.
   [Ding, Changhai] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Guangzhou, Peoples R China.
   [Ding, Changhai] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Ruan, Guangfeng] South China Univ Technol, Guangzhou Peoples Hosp 1, Clin Res Ctr, Sch Med, Guangzhou, Peoples R China.
C3 Anhui Medical University; Shanghai Jiao Tong University; Anhui Medical
   University; Southern Medical University   China; University of Tasmania;
   Menzies Institute for Medical Research; South China University of
   Technology
RP Ding, CH (通讯作者)，Anhui Med Univ, Arthrit Res Inst, Dept Rheumatol & Immunol, Affiliated Hosp 1, Hefei, Peoples R China.; Sang, WL (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai, Peoples R China.; Hu, Y (通讯作者)，Anhui Med Univ, Dept Orthoped, Affiliated Hosp 1, Hefei, Peoples R China.
EM 526597676@qq.com; changhai.ding@utas.edu.au; Sang_weilin@163.com
RI Xu, Yiming/ABD 3931 2020; Xue, Song/GSM 9259 2022; sang,
   wei/MZQ 2526 2025; xu, shenglin/MFI 4113 2025
OI RUAN, GUANGFENG/0000 0002 1471 7358; Xue, Song/0000 0002 2932 5488
FU National Natural Science of China [81974342, 81871795, 8217090554];
   Shanghai Municipal Health Commission Clinical Research project
   [202040446]; Medical Engineering Cross Research Project [YG2019QNB37];
   Songjiang District Science and Technology Research project [19SJKJGG13];
   Program for Upgrading Basic and Clinical Collaborative Research of Anhui
   Medical University [2020xkjT033]; Major Projects of Natural Science
   Foundation of Universities in Anhui Province [KJ2020ZD17]; Graduate
   Scientific Research Project of Anhui Province [YJS20210272]
FX This study was funded by the National Natural Science of China (No.
   81974342, No. 81871795 and No. 8217090554) , Shanghai Municipal Health
   Commission Clinical Research project (No. 202040446) , Medical
   Engineering Cross Research Project of (YG2019QNB37) , Songjiang District
   Science and Technology Research project (19SJKJGG13) , Pro gram for
   Upgrading Basic and Clinical Collaborative Research of Anhui Medical
   University (2020xkjT033) , Major Projects of Natural Science Foundation
   of Universities in Anhui Province (KJ2020ZD17) and Graduate Scientific
   Research Project of Anhui Province (YJS20210272) . We would like to
   thank the Home for Researchers ( www.home for re searchers.com ) for
   providing powerful technical support.
CR Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022
   Budden CF, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12127
   Chen FR, 2017, APMIS, V125, P880, DOI 10.1111/apm.12730
   Choi GE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20679 y
   Cui WY, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.496
   Deb M, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148 021 01125 2
   Delanois RE, 2017, J ARTHROPLASTY, V32, P2663, DOI 10.1016/j.arth.2017.03.066
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Deng ZT, 2017, ACTA BIOMATER, V49, P541, DOI 10.1016/j.actbio.2016.11.051
   Ding XJ, 2020, THERANOSTICS, V10, P11110, DOI 10.7150/thno.47413
   Early JO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695257
   Evangelopoulos DS, 2019, J KNEE SURG, V32, P941, DOI 10.1055/s 0038 1672203
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Grebe A, 2018, CIRC RES, V122, P1722, DOI 10.1161/CIRCRESAHA.118.311362
   Hass DT, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2021.100941
   Hodges NA, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121127
   Hou J, 2021, J BUON, V26, P1187
   Hu SH, 2021, BIOMATER SCI UK, V9, P5791, DOI 10.1039/d1bm00563d
   Husain I, 2017, CHEM BIOL INTERACT, V274, P35, DOI 10.1016/j.cbi.2017.07.001
   Iovine JC, 2021, TRENDS BIOCHEM SCI, V46, P902, DOI 10.1016/j.tibs.2021.06.003
   Jourdan T, 2013, NAT MED, V19, P1132, DOI 10.1038/nm.3265
   Kim J, 2014, VET RES COMMUN, V38, P193, DOI 10.1007/s11259 014 9602 5
   Kocabey AE, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101079
   Latz E, 2021, NAT REV IMMUNOL, V21, P622, DOI 10.1038/s41577 021 00600 4
   Linden J, 2012, NATURE, V487, P179, DOI 10.1038/487179a
   Liu T, 2019, J ALLERGY CLIN IMMUN, V144, P777, DOI 10.1016/j.jaci.2019.05.006
   Lu CY, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202100147
   Ma M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.718779
   Ma YG, 2021, J HAZARD MATER, V405, DOI 10.1016/j.jhazmat.2020.124251
   Magupalli VG, 2021, TRENDS IMMUNOL, V42, P948, DOI 10.1016/j.it.2021.09.014
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Nabeshima A, 2017, BIOMATERIALS, V117, P1, DOI 10.1016/j.biomaterials.2016.11.039
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Rodland ES, 2022, J HAZARD MATER, V423, DOI 10.1016/j.jhazmat.2021.127092
   Sawant A, 2013, CANCER RES, V73, P4606, DOI 10.1158/0008 5472.CAN 13 0305
   Shao Q, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106376
   Song JY, 2021, NAT REV MOL CELL BIO, V22, P54, DOI 10.1038/s41580 020 00300 2
   Strappazzon F, 2015, CELL DEATH DIFFER, V22, P419, DOI 10.1038/cdd.2014.139
   Sulkshane P, 2021, REDOX BIOL, V45, DOI 10.1016/j.redox.2021.102047
   Sun KY, 2022, BIOACT MATER, V8, P435, DOI 10.1016/j.bioactmat.2021.06.016
   Tang TT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00227 x
   Wang LL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657687
   Wang SH, 2015, MOL NEUROBIOL, V51, P718, DOI 10.1007/s12035 014 8755 0
   Wang Y, 2017, J MECH BEHAV BIOMED, V68, P124, DOI 10.1016/j.jmbbm.2017.01.041
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wang ZH, 2015, ACTA BIOMATER, V24, P352, DOI 10.1016/j.actbio.2015.06.024
   Wise JTF, 2018, J ENVIRON PATHOL TOX, V37, P317, DOI 10.1615/JEnvironPatholToxicolOncol.2018028689
   Wu X, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.628168
   Xie CF, 2020, J HAZARD MATER, V394, DOI 10.1016/j.jhazmat.2020.122549
   Xu YM, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13142
   Xue S, 2021, BIOACT MATER, V6, P2372, DOI 10.1016/j.bioactmat.2021.01.017
   Xue S, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105826
   Xue S, 2019, BIOCHEM BIOPH RES CO, V517, P132, DOI 10.1016/j.bbrc.2019.07.032
   Yang C, 2020, J CELL MOL MED, V24, P1553, DOI 10.1111/jcmm.14842
   Yang F, 2021, J HAZARD MATER, V408, DOI 10.1016/j.jhazmat.2020.124888
   Zaveri TD, 2017, BIOMATERIALS, V115, P128, DOI 10.1016/j.biomaterials.2016.10.038
   Zewinger S, 2020, NAT IMMUNOL, V21, P30, DOI 10.1038/s41590 019 0548 1
   Zheng M, 2020, IMMUNOL REV, V297, P26, DOI 10.1111/imr.12909
   Zhou H, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0094 1
   Zhu HL, 2022, J HAZARD MATER, V424, DOI 10.1016/j.jhazmat.2021.127268
NR 60
TC 15
Z9 15
U1 4
U2 89
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD MAY 1
PY 2022
VL 435
AR 135115
DI 10.1016/j.cej.2022.135115
EA FEB 2022
PN 2
PG 16
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA ZZ0LQ
UT WOS:000772968800003
DA 2025 08 17
ER

PT J
AU Yu, YT
   Rong, KW
   Yao, DQ
   Zhang, Q
   Cao, XK
   Rao, B
   Xia, Y
   Lu, Y
   Shen, YF
   Yao, Y
   Xu, HT
   Ma, PX
   Cao, Y
   Qin, A
AF Yu, Yating
   Rong, Kewei
   Yao, Deqiang
   Zhang, Qing
   Cao, Xiankun
   Rao, Bing
   Xia, Ying
   Lu, Yi
   Shen, Yafeng
   Yao, Ying
   Xu, Hongtao
   Ma, Peixiang
   Cao, Yu
   Qin, An
TI The structural pathology for hypophosphatasia caused by malfunctional
   tissue non specific alkaline phosphatase
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ENZYME REPLACEMENT THERAPY; TNSALP GENE; PYROPHOSPHATE; MUTATIONS;
   CHILDREN; MINERALIZATION; SUBSTITUTION; RESOLUTION; PHENOTYPE; MECHANISM
AB Hypophosphatasia (HPP) is a bone disease caused by mutations in tissue non specific alkaline phosphatase (TNAP). Here, authors solved the crystal and cryoEM structures of TNAP, shedding light on the molecular mechanisms underlying HPP.
   Hypophosphatasia (HPP) is a metabolic bone disease that manifests as developmental abnormalities in bone and dental tissues. HPP patients exhibit hypo mineralization and osteopenia due to the deficiency or malfunction of tissue non specific alkaline phosphatase (TNAP), which catalyzes the hydrolysis of phosphate containing molecules outside the cells, promoting the deposition of hydroxyapatite in the extracellular matrix. Despite the identification of hundreds of pathogenic TNAP mutations, the detailed molecular pathology of HPP remains unclear. Here, to address this issue, we determine the crystal structures of human TNAP at near atomic resolution and map the major pathogenic mutations onto the structure. Our study reveals an unexpected octameric architecture for TNAP, which is generated by the tetramerization of dimeric TNAPs, potentially stabilizing the TNAPs in the extracellular environments. Moreover, we use cryo electron microscopy to demonstrate that the TNAP agonist antibody (JTALP001) forms a stable complex with TNAP by binding to the octameric interface. The administration of JTALP001 enhances osteoblast mineralization and promoted recombinant TNAP rescued mineralization in TNAP knockout osteoblasts. Our findings elucidate the structural pathology of HPP and highlight the therapeutic potential of the TNAP agonist antibody for osteoblast associated bone disorders.
C1 [Yu, Yating; Rong, Kewei; Zhang, Qing; Cao, Xiankun; Rao, Bing; Ma, Peixiang; Cao, Yu; Qin, An] Shanghai Jiao Tong Univ, Sch Med,Peoples Hosp 9, Dept Orthoped, Shanghai Key Lab Orthoped Implant, Shanghai 200011, Peoples R China.
   [Yu, Yating; Zhang, Qing; Rao, Bing; Xia, Ying; Lu, Yi; Shen, Yafeng; Cao, Yu] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Inst Precis Med, 115 Jinzun Rd, Shanghai 200125, Peoples R China.
   [Yao, Deqiang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai 200127, Peoples R China.
   [Yao, Ying; Xu, Hongtao] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; ShanghaiTech University
RP Ma, PX; Cao, Y; Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med,Peoples Hosp 9, Dept Orthoped, Shanghai Key Lab Orthoped Implant, Shanghai 200011, Peoples R China.; Cao, Y (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Inst Precis Med, 115 Jinzun Rd, Shanghai 200125, Peoples R China.
EM mapx@shsmu.edu.cn; yu.cao@shsmu.edu.cn; dr_qinan@163.com
RI Qin, An/J 2518 2019; Xu, Hongtao/AAH 8882 2020; Cao, Yu/GNP 6653 2022;
   Ma, Peixiang/HJY 4358 2023
OI Rao, Bing/0000 0001 9895 4133; ma, peixiang/0000 0001 6794 1663; Cao,
   Yu/0000 0003 1409 2068; Xu, Hongtao/0000 0001 5174 9079; 
FU National Natural Science Foundation of China [82272519, 82072468,
   92068102, 81772373]; National Key Research and Development Program of
   China [2018YFC1004704]; Shanghai Frontiers Science Center of
   Degeneration and Regeneration in Skeletal System; Shanghai Science and
   Technology Committee [20S11902000, 23ZR1437600]; Shanghai Institute of
   Precision Medicine [JY201804]; Ninth People's Hospital, Shanghai Jiao
   Tong University School of Medicine, Shanghai Key Laboratory of
   Orthopedic Implants [KFKT202207]; Innovative Research Team of High level
   Local Universities in Shanghai [SHSMU ZLCX20211700]; Special Project of
   Shanghai Synchrotron Radiation Facility (SSRF) [2020 NFPS ZD 000146]
FX The authors thank Drs. Ming Lei, Jie Zhao, and Lijun Wang (for
   scientific discussion); Yijun Gu, Rijing Liao, Shufang He and Mi Cao
   (for assistance with the data analysis). This work was supported by
   National Natural Science Foundation of China (82272519 and 82072468,
   Y.C.; 92068102 and 81772373 A.Q.), National Key Research and Development
   Program of China (2018YFC1004704, Y.C.), Shanghai Frontiers Science
   Center of Degeneration and Regeneration in Skeletal System, the Shanghai
   Science and Technology Committee (20S11902000 Y.C.; 23ZR1437600 P.M.),
   SHIPM pi fund (No. JY201804, Y.C.) from Shanghai Institute of Precision
   Medicine, the Ninth People's Hospital, Shanghai Jiao Tong University
   School of Medicine, Shanghai Key Laboratory of Orthopedic Implants
   (KFKT202207). This work was also supported by Innovative Research Team
   of High level Local Universities in Shanghai (SHSMU ZLCX20211700) and
   the Special Project of Shanghai Synchrotron Radiation Facility (SSRF)
   BL18U1 (2020 NFPS ZD 000146). We thank the staff members of the Electron
   Microimaging Center, Bioimaging Facility, and Proteomics Platform at
   Shanghai Institute of Precision Medicine for providing technical support
   and assistance in data collection. SSRF beamlines BL18U1 and BL19U1 were
   used for X ray crystallography data collection.
CR Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Brun Heath I, 2008, CLIN GENET, V73, P245, DOI 10.1111/j.1399 0004.2007.00902.x
   Brun Heath I, 2005, MOL GENET METAB, V84, P273, DOI 10.1016/j.ymgme.2004.11.003
   BUBLITZ R, 1993, EUR J BIOCHEM, V217, P199, DOI 10.1111/j.1432 1033.1993.tb18234.x
   Chen SX, 2013, ULTRAMICROSCOPY, V135, P24, DOI 10.1016/j.ultramic.2013.06.004
   Ciancaglini P, 2006, BRAZ J MED BIOL RES, V39, P603, DOI 10.1590/S0100 879X2006000500006
   COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441
   Concolino D, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052 018 0562 1
   Ermonval M, 2015, SUBCELL BIOCHEM, V76, P167, DOI 10.1007/978 94 017 7197 9_9
   Fauvert D, 2009, BMC MED GENET, V10, DOI 10.1186/1471 2350 10 51
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Gao CS, 1999, J AM CHEM SOC, V121, P6517, DOI 10.1021/ja990966e
   HAWRYLAK K, 1988, J BIOL CHEM, V263, P14368
   Holtz KM, 1999, J BIOL CHEM, V274, P8351, DOI 10.1074/jbc.274.13.8351
   KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022 2836(91)90724 K
   Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200
   Litmanovitz I, 2002, J INHERIT METAB DIS, V25, P35, DOI 10.1023/A:1015121414782
   Liu WJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0029 4
   Llinas P, 2005, J MOL BIOL, V350, P441, DOI 10.1016/j.jmb.2005.04.068
   Makita S, 2012, FEBS J, V279, P4327, DOI 10.1111/febs.12022
   Martins L, 2013, BONE, V56, P390, DOI 10.1016/j.bone.2013.06.010
   Millán JL, 2008, J BONE MINER RES, V23, P777, DOI 10.1359/JBMR.071213
   Millan Jose Luis, 2006, Purinergic Signal, V2, P335, DOI 10.1007/s11302 005 5435 6
   Millán JL, 2016, CALCIFIED TISSUE INT, V98, P398, DOI 10.1007/s00223 015 0079 1
   Mornet E, 1998, EUR J HUM GENET, V6, P308, DOI 10.1038/sj.ejhg.5200190
   Mornet E, 2001, J BIOL CHEM, V276, P31171, DOI 10.1074/jbc.M102788200
   Müller WEG, 2017, MAR DRUGS, V15, DOI 10.3390/md15060172
   Müller HL, 2000, J CLIN ENDOCR METAB, V85, P743, DOI 10.1210/jc.85.2.743
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Nakamura T, 2020, BIOCHEM BIOPH RES CO, V524, P702, DOI 10.1016/j.bbrc.2020.01.136
   Nosjean O, 1997, BIOCHEM J, V321, P297, DOI 10.1042/bj3210297
   Numa N, 2008, FEBS J, V275, P2727, DOI 10.1111/j.1742 4658.2008.06414.x
   Price PA, 2009, J BIOL CHEM, V284, P17092, DOI 10.1074/jbc.M109.007013
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/nmeth.4169, 10.1038/NMETH.4169]
   Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013
   SAY JC, 1991, BIOCHIM BIOPHYS ACTA, V1074, P256, DOI 10.1016/0304 4165(91)90161 9
   Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174
   SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022 2836(85)90115 9
   Sultana S, 2013, MOL GENET METAB, V109, P282, DOI 10.1016/j.ymgme.2013.04.016
   Sun YZ, 2021, NATURE, V593, P580, DOI 10.1038/s41586 021 03533 z
   Taillandier A, 1999, Hum Mutat, V13, P171, DOI 10.1002/(SICI)1098 1004(1999)13:2<171::AID HUMU16>3.0.CO;2 T
   Taillandier A, 2001, Hum Mutat, V18, P83, DOI 10.1002/humu.1154
   Taillandier A, 2018, J BONE MINER METAB, V36, P723, DOI 10.1007/s00774 017 0888 6
   Terkeltaub RA, 2001, AM J PHYSIOL CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1
   UNAKAMI S, 1987, COMP BIOCHEM PHYS B, V88, P111, DOI 10.1016/0305 0491(87)90088 5
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Watanabe H, 2005, BIOCHEM BIOPH RES CO, V327, P124, DOI 10.1016/j.bbrc.2004.11.155
   Whyte MP, 2019, LANCET DIABETES ENDO, V7, P93, DOI 10.1016/S2213 8587(18)30307 3
   Whyte MP, 2015, BONE, V75, P229, DOI 10.1016/j.bone.2015.02.022
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Whyte MP, 2010, ANN NY ACAD SCI, V1192, P190, DOI 10.1111/j.1749 6632.2010.05387.x
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
   Xu LJ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171377
   Yang HO, 2013, CELL PHYSIOL BIOCHEM, V32, P635, DOI 10.1159/000354467
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
   Zurutuza L, 1999, HUM MOL GENET, V8, P1039, DOI 10.1093/hmg/8.6.1039
NR 56
TC 24
Z9 24
U1 2
U2 13
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 8
PY 2023
VL 14
IS 1
AR 4048
DI 10.1038/s41467 023 39833 3
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA L7TG7
UT WOS:001025242000014
PM 37422472
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ishizaka, K
   Machida, T
   Kobayashi, S
   Kanbe, N
   Kitahara, S
   Yoshida, KI
AF Ishizaka, Kazuhiro
   Machida, Tatsuya
   Kobayashi, Shuichiro
   Kanbe, Naoko
   Kitahara, Satoshi
   Yoshida, Ken Ichiro
TI Preventive effect of risedronate on bone loss in men receiving
   androgen deprivation therapy for prostate cancer
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article
DE androgen deprivation therapy; bisphosphonate; osteoporosis; prostate
   cancer
ID AGED MALE RATS; HORMONE AGONISTS; OSTEOPOROSIS; BISPHOSPHONATES;
   FRACTURES; MECHANISMS; TRIAL; WOMEN
AB Aim: Androgen deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture. The effect of risedronate, a potent third generation oral bisphosphonate, on bone loss during androgen deprivation therapy was investigated.
   Methods: Sixty one prostate cancer patients with a mean age ( +/  SD) of 79 +/  6 years who had received androgen deprivation therapy for 42 +/  29 months were enrolled, and were treated with 2.5 mg of risedronate daily for six months. Bone mineral density was measured at the femoral neck, lumbar spine, and ultradistal radius by dual energy X  ray absorptiometry. The percent change of bone mineral density after treatment with risedronate was calculated as the primary efficacy. variable. Urinary N  telopeptide of type I collagen was measured as a bone resorption marker.
   Results: Bone mineral density remained stable in the femoral neck and radius during risedronate therapy. In contrast, the bone mineral density of the lumbar spine showed a significant. cant increase from 1069 +/  488 mg/cm(2)  1112 +/  497 mg/cm(2) (P < 0.001), representing a gain of 4.9 +/  8.9%. Urinary N telopeptide of type I collagen decreased significantly (P < 0.001) after three months of risedronate treatment.
   Conclusions: Risedronate could prevent and reverse bone loss in men receiving androgen deprivation therapy for prostate cancer by inhibiting bone resorption.
C1 Kanto Cent Hosp, Dept Urol, Tokyo, Japan.
   Dokkyo Univ, Sch Med, Koshigaya Hosp, Dept Urol, Koshigaya, Japan.
   Dokkyo Univ, Sch Med, Dept Urol, Tochigi, Japan.
C3 Dokkyo Medical University; Dokkyo Medical University
RP Ishizaka, K (通讯作者)，6 25 1 Kamiyoga,Setagaya Ku, Tokyo 1588531, Japan.
EM ishizaka@kanto ctr hsp.com
CR [Anonymous], 1997, Br J Urol, V79, P235
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   DEARNALEY DP, 2003, J NATL CANCER I, V31, P62
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Erben RG, 2000, J BONE MINER RES, V15, P1085, DOI 10.1359/jbmr.2000.15.6.1085
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fogelman I, 2000, J CLIN ENDOCR METAB, V85, P1895, DOI 10.1210/jc.85.5.1895
   Hatano T, 2000, BJU INT, V86, P449, DOI 10.1046/j.1464 410X.2000.00774.x
   JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792 199005000 00002
   Leder BZ, 2000, GASTROENTEROLOGY, V119, P866, DOI 10.1053/gast.2000.17841
   Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656
   MURPHY S, 1993, BONE MINER, V20, P133, DOI 10.1016/S0169 6009(08)80022 0
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Ross RW, 2002, J UROLOGY, V167, P1952, DOI 10.1016/S0022 5347(05)65060 4
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097 0142(19970201)79:3<545::AID CNCR17>3.0.CO;2 3
   VANDERSCHUEREN D, 1992, ENDOCRINOLOGY, V130, P2906, DOI 10.1210/en.130.5.2906
   YATURU S, 2002, ASBMR 24 ANN M SAN A, pM354
NR 24
TC 30
Z9 31
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0919 8172
EI 1442 2042
J9 INT J UROL
JI Int. J. Urol.
PD DEC
PY 2007
VL 14
IS 12
BP 1071
EP 1075
DI 10.1111/j.1442 2042.2007.01911.x
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 234VF
UT WOS:000251191400006
PM 18036042
DA 2025 08 17
ER

PT J
AU Costa, V
   Carina, V
   Conigliaro, A
   Raimondi, L
   De Luca, A
   Bellavia, D
   Salamanna, F
   Setti, S
   Alessandro, R
   Fini, M
   Giavaresi, G
AF Costa, Viviana
   Carina, Valeria
   Conigliaro, Alice
   Raimondi, Lavinia
   De Luca, Angela
   Bellavia, Daniele
   Salamanna, Francesca
   Setti, Stefania
   Alessandro, Riccardo
   Fini, Milena
   Giavaresi, Gianluca
TI miR 31 5p Is a LIPUS Mechanosensitive MicroRNA that Targets HIF 1α
   Signaling and Cytoskeletal Proteins
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE hypoxia; mesenchymal stem cells; microRNAs; Rho family protein;
   regenerative medicine
ID MESENCHYMAL STEM CELLS; HYPOXIA INDUCIBLE FACTOR; OSTEOGENIC
   DIFFERENTIATION; UP REGULATION; EXPRESSION; RHOA; PATHWAY; COMMITMENT;
   CROSSTALK; SATB2
AB The roles of low intensity pulsed ultrasound (LIPUS) and microRNAs (miRNAs) on hMSCs commitments have already been investigated; however, the effects of the application of their co treatments in an in vitro cell model are still unknown. Our previous studies demonstrated that (i) LIPUS modulated hMSCs cytoskeletal organization and (ii) miRNA 675 5p have a role in HIF 1 alpha signaling modulation during hMSCs osteoblast commitment. We investigated for the first time the role of LIPUS as promoter tool for miRNA expression. Thanks to bioinformatic analysis, we identified miR 31 5p as a LIPUS induced miRNA and investigated its role through in vitro studies of gain and loss of function. Results highlighted that LIPUS stimulation induced a hypoxia adaptive cell response, which determines a reorganization of cell membrane and cytoskeleton proteins. MiR 31 5p gain and loss of function studies, demonstrated as miR 31 5p overexpression, were able to induce hypoxic and cytoskeletal responses. Moreover, the co treatments LIPUS and miR 31 5p inhibitor abolished the hypoxic responses including angiogenesis and the expression of Rho family proteins. MiR 31 5p was identified as a LIPUS mechanosensitive miRNAs and may be considered a new therapeutic option to promote or abolish hypoxic response and cytoskeletal organization on hMSCs during the bone regeneration process.
C1 [Costa, Viviana; Carina, Valeria; Raimondi, Lavinia; De Luca, Angela; Bellavia, Daniele] IRCCS Ist Ortoped Rizzoli, I 40136 Bologna, Italy.
   [Conigliaro, Alice; Alessandro, Riccardo] Univ Palermo, Dept BioMed Neurosci & Adv Diagnost BiND, I 90100 Palermo, Italy.
   [Salamanna, Francesca; Fini, Milena; Giavaresi, Gianluca] IRCCS Ist Ortoped Rizzoli, Lab Preclin & Surg Studies, I 40136 Bologna, Italy.
   [Setti, Stefania] IGEA SpA, I 41012 Modena, Italy.
   [Alessandro, Riccardo] CNR, Inst Biomed & Mol Immunol IBIM, I 90100 Palermo, Italy.
C3 University of Palermo; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy"
   (IBIM CNR)
RP Costa, V (通讯作者)，IRCCS Ist Ortoped Rizzoli, I 40136 Bologna, Italy.
EM viviana.costa@ior.it; valeria.carina@ior.it; alice.conigliaro@unipa.it;
   lavinia.raimondi@ior.it; angela.deluca@ior.it; daniele.bellavia@ior.it;
   francesca.salamanna@ior.it; s.setti@igeamedical.com;
   riccardo.alessandro@unipa.it; milena.fini@ior.it;
   gianluca.giavaresi@ior.it
RI COSTA, VIVIANA/K 4084 2016; De Luca, Angela/ABD 3384 2020; Conigliaro,
   Alice/ACW 5549 2022; Bellavia, Daniele/H 9774 2019; Conigliaro,
   Alice/J 8717 2016; Fini, Milena/J 4808 2016; Giavaresi,
   Gianluca/J 5583 2016; carina, valeria/K 2001 2016; deluca,
   angela/ABD 3384 2020; costa, viviana/K 4084 2016; Salamanna,
   Francesca/J 6032 2016; Raimondi, Lavinia/K 4085 2016
OI De Luca, Angela/0000 0001 5493 9441; Bellavia,
   Daniele/0000 0003 3308 9112; Conigliaro, Alice/0000 0002 3037 835X;
   costa, viviana/0000 0002 2425 6460; Salamanna,
   Francesca/0000 0001 7402 4054; Raimondi, Lavinia/0000 0001 9394 2002
FU National Operative Program for Research and Competitiveness
   [2007 2013 PON03_00011]
FX The study was developed with the contribution of the National Operative
   Program for Research and Competitiveness 2007 2013 PON03_00011
   "Potenziamento strutturale di una rete di eccellenza per la ricerca
   preclinica e clinica sulla terapia personalizzata in oncologia e in
   medicina rigenerativa". Associazione Italiana per la Ricerca sul Cancro
   (Italian Association for Cancer Research) MFAG 2017 Id.19982. No
   benefits in any form were received or will be received from a commercial
   party related directly or indirectly to the subject of this article.
CR Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Bellavia D, 2019, BONE, V122, P52, DOI 10.1016/j.bone.2019.02.013
   Carina V, 2017, J APPL BIOMATER FUNC, V15, pE215, DOI 10.5301/jabfm.5000342
   Chen T, 2014, CANCER BIOL THER, V15, P516, DOI 10.4161/cbt.28017
   Costa V, 2017, CYTOTHERAPY, V19, P1412, DOI 10.1016/j.jcyt.2017.09.007
   Costa V, 2018, J CELL PHYSIOL, V233, P1558, DOI 10.1002/jcp.26058
   Costa V, 2017, ONCOTARGET, V8, P24292, DOI 10.18632/oncotarget.14464
   Deng Y, 2014, EUR CELLS MATER, V27, P13, DOI 10.22203/eCM.v027a02
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Dispenza C, 2017, RSC ADV, V7, P52039, DOI 10.1039/c7ra09797b
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Erdogan Ö, 2009, J ULTRAS MED, V28, P765, DOI 10.7863/jum.2009.28.6.765
   Fang BW, 2008, J CELL SCI, V121, P358, DOI 10.1242/jcs.017145
   Gilkes DM, 2014, P NATL ACAD SCI USA, V111, pE384, DOI 10.1073/pnas.1321510111
   Griffiths Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Güntert T, 2016, BRAIN RES, V1642, P298, DOI 10.1016/j.brainres.2016.03.025
   Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200
   Kusuyama J., 2015, J ORTHOP TRAUMA, V29, pS2, DOI DOI 10.1097/01.BOT.0000462953.87235.74
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo Dico A, 2016, THERANOSTICS, V6, P1105, DOI 10.7150/thno.14700
   Manochantr S, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/7257628
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   McCully M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192562
   Pacary E, 2007, MOL CELL NEUROSCI, V35, P409, DOI 10.1016/j.mcn.2007.04.002
   Peng SP, 2016, MOL MED REP, V14, P623, DOI 10.3892/mmr.2016.5335
   R Foundation for Statistical Computing, 2008, LANG ENV STAT COMP
   Raheja LF, 2011, CELL BIOL INT, V35, P981, DOI 10.1042/CBI20100733
   Stepicheva NA, 2016, MOL REPROD DEV, V83, P654, DOI 10.1002/mrd.22678
   Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427
   Vertelov G, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt153
   Wang H, 2016, SCI REP UK, V6, DOI 10.1038/srep23170
   Wang J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.112
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012
   Xie Q, 2014, BIOCHEM BIOPH RES CO, V446, P98, DOI 10.1016/j.bbrc.2014.02.058
   Xue Y, 2006, INT J CANCER, V118, P2965, DOI 10.1002/ijc.21763
   Yang CZ, 2013, CELL REP, V3, P52, DOI 10.1016/j.celrep.2012.12.007
   Yin CP, 2015, MOL MED REP, V12, P7123, DOI 10.3892/mmr.2015.4267
   Yue Y, 2013, CELL PROLIFERAT, V46, P320, DOI 10.1111/cpr.12035
   Zhang XB, 2016, TUMOR BIOL, V37, P8317, DOI 10.1007/s13277 015 4511 y
   Zieseniss A, 2014, HYPOXIA, V2, P11, DOI 10.2147/HP.S53575
NR 42
TC 20
Z9 21
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR 28
PY 2019
VL 20
IS 7
AR 1569
DI 10.3390/ijms20071569
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HU0RO
UT WOS:000464978800005
PM 30925808
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Roberts, SJ
   Owen, HC
   Tam, WL
   Solie, L
   Van Cromphaut, SJ
   Van den Berghe, G
   Luyten, FP
AF Roberts, Scott J.
   Owen, Helen C.
   Tam, Wai Long
   Solie, Lien
   Van Cromphaut, Sophie J.
   Van den Berghe, Greet
   Luyten, Frank P.
TI Humanized Culture of Periosteal Progenitors in Allogeneic Serum Enhances
   Osteogenic Differentiation and In Vivo Bone Formation
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Adult stem cells; Bone; Culture; Differentiation; Mesenchymal stem
   cells; Osteoblast; Tissue regeneration
ID MESENCHYMAL STEM CELLS; FETAL BOVINE SERUM; CALCIUM PHOSPHATE;
   GENE EXPRESSION; FORMING POTENCY; CALF SERUM; MARROW; TRANSPLANTATION;
   OSTEOINDUCTION; THERAPY
AB The translation of stem cell based regenerative solutions from the laboratory to the clinic is often hindered by the culture conditions used to expand cell populations. Although fetal bovine serum (FBS) is widely used, regulatory bodies and safety concerns encourage alternative, xeno free culturing practices. In an attempt to apply this approach to a bone forming combination product of human periosteal progenitors (human periosteum derived cells) on a clinically used calcium phosphate carrier, FBS was substituted for human allogeneic serum (hAS) during cell expansion. It was found that cell proliferation was increased in hAS along with an apparent commitment to the osteogenic lineage, indicated by enhanced Runx2 expression, as well as alkaline phosphatase activity and matrix mineralization. Following analysis of signaling pathways, it was found that interferon mediated signaling was downregulated, whereas JAK STAT signaling was upregulated. STAT3 phosphorylation was enhanced in hAS cultured human periosteum derived cells, inhibition of which ablated the proliferative effect of hAS. Furthermore, following in vivo implantation of hAS cultured cells on NuOss scaffolds, enhanced bone formation was observed compared with FBS (71% increase, p < .001). Interestingly, the de novo formed bone appeared to have a higher ratio of immature regions to mature regions, indicating that after 8 weeks implantation, tissue formation processes were continuing. Integration of the implant with the environment appeared to be altered, with a decrease in calcium phosphate grain size and surface area, indicative of accelerated resorption. This study highlights the advantages of using humanized culture conditions for the expansion of human periosteal progenitors intended for bone regeneration.
C1 [Roberts, Scott J.; Tam, Wai Long; Luyten, Frank P.] Katholieke Univ Leuven, Skeletal Biol & Engn Res Ctr, Lab Dev & Stem Cell Biol, Louvain, Belgium.
   [Roberts, Scott J.; Tam, Wai Long; Luyten, Frank P.] Katholieke Univ Leuven, Prometheus, Div Skeletal Tissue Engn, Louvain, Belgium.
   [Owen, Helen C.; Solie, Lien; Van Cromphaut, Sophie J.; Van den Berghe, Greet] Katholieke Univ Leuven, Dept & Lab Intens Care Med, Louvain, Belgium.
   [Roberts, Scott J.] Univ Coll London, Royal Natl Orthopaed Hosp, Div Surg & Intervent Sci, Inst Orthopaed & Musculoskeletal Sci, Stanmore, Middx, England.
C3 KU Leuven; KU Leuven; KU Leuven; University of London; University
   College London; Royal National Orthopaedic Hospital NHS Trust
RP Roberts, SJ (通讯作者)，Skeletal Biol & Engn Res Ctr, Onderwijs & Navorsing 8th Floor,Bus 813, B 3000 Louvain, Belgium.
EM scott.roberts@med.kuleuven.be
RI Roberts, Helen C./F 8906 2018; Roberts, Helen/F 8906 2018; Van den
   Berghe, Greet/J 6788 2018; Luyten, Frank/GPS 7793 2022
OI Roberts, Helen C./0000 0003 1974 0319; Van den Berghe,
   Greet/0000 0002 5320 1362
FU Stem Cell Institute of Leuven KU Leuven; FWO [1508412N]
FX We thank Carla Geeroms and Kathleen Bosmans for excellent technical
   assistance. We also thank all collaborators of the Skeletal Biology and
   Engineering Research Center for useful comments and discussions. Funding
   for this research was obtained from the Stem Cell Institute of Leuven KU
   Leuven and FWO project 1508412N. S.J.R. is a postdoctoral fellow of the
   Research Foundation Flanders (FWO). This work is also part of
   Prometheus, the Leuven Research and Development Division of Skeletal
   Tissue Engineering of the Katholieke Universiteit Leuven
   (http://www.kuleuven.be/prometheus).
CR Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Aldahmash A, 2011, STEM CELL REV REP, V7, P860, DOI 10.1007/s12015 011 9274 2
   Brunner D, 2010, ALTEX ALTERN ANIM EX, V27, P53
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chai YC, 2011, TISSUE ENG PT A, V17, P1083, DOI [10.1089/ten.TEA.2010.0160, 10.1089/ten.tea.2010.0160]
   Chai YC, 2012, BIOMATERIALS, V33, P3127, DOI 10.1016/j.biomaterials.2012.01.015
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cifrian E, 1996, AM J VET RES, V57, P308
   Colnot C, 2006, BIOCHEM BIOPH RES CO, V350, P557, DOI 10.1016/j.bbrc.2006.09.079
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Croitoru Lamoury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014698
   De Bari C, 2006, ARTHRITIS RHEUM, V54, P1209, DOI 10.1002/art.21753
   De Bari C, 2008, ARTHRITIS RHEUM, V58, P240, DOI 10.1002/art.23143
   Doucet C, 2005, J CELL PHYSIOL, V205, P228, DOI 10.1002/jcp.20391
   ERICKSON GA, 1991, DEV BIOLOGICALS, V75, P173
   Eyckmans J, 2010, J CELL MOL MED, V14, P1845, DOI 10.1111/j.1582 4934.2009.00807.x
   Eyckmans J, 2013, BIOMATERIALS, V34, P4612, DOI 10.1016/j.biomaterials.2013.03.011
   GAO J, 1993, J BIOL REG HOMEOS AG, V7, P115
   Haasters F, 2009, J ANAT, V214, P759, DOI 10.1111/j.1469 7580.2009.01065.x
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   HODGSON J, 1995, BIO TECHNOL, V13, P333, DOI 10.1038/nbt0495 333
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204
   Janicki P, 2011, EUR CELLS MATER, V21, P488, DOI 10.22203/eCM.v021a37
   Jochems CEA, 2002, ATLA ALTERN LAB ANIM, V30, P219, DOI 10.1177/026119290203000208
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martin I, 2002, TISSUE ENG, V8, P847, DOI 10.1089/10763270260424204
   Nimura A, 2008, ARTHRITIS RHEUM, V58, P501, DOI 10.1002/art.23219
   Roberts SJ, 2011, STEM CELL RES, V7, P137, DOI 10.1016/j.scr.2011.04.003
   Roberts SJ, 2011, BIOMATERIALS, V32, P4393, DOI 10.1016/j.biomaterials.2011.02.047
   Shahdadfar A, 2005, STEM CELLS, V23, P1357, DOI 10.1634/stemcells.2005 0094
   Simonetti AB, 2007, BRAZ J MICROBIOL, V38, P153, DOI 10.1590/S1517 83822007000100032
   Sundin M, 2007, HAEMATOLOGICA, V92, P1208, DOI 10.3324/haematol.11446
   Taguchi K, 2005, BIOCHEM BIOPH RES CO, V331, P31, DOI 10.1016/j.bbrc.2005.03.119
   van der Valk J, 2004, TOXICOL IN VITRO, V18, P1, DOI 10.1016/j.tiv.2003.08.009
   Zhou XH, 2013, TISSUE ENG PART C ME, V19, P720, DOI [10.1089/ten.TEC.2012.0601, 10.1089/ten.tec.2012.0601]
NR 38
TC 26
Z9 28
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD FEB
PY 2014
VL 3
IS 2
BP 218
EP 228
DI 10.5966/sctm.2012 0137
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AB0SG
UT WOS:000331501800016
PM 24375540
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, CC
   Qiao, WX
   Xue, Q
   Goltzman, D
   Miao, DS
   Dong, Z
AF Yang, Cuicui
   Qiao, Wanxin
   Xue, Qi
   Goltzman, David
   Miao, Dengshun
   Dong, Zhan
TI The senolytic agent ABT263 ameliorates osteoporosis caused by active
   vitamin D insufficiency through selective clearance of senescent
   skeletal cells
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Cellular senescence; Osteoporosis; SASP; Senolytics; Vitamin D
   insufficiency
ID CELLULAR SENESCENCE; SECRETORY PHENOTYPE; PARATHYROID HORMONE; BONE LOSS
AB Background/Objective: Active vitamin D insufficiency accelerates the development of osteoporosis, with senescent bone cells and the senescence associated secretory phenotype (SASP) playing crucial roles. This study aimed to investigate whether the senolytic agent ABT263 could correct osteoporosis caused by active vitamin D insufficiency by selectively clearing senescent cells. Methods: Bone marrow mesenchymal stem cells (BM MSCs) from young and aged mice were treated with ABT263 in vitro, and 1,25(OH)2D insufficient (Cyp27b1+/  ) mice were administered ABT263 in vivo. Cellular, molecular, imaging, and histopathological analyses were performed to compare treated cells and mice with control groups. Results: ABT263 induced apoptosis in senescent BM MSCs by downregulating Bcl2 and upregulating Bax expression. It also induced apoptosis in senescent BM MSCs from 1,25(OH)2D insufficient mice. ABT263 administration corrected bone loss caused by 1,25(OH)2D insufficiency by increasing bone density, bone volume, trabecular number, trabecular thickness, and collagen synthesis. It also enhanced osteoblastic bone formation and reduced osteoclastic bone resorption in vivo. ABT263 treatment corrected the impaired osteogenic action of BM MSCs by promoting their proliferation and osteogenic differentiation. Furthermore, it corrected oxidative stress and DNA damage caused by 1,25(OH)2D insufficiency by increasing SOD 2 and decreasing gamma H2A.X expression. Finally, ABT263 corrected bone cell senescence and SASP caused by 1,25(OH)2D insufficiency by reducing the expression of senescence and SASP related genes and proteins. Conclusion: ABT263 can correct osteoporosis caused by active vitamin D insufficiency by selectively clearing senescent skeletal cells, reducing oxidative stress, DNA damage, and SASP, and promoting bone formation while inhibiting bone resorption. These findings provide new insights into the potential therapeutic application of senolytic agents in the treatment of osteoporosis associated with active vitamin D insufficiency. The translational potential of this article: This study highlights the therapeutic potential of ABT263, a senolytic compound, in treating osteoporosis caused by active vitamin D insufficiency. By selectively eliminating senescent bone cells and their associated SASP, ABT263 intervention demonstrates the ability to restore bone homeostasis, prevent further bone loss, and promote bone formation. These findings contribute to the growing body of research supporting the use of senolytic therapies for the prevention and treatment of age related bone disorders. The translational potential of this study lies in the development of novel therapeutic strategies targeting cellular senescence to combat osteoporosis, particularly in cases where vitamin D insufficiency is a contributing factor. Further clinical studies are warranted to validate the efficacy and safety of ABT263 and other senolytic agents in the treatment of osteoporosis in humans.
C1 [Yang, Cuicui; Qiao, Wanxin; Xue, Qi; Miao, Dengshun] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing 211166, Jiangsu, Peoples R China.
   [Goltzman, David] McGill Univ, Hlth Ctr, Calcium Res Lab, Montreal, PQ H4A 3J1, Canada.
   [Goltzman, David] McGill Univ, Dept Med, Montreal, PQ H4A 3J1, Canada.
   [Dong, Zhan] Nanjing Med Univ, Dept Orthoped, Nanjing 210008, Jiangsu, Peoples R China.
C3 Nanjing Medical University; McGill University; McGill University;
   Nanjing Medical University
RP Miao, DS (通讯作者)，Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing 211166, Jiangsu, Peoples R China.; Dong, Z (通讯作者)，Nanjing Med Univ, Dept Orthoped, Nanjing 210008, Jiangsu, Peoples R China.
EM dsmiao@njmu.edu.cn; dongzhan121@163.com
OI Miao, Dengshun/0000 0002 2682 3502
FU National Key R & D Program of China, China [2018YFA0800800]; National
   Natural Science Foundation of China, China [81730066]; Canadian
   Institutes of Health Research, Canada [PJT 152963]
FX This work was supported by grants from the National Key R & D Program of
   China, China (2018YFA0800800 to DM), the National Natural Science
   Foundation of China, China (81730066 to DM) and the Canadian Institutes
   of Health Research, Canada (PJT 152963).
CR Adami S, 2009, OSTEOPOROSIS INT, V20, P239, DOI 10.1007/s00198 008 0650 y
   Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Anuar NNM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.564108
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301 472X(00)00160 0
   Bikle DD, 2012, CURR OSTEOPOROS REP, V10, P151, DOI 10.1007/s11914 012 0098 z
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008 0004
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   de Vos S, 2021, LEUKEMIA LYMPHOMA, V62, P810, DOI 10.1080/10428194.2020.1845332
   Doolittle ML, 2021, MECH AGEING DEV, V199, DOI 10.1016/j.mad.2021.111565
   Fang HK, 2022, CLIN INTERV AGING, V17, P405, DOI 10.2147/CIA.S349604
   Farr JN, 2019, BONE, V121, P121, DOI 10.1016/j.bone.2019.01.015
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI154888
   Khosla S, 2020, NAT REV ENDOCRINOL, V16, P263, DOI 10.1038/s41574 020 0335 y
   Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013
   Lips P, 2010, J STEROID BIOCHEM, V121, P297, DOI 10.1016/j.jsbmb.2010.02.021
   Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002
   Marcinowska Suchowierska E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00550
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pignolo RJ, 2019, CURR OSTEOPOROS REP, V17, P70, DOI 10.1007/s11914 019 00504 2
   Pike JW, 2017, ENDOCRIN METAB CLIN, V46, P815, DOI 10.1016/j.ecl.2017.07.001
   Qiao WX, 2020, AM J TRANSL RES, V12, P507
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Sharma AK, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00354
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Wang P, 2023, J ORTHOP TRANSL, V40, P13, DOI 10.1016/j.jot.2023.04.003
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591 018 0092 9
   Yang RL, 2022, FREE RADICAL BIO MED, V178, P246, DOI 10.1016/j.freeradbiomed.2021.12.010
   Yang RL, 2020, AGING CELL, V19, DOI 10.1111/acel.13095
   Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 44
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD NOV
PY 2024
VL 49
BP 107
EP 118
DI 10.1016/j.jot.2024.08.012
EA OCT 2024
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA I9L6E
UT WOS:001333397800001
PM 39430127
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Habberstad, R
   Froseth, TCS
   Aass, N
   Abramova, T
   Baas, T
   Morkeset, ST
   Caraceni, A
   Laird, B
   Boland, JW
   Rossi, R
   Garcia Alonso, E
   Stensheim, H
   Loge, JH
   Hjermstad, MJ
   Bjerkeset, E
   Bye, A
   Lund, JA
   Solheim, TS
   Vagnildhaug, OM
   Brunelli, C
   Damås, JK
   Mollnes, TE
   Kaasa, S
   Klepstad, P
AF Habberstad, Ragnhild
   Froseth, Trude Camilla Salvesen
   Aass, Nina
   Abramova, Tatiana
   Baas, Theo
   Morkeset, Siri Tessem
   Caraceni, Augusto
   Laird, Barry
   Boland, Jason W.
   Rossi, Romina
   Garcia Alonso, Elena
   Stensheim, Hanne
   Loge, Jon Havard
   Hjermstad, Marianne Jensen
   Bjerkeset, Ellen
   Bye, Asta
   Lund, Jo Asmund
   Solheim, Tora Skeidsvoll
   Vagnildhaug, Ola Magne
   Brunelli, Cinzia
   Damas, Jan Kristian
   Mollnes, Tom Eirik
   Kaasa, Stein
   Klepstad, Pal
TI The Palliative Radiotherapy and Inflammation Study (PRAIS)   protocol
   for a longitudinal observational multicenter study on patients with
   cancer induced bone pain
SO BMC PALLIATIVE CARE
LA English
DT Article
DE Cancer; Radiation therapy; Palliative; Bone metastases; Pain;
   Depression; Cachexia; Inflammation
ID FUTURE CLINICAL TRIALS; INTERNATIONAL CONSENSUS; CLASSIFICATION SYSTEM;
   OSTEOCLAST ACTIVITY; RADIATION THERAPY; MAJOR DEPRESSION; URINARY
   MARKERS; BREAST CANCER; CARE RESEARCH; END POINTS
AB Background: Radiation therapy (RT) results in pain relief for about 6 of 10 patients with cancer induced bone pain (CIBP) caused by bone metastases. The high number of non responders, the long median time from RT to pain response and the risk of adverse effects, makes it important to determine predictors of treatment response. Clinical features such as cancer type, performance status and pain intensity, and biomarkers for osteoclast activity are proposed as predictors of response to RT. However, results are inconsistent and there is a need for better predictors of RT response. A similar argument can be stated for the development of cachexia; there are currently no predictors that can identify patients who will develop cachexia later in the cancer disease trajectory. Experimental and preclinical studies show that pain, depression and cachexia are related to inflammation. However, it is not known if inflammatory biomarkers can predict CIBP, depression or development of cachexia.
   Methods: This multicenter, multinational longitudinal observational study will include 600 adult patients receiving RT for CIBP. Demographic data, clinical variables, osteoclast and inflammatory biomarkers will be assessed before start of RT, and 3, 8, 16, 24 and 52 weeks after last course of RT. The primary aim of the study is to identify potential predictors for pain relief from RT. Secondary aims are to explore potential predictors for development of cachexia, the longitudinal relationship between pain intensity and depression, and if inflammatory biomarkers are associated with changes in pain intensity, cachexia and depression during one year follow up.
   Discussion: The immediate clinical implication of the PRAIS study is to identify potential predictive factors for a RT response on CIBP, and thereby reduce non efficacious RT. Patient benefits are fewer hospital visits, reduced risk of adverse effects and more individualized pain treatment. The long term clinical implication of the PRAIS study is to improve the knowledge about inflammation in relation to CIBP, cachexia and depression and potentially identify associations and mechanisms that can be targeted for treatment.
C1 [Habberstad, Ragnhild; Froseth, Trude Camilla Salvesen; Lund, Jo Asmund; Solheim, Tora Skeidsvoll; Vagnildhaug, Ola Magne] Norwegian Univ Sci & Technol, European Palliat Care Res Ctr PRC, Dept Clin & Mol Med, Fac Med & Hlth Sci,NTNU, Trondheim, Norway.
   [Habberstad, Ragnhild; Froseth, Trude Camilla Salvesen; Lund, Jo Asmund; Solheim, Tora Skeidsvoll; Vagnildhaug, Ola Magne] Trondheim Reg & Univ Hosp, St Olavs Hosp, Trondheim, Norway.
   [Habberstad, Ragnhild; Solheim, Tora Skeidsvoll; Vagnildhaug, Ola Magne] Trondheim Reg & Univ Hosp, St Olavs Hosp, Canc Clin, Trondheim, Norway.
   [Aass, Nina; Loge, Jon Havard; Hjermstad, Marianne Jensen; Bjerkeset, Ellen; Bye, Asta; Kaasa, Stein] Univ Oslo, Oslo Univ Hosp, Dept Oncol, European Palliat Care Res Ctr PRC, Oslo, Norway.
   [Aass, Nina; Loge, Jon Havard; Hjermstad, Marianne Jensen; Bjerkeset, Ellen; Bye, Asta; Kaasa, Stein] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Aass, Nina; Stensheim, Hanne; Loge, Jon Havard; Kaasa, Stein] Univ Oslo, Oslo, Norway.
   [Aass, Nina; Stensheim, Hanne; Loge, Jon Havard; Kaasa, Stein] Oslo Univ Hosp, Dept Oncol, Oslo, Norway.
   [Abramova, Tatiana; Baas, Theo; Morkeset, Siri Tessem; Lund, Jo Asmund] More & Romsdal Hosp Trust, Alesund Hosp, Dept Oncol, Alesund, Norway.
   [Caraceni, Augusto; Brunelli, Cinzia] Fdn IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Unit, Milan, Italy.
   [Laird, Barry] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland.
   [Boland, Jason W.] Univ Hull, Hull York Med Sch, Wolfson Palliat Care Res Ctr, Kingston Upon Hull, N Humberside, England.
   [Rossi, Romina] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Palliat Care Unit, Meldola, Italy.
   [Garcia Alonso, Elena] Arnau de Vilanova Univ Hosp, IRB, Radiat Oncol Dept, Lleida, Spain.
   [Stensheim, Hanne] Canc Registry Norway, Inst Populationbased Canc Res, Oslo, Norway.
   [Damas, Jan Kristian] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Ctr Mol Inflammat Res, Trondheim, Norway.
   [Damas, Jan Kristian] St Olavs Hosp, Dept Infect Dis, Trondheim, Norway.
   [Mollnes, Tom Eirik] Oslo Univ Hosp, Dept Immunol, KG Jebsen Inflammat Res Ctr, Oslo, Norway.
   [Mollnes, Tom Eirik] Nordland Hosp, Res Lab, Bodo, Norway.
   [Mollnes, Tom Eirik] Univ Tromso, KG Jebsen Thrombosis Res & Expertise Ctr, Fac Hlth Sci, Tromso, Norway.
   [Klepstad, Pal] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Med Imaging, Trondheim, Norway.
   [Klepstad, Pal] Univ Trondheim Hosp, St Olavs Hosp, Dept Anesthesiol & Intens Care Med, Trondheim, Norway.
C3 Norwegian University of Science & Technology (NTNU); Norwegian
   University of Science & Technology (NTNU); Norwegian University of
   Science & Technology (NTNU); University of Oslo; University of Oslo;
   University of Oslo; University of Oslo; Fondazione IRCCS Istituto
   Nazionale Tumori Milan; University of Edinburgh; University of York  
   UK; University of Hull; IRCCS Meldola (IRST); Institut de Recerca
   Biomedica   IRB Lleida; University of Oslo; Norwegian University of
   Science & Technology (NTNU); Norwegian University of Science &
   Technology (NTNU); University of Oslo; UiT The Arctic University of
   Tromso; Norwegian University of Science & Technology (NTNU); Norwegian
   University of Science & Technology (NTNU)
RP Habberstad, R (通讯作者)，Norwegian Univ Sci & Technol, European Palliat Care Res Ctr PRC, Dept Clin & Mol Med, Fac Med & Hlth Sci,NTNU, Trondheim, Norway.; Habberstad, R (通讯作者)，Trondheim Reg & Univ Hosp, St Olavs Hosp, Trondheim, Norway.; Habberstad, R (通讯作者)，Trondheim Reg & Univ Hosp, St Olavs Hosp, Canc Clin, Trondheim, Norway.
EM ragnhild.habberstad@gmail.com
RI Stensheim, Hanne/AAH 5328 2021; Brunelli, Cinzia/B 9361 2017; Mollnes,
   Tom/ABI 5183 2020; Boland, Jason/D 9843 2015; GARCÍA ALONSO, ELENA
   MARÍA/KLZ 0979 2024; rossi, romina/KBB 0507 2024; Bye, Asta/H 8939 2019;
   Caraceni, Augusto/C 1012 2017
OI Brunelli, Cinzia/0000 0003 3905 1289; rossi, romina/0009 0002 7076 9846;
   Boland, Jason/0000 0001 5272 3057; Bye, Asta/0000 0003 4902 0240;
   Solheim, Tora Skeidsvoll/0000 0002 2565 8437; Caraceni,
   Augusto/0000 0002 0375 6204
FU Norwegian Cancer Society (NCS); Liaison Committee for Education,
   Research and Innovation in Central Norway
FX The Palliative Radiotherapy and Inflammation Study (PRAIS) is funded by
   a non restricted grant given by the Norwegian Cancer Society (NCS) to
   the European Palliative Care Research Centre (PRC). In addition, the
   study has financing for a PhD scholarship from the Liaison Committee for
   Education, Research and Innovation in Central Norway. The study sponsors
   and funders are not involved in data collection, analyses,
   interpretation or publication of data.
CR Adli M, 2013, RADIOLOGY, V269, P850, DOI 10.1148/radiol.13121981
   [Anonymous], MEDIATORS INFLAMMATI
   Baamonde A, 2007, LIFE SCI, V81, P673, DOI 10.1016/j.lfs.2007.07.003
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021 9681(87)90171 8
   Chow E, 2012, CLIN ONCOL UK, V24, P112, DOI 10.1016/j.clon.2011.11.004
   Chow E, 2009, CLIN ONCOL UK, V21, P336, DOI 10.1016/j.clon.2009.01.013
   Chow E, 2002, RADIOTHER ONCOL, V64, P275, DOI 10.1016/S0167 8140(02)00170 6
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Chow E, 2015, RADIOTHER ONCOL, V115, P141, DOI 10.1016/j.radonc.2015.02.025
   Chow E, 2012, INT J RADIAT ONCOL, V82, P1730, DOI 10.1016/j.ijrobp.2011.02.008
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033
   EVANS C, 1985, LANCET, V1, P1204
   Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470 2045(10)70218 7
   Geis C, 2010, NEUROSCIENCE, V169, P463, DOI 10.1016/j.neuroscience.2010.04.022
   Gomez Iturriaga A, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904 015 0045 8
   Groenvold M, 2006, EUR J CANCER, V42, P55, DOI 10.1016/j.ejca.2005.06.022
   Grond S, 1996, PAIN, V64, P107, DOI 10.1016/0304 3959(95)00076 3
   Grotmol KS, 2017, J PAIN SYMPTOM MANAG, V54, P889, DOI 10.1016/j.jpainsymman.2017.04.010
   Hardy J, 2013, SUPPORT CARE CANCER, V21, P3387, DOI 10.1007/s00520 013 1921 5
   Hjermstad Marianne J, 2009, Curr Opin Support Palliat Care, V3, P24, DOI 10.1097/SPC.0b013e3283260644
   Holtan A, 2007, PALLIATIVE MED, V21, P7, DOI 10.1177/0269216306073127
   Hoskin PJ, 2000, LANCET, V355, P1428, DOI 10.1016/S0140 6736(00)02144 9
   Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa
   Janberidze E, 2014, J PAIN SYMPTOM MANAG, V48, P678, DOI 10.1016/j.jpainsymman.2013.11.013
   Jehn CF, 2012, BREAST CANCER RES TR, V136, P789, DOI 10.1007/s10549 012 2311 2
   Kaasa Stein, 2011, BMJ Support Palliat Care, V1, P281, DOI 10.1136/bmjspcare 2011 000078
   Kane CM, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h315
   Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa
   Klepstad P, 2012, CURR OPIN SUPPORT PA, V6, P508, DOI 10.1097/SPC.0b013e32835a0c70
   Knudsen AK, 2012, PAIN, V153, P696, DOI 10.1016/j.pain.2011.12.005
   Knudsen AK, 2011, EUR J PAIN, V15, P320, DOI 10.1016/j.ejpain.2010.08.001
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525 1497.2001.016009606.x
   Laird BJ, 2013, ONCOLOGIST, V18, P1050, DOI 10.1634/theoncologist.2013 0120
   Laird BJA, 2011, SUPPORT CARE CANCER, V19, P1393, DOI 10.1007/s00520 010 0961 3
   Laird BJA, 2011, PAIN, V152, P460, DOI 10.1016/j.pain.2010.10.035
   Lie HC, 2015, J AFFECT DISORDERS, V173, P176, DOI 10.1016/j.jad.2014.11.006
   Lindqvist D, 2017, PSYCHONEUROENDOCRINO, V76, P197, DOI 10.1016/j.psyneuen.2016.11.031
   Lozano Ondoua AN, 2013, NEUROSCI LETT, V557, P52, DOI 10.1016/j.neulet.2013.08.003
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantyh P, 2013, PAIN, V154, pS54, DOI 10.1016/j.pain.2013.07.044
   McDonald R, 2017, JAMA ONCOL, V3, P953, DOI 10.1001/jamaoncol.2016.6770
   McDonald R, 2014, J BONE ONCOL, V3, P84, DOI 10.1016/j.jbo.2014.10.001
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Nekolaichuk CL, 2013, J PALLIAT MED, V16, P516, DOI 10.1089/jpm.2012.0390
   Nieder C, 2016, IN VIVO, V30, P581
   Ottery FD, 1996, NUTRITION, V12, pS15, DOI 10.1016/0899 9007(95)00067 4
   Reginelli A, 2016, INT J SURG, V33, pS148, DOI 10.1016/j.ijsu.2016.06.018
   Schrepf A, 2013, BRAIN BEHAV IMMUN, V30, pS126, DOI 10.1016/j.bbi.2012.07.022
   Switlyk MD, 2014, J BONE ONCOL, V3, P5, DOI 10.1016/j.jbo.2014.02.003
   Tan BHL, 2012, EMBO MOL MED, V4, P462, DOI 10.1002/emmm.201200231
   Tobias K, 2015, MED HYPOTHESES, V84, P231, DOI 10.1016/j.mehy.2015.01.002
   van der Velden JM, 2017, INT J RADIAT ONCOL, V99, P859, DOI 10.1016/j.ijrobp.2017.07.029
   Wang XS, 2010, BRAIN BEHAV IMMUN, V24, P968, DOI 10.1016/j.bbi.2010.03.009
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Wasteson E, 2009, PALLIATIVE MED, V23, P739, DOI 10.1177/0269216309106978
   Watkins LR, 2007, BRAIN BEHAV IMMUN, V21, P131, DOI 10.1016/j.bbi.2006.10.011
   Westhoff PG, 2015, INT J RADIAT ONCOL, V93, P694, DOI 10.1016/j.ijrobp.2015.06.024
   Wu JSY, 2010, J PAIN SYMPTOM MANAG, V39, P230, DOI 10.1016/j.jpainsymman.2009.07.006
   Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360 3016(02)04147 0
   Zhao F, 2015, CLIN LUNG CANCER, V16, pE111, DOI 10.1016/j.cllc.2015.01.005
NR 62
TC 11
Z9 11
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 684X
J9 BMC PALLIAT CARE
JI BMC Palliat. Care
PD SEP 28
PY 2018
VL 17
AR 110
DI 10.1186/s12904 018 0362 9
PG 11
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA GV2SU
UT WOS:000445942200001
PM 30266081
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, Y
   Wei, Q
   An, R
   Zhang, HM
   Shen, JY
   Qin, XY
   Han, XL
   Li, J
   Li, XW
   Gao, XM
   He, J
   Mao, HP
AF Yang, Yun
   Wei, Qiu
   An, Ran
   Zhang, Hua mei
   Shen, Jia yuan
   Qin, Xiao yan
   Han, Xiao ling
   Li, Jie
   Li, Xiao wei
   Gao, Xiu mei
   He, Jun
   Mao, Hao ping
TI Anti osteoporosis effect of Semen Cuscutae in ovariectomized mice
   through inhibition of bone resorption by osteoclasts
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Semen cuscutae; Ovariectomy; Osteoclast differentiation
ID DIFFERENTIATION
AB Ethnopharmacological relevance: Semen Cuscutae, called Tu si zi in Chinese, is a kind of dried mature seed in the Convolvulaceae family. It mainly distributes in China, Korea, Pakistan, Vietnam, India and Thailand. It is used as a kidney tonifying drug for treatment of aging related diseases such as osteoporosis in traditional Chinese medicine. However, the exact mechanisms on bone resorption are poorly studied. Aim of the study: The aim of this study was to investigate the potential effect of Semen Cuscutae on ovariectomy (OVX) induced osteoporosis in mice and clarify the exact mechanisms by which Semen Cuscutae exert the anti osteoporosis effect. Materials and methods: Qualitative and quantitative analyses of Semen Cuscutae were performed by UPLC Q TOFMS and HPLC MS/MS, respectively. Changes in bone mineral density (BMD) induced by OVX in mice were measured by dual energy X ray absorptiometry and micro computed tomography (mu CT). Tartrate resistant acid phosphatase (TRAP) staining as well as hematoxylin and eosin (HE) staining were used to observe bone microarchitectural changes. ELISA kits were used to assess the therapeutic effects of Semen Cuscutae on the serum levels of osteoprotegerin (OPG), tartrate resistant acid phosphatase 5b (TRACP 5b), and receptor activator of nuclear factor kappa B (RANKL). The effect of Semen Cuscutae on primary cell viability was assessed using CCK 8 and anti tartrate phosphatase assays. TRAP staining and actin ring staining were used to observe the effect of Semen Cuscutae on osteoclast differentiation. Western blotting was used to measure the effects of Semen Cuscutae on expressions of NFATC1, c Src kinase, and c fos. Results: Results from UPLC Q TOF MS showed that the main components of Semen Cuscutae were flavonoid compounds that included quercitrin, quercetin, hyperoside, caffeic acid, rutin, chlorogenic acid, luteolin, apigenin, kaempferol, isoquercetin, cryptochlorogenic acid, isorhamnetin 3 O glucoside, and astragalin. After the Semen Cuscutae extract was orally administered to OVX mice, bone density increased (P < 0.01) and bone microstructure was significantly improved (P < 0.01 or 0.05). Additionally, Semen Cuscutae exhibited a significant descending effect in the levels of serum TRACP 5b and RANKL, while there was a significant increase in OPG in the Semen Cuscutae group compared with the OVX group, especially at high doses. Moreover, we found that increasing of c fos, c Src kinase, and NFATC1 protein expressions were reversed by Semen Cuscutae in vitro and in vivo.
C1 [Yang, Yun; Wei, Qiu; An, Ran; Zhang, Hua mei; Shen, Jia yuan; Qin, Xiao yan; Han, Xiao ling; Li, Jie; Li, Xiao wei; Gao, Xiu mei; He, Jun; Mao, Hao ping] Tianjin Univ Tradit Chinese Med, Key Lab Pharmacol Tradit Chinese Med Formulae, Minist Educ, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine
RP He, J; Mao, HP (通讯作者)，Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
EM hejun673@163.com; maohaoping@tjutcm.edu.cn
RI Qin, Xiaoyan/KLZ 0501 2024; An, Ran/AAD 5607 2020; Wei,
   qiu/MGW 5625 2025; GAO, Xiumei/IWD 8697 2023; mao, haoping/KIH 6773 2024
FU National Natural Science Foundation of China [81630106]; Tianjin
   Graduate Research Innovation Project Tianjin [2019YJSB140]; Graduate
   Research Innovation Project of Tianjin University of Traditional Chinese
   Medicine [YJSKC 20191002]
FX Acknowledgment This work was supported by the National Natural Science
   Foundation of China (Grant No. 81630106) . Tianjin Graduate Research
   Innovation Project Tianjin (No.2019YJSB140) and Graduate Research
   Innovation Project of Tianjin University of Traditional Chinese Medicine
   (No. YJSKC 20191002) .
CR Al Dabbagh B., 2018, American Journal of Plant Sciences, V9, P1228, DOI 10.4236/ajps.2018.96091
   Al Hrout A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34855 0
   Amin A, 2021, MOLECULES, V26, DOI 10.3390/molecules26133855
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   [Anonymous], 2021, Calcified Tissue International, V108, P439, DOI [DOI 10.1007/S00223 020 00803 2, 10.1007/s00223 020 00803 2]
   Ashktorab H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11050943
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   EL Dakhly SM, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104 020 05094 2
   [高健美 Gao Jianmei], 2014, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V30, P89
   Gao ZT, 2017, CHIN HERB MED, V9, P218, DOI 10.1016/S1674 6384(17)60098 4
   Hamza AA, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111102
   Hamza AA, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9121173
   Huang J, 2019, J ANIM SCI, V97, P6
   Kamal H, 2018, J DAIRY SCI, V101, P8711, DOI 10.3168/jds.2018 14586
   Khosla S, 2018, J CLIN ENDOCR METAB, V103, P1282, DOI 10.1210/jc.2017 02694
   Kikuta J, 2018, METHODS MOL BIOL, V1763, P1, DOI 10.1007/978 1 4939 7762 8_1
   Lai L., 2020, CHIN J TISS ENG RES, V24, P171
   Li Y., 2015, THESIS JIAOTONG U
   Lin X.F., 2018, J ZHEJIANG CHIN TRAD, DOI [10.16466/j.issn1005  5509.2018.02.001, DOI 10.16466/J.ISSN1005 5509.2018.02.001]
   Ling YY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.693777
   Liu HJ, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110613
   Liu Q., 2021, CHIN J ENDOCR SURG, V15, P71
   Liu Y., 2004, CHIN J NAT MED CNKIS
   Matsubara T, 2010, J BONE MINER RES, V25, P1068, DOI 10.1359/jbmr.091039
   Mira Pascual L, 2020, CALCIFIED TISSUE INT, V106, P194, DOI 10.1007/s00223 019 00618 w
   Murali C, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 86391 z
   Neuprez A, 2015, ANN RHEUM DIS, V74, P1942, DOI 10.1136/annrheumdis 2015 207718
   乔林, 2020, [实用妇产科杂志, Journal of Practical Obstetrics and Gynecology], V36, P481
   Salminen E, 2005, ACTA ONCOL, V44, P742, DOI 10.1080/02841860500327586
   Shen JY, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/6518528
   Sripada A, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001063
   Wang H, 2018, J FUNCT FOODS, V49, P113, DOI 10.1016/j.jff.2018.08.021
   [王礼宁 Wang Lining], 2018, [中华骨质疏松和骨矿盐疾病杂志, Chinese Journal of Osteoporosis and Bone Mineral Research], V11, P475
   [王翔宇 Wang Xiangyu], 2019, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V34, P2687
   Wang Y., 2020, J SHANDONG U TRADIT, V44, P705, DOI [10.16294/j.cnki.1007 659x.2020.06.022, DOI 10.16294/J.CNKI.1007 659X.2020.06.022]
   Xiang Y., 2019, CHIN J TRADIT MED TR, V27, P86
   Xu Zhong Kun, 2018, Zhongguo Zhong Yao Za Zhi, V43, P3140, DOI 10.19540/j.cnki.cjcmm.20180611.003
   Yang S, 2017, CARBOHYD POLYM, V175, P249, DOI 10.1016/j.carbpol.2017.07.077
   Yang X, 2010, THESIS JILIN U
   Zhang L., 2016, THESIS WUHAN U
   Zhang L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18670 7
   Zhang QL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9281481
   Zhang Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23051199
   Zhao S., 2018, INT J CLIN EXP MED, V17, P25
   Zhao Z., 2019, THESIS YUNNAN U CHIN
NR 46
TC 27
Z9 29
U1 5
U2 64
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 1
PY 2022
VL 285
AR 114834
DI 10.1016/j.jep.2021.114834
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1C6QV
UT WOS:000793242000003
PM 34801609
DA 2025 08 17
ER

PT J
AU Li, M
   Zhang, AQ
   Li, JJ
   Zhou, J
   Zheng, YN
   Zhang, C
   Xia, DD
   Mao, HJ
   Zhao, JY
AF Li, Mei
   Zhang, Anqi
   Li, Jiajing
   Zhou, Jing
   Zheng, Yanan
   Zhang, Chi
   Xia, Dongdong
   Mao, Haijiao
   Zhao, Jiyuan
TI Osteoblast/fibroblast coculture derived bioactive ECM with unique
   matrisome profile facilitates bone regeneration
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Cell coculture; Bioactive ECM; Matrisome; Bone mimetic microenvironment;
   Bone regeneration
ID EXTRACELLULAR MATRIX; STEM CELLS; ENDOTHELIAL CELLS; REPAIR;
   DIFFERENTIATION; SUBMUCOSA; BIOFILM; BIOMATERIALS; SCAFFOLD; ICARIIN
AB Extracellular matrix (ECM) with mimetic tissue niches was attractive to facilitate tissue regeneration in situ via recruitment of endogenous cells and stimulation of self healing process. However, how to engineer the complicate tissue specific ECM with unique matrisome in vitro was a challenge of ECM based biomaterials in tissue engineering and regenerative medicine. Here, we introduced coculture system to engineer bone mimetic ECM niche guided by cell cell communication. In the cocultures, fibroblasts promoted osteogenic differentiation of osteoblasts via extracellular vesicles. The generated ECM (MN ECM) displayed a unique appearance of morphology and biological components. The advantages of MN ECM were demonstrated with promotion of multiple cellular behaviors (proliferation, adhesion and osteogenic mineralization) in vitro and bone regeneration in vivo. Moreover, proteomic analysis was used to clarify the molecular mechanism of MN ECM, which revealed a specific matrisome signature. The present study provides a novel strategy to generate ECM with tissue mimetic niches via cell cell communication in a coculture system, which forwards the development of tissue bioactive ECM engineering along with deepening the understanding of ECM niches regulated by cells for bone tissue engineering.
C1 [Li, Mei; Zhang, Anqi; Li, Jiajing; Zhou, Jing; Zheng, Yanan; Zhao, Jiyuan] Ningbo Univ, Zhejiang Key Lab Pathophysiol, Med Sch, Ningbo, Zhejiang, Peoples R China.
   [Li, Mei] Ningbo Inst Med Sci, Ningbo, Zhejiang, Peoples R China.
   [Zhang, Chi; Xia, Dongdong] Ningbo First Hosp, Orthoped Dept, Ningbo, Zhejiang, Peoples R China.
   [Mao, Haijiao] Ningbo Univ, Affiliated Hosp, Dept Orthopaed Surg, Med Sch, Ningbo, Zhejiang, Peoples R China.
C3 Ningbo University; Ningbo University; Ningbo University
RP Zhao, JY (通讯作者)，Ningbo Univ, Med Sch, 818 Fenghua Rd, Ningbo 315211, Zhejiang, Peoples R China.
EM zhaojiyuan@nbu.edu.cn
RI ; Li, Mei/JDD 8859 2023
OI Zhao, Jiyuan/0000 0002 1327 7119; 
FU National Natural Science Foundation of China [31300800, 81702625];
   Zhejiang Province Welfare Technology Application Research Project
   [2017C33135]; Natural Science Foundation of Ningbo [2018A610202,
   2019A610309]; K.C. Wong Magna Fund in Ningbo University
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 31300800 and 81702625), the Zhejiang Province Welfare
   Technology Application Research Project (Grant No. 2017C33135), the
   Natural Science Foundation of Ningbo (Grant No. 2018A610202 and
   2019A610309) and the K.C. Wong Magna Fund in Ningbo University.
CR Aamodt JM, 2016, BIOMATERIALS, V86, P68, DOI 10.1016/j.biomaterials.2016.02.003
   Allison DG, 2003, BIOFOULING, V19, P139, DOI [10.1080/0892701031000072190, 10.1038/nrmicro2415]
   Baroncelli M, 2018, J CELL PHYSIOL, V233, P387, DOI 10.1002/jcp.25898
   Bi HJ, 2020, BIOMATERIALS, V233, DOI 10.1016/j.biomaterials.2019.119673
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Chua ILS, 2016, TISSUE ENG REGEN MED, V13, P1, DOI 10.1007/s13770 016 9075 0
   Cook CD, 2017, INTEGR BIOL UK, V9, P271, DOI 10.1039/c6ib00245e
   Cui ZK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11511 3
   Giobbe GG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13605 4
   Han W, 2019, BIOMATERIALS, V224, DOI 10.1016/j.biomaterials.2019.119496
   Huang GY, 2017, CHEM REV, V117, P12764, DOI 10.1021/acs.chemrev.7b00094
   Hussey GS, 2018, NAT REV MATER, V3, P159, DOI 10.1038/s41578 018 0023 x
   Janjic K, 2019, J PERIODONTAL RES, V54, P489, DOI 10.1111/jre.12649
   Johnston LA, 2009, SCIENCE, V324, P1679, DOI 10.1126/science.1163862
   Kim IG, 2015, BIOMATERIALS, V50, P75, DOI 10.1016/j.biomaterials.2015.01.054
   Kim M, 2019, P NATL ACAD SCI USA, V116, P1569, DOI 10.1073/pnas.1815447116
   Koo H, 2016, CURR OPIN CELL BIOL, V42, P102, DOI 10.1016/j.ceb.2016.05.005
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Hong LTA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00583 8
   Lee JH, 2014, CELL, V156, P440, DOI 10.1016/j.cell.2013.12.039
   Li CJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11455
   Li M, 2018, TISSUE ENG PT A, V24, P1099, DOI [10.1089/ten.tea.2017.0407, 10.1089/ten.TEA.2017.0407]
   Li M, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110039
   Li M, 2017, ANN BIOMED ENG, V45, P2673, DOI 10.1007/s10439 017 1900 y
   Li M, 2017, MAT SCI ENG C MATER, V75, P149, DOI 10.1016/j.msec.2017.02.042
   Li M, 2017, MAT SCI ENG C MATER, V71, P260, DOI 10.1016/j.msec.2016.10.016
   Li M, 2018, CANCER BIOL THER, V19, P898, DOI 10.1080/15384047.2018.1480296
   Li QY, 2016, BIOMATERIALS, V75, P37, DOI 10.1016/j.biomaterials.2015.10.011
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   Madhusoodanan J, 2019, NATURE, V566, P563, DOI 10.1038/d41586 019 00681 1
   Mann EE, 2012, FEMS MICROBIOL REV, V36, P893, DOI 10.1111/j.1574 6976.2011.00322.x
   Miller FD, 2012, CELL STEM CELL, V10, P650, DOI 10.1016/j.stem.2012.05.004
   Moroni L, 2018, NAT REV MATER, V3, P21, DOI 10.1038/s41578 018 0006 y
   Naskar S, 2020, BIOMATERIALS, V226, DOI 10.1016/j.biomaterials.2019.119522
   Pati F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4935
   Piard C, 2019, BIOMATERIALS, V222, DOI 10.1016/j.biomaterials.2019.119423
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]
   Prewitz MC, 2013, NAT METHODS, V10, P788, DOI [10.1038/nmeth.2523, 10.1038/NMETH.2523]
   Qazi TH, 2017, BIOMATERIALS, V140, P103, DOI 10.1016/j.biomaterials.2017.06.019
   Ragelle H, 2017, BIOMATERIALS, V128, P147, DOI 10.1016/j.biomaterials.2017.03.008
   Raghunathan R, 2019, MOL CELL PROTEOMICS, V18, P2138, DOI 10.1074/mcp.R119.001543
   Rosales AM, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2015.12
   Sadtler K, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.40
   Sapir Liel, 2017, Semin Cell Dev Biol, V71, P99, DOI 10.1016/j.semcdb.2017.06.010
   Schwarze U, 2019, AM J MED GENET A, V179, P1466, DOI 10.1002/ajmg.a.61170
   Shih YV, 2019, BIOMATERIALS, V198, P107, DOI 10.1016/j.biomaterials.2018.06.005
   Stanton AE, 2019, ACTA BIOMATER, V96, P310, DOI 10.1016/j.actbio.2019.06.048
   Toda S, 2019, CURR OPIN CHEM BIOL, V52, P31, DOI 10.1016/j.cbpa.2019.04.020
   Toda S, 2018, SCIENCE, V361, P156, DOI 10.1126/science.aat0271
   Uroz M, 2018, NAT CELL BIOL, V20, DOI 10.1038/s41556 018 0107 2
   Wang C, 2019, BIOMATERIALS, V202, P35, DOI 10.1016/j.biomaterials.2019.02.024
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Xia HM, 2018, NAT REV MATER, V3, P174, DOI 10.1038/s41578 018 0027 6
   Xing Q, 2017, ACS BIOMATER SCI ENG, V3, P1462, DOI 10.1021/acsbiomaterials.6b00235
   Zepp JA, 2017, CELL, V170, P1134, DOI 10.1016/j.cell.2017.07.034
   Zhang C, 2017, REGEN MED, V12, P541, DOI 10.2217/rme 2017 0024
   Zhang XQ, 2020, ACTA BIOMATER, V103, P129, DOI 10.1016/j.actbio.2019.12.006
   Zhu MF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12545 3
   Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102
NR 59
TC 48
Z9 52
U1 10
U2 150
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD DEC
PY 2020
VL 5
IS 4
BP 938
EP 948
DI 10.1016/j.bioactmat.2020.06.017
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA NE3DP
UT WOS:000562478100018
PM 32637756
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hamed, A
   Kim, P
   Cho, M
AF Hamed, Ayman
   Kim, Paul
   Cho, Michael
TI Synthesis of nitric oxide in human osteoblasts in response to
   physiologic stimulation of electrotherapy
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE nitric oxide; nitric oxide synthase; osteoblasts; electrotherapy;
   estrogen
ID FIELD INDUCED REDISTRIBUTION; ESTROGEN; RECEPTORS; TRANSLOCATION;
   RELAXATION; MECHANISMS; SURFACES; THERAPY
AB Electrotherapy for bone healing, remodeling and wound healing may be mediated by modulation of nitric oxide (NO). Using NO specific fluorophore (DAF 2), we report here that application of non invasive, physiologic electrical stimulation induces NO synthesis in human osteoblasts, and that such NO generation is comparable to that induced by estrogen treatment. For example, application of a sinusoidal 1 Hz, 2 V/cm (peak to peak) electrical stimulation (ES) increases NO bound DAF 2 fluorescence intensity by a 2 fold within 60 min exposure by activating nitric oxide synthase (NOS). Increase in the NO level is found to depend critically on the frequency and strength of ES. While the frequency of I Hz ES seems optimal, the ES strength > 0.5 V/cm is required to induce significant NO increase, however. Nitric oxide synthesis in response to ES is completely prevented by blocking estrogen receptors using a competitive inhibitor, suggesting that NO generation is likely initiated by activation of estrogen receptors at the cell surface. Based on these findings, physiologic stimulation of electrotherapy appears to represent a potential non invasive, non genomic, and novel physical technique that could be used to regulate NO mediated bone density and facilitate bone remodeling without adverse effects associated with hormone therapy.
C1 Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Cho, M (通讯作者)，Univ Illinois, Dept Bioengn, 851 S Morgan St,M C 063, Chicago, IL 60607 USA.
EM mcho@uic.edu
OI Cho, Myoung Rae/0000 0002 8191 8045
FU NIBIB NIH HHS [EB006067] Funding Source: Medline; NIGMS NIH HHS
   [GM060741] Funding Source: Medline
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000118699.26862.41
   [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288
   BRIGHTON CT, 1981, J BONE JOINT SURG AM, V63, P847, DOI 10.2106/00004623 198163050 00030
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   BRIGHTON CT, 1995, CLIN ORTHOP RELAT R, V321, P223
   Calabrese V, 2004, IN VIVO, V18, P245
   Cho MR, 2002, IEEE T PLASMA SCI, V30, P1504, DOI 10.1109/TPS.2002.804200
   CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677
   Cho MR, 1996, FASEB J, V10, P1552, DOI 10.1096/fasebj.10.13.8940302
   Cho MR, 2000, ANN BIOMED ENG, V28, P234, DOI 10.1114/1.263
   CHO MR, 2002, FRONT BIOSCI, V7, P1
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Contreras JL, 2002, TRANSPLANTATION, V74, P1252, DOI 10.1097/00007890 200211150 00010
   Cushman M, 2004, JAMA J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573
   Cutolo M, 2003, CLIN EXP RHEUMATOL, V21, P687
   Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/BST0310502
   Das UN, 2002, EXP BIOL MED, V227, P88, DOI 10.1177/153537020222700202
   Diniz P, 2002, NITRIC OXIDE BIOL CH, V7, P18, DOI 10.1016/S1089 8603(02)00004 6
   Evans DM, 1996, J BONE MINER RES, V11, P300
   GIUGNI TD, 1987, J CELL BIOL, V104, P1291, DOI 10.1083/jcb.104.5.1291
   Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788
   GRUNKERNIER J, 1996, J BIOMAT SCI POLYM E, P189
   IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868
   Isenberg JS, 2004, MICROSURG, V24, P385, DOI 10.1002/micr.20051
   Ishino T, 2004, PLOS BIOL, V2, P77, DOI 10.1371/journal.pbio.0020004
   Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04 1814fje
   Kondo T, 2004, MOL CELL BIOCHEM, V264, P25, DOI 10.1023/B:MCBI.0000044371.06317.0a
   Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27
   Kone BC, 2003, AM J PHYSIOL RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003
   Lauffenburger D., RECEPTORS MODELS BIN
   Lin SK, 2003, J BONE MINER RES, V18, P39, DOI 10.1359/jbmr.2003.18.1.39
   Lindsay R, 2004, ENDOCRINE, V24, P223, DOI 10.1385/ENDO:24:3:223
   McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930
   MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006 3495(81)84838 2
   Min KR, 2004, ARCH PHARM RES, V27, P1053, DOI 10.1007/BF02975431
   Miyamoto Masafumi, 2003, Physiological Chemistry and Physics and Medical NMR, V35, P1
   ORTIZ NDA, 2004, GINECOL OBSTET MEX, V72, P349
   PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0
   POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333
   Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383
   Pritsch O, 1996, J CLIN INVEST, V98, P2235, DOI 10.1172/JCI119033
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Rosenfeld RJ, 2002, BIOCHEMISTRY US, V41, P13915, DOI 10.1021/bi026313j
   Schmidt K, 2004, FEBS LETT, V577, P199, DOI 10.1016/j.febslet.2004.10.010
   Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131
   Somboonporn W, 2004, MATURITAS, V49, P267, DOI 10.1016/j.maturitas.2004.06.020
   Staren ED, 2004, AM J SURG, V188, P136, DOI 10.1016/j.amjsurg.2003.12.063
   TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148
   Titushkin IA, 2004, IEEE T PLASMA SCI, V32, P1614, DOI 10.1109/TPS.2004.832625
   Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365
   Witte MB, 2002, AM J SURG, V183, P406, DOI 10.1016/S0002 9610(02)00815 2
   Yoshida M, 2003, J BIOL CHEM, V278, P36953, DOI 10.1074/jbc.M305214200
   Zheng Xiaoxiang, 2004, V279, P69
   Zhuang DM, 2004, AM J PHYSIOL HEART C, V286, pH2103, DOI 10.1152/ajpheart.01118.2003
   2004, FERTIL STERIL, V82, pS70
NR 56
TC 6
Z9 7
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090 6964
EI 1573 9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD DEC
PY 2006
VL 34
IS 12
BP 1908
EP 1916
DI 10.1007/s10439 006 9206 5
PG 9
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 113PL
UT WOS:000242609700009
PM 17066323
DA 2025 08 17
ER

PT J
AU Pu, R
   Zhao, QH
   Li, ZM
   Zhang, LY
   Luo, XL
   Zeren, YJ
   Yu, C
   Li, XY
AF Pu, Rong
   Zhao, Qianhong
   Li, Zhimei
   Zhang, Lingyan
   Luo, Xiaolu
   Zeren, Yangji
   Yu, Cui
   Li, Xianyong
TI Rapid bone repair in a patient with lung cancer metastases to the spine
   using a novel herbal medicine: A case report
SO ONCOLOGY LETTERS
LA English
DT Article
DE lung cancer; bone metastasis; rapid repair; herbal medicine; biological
   intracontrol treatment
ID RADIOTHERAPY; PAIN; PEMBROLIZUMAB; MANAGEMENT; NIVOLUMAB; SAFETY;
   SYSTEM; TRIAL
AB The prognosis of lung carcinoma with metastasis to the bone, particularly to the spine, is poor. Chemotherapy and radiotherapy are established treatments for metastatic bone disease, but their effectiveness is unsatisfactory and bone repair following their use is slow and difficult. Medicine prepared from herbal extracts may be an alternative treatment option. The present study discusses the case of a 59 year old patient diagnosed with squamous cell lung cancer (T2N3M1) in which first line chemotherapy using docetaxel plus cisplatin failed. Heavy multiple bone metastases were detected in the T9 vertebra and sixth left rib, resulting in a high risk of pathological fracture. Eastern Cooperative Oncology Group (ECOG) and numerical rating scale (NRS) scores of pain were 2 and 4, respectively. A second line treatment was chosen consisting of biological intracontrol treatment (BICT) plus bisphosphonates administered over 40 days. BICT is a therapy involving the use of herbal extracts (including ginseng, herba agrimoniae, hairyvein agrimonia herb, white flower patrinia herb and arginine) and palliative care. A partial positive response was reached following use of this regimen, particularly with regard to bone repair. A computed tomography scan revealed a 90% reduction in the broken area of the rib cage and T9 vertebra. The bone repair was rapid and almost complete. In addition, growth of the primary tumor in the right pulmonary hilar and metastasis in the mediastinal lymph nodes were stabilized following treatment. ECOG and NRS scores were decreased to 1 and 0, respectively, leading to an improved quality of life. Based on these results, the present study suggests that this herbal medicine based regimen promotes bone repair and inhibits tumor growth, with low toxicity. However, the mechanism by which herbal medicine promotes rapid bone repair is unclear. Further studies are required to determine whether cells in the tumor microenvironment are stimulated to undergo re differentiation by unidentified herbal substances.
C1 [Pu, Rong; Zhao, Qianhong; Zhang, Lingyan; Li, Xianyong] Chengdu Fuxing Hosp, Dept Oncol, Chengdu 610036, Sichuan, Peoples R China.
   [Li, Zhimei; Luo, Xiaolu; Zeren, Yangji] Chengdu Fuxing Hosp, Dept Nursing, Chengdu 610036, Sichuan, Peoples R China.
   [Yu, Cui] Chengdu Fuxing Hosp, Dept Radiol, Chengdu 610036, Sichuan, Peoples R China.
RP Li, XY (通讯作者)，Chengdu Fuxing Hosp, Dept Oncol, Chengdu 610036, Sichuan, Peoples R China.
EM lxy1956@yeah.net
RI Zhao, Qianhong/NRB 1504 2025
CR American Association of Neurological Surgeons, PAT INF SPIN TUM
   Ashton A, 1999, RADIOTHER ONCOL, V52, P111
   Azoury SC, 2015, CURR CANCER DRUG TAR, V15, P452, DOI 10.2174/156800961506150805145120
   Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627
   Dodwad Shah Nawaz M, 2014, Cancer Treat Res, V162, P131, DOI 10.1007/978 3 319 07323 1_7
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824
   Hartsell WF, 2005, JNCI J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139
   Li X, 2013, JSMO JAP
   Li X, 2014, JSMO JAP
   McDermott J, 2015, DRUG TODAY, V51, P7, DOI 10.1358/dot.2015.51.1.2250387
   OKEN MM, 1982, AM J CLIN ONCOL CANC, V5, P649, DOI 10.1097/00000421 198212000 00014
   Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470 2045(15)70054 9
   Salvo N, 2009, J PALLIAT MED, V12, P195, DOI 10.1089/jpm.2008.0055
   Sciubba DM, 2010, J NEUROSURG SPINE, V13, P94, DOI 10.3171/2010.3.SPINE09202
   Sugiura H, 2008, CLIN ORTHOP RELAT R, V466, P729, DOI 10.1007/s11999 007 0051 0
   Sundaresan N, 2004, J NEURO ONCOL, V69, P273, DOI 10.1023/B:NEON.0000041888.33499.03
   Tokuhashi Y, 2009, SPINE, V34, P69, DOI 10.1097/BRS.0b013e3181913f19
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053 4296(03)00031 6
   Xu SF, 2015, EXP THER MED, V9, P117, DOI 10.3892/etm.2014.2055
   Zhao F, 2015, CLIN LUNG CANCER, V16, pE111, DOI 10.1016/j.cllc.2015.01.005
NR 21
TC 4
Z9 5
U1 0
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2016
VL 12
IS 3
BP 2023
EP 2027
DI 10.3892/ol.2016.4879
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DU4VX
UT WOS:000382211900065
PM 27602132
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, N
   Wang, QP
   Li, H
   Wu, XP
   Sun, ZQ
   Luo, XH
AF Wu, Nan
   Wang, Qing Ping
   Li, Hui
   Wu, Xian Ping
   Sun, Zhen Qiu
   Luo, Xiang Hang
TI Relationships between serum adiponectin, leptin concentrations and bone
   mineral density, and bone biochemical markers in Chinese women
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Adiponectin; Leptin; Bone mineral density; Bone biochemical marker;
   Women
ID MAPK SIGNALING PATHWAY; POSTMENOPAUSAL WOMEN; PERIMENOPAUSAL WOMEN;
   PLASMA ADIPONECTIN; BODY COMPOSITION; HUMAN OSTEOBLASTS; MASS;
   OSTEOPOROSIS; FAT; ESTABLISHMENT
AB Background: Adiponectin and leptin, as the main circulating peptides secreted by adipose tissue, are potential contributors to bone metabolism. However, their association with bone mineral density (BMD) is unknown. We investigated whether these serum adipocytokines concentrations are associated with BMD and bone turnover markers.
   Methods: Serum adiponectin, leptin concentrations, bone turnover biochemical markers, and BMD were determined in 265 premenopausal and 336 postmenopausal Chinese women.
   Results: In postmenopausal Chinese women, the multiple linear stepwise regression analysis showed that year since menopause, lean mass, estradiol, and adiponectin, but not fat mass, leptin, were independent predictors of BMD in postmenopausal Chinese women. However, in premenopausal Chinese women, adiponectin was not the predictor of BMD. The significant positive correlations between adiponectin and bone specific alkaline phosphatase (BAP). bone cross linked N telopeptides of type I collagen (NTX) were found only in postmenopausal women. Serum BAP, and NTX, but not adiponectin, decreased in response to alendronate therapy.
   Conclusions: Adiponectin was an independent predictor of BMD, and positively correlated with bone turnover biochemical markers in postmenopausal Chinese women, but not premenopausal women. It suggested that adiponectin may exert a negative effect on bone mass by promoting excessive bone resorption associated with bone loss. However, these effects may be mediated by menopausal status. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Wang, Qing Ping; Li, Hui; Wu, Xian Ping; Luo, Xiang Hang] Cent S Univ, Inst Endocrinol & Metab, Xiangya Hosp, Changsha 410011, Hunan, Peoples R China.
   [Wu, Nan; Sun, Zhen Qiu] Cent S Univ, Sch Publ Hlth, Dept Epidemiol & Stat, Changsha 410078, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Luo, XH (通讯作者)，Cent S Univ, Inst Endocrinol & Metab, Xiangya Hosp 2, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM xianghangluo@21cn.com
RI Qingping, Wang/K 2645 2019
OI Wang, Qing ping/0000 0002 7239 9693
FU China National Natural Scientific Foundation [30672197, 30700891];
   National Excellent Doctoral Dissertation of PR China [200259]; Fok Ying
   Tung Education Foundation [20060533031]; Specialized Research Fund
   [101035]
FX This work was supported by Grant 30672197 and Grant 30700891 from the
   China National Natural Scientific Foundation, A Foundation for the
   Author of National Excellent Doctoral Dissertation of PR China (200259),
   Grant 20060533031 from Fok Ying Tung Education Foundation, and
   Grant 101035 from the Specialized Research Fund for the Doctoral Program
   of Higher Education.
CR Blain H, 2002, J CLIN ENDOCR METAB, V87, P1030, DOI 10.1210/jc.87.3.1030
   Gavrila A, 2003, J CLIN ENDOCR METAB, V88, P4823, DOI 10.1210/jc.2003 030214
   Goulding A, 1998, CALCIFIED TISSUE INT, V63, P456, DOI 10.1007/s002239900557
   Hla MM, 1996, AM J CLIN NUTR, V64, P354, DOI 10.1093/ajcn/64.3.345
   Huang KC, 2004, CLIN ENDOCRINOL, V61, P204, DOI 10.1111/j.1365 2265.2004.02081.x
   Im JA, 2006, MATURITAS, V54, P65, DOI 10.1016/j.maturitas.2005.08.008
   Jürimäe J, 2005, HORM METAB RES, V37, P297, DOI 10.1055/s 861483
   Jürimäe J, 2007, AM J PHYSIOL ENDOC M, V293, pE42, DOI 10.1152/ajpendo.00610.2006
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Kontogianni MD, 2004, J BONE MINER RES, V19, P546, DOI 10.1359/JBMR.040107
   Li SL, 2004, MATURITAS, V47, P99, DOI 10.1016/S0378 5122(03)00249 4
   Liao EY, 2003, J BONE MINER METAB, V21, P184, DOI 10.1007/s007740300029
   Liao EY, 2002, OSTEOPOROSIS INT, V13, P669, DOI 10.1007/s001980200091
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2006, OSTEOPOROSIS INT, V17, P521, DOI 10.1007/s00198 005 0017 6
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587
   OCONNOR S, 1973, J STEROID BIOCHEM, V4, P331, DOI 10.1016/0022 4731(73)90002 2
   Odabasi E, 2000, EUR J ENDOCRINOL, V142, P170, DOI 10.1530/eje.0.1420170
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Richards JB, 2007, J CLIN ENDOCR METAB, V92, P1517, DOI 10.1210/jc.2006 2097
   Ruhl CE, 2002, J BONE MINER RES, V17, P1896, DOI 10.1359/jbmr.2002.17.10.1896
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Szymczak J, 1998, STEROIDS, V63, P319, DOI 10.1016/S0039 128X(98)00019 1
   Tang GWK, 2001, OSTEOPOROSIS INT, V12, P647, DOI 10.1007/s001980170064
   Thomas T, 2000, METABOLISM, V49, P1278, DOI 10.1053/meta.2000.9519
   TREMBLAY RR, 1974, CONTRACEPTION, V10, P599, DOI 10.1016/0010 7824(74)90099 7
   Wu XP, 2004, OSTEOPOROSIS INT, V15, P71, DOI 10.1007/s00198 003 1517 x
NR 28
TC 47
Z9 53
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009 8981
EI 1873 3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD MAY 2
PY 2010
VL 411
IS 9 10
BP 771
EP 775
DI 10.1016/j.cca.2010.02.064
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA 590KJ
UT WOS:000277224200030
PM 20184866
DA 2025 08 17
ER

PT J
AU Cantorán Castillo, A
   Beltran Salinas, B
   Antúnez Trevino, JM
   Martínez Pedraza, R
   Franco Márquez, R
   Guzmán García, MA
   Cerda Flores, RM
   Perales Pérez, RV
   Zakian, C
   Ancer Rodríguez, J
   Márquez Méndez, M
AF Cantoran Castillo, Arquimedes
   Beltran Salinas, Belinda
   Antunez Trevino, Jorge M.
   Martinez Pedraza, Ricardo
   Franco Marquez, Rodolfo
   Guzman Garcia, Mario A.
   Cerda Flores, Ricardo M.
   V. Perales Perez, Raul
   Zakian, Christian
   Ancer Rodriguez, Jesus
   Marquez Mendez, Marcela
TI Preventing bisphosphonate induced osteonecrosis of the jaw with a
   polyguanidine conjugate (GuaDex): A promising new approach
SO BONE
LA English
DT Article
DE Polyguanidine; Bisphosphonates; Osteonecrosis; Rat model; Bone
   regeneration; Bone injury healing
ID EXPERIMENTAL MODEL; BONE; CELLS; ACTIVATION; MECHANISM; ORNITHINE;
   TISSUE
AB Osteonecrosis of the jaw (ONJ) is a relatively rare side effect after prolonged use of bisphosphonates, which are drugs used to treat bone resorption in osteoporosis and certain cancers. This study introduces a novel ONJ model in rats by combining exposure to bisphosphonates, oral surgery, and bacterial inoculation. Potential ONJ preventive effects of polyguanidine (GuaDex) or antibiotics were evaluated. The study consisted of twenty four male Wistar rats were divided into four groups. Groups 1 to 3 were given weekly doses of i.v. Zoledronic acid (ZA), four weeks before and two weeks after an osteotomy procedure on their left mandibular first molar. Group 4 was a negative control. Streptococcus gordonii bacteria were introduced into the osteotomy pulp chamber and via the food for seven days. On day eight, the rats were given different treatments. Group 1 was given a GuaDex injection into the osteotomy socket, Group 2 was given an intramuscular (i.m.) injection of clindamycin, Group 3 (positive control) was given an i.m. injection of saline, and Group 4 was given an i.m. injection of saline. Blood samples were taken two weeks after the osteotomy procedure, after which the rats were euthanized. Bone healing, bone mineral density, histology, and blood status were analyzed. The results showed that Group 1 (GuaDex) had no ONJ, extensive ongoing bone regeneration, active healing activity, vascularization, and no presence of bacteria. Group 2 (clindamycin) showed early stages of ONJ, avascular areas, and bacteria. Group 3 showed stages of ONJ, inflammatory infiltrates, defective healing, and bacterial presence, and Group 4 had normal healing activity and no bacterial presence. Conclusion: ZA treatment and bacterial inoculation after tooth extraction inhibited bone remodeling/healing and induced ONJ characteristic lesions in the rats. Only GuaDex apparently prevented ONJ development, stimulated bone remodeling, and provided an antimicrobial effect.
C1 [Cantoran Castillo, Arquimedes; Beltran Salinas, Belinda; Antunez Trevino, Jorge M.; Martinez Pedraza, Ricardo] Autonomous Univ Nuevo Leon, Fac Dent, Monterrey 64460, NL, Mexico.
   [Franco Marquez, Rodolfo] Autonomous Univ Nuevo Leon, Hosp Univ, Dept Pathol & Cytopathol, Ave Dr J Eleuterio Gonzalez S N, Monterrey 64460, NL, Mexico.
   [Guzman Garcia, Mario A.; Cerda Flores, Ricardo M.] Autonomous Univ Nuevo Leon, Fac Vet Med & Zootech, Gral Escobedo 66054, NL, Mexico.
   [Ancer Rodriguez, Jesus; Marquez Mendez, Marcela] Autonomous Univ Nuevo Leon, Ctr Res & Dev Hlth Sci, Ave Jose Eleuterio Gonzalez, Monterrey 64460, NL, Mexico.
   [V. Perales Perez, Raul] Odontol Avanzada Laser, Calle Juarez 109, Montemorelos 67500, NL, Mexico.
   [Zakian, Christian] Kevork Instruments, Palacio Justicia 888, San Nicolas De Los Garza 66450, NL, Mexico.
C3 Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon;
   Universidad Autonoma de Nuevo Leon
RP Márquez Méndez, M (通讯作者)，Autonomous Univ Nuevo Leon, Ctr Res & Dev Hlth Sci, Ave Jose Eleuterio Gonzalez, Monterrey 64460, NL, Mexico.
RI ; FRANCO MARQUEZ, RODOLFO/JFS 8174 2023
OI Franco Marquez, Rodolfo/0000 0002 6853 8726; 
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   Barba Recreo P, 2014, J CRANIO MAXILL SURG, V42, P744, DOI 10.1016/j.jcms.2013.11.005
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Bonnaire A, 2021, DIAGN MICR INFEC DIS, V99, DOI 10.1016/j.diagmicrobio.2020.115225
   Carillo Sosa Mara F.M., 2018, J Dent Oral Hygiene, V10, P13, DOI [10.5897/JDOH2018.0231, DOI 10.5897/JDOH2018.0231]
   Cipriani C, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00122
   Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919
   De Bruyn L, 2018, OR SURG OR MED OR PA, V125, P268, DOI 10.1016/j.oooo.2017.11.022
   deCathelineau AM, 2003, ESSAYS BIOCHEM, V39, P105, DOI 10.1042/bse0390105
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Erwig LP, 2007, AM J PATHOL, V171, P2, DOI 10.2353/ajpath.2007.070135
   Escamilla García E, 2017, INT J MICROBIOL, V2017, DOI 10.1155/2017/5924717
   Faiman Beth, 2013, J Adv Pract Oncol, V4, P25
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Ge Y, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.839248
   Gobert AP, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108510
   Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114
   Hasan KMM, 2018, FOOD SCI HUM WELL, V7, P77, DOI 10.1016/j.fshw.2017.12.002
   Hinson AM, 2014, INT J DENT, V2014, DOI 10.1155/2014/452737
   Hinson AM, 2015, J ORAL MAXIL SURG, V73, P53, DOI 10.1016/j.joms.2014.07.012
   Ito D, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964 021 00717 y
   Itoh S, 2006, KEY ENG MATER, V309 311, P153, DOI 10.4028/www.scientific.net/KEM.309 311.153
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Kanazawa I, 2017, ENDOCR J, V64, P1043, DOI 10.1507/endocrj.EJ17 0323
   Kim J, 2021, INT J MED SCI, V18, P3261, DOI 10.7150/ijms.61552
   Kim SH, 2021, EUR J MED CHEM, V216, DOI 10.1016/j.ejmech.2021.113293
   Kolpakova ME, 2017, BRIT J ORAL MAX SURG, V55, P156, DOI 10.1016/j.bjoms.2016.10.006
   Latour YL, 2020, AMINO ACIDS, V52, P151, DOI 10.1007/s00726 019 02719 0
   Li H, 2016, AMINO ACIDS, V48, P2401, DOI 10.1007/s00726 016 2256 6
   Márquez M, 2004, ANTICANCER RES, V24, P1347
   Márquez M, 2022, INVEST NEW DRUG, V40, P565, DOI 10.1007/s10637 022 01233 7
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Mawardi H, 2011, J DENT RES, V90, P1339, DOI 10.1177/0022034511420430
   Meurling L, 2009, INT J ONCOL, V35, P281, DOI 10.3892/ijo_00000338
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Mozzati M, 2013, CLIN ORAL INVEST, V17, P1259, DOI 10.1007/s00784 012 0800 7
   Nakagawa T, 2021, J PROSTHODONT RES, V65, P219, DOI 10.2186/jpr.JPOR_2019_629
   Nastro E, 2007, ACTA HAEMATOL BASEL, V117, P181, DOI 10.1159/000097876
   Palaska PK, 2009, ONCOLOGIST, V14, P1154, DOI 10.1634/theoncologist.2009 0115
   Palla B, 2021, J ORAL MAXIL SURG, V79, P1045, DOI 10.1016/j.joms.2020.11.017
   Park OJ, 2019, MICROB PATHOGENESIS, V126, P218, DOI 10.1016/j.micpath.2018.11.005
   Ruggiero B.L., 2020, Bones, Joints, and Hormones Series, Diabetes Mellitus, P159, DOI [10.1016/B978 0 12 820605 8.00008 5, DOI 10.1016/B978 0 12 820605 8.00008 5]
   Shu JT, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05438 y
   Singh K, 2018, CANCER RES, V78, P4303, DOI 10.1158/0008 5472.CAN 18 0116
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Thellenberg Karlsson C, 2023, EUR J CANCER, V181, P198, DOI 10.1016/j.ejca.2022.12.006
   Thellenberg Karlsson C, 2016, ANTICANCER RES, V36, P6499, DOI 10.21873/anticanres.11249
   Xie XF, 2023, J MATER SCI TECHNOL, V144, P198, DOI 10.1016/j.jmst.2022.09.062
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Yamamoto T, 2012, BRIT J PHARMACOL, V166, P1084, DOI 10.1111/j.1476 5381.2012.01856.x
   Yan R, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00182 4
   Yang HY, 2013, MOL CELL PROTEOMICS, V12, P2674, DOI 10.1074/mcp.M112.026740
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Zhang MH, 1997, J EXP MED, V185, P1759, DOI 10.1084/jem.185.10.1759
NR 54
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2024
VL 187
AR 117211
DI 10.1016/j.bone.2024.117211
EA JUL 2024
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA A6G8M
UT WOS:001283506600001
PM 39053792
OA hybrid
DA 2025 08 17
ER

PT J
AU Qin, XY
   Wei, Q
   An, R
   Yang, Y
   Cai, MQ
   Han, XL
   Mao, HP
   Gao, XM
AF Qin, Xiaoyan
   Wei, Qiu
   An, Ran
   Yang, Yun
   Cai, Mingqi
   Han, Xiaoling
   Mao, Haoping
   Gao, Xiumei
TI Regulation of bone and fat balance by Fructus Ligustri Lucidi in
   ovariectomized mice
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Ovariectomy; osteoblastogenesis; adipogenesis; postmenopausal
   osteoporosis (PMOP); bone marrow mesenchymal stem cells (BMMSCs)
ID POSTMENOPAUSAL WOMEN; CALCIUM BALANCE; DIFFERENTIATION; OSTEOPOROSIS;
   EXTRACT; DENSITY; EXPRESSION; IMPROVES; OBESITY; CANCER
AB Context Fructus Ligustri Lucidi (FLL), a commonly used herb of traditional Chinese medicine (TCM), is the fruit of Ligustrum lucidum Ait. (Oleaceae). The ethanol extract of FLL is a potential candidate for preventing and treating postmenopausal osteoporosis (PMOP) by nourishing the liver and kidneys. Objective This study determines whether an ethanol extract of FLL has anti osteoporotic effects in ovariectomized (OVX) mice and explores the underlying mechanism. Materials and methods The OVX model of eight week old C57BL/6J female mice was taken, and ovariectomy was used as PMOP. Mice were divided into five groups: sham operated group (n = 10), OVX group (n = 10), OVX + E 2 group (n = 10; 0.039 mg/kg), OVX + FLL group (n = 10; 2 g/kg) and OVX + FLL group (n = 10; 4 g/kg). Mice were treated by gavage with FLL or CMCNa once daily for 8 weeks. We harvested uteri, femur, and tibias from mice; bone mineral density (BMD) and bone microstructure were obtained by X ray absorptiometry and micro CT. Furthermore, the effect of FLL on the balance of osteoblast and adipocyte differentiation was investigated using bone marrow mesenchymal stem cells (BMMSCs). Results The results indicated that FLL did not affect OVX induced estradiol reduction. Compared with OVX mice, FLL significantly increased BMD (63.54 vs. 61.96), Conn. D (86.46 vs. 57.00), and left tibial strength (13.91 vs. 11.27), decreased Tb. Sp (0.38 vs. 0.44) and body fat content (4.19% vs. 11.24%). FLL decreased osteoclast activity and enhanced RUNX2 expression; inhibited perilipin peroxisome proliferator activated receptor gamma (PPAR gamma) expression and adipocyte differentiation from BMMSCs. Conclusions FLL prevented additional bone loss and improved bone microstructure in OVX mice by modulating bone and fat balance, suggesting that FLL might be a therapeutic agent for PMOP.
C1 [Qin, Xiaoyan; Wei, Qiu; An, Ran; Yang, Yun; Cai, Mingqi; Han, Xiaoling; Mao, Haoping; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Key Lab Pharmacol Tradit Chinese Med Formulae, Minist Educ, Tianjin, Peoples R China.
   [Qin, Xiaoyan; Wei, Qiu; An, Ran; Yang, Yun; Cai, Mingqi; Han, Xiaoling; Mao, Haoping; Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine
RP Mao, HP; Gao, XM (通讯作者)，Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
EM maohaoping@tjutcm.edu.cn; gaoxiumei@tjutcm.edu.cn
RI GAO, Xiumei/IWD 8697 2023; mao, haoping/KIH 6773 2024; An,
   Ran/AAD 5607 2020; Qin, Xiaoyan/KLZ 0501 2024; Wei, qiu/MGW 5625 2025
FU National Natural Science Foundation of China [81630106]; Scientific
   research project of the Tianjin Education Commission [2021ZD007];
   Graduate Research and Innovation Project of Tianjin [2019YJSB140,
   YJSKC 20191002]
FX This work was supported by grants from the National Natural Science
   Foundation of China [Grant No. 81630106], the scientific research
   project of the Tianjin Education Commission [Grant No. 2021ZD007] and
   the Graduate Research and Innovation Project of Tianjin [Grant No.
   2019YJSB140; YJSKC 20191002].
CR Albala C, 1996, INT J OBESITY, V20, P1027
   Anagnostis P, 2019, CURR VASC PHARMACOL, V17, P564, DOI 10.2174/1570161116666180709095348
   Bian Qin, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P179, DOI 10.3736/jcim20110211
   Bonnet N, 2017, J BONE MINER RES, V32, P1432, DOI 10.1002/jbmr.3136
   Chen BB, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114348
   Chow SKH, 2016, OSTEOPOROSIS INT, V27, P2989, DOI 10.1007/s00198 016 3619 2
   Crivelli M, 2021, J CLIN DENSITOM, V24, P397, DOI 10.1016/j.jocd.2020.10.005
   Dam TV, 2021, MENOPAUSE, V28, P1214, DOI 10.1097/GME.0000000000001841
   de Castro LF, 2019, J BONE MINER RES, V34, P290, DOI 10.1002/jbmr.3602
   Dong XL, 2012, BRIT J NUTR, V108, P92, DOI 10.1017/S0007114511005186
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Duan L, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02374 x
   Eastelll R, 2019, J CLIN ENDOCR METAB, V104, P3537, DOI 10.1210/jc.2019 00777
   Fan JZ, 2014, MOL CELL BIOCHEM, V392, P85, DOI 10.1007/s11010 014 2021 7
   Gao LL, 2015, NAT PROD RES, V29, P493, DOI 10.1080/14786419.2014.954114
   Gartlehner G, 2017, JAMA J AM MED ASSOC, V318, P2234, DOI 10.1001/jama.2017.16952
   Georgiou KR, 2012, J CELL PHYSIOL, V227, P909, DOI 10.1002/jcp.22807
   Giuliani M, 2005, HAEMATOLOGICA, V90, P275
   Greco EA, 2015, THER ADV ENDOCRINOL, V6, P273, DOI 10.1177/2042018815611004
   Griffith JF, 2006, RADIOLOGY, V241, P831, DOI 10.1148/radiol.2413051858
   Hui S., 2018, ACTA BIOMATER, V78, P178
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jang HJ, 2020, FASEB J, V34, P1270, DOI 10.1096/fj.201901437R
   Jang SA, 2020, FOODS, V9, DOI 10.3390/foods9091181
   Ji K, 2020, CURR STEM CELL RES T, V15, P602, DOI 10.2174/1574888X15666200324165655
   Kase NG, 2020, AM J OBSTET GYNECOL, V223, P834, DOI 10.1016/j.ajog.2020.06.008
   Kim ME, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.734483
   김수경, 2003, [The Korean Journal of Medicine, 대한내과학회지], V65, P49
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Liu C, 2018, EUR J MED CHEM, V145, P661, DOI 10.1016/j.ejmech.2018.01.022
   Liu HF, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19373 3
   Liu P, 2017, NATURE, V546, P107, DOI 10.1038/nature22342
   Liu SY, 2015, CELL PHYSIOL BIOCHEM, V36, P1552, DOI 10.1159/000430318
   [刘亚鸽 Liu Yage], 2022, [中草药, Chinese Traditional and Herbal Drugs], V53, P3680
   Liu ZG, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/1926947
   Loh WJ, 2019, CLIN ENDOCRINOL, V91, P63, DOI 10.1111/cen.13989
   Lyu Y, 2014, J BONE MINER METAB, V32, P616, DOI 10.1007/s00774 013 0536 8
   Ornstrup MJ, 2015, EUR J ENDOCRINOL, V172, DOI 10.1530/EJE 14 0792
   Pang X, 2018, BIOORG MED CHEM LETT, V28, P1516, DOI 10.1016/j.bmcl.2018.03.080
   Peyroteo MA., 2021, COMPUT BIOL MED, V129, P104
   Qin XY, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113815
   Rajfer RA, 2019, J OSTEOPOROS, V2019, DOI 10.1155/2019/1592328
   Ruixian W., 2017, EVID BASED COMPL ALT, V2017
   Saleh N, 2020, EXP GERONTOL, V137, DOI 10.1016/j.exger.2020.110935
   Siu WS, 2013, PHYTOTHER RES, V27, P484, DOI 10.1002/ptr.4743
   Stopeck AT, 2017, CANCER AM CANCER SOC, V123, P2392, DOI 10.1002/cncr.30678
   Tang YQ, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2171 3
   van Gemert WA, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889 019 6510 1
   Wang F, 2012, PHYTOMEDICINE, V19, P1035, DOI 10.1016/j.phymed.2012.06.001
   Wang YC, 2020, BIOMED CHROMATOGR, V34, DOI 10.1002/bmc.4833
   Wei F., 2002, NOTIFICATION MINISTR
   Wong AK, 2020, J BONE MINER RES, V35, P516, DOI 10.1002/jbmr.3910
   Wu Y, 2021, VET SCI, V8, DOI 10.3390/vetsci8090198
   Xiao Ya Ping, 2018, Zhongguo Zhong Yao Za Zhi, V43, P21, DOI 10.19540/j.cnki.cjcmm.20171106.002
   Yu B, 2018, CELL STEM CELL, V23, P193, DOI 10.1016/j.stem.2018.06.009
   Yu P, 2021, INT J PHARMACEUT, V593, DOI 10.1016/j.ijpharm.2020.120171
   Yu X, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00392 2
   Yuasa Y, 2020, J BONE MINER METAB, V38, P179, DOI 10.1007/s00774 019 01045 5
   Zhang P, 2015, AM J CLIN NUTR, V101, P337, DOI 10.3945/ajcn.113.081778
   Zhang Y, 2006, BIOL PHARM BULL, V29, P291, DOI 10.1248/bpb.29.291
NR 60
TC 11
Z9 14
U1 4
U2 52
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388 0209
EI 1744 5116
J9 PHARM BIOL
JI Pharm. Biol.
PD DEC 31
PY 2023
VL 61
IS 1
BP 391
EP 403
DI 10.1080/13880209.2023.2168019
PG 13
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA 8N0AI
UT WOS:000924816300001
PM 36740874
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Suryani, L
   Too, JH
   Hassanbhai, AM
   Wen, F
   Lin, DJ
   Yu, N
   Teoh, SH
AF Suryani, Luvita
   Too, Jian Hui
   Hassanbhai, Ammar Mansoor
   Wen, Feng
   Lin, Daryl Jimian
   Yu, Na
   Teoh, Swee Hin
TI Effects of Electromagnetic Field on Proliferation, Differentiation, and
   Mineralization of MC3T3 Cells
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE bone; pulsed electromagnetic field; osteogenic; cell differentiation;
   cell proliferation; cell mineralization
ID DIFFERENT INTENSITIES; SIGNALING PATHWAYS; OSTEOGENESIS; STIMULATION;
   EXPOSURE; ADHESION; CALCIUM; CANCER
AB The steep increasing incidence of bone diseases and fractures provides a commanding impetus and growing demands for bone tissue engineering research. Pulsed electromagnetic fields (PEMFs) have been documented to promote bone fracture healing in nonunions and to enhance the maturation of osteoblastic cell, which is the key element in bone tissues. However, the optimal parameters for PEMF stimulation are still being explored. In this study, we investigated the effects of PEMF treatment on the proliferation, differentiation, and mineralization of osteoblast precursor cells MC3T3 E1 to explore the cell growth profile under different PEMF exposure durations (15, 30, and 60 min daily) with a magnetic field strength of 0.6 mT, at a frequency of 50 Hz, and cultured in media with or without osteogenic supplements for 28 days. Cell viability and metabolic activity were accessed by confocal microscopy, and alamarBlue time course measurements and results indicated that there were no adverse effects under designated PEMF condition. After 7 days of PEMF exposure, in comparison with negative controls, cell numbers increased when exposed to PEMF in culture medium and were independent of osteogenic supplements. However, PEMF might not have significant impact on cellular mineralization as observed from calcium deposition analysis, even though osteogenic gene expression was upregulated for cells with PEMF exposure. Von Kossa and Alizarin Red staining indicated that extracellular matrix mineralization occurred at day 28 with osteogenic supplements only, and no significant differences were found among those samples with different PEMF treatment durations. In summary, our results suggested that PEMF stimulation for as short as 15 min could improve cell proliferation but not mineralization in vitro. Thus, this study highlights the importance of choosing appropriate PEMF parameters to achieve the desired effect on target cells. The optimization of PEMFs will enhance the efficiency of its usage as a clinical, adjuvant therapeutic treatment for bone defect regeneration. Impact Statement We present the study about how the parameters of pulsed electromagnetic field (PEMF) stimulus affected calvarial osteoblast precursor cell in terms of growth, viability, and differentiation. This research provides insight and foundation to clinical application of noninvasive therapy using PEMF to improve bone regeneration.
C1 [Suryani, Luvita; Hassanbhai, Ammar Mansoor; Wen, Feng; Lin, Daryl Jimian; Teoh, Swee Hin] Nanyang Technol Univ, Sch Chem & Biomed Engn, 70 Nanyang Dr, Singapore 637457, Singapore.
   [Suryani, Luvita; Hassanbhai, Ammar Mansoor; Wen, Feng; Teoh, Swee Hin] Ctr Dev Biol Tissue Engn Regenerat Med & Innovat, Singapore, Singapore.
   [Too, Jian Hui; Yu, Na] Natl Dent Ctr Singapore, Singapore, Singapore.
   [Yu, Na] Duke NUS Med Sch Singapore, Singapore, Singapore.
   [Teoh, Swee Hin] Lee Kong Chian Sch Med Singapore, Singapore, Singapore.
C3 Nanyang Technological University; National University of Singapore
RP Teoh, SH (通讯作者)，Nanyang Technol Univ, Sch Chem & Biomed Engn, 70 Nanyang Dr, Singapore 637457, Singapore.
OI Too, Jian Hui/0000 0001 8368 5559; Lin, Daryl/0000 0002 3799 1843
FU A*STAR (IAF PP) [H17/01/a0/0S9];  [MOE2016 T2 2 108]
FX The authors acknowledge the financial support from the MOE2016 T2 2 108
   and A*STAR (IAF PP, H17/01/a0/0S9).
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Anbarasan S, 2016, INDIAN J ORTHOP, V50, P87, DOI 10.4103/0019 5413.173522
   Atkins G.J., 2011, Vitamin D, VThird, P411, DOI DOI 10.1016/B978 0 12 381978 9.10023 X
   Bloise N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199046
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   Chao EYS, 2004, CLIN ORTHOP RELAT R, P12, DOI 10.1097/01.blo.0000132263.14046.0c
   Crocetti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072944
   DOWNS TR, 1983, ANAL BIOCHEM, V131, P538, DOI 10.1016/0003 2697(83)90212 9
   Ferroni L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23499 9
   Fredericks DC, 2000, J ORTHOP TRAUMA, V14, P93, DOI 10.1097/00005131 200002000 00004
   Funk RHW, 2009, PROG HISTOCHEM CYTO, V43, P177, DOI 10.1016/j.proghi.2008.07.001
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   Heath CW, 1996, CA CANCER J CLIN, V46, P29, DOI 10.3322/canjclin.46.1.29
   Huegel J, 2018, J SHOULDER ELB SURG, V27, P553, DOI 10.1016/j.jse.2017.09.024
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Jing D, 2016, SCI REP UK, V6, DOI 10.1038/srep32045
   Kang H, 2017, ACS NANO, V11, P9636, DOI 10.1021/acsnano.7b02857
   Kang KS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.11
   KHALIL AM, 1991, MUTAT RES, V247, P141, DOI 10.1016/0027 5107(91)90041 L
   Kim JY, 2011, APOPTOSIS, V16, P347, DOI 10.1007/s10495 010 0567 8
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li JKJ, 2007, ELECTROMAGN BIOL MED, V26, P153, DOI 10.1080/15368370701572837
   Lim KT, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/895816
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   Luo Erping, 2005, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V22, P1168
   Markov MS, 2007, ELECTROMAGN BIOL MED, V26, P257, DOI 10.1080/15368370701580806
   Markov MS, 2017, ELECTROMAGNETIC FIEL, P15
   Martino CF, 2008, BIOELECTROMAGNETICS, V29, P125, DOI 10.1002/bem.20372
   Oschman JL., 2016, ELECT MAGNETISM DIAG, P75, DOI [10.1016/B978 0 443 06729 7.00006 5, DOI 10.1016/B978 0 443 06729 7.00006 5]
   Petecchia L, 2015, SCI REP UK, V5, DOI 10.1038/srep13856
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Punt BJ, 2008, EUR J ORTHOP SURG TR, V18, P127, DOI 10.1007/s00590 007 0271 8
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Sergeev IN, 2005, J STEROID BIOCHEM, V97, P145, DOI 10.1016/j.jsbmb.2005.06.007
   Sergeev IN, 2004, J STEROID BIOCHEM, V89 90, P419, DOI 10.1016/j.jsbmb.2004.03.010
   Soda A, 2008, J MED INVESTIG, V55, P267, DOI 10.2152/jmi.55.267
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   TABRAH F, 1990, J BONE MINER RES, V5, P437, DOI 10.1002/jbmr.5650050504
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Teodori L, 2006, CYTOM PART A, V69A, P75, DOI 10.1002/cyto.a.20208
   Tsai MT, 2007, BIOELECTROMAGNETICS, V28, P519, DOI 10.1002/bem.20336
   Wang YH, 2006, BIOTECHNOL PROGR, V22, P1697, DOI 10.1021/bp060274b
   Wong DSH, 2017, NANO LETT, V17, P1685, DOI 10.1021/acs.nanolett.6b04958
   Yan JL, 2015, MOL CELL ENDOCRINOL, V404, P132, DOI 10.1016/j.mce.2015.01.031
   Yan XZ, 2014, TISSUE ENG PART C ME, V20, P198, DOI 10.1089/ten.tec.2012.0412
   Zhang J, 2017, ELECTROMAGN BIOL MED, V36, P8, DOI 10.3109/15368378.2016.1141362
NR 49
TC 20
Z9 21
U1 1
U2 32
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD FEB 1
PY 2019
VL 25
IS 2
BP 114
EP 125
DI 10.1089/ten.tec.2018.0364
PG 12
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA HU5BV
UT WOS:000465291600006
PM 30661463
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Bhattacharya, S
   Chalk, AM
   Ng, AJM
   Martin, TJ
   Zannettino, AC
   Purton, LE
   Lu, J
   Baker, EK
   Walkley, CR
AF Bhattacharya, S.
   Chalk, A. M.
   Ng, A. J. M.
   Martin, T. J.
   Zannettino, A. C.
   Purton, L. E.
   Lu, J.
   Baker, E. K.
   Walkley, C. R.
TI Increased miR 155 5p and reduced miR 148a 3p contribute to the
   suppression of osteosarcoma cell death
SO ONCOGENE
LA English
DT Article
ID TARGETING ROCK1; POOR PROGNOSIS; MOUSE MODEL; KINASE; MICRORNA 148A;
   PROGRESSION; RIP1; GENE; HYPERMETHYLATION; IDENTIFICATION
AB Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer related death in young adults. Currently, 5 year survival rates have plateaued at similar to 70% for patients with localized disease. Those with disseminated disease have an similar to 20% 5 year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross species comparison with human osteoblasts and OS cultures. We identified miR 155 5p and miR 148a 3p as deregulated in OS. miR 155 5p suppression or miR 148a 3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR 148a 3p impacts OS, we identified that miR 155 5p overexpression suppressed its target Ripk1 (receptor (TNFRSF) interacting serine threonine kinase 1) expression, and miR 155 5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR 155 5p. Collectively, we show that miR 148a 3p and miR 155 5p are species conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA based therapies for OS.
C1 [Bhattacharya, S.; Chalk, A. M.; Ng, A. J. M.; Martin, T. J.; Purton, L. E.; Baker, E. K.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic, Australia.
   [Zannettino, A. C.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia.
   [Zannettino, A. C.] Univ Adelaide, Fac Hlth Sci, Sch Med, Myeloma Res Lab, Adelaide, SA, Australia.
   [Purton, L. E.; Walkley, C. R.] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia.
   [Lu, J.] St Vincents Inst Med Res, ACRF Rat Drug Discovery Ctr, Fitzroy, Vic, Australia.
   [Baker, E. K.; Walkley, C. R.] Yale Univ, Dept Genet, New Haven, CT USA.
   [Baker, E. K.; Walkley, C. R.] Yale Univ, Yale Stem Cell Ctr, New Haven, CT USA.
C3 St Vincent's Health; St Vincent's Hospital Melbourne; University of
   Melbourne; NSW Health; St Vincents Hospital Sydney; St. Vincent's
   Institute of Medical Research; NSW Health; St Vincents Hospital Sydney;
   St Vincent's Health; St Vincent's Hospital Melbourne; University of
   Melbourne; University of Adelaide; South Australian Health & Medical
   Research Institute (SAHMRI); St. Vincent's Institute of Medical
   Research; Yale University; Yale University
RP Walkley, CR (通讯作者)，St Vincents Inst, 9 Princes St, Fitzroy, Vic 3065, Australia.
EM cwalkley@svi.edu.au
RI Chalk, Alistair/B 3019 2008; Purton, Louise/AAI 8956 2021; Ng,
   Alvin/AAQ 5759 2020; Walkley, Carl/AAO 6021 2020
OI Chalk, Alistair/0000 0002 9630 6236; Walkley, Carl/0000 0002 4784 9031;
   Purton, Louise/0000 0001 6593 3168; Zannettino,
   Andrew/0000 0002 6646 6167; 
FU National Health and Medical Research Council (NHMRC), Australia; Cancer
   Council of Victoria; Cure Cancer Australia Foundation; 5point
   foundation; Zig Inge Foundation; NHMRC Career Development Award; NHMRC
   Dora Lush postgraduate scholarship; Victorian State Government OIS
   Program; Phillip Desbrow Senior Research Fellow of the Leukaemia
   Foundation
FX We thank A Pfeiffer (University of Bonn) for providing the miR 155 5p
   sponge, control sponge and miR 155 5p overexpression vector. We thank A
   Gupte for technical assistance; C Hawkins for discussion and comments;
   the BioResource Facility (St Vincent's Hospital) for housing and care of
   experimental animals, and M Thomson (SVI Flow Cytometry Facility) for
   help with FACS analysis. This work was supported by grants from the
   National Health and Medical Research Council (NHMRC), Australia (CW and
   TJM), Cancer Council of Victoria (CW and EB); Cure Cancer Australia
   Foundation (EB); 5point foundation (EB); Zig Inge Foundation (CW); NHMRC
   Career Development Award (CW); NHMRC Dora Lush postgraduate scholarship
   (SB); in part by the Victorian State Government OIS Program (to St.
   Vincent's Institute); CW was the Phillip Desbrow Senior Research Fellow
   of the Leukaemia Foundation.
CR Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614
   Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756 3282(02)00858 X
   Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Batanian JR, 2002, J CLIN PATHOL MOL PA, V55, P389, DOI 10.1136/mp.55.6.389
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905
   Dohi O, 2013, INT J ONCOL, V42, P411, DOI 10.3892/ijo.2012.1724
   Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715
   Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923
   Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078
   Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008 5472.CAN 11 2663
   Jouan Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406
   Kim S, 2010, CANCER SCI, V101, P2425, DOI 10.1111/j.1349 7006.2010.01697.x
   Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Li JP, 2013, MOL CELL BIOCHEM, V380, P277, DOI 10.1007/s11010 013 1682 y
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Lu J, 2008, DEV CELL, V14, P843, DOI 10.1016/j.devcel.2008.03.012
   Lv HC, 2014, EXP THER MED, V8, P1575, DOI 10.3892/etm.2014.1942
   Ma WL, 2014, TUMOR BIOL, V35, P12467, DOI 10.1007/s13277 014 2565 x
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016
   Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078 0432.CCR 07 5090
   Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305
   Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683
   Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523
   PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408
   Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211
   Sarver AL, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 7
   STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092 8674(95)90072 1
   Sun JX, 2014, ONCOTARGETS THER, V7, P853, DOI 10.2147/OTT.S60888
   Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490
   Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036
   Wang Y, 2013, MOL CELL BIOCHEM, V384, P105, DOI 10.1007/s11010 013 1786 4
   Wu XY, 2013, INT J MED SCI, V10, P676, DOI 10.7150/ijms.5528
   Yang J, 2013, MOL CELL BIOCHEM, V381, P9, DOI 10.1007/s11010 013 1677 8
   Yen CC, 2009, INT J ONCOL, V35, P775, DOI 10.3892/ijo_00000390
   Yuan J, 2009, CANCER INVEST, V27, P435, DOI 10.1080/07357900802491477
   Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127386
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
   Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078 0432.CCR 11 1714
   Zhu A, 2012, MED ONCOL, V29, P2701, DOI 10.1007/s12032 011 0134 3
NR 57
TC 64
Z9 67
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD OCT 6
PY 2016
VL 35
IS 40
BP 5282
EP 5294
DI 10.1038/onc.2016.68
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA DZ7NO
UT WOS:000386053000007
PM 27041566
OA Bronze
DA 2025 08 17
ER

PT J
AU Ralston, SH
   Corral Gudino, L
   Cooper, C
   Francis, RM
   Fraser, WD
   Gennari, L
   Guañabens, N
   Javaid, MK
   Layfield, R
   O'Neill, TW
   Russell, RGG
   Stone, MD
   Simpson, K
   Wilkinson, D
   Wills, R
   Zillikens, MC
   Tuck, SP
AF Ralston, Stuart H.
   Corral Gudino, Luis
   Cooper, Cyrus
   Francis, Roger M.
   Fraser, William D.
   Gennari, Luigi
   Guanabens, Nuria
   Javaid, M. Kassim
   Layfield, Robert
   O'Neill, Terence W.
   Russell, R. Graham G.
   Stone, Michael D.
   Simpson, Keith
   Wilkinson, Diana
   Wills, Ruth
   Zillikens, M. Carola
   Tuck, Stephen P.
TI Diagnosis and Management of Paget's Disease of Bone in Adults: A
   Clinical Guideline
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PAGET'S DISEASE OF BONE; ANTIRESORPTIVES; RADIONUCLIDE BONE SCANS; ALP;
   BISPHOSPHONATES
ID GIANT CELL TUMOR; DISTEMPER VIRUS TRANSCRIPTS; TOTAL HIP ARTHROPLASTY;
   MEASLES VIRUS; DOUBLE BLIND; DISODIUM ETIDRONATE; BISPHOSPHONATE
   TREATMENT; INTRAVENOUS PAMIDRONATE; SYMPTOMATIC MANAGEMENT; FAMILIAL
   AGGREGATION
AB An evidence based clinical guideline for the diagnosis and management of Paget's disease of bone (PDB) was developed using GRADE methodology, by a Guideline Development Group (GDG) led by the Paget's Association (UK). A systematic review of diagnostic tests and pharmacological and nonpharmacological treatment options was conducted that sought to address several key questions of clinical relevance. Twelve recommendations and five conditional recommendations were made, but there was insufficient evidence to address eight of the questions posed. The following recommendations were identified as the most important: 1) Radionuclide bone scans, in addition to targeted radiographs, are recommended as a means of fully and accurately defining the extent of metabolically active disease in patients with PDB. 2) Serum total alkaline phosphatase (ALP) is recommended as a first line biochemical screening test in combination with liver function tests in screening for the presence of metabolically active PDB. 3) Bisphosphonates are recommended for the treatment of bone pain associated with PDB. Zoledronic acid is recommended as the bisphosphonate most likely to give a favorable pain response. 4) Treatment aimed at improving symptoms is recommended over a treat to target strategy aimed at normalizing total ALP in PDB. 5) Total hip or knee replacements are recommended for patients with PDB who develop osteoarthritis in whom medical treatment is inadequate. There is insufficient information to recommend one type of surgical approach over another. The guideline was endorsed by the European Calcified Tissues Society, the International Osteoporosis Foundation, the American Society of Bone and Mineral Research, the Bone Research Society (UK), and the British Geriatric Society. The GDG noted that there had been a lack of research on patient focused clinical outcomes in PDB and identified several areas where further research was needed. (c) 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
C1 [Ralston, Stuart H.] Univ Edinburgh, MRC Inst Genet & Mol Med, Ctr Genom & Expt Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Corral Gudino, Luis] Univ Valladolid, Hosp Univ Rio Hortega, Dept Internal Med, Valladolid, Spain.
   [Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Cooper, Cyrus; Javaid, M. Kassim; Russell, R. Graham G.; Simpson, Keith; Wilkinson, Diana] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford, England.
   [Francis, Roger M.] Pagets Assoc, Manchester, Lancs, England.
   [Fraser, William D.] Univ East Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich, Norfolk, England.
   [Gennari, Luigi] Univ Siena, Dept Med Surg & Neurosci, Siena, Italy.
   [Guanabens, Nuria] Univ Barcelona, IDIBAPS, CiberEHD, Hosp Clin, Barcelona, Spain.
   [Layfield, Robert] Univ Nottingham, Sch Med, Sch Life Sci, Queens Med Ctr, Nottingham, England.
   [O'Neill, Terence W.] Univ Manchester, Arthrit Res UK Ctr Epidemiol, Manchester, Lancs, England.
   [O'Neill, Terence W.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England.
   [Russell, R. Graham G.] Univ Sheffield, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.
   [Stone, Michael D.] Univ Hosp Llandough, Bone Res Unit, Penarth, S Glam, Wales.
   [Wills, Ruth] Int Med Press, London, England.
   [Zillikens, M. Carola] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Tuck, Stephen P.] James Cook Univ Hosp, Dept Rheumatol, Middlesbrough, Cleveland, England.
   [Tuck, Stephen P.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
C3 University of Edinburgh; Hospital del Rio Hortega; Universidad de
   Valladolid; University of Southampton; University of Oxford; University
   of East Anglia; University of Siena; University of Barcelona; Hospital
   Clinic de Barcelona; IDIBAPS; CIBER   Centro de Investigacion Biomedica
   en Red; CIBEREHD; University of Nottingham; University of Manchester;
   University of Manchester; Manchester University NHS Foundation Trust;
   University of Sheffield; Erasmus University Rotterdam; Erasmus MC; James
   Cook University Hospital; Newcastle University   UK
RP Ralston, SH (通讯作者)，Univ Edinburgh, MRC Inst Genet & Mol Med, Ctr Genom & Expt Med, Edinburgh EH4 2XU, Midlothian, Scotland.
EM stuart.ralston@ed.ac.uk
RI Corral Gudino, Luis/K 4863 2019; Russell, R/JEF 5877 2023; Russell,
   Robert Graham G/JEF 5877 2023; Cooper, Cyrus/ADV 7232 2022
OI Cooper, Cyrus/0000 0003 3510 0709; Javaid, Muhammad/0000 0001 7985 0048;
   Russell, Robert Graham G/0000 0002 4136 1828; Wilkinson,
   Diana/0000 0001 8587 293X
FU International Osteoporosis Foundation; European Calcified Tissues
   Society; Paget's Association; European Commission [787270]; National
   Institute for Health Research (NIHR) Oxford Biomedical Research Centre;
   EPSRC [EP/J008192/1] Funding Source: UKRI; MRC [G0701603, MC_UU_12011/2,
   G0400491, MC_U147585819, G0801462, MC_UP_A620_1015, MC_U147585827]
   Funding Source: UKRI; Engineering and Physical Sciences Research Council
   [EP/J008192/1] Funding Source: researchfish; Medical Research Council
   [MC_U147585824, G0801462, MC_UU_12011/2, MC_UU_12011/1, U1475000002,
   G0400491, MC_U147585819, MC_UP_A620_1015, U1475000001, MC_UP_A620_1014,
   MC_U147585827, G0701603] Funding Source: researchfish; National
   Institute for Health Research [NF SI 0513 10085, NF SI 0508 10082]
   Funding Source: researchfish; Versus Arthritis [17702] Funding Source:
   researchfish; European Research Council (ERC) [787270] Funding Source:
   European Research Council (ERC)
FX Development of the guideline was supported by unrestricted educational
   grants from the International Osteoporosis Foundation, the European
   Calcified Tissues Society, and the Paget's Association. The work was
   supported in part by an Advanced Investigator Award to SHR from the
   European Commission (787270). MKG was supported by the National
   Institute for Health Research (NIHR) Oxford Biomedical Research Centre.
   The authors acknowledge the assistance of Cara Steiger (International
   Medical Press), who assisted with the literature search and screening of
   articles for the literature review. The guideline has been reviewed and
   endorsed by the American Society of Bone and Mineral Research (ASBMR),
   the European Calcified Tissues Society, the Bone Research Society, and
   the Paget's Association. The authors thank representatives of the
   Professional Practice Committee of the ASBMR for critical review of the
   guideline when it was in draft form.
CR Al Nofal AA, 2015, OSTEOPOROSIS INT, V26, P1875, DOI 10.1007/s00198 015 3095 0
   Albagha OME, 2011, NAT GENET, V43, P685, DOI 10.1038/ng.845
   Alonso Coello P, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i2089
   Alonso Coello P, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i2016
   ALTMAN RD, 1973, NEW ENGL J MED, V289, P1379, DOI 10.1056/NEJM197312272892601
   Alvarez L, 1997, ARTHRITIS RHEUM, V40, P461, DOI 10.1002/art.1780400312
   ALVAREZ L, 1995, J BONE MINER RES, V10, P458
   Atkins D, 2004, BMJ BRIT MED J, V328, P1490
   Beyens G, 2004, CALCIFIED TISSUE INT, V75, P144, DOI 10.1007/s00223 004 0244 4
   BICKERSTAFF DR, 1990, J BONE JOINT SURG BR, V72, P132, DOI 10.1302/0301 620X.72B1.2137127
   Bidner S, 1989, J Orthop Trauma, V3, P317, DOI 10.1097/00005131 198912000 00011
   BIRCH MA, 1994, J BONE MINER RES, V9, P11
   BOCKMAN RS, 1995, J CLIN ENDOCR METAB, V80, P595, DOI 10.1210/jc.80.2.595
   Bolland MJ, 2007, J BONE MINER RES, V22, P411, DOI 10.1359/JBMR.061204
   BOUDREAU RJ, 1983, J NUCL MED, V24, P880
   BRADLEY CM, 1992, AUST NZ J SURG, V62, P39, DOI 10.1111/j.1445 2197.1992.tb05352.x
   Britton C, 2017, CALCIFIED TISSUE INT, V101, P564, DOI 10.1007/s00223 017 0312 1
   Brouwers MC, 2016, BMJ BRIT MED J, V352, DOI 10.1136/bmj.i1152
   CANFIELD R, 1977, J CLIN ENDOCR METAB, V44, P96, DOI 10.1210/jcem 44 1 96
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   CHEN JR, 1979, NEUROLOGY, V29, P448, DOI 10.1212/WNL.29.4.448
   CONDON JR, 1971, BRIT MED J, V4, P719, DOI 10.1136/bmj.4.5789.719
   Cooper C, 1999, J BONE MINER RES, V14, P192, DOI 10.1359/jbmr.1999.14.2.192
   Corral Gudino L, 2013, OSTEOPOROSIS INT, V24, P443, DOI 10.1007/s00198 012 1954 5
   Corral Gudino L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004956.pub3
   Corral Gudino L, 2013, BONE, V55, P347, DOI 10.1016/j.bone.2013.04.024
   Cosso R, 2010, CLIN CASES MINER BON, V7, P145
   Cundy HR, 2004, CALCIFIED TISSUE INT, V75, P358, DOI 10.1007/s00223 004 0281 z
   Davie M, 1999, BONE, V24, p11S, DOI 10.1016/S8756 3282(99)00027 7
   Divisato G, 2016, AM J HUM GENET, V98, P275, DOI 10.1016/j.ajhg.2015.12.016
   Donáth J, 2004, RHEUMATOLOGY, V43, P89, DOI 10.1093/rheumatology/keg477
   DOUGLAS DL, 1981, J BONE JOINT SURG BR, V63, P495, DOI 10.1302/0301 620X.63B4.6457839
   Doyle T, 2002, BONE, V31, P616, DOI 10.1016/S8756 3282(02)00876 1
   Eekhoff MEMW, 2004, J BONE MINER RES, V19, P566, DOI 10.1359/jbmr.2004.19.4.566
   FENNELLY JJ, 1971, BRIT MED J, V1, P423, DOI 10.1136/bmj.1.5746.423
   FOGELMAN I, 1980, EUR J NUCL MED, V5, P417
   Fraser WD, 1997, POSTGRAD MED J, V73, P496, DOI 10.1136/pgmj.73.862.496
   GABEL GT, 1991, J BONE JOINT SURG AM, V73A, P739, DOI 10.2106/00004623 199173050 00013
   GORDON MT, 1992, BONE MINER, V19, P159, DOI 10.1016/0169 6009(92)90923 2
   GRUNDY M, 1970, Journal of Bone and Joint Surgery British Volume, V52, P252
   Guañabens N, 2012, CALCIFIED TISSUE INT, V91, P409, DOI 10.1007/s00223 012 9652 z
   Gutteridge DH, 1996, BONE, V19, P387, DOI 10.1016/S8756 3282(96)00224 4
   HAMDY R, 1979, BRIT MED J, V1, P1487, DOI 10.1136/bmj.1.6176.1487 b
   HEATH DA, 1981, METAB BONE DIS RELAT, V3, P343, DOI 10.1016/0221 8747(81)90051 5
   Helfrich MH, 2000, J BONE MINER RES, V15, P2315, DOI 10.1359/jbmr.2000.15.12.2315
   Helfrich MH, 2014, ARCH BIOCHEM BIOPHYS, V473, P172
   Hocking L, 2000, BONE, V26, P577, DOI 10.1016/S8756 3282(00)00278 7
   Hocking LJ, 2004, J BONE MINER RES, V19, P1122, DOI 10.1359/JBMR.0403015
   Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735
   Hsu J, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748 5908 6 62
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Jorge Mora Alberto, 2016, Eur J Orthop Surg Traumatol, V26, P27, DOI 10.1007/s00590 015 1659 5
   KANIS JA, 1975, Q J MED, V44, P399
   Kim CK, 1997, CLIN NUCL MED, V22, P104, DOI 10.1097/00003072 199702000 00007
   Kim HJ, 2013, NATURE, V495, P467, DOI 10.1038/nature11922
   Langston AL, 2007, CALCIFIED TISSUE INT, V80, P1, DOI 10.1007/s00223 006 0184 2
   Langston AL, 2010, J BONE MINER RES, V25, P20, DOI 10.1359/jbmr.090709
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Lee GC, 2005, J ARTHROPLASTY, V20, P689, DOI 10.1016/j.arth.2004.11.007
   Lever JH, 2002, BONE, V31, P434, DOI 10.1016/S8756 3282(02)00833 5
   Mangham DC, 2009, BONE, V44, P431, DOI 10.1016/j.bone.2008.11.002
   MARTIN TJ, 1977, AUST NZ J MED, V7, P36, DOI 10.1111/j.1445 5994.1977.tb03354.x
   Matthews BG, 2008, J CLIN ENDOCR METAB, V93, P1398, DOI 10.1210/jc.2007 1978
   Mays S, 2010, J BONE MINER RES, V25, P1839, DOI 10.1002/jbmr.64
   MCCLUNG MR, 1995, BONE, V17, pS493, DOI 10.1016/8756 3282(95)00282 1
   MCDONALD DJ, 1987, J BONE JOINT SURG AM, V69A, P766, DOI 10.2106/00004623 198769050 00020
   Merlotti D, 2007, J BONE MINER RES, V22, P1510, DOI 10.1359/JBMR.070704
   Merlotti D, 2011, J BONE MINER RES, V26, P512, DOI 10.1002/jbmr.237
   MEUNIER PJ, 1987, CLIN ORTHOP RELAT R, P37
   MEUNIER PJ, 1980, ARTHRITIS RHEUM US, V23, P1095, DOI 10.1002/art.1780231005
   Miller PD, 1999, AM J MED, V106, P513, DOI 10.1016/S0002 9343(99)00062 5
   MILLS BG, 1984, CLIN ORTHOP RELAT R, P303
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   MIRRA JM, 1995, SKELETAL RADIOL, V24, P173
   MONSELL EM, 1995, AM J OTOL, V16, P27
   MORALESPIGA AA, 1995, J BONE MINER RES, V10, P663
   Morissette J, 2006, J BONE MINER RES, V21, pP38, DOI 10.1359/JBMR.06S207
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   NICHOLAS JA, 1965, J BONE JOINT SURG AM, VA 47, P450, DOI 10.2106/00004623 196547030 00002
   ODONOGHUE DJ, 1987, BONE, V8, P219, DOI 10.1016/8756 3282(87)90168 2
   ODRISCOLL JB, 1985, LANCET, V2, P919
   Ooi CG, 2000, BONE, V27, P417, DOI 10.1016/S8756 3282(00)00343 4
   Parvizi J, 2003, J BONE JOINT SURG AM, V85A, P697, DOI 10.2106/00004623 200304000 00017
   Parvizi J, 2002, CLIN ORTHOP RELAT R, P127, DOI 10.1097/01.blo.0000022177.66847.d2
   Poór G, 2006, J BONE MINER RES, V21, P1545, DOI [10.1359/JBMR.060704, 10.1359/jbmr.060704]
   RALSTON SH, 1987, J BONE MINER RES, V2, P5
   RALSTON SH, 1991, J BONE MINER RES, V6, P1243
   Ralston SH, 2007, J BONE MINER RES, V22, P569, DOI 10.1359/JBMR.070103
   Ralston SH, 2013, NEW ENGL J MED, V368, P644, DOI 10.1056/NEJMcp1204713
   REBEL A, 1974, REV RHUM, V41, P767
   Reddy SV, 1996, J BONE MINER RES, V11, P1602
   REGINSTER JY, 1992, ARTHRITIS RHEUM, V35, P967, DOI 10.1002/art.1780350819
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Reid IR, 2016, CALCIFIED TISSUE INT, V99, P322, DOI 10.1007/s00223 016 0150 6
   Reid IR, 2011, J BONE MINER RES, V26, P2261, DOI 10.1002/jbmr.438
   Reid IR, 1996, AM J MED, V101, P341, DOI 10.1016/S0002 9343(96)00227 6
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Rendina D, 2015, J BONE MINER RES, V30, P257, DOI 10.1002/jbmr.2349
   Reyes R, 2008, CLIN RHEUMATOL, V27, P1585, DOI 10.1007/s10067 008 1001 2
   ROBERTS MC, 1989, RADIOLOGY, V173, P341, DOI 10.1148/radiology.173.2.2798865
   ROPER B A, 1971, Journal of Bone and Joint Surgery British Volume, V53, P660
   Rotés Sala D, 2004, BONE, V34, P605, DOI 10.1016/j.bone.2003.10.014
   Ruggieri P, 2010, CLIN ORTHOP RELAT R, V468, P2962, DOI 10.1007/s11999 010 1473 7
   Schwarz P, 2012, BONE, V50, P1023, DOI 10.1016/j.bone.2012.01.020
   Selby PL, 2002, BONE, V31, P366, DOI 10.1016/S8756 3282(02)00817 7
   Shirazi P H, 1974, CRC Crit Rev Clin Radiol Nucl Med, V5, P523
   Singer FR, 2014, J CLIN ENDOCR METAB, V99, P4408, DOI 10.1210/jc.2014 2910
   Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961
   SIRIS ES, 1994, SEMIN ARTHRITIS RHEU, V23, P222, DOI 10.1016/0049 0172(94)90037 X
   SIRIS ES, 1991, J BONE MINER RES, V6, P495
   SOFAER JA, 1983, J EPIDEMIOL COMMUN H, V37, P226, DOI 10.1136/jech.37.3.226
   SOLOMON LR, 1979, BRIT MED J, V1, P931, DOI 10.1136/bmj.1.6168.931
   Takata S, 2006, J BONE MINER METAB, V24, P359, DOI 10.1007/s00774 006 0696 x
   Tan A, 2017, J BONE MINER RES, V32, P1165, DOI 10.1002/jbmr.3066
   Tan A, 2014, CALCIFIED TISSUE INT, V95, P385, DOI 10.1007/s00223 014 9904 1
   Tanaka T, 2017, ONCOL LETT, V13, P2105, DOI 10.3892/ol.2017.5693
   Tehranzadeh J, 1998, SKELETAL RADIOL, V27, P664, DOI 10.1007/s002560050456
   Teramachi J, 2016, J CLIN INVEST, V126, P1012, DOI 10.1172/JCI82012
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tuck SP, 2017, RHEUMATOLOGY, V56, P2050, DOI 10.1093/rheumatology/kew430
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Van Staa TP, 2002, J BONE MINER RES, V17, P465, DOI 10.1359/jbmr.2002.17.3.465
   VERINDER DGR, 1979, INJURY, V10, P276, DOI 10.1016/0020 1383(79)90043 3
   Verma Vivek, 2016, J Orthop Case Rep, V6, P103, DOI 10.13107/jocr.2250 0685.594
   Visconti MR, 2017, CALCIFIED TISSUE INT, V101, P141, DOI 10.1007/s00223 017 0265 4
   Walsh JP, 2004, BONE, V34, P747, DOI 10.1016/j.bone.2003.12.011
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Wegrzyn J, 2010, INT ORTHOP, V34, P1103, DOI 10.1007/s00264 009 0853 7
   WELLMAN HN, 1977, CLIN ORTHOP RELAT R, P55
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Woitge HW, 1999, J BONE MINER RES, V14, P792, DOI 10.1359/jbmr.1999.14.5.792
NR 132
TC 124
Z9 133
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2019
VL 34
IS 4
BP 579
EP 604
DI 10.1002/jbmr.3657
PG 26
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IJ1XC
UT WOS:000475691400002
PM 30803025
OA Green Accepted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hoggatt, J
   Mohammad, KS
   Singh, P
   Hoggatt, AF
   Chitteti, BR
   Speth, JM
   Hu, PR
   Poteat, BA
   Stilger, KN
   Ferraro, F
   Silberstein, L
   Wong, FK
   Farag, SS
   Czader, M
   Milne, GL
   Breyer, RM
   Serezani, CH
   Scadden, DT
   Guise, TA
   Srour, EF
   Pelus, LM
AF Hoggatt, Jonathan
   Mohammad, Khalid S.
   Singh, Pratibha
   Hoggatt, Amber F.
   Chitteti, Brahmananda R.
   Speth, Jennifer M.
   Hu, Peirong
   Poteat, Bradley A.
   Stilger, Kayla N.
   Ferraro, Francesca
   Silberstein, Lev
   Wong, Frankie K.
   Farag, Sherif S.
   Czader, Magdalena
   Milne, Ginger L.
   Breyer, Richard M.
   Serezani, Carlos H.
   Scadden, David T.
   Guise, Theresa A.
   Srour, Edward F.
   Pelus, Louis M.
TI Differential stem  and progenitor cell trafficking by prostaglandin
   E2
SO NATURE
LA English
DT Article
ID BONE MARROW NICHE; HEMATOPOIETIC STEM; RECEPTOR; MICROENVIRONMENT;
   OSTEOPONTIN; IMPACT; SIZE
AB To maintain lifelong production of blood cells, haematopoietic stem cells (HSCs) are tightly regulated by inherent programs and extrinsic regulatory signals received from their microenvironmental niche. Long term repopulating HSCs reside in several, perhaps overlapping, niches that produce regulatory molecules and signals necessary for homeostasis and for increased output after stress or injury(1 5). Despite considerable advances in the specific cellular or molecular mechanisms governing HSC niche interactions, little is known about the regulatory function in the intact mammalian haematopoietic niche. Recently, we and others described a positive regulatory role for prostaglandin E 2 (PGE(2)) on HSC function ex vivo(6,7). Here we show that inhibition of endogenous PGE(2) by nonsteroidal anti inflammatory drug (NSAID) treatment in mice results in modest HSC egress from the bone marrow. Surprisingly, this was independent of the SDF 1 CXCR4 axis implicated in stem cell migration. Stem and progenitor cells were found to have differing mechanisms of egress, with HSC transit to the periphery dependent on niche attenuation and reduction in the retentive molecule osteopontin. Haematopoietic grafts mobilized with NSAIDs had superior repopulating ability and long term engraftment. Treatment of non human primates and healthy human volunteers confirmed NSAID mediated egress in other species. PGE(2) receptor knockout mice demonstrated that progenitor expansion and stem/progenitor egress resulted from reduced E prostanoid 4 (EP4) receptor signalling. These results not only uncover unique regulatory roles for EP4 signalling in HSC retention in the niche, but also define a rapidly translatable strategy to enhance transplantation therapeutically.
C1 [Hoggatt, Jonathan; Mohammad, Khalid S.; Singh, Pratibha; Hoggatt, Amber F.; Speth, Jennifer M.; Hu, Peirong; Stilger, Kayla N.; Czader, Magdalena; Serezani, Carlos H.; Guise, Theresa A.; Srour, Edward F.; Pelus, Louis M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Hoggatt, Jonathan; Ferraro, Francesca; Silberstein, Lev; Wong, Frankie K.; Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Harvard Med Sch, Ctr Regenerat Med,Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Hoggatt, Amber F.] Univ Illinois, Biol Resources Lab, Chicago, IL 60612 USA.
   [Chitteti, Brahmananda R.; Poteat, Bradley A.; Farag, Sherif S.; Srour, Edward F.] Indiana Univ Sch Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA.
   [Milne, Ginger L.] Vanderbilt Univ, Div Clin Pharmacol, Eicosanoid Core Lab, Nashville, TN 37232 USA.
   [Breyer, Richard M.] Vanderbilt Univ, Div Nephrol & Hypertens, Nashville, TN 37232 USA.
C3 Indiana University System; Indiana University Bloomington; Harvard
   University; Harvard Medical School; Harvard University Medical
   Affiliates; Massachusetts General Hospital; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital; Indiana University System; Indiana University Bloomington;
   Vanderbilt University; Vanderbilt University
RP Pelus, LM (通讯作者)，Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
EM lpelus@iupui.edu
RI Mohammad, Khalid/AFE 4205 2022; serezani, C. Henrique/H 1675 2013;
   Milne, Ginger/D 7648 2014; Singh, Pratibha/AAI 9796 2020
OI Speth, Jennifer/0000 0002 7724 6995; serezani, C.
   Henrique/0000 0002 5363 415X; Milne, Ginger/0000 0003 3890 151X; 
FU National Institutes of Health (NIH) [HL096305, CA143057, CA069158,
   HL100402, DK37097]; NIH [DK07519, HL07910, HL087735]; Center of
   Excellence in Hematology [P01 DK090948]
FX These studies were supported by National Institutes of Health (NIH)
   grants HL096305 (L.M.P.), CA143057, CA069158 (T.A.G., K.S.M.), HL100402
   (D.T.S.) and DK37097 (R.M.B.). J.H. was supported by NIH training grants
   DK07519, HL07910 and HL087735. Flow cytometry was performed in the Flow
   Cytometry Resource Facility of the Indiana University Simon Cancer
   Center (NCI P30 CA082709). Additional core support was provided by a
   Center of Excellence in Hematology grant P01 DK090948. The authors would
   like to thank H. E. Broxmeyer and B. Saez for critically reading the
   manuscript.
CR Ahmed Mansoor, 2005, Expert Opin Drug Metab Toxicol, V1, P739, DOI 10.1517/17425255.1.4.739
   Bethel Monique, 2011, Curr Osteoporos Rep, V9, P96, DOI 10.1007/s11914 011 0048 1
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chitteti BR, 2010, BLOOD, V115, P3239, DOI 10.1182/blood 2009 09 246173
   Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688
   Christopher MJ, 2011, J EXP MED, V208, P251, DOI 10.1084/jem.20101700
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Grassinger J, 2009, BLOOD, V114, P49, DOI 10.1182/blood 2009 01 197988
   Guan Y, 2007, J CLIN INVEST, V117, P2496, DOI 10.1172/JCI29838
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092 8674(02)00754 7
   Hoggatt J, 2011, CURR OPIN HEMATOL, V18, P231, DOI 10.1097/MOH.0b013e3283477962
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood 2009 01 201335
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood 2009 08 239194
   Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rinder HM, 2002, J CLIN PHARMACOL, V42, P881, DOI 10.1177/009127002401102795
   Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood 2009 11 253534
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 26
TC 122
Z9 138
U1 1
U2 35
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD MAR 21
PY 2013
VL 495
IS 7441
BP 365
EP 369
DI 10.1038/nature11929
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 113EY
UT WOS:000316650500042
PM 23485965
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, SB
   Han, XG
   Yang, Y
   Qiao, H
   Yu, ZF
   Liu, Y
   Wang, J
   Tang, TT
AF Yang, Shengbing
   Han, Xiuguo
   Yang, Ying
   Qiao, Han
   Yu, Zhifeng
   Liu, Yang
   Wang, Jing
   Tang, Tingting
TI Bacteria Targeting Nanoparticles with Microenvironment Responsive
   Antibiotic Release To Eliminate Intracellular Staphylococcus
   aureus and Associated Infection
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE nanoparticles; targeting; intracellular infection; bacterial toxin
   responsive; mesoporous silica nanoparticles
ID MESOPOROUS SILICA NANOPARTICLES; DRUG DELIVERY; ANTIMICROBIAL PEPTIDE;
   GENTAMICIN; LIPOSOMES; CANCER; PHARMACODYNAMICS; CIPROFLOXACIN;
   AZITHROMYCIN; MACROPHAGE
AB Staphylococcus aureus (S. aureus) is a causative agent in life threatening human diseases that afflict millions of people annually. Traditional antibiotic treatments are becoming less efficient because S. aureus can invade host cells including osteoblasts and macrophages, constituting a reservoir that is relatively protected from antibiotics that can lead to recrudescent infection. We herein report a unique intracellular antibiotic delivery nanoparticle, which is composed of (i) a mesoporous silica nanoparticle (MSN) core loaded with gentamicin, (ii) an infected microenvironment (bacterial toxin) responsive lipid bilayer surface shell, and (iii) bacteria targeting peptide ubiquicidin (UBI29 41) that is immobilized on the lipid bilayer surface shell. The lipid material acts as a gate that prevents drug release before the MSNs reach the target cells or tissue, at which point they are degraded by bacterial toxins to rapidly release the drug, thus eliminating efficient bacteria. We confirm rapid drug release in the presence of bacteria in an extracellular model and observe that S. aureus growth is effectively inhibited both in vitro and in vivo of planktonic and intracellular infection. The inflammation related gene expression in infected preosteoblast or macrophage is also downregulated significantly after treatment by the antibiotic delivery nanoparticles. The antibiotic delivery nanoparticles offer advantages in fighting intracellular pathogens and eliminating the inflammation caused by intracellular bacterial infections.
C1 [Yang, Shengbing; Han, Xiuguo; Yang, Ying; Qiao, Han; Yu, Zhifeng; Tang, Tingting] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Liu, Yang; Wang, Jing] East China Univ Sci & Technol, Minist Educ, Key Lab Ultrafine Mat, 130 Meilong Rd, Shanghai 200237, Peoples R China.
C3 Shanghai Jiao Tong University; East China University of Science &
   Technology
RP Tang, TT (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM ttt@sjtu.edu.cn
RI Yu, Zhifeng/L 2248 2017; Yang, Ying/KDP 1488 2024; Tang,
   Tingting/B 1361 2013
OI Yu, Zhifeng/0000 0002 2224 8344; Tang, Tingting/0000 0002 1670 7452;
   Yang, Ying/0000 0001 5433 1399
FU National Key RD Program [2016YFC1102100]; National Natural Science
   Foundation of China [81672205, 81401819]; Biomedical Engineering
   Crossover Project of Shanghai JiaoTong University [YG2014ZD01]; China
   Postdoctoral Science Foundation [2015M571574]
FX This work was funded by the National Key R&D Program (2016YFC1102100),
   National Natural Science Foundation of China (81672205), Biomedical
   Engineering Crossover Project of Shanghai JiaoTong University
   (YG2014ZD01), the grant from the National Natural Science Foundation of
   China (81401819), and the China Postdoctoral Science Foundation
   (2015M571574).
CR Abraham AM, 2005, INT J ANTIMICROB AG, V25, P392, DOI 10.1016/j.ijantimicag.2005.01.018
   Akbari V, 2013, J NANOPART RES, V15, DOI 10.1007/s11051 013 1556 y
   Briones E, 2008, J CONTROL RELEASE, V125, P210, DOI 10.1016/j.jconrel.2007.10.027
   Carrasco L.D., 2017, Drug Deliv. Lett, V7, P39, DOI [10.2174/2210303107666170203163102, DOI 10.2174/2210303107666170203163102]
   Carryn S, 2003, INFECT DIS CLIN N AM, V17, P615, DOI 10.1016/S0891 5520(03)00066 7
   Carryn S, 2002, ANTIMICROB AGENTS CH, V46, P2095, DOI 10.1128/AAC.46.7.2095 2103.2002
   Chen HY, 2015, MOL PHARMACEUT, V12, P2505, DOI 10.1021/acs.molpharmaceut.5b00053
   Chen SY, 2016, ACS APPL MATER INTER, V8, P22457, DOI 10.1021/acsami.6b05041
   de Faria TJ, 2012, ANTIMICROB AGENTS CH, V56, P2259, DOI 10.1128/AAC.05993 11
   Dicheva BM, 2013, NANO LETT, V13, P2324, DOI 10.1021/nl3014154
   Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184
   Fraunholz M, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00043
   Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005
   Han XG, 2015, CANCER LETT, V369, P405, DOI 10.1016/j.canlet.2015.09.002
   He QJ, 2014, ADV MATER, V26, P391, DOI 10.1002/adma.201303123
   Imbuluzqueta E, 2010, FRONT BIOSCI LANDMRK, V15, P397, DOI 10.2741/3627
   Jeon SJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0092723, 10.1109/CICC.2014.6946008]
   Jiao YF, 2015, SMALL, V11, P1962, DOI 10.1002/smll.201402297
   Kim HJ, 2006, ADV MATER, V18, P3083, DOI 10.1002/adma.200600387
   Kwon D, 2017, NANO LETT, V17, P2747, DOI 10.1021/acs.nanolett.6b04130
   Lehar SM, 2015, NATURE, V527, P323, DOI 10.1038/nature16057
   Li JY, 2015, ADV FUNCT MATER, V25, P1404, DOI 10.1002/adfm.201403636
   López V, 2017, ACS APPL MATER INTER, V9, P26697, DOI 10.1021/acsami.7b06906
   Mackowiak SA, 2013, NANO LETT, V13, P2576, DOI 10.1021/nl400681f
   MAJUMDAR S, 1992, ANTIMICROB AGENTS CH, V36, P2808, DOI 10.1128/AAC.36.12.2808
   Maurin M, 2001, ANTIMICROB AGENTS CH, V45, P2977, DOI 10.1128/AAC.45.11.2977 2986.2001
   Maya S, 2012, INT J BIOL MACROMOL, V51, P392, DOI 10.1016/j.ijbiomac.2012.06.009
   Mohamed W, 2014, EUR CELLS MATER, V28, P258, DOI 10.22203/eCM.v028a18
   MOR N, 1994, ANTIMICROB AGENTS CH, V38, P2738, DOI 10.1128/AAC.38.12.2738
   Pan LM, 2014, ADV MATER, V26, P6742, DOI 10.1002/adma.201402752
   Paterson GK, 2012, J ANTIMICROB CHEMOTH, V67, P2809, DOI 10.1093/jac/dks329
   Pornpattananangkul D, 2011, J AM CHEM SOC, V133, P4132, DOI 10.1021/ja111110e
   Qu QY, 2016, ACS APPL MATER INTER, V8, P34261, DOI 10.1021/acsami.6b13974
   Saeed S, 2013, EUR J NUCL MED MOL I, V40, P737, DOI 10.1007/s00259 012 2327 1
   Schwarz Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365 2958.2004.04027.x
   Seral C, 2003, ANTIMICROB AGENTS CH, V47, P2283, DOI 10.1128/AAC.47.7.2283 2292.2003
   Skidan I. N., 2003, Antibiotiki i Khimioterapiya, V48, P23
   Thamphiwatana S, 2014, J MATER CHEM B, V2, P8201, DOI 10.1039/c4tb01110d
   Van Bambeke F, 2006, CURR OPIN DRUG DISC, V9, P218
   Veeranarayanan S, 2012, SMALL, V8, P3476, DOI 10.1002/smll.201200874
   Wang D, 2013, BIOMATERIALS, V34, P7662, DOI 10.1016/j.biomaterials.2013.06.042
   Xiong MH, 2012, J AM CHEM SOC, V134, P4355, DOI 10.1021/ja211279u
   Yang C, 2016, ADV HEALTHC MATER, V5, P1272, DOI 10.1002/adhm.201600070
   Zaru M, 2009, J LIPOSOME RES, V19, P68, DOI 10.1080/08982100802610835
   Zhang XY, 2013, ACS APPL MATER INTER, V5, P1943, DOI 10.1021/am302512u
   Zhou J, 2010, J AM CHEM SOC, V132, P6566, DOI 10.1021/ja101554a
NR 46
TC 174
Z9 186
U1 10
U2 256
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 2
PY 2018
VL 10
IS 17
BP 14299
EP 14311
DI 10.1021/acsami.7b15678
PG 13
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA GF1VJ
UT WOS:000431723400011
PM 29633833
DA 2025 08 17
ER

PT J
AU Zhang, XM
   Xie, HN
   Chang, P
   Zhao, HS
   Xia, YL
   Zhang, L
   Guo, X
   Huang, C
   Yan, F
   Hu, L
   Lin, C
   Li, YY
   Xiong, ZY
   Wang, X
   Li, GH
   Deng, LX
   Wang, S
   Tao, L
AF Zhang, Xiaomeng
   Xie, Huaning
   Chang, Pan
   Zhao, Huishou
   Xia, Yunlong
   Zhang, Ling
   Guo, Xiong
   Huang, Chong
   Yan, Feng
   Hu, Lang
   Lin, Chen
   Li, Yueyang
   Xiong, Zhenyu
   Wang, Xiong
   Li, Guohua
   Deng, Longxiang
   Wang, Shan
   Tao, Ling
TI Glycoprotein M6B Interacts with TβRI to Activate TGF β Smad2/3 Signaling
   and Promote Smooth Muscle Cell Differentiation
SO STEM CELLS
LA English
DT Article
DE Glycoprotein M6B; Stem cells; Smooth muscle cells; Cell differentiation;
   TGF beta pathway
ID MESENCHYMAL STEM CELLS; TGF BETA; IN VITRO; GROWTH; TRANSCRIPTION;
   RECEPTOR; MYELINATION; EXPRESSION; INDUCTION; NEURONS
AB Smooth muscle cells (SMCs), which form the walls of blood vessels, play an important role in vascular development and the pathogenic process of vascular remodeling. However, the molecular mechanisms governing SMC differentiation remain poorly understood. Glycoprotein M6B (GPM6B) is a four transmembrane protein that belongs to the proteolipid protein family and is widely expressed in neurons, oligodendrocytes, and astrocytes. Previous studies have revealed that GPM6B plays a role in neuronal differentiation, myelination, and osteoblast differentiation. In the present study, we found that the GPM6B gene and protein expression levels were significantly upregulated during transforming growth factor beta 1 (TGF beta 1) induced SMC differentiation. The knockdown of GPM6B resulted in the downregulation of SMC specific marker expression and repressed the activation of Smad2/3 signaling. Moreover, GPM6B regulates SMC Differentiation by Controlling TGF beta Smad2/3 Signaling. Furthermore, we demonstrated that similar to p Smad2/3, GPM6B was profoundly expressed and coexpressed with SMC differentiation markers in embryonic SMCs. Moreover, GPM6B can regulate the tightness between T beta RI, T beta RII, or Smad2/3 by directly binding to T beta RI to activate Smad2/3 signaling during SMC differentiation, and activation of TGF beta Smad2/3 signaling also facilitate the expression of GPM6B. Taken together, these findings demonstrate that GPM6B plays a crucial role in SMC differentiation and regulates SMC differentiation through the activation of TGF beta Smad2/3 signaling via direct interactions with T beta RI. This finding indicates that GPM6B is a potential target for deriving SMCs from stem cells in cardiovascular regenerative medicine. Stem Cells 2018 Stem Cells 2019;37:190 201
C1 [Zhang, Xiaomeng; Xie, Huaning; Zhao, Huishou; Xia, Yunlong; Zhang, Ling; Huang, Chong; Yan, Feng; Hu, Lang; Lin, Chen; Li, Yueyang; Wang, Xiong; Li, Guohua; Deng, Longxiang; Wang, Shan; Tao, Ling] Fourth Mil Med Univ, Dept Cardiol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
   [Chang, Pan] Xian Med Univ, Cent Lab, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
   [Guo, Xiong] Hosp Peoples Liberat Army, Dept Cardiol, Golmud, Qinghai, Peoples R China.
   [Xiong, Zhenyu] Fourth Mil Med Univ, Dept Cardiol, Tangdu Hosp, Xian, Shaanxi, Peoples R China.
C3 Air Force Medical University; Xi'an Medical University; Air Force
   Medical University
RP Wang, S; Tao, L (通讯作者)，Fourth Mil Med Univ, Dept Cardiol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
EM wangshan1984@163.com; lingtao@fmmu.edu.cn
RI ; Li, Guohua/AFK 1773 2022
OI wang, shan/0000 0002 9487 0829; Zhang, Xiaomeng/0000 0002 3794 6823;
   zhao, huishou/0000 0003 2630 5729
FU Program for National Science Funds of China [81600683, 81730011,
   81470478, 81400201]; Program for Changjiang Scholars and Innovative
   Research Teams in the University [PCSIRT 14R08]; Fourth Military Medical
   University's Young Talent Project (the first level); National Science
   Fund for Distinguished Young Scholars of China [81225001]; National Key
   Basic Research Program of China (973 Program) [2013CB531204]; Key
   Science and Technology Innovation Team in the Shaanxi Province
   [2014KCT 19]; Major Science and Technology Project of China "Significant
   New Drug Development" [2012ZX09J12108 06B]; Key Problems of Social
   Development Science and Technology of the Shaanxi Province [2018SF 129];
   Shaanxi Key Laboratory of Ischemic Cardiovascular Disease [2016ZDKF09]
FX This work was financially supported by the Program for National Science
   Funds of China (Grant Nos. 81600683, 81730011, 81470478, and 81400201),
   Program for Changjiang Scholars and Innovative Research Teams in the
   University (Grant No. PCSIRT 14R08), the Fourth Military Medical
   University's Young Talent Project (the first level), National Science
   Fund for Distinguished Young Scholars of China (Grant No. 81225001),
   National Key Basic Research Program of China (973 Program, Grant No.
   2013CB531204), Key Science and Technology Innovation Team in the Shaanxi
   Province (Grant No. 2014KCT 19), Major Science and Technology Project of
   China "Significant New Drug Development" (Grant No. 2012ZX09J12108 06B),
   Key Problems of Social Development Science and Technology of the Shaanxi
   Province (2018SF 129), and Shaanxi Key Laboratory of Ischemic
   Cardiovascular Disease (2016ZDKF09).
CR Bilecova Rabajdova M, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/156034
   Cai Y, 2012, J DIGEST DIS, V13, P327, DOI 10.1111/j.1751 2980.2012.00592.x
   Chen SY, 2004, CIRC RES, V94, P1195, DOI 10.1161/01.RES.0000126897.41658.81
   Drabek K, 2011, J BONE MINER RES, V26, P2045, DOI 10.1002/jbmr.435
   Fjorback AW, 2009, J MOL NEUROSCI, V37, P191, DOI 10.1007/s12031 008 9092 4
   Formoso K, 2016, MOL CELL NEUROSCI, V77, P95, DOI 10.1016/j.mcn.2016.10.005
   Ghionzoli M, 2013, FASEB J, V27, P4853, DOI 10.1096/fj.12 218578
   Goumans MJ, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022210
   Grieskamp T, 2011, CIRC RES, V108, P813, DOI 10.1161/CIRCRESAHA.110.228809
   Gu WD, 2018, J BIOL CHEM, V293, P8089, DOI 10.1074/jbc.RA118.001739
   Gudz TI, 2002, J NEUROSCI, V22, P7398
   Guo Xia, 2012, World J Biol Chem, V3, P41, DOI 10.4331/wjbc.v3.i3.41
   Hao XB, 2011, CELL SIGNAL, V23, P935, DOI 10.1016/j.cellsig.2011.01.022
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805
   Honda A, 2017, J NEUROSCI, V37, P4046, DOI 10.1523/JNEUROSCI.3319 16.2017
   Horita H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10830
   Huang Y, 2013, STEM CELLS, V31, P906, DOI 10.1002/stem.1324
   Jeon ES, 2006, J CELL SCI, V119, P4994, DOI 10.1242/jcs.03281
   Jin M, 2016, STEM CELL RES, V17, P277, DOI 10.1016/j.scr.2016.07.011
   Lien SC, 2013, CELL SIGNAL, V25, P1252, DOI 10.1016/j.cellsig.2013.01.021
   Liu XJ, 2013, BIOCHEM BIOPH RES CO, V438, P551, DOI 10.1016/j.bbrc.2013.07.090
   Lönneborg A, 2009, EXPERT REV ANTICANC, V9, P1115, DOI 10.1586/ERA.09.31
   Massagué J, 2012, FEBS LETT, V586, P1833, DOI 10.1016/j.febslet.2012.05.030
   Mita S, 2015, CEREB CORTEX, V25, P4111, DOI 10.1093/cercor/bhu129
   Möbius W, 2008, NEURON GLIA BIOL, V4, P111, DOI 10.1017/S1740925X0900009X
   Montague CR, 2006, CIRC RES, V99, P477, DOI 10.1161/01.RES.0000238376.72592.a2
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338
   Owens Gary K, 2007, Novartis Found Symp, V283, P174
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   Pavone LM, 2009, J MOL CELL CARDIOL, V47, P691, DOI 10.1016/j.yjmcc.2009.07.021
   Pepe AE, 2010, CIRC RES, V106, P870, DOI 10.1161/CIRCRESAHA.109.211417
   Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002
   Qiu P, 2005, CIRC RES, V97, P983, DOI 10.1161/01.RES.0000190604.90049.71
   Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006
   Sezaki T, 2013, FEBS LETT, V587, P1624, DOI 10.1016/j.febslet.2013.04.015
   Shi N, 2016, J CELL PHYSIOL, V231, P777, DOI 10.1002/jcp.25208
   Singh N, 2011, CIRC RES, V109, P1240, DOI 10.1161/CIRCRESAHA.111.255067
   Sinha S, 2004, AM J PHYSIOL CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004
   Tang R, 2017, J BIOL CHEM, V292, P14270, DOI 10.1074/jbc.M117.790030
   Urban P, 2014, TUMOR BIOL, V35, P11229, DOI 10.1007/s13277 014 2447 2
   Wang G, 2012, J BIOL CHEM, V287, P2896, DOI 10.1074/jbc.M111.297028
   Wang YC, 2018, J BIOL CHEM, V293, P5668, DOI 10.1074/jbc.RA117.001578
   Wang ZH, 2016, ACTA HISTOCHEM, V118, P393, DOI 10.1016/j.acthis.2016.04.001
   Werner H, 2001, MOL CELL NEUROSCI, V18, P593, DOI 10.1006/mcne.2001.1044
   Werner HB, 2013, GLIA, V61, P567, DOI 10.1002/glia.22456
   Wu DF, 2007, J BIOL CHEM, V282, P22239, DOI 10.1074/jbc.M700941200
   Xiao QZ, 2012, ARTERIOSCL THROM VAS, V32, P730, DOI 10.1161/ATVBAHA.111.243188
   Xiao QZ, 2011, ARTERIOSCL THROM VAS, V31, P1842, DOI 10.1161/ATVBAHA.111.230110
   Xie WB, 2013, CIRC RES, V113, pE76, DOI 10.1161/CIRCRESAHA.113.301921
   Yan XH, 2011, MOL CELL BIOL, V31, P3700, DOI 10.1128/MCB.05448 11
   YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896 6273(93)90147 J
   Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860 14.2014, 10.11772/j.issn.1001 9081.2014.07.1929]
   Zhao B, 2012, CELL RES, V22, P1467, DOI 10.1038/cr.2012.92
   Zhao HQ, 2015, ARTERIOSCL THROM VAS, V35, P918, DOI 10.1161/ATVBAHA.114.305212
   Zhu L, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.388009
NR 57
TC 22
Z9 23
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2019
VL 37
IS 2
BP 190
EP 201
DI 10.1002/stem.2938
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA HK9TN
UT WOS:000458334900004
PM 30372567
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Noh, BJ
   Park, YK
AF Noh, Byeong Joo
   Park, Yong Koo
TI Giant cell tumor of bone: updated molecular pathogenesis and tumor
   biology
SO HUMAN PATHOLOGY
LA English
DT Article
DE Giant cell tumor of bone; G34W mutation; H3F3A; Molecular pathogenesis;
   Tumor microenvironment; RANKLs; Cytokines; Chemokines
ID DIAGNOSTIC VALUE; GENE EXPRESSION; H3F3A MUTATION; STROMAL CELLS; CYCLIN
   D1; TGF BETA; DENOSUMAB; PROTEIN; OSTEOCLASTOGENESIS; LOCALIZATION
AB Giant cell tumor of bone (GCTB) related clonal aberrations occur in a background of epigenetic histone modifications (especially the G34W mutation of H3F3A gene) that induce cytogenetic abnormalities. Clonal aberrations are closely linked to the aggressiveness of GCTB. The "neoplastic" mononuclear stromal cells in GCTB express fundamental RANKLs and various chemokines and cytokines associated with monocyte recruitment and "reactive" multinucleated giant cells (osteoclastogenesis). The reciprocal and orchestrated actions between mononuclear stromal cells and multinucleated giant cells help in the understanding of the molecular pathogenesis and tumor biology of GCTB. In the future, novel targets in the updated tumor biology and molecular pathogenesis of GCTB should be explored and scrutinized for the development of systemic therapy. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Noh, Byeong Joo] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Pathol, Kangnung 25440, South Korea.
   [Park, Yong Koo] Kyung Hee Univ, Sch Med, Dept Pathol, Seoul 02447, South Korea.
C3 University of Ulsan; Kyung Hee University
RP Park, YK (通讯作者)，Kyung Hee Univ Hosp, Dept Pathol, 23 Kyungheedaero, Seoul 02447, South Korea.
EM ykpark0204@gmail.com
CR Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Atkins GJ, 2000, J BONE MINER RES, V15, P640, DOI 10.1359/jbmr.2000.15.4.640
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853
   Girolami I, 2016, J CLIN PATHOL, V69, P240, DOI 10.1136/jclinpath 2015 203248
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Gorunova L, 2009, GENE CHROMOSOME CANC, V48, P583, DOI 10.1002/gcc.20667
   Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023
   Herr I, 2017, CANCER LETT, V409, P49, DOI 10.1016/j.canlet.2017.08.029
   Kandel R, 2006, J ORTHOP RES, V24, P428, DOI 10.1002/jor.20036
   Kato I, 2018, HISTOPATHOLOGY, V72, P914, DOI 10.1111/his.13448
   Kauzman A, 2003, MODERN PATHOL, V16, P210, DOI 10.1097/01.MP.0000057235.65327.40
   Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Lüke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Mak IWY, 2013, BONE, V55, P198, DOI 10.1016/j.bone.2013.02.020
   Mancini I, 2017, HISTOPATHOLOGY, V71, P453, DOI 10.1111/his.13249
   Matsubayashi S, 2009, PATHOL RES PRACT, V205, P626, DOI 10.1016/j.prp.2009.02.011
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Moskovszky L, 2010, MODERN PATHOL, V23, P359, DOI 10.1038/modpathol.2009.134
   Mukaihara K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148401
   Ng PKS, 2010, J CELL BIOCHEM, V110, P438, DOI 10.1002/jcb.22556
   Ng RK, 2008, NAT CELL BIOL, V10, P102, DOI 10.1038/ncb1674
   Nohr E, 2017, HUM PATHOL, V68, P119, DOI 10.1016/j.humpath.2017.08.030
   Okubo T, 2013, VIRCHOWS ARCH, V463, P67, DOI 10.1007/s00428 013 1435 z
   Pilkington MF, 2001, J BONE MINER RES, V16, P1237, DOI 10.1359/jbmr.2001.16.7.1237
   Pratap J, 2003, CANCER RES, V63, P5357
   Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13
   Rao UNM, 2005, CANCER GENET CYTOGEN, V158, P126, DOI 10.1016/j.cancergencyto.2004.09.015
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Saâda E, 2011, J CLIN ONCOL, V29, pE86, DOI 10.1200/JCO.2010.31.4286
   Si AIC, 2003, J CELL BIOCHEM, V89, P1154, DOI 10.1002/jcb.10578
   Singh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046769
   Singh S, 2011, J CELL BIOCHEM, V112, P2287, DOI 10.1002/jcb.23149
   Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092 8674(03)01064 X
   Tian BL, 2002, J CLIN PATHOL MOL PA, V55, P394, DOI 10.1136/mp.55.6.394
   van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang T, 2017, INT J CANCER, V141, P1630, DOI 10.1002/ijc.30862
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wuelling M, 2004, VIRCHOWS ARCH, V445, P621, DOI 10.1007/s00428 004 1113 2
   Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111
   Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020
   Yu Q, 2000, GENE DEV, V14, P163
   Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001
   Zheng MH, 1998, J CELL BIOCHEM, V70, P121, DOI 10.1002/(SICI)1097 4644(19980701)70:1<121::AID JCB12>3.3.CO;2 D
NR 50
TC 43
Z9 45
U1 0
U2 16
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0046 8177
EI 1532 8392
J9 HUM PATHOL
JI Hum. Pathol.
PD NOV
PY 2018
VL 81
BP 1
EP 8
DI 10.1016/j.humpath.2018.06.017
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA HB5LM
UT WOS:000451102300001
PM 29944971
DA 2025 08 17
ER

PT J
AU Smith, MV
   Lee, MJ
   Islam, AS
   Rohrer, JL
   Goldberg, VM
   Beidelschies, MA
   Greenfield, EM
AF Smith, Matthew V.
   Lee, Michael J.
   Islam, Andrew S.
   Rohrer, Jacqueline L.
   Goldberg, Victor M.
   Beidelschies, Michelle A.
   Greenfield, Edward M.
TI Inhibition of the PI3K Akt signaling pathway reduces tumor necrosis
   factor α production in response to titanium particles in vitro
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article
ID TOTAL HIP ARTHROPLASTY; KAPPA B ACTIVATION; ADHERENT ENDOTOXIN;
   EMBRYONIC LETHALITY; WEAR DEBRIS; PROTEIN; POLYETHYLENE; OSTEOLYSIS;
   PEPTIDOGLYCAN; MACROPHAGES
AB Background: Wear debris contributes to implant loosening after total joint arthroplasty, and few advances have been made in our ability to inhibit the biological response to wear particles. Bacterial endotoxins augment the effects of wear particles in vitro and in vivo. The cytokine, tumor necrosis factor alpha (TNF alpha), is produced by macrophages in response to bacterial endotoxins and wear particles, and it increases osteoclast activity resulting in bone resorption and implant loosening. The phosphoinositol 3 kinase (PI3K) Akt intracellular signal transduction pathway contributes to cytokine production in response to soluble endotoxin. We investigated the role of the PI3K Akt pathway in the production of TNF alpha in response to wear particles with adherent endotoxin and so called endotoxin free wear particles.
   Methods: Cultured RAW264.7 murine macrophages were incubated with titanium particles with adherent endotoxin or with endotoxin free titanium particles in the presence and absence of specific inhibitors of PI3K (LY294002) or Akt (SH 5). Akt activation was assessed with use of Western blot. TNF alpha production was measured with use of enzyme linked immunosorbent assay. Cytotoxicity was determined by measuring lactic dehydrogenase release.
   Results: Titanium particles with adherent endotoxin increased Akt activation, whereas endotoxin free titanium particles did not. The PI3K inhibitor reduced TNF alpha production by 70% in response to titanium with adherent endotoxin without increasing cytotoxicity. Similarly, the Akt inhibitor reduced TNF alpha production by 83% in response to titanium particles with adherent endotoxin without increasing cytotoxicity. High concentrations of endotoxin free titanium particles resulted in a small delayed increase in TNF alpha production that was completely blocked by the PI3K inhibitor.
   Conclusions: Inhibition of the PI3K Akt pathway reduces macrophage TNF alpha production in response to titanium particles with adherent endotoxin and endotoxin free particles in vitro.
   Clinical Relevance: In vivo studies are needed as these results suggest a possible pharmacological target to reduce wear particle induced osteolysis and subsequent implant loosening.
C1 Case Western Reserve Univ, Univ Hosp Cleveland, Dept Orthopaed, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Univ Hosp Cleveland, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; Case Western
   Reserve University Hospital; University Hospitals of Cleveland;
   University System of Ohio; Case Western Reserve University; Case Western
   Reserve University Hospital; University Hospitals of Cleveland;
   University System of Ohio; Case Western Reserve University; Case Western
   Reserve University Hospital; University Hospitals of Cleveland
RP Smith, MV (通讯作者)，Case Western Reserve Univ, Univ Hosp Cleveland, Dept Orthopaed, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM mvsmith23@gmail.com; mai6@case.edu; emg3@po.cwru.edu
RI ; Beidelschies, Michelle/AAM 6446 2021
OI Beidelschies, Michelle/0000 0002 6344 0674; 
FU NIAMS NIH HHS [AR07505, R01 AR43769] Funding Source: Medline
CR Akisue T, 2002, J BIOMED MATER RES, V59, P507, DOI 10.1002/jbm.1264
   Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963
   Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335 001 2123 x
   Bi YM, 2001, J BONE MINER RES, V16, P2082, DOI 10.1359/jbmr.2001.16.11.2082
   Bi YM, 2002, J ORTHOP RES, V20, P696, DOI 10.1016/S0736 0266(01)00176 0
   Blaine TA, 1996, J BONE JOINT SURG AM, V78A, P1181, DOI 10.2106/00004623 199608000 00008
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955 0674(96)80060 3
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079 6107(98)00056 X
   COOPERSTOCK MS, 1975, LANCET, V1, P1272
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264 6021:3510095
   Dorr LD, 2005, J BONE JOINT SURG AM, V87A, P1816, DOI 10.2106/JBJS.D.01915
   Engesæter LB, 2003, ACTA ORTHOP SCAND, V74, P644, DOI 10.1080/00016470310018135
   FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627
   FRANKE T, 1999, NEURAL NOTES, V15, P3
   Greenfield EM, 2005, J BIOMED MATER RES B, V72B, P179, DOI 10.1002/jbm.b.30150
   Hauschildt S, 2000, HANDB EXP PHARM, V145, P619
   Ingram JH, 2004, BIOMATERIALS, V25, P3511, DOI 10.1016/j.biomaterials.2003.10.054
   INNOCENTI MA, 2005, 51 ANN M ORTH RES SO, V30
   Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022
   Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159
   Lim HK, 2003, J BIOL CHEM, V278, P45117, DOI 10.1074/jbc.M303789200
   MARGEVICIUS KJ, 1994, J BONE JOINT SURG AM, V76A, P1664, DOI 10.2106/00004623 199411000 00010
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Nalepka JL, 2006, CLIN ORTHOP RELAT R, P229, DOI 10.1097/01.blo.0000224050.94248.38
   Nalepka JL, 2004, BIOTECHNIQUES, V37, P413, DOI 10.2144/04373ST06
   Nelson CL, 2005, CLIN ORTHOP RELAT R, P25, DOI 10.1097/01.blo.0000175715.68624.3d
   Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376
   Ragab AA, 1999, J ORTHOPAED RES, V17, P803, DOI 10.1002/jor.1100170603
   Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014 5793(03)00562 3
   Schrijver IA, 2000, ARTHRITIS RHEUM US, V43, P2160, DOI 10.1002/1529 0131(200010)43:10<2160::AID ANR3>3.0.CO;2 T
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Soloviev A, 2002, J ORTHOP RES, V20, P714, DOI 10.1016/S0736 0266(01)00180 2
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   Tatro JM, 2007, J ORTHOP RES, V25, P361, DOI 10.1002/jor.20289
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199
   Wilkinson JM, 2003, J BONE MINER RES, V18, P1995, DOI 10.1359/jbmr.2003.18.11.1995
   Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200
   Wright T.M., 2001, IMPLANT WEAR TOTAL J
   Zhu W, 2000, J IMMUNOL, V164, P6349, DOI 10.4049/jimmunol.164.12.6349
NR 43
TC 30
Z9 34
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021 9355
EI 1535 1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD MAY
PY 2007
VL 89A
IS 5
BP 1019
EP 1027
DI 10.2106/JBJS.F.00615
PG 9
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 166KK
UT WOS:000246377400014
PM 17473139
DA 2025 08 17
ER

PT J
AU Groen, N
   van de Peppel, J
   Yuan, HP
   van Leeuwen, JPTM
   van Blitterswijk, CA
   de Boer, J
AF Groen, Nathalie y
   van de Peppel, Jeroen
   Yuan, Huipin
   van Leeuwen, Johannes P. T. M.
   van Blitterswijk, Clemens A.
   de Boer, Jan
TI Bioinformatics based selection of a model cell type for in vitro
   biomaterial testing
SO BIOMATERIALS
LA English
DT Article
DE Biomaterials; Bioactivity; Bone regeneration; In vitro testing; Cell
   type comparison; Whole genome expression profiling
ID MESENCHYMAL STEM CELLS; CALCIUM PHOSPHATE CERAMICS; BONE FORMATION;
   DONOR VARIATION; EXPRESSION; SCAFFOLDS; LIBRARY; GROWTH;
   DIFFERENTIATION; OSTEOBLASTS
AB Biomaterial properties can be tailored for specific applications via systematic and high throughput screening of biomaterial cell interactions. However, progress in material development is often hampered by the lack of adequate in vitro testing methods, frequently due to incomplete understanding of involved in vivo mechanisms. In line with drug discovery in pharmacology, a crucial step in assay development for biomaterial screening is the identification of a target to direct the screen against. Herein, the cell type to be used for screening is of essential importance and has to be carefully chosen. So far, few attention has been put on selecting a cell type specifically suitable for in vitro testing of materials for predefined applications. In this manuscript, we describe an approach to define a suitable cell type for screening assays, for which biomaterials for bone regeneration served as example. Using a bioinformatics methodology, different cell lines are compared on three well characterized model materials. The transcriptional profiles of MG63, iMSC, SV HFO, hPPCT, hBPCT and SW480 cells are assessed on 3 calcium phosphate based materials to evaluate their potential application in a screening assay. We show that MG63 is the most suitable cell line to evaluate biomaterials for bone regeneration applications, evidenced by their robust gene expression differences between the 3 model materials. The gene expression differences between the cell lines were assessed based on the overall gene expression profiles and specific subsets of genes and pathways related to osteogenesis and bone homeostasis in response to the 3 materials tested. In the next phase, this cell line will be used to identify a target correlating with in vivo biomaterial performance and henceforth to develop an in vitro screening system. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Groen, Nathalie y; Yuan, Huipin; van Blitterswijk, Clemens A.; de Boer, Jan] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Tissue Regenerat, NL 7500 AE Enschede, Netherlands.
   [van de Peppel, Jeroen; van Leeuwen, Johannes P. T. M.] Erasmus MC, Dept Internal Med, NL 3015 GE Rotterdam, Netherlands.
C3 University of Twente; Erasmus University Rotterdam; Erasmus MC
RP de Boer, J (通讯作者)，Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Tissue Regenerat, Drienerlolaan 5, NL 7500 AE Enschede, Netherlands.
EM j.deboer@utwente.nl
RI van Leeuwen, Johannes/D 5015 2014; van de Peppel, Jeroen/K 6683 2019
OI van Leeuwen, Johannes/0000 0002 2282 4006; de Boer,
   Jan/0000 0001 9188 9324; van de peppel, jeroen/0000 0002 6524 727X; van
   Blitterswijk, Clemens/0000 0003 2371 4615
FU Dutch Ministry of Economic Affairs, Agriculture and Innovation; STW
FX This research forms part of the Project BONE IP of the research program
   of the BioMedical Materials Institute, co funded by the Dutch Ministry
   of Economic Affairs, Agriculture and Innovation. The authors acknowledge
   STW for funding JdB. We wish to acknowledge Takashi Kanda for kindly
   providing us with the two pericyte cell lines, H. Chiba (Department of
   Basic Pathology, Fukushima Medical University, Japan) for the SV HFO
   cell line, Hans Clevers for the SW480 cell line and Ola Myklebost for
   the iMSC cell line.
CR Alves H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042908
   Alves H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026678
   Barbieri D, 2010, EUR CELLS MATER, V19, P252, DOI 10.22203/eCM.v019a24
   Barradas AMC, 2012, BIOMATERIALS, V33, P5696, DOI 10.1016/j.biomaterials.2012.04.021
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Brey DM, 2011, BIOTECHNOL BIOENG, V108, P163, DOI 10.1002/bit.22925
   Brown SA, 1983, ASTM SPECIAL TECHNIC, P810
   Chan BP, 2007, TISSUE ENG, V13, P73, DOI 10.1089/ten.2006.004
   Chatterjee K, 2011, BIOMATERIALS, V32, P1361, DOI 10.1016/j.biomaterials.2010.10.043
   Chatterjee K, 2010, BIOMATERIALS, V31, P5051, DOI 10.1016/j.biomaterials.2010.03.024
   CHIBA H, 1993, JPN J CANCER RES, V84, P290, DOI 10.1111/j.1349 7006.1993.tb02869.x
   Corum LE, 2010, BIOMATERIALS, V31, P3148, DOI 10.1016/j.biomaterials.2010.01.025
   De Bari C, 2008, ARTHRITIS RHEUM, V58, P240, DOI 10.1002/art.23143
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Doorn J, 2011, BIOMATERIALS, V32, P6089, DOI 10.1016/j.biomaterials.2011.05.010
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng JF, 2011, P NATL ACAD SCI USA, V108, P6503, DOI 10.1073/pnas.1015449108
   Fernandes H, 2009, TISSUE ENG PT A, V15, P3857, DOI 10.1089/ten.tea.2009.0011
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035
   Goeman JJ, 2004, BIOINFORMATICS, V20, P93, DOI 10.1093/bioinformatics/btg382
   Habibovic P, 2006, ADV EXP MED BIOL, V585, P327
   Kaltz N, 2010, EXP CELL RES, V316, P2609, DOI 10.1016/j.yexcr.2010.06.002
   Kobel S, 2010, BIOTECHNIQUES, V48, pIX, DOI 10.2144/000113401
   Li SH, 2003, TISSUE ENG, V9, P535, DOI 10.1089/107632703322066714
   Mei Y, 2010, NAT MATER, V9, P768, DOI [10.1038/NMAT2812, 10.1038/nmat2812]
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Menicanin D, 2010, STEM CELLS DEV, V19, P1501, DOI 10.1089/scd.2009.0492
   Meredith JC, 2003, J BIOMED MATER RES A, V66A, P483, DOI 10.1002/jbm.a.10004
   Olivares Navarrete R, 2012, J BONE MINER RES, V27, P1773, DOI 10.1002/jbmr.1628
   Olivares Navarrete R, 2012, SPINE J, V12, P265, DOI 10.1016/j.spinee.2012.02.002
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]
   Shikinami Y, 2006, J R SOC INTERFACE, V3, P805, DOI 10.1098/rsif.2006.0144
   Shimizu F, 2011, J CELL PHYSIOL, V226, P255, DOI 10.1002/jcp.22337
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Svensen N, 2011, CHEM BIOL, V18, P1284, DOI 10.1016/j.chembiol.2011.07.017
   Takagishi Y, 2006, TISSUE ENG, V12, P927, DOI 10.1089/ten.2006.12.927
   Tenstad E, 2010, LAB CHIP, V10, P1401, DOI 10.1039/b926738g
   Unadkat HV, 2011, P NATL ACAD SCI USA, V108, P16565, DOI 10.1073/pnas.1109861108
   van Driel M, 2006, FASEB J, V20, P2417, DOI 10.1096/fj.06 6374fje
   Vohra S, 2008, J MATER SCI MATER M, V19, P3567, DOI 10.1007/s10856 008 3525 z
   Yuan H, 2011, NAT REV RHEUMATOL, V7, pc2
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Yuan HP, 2001, BIOMATERIALS, V22, P2617, DOI 10.1016/S0142 9612(00)00450 6
   Yuan Huipin, 2011, Nat Rev Rheumatol, V7, pc2
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zinger O, 2005, BIOMATERIALS, V26, P1837, DOI 10.1016/j.biomaterials.2004.06.035
NR 51
TC 8
Z9 9
U1 0
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2013
VL 34
IS 22
BP 5552
EP 5561
DI 10.1016/j.biomaterials.2013.04.001
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 156WW
UT WOS:000319855600011
PM 23632322
DA 2025 08 17
ER

PT J
AU Lattanzi, W
   Barba, M
   Novegno, F
   Massimi, L
   Tesori, V
   Tamburrini, G
   Galgano, S
   Bernardini, C
   Caldarelli, M
   Michetti, F
   Di Rocco, C
AF Lattanzi, Wanda
   Barba, Marta
   Novegno, Federica
   Massimi, Luca
   Tesori, Valentina
   Tamburrini, Gianpiero
   Galgano, Salvatore
   Bernardini, Camilla
   Caldarelli, Massimo
   Michetti, Fabrizio
   Di Rocco, Concezio
TI Lim mineralization protein is involved in the premature calvarial
   ossification in sporadic craniosynostoses
SO BONE
LA English
DT Article
DE Lim mineralization protein; Craniosynostosis; Suture; Calvarial cells;
   Osteogenic differentiation
ID VIVO GENE THERAPY; BONE FORMATION; SUTURE OSSIFICATION; ADENOVIRAL
   DELIVERY; SPINE FUSION; IN VITRO; CELLS; EXPRESSION; GROWTH; FIBROBLASTS
AB Sporadic mono sutural craniosynostosis represents a highly prevalent regional bone disorder, where a single cranial suture undergoes premature ossification due to a generally unclear etiopathogenesis. The LIM mineralization protein (LMP) was recently described as an efficient osteogenic molecule involved in osteoblast differentiation, expressed in calvarial tissues upon corticosteroid osteogenic induction and used as a potent inducer of bone formation in several animal models. In this study, calvarial cells isolated from both prematurely fused and physiologically patent sutures of children with sporadic craniosynostosis, were used as an in vitro paradigmatic model for the study of the molecular events involved in calvarial osteogenesis, focusing on the possible role of the LMP related osteogenic signaling. Calvarial cells isolated from both patent and fused sutures expressed a mesenchymal like immunophenotype. Cells isolated from fused sutures displayed an increased osteogenic potential, being able to undergo spontaneous mineralization and premature response to osteogenic induction, leading to in vitro bone nodule formation. The expression of LMP and its target genes (bone morphogenetic protein 2, osteocalcin and Runt related transcription factor 2) was significantly up regulated in cells derived from the fused sutures. Upon silencing the expression of LMP in fused suture derived cells, the osteogenic potential along with the expression of osteo specific transcription factors decreased, restoring the "physiologic" cell behavior. These results suggested that: 1. mesenchymal cells residing in fused sutures display a constitutionally active osteogenic disposition leading to the premature suture ossification; 2. the molecular basis of the overactive osteogenic process may at least in part involve a deregulation of the LMP related pathway in calvarial cells. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lattanzi, Wanda; Barba, Marta; Galgano, Salvatore; Bernardini, Camilla; Michetti, Fabrizio] Univ Cattolica Sacro Cuore, Inst Anat & Cell Biol, I 00168 Rome, Italy.
   [Lattanzi, Wanda; Michetti, Fabrizio] Latium Musculoskeletal Tissue Bank, Rome, Italy.
   [Novegno, Federica; Massimi, Luca; Tamburrini, Gianpiero; Caldarelli, Massimo; Di Rocco, Concezio] Univ Cattolica Sacro Cuore, Pediat Neurosurg Unit, I 00168 Rome, Italy.
   [Tesori, Valentina] Univ Cattolica Sacro Cuore, Inst Internal Med & Gastroenterol, I 00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Lattanzi, W (通讯作者)，Univ Cattolica Sacro Cuore, Inst Anat & Cell Biol, Lgo F Vito 1, I 00168 Rome, Italy.
EM wanda.lattanzi@rm.unicatt.it
RI Barba, Marta/K 5966 2016; lattanzi, wanda/K 5978 2016; Tamburrini,
   Gianpiero/K 4521 2018; Lattanzi, Wanda/K 5978 2016; tamburrini,
   gianpiero/K 4521 2018; Galgano, Salvatore/JCE 6685 2023; Massimi,
   Luca/JRW 2578 2023
OI Barba, Marta/0000 0001 6084 7666; massimi, luca/0000 0003 3088 0822;
   Galgano, Salvatore/0000 0002 5600 3206; lattanzi,
   wanda/0000 0003 3092 4936; Tamburrini, Gianpiero/0000 0002 8017 4830; 
FU "GENE" Federation of pediatric neurosurgeons; patients' association "Il
   Cigno"; Universita Cattolica S. Cuore
FX This work was supported by the "GENE" Federation of pediatric
   neurosurgeons, by the patients' association "Il Cigno" and by grants to
   WL from the Universita Cattolica S. Cuore ("Linea D.1"). The authors
   wish to thank Paola Leonardi and Davide Bonvissuto for their precious
   help, along with all the patients and families for their kind
   participation in the study.
CR Behr B, 2010, DEV BIOL, V344, P922, DOI 10.1016/j.ydbio.2010.06.009
   Bernardini C, 2012, CHILD NERV SYST, V28, P1295, DOI 10.1007/s00381 012 1780 2
   Bernardini C, 2010, GENE EXPRESSION, V15, P27, DOI 10.3727/105221610X12819686555097
   Bhat A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025990
   Bochukova EG, 2010, J MED GENET, V47, P803, DOI 10.1136/jmg.2009.069617
   Boden SD, 1998, SPINE, V23, P2486, DOI 10.1097/00007632 199812010 00003
   Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Bünger MH, 2003, CALCIFIED TISSUE INT, V73, P446, DOI 10.1007/s00223 002 2109 z
   BURKE MJ, 1995, PEDIATR NEUROSURG, V22, P241, DOI 10.1159/000120908
   COHEN MM, 1993, AM J MED GENET, V47, P581, DOI 10.1002/ajmg.1320470507
   Corvino V, 2012, J NEUROCHEM, V122, P415, DOI 10.1111/j.1471 4159.2012.07770.x
   Coussens AK, 2008, DIFFERENTIATION, V76, P531, DOI 10.1111/j.1432 0436.2007.00244.x
   Coussens AK, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 458
   DePollack C, 1996, J BONE MINER RES, V11, P401
   dePollak C, 1997, J CELL BIOCHEM, V64, P128, DOI 10.1002/(SICI)1097 4644(199701)64:1<128::AID JCB15>3.3.CO;2 K
   Kim HS, 2003, SPINE, V28, P219, DOI 10.1097/00007632 200302010 00004
   Lana Elola E, 2007, DEV BIOL, V311, P335, DOI 10.1016/j.ydbio.2007.08.028
   Lattanzi W, 2008, GENE THER, V15, P1330, DOI 10.1038/gt.2008.116
   Lattanzi W, 2011, OSTEOGENESIS, P21
   Lattanzi W, 2012, CHILD NERV SYST, V28, P1301, DOI 10.1007/s00381 012 1781 1
   Lee JC, 2011, J CRANIOFAC SURG, V22, P699, DOI 10.1097/SCS.0b013e3182077fbd
   Lin Z, 2010, BONE, V47, P55, DOI 10.1016/j.bone.2010.03.013
   Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114
   Liu YS, 2002, J BONE MINER RES, V17, P406, DOI 10.1359/jbmr.2002.17.3.406
   MARIE PJ, 1989, IN VITRO CELL DEV B, V25, P373
   Marie PJ, 2002, HISTOL HISTOPATHOL, V17, P877, DOI 10.14670/HH 17.877
   Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623 200306000 00007
   Morriss Kay GM, 2005, J ANAT, V207, P637, DOI 10.1111/j.1469 7580.2005.00475.x
   Nostro MC, 2011, DEVELOPMENT, V138, P861, DOI 10.1242/dev.055236
   Parrilla C, 2010, HEAD NECK J SCI SPEC, V32, P310, DOI 10.1002/hed.21185
   Pola E, 2004, GENE THER, V11, P683, DOI 10.1038/sj.gt.3302207
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Sangadala S, 2008, ACTA BIOCH BIOPH SIN, V40, P909, DOI 10.1111/j.1745 7270.2008.00478.x
   Saulnier N, 2009, EUR REV MED PHARMACO, V13, P71
   Stamper BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026557
   Stolzing A, 2006, REJUV RES, V9, P31, DOI 10.1089/rej.2006.9.31
   Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80
   Ting MC, 2009, DEVELOPMENT, V136, P855, DOI 10.1242/dev.028605
   Truong T, 2007, J BONE MINER RES, V22, P7, DOI 10.1359/JBMR.061012
   Viggeswarapu M, 2001, J BONE JOINT SURG AM, V83A, P364, DOI 10.2106/00004623 200103000 00008
   Wilkie AOM, 2007, AM J MED GENET A, V143A, P1941, DOI 10.1002/ajmg.a.31905
   Wilkie AOM, 2000, AM J MED GENET, V90, P82, DOI 10.1002/(SICI)1096 8628(20000103)90:1<82::AID AJMG15>3.0.CO;2 5
   Yen HY, 2010, DEV BIOL, V347, P258, DOI 10.1016/j.ydbio.2010.08.010
   Zhang Q, 2007, ARCH ORAL BIOL, V52, P720, DOI 10.1016/j.archoralbio.2007.02.005
   Zhang XL, 2011, J BONE MINER RES, V26, P777, DOI 10.1002/jbmr.267
NR 46
TC 28
Z9 28
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2013
VL 52
IS 1
BP 474
EP 484
DI 10.1016/j.bone.2012.09.004
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 060BK
UT WOS:000312750700056
PM 22982077
DA 2025 08 17
ER

PT J
AU Lin, WL
   Wu, XP
   He, WW
   Wang, XM
   Gao, YF
   Dong, WJ
AF Lin, Weilong
   Wu, Xiaopei
   He, Weiwei
   Wang, Xiaoming
   Gao, Yanfei
   Dong, Wenjie
TI LncRNA XIST regulates osteoclast formation and promotes orthodontically
   induced inflammatory root resorption through miR 130b 3p/PTEN axis
SO BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS
LA English
DT Article
DE The long non coding RNA (LncRNA) X inactive specific transcript (XIST);
   microRNA 130b 3p (miR 130b 3p); phosphatase and tensin homolog deleted
   on chromosome 10 (PTEN); osteoclast; orthodontic induced inflammatory
   root resorption (OIIRR)
ID PERIODONTAL LIGAMENT CELLS; RANKL; GROWTH
AB The long non coding RNA (LncRNA) X inactive specific transcript (XIST) regulates the biological process of osteoclasts and the process of related diseases. This study was attempted to investigate the mechanism of LncRNA XIST acting in osteoclast formation and orthodontic induced inflammatory root resorption (OIIRR). The compression force (CF)  induced cell model and the orthodontic tooth movement (OTM) rat model were designed and established in this study. The expression of LncRNA XIST, miR 130b 3p, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) as well as osteoclast related marker genes and inflammatory factors level were measured in this study. The interaction among LncRNA XIST, microRNA 130b 3p (miR 130b 3p) and PTEN were researched through luciferase activity and western blot assay. Pathological sections were used to analyze root resorption and osteoclast formation. The OTM rat model was successfully constructed, which was characterized by increased tooth spacing and increased root resorption pits. PTEN and LncRNA XIST was overexpressed in OTM group. Mechanism analysis showed that the overexpression of LncRNA XIST enhanced the PTEN level by sponging miR 130b 3p. The overexpression of LncRNA XIST increased the secretion of inflammatory factors and positive osteoclasts number, but inhibited the differentiation of osteoclasts by sponging miR 130b 3p and promoting the level of PTEN. This finding demonstrates that LncRNA XIST regulates osteoclast formation and aggravated OIIRR through miR 130b 3p/PTEN axis, suggesting that LncRNA XIST may be used as potential targets for OIIRR therapy.
C1 [Lin, Weilong; He, Weiwei; Wang, Xiaoming] Hebei North Univ, Hosp 1, Dept Stomatol, Zhangjiakou, Hebei, Peoples R China.
   [Wu, Xiaopei; Gao, Yanfei] Zhangjiakou Univ, Med Coll, Dept Stomatol, Zhangjiakou, Peoples R China.
   [Dong, Wenjie] Mudanjiang Med Coll, Affiliated Hosp 2, Dept Stomatol, Mudanjiang 157000, Heilongjiang, Peoples R China.
C3 Hebei North University; Zhangjiakou University; Mudanjiang Medical
   University
RP Dong, WJ (通讯作者)，Mudanjiang Med Coll, Affiliated Hosp 2, Dept Stomatol, Mudanjiang 157000, Heilongjiang, Peoples R China.
EM dongwenjieyy@163.com
RI gao, yanfei/KOC 9214 2024; He, Weiwei/ABE 8547 2021
FU Hebei Medical Science Research Project [20200506]
FX This research was funded by Hebei Medical Science Research Project,
   grant number 20200506.
CR Amuk NG, 2018, PHOTOMED LASER SURG, V36, P653, DOI 10.1089/pho.2018.4508
   Asano M, 2011, ORAL DIS, V17, P489, DOI 10.1111/j.1601 0825.2010.01780.x
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   Fei Q, 2018, INT J MOL MED, V41, P3537, DOI 10.3892/ijmm.2018.3575
   Gurien SD, 2020, EMBO REP, V21, DOI 10.15252/embr.201948075
   Hai B, 2020, ONCOTARGETS THER, V13, P4755, DOI 10.2147/OTT.S252195
   Han X, 2016, ARTHRITIS RHEUMATOL, V68, P2232, DOI 10.1002/art.39725
   Han Y, 2018, MOL IMMUNOL, V93, P107, DOI 10.1016/j.molimm.2017.11.017
   Hayashi N, 2012, ORAL DIS, V18, P375, DOI 10.1111/j.1601 0825.2011.01886.x
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Kikuta J, 2015, J DENT RES, V94, P140, DOI 10.1177/0022034514555364
   Kim C, 2013, FEBS LETT, V587, P3853, DOI 10.1016/j.febslet.2013.10.018
   Kunii R, 2013, KOREAN J ORTHOD, V43, P294, DOI 10.4041/kjod.2013.43.6.294
   Kurol J, 1998, ANGLE ORTHOD, V68, P161
   Li CX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.516
   Liu JL, 2019, AGING US, V11, P7830, DOI 10.18632/aging.102291
   Mishra M, 2017, EXPERT REV PROTEOMIC, V14, P1037, DOI 10.1080/14789450.2017.1388167
   Nakajima R, 2008, J PERIODONTAL RES, V43, P168, DOI 10.1111/j.1600 0765.2007.01008.x
   Nakano Y, 2011, EUR J ORTHODONT, V33, P335, DOI 10.1093/ejo/cjq068
   Owman Moll P, 2000, EUR J ORTHODONT, V22, P657, DOI 10.1093/ejo/22.6.657
   Patel S, 2018, INT ENDOD J, V51, P206, DOI 10.1111/iej.12824
   Rieger JK, 2015, DRUG METAB DISPOS, V43, P884, DOI 10.1124/dmd.114.062844
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang P, 2017, INT IMMUNOPHARMACOL, V51, P9, DOI 10.1016/j.intimp.2017.07.020
   Wang WP, 2015, SCI REP UK, V5, DOI 10.1038/srep12644
   Xue N, 2018, CELL PHYSIOL BIOCHEM, V48, P1771, DOI 10.1159/000492350
   Yamaguchi M, 2006, J DENT RES, V85, P751, DOI 10.1177/154405910608500812
   Yamaguchi M, 2009, ORTHOD CRANIOFAC RES, V12, P113, DOI 10.1111/j.1601 6343.2009.01444.x
   Yuan B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082172
   Zhang DW, 2022, J BONE MINER METAB, V40, P240, DOI 10.1007/s00774 021 01294 3
   Zhang HW, 2013, J OVARIAN RES, V6, DOI 10.1186/1757 2215 6 84
   Zhang XG, 2021, INT IMMUNOPHARMACOL, V100, DOI 10.1016/j.intimp.2021.107991
   Zhang XG, 2019, CELL CYCLE, V18, P1759, DOI 10.1080/15384101.2019.1632638
NR 35
TC 2
Z9 2
U1 2
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0264 8725
EI 2046 5556
J9 BIOTECHNOL GENET ENG
JI Biotechnol. Genet. Eng. Rev.
PD NOV 1
PY 2024
VL 40
IS 3
BP 2560
EP 2576
DI 10.1080/02648725.2023.2200331
EA APR 2023
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA K4Z0B
UT WOS:000971662700001
PM 37057740
DA 2025 08 17
ER

PT J
AU Beige, J
   Wendt, R
   Girndt, M
   Queck, KH
   Fiedler, R
   Jehle, P
AF Beige, Joachim
   Wendt, Ralph
   Girndt, Matthias
   Queck, Karl Heinz
   Fiedler, Roman
   Jehle, Peter
TI Association of serum alkaline phosphatase with mortality in non selected
   European patients with CKD5D: an observational, three centre survival
   analysis
SO BMJ OPEN
LA English
DT Article
DE Statistics & Research Methods
ID MAINTENANCE HEMODIALYSIS PATIENTS; CHRONIC KIDNEY DISEASE; VASCULAR
   CALCIFICATION; RISK; HOSPITALIZATION; PYROPHOSPHATE; PREDICTOR;
   MECHANISM; STROKE
AB Objectives For characterisation of mineral bone disease in chronic kidney disease (CKD), laboratory surrogates have been suggested. This observational should investigate the association of total and skeletal alkaline phosphatase (AP) with mortality of patients undergoing maintenance renal replacement therapy.
   Setting Three renal outpatient centers in eastern central Germany (secondary and tertiary care).
   Participants Complete survival and laboratory datasets were available in 407 of 493 patients. Age and gender distribution was equivalent to a general population with end stage CKD (CKD5D). Patients were included between 2008 and 2010 if at least 2weeks of maintenance treatment were documented.
   Primary outcome measures Mortality was estimated by setting the end of dialysis date as event date. Events other than death (change to another centre, life sustaining renal function or transplantation) were censored.
   Results The OR to die within follow up for patients in the higher of two total AP strata was 2.70 (95% CI 1.76 to 4.15). In univariate Kaplan Meier analysis, total AP had a strong association with all cause mortality (LogRank=24.1, p<0.001). Mean total AP and individual lowest skeletal AP, but not mean skeletal AP entered step wise Cox models for survival from dialysis start ((2)=22.4; p<0.001) after adjusting for age, Kt/V, diabetes and vintage. Mean values of skeletal, total AP and parathyroid hormone were 14.88.9 mu g/L, 91.9 +/  55.3U/L and 188 +/  164ng/L, respectively. Skeletal and total AP were highly correlated (R=0.86; p<0.001).
   Conclusions This unselected CKD5D population exhibited a clinical significant association of total AP with crude mortality and a stronger death risk association of total AP and individual lowest skeletal AP with crude mortality.
C1 [Beige, Joachim; Wendt, Ralph] Hosp St Georg, Dept Nephrol, Leipzig, Germany.
   [Beige, Joachim; Wendt, Ralph] Hosp St Georg, KfH Renal Unit, Leipzig, Germany.
   [Girndt, Matthias; Fiedler, Roman] Univ Halle Wittenberg, Dept Internal Med 2, D 06108 Halle, Germany.
   [Queck, Karl Heinz; Jehle, Peter] Hosp Paul Gerhard Stift, Dept Internal Med, Lutherstadt Wittenberg, Germany.
   [Queck, Karl Heinz; Jehle, Peter] Hosp Paul Gerhard Stift, KfH Renal Unit, Lutherstadt Wittenberg, Germany.
C3 Martin Luther University Halle Wittenberg
RP Beige, J (通讯作者)，Hosp St Georg, Dept Nephrol, Leipzig, Germany.
EM Joachim.Beige@sanktgeorg.de
RI Girndt, Matthias/M 1436 2019; Beige, Joachim/A 3446 2017; Wendt,
   Ralph/AAC 6878 2022
OI Beige, Joachim/0000 0002 1907 825X; Wendt, Ralph/0000 0003 1600 6581;
   Girndt, Matthias/0000 0003 2823 0847; Fiedler,
   Roman/0000 0001 7924 8495; 
CR Abramowitz M, 2010, CLIN J AM SOC NEPHRO, V5, P1064, DOI 10.2215/CJN.08621209
   Beddhu S, 2009, CLIN J AM SOC NEPHRO, V4, P1805, DOI 10.2215/CJN.01560309
   Blayney MJ, 2008, KIDNEY INT, V74, P655, DOI 10.1038/ki.2008.248
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Drechsler C, 2011, CLIN J AM SOC NEPHRO, V6, P1752, DOI 10.2215/CJN.10091110
   Fahrleitner Pammer A, 2008, J BONE MINER RES, V23, P1850, DOI 10.1359/JBMR.080610
   Kobayashi I, 2012, LIFE SCI, V90, P212, DOI 10.1016/j.lfs.2011.11.006
   Kovesdy CP, 2010, NEPHROL DIAL TRANSPL, V25, P3003, DOI 10.1093/ndt/gfq144
   Lee HL, 2010, BIOCHEM BIOPH RES CO, V391, P1087, DOI 10.1016/j.bbrc.2009.12.027
   Lewis R, 2012, ANN CLIN BIOCHEM, V49, P432, DOI 10.1258/acb.2012.012004
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   Millan J.L., 2006, MAMMALIAN ALKALINE P
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   National Kidney Foundation, 1997, AM J KIDNEY DIS S, V30, pS15
   Regidor DL, 2008, J AM SOC NEPHROL, V19, P2193, DOI 10.1681/ASN.2008010014
   Ryu WS, 2010, NEUROLOGY, V75, P1995, DOI 10.1212/WNL.0b013e3181ff966a
   Shantouf R, 2009, CLIN J AM SOC NEPHRO, V4, P1106, DOI 10.2215/CJN.06091108
   Shimizu Y, 2013, J STROKE CEREBROVASC, V22, P1046, DOI 10.1016/j.jstrokecerebrovasdis.2012.06.009
   STEPAN JJ, 1987, BONE MINER, V3, P177
   Taliercio JJ, 2013, AM J KIDNEY DIS, V62, P703, DOI 10.1053/j.ajkd.2013.04.012
   Towler DA, 2005, ARTERIOSCL THROM VAS, V25, P651, DOI 10.1161/01.ATV.0000158943.79580.9d
   Yamashital Tetsuri., 2011, International Journal of Clinical Medicine, V2, P388
NR 22
TC 13
Z9 13
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044 6055
J9 BMJ OPEN
JI BMJ Open
PY 2014
VL 4
IS 2
AR e004275
DI 10.1136/bmjopen 2013 004275
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AF1FF
UT WOS:000334459100087
PM 24578540
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Partoazar, A
   Goudarzi, R
AF Partoazar, Alireza
   Goudarzi, Ramin
TI Phosphatidylserine liposomes containing curcumin inhibit bone loss in
   osteoporotic rats: A possible synergy through a common signaling pathway
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article
DE bisphosphonates; methylprednisolone; nanoliposome; nutrition; synergy
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; IN VIVO; DIFFERENTIATION;
   OSTEOPROTEGERIN
AB The present study aimed to investigate the effect of phosphatidylserine liposomes containing curcumin (PSLs Cur) on the development of osteoporosis induced by glucocorticoids (GCs) in the rat model. PSL Cur, phosphatidylserine (PSL), curcumin (Cur), and alendronate (AL) drugs as a positive control were administrated orally to evaluate the beneficial effects of 3 week treatments on osteoporotic rats. The biochemical and biomechanical properties of bone parameters as well as gene expression were evaluated in treated rats. Moreover, histomorphometric examinations were performed on the bone tissues of the animals. The results revealed that PSL Cur oral administration caused a significant improvement in serum markers, mechanical strength, and OPG gene expression rather than PSL or Cur administration in osteoporotic rats. Also, PSL Cur significantly increased the thickness and volume of cortical and trabecular bone mass in comparison with the untreated osteoporotic group. The results of this study indicated that PSL Cur had a more inhibitory effect on bone loss induced by GCs compared to AL standard drug. Our findings suggested that PSL loaded Cur may be an appropriate alternative therapy for glucocorticoid induced osteoporosis. Practical applications Osteoporosis is one of the most serious metabolic chronic diseases that causes fragile bone due to decreased mineral density and microarchitectural deterioration in humans. The osteoprotective effects of curcumin and phosphatidylserine, as a food spice and supplementary diet, respectively, have been shown, previously. However, the low bioavailability of curcumin (Cur) due to its poor absorption, rapid metabolism, and fast systemic elimination, limits its benefits. This deficit can be modified with phosphatidylserine liposome (PSL) formulation that facilitates the gastrointestinal delivery of Cur. Moreover, PSL is known as an osteoprotective agent that may make synergy effect with Cur against GC induced osteoporosis. In this study, daily oral administration of phosphatidylserine liposomes containing curcumin (PSL Cur) for 3 weeks, considerably improved biochemical, biomechanical, and gene expression of bone parameters in the treated animals subjected to osteoporosis. PSL Cur can significantly increase the thickness and volume of cortical and trabecular bone mass as well as the mechanical bone strength in animals. Experimental findings proposed PSL Cur consumption as a proper and safe supplementary medication in the controlling of bone loss in patients with a high risk of osteoporosis.
C1 [Partoazar, Alireza] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran.
   [Partoazar, Alireza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
   [Goudarzi, Ramin] Pharmin USA LLC, Div Res & Dev, San Jose, CA USA.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences
RP Goudarzi, R (通讯作者)，Pharmin USA LLC, Div Res & Dev, 26841 La Alameda Unit 633, Mission Viejo, CA 92691 USA.
EM ramin.goudarzi@pharminusa.com
FU Tehran University of Medical Sciences and Health Services grant
   [1400 1 101 52268]
FX This research has been supported by Tehran University of Medical
   Sciences and Health Services grant (No: 1400 1 101 52268).
CR Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Bukhari SNA, 2019, J INTEGR MED JIM, V17, P38, DOI 10.1016/j.joim.2018.08.003
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   Chen ZG, 2016, CLIN EXP PHARMACOL P, V43, P268, DOI 10.1111/1440 1681.12513
   Cho DC, 2013, J KOREAN NEUROSURG S, V54, P461, DOI 10.3340/jkns.2013.54.6.461
   Colón Emeric CS, 2006, BEST PRACT RES CL RH, V20, P695, DOI 10.1016/j.berh.2006.04.004
   Daeihamed M, 2017, CURR DRUG DELIV, V14, P289, DOI 10.2174/1567201813666160115125756
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   Epstein H, 2008, AAPS J, V10, P505, DOI 10.1208/s12248 008 9060 5
   Eskandarynasab M, 2020, NANOMED NANOTECHNOL, V29, DOI 10.1016/j.nano.2020.102273
   Eskandarynasab M, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118033
   Folwarczna J, 2010, PHARMACOL REP, V62, P900, DOI 10.1016/S1734 1140(10)70350 9
   Hussan Farida, 2012, Evid Based Complement Alternat Med, V2012, P174916, DOI 10.1155/2012/174916
   Jurenka JS, 2009, ALTERN MED REV, V14, P277
   Kianvash N, 2017, DRUG DELIV TRANSL RE, V7, P654, DOI 10.1007/s13346 017 0405 4
   Kim WK, 2011, J CELL BIOCHEM, V112, P3159, DOI 10.1002/jcb.23242
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lestari Maria L A D, 2014, Profiles Drug Subst Excip Relat Methodol, V39, P113, DOI 10.1016/B978 0 12 800173 8.00003 9
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Li GW, 2015, INT J CLIN EXP PATHO, V8, P15684
   Merolli A, 2009, MOLECULES, V14, P5367, DOI 10.3390/molecules14125367
   Papadopouli AE, 2008, HISTOL HISTOPATHOL, V23, P497, DOI 10.14670/HH 23.497
   Partoazar A, 2017, FUND CLIN PHARMACOL, V31, P185, DOI 10.1111/fcp.12244
   REID IR, 1987, HORM RES, V27, P200, DOI 10.1159/000180820
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Sun MH, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.544697
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   Wu Z, 2010, J IMMUNOL, V184, P3191, DOI 10.4049/jimmunol.0803609
   Xu CX, 2013, MAT SCI ENG C MATER, V33, P1783, DOI 10.1016/j.msec.2013.01.005
NR 33
TC 8
Z9 9
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0145 8884
EI 1745 4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
PD JUL
PY 2022
VL 46
IS 7
AR e14120
DI 10.1111/jfbc.14120
EA FEB 2022
PG 9
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA 2S1BL
UT WOS:000762107100001
PM 35229314
OA gold
DA 2025 08 17
ER

PT J
AU Hytönen, MK
   Arumilli, M
   Lappalainen, AK
   Owczarek Lipska, M
   Jagannathan, V
   Hundi, S
   Salmela, E
   Venta, P
   Sarkiala, E
   Jokinen, T
   Gorgas, D
   Kere, J
   Nieminen, P
   Drögemüller, C
   Lohi, H
AF Hytonen, Marjo K.
   Arumilli, Meharji
   Lappalainen, Anu K.
   Owczarek Lipska, Marta
   Jagannathan, Vidhya
   Hundi, Sruthi
   Salmela, Elina
   Venta, Patrick
   Sarkiala, Eva
   Jokinen, Tarja
   Gorgas, Daniela
   Kere, Juha
   Nieminen, Pekka
   Drogemuller, Cord
   Lohi, Hannes
TI Molecular Characterization of Three Canine Models of Human Rare Bone
   Diseases: Caffey, van den Ende Gupta, and Raine Syndromes
SO PLOS GENETICS
LA English
DT Article
ID PUTATIVE GLUCOSE 6 PHOSPHATE TRANSLOCASE; EXONIC SPLICING ENHANCERS;
   EPIDERMAL DIFFERENTIATION; COL1A1 MUTATION; ANIMAL MODEL; FAM20C GENE;
   DYSPLASIA; PROTEINS; FAMILY; IB
AB One to two percent of all children are born with a developmental disorder requiring pediatric hospital admissions. For many such syndromes, the molecular pathogenesis remains poorly characterized. Parallel developmental disorders in other species could provide complementary models for human rare diseases by uncovering new candidate genes, improving the understanding of the molecular mechanisms and opening possibilities for therapeutic trials. We performed various experiments, e. g. combined genome wide association and next generation sequencing, to investigate the clinico pathological features and genetic causes of three developmental syndromes in dogs, including craniomandibular osteopathy (CMO), a previously undescribed skeletal syndrome, and dental hypomineralization, for which we identified pathogenic variants in the canine SLC37A2 (truncating splicing enhancer variant), SCARF2 (truncating 2 bp deletion) and FAM20C (missense variant) genes, respectively. CMO is a clinical equivalent to an infantile cortical hyperostosis (Caffey disease), for which SLC37A2 is a new candidate gene. SLC37A2 is a poorly characterized member of a glucose phosphate transporter family without previous disease associations. It is expressed in many tissues, including cells of the macrophage lineage, e. g. osteoclasts, and suggests a disease mechanism, in which an impaired glucose homeostasis in osteoclasts compromises their function in the developing bone, leading to hyperostosis. Mutations in SCARF2 and FAM20C have been associated with the human van den Ende Gupta and Raine syndromes that include numerous features similar to the affected dogs. Given the growing interest in the molecular characterization and treatment of human rare diseases, our study presents three novel physiologically relevant models for further research and therapy approaches, while providing the molecular identity for the canine conditions.
C1 [Hytonen, Marjo K.; Arumilli, Meharji; Hundi, Sruthi; Salmela, Elina; Jokinen, Tarja; Lohi, Hannes] Univ Helsinki, Dept Vet Biosci, Helsinki, Finland.
   [Hytonen, Marjo K.; Arumilli, Meharji; Hundi, Sruthi; Salmela, Elina; Kere, Juha; Lohi, Hannes] Univ Helsinki, Res Programs Unit, Mol Neurol, Helsinki, Finland.
   [Hytonen, Marjo K.; Arumilli, Meharji; Hundi, Sruthi; Salmela, Elina; Kere, Juha; Lohi, Hannes] Folkhalsan Inst Genet, Helsinki, Finland.
   [Lappalainen, Anu K.; Sarkiala, Eva; Jokinen, Tarja] Univ Helsinki, Dept Equine & Small Anim Med, Helsinki, Finland.
   [Owczarek Lipska, Marta; Jagannathan, Vidhya; Drogemuller, Cord] Univ Bern, Vetsuisse Fac, Inst Genet, Bern, Switzerland.
   [Venta, Patrick] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
   [Gorgas, Daniela] Univ Bern, Vetsuisse Fac, Div Clin Radiol, Dept Clin Vet Med, Bern, Switzerland.
   [Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden.
   [Nieminen, Pekka] Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   University of Bern; Michigan State University; University of Bern;
   Karolinska Institutet; University of Helsinki
RP Lohi, H (通讯作者)，Univ Helsinki, Dept Vet Biosci, Helsinki, Finland.
EM hannes.lohi@helsinki.fi
RI ; Kere, Juha/A 9179 2008; Salmela, Elina/KHC 8060 2024; Lohi,
   Hannes/F 4596 2011; Drögemüller, Cord/HZL 0792 2023; Jagannathan,
   Vidhya/P 1055 2019
OI Jokinen, Tarja/0000 0001 6389 0109; Kere, Juha/0000 0003 1974 0271;
   Arumilli, Meharji/0000 0003 4072 0996; Lohi, Hannes/0000 0003 1087 5532;
   Hundi, Sruthi/0000 0002 5803 1841; Drogemuller,
   Cord/0000 0001 9773 522X; Hytonen, Marjo/0000 0003 1976 5874; Salmela,
   Elina/0000 0003 1326 4462; 
FU Academy of Finland [1268091]; Sigrid Juselius Foundation; Jane and Aatos
   Erkko Foundation; ERCStG [260997]; Biocentrum Helsinki; Morris Animal
   Foundation [D13CA 403]; Jenni and Antti Wihuri Foundation
FX This work was partially supported by the Academy of Finland (1268091),
   the Sigrid Juselius Foundation, the Jane and Aatos Erkko Foundation,
   ERCStG (260997), Biocentrum Helsinki, the Morris Animal Foundation
   (D13CA 403) and the Jenni and Antti Wihuri Foundation. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ababneh FK, 2013, AM J MED GENET A, V161, P3155, DOI 10.1002/ajmg.a.36160
   Acevedo AC, 2015, BMC MED GENET, V16, DOI 10.1186/s12881 015 0154 5
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410 248
   Ahonen SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072122
   Anastasio N, 2010, AM J HUM GENET, V87, P553, DOI 10.1016/j.ajhg.2010.09.005
   Bareil C, 2001, HUM GENET, V108, P328, DOI 10.1007/s004390100496
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   Casal ML, 2007, AM J HUM GENET, V81, P1050, DOI 10.1086/521988
   Chou JY, 2014, CURR TOP MEMBR, V73, P357, DOI 10.1016/B978 0 12 800223 0.00010 4
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Drögemüller M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004370
   Fradin M, 2011, CLIN GENET, V80, P177, DOI 10.1111/j.1399 0004.2010.01516.x
   Gensure RC, 2005, J CLIN INVEST, V115, P1250, DOI 10.1172/JCI200522760
   Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014 5793(97)01463 4
   Ha BG, 2008, PROTEOMICS, V8, P2625, DOI 10.1002/pmic.200701192
   Hwang M, 2005, GENE EXPR PATTERNS, V5, P801, DOI 10.1016/j.modgep.2005.03.010
   Hwang M, 2003, J BIOL CHEM, V278, P47827, DOI 10.1074/jbc.M306561200
   Hytönen MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040281
   Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200
   Ishikawa HO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042988
   Kim JY, 2007, AM J PHYSIOL ENDOC M, V293, pE110, DOI 10.1152/ajpendo.00404.2006
   Kitaoka T, 2014, EUR J PEDIATR, V173, P799, DOI 10.1007/s00431 013 2252 8
   Kure S, 1998, BIOCHEM BIOPH RES CO, V248, P426, DOI 10.1006/bbrc.1998.8985
   Kyöstilä K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005169
   LaFond E, 2002, J AM ANIM HOSP ASSOC, V38, P467, DOI 10.5326/0380467
   Littlewort MCG, 1958, THE VETERINARY RECOR, V70, P977
   Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601
   Nistala H, 2014, BONE, V60, P246, DOI 10.1016/j.bone.2013.12.030
   PADGETT GA, 1986, AM J MED GENET, V25, P9, DOI 10.1002/ajmg.1320250103
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rabbani B, 2012, J HUM GENET, V57, P621, DOI 10.1038/jhg.2012.91
   Rafaelsen SH, 2013, J BONE MINER RES, V28, P1378, DOI 10.1002/jbmr.1850
   RAINE J, 1989, J MED GENET, V26, P786, DOI 10.1136/jmg.26.12.786
   Saksa N, 2015, J STEROID BIOCHEM, V148, P275, DOI 10.1016/j.jsbmb.2014.11.012
   Schweiger S, 2003, AM J MED GENET A, V120A, P547, DOI 10.1002/ajmg.a.20062
   SCRIVER CR, 1995, PEDIATR RES, V38, P819, DOI 10.1203/00006450 199512000 00001
   Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200
   Simpson MA, 2007, AM J HUM GENET, V81, P906, DOI 10.1086/522240
   Simpson MA, 2009, CLIN GENET, V75, P271, DOI 10.1111/j.1399 0004.2008.01118.x
   Smith PJ, 2006, HUM MOL GENET, V15, P2490, DOI 10.1093/hmg/ddl171
   Tagliabracci VS, 2012, SCIENCE, V336, P1150, DOI 10.1126/science.1217817
   Takeyari S, 2014, BONE, V67, P56, DOI 10.1016/j.bone.2014.06.026
   THORNBURG LP, 1979, AM J PATHOL, V95, P575
   Tonnessen R, 2012, THERIOGENOLOGY, V77, P1788, DOI 10.1016/j.theriogenology.2011.12.023
   Veiga da Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068
   Wang X, 2015, J DENT RES, V94, P330, DOI 10.1177/0022034514563334
   Wang X, 2013, J DENT RES, V92, P995, DOI 10.1177/0022034513504588
   Wang XF, 2012, J BIOL CHEM, V287, P35934, DOI 10.1074/jbc.M112.386862
   Wang XF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002708
NR 49
TC 35
Z9 37
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553 7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2016
VL 12
IS 5
AR e1006037
DI 10.1371/journal.pgen.1006037
PG 20
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA DN6PH
UT WOS:000377197100038
PM 27187611
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Neogi, T
AF Neogi, T.
TI Structural correlates of pain in osteoarthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE osteoarthritis; pain; structure; synovitis; effusion; bone marrow
   lesions; sensitisation
ID BONE MARROW LESIONS; KNEE OSTEOARTHRITIS; UNITED STATES; ARTHRITIS;
   SENSITIZATION; PREVALENCE; MRI; LIMITATIONS; SEVERITY; TRIAL
AB Osteoarthritis (OA) is the most common form of arthritis, with knee OA itself being among the most common conditions and a leading cause of disability among older adults worldwide. Pain is a key symptom in the decision to seek medical attention, yet available therapies for managing OA are limited with only minimal or moderate efficacy. Current approaches to pain management in OA have been rather non specific, limited to acetaminophen or NSAIDs primarily, without targeting underlying structural lesions that may be contributing to pain in OA. With the advent of MRI, a number of studies have noted the importance of bone marrow lesions and synovitis/effusion to the pain experience in OA. These pathologic features are therefore attractive treatment targets, with some proof of concept studies demonstrating the potential efficacy of targeting these lesions. Another increasingly recognised important contribution to pain in OA is sensitisation, which is associated with pain severity. Synovitis/effusion have been identified as potentially leading to development and worsening of sensitisation. Much work remains to be done in understanding the mechanisms by which structural pathology causes pain; such insights are urgently needed to develop new treatment approaches to help millions of people worldwide who are burdened by pain from OA.
C1 [Neogi, T.] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Neogi, T.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
C3 Boston University; Boston University
RP Neogi, T (通讯作者)，Boston Univ, Sch Med, Clin Epi Unit, 650 Albany St,Suite X200, Boston, MA 02118 USA.
EM tneogi@bu.edu
RI Neogi, Tuhina/AAM 1110 2020
CR ARENDT NIELSEN, 2017, CLIN EXP RHEUMA S107, V35, pS68
   Arroll B, 2004, BMJ BRIT MED J, V328, P869, DOI 10.1136/bmj.38039.573970.7C
   Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 116
   Callaghan MJ, 2015, ANN RHEUM DIS, V74, P1164, DOI 10.1136/annrheumdis 2014 206376
   *CDCP, 2001, MMWR MORBID MORTAL W, V50, P149
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P345
   Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P120
   Creamer P, 1996, J RHEUMATOL, V23, P1031
   Dunlop DD, 2001, ARTHRITIS RHEUM US, V44, P212, DOI 10.1002/1529 0131(200101)44:1<212::AID ANR28>3.0.CO;2 Q
   Dye SF, 1998, AM J SPORT MED, V26, P773, DOI 10.1177/03635465980260060601
   Englund M, 2008, NEW ENGL J MED, V359, P1108, DOI 10.1056/NEJMoa0800777
   Finan PH, 2013, ARTHRITIS RHEUM US, V65, P363, DOI 10.1002/art.34646
   GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351
   Guermazi A, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5339
   Hunter DJ, 2013, OSTEOARTHR CARTILAGE, V21, P1170, DOI 10.1016/j.joca.2013.05.017
   Hunter DJ, 2011, OSTEOARTHR CARTILAGE, V19, P557, DOI 10.1016/j.joca.2010.10.029
   Laslett L. L., 2011, ANN RHEUM DIS     S3, V70, P138
   Lawrence RC, 1998, ARTHRITIS RHEUM US, V41, P778, DOI 10.1002/1529 0131(199805)41:5<778::AID ART4>3.0.CO;2 V
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140 6736(12)61766 8
   McAlindon TE, 2017, JAMA J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283
   Neogi T, 2016, ARTHRITIS RHEUMATOL, V68, P654, DOI 10.1002/art.39488
   Neogi T, 2015, ANN RHEUM DIS, V74, P682, DOI 10.1136/annrheumdis 2013 204191
   Neogi T, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b2844
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Yusuf E, 2011, ANN RHEUM DIS, V70, P60, DOI 10.1136/ard.2010.131904
   Zhang YQ, 2011, ARTHRITIS RHEUM US, V63, P691, DOI 10.1002/art.30148
NR 27
TC 45
Z9 45
U1 0
U2 2
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PY 2017
VL 35
IS 5
SU 107
BP S75
EP S78
PG 4
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA FQ5SF
UT WOS:000418420600014
DA 2025 08 17
ER

PT J
AU Ye, GL
   Li, CK
   Zhao, XL
   Wen, F
   Wang, LY
   Qiu, XZ
AF Ye, Genlan
   Li, Chuangkun
   Zhao, Xiaoliang
   Wen, Feng
   Wang, Leyu
   Qiu, Xiaozhong
TI A Humanized Cancer Bone Metastasis Mouse Model Based on Silica
   Nanoparticles Incorporated Human Demineralized Bone Matrix
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Humanized Mouse Model; Breast Cancer; Bone Metastasis; Silica
   Nanoparticles; Demineralized Bone Matrix
ID HUMAN BREAST CANCER; OSTEOGENIC DIFFERENTIATION; CELLS; SCAFFOLD;
   BIOMATERIALS
AB Breast cancer tends to spread to other organs and bone metastasis has the highest frequency in breast cancer metastasis, while its mechanisms are not clear and the current treatments are not very effective. To better study the mechanisms and facilitate drug screening for breast cancer bone metastasis, an in vivo mouse model needs to be constructed. However, the construction of the humanized mouse model for cancer bone metastasis which will mimick real interactions between cancer tissue and bone tissue in the human microenvironment remains a challenge. In this study, we constructed a human engineering bone tissue composed with the human osteoblast like cells (SaOS 2 cells) and the silica nanoparticles incorporated human demineralized bone matrix (Si/DBM). The engineered bone was then transplanted into a nude mouse to build a humanized bone microenvironment. The human breast cancer cells were then injected into the fat pads of the nude mouse to form an orthotopic tumor. The results showed that the engineered bone tissue constructed humanized bone microenvironment had significant advantages when inducing human cancer cells to metastasize into the engineered bone tissue. Further, the SaOS 2/Si/DBM had a stronger ability to entice cancer bone metastasis through promoting osteogenesis compared to the SaOS 2/DBM. Accordingly, this study highlights a novel, facile and effective mouse model for human cancer bone metastasis, which will provide a platform to explore the mechanisms and anti tumor drug screening for cancer bone metastasis.
C1 [Ye, Genlan; Li, Chuangkun; Zhao, Xiaoliang; Wen, Feng; Wang, Leyu; Qiu, Xiaozhong] Southern Med Univ, Sch Basic Med Sci, Guangdong Prov Key Lab Construct & Detect Tissue, Biomat Res Ctr,Sch Biomed Engn, Guangzhou 510515, Guangdong, Peoples R China.
   [Ye, Genlan] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510005, Guangdong, Peoples R China.
C3 Southern Medical University   China; Bioland Lab
RP Wang, LY; Qiu, XZ (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Guangdong Prov Key Lab Construct & Detect Tissue, Biomat Res Ctr,Sch Biomed Engn, Guangzhou 510515, Guangdong, Peoples R China.
EM wangleyu889@163.com; qqiuxzh@163.com
RI zhang, bx/HNR 3314 2023; Wen, Feng/AAV 6591 2020; Qiu,
   Xiaozhong/B 8466 2014
FU National Natural Science Foundation of China [31572343]; NSFC Guangdong
   Joint Fund [U1601221]; Science and Technology Projects of Guangzhou City
   [201804020035, 201904020031]; Guangdong Province Science and Technology
   Projects [2017B030314038, 2016B090913004]; Key Research and Development
   Program of Guangzhou Regenerative Medicine and Health Guangdong
   Laboratory [2018GZR110104002]; Central Laboratory of Southern Medical
   University China
FX This study was supported by the National Natural Science Foundation of
   China (31572343), NSFC Guangdong Joint Fund (U1601221), Science and
   Technology Projects of Guangzhou City (201804020035, 201904020031),
   Guangdong Province Science and Technology Projects (2017B030314038), Key
   Research and Development Program of Guangzhou Regenerative Medicine and
   Health Guangdong Laboratory (2018GZR110104002), Guangdong Province
   Science and Technology Projects (2016B090913004), and the Central
   Laboratory of Southern Medical University China.
CR Abedin E, 2018, TISSUE CELL, V55, P46, DOI 10.1016/j.tice.2018.09.003
   An SF, 2015, INT J MOL MED, V35, P1341, DOI 10.3892/ijmm.2015.2122
   [Anonymous], CURR PROTOC IMMUNOL
   Barboza EP, 2004, J PERIODONTOL, V75, P702, DOI 10.1902/jop.2004.75.5.702
   Breznan D, 2018, ACS NANO, V12, P12062, DOI 10.1021/acsnano.8b04910
   Cai WL, 2018, MOL CANCER, V17, DOI 10.1186/s12943 017 0746 0
   Cheng YX, 2014, J BIOMED NANOTECHNOL, V10, P287, DOI 10.1166/jbn.2014.1753
   Choi S, 2019, BIOMATERIALS, V198, P95, DOI 10.1016/j.biomaterials.2018.05.002
   Cristofaro F, 2018, NANOSCALE, V10, P8689, DOI 10.1039/c8nr00677f
   Duarte RM, 2017, TISSUE ENG PART B RE, V23, P540, DOI [10.1089/ten.teb.2017.0072, 10.1089/ten.TEB.2017.0072]
   Fili S, 2009, CANCER LETT, V283, P10, DOI 10.1016/j.canlet.2009.01.011
   Fokas E, 2007, CANCER METAST REV, V26, P705, DOI 10.1007/s10555 007 9088 5
   Foroutan T, 2018, J BIOMED MATER RES A, V106, P293, DOI 10.1002/jbm.a.36231
   Futakuchi M, 2013, BREAST CANCER TOKYO, V20, P195, DOI 10.1007/s12282 013 0439 5
   Gruskin E, 2012, ADV DRUG DELIVER REV, V64, P1063, DOI 10.1016/j.addr.2012.06.008
   Hou TY, 2014, BIOMATERIALS, V35, P5689, DOI 10.1016/j.biomaterials.2014.03.079
   Hu QX, 2018, ACS APPL MATER INTER, V10, P27669, DOI 10.1021/acsami.8b08668
   Itel F, 2018, ACS APPL MATER INTER, V10, P30180, DOI 10.1021/acsami.8b10886
   Jiang J, 2018, MATERIALS, V11, DOI 10.3390/ma11112074
   Jiang PL, 2019, THERANOSTICS, V9, P2950, DOI 10.7150/thno.29617
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Kar S, 2019, J TISSUE ENG REGEN M, V13, P119, DOI 10.1002/term.2773
   Kavya KC, 2012, J BIOMED NANOTECHNOL, V8, P149, DOI 10.1166/jbn.2012.1363
   Ke DX, 2019, MAT SCI ENG C MATER, V96, P10, DOI 10.1016/j.msec.2018.10.073
   Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261
   Kim H, 2016, J BIOMED NANOTECHNOL, V12, P536, DOI 10.1166/jbn.2016.2189
   Kim SM, 2019, J BIOMED NANOTECHNOL, V15, P113, DOI 10.1166/jbn.2019.2671
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Li Y, 2011, TOXICOL IN VITRO, V25, P1343, DOI 10.1016/j.tiv.2011.05.003
   Liu J, 2018, ACM T INTEL SYST TEC, V9, DOI 10.1145/3078845
   Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Moghaddam SPH, 2018, J CONTROL RELEASE, V282, P62, DOI 10.1016/j.jconrel.2018.04.032
   Moreau JE, 2007, CANCER RES, V67, P10304, DOI 10.1158/0008 5472.CAN 07 2483
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Ning CQ, 2005, J MATER SCI MATER M, V16, P355, DOI 10.1007/s10856 005 0635 8
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Sethi Alok Kumar, 2018, Natl J Maxillofac Surg, V9, P174, DOI 10.4103/njms.NJMS_33_18
   Thibaudeau L, 2014, CANCER METAST REV, V33, P721, DOI 10.1007/s10555 014 9499 z
   Thibaudeau L, 2014, DIS MODEL MECH, V7, P299, DOI 10.1242/dmm.014076
   Tian Song X., 2010, ONCOL REP, V24, P203
   Wakabayashi H., 2018, BREAST CANC, V25, P1
   Wang Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0603 7
   Yamaguchi A, 2006, J NANOSCI NANOTECHNO, V6, P1689, DOI 10.1166/jnn.2006.229
   Yang H, 2009, J BIOMED NANOTECHNOL, V5, P528, DOI 10.1166/jbn.2009.1061
   Yang X, 2018, REGEN BIOMATER, V5, P229, DOI 10.1093/rb/rby014
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhang TR, 2009, J PHYS CHEM C, V113, P3168, DOI 10.1021/jp810360a
NR 48
TC 3
Z9 3
U1 0
U2 29
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1550 7033
EI 1550 7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD DEC
PY 2019
VL 15
IS 12
BP 2363
EP 2375
DI 10.1166/jbn.2019.2860
PG 13
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA JP1HS
UT WOS:000498023900006
PM 31748017
DA 2025 08 17
ER

PT S
AU Saag, KG
AF Saag, Kenneth G.
BE Cutolo, M
   Straub, RH
   Masi, AT
   Bijlsma, JWJ
TI Bone safety of low dose glucocorticoids in rheumatic diseases
SO STEROIDS IN NEUROENDOCRINE IMMUNOLOGY AND THERAPY OF RHEUMATIC DISEASES
   II
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 5th International Conference on the Neuroendocrine Immune Basis of the
   Rheumatic Diseases (NEIRD)
CY OCT 01 03, 2013
CL Genoa, ITALY
DE glucocorticoids; osteoporosis; rheumatoid arthritis
ID CORTICOSTEROID INDUCED OSTEOPOROSIS; MINERAL DENSITY; POSTMENOPAUSAL
   WOMEN; DOUBLE BLIND; LONG TERM; ORAL CORTICOSTEROIDS; VERTEBRAL
   FRACTURE; INTRAVENOUS PAMIDRONATE; SECONDARY OSTEOPOROSIS; ETIDRONATE
   THERAPY
AB Glucocorticoids are widely used internationally for the treatment of inflammatory disease, such as rheumatoid arthritis (RA). Although the benefit of glucocorticoids in RA on both disease activity and severity are well known, there remain unanswered questions about the overall bone safety of chronic low dose glucocorticoids in RA. Debate exists about the merits of glucocorticoids for bone health on the basis of their benefits in promoting activity and reducing proinflammatory cytokines. Overall current evidence supports the view that bone loss is a disease related both to RA and to glucocorticoid use independently. Calcium and vitamin D, along with prescription antiosteoporosis therapies, particularly bisphosphonates and teriparatide, play an important role in stabilizing bone mineral density and potentially lowering spinal fracture risk at the spine. International guidelines provide pathways for appropriate prevention of glucocorticoid induced osteoporosis (GIOP). Despite the evidence and these guidelines, many patients do not receive adequate management to prevent GIOP.
C1 [Saag, Kenneth G.] Univ Alabama Birmingham, Dept Med, Div Immunol, Birmingham, AL 35294 USA.
   [Saag, Kenneth G.] Univ Alabama Birmingham, Dept Med, Div Rheumatol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Saag, KG (通讯作者)，Univ Alabama Birmingham, Dept Med, Div Immunol, 1720 2nd Ave South, Birmingham, AL 35294 USA.
EM Ksaag@uab.edu
CR Aagaard EM, 1999, AM J MED, V107, P456, DOI 10.1016/S0002 9343(99)00265 X
   Adachi JD, 2000, J RHEUMATOL, V27, P2424
   Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   Adachi JD, 2001, ARTHRITIS RHEUM US, V44, P202, DOI 10.1002/1529 0131(200101)44:1<202::AID ANR27>3.0.CO;2 W
   Adachi JD, 2000, SEMIN ARTHRITIS RHEU, V29, P228, DOI 10.1016/S0049 0172(00)80011 6
   Alvarez Hernández E, 2008, JCR J CLIN RHEUMATOL, V14, P148, DOI 10.1097/RHU.0b013e31817738bd
   Amin S, 1999, ARTHRITIS RHEUM US, V42, P1740, DOI 10.1002/1529 0131(199908)42:8<1740::AID ANR25>3.0.CO;2 E
   Bijlsma JWJ, 2005, RHEUM DIS CLIN N AM, V31, P1, DOI 10.1016/j.rdc.2004.10.003
   Boers M, 2011, CLIN EXP RHEUMATOL, V29, pS46
   Boutsen Y, 1997, CALCIFIED TISSUE INT, V61, P266, DOI 10.1007/s002239900334
   BRAUN JJ, 1983, CLIN ENDOCRINOL, V19, P265, DOI 10.1111/j.1365 2265.1983.tb02989.x
   Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496
   Buckley LM, 1999, ARTHRITIS RHEUM, V42, P1736, DOI 10.1002/1529 0131(199908)42:8<1736::AID ANR24>3.0.CO;2 E
   BUCKLEY LM, 1995, J RHEUMATOL, V22, P1055
   Buckley LM, 1998, J RHEUMATOL, V25, P2195
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Compston J, 2013, MATURITAS, V75, P392, DOI 10.1016/j.maturitas.2013.05.013
   Compston Juliet, 2004, Curr Rheumatol Rep, V6, P66, DOI 10.1007/s11926 004 0085 1
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Curtis JR, 2005, ARTHRITIS RHEUM US, V52, P2485, DOI 10.1002/art.21194
   Da Silva JAP, 2006, ANN RHEUM DIS, V65, P285, DOI 10.1136/ard.2005.038638
   de Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198 004 1614 5
   de Nijs RNJ, 2001, RHEUMATOLOGY, V40, P1375, DOI 10.1093/rheumatology/40.12.1375
   Duyvendak M, 2007, OSTEOPOROSIS INT, V18, P1429, DOI 10.1007/s00198 007 0345 9
   DYKMAN TR, 1985, ARTHRITIS RHEUM US, V28, P361, DOI 10.1002/art.1780280402
   Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365 2796.1998.00408.x
   Emkey RD, 1996, ARTHRITIS RHEUM, V39, P277, DOI 10.1002/art.1780390215
   Engvall IL, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2542
   GALLACHER SJ, 1992, THORAX, V47, P932, DOI 10.1136/thx.47.11.932
   GARTON MJ, 1993, ARTHRITIS RHEUM, V36, P222, DOI 10.1002/art.1780360213
   GLUCK OS, 1981, ARTHRITIS RHEUM US, V24, P892, DOI 10.1002/art.1780240705
   Glüer CC, 2013, J BONE MINER RES, V28, P1355, DOI 10.1002/jbmr.1870
   Goekoop Ruiterman YPM, 2007, ANN INTERN MED, V146, P406, DOI 10.7326/0003 4819 146 6 200703200 00005
   Gough A, 1998, J RHEUMATOL, V25, P1282
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Grijalva CG, 2008, RHEUMATOLOGY, V47, P1061, DOI 10.1093/rheumatology/ken193
   Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
   HALL GM, 1993, ARTHRITIS RHEUM, V36, P1510, DOI 10.1002/art.1780361105
   Hansen M, 1996, SCAND J RHEUMATOL, V25, P367, DOI 10.3109/03009749609065648
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Haugeberg G, 2002, ARTHRITIS RHEUM US, V46, P1720, DOI 10.1002/art.10408
   Hoes JN, 2007, ANN RHEUM DIS, V66, P1560, DOI 10.1136/ard.2007.072157
   HOMIK J, 2000, COCHRANE DB SYST REV
   Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304
   Kanis JA, 2007, HEALTH TECHNOL ASSES, V11, P1
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P809, DOI 10.1007/s00198 010 1524 7
   KROGER H, 1994, ANN RHEUM DIS, V53, P18, DOI 10.1136/ard.53.1.18
   Kvien TK, 2000, ANN RHEUM DIS, V59, P805, DOI 10.1136/ard.59.10.805
   LAAN RFJM, 1993, CALCIFIED TISSUE INT, V52, P5, DOI 10.1007/BF00675619
   LANE NE, 1995, J BONE MINER RES, V10, P257
   LEBOFF MS, 1991, J RHEUMATOL, V18, P339
   Lee YH, 2008, J INVEST MED, V56, P1011, DOI 10.2310/JIM.0b013e31818e82d7
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   LEMS WF, 1995, CLIN EXP RHEUMATOL, V13, P293
   Leonard MB, 2004, NEW ENGL J MED, V351, P868, DOI 10.1056/NEJMoa040367
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   MCDOUGALL R, 1994, J RHEUMATOL, V21, P1207
   McKeown E, 2012, RHEUMATOLOGY, V51, P1662, DOI 10.1093/rheumatology/kes079
   MESSINA OD, 1992, J RHEUMATOL, V19, P1520
   MICHEL BA, 1993, J RHEUMATOL, V20, P1666
   Mudano A, 2001, J RHEUMATOL, V28, P1298
   Murphy DR, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 213
   Nair B., 1997, Arthritis and Rheumatism, V40, pS309
   NIELSEN HK, 1988, J CLIN ENDOCR METAB, V67, P1025, DOI 10.1210/jcem 67 5 1025
   Osiri M, 2000, JCR J CLIN RHEUMATOL, V6, P117, DOI 10.1097/00124743 200006000 00001
   Reginster JY, 1999, OSTEOPOROSIS INT, V9, P75, DOI 10.1007/s001980050118
   Rehman Q, 2003, OSTEOPOROSIS INT, V14, P77, DOI 10.1007/s00198 002 1312 0
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006
   REID IR, 1993, BAILLIERE CLIN RHEUM, V7, P573, DOI 10.1016/S0950 3579(05)80080 9
   REID IR, 1988, LANCET, V1, P143
   REID IR, 1990, ARCH INTERN MED, V150, P2545, DOI 10.1001/archinte.150.12.2545
   Richy F, 2005, CALCIFIED TISSUE INT, V76, P176, DOI 10.1007/s00223 004 0005 4
   Ringe JD, 2003, RHEUMATOLOGY, V42, P743, DOI 10.1093/rheumatology/keg205
   Saag K. G., 1999, RHEUM ARTHRITIS IND, VII, P3
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002 9343(94)90131 7
   Saag KG, 1997, AM J MED, V103, P31, DOI 10.1016/S0002 9343(97)90006 1
   SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404
   Sambrook P N, 2001, Aust Fam Physician, V30, P793
   SAMBROOK PN, 1986, ANN RHEUM DIS, V45, P950, DOI 10.1136/ard.45.11.950
   SAMBROOK PN, 1987, ARTHRITIS RHEUM US, V30, P721, DOI 10.1002/art.1780300701
   SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Solomon DH, 2000, ARTHRITIS RHEUM US, V43, P1967, DOI 10.1002/1529 0131(200009)43:9<1967::AID ANR7>3.0.CO;2 W
   Soucy E, 2000, J RHEUMATOL, V27, P1506
   SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558
   Suzuki Y, 1997, OSTEOPOROSIS INT, V7, P217, DOI 10.1007/BF03194376
   Teitelbaum SL, 2011, ARTHRITIS RHEUM US, V63, P325, DOI 10.1002/art.30135
   Thiele K, 2005, ARTHRIT RHEUM ARTHR, V53, P740, DOI 10.1002/art.21467
   TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091 6749(95)70003 X
   TOWHEED TE, 1995, J RHEUMATOL, V22, P440
   VALKEMA R, 1989, BONE MINER, V5, P183, DOI 10.1016/0169 6009(89)90095 0
   van Everdingen AA, 2002, ANN INTERN MED, V136, P1, DOI 10.7326/0003 4819 136 1 200201010 00006
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Verhoeven AC, 1997, J RHEUMATOL, V24, P1495
   VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Walsh LJ, 1996, BRIT MED J, V313, P344, DOI 10.1136/bmj.313.7053.344
   Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140 6736(00)02138 3
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yood RA, 2001, ARCH INTERN MED, V161, P1322, DOI 10.1001/archinte.161.10.1322
NR 106
TC 8
Z9 9
U1 0
U2 6
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2014
VL 1318
BP 55
EP 64
DI 10.1111/nyas.12446
PG 10
WC Endocrinology & Metabolism; Immunology; Rheumatology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Rheumatology
GA BA7XF
UT WOS:000337847000008
PM 24815076
DA 2025 08 17
ER

PT J
AU Zhang, XL
   Wang, YN
   Ma, LY
   Liu, ZS
   Ye, F
   Yang, JH
AF Zhang, Xiao lin
   Wang, Ya nan
   Ma, Lu yao
   Liu, Zhong sheng
   Ye, Fei
   Yang, Jian hong
TI Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid
   metabolism in KKAy mice via activating insulin signaling pathway
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE metabolic syndrome; uncarboxylated osteocalcin (GluOC); insulin
   resistance; hyperglycemia; dyslipidemia; non alcoholic fatty liver
   disease (NAFLD); obese; KKAy mouse
ID FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; RESISTANCE; ACID;
   EXPRESSION; PATHOGENESIS; MECHANISMS; COENZYME; INSIGHTS; PROTEIN
AB Osteocalcin, expressed in osteoblasts of the bone marrow, undergoes post translational carboxylation and deposits in mineralized bone matrix. A portion of osteocalcin remains uncarboxylated (uncarboxylated osteocalcin, GluOC) that is released into blood where it functions as a hormone to regulate insulin secretion and insulin sensitivity. As insulin resistance is closely associated with metabolic syndrome, this study is aimed to elucidate how GluOC regulates glucose and lipid metabolism in KKAy mice, an animal model displaying obese, hyperglycemia, hyperinsulinemia, insulin resistance, and hepatic steatosis. GluOC (3, 30 ng/g per day, ig) was orally administered to female KKAy mice for 4 weeks. Whole body insulin sensitivity, glucose metabolism, hepatic steatosis, dyslipidemia were examined using routine laboratory assays. We found that GluOC administration significantly enhanced insulin sensitivity in KKAy mice by activating hepatic IR beta/PI3K/Akt pathway and elevated the whole body insulin sensitivity with decreased FPI and HOMA IR index. Furthermore, GluOC administration alleviated hyperglycemia through suppressing gluconeogenesis and promoting glycogen synthesis in KKAy mice and in cultured hepatocytes in vitro. Moreover, GluOC administration dose dependently ameliorated dyslipidemia and attenuated hepatic steatosis in KKAy mice by inhibiting hepatic de novo lipogenesis and promoting fatty acid beta oxidation. These results demonstrate that GluOC effectively enhances hepatic insulin sensitivity, improves hyperglycemia and ameliorates hepatic steatosis in KKAy mice, suggesting that GluOC could be a promising drug candidate for treating metabolic syndrome.
C1 [Zhang, Xiao lin; Ma, Lu yao; Liu, Zhong sheng; Yang, Jian hong] Univ Chinese Acad Sci, Med Sch, Beijing 101400, Peoples R China.
   [Zhang, Xiao lin; Wang, Ya nan; Ye, Fei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Beijing Key Lab New Drug Mech & Pharmacol Evaluat, Beijing 100050, Peoples R China.
C3 Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College
RP Yang, JH (通讯作者)，Univ Chinese Acad Sci, Med Sch, Beijing 101400, Peoples R China.; Ye, F (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Beijing Key Lab New Drug Mech & Pharmacol Evaluat, Beijing 100050, Peoples R China.
EM yefei@imm.ac.cn; yangjh@ucas.edu.cn
RI Zhang, Xinyu/KDP 0796 2024; Ma, Luyao/L 8087 2013; Wang,
   Yanan/GQQ 8438 2022
OI Wang, Yanan/0000 0001 7401 047X; Zhang, Xiaolin/0000 0002 2908 5920; 
FU College of Life Sciences, University of Chinese Academy of Sciences
   [KJRH2015 006]; CAMS Innovation Fund for Medical Sciences
   [CIFMS 2016 I2M 3 012]; Drug Innovation Major Project
   [2018ZX09711001 003 005]
FX This work was supported by the grant for a combined research and
   teaching program from the College of Life Sciences, University of
   Chinese Academy of Sciences (KJRH2015 006). We also thank the support of
   the CAMS Innovation Fund for Medical Sciences (CIFMS 2016 I2M 3 012) and
   the Drug Innovation Major Project (2018ZX09711001 003 005).
CR Alam Shahinul, 2016, World J Gastrointest Pathophysiol, V7, P211, DOI 10.4291/wjgp.v7.i2.211
   Asrih M, 2015, MOL CELL ENDOCRINOL, V418, P55, DOI 10.1016/j.mce.2015.02.018
   Basaranoglu M, 2010, WORLD J GASTROENTERO, V16, P2223, DOI 10.3748/wjg.v16.i18.2223
   Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bugianesi E, 2010, CURR PHARM DESIGN, V16, P1941, DOI 10.2174/138161210791208875
   Crespo M, 2016, METABOLISM, V65, P1161, DOI 10.1016/j.metabol.2016.01.008
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2012, BONE, V50, P568, DOI 10.1016/j.bone.2011.04.017
   Fu C, 2015, INT J MOL SCI, V16, P8213, DOI 10.3390/ijms16048213
   Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25
   Gruben N, 2014, BBA MOL BASIS DIS, V1842, P2329, DOI 10.1016/j.bbadis.2014.08.004
   Guedes JAC, 2018, BONE, V115, P68, DOI 10.1016/j.bone.2017.11.020
   Gupte AA, 2014, ENDOCRINOLOGY, V155, P4697, DOI 10.1210/en.2014 1430
   Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016
   Hong F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082189
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Huang YY, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476 511X 12 171
   Könner AC, 2012, CELL METAB, V16, P144, DOI 10.1016/j.cmet.2012.07.004
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Liu HY, 2007, J BIOL CHEM, V282, P14205, DOI 10.1074/jbc.M609701200
   Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049
   Ma YM, 2011, MOL CELL BIOCHEM, V357, P65, DOI 10.1007/s11010 011 0876 4
   Machado M, 2006, CURR OPIN CLIN NUTR, V9, P637, DOI 10.1097/01.mco.0000241677.40170.17
   Magaña MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726
   MATSUBARA Y, 1986, P NATL ACAD SCI USA, V83, P6543, DOI 10.1073/pnas.83.17.6543
   Mizokami A, 2014, BONE, V69, P68, DOI 10.1016/j.bone.2014.09.006
   Mizokami A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057375
   Paschos P, 2009, HIPPOKRATIA, V13, P9
   Patti A, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/846480
   Pi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003858
   Qu S, 2006, ENDOCRINOLOGY, V147, P5641, DOI 10.1210/en.2006 0541
   Sanyal AJ, 2005, NAT CLIN PRACT GASTR, V2, P46, DOI 10.1038/ncpgasthep0084
   Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002
   Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471
   Shi QZ, 2010, WORLD J GASTROENTERO, V16, P897, DOI 10.3748/wjg.v16.i7.897
   Takamura T, 2012, ENDOCR J, V59, P745, DOI 10.1507/endocrj.EJ12 0228
   Tanaka N, 2019, WORLD J GASTROENTERO, V25, P163, DOI 10.3748/wjg.v25.i2.163
   Tang YB, 2018, ACTA PHARM SIN B, V8, P919, DOI 10.1016/j.apsb.2018.05.001
   Titchenell PM, 2016, CELL METAB, V23, P1154, DOI 10.1016/j.cmet.2016.04.022
   Tyanova S, 2015, PROTEOMICS, V15, P1453, DOI 10.1002/pmic.201400449
   Wang YH, 2015, NAT REV MOL CELL BIO, V16, P678, DOI 10.1038/nrm4074
   White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Wong RHF, 2010, CURR OPIN PHARMACOL, V10, P684, DOI 10.1016/j.coph.2010.08.004
   Yamamoto T, 2010, EUR J PHARMACOL, V640, P243, DOI 10.1016/j.ejphar.2010.04.050
   Yki Järvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213 8587(14)70032 4
   Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200
   Zhang Y, 2017, ONCOTARGET, V8, P75254, DOI 10.18632/oncotarget.20766
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 50
TC 33
Z9 38
U1 3
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD MAR
PY 2020
VL 41
IS 3
BP 383
EP 393
DI 10.1038/s41401 019 0311 z
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA KM5EV
UT WOS:000514159600010
PM 31659239
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Dick, IM
   Devine, A
   Beilby, J
   Prince, RL
AF Dick, IM
   Devine, A
   Beilby, J
   Prince, RL
TI Effects of endogenous estrogen on renal calcium and phosphate handling
   in elderly women
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE estradiol; calcium homeostasis; phosphate homeostasis; renal tubular
   calcium reabsorption; osteoporosis
ID POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; CALCITROPIC HORMONES;
   PARATHYROID HORMONE; OLDER WOMEN; BONE LOSS; OSTEOPOROSIS; MENOPAUSE;
   PLASMA; KIDNEY
AB High postmenopausal endogenous estrogen concentrations are an important determinant of preservation of bone mass and reduced fracture in elderly women. Calcium supplementation can also reduce bone loss in these patients, suggesting an interaction between estrogen deficiency and calcium balance. Potential mechanisms of estrogen on calcium transport include direct effects on the bone, the kidney, and the bowel. Previous studies have demonstrated effects of estrogen on renal phosphate handling. We have used a cross sectional, population based analysis of biochemical data obtained from ambulant elderly women to determine the association of endogenous estradiol with urine calcium and phosphorus excretion. The subjects were 293 postmenopausal women > 70 yr old. Factors associated with renal calcium and phosphate excretion were measured, including the filtered calcium and phosphate load, parathyroid hormone (PTH), estradiol, and sex hormone binding globulin ( SHBG). The free estradiol concentration (FE) was calculated from a previously described formula. A high plasma estradiol concentration (r(2) = 0.023, P = 0.01) and a high FE (r(2) = 0.045, P = 0.001) were associated with reduced renal calcium excretion. The estradiol and FE effect on renal calcium excretion remained significant after adjusting for calcium filtered at the glomerulus and serum PTH. A high FE was associated with a reduced renal phosphate threshold in univariate analysis (r(2) = 0.023, P = 0.010). The effect remained significant after adjustment for serum PTH. The size of the effect of the FE was of the same order of magnitude as the effect of PTH on reducing renal calcium excretion and increasing renal phosphate excretion. These data support in vitro and animal data demonstrating an effect of estradiol on renal calcium and phosphate handling and indicate that, in elderly postmenopausal women, the effect is of a similar magnitude to the well recognized effects of PTH on these physiologically regulated parameters.
C1 Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, Nedlands, WA 6009, Australia.
   Sir Charles Gairdner Hosp, Western Australian Ctr Pathol & Med Res, Nedlands, WA 6009, Australia.
   Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia.
   Western Australian Inst Med Ctr, Nedlands, WA, Australia.
C3 University of Western Australia; Sir Charles Gairdner Hospital;
   University of Western Australia; Sir Charles Gairdner Hospital; Sir
   Charles Gairdner Hospital; University of Western Australia
RP Univ Western Australia, Sir Charles Gairdner Hosp, Sch Med & Pharmacol, 4th Floor G Block, Nedlands, WA 6009, Australia.
EM iand@cyllene.uwa.edu.au
RI ; Devine, Amanda/D 1714 2016
OI Beilby, John/0000 0002 4915 2254; Devine, Amanda/0000 0001 6978 6249
CR ADAMI S, 1992, OSTEOPOROSIS INT, V2, P180, DOI 10.1007/BF01623924
   Bruce DG, 2002, J AM GERIATR SOC, V50, P84, DOI 10.1046/j.1532 5415.2002.50012.x
   CAULEY JA, 1986, AM J EPIDEMIOL, V124, P752, DOI 10.1093/oxfordjournals.aje.a114451
   Chapurlat RD, 2000, J BONE MINER RES, V15, P1835, DOI 10.1359/jbmr.2000.15.9.1835
   Christakos S, 2003, J BONE MINER RES, V18, P1737, DOI 10.1359/jbmr.2003.18.10.1737
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   DEVINE A, IN PRESS OSTEOPOROS
   Dick IA, 2003, MOL CELL ENDOCRINOL, V212, P11, DOI 10.1016/j.mce.2003.09.028
   Dick IM, 2001, AM J NEPHROL, V21, P323, DOI 10.1159/000046269
   Doherty DA, 2001, OSTEOPOROSIS INT, V12, P16, DOI 10.1007/s001980170152
   Geelhoed E., 1994, CLIN BIOCHEM REV, V15, P173
   HAGENFELDT Y, 1988, J STEROID BIOCHEM, V31, P49, DOI 10.1016/0022 4731(88)90204 X
   HEANEY RP, 1978, J LAB CLIN MED, V92, P953
   HEANEY RP, 1982, AM J CLIN NUTR, V36, P986, DOI 10.1093/ajcn/36.5.986
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   MARSHALL DH, 1976, CALCIUM PHOSPHATE MA, P257
   MCKANE WR, 1995, J CLIN ENDOCR METAB, V80, P3458, DOI 10.1210/jc.80.12.3458
   NORDIN BEC, 1991, J CLIN ENDOCR METAB, V72, P401, DOI 10.1210/jcem 72 2 401
   Nordin BEC, 1997, NUTRITION, V13, P664, DOI 10.1016/S0899 9007(97)00136 6
   NORDIN BEC, 1989, CLIN CHEM, V35, P14
   PRINCE RL, 1994, ENDOCR REV, V15, P301, DOI 10.1210/er.15.3.301
   PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701
   PRINCE RL, 1995, J BONE MINER RES, V10, P835
   RAE MH, 1991, MATURITAS, V13, P319, DOI 10.1016/0378 5122(91)90240 Q
   Rinaldi S, 2002, CANCER EPIDEM BIOMAR, V11, P1065
   Slemenda C, 1996, J CLIN INVEST, V97, P14, DOI 10.1172/JCI118382
   SODERGARD R, 1982, J STEROID BIOCHEM, V16, P801, DOI 10.1016/0022 4731(82)90038 3
   STJOHN A, 1988, CLIN CHIM ACTA, V178, P215, DOI 10.1016/0009 8981(88)90227 6
   Stone K, 1998, J BONE MINER RES, V13, P1167, DOI 10.1359/jbmr.1998.13.7.1167
   Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A
   Vincent A, 2003, MENOPAUSE, V10, P165, DOI 10.1097/00042192 200310020 00009
NR 34
TC 46
Z9 53
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD FEB
PY 2005
VL 288
IS 2
BP E430
EP E435
DI 10.1152/ajpendo.00140.2004
PG 6
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 888LH
UT WOS:000226375100021
PM 15466921
DA 2025 08 17
ER

PT J
AU Karnik, S
   Hines, K
   Mills, DK
AF Karnik, Sonali
   Hines, Kanesha
   Mills, David K.
TI Nanoenhanced hydrogel system with sustained release capabilities
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE halloysite nanotubes; osteoblasts; growth factors; sustained release;
   tissue repair
ID CONTROLLED DRUG DELIVERY; BONE MORPHOGENETIC PROTEINS; GROWTH FACTORS;
   CLAY NANOTUBES; IN VITRO; SCAFFOLDS; BIOMATERIALS; CHALLENGES;
   HALLOYSITE; DESIGN
AB An alginate/halloysite nanotube (HNT) nanocomposite was developed with sustained release of bone morphogenetic proteins (BMPs) at picogram low levels. BMP 2, 4, and 6 and osteoblasts were chosen as our model growth factor and cell type as the interaction of BMPs with osteoblasts is well known and thoroughly investigated. Alginate hydrogels with HNTs doped with BMP 2, 4, or 6 only or BMP 4 and 6 in combination. Osteoblasts were seeded within the hydrogels and studied for changes in cell proliferation, phenotypic expression, and mineralization over a 28 day experimental period. Osteoblast behavior was enhanced in BMP doped hydrogel/HNTs nanocomposites as compared with control groups. Release profiles showed that BMP 2 was released in a sustained fashion over a 7 day period and at picogram levels. Mineralization, as showed by Von Kossa staining, and protein synthesis peaked at 28 days, for all three growth factor combinations. BMP 4 provided a marked stimulus for osteoblast functionality base and was comparable to BMP 6 in terms of osteoblast differentiation and mineralization. BMP 4 and 6, in combination, showed a marked enhancement in osteoblast differentiation and functionality; however, the response seemed to be delayed when compared with BMP 4 and 6 release. Hydrogel surfaces had a complex surface topography and greater structural integrity with increased halloysite addition. The data suggest that these nanocomposites may provide a mechanism to enhance repair and regeneration in damaged or diseased tissues, reducing the need for more invasive treatment modalities. (c) 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103: 2416 2426, 2015.
C1 [Karnik, Sonali; Hines, Kanesha; Mills, David K.] Louisiana Tech Univ, Ctr Biomed Engn & Rehabil Sci, Ruston, LA 71272 USA.
   [Mills, David K.] Louisiana Tech Univ, Sch Biol Sci, Ruston, LA 71272 USA.
C3 University of Louisiana System; Louisiana Technical University;
   University of Louisiana System; Louisiana Technical University
RP Mills, DK (通讯作者)，Louisiana Tech Univ, Ctr Biomed Engn & Rehabil Sci, Ruston, LA 71272 USA.
EM dkmills@latech.edu
RI Mills, David/H 1414 2012
FU Golden Key International Honor Society
FX Contract grant sponsor: Golden Key International Honor Society (to S.K.)
CR Abdullayev E, 2009, ACS APPL MATER INTER, V1, P1437, DOI 10.1021/am9002028
   Antoine EE, 2014, TISSUE ENG PART B RE, V20, P683, DOI [10.1089/ten.TEB.2014.0086, 10.1089/ten.teb.2014.0086]
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524 475X.2008.00410.x
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bindu Sri M., 2012, Int. J. Pharm. Chem. Sci, V1, P642
   Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963
   Chung HJ, 2007, ADV DRUG DELIVER REV, V59, P249, DOI 10.1016/j.addr.2007.03.015
   Huynh CT, 2011, MACROMOLECULES, V44, P6629, DOI 10.1021/ma201261m
   Dai WD, 2010, BIOMATERIALS, V31, P2141, DOI 10.1016/j.biomaterials.2009.11.070
   Francioli SE, 2010, J BIOMED MATER RES A, V95A, P924, DOI 10.1002/jbm.a.32917
   Ganji F, 2009, IRAN POLYM J, V18, P63
   Ji W, 2011, PHARM RES DORDR, V28, P1259, DOI 10.1007/s11095 010 0320 6
   Juhasz JA, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014103
   Kamik S., 2013, JN anom edN anotechnol, V4, P104
   Kamoun E., 2010, ALGINATE HYDROGEL DR
   Karnik S., 2011, THESIS LOUISIANA TEC
   Karnik SJ, 2012, FASEB J, V26
   Khan SN, 2004, EXPERT OPIN BIOL TH, V4, P741
   Kommireddy DS, 2005, J BIOMED NANOTECHNOL, V1, P286, DOI 10.1166/jbn.2005.046
   Kommireddy DS, 2005, J NANOSCI NANOTECHNO, V5, P1081, DOI 10.1166/jnn.2005.149
   Kumar MNVR, 2000, J PHARM PHARM SCI, V3, P234
   Liu X, 2014, BIOMACROMOLECULES, V15, P1019, DOI 10.1021/bm401911p
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Lvov Y, 2013, PROG POLYM SCI, V38, P1690, DOI 10.1016/j.progpolymsci.2013.05.009
   Lvov YM, 2008, ACS NANO, V2, P814, DOI 10.1021/nn800259q
   Marie PJ, 2002, HISTOL HISTOPATHOL, V17, P877, DOI 10.14670/HH 17.877
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Nakashima M, 2003, NAT BIOTECHNOL, V21, P1025, DOI 10.1038/nbt864
   Nichol JW, 2009, SOFT MATTER, V5, P1312, DOI 10.1039/b814285h
   Pagliari S, 2013, CURR MED CHEM, V20, P3429, DOI 10.2174/09298673113209990032
   Paolino D., 2006, Encyclopedia of Medical Devices and Instrumentation
   Parenteau Bareil R, 2010, MATERIALS, V3, P1863, DOI 10.3390/ma3031863
   Patravale V, 2012, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818195
   Prabaharan M, 2005, DRUG DELIV, V12, P41, DOI 10.1080/10717540590889781
   Price RR, 2001, J MICROENCAPSUL, V18, P713
   Ramteke K.H., 2012, IOSRPHR, V2, P44, DOI DOI 10.9790/3013 24204448
   Rose FRAJ, 2004, J PHARM PHARMACOL, V56, P415, DOI 10.1211/0022357023312
   Saralidze K, 2010, MATERIALS, V3, P3537, DOI 10.3390/ma3063537
   Sauter T, 2012, NANO LIFE, V2, DOI 10.1142/S1793984411000372
   Sezer AD, 2012, RECENT ADV NOVEL DRU, P512
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Sohier J, 2008, EXPERT OPIN DRUG DEL, V5, P543, DOI [10.1517/17425247.5.5.543, 10.1517/17425247.5.5.543 ]
   Sun GM, 2012, NANOMEDICINE UK, V7, P1771, DOI [10.2217/NNM.12.149, 10.2217/nnm.12.149]
   Suri Sarabjeet Singh, 2007, J Occup Med Toxicol, V2, P16, DOI 10.1186/1745 6673 2 16
   Tamayol A, 2013, BIOTECHNOL ADV, V31, P669, DOI 10.1016/j.biotechadv.2012.11.007
   UNGARO F, 2005, TOPICS TISSUE ENG, V2
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Van Vlierberghe S, 2011, BIOMACROMOLECULES, V12, P1387, DOI 10.1021/bm200083n
   Veerabadran NG, 2007, NANO, V2, P115, DOI 10.1142/S1793292007000441
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wei W, 2012, MACROMOL MAT ENG RCS, V4, P488
   Wei WB, 2012, MACROMOL MATER ENG, V297, P645, DOI 10.1002/mame.201100309
   Weinand C, 2009, J BIOMED MATER RES B, V91B, P80, DOI 10.1002/jbm.b.31376
   Wenbo W, 2013, RSC ADV, V4, P488
   Wingard JR, 1999, DEV ONCOL, V80, P407
   WOZNEY JM, 1990, J CELL SCI, P149
NR 57
TC 23
Z9 25
U1 0
U2 63
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUL
PY 2015
VL 103
IS 7
BP 2416
EP 2426
DI 10.1002/jbm.a.35376
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA CJ1LZ
UT WOS:000355246400021
PM 25424733
DA 2025 08 17
ER

PT J
AU Yang, F
   Xue, F
   Guan, JJ
   Zhang, Z
   Yin, JM
   Kang, QL
AF Yang, Fan
   Xue, Feng
   Guan, Junjie
   Zhang, Zeng
   Yin, Jimin
   Kang, Qinglin
TI Stromal Cell Derived Factor (SDF) 1 Alpha Overexpression Promotes Bone
   Regeneration by Osteogenesis and Angiogenesis in Osteonecrosis of the
   Femoral Head
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Osteonecrosis of the femoral head; Bone marrow stem cells; SDF alpha
ID MESENCHYMAL STEM CELLS; ALCOHOL INDUCED OSTEONECROSIS; OSTEOBLAST
   DIFFERENTIATION; PROLIFERATION; CXCR4; EXPRESSION; MIGRATION;
   TRANSPLANTATION; PATHWAY; ANTAGONIST
AB Background/Aims: Osteonecrosis of the femoral head (ONFH) is a devastating orthopedic disease. Previous studies suggested that stromal cell derived factor (SDF) 1 was involved in osteogenesis and angiogenesis. However, whether SDF 1 potentiates the angiogenesis and osteogenesis of bone marrow derived stromal stem cells (BMSCs) in ONFH is not clear. Methods: BMSCs were transfected with green fluorescent protein (GFP) or the fusion gene encoding GFP and SDF l alpha, and transgenic efficacy was monitored by immunofluorescence. The expression of SDF l alpha, runt related transcription factor 2 (Runx2), osteocalcin (OCN), and alkaline phosphatase (ALP) at the mRNA level was measured by real time polymerase chain reactions (RT PCR). The expression of SDF l alpha, Runx2, OCN, and p Smad1/5 were measured at the protein level by Western blot. Transwell migration assay and tube formation assay were utilized to detect the angiogenesis in vitro, whereas the in vivo angiogenesis was monitored by angiography. Immunohistological staining and micro CT scanning were conducted to assess the histological changes in morphology. Results: In vitro, SDF l alpha overexpression in BMSCs promoted osteogenic differentiation and upregulated the expression of osteogenicrelated proteins, such as ALP, Runx2, OCN, and p Smad1/5. In the methylprednisolone induced ONFH rat model used in our investigation, the overexpression of SDF l alpha in BMSCs promoted significantly more bone regeneration and the expression of OCN and Runx2 as compared with the effect of vehicle overexpression. Moreover, the morphology of ONFH was ameliorated after the transplantation of BMSCs with SDF l alpha overexpression. Furthermore, SDF l alpha overexpression in BMSCs significantly increased osteoblastic angiogenesis as indicated by the increased tube formation ability, CD31 expression, and vessel volume. Conclusion: SDFla overexpression in BMSCs promotes bone generation as indicated by osteogenesis and angiogenesis, suggesting SDF la alpha may serve as a therapeutic drug target for ONFH treatment. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Yang, Fan; Xue, Feng; Guan, Junjie; Zhang, Zeng; Yin, Jimin; Kang, Qinglin] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Peoples Hosp 6, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Kang, QL (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Peoples Hosp 6, Shanghai, Peoples R China.
EM orthokang@163.com
RI ; Yang, Fan/HLX 3556 2023; Kang, Qinglin/IUM 3978 2023
OI Kang, Qinglin/0000 0001 9825 0451; 
FU National Natural Science Foundation of China [81572121]
FX This study was funded by the National Natural Science Foundation of
   China (No. 81572121).
CR [Anonymous], ANIMAL BIOTECHNOLOGY
   Baniwal SK, 2012, OSTEOPOROSIS INT, V23, P1399, DOI 10.1007/s00198 011 1728 5
   Bozec A, 2017, ONCOTARGET, V8, P57174, DOI 10.18632/oncotarget.19170
   Capone A, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1662 6
   Chen YX, 2017, CELL PHYSIOL BIOCHEM, V42, P2391, DOI 10.1159/000480181
   Chen YX, 2017, ONCOTARGET, V8, P31065, DOI 10.18632/oncotarget.16075
   Datta I, 2017, CYTOTHERAPY, V19, P1208, DOI 10.1016/j.jcyt.2017.07.009
   Dhoke NR, 2018, ANTIOXID REDOX SIGN, V28, P1047, DOI 10.1089/ars.2016.6974
   Du LQ, 2016, CELL PROLIFERAT, V49, P599, DOI 10.1111/cpr.12286
   Du LQ, 2012, J PERIODONTOL, V83, P379, DOI 10.1902/jop.2011.110201
   Fahy N, 2018, J ORTHOP RES, V36, P52, DOI 10.1002/jor.23670
   Han N, 2016, J CELL MOL MED, V20, P2173, DOI 10.1111/jcmm.12917
   Hang DH, 2012, CELLS TISSUES ORGANS, V195, P495, DOI 10.1159/000329502
   Heidrich K, 2017, ANN ONCOL, V28, P2793, DOI 10.1093/annonc/mdx500
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Hostettler KE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181946
   Jeng KS, 2017, ONCOL LETT, V14, P1905, DOI 10.3892/ol.2017.6396
   Jones GN, 2012, STEM CELL TRANSL MED, V1, P70, DOI 10.5966/sctm.2011 0007
   Kaku M, 2015, J PROSTHODONT RES, V59, P96, DOI 10.1016/j.jpor.2015.02.001
   Kang JS, 2013, YONSEI MED J, V54, P510, DOI 10.3349/ymj.2013.54.2.510
   Kim SC, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1605 2
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Lazaro LE, 2017, ARCH ORTHOP TRAUM SU, V137, P1529, DOI 10.1007/s00402 017 2778 8
   Liu C, 2013, INT J MED SCI, V10, P1181, DOI 10.7150/ijms.6657
   Liu F, 2017, J RES MED SCI, V22, DOI 10.4103/1735 1995.200273
   Liu H, 2017, WOUND REPAIR REGEN, V25, P652, DOI 10.1111/wrr.12552
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Nowicki M, 2017, ANN HEMATOL, V96, P2103, DOI 10.1007/s00277 017 3133 4
   Peng WX, 2017, CELL PHYSIOL BIOCHEM, V43, P1648, DOI 10.1159/000484026
   Perrucci GL, 2016, INT J CARDIOL, V212, P324, DOI 10.1016/j.ijcard.2016.03.082
   Qin G, 2016, MOL MED REP, V14, P57, DOI 10.3892/mmr.2016.5215
   Rodrigues Moreira S, 2017, CELL REP, V20, P3199, DOI 10.1016/j.celrep.2017.09.013
   Sha YQ, 2017, LIFE SCI, V189, P52, DOI 10.1016/j.lfs.2017.09.017
   Shabbir A, 2015, STEM CELLS DEV, V24, P1635, DOI 10.1089/scd.2014.0316
   Shafiq M, 2017, J BIOMED MATER RES A, V105, P2670, DOI 10.1002/jbm.a.36130
   Shiraishi K, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8740294
   Silva Luanne Lisle Dos Santos, 2016, Ortop Traumatol Rehabil, V18, P445, DOI 10.5604/15093492.1226274
   Sun MY, 2018, INT J MED SCI, V15, P257, DOI 10.7150/ijms.21620
   Sun Y Q, 2017, Zhonghua Xue Ye Xue Za Zhi, V38, P732, DOI 10.3760/cma.j.issn.0253 2727.2017.08.018
   Tan G, 2012, CHINESE MED J PEKING, V125, P134, DOI 10.3760/cma.j.issn.0366 6999.2012.01.025
   Tang CH, 2008, CARCINOGENESIS, V29, P1483, DOI 10.1093/carcin/bgn045
   Tang QM, 2017, ACTA BIOMATER, V61, P101, DOI 10.1016/j.actbio.2017.08.001
   Toupadakis CA, 2012, J ORTHOP RES, V30, P1853, DOI 10.1002/jor.22145
   Walenkamp AME, 2017, J NUCL MED, V58, p77S, DOI 10.2967/jnumed.116.186874
   Wang FL, 2017, MAR DRUGS, V15, DOI 10.3390/md15060186
   Wang XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174145
   Xu X, 2013, CELLS TISSUES ORGANS, V197, P103, DOI 10.1159/000342921
   Yang X, 2016, FOOD CHEM TOXICOL, V97, P120, DOI 10.1016/j.fct.2016.09.004
   Yiou R, 2017, BIO MED MATER ENG, V28, pS81, DOI 10.3233/BME 171627
   YU Y, 2016, MEDICINE, V95, DOI DOI 10.1097/MD.0000000000005407
   Yuan WM, 2017, BIOTECHNOL LETT, V39, P1649, DOI 10.1007/s10529 017 2411 5
   Zalavras CG, 2014, J AM ACAD ORTHOP SUR, V22, P455, DOI 10.5435/JAAOS 22 07 455
   Zhang L, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10971 1
   Zhang YL, 2016, INT J BIOL SCI, V12, P347, DOI 10.7150/ijbs.13269
   Zhong JX, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00477
   Zhou Q, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700641
   Zhou WQ, 2019, CURR MED CHEM, V26, P3026, DOI 10.2174/0929867324666170830111531
   Zhu W, 2011, J BIOL CHEM, V286, P26794, DOI 10.1074/jbc.M111.250985
NR 59
TC 62
Z9 67
U1 0
U2 21
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 46
IS 6
BP 2561
EP 2575
DI 10.1159/000489684
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GH2SJ
UT WOS:000433251900032
PM 29758548
OA gold
DA 2025 08 17
ER

PT J
AU Yamauchi, N
   Taguchi, Y
   Kato, H
   Umeda, M
AF Yamauchi, Nobuhiro
   Taguchi, Yoichiro
   Kato, Hirohito
   Umeda, Makoto
TI High power, red light emitting diode irradiation enhances proliferation,
   osteogenic differentiation, and mineralization of human periodontal
   ligament stem cells via ERK signaling pathway
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE Low level light therapy; MAP kinase signaling system; periodontal
   ligament; phototherapy; regeneration; stem cells
ID ANTIMICROBIAL PHOTODYNAMIC THERAPY; LEVEL LASER THERAPY; TRANSCRIPTION
   FACTOR OSTERIX; OSTEOBLAST DIFFERENTIATION; INSITU HYBRIDIZATION;
   MAMMALIAN CELLS; MATRIX PROTEINS; BONE FORMATION; IN VITRO; EXPRESSION
AB Background: Light emitting diode (LED) is attracting attention as a new light source for phototherapy. However, its effects on periodontal tissue regeneration remain unknown. The aim of this study was to examine the effects of high power, red LED irradiation on human periodontal ligament stem cells (PDLSCs), which play an important role in periodontal tissue regeneration.
   Methods: PDLSCs were derived from adult human third molars. The light source was red LED (peak wavelength: 650nm). Energy densities ranging from 0 to 10 J/cm(2) were tested to determine the optimal dose. PDLSC proliferation was measured using two parameters: live cell protease and ATP levels. After the cells were induced to differentiate, the effect of LED irradiation on osteogenic differentiation and mineralization was examined, with particular focus on the extracellular signal regulated kinase (ERK)1/2 signaling pathway using an ERK inhibitor (PD98059).
   Results: LED irradiation at 8 J/cm(2) led to a significant increase in PDLSC proliferation and enhanced Runx2 and Osterix mRNA expression, Alkaline phosphatase activity, procollagen type I C peptide and osteocalcin production, calcium deposition, and alizarin red S staining. In addition, LED induced the activation of ERK1/2, and the effects of LED on PDLSC proliferation, differentiation, and mineralization could be suppressed by treatment with PD98059.
   Conclusions: The results of this study show that 650 nm high power, red, LED irradiation increases PDLSCs proliferation, and osteogenic differentiation and mineralization, mediated by ERK1/2 activation. These findings suggest that LED may be a useful tool for periodontal tissue regeneration.
C1 [Yamauchi, Nobuhiro; Taguchi, Yoichiro; Kato, Hirohito; Umeda, Makoto] Osaka Dent Univ, Dept Periodontol, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka, Japan.
RP Taguchi, Y (通讯作者)，Osaka Dent Univ, Dept Periodontol, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka, Japan.
EM taguchi@cc.osaka dent.ac.jp
FU Japan Society for the Promotion of Science [16K11617, 16K20476,
   16K20551, 17K11818]; Osaka Dental University Research Funds [17 05];
   Grants in Aid for Scientific Research [17K11818, 16K20476, 16K11617,
   16K20551] Funding Source: KAKEN
FX The authors would like to thank Dr. Okagami and Mr. Okawa from J. Morita
   Mfg. (Kyoto, Japan) for their helpful suggestions. This work was
   supported by Grants in Aid for Scientific Research from Japan Society
   for the Promotion of Science (16K11617, 16K20476, 16K20551, 17K11818),
   and Osaka Dental University Research Funds (17 05). The authors declare
   that they have no conflicts of interest related to this study.
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
   Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165
   Braham P, 2009, J PERIODONTOL, V80, P1790, DOI 10.1902/jop.2009.090214
   Carroll JD, 2014, DENT MATER, V30, P465, DOI 10.1016/j.dental.2014.02.006
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chow RT, 2006, PAIN, V124, P201, DOI 10.1016/j.pain.2006.05.018
   Mima EGD, 2010, ORAL SURG ORAL MED O, V109, P392, DOI 10.1016/j.tripleo.2009.10.006
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Finke B, 2007, BIOMATERIALS, V28, P4521, DOI 10.1016/j.biomaterials.2007.06.028
   Flecha OD, 2013, J PERIODONTOL, V84, P287, DOI 10.1902/jop.2012.120165
   Gautam AP, 2012, RADIOTHER ONCOL, V104, P349, DOI 10.1016/j.radonc.2012.06.011
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Hawkins TA, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 42
   Holder MJ, 2012, J DENT RES, V91, P961, DOI 10.1177/0022034512456040
   Hopkins JT, 2004, J ATHL TRAINING, V39, P223
   Huang TH, 2012, LASER MED SCI, V27, P621, DOI 10.1007/s10103 011 1006 y
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Ichinose Tsuno A, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472 6831 14 152
   IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751 1097.2008.00394.x
   Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359
   Kato H, 2016, J PERIODONTOL, V87, pE44, DOI 10.1902/jop.2015.150474
   Kato H, 2013, J PERIODONTOL, V84, P1476, DOI 10.1902/jop.2012.120469
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103 008 0550 6
   Komine N, 2010, LASER MED SCI, V25, P531, DOI 10.1007/s10103 009 0743 7
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kreisler M, 2003, J CLIN PERIODONTOL, V30, P353, DOI 10.1034/j.1600 051X.2003.00001.x
   Lin F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 16
   Lizarelli R.F.Z., 2007, J Oral Laser Appl, V7, P129
   Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ning HX, 2011, BIOCHEM BIOPH RES CO, V413, P353, DOI 10.1016/j.bbrc.2011.08.104
   Patti A, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/846480
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103 011 1005 z
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Rios A, 2011, J ENDODONT, V37, P856, DOI 10.1016/j.joen.2011.03.014
   Roelandts R, 2005, PHOTODERMATOL PHOTO, V21, P115, DOI 10.1111/j.1600 0781.2005.00160.x
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Turrioni APS, 2014, J DENT, V42, P1292, DOI 10.1016/j.jdent.2014.07.014
   Umeda M, 2011, J INVESTIG CLIN DENT, V2, P268, DOI 10.1111/j.2041 1626.2011.00071.x
   Vladimirov YA, 2004, BIOCHEMISTRY MOSCOW+, V69, P81, DOI 10.1023/B:BIRY.0000016356.93968.7e
   WEINREB M, 1990, J BONE MINER RES, V5, P831
   Wiesmann HP, 2005, INT REV CYTOL, V242, P121
   Wu YK, 2013, ARCH ORAL BIOL, V58, P1357, DOI 10.1016/j.archoralbio.2013.03.011
NR 49
TC 41
Z9 42
U1 1
U2 27
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611 2690 USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD MAR
PY 2018
VL 89
IS 3
BP 351
EP 360
DI 10.1002/JPER.17 0365
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GD5UF
UT WOS:000430571500011
PM 29528486
DA 2025 08 17
ER

PT J
AU Qi, WX
   Lin, F
   He, AN
   Tang, LN
   Shen, Z
   Yao, Y
AF Qi, Wei Xiang
   Lin, Feng
   He, Ai Na
   Tang, Li Na
   Shen, Zan
   Yao, Yang
TI Incidence and risk of denosumab related hypocalcemia in cancer patients:
   a systematic review and pooled analysis of randomized controlled studies
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Cancer; Denosumab; Hypocalcemia; Meta analysis
ID PLACEBO CONTROLLED TRIAL; CELL LUNG CANCER; QUALITY OF LIFE; BONE
   METASTASES; PROSTATE CANCER; ZOLEDRONIC ACID; BREAST CANCER;
   METAANALYSIS; THERAPY; MECHANISMS
AB Purpose:
   The aim of this study is to evaluate the frequency and relative risk of hypocalcemia in cancer patients receiving denosumab.
   Methods:
   We searched the PubMed (data from 1966 to October 2012), Embase (data from 1980 to October 2012) and Cochrane Library (up to October 2012) electronic databases for relevant randomized controlled trials (RCTs). Abstracts presented at conferences were also searched. Phase II and III trials of denosumab in patients with any type of cancer that reported occurrence of hypocalcemia were eligible. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed or random effects models depending on the heterogeneity among included trials.
   Results:
   A total of 8990 patients with a variety of solid tumors from seven RCTs were included for the meta analysis. The overall incidences of all grade and high grade hypocalcemia in cancer patients were 5.2% (95% confidence interval [CI]: 2.8 9.3%) and 2.0% (95% CI: 0.7 5.5%), respectively. The use of denosumab was associated with significantly increased risk of developing all grade (RR 1.932, 95% CI: 1.590 2.347, p<0.001) and high grade hypocalcemia (RR 4.027, 95% CI: 2.346 6.912, p<0.001) in comparison with controls.
   Conclusions:
   The use of denosumab is associated with a significantly increased risk of developing hypocalcemia (p<0.001). Physicians should be aware of this adverse effect and should monitor cancer patients receiving denosumab.
C1 [Qi, Wei Xiang; Lin, Feng; He, Ai Na; Tang, Li Na; Shen, Zan; Yao, Yang] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Oncol, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Yao, Y (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Oncol, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM qwxzlk@163.com
RI Tang, Lina/AAA 4121 2022
OI Qi, wei xiang/0000 0001 5484 3343
CR Aapro MS, 2011, J CLIN ONCOL, V29, pE419, DOI 10.1200/JCO.2010.33.9150
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brown Glaberman U, 2012, BIOL TARGETS THER, V6, P89, DOI 10.2147/BTT.S20677
   Bundred N, 2012, CANCER TREAT REV, V38, P776, DOI 10.1016/j.ctrv.2012.02.002
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cooper MS, 2008, BRIT MED J, V336, P1298, DOI 10.1136/bmj.39582.589433.BE
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fong J, 2012, CAN FAM PHYSICIAN, V58, P158
   Gulley JL, 2007, CLIN GENITOURIN CANC, V5, P403, DOI 10.3816/CGC.2007.n.025
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Kim Byung Gee, 2010, Korean Circ J, V40, P201, DOI 10.4070/kcj.2010.40.4.201
   McCormick BB, 2012, AM J KIDNEY DIS, V60, P626, DOI 10.1053/j.ajkd.2012.06.019
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Mishra A, 2008, J POSTGRAD MED, V54, P237, DOI 10.4103/0022 3859.41815
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Qi WX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055637
   Qi WX, 2013, INT J CANCER, V132, pE66, DOI 10.1002/ijc.27775
   Qi WX, 2012, CURR MED RES OPIN, V28, P643, DOI 10.1185/03007995.2012.675880
   Qi WX, 2011, LUNG, V189, P437, DOI 10.1007/s00408 011 9332 1
   Reddy G Kesava, 2006, Support Cancer Ther, V4, P15, DOI 10.3816/SCT.2006.n.026
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Segal E, 2012, ISR MED ASSOC J, V14, P607
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Su Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035629
   Tabrizi MA, 2006, DRUG DISCOV TODAY, V11, P81, DOI 10.1016/S1359 6446(05)03638 X
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Tomar M, 2010, INDIAN PEDIATR, V47, P781, DOI 10.1007/s13312 010 0117 z
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033 0620(85)80003 7
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 37
TC 38
Z9 39
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD SEP
PY 2013
VL 29
IS 9
BP 1067
EP 1073
DI 10.1185/03007995.2013.813840
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 206AS
UT WOS:000323488400005
PM 23745518
DA 2025 08 17
ER

PT J
AU No, JH
   Dossin, FD
   Zhang, YH
   Liu, YL
   Zhu, W
   Feng, XX
   Yoo, JA
   Lee, E
   Wang, K
   Hui, R
   Freitas Junior, LH
   Oldfield, E
AF No, Joo Hwan
   Dossin, Fernando de Macedo
   Zhang, Yonghui
   Liu, Yi Liang
   Zhu, Wei
   Feng, Xinxin
   Yoo, Jinyoung Anny
   Lee, Eunhae
   Wang, Ke
   Hui, Raymond
   Freitas Junior, Lucio H.
   Oldfield, Eric
TI Lipophilic analogs of zoledronate and risedronate inhibit
   Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and
   exhibit potent antimalarial activity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID FARNESYL PYROPHOSPHATE SYNTHASE; IN VIVO; TRYPANOSOMA BRUCEI;
   INTRAERYTHROCYTIC STAGES; ENTAMOEBA HISTOLYTICA; LEISHMANIA DONOVANI;
   TOXOPLASMA GONDII; HUMAN BONE; BISPHOSPHONATES; GROWTH
AB We report the results of an in vitro screening assay targeting the intraerythrocytic form of the malaria parasite Plasmodium falciparum using a library of 560 prenyl synthase inhibitors. Based on "growth rescue" and enzyme inhibition experiments, geranylgeranyl diphosphate synthase (GGPPS) is shown to be a major target for the most potent leads, BPH 703 and BPH 811, lipophilic analogs of the bone resorption drugs zoledronate and risedronate. We determined the crystal structures of these inhibitors bound to a Plasmodium GGPPS finding that their head groups bind to the [Mg2+](3) cluster in the active site in a similar manner to that found with their more hydrophilic parents, whereas their hydrophobic tails occupy a long hydrophobic tunnel spanning both molecules in the dimer. The results of isothermal titration calorimetric experiments show that both lipophilic bisphosphonates bind to GGPPS with, on average, a Delta G of  9 kcal mol( 1), only 0.5 kcal mol( 1) worse than the parent bisphosphonates, consistent with the observation that conversion to the lipophilic species has only a minor effect on enzyme activity. However, only the lipophilic species are active in cells. We also tested both compounds in mice, finding major decreases in parasitemia and 100% survival. These results are of broad general interest because they indicate that it may be possible to overcome barriers to cell penetration of existing bisphosphonate drugs in this and other systems by simple covalent modification to form lipophilic analogs that retain their enzyme inhibition activity and are also effective in vitro and in vivo.
C1 [Dossin, Fernando de Macedo; Freitas Junior, Lucio H.] Inst Pasteur Korea, Ctr Neglected Dis Drug Discovery, Songnam 463400, Gyeonggi Do, South Korea.
   [No, Joo Hwan; Liu, Yi Liang; Zhu, Wei; Oldfield, Eric] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.
   [Zhang, Yonghui; Feng, Xinxin; Yoo, Jinyoung Anny; Wang, Ke; Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [Lee, Eunhae] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.
   [Hui, Raymond] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada.
C3 Institut Pasteur Korea; University of Illinois System; University of
   Illinois Urbana Champaign; University of Illinois System; University of
   Illinois Urbana Champaign; University of Illinois System; University of
   Illinois Urbana Champaign; University of Toronto; Structural Genomics
   Consortium
RP Freitas Junior, LH (通讯作者)，Inst Pasteur Korea, Ctr Neglected Dis Drug Discovery, Songnam 463400, Gyeonggi Do, South Korea.
EM freitasjunior@ip korea.org; eo@chad.scs.uiuc.edu
RI Feng, Xinixn/HPD 6503 2023; Zhu, Wei/H 9572 2013; de M. Dossin,
   Fernando/D 1503 2011; Freitas Junior, Lucio/C 8677 2011; Liu,
   Yi Liang/C 3652 2013; wang, ke/O 4922 2015
OI , Yonghui/0000 0002 9842 3049; 
FU United States Public Health Science, National Institutes of Health [GM
   65307]; National Research Foundation of Korea; Korean government,
   Ministry of Education, Science, and Technology [2010 00395]; Korea
   Institute of Science and Technology Information; US Department of
   Energy, Office of Science, Office of Basic Energy Sciences
   [DE AC02 06CH11357]; Michigan Economic Development Corporation; Michigan
   Technology Tri Corridor [085P1000817]
FX We thank Fabio T. M. Costa (Universidade Estadual de Campinas, Sao
   Paulo, Brazil) for providing P. chabaudi stocks and protocols for in
   vivo compound tests, Yigui Gao from University of Illinois at
   Urbana Champaign Macromolecular Crystallization Lab for providing
   crystallization facilities, and Minje Ku and Minjung Ma for helping with
   parasite culture and handling of infected animals. This work was
   supported by the United States Public Health Science, National
   Institutes of Health (Grant GM 65307) and by a National Research
   Foundation of Korea grant funded by the Korean government, Ministry of
   Education, Science, and Technology (2010 00395), and Korea Institute of
   Science and Technology Information. Use of the Advanced Photon Source
   was supported by the US Department of Energy, Office of Science, Office
   of Basic Energy Sciences, under Contract DE AC02 06CH11357. Use of the
   Life Science Collaborative Access Team Sector 21 was supported by the
   Michigan Economic Development Corporation and the Michigan Technology
   Tri Corridor for the support of this research program (Grant
   085P1000817).
CR Artz JD, 2011, J BIOL CHEM, V286, P3315, DOI 10.1074/jbc.M109.027235
   Artz JD, 2008, CHEM BIOL, V15, P1296, DOI 10.1016/j.chembiol.2008.10.017
   Bruchhaus I, 1996, BIOCHEM J, V316, P57, DOI 10.1042/bj3160057
   Cammerer SB, 2007, ANTIMICROB AGENTS CH, V51, P4049, DOI 10.1128/AAC.00205 07
   Chakrabarti D, 1998, MOL BIOCHEM PARASIT, V94, P175, DOI 10.1016/S0166 6851(98)00065 6
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   D'Alexandri FL, 2006, ANAL BIOCHEM, V355, P189, DOI 10.1016/j.ab.2006.06.014
   Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573
   Jordao FM, 2011, ANTIMICROB AGENTS CH, V55, P2026, DOI 10.1128/AAC.01820 10
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Lin FY, 2010, P NATL ACAD SCI USA, V107, P21337, DOI 10.1073/pnas.1010907107
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Liu CI, 2008, SCIENCE, V319, P1391, DOI 10.1126/science.1153018
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   Moreno B, 2001, BIOCHEM BIOPH RES CO, V284, P632, DOI 10.1006/bbrc.2001.5009
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Mukkamala D, 2008, J MED CHEM, V51, P7827, DOI 10.1021/jm8009074
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Singh AP, 2010, ANTIMICROB AGENTS CH, V54, P2987, DOI 10.1128/AAC.00198 10
   Song YC, 2009, J MED CHEM, V52, P3869, DOI 10.1021/jm9001764
   Song YC, 2009, J MED CHEM, V52, P976, DOI 10.1021/jm801023u
   Tonhosolo R, 2010, FEBS LETT, V584, P4761, DOI 10.1016/j.febslet.2010.10.055
   Tonhosolo R, 2009, J BIOL CHEM, V284, P9974, DOI 10.1074/jbc.M807464200
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929 931.2002
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 39
TC 51
Z9 67
U1 0
U2 33
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 13
PY 2012
VL 109
IS 11
BP 4058
EP 4063
DI 10.1073/pnas.1118215109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 907OH
UT WOS:000301426700015
PM 22392982
OA Green Published
DA 2025 08 17
ER

PT J
AU Alexandrino, EM
   Ritz, S
   Marsico, F
   Baier, G
   Mailänder, V
   Landfester, K
   Wurm, FR
AF Alexandrino, Evandro M.
   Ritz, Sandra
   Marsico, Filippo
   Baier, Grit
   Mailaender, Volker
   Landfester, Katharina
   Wurm, Frederik R.
TI Paclitaxel loaded polyphosphate nanoparticles: a potential strategy for
   bone cancer treatment
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID CALCIUM PHOSPHATE CERAMICS; TARGETED DRUG DELIVERY; IN VITRO; METATHESIS
   POLYMERIZATION; PLGA NANOPARTICLES; CONTROLLED RELEASE; SOFT TISSUE;
   SYSTEMS; DOXORUBICIN; BISPHOSPHONATES
AB While it has been shown that phosphates can target molecules and nanocarriers to bone we herein demonstrate the preparation of polyphosphate nanoparticles loaded with paclitaxel using a simple miniemulsion/solvent evaporation technique as a model for chemotherapeutic delivery. Polyphosphates exhibit much higher structural versatility, relying on the pentavalence of the phosphorus center compared to conventional polyesters. This versatility allows for the development of new degradable polymeric carriers with inherent bone adhesion ability by the interaction of the nanoparticles with a calcium phosphate material used for bone regeneration. The novel polyphosphate nanoparticles were investigated in detail with respect to their size distribution, zeta potential, thermal and morphological properties and were further proven to be efficiently loaded with a hydrophobic drug (up to 15 wt%). The in vitro cytotoxicity was assessed against human cancer cell lines (HeLa and Saos 2), and the paclitaxel loaded nanoparticles showed a similar cytotoxicity profile similar to the commercially available formulation Taxomedac (R) and the pure paclitaxel for loading ratios of 10 wt% but additionally proved efficient adhesion on calcium phosphate granules allowing drug delivery to bone. This first report demonstrates that polyphosphate nanoparticles are promising materials for the development of systemic or local bone cancer treatment, even by direct application or by formation of composites with calcium phosphate cements.
C1 [Alexandrino, Evandro M.; Ritz, Sandra; Marsico, Filippo; Baier, Grit; Mailaender, Volker; Landfester, Katharina; Wurm, Frederik R.] Max Planck Inst Polymer Res, D 55128 Mainz, Germany.
   [Mailaender, Volker] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Med Clin Hematol Oncol & Pulmonol 3, D 55131 Mainz, Germany.
C3 Max Planck Society; Johannes Gutenberg University of Mainz
RP Wurm, FR (通讯作者)，Max Planck Inst Polymer Res, Ackermannweg 10, D 55128 Mainz, Germany.
EM wurm@mpip mainz.mpg.de
RI Wurm, Frederik/A 2522 2010; Mailänder, Volker/H 3589 2012; Wurm,
   Frederik R./A 2522 2010; Landfester, Katharina/F 9449 2011; Mailander,
   Volker/H 3589 2012
OI Wurm, Frederik R./0000 0002 6955 8489; Landfester,
   Katharina/0000 0001 9591 4638; Mailander, Volker/0000 0001 6583 8136
FU International Max Planck Research School (IMPRS); Excellence Initiative
   in the context of the graduate school of excellence "MAINZ" (Materials
   Science in Mainz) [DFG/GSC 266]; Max Planck Graduate Center (MPGC); EU;
   7th EU Framework program REBORNE [HEALTH 2009 1.4 2]
FX E. M. A. thanks the International Max Planck Research School (IMPRS) for
   a fellowship. F. M. is a recipient of a fellowship through funding of
   the Excellence Initiative (DFG/GSC 266) in the context of the graduate
   school of excellence "MAINZ" (Materials Science in Mainz). F. R. W.
   thanks the Max Planck Graduate Center (MPGC) for support. We gratefully
   acknowledge the EU for financing. This study is supported by the 7th EU
   Framework program REBORNE (HEALTH 2009 1.4 2). The authors thank Dr
   Andrey Turshatov for experimental support and Melanie Stichelberger,
   Beate Stradmann Bellinghausen and Carolin Hogl for skillful technical
   assistance. The authors thank Guy Daculsi (BIOMATLANE, France) for the
   kind donation of MBCP+.
CR Anderson P, 2008, EXPERT OPIN INV DRUG, V17, P1703, DOI [10.1517/13543784.17.11.1703, 10.1517/13543784.17.11.1703 ]
   Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Baier G, 2014, NANOMED NANOTECHNOL, V10, P131, DOI 10.1016/j.nano.2013.07.002
   Baier G, 2011, MACROMOL BIOSCI, V11, P628, DOI 10.1002/mabi.201000395
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   BARAN J, 1995, MACROMOLECULES, V28, P5167, DOI 10.1021/ma00119a002
   Brannon Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Cenni E, 2012, J BIOMAT SCI POLYM E, V23, P1285, DOI 10.1163/092050611X580373
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Clohisy DR, 2003, CANCER AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144
   Daculsi G., 2010, Advanced Biomaterials: Fundamentals, Processing, and Applications, pp 101
   Danhier F, 2009, J CONTROL RELEASE, V133, P11, DOI 10.1016/j.jconrel.2008.09.086
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Feng SS, 2004, CURR MED CHEM, V11, P413, DOI 10.2174/0929867043455909
   Fonseca C, 2002, J CONTROL RELEASE, V83, P273, DOI 10.1016/S0168 3659(02)00212 2
   Gauthier O, 1998, BIOMATERIALS, V19, P133, DOI 10.1016/S0142 9612(97)00180 4
   Gauthier O, 2001, J MATER SCI MATER M, V12, P385, DOI 10.1023/A:1011284517429
   Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959 8049(01)00171 X
   Ginebra MP, 2012, ADV DRUG DELIVER REV, V64, P1090, DOI 10.1016/j.addr.2012.01.008
   Hofmann D, 2014, CHEM COMMUN, V50, P1369, DOI 10.1039/c3cc48130a
   Ikeuchi R, 2013, J BIOMED MATER RES A, V101, P318, DOI 10.1002/jbm.a.34321
   Jäger A, 2012, SOFT MATTER, V8, P4343, DOI 10.1039/c2sm07247e
   Jiang XY, 2013, BIOMATERIALS, V34, P1739, DOI 10.1016/j.biomaterials.2012.11.016
   Keedy VL, 2012, ONCOTARGETS THER, V5, P153, DOI 10.2147/OTT.S19055
   Li Q, 2006, BIOMATERIALS, V27, P1027, DOI 10.1016/j.biomaterials.2005.07.019
   Liggins RT, 1997, J PHARM SCI, V86, P1458, DOI 10.1021/js9605226
   López Gasco P, 2011, J MICROENCAPSUL, V28, P417, DOI 10.3109/02652048.2011.576785
   Lopez Heredia MA, 2011, BIOMATERIALS, V32, P5411, DOI 10.1016/j.biomaterials.2011.04.010
   Luo C, 2012, MINI REV MED CHEM, V12, P434, DOI 10.2174/138955712800493924
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Marsico F, 2012, MACROMOLECULES, V45, P8511, DOI 10.1021/ma301508s
   Mu L, 2003, J CONTROL RELEASE, V86, P33, DOI 10.1016/S0168 3659(02)00320 6
   Mu L, 2003, PHARM RES, V20, P1864, DOI 10.1023/B:PHAM.0000003387.15428.42
   Musyanovych A, 2008, MACROMOL BIOSCI, V8, P127, DOI 10.1002/mabi.200700241
   Mutlu H, 2011, CHEM SOC REV, V40, P1404, DOI 10.1039/b924852h
   Özcan I, 2011, J PHARM SCI US, V100, P4877, DOI 10.1002/jps.22678
   Qiu JJ, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/4/044107
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Sauer R, 2012, CHEM EUR J, V18, P5201, DOI 10.1002/chem.201103256
   Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124
   Steinbach T, 2013, POLYM CHEM UK, V4, P3800, DOI 10.1039/c3py00437f
   Tani T, 2006, IN VIVO, V20, P55
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   van de Watering FCJ, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/3/035012
   Wagner RW, 1996, PURE APPL CHEM, V68, P1373, DOI 10.1351/pac199668071373
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097 0142(20000601)88:11<2619::AID CNCR26>3.0.CO;2 J
   Wang YC, 2009, MACROMOL BIOSCI, V9, P1154, DOI 10.1002/mabi.200900253
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
   Zhang SY, 2013, MACROMOLECULES, V46, P5141, DOI 10.1021/ma400675m
   Zhang SY, 2013, CHEM SCI, V4, P2122, DOI 10.1039/c3sc50252j
   Zhang SY, 2012, ACS MACRO LETT, V1, P328, DOI 10.1021/mz200226m
   Zhang SF, 2007, MACROMOL BIOSCI, V7, P656, DOI 10.1002/mabi.200600286
   Zhang ZP, 2013, EXPERT OPIN DRUG DEL, V10, P325, DOI 10.1517/17425247.2013.752354
   Zhang ZX, 2009, BIOCHEM BIOPH RES CO, V379, P557, DOI 10.1016/j.bbrc.2008.12.084
NR 57
TC 48
Z9 52
U1 0
U2 73
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2014
VL 2
IS 10
BP 1298
EP 1306
DI 10.1039/c3tb21295e
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AC0QN
UT WOS:000332199900002
PM 32261444
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Radwan, NH
   Nasr, M
   Ishak, RAH
   Awad, GAS
AF Radwan, Noha H.
   Nasr, Maha
   Ishak, Rania A. H.
   Awad, Gehanne A. S.
TI Moxifloxacin loaded in situ synthesized Bioceramic/Poly
   (L lactide co e caprolactone) composite scaffolds for treatment of
   osteomyelitis and orthopedic regeneration
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Osteomyelitis; Calcium Phosphate; Composites; Scaffolds; Moxifloxacin
   hydrochloride; Poly lactide co e caprolactone
ID RESISTANT STAPHYLOCOCCUS AUREUS; DRUG DELIVERY SYSTEM; BONE TISSUE;
   HYDROXYAPATITE SCAFFOLD; POROUS HYDROXYAPATITE; TRICALCIUM PHOSPHATE;
   VITRO; FABRICATION; POLY(L LACTIDE CO EPSILON CAPROLACTONE); VANCOMYCIN
AB High local intraosseous levels of antimicrobial agents are required for adequate long term treatment of chronic osteomyelitis (OM). In this study, biodegradable composite scaffolds of poly lactide co e caprolactone/calcium phosphate (CaP) were in situ synthesized using two different polymer grades and synthesis pathways and compared to composites prepared by pre formed (commercially available) CaP for delivery of the antibiotic moxifloxacin hydrochloride (MOX). Phase identification and characterization by Fourier transform infra red (FTIR) spectroscopy, X ray powder diffraction (XRPD) and scanning electron microscope (SEM) confirmed the successful formation of different CaP phases within the biodegradable polymer matrix. The selected in situ formed CaP scaffold showed a sustained release for MOX for six weeks and adequate porosity. Cell viability study on MG 63 osteoblast like cells revealed that the selected composite scaffold maintained the cellular proliferation and differentiation. Moreover, it was able to diminish the bacterial load, inflammation and sequestrum formation in the bones of OM induced animals. The results of the present work deduce that the selected in situ formed CaP composite scaffold is a propitious candidate for OM treatment, and further clinical experiments are recommended.
C1 [Radwan, Noha H.; Nasr, Maha; Ishak, Rania A. H.; Awad, Gehanne A. S.] Ain Shams Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo 11566, Egypt.
C3 Egyptian Knowledge Bank (EKB); Ain Shams University
RP Ishak, RAH (通讯作者)，Ain Shams Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo 11566, Egypt.
EM raniaaziz@pharma.asu.edu.eg
RI ; Ishak, Rania/ABG 8009 2021
OI Ishak, Rania/0000 0003 3393 0477; Nasr, Maha/0000 0002 0912 7011; 
CR Agyemang FO, 2015, CERAM INT, V41, P7066, DOI 10.1016/j.ceramint.2015.02.014
   Ahmadi SA, 2019, INT J NANO DIMENS, V10, P169
   Ahola Niina, 2013, Biomatter, V3, DOI 10.4161/biom.23162
   Ahola Niina, 2012, Biomatter, V2, P213, DOI 10.4161/biom.22793
   Akkouch A, 2011, J BIOMED MATER RES A, V96A, P693, DOI 10.1002/jbm.a.33033
   Ambrosio AMA, 2001, J BIOMED MATER RES, V58, P295, DOI 10.1002/1097 4636(2001)58:3<295::AID JBM1020>3.0.CO;2 8
   Ataie M, 2019, J BIOMED MATER RES A, V107, P586, DOI 10.1002/jbm.a.36574
   Bancroft J.D., 1990, THEORY PRACTICE HIST, V3rd
   Bernstein M, 2010, ADV ENG MATER, V12, pB341, DOI 10.1002/adem.201080027
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574 695X.2007.00357.x
   Cao XY, 2019, COATINGS, V9, DOI 10.3390/coatings9050284
   Cao Y, 2020, CERAM INT, V46, P2300, DOI 10.1016/j.ceramint.2019.09.219
   Chehreghanianzabi Y, 2020, J BIOMED MATER RES B, V108, P475, DOI 10.1002/jbm.b.34404
   Chen JP, 2013, COLLOID SURFACE B, V110, P120, DOI 10.1016/j.colsurfb.2013.04.028
   Cheng T, 2018, ARTIF CELL NANOMED B, V46, P1935, DOI 10.1080/21691401.2017.1396997
   Choi D, 2007, MAT SCI ENG C BIO S, V27, P377, DOI 10.1016/j.msec.2006.05.035
   Choi DW, 2004, MATER RES BULL, V39, P417, DOI 10.1016/j.materresbull.2003.10.013
   Dasgupta S, 2019, MAT SCI ENG C MATER, V94, P713, DOI 10.1016/j.msec.2018.10.022
   Dong YX, 2010, TISSUE ENG PT A, V16, P283, DOI 10.1089/ten.tea.2008.0537
   Dorati R, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10040096
   Dziadek M, 2019, J BIOMED MATER RES A, V107, P2479, DOI 10.1002/jbm.a.36754
   Ellington JK, 2003, J BONE JOINT SURG BR, V85B, P918, DOI 10.1302/0301 620X.85B6.13509
   Fernández J, 2012, J MECH BEHAV BIOMED, V9, P100, DOI 10.1016/j.jmbbm.2012.01.003
   Ferrari M, 2019, COLLOID INTERFAC, V3, DOI 10.3390/colloids3020048
   Ferri JM, 2016, J COMPOS MATER, V50, P4189, DOI 10.1177/0021998316636205
   Garkhal K, 2007, J POLYM SCI POL CHEM, V45, P2755, DOI 10.1002/pola.22031
   Gritsch L, 2019, J MATER CHEM B, V7, P6109, DOI 10.1039/c9tb00897g
   Groll ME, 2018, ADV SKIN WOUND CARE, V31, P253, DOI 10.1097/01.ASW.0000532737.64628.2a
   He XC, 2019, INT J BIOL MACROMOL, V137, P45, DOI 10.1016/j.ijbiomac.2019.06.098
   Huang H, 2020, CONSTR BUILD MATER, V242, DOI 10.1016/j.conbuildmat.2019.117221
   Ishaug Riley SL, 1999, BIOMATERIALS, V20, P2245, DOI 10.1016/S0142 9612(99)00155 6
   Jegal SH, 2011, ACTA BIOMATER, V7, P1609, DOI 10.1016/j.actbio.2010.12.003
   Jung Y, 2008, BIOMATERIALS, V29, P4630, DOI 10.1016/j.biomaterials.2008.08.031
   Kalteis T, 2006, ACTA ORTHOP, V77, P315, DOI 10.1080/17453670610046082
   Kanellakopoulou K, 2009, INT J ANTIMICROB AG, V33, P354, DOI 10.1016/j.ijantimicag.2008.09.008
   Kim BS, 2013, J BIOMED MATER RES B, V101, P1302, DOI 10.1002/jbm.b.32943
   Kucko NW, 2020, J MECH BEHAV BIOMED, V109, DOI 10.1016/j.jmbbm.2020.103776
   Kumar GS, 2014, J MATER CHEM B, V2, P5052, DOI 10.1039/c4tb00339j
   Kundu B, 2010, PHARM RES DORDR, V27, P1659, DOI 10.1007/s11095 010 0166 y
   Lim SS, 2019, ADV POLYM TECH, V2019, DOI 10.1155/2019/9679627
   Lin BR, 2017, SURG INFECT, V18, P221, DOI 10.1089/sur.2016.189
   Lin WC, 2019, DENT MATER, V35, P751, DOI 10.1016/j.dental.2019.02.023
   Lu Y, 2016, FIBRES TEXT EAST EUR, V24, P17, DOI 10.5604/12303666.1196607
   Luo J, 2017, ACS APPL MATER INTER, V9, P36392, DOI 10.1021/acsami.7b10159
   Mader JT, 1997, ANTIMICROB AGENTS CH, V41, P415, DOI 10.1128/AAC.41.2.415
   Maheshwari SU, 2014, CERAM INT, V40, P8469, DOI 10.1016/j.ceramint.2014.01.058
   Makarov C, 2014, EUR J PHARM SCI, V62, P49, DOI 10.1016/j.ejps.2014.05.008
   Makarov C, 2010, J MATER SCI MATER M, V21, P1771, DOI 10.1007/s10856 010 4039 z
   Mannisto N. M., 2014, British Microbiology Research Journal, V4, P235
   Masters EA, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0061 z
   Mestres G, 2019, MAT SCI ENG C MATER, V97, P84, DOI 10.1016/j.msec.2018.11.064
   Milovac D, 2014, MAT SCI ENG C MATER, V42, P264, DOI 10.1016/j.msec.2014.05.034
   Miyazaki T, 2009, J PHARM SCI US, V98, P905, DOI 10.1002/jps.21443
   Mostafa AA, 2017, AAPS PHARMSCITECH, V18, P1056, DOI 10.1208/s12249 016 0605 0
   Nasr M, 2011, EUR J PHARM BIOPHARM, V79, P601, DOI 10.1016/j.ejpb.2011.07.010
   Neut D, 2015, EUR CELLS MATER, V29, P42, DOI 10.22203/eCM.v029a04
   Nikcevic I, 2006, MATER TRANS, V47, P2980, DOI 10.2320/matertrans.47.2980
   NORDEN CW, 1970, J INFECT DIS, V122, P410, DOI 10.1093/infdis/122.5.410
   Nurqadar R., 2013, EXPRESS POLYM LETT, P7
   Patrício T, 2013, PROC CIRP, V5, P110, DOI 10.1016/j.procir.2013.01.022
   Peng KT, 2010, BIOMATERIALS, V31, P5227, DOI 10.1016/j.biomaterials.2010.03.027
   Qian M, 2015, CELL BIOCHEM BIOPHYS, V71, P127, DOI 10.1007/s12013 014 0172 5
   Qiao ZW, 2019, ARTIF CELL NANOMED B, V47, P790, DOI 10.1080/21691401.2019.1581792
   Qiu ZY, 2019, WOODH PUBL SER BIOM, P1, DOI 10.1016/B978 0 08 102717 2.00001 1
   Radwan NH, 2020, CARBOHYD POLYM, V244, DOI 10.1016/j.carbpol.2020.116482
   Rafeek A, 2018, J AUST CERAM SOC, V54, P161, DOI 10.1007/s41779 017 0137 4
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Ruiz Aguilar C., 2020, IRBM
   Sahmani S, 2020, CERAM INT, V46, P2447, DOI 10.1016/j.ceramint.2019.09.238
   Said Elbahr R, 2016, EUR J PHARM BIOPHARM, V103, P1, DOI 10.1016/j.ejpb.2016.03.025
   Sang QQ, 2018, J BIOMATER APPL, V32, P1105, DOI 10.1177/0885328217749962
   Sarigol Calamak E, 2018, ADV EXP MED BIOL, V1078, P475, DOI 10.1007/978 981 13 0950 2_25
   Schumacher M, 2017, BIOMATER SCI UK, V5, P578, DOI 10.1039/c6bm00903d
   Smeltzer MS, 1997, J ORTHOPAED RES, V15, P414, DOI 10.1002/jor.1100150314
   Soranoglou V, 2017, INT J ANTIMICROB AG, V50, P186, DOI 10.1016/j.ijantimicag.2017.01.041
   Sukhodub LF, 2004, J MOL STRUCT, V704, P53, DOI 10.1016/j.molstruc.2003.12.061
   Suryawanshi V. B., 2014, Indian Journal of Materials Science, DOI 10.1155/2014/189839
   Vallet Regi M, 1997, SOLID STATE IONICS, V101, P1279, DOI 10.1016/S0167 2738(97)00213 0
   Wang JL, 2006, MACROMOL CHEM PHYS, V207, P554, DOI 10.1002/macp.200500546
   Wei JW, 2019, J BIOMED NANOTECHNOL, V15, P1097, DOI 10.1166/jbn.2019.2743
   Xidaki D, 2018, MATERIALS, V11, DOI 10.3390/ma11040595
   Xie J, 2006, TISSUE ENG, V12, P449, DOI 10.1089/ten.2006.12.449
   Xu Y, 2013, TISSUE ENG PART C ME, V19, P925, DOI [10.1089/ten.tec.2012.0328, 10.1089/ten.TEC.2012.0328]
   Yan L, 2015, DRUG DES DEV THER, V9, P3665, DOI 10.2147/DDDT.S84486
   Yu K, 2020, BONE JOINT RES, V9, P49, DOI 10.1302/2046 3758.92.BJR 2019 0131.R1
   Zambanini T., 2019, Biomedical, Therapeutic and Clinical Applications of Bioactive Glasses, P383
   Zhou J, 2018, BONE JOINT RES, V7, P46, DOI 10.1302/2046 3758.71.BJR 2017 0129.R2
NR 88
TC 14
Z9 14
U1 2
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUN 1
PY 2021
VL 602
AR 120662
DI 10.1016/j.ijpharm.2021.120662
EA MAY 2021
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SM4TQ
UT WOS:000657600400001
PM 33933641
DA 2025 08 17
ER

PT J
AU Morales Santana, S
   Díez Pérez, A
   Olmos, JM
   Nogués, X
   Sosa, M
   Díaz Curiel, M
   Pérez Castrillón, JL
   Pérez Cano, R
   Torrijos, A
   Jodar, E
   Del Rio, L
   Caeiro Rey, JR
   Reyes García, R
   García Fontana, B
   González Macías, J
   Muñoz Torres, M
AF Morales Santana, Sonia
   Diez Perez, Adolfo
   Olmos, Jose M.
   Nogues, Xavier
   Sosa, Manuel
   Diaz Curiel, Manuel
   Perez Castrillon, Jose L.
   Perez Cano, Ramon
   Torrijos, Antonio
   Jodar, Esteban
   Del Rio, Luis
   Caeiro Rey, Jose R.
   Reyes Garcia, Rebeca
   Garcia Fontana, Beatriz
   Gonzalez Macias, Jesus
   Munoz Torres, Manuel
TI Circulating sclerostin and estradiol levels are associated with
   inadequate response to bisphosphonates in postmenopausal women with
   osteoporosis
SO MATURITAS
LA English
DT Article
DE Postmenopausal osteoporosis; Fracture risk; Inadequate responders;
   Bisphosphonates; Sclerostin
ID VAN BUCHEM DISEASE; SERUM SCLEROSTIN; BONE FORMATION; ELDERLY WOMEN; HIP
   FRACTURE; RISK FACTORS; SOST; PREDICTION; TURNOVER; HORMONES
AB Introduction: The biological mechanisms associated with an inadequate response to treatment with bisphosphonates are not well known. This study investigates the association between circulating levels of sclerostin and estradiol with an inadequate clinical outcome to bisphosphonate therapy in women with postmenopausal osteoporosis.
   Methods: This case control study is based on 120 Spanish women with postmenopausal osteoporosis being treated with oral bisphosphonates. Patients were classified as adequate responders (ARs, n = 66, mean age 68.2 +/  8 years) without incident fractures during 5 years of treatment, or inadequate responders (IRs, n = 54, mean age 67 +/  9 years), with incident fractures between Ti and 5 years of treatment. Bone mineral density (DXA), structural analysis of the proximal femur and structural/fractal analysis of the distal radius were assessed. Sclerostin concentrations were measured by ELISA and 17 beta estradiol levels by radioimmunoassay based on ultrasensitive methods.
   Results: In the ARs group, sclerostin serum levels were significantly lower (p = 0.02) and estradiol concentrations significantly higher (p = 0.023) than in the IRs group. A logistic regression analysis was performed, including as independent variables in the original model femoral fracture load, 25 hydroxyvitamin D, previus history of fragility fracture, sclerostin and estradiol. Only previous history of fragility fracture (OR 14.04,95% CI 2.38 82.79, p = 0.004) and sclerostin levels (OR 1.11,95% Cl 1.02 1.20, p = 0.011), both adjusted by estradiol levels remained associated with IRs. Also, sclerostin concentrations were associated with the index of resistance to compression (IRC) in the fractal analysis of the distal radius, a parameter on bone microstructure.
   Conclusions: Sclerostin and estradiol levels are associated with the response to bisphosphonate therapy in women with postmenopausal osteoporosis. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Morales Santana, Sonia; Reyes Garcia, Rebeca; Garcia Fontana, Beatriz; Munoz Torres, Manuel] Hosp Univ San Cecilio, Endocrinol Div RETICEF, Bone Metab Unit, Inst Invest Biosanitaria Ibs GRANADA, Granada 18012, Spain.
   [Morales Santana, Sonia; Diez Perez, Adolfo; Olmos, Jose M.; Nogues, Xavier; Diaz Curiel, Manuel; Perez Castrillon, Jose L.; Perez Cano, Ramon; Torrijos, Antonio; Jodar, Esteban; Del Rio, Luis; Caeiro Rey, Jose R.; Reyes Garcia, Rebeca; Garcia Fontana, Beatriz; Gonzalez Macias, Jesus; Munoz Torres, Manuel] Inst Salud Carlos III, RETICEF, Madrid, Spain.
   [Morales Santana, Sonia] Hosp Univ San Cecilio, Prote Res Serv, Inst Invest Biosanitaria Granada Ibs GRANADA, Granada 18012, Spain.
   [Diez Perez, Adolfo; Nogues, Xavier] Hosp del Mar, IMIM, UAB, Dept Internal Med, Barcelona, Spain.
   [Olmos, Jose M.; Gonzalez Macias, Jesus] Hosp Univ Marques Valdecilla, Dept Internal Med, Santander, Spain.
   [Sosa, Manuel] Univ Las Palmas Gran Canaria, Osteoporosis Res Grp, Las Palmas Gran Canaria, Spain.
   [Diaz Curiel, Manuel] Fdn Jimenez Diaz, Dept Internal Med, E 28040 Madrid, Spain.
   [Perez Castrillon, Jose L.] Hosp Univ Rio Ortega, Dept Internal Med, Valladolid, Spain.
   [Perez Cano, Ramon] Hosp Virgen Macarena, Dept Internal Med, Seville, Spain.
   [Torrijos, Antonio] Hosp La Paz, Dept Rheumatol, Madrid, Spain.
   [Jodar, Esteban] Hosp Univ Quiron, Dept Endocrinol, Madrid, Spain.
   [Del Rio, Luis] CETIR Med Ctr, Barcelona, Spain.
   [Caeiro Rey, Jose R.] Trabeculae, Orense, Spain.
C3 Instituto de Investigacion Biosanitaria IBS Granada; Hospital
   Universitario San Cecilio; Instituto de Salud Carlos III; Hospital
   Universitario San Cecilio; Instituto de Investigacion Biosanitaria IBS
   Granada; Hospital del Mar Research Institute; Hospital del Mar;
   Autonomous University of Barcelona; Hospital Universitario Marques de
   Valdecilla (HUMV); Universidad de Las Palmas de Gran Canaria; Hospital
   Universitario Virgen Macarena; Hospital Universitario La Paz
RP Muñoz Torres, M (通讯作者)，Hosp Univ San Cecilio, Div Endocrinol, Bone Metab Unit, Ave Dr Oloriz 16, Granada 18012, Spain.
EM mmt@mamuto.es
RI Fontana, Cristina/L 8184 2014; Del Rio, Luis/H 3037 2016;
   Morales Santana, Sonia/ABG 8889 2020; Torres, Manuel/O 2330 2016;
   Sosa Henríquez, Manuel/MZQ 4015 2025; Perez Castrillon,
   Jose Luis/AGI 1029 2022; Munoz Torres, Manuel/O 2330 2016; Reyes,
   Rebeca/LPQ 9210 2024
OI Garcia Fontana, Beatriz/0000 0002 4134 5561; Morales Santana,
   Sonia/0000 0001 8403 2496; Nogues, Xavier/0000 0002 5537 1859;
   Diez Perez, Adolfo/0000 0001 8162 0209; Nogues,
   Xavier/0000 0001 8201 9933; Olmos, Jose M./0000 0002 7765 0891;
   Sosa Henriquez, Manuel/0000 0001 6845 2933; Diaz Curiel,
   Manuel/0000 0002 7762 9398; Munoz Torres, Manuel/0000 0002 9645 3260;
   Reyes Garcia, Rebeca/0000 0003 1729 4431; 
FU Consejeria de Salud y Bienestar Social, Junta de Andalucia
   [PI 0514 2012]; Red Tematica de Investigacion Cooperativa en
   Envejecimiento y Fragilidad (RETICEF) of the Instituto Carlos III,
   Spanish Ministry of Economy and Competitiveness
   [RD06/0013/1014 RD12/0043/0014]
FX The study was supported by grants from the Consejeria de Salud y
   Bienestar Social, Junta de Andalucia (PI 0514 2012) and by the Red
   Tematica de Investigacion Cooperativa en Envejecimiento y Fragilidad
   (RETICEF) of the Instituto Carlos III, Spanish Ministry of Economy and
   Competitiveness (RD06/0013/1014 RD12/0043/0014), Plan Nacional de I + D
   +I2008 2011/Plan Estatal de I + D +I 2013 2016.
CR Arasu A, 2012, J CLIN ENDOCR METAB, V97, P2027, DOI 10.1210/jc.2011 3419
   Ardawi MSM, 2012, J BONE MINER RES, V27, P2592, DOI 10.1002/jbmr.1718
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225
   Boonen S, 2009, INT J CLIN PRACT, V63, P1792, DOI 10.1111/j.1742 1241.2009.02206.x
   Chapurlat RD, 2000, J BONE MINER RES, V15, P1835, DOI 10.1359/jbmr.2000.15.9.1835
   Chung Y.E., 2011, OSTEOPOROS INT
   Costa AG, 2013, J CLIN ENDOCR METAB, V98, P4736, DOI 10.1210/jc.2013 2106
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Devine A, 2005, OSTEOPOROSIS INT, V16, P216, DOI 10.1007/s00198 004 1674 6
   Díez Pérez A, 2008, OSTEOPOROSIS INT, V19, P1511, DOI 10.1007/s00198 008 0659 2
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Díez Pérez A, 2012, J BONE MINER RES, V27, P817, DOI 10.1002/jbmr.1496
   Finigan J, 2012, CALCIFIED TISSUE INT, V91, P59, DOI 10.1007/s00223 012 9611 8
   Garnero P, 2013, OSTEOPOROSIS INT, V24, P489, DOI 10.1007/s00198 012 1978 x
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Hampson G, 2013, BONE, V56, P42, DOI 10.1016/j.bone.2013.05.010
   Hernández JL, 2004, CALCIFIED TISSUE INT, V74, P357, DOI 10.1007/s00223 003 0158 6
   Huang QY, 2009, BONE, V45, P289, DOI 10.1016/j.bone.2009.03.676
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Kirmani S, 2011, OSTEOPOROS INT
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   McClung MR, 2014, N ENGL J MED
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650 198601000 00007
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Szulc P, 2013, J BONE MINER RES, V28, P1760, DOI 10.1002/jbmr.1888
   Thorson S, 2013, J BONE MINER RES, V28, P2008, DOI 10.1002/jbmr.1929
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Van Hul W, 1998, AM J HUM GENET, V62, P391, DOI 10.1086/301721
   Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011 1050
NR 43
TC 6
Z9 7
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 5122
EI 1873 4111
J9 MATURITAS
JI Maturitas
PD DEC
PY 2015
VL 82
IS 4
BP 402
EP 410
DI 10.1016/j.maturitas.2015.08.007
PG 9
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA CY0DI
UT WOS:000366076100013
PM 26358930
DA 2025 08 17
ER

PT J
AU Rajamannan, NM
AF Rajamannan, Nalini M.
TI Update on the pathophysiology of aortic stenosis
SO EUROPEAN HEART JOURNAL SUPPLEMENTS
LA English
DT Article; Proceedings Paper
CT Satellite Symposium on Hot Topics in Aortic Stenosis held at the
   EUROECHO 2007
CY DEC 06, 2007
CL Lisbon, PORTUGAL
SP Sci Comm Simvastatin & Ezetimibe Aort Stenosis Study
DE aortic valve stenosis; pathophysiology; atherosclerosis; calcification;
   endothelial dysfunction
ID BASE LINE CHARACTERISTICS; VALVE CALCIFICATION; RANDOMIZED TRIAL;
   RISK FACTORS; PROGRESSION; HYPERCHOLESTEROLEMIA; ASSOCIATION;
   GUIDELINES; MANAGEMENT; DISEASE
AB The objective of this review is to explain the basis for the current appreciation of the role of active atherosclerotic and bone forming processes in the pathophysiology of calcific aortic stenosis (AS). Relevant epidemiological, histopathological, and experimental studies are reviewed. Calcific AS and atherosclerosis share similar risk factors, including elevated LDL cholesterol levels, hypertension, mate gender, smoking, and diabetes mellitus. Both atherosclerosis and calcific AS often occur in individuals with familial hypercholesterolaemia, and elderly patients with AS are also at an increased risk of myocardial infarction and death from cardiovascular causes. Lipoprotein deposition is prominent in both conditions. Aortic valve mineralisation occurs as the result of mechanisms similar to those active in bone formation, including upregulation of the Lrp5 pathway and the presence of an osteoblast phenotype in calcified valves. An active atherosclerosis type pathophysiology involving oxidative stress, inflammation, and endothelial dysfunction in aortic valves has been induced by hypercholesterolaemia, and inhibited by administering HMG CoA reductase inhibitors (statins), in animal models. Evidence of endothelial dysfunction with neovascularisation and an increase in endothelial macrophages and metalloproteinases has been found in surgically excised human valves with calcific AS. The initiating factors and pathophysiology of calcific AS are broadly similar to those of atherosclerosis of coronary and other arteries. The sclerosis and calcification of aortic valves may therefore be addressed with pharmacological therapies that are effective in stowing or reversing atherosclerosis.
C1 Northwestern Univ, Feinberg Sch Med, Bluhm Cardiovasc Inst, Div Cardiol,Dept Pathol, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Rajamannan, NM (通讯作者)，Northwestern Univ, Feinberg Sch Med, Bluhm Cardiovasc Inst, Div Cardiol,Dept Pathol, 300 E Chicago Ave,Tarry 12 717, Chicago, IL 60611 USA.
EM n rajamannan@northwestern.edu
CR Aronow WS, 2001, AM J CARDIOL, V88, P693, DOI 10.1016/S0002 9149(01)01821 5
   Bonow RO, 2006, CIRCULATION, V114, pE84, DOI 10.1161/CIRCULATIONAHA.106.176857
   Caira FC, 2006, J AM COLL CARDIOL, V47, P1707, DOI 10.1016/j.jacc.2006.02.040
   Chan KL, 2007, AM HEART J, V153, P925, DOI 10.1016/j.ahj.2007.03.011
   Charest A, 2006, HEART, V92, P1844, DOI 10.1136/hrt.2005.086595
   Chui MCK, 2001, CLIN CARDIOL, V24, P52, DOI 10.1002/clc.4960240109
   Cleeman JI, 2001, JAMA J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   *CLEV CLIN, 2008, EFF STAT THER AT PRO
   Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876
   Mohler ER, 1997, ARTERIOSCL THROM VAS, V17, P547, DOI 10.1161/01.ATV.17.3.547
   Moura LM, 2007, J AM COLL CARDIOL, V49, P554, DOI 10.1016/j.jacc.2006.07.072
   OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523
   Otto CM, 1999, NEW ENGL J MED, V341, P142, DOI 10.1056/NEJM199907153410302
   Palta S, 2000, CIRCULATION, V101, P2497, DOI 10.1161/01.CIR.101.21.2497
   Peltier M, 2003, AM J CARDIOL, V91, P97, DOI 10.1016/S0002 9149(02)03010 2
   Pohle K, 2001, CIRCULATION, V104, P1927, DOI 10.1161/hc4101.097527
   Rajamannan NM, 2007, NAT CLIN PRACT CARD, V4, P254, DOI 10.1038/ncpcardio0827
   Rajamannan NM, 2005, CIRCULATION, V112, pI229, DOI 10.1161/01.CIRCULATIONAHA.104.524306
   Rajamannan NM, 2005, HEART, V91, P806, DOI 10.1136/hrt.2003.029785
   Rajamannan NM, 2003, NEW ENGL J MED, V349, P717, DOI 10.1056/NEJMc031360
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rajamannan NM, 2001, J HEART VALVE DIS, V10, P371
   Rajamannan NM, 2002, CIRCULATION, V105, P2660, DOI 10.1161/01.CIR.0000017435.87463.72
   Ross J Jr, 1968, Circulation, V38, P61
   Rossebo AB, 2007, AM J CARDIOL, V99, P970, DOI 10.1016/j.amjcard.2006.10.064
   *SOC THOR SURG, 2007, AD CV SURG NAT DAT
   SPRECHER DL, 1984, AM J CARDIOL, V54, P20, DOI 10.1016/0002 9149(84)90298 4
   Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735 1097(96)00563 3
   Vahanian A, 2007, EUR HEART J, V28, P230, DOI 10.1093/eurheartj/ehl428
   Weiss RM, 2006, CIRCULATION, V114, P2065, DOI 10.1161/CIRCULATIONAHA.106.634139
NR 30
TC 10
Z9 11
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1520 765X
EI 1554 2815
J9 EUR HEART J SUPPL
JI Eur. Heart J. Suppl.
PD JUL
PY 2008
VL 10
IS E
BP E4
EP E10
DI 10.1093/eurheartj/sun013
PG 7
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Cardiovascular System & Cardiology
GA 327UQ
UT WOS:000257754400003
OA Bronze
DA 2025 08 17
ER

PT J
AU Canal, C
   Fontelo, R
   Hamouda, I
   Guillem Marti, J
   Cvelbar, U
   Ginebra, MP
AF Canal, Cristina
   Fontelo, Raul
   Hamouda, Ines
   Guillem Marti, Jordi
   Cvelbar, Uros
   Ginebra, Maria Pau
TI Plasma induced selectivity in bone cancer cells death
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Atmospheric pressure plasma jet; Bone cancer; Osteosarcoma; Osteoblasts;
   SaOS 2; hMSC; HOb; Liquids
ID ATMOSPHERIC PRESSURE PLASMA
AB Background: Current therapies for bone cancers   either primary or metastatic   are difficult to implement and unfortunately not completely effective. An alternative therapy could be found in cold plasmas generated at atmospheric pressure which have already demonstrated selective anti tumor action in a number of carcinomas and in more relatively rare brain tumors. However, its effects on bone cancer are still unknown.
   Methods: Herein, we employed an atmospheric pressure plasma jet (APPJ) to validate its selectivity towards osteosarcoma cell line vs. osteoblasts & human mesenchymal stem cells.
   Results: Cytotoxicity following direct interaction of APPJ with cells is comparable to indirect interaction when only liquid medium is treated and subsequently added to the cells, especially on the long term (72 h of cell culture). Moreover, following contact of the APPJ treated medium with cells, delayed effects are observed which lead to 100% bone cancer cell death through apoptosis (decreased cell viability with incubation time in contact with APPJ treated medium from 24 h to 72 h), while healthy cells remain fully viable and unaffected by the treatment.
   Conclusions: The high efficiency of the indirect treatment indicates that an important role is played by the reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the gaseous plasma stage and then transmitted to the liquid phase, which overall lead to lethal and selective action towards osteosarcoma cells. These findings open new pathways for treatment of metastatic bone disease with a minimally invasive approach.
C1 [Canal, Cristina; Fontelo, Raul; Hamouda, Ines; Guillem Marti, Jordi; Ginebra, Maria Pau] Tech Univ Catalonia UPC, Dept Mat Sci & Met, Biomat Biomech & Tissue Engn Grp, C Eduard Maristany 10 14, Barcelona 08019, Spain.
   [Canal, Cristina; Guillem Marti, Jordi; Ginebra, Maria Pau] Univ Politecn Cataluna, Barcelona Res Ctr Multiscale Sci & Engn, Barcelona, Spain.
   [Cvelbar, Uros] Jozef Stefan Inst, Dept Surface Engn & Optoelect F4, Jamova Cesta 39, Ljubljana 1000, Slovenia.
   [Ginebra, Maria Pau] Inst Bioengn Catalonia, C Baldiri i Reixach 10 12, Barcelona 08028, Spain.
C3 Universitat Politecnica de Catalunya; Universitat Politecnica de
   Catalunya; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan
   Institute; Barcelona Institute of Science & Technology; Institut de
   Bioenginyeria de Catalunya; University of Barcelona
RP Canal, C (通讯作者)，Tech Univ Catalonia UPC, Dept Mat Sci & Met, Biomat Biomech & Tissue Engn Grp, C Eduard Maristany 10 14, Barcelona 08019, Spain.
EM cristina.canal@upc.edu
RI ; Canal, Cristina/AGJ 6002 2022; Hamouda, Ines/IYJ 7378 2023; Ginebra,
   Maria Pau/J 8149 2017; Guillem Marti, Jordi/G 8411 2015; Rodríguez,
   Raúl/AAB 5429 2020; Cvelbar, Uros/AAE 7916 2019
OI Fontelo Rodriguez, Raul/0000 0002 0451 7862; Ginebra,
   Maria Pau/0000 0002 4700 5621; Canal, Cristina/0000 0002 3039 7462;
   Guillem Marti, Jordi/0000 0003 0307 2221; Hamouda,
   Ines/0000 0002 9842 4287; Cvelbar, Uros/0000 0002 1957 0789; 
FU COST Action [TD1208]; MINECO/FEDER, EU [MAT2015 65601 R]; European
   Research Council (ERC) under the European Union's Horizon research and
   innovation programme [714793]; MINECO; AGAUR of the Government of
   Catalonia [2014 PDJR 00014]; ICREA Academia Award for excellence in
   research   Generalitat de Catalunya; NATO Grant [SPS.984555]; Slovenian
   Research Agency (ARRS);  [SGR2014 01333]
FX Authors acknowledge the financial support of the COST Action TD1208, of
   MAT2015 65601 R project (MINECO/FEDER, EU) and of SGR2014 01333. This
   project has received funding from the European Research Council (ERC)
   under the European Union's Horizon 2020 research and innovation
   programme (Grant agreement No 714793). CC acknowledges MINECO for the
   Ramon y Cajal fellowship. JGM thanks the support of the AGAUR of the
   Government of Catalonia (2014 PDJR 00014). Support for the research of
   MPG was received through the ICREA Academia Award for excellence in
   research, funded by the Generalitat de Catalunya. UC acknowledges
   financial support from NATO Grant SPS.984555 and Slovenian Research
   Agency (ARRS). L. Thevenart is acknowledged for technical support.
CR Adachi T, 2015, FREE RADICAL BIO MED, V79, P28, DOI 10.1016/j.freeradbiomed.2014.11.014
   Ahn HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028154
   [Anonymous], 2016, Cancer Facts Fig, V2016, P1, DOI DOI 10.1097/01.NNR.0000289503.22414.79
   Graham WG, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022 3727/44/17/174037
   Graves D. B., 2014, PLASMA PROCESS POLYM, P1
   Graves DB, 2014, CLIN PLASMA MED, V2, P38, DOI 10.1016/j.cpme.2014.11.001
   Häcker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193
   Hattori N, 2015, INT J ONCOL, V47, P1655, DOI 10.3892/ijo.2015.3149
   Hori M., 2015, AntiCancer Agent, and METHODA FOR PRODUCING said aueous solutions ans said anti cancer Agent, Patent No. 20150030693
   Lu X., 2016, PHYS REP
   Lukes P, 2005, J PHYS D APPL PHYS, V38, P4074, DOI 10.1088/0022 3727/38/22/010
   Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558
   Oehmigen K, 2010, PLASMA PROCESS POLYM, V7, P250, DOI 10.1002/ppap.200900077
   Park SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129931
   Ratovitski EA, 2014, PLASMA PROCESS POLYM, V11, P1128, DOI 10.1002/ppap.201400071
   Rumbach P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8248
   Schlegel J., 2013, PLASMA CANC TREAT, V1, P2
   Schmidt A, 2015, CLIN PLASMA MED, V3, P24, DOI 10.1016/j.cpme.2015.05.003
   Soares PIP, 2016, CARBOHYD POLYM, V147, P304, DOI 10.1016/j.carbpol.2016.03.028
   Tanaka H., 2011, PLASMA MED, V1, P265, DOI DOI 10.1615/PLASMAMED.2012006275
   Tanaka H., 2012, PLASMA MED, V2, P207, DOI [DOI 10.1615/PLASMAMED.2013008267, 10.1615/PlasmaMed.2013008267]
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Torii K, 2015, GASTRIC CANCER, V18, P635, DOI 10.1007/s10120 014 0395 6
   Utsumi F, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 398
   Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576
   Van Driel M., 2016, CANC BONE COMPLEX CO, V561, P159
   Vandamme M, 2012, INT J CANCER, V130, P2185, DOI 10.1002/ijc.26252
   Wende K, 2014, PLASMA PROCESS POLYM, V11, P655, DOI 10.1002/ppap.201300172
   Wende K, 2014, CELL BIOL INT, V38, P412, DOI 10.1002/cbin.10200
   Wiseman H., 1996, Nitric Oxide, V29, P17
   Zaplotnik R, 2015, SPECTROCHIM ACTA B, V103, P124, DOI 10.1016/j.sab.2014.12.004
   Zou J, 2010, ARCH MED RES, V41, P162, DOI 10.1016/j.arcmed.2010.04.006
NR 32
TC 86
Z9 88
U1 1
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD SEP
PY 2017
VL 110
BP 72
EP 80
DI 10.1016/j.freeradbiomed.2017.05.023
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA FB3NK
UT WOS:000406049200008
PM 28571751
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Shih, HY
   Lu, JH
   Xiong, AH
   Tse, JMW
   Wong, BST
AF Shih, Hui Yuan
   Lu, Jun Hua
   Xiong, Ai Hua
   Tse, Juliana Man Wai
   Wong, Ben Siu Tak
TI Topical application of the plant extract SDTL E in ovariectomized rats:
   A potential new approach for treating osteoporosis
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE ovariectomy (OVX); calcium; trabecular bone; bone strength; estradiol;
   plant extract; topical application; osteoporosis
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; URINARY
   CALCIUM; TRABECULAR BONE; ESTROGEN; STRENGTH; SERUM; ALENDRONATE;
   PREVENTION
AB Current osteoporosis medications have drawbacks of causing side effects and having slow onset, therefore developing osteoporosis drugs with faster onset and less side effects is essential. This study investigated the effects of the natural plant extract, SDTL E, in ovariectomized (OVX) induced osteoporosis rats. Rats were randomly assigned to sham operation control group (Control Group); OVX rat model group (Model Group) or OVX rat SDTL E treatment group (SDTL E Group). All groups underwent ovariectomy, but the Control Group did not have the ovaries removed. SDTL E Group was treated with SDTL E, Model and Control Groups were treated with vegetable oil, treatments were topically applied twice daily for 20 days. Results showed when compared with Model Group, SDTL E Group significantly restored serum estradiol back to near Control Group level, serum ALP activity, serum and urinary calcium were significantly decreased, bone mechanics indicators increased and trabecular bone numbers slightly increased. These results demonstrated 20 days of SDTL E topical treatment improved bone strength and trabecular bone structure in OVX induced osteoporosis rats. The underlying mechanisms include restoring estradiol level, reducing bone turnover, net bone resorption, bone calcium loss, and calcium excretion through kidney. These findings suggest topical application of plant extract is a potential new approach with quick efficacy for treating osteoporosis.
C1 [Shih, Hui Yuan] Hong Kong Small Biomol Lab, Hong Kong, Peoples R China.
   [Lu, Jun Hua] Jinan Univ, Coll Pharm, Dept Pharmacol, Guangzhou, Peoples R China.
   [Xiong, Ai Hua] Jinan Univ, Coll Pharm, Lab Tech Teaching Ctr, Hong Kong, Peoples R China.
   [Tse, Juliana Man Wai; Wong, Ben Siu Tak] SDTL Reborntech Co Ltd, Hong Kong, Peoples R China.
C3 Jinan University
RP Wong, BST (通讯作者)，SDTL Reborntech Co Ltd, Hong Kong, Peoples R China.
EM ben.wong@life720.com
CR Abou Ismail MY, 2020, THROMB RES, V192, P40, DOI 10.1016/j.thromres.2020.05.008
   Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w
   Ammann P, 2003, OSTEOPOROSIS INT, V14, pS13, DOI 10.1007/s00198 002 1345 4
   Antoniucci DM, 2007, J CLIN ENDOCR METAB, V92, P942, DOI 10.1210/jc.2006 1788
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Chapurlat RD, 2016, RHEUMATOLOGY, V55, P1714, DOI 10.1093/rheumatology/kev410
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cranney A, 2006, CAN MED ASSOC J, V175, P52, DOI 10.1503/cmaj.050929
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dalemo S, 2018, SCAND J PRIM HEALTH, V36, P198, DOI 10.1080/02813432.2018.1459430
   Folwarczna J, 2007, PHARMACOL REP, V59, P349
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Greco EA, 2015, THER ADV ENDOCRINOL, V6, P273, DOI 10.1177/2042018815611004
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Hart NH, 2017, J MUSCULOSKEL NEURON, V17, P114
   Houillier P, 2006, NEPHROL DIAL TRANSPL, V21, P29, DOI 10.1093/ndt/gfi268
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim B, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8080306
   Kim HL, 2011, YONSEI MED J, V52, P739, DOI 10.3349/ymj.2011.52.5.739
   Kim SY, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18168598
   Lee J, 2013, ENDOCRINOL METAB, V28, P180, DOI 10.3803/EnM.2013.28.3.180
   Leeners B, 2017, HUM REPROD UPDATE, V23, P300, DOI 10.1093/humupd/dmw045
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Maddukuri Vinaya C, 2014, Clin Liver Dis (Hoboken), V4, P1, DOI 10.1002/cld.364
   Melton LJ, 2013, OSTEOPOROSIS INT, V24, P1689, DOI 10.1007/s00198 012 2225 1
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Müller FC, 2021, EUR J RADIOL, V139, DOI 10.1016/j.ejrad.2021.109725
   Nakada D, 2014, NATURE, V505, P555, DOI 10.1038/nature12932
   Nelson LR, 2001, J AM ACAD DERMATOL, V45, pS116, DOI 10.1067/mjd.2001.117432
   Nombela Arrieta C, 2017, BLOOD ADV, V1, P407, DOI 10.1182/bloodadvances.2016003194
   Rull MAOH, 2015, CUAJ CAN UROL ASSOC, V9, pE183, DOI 10.5489/cuaj.2695
   Osterhoff G, 2016, INJURY, V47, pS11, DOI 10.1016/S0020 1383(16)47003 8
   Ott SM, 2018, AM J NEPHROL, V47, P373, DOI 10.1159/000489672
   Özsahin ET, 2017, TURK J PH MED REHAB, V63, P165, DOI 10.5606/tftrd.2017.164
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960 0760(03)00360 1
   Singh Vibha, 2017, Natl J Maxillofac Surg, V8, P4, DOI 10.4103/0975 5950.208972
   Tavani A, 1999, DRUG AGING, V14, P347, DOI 10.2165/00002512 199914050 00003
   Teng YR, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.925707
   Torgerson D J, 2001, BMC Musculoskelet Disord, V2, P7, DOI 10.1186/1471 2474 2 7
   Tu Kristie N, 2018, P T, V43, P92
   Wang SP, 2022, BIOMED ENG ONLINE, V21, DOI 10.1186/s12938 022 00978 9
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
NR 48
TC 2
Z9 2
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD OCT 20
PY 2022
VL 9
AR 988235
DI 10.3389/fmed.2022.988235
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 5Y7GU
UT WOS:000879450000001
PM 36341259
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pountos, I
   Panteli, M
   Panagiotopoulos, E
   Jones, E
   Giannoudis, PV
AF Pountos, Ippokratis
   Panteli, Michalis
   Panagiotopoulos, Elias
   Jones, Elena
   Giannoudis, Peter V.
TI Can we enhance fracture vascularity: What is the evidence?
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Mesenchymal stem cells; Bone healing; Angiogenesis
ID ENDOTHELIAL GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL
   STEM CELLS; PLATELET RICH PLASMA; VEGF GENE TRANSFER; DISTRACTION
   OSTEOGENESIS; SEGMENTAL DEFECT; ANGIOPOIETIN 1; OSTEOBLAST
   DIFFERENTIATION; SYNERGISTIC ENHANCEMENT
AB Angiogenesis is a vital component of bone healing. The formation of the new blood vessels at the fracture site restores the hypoxia and nutrient deprivation found at the early stages after fracture whilst at a later stage facilitates osteogenesis by the activity of the osteoprogenitor cells. Emerging evidence suggests that there are certain molecules and gene therapies that could promote new blood vessel formation and as a consequence enhance the local bone healing response. This article summarizes the current in vivo evidence on therapeutic approaches aiming at the augmentation of the angiogenic signalling during bone repair. (C) 2014 Published by Elsevier Ltd.
C1 [Pountos, Ippokratis; Panteli, Michalis; Giannoudis, Peter V.] Univ Leeds, Sch Med, Acad Dept Trauma & Orthopaed, Leeds LS2 9JT, W Yorkshire, England.
   [Panagiotopoulos, Elias] Univ Patras, Sch Med, Acad Dept Trauma & Orthopaed, GR 26110 Patras, Greece.
   [Jones, Elena] Univ Leeds, Sect Musculoskeletal Dis, LIMM, Leeds LS2 9JT, W Yorkshire, England.
C3 University of Leeds; University of Patras; University of Leeds
RP Giannoudis, PV (通讯作者)，Leeds Gen Infirm, Acad Dept Trauma & Orthopaed, Clarendon Wing Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England.
EM pgiannoudi@aol.com
RI Giannoudis, Peter/AAA 3617 2020; Jones, Elena/AAL 2818 2021;
   Panagiotopoulos, Elias/Z 2081 2018; Pountos, Ippokratis/AAB 5697 2019
OI Panteli, Michalis/0000 0002 0905 1432; Pountos,
   Ippokratis/0000 0002 0050 5151; Jones, Elena/0000 0001 9365 2283
CR Abreu Fernando Antonio Mauad de, 2013, Braz. Dent. J., V24, P299, DOI 10.1590/0103 6440201302238
   Akiyama I, 2014, REPROD SCI, V21, P477, DOI 10.1177/1933719113503411
   Amir LR, 2007, CELL TISSUE RES, V330, P35, DOI 10.1007/s00441 007 0448 9
   Andreshak JL, 1997, ANAT RECORD, V248, P198, DOI 10.1002/(SICI)1097 0185(199706)248:2<198::AID AR6>3.0.CO;2 P
   Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S
   Bland YS, 1995, ACTA ORTHOP SCAND, V66, P543, DOI 10.3109/17453679509002313
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V110, P139, DOI 10.1097/00006534 200207000 00025
   Calori GM, 2013, INJURY, V44, pS63, DOI 10.1016/S0020 1383(13)70015 9
   Cao K, 2009, CHIN J TRAUMATOL, V12, P269, DOI 10.3760/cma.j.issn.1008 1275.2009.05.003
   Carmeliet P, 2005, ONCOLOGY BASEL, V69, P4, DOI 10.1159/000088478
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603 653
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774 004 0487 6
   Claes L, 2003, LANGENBECK ARCH SURG, V388, P316, DOI 10.1007/s00423 003 0396 0
   Clarkin CE, 2013, CELL BIOCHEM FUNCT, V31, P1, DOI 10.1002/cbf.2911
   Colnot C, 2004, DEV BIOL, V269, P55, DOI 10.1016/j.ydbio.2004.01.011
   Copuroglu C, 2013, INJURY, V44, P1379, DOI 10.1016/j.injury.2013.08.003
   Cui FA, 2010, GROWTH FACTORS, V28, P306, DOI 10.3109/08977194.2010.484423
   Dai J, 2008, ANGLE ORTHOD, V78, P89, DOI 10.2319/102606 441.1
   David L, 2009, CYTOKINE GROWTH F R, V20, P203, DOI 10.1016/j.cytogfr.2009.05.001
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09
   Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765
   Diaz Arlhee, 2011, Cancers (Basel), V3, P3331, DOI 10.3390/cancers3033331
   Dickson K F, 1995, Contemp Orthop, V30, P489
   Donati D, 2008, INJURY, V39, pS65, DOI 10.1016/S0020 1383(08)70017 2
   Dunn SE, 2000, GROWTH HORM IGF RES, V10, pS41, DOI 10.1016/S1096 6374(00)90020 0
   Eckardt H, 2005, ACTA ORTHOP, V76, P459, DOI 10.1080/17453670510041411
   Eckardt H, 2005, INJURY, V36, P489, DOI 10.1016/j.injury.2004.10.019
   Eckardt H, 2003, J ORTHOP RES, V21, P335, DOI 10.1016/S0736 0266(02)00159 6
   Eckardt H, 2005, J BONE JOINT SURG BR, V87B, P1434, DOI 10.1302/0301 620X.87B10
   Ejaz S, 2005, ENVIRON TOXICOL PHAR, V20, P335, DOI 10.1016/j.etap.2005.03.011
   EPPLEY BL, 1988, J ORAL MAXIL SURG, V46, P391, DOI 10.1016/0278 2391(88)90223 6
   Farokhi M, 2013, INT J PHARMACEUT, V454, P216, DOI 10.1016/j.ijpharm.2013.06.080
   Fassbender M, 2011, EUR CELLS MATER, V22, P1
   Ferrari G, 2009, J CELL PHYSIOL, V219, P449, DOI 10.1002/jcp.21706
   Ferreira CL, 2013, ARCH ORAL BIOL, V58, P646, DOI 10.1016/j.archoralbio.2012.11.013
   Fiedler J, 2002, J CELL BIOCHEM, V87, P305, DOI 10.1002/jcb.10309
   Fong GH, 2009, J MOL MED JMM, V87, P549, DOI 10.1007/s00109 009 0458 z
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   Galeano M, 2006, CRIT CARE MED, V34, P1139, DOI 10.1097/01.CCM.0000206468.18653.EC
   Galiano RD, 2004, AM J PATHOL, V164, P1935, DOI 10.1016/S0002 9440(10)63754 6
   Gao C, 2013, EUR CELLS MATER, V26, P195, DOI 10.22203/eCM.v026a14
   Garcia P, 2012, J BONE JOINT SURG AM, V94A, P49, DOI 10.2106/JBJS.J.00795
   Garcia P, 2011, J ORTHOP RES, V29, P165, DOI 10.1002/jor.21219
   Geiger F, 2007, BONE, V41, P516, DOI 10.1016/j.bone.2007.06.018
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Giannoudis PV, 2013, INJURY, V44, pS1, DOI 10.1016/S0020 1383(13)70002 0
   GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo 124 3 1539
   Guo X, 2006, BIOMED MATER, V1, P93, DOI 10.1088/1748 6041/1/3/001
   Hackenbroich C, 2008, LAB ANIM UK, V42, P305, DOI 10.1258/la.2007.06025e
   Haroon ZSA, 2003, AM J PATHOL, V163, P993, DOI 10.1016/S0002 9440(10)63459 1
   Hiltunen MO, 2003, FASEB J, V17, P1147, DOI 10.1096/fj.02 0514fje
   Hoff P, 2013, CELL MOL IMMUNOL, V10, P151, DOI 10.1038/cmi.2012.56
   Holstein JH, 2011, BONE, V49, P1037, DOI 10.1016/j.bone.2011.08.004
   Holstein JH, 2007, LIFE SCI, V80, P893, DOI 10.1016/j.lfs.2006.11.023
   Hou HL, 2009, BIOTECHNOL LETT, V31, P1183, DOI 10.1007/s10529 009 0007 4
   Isowa S, 2010, ANTICANCER RES, V30, P2755
   Ito H, 2005, NAT MED, V11, P291, DOI 10.1038/nm1190
   Iwakura A, 2003, J THORAC CARDIOV SUR, V126, P1113, DOI 10.1016/S0022 5223(03)00025 4
   Iwakura A, 2001, CIRCULATION, V104, pI325
   Iwakura A, 2000, ANN THORAC SURG, V70, P824, DOI 10.1016/S0003 4975(00)01645 3
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Jakobsson L, 2013, EXP CELL RES, V319, P1264, DOI 10.1016/j.yexcr.2013.02.015
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Kaigler D, 2006, J BONE MINER RES, V21, P735, DOI 10.1359/JBMR.060120
   Kanczler JA, 2008, BIOMATERIALS, V29, P1892, DOI 10.1016/j.biomaterials.2007.12.031
   Kanczler JM, 2010, BIOMATERIALS, V31, P1242, DOI 10.1016/j.biomaterials.2009.10.059
   Kang SY, 2013, BONE, V56, P9, DOI 10.1016/j.bone.2013.04.022
   Kasten P, 2012, CELLS TISSUES ORGANS, V196, P523, DOI 10.1159/000337490
   Katsube K, 2005, J ORTHOP RES, V23, P469, DOI 10.1016/j.orthres.2004.08.013
   Keeney M, 2010, BIOMATERIALS, V31, P2893, DOI 10.1016/j.biomaterials.2009.12.041
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kigami R, 2013, IMPLANT DENT, V22, P422, DOI 10.1097/ID.0b013e31829d19f0
   Kim TK, 2010, ANAL BIOANAL CHEM, V397, P3173, DOI 10.1007/s00216 010 3821 6
   KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133
   KIVIRIKK.KI, 1967, P NATL ACAD SCI USA, V57, P782, DOI 10.1073/pnas.57.3.782
   Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955 2235(89)90012 4
   Kleinheinz J, 2005, J ORAL MAXIL SURG, V63, P1310, DOI 10.1016/j.joms.2005.05.303
   Langlois D, 2010, TRANSGENIC RES, V19, P1069, DOI 10.1007/s11248 010 9379 4
   Larsen M, 2010, J ORTHOP RES, V28, P1015, DOI 10.1002/jor.21098
   Leach JK, 2006, BIOMATERIALS, V27, P3249, DOI 10.1016/j.biomaterials.2006.01.033
   Lee KN, 2010, PHARMACOLOGY, V86, P327, DOI 10.1159/000321885
   Levi B, 2012, PLAST RECONSTR SURG, V129, P53, DOI 10.1097/PRS.0b013e3182361ff5
   Li G, 2005, J ORTHOP RES, V23, P680, DOI 10.1016/j.orthres.2004.12.005
   Li R, 2009, J ORTHOP RES, V27, P8, DOI 10.1002/jor.20658
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Liu YF, 2013, INJURY, V44, P923, DOI 10.1016/j.injury.2013.02.029
   Lu CY, 2007, J ORTHOP RES, V25, P51, DOI 10.1002/jor.20264
   Lu CY, 2011, J ORTHOP TRAUMA, V25, P494, DOI 10.1097/BOT.0b013e31822511e0
   Luo T, 2012, CLIN ORAL IMPLAN RES, V23, P467, DOI 10.1111/j.1600 0501.2011.02164.x
   Macdonald W, 2013, MED BIOL ENG COMPUT, V51, P1157, DOI 10.1007/s11517 013 1100 3
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mandu Hrit M, 2008, GROWTH FACTORS, V26, P143, DOI 10.1080/08977190802106154
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Marquez L, 2013, INJURY, V44, P558, DOI 10.1016/j.injury.2012.10.014
   Matsumoto T, 2008, BONE, V43, P434, DOI 10.1016/j.bone.2008.05.001
   Mattar T, 2013, J ORTHOP RES, V31, P561, DOI 10.1002/jor.22277
   Melnyk M, 2008, ARCH ORTHOP TRAUM SU, V128, P1159, DOI 10.1007/s00402 007 0543 0
   Mines D, 2011, PHARMACOEPIDEM DR S, V20, P111, DOI 10.1002/pds.2057
   MOHANTI RC, 1983, INT ORTHOP, V7, P173, DOI 10.1007/BF00269502
   Murphy WL, 2004, J DENT RES, V83, P204, DOI 10.1177/154405910408300304
   Muzylak M, 2006, CALCIFIED TISSUE INT, V79, P301, DOI 10.1007/s00223 006 0082 7
   Nicolaije C, 2012, J CELL PHYSIOL, V227, P1309, DOI 10.1002/jcp.22841
   Ozturk Burak Yagmur, 2013, Eur J Orthop Surg Traumatol, V23, P767, DOI 10.1007/s00590 012 1070 4
   Park BH, 2011, BONE, V49, P447, DOI 10.1016/j.bone.2011.05.020
   Park EJ, 2008, INT J ORAL MAX IMPL, V23, P818
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403
   Pneumaticos SG, 2013, SURGEON
   Pountos I, 2013, INJURY, V44, P1725, DOI 10.1016/j.injury.2013.09.009
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Pountos I, 2013, ACTA ORTHOP, V84, P65, DOI 10.3109/17453674.2013.765624
   Pountos I, 2010, J ORTHOP TRAUMA, V24, P552, DOI 10.1097/BOT.0b013e3181efa8fe
   Pountos I, 2010, INT ORTHOP, V34, P3, DOI 10.1007/s00264 009 0892 0
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/00007632 200208151 00010
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Rabie ABM, 2007, GENE THER, V14, P972, DOI 10.1038/sj.gt.3302943
   Radomsky ML, 1999, J ORTHOP RES, V17, P607, DOI 10.1002/jor.1100170422
   Ripamonti U, 1996, GROWTH FACTORS, V13, P273, DOI 10.3109/08977199609003228
   Robson A, 2010, DEV DYNAM, V239, P2435, DOI 10.1002/dvdy.22376
   Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1
   Ryaby JT, 2006, J BONE JOINT SURG AM, V88A, P132, DOI 10.2106/JBJS.F.00892
   Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756 3282(98)00053 2
   Samee M, 2008, J PHARMACOL SCI, V108, P18, DOI 10.1254/jphs.08036FP
   Santos TC, 2013, TISSUE ENG PT A, V19, P834, DOI [10.1089/ten.tea.2010.0741, 10.1089/ten.TEA.2010.0741]
   Schliephake H, 2009, J BIOMED MATER RES A, V90A, P429, DOI 10.1002/jbm.a.32104
   Schmidmaier G, 2003, ACTA ORTHOP SCAND, V74, P604, DOI 10.1080/00016470310018036
   SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955 2235(91)90003 M
   Simmonds MC, 2013, ANN INTERN MED, V158, P877, DOI 10.7326/0003 4819 158 12 201306180 00005
   Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73
   SMITH RJ, 1991, ARTHRITIS RHEUM US, V34, P697, DOI 10.1002/art.1780340610
   Solheim E, 1998, INT ORTHOP, V22, P410, DOI 10.1007/s002640050290
   Stewart R, 2011, J ORTHOP TRAUMA, V25, P472, DOI 10.1097/BOT.0b013e31822588d8
   STRACHAN RK, 1990, J BONE JOINT SURG BR, V72, P391, DOI 10.1302/0301 620X.72B3.2341434
   Strammiello R, 2003, HORM METAB RES, V35, P675
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Sun HL, 2012, TISSUE ENG PT A, V18, P2095, DOI [10.1089/ten.tea.2011.0742, 10.1089/ten.TEA.2011.0742]
   Takahata M, 2012, CELL TISSUE RES, V347, P545, DOI 10.1007/s00441 011 1188 4
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Tarkka T, 2003, J GENE MED, V5, P560, DOI 10.1002/jgm.392
   Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood 2004 03 1051
   Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46
   Wang HL, 2005, J ORTHOP RES, V23, P671, DOI 10.1016/j.orthres.2004.10.002
   Wildemann B, 2003, J BIOMED MATER RES B, V65B, P150, DOI 10.1002/jbm.b.10512
   Willems WF, 2011, J ORTHOP RES, V29, P1431, DOI 10.1002/jor.21338
   Wong VW, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/190486
   Yang P, 2009, CELLS TISSUES ORGANS, V189, P327, DOI 10.1159/000142162
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zhang C, 2010, ACTA PHARMACOL SIN, V31, P821, DOI 10.1038/aps.2010.67
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhao DM, 2007, CHINESE MED J PEKING, V120, P1187, DOI 10.1097/00029330 200707010 00015
   Zheng YH, 2011, J TISSUE ENG REGEN M, V5, P540, DOI 10.1002/term.346
NR 158
TC 13
Z9 14
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD JUN
PY 2014
VL 45
SU 2
BP S49
EP S57
DI 10.1016/j.injury.2014.04.009
PG 9
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA AR0DK
UT WOS:000343236400009
PM 24857029
DA 2025 08 17
ER

PT J
AU Zhang, GN
   Zhang, M
   Feng, QC
   Wang, RH
   Mei, HX
   Xing, K
   Li, J
AF Zhang, Guanning
   Zhang, Mei
   Feng, Qingchen
   Wang, Ruohan
   Mei, Hongxiang
   Xing, Ke
   Li, Juan
TI Supramolecular Composite Hydrogel Loaded with CaF2
   Nanoparticles Promotes the Recovery of Periodontitis Bone Resorption
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE supramolecular hydrogel; nanoparticles; periodontitis; antibacterial;
   bone regeneration
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; EXTRACELLULAR CALCIUM; ANTIBACTERIAL; RISK; MECHANISMS;
   FLUOROSIS; DELIVERY; THERAPY
AB Treatments to reduce periodontal inflammation and rescue periodontitis bone resorption have been of interest to researchers. Bone tissue engineering materials have been gradually used in the treatment of bone defects, but periodontal bone tissue regeneration still faces challenges. Considering the biocompatibility factor, constructing bionic scaffolds with natural extracellular matrix properties is an ideal therapeutic pathway. Based on the pathological mechanism of periodontitis, in this study, short peptide and nanometer inorganic particles were comingled to construct NapKFF nano CaF2 supramolecular composite hydrogels with different ratios. Material characterization experiments confirmed that the composite hydrogel had suitable mechanical properties and a three dimensional structure that can function in the resorption region of the alveolar bone and provide spaces for cell proliferation and adhesion. The release of low concentrations of fluoride and calcium ions has been shown to have positive biological effects in both in vivo and in vitro experiments. Vitro experiments confirmed that the composite hydrogel had good biocompatibility and promoted osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Microbiological experiments confirmed that the composite hydrogel inhibited the activity of periodontal pathogenic bacteria. In animal studies, composite hydrogel applied to periodontitis rats in vivo can effectively repair alveolar bone resorption. This composite hydrogel has a simple preparation method and is inexpensive to produce, yet it has antibacterial and osteogenesis promoting incremental effects, which makes it well suited for the treatment of periodontitis bone resorption, providing a new strategy for periodontal bone tissue engineering.
C1 [Zhang, Guanning; Zhang, Mei; Feng, Qingchen; Mei, Hongxiang; Xing, Ke; Li, Juan] Sichuan Univ, State Key Lab Oral Dis, West China Hosp Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Guanning; Zhang, Mei; Feng, Qingchen; Mei, Hongxiang; Xing, Ke; Li, Juan] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Guanning; Zhang, Mei; Feng, Qingchen; Mei, Hongxiang; Xing, Ke; Li, Juan] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Ruohan] Sichuan Univ, Coll Biomed Engn, Natl Engn Res Ctr Biomat, Chengdu 610064, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University
RP Li, J (通讯作者)，Sichuan Univ, State Key Lab Oral Dis, West China Hosp Stomatol, Chengdu 610041, Sichuan, Peoples R China.; Li, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.; Li, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China.
EM lijuan@scu.edu.cn
RI WANG, Ruohan/HDM 2651 2022
OI Qingchen, Feng/0000 0002 0094 6029; Hongxiang, Mei/0000 0002 8462 638X
FU National Natural Science Foundation of China [32271364, 31971240];
   Research and Develop Program, West China Hospital of Stomatology,
   Sichuan University [RD 03 202305]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 32271364, 31971240) and the Research and Develop
   Program, West China Hospital of Stomatology, Sichuan University (grant
   numbers RD 03 202305) in study design, investigation, data collection,
   data analysis and the decision to submit the article for publication.
CR Amaliya A, 2015, J CLIN PERIODONTOL, V42, P325, DOI 10.1111/jcpe.12381
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Antonarakis GS, 2014, ACTA ODONTOL SCAND, V72, P1066, DOI 10.3109/00016357.2014.882982
   Arakawa Y, 2009, BIOMED RES TOKYO, V30, P271, DOI 10.2220/biomedres.30.271
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Bhawal UK, 2020, DENT TRAUMATOL, V36, P278, DOI 10.1111/edt.12532
   BOIVIN G, 1989, BONE, V10, P89, DOI 10.1016/8756 3282(89)90004 5
   Cai HT, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11764
   Chang PC, 2013, BIOMATERIALS, V34, P9990, DOI 10.1016/j.biomaterials.2013.09.030
   DenBesten PK, 1999, COMMUNITY DENT ORAL, V27, P41, DOI 10.1111/j.1600 0528.1999.tb01990.x
   Ding R, 2024, BIOMATERIALS, V307, DOI 10.1016/j.biomaterials.2024.122536
   Divband B, 2021, CARBOHYD POLYM, V273, DOI 10.1016/j.carbpol.2021.118589
   Duan XQ, 2014, BIOL TRACE ELEM RES, V162, P219, DOI 10.1007/s12011 014 0118 1
   Molina MIE, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.617141
   Eke PI, 2016, J PERIODONTOL, V87, P1174, DOI 10.1902/jop.2016.160013
   Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866
   Estroff LA, 2004, CHEM REV, V104, P1201, DOI 10.1021/cr0302049
   Fu B, 2019, ANAL CHIM ACTA, V1078, P119, DOI 10.1016/j.aca.2019.06.005
   Gong X, 2016, MAT SCI ENG C MATER, V58, P478, DOI 10.1016/j.msec.2015.08.059
   Graves D, 2008, J PERIODONTOL, V79, P1585, DOI 10.1902/jop.2008.080183
   Guo HL, 2021, ACS APPL MATER INTER, V13, P61638, DOI 10.1021/acsami.1c18701
   Haines Butterick L, 2007, P NATL ACAD SCI USA, V104, P7791, DOI 10.1073/pnas.0701980104
   Hajishengallis G, 2012, MOL ORAL MICROBIOL, V27, P409, DOI 10.1111/j.2041 1014.2012.00663.x
   Han L, 2017, ACS NANO, V11, P2561, DOI 10.1021/acsnano.6b05318
   Haubek D, 2008, LANCET, V371, P237, DOI 10.1016/S0140 6736(08)60135 X
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   How KY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00053
   Ikeda R, 2005, J BIOL CHEM, V280, P8523, DOI 10.1074/jbc.M409442200
   Janarthanan G, 2021, J MATER SCI TECHNOL, V63, P35, DOI 10.1016/j.jmst.2020.02.052
   Jeong SH, 2018, ACS BIOMATER SCI ENG, V4, P2380, DOI 10.1021/acsbiomaterials.8b00198
   Kawamura J, 2019, ORTHOD CRANIOFAC RES, V22, P329, DOI 10.1111/ocr.12331
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Lalla E, 2011, NAT REV ENDOCRINOL, V7, P738, DOI 10.1038/nrendo.2011.106
   Lee M, 2017, BIOL TRACE ELEM RES, V178, P283, DOI 10.1007/s12011 017 0930 5
   Lei Q, 2015, CHEM BIOL INTERACT, V233, P139, DOI 10.1016/j.cbi.2015.03.021
   Li X, 2021, ACTA BIOMATER, V131, P128, DOI 10.1016/j.actbio.2021.07.007
   Li YX, 2023, INT J BIOL MACROMOL, V242, DOI 10.1016/j.ijbiomac.2023.124920
   Liu H, 2018, EXP THER MED, V15, P3715, DOI 10.3892/etm.2018.5894
   Liu HZ, 2023, FRONT BIOSCI LANDMRK, V28, DOI 10.31083/j.fbl2809231
   Liu JR, 2014, INFLAMMATION, V37, P522, DOI 10.1007/s10753 013 9766 0
   Liu J, 2016, DENT MATER, V32, pE221, DOI 10.1016/j.dental.2016.07.003
   Liu SB, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12613
   Liu YK, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/2/025004
   Liu ZX, 2023, J MINIM INVAS GYN, V30, P45, DOI 10.1016/j.jmig.2022.10.004
   Marth JD, 2008, NAT CELL BIOL, V10, P1015, DOI 10.1038/ncb0908 1015
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mei JJ, 2014, RSC ADV, V4, P1193, DOI 10.1039/c3ra45023f
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Michalowicz BS, 2000, J PERIODONTOL, V71, P1699, DOI 10.1902/jop.2000.71.11.1699
   Montazerian H, 2021, ACS APPL MATER INTER, V13, P40290, DOI 10.1021/acsami.1c10048
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nociti FH, 2015, PERIODONTOL 2000, V67, P187, DOI 10.1111/prd.12063
   Olsen I, 2017, J ORAL MICROBIOL, V9, DOI 10.1080/20002297.2017.1340085
   Petersen PE, 2012, PERIODONTOL 2000, V60, P7, DOI 10.1111/j.1600 0757.2012.00452.x
   Ringe D, 2008, SCIENCE, V320, P1428, DOI 10.1126/science.1159747
   Rizikalo A, 2024, LIFE BASEL, V14, DOI 10.3390/life14030316
   Shi JF, 2011, LANGMUIR, V27, P14425, DOI 10.1021/la2033862
   Shimogishi M, 2014, DENT MATER J, V33, P70, DOI 10.4012/dmj.2013 158
   Shin DY, 2019, INT J BIOL MACROMOL, V123, P866, DOI 10.1016/j.ijbiomac.2018.11.108
   Skaik A, 2019, AM J ORTHOD DENTOFAC, V155, P98, DOI 10.1016/j.ajodo.2018.03.017
   Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600 051X.1998.tb02419.x
   Sun Y, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120614
   Sunintaboon P, 2006, J AM CHEM SOC, V128, P2168, DOI 10.1021/ja056065p
   Suzuki M, 2009, SCIENCE, V325, P1388, DOI 10.1126/science.1173793
   Tang JD, 2019, J AM CHEM SOC, V141, P4886, DOI 10.1021/jacs.8b13363
   Tian YJ, 2022, BIOACT MATER, V9, P428, DOI 10.1016/j.bioactmat.2021.07.033
   Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202
   Wagner AS, 2017, ANN ANAT, V209, P18, DOI 10.1016/j.aanat.2016.09.005
   Wang WH, 2023, ACS BIOMATER SCI ENG, V9, P1961, DOI 10.1021/acsbiomaterials.2c01440
   Wang XZ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020962
   Wong PY, 2023, INT DENT J, V73, P354, DOI 10.1016/j.identj.2023.01.002
   Wu HA, 2018, ACTA BIOMATER, V74, P302, DOI 10.1016/j.actbio.2018.04.052
   Wu JW, 2023, ACS APPL MATER INTER, V15, P55409, DOI 10.1021/acsami.3c13047
   Wu T, 2021, CARBOHYD POLYM, V269, DOI 10.1016/j.carbpol.2021.118276
   Xu J, 2011, MATER LETT, V65, P2404, DOI 10.1016/j.matlet.2011.04.080
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Xuan QZ, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.718883
   Yin JY, 2023, J APPL ORAL SCI, V31, DOI 10.1590/1678 7757 2022 0447
   Zhang FX, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121169
   Zhang JW, 2014, CHEM COMMUN, V50, P12873, DOI 10.1039/c4cc05826g
   Zhang SB, 2023, REGEN BIOMATER, V10, DOI 10.1093/rb/rbad009
   Zhang XX, 2022, MATTER US, V5, P666, DOI 10.1016/j.matt.2021.11.017
   Zhang Y, 2011, LANGMUIR, V27, P529, DOI 10.1021/la1020324
   Zhao XD, 2022, BIOMATERIALS, V282, DOI 10.1016/j.biomaterials.2022.121387
   Zheng LY, 2021, J DENT, V113, DOI 10.1016/j.jdent.2021.103772
   Zhou J, 2017, BIOMATERIALS, V129, P1, DOI 10.1016/j.biomaterials.2017.03.014
   Zhou XH, 2022, CARBOHYD POLYM, V298, DOI 10.1016/j.carbpol.2022.120127
NR 87
TC 5
Z9 5
U1 23
U2 44
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 26
PY 2024
VL 16
IS 35
BP 45929
EP 45947
DI 10.1021/acsami.4c07210
EA AUG 2024
PG 19
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA E7C2C
UT WOS:001299121000001
PM 39183483
DA 2025 08 17
ER

PT J
AU Corazza, GR
   Di Stefano, M
   Mauriño, E
   Bai, JC
AF Corazza, GR
   Di Stefano, M
   Mauriño, E
   Bai, JC
TI Bones in coeliac disease: diagnosis and treatment
SO BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE coeliac disease; bone mineral density; bone densitometry; gluten free
   diet; osteopenia; osteoporosis
ID GLUTEN FREE DIET; X RAY ABSORPTIOMETRY; MINERAL DENSITY; FRACTURE RISK;
   NUTRITIONAL DISTURBANCE; CALCIUM METABOLISM; BODY COMPOSITION;
   MALABSORPTION; OSTEOPENIA; MASS
AB Coeliac disease predisposes to metabolic osteopathy. The entity of bone loss is higher in patients with malabsorption at diagnosis but it is also present in asymptomatic or poorly symptomatic patients, occurring in roughly half of them. Calcium malabsorption and the release of proinflammatory cytokines, activating osteoclasts, represent the main mechanisms responsible for bone derangement. In coeliacs, the presence of an increased fracture risk was recently questioned and its importance on clinical grounds was reconsidered, in view of the fact that gluten free diet generally improves bone mass and, consequently, reduces fracture risk. However, gluten free diet rarely normalizes bone mass and the co administration of mineral active drugs may be useful in a subgroup of coeliacs.
C1 Univ Pavia, Dept Med, IRCCS, S Matteo Hosp, I 27100 Pavia, Italy.
   Univ Salvador, Carlos Bonorino Udaondo Gastroenterol Hosp, Dept Med, RA 1264 Buenos Aires, DF, Argentina.
C3 University of Pavia
RP Corazza, GR (通讯作者)，Univ Pavia, Dept Med, IRCCS, S Matteo Hosp, Ple C Golgi 19, I 27100 Pavia, Italy.
EM gr.corazza@smatteo.pv.it
RI di stefano, michele/AAC 2205 2019; Corazza, Gino/K 8500 2016; CORAZZA,
   GINO ROBERTO/K 8500 2016
OI CORAZZA, GINO ROBERTO/0000 0001 9532 0573; di stefano,
   michele/0000 0002 6971 6854
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bai JC, 1997, ALIMENT PHARM THER, V11, P157, DOI 10.1046/j.1365 2036.1997.112283000.x
   Bennett TI, 1932, Q J MED, V1, P603
   BODE S, 1991, GUT, V32, P1342, DOI 10.1136/gut.32.11.1342
   CARACENI MP, 1988, AM J GASTROENTEROL, V83, P274
   Ciacci C, 1997, AM J GASTROENTEROL, V92, P992
   CIACCI C, 1995, AM J GASTROENTEROL, V90, P1480
   COLSTON KW, 1994, GUT, V35, P1219, DOI 10.1136/gut.35.9.1219
   Compston J, 2003, GUT, V52, P459, DOI 10.1136/gut.52.4.459
   CORAZZA GR, 1995, BAILLIERE CLIN GASTR, V9, P329, DOI 10.1016/0950 3528(95)90034 9
   Corazza GR, 1997, GASTROENTEROLOGY, V113, P67, DOI 10.1016/S0016 5085(97)70081 7
   CORAZZA GR, 1995, GASTROENTEROLOGY, V109, P122, DOI 10.1016/0016 5085(95)90276 7
   Corazza GR, 1996, BONE, V18, P525, DOI 10.1016/8756 3282(96)00071 3
   CORAZZA GR, 1999, P 8 INT S COEL DIS N, P125
   Cranney A, 2003, BRIT MED J, V327, P355, DOI 10.1136/bmj.327.7411.355
   Devlin RD, 1996, J CLIN ENDOCR METAB, V81, P1893, DOI 10.1210/jc.81.5.1893
   Di Stefano M, 2002, GASTROENTEROLOGY, V122, P1793, DOI 10.1053/gast.2002.33600
   Di Stefano M, 2000, EUR J GASTROEN HEPAT, V12, P1195, DOI 10.1097/00042737 200012110 00005
   Di Stefano M, 1997, ITAL J GASTROENTE S2, V29, P31
   FARTHING MJG, 1983, GUT, V24, P127, DOI 10.1136/gut.24.2.127
   Ferretti J, 2003, AM J GASTROENTEROL, V98, P382, DOI 10.1016/S0002 9270(02)05905 1
   Fickling WE, 2001, POSTGRAD MED J, V77, P33, DOI 10.1136/pmj.77.903.33
   Fornari MC, 1998, AM J GASTROENTEROL, V93, P413, DOI 10.1016/S0002 9270(97)00115 9
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223 002 1049 y
   HANSEN MA, 1990, J NUCL MED, V31, P1156
   HARRIS OD, 1970, SCAND J GASTROENTERO, V5, P169
   HARRISON JE, 1969, GASTROENTEROLOGY, V56, P751
   Holmes WH, 1929, J AMER MED ASSOC, V92, P975, DOI 10.1001/jama.1929.02700380033011
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413
   JOHNSTON CC, 1990, NEW ENGL J MED, V323, P1271, DOI 10.1056/NEJM199011013231809
   JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1
   Keaveny AP, 1996, AM J GASTROENTEROL, V91, P1226
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KONTAKOU M, 1995, SCAND J GASTROENTERO, V30, P456, DOI 10.3109/00365529509093307
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   MAIERHOFER WJ, 1983, KIDNEY INT, V24, P555, DOI 10.1038/ki.1983.193
   Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200
   Mautalen C, 1997, AM J GASTROENTEROL, V92, P313
   MAZURE R, 1994, AM J GASTROENTEROL, V89, P2130
   McFarlane XA, 1996, GUT, V39, P180, DOI 10.1136/gut.39.2.180
   MCFARLANE XA, 1995, GUT, V36, P710, DOI 10.1136/gut.36.5.710
   MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003 4819 112 7 516
   MELVIN KEW, 1970, Q J MED, V39, P83
   MOLTENI N, 1995, AM J GASTROENTEROL, V90, P2025
   Mora S, 1998, AM J CLIN NUTR, V67, P477, DOI 10.1093/ajcn/67.3.477
   MORA S, 1993, AM J CLIN NUTR, V57, P224, DOI 10.1093/ajcn/57.2.224
   Moreno ML, 2004, CLIN GASTROENTEROL H, V2, P127, DOI 10.1016/S1542 3565(03)00320 3
   Mustalahti K, 1999, LANCET, V354, P744, DOI 10.1016/S0140 6736(99)01990 X
   Oleksik A, 2000, J BONE MINER RES, V15, P1384, DOI 10.1359/jbmr.2000.15.7.1384
   PLOTKIN GR, 1964, NEW ENGL J MED, V271, P1033, DOI 10.1056/NEJM196411122712003
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   RAISZ LG, 1988, NEW ENGL J MED, V318, P818
   Riggs B. L., 1988, OSTEOPOROSIS ETIOLOG
   SALVESEN HA, 1953, ACTA MED SCAND, V146, P290
   Scott EM, 2000, GUT, V46, P1, DOI 10.1136/gut.46.suppl_1.I1
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smecuol E, 1996, EUR J GASTROEN HEPAT, V8, P63, DOI 10.1097/00042737 199601000 00012
   STAUN M, 1988, SCAND J GASTROENTERO, V23, P827, DOI 10.3109/00365528809090768
   Sugai E, 2002, J CLIN IMMUNOL, V22, P353, DOI 10.1023/A:1020786315956
   Taranta A, 2004, J BONE MINER RES, V19, P1112, DOI 10.1359/JBMR.040319
   Thomason K, 2003, GUT, V52, P518, DOI 10.1136/gut.52.4.518
   Valdimarsson T, 1996, GUT, V38, P322, DOI 10.1136/gut.38.3.322
   VALDIMARSSON T, 1994, SCAND J GASTROENTERO, V29, P457, DOI 10.3109/00365529409096838
   Vazquez H, 2000, AM J GASTROENTEROL, V95, P183
   Vestergaard P, 2002, AM J EPIDEMIOL, V156, P1, DOI 10.1093/aje/kwf007
   WALTERS JRF, 1995, GUT, V37, P220, DOI 10.1136/gut.37.2.220
   West J, 2003, GASTROENTEROLOGY, V125, P429, DOI 10.1016/S0016 5085(03)00891 6
   WOOD AJJ, 1998, NEW ENGL J MED, V336, P736
   Yamada N, 2002, BONE, V30, P901, DOI 10.1016/S8756 3282(02)00722 6
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 72
TC 74
Z9 79
U1 0
U2 5
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 6918
EI 1532 1916
J9 BEST PRACT RES CL GA
JI Best Pract. Res. Clin. Gastroenterol.
PD JUN
PY 2005
VL 19
IS 3
BP 453
EP 465
DI 10.1016/j.bpg.2005.01.002
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 939TD
UT WOS:000230094400013
PM 15925849
DA 2025 08 17
ER

PT J
AU Tan, J
   Deng, P
   Wang, L
   Bi, XY
   Zhou, YY
   Wang, Y
   Zhang, P
AF Tan, Juan
   Deng, Ping
   Wang, Li
   Bi, Xiaoya
   Zhou, Yiyao
   Wang, Yi
   Zhang, Pu
TI Signal on and selective detection of anti tumor adjunctive drug
   zoledronic acid using fluorescent sulfur quantum dots
SO DYES AND PIGMENTS
LA English
DT Article
DE Photoluminescence; Sulfur; Ferricions; Bisphosphonate; Fluorescence
   quenching
ID BISPHOSPHONATES; INHIBITION; CANCER
AB As a representative of the third generation of bisphosphonate drugs, zoledronic acid (ZA) is clinically used to treat osteolytic bone metastases from malignant tumors and osteoporosis. Herein, a novel signal on strategy for highly selective detection of ZA is proposed, employing Fe3+ mediated fluorescent sulfur quantum dots (SQDs) as a probe. Specifically, Fe3+ can induce the aggregation of SQDs in aqueous solution and strongly quench their fluorescence, however, which recovers again in the presence of ZA owing to its emulative complexation with Fe3+. The complex ratio and binding mode between ZA and Fe3+ are also theoretically simulated. This method exhibits the merits of rapidness, high selectivity, reliability, and with no need of derivatization for ZA detection, with a detectable range of 5 200 mu M and a detection limit of 1.7 mu M. It has also been successfully applied to determine ZA in real samples including human serum, urine, and drugs.
C1 [Tan, Juan; Bi, Xiaoya; Zhou, Yiyao; Wang, Yi] Chongqing Normal Univ, Coll Chem,Minist Educ, Engn Res Ctr Biotechnol Act Subst, Chongqing Key Lab Green Synth & Applicat, Chongqing 401331, Peoples R China.
   [Deng, Ping; Zhang, Pu] Chongqing Med Univ, Coll Pharm, Chongqing Res Ctr Pharmaceut Engn, Chongqing 400016, Peoples R China.
   [Wang, Li] Chongqing Med Univ, Childrens Hosp, Chongqing 400014, Peoples R China.
C3 Chongqing Normal University; Chongqing Medical University; Chongqing
   Medical University
RP Wang, Y (通讯作者)，Chongqing Normal Univ, Coll Chem,Minist Educ, Engn Res Ctr Biotechnol Act Subst, Chongqing Key Lab Green Synth & Applicat, Chongqing 401331, Peoples R China.; Zhang, P (通讯作者)，Chongqing Med Univ, Coll Pharm, Chongqing Res Ctr Pharmaceut Engn, Chongqing 400016, Peoples R China.
EM ywang@cqnu.edu.cn; zhangpu@cqmu.edu.cn
RI Yiyao, Zhou/LZE 6370 2025; ZHANG, PU/KZV 0280 2024; Wang, Yi/J 5439 2015
FU National Natural Science Foundation of China [21775014, 81972020];
   Chongqing Innovation Research Group Project [CXQT21015]; Chongqing
   Talent Program [202010637002]; National College Students Innovation and
   Entrepreneurship Training Program of China
FX Acknowledgements This work was supported by the National Natural Science
   Foundation of China (no. 21775014 and 81972020) and Chongqing Innovation
   Research Group Project (no. CXQT21015) . P.Z. was also sponsored by the
   Chongqing Talent Program. X.B. and Y.Z. were also supported by the
   National College Students Innovation and Entrepreneurship Training
   Program of China (no. 202010637002) .
CR Amin N, 2018, ANAL CHIM ACTA, V1030, P183, DOI 10.1016/j.aca.2018.05.014
   Arshad F, 2021, ACS APPL NANO MATER, V4, P3339, DOI 10.1021/acsanm.1c00509
   Arshad F, 2020, ACS APPL NANO MATER, V3, P3044, DOI 10.1021/acsanm.0c00394
   Caraglia M, 2013, MOL PHARMACEUT, V10, P1111, DOI 10.1021/mp3006215
   Chen DJ, 2016, ANAL METHODS UK, V8, P632, DOI [10.1039/C5AY02451J, 10.1039/c5ay02451j]
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Duan YX, 2020, CARBOHYD POLYM, V249, DOI 10.1016/j.carbpol.2020.116882
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fu L, 2020, SENSOR ACTUAT B CHEM, V304, DOI 10.1016/j.snb.2019.127390
   Gao PX, 2020, CHEMPHOTOCHEM, V4, P5235, DOI 10.1002/cptc.202000158
   Guilminot E, 2002, CORROS SCI, V44, P2199, DOI 10.1016/S0010 938X(02)00010 0
   HARIHARA.PC, 1973, THEOR CHIM ACTA, V28, P213, DOI 10.1007/BF00533485
   Huang ZM, 2021, MICROCHEM J, V170, DOI 10.1016/j.microc.2021.106656
   Huang ZM, 2021, MICROCHEM J, V164, DOI 10.1016/j.microc.2021.106031
   Kohn W, 1996, J PHYS CHEM US, V100, P12974, DOI 10.1021/jp960669l
   Kolhe P, 2003, BIOMACROMOLECULES, V4, P173, DOI 10.1021/bm025689+
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Lei JH, 2021, PART PART SYST CHAR, V38, DOI 10.1002/ppsc.202000332
   Li L, 2021, J MATER SCI, V56, P4782, DOI 10.1007/s10853 020 05544 z
   Li P, 2018, J ANAL METHODS CHEM, V2018, DOI 10.1155/2018/3631249
   Li SX, 2014, ADV FUNCT MATER, V24, P7133, DOI 10.1002/adfm.201402087
   Liu LL, 2020, ANAL CHEM, V92, P15112, DOI 10.1021/acs.analchem.0c03311
   Matuszewski L, 2011, J FAC AGR KYUSHU U, V56, P213
   Mccue AJ, 2014, CATAL SCI TECHNOL, V4, P272, DOI 10.1039/c3cy00754e
   Pal A, 2020, ADV COLLOID INTERFAC, V285, DOI 10.1016/j.cis.2020.102274
   Raghu NS, 2011, J LIQ CHROMATOGR R T, V34, P476, DOI 10.1080/10826076.2011.555700
   Risser F, 1997, J PHARMACEUT BIOMED, V15, P1877, DOI 10.1016/S0731 7085(96)02021 3
   Sahoo SK, 2012, CHEM SOC REV, V41, P7195, DOI 10.1039/c2cs35152h
   Shankar S, 2018, MAT SCI ENG C MATER, V92, P508, DOI 10.1016/j.msec.2018.07.015
   Shen LH, 2018, J AM CHEM SOC, V140, P7878, DOI 10.1021/jacs.8b02792
   Shi BF, 2016, ACS APPL MATER INTER, V8, P10717, DOI 10.1021/acsami.6b01325
   Shi YE, 2020, CHEM COMMUN, V56, P10982, DOI 10.1039/d0cc04341a
   Song YH, 2020, CHEM SCI, V11, P772, DOI 10.1039/c9sc05019a
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Teng Y, 2019, CRIT REV ENV SCI TEC, V49, P2314, DOI 10.1080/10643389.2019.1609856
   Wang HG, 2019, ANGEW CHEM INT EDIT, V58, P7040, DOI 10.1002/anie.201902344
   Wang ZG, 2020, ANGEW CHEM INT EDIT, V59, P9997, DOI 10.1002/anie.201915511
   Xia WQ, 2019, CHEM COMMUN, V55, P2039, DOI 10.1039/c8cc09799b
   Xiao L, 2019, ACS APPL NANO MATER, V2, P6622, DOI 10.1021/acsanm.9b01507
   Xie Z, 2006, J CHROMATOGR A, V1104, P173, DOI 10.1016/j.chroma.2005.11.113
   Zhang CC, 2019, CHEM COMMUN, V55, P13004, DOI 10.1039/c9cc06586e
   [张普 ZHANG Pu], 2011, [中国科学. 化学, Scientia Sinica Chimica], V41, P1037
   Zhao J, 2020, MICROCHIM ACTA, V187, DOI 10.1007/s00604 019 4020 6
   Zhao XM, 2015, J BONE ONCOL, V4, P98, DOI 10.1016/j.jbo.2015.08.001
NR 44
TC 6
Z9 6
U1 2
U2 16
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0143 7208
EI 1873 3743
J9 DYES PIGMENTS
JI Dyes Pigment.
PD SEP
PY 2022
VL 205
AR 110520
DI 10.1016/j.dyepig.2022.110520
EA JUL 2022
PG 8
WC Chemistry, Applied; Engineering, Chemical; Materials Science, Textiles
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Materials Science
GA 3A7RI
UT WOS:000827452600001
DA 2025 08 17
ER

PT J
AU Bolzoni, M
   Storti, P
   Bonomini, S
   Todoerti, K
   Guasco, D
   Toscani, D
   Agnelli, L
   Neri, A
   Rizzoli, V
   Giuliani, N
AF Bolzoni, Marina
   Storti, Paola
   Bonomini, Sabrina
   Todoerti, Katia
   Guasco, Daniela
   Toscani, Denise
   Agnelli, Luca
   Neri, Antonino
   Rizzoli, Vittorio
   Giuliani, Nicola
TI Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple
   myeloma induced osteoclast formation and the RANKL/OPG ratio in the
   myeloma microenvironment targeting the expression of adhesion molecules
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID INFLAMMATORY PROTEIN 1 ALPHA; RECEPTOR ACTIVATOR; BONE DESTRUCTION;
   THALIDOMIDE ANALOGS; CYTOKINE PRODUCTION; DOWN REGULATION;
   T LYMPHOCYTES; VICIOUS CYCLE; CELL GROWTH; CC 4047
AB Multiple myeloma (MM) induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF kappa B ligand (RANKL) osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells. The purpose of the study was to investigate the effect of the immunomodulatory drugs on RANKL/OPG ratio, the production of pro osteoclastogenic cytokines, and MM induced OC formation. We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co cultured with MM cells and also inhibited CCL3 production by MM cells. A reduction in CD49d expression, a molecule critically involved in RANKL upregulation in the MM microenvironment, accompanied this effect. Consistently, the pro osteoclastogenic property of MM cells co cultured with PreOBs was reduced by both LEN and POM. We further investigated the effect of these drugs on the transcriptional profile of both MM cells and PreOBs by microarray analysis, which showed that adhesion molecules, such as ITGA8 and ICAM2, are significantly downregulated in MM cells. Our data suggest that LEN and POM inhibit MM induced OC formation through normalization of the RANKL/OPG ratio targeting the expression of adhesion molecules by MM cells. (C) 2013 ISEH   Society for Hematology and Stem Cells. Published by Elsevier Inc.
C1 [Bolzoni, Marina; Storti, Paola; Bonomini, Sabrina; Guasco, Daniela; Toscani, Denise; Rizzoli, Vittorio; Giuliani, Nicola] Univ Parma, Hematol & BMT Ctr, I 43126 Parma, Italy.
   [Todoerti, Katia; Agnelli, Luca; Neri, Antonino] Univ Milan, Dept Clin Sci & Community Hlth, I 20122 Milan, Italy.
C3 University of Parma; University of Milan
RP Giuliani, N (通讯作者)，Univ Parma, Dept Clin & Expt Med, Hematol & BMT Ctr, Via Gramsci 14, I 43126 Parma, Italy.
EM nicola.giuliani@unipr.it
RI Neri, Antonino/I 9690 2014; Agnelli, Luca/H 8238 2012; Storti,
   Paola/M 2015 2013; Bolzoni, Marina/K 4032 2016; Giuliani,
   Nicola/AAT 7968 2020; toscani, denise/N 8100 2019
OI Neri, Antonino/0000 0001 9047 5912; Giuliani,
   Nicola/0000 0003 3457 3774; Storti, Paola/0000 0001 8014 8205; Toscani,
   Denise/0000 0003 3492 4415; Bolzoni, Marina/0000 0002 0821 8093;
   Todoerti, Katia/0000 0001 6687 6871; Agnelli, Luca/0000 0003 0582 6170
FU Celgene SRL Italy; International Myeloma Foundation; Italian Minister of
   Health Progetti Regione Emilia Romagna; Associazione Italiana per la
   Ricerca sul Cancro [IG2099, 8530, 9965, IG4569]
FX This work was supported by a grant from Celgene SRL Italy (to M.B.) and
   a grant from the International Myeloma Foundation, the Italian Minister
   of Health Progetti Regione Emilia Romagna and the Associazione Italiana
   per la Ricerca sul Cancro (N.G.: IG2099 no 8530, and Special Program
   Molecular Clinical Oncology 5 per mine n. 9965; A.N.: IG4569). We thank
   Rebecca Silbermann for her editing of the manuscript.
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Agnelli L, 2011, CLIN CANCER RES, V17, P7402, DOI 10.1158/1078 0432.CCR 11 0596
   Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   Armoiry X, 2008, J CLIN PHARM THER, V33, P219, DOI 10.1111/j.1365 2710.2008.00920.x
   Bloemen V, 2009, BIOCHEM BIOPH RES CO, V385, P640, DOI 10.1016/j.bbrc.2009.05.145
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Breitling R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471 2105 5 100
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Choi SJ, 2000, BLOOD, V96, P671
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Corral LG, 1999, J IMMUNOL, V163, P380
   Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210
   Dimopoulos MA, 2011, LEUKEMIA, V25, P749, DOI 10.1038/leu.2011.3
   Escoubet Lozach L, 2009, CANCER RES, V69, P7347, DOI 10.1158/0008 5472.CAN 08 4898
   Garcia Palacios V, 2006, ANN NY ACAD SCI, V1068, P240, DOI 10.1196/annals.1346.048
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Giuliani N, 2004, EXP HEMATOL, V32, P685, DOI 10.1016/j.exphem.2004.03.015
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885
   Hayashi H, 2008, FEBS LETT, V582, P3243, DOI 10.1016/j.febslet.2008.08.023
   Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943
   Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200
   Koh KR, 2005, BLOOD, V105, P3833, DOI 10.1182/blood 2004 03 0828
   KURACHI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P259, DOI 10.1016/0167 4889(93)90202 Z
   Lacy MQ, 2011, CURR HEMATOL MALIG R, V6, P120, DOI 10.1007/s11899 011 0077 y
   Lacy MQ, 2010, AM J HEMATOL, V85, P95, DOI 10.1002/ajh.21610
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525
   Pal R, 2010, BLOOD, V115, P605, DOI 10.1182/blood 2009 05 221077
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pan BQ, 2012, PHARMACOL THERAPEUT, V136, P56, DOI 10.1016/j.pharmthera.2012.07.004
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   PellatDeceunynck C, 1996, CANCER RES, V56, P1909
   Quach H, 2010, LEUKEMIA, V24, P22, DOI 10.1038/leu.2009.236
   Reddy N, 2008, BRIT J HAEMATOL, V140, P36, DOI 10.1111/j.1365 2141.2007.06841.x
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Schey SA, 2004, J CLIN ONCOL, V22, P3269, DOI 10.1200/JCO.2004.10.052
   Zeldis JB, 2011, ANN NY ACAD SCI, V1222, P76, DOI 10.1111/j.1749 6632.2011.05974.x
NR 40
TC 60
Z9 64
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 472X
EI 1873 2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD APR
PY 2013
VL 41
IS 4
BP 387
EP 397
DI 10.1016/j.exphem.2012.11.005
PG 11
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Research & Experimental Medicine
GA 128YN
UT WOS:000317805700008
PM 23178378
OA Bronze
DA 2025 08 17
ER

PT J
AU Palumbo, I
   Ruggiero, C
   Festa, E
   De Fano, M
   Baroni, M
   Bellavita, R
   Ingrosso, G
   Saldi, S
   Duranti, M
   Mecocci, P
   Falorni, A
   Aristei, C
AF Palumbo, Isabella
   Ruggiero, Carmelinda
   Festa, Eleonora
   De Fano, Michelantonio
   Baroni, Marta
   Bellavita, Rita
   Ingrosso, Gianluca
   Saldi, Simonetta
   Duranti, Michele
   Mecocci, Patrizia
   Falorni, Alberto
   Aristei, Cynthia
TI Bone Health Care Pathway for Non metastatic Prostate Cancer Patients on
   Radiation and Androgen Deprivation Therapy
SO ANTICANCER RESEARCH
LA English
DT Article
DE Non metastatic prostate cancer; radiotherapy; androgen deprivation
   therapy; cancer treatment induced bone loss
ID FRAGILITY FRACTURES; MINERAL DENSITY; OSTEOPOROSIS; PREVENTION;
   DENOSUMAB; MEN; TRIAL
AB Background/Aim: Survival rates of prostate cancer (PCa) patients have improved considerably as a result of earlier diagnosis and therapies, including radiotherapy (RT) and androgen deprivation therapy (ADT). Patients on ADT develop cancer treatment induced bone loss (CTIBL) and a high risk of fragility fractures. Bone health (BH) assessment is strongly recommended, together with timely initiation of treatments, to counteract CTIBL and preserve bone strength. Therefore, we decided to develop an interdisciplinary pathway of care (IPC) dedicated to non  metastatic PCa patients on long term ADT and RT. Patients and Methods: An interdisciplinary team allocated resources to support an IPC to manage patients' CTIBL and prevent fragility fractures. The team provided a diagnostic and therapeutic workflow according to patients' and professional perspectives, consistent with recommendations and healthcare policies. The hospital's quality department certified the IPC, the Ethical Committee approved procedures over the workflow. The Fracture Liaison Service (FLS) standards inspired services and professionals' activities and interactions. Results: Preliminary data support the feasibility of the IPC from professionals' and patients' perspectives. Median age of the enrolled patients was 75 years, more than a half (58.9%) had low grade osteopenia or normal BMD (T score >= 1.5 standard deviation, SD), while 23.5% and 17.6% had osteoporosis and osteopenia, respectively. The IPC meets the requirements of a FLS concerning crucial indicators. Conclusion: Our IPC was a suitable approach to assure timely identification, assessment, initiation, and monitoring of adherence to anti fracture treatments among non metastatic PCa patients on long term ADT and RT. Further data are required to show its effectiveness on fragility fracture prevention.
C1 [Palumbo, Isabella; Ingrosso, Gianluca] Univ Perugia, Radiat Oncol Sect, Perugia, Italy.
   [Palumbo, Isabella; Ruggiero, Carmelinda; De Fano, Michelantonio; Baroni, Marta; Ingrosso, Gianluca; Mecocci, Patrizia; Falorni, Alberto; Aristei, Cynthia] Perugia Gen Hosp, Perugia, Italy.
   [Ruggiero, Carmelinda; Baroni, Marta; Mecocci, Patrizia] Univ Perugia, Geriatr Unit, Perugia, Italy.
   [Festa, Eleonora] Univ Perugia, Radiat Oncol Sect, Perugia, Italy.
   [De Fano, Michelantonio; Falorni, Alberto] Univ Perugia, Internal Med & Endocrinol & Metab Sci Sect, Perugia, Italy.
   [Bellavita, Rita; Saldi, Simonetta] Perugia Gen Hosp, Radiat Oncol Div, Perugia, Italy.
   [Duranti, Michele] Perugia Gen Hosp, Radiol Div, Perugia, Italy.
   [Palumbo, Isabella] Univ Perugia, Perugia Gen Hosp, Dept Med & Surg, Radiat Oncol Sect, I 06156 Perugia, Italy.
C3 University of Perugia; University of Perugia; University of Perugia;
   University of Perugia; University of Perugia
RP Palumbo, I (通讯作者)，Univ Perugia, Perugia Gen Hosp, Dept Med & Surg, Radiat Oncol Sect, I 06156 Perugia, Italy.
EM isabella.palumbo@unipg.it
RI Ingrosso, Gianluca/JDC 5539 2023; RUGGIERO, CARMELINDA/K 6169 2016;
   Baroni, Marta/AAB 8697 2019; Mecocci, Patrizia/W 2116 2019
CR Abdollah F, 2015, EJSO EUR J SURG ONC, V41, P1529, DOI 10.1016/j.ejso.2015.06.011
   Aggarwal V, 2021, THER ADV MUSCULOSKEL, V13, DOI 10.1177/1759720X211024029
   aifa, DET NO 446 2017 14 0
   Balestroni Gianluigi, 2012, Monaldi Arch Chest Dis, V78, P155
   Banu J, 2013, DRUG DES DEV THER, V7, P849, DOI 10.2147/DDDT.S46101
   Briot K, 2019, JOINT BONE SPINE, V86, P21, DOI 10.1016/j.jbspin.2018.09.017
   Capture the Fracture, SANT MAR MIS FRACT U
   Casado E, 2022, WORLD J MENS HEALTH, V40, P74, DOI 10.5534/wjmh.210061
   Choo R, 2013, INT J RADIAT ONCOL, V85, P1239, DOI 10.1016/j.ijrobp.2012.11.007
   Cianferotti L, 2017, ONCOTARGET, V8, P75646, DOI 10.18632/oncotarget.17980
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Damji AN, 2015, OSTEOPOROSIS INT, V26, P951, DOI 10.1007/s00198 014 2997 6
   Denham JW, 2014, BJU INT, V114, P344, DOI 10.1111/bju.12497
   Doria C, 2016, CLIN CASES MINER BON, V13, P195, DOI 10.11138/ccmbm/2016.13.3.195
   FRAX®, FRACT RISK ASS TOOL
   Fukumoto S, 2020, J BONE MINER METAB, V38, P141, DOI 10.1007/s00774 020 01087 0
   Galvano A, 2019, J BONE ONCOL, V18, DOI 10.1016/j.jbo.2019.100252
   Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003 4819 146 6 200703200 00006
   Javaid MK, 2021, AGING CLIN EXP RES, V33, P2061, DOI 10.1007/s40520 021 01844 9
   Morizio P, 2018, ANN PHARMACOTHER, V52, P1031, DOI 10.1177/1060028018768808
   Nakanishi E, 2022, ANTICANCER RES, V42, P3529, DOI 10.21873/anticanres.15839
   Pinedo Villanueva R, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0569 2
   Rinonapoli G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042105
   Rizzoli R, OSTEOPOROSIS INT, V24
   Russell N, 2021, UROL ONCOL SEMIN ORI, V39, P704, DOI 10.1016/j.urolonc.2018.10.007
   Santini D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen 2019 000652
   Shapiro CL, 2019, J CLIN ONCOL, V37, P2916, DOI 10.1200/JCO.19.01696
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Svedbom A, 2019, OSTEOPOROSIS INT, V30, P1745, DOI 10.1007/s00198 019 05064 w
   Thorstenson A, 2012, EUR J CANCER, V48, P1672, DOI 10.1016/j.ejca.2012.01.035
NR 31
TC 2
Z9 2
U1 1
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2023
VL 43
IS 1
BP 493
EP 499
DI 10.21873/anticanres.16186
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA E2ZZ1
UT WOS:000974291900060
PM 36585208
DA 2025 08 17
ER

PT J
AU Ding, ZB
   Chen, Y
   Zheng, YR
   Wang, YY
   Deng, WD
   Zheng, JH
   Yang, Q
   Chen, ZY
   Li, LH
   Jiang, H
   Li, XJ
AF Ding, Zong bao
   Chen, Yan
   Zheng, Yu rong
   Wang, Yi yuan
   Deng, Wen de
   Zheng, Jie huang
   Yang, Qin
   Chen, Zi ye
   Li, Li hong
   Jiang, Hui
   Li, Xiao juan
TI Inhibition of PPP1R15A alleviates osteoporosis via suppressing
   RANKL induced osteoclastogenesis
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE osteoporosis; Sephin1; osteoclastogenesis; RANKL; eIF2 alpha
ID NF KAPPA B; TRANSLATIONAL CONTROL; SELECTIVE INHIBITION; BONE; MICE;
   PREVENTION
AB Osteoporosis results from overactivation of osteoclasts. There are currently few drug options for treatment of this disease. Since the successful development of allosteric inhibitors, phosphatases have become attractive therapeutic targets. Protein phosphatase 1, regulatory subunit 15 A (PPP1R15A), is a stress responsive protein, which promotes the UPR (unfolded protein response) and restores protein homeostasis. In this study we investigated the role of PPP1R15A in osteoporosis and osteoclastogenesis. Ovariectomy (OVX) induced osteoporosis mouse model was established, osteoporosis was evaluated in the left femurs using micro CT. RANKL stimulated osteoclastogenesis was used as in vitro models. We showed that PPP1R15A expression was markedly increased in BMMs derived from OVX mice and during RANKL induced osteoclastogenesis in vitro. Knockdown of PPP1R15A or application of Sephin1 (a PPP1R15A allosteric inhibitor in a phase II clinical trial) significantly inhibited osteoclastogenesis in vitro. Sephin1 (0.78, 3.125 and 12.5 mu M) dose dependently mitigated the changes in NF kappa B, MAPK, and c FOS and the subsequent nuclear factor of activated T cells 1 (NFATc1) translocation in RANKL stimulated BMMs. Both Sephin1 and PPP1R15A knockdown increased the phosphorylated form of eukaryotic initiation factor 2 alpha (eIF2 alpha); knockdown of eIF2 alpha reduced the inhibitory effects of Sephin1 on NFATc1 luc transcription and osteoclast formation. Furthermore, Sephin1 or PPP1R15A knockdown suppressed osteoclastogenesis in CD14(+) monocytes from osteoporosis patients. In OVX mice, injection of Sephin1 (4, 8 mg/kg, i.p.) every two days for 6 weeks significantly inhibited bone loss, and restored bone destruction and decreased TRAP positive cells. This study has identified PPP1R15A as a novel target for osteoclast differentiation, and genetic inhibition or allosteric inhibitors of PPP1R15A, such as Sephin1, can be used to treat osteoporosis.
C1 [Ding, Zong bao; Chen, Yan; Wang, Yi yuan; Deng, Wen de; Zheng, Jie huang; Yang, Qin; Chen, Zi ye; Li, Li hong; Li, Xiao juan] Southern Med Univ, Lab Antiinflammatory & Immunomodulatory Pharmacol,, NMPA Key Lab Res & Evaluat Drug Metab, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China.
   [Ding, Zong bao; Chen, Yan; Wang, Yi yuan; Deng, Wen de; Zheng, Jie huang; Yang, Qin; Chen, Zi ye; Li, Li hong; Li, Xiao juan] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.
   [Ding, Zong bao] Zunyi Med Univ, Dept Bioengn, Zhuhai Campus, Zhuhai 519041, Peoples R China.
   [Zheng, Yu rong; Jiang, Hui] Southern Med Univ, Nanfang Hosp, Dept Orthoped, Div Spine Surg, Guangzhou 510515, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Zunyi Medical University; Southern Medical University   China
RP Li, XJ (通讯作者)，Southern Med Univ, Lab Antiinflammatory & Immunomodulatory Pharmacol,, NMPA Key Lab Res & Evaluat Drug Metab, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China.; Li, XJ (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.; Jiang, H (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthoped, Div Spine Surg, Guangzhou 510515, Peoples R China.
EM jianghui@smu.edu.cn; lixiaoj@smu.edu.cn
OI Li, Xiaojuan/0000 0002 2668 3044
FU National Natural Science Foundation of China [82173825, 81773740,
   81972064]; Science and Technology Plan Project of Guangzhou City
   [201804010027]
FX This work was supported by the National Natural Science Foundation of
   China (82173825, 81773740, and 81972064) and the Science and Technology
   Plan Project of Guangzhou City (201804010027).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Briggs Michael D, 2020, F1000Res, V9, DOI 10.12688/f1000research.22275.1
   Callejo G, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113834
   Carrara M, 2017, NAT STRUCT MOL BIOL, V24, P708, DOI 10.1038/nsmb.3443
   Chen YA, 2019, BRAIN, V142, P344, DOI 10.1093/brain/awy322
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Das I, 2015, SCIENCE, V348, P239, DOI 10.1126/science.aaa4484
   Dömötör ZR, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.573976
   Ferrari S, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115287
   Fusade Boyer M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00134
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097 2765(01)00264 7
   Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624
   Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097 0215(20010220)96:1<22::AID IJC3>3.0.CO;2 K
   Huang WL, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13071050
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kitamura M, 2009, ANTIOXID REDOX SIGN, V11, P2353, DOI [10.1089/ars.2008.2391, 10.1089/ARS.2008.2391]
   Kittaka M, 2018, J BONE MINER RES, V33, P167, DOI 10.1002/jbmr.3295
   Krzyzosiak A, 2018, CELL, V174, P1216, DOI 10.1016/j.cell.2018.06.030
   LaMarche MJ, 2020, J MED CHEM, V63, P13578, DOI 10.1021/acs.jmedchem.0c01170
   Lamy O, 2019, CURR OSTEOPOROS REP, V17, P8, DOI 10.1007/s11914 019 00502 4
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Liu FC, 2023, OSTEOPOROSIS INT, V34, P1729, DOI 10.1007/s00198 023 06818 3
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Ma T, 2013, NAT NEUROSCI, V16, P1299, DOI 10.1038/nn.3486
   Madeira M, 2020, ARCH ENDOCRIN METAB, V64, P664, DOI 10.20945/2359 3997000000301
   Marciniak SJ, 2022, NAT REV DRUG DISCOV, V21, P115, DOI 10.1038/s41573 021 00320 3
   Mullard A, 2018, NAT REV DRUG DISCOV, V17, P847, DOI 10.1038/nrd.2018.201
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pardo VG, 2006, INT J BIOCHEM CELL B, V38, P1181, DOI 10.1016/j.biocel.2005.12.018
   Querrer R, 2021, SUPPORT CARE CANCER, V29, P2811, DOI 10.1007/s00520 020 05855 6
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ruiz A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176088
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Sun XT, 2018, EXP NEUROL, V303, P95, DOI 10.1016/j.expneurol.2018.01.015
   Teng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.24
   Thapa S, 2020, MOL NEUROBIOL, V57, P2206, DOI 10.1007/s12035 020 01880 y
   Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Vainonen JP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe2967
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Way SW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7532
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Zalli D, 2016, J BONE MINER RES, V31, P1701, DOI 10.1002/jbmr.2851
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zheng Chao, 2022, Methods Mol Biol, V2378, P205, DOI 10.1007/978 1 0716 1732 8_13
   Zhong ML, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115134
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zou BH, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153377
NR 54
TC 3
Z9 4
U1 2
U2 14
PU NATURE PUBL GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD APR
PY 2024
VL 45
IS 4
BP 790
EP 802
DI 10.1038/s41401 023 01209 0
EA JAN 2024
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA LA5M8
UT WOS:001137750400002
PM 38191913
DA 2025 08 17
ER

PT J
AU Starlinger, J
   Santol, J
   Kaiser, G
   Sarahrudi, K
AF Starlinger, Julia
   Santol, Jonas
   Kaiser, Georg
   Sarahrudi, Kambiz
TI Close negative correlation of local and circulating Dickkopf 1 and
   Sclerostin levels during human fracture healing
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Dickkopf 1; DKK1; Fracture healing; Nonunion
ID DIABETES MELLITUS; SERUM LEVELS; BONE MASS; DKK1; ROMOSOZUMAB;
   ADOLESCENTS; INHIBITION; CHILDREN
AB Wnt signaling is critically involved in fracture healing. Existing data predominantly relies on rodent models. Here, we explored local and circulating Dickkopf 1 (DKK1) levels in patients with respect to fracture healing and explore its association to sclerostin (SOST). 69 patients after surgical stabilization of long bone fractures of which six patients had impaired fracture healing were included in this study. Life style and patient related factors with a known effect on DKK1 and SOST were recorded. DKK1 and SOST concentrations were measured using enzyme linked immunosorbent assay (ELISA) at the fracture site and in circulation. DKK1 and SOST showed a close inverse correlation. In fracture hematoma and immediately after trauma DKK1 levels were significantly reduced while SOST levels were significantly increased, compared to healthy control. Postoperatively, DKK1 peaked at week 2 and SOST at week 8, again demonstrating a close negative correlation. Age and smoking status affected the balance of DKK1 and SOST, while type 2 diabetes and sex did not demonstrate a significant influence. Early postoperative elevation of SOST without compensatory DKK1 decrease was associated with fracture non union in younger patients (< 50a). The close inverse correlation and very rapid dynamics of DKK1 and SOST locally as well as systemically suggest their critical involvement during human fracture healing. Importantly, as immediate compensatory feedback mechanism are apparent, we provide evidence that dual blockade of DKK1 and SOST could be critical to allow for therapeutic efficiency of Wnt targeted therapies for fracture healing.
C1 [Starlinger, Julia; Santol, Jonas; Kaiser, Georg; Sarahrudi, Kambiz] Med Univ Vienna, Gen Hosp Vienna, Dept Orthoped & Trauma Surg, Vienna, Austria.
   [Santol, Jonas] Sigmund Freud Private Univ, Viennese Hlth Network, Dept Surg, HPB Ctr,Clin Favoriten, Vienna, Austria.
   [Santol, Jonas] Mayo Clin, Dept Surg, Div Hepatobiliary & Pancreas Surg, Rochester, MN USA.
   [Sarahrudi, Kambiz] Wiener Neustadt Reg Hosp, Dept Trauma Surg, Wiener Neustadt, Austria.
C3 Medical University of Vienna; Mayo Clinic
RP Starlinger, J (通讯作者)，Med Univ Vienna, Gen Hosp Vienna, Dept Orthoped & Trauma Surg, Vienna, Austria.
EM tellstarlinger@gmail.com
OI Santol, Jonas/0000 0002 8097 9735
CR Bhandari M, 2020, J BONE JOINT SURG AM, V102, P1416, DOI 10.2106/JBJS.19.01008
   Dovjak P, 2014, GERONTOLOGY, V60, P493, DOI 10.1159/000358303
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   ElHawary H, 2021, SEMIN PLAST SURG, V35, P198, DOI 10.1055/s 0041 1732334
   Faienza MF, 2017, J CLIN ENDOCR METAB, V102, P1174, DOI 10.1210/jc.2016 2371
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Hay E, 2016, GERONTOLOGY, V62, P618, DOI 10.1159/000446278
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Hildebrandt N, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81543 7
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Jorde R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225539
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   McDonald MM, 2018, CALCIFIED TISSUE INT, V102, P105, DOI 10.1007/s00223 017 0338 4
   McDonald MM, 2012, J ORTHOP RES, V30, P1541, DOI 10.1002/jor.22109
   Mihara A, 2021, WORLD J ORTHOP, V12, P651, DOI 10.5312/wjo.v12.i9.651
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Pacicca DM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52224 3
   Ren Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.670960
   Sarahrudi K, 2012, J ORTHOP RES, V30, P1549, DOI 10.1002/jor.22129
   Schemitsch EH, 2020, J BONE JOINT SURG AM, V102, P693, DOI 10.2106/JBJS.19.00790
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Toor SM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.781272
   Tsentidis C, 2017, OSTEOPOROSIS INT, V28, P945, DOI 10.1007/s00198 016 3802 5
   van Lierop AH, 2014, J CLIN ENDOCR METAB, V99, pE252, DOI 10.1210/jc.2013 3278
   Wang N, 2018, ENDOCR RES, V43, P29, DOI 10.1080/07435800.2017.1373662
   Witcher PC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98673
NR 30
TC 6
Z9 6
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 19
PY 2024
VL 14
IS 1
AR 6524
DI 10.1038/s41598 024 55756 5
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LO3Y5
UT WOS:001187716400001
PM 38499638
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Mizobuchi, M
   Ogata, H
   Koiwa, F
   Kinugasa, E
   Akizawa, T
AF Mizobuchi, Masahide
   Ogata, Hiroaki
   Koiwa, Fumihiko
   Kinugasa, Eriko
   Akizawa, Tadao
TI Vitamin D and vascular calcification in chronic kidney disease
SO BONE
LA English
DT Article
DE Vascular calcification; Vitamin D; Calcium; Phosphate; Chronic kidney
   disease; Cardiovascular disease
ID SMOOTH MUSCLE CELLS; HEMODIALYSIS PATIENTS; SECONDARY
   HYPERPARATHYROIDISM; PARATHYROID HORMONE; UREMIC RATS; D ANALOGS;
   1,25 DIHYDROXYVITAMIN D 3; AORTIC CALCIFICATION; CARDIOVASCULAR
   CALCIFICATION; CALCITRIOL THERAPY
AB Vascular calcification is frequently observed and is closely associated with cardiovascular mortality in patients with chronic kidney disease (CKD). Vascular calcification is largely divided into two types. One is atherosclerotic intimal layer calcification and the other is medial layer calcification (Monckeberg's calcification). The latter is more common in patients with CKD than in general population. Evidence is growing that vascular calcification is a regulated active process as well as a passive process resulting from elevated serum phosphate (P) and an increase in the calcium phosphate (Ca x P) product leading to oversaturated plasma. Proving the active process, in vitro Studies have demonstrated that the transformation of vascular smooth muscle cells (VSMCs) into osteoblast like cells is a crucial mechanism in the Progression Of Vascular calcification. Reduction of the activity of systemic and local inhibitors has also been recognized to be important. The link between vitamin D and vascular calcification is complex. Experimental and clinical researches have revealed that both vitamin D excess and vitamin D deficiency have been shown to be associated With Vascular calcification in uremic milieu. On the other hand, although there are some biases, recent large observational Studies have demonstrated that vitamin D has beneficial effects on the mortality of patients with CKD independent of serum Ca, P, and parathyroid hormone levels, likely due to its activation of the vitamin D receptor in vasculature and cardiac myocytes. Further prospective Studies are necessary to evaluate the direct effect of vitamin D on vascular calcification in order to improve the cardiovascular health of patients with CKD. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Mizobuchi, Masahide; Akizawa, Tadao] Showa Univ, Sch Med, Dept Nephrol, Tokyo 142, Japan.
   [Ogata, Hiroaki; Kinugasa, Eriko] Showa Univ, No Yokohama Hosp, Dept Internal Med, Yokohama, Kanagawa, Japan.
   [Koiwa, Fumihiko] Showa Univ, Fujigaoka Hosp, Div Nephrol, Dept Internal Med, Yokohama, Kanagawa 227, Japan.
C3 Showa University; Showa University; Showa University
RP Mizobuchi, M (通讯作者)，Showa Univ, Sch Med, Dept Nephrol, Tokyo 142, Japan.
EM mizobu@med.showa u.ac.jp
RI Ogata, Hiroaki/A 7946 2011
OI Ogata, Hiroaki/0000 0002 0046 5575
CR [Anonymous], 2003, Am J Kidney Dis, V42, pS1
   Boström K, 2001, AM J CARDIOL, V88, p20E
   Brown A J., 2008, Molecular Aspects of Medicine
   Cardús A, 2006, KIDNEY INT, V69, P1377, DOI 10.1038/sj.ki.5000304
   Cardús A, 2003, NEFROLOGIA, V23, P117
   Cardus A, 2007, J BONE MINER RES, V22, P860, DOI 10.1359/JBMR.070305
   Cranenburg ECM, 2008, J VASC RES, V45, P427, DOI 10.1159/000124863
   Craver L, 2007, NEPHROL DIAL TRANSPL, V22, P1171, DOI 10.1093/ndt/gfl718
   Derici U, 2006, SEMIN DIALYSIS, V19, P60, DOI 10.1111/j.1525 139X.2006.00120.x
   Doherty TM, 1997, CIRCULATION, V96, P1477, DOI 10.1161/01.CIR.96.5.1477
   Dusso AS, 2005, AM J PHYSIOL RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004
   Giachelli CM, 2005, CIRC RES, V96, P717, DOI 10.1161/01.RES.0000161997.24797.c0
   Goldsmith DJA, 1997, NEPHRON, V77, P37, DOI 10.1159/000190244
   Goodman WG, 2004, AM J KIDNEY DIS, V43, P572, DOI 10.1053/j.ajkd.2003.12.005
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   Haffner D, 2005, J HYPERTENS, V23, P1067, DOI 10.1097/01.hjh.0000166849.72721.1c
   Henley C, 2005, NEPHROL DIAL TRANSPL, V20, P1370, DOI 10.1093/ndt/gfh834
   Hirata M, 2003, NEPHROL DIAL TRANSPL, V18, P1770, DOI 10.1093/ndt/gfg296
   INOUE T, 1988, BIOCHEM BIOPH RES CO, V152, P1388, DOI 10.1016/S0006 291X(88)80439 X
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Ketteler M, 2005, CURR OPIN NEPHROL HY, V14, P337, DOI 10.1097/01.mnh.0000172719.26606.6f
   Kovesdy CP, 2008, ARCH INTERN MED, V168, P397, DOI 10.1001/archinternmed.2007.110
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   Lopez I, 2006, J AM SOC NEPHROL, V17, P795, DOI 10.1681/ASN.2005040342
   MACCARTHY EP, 1989, HYPERTENSION, V13, P954, DOI 10.1161/01.HYP.13.6.954
   MATIAS PJ, 2008, NEPHROL DIAL TRANSPL
   MCGONIGLE RJS, 1984, NEPHRON, V36, P94, DOI 10.1159/000183125
   Mizobuchi M, 2007, KIDNEY INT, V72, P709, DOI 10.1038/sj.ki.5002406
   Mizobuchi M, 2006, NEPHROL DIAL TRANSPL, V21, P911, DOI 10.1093/ndt/gfk008
   Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854
   Moe SM, 2003, KIDNEY INT, V63, P1003, DOI 10.1046/j.1523 1755.2003.00820.x
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Nibbelink KA, 2007, J STEROID BIOCHEM, V103, P533, DOI 10.1016/j.jsbmb.2006.12.099
   NOONAN W, 2008, NEPHROL DIAL TRANSPL
   Park CW, 1999, AM J KIDNEY DIS, V33, P73, DOI 10.1016/S0272 6386(99)70260 X
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Rajasree S, 2002, LIFE SCI, V70, P1777, DOI 10.1016/S0024 3205(02)01473 X
   Shanahan CM, 2005, CURR OPIN NEPHROL HY, V14, P361, DOI 10.1097/01.mnh.0000172723.52499.38
   Shoben AB, 2008, J AM SOC NEPHROL, V19, P1613, DOI 10.1681/ASN.2007111164
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   Shroff RC., 2008, NEPHROL DIAL TRANSPL
   Shroff R, 2008, J AM SOC NEPHROL, V19, P1239, DOI 10.1681/ASN.2007090993
   Shroff RC, 2007, SEMIN DIALYSIS, V20, P103, DOI 10.1111/j.1525 139X.2007.00255.x
   Somjen D, 2005, CIRCULATION, V111, P1666, DOI 10.1161/01.CIR.0000160353.27927.70
   Tamura K, 2005, J PHARMACOL SCI, V99, P89, DOI 10.1254/jphs.FPJ05019X
   Tamura K, 2007, EUR J PHARMACOL, V558, P159, DOI 10.1016/j.ejphar.2006.12.006
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Tishkoff DX, 2008, ENDOCRINOLOGY, V149, P558, DOI 10.1210/en.2007 0805
   Verberckmoes SC, 2007, KIDNEY INT, V71, P298, DOI 10.1038/sj.ki.5002028
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   Wolisi GO, 2005, SEMIN DIALYSIS, V18, P307, DOI 10.1111/j.1525 139X.2005.18407.x
   Wu Wong JR, 2007, J CELL BIOCHEM, V100, P1395, DOI 10.1002/jcb.21133
   Wu Wong JR, 2006, ATHEROSCLEROSIS, V186, P20, DOI 10.1016/j.atherosclerosis.2005.06.046
   Wu Wong JR, 2006, J PHARMACOL EXP THER, V318, P90, DOI 10.1124/jpet.106.101261
   Xiang W, 2005, AM J PHYSIOL ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004
NR 61
TC 34
Z9 36
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2009
VL 45
SU 1
BP S26
EP S29
DI 10.1016/j.bone.2009.01.011
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 458PU
UT WOS:000267036800006
PM 19442619
DA 2025 08 17
ER

PT J
AU Zhang, W
   Zhao, W
   Li, W
   Geng, Q
   Zhao, R
   Yang, YG
   Lv, LY
   Chen, WW
AF Zhang, Wei
   Zhao, Wei
   Li, Wei
   Geng, Qi
   Zhao, Rui
   Yang, Yungui
   Lv, Luyan
   Chen, Weiwen
TI The Imbalance of Cytokines and Lower Levels of Tregs in Elderly Male
   Primary Osteoporosis
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE male primary osteoporosis; bone mineral density; cytokines; Treg cells;
   bone turnover markers
ID REGULATORY T CELLS; BONE TURNOVER MARKERS; OSTEOCLAST FORMATION;
   POSTMENOPAUSAL WOMEN; MINERAL DENSITY; IDENTIFICATION; EXPRESSION;
   FOXP3; CD127
AB IntroductionOsteoporosis (OP) is a debilitating disease that brings a heavy burden to individuals and society with reduced quality of life and lifespan. However, it's frequently overlooked and poorly studied in elderly male patients. Worse still, few anti osteoporosis drugs are effective at the prevention and treatment of osteoporosis in men. It has been reported that the cells of bone and the immune system share common progenitors, cytokines and growth factors, and that reciprocal interactions occur during health and disease. Nevertheless, the role of immune system in OP is not fully understood, especially in male patients. Therefore, this study aimed to investigate molecular alterations in immune cells in men with OP and to identify immunomodulatory strategies with potential therapeutic value. Materials and MethodsA population of 121 men aged between 51 and 80 years old was recruited. Bone mineral density (BMD) was measured at the lumbar spine L1 4 and femoral neck using dual energy X ray absorptiometry (DXA). Twenty people were healthy, 66 people had osteopenia and 35 people had OP. Bone metabolic markers, Th1, Th2, Tregs and immune molecules were evaluated at the time of enrollment. ResultsSmoking was a risk factor for OP. C terminal crosslinking of type I collagen (beta CTX) and the ratio of receptor activator of nuclear factor kappa B ligand (RANKL) to osteoprotegerin (OPG) were higher in OP group, which had lower 25 hydroxyvitamin D [25(OH)D] levels. OP had the higher levels of IL 6 and TNF alpha and lower levels of IFN gamma and IL 10. CD4(+)CD25(+)CD127( /low) Tregs were significantly lower in the OP group. The imbalance of Th1/Th2 cells may play an important role in the development of OP. 25(OH)D may play essential roles in maintaining bone health. The low level of Tregs is also one of the underlying immune mechanism that leads to male primary OP. ConclusionThe active function of osteoclasts and the decline in osteoblasts were characteristics of OP, and the imbalance in cytokines and lower levels of Tregs were observed in elderly male patients with primary OP.
C1 [Zhang, Wei; Zhao, Rui; Chen, Weiwen] Kunming Med Univ, Dept Endocrinol, Qujing Affiliated Hosp, Yunnan, Peoples R China.
   [Zhao, Wei] Dali Bai Autonomous Prefecture Peoples Hosp, Dept Spinal Surg, Yunnan, Peoples R China.
   [Li, Wei] Kunming Med Univ, Dept Med Adm, Qujing Affiliated Hosp, Yunnan, Peoples R China.
   [Geng, Qi] Kunming Med Univ, Dept Med Labs, Qujing Affiliated Hosp, Yunnan, Peoples R China.
   [Yang, Yungui] Third Peoples Hosp Qujing City, Dept Geriatr, Yunnan, Peoples R China.
   [Lv, Luyan] Kunming Med Univ, Dept Geriatr, Qujing Affiliated Hosp, Yunnan, Peoples R China.
C3 Kunming Medical University; Kunming Medical University; Kunming Medical
   University; Kunming Medical University
RP Chen, WW (通讯作者)，Kunming Med Univ, Dept Endocrinol, Qujing Affiliated Hosp, Yunnan, Peoples R China.; Yang, YG (通讯作者)，Third Peoples Hosp Qujing City, Dept Geriatr, Yunnan, Peoples R China.; Lv, LY (通讯作者)，Kunming Med Univ, Dept Geriatr, Qujing Affiliated Hosp, Yunnan, Peoples R China.
EM yygls3988@126.com; 215223784@qq.com; 30620765@qq.com
RI 陈, 伟文/HZJ 7316 2023
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Apalset EM, 2014, CLIN EXP IMMUNOL, V176, P452, DOI 10.1111/cei.12288
   Arenas Ramirez N, 2015, TRENDS IMMUNOL, V36, P763, DOI 10.1016/j.it.2015.10.003
   Biver E, 2012, CURR OPIN ENDOCRINOL, V19, P468, DOI 10.1097/MED.0b013e3283591492
   Bozec A, 2017, CURR OSTEOPOROS REP, V15, P121, DOI 10.1007/s11914 017 0356 1
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Cao DJ, 2004, ARTHRITIS RES THER, V6, pR335, DOI 10.1186/ar1192
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   D'Amelio P, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/907689
   de Vries TJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01395
   Dean JW, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2020.102417
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Fischer L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00578
   Gao C, 2017, OSTEOPOROSIS INT, V28, P211, DOI 10.1007/s00198 016 3692 6
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Hartigan O'Connor DJ, 2007, J IMMUNOL METHODS, V319, P41, DOI 10.1016/j.jim.2006.10.008
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Ishimi Y, 2015, J NUTR SCI VITAMINOL, V61, pS139, DOI 10.3177/jnsv.61.S139
   Jiang ZF, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100272
   LaCroix AZ, 2013, BONE, V56, P474, DOI 10.1016/j.bone.2013.05.018
   Leeming D J, 2011, Biomark Cancer, V3, P15, DOI 10.4137/BIC.S6484
   Leslie WD, 2014, CURR OPIN RHEUMATOL, V26, P440, DOI 10.1097/BOR.0000000000000064
   Li M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103841
   Li Yan, 2014, Open Bone J, V6, P8
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Mauri C, 2015, INT IMMUNOL, V27, P479, DOI 10.1093/intimm/dxv038
   Moniuszko M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/459210
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Nahas Neto J, 2018, OSTEOPOROSIS INT, V29, P1125, DOI 10.1007/s00198 018 4395 y
   Nam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040044
   O'Brien W, 2016, ARTHRITIS RHEUMATOL, V68, P2889, DOI 10.1002/art.39837
   Pagliari D, 2015, ANAL CELL PATHOL, V2015, P1, DOI 10.1155/2015/434389
   Shizuku M, 2020, BREAST CANCER TOKYO, V27, P1065, DOI 10.1007/s12282 020 01109 9
   Sun JJ, 2012, CANCER DISCOV, V2, P122, DOI 10.1158/2159 8290.CD 11 0236
   Tanaka Y, 2019, J BONE MINER METAB, V37, P2, DOI 10.1007/s00774 018 0965 5
   Tang MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01508
   Valencia K, 2013, BONE, V52, P532, DOI 10.1016/j.bone.2012.10.033
   Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343
   Wang TY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03102
   Yokota Kazuhiro, 2017, Nihon Rinsho Meneki Gakkai Kaishi, V40, P367, DOI 10.2177/jsci.40.367
   Yuan FL, 2010, BIOCHEM BIOPH RES CO, V402, P173, DOI 10.1016/j.bbrc.2010.09.120
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zhang XY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01982
   Zhao HY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00262
   Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547
NR 47
TC 11
Z9 13
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 31
PY 2022
VL 13
AR 779264
DI 10.3389/fendo.2022.779264
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 2B5CQ
UT WOS:000810206500001
PM 35721756
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yamaguchi, M
   Levy, RM
AF Yamaguchi, Masayoshi
   Levy, Robert M.
TI Combination of alendronate and genistein synergistically suppresses
   osteoclastic differentiation of RAW267.4 cells in vitro
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE bisphosphonate; alendronate; isoflavone; genistein; osteoclastic
   differentiation; RAW267.4 cell
ID HEPATOMA H4 II E CELLS; BONE RESORPTION; TISSUE CULTURE; CANCER RISK;
   BISPHOSPHONATES; OSTEOPOROSIS; ACTIVATION; OVEREXPRESSION; INVOLVEMENT;
   MECHANISMS
AB Bone is a dynamic tissue that undergoes constant remodeling, with removal by osteoclastic bone resorption and replacement via osteoblastic bone formation and mineralization. Deterioration of bone mass with aging leads to osteoporosis. Bisphosphonates are potent inhibitors of osteoclastic bone resorption. Genistein, an isoflavone, exerts a bone anabolic effect by suppressing osteoclastic bone resorption and stimulating osteoblastic bone formation. The present study was undertaken to investigate the anabolic effects of a combination of alendronate and genistein on osteoclastic differentiation. Preosteoclastic RAW267.4 cells were cultured with alendronate (0.1 100 mu M) and/or genistein (0.1 100 mu M) in vitro. Alendronate or genistein alone had no significant effect on the proliferation and death of RAW267.4 cells. Notably, the combination of the two agents was found to potently and synergistically repress the proliferation and death of RAW267.4 cells. Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor kappa B ligand (RANKL) in vitro. However, combinations of the two agents (0.1 100 mu M) synergistically suppressed the RANKL induced osteoclastic differentiation. In conclusion, bisphosphonate and genistein combination therapy may provide a novel strategy for the prevention and treatment of osteoclastic bone resorption.
C1 [Yamaguchi, Masayoshi] Emory Univ, Sch Med, Dept Hematol & Med Oncol, C 5054,1365C Clifton Rd NE, Atlanta, GA 30322 USA.
   [Levy, Robert M.] Primus Pharmaceut Inc, Dept Clin Dev, Scottsdale, AZ 85253 USA.
C3 Emory University
RP Yamaguchi, M (通讯作者)，Emory Univ, Sch Med, Dept Hematol & Med Oncol, C 5054,1365C Clifton Rd NE, Atlanta, GA 30322 USA.
EM yamamasa1155@yahoo.co.jp
CR Cardwell CR, 2012, INT J CANCER, V131, pE717, DOI 10.1002/ijc.27389
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Chambers TJ, 2011, ANN NY ACAD SCI, V1240, P1, DOI 10.1111/j.1749 6632.2011.06249.x
   COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043 2760(92)90032 V
   Faiman Beth, 2013, J Adv Pract Oncol, V4, P25
   Feng ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080890
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gao YH, 1999, BIOCHEM PHARMACOL, V58, P767, DOI 10.1016/S0006 2952(99)00162 8
   Gao YH, 1999, MOL CELL BIOCHEM, V194, P93, DOI 10.1023/A:1006949912266
   Gao YH, 2000, INT J MOL MED, V5, P261
   Izumi T, 2004, J CELL BIOCHEM, V92, P296, DOI 10.1002/jcb.20056
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Mottaghi P, 2010, J RES MED SCI, V15, P175
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Oh YH, 2012, WORLD J GASTROENTERO, V18, P5779, DOI 10.3748/wjg.v18.i40.5779
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sutherland KA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2681
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yamaguchi M, 2000, MOL CELL BIOCHEM, V214, P97, DOI 10.1023/A:1007199120295
   Yamaguchi M, 2005, J CELL BIOCHEM, V95, P1169, DOI 10.1002/jcb.20490
   Yamaguchi M, 1998, BIOCHEM PHARMACOL, V55, P71, DOI 10.1016/S0006 2952(97)00402 4
   Yamaguchi M., 2013, Int J Food Sci Nutr Diet, V2, P27, DOI DOI 10.19070/2326 3350 130006
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V366, P201, DOI 10.1007/s11010 012 1298 7
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
   Yamaguchi M, 2011, INT J MOL MED, V27, P3, DOI 10.3892/ijmm.2010.562
   Yamaguchi M, 2009, INT J MOL MED, V23, P297, DOI 10.3892/ijmm_00000131
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
NR 28
TC 6
Z9 7
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD AUG
PY 2017
VL 14
IS 2
BP 1769
EP 1774
DI 10.3892/etm.2017.4695
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FB7BY
UT WOS:000406297300127
PM 28810648
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhai, L
   Sun, N
   Zhang, B
   Liu, ST
   Zhao, Z
   Jin, HC
   Ma, XL
   Xing, GY
AF Zhai, Lei
   Sun, Nan
   Zhang, Bo
   Liu, Shui Tao
   Zhao, Zhe
   Jin, Hai Chao
   Ma, Xin Long
   Xing, Geng Yan
TI EFFECTS OF FOCUSED EXTRACORPOREAL SHOCK WAVES ON BONE MARROW MESENCHYMAL
   STEM CELLS IN PATIENTS WITH AVASCULAR NECROSIS OF THE FEMORAL HEAD
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Extracorporeal shock wave; Femoral head; Bone marrow mesenchymal stem
   cells
ID OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION; THERAPY; OSTEONECROSIS;
   GAMMA; PROTEINS; HIP
AB To observe the effect of extracorporeal shock waves (ESWs) on bone marrow mesenchymal stem cells (MSCs) in patients with avascular necrosis of the femoral head, we collected bone marrow donated by patients and then cultivated and passaged MSCs in vitro using density gradient centrifugation combined with adherence screening methods. The P3 generation MSCs were divided into the ESW group and the control group. The cell counting kit for MSCs detected some proliferation differences. Cytochemistry, alkaline phosphatase staining and Alizarin red staining were used to determine alkaline phosphatase content. Simultaneously, real time polymerase factor alpha 1, osteocalcin and peroxisome proliferator activated receptor gamma. Together, the results of our study first indicate that moderate ESW intensity, which is instrumental in enhancing MSC proliferation, inducing conversion of MSCs into osteoblasts, and inhibiting differentiation of MSCs into adipocytes from MSCs, is one of the effective mechanisms for treating avascular necrosis of the femoral head. (E mail: zhangbomianyi@163.com) (C) 2016 World Federation for Ultrasound in Medicine & Biology.
C1 [Zhai, Lei] Chinese Peoples Armed Police Force, Logist Coll, Affiliated Hosp, Dept Orthopaed Surg, Tianjin 300162, Peoples R China.
   [Zhai, Lei; Liu, Shui Tao; Jin, Hai Chao] Tianjin Med Univ, Gen Hosp, Dept Orthopaed Surg, Tianjin 300052, Peoples R China.
   [Sun, Nan] Chinese Peoples Armed Police Force, Logist Coll, Affiliated Hosp, Dept Nephropathy, Tianjin 300162, Peoples R China.
   [Zhang, Bo] Tianjin Med Univ, Sch Basic Med Sci, Dept Immunol, Tianjin Key Lab Cellular & Mol Immunol, Tianjin 300052, Peoples R China.
   [Zhao, Zhe; Xing, Geng Yan] Chinese Peoples Armed Police Force, Gen Hosp, Dept Orthopaed Surg, Beijing 100039, Peoples R China.
   [Ma, Xin Long] Tianjin Hosp, Dept Orthopaed Surg, 406 Jiefang Nan Rd, Tianjin 300211, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Xing, GY (通讯作者)，Chinese Peoples Armed Police Force, Gen Hosp, Dept Orthopaed Surg, Beijing 100039, Peoples R China.
EM zhangbomianyi@163.com
RI Zhao, zhuo/JYO 7894 2024; zhang, bo/HJY 1433 2023; Ma,
   Xinlong/HSI 2099 2023; Sun, Nan/IWM 5170 2023
OI Zhao, Zhe/0000 0003 4300 2391; 
FU NSFC [31172169]; Affiliated Hospital of Logistics College of Chinese
   People's Armed Police Force [FYQ201456]; Tianjin Medical University
   [2014KYM12]
FX This work was supported by a grant from NSFC (31172169) and a grant from
   The Affiliated Hospital of Logistics College of Chinese People's Armed
   Police Force (FYQ201456) as well as a fund from Tianjin Medical
   University (2014KYM12).
CR Bannuru RR, 2014, ANN INTERN MED, V160, P542, DOI 10.7326/M13 1982
   Catalano M. G, 2014, J TISSUE ENG REGEN M
   Chen JM, 2009, ARCH ORTHOP TRAUM SU, V129, P837, DOI 10.1007/s00402 008 0812 6
   Chen TW, 2014, KAOHSIUNG J MED SCI, V30, P362, DOI 10.1016/j.kjms.2014.03.006
   Chen YJ, 2004, J ORTHOP RES, V22, P526, DOI 10.1016/j.orthres.2003.10.005
   DELIUS M, 1995, ULTRASOUND MED BIOL, V21, P1219, DOI 10.1016/0301 5629(95)00030 5
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Hofmann A, 2008, J TRAUMA, V65, P1402, DOI 10.1097/TA.0b013e318173e7c2
   Hsu SL, 2010, ARCH ORTHOP TRAUM SU, V130, P23, DOI 10.1007/s00402 009 0918 5
   Huang J, 2013, INT J MOL MED, V32, P423, DOI 10.3892/ijmm.2013.1398
   Jin HT, 2012, INT ORTHOP, V36, P2589, DOI 10.1007/s00264 012 1674 7
   Korda M, 2008, J ORTHOP RES, V26, P880, DOI 10.1002/jor.20598
   Lee JS, 2006, J ORTHOP RES, V24, P604, DOI 10.1002/jor.20078
   Lee S, 2014, J PHYS THER SCI, V26, P7, DOI 10.1589/jpts.26.7
   Lee SJ, 2011, BIOTECHNOL LETT, V33, P229, DOI 10.1007/s10529 010 0440 4
   Lennon DP, 2006, EXP HEMATOL, V34, P1604, DOI 10.1016/j.exphem.2006.07.014
   Li L, 2013, CELL MOL BIOL, V59, P1889, DOI 10.1170/225
   Lim YW, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.128
   Liu X, 2014, TISSUE ENG PT A, V20, P883, DOI 10.1089/ten.TEA.2012.0677
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miao TX, 2014, J CONTROL RELEASE, V192, P57, DOI 10.1016/j.jconrel.2014.06.029
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nallamshetty S, 2014, BONE, V67, P281, DOI 10.1016/j.bone.2014.07.005
   Pan K, 2009, CELL PROLIFERAT, V42, P364, DOI 10.1111/j.1365 2184.2009.00599.x
   Prall WC, 2013, BIOCHEM BIOPH RES CO, V440, P617, DOI 10.1016/j.bbrc.2013.09.114
   Takahashi K, 2004, CALCIFIED TISSUE INT, V74, P187, DOI 10.1007/s00223 003 0043 3
   Vulpiani MC, 2012, ARCH ORTHOP TRAUM SU, V132, P499, DOI 10.1007/s00402 011 1444 9
   Wang BL, 2013, ORTHPEDICS, V31, P444
   Wang CJ, 2008, ARCH ORTHOP TRAUM SU, V128, P901, DOI 10.1007/s00402 007 0530 5
   Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756 3282(03)00029 2
   Yu WH, 2012, INT J BIOCHEM CELL B, V44, P377, DOI 10.1016/j.biocel.2011.11.013
   Zhou C, 2014, CELL PROLIFERAT, V47, P124, DOI 10.1111/cpr.12097
NR 33
TC 25
Z9 28
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD MAR
PY 2016
VL 42
IS 3
BP 753
EP 762
DI 10.1016/j.ultrasmedbio.2015.10.021
PG 10
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA DI3FH
UT WOS:000373383400012
PM 26674675
DA 2025 08 17
ER

PT J
AU Lu, Y
   Liu, YZ
   Liu, PY
   Dvornyk, V
   Deng, HW
AF Lu, Yan
   Liu, Yao Zhong
   Liu, Peng Yuan
   Dvornyk, Volodymyr
   Deng, Hong Wen
TI A bootstrap based regression method for comprehensive discovery of
   differential gene expressions: An application to the osteoporosis study
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE Microarray; Bootstrap; Regression; Osteoporosis
ID BONE MINERAL DENSITY; QUANTITATIVE TRAIT LOCI; ESTROGEN RECEPTOR ALPHA;
   METHYLENETETRAHYDROFOLATE REDUCTASE; PLASMA HOMOCYSTEINE; MICROARRAY
   DATA; FORMATION INVITRO; COMMON MUTATION; FOLATE STATUS; WOMEN
AB A common purpose of microarray experiments is to study the variation in gene expression across the categories of an experimental factor such as tissue types and drug treatments. However, it is not uncommon that the studied experimental factor is a quantitative variable rather than categorical variable. Loss of information would occur by comparing gene expression levels between groups that are factitiously defined according to the quantitative threshold values of an experimental factor. Additionally, lack of control for some sensitive clinical factors may bring serious false positive or negative findings.
   In the present study, we described a bootstrap based regression method for analyzing gene expression data from the non categorical microarray experiments. To illustrate the utility of this method, we applied it to our recent gene expression study of circulating monocytes in subjects with a wide range of variations in bone mineral density (BMD). This method allows a comprehensive discovery of gene expressions associated with osteoporosis related traits while controlling other common confounding factors such as height, weight and age. Several genes identified in our study are involved in osteoblast and osteoclast functions and bone remodeling and/or menopause associated estrogen dependent pathways, which provide important clues to understand the etiology of osteoporosis. Availability: SAS code is available from the authors upon request. (C) 2011 Elsevier Masson SAS. All rights reserved.
C1 [Lu, Yan; Deng, Hong Wen] Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China.
   [Lu, Yan; Liu, Peng Yuan] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA.
   [Lu, Yan; Liu, Peng Yuan] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA.
   [Liu, Yao Zhong; Deng, Hong Wen] Tulane Univ, Sch Publ Hlth, Dept Biostat & Bioinformat, New Orleans, LA 70112 USA.
   [Liu, Yao Zhong; Deng, Hong Wen] Tulane Univ, Sch Publ Hlth, Ctr Bioinformat & Genom, New Orleans, LA 70112 USA.
   [Dvornyk, Volodymyr] Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China.
C3 Beijing Jiaotong University; Medical College of Wisconsin; Medical
   College of Wisconsin; Tulane University; Tulane University; University
   of Hong Kong
RP Deng, HW (通讯作者)，Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China.
EM hdeng2@tulane.edu
RI Dvornyk, Volodymyr/X 6072 2019; Liu, Yaozhong/ABD 5544 2020; Liu,
   Pengyuan/ITV 9407 2023
OI Deng, Hong Wen/0000 0002 0387 8818; 
FU NIH; State of Nebraska; CNSF; Huo Ying Dong Education Foundation;
   Ministry of Education of China; Xi'an Jiaotong University
FX Investigators of this work were partially supported by grants from NIH,
   State of Nebraska and CNSF. The study was also benefited by grants from
   Huo Ying Dong Education Foundation, the Ministry of Education of China,
   and Xi'an Jiaotong University.
CR Abrahamsen B, 2003, J BONE MINER RES, V18, P723, DOI 10.1359/jbmr.2003.18.4.723
   Azoulay É, 2005, INTENS CARE MED, V31, P56, DOI 10.1007/s00134 004 2484 1
   Azoulay E, 1999, INTENS CARE MED, V25, P1395, DOI 10.1007/s001340051087
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207
   Deng HW, 2002, J BONE MINER METAB, V20, P358, DOI 10.1007/s007740200052
   Dudoit S., 2000, STAT SINICA, V11, P111
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595 111
   GILSANZ V, 1995, J CLIN INVEST, V95, P2332, DOI 10.1172/JCI117925
   GOYETTE P, 1994, NAT GENET, V7, P551, DOI 10.1038/ng0894 551a
   Graves Dana T., 1999, Frontiers in Bioscience, V4, pd571, DOI 10.2741/Graves
   Hak AE, 2000, ATHEROSCLEROSIS, V149, P163, DOI 10.1016/S0021 9150(99)00321 4
   Hatano H, 2004, J BONE MINER METAB, V22, P224, DOI 10.1007/s00774 003 0482 y
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7
   Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045
   Kerr M K, 2001, Biostatistics, V2, P183, DOI 10.1093/biostatistics/2.2.183
   Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954
   Kimura S, 2004, PATHOL INT, V54, P465, DOI 10.1111/j.1440 1827.2004.01653.x
   Klein RF, 2002, J BONE MINER RES, V17, P1752, DOI 10.1359/jbmr.2002.17.10.1752
   Klein RF, 1998, J BONE MINER RES, V13, P1648, DOI 10.1359/jbmr.1998.13.11.1648
   Liu YZ, 2003, J ENDOCRINOL, V177, P147, DOI 10.1677/joe.0.1770147
   Liu YZ, 2005, J BIOL CHEM, V280, P29011, DOI 10.1074/jbc.M501164200
   Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007
   Lu Y, 2005, CURR GENET, V47, P121, DOI 10.1007/s00294 004 0551 3
   MacDonald ND, 2004, INT J GYNECOL CANCER, V14, P957, DOI 10.1111/j.1048 891X.2004.014535.x
   Mandelin J, 2003, J RHEUMATOL, V30, P2033
   McLean RR, 2004, J BONE MINER RES, V19, P410, DOI 10.1359/JBMR.0301261
   Miles RR, 2000, ENDOCRINOLOGY, V141, P4533, DOI 10.1210/en.141.12.4533
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Miyao M, 2000, CALCIFIED TISSUE INT, V66, P190, DOI 10.1007/s002230010038
   Nagel D, 2002, BIOCHEM BIOPH RES CO, V290, P1558, DOI 10.1006/bbrc.2002.6387
   NGUYEN L, 1991, LYMPHOKINE CYTOK RES, V10, P15
   Novaro V, 2004, CLIN CANCER RES, V10, p402S, DOI 10.1158/1078 0432.CCR 031209
   Passaro A, 2001, ATHEROSCLEROSIS, V157, P175, DOI 10.1016/S0021 9150(00)00696 1
   RALSTON SH, 1994, J BONE MINER RES, V9, P883
   Recker R, 2000, J BONE MINER RES, V15, P1965, DOI 10.1359/jbmr.2000.15.10.1965
   RUFF CB, 1988, J ORTHOP RES, V6, P886, DOI 10.1002/jor.1100060613
   Schurman L, 2001, EXP CLIN ENDOCR DIAB, V109, P340, DOI 10.1055/s 2001 17401
   Seeman E, 1999, BONE, V25, P143, DOI 10.1016/S8756 3282(99)00117 9
   STASHENKO P, 1987, J BONE MINER RES, V2, P559
   Stein MS, 1998, J BIOMECH, V31, P1101, DOI 10.1016/S0021 9290(98)00127 4
   Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895 4356(03)00047 7
   Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   Zhou HM, 2004, MOL CELL BIOL, V24, P96, DOI 10.1128/MCB.24.1.96 104.2004
NR 46
TC 3
Z9 4
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1769 7212
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD NOV DEC
PY 2011
VL 54
IS 6
BP E560
EP E564
DI 10.1016/j.ejmg.2011.07.002
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 989CF
UT WOS:000307537100006
PM 21843665
DA 2025 08 17
ER

PT J
AU Sakolish, C
   House, JS
   Chramiec, A
   Liu, YZ
   Chen, ZW
   Halligan, SP
   Vunjak Novakovic, G
   Rusyn, I
AF Sakolish, Courtney
   House, John S.
   Chramiec, Alan
   Liu, Yizhong
   Chen, Zunwei
   Halligan, Susan P.
   Vunjak Novakovic, Gordana
   Rusyn, Ivan
TI Tissue Engineered Bone Tumor as a Reproducible Human in Vitro
   Model for Studies of Anticancer Drugs
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE tissue chip; alternatives to animal testing < in vitro and alternatives;
   toxicogenomics < methods; safety evaluation; bone < systems toxicology
ID LC MS/MS METHOD; VALIDATION; DOXORUBICIN; METHOTREXATE; COMBINATION;
   BIOLOGY; PLASMA
AB Studies of anticancer therapies in traditional cell culture models can demonstrate efficacy of direct acting compounds but lack the 3 dimensional arrangement of the tumor cells and their tissue specific microenvironments, both of which are important modulators of treatment effects in vivo. Bone cells reside in complex environments that regulate their fate and function. A bioengineered human bone tumor model has been shown to provide a microphysiological niche for studies of cancer cell behavior. Here, we demonstrate successful transfer between 2 laboratories and utility of this model in efficacy studies using well established chemotherapeutic agents. The bioengineered human bone tumor model consisted of Ewing sarcoma (RD ES) cancer cell aggregates infused into tissue engineered bone that was grown from human mesenchymal stem cell derived differentiated into osteoblasts within mineralized bone scaffolds. The tumor model was maintained in culture for over 5weeks and subjected to clinically relevant doses of linsitinib, doxorubicin, cisplatin, methotrexate, vincristine, dexamethasone, or MAP (methotrexate, doxorubicin, and cisplatin combination). Drug administration cycles were designed to mimic clinical treatment regimens. The bioengineered tumors were evaluated days to weeks after the cessation of treatment to monitor the potential for relapse, using bioengineered bone and ES cell monolayers as controls. Drug binding to the scaffolds and media proteins and gene expression were also evaluated. We show that a bioengineered human bone tumor can be used as a microphysiological model for preclinical studies of anticancer drugs. We found that anticancer efficacy was achieved at concentrations approximating the human C max, in contrast to traditional ES cell monolayers. These studies show that the bone tumor model can be successfully transferred between laboratories and has predictive power in preclinical studies. The effects of drugs on the bone tumors and healthy bone were studied in parallel, in support of the utility of this model for identification of new therapeutic targets.
C1 [Sakolish, Courtney; Liu, Yizhong; Chen, Zunwei; Rusyn, Ivan] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
   [House, John S.] North Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA.
   [Chramiec, Alan; Halligan, Susan P.; Vunjak Novakovic, Gordana] Columbia Univ, Dept Biomed Engn, New York, NY 10032 USA.
C3 Texas A&M University System; Texas A&M University College Station; North
   Carolina State University; Columbia University
RP Rusyn, I (通讯作者)，Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.; Vunjak Novakovic, G (通讯作者)，Columbia Univ, Dept Biomed Engn, New York, NY 10032 USA.
EM gv2131@columbia.edu; irusyn@cvm.tamu.edu
RI Liu, Yizhong/B 1548 2017; vunjak novakovic, gordana/J 9279 2012; House,
   John/A 1933 2013; Rusyn, Ivan/S 2426 2016; Chen, Zunwei/N 4970 2017
OI House, John S./0000 0002 8447 7871; Rusyn, Ivan/0000 0001 9340 7384;
   Chen, Zunwei/0000 0001 7773 1635
FU National Institutes of Health: National Center for Advancing
   Translational Sciences [TR001950]; National Institute of Biomedical
   Imaging and Bioengineering [EB0025765]; National Institute of
   Environmental Health Sciences [T32ES026568] Funding Source: NIH RePORTER
FX National Institutes of Health: National Center for Advancing
   Translational Sciences (TR001950 to I.R.) and National Institute of
   Biomedical Imaging and Bioengineering (EB0025765 to G.V.N.).
CR Abdel Hamid ME, 2004, J LIQ CHROMATOGR R T, V27, P641, DOI 10.1081/JLC 120028254
   Auner AW, 2019, LAB CHIP, V19, P864, DOI 10.1039/c8lc00796a
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 293
   Carvalho MR, 2017, STEM CELL REV REP, V13, P347, DOI 10.1007/s12015 017 9720 x
   Chen Z, 2018, TOXICOL APPL PHARM, V351, P12, DOI 10.1016/j.taap.2018.05.005
   Chramiec A, 2019, ADV DRUG DELIVER REV, V140, P78, DOI 10.1016/j.addr.2019.04.003
   Dutton P, 2018, STAT METHODS MED RES, V27, P1451, DOI 10.1177/0962280216662070
   Ewart L, 2017, EXP BIOL MED, V242, P1579, DOI 10.1177/1535370217715441
   Fan CM, 2017, BREAST CANCER RES TR, V165, P41, DOI 10.1007/s10549 017 4308 3
   Ferguson JL, 2018, AM FAM PHYSICIAN, V98, P205
   Grayson WL, 2010, P NATL ACAD SCI USA, V107, P3299, DOI 10.1073/pnas.0905439106
   Griesinger C, 2016, ADV EXP MED BIOL, V856, P65, DOI 10.1007/978 3 319 33826 2_4
   Grimm FA, 2016, GREEN CHEM, V18, P4407, DOI 10.1039/c6gc01147k
   Guilhaumou R, 2010, J CHROMATOGR B, V878, P423, DOI 10.1016/j.jchromb.2009.12.015
   Havas AP, 2016, CANCER BIOL THER, V17, P1240, DOI 10.1080/15384047.2016.1250046
   House JS, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00168
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jacques C, 2019, METHODS MOL BIOL, V1914, P331, DOI 10.1007/978 1 4939 8997 3_18
   Jacques C, 2018, J BONE ONCOL, V12, P7, DOI 10.1016/j.jbo.2018.02.004
   Khanna N, 2017, INDIAN J MED PAEDIAT, V38, P173, DOI 10.4103/ijmpo.ijmpo_24_17
   Lamhamedi Cherradi SE, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djw182
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Low LA, 2017, EXP BIOL MED, V242, P1573, DOI 10.1177/1535370217700523
   Marcos Campos I, 2012, BIOMATERIALS, V33, P8329, DOI 10.1016/j.biomaterials.2012.08.013
   Marturano Kruik A, 2015, IEEE ENG MED BIO, P3561, DOI 10.1109/EMBC.2015.7319162
   Marturano Kruik A, 2016, METHODS MOL BIOL, V1502, P203, DOI 10.1007/7651_2016_353
   Marx U, 2016, ALTEX ALTERN ANIM EX, V33, P272, DOI 10.14573/altex.1603161
   Meyers Paul A, 2015, Am Soc Clin Oncol Educ Book, pe644, DOI 10.14694/EdBook_AM.2015.35.e644
   Moore Drew D, 2014, Cancer Treat Res, V162, P93, DOI 10.1007/978 3 319 07323 1_5
   Poondru S, 2016, CANCER CHEMOTH PHARM, V77, P829, DOI 10.1007/s00280 016 2999 5
   Rodin I, 2013, J CHROMATOGR B, V937, P1, DOI 10.1016/j.jchromb.2013.07.026
   Ronaldson Bouchard K, 2018, CELL STEM CELL, V22, P310, DOI 10.1016/j.stem.2018.02.011
   Sakolish C, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 33099 2
   Smalley KSM, 2006, IN VITRO CELL DEV AN, V42, P242
   Sun Y, 2014, INT IMMUNOPHARMACOL, V18, P135, DOI 10.1016/j.intimp.2013.11.014
   Villasante A, 2017, TISSUE ENG PART C ME, V23, P98, DOI [10.1089/ten.tec.2016.0371, 10.1089/ten.TEC.2016.0371]
   Villasante A, 2014, BIOMATERIALS, V35, P5785, DOI 10.1016/j.biomaterials.2014.03.081
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Yu HJ, 2017, ONCOTARGET, V8, P5523, DOI 10.18632/oncotarget.12566
   Yu L, 2016, COLLOID SURFACE B, V145, P392, DOI 10.1016/j.colsurfb.2016.05.029
   Yuan Y, 2015, BIOMED CHROMATOGR, V29, P578, DOI 10.1002/bmc.3316
   Zhang T, 2016, APPL SPECTROSC, V70, P1529, DOI 10.1177/0003702816662607
   Zschenker O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034279
NR 43
TC 10
Z9 11
U1 1
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096 6080
EI 1096 0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD JAN
PY 2020
VL 173
IS 1
BP 65
EP 76
DI 10.1093/toxsci/kfz220
PG 12
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA KD8MR
UT WOS:000508116400008
PM 31626302
OA Green Published
DA 2025 08 17
ER

PT J
AU Holding, CA
   Findlay, DM
   Stamenkov, R
   Neale, SD
   Lucas, H
   Dharmapatni, ASSK
   Callary, SA
   Shrestha, KR
   Atkins, GJ
   Howie, DW
   Haynes, DR
AF Holding, Christopher A.
   Findlay, David M.
   Stamenkov, Roumen
   Neale, Susan D.
   Lucas, Helen
   Dharmapatni, A. S. S. K.
   Callary, Stuart A.
   Shrestha, Kush R.
   Atkins, Gerald J.
   Howie, Donald W.
   Haynes, David R.
TI The correlation of RANK, RANKL and TNFα expression with bone loss volume
   and polyethylene wear debris around hip implants
SO BIOMATERIALS
LA English
DT Article
DE osteolysis; osteoclast; wear debris; polyethylene; image analysis
ID HUMAN OSTEOCLAST FORMATION; COMPUTERIZED TOMOGRAPHY; ACETABULAR
   COMPONENTS; OSTEOLYSIS; PARTICLES; LIGAND; MACROPHAGES; RESORPTION;
   CELLS; MODEL
AB This study investigates receptor activator NF kappa B (RANK), RANK ligand (RANKL) and tumour necrosis factor (TNF alpha), key factors regulating bone turnover, present in the tissues near peri prosthetic osteolysis. Tissue was obtained from zones of peri prosthetic osteolysis from 11 patients undergoing revision of total hip prostheses, analysed preoperatively by high resolution spiral multislice CT using a metal artefact suppression protocol. Synovial tissue from 10 patients with osteoarthritis undergoing primary hip replacement was used as control tissue. Immunohistochemical analysis of formalin fixed tissue sections demonstrated that RANK, RANKL and TNFa were strongly expressed by large multinucleated cells containing polyethylene wear debris in revision tissues. Control tissue stained weakly for RANK, RANKL and TNFa. A strong statistical correlation (p < 0.02) was found between the five parameters, volume of bone loss, polyethylene wear debris, RANK, RANKL and TNFa expression. Importantly, in vitro studies revealed that RANKL and TNF alpha synergise to increase the volume of bone resorbed, by more than seven fold, when compared to the effect of either cytokine treatment alone. This suggests that the interaction of TNFa and RANKL promotes osteoclast activity associated with polyethylene wear and therapies targeting TNF activity may be useful to treat peri implant osteolysis. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Adelaide, Dept Pathol, Adelaide, SA 5000, Australia.
   Univ Adelaide, Dept Orthopaed & Trauma, Adelaide, SA 5000, Australia.
   Hanson Inst, Adelaide, SA 5000, Australia.
C3 University of Adelaide; University of Adelaide; Hanson Institute
RP Haynes, DR (通讯作者)，Univ Adelaide, Dept Pathol, Adelaide, SA 5000, Australia.
EM david.haynes@adelaide.edu.au
OI Callary, Stuart/0000 0002 2892 5238; Howie, Donald/0000 0003 1702 3279;
   Atkins, Gerald/0000 0002 3123 9861
CR ALSAFFAR N, 1994, BRIT J RHEUMATOL, V33, P309
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Baumann B, 2004, ACTA ORTHOP SCAND, V75, P295, DOI 10.1080/00016470410001222
   Brooks RA, 2000, J BONE JOINT SURG BR, V82B, P595, DOI 10.1302/0301 620X.82B4.9744
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Frick KK, 2005, AM J PHYSIOL RENAL, V289, pF1005, DOI 10.1152/ajprenal.00420.2004
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Garrigues GE, 2005, BIOMATERIALS, V26, P2933, DOI 10.1016/j.biomaterials.2004.06.034
   GRAVES SE, 2004, MED J AUSTRALIA, V180, P531
   Hansen T, 2001, J RHEUMATOL, V28, P1615
   HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46
   Haynes DR, 2004, INFLAMM RES, V53, P596, DOI 10.1007/s00011 004 1303 z
   Haynes DR, 2004, BIOMATERIALS, V25, P4877, DOI 10.1016/j.biomaterials.2004.01.003
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Haynes DR, 1999, BONE, V25, P269, DOI 10.1016/S8756 3282(99)00176 3
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Horowitz SM, 1997, J ORTHOP RES, V15, P50, DOI 10.1002/jor.1100150108
   HOWIE DW, 1988, J BONE JOINT SURG AM, V70A, P257, DOI 10.2106/00004623 198870020 00015
   HOWIE DW, 1990, CLIN ORTHOP RELAT R, P144
   JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623 199306000 00007
   Kim KJ, 1998, CLIN ORTHOP RELAT R, P46
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071
   Link TM, 2000, J COMPUT ASSIST TOMO, V24, P165, DOI 10.1097/00004728 200001000 00029
   Looney RJ, 2002, ARTHRITIS RES, V4, P59, DOI 10.1186/ar384
   Matthews JB, 2001, J MATER SCI MATER M, V12, P249, DOI 10.1023/A:1008967200706
   Orishimo KF, 2003, J BONE JOINT SURG AM, V85A, P1095, DOI 10.2106/00004623 200306000 00018
   Quinn JMW, 1998, CALCIFIED TISSUE INT, V62, P527, DOI 10.1007/s002239900473
   Rader CP, 1999, J ARTHROPLASTY, V14, P840, DOI 10.1016/S0883 5403(99)90035 9
   Ren W, 2004, SCAND J RHEUMATOL, V33, P349, DOI 10.1080/03009740410005944
   Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736 0266(02)00106 7
   SANTAVIRTA S, 1990, J BONE JOINT SURG BR, V72, P980, DOI 10.1302/0301 620X.72B6.2246301
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Stamenkov R, 2003, CLIN ORTHOP RELAT R, P117, DOI 10.1097/01.blo.0000069001.16315.f4
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
NR 36
TC 105
Z9 128
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 2006
VL 27
IS 30
BP 5212
EP 5219
DI 10.1016/j.biomaterials.2006.05.054
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 084BK
UT WOS:000240506400007
PM 16806459
DA 2025 08 17
ER

PT J
AU Hutchins Wiese, HL
   Picho, K
   Watkins, BA
   Li, Y
   Tannenbaum, S
   Claffey, K
   Kenny, AM
AF Hutchins Wiese, Heather L.
   Picho, Katherine
   Watkins, Bruce A.
   Li, Yong
   Tannenbaum, Susan
   Claffey, Kevin
   Kenny, Anne M.
TI High Dose Eicosapentaenoic Acid and Docosahexaenoic Acid Supplementation
   Reduces Bone Resorption in Postmenopausal Breast Cancer Survivors on
   Aromatase Inhibitors: A Pilot Study
SO NUTRITION AND CANCER AN INTERNATIONAL JOURNAL
LA English
DT Article
ID N 3 FATTY ACIDS; MINERAL DENSITY; HIP FRACTURE; OSTEOCLAST
   DIFFERENTIATION; INFLAMMATORY CYTOKINES; ARACHIDONIC ACID; LINOLENIC
   ACID; OLDER ADULTS; WOMEN; RISK
AB Postmenopausal breast cancer survivors are living longer; however, a common class of drugs, aromatase inhibitors (AI), depletes estrogen levels, promotes bone loss, and heightens fracture risk. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may offset AI effects to bone because of the known effects on cellular processes of bone turnover. Therefore, we hypothesized that 4g of EPA and DHA daily for 3 mo would decrease bone turnover in postmenopausal breast cancer survivors on AI therapy in a randomized, double blind, placebo controlled pilot study that included 38 women. At baseline and 3 mo, serum fatty acids, bone turnover, and inflammatory markers were analyzed. Serum EPA and DHA, total and long chain (LC) omega (n) 3 polyunsaturated fatty acids (PUFA) increased, whereas arachidonic acid, total and LC n 6 PUFA, and the LC n 6:n 3 PUFA ratio decreased compared to placebo (all P < .05). Bone resorption was inhibited in the fish oil responders compared to placebo (P < .05). Inflammatory markers were not altered. This short term, high dose fish oil supplementation study's findings demonstrate that fish oil can reduce bone resorption; however, longer term studies are needed to assess bone density preservation and to explore mechanistic pathways in this population at high risk for bone loss.
C1 [Hutchins Wiese, Heather L.] Eastern Michigan Univ, Ypsilanti, MI 48197 USA.
   [Hutchins Wiese, Heather L.; Watkins, Bruce A.; Kenny, Anne M.] Univ Connecticut, Ctr Aging, Farmington, CT 06030 USA.
   [Picho, Katherine] Univ Connecticut, Ctr Hlth, Ctr Biostat, Farmington, CT 06030 USA.
   [Watkins, Bruce A.; Li, Yong] Univ Connecticut, Lipid Chem & Mol Biol Lab, Storrs, CT USA.
   [Tannenbaum, Susan; Claffey, Kevin] Univ Connecticut, Ctr Hlth, Neag Canc Ctr, Farmington, CT 06030 USA.
C3 Eastern Michigan University; University of Connecticut; University of
   Connecticut; University of Connecticut; University of Connecticut
RP Kenny, AM (通讯作者)，Univ Connecticut, Ctr Aging, 263 Farmington Ave,MC 5215, Farmington, CT 06030 USA.
EM kenny@uchc.edu
RI ; tannenbaum, susan/AHB 1525 2022
OI Picho, Katherine/0000 0003 0003 2531; Watkins, Bruce/0000 0002 2793 4538
FU The Connecticut Breast Health Initiative; University of Connecticut
   Health Center General Clinical Research Center
FX This study was funded by The Connecticut Breast Health Initiative and
   the University of Connecticut Health Center General Clinical Research
   Center.
CR Alfano CM, 2012, J CLIN ONCOL, V30, P1280, DOI 10.1200/JCO.2011.36.4109
   Appleton KM, 2011, BRIT J NUTR, V105, P1145, DOI 10.1017/S0007114510004861
   Bassey EJ, 2000, BRIT J NUTR, V83, P629, DOI 10.1017/S0007114500000805
   Bhattacharya A, 2007, J NUTR BIOCHEM, V18, P372, DOI 10.1016/j.jnutbio.2006.07.002
   Bhattacharya A, 2007, J NUTR BIOCHEM, V18, P23, DOI 10.1016/j.jnutbio.2006.02.005
   Body JJ, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 384
   Calder PC, 2006, PROSTAG LEUKOTR ESS, V75, P197, DOI 10.1016/j.plefa.2006.05.012
   CLAASSEN N, 1995, PROSTAG LEUKOTR ESS, V53, P13, DOI 10.1016/0952 3278(95)90078 0
   Coetzee M, 2009, CELL BIOCHEM FUNCT, V27, P3, DOI 10.1002/cbf.1526
   Corwin RL, 2006, J NUTR, V136, P159, DOI 10.1093/jn/136.1.159
   Crandall C J., 2012, Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report
   Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   Farina EK, 2011, J NUTR, V141, P1146, DOI 10.3945/jn.110.133728
   Farina EK, 2011, AM J CLIN NUTR, V93, P1142, DOI 10.3945/ajcn.110.005926
   Gallicchio L, 2012, J BONE MINER RES, V27, P1959, DOI 10.1002/jbmr.1641
   Griel AE, 2007, NUTR J, V6, DOI 10.1186/1475 2891 6 2
   Gronowitz E, 2008, BRIT J NUTR, V99, P160, DOI 10.1017/S000711450780105X
   Gronowitz E, 2006, BRIT J NUTR, V95, P1159, DOI 10.1079/BJN20061778
   Haag M, 2003, PROSTAG LEUKOTR ESS, V68, P423, DOI 10.1016/S0952 3278(03)00067 X
   Henry NL, 2010, BRIT J CANCER, V103, P291, DOI 10.1038/sj.bjc.6605768
   Herrera BS, 2008, BRIT J PHARMACOL, V155, P1214, DOI 10.1038/bjp.2008.367
   Högström M, 2007, AM J CLIN NUTR, V85, P803
   Hutchins HL, 2011, J NUTR BIOCHEM, V22, P195, DOI 10.1016/j.jnutbio.2010.06.001
   Kanapuru B, 2012, BREAST CANCER RES TR, V134, P853, DOI 10.1007/s10549 012 2115 4
   Kolahi S, 2010, CLIN BIOCHEM, V43, P576, DOI 10.1016/j.clinbiochem.2009.12.011
   Kruger MC, 2010, PROG LIPID RES, V49, P438, DOI 10.1016/j.plipres.2010.06.002
   Kruger MC, 2005, PROSTAG LEUKOTR ESS, V73, P327, DOI 10.1016/j.plefa.2005.08.001
   Kruger MC, 1998, AGING CLIN EXP RES, V10, P385, DOI 10.1007/BF03339885
   Li Y, 2010, BRIT J NUTR, V104, P674, DOI 10.1017/S0007114510001133
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Oh SR, 2010, J LIPID RES, V51, P892, DOI [10.1194/jlr.M800626 JLR200, 10.1194/jlr.M800626]
   Orchard TS, 2013, J BONE MINER RES, V28, P505, DOI 10.1002/jbmr.1772
   Orchard TS, 2010, AM J CLIN NUTR, V92, P1452, DOI 10.3945/ajcn.2010.29955
   Poulsen RC, 2008, PROSTAG OTH LIPID M, V85, P42, DOI 10.1016/j.prostaglandins.2007.10.004
   Prestwood KM, 1996, OSTEOPOROSIS INT, V6, P314, DOI 10.1007/BF01623391
   Quispe D, 2011, BREAST J, V17, P510, DOI 10.1111/j.1524 4741.2011.01119.x
   Rahman MM, 2009, J CELL MOL MED, V13, P1833, DOI 10.1111/j.1582 4934.2009.00649.x
   Rahman M, 2008, J CELL PHYSIOL, V214, P201, DOI 10.1002/jcp.21188
   Rousseau JH, 2009, J AM GERIATR SOC, V57, P1781, DOI 10.1111/j.1532 5415.2008.01870.x
   Santen RJ, 2011, J CLIN ENDOCR METAB, V96, P308, DOI 10.1210/jc.2010 1679
   Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c
   Shen CL, 2008, J MED FOOD, V11, P105, DOI 10.1089/jmf.2007.540
   Stark KD, 2004, AM J CLIN NUTR, V79, P765
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007 0001
   Sun DX, 2003, J BONE MINER RES, V18, P1206, DOI 10.1359/jbmr.2003.18.7.1206
   Trichopoulou A, 1997, PREV MED, V26, P395, DOI 10.1006/pmed.1997.0160
   Virtanen JK, 2010, J BONE MINER RES, V25, P1972, DOI 10.1002/jbmr.87
   Watkins BA, 2000, J NUTR, V130, P2274, DOI 10.1093/jn/130.9.2274
   Watkins BA, 2003, PROSTAG LEUKOTR ESS, V68, P387, DOI 10.1016/S0952 3278(03)00063 2
   Weiss LA, 2005, AM J CLIN NUTR, V81, P934, DOI 10.1093/ajcn/81.4.934
   Yuan J, 2010, PROSTAG OTH LIPID M, V92, P85
NR 52
TC 50
Z9 51
U1 0
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163 5581
EI 1532 7914
J9 NUTR CANCER
JI Nutr. Cancer
PD JAN 1
PY 2014
VL 66
IS 1
BP 68
EP 76
DI 10.1080/01635581.2014.847964
PG 9
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Nutrition & Dietetics
GA 281ZZ
UT WOS:000329141100008
PM 24274259
DA 2025 08 17
ER

PT J
AU Long, J
   Zhang, W
   Chen, YQ
   Teng, B
   Liu, B
   Li, HL
   Yao, ZY
   Wang, D
   Li, L
   Yu, XF
   Qin, L
   Lai, YX
AF Long, Jing
   Zhang, Wei
   Chen, Yingqi
   Teng, Bin
   Liu, Ben
   Li, Huilin
   Yao, Zhenyu
   Wang, Dou
   Li, Long
   Yu, Xue Feng
   Qin, Ling
   Lai, Yuxiao
TI Multifunctional magnesium incorporated scaffolds by 3D Printing for
   comprehensive postsurgical management of osteosarcoma
SO BIOMATERIALS
LA English
DT Article
DE Magnesium; Osteosarcoma; Photothermal therapy; Bone regeneration;
   3D printed scaffolds
ID PHOTOTHERMAL THERAPY; BONE; BIOMATERIAL; COMPOSITE; RUNX2;
   NANOPARTICLES; OSTEONECROSIS; REGENERATION; EXPRESSION; OSTEOBLAST
AB Clinical treatment of Osteosarcoma (OS) encounters great challenges of postsurgical tumor recurrence and extensive bone defect. To address these issues, innovative multifunctional PLGA/Mg porous scaffolds were designed for comprehensive postsurgical management of OS. The PLGA/Mg composite scaffolds exhibited several unique features: (1) The multiple functions of Mg particles were explored for the first time to fulfill the requirement for postsurgical management of OS. The intact Mg particles exhibits excellent photothermal effect for tumor eradication, and the released Mg ions could subsequently promote bone regeneration, thus endowing the PLGA/Mg scaffolds dual functions of suppressing OS recurrence and repairing bone defect in a sequential way; (2) A low temperature rapid prototyping (LT RP) 3D printing technology was used to fabricate the scaffolds with biomimetic hierarchical porous structures, which could structurally promote bone regeneration; (3) The PLGA/Mg scaffolds have excellent biodegradability and biocompatibility, exhibiting great promise for clinical translation. Finally, the PLGA/Mg scaffolds achieved complete suppression of tumor recurrence in the presence of near infrared laser irradiation, as well as efficient bone defect repair in vivo. Activation of the AKT and beta catenin pathways of osteoblast cells by PLGA/Mg scaffolds was identified, which might be the modulators to accelerate the ossification. The innovative PLGA/Mg scaffolds demonstrated excellent capabilities in postsurgical OS recurrence suppression and bone regeneration, providing a promising clinical strategy for comprehensive postsurgical management of OS.
C1 [Long, Jing; Zhang, Wei; Chen, Yingqi; Liu, Ben; Li, Huilin; Yao, Zhenyu; Wang, Dou; Li, Long; Qin, Ling; Lai, Yuxiao] Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen, Peoples R China.
   [Lai, Yuxiao] Chinese Acad Sci, Key Lab Hlth Informat, Shenzhen, Peoples R China.
   [Teng, Bin] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Biotechnol, Res Ctr Reprod & Hlth Dev, Shenzhen, Peoples R China.
   [Yu, Xue Feng] Chinese Acad Sci, Shenzhen Inst Adv Technol, Mat & Interfaces Ctr, Shenzhen, Peoples R China.
   [Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Musculoskeletal Res Lab, Hong Kong, Hong Kong, Peoples R China.
   [Qin, Ling; Lai, Yuxiao] CAS HK Joint Lab Biomat, Shenzhen, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese Academy of Sciences; Chinese Academy of Sciences; Shenzhen
   Institute of Advanced Technology, CAS; Chinese Academy of Sciences;
   Shenzhen Institute of Advanced Technology, CAS; Chinese University of
   Hong Kong
RP Lai, YX (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen, Peoples R China.
EM yx.lai@siat.ac.cn
RI ; qin, ling/KIB 1029 2024; Liu, Ben/AAG 9784 2021; Li,
   Huilin/ABD 8451 2020; Lai, Yuxiao/AFN 1336 2022; Chen,
   Yingqi/NOF 6550 2025; yu, xuefeng/AGT 5190 2022
OI Zhang, Wei/0000 0002 5663 4438; 
FU National Natural Science Foundation of China [82022045, 22007098]; CAS
   Interdisciplinary Innovation Team [JCTD 2020 19]; Shenzhen Double Chain
   Project for Innovation and Development Industry; Bureau of Industry and
   Information Technology of Shenzhen [201806081503414910]; Shenzhen
   Fundamental Research Foundation [JCYJ20190807154807663]; Key Laboratory
   of Health Informatics, Chinese Academy of Sciences; Natural Science
   Foundation of Guangdong Province [2018A030310670]; Shenzhen Engineering
   Research Center for Medical Bioactive Materials [XMHT20190106001]; SIAT
   Innovation Program for Excellent Young Researchers [2020001345]; CAS HK
   Joint Lab of Biomaterials
FX This work was supported by the National Natural Science Foundation of
   China (82022045 & 22007098), CAS Interdisciplinary Innovation Team
   (JCTD 2020 19), Shenzhen Double Chain Project for Innovation and
   Development Industry supported by Bureau of Industry and Information
   Technology of Shenzhen (201806081503414910), Shenzhen Fundamental
   Research Foundation (JCYJ20190807154807663), Key Laboratory of Health
   Informatics, Chinese Academy of Sciences, CAS HK Joint Lab of
   Biomaterials and Natural Science Foundation of Guangdong Province
   (2018A030310670), Shenzhen Engineering Research Center for Medical
   Bioactive Materials (XMHT20190106001), SIAT Innovation Program for
   Excellent Young Researchers (2020001345).
CR Behrouzkia Zhaleh, 2016, Oman Med J, V31, P89, DOI 10.5001/omj.2016.19
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brandao Burch A, 2005, CALCIFIED TISSUE INT, V77, P167, DOI 10.1007/s00223 004 0285 8
   Brown A, 2015, ACTA BIOMATER, V11, P543, DOI 10.1016/j.actbio.2014.09.008
   Cao HJ, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2019.152860
   CAVALIER.R, 1967, CANCER AM CANCER SOC, V20, P1351, DOI 10.1002/1097 0142(196709)20:9<1351::AID CNCR2820200902>3.0.CO;2 #
   Cheng Liang, 2014, Chem Rev, V114, P10869, DOI 10.1021/cr400532z
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   Cifuentes SC, 2012, MATER LETT, V74, P239, DOI 10.1016/j.matlet.2012.01.134
   Dai YL, 2019, J BIOMED MATER RES B, V107, P2537, DOI 10.1002/jbm.b.34344
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Derby B, 2012, SCIENCE, V338, P921, DOI 10.1126/science.1226340
   FEENSTRA TP, 1981, J COLLOID INTERF SCI, V83, P583, DOI 10.1016/0021 9797(81)90352 0
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Galow Anne Marie, 2017, Biochem Biophys Rep, V10, P17, DOI 10.1016/j.bbrep.2017.02.001
   Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470 2045(05)01734 1
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103 007 0470 x
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kim HM, 2005, BIOMATERIALS, V26, P4366, DOI 10.1016/j.biomaterials.2004.11.022
   Lai YX, 2019, BIOMATERIALS, V197, P207, DOI 10.1016/j.biomaterials.2019.01.013
   Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025
   Lee JW, 2016, P NATL ACAD SCI USA, V113, P716, DOI 10.1073/pnas.1518238113
   Locatelli E, 2014, CHEM COMMUN, V50, P7783, DOI 10.1039/c4cc01513d
   Ma HS, 2016, ADV FUNCT MATER, V26, P1197, DOI 10.1002/adfm.201504142
   Ma L, 2020, MATER TODAY, V36, P48, DOI 10.1016/j.mattod.2019.12.005
   Ma N, 2014, J BIOMED MATER RES A, V102, P2644, DOI 10.1002/jbm.a.34933
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958
   Qin L, 2015, BIOMATERIALS, V59, P125, DOI 10.1016/j.biomaterials.2015.04.038
   Rastinehad AR, 2019, P NATL ACAD SCI USA, V116, P18590, DOI 10.1073/pnas.1906929116
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Rohani N, 2019, CANCER RES, V79, P1952, DOI 10.1158/0008 5472.CAN 18 1604
   Staiger MP, 2006, BIOMATERIALS, V27, P1728, DOI 10.1016/j.biomaterials.2005.10.003
   Sterl F, 2015, NANO LETT, V15, P7949, DOI 10.1021/acs.nanolett.5b03029
   Stürmer EK, 2006, J BONE MINER RES, V21, P89, DOI 10.1359/JBMR.050913
   Tian L, 2019, J ORTHOP TRANSL, V16, P1, DOI 10.1016/j.jot.2018.06.006
   van Ladesteijn R, 2018, MED ENG PHYS, V53, P75, DOI 10.1016/j.medengphy.2018.01.005
   Vega OA, 2017, J CELL BIOCHEM, V118, P3662, DOI 10.1002/jcb.26011
   Walker J, 2014, J BIOMED MATER RES B, V102, P1316, DOI 10.1002/jbm.b.33113
   Wang JL, 2020, ADV SCI, V7, DOI 10.1002/advs.201902443
   Wang JL, 2018, BIOMATERIALS, V157, P86, DOI 10.1016/j.biomaterials.2017.12.007
   Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684
   Windhagen H, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475 925X 12 62
   Yang BW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705611
   Yang HT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14153 7
   Yoshizawa S, 2014, ACTA BIOMATER, V10, P2834, DOI 10.1016/j.actbio.2014.02.002
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6946
   Zhang KY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701642
   Zhang L, 2019, ACTA BIOMATER, V84, P16, DOI 10.1016/j.actbio.2018.11.039
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zhao DW, 2017, BIOMATERIALS, V112, P287, DOI 10.1016/j.biomaterials.2016.10.017
   Zhao DW, 2016, BIOMATERIALS, V81, P84, DOI 10.1016/j.biomaterials.2015.11.038
   Zheng LZ, 2020, BIOMATERIALS, V238, DOI 10.1016/j.biomaterials.2020.119828
   Zheng YF, 2014, MAT SCI ENG R, V77, P1, DOI 10.1016/j.mser.2014.01.001
   Zhou WX, 2021, SMALL METHODS, V5, DOI 10.1002/smtd.202000920
NR 60
TC 87
Z9 94
U1 13
U2 309
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2021
VL 275
AR 120950
DI 10.1016/j.biomaterials.2021.120950
EA JUN 2021
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA TV4AQ
UT WOS:000681664700001
PM 34119886
DA 2025 08 17
ER

PT J
AU Doi, T
   Hioki, T
   Tachi, J
   Ueda, K
   Matsushima Nishiwaki, R
   Iida, H
   Ogura, S
   Kozawa, O
   Tokuda, H
AF Doi, Tomoaki
   Hioki, Tomoyuki
   Tachi, Junko
   Ueda, Kyohei
   Matsushima Nishiwaki, Rie
   Iida, Hiroki
   Ogura, Shinji
   Kozawa, Osamu
   Tokuda, Haruhiko
TI Oncostatin M reduces the synthesis of macrophage colony stimulating
   factor stimulated by TGF β via suppression of p44/p42 MAP kinase and JNK
   in osteoblasts
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; INDUCED VEGF SYNTHESIS; CYCLIC AMP;
   CROSS TALK; IN VITRO; INHIBITOR; DIFFERENTIATION; EXPRESSION; CYTOKINE;
   CELLS
AB Bone fracture is an important trauma frequently encountered into emergency medicine as well as orthopedics reflecting an aging society. Oncostatin M, an inflammatory cytokine produced by osteal macrophages, has been considered to play a crucial role in fracture healing. Macrophage colony stimulating factor (M CSF) secreted from osteoblasts is essential in osteoclastgenesis, and the secretion is stimulated by transforming growth factor beta (TGF beta). The aim of this study is to elucidate the effects of oncostatin M on the TGF beta induced M CSF synthesis in osteoblast like MC3T3 El cells and the underlying mechanisms. Oncostatin M attenuated the TGF beta stimulated M CSF release and the mRNA expressions. SMAD3 inhibitor SIS3, p38 MAP kinase inhibitor SB203580, MEK1/2 inhibitor PD98059, and SAPK/JNK inhibitor SP600125 significantly suppressed the M CSF release. Oncostatin M suppressed the TGF beta induced phosphorylation of p44/ p42 MAP kinase and SAPK/JNK, but failed to affect the phosphorylation of SMAD3 and p38 MAP kinase. Oncostatin M attenuated the TGF beta stimulated vascular endothelial growth factor (VEGF) release and the TGF beta induced mRNA expressions of VEGF. These results strongly suggest that oncostatin M downregulates TGF beta signaling upstream of p44/p42 MAP kinase and SAPK/JNK, but not SMAD 2/3 and p38 MAP kinase, in osteoblasts, leading to the attenuation of M CSF synthesis. Our findings might provide a new therapeutic strategy for the acceleration of fracture healing process.
C1 [Doi, Tomoaki; Ogura, Shinji] Gifu Univ, Dept Emergency & Disaster Med, Grad Sch Med, Gifu 5011194, Japan.
   [Doi, Tomoaki; Hioki, Tomoyuki; Tachi, Junko; Ueda, Kyohei; Matsushima Nishiwaki, Rie; Kozawa, Osamu; Tokuda, Haruhiko] Gifu Univ, Dept Pharmacol, Grad Sch Med, Gifu 5011194, Japan.
   [Hioki, Tomoyuki] Cent Japan Int Med Ctr, Dept Dermatol, Gifu 5058510, Japan.
   [Tachi, Junko; Ueda, Kyohei; Iida, Hiroki] Gifu Univ, Dept Anesthesiol & Pain Med, Grad Sch Med, Gifu 5011194, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Clin Lab, Med Genome Ctr, Obu, Aichi 4748511, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Metab Res, Obu, Aichi 4748511, Japan.
C3 Gifu University; Gifu University; Gifu University; National Center for
   Geriatrics & Gerontology; National Center for Geriatrics & Gerontology
RP Kozawa, O (通讯作者)，Gifu Univ, Dept Pharmacol, Grad Sch Med, Gifu 5011194, Japan.
EM okkasugai@yahoo.co.jp
RI Ueda, Kyohei/AAQ 1998 2021
OI Matsushima Nishiwaki, Rie/0009 0003 7496 737X
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [26462289, 15K10487]; National Center for Geriatrics and Gerontology,
   Japan [20 12, 21 1]; Grants in Aid for Scientific Research [22K09179,
   21K09068, 26462289, 15K10487] Funding Source: KAKEN
FX This study was supported in part by a Grant in Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan [grant numbers 26462289, 15K10487]; the Research
   Funding for Longevity Sciences from the National Center for Geriatrics
   and Gerontology, Japan [grant number 20 12, 21 1]. We are very grateful
   to Mrs. Yumiko Kurokawa for her skillful technical assistance.
CR ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014 5793(95)00357 F
   Danks L, 2013, J BIOCHEM, V154, P29, DOI 10.1093/jb/mvt049
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003 0027
   Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249
   Gioffrè Florio M, 2018, G CHIR, V39, P35, DOI 10.11138/gchir/2018.39.1.035
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Gómez Lechón MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024 3205(99)00296 9
   Guihard P, 2015, AM J PATHOL, V185, P765, DOI 10.1016/j.ajpath.2014.11.008
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Hioki T, 2021, BIOMED PHARMACOTHER, V141, DOI 10.1016/j.biopha.2021.111816
   Jay PR, 1996, ENDOCRINOLOGY, V137, P1151, DOI 10.1210/en.137.4.1151
   Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483
   Kanno Y, 2005, HORM METAB RES, V37, P140, DOI 10.1055/s 2005 861291
   Kato K, 1996, J NEUROCHEM, V66, P946
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014 4827(92)90158 5
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Repovic P, 2002, J NEUROSCI, V22, P5334
   Simpson D, 2000, MOL VIS, V6, P178
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   TAKAISHI T, 1994, AM J PHYSIOL, V267, pC25, DOI 10.1152/ajpcell.1994.267.1.C25
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Tokuda H, 2003, ARCH BIOCHEM BIOPHYS, V415, P117, DOI 10.1016/S0003 9861(03)00225 X
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Yamamoto N, 2015, MOL CELL ENDOCRINOL, V405, P35, DOI 10.1016/j.mce.2015.02.002
   ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
   Zuscik MJ., 2013, AM SOC BONE MINERAL, P90
NR 40
TC 4
Z9 4
U1 0
U2 2
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PY 2022
VL 43
IS 2
BP 41
EP 51
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 0X7IX
UT WOS:000789876300002
PM 35431291
OA gold
DA 2025 08 17
ER

PT J
AU Lorenzo, V
   Martin Malo, A
   Perez Garcia, R
   Torregrosa, JV
   Vega, N
   de Francisco, ALM
   Cases, A
AF Lorenzo, V
   Martin Malo, A
   Perez Garcia, R
   Torregrosa, JV
   Vega, N
   de Francisco, ALM
   Cases, A
TI Prevalence, clinical correlates and therapy cost of mineral
   abnormalities among haemodialysis patients: a cross sectional
   multicentre study
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE calcium; calcium phosphorus product; haemodialysis; parathyroid hormone;
   phosphate; renal osteodystrophy
ID STAGE RENAL DISEASE; PARATHYROID HORMONE; DIALYSIS OUTCOMES; PRACTICE
   PATTERNS; SERUM PHOSPHORUS; MORTALITY RISK; ASSOCIATION; PHOSPHATE;
   CALCIUM; CALCIFICATION
AB Background. This study evaluated the proportion of patients who met National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF K/DOQI) guidelines for mineral status, and assessed the cost of therapy for mineral management of patients under haemodialysis treatment in Spain.
   Methods. Demographic and biochemical data were collected for 1312 patients undergoing standard three times weekly maintenance haemodialysis at six Spanish centres during December 2003. Age, gender, diabetic nephropathy, haemodialysis duration, serum calcium, phosphorus, calcium phosphorus product (Ca x P), and intact parathyroid hormone (iPTH) levels were monitored. Exploratory analyses of associations between demographic and biochemical parameters, were undertaken using bivariate and multivariate regression techniques.
   Results. Mean age of patients was 62 years. 97% were Caucasian, 23% were diabetic. In total, 51% of patients received calcium binders, 21% sevelamer, 16% aluminium hydroxide, and 29% received no binders; 33% of patients received calcitriol. Prevalence of patients outside K/DOQI targets was: calcium 50%, phosphorus 46%; Ca x P 33%; iPTH 77%. Elevated phosphorus (> 5.5 mg/dl) was independently associated with younger age [OR 0.972 (95% CI 0.963 0.980), P < 0.001] and higher iPTH [OR 1.0005 (95% CI 1.0002 1.0008), P < 0.001]. Elevated Ca x P (>= 55 mg(2) x dl(2)) showed a similar relationship. High iPTH levels (> 300 pmol/l) were associated with female gender [OR 1.574 (95% CI 1.213 2.041), P < 0.001], high serum phosphorus [OR 1.230 (95% CI 1.130 1.338), P < 0.001], and longer duration of dialysis [OR 1.003 (95% CI 1.001 1.005), P < 0.01]. Poorly controlled serum phosphorus, Ca x P and iPTH were associated with more expensive therapy for mineral management.
   Conclusions. One in three haemodialysis patients in Spain remains above the upper target range defined in current mineral metabolism guidelines. This abnormal profile is more common in younger patients and females and therapy is more expensive in younger patients.
C1 Univ Hosp Canary Isl, Div Nephrol, Serv Nephrol, San Cristobal la Laguna 38320, Santa Cruz Tene, Spain.
   Hosp Univ Reina Sofia, Serv Nephrol, Cordoba, Spain.
   Hosp Clin Barcelona, Nephrol Unit, Barcelona, Spain.
   Hosp Gregorio Maranon, Serv Nephrol, Madrid, Spain.
   Hosp Univ Dr Negrin, Serv Nephrol, Las Palmas Gran Canaria, Spain.
   Hosp Univ Marques Valdecilla, Serv Nephrol, Santander, Spain.
C3 Universidad de la Laguna; University Hospital of the Canary Islands;
   Hospital Universitario Reina Sofia   Cordoba; University of Barcelona;
   Hospital Clinic de Barcelona; General University Gregorio Maranon
   Hospital; Hospital Universitario Marques de Valdecilla (HUMV)
RP Lorenzo, V (通讯作者)，Univ Hosp Canary Isl, Div Nephrol, Serv Nephrol, San Cristobal la Laguna 38320, Santa Cruz Tene, Spain.
EM viclorenzo@terra.es
RI Díaz, Nicanor/R 4903 2019; Cases Amenos, Aleix/N 4736 2018; Cases,
   Aleix/N 4736 2018
OI Cases Amenos, Aleix/0000 0002 6962 8184; Torregrosa,
   Jose Vicente/0000 0001 5160 3248
CR Almaden Y, 2003, KIDNEY INT, V64, P2311, DOI 10.1046/j.1523 1755.2003.00331.x
   [Anonymous], 2003, AM J KIDNEY DIS S, V42, pS1
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Gallieni M, 2002, J NEPHROL, V15, P165
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Guérin AP, 2000, NEPHROL DIAL TRANSPL, V15, P1014, DOI 10.1093/ndt/15.7.1014
   LORENZO V, 1995, NEPHROL DIAL TRANSPL, V10, P1885
   Lorenzo V, 2001, AM J KIDNEY DIS, V37, P1260, DOI 10.1053/ajkd.2001.24532
   LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272 6386(12)70364 5
   Malberti F, 2001, J AM SOC NEPHROL, V12, P1242, DOI 10.1681/ASN.V1261242
   NAVEHMANY T, 1992, J CLIN INVEST, V90, P2434, DOI 10.1172/JCI116134
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Rufino M, 1998, NEPHROL DIAL TRANSPL, V13, P65, DOI 10.1093/ndt/13.suppl_3.65
   Silverberg SJ, 1997, J BONE MINER RES, V12, P856, DOI 10.1359/jbmr.1997.12.5.856
   Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F
   TORRES A, 1995, KIDNEY INT, V47, P1434, DOI 10.1038/ki.1995.201
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 20
TC 28
Z9 30
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD FEB
PY 2006
VL 21
IS 2
BP 459
EP 465
DI 10.1093/ndt/gfi213
PG 7
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA 004WI
UT WOS:000234782900032
PM 16263739
OA Bronze
DA 2025 08 17
ER

PT J
AU Han, YH
   Liu, CG
   Chen, BQ
   Fu, CP
   Kankala, RK
   Wang, SB
   Chen, AZ
AF Han, Ya Hui
   Liu, Chen Guang
   Chen, Biao Qi
   Fu, Chao Ping
   Kankala, Ranjith Kumar
   Wang, Shi Bin
   Chen, Ai Zheng
TI Orchestrated tumor apoptosis (Cu<SUP>2+</SUP>) and bone tissue
   calcification (Ca<SUP>2+</SUP>) by hierarchical Copper/Calcium ensembled
   bioactive silica for osteosarcoma therapy
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Bioactive glass; Fenton like reaction; Calcium overload; Osteosarcoma;
   Synergism
ID IN VITRO; OVERLOAD; GLASSES; NANOPARTICLES; REGENERATION; DEGRADATION;
   STABILITY; LIGHT; DYES
AB Malignant osteosarcoma is one of the serious health concerns attributed to inferior prognosis and uncontrolled metastasis in clinics. Indeed, multifunctional therapeutics with precise tumor killing and subsequent regeneration of damaged tissue are of immense requirement in treating osteosarcoma. Herein, this study demonstrates the fabrication of versatile calcium/copper impregnated bioactive glass (Ca BG/Cu BG) frameworks with orchestrated cancer inhibition and bone tissue calcification towards osteosarcoma therapy. Initially, the designed composites are systematically characterized to explore various morphological attributes and physicochemical properties. The optimal formulation of Cu BG (10 mol%) presented orchestrated effects of an excellent pHresponsive anticancer effect through hydroxyl radical (center dot OH) generation and facilitated hydroxyapatite formation towards bone tissue calcification. Further, in vitro investigations demonstrated substantial biocompatibility in mouse embryo osteoblast precursor cell line (MC3T3 E1) and exceptional anti tumor effects in human osteosarcoma cells (HOS) through improved cellular internalization efficacy and free radical generation, respectively. Finally, in vivo immunostaining and micro computed tomography (mu CT) images of osteosarcoma bearing mice confirmed Fenton like reaction induced chemodynamic therapy (CDT), over expressed hypoxia inducible factor (HIF) 1 alpha through p53 pathway, and formation of calcified nodules. In addition, hematological analyses of hematoxylin eosin (HE) stained main organ sections presented biosafety elucidations. Together, the synergistic prospects of Cu2+ and Ca2+ species had substantially orchestrated towards regenerative medicine.
C1 [Han, Ya Hui; Liu, Chen Guang; Kankala, Ranjith Kumar; Chen, Ai Zheng] Huaqiao Univ, Coll Chem Engn, Xiamen 361021, Peoples R China.
   [Han, Ya Hui; Liu, Chen Guang; Chen, Biao Qi; Fu, Chao Ping; Kankala, Ranjith Kumar; Wang, Shi Bin; Chen, Ai Zheng] Huaqiao Univ, Inst Biomat & Tissue Engn, Xiamen 361021, Peoples R China.
   [Liu, Chen Guang] Zhejiang Sci Tech Univ, Coll Life Sci & Med, Hangzhou 310018, Peoples R China.
   [Fu, Chao Ping; Kankala, Ranjith Kumar; Wang, Shi Bin; Chen, Ai Zheng] Huaqiao Univ, Fujian Prov Key Lab Biochem Technol, Xiamen 361021, Peoples R China.
C3 Huaqiao University; Huaqiao University; Zhejiang Sci Tech University;
   Huaqiao University
RP Kankala, RK; Chen, AZ (通讯作者)，Huaqiao Univ, Coll Chem Engn, Xiamen 361021, Peoples R China.; Kankala, RK; Chen, AZ (通讯作者)，Huaqiao Univ, Inst Biomat & Tissue Engn, Xiamen 361021, Peoples R China.; Kankala, RK; Chen, AZ (通讯作者)，Huaqiao Univ, Fujian Prov Key Lab Biochem Technol, Xiamen 361021, Peoples R China.
EM ranjithkankala@hqu.edu.cn; azchen@hqu.edu.cn
RI Kankala, Ranjith/R 8396 2016; Wang, Shibin/AAH 1793 2019
OI Fu, Chaoping/0000 0002 4757 6889; 
FU National Natural Science Foundation of China [31800794, 81971734,
   32071323]; Natural Science Foundation of Fujian Province [2019J01076];
   Fundamental Research Funds for Central Universities [ZQN 713]; Funds for
   Foreign Experts from the Ministry of Science and Technology, China
   [G20190013023]; Program for Innovation Research Team in Science and
   Technology in Fujian Province University
FX Acknowledgment The authors acknowledge the financial support from the
   National Natural Science Foundation of China (31800794, 81971734, and
   32071323) , Natural Science Foundation of Fujian Province (2019J01076) ,
   Fundamental Research Funds for Central Universities (ZQN 713) , Funds
   for Foreign Experts from the Ministry of Science and Technology, China
   (G20190013023) , and Program for Innovation Research Team in Science and
   Technology in Fujian Province University.
CR Autefage H, 2019, BIOMATERIALS, V209, P152, DOI 10.1016/j.biomaterials.2019.03.035
   Bari A, 2017, ACTA BIOMATER, V55, P493, DOI 10.1016/j.actbio.2017.04.012
   Barrioni BR, 2019, J COLLOID INTERF SCI, V547, P382, DOI 10.1016/j.jcis.2019.04.016
   Barros TC, 2010, J PHYS ORG CHEM, V23, P893, DOI 10.1002/poc.1692
   Bates S, 2006, PHARM RES DORDR, V23, P2333, DOI 10.1007/s11095 006 9086 2
   Bodenstine Thomas M, 2011, Chin J Cancer, V30, P189
   Borkowska M, 2020, NAT NANOTECHNOL, V15, P331, DOI 10.1038/s41565 020 0643 3
   Brillas E, 2004, NEW J CHEM, V28, P314, DOI 10.1039/b312445b
   Cao CY, 2020, SMALL, V16, DOI 10.1002/smll.202000436
   Chang MY, 2020, ADV MATER, V32, DOI 10.1002/adma.202004647
   Chu X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202008507
   Croissant JG, 2017, ADV MATER, V29, DOI 10.1002/adma.201604634
   Danewalia SS, 2021, MATER TODAY BIO, V10, DOI 10.1016/j.mtbio.2021.100100
   de Azevedo JWV, 2020, ONCOL LETT, V19, P1099, DOI 10.3892/ol.2019.11229
   Dong SJ, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907071
   Dong ZW, 2017, MOL CELL, V65, P1014, DOI 10.1016/j.molcel.2017.01.032
   Duong QV, 2020, MITOCHONDRION, V51, P126, DOI 10.1016/j.mito.2020.01.005
   Ferreira FV, 2019, NANOSCALE, V11, P19842, DOI 10.1039/c9nr05383b
   Gao ST, 2019, ADV SCI, V6, DOI 10.1002/advs.201902137
   Greasley SL, 2016, J COLLOID INTERF SCI, V469, P213, DOI 10.1016/j.jcis.2016.01.065
   Han Y, 2019, CANCER LETT, V440, P116, DOI 10.1016/j.canlet.2018.10.011
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Henary M, 2008, TOP HETEROCYCL CHEM, V14, P221, DOI 10.1007/7081_2008_111
   Hernandez R, 2017, THERANOSTICS, V7, P1, DOI 10.7150/thno.15124
   Ho CJ, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00658 y
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Ji LJ, 2019, SMALL, V15, DOI 10.1002/smll.201905451
   Jia CY, 2022, SMALL, V18, DOI 10.1002/smll.202103868
   Kang MS, 2018, BIOMATERIALS, V162, P183, DOI 10.1016/j.biomaterials.2018.02.005
   Kankala RK, 2020, ADV MATER, V32, DOI 10.1002/adma.201907035
   Kankala RK, 2020, CHEM ENG J, V383, DOI 10.1016/j.cej.2019.123138
   Kiran P, 2017, APPL NANOSCI, V7, P731, DOI 10.1007/s13204 017 0616 5
   Koutsopoulos S, 2002, J BIOMED MATER RES, V62, P600, DOI 10.1002/jbm.10280
   Lei Q, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909539
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   Li SL, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202100243
   Li YN, 2018, ACS APPL MATER INTER, V10, P17722, DOI 10.1021/acsami.8b04856
   Lin LS, 2018, ANGEW CHEM INT EDIT, V57, P4902, DOI 10.1002/anie.201712027
   Lin LS, 2020, J AM CHEM SOC, V142, P15320, DOI 10.1021/jacs.0c05604
   Lin RC, 2019, THERANOSTICS, V9, P6300, DOI 10.7150/thno.36120
   Liu CG, 2020, ACS APPL MATER INTER, V12, P40673, DOI 10.1021/acsami.0c11739
   Liu CG, 2020, INT J NANOMED, V15, P675, DOI 10.2147/IJN.S226186
   Liu CG, 2019, CHEM ENG J, V370, P1188, DOI 10.1016/j.cej.2019.03.272
   Liu JW, 2021, ACS APPL MATER INTER, V13, P3669, DOI 10.1021/acsami.0c20060
   Ma BJ, 2019, J AM CHEM SOC, V141, P849, DOI 10.1021/jacs.8b08714
   Ma LL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb1311
   Michael J., 2012, BIOCHEM SOC T, V40, P297, DOI [10.1042/bst20110766, DOI 10.1042/BST20110766]
   Miola M, 2019, ACTA BIOMATER, V83, P55, DOI 10.1016/j.actbio.2018.11.013
   Moses JC, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701418
   Naruphontjirakul P., 2016, BIOMEDICAL GLASSES, P72, DOI DOI 10.1515/BGLASS 2016 0009
   Naruphontjirakul P, 2019, ACTA BIOMATER, V90, P373, DOI 10.1016/j.actbio.2019.03.038
   Naruphontjiralcul P, 2018, ACTA BIOMATER, V66, P67, DOI 10.1016/j.actbio.2017.11.008
   Omar AE, 2021, J BIOMED MATER RES B, V109, P1059, DOI 10.1002/jbm.b.34769
   Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
   Pajares Chamorro N, 2019, ACTA BIOMATER, V96, P537, DOI 10.1016/j.actbio.2019.07.012
   Rana KS, 2017, ACS BIOMATER SCI ENG, V3, P3425, DOI 10.1021/acsbiomaterials.7b00283
   Raturi A, 2014, HISTOL HISTOPATHOL, V29, P543, DOI 10.14670/HH 29.10.543
   Schumacher M, 2021, BIOACT MATER, V6, P1921, DOI 10.1016/j.bioactmat.2020.12.007
   Sedighi O, 2022, J AM CERAM SOC, V105, P1723, DOI 10.1111/jace.17861
   Shuai CJ, 2019, CHEM ENG J, V374, P304, DOI 10.1016/j.cej.2019.03.273
   Simpson E, 2018, JAAPA J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d
   Stevens MM, 2005, P NATL ACAD SCI USA, V102, P11450, DOI 10.1073/pnas.0504705102
   Taale M, 2018, ACS APPL MATER INTER, V10, P43874, DOI 10.1021/acsami.8b13631
   Tang ZM, 2021, CHEM REV, V121, P1981, DOI 10.1021/acs.chemrev.0c00977
   Tang ZM, 2019, ANGEW CHEM INT EDIT, V58, P946, DOI 10.1002/anie.201805664
   Valliant EM, 2012, J MATER CHEM, V22, P1613, DOI 10.1039/c1jm13225c
   Wan ZQ, 2020, THERANOSTICS, V10, P11837, DOI 10.7150/thno.49784
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14870 4
   Weng L, 2017, ACS APPL MATER INTER, V9, P24484, DOI 10.1021/acsami.7b06521
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   Xiang HJ, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909938
   Xue X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009432
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Yang BW, 2019, CHEM REV, V119, P4881, DOI 10.1021/acs.chemrev.8b00626
   Yang C, 2021, ADV SCI, V8, DOI 10.1002/advs.202100894
   Zhang M, 2019, CHEM US, V5, P2171, DOI 10.1016/j.chempr.2019.06.003
   Zhang YG, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202102911
   Zheng K, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00497
   Zheng P, 2021, NANO LETT, V21, P2088, DOI 10.1021/acs.nanolett.0c04778
   Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20059 6
   Zhu PJ, 2018, REDOX BIOL, V16, P157, DOI 10.1016/j.redox.2018.02.019
NR 82
TC 42
Z9 42
U1 14
U2 129
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD MAY 1
PY 2022
VL 435
AR 134820
DI 10.1016/j.cej.2022.134820
EA JAN 2022
PN 1
PG 15
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA ZZ8HI
UT WOS:000773505300004
DA 2025 08 17
ER

PT J
AU Morgan, C
   Jeremiah, S
   Wagstaff, J
AF Morgan, Claire
   Jeremiah, Steve
   Wagstaff, John
TI Metronomic administration of ibandronate and its anti angiogenic effects
   in vitro
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Angiogenesis; Endothelial cells; Ibandronate; Metronomic therapy; Cell
   growth; Capillary morphogenesis; bFGF
ID ENDOTHELIAL GROWTH FACTOR; CLINICAL DOSING REGIMENS; METASTATIC
   BONE DISEASE; ZOLEDRONIC ACID; CANCER PATIENTS; CELL LINES;
   BISPHOSPHONATES; BFGF
AB Background: Angiogenesis plays an essential role in the growth and metastatic development of tumours. Recent in vitro studies have reported bisphosphonates as having anti angiogenic properties. They have been shown to inhibit proliferation, induce apoptosis and decrease capillary like tube formation but often the in, vitro concentrations and dosing schedules used do not reflect drug pharmacokinetics or clinical dosing regimens.
   Materials and methods: Human umbilical vein endothelial cells were exposed to physiologically relevant doses of the bisphosphonate ibandronate, mimicking the clinical administration of oral ibandronate (1 h daily dosing over 8 days at concentrations ranging from 1 10 mu M). Cellular growth characteristics were then assessed.
   Results: Low dose ibandronate (1.25 2 mu M) significantly reduced endothelial cell growth, while 2 mu M ibandronate also significantly reduced capillary like tube formation and increased apoptosis of endothelial cells compared to untreated cells. There was no significant difference in activity with doses above 2 mu M. However, inhibiting bFGF stimulated cell growth increased VEGF expression.
   Conclusion: This work has demonstrated that repeated low dose drug administration (metronomic therapy) of ibandronate has certain anti angiogenic properties by inhibiting the stimulatory effects of bFGF. However targeting the inhibition of bFGF alone is unlikely to be a successful approach for completely inhibiting angiogenesis due to the interplay between bFGF and VEGF. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Morgan, Claire; Jeremiah, Steve; Wagstaff, John] Swansea Univ, Inst Life Sci, Human Canc Studies Grp, Swansea SA2 8PP, W Glam, Wales.
   [Wagstaff, John] Singleton Hosp, S W Wales Canc Inst, Swansea SA2 8QA, W Glam, Wales.
C3 Swansea University; Singleton Hospital
RP Morgan, C (通讯作者)，Swansea Univ, Inst Life Sci, Human Canc Studies Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.
EM c.morgan@swansea.ac.uk
RI Wagstaff, John/KBB 6135 2024; Morgan, Claire/IUQ 5577 2023
OI Wagstaff, John/0000 0002 1140 5981; Morgan, Claire/0000 0002 3969 0710
CR Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Ferretti G, 2007, BONE, V41, P155, DOI 10.1016/j.bone.2007.04.177
   Fournier P, 2002, CANCER RES, V62, P6538
   Jih Yng Jyh, 2001, Angiogenesis, V4, P313, DOI 10.1023/A:1016080321956
   Kuhn H, 2006, LUNG CANCER, V54, P149, DOI 10.1016/j.lungcan.2006.07.016
   Leyland Jones B, 2004, EJC SUPPL, V2, P9, DOI 10.1016/j.ejcsup.2004.01.003
   Martin TJ., 2000, Aust Prescriber, V23, P130
   MICHAILIDOU M, 2006, HEAMATOLOGICA REPORT, V2, P48
   Mystakidou K, 2008, J CANCER RES CLIN, V134, P1303, DOI 10.1007/s00432 008 0419 x
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864
   Vujasinovic T., 2006, ARCH ONCOL, V14, P126
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 16
TC 6
Z9 6
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0026 2862
J9 MICROVASC RES
JI Microvasc. Res.
PD DEC
PY 2009
VL 78
IS 3
BP 453
EP 458
DI 10.1016/j.mvr.2009.07.004
PG 6
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 528HI
UT WOS:000272433300025
PM 19651147
DA 2025 08 17
ER

PT J
AU Xia, XC
   Kar, R
   Gluhak Heinrich, J
   Yao, W
   Lane, NE
   Bonewald, LF
   Biswas, SK
   Lo, WK
   Jiang, JX
AF Xia, Xuechun
   Kar, Rekha
   Gluhak Heinrich, Jelica
   Yao, Wei
   Lane, Nancy E.
   Bonewald, Lynda F.
   Biswas, Sondip K.
   Lo, Woo Kuen
   Jiang, Jean X.
TI Glucocorticoid Induced Autophagy in Osteocytes
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE GLUCOCORTICOID; OSTEOCYTE; AUTOPHAGY; VIABILITY
ID IN VIVO; INDUCED APOPTOSIS; OSTEOBLASTS; MECHANISMS; MICE; YEAST; VITRO;
   LC3
AB Glucocorticoid (GC) therapy is the most frequent cause of secondary osteoporosis In this study we have demonstrated that GC treatment induced the development of autophagy preserving osteocyte viability GC treatment resulted in an increase in autophagy markers and the accumulation of autophagosome vacuoles in vitro and in vivo promoted the onset of the osteocyte autophagy as determined by expression of autophagy markers in an animal model of GC induced osteoporosis An autophagy inhibitor reversed the protective effects of GCs The effects of GCs on osteocytes were in contrast to tumor necrosis factor alpha (TNF alpha) which induced apoptosis but not autophagy Together this study reveals a novel mechanism for the effect of GC on osteocytes shedding new insight into mechanisms responsible for bone loss in patients receiving GC therapy (C) 2010 American Society for Bone and Mineral Research
C1 [Xia, Xuechun; Kar, Rekha; Jiang, Jean X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
   [Gluhak Heinrich, Jelica] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA.
   [Yao, Wei; Lane, Nancy E.] Univ Calif Davis, Med Ctr, Ctr Healthy Aging Internal Med, Sacramento, CA 95817 USA.
   [Bonewald, Lynda F.] Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO USA.
   [Biswas, Sondip K.; Lo, Woo Kuen] Morehouse Sch Med, Dept Neurobiol, Atlanta, GA 30310 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of California System;
   University of California Davis; University of Missouri System;
   University of Missouri Kansas City; Morehouse School of Medicine
RP Jiang, JX (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
RI Jiang, Jia Xing/F 4036 2012; Yao, Wei/O 8187 2019; Bonewald,
   Lynda/Q 3638 2019
OI Jiang, Jean/0000 0002 2185 5716; 
FU National Institutes of Health (NIH) [PO1 AR46798, R01 AR043052, K24
   AR04884, K12 HD05195801]; Welch Foundation [AQ 1507]; University of
   California at Davis; Endowed Chair for Aging at the University of
   California at Davis
FX We thank Dr Noboru Mizushima at Tokyo Medical and Dental University,
   Tokyo, Japan for generously providing GFP tagged LC3 expression vector
   and Dr Pothana Saikumar at the University of Texas Health Science Center
   San Antonio TX USA for E64d calpeptin and anti LC3 monoclonal antibody
   We also thank Ms Sirisha Burra and Erin Kennedy for critical reading of
   the manu script This work was supported by National Institutes of Health
   (NIH) Grant PO1 AR46798 (to JXJ and LFB), Welch Foundation Grant AQ 1507
   (to JXJ) NIH Grants R01 AR043052 and K24 AR04884 and the Endowed Chair
   for Aging at the University of California at Davis (to NEL) and NIH
   Grant K12 HD05195801 (to WY)
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04 10 0912
   Conradie MM, 2007, J ENDOCRINOL, V195, P229, DOI 10.1677/JOE 07 0217
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Gurusamy N, 2009, ACTA PHYSIOL HUNG, V96, P267, DOI 10.1556/APhysiol.96.2009.3.2
   HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146
   Hunter AL, 2005, METH MOLEC MED, V112, P277
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MAO J, 1992, MOL CELL BIOCHEM, V109, P1
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03 09 0704
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Valamanesh F, 2007, MOL VIS, V13, P1746
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   WEINSTEIN R, 2008, PRIMER METABOLIC BON
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Zhang F, 2007, J CELL PHYSIOL, V213, P730, DOI 10.1002/jcp.21141
NR 30
TC 154
Z9 176
U1 0
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2010
VL 25
IS 11
BP 2479
EP 2488
DI 10.1002/jbmr.160
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 679BD
UT WOS:000284133500023
PM 20564240
OA Bronze, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Hu, XQ
   Zhang, X
   Dai, LH
   Zhu, JX
   Jia, ZQ
   Wang, WP
   Zhou, CY
   Ao, YF
AF Hu, Xiaoqing
   Zhang, Xin
   Dai, Linghui
   Zhu, Jingxian
   Jia, Zhuqing
   Wang, Weiping
   Zhou, Chunyan
   Ao, Yingfang
TI Histone Deacetylase Inhibitor Trichostatin A Promotes the Osteogenic
   Differentiation of Rat Adipose Derived Stem Cells by Altering the
   Epigenetic Modifications on Runx2 Promoter in a BMP
   Signaling Dependent Manner
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID BONE FORMATION; IN VITRO; TISSUE; EXPRESSION; RUNX2/CBFA1; PHENOTYPE;
   MARROW
AB Adult stem cells reside in many types of tissues and adult stem cell based regenerative medicine holds great promise for repair of diseased tissues. Recently, adipose derived stem cells (ADSCs) were found to be an appealing alternative to bone marrow stem cells (BMSCs) for tissue engineered bone regeneration. Compared with BMSCs, ADSCs can be easily and abundantly available from adipose tissue. However, our previous study has discovered an important phenomenon that BMSCs have greater osteogenic potential than ADSCs in vitro. In this study, we aimed to explore its mechanism and improve the osteogenic potential of ADSCs for bone tissue regeneration. It has been reported that the epigenetic states could contribute to lineage specific differentiation of adult stem cells. We observed that the epigenetic changes of BMSCs were much greater compared with ADSCs after a 3 day osteogenic induction. Runt related transcription factor 2 (Runx2) is essential for osteoblast differentiation and bone formation. We found that BMSCs underwent more obvious epigenetic changes on the Runx2 promoter than ADSCs after osteogenic induction. These results suggest the epigenetic regulation involvement in Runx2 expression, and thus osteogenesis. We subsequently used a histone deacetylase inhibitor, trichostatin A (TSA), to promote the osteogenesis capacity of ADSCs. The results showed that TSA promoted rat ADSCs osteogenic differentiation by altering the epigenetic modifications on the Runx2 promoter in a bone morphogenetic protein signaling dependent manner.
C1 [Hu, Xiaoqing; Zhang, Xin; Dai, Linghui; Zhu, Jingxian; Ao, Yingfang] Peking Univ, Inst Sports Med, Hosp 3, Beijing 100191, Peoples R China.
   [Jia, Zhuqing; Wang, Weiping; Zhou, Chunyan] Peking Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Ao, YF (通讯作者)，Peking Univ, Inst Sports Med, Hosp 3, 49 N Garden Rd, Beijing 100191, Peoples R China.
EM chunyanzhou@bjmu.edu.cn; yingfang.ao@gmail.com
RI ; Zhou, Chunyan/H 1529 2016; xu, wei/JZD 2112 2024
OI Zhang, Xin/0009 0000 6975 4730; Hu, Xiaoqing/0000 0001 9824 1109; 
FU Specialized Research Fund for the Doctoral Program of Higher Education
   [20110001130001]; National Natural Sciences Foundation of China
   [90919022, 81101350, 81070112, 81071675]; 111 Project of China [B07001];
   China Postdoctoral Science Foundation [20110490249]
FX This work was supported by Specialized Research Fund for the Doctoral
   Program of Higher Education (20110001130001), the National Natural
   Sciences Foundation of China (90919022, 81101350, 81070112, 81071675),
   the 111 Project of China (B07001), China Postdoctoral Science Foundation
   (20110490249).
CR Al B. F., 2011, SCI WORLD J, V11, P1568
   Berdasco M, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt83
   Collas P, 2008, TRANSFUS MED HEMOTH, V35, P205, DOI 10.1159/000127449
   Gabory A, 2011, AM J CLIN NUTR, V94, p1943S, DOI 10.3945/ajcn.110.000927
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Han JW, 2012, ANTIOXID REDOX SIGN, V17, P205, DOI 10.1089/ars.2011.4375
   Han S, 2007, IMMUNOL LETT, V108, P143, DOI 10.1016/j.imlet.2006.12.001
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Li ZL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020526
   Liu ZQ, 2009, BBA MOL CELL RES, V1793, P300, DOI 10.1016/j.bbamcr.2008.08.013
   Musumeci G, 2011, EXP BIOL MED, V236, P1333, DOI 10.1258/ebm.2011.011183
   Peng LY, 2008, STEM CELLS DEV, V17, P761, DOI 10.1089/scd.2007.0217
   Phillips JE, 2007, TISSUE ENG, V13, P2029, DOI 10.1089/ten.2006.0041
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   SASANO Y, 1993, ANAT REC, V236, P373, DOI 10.1002/ar.1092360211
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Vishnubalaji R, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 7
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 22
TC 49
Z9 52
U1 0
U2 39
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JAN
PY 2013
VL 22
IS 2
BP 248
EP 255
DI 10.1089/scd.2012.0105
PG 8
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 071GE
UT WOS:000313577400007
PM 22873791
DA 2025 08 17
ER

PT J
AU Hernandez, MJ
   dos Reis, LM
   Marques, ID
   Araujo, MJ
   Truyts, CAM
   Oliveira, IB
   Barreto, FC
   David Neto, E
   Custodio, MR
   Moyses, RM
   Bellorin Font, E
   Jorgetti, V
AF Hernandez, Mariel J.
   dos Reis, Luciene M.
   Marques, Igor D.
   Araujo, Maria J.
   Truyts, Cesar A. M.
   Oliveira, Ivone B.
   Barreto, Fellype C.
   David Neto, Elias
   Custodio, Melani R.
   Moyses, Rosa M.
   Bellorin Font, Ezequiel
   Jorgetti, Vanda
TI The effect of vitamin D and zoledronic acid in bone marrow adiposity in
   kidney transplant patients: A post hoc analysis
SO PLOS ONE
LA English
DT Article
ID MAGNETIC RESONANCE SPECTROSCOPY; MESENCHYMAL STEM CELLS;
   HISTOMORPHOMETRIC ANALYSIS; ADIPOCYTE DIFFERENTIATION; MINERAL
   DISORDERS; TRABECULAR BONE; 3T3 L1 CELLS; DISEASE; SCLEROSTIN;
   ALENDRONATE
AB Purpose
   Osteoblasts and adipocytes are derived from mesenchymal stem cells. An imbalance in the differentiation of these lineages could affect the preservation of bone integrity. Several studies have suggested the importance of this imbalance in the pathogenesis of osteoporosis after kidney transplant (KT), but the role of bone marrow adiposity in this process is not well known, and if the treatment with the anti absorptive (zoledronic acid ZA) drugs could attenuate bone loss. Thus, our objective was compare bone marrow adiposity, osteoblasts and osteocytes before and after KT, verify an association between bone remodeling process (Turnover, Volume, and Mineralization TMV classification), the osteocyte sclerostin expression to evaluate if there is a role of Wnt pathway, as well as the effect of ZA on these cells.
   Methods
   We studied 29 new living adonor KT patients. One group received ZA at the time of KT plus cholecalciferol for twelve months, and the other group received only cholecalciferol. Bone biopsies were performed at baseline and after 12 months of treatment. Histomorphometric evaluation was performed in bone and bone marrow adipocytes. Sclerostin (Scl) expression in osteocytes was evaluated by immunohistochemistry.
   Results
   Some bone marrow adiposity parameters were increased before KT. After KT, some of them remained increased and they worsened with the use of ZA. In the baseline, lower bone Volume and Turnover, were associated with increased bone marrow adiposity parameters (some of them). After KT, both groups showed the same associations. Osteocyte Scl expression after KT decreased with the use of ZA. We observed also an inverse association between bone adiposity parameters and lower osteocyte sclerostin expression 12 months after KT.
   Conclusion
   In conclusion, the present study suggests that KT fails to normalize bone marrow adiposity, and it even gets worse with the use of ZA. Moreover, bone marrow adiposity is inversely associated with bone Volume and Turnover, which seems to be accentuated by the antiresorptive therapy.
C1 [Hernandez, Mariel J.; dos Reis, Luciene M.; Marques, Igor D.; Araujo, Maria J.; Truyts, Cesar A. M.; Oliveira, Ivone B.; Custodio, Melani R.; Moyses, Rosa M.; Jorgetti, Vanda] Univ Sao Paulo, Hosp Clin HCFMUSP, LIM Lab Fisiopatol Renal 16, Fac Med, Sao Paulo, SP, Brazil.
   [Hernandez, Mariel J.; Bellorin Font, Ezequiel] Univ Cent Venezuela, Hosp Univ Caracas, Serv Nefrol & Trasplante Renal, Caracas, Venezuela.
   [Araujo, Maria J.; David Neto, Elias] Univ Sao Paulo, Div Urol, HCFMUSP, Hosp Clin,Fac Med, Sao Paulo, SP, Brazil.
   [Barreto, Fellype C.] Univ Fed Parana, Div Nefrol, Curitiba, Parana, Brazil.
   [Moyses, Rosa M.] Univ Nove Julho UNINOVE, Programa Posgrad Med, Sao Paulo, SP, Brazil.
   [Jorgetti, Vanda] Hosp Samaritano Amer Serv Med, Sao Paulo, SP, Brazil.
C3 Universidade de Sao Paulo; University of Central Venezuela; Universidade
   de Sao Paulo; Universidade Federal do Parana; Universidade Nove de Julho
RP Jorgetti, V (通讯作者)，Univ Sao Paulo, Hosp Clin HCFMUSP, LIM Lab Fisiopatol Renal 16, Fac Med, Sao Paulo, SP, Brazil.; Jorgetti, V (通讯作者)，Hosp Samaritano Amer Serv Med, Sao Paulo, SP, Brazil.
EM vandajor@usp.br
RI Moyses, Rosa/F 8268 2012; JORGETTI, VANDA/C 9470 2012; dos Reis,
   Luciene/C 7143 2013; Dos Reis, Luciene/C 7143 2013; Truyts,
   Cesar/LKK 9401 2024; Neto, Elias/O 3866 2018; Marques, Igor/C 7748 2012;
   Barreto, Fellype/C 6517 2012; Jorgetti, Vanda/C 9470 2012; Araújo,
   Maria/AHA 8107 2022; Custodio, Melani/L 9509 2015
OI Dos Reis, Luciene/0000 0001 8476 6780; Ribeiro Custodio,
   Melani/0000 0001 6358 8727; truyts, cesar/0000 0001 5334 0496; Jorgetti,
   Vanda/0000 0002 4824 8879; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [303899/2016 6, 304773/2013 1]; Fundacao de Amparo a Pesquisa de Estado
   de Sao Paulo (FAPESP) [2011/22962 3]
FX R. Moyses and V. Jorgetti were supported by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, 303899/2016 6 and
   304773/2013 1) and E. David Neto was supported by Fundacao de Amparo a
   Pesquisa de Estado de Sao Paulo (FAPESP, 2011/22962 3). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018 013 1440 z
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Bonani M, 2014, KIDNEY BLOOD PRESS R, V39, P230, DOI 10.1159/000355781
   Carvalho C, 2016, NEPHROLOGY, V21, P55, DOI 10.1111/nep.12570
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Chavassieux PM, 2000, J BONE MINER RES, V15, P754, DOI 10.1359/jbmr.2000.15.4.754
   Coco M, 2012, J AM SOC NEPHROL, V23, P1426, DOI 10.1681/ASN.2011060623
   Cohen A, 2015, OSTEOPOROSIS INT, V26, P2471, DOI 10.1007/s00198 015 3161 7
   Cohen A, 2012, J CLIN ENDOCR METAB, V97, P2782, DOI 10.1210/jc.2012 1477
   Contador D, 2015, EXP BIOL MED, V240, P1235, DOI 10.1177/1535370214566565
   Cunningham J, 2007, J AM SOC NEPHROL, V18, P223, DOI 10.1681/ASN.2006050427
   de Oliveira RA, 2015, KIDNEY INT, V87, P1039, DOI 10.1038/ki.2014.372
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dos Reis LM, 2007, J BONE MINER METAB, V25, P400, DOI 10.1007/s00774 007 0778 4
   Duque G, 2011, OSTEOPOROSIS INT, V22, P1547, DOI 10.1007/s00198 010 1353 8
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Fairfield Heather, 2017, Curr Mol Biol Rep, V3, P114, DOI 10.1007/s40610 017 0057 7
   Giovanini AF, 2018, ENDOCRINE, V59, P685, DOI 10.1007/s12020 017 1490 3
   Gomes SA, 2008, J BONE MINER METAB, V26, P110, DOI 10.1007/s00774 007 0788 2
   Graciolli FG, 2017, KIDNEY INT, V91, P1436, DOI 10.1016/j.kint.2016.12.029
   Hida Y, 1998, LIFE SCI, V62, pPL205, DOI 10.1016/S0024 3205(98)00059 9
   Iyer SP, 2014, J AM SOC NEPHROL, V25, P1331, DOI 10.1681/ASN.2013080851
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Li GW, 2014, ENDOCRINOLOGY, V155, P4731, DOI 10.1210/en.2014 1359
   Li GW, 2013, BONE, V52, P668, DOI 10.1016/j.bone.2012.11.002
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Marques IDB, 2017, OSTEOPOROSIS INT, V28, P1675, DOI 10.1007/s00198 017 3956 9
   MELSEN F, 1980, ACTA PATH MICRO IM A, V88, P83
   MELSEN F, 1978, CALC TISS RES, V26, P99, DOI 10.1007/BF02013242
   Menagh PJ, 2010, J BONE MINER RES, V25, P757, DOI 10.1359/jbmr.091015
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Molnar MZ, 2014, TRANSPLANT REV ORLAN, V28, P56, DOI 10.1016/j.trre.2013.12.003
   Moorthi RN, 2015, OSTEOPOROSIS INT, V26, P1801, DOI 10.1007/s00198 015 3064 7
   Moysés RMA, 2015, INT UROL NEPHROL, V47, P847, DOI 10.1007/s11255 015 0971 7
   Neves CL, 2013, TRANSPLANTATION, V96, P290, DOI 10.1097/TP.0b013e3182985468
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Parajuli S, 2016, ADV CHRONIC KIDNEY D, V23, P287, DOI 10.1053/j.ackd.2016.09.006
   Pereira RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138156
   Recker R.R., 2013, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P307
   Rojas E, 2003, KIDNEY INT, V63, P1915, DOI 10.1046/j.1523 1755.2003.00938.x
   Ukita M, 2016, J CELL BIOCHEM, V117, P1419, DOI 10.1002/jcb.25432
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Watanabe R, 2010, CLIN J AM SOC NEPHRO, V5, P189, DOI 10.2215/CJN.06240909
   Wood RJ, 2008, NUTR REV, V66, P40, DOI 10.1111/j.1753 4887.2007.00004.x
   Yamamoto S, 2013, J BONE MINER METAB, V31, P116, DOI 10.1007/s00774 012 0391 z
NR 47
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2018
VL 13
IS 5
AR e0197994
DI 10.1371/journal.pone.0197994
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GH1HI
UT WOS:000433153400034
PM 29799857
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Alkhayal, Z
   Shinwari, Z
   Gaafar, A
   Alaiya, A
AF Alkhayal, Zikra
   Shinwari, Zakia
   Gaafar, Ameera
   Alaiya, Ayodele
TI Fluconazole Induced Protein Changes in Osteogenic and Immune Metabolic
   Pathways of Dental Pulp Mesenchymal Stem Cells of Osteopetrosis Patients
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE carbonic anhydrase II activators; human exfoliated deciduous teeth;
   dental pulp; mesenchymal stem/stromal cells (MSSCs); proteomics;
   osteopetrosis; azole; fluconazole
ID RENAL TUBULAR ACIDOSIS; ANHYDRASE II DEFICIENCY; CARBONIC ANHYDRASE;
   RECESSIVE OSTEOPETROSIS; BONE MARROW; ISOFORMS I; ACTIVATION;
   EXPRESSION; BIOMARKERS; MANAGEMENT
AB Osteopetrosis is a rare inherited disease caused by osteoclast failure, resulting in increasing bone density in humans. Patients with osteopetrosis possess several dental and cranial complications. Since carbonic anhydrase II (CA II) deficiency is a major cause of osteopetrosis, CA II activators might be an attractive potential treatment option for osteopetrosis patients. We conducted comprehensive label free quantitative proteomics analysis on Fluconazole treated Dental Pulp Mesenchymal Stem/Stromal Cells from CA II Deficient Osteopetrosis Patients. We identified 251 distinct differentially expressed proteins between healthy subjects, as well as untreated and azole treated derived cells from osteopetrosis patients. Twenty six (26) of these proteins were closely associated with osteogenesis and osteopetrosis disease. Among them are ATP1A2, CPOX, Ap2 alpha, RAP1B and some members of the RAB protein family. Others include AnnexinA1, 5, PYGL, OSTF1 and PGAM4, all interacting with OSTM1 in the catalytic reactions of HCO3 and the Cl  channel via CAII regulation. In addition, the pro inflammatory/osteoclast regulatory proteins RACK1, MTSE, STING1, S100A13, ECE1 and TRIM10 are involved. We have identified proteins involved in osteogenic and immune metabolic pathways, including ERK 1/2, phosphatase and ATPase, which opens the door for some CA activators to be used as an alternative drug therapy for osteopetrosis patients. These findings propose that fluconazole might be a potential treatment agent for CAII  deficient OP patients. Altogether, our findings provide a basis for further work to elucidate the clinical utility of azole, a CA activator, as a therapeutic for OP.
C1 [Alkhayal, Zikra; Shinwari, Zakia; Gaafar, Ameera; Alaiya, Ayodele] King Faisal Specialist Hosp & Res Ctr, Cell Therapy & Immunobiol Dept, Therapeut & Biomarker Discovery Clin Applicat, POB 3354, Riyadh 11211, Saudi Arabia.
   [Alkhayal, Zikra] King Faisal Specialist Hosp & Res Ctr, Dept Dent, POB 3354, Riyadh 11211, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center; King Faisal
   Specialist Hospital & Research Center
RP Alkhayal, Z; Alaiya, A (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Cell Therapy & Immunobiol Dept, Therapeut & Biomarker Discovery Clin Applicat, POB 3354, Riyadh 11211, Saudi Arabia.; Alkhayal, Z (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Dent, POB 3354, Riyadh 11211, Saudi Arabia.
EM zalkhayal@kfshrc.edu.sa; szakia@kfshrc.edu.sa; agaafar@kfshrc.edu.sa;
   aalaiya@kfshrc.edu.sa
RI Gaafar, Ameera/C 5001 2018; Alaiya, Ayodele/ACA 6311 2022; GAAFAR,
   AMEERA/C 5001 2018; , alaiya/ACA 6311 2022
OI GAAFAR, AMEERA/0000 0001 8009 7962; , alaiya/0000 0003 2124 8550
FU This study was approved by the Research Advisory Council (RAC) of King
   Faisal Specialist Hospital and Research Centre (RAC #2110024). We thank
   the Research amp;amp; Innovation administration, KFSHamp;amp;RC for
   support. We thank Mohamed Noreldin for tech [2110024]; Research Advisory
   Council (RAC) of King Faisal Specialist Hospital and Research Centre
   (RAC); Research amp;amp; Innovation administration, KFSHamp;amp;RC
FX This study was approved by the Research Advisory Council (RAC) of King
   Faisal Specialist Hospital and Research Centre (RAC #2110024). We thank
   the Research & amp; Innovation administration, KFSH & amp;RC for
   support. We thank Mohamed Noreldin for technical assistance.
CR Akocak S, 2019, J ENZYM INHIB MED CH, V34, P1652, DOI 10.1080/14756366.2019.1664501
   Akocak S, 2019, J ENZYM INHIB MED CH, V34, P1193, DOI 10.1080/14756366.2019.1630616
   Akocak S, 2019, BIOORGAN MED CHEM, V27, P800, DOI 10.1016/j.bmc.2019.01.017
   Alaiya A, 2021, J INFLAMM RES, V14, P4313, DOI 10.2147/JIR.S322430
   Alaiya AA, 2016, INT J ONCOL, V49, P913, DOI 10.3892/ijo.2016.3618
   Alkhayal Z, 2023, CURR ISSUES MOL BIOL, V45, P1373, DOI 10.3390/cimb45020089
   Alkhayal Z, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010380
   Almstedt K, 2009, BIOCHEMISTRY US, V48, P5358, DOI 10.1021/bi900128e
   AlZahrani S, 2023, CELLS BASEL, V12, DOI 10.3390/cells12010122
   Askmyr MK, 2008, BRIT J HAEMATOL, V140, P597, DOI 10.1111/j.1365 2141.2008.06983.x
   Athanasiadou E, 2020, SPEC CARE DENT, V40, P113, DOI 10.1111/scd.12427
   Blandina P., 2019, Carbonic Anhydrases, DOI [10.1016/B978 0 12 816476 1.00021 6, DOI 10.1016/B978 0 12 816476 1.00021 6]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Chang XT, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3929
   Chávez Güitrón LE, 2018, B MED HOSP INFANT M, V75, P255, DOI [10.24875/BMHIM.M18000028, 10.24875/bmhim.m18000028]
   Coban TA, 2009, BIOORGAN MED CHEM, V17, P5791, DOI 10.1016/j.bmc.2009.07.019
   Coudert AE, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/372156
   Dasouki M, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102214
   Datta R, 2010, P NATL ACAD SCI USA, V107, P6448, DOI 10.1073/pnas.1001905107
   DEBRUYNE D, 1993, CLIN PHARMACOKINET, V24, P10, DOI 10.2165/00003088 199324010 00002
   Even Or E, 2021, BONE MARROW TRANSPL, V56, P434, DOI 10.1038/s41409 020 01040 9
   Feldshtein M, 2010, AM J HUM GENET, V87, P713, DOI 10.1016/j.ajhg.2010.10.008
   FRANZEN B, 1993, ELECTROPHORESIS, V14, P1045, DOI 10.1002/elps.11501401167
   FRANZEN B, 1995, ELECTROPHORESIS, V16, P1087, DOI 10.1002/elps.11501601184
   Handler DC, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201800222
   Hayashi Y, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 99585 2
   Kim JM, 2022, ELIFE, V11, DOI 10.7554/eLife.78069
   Landa J, 2007, J AM ACAD ORTHOP SUR, V15, P654, DOI 10.5435/00124635 200711000 00004
   Li P, 2016, INT J MED SCI, V13, P629, DOI 10.7150/ijms.16045
   Lolak N, 2019, BIOORG CHEM, V82, P117, DOI 10.1016/j.bioorg.2018.10.005
   Lolak N, 2018, BIOORG CHEM, V77, P542, DOI 10.1016/j.bioorg.2018.02.015
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Margolis DS, 2008, CALCIFIED TISSUE INT, V82, P66, DOI 10.1007/s00223 007 9098 x
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Müller WEG, 2013, BIOMATERIALS, V34, P8671, DOI 10.1016/j.biomaterials.2013.07.096
   Nagai R, 1997, PEDIATR NEPHROL, V11, P633, DOI 10.1007/s004670050354
   Ogilvie JM, 2007, P NATL ACAD SCI USA, V104, P8514, DOI 10.1073/pnas.0702899104
   OHLSSON A, 1980, DEV MED CHILD NEUROL, V22, P72
   OHLSSON A, 1986, PEDIATRICS, V77, P371
   Penna S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00085
   Rose AS, 2018, BIOINFORMATICS, V34, P3755, DOI 10.1093/bioinformatics/bty419
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   SCHLESINGER PH, 1994, MINER ELECTROL METAB, V20, P31
   Schneider MR, 2009, TRENDS ENDOCRIN MET, V20, P517, DOI 10.1016/j.tem.2009.06.008
   Stark Z, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750 1172 4 5
   Sugimoto A, 2010, BIOL PHARM BULL, V33, P301, DOI 10.1248/bpb.33.301
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   van Karnebeek CD, 2014, AM J HUM GENET, V94, P453, DOI 10.1016/j.ajhg.2014.01.006
   Van Wesenbeeck L, 2007, J CLIN INVEST, V117, P919, DOI 10.1172/JCI30328
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   WALKER DG, 1975, J EXP MED, V142, P651, DOI 10.1084/jem.142.3.651
   Wang A.M., 2017, Fetal and Neonatal Physiology, V4th ed.
   Wang XH, 2014, BEILSTEIN J NANOTECH, V5, P610, DOI 10.3762/bjnano.5.72
   Wang XW, 2023, J ORTHOP SCI, V28, P468, DOI 10.1016/j.jos.2021.12.018
   Wu CC, 2017, J CLIN ENDOCR METAB, V102, P3111, DOI 10.1210/jc.2017 01127
   Zhang SS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb4747
NR 57
TC 4
Z9 4
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2023
VL 24
IS 18
AR 13841
DI 10.3390/ijms241813841
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA S5RT3
UT WOS:001071743300001
PM 37762144
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chatterjee, M
   Hatori, K
   Duyck, J
   Sasaki, K
   Naert, I
   Vandamme, K
AF Chatterjee, M.
   Hatori, K.
   Duyck, J.
   Sasaki, K.
   Naert, I.
   Vandamme, K.
TI High frequency loading positively impacts titanium implant
   osseointegration in impaired bone
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Animal study; Bone healing; High frequency loading; Implant
   osseointegration
ID LOW MAGNITUDE; MECHANICAL SIGNALS; SURFACE ROUGHNESS; DENTAL IMPLANTS;
   TRABECULAR BONE; CORTICAL BONE; REGENERATION; BISPHOSPHONATES;
   PERIOSTEAL; RAT
AB High frequency loading via whole body vibration promotes bone formation and increases bone strength. Whether this translates to positive titanium implant osseointegration in osteoporotic bone was explored in this animal study. An anabolic effect of not only bisphosphonate treatment but also high frequency loading on implant osseointegration in osteoporotic bone was observed.
   The present study investigated the impact of high frequency (HF) loading, applied via whole body vibration (WBV), on titanium implant osseointegration in healthy versus ovariectomy induced compromised versus pharmacologically treated compromised bone.
   A custom made Ti implant was inserted into the metaphyseal tibia of 59 rats and left to heal for either 4 or 14 days. Rats were divided into six groups according to their hormonal and mechanical status. WBV, consisting of 10 consecutive frequency steps at an acceleration of 0.3g, was applied daily for either 4 or 14 days. Tissue samples were processed for quantitative histology at the tibial cortical and medullar level. Data were analyzed by three way ANOVA and by post hoc pairwise comparisons.
   The bone healing response at the interface and surrounding titanium implants was negatively influenced by osteoporotic bone conditions, mainly at the trabecular bone level. Furthermore, the administration of bisphosphonates for preventing the ovariectomy induced impaired peri implant response was successful. Finally, the effect of HF WBV loading on the peri implant bone healing was dependent on the bone condition and was anabolic solely in untreated osteoporotic trabecular bone when applied for an extended period of time.
   The bone healing response to implant installation is compromised in osteoporotic bone conditions, in particular at the trabecular bone compartment. Meanwhile, not only pharmacological treatment but also mechanical loading via HF WBV can exert a positive effect on implant osseointegration in this specific bone micro environment. The peri implant cortical bone, however, seems to be less sensitive to HF WBV loading influences.
C1 [Chatterjee, M.; Hatori, K.; Duyck, J.; Naert, I.; Vandamme, K.] Katholieke Univ Leuven, BIOMAT Res Grp, Dept Oral Hlth Sci, B 3000 Leuven, Belgium.
   [Chatterjee, M.; Hatori, K.; Duyck, J.; Naert, I.; Vandamme, K.] Katholieke Univ Leuven, BIOMAT Res Grp, Dent Clin, B 3000 Leuven, Belgium.
   [Chatterjee, M.; Hatori, K.; Duyck, J.; Naert, I.; Vandamme, K.] Univ Hosp Leuven, B 3000 Leuven, Belgium.
   [Hatori, K.; Sasaki, K.] Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi 980, Japan.
C3 KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; Tohoku
   University
RP Vandamme, K (通讯作者)，Katholieke Univ Leuven, BIOMAT Res Grp, Dept Oral Hlth Sci, Kapucijnenvoer 7 Blok a,Box 7001, B 3000 Leuven, Belgium.
EM Katleen.Vandamme@med.kuleuven.be
RI ; Duyck, Joke/AGN 7677 2022
OI Duyck, Joke/0000 0002 8698 1692; 
FU Fund for Scientific Research Flanders (FWO) [G.0726.09]
FX This study was funded by the Fund for Scientific Research Flanders (FWO)
   (G.0726.09).
CR Akca Kivanc, 2007, Head Face Med, V3, P28, DOI 10.1186/1746 160X 3 28
   Alghamdi HS, 2013, TISSUE ENG PART B RE, V19, P233, DOI [10.1089/ten.TEB.2012.0400, 10.1089/ten.teb.2012.0400]
   Alsaadi G, 2008, CLIN ORAL IMPLAN RES, V19, P670, DOI 10.1111/j.1600 0501.2008.01534.x
   [Anonymous], COMPEND CONTIN ED DE
   [Anonymous], COMPEND CONTIN ED DE
   August M, 2001, J ORAL MAXIL SURG, V59, P1285, DOI 10.1053/joms.2001.27515
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Botticelli D, 2005, J CLIN PERIODONTOL, V32, P448, DOI 10.1111/j.1600 051X.2005.00693.x
   Chang PC, 2010, CLIN ORAL IMPLAN RES, V21, P1, DOI 10.1111/j.1600 0501.2009.01826.x
   Chen BL, 2011, OSTEOPOROSIS INT, V22, P265, DOI 10.1007/s00198 010 1186 5
   Chen BL, 2012, J ORTHOP RES, V30, P733, DOI 10.1002/jor.22004
   Christiansen BA, 2009, BONE, V45, P750, DOI 10.1016/j.bone.2009.06.025
   Coughlin TR, 2012, J BIOMECH, V45, P2222, DOI 10.1016/j.jbiomech.2012.06.020
   Dao T T, 1993, Int J Oral Maxillofac Implants, V8, P137
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   Duarte PM, 2005, J PERIODONTOL, V76, P107, DOI 10.1902/jop.2005.76.1.107
   Duyck J, 2006, ARCH ORAL BIOL, V51, P1, DOI 10.1016/j.archoralbio.2005.04.003
   Duyck J, 2007, J CLIN PERIODONTOL, V34, P998, DOI 10.1111/j.1600 051X.2007.01135.x
   Esposito M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003607.pub4
   Feine J S, 2002, Gerodontology, V19, P3
   Friberg B, 2001, Clin Implant Dent Relat Res, V3, P50, DOI 10.1111/j.1708 8208.2001.tb00128.x
   Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612
   Goodship AE, 2009, J ORTHOP RES, V27, P922, DOI 10.1002/jor.20824
   Hatori K, 2014, OSTEOPOROSI IN PRESS
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hwang SJ, 2009, CLIN ORTHOP RELAT R, V467, P1083, DOI 10.1007/s11999 008 0552 5
   Judex S, 2002, FASEB J, V16, P1280, DOI 10.1096/fj.01 0913fje
   Judex S, 2009, ORTHOD CRANIOFAC RES, V12, P94, DOI 10.1111/j.1601 6343.2009.01442.x
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   Mellado Valero A, 2010, MED ORAL PATOL ORAL, V15, pE52, DOI 10.4317/medoral.15.e52
   Minsk L, 1998, Compend Contin Educ Dent, V19, P859
   Mori H, 1997, J ORAL MAXIL SURG, V55, P351, DOI 10.1016/S0278 2391(97)90124 5
   Nijenhuis T, 2008, J BONE MINER RES, V23, P1815, DOI 10.1359/JBMR.080613
   Ogawa T, 2011, J CLIN PERIODONTOL, V38, P180, DOI 10.1111/j.1600 051X.2010.01637.x
   Ozawa S, 2002, BONE, V30, P137, DOI 10.1016/S8756 3282(01)00646 9
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Pazzaglia UE, 1996, BIOMATERIALS, V17, P1009, DOI 10.1016/0142 9612(96)84676 X
   PILLIAR RM, 1979, J BIOMED MATER RES, V13, P799, DOI 10.1002/jbm.820130510
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756 3282(01)00689 5
   Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251
   Rubinacci A, 2008, CALCIFIED TISSUE INT, V82, P316, DOI 10.1007/s00223 008 9115 8
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Seeman E, 2003, NEW ENGL J MED, V349, P320, DOI 10.1056/NEJMp038101
   Shi HF, 2010, BONE, V46, P1299, DOI 10.1016/j.bone.2009.11.028
   STEIGER P, 1992, J BONE MINER RES, V7, P625
   Szulc P, 2006, J BONE MINER RES, V21, P1856, DOI 10.1359/JBMR.060904
   Vandamme K, 2008, J PERIODONTOL, V79, P150, DOI 10.1902/jop.2008.060413 
   Vandamme K, 2007, EUR J ORAL SCI, V115, P21, DOI 10.1111/j.1600 0722.2007.00416.x
   Viera Negron Yeritxa E, 2008, J Oral Implantol, V34, P76, DOI 10.1563/1548 1336(2008)34[76:EOOAAO]2.0.CO;2
   Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
   Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199
NR 52
TC 10
Z9 12
U1 1
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2015
VL 26
IS 1
BP 281
EP 290
DI 10.1007/s00198 014 2824 0
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY6PZ
UT WOS:000347689400030
PM 25164696
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, SJ
   Yue, W
   Rahman, K
   Xin, HL
   Zhang, QY
   Qin, LP
   Zhang, H
AF Wang, Su Juan
   Yue, Wei
   Rahman, Khalid
   Xin, Hai Liang
   Zhang, Qiao Yan
   Qin, Lu Ping
   Zhang, Hong
TI Mechanism of Treatment of Kidney Deficiency and Osteoporosis is Similar
   by Traditional Chinese Medicine
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Traditional chinese medicine; western medicine; syndrome; disease;
   pathological basis
ID INDUCED BONE LOSS; OVARIECTOMIZED RAT MODEL; ESTROGEN PLUS PROGESTIN;
   OSTEOBLAST DIFFERENTIATION; ETHANOL EXTRACT; RUBUS COREANUS; HEALTH;
   OSTEOCLASTOGENESIS; PREVENTION; FRACTURE
AB Traditional Chinese medicine (TCM) is a theoretical based system and is completely different from western medicine and states that numerous diseases, especially chronic diseases, are cured or relieved. "Zheng" (syndrome) is a summarization of the pathological changes which take place during the different stages of the development of a disease, including its location, cause and nature as well as the state of both Xie qi (pathogenic factors) and Zheng qi (healthy energy). Compared to a single symptom, syndrome can demonstrate the nature of a disease more extensively, completely and correctly. However, it is difficult to compare "Zheng" to the western medicine theory, which is based on scientific evidence for the diagnosis and treatment of a specific disease. Estrogen deficiency is a major pathogenetic factor in bone loss after menopause and oophorectomy with the subsequent risk of developing osteoporosis. According to TCM theory, the kidney stores essence and this can transform into bone marrow to nourish the bones, strenghthen the skeleton by promoting growth and repair. The kidney deficiency can decrease the estrogen level adjusted by the gonadal axis, causing osteoporosis. Traditional Chinese medicines tonifying the kidney can significantly enhance the level of estrogen to alleviate osteoporosis. In combination with other evidence, we further deduce that the syndrome as defined within TCM has a similar pathological mechanism to that defined by western medicine. If TCM theory is to be understood and accepted, and further fused with the western medicine theory, the micro pathological basis of TCM syndrome must be investigated extensively, which will lead to bridging the two theories together. The fusion of TCM with western medicine will pay more attention to analyzing the common nature and difference of disease and syndrome. This paper reviews the way forward for new translational advances.
C1 [Wang, Su Juan; Yue, Wei; Zhang, Hong] Shanghai Seventh Peoples Hosp, Cent Lab, Shanghai 200137, Peoples R China.
   [Rahman, Khalid] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Fac Sci, Liverpool L3 3AF, Merseyside, England.
   [Xin, Hai Liang; Zhang, Qiao Yan; Qin, Lu Ping] Second Mil Med Univ, Sch Pharm, Dept Pharmacognosy, Shanghai 200433, Peoples R China.
   [Zhang, Hong] Second Mil Med Univ, Sch Pharm, Dept Pharmaceut Bot, Shanghai 200433, Peoples R China.
C3 Liverpool John Moores University; Naval Medical University; Naval
   Medical University
RP Zhang, H (通讯作者)，Shanghai Seventh Peoples Hosp, Cent Lab, Shanghai 200137, Peoples R China.
EM zhanghong@smmu.edu.cn
FU National Natural Science Foundation of China [81173462]; Open Research
   Fund of State Key Laboratory Breeding Base of Systematic Research,
   Development and Utilization of Chinese Medicine Resources [ME2015006]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81173462) and the Open Research Fund of State Key Laboratory
   Breeding Base of Systematic Research, Development and Utilization of
   Chinese Medicine Resources (ME2015006).
CR [Anonymous], HEILONGJIANG MED J
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chen MC, 2012, ORTHOP TRAUMATOL, V24, P12
   Chen ST, 2008, NAT BIOTECHNOL, V26, P1077, DOI 10.1038/nbt1008 1077
   Chen ZL, 1992, CHINESE MED, V2, P120
   Compston J, 2009, EUR J RADIOL, V71, P388, DOI 10.1016/j.ejrad.2008.04.063
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   de Villiers TJ, 2009, BEST PRACT RES CL OB, V23, P73, DOI 10.1016/j.bpobgyn.2008.10.009
   Devareddy L, 2008, J NUTR BIOCHEM, V19, P694, DOI 10.1016/j.jnutbio.2007.09.004
   Do SH, 2008, MENOPAUSE, V15, P676, DOI 10.1097/gme.0b013e31815bb687
   Dören M, 2002, MATURITAS, V43, pS53
   El Shitany NA, 2010, PHYTOMEDICINE, V17, P116, DOI 10.1016/j.phymed.2009.05.012
   Ferretti M, 2010, J ANAT, V217, P48, DOI 10.1111/j.1469 7580.2010.01242.x
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Hesch R D, 1990, Fortschr Med, V108, P219
   Hwang YC, 2009, J BONE MINER METAB, V27, P584, DOI 10.1007/s00774 009 0093 3
   Isoniemi H, 2001, J HEPATOL, V34, P299, DOI 10.1016/S0168 8278(00)00067 2
   Kanis JA, 1996, BONE, V19, pS185, DOI 10.1016/S8756 3282(96)00257 8
   Kapur P, 2008, MATURITAS, V59, P329, DOI 10.1016/j.maturitas.2008.03.006
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lee KH, 2006, AM J CHINESE MED, V34, P643, DOI 10.1142/S0192415X0600417X
   Li QL, 2009, J CHANGCHUN U TRADIT, V25, P372
   Li Y, 2011, PHYTOTHER RES, V25, P1895, DOI 10.1002/ptr.3543
   Li YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057168
   Liang HD, 2011, INT J MOL SCI, V12, P5060, DOI 10.3390/ijms12085060
   Liang QM, 2011, GUIDE CHINA MED, V9, P5
   Liu TC, 2007, EXPT STUDY YOUGUI WA, V4, P56
   Liu ZG, 2009, J ETHNOPHARMACOL, V123, P74, DOI 10.1016/j.jep.2009.02.025
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Masuda K, 2008, J BONE MINER METAB, V26, P123, DOI 10.1007/s00774 007 0810 8
   Mukherjee M, 2004, PHYTOTHER RES, V18, P389, DOI 10.1002/ptr.1448
   Nagareddy PR, 2006, J PHARM PHARMACOL, V58, P513, DOI 10.1211/jpp.58.4.0011
   Nanes MS, 2009, FERTIL STERIL, V92, P403, DOI 10.1016/j.fertnstert.2009.05.049
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Niu YB, 2011, PHYTOTHER RES, V25, P1700, DOI 10.1002/ptr.3414
   Oh KO, 2003, CLIN CHIM ACTA, V334, P185, DOI 10.1016/S0009 8981(03)00238 9
   Opar A, 2009, NAT REV DRUG DISCOV, V8, P757, DOI 10.1038/nrd3015
   Pandey R, 2010, MENOPAUSE, V17, P602, DOI 10.1097/gme.0b013e3181d0f7f0
   Puel C, 2005, J ETHNOPHARMACOL, V99, P55, DOI 10.1016/j.jep.2005.01.047
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sharan K, 2010, MENOPAUSE, V17, P577, DOI 10.1097/gme.0b013e3181d2ce7f
   Shen ZY, 1995, TCM J, V9, P560
   Shirke SS, 2008, EXP BIOL MED, V233, P1403, DOI 10.3181/0803 RM 93
   Shirke SS, 2009, MENOPAUSE, V16, P589, DOI 10.1097/gme.0b013e31818e64c4
   Shirwaikar A, 2003, J ETHNOPHARMACOL, V89, P245, DOI 10.1016/j.jep.2003.08.004
   Si FC, 1994, TCM RES, V7, P2
   Siddiqui JA, 2011, MENOPAUSE, V18, P198, DOI 10.1097/gme.0b013e3181e84e67
   Tang CH, 2009, OSTEOPOROSIS INT, V20, P93, DOI 10.1007/s00198 008 0630 2
   Tural S, 2013, GENE, V515, P167, DOI 10.1016/j.gene.2012.10.041
   Wang WJ, 1986, TCM J, V4, P32
   Wang WJ, 1982, CJITWM, V3, P149
   Weerachayaphorn J, 2011, J ETHNOPHARMACOL, V137, P956, DOI 10.1016/j.jep.2011.06.040
   Xing WW, 2008, FUJIAN J TRADIT CHIN, V39, P45
   Yin J, 2006, PHYTOMEDICINE, V13, P37, DOI 10.1016/j.phymed.2004.06.017
   沈自尹, 2012, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V32, P304
   Zhang H, 2001, ORTHOPAEDICS TRAUMAT, V3, P55
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang Y, 2011, OSTEOPOROSIS INT, V22, P703, DOI 10.1007/s00198 010 1240 3
   Zhang YZ, 2006, J ETHNOPHARMACOL, V105, P274, DOI 10.1016/j.jep.2005.12.013
   Zhao H, 2008, J GUANGZHOU U TRADIT, V25, P533
   Zhao RC, 2010, GUIDE CHINA MED, V8, P60
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
NR 65
TC 38
Z9 41
U1 0
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 3
BP 312
EP 320
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DG4VG
UT WOS:000372070600007
PM 26561071
DA 2025 08 17
ER

PT J
AU Duong, LT
   Wesolowski, GA
   Leung, P
   Oballa, R
   Pickarski, M
AF Duong, Le T.
   Wesolowski, Gregg A.
   Leung, Patrick
   Oballa, Renata
   Pickarski, Maureen
TI Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for
   Prevention and Treatment of Breast Cancer Bone Metastasis
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ZOLEDRONIC ACID; CYSTEINE CATHEPSINS; SOLID TUMORS; DOUBLE BLIND;
   PLACEBO; TARGET; EXPRESSION; DESIGN; TRIAL
AB Cathepsin K (CatK) is essential for osteoclast mediated bone resorption. CatK expression is also detected in breast cancer cells that metastasize to bone. Here, the CatK inhibitor L 235 dosed in prevention (10, 30, and 100 mg/kg, p.o., b.i.d.) or treatment regimen (30 mg/kg) was compared with the bisphosphonate zoledronic acid (ZOL, 7.5 mu g/kg/wk, s.c.) in the intratibial injection model of MDA MB 231 breast carcinoma in nude rats. Progression of osteolysis, skeletal tumor burden, and local metastasis was evaluated by radiography through 42 days and ex vivo mu CT and histology. IHC and RT PCR confirmed the increases in CatK protein and mRNA levels in human breast cancer primary and metastatic tumors. In the experimental model of breast cancer bone metastasis, L 235 dosed in preventive mode resulted in a dose related reduction of osteolysis of 72%, 75%, and 87% respectively, compared with ZOL by 86% versus intact. Similarly, L 235 significantly reduced intratibial tumor volume by 29%, 40%, and 63%, respectively, compared with 56% by ZOL versus vehicle. Efficacy of L 235 and ZOL on reduction of osteolytic lesions and tumor burden was comparable in treatment versus preventive regimens. All L 235 doses inhibited cortical disruption and extraskeletal tumor growth to a level comparable with ZOL. Assessment of local metastasis demonstrated that treatment with the CatK inhibitor was more effective than ZOL in reducing breast cancer invasion. These data support the role of CatK in breast cancer skeletal growth and metastasis and CatK inhibitors may represent a novel oral therapy for treatment of metastatic breast cancer. (C)2014 AACR.
C1 [Duong, Le T.; Wesolowski, Gregg A.; Leung, Patrick; Pickarski, Maureen] Merck & Co Inc, Whitehouse Stn, NJ USA.
   [Oballa, Renata] Incept Sci Canada Inc, Vancouver, BC, Canada.
C3 Merck & Company; Merck & Company USA
RP Duong, LT (通讯作者)，Merck & Co Inc, Bone Biol, 770 Sumneytown Pike, West Point, PA 19486 USA.
EM le_duong@merck.com
FU Merck Co.
FX This work was funded by Merck & Co.
CR Altmann E, 2002, J MED CHEM, V45, P2352, DOI 10.1021/jm010801s
   Bellahcene A, 2002, BREAST CANC RES TREA, V101, P135
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2013, J BONE ONCOL, V2, P70, DOI 10.1016/j.jbo.2013.01.002
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Desmarais S, 2008, MOL PHARMACOL, V73, P147, DOI 10.1124/mol.107.039511
   Duong LT, 2012, BONEKEY, V67, P3
   Falgueyret JP, 2005, J MED CHEM, V48, P7535, DOI 10.1021/jm0504961
   Ferguson VL, 2002, BONE, V30, P109, DOI 10.1016/S8756 3282(01)00618 4
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059
   Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008 5472.CAN 06 3940
   Le Gall Celine, 2008, Curr Opin Support Palliat Care, V2, P218, DOI 10.1097/SPC.0b013e32830baea9
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Palmer JT, 2005, J MED CHEM, V48, P7520, DOI 10.1021/jm058198r
   Pavlakis N, 2012, COCHRANE DB SYST REV, V2
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Simoni D, 2008, J MED CHEM, V51, P6800, DOI 10.1021/jm801003y
   Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962
NR 29
TC 68
Z9 74
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2014
VL 13
IS 12
BP 2898
EP 2909
DI 10.1158/1535 7163.MCT 14 0253
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AW2QH
UT WOS:000346132900012
PM 25249554
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Papasian, CJ
   Deng, HW
AF Zhang, Y.
   Papasian, C. J.
   Deng, H.  W.
TI Alteration of vitamin D metabolic enzyme expression and calcium
   transporter abundance in kidney involved in type 1 diabetes induced bone
   loss
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone; Calcium; Kidney; Type 1 diabetes; Vitamin D
ID FRUCTUS LIGUSTRI LUCIDI; BIOMECHANICAL BEHAVIOR; COMBINATION THERAPY;
   GENE EXPRESSION; RATS; NEPHROPATHY; OSTEOPOROSIS; MELLITUS; EXTRACT;
   DISEASE
AB This study aimed to delineate the mechanism involved in type 1 diabetes induced bone loss. The results revealed the alteration of vitamin D metabolic enzyme expression and the downregulation of renal calcium transporter abundance in type 1 diabetic mice.
   The purpose of this study was to investigate the changes of the expression of vitamin D metabolic enzymes and transcellular calcium transporting proteins in kidneys from mice with experimentally induced diabetes.
   Male DBA/2J mice were injected with either vehicle (control) or streptozotocin (STZ) daily for five consecutive days. Bone mineral density was measured by peripheral quantitative computerized tomography, and bone histomorphology was analyzed by Safranin O staining. Real time PCR and Western blotting were applied to determine the expression of target genes and proteins.
   Type 1 diabetes produced high urinary calcium excretion and loss of trabecular bone measured at the proximal metaphysis of the tibia and the distal femur. Bone loss was associated with deterioration of trabecular bone microstructure. Quantified PCR results showed that mRNA expression level in the kidney of diabetic mice for 25 hydroxyvitamin D 24 hydroxylase was downregulated at week 10, while those for 25 hydroxyvitamin D 1 alpha hydroxylase were upregulated at week 20. In addition, mRNA expression levels for renal transient receptor potential V6, plasma membrane Ca ATPase (PMCA)1b, and vitamin D receptor (VDR) genes were decreased in STZ treated mice. Western blot analysis showed that protein expression of PMCA1b and VDR was significantly decreased in kidneys from STZ treated mice compared to that of controls.
   The limitation in this study is the lack of vitamin D, parathyroid hormone, and phosphorus levels in serum. However, the present study supports the conclusion that the underlying mechanism contributing to type 1 diabetes associated bone loss may be alterations of vitamin D metabolic enzyme expression and associated decreases in expression of renal calcium transporters.
C1 [Zhang, Y.; Deng, H.  W.] Shanghai Univ Sci & Technol, Sch Med Instrument & Food Engn, Ctr Syst Biomed Sci, Shanghai 200093, Peoples R China.
   [Papasian, C. J.; Deng, H.  W.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
C3 University of Shanghai for Science & Technology; University of Missouri
   System; University of Missouri Kansas City
RP Zhang, Y (通讯作者)，Shanghai Univ Sci & Technol, Sch Med Instrument & Food Engn, Ctr Syst Biomed Sci, Shanghai 200093, Peoples R China.
EM medicineyan@yahoo.com.cn
OI Deng, Hong Wen/0000 0002 0387 8818
FU Shanghai Pujiang Program [10PJ1407700]; Shanghai Municipal Education
   Commission [11ZZ137]; NIH [P50AR055081, R01AG026564, R01AR050496,
   RC2DE020756, R01AR057049, R03TW008221]; Franklin D. Dickson/Missouri
   Endowment
FX This project was sponsored by Shanghai Pujiang Program (10PJ1407700) and
   Innovation Program of Shanghai Municipal Education Commission (11ZZ137)
   for Yan Zhang. HWD was partially supported by grants from NIH
   (P50AR055081, R01AG026564, R01AR050496, RC2DE020756, R01AR057049, and
   R03TW008221) and Franklin D. Dickson/Missouri Endowment.
CR Altan MF, 2007, ACTA HISTOCHEM, V109, P304, DOI 10.1016/j.acthis.2007.02.006
   Baeke F, 2008, MOL ASPECTS MED, V29, P376, DOI 10.1016/j.mam.2008.05.004
   Boros S, 2009, PFLUG ARCH EUR J PHY, V458, P99, DOI 10.1007/s00424 008 0602 6
   Danescu LG, 2009, ENDOCRINE, V35, P11, DOI 10.1007/s12020 008 9115 5
   den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143 4160(03)00065 4
   Diaz VA, 2009, J AM BOARD FAM MED, V22, P521, DOI 10.3122/jabfm.2009.05.080231
   Heaney RP, 2008, CLIN J AM SOC NEPHRO, V3, P1535, DOI 10.2215/CJN.01160308
   Hendrix I, 2004, J STEROID BIOCHEM, V89 90, P139, DOI 10.1016/j.jsbmb.2004.03.093
   Hie M, 2007, BONE, V41, P1045, DOI 10.1016/j.bone.2007.08.030
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Holick MF, 2008, CURR DIABETES REP, V8, P393, DOI 10.1007/s11892 008 0068 0
   Kanter M, 2007, CELL BIOCHEM FUNCT, V25, P747, DOI 10.1002/cbf.1397
   Kip SN, 2004, AM J PHYSIOL RENAL, V286, pF363, DOI 10.1152/ajprenal.00076.2003
   Lee CT, 2006, KIDNEY INT, V69, P1786, DOI 10.1038/sj.ki.5000344
   Martin LM, 2007, HISTOCHEM CELL BIOL, V128, P125, DOI 10.1007/s00418 007 0308 4
   Mathieu C, 2005, DIABETOLOGIA, V48, P1247, DOI 10.1007/s00125 005 1802 7
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P376, DOI 10.1002/jcp.21608
   Nickolas TL, 2008, KIDNEY INT, V74, P721, DOI 10.1038/ki.2008.264
   Ogasawara A, 2008, BONE, V43, P832, DOI 10.1016/j.bone.2008.07.246
   Panierakis C, 2009, CLIN IMMUNOL, V133, P276, DOI 10.1016/j.clim.2009.08.004
   Qi ZH, 2005, DIABETES, V54, P2628, DOI 10.2337/diabetes.54.9.2628
   Quarles LD, 2008, J CLIN INVEST, V118, P3820, DOI 10.1172/JCI36479
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Reidy K, 2009, AM J KIDNEY DIS, V54, P590, DOI 10.1053/j.ajkd.2009.07.003
   Saller A, 2008, AGING CLIN EXP RES, V20, P280
   Schwartz Ann V, 2007, Curr Osteoporos Rep, V5, P105
   Silva MJ, 2009, J BONE MINER RES, V24, P1618, DOI [10.1359/JBMR.090316, 10.1359/jbmr.090316]
   Strehler EE, 2007, ANN NY ACAD SCI, V1099, P226, DOI 10.1196/annals.1387.023
   Suzuki K, 2003, BONE, V33, P108, DOI 10.1016/S8756 3282(03)00169 8
   Szkudelski T, 2001, PHYSIOL RES, V50, P537
   Tao B, 2008, J CLIN ENDOCR METAB, V93, P1670, DOI 10.1210/jc.2007 1760
   Uchiyama S, 2005, BIOL PHARM BULL, V28, P1766, DOI 10.1248/bpb.28.1766
   Ward DT, 2001, J AM SOC NEPHROL, V12, P779, DOI 10.1681/ASN.V124779
   Yamaguchi M, 2003, INT J MOL MED, V12, P755
   Yamaguchi M, 2007, INT J MOL MED, V19, P803
   Yamaguchi Toru, 2008, Clin Calcium, V18, P904, DOI CliCa0807904911
   Zhang Y, 2008, OSTEOPOROSIS INT, V19, P235, DOI 10.1007/s00198 007 0442 9
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
   Zhang Y, 2008, MENOPAUSE, V15, P558, DOI 10.1097/gme.0b013e31814fad27
   Zhang Y, 2007, AM J PHYSIOL ENDOC M, V292, pE723, DOI 10.1152/ajpendo.00445.2006
   Zhang Y, 2009, AM J PHYSIOL RENAL, V297, pF791, DOI 10.1152/ajprenal.00247.2009
   Zhang Z, 2008, P NATL ACAD SCI USA, V105, P15896, DOI 10.1073/pnas.0803751105
NR 43
TC 26
Z9 26
U1 2
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2011
VL 22
IS 6
BP 1781
EP 1788
DI 10.1007/s00198 010 1404 1
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 763HA
UT WOS:000290544900016
PM 20878391
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Edwards, BJ
   Bunta, AD
   Lane, J
   Odvina, C
   Rao, DS
   Raisch, DW
   McKoy, JM
   Omar, I
   Belknap, SM
   Garg, V
   Hahr, AJ
   Samaras, AT
   Fisher, MJ
   West, DP
   Langman, CB
   Stern, PH
AF Edwards, Beatrice J.
   Bunta, Andrew D.
   Lane, Joseph
   Odvina, Clarita
   Rao, D. Sudhaker
   Raisch, Dennis W.
   McKoy, June M.
   Omar, Imran
   Belknap, Steven M.
   Garg, Vishvas
   Hahr, Allison J.
   Samaras, Athena T.
   Fisher, Matthew J.
   West, Dennis P.
   Langman, Craig B.
   Stern, Paula H.
TI Bisphosphonates and Nonhealing Femoral Fractures: Analysis of the FDA
   Adverse Event Reporting System (FAERS) and International Safety Efforts
   A Systematic Review from the Research on Adverse Drug Events And Reports
   (RADAR) Project
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article
ID SUPPRESSED BONE TURNOVER; RED CELL APLASIA; INSUFFICIENCY FRACTURES;
   FEMUR FRACTURES; CROSS LINKING; MICRODAMAGE ACCUMULATION; ALENDRONATE
   THERAPY; STRESS FRACTURES; ZOLEDRONIC ACID; SHAFT FRACTURES
AB Background: In the United States, hip fracture rates have declined by 30% coincident with bisphosphonate use. However, bisphosphonates are associated with sporadic cases of atypical femoral fracture. Atypical femoral fractures are usually atraumatic, may be bilateral, are occasionally preceded by prodromal thigh pain, and may have delayed fracture healing. This study assessed the occurrence of bisphosphonate associated nonhealing femoral fractures through a review of data from the U.S. FDA (Food and Drug Administration) Adverse Event Reporting System (FAERS) (1996 to 2011), published case reports, and international safety efforts.
   Methods: We analyzed the FAERS database with use of the proportional reporting ratio (PRR) and empiric Bayesian geometric mean (EBGM) techniques to assess whether a safety signal existed. Additionally, we conducted a systematic literature review (1990 to February 2012).
   Results: The analysis of the FAERS database indicated a PRR of 4.51 (95% confidence interval [CI], 3.44 to 5.92) for bisphosphonate use and nonhealing femoral fractures. Most cases (n = 317) were attributed to use of alendronate (PRR = 3.32; 95% CI, 2.71 to 4.17). In 2008, international safety agencies issued warnings and required label changes. In 2010, the FDA issued a safety notification, and the American Society for Bone and Mineral Research (ASBMR) issued recommendations about bisphosphonate associated atypical femoral fractures.
   Conclusions: Nonhealing femoral fractures are unusual adverse drug reactions associated with bisphosphonate use, as up to 26% of published cases of atypical femoral fractures exhibited delayed healing or nonhealing.
C1 [Edwards, Beatrice J.; Bunta, Andrew D.; Lane, Joseph; Odvina, Clarita; Rao, D. Sudhaker; Raisch, Dennis W.; McKoy, June M.; Omar, Imran; Belknap, Steven M.; Garg, Vishvas; Hahr, Allison J.; Samaras, Athena T.; Fisher, Matthew J.; West, Dennis P.; Langman, Craig B.; Stern, Paula H.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
C3 Northwestern University; Robert H. Lurie Comprehensive Cancer Center;
   Ann & Robert H. Lurie Children's Hospital of Chicago
RP Edwards, BJ (通讯作者)，Northwestern Univ, Feinberg Sch Med, Bone Hlth & Osteoporosis Ctr, 676 North St Clair,Suite 1350, Chicago, IL 60611 USA.
RI Lane, Joseph/F 8011 2011; garg, vishvas/D 8985 2011; Rao,
   Sudhaker/ABG 8204 2021; MCKOY, JUNE/GRJ 5660 2022
OI Edwards, Beatrice/0000 0002 7900 5159; West, Dennis
   Paul/0000 0002 9107 6697; Belknap, Steven/0000 0002 3670 7409; 
CR Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   American Dental Association Council on Scientific Affairs, 2006, J Am Dent Assoc, V137, P1144
   [Anonymous], BISPH OST DRUGS LAB
   [Anonymous], 2002, Principles of bone biology
   [Anonymous], SAF REV BISPH DRUGS
   [Anonymous], RISEDRONATE EXPOSURE
   [Anonymous], FDA DRUG SAF COMM ON
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   [Anonymous], 2009 NAT M HLTH SERV
   [Anonymous], ANN M AM AC ORTH SUR
   [Anonymous], ASS REP FOS
   [Anonymous], BISPH FRACT MED SUMM
   [Anonymous], SUBTROCHANTERIC FRAC
   Armamento Villareal R, 2006, NEW ENGL J MED, V355, P2048, DOI 10.1056/NEJMc062268
   Beaupre LA, 2011, OSTEOPOROSIS INT, V22, P983, DOI 10.1007/s00198 010 1411 2
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bennett CL, 2007, SEMIN THROMB HEMOST, V33, P365, DOI 10.1055/s 2007 976172
   Bennett CL, 2007, ARCH INTERN MED, V167, P1041, DOI 10.1001/archinte.167.10.1041
   Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402
   Bennett CL, 2005, JAMA J AM MED ASSOC, V293, P2131, DOI 10.1001/jama.293.17.2131
   Bennett CL, 2004, NEW ENGL J MED, V351, P1403, DOI 10.1056/NEJMoa040528
   Bennett CL, 2002, AM J MED, V113, P603, DOI 10.1016/S0002 9343(02)01300 1
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Boivin G, 2001, ADV EXP MED BIOL, V496, P123
   Boskey AL, 2009, OSTEOPOROSIS INT, V20, P793, DOI 10.1007/s00198 008 0725 9
   BOSKEY AL, 1985, CALCIFIED TISSUE INT, V37, P287, DOI 10.1007/BF02554876
   Boskey AL, 1999, J BONE MINER RES, V14, P330, DOI 10.1359/jbmr.1999.14.3.330
   Boskey AL, 2005, OSTEOPOROSIS INT, V16, P2031, DOI 10.1007/s00198 005 1992 3
   Brauer CA, 2009, JAMA J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462
   Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521
   Burr D. B., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P201
   Burr DB, 2002, BONE, V31, P8, DOI 10.1016/S8756 3282(02)00815 3
   Calton EF, 2011, CELLS TISSUES ORGANS, V194, P302, DOI 10.1159/000324236
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Cheung Ralph K. H., 2007, Hong Kong Medical Journal, V13, P485
   Coleman R, 2007, BREAST, V16, pS21, DOI 10.1016/j.breast.2007.10.006
   Compston J, 2012, OSTEOPOROSIS INT, V23, P793, DOI 10.1007/s00198 011 1827 3
   Compston J, 2011, OSTEOPOROSIS INT, V22, P2951, DOI 10.1007/s00198 011 1804 x
   Costa L, 2011, CRIT REV ONCOL HEMAT, V77, pS31, DOI 10.1016/S1040 8428(11)70006 3
   Cree MW, 2003, OSTEOPOROSIS INT, V14, P722, DOI 10.1007/s00198 003 1430 3
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   DuMouchel W, 2004, CLIN THER, V26, P1092, DOI 10.1016/S0149 2918(04)90181 6
   Edwards BJ, 2008, LANCET ONCOL, V9, P1166, DOI 10.1016/S1470 2045(08)70305 X
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Feldstein AC, 2012, J BONE MINER RES, V27, P977, DOI 10.1002/jbmr.1550
   GASSER AB, 1972, CLIN SCI, V43, P31, DOI 10.1042/cs0430031
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Geusens Piet, 2009, Curr Osteoporos Rep, V7, P12
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Gourion Arsiquaud S, 2010, BONE, V46, P666, DOI 10.1016/j.bone.2009.11.011
   Gourion Arsiquaud S, 2009, J BONE MINER RES, V24, P1565, DOI [10.1359/jbmr.090414, 10.1359/JBMR.090414]
   Ha YC, 2010, CLIN ORTHOP RELAT R, V468, P3393, DOI 10.1007/s11999 010 1583 2
   Hauben M, 2003, DRUG SAFETY, V26, P159, DOI 10.2165/00002018 200326030 00003
   Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018 200629050 00003
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Ing Lorenzini K, 2009, DRUG SAFETY, V32, P775, DOI 10.2165/00002018 200932090 00002
   Ioannidis JPA, 2001, JAMA J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437
   Isaacs JD, 2010, CLIN ORTHOP RELAT R, V468, P3384, DOI 10.1007/s11999 010 1535 x
   Jamal SA, 2011, NEW ENGL J MED, V365, P1261, DOI 10.1056/NEJMc1107029
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Juby AG, 2002, OSTEOPOROSIS INT, V13, P205, DOI 10.1007/s001980200015
   KEAVENY TM, 1993, J BIOMECH ENG T ASME, V115, P534, DOI 10.1115/1.2895536
   Kelly WN, 2003, ANN PHARMACOTHER, V37, P1774, DOI 10.1345/aph.1D202
   Kennedy CC, 2006, EXPERT OPIN PHARMACO, V7, P1457, DOI 10.1517/14656566.7.11.1457
   Kidd LJ, 2011, J ORTHOP RES, V29, P1827, DOI 10.1002/jor.21464
   Kim SY, 2011, J BONE MINER RES, V26, P993, DOI 10.1002/jbmr.288
   Koh JSB, 2010, J ORTHOP TRAUMA, V24, P75, DOI 10.1097/BOT.0b013e3181b6499b
   Lasser KE, 2002, JAMA J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Lipton A, 2011, EXPERT REV ANTICANC, V11, P999, DOI [10.1586/ERA.11.71, 10.1586/era.11.71]
   Lipton A, 2011, EXPERT OPIN PHARMACO, V12, P749, DOI 10.1517/14656566.2011.538384
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Mckoy JM, 2008, TRANSFUSION, V48, P1754, DOI 10.1111/j.1537 2995.2008.01749.x
   Nagahama K, 2011, J NEUROSURG SPINE, V14, P500, DOI 10.3171/2010.11.SPINE10245
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Peter CP, 1996, J ORTHOP RES, V14, P74, DOI 10.1002/jor.1100140113
   Renders GAP, 2008, J BIOMECH, V41, P2793, DOI 10.1016/j.jbiomech.2008.07.009
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rozental TD, 2009, J HAND SURG AM, V34A, P595, DOI 10.1016/j.jhsa.2008.12.011
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Saad F, 2007, SEMIN ONCOL, V34, pS17, DOI 10.1053/j.seminoncol.2007.10.006
   Saito M, 2010, BONE, V46, P1170, DOI 10.1016/j.bone.2009.12.008
   Sama AA, 2004, CLIN ORTHOP RELAT R, P135, DOI 10.1097/01.blo.0000137825.50462.c5
   Sambrook PN, 2010, MED J AUSTRALIA, V193, P154, DOI 10.5694/j.1326 5377.2010.tb03835.x
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schilcher J, 2009, ACTA ORTHOP, V80, P413, DOI 10.3109/17453670903139914
   Shakir SAW, 2002, DRUG SAFETY, V25, P467, DOI 10.2165/00002018 200225060 00012
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shimizu E, 2012, J DENT RES, V91, P268, DOI 10.1177/0022034511432170
   Somford MP, 2009, J BONE MINER RES, V24, P1736, DOI [10.1359/jbmr.090408, 10.1359/JBMR.090408]
   Ste Marie LG, 2004, CALCIFIED TISSUE INT, V75, P469, DOI 10.1007/s00223 004 0039 7
   Tan SC, 2011, OSTEOPOROSIS INT, V22, P2211, DOI 10.1007/s00198 010 1384 1
   Vestergaard P, 2011, OSTEOPOROSIS INT, V22, P993, DOI 10.1007/s00198 010 1512 y
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Wang XD, 2003, ANN BIOMED ENG, V31, P1365, DOI 10.1114/1.1623488
   Wang Z, 2011, J BONE MINER RES, V26, P553, DOI 10.1002/jbmr.233
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Weil YA, 2011, J TRAUMA, V71, P186, DOI 10.1097/TA.0b013e31821957e3
   Whyte M., 2001, The metabolic and molecular bases of inherited disease, P5313
   Whyte MP, 2008, J BONE MINER RES, V23, P1698, DOI 10.1359/JBMR.080511
   Whyte MP, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1573, DOI 10.1016/B978 0 12 373884 4.00080 X
   Whyte MP, 2009, J BONE MINER RES, V24, P1132, DOI [10.1359/JBMR.081253, 10.1359/jbmr.081253]
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Wu P., 2003, Trans Orthop Res Soc, V28, P404
   YAMAUCHI M, 1988, BONE, V9, P415, DOI 10.1016/8756 3282(88)90124 X
   YAMAUCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P898, DOI 10.1016/S0006 291X(88)80124 4
   Yang KY, 2007, YONSEI MED J, V48, P653, DOI 10.3349/ymj.2007.48.4.653
NR 119
TC 94
Z9 105
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021 9355
EI 1535 1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD FEB 20
PY 2013
VL 95A
IS 4
BP 297
EP 307
DI 10.2106/JBJS.K.01181
PG 11
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA AF7LR
UT WOS:000334897100003
PM 23426763
OA Green Published
DA 2025 08 17
ER

PT J
AU Akbari, B
   Shomalizadeh, N
   Shahi, S
AF Akbari, Babak
   Shomalizadeh, Narges
   Shahi, Shabnam
TI Evaluating the effect of liposomes containing vitamin E on bone
   metabolism
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article; Early Access
ID CELL; DRUGS
AB To prevent causing pain during movement of the skeleton system, modern drug delivery systems use carriers to protect the drug, deliver it to the target site, and increase its efficiency. Liposomal encapsulation technology is one of the most promising carriers due to its biocompatibility, natural components, and cell membrane like structure. In this study, liposomes containing vitamin E were used to increase osteoblast cells' metabolism. Liposomes were prepared by hydrating a lipid film and loaded using a passive loading technique. DLS and zeta potential tests showed good stability and optimal size distribution. The cell culture results showed non toxicity and improved bone cell growth. Alkaline phosphatase activity increased in the samples containing vitamin E. Samples were prepared in three DOPE: CHEMS ratios and sonication times. The best result was from the sample with a 4:1 ratio and 20 min sonication time, which showed the maximum vitamin E loading capacity.
C1 [Akbari, Babak; Shomalizadeh, Narges] Univ Tehran, Fac New Sci & Technol, Dept Life Sci Engn, Tehran, Iran.
   [Shahi, Shabnam] Islamic Azad Univ, Dept Mat Engn, Shahreza Branch, Shahreza 86145311, Isfahan, Iran.
C3 University of Tehran; Islamic Azad University
RP Akbari, B (通讯作者)，Univ Tehran, Fac New Sci & Technol, Dept Life Sci Engn, Tehran, Iran.
EM babakbari@ut.ac.ir
RI Akbari, Babak/L 1017 2017
OI Akbari, Babak/0000 0002 7175 3742
CR Aggarwal BB, 2010, BIOCHEM PHARMACOL, V80, P1613, DOI 10.1016/j.bcp.2010.07.043
   Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556 276X 8 102
   Alves RF, 2017, COLLOID SURFACE A, V513, P1, DOI 10.1016/j.colsurfa.2016.11.019
   Basu SC, 2008, Liposome Methods and Protocols, V2nd
   Beloti Márcio Mateus, 2005, Braz. Dent. J., V16, P156
   Camolezi FL, 2002, INT J BIOCHEM CELL B, V34, P1091, DOI 10.1016/S1357 2725(02)00029 8
   Chen JC, 2013, J NANOMATER, V2013, DOI 10.1155/2013/752863
   Chen YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137097
   de Villiers TJ, 2022, CLIMACTERIC, V25, P1, DOI 10.1080/13697137.2021.1965408
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Fathi M, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109743
   Hermizi H, 2009, CALCIFIED TISSUE INT, V84, P65, DOI 10.1007/s00223 008 9190 x
   Koudelka S, 2015, J CONTROL RELEASE, V207, P59, DOI 10.1016/j.jconrel.2015.04.003
   Laouini A, 2012, J COLLOID SCI BIOTEC, V1, P147, DOI 10.1166/jcsb.2012.1020
   Liu N, 2010, COLLOID SURFACE B, V76, P16, DOI 10.1016/j.colsurfb.2009.09.041
   Marras F, 2016, CLIN CASES MINER BON, V13, P93, DOI 10.11138/ccmbm/2016.13.2.093
   Mohammed AR, 2004, INT J PHARMACEUT, V285, P23, DOI 10.1016/j.ijpharm.2004.07.010
   Nogueira E, 2015, COLLOID SURFACE B, V136, P514, DOI 10.1016/j.colsurfb.2015.09.034
   Patil YP, 2014, CHEM PHYS LIPIDS, V177, P8, DOI 10.1016/j.chemphyslip.2013.10.011
   Sadeghi D., 2012, J Dent Sch, V30, P203
   Tan LW, 2022, J ENERGY CHEM, V69, P221, DOI 10.1016/j.jechem.2022.01.024
   Wang CC, 2022, ANAL CHIM ACTA, V1221, DOI 10.1016/j.aca.2022.340168
   Wang KJ, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.1024722
   Wu Y, 2018, ONCOL LETT, V16, P97, DOI 10.3892/ol.2018.8643
   Xu YH, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14030566
   Yang K, 2023, CELL REP PHYS SCI, V4, DOI 10.1016/j.xcrp.2023.101576
   Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011
NR 27
TC 0
Z9 0
U1 2
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0884 2914
EI 2044 5326
J9 J MATER RES
JI J. Mater. Res.
PD 2024 MAR 15
PY 2024
DI 10.1557/s43578 024 01320 w
EA MAR 2024
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LH3K8
UT WOS:001185857600005
DA 2025 08 17
ER

PT J
AU Zhang, YF
   Wu, CT
   Luo, T
   Li, S
   Cheng, XR
   Miron, RJ
AF Zhang, Yufeng
   Wu, Chengtie
   Luo, Tao
   Li, Shue
   Cheng, Xiangrong
   Miron, Richard J.
TI Synthesis and inflammatory response of a novel silk fibroin scaffold
   containing BMP7 adenovirus for bone regeneration
SO BONE
LA English
DT Article
DE Biomedical applications; Biomimetics; Drug delivery; Medical
   applications; Bone healing
ID NECROSIS FACTOR ALPHA; GENE DELIVERY; GROWTH FACTOR; MORPHOGENETIC
   PROTEIN 7; CONTROLLED RELEASE; BASIC SCIENCE; IN VITRO; DEFECTS;
   THERAPY; VECTOR
AB Gene therapy has garnished tremendous awareness for the repair of osseous defects. It exhibits high efficiency gene transfer and osteogenic differentiation potential making it well suitable for the sustained delivery of growth factors to local tissues. In the present study a simplified solution based in situ biomimetic synthesis method is demonstrated for bone morphogenetic protein 7 (BMP7) adenovirus combined with silk fibroin scaffolds. This scaffold not only provides the three dimensional space for bone ingrowth, but also releases the BMP7 adenovirus which targets its secretion by host cells in vivo. Scaffolds were tested both in vitro for their osteogenic potential as well as in vivo in a critical size calvarial defect in mice. Scaffolds loaded with bone morphogenetic protein 7 adenovirus (adBMP7) were able to sustain release of adBMP7 for up to 21 days and support cell proliferation and differentiation to bone forming osteoblasts. Calvarial defects treated with scaffolds containing adBMP7 significantly induced new bone formation in vivo. To demonstrate immuno compatibility with host tissues, IL 2, IL 6 and TNF alpha were measured up to 4 weeks post implantation. Although these scaffolds demonstrated an initial pro inflammatory response, levels of IL 2, IL 6 and TNF alpha returned to baseline control values at either 2 or 4 weeks post implantation demonstrating long term compatibility for growth factor delivery via gene therapy. The results from the present study indicate the promise of gene delivery scaffold systems for robust, low cost, and high quality bone tissue engineering applications. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Zhang, Yufeng; Wu, Chengtie; Luo, Tao; Li, Shue; Cheng, Xiangrong; Miron, Richard J.] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Peoples R China.
   [Zhang, Yufeng; Wu, Chengtie; Luo, Tao; Li, Shue; Cheng, Xiangrong; Miron, Richard J.] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan 430079, Peoples R China.
   [Wu, Chengtie] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
C3 Wuhan University; Wuhan University; Chinese Academy of Sciences;
   Shanghai Institute of Ceramics, CAS
RP Zhang, YF (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
EM zyf@whu.edu.cn
RI Zhang, Yufeng/GZL 1973 2022; Miron, Richard/J 4995 2012
FU ITI Foundation for the Promotion of lmplantology, Basel, Switzerland
   [586_2008]
FX The study was funded by the ITI Foundation for the Promotion of
   lmplantology (586_2008), Basel, Switzerland. The authors declare no
   conflict of interest related to this work.
CR Awad HA, 2007, TISSUE ENG, V13, P1973, DOI 10.1089/ten.2006.0107
   Baltzer AWA, 2000, GENE THER, V7, P734, DOI 10.1038/sj.gt.3301166
   Bertone AL, 2004, J ORTHOP RES, V22, P1261, DOI 10.1016/j.orthres.2004.03.014
   Betz OB, 2007, GENE THER, V14, P1039, DOI 10.1038/sj.gt.3302956
   Betz OB, 2006, J BONE JOINT SURG AM, V88A, P355, DOI 10.2106/JBJS.E.00464
   Brodbeck WG, 2002, J LAB CLIN MED, V139, P90, DOI 10.1067/mlc.2002.121260
   Broughton G, 2006, PLAST RECONSTR SURG, V117, p12S, DOI 10.1097/01.prs.0000225430.42531.c2
   CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923
   Cho SB, 1997, BIOMATERIALS, V18, P1479, DOI 10.1016/S0142 9612(97)00084 7
   Delgado JJ, 2006, J CONTROL RELEASE, V114, P223, DOI 10.1016/j.jconrel.2006.05.026
   Dupont KM, 2012, CELL TISSUE RES, V347, P575, DOI 10.1007/s00441 011 1197 3
   Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10 5284
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   Egermann M, 2006, HUM GENE THER, V17, P507, DOI 10.1089/hum.2006.17.507
   Evans C, 2011, INJURY, V42, P599, DOI 10.1016/j.injury.2011.03.032
   Evans CH, 2009, MOL THER, V17, P231, DOI 10.1038/mt.2008.265
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Gentleman E, 2009, NAT MATER, V8, P763, DOI [10.1038/NMAT2505, 10.1038/nmat2505]
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Guan M, 2006, CANCER RES, V66, P1620, DOI 10.1158/0008 5472.CAN 05 0877
   Gugala Z, 2003, GENE THER, V10, P1289, DOI 10.1038/sj.gt.3302006
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Hsu WK, 2007, BONE, V40, P931, DOI 10.1016/j.bone.2006.10.030
   Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kong SW, 2011, BONE, V48, P298, DOI 10.1016/j.bone.2010.09.029
   Lattanzi W, 2005, Eur Rev Med Pharmacol Sci, V9, P167
   Lee HH, 2011, TISSUE ENG PT A, V17, P1969, DOI [10.1089/ten.tea.2010.0586, 10.1089/ten.TEA.2010.0586]
   Liao IC, 2009, J CONTROL RELEASE, V139, P48, DOI 10.1016/j.jconrel.2009.06.007
   Menendez MI, 2011, OSTEOARTHR CARTILAGE, V19, P1066, DOI 10.1016/j.joca.2011.05.007
   Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260
   Oe S, 2003, J CONTROL RELEASE, V88, P193, DOI 10.1016/S0168 3659(02)00463 7
   Park YJ, 2000, J CONTROL RELEASE, V67, P385, DOI 10.1016/S0168 3659(00)00232 7
   Rios HF, 2011, J PERIODONTOL, V82, P1223, DOI 10.1902/jop.2011.100710
   Santos JL, 2009, J CONTROL RELEASE, V134, P141, DOI 10.1016/j.jconrel.2008.11.007
   Sawyer AA, 2009, BIOMATERIALS, V30, P2479, DOI 10.1016/j.biomaterials.2008.12.055
   Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097 4636(200101)54:1<139::AID JBM17>3.0.CO;2 7
   Tanigawa K, 2000, J IMMUNOTHER, V23, P528, DOI 10.1097/00002371 200009000 00003
   Toro H, 2007, VACCINE, V25, P2886, DOI 10.1016/j.vaccine.2006.09.047
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Virk MS, 2008, BONE, V42, P921, DOI 10.1016/j.bone.2007.12.216
   Wissink MJB, 2000, J CONTROL RELEASE, V64, P103, DOI 10.1016/S0168 3659(99)00145 5
   Wu G, 2011, BONE, V49, P1323, DOI 10.1016/j.bone.2011.09.046
   Xu XL, 2005, ACTA ORTHOP, V76, P637, DOI 10.1080/17453670510041709
   Young CS, 2009, J CONTROL RELEASE, V140, P250, DOI 10.1016/j.jconrel.2009.06.030
   Zhang YF, 2007, BIOMATERIALS, V28, P4635, DOI 10.1016/j.biomaterials.2007.07.009
   Zhang YF, 2011, TISSUE ENG PART C ME, V17, P789, DOI 10.1089/ten.tec.2010.0453
   Zhang YF, 2010, ACTA BIOMATER, V6, P3021, DOI 10.1016/j.actbio.2010.02.030
NR 49
TC 51
Z9 58
U1 1
U2 50
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2012
VL 51
IS 4
BP 704
EP 713
DI 10.1016/j.bone.2012.06.029
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 005DH
UT WOS:000308730200010
PM 22796416
DA 2025 08 17
ER

PT J
AU Slota, D
   Urbaniak, MM
   Tomaszewska, A
   Niziolek, K
   Wlodarczyk, M
   Florkiewicz, W
   Szwed Georgiou, A
   Krupa, A
   Sobczak Kupiec, A
AF Slota, Dagmara
   Urbaniak, Mateusz M.
   Tomaszewska, Agata
   Niziolek, Karina
   Wlodarczyk, Marcin
   Florkiewicz, Wioletta
   Szwed Georgiou, Aleksandra
   Krupa, Agnieszka
   Sobczak Kupiec, Agnieszka
TI Crosslinked hybrid polymer/ceramic composite coatings for the controlled
   release of clindamycin
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID DRUG DELIVERY; PREVENTION
AB A major risk associated with surgery, including bone tissue procedures, is surgical site infection. It is one of the most common as well as the most serious complications of modern surgery. A helpful countermeasure against infection is antibiotic therapy. In the present study, a methodology has been developed to obtain clindamycin modified polymer ceramic hybrid composite coatings for potential use in bone regenerative therapy. The coatings were prepared using a UV light photocrosslinking method, and the drug was bound to a polymeric and/or ceramic phase. The sorption capacity of the materials in PBS was evaluated by determining the swelling ability and equilibrium swelling. The influence of the presence of ceramics on the amount of liquid bound was demonstrated. The results were correlated with the rate of drug release measured by high performance liquid chromatography (HPLC). Coatings with higher sorption capacity released the drug more rapidly. Scanning electron microscopy (SEM) imaging was carried out comparing the surface area of the coatings before and after immersion in PBS, and the proportions of the various elements were also determined using the EDS technique. Changes in surface waviness were observed, and chlorine ions were also determined in the samples before incubation. This proves the presence of the drug in the material. The in vitro tests conducted indicated the release of the drug from the biomaterials. The antimicrobial efficacy of the coatings was tested against Staphylococcus aureus. The most promising material was tested for cytocompatibility (MTT reduction assay) against the mouse fibroblast cell line L929 as well as human osteoblast cells hFOB. It was demonstrated that the coating did not exhibit cytotoxicity. Overall, the results signaled the potential use of the developed polymer ceramic hybrid coatings as drug carriers for the controlled delivery of clindamycin in bone applications. The studies conducted were the basis for directing samples for further in vivo experiments determining clinical efficacy.
   The main risk associated with surgical procedures, including those on bone tissue, is infection of the surgical site. These can be prevented by using multifunctional materials that demonstrate the nature of a drug carrier.
C1 [Slota, Dagmara; Niziolek, Karina] Cracow Univ Technol, Fac Mat Engn & Phys, CUT Doctoral Sch, Dept Mat Engn, 37 Jana Pawla II Ave, PL 31864 Krakow, Poland.
   [Urbaniak, Mateusz M.; Tomaszewska, Agata; Wlodarczyk, Marcin; Szwed Georgiou, Aleksandra; Krupa, Agnieszka] Univ Lodz, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, 12 16 Banacha St, PL 90237 Lodz, Poland.
   [Urbaniak, Mateusz M.] Univ Lodz, Fac Chem, Dept Inorgan & Analyt Chem, 12 Tamka St, PL 91403 Lodz, Poland.
   [Tomaszewska, Agata] Univ Lodz, Biomed Chem Doctoral Sch, 12 16 Banacha St, PL 90237 Lodz, Poland.
   [Tomaszewska, Agata] Polish Acad Sci, Lodz Inst, 12 16 Banacha St, PL 90237 Lodz, Poland.
   [Florkiewicz, Wioletta; Sobczak Kupiec, Agnieszka] Cracow Univ Technol, Fac Mat Engn & Phys, Dept Mat Engn, 37 Jana Pawla II Ave, PL 31864 Krakow, Poland.
C3 Cracow University of Technology; University of Lodz; University of Lodz;
   University of Lodz; Polish Academy of Sciences; Cracow University of
   Technology
RP Slota, D (通讯作者)，Cracow Univ Technol, Fac Mat Engn & Phys, CUT Doctoral Sch, Dept Mat Engn, 37 Jana Pawla II Ave, PL 31864 Krakow, Poland.
EM dagmara.slota@pk.edu.pl
RI Florkiewicz, Wioletta/ABU 0317 2022; Szwed Georgiou,
   Aleksandra/AFR 0930 2022; Sobczak Kupiec, Agnieszka/N 2799 2013; Krupa,
   Agnieszka/AFR 0905 2022; Urbaniak, Mateusz M./JLK 9099 2023
OI Slota, Dagmara/0000 0002 8570 3594; Szwed Georgiou,
   Aleksandra/0000 0003 0850 7204; Tomaszewska, Agata/0000 0003 4290 4115;
   Urbaniak, Mateusz M./0000 0002 2800 2054; Krupa,
   Agnieszka/0000 0003 1303 4608; 
FU Fundacja na rzecz Nauki Polskiej; Foundation for Polish Science
   [POIR.04.04.00 00 16D7/18]; European Union under the European Regional
   Development Fund
FX The "Multifunctional biologically active composites for applications in
   bone regenerative medicine" project was carried out within the TEAM NET
   program of the Foundation for Polish Science, financed by the European
   Union under the European Regional Development Fund (grant number
   POIR.04.04.00 00 16D7/18). The authors gratefully acknowledge the
   financial support.
CR Agathe B., 2021, DIAGN MICR INFEC DIS, V99
   [Anonymous], 2013, Breakpoint tables for interpretation of MICs and zone diameters
   Arcos D, 2014, ACTA BIOMATER, V10, P1793, DOI 10.1016/j.actbio.2014.01.004
   Bhattacharya M, 2015, EXPERT REV ANTI INFE, V13, P1499, DOI 10.1586/14787210.2015.1100533
   Biernat M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232214315
   Browning MB, 2014, J BIOMED MATER RES A, V102, P4244, DOI 10.1002/jbm.a.35096
   Bustamante Torres M, 2022, MACROMOL BASEL, V2, P258, DOI 10.3390/macromol2030018
   Diotallevi M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01239
   Djoi M., 2021, MATERIALS, V14, P5391
   Dogan EE, 2019, ADV MATER SCI, V19, P32, DOI 10.2478/adms 2019 0015
   Ferguson Jamie, 2017, J Bone Jt Infect, V2, P38, DOI 10.7150/jbji.17234
   Franco P, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12051114
   Gaucher C, 2018, ANTIOXIDANTS BASEL, V7, DOI 10.3390/antiox7050062
   Gong XH, 2020, REGEN BIOMATER, V7, P271, DOI 10.1093/rb/rbaa002
   Husain MSB, 2018, ENERG SOURCE PART A, V40, P2388, DOI 10.1080/15567036.2018.1495786
   Jardini AL, 2014, J CRANIO MAXILL SURG, V42, P1877, DOI 10.1016/j.jcms.2014.07.006
   Joe C., 2023, TOP CO BIOCOMPOSITES
   Kabiri K, 2003, EUR POLYM J, V39, P1341, DOI 10.1016/S0014 3057(02)00391 9
   Karna E, 2020, CELL MOL LIFE SCI, V77, P1911, DOI 10.1007/s00018 019 03363 3
   Kavarthapu V, 2023, J CLIN MED, V12, DOI 10.3390/jcm12093239
   Kolasinski W, 2019, POL J SURG, V91, P41, DOI 10.5604/01.3001.0012.7253
   Kumiska A., 2020, COLLOID SURFACE, V192, P4
   Leyva Gómez G, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050217
   Lister JL, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00178
   Lu XL, 2019, ACTA BIOMATER, V99, P363, DOI 10.1016/j.actbio.2019.08.043
   Martinac A, 2005, J MICROENCAPSUL, V22, P549, DOI 10.1080/02652040500098960
   Masters EA, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0061 z
   Naique SB, 2006, J BONE JOINT SURG BR, V88B, P351, DOI 10.1302/0301 620X.88B3.17120
   Nawrotek K, 2016, CARBOHYD POLYM, V152, P119, DOI 10.1016/j.carbpol.2016.07.002
   Parvizi J, 2017, AM J INFECT CONTROL, V45, P1267, DOI 10.1016/j.ajic.2017.06.027
   Peng ZL, 2020, APPL MATER TODAY, V20, DOI 10.1016/j.apmt.2020.100677
   Piszko P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168587
   Rodriguez A, 2009, J BIOMED MATER RES A, V89A, P152, DOI 10.1002/jbm.a.31939
   Ruiz Rodriguez L, 2021, MRS BULL, V46, P889, DOI 10.1557/s43577 021 00138 9
   Sbricoli L, 2020, MATERIALS, V13, DOI 10.3390/ma13030786
   Singampalli KL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00636
   Sionkowska A, 2020, MATERIALS, V13, DOI 10.3390/ma13194217
   Slota D, 2023, NANOMATERIALS BASEL, V13, DOI 10.3390/nano13091469
   Sokolsky Papkov M, 2007, ADV DRUG DELIVER REV, V59, P187, DOI 10.1016/j.addr.2007.04.001
   SUSI H, 1971, BIOPOLYMERS, V10, P1597, DOI 10.1002/bip.360100913
   Terzi A, 2020, MACROMOL BIOSCI, V20, DOI 10.1002/mabi.202000017
   Tomala AM, 2022, LUBRICANTS, V10, DOI 10.3390/lubricants10040058
   Wang LL, 2022, INT J BIOL MACROMOL, V222, P1175, DOI 10.1016/j.ijbiomac.2022.09.236
   Winiarczyk K., 2017, J. Achiev. Mater. Manuf. Eng, V81, P35, DOI [DOI 10.5604/01.3001.0010.2034, 10.5604/01.3001.0010.2034]
   Yu L, 2020, ACS APPL MATER INTER, V12, P18235, DOI 10.1021/acsami.0c00275
   Zhang YX, 2023, EXPLORATION PRC, V3, DOI 10.1002/EXP.20210170
NR 46
TC 1
Z9 1
U1 0
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD OCT 8
PY 2024
VL 12
IS 20
BP 5253
EP 5265
DI 10.1039/d4bm00055b
EA SEP 2024
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA I1Q6Q
UT WOS:001304918000001
PM 39235306
OA hybrid
DA 2025 08 17
ER

PT J
AU Sellmeyer, DE
AF Sellmeyer, Deborah E.
TI Atypical Fractures as a Potential Complication of Long term
   Bisphosphonate Therapy
SO JAMA JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID SUPPRESSED BONE TURNOVER; TOTAL KNEE ARTHROPLASTY; POSTMENOPAUSAL
   OSTEOPOROSIS; ALENDRONATE THERAPY; VERTEBRAL FRACTURES; INTERVENTION
   TRIAL; FEMORAL FRACTURES; RANDOMIZED TRIAL; DIAPHYSEAL FEMUR; ZOLEDRONIC
   ACID
AB The development of bisphosphonate therapy represented an important advance in the treatment of low bone mass and osteoporosis, conditions that affect more than half of individuals older than 50 years. Currently available bisphosphonates have been shown to reduce spine, nonspine, and hip fractures in individuals at increased risk of fracture. Case reports and limited clinical series over the past 5 years have raised concern that prolonged bisphosphonate therapy may suppress bone remodeling to the extent that normal bone repair is impaired, resulting in increased fracture risk. Fractures potentially resulting from suppressed bone turnover have been described as "atypical," affecting sites such as the subtrochanteric femur that are infrequently affected by osteoporotic fractures. A prodrome of thigh pain, lack of trauma prior to the fracture, and specific radiological characteristics have also been reported. Data are limited on the prevalence of, risk factors for, and treatment of this potential problem. Current strategies include fracture risk assessment, targeting bisphosphonate therapy appropriately to individuals at increased risk of fracture, considering a 12 month interruption in therapy after 5 years in patients who are clinically stable, and considering teriparatide treatment in individuals who experience an atypical fracture while receiving bisphosphonate therapy. JAMA. 2010; 304(13): 1480 1484
C1 Johns Hopkins Sch Med, Baltimore, MD 21224 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Sellmeyer, DE (通讯作者)，Johns Hopkins Sch Med, 5200 Eastern Ave,Mason F Lord Ctr Tower,Ste 4300, Baltimore, MD 21224 USA.
EM dsellme1@jhmi.edu
FU Novartis; Amgen
FX Dr Sellmeyer reports having received research funding from Novartis and
   Amgen.
CR Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   [Anonymous], 2010, CLIN GUID PREV TREAT
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Capeci CM, 2009, J BONE JOINT SURG AM, V91A, P2556, DOI 10.2106/JBJS.H.01774
   Chapurlat RD, 2007, J BONE MINER RES, V22, P1502, DOI 10.1359/JBMR.070609
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dawson Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198 008 0559 5
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Farley JF, 2009, AM J HEALTH SYST PH, V66, P1191, DOI 10.2146/ajhp080248
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Ing Lorenzini K, 2009, DRUG SAFETY, V32, P775, DOI 10.2165/00002018 200932090 00002
   Kumm DA, 1997, J ARTHROPLASTY, V12, P580, DOI 10.1016/S0883 5403(97)90184 4
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nieves JW, 2010, OSTEOPOROSIS INT, V21, P399, DOI 10.1007/s00198 009 0962 6
   Niimi R, 2008, J ORTHOP SCI, V13, P572, DOI 10.1007/s00776 008 1262 2
   Odvina CV, 2010, CLIN ENDOCRINOL, V72, P161, DOI 10.1111/j.1365 2265.2009.03581.x
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Recker R, 2004, J BONE MINER RES, V19, pS45
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Schwartz AV, 2010, J BONE MINER RES, V25, P976, DOI 10.1002/jbmr.11
   Seeman E, 2009, OSTEOPOROSIS INT, V20, P187, DOI 10.1007/s00198 008 0813 x
   Siris ES, 2003, J CLIN ENDOCR METAB, V88, P3482, DOI 10.1210/jc.2003 030568
   Ste Marie LG, 2004, CALCIFIED TISSUE INT, V75, P469, DOI 10.1007/s00223 004 0039 7
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198 007 0550 6
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
NR 39
TC 80
Z9 86
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654 0946 USA
SN 0098 7484
J9 JAMA J AM MED ASSOC
JI JAMA J. Am. Med. Assoc.
PD OCT 6
PY 2010
VL 304
IS 13
BP 1480
EP 1484
DI 10.1001/jama.2010.1360
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 658SO
UT WOS:000282509900024
PM 20924014
DA 2025 08 17
ER

PT J
AU Ma, JQ
   Chen, W
   Zhang, LJ
   Tucker, B
   Zhu, GC
   Sasaki, H
   Hao, L
   Wang, L
   Ci, HL
   Jiang, HB
   Stashenko, P
   Li, YP
AF Ma, Junqing
   Chen, Wei
   Zhang, Lijie
   Tucker, Byron
   Zhu, Guochun
   Sasaki, Hajime
   Hao, Liang
   Wang, Lin
   Ci, Hongliang
   Jiang, Hongbing
   Stashenko, Philip
   Li, Yi Ping
TI RNA Interference Mediated Silencing of Atp6i Prevents Both
   Periapical Bone Erosion and Inflammation in the Mouse Model of
   Endodontic Disease
SO INFECTION AND IMMUNITY
LA English
DT Article
ID PERIODONTAL LIGAMENT CELLS; MICRO COMPUTED TOMOGRAPHY; T CELL; IN VITRO;
   OSTEOCLAST DIFFERENTIATION; APICAL PERIODONTITIS; PARKINSONS DISEASE;
   ROOT RESORPTION; B LYMPHOCYTE; DENTAL PULP
AB Dental caries is one of the most prevalent infectious diseases in the United States, affecting approximately 80% of children and the majority of adults. Dental caries may lead to endodontic disease, where the bacterial infection progresses to the root canal system of the tooth, leading to periapical inflammation, bone erosion, severe pain, and tooth loss. Periapical inflammation may also exacerbate inflammation in other parts of the body. Although conventional clinical therapies for this disease are successful in approximately 80% of cases, there is still an urgent need for increased efficacy of treatment. In this study, we applied a novel gene therapeutic approach using recombinant adeno associated virus (AAV) mediated Atp6i RNA interference (RNAi) knockdown of Atp6i/TIRC7 gene expression to simultaneously target periapical bone resorption and periapical inflammation. We found that Atp6i inhibition impaired osteoclast function in vitro and in vivo and decreased the number of T cells in the periapical lesion. Notably, AAV mediated Atp6i/TIRC7 knockdown gene therapy reduced bacterial infection stimulated bone resorption by 80% in the mouse model of endodontic disease. Importantly, Atp6i(+/ ) mice with haploinsufficiency of Atp6i exhibited protection similar to that in mice with bacterial infection stimulated bone erosion and periapical inflammation, which confirms the potential therapeutic effect of AAV small hairpin RNA (shRNA) Atp6i/TIRC7. Our results demonstrate that AAV mediated Atp6i/TIRC7 knockdown in periapical tissues can inhibit endodontic disease development, bone resorption, and inflammation, indicating for the first time that this potential gene therapy may significantly improve the health of those who suffer from endodontic disease.
C1 [Ma, Junqing; Chen, Wei; Tucker, Byron; Zhu, Guochun; Hao, Liang; Ci, Hongliang; Jiang, Hongbing; Li, Yi Ping] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Ma, Junqing; Wang, Lin; Jiang, Hongbing] Nanjing Med Univ, Inst Stomatol, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Lijie; Sasaki, Hajime; Stashenko, Philip] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
   [Tucker, Byron] Harvard Univ, Dept Restorat Dent Endodont, Sch Dent Med, Owings Mills, MD USA.
C3 University of Alabama System; University of Alabama Birmingham; Nanjing
   Medical University; Harvard University; Harvard University Medical
   Affiliates; Forsyth Institute; Harvard University
RP Li, YP (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM wechen@uab.edu; ypli@uab.edu
RI ; Jiang, Hongbing/I 3016 2017; Zhang, Lijie/IWE 4008 2023
OI Jiang, Hongbing/0000 0002 3748 0381; Hao, Liang/0000 0003 2071 7044
FU NIH [RC1 DE 020533, R01 AR 055307]
FX This work was supported by NIH grants RC1 DE 020533 (Y.P.L.) and
   R01 AR 055307 (Y.P.L.).
CR Alexander B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001079
   Allaire JM, 2011, AM J PHYSIOL GASTR L, V300, pG586, DOI 10.1152/ajpgi.00041.2010
   [Anonymous], 2012, Oral health
   Balto K, 2000, J DENT RES, V79, P35, DOI 10.1177/00220345000790010401
   Balto K, 2002, ORAL SURG ORAL MED O, V93, P461, DOI 10.1067/moe.2002.122641
   Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Gasmi M, 2007, MOL THER, V15, P62, DOI 10.1038/sj.mt.6300010
   Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   Jules J, 2010, J BIOL CHEM, V285, P37427, DOI 10.1074/jbc.M110.149484
   KAKEHASHI S, 1965, ORAL SURG ORAL MED O, V20, P340, DOI 10.1016/0030 4220(65)90166 0
   Kamolmatyakul S, 2004, J DENT RES, V83, P791, DOI 10.1177/154405910408301011
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140 6736(07)60982 9
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kawashima N, 1999, IMMUNOLOGY, V97, P117
   Kelly KA, 1998, ENDOCRINOLOGY, V139, P2092, DOI 10.1210/en.139.4.2092
   Kojima T, 2006, INFLAMM RES, V55, P78, DOI 10.1007/s00011 005 0013 5
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   KURLAND JI, 1977, J EXP MED, V146, P1420, DOI 10.1084/jem.146.5.1420
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Lin SK, 2002, EUR J ORAL SCI, V110, P246, DOI 10.1034/j.1600 0447.2002.11227.x
   Lin XP, 2011, INFECT IMMUN, V79, P911, DOI 10.1128/IAI.00944 10
   Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103
   Nair PNR, 1997, PERIODONTOL 2000, V13, P121, DOI 10.1111/j.1600 0757.1997.tb00098.x
   Nair PNR, 2004, CRIT REV ORAL BIOL M, V15, P348, DOI 10.1177/154411130401500604
   Nijenhuis T, 2008, J BONE MINER RES, V23, P1815, DOI 10.1359/JBMR.080613
   Oseko F, 2009, MICROBIOL IMMUNOL, V53, P287, DOI 10.1111/j.1348 0421.2009.00123.x
   Ramamurthy HS, 2005, J PERIODONTOL, V76, P229, DOI 10.1902/jop.2005.76.2.229
   Sasaki H, 2000, J IMMUNOL, V165, P3626, DOI 10.4049/jimmunol.165.7.3626
   Sasaki H, 2004, J PERIODONTAL RES, V39, P432, DOI 10.1111/j.1600 0765.2004.00760.x
   Sasaki H, 2008, J IMMUNOL, V180, P6193, DOI 10.4049/jimmunol.180.9.6193
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   STASHENKO P, 1990, ENDOD DENT TRAUMATOL, V6, P89
   Tomar RS, 2003, ONCOGENE, V22, P5712, DOI 10.1038/sj.onc.1206733
   Uchiyama M, 2009, J DENT RES, V88, P609, DOI 10.1177/0022034509340008
   Utku N, 2006, CLIN EXP IMMUNOL, V144, P142, DOI 10.1111/j.1365 2249.2006.03044.x
   Utku N, 2004, J IMMUNOL, V173, P2342, DOI 10.4049/jimmunol.173.4.2342
   von Stechow D, 2003, J ENDODONT, V29, P252, DOI 10.1097/00004770 200304000 00005
   Wilensky A, 2009, J CLIN PERIODONTOL, V36, P915, DOI 10.1111/j.1600 051X.2009.01464.x
   Yamaguchi M, 2006, J DENT RES, V85, P751, DOI 10.1177/154405910608500812
   Yang SY, 2007, J CELL SCI, V120, P3362, DOI 10.1242/jcs.008300
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Yu H, 2011, GENE THER, V18, P344, DOI 10.1038/gt.2010.139
NR 46
TC 28
Z9 32
U1 0
U2 26
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0019 9567
EI 1098 5522
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2013
VL 81
IS 4
BP 1021
EP 1030
DI 10.1128/IAI.00756 12
PG 10
WC Immunology; Infectious Diseases
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases
GA 108RM
UT WOS:000316313700001
PM 23166162
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Salzano, G
   Marra, M
   Leonetti, C
   Porru, M
   Zappavigna, S
   Abbruzzese, A
   La Rotonda, MI
   Caraglia, M
   De Rosa, G
AF Salzano, G.
   Marra, M.
   Leonetti, C.
   Porru, M.
   Zappavigna, S.
   Abbruzzese, A.
   La Rotonda, M. I.
   Caraglia, M.
   De Rosa, G.
TI Nanotechnologies to use zoledronic acid as a potent antitumoral agent
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Zoledronic acid; Stealth liposomes; Self assembly nanoparticles
ID PROSTATE CANCER; BISPHOSPHONATES; INHIBITION
AB Zoledronic acid, a new highly potent third generation aminobisphosphonate, is the drug currently used to prevent bone resorption in patients with bone metastases. Moreover, ZOL is a potent inducer of apoptosis in several cancer cell types, suggesting a direct anti cancer activity that may affect a broad range of tumors. However, the rapid elimination from plasma, along with the rapid uptake and accumulation within bone, hampers the direct anti cancer activity of ZOL in vivo. On the other hand, long circulating nanocarriers offer the opportunity to change the pharmacokinetics of encapsulated drugs, targeting tissues with an increased permeability of the vessels (e.g. tumors). In this study, we proposed two different strategies in order to avoid ZOL accumulation in hone and address the drug toward tumors. In particular, we designed and developed long circulating liposomes and self assembly PEGylated nanoparticles for the delivery of ZOL into solid tumors.
C1 [Salzano, G.; La Rotonda, M. I.; De Rosa, G.] Univ Naples Federico 2, Dept Pharmaceut & Toxicol Chem, I 80131 Naples, Italy.
   [Marra, M.; Zappavigna, S.; Abbruzzese, A.; Caraglia, M.] Univ Naples 2, Dept Biochem & Biophys, I 80138 Naples, Italy.
   [Leonetti, C.; Porru, M.] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I 00158 Rome, Italy.
C3 University of Naples Federico II; Universita della Campania Vanvitelli;
   IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena
RP De Rosa, G (通讯作者)，Univ Naples Federico 2, Dept Pharmaceut & Toxicol Chem, Via Montesano 49, I 80131 Naples, Italy.
EM gederosa@unina.it
RI Porru, Manuela/AAA 5510 2021; De Rosa, Giuseppe/G 6343 2012; Caraglia,
   Michele/AFY 9729 2022; Leonetti, Carlo/B 2860 2018; Caraglia,
   Michele/N 5670 2015; Salzano, Giuseppina/IQV 5941 2023; Porru,
   Manuela/K 4809 2018
OI Leonetti, Carlo/0000 0002 3526 7827; Caraglia,
   Michele/0000 0003 2408 6091; Porru, Manuela/0000 0002 6614 9110
FU Italian Association for Cancer Research (AIRC); Regione Campania for
   "Hauteville" Public Laboratory
FX MC received a grant from Italian Association for Cancer Research (AIRC).
   MC and AB received a grant from Regione Campania for "Hauteville" Public
   Laboratory.
CR Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Cheer SM, 2001, DRUGS, V61, P799, DOI 10.2165/00003495 200161060 00010
   Green JR, 2005, ACTA ONCOL, V44, P282, DOI 10.1080/02841860510029644
   Marra M, 2009, CURR CANCER DRUG TAR, V9, P791, DOI 10.2174/156800909789760285
   Salzano G, 2011, INT J PHARMACEUT, V403, P292, DOI 10.1016/j.ijpharm.2010.10.046
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003 2697(80)90269 9
   Zuidam Nicolaas Jan, 2003, P149
NR 9
TC 2
Z9 2
U1 0
U2 12
PU EDITIONS SANTE
PI PARIS
PA 47 RUE GALILEE, 75116 PARIS, FRANCE
SN 1773 2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD MAY JUN
PY 2011
VL 21
IS 3
BP 283
EP 284
DI 10.1016/S1773 2247(11)50039 5
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 783YK
UT WOS:000292120600010
DA 2025 08 17
ER

PT J
AU Liang, C
   Yang, T
   Wu, GY
   Li, J
   Geng, W
AF Liang, Chao
   Yang, Tao
   Wu, Gaoyi
   Li, Jun
   Geng, Wei
TI Therapeutic effect of low intensity pulsed ultrasound on
   temporomandibular joint injury induced by chronic sleep deprivation in
   rats
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Low intensity pulsed ultrasound (LIPUS); chronic sleep deprivation
   (CSD); temporomandibular joint disorders (TMDs); condylar cartilage
ID MATRIX METALLOPROTEINASE EXPRESSION; ARTICULAR CARTILAGE; MODEL;
   DEGRADATION; MMP 3; METABOLISM; APOPTOSIS; PATHWAY; DAMAGE; PAIN
AB Low intensity pulsed ultrasound (LIPUS) treatment is an emerging physical therapy for treating bone, nerve, and muscle disorders. However, there have been no reports on the effectiveness of LIPUS for the treatment of temporomandibular joint injury, and the mechanisms of LIPUS remain unclear. The purpose of this study was to examine the therapeutic effects of LIPUS on temporomandibular joint injury in rats subjected to chronic sleep deprivation (CSD). In this study, after 2 weeks of chronic sleep deprivation in rats, the condylar cartilage exhibited rough surfaces, with a disorganized arrangement and partial sloughing of collagen fibers, decreased proliferation of chondrocytes, increased osteoclast activity in the calcified cartilage layer, and increased ratios of MMP 3/TIMP 1 and RANKL/OPG expression. After 4 weeks of LIPUS intervention in rats, the condylar cartilage displayed prominent reductions in these pathological changes, including noticeable repair of the injured cartilage structure, increased chondrocyte proliferation, a reduced number of osteoclasts, and marked reductions in the expression ratios of MMP 3/TIMP 1 and RANKL/OPG. These results demonstrated that LIPUS can effectively inhibit CSD induced injury to condylar cartilage in rats. The therapeutic mechanism of LIPUS may involve promotingthe repair function of chondrocytes and reducing the expression ratios of MMP 3/TIMP 1 and RANKL/OPG in condylar tissue, thus inhibiting the cleavage activity of MMP 3 on the condylar cartilage matrix and inhibiting osteoclast activation.
C1 [Liang, Chao; Yang, Tao; Li, Jun; Geng, Wei] Capital Med Univ, Sch Stomatol, Beijing Stomatol Hosp, Dept Dent Implant Ctr, 4 Tian Tan Xi Li, Beijing 100050, Peoples R China.
   [Wu, Gaoyi] Jinan Mil Gen Hosp, Dept Stomatol, Jinan, Shandong, Peoples R China.
   [Li, Jun] Capital Med Univ, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Geng, W (通讯作者)，Capital Med Univ, Sch Stomatol, Beijing Stomatol Hosp, Dept Dent Implant Ctr, 4 Tian Tan Xi Li, Beijing 100050, Peoples R China.
EM gengwei717@163.com
RI Geng, Wei/KYQ 4201 2024
FU National Natural Science Foundation of China [61571311]; High Level
   Health Technical Personnel in Beijing Preferred Foundation [20 15 3 091]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 61571311) and the High Level Health Technical Personnel
   in Beijing Preferred Foundation (20 15 3 091). The authors thank
   American Journal Experts (AJE) for professional English editing.
CR Ahmad Mansur, 2016, Dent Clin North Am, V60, P105, DOI 10.1016/j.cden.2015.08.004
   Ashraf S, 2011, ARTHRITIS RHEUM US, V63, P2700, DOI 10.1002/art.30422
   Chan YS, 2010, ULTRASOUND MED BIOL, V36, P743, DOI 10.1016/j.ultrasmedbio.2010.02.010
   Cheng K, 2014, ULTRASOUND MED BIOL, V40, P1609, DOI 10.1016/j.ultrasmedbio.2014.03.002
   Sá Milena Peixoto Nogueira de, 2013, Dental Press J. Orthod., V18, P113
   Ding F, 2017, AM J TRANSL RES, V9, P316
   Dussik KT, 1942, Z GESAMTE NEUROL PSY, V174, P153, DOI 10.1007/BF02877929
   Fernandes G, 2015, J ORAL REHABIL, V42, P113, DOI 10.1111/joor.12238
   Ge XP, 2009, ARTHRITIS RHEUM US, V60, P2714, DOI 10.1002/art.24779
   Geng W, 2015, INT J CLIN EXP MED, V8, P395
   Guo L, 2018, INT IMMUNOPHARMACOL, V55, P231, DOI 10.1016/j.intimp.2017.11.035
   Jia L, 2016, SCI REP UK, V6, DOI 10.1038/srep35453
   Jia L, 2016, ULTRASOUND MED BIOL, V42, P208, DOI 10.1016/j.ultrasmedbio.2015.08.010
   Koide M, 2013, ENDOCRINOLOGY, V154, P773, DOI 10.1210/en.2012 1928
   Lee YJ, 2003, RHEUMATOL INT, V23, P282, DOI 10.1007/s00296 003 0312 5
   Leong DJ, 2010, MATRIX BIOL, V29, P420, DOI 10.1016/j.matbio.2010.02.004
   Licini F, 2009, Minerva Stomatol, V58, P557
   Liu YD, 2014, OSTEOARTHR CARTILAGE, V22, P302, DOI 10.1016/j.joca.2013.11.014
   Lou SH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008181
   Lv YG, 2015, BIOTECHNOL LETT, V37, P2497, DOI 10.1007/s10529 015 1939 5
   Ma C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107544
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Mitsui Silvia Naomi, 2016, J Orthod Sci, V5, P104, DOI 10.4103/2278 0203.186168
   Naito K, 2010, J ORTHOP RES, V28, P361, DOI 10.1002/jor.20995
   Pomini KT, 2014, J ULTRAS MED, V33, P713, DOI 10.7863/ultra.33.4.713
   Rutten S, 2016, JBJS REV, V4, DOI 10.2106/JBJS.RVW.O.00027
   Slade GD, 2016, J DENT RES, V95, P1084, DOI 10.1177/0022034516653743
   Tiilikainen P, 2005, J ORAL PATHOL MED, V34, P39, DOI 10.1111/j.1600 0714.2004.00262.x
   Verstappen J, 2006, J DENT RES, V85, P1074, DOI 10.1177/154405910608501202
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang L, 2002, OSTEOARTHR CARTILAGE, V10, P188, DOI 10.1053/joca.2001.0492
   Wu GY, 2011, ORAL SURG ORAL MED O, V112, pE106, DOI 10.1016/j.tripleo.2011.06.005
   Xia P, 2015, J ULTRAS MED, V34, P1991, DOI 10.7863/ultra.14.10016
   Xie LK, 2011, INT J ORAL MAX SURG, V40, P730, DOI 10.1016/j.ijom.2011.03.016
   Yatani H, 2002, J OROFAC PAIN, V16, P221
   Zhang P, 2017, ONCOL REP, V37, P1497, DOI 10.3892/or.2017.5392
NR 36
TC 18
Z9 26
U1 0
U2 17
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2019
VL 11
IS 6
BP 3328
EP 3340
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA IF7TW
UT WOS:000473288500006
PM 31312347
DA 2025 08 17
ER

PT J
AU Wang, YJ
   Cui, J
   Gu, ZR
   Fang, C
   Hu, Y
   Weng, WZ
   Li, XQ
   Zhou, QR
   Chen, HW
   Zhang, H
   Guo, JW
   Zhuang, XC
   Sheng, SA
   Wang, SC
   Chen, X
   Su, JC
AF Wang Yajun
   Cui Jin
   Gu Zhengrong
   Fang Chao
   Hu Yan
   Weng Weizong
   Li Xiaoqun
   Zhou Qirong
   Chen Huiwen
   Zhang Hao
   Guo Jiawei
   Zhuang Xinchen
   Sheng Shihao
   Wang Sicheng
   Chen Xiao
   Su Jiacan
TI Betaine Attenuates Osteoarthritis by Inhibiting Osteoclastogenesis and
   Angiogenesis in Subchondral Bone
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE betaine; osteoclastogenesis; subchondral bone; angiogenesis;
   osteoarthritis
ID KNEE OSTEOARTHRITIS; ARTICULAR CARTILAGE; RAT MODEL; INFLAMMATION;
   SUPPRESSION; RESORPTION; PAIN; PATHOGENESIS; PROGRESSION; COMPONENTS
AB Osteoarthritis (OA) is the most common type of arthritis with no effective therapy. Subchondral bone and overlying articular cartilage are closely associated and function as "osteo chondral unit" in the joint. Abnormal mechanical load leads to activated osteoclast activity and increased bone resorption in the subchondral bone, which is implicated in the onset of OA pathogenesis. Thus, inhibiting subchondral bone osteoclast activation could prevent OA onset. Betaine, isolated from the Lycii Radicis Cortex (LRC), has been demonstrated to exert anti inflammatory, antifibrotic and antiangiogenic properties. Here, we evaluated the effects of betaine on anterior cruciate ligament transection (ACLT) induced OA mice. We observed that betaine decreased the number of matrix metalloproteinase 13 (MMP 13) positive and collagen X (Col X) positive cells, prevented articular cartilage proteoglycan loss and lowered the OARSI score. Betaine decreased the thickness of calcified cartilage and increased the expression level of lubricin. Moreover, betaine normalized uncoupled subchondral bone remodeling as defined by lowered trabecular pattern factor (Tb.pf) and increased subchondral bone plate thickness (SBP). Additionally, aberrant angiogenesis in subchondral bone was blunted by betaine treatment. Mechanistically, we demonstrated that betaine suppressed osteoclastogenesis in vitro by inhibiting reactive oxygen species (ROS) production and subsequent mitogen activated protein kinase (MAPK) signaling. These data demonstrated that betaine attenuated OA progression by inhibiting hyperactivated osteoclastogenesis and maintaining microarchitecture in subchondral bone.
C1 [Wang Yajun; Fang Chao; Chen Huiwen; Zhang Hao; Guo Jiawei; Zhuang Xinchen; Sheng Shihao] Naval Med Univ, Shanghai Changhai Hosp, Grad Management Unit, Shanghai, Peoples R China.
   [Cui Jin; Hu Yan; Weng Weizong; Li Xiaoqun; Zhou Qirong; Chen Xiao; Su Jiacan] Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Gu Zhengrong] Luodian Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Hu Yan; Wang Sicheng; Su Jiacan] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
   [Wang Sicheng] Zhongye Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Su Jiacan] Shanghai Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University; Shanghai University
RP Chen, X; Su, JC (通讯作者)，Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.; Wang, SC; Su, JC (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.; Wang, SC (通讯作者)，Zhongye Hosp, Dept Orthoped, Shanghai, Peoples R China.; Su, JC (通讯作者)，Shanghai Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
EM 464716070@qq.com; sirchenxiao@126.com; drsujiacan@163.com
RI Su, Jiacan/N 7068 2019; Chen, Huiwen/LZF 7424 2025; Cui,
   Jin/HDL 7327 2022; Wang, Sicheng/LXV 9883 2024; Guo,
   Jiawei/JMH 1084 2023; Gu, Jimmy/N 4439 2019
OI Shihao, Sheng/0000 0003 4624 1160; Su, Jiacan/0000 0001 7080 263X; Guo,
   Jiawei/0000 0002 7613 932X; 
FU National key research and development plan [2018YFC2001500]; National
   Natural Science Foundation of China [82172098, 81901426, 81871099,
   81972254]; National Natural Science Foundation (NNSF) Key Research
   Program in Aging [91749204]; Shanghai Sailing Program [19YF1447400];
   Shanghai Rising Star program [21QA1412000]; Shanghai Baoshan Medical
   Health Project [20 E 22]
FX National key research and development plan (2018YFC2001500); National
   Natural Science Foundation of China (82172098, 81901426, 81871099,
   81972254, 82172098); National Natural Science Foundation (NNSF) Key
   Research Program in Aging (91749204); Shanghai Sailing Program
   (19YF1447400); Shanghai Rising Star program (21QA1412000); Shanghai
   Baoshan Medical Health Project (20 E 22).
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   ARNOLDI C C, 1972, Journal of Bone and Joint Surgery British Volume, V54B, P409
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Bingül I, 2016, ENVIRON TOXICOL PHAR, V45, P170, DOI 10.1016/j.etap.2016.05.033
   Brooks PM, 2002, CURR OPIN RHEUMATOL, V14, P573, DOI 10.1097/00002281 200209000 00017
   Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen XF, 2014, ANAL CHEM, V86, P4748, DOI 10.1021/ac500287e
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Cui Z, 2015, BONE, V74, P37, DOI 10.1016/j.bone.2014.12.065
   Dar AA, 2020, J SEP SCI, V43, P105, DOI 10.1002/jssc.201900656
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   Dibaba DT, 2020, DIABETES CARE, V43, P2840, DOI 10.2337/dc20 0733
   Ding X, 2014, J CHROMATOGR A, V1359, P330, DOI 10.1016/j.chroma.2014.07.071
   Fan CY, 2014, J NUTR BIOCHEM, V25, P353, DOI 10.1016/j.jnutbio.2013.11.010
   Fernandopulle S, 2017, AM J PHYS MED REHAB, V96, P773, DOI 10.1097/PHM.0000000000000736
   Findlay DM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.28
   Ge CX, 2016, EUR J PHARMACOL, V770, P154, DOI 10.1016/j.ejphar.2015.11.043
   Geurts J, 2016, J ORTHOP RES, V34, P262, DOI 10.1002/jor.23009
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Gore Mugdha, 2011, J Med Econ, V14, P497, DOI 10.3111/13696998.2011.594347
   Gu YQ, 2020, ACTA PHARM SIN B, V10, P1856, DOI 10.1016/j.apsb.2020.01.019
   Gu YQ, 2019, J PHARMACEUT BIOMED, V164, P550, DOI 10.1016/j.jpba.2018.10.028
   Hamilton JL, 2016, J BONE MINER RES, V31, P911, DOI 10.1002/jbmr.2828
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Herrero Beaumont G, 2019, BIOCHEM PHARMACOL, V165, P24, DOI 10.1016/j.bcp.2019.02.030
   Jiang YP, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109474
   Kadri A, 2010, ANN RHEUM DIS, V69, P1533, DOI 10.1136/ard.2009.124586
   Kanzaki H, 2017, FASEB J, V31, P781, DOI 10.1096/fj.201600826R
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Khorasani MS, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0546 0
   Kim DH, 2014, INT J ONCOL, V45, P1250, DOI 10.3892/ijo.2014.2515
   Kim YG, 2015, MOL MED REP, V12, P1639, DOI 10.3892/mmr.2015.3613
   Kothari A, 2010, ARTHRIT CARE RES, V62, P198, DOI 10.1002/acr.20068
   Lajeunesse D, 2003, CURR OPIN RHEUMATOL, V15, P628, DOI 10.1097/00002281 200309000 00018
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Le Graverand Gastineau MPH, 2010, CURR DRUG TARGETS, V11, P528
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li JM, 2015, MOL NUTR FOOD RES, V59, P189, DOI 10.1002/mnfr.201400307
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Lotz M, 2012, OSTEOARTHR CARTILAGE, V20, P192, DOI 10.1016/j.joca.2011.11.015
   Lu JS, 2018, J BONE MINER RES, V33, P909, DOI 10.1002/jbmr.3388
   Mapp PI, 2010, OSTEOARTHR CARTILAGE, V18, P593, DOI 10.1016/j.joca.2009.12.006
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Mu WB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00269
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Pan J, 2009, J ORTHOP RES, V27, P1347, DOI 10.1002/jor.20883
   Park SW, 2017, VASC PHARMACOL, V90, P19, DOI 10.1016/j.vph.2016.07.007
   Percival CJ, 2013, DEV DYNAM, V242, P909, DOI 10.1002/dvdy.23992
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Roemer FW, 2009, ANN RHEUM DIS, V68, P1461, DOI 10.1136/ard.2008.096834
   Saltzman BM, 2018, SPORTS HEALTH, V10, P412, DOI 10.1177/1941738118782453
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Shi H, 2019, MOLECULES, V24, DOI 10.3390/molecules24020367
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Tanamas SK, 2010, RHEUMATOLOGY, V49, P2413, DOI 10.1093/rheumatology/keq286
   Veskovic M, 2019, EUR J PHARMACOL, V848, P39, DOI 10.1016/j.ejphar.2019.01.043
   Wang YY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.129
   Xia YY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02670
   Yang JM, 2018, MOLECULES, V23, DOI 10.3390/molecules23061274
   Yi EY, 2012, INT J ONCOL, V41, P1879, DOI 10.3892/ijo.2012.1616
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 75
TC 55
Z9 58
U1 4
U2 43
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 29
PY 2021
VL 12
AR 723988
DI 10.3389/fphar.2021.723988
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WV4PD
UT WOS:000717219200001
PM 34658862
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, J
   Wu, XH
   Lu, J
   Huang, GX
   Dang, L
   Zhang, HR
   Zhong, CX
   Zhang, ZK
   Li, DJ
   Li, FF
   Liang, C
   Yu, YY
   Zhang, BT
   Chen, L
   Lu, AP
   Zhang, G
AF Liu, Jin
   Wu, Xiaohao
   Lu, Jun
   Huang, Guangxin
   Dang, Lei
   Zhang, Huarui
   Zhong, Chuanxin
   Zhang, Zongkang
   Li, Dijie
   Li, Fangfei
   Liang, Chao
   Yu, Yuanyuan
   Zhang, Bao Ting
   Chen, Lin
   Lu, Aiping
   Zhang, Ge
TI Exosomal transfer of osteoclast derived miRNAs to chondrocytes
   contributes to osteoarthritis progression
SO NATURE AGING
LA English
DT Article
ID BONE; ANGIOGENESIS; CELLS; MODEL; DESTABILIZATION; INHIBITION;
   MICRORNAS; DELIVERY; TIMP 2; UNIT
AB Osteoarthritis (OA) is a prevalent aging related joint disease lacking disease modifying therapies. Here, we identified an upregulation of circulating exosomal osteoclast (OC) derived microRNAs (OC miRNAs) during the progression of surgery induced OA in mice. We found that reducing OC miRNAs by Cre mediated excision of the key miRNA processing enzyme Dicer or blocking the secretion of OC originated exosomes by short interfering RNA mediated silencing of Rab27a substantially delayed the progression of surgery induced OA in mice. Mechanistically, the exosomal transfer of OC miRNAs to chondrocytes reduced the resistance of cartilage to matrix degeneration, osteochondral angiogenesis and sensory innervation during OA progression by suppressing tissue inhibitor of metalloproteinase 2 (TIMP 2) and TIMP 3. Furthermore, systemic administration of a new OC targeted exosome inhibitor (OCExoInhib) blunted the progression of surgery induced OA in mice. We suggest that targeting the exosomal transfer of OC miRNAs to chondrocytes represents a potential therapeutic avenue to tackle OA progression.
   The authors show that exosomal transfer of osteoclast derived microRNAs to chondrocytes decreases the resistance of cartilage to matrix degeneration, angiogenesis and sensory innervation, and promotes osteoarthritis progression in mice.
C1 [Liu, Jin; Wu, Xiaohao; Lu, Jun; Dang, Lei; Zhang, Huarui; Zhong, Chuanxin; Li, Dijie; Li, Fangfei; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Peoples R China.
   [Liu, Jin; Li, Fangfei; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Integrated Bioinfomed & Translat Sci, Hong Kong, Peoples R China.
   [Liu, Jin; Li, Fangfei; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Precis Med & Innovat Drug Discovery, Hong Kong, Peoples R China.
   [Liu, Jin; Dang, Lei; Zhang, Huarui; Zhong, Chuanxin; Li, Fangfei; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Peoples R China.
   [Liu, Jin; Lu, Jun; Dang, Lei; Li, Fangfei; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Shenzhen Inst Res & Continuing Educ IRACE, Shenzhen, Peoples R China.
   [Lu, Jun] Chengdu Univ Tradit Chinese Med, Sch Pharm, Chengdu, Peoples R China.
   [Huang, Guangxin] Southern Med Univ, Sch Clin Med 3, Dept Joint Surg, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Zhong, Chuanxin] Southern Univ Sci & Technol, Dept Mat Sci & Engn, Shenzhen, Peoples R China.
   [Zhang, Zongkang; Zhang, Bao Ting] Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
   [Li, Dijie] Northwestern Polytech Univ, Sch Life Sci, Xian, Peoples R China.
   [Chen, Lin] Army Med Univ, Daping Hosp, Lab Wound Repair & Rehabil,Res Inst Surg, State Key Lab Trauma Burns & Combined Injury,Trau, Chongqing, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; Hong Kong
   Baptist University; Hong Kong Baptist University; Hong Kong Baptist
   University; Chengdu University of Traditional Chinese Medicine; Southern
   Medical University   China; Southern University of Science & Technology;
   Chinese University of Hong Kong; Northwestern Polytechnical University;
   Army Medical University
RP Liu, J; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Peoples R China.; Liu, J; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Inst Integrated Bioinfomed & Translat Sci, Hong Kong, Peoples R China.; Liu, J; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Inst Precis Med & Innovat Drug Discovery, Hong Kong, Peoples R China.; Liu, J; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Peoples R China.; Liu, J; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Shenzhen Inst Res & Continuing Educ IRACE, Shenzhen, Peoples R China.
EM liujin@hkbu.edu.hk; aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk
RI Xiaohao, Wu/HNI 5943 2023; Zhang, Ge/N 4150 2013; Lu, Jun/JBJ 8742 2023;
   LU, Aiping/JDX 0577 2023; Zhang, Baoting/B 6273 2015; Yu,
   YY/ADO 6482 2022; Li, Dijie/KVB 3667 2024; Liang, Chao/AAS 6999 2021;
   Zhang, Zongkang/AAB 2564 2020
OI Liu, Jin/0000 0001 6308 6719; Wu, Xiaohao/0000 0002 0984 7414; ZHONG,
   CHUANXIN/0000 0001 9157 8497; Zhang, Huarui/0000 0001 5008 3447; Lu,
   Jun/0000 0003 1625 8682; Liang, Chao/0000 0002 5617 3483; Yu,
   Yuanyuan/0000 0003 1276 5695; 
FU National Key R&D Program of China [2018YFA0800804]; National Natural
   Science Foundation Council of China [81702189, 81803374, 81802187,
   81703049, 81700780]; Theme based Research Scheme from the Research
   Grants Council of Hong Kong [T12 201/20 R]; General Research Funds from
   the Research Grants Council of Hong Kong [12102914, 12101117, 12136616,
   12103519, 12101018, 12102120, 12102518, 12100719, 14112915]; Department
   of Science and Technology of Guangdong Province [2019B1515120089];
   Natural Science Fund of Guangdong Province [2018030310355]; Shenzhen
   Science and Technology innovation fund [JCYJ20180302174121208];
   Interdisciplinary Research Clusters Matching Scheme of Hong Kong Baptist
   University [RC IRCs/17 18/02, RC IRCs/17 18/04, RC IRMS/15 16/01];
   Inter institutional Collaborative Research Scheme from Hong Kong Baptist
   University [RC ICRS/19 20/01]
FX We thank technical staff (Y. S. Cheung, W. K. Chan, S. Lee and C. L.
   Chan) from Law Sau Fai Institute for Advancing Translational Medicine in
   Bone and Joint Diseases, Hong Kong Baptist University for providing
   technical support on micro CT, confocal imaging and flow cytometry
   analysis. We thank Guangzhou Biogene Biotechnology Co., Ltd. for
   providing technical support on mouse genotyping and AAV packaging. This
   work was supported by the funds from National Key R&D Program of China
   (2018YFA0800804 to L.C.) and National Natural Science Foundation Council
   of China (81702189 to J. Liu; 81803374 to J. Lu., 81802187 to G.H.,
   81703049 to F.L. and 81700780 to C.L.), the Theme based Research Scheme
   from the Research Grants Council of Hong Kong (T12 201/20 R to A.L.),
   the General Research Funds from the Research Grants Council of Hong Kong
   (12102914 to G.Z., 12101117 to G.Z., 12136616 and 12103519 to J. Liu,
   12101018 to F.L., 12102120 to Y.Y., 12102518 and 12100719 to A.L. and
   14112915 to B. T.Z.), the Basic and Applied Basic Research Fund from
   Department of Science and Technology of Guangdong Province
   (2019B1515120089 to G.Z.), the Natural Science Fund of Guangdong
   Province (2018030310355 to G.H.), the Shenzhen Science and Technology
   innovation fund (JCYJ20180302174121208 to J. Lu.), the Interdisciplinary
   Research Clusters Matching Scheme of Hong Kong Baptist University
   (RC IRCs/17 18/02 to G.Z.; RC IRCs/17 18/04 and RC IRMS/15 16/01 to
   A.L.), the Inter institutional Collaborative Research Scheme from Hong
   Kong Baptist University (RC ICRS/19 20/01 to A.L.)
CR Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Basappa, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039444
   Birch CE, 2018, OSTEOARTHR CARTILAGE, V26, P762, DOI 10.1016/j.joca.2018.02.905
   Bryden LA, 2015, OSTEOARTHR CARTILAGE, V23, P1605, DOI 10.1016/j.joca.2015.05.001
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chen YL, 2020, AM J TRANSL RES, V12, P261
   Datta A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26411 7
   Deacon R, 2012, JOVE J VIS EXP, DOI 10.3791/2607
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   EISENSTEIN R, 1973, AM J PATHOL, V73, P765
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Huang F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01327
   Jiang M, 2018, CELL PHYSIOL BIOCHEM, V47, P864, DOI [10.1159/000490078and, 10.1159/000490078]
   Johnson JL, 2016, J BIOL CHEM, V291, P25965, DOI 10.1074/jbc.M116.741884
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Liang C, 2017, BIOMATERIALS, V147, P68, DOI 10.1016/j.biomaterials.2017.09.015
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Mandl LA, 2019, OSTEOARTHR CARTILAGE, V27, P359, DOI 10.1016/j.joca.2018.11.001
   Mi M, 2012, BIOCHEM BIOPH RES CO, V423, P366, DOI 10.1016/j.bbrc.2012.05.132
   Mizoguchi F, 2010, J CELL BIOCHEM, V109, P866, DOI 10.1002/jcb.22228
   Newton PT, 2012, INT J MOL MED, V30, P1187, DOI 10.3892/ijmm.2012.1114
   Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Rückerl D, 2012, BLOOD, V120, P2307, DOI 10.1182/blood 2012 02 408252
   Sahebjam S, 2007, ARTHRITIS RHEUM, V56, P905, DOI 10.1002/art.22427
   Saunders WB, 2006, J CELL BIOL, V175, P179, DOI 10.1083/jcb.200603176
   Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092 8674(03)00551 8
   Shibakawa A, 2005, OSTEOARTHR CARTILAGE, V13, P679, DOI 10.1016/j.joca.2005.04.010
   Simon D, 2015, ADV ORTHOP, V2015, DOI 10.1155/2015/928301
   Sleigh James N, 2016, BMC Res Notes, V9, P82, DOI 10.1186/s13104 016 1915 8
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Weber Johannes, 2018, J Exp Orthop, V5, P10, DOI 10.1186/s40634 018 0122 z
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zhuo ZJ, 2020, ADV SCI, V7, DOI 10.1002/advs.201903451
NR 46
TC 43
Z9 44
U1 5
U2 28
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2662 8465
J9 NATURE AGING
JI Nature Aging
PD APR
PY 2021
VL 1
IS 4
BP 368
EP +
DI 10.1038/s43587 021 00050 6
PG 32
WC Cell Biology; Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology; Neurosciences & Neurology
GA 7B5DY
UT WOS:000899154800009
PM 37117596
DA 2025 08 17
ER

PT J
AU Ocando, C
   Dinescu, S
   Samoila, I
   Ghitulica, CD
   Cucuruz, A
   Costache, M
   Averous, L
AF Ocando, Connie
   Dinescu, Sorina
   Samoila, Iuliana
   Ghitulica, Cristina Daniela
   Cucuruz, Andreia
   Costache, Marieta
   Averous, Luc
TI Fabrication and properties of alginate hydroxyapatite biocomposites as
   efficient biomaterials for bone regeneration
SO EUROPEAN POLYMER JOURNAL
LA English
DT Article
DE Alginate; Hydroxyapatite; Click chemistry; Scaffolds; In vitro
   biological behavior
ID ALDER CLICK CHEMISTRY; CROSS LINKING; DRUG DELIVERY; HYDROGELS;
   SCAFFOLDS; GELATIN; METHACRYLATE
AB Restricted self recovery that pursues a bone injury and the need of inexpensive and painless clinical treatments for tissue regeneration require new pathways developments to fabricate biocompatible and biodegradable scaffolding materials. For these requirements, covalent crosslinked alginate and alginate/Mg doped hydroxyapatite (MgHAp) hydrogels are fabricated by "click" chemistry to mimic highly porous structures with the dimensional hierarchy of bone tissue. Cells viability, proliferation and cytotoxicity are reported. These scaffolds show high pore volume with adequate size and interconnectivity for osseous tissue regeneration. An uniform dispersion of low content of bioactive MgHAp nanoparticles on the surface of pore walls allows a good pre osteoblast cell attachment and proliferation.
C1 [Ocando, Connie; Averous, Luc] Univ Strasbourg, BioTeam, UMR CNRS 7515, ICPEES ECPM, Strasbourg 2, France.
   [Dinescu, Sorina; Samoila, Iuliana; Costache, Marieta] Univ Bucharest, Dept Biochem & Mol Biol, Bucharest 050095, Romania.
   [Ghitulica, Cristina Daniela; Cucuruz, Andreia] Univ Politehn Bucuresti, Fac Appl Chem & Mat Sci, Bucharest 011061, Romania.
   [Ocando, Connie] Univ Basque Country, POLYMAT, UPV EHU, Paseo Manuel Lardizabal 3, Donostia San Sebastian 20018, Spain.
   [Ocando, Connie] Univ Basque Country, Polymer Sci & Technol Dept, UPV EHU, Paseo Manuel Lardizabal 3, Donostia San Sebastian 20018, Spain.
C3 Centre National de la Recherche Scientifique (CNRS); Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg; University
   of Bucharest; National University of Science & Technology POLITEHNICA
   Bucharest; University of Basque Country; POLYMAT; University of Basque
   Country
RP Averous, L (通讯作者)，Univ Strasbourg, BioTeam, UMR CNRS 7515, ICPEES ECPM, Strasbourg 2, France.
EM luc.averous@unistra.fr
RI Cucuruz, Andreia/AAS 9619 2021; Samoila, Iuliana/G 3146 2019; Dinescu,
   Sorina/H 1410 2016; Avérous, Luc/B 3471 2008
OI Cucuruz, Andreia/0000 0001 5567 1934; Averous, Luc/0000 0002 2797 226X; 
FU National Program III, Subprogram 3.1 Bilateral/Multilateral, Module
   AUF RO; East region in France; MIPPI 4D Project; Romanian Ministry of
   Research and Innovation, CCCDI UEFISCDI within PNCDI III
   [PNIII P1 1.2 PCCDI 2017 0782/65PCCDI/2018]; University Agency for
   Francophony (AUF) [05 AUF, 12 AUF]
FX This activity was financed by the National Program III, Subprogram 3.1
   Bilateral/Multilateral, Module AUF RO which are developed in cooperation
   with the University Agency for Francophony (AUF) with the project
   BIOCOMPMAT "Composite materials based on biopolymers and ceramic
   particles with applications in tissue engineering and controlled drug
   release systems " 05 AUF and with also the project BIOCOMP3DPRINT
   "Obtaining composite biomaterials with antibacterial properties by 3D
   printing technique" (Obtention par impression 3D de biomateriaux
   composites aux proprietes antibacteriennes)  12 AUF. Another part of
   this project was funded by East region in France with MIPPI 4D Project.
   The biological testing of the materials was supported by a grant of the
   Romanian Ministry of Research and Innovation, CCCDI UEFISCDI, project
   number PNIII P1 1.2 PCCDI 2017 0782/65PCCDI/2018, within PNCDI III.
CR Augst AD, 2006, MACROMOL BIOSCI, V6, P623, DOI 10.1002/mabi.200600069
   Bhattarai N, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/45/455601
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Cai YR, 2016, MATER CHEM PHYS, V181, P227, DOI 10.1016/j.matchemphys.2016.06.053
   Caló E, 2015, EUR POLYM J, V65, P252, DOI 10.1016/j.eurpolymj.2014.11.024
   Desai RM, 2015, BIOMATERIALS, V50, P30, DOI 10.1016/j.biomaterials.2015.01.048
   Draget KI, 2011, FOOD HYDROCOLLOID, V25, P251, DOI 10.1016/j.foodhyd.2009.10.007
   Drury JL, 2005, J BIOMECH ENG T ASME, V127, P220, DOI 10.1115/1.1865194
   Drury JL, 2004, BIOMATERIALS, V25, P3187, DOI 10.1016/j.biomaterials.2003.10.002
   Gandini A, 2013, PROG POLYM SCI, V38, P1, DOI 10.1016/j.progpolymsci.2012.04.002
   Gao CC, 2017, CARBOHYD POLYM, V157, P669, DOI 10.1016/j.carbpol.2016.10.037
   Gao CC, 2017, FOOD HYDROCOLLOID, V63, P414, DOI 10.1016/j.foodhyd.2016.09.023
   García Astrain C, 2016, MATER LETT, V182, P134, DOI 10.1016/j.matlet.2016.06.115
   García Astrain C, 2014, RSC ADV, V4, P35578, DOI 10.1039/c4ra06122e
   García Astrain C, 2013, EUR POLYM J, V49, P3998, DOI 10.1016/j.eurpolymj.2013.09.004
   García Astrain C, 2018, CARBOHYD POLYM, V190, P271, DOI 10.1016/j.carbpol.2018.02.086
   García Astrain C, 2015, J POLYM SCI POL CHEM, V53, P699, DOI 10.1002/pola.27495
   Ghiulica C.D, 2019, INT J APP CERAM TECH, V17, P342
   Gibbs DMR, 2016, J TISSUE ENG REGEN M, V10, P187, DOI 10.1002/term.1968
   Kolambkar YM, 2011, BIOMATERIALS, V32, P65, DOI 10.1016/j.biomaterials.2010.08.074
   Kuo CK, 2001, BIOMATERIALS, V22, P511, DOI 10.1016/S0142 9612(00)00201 5
   Laurencin D, 2011, BIOMATERIALS, V32, P1826, DOI 10.1016/j.biomaterials.2010.11.017
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Lee KY, 2004, BIOMATERIALS, V25, P2461, DOI 10.1016/j.biomaterials.2003.09.030
   Lee KY, 2003, ADV MATER, V15, P1828, DOI 10.1002/adma.200305406
   Li JJ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701061
   Mygind T, 2007, BIOMATERIALS, V28, P1036, DOI 10.1016/j.biomaterials.2006.10.003
   O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369 7021(11)70058 X
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Sancilio S, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9643721
   Sangeetha K, 2013, MATER LETT, V91, P27, DOI 10.1016/j.matlet.2012.09.054
   Smeds KA, 2001, J BIOMED MATER RES, V54, P115, DOI 10.1002/1097 4636(200101)54:1<115::AID JBM14>3.0.CO;2 Q
   Song FF, 2015, J BIOMED NANOTECHNOL, V11, P40, DOI 10.1166/jbn.2015.1962
   Swetha M, 2010, INT J BIOL MACROMOL, V47, P1, DOI 10.1016/j.ijbiomac.2010.03.015
   Torres ML, 2019, ALGAL RES, V40, DOI 10.1016/j.algal.2019.101499
   Venkatesan J, 2015, INT J BIOL MACROMOL, V72, P269, DOI 10.1016/j.ijbiomac.2014.07.008
   Woodard JR, 2007, BIOMATERIALS, V28, P45, DOI 10.1016/j.biomaterials.2006.08.021
   Yu F, 2014, POLYM CHEM UK, V5, P5116, DOI 10.1039/c4py00473f
   Yu F, 2013, CARBOHYD POLYM, V97, P188, DOI 10.1016/j.carbpol.2013.04.046
   Zamani D, 2019, INT J BIOL MACROMOL, V137, P1256, DOI 10.1016/j.ijbiomac.2019.06.182
   Zhou K, 2015, CERAM INT, V41, P14029, DOI 10.1016/j.ceramint.2015.07.016
NR 41
TC 27
Z9 29
U1 2
U2 33
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0014 3057
EI 1873 1945
J9 EUR POLYM J
JI Eur. Polym. J.
PD MAY 15
PY 2021
VL 151
AR 110444
DI 10.1016/j.eurpolymj.2021.110444
EA APR 2021
PG 9
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA RV7SL
UT WOS:000646028400016
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Chen, HM
   Chen, FP
   Yang, KC
   Yuan, SS
AF Chen, Hsiu Man
   Chen, Fang Ping
   Yang, Kang Chung
   Yuan, Shin Sheng
TI Association of Bone Metastasis With Early Stage Breast Cancer in Women
   With and Without Precancer Osteoporosis According to Osteoporosis
   Therapy Status
SO JAMA NETWORK OPEN
LA English
DT Article
ID DISTANT METASTASIS; RISK; MECHANISMS; AGE
AB IMPORTANCE Deaths from cancer are attributed more to secondary than primary tumors, but the pathogenesis of organ specific cancer metastasis has not been determined.
   OBJECTIVE To investigate whether precancer osteoporosis and osteoporosis therapy are associated with alteration of bone metastasis patterns.
   DESIGN, SETTING, AND PARTICIPANTS This nationwide retrospective cohort study was performed from January 1, 2002, to December 31, 2013, using 2 cohorts from the Taiwan National Health Insurance Research Database: a random sample of 1 million beneficiaries from the Longitudinal Health Insurance Database who were enrolled in 2005 (LHID2005) and a specific data set of all the patients with osteoporosis. Patients diagnosed with breast cancer and precancer osteoporosis from January 1, 2002, to December 31, 2011, were included in the study, and their records were examined through December 31, 2013. From LHID2005, we selected 9104 women with early stage breast cancer, of whom 705 had precancer osteoporosis. We identified 29 183 patients from the cohort of patients with breast cancer and osteoporosis, 14 020 of whom had precancer osteoporosis. Data analysis was performed from December 31, 2016, to August 31, 2018.
   EXPOSURES Precancer osteoporosis and osteoporosis therapy.
   MAIN OUTCOMES AND MEASURES The risk of bone metastasis in patients with and without precancer osteoporosis and patients receiving and not receiving osteoporosis therapy as well as time to bone metastasis development.
   RESULTS Among 9104 patients with breast cancer from the Longitudinal Health Insurance Database (mean [SD] age, 46.7 [14.0] years), precancer osteoporosis was not associated with a difference in risk of bone metastasis (adjusted hazard ratio [aHR], 0.87; 95% CI, 0.58 1.30; P=.49). Among 14 020 patients with precancer osteoporosis from the other cohort (mean [SD] age, 58.9 [11.6] years), osteoporosis therapy had no association with the risk of bone metastasis (bisphosphonates: aHR, 1.47; 95% CI, 1.00 2.17; P=.05; nonbisphosphonate drugs: aHR, 1.00; 95% CI, 0.72 1.39; P>.99). Compared with those without precancer osteoporosis (median time to bone metastasis development, 2.87 years; interquartile range [IQR], 1.34 4.86 years), among those with precancer osteoporosis, the median time to develop bone metastasis was shorter in those who did not receive treatment (1.74 years; IQR, 0.58 3.60 years; P<.001), whereas this time was the same for those who received treatment (bisphosphonates: 2.34 years; IQR, 1.23 3.13 years; nonbisphosphonate drugs: 2.08 years; IQR, 0.92 4.95 years).
   CONCLUSIONS AND RELEVANCE Precancer osteoporosis was not associated with risk of bone metastasis, but untreated osteoporosis was associated with accelerated progression of bone metastasis when it occurred. Organ microenvironments interact with disseminated cancer mostly after the specific organ has been predetermined to be the designated location. Because recurrences and metastases are major obstacles to cancer treatments, determining which organs may be at risk for metastases may be crucial to treating the disease.
C1 [Chen, Hsiu Man; Yuan, Shin Sheng] Acad Sinica, Inst Stat Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.
   [Chen, Hsiu Man] Natl Yang Ming Univ, Inst Biomed Informat, Taipei, Taiwan.
   [Chen, Hsiu Man] Acad Sinica, Inst Informat Sci, Taiwan Int Grad Program, Bioinformat Program, Taipei, Taiwan.
   [Chen, Fang Ping] Keelung Chang Gung Mem Hosp, Dept Obstet & Gynecol, Osteoporosis Prevent & Treatment Ctr, Keelung, Taiwan.
   [Chen, Fang Ping] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Yang, Kang Chung] Keelung Chang Gung Mem Hosp, Community Med Res Ctr, Keelung, Taiwan.
C3 Academia Sinica   Taiwan; National Yang Ming Chiao Tung University;
   Academia Sinica   Taiwan; Chang Gung Memorial Hospital; Chang Gung
   University; Chang Gung Memorial Hospital
RP Yuan, SS (通讯作者)，Acad Sinica, Inst Stat Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.
EM syuan@stat.sinica.edu.tw
RI Yuan, Shinsheng/AAP 4855 2021
FU Medical Research Center of Keelung Chang Gung Memorial Hospital;
   Clinical Monitoring Research Program of Keelung Chang Gung Memorial
   Hospital [CMRPG2D0363]; Academia Sinica Student Grant
FX This study was supported by the Medical Research Center of Keelung Chang
   Gung Memorial Hospital and research grant CMRPG2D0363 from the Clinical
   Monitoring Research Program of Keelung Chang Gung Memorial Hospital. Ms.
   Chen is supported by an Academia Sinica Student Grant.
CR [Anonymous], INT J CARDIOL
   Bernstein A, 1996, MAMMALIAN DEV, P101
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Colzani E, 2014, BRIT J CANCER, V110, P1378, DOI 10.1038/bjc.2014.5
   Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549 008 0086 2
   Drake MT, 2013, CURR OSTEOPOROS REP, V11, P163, DOI 10.1007/s11914 013 0154 3
   FIDLER IJ, 1970, JNCI J NATL CANCER I, V45, P773
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Hung M. H., 2014, PLOS ONE, V9, P2, DOI DOI 10.1371/J0URNAL.P0NE.0089389
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kremer R, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju264
   Kurra V, 2013, CANCER IMAGING, V13, P113, DOI 10.1102/1470 7330.2013.0011
   Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105
   Lipton A, 2017, CANCER AM CANCER SOC, V123, P2444, DOI 10.1002/cncr.30682
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Purushotham A, 2014, EUR J CANCER, V50, P1697, DOI 10.1016/j.ejca.2014.04.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Silvers WK, 1979, The coat colors of mice, DOI [10.1007/978 1 4612 6164 3, DOI 10.1007/978 1 4612 6164 3]
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008 5472.CAN 10 1040
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang LJ, 2016, J PSYCHIATR RES, V72, P6, DOI 10.1016/j.jpsychires.2015.10.014
   Weiss L, 2000, CANCER METAST REV, V19, P193, DOI 10.1023/A:1010646304844
   Wu CY, 2012, JAMA J AM MED ASSOC, V308, P1906, DOI 10.1001/2012.jama.11975
NR 31
TC 28
Z9 29
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611 5885 USA
SN 2574 3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD MAR
PY 2019
VL 2
IS 3
AR e190429
DI 10.1001/jamanetworkopen.2019.0429
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA HU6XA
UT WOS:000465424000021
PM 30848812
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, Z
   Wu, GS
   van der Veen, JN
   Hermansson, M
   Vance, DE
AF Li, Zhuo
   Wu, Gengshu
   van der Veen, Jelske N.
   Hermansson, Martin
   Vance, Dennis E.
TI Phosphatidylcholine metabolism and choline kinase in human osteoblasts
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE Choline kinase; Phosphocholine; Phosphatidylcholine; Proliferation;
   Mineralization; MG 63 cells
ID MUSCULAR DYSTROPHY; BREAST CANCER; SCAVENGER RECEPTOR; CLASS B;
   PHOSPHOCHOLINE; INHIBITORS; PHOSPHO1; BETA; PYROPHOSPHATASE;
   PURIFICATION
AB There is a paucity of information about phosphatidylcholine (PC) biosynthesis in bone formation. Thus, we characterized PC metabolism in both primary human osteoblasts (HOB) and human osteosarcoma MG 63 cells. Our results show that the CDP choline pathway is the only de novo route for PC biosynthesis in both HOB and MG 63 cells. Both CK activity and CK alpha expression in MG 63 cells were significantly higher than those in HOB cells. Silencing of CK alpha in MG 63 cells had no significant effect on PC concentration but decreased the amount of phosphocholine by approximately 80%. The silencing of CK alpha also reduced cell proliferation. Moreover, pharmacological inhibition of CK activity impaired the mineralization capacity of MG 63 cells. Our data suggest that CK and its product phosphocholine are required for the normal growth and mineralization of MG 63 cells. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Vance, Dennis E.] Univ Alberta, Dept Biochem, Alberta Diabet Inst, Edmonton, AB T6G 2S2, Canada.
   Univ Alberta, Mazankowski Alberta Heart Inst, Edmonton, AB T6G 2S2, Canada.
C3 University of Alberta; University of Alberta
RP Vance, DE (通讯作者)，Univ Alberta, Grp Mol & Cell Biol Lipids, 328 HMRC, Edmonton, AB T6G 2S2, Canada.
EM dennis.vance@ualberta.ca
RI Hermansson, Martin/B 7854 2008
OI Hermansson, Martin/0000 0003 3387 8365
FU Canadian Institutes of Health Research [MOP 5182]
FX We appreciate the excellent technical assistance from Susanne Lingrell
   and Randy Nelson. We thank Professor Jean Vance for the helpful comments
   on the manuscript. M.H. is a fellow of the Sigrid Juselius Foundation.
   This study was supported by a grant (MOP 5182) from Canadian Institutes
   of Health Research.
CR ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001
   Aoyama C, 1998, BBA LIPID LIPID MET, V1393, P179, DOI 10.1016/S0005 2760(98)00062 9
   Aoyama C, 2002, BIOCHEM J, V363, P777, DOI 10.1042/0264 6021:3630777
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brodeur MR, 2008, J BONE MINER RES, V23, P326, DOI 10.1359/JBMR.071022
   CUADRADO A, 1993, ONCOGENE, V8, P2959
   Czekanska E. M., 2013, J BIOMED MAT RES A
   Debray J, 2013, BIOORGAN MED CHEM, V21, P7981, DOI 10.1016/j.bmc.2013.09.053
   Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Gallego Ortega D, 2011, ADV ENZYME REGUL, V51, P183, DOI 10.1016/j.advenzreg.2010.09.010
   Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008 5472.CAN 05 1807
   Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162
   Gorustovich AA, 2003, J PERIODONTOL, V74, P831, DOI 10.1902/jop.2003.74.6.831
   Gorustovich Alejandro, 2003, Clin Implant Dent Relat Res, V5, P124, DOI 10.1111/j.1708 8208.2003.tb00193.x
   HAMZA M, 1983, BIOCHEM PHARMACOL, V32, P1893, DOI 10.1016/0006 2952(83)90055 2
   Hermansson M, 2005, ANAL CHEM, V77, P2166, DOI 10.1021/ac048489s
   Hernández Alcoceba R, 1999, CANCER RES, V59, P3112
   HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414
   Hong BS, 2010, J BIOL CHEM, V285, P16330, DOI 10.1074/jbc.M109.039024
   Houston B, 2004, BONE, V34, P629, DOI 10.1016/j.bone.2003.12.023
   ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121
   JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114
   Jukes TH, 1940, J NUTR, V20, P445, DOI 10.1093/jn/22.5.445
   Kainu V, 2008, J BIOL CHEM, V283, P3676, DOI 10.1074/jbc.M709176200
   Katz Brull R, 2002, JNCI J NATL CANCER I, V94, P1197
   KENNEDY EP, 1956, J BIOL CHEM, V222, P193
   KENNEDY EP, 1957, ANNU REV BIOCHEM, V26, P119, DOI 10.1146/annurev.bi.26.070157.001003
   Kenny LM, 2010, CLIN CANCER RES, V16, P4236, DOI 10.1158/1078 0432.CCR 10 0468
   KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163 7827(90)90010 I
   Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791
   Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090
   Krishnamachary B, 2009, CANCER RES, V69, P3464, DOI 10.1158/0008 5472.CAN 08 4120
   Lacal J C, 2001, IDrugs, V4, P419
   MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005 2744(75)90151 5
   Minahk C, 2008, J BIOL CHEM, V283, P6449, DOI 10.1074/jbc.M706995200
   Mitsuhashi S, 2013, CURR OPIN NEUROL, V26, P536, DOI 10.1097/WCO.0b013e328364c82d
   MOSS DW, 1967, BIOCHEM J, V102, P53, DOI 10.1042/bj1020053
   Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349 7006.1999.tb00764.x
   Niemeier A, 2005, J BONE MINER RES, V20, P283, DOI 10.1359/JBMR.041102
   Niemeier A, 2008, BONE, V43, P230, DOI 10.1016/j.bone.2008.03.022
   Nimmagadda S, 2009, NEOPLASIA, V11, P477, DOI 10.1593/neo.81430
   Poli A, 2003, OBSTET GYNECOL, V102, P922, DOI 10.1016/j.obstetgynecol.2003.07.004
   PORTER TJ, 1990, J BIOL CHEM, V265, P414
   Ramirez de Molina A., 2002, BIOCHEM BIOPH RES CO, V296, P580
   Ramírez de Molina A, 2008, INT J BIOCHEM CELL B, V40, P1753, DOI 10.1016/j.biocel.2008.01.013
   Ramírez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470 2045(07)70279 6
   Roberts S, 2007, J BONE MINER RES, V22, P617, DOI 10.1359/JBMR.070108
   Roberts SJ, 2004, BIOCHEM J, V382, P59, DOI 10.1042/BJ20040511
   Roberts SJ, 2005, BBA PROTEINS PROTEOM, V1752, P73, DOI 10.1016/j.bbapap.2005.06.009
   Robichaud JC, 2009, BBA GEN SUBJECTS, V1790, P538, DOI 10.1016/j.bbagen.2009.02.010
   Robichaud JC, 2008, J BIOL CHEM, V283, P35496, DOI 10.1074/jbc.M807433200
   Rodriguez Gonzalez Agustin, 2003, Prog Cell Cycle Res, V5, P191
   Sher RB, 2006, J BIOL CHEM, V281, P4938, DOI 10.1074/jbc.M512578200
   STERN PH, 1987, BIOCHEM J, V244, P409, DOI 10.1042/bj2440409
   van der Veen JN, 2012, J BIOL CHEM, V287, P23418, DOI 10.1074/jbc.M112.381723
   VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163 7827(88)90005 7
   Vance DE, 2009, J LIPID RES, V50, pS132, DOI 10.1194/jlr.R800048 JLR200
   Vance DE, 2008, N COMP BIOC, P213, DOI 10.1016/B978 044453219 0.50010 6
   WITTENBERG J, 1953, J BIOL CHEM, V202, P431
   Wu GS, 2008, J BIOL CHEM, V283, P1456, DOI 10.1074/jbc.M708766200
   Wu GS, 2009, BBA MOL CELL BIOL L, V1791, P347, DOI 10.1016/j.bbalip.2009.02.006
   Xiong YP, 2012, J CHROMATOGR B, V911, P170, DOI 10.1016/j.jchromb.2012.10.038
   Yadav MC, 2011, J BONE MINER RES, V26, P286, DOI 10.1002/jbmr.195
NR 65
TC 23
Z9 23
U1 0
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1388 1981
EI 1879 2618
J9 BBA MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD JUN
PY 2014
VL 1841
IS 6
BP 859
EP 867
DI 10.1016/j.bbalip.2014.02.004
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AG7SI
UT WOS:000335618300004
PM 24583375
DA 2025 08 17
ER

PT J
AU Steiner, D
   Lampert, F
   Stark, GB
   Finkenzeller, G
AF Steiner, Dominik
   Lampert, Florian
   Stark, G. Bjoern
   Finkenzeller, Guenter
TI Effects of endothelial cells on proliferation and survival of human
   mesenchymal stem cells and primary osteoblasts
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE HUVEC; osteoblast; MSC; proliferation; apoptosis
ID ENDOCHONDRAL BONE FORMATION; SPHEROIDAL COCULTURE MODEL; GROWTH FACTOR;
   GENE EXPRESSION; GAP JUNCTION; IN VITRO; PHOSPHORYLATION; ANGIOGENESIS;
   BAD; DIFFERENTIATION
AB Angiogenesis is a fundamental process in bone formation, remodeling, and regeneration. Moreover, for the regeneration of bone in tissue engineering applications, it is essential to support neovascularization. This can be achieved by cell based therapies using primary endothelial cells, which are able to form functional blood vessels upon implantation. In bone composite grafts, coimplanted endothelial cells do not only support neovascularization but also support osteogenic differentiation of osteoblasts and osteoprogenitor cells. In this study, we investigated the effect of endothelial cells on proliferation and cell survival of human primary osteoblasts (hOBs) and human mesenchymal stem cells (MSCs). Human umbilical vein endothelial cells (HUVECs) stimulated hOB and MSC proliferation, whereas proliferation of HUVECs was unaffected by cocultured hOBs or MSCs. The effect of HUVEC cocultivation on hOB and MSC proliferation was more pronounced in direct cocultures than in indirect cocultures, indicating that this effect is at least partially dependent on the formation of heterotypic cell contacts between HUVECs and hOBs or MSCs. Furthermore, HUVEC cocultivation reduced low serum induced apotosis of hOBs and MSCs by a mechanism involving increased phosphorylation and inactivation of the proapoptotic protein Bad. In summary, our experiments have shown that cocultured HUVECs increase the proliferation and reduce low serum induced apoptosis of hOBs and MSCs. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:16821689, 2012
C1 [Steiner, Dominik; Lampert, Florian; Stark, G. Bjoern; Finkenzeller, Guenter] Univ Freiburg, Med Ctr, Dept Plast & Hand Surg, D 79106 Freiburg, Germany.
C3 University of Freiburg
RP Finkenzeller, G (通讯作者)，Univ Freiburg, Med Ctr, Dept Plast & Hand Surg, Hugstetter Str 55, D 79106 Freiburg, Germany.
EM guenter.finkenzeller@uniklinik freiburg.de
OI Lampert, Florian/0000 0003 4052 0601
FU Deutsche Forschungsgemeinschaft [FI 790/4 1]
FX We thank Beate vom Hoevel for excellent technical assistance. This work
   was supported by funding through the Deutsche Forschungsgemeinschaft (FI
   790/4 1).
CR Bidarra SJ, 2011, STEM CELL RES, V7, P186, DOI 10.1016/j.scr.2011.05.006
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097 2765(00)00006 X
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092 8674(00)80405 5
   DECKER B, 1995, ANAT RECORD, V242, P310, DOI 10.1002/ar.1092420304
   Finkenzeller G, 2006, TISSUE ENG, V12, P2889, DOI 10.1089/ten.2006.12.2889
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Glazebrook H, 1998, J VASC RES, V35, P143, DOI 10.1159/000025577
   Grellier M, 2009, J CELL BIOCHEM, V106, P390, DOI 10.1002/jcb.22018
   GUENTHER HL, 1986, ENDOCRINOLOGY, V119, P193, DOI 10.1210/endo 119 1 193
   Hager S, 2009, TISSUE ENG PT A, V15, P3437, DOI [10.1089/ten.tea.2009.0133, 10.1089/ten.TEA.2009.0133]
   JONES AR, 1995, J ORTHOP RES, V13, P553, DOI 10.1002/jor.1100130410
   Kaufmann T, 2012, CELL DEATH DIFFER, V19, P42, DOI 10.1038/cdd.2011.121
   Mandracchia V J, 2001, Clin Podiatr Med Surg, V18, P55
   Mehlhorn AT, 2006, TISSUE ENG, V12, P1393, DOI 10.1089/ten.2006.12.1393
   MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Saleh FA, 2011, STEM CELLS DEV, V20, P391, DOI 10.1089/scd.2010.0168
   Stahl A, 2004, BIOCHEM BIOPH RES CO, V322, P684, DOI 10.1016/j.bbrc.2004.07.175
   Stevens DA, 1999, MOL CELL ENDOCRINOL, V151, P195, DOI 10.1016/S0303 7207(99)00037 4
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Street John, 2009, J Orthop Surg Res, V4, P19, DOI 10.1186/1749 799X 4 19
   Sun HC, 2007, BIOMED ENG ONLINE, V6, DOI 10.1186/1475 925X 6 41
   Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200
   Vanlangenakker N, 2012, CELL DEATH DIFFER, V19, P75, DOI 10.1038/cdd.2011.164
   Villars F, 2000, J CELL BIOCHEM, V79, P672, DOI 10.1002/1097 4644(20001215)79:4<672::AID JCB150>3.0.CO;2 2
   Villars F, 2002, AM J PHYSIOL CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wenger A, 2004, TISSUE ENG, V10, P1536, DOI 10.1089/ten.2004.10.1536
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092 8674(00)81382 3
   Zhang W., 2012, CELL BIOCH FUNCT
NR 32
TC 54
Z9 61
U1 0
U2 55
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD OCT
PY 2012
VL 30
IS 10
BP 1682
EP 1689
DI 10.1002/jor.22130
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 994VP
UT WOS:000307962500024
PM 22508550
OA Bronze
DA 2025 08 17
ER

PT J
AU Ling, Y
   Li, ZH
   Miranda, K
   Oldfield, E
   Moreno, SNJ
AF Ling, Yan
   Li, Zhu Hong
   Miranda, Kildare
   Oldfield, Eric
   Moreno, Silvia N. J.
TI The Farnesyl diphosphate/geranylgeranyl diphosphate synthase of
   Toxoplasma gondii is a bifunctional enzyme and a molecular target
   of bisphosphonates
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CHAIN LENGTH DETERMINATION; T CELL ACTIVATION; IN VIVO; PYROPHOSPHATE
   SYNTHASE; ARABIDOPSIS THALIANA; TRYPANOSOMA CRUZI; LEISHMANIA DONOVANI;
   POTENTIAL ROUTE; BONE RESORPTION; EXPRESSION
AB Farnesyl diphosphate synthase ( FPPS) catalyzes the synthesis of farnesyl diphosphate, an important precursor of sterols, dolichols, ubiquinones, and prenylated proteins. We report the cloning and characterization of two Toxoplasma gondii farnesyldiphosphate synthase ( TgFPPS) homologs. A single genetic locus produces two transcripts, TgFPPS and TgFPPSi, by alternative splicing. Both isoforms were heterologously expressed in Escherichia coli, but only TgFPPS was active. The protein products predicted from the nucleotide sequences have 646 and 605 amino acids and apparent molecular masses of 69.5 and 64.5 kDa, respectively. Several conserved sequence motifs found in other prenyl diphosphate synthases are present in both TgFPPSs. TgFPPS was also expressed in the baculovirus system and was biochemically characterized. In contrast to the FPPS of other eukaryotic organisms, TgFPPS is bifunctional, catalyzing the formation of both farnesyl diphosphate and geranylgeranyl diphosphate. TgFPPS localizes to the mitochondria, as determined by the co localisation of the affinity purified antibodies against the protein with MitoTracker, and in accord with the presence of an N terminal mitochondria targeting signal in the protein. This enzyme is an attractive target for drug development, because the order of inhibition of the enzyme by a number of bisphosphonates is the same as that for inhibition of parasite growth. In summary, we report the first bifunctional farnesyl diphosphate/geranylgeranyl diphosphate synthase identified in eukaryotes, which, together with previous results, establishes this enzyme as a valid target for the chemotherapy of toxoplasmosis.
C1 Univ Georgia, Paul D Coverdell Ctr Biomed & Hlth Sci, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.
   Univ Georgia, Paul D Coverdell Ctr Biomed & Hlth Sci, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.
   Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
   Univ Illinois, Dept Pathobiol, Urbana, IL 61801 USA.
   Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
C3 University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia; University System of Georgia;
   University of Georgia; University of Illinois System; University of
   Illinois Urbana Champaign; University of Illinois System; University of
   Illinois Urbana Champaign
RP Moreno, SNJ (通讯作者)，Univ Georgia, Paul D Coverdell Ctr Biomed & Hlth Sci, Ctr Trop & Emerging Global Dis, 500 DW Brooks Dr, Athens, GA 30602 USA.
EM smoreno@cb.uga.edu
OI Miranda, Kildare/0000 0001 9799 773X
FU NCRR NIH HHS [C06 RR16515 01] Funding Source: Medline; NIAID NIH HHS
   [AI1968467, AI05093, 1R01AI045806] Funding Source: Medline; NIGMS NIH
   HHS [GM65307] Funding Source: Medline; Wellcome Trust Funding Source:
   Medline
CR ANDERSON MS, 1989, J BIOL CHEM, V264, P19176
   APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432 1033.1989.tb15142.x
   Biardi L, 1996, J BIOL CHEM, V271, P1784, DOI 10.1074/jbc.271.3.1784
   BLANCHARD L, 1993, GENE, V125, P185, DOI 10.1016/0378 1119(93)90326 X
   BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025
   Chaudhary K, 2005, J BIOL CHEM, V280, P22053, DOI 10.1074/jbc.M503178200
   CHEN AJ, 1993, J BIOL CHEM, V268, P11002
   CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432 1033.1996.00779.x
   Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381
   Cunillera N, 1996, J BIOL CHEM, V271, P7774, DOI 10.1074/jbc.271.13.7774
   Delbac F, 2001, J CELL BIOL, V155, P613, DOI 10.1083/jcb.200012116
   Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092 8674(00)81071 5
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fujiwara S, 2004, BIOCHEM BIOPH RES CO, V325, P1066, DOI 10.1016/j.bbrc.2004.10.129
   Gossman W, 2002, J MED CHEM, V45, P4868, DOI 10.1021/jm020224n
   Grünler J, 1999, FEBS LETT, V455, P233, DOI 10.1016/S0014 5793(99)00892 3
   Hemmi H, 2003, EUR J BIOCHEM, V270, P2186, DOI 10.1046/j.1432 1033.2003.03583.x
   Hugueney P, 1996, PLANT PHYSIOL, V111, P619, DOI 10.1104/pp.111.2.619
   Ibrahim M, 2001, INT J PARASITOL, V31, P1489, DOI 10.1016/S0020 7519(01)00268 5
   Kuzuguchi T, 1999, J BIOL CHEM, V274, P5888, DOI 10.1074/jbc.274.9.5888
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LERICHE MA, 1991, MOL BIOCHEM PARASIT, V45, P249, DOI 10.1016/0166 6851(91)90092 K
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655
   NAGEL SD, 1988, MOL BIOCHEM PARASIT, V29, P261, DOI 10.1016/0166 6851(88)90081 3
   Okada K, 2000, PLANT PHYSIOL, V122, P1045, DOI 10.1104/pp.122.4.1045
   Ortiz Gómez A, 2006, EUKARYOT CELL, V5, P1057, DOI 10.1128/EC.00034 06
   Parmryd I, 1999, ARCH BIOCHEM BIOPHYS, V364, P153, DOI 10.1006/abbi.1999.1134
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Roullet E, 1999, J NEUROL, V246, P237, DOI 10.1007/s004150050341
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Sanmiya K, 1999, PLANT CELL PHYSIOL, V40, P348, DOI 10.1093/oxfordjournals.pcp.a029549
   SHEARES BT, 1989, BIOCHEMISTRY US, V28, P8129, DOI 10.1021/bi00446a025
   SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986
   SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044
   Szabo CM, 2002, J MED CHEM, V45, P2894, DOI 10.1021/jm010279+
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   THOMPSON SL, 1987, J BIOL CHEM, V262, P17420
   Toursel C, 2000, MOL BIOCHEM PARASIT, V111, P319, DOI 10.1016/S0166 6851(00)00324 8
   Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609
   Vercesi AE, 1998, J BIOL CHEM, V273, P31040, DOI 10.1074/jbc.273.47.31040
   Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352
   Wang K, 1999, TRENDS BIOCHEM SCI, V24, P445, DOI 10.1016/S0968 0004(99)01464 4
   Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929 931.2002
   Zhu XF, 1997, PLANT MOL BIOL, V35, P331, DOI 10.1023/A:1005898805326
NR 51
TC 82
Z9 94
U1 2
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 19
PY 2007
VL 282
IS 42
BP 30804
EP 30816
DI 10.1074/jbc.M703178200
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 220DE
UT WOS:000250136300049
PM 17724033
OA hybrid
DA 2025 08 17
ER

PT J
AU Ma, HP
   Ming, LG
   Ge, BF
   Zhai, YK
   Song, P
   Xian, CJ
   Chen, KM
AF Ma, Hui Ping
   Ming, Lei Guo
   Ge, Bao Feng
   Zhai, Yuan Kun
   Song, Peng
   Xian, Cory J.
   Chen, Ke Ming
TI Icariin is More Potent Than Genistein in Promoting Osteoblast
   Differentiation and Mineralization In vitro
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE GENISTEIN; ICARIIN; OSTEOBLASTS; DIFFERENTIATION; MINERALIZATION;
   OSTEOPOROSIS
ID OSTEOGENIC DIFFERENTIATION; BONE LOSS; PHOSPHODIESTERASE 5; ISOFLAVONES;
   DERIVATIVES; EXPRESSION; CELLS
AB There has been a strong interest in searching for natural therapies for osteoporosis. Genistein, an isoflavone abundant in soy, and icariin, a prenylated flavonol glycoside isolated from Epimedium Herb, have both been identified to exert beneficial effects in preventing postmenopausal bone loss. However, the relative potency in osteogenesis between the individual phytoestrogen flavonoids remains unknown. The present study compared ability of genistein and icariin in enhancing differentiation and mineralization of cultured rat calvarial osteoblasts in vitro. Dose dependent studies in osteoblast differentiation measuring alkaline phosphatase (ALP) activity revealed optimal concentrations of genistein and icarrin for stimulating osteogenesis to be both at 10( 5)M. Time course studies comparing the two compounds both at 10( 5)M demonstrated that icariin treatment always produced higher ALP activity, more and larger areas of CFU F ALP, colonies and mineralized nodules, more osteocalcin secretion, and calcium deposition, and a higher level of mRNA expression of osteogenesis related genes COL1 alpha 2, BMP 2, OSX, and RUNX 2. However, they inhibited the proliferation of osteoblasts to a similar degree. In conclusion, although future in vivo studies are required to investigate whether icariin is more efficient in improving bone mass and/or preventing bone loss, our in vitro studies have demonstrated that icariin has a stronger osteogenic activity than genistein. In addition, while the prenyl group on C 8 of icariin could be the active group that takes part in osteoblastic differentiation and explains its greater potency in osteogenesis, mechanisms of action, and reasons for the relative potency of icariin versus genistein need to be further studied. J. Cell. Biochem. 112: 916 923, 2011. (C) 2010 Wiley Liss, Inc.
C1 [Ming, Lei Guo; Ge, Bao Feng; Zhai, Yuan Kun; Song, Peng; Chen, Ke Ming] Lanzhou Gen Hosp, Lanzhou Command CPLA, Inst Orthopaed, Lanzhou 730050, Peoples R China.
   [Ma, Hui Ping] Lanzhou Gen Hosp, Lanzhou Command CPLA, Dept Pharm, Lanzhou 730050, Peoples R China.
   [Xian, Cory J.] Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia.
C3 University of South Australia
RP Chen, KM (通讯作者)，Lanzhou Gen Hosp, Lanzhou Command CPLA, Inst Orthopaed, Lanzhou 730050, Peoples R China.
EM chkeming@yahoo.com.cn
RI zhai, Yuankun/AGU 0571 2022; Xian, Cory/D 2646 2009
OI Xian, Cory/0000 0002 8467 2845
FU Gansu Provincial Science & Technology Department, P.R. China
   [092NKDA025]
FX Grant sponsor: Gansu Provincial Science & Technology Department, P.R.
   China; Grant number: 092NKDA025.
CR Atmaca A, 2008, MENOPAUSE, V15, P748, DOI 10.1097/gme.0b013e31815c1e7f
   Borrelli F, 2010, MATURITAS, V66, P333, DOI 10.1016/j.maturitas.2010.05.010
   Chang H, 2003, BIOMED ENVIRON SCI, V16, P83
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen KM, 2005, PHARMAZIE, V60, P939
   Chen XW, 2003, J NUTR BIOCHEM, V14, P342, DOI 10.1016/S0955 2863(03)00056 1
   Dell'Agli M, 2008, J NAT PROD, V71, P1513, DOI 10.1021/np800049y
   Guo BL, 1996, CHIN TRADIT HERB DRU, V27, P524
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   HSIEH TP, 2010, PHYTOMEDICINE   0527
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Kretzschmar G, 2010, J STEROID BIOCHEM, V118, P1, DOI 10.1016/j.jsbmb.2009.08.005
   Liao QC, 2008, ACTA PHARMACOL SIN, V29, P176
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Morris C, 2006, J NUTR, V136, P1166, DOI 10.1093/jn/136.5.1166
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Ning HX, 2006, UROLOGY, V68, P1350, DOI 10.1016/j.urology.2006.09.031
   Okumura N, 2006, BIO MED MATER ENG, V16, P23
   Pan W, 2005, J CELL BIOCHEM, V94, P307, DOI 10.1002/jcb.20308
   POWELL MEA, 1954, J CLIN PATHOL, V7, P245, DOI 10.1136/jcp.7.3.245
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Tumber A, 2000, J ENDOCRINOL, V167, P383, DOI 10.1677/joe.0.1670383
   Ullmann U, 2005, J PHYSIOL PHARMACOL, V56, p79S
   Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087
   Wang ZQ, 2004, EUR J PHARMACOL, V504, P147, DOI 10.1016/j.ejphar.2004.10.002
   Xu HB, 2007, VASC PHARMACOL, V47, P18, DOI 10.1016/j.vph.2007.03.002
   Ye HY, 2005, PHYTOMEDICINE, V12, P735, DOI 10.1016/j.phymed.2004.10.002
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang Y, 2008, ARCH PHARM RES, V31, P1534, DOI 10.1007/s12272 001 2147 5
   Zhang ZB, 2006, ASIAN J ANDROL, V8, P601, DOI 10.1111/j.1745 7262.2006.00197.x
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 35
TC 132
Z9 166
U1 1
U2 54
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR
PY 2011
VL 112
IS 3
BP 916
EP 923
DI 10.1002/jcb.23007
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 728YK
UT WOS:000287910200020
PM 21328465
DA 2025 08 17
ER

PT J
AU Pribadi, C
   Camp, E
   Cakouros, D
   Anderson, P
   Glackin, C
   Gronthos, S
AF Pribadi, Clara
   Camp, Esther
   Cakouros, Dimitrios
   Anderson, Peter
   Glackin, Carlotta
   Gronthos, Stan
TI Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic
   strategy for treating craniosynostosis in Saethre Chotzen syndrome
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Epigenetics; KDM6A; KDM6B; Calvarial cells; Osteogenesis; Coronal
   sutures; TWIST 1; Twist 1(del+) mice; Saethre Chotzen syndrome;
   Craniosynostosis
ID H3K27 DEMETHYLASE INHIBITOR; BONE FORMATION; OSTEOBLAST DIFFERENTIATION;
   OSTEOGENIC DIFFERENTIATION; MOLECULAR MECHANISMS; CALVARIAL BONE;
   SUTURE; TWIST; UTX; JMJD3
AB BackgroundDuring development, excessive osteogenic differentiation of mesenchymal progenitor cells (MPC) within the cranial sutures can lead to premature suture fusion or craniosynostosis, leading to craniofacial and cognitive issues. Saethre Chotzen syndrome (SCS) is a common form of craniosynostosis, caused by TWIST 1 gene mutations. Currently, the only treatment option for craniosynostosis involves multiple invasive cranial surgeries, which can lead to serious complications.MethodsThe present study utilized Twist 1 haploinsufficient (Twist 1(del/+)) mice as SCS mouse model to investigate the inhibition of Kdm6a and Kdm6b activity using the pharmacological inhibitor, GSK J4, on calvarial cell osteogenic potential.ResultsThis study showed that the histone methyltransferase EZH2, an osteogenesis inhibitor, is downregulated in calvarial cells derived from Twist 1(del/+) mice, whereas the counter histone demethylases, Kdm6a and Kdm6b, known promoters of osteogenesis, were upregulated. In vitro studies confirmed that siRNA mediated inhibition of Kdm6a and Kdm6b expression suppressed osteogenic differentiation of Twist 1(del/+) calvarial cells. Moreover, pharmacological targeting of Kdm6a and Kdm6b activity, with the inhibitor, GSK J4, caused a dose dependent suppression of osteogenic differentiation by Twist 1(del/+) calvarial cells in vitro and reduced mineralized bone formation in Twist 1(del/+) calvarial explant cultures. Chromatin immunoprecipitation and Western blot analyses found that GSK J4 treatment elevated the levels of the Kdm6a and Kdm6b epigenetic target, the repressive mark of tri methylated lysine 27 on histone 3, on osteogenic genes leading to repression of Runx2 and Alkaline Phosphatase expression. Pre clinical in vivo studies showed that local administration of GSK J4 to the calvaria of Twist 1(del/+) mice prevented premature suture fusion and kept the sutures open up to postnatal day 20.ConclusionThe inhibition of Kdm6a and Kdm6b activity by GSK J4 could be used as a potential non invasive therapeutic strategy for preventing craniosynostosis in children with SCS.Graphical abstractPharmacological targeting of Kdm6a/b activity can alleviate craniosynostosis in Saethre Chotzen syndrome. Aberrant osteogenesis by Twist 1 mutant cranial suture mesenchymal progenitor cells occurs via deregulation of epigenetic modifiers Ezh2 and Kdm6a/Kdm6b. Suppression of Kdm6a  and Kdm6b mediated osteogenesis with GSK J4 inhibitor can prevent prefusion of cranial sutures.
C1 [Pribadi, Clara; Camp, Esther; Cakouros, Dimitrios; Gronthos, Stan] Univ Adelaide, Adelaide Med Sch, Fac Hlth & Med Sci, Mesenchymal Stem Cell Lab, Adelaide, SA, Australia.
   [Pribadi, Clara; Camp, Esther; Cakouros, Dimitrios; Anderson, Peter; Gronthos, Stan] South Australian Hlth & Med Res Inst, Precis Med Theme, Adelaide, SA, Australia.
   [Anderson, Peter] Women & Children Hosp, Adelaide Craniofacial Unit, Adelaide, SA, Australia.
   [Glackin, Carlotta] City Hope Natl Med Ctr, Mol Med & Neurosci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
   [Glackin, Carlotta; Gronthos, Stan] Beckman Res Inst, Duarte, CA USA.
C3 University of Adelaide; South Australian Health & Medical Research
   Institute (SAHMRI); City of Hope; City of Hope; Beckman Research
   Institute of City of Hope
RP Gronthos, S (通讯作者)，Univ Adelaide, Adelaide Med Sch, Fac Hlth & Med Sci, Mesenchymal Stem Cell Lab, Adelaide, SA, Australia.; Gronthos, S (通讯作者)，South Australian Hlth & Med Res Inst, Precis Med Theme, Adelaide, SA, Australia.
EM stan.gronthos@adelaide.edu.au
RI ; Gronthos, Stan/Y 4419 2019; Anderson, Peter/O 5302 2019; Cakouros,
   Dimitrios/NEU 7365 2025
OI ANDERSON, Peter/0000 0002 3730 4652; 
FU NHMRC [APP1142954]; University of Adelaide International Postgraduate
   Research Scholarship
FX This project is funded by the NHMRC Project Grant APP1142954 and the
   University of Adelaide International Postgraduate Research Scholarship.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Anderson PM, 1996, HANDS SAETHRE CHOTZE, P228
   Beederman M, 2014, GENES DIS, V1, P120, DOI 10.1016/j.gendis.2014.07.004
   Benyoucef A, 2016, GENE DEV, V30, P508, DOI 10.1101/gad.276790.115
   Bergquist CS, 2016, PLAST RECONSTR SURG, V137, P1557, DOI 10.1097/PRS.0000000000002049
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bildsoe H, 2016, DEV BIOL, V418, P189, DOI 10.1016/j.ydbio.2016.08.016
   Bildsoe H, 2009, DEV BIOL, V331, P176, DOI 10.1016/j.ydbio.2009.04.034
   Cakouros D, 2012, MOL CELL BIOL, V32, P1433, DOI 10.1128/MCB.06315 11
   Camp E, 2018, J CELL PHYSIOL, V233, P7320, DOI 10.1002/jcp.26563
   Camp E, 2017, BONE, V94, P98, DOI 10.1016/j.bone.2016.09.019
   Carver EA, 2002, ANAT REC, V268, P90, DOI 10.1002/ar.10124
   CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686
   Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Doro DH, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00956
   El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Gallagher E.R., 1993, GeneReviews
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   Goodnough LH, 2016, DEV DYNAM, V245, P144, DOI [10.1002/DVDY.24367, 10.1002/dvdy.24367]
   Han RH, 2016, J NEUROSURG PEDIATR, V17, P361, DOI 10.3171/2015.7.PEDS15187
   Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716
   Hemming S, 2017, FASEB J, V31, P1011, DOI 10.1096/fj.201600748R
   Hemming S, 2016, STEM CELLS DEV, V25, P909, DOI 10.1089/scd.2015.0384
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Hersh DS, 2017, J NEUROSURG PEDIATR, V20, P91, DOI 10.3171/2017.2.PEDS16710
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Johnson D, 2000, MECH DEVELOP, V91, P341, DOI 10.1016/S0925 4773(99)00278 6
   Katsianou MA, 2016, BBA CLIN, V6, P165, DOI 10.1016/j.bbacli.2016.04.006
   Knight SJ, 2014, DEV NEUROPSYCHOL, V39, P159, DOI 10.1080/87565641.2014.886690
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Lakin GE, 2012, PLAST RECONSTR SURG, V129, P945, DOI 10.1097/PRS.0b013e31824422a8
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee HQ, 2012, J CRANIOFAC SURG, V23, P1256, DOI 10.1097/SCS.0b013e31824e26d6
   Lenton KA, 2005, CURR TOP DEV BIOL, V66, P287, DOI 10.1016/S0070 2153(05)66009 7
   Lhuissier E, 2019, IUBMB LIFE, V71, P1711, DOI 10.1002/iub.2110
   Li YN, 2018, J CANCER RES CLIN, V144, P1065, DOI 10.1007/s00432 018 2631 7
   Magge SN, 2017, J CRANIOFAC SURG, V28, P14, DOI 10.1097/SCS.0000000000003368
   MARCHAC D, 1990, WORLD J SURG, V14, P725, DOI 10.1007/BF01670519
   Miyake N, 2013, HUM MUTAT, V34, P108, DOI 10.1002/humu.22229
   Mohammad Khalid S., 2008, V455, P37, DOI 10.1007/978 1 59745 104 8_3
   Morozov VM, 2017, ONCOTARGET, V8, P62131, DOI 10.18632/oncotarget.19100
   Nam HK, 2019, BONE, V120, P125, DOI 10.1016/j.bone.2018.10.013
   Proctor MR, 2012, J CRANIOFAC SURG, V23, P225, DOI [10.1097/SCS.0b013e318241b8f6, 10.4103/sni.sni_17_18]
   Rice DPC, 2003, EUR J ORTHODONT, V25, P139, DOI 10.1093/ejo/25.2.139
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Sakaki H, 2015, ANTICANCER RES, V35, P6607
   Shpargel KB, 2017, P NATL ACAD SCI USA, V114, pE9046, DOI 10.1073/pnas.1705011114
   Shpargel KB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002964
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Tang QY, 2020, STEM CELL REP, V15, P439, DOI 10.1016/j.stemcr.2020.06.015
   Van der Meulen J, 2014, EPIGENETICS US, V9, P658, DOI 10.4161/epi.28298
   Vu HL, 2001, J CRANIOFAC SURG, V12, P527, DOI 10.1097/00001665 200111000 00005
   Walport LJ, 2014, J BIOL CHEM, V289, P18302, DOI 10.1074/jbc.M114.555052
   Wang FS, 2017, J MOL MED, V95, P499, DOI 10.1007/s00109 017 1512 x
   Welstead GG, 2012, P NATL ACAD SCI USA, V109, P13004, DOI 10.1073/pnas.1210787109
   Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601
   Xu J, 2008, J NEUROSCI, V28, P4521, DOI 10.1523/JNEUROSCI.5382 07.2008
   Yan NN, 2017, EXP CELL RES, V359, P405, DOI 10.1016/j.yexcr.2017.08.024
   Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023965
   Yang D, 2013, J BIOL CHEM, V288, P33530, DOI 10.1074/jbc.M113.497040
   Yapp C, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1053 7
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Yoshida T, 2005, J ANAT, V206, P437, DOI 10.1111/j.1469 7580.2005.00411.x
   Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006 291X(02)02260 X
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
   Zhang F, 2015, SCI REP UK, V5, DOI 10.1038/srep13418
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
NR 71
TC 13
Z9 14
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 9
PY 2020
VL 11
IS 1
AR 529
DI 10.1186/s13287 020 02051 5
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA PH0FX
UT WOS:000600101100005
PM 33298158
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sardar, A
   Gautam, S
   Sinha, S
   Rai, D
   Tripathi, AK
   Dhaniya, G
   Mishra, PR
   Trivedi, R
AF Sardar, Anirban
   Gautam, Shalini
   Sinha, Shradha
   Rai, Divya
   Tripathi, Ashish Kumar
   Dhaniya, Geeta
   Mishra, Prabhat Ranjan
   Trivedi, Ritu
TI Nanoparticles of naturally occurring PPAR γ inhibitor betulinic acid
   ameliorates bone marrow adiposity and pathological bone loss in
   ovariectomized rats via Wnt/β catenin pathway
SO LIFE SCIENCES
LA English
DT Article
DE Postmenopausal osteoporosis; Bone metabolism; Bone marrow adiposity;
   Wnt/beta catenin; Betulinic acid; Nano formulation
ID MESENCHYMAL STEM CELLS; METABOLIC SYNDROME; DIFFERENTIATION;
   OSTEOPOROSIS; ESTROGEN; PROMOTES; ADIPOGENESIS; OSTEOGENESIS;
   INVOLVEMENT; OSTEOPENIA
AB Aims: Postmenopausal osteoporosis is one of the world's biggest yet unnoticed health issues. After ovariectomy, declined estrogen level significantly contributes to the elevation of bone marrow adiposity and bone loss leading to osteoporosis. Therapeutics to prevent osteoporosis addressing various aspects are now in short supply. In this study we made an approach to synthesize nanoparticles of naturally occurring PPAR gamma inhibitor, betulinic acid (BA/NPs) and tested the same in altered bone metabolisms developed after ovariectomy. Main methods: The osteogenic efficacy of BA/NPs was established in human and rat primary osteoblast cells using qRT PCR and immunoblot analysis. Furthermore, lineage allocations of multipotent bone marrow stromal cells were evaluated. Various aspects of altered bone metabolism after ovariectomy such as bone marrow adiposity and pathological bone loss were evaluated using mu CT and histological assessments. Key findings: BA/NPs exert potential osteogenic efficacy by modulating key osteogenic markers such as RUNX2 and BMP2. Mechanistically BA/NPs regulate osteoblastogenesis through Wnt/beta catenin signaling. Further, BA/ NPs showed the potential to inhibit the differentiation of multipotent BMSCs towards adipogenesis while favouring the osteogenic lineage via Wnt/beta catenin pathway. In the in vivo study, increased bone marrow adiposity was reduced in ovariectomized rats after BA/NPs treatment as assessed by histology and mu CT analysis. Loss of bone mineral density as a hallmark of pathological bone loss was also abrogated by BA/NPs. Furthermore, increased obesity after OVX was also prevented in BA/NPs treated animals. Significance: Our findings imply that BA/NPs could be used further as a viable drug lead to counteract various pathophysiological challenges after menopause.
C1 [Sardar, Anirban; Sinha, Shradha; Rai, Divya; Tripathi, Ashish Kumar; Dhaniya, Geeta; Trivedi, Ritu] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow, Uttar Pradesh, India.
   [Gautam, Shalini; Mishra, Prabhat Ranjan] CSIR Cent Drug Res Inst, Div Pharmaceut & Pharmacokinet, Lucknow, Uttar Pradesh, India.
   [Sardar, Anirban; Gautam, Shalini; Sinha, Shradha; Rai, Divya; Mishra, Prabhat Ranjan; Trivedi, Ritu] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
   [Mishra, Prabhat Ranjan] CSIR Cent Drug Res Inst, Div Pharmaceut & Pharmacokinet, 10 1,Sect 10, Jankipuram Extensi Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Trivedi, Ritu] CSIR Cent Drug Res Inst, Div Endocrinol, 10 1,Sect 10 Jankipuram Extens Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Academy of Scientific & Innovative Research (AcSIR);
   Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI)
RP Mishra, PR (通讯作者)，CSIR Cent Drug Res Inst, Div Pharmaceut & Pharmacokinet, 10 1,Sect 10, Jankipuram Extensi Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.; Trivedi, R (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, 10 1,Sect 10 Jankipuram Extens Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM prabhat_mishra@cdri.res.in; ritu_trivedi@cdri.res.in
RI ; SARDAR, ANIRBAN/GLV 3193 2022; Tripathi, Ashish/JXY 6318 2024; Mishra,
   Prabhat/KHY 3664 2024
OI Tripathi, Ashish Kumar/0000 0002 0976 8476; SARDAR,
   ANIRBAN/0000 0002 7840 1862; Trivedi, Ritu/0000 0002 9524 2541; Rai,
   Divya/0000 0002 4610 0088
FU CSIR, India; DST, India; UGC, India;  [10469]
FX The authors A.S., S.S., A.K.T. and G.D. are thankful to CSIR, India;
   S.G. acknowledges DST, India and D.R. is thankful to UGC, India, for the
   financial assistance in the form of fellowships.
CR Ahmad N, 2019, MOL THER NUCL ACIDS, V14, P536, DOI 10.1016/j.omtn.2019.01.002
   Ahmad N, 2016, RSC ADV, V6, P97613, DOI 10.1039/c6ra17141a
   Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Berendsen AD, 2015, J INTERN MED, V277, P674, DOI 10.1111/joim.12364
   Bollag AE, 2019, J ENDOCRINOL, V243, P15, DOI 10.1530/JOE 18 0691
   Bravo Alfaro DA, 2022, J MOL LIQ, V364, DOI 10.1016/j.molliq.2022.119946
   Brusotti G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05666 6
   Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003 030242
   Chen N, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00792
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chindamo G, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10050875
   Choi B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082187
   Choudhary D, 2017, BIOMED PHARMACOTHER, V92, P757, DOI 10.1016/j.biopha.2017.05.120
   Cichewicz RH, 2004, MED RES REV, V24, P90, DOI 10.1002/med.10053
   CLARK RG, 1982, PHYSIOL BEHAV, V28, P963, DOI 10.1016/0031 9384(82)90161 5
   de Winter TJJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.627429
   Dehelean CA, 2011, FARMACIA, V59, P51
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Furtado NAJC, 2017, MOLECULES, V22, DOI 10.3390/molecules22030400
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Han HS, 2022, BIOACT MATER, V14, P182, DOI 10.1016/j.bioactmat.2021.11.027
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang P, 2019, PHARMACOL THERAPEUT, V196, P79, DOI 10.1016/j.pharmthera.2018.11.008
   Kerensa X., 2019, AM J PHYSIOL ENDOC M, V316, P96, DOI [10.1152/ ajpendo.00265.2018. Bone, DOI 10.1152/AJPENDO.00265.2018. BONE]
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kothari P, 2020, FOOD FUNCT, V11, P8273, DOI [10.1039/D0FO01125H, 10.1039/d0fo01125h]
   Kwasniewska M, 2012, MENOPAUSE, V19, P194, DOI 10.1097/gme.0b013e3182273035
   Li C, 2021, ACTA BIOCH BIOPH SIN, V53, P1266, DOI 10.1093/abbs/gmab111
   Li GW, 2013, SKELETAL RADIOL, V42, P195, DOI 10.1007/s00256 012 1473 7
   Li XS, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0338 2
   LINDHEIM SR, 1994, J SOC GYNECOL INVEST, V1, P150, DOI 10.1177/107155769400100210
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Majidinia M, 2018, J CELL PHYSIOL, V233, P5598, DOI 10.1002/jcp.26265
   Mazziotti G, 2012, ENDOCRINE, V41, P58, DOI 10.1007/s12020 011 9570 2
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Pal S, 2022, CALCIFIED TISSUE INT, V111, P196, DOI 10.1007/s00223 022 00979 9
   Pal S, 2021, ACS APPL MATER INTER, V13, P17300, DOI 10.1021/acsami.1c01513
   Pal S, 2019, CALCIFIED TISSUE INT, V105, P294, DOI 10.1007/s00223 019 00567 4
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Pandey AR, 2021, J MED CHEM, V64, P12487, DOI 10.1021/acs.jmedchem.1c00112
   Picke AK, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao6806
   Porwal K, 2019, TOXICOL SCI, V172, P167, DOI 10.1093/toxsci/kfz172
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rai Divya, 2022, Free Radic Biol Med, V190, P124, DOI 10.1016/j.freeradbiomed.2022.08.007
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Saneja A, 2017, INT J PHARMACEUT, V531, P153, DOI 10.1016/j.ijpharm.2017.08.076
   Siddiqui S, 2014, DARU, V22, DOI 10.1186/s40199 014 0072 7
   Soica C, 2012, INT J MOL SCI, V13, P14992, DOI 10.3390/ijms131114992
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tripathi AK, 2022, APOPTOSIS, V27, P90, DOI 10.1007/s10495 021 01702 z
   Tripathi AK, 2020, TOXICOL IN VITRO, V66, DOI 10.1016/j.tiv.2020.104872
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231
   Veldhuis Vlug AG, 2018, J INTERN MED, V283, P121, DOI 10.1111/joim.12718
   Wang RN, 2020, INT J PHARMACEUT, V588, DOI 10.1016/j.ijpharm.2020.119799
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
NR 62
TC 21
Z9 23
U1 0
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD NOV 15
PY 2022
VL 309
AR 121020
DI 10.1016/j.lfs.2022.121020
EA OCT 2022
PG 25
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 5M5EK
UT WOS:000871118000002
PM 36191680
DA 2025 08 17
ER

PT J
AU Prasarn, ML
   Ahn, J
   Helfet, DL
   Lane, JM
   Lorich, DG
AF Prasarn, Mark L.
   Ahn, Jaimo
   Helfet, David L.
   Lane, Joseph M.
   Lorich, Dean G.
TI Bisphosphonate associated Femur Fractures Have High Complication Rates
   with Operative Fixation
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID SUBTROCHANTERIC STRESS FRACTURES; FEMORAL INSUFFICIENCY FRACTURES; TERM
   ALENDRONATE THERAPY; POSTMENOPAUSAL OSTEOPOROSIS; MICRODAMAGE
   ACCUMULATION; NONVERTEBRAL FRACTURES; MEVALONATE PATHWAY; BONE;
   PREVENTION; WOMEN
AB Bisphosphonate associated femur fractures have been well described but the preoperative patient factors, treatment modalities, and complications of treatment are unclear.
   We asked whether a diagnosis of osteoporosis, the characteristic radiographic features of bisphosphonate related femur fractures, and complication rates differed in patients with operatively treated femoral shaft fractures receiving bisphosphonates and in patients not receiving bisphosphonates.
   We retrospectively reviewed 43 patients with bisphosphonate associated femoral shaft fractures (including subtrochanteric) from 2002 to 2008 and 20 patients with similar fractures but not treated with bisphosphonates. Similar implants were used in both groups, but a greater number of adjuvants were used in the bisphosphonate cohort. We recorded preoperative osteoporosis and radiographic findings of the characteristic bisphosphonate femur fracture and early complications. The minimum followup was 5 months (mean, 29 months; range 5 60 months).
   Preoperatively a greater percentage of patients treated with bisphosphonates had confirmed osteoporosis than those not treated with bisphosphonates (24% versus 5%, respectively), a greater percentage had a proximal fracture location (48% versus 40%, respectively), and their mean cortex to shaft diameter ratio was greater (24% versus 15%, respectively). The bisphosphonate cohort had a higher rate of intraoperative fractures (21% versus 0%) and postoperative plate failures (30% versus 0%).
   Despite low rates of other risk factors and ample use of biologic adjuvants, patients treated with bisphosphonates having femur fractures have more complications.
   Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
C1 [Prasarn, Mark L.; Ahn, Jaimo; Helfet, David L.; Lane, Joseph M.; Lorich, Dean G.] Hosp Special Surg, Orthoped Trauma Serv, New York, NY 10021 USA.
   [Prasarn, Mark L.; Ahn, Jaimo; Helfet, David L.; Lane, Joseph M.; Lorich, Dean G.] New York Presbyterian Hosp, New York, NY USA.
   [Prasarn, Mark L.; Ahn, Jaimo; Helfet, David L.; Lane, Joseph M.; Lorich, Dean G.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
C3 NewYork Presbyterian Hospital; Cornell University; Weill Cornell
   Medicine
RP Helfet, DL (通讯作者)，Hosp Special Surg, Orthoped Trauma Serv, 535 E 70th St, New York, NY 10021 USA.
EM helfetd@hss.edu
RI Ahn, Jaimo/KVZ 0734 2024
OI Ahn, Jaimo/0000 0001 8151 9987
CR Ahn JK, 2011, RHEUMATOL INT, V31, P973, DOI 10.1007/s00296 010 1477 3
   Aspenberg P, 2008, ACTA ORTHOP, V79, P459, DOI 10.1080/17453670710015427
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Capeci CM, 2009, J BONE JOINT SURG AM, V91A, P2556, DOI 10.2106/JBJS.H.01774
   Cermak K, 2010, CLIN ORTHOP RELAT R, V468, P1991, DOI 10.1007/s11999 009 1192 0
   Chrischilles EA, 2001, OSTEOPOROSIS INT, V12, P654, DOI 10.1007/s001980170065
   Das De S, 2010, J BONE JOINT SURG BR, V92B, P679, DOI 10.1302/0301 620X.92B5.22941
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Goddard Maria S, 2009, Orthopedics, V32, DOI 10.3928/01477447 20090624 27
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Gomberg SJ, 2011, J CLIN ENDOCR METAB, V96, P1627, DOI 10.1210/jc.2010 2520
   Ha YC, 2010, CLIN ORTHOP RELAT R, V468, P3393, DOI 10.1007/s11999 010 1583 2
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801
   Isaacs JD, 2010, CLIN ORTHOP RELAT R, V468, P3384, DOI 10.1007/s11999 010 1535 x
   Karpf DB, 1997, JAMA J AM MED ASSOC, V277, P1159
   Koh JSB, 2010, J ORTHOP TRAUMA, V24, P75, DOI 10.1097/BOT.0b013e3181b6499b
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   Mashiba T, 2005, CALCIFIED TISSUE INT, V77, P180, DOI 10.1007/s00223 005 1295 x
   Napoli N, 2010, OSTEOPOROSIS INT, V21, P705, DOI 10.1007/s00198 009 1012 0
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ott SM, 2010, ORTHOPEDICS, V33, P468, DOI 10.3928/01477447 20100526 10
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   Sayed Noor AS, 2008, ACTA ORTHOP, V79, P565, DOI 10.1080/17453670710015580
   Sayed Noor AS, 2009, CLIN ORTHOP RELAT R, V467, P1921, DOI 10.1007/s11999 009 0725 x
   Somford MP, 2009, INT J RHEUMATOL, V2009, DOI 10.1155/2009/253432
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
NR 33
TC 100
Z9 104
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD AUG
PY 2012
VL 470
IS 8
BP 2295
EP 2301
DI 10.1007/s11999 012 2412 6
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 971PD
UT WOS:000306215400032
PM 22669553
OA Green Published
DA 2025 08 17
ER

PT J
AU He, JS
   Chen, QX
   Gu, HY
   Chen, J
   Zhang, EF
   Guo, X
   Huang, X
   Yan, HM
   He, DH
   Yang, Y
   Zhao, Y
   Wang, G
   He, H
   Yi, Q
   Cai, Z
AF He, Jingsong
   Chen, Qingxiao
   Gu, Huiyao
   Chen, Jing
   Zhang, Enfan
   Guo, Xing
   Huang, Xi
   Yan, Haimeng
   He, DongHua
   Yang, Yang
   Zhao, Yi
   Wang, Gang
   He, Huang
   Yi, Qing
   Cai, Zhen
TI Therapeutic effects of the novel subtype selective histone deacetylase
   inhibitor chidamide on myeloma associated bone disease
SO HAEMATOLOGICA
LA English
DT Article
ID MULTIPLE MYELOMA; CELL LYMPHOMA; EXPRESSION; CANCER; ACTIVATION;
   MANAGEMENT; APOPTOSIS; STAT3
AB Histone deacetylases are promising therapeutic targets in hematological malignancies. In the work herein, we investigated the effect of chidamide, a new subtype selective histone deacetylase inhibitor that was independently produced in China, on multiple myeloma and its associated bone diseases using different models. The cytotoxicity of chidamide toward myeloma is due to its induction of cell apoptosis and cell cycle arrest by increasing the levels of caspase family proteins p21 and p27, among others. Furthermore, chidamide exhibited significant cytotoxicity against myeloma cells co cultured with bone mesenchymal stromal cells and chidami de pretreated osteoclasts. Importantly, chidamide suppressed osteoclast differentiation and resorption in vitro by dephosphorylating p ERK, p p38, p AKT and p JNK and inhibiting the expression of Cathepsin K, NFATc1 and c fos. Finally, chidamide not only prevented tumor associated bone loss in a disseminated murine model by partially decreasing the tumor burden but also prevented rapid receptor activator of nuclear factor kappa beta ligand (RANKL) induced bone loss in a non tumor bearing mouse model. Based on our results, chidamide exerted dual anti myeloma and bone protective effects in vitro and in vivo. These findings strongly support the potential clinical use of this drug as a treatment for multiple myeloma in the near future.
C1 [He, Jingsong; Chen, Qingxiao; Gu, Huiyao; Chen, Jing; Zhang, Enfan; Guo, Xing; Huang, Xi; Yan, Haimeng; He, DongHua; Yang, Yang; Zhao, Yi; Wang, Gang; He, Huang; Cai, Zhen] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Gang] Quzhou Peoples Hosp, Quzhou, Zhejiang, Peoples R China.
   [Yi, Qing] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA.
C3 Zhejiang University; Cleveland Clinic Foundation
RP Cai, Z (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Zhejiang, Peoples R China.
EM caiz@zju.edu.cn
RI Zhang, Qian/KVZ 3651 2024; He, Dong/LBH 8540 2024
FU Funds for the National Natural Science Foundation of China [91742110,
   81471532]; Funds for the Natural Science Foundation of Zhejiang
   province, China [LY17H080001]
FX This work was supported by the Funds for the National Natural Science
   Foundation of China (Grant No. 91742110 and 81471532) and the Funds for
   the Natural Science Foundation of Zhejiang province, China
   (LY17H080001).
CR Blixt NC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185441
   Cantley MD, 2017, BONE, V95, P162, DOI 10.1016/j.bone.2016.11.028
   Cantley MD, 2015, RHEUMATOLOGY, V54, P1713, DOI 10.1093/rheumatology/kev022
   Christoulas D, 2009, EXPERT REV HEMATOL, V2, P385, DOI 10.1586/ehm.09.36
   Dotterweich J, 2016, BONE, V93, P155, DOI 10.1016/j.bone.2016.08.006
   Dou C, 2016, AM J PHYSIOL CELL PH, V310, pC780, DOI 10.1152/ajpcell.00351.2015
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Gong K, 2012, BIOCHEM J, V443, P735, DOI 10.1042/BJ20111685
   Harada T, 2017, LEUKEMIA, V31, P2670, DOI 10.1038/leu.2017.144
   He M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166896
   Hu XS, 2016, CHINESE J CANCER RES, V28, P444, DOI 10.21147/j.issn.1000 9604.2016.04.08
   Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233
   Pham L, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.216853
   Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017
   Laubach JP, 2017, EXPERT REV HEMATOL, V10, P229, DOI 10.1080/17474086.2017.1280388
   Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009
   Liang P, 2013, HAEMATOLOGICA, V98, P288, DOI 10.3324/haematol.2012.065607
   Minami J, 2014, LEUKEMIA, V28, P680, DOI 10.1038/leu.2013.231
   Ortega Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943
   Paíno T, 2017, CLIN CANCER RES, V23, P225, DOI 10.1158/1078 0432.CCR 16 0230
   Paton Hough J, 2015, BONE, V77, P57, DOI 10.1016/j.bone.2015.04.004
   Pavithra L, 2009, J MOL BIOL, V388, P691, DOI 10.1016/j.jmb.2009.03.033
   Röllig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140 6736(14)60493 1
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Shi YK, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0439 6
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Siveen KS, 2014, BBA REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Tan E, 2011, LEUKEMIA LYMPHOMA, V52, P1630, DOI 10.3109/10428194.2011.573036
   Tang JH, 2013, CLIN SCI, V124, P651, DOI 10.1042/CS20120504
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
NR 34
TC 24
Z9 26
U1 0
U2 10
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390 6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUL 31
PY 2018
VL 103
IS 8
BP 1369
EP 1379
DI 10.3324/haematol.2017.181172
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA GO7WX
UT WOS:000440290800030
PM 29773595
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Franco Trepat, E
   Alonso Pérez, A
   Guillán Fresco, M
   López Fagúndez, M
   Pazos Pérez, A
   Crespo Golmar, A
   Bravo, SB
   López López, V
   Jorge Mora, A
   Cerón Carrasco, JP
   Iglesias, AL
   Gómez, R
AF Franco Trepat, Eloi
   Alonso Perez, Ana
   Guillan Fresco, Maria
   Lopez Fagundez, Miriam
   Pazos Perez, Andres
   Crespo Golmar, Antia
   Belen Bravo, Susana
   Lopez Lopez, Veronica
   Jorge Mora, Alberto
   Ceron Carrasco, Jose P.
   Lois Iglesias, Ana
   Gomez, Rodolfo
TI β Boswellic Acid Blocks Articular Innate Immune Responses: An In Silico
   and In Vitro Approach to Traditional Medicine
SO ANTIOXIDANTS
LA English
DT Article
DE osteoarthritis; chondrocytes; synoviocytes; ROS; TLR4; IL1; NLRP3
ID NF KAPPA B; MURINE RECOMBINANT INTERLEUKIN 1; TOLL LIKE RECEPTORS;
   SERRATA EXTRACT; INFLAMMATORY MEDIATORS; OSTEOARTHRITIS; PROTEIN;
   CARTILAGE; COLLAGENASE; MODULATION
AB Osteoarthritis (OA) is hallmarked as a silent progressive rheumatic disease of the whole joint. The accumulation of inflammatory and catabolic factors such as IL6, TNF alpha, and COX2 drives the OA pathophysiology into cartilage degradation, synovia inflammation, and bone destruction. There is no clinical available OA treatment. Although traditional ayurvedic medicine has been using Boswellia serrata extracts (BSE) as an antirheumatic treatment for a millennium, none of the BSE components have been clinically approved. Recently, beta boswellic acid (BBA) has been shown to reduce in vivo OA cartilage loss through an unknown mechanism. We used computational pharmacology, proteomics, transcriptomics, and metabolomics to present solid evidence of BBA therapeutic properties in mouse and primary human OA joint cells. Specifically, BBA binds to the innate immune receptor Toll like Receptor 4 (TLR4) complex and inhibits both TLR4 and Interleukin 1 Receptor (IL1R) signaling in OA chondrocytes, osteoblasts, and synoviocytes. Moreover, BBA inhibition of TLR4/IL1R downregulated reactive oxygen species (ROS) synthesis and MAPK p38/NF kappa B, NLRP3, IFN alpha beta, TNF, and ECM related pathways. Altogether, we present a solid bulk of evidence that BBA blocks OA innate immune responses and could be transferred into the clinic as an alimentary supplement or as a therapeutic tool after clinical trial evaluations.
C1 [Franco Trepat, Eloi; Alonso Perez, Ana; Guillan Fresco, Maria; Lopez Fagundez, Miriam; Pazos Perez, Andres; Crespo Golmar, Antia; Belen Bravo, Susana; Lopez Lopez, Veronica; Jorge Mora, Alberto; Lois Iglesias, Ana; Gomez, Rodolfo] Santiago Univ Clin Hosp, Inst IDIS, Musculoskeletal Pathol Grp, Santiago De Compostela 15706, Spain.
   [Ceron Carrasco, Jose P.] Univ Politecn Cartagena, Ctr Univ Def, C Coronel Lopez Pena S N,Base Aerea San Javier, Murcia 30720, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela;
   Universidad Politecnica de Cartagena
RP Gómez, R (通讯作者)，Santiago Univ Clin Hosp, Inst IDIS, Musculoskeletal Pathol Grp, Santiago De Compostela 15706, Spain.
EM rodolfo.gomez.bahamonde@sergas.es
RI ; Gomez, Rodolfo/B 4642 2012; Franco Trepat, Eloi/AAD 7837 2020; Bravo
   Lopez, Susana Belen/F 8487 2016; Jorge Mora, Alberto/AAB 3156 2019;
   Lopez, Susana/F 8487 2016; Cerón Carrasco, José Pedro/H 3705 2013;
   Guillán Fresco, María/IWM 5573 2023
OI Franco Trepat, Eloi/0000 0001 7514 4672; Bravo Lopez, Susana
   Belen/0000 0001 7615 3079; Lopez Lopez, Veronica/0000 0003 2628 8260; 
CR Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443
   Abdel Tawab M, 2011, CLIN PHARMACOKINET, V50, P349, DOI 10.2165/11586800 000000000 00000
   Abdollahi Roodsaz S, 2007, ARTHRITIS RHEUM, V56, P2957, DOI 10.1002/art.22848
   Al Bahlani S, 2020, BMC PHARMACOL TOXICO, V21, DOI 10.1186/s40360 020 00442 1
   Alonso Pérez A, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11010031
   Alonso Pérez A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00504
   [Anonymous], QUANTSTUDIO 3 5 REAL
   [Anonymous], QUANTSTUDIO DESIGN A
   AppliedBiosystems, 2018, HIGH CAP RNA TO CDNA
   Bai F, 2018, J CRANIOFAC SURG, V29, P1996, DOI 10.1097/SCS.0000000000004691
   BALAVOINE JF, 1986, J CLIN INVEST, V78, P1120, DOI 10.1172/JCI112669
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cernanec JM, 2007, J RHEUMATOL, V34, P401
   Cerón Carrasco JP, 2022, CHEMMEDCHEM, V17, DOI 10.1002/cmdc.202200278
   Cerón Carrasco JP, 2021, CHEMMEDCHEM, V16, P1764, DOI 10.1002/cmdc.202100046
   Chi CT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133170
   Choi MC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070734
   Conde J, 2011, ANN RHEUM DIS, V70, P551, DOI 10.1136/ard.2010.132399
   Coryell PR, 2021, NAT REV RHEUMATOL, V17, P47, DOI 10.1038/s41584 020 00533 7
   Couselo Seijas M, 2019, J CELL PHYSIOL, V234, P10512, DOI 10.1002/jcp.27723
   Davies CM, 2008, OSTEOARTHR CARTILAGE, V16, P624, DOI 10.1016/j.joca.2007.09.012
   Demidowich AP, 2016, MED HYPOTHESES, V92, P67, DOI 10.1016/j.mehy.2016.04.039
   Dixon SL, 2016, FUTURE MED CHEM, V8, P1825, DOI 10.4155/fmc 2016 0093
   Efferth T, 2022, SEMIN CANCER BIOL, V80, P39, DOI 10.1016/j.semcancer.2020.01.015
   El Sharkawy LY, 2020, MOLECULES, V25, DOI 10.3390/molecules25235533
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI 10.1093/nar/gkx1132
   Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041
   Franco Trepat E, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113671
   Franco Trepat E, 2022, BRIT J PHARMACOL, V179, P270, DOI 10.1111/bph.15707
   Frazao JB, 2013, ARCH IMMUNOL THER EX, V61, P427, DOI 10.1007/s00005 013 0243 0
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   GADHER SJ, 1988, EUR J BIOCHEM, V175, P1, DOI 10.1111/j.1432 1033.1988.tb14158.x
   Gerbeth K, 2011, J PHARMACEUT BIOMED, V56, P998, DOI 10.1016/j.jpba.2011.07.026
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   Gómez R, 2015, NAT REV RHEUMATOL, V11, P159, DOI 10.1038/nrrheum.2014.209
   Gómez R, 2011, NAT REV RHEUMATOL, V7, P528, DOI 10.1038/nrrheum.2011.107
   Goswami D, 2018, PHYTOMEDICINE, V51, P94, DOI 10.1016/j.phymed.2018.10.016
   Gupta S, 2018, CYTOKINE, V107, P93, DOI 10.1016/j.cyto.2017.12.004
   Ha SH, 2017, KOREAN J PHYSIOL PHA, V21, P531, DOI 10.4196/kjpp.2017.21.5.531
   Haglund L, 2008, MATRIX BIOL, V27, P107, DOI 10.1016/j.matbio.2007.09.009
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Han CW, 2019, COMB CHEM HIGH T SCR, V22, P483, DOI 10.2174/1386207322666190916120128
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Hussey SE, 2013, BIOSCIENCE REP, V33, P37, DOI 10.1042/BSR20120098
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022 2836(02)00470 9
   Karsdal MA, 2016, OSTEOARTHR CARTILAGE, V24, P2013, DOI 10.1016/j.joca.2016.07.017
   Kessler CS, 2015, RHEUMATOL INT, V35, P211, DOI 10.1007/s00296 014 3095 y
   Kimmatkar N, 2003, PHYTOMEDICINE, V10, P3, DOI 10.1078/094471103321648593
   Komander D, 2009, BIOCHEM SOC T, V37, P937, DOI 10.1042/BST0370937
   Kovács B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184653
   Krasselt M, 2019, EXPERT OPIN PHARMACO, V20, P1689, DOI 10.1080/14656566.2019.1645123
   LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167 4889(90)90145 4
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Li K, 2018, ANN RHEUM DIS, V77, P935, DOI 10.1136/annrheumdis 2017 212658
   Li XX, 2005, J MOL MED, V83, P258, DOI 10.1007/s00109 004 0622 4
   Litwic A., 2013, Epidemiology and Burden of Osteoarthritis, V44, P185, DOI [DOI 10.1093/BMB/LDS038.EPIDEMIOLOGY, 10.1093/bmb/lds038.Epidemiology]
   Loiarro M, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/674363
   López Pedrouso M, 2019, J PROTEOMICS, V205, DOI 10.1016/j.jprot.2019.103422
   Majeed M, 2019, PHYTOTHER RES, V33, P1457, DOI 10.1002/ptr.6338
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Martin MU, 2002, BBA MOL CELL RES, V1592, P265, DOI 10.1016/S0167 4889(02)00320 8
   Mathiessen A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1229 9
   Mertens M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005121.pub3
   Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331
   Mobasheri Ali, 2019, F1000Res, V8, DOI 10.12688/f1000research.20575.1
   MULLER CW, 1995, FEBS LETT, V369, P113, DOI 10.1016/0014 5793(95)00541 G
   Ohto U, 2012, P NATL ACAD SCI USA, V109, P7421, DOI 10.1073/pnas.1201193109
   Omega Biotek E.Z.N., 2012, TOTAL RNA KIT PRODUC
   Oo WM, 2018, EXPERT OPIN EMERG DR, V23, P331, DOI 10.1080/14728214.2018.1547706
   Park H, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74544 5
   Park Kyungsoo, 2019, Transl Clin Pharmacol, V27, P59, DOI 10.12793/tcp.2019.27.2.59
   Pascart T, 2017, EXPERT OPIN PHARMACO, V18, P1201, DOI 10.1080/14656566.2017.1351945
   Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455
   Pathania M, 2020, J FAM MED PRIM CARE, V9, P3826, DOI 10.4103/jfmpc.jfmpc_504_20
   Qing YF, 2013, GENE, V524, P412, DOI 10.1016/j.gene.2013.04.039
   Ranzato E, 2017, PHYTOMEDICINE, V36, P176, DOI 10.1016/j.phymed.2017.09.010
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Riva A, 2017, EUR REV MED PHARMACO, V21, P5258, DOI 10.26355/eurrev_201711_13849
   Roelofs AJ, 2020, ANN RHEUM DIS, V79, P1625, DOI 10.1136/annrheumdis 2020 218350
   Rousseau JC, 2012, BONE, V51, P265, DOI 10.1016/j.bone.2012.04.001
   Saito T, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1296 y
   Samarpita S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2097 2
   Sandall CF, 2020, MOLECULES, V25, DOI 10.3390/molecules25194572
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Schaible HG, 2018, CURR OPIN SUPPORT PA, V12, P148, DOI 10.1097/SPC.0000000000000334
   Shah SA, 2007, J CHROMATOGR B, V848, P232, DOI 10.1016/j.jchromb.2006.10.026
   Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586 019 1295 z
   Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050 MCP200
   Sinyeue C, 2022, MOLECULES, V27, DOI 10.3390/molecules27061781
   Sohn DH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3555
   Szekanecz Z, 2019, ARCH BIOCHEM BIOPHYS, V670, P82, DOI 10.1016/j.abb.2019.01.031
   Tapia Abelián A, 2019, NAT CHEM BIOL, V15, P560, DOI 10.1038/s41589 019 0278 6
   Tardif G, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02801 1
   Thomas E, 2014, RHEUMATOLOGY, V53, P338, DOI 10.1093/rheumatology/ket346
   Thummuri D, 2014, ENVIRON TOXICOL PHAR, V38, P58, DOI 10.1016/j.etap.2014.05.002
   Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664
   TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869
   Umar S, 2014, PHYTOMEDICINE, V21, P847, DOI 10.1016/j.phymed.2014.02.001
   United Nations, World Population Prospects Population Division United Nations, DOI DOI 10.1001/JAMAOPHTHALMOL.2018.5449
   VANDELOO AAJ, 1990, ANN RHEUM DIS, V49, P238, DOI 10.1136/ard.49.4.238
   VANDENBERG WB, 1988, ANN RHEUM DIS, V47, P855, DOI 10.1136/ard.47.10.855
   Villalvilla A, 2014, MOL NUTR FOOD RES, V58, P256, DOI 10.1002/mnfr.201200833
   Vina ER, 2018, CURR OPIN RHEUMATOL, V30, P160, DOI 10.1097/BOR.0000000000000479
   Vincent Tonia L, 2019, F1000Res, V8, DOI 10.12688/f1000research.18831.1
   Wang Q, 2014, OSTEOARTHR CARTILAGE, V22, P128, DOI 10.1016/j.joca.2013.10.012
   Whiteman M, 2006, OSTEOARTHR CARTILAGE, V14, P460, DOI 10.1016/j.joca.2005.11.002
   World Health Organization Disease Incidence Prevalence and Disability, 2004, GLOB BURD DIS 2004 U, V3, P28
   Xu GZ, 2011, NATURE, V472, P325, DOI 10.1038/nature09853
   Yang G, 2020, ARTHRITIS RHEUMATOL, V72, P1192, DOI 10.1002/art.41245
   Yang M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189884
   Zhou F, 2022, INT IMMUNOPHARMACOL, V110, DOI 10.1016/j.intimp.2022.109072
   Zhou YC, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0679 z
NR 117
TC 9
Z9 11
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD FEB
PY 2023
VL 12
IS 2
AR 371
DI 10.3390/antiox12020371
PG 26
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 9G4XK
UT WOS:000938157400001
PM 36829930
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tong, CJ
   Deng, QC
   Ou, DJ
   Long, X
   Liu, H
   Huang, K
AF Tong, Chang Jun
   Deng, Qing Chun
   Ou, Di Jun
   Long, Xia
   Liu, He
   Huang, Kang
TI lncRNA RUSC1 AS1 promotes osteosarcoma progression through regulating
   the miR 340 5p and in3K/AKT pathway
SO AGING US
LA English
DT Article
DE RUSC1 AS1; miR 340 5p; PI3K/AKT; osteosarcoma
ID CISPLATIN RESISTANCE; SIGNALING PATHWAY; BREAST CANCER; RNA;
   CHEMOTHERAPY; CONTRIBUTES; EXPRESSION; CHILDHOOD; THERAPY; SYSTEM
AB Dysregulation of long noncoding RNA (lncRNA) is frequently involved in the progression and development of osteosarcoma. LncRNA RUSC1 AS1 is reported to be upregulated and acts as an oncogene in hepatocellular carcinoma, cervical cancer and breast cancer. However, its role in osteosarcoma has not been studied yet. In the present study, we investigated the role of RUSC1 AS1 in osteosarcoma both in vitro and in vivo. The results showed that the expression of RUSC1 AS1 was significantly upregulated in osteosarcoma cell line U2OS and HOS compared to that in human osteoblast cell line hFOB1.19. Similar results were found in human samples. Silencing RUSC1 AS1 by siRNA significantly inhibited U2OS and HOS cell proliferation and invasion, measured by CCK 8 and transwell assay. Besides, knockdown of RUSC1 AS1 increased cell apoptosis in osteosarcoma cell lines. In addition, RUSC1 AS1 promoted the epithelial mesenchymal transition (EMT) process of osteosarcoma cells. In vivo experiments confirmed that RUSC1 AS1 knockdown had an inhibitory effect on osteosarcoma tumor growth. Mechanically, we showed that RUSC1 AS1 directly binds to and inhibits miR 340 5p and activates the PI3K/AKT signaling pathway. In conclusion, our study demonstrated that RUSC1 AS1 promoted osteosarcoma development both in vitro and in vivo through sponging to miR 340 5p and activating the PI3K/AKT signaling pathway. Therefore, RUSC1 AS1 becomes a potential therapeutic target for osteosarcoma.
C1 [Tong, Chang Jun; Ou, Di Jun; Liu, He; Huang, Kang] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Orthoped, Shenzhen 518000, Peoples R China.
   [Deng, Qing Chun] Hainan Med Univ, Affiliated Hosp 2, Dept Gynecol, Haikou 570102, Hainan, Peoples R China.
   [Long, Xia] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Operating Room, Shenzhen 518000, Peoples R China.
C3 Huazhong University of Science & Technology; Hainan Medical University;
   Huazhong University of Science & Technology
RP Huang, K (通讯作者)，Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Orthoped, Shenzhen 518000, Peoples R China.
EM huangkanghuster@163.com
OI Huang, Kang/0000 0003 1169 598X; deng, qingchun/0000 0001 7390 5271
FU Science and Technology Plan of Nanshan District of Shenzhen City, China
   [2020113]; Young Talents' Science and Technology Innovation Project of
   Hainan Association for Science and Technology [QCXM202018]
FX This study was supported by: Dr. Kang Huang: The Science and Technology
   Plan of Nanshan District of Shenzhen City, China (Grant number: No.
   2020113 (Normal) ) . Dr. Qing chun Deng: Young Talents' Science and
   Technology Innovation Project of Hainan Association for Science and
   Technology (QCXM202018) .
CR Algaber A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73792 9
   Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   CASSADY JR, 1973, CANCER AM CANCER SOC, V32, P598, DOI 10.1002/1097 0142(197309)32:3<598::AID CNCR2820320312>3.0.CO;2 7
   Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003
   Chen YA, 2020, NEOPLASMA, V67, P1204, DOI 10.4149/neo_2020_191010N1024
   Cheng B, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 019 1510 7
   CORTES EP, 1974, NEW ENGL J MED, V291, P998, DOI 10.1056/NEJM197411072911903
   Deng QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103022
   ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106
   Fletcher ChristopherDM., 2002, PATHOLOGY GENETICS T, V4
   Gao TY, 2015, MOL CARCINOGEN, V54, P359, DOI 10.1002/mc.22106
   Godinho MFE, 2012, BRIT J CANCER, V107, P947, DOI 10.1038/bjc.2012.351
   Godinho M, 2011, J CELL PHYSIOL, V226, P1741, DOI 10.1002/jcp.22503
   Gu XF, 2020, CANCER MED US, V9, P5719, DOI 10.1002/cam4.3275
   Guo QZ, 2020, CELL CYCLE, V19, P1222, DOI 10.1080/15384101.2020.1749468
   HARRIS MB, 1995, MED PEDIATR ONCOL, V24, P87, DOI 10.1002/mpo.2950240205
   Hu CC, 2019, EUR REV MED PHARMACO, V23, P6602, DOI 10.26355/eurrev_201908_18548
   Hui L, 2019, PEERJ, V7, DOI 10.7717/peerj.7456
   Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114586
   Martin Broto J, 2017, ANN ONCOL, V28, P2994, DOI 10.1093/annonc/mdx536
   Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008 5472.CAN 09 3880
   OCHS JJ, 1978, CANCER TREAT REP, V62, P239
   Reich NC, 2013, J INTERF CYTOK RES, V33, P199, DOI 10.1089/jir.2012.0159
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Rongxin S, 2019, EUR REV MED PHARMACO, V23, P982, DOI 10.26355/eurrev_201902_16985
   Sauerbrey A, 2001, BONE MARROW TRANSPL, V27, P933, DOI 10.1038/sj.bmt.1703023
   Schaukowitch K, 2014, NEUROSCIENCE, V264, P25, DOI 10.1016/j.neuroscience.2013.12.009
   Schwarz R, 2009, CANCER TREAT RES, V152, P147, DOI 10.1007/978 1 4419 0284 9_7
   Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013
   Sobin LH, 2002, TNM CLASSIFICATON MA, VSixth
   Sobin LH., 2011, TNM classification of malignant tumours
   Song L, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414 431X20176359, 10.1590/1414 431x20176359]
   Song L, 2019, J CELL BIOCHEM, V120, P9656, DOI 10.1002/jcb.28244
   Stiller CA, 2006, EUR J CANCER, V42, P2006, DOI 10.1016/j.ejca.2006.05.015
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Wang Y, 2017, ONCOTARGETS THER, V10, P5355, DOI 10.2147/OTT.S149889
   Wang Y, 2016, CANCER LETT, V382, P137, DOI 10.1016/j.canlet.2016.08.024
   Xia WK, 2016, ONCOTARGETS THER, V9, P4645, DOI 10.2147/OTT.S103376
   Xia Y, 2015, MOL MED REP, V12, P4530, DOI 10.3892/mmr.2015.3897
   Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013
   Yao Jie, 2015, Onco Targets Ther, V8, P3467, DOI 10.2147/OTT.S81393
   Yu X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1509 1
   Yue M, 2021, RNA BIOL, V18, P1981, DOI 10.1080/15476286.2021.1885232
   Zhang K, 2014, GENE, V547, P1, DOI 10.1016/j.gene.2014.06.043
   Zhang T, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.620320
   Zhao P, 2018, J ENDOCRINOL INVEST, V41, P1165, DOI 10.1007/s40618 018 0848 6
   Zhu KP, 2017, MOL THER, V25, P2383, DOI 10.1016/j.ymthe.2017.06.027
NR 47
TC 23
Z9 25
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD AUG 31
PY 2021
VL 13
IS 16
BP 20116
EP 20130
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA UK6RL
UT WOS:000692094800013
PM 34048366
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, TL
   Fu, XK
   Wang, N
   Yang, M
   Zhang, MY
   Wang, BX
   Chen, TK
   Majaz, S
   Wang, HY
   Wong, CW
   Liu, JS
   Guan, M
AF Huang, Tongling
   Fu, Xuekun
   Wang, Na
   Yang, Meng
   Zhang, Minyi
   Wang, Binxu
   Chen, Tianke
   Majaz, Sidra
   Wang, Huaiyu
   Wong, Chi Wai
   Liu, Jinsong
   Guan, Min
TI Andrographolide prevents bone loss via targeting estrogen related
   receptor α regulated metabolic adaption of osteoclastogenesis
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE andrographolide; energy metabolism; ERR alpha; glutaminase;
   osteoclastogenesis
ID VITAMIN E TPGS; ERR ALPHA; DIFFERENTIATION; ACTIVATION; PANICULATA;
   RESORPTION; GAMMA; IDENTIFICATION; INVOLVEMENT; EXPRESSION
AB Background and Purpose: Metabolic adaptation driven by oestrogen related receptor alpha (ERR alpha/NR3B1) is required to meet the increased energy demand during osteoclast differentiation. Here, we hypothesize that natural product, andrographolide, acts as an ERR alpha inverse agonist to inhibit osteoclastogenesis.
   Experimental Approach: Virtual docking and site directed mutagenesis analysis were employed to study the binding mode of andrographolide to ERR alpha. Co immunoprecipitation, luciferase reporter assay, real time polymerase chain reaction (PCR) and immunoblot analyses were performed to identify andrographolide as an ERR alpha inverse agonist. The pharmacological effects of andrographolide in vivo were assessed in mice models of osteopenia induced by either a high fat diet in male or ovariectomy in female mice.
   Key Results: ERR alpha dependent expression of glutaminase, a rate limiting enzyme of mitochondrial glutamine anaplerosis, is required for ex vivo bone marrow osteoclast differentiation. Andrographolide inhibited glutaminase expression induced by ERR alpha and co activator peroxisome proliferator activated receptor gamma co activator 1 beta (PGC 1 beta), leading to reduction in osteoclastogenesis. Andrographolide acted as an inverse agonist of ERR alpha by disrupting its interaction with co activator PGC 1 beta. Phenylalanine 232, valine 395 and phenylalanine 399 of ERR alpha ligand binding domain were confirmed to be essential for this effect. In contrast, glutaminase overexpression restored the impairment triggered by andrographolide. Accordingly, andrographolide suppressed osteoclastic bone resorption and attenuated bone loss in vivo.
   Conclusions and Implications: These findings demonstrate that andrographolide acts as an ERR alpha inverse agonist for perturbation of ERR alpha/PGC 1 beta/glutaminase axis driven metabolic adaption during osteoclast differentiation, implying that andrographolide may be a promising natural compound for preventing physiological and pathological bone loss.
C1 [Huang, Tongling; Fu, Xuekun; Yang, Meng; Zhang, Minyi; Wang, Binxu; Chen, Tianke; Majaz, Sidra; Wang, Huaiyu; Guan, Min] Chinese Acad Sci, Ctr Human Tissues & Organs Degenerat, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, 1068 Xueyuan Ave, Shenzhen 518055, Peoples R China.
   [Huang, Tongling] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Wong, Chi Wai] NeuMed Pharmaceut Ltd, Yuen Long, Hong Kong, Peoples R China.
   [Wang, Na; Liu, Jinsong] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Prov Key Lab Biocomp, Guangzhou, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS; Chinese Academy of Sciences; Guangzhou Institute of
   Biomedicine & Health, CAS
RP Guan, M (通讯作者)，Chinese Acad Sci, Ctr Human Tissues & Organs Degenerat, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, 1068 Xueyuan Ave, Shenzhen 518055, Peoples R China.
EM min.guan@siat.ac.cn
RI ; Wang, Huaiyu/S 7019 2019; Fu, Xuekun/ABC 7179 2021
OI Guan, Min/0000 0003 3851 8553; Majaz, Sidra/0000 0003 3467 6984; Fu,
   Xuekun/0000 0002 8208 9939; 
FU Science and Technology Planning Project of Guangdong Province
   [2015A030312017]; Guangdong Provincial Key Laboratory of Biocomputing
   [2016B030301007]; Tip top Scientific and Technical Innovative Youth
   Talents of Guangdong Special Support Program [2017TQ04R394]; Shenzhen
   Science and Technology Research Funding [20170502171625936,
   KQJSCX20180330170052049]; National Natural Science Foundation of China
   [31770817, 81770882, 82072493]; National Key R&D Program of China
   [2018YFA0703100]
FX Science and Technology Planning Project of Guangdong Province,
   Grant/Award Number: 2015A030312017; Guangdong Provincial Key Laboratory
   of Biocomputing, Grant/Award Number: 2016B030301007; Tip top Scientific
   and Technical Innovative Youth Talents of Guangdong Special Support
   Program, Grant/Award Number: 2017TQ04R394; Shenzhen Science and
   Technology Research Funding, Grant/Award Numbers: 20170502171625936,
   KQJSCX20180330170052049; National Natural Science Foundation of China,
   Grant/Award Numbers: 31770817, 81770882, 82072493; National Key R&D
   Program of China, Grant/Award Number: 2018YFA0703100
CR Agarwal R, 2005, MALAYS J MED SCI, V12, P13
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS229, DOI 10.1111/bph.14750
   Alexander SPH, 2018, BRIT J PHARMACOL, V175, P407, DOI 10.1111/bph.14112
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Bertoglio JC, 2016, BMC NEUROL, V16, DOI 10.1186/s12883 016 0595 2
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Bonnelye E, 2010, J MOL ENDOCRINOL, V45, P365, DOI 10.1677/JME 10 0024
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Busch BB, 2004, J MED CHEM, V47, P5593, DOI 10.1021/jm049334f
   Carson JA, 2015, BONE, V80, P67, DOI 10.1016/j.bone.2015.04.015
   Chang YY, 2019, J ORTHOP TRANSL, V19, P47, DOI 10.1016/j.jot.2019.02.001
   Chaveroux C, 2013, CELL METAB, V17, P586, DOI 10.1016/j.cmet.2013.03.003
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Czupalla C, 2005, PROTEOMICS, V5, P3868, DOI 10.1002/pmic.200402059
   Ding LL, 2014, J PHARMACOL EXP THER, V351, P474, DOI 10.1124/jpet.114.217968
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI [10.1186/s12917 020 02451 y, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823]
   Du YL, 2017, EUR J MED CHEM, V136, P457, DOI 10.1016/j.ejmech.2017.04.050
   Eichner LJ, 2011, MITOCHONDRION, V11, P544, DOI 10.1016/j.mito.2011.03.121
   Garnero P., 2004, Encyclopedia of Endocrine Diseases, V1, P401, DOI 10.1016/B0 12 475570 4/00218 3
   Goulding A, 2000, INT J OBESITY, V24, P627, DOI 10.1038/sj.ijo.0801207
   Guo YY, 2013, EUR J PHARM SCI, V49, P175, DOI 10.1016/j.ejps.2013.02.006
   Hancke JL, 2019, PHYTOTHER RES, V33, P1469, DOI 10.1002/ptr.6339
   HANDA SS, 1990, INDIAN J MED RES B, V92, P276
   Huang TL, 2017, STEM CELLS, V35, P411, DOI 10.1002/stem.2470
   Huss JM, 2015, BBA MOL BASIS DIS, V1852, P1912, DOI 10.1016/j.bbadis.2015.06.016
   Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200
   Hwang DK, 2010, OSTEOPOROSIS INT, V21, P425, DOI 10.1007/s00198 009 0990 2
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024
   Jiang TM, 2015, CELL PHYSIOL BIOCHEM, V36, P2327, DOI 10.1159/000430196
   Jin LN, 2012, MOL CELL ENDOCRINOL, V358, P81, DOI 10.1016/j.mce.2012.02.025
   Jin LN, 2011, MOL CELL ENDOCRINOL, V332, P134, DOI 10.1016/j.mce.2010.10.005
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   King CM, 2012, J FOOT ANKLE SURG, V51, P543, DOI 10.1053/j.jfas.2012.05.016
   Larsen Peter, 2019, Joints, V7, P8, DOI 10.1055/s 0039 1697612
   Lee SK, 2006, J BONE MINER RES, V21, P695, DOI 10.1359/JBMR.060117
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Lilley E, 2020, BRIT J PHARMACOL, V177, P3611, DOI 10.1111/bph.15178
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   McCabe LR, 2019, BONE, V118, P20, DOI 10.1016/j.bone.2018.03.024
   McGuirk S, 2013, CANCER METAB, V1, DOI 10.1186/2049 3002 1 22
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Moller AMJ, 2017, J CELL PHYSIOL, V232, P1396, DOI 10.1002/jcp.25633
   Oburoglu L, 2014, CELL STEM CELL, V15, P169, DOI 10.1016/j.stem.2014.06.002
   Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182
   Patch RJ, 2011, J MED CHEM, V54, P788, DOI 10.1021/jm101063h
   Pulgaron ER, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892 014 0508 y
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ren YQ, 2015, GENET MOL RES, V14, P15955, DOI 10.4238/2015.December.7.7
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Sambandam Y, 2017, BONE, V101, P236, DOI 10.1016/j.bone.2017.05.013
   Sandborn WJ, 2013, AM J GASTROENTEROL, V108, P90, DOI 10.1038/ajg.2012.340
   Shao D, 2010, MITOCHONDRION, V10, P516, DOI 10.1016/j.mito.2010.05.012
   Shu L, 2015, CALCIFIED TISSUE INT, V96, P313, DOI 10.1007/s00223 015 9954 z
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Uddin Md Kamal, 2014, ScientificWorldJournal, V2014, P951019, DOI 10.1155/2014/951019
   Vekic J, 2019, METABOLISM, V92, P71, DOI 10.1016/j.metabol.2018.11.005
   Villena JA, 2008, TRENDS ENDOCRIN MET, V19, P269, DOI 10.1016/j.tem.2008.07.005
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Yang CL, 2018, THERANOSTICS, V8, P464, DOI 10.7150/thno.22711
   Yao GQ, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.22
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhang JJ, 2019, INT J NEUROPSYCHOPH, V22, P585, DOI 10.1093/ijnp/pyz032
   Zhang Y, 2018, J BONE MINER RES, V33, P1114, DOI 10.1002/jbmr.3398
NR 68
TC 8
Z9 9
U1 1
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2021
VL 178
IS 21
BP 4352
EP 4367
DI 10.1111/bph.15614
EA AUG 2021
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WI7NN
UT WOS:000687778500001
PM 34233019
OA Bronze
DA 2025 08 17
ER

PT J
AU Grol, MW
   Zelner, I
   Dixon, SJ
AF Grol, Matthew W.
   Zelner, Irene
   Dixon, S. Jeffrey
TI P2X7 mediated calcium influx triggers a sustained,
   PI3K dependent increase in metabolic acid production by osteoblast like
   cells
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE adenosine 5' triphosphate; microphysiometer; proton efflux;
   phosphatidylinositol 3 kinase; metabolism
ID P2X(7) NUCLEOTIDE RECEPTOR; IN VITRO; PHARMACOLOGICAL CHARACTERIZATION;
   PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL TRANSDUCTION; P2X7 RECEPTORS;
   DIFFERENTIATION; ACTIVATION; KINASE; PHOSPHORYLATION
AB Grol MW, Zelner I, Dixon SJ. P2X(7) mediated calcium influx triggers a sustained, PI3K dependent increase in metabolic acid production by osteoblast like cells. Am J Physiol Endocrinol Metab 302: E561 E575, 2012. First published December 20, 2011; doi:10.1152/ajpendo.00209.2011. The P2X(7) receptor is an ATP gated cation channel expressed by a number of cell types, including osteoblasts. Genetically modified mice with loss of P2X(7) function exhibit altered bone formation. Moreover, activation of P2X(7) in vitro stimulates osteoblast differentiation and matrix mineralization, although the underlying mechanisms remain unclear. Because osteogenesis is associated with enhanced cellular metabolism, our goal was to characterize the effects of nucleotides on metabolic acid production (proton efflux) by osteoblasts. The P2X(7) agonist 2', 3' O (4 benzoylbenzoyl) ATP (BzATP; 300 mu M) induced dynamic membrane blebbing in MC3T3 E1 osteoblast like cells (consistent with activation of P2X(7) receptors) but did not induce cell death. Using a Cytosensor microphysiometer, we found that 9 min exposure to BzATP (300 mu M) caused a dramatic increase in proton efflux from MC3T3 E1 cells (similar to 2 fold), which was sustained for at least 1 h. In contrast, ATP or UTP (100 mu M), which activate P2 receptors other than P2X(7), failed to elicit a sustained increase in proton efflux. Specific P2X(7) receptor antagonists A 438079 and A 740003 inhibited the sustained phase of the BzATP induced response. Extracellular Ca2+ was required during P2X(7) receptor stimulation for initiation of sustained proton efflux, and removal of extracellular glucose within the sustained phase abolished the elevation elicited by BzATP. In addition, inhibition of phosphatidylinositol 3 kinase blocked the maintenance but not initiation of the sustained phase. Taken together, we conclude that brief activation of P2X(7) receptors on osteoblast like cells triggers a dramatic, Ca2+  dependent stimulation of metabolic acid production. This increase in proton efflux is sustained and dependent on glucose and phosphatidylinositol 3 kinase activity.
C1 [Zelner, Irene; Dixon, S. Jeffrey] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.
   [Grol, Matthew W.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Dixon, SJ (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.
EM jeff.dixon@schulich.uwo.ca
RI Grol, Matthew William/HOF 9774 2023; Grol, Matthew/HOF 9774 2023; Dixon,
   S. Jeffrey/G 3657 2013; Dixon, S./G 3657 2013
OI Grol, Matthew William/0000 0001 6514 9066; Dixon, S.
   Jeffrey/0000 0001 9162 1686; 
FU Canadian Institutes of Health Research (CIHR); Charles Best Canada
   Graduate Scholarship Doctoral Award
FX This study was funded by the Canadian Institutes of Health Research
   (CIHR). M. W. Grol is supported by a CIHR Frederick Banting and Charles
   Best Canada Graduate Scholarship Doctoral Award.
CR Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04 11 1025
   Adinolfi Elena, 2005, Purinergic Signal, V1, P219, DOI 10.1007/s11302 005 6322 x
   Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756 3282(95)00486 6
   Austin C, 2000, CIRC RES, V86, P355, DOI 10.1161/01.RES.86.3.355
   BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377
   Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014 2999(99)00350 7
   Burnstock G, 2008, J PHYSIOL LONDON, V586, P3307, DOI 10.1113/jphysiol.2008.155903
   Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909
   Denton RM, 2009, BBA BIOENERGETICS, V1787, P1309, DOI 10.1016/j.bbabio.2009.01.005
   Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098 2299(200003)49:3<187::AID DDR9>3.0.CO;2 F
   Dixon SJ, 2004, GLIA, V47, P367, DOI 10.1002/glia.20048
   Donnelly Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.160
   Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846
   Gendron FP, 2003, AM J PHYSIOL CELL PH, V284, pC571, DOI 10.1152/ajpcell.00286.2002
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Gómez Villafuertes R, 2009, FEBS J, V276, P5307, DOI 10.1111/j.1742 4658.2009.07228.x
   Griffiths EJ, 2009, BBA BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   Gudipaty L, 2003, AM J PHYSIOL CELL PH, V285, pC286, DOI 10.1152/ajpcell.00070.2003
   Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Jacques Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886
   Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347
   KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960 9822(00)00177 9
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Komarova SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220, DOI 10.1152/ajpcell.2000.279.4.C1220
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Liu YP, 2010, J NEUROCHEM, V113, P213, DOI 10.1111/j.1471 4159.2010.06589.x
   MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199
   Mistafa O, 2008, BIOCHEM BIOPH RES CO, V365, P131, DOI 10.1016/j.bbrc.2007.10.148
   Mistafa O, 2009, BIOCHEM PHARMACOL, V78, P1115, DOI 10.1016/j.bcp.2009.06.016
   Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200
   Nelson DW, 2006, J MED CHEM, V49, P3659, DOI 10.1021/jm051202e
   Nicke A, 2009, J BIOL CHEM, V284, P25813, DOI 10.1074/jbc.M109.033134
   North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002
   Okada Y, 2002, EUR J PHARMACOL, V455, P19, DOI 10.1016/S0014 2999(02)02556 6
   Okumura H, 2008, BIOCHEM BIOPH RES CO, V372, P486, DOI 10.1016/j.bbrc.2008.05.066
   Orriss IR, 2010, CURR OPIN PHARMACOL, V10, P322, DOI 10.1016/j.coph.2010.01.003
   Ortega F, 2010, CELL MOL LIFE SCI, V67, P1723, DOI 10.1007/s00018 010 0278 x
   Ortega F, 2009, NEUROTOX RES, V15, P193, DOI 10.1007/s12640 009 9020 6
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Panupinthu N, 2007, J BIOL CHEM, V282, P3403, DOI 10.1074/jbc.M605620200
   PARTRIDGE NC, 1983, CANCER RES, V43, P4308
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Pereverzev A, 2008, BONE, V42, P150, DOI 10.1016/j.bone.2007.08.044
   Qi J, 2007, J APPL PHYSIOL, V102, P1152, DOI 10.1152/japplphysiol.00535.2006
   Qu Y, 2009, PURINERG SIGNAL, V5, P163, DOI 10.1007/s11302 009 9132 8
   REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Santhanagopal A, 1999, AM J PHYSIOL ENDOC M, V277, pE423, DOI 10.1152/ajpendo.1999.277.3.E423
   Santhanagopal A, 2001, ENDOCRINOLOGY, V142, P4401, DOI 10.1210/en.142.10.4401
   Smart D, 2000, BIOCHEM CELL BIOL, V78, P281, DOI 10.1139/bcb 78 3 281
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Taylor SRJ, 2009, J LEUKOCYTE BIOL, V85, P978, DOI 10.1189/jlb.0408251
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147
NR 65
TC 36
Z9 41
U1 1
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD MAR
PY 2012
VL 302
IS 5
BP E561
EP E575
DI 10.1152/ajpendo.00209.2011
PG 15
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 898FR
UT WOS:000300723500009
PM 22185840
DA 2025 08 17
ER

PT J
AU Lüder, E
   Ramer, R
   Peters, K
   Hinz, B
AF Lueder, Ellen
   Ramer, Robert
   Peters, Kirsten
   Hinz, Burkhard
TI Decisive role of P42/44 mitogen activated protein kinase in
   Δ<SUP>9</SUP> tetrahydrocannabinol induced migration of human
   mesenchymal stem cells
SO ONCOTARGET
LA English
DT Article
DE migration; stem cells; THC; p42/44 MAPK
ID PERIPHERAL CANNABINOID RECEPTOR; BONE MASS; OSTEOCLAST FUNCTION;
   IN VITRO; CANNABIDIOL; DIFFERENTIATION; INHIBITION; EXPRESSION; GPR55;
   CB2
AB In past years, medical interest in.9 tetrahydrocannabinol (THC), the major psychoactive ingredient of the Cannabis plant, has been renewed due to the elucidation of the endocannabinoid system and diverse other receptor targets involved in biological cannabinoid effects. The present study therefore investigates the impact of THC on the migration of mesenchymal stem cells (MSCs) which are known to be involved in various regenerative processes such as bone healing. Using Boyden chamber assays, THC was found to increase the migration of adipose derived MSCs. Migration by THC was almost completely suppressed by the CB1 receptor antagonist AM 251 and to a lesser extent by the CB2 receptor antagonist AM 630. By contrast, the TRPV1 antagonist capsazepine as well as the G protein coupled receptor 55 (GRP55) agonist O 1602 did not significantly interfere with the promigratory effect of THC. Furthermore, increased migration by THC was fully suppressed by PD98059, an inhibitor of p42/44 mitogen activated protein kinase (MAPK) activation, and was accompanied by a time dependent activation of this pathway accordingly. In line with the migration data, additional inhibitor experiments pointed towards a decisive role of the CB1 receptor in conferring THC induced activation of p42/44 MAPK. Collectively, this study demonstrates THC to exert a promigratory effect on MSCs via a CB1 receptordependent activation of p42/44 MAPK phosphorylation. This pathway may be involved in regenerative effects of THC and could be a target of pharmacological intervention.
C1 [Lueder, Ellen; Ramer, Robert; Hinz, Burkhard] Rostock Univ, Med Ctr, Inst Pharmacol & Toxicol, Rostock, Germany.
   [Lueder, Ellen; Peters, Kirsten] Rostock Univ, Med Ctr, Dept Cell Biol, Rostock, Germany.
C3 University of Rostock; University of Rostock
RP Hinz, B (通讯作者)，Rostock Univ, Med Ctr, Inst Pharmacol & Toxicol, Rostock, Germany.
EM burkhard.hinz@med.uni rostock.de
RI Peters, Kirsten/S 3484 2016
OI Peters, Kirsten/0000 0003 0254 176X
FU FORUN program of the Medical Faculty, University of Rostock
FX This study was supported by the FORUN program of the Medical Faculty,
   University of Rostock.
CR Augello A, 2010, EUR CELLS MATER, V20, P121
   Bakhshayesh M, 2012, INFLAMMATION, V35, P138, DOI 10.1007/s10753 011 9298 4
   Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902
   Chiurchiù V, 2015, INT IMMUNOL, V27, P153, DOI 10.1093/intimm/dxu097
   Choi HJ, 2011, J KOREAN MED SCI, V26, P482, DOI 10.3346/jkms.2011.26.4.482
   De Bari C, 2008, BIO MED MATER ENG, V18, pS11
   De Filippis D, 2008, NEUROGASTROENT MOTIL, V20, P919, DOI 10.1111/j.1365 2982.2008.01114.x
   Fiedler J, 2002, J CELL BIOCHEM, V87, P305, DOI 10.1002/jcb.10309
   Fraga D, 2011, J NEUROIMMUNE PHARM, V6, P566, DOI 10.1007/s11481 011 9291 6
   Gao H, 2009, STEM CELLS, V27, P857, DOI 10.1002/stem.23
   Gowran A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/796715
   Herzmann N, 2016, EXP CELL RES, V342, P95, DOI 10.1016/j.yexcr.2016.03.016
   Huang J, 2010, CIRC RES, V106, P1753, DOI 10.1161/CIRCRESAHA.109.196030
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Izzo AA, 2009, PHARMACOL RES, V60, P117, DOI 10.1016/j.phrs.2009.03.008
   Johns DG, 2007, BRIT J PHARMACOL, V152, P825, DOI 10.1038/sj.bjp.0707419
   Karschner EL, 2011, CLIN CHEM, V57, P66, DOI 10.1373/clinchem.2010.152439
   Kogan NM, 2015, J BONE MINER RES, V30, P1905, DOI 10.1002/jbmr.2513
   Kozono S, 2010, BIOCHEM BIOPH RES CO, V394, P928, DOI 10.1016/j.bbrc.2010.03.080
   Kramer JL, 2015, CA CANCER J CLIN, V65, P109, DOI 10.3322/caac.21260
   Lakshminarasimhan H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04634 4
   Lam PMW, 2005, BRIT J ANAESTH, V94, P649, DOI 10.1093/bja/aei098
   Lamarca A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098998
   Landeros RV, 2017, J PHYSIOL LONDON, V595, P4663, DOI 10.1113/JP274119
   Leelawat S, 2010, CANCER INVEST, V28, P357, DOI 10.3109/07357900903405934
   MacLennan S., 1998, S CANN BURL VERM USA, P7
   Mann A, 2015, J NEUROIMMUNE PHARM, V10, P356, DOI 10.1007/s11481 015 9595 z
   Massi P, 2004, J PHARMACOL EXP THER, V308, P838, DOI 10.1124/jpet.103.061002
   McHugh D, 2012, BRIT J PHARMACOL, V165, P2414, DOI 10.1111/j.1476 5381.2011.01497.x
   Meyer J, 2015, AESTHET SURG J, V35, P1030, DOI 10.1093/asj/sjv075
   Naef M, 2004, J PHARM SCI US, V93, P1176, DOI 10.1002/jps.20037
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Raborn ES, 2010, J PHARMACOL EXP THER, V333, P319, DOI 10.1124/jpet.109.163055
   Ramer R, 2003, MOL PHARMACOL, V64, P1189, DOI 10.1124/mol.64.5.1189
   Ramer R, 2008, J NATL CANCER I, V100, P59, DOI 10.1093/jnci/djm268
   Ramer R, 2010, BIOCHEM PHARMACOL, V80, P846, DOI 10.1016/j.bcp.2010.05.010
   Rhee MH, 1997, J MED CHEM, V40, P3228, DOI 10.1021/jm970126f
   Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460
   Sacerdote P, 2005, J NEUROIMMUNOL, V159, P97, DOI 10.1016/j.jneuroim.2004.10.003
   Salamon A, 2013, EXP CELL RES, V319, P2856, DOI 10.1016/j.yexcr.2013.09.008
   Schilling T, 2009, J CELL PHYSIOL, V221, P325, DOI 10.1002/jcp.21857
   Schmuhl E, 2014, BIOCHEM PHARMACOL, V87, P489, DOI 10.1016/j.bcp.2013.11.016
   Shoji T, 2010, LAB INVEST, V90, P637, DOI 10.1038/labinvest.2010.39
   Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Walker JL, 2010, P NATL ACAD SCI USA, V107, P13730, DOI 10.1073/pnas.0910382107
   Waning J, 2007, CELL CALCIUM, V42, P17, DOI 10.1016/j.ceca.2006.11.005
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Wollank Y, 2015, J LIPID RES, V56, P1947, DOI 10.1194/jlr.M061473
   Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026
   Yang H, 2010, EXP EYE RES, V91, P462, DOI 10.1016/j.exer.2010.06.022
   Yao W, 2013, STEM CELLS, V31, P2003, DOI 10.1002/stem.1461
   Yu TS, 2010, INT J LEGAL MED, V124, P397, DOI 10.1007/s00414 010 0465 1
   Yun DH, 2009, EXP MOL MED, V41, P17, DOI 10.3858/emm.2009.41.1.003
   Zhang X, 2010, BRIT J PHARMACOL, V160, P1583, DOI 10.1111/j.1476 5381.2010.00841.x
NR 59
TC 5
Z9 5
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 1
PY 2017
VL 8
IS 62
BP 105984
EP 105994
DI 10.18632/oncotarget.22517
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FS1UI
UT WOS:000419563600103
PM 29285308
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Klauschen, F
   Ishii, M
   Qi, H
   Bajénoff, M
   Egen, JG
   Germain, RN
   Meier Schellersheim, M
AF Klauschen, Frederick
   Ishii, Masaru
   Qi, Hai
   Bajenoff, Marc
   Egen, Jackson G.
   Germain, Ronald N.
   Meier Schellersheim, Martin
TI Quantifying cellular interaction dynamics in 3D fluorescence microscopy
   data
SO NATURE PROTOCOLS
LA English
DT Article
ID BONE; OSTEOCLAST; COMPONENT; RECEPTOR; CELLS
AB The wealth of information available from advanced fluorescence imaging techniques used to analyze biological processes with high spatial and temporal resolution calls for high throughput image analysis methods. Here, we describe a fully automated approach to analyzing cellular interaction behavior in 3D fluorescence microscopy images. As example application, we present the analysis of drug induced and S1P(1) knockout related changes in bone osteoclast interactions. Moreover, we apply our approach to images showing the spatial association of dendritic cells with the fibroblastic reticular cell network within lymph nodes and to microscopy data regarding T B lymphocyte synapse formation. Such analyses that yield important information about the molecular mechanisms determining cellular interaction behavior would be very difficult to perform with approaches that rely on manual/semi automated analyses. This protocol integrates adaptive threshold segmentation, object detection, adaptive color channel merging, and neighborhood analysis and permits rapid, standardized, quantitative analysis and comparison of the relevant features in large data sets.
C1 [Klauschen, Frederick; Germain, Ronald N.; Meier Schellersheim, Martin] NIAID, Program Syst Immunol & Infect Dis Modeling, NIH, Bethesda, MD 20892 USA.
   [Klauschen, Frederick] Univ Med Berlin, Inst Pathol, Berlin, Germany.
   [Ishii, Masaru; Qi, Hai; Bajenoff, Marc; Egen, Jackson G.; Germain, Ronald N.] NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Allergy & Infectious Diseases (NIAID); Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   National Institutes of Health (NIH)   USA; NIH National Institute of
   Allergy & Infectious Diseases (NIAID)
RP Klauschen, F (通讯作者)，NIAID, Program Syst Immunol & Infect Dis Modeling, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM fklauschen@mail.nih.gov; mms@niaid.nih.gov
RI Germain, Ronald/Z 1945 2019; Klauschen, Frederick/C 5637 2015; Qi,
   Hai/A 3955 2009
OI Klauschen, Frederick/0000 0002 9131 2389; Egen,
   Jackson/0000 0003 2053 0837; Qi, Hai/0000 0001 5475 3989
FU NIAID; NIH; International Human Frontier Science Program
FX This research was supported by the Intramural Research Program of NIAID,
   NIH. M. I. was supported by a fellowship grant from the International
   Human Frontier Science Program.
CR Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651
   Fisher DT, 2006, IMMUNOL INVEST, V35, P251, DOI 10.1080/08820130600745430
   Germain RN, 2005, SEMIN IMMUNOL, V17, P431, DOI 10.1016/j.smim.2005.09.003
   Henrickson SE, 2008, NAT IMMUNOL, V9, P282, DOI 10.1038/ni1559
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kervrann C, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, P788
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nishida Hideko, 2007, Brain and Nerve (Tokyo), V59, P755
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345
   Sezgin M, 2004, J ELECTRON IMAGING, V13, P146, DOI 10.1117/1.1631315
   Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065
   Suzuki K, 2003, COMPUT VIS IMAGE UND, V89, P1, DOI 10.1016/S1077 3142(02)00030 9
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Wollman R, 2007, J CELL SCI, V120, P3715, DOI 10.1242/jcs.013623
   Xu X, 2007, J CELL BIOL, V178, P141, DOI 10.1083/jcb.200611096
   Yamada C, 2008, ENDOCRINOLOGY, V149, P574, DOI 10.1210/en.2007 1292
NR 19
TC 34
Z9 36
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754 2189
EI 1750 2799
J9 NAT PROTOC
JI Nat. Protoc.
PY 2009
VL 4
IS 9
BP 1305
EP 1312
DI 10.1038/nprot.2009.129
PG 8
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 504FQ
UT WOS:000270601700008
PM 19696749
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rahman, MM
   Fernandes, G
   Williams, P
AF Rahman, Md Mizanur
   Fernandes, Gabriel
   Williams, Paul
TI Conjugated Linoleic Acid Prevents Ovariectomy Induced Bone Loss in Mice
   by Modulating Both Osteoclastogenesis and Osteoblastogenesis
SO LIPIDS
LA English
DT Article
DE Osteoporosis; Ovariectomy; Bone mineral density; Osteoclastogenesis;
   Osteoblastogenesis; Inflammation
ID ESTROGEN RECEPTOR ALPHA; LEAN BODY MASS; NF KAPPA B; MINERAL DENSITY;
   GENE EXPRESSION; FATTY ACIDS; OSTEOPROTEGERIN LIGAND;
   CALCIUM ABSORPTION; IMMUNE FUNCTION; FISH OIL
AB Postmenopausal osteoporosis due to estrogen deficiency is associated with severe morbidity and mortality. Beneficial effects of conjugated linoleic acid (CLA) on bone mineral density (BMD) have been reported in mice, rats and humans, but the effect of long term CLA supplementation against ovariectomy induced bone loss in mice and the mechanisms underlying this effect have not been studied yet. Eight week old ovariectomized (Ovx) and sham operated C57BL/6 mice were fed either a diet containing 0.5 % safflower oil (SFO) or 0.5 % CLA for 24 weeks to examine BMD, bone turn over markers and osteotropic factors. Bone marrow (BM) cells were cultured to determine the effect on inflammation, osteoclastogenesis, and osteoblastogenesis. SFO/Ovx mice had significantly lower femoral, tibial and lumbar BMD compared to SFO/Sham mice; whereas, no difference was found between CLA/Ovx and CLA/Sham mice. CLA inhibited bone resorption markers whereas enhanced bone formation markers in Ovx mice as compared to SFO fed mice. Reverse transcriptase polymerase chain reaction and fluorescence activated cell sorting analyses of splenocytes revealed that CLA inhibited pro osteoclastogenic receptor activator of NF kappa B (RANKL) and stimulated decoy receptor of RANKL, osteoprotegerin expression. CLA also inhibited pro inflammatory cytokine and enhanced anti inflammatory cytokine production of lipopolysaccharide stimulated splenocytes and BM cells. Furthermore, CLA inhibited osteoclast differentiation in BM and stimulated osteoblast differentiation in BM stromal cells as confirmed by tartrate resistant acid phosphatase and Alizarin Red staining, respectively. In conclusion, CLA may prevent postmenopausal bone loss not only by inhibiting excessive bone resorption due to estrogen deficiency but also by stimulating new bone formation. CLA might be a potential alternative therapy against osteoporotic bone loss.
C1 [Rahman, Md Mizanur; Fernandes, Gabriel; Williams, Paul] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Immunol & Rheumatol, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Rahman, MM (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Immunol & Rheumatol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM rahmanm@uthscsa.edu
RI Rahman, Mizanur/N 7076 2013; Williams, Paul/MIO 5156 2025
FU NIH [NIH AG034233]
FX We acknowledge Emily Molina for her kind review of our manuscript for
   grammatical corrections. We are grateful to Dr. Harris for providing
   alpha SMA positive BM stromal cells. This study was supported by NIH
   grant numbers, NIH AG034233 (M.M.R.).
CR Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Banu J, 2008, J BONE MINER METAB, V26, P436, DOI 10.1007/s00774 008 0863 3
   Banu J, 2006, LIPIDS HEALTH DIS, V5, DOI 10.1186/1476 511X 5 7
   Barbour KE, 2012, J BONE MINER RES, V27, P1167, DOI 10.1002/jbmr.1559
   BARLET JP, 1994, REPROD NUTR DEV, V34, P221, DOI 10.1051/rnd:19940305
   Belury MA, 2002, ANNU REV NUTR, V22, P505, DOI 10.1146/annurev.nutr.22.021302.121842
   Bhattacharya A, 2005, J NUTR, V135, P1124, DOI 10.1093/jn/135.5.1124
   Bhattacharya A, 2005, J AM COLL NUTR, V24, P200, DOI 10.1080/07315724.2005.10719466
   Bhattacharya A, 2007, J NUTR BIOCHEM, V18, P372, DOI 10.1016/j.jnutbio.2006.07.002
   Bhattacharya A, 2006, J NUTR BIOCHEM, V17, P789, DOI 10.1016/j.jnutbio.2006.02.009
   Bhattacharya A, 2006, LIPIDS, V41, P437, DOI 10.1007/s11745 006 5117 3
   Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943
   Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   Brownbill RA, 2005, J AM COLL NUTR, V24, P177, DOI 10.1080/07315724.2005.10719463
   DeGuire JR, 2012, NUTR RES, V32, P911, DOI 10.1016/j.nutres.2012.08.006
   Demaree SR, 2002, J NUTR, V132, P3272, DOI 10.1093/jn/132.11.3272
   Dilzer Allison, 2012, Crit Rev Food Sci Nutr, V52, P488, DOI 10.1080/10408398.2010.501409
   Doyle L, 2005, EUR J CLIN NUTR, V59, P432, DOI 10.1038/sj.ejcn.1602093
   Durgam VR, 1997, CANCER LETT, V116, P121, DOI 10.1016/S0304 3835(97)00192 4
   Evans KR, 2007, CANCER LETT, V249, P1, DOI 10.1016/j.canlet.2006.12.033
   Halade GV, 2011, J NUTR BIOCHEM, V22, P459, DOI 10.1016/j.jnutbio.2010.03.015
   Halade GV, 2010, J NUTR BIOCHEM, V21, P332, DOI 10.1016/j.jnutbio.2009.01.006
   Halade GV, 2009, EUR J NUTR, V48, P409, DOI 10.1007/s00394 009 0029 7
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jain Tarun Pankaj, 2012, Indian J Radiol Imaging, V22, P178, DOI 10.4103/0971 3026.107178
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kanaya N, 2010, NUTR RES, V30, P714, DOI 10.1016/j.nutres.2010.09.001
   Kelly O, 2004, PROSTAG LEUKOTR ESS, V71, P295, DOI 10.1016/j.plefa.2004.04.003
   Kelly O, 2003, BRIT J NUTR, V90, P743, DOI 10.1079/BJN2003951
   Kim J, 2013, J NUTR BIOCHEM, V24, P672, DOI 10.1016/j.jnutbio.2012.03.017
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Lawson RE, 2001, NUTR RES REV, V14, P153, DOI [10.1079/095442201108729178, 10.1079/NRR200121]
   Li Y, 1999, J BONE MINER RES, V14, P1153, DOI 10.1359/jbmr.1999.14.7.1153
   Liu DW, 2006, EUR J ORAL SCI, V114, P42, DOI 10.1111/j.1600 0722.2006.00283.x
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   McCarthy C, 2013, FASEB J, V27, P499, DOI 10.1096/fj.12 215442
   Moon J, 2013, ARCH ORTHOP TRAUM SU, V133, P889, DOI 10.1007/s00402 013 1760 3
   Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47
   NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem 65 4 697
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Owens JM, 1996, J IMMUNOL, V157, P936
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745 997 0109 x
   Park Y, 2013, FOOD CHEM, V140, P280, DOI 10.1016/j.foodchem.2012.12.067
   Platt I, 2007, EXP BIOL MED, V232, P246
   Platt I, 2009, LIPIDS HEALTH DIS, V8, DOI 10.1186/1476 511X 8 15
   Platt ID, 2009, J NUTR BIOCHEM, V20, P956, DOI 10.1016/j.jnutbio.2008.08.008
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Rahman MM, 2011, J CELL PHYSIOL, V226, P2406, DOI 10.1002/jcp.22578
   Rahman MM, 2009, BIOCHEM BIOPH RES CO, V383, P513, DOI 10.1016/j.bbrc.2009.04.071
   Rahman MM, 2007, J NUTR BIOCHEM, V18, P467, DOI 10.1016/j.jnutbio.2006.08.002
   Rahman MM, 2006, J LIPID RES, V47, P1739, DOI 10.1194/jlr.M600151 JLR200
   Rahman MM, 2009, J CELL MOL MED, V13, P1833, DOI 10.1111/j.1582 4934.2009.00649.x
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood 2002 08 2622
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Schett G, 2011, EUR J CLIN INVEST, V41, P1361, DOI 10.1111/j.1365 2362.2011.02545.x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Song HJ, 2005, EUR J CLIN NUTR, V59, P508, DOI 10.1038/sj.ejcn.1602102
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Steck SE, 2007, J NUTR, V137, P1188, DOI 10.1093/jn/137.5.1188
   Sun DX, 2004, CELL IMMUNOL, V228, P54, DOI 10.1016/j.cellimm.2004.04.001
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Thiel Cooper RL, 2001, J ANIM SCI, V79, P1821
   Wahle KWJ, 2004, PROG LIPID RES, V43, P553, DOI 10.1016/j.plipres.2004.08.002
   Watkins BA, 1997, J NUTR, V127, P1084, DOI 10.1093/jn/127.6.1084
   Watkins BA, 2004, AM J CLIN NUTR, V79, p1175S, DOI 10.1093/ajcn/79.6.1175S
   Watkins BA, 2001, PROG LIPID RES, V40, P125, DOI 10.1016/S0163 7827(00)00016 3
   Watkins BA, 2000, J AM COLL NUTR, V19, p478S, DOI 10.1080/07315724.2000.10718951
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 78
TC 17
Z9 18
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0024 4201
EI 1558 9307
J9 LIPIDS
JI Lipids
PD MAR
PY 2014
VL 49
IS 3
BP 211
EP 224
DI 10.1007/s11745 013 3872 5
PG 14
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA AC6WF
UT WOS:000332665600001
PM 24338525
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, X
   Niu, YM
   Xie, WL
   Wei, DQ
   Du, Q
AF Liu, Xin
   Niu, Yumei
   Xie, Weili
   Wei, Daqing
   Du, Qing
TI Tanshinone IIA promotes osteogenic differentiation of human periodontal
   ligament stem cells via ERK1/2 dependent Runx2 induction
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Tanshinone IIA; human periodontal ligament stem cells; osteogenic
   differentiation; Runx2; ERK1/2
ID MESENCHYMAL STROMAL CELLS; BONE MARROW; OXIDATIVE STRESS; MUSCLE CELLS;
   PROLIFERATION; INFLAMMATION; SULFONATE; INJURY; ACTIVATION; EXPRESSION
AB Mesenchymal stem cells (MSCs) of the dental or craniofacial origin include Human periodontal ligament stem cells (hPDLSCs), which are able to readily differentiate into osteoblasts. Tanshinone IIA (TSA) is a diterpene quinone compound that is derived from Danshen (also known as Salvia miltiorrhiza) used frequently in the context of traditional Chinese medicine (TCM). This study sought to assess how TSA affects the osteogenic differentiation of hPDLSCs. We found that TSA promotes both this differentiation and hPDLSC maturation. This was dependent on TSA mediated activation of the ERK1/2 signaling pathway, and ERK1/2 inhibition disrupted TSA induced Runx2 expression. From these results, we conclude that TSA can induce hPDLSC osteogenesis through the ERK1/2 Runx2 axis, suggesting that TSA is a viable therapeutic option for regenerative medical approaches aimed at the treatment of periodontitis.
C1 [Liu, Xin; Niu, Yumei; Xie, Weili] Harbin Med Univ, Affiliated Hosp 1, Dept Prosthodont, 143 Yiman St, Harbin 150001, Heilongjiang, Peoples R China.
   [Wei, Daqing; Du, Qing] Harbin Inst Technol, Sch Mat Sci & Engn, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Institute of Technology
RP Niu, YM (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Prosthodont, 143 Yiman St, Harbin 150001, Heilongjiang, Peoples R China.
EM niuyumeihlj@gmail.com
RI Du, Qing/HKN 6976 2023; Xie, Weili/NDT 6370 2025
FU Heilongjiang Provincial Health Department Project [2013 029]
FX This work was supported by Heilongjiang Provincial Health Department
   Project (2013 029).
CR Arigbede Abiodun O, 2012, J Indian Soc Periodontol, V16, P487, DOI 10.4103/0972 124X.106878
   Ariyamuthu VK, 2013, CARDIORENAL MED, V3, P71, DOI 10.1159/000350046
   Bassir SH, 2016, J CELL PHYSIOL, V231, P50, DOI 10.1002/jcp.25067
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Cheng L, 2018, AM J TRANSL RES, V10, P1457
   Elahi KC, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5646384
   Guan RJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00263
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hu HL, 2015, PHARM BIOL, V53, P1752, DOI 10.3109/13880209.2015.1005753
   Hu L, 2018, ORAL DIS, V24, P696, DOI 10.1111/odi.12703
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Kato H, 2016, J PERIODONTOL, V87, pE44, DOI 10.1902/jop.2015.150474
   Kim Su Hwan, 2010, Int J Stem Cells, V3, P16
   Li MY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0530 5
   Li M, 2018, CANCER BIOL THER, V19, P898, DOI 10.1080/15384047.2018.1480296
   Liu Y, 2018, MUTAGENESIS, V33, P203, DOI 10.1093/mutage/gey010
   Lu M, 2018, IRAN J BASIC MED SCI, V21, P83, DOI 10.22038/IJBMS.2017.20100.5276
   Maderal AD, 2018, J AM ACAD DERMATOL, V78, P839, DOI 10.1016/j.jaad.2017.05.056
   Mangal B, 2012, J ACUPUNCT MERIDIAN, V5, P51
   McGee Lawrence ME, 2014, BONE, V66, P277, DOI 10.1016/j.bone.2014.06.022
   Moshaverinia A, 2014, BIOMATERIALS, V35, P2642, DOI 10.1016/j.biomaterials.2013.12.053
   Pan Y, 2017, IRAN J BASIC MED SCI, V20, P308, DOI 10.22038/ijbms.2017.8361
   Pérez Campo FM, 2016, CALCIFIED TISSUE INT, V99, P302, DOI 10.1007/s00223 016 0144 4
   Rashed L, 2016, TISSUE CELL, V48, P644, DOI 10.1016/j.tice.2016.09.006
   Ren BX, 2015, GENET MOL RES, V14, P2133, DOI 10.4238/2015.March.20.24
   Scannapieco FA, 2016, PERIODONTOL 2000, V72, P153, DOI 10.1111/prd.12129
   Shen JuiLung Shen JuiLung, 2011, Evidence based Complementary and Alternative Medicine, V2011, P378907
   Su F, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0023 3
   Sui H, 2017, CANCER LETT, V403, P86, DOI 10.1016/j.canlet.2017.05.013
   Tan JL, 2015, CURR STEM CELL RES T, V10, P375, DOI 10.2174/1574888X09666141110150634
   Teplyuk NM, 2009, MOL ENDOCRINOL, V23, P849, DOI 10.1210/me.2008 0270
   Tong YH, 2011, PHYTOMEDICINE, V18, P443, DOI 10.1016/j.phymed.2010.10.009
   Vieira NM, 2010, STEM CELL REV REP, V6, P560, DOI 10.1007/s12015 010 9187 5
   Wang T, 2017, J CELL MOL MED, V21, P3100, DOI 10.1111/jcmm.13222
   Wei B, 2014, ATHEROSCLEROSIS, V235, P318, DOI 10.1016/j.atherosclerosis.2014.05.924
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Xu SW, 2013, EXPERT OPIN THER PAT, V23, P149, DOI 10.1517/13543776.2013.743995
   Xu YM, 2016, EXP THER MED, V12, P2741, DOI 10.3892/etm.2016.3674
   Yang XJ, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/9867150
   Yao SQ, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3028647
   Yin X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038381, 10.1371/journal.pone.0051853]
   Zayed MN, 2016, VET J, V217, P26, DOI 10.1016/j.tvjl.2016.05.014
   Zhang BJ, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/2789847
   Zhu WJ, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/972313
   Zou L, 2015, STEM CELL REP, V4, P190, DOI 10.1016/j.stemcr.2015.01.008
NR 45
TC 25
Z9 26
U1 0
U2 16
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2019
VL 11
IS 1
BP 340
EP 350
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HI7YB
UT WOS:000456671200026
PM 30787991
DA 2025 08 17
ER

PT J
AU Chen, YMF
   Aspera Werz, RH
   Menger, MM
   Falldorf, K
   Ronniger, M
   Stacke, C
   Histing, T
   Nussler, AK
   Ehnert, S
AF Chen, Yangmengfan
   Aspera Werz, Romina H.
   Menger, Maximilian M.
   Falldorf, Karsten
   Ronniger, Michael
   Stacke, Christina
   Histing, Tina
   Nussler, Andreas K.
   Ehnert, Sabrina
TI Exposure to 16 Hz Pulsed Electromagnetic Fields Protect the Structural
   Integrity of Primary Cilia and Associated TGF β Signaling in
   Osteoprogenitor Cells Harmed by Cigarette Smoke
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE extremely low frequency pulsed electromagnetic fields (ELF PEMFs);
   mesenchymal stem cells; bone healing; cigarette smoke extract; TGF beta
   signaling; primary cilium
ID MESENCHYMAL STEM CELLS; MATRIX; OSTEOBLASTS; MATURATION; PATHWAYS;
   REPAIR
AB Cigarette smoking (CS) is one of the main factors related to avoidable diseases and death across the world. Cigarette smoke consists of numerous toxic compounds that contribute to the development of osteoporosis and fracture nonunion. Exposure to pulsed electromagnetic fields (PEMF) was proven to be a safe and effective therapy to support bone fracture healing. The aims of this study were to investigate if extremely low frequency (ELF ) PEMFs may be beneficial to treat CS related bone disease, and which effect the duration of the exposure has. In this study, immortalized human mesenchymal stem cells (SCP 1 cells) impaired by 5% cigarette smoke extract (CSE) were exposed to ELF PEMFs (16 Hz) with daily exposure ranging from 7 min to 90 min. Cell viability, adhesion, and spreading were evaluated by Sulforhodamine B, Calcein AM staining, and Phalloidin TRITC/Hoechst 33342 staining. A migration assay kit was used to determine cell migration. Changes in TGF beta signaling were evaluated with an adenoviral Smad2/3 reporter assay, RT PCR, and Western blot. The structure and distribution of primary cilia were analyzed with immunofluorescent staining. Our data indicate that 30 min daily exposure to a specific ELF PEMF most effectively promoted cell viability, enhanced cell adhesion and spreading, accelerated migration, and protected TGF beta signaling from CSE induced harm. In summary, the current results provide evidence that ELF PEMF can be used to support early bone healing in patients who smoke.
C1 [Chen, Yangmengfan; Aspera Werz, Romina H.; Menger, Maximilian M.; Histing, Tina; Nussler, Andreas K.; Ehnert, Sabrina] Univ Tubingen, Siegfried Weller Res Inst, Dept Trauma & Reconstruct Surg, BG Trauma Ctr Tubingen, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
   [Falldorf, Karsten; Ronniger, Michael; Stacke, Christina] Sachtleben GmbH, Haus Spectrum UKE, Martinistr 64, D 20251 Hamburg, Germany.
C3 Eberhard Karls University of Tubingen
RP Nussler, AK (通讯作者)，Univ Tubingen, Siegfried Weller Res Inst, Dept Trauma & Reconstruct Surg, BG Trauma Ctr Tubingen, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
EM chenyangmengfantj@163.com; rominaaspera@hotmail.com;
   mmenger@bgu tuebingen.de; falldorf@citresearch.de;
   ronniger@citresearch.de; stacke@citresearch.de;
   thisting@bgu tuebingen.de; andreas.nuessler@gmail.com;
   sabrina.ehnert@med.uni tuebingen.de
RI chen, yangmengfan/AHC 5544 2022; Chen, Yangmengfan/AHC 5544 2022;
   Menger, Maximilian M/HHZ 8483 2022; Ehnert, Sabrina/AAE 8163 2019;
   Falldorf, Karsten/AAJ 1118 2020
OI chen, yangmengfan/0000 0003 1741 8334; 
FU German Research Foundation [DFG EH 471/2]; China Scholarship Council
FX S.E. received funding from the German Research Foundation (DFG EH
   471/2). Y.C. received support from the China Scholarship Council to
   cover his living expenses.
CR Alvarez Satta M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.623829
   Aspera Werz RH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122915
   Aspera Werz RH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3172480
   Bhandari Mohit, 2012, J Bone Joint Surg Am, V94, pe1091, DOI 10.2106/JBJS.K.01344
   Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315
   Cheng Y, 2017, INT J CHRONIC OBSTR, V12, P3133, DOI 10.2147/COPD.S146201
   Clement CA, 2013, CELL REP, V3, P1806, DOI 10.1016/j.celrep.2013.05.020
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Daish C, 2018, ANN BIOMED ENG, V46, P525, DOI 10.1007/s10439 018 1982 1
   Deng Y, 2013, TOXICOL APPL PHARM, V269, P25, DOI 10.1016/j.taap.2013.02.008
   Ehnert S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122028
   Ehnert S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030406
   Ehnert S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082239
   Ehnert S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14983 9
   Ehnert S, 2017, J MOL MED, V95, P653, DOI 10.1007/s00109 017 1526 4
   Ehnert Sabrina, 2015, Bone Rep, V3, P48, DOI 10.1016/j.bonr.2015.08.002
   Horiguchi M, 2012, J BIOCHEM, V152, P321, DOI 10.1093/jb/mvs089
   Hua K, 2018, CELL MOL LIFE SCI, V75, P1521, DOI 10.1007/s00018 017 2740 5
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Kaku M, 2017, CURR OSTEOPOROS REP, V15, P96, DOI 10.1007/s11914 017 0351 6
   Li HQ, 2020, J BONE MINER RES, V35, P1424, DOI 10.1002/jbmr.4014
   Liu M, 2020, J BONE MINER RES, V35, P571, DOI 10.1002/jbmr.3902
   Liu RH, 2016, MOL MED REP, V13, P2359, DOI 10.3892/mmr.2016.4834
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Moghaddam A, 2010, INJURY, V41, P1020, DOI 10.1016/j.injury.2010.03.014
   Pala R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112272
   Pedersen LB, 2016, TRENDS BIOCHEM SCI, V41, P784, DOI 10.1016/j.tibs.2016.06.002
   Qiu N, 2012, J CELL SCI, V125, P1945, DOI 10.1242/jcs.095893
   Scolaro JA, 2014, J BONE JOINT SURG AM, V96A, P674, DOI 10.2106/JBJS.M.00081
   Seeger Nukpezah T, 2012, CURR OPIN CELL BIOL, V24, P652, DOI 10.1016/j.ceb.2012.06.002
   Selvamurugan N, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2450327
   Spasic M, 2017, EUR CELLS MATER, V33, P158, DOI 10.22203/eCM.v033a12
   Sreekumar V, 2018, ARCH TOXICOL, V92, P1525, DOI 10.1007/s00204 017 2149 9
   Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091
   Tamaki J, 2011, OSTEOPOROSIS INT, V22, P133, DOI 10.1007/s00198 010 1238 x
   Xie YF, 2016, BONE, V93, P22, DOI 10.1016/j.bone.2016.09.008
   Yan JL, 2015, MOL CELL ENDOCRINOL, V404, P132, DOI 10.1016/j.mce.2015.01.031
   YASUDA I, 1977, CLIN ORTHOP RELAT R, P5
   Yuan J, 2018, CELL PHYSIOL BIOCHEM, V46, P1581, DOI 10.1159/000489206
   Zhou J, 2019, J BONE MINER RES, V34, P1336, DOI 10.1002/jbmr.3704
   Ziegler P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8112008
   Zimmermann G, 2007, UNFALLCHIRURG, V110, P130, DOI 10.1007/s00113 006 1199 x
NR 43
TC 12
Z9 13
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 13
AR 7036
DI 10.3390/ijms22137036
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TF9DM
UT WOS:000671014600001
PM 34210094
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Arciero, I
   Buonvino, S
   Melino, S
AF Arciero, Ilaria
   Buonvino, Silvia
   Melino, Sonia
TI Slow H2S Releasing Donors and 3D Printable Arrays Cellular
   Models in Osteo Differentiation of Mesenchymal Stem Cells for
   Personalized Therapies
SO BIOMOLECULES
LA English
DT Article
DE bone matrix; osteoarthritis; IL 6; osteocalcin; osteoblast; actin;
   garlic
ID FIBROBLAST LIKE SYNOVIOCYTES; NF KAPPA B; HYDROGEN SULFIDE; SIGNALING
   PATHWAY; HEME OXYGENASE 1; IN VITRO; EXPRESSION; H2S; INFLAMMATION;
   DYSFUNCTION
AB The effects of the hydrogen sulfide (H2S) slow releasing donor, named GSGa, a glutathione conjugate water soluble garlic extract, on human mesenchymal stem cells (hMSCs) in both bidimensional (2D) and three dimensional (3D) cultures were investigated, demonstrating increased expression of the antioxidant enzyme HO 1 and decreased expression of the pro inflammatory cytokine interleukin 6 (IL 6). The administration of the H2S donor can therefore increase the expression of antioxidant enzymes, which may have potential therapeutic applications in osteoarthritis (OA). Moreover, GSGa was able to promote the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), but not of cardiac mesenchymal stem cells (cMSCs) in a 2D culture system. This result highlights the varying sensitivity of hMSCs to the H2S donor GSGa, suggesting that the induction of osteogenic differentiation in stem cells by chemical factors is dependent on the tissue of origin. Additionally, a 3D printable mesenchymal stem cells bone matrix array (MSCBM), designed to closely mimic the stiffness of bone tissue, was developed to serve as a versatile tool for evaluating the effects of drugs and stem cells on bone repair in chronic diseases, such as OA. We demonstrated that the osteogenic differentiation process in cMSCs can be induced just by simulating bone stiffness in a 3D system. The expression of osteocalcin, RUNX2, and antioxidant enzymes was also assessed after treating MSCs with GSGa and/or increasing the stiffness of the culture environment. The printability of the array may enable better customization of the cavities, enabling an accurate replication of real bone defects. This could optimize the BM array to mimic bone defects not only in terms of stiffness, but also in terms of shape. This culture system may enable a rapid screening of antioxidant and anti inflammatory compounds, facilitating a more personalized approach to regenerative therapy.
C1 [Arciero, Ilaria] Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I 00133 Rome, Italy.
   [Buonvino, Silvia; Melino, Sonia] Univ Roma Tor Vergata, Dept Expt Med, Via Montpellier 1, I 00133 Rome, Italy.
C3 University of Rome Tor Vergata; University of Rome Tor Vergata
RP Melino, S (通讯作者)，Univ Roma Tor Vergata, Dept Expt Med, Via Montpellier 1, I 00133 Rome, Italy.
EM ilaria 29@libero.it; silvia.buonvino95@gmail.com; melinos@uniroma2.it
OI ARCIERO, ILARIA/0009 0003 5701 4796; Buonvino,
   Silvia/0009 0005 3124 3317; MELINO, SONIA/0000 0001 7694 5279
FU Italian network of excellence for advanced diagnosis; European
   Union Next Generation EU [PNRR M4C2 I1.3, PE_00000019 "HEAL ITALIA"];
   Italian Ministry of University [PNC E3 2022 23683266]; Italian network
   of excellence for advanced diagnosis (INNOVA)
FX This research received has received funding from the European Union Next
   Generation EU through the Italian Ministry of University and Research
   under PNRR M4C2 I1.3 Project PE_00000019 "HEAL ITALIA". The views and
   opinions expressed are those of the authors only and do not necessarily
   reflect those of the European Union or the European Commission. Neither
   the European Union nor the European Commission can be held responsible
   for them. The research was also partially supported by the Italian
   network of excellence for advanced diagnosis (INNOVA)
   PNC E3 2022 23683266.
CR Ahmed SMU, 2017, BBA MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Altaany Z, 2013, J CELL MOL MED, V17, P879, DOI 10.1111/jcmm.12077
   Ambriz X, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2891957
   Batallé G, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9010031
   Bhuiyan AI, 2015, MOLECULES, V20, P1731, DOI 10.3390/molecules20011731
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Buonvino S, 2023, MATER TODAY BIO, V23, DOI 10.1016/j.mtbio.2023.100862
   Buonvino S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116095
   Burguera EF, 2014, OSTEOARTHR CARTILAGE, V22, P1026, DOI 10.1016/j.joca.2014.04.031
   Burguera EF, 2020, INT J BIOMETEOROL, V64, P997, DOI 10.1007/s00484 019 01823 w
   Cacciotti I, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082368
   Chen YQ, 2018, J ENVIRON PATHOL TOX, V37, P291, DOI 10.1615/JEnvironPatholToxicolOncol.2018027078
   Choi MC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070734
   Ciocci M, 2018, INT J BIOL MACROMOL, V108, P960, DOI 10.1016/j.ijbiomac.2017.11.013
   COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214
   Consoli V, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040589
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dawe GS, 2008, NEUROSCIENCE, V152, P169, DOI 10.1016/j.neuroscience.2007.12.008
   Di Giovanni E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051638
   Dief AE, 2015, EUR REV MED PHARMACO, V19, P1537
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Ferrai C, 2024, EUR J CELL BIOL, V103, DOI 10.1016/j.ejcb.2024.151417
   Fois MG, 2024, TRENDS BIOTECHNOL, V42, P910, DOI 10.1016/j.tibtech.2024.01.004
   Forte G, 2011, STEM CELLS, V29, P2051, DOI 10.1002/stem.763
   Fox B, 2012, J CELL MOL MED, V16, P896, DOI 10.1111/j.1582 4934.2011.01357.x
   Frantzias J, 2012, BRIT J PHARMACOL, V165, P1914, DOI 10.1111/j.1476 5381.2011.01704.x
   Gambari L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205231
   Gambari L, 2019, MAT SCI ENG C MATER, V102, P471, DOI 10.1016/j.msec.2019.04.039
   Garibbo A., 2015, U.S. Patent, Patent No. [8,974,714, 8974714]
   Gjorgjieva T, 2020, ADV SCI, V7, DOI 10.1002/advs.202002261
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Ha CZ, 2015, INT J MOL MED, V35, P1657, DOI 10.3892/ijmm.2015.2183
   Hao YM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.661601
   Ju YJ, 2013, CAN J PHYSIOL PHARM, V91, P8, DOI 10.1139/cjpp 2012 0293
   Kimura H, 2013, NEUROCHEM INT, V63, P492, DOI 10.1016/j.neuint.2013.09.003
   Kloesch B, 2012, IMMUNOL LETT, V141, P197, DOI 10.1016/j.imlet.2011.10.004
   Kloesch B, 2010, CELL BIOL INT, V34, P477, DOI 10.1042/CBI20090436
   Koyanagi M, 2016, CYTOTECHNOLOGY, V68, P1489, DOI 10.1007/s10616 015 9909 2
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302 240
   Li L, 2013, J CELL MOL MED, V17, P365, DOI 10.1111/jcmm.12016
   Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu Y, 2014, CELL STEM CELL, V15, P66, DOI 10.1016/j.stem.2014.03.005
   Lu HJ, 2023, ADV THER GERMANY, V6, DOI 10.1002/adtp.202200349
   Lu T, 2015, BIOMATERIALS, V51, P173, DOI 10.1016/j.biomaterials.2015.02.018
   Mard SA, 2012, DIGEST DIS SCI, V57, P1496, DOI 10.1007/s10620 012 2051 5
   Nasi S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02147 6
   Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342
   Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680
   Pan L P, 2016, Beijing Da Xue Xue Bao Yi Xue Ban, V48, P194
   Pan LL, 2012, INT J CARDIOL, V155, P327, DOI 10.1016/j.ijcard.2011.12.059
   Pan LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019766
   Perry MM, 2011, AM J RESP CELL MOL, V45, P746, DOI 10.1165/rcmb.2010 0304OC
   Putra VDL, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 022 04320 w
   Raggio R, 2018, ACS BIOMATER SCI ENG, V4, P2956, DOI 10.1021/acsbiomaterials.8b00212
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Rios ECS, 2015, INT J MOL MED, V35, P1741, DOI 10.3892/ijmm.2015.2176
   Rong F, 2023, BIOACT MATER, V19, P198, DOI 10.1016/j.bioactmat.2022.03.043
   Sen U, 2010, CELL BIOCHEM BIOPHYS, V57, P49, DOI 10.1007/s12013 010 9079 y
   Sieghart D, 2015, J CELL MOL MED, V19, P187, DOI 10.1111/jcmm.12405
   Song YJ, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1336693
   Sui C, 2022, DNA CELL BIOL, V41, P617, DOI 10.1089/dna.2021.1182
   Sunzini F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041180
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Talele NP, 2015, STEM CELL REP, V4, P1016, DOI 10.1016/j.stemcr.2015.05.004
   Tang GH, 2005, MOL PHARMACOL, V68, P1757, DOI 10.1124/mol.105.017467
   Vela Anero A, 2017, NITRIC OXIDE BIOL CH, V70, P42, DOI 10.1016/j.niox.2017.08.004
   Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433
   Wallace JL, 2010, ANTIOXID REDOX SIGN, V12, P1125, DOI 10.1089/ars.2009.2900
   Wang YZ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042194
   Watt FM, 2013, NAT REV MOL CELL BIO, V14, P467, DOI 10.1038/nrm3620
   Wei K, 2023, INT IMMUNOPHARMACOL, V120, DOI 10.1016/j.intimp.2023.110289
   Whiteman M, 2010, ANTIOXID REDOX SIGN, V12, P1147, DOI 10.1089/ars.2009.2899
   Wu XW, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/9477332
   Xin H, 2016, ANTIOXID REDOX SIGN, V24, P70, DOI 10.1089/ars.2015.6315
   Xu LL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0716 x
   Zhang HL, 2007, AM J PHYSIOL LUNG C, V292, pL960, DOI 10.1152/ajplung.00388.2006
   Zhang T, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12338
   Zhou LN, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12030652
NR 80
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD NOV
PY 2024
VL 14
IS 11
AR 1380
DI 10.3390/biom14111380
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA N8Q0G
UT WOS:001366900600001
PM 39595557
OA gold
DA 2025 08 17
ER

PT J
AU Bakhsh, A
   Mustapha, NM
   Mohamed, S
AF Bakhsh, Ahdab
   Mustapha, Noordin Mohamed
   Mohamed, Suhaila
TI Catechin rich oil palm leaf extract enhances bone calcium content of
   estrogen deficient rats
SO NUTRITION
LA English
DT Article
DE Bone calcium content; Estrogen deficiency; Oil palm leaves;
   Osteoporosis; Polyphenols
ID HORMONE REPLACEMENT THERAPY; OSTEOCLAST DIFFERENTIATION; TEA
   POLYPHENOLS; GREEN TEA; PHYTOESTROGENS; OSTEOPOROSIS; OSTEOPENIA;
   MECHANISM
AB Objective: Postmenopausal estrogen deficiency often causes bone density loss and osteoporosis. This study evaluated the effects of an oral administration of oil palm leaf extract (OPL) on bone calcium content and structure, bone density, ash weights, and serum total alkaline phosphatase (T ALP) of estrogen deficient ovariectomized (OVX) rats.
   Methods: Female Sprague Dawley rats were divided into five experimental groups: 1) intact (normal control); 2) ovariectomized (OVX control), and OVX rats supplemented with 3) 2% (w/v) green tea (OVX + GT), 4) OPL 150 mg/kg of body weight, or 5) OPL 300 mg/kg of body weight in the drinking water.
   Results: After 3 mo, the OVX control rats had significantly decreased femur and tibia masses ( 5% and  3%, respectively), ash ( 15% and  10%), calcium content ( 0.5% and  2.7%), and bone density and T ALP concentrations ( 40%) compared with intact rats. The catechin rich OPL dose dependently increased the OVX bone density and structure, femur and tibia masses (by +8% and +12% respectively), ash (by +30% and +20% respectively), calcium (by +3% and +5%), and T ALP concentrations (by +76%) compared with the OVX rats. The increases by OPL were higher than that in OVX + GT and control intact rats.
   Conclusion: The catechin rich OPL increased the bone mass in estrogen deficient rats by increasing osteoblast activities to higher levels than in normal rats and those supplemented with GT. This was shown by the modulation of serum T ALP levels, bone calcium content, total mineral content, and bone histologic structure. The OPL is a potential inexpensive ingredient for protection against osteoporosis and influences bone metabolism by encouraging bone formation. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bakhsh, Ahdab; Mohamed, Suhaila] Univ Putra Malaysia, Inst Biosci, Serdang, Selangor, Malaysia.
   [Mustapha, Noordin Mohamed] Univ Putra Malaysia, Fac Vet Med, Serdang, Selangor, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia
RP Mohamed, S (通讯作者)，Univ Putra Malaysia, Inst Biosci, Serdang, Selangor, Malaysia.
EM mohamed.suhaila@gmail.com
OI Mohamed Mustapha, Noordin/0000 0001 9288 797X
FU Government of Malaysia
FX This research was supported by the Government of Malaysia.
CR Bakhireva LN, 2004, AM J PREV MED, V26, P436, DOI 10.1016/j.ampere.2004.02.013
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Bin Hafeez B, 2006, TOXICOL APPL PHARM, V216, P11, DOI 10.1016/j.taap.2006.03.013
   CASTELOBRANCO C, 1992, EUR J OBSTET GYN R B, V44, P131, DOI 10.1016/0028 2243(92)90058 7
   Chiechi LM, 2002, MATURITAS, V42, P295, DOI 10.1016/S0378 5122(02)00158 5
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   Eviö S, 2007, MATURITAS, V56, P122, DOI 10.1016/j.maturitas.2006.06.009
   Fazzalari NL, 2008, SEMIN CELL DEV BIOL, V19, P467, DOI 10.1016/j.semcdb.2008.08.003
   Fitzpatrick LA, 2003, ENDOCRIN METAB CLIN, V32, P233, DOI 10.1016/S0889 8529(02)00085 3
   Ho Ying Jui, 2007, Ann Gen Psychiatry, V6, P21, DOI 10.1186/1744 859X 6 21
   Horcajada Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Jaffri JM, 2011, FOOD CHEM, V128, P433, DOI 10.1016/j.foodchem.2011.03.050
   Khan N, 2007, LIFE SCI, V81, P519, DOI 10.1016/j.lfs.2007.06.011
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lin RW, 2009, BIOCHEM BIOPH RES CO, V379, P1033, DOI 10.1016/j.bbrc.2009.01.007
   Maggio D, 2006, BONE, V38, P244, DOI 10.1016/j.bone.2005.08.003
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McGowan JA, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P1687
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Nadia ME, 2012, ADV PHARM SCI
   Nakagawa H, 2007, BIOCHEM PHARMACOL, V73, P34, DOI 10.1016/j.bcp.2006.09.002
   Namvar F., 2009, PHARMACOLOGYONLINE, V2, P818
   New SA, 2000, AM J CLIN NUTR, V71, P142
   Picherit C, 2001, J NUTR, V131, P723, DOI 10.1093/jn/131.3.723
   Rassi CM, 2002, J BONE MINER RES, V17, P630, DOI 10.1359/jbmr.2002.17.4.630
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Shen CL, 2011, OSTEOPOROSIS INT, V22, P327, DOI 10.1007/s00198 010 1209 2
   Shen CL, 2010, OSTEOPOROSIS INT, V21, P1841, DOI 10.1007/s00198 009 1122 8
   Shen CL, 2011, PHARMACOL RES, V64, P155, DOI 10.1016/j.phrs.2011.03.012
   Shuid AN, 2011, J ETHNOPHARMACOL, V133, P538, DOI 10.1016/j.jep.2010.10.033
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756 3282(95)00185 G
   Takahashi N, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P175
   Tempfer CB, 2009, AM J MED, V122, P939, DOI 10.1016/j.amjmed.2009.04.018
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   Vali B, 2007, J NUTR BIOCHEM, V18, P341, DOI 10.1016/j.jnutbio.2006.06.005
   Wei YJ, 2011, OSTEOPOROSIS INT, V22, P1469, DOI 10.1007/s00198 010 1352 9
NR 36
TC 17
Z9 17
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0899 9007
EI 1873 1244
J9 NUTRITION
JI Nutrition
PD APR
PY 2013
VL 29
IS 4
BP 667
EP 672
DI 10.1016/j.nut.2012.09.005
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 114YQ
UT WOS:000316779300014
PM 23290096
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhao, HJ
   Pond, G
   Simos, D
   Wang, Z
   Robertson, S
   Singh, G
   Vandermeer, L
   Clemons, M
   Addison, CL
AF Zhao, Huijun
   Pond, Gregory
   Simos, Demetrios
   Wang, Zhou
   Robertson, Susan
   Singh, Gurmit
   Vandermeer, Lisa
   Clemons, Mark
   Addison, Christina Lynn
TI Doxycycline Induced Changes in Circulating MMP or TIMP2 Levels Are Not
   Associated with Skeletal Related Event Free or Overall Survival in
   Patients with Bone Metastases from Breast Cancer
SO CANCERS
LA English
DT Article
DE doxycycline; breast cancer; bone metastasis; matrix metalloproteinase;
   MMP2; MMP9; TIMP2; SRE
ID TO MESENCHYMAL TRANSITION; FUNCTIONAL ASSESSMENT; MATRIX
   METALLOPROTEINASES; TISSUE INHIBITOR; TARGETING TIMP2; TUMOR BURDEN;
   STEM CELLS; THERAPY; MIGRATION; BISPHOSPHONATES
AB Simple Summary The current study was a retrospective exploratory study evaluating whether circulating levels of known targets of doxycycline were altered following administration of doxycycline to bone metastatic breast cancer patients as an indicator of its expected on target efficacy. Although we saw predicted changes in these proteins, namely MMP2, MMP9 and TIMP2 pre  and post doxycycline, they were not prognostic for skeletal related event free or overall survival in this cohort. This is likely due in part to confounding effects of doxycycline administration on other cell types in the bone and effects of concurrent treatment regimens on these same target proteins. Although use of doxycycline in cancer patients remains an attractive modality, our findings suggest that studies assessing biomarkers of doxycycline efficacy should carefully consider putative confounding factors and account for this prospectively in the study design. Doxycycline is often used as a promoter of inducible gene expression in preclinical models; however, it can also have direct effects on tumor growth and survival. This is due in part to its ability to inhibit cell invasion and regulate matrix metalloproteinase (MMP) expression. Given that doxycycline is also osteotropic, a clinical study to assess its effects on modulation of tumor progression or prevention of skeletal related events (SRE) in patients with bone metastases from breast cancer (the Achilles trial) was undertaken. Patients received 100 mg of oral doxycycline twice daily for 12 weeks, with serum obtained at baseline and 4, 8 and 12 weeks post initiation of doxycycline treatment. Exploratory analysis of the effects of doxycycline on circulating levels of MMP or tissue inhibitor of matrix metalloproteinase 2 (TIMP2) was performed in enrolled patients. Statistically significant associations were observed between MMP2, MMP9 and TIMP2 at baseline with significant associations maintained between absolute levels and changes in levels of MMP2 and TIMP2 at weeks 4 12 post initiation of doxycycline. Treatment with doxycycline generally resulted in decreases in MMP2 and MMP9 levels with concurrent upregulation of TIMP2 at 12 weeks post initiation of doxycycline treatment. Despite this, we observed no association with the levels of any of these factors with either SRE free or overall survival in this patient cohort. In summary, despite observing hypothesized effects of doxycycline administration on surrogate markers of its anti tumor activity, measures of circulating levels of these biomarkers were not prognostic in this patient population.
C1 [Zhao, Huijun; Wang, Zhou; Vandermeer, Lisa; Clemons, Mark; Addison, Christina Lynn] Ottawa Hosp, Res Inst, Program Canc Therapeut, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
   [Pond, Gregory] McMaster Univ, Dept Oncol, 699 Concess St, Hamilton, ON L8V 5C2, Canada.
   [Simos, Demetrios; Clemons, Mark] Univ Ottawa, Dept Med, Div Med Oncol, 451 Smyth Rd, Ottawa, ON K1H 4M5, Canada.
   [Robertson, Susan] Univ Ottawa, Dept Pathol & Lab Med, 451 Smyth Rd, Ottawa, ON K1H 4M5, Canada.
   [Singh, Gurmit] McMaster Univ, Dept Pathol & Mol Med, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
   [Addison, Christina Lynn] Univ Ottawa, Dept Med & Biochem, 451 Smyth Rd, Ottawa, ON K1H 4M5, Canada.
   [Addison, Christina Lynn] Univ Ottawa, Dept Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 4M5, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; McMaster
   University; University of Ottawa; University of Ottawa; McMaster
   University; University of Ottawa; University of Ottawa
RP Addison, CL (通讯作者)，Ottawa Hosp, Res Inst, Program Canc Therapeut, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.; Addison, CL (通讯作者)，Univ Ottawa, Dept Med & Biochem, 451 Smyth Rd, Ottawa, ON K1H 4M5, Canada.; Addison, CL (通讯作者)，Univ Ottawa, Dept Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 4M5, Canada.
EM caddison@ohri.ca
RI ; Pond, Gregory/JOZ 2926 2023; ZHAO, HUANYU/JFD 8853 2023
OI Pond, Gregory/0000 0003 1033 0882; Addison,
   Christina/0000 0002 3492 475X; Clemons, Mark/0000 0001 9392 8219; Singh,
   Gurmit/0000 0002 6256 5790
CR Addison CL, 2016, J BONE ONCOL, V5, P173, DOI 10.1016/j.jbo.2016.06.003
   Addison CL, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 577
   Broom R, 2009, J PAIN SYMPTOM MANAG, V38, P244, DOI 10.1016/j.jpainsymman.2008.08.005
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Chen YF, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.829788
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   Clemons MJ, 2014, BREAST CANCER RES TR, V146, P153, DOI 10.1007/s10549 014 3015 6
   DAY LE, 1966, J BACTERIOL, V91, P1917, DOI 10.1128/JB.91.5.1917 1923.1966
   Dhesy Thind S.K., 2005, J CLIN ONCOL, V23, P3198, DOI [10.1200/jco.2005.23.16_suppl.3198, DOI 10.1200/JCO.2005.23.16_SUPPL.3198]
   Duivenvoorden WCM, 2007, BRIT J CANCER, V96, P1526, DOI 10.1038/sj.bjc.6603740
   Duivenvoorden WCM, 2002, CANCER RES, V62, P1588
   FIFE RS, 1995, J LAB CLIN MED, V125, P407
   Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304 3835(98)00003 2
   Holmes NE, 2009, CLIN MED INSIGHTS TH, V1, P471
   Jakob A, 2022, J BONE ONCOL, V33, DOI 10.1016/j.jbo.2022.100420
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kuchuk I, 2013, J BONE ONCOL, V2, P154, DOI 10.1016/j.jbo.2013.07.004
   Lamb R, 2015, ONCOTARGET, V6, P4569, DOI 10.18632/oncotarget.3174
   Lamb R, 2014, ONCOTARGET, V5, P11029, DOI 10.18632/oncotarget.2789
   Liang B, 2015, INT J CLIN EXP PATHO, V8, P9168
   Liu HJ, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.619317
   Lu GJ, 2015, INT J CLIN EXP PATHO, V8, P5224
   Lu WS, 2004, CANCER LETT, V214, P205, DOI 10.1016/j.canlet.2003.08.012
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Lymperatou D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/147514
   Meng J, 2014, MOL CANCER THER, V13, P3107, DOI 10.1158/1535 7163.MCT 13 1060
   Mortison JD, 2018, CELL CHEM BIOL, V25, P1506, DOI 10.1016/j.chembiol.2018.09.010
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200
   Nilsson UW, 2007, BREAST CANCER RES TR, V102, P253, DOI 10.1007/s10549 006 9335 4
   Oehler R, 1997, NUCLEIC ACIDS RES, V25, P1219, DOI 10.1093/nar/25.6.1219
   Ogut D, 2016, FOLIA HISTOCHEM CYTO, V54, P171, DOI 10.5603/FHC.a2016.0022
   Peeney D, 2020, CARCINOGENESIS, V41, P313, DOI 10.1093/carcin/bgz172
   Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329
   Scatena C, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00452
   Tang XY, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0607 x
   Teronen O, 2000, BLOOD, V96, P4006, DOI 10.1182/blood.V96.12.4006.h8004000f_4006_4007
   Trinkaus M, 2010, SUPPORT CARE CANCER, V18, P197, DOI 10.1007/s00520 009 0645 z
   Valleala H, 2003, LIFE SCI, V73, P2413, DOI 10.1016/S0024 3205(03)00657 X
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   von Moos R, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116243
   Wang CH, 2015, MOL MED REP, V12, P3374, DOI 10.3892/mmr.2015.3833
   Wang S., 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317718192
   Wang SQ, 2016, INT J ONCOL, V48, P1353, DOI 10.3892/ijo.2016.3375
   Zhang L, 2017, CELL CYCLE, V16, P737, DOI 10.1080/15384101.2016.1241929
   Zhong WL, 2017, ONCOTARGET, V8, P104855, DOI 10.18632/oncotarget.20418
NR 46
TC 3
Z9 3
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD FEB
PY 2023
VL 15
IS 3
AR 571
DI 10.3390/cancers15030571
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 8T5AM
UT WOS:000929274600001
PM 36765529
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Boroujerdi, MA
   Schmidt, S
AF Boroujerdi, M. A.
   Schmidt, S.
TI A Negative Feedback Model for a Mechanism Based Description of
   Longitudinal Observations Application for Bone Turnover Biomarkers
SO METHODS OF INFORMATION IN MEDICINE
LA English
DT Article
DE Second order model; negative feedback; clearance rate constant; bone
   mineral density; bone specific alkaline phosphatase; osteoporosis
ID MATHEMATICAL MODEL; RESORPTION
AB In modern medicine the diagnosis and prognosis of an abnormal metabolic condition is based on blood borne measurements involving one or more biomarker.
   Objective: This paper reports the development of a minimal negative feedback model for the description of longitudinal biomarkers concentrations for treatment of osteoporosis in postmenopausal women.
   Methods: Literature data were obtained from double blind, placebo controlled clinical trial over three years. There were four treatment groups: 1) Placebo, 2) Alendronate, 3) Conjugated Estrogen, and/or 4) Combination therapy. The negative feedback, model consists of a biomarker and a companion controller. By considering the above basal biomarker values it is shown that the dynamics can be described by a second order differential equation without the involvement of biomarker production rate. The second order differential equation is also analogous to classical negative feedback servomechanism model with two parameters omega(n) and xi. It was assumed that the rate constants defining the negative feedback model were equal which would set xi to 0.707 with only omega(n) to be estimated.
   Results: omega(n) was estimated for both lumbar spine bone mineral density (BMD) and bone specific alkaline phosphatase (BAP) in four treatments groups. The t(1/2) of BMD and BAP were estimated at 26.8 (0.30) and 9.4 (0.30) days respectively.
   Conclusions: The negative feedback model of BMD supports the mechanism whereby Conjugated Estrogen and Alendronate decrease the clearance rate constant of BMD analogous to increased apoptosis of osteoclasts. The linked negative feedback models facilitate a mechanism based prediction of BMD using the concentrations of the bone turnover marker BAP.
C1 [Boroujerdi, M. A.; Schmidt, S.] Leiden Univ, Div Pharmacol, Leiden, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University
RP Boroujerdi, MA (通讯作者)，LACDR, Div Pharmacol, Gorlaeus Labs, Einsteinweg 55, NL 2300 RA Leiden, Netherlands.
EM massoud.boroujerdi@gmail.com
RI Boroujerdi, Massoud/AAO 9177 2020
OI Boroujerdi, Massoud/0000 0002 5722 9645
FU Dutch Top Institute Pharma, Mechanism based PK/PD modeling platform
   [D2 14]
FX The authors would like to thank Drs. Oscar E. Della Pasqua and Meindert
   Danhof for their valuable comments and suggestions. This study was
   performed within the framework of the Dutch Top Institute Pharma,
   Mechanism based PK/PD modeling platform (project number D2 14).
CR ACKERMAN E, 1964, PHYS MED BIOL, V9, P203, DOI 10.1088/0031 9155/9/2/307
   [Anonymous], CLIN TRIAL SIMULATIO
   [Anonymous], 2011, R LANGUAGE ENV STAT
   [Anonymous], PRINCIPLES AUTOMATIC
   Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097 0258(19971030)16:20<2349::AID SIM667>3.0.CO;2 E
   Co Hedge NR, 2010, DAVIDSONS PRINCIPLES
   Cobelli Claudio, 2009, IEEE Rev Biomed Eng, V2, P54, DOI 10.1109/RBME.2009.2036073
   Danhof M, 2005, PHARM RES, V22, P1432, DOI 10.1007/s11095 005 5882 3
   De Stavola BL, 2006, AM J EPIDEMIOL, V163, P84, DOI 10.1093/aje/kwj003
   DENNIS JE, 1983, NUMERICAL METHODS UN
   Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119
   Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003 4819 137 11 200212030 00008
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kulikowski CA, 2009, METHOD INFORM MED, V48, P4, DOI 10.3414/ME9135
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Marincola Francesco M, 2003, J Transl Med, V1, P1, DOI 10.1186/1479 5876 1 1
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Pivonka P, 2010, BONE, V47, P181, DOI 10.1016/j.bone.2010.04.601
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   POSEN S, 1982, CLIN CHEM, V28, P153
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   UMPLEBY AM, 1986, DIABETOLOGIA, V29, P131, DOI 10.1007/BF02427082
   VELDHUIS JD, 1990, J NEUROENDOCRINOL, V2, P755, DOI 10.1111/j.1365 2826.1990.tb00638.x
   Visvanothan M, 2008, METHOD INFORM MED, V47, P140, DOI 10.3414/ME0461
NR 25
TC 0
Z9 0
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0026 1270
EI 2511 705X
J9 METHOD INFORM MED
JI Methods Inf. Med.
PY 2013
VL 52
IS 6
BP 484
EP 493
DI 10.3414/ME12 01 0076
PG 10
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA 275GC
UT WOS:000328663300004
PM 23907233
DA 2025 08 17
ER

PT J
AU Yang, JP
   Cao, Y
   Lv, ZX
   Jiang, T
   Wang, LM
   Li, Z
AF Yang, Jianping
   Cao, Yan
   Lv, Zhengxiang
   Jiang, Tao
   Wang, Liming
   Li, Zhong
TI Cordycepin protected against the TNF  induced inhibition of osteogenic
   differentiation of human adipose derived mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Article
DE adipose derived mesenchymal stem cells; bone diseases; cordycepin;
   inflammation
ID TUMOR NECROSIS FACTOR; OSTEOBLAST DIFFERENTIATION; IN VITRO;
   FACTOR ALPHA; BONE MARROW; INFLAMMATION; REGULATOR; PATHWAYS; RECEPTOR;
   MODEL
AB Cordycepin, 3' deoxyadenosine, is an effective component isolated from the rare Chinese caterpillar fungus Cordyceps militaris. It exerts potent anti inflammatory actions in different cell and animal models. However, its action remains unclear on the TNF  induced inhibition of osteogenic differentiation of adipose derived mesenchymal stem cells (ADMSCs). In the present study, we demonstrated that cordycepin induced cell death at 20 and 40 g/mL. Interestingly, 10 g/mL cordycepin abrogated the cell death induced by 20 ng/mL TNF . Meanwhile, cordycepin exhibited a dose dependent regulation of the osteogenesis of human ADMSCs: it promoted the differentiation at 10 g/mL, whereas inhibited differentiation at 40 g/mL. Furthermore, we discovered that 10 g/mL cordycepin protected against the TNF  (induced inhibition of osteogenic differentiation of human ADMSCs. It was also revealed that 10 g/mL cordycepin restored Runx2 and Osx mRNA levels, which were significantly inhibited by TNF during osteogenesis. At the same time, we found that 10 g/mL cordycepin suppressed TNF  activated NF B signaling, by inhibiting IB phosphorylation and subsequent p65 release and translocation into the cell nucleus. Of clinical interest, the present study revealed mechanisms involved in inflammatory cytokine inhibited osteogenesis, and it highlights the potential of cordycepin to promote the osteogenesis of human ADMSCs in cell based therapy for inflammatory bone diseases.
C1 [Yang, Jianping; Wang, Liming] Nanjing Med Univ, Nanjing Hosp 1, Dept Orthopaed, Nanjing 210012, Jiangsu, Peoples R China.
   [Cao, Yan] Nanjing Med Univ, Changzhou Peoples Hosp 2, Dept Dermatol, Changzhou 213003, Peoples R China.
   [Yang, Jianping; Lv, Zhengxiang; Jiang, Tao] Nanjing Univ Tradit Chinese Med, Dept Orthopaed, Changzhou Tradit Chinese Med Hosp, Changzhou 213000, Peoples R China.
   [Li, Zhong] Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Dept Nutr & Food Hyg,Key Lab Modern Toxicol, Nanjing 211166, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing
   University of Chinese Medicine; Nanjing Medical University
RP Li, Z (通讯作者)，Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Dept Nutr & Food Hyg,Key Lab Modern Toxicol, 818 East Tianyuan Rd, Nanjing 211166, Jiangsu, Peoples R China.
EM lmwang4@163.com; uiuciz@126.com
RI Wang, Liming/AAD 7697 2020; Yang, Jianping/AIF 4075 2022; xu,
   zhipeng/M 7708 2019
FU Department of Orthopaedics, Changzhou Traditional Chinese Medical
   Hospital, Nanjing University of Traditional Chinese Medicine
FX This work was supported by the Department of Orthopaedics, Changzhou
   Traditional Chinese Medical Hospital, Affiliated to Nanjing University
   of Traditional Chinese Medicine, and we thank them for their assistance
   with the study.
CR Cheng ZY, 2011, EUR J PHARMACOL, V664, P20, DOI 10.1016/j.ejphar.2011.04.052
   Choi YH, 2014, DRUG DES DEV THER, V8, P1941, DOI 10.2147/DDDT.S71957
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007 2325
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gruber HE, 2012, BIOTECH HISTOCHEM, V87, P303, DOI 10.3109/10520295.2011.649785
   Hu PF, 2014, INT J CLIN EXP PATHO, V7, P6575
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kim H, 2011, MOL MED, V17, P893, DOI 10.2119/molmed.2011.00032
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   KRUPPA G, 1992, J IMMUNOL, V148, P3152
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Park ES, 2014, CARDIOVASC TOXICOL, V14, P1, DOI 10.1007/s12012 013 9232 0
   Pascher E, 1999, HORM METAB RES, V31, P653, DOI 10.1055/s 2007 978815
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Scholtysek Carina, 2012, Inflammation & Allergy Drug Targets, V11, P188
   Shin Seulmee, 2009, Immune Netw, V9, P255, DOI 10.4110/in.2009.9.6.255
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tuli HS, 2013, LIFE SCI, V93, P863, DOI 10.1016/j.lfs.2013.09.030
   Vishnubalaji R, 2012, CELL TISSUE RES, V347, P419, DOI 10.1007/s00441 011 1306 3
   Weiss RJ, 2010, J RHEUMATOL, V37, P2247, DOI 10.3899/jrheum.100363
   Xu CP, 2015, J PROTEOMICS, V114, P234, DOI 10.1016/j.jprot.2014.11.002
   YOSHIHARA R, 1990, LYMPHOKINE RES, V9, P59
   Yoshimura H, 2007, CELL TISSUE RES, V327, P449, DOI 10.1007/s00441 006 0308 z
   Zhang DW, 2014, INFLAMMATION, V37, P1044, DOI 10.1007/s10753 014 9827 z
   Zhang TZ, 2015, INFLAMMATION, V38, P1036, DOI 10.1007/s10753 014 0068 y
   Zhu XS, 2012, CLIN LAB, V58, P897, DOI 10.7754/Clin.Lab.2012.120312
NR 29
TC 18
Z9 19
U1 0
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394 6320
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD SEP
PY 2015
VL 28
IS 3
BP 296
EP 307
DI 10.1177/0394632015592160
PG 12
WC Immunology; Pathology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pathology; Pharmacology & Pharmacy
GA CP7SA
UT WOS:000360087100003
PM 26130747
OA Bronze
DA 2025 08 17
ER

PT J
AU Havens, PL
   Long, D
   Schuster, GU
   Gordon, CM
   Price, G
   Wilson, CM
   Kapogiannis, BG
   Mulligan, K
   Stephensen, CB
AF Havens, Peter L.
   Long, Dustin
   Schuster, Gertrud U.
   Gordon, Catherine M.
   Price, Georgine
   Wilson, Craig M.
   Kapogiannis, Bill G.
   Mulligan, Kathleen
   Stephensen, Charles B.
CA Adolescent Med Trials Network HIV
   Adolescent Med Trials Network HIV
TI Tenofovir disoproxil fumarate appears to disrupt the relationship of
   vitamin D and parathyroid hormone
SO ANTIVIRAL THERAPY
LA English
DT Article
ID BONE MINERAL DENSITY; D BINDING PROTEIN; PREEXPOSURE PROPHYLAXIS;
   RACIAL DIFFERENCES; SUPPLEMENTATION; 25(OH)D; SAFETY; MEN
AB Background: Tenofovir disoproxil fumarate (TDF) increases serum parathyroid hormone (PTH) and 1,25 dihydroxy vitamin D (1,25 (OH)(2)D), and decreases bone mineral density (BMD). Optimal treatment of TDF associated BMD loss requires an understanding of the primary cause of these abnormalities.
   Methods: Secondary review of data from two studies of TDF use in youth, comparing the relationship of PTH, 25 hydroxy vitamin D (25 OHD) and 1,25 (OH)(2)D in three groups with varying exposures to TDF: youth without HIV enrolled in a trial of TDF/emtricitabine (FTC) for HIV pre exposure prophylaxis (PrEP) at baseline (no TDF exposure) and after 12 weeks of TDF (short term TDF exposure); and youth with HIV treated with TDF containing combination antiretroviral therapy (cART) for at least 6 months at study entry (long term TDF exposure). Relationships were evaluated by correlation analyses.
   Results: Participants ranged in age from 17 to 24 years and >50% were Black/African American. In persons not treated with TDF, PTH had the physiologically appropriate negative correlation with 25 OHD (r= 0.3504, P=0.004). Correlations between PTH and 25 OHD in groups treated with TDF were weaker or absent. With longer term TDF treatment in persons with HIV, 25 OHD and 1,25 (OH)(2)D had the positive correlation similar to that found in vitamin D deficiency.
   Conclusions: TDF changes the relationship of 25 OHD to PTH, suggesting that in persons using TDF for PrEP or cART, a higher than usual target for serum 25 OHD concentration might be needed to reduce PTH and optimize bone health.
C1 [Havens, Peter L.] Med Coll Wisconsin, Childrens Hosp Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA.
   [Long, Dustin] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
   [Schuster, Gertrud U.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
   [Gordon, Catherine M.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
   [Price, Georgine] Westat Corp, Rockville, MD USA.
   [Wilson, Craig M.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
   [Kapogiannis, Bill G.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, Bethesda, MD USA.
   [Mulligan, Kathleen] Univ Calif San Francisco, Dept Med, Div Endocrinol, Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA.
   [Stephensen, Charles B.] ARS, USDA, Western Human Nutr Res Ctr, Davis, CA USA.
C3 Medical College of Wisconsin; Children's Hospital of Wisconsin;
   University of Alabama System; University of Alabama Birmingham;
   University of California System; University of California Davis;
   University System of Ohio; University of Cincinnati; Cincinnati
   Children's Hospital Medical Center; Westat; University of Alabama
   System; University of Alabama Birmingham; National Institutes of Health
   (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); University of California System;
   University of California San Francisco; United States Department of
   Agriculture (USDA)
RP Havens, PL (通讯作者)，Med Coll Wisconsin, Childrens Hosp Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA.
EM phavens@mcw.edu
RI Stephensen, Charles/AAF 1742 2021; Havens, Patrick/MAI 4858 2025; Long,
   Dustin/AAA 5006 2019; Gordon, Catherine/GOH 1814 2022
OI Wilson, Craig/0000 0001 6869 1053; 
FU Adolescent Medicine Network for HIV/AIDS Interventions (ATN) from the
   National Institutes of Health through the Eunice Kennedy Shriver
   National Institute of Child Health and Human Development [U01 HD 040533,
   U01 HD 040474]; National Institutes on Drug Abuse and Mental Health;
   Gilead Sciences, Inc. (Foster City, CA, USA)
FX This work was supported by The Adolescent Medicine Network for HIV/AIDS
   Interventions (ATN) from the National Institutes of Health (U01 HD
   040533 and U01 HD 040474) through the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (BGK), with supplemental
   funding from the National Institutes on Drug Abuse (S Kahana) and Mental
   Health (P Brouwers and S Allison). The study was scientifically reviewed
   by the ATN's Therapeutic Leadership Group. Network, scientific and
   logistical support was provided by the ATN Coordinating Center (C Wilson
   and C Partlow) at The University of Alabama at Birmingham (AL, USA).
   Network operations and analytic support was provided by the ATN Data and
   Operations Center at Westat, Inc. (B Harris and B Driver). The comments
   and views of the authors do not necessarily represent the views of the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development. For ATN 117 study medication and partial funding were
   supplied by Gilead Sciences, Inc. (Foster City, CA, USA). Further
   acknowledgements for ATN 117 and ATN 109 can be found in Additional file
   1. Presented in part at the Conference on Retroviruses and Opportunistic
   Infections (Seattle, WA, USA) on 16 February 2017 (ATN 109).
CR Arabi A, 2010, BONE, V47, P408, DOI 10.1016/j.bone.2010.05.002
   Eckard AR, 2017, JAIDS J ACQ IMM DEF, V76, P539, DOI [10.1097/QAI.0000000000001545, 10.1097/qai.0000000000001545]
   Gutiérrez OM, 2011, OSTEOPOROSIS INT, V22, P1745, DOI 10.1007/s00198 010 1383 2
   Havens PL, 2018, CLIN INFECT DIS, V66, P220, DOI 10.1093/cid/cix753
   Havens PL, 2017, CLIN INFECT DIS, V64, P317, DOI 10.1093/cid/ciw765
   Havens PL, 2013, ANTIMICROB AGENTS CH, V57, P5619, DOI 10.1128/AAC.01096 13
   Havens PL, 2012, CLIN INFECT DIS, V54, P1013, DOI 10.1093/cid/cir968
   Holick MF, 2011, AM J MED, V124, P1095, DOI 10.1016/j.amjmed.2011.08.013
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Hosek SG, 2017, JAMA PEDIATR, V171, P1063, DOI 10.1001/jamapediatrics.2017.2007
   Hosek SG, 2017, JAIDS J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
   Hsieh E, 2016, AIDS, V30, P1935, DOI 10.1097/QAD.0000000000001131
   Institute of Medicine, DIETARY REFERENCE IN
   Khundmiri SJ, 2016, COMPR PHYSIOL, V6, P561, DOI 10.1002/cphy.c140071
   Lips P, 2007, J BONE MINER RES, V22, P1668, DOI 10.1359/JBMR.070716
   Masiá M, 2012, AIDS RES HUM RETROV, V28, P242, DOI [10.1089/aid.2011.0052, 10.1089/AID.2011.0052]
   McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188
   Saliba W, 2011, AM J MED, V124, P1165, DOI 10.1016/j.amjmed.2011.07.009
   Samarawickrama A, 2014, J INT AIDS SOC, V17, P54, DOI 10.7448/IAS.17.4.19568
   Yin MT, 2017, AIDS, V31, P2337, DOI 10.1097/QAD.0000000000001621
NR 20
TC 9
Z9 11
U1 0
U2 2
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2 4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359 6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2018
VL 23
IS 7
BP 623
EP 628
DI 10.3851/IMP3269
PG 6
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA HG3RL
UT WOS:000454892000009
PM 30260797
DA 2025 08 17
ER

PT J
AU Liu, J
   Chen, BH
   Yue, B
   Yang, JD
AF Liu, Jian
   Chen, Bohua
   Yue, Bin
   Yang, Junde
TI 被撤回的出版物: MicroRNA 212 suppresses the proliferation and migration of
   osteosarcoma cells by targeting forkhead box protein A1 (Retracted
   Article)
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Retracted Publication
DE osteosarcoma; microRNA 212; forkhead box protein A1; proliferation;
   migration
ID GENE EXPRESSION; DOWN REGULATION; CANCER CELLS; INVASION; MIR 212;
   GROWTH; PATHWAY
AB MicroRNAs (miRNAs) are a class of small non coding RNAs that function as critical gene regulators by targeting the 3' untranslated region (UTR) of mRNA, causing translational repression or mRNA degradation. Deregulation of specific miRNAs, including miR 212, has been identified in patients with osteosarcoma. However, the underlying mechanism is yet to be fully elucidated. The present study aimed to reveal the regulatory mechanism of miR 212 in osteosarcoma cell viability and migration. Quantitative polymerase chain reaction data revealed that miR 212 was significantly down regulated in osteosarcoma tissues compared with normal bone tissues. miR 212 was also downregulated in osteosarcoma cell lines compared with normal osteoblast cell lines. Over expression of miR 212 significantly suppressed the viability and migration of human osteosarcoma MG 63 and Saos 2 cell lines. In addition, forkhead box protein A1 (FOXA1), an oncogene in osteosarcoma, was predicted to be a putative target of miR 212 by bioinformatical analysis. Furthermore, luciferase reporter assay data confirmed that miR 212 could directly bind to the seed sequences within the 3'UTR of FOXA1 mRNA, and miR 212 negatively mediated the protein levels of FOXA1 in osteosarcoma MG 63 and Saos 2 cells. Moreover, knockdown of FOXA1 also led to a significant decrease in the viability and migration of osteosarcoma MG 63 and Saos 2 cells and the expression levels of FOXA1 were significantly upregulated in osteosarcoma tissues and cell lines. These data suggest that miR 212 inhibits the viability and migration of osteosarcoma cells by targeting FOXA1. Accordingly, miR 212 may become a potential candidate for osteosarcoma therapy.
C1 [Liu, Jian; Chen, Bohua; Yue, Bin; Yang, Junde] Qingdao Univ, Sch Med, Peoples Hosp Qingdao 8, Dept Orthoped, 84 Fengshan Rd, Qingdao 266100, Shandong, Peoples R China.
C3 Qingdao University
RP Liu, J (通讯作者)，Qingdao Univ, Sch Med, Peoples Hosp Qingdao 8, Dept Orthoped, 84 Fengshan Rd, Qingdao 266100, Shandong, Peoples R China.
EM qduliujian2009@163.com
CR Chang Z., 2014, SCI WORLD J, V2014, DOI DOI 10.1155/2014/794756
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Dou CW, 2015, ONCOTARGET, V6, P13216, DOI 10.18632/oncotarget.3916
   Fan L, 2012, ACTA BIOCH BIOPH SIN, V44, P407, DOI 10.1093/abbs/gms019
   Geng S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091566
   Guo WH, 2015, PROSTATE, V75, P976, DOI 10.1002/pros.22982
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Jiang LD, 2014, TUMOR BIOL, V35, P12645, DOI 10.1007/s13277 014 2588 3
   Li Y, 2012, MOL BIOL CELL, V23, P1423, DOI 10.1091/mbc.E11 09 0777
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo XJ, 2014, CELL PHYSIOL BIOCHEM, V34, P2180, DOI 10.1159/000369661
   Park JK, 2011, BIOCHEM BIOPH RES CO, V406, P518, DOI 10.1016/j.bbrc.2011.02.065
   Qiu MT, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 78
   Robinson Jessica L L, 2012, Front Endocrinol (Lausanne), V3, P68, DOI 10.3389/fendo.2012.00068
   Thompson LDR, 2013, ENT EAR NOSE THROAT, V92, P288
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Wei LQ, 2014, TUMOR BIOL, V35, P12427, DOI 10.1007/s13277 014 2560 2
   Xu L, 2011, MED ONCOL, V28, pS189, DOI 10.1007/s12032 010 9691 0
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
   Zhao JL, 2015, IUBMB LIFE, V67, P380, DOI 10.1002/iub.1381
   Zheng L, 2015, INT J CLIN EXP PATHO, V8, P96
   Zhou Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756 9966 33 12
NR 22
TC 13
Z9 14
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2016
VL 12
IS 6
BP 4135
EP 4141
DI 10.3892/etm.2016.3880
PN B
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EG5IC
UT WOS:000391076500050
PM 28101191
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ma, XX
   Meng, XQ
   Wang, YL
   Liu, Y
   Shi, XR
   Shao, S
   Duan, SZ
   Lu, HX
AF Ma, X. X.
   Meng, X. Q.
   Wang, Y. L.
   Liu, Y.
   Shi, X. R.
   Shao, S.
   Duan, S. Z.
   Lu, H. X.
TI Ncor1 Deficiency Promotes Osteoclastogenesis and Exacerbates
   Periodontitis
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE periodontitis; animal experimentation; osteoclasts; neutrophil; tooth
   loss; gene therapy
ID SYSTEMATIC ANALYSIS; GLOBAL BURDEN; 195 COUNTRIES; C/EBP ALPHA;
   TRANSREPRESSION; SUMOYLATION; PREVALENCE; METABOLISM; ACTIVATION;
   DISABILITY
AB Nuclear receptor corepressor 1 (Ncor1) has been reported to regulate different transcription factors in different biological processes, including metabolism, inflammation, and circadian rhythms. However, the role of Ncor1 in periodontitis has not been elucidated. The aims of the present study were to investigate the role of Ncor1 in experimental periodontitis and to explore the underlying mechanisms through an experimental periodontitis model in myeloid cell specific Ncor1 deficient mice. Myeloid cell specific Ncor1 knockout (MNKO) mice were generated, and experimental periodontitis induced by ligation using 5 0 silk sutures was established. Ncor1 flox/flox mice were used as littermate controls (LC). Histological staining and micro computed tomography scanning were used to evaluate osteoclastogenesis and alveolar bone resorption. Flow cytometry was conducted to observe the effect of Ncor1 on myeloid cells. RNA sequencing was used to explore the differentially targeted genes in osteoclastogenesis in the absence of Ncor1. Coimmunoprecipitation (Co IP), chromatin immunoprecipitation (ChIP) experiments, and dual luciferase assays were performed to explore the relationship between NCoR1 and the targeted gene. Alveolar bone resorption in the MNKO mice was significantly greater than that in the LC mice after periodontitis induction and osteoclastogenesis in vitro. The percentage of CD11b+ cells, particularly CD11b+ Ly6G+ neutrophils, was substantially higher in gingival tissues in the MNKO mice than in the LC mice. Results of RNA sequencing demonstrated that CCAAT enhancer binding protein alpha (Cebp alpha) was one of the most differentially expressed genes between the MNKO and LC groups. Mechanistically, Co IP assays, ChIP experiments, and dual luciferase assays revealed that NCOR1 interacted with peroxisome proliferator activated receptor gamma (PPAR gamma) and cooperated with HDAC3 to control the transcription of Cebp alpha. In conclusion, Ncor1 deficiency promoted osteoclast and neutrophil formation in mice with experimental periodontitis. It regulated the transcription of Cebp alpha via PPAR gamma to promote osteoclast differentiation.
C1 [Ma, X. X.; Lu, H. X.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prevent Dent, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Ma, X. X.; Meng, X. Q.; Wang, Y. L.; Liu, Y.; Shi, X. R.; Duan, S. Z.; Lu, H. X.] Shanghai Jiao Tong Univ, Coll Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Ma, X. X.; Meng, X. Q.; Wang, Y. L.; Liu, Y.; Shi, X. R.; Duan, S. Z.; Lu, H. X.] Natl Ctr Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Ma, X. X.; Meng, X. Q.; Wang, Y. L.; Liu, Y.; Shi, X. R.; Duan, S. Z.; Lu, H. X.] Natl Clin Res Ctr Oral Dis, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Ma, X. X.; Lu, H. X.] Chinese Acad Med Sci, Res Unit Oral & Maxillofacial Regenerat Med, Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Meng, X. Q.; Wang, Y. L.; Liu, Y.; Shi, X. R.; Duan, S. Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Lab Oral Microbiota & Syst Dis, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Meng, X. Q.; Wang, Y. L.; Liu, Y.; Shi, X. R.; Duan, S. Z.] Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Shao, S.] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Medical Sciences   Peking Union Medical College; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University
RP Lu, HX (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prevent Dent, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Duan, SZ; Lu, HX (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Duan, SZ; Lu, HX (通讯作者)，Natl Ctr Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Duan, SZ; Lu, HX (通讯作者)，Natl Clin Res Ctr Oral Dis, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Lu, HX (通讯作者)，Chinese Acad Med Sci, Res Unit Oral & Maxillofacial Regenerat Med, Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Duan, SZ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Lab Oral Microbiota & Syst Dis, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Duan, SZ (通讯作者)，Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM duansz@shsmu.edu.cn; ritalu0225@hotmail.com
OI meng, xiao qian/0000 0002 3585 7085; Lu, Haixia/0000 0002 0013 6472
FU General Project of Shanghai Municipal Health Committee [201940041];
   Clinical Research Program of the Ninth People's Hospital, Shanghai Jiao
   Tong University School of Medicine [JYLJ201909]; National Natural
   Science Foundation of China [81991503, 81991500, 81921002]; Shanghai
   Clinical Research Center for Oral Diseases [19MC1910600]; Innovative
   Research Team of High Level Local Universities in Shanghai
   [SHSMU ZLCX20212401, SHSMU ZDCX20212500]; CAMS Innovation Fund for
   Medical Sciences (CIFMS) [2019 I2M 5 037]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: this study was
   supported by grants from the General Project of Shanghai Municipal
   Health Committee (201940041), the Clinical Research Program of the Ninth
   People's Hospital, Shanghai Jiao Tong University School of Medicine
   (JYLJ201909), the National Natural Science Foundation of China
   (81991503, 81991500, and 81921002), the Shanghai Clinical Research
   Center for Oral Diseases (19MC1910600), Innovative Research Team of
   High Level Local Universities in Shanghai (SHSMU ZLCX20212401 and
   SHSMU ZDCX20212500), CAMS Innovation Fund for Medical Sciences (CIFMS)
   (2019 I2M 5 037).
CR Avellino R, 2017, BLOOD, V129, P2083, DOI 10.1182/blood 2016 09 687822
   Bai L, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.842845
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Chen W, 2018, J BONE MINER RES, V33, P691, DOI 10.1002/jbmr.3342
   Chen W, 2013, P NATL ACAD SCI USA, V110, P7294, DOI 10.1073/pnas.1211383110
   Chen Y, 2022, THERANOSTICS, V12, P1074, DOI 10.7150/thno.65694
   Du LJ, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.015862
   Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125
   Francis M, 2020, J DENT RES, V99, P1486, DOI 10.1177/0022034520939029
   Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001
   Hogg SJ, 2021, MOL CELL, V81, P2183, DOI 10.1016/j.molcel.2021.04.015
   Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE635, DOI 10.1073/pnas.1522826113
   James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140 6736(18)32335 3, 10.1016/S0140 6736(18)32335 3]
   Kassebaum NJ, 2017, J DENT RES, V96, P380, DOI 10.1177/0022034517693566
   Kelly KA, 1998, ENDOCRINOLOGY, V139, P2092, DOI 10.1210/en.139.4.2092
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kong Y, 2020, MOL PSYCHIATR, V25, P2220, DOI 10.1038/s41380 020 0667 y
   Kyle SM, 2016, HUM MOL GENET, V25, P3029, DOI 10.1093/hmg/ddw156
   Kylmäoja E, 2013, CALCIFIED TISSUE INT, V92, P270, DOI 10.1007/s00223 012 9680 8
   Lewandowski SL, 2015, J BIOL CHEM, V290, P27067, DOI 10.1074/jbc.M115.684753
   Li C, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809127
   Li PP, 2013, CELL, V155, P200, DOI 10.1016/j.cell.2013.08.054
   Martins MD, 2016, J DENT RES, V95, P215, DOI 10.1177/0022034515611876
   Matsumura Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27321 5
   Mottis A, 2013, GENE DEV, V27, P819, DOI 10.1101/gad.214023.113
   Müller L, 2018, J LEUKOCYTE BIOL, V104, P1061, DOI 10.1002/JLB.1RI0418 168R
   Munz M, 2018, HUM MOL GENET, V27, P941, DOI 10.1093/hmg/ddy015
   Oppi S, 2020, EUR HEART J, V41, P995, DOI 10.1093/eurheartj/ehz667
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736
   Perlman RL, 2016, EVOL MED PUBLIC HLTH, P170, DOI 10.1093/emph/eow014
   Rhodin K, 2014, J DENT RES, V93, P882, DOI 10.1177/0022034514544506
   Saito T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08829 3
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Shungin D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10630 1
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wan XL, 2019, BLOOD ADV, V3, P644, DOI 10.1182/bloodadvances.2018022756
   Wei W, 2019, J DENT RES, V98, P1027, DOI 10.1177/0022034519858063
   Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 40
TC 11
Z9 12
U1 4
U2 30
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JAN
PY 2023
VL 102
IS 1
BP 72
EP 81
DI 10.1177/00220345221116927
EA AUG 2022
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 7F7XB
UT WOS:000841971900001
PM 35983582
DA 2025 08 17
ER

PT J
AU Wang, Z
   Fu, CF
   Chen, Y
   Xu, F
   Wang, ZY
   Qu, ZG
   Liu, Y
AF Wang, Zheng
   Fu, Changfeng
   Chen, Yong
   Xu, Feng
   Wang, Zhenyu
   Qu, Zhigang
   Liu, Yi
TI FoxC2 Enhances BMP7 Mediated Anabolism in Nucleus Pulposus Cells of the
   Intervertebral Disc
SO PLOS ONE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; ADULT ARTICULAR CHONDROCYTES; OSTEOGENIC
   PROTEIN 1; TRANSCRIPTION FACTOR; TNF ALPHA; TGF BETA; KAPPA B; MATRIX
   METALLOPROTEINASE 13; EXTRACELLULAR MATRIX; WNT/BETA CATENIN
AB Bone morphogenetic protein 7 (BMP 7) is a growth factor that plays a major role in mediating anabolism and anti catabolism of the intervertebral disc matrix and cell homeostasis. In osteoblasts, Forkhead box protein C2 (FoxC2) is a downstream target of BMPs and promotes cell proliferation and differentiation. However, the role FoxC2 may play in degenerative human intervertebral disc tissue and the relationship between FoxC2 and BMP 7 in nucleus pulposus (NP) cells remain to be elucidated. This study aims to investigate the presence and signaling mechanisms of FoxC2 in degenerative human intervertebral disc tissue and NP cells. Western blot and real time quantitative reverse transcription polymerase chain reaction (qRT PCR) analyses were used to measure FoxC2 expression in the NP tissue and cells. Transfections were carried out to measure the effect of FoxC2 on BMP 7 mediated extracellular matrix upregulation. Adenoviral knock down of Smad1 was performed to investigate the mechanism of BMP 7 induced FoxC2 expression. In degenerative NP tissue, FoxC2 was markedly upregulated and positively correlated with increased disc degeneration. Induction of NP cell proliferation was confirmed by using cell counting kit 8 assay, immunocytochemistry and real time qRT PCR for Ki67. FoxC2 led to decreased noggin expression and increased Smad1/5/8 phosphorylation. During combined treatment with BMP 7, FoxC2 greatly potentiated anabolism through synergistic mechanisms on ECM formation. Combination therapy using BMP 7 and FoxC2 may be beneficial to the treatment of intervertebral disc degeneration.
C1 [Wang, Zheng; Fu, Changfeng; Xu, Feng; Wang, Zhenyu; Qu, Zhigang; Liu, Yi] Jilin Univ, Hosp 1, Dept Spinal Surg, 71 Xinmin Ave, Changchun 130021, Jilin Province, Peoples R China.
   [Chen, Yong] Jilin Univ, Hosp 1, Dept Neurosurg, 71 Xinmin Ave, Changchun 130021, Jilin Province, Peoples R China.
C3 Jilin University; Jilin University
RP Qu, ZG; Liu, Y (通讯作者)，Jilin Univ, Hosp 1, Dept Spinal Surg, 71 Xinmin Ave, Changchun 130021, Jilin Province, Peoples R China.
EM spinal9493@foxmail.com; Liuyi89757@gmail.com
RI Wang, Zhen Yu/G 6872 2015
CR Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140 6736(99)01312 4
   Applebaum M, 2014, BMC BIOL, V12, DOI 10.1186/s12915 014 0053 9
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915
   Feng HY, 2006, J BONE JOINT SURG AM, V88A, P25, DOI 10.2106/JBJS.E.01341
   Fujita H, 2006, CIRC RES, V98, P626, DOI 10.1161/01.RES.0000207407.51752.3c
   Gozo MC, 2013, CELL DEATH DIFFER, V20, P1031, DOI 10.1038/cdd.2013.34
   Gruber HE, 1997, EXP CELL RES, V235, P13, DOI 10.1006/excr.1997.3647
   Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397
   Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200
   Hiyama A, 2008, BIOCHEM BIOPH RES CO, V369, P679, DOI 10.1016/j.bbrc.2008.02.087
   Hiyama A, 2011, J CELL PHYSIOL, V226, P1139, DOI 10.1002/jcp.22438
   Hiyama A, 2010, ARTHRITIS RHEUM US, V62, P3036, DOI 10.1002/art.27599
   Huang J, 2009, DEVELOPMENT, V136, P1741, DOI 10.1242/dev.034082
   Hwang PY, 2014, J BIOMECH ENG T ASME, V136, DOI 10.1115/1.4026360
   Im HJ, 2007, J BIOL CHEM, V282, P11110, DOI 10.1074/jbc.M609040200
   Imai Y, 2007, SPINE, V32, P1197, DOI 10.1097/BRS.0b013e3180574d26
   Le Maitre CL, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2275
   Masuda K, 2006, SPINE, V31, P742, DOI 10.1097/01.brs.0000206358.66412.7b
   Masuda K, 2008, EUR SPINE J, V17, pS441, DOI 10.1007/s00586 008 0749 z
   Mayer JE, 2013, SPINE J, V13, P299, DOI 10.1016/j.spinee.2013.01.041
   McCulloch JA, 1996, THE LUMBAR SPINE, P492
   Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529 0131(200004)43:4<801::AID ANR10>3.0.CO;2 4
   Muddasani P, 2007, J BIOL CHEM, V282, P31409, DOI 10.1074/jbc.M706508200
   Nasto LA, 2012, SPINE, V37, P1819, DOI 10.1097/BRS.0b013e31824ee8f7
   Nifuji A, 2001, J BONE MINER RES, V16, P1765, DOI 10.1359/jbmr.2001.16.10.1765
   Park SJ, 2011, BONE, V49, P428, DOI 10.1016/j.bone.2011.05.012
   Pockert AJ, 2009, ARTHRITIS RHEUM US, V60, P482, DOI 10.1002/art.24291
   Risbud MV, 2006, J CELL BIOCHEM, V98, P152, DOI 10.1002/jcb.20765
   Roughley PJ, 2004, SPINE, V29, P2691, DOI 10.1097/01.brs.0000146101.53784.b1
   Sartori R, 2014, TRENDS ENDOCRIN MET, V25, P464, DOI 10.1016/j.tem.2014.06.002
   Séguin CA, 2008, SPINE, V33, P356, DOI 10.1097/BRS.0b013e3181642a5e
   Takegami K, 2002, SPINE, V27, P1318, DOI 10.1097/00007632 200206150 00014
   Than KD, 2012, NEUROSURGERY, V70, P996, DOI 10.1227/NEU.0b013e318235d65f
   TOLONEN J, 1995, SPINE, V20, P271, DOI 10.1097/00007632 199502000 00003
   Wang CF, 2011, J ORTHOP RES, V29, P838, DOI 10.1002/jor.21310
   Wang S, 2014, CELL PROLIFERAT, V47, P381, DOI 10.1111/cpr.12121
   Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405
   Yoon ST, 2006, EUR SPINE J, V15, pS379, DOI 10.1007/s00586 006 0155 3
   You WL, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 199
   Yu X. C., 2014, SCI CHINA EARTH SCI, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0083080
   Zhang Y, 2008, SPINE, V33, P831, DOI 10.1097/BRS.0b013e31816b1f38
   Zhang Y, 2007, SPINE, V32, P2515, DOI 10.1097/BRS.0b013e318158cc09
   Zhang YJ, 2004, AM J PHYS MED REHAB, V83, P515, DOI 10.1097/01.PHM.0000130031.64343.59
NR 46
TC 8
Z9 9
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2016
VL 11
IS 1
AR e0147764
DI 10.1371/journal.pone.0147764
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DC9GH
UT WOS:000369528600056
PM 26824865
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Buvanendran, A
   Barkin, R
AF Buvanendran, Asokumar
   Barkin, Robert
TI Lumiracoxib
SO DRUGS OF TODAY
LA English
DT Article
ID CENTRAL NERVOUS SYSTEM; THERAPEUTIC ARTHRITIS RESEARCH; EVENT TRIAL
   TARGET; PROSTAGLANDIN E 2; CYCLOOXYGENASE INHIBITORS; SPINAL
   CYCLOOXYGENASE 2; ANTIINFLAMMATORY DRUGS; ANALGESIC EFFICACY;
   UP REGULATION; COX 2
AB Lumiracoxib is a selective cyclooxygenase (COX) 2 inhibitor that possesses a carboxylic acid group that makes it weakly acidic. It has good oral bioavailability; maximum plasma concentrations are reached two hours after oral administration.
   Despite its short elimination half life of four hours from the plasma, the drug is distributed to inflamed tissues and is retained for up to 24 hours. This unique property suggests that lumiracoxib, while having reduced systemic exposure, can still reach sites where COX 2 inhibition is required for pain relief.
   Lumiracoxib is metabolized extensively with only a small amount excreted in the urine. Selectivity for COX 2 is high compared to all other similar agents. It is indicated for the relief of pain in osteoarthritis, rheumatoid arthritis, acute pain and primary dysmenorrhea. Lumiracoxib has been found to be effective at doses of 100 400 mg once a day for chronic pain and 400 mg/day for acute pain.
   Large clinical trials where lumiracoxib was administered to patients with osteoarthritis have demonstrated that this drug is equally effective as other COX 2 inhibitors and nonsteroidal anti inflammatory drugs (NSAIDs). In comparison to NSAIDs, patients taking lumiracoxib experience significantly fewer adverse events and greater tolerability. It has also been shown to be effective in acute pain states, like the dental pain model and postoperative pain after orthopedic surgery. A large clinical study (TARGET) has demonstrated the gastrointestinal safety of lumiracoxib over one year. The study also showed that there was no increase in cardiovascular events in non high risk patients. However, a black box warning similar to those accompanying other COX 2 inhibitors has been placed by regulatory agencies that have approved this drug for clinical use. When lumiracoxib is coadministered with warfarin or aspirin, no dosage adjustment is required. (c) 2007 Prous Science. All rights reserved.
C1 Rush Univ, Med Ctr, Dept Anesthesiol, Chicago, IL 60612 USA.
C3 Rush University
RP Buvanendran, A (通讯作者)，Rush Univ, Med Ctr, Dept Anesthesiol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.
EM Asokumar@aol.com
CR Berenbaum F, 2005, J INT MED RES, V33, P21, DOI 10.1177/147323000503300102
   Bitner M, 2004, INT J CLIN PRACT, V58, P340, DOI 10.1111/j.1368 5031.2004.00179.x
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bonner J, 2003, ANN RHEUM DIS, V62, P264
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542 200603000 00005
   Buvanendran A, 2005, ANESTH ANALG, V100, P1320, DOI 10.1213/01.ANE.0000150597.94682.85
   Capone ML, 2007, PROSTAG OTH LIPID M, V82, P85, DOI 10.1016/j.prostaglandins.2006.05.019
   CASHMAN J, 1995, DRUGS, V49, P51, DOI 10.2165/00003495 199549010 00005
   Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031
   Couzin J, 2004, SCIENCE, V306, P2170
   Dai YQ, 2006, NEUROSCI RES, V55, P154, DOI 10.1016/j.neures.2006.02.013
   Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542 200502000 00026
   DRAY A, 1993, TRENDS PHARMACOL SCI, V14, P287, DOI 10.1016/0165 6147(93)90041 H
   Esser R, 2005, BRIT J PHARMACOL, V144, P538, DOI 10.1038/sj.bjp.0706078
   Everts B, 2000, CLIN RHEUMATOL, V19, P331, DOI 10.1007/s100670070024
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   FERREIRA SH, 1972, NATURE NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0
   Fleischmann R, 2006, CLIN RHEUMATOL, V25, P42, DOI 10.1007/s10067 005 1126 5
   FLOWERS R, 1985, PHARM BASIS THERAPEU
   Giuliano F, 2002, J PHARMACOL EXP THER, V303, P1001, DOI 10.1124/jpet.102.041244
   Grifka JK, 2004, CLIN EXP RHEUMATOL, V22, P589
   Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291
   Hartmann SN, 2004, ANN PHARMACOTHER, V38, P1582, DOI 10.1345/aph.1E044
   Hawkey CC, 2004, J RHEUMATOL, V31, P1804
   Heim HK, 2006, THROMB HAEMOSTASIS, V96, P423, DOI 10.1160/TH06 08 0462
   HIGGS GA, 1980, BRIT J CLIN PHARMACO, V10, pS233, DOI 10.1111/j.1365 2125.1980.tb01805.x
   Jermany J, 2005, J CLIN PHARMACOL, V45, P1172, DOI 10.1177/0091270005280377
   Kalbag J, 2004, PHARMACOL RES, V50, P181, DOI 10.1016/j.phrs.2004.03.002
   Kalbag J, 2004, J CLIN PHARMACOL, V44, P646, DOI 10.1177/0091270004265363
   Kellstein D, 2004, INT J CLIN PRACT, V58, P244, DOI 10.1111/j.1368 5031.2004.00155.x
   KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003 9861(92)90411 O
   Kroin JS, 2004, ANESTHESIOLOGY, V100, P364, DOI 10.1097/00000542 200402000 00027
   Kroin JS, 2002, REGION ANESTH PAIN M, V27, P451, DOI 10.1053/rapm.2002.35521
   Lyseng Williamson KA, 2004, DRUGS, V64, P2237, DOI 10.2165/00003495 200464190 00008
   Mangold JB, 2004, DRUG METAB DISPOS, V32, P566, DOI 10.1124/dmd.32.5.566
   Matchaba P, 2005, CLIN THER, V27, P1196, DOI 10.1016/j.clinthera.2005.07.019
   Mysler E, 2004, INT J CLIN PRACT, V58, P606, DOI 10.1111/j.1368 5031.2004.00199.x
   *NIH, 2004, FDA M DEC
   O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30
   OBANION MK, 1991, J BIOL CHEM, V266, P23261
   Packman E, 2005, HEADACHE, V45, P1163, DOI 10.1111/j.1526 4610.2005.00239.x
   Reuben SS, 2006, ANESTHESIOLOGY, V104, P411, DOI 10.1097/00000542 200603000 00006
   RORDORF C, 2002, ANN RHEUM DIS S1, V61, P420
   Rordorf CM, 2005, CLIN PHARMACOKINET, V44, P1247, DOI 10.2165/00003088 200544120 00004
   Samad TA, 2002, TRENDS MOL MED, V8, P390, DOI 10.1016/S1471 4914(02)02383 3
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   Schnitzer TJ, 2004, ARTHRIT RHEUM ARTHR, V51, P549, DOI 10.1002/art.20525
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Scott G, 2004, CLIN PHARMACOKINET, V43, P467, DOI 10.2165/00003088 200443070 00003
   SCOTT G, 2002, ANN RHEUM DIS S1, V61, P244
   Sheldon E, 2005, CLIN THER, V27, P64, DOI 10.1016/j.clinthera.2005.01.002
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   van der Heijde D, 2005, ARTHRITIS RHEUM US, V52, P582, DOI 10.1002/art.20852
   VANE JR, 1976, J ALLERGY CLIN IMMUN, V58, P691, DOI 10.1016/0091 6749(76)90181 0
   von Euler US, 1936, J PHYSIOL LONDON, V88, P213, DOI 10.1113/jphysiol.1936.sp003433
   Wilding IR, 2004, PHARM RES DORDR, V21, P443, DOI 10.1023/B:PHAM.0000019297.07378.bd
   Yaksh TL, 2001, J NEUROSCI, V21, P5847, DOI 10.1523/JNEUROSCI.21 16 05847.2001
   Zelenakas K, 2004, INT J CLIN PRACT, V58, P251, DOI 10.1111/j.1368 5031.2004.00156.x
NR 60
TC 16
Z9 19
U1 0
U2 6
PU PROUS SCIENCE, SAU THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699 3993
EI 1699 4019
J9 DRUG TODAY
JI Drugs Today
PD MAR
PY 2007
VL 43
IS 3
BP 137
EP 147
DI 10.1358/dot.2007.43.3.1062673
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 157CO
UT WOS:000245696400002
PM 17380211
DA 2025 08 17
ER

PT J
AU Higano, CS
   Crawford, ED
AF Higano, Celestia S.
   Crawford, E. David
TI New and emerging agents for the treatment of castration resistant
   prostate cancer
SO UROLOGIC ONCOLOGY SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Prostate cancer; Castration resistant; Treatments
ID MITOXANTRONE PLUS PREDNISONE; REMAINS HORMONE DRIVEN; CTLA 4 BLOCKADE;
   OPEN LABEL; ABIRATERONE ACETATE; ANTITUMOR ACTIVITY; SIPULEUCEL T;
   DOUBLE BLIND; 2ND LINE CHEMOTHERAPY; DENDRITIC CELLS
AB Most men with recurrent prostate cancer (CaP) initially respond to androgen deprivation therapy but eventually develop metastatic castration resistant prostate cancer (CRPC). Over the last decade, new therapeutic targets have been identified in CRPC and several new drugs have reached advanced stages of clinical development. In 2010, the Food and Drug Administration (FDA) approved sipuleucel T and cabazitaxel, and in 2011, abiraterone for patients with metastatic CRPC based on phase 3 trials showing improved survival. Although not yet available for clinical use, a press release in June 2011 announced that radium 223 also demonstrated a survival advantage in men with metastatic CRPC. Emerging therapies in advanced stages of clinical development in CRPC include the hormonal therapies MDV3100 and TAK 700, and the immunotherapy ipilimumab. Results are also pending on phase 3 studies comparing docetaxel plus prednisone with docetaxel given with the novel agents aflibercept, dasatinib, lenalidomide, and custirsen. In addition to these new and emerging therapeutic agents, denosumab was approved for the prevention of skeletal complications in patients with bone metastases due to solid tumor malignancies, providing an alternative to zoledronic acid. While the addition of these new treatment options is a great advance for men with metastatic CRPC, there are many new questions arising regarding sequencing of these treatments with each other, with previously existing therapies, and with the emerging agents now in clinical trials. Furthermore, there are concerns that on going phase 3 trials may be contaminated if patients go off study treatment to start I of the newly approved agents or take the agent subsequently. These realities make clinical trial design more challenging than ever. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Higano, Celestia S.] Univ Washington, Sch Med, Div Clin Res, Dept Med,Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
   [Higano, Celestia S.] Univ Washington, Sch Med, Div Clin Res, Dept Urol,Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
   [Crawford, E. David] Univ Colorado, Denver Hlth Sci Ctr, Dept Surg, Aurora, CO 80046 USA.
   [Crawford, E. David] Univ Colorado, Denver Hlth Sci Ctr, Dept Urol, Aurora, CO 80046 USA.
   [Crawford, E. David] Univ Colorado, Denver Hlth Sci Ctr, Dept Radiat Oncol, Aurora, CO 80046 USA.
C3 Fred Hutchinson Cancer Center; University of Washington; University of
   Washington Seattle; University of Washington; University of Washington
   Seattle; Fred Hutchinson Cancer Center; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus; University of
   Colorado System; University of Colorado Anschutz Medical Campus
RP Higano, CS (通讯作者)，Univ Washington, Sch Med, Div Clin Res, Dept Med,Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
EM thigano@u.washington.edu
RI Higano, Celestia/ABB 1153 2022
CR AGUS DB, 2011, P ASCO M CHIC ILL JU
   [Anonymous], NCCN CLIN PRACT GUID
   Attar RM, 2009, CLIN CANCER RES, V15, P3251, DOI 10.1158/1078 0432.CCR 08 1171
   Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749
   Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642
   Attard G, 2009, CANCER RES, V69, P4937, DOI 10.1158/0008 5472.CAN 08 4531
   Berthold DR, 2008, ANN ONCOL, V19, P1749, DOI 10.1093/annonc/mdn288
   Burch PA, 2000, CLIN CANCER RES, V6, P2175
   Byar D P, 1988, NCI Monogr, P165
   BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097 0142(197311)32:5<1126::AID CNCR2820320518>3.0.CO;2 C
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   de Bono JS, 2010, ANN ONCOL
   DEVOOGT HJ, 1986, J UROLOGY, V135, P303, DOI 10.1016/S0022 5347(17)45620 5
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Goldstein NS, 2002, AM J CLIN PATHOL, V117, P471, DOI 10.1309/G6PR Y774 X738 FG2K
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Higano CS, 2009, CANCER AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429
   HIGANO CS, 2010, P ASCO M CHIC ILL JU
   Huggins C, 1941, CANCER RES, V1, P293
   Huggins C, 1941, ARCH SURG CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004
   HUGGINS C, 1967, SCIENCE, V156, P1050, DOI 10.1126/science.156.3778.1050
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   KELLY WK, 2010, P ASCO M CHIC ILL JU
   Klotz L, 2008, BJU INT, V102, P1531, DOI 10.1111/j.1464 410X.2008.08183.x
   Kwon ED, 1999, P NATL ACAD SCI USA, V96, P15074, DOI 10.1073/pnas.96.26.15074
   Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099
   Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734
   Loblaw DA, 2004, J CLIN ONCOL, V22, P2927, DOI 10.1200/jco.2004.04.579
   Longo DL, 2010, NEW ENGL J MED, V363, P479, DOI 10.1056/NEJMe1006300
   McLeod D, 2001, UROLOGY, V58, P756, DOI 10.1016/S0090 4295(01)01342 5
   Michels J, 2006, CANCER AM CANCER SOC, V106, P1041, DOI 10.1002/cncr.21695
   Mostaghel EA, 2009, UROL ONCOL SEMIN ORI, V27, P251, DOI 10.1016/j.urolonc.2009.03.016
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   O'Mahony D, 2007, CLIN CANCER RES, V13, P958, DOI 10.1158/1078 0432.CCR 06 1974
   Osoba D, 1999, J CLIN ONCOL, V17, P1654, DOI 10.1200/JCO.1999.17.6.1654
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819
   Rosenberg JE, 2007, CANCER AM CANCER SOC, V110, P556, DOI 10.1002/cncr.22811
   SCHALLY AV, 1971, SCIENCE, V173, P1036, DOI 10.1126/science.173.4001.1036
   Scher HI, 2000, UROLOGY, V55, P323, DOI 10.1016/S0090 4295(99)00471 9
   SCHER HI, 2010, P ASCO M CHIC ILL JU
   Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140 6736(10)60172 9
   Seidenfeld J, 2000, ANN INTERN MED, V132, P566, DOI 10.7326/0003 4819 132 7 200004040 00009
   Siegel R, 2011, CA CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   SLOVIN SF, 2009, P ASCO M ORL FLOR MA
   SMALL E, 2009, P GEN CANC S ORL FLO
   Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894
   Small EJ, 2007, CLIN CANCER RES, V13, P1810, DOI 10.1158/1078 0432.CCR 06 2318
   Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   TOLIS G, 1982, P NATL ACAD SCI BIOL, V79, P1658, DOI 10.1073/pnas.79.5.1658
   Trachtenberg J, 2002, J UROLOGY, V167, P1670
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   1967, SURG GYNECOL OBSTET, V124, P1011
NR 59
TC 48
Z9 54
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1078 1439
J9 UROL ONCOL SEMIN ORI
JI Urol. Oncol. Semin. Orig. Investig.
PD NOV DEC
PY 2011
VL 29
IS 6
SU S
BP S1
EP S8
DI 10.1016/j.urolonc.2011.08.013
PG 8
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA 853RN
UT WOS:000297443500001
PM 22074657
DA 2025 08 17
ER

PT J
AU Muok, L
   Liu, C
   Chen, XC
   Esmonde, C
   Arthur, P
   Wang, XJ
   Singh, M
   Driscoll, T
   Li, Y
AF Muok, Laureana
   Liu, Chang
   Chen, Xingchi
   Esmonde, Colin
   Arthur, Peggy
   Wang, Xueju
   Singh, Mandip
   Driscoll, Tristan
   Li, Yan
TI Inflammatory Response and Exosome Biogenesis of Choroid Plexus Organoids
   Derived from Human Pluripotent Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE human pluripotent stem cells; choroid plexus organoids; Wnt signaling;
   inflammatory response; extracellular vesicles
ID AMYLOID BETA; DISEASE; MECHANISMS; MODELS; WNT
AB The choroid plexus (ChP) is a complex structure in the human brain that is responsible for the secretion of cerebrospinal fluid (CSF) and forming the blood CSF barrier (B CSF B). Human induced pluripotent stem cells (hiPSCs) have shown promising results in the formation of brain organoids in vitro; however, very few studies to date have generated ChP organoids. In particular, no study has assessed the inflammatory response and the extracellular vesicle (EV) biogenesis of hiPSC derived ChP organoids. In this study, the impacts of Wnt signaling on the inflammatory response and EV biogenesis of ChP organoids derived from hiPSCs was investigated. During days 10 15, bone morphogenetic protein 4 was added along with (+/ ) CHIR99021 (CHIR, a small molecule GSK 3 beta inhibitor that acts as a Wnt agonist). At day 30, the ChP organoids were characterized by immunocytochemistry and flow cytometry for TTR (similar to 72%) and CLIC6 (similar to 20%) expression. Compared to the  CHIR group, the +CHIR group showed an upregulation of 6 out of 10 tested ChP genes, including CLIC6 (2 fold), PLEC (4 fold), PLTP (2 4 fold), DCN (similar to 7 fold), DLK1 (2 4 fold), and AQP1 (1.4 fold), and a downregulation of TTR (0.1 fold), IGFBP7 (0.8 fold), MSX1 (0.4 fold), and LUM (0.2 0.4 fold). When exposed to amyloid beta 42 oligomers, the +CHIR group had a more sensitive response as evidenced by the upregulation of inflammation related genes such as TNF alpha, IL 6, and MMP2/9 when compared to the  CHIR group. Developmentally, the EV biogenesis markers of ChP organoids showed an increase over time from day 19 to day 38. This study is significant in that it provides a model of the human B CSF B and ChP tissue for the purpose of drug screening and designing drug delivery systems to treat neurological disorders such as Alzheimer's disease and ischemic stroke.
C1 [Muok, Laureana; Liu, Chang; Chen, Xingchi; Esmonde, Colin; Driscoll, Tristan; Li, Yan] Florida State Univ, FAMU FSU Coll Engn, Dept Chem & Biomed Engn, Tallahassee, FL 32310 USA.
   [Arthur, Peggy; Singh, Mandip] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.
   [Wang, Xueju] Univ Connecticut, Dept Mat Sci & Engn, Storrs, CT 06268 USA.
C3 State University System of Florida; Florida A&M University; Florida
   State University; State University System of Florida; Florida A&M
   University; University of Connecticut
RP Li, Y (通讯作者)，Florida State Univ, FAMU FSU Coll Engn, Dept Chem & Biomed Engn, Tallahassee, FL 32310 USA.
EM yli4@fsu.edu
RI Esmonde, Colin/KOC 2400 2024; Driscoll, Tristan/AAE 7173 2021
OI Arthur, Peggy/0000 0002 6225 2639; Driscoll,
   Tristan/0000 0002 2426 5551; Li, Yan/0000 0002 5938 8519; Sachdeva,
   Mandip/0000 0001 9192 8143
CR Arthur P, 2023, PHARM RES DORDR, V40, P801, DOI 10.1007/s11095 022 03350 7
   Balusu S, 2016, EMBO MOL MED, V8, P1162, DOI 10.15252/emmm.201606271
   Bejoy J, 2020, TISSUE ENG PT A, V26, P419, DOI [10.1089/ten.TEA.2019.0202, 10.1089/ten.tea.2019.0202]
   Bejoy J, 2018, TISSUE ENG PT A, V24, P546, DOI [10.1089/ten.TEA.2017.0153, 10.1089/ten.tea.2017.0153]
   Blanchette CR, 2020, CURR OPIN NEUROBIOL, V63, P104, DOI 10.1016/j.conb.2020.03.013
   Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847
   Bolos M, 2013, CELL MOL LIFE SCI, V70, P2787, DOI 10.1007/s00018 013 1300 x
   Brkic M, 2015, J NEUROSCI, V35, P12766, DOI 10.1523/JNEUROSCI.0006 15.2015
   Busatto S, 2021, FASEB BIOADV, V3, P665, DOI 10.1096/fba.2021 00045
   Chhabra S, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000498
   Chiaradia I, 2020, NAT NEUROSCI, V23, P1496, DOI 10.1038/s41593 020 00730 3
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev cellbio 101512 122326
   Crossgrove JS, 2005, EXP BIOL MED, V230, P771, DOI 10.1177/153537020523001011
   Cvjetkovic A, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23111
   Garreta E, 2021, NAT MATER, V20, P145, DOI 10.1038/s41563 020 00804 4
   Gonzalez C, 2018, MOL PSYCHIATR, V23, P2363, DOI 10.1038/s41380 018 0229 8
   Gonzalez Marrero I, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00017
   Hébert JM, 2002, NEURON, V35, P1029, DOI 10.1016/S0896 6273(02)00900 5
   Hua T, 2021, TISSUE ENG PT A, V27, P881, DOI [10.1089/ten.tea.2020.0135, 10.1089/ten.TEA.2020.0135]
   Hua TM, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 16970 1
   Iram T, 2022, NATURE, V605, P509, DOI 10.1038/s41586 022 04722 0
   Jacob F, 2020, CELL STEM CELL, V27, P937, DOI 10.1016/j.stem.2020.09.016
   Jeske R, 2023, BIOACT MATER, V25, P732, DOI 10.1016/j.bioactmat.2022.07.004
   Jeske R, 2020, TISSUE ENG PART B RE, V26, P129, DOI [10.1089/ten.TEB.2019.0252, 10.1089/ten.teb.2019.0252]
   Kelava I, 2016, CELL STEM CELL, V18, P736, DOI 10.1016/j.stem.2016.05.022
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Lässer C, 2012, JOVE J VIS EXP, DOI 10.3791/3037
   Lehtinen MK, 2013, J NEUROSCI, V33, P17553, DOI 10.1523/JNEUROSCI.3258 13.2013
   Li JH, 2013, NAT IMMUNOL, V14, P793, DOI 10.1038/ni.2647
   Liu C, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10123060
   Lun MP, 2015, NAT REV NEUROSCI, V16, P445, DOI 10.1038/nrn3921
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marzano M, 2021, ACS BIOMATER SCI ENG, V7, P1111, DOI 10.1021/acsbiomaterials.0c01286
   Marzano M, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090993
   Morrisette Thomas V, 2014, MECH AGEING DEV, V139, P49, DOI 10.1016/j.mad.2014.06.005
   Moya N, 2014, STEM CELL REP, V3, P1015, DOI 10.1016/j.stemcr.2014.10.004
   Parichha A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27602 z
   Pellegrini L, 2020, SCIENCE, V369, P159, DOI 10.1126/science.aaz5626
   Reiner AT, 2017, STEM CELL TRANSL MED, V6, P1730, DOI 10.1002/sctm.17 0055
   Rider MA, 2016, SCI REP UK, V6, DOI 10.1038/srep23978
   Sakaguchi H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9896
   Si Tayeb K, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 81
   Si Tayeb K, 2010, HEPATOLOGY, V51, P297, DOI 10.1002/hep.23354
   Solár P, 2020, FLUIDS BARRIERS CNS, V17, DOI 10.1186/s12987 020 00196 2
   Song GN, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.646921
   Song LQ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47444 6
   Song LQ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42439 9
   Sonnen KF, 2018, CELL, V172, P1079, DOI 10.1016/j.cell.2018.01.026
   Thompson AG, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201800257
   Vandendriessche C, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478 021 01245 z
   Watanabe M, 2012, J NEUROSCI, V32, P15934, DOI 10.1523/JNEUROSCI.3227 12.2012
   Xiang JM, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987 017 0056 3
   Yan YW, 2018, TISSUE ENG PT A, V24, P1125, DOI [10.1089/ten.TEA.2017.0423, 10.1089/ten.tea.2017.0423]
   Yan YW, 2018, TISSUE ENG PT A, V24, P418, DOI [10.1089/ten.tea.2016.0400, 10.1089/ten.TEA.2016.0400]
   Yan YW, 2016, ACTA BIOMATER, V42, P114, DOI 10.1016/j.actbio.2016.06.027
   Yuan XG, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12235
   Zhang DW, 2014, BIOMATERIALS, V35, P1420, DOI 10.1016/j.biomaterials.2013.11.028
   Zhang ZJ, 2022, CURR OPIN NEUROBIOL, V74, DOI 10.1016/j.conb.2022.102536
   Zhao J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19264 0
   Zhu SY, 2011, ANNU REV BIOMED ENG, V13, P73, DOI 10.1146/annurev bioeng 071910 124715
   Zolezzi JM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00187
NR 62
TC 4
Z9 5
U1 1
U2 16
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2023
VL 24
IS 8
AR 7660
DI 10.3390/ijms24087660
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA E7WZ3
UT WOS:000977615000001
PM 37108817
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fang, C
   Kang, YB
AF Fang, Cao
   Kang, Yibin
TI Cellular plasticity in bone metastasis
SO BONE
LA English
DT Article
DE Epithelial mesenchymal transition; Cellular plasticity; Bone metastasis
ID EPITHELIAL MESENCHYMAL TRANSITION; DISSEMINATED TUMOR CELLS;
   BREAST CANCER CELLS; GENE EXPRESSION SIGNATURE; PROSTATE CANCER;
   E CADHERIN; IMMUNOCYTOLOGICAL DETECTION; OSTEOBLAST DIFFERENTIATION;
   MARROW MICROMETASTASIS; MOLECULAR MECHANISM
AB Metastasis is responsible for a large majority of death from malignant solid tumors. Bone is one of the most frequently affected organs in cancer metastasis, especially in breast and prostate cancer. Development of bone metastasis requires cancer cells to successfully complete a number of challenging steps, including local invasion and intravasation, survival in circulation, extravasation and initial seeding, and finally, formation of metastatic colonies after a period of dormancy or indolent growth. During this process, cancer cells often undergo a series of cellular and molecular changes to gain cellular plasticity that helps them adapt to various environments they encounter along the journey of metastasis. Understanding the mechanisms behind cellular plasticity and adaptation during the formation of bone metastasis is crucial for the development of novel therapies.
C1 [Fang, Cao; Kang, Yibin] Princeton Univ, Dept Mol Biol, LTL255,Washington Rd, Princeton, NJ 08544 USA.
C3 Princeton University
RP Kang, YB (通讯作者)，Princeton Univ, Dept Mol Biol, LTL255,Washington Rd, Princeton, NJ 08544 USA.
EM ykang@princeton.edu
OI Kang, Yibin/0000 0002 1626 6730
FU China Scholarship Council Scholarship; American Cancer Society
   Professorship; Brewster Foundation; Breast Cancer Research Foundation;
   US Department of Defense; Susan G. Komen Foundation; US National
   Institutes of Health; National Cancer Institute [R01CA212410] Funding
   Source: NIH RePORTER
FX We thank members of our laboratories, especially Dr. Mark Esposito, for
   helpful discussions and critical reading of the manuscript. We also
   apologize to the many investigators whose important studies could not be
   cited directly here because of space limitations. All figures in this
   article are created with BioRender.com. The work was supported by a
   China Scholarship Council Scholarship to C. F. and an American Cancer
   Society Professorship to Y. K. and grants from the Brewster Foundation,
   the Breast Cancer Research Foundation, the US Department of Defense,
   Susan G. Komen Foundation and the US National Institutes of Health to
   Y.K.
CR Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013
   Aguirre Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027
   Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333
   Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alsuliman A, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0421 2
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Awolaran O, 2016, BREAST, V30, P156, DOI 10.1016/j.breast.2016.09.017
   Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078 0432.CCR 06 0169
   Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444
   Barbier V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15817 5
   Barbieri I, 2020, NAT REV CANCER, V20, P303, DOI 10.1038/s41568 020 0253 2
   Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830
   Blagosklonny MV, 2011, AGING US, V3, P94, DOI 10.18632/aging.100281
   Bourcy M, 2016, CANCER RES, V76, P4270, DOI 10.1158/0008 5472.CAN 15 2263
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Brenner S, 2004, STEM CELLS, V22, P1128, DOI 10.1634/stemcells.2003 0196
   Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768
   Casimiro S, 2012, CLIN EXP METASTAS, V29, P155, DOI 10.1007/s10585 011 9438 0
   Charpentier Monica, 2013, Cancers (Basel), V5, P1545, DOI 10.3390/cancers5041545
   CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934 8832(11)80070 3
   Chéry L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480
   Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Cieply B, 2015, MATRIX BIOL, V48, P55, DOI 10.1016/j.matbio.2015.04.010
   Cosphiadi I, 2018, CLIN BREAST CANCER, V18, pE1117, DOI 10.1016/j.clbc.2018.03.001
   Cox RF, 2012, BRIT J CANCER, V106, P525, DOI 10.1038/bjc.2011.583
   Cox RF, 2013, BONE, V53, P437, DOI 10.1016/j.bone.2013.01.013
   Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492
   Dardaei L, 2011, CLIN BIOCHEM, V44, P325, DOI 10.1016/j.clinbiochem.2010.11.005
   de Prati AC, 2017, J CELL BIOCHEM, V118, P3237, DOI 10.1002/jcb.25972
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777
   Domanska UM, 2012, NEOPLASIA, V14, P709, DOI 10.1593/neo.12324
   Dong J, 2018, GENOME BIOL, V19, DOI 10.1186/s13059 018 1416 2
   Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008 5472.CAN 16 3292
   Dunn LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006896
   Egan K, 2014, CLIN EXP METASTAS, V31, P697, DOI 10.1007/s10585 014 9660 7
   Esposito M, 2019, NAT CELL BIOL, V21, P627, DOI 10.1038/s41556 019 0309 2
   Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465
   Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907
   Fujisaki J, 2011, NATURE, V474, P216, DOI 10.1038/nature10160
   Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89
   GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130
   Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011
   Hong YP, 2016, INT J ONCOL, V49, P2206, DOI 10.3892/ijo.2016.3747
   Hou JM, 2011, AM J PATHOL, V178, P989, DOI 10.1016/j.ajpath.2010.12.003
   Hsu JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04313 6
   Hu BG, 2020, CANCER MED US, V9, P2686, DOI 10.1002/cam4.2871
   Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008 5472.CAN 04 3448
   Hyun KA, 2016, ONCOTARGET, V7, P24677, DOI 10.18632/oncotarget.8250
   Ishay Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002
   Janni W, 2011, CLIN CANCER RES, V17, P2967, DOI 10.1158/1078 0432.CCR 10 2515
   Jiang YY, 2020, CANCER LETT, V468, P72, DOI 10.1016/j.canlet.2019.10.013
   JUHL H, 1994, INT J CANCER, V57, P330, DOI 10.1002/ijc.2910570307
   Kallergi G, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058 018 0993 z
   Kallergi G, 2013, MOL CANCER THER, V12, P1886, DOI 10.1158/1535 7163.MCT 12 1167
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kawaguchi J, 2001, J BONE MINER RES, V16, P1265, DOI 10.1359/jbmr.2001.16.7.1265
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Köllermann J, 2008, J CLIN ONCOL, V26, P4928, DOI 10.1200/JCO.2007.15.0441
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Kong DG, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00072
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Kröger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116
   Kumar S, 2011, MOL CELL BIOL, V31, P4036, DOI 10.1128/MCB.01342 10
   Kuol N, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0674 x
   Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009
   Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260
   Lecharpentier A, 2011, BRIT J CANCER, V105, P1338, DOI 10.1038/bjc.2011.405
   Li XQ, 2016, CANCER LETT, V380, P78, DOI 10.1016/j.canlet.2016.06.007
   Liang MM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1594 1
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008 5472.CAN 06 4493
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Liu LL, 2019, BIOCHEM CELL BIOL, V97, P463, DOI 10.1139/bcb 2018 0263
   Lo HC, 2020, NAT CANCER, V1, P709, DOI 10.1038/s43018 020 0068 9
   Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Luis Ravelo D, 2014, ONCOGENE, V33, P5090, DOI 10.1038/onc.2013.440
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Naume B, 2014, J CLIN ONCOL, V32, P3848, DOI 10.1200/JCO.2014.56.9327
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   OGHISO Y, 1979, JPN J EXP MED, V49, P223
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008 5472.CAN 07 2938
   Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162
   Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586 019 1526 3
   Palumbo JS, 2008, SEMIN THROMB HEMOST, V34, P154, DOI 10.1055/s 2008 1079255
   Palumbo JS, 2005, BLOOD, V105, P178, DOI 10.1182/blood 2004 06 2272
   Pang HL, 2018, ONCOL LETT, V15, P6739, DOI 10.3892/ol.2018.8160
   PANTEL K, 1993, CANCER RES, V53, P1027
   Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79
   Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586 018 0040 3
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813
   Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044
   Qiu XY, 2018, BBA MOL BASIS DIS, V1864, P1754, DOI 10.1016/j.bbadis.2018.03.002
   Recasens A, 2019, TRENDS PHARMACOL SCI, V40, P128, DOI 10.1016/j.tips.2018.12.004
   Sänger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895
   Satelli A, 2015, CLIN CANCER RES, V21, P899, DOI 10.1158/1078 0432.CCR 14 0894
   Savci Heijink CD, 2016, BREAST CANCER RES TR, V156, P249, DOI 10.1007/s10549 016 3741 z
   Scimeca M, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 286
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371
   Soundararajan R, 2015, SCI REP UK, V5, DOI 10.1038/srep11766
   Sultan M, 2018, STEM CELLS, V36, P641, DOI 10.1002/stem.2780
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Taichman RS, 2002, CANCER RES, V62, P1832
   Tamura T.H. Daisuke, 2008, CADHERIN 11 MEDIATED
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Voon DCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070427
   Wang B, 2014, CANCER RES, V74, P5746, DOI 10.1158/0008 5472.CAN 13 2563
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10379 7
   Wang XW, 2015, INT J CLIN EXP MED, V8, P5839
   Wang YW, 2015, MED ONCOL, V32, DOI 10.1007/s12032 015 0655 2
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008 5472.CAN 07 6589
   Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976
   Xie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061212
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580 020 0237 9
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
   Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159 8290.CD 19 0015
   Yumoto K, 2016, SCI REP UK, V6, DOI 10.1038/srep36520
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 143
TC 4
Z9 4
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2022
VL 158
AR 115693
DI 10.1016/j.bone.2020.115693
EA MAR 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 0P2ZE
UT WOS:000784088900002
PM 33069922
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cheng, SN
   Li, YX
   Yu, CG
   Deng, ZW
   Huang, J
   Zhang, ZJ
AF Cheng, Shengnan
   Li, Yuxuan
   Yu, Chenggong
   Deng, Zongwu
   Huang, Jie
   Zhang, Zhijun
TI 3D bioprinted tumor vessel bone co culture scaffold for breast cancer
   bone metastasis modeling and drug testing
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Cell laden 3D bioprinting; Vascularized tissue; Breast cancer bone
   metastasis; Drug testing
ID HYDROGELS; COLLAGEN; MATRIX; CONSTRUCTS; CELLS
AB Bone metastasis is one of the most common complications of advanced breast cancer (BrCa) with a poor clinical prognosis, due to the lack of effective drugs and therapeutics. Traditional screening systems for anti cancer drugs are not capable of exactly reflecting the efficacy of drugs in vivo, mainly because they cannot replicate the dynamic metastasis process involving primary tumor, blood circulation and bone microenvironment. To precisely simulate the behavior of native BrCa cells, herein, a biomimetic 3D co culture metastatic model composed of tumor, hollow vascular, and bone tissues is fabricated by one step 3D bioprinting method for effective drug testing. Gelatin methacryloyl based photocrosslinkable bioinks containing breast cancer cells (MDA MB 231), human umbilical vein endothelial cells (HUVECs) and osteoblasts (h OB) are applied to highly imitate the native metastatic niches with the formation of blood vessels, vascularized tumors, as well as vascularized bone tissues. The dynamic invasion behavior of BrCa cells from original sites to bone tissues through blood vessels is reproduced, and the interactive effect of cancer, vascular and bone cells are investigated. Moreover, the 3D co culture metastatic model allows for higher drug resistance of BrCa cells than 2D culture and 3D mono culture models. These results demonstrate that the 3D bioprinted co culture metastatic model facilitates in depth understanding of the basic mechanisms of BrCa migration and provides a physiologically relevant platform for the development of new therapeutic drugs.
C1 [Cheng, Shengnan; Li, Yuxuan; Yu, Chenggong; Deng, Zongwu; Huang, Jie; Zhang, Zhijun] Univ Sci & Technol China, Sch Nanotech & Nanobion, Hefei 230026, Peoples R China.
   [Cheng, Shengnan; Li, Yuxuan; Yu, Chenggong; Deng, Zongwu; Huang, Jie; Zhang, Zhijun] Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, Organoid Innovat Ctr, Div Nanobiomed,CAS Key Lab Nanobio Interface, Suzhou 215123, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Chinese Academy of Sciences; Suzhou Institute of Nano Tech &
   Nano Bionics, CAS
RP Deng, ZW; Huang, J; Zhang, ZJ (通讯作者)，Univ Sci & Technol China, Sch Nanotech & Nanobion, Hefei 230026, Peoples R China.
EM zwdeng2007@sinano.ac.cn; jhuang2008@sinano.ac.cn;
   zjzhang2007@sinano.ac.cn
RI Zhang, Zhijun/E 5980 2014; Yu, Chenggong/HRD 4455 2023
OI Zhang, Zhijun/0000 0002 9853 1031; Yu, Chenggong/0009 0007 0900 3696
FU Suzhou Basic Research Pilot Project [SJC2021011]
FX This work was supported by the Suzhou Basic Research Pilot Project
   (SJC2021011) .
CR Alemany Ribes M, 2014, ADV DRUG DELIVER REV, V79 80, P40, DOI 10.1016/j.addr.2014.06.004
   Antunes J, 2019, ACTA BIOMATER, V94, P392, DOI 10.1016/j.actbio.2019.06.012
   Bernhardt A, 2008, J MATER SCI MATER M, V19, P269, DOI 10.1007/s10856 006 0059 0
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Bertassoni LE, 2014, LAB CHIP, V14, P2202, DOI 10.1039/c4lc00030g
   Billiet T, 2014, BIOMATERIALS, V35, P49, DOI 10.1016/j.biomaterials.2013.09.078
   Bray LJ, 2015, BIOMATERIALS, V53, P609, DOI 10.1016/j.biomaterials.2015.02.124
   Byambaa B, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700015
   Carvalho MR, 2015, TRENDS BIOTECHNOL, V33, P667, DOI 10.1016/j.tibtech.2015.09.009
   Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
   Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142 9612(98)00025 8
   Cui HT, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201900924
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   DiMasi JA, 2007, J CLIN ONCOL, V25, P209, DOI 10.1200/JCO.2006.09.0803
   Ferreira LP, 2018, BIOMATERIALS, V185, P155, DOI 10.1016/j.biomaterials.2018.09.007
   Ferreira LP, 2018, ACTA BIOMATER, V75, P11, DOI 10.1016/j.actbio.2018.05.034
   Gao C, 2023, CHEM ENG J, V451, DOI 10.1016/j.cej.2022.138788
   Gradishar WJ, 2012, BREAST CANCER BASIC, V6, P159, DOI 10.4137/BCBCR.S8205
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Han CP, 2021, ANAL CHIM ACTA, V1187, DOI 10.1016/j.aca.2021.339160
   Hann SY, 2021, ACTA BIOMATER, V123, P263, DOI 10.1016/j.actbio.2021.01.012
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767
   Jiang TM, 2019, BIOMATERIALS, V188, P130, DOI 10.1016/j.biomaterials.2018.10.015
   Kingsley DM, 2019, ACTA BIOMATER, V95, P357, DOI 10.1016/j.actbio.2019.02.014
   Lai TC, 2016, J MATER CHEM B, V4, P2304, DOI 10.1039/c5tb02518d
   Lipton A, 2009, J NATL COMPR CANC NE, V7, pS1
   Liu JY, 2019, MATER DESIGN, V171, DOI 10.1016/j.matdes.2019.107708
   Ma XY, 2018, ADV DRUG DELIVER REV, V132, P235, DOI 10.1016/j.addr.2018.06.011
   Malandrino A, 2018, ACS BIOMATER SCI ENG, V4, P294, DOI 10.1021/acsbiomaterials.7b00041
   Mamaghani KR, 2018, MATER TODAY PROC, V5, P15790, DOI 10.1016/j.matpr.2018.04.193
   Meng FB, 2019, ADV MATER, V31, DOI 10.1002/adma.201806899
   Nerger BA, 2019, SOFT MATTER, V15, P5728, DOI 10.1039/c8sm02605j
   Nie J, 2020, MATER HORIZONS, V7, P82, DOI 10.1039/c9mh01283d
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Qiao H, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0008 9
   Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265
   Salgado CL, 2016, J BIOMED MATER RES A, V104, P57, DOI 10.1002/jbm.a.35540
   Shao L, 2018, SMALL, V14, DOI 10.1002/smll.201802187
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Sitarski AM, 2018, ACS BIOMATER SCI ENG, V4, P324, DOI 10.1021/acsbiomaterials.7b00097
   Trivedi P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126225
   Valarmathi MT, 2009, BIOMATERIALS, V30, P1098, DOI 10.1016/j.biomaterials.2008.10.044
   WANG RZ, 1995, J MATER SCI LETT, V14, P490, DOI 10.1007/BF00665911
   Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14 04 0916
   Wu DW, 2018, MATER DESIGN, V160, P486, DOI 10.1016/j.matdes.2018.09.040
   Wu PK, 2010, BIOFABRICATION, V2, DOI 10.1088/1758 5082/2/1/014111
   Xu BH, 2021, LANCET ONCOL, V22, P351, DOI 10.1016/S1470 2045(20)30702 6
   Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109
   Zhang LJ, 2009, NANO TODAY, V4, P66, DOI 10.1016/j.nantod.2008.10.014
   Zheng XB, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.617597
NR 51
TC 8
Z9 9
U1 5
U2 52
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD NOV 15
PY 2023
VL 476
AR 146685
DI 10.1016/j.cej.2023.146685
EA OCT 2023
PG 13
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA Y0PB0
UT WOS:001102363400001
DA 2025 08 17
ER

PT J
AU Rajamannan, NM
AF Rajamannan, Nalini M.
TI Mechanisms of aortic valve calcification: the LDL density radius theory:
   a translation from cell signaling to physiology
SO AMERICAN JOURNAL OF PHYSIOLOGY HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE valvular heart disease; lipids; pathophysiology atherosclerosis;
   experimental models
ID C REACTIVE PROTEIN; ANGIOTENSIN CONVERTING ENZYME; LIPID LOWERING
   THERAPY; NITRIC OXIDE SYNTHASE; RISK FACTORS; INTERSTITIAL CELLS; MATRIX
   METALLOPROTEINASE 2; CORONARY ATHEROSCLEROSIS; SURFACE PROPERTIES;
   APOLIPOPROTEIN B
AB Rajamannan NM. Mechanisms of aortic valve calcification: the LDL density radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 298: H5 H15, 2010. First published October 23, 2009; doi:10.1152/ajpheart.00824.2009. Recent epidemiologic studies have revealed the risk factors associated for vascular atherosclerosis, including the male sex, smoking, hypertension, and elevated serum cholesterol, similar to the risk factors associated with the development of AV stenosis. An increasing number of models of experimental hypercholesterolemia demonstrate features of atherosclerosis in the AV, which are similar to the early stages of vascular atherosclerotic lesions. Experimental and clinical studies demonstrate that the hypercholesterolemic AV develops an atherosclerotic lesion which is proliferative and expresses high levels of osteoblast bone markers which mineralize over time to form bone. Calcification, the end stage process of the disease, is necessary to understand as a prognostic indicator in the modification of this cellular process before it is too late. In summary, these findings suggest that medical therapies may have a potential role in patients in the early stages of this disease process to slow the progression to severe aortic stenosis and to delay the timing of the need for surgery. The translation of these experimental studies to clinical practice will be important to understand the potential for medical therapy for this disease process.
C1 [Rajamannan, Nalini M.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA.
   [Rajamannan, Nalini M.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine
RP Rajamannan, NM (通讯作者)，Northwestern Univ, Feinberg Sch Med, Div Cardiol, 303 E Chicago Ave,Tarry 12 717, Chicago, IL 60611 USA.
EM n rajamannan@northwestern.edu
FU American Heart Association [0555714Z]; National Heart, Lung, and Blood
   Institute [5K08 HL 073927 04, 1R01 HL 085591 01A1]; American Heart
   Association (AHA) [0555714Z] Funding Source: American Heart Association
   (AHA)
FX This work was completed with the support of an American Heart
   Association Grant in Aid 0555714Z and National Heart, Lung, and Blood
   Institute Grants 5K08 HL 073927 04 and 1R01 HL 085591 01A1.
CR Agmon Y, 2001, J AM COLL CARDIOL, V38, P827, DOI 10.1016/S0735 1097(01)01422 X
   Aikawa E, 2007, CIRCULATION, V115, P377, DOI 10.1161/CIRCULATIONAHA.106.654913
   Antonini Canterin F, 2008, AM J CARDIOL, V102, P738, DOI 10.1016/j.amjcard.2008.04.056
   Arishiro K, 2007, J AM COLL CARDIOL, V49, P1482, DOI 10.1016/j.jacc.2006.11.043
   ARONOW WS, 1987, AM J CARDIOL, V59, P998, DOI 10.1016/0002 9149(87)91144 1
   Aronow WS, 2001, AM J CARDIOL, V88, P693, DOI 10.1016/S0002 9149(01)01821 5
   Avakian SD, 2001, CLIN GENET, V60, P381, DOI 10.1034/j.1399 0004.2001.600511.x
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Balachandran K, 2009, AM J PHYSIOL HEART C, V296, pH756, DOI 10.1152/ajpheart.00900.2008
   BERNOULLI D, 1738, HYDRODYNAMICA SIVE V
   Blevins TL, 2008, CELLS TISSUES ORGANS, V187, P113, DOI 10.1159/000108582
   Boon A, 1997, HEART, V78, P472, DOI 10.1136/hrt.78.5.472
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Briand M, 2006, J AM COLL CARDIOL, V47, P2229, DOI 10.1016/j.jacc.2005.12.073
   Busseuil D, 2008, BRIT J PHARMACOL, V154, P765, DOI 10.1038/bjp.2008.122
   Caira FC, 2006, J AM COLL CARDIOL, V47, P1707, DOI 10.1016/j.jacc.2006.02.040
   Chan KL, 2001, AM J CARDIOL, V88, P690, DOI 10.1016/S0002 9149(01)01820 3
   Charest A, 2006, HEART, V92, P1844, DOI 10.1136/hrt.2005.086595
   Chui MCK, 2001, CLIN CARDIOL, V24, P52, DOI 10.1002/clc.4960240109
   Cimini M, 2005, J HEART VALVE DIS, V14, P365
   Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876
   Davies PF, 2004, ARTERIOSCL THROM VAS, V24, P1331, DOI 10.1161/01.ATV.0000130659.89433.c1
   Demer LL, 2001, CIRCULATION, V104, P1881, DOI 10.1161/circ.104.16.1881
   DEUTSCHER S, 1984, J CHRON DIS, V37, P407, DOI 10.1016/0021 9681(84)90108 5
   DODGE JT, 1992, CIRCULATION, V86, P232, DOI 10.1161/01.CIR.86.1.232
   Drolet MC, 2006, J AM COLL CARDIOL, V47, P850, DOI 10.1016/j.jacc.2005.09.049
   Drolet MC, 2003, J AM COLL CARDIOL, V41, P1211, DOI 10.1016/S0735 1097(03)00090 1
   Faggiano Pompilio, 2006, Cardiovasc Ultrasound, V4, P27, DOI 10.1186/1476 7120 4 27
   Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100
   Galante A, 2001, J AM COLL CARDIOL, V38, P1078, DOI 10.1016/S0735 1097(01)01484 X
   Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940
   Giachelli CM, 2001, AM J KIDNEY DIS, V38, pS34, DOI 10.1053/ajkd.2001.27394
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gu XX, 2009, AM J PHYSIOL HEART C, V296, pH1748, DOI 10.1152/ajpheart.00099.2009
   Gunduz H, 2005, CARDIOLOGY, V103, P207, DOI 10.1159/000085199
   HATLE L, 1978, BRIT HEART J, V40, P131
   HATLE L, 1980, BRIT HEART J, V43, P284
   Helske S, 2006, ARTERIOSCL THROM VAS, V26, P1791, DOI 10.1161/01.ATV.0000228824.01604.63
   HOAGLAND PM, 1985, AM J CARDIOL, V55, P744, DOI 10.1016/0002 9149(85)90149 3
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Hsu SY, 2006, AM J MED SCI, V331, P264, DOI 10.1097/00000441 200605000 00005
   Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003 4975(02)04312 6
   Jian B, 2001, AM J PATHOL, V159, P321, DOI 10.1016/S0002 9440(10)61698 7
   JOHNSON CM, 1987, J MOL CELL CARDIOL, V19, P1185, DOI 10.1016/S0022 2828(87)80529 1
   Kaden JJ, 2005, INT J MOL MED, V16, P869
   Kaden JJ, 2004, Z KARDIOL, V93, P124, DOI 10.1007/s00392 004 1021 0
   Kaden JJ, 2004, J MOL CELL CARDIOL, V36, P57, DOI 10.1016/j.yjmcc.2003.09.015
   Kaden JJ, 2003, ATHEROSCLEROSIS, V170, P205, DOI 10.1016/S0021 9150(03)00284 3
   Kim DH, 1998, J BIOCHEM TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223
   Kumar V, 2007, ROBBINS BASIC PATHOL, P402
   Leskelä HV, 2006, J MOL CELL CARDIOL, V41, P642, DOI 10.1016/j.yjmcc.2006.07.014
   LINDROOS M, 1994, EUR HEART J, V15, P865
   Liu AC, 2007, AM J PATHOL, V171, P1407, DOI 10.2353/ajpath.2007.070251
   Makkena B, 2005, J AM COLL CARDIOL, V45, P631, DOI 10.1016/j.jacc.2004.11.023
   Messika Zeitoun D, 2004, CIRCULATION, V110, P356, DOI 10.1161/01.CIR.0000135469.82545.D0
   Miller JD, 2008, J AM COLL CARDIOL, V52, P843, DOI 10.1016/j.jacc.2008.05.043
   Miller JD, 2009, CIRCULATION, V119, P2693, DOI 10.1161/CIRCULATIONAHA.108.834614
   MOHLER ER, 1991, CLIN CARDIOL, V14, P995, DOI 10.1002/clc.4960141210
   Mohler ER, 1997, ARTERIOSCL THROM VAS, V17, P547, DOI 10.1161/01.ATV.17.3.547
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Mohty D, 2008, ARTERIOSCL THROM VAS, V28, P187, DOI 10.1161/ATVBAHA.107.154989
   Monzack EL, 2009, ARTERIOSCL THROM VAS, V29, P246, DOI 10.1161/ATVBAHA.108.179218
   MOURA LM, 2008, J AM COLL CARDIOL S1, V51, pA1
   Moura LM, 2007, J AM COLL CARDIOL, V49, P554, DOI 10.1016/j.jacc.2006.07.072
   Moura Luis M, 2008, Expert Rev Cardiovasc Ther, V6, P945, DOI 10.1586/14779072.6.7.945
   Newby DE, 2006, HEART, V92, P729, DOI 10.1136/hrt.2005.066852
   Nissen SE, 2004, JAMA J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071
   Nordström P, 2003, J INTERN MED, V254, P140, DOI 10.1046/j.1365 2796.2003.01179.x
   Novaro GM, 2007, J AM COLL CARDIOL, V50, P1992, DOI 10.1016/j.jacc.2007.07.064
   Novaro GM, 2003, CIRCULATION, V108, P1804, DOI 10.1161/01.CIR.0000097560.96431.3E
   O'Brien KD, 2002, CIRCULATION, V106, P2224, DOI 10.1161/01.CIR.0000035655.45453.D2
   OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163
   OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523
   Oh J, 2007, ECHO MANUAL, p[59, 189]
   Orlowska Baranowska Ewa, 2002, Pol Arch Med Wewn, V108, P855
   Ortlepp JR, 2004, EUR HEART J, V25, P514, DOI 10.1016/j.ehj.2003.09.006
   Ortlepp JR, 2001, HEART, V85, P635, DOI 10.1136/heart.85.6.635
   Osman L, 2006, NUCLEOS NUCLEOT NUCL, V25, P1125, DOI 10.1080/15257770600894196
   OSMAN L, 2006, CIRCULATION, V114, P547, DOI DOI 10.1161/CIRCULATIONAHA.105.001115
   Osman L, 2006, CIRCULATION, V114, pI566, DOI 10.1161/CIRCULATIONAHA.105.001214
   Otto CM, 1999, NEW ENGL J MED, V341, P142, DOI 10.1056/NEJM199907153410302
   Palta S, 2000, CIRCULATION, V101, P2497, DOI 10.1161/01.CIR.101.21.2497
   Peltier M, 2003, AM J CARDIOL, V91, P97, DOI 10.1016/S0002 9149(02)03010 2
   Pohle K, 2001, CIRCULATION, V104, P1927, DOI 10.1161/hc4101.097527
   Probst V, 2006, CIRCULATION, V113, P856, DOI 10.1161/CIRCULATIONAHA.105.569467
   Rajamannan NM, 2008, CIRCULATION, V118, pS1071
   Rajamannan NM, 2005, CIRCULATION, V112, pI229, DOI 10.1161/01.CIRCULATIONAHA.104.524306
   Rajamannan NM, 2005, CIRCULATION, V111, P3296, DOI 10.1161/CIRCULATIONAHA.104.473165
   Rajamannan NM, 2005, HEART, V91, P806, DOI 10.1136/hrt.2003.029785
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rajamannan NM, 2001, J HEART VALVE DIS, V10, P371
   Rajamannan NM, 2002, CIRCULATION, V105, P2660, DOI 10.1161/01.CIR.0000017435.87463.72
   Rosenhek R, 2004, EUR HEART J, V25, P199, DOI 10.1016/j.ehj.2003.12.002
   Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903
   Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602
   SARPHIE TG, 1985, AM J ANAT, V174, P145, DOI 10.1002/aja.1001740205
   SARPHIE TG, 1985, ATHEROSCLEROSIS, V54, P283, DOI 10.1016/0021 9150(85)90122 4
   SARPHIE TG, 1986, EXP MOL PATHOL, V44, P281, DOI 10.1016/0014 4800(86)90042 0
   SARPHIE TG, 1987, ATHEROSCLEROSIS, V68, P199, DOI 10.1016/0021 9150(87)90199 7
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Shuvy M, 2008, CARDIOVASC RES, V79, P492, DOI 10.1093/cvr/cvn088
   SMITH MD, 1986, JAMA J AM MED ASSOC, V255, P3145, DOI 10.1001/jama.255.22.3145
   Steiner I, 2007, VIRCHOWS ARCH, V450, P653, DOI 10.1007/s00428 007 0430 7
   Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735 1097(96)00563 3
   Tintut Y, 2003, CIRCULATION, V108, P2505, DOI 10.1161/01.CIR.0000096485.64373.C5
   Weiss RM, 2006, CIRCULATION, V114, P2065, DOI 10.1161/CIRCULATIONAHA.106.634139
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479
   Wilmshurst PT, 1997, HEART, V78, P475, DOI 10.1136/hrt.78.5.475
   Wu B, 2005, ARTERIOSCL THROM VAS, V25, P592, DOI 10.1161/01.ATV.0000154278.01871.64
   Yang XP, 2009, J AM COLL CARDIOL, V53, P491, DOI 10.1016/j.jacc.2008.09.052
   Yilmaz MB, 2004, AM HEART J, V147, P915, DOI 10.1016/j.ahj.2003.11.011
   Yip CYY, 2009, ARTERIOSCL THROM VAS, V29, P936, DOI 10.1161/ATVBAHA.108.182394
NR 113
TC 55
Z9 63
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363 6135
EI 1522 1539
J9 AM J PHYSIOL HEART C
JI Am. J. Physiol. Heart Circul. Physiol.
PD JAN
PY 2010
VL 298
IS 1
BP H5
EP H15
DI 10.1152/ajpheart.00824.2009
PG 11
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
   Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Physiology
GA 533NT
UT WOS:000272831600003
PM 19855055
OA Green Published
DA 2025 08 17
ER

PT J
AU Jiang, R
   Zhang, C
   Liu, GY
   Gu, R
   Wu, H
AF Jiang, Rui
   Zhang, Chao
   Liu, Guangyao
   Gu, Rui
   Wu, Han
TI MicroRNA 101 inhibits proliferation, migration and invasion in
   osteosarcoma cells by targeting ROCK1
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Osteosarcoma; microRNA 101; ROCK1; cell apoptosis; cell migration
ID POTENTIAL THERAPEUTIC TARGET; DOWN REGULATION; GASTRIC CANCER;
   TUMOR GROWTH; SUPPRESSES; METASTASIS; EXPRESSION; CARCINOMA; MIR 101
AB Osteosarcoma is a rare malignant bone tumor in adolescents, with high degree of malignancy, and highly incidence of recurrence and metastasis. Our study aimed to explore the role of miR 101 in osteosarcoma cells by targeting ROCK1. In the present study, reverse transcription quantitative polymerase chain reaction data revealed that miR 101 was down regulated in the tissue samples of 20 patients with osteosarcoma compared with their matched adjacent non tumor tissues (P < 0.01). Furthermore, miR 101 was significantly down regulated in three common OS cell lines, MG63, U2OS, and OS732 compared with the human osteoblast cell line, hFOB1.19 (P < 0.01). MiR 101 was shown to target the ROCK1 3' UTR in dual luciferase reporter assays in MG63 cells. Overexpression of miR 101 significantly suppressed the protein expression levels of ROCK1, while knockdown of miR 101 significantly enhanced the formers' expression levels in MG63 cells (P < 0.05). Overexpression of miR 101 inhibited cell viability, migration, and invasion while promoted apoptosis. Independent inhibition of ROCK1 and knockdown of miR 101 expression levels significantly promoted MG63 cell proliferation, migration and invasion while inhibited apoptosis (P < 0.01). Moreover, knockdown of ROCK1 reversed the promotion effect of miR 101 knockdown on proliferation, migration, and invasion while promoted apoptosis of MG63 cells, suggesting that miR 101 acts as a tumor suppressor in osteosarcoma cells via targeting ROCK1. Furthermore, overexpression of miR 101 inhibited tumor growth and motion by inactivating PI3K/AKT and JAK/STAT signaling pathways via downregulation of ROCK1. To conclude, miR 101/ROCK1 may be a potential therapeutic target for osteosarcoma therapy.
C1 [Jiang, Rui; Liu, Guangyao; Gu, Rui; Wu, Han] Jilin Univ, Dept Orthoped, China Japan Union Hosp, 126 Xiantai St, Changchun 130033, Jilin Province, Peoples R China.
   [Zhang, Chao] Jilin Univ, Dept Ophthalmol, Hosp 2, Changchun 130041, Peoples R China.
C3 Jilin University; Jilin University
RP Wu, H (通讯作者)，Jilin Univ, Dept Orthoped, China Japan Union Hosp, 126 Xiantai St, Changchun 130033, Jilin Province, Peoples R China.
EM wuhan 12019@126.com
CR Chang Z., 2014, SCI WORLD J, V2014, DOI DOI 10.1155/2014/794756
   Deng L, 2010, CANCER BIOL THER, V9, P875, DOI 10.4161/cbt.9.11.11634
   Duan ZF, 2011, MOL CANCER THER, V10, P1337, DOI 10.1158/1535 7163.MCT 11 0096
   Duan ZF, 2010, CANCER LETT, V293, P220, DOI 10.1016/j.canlet.2010.01.014
   Gao Y, 2014, BIOCHEM BIOPH RES CO, V444, P230, DOI 10.1016/j.bbrc.2014.01.061
   Guo F, 2014, ONCOL REP, V31, P2021, DOI 10.3892/or.2014.3106
   He XP, 2012, FEBS J, V279, P4201, DOI 10.1111/febs.12013
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Lei Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117809
   Lin S, 2014, J HUAZHONG U SCI MED, V34, P889, DOI 10.1007/s11596 014 1369 y
   Liu XZ, 2011, J ORTHOP RES, V29, P1259, DOI 10.1002/jor.21403
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867
   Sampson VB, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00069
   Thompson LDR, 2013, ENT EAR NOSE THROAT, V92, P288
   Villalonga P, 2009, J BIOL CHEM, V284, P35287, DOI 10.1074/jbc.M109.050120
   Wada T, 1996, ONCOLOGY, V53, P221
   Wang HJ, 2010, EUR J CANCER, V46, P2295, DOI 10.1016/j.ejca.2010.05.012
   Wang ZL, 2016, EXP THER MED, V11, P1293, DOI 10.3892/etm.2016.3085
   Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950
   Yang C, 2010, CARCINOGENESIS, V31, P552, DOI 10.1093/carcin/bgp330
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Zhang JG, 2011, J THORAC ONCOL, V6, P671, DOI 10.1097/JTO.0b013e318208eb35
   Zhang KL, 2014, ONCOL REP, V32, P2143, DOI 10.3892/or.2014.3459
   Zhang YQ, 2012, FEBS LETT, V586, P4362, DOI 10.1016/j.febslet.2012.10.053
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
NR 28
TC 50
Z9 53
U1 0
U2 1
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156 6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2017
VL 7
IS 1
BP 88
EP 97
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EJ4RZ
UT WOS:000393205800008
PM 28123850
DA 2025 08 17
ER

PT J
AU Hou, KL
   Lin, SK
   Chao, LH
   Hsiang Hua Lai, E
   Chang, CC
   Shun, CT
   Lu, WY
   Wang, JH
   Hsiao, M
   Hong, CY
   Kok, SH
AF Hou, Kuo Liang
   Lin, Sze Kwan
   Chao, Ling Hsiu
   Hsiang Hua Lai, Eddie
   Chang, Cheng Chi
   Shun, Chia Tung
   Lu, Wan Yu
   Wang, Jyh Horng
   Hsiao, Michael
   Hong, Chi Yuan
   Kok, Sang Heng
TI Sirtuin 6 suppresses hypoxia induced inflammatory response in human
   osteoblasts via inhibition of reactive oxygen species production and
   glycolysis A therapeutic implication in inflammatory bone resorption
SO BIOFACTORS
LA English
DT Article
DE sirtuin 6; inflammation; osteoblasts; reactive oxygen species;
   glycolysis; bone resorption; arthritis
ID MONOCYTE CHEMOATTRACTANT PROTEIN 1; HISTONE DEACETYLASE SIRT6;
   RHEUMATOID ARTHRITIS; MITOCHONDRIAL RESPIRATION; INDUCIBLE FACTOR 1;
   MUSCLE CELLS; EXPRESSION; METABOLISM; ACTIVATION; LACTATE
AB Elevated glycolytic activity and redox imbalance induced by tissue hypoxia are common phenomena of chronic inflammation, including inflammatory bone diseases such as arthritis. However, relation between glycolysis and redox signaling in the inflammatory milieu is unclear. The histone deacetylase sirtuin 6 (SIRT6) is a crucial modulator of inflammation and glucose metabolism, and it is also involved in cellular protection against oxidative injury. The aims of the study were to examine the connection between glycolysis and reactive oxygen species (ROS) production in human osteoblastic cells (HOB) and whether SIRT6 modulates inflammatory response via regulation of glycolytic activity and ROS generation. In HOB cultured under hypoxia, expression of lactate dehydrogenase A (LDHA), lactate production and ROS generation were examined. The reciprocal effects between lactate and ROS production and their impact on inflammatory cytokine induction were assessed. The action of SIRT6 on the above reactions was determined. In a rat model of collagen induced arthritis (CIA), the relation between inflammatory activity and osteoblastic expression of LDHA, level of oxidative lesions, Cyr61 synthesis and macrophage recruitment were examined in joints with or without lentiviral SIRT6 gene therapy. Results showed that hypoxia stress enhanced lactate and LDHA production in HOB. ROS generation was also increased, and there was a positive feedback between glycolysis and ROS formation. Overexpression of SIRT6 attenuated hypoxia enhanced glycolysis and ROS generation. Hypoxia induced expressions of Cyr61, TNF , IL 1, and IL 6 were suppressed by SIRT6 and the inhibitory effects overlapped with antiglycolytic and antioxidation mechanisms. In the model of CIA, forced expression of SIRT6 ameliorated disease progression, osteoblastic synthesis of Cyr61, and macrophage recruitment. More importantly, expression of LDHA and oxidative lesions were decreased in osteoblasts of SIRT6 treated joints. Our findings suggest that SIRT6 suppresses inflammatory response in osteoblasts via modulation of glucose metabolism and redox homeostasis. SIRT6 based strategy may possess therapeutic potential for inflammatory bone resorption. (c) 2016 BioFactors
C1 [Hou, Kuo Liang; Chao, Ling Hsiu; Lu, Wan Yu] Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, Taipei, Taiwan.
   [Lin, Sze Kwan; Hsiang Hua Lai, Eddie; Hong, Chi Yuan; Kok, Sang Heng] Natl Taiwan Univ, Sch Dent, Dept Dent, Taipei, Taiwan.
   [Lin, Sze Kwan; Hsiang Hua Lai, Eddie; Lu, Wan Yu; Hong, Chi Yuan; Kok, Sang Heng] Natl Taiwan Univ Hosp, Dept Dent, 1 Chang Te St, Taipei, Taiwan.
   [Chang, Cheng Chi] Natl Taiwan Univ, Grad Inst Oral Biol, Sch Dent, Taipei, Taiwan.
   [Shun, Chia Tung] Natl Taiwan Univ, Dept & Grad Inst Forens Med, Coll Med, Taipei, Taiwan.
   [Wang, Jyh Horng] Natl Taiwan Univ Hosp, Dept Orthopaed Surg, Taipei, Taiwan.
   [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Hong, Chi Yuan] Natl Taiwan Univ, Coll Bioresources & Agr, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University; National Taiwan University;
   National Taiwan University Hospital; Academia Sinica   Taiwan; National
   Taiwan University
RP Kok, SH (通讯作者)，Natl Taiwan Univ Hosp, Dept Dent, 1 Chang Te St, Taipei, Taiwan.
EM shkok@ntu.edu.tw
RI Hsiao, Michael/U 6238 2019; KOK, SANG HENG/AAJ 5497 2020; Shun,
   Chia Tung/M 1400 2019
OI Wang, Jyh  Horng/0000 0002 1531 5297; Hsiao,
   Michael/0000 0001 8529 9213; SHUN, CHIA TUNG/0000 0002 0468 4468
FU Ministry of Science and Technology of Taiwan [MOST101 2314 B 002 107,
   MOST 102 2314 B 002 047, MOST 102 2314 B 002 053, MOST
   102 2314 B 002 057 MY3]; National Taiwan University Hospital
   [NTUH103 S2496, NTUH 102 S2145, NTUH103 S2391]
FX The project was supported by grants to SHK from Ministry of Science and
   Technology of Taiwan (MOST101 2314 B 002 107; MOST 102 2314 B 002 047)
   and National Taiwan University Hospital (NTUH103 S2496), SKL from
   Ministry of Science and Technology of Taiwan (MOST 102 2314 B 002 053)
   and National Taiwan University Hospital (NTUH 102 S2145, NTUH103 S2391),
   and EHHL from Ministry of Science and Technology of Taiwan (MOST
   102 2314 B 002 057 MY3). All authors declare that they have no conflict
   of interest.
CR Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200
   Chang XT, 2011, INT J RHEUM DIS, V14, P217, DOI 10.1111/j.1756 185X.2011.01598.x
   Chi PL, 2012, ARTHRITIS RHEUM US, V64, P2114, DOI 10.1002/art.34371
   Pinheiro CHD, 2010, FREE RADICAL BIO MED, V48, P953, DOI 10.1016/j.freeradbiomed.2010.01.016
   desBari L., 2010, FEBS LETT, V584, P2285
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002 9343(70)80078 X
   Filippin LI, 2008, CLIN EXP IMMUNOL, V152, P415, DOI 10.1111/j.1365 2249.2008.03634.x
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Grimley R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039847
   Hitchon CA, 2004, ARTHRITIS RES THER, V6, P265, DOI 10.1186/ar1447
   Hu HL, 2010, AM J RESP CELL MOL, V42, P661, DOI 10.1165/rcmb.2009 0017OC
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev pharmtox 010611 134537
   Kaminski MM, 2012, CELL REP, V2, P1300, DOI 10.1016/j.celrep.2012.10.009
   Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052
   Kok SH, 2011, ARTHRITIS RHEUM US, V63, P1010, DOI 10.1002/art.27433
   Lee HS, 2013, ARTHRITIS RHEUM US, V65, P1776, DOI 10.1002/art.37963
   Lin LD, 2013, J ENDODONT, V39, P619, DOI 10.1016/j.joen.2012.12.014
   Lin SK, 2008, ARTHRITIS RHEUM, V58, P3145, DOI 10.1002/art.23937
   Lisignoli G, 1999, J RHEUMATOL, V26, P791
   Lottes RG, 2015, AM J PHYSIOL LUNG C, V308, pL953, DOI 10.1152/ajplung.00335.2014
   Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200
   LUNDOLESEN K, 1970, ARTHRITIS RHEUM US, V13, P769, DOI 10.1002/art.1780130606
   Maksin Matveev A, 2015, EXP CELL RES, V330, P81, DOI 10.1016/j.yexcr.2014.07.013
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Movafagh S, 2015, J CELL BIOCHEM, V116, P696, DOI 10.1002/jcb.25074
   Galardo MN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088024
   OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153
   Pan HZ, 2016, CELL RES, V26, P190, DOI 10.1038/cr.2016.4
   Procaccini C, 2012, TRENDS IMMUNOL, V33, P1, DOI 10.1016/j.it.2011.09.002
   RAHIMI P, 1995, ENDOCRINOLOGY, V136, P2752, DOI 10.1210/en.136.6.2752
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Sasaki M, 2013, DIABETES, V62, P1996, DOI 10.2337/db12 0903
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389
   Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278
   Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TREUHAFT PS, 1971, ARTHRITIS RHEUM, V14, P475, DOI 10.1002/art.1780140407
   Végran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008 5472.CAN 10 2828
   Volejnikova S, 1997, AM J PATHOL, V150, P1711
   Wang XX, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395 016 0531 z
   WILLIAMS SR, 1992, AM J PHYSIOL, V263, pC194, DOI 10.1152/ajpcell.1992.263.1.C194
   Zhi L, 2012, J IMMUNOL, V189, P1639, DOI 10.4049/jimmunol.1200528
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041
   ZHU JF, 1994, J BONE MINER RES, V9, P1123
NR 46
TC 27
Z9 31
U1 1
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 6433
EI 1872 8081
J9 BIOFACTORS
JI Biofactors
PD MAR
PY 2017
VL 43
IS 2
BP 170
EP 180
DI 10.1002/biof.1320
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA ES7ME
UT WOS:000399733500003
PM 27534902
DA 2025 08 17
ER

PT J
AU Fatima, I
   El Ayachi, I
   Playa, HC
   Alva Ornelas, JA
   Khalid, AB
   Kuenzinger, WL
   Wend, P
   Pence, JC
   Brakefield, L
   Krutilina, RI
   Johnson, DL
   O'Regan, RM
   Seewaldt, V
   Seagroves, TN
   Krum, SA
   Miranda Carboni, GA
AF Fatima, Iram
   El Ayachi, Ikbale
   Playa, Hilaire C.
   Alva Ornelas, Jackelyn A.
   Khalid, Aysha B.
   Kuenzinger, William L.
   Wend, Peter
   Pence, Jackelyn C.
   Brakefield, Lauren
   Krutilina, Raisa, I
   Johnson, Daniel L.
   O'Regan, Ruth M.
   Seewaldt, Victoria
   Seagroves, Tiffany N.
   Krum, Susan A.
   Miranda Carboni, Gustavo A.
TI Simultaneous Multi Organ Metastases from Chemo Resistant Triple Negative
   Breast Cancer Are Prevented by Interfering with WNT Signaling
SO CANCERS
LA English
DT Article
DE triple negative breast cancer; metastasis; inhibiting WNT/beta catenin
   signaling
ID SUBTYPES; WOMEN
AB Triple negative breast cancers (TNBCs), which lack specific targeted therapy options, evolve into highly chemo resistant tumors that metastasize to multiple organs simultaneously. We have previously shown that TNBCs maintain an activated WNT10B driven network that drives metastasis. Pharmacologic inhibition by ICG 001 decreases beta catenin mediated proliferation of multiple TNBC cell lines and TNBC patient derived xenograft (PDX) derived cell lines. In vitro, ICG 001 was effective in combination with the conventional cytotoxic chemotherapeutics, cisplatin and doxorubicin, to decrease the proliferation of MDA MB 231 cells. In contrast, in TNBC PDX derived cells doxorubicin plus ICG 001 was synergistic, while pairing with cisplatin was not as effective. Mechanistically, cytotoxicity induced by doxorubicin, but not cisplatin, with ICG 001 was associated with increased cleavage of PARP 1 in the PDX cells only. In vivo, MDA MB 231 and TNBC PDX orthotopic primary tumors initiated de novo simultaneous multi organ metastases, including bone metastases. WNT monotherapy blocked multi organ metastases as measured by luciferase imaging and histology. The loss of expression of the WNT10B/beta catenin direct targets HMGA2, EZH2, AXIN2, MYC, PCNA, CCND1, transcriptionally active beta catenin, SNAIL and vimentin both in vitro and in vivo in the primary tumors mechanistically explains loss of multi organ metastases. WNT monotherapy induced VEGFA expression in both tumor model systems, whereas increased CD31 was observed only in the MDA MB 231 tumors. Moreover, WNT inhibition sensitized the anticancer response of the TNBC PDX model to doxorubicin, preventing simultaneous metastases to the liver and ovaries, as well as to bone. Our data demonstrate that WNT inhibition sensitizes TNBC to anthracyclines and treats multi organ metastases of TNBC.
C1 [Fatima, Iram; El Ayachi, Ikbale; Kuenzinger, William L.; Brakefield, Lauren; Miranda Carboni, Gustavo A.] UTHSC, Coll Med, Dept Med, UTHSC Ctr Canc Res Memphis, Memphis, TN 38163 USA.
   [Playa, Hilaire C.; Krutilina, Raisa, I; Seagroves, Tiffany N.] UTHSC, UTHSC Ctr Canc Res, Dept Pathol & Lab Med, Coll Med, Memphis, TN 38163 USA.
   [Alva Ornelas, Jackelyn A.; Seewaldt, Victoria] City Hope Comprehens Canc Ctr, Dept Populat Sci, Duarte, CA 91010 USA.
   [Alva Ornelas, Jackelyn A.; Seewaldt, Victoria] Beckman Inst, Duarte, CA 91010 USA.
   [Khalid, Aysha B.; Pence, Jackelyn C.; Krum, Susan A.] UTHSC, Dept Orthopaed Surg & Biomed Engn, UTHSC Ctr Canc Res, Memphis, TN 38163 USA.
   [Wend, Peter] UCLA, David Geffen Sch Med, Dept Obstet & Gynecol, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Johnson, Daniel L.] UTHSC, Mol Bioinformat Core, Memphis, TN 38163 USA.
   [O'Regan, Ruth M.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Sch Med & Publ Hlth, Madison, WI 53705 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; City of Hope; City of Hope; Beckman Research Institute
   of City of Hope; University of Tennessee System; University of Tennessee
   Health Science Center; UCLA Jonsson Comprehensive Cancer Center;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Tennessee System; University of
   Tennessee Health Science Center; University of Wisconsin System;
   University of Wisconsin Madison
RP Miranda Carboni, GA (通讯作者)，UTHSC, Coll Med, Dept Med, UTHSC Ctr Canc Res Memphis, Memphis, TN 38163 USA.
EM iram.fatima@unmc.edu; Ikbale.ElAyachi@osumc.edu; hplaya@uthsc.edu;
   jalvao@coh.org; khalidaysha2000@gmail.com; willkuen@uthsc.edu;
   peterwend@web.de; jpence3@uthsc.edu; lbrakefi@uthsc.edu;
   rkrutili@uthsc.edu; djohn166@uthsc.edu; roregan@medicine.wisc.edu;
   vseewaldt@coh.org; tseagro1@uthsc.edu; smirand5@uthsc.edu;
   gmirand1@uthsc.edu
RI Fatima, Iram/AAO 3159 2020; Fatima, Iram/P 1237 2016; Krum,
   Susan/D 7282 2013; Seagroves, Tiffany/AAE 3278 2019
OI Fatima, Iram/0000 0003 3492 3068; Johnson, Daniel/0000 0003 1600 6768;
   Playa, Hilaire/0000 0002 7850 5610; Wend, Peter/0000 0002 9252 472X;
   Krum, Susan/0000 0002 6414 6397; Krutilina, Raisa/0000 0002 2118 4019
FU NCI [CA138488]; Susan G. Komen for the Cure Grant [KG110317]; R21 grant
   from NCI/Center to Reduce Cancer Health Disparities [CA179735];
   UTHSC/West Cancer Center grant; NIH U01 grant [CA189283]
FX Development of the Luc2 labeled HCI PDX sublines was supported by NCI
   CA138488 (to TNS). This work was supported by a Susan G. Komen for the
   Cure Grant KG110317 to SAK. GAMC is currently supported by a R21 grant
   from NCI/Center to Reduce Cancer Health Disparities (CA179735),
   UTHSC/West Cancer Center grant and a NIH U01 grant (CA189283).
CR Ahn SG, 2013, YONSEI MED J, V54, P1168, DOI 10.3349/ymj.2013.54.5.1168
   Chatterjee K, 2010, CARDIOLOGY, V115, P155, DOI 10.1159/000265166
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 537
   Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896
   El Ayachi I, 2019, CANCER RES, V79, P982, DOI 10.1158/0008 5472.CAN 18 1069
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Goel S, 2013, JNCI J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164
   Harries M, 2014, CANCER EPIDEMIOL, V38, P427, DOI 10.1016/j.canep.2014.05.005
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Khalid AB, 2018, BONE, V116, P78, DOI 10.1016/j.bone.2018.07.014
   Khalid AB, 2018, JBMR PLUS, V2, P81, DOI 10.1002/jbm4.10027
   Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liu B, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2475
   Maher MT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010184
   Mariano G, 2015, ONCOTARGET, V6, P15008, DOI 10.18632/oncotarget.3634
   Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008 5472.CAN 12 3000
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Miranda Carboni G.A., GORDON RES C MAMMARY
   Miranda Carboni GA, 2008, GENE DEV, V22, P3121, DOI 10.1101/gad.1692808
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146
   Rakha EA, 2011, CLIN ONCOL UK, V23, P587, DOI 10.1016/j.clon.2011.03.013
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Tallarida RJ, 2006, J PHARMACOL EXP THER, V319, P1, DOI 10.1124/jpet.106.104117
   Wend P, 2012, ACTA PHYSIOL, V204, P34, DOI 10.1111/j.1748 1716.2011.02296.x
   Wend P, 2013, EMBO MOL MED, V5, P264, DOI 10.1002/emmm.201201320
   Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097
NR 31
TC 26
Z9 29
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD DEC
PY 2019
VL 11
IS 12
AR 2039
DI 10.3390/cancers11122039
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KC7VZ
UT WOS:000507382100216
PM 31861131
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sruthi, R
   Balagangadharan, K
   Selvamurugan, N
AF Sruthi, R.
   Balagangadharan, K.
   Selvamurugan, N.
TI Polycaprolactone/polyvinylpyrrolidone coaxial electrospun fibers
   containing veratric acid loaded chitosan nanoparticles for bone
   regeneration
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Bone tissue engineering; Veratric acid; Coaxial electrospinning;
   Polycaprolactone; Polyvinylpyrrolidone
ID DRUG DELIVERY; SCAFFOLDS; FABRICATION; OSTEOBLAST; BIOMATERIALS;
   DEGRADATION; MECHANISMS; ADSORPTION; MEMBRANES; INSIGHTS
AB Veratric acid (3,4 dimethoxy benzoic acid) (VA) is a hydrophobic phenolic phytocompound possessing therapeutic potential, but it has not been reported as actuating bone regeneration to date. Furthermore, delivery of hydrophobic compounds is often impeded in the body, thus depreciating their bioavailability. In this study, VA was found to have osteogenic potential and its sustained delivery was facilitated through a nanoparticle embedded coaxial electrospinning technique. Polycaprolactone/polyvinylpyrrolidone (PCL/PVP) coaxial fibers were electrospun, encasing VA loaded chitosan nanoparticles (CHS NP). The fibers showed commendable physiochemical and material properties and were biocompatible with mouse mesenchymal stem cells (mMSCs). When mMSCs were grown on coaxial fibers, VA promoted these cells towards osteoblast differentiation as was reflected by calcium deposits. The mRNA expression of Runx2, an important bone transcriptional regulator, and other differentiation markers such as alkaline phosphatase, collagen type I, and osteocalcin were found to be upregulated in mMSCs grown on the PCL/PVP/CHS NP VA fibers. Overall, the study portrays the delivery of the phytocompound, VA, in a sustained manner to promote bone regeneration.
C1 [Sruthi, R.; Balagangadharan, K.; Selvamurugan, N.] SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamun@srmist.edu.in
RI Selvamurugan, Nagarajan/P 7894 2016
OI Selvamurugan, Nagarajan/0000 0003 3713 1920; Ranganathan,
   Sruthi/0009 0009 8958 0681
FU SRM Institute of Science and Technology, Kattankulathur
FX This work was, in part, supported by the SRM Institute of Science and
   Technology, Kattankulathur.
CR Arima Y, 2015, ACTA BIOMATER, V26, P72, DOI 10.1016/j.actbio.2015.08.033
   Balagangadharan K, 2017, INT J BIOL MACROMOL, V104, P1372, DOI 10.1016/j.ijbiomac.2016.12.046
   Balagangadharan K, 2019, CARBOHYD POLYM, V216, P1, DOI 10.1016/j.carbpol.2019.04.002
   Baranwal A, 2018, INT J BIOL MACROMOL, V110, P110, DOI 10.1016/j.ijbiomac.2018.01.006
   Camci Unal G, 2016, SCI REP UK, V6, DOI 10.1038/srep27693
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Carbinatto FM, 2014, ASIAN J PHARM SCI, V9, P27, DOI 10.1016/j.ajps.2013.12.002
   Chandran SV, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48429 1
   Charernsriwilaiwat N, 2016, INT J NANOSCI, V15, DOI 10.1142/S0219581X16500058
   Chaudhuri B, 2016, COLLOID SURFACE B, V143, P71, DOI 10.1016/j.colsurfb.2016.03.027
   Choi WS, 2012, CELL IMMUNOL, V280, P164, DOI 10.1016/j.cellimm.2012.12.007
   Coimbra P, 2017, COLLOID SURFACE B, V159, P7, DOI 10.1016/j.colsurfb.2017.07.065
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Davison N.L., 2014, TISSUE ENG
   Dhivya S, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0099 z
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Eftekhari H, 2018, J VET RES, V62, P385, DOI 10.2478/jvetres 2018 0055
   El Achaby M, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.41042
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Han D, 2019, CHEMPLUSCHEM, V84, P1453, DOI 10.1002/cplu.201900281
   Han D, 2017, J DRUG DELIV SCI TEC, V40, P45, DOI 10.1016/j.jddst.2017.05.017
   Holmes D, 2017, NATURE, V550, pS193, DOI 10.1038/550S193a
   Honary S, 2013, TROP J PHARM RES, V12, P255, DOI 10.4314/tjpr.v12i2.19
   Hou JZ, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10091032
   Islam N, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01684
   Jain D, 2008, J BIOMED MATER RES B, V86B, P105, DOI 10.1002/jbm.b.30994
   Jia YT, 2011, ADV MATER RES SWITZ, V332 334, P1330, DOI 10.4028/www.scientific.net/AMR.332 334.1330
   Joseph JJ, 2016, INT J BIOL MACROMOL, V82, P952, DOI 10.1016/j.ijbiomac.2015.10.079
   Kim GM, 2013, J MATER SCI MATER M, V24, P1425, DOI 10.1007/s10856 013 4893 6
   Kopf BS, 2015, J BIOMED MATER RES A, V103, P2661, DOI 10.1002/jbm.a.35401
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Li PC, 2019, CHINESE CHEM LETT, V30, P157, DOI 10.1016/j.cclet.2018.01.037
   Lin DR, 2016, MOLECULES, V21, DOI 10.3390/molecules21101374
   Lu TL, 2013, INT J NANOMED, V8, P337, DOI 10.2147/IJN.S38635
   Lu Y, 2016, WIRES NANOMED NANOBI, V8, P654, DOI 10.1002/wnan.1391
   McClellan P, 2016, BIORESEARCH OPEN ACC, V5, P212, DOI 10.1089/biores.2016.0022
   Mishra R, 2019, EUR POLYM J, V119, P155, DOI 10.1016/j.eurpolymj.2019.07.007
   Mohammed MA, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040053
   Mondal D, 2016, INT J POLYM MATER PO, V65, P255, DOI 10.1080/00914037.2015.1103241
   Nainar S., 2014, Sch. J. Eng. Technol., V2, P184
   Ning WY, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10020214
   Okudan A, 2019, INT J POLYM SCI, V2019, DOI 10.1155/2019/7324181
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Padalhin AR, 2014, J BIOMAT SCI POLYM E, V25, P487, DOI 10.1080/09205063.2013.878870
   Pan JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112885
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Pooja D, 2014, INT J BIOL MACROMOL, V69, P267, DOI 10.1016/j.ijbiomac.2014.05.035
   Prasadh S, 2018, ORAL SCI INT, V15, P48, DOI 10.1016/S1348 8643(18)30005 3
   Ratnaparkhi M., 2013, TERMINOLOGY, V3
   Rizvi SAA, 2018, SAUDI PHARM J, V26, P64, DOI 10.1016/j.jsps.2017.10.012
   Rojas A, 2015, J BIOL CHEM, V290, P28329, DOI 10.1074/jbc.M115.657825
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Safadi FF, 2009, BONE PATHOLOGY, SECOND EDITION, P1, DOI 10.1007/978 1 59745 347 9_1
   Sainitya R, 2015, INT J BIOL MACROMOL, V80, P481, DOI 10.1016/j.ijbiomac.2015.07.016
   Saravanakumar M, 2011, EUR J PHARMACOL, V671, P87, DOI 10.1016/j.ejphar.2011.08.052
   Saravanan S, 2016, INT J BIOL MACROMOL, V93, P1354, DOI 10.1016/j.ijbiomac.2016.01.112
   Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878
   Shadamarshan RP, 2018, COLLOID SURFACE B, V171, P698, DOI 10.1016/j.colsurfb.2018.08.005
   Shahriar SMS, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9040532
   Shen JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093514
   Shin SW, 2013, MOLECULES, V18, P5405, DOI 10.3390/molecules18055405
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Sun B, 2006, J APPL POLYM SCI, V102, P39, DOI 10.1002/app.24297
   Tayebi L., 2012, Curr. Microsc. Contrib. to Adv. Sci. Technol, P591
   Teodorescu M, 2015, POLYM PLAST TECHNOL, V54, P923, DOI 10.1080/03602559.2014.979506
   Thrivikraman G, 2014, RSC ADV, V4, P12763, DOI 10.1039/c3ra44483j
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093
   Vielreicher M, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0263
   Wang X, 2015, INT J PHARMACEUT, V490, P384, DOI 10.1016/j.ijpharm.2015.05.077
   Wei QL, 2016, FRONT MATER SCI, V10, P113, DOI 10.1007/s11706 016 0339 7
   Woodard LN, 2018, ACS MACRO LETT, V7, P976, DOI 10.1021/acsmacrolett.8b00424
   Wu T, 2017, MATERIALS, V10, DOI 10.3390/ma10101187
   Xie JW, 2013, ACTA BIOMATER, V9, P5698, DOI 10.1016/j.actbio.2012.10.042
   Younes I, 2015, MAR DRUGS, V13, P1133, DOI 10.3390/md13031133
   Yu DG, 2013, ACTA BIOMATER, V9, P5665, DOI 10.1016/j.actbio.2012.10.021
   Yu DG, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/43/435301
   Zandi N, 2020, MAT SCI ENG C MATER, V108, DOI 10.1016/j.msec.2019.110432
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 79
TC 47
Z9 51
U1 5
U2 88
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD SEP
PY 2020
VL 193
AR 111110
DI 10.1016/j.colsurfb.2020.111110
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA MH4TI
UT WOS:000546723100039
PM 32416516
DA 2025 08 17
ER

PT J
AU Bruzzese, F
   Pucci, B
   Milone, MR
   Ciardiello, C
   Franco, R
   Chianese, MI
   Rocco, M
   Di Gennaro, E
   Leone, A
   Luciano, A
   Arra, C
   Santini, D
   Caraglia, M
   Budillon, A
AF Bruzzese, F.
   Pucci, B.
   Milone, M. R.
   Ciardiello, C.
   Franco, R.
   Chianese, M. I.
   Rocco, M.
   Di Gennaro, E.
   Leone, A.
   Luciano, A.
   Arra, C.
   Santini, D.
   Caraglia, M.
   Budillon, A.
TI Panobinostat synergizes with zoledronic acid in prostate cancer and
   multiple myeloma models by increasing ROS and modulating mevalonate and
   p38 MAPK pathways
SO CELL DEATH & DISEASE
LA English
DT Article
DE panobinostat; zoledronic acid; prostate cancer; multiple myeloma;
   p38 MAPK
ID HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; P38 MAP
   KINASE; BREAST CANCER; INDUCED APOPTOSIS; CELLS; VORINOSTAT;
   BISPHOSPHONATE; ACTIVATION; RESISTANCE
AB Patients with advanced prostate cancer (PCa) and multiple myeloma (MM) have limited long term responses to available therapies. The histone deacetylase inhibitor panobinostat has shown significant preclinical and clinical anticancer activity in both hematological and solid malignancies and is currently in phase III trials for relapsed MM. Bisphosphonates (BPs), such as zoledronic acid (ZOL), inhibit osteoclast mediated bone resorption and are indicated for the treatment of bone metastasis. BPs, including ZOL, have also shown anticancer activity in several preclinical and clinical studies. In the present report, we found a potent synergistic antiproliferative effect of panobinostat/ZOL treatment in three PCa and three MM cell lines as well as in a PCa ZOL resistant subline, independently of p53/KRAS status, androgen dependency, or the schedule of administration. The synergistic effect was also observed in an anchorage independent agar assay in both ZOL sensitive and ZOL resistant cells and was confirmed in vivo in a PCa xenograft model. The co administration of the antioxidant N acetyl L cysteine blocked the increased reactive oxygen species generation and apoptosis observed in the combination setting compared with control or single agent treatments, suggesting that oxidative injury plays a functional role in the synergism. Proapoptotic synergy was also partially antagonized by the addition of geranyl geraniol, which bypasses the inhibition of farnesylpyrophosphate synthase by ZOL in the mevalonate pathway, supporting the involvement of this pathway in the synergy. Finally, at the molecular level, the inhibition of basal and ZOL induced activation of p38 MAPK by panobinostat in sensitive and ZOL resistant cells and in tumor xenografts could explain, at least in part, the observed synergism.
C1 [Bruzzese, F.; Ciardiello, C.; Chianese, M. I.; Rocco, M.; Di Gennaro, E.; Leone, A.; Budillon, A.] Ist Nazl Studio & Cura Tumori Fdn Giovanni Pascal, Expt Pharmacol Unit, I 80131 Naples, Italy.
   [Pucci, B.; Milone, M. R.; Budillon, A.] Ist Nazl Studio & Cura Tumori Fdn Giovanni Pascal, Mercogliano Oncol Res Ctr CROM, I 80131 Naples, Italy.
   [Franco, R.] Ist Nazl Studio & Cura Tumori Fdn Giovanni Pascal, Pathol Unit, I 80131 Naples, Italy.
   [Luciano, A.; Arra, C.] Ist Nazl Studio & Cura Tumori Fdn Giovanni Pascal, Anim Facil, I 80131 Naples, Italy.
   [Santini, D.] Univ Campus Biomedico, Dept Med Oncol, Rome, Italy.
   [Caraglia, M.] Univ Naples 2, Dept Biochem & Biophys, Naples, Italy.
C3 University Campus Bio Medico   Rome Italy; Universita della Campania
   Vanvitelli
RP Budillon, A (通讯作者)，Ist Nazl Studio & Cura Tumori Fdn Giovanni Pascal, Expt Pharmacol Unit, Via M Semmola, I 80131 Naples, Italy.
EM a.budillon@istitutotumori.na.it
RI Caraglia, Michele/AFY 9729 2022; pucci, biagio/AAA 9268 2020; Bruzzese,
   Francesca/ABI 1665 2020; Leone, Alessandra/K 3989 2016; Caraglia,
   Michele/N 5670 2015; Budillon, Alfredo/K 4763 2016; Di+Gennaro,
   Elena/ABG 1579 2021
OI Budillon, Alfredo/0000 0002 6330 6053; Franco,
   Renato/0000 0002 8340 3184; Ciardiello, Chiara/0000 0003 2042 8672;
   Pucci, Biagio/0000 0003 4502 1748; Luciano, Antonio/0000 0003 0183 6574;
   Di Gennaro, Elena/0000 0001 6223 7845; Arra,
   Claudio/0000 0003 3162 2091; Leone, Alessandra/0000 0002 1051 2937;
   Caraglia, Michele/0000 0003 2408 6091; Milone, Maria
   Rita/0000 0001 6807 3677; Santini, Daniele/0000 0002 9118 3337
FU nonprofit 'Associazione Italiana per la Ricerca sul Cancro' [AIRC IG
   9332]; Italian Ministry of Health (FSN); Novartis Pharmaceuticals
   (Basel, Switzerland); Italian Ministry of Education, Research and
   University [2009 EHW394]
FX This work was partially supported by research grants to A Budillon from
   the nonprofit 'Associazione Italiana per la Ricerca sul Cancro' (AIRC IG
   9332), the Italian Ministry of Health (FSN), and Novartis
   Pharmaceuticals (Basel, Switzerland). M Caraglia was supported by the
   Italian Ministry of Education, Research and University (PRIN 2009, Grant
   Number: 2009 EHW394). We are beholden to Dr. Alessandra Trocino from the
   National Cancer Institute of Naples for providing excellent
   bibliographic service and assistance.
CR Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bianchi L, 2011, PROTEOMICS, V11, P3725, DOI 10.1002/pmic.201100092
   Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574
   Bruzzese F, 2009, MOL CANCER THER, V8, P3075, DOI 10.1158/1535 7163.MCT 09 0254
   Budillon A, 2010, FRONTIERS ANTICANCER
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Cuenda A, 2007, BBA MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936 9948.2005
   Dayyani F, 2011, JNCI J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362
   De Luca A, 2011, EXPERT OPIN DRUG MET, V7, P911, DOI 10.1517/17425255.2011.585156
   Di Gennaro E, 2010, BRIT J CANCER, V103, P1680, DOI 10.1038/sj.bjc.6605969
   Di Gennaro E, 2009, CANCER BIOL THER, V8, P782, DOI 10.4161/cbt.8.9.8118
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Kaizu KNH, 2004, ORAL MED PATHOL, V9, P103
   Khan AQ, 2013, EXP MOL PATHOL, V94, P419, DOI 10.1016/j.yexmp.2013.01.006
   Koto K, 2013, INT J ONCOL, V42, P525, DOI 10.3892/ijo.2012.1735
   Kubo T, 2008, CANCER CHEMOTH PHARM, V62, P111, DOI 10.1007/s00280 007 0580 y
   Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Mahon KL, 2011, ENDOCR RELAT CANCER, V18, pR103, DOI 10.1530/ERC 10 0343
   Melisi D, 2005, ENDOCR RELAT CANCER, V12, P1051, DOI 10.1677/erc.1.01061
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Milone MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.165
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Morii T, 2010, ANTICANCER RES, V30, P3565
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Qi XF, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.44
   Rathkopf D, 2010, CANCER CHEMOTH PHARM, V66, P181, DOI 10.1007/s00280 010 1289 x
   Richardson PG, 2013, LEUKEMIA RES, V37, P829, DOI 10.1016/j.leukres.2013.03.006
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Roy M, 2011, AM J CANCER RES, V1, P542
   Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Sinisl AA, 2002, IN VITRO CELL DEV AN, V38, P165
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Sonnemann J, 2007, MOL CANCER THER, V6, P2976, DOI 10.1158/1535 7163.MCT 07 0221
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   van de Donk NWCJ, 2005, CLIN CANCER RES, V11, P429
   Verheul HMW, 2008, CLIN CANCER RES, V14, P3589, DOI 10.1158/1078 0432.CCR 07 4306
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
NR 45
TC 55
Z9 59
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2013
VL 4
AR e878
DI 10.1038/cddis.2013.406
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 251XK
UT WOS:000326967100064
PM 24157872
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tsubaki, M
   Mashimo, K
   Takeda, T
   Kino, T
   Fujita, A
   Itoh, T
   Imano, M
   Sakaguchi, K
   Satou, T
   Nishida, S
AF Tsubaki, Masanobu
   Mashimo, Kenji
   Takeda, Tomoya
   Kino, Toshiki
   Fujita, Arisa
   Itoh, Tatsuki
   Imano, Motohiro
   Sakaguchi, Katsuhiko
   Satou, Takao
   Nishida, Shozo
TI Statins inhibited the MIP 1α expression via inhibition of Ras/ERK and
   Ras/Akt pathways in myeloma cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Statin; MIP 1 alpha; Myeloma; Ras
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; BONE MARROW; OSTEOCLAST
   FORMATION; RECEPTOR ACTIVATOR; M CSF; APOPTOSIS; CHEMOKINE; RANKL;
   LIPOPOLYSACCHARIDE; BISPHOSPHONATE
AB Macrophage inflammatory protein 1alpha (MIP 1 alpha) is detected at high concentrations in patients with multiple myeloma. It is thought to play an important role in the etiology of multiple myeloma and osteolysis. Thus, inhibiting MIP 1 alpha expression may be useful in developing therapeutic treatments for multiple myeloma induced osteolysis. In this study, we investigated the potential of statins to inhibit mRNA expression and secretion of MIP 1 alpha in mouse myeloma cells (MOPC 31C). We found that statins inhibited the lipopolysaccharide (LPS) induced MIP 1 alpha mRNA expression and protein secretion in MOPC 31C cells. This inhibition was reversed when farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), intermediates of the mevalonate pathway, were combined with statins. Furthermore, statins reduced the GTP form of Ras, a phosphorylated extracellular signal regulated kinase 1/2 (ERK1/2), and phosphorylated Akt. Our results indicate that statins inhibit biosynthesis of FPP and GGPP and thereby down regulate signal transduction of Ras/ERK and Ras/Akt pathways. The net effect suppresses LPS induced MIP 1 alpha mRNA expression and protein secretion in MOPC 31C cells. Thus, statins hold great promise for developing effective therapies against myeloma induced osteolysis. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Tsubaki, Masanobu; Mashimo, Kenji; Takeda, Tomoya; Kino, Toshiki; Fujita, Arisa; Nishida, Shozo] Kinki Univ, Sch Pharm, Div Pharmacotherapy, Higashiosaka, Osaka 577, Japan.
   [Mashimo, Kenji; Sakaguchi, Katsuhiko] Japanese Red Cross Soc, Wakayama Med Ctr, Dept Pharm, Wakayama, Japan.
   [Itoh, Tatsuki] Kinki Univ, Sch Agr, Dept Food Sci & Nutr, Nara, Nara, Japan.
   [Imano, Motohiro] Dept Surg, Osaka, Japan.
   [Imano, Motohiro] Kinki Univ, Sch Med, Osaka 589, Japan.
   [Satou, Takao] Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University); Kindai University (Kinki University); Kindai University
   (Kinki University)
RP Nishida, S (通讯作者)，Kinki Univ, Sch Pharm, Div Pharmacotherapy, Higashiosaka, Osaka 577, Japan.
EM nishida@phar.kindai.ac.jp
RI 正寛, 椿/JDF 1457 2023
FU Japan Society for the Promotion of Science (JSPS); Ministry of
   Education, Culture, Sports, Science, and Technology (MEXT);
   Grants in Aid for Scientific Research [26350597, 15K00898] Funding
   Source: KAKEN
FX This work was supported in part by a Grant in Aid for Scientific
   Research (C) from the Japan Society for the Promotion of Science (JSPS)
   and by Ministry of Education, Culture, Sports, Science, and Technology
   (MEXT) Supported Program for the Strategic Research Foundation at
   Private Universities, 2014 2018.
CR Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Azor MH, 2011, CLIN EXP IMMUNOL, V166, P291, DOI 10.1111/j.1365 2249.2011.04473.x
   Bruegel M, 2006, CLIN EXP PHARMACOL P, V33, P1144, DOI 10.1111/j.1440 1681.2006.04493.x
   Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007
   Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   Choi SJ, 2000, BLOOD, V96, P671
   Ciesielski CJ, 2002, EUR J IMMUNOL, V32, P2037, DOI 10.1002/1521 4141(200207)32:7<2037::AID IMMU2037>3.0.CO;2 I
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Horiguchi A, 2004, CLIN CANCER RES, V10, P8648, DOI 10.1158/1078 0432.CCR 04 1568
   Kidera Yasuhiro, 2010, J Exp Clin Cancer Res, V29, P127, DOI 10.1186/1756 9966 29 127
   Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092 8674(02)00827 9
   Kukita T, 1997, LAB INVEST, V76, P399
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Menten P, 2002, J LEUKOCYTE BIOL, V72, P780
   Nareika A, 2007, J PERIODONTAL RES, V42, P31, DOI 10.1111/j.1600 0765.2006.00911.x
   Nishida S, 2005, MOL CELL BIOCHEM, V269, P109, DOI 10.1007/s11010 005 3086 0
   Park HJ, 2007, J PINEAL RES, V43, P121, DOI 10.1111/j.1600 079X.2007.00452.x
   Sondergaard TE, 2009, HEMATOL ONCOL, V27, P17, DOI 10.1002/hon.869
   Tsubaki M, 2008, CANCER SCI, V99, P152, DOI 10.1111/j.1349 7006.2007.00651.x
   Tsubaki M, 2007, MOL CELL BIOCHEM, V304, P53, DOI 10.1007/s11010 007 9485 7
   Tsubaki M, 2015, AM J CANCER RES, V5, P168
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Tsubaki M, 2012, TOXICOL APPL PHARM, V259, P402, DOI 10.1016/j.taap.2012.01.024
   Tsubaki M, 2011, CYTOKINE, V54, P100, DOI 10.1016/j.cyto.2011.01.005
   Tsubaki M, 2010, J CELL BIOCHEM, V111, P1661, DOI 10.1002/jcb.22907
   Veillard NR, 2006, ATHEROSCLEROSIS, V188, P51, DOI 10.1016/j.atherosclerosis.2005.10.015
   Wang XT, 2014, LEUKEMIA RES, V38, P525, DOI 10.1016/j.leukres.2014.02.010
   Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008 5472.CAN 04 0866
   Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200
   Yanae M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756 9966 30 74
NR 34
TC 26
Z9 29
U1 0
U2 10
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAR
PY 2016
VL 78
BP 23
EP 29
DI 10.1016/j.biopha.2015.12.017
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DE3MZ
UT WOS:000370535300004
PM 26898421
DA 2025 08 17
ER

PT J
AU Micha, D
   Voermans, E
   Eekhoff, MEW
   van Essen, HW
   Zandieh Doulabi, B
   Netelenbos, C
   Rustemeyer, T
   Sistermans, EA
   Pals, G
   Bravenboer, N
AF Micha, Dimitra
   Voermans, Elise
   Eekhoff, Marelise E. W.
   van Essen, Huib W.
   Zandieh Doulabi, Behrouz
   Netelenbos, Coen
   Rustemeyer, Thomas
   Sistermans, E. A.
   Pals, Gerard
   Bravenboer, Nathalie
TI Inhibition of TGFβ signaling decreases osteogenic differentiation of
   fibrodysplasia ossificans progressiva fibroblasts in a novel in vitro
   model of the disease
SO BONE
LA English
DT Article
DE Fibrodyplasia ossificans progressiva; Transforming growth factor beta;
   Fibroblast; Osteogenic differentiation; Inflammation; Ossification
ID ALKALINE PHOSPHATASE ACTIVITY; HETEROTOPIC OSSIFICATION; RECEPTOR
   INHIBITION; NATURAL HISTORY; PLATELET LYSATE; STROMAL CELLS; STEM CELLS;
   SKIN; EXPRESSION; MECHANISM
AB Fibrodysplasia ossificans progressiva is a rare genetic disorder characterized by progressive heterotopic ossification. FOP patients develop soft tissue lumps as a result of inflammation induced flare ups which leads to the irreversible replacement of skeletal muscle tissue with bone tissue. Classical FOP patients possess a mutation (c.617G>A; R206H) in the ACVR1 encoding gene which leads to dysregulated BMP signaling. Nonetheless, not all FOP patients with this mutation exhibit equal severity in symptom presentation or disease progression which indicates a strong contribution by environmental factors. Given the pro inflammatory role of TGF beta, we studied the role of TGF beta in the progression of osteogenic differentiation in primary dermal fibroblasts from five classical FOP patients based on a novel method of platelet lysate based osteogenic transdifferentiation. During the course of transdifferentiation the osteogenic properties of the cells were evaluated by the mRNA expression of Sp7/Osterix, Runx2, Alp, OC and the presence of mineralization. During transdifferentiation the expression of osteoblast markers Runx2 (p < 0.05) and Alp were higher in patient cells compared to healthy controls. All cell lines exhibited increase in mineralisation. FOP fibroblasts also expressed higher baseline Sp7/0sterix levels (p < 0.05) confirming their higher osteogenic potential. The pharmacological inhibition of TGF beta signaling during osteogenic transdifferentiation resulted in the attenuation of osteogenic transdifferentiation in all cell lines as shown by the decrease in the expression of Runx2 (p < 0.05), Alp and mineralization. We suggest that blocking of TGF beta signaling can decrease the osteogenic transdifferentiation of FOP fibroblasts. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Micha, Dimitra; Voermans, Elise; Sistermans, E. A.; Pals, Gerard] Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, Van der Boechorststr 7, NL 1081 BT Amsterdam, Netherlands.
   [Eekhoff, Marelise E. W.; Netelenbos, Coen] Vrije Univ Amsterdam, Med Ctr, Internal Med, Endocrinol Sect, Amsterdam, Netherlands.
   [van Essen, Huib W.; Bravenboer, Nathalie] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, MOVE Res Inst, NL 1007 MB Amsterdam, Netherlands.
   [Zandieh Doulabi, Behrouz] Univ Amsterdam, Dept Oral Cell Biol, Acad Ctr Dent Amsterdam ACTA, Amsterdam, Netherlands.
   [Zandieh Doulabi, Behrouz] Vrije Univ Amsterdam, MOVE Res Inst, Amsterdam, Netherlands.
   [Rustemeyer, Thomas] Vrije Univ Amsterdam, Med Ctr, Dept Dermatol, Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije
   Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of
   Amsterdam; Academic Center for Dentistry Amsterdam; Vrije Universiteit
   Amsterdam; Vrije Universiteit Amsterdam
RP Micha, D (通讯作者)，Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, Van der Boechorststr 7, NL 1081 BT Amsterdam, Netherlands.; Bravenboer, N (通讯作者)，Vrije Univ Amsterdam, Dept Clin Chem, Med Ctr, PK2 Br 030,POB 7057, NL 1007 MB Amsterdam, Netherlands.
EM d.micha@vumc.nl; elisevoermans@hotmail.com; EMW.Eekhoff@vumc.nl;
   HW.vanEssen@vumc.nl; bzandiehdoulabi@acta.nl; cnetelen@planet.nl;
   t.rustemeyer@vumc.nl; e.sistermans@vumc.nl; g.pals@vumc.nl;
   n.bravenboer@vumc.nl
RI Sistermans, Erik/B 1109 2009; Rustemeyer, Thomas/G 1585 2012; Micha,
   Dimitra/U 4979 2019; Pals, Gerard/A 5198 2011
OI Sistermans, Erik/0000 0001 7187 4563; Micha,
   Dimitra/0000 0001 7890 4411; Eekhoff, Elisabeth/0000 0001 5399 676X;
   Zandieh Doulabi, Behrouz/0000 0002 0290 3241; Rustemeyer,
   Thomas/0000 0001 7580 0684; Pals, Gerard/0000 0003 4091 7115; 
CR [Anonymous], 2005, GENETICS FIBRODYSPLA
   [Anonymous], 1991, RESPONSIVENESS TRANS
   BERATIS NG, 1976, J MED GENET, V13, P307, DOI 10.1136/jmg.13.4.307
   Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030
   Bravenboer N, 2015, EUR J HUM GENET, V23, DOI 10.1038/ejhg.2014.274
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866
   COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623 199302000 00008
   CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76, DOI 10.1302/0301 620X.64B1.7068725
   CONNOR JM, 1993, J MED GENET, V30, P687, DOI 10.1136/jmg.30.8.687
   CONNOR JM, 1981, CLIN CHIM ACTA, V117, P355, DOI 10.1016/0009 8981(81)90123 6
   Convente MR, 2015, CURR OSTEOPOROS REP, V13, P116, DOI 10.1007/s11914 015 0258 z
   de la Peña LS, 2005, J BONE MINER RES, V20, P1168, DOI 10.1359/JBMR.050305
   Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   Evans KN, 2012, J ORTHOP TRAUMA, V26, pE204, DOI 10.1097/BOT.0b013e31825d60a5
   Fekete N, 2012, CYTOTHERAPY, V14, P540, DOI 10.3109/14653249.2012.655420
   Gannon FH, 1998, CLIN ORTHOP RELAT R, P19
   Gannon FH, 1997, HUM PATHOL, V28, P339, DOI 10.1016/S0046 8177(97)90133 7
   Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464
   Glaser DL, 2005, CLIN REV BONE MINER, V3, P243, DOI 10.1385/BMM:3:3 4:243
   Han GW, 2012, INT J BIOL SCI, V8, P228, DOI 10.7150/ijbs.8.228
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Hebela N, 2005, CLIN REV BONE MINER, V3, P205, DOI 10.1385/BMM:3:3 4:205
   Hegyi L, 2003, J PATHOL, V201, P141, DOI 10.1002/path.1413
   Jackson L, 2007, J POSTGRAD MED, V53, P121
   Jonsdottir Buch SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068984
   Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008 0576
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   Kaplan FS, 2005, CLIN REV BONE MINER, V3, P229, DOI 10.1385/BMM:3:3 4:229
   Kaplan FS, 2005, CLIN REV BONE MINER, V3, P213, DOI 10.1385/BMM:3:3 4:213
   Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472
   Kaplan FS, 2012, DIS MODEL MECH, V5, P756, DOI 10.1242/dmm.010280
   Kaplan FS, 2011, NAT MED, V17, P420, DOI 10.1038/nm0411 420
   Kaplan Frederick S, 2009, Hum Mutat, V30, P379, DOI 10.1002/humu.20868
   KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623 199302000 00009
   Keller B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016421
   Kitoh H, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 163
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   Lo WC, 2009, J NUCL MED, V50, P765, DOI 10.2967/jnumed.108.057372
   LUTWAK L, 1964, AM J MED, V37, P269, DOI 10.1016/0002 9343(64)90011 7
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092 8674(00)00121 5
   Matsumoto Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 190
   MILLER RL, 1977, LAB INVEST, V37, P254
   Naaijkens BA, 2012, CELL TISSUE RES, V348, P119, DOI 10.1007/s00441 012 1360 5
   Phan Sem H, 2008, Proc Am Thorac Soc, V5, P334, DOI 10.1513/pats.200708 146DR
   Pignolo RJ, 2005, CLIN REV BONE MINER, V3, P195, DOI 10.1385/BMM:3:3 4:195
   Rifas L, 2006, J CELL BIOCHEM, V98, P706, DOI 10.1002/jcb.20933
   Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008
   Scarlett RF, 2004, CLIN ORTHOP RELAT R, P275, DOI 10.1097/01.blo.0000129557.38803.26
   Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804
   Shen Q, 2009, J CLIN INVEST, V119, P3462, DOI 10.1172/JCI37412
   SHORE EM, 2013, SEMIN ARTHRITIS RHEU, V42, P546, DOI DOI 10.1016/j.semarthrit.2012.12.010
   Sipe JB, 2004, BONE, V35, P1316, DOI 10.1016/j.bone.2004.08.020
   Solanas G, 2013, NAT REV MOL CELL BIO, V14, P737, DOI 10.1038/nrm3675
   ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016
   Wen FQ, 2002, INFLAMMATION, V26, P279, DOI 10.1023/A:1021412601538
   Xia WJ, 2011, CELL BIOL INT, V35, P639, DOI 10.1042/CBI20100361
   Yano M, 2014, J BIOL CHEM, V289, P16966, DOI 10.1074/jbc.M113.526038
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
NR 59
TC 41
Z9 46
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2016
VL 84
BP 169
EP 180
DI 10.1016/j.bone.2016.01.004
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DE8VK
UT WOS:000370914600020
PM 26769004
DA 2025 08 17
ER

PT J
AU Ahmad, K
   Budoff, MJ
   Delaney, JA
   Mao, SS
   Gao, YL
   Nasir, K
   Tracy, R
   Li, D
AF Ahmad, Khadije
   Budoff, Matthew J.
   Delaney, Joseph A.
   Mao, SongShou
   Gao, Yanlin
   Nasir, Khurram
   Tracy, Russell
   Li, Dong
TI Association of Aspirin and Other Nonsteroidal Anti inflammatory Drugs
   With Vertebral Trabecular Bone: Data From Multiethnic Study of
   Atherosclerosis, a Population Based Multicenter Cohort Study
SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
LA English
DT Article
DE bone mineral density; CT; aspirin; NSAIDs; fracture risk
ID QUANTITATIVE COMPUTED TOMOGRAPHY; MINERAL DENSITY; OSTEOPOROSIS;
   FRACTURE; WOMEN; MEDICATIONS; RISK
AB Objective The objective of this article was to study the association of aspirin and other nonsteroidal anti inflammatory drugs (NSAIDs) with bone mineral density (BMD). Methods Spine BMD was evaluated in a subset of 2028 participants from the Multiethnic Study of Atherosclerosis cohort who were NSAID users (including aspirin) and underwent both lumbar and thoracic imaging. Multiethnic Study of Atherosclerosis is a prospective cohort study that includes 4 ethnic groups (white, Asian, African American, and Hispanic). Trabecular BMD was evaluated by quantitative computed tomography based on cardiac computed tomography images, which were obtained during coronary calcium scans. The analyses were cross sectional using baseline examination data for exposure and outcomes. Results After adjustment for potential confounders including age, sex, race, and traditional cardiovascular risk factors, a small association between trabecular BMD and baseline use of COX 2 selective NSAID was observed. COX 2 selective NSAID use was associated with 7.4 mg/cm(3)(95% confidence interval [CI], 1.6 13.3;P= 0. 013) higher trabecular BMD in thoracic spine and 10.6 mg/cm(3)higher at lumbar spine (95% CI, 5.1 16.1;P< 0.001). Among regular aspirin users, there was no association between drug use and trabecular BMD. Considering all spine fractures together, the prevalence ratio of fractures among aspirin users was 1.0 (95% CI, 0.6 1.6) and 1.1 (95% CI, 0.5 2.3) among COX 2 selective NSAID users. Conclusions Regular use of aspirin has no significant association with trabecular BMD in either the thoracic or lumbar spine and no association with fracture prevalence. COX 2 selective NSAIDs may have modest positive association with BMD, but the mechanisms were not assessed and the observational study design makes residual confounding a possible alternate explanation. Potential pathological mechanisms warrant further longitudinal exploration.
C1 [Ahmad, Khadije; Budoff, Matthew J.; Mao, SongShou; Gao, Yanlin; Li, Dong] Harbor UCLA Med Ctr, Lundquist Inst, Div Cardiol, Dept Med, Torrance, CA 90502 USA.
   [Delaney, Joseph A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Nasir, Khurram] Yale Univ, Houston Methodist, Ctr Outcomes Res & Evaluat, Dept Med Populat Hlth & Hlth Syst Res, Houston, TX USA.
   [Tracy, Russell] Univ Vermont, Dept Pathol, Robert Lamer MD Coll Med, Burlington, VT 05405 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; University of
   Washington; University of Washington Seattle; Yale University; Houston
   Methodist; University of Vermont
RP Budoff, MJ (通讯作者)，Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Cardiol, 1124 W Carson St, Torrance, CA 90502 USA.
EM mbudoff@labiomed.org
RI Delaney, Joseph/J 8204 2019; LI, DONG/AAW 5856 2021; Nasir,
   Khurram/A 2317 2008; Budoff, Matthew/ABD 5175 2021; Ahmad,
   Khadije/AAA 5324 2022
OI Budoff, Matthew/0000 0002 9616 1946; Delaney, Joseph
   A/0000 0003 1771 1776; 
FU National Heart, Lung, and Blood Institute [HHSN268201500003I,
   N01 HC 95159, N01 HC 95160, N01 HC 95161, N01 HC 95162, N01 HC 95163,
   N01 HC 95164, N01 HC 95165, N01 HC 95166, N01 HC 95167, N01 HC 95168,
   N01 HC 95169]; National Center for Research Resources [UL1 TR 000040,
   UL1 RR 025005]
FX This research was supported by contracts HHSN268201500003I,
   N01 HC 95159, N01 HC 95160, N01 HC 95161, N01 HC 95162, N01 HC 95163,
   N01 HC 95164, N01 HC 95165, N01 HC 95166, N01 HC 95167, N01 HC 95168,
   and N01 HC 95169 from the National Heart, Lung, and Blood Institute and
   by grants UL1 TR 000040 and UL1 RR 025005 from National Center for
   Research Resources.
CR Ahmadi N, 2018, OSTEOPOROSIS INT, V29, P1609, DOI 10.1007/s00198 018 4524 7
   Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Budoff MJ, 2013, RADIOLOGY, V267, P830, DOI 10.1148/radiol.13111987
   Budoff MJ, 2012, ACAD RADIOL, V19, P179, DOI 10.1016/j.acra.2011.10.006
   Budoff MJ, 2010, RADIOLOGY, V257, P434, DOI 10.1148/radiol.10100132
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Campbell CL, 2007, JAMA J AM MED ASSOC, V297, P2018, DOI 10.1001/jama.297.18.2018
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Cauley JA, 2007, J BONE MINER RES, V22, P1088, DOI 10.1359/JBMR.070409
   Delaney JAC, 2011, PHARMACOEPIDEM DR S, V20, P83, DOI 10.1002/pds.2065
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Gilsanz V, 2009, RADIOLOGY, V250, P222, DOI 10.1148/radiol.2493080206
   Goodman SB, 2007, J AM ACAD ORTHOP SUR, V15, P450, DOI 10.5435/00124635 200708000 00002
   HEANEY RP, 1975, NEW YORK STATE J MED, V75, P1656
   ITO M, 1989, Nippon Acta Radiologica, V49, P1382
   Jensky NE, 2011, J BONE MINER RES, V26, P2702, DOI 10.1002/jbmr.469
   KOTZKI PO, 1993, BRIT J RADIOL, V66, P55, DOI 10.1259/0007 1285 66 781 55
   Lack WD, 2013, J BONE JOINT SURG AM, V95A, P488, DOI 10.2106/JBJS.L.00462
   Lenchik L, 2004, AM J ROENTGENOL, V183, P949, DOI 10.2214/ajr.183.4.1830949
   Lewiecki EM, 2009, CLEV CLIN J MED, V76, P457, DOI 10.3949/ccjm.76a.09019
   Li D, 2013, ACAD RADIOL, V20, P621, DOI 10.1016/j.acra.2013.01.007
   Liu C, 2012, J CELL BIOCHEM, V113, P148, DOI 10.1002/jcb.23338
   Mao SS, 2017, ACAD RADIOL, V24, P1582, DOI 10.1016/j.acra.2017.06.013
   Mao SS, 2016, CLIN IMAG, V40, P330, DOI 10.1016/j.clinimag.2015.09.016
   Piscitelli P, 2008, CLIN CASES MINER BON, V5, P14
   PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895 4356(92)90143 B
   REYNOLDS JF, 1995, S AFR MED J, V85, P517
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198 011 1692 0
   WASNICH RD, 1991, TRENDS ENDOCRIN MET, V2, P59, DOI 10.1016/1043 2760(91)90041 K
NR 31
TC 4
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0363 8715
EI 1532 3145
J9 J COMPUT ASSIST TOMO
JI J. Comput. Assist. Tomogr.
PD JUL AUG
PY 2020
VL 44
IS 4
BP 562
EP 568
DI 10.1097/RCT.0000000000001022
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA NA4BB
UT WOS:000559758400015
PM 32697527
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Manetti, F
   Petricci, E
   Gabrielli, A
   Mann, A
   Faure, H
   Gorojankina, T
   Brasseur, L
   Hoch, L
   Ruat, M
   Taddei, M
AF Manetti, Fabrizio
   Petricci, Elena
   Gabrielli, Annalisa
   Mann, Andre
   Faure, Helene
   Gorojankina, Tatiana
   Brasseur, Laurent
   Hoch, Lucile
   Ruat, Martial
   Taddei, Maurizio
TI Design, synthesis and biological characterization of a new class of
   osteogenic (1H) quinolone derivatives
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Stem cells; Smoothened agonists; Structure activity relationships;
   Osteogenic activity; Heterocycle; Synthesis; Pharmacophore; Hedgehog
   signaling pathway
ID HEDGEHOG; PROLIFERATION; OXYSTEROLS; AGONISTS
AB Smoothened (Smo) is the signal transducer of the Hedgehog (Hh) pathway and its stimulation is considered a potential powerful tool in regenerative medicine to treat severe tissue injuries. Starting from GSA 10, a recently reported Hh activator acting on Smo, we have designed and synthesized a new class of quinolone based compounds. Modification and decoration of three different portions of the original scaffold led to compounds able to induce differentiation of multipotent mesenchymal cells into osteoblasts. The submicromolar activity of several of these new quinolones (0.4 0.9 mu M) is comparable to or better than that of SAG and purmorphamine, two reference Smo agonists. Structure activity relationships allow identification of several molecular determinants important for the activity of these compounds. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Manetti, Fabrizio; Petricci, Elena; Gabrielli, Annalisa; Taddei, Maurizio] Univ Siena, Dipartimento Biotecnol Chim & Farm, Via Aldo Moro 2, I 53100 Siena, Italy.
   [Mann, Andre] Univ Strasbourg, CNRS, UMR 7200, Lab Innovat Therapeut, F 67401 Illkirch Graffenstaden, France.
   [Faure, Helene; Gorojankina, Tatiana; Brasseur, Laurent; Hoch, Lucile; Ruat, Martial] Neurosci Paris Saclay Inst, CNRS, UMR 9197, 1 Ave Terrasse, F 91198 Gif Sur Yvette, France.
C3 University of Siena; Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; Centre National de la Recherche Scientifique
   (CNRS); CNRS   Institute of Chemistry (INC); Universite Paris Saclay;
   Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB)
RP Petricci, E (通讯作者)，Univ Siena, Dipartimento Biotecnol Chim & Farm, Via Aldo Moro 2, I 53100 Siena, Italy.
EM elena.petricci@unisi.it
RI ; Manetti, Fabrizio/Q 9412 2019; FAURE, Helene/E 4641 2010; Ruat,
   Martial/E 5544 2016; Petricci, Elena/AAB 9275 2022
OI FAURE, Helene/0000 0002 0005 9331; Manetti,
   Fabrizio/0000 0002 9598 2339; Hoch, Lucile/0000 0002 7264 9031;
   PETRICCI, ELENA/0000 0002 9685 6342; 
FU PRIN [2009RMW3Z5_006]; La Ligue contre le Cancer (comite des Yvelines et
   de l'Essonne); Association pour la Recherche sur le Cancer (ARC); La
   ligue contre le Cancer; Fondation pour la Recherche Medicale (FRM)
   [FDT20140930825]
FX PRIN 2009RMW3Z5_006 (M.T.) is acknowledged for a partial financial
   support to M.T., La Ligue contre le Cancer (comite des Yvelines et de
   l'Essonne) and the Association pour la Recherche sur le Cancer (ARC) for
   supporting M.R. and La ligue contre le Cancer and the Fondation pour la
   Recherche Medicale (FRM; FDT20140930825) for a doctoral fellowship to L.
   H. Andreina Ramirez is acknowledged for expert technical support.
CR Bambakidis NC, 2009, J NEUROSURG SPINE, V10, P171, DOI 10.3171/2008.10.SPI08231
   Bragina O, 2010, NEUROSCI LETT, V482, P81, DOI 10.1016/j.neulet.2010.06.068
   Brunton SA, 2009, BIOORG MED CHEM LETT, V19, P4308, DOI 10.1016/j.bmcl.2009.05.096
   Choi SS, 2011, INT J BIOCHEM CELL B, V43, P238, DOI 10.1016/j.biocel.2010.10.015
   Fleury A, 2016, SCI REP UK, V6, DOI 10.1038/srep23479
   Gorojankina T, 2013, MOL PHARMACOL, V83, P1020, DOI 10.1124/mol.112.084590
   Han QQ, 2013, FUTURE MED CHEM, V5, P1671, DOI 10.4155/fmc.13.133
   Hoch L, 2015, FASEB J, V29, P1817, DOI 10.1096/fj.14 267849
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Mak SK, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/140427
   Maschinot CA, 2016, CHEMMEDCHEM, V11, P679, DOI 10.1002/cmdc.201500550
   Nachtergaele S, 2012, NAT CHEM BIOL, V8, P211, DOI 10.1038/nchembio.765
   Ochoa B., 2006, BIOCHEM BIOPH RES CO, V349, P471
   Renault MA, 2013, CIRC RES, V112, P762, DOI 10.1161/CIRCRESAHA.113.300871
   Rognan D, 2015, TOP MED CHEM SER, V16, P127, DOI 10.1007/7355_2014_64
   Roudaut H, 2011, MOL PHARMACOL, V79, P453, DOI 10.1124/mol.110.069708
   Ruat M, 2014, TRENDS PHARMACOL SCI, V35, P237, DOI 10.1016/j.tips.2014.03.002
   Ruat M, 2012, DIFFERENTIATION, V83, pS97, DOI 10.1016/j.diff.2011.11.011
   Seifert K, 2012, BIOORGAN MED CHEM, V20, P6465, DOI 10.1016/j.bmc.2012.08.026
   Wang ND, 2008, J COMB CHEM, V10, P825, DOI 10.1021/cc800025n
   Wang Y, 2012, CHEM BIOL, V19, P972, DOI 10.1016/j.chembiol.2012.06.012
   Wechsler Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896 6273(00)80682 0
NR 22
TC 13
Z9 15
U1 0
U2 18
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD OCT 4
PY 2016
VL 121
BP 747
EP 757
DI 10.1016/j.ejmech.2016.05.062
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DU5RT
UT WOS:000382269700060
PM 27429255
DA 2025 08 17
ER

PT J
AU Maupin, KA
   Dick, D
   Lee, J
   Williams, BO
AF Maupin, Kevin A.
   Dick, Daniel
   Lee, Johan
   Williams, Bart O.
TI Loss of Lgals3 Protects Against Gonadectomy Induced Cortical Bone
   Loss in Mice
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Genetic animal models; Sex steroids; Bone mu CT; Bone histomorphometry;
   Galectin
ID ANDROGEN RECEPTOR; GALECTIN 3; OSTEOCLASTOGENESIS; DIFFERENTIATION;
   OSTEOGENESIS; CONTRIBUTES; MECHANISMS; REGULATOR; DENSITY; MODEL
AB Sex hormone deprivation commonly occurs following menopause in women or after androgen depletion during prostate cancer therapy in men, resulting in rapid bone turnover and loss of bone mass. There is a need to identify novel therapies to improve bone mass in these conditions. Previously, we identified age  and sex dependent effects on bone mass in mice with deletion of the gene encoding the beta galactoside binding lectin, galectin 3 (Lgals3 KO). Due to the influence of sex on the phenotype, we tested the role of sex hormones, estrogen (beta estradiol; E 2), and androgen (5 alpha dihydroxytestosterone; DHT) in Lgals3 KO mice. To address this, we subjected male and female wild type and Lgals3 KO mice to gonadectomy +/  E 2 or DHT rescue and compared differential responses in bone mass and bone formation. Following gonadectomy, male and female Lgals3 KO mice had greater cortical bone expansion (increased total area; T.Ar) and reduced loss of bone area (B.Ar). While T.Ar and B.Ar were increased in response to DHT in wild type mice, DHT did not alter these parameters in Lgals3 KO mice. E 2 rescue more strongly increased B.Ar in Lgals3 KO compared to wild type female mice due to a failure of E 2 to repress the increase in T.Ar following gonadectomy. Lgals3 KO mice had more osteoblasts relative to bone surface when compared to wild type animals in sham, gonadectomy, and E 2 rescue groups. DHT suppressed this increase. This study revealed a mechanism for the sex dependency of the Lgals3 KO aging bone phenotype and supports targeting galectin 3 to protect against bone loss associated with decreased sex hormone production.
C1 [Maupin, Kevin A.; Dick, Daniel; Lee, Johan; Williams, Bart O.] Van Andel Res Inst, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.
   [Maupin, Kevin A.; Dick, Daniel; Lee, Johan; Williams, Bart O.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA.
C3 Van Andel Institute; Van Andel Research Institute; Van Andel Institute;
   Van Andel Research Institute
RP Williams, BO (通讯作者)，Van Andel Res Inst, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.; Williams, BO (通讯作者)，Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA.
EM bart.williams@vai.org
RI Williams, Bart/A 3539 2013
OI Lee, John/0009 0002 1286 5354; Williams, Bart/0000 0002 5261 5301
CR Chernichenko O. A., 2014, Experimental Oncology, V36, P276
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Colnot C, 1999, CELL MOL BIOL, V45, P1191
   Darrow AL, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933 015 0230 3
   de Boer RA, 2012, J INTERN MED, V272, P55, DOI 10.1111/j.1365 2796.2011.02476.x
   FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211
   Iacobini C, 2018, METABOLISM, V83, P149, DOI 10.1016/j.metabol.2018.02.001
   Janelle Montcalm A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2130
   Li YJ, 2009, LAB INVEST, V89, P26, DOI 10.1038/labinvest.2008.111
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   MacLean HE, 2010, J ENDOCRINOL, V206, P93, DOI 10.1677/JOE 10 0026
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Maupin KA, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0003 6
   MCDONALD TP, 1992, J LAB CLIN MED, V120, P168
   Menini S, 2013, CARDIOVASC RES, V100, P472, DOI 10.1093/cvr/cvt206
   Migliaccio S, 1996, ENDOCRINOLOGY, V137, P2118, DOI 10.1210/en.137.5.2118
   Migliaccio S, 2000, BONE, V27, P47, DOI 10.1016/S8756 3282(00)00286 6
   Nakajima K, 2016, CANCER RES, V76, P1391, DOI 10.1158/0008 5472.CAN 15 1793
   Nakajima K, 2014, NEOPLASIA, V16, P939, DOI 10.1016/j.neo.2014.09.005
   Oestreich AK, 2016, P NATL ACAD SCI USA, V113, P13522, DOI 10.1073/pnas.1607644113
   Ortega N, 2005, MOL BIOL CELL, V16, P3028, DOI 10.1091/mbc.e04 12 1119
   Pugliese G, 2015, ATHEROSCLEROSIS, V238, P220, DOI 10.1016/j.atherosclerosis.2014.12.011
   Sádaba JR, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004360
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rowas SAI, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3696
   Russell PK, 2012, J MOL ENDOCRINOL, V49, P1, DOI 10.1530/JME 12 0014
   Schweizer MT, 2017, CANCERS, V9, DOI 10.3390/cancers9010007
   Seeman E, 2001, J CLIN ENDOCR METAB, V86, P4576, DOI 10.1210/jc.86.10.4576
   Simon D, 2017, BONE, V105, P35, DOI 10.1016/j.bone.2017.08.013
   Tchaikovski SN, 2010, THROMB RES, V126, P5, DOI 10.1016/j.thromres.2010.01.045
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Wang A, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1843 3
   Weilner S, 2016, AGING US, V8, P16, DOI 10.18632/aging.100865
NR 34
TC 4
Z9 4
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD MAR
PY 2020
VL 106
IS 3
BP 283
EP 293
DI 10.1007/s00223 019 00630 0
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KL1IT
UT WOS:000513185400008
PM 31745588
DA 2025 08 17
ER

PT J
AU Kaushal, K
   Tyagi, A
   Karapurkar, JK
   Kim, EJ
   Tanguturi, P
   Kim, KS
   Jung, HS
   Ramakrishna, S
AF Kaushal, Kamini
   Tyagi, Apoorvi
   Karapurkar, Janardhan Keshav
   Kim, Eun Jung
   Tanguturi, Parthasaradhireddy
   Kim, Kye Seong
   Jung, Han Sung
   Ramakrishna, Suresh
TI Genome Wide CRISPR/Cas9 Based Screening for Deubiquitinase Subfamily
   Identifies Ubiquitin Specific Protease 11 as a Novel Regulator of
   Osteogenic Differentiation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE protein degradation; ubiquitination; stem cells; regenerative medicine
ID OSTEOBLAST DIFFERENTIATION; BONE FORMATION; HOMEOBOX GENES; LIGASE
   SMURF1; MSX GENES; IN VITRO; TGF BETA; CELLS; EXPRESSION; DISEASE
AB The osteoblast differentiation capacity of mesenchymal stem cells must be tightly regulated, as inadequate bone mineralization can lead to osteoporosis, and excess bone formation can cause the heterotopic ossification of soft tissues. The balanced protein level of Msh homeobox 1 (MSX1) is critical during normal osteogenesis. To understand the factors that prevent MSX1 protein degradation, the identification of deubiquitinating enzymes (DUBs) for MSX1 is essential. In this study, we performed loss of function based screening for DUBs regulating MSX1 protein levels using the CRISPR/Cas9 system. We identified ubiquitin specific protease 11 (USP11) as a protein regulator of MSX1 and further demonstrated that USP11 interacts and prevents MSX1 protein degradation by its deubiquitinating activity. Overexpression of USP11 enhanced the expression of several osteogenic transcriptional factors in human mesenchymal stem cells (hMSCs). Additionally, differentiation studies revealed reduced calcification and alkaline phosphatase activity in USP11 depleted cells, while overexpression of USP11 enhanced the differentiation potential of hMSCs. These results indicate the novel role of USP11 during osteogenic differentiation and suggest USP11 as a potential target for bone regeneration.
C1 [Kaushal, Kamini; Tyagi, Apoorvi; Karapurkar, Janardhan Keshav; Tanguturi, Parthasaradhireddy; Kim, Kye Seong; Ramakrishna, Suresh] Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul 04763, South Korea.
   [Kim, Eun Jung; Jung, Han Sung] Yonsei Univ, Div Anat & Dev Biol, Oral Sci Res Ctr,Coll Dent, Dept Oral Biol,Taste Res Ctr,BK21 FOUR Project, Seoul 03722, South Korea.
   [Kim, Kye Seong; Ramakrishna, Suresh] Hanyang Univ, Coll Med, Seoul 04763, South Korea.
C3 Hanyang University; Yonsei University; Yonsei University Health System;
   Hanyang University
RP Kim, KS; Ramakrishna, S (通讯作者)，Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul 04763, South Korea.; Jung, HS (通讯作者)，Yonsei Univ, Div Anat & Dev Biol, Oral Sci Res Ctr,Coll Dent, Dept Oral Biol,Taste Res Ctr,BK21 FOUR Project, Seoul 03722, South Korea.; Kim, KS; Ramakrishna, S (通讯作者)，Hanyang Univ, Coll Med, Seoul 04763, South Korea.
EM kaminikaushal10@gmail.com; apoorvityagi09@gmail.com;
   kalpesh25021992@gmail.com; BLUELEAH@yuhs.ac; parthabiochem7@gmail.com;
   ks66kim@hanyang.ac.kr; HSJUNG@yuhs.ac; suri28@hanyang.ac.kr
RI ; Jung, Han Sung/I 3848 2012; KIM, SUNG MIN/U 5269 2017; Kim, Seong
   Cheol/ABD 1493 2022; Ramakrishna, Suresh/AAX 4096 2021
OI Tanguturi, Parthasaradhi/0000 0002 2566 9312; Karapurkar,
   Janardhan/0000 0002 0198 4035; Jung, Han Sung/0000 0003 2795 531X; Kim,
   Eun Jung/0000 0002 9515 7590; Kim, Kye Seong/0000 0001 5550 1660;
   Kaushal, Kamini/0000 0002 0075 3251; 
CR Al Salihi MA, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120063
   Antao AM, 2020, CANCERS, V12, DOI 10.3390/cancers12061579
   Bendall AJ, 1999, DEVELOPMENT, V126, P4965
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Danikowski KM, 2019, JOVE J VIS EXP, DOI 10.3791/59285
   Das S, 2020, CELL DEATH DIFFER, V27, P3004, DOI 10.1038/s41418 020 0557 5
   DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Gomathi K, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117389
   Goto N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8035759
   Gou YC, 2018, MECH DEVELOP, V152, P13, DOI 10.1016/j.mod.2018.05.001
   Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Guo YC, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3712083
   Gupta V, 2006, BIOCHEM BIOPH RES CO, V345, P74, DOI 10.1016/j.bbrc.2006.03.232
   Herhaus L, 2014, CELL SIGNAL, V26, P2186, DOI 10.1016/j.cellsig.2014.06.012
   Holland PWH, 2005, BRAIN RES BULL, V66, P484, DOI 10.1016/j.brainresbull.2005.06.003
   Houzelstein D, 1999, DEVELOPMENT, V126, P2689
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Kamiya N, 2001, J Oral Sci, V43, P179
   Kaushal K, 2020, CANCERS, V12, DOI 10.3390/cancers12113253
   Kaushal K, 2018, DRUG DISCOV TODAY, V23, P1974, DOI 10.1016/j.drudis.2018.05.035
   Kim HJ, 2009, GENOME RES, V19, P1279, DOI 10.1101/gr.089417.108
   Kurihara LJ, 2001, HUM MOL GENET, V10, P1963, DOI 10.1093/hmg/10.18.1963
   Lallemand Y, 2005, DEVELOPMENT, V132, P3003, DOI 10.1242/dev.01877
   Liang J, 2016, EUR J HUM GENET, V24, P1663, DOI 10.1038/ejhg.2016.78
   Liu J, 2017, BONE JOINT RES, V6, P154, DOI 10.1302/2046 3758.63.BJR 2016 0237.R1
   Maas R, 1996, ANN NY ACAD SCI, V785, P171, DOI 10.1111/j.1749 6632.1996.tb56256.x
   Nassif A, 2014, BONE, V66, P96, DOI 10.1016/j.bone.2014.06.003
   Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092 8674(00)00212 9
   Ogawa T, 2006, J BIOL CHEM, V281, P18363, DOI 10.1074/jbc.M601543200
   Orestes Cardoso S, 2002, CONNECT TISSUE RES, V43, P153, DOI 10.1080/03008200290000547
   Orestes Cardoso SM, 2001, DEV DYNAM, V221, P1, DOI 10.1002/dvdy.1120
   Petroski MD, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471 2091 9 S1 S7
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0083 6
   Ramakrishna S, 2014, GENOME RES, V24, P1020, DOI 10.1101/gr.171264.113
   Ramos C, 2005, TRENDS GENET, V21, P624, DOI 10.1016/j.tig.2005.09.001
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494 348
   Sévère N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.217
   Shanmugham A, 2008, CURR OPIN DRUG DISC, V11, P688
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Singer FR, 2016, CURR OSTEOPOROS REP, V14, P39, DOI 10.1007/s11914 016 0303 6
   Singhal S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471 2091 9 S1 S3
   Son MJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081854
   Song YJ, 2011, MOL CELLS, V32, P221, DOI 10.1007/s10059 011 1020 8
   Strickson S, 2017, P NATL ACAD SCI USA, V114, pE3481, DOI 10.1073/pnas.1702367114
   Sun XW, 2018, J CELL PHYSIOL, V233, P596, DOI 10.1002/jcp.25920
   Suresh B, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6705927
   Tang YM, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0637 8
   van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155
   Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896 417
   Vi Fane Brigitte, 2007, Orthod Fr, V78, P39
   Vlasschaert C, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862 015 0511 1
   Wu J, 2019, MOL CELL ENDOCRINOL, V479, P117, DOI 10.1016/j.mce.2018.09.008
   Yamaguchi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102944
   Yang YN, 2020, NUCLEIC ACIDS RES, V48, P11452, DOI 10.1093/nar/gkaa905
   ZERNIK J, 1990, DIFFERENTIATION, V44, P207, DOI 10.1111/j.1432 0436.1990.tb00619.x
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zheng JL, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 020 00106 0
   Zhou FF, 2016, J BONE MINER RES, V31, P1888, DOI 10.1002/jbmr.2863
   Zhou J, 2015, CALCIFIED TISSUE INT, V96, P465, DOI 10.1007/s00223 015 9967 7
NR 66
TC 9
Z9 10
U1 0
U2 14
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2022
VL 23
IS 2
AR 856
DI 10.3390/ijms23020856
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YN4AP
UT WOS:000747202300001
PM 35055037
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ando, T
   Ichikawa, J
   Fujimaki, T
   Taniguchi, N
   Takayama, Y
   Haro, H
AF Ando, Takashi
   Ichikawa, Jiro
   Fujimaki, Taro
   Taniguchi, Naofumi
   Takayama, Yoshihiro
   Haro, Hirotaka
TI Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma
   by Targeting Autophagy and Apoptosis
SO CANCERS
LA English
DT Article
DE gemcitabine; rapamycin; autophagy; apoptosis; angiogenesis
ID PHASE II TRIAL; MAMMALIAN TARGET; CHEMOTHERAPY; DOCETAXEL; SIROLIMUS;
   PATHWAY; CYCLOPHOSPHAMIDE; METASTASIS; INHIBITION; SURVIVAL
AB Simple Summary
   Osteosarcoma is the most common solid cancer of the bone. Unfortunately, the expected outcome for patients with this and similar types of cancers has changed little over the last 20 years. One important need is to develop new therapies that overcome the development of drug resistance in osteosarcoma cells. The drug gemcitabine (Gem) can kill osteosarcoma cells and prevent them from growing and spreading. Another drug, rapamycin (Rapa), can also kill osteosarcoma cells, but does so in a different way. Here, we investigated whether a combination of Rapa and Gem would exhibit better osteosarcoma treatment efficiency than Rapa and Gem monotherapies. We found that this drug combination was very effective at killing osteosarcoma cells, both in cell cultures and in mice, and the combinatorial treatment was better than treatment with a single agent. Therefore, combinatorial therapy with Gem and Rapa may be an effective approach for treating drug resistant osteosarcoma cells.
   The overall prognosis for sarcoma based cancer patients has remained largely unchanged over the past 10 years. Because there is no effective anticancer drug for patients with chemoresistant osteosarcoma (OS), novel approaches are needed to improve the prognosis. Here, we investigated whether rapamycin (Rapa) could enhance the anti tumor effects of gemcitabine (Gem) in OS. Gem dose dependently killed the OS cells, but exhibited much lower cytotoxicity on osteoblasts. Treatment with a combination Gem and Rapa was much more effective than that of either single agent with respect to reducing cell viability, cell invasion, cell migration, and vascular endothelial growth factor production in vitro. Moreover, the combination of these agents suppressed tumor growth, angiogenesis, and lung metastasis in allograft and xenograft murine models of OS with minimal adverse effects. Overall, the combination therapy prolonged the overall survival of tumor bearing mice. Mechanistically, Gem induced apoptosis and increased the levels of cleaved caspases, while Rapa induced autophagy and microtubule associated protein light chain 3 (LC3) I/LC3 II expression both in vitro and in vivo. Our findings suggest that chemotherapy using Gem combined with Rapa may be a novel and promising therapeutic approach for the treatment of OS.
C1 [Ando, Takashi; Ichikawa, Jiro; Fujimaki, Taro; Taniguchi, Naofumi; Takayama, Yoshihiro; Haro, Hirotaka] Yamanashi Univ, Dept Orthopead Surg, Sch Med, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Ando, T (通讯作者)，Yamanashi Univ, Dept Orthopead Surg, Sch Med, Yamanashi 4093898, Japan.
EM andou@yamanashi.ac.jp; jiro@yamanashi.ac.jp; tfujimaki@yamanashi.ac.jp;
   naofumit@yamanashi.ac.jp; ytakayama@yamanashi.ac.jp;
   haro@yamanashi.ac.jp
FU JSPS KAKENHI [16K10851, 18K09060, 19K09594, 20K17995, 20K18027];
   Grants in Aid for Scientific Research [19K09594, 18K09060, 16K10851,
   20K18027, 20K17995] Funding Source: KAKEN
FX This research was funded by JSPS KAKENHI, grant numbers 16K10851,
   18K09060, 19K09594, 20K17995, and 20K18027.
CR Al Saedi A, 2020, J GERONTOL A BIOL, V75, P58, DOI 10.1093/gerona/glz149
   Ando T, 2005, J ORTHOP RES, V23, P964, DOI 10.1016/j.orthres.2005.01.010
   Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   Benjamin RS, 2020, ADV EXP MED BIOL, V1257, P1, DOI 10.1007/978 3 030 43032 0_1
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008 5472.CAN 06 0802
   Caporarello N, 2017, MOL MED REP, V16, P4393, DOI 10.3892/mmr.2017.7179
   Chawla SP, 2012, J CLIN ONCOL, V30, P78, DOI 10.1200/JCO.2011.35.6329
   Chen M, 2014, INT J MOL MED, V34, P276, DOI 10.3892/ijmm.2014.1772
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Dennis MD, 2011, J BIOL CHEM, V286, P8287, DOI 10.1074/jbc.M110.209171
   Díaz Troya S, 2008, AUTOPHAGY, V4, P851, DOI 10.4161/auto.6555
   du Rusquec P, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920940939
   Duffaud F, 2012, EUR J CANCER, V48, P564, DOI 10.1016/j.ejca.2011.12.015
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Han TY, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720926153
   Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549 013 2560 8
   Ishibashi Y, 2019, ANTICANCER RES, V39, P649, DOI 10.21873/anticanres.13159
   Jemal A., 2010, CA CANCER J CLIN, V60, P277, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Jia SQ, 2016, ANTICANCER RES, V36, P1111
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Lamplot JD, 2013, CURR CANCER THER REV, V9, P55, DOI 10.2174/1573394711309010006
   Leu KM, 2004, J CLIN ONCOL, V22, P1706, DOI 10.1200/JCO.2004.08.043
   Li L, 2004, ANTICANCER RES, V24, P1973
   Liu WT, 2020, ADV EXP MED BIOL, V1207, P275, DOI 10.1007/978 981 15 4272 5_20
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Maki RG, 2007, ONCOLOGIST, V12, P999, DOI 10.1634/theoncologist.12 8 999
   Martin Broto J, 2017, ANN ONCOL, V28, P2994, DOI 10.1093/annonc/mdx536
   Martin Liberal J, 2014, BRIT J CANCER, V111, P858, DOI 10.1038/bjc.2014.370
   Massimo B, 2009, CANCER AM CANCER SOC, V115, P2980, DOI 10.1002/cncr.24368
   Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941
   Miyake N, 2012, ONCOL REP, V28, P848, DOI 10.3892/or.2012.1855
   Morrow JJ, 2018, NAT MED, V24, P176, DOI 10.1038/nm.4475
   Mousa Luay, 2015, Biomark Cancer, V7, P13, DOI 10.4137/BIC.S25250
   Navid F, 2008, CANCER, V113, P419, DOI 10.1002/cncr.23586
   Nikoletopoulou V, 2013, BBA MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Prater S., 2020, StatPearls., StatPearls Publishing Copyright
   Richardsen E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186852
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Ropolo A, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00411
   Saito M, 2018, J BONE MINER RES, V33, P2048, DOI 10.1002/jbmr.3537
   Saman H, 2020, CANCERS, V12, DOI 10.3390/cancers12051172
   Sato N, 2016, BONE, V83, P23, DOI 10.1016/j.bone.2015.10.005
   Schuetze SM, 2012, EUR J CANCER, V48, P1347, DOI 10.1016/j.ejca.2012.03.022
   Takahara T, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929 020 00679 2
   Tamaddoni A, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104798
   Usman RM, 2021, ASIA PAC J CLIN ONCO, V17, P193, DOI 10.1111/ajco.13449
   Wang B, 2015, ONCOTARGET, V6, P38348, DOI 10.18632/oncotarget.5276
   Wu ML, 2018, ANN CLIN TRANSL NEUR, V5, P138, DOI 10.1002/acn3.507
   Xiao X, 2014, PEDIATR DRUGS, V16, P503, DOI 10.1007/s40272 014 0095 z
   Yu WX, 2020, EUR REV MED PHARMACO, V24, P915, DOI 10.26355/eurrev_202001_20076
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang Y, 2018, ONCOL LETT, V16, P6228, DOI 10.3892/ol.2018.9434
   Zhou QA, 2010, MED ONCOL, V27, P1239, DOI 10.1007/s12032 009 9365 y
   Zhu JH, 2018, BIOTECHNOL APPL BIOC, V65, P665, DOI 10.1002/bab.1657
NR 55
TC 21
Z9 21
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD NOV
PY 2020
VL 12
IS 11
AR 3097
DI 10.3390/cancers12113097
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OX6CT
UT WOS:000593650900001
PM 33114161
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Casula, M
   Catapano, AL
   Piccinelli, R
   Menditto, E
   Manzoli, L
   De Fendi, L
   Orlando, V
   Flacco, ME
   Gambera, M
   Filippi, A
   Tragni, E
AF Casula, Manuela
   Catapano, Alberico Luigi
   Piccinelli, Rossana
   Menditto, Enrica
   Manzoli, Lamberto
   De Fendi, Luisa
   Orlando, Valentina
   Flacco, Maria Elena
   Gambera, Marco
   Filippi, Alessandro
   Tragni, Elena
TI Assessment and Potential Determinants of Compliance and Persistence to
   Antiosteoporosis Therapy in Italy
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID POSTMENOPAUSAL OSTEOPOROSIS; MEDICATION ADHERENCE; MONTHLY IBANDRONATE;
   PATIENT PREFERENCE; FRACTURE RISK; DRUG THERAPY; BISPHOSPHONATES;
   ALENDRONATE; WOMEN; RISEDRONATE
AB Objectives
   To analyze adherence to antiosteoporosis drugs (A0Ds) and to assess the influence of patient related and drug related factors.
   Study Design
   Observational, retrospective study. Methods Data on prescriptions for AODs from 2007 through 2008 were retrieved from administrative databases of 10 Italian local health units. Key measurements included compliance and persistence tran,yneati. Multivariate regression analyses were performed to.,estimate adjusted risk ratios for compliance less than 80% and adjusted hazard ratios for no persistence.
   Results
   Of 40,004 new patients (89.9% women, mean age 69.8 years), 84.0% were treated with bisphosphonates and 74.6% of administration regimens were weekly. Overall, 75.1% of patients had suboptimal levels of compliance and 84.7% were not persistent; almost one third had only 1 prescription. In regression analyses, younger age, change of drug, and concomitant corticosteroid therapy were significantly associated to compliance and persistence in both genders. In women, weekly and monthly regimens reduced the risk for poor compliance (sex adjusted relative risks 0.729 10.697 0.7621, 0.846 10.817 0.8761, respectively) and no persistence (sex adjusted hazard ratios 0.591 10.541 0.6461, 0.508 10.461 0.5601, respectively) compared with a daily regimen.
   Conclusions
   In our study, 75% of subjects had discontinuous treatment and inadequate drug supply. Age and frequency of administration were strongly associated with adherence. Improvement is urgently needed, and occasional prescriptions represent the main target.
C1 [Casula, Manuela; Catapano, Alberico Luigi; Tragni, Elena] Univ Milan, SEFAP, Epidemiol & Prevent Pharmacol Cen tre, Dept Pharmacol & Biomol Sci, I 20133 Milan, Italy.
   [Catapano, Alberico Luigi] IRCCS MultiMed, Milan, Italy.
   [Piccinelli, Rossana; De Fendi, Luisa; Gambera, Marco] LHU Bergamo, Local Pharmaceut Serv, Bergamo, Italy.
   [Menditto, Enrica; Orlando, Valentina] Univ Naples Federico II, CIRFF, Ctr Pharmacoecon, Naples, Italy.
   [Manzoli, Lamberto; Flacco, Maria Elena] Univ G dAnnunzio, Dept Med & Aging Sci, Chieti, Italy.
   [Filippi, Alessandro] SIMG, Italian Soc Gen Med, Florence, Italy.
C3 University of Milan; IRCCS Multimedica; University of Naples Federico
   II; G d'Annunzio University of Chieti Pescara
RP Casula, M (通讯作者)，Univ Milan, SEFAP, Epidemiol & Prevent Pharmacol Ctr, Dept Pharmacol Sci, I 20133 Milan, Italy.
EM sefap@unimi.it
RI Flacco, Maria Elena/E 3306 2017; Casula, Manuela/AAC 4470 2019; Manzoli,
   Lamberto/K 1895 2018; Flacco, Maria/E 3306 2017; Orlando,
   Valentina/AAD 1791 2019; Catapano, alberico/AAC 2827 2019
OI Flacco, Maria Elena/0000 0003 1404 4314; Manzoli,
   Lamberto/0000 0002 8129 9344; orlando, valentina/0000 0002 8209 8878;
   menditto, enrica/0000 0001 8633 5650; Catapano, Alberico
   Luigi/0000 0002 7593 2094; 
FU Regione Lombardia
FX This analysis was partially performed under the IFI project, funded by
   Regione Lombardia (according to DGR 8501 March 22, 2002).
CR Amin Shreyasee, 2003, Curr Osteoporos Rep, V1, P71, DOI 10.1007/s11914 003 0012 9
   Beest FJAPV, 2008, OSTEOPOROSIS INT, V19, P511, DOI 10.1007/s00198 007 0466 1
   Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003
   Brookhart MA, 2007, AM J MED, V120, P251, DOI 10.1016/j.amjmed.2006.03.029
   Corsonello Andrea, 2009, Ther Clin Risk Manag, V5, P209
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524 4733.2007.00213.x
   Curtis JR, 2006, OSTEOPOROSIS INT, V17, P1268, DOI 10.1007/s00198 006 0136 8
   Downey TW, 2006, SOUTH MED J, V99, P570, DOI 10.1097/01.smj.0000221637.90495.66
   Emkey R, 2005, CURR MED RES OPIN, V21, P1895, DOI 10.1185/030079905X74862
   Gellad WF, 2011, AM J GERIATR PHARMAC, V9, P11, DOI 10.1016/j.amjopharm.2011.02.004
   Gold DT, 2006, CURR MED RES OPIN, V22, P2383, DOI 10.1185/030079906X154042
   Hadji P, 2008, JOINT BONE SPINE, V75, P303, DOI 10.1016/j.jbspin.2007.07.011
   Hansen KE, 2008, OSTEOPOROSIS INT, V19, P349, DOI 10.1007/s00198 007 0471 4
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   Iversen MD, 2011, J GERIATR PHYS THER, V34, P72, DOI 10.1097/JPT.0b013e3181ff03b4
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kertes J, 2008, ISR MED ASSOC J, V10, P207
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Lee S, 2011, OSTEOPOROSIS INT, V22, P741, DOI 10.1007/s00198 010 1335 x
   Lekkerkerker F, 2007, OSTEOPOROSIS INT, V18, P1311, DOI 10.1007/s00198 007 0410 4
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   Netelenbos JC, 2011, OSTEOPOROSIS INT, V22, P1537, DOI 10.1007/s00198 010 1372 5
   Penning van Beest FJA, 2006, CLIN THER, V28, P236, DOI 10.1016/j.clinthera.2006.01.002
   Peterson AM, 2007, VALUE HEALTH, V10, P3, DOI 10.1111/j.1524 4733.2006.00139.x
   Petrella Robert J, 2006, BMC Fam Pract, V7, P31, DOI 10.1186/1471 2296 7 31
   Rabenda V, 2008, OSTEOPOROSIS INT, V19, P811, DOI 10.1007/s00198 007 0506 x
   Recker RR, 2005, MAYO CLIN PROC, V80, P856, DOI 10.4065/80.7.856
   Rizzoli R, 2007, NAT CLIN PRACT ENDOC, V3, P80, DOI 10.1038/ncpendmet0371
   Rossini M, 2006, OSTEOPOROSIS INT, V17, P914, DOI 10.1007/s00198 006 0073 6
   Roughead EE, 2009, PHARMACOEPIDEM DR S, V18, P69, DOI 10.1002/pds.1687
   Scoville EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018468
   Sunyecz JA, 2008, OSTEOPOROSIS INT, V19, P1421, DOI 10.1007/s00198 008 0586 2
   The Adherence Gap: why osteoporosis patients don't continue with treatment, 2005, ADH GAP WHY OST PAT
   Tosteson ANA, 2010, OSTEOPOROSIS INT, V21, P1769, DOI 10.1007/s00198 009 1133 5
   Weycker D, 2006, OSTEOPOROSIS INT, V17, P1645, DOI 10.1007/s00198 006 0179 x
   Wilkes MM, 2010, OSTEOPOROSIS INT, V21, P679, DOI 10.1007/s00198 009 0991 1
   World Health Organization Collaborating Centre for Drug Statistics Methodology, 2013, ATC DDD IND 2009
NR 38
TC 26
Z9 26
U1 0
U2 4
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088 0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2014
VL 20
IS 5
BP E138
EP E145
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA AL5AV
UT WOS:000339146800003
PM 25326928
DA 2025 08 17
ER

PT J
AU Vulpio, C
   Maresca, G
   Distasio, E
   Cacaci, S
   Panocchia, N
   Luciani, G
   Bossola, M
AF Vulpio, Carlo
   Maresca, Giulia
   Distasio, Enrico
   Cacaci, Silvia
   Panocchia, Nicola
   Luciani, Giovanna
   Bossola, Maurizio
TI Switch from calcitriol to paricalcitol in secondary hyperparathyroidism
   of hemodialysis patients: Responsiveness is related to parathyroid gland
   size
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article
DE Paricalcitol; calcitriol; secondary hyperparathyroidism;
   ultrasonography; hemodialysis; parathyroid hormone
ID LONG TERM; ULTRASONOGRAPHY; THERAPY; CALCIUM; MULTICENTER; BONE
AB Paricalcitol is more effective than calcitriol in hemodialysis patients (HD) with secondary hyperparathyroidism (SHPT), but it is not effective in some of them. We have investigated the relationship between paricalcitol responsiveness and parathyroid gland (PTG) size. Thirty HD with SHPT treated previously with calcitriol for at least 6 months were switched to paricalcitol (1:4 conversion ratio). Parathyroid gland number and size (maximum longitudinal diameter [MLD] of largest PTG) was measured by ultrasonography. Patients were divided into 2 groups: group A (MLD < 9.0 mm [17 HD]); and group B (MLD > 9.0 mm [13 HD]). They were defined responder if both the last 2 monthly determinations of inhibit parathyroid hormone (iPTH) were within the target (< 300 pg/mL) according to National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommendations. Twenty six and 20 HD completed 6 month and 12 month paricalcitol therapy, respectively. After 6 months of paricalcitol treatment, 23.5% HD of group A and 7.7% of group B were responders. At 12 months, 41.2 % of group A and 7.7% of group B were responders. Throughout paricalcitol therapy, serum calcium and phosphorus concentrations slightly increased in all HD but more significantly in group B. The baseline iPTH and MLD of the largest PTG were significantly correlated with final iPTH levels. Paricalcitol is more effective than calcitriol in SHPT, but the responsiveness to paricalcitol and hypercalcemia are related to PTG size. The measurement of MLD by ultrasonography may be useful for predicting responsiveness to paricalcitol, avoiding an unnecessary and expensive therapy.
C1 [Vulpio, Carlo; Panocchia, Nicola; Luciani, Giovanna; Bossola, Maurizio] Univ Cattolica Sacro Cuore, Ist Clin Chirurg, I 00168 Rome, Italy.
   [Maresca, Giulia; Cacaci, Silvia] Univ Cattolica Sacro Cuore, Ist Radiol, I 00168 Rome, Italy.
   [Distasio, Enrico] Univ Cattolica Sacro Cuore, Ist Biochim, I 00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Vulpio, C (通讯作者)，Univ Cattolica Sacro Cuore, Ist Clin Chirurg, Largo A Gemelli 8, I 00168 Rome, Italy.
EM c.vulpio@alice.it
RI di stasio, enrico/AAL 3082 2020; Panocchia, Nicola/AAW 2192 2020;
   vulpio, carlo/L 2600 2013
OI Panocchia, Nicola/0000 0003 0381 765X; Di Stasio,
   Enrico/0000 0003 1047 4261; VULPIO, CARLO/0000 0002 0148 4620
CR Brancaccio D, 2007, DRUGS, V67, P1981, DOI 10.2165/00003495 200767140 00002
   Capuano A, 2009, J NEPHROL, V22, P59
   Dobrez DG, 2004, NEPHROL DIAL TRANSPL, V19, P1174, DOI 10.1093/ndt/gfh123
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   FUKAGAWA M, 1994, NEPHRON, V68, P221, DOI 10.1159/000188261
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   Indridason OS, 1996, KIDNEY INT, V50, P1663, DOI 10.1038/ki.1996.483
   Katoh N, 2000, AM J KIDNEY DIS, V35, P465, DOI 10.1016/S0272 6386(00)70199 5
   Lindberg J, 2001, CLIN NEPHROL, V56, P315
   Llach F, 2001, AM J KIDNEY DIS, V38, pS45, DOI 10.1053/ajkd.2001.28114
   Lund RJ, 2010, AM J NEPHROL, V31, P165, DOI 10.1159/000266204
   Malberti F, 1999, NEPHROL DIAL TRANSPL, V14, P2398, DOI 10.1093/ndt/14.10.2398
   Martin KJ, 2001, AM J KIDNEY DIS, V38, pS57, DOI 10.1053/ajkd.2001.28112
   Matsuoka S, 2008, THER APHER DIAL, V12, P391, DOI 10.1111/j.1744 9987.2008.00615.x
   Mitsopoulos E, 2006, AM J KIDNEY DIS, V48, P114, DOI 10.1053/j.ajkd.2006.04.060
   Mittman N, 2006, KIDNEY INT, V70, pS64, DOI 10.1038/sj.ki.5001981
   Moe SM, 2003, AM J NEPHROL, V23, P369, DOI 10.1159/000073945
   Okuno S, 2003, NEPHROL DIAL TRANSPL, V18, P2613, DOI 10.1093/ndt/gfg451
   QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223
   Rodriguez M, 2002, KIDNEY INT, V61, pS155, DOI 10.1046/j.1523 1755.61.s80.26.x
   Seeherunvong W, 2006, PEDIATR NEPHROL, V21, P1434, DOI 10.1007/s00467 006 0204 5
   Slatopolsky E, 1998, AM J KIDNEY DIS, V32, pS40, DOI 10.1053/ajkd.1998.v32.pm9808142
   Slatopolsky E, 2002, KIDNEY INT, V61, pS143, DOI 10.1046/j.1523 1755.61.s80.24.x
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Sprague SM, 2001, AM J KIDNEY DIS, V38, pS51, DOI 10.1053/ajkd.2001.28110
   TANIGUCHI M, 2008, NEPHROL DIAL TRANSPL, V4, P1
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tominaga Y, 2006, THER APHER DIAL, V10, P198, DOI 10.1111/j.1744 9987.2006.00364.x
   Vulpio C, 2008, AM J NEPHROL, V28, P589, DOI 10.1159/000116875
   Vulpio C, 2010, HEAD NECK J SCI SPEC, V32, P1226, DOI 10.1002/hed.21320
NR 31
TC 15
Z9 18
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1492 7535
EI 1542 4758
J9 HEMODIAL INT
JI Hemodial. Int.
PD JAN
PY 2011
VL 15
IS 1
BP 69
EP 78
DI 10.1111/j.1542 4758.2010.00514.x
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 712MH
UT WOS:000286670400011
PM 21223484
DA 2025 08 17
ER

PT J
AU Rethinam, S
   Basaran, B
   Vijayan, S
   Mert, A
   Bayraktar, O
   Aruni, AW
AF Rethinam, Senthil
   Basaran, Bahri
   Vijayan, Sumathi
   Mert, Ali
   Bayraktar, Oguz
   Aruni, A. Wilson
TI Electrospun nano bio membrane for bone tissue engineering application a
   new approach
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE Nanomembrane; Nanofiber; Nanoparticles; Electrospun; Tissue engineering
ID MULTIWALLED CARBON NANOTUBES; REINFORCEMENT; SPECTROSCOPY; COMPOSITES;
   MECHANISMS; PERIOSTEUM; SCAFFOLDS
AB The aim of this research study, develop electrospun nano bio membrane (ENBM) from Poly (vinyl) alcohol (PVA), nano Demineralized Bone Matrix (nano DBM) and to impart additional strength, incorporation of carbon nanoparticles (CNP) by elctrospinning machine for their potential application in bone tissue regeneration. The effective of ENBM for biocompatibility properties were evaluated using MG 63 osteoblast cell line, which showed 100% biocompatibility and more viable cell present in the electrospun nano biomembrane. In vitro biomineralization, more apatite formation was observed SEM images. Electrospun nanoscaffold prepared using PVA, nano DBM and CNP (0.6%) possessed improved mechanical properties viz. 14.58 +/  0.13 Mpa of tensile strength, 13.87 +/  0.05% of elongation at break and 36.84 +/  0.11% water absorption. This research study proved the bone formation of these ENBM in bone tissue regeneration and regenerative medicine.
C1 [Rethinam, Senthil; Basaran, Bahri] Ege Univ, Sch Nat & Appl Sci, TR 35100 Bornova, Turkey.
   [Rethinam, Senthil] Sathyabama Inst Sci & Technol, Dept Biotechnol, Chennai 600199, Tamil Nadu, India.
   [Vijayan, Sumathi] VIT, Sch Elect & Elect Engn, Chennai 600127, Tamil Nadu, India.
   [Mert, Ali] Ege Univ, Dept Stat, TR 35100 Bornova, Turkey.
   [Bayraktar, Oguz] Ege Univ, Dept Chem Engn, TR 35100 Bornova, Turkey.
   [Aruni, A. Wilson] Sathyabama Inst Sci & Technol, Sch Bio & Chem Engn, Chennai 600119, Tamil Nadu, India.
   [Aruni, A. Wilson] Calif Univ Sci & Med, 217 E Club Ctr Dr Suite A, San Bernardino, CA 92408 USA.
C3 Ege University; Sathyabama Institute of Science & Technology; Vellore
   Institute of Technology (VIT); VIT Chennai; Ege University; Ege
   University; Sathyabama Institute of Science & Technology
RP Rethinam, S (通讯作者)，Ege Univ, Sch Nat & Appl Sci, TR 35100 Bornova, Turkey.
EM senthilbiop@gmail.com
RI WILSON, ARUNI/AAU 1908 2020; Bayraktar, Oguz/Q 9265 2019; Basaran,
   Bahri/ABC 1602 2020; BAŞARAN, BAHRİ/ABC 1602 2020; V,
   Sumathi/AAC 1232 2021; Rethinam, Senthil/ADQ 7052 2022; Mert,
   Ali/HJA 5487 2022
OI bayraktar, oguz/0000 0003 4210 2825; Basaran, Bahri/0000 0002 0893 6300;
   Rethinam, Senthil/0000 0002 3187 5673; Aruni,
   Wilson/0000 0002 9208 0153; , Sumathi/0000 0002 6042 0934
FU 2232 International Fellowship for Outstanding Researcher Program of
   TUBITAK [118C350]
FX Dr. Senthil Rethinam (Project Coordinator) acknowledges the funding
   support granted by the 2232 International Fellowship for Outstanding
   Researcher Program of TUBITAK (Project No: 118C350).
CR Alshehri R, 2016, J MED CHEM, V59, P8149, DOI 10.1021/acs.jmedchem.5b01770
   [Anonymous], J NANOMATER
   [Anonymous], MAT CHEM PHYS
   [Anonymous], SCI TECHNOLOGY GELAT
   Asencio IO, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418799851
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   Burjanadze TV, 2000, BIOPOLYMERS, V53, P523, DOI 10.1002/(SICI)1097 0282(200005)53:6<523::AID BIP8>3.0.CO;2 7
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Cassereau L, 2015, J BIOTECHNOL, V193, P66, DOI 10.1016/j.jbiotec.2014.11.008
   Cha CY, 2013, ACS NANO, V7, P2891, DOI 10.1021/nn401196a
   de Grado GF, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418776819
   Della Valle C, 2012, INT J ARTIF ORGANS, V35, P864, DOI 10.5301/ijao.5000161
   Di Martino Alberto, 2011, Musculoskelet Surg, V95, P69, DOI 10.1007/s12306 011 0097 8
   Foolen J, 2008, J ORTHOP RES, V26, P1263, DOI 10.1002/jor.20586
   Fuente E, 2003, J PHYS CHEM B, V107, P6350, DOI 10.1021/jp027482g
   Gerhardt LC, 2010, MATERIALS, V3, P3867, DOI 10.3390/ma3073867
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Kouklin N, 2004, APPL PHYS LETT, V85, P4463, DOI 10.1063/1.1812837
   Krishna R, 1996, J PHARM PHARMACOL, V48, P367, DOI 10.1111/j.2042 7158.1996.tb05934.x
   Lewis K, 2013, NAT REV DRUG DISCOV, V12, P371, DOI 10.1038/nrd3975
   Liu Y, 2014, J BIOMED NANOTECHNOL, V10, P1049, DOI 10.1166/jbn.2014.1794
   Marrese M, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9020027
   Meurice E, 2012, J MATER SCI MATER M, V23, P2445, DOI 10.1007/s10856 012 4711 6
   Misra A, 2007, J NANOSCI NANOTECHNO, V7, P1820, DOI 10.1166/jnn.2007.723
   Osswald S, 2007, J RAMAN SPECTROSC, V38, P728, DOI 10.1002/jrs.1686
   Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646
   Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9
   Pieske Oliver, 2009, J Trauma Manag Outcomes, V3, P11, DOI 10.1186/1752 2897 3 11
   Rethinam S, 2019, J DRUG DELIV SCI TEC, V53, DOI 10.1016/j.jddst.2019.101163
   Rethinam S, 2018, MICRO NANO LETT, V13, P1404, DOI 10.1049/mnl.2018.5033
   Rethinam S, 2018, J DRUG DELIV SCI TEC, V47, P454, DOI 10.1016/j.jddst.2018.08.010
   Rethinam S, 2016, INT J ARTIF ORGANS, V39, P509, DOI 10.5301/ijao.5000531
   Santos C, 2002, BIOMATERIALS, V23, P1897, DOI 10.1016/S0142 9612(01)00331 3
   Senthil R., 2018, Am. J. Mater. Synth. Process., V3, P1, DOI 10.11648/j.ajmsp.20180301.11
   Senthil R, 2018, INT J ARTIF ORGANS, V41, P467, DOI 10.1177/0391398818775949
   Senthil R, 2015, FIBER POLYM, V16, P181, DOI 10.1007/s12221 015 0181 z
   Spasova M, 2007, J BIOACT COMPAT POL, V22, P62, DOI 10.1177/0883911506073570
   Sternstein SS, 2002, MACROMOLECULES, V35, P7262, DOI 10.1021/ma020482u
   Vig K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040789
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Winkler T, 2018, BONE JOINT RES, V7, P232, DOI 10.1302/2046 3758.73.BJR 2017 0270.R1
   Yeo LY, 2006, J EXP NANOSCI, V1, P177, DOI 10.1080/17458080600670015
   Zhang XL, 2015, J WUHAN UNIV TECHNOL, V30, P840, DOI 10.1007/s11595 015 1239 x
   Zhang XP, 2008, CLIN ORTHOP RELAT R, V466, P1777, DOI 10.1007/s11999 008 0312 6
NR 44
TC 18
Z9 18
U1 1
U2 37
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254 0584
EI 1879 3312
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD JUL 15
PY 2020
VL 249
AR 123010
DI 10.1016/j.matchemphys.2020.123010
PG 9
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LY2LQ
UT WOS:000540352000036
DA 2025 08 17
ER

PT J
AU Lau, KHW
   Rundle, CH
   Zhou, XD
   Baylink, DJ
   Sheng, MHC
AF Lau, K.  H. William
   Rundle, Charles H.
   Zhou, Xiao Dong
   Baylink, David J.
   Sheng, Matilda H.  C.
TI Conditional deletion of IGF I in osteocytes unexpectedly accelerates
   bony union of the fracture gap in mice
SO BONE
LA English
DT Article
DE Fracture repair; Insulin like growth factor I; Osteocytes; Conditional
   deletion; Intramembranous bone formation; Endochondral bone remodeling;
   Bony union; Transgenic mice
ID GROWTH FACTOR I; SCLEROSTIN ANTIBODY; GENE THERAPY; OSTEOTOMY MODEL;
   BETA CATENIN; MOUSE MODEL; SS CATENIN; RATS; DIFFERENTIATION; EXPRESSION
AB This study evaluated the effects of deficient IGF I expression in osteocytes on fracture healing. Transgenic mice with conditional knockout (cKO) of Igf1 in osteocytes were generated by crossing Dmp1 Cre mice with Igf1 flax mice. Fractures were created on the mid shaft of tibia of 12 week old male cKO mice and wild type (WT) littermates by three point bending. At 21 and 28 days post fracture healing, the increases in cortical bone mineral density, mineral content, bone area, and thickness, as well as sub cortical bone mineral content at the fracture site were each greater in cKO calluses than in WT calluses. There were 85% decrease in the cartilage area and >2 fold increase in the number of osteoclasts in cKO calluses at 14 days post fracture, suggesting a more rapid remodeling of endochondral bone. The upregulation of mRNA levels of osteoblast marker genes (cbfa1, alp, Opn, and Ocn) was greater in cKO calluses than in WT calluses. mu CT analysis suggested an accelerated bony union of the fracture gap in cKO mice. The Sost mRNA level was reduced by 50% and the Bmp2 mRNA level was increased 3 fold in cKO fractures at 14 days post fracture, but the levels of these two mRNAs in WT fractures were unchanged, suggesting that the accelerated fracture repair may in part act through the Wnt and/or BMP signaling. In conclusion, conditional deletion of Igf1 in osteocytes not only did not impair, but unexpectedly enhanced, bony union of the fracture gap. The accelerated bony union was due in part to upregulation of the Wnt and BMP2 signaling in response to deficient osteocyte derived IGF I expression, which in turn favors intramembranous over endochondral bone repair. (C) 2016 Elsevier Inc All rights reserved.
C1 [Lau, K.  H. William; Zhou, Xiao Dong; Baylink, David J.; Sheng, Matilda H.  C.] Loma Linda Univ, Sch Med, Dept Med, Div Regenerat Med, 11234 Anderson St, Loma Linda, CA 92350 USA.
   [Lau, K.  H. William; Rundle, Charles H.] Jerry L Pettis Mem VA Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA USA.
C3 Loma Linda University
RP Sheng, MHC (通讯作者)，Loma Linda Univ, Sch Med, Dept Med, Div Regenerat Med, 11234 Anderson St, Loma Linda, CA 92350 USA.
EM MSheng@llu.edu
RI Zhou, Xiaodong/B 4017 2011
OI Lau, Kin Hing/0000 0003 1109 5052
FU Telemedicine and Advanced Technology Research Center (TATRC) at the US
   Army Medical Research and Material Command (USAMRMC) [W81XWH 08 1 0697]
FX This work was supported by the Telemedicine and Advanced Technology
   Research Center (TATRC) at the US Army Medical Research and Material
   Command (USAMRMC) under Grant # W81XWH 08 1 0697. The views, opinions
   and/or findings contained in this report are those of the authors and
   should not be construed as an official Department of the Army position,
   policy or decision unless so designated by other documentation. The
   authors thank Prof. Derek LeRoith for the generous gift of the
   Igf1<SUP>flox/flox</SUP> breeding pair and acknowledge the excellent
   technical assistance of Ms. Denise Galvan.
CR [Anonymous], EXP BIOL MED
   Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198 004 1728 9
   Beier EE, 2014, J ORTHOP RES, V32, P1397, DOI 10.1002/jor.22677
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Caetano Lopes J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016947
   Chen SX, 2015, J BONE MINER RES, V30, P1184, DOI 10.1002/jbmr.2453
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Clinkenbeard EL, 2016, J BONE MINER RES, V31, P1247, DOI 10.1002/jbmr.2792
   Cui L, 2013, J MUSCULOSKEL NEURON, V13, P178
   Ellegaard M, 2013, J BONE MINER RES, V28, P2145, DOI 10.1002/jbmr.1957
   Feng G, 2015, INT IMMUNOPHARMACOL, V24, P7, DOI 10.1016/j.intimp.2014.11.010
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Han B, 2014, STEM CELL RES, V12, P562, DOI 10.1016/j.scr.2014.01.003
   HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551
   Huang Y, 2012, J ORTHOP RES, V30, P304, DOI 10.1002/jor.21505
   Igarashi A, 2001, INT J MOL MED, V8, P433
   Javaheri B, 2014, J BONE MINER RES, V29, P705, DOI 10.1002/jbmr.2064
   Jawad MU, 2013, J ORTHOP RES, V31, P155, DOI 10.1002/jor.22186
   Jensen ED, 2010, J CELL BIOCHEM, V109, P672, DOI 10.1002/jcb.22462
   Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756 3282(00)00421 X
   KENWRIGHT J, 1991, J BONE JOINT SURG BR, V73, P654, DOI 10.1302/0301 620X.73B4.2071654
   Koh A, 2011, J ORTHOP RES, V29, P1820, DOI 10.1002/jor.21457
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Larsson S, 2001, CLIN ORTHOP RELAT R, P240
   Lau KHW, 2013, AM J PHYSIOL ENDOC M, V305, pE271, DOI 10.1152/ajpendo.00092.2013
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Lau KHW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115897
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li MQ, 2004, MICROSC RES TECHNIQ, V64, P330, DOI 10.1002/jemt.20088
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Loiselle AE, 2013, J ORTHOP RES, V31, P147, DOI 10.1002/jor.22178
   McGee Lawrence ME, 2013, BIOCHEM BIOPH RES CO, V441, P886, DOI 10.1016/j.bbrc.2013.10.155
   Meinel L, 2003, BONE, V33, P660, DOI 10.1016/S8756 3282(03)00207 2
   Morse A, 2015, BONE, V71, P155, DOI 10.1016/j.bone.2014.10.018
   Myers TJ, 2015, J BONE MINER RES, V30, P2014, DOI 10.1002/jbmr.2548
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Rundle CH, 2003, BONE, V32, P591, DOI 10.1016/S8756 3282(03)00096 6
   Rundle CH, 2008, J GENE MED, V10, P229, DOI 10.1002/jgm.1148
   Sarahrudi K, 2012, J ORTHOP RES, V30, P1549, DOI 10.1002/jor.22129
   Schmidmaier G, 2003, ACTA ORTHOP SCAND, V74, P604, DOI 10.1080/00016470310018036
   Shen FH, 2002, J ORTHOP TRAUMA, V16, P651, DOI 10.1097/00005131 200210000 00007
   Sheng MHC, 2013, BONE, V52, P133, DOI 10.1016/j.bone.2012.09.027
   Sheng MHC, 1999, BONE, V25, P421, DOI 10.1016/S8756 3282(99)00184 2
   Sinnesael M, 2012, J BONE MINER RES, V27, P2535, DOI 10.1002/jbmr.1713
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Tachi K, 2010, CELL TISSUE RES, V342, P213, DOI 10.1007/s00441 010 1052 y
   Ulstrup AK, 2008, ACTA ORTHOP BELG, V74, P291
   Windahl SH, 2013, P NATL ACAD SCI USA, V110, P2294, DOI 10.1073/pnas.1220811110
   Xiao ZS, 2011, FASEB J, V25, P2418, DOI 10.1096/fj.10 180299
   Xing DG, 2015, BRATISL MED J, V116, P64, DOI 10.4149/BLL_2015_012
   Yee CS, 2016, BONE, V82, P122, DOI 10.1016/j.bone.2015.04.048
   Yeung TM, 2011, CELL MOL LIFE SCI, V68, P2513, DOI 10.1007/s00018 011 0687 5
   Yu YY, 2010, BONE, V46, P841, DOI 10.1016/j.bone.2009.11.005
NR 56
TC 19
Z9 22
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2016
VL 92
BP 18
EP 28
DI 10.1016/j.bone.2016.08.005
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DZ2TC
UT WOS:000385693400003
PM 27519969
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, MJ
   Xiao, J
   Du, QA
   Zhang, WC
   Zhang, JY
   Yan, ZW
   Luo, JF
   Yu, C
   Ye, ZB
   Chen, J
AF Wang, Mengjing
   Xiao, Jing
   Du, Qiuna
   Zhang, Weichen
   Zhang, Jiaying
   Yan, Zhenwen
   Luo, Jianfeng
   Yu, Chen
   Ye, Zhibin
   Chen, Jing
TI Phosphorus balance calculator: an individualized tool for treatment of
   hyperphosphatemia in hemodialysis patients
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE hyperphosphatemia; maintenance hemodialysis; phosphorus balance
   calculator
ID CHRONIC KIDNEY DISEASE; LANTHANUM CARBONATE; MINERAL METABOLISM;
   PARATHYROID HORMONE; CALCIUM CARBONATE; CIRCADIAN RHYTHM; BONE DISORDER;
   PHOSPHATE; DIALYSIS; MORTALITY
AB Background. Lack of evaluations of the dietary phosphorus and dialysis phosphorus removal in daily clinical practice are common obstacles to assessing phosphorus balance and controlling phosphorus in hemodialysis patients. We aimed to investigate whether individualized therapy using a phosphorus balance calculator improves phosphorus control.Methods. A randomized, open label, multicenter, 4 week clinical trial was conducted. A total of 119 maintenance hemodialysis patients aged 18 85 years old and with serum phosphorus level >1.45 mmol/L from three university teaching hospitals in Shanghai were enrolled. Patients were randomized in a 1:1 ratio to individualized therapy (n = 60) or conventional therapy (n = 59). The primary outcome was the serum phosphorus concentration after 4 week treatment. Secondary outcomes included the serum calcium and parathyroid hormone (PTH) concentrations, changes in serum phosphorus, calcium and PTH concentrations, and the proportion of patients achieving target ranges of serum phosphorus, calcium and PTH after 4 week treatment.Results. Among 119 randomized participants [mean age 62 years; 68 male (57%)], 116 completed the trial. Using the phosphorus balance calculator, the individualized group achieved a better phosphorus balance state and significantly reduced serum phosphorus (1.62 +/  0.45 mmol/L versus 1.85 +/  0.45 mmol/L, P = .006), increased the proportions of patients achieving target serum phosphorus range (41% versus 18%, P = .006) and had greater adjusted mean difference in change in serum phosphorus over the 4 weeks ( 0.47 versus  0.23 mmol/L, P = .010) when compared with conventional therapy. No significant changes were observed in serum calcium and PTH levels, the proportion of patients achieving target serum calcium or PTH levels, or the adjusted mean difference of serum calcium and PTH levels over the treatment period.Conclusion. Phosphorus balance calculator was proved to improve serum phosphorus control in patients undergoing maintenance hemodialysis, offering a new tool for managing hyperphosphatemia.
C1 [Wang, Mengjing; Zhang, Weichen; Chen, Jing] Fudan Univ, Huashan Hosp, Nephrol, Shanghai, Peoples R China.
   [Wang, Mengjing; Chen, Jing] Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
   [Yan, Zhenwen; Ye, Zhibin; Chen, Jing] Fudan Univ, Huadong Hosp, Nephrol, Shanghai, Peoples R China.
   [Du, Qiuna; Yu, Chen] Tongji Univ, Tongji Hosp, Nephrol, Shanghai, Peoples R China.
   [Zhang, Jiaying] Fudan Univ, Huashan Hosp, Div Nutr, Shanghai, Peoples R China.
   [Luo, Jianfeng] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Tongji University;
   Fudan University; Fudan University
RP Wang, MJ; Chen, J (通讯作者)，Fudan Univ, Huashan Hosp, Nephrol, Shanghai, Peoples R China.; Wang, MJ; Chen, J (通讯作者)，Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
EM fiyona27@126.com; chenjing1998@fudan.edu.cn
RI Chen, Jing/AAM 2184 2021
FU National Key R&D Program of China [2020YFC2005003, 2021YFC2500202,
   2022YFC3602905]; Shanghai Shenkang hospital development center clinical
   science and technology innovation project [SHDC12018111]; Key Project of
   National Natural Science Foundation of China [81 730 017]; Medical
   Engineering fund of Fudan University; Shenkang three year action plan
   project [SHDC2020CR4014]
FX This work was supported by grants from the National Key R&D Program of
   China (2020YFC2005003, 2021YFC2500202, 2022YFC3602905), Shanghai
   Shenkang hospital development center clinical science and technology
   innovation project (SHDC12018111), Key Project of National Natural
   Science Foundation of China (81 730 017), Medical Engineering fund of
   Fudan University (for Mengjing Wang) and Shenkang three year action plan
   project (SHDC2020CR4014).
CR Achinger SG, 2005, KIDNEY INT, V67, pS28, DOI 10.1111/j.1523 1755.2005.09504.x
   Asmus HG, 2005, NEPHROL DIAL TRANSPL, V20, P1653, DOI 10.1093/ndt/gfh894
   Ayus JC, 2007, KIDNEY INT, V71, P336, DOI 10.1038/sj.ki.5002044
   Barreto FC, 2019, KIDNEY INT REP, V4, P1043, DOI 10.1016/j.ekir.2019.06.002
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Copland M, 2016, AM J KIDNEY DIS, V68, pS24, DOI 10.1053/j.ajkd.2016.05.024
   Cozzolino M, 2019, TOXINS, V11, DOI 10.3390/toxins11040213
   D'Haese PC, 2003, KIDNEY INT, V63, pS73, DOI 10.1046/j.1523 1755.63.s85.18.x
   dopps, 2021, SER PHOSPH 3 MONTH A
   Estepa JC, 1999, J BONE MINER RES, V14, P1848, DOI 10.1359/jbmr.1999.14.11.1848
   Fishbane SN, 2021, KIDNEY MED, V3, P1057, DOI 10.1016/j.xkme.2021.07.003
   Floege J, 2010, NEPHROL DIAL TRANSPL, V25, P1916, DOI 10.1093/ndt/gfp762
   Gardham C, 2010, CLIN J AM SOC NEPHRO, V5, P1261, DOI 10.2215/CJN.09471209
   Hernandez A, 1996, KIDNEY INT, V50, P1872, DOI 10.1038/ki.1996.508
   Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130
   Hruska KA, 2008, CLIN CASES MINER BON, V5, P35
   Hutchison AJ, 2005, NEPHRON CLIN PRACT, V100, pC8, DOI 10.1159/000084653
   Hutchison AJ, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 40
   Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019
   Ix JH, 2019, J AM SOC NEPHROL, V30, P1096, DOI 10.1681/ASN.2018101058
   Ix JH, 2014, AM J CLIN NUTR, V100, P1392, DOI 10.3945/ajcn.114.085498
   KEMP GJ, 1992, CLIN CHEM, V38, P400
   Kendrick J, 2011, ADV CHRONIC KIDNEY D, V18, P113, DOI 10.1053/j.ackd.2010.12.003
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kim Youngmee, 2010, Nephrol Nurs J, V37, P377
   Kooienga L, 2007, SEMIN DIALYSIS, V20, P342, DOI 10.1111/j.1525 139X.2007.00304.x
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Malluche HH, 2012, J AM SOC NEPHROL, V23, P525, DOI 10.1681/ASN.2010121253
   Martin P, 2011, AM J KIDNEY DIS, V57, P700, DOI 10.1053/j.ajkd.2010.11.028
   National Clinical Research Center for Kidney Diseases, 2019, J NEPHROL DAILY TRAN, V28, P52, DOI DOI 10.3969/J.ISSN.1006 298X.2019.01.012
   Peacock M, 2021, CALCIFIED TISSUE INT, V108, P3, DOI 10.1007/s00223 020 00686 3
   Penido MGMG, 2012, PEDIATR NEPHROL, V27, P2039, DOI 10.1007/s00467 012 2175 z
   Pergola PE, 2021, J AM SOC NEPHROL, V32, P1465, DOI 10.1681/ASN.2020101398
   PORTALE AA, 1987, J CLIN INVEST, V80, P1147, DOI 10.1172/JCI113172
   Rastogi A, 2021, J RENAL NUTR, V31, P21, DOI 10.1053/j.jrn.2020.02.003
   Schulz KF, 2010, TRIALS, V11, DOI [10.1016/j.jclinepi.2010.03.004, 10.1186/1741 7015 8 18, 10.1016/j.jclinepi.2010.02.005, 10.1186/1745 6215 11 32, 10.1136/bmj.c332, 10.4103/0976 500X.72352, 10.1136/bmj.c869, 10.1016/j.ijsu.2011.10.001, 10.1097/AOG.0b013e3181d9d421]
   Scialla JJ, 2014, NAT REV NEPHROL, V10, P268, DOI 10.1038/nrneph.2014.49
   SHEIKH MS, 1989, J CLIN INVEST, V83, P66, DOI 10.1172/JCI113886
   Slouma M, 2020, ADV RHEUMATOL, V60, DOI 10.1186/s42358 020 0118 0
   Sprague SM, 2021, KIDNEY INT REP, V6, P2049, DOI 10.1016/j.ekir.2021.05.012
   Sprague SM, 2016, AM J KIDNEY DIS, V67, P559, DOI 10.1053/j.ajkd.2015.06.023
   St Jules DE, 2016, J RENAL NUTR, V26, P136, DOI 10.1053/j.jrn.2015.12.004
   Stremke ER, 2021, J AM SOC NEPHROL, V32, P2057, DOI 10.1681/ASN.2020091340
   Vemuri N, 2011, BMC NEPHROL, V12, DOI 10.1186/1471 2369 12 49
   Wang MJ, 2023, NUTRIENTS, V15, DOI 10.3390/nu15051236
   Wang MJ, 2012, HEMODIAL INT, V16, P363, DOI 10.1111/j.1542 4758.2012.00678.x
   Zhang JY, 2021, J CLIN HYPERTENS, V23, P849, DOI 10.1111/jch.14182
   Zhang WC, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882 021 02547 z
   Zhang WC, 2021, KIDNEY BLOOD PRESS R, V46, P53, DOI 10.1159/000511375
NR 49
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JAN 11
PY 2024
VL 39
IS 7
BP 1159
EP 1170
DI 10.1093/ndt/gfad256
EA JAN 2024
PG 12
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA WO0O7
UT WOS:001141041000001
PM 38037501
DA 2025 08 17
ER

PT J
AU Woo, HE
   Cho, JY
   Lim, YH
AF Woo, Hee Eun
   Cho, Joo Young
   Lim, Young Hee
TI Propionibacterium freudenreichii MJ2 derived extracellular
   vesicles inhibit RANKL induced osteoclastogenesis and improve
   collagen induced rheumatoid arthritis
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Propionibacterium freudenreichii; Extracellular
   vesicles; Osteoclastogenesis; Collagen induced arthritis;
   Anti inflammation
ID GENE EXPRESSION
AB Rheumatoid arthritis causes excessive bone loss by stimulating osteoclast differentiation. Extracellular vesicles are valuable disease markers, conveyors of distant cell to cell communication, and carriers for drug delivery. The aim of this study was to investigate the anti osteoclastogenic effects of extracellular vesicles derived from dairy Propionibacterium freudenreichii MJ2 (PFEVs) and the improvement effect of PFEVs on collagen induced arthritis (CIA) animal model. PFEVs were observed by scanning electron microscopy, transmission electron microscopy, nanoparticle tracking analysis, and LC MS/MS. The inhibitory activity of PFEVs against receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation was investigated in RAW 264.7 cells. PFEVs significantly decreased the expression levels of genes and proteins related to osteoclast differentiation. PFEVs decreased RANK RANKL binding. In a CIA mouse model, PFEVs treatment significantly reduced arthritis scores and collagen specific immunoglobulins. PFEVs treatment also reduced pro inflammatory cytokines and increased anti inflammatory cytokines. The anti inflammatory effects were confirmed by H&E staining, and PFEVs treatment inhibited osteoclastogenesis in the CIA mouse model. In conclusion, PFEVs inhibited osteoclast differentiation by inhibiting RANK RANKL signaling, thereby decreasing the expression of osteoclast differentiation related genes. PFEVs also improved collagen induced arthritis by inhibiting inflammation and osteoclastogenesis.
C1 [Woo, Hee Eun; Cho, Joo Young; Lim, Young Hee] Korea Univ, Grad Sch, Dept Integrated Biomed & Life Sci, Seoul 02841, South Korea.
   [Lim, Young Hee] Korea Univ, Sch Biosyst & Biomed Sci, Seoul 02841, South Korea.
   [Lim, Young Hee] Korea Univ, Guro Hosp, Dept Lab Med, Seoul 08308, South Korea.
C3 Korea University; Korea University; Korea University; Korea University
   Medicine (KU Medicine)
RP Lim, YH (通讯作者)，Korea Univ, Grad Sch, Dept Integrated Biomed & Life Sci, Seoul 02841, South Korea.; Lim, YH (通讯作者)，Korea Univ, Sch Biosyst & Biomed Sci, Seoul 02841, South Korea.; Lim, YH (通讯作者)，Korea Univ, Guro Hosp, Dept Lab Med, Seoul 08308, South Korea.
EM yhlim@korea.ac.kr
RI CHO, JOO/AAJ 2012 2020
FU National Research Foundation of Korea (NRF)   Korean government (MSIP)
   [2022R1A2C1010264]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIP) (2022R1A2C1010264).
CR Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Buch MH, 2021, NAT REV RHEUMATOL, V17, P17, DOI 10.1038/s41584 020 00541 7
   Cecchin R, 2023, MOL THER, V31, P1225, DOI 10.1016/j.ymthe.2023.01.021
   Cho YG, 2007, AUTOIMMUN REV, V7, P65, DOI 10.1016/j.autrev.2007.08.001
   Choi JH, 2020, EXP MOL MED, V52, P423, DOI 10.1038/s12276 019 0359 3
   Choi J, 2019, EXP NEUROBIOL, V28, P158, DOI 10.5607/en.2019.28.2.158
   Ghaffary EM, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117420
   Gravallese EM, 2023, NEW ENGL J MED, V388, P529, DOI 10.1056/NEJMra2103726
   Gurunathan S, 2023, MICROB PATHOGENESIS, V185, DOI 10.1016/j.micpath.2023.106396
   Hosseini Giv N, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.962216
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim MH, 2018, ALLERGY ASTHMA IMMUN, V10, P516, DOI 10.4168/aair.2018.10.5.516
   Kim M, 2022, IMMUNE NETW, V22, DOI 10.4110/in.2022.22.e8
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li YJ, 2023, BIOMED PHARMACOTHER, V168, DOI 10.1016/j.biopha.2023.115767
   Liu Y, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01502
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma LY, 2023, MOL NUTR FOOD RES, V67, DOI 10.1002/mnfr.202200884
   Niu Q, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1034050
   Okamoto K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3323
   Park JH, 2017, MOL CELLS, V40, P706
   Radu AF, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112857
   Rodovalho VD, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01544
   Rolph D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00937
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Schneider AH, 2024, BRIT J PHARMACOL, V181, P429, DOI 10.1111/bph.16227
   Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525
   Sheta M, 2023, BIOLOGY BASEL, V12, DOI 10.3390/biology12010110
   Sun DS, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1274295
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang XG, 2020, P NATL ACAD SCI USA, V117, P3174, DOI 10.1073/pnas.1915829117
   Wang YZ, 2023, FRONT MICROBIOL, V14, DOI 10.3389/fmicb.2023.1258860
   Xin YJ, 2020, CALCIFIED TISSUE INT, V106, P553, DOI 10.1007/s00223 020 00666 7
   Yahara Y, 2022, DEVELOPMENT, V149, DOI 10.1242/dev.199908
   Yang ZF, 2017, J BIOL CHEM, V292, P1178, DOI 10.1074/jbc.M116.764928
   Yeom J, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 42944 y
   Yeom J, 2022, MICROORGANISMS, V10, DOI 10.3390/microorganisms10010048
   Yeom J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040673
   Yokota K, 2024, IMMUNOL MED, V47, P6, DOI 10.1080/25785826.2023.2220931
   Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455
   Zhang XY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.777441
NR 45
TC 3
Z9 3
U1 3
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 23
PY 2024
VL 14
IS 1
AR 24973
DI 10.1038/s41598 024 76911 y
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA K1D2Y
UT WOS:001341352800063
PM 39443658
OA gold
DA 2025 08 17
ER

PT J
AU El Mouedden, M
   Meert, TF
AF El Mouedden, Mohammed
   Meert, Theo Frans
TI Pharmacological evaluation of opioid and non opioid analgesics in a
   murine bone cancer model of pain
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article
DE analgesics; bone cancer pain; hypersensitivity; opioid; murine bone
   tumor model; anticonvulsants; antidepressants; NSAIDS; COX 2;
   acetaminophen
ID ORTHOTOPIC TUMOR INOCULATION; NEUROPATHIC PAIN; FORMALIN TEST; POSSIBLE
   INVOLVEMENT; RECEPTOR AGONISTS; MOUSE MODEL; MICE; GABAPENTIN;
   MECHANISMS; MORPHINE
AB The intramedulary injection of osteosarcoma, cells in the mouse femur has served as a laboratory model to study bone cancer pain. However, the efficacy of different classes of analgesics has not fully been analyzed in this model. Therefore, the acute antinociceptive properties of different classes of drugs were evaluated on post inoculation day 15 when the degrees of spontaneous pain and mechanical hypersensitivity in the ipsilateral inoculated hind paw reached almost their maximal effects. At high doses, the opioids fentanyl, morphine, and tramadol had full efficacies for all pain parameters tested. Antagonism experiments with naloxone (10 mg/kg s.c.) or its peripheral analogue methylnaltrexone (10 mg/kg s.c.), suggest that the analgesic effects of fentanyl were predominantly mediated by centrally located mu opiate receptors.
   Acetaminophen, the non steroidal anti inflammatory drug indomethacin, and the COX 2 inhibitor celecoxib did not significantly improve pain behavior. The tricyclic antidepressants amitriptyline and desipramine significantly reduced spontaneous pain behavior but this only at sedative doses, the serotonin reuptake inhibitor fluoxetine had limited efficacy. Also with the anticonvulsants lamotrigine, topiramate, and gabapentin limited or no efficacies were found. In conclusion, the present study provided integrated information about the tumor induced bone pain in mice, and clarified acute efficacies of different categories of analgesics for the spontaneous lifting, limb use impairment, and mechanical hypersensitivity. Moreover, the finding that bone cancer pain behaviors are attenuated by various established compounds further supports the validity of the murine bone cancer model for the study of bone cancer pain and its use for the identification of novel treatments. (c) 2007 Elsevier Inc. All rights reserved.
C1 Johnson & Johnson Pharmaceut Res & Dev, Dept Pain & Neurol, B 2340 Beerse, Belgium.
C3 Johnson & Johnson; Johson & Johnson Belgium; Janssen Pharmaceuticals
RP Meert, TF (通讯作者)，Johnson & Johnson Pharmaceut Res & Dev, Dept Pain & Neurol, Turnhoutseweg 30, B 2340 Beerse, Belgium.
EM tmeert@prdbe.jnj.com
CR Anjaneyulu M, 2006, EUR J PHARMACOL, V538, P80, DOI 10.1016/j.ejphar.2006.03.067
   Baamonde A, 2005, N S ARCH PHARMACOL, V372, P213, DOI 10.1007/s00210 005 0013 6
   Braga MFM, 2002, NEUROPHARMACOLOGY, V42, P522, DOI 10.1016/S0028 3908(01)00198 8
   Brainin Mattos J, 2006, PAIN, V122, P174, DOI 10.1016/j.pain.2006.01.032
   Caraceni A, 1999, J PAIN SYMPTOM MANAG, V17, P441, DOI 10.1016/S0885 3924(99)00033 0
   Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
   Collins SL, 2000, J PAIN SYMPTOM MANAG, V20, P449, DOI 10.1016/S0885 3924(00)00218 9
   Deffois A, 1996, NEUROSCI LETT, V220, P117, DOI 10.1016/S0304 3940(96)13227 4
   Donovan Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542 200501000 00022
   Duman EN, 2004, J PHARMACOL SCI, V94, P161, DOI 10.1254/jphs.94.161
   Dworkin RH, 2003, ARCH NEUROL CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524
   El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016
   Fox A, 2004, PAIN, V107, P33, DOI 10.1016/j.pain.2003.09.003
   Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768
   GLASSMAN AH, 1981, ARCH GEN PSYCHIAT, V38, P815
   Gustafsson H, 2003, EXP NEUROL, V182, P427, DOI 10.1016/S0014 4886(03)00097 9
   Hofmann HA, 2003, EUR J PHARMACOL, V470, P17, DOI 10.1016/S0014 2999(03)01753 9
   Honore P, 2000, Prog Brain Res, V129, P389
   Kögel B, 2005, EUR J PAIN, V9, P599, DOI 10.1016/j.ejpain.2005.02.002
   Koltzenburg M, 1998, CURR OPIN NEUROL, V11, P515, DOI 10.1097/00019052 199810000 00014
   Kuraishi Y, 2003, BIOL PHARM BULL, V26, P550
   Laughlin TM, 2002, J PHARMACOL EXP THER, V302, P1168, DOI 10.1124/jpet.302.3.1168
   LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006 8993(93)91660 K
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811
   Medhurst JL, 2002, TREE PHYSIOL, V22, P775, DOI 10.1093/treephys/22.11.775
   Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002
   Menéndez L, 2005, PHARMACOL BIOCHEM BE, V81, P114, DOI 10.1016/j.pbb.2005.02.007
   Menéndez L, 2003, NEUROREPORT, V14, P867, DOI 10.1097/01.wnr.0000069963.11849.af
   Nitu AN, 2003, EXPERT OPIN INV DRUG, V12, P545, DOI 10.1517/13543784.12.4.545
   ONGHENA P, 1992, PAIN, V49, P205, DOI 10.1016/0304 3959(92)90144 Z
   Pancrazio JJ, 1998, J PHARMACOL EXP THER, V284, P208
   PRESKORN SH, 1982, J PHARMACOL EXP THER, V223, P388
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Saito Osamu, 2005, J Anesth, V19, P218, DOI 10.1007/s00540 005 0323 3
   Sasamura T, 2002, EUR J PHARMACOL, V441, P185, DOI 10.1016/S0014 2999(02)01450 4
   Sawynok J, 1999, PAIN, V80, P45, DOI 10.1016/S0304 3959(98)00195 X
   Schreiber S, 1999, NEUROSCI LETT, V273, P85, DOI 10.1016/S0304 3940(99)00627 8
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Shannon HE, 2005, NEUROPHARMACOLOGY, V48, P1012, DOI 10.1016/j.neuropharm.2005.01.013
   Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304 3959(99)00154 2
   Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920 1211(97)00084 3
   Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011
   Vissers KCP, 2006, PHARMACOL BIOCHEM BE, V84, P479, DOI 10.1016/j.pbb.2006.06.011
   Vit JP, 2006, PAIN, V120, P188, DOI 10.1016/j.pain.2005.10.033
   Watson CPN, 2000, CLIN J PAIN, V16, pS49
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 47
TC 33
Z9 45
U1 0
U2 2
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091 3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD MAR
PY 2007
VL 86
IS 3
BP 458
EP 467
DI 10.1016/j.pbb.2007.01.003
PG 10
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 160SD
UT WOS:000245961700005
PM 17306872
DA 2025 08 17
ER

PT J
AU Ibrahim, A
   Yahata, T
   Onizuka, M
   Dan, T
   De Strihou, CV
   Miyata, T
   Ando, K
AF Ibrahim, Abd Aziz
   Yahata, Takashi
   Onizuka, Makoto
   Dan, Takashi
   De Strihou, Charles Van Ypersele
   Miyata, Toshio
   Ando, Kiyoshi
TI Inhibition of Plasminogen Activator Inhibitor Type 1 Activity Enhances
   Rapid and Sustainable Hematopoietic Regeneration
SO STEM CELLS
LA English
DT Article
DE Osteoblast; Stem cell transplantation; Tissue regeneration;
   Hematopoiesis; Bone marrow stromal cells; Hematopoietic stem cells
ID MESENCHYMAL STROMAL CELLS; GENE DEFICIENT MICE; EX VIVO EXPANSION;
   STEM CELLS; BONE MARROW; FIBRINOLYSIS; FIBROSIS; THROMBOLYSIS;
   MODULATION; RADIATION
AB Abstract
   The prognosis of patients undergoing hematopoietic stem cell transplantation (HSCT) depends on the rapid recovery and sustained life long hematopoiesis. The activation of the fibrinolytic pathway promotes hematopoietic regeneration; however, the role of plasminogen activator inhibitor 1 (PAI 1), a negative regulator of the fibrinolytic pathway, has not yet been elucidated. We herein demonstrate that bone marrow (BM) stromal cells, especially osteoblasts, produce PAI 1 in response to myeloablation, which negatively regulates the hematopoietic regeneration in the BM microenvironment. Total body irradiation in mice dramatically increased the local expression levels of fibrinolytic factors, including tissue type plasminogen activator (tPA), plasmin, and PAI 1. Genetic disruption of the PAI 1 gene, or pharmacological inhibition of PAI 1 activity, significantly improved the myeloablation related mortality and promoted rapid hematopoietic recovery after HSCT through the induction of hematopoiesis promoting factors. The ability of a PAI 1 inhibitor to enhance hematopoietic regeneration was abolished when tPA deficient mice were used as recipients, thus indicating that PAI 1 represses tPA dependent hematopoietic regeneration. The PAI 1 inhibitor not only accelerated the expansion of the donor HSCs during the early stage of regeneration, but also supported long term hematopoiesis. Our results indicate that the inhibition of PAI 1 activity could be a therapeutic approach to facilitate the rapid recovery and sustained hematopoiesis after HSCT. Stem Cells 2014;32:946 958
C1 [Ibrahim, Abd Aziz; Yahata, Takashi; Onizuka, Makoto; Ando, Kiyoshi] Tokai Univ, Sch Med, Div Hemopoiesis, Res Ctr Regenerat Med, Isehara, Kanagawa 2591193, Japan.
   [Ibrahim, Abd Aziz; Onizuka, Makoto; Ando, Kiyoshi] Tokai Univ, Sch Med, Dept Hematol & Oncol, Isehara, Kanagawa 2591193, Japan.
   [Yahata, Takashi] Tokai Univ, Sch Med, Dept Cell Transplantat & Regenerat Med, Isehara, Kanagawa 2591193, Japan.
   [Dan, Takashi; Miyata, Toshio] Tohoku Univ, Grad Sch Med, United Ctr Adv Res, Sendai, Miyagi 980, Japan.
   [Dan, Takashi; Miyata, Toshio] Tohoku Univ, Grad Sch Med, United Ctr Translat Med, Sendai, Miyagi 980, Japan.
   [De Strihou, Charles Van Ypersele] Catholic Univ Louvain, Serv Nephrol, Brussels, Belgium.
C3 Tokai University; Tokai University; Tokai University; Tohoku University;
   Tohoku University; Universite Catholique Louvain
RP Yahata, T (通讯作者)，Tokai Univ, Sch Med, Isehara, Kanagawa 2591193, Japan.
EM yahata@is.icc.u tokai.ac.jp; andok@keyaki.cc.u tokai.ac.jp
RI ; Miyata, Toshio/A 4872 2010
OI ONIZUKA, MAKOTO/0000 0003 3864 0823; Yahata,
   Takashi/0000 0002 9332 0358; Ibrahim, Abd Aziz/0000 0003 1374 1089
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT);
   Ministry of Health, Labor and Welfare (MHLW); National Institute of
   Biomedical Innovation (NIBIO); Japan Science and Technology Agency
   (JST); Tokai University School of Medicine Research Aid; MARA Education
   Foundation, Malaysia; Grants in Aid for Scientific Research [26890022]
   Funding Source: KAKEN
FX We appreciate the help of Dr. Koichi Hattori (Institute of Medical
   Science, University of Tokyo, Japan) for kindly providing the tPA KO
   mice. We thank Dr. Nobuo Watanabe (Tokai University School of Medicine,
   Japan) for helpful discussion and wrote the manuscript. We also thank
   the members of the Research Center for Regenerative Medicine of Tokai
   University, especially Tomomi Takanashi, Kozue Hiyama, and Tomoko Uno,
   for the technical support. We thank the members of the Animal Care
   Center of Tokai University for their meticulous care of the experimental
   animals. This work was supported by Japanese Grants in Aid for
   Scientific Research from the Ministry of Education, Culture, Sports,
   Science and Technology (MEXT), from the Ministry of Health, Labor and
   Welfare (MHLW), from the National Institute of Biomedical Innovation
   (NIBIO), from the Japan Science and Technology Agency (JST), and from
   the Tokai University School of Medicine Research Aid. Special thanks are
   due to the MARA Education Foundation, Malaysia, for supporting the
   scholarship awarded to A.A.I.
CR Ando K, 2006, BLOOD, V107, P3371, DOI 10.1182/blood 2005 08 3108
   [Anonymous], INT J CELL BIOL
   Balsara RD, 2008, THROMB HAEMOSTASIS, V100, P1029, DOI 10.1160/TH08 07 0427
   Bergheim I, 2006, J PHARMACOL EXP THER, V316, P592, DOI 10.1124/jpet.105.095042
   CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0
   CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893
   CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892
   Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002 9440(10)63015 5
   CHAWLA R, INFECT BONE MARROW T
   COLLEN D, 1991, BLOOD, V78, P3114
   Copland IB, 2009, STEM CELLS, V27, P467, DOI 10.1634/stemcells.2008 0520
   Dahlberg A, 2011, BLOOD, V117, P6083, DOI 10.1182/blood 2011 01 283606
   Diebold I, 2008, THROMB HAEMOSTASIS, V100, P984, DOI 10.1160/TH08 08 0524
   Heissig B, 2007, CELL STEM CELL, V1, P658, DOI 10.1016/j.stem.2007.10.012
   Heissig B, 2009, J CELL PHYSIOL, V221, P521, DOI 10.1002/jcp.21897
   Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992
   Izuhara Y, 2008, ARTERIOSCL THROM VAS, V28, P672, DOI 10.1161/ATVBAHA.107.157479
   Izuhara Y, 2010, J CEREBR BLOOD F MET, V30, P904, DOI 10.1038/jcbfm.2009.272
   Jaroscak J, 2003, BLOOD, V101, P5061, DOI 10.1182/blood 2001 12 0290
   Kolev K, 2003, THROMB HAEMOSTASIS, V89, P610, DOI 10.1055/s 0037 1613567
   Milliat F, 2008, AM J PATHOL, V172, P691, DOI 10.2353/ajpath.2008.070930
   Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272
   NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Perumbeti Ajay., 2016, HEMATOPOIETIC STEM C
   RAO JS, 1994, J NEURO ONCOL, V22, P161, DOI 10.1007/BF01052891
   RUBIN P, 1989, FRONT RADIAT THER ON, V23, P7
   Sugrue T, 2013, IMMUNOL CELL BIOL, V91, P5, DOI 10.1038/icb.2012.61
   Yahata T, 2008, STEM CELLS, V26, P3228, DOI 10.1634/stemcells.2008 0552
   Yamaoka N, 2011, CHEM PHARM BULL, V59, P215, DOI 10.1248/cpb.59.215
   Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018
   Zhao WL, 1999, RADIAT RES, V152, P160, DOI 10.2307/3580089
NR 32
TC 27
Z9 28
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD APR
PY 2014
VL 32
IS 4
BP 946
EP 958
DI 10.1002/stem.1577
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA AC9DI
UT WOS:000332834100011
PM 24155177
OA Bronze
DA 2025 08 17
ER

PT J
AU Oelzner, P
   Franke, S
   Lehmann, G
   Eidner, T
   Hein, G
   Wolf, G
AF Oelzner, Peter
   Franke, Sybille
   Lehmann, Gabriele
   Eidner, Thorsten
   Hein, Gert
   Wolf, Gunter
TI The balance between soluble receptors regulating IL 6 trans signaling is
   predictive for the RANKL/osteoprotegerin ratio in postmenopausal women
   with rheumatoid arthritis
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Soluble gp130; Soluble IL 6 receptor; RANKL/OPG ratio; Bone mineral
   density; Rheumatoid arthritis
ID KAPPA B LIGAND; BONE LOSS; PROSTAGLANDIN E 2; OSTEOPROTEGERIN LIGAND;
   INTERLEUKIN 6 RECEPTOR; SERUM INTERLEUKIN 6; PARATHYROID HORMONE;
   CIRCULATING LEVELS; CYTOKINE SYSTEM; GENE EXPRESSION
AB The objective of this study is to investigate the relationship between soluble components of the interleukin 6 (IL 6) system mediating and modifying IL 6 trans signaling and the RANKL RANK osteoprotegerin system in postmenopausal women with rheumatoid arthritis (RA). The following parameters were investigated in 126 postmenopausal women with RA: IL 6, soluble IL 6 receptor (sIL 6R), soluble glycoprotein 130 (sgp130), sRANKL, osteoprotegerin (OPG), osteocalcin, erythrocyte sedimentation rate and C reactive protein in sera, pyridinolin and desoxypyridinolin crosslinks in the morning urine. Bone mineral density (BMD) was measured by dual X ray absorptiometry at the lumbar spine (BMD LS) and at the femoral neck (BMD FN). Predictors of RANKL/OPG ratio and BMD were evaluated by multiple linear regression analysis. The following determinants of the RANKL/OPG ratio were identified: sIL 6R/sgp130 ratio and daily glucocorticoid (GC) dose as positive determinants in the whole group (R (2) = 0.56; P = 0.001), sIL 6R/sgp130 ratio as the exclusive positive determinant in patients with GC therapy (R (2) = 0.48; P = 0.001) and sgp130 as negative determinant in patients without GC (R (2) = 0.42; P = 0.031). Sgp130 was highly significantly positively correlated with OPG in the whole group (P < 0.001) as well as in patients with (n = 70; P < 0.05) and without GC therapy (n = 56; P < 0.01). sIL 6R was the main negative predictor of BMD LS (R (2) = 0.41; P = 0.019). High sIL 6R/sgp130 ratio and/or low sgp130 are associated with a high sRANKL/OPG ratio in sera of postmenopausal women with RA indicating the critical significance of IL 6 trans signaling for an increase in the RANKL/OPG ratio and of bone resorption. Inhibition of IL 6 trans signaling may be an effective bone protecting principle in postmenopausal women with RA.
C1 [Oelzner, Peter; Franke, Sybille; Lehmann, Gabriele; Eidner, Thorsten; Hein, Gert; Wolf, Gunter] Univ Jena, Div Rheumatol Osteol, Dept Internal Med 3, D 07740 Jena, Germany.
C3 Friedrich Schiller University of Jena
RP Oelzner, P (通讯作者)，Univ Jena, Div Rheumatol Osteol, Dept Internal Med 3, Erlanger Allee 101, D 07740 Jena, Germany.
EM peter.oelzner@med.uni jena.de
FU Thuringian Ministry of Science, Research and Art [FKZ B307 01025]
FX This work was supported by the Thuringian Ministry of Science, Research
   and Art (FKZ B307 01025).
CR Angeli A, 2002, ANN NY ACAD SCI, V966, P97, DOI 10.1111/j.1749 6632.2002.tb04207.x
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007 2325
   Dovio A, 2006, EUR J ENDOCRINOL, V154, P745, DOI 10.1530/eje.1.02147
   Einspruch EL., 2005, An introductory guide to SPSS for Windows, V2nd
   Ferrari SL, 2003, J CLIN ENDOCR METAB, V88, P255, DOI 10.1210/jc.2002 020092
   Giuliani N, 2001, EXP GERONTOL, V36, P547, DOI 10.1016/S0531 5565(00)00220 5
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683
   Hayashi M, 2002, P NATL ACAD SCI USA, V99, P14728, DOI 10.1073/pnas.232562799
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Insogna K, 2002, J BONE MINER RES, V17, pN108
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Lange U, 2007, Z RHEUMATOL, V66, P129, DOI 10.1007/s00393 007 0151 y
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   Liu XH, 2006, ANN NY ACAD SCI, V1068, P225, DOI 10.1196/annals.1346.047
   Mossetti G, 2005, BONE, V36, P549, DOI 10.1016/j.bone.2004.11.004
   Muller A, 1996, RHEUMATOL INT, V16, P23, DOI 10.1007/BF01419951
   MurakamiMori K, 1997, J IMMUNOL, V158, P5518
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nakchbandi IA, 2008, J CLIN ENDOCR METAB, V93, P967, DOI 10.1210/jc.2007 1645
   Nowell MA, 2009, J IMMUNOL, V182, P613, DOI 10.4049/jimmunol.182.1.613
   Oelzner P, 1998, CALCIFIED TISSUE INT, V62, P193, DOI 10.1007/s002239900416
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Polgár A, 2002, ACTA BIOL HUNG, V53, P307, DOI 10.1556/ABiol.53.2002.3.7
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Richards PJ, 2006, ARTHRITIS RHEUM US, V54, P1662, DOI 10.1002/art.21818
   Rose John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674
   Sanchez C, 2009, OSTEOARTHR CARTILAGE, V17, P473, DOI 10.1016/j.joca.2008.09.007
   Scheidt Nave C, 2001, J CLIN ENDOCR METAB, V86, P2032, DOI 10.1210/jc.86.5.2032
   Scheller J, 2006, MED MICROBIOL IMMUN, V195, P173, DOI 10.1007/s00430 006 0019 9
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Shin HI, 2004, ENDOCRINOLOGY, V145, P1376, DOI 10.1210/en.2003 0839
   Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872
   Sims NA, 2009, MOL CELL ENDOCRINOL, V310, P30, DOI 10.1016/j.mce.2008.08.025
   Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601
   Sugiyama T, 2001, J BONE MINER METAB, V19, P89, DOI 10.1007/s007740170046
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takeda T, 1998, J ENDOCRINOL, V159, P323, DOI 10.1677/joe.0.1590323
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Tat SK, 2008, BONE, V43, P284, DOI 10.1016/j.bone.2008.04.006
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tsangari H, 2004, BONE, V35, P334, DOI 10.1016/j.bone.2004.02.006
   Vermes C, 2002, J BIOL CHEM, V277, P16879, DOI 10.1074/jbc.M200546200
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
NR 48
TC 12
Z9 16
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
EI 1437 160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD JAN
PY 2012
VL 32
IS 1
BP 199
EP 206
DI 10.1007/s00296 010 1606 z
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 875CJ
UT WOS:000299007300032
PM 20821212
DA 2025 08 17
ER

PT J
AU Shukla, P
   Mathur, V
   Kumar, A
   Khedgikar, V
   Teja, BV
   Chaudhary, D
   Kushwaha, P
   Bora, HK
   Konwar, R
   Trivedi, R
   Mishra, PR
AF Shukla, Prashant
   Mathur, Vineet
   Kumar, Amit
   Khedgikar, Vikram
   Teja, B. Venkatesh
   Chaudhary, Dharmendra
   Kushwaha, Priyanka
   Bora, Himangsu K.
   Konwar, Rituraj
   Trivedi, Ritu
   Mishra, Prabhat Ranjan
TI Nanoemulsion Based Concomitant Delivery of Curcumin and Etoposide:
   Impact on Cross Talk Between Prostate Cancer Cells and Osteoblast During
   Metastasis
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Multidrug Resistance; Chemoprotective; Etoposide; Curcumin;
   Nanoemulsions; Combination Therapy; PC3 Prostate Cancer Cells; HEK 293
   (Human Embryonic Kidney Cells)
ID IN VITRO; MECHANISMS; LINES; PC3; MICROEMULSIONS; RESISTANCE; APOPTOSIS;
   KINETICS; BONE
AB An attempt has been made to use curcumin (CUR) in combination with Etoposide (ETP) by encapsulating in nanoemulsion, as two tier approach i.e., to evaluate improvement in efficacy of ETP on prostate cancer cells (PC3 and DU145) and to assess their effect on cross talk between osteoblast and tumor cells leading to metastatic cascade in bones. Nanoemulsion was developed and evaluated for size, charge, in vitro drug release and anticancer activity, effect on cross talk between osteoblast and prostate cancer cells and pharmacokinetics in rats. The entrapment efficiency of both ETP and CUR in nanoemulsion was more than 98% while the globule size was less than 150 nm with zeta potential  29.8 mV. The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 +/  1.2 and 41.13 +/  2.4% (at 5 mu M) respectively when tested in PC3 cells. DU 145 seemed to be less responsive in comparison to PC3 cells both in respect of ETP and their mixture (ETP + CUR). Our data shows that CUR and ETP after encapsulation in nanoemulsion (F5) were effectively delivered intracellularly in PC3 cells and the cytotoxicity of F5 was enhanced by 1.5 fold as compared to ETP + CUR at 5 mu M concentration. It has also been observed that mice calvarial osteoblasts cultured and incubated with PC 3 and DU 145 cells conditioned media induces inhibition of osteoblast differentiation event. While this inhibition was significantly reversed by F5 at 5 mu M concentration over other treated groups, the pharmacokinetic profile of both ETP and CUR was also significantly improved when administered in nanoemulsion.
C1 [Shukla, Prashant; Teja, B. Venkatesh; Mishra, Prabhat Ranjan] CSIR, Cent Drug Res Inst, Div Pharmaceut, Lucknow 226031, Uttar Pradesh, India.
   [Mathur, Vineet] Natl Inst Pharmaceut Educ & Res, Rae Bareli 229010, UP, India.
   [Kumar, Amit; Khedgikar, Vikram; Chaudhary, Dharmendra; Kushwaha, Priyanka; Konwar, Rituraj; Trivedi, Ritu] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Bora, Himangsu K.] CSIR, Cent Drug Res Inst, Div Lab Anim, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); National Institute of
   Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Mishra, PR (通讯作者)，CSIR, Cent Drug Res Inst, Div Pharmaceut, B 10 1,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM mishrapr@hotmail.com
RI ; shukla, prashant/M 9507 2019; Konwar, Rituraj/B 2272 2010; Shukla,
   Prashant/E 5981 2012; Mishra, Prabhat/C 3814 2009
OI Konwar, Rituraj/0000 0002 3740 8363; Trivedi, Ritu/0000 0002 9524 2541;
   Shukla, Prashant/0000 0003 1286 4183; Kumar, Professor
   Amit/0000 0002 5913 4308
FU Council of Scientific and Industrial Research under network project
   "BIOCERAM" [ESC0103]; Council of Scientific and Industrial Research, New
   Delhi, India
FX The work was supported by grants from Council of Scientific and
   Industrial Research for providing financial assistance under network
   project "BIOCERAM" (ESC0103) entitled Tailor made bio materials and
   Noble Implants for specific diseases and patients. Prashant Shukla is
   grateful to the Council of Scientific and Industrial Research, New
   Delhi, India for providing senior research fellowship. This is CDRI
   communication number 8608.
CR Ali I, 2011, CURR CANCER DRUG TAR, V11, P135, DOI 10.2174/156800911794328493
   Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741
   Bock C, 2012, NAT REV CANCER, V12, P494, DOI 10.1038/nrc3297
   Constantinides PP, 2004, ADV DRUG DELIVER REV, V56, P1243, DOI 10.1016/j.addr.2003.12.005
   Cort A, 2012, MOL MED REP, V5, P1481, DOI 10.3892/mmr.2012.848
   Date AA, 2008, INT J PHARMACEUT, V355, P19, DOI 10.1016/j.ijpharm.2008.01.004
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555 006 7886 9
   Dixit P, 2012, BIOORG MED CHEM LETT, V22, P890, DOI 10.1016/j.bmcl.2011.12.036
   Guo Jinjin, 2010, Genes Cancer, V1, P836, DOI 10.1177/1947601910381645
   Guo LD, 2013, PHYTOTHER RES, V27, P422, DOI 10.1002/ptr.4731
   Gupta GK, 2009, J PHARM PHARMACOL, V61, P1601, DOI 10.1211/jpp/61.12.0003
   Halbersztadt Alicja, 2006, Ginekol Pol, V77, P63
   Hilchie AL, 2010, NUTR CANCER, V62, P379, DOI 10.1080/01635580903441238
   Hu LD, 2012, J AGR FOOD CHEM, V60, P7137, DOI 10.1021/jf204078t
   Kaplan RN, 2006, CANCER METAST REV, V25, P521, DOI 10.1007/s10555 006 9036 9
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483
   Martinez J, 1996, J CELL BIOCHEM, V61, P18, DOI 10.1002/(SICI)1097 4644(19960401)61:1<18::AID JCB3>3.0.CO;2 5
   Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997
   Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280 005 0090 8
   Quan JJ, 2012, PATHOLOGY, V44, P221, DOI 10.1097/PAT.0b013e3283513f3b
   Reddy LH, 2004, AAPS J, V6
   Ren XZ, 2012, INT J PHARMACEUT, V431, P130, DOI 10.1016/j.ijpharm.2012.04.020
   Rodríguez Hornedo N, 1999, J PHARM SCI, V88, P651, DOI 10.1021/js980490h
   Santibanez JF, 1996, BRIT J CANCER, V74, P418, DOI 10.1038/bjc.1996.375
   Sardana G, 2008, J PROTEOME RES, V7, P3329, DOI 10.1021/pr8003216
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Shukla P, 2010, EXPERT OPIN DRUG DEL, V7, P993, DOI 10.1517/17425247.2010.510830
   Siegel R, 2013, CA CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Singodia D., 2010, J BIONANOSCIENCE, V4, P66
   Surh YJ, 1999, MUTAT RES FUND MOL M, V428, P305, DOI 10.1016/S1383 5742(99)00057 5
   Swarnkar G., BR J PHARM, V165, P1526
   Tantivejkul K, 2004, J CELL BIOCHEM, V91, P706, DOI 10.1002/jcb.10664
   Ukawala M, 2012, DRUG DELIV, V19, P155, DOI 10.3109/10717544.2012.657721
   van Brussel JP, 1999, EUR J CANCER, V35, P664, DOI 10.1016/S0959 8049(98)00435 3
   Yang CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037960
NR 36
TC 23
Z9 23
U1 0
U2 59
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1550 7033
EI 1550 7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD NOV
PY 2014
VL 10
IS 11
BP 3381
EP 3391
DI 10.1166/jbn.2014.1912
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA AL9AF
UT WOS:000339430900017
PM 26000396
DA 2025 08 17
ER

PT J
AU Innes, J
   O'Neill, T
   Lascelles, D
AF Innes, John
   O'Neill, Turlough
   Lascelles, Duncan
TI Use of non steroidal anti inflammatory drugs for the treatment of canine
   osteoarthritis
SO IN PRACTICE
LA English
DT Article
ID PROSTAGLANDIN SYNTHASE; PAIN MECHANISMS; MESSENGER RNA; DOGS;
   CYCLOOXYGENASE; CARPROFEN; EXPRESSION; MELOXICAM; TEPOXALIN; CARTILAGE
AB Non steroidal anti inflammatory drugs (NSAIDs) are one of the most commonly used classes of pharmaceutical in canine practice. Globally, the current oral NSAID market for chronic pain in small animals is estimated to be US$330 million, with the UK market valued at around US$47 million. As NSAIDs have developed, pharmaceutical companies have strived to optimise efficacy and reduce the incidence of adverse events, particularly those associated with the gastrointestinal system, through a greater understanding of basic pharmacology. This article discusses the latest innovations, including those relating to drug delivery and pharmacokinetics, in the NSAIDs used in dogs with osteoarthritis, which often requires long term treatment.
C1 [Lascelles, Duncan] N Carolina State Univ, Coll Vet Med, Comparat Pain Res Lab, Raleigh, NC 27695 USA.
   [Lascelles, Duncan] N Carolina State Univ, Coll Vet Med, Integrated Pain Management Serv, Raleigh, NC 27695 USA.
C3 North Carolina State University; North Carolina State University
RI O'Neill, Turlough/LDG 3445 2024
OI Lascelles, B. Duncan X./0000 0002 2950 9009
CR Benton HP, 1997, AM J VET RES, V58, P286
   Creamer P, 1996, J RHEUMATOL, V23, P1031
   García Hernández L, 2007, PHARMACOL BIOCHEM BE, V87, P331, DOI 10.1016/j.pbb.2007.05.007
   Giraudel JM, 2009, J VET PHARMACOL THER, V32, P102
   Goodman L, 2009, J VET INTERN MED, V23, P56, DOI 10.1111/j.1939 1676.2008.0226.x
   GORDON W, 2006, VET THERAPEUTICS, V7, P127
   Innes JF, 2010, VET REC, V166, P226, DOI 10.1136/vr.c97
   Jung M, 2009, J VET PHARMACOL THER, V32, P41, DOI 10.1111/j.1365 2885.2008.01035.x
   KUJUBU DA, 1991, J BIOL CHEM, V266, P12866
   Lascelles BDX, 2008, J VET INTERN MED, V22, P53, DOI 10.1111/j.1939 1676.2007.0014.x
   Lascelles BDX, 2009, J ORTHOP RES, V27, P1204, DOI 10.1002/jor.20864
   Lees P, 2009, J VET PHARMACOL THER, V32, P105
   Li J, 2004, BIOORG MED CHEM LETT, V14, P95, DOI 10.1016/j.bmcl.2003.10.004
   Macrory L, 2009, BMC VET RES, V5, DOI 10.1186/1746 6148 5 25
   Mannion RJ, 2000, CLIN J PAIN, V16, pS144
   McCann ME, 2004, AM J VET RES, V65, P503, DOI 10.2460/ajvr.2004.65.503
   Muir WW, 2001, J AM VET MED ASSOC, V219, P1346, DOI 10.2460/javma.2001.219.1346
   Ostrom RS, 2001, AM J PHYSIOL CELL PH, V281, pC524, DOI 10.1152/ajpcell.2001.281.2.C524
   Pelletier JP, 2000, J RHEUMATOL, V27, P2893
   Peterson KD, 2004, JAVMA J AM VET MED A, V225, P1056, DOI 10.2460/javma.2004.225.1056
   Punke JP, 2008, AM J VET RES, V69, P1203, DOI 10.2460/ajvr.69.9.1203
   Rainsford KD, 1999, VET RES COMMUN, V23, P101, DOI 10.1023/A:1006254402163
   Sanderson RO, 2009, VET REC, V164, P418, DOI 10.1136/vr.164.14.418
   Schmassmann A, 2006, AM J PHYSIOL GASTR L, V290, pG747, DOI 10.1152/ajpgi.00416.2005
   Schneider TA, 2001, VET COMP ORTHOPAED, V14, P19
   Streppa HK, 2002, AM J VET RES, V63, P91, DOI 10.2460/AJVR.2002.63.91
   Torring ML, 2008, BRIT J CLIN PHARMACO, V65, P565, DOI 10.1111/j.1365 2125.2007.03038.x
   VASSEUR PB, 1995, J AM VET MED ASSOC, V206, P807
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Wooten JG, 2008, AM J VET RES, V69, P457, DOI 10.2460/ajvr.69.4.457
   XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692
NR 31
TC 11
Z9 13
U1 0
U2 33
PU BRITISH VETERINARY ASSOC
PI LONDON
PA 7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND
SN 0263 841X
J9 IN PRACTICE
JI In Practice
PD APR
PY 2010
VL 32
IS 4
BP 126
EP +
DI 10.1136/inp.c1436
PG 8
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 587LF
UT WOS:000276993100001
DA 2025 08 17
ER

PT J
AU Miguel, BS
   Ghayor, C
   Ehrbar, M
   Jung, RE
   Zwahlen, RA
   Hortschansky, P
   Schmoekel, HG
   Weber, FE
AF Miguel, Blanca San
   Ghayor, Chafik
   Ehrbar, Martin
   Jung, Ronald E.
   Zwahlen, Roger A.
   Hortschansky, Peter
   Schmoekel, Hugo G.
   Weber, Franz E.
TI N Methyl Pyrrolidone as a Potent Bone Morphogenetic Protein Enhancer for
   Bone Tissue Regeneration
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID OSTEOBLASTIC CELL DIFFERENTIATION; RECEPTOR BMPR II; HETEROTOPIC
   OSSIFICATION; EXTRACELLULAR MATRICES; SIGNAL TRANSDUCTION; ANTAGONISTS;
   ACTIVATION; HUMANS; KINASE; BETA
AB In medicine, N methyl pyrrolidone (NMP) has a long track record as a constituent in medical devices approved by the Food and Drug Administration and thus can be considered as a safe and biologically inactive small chemical. In the present study, we report on the newly discovered pharmaceutical property of NMP in enhancing bone regeneration in a rabbit calvarial defect model in vivo. At the cellular level, the pharmaceutical effect of NMP was confirmed, in particular, in combination with bone morphogenetic protein (BMP) 2, because NMP increased early and late markers for maturation of preosteoblasts and human bone marrow derived stem cells in vitro. When we used the multipotent cell line C2C12 without autologous BMP expression, NMP alone had no effect on alkaline phosphatase activity, a marker for osteogenic transdifferentiation. Nevertheless, in combination with low BMP 2 doses, alkaline phosphatase activity was more than eight times as great. Thus, the pharmaceutical NMP mode of action is that of an enhancer of BMP activity. The dependency of the effects of NMP on BMP was confirmed in preosteoblasts because noggin, an extracellular BMP inhibitor, suppressed NMP induced increases in early markers for osteoblast maturation in vitro. At the molecular level, NMP was shown to have no effect on the binding of BMP 2 to the ectodomain of the high affinity BMP receptor IA. However, NMP further increased the phosphorylation of p38 and Smad1,5,8 induced by BMP 2. Thus, the small chemical NMP enhances BMP activity by increasing the kinase activity of the BMP receptor complex for Smad1,5,8 and p38 and could be employed as a potent drug for bone tissue regeneration and engineering.
C1 [Miguel, Blanca San; Ghayor, Chafik; Ehrbar, Martin; Zwahlen, Roger A.; Weber, Franz E.] Univ Zurich Hosp, Dept Craniomaxillofacial Surg, CH 8091 Zurich, Switzerland.
   [Jung, Ronald E.] Univ Zurich, Dept Fixed & Removable Prosthodont & Dent Mat Sci, CH 8006 Zurich, Switzerland.
   [Hortschansky, Peter] Hans Knoell Inst, Leibniz Inst Nat Stoff Forsch & Infekt Biol, Jena, Germany.
   [Schmoekel, Hugo G.] Great Western Referrals, Swindon, Wilts, England.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Leibniz Association; Hans Knoll Institute (HKI)
RP Weber, FE (通讯作者)，Univ Spital Zurich, Klin Kiefer & Gesichtschirurg, Frauenklin Str 24, CH 8091 Zurich, Switzerland.
EM franz.weber@zzmk.uzh.ch
RI ; Weber, Franz/I 7831 2019; Zwahlen, Roger/B 2185 2009; Ehrbar,
   Martin/F 4578 2012
OI Weber, Franz/0000 0003 1670 2296; Ghayor, Chafik/0000 0002 3016 3412;
   Ehrbar, Martin/0000 0003 2707 4870; ZWAHLEN, Roger
   Arthur/0000 0003 4666 7567; 
FU AO Foundation; Swiss National Funds [310000 116240]
FX The authors would like to thank Inion OY, Tampere, Finland, for the
   support of M. E. and B. SM. This research work was partly supported by a
   grant from the AO Foundation (Davos, Switzerland) through the
   Biotechnology Advisory Board and the Swiss National Funds
   (310000 116240). We also would like to acknowledge the technical
   assistance of Alexandr Tchouboukov, Yvonne Bloemhard, and Flora Nichols.
CR Akesson B, 1997, DRUG METAB DISPOS, V25, P267
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Foletta VC, 2003, J CELL BIOL, V163, P421
   Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060
   Ghayor C, 2005, BONE, V36, P93, DOI 10.1016/j.bone.2004.10.007
   Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hämmerle CHF, 2003, PERIODONTOL 2000, V33, P36, DOI 10.1046/j.0906 6713.2003.03304.x
   Hassel S, 2006, J CELL PHYSIOL, V206, P457, DOI 10.1002/jcp.20480
   Hassel S, 2004, PROTEOMICS, V4, P1346, DOI 10.1002/pmic.200300770
   Jadlowiec JA, 2003, EXPERT OPIN BIOL TH, V3, P409, DOI 10.1517/eobt.3.3.409.21183
   Jung RE, 2005, CLIN ORAL IMPLAN RES, V16, P676, DOI 10.1111/j.1600 0501.2005.01183.x
   Jung RE, 2003, CLIN ORAL IMPLAN RES, V14, P556, DOI 10.1034/j.1600 0501.2003.00921.x
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   KATAGIRI T, 1995, J CELL BIOL, V128, pU8
   Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   LEECHUAN C, 2004, J CELLULAR PHYSL, V201, P401
   Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   Pirhonen EM, 2006, INT J ARTIF ORGANS, V29, P834, DOI 10.1177/039139880602900904
   Pratt AB, 2004, BIOTECHNOL BIOENG, V86, P27, DOI 10.1002/bit.10897
   Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217
   Sebald W, 2004, BIOL CHEM, V385, P697, DOI 10.1515/BC.2004.086
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Urist MR, 2002, CLIN ORTHOP RELAT R, P5
   Wallner M, 2003, P NATL ACAD SCI USA, V100, P15218, DOI 10.1073/pnas.2435171100
   Weber FE, 2003, J DENT RES, V82, pB243
   Weber FE, 2003, J BONE MINER RES, V18, P2142, DOI 10.1359/jbmr.2003.18.12.2142
   Weber FE, 2001, BIOCHEM BIOPH RES CO, V286, P554, DOI 10.1006/bbrc.2001.5408
   WELLS DA, 1992, DRUG METAB DISPOS, V20, P124
NR 37
TC 52
Z9 56
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD OCT
PY 2009
VL 15
IS 10
BP 2955
EP 2963
DI 10.1089/ten.tea.2009.0009
PG 9
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 503QG
UT WOS:000270553200018
PM 19320543
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Young, SK
   Shao, Y
   Bidwell, JP
   Wek, RC
AF Young, Sara K.
   Shao, Yu
   Bidwell, Joseph P.
   Wek, Ronald C.
TI Nuclear Matrix Protein 4 Is a Novel Regulator of Ribosome Biogenesis and
   Controls the Unfolded Protein Response via Repression of Gadd34
   Expression
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE endoplasmic reticulum stress (ER stress); eukaryotic initiation factor 2
   (eIF2); protein synthesis; translation control; unfolded protein
   response (UPR); protein homeostasis
ID ENDOPLASMIC RETICULUM STRESS; TRANSLATIONAL CONTROL; TRANSCRIPTION
   FACTORS; OSTEOBLAST DIFFERENTIATION; MAMMALIAN CELLS; ER STRESS; GENE;
   KINASE; BONE; DEPHOSPHORYLATION
AB The unfolded protein response (UPR) maintains protein homeostasis by governing the processing capacity of the endoplasmic reticulum (ER) to manage ER client loads; however, key regulators within the UPR remain to be identified. Activation of the UPR sensor PERK (EIFAK3/PEK) results in the phosphorylation of the subunit of eIF2 (eIF2 P), which represses translation initiation and reduces influx of newly synthesized proteins into the overloaded ER. As part of this adaptive response, eIF2 P also induces a feedback mechanism through enhanced transcriptional and translational expression of Gadd34 (Ppp1r15A),which targets type 1 protein phosphatase for dephosphorylation of eIF2 P to restore protein synthesis. Here we describe a novel mechanism by which Gadd34 expression is regulated through the activity of the zinc finger transcription factor NMP4 (ZNF384, CIZ). NMP4 functions to suppress bone anabolism, and we suggest that this occurs due to decreased protein synthesis of factors involved in bone formation through NMP4 mediated dampening of Gadd34 and c Myc expression. Loss of Nmp4 resulted in an increase in c Myc and Gadd34 expression that facilitated enhanced ribosome biogenesis and global protein synthesis. Importantly, protein synthesis was sustained during pharmacological induction of the UPR through a mechanism suggested to involve GADD34 mediated dephosphorylation of eIF2 P. Sustained protein synthesis sensitized cells to pharmacological induction of the UPR, and the observed decrease in cell viability was restored upon inhibition of GADD34 activity. We conclude that NMP4 is a key regulator of ribosome biogenesis and the UPR, which together play a central role in determining cell viability during endoplasmic reticulum stress.
C1 [Young, Sara K.; Wek, Ronald C.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.
   [Bidwell, Joseph P.] Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.
   [Shao, Yu] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington
RP Wek, RC (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.; Bidwell, JP (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM jbidwell@iu.edu; rwek@iu.edu
OI Young Baird, Sara/0000 0002 8915 3139
FU National Institutes of Health [GM049164]; Ralph W. and Grace M.
   Showalter Research Trust Fund; Department of Defense [PR120563]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant GM049164 (to R. C. W.). This work was also supported by the
   Ralph W. and Grace M. Showalter Research Trust Fund (to R. C. W.) and
   Department of Defense Grant PR120563 (to J. P. B.). The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health. The
   authors declare no conflicts of interest with the contents of this
   manuscript.
CR Alvarez M, 2005, GENE, V347, P43, DOI 10.1016/j.gene.2004.10.025
   Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113
   Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Childress P, 2015, MOL ENDOCRINOL, V29, P1269, DOI 10.1210/me.2014 1406
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841 6850.2001
   Feister HA, 2000, J CELL BIOCHEM, V79, P506, DOI 10.1002/1097 4644(20001201)79:3<506::AID JCB150>3.0.CO;2 A
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097 2765(00)80330 5
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097 2765(00)00108 8
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097 2765(03)00105 9
   Iadevaia V, 2014, SEMIN CELL DEV BIOL, V36, P113, DOI 10.1016/j.semcdb.2014.08.004
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kondo S, 2011, IUBMB LIFE, V63, P233, DOI 10.1002/iub.433
   Lee YY, 2009, J BIOL CHEM, V284, P6661, DOI 10.1074/jbc.M806735200
   Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Mertins P, 2014, MOL CELL PROTEOMICS, V13, P1690, DOI 10.1074/mcp.M113.036392
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649 1658.2000
   Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011
   Preston AM, 2013, J CELL SCI, V126, P4253, DOI 10.1242/jcs.130336
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097 2765(01)00265 9
   Sharma K, 2014, CELL REP, V8, P1583, DOI 10.1016/j.celrep.2014.07.036
   Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819
   Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Young SK, 2015, J BIOL CHEM, V290, P28257, DOI 10.1074/jbc.M115.693184
NR 40
TC 17
Z9 25
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 24
PY 2016
VL 291
IS 26
BP 13780
EP 13788
DI 10.1074/jbc.M116.729830
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA DR2YZ
UT WOS:000379771100032
PM 27129771
OA Green Published
DA 2025 08 17
ER

PT J
AU Cecchinato, F
   Atefyekta, S
   Wennerberg, A
   Andersson, M
   Jimbo, R
   Davies, JR
AF Cecchinato, Francesca
   Atefyekta, Saba
   Wennerberg, Ann
   Andersson, Martin
   Jimbo, Ryo
   Davies, Julia R.
TI Modulation of the nanometer pore size improves magnesium adsorption into
   mesoporous titania coatings and promotes bone morphogenic protein 4
   expression in adhering osteoblasts
SO DENTAL MATERIALS
LA English
DT Article
DE Titanium implant; Mesoporous titania films; Pore size; Magnesium
   release; Osteogenesis
ID DRUG DELIVERY; SIGNALING PATHWAYS; SURFACE CHEMISTRY; BIOFILM FORMATION;
   TGF BETA; IN VIVO; DIFFERENTIATION; TOPOGRAPHY; IMPLANTS; MATRIX
AB Objective. Mesoporous (MP) titania films used as implant coatings have recently been considered as release systems for controlled administration of magnesium to enhance initial osteoblast proliferation in vitro. Tuning of the pore size in such titania films is aimed at increasing the osteogenic potential through effects on the total loading capacity and the release profile of magnesium.
   Methods. In this study, evaporation induced self assembly (EISA) was used with different structure directing agents to form three mesoporous films with average pore sizes of 2 nm (MP1), 6 nm (MP2) and 7 nm (MP3). Mg adsorption and release was monitored using quartz crystal microbalance with dissipation (QCM D). The film surfaces were characterized with atomic force microscopy (AFM), scanning electron microscopy (SEM) and X ray photoelectron spectroscopy (XPS). The effect of different Mg release on osteogenesis was investigated in human fetal osteoblasts (hFOB) using pre designed osteogenesis arrays and real time polymerase chain reaction (RT PCR).
   Results. Results showed a sustained release from all the films investigated, with higher magnesium adsorption into MP1 and MP3 films. No significant differences were observed in the surface nanotopography of the films, either with or without the presence of magnesium. MP3 films (7 nm pore size) had the greatest effect on osteogenesis, up regulating 15 bone related genes after 1 week of hFOB growth and significantly promoting bone morphogenic protein (BMP4) expression after 3 weeks of growth.
   Significance. The findings indicate that the increase in pore width on the nano scale significantly enhanced the bioactivity of the mesoporous coating, thus accelerating osteogenesis without creating differences in surface roughness. (C) 2016 The Academy of Dental Materials. Published by Elsevier Ltd. All rights reserved.
C1 [Cecchinato, Francesca; Wennerberg, Ann; Jimbo, Ryo] Malmo Univ, Fac Odontol, Dept Prosthodont, Malmo, Sweden.
   [Davies, Julia R.] Malmo Univ, Fac Odontol, Dept Oral Biol, Malmo, Sweden.
   [Atefyekta, Saba; Andersson, Martin] Chalmers Univ Technol, Appl Chem, Dept Chem & Chem Engn, S 41296 Gothenburg, Sweden.
   [Jimbo, Ryo] Nagasaki Univ, Grad Sch Biomed Sci, Dept Appl Prosthodont, Nagasaki 852, Japan.
C3 Malmo University; Malmo University; Chalmers University of Technology;
   Nagasaki University
RP Cecchinato, F (通讯作者)，Malmo Univ, Fac Odontol, Dept Prosthodont, Malmo, Sweden.
EM francesca.cecchinato@mah.se
RI Davies, Julia/H 4194 2011; Davies, Julia/ABR 3116 2022; Andersson,
   Martin/ADK 9763 2022
OI Davies, Julia/0000 0001 5888 664X; 
FU European Union under REA [n289163]; Knut and Alice Wallenberg Foundation
FX The research leading to these results has received funding from the
   People Program (Marie Curie Actions) of the European Union's Seventh
   Framework Program FP7/2007 2013/ under REA grant agreement no. n289163.
   SA and MA thank the Knut and Alice Wallenberg Foundation for funding
   this research.
CR Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282
   Anderson MW, 2004, CHEM COMMUN, P907, DOI 10.1039/b313208k
   [Anonymous], 2012, NANOMEDICINE UK, V7, P20
   Armstrong DG, 2002, J AM PODIAT MED ASSN, V92, P12, DOI 10.7547/87507315 92 1 12
   Biggs MJP, 2009, J BIOMED MATER RES A, V91A, P195, DOI 10.1002/jbm.a.32196
   Bressan E, 2013, INT J MOL SCI, V14, P1918, DOI 10.3390/ijms14011918
   Bürgers R, 2010, CLIN ORAL IMPLAN RES, V21, P156, DOI 10.1111/j.1600 0501.2009.01815.x
   Carcuac O, 2016, J DENT RES, V95, P50, DOI 10.1177/0022034515601961
   Cecchinato F, 2015, MAT SCI ENG C MATER, V52, P225, DOI 10.1016/j.msec.2015.03.026
   Cecchinato F, 2014, J BIOMED MATER RES A, V102, P3862, DOI 10.1002/jbm.a.35062
   Chang SF, 2009, MOL ENDOCRINOL, V23, P1827, DOI 10.1210/me.2009 0143
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JM, 2014, NEUROSCI LETT, V566, P275, DOI 10.1016/j.neulet.2014.02.067
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   Ellingsen JE, 2004, INT J ORAL MAX IMPL, V19, P659
   Fröjd V, 2011, MOL ORAL MICROBIOL, V26, P241, DOI 10.1111/j.2041 1014.2011.00610.x
   Galli S, 2015, CLIN IMPLANT DENT R, V17, P1048, DOI 10.1111/cid.12211
   Galli S, 2014, ACTA BIOMATER, V10, P5193, DOI 10.1016/j.actbio.2014.08.011
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Janovska Zuzana, 2012, Acta Medica (Hradec Kralove), V55, P111
   Jimbo R, 2011, J DENT RES, V90, P1422, DOI 10.1177/0022034511422911
   Johansson CB, 2012, CLIN ORAL IMPLAN RES, V23, P943, DOI 10.1111/j.1600 0501.2011.02233.x
   Karlsson J, 2015, INT J NANOMED, V10, P4425, DOI 10.2147/IJN.S83005
   Karlsson J, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 014 5337 7
   Karlsson J, 2012, ACTA BIOMATER, V8, P4438, DOI 10.1016/j.actbio.2012.07.035
   Lu WJ, 2010, AM J PHYSIOL CELL PH, V299, pC1370, DOI 10.1152/ajpcell.00040.2010
   Mendonca G, 2009, BIOMATERIALS, V30, P4053, DOI 10.1016/j.biomaterials.2009.04.010
   Müller P, 2008, J CELL MOL MED, V12, P281, DOI 10.1111/j.1582 4934.2007.00103.x
   Patti A, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/846480
   Shen SC, 2013, CURR PHARM DESIGN, V19, P6270
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Simion M, 2015, CLIN IMPLANT DENT R, V17, pE343, DOI 10.1111/cid.12236
   Simon M, 2015, INT J PERIODONT REST, V35, P9, DOI 10.11607/prd.2217
   Sul Y T, 2005, J Appl Biomater Biomech, V3, P18
   Sul YT, 2009, J BIOMED MATER RES A, V89A, P942, DOI 10.1002/jbm.a.32041
   Tachi K, 2011, TISSUE ENG PT A, V17, P597, DOI [10.1089/ten.tea.2010.0094, 10.1089/ten.TEA.2010.0094]
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Vallet Regí M, 2006, CHEM EUR J, V12, P5934, DOI 10.1002/chem.200600226
   Vescovi P, 2010, Minerva Stomatol, V59, P181
   Vescovi P, 2010, MINERVA STOMATOL, V59, P4
   Wennerberg A, 1996, Int J Oral Maxillofac Implants, V11, P38
   Wennerberg A, 2000, INT J ORAL MAX IMPL, V15, P331
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yang LJ, 2004, J AM CHEM SOC, V126, P8441, DOI 10.1021/ja049412o
   Zhu Xin yong, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P844
   Zreiqat H, 2005, BIOMATERIALS, V26, P7579, DOI 10.1016/j.biomaterials.2005.05.024
NR 50
TC 7
Z9 8
U1 0
U2 38
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0109 5641
EI 1879 0097
J9 DENT MATER
JI Dent. Mater.
PD JUL
PY 2016
VL 32
IS 7
BP E148
EP E158
DI 10.1016/j.dental.2016.04.002
PG 11
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA DN7YP
UT WOS:000377296400002
PM 27160880
DA 2025 08 17
ER

PT J
AU Slade, L
   Bollen, SE
   Bass, JJ
   Phillips, BE
   Smith, K
   Wilkinson, DJ
   Szewczyk, NJ
   Atherton, PJ
   Etheridge, T
AF Slade, Luke
   Bollen, Shelby E.
   Bass, Joseph J.
   Phillips, Bethan E.
   Smith, Kenneth
   Wilkinson, Daniel J.
   Szewczyk, Nathaniel J.
   Atherton, Philip J.
   Etheridge, Timothy
TI Bisphosphonates attenuate age related muscle decline in
   Caenorhabditis elegans
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Article
DE Healthspan; Lifespan; Muscle; Sarcopenia; Zoledronic acid
ID SARCOPENIA; BONE; ACID; OSTEOPOROSIS; RESISTANCE; EXERCISE; PATHWAY;
   BAIBA
AB Background Age related muscle decline (sarcopenia) associates with numerous health risk factors and poor quality of life. Drugs that counter sarcopenia without harmful side effects are lacking, and repurposing existing pharmaceuticals could expedite realistic clinical options. Recent studies suggest bisphosphonates promote muscle health; however, the efficacy of bisphosphonates as an anti sarcopenic therapy is currently unclear.
   Methods Using Caenorhabditis elegans as a sarcopenia model, we treated animals with 100 nM, 1, 10, 100 and 500 mu M zoledronic acid (ZA) and assessed lifespan and healthspan (movement rates) using a microfluidic chip device. The effects of ZA on sarcopenia were examined using GFP tagged myofibres or mitochondria at days 0, 4 and 6 post adulthood. Mechanisms of ZA mediated healthspan extension were determined using combined ZA and targeted RNAi gene knockdown across the life course.
   Results We found 100 nM and 1 mu M ZA increased lifespan (P < 0.001) and healthspan [954 +/  53 (100 nM) and 963 +/  48 (1 mu M) vs. 834 +/  59% (untreated) population activity AUC, P < 0.05]. 10 mu M ZA shortened lifespan (P < 0.0001) but not healthspan (758.9 +/  37 vs. 834 +/  59, P > 0.05), whereas 100 and 500 mu M ZA were larval lethal. ZA (1 mu M) significantly improved myofibrillar structure on days 4 and 6 post adulthood (83 and 71% well organized myofibres, respectively, vs. 56 and 34% controls, P < 0.0001) and increased well networked mitochondria at day 6 (47 vs. 16% in controls, P < 0.01). Genes required for ZA mediated healthspan extension included fdps 1/FDPS 1 (278 +/  9 vs. 894 +/  17% population activity AUC in knockdown + 1 mu M ZA vs. untreated controls, respectively, P < 0.0001), daf 16/FOXO (680 +/  16 vs. 894 +/  17%, P < 0.01) and agxt 2/BAIBA (531 +/  23 vs. 552 +/  8%, P > 0.05). Life/healthspan was extended through knockdown of igdb 1/FNDC5 (635 +/  10 vs. 523 +/  10% population activity AUC in gene knockdown vs. untreated controls, P < 0.01) and sir 2.3/SIRT 4 (586 +/  10 vs. 523 +/  10%, P < 0.05), with no synergistic improvements in ZA co treatment vs. knockdown alone [651 +/  12 vs. 635 +/  10% (igdb 1/FNDC5) and 583 +/  9 vs. 586 +/  10% (sir 2.3/SIRT 4), both P > 0.05]. Conversely, let 756/FGF21 and sir2.2/SIRT 4 were dispensable for ZA induced healthspan [630 +/  6 vs. 523 +/  10% population activity AUC in knockdown + 1 mu M ZA vs. untreated controls, P < 0.01 (let 756/FGF21) and 568 +/  9 vs. 523 +/  10%, P < 0.05 (sir2.2/SIRT 4)].
   Conclusions Despite lacking an endoskeleton, ZA delays Caenorhabditis elegans sarcopenia, which translates to improved neuromuscular function across the life course. Bisphosphonates might, therefore, be an immediately exploitable anti sarcopenia therapy.
C1 [Slade, Luke] Univ Exeter, Med Sch, Exeter, England.
   [Slade, Luke; Etheridge, Timothy] Univ Exeter, Fac Hlth & Life Sci, Exeter, England.
   [Bollen, Shelby E.; Bass, Joseph J.; Phillips, Bethan E.; Smith, Kenneth; Wilkinson, Daniel J.; Atherton, Philip J.] Univ Nottingham, MRC Versus Arthrit Ctr Musculoskeletal Ageing Res, Sch Med, Unit Injury Recovery & Inflammat Sci IRIS,Ctr Meta, Derby, England.
   [Szewczyk, Nathaniel J.] Heritage Coll Osteopath Med, Ohio Musculoskeletal & Neurol Inst, Athens, OH USA.
C3 University of Exeter; University of Exeter; University of Nottingham
RP Etheridge, T (通讯作者)，Univ Exeter, Fac Hlth & Life Sci, Exeter, England.
EM t.etheridge@exeter.ac.uk
RI ; Slade, Luke/JPX 7440 2023; Bollen, Shelby/AAJ 3892 2021; Atherton,
   Paul/GLS 3029 2022
OI Slade, Luke/0000 0001 7660 7392; 
FU L.S. was supported by the United Mitochondrial Disease Foundation Grant
   PI 19 0985 and the University of Exeter Diamond Jubilee Scholarship, and
   L.S. and T.E. were supported by the US Army Research Office (74014 LS).
   S.E.B., J.J.B., P.J.A., B.E.P., K.S. an [PI 19 0985]; United
   Mitochondrial Disease Foundation; University of Exeter Diamond Jubilee
   Scholarship [74014 LS]; US Army Research Office [MR/P021220/1]; Medical
   Research Council, UK; National Institute for Health Research (NIHR),
   Nottingham Biomedical Research Centre, UK [NSSC22K0250, NSSC22K0278];
   NASA; Osteopathic Heritage Foundation; Research Endowment in the
   Heritage College of Osteopathic Medicine; MRC [MR/P021220/1] Funding
   Source: UKRI; Medical Research Council [MR/P021220/1] Funding Source:
   researchfish
FX L.S. was supported by the United Mitochondrial Disease Foundation Grant
   PI 19 0985 and the University of Exeter Diamond Jubilee Scholarship, and
   L.S. and T.E. were supported by the US Army Research Office (74014 LS).
   S.E.B., J.J.B., P.J.A., B.E.P., K.S. and D.J.W. were supported by the
   Medical Research Council, UK (grant no. MR/P021220/1) as part of the
   MRC Versus Arthritis Centre for Musculoskeletal Ageing Research awarded
   to the Universities of Nottingham and Birmingham, and the National
   Institute for Health Research (NIHR), Nottingham Biomedical Research
   Centre, UK. N.J.S. was supported by grants from NASA (NSSC22K0250 and
   NSSC22K0278) and acknowledges the support of the Osteopathic Heritage
   Foundation through funding for the Osteopathic Heritage Foundation Ralph
   S. Licklider, D.O., Research Endowment in the Heritage College of
   Osteopathic Medicine.
CR Age UK, 2015, AI Policy  United Kingdom
   Bansal A, 2015, P NATL ACAD SCI USA, V112, pE277, DOI 10.1073/pnas.1412192112
   Brook MS, 2016, J PHYSIOL LONDON, V594, P7399, DOI 10.1113/JP272857
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Chang JS, 2017, GERIATR GERONTOL INT, V17, P2266, DOI 10.1111/ggi.13030
   Chang SM., 2017, BIORXIV
   Chen ZQ, 2022, J GERONTOL A BIOL, V77, P1494, DOI 10.1093/gerona/glab172
   Chiu HC, 2018, J CACHEXIA SARCOPENI, V9, P585, DOI 10.1002/jcsm.12289
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ellwood RA, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003 022 04212 z
   Etheridge T, 2015, FASEB J, V29, P1235, DOI 10.1096/fj.14 259119
   Farina F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04256 w
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Gaffney CJ, 2018, AGING US, V10, P3382, DOI 10.18632/aging.101654
   Hain BA, 2020, J BONE MINER RES, V35, P368, DOI 10.1002/jbmr.3890
   Harada Atsushi, 2015, English, V1, P53
   He C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.585644
   Huang CF, 2021, DRUG DES DEV THER, V15, P3711, DOI 10.2147/DDDT.S328858
   Jung TW, 2015, DIABETOLOGIA, V58, P2096, DOI 10.1007/s00125 015 3663 z
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   Kitase Y, 2018, CELL REP, V22, P1531, DOI 10.1016/j.celrep.2018.01.041
   Lin H, 2022, AGING CLIN EXP RES, V34, P2317, DOI 10.1007/s40520 022 02190 0
   Liu P, 2017, MATURITAS, V103, P16, DOI 10.1016/j.maturitas.2017.04.007
   Marcus JM, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00799
   MORITA J, 1985, AGR BIOL CHEM TOKYO, V49, P1397, DOI 10.1080/00021369.1985.10866900
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Pacifico J, 2020, EXP GERONTOL, V131, DOI 10.1016/j.exger.2019.110801
   Park JH, 2013, MENOPAUSE, V20, P747, DOI [10.1097/GME.0b013e31827cabca, 10.1097/gme.0b013e31827cabca]
   Phillips BE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95581
   Pinedo Villanueva R, 2019, CALCIFIED TISSUE INT, V104, P137, DOI 10.1007/s00223 018 0478 1
   Rahman M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73002 6
   Shafiee G, 2017, J DIABETES METAB DIS, V16, DOI 10.1186/s40200 017 0299 1
   Sun XJ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00548
   Waldner M, 2016, BRIT J CLIN PHARMACO, V82, P1158, DOI 10.1111/bcp.12893
   Walsh MC, 2006, OSTEOPOROSIS INT, V17, P61, DOI 10.1007/s00198 005 1900 x
   Wirth M, 2013, MITOCHONDRION, V13, P705, DOI 10.1016/j.mito.2013.02.002
   Wu PY, 2021, MATURITAS, V145, P38, DOI 10.1016/j.maturitas.2020.12.009
   Yoon SH, 2016, NEUROMUSCULAR DISORD, V26, P73, DOI 10.1016/j.nmd.2015.09.015
   Zuela N, 2016, J CELL SCI, V129, P1781, DOI 10.1242/jcs.184309
NR 39
TC 2
Z9 2
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2190 5991
EI 2190 6009
J9 J CACHEXIA SARCOPENI
JI J. Cachexia Sarcopenia Muscle
PD DEC
PY 2023
VL 14
IS 6
BP 2613
EP 2622
DI 10.1002/jcsm.13335
EA SEP 2023
PG 10
WC Geriatrics & Gerontology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; General & Internal Medicine
GA EJ4X8
UT WOS:001069290900001
PM 37722921
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lewicki, M
   Paez, H
   Mandalunis, PM
AF Lewicki, Marianela
   Paez, Hugo
   Mandalunis, Patricia M.
TI Effect of lithium carbonate on subchondral bone in sexually mature
   Wistar rats
SO EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE lithium carbonate; bone histomorphometryl; subchondral bone; bone
   toxicity
ID RENAL FAILURE; TOXICITY; HYPERPARATHYROIDISM; THERAPY; OVERLOAD
AB Clinical and experimental studies have shown that lithium carbonate causes a number of clinical manifestations such as hyperparathyroidism, hypothyroidism, renal toxicity, and diabetes insipidus. The effect of this drug on the bone biology of experimental animals has not been studied to date. Therefore, the aim of the present experimental work was to study the effect of lithium on bone tissue in healthy sexually mature Wistar rats.
   Ten female Wistar rats, aged 3(1)/(2) 4(1)/(2) months, 210 220 g body weight, were assigned to one of the following groups: untreated control group and experimental group receiving 45 mg/kg body weight/day of lithium carbonate in their drinking water during 3 months. Prior to euthanasia, blood samples were obtained in order to determine plasma phosphorus, calcium alkaline phosphatase, and lithium. After sacrifice, the tibiae were resected, processed, and embedded in paraffin. The following histomorphometric parameters were determined on digital photographs of the histologic sections: BV/TV (%), bone volume; Tb.Th (mu m), trabecular thickness; Tb.N (mm( 2)/mm), trabecular number; Tb.Sp (mu m), trabecular separation; Ob.S/BS (%), osteoblast surface; ES/BS (%), total erosive surface; Lc.S (%), lining cells surface; and GPC.Th (mu m), thickness of growth plate cartilage.
   The results showed that administration of lithium carbonate cause bone loss in healthy sexually mature Wistar rats. Although the mechanism involved in bone toxicity remains to be clarified, the results obtained in the present study suggest that patients under long term lithium therapy should be thoroughly evaluated, particularly those presenting other risk factors of osteopenia, such as menopause, low calcium intake, alcohol consumption, and glucocorticoid therapy. (c) 2006 Elsevier GmbH. All rights reserved.
C1 Univ Buenos Aires, Sch Dent, Dept Histol & Embryol, RA 1122 Buenos Aires, DF, Argentina.
C3 University of Buenos Aires
RP Mandalunis, PM (通讯作者)，Univ Buenos Aires, Sch Dent, Dept Histol & Embryol, Marcelo T Alvear 2142 1 A, RA 1122 Buenos Aires, DF, Argentina.
EM patricia@histo.odon.uba.ar
CR BESKID M, 1989, Materia Medica Polona, V21, P280
   BROULIK PD, 1984, CLIN CHIM ACTA, V140, P151, DOI 10.1016/0009 8981(84)90339 5
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cohen O, 1998, HORM METAB RES, V30, P594, DOI 10.1055/s 2007 978939
   Cohen Solal M, 2002, NEPHROL DIAL TRANSPL, V17, P30, DOI 10.1093/ndt/17.suppl_2.30
   Dieserud G, 2001, TIDSSKR NORSKE LAEGE, V121, P1026
   HENG MCY, 1982, ARCH DERMATOL, V118, P246, DOI 10.1001/archderm.118.4.246
   Imam Syed Khalid, 2005, JPMA Journal of the Pakistan Medical Association, V55, P125
   Jeffery EH, 1996, J TOXICOL ENV HEALTH, V48, P649, DOI 10.1080/009841096161122
   Kendler David L, 2006, Curr Osteoporos Rep, V4, P34, DOI 10.1007/s11914 006 0013 6
   KLING MA, 1984, LAB INVEST, V50, P526
   Laroche M, 1997, REV RHUM, V64, P132
   Mandalunis P, 2002, EXP TOXICOL PATHOL, V54, P85, DOI 10.1078/0940 2993 00246
   Mandalunis P M, 1997, Acta Odontol Latinoam, V10, P55
   MARATHE MR, 1986, TOXICOL LETT, V34, P115, DOI 10.1016/0378 4274(86)90153 0
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114
   Pieri Balandraud N, 2001, REV MED INTERNE, V22, P460, DOI 10.1016/S0248 8663(01)00371 X
   Schrooten I, 1998, KIDNEY INT, V54, P448, DOI 10.1046/j.1523 1755.1998.00035.x
   Sharma SD, 2005, BIOL PHARM BULL, V28, P834, DOI 10.1248/bpb.28.834
   STANCER HC, 1989, ARCH INTERN MED, V149, P1042, DOI 10.1001/archinte.149.5.1042
   SYLESTER PLD, 2002, ARCH ENVIRON HEALTH, V57, P320
   Tannirandorn P, 2000, OSTEOPOROSIS INT, V11, P637, DOI 10.1007/s001980070062
NR 24
TC 16
Z9 17
U1 0
U2 5
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0940 2993
EI 1618 1433
J9 EXP TOXICOL PATHOL
JI Exp. Toxicol. Pathol.
PD NOV
PY 2006
VL 58
IS 2 3
BP 197
EP 201
DI 10.1016/j.etp.2006.06.003
PG 5
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Toxicology
GA 111YS
UT WOS:000242492400011
PM 16846729
DA 2025 08 17
ER

PT J
AU Merz, M
   Komljenovic, D
   Zwick, S
   Semmler, W
   Bäuerle, T
AF Merz, Maximilian
   Komljenovic, Dorde
   Zwick, Stefan
   Semmler, Wolfhard
   Baeuerle, Tobias
TI Sorafenib tosylate and paclitaxel induce anti angiogenic, anti tumour
   and anti resorptive effects in experimental breast cancer bone
   metastases
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Bone metastases; Angiogenesis; Dynamic contrast enhanced MRI; Vessel
   remodelling; Vessel size imaging; Diffusion weighted imaging; Sorafenib
   tosylate; Paclitaxel
ID ANTIANGIOGENIC THERAPY; TUMOR GROWTH; IN VIVO; INHIBITION; RESORPTION;
   BEVACIZUMAB; OSTEOCLASTS; SURVIVAL; PATHWAY; DISEASE
AB Purpose: In this study we investigated sorafenib tosylate and paclitaxel as single and combination therapies regarding their effects on tumour growth and vasculature as well as their potency to inhibit osteolysis in experimental breast cancer bone metastases.
   Experimental design: Nude rats bearing breast cancer bone metastases were treated with sorafenib tosylate (7 mg/kg, n = 11), paclitaxel (5 mg/kg, n = 11) or the combination of both.(n = 10) and were compared to untreated controls (n = 11). In a longitudinal study, volumes of osteolyses and respective soft tissue tumours were measured in these groups by MRI and volume CT, while changes in cellularity within bone metastases were assessed by diffusion weighted imaging. Dynamic contrast enhanced MRI and vessel size imaging was performed to determine changes of tumour vasculature within osseous lesions non invasively.
   Results: Animals treated with sorafenib tosylate or paclitaxel showed significantly reduced growth of both, the osteolytic lesions and the soft tissue tumours as well as a decreased cellularity in bone metastases compared to control rats. Effects on the tumour vasculature of these drugs included significantly reduced blood volume as well as significant changes of the vessel permeability and the mean vessel calibers. When combining sorafenib tosylate with paclitaxel for the treatment of bone metastases positive combination effects were observed, particularly on reducing vessel permeability in these lesions.
   Conclusion: The application of sorafenib tosylate monotherapy or in combination with paclitaxel is effective against experimental breast cancer bone metastases resulting in anti angiogenic, anti tumour and anti resorptive effects. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Merz, Maximilian; Komljenovic, Dorde; Semmler, Wolfhard; Baeuerle, Tobias] German Canc Res Ctr, Dept Med Phys Radiol, D 69120 Heidelberg, Germany.
   [Zwick, Stefan] Univ Hosp Freiburg, Dept Diagnost Radiol, D 79106 Freiburg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); University
   of Freiburg
RP Bäuerle, T (通讯作者)，German Canc Res Ctr, Dept Med Phys Radiol, Neuenheimer Feld 280, D 69120 Heidelberg, Germany.
EM t.baeuerle@dkfz.de
RI Merz, Maximilian/AAO 6220 2020; Baeuerle, Tobias/LSL 3005 2024; Merz,
   Maximilian/LWH 6815 2024
OI Bauerle, Tobias/0000 0002 0206 6199; Merz,
   Maximilian/0000 0002 2805 5973
FU Deutsche Forschungsgemeinschaft [SFB TR23]
FX Tobias Bauerle and Dorde Komljenovic (Deutsche Forschungsgemeinschaft,
   SFB TR23).
CR Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Bäuerle T, 2008, NEOPLASIA, V10, P511, DOI 10.1593/neo.08220
   Bäuerle T, 2010, CLIN CANCER RES, V16, P3215, DOI 10.1158/1078 0432.CCR 09 2932
   Bäuerle T, 2005, INT J CANCER, V115, P177, DOI 10.1002/ijc.20840
   Belotti D, 1996, CLIN CANCER RES, V2, P1843
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Body JJ, 2006, CLIN CANCER RES, V12, p6258S, DOI 10.1158/1078 0432.CCR 06 0840
   BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621, DOI 10.1097/00004728 199107000 00018
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dunn LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006896
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Herneth AM, 2003, EUR J RADIOL, V45, P208, DOI 10.1016/S0720 048X(02)00310 8
   Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kiessling F, 2007, EUR RADIOL, V17, P2136, DOI 10.1007/s00330 006 0566 x
   Lee KC, 2007, CANCER RES, V67, P3524, DOI 10.1158/0008 5472.CAN 06 4236
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Naumova E, 2006, CLIN CANCER RES, V12, P1839, DOI 10.1158/1078 0432.CCR 05 1615
   Peng HJ, 2007, CANCER RES, V67, P9346, DOI 10.1158/0008 5472.CAN 06 4508
   Plunkett TA, 2000, EUR J CANCER, V36, P476, DOI 10.1016/S0959 8049(99)00331 7
   Schwartz EL, 2009, CLIN CANCER RES, V15, P2594, DOI 10.1158/1078 0432.CCR 08 2710
   Strube A, 2009, CLIN CANCER RES, V15, P3751, DOI 10.1158/1078 0432.CCR 08 3123
   Troprès I, 2001, MAGN RESON MED, V45, P397, DOI 10.1002/1522 2594(200103)45:3<397::AID MRM1052>3.0.CO;2 3
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008 5472.CAN 04 1443
   Zwick S, 2009, J MAGN RESON IMAGING, V29, P1125, DOI 10.1002/jmri.21710
NR 29
TC 39
Z9 40
U1 0
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JAN
PY 2011
VL 47
IS 2
BP 277
EP 286
DI 10.1016/j.ejca.2010.08.019
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 713DS
UT WOS:000286715800015
PM 20863686
DA 2025 08 17
ER

PT J
AU Hirahara, N
   Muraoka, H
   Noda, M
   Muramatsu, T
   Tokunaga, S
   Kaneda, T
AF Hirahara, Naohisa
   Muraoka, Hirotaka
   Noda, Marie
   Muramatsu, Teruaki
   Tokunaga, Satoshi
   Kaneda, Takashi
TI Change in the Magnetic Resonance Imaging Signal of the Mandibular
   Condyle Due to Bisphosphonate Related Osteonecrosis of the Jaw
SO JOURNAL OF HARD TISSUE BIOLOGY
LA English
DT Article
DE Magnetic resonance imaging signal; Mandibular condyle;
   Bisphosphonate related osteonecrosis of the jaw; Bone marrow signal
ID MARROW EDEMA PATTERN; BONE MARROW; RISK FACTORS; OSTEOMYELITIS
AB Marx was the first to report osteonecrosis of the jaw due to administration of BPs in 2003. Bisphosphonate related osteonecrosis of the jaw (BRONJ) is the result of an adverse drug reaction. Moreover, many studies worldwide have reported an association between a range of serious dental diseases and the use of bisphosphonates (BPs). Few studies, however, have evaluated BRONJ based on an abnormal signal detected by MRI in the bone marrow of the mandibular condyle. The aim of this study was to assess changes in the magnetic resonance imaging (MRI) signal from the mandibular condyle that could be due to BRONJ. In particular, we focused on the presence of an abnormal MRI signal emanating from mandibular condyle bone marrow. Twenty eight patients (11 men, 17 women; 56 temporomandibular joints) with BRONJ were evaluated for jaw pain. The patients, whose mean age was 72.9 +/  9.4 years (range 48   88 years), underwent MRI examination of the jawbone at our hospital from August 2006 to December 2015 and were included in the study. Overall, 80.0% of the patients diagnosed with BRONJ exhibited an abnormal bone marrow signal in the mandibular condyle on the same side of the face that suffered jaw pain. This abnormal signal was present significantly more frequently on the side of the face with the jaw symptoms than on the side without symptoms. Patients with BRONJ displayed an abnormal MRI signal in the mandibular condyle on the side of the face with jaw symptoms, suggesting that MRI findings could be useful clinically for detecting BRONJ in the mandibular condyle.
C1 [Hirahara, Naohisa; Muraoka, Hirotaka; Noda, Marie; Muramatsu, Teruaki; Tokunaga, Satoshi; Kaneda, Takashi] Nihon Univ, Dept Radiol, Sch Dent Matsudo, 2 870 1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.
C3 Nihon University
RP Hirahara, N (通讯作者)，Nihon Univ, Dept Radiol, Sch Dent Matsudo, 2 870 1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.
EM mana13014@g.nihon u.ac.jp
CR [Anonymous], 2011, It J Maxillofac Surg
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Fedele S, 2010, AM J MED, V123, P1060, DOI 10.1016/j.amjmed.2010.04.033
   Ficarra G, 2007, CLIN CASES MINER BON, V4, P53
   García Ferrer L, 2008, AM J ROENTGENOL, V190, P949, DOI 10.2214/AJR.07.3045
   HAYES CW, 1993, RADIOGRAPHICS, V13, P1001, DOI 10.1148/radiographics.13.5.8210586
   Kaneda T, 1996, ORAL SURG ORAL MED O, V82, P229, DOI 10.1016/S1079 2104(96)80262 9
   KANEDA T, 1995, ORAL SURG ORAL MED O, V79, P634, DOI 10.1016/S1079 2104(05)80107 6
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Lee K, 2003, ORAL SURG ORAL MED O, V96, P499, DOI 10.1016/S1079 2104(03)00351 2
   Leite AF, 2014, INT J DENT, V2014, DOI 10.1155/2014/784348
   Lieberman JM, 1996, J ORAL MAXIL SURG, V54, P434, DOI 10.1016/S0278 2391(96)90115 9
   Longo F, 2014, INT J DENT, V2014, DOI 10.1155/2014/298945
   Manzon L, 2014, CLIN INTERV AGING, V9, P1409, DOI 10.2147/CIA.S67726
   Rocha GCMA, 2012, OR SURG OR MED OR PA, V114, pS19, DOI 10.1016/j.tripleo.2011.08.016
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mast G, 2012, J CRANIO MAXILL SURG, V40, P568, DOI 10.1016/j.jcms.2011.10.012
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   McLeod NMH, 2012, SURG J R COLL SURG E, V10, P36, DOI 10.1016/j.surge.2011.09.002
   Nicolatou Galitis O, 2011, ORAL SURG ORAL MED O, V112, P195, DOI 10.1016/j.tripleo.2011.02.037
   Nomura Takeshi, 2013, Bull Tokyo Dent Coll, V54, P117
   O'Ryan FS, 2009, J ORAL MAXIL SURG, V67, P1363, DOI 10.1016/j.joms.2009.03.005
   Otto S, 2012, J CRANIO MAXILL SURG, V40, P303, DOI 10.1016/j.jcms.2011.05.003
   Paulo S, 2014, ONCOL REV, V8, P44, DOI 10.4081/oncol.2014.254
   Phal PM, 2007, AM J NEURORADIOL, V28, P1139, DOI 10.3174/ajnr.A0518
   Raje N, 2008, CLIN CANCER RES, V14, P2387, DOI 10.1158/1078 0432.CCR 07 1430
   REINUS WR, 1994, RADIOLOGY, V192, P195, DOI 10.1148/radiology.192.1.8208937
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Stockmann P, 2010, CLIN ORAL INVEST, V14, P311, DOI 10.1007/s00784 009 0293 1
   Torres SR, 2011, DENTOMAXILLOFAC RAD, V40, P501, DOI 10.1259/dmfr/14636637
   Vande Berg BC, 1998, SKELETAL RADIOL, V27, P471, DOI 10.1007/s002560050423
   VOGLER JB, 1988, RADIOLOGY, V168, P679, DOI 10.1148/radiology.168.3.3043546
   Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835
NR 34
TC 1
Z9 1
U1 0
U2 1
PU JOURNAL HARD TISSUE BIOLOGY
PI MINATO KU
PA NIHON GAKUKUTSU KYORYOKU ZAIDAN, 3  24  20, NISHIAZABU, MINATO KU, TOKYO
   106 0031, JAPAN
SN 1341 7649
J9 J HARD TISSUE BIOL
JI J. Hard Tissue Biol.
PD APR
PY 2017
VL 26
IS 2
BP 161
EP 167
DI 10.2485/jhtb.26.161
PG 7
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA ER5YT
UT WOS:000398881600008
OA Bronze
DA 2025 08 17
ER

PT J
AU Akiva, A
   Melke, J
   Ansari, S
   Liv, N
   van der Meijden, R
   van Erp, M
   Zhao, FH
   Stout, M
   Nijhuis, WH
   de Heus, C
   Ortera, CM
   Fermie, J
   Klumperman, J
   Ito, K
   Sommerdijk, N
   Hofmann, S
AF Akiva, Anat
   Melke, Johanna
   Ansari, Sana
   Liv, Nalan
   van der Meijden, Robin
   van Erp, Merijn
   Zhao, Feihu
   Stout, Merula
   Nijhuis, Wouter H.
   de Heus, Cilia
   Muniz Ortera, Claudia
   Fermie, Job
   Klumperman, Judith
   Ito, Keita
   Sommerdijk, Nico
   Hofmann, Sandra
TI An Organoid for Woven Bone
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE 3D cell culture; 3D electron microscopy; biomineralization; bone model;
   organoid
AB Bone formation (osteogenesis) is a complex process in which cellular differentiation and the generation of a mineralized organic matrix are synchronized to produce a hybrid hierarchical architecture. To study the mechanisms of osteogenesis in health and disease, there is a great need for functional model systems that capture in parallel, both cellular and matrix formation processes. Stem cell based organoids are promising as functional, self organizing 3D in vitro models for studying the physiology and pathology of various tissues. However, for human bone, no such functional model system is yet available. This study reports the in vitro differentiation of human bone marrow stromal cells into a functional 3D self organizing co culture of osteoblasts and osteocytes, creating an organoid for early stage bone (woven bone) formation. It demonstrates the formation of an organoid where osteocytes are embedded within the collagen matrix that is produced by the osteoblasts and mineralized under biological control. Alike in in vivo osteocytes, the embedded osteocytes show network formation and communication via expression of sclerostin. The current system forms the most complete 3D living in vitro model system to investigate osteogenesis, both in physiological and pathological situations, as well as under the influence of external triggers (mechanical stimulation, drug administration).
C1 [Akiva, Anat; van Erp, Merijn] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Cell Biol, Geert Grootepl, NL 6525 Nijmegen, Gelderland, Netherlands.
   [Akiva, Anat; Melke, Johanna; Ansari, Sana; Zhao, Feihu; Ito, Keita; Sommerdijk, Nico; Hofmann, Sandra] Eindhoven Univ Technol, Inst Complex Mol Syst ICMS, NL 5600 Eindhoven, North Brabant, Netherlands.
   [Akiva, Anat; van Erp, Merijn; Sommerdijk, Nico] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Electron Microscopy Ctr, Geert Grootepl, NL 6525 Nijmegen, Gelderland, Netherlands.
   [Akiva, Anat; Ansari, Sana; van der Meijden, Robin; Stout, Merula; Muniz Ortera, Claudia; Sommerdijk, Nico] Dept Chem Engn & Chem, Lab Mat & Interface Chem, NL 5600 Eindhoven, North Brabant, Netherlands.
   [Melke, Johanna; Ansari, Sana; Zhao, Feihu; Ito, Keita; Hofmann, Sandra] Eindhoven Univ Technol, Dept Biomed Engn, Orthopaed Biomech, NL 5600 Eindhoven, North Brabant, Netherlands.
   [Liv, Nalan; de Heus, Cilia; Fermie, Job; Klumperman, Judith] Univ Med Ctr Utrecht, Ctr Mol Med, Sect Cell Biol, NL 3584 Utrecht, Utrecht, Netherlands.
   [van der Meijden, Robin; Sommerdijk, Nico] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Biochem, Geert Grootepl, NL 6525 Nijmegen, Gelderland, Netherlands.
   [Zhao, Feihu] Swansea Univ, Coll Engn, Zienkiewicz Ctr Computat Engn, Swansea SA1 8EN, W Glam, Wales.
   [Nijhuis, Wouter H.] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Orthopaed Surg, NL 3584 Utrecht, Utrecht, Netherlands.
C3 Radboud University Nijmegen; Eindhoven University of Technology; Radboud
   University Nijmegen; Eindhoven University of Technology; Utrecht
   University; Utrecht University Medical Center; Radboud University
   Nijmegen; Swansea University; Utrecht University; Utrecht University
   Medical Center; Wilhelmina Kinderziekenhuis
RP Akiva, A (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Cell Biol, Geert Grootepl, NL 6525 Nijmegen, Gelderland, Netherlands.; Akiva, A; Sommerdijk, N; Hofmann, S (通讯作者)，Eindhoven Univ Technol, Inst Complex Mol Syst ICMS, NL 5600 Eindhoven, North Brabant, Netherlands.; Akiva, A; Sommerdijk, N (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Electron Microscopy Ctr, Geert Grootepl, NL 6525 Nijmegen, Gelderland, Netherlands.; Akiva, A; Sommerdijk, N (通讯作者)，Dept Chem Engn & Chem, Lab Mat & Interface Chem, NL 5600 Eindhoven, North Brabant, Netherlands.; Hofmann, S (通讯作者)，Eindhoven Univ Technol, Dept Biomed Engn, Orthopaed Biomech, NL 5600 Eindhoven, North Brabant, Netherlands.; Sommerdijk, N (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Biochem, Geert Grootepl, NL 6525 Nijmegen, Gelderland, Netherlands.
EM anat.akiva@radboudumc.nl; nico.sommerdijk@radboudumc.nl;
   s.hofmann@tue.nl
RI ; ZHAO, FEIHU/W 5058 2019; Akiva, Anat/A 2086 2017; Sommerdijk,
   Nico/B 7239 2013; Melke, Johanna/N 3313 2018; Liv, Nalan/AAK 8588 2021
OI Stout, Merula/0000 0001 6643 7860; Sommerdijk, Nico/0000 0002 8956 195X;
   Liv, Nalan/0000 0003 2654 9117; Hofmann, Sandra/0000 0002 2568 8388; 
FU Marie Curie Individual Fellowship [H2020 MSCA IF 2017 794296 SUPERMIN];
   Netherlands Organization for Scientific Research (NWO) through an ECHO
   grant; National Postdoctoral Award Program for Advancing Women in
   Science   the Weizmann Institute of Science, Israel; European Research
   Council (ERC) Advanced Investigator grant
   [H2020 ERC 2017 ADV 788982 COLMIN]; Ministry of Education, Culture and
   Science [024.003.013]; Netherlands Organization for Scientific Research
   (NWO) through a ZonMW TOP grant; ERC Starting grant
   [FP7 ERC 2013 StG 336043 REMOTE]
FX A.A. and J.M. contributed equally to this work. The authors would like
   to thank Lia Addadi and Steve Weiner for providing the zebrafish and
   embryonic chicken data, the ICMS animation studio (Koen Pieterse) for
   the graphics of the cells, and Carlijn Bouten for providing CNA35
   collagen probe. The authors also thank Deniz Daviran for her help in
   preparing the figures. A.A. was supported by the Marie Curie Individual
   Fellowship (H2020 MSCA IF 2017 794296 SUPERMIN), by the Netherlands
   Organization for Scientific Research (NWO) through an ECHO grant to NS,
   and by the National Postdoctoral Award Program for Advancing Women in
   Science   the Weizmann Institute of Science, Israel. N.S., R.v.d.M. and
   M.v.E. were supported by the European Research Council (ERC) Advanced
   Investigator grant (H2020 ERC 2017 ADV 788982 COLMIN) to N.S. S.A. was
   supported by the Ministry of Education, Culture and Science (Gravitation
   Program 024.003.013). N.L. was supported by the Netherlands Organization
   for Scientific Research (NWO) through a ZonMW TOP grant to JK. J.M.,
   F.Z., and S.H. were supported by the ERC Starting grant
   (FP7 ERC 2013 StG 336043 REMOTE) to SH.
CR Akiva A, 2016, J AM CHEM SOC, V138, P14481, DOI 10.1021/jacs.6b09442
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Brackmann C, 2012, TISSUE ENG PART C ME, V18, P227, DOI [10.1089/ten.tec.2011.0211, 10.1089/ten.TEC.2011.0211]
   Clemens, 2020, PRINCIPLES BONE BIOL, P1943
   de Wildt BWM, 2019, CURR OPIN BIOMED ENG, V10, P107, DOI 10.1016/j.cobme.2019.05.005
   Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312
   Fermie J, 2018, TRAFFIC, V19, P354, DOI 10.1111/tra.12557
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Hofmann S, 2007, BIOMATERIALS, V28, P1152, DOI 10.1016/j.biomaterials.2006.10.019
   Iordachescu A, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201700156
   Kazanci M, 2006, J STRUCT BIOL, V156, P489, DOI 10.1016/j.jsb.2006.06.011
   Kerschnitzki M, 2016, J STRUCT BIOL, V195, P82, DOI 10.1016/j.jsb.2016.04.011
   Kerschnitzki M, 2011, J STRUCT BIOL, V173, P303, DOI 10.1016/j.jsb.2010.11.014
   Krahn KN, 2006, ANAL BIOCHEM, V350, P177, DOI 10.1016/j.ab.2006.01.013
   Mastrogiacomo M, 2004, TISSUE ENG, V10, P1767, DOI 10.1089/ten.2004.10.1767
   MCKEE MD, 1995, MICROSC RES TECHNIQ, V31, P44, DOI 10.1002/jemt.1070310105
   Melke J, 2018, EUR CELLS MATER, V36, P57, DOI 10.22203/eCM.v036a05
   Nasello G, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00336
   Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e
   Nyman JS, 2011, CALCIFIED TISSUE INT, V89, P111, DOI 10.1007/s00223 011 9497 x
   Park SE, 2019, SCIENCE, V364, P960, DOI 10.1126/science.aaw7894
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Ramm G, 2014, CORRELATIVE LIGHT EL, VII, P241
   Reznikov N, 2014, ACTA BIOMATER, V10, P3815, DOI 10.1016/j.actbio.2014.05.024
   Reznikov N, 2014, BONE, V59, P93, DOI 10.1016/j.bone.2013.10.023
   Skottke J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081998
   Slot JW, 2007, NAT PROTOC, V2, P2480, DOI 10.1038/nprot.2007.365
   Thrivikraman G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11455 8
   Tokarz D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186846
   van Apeldoorn AA, 2005, J ROY SOC INTERFACE, V2, P39, DOI 10.1098/rsif.2004.0018
   van Lenthe GH, 2007, BIOMATERIALS, V28, P2479, DOI 10.1016/j.biomaterials.2007.01.017
   van Meel E, 2011, TRAFFIC, V12, P912, DOI 10.1111/j.1600 0854.2011.01203.x
   Varga P, 2015, BIOMECH MODEL MECHAN, V14, P267, DOI 10.1007/s10237 014 0601 9
   Verbruggen SW, 2012, J R SOC INTERFACE, V9, P2735, DOI 10.1098/rsif.2012.0286
   Vetsch JR, 2015, ACTA BIOMATER, V13, P277, DOI 10.1016/j.actbio.2014.11.025
   Wang K, 2019, J BONE MINER RES, V34, P979, DOI 10.1002/jbmr.3720
   Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271
   WEINER S, 1986, FEBS LETT, V206, P262, DOI 10.1016/0014 5793(86)80993 0
   Yair R, 2017, POULTRY SCI, V96, P2301, DOI 10.3382/ps/pex021
   Zhang C, 2019, CURR OSTEOPOROS REP, V17, P207, DOI 10.1007/s11914 019 00521 1
NR 41
TC 80
Z9 90
U1 14
U2 206
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD APR
PY 2021
VL 31
IS 17
AR 2010524
DI 10.1002/adfm.202010524
EA MAR 2021
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA RT1LI
UT WOS:000626555200001
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Minisola, S
   Cianferotti, L
   Biondi, P
   Cipriani, C
   Fossi, C
   Franceschelli, F
   Giusti, F
   Leoncini, G
   Pepe, J
   Bischoff Ferrari, HA
   Brandi, ML
AF Minisola, S.
   Cianferotti, L.
   Biondi, P.
   Cipriani, C.
   Fossi, C.
   Franceschelli, F.
   Giusti, F.
   Leoncini, G.
   Pepe, J.
   Bischoff Ferrari, H. A.
   Brandi, M. L.
TI Correction of vitamin D status by calcidiol: pharmacokinetic profile,
   safety, and biochemical effects on bone and mineral metabolism of daily
   and weekly dosage regimens
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Fracture; Hypovitaminosis D; Osteomalacia; Osteoporosis; Rickets;
   Vitamin D deficiency
ID RANDOMIZED CONTROLLED TRIAL; SERUM 25 HYDROXYVITAMIN D; D
   SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; OSTEOARTHRITIS ESCEO; ORAL
   VITAMIN D 3; EUROPEAN SOCIETY; ECONOMIC ASPECTS; PARATHYROID HORMONE;
   TURNOVER MARKERS
AB Rationale: Calcidiol can be employed to correct vitamin D deficiency. Main results: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25 hydroxyvitamin D levels without altering other markers related to bone and mineral metabolism. Significance: Calcidiol supplementation is effective and safe.
   Introduction The correction of vitamin D status is necessary to maintain an optimal mineral and skeletal homeostasis. Despite cholecalciferol (vitamin D 3) is the most commonly used drug for vitamin D supplementation, the more hydrophilic compound calcidiol (25 hydroxyvitamin D 3) can be employed at daily, weekly, and monthly regimens to reach in the short term the target levels of serum 25 hydroxyvitamin D [25(OH)D]. In the administration of different doses of calcidiol pharmacokinetic study (ADDI D study), the efficacy and safety of daily and weekly dosages of calcidiol were tested.
   Methods A total of 87 Caucasian, community dwelling, postmenopausal women, aged 55 years or older, with vitamin D inadequacy (serum 25(OH)D levels < 30 ng/ml, with mean 25(OH)D below 20 ng/ml, namely 16.5 +/  7.5 ng/ml) were randomized to receive three different dosages of calcidiol: 20 mu g/day, 40 mu g/day, and 125 mu g/week for 3 months. The attained level of serum 25(OH)D was selected as primary endpoint to assess efficacy, while other parameters of mineral metabolism, (serum calcium, parathyroid hormone, phosphate, FGF23, urinary calcium, and markers of bone turnover) were assessed as secondary endpoints to establish safety.
   Results In all the three groups, serum 25(OH)D values significantly and promptly rose and plateaued above the 30 ng/ml threshold remaining within safety interval after 14 days of treatment, with similar efficacy for the similar daily and weekly dose regimens. The different dosages were also equally effective in controlling secondary hyperparathyroidism. No significant changes in calcium and phosphate metabolism and in bone turnover markers were observed for any of the treatments, confirming the safety of this compound.
   Conclusions The results of this study demonstrate the short  and mid term efficacy and safety on core parameters of mineral metabolism of different daily or weekly dosages of calcidiol when used to treat vitamin D inadequacy or deficiency in postmenopausal women. Further studies are needed to assess falls as primary outcome of calcidiol supplementation.
C1 [Minisola, S.; Biondi, P.; Cipriani, C.; Pepe, J.] Sapienza Univ Rome, Dept Internal Med & Med Disciplines, Rome, Italy.
   [Cianferotti, L.; Fossi, C.; Franceschelli, F.; Giusti, F.; Leoncini, G.; Brandi, M. L.] Univ Florence, Dept Surg & Translat Med, Metab Bone Dis Unit, Florence, Italy.
   [Bischoff Ferrari, H. A.] Univ Hosp, Dept Geriatr & Aging Res, Zurich, Switzerland.
   [Bischoff Ferrari, H. A.] Univ Zurich, Zurich, Switzerland.
C3 Sapienza University Rome; University of Florence; University of Zurich;
   University Zurich Hospital; University of Zurich
RP Brandi, ML (通讯作者)，Univ Florence, Dept Surg & Translat Med, Metab Bone Dis Unit, Florence, Italy.
EM marialuisa.brandi@unifi.it
RI Cipriani, Cristiana/K 9497 2016; CIANFEROTTI, LUISELLA/LSK 2125 2024;
   Cianferotti, Luisella/LSK 2125 2024
OI Cipriani, Cristiana/0000 0002 0141 1202; brandi, maria
   luisa/0000 0002 8741 0592; Giusti, Francesca/0000 0002 8576 9606;
   Bischoff Ferrari, Heike/0000 0002 4554 658X; CIANFEROTTI,
   LUISELLA/0000 0001 7424 6212; 
FU Bruno Farmaceutici
FX This work was supported though a dedicated grant from Bruno Farmaceutici
   (to Maria Luisa Brandi and Salvatore Minisola). We are indebted to Guido
   Fedele for the statistical analyses of the data.
CR Bischoff Ferrari HA, 2010, OSTEOPOROSIS INT, V21, P1121, DOI 10.1007/s00198 009 1119 3
   Bischoff Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029
   Bischoff Ferrari HA, 2016, JAMA INTERN MED, V176, P175, DOI 10.1001/jamainternmed.2015.7148
   Bischoff Ferrari HA, 2012, NEW ENGL J MED, V367, P40, DOI 10.1056/NEJMoa1109617
   Bischoff Ferrari HA, 2012, J BONE MINER RES, V27, P160, DOI 10.1002/jbmr.551
   Blau JE, 2015, REV ENDOCR METAB DIS, V16, P165, DOI 10.1007/s11154 015 9318 z
   Brandi ML, 2013, CURR MED RES OPIN, V29, P1565, DOI 10.1185/03007995.2013.838549
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Cashman KD, 2012, AM J CLIN NUTR, V95, P1350, DOI 10.3945/ajcn.111.031427
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Chun RF, 2014, J STEROID BIOCHEM, V144, P132, DOI 10.1016/j.jsbmb.2013.09.012
   Cianferotti L, 2015, OSTEOPOROSIS INT, V26, P2695, DOI 10.1007/s00198 015 3187 x
   Cianferotti L, 2015, ENDOCRINE, V50, P12, DOI 10.1007/s12020 015 0606 x
   Cipriani C, 2013, J CLIN ENDOCR METAB, V98, P2709, DOI 10.1210/jc.2013 1586
   DAVIES M, 1980, GUT, V21, P287, DOI 10.1136/gut.21.4.287
   Fuleihan GE, 2015, J BONE MINER RES, V30, P1119, DOI 10.1002/jbmr.2536
   Gallagher JC, 2012, ANN INTERN MED, V156, P425, DOI 10.7326/0003 4819 156 6 201203200 00005
   Gonnelli S, 2009, CALCIFIED TISSUE INT, V85, P221, DOI 10.1007/s00223 009 9264 4
   HADDAD JG, 1976, J CLIN ENDOCR METAB, V42, P284, DOI 10.1210/jcem 42 2 284
   Han XB, 2016, CURR OPIN NEPHROL HY, V25, P333, DOI 10.1097/MNH.0000000000000240
   Heaney RP, 2008, AM J CLIN NUTR, V87, P1738, DOI 10.1093/ajcn/87.6.1738
   Herrmann M, 2017, CLIN CHEM LAB MED, V55, P3, DOI 10.1515/cclm 2016 0264
   Holick MF, 2012, J CLIN ENDOCR METAB, V97, P1153, DOI 10.1210/jc.2011 2601
   Jetter A, 2014, BONE, V59, P14, DOI 10.1016/j.bone.2013.10.014
   LAWSON DEM, 1986, BIOCHEM J, V233, P535, DOI 10.1042/bj2330535
   Meyer O, 2015, OSTEOPOROSIS INT, V26, P373, DOI 10.1007/s00198 014 2949 1
   Michaud J, 2010, J AM SOC NEPHROL, V21, P1488, DOI 10.1681/ASN.2009080815
   Pepe J, 2005, OSTEOPOROSIS INT, V16, P805, DOI 10.1007/s00198 004 1757 4
   Rizzoli R, 2013, CURR MED RES OPIN, V29, P305, DOI 10.1185/03007995.2013.766162
   Rizzoli R, 2014, MATURITAS, V79, P122, DOI 10.1016/j.maturitas.2014.07.005
   Romagnoli E, 2013, EUR J ENDOCRINOL, V169, pR59, DOI 10.1530/EJE 13 0435
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P365, DOI 10.1007/s00223 012 9637 y
   Rossini M, 2012, J CLIN ENDOCR METAB, V97, pE622, DOI 10.1210/jc.2011 2448
   Russo S, 2011, CALCIFIED TISSUE INT, V89, P252, DOI 10.1007/s00223 011 9513 1
   Sanders KM, 2010, JAMA J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Smith H, 2007, RHEUMATOLOGY, V46, P1852, DOI 10.1093/rheumatology/kem240
   Smith LM, 2017, J STEROID BIOCHEM, V173, P317, DOI 10.1016/j.jsbmb.2017.03.015
   Souberbielle JC, 2017, J ENDOCRINOL INVEST, V40, P241, DOI 10.1007/s40618 016 0553 2
   Vieth R, 1999, AM J CLIN NUTR, V69, P842
NR 39
TC 30
Z9 31
U1 0
U2 9
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2017
VL 28
IS 11
BP 3239
EP 3249
DI 10.1007/s00198 017 4180 3
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FJ5VT
UT WOS:000412822100017
PM 28815282
DA 2025 08 17
ER

PT J
AU Hamada, Y
   Fujii, H
   Fukagawa, M
AF Hamada, Yasuhiro
   Fujii, Hideki
   Fukagawa, Masafumi
TI Role of oxidative stress in diabetic bone disorder
SO BONE
LA English
DT Article
DE Antioxidants; Diabetes mellitus; Histomorphometry; Low turnover bone;
   Reactive oxygen species
ID OSTEOBLASTIC DIFFERENTIATION; MELLITUS; COMPLICATIONS; OSTEOPOROSIS;
   OSTEOPENIA; GLYCATION; CELLS; MODEL
AB Diabetes mellitus induces alterations in bone and mineral metabolism. Diabetic bone disorder causes an increase in bone fractures, delays healing of fractures, and affects the quality of life. There are few optimal therapies for these disorders and the mechanisms responsible for their complications have not been clearly identified. Bone histology studies in humans and animals have demonstrated that decreased bone formation is a critical mechanism of bone mass reduction in diabetes. A major hypothesis about the mechanisms of diabetic complications is a diabetes induced increase in oxidative stress, because reactive oxygen species (ROS) are increased under diabetic conditions and are known to induce cellular dysfunction in a wide variety of cell types. Oxidative stress is induced by a variety of mechanisms including formation of increased advanced glycation end products (AGEs), increased polyol pathway flux, activation of protein kinase C isoforms, glucose autoxidation, and mitochondrial overproduction of superoxide under diabetic conditions. Other circulating factors that are elevated in diabetes, such as free fatty acids and leptin, also contribute to increased ROS generation. It is now widely accepted that ROS can cause severe damage to DNA, proteins, and lipids. Concerning bone metabolism, in vitro studies have shown that oxidative stress inhibits osteoblastic differentiation and induces osteoblast insults and apoptosis. Moreover, we have demonstrated that both streptozotocin induced diabetic mice, an animal model of type I diabetes, and spontaneously diabetic Torii (SDT) rats, an animal model of type 2 diabetes, have low turnover osteopenia associated with increased oxidative stress and that markers of oxidative stress are inversely associated with the histomorphometric parameters of bone formation. Growing evidence Suggests that the increase in oxidative stress may at least partly contribute to the development of diabetic osteopenia. This review focuses on the impact of diabetes induced oxidative stress in the development of diabetic bone disorder. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Hamada, Yasuhiro] Kobe Univ Hosp, Dept Nutr, Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Hamada, Yasuhiro; Fujii, Hideki; Fukagawa, Masafumi] Kobe Univ, Sch Med, Div Nephrol, Kobe, Hyogo 650, Japan.
   [Hamada, Yasuhiro; Fujii, Hideki; Fukagawa, Masafumi] Kobe Univ, Sch Med, Kidney Ctr, Kobe, Hyogo 650, Japan.
C3 Kobe University; Kobe University; Kobe University
RP Hamada, Y (通讯作者)，Kobe Univ Hosp, Dept Nutr, Chuo Ku, 7 5 1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM hamada@med.kobe u.ac.jp
RI ; Fujii, Hideki/AAF 6610 2020
OI Fukagawa, Masafumi/0000 0002 7832 2339; Fujii,
   Hideki/0000 0001 7610 1068
FU Kidney Foundation, Japan [JKFB08 37]
FX This work was partly supported by a grant from The Kidney Foundation,
   Japan (JKFB08 37). We are grateful to Kureha Special Laboratory Co. Ltd.
   for technical assistance.
CR Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891 5849(99)00242 7
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   BOUILLON R, 1991, CALCIFIED TISSUE INT, V49, P155, DOI 10.1007/BF02556109
   BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Chen RM, 2005, ANN NY ACAD SCI, V1042, P448, DOI 10.1196/annals.1338.038
   Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   COZEN L, 1972, CLIN ORTHOP RELAT R, P134
   Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   Forsén L, 1999, DIABETOLOGIA, V42, P920, DOI 10.1007/s001250051248
   Fujii H, 2008, BONE, V42, P372, DOI 10.1016/j.bone.2007.10.007
   Hamada Y, 2007, BONE, V40, P1408, DOI 10.1016/j.bone.2006.12.057
   Hamada Y, 2009, BONE, V44, P936, DOI 10.1016/j.bone.2008.12.011
   HERSKIND AM, 1992, DIABETES METAB, V18, P63
   IGARASHI C, 1994, BONE MINER, V27, P133, DOI 10.1016/S0169 6009(08)80215 2
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   LORENTZON R, 1986, Diabetes Research and Clinical Practice, V2, P157, DOI 10.1016/S0168 8227(86)80017 1
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Saito M, 2006, OSTEOPOROSIS INT, V17, P1514, DOI 10.1007/s00198 006 0155 5
   Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891 5849(00)00224 0
   Shibata T, 2000, BRIT J PHARMACOL, V130, P495, DOI 10.1038/sj.bjp.0703328
   Shinohara M, 2000, Int J Exp Diabetes Res, V1, P89, DOI 10.1155/EDR.2000.89
   Slater AFG, 1995, TOXICOL LETT, V82 3, P149, DOI 10.1016/0378 4274(95)03474 9
   VERHAEGHE J, 1990, HORM RES, V34, P245, DOI 10.1159/000181834
   WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891 5849(91)90040 A
NR 32
TC 128
Z9 140
U1 2
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2009
VL 45
SU 1
BP S35
EP S38
DI 10.1016/j.bone.2009.02.004
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 458PU
UT WOS:000267036800008
PM 19232402
DA 2025 08 17
ER

PT J
AU Windischhofer, W
   Huber, E
   Rossmann, C
   Semlitsch, M
   Kitz, K
   Rauh, A
   Devaney, T
   Leis, HJ
   Malle, E
AF Windischhofer, Werner
   Huber, Evelyn
   Rossmann, Christine
   Semlitsch, Michaela
   Kitz, Kerstin
   Rauh, Anamaria
   Devaney, Trevor
   Leis, Hans Jorg
   Malle, Ernst
TI LPA induced suppression of periostin in human osteosarcoma cells is
   mediated by the LPA1/Egr 1 axis
SO BIOCHIMIE
LA English
DT Article
DE LPA; EGF receptor; Egr 1; Bone; Periostin; MAPK
ID LYSOPHOSPHATIDIC ACID RECEPTOR; PROTEIN COUPLED RECEPTOR; EPIDERMAL
   GROWTH FACTOR; OSTEOBLAST LIKE CELLS; TRANSCRIPTION FACTOR EGR 1;
   SIGNAL REGULATED KINASE; AMYLOID A TRANSCRIPTS; GENE EXPRESSION;
   MESSENGER RNA; EDG FAMILY
AB Lysophosphatidic acid (LPA), a naturally occurring bioactive phospholipid, mediates a multitude of (patho)physiological events including activation of mitogen activated protein kinases (MAPKs). As LPA may induce cellular reponses in human osteosarcoma, the present study aimed at investigating expression of various LPA receptors, LPA mediated activation of MAPK via G protein coupling, and expression of early response genes in a cellular model for human osteosarcoma. We show that MG 63 cells express three members of the endothelial differentiation gene (Edg) family of G protein coupled receptor transcripts (LPA(1 3)) but only two (LPA(4/5)) out of three members of the non Edg family LPA receptor transcripts. Stimulation of MG 63 cells with LPA or synthetic LPA receptor agonists resulted in p42/44 MAPK phosphorylation via LPA(1) LPA(3) receptors. Using pharmacological inhibitors, we show that LPA mediated phosphorylation of p42/44 MAPK by LPA receptor engagement is transmitted by God dependent pathways through the Src family of tyrosine kinases. As a consequence, a rapid and transient upregulation of the zinc finger transcription factor early growth response 1 (Egr 1) was observed. Egr 1 expression was strictly mediated via G(alpha i)/Src/p42/44 MAPK pathway; no involvement of the G(alpha q/11)/PLC/PKC or the PLD/PI3 kinase/Akt pathways was found. LPA induced expression of functional Egr 1 in MG 63 cells could be confirmed by electrophoretic mobility shift assay. LPA induced Egr 1 upregulation was accompanied by a time dependent decrease of periostin (previously called osteoblast specific factor 2), a cell adhesion protein for pre osteoblasts. Silencing of LPA(1) and/or Egr 1 in MG 63 cells reversed LPA mediated suppression of periostin. We here demonstrate a crosslink between Egr 1 and periostin in cancer cells, in particular in human osteosarcoma. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Windischhofer, Werner; Huber, Evelyn; Kitz, Kerstin; Leis, Hans Jorg] Med Univ Graz, Univ Clin Pediat & Adolescent Med, Res Unit Osteol Res & Analyt Mass Spectrometry, A 8036 Graz, Austria.
   [Rossmann, Christine; Semlitsch, Michaela; Rauh, Anamaria; Malle, Ernst] Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A 8036 Graz, Austria.
   [Devaney, Trevor] Med Univ Graz, Ctr Physiol Med, Inst Biophys, A 8036 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz
RP Windischhofer, W (通讯作者)，Med Univ Graz, Univ Clin Pediat & Adolescent Med, Res Unit Osteol Res & Analyt Mass Spectrometry, Auenbruggerpl 30, A 8036 Graz, Austria.
EM werner.windischhofer@medunigraz.at
RI ; DeVaney, Trevor/AAF 7731 2020; Malle, Ernst/D 3071 2013; DeVaney,
   Trevor/C 5015 2011
OI Rossmann, Christine/0000 0002 1791 1981; DeVaney,
   Trevor/0000 0002 5684 3715
FU Medical University of Graz; Austrian Science Fund (FWF) [P3007,
   P19074 B05]; Austrian Science Fund (FWF) [F 3007] Funding Source:
   researchfish
FX The authors thank Dr. A. Prokesch for data base search for Egr 1
   consensus sequences. C.R and K.K. were funded by the PhD program
   Molecular Medicine of the Medical University of Graz. This work was
   supported by the Austrian Science Fund (FWF, P3007 and P19074 B05).
CR Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231
   Bernhart E, 2010, PROTEOMICS, V10, P141, DOI 10.1002/pmic.200900195
   BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11
   Budnik LT, 2003, MOL ENDOCRINOL, V17, P1593, DOI 10.1210/me.2002 0371
   Caverzasio J, 2000, J BONE MINER RES, V15, P1697, DOI 10.1359/jbmr.2000.15.9.1697
   CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662
   Choi KU, 2011, INT J CANCER, V128, P332, DOI 10.1002/ijc.25341
   Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384
   Cui MZ, 2006, ARTERIOSCL THROM VAS, V26, P1029, DOI 10.1161/01.ATV.0000214980.90567.b5
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dziak R, 2003, PROSTAG LEUKOTR ESS, V68, P239, DOI 10.1016/S0952 3278(02)00277 6
   Eid MA, 1998, CANCER RES, V58, P2461
   Estrella VC, 2007, INT J ONCOL, V31, P441
   FANG MA, 1995, CALCIFIED TISSUE INT, V57, P450, DOI 10.1007/BF00301949
   Fortunati D, 2010, MATRIX BIOL, V29, P594, DOI 10.1016/j.matbio.2010.07.001
   FRICK KK, 1990, MOL CELL BIOL, V10, P184, DOI 10.1128/MCB.10.1.184
   GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079 6603(08)60815 6
   Gennero I, 2011, BONE, V49, P395, DOI 10.1016/j.bone.2011.04.018
   Gidley J, 2006, PROSTAG OTH LIPID M, V80, P46, DOI 10.1016/j.prostaglandins.2006.04.001
   Goetzl EJ, 1999, CANCER RES, V59, P5370
   Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071
   Heo SC, 2011, BBA MOL CELL RES, V1813, P2061, DOI 10.1016/j.bbamcr.2011.08.004
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135
   Kaufmann K, 2002, J CELL BIOCHEM, V85, P381, DOI 10.1002/jcb.10145
   KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679
   Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427
   Kim J, 2006, CELL SIGNAL, V18, P1695, DOI 10.1016/j.cellsig.2006.01.009
   Kitz K, 2011, FREE RADICAL BIO MED, V50, P854, DOI 10.1016/j.freeradbiomed.2010.12.039
   Kovacevic A, 2006, FEBS LETT, V580, P161, DOI 10.1016/j.febslet.2005.11.067
   Kovacevic A, 2008, J CELL BIOCHEM, V103, P994, DOI 10.1002/jcb.21472
   Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187
   Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH 22.1167
   Ladanyi M, 2000, PEDIATR PATHOL MOL M, V19, P391, DOI 10.1080/15513810009168647
   Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200
   Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200
   Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302
   Liu C, 2010, CHINESE MED J PEKING, V123, P3677, DOI 10.3760/cma.j.issn.0366 6999.2010.24.030
   Liu YB, 2010, J CELL BIOCHEM, V109, P794, DOI 10.1002/jcb.22471
   MCMAHON AP, 1990, DEVELOPMENT, V108, P281
   Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143
   Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702
   Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081
   Mutoh T, 2012, BRIT J PHARMACOL, V165, P829, DOI 10.1111/j.1476 5381.2011.01622.x
   Nishi H, 2002, CANCER RES, V62, P827
   Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200
   Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994
   Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84
   PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445
   Peyruchaud O, 2000, CELL MOL LIFE SCI, V57, P1109
   Pompetti F, 1996, J CELL BIOCHEM, V63, P37
   Rauh A, 2008, BRIT J PHARMACOL, V154, P13, DOI 10.1038/bjp.2008.92
   Reiser COA, 1998, BIOCHEM J, V330, P1107
   Riggs PK, 2000, MOL CARCINOGEN, V27, P247, DOI 10.1002/(SICI)1098 2744(200004)27:4<247::AID MC1>3.0.CO;2 4
   Rockel JS, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2595
   Rossmann C, 2011, ARCH BIOCHEM BIOPHYS, V509, P16, DOI 10.1016/j.abb.2011.02.016
   Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02 1145fje
   Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146
   Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200
   Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178
   VANEL D, 1984, AM J ROENTGENOL, V143, P519, DOI 10.2214/ajr.143.3.519
   Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097 0215(19990118)80:2<199::AID IJC7>3.0.CO;2 4
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Windischhofer W, 2002, J BONE MINER RES, V17, P1774, DOI 10.1359/jbmr.2002.17.10.1774
   Yanagida K, 2011, J BIOCHEM, V150, P223, DOI 10.1093/jb/mvr087
   Yanagida K, 2009, J BIOL CHEM, V284, P17731, DOI 10.1074/jbc.M808506200
   Zhang QH, 1999, BLOOD, V93, P2984
   Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415
   zu Heringdorf DM, 2007, BBA BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026
NR 71
TC 13
Z9 16
U1 0
U2 6
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD SEP
PY 2012
VL 94
IS 9
BP 1997
EP 2005
DI 10.1016/j.biochi.2012.05.023
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 983AG
UT WOS:000307087900020
PM 22659570
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Siddhivarn, C
   Banes, A
   Champagne, C
   Riché, EL
   Weerapradist, W
   Offenbacher, S
AF Siddhivarn, C.
   Banes, A.
   Champagne, C.
   Riche, E. L.
   Weerapradist, W.
   Offenbacher, S.
TI Mechanical loading and Δ<SUP>12</SUP>prostaglandin J2 induce
   bone morphogenetic protein 2, peroxisome proliferator activated receptor
   γ 1, and bone nodule formation in an osteoblastic cell line
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE bone morphogenetic protein; cyclopentenone; mechanical loading; mouse
   osteoblast; Delta(12)prostaglandin J(2); peroxisome
   proliferator activated receptor
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCELLOUS BONE; FLUID FLOW;
   IN VIVO; PROSTAGLANDIN; EXPRESSION; STRAIN; CALCIFICATION; HETERODIMERS;
   OSTEOCYTES
AB Background and Objective: We have previously reported that mechanical strain applied at a 1% level to an osteoblastic cell line induces the transcription of prostaglandin D 2 synthase and increases the levels of prostaglandin D 2 and its Delta(12)prostaglandin J(2) metabolite. Mechanical strain also induces the expression of peroxisome proliferator activated receptor gamma 1 and bone nodule formation. We hypothesized that mechanical load induces bone formation via Delta(12)prostaglandin J(2) dependent synthesis of bone morphogenetic proteins. Our goal was to investigate the molecular events involved in osteogenesis induced by mechanical loading and Delta(12)prostaglandin J(2), namely the induction of bone morphogenetic proteins and peroxisome proliferator activated receptor gamma 1, a nuclear receptor for Delta(12)prostaglandin J(2).
   Material and Methods: Osteoblast monolayers were stretched for 1 h with a 1 h resting period and stretched for another hour at 1 Hz with 1% elongation. Cells were collected 0, 1, 6 and 16 h after stretching. Cyclooxygenase inhibitors and Delta(12)prostaglandin J(2) were added in some experiments. Relative quantitative reverse transcriptase polymerase chain reaction was used to examine whether the mRNA of bone morphogenetic protein 2,  4,  6,  7 and peroxisome proliferator activated receptor gamma 1 was induced. Immunohistochemistry was used to evaluate bone morphogenetic protein expression in cells.
   Results: Mechanical strain significantly increased the mRNA expression of bone morphogenetic protein 2,  6,  7 and of peroxisome proliferator activated receptor gamma 1, but not of bone morphogenetic protein 4. In stretched cells, bone morphogenetic protein 2 and peroxisome proliferator activated receptor gamma 1 expression was blocked by cyclooxygenase inhibitors, but restored by exogenous Delta(12)prostaglandin J(2). Delta(12)Prostaglandin J(2) significantly enhanced bone nodule formation and bone morphogenetic protein 2 expression when added alone to resting osteoblasts.
   Conclusion: These results suggest that the osteoblastic biomechanical pathways that trigger bone formation involve cyclooxygenase and prostaglandin D 2 synthase activation, induction of Delta(12)prostaglandin J(2) and its nuclear receptor, peroxisome proliferator activated receptor gamma 1, and increased expression of bone morphogenetic protein 2. These data suggest that the Delta(12)prostaglandin J(2)/peroxisome proliferator activated receptor gamma 1/bone morphogenetic protein 2 pathway plays an important role in osteogenesis.
C1 Univ N Carolina, Sch Dent, Ctr Oral & Syst Dis, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Dent, Ctr Oral & Syst Dis, Dept Periodontol, Chapel Hill, NC USA.
   Univ N Carolina, Sch Med, Dept Orthopaed, Chapel Hill, NC USA.
   Mahidol Univ, Fac Dent, Dept Oral Pathol, Bangkok 10700, Thailand.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Mahidol University
RP Offenbacher, S (通讯作者)，Univ N Carolina, Sch Dent, Ctr Oral & Syst Dis, Room 222 DRC, Chapel Hill, NC 27599 USA.
EM Steve_Offenbacher@Dentistry.UNC.edu
FU NCRR NIH HHS [RR00046] Funding Source: Medline; NIDCR NIH HHS [P60 DE
   13079] Funding Source: Medline
CR Batra NN, 2005, J BIOMECH, V38, P1909, DOI 10.1016/j.jbiomech.2004.08.009
   BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565
   Bodic F, 2005, JOINT BONE SPINE, V72, P215, DOI 10.1016/j.jbspin.2004.03.007
   BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309
   BUCKLEY MJ, 1990, J ORAL MAXIL SURG, V48, P276, DOI 10.1016/0278 2391(90)90393 G
   Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Cowin SC, 1998, AM J MED SCI, V316, P184, DOI 10.1097/00000441 199809000 00006
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364
   FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189
   Ghosh Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351
   Giesen EBW, 2004, J DENT RES, V83, P255, DOI 10.1177/154405910408300314
   Giesen EBW, 2003, CLIN BIOMECH, V18, P358, DOI 10.1016/S0268 0033(03)00018 4
   GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Hull MA, 1999, GUT, V45, P529, DOI 10.1136/gut.45.4.529
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Kamata A, 1998, BIOCHEM BIOPH RES CO, V246, P404, DOI 10.1006/bbrc.1998.8632
   KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092 8674(92)90510 J
   KOJIMA A, 1980, PROSTAG OTH LIPID M, V20, P171, DOI 10.1016/0090 6980(80)90016 7
   KOSHIHARA Y, 1989, BIOCHEM BIOPH RES CO, V159, P1206, DOI 10.1016/0006 291X(89)92238 9
   KOSHIHARA Y, 1991, THROMBOXANE LEUKOT R, V21, P847
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   LI J, 2005, J BIOL CHEM, V180, P42925
   MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092 8674(95)90200 7
   McGarry JG, 2005, BIOCHEM BIOPH RES CO, V330, P341, DOI 10.1016/j.bbrc.2005.02.175
   Mikuni Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065
   Mitsui N, 2005, LIFE SCI, V77, P3168, DOI 10.1016/j.lfs.2005.03.037
   Ramirez Yañez GO, 2004, BONE, V35, P1361, DOI 10.1016/j.bone.2004.08.006
   RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345
   Sato M, 1999, J BONE MINER RES, V14, P1084, DOI 10.1359/jbmr.1999.14.7.1084
   Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217
   Siddhivarn C, 2006, J PERIODONTAL RES, V41, P92, DOI 10.1111/j.1600 0765.2005.00834.x
   Tanaka SM, 2005, CALCIFIED TISSUE INT, V76, P261, DOI 10.1007/s00223 004 0238 2
   TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090 6980(91)90001 V
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
NR 39
TC 15
Z9 19
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD OCT
PY 2007
VL 42
IS 5
BP 383
EP 392
DI 10.1111/j.1600 0765.2006.00965.x
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 209XJ
UT WOS:000249421000001
PM 17760815
DA 2025 08 17
ER

PT J
AU Chen, ZH
   Xing, WR
   Fan, L
AF Chen, Zhenhang
   Xing, Weirong
   Fan, Li
TI Chemical IN04 Inhibits the Kinase Domain not the ROC Domain of LRRK1:
   Results from Homology Modeling and Molecular Docking
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE bone loss; leucine rich repeat kinase 1; IN04; homology model; molecular
   docking; kinase inhibitor; ROC GTPase
ID SWISS MODEL; PROTEIN; MUTATIONS; REVEALS
AB Background: Bone loss is the most common reason for broken bones among the elderly. An ideal agent for the treatment of bone loss should have both osteoclast inhibitory and osteoblast stimulatory functions. Leucine rich repeat kinase 1 (LRRK1) is a novel target for alternative antiresorptive drugs to treat osteoporosis and osteoporotic fractures. Recently a chemical IN04, Methyl 3 [({([5 (3,5 dimethoxyphenyl) 1,3,4 oxadiazol 2 yl] thio} acetyl) amino] benzoate, has been identified as a potential LRRK1 inhibitor.
   Objective: The aim of this work is to investigate how the chemical IN04 interacts with LRRK1 and inhibits its activity.
   Methods: A structural model of the LRRK1 kinase domain was constructed with SWISS MODEL. The human protein kinase ROCO4 (PDB ID: 4YZN) was chosen as the template based on sequence homology, structural and phylogenetic analysis. In addition, a homology model of the LRRK1 ROC domain was also prepared based on the LRRK2 ROC domain structure (PDB ID: 2ZEJ). The interactions of IN04 with the active sites in the LRRK1 kinase domain and ROC domain were investigated by SwissDock.
   Results: IN04 was docked into the active site of the LRRK1 kinase domain with similar interactions as ATP comparable to the ligand bound to homologous kinases. Many rational binding modes of IN04 to LRRK1 kinase domain were investigated and the most likely binding pose containing multiple hydrogen bonds and a salt bridge was discovered. However, IN04 cannot fit into the GDP binding site of the ROC domain.
   Conclusion: Chemical IN04 inhibits LRRK1 by binding to the active site of the kinase domain but not the ROC domain.
C1 [Chen, Zhenhang; Fan, Li] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.
   [Xing, Weirong] Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA.
C3 University of California System; University of California Riverside;
   Loma Linda University
RP Fan, L (通讯作者)，Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.; Xing, WR (通讯作者)，Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA.
EM Weirong.xing@va.gov; lifan@ucr.edu
RI ; Chen, Zhenhang/HJP 9062 2023
OI Chen, Zhenhang/0000 0001 5803 9491; 
FU National Insti tutes of Health [1R21AR072831 01, R01GM108893]
FX This work was partially supported by the National Insti tutes of Health
   grant 1R21AR072831 01 (to W.X.) and grant R01GM108893 (to L.F.) .
CR Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Bertoni M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09654 8
   Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Brown K, 2005, J MOL BIOL, V354, P1013, DOI 10.1016/j.jmb.2005.09.098
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Deng JP, 2008, P NATL ACAD SCI USA, V105, P1499, DOI 10.1073/pnas.0709098105
   Gilsbach BK, 2015, J MED CHEM, V58, P3751, DOI 10.1021/jm5018779
   Gilsbach BK, 2012, P NATL ACAD SCI USA, V109, P10322, DOI 10.1073/pnas.1203223109
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Grosdidier A, 2011, J COMPUT CHEM, V32, P2149, DOI 10.1002/jcc.21797
   Guaitoli G, 2016, P NATL ACAD SCI USA, V113, pE4357, DOI 10.1073/pnas.1523708113
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Hudkins RL, 2008, J MED CHEM, V51, P5680, DOI 10.1021/jm8005838
   Iida A, 2016, J MED GENET, V53, P568, DOI 10.1136/jmedgenet 2016 103756
   Kidd LJ, 2011, J ORTHOP RES, V29, P1827, DOI 10.1002/jor.21464
   Li TX, 2014, HUM MOL GENET, V23, P6212, DOI 10.1093/hmg/ddu341
   Marusiak AA, 2016, CANCER RES, V76, P724, DOI 10.1158/0008 5472.CAN 15 0701 T
   Mathea S, 2016, ACS CHEM BIOL, V11, P1595, DOI 10.1021/acschembio.6b00043
   Nase JB, 2006, J AM DENT ASSOC, V137, P1115, DOI 10.14219/jada.archive.2006.0350
   Roskoski R, 2015, PHARMACOL RES, V100, P1, DOI 10.1016/j.phrs.2015.07.010
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Si MJ, 2019, AGING US, V11, P3250, DOI 10.18632/aging.101977
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Xing WR, 2013, J BONE MINER RES, V28, P1962, DOI 10.1002/jbmr.1935
NR 26
TC 0
Z9 0
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
EI 1875 6638
J9 MED CHEM
JI Med. Chem.
PY 2021
VL 17
IS 10
BP 1140
EP 1150
DI 10.2174/1573406416666200924125620
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UR8JV
UT WOS:000696989400005
PM 32972350
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Kamalakar, A
   Bendre, MS
   Washam, CL
   Fowler, TW
   Carver, A
   Dilley, JD
   Bracey, JW
   Akel, NS
   Margulies, AG
   Skinner, RA
   Swain, FL
   Hogue, WR
   Montgomery, CO
   Lahiji, P
   Maher, JJ
   Leitzel, KE
   Ali, SM
   Lipton, A
   Nicholas, RW
   Gaddy, D
   Suva, LJ
AF Kamalakar, Archana
   Bendre, Manali S.
   Washam, Charity L.
   Fowler, Tristan W.
   Carver, Adam
   Dilley, Joshua D.
   Bracey, John W.
   Akel, Nisreen S.
   Margulies, Aaron G.
   Skinner, Robert A.
   Swain, Frances L.
   Hogue, William R.
   Montgomery, Corey O.
   Lahiji, Parshawn
   Maher, Jacqueline J.
   Leitzel, Kim E.
   Ali, Suhail M.
   Lipton, Alan
   Nicholas, Richard W.
   Gaddy, Dana
   Suva, Larry J.
TI Circulating interleukin 8 levels explain breast cancer osteolysis in
   mice and humans
SO BONE
LA English
DT Article
DE Osteoclast; Therapy; Chemokine; Osteolysis
ID BONE METASTASES; PROSTATE CANCER; STEM CELLS; THERAPEUTIC OPPORTUNITIES;
   SERUM INTERLEUKIN 8; CARCINOMA CELLS; GROWTH FACTOR; MECHANISMS;
   EXPRESSION; IDENTIFICATION
AB Skeletal metastases of breast cancer and subsequent osteolysis connote a dramatic change in the prognosis for the patient and significantly increase the morbidity associated with disease. The cytokine interleukin 8 (IL 8/CXCL8) is able to directly stimulate osteoclastogenesis and bone resorption in mouse models of breast cancer bone metastasis. In this study, we determined whether circulating levels of IL 8 were associated with increased bone resorption and breast cancer bone metastasis in patients and investigated IL 8 action in vitro and in vivo in mice. Using breast cancer patient plasma (36 patients), we identified significantly elevated IL 8 levels in bone metastasis patients compared with patients lacking bone metastasis (p < 0.05), as well as a correlation between plasma IL 8 and increased bone resorption (p < 0.05), as measured by NTx levels. In a total of 22 ER+ and 15 ER   primary invasive ductal carcinomas, all cases examined stained positive for IL 8 expression. In vitro, human MDA MB 231 and MDA MET breast cancer cell lines secrete two distinct IL 8 isoforms, both of which were found to stimulate osteoclastogenesis. However, the more osteolytic MDA MET derived full length IL 8(1 77) had significantly higher potency than the non osteolytic MDA MB 231 derived IL 8(6 77), via the CXCR1 receptor. MDA MET breast cancer cells were injected into the tibia of nude mice and 7 days later treated daily with a neutralizing IL 8 monoclonal antibody. All tumor injected mice receiving no antibody developed large osteolytic bone tumors, whereas 83% of the IL 8 antibody treated mice had no evidence of tumor at the end of 28 days and had significantly increased survival. The pro osteoclastogenic activity of IL 8 in vivo was confirmed when transgenic mice expressing human IL 8 were examined and found to have a profound osteopenic phenotype, with elevated bone resorption and inherently low bone mass. Collectively, these data suggest that IL 8 plays an important role in breast cancer osteolysis and that anti IL 8 therapy may be useful in the treatment of the skeletal related events associated with breast cancer. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Kamalakar, Archana; Bendre, Manali S.; Washam, Charity L.; Fowler, Tristan W.; Carver, Adam; Dilley, Joshua D.; Bracey, John W.; Skinner, Robert A.; Swain, Frances L.; Hogue, William R.; Montgomery, Corey O.; Nicholas, Richard W.; Gaddy, Dana; Suva, Larry J.] Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA.
   [Fowler, Tristan W.; Akel, Nisreen S.; Gaddy, Dana; Suva, Larry J.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.
   [Margulies, Aaron G.] Knoxville Comprehens Breast Ctr, Knoxville, TN USA.
   [Lahiji, Parshawn; Maher, Jacqueline J.] Univ Calif San Francisco, Ctr Liver, San Francisco Gen Hosp, Div Gastroenterol, San Francisco, CA 94143 USA.
   [Leitzel, Kim E.; Ali, Suhail M.; Lipton, Alan] Penn State Univ, Penn State Hershey Med Ctr, Hershey Canc Inst, Div Oncol, Hershey, PA USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of California System; University of California San Francisco;
   San Francisco General Hospital Medical Center; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Pennsylvania State University; Penn
   State Health
RP Suva, LJ (通讯作者)，Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, 4301 West Markham St, Little Rock, AR 72205 USA.
EM suvalarryj@uams.edu
OI Suva, Larry/0000 0002 2892 9757
FU NIH [R01 CA166060 01A1]; AR Breast Cancer Research Program (ABCRP); Carl
   L. Nelson Chair of Orthopaedic Creativity; ABCRP; UAMS Translational
   Research Institute (TRI) (CTSA grant award) [1 UL1TR000039]; National
   Institute of Diabetes and Digestive and Kidney Diseases [P30DK026743]
   Funding Source: NIH RePORTER
FX This work was supported by NIH R01 CA166060 01A1 (LJS), a Pilot grant
   from AR Breast Cancer Research Program (ABCRP) (LJS), the Carl L. Nelson
   Chair of Orthopaedic Creativity (LJS), a Graduate Studentship from the
   ABCRP (CLW), and the UAMS Translational Research Institute (TRI) (CTSA
   grant award #1 UL1TR000039) and is dedicated to the memory of the late
   Dr. Carl L. Nelson.
CR Aalinkeel R, 2004, CANCER RES, V64, P5311, DOI 10.1158/0008 5472.CAN 2506 2
   BenBaruch A, 1997, CYTOKINE, V9, P37, DOI 10.1006/cyto.1996.0133
   BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bendre MS, 2002, CANCER RES, V62, P5571
   Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078 0432.CCR 04 0812
   Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Charafe Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008 5472.CAN 08 2741
   Chung HW, 2013, CANCER AM CANCER SOC, V119, P233, DOI 10.1002/cncr.27669
   Coleman RE, 2009, EUR J CANCER, V45, P1909, DOI 10.1016/j.ejca.2009.04.022
   De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002 9440(10)64005 9
   Ewington L, 2012, CYTOKINE, V59, P417, DOI 10.1016/j.cyto.2012.04.036
   Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008 5472.CAN 11 0156
   Fowler TW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042967
   Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397
   Glover SJ, 2009, J BONE MINER RES, V24, P389, DOI 10.1359/JBMR.080703
   Hanson JC, 2006, J HEPATOL, V44, P359, DOI 10.1016/j.jhep.2005.06.022
   Kelly T, 2005, CANCER RES, V65, P5778, DOI 10.1158/0008 5472.CAN 05 0749
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Korkaya H, 2013, CLIN CANCER RES, V19, P511, DOI 10.1158/1078 0432.CCR 12 3450
   Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099
   Lehrer S, 2004, TECHNOL CANCER RES T, V3, P411, DOI 10.1177/153303460400300501
   Li KC, 2012, ORAL ONCOL, V48, P507, DOI 10.1016/j.oraloncology.2012.01.006
   Lin Y, 2004, INT J CANCER, V109, P507, DOI 10.1002/ijc.11724
   Lu Y, 2007, CANCER RES, V67, P3646, DOI 10.1158/0008 5472.CAN 06 1210
   Moscova M, 2006, CANCER RES, V66, P1376, DOI 10.1158/0008 5472.CAN 05 2666
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Salcedo R, 2002, CLIN CANCER RES, V8, P2655
   SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450
   Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078 0432.CCR 12 1063
   St John MAR, 2004, ARCH OTOLARYNGOL, V130, P929, DOI 10.1001/archotol.130.8.929
   Suva LJ, 2008, AM J PATHOL, V172, P430, DOI 10.2353/ajpath.2008.070417
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Suva Larry J, 2010, Curr Osteoporos Rep, V8, P57, DOI 10.1007/s11914 010 0012 5
   Suva LJ, 2009, ENDOCR RELAT CANCER, V16, P703, DOI 10.1677/ERC 09 0012
   Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432 1033.2003.03760.x
   Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681
   VANDAMME J, 1989, EUR J IMMUNOL, V19, P2367
   Washam CL, 2013, CANCER EPIDEM BIOMAR, V22, P972, DOI 10.1158/1055 9965.EPI 12 1318 T
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Zakrzewska Irena, 2002, Pol Merkur Lekarski, V13, P302
   Zhu YM, 2004, BRIT J CANCER, V91, P1970, DOI 10.1038/sj.bjc.6602227
NR 47
TC 51
Z9 58
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2014
VL 61
BP 176
EP 185
DI 10.1016/j.bone.2014.01.015
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AC8WL
UT WOS:000332815700023
PM 24486955
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Margulies, BS
   Horton, JA
   Wang, Y
   Damron, TA
   Allen, MJ
AF Margulies, B. S.
   Horton, J. A.
   Wang, Y.
   Damron, T. A.
   Allen, M. J.
TI Effects of radiation therapy on chondrocytes in vitro
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE chondrocyte; cell growth; growth factor; cell differentiation; apoptosis
ID GROWTH PLATE CHONDROCYTES; TERMINAL DIFFERENTIATION; IRRADIATION;
   PROLIFERATION; EXPRESSION; DAMAGE; PTHRP; FGF2
AB The negative irradiation complications of growth loss leading to limb length asymmetry and pathological fracture incurred following radiation therapy in pediatric patients has led to a renewed interest in understanding the specific effects of irradiation on the growth plate and the surrounding bone. In the present report, we examined the radiation therapy effects on primary rat growth cartilage chondrocytes in order to determine the chondrocyte radiosensitivity relative to other bone cell constituents and tumor cells, the postirradiation temporal progression of radiation induced alterations in chondrocyte function, and the time course for the functional restoration of chondrocyte pathways that drive the eventual recovery in growth function. We employed an in vitro primary rat costochondral growth cartilage cell culture model system to evaluate the radiation therapy effects on proliferative chondrocytes using serial radiation doses (0 20 Gy) that are well within the clinically relevant range. Following irradiation, all of the following occurred in a dose dependent manner: proliferation decreased, cytotoxicity increased, several markers of apoptosis increased, markers of radiation induced cellular differentiation increased, and cell synthetic activity was disturbed. Alterations in proliferation, cell death, and induction of apoptosis are likely due to a transient radiation induced derangement of the parathyroid hormone related protein Indian hedgehog proliferation maturation pathway. Alterations in cellular differentiation and cell synthetic activity are novel observations for chondrocytes. Further, these results correspond very well to our previous work in an in vivo Sprague Dawley rat model, making this model particularly relevant to researching the radiation therapy effects on longitudinal growth.
C1 SUNY Syracuse, Dept Orthoped Surg, Syracuse, NY 13210 USA.
C3 State University of New York (SUNY) System
RP Margulies, BS (通讯作者)，SUNY Syracuse, Dept Orthoped Surg, 505 Irving Ave, Syracuse, NY 13210 USA.
EM margulib@upstate.edu
RI Damron, Timothy/AAE 5816 2020
OI Horton, Jason A/0000 0003 3396 5063
FU NCCIH NIH HHS [F31 AT01994] Funding Source: Medline; NCI NIH HHS [2R01
   CA083892] Funding Source: Medline
CR Alvarez J, 2002, DEVELOPMENT, V129, P1913
   Beier F, 2005, J CELL PHYSIOL, V202, P1, DOI 10.1002/jcp.20111
   BUTLER MS, 1990, CLIN ORTHOP RELAT R, V251, P235
   CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148
   Damron TA, 2004, J HISTOCHEM CYTOCHEM, V52, P157, DOI 10.1177/002215540405200203
   Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623 200307000 00017
   Damron TA, 2001, INT J RADIAT ONCOL, V50, P479, DOI 10.1016/S0360 3016(01)01532 2
   Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695
   Erez N, 2004, FEBS LETT, V567, P311, DOI 10.1016/j.febslet.2004.05.003
   Gustafsson E, 2003, ANN NY ACAD SCI, V995, P140, DOI 10.1111/j.1749 6632.2003.tb03217.x
   Hiranuma H, 1996, BONE, V18, P233, DOI 10.1016/8756 3282(95)00478 5
   Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432 1033.2003.03846.x
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Koscielniak Ewa, 2002, Paediatr Drugs, V4, P21, DOI 10.2165/00148581 200204010 00003
   Krejci P, 2004, EXP CELL RES, V297, P152, DOI 10.1016/j.yexcr.2004.03.011
   Laplantine E, 2002, J CELL BIOL, V158, P741, DOI 10.1083/jcb.200205025
   MARGULIES B, 2003, T ORTH RES SOC M NEW
   Margulies Bryan, 2003, Am J Clin Oncol, V26, pe106, DOI 10.1097/00000421 200308000 00032
   Merchant TE, 1999, MED PEDIATR ONCOL, V33, P65, DOI 10.1002/(SICI)1096 911X(199908)33:2<65::AID MPO1>3.0.CO;2 L
   Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696 233
   Olney RC, 2004, BIOCHEM BIOPH RES CO, V317, P1171, DOI 10.1016/j.bbrc.2004.03.170
   Pateder DB, 2002, RADIAT RES, V157, P62, DOI 10.1667/0033 7587(2002)157[0062:ROPIPR]2.0.CO;2
   Pateder DB, 2001, RADIAT RES, V155, P847, DOI 10.1667/0033 7587(2001)155[0847:TROAGF]2.0.CO;2
   Roederer M, 2001, CYTOMETRY, V45, P37, DOI 10.1002/1097 0320(20010901)45:1<37::AID CYTO1142>3.0.CO;2 E
   Ruchon AF, 2000, J BONE MINER RES, V15, P1266, DOI 10.1359/jbmr.2000.15.7.1266
   TRIPPEL SB, 1993, J BONE JOINT SURG AM, V75A, P177, DOI 10.2106/00004623 199302000 00004
   Wall JE, 1996, ORTHOPEDICS, V19, P657
   Weksler NB, 1999, BIOCHEM J, V342, P677, DOI 10.1042/0264 6021:3420677
NR 28
TC 25
Z9 27
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD MAY
PY 2006
VL 78
IS 5
BP 302
EP 313
DI 10.1007/s00223 005 0135 3
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 042BF
UT WOS:000237501400006
PM 16691495
DA 2025 08 17
ER

PT J
AU Liu, YN
   Yang, CX
   Li, ZF
   Zhou, JL
   Lv, YN
   Zhang, Y
   Zeng, FD
   Shi, SJ
AF Liu, Yani
   Yang, Chunxiao
   Li, Zhongfang
   Zhou, Jiali
   Lv, Yongning
   Zhang, Yu
   Zeng, Fandian
   Shi, Shaojun
TI Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of
   Recombinant Human Parathyroid Hormone (1 34) in Healthy Chinese Subjects
SO CLINICAL THERAPEUTICS
LA English
DT Article
DE pharmacodynamic parameters; pharmacokinetic parameters; recombinant
   human parathyroid hormone (1 34); safety profile; tolerability
ID BONE MINERAL DENSITY; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   POSTMENOPAUSAL WOMEN; TERIPARATIDE; ALENDRONATE; VOLUNTEERS; SINGLE;
   EXPERIENCE; FRACTURES; EFFICACY
AB Background: The recombinant human parathyroid hormone (1 34) (rhPTH[1 34]) teriparatide is the first anabolic agent approved by the US Food and Drug Administration for the treatment of osteoporosis in men and women. This study was conducted to provide support for marketing authorization of an agent biosimilar to teriparatide in China.
   Objective: The main aim of the present study was to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic parameters of rhPTH(1 34) after single and multiple subcutaneous doses in healthy Chinese subjects.
   Methods: Two open label, randomized, single center, dose escalation studies were performed. In study 1, subjects were randomized to receive a single dose of rhPTH(1 34) (10, 20, 30, 40, 50, or 60 mu g) or a multiple dose of rhPTH(1 34) (10 and 20 mu g once daily for 7 consecutive days) to determine the safety profile and tolerability, as reflected by the incidence, intensity, and seriousness of the observed adverse events. In study 2, a single dose of rhPTH(1 34) (10, 20, or 40 mu g) and a multiple dose of rhPTH(1 34) (20 mu g) were administrated subcutaneously to investigate the pharmacokinetic and pharmacodynamic parameters.
   Results: Forty two subjects completed study 1, and 30 subjects completed study 2. rhPTH(1 34) was well tolerated during the investigated single (10 60 mu g) and multiple (10 20 mu g once daily for 7 consecutive days) dose ranges. The most generally reported adverse events were erythema at the injection site and gastrointestinal reactions. After single and multiple subcutaneous administration of rhPTH(1 34), the drug was rapidly absorbed, with a T max of 20 to 30 minutes, and rapidly cleared from the plasma, with a t(1/2), of 47.2 to 60.6 minutes. The mean C max, AUC(0 t), and AUC(0 infinity), increased in proportion to the doses, whereas the t(1/2), total clearance, and T max values were independent of the administered dose. No significant differences in pharmacokinetic parameters were noted by sex except for Tmax in the 10 mu g and 20 mu g single dose groups. Compared with the baseline levels, no significant changes or dose related significant effects were observed in serum calcium and phosphate levels.
   Conclusions: All rhPTH(1 34) doses appeared to be well tolerated in the population studied. Linear pharmacokinetic characteristics were displayed in the dose range studied. Chinese ClinicalTrials.gov identifier: ChiCTR ONC 12002874. (C) 2014 Elsevier HS Journals, Inc. All rights reserved.
C1 [Liu, Yani; Yang, Chunxiao; Li, Zhongfang; Zhou, Jiali; Lv, Yongning; Zhang, Yu; Zeng, Fandian; Shi, Shaojun] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Res Org Pharmaceut Prod, Wuhan 430022, Peoples R China.
   [Zeng, Fandian] Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Clin Pharmacol, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Shi, SJ (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Res Org Pharmaceut Prod, 1277 Jiefang Ave, Wuhan 430022, Peoples R China.
EM sjshicn@163.com
RI LIU, Yani/ISB 3249 2023; Zhang, Yu/U 2723 2017; Shi,
   Shaojun/IZD 9784 2023
FU Shanghai Shenjiu Medpharm Biotech Co, Ltd, Shanghai, China
FX This research was funded by Shanghai Shenjiu Medpharm Biotech Co, Ltd,
   Shanghai, China. The sponsor had no influence in the study design,
   conduct, monitoring, analysis, presentation, or publication of the
   results. There were no benefits from commercial sources for the work
   reported in this article. The authors would like to thank the subjects
   who participated in the study. The authors declare that they have no
   conflicts of interest.
CR Anastasilakis AD, 2008, ENDOCR J, V55, P613, DOI 10.1507/endocrj.K07E 123
   [Anonymous], 2004, FORT TER PACK INS
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Bogado CE, 2006, WOMENS HEALTH, V2, P447, DOI 10.2217/17455057.2.3.447
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Chen JD, 2011, GI MOTILITY TESTING: A LABORATORY AND OFFICE HANDBOOK, P81
   Cheng Marilyn Lee, 2012, Indian J Endocrinol Metab, V16, P343, DOI 10.4103/2230 8210.95661
   Chu NN, 2007, PHARMAZIE, V62, P869, DOI 10.1691/ph.2007.11.7576
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cusano NE, 2012, ENDOCRIN METAB CLIN, V41, P643, DOI 10.1016/j.ecl.2012.04.005
   *EUR MED AG, ICH TOP E 6 R1 GUID
   European Medicines Agency, 2006, GUID SIM BIOL MED PR
   File Elizabeth, 2009, Curr Rheumatol Rep, V11, P169
   FRAHER LJ, 1995, J CLIN ENDOCR METAB, V80, P60, DOI 10.1210/jc.80.1.60
   Hu ZP, 2006, INT J PHARMACEUT, V317, P144, DOI 10.1016/j.ijpharm.2006.03.005
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jones KO, 2006, J PHARM SCI US, V95, P2499, DOI 10.1002/jps.20720
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lasco A, 2011, OSTEOPOROSIS INT, V22, P299, DOI 10.1007/s00198 010 1222 5
   LINDSAY R, 1993, J CLIN ENDOCR METAB, V77, P1535, DOI 10.1210/jc.77.6.1535
   Liu Y, 2012, BASIC CLIN PHARMACOL, V110, P154, DOI 10.1111/j.1742 7843.2011.00768.x
   Marcus R, 2003, J BONE MINER RES, V18, P18, DOI 10.1359/jbmr.2003.18.1.18
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Michalska D, 2012, OSTEOPOROSIS INT, V23, P2885, DOI 10.1007/s00198 012 1955 4
   Nabanita S., 2011, WORLD J ORTHOP, V2, P67
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Papapoulos S, 2008, NAT CLIN PRACT ENDOC, V4, P514, DOI 10.1038/ncpendmet0941
   Prevrhal S, 2009, CURR MED RES OPIN, V25, P921, DOI 10.1185/03007990902790993 
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Schwietert HR, 1997, CLIN PHARMACOL THER, V61, P360, DOI 10.1016/S0009 9236(97)90169 7
   Serada M, 2012, XENOBIOTICA, V42, P398, DOI 10.3109/00498254.2011.622811
   Sethi B K, 2008, J Assoc Physicians India, V56, P418
   Shiraki M, 2013, OSTEOPOROSIS INT, V24, P219, DOI 10.1007/s00198 012 2159 7
   Stroup J, 2008, AM J HEALTH SYST PH, V65, P532, DOI 10.2146/ajhp070171
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tsujimoto M, 2012, J BONE MINER METAB, V30, P326, DOI 10.1007/s00774 011 0314 4
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Veterinary Medicine, 2001, Bioanalytical method validation
   Wang Y, 2009, OSTEOPOROSIS INT, V20, P1651, DOI 10.1007/s00198 009 0925 y
   Xia WB, 2012, J BONE MINER RES, V27, P125, DOI 10.1002/jbmr.519
NR 42
TC 8
Z9 9
U1 0
U2 18
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202 206, BRIDGEWATER, NJ 08807 USA
SN 0149 2918
EI 1879 114X
J9 CLIN THER
JI Clin. Ther.
PD JUN
PY 2014
VL 36
IS 6
BP 940
EP 952
DI 10.1016/j.clinthera.2014.03.015
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AK5QR
UT WOS:000338481600012
PM 24793535
DA 2025 08 17
ER

PT J
AU Ariji, Y
   Ariji, E
AF Ariji, Yoshiko
   Ariji, Eiichiro
TI Role of magnetic resonance imaging in diagnosis of
   bisphosphonate related osteonecrosis of the jaw
SO ORAL RADIOLOGY
LA English
DT Article
DE MRI; Bisphosphonate related osteonecrosis; Jaw
ID BIPHOSPHONATE INDUCED OSTEONECROSIS; AVASCULAR NECROSIS; MRI SPECTRUM;
   PREVENTION; SECONDARY; THERAPY; CANCER; CT
AB To clarify the magnetic resonance (MR) imaging features of bisphosphonate related osteonecrosis of the jaw (BRONJ), particularly those in the early stage, through a literature review and case analysis.
   Literature on MR imaging of BRONJ was collected, and the MR imaging features were summarized. On MR images of patients with BRONJ, the signal intensity of the bone marrow was evaluated quantitatively by means of the contrast to noise ratio (CNR). The relationships of the imaging features with the presence of exposed bone, types and administration routes of bisphosphonates (BP), and duration of symptoms were investigated.
   Fifteen articles were identified. In the early stages, the region of osteonecrosis displayed decreased signal intensity on T1 weighted images and normal signal intensity on T2 weighted images. In the late stages, the signal intensity of the bone marrow on T2 weighted images was variable: the exposed diseased bone displayed decreased signal intensity, and the unexposed diseased bone displayed increased signal intensity. These changes were also seen in BRONJ cases. There was a significant difference in the CNR between the exposed and unexposed diseased bones on STIR images. There were no significant differences in the CNR among the three groups by types and administration routes of BP, both on T1 weighted and STIR images. Changes in the signal intensity of bone marrow were seen at the early duration of symptoms. In the early stage, the CNR on T1 weighted images had a significant correlation with duration of symptoms.
   MR imaging may provide visualization of useful features in the early stage of BRONJ.
C1 [Ariji, Yoshiko; Ariji, Eiichiro] Aichi Gakuin Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, Chikusa Ku, Nagoya, Aichi 4648651, Japan.
C3 Aichi Gakuin University
RP Ariji, Y (通讯作者)，Aichi Gakuin Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, Chikusa Ku, 2 11 Suemori Dori, Nagoya, Aichi 4648651, Japan.
EM yoshiko@dpc.agu.ac.jp
RI Ariji, Eiichiro/AAD 9857 2021
OI Ariji, Eiichiro/0000 0002 5245 5395
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Arce K, 2009, J ORAL MAXIL SURG, V67, P75, DOI 10.1016/j.joms.2008.12.002
   Ariji Y, 2008, ORAL SURG ORAL MED O, V105, P503, DOI 10.1016/j.tripleo.2007.04.029
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bantis A, 2011, TUMORI J, V97, P479, DOI 10.1700/950.10401
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Bisdas S, 2008, CLIN RADIOL, V63, P71, DOI 10.1016/j.crad.2007.04.023
   Carter G, 2005, MED J AUSTRALIA, V182, P413, DOI 10.5694/j.1326 5377.2005.tb06761.x
   Chiandussi S, 2006, DENTOMAXILLOFAC RAD, V35, P236, DOI 10.1259/dmfr/27458726
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   Dore F, 2009, J NUCL MED, V50, P30, DOI 10.2967/jnumed.107.048785
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   García Ferrer L, 2008, AM J ROENTGENOL, V190, P949, DOI 10.2214/AJR.07.3045
   Gill SB, 2009, J COMPUT ASSIST TOMO, V33, P449, DOI 10.1097/RCT.0b013e318186b179
   Gonzalez Moles MA, 2000, J ORAL PATHOL MED, V29, P514, DOI 10.1034/j.1600 0714.2000.291006.x
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Krishnan A, 2009, J COMPUT ASSIST TOMO, V33, P298, DOI 10.1097/RCT.0b013e31817e4986
   Kumar Satish K S, 2008, J Contemp Dent Pract, V9, P63
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Morag Y, 2009, RADIOGRAPHICS, V29, P1971, DOI 10.1148/rg.297095050
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Schubert M, 2012, ORAL ONCOL, V48, P349, DOI 10.1016/j.oraloncology.2011.11.004
   Stockmann P, 2010, CLIN ORAL INVEST, V14, P311, DOI 10.1007/s00784 009 0293 1
   Urade M, 2011, J ORAL MAXIL SURG, V69, pE364, DOI 10.1016/j.joms.2011.03.051
   Wass JAH, 2008, CLIN RADIOL, V63, P78, DOI 10.1016/j.crad.2007.07.016
   Wellington K, 2003, DRUGS, V63, P417, DOI 10.2165/00003495 200363040 00009
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wutzl A, 2006, WIEN KLIN WOCHENSCHR, V118, P473, DOI 10.1007/s00508 006 0644 8
   Yoneda T, 2010, J BONE MINER METAB, V28, P365, DOI 10.1007/s00774 010 0162 7
NR 31
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0911 6028
EI 1613 9674
J9 ORAL RADIOL
JI Oral Radiol.
PD JUL
PY 2013
VL 29
IS 2
BP 111
EP 120
DI 10.1007/s11282 013 0124 6
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 180YS
UT WOS:000321635800004
DA 2025 08 17
ER

PT J
AU Mackey, AL
   Kjaer, M
   Dandanell, S
   Mikkelsen, KH
   Holm, L
   Dossing, S
   Kadi, F
   Koskinen, SO
   Jensen, CH
   Schroder, HD
   Langberg, H
AF Mackey, Abigail L.
   Kjaer, Michael
   Dandanell, Sune
   Mikkelsen, Kristian H.
   Holm, Lars
   Dossing, Simon
   Kadi, Fawzi
   Koskinen, Satu O.
   Jensen, Charlotte H.
   Schroder, Henrik D.
   Langberg, Henning
TI The influence of anti inflammatory medication on exercise induced
   myogenic precursor cell responses in humans
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE skeletal muscle; nonsteroidal anti inflammatory drug; running; neural
   cell adhesion molecule; fetal antigen 1
ID HUMAN SKELETAL MUSCLE; SATELLITE CELL; BLOOD FLOW; OLDER MEN; TRAPEZIUS
   MUSCLE; NITRIC OXIDE; STEM CELLS; PROLIFERATION; GROWTH; EXPRESSION
AB The consumption of nonsteroidal anti inflammatory drugs ( NSAIDs) is widespread among athletes when faced with muscle soreness or injury, but the effects of NSAIDs on satellite cell activity in humans are unknown. To investigate this, 14 healthy male endurance athletes ( mean peak oxygen consumption 62 ml.kg( 1).min( 1)) volunteered for the study, which involved running 36 km. They were divided into two groups and received either 100 mg indomethacin per day or placebo. Muscle biopsies collected before the run and on days 1, 3, and 8 afterward were analyzed for satellite cells by immunohistochemistry with the aid of neural cell adhesion molecule ( NCAM) and fetal antigen 1 ( FA1) antibodies. Muscle biopsies were also collected from untrained individuals for comparison. Compared with preexercise levels, a 27% increase in the number of NCAM+ cells was observed on day 8 postexercise in the placebo group ( P < 0.05), while levels remained similar at all time points in the NSAID group. No change was seen in the proportion of FA1+ cells, although lower levels were found in the muscle of endurance trained athletes compared with untrained individuals ( P < 0.05). These results suggest that ingestion of antiinflammatory drugs attenuates the exercise induced increase in satellite cell number, supporting the role of the cyclooxygenase pathway in satellite cell activity.
C1 Bispebjerg Hosp, Inst Sports Med Copenhagen, DK 2400 Copenhagen N, Denmark.
   Univ Orebro, Dept Phys Educ & Hlth, S 70130 Orebro, Sweden.
   Univ So Denmark, Dept Immunol & Microbiol, Odense, Denmark.
   Odense Univ Hosp, Dept Pathol, DK 5000 Odense, Denmark.
C3 University of Copenhagen; Bispebjerg Hospital; Copenhagen University
   Hospital; Orebro University; University of Southern Denmark; University
   of Southern Denmark; Odense University Hospital
RP Mackey, AL (通讯作者)，Bispebjerg Hosp, Inst Sports Med Copenhagen, Bldg 8,Bispebjerg Bakke 23, DK 2400 Copenhagen N, Denmark.
EM abigail.mackey@gmail.com
RI ; Holm, Lars/G 8181 2017; Schroder, Henrik Daa/E 2077 2013; Jensen,
   Charlotte Harken/P 4612 2014; Schrøder, Henrik/E 2077 2013; Mackey,
   Abigail/D 1060 2009; Kadi, Fawzi/LDV 8063 2024; Kjaer,
   Michael/W 6842 2019; Jensen, Charlotte/P 4612 2014
OI Kjaer, Michael/0000 0002 4582 8755; Holm, Lars/0000 0002 4392 9616;
   Schroder, Henrik Daa/0000 0001 7588 235X; Jensen, Charlotte
   Harken/0000 0001 9683 8761; Mackey, Abigail/0000 0002 2017 4580;
   Langberg, Henning/0000 0001 8454 6534; kadi, fawzi/0000 0002 9831 0896
CR ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211
   ALMEKINDERS LC, 1986, AM J SPORT MED, V14, P303, DOI 10.1177/036354658601400411
   Anderson JE, 2004, CAN J PHYSIOL PHARM, V82, P300, DOI 10.1139/Y04 020
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Boushel R, 2004, CURR VASC PHARMACOL, V2, P191, DOI 10.2174/1570161043476410
   Charifi N, 2003, MUSCLE NERVE, V28, P87, DOI 10.1002/mus.10394
   Clarkson PM, 2002, AM J PHYS MED REHAB, V81, pS52, DOI [10.1097/00002060 200211001 00007, 10.1097/01.PHM.0000029772.45258.43]
   Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721
   Crameri RM, 2004, J PHYSIOL LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   Dreyer HC, 2006, MUSCLE NERVE, V33, P242, DOI 10.1002/mus.20461
   Eriksson A, 2005, HISTOCHEM CELL BIOL, V124, P167, DOI 10.1007/s00418 005 0029 5
   Floridon C, 2000, DIFFERENTIATION, V66, P49, DOI 10.1046/j.1432 0436.2000.066001049.x
   Grounds MD, 2002, J HISTOCHEM CYTOCHEM, V50, P589, DOI 10.1177/002215540205000501
   Hawke TJ, 2005, EXERC SPORT SCI REV, V33, P63, DOI 10.1097/00003677 200504000 00002
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   Hikida RS, 1998, BASIC APPL MYOL, V8, P419
   Hill M, 2003, J PHYSIOL LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832
   Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028
   Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265
   Kadi F, 2005, PFLUG ARCH EUR J PHY, V451, P319, DOI 10.1007/s00424 005 1406 6
   Kadi F, 2004, J PHYSIOL LONDON, V558, P1005, DOI 10.1113/jphysiol.2004.065904
   Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012
   Kadi F, 1999, HISTOCHEM CELL BIOL, V111, P189, DOI 10.1007/s004180050348
   Kalliokoski KK, 2006, AM J PHYSIOL REG I, V291, pR803, DOI 10.1152/ajpregu.00808.2005
   Langberg H, 2003, J PHYSIOL LONDON, V551, P683, DOI 10.1113/jphysiol.2003.046094
   Mackey AL, 2007, SCAND J MED SCI SPOR, V17, P34, DOI 10.1111/j.1600 0838.2006.00534.x
   Mahler N, 2001, Ther Umsch, V58, P226, DOI 10.1024/0040 5930.58.4.226
   Malm C, 2000, J PHYSIOL LONDON, V529, P243, DOI 10.1111/j.1469 7793.2000.00243.x
   Malm C, 2004, J PHYSIOL LONDON, V556, P983, DOI 10.1113/jphysiol.2003.056598
   MCLENNAN IS, 1987, J EXP ZOOL, V241, P237, DOI 10.1002/jez.1402410210
   Mendias CL, 2004, MUSCLE NERVE, V30, P497, DOI 10.1002/mus.20102
   MESSINA EJ, 1975, CIRC RES, V37, P430, DOI 10.1161/01.RES.37.4.430
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   Olsen S, 2006, J PHYSIOL LONDON, V573, P525, DOI 10.1113/jphysiol.2006.107359
   Petrella JK, 2006, AM J PHYSIOL ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006
   Rabinovsky ED, 2002, FASEB J, V16, P53, DOI 10.1096/fj.02 0183fje
   Roth SM, 2001, J GERONTOL A BIOL, V56, pB240, DOI 10.1093/gerona/56.6.B240
   Roth SM, 2000, ANAT REC, V260, P351, DOI 10.1002/1097 0185(200012)260:4<350::AID AR30>3.0.CO;2 6
   SCHULTZ E, 1985, MECH AGEING DEV, V30, P63, DOI 10.1016/0047 6374(85)90059 4
   SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904
   Shibuya Seiji, 2003, Medical Electron Microscopy, V36, P213, DOI 10.1007/s00795 003 0227 y
   Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028
   Tatsumi R, 2006, AM J PHYSIOL CELL PH, V290, pC1487, DOI 10.1152/ajpcell.00513.2005
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01 0390rev
   Thorsson O, 1998, AM J SPORT MED, V26, P172, DOI 10.1177/03635465980260020401
   TRAPPE TA, 2002, AM J PHYSIOL ENDOC M, V282, pR551
   Verdijk LB, 2007, AM J PHYSIOL ENDOC M, V292, pE151, DOI 10.1152/ajpendo.00278.2006
   Warner DC, 2002, J ADOLESCENT HEALTH, V30, P150, DOI 10.1016/S1054 139X(01)00325 1
   ZALIN RJ, 1987, EXP CELL RES, V172, P265, DOI 10.1016/0014 4827(87)90386 7
   ZALIN RJ, 1977, DEV BIOL, V59, P241, DOI 10.1016/0012 1606(77)90258 5
NR 50
TC 148
Z9 169
U1 0
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
EI 1522 1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD AUG
PY 2007
VL 103
IS 2
BP 425
EP 431
DI 10.1152/japplphysiol.00157.2007
PG 7
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 196CP
UT WOS:000248459600006
PM 17463304
DA 2025 08 17
ER

PT J
AU Chen, Y
   Zhu, XW
   Lai, WF
   Liu, YP
   Xu, XF
   Liu, LM
   Chen, YJ
   Zhang, CF
   Wang, GY
   Cheng, ZQ
   Liu, DZ
AF Chen, Yong
   Zhu, Xing wang
   Lai, Wing Fu
   Liu, Yong pu
   Xu, Xuan feng
   Liu, Li ming
   Chen, Yan juan
   Zhang, Chuan fu
   Wang, Guang yi
   Cheng, Zhi qiang
   Liu, Dong zhou
TI Gancao Nourishing Yin decoction combined with methotrexate in
   treatment of aging CIA mice: a study based on DIA proteomic analysis
SO CHINESE MEDICINE
LA English
DT Article
DE Traditional chinese medicine; Aging; Rheumatoid arthritis; Integrative
   treatment; Synergic action
ID COLLAGEN INDUCED ARTHRITIS; RHEUMATOID ARTHRITIS
AB Background Elderly rheumatoid arthritis (ERA) population faces multiple treatment dilemma. Here we aim to investigate if Gancao Nourishing Yin decoction (GCNY) added to methotrexate (MTX) exhibit better effects in an ERA mice model.
   Methods ERA mice model was established by adding D galactose (Dgal) to collagen induced arthritis (CIA) mice. The model was then assigned into control group (CIA + Dgal), MTX treatment group (MTX), GCNY treatment group (GCNY), and integrative treatment group (MTX + GCNY). Pathological scoring was performed to evaluate the severity between the groups. Proteomic analysis was applied to investigate the secretory phenotype of the ERA mouse model and the underlying mechanism of GCNY, MTX and their combination. Representative cytokines related to proteomic results were further validated by ELISAs.
   Results CIA + Dgal mice showed more aggressive joints damage than the CIA mice. Besides changes in the inflammatory pathway such as Pi3k Akt signaling pathway in both model, differential expressed proteins (DEPs) indicated metabolism related pathways were more obvious in CIA + Dgal mice. Low dose MTX failed to show pathological improvement in CIA + Dgal mice, while GCNY improved joints damage significantly. Besides down regulated inflammation related targets, GCNY regulated DEPs (such as Apoc1 similar to 3, Grk2 and Creb3l3) were broadly enriched in metabolism related pathways. MTX + GCNY showed the best therapeutic effect, and the DEPs enriched in a variety of inflammatory,metabolism and osteoclast differentiation signaling pathway. Notably, MTX + GCNY treatment up regulated Dhfr, Cbr1, Shmt1 involved in folic acid biosynthesis and anti folate resistance pathways indicated a coincidence synergic action. ELISAs confirmed CPR and Akt that elevated in CIA + Dgal mice were significantly ameliorated by treatments, and adding on GCNY elevated folic acid levels and its regulator Dhfr.
   Conclusion Aging aggravated joints damage in CIA, which probably due to metabolic changes rather than more severe inflammation. GCNY showed significant effects in the ERA mice model especially when integrated with MTX to obtain a synergic action.
C1 [Chen, Yong; Liu, Li ming; Chen, Yan juan; Cheng, Zhi qiang; Liu, Dong zhou] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Guangzhou, Peoples R China.
   [Chen, Yong; Liu, Li ming; Chen, Yan juan; Cheng, Zhi qiang; Liu, Dong zhou] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Peoples R China.
   [Chen, Yong] Shenzhen Peoples Hosp, Shenzhen Clin Res Ctr Geriatr, Shenzhen, Peoples R China.
   [Zhu, Xing wang; Liu, Yong pu; Xu, Xuan feng] Southern Med Univ Hosp Integrated Tradit Chinese &, Guangzhou, Peoples R China.
   [Lai, Wing Fu] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.
   [Lai, Wing Fu] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Urol, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Chuan fu] Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Shanghai, Peoples R China.
   [Wang, Guang yi] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China.
C3 Jinan University; Southern University of Science & Technology; Jinan
   University; Hong Kong Polytechnic University; Hangzhou Medical College;
   Zhejiang Provincial People's Hospital; Shanghai University of
   Traditional Chinese Medicine; Guizhou Medical University
RP Liu, DZ (通讯作者)，Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Guangzhou, Peoples R China.; Liu, DZ (通讯作者)，Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Peoples R China.
EM liu_dz2001@sina.com
RI Xu, Xiaofeng/B 2391 2008; Lai, Wing Fu/J 3170 2015; Cheng,
   Zhiqiang/F 5016 2016; Chen, Yong/HLG 9117 2023; Liu,
   Liming/AAN 4708 2020; Wang, Guangyi/MGW 2039 2025
OI Lai, Wing Fu/0000 0003 0585 6396; Chen, Yong/0000 0001 5538 5081; 
CR Alqarni AM, 2020, BIOCHEM SOC T, V48, P559, DOI 10.1042/BST20190803
   Ba X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.696802
   Brouwers H, 2015, BEST PRACT RES CL RH, V29, P741, DOI 10.1016/j.berh.2016.02.003
   Chalan Paulina, 2015, Curr Aging Sci, V8, P131
   Chen X, 2020, FOOD FUNCT, V11, P4752, DOI [10.1039/d0fo00549e, 10.1039/D0FO00549E]
   Chen Y, 2022, FRONT NEUROSCI SWITZ, V16, DOI 10.3389/fnins.2022.990040
   Chen Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.888612
   Chen Y, 2021, J INFLAMM RES, V14, P5501, DOI 10.2147/JIR.S335671
   Cronstein BN, 2020, NAT REV RHEUMATOL, V16, P145, DOI 10.1038/s41584 020 0373 9
   Gong Zhanfeng, 2019, Panminerva Med, DOI 10.23736/S0031 0808.19.03713 3
   Hui W, 2012, ANN RHEUM DIS, V71, P455, DOI 10.1136/annrheumdis 2011 200372
   Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000
   Li Jiapeng, 2021, Drug Discov Today Technol, V39, P49, DOI 10.1016/j.ddtec.2021.06.006
   Liang YJ, 2020, INFLAMMATION, V43, P1044, DOI 10.1007/s10753 020 01189 x
   Liu LJ, 2019, JCR J CLIN RHEUMATOL, V25, P197, DOI 10.1097/RHU.0000000000000810
   Liu RP, 2016, PHYTOTHER RES, V30, P1672, DOI 10.1002/ptr.5671
   Ma YX, 2018, BIOCHEM PHARMACOL, V153, P269, DOI 10.1016/j.bcp.2018.01.033
   Maidarti M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010200
   Mutlu AS, 2021, DEV CELL, V56, P1394, DOI 10.1016/j.devcel.2021.03.034
   Nayak RR, 2021, CELL HOST MICROBE, V29, P362, DOI 10.1016/j.chom.2020.12.008
   Pan R., 2022, PHARM RES MOD CHIN M, V2, DOI DOI 10.1016/J.PRMCM.2022.100062
   Pope JE, 2021, SEMIN ARTHRITIS RHEU, V51, P219, DOI 10.1016/j.semarthrit.2020.11.005
   Pourmemar E, 2017, EXP GERONTOL, V87, P16, DOI 10.1016/j.exger.2016.11.011
   Rosloniec EF, 2021, CURR PROTOC, V1, DOI 10.1002/cpz1.313
   Ruban TN, 2016, CLIN RHEUMATOL, V35, P759, DOI 10.1007/s10067 015 3031 x
   Serhal L, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102528
   Singh RK, 2019, EUR J PHARMACOL, V853, P264, DOI 10.1016/j.ejphar.2019.03.052
   Söderlin MK, 2021, J PERIODONTAL RES, V56, P907, DOI 10.1111/jre.12887
   Sugihara T, 2022, MOD RHEUMATOL, V32, P493, DOI 10.1093/mr/roab087
   Takahashi N, 2019, MOD RHEUMATOL, V29, P910, DOI 10.1080/14397595.2018.1525019
   Wang J, 2013, GENET MED, V15, P106, DOI 10.1038/gim.2012.104
   Wang ZK, 2019, PROTEOM CLIN APPL, V13, DOI 10.1002/prca.201800024
   Wu H., 2022, J TIANJIN U TRADITIO, V41, P457
   Yong C., 2022, CLIN J CHIN MED, V34, P491
   Yong C., 2021, ACTA CHIN MED, V36, P1734
   Yu C, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6635460
   Zheng LL, 2021, AGEING RES REV, V66, DOI 10.1016/j.arr.2020.101249
NR 37
TC 2
Z9 2
U1 2
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD JAN 28
PY 2023
VL 18
IS 1
AR 9
DI 10.1186/s13020 023 00709 9
PG 14
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 8E1QO
UT WOS:000918756600001
PM 36709303
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Santoni, M
   Conti, A
   Procopio, G
   Porta, C
   Ibrahim, T
   Barni, S
   Guida, FM
   Fontana, A
   Berruti, A
   Berardi, R
   Massari, F
   Vincenzi, B
   Ortega, C
   Ottaviani, D
   Carteni, G
   Lanzetta, G
   De Lisi, D
   Silvestris, N
   Satolli, MA
   Collovà, E
   Russo, A
   Badalamenti, G
   Fedeli, SL
   Tanca, FM
   Adamo, V
   Maiello, E
   Sabbatini, R
   Felici, A
   Cinieri, S
   Montironi, R
   Bracarda, S
   Tonini, G
   Cascinu, S
   Santini, D
AF Santoni, Matteo
   Conti, Alessandro
   Procopio, Giuseppe
   Porta, Camillo
   Ibrahim, Toni
   Barni, Sandro
   Guida, Francesco Maria
   Fontana, Andrea
   Berruti, Alfredo
   Berardi, Rossana
   Massari, Francesco
   Vincenzi, Bruno
   Ortega, Cinzia
   Ottaviani, Davide
   Carteni, Giacomo
   Lanzetta, Gaetano
   De Lisi, Delia
   Silvestris, Nicola
   Satolli, Maria Antonietta
   Collova, Elena
   Russo, Antonio
   Badalamenti, Giuseppe
   Fedeli, Stefano Luzi
   Tanca, Francesca Maria
   Adamo, Vincenzo
   Maiello, Evaristo
   Sabbatini, Roberto
   Felici, Alessandra
   Cinieri, Saverio
   Montironi, Rodolfo
   Bracarda, Sergio
   Tonini, Giuseppe
   Cascinu, Stefano
   Santini, Daniele
TI Bone metastases in patients with metastatic renal cell carcinoma: are
   they always associated with poor prognosis?
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Bone metastasis; Prognostic factors; Renal cell carcinoma; Time to
   distant metastasis
ID PROSTATE CANCER CELLS; SKELETAL COMPLICATIONS; TARGETED THERAPY;
   ZOLEDRONIC ACID; LUNG CANCER; SURVIVAL; SUNITINIB; OSTEOBLASTS;
   SORAFENIB
AB Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC).
   Materials and methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG  Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: < 1 year, between 1 and 5 years and > 5 years) and time from BMs to skeletal related event (SRE) were included in the Cox analysis to investigate their prognostic relevance.
   Results: 470 patients were enrolled in this analysis. In 19 patients (4%), bone was the only metastatic site; 277 patients had concomitant metastases in other sites. Median time to BMs was 16 months (range 0   44y) with Median OS of 17 months. Number of metastatic sites (including bone, p = 0.01), concomitant metastases, high Fuhrman grade (p < 0.001) and non  clear cell histology (p = 0.013) were significantly associated with poor prognosis. Patients with TTBM > 5 years had longer OS (22 months) compared to patients with TTBM < 1 year (13 months) or between 1 and 5 years (19 months) from nephrectomy (p < 0.001), no difference was found between these two last groups (p = 0.18). At multivariate analysis, ECOG PS, MSKCC group and concomitant lung or lymph node metastases were independent predictors of OS in patients with BMs.
   Conclusions: Our study suggest that age, ECOG PS, histology, MSKCC score, TTBM and the presence of concomitant metastases should be considered in order to optimize the management of RCC patients with BMs.
C1 [Santoni, Matteo; Berardi, Rossana; Cascinu, Stefano] Univ Politecn, AOU Osped Riuniti, Dept Med Oncol, Ancona, Italy.
   [Conti, Alessandro] Univ Politecn Marche, Dept Clin & Specialist Sci, Ancona, Italy.
   [Procopio, Giuseppe] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy.
   [Porta, Camillo] IRCCS San Matteo Univ Hosp Fdn, Div Med Oncol, Pavia, Italy.
   [Ibrahim, Toni] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Osteoncol & Rare Tumors Ctr, Meldola, FC, Italy.
   [Barni, Sandro] Azienda Osped Treviglio Caravaggio, Dept Med Oncol, Treviglio, Italy.
   [Guida, Francesco Maria; Vincenzi, Bruno; De Lisi, Delia; Tonini, Giuseppe; Santini, Daniele] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy.
   [Fontana, Andrea] Azienda Osped Univ Pisana, Ist Toscano Tumori, Unit Med Oncol 2, Pisa, Italy.
   [Berruti, Alfredo] Univ Brescia, Azienda Osped Spedali Civili, Dipartimento Specialita Med Chirurg Med Oncol Sci, Brescia, Italy.
   [Massari, Francesco] Univ Verona, Azienda Osped Univ Integrata, Dept Med Oncol, GB Rossi Acad Hosp, I 37100 Verona, Italy.
   [Ortega, Cinzia] Inst Canc Res & Treatment IRCC, Dept Med Oncol, Turin, Italy.
   [Ottaviani, Davide] Presidio Sanit Gradenigo, Dept Med Oncol, Turin, Italy.
   [Carteni, Giacomo] Cardarelli Hosp, Dept Med Oncol, Naples, Italy.
   [Lanzetta, Gaetano] IRCSS, Neuromed Inst, Dept Neurol Sci, Pozzilli, IS, Italy.
   [Lanzetta, Gaetano] Ist Neurotraumatol Italiano, Unita Funz Oncol, Grottaferrata, Italy.
   [Silvestris, Nicola] Natl Canc Res Ctr Giovanni Paolo II, Med Oncol Unit, Bari, Italy.
   [Satolli, Maria Antonietta] Univ Turin, Dept Oncol, AOU Citta Salute & Sci, Turin, Italy.
   [Collova, Elena] Hosp Legnano, Div Med Oncol, Milan, Italy.
   [Russo, Antonio; Badalamenti, Giuseppe] Univ Palermo, Sect Med Oncol, Dept Surg & Oncol, Palermo, Italy.
   [Fedeli, Stefano Luzi] Univ Politecn Marche, AOU Osped Riuniti, Dept Med Oncol, Presidio San Salvatore, Pesaro, Italy.
   [Tanca, Francesca Maria] Univ Cagliari, Dept Med Oncol, Cagliari, Italy.
   [Adamo, Vincenzo] Univ Messina, Med Oncol Unit, AOOR Papardo Piemonte, Dept Human Pathol, Messina, Italy.
   [Maiello, Evaristo] IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, FG, Italy.
   [Sabbatini, Roberto] Univ Modena & Reggio Emilia, Dipartimento Integrato Oncol & Ematol, Div Med Oncol, Modena, Italy.
   [Felici, Alessandra] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy.
   [Cinieri, Saverio] Hosp Brindisi, Med Oncol Dept, Milan, Italy.
   [Cinieri, Saverio] Hosp Brindisi, Breast Unit, Milan, Italy.
   [Cinieri, Saverio] European Inst Oncol, Dept Med Oncol, Milan, Italy.
   [Montironi, Rodolfo] Polytech Univ Marche Reg, Sch Med, Sect Pathol Anat, United Hosp, Ancona, Italy.
   [Bracarda, Sergio] Osped San Donato, USL 8, Dept Oncol, Arezzo, Italy.
C3 Marche Polytechnic University; Fondazione IRCCS Istituto Nazionale
   Tumori Milan; IRCCS Fondazione San Matteo; IRCCS Meldola (IRST);
   Ospedale di Treviglio Caravaggio; University Campus Bio Medico   Rome
   Italy; University of Pisa; Azienda Ospedaliero Universitaria Pisana;
   ISPRO Istituto per lo studio, la prevenzione e la rete oncologica;
   University of Brescia; Hospital Spedali Civili Brescia; University of
   Verona; Azienda Ospedaliera Universitaria Integrata Verona; IRCCS
   Fondazione del Piemonte per l'Oncologia; Humanitas Hospital Gradenigo;
   Antonio Cardarelli Hospital; IRCCS Neuromed; IRCCS Istituto Tumori Bari
   Giovanni Paolo II; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; University of Palermo; University of Cagliari;
   University of Messina; IRCCS Casa Sollievo Della Sofferenza; Universita
   di Modena e Reggio Emilia; IRCCS Istituti Fisioterapici Ospitalieri
   (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO);
   Marche Polytechnic University; IRCCS Policlinico San Donato
RP Santini, D (通讯作者)，Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy.
EM d.santini@unicampus.it
RI ; fontana, andrea/AAC 7349 2022; Berruti, Alfredo/AAC 2069 2019;
   Carteni, Giacomo/K 5810 2016; GIACOMO, CARTENI/K 5810 2016; Cascinu,
   Stefano/AAN 1923 2020; Cascinu, Stefano/G 2399 2017; Procopio,
   Giuseppe/K 2072 2016; Tonini, Giuseppe/ISA 1908 2023; Berardi,
   Rossana/AAC 5758 2022; SATOLLI, MARIA ANTONIETTA/AHE 0053 2022; Maiello,
   Evaristo/C 5224 2017; Porta, Camillo/AAB 9482 2020; Massari,
   Francesco/K 7239 2016; Sabbatini, Roberto/AAC 5398 2022; Silvestris,
   Nicola/K 5889 2012
OI Berardi, Rossana/0000 0002 9529 2960; CINIERI,
   Saverio/0000 0002 5555 0814; Bracarda, Sergio/0000 0002 0703 2959;
   Santoni, Matteo/0000 0001 7340 6173; Carteni,
   Giacomo/0000 0003 1441 6376; Vincenzi, Bruno/0000 0001 8222 9025;
   Cascinu, Stefano/0000 0003 2215 0731; Procopio,
   Giuseppe/0000 0002 2498 402X; FONTANA, ANDREA/0000 0003 2496 2506;
   Porta, Camillo/0000 0003 2412 1563; Montironi,
   Rodolfo/0000 0003 3938 610X; Maiello, Evaristo/0000 0003 3890 3435;
   Conti, Alessandro/0000 0002 7322 9880; Ibrahim,
   Toni/0000 0003 0259 4167; Massari, Francesco/0000 0001 6476 6871;
   Tonini, Giuseppe/0000 0003 4442 8677; Santini,
   Daniele/0000 0002 9118 3337; Sabbatini, Roberto/0000 0002 8943 7545
CR [Anonymous], 1999, APPL SURVIVAL ANAL R
   Athar U, 2008, CAN J UROL, V15, P3954
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Chen YZ, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756 9966 32 45
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Choueiri TK, 2007, CANCER AM CANCER SOC, V110, P543, DOI 10.1002/cncr.22827
   Facchini G, 2007, J EXP CLIN CANC RES, V26, P307
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Joeckel E, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 42
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kroeger N, 2014, EUR UROL, V65, P1086, DOI 10.1016/j.eururo.2013.07.031
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207
   Motzer RJ, 2004, J CLIN ONCOL, V22, P454, DOI 10.1200/JCO.2004.06.132
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Murai M, 2004, CURR OPIN UROL, V14, P229, DOI 10.1097/01.mou.0000135078.04721.f5
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097 0258(19980430)17:8<873::AID SIM779>3.0.CO;2 I
   Riechelmann RP, 2008, AM J CLIN ONCOL CANC, V31, P182, DOI 10.1097/COC.0b013e3181574084
   Sahi Chakshu, 2010, Ther Adv Med Oncol, V2, P75, DOI 10.1177/1758834009358417
   Santini D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083026
   Santoni M, 2015, J UROLOGY, V193, P41, DOI 10.1016/j.juro.2014.07.011
   Santoni M, 2014, CANCER METAST REV, V33, P321, DOI 10.1007/s10555 013 9453 5
   Satcher RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089880
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Yang L, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756 9966 31 40
NR 29
TC 66
Z9 69
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756 9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD FEB 5
PY 2015
VL 34
AR 10
DI 10.1186/s13046 015 0122 0
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CB6AU
UT WOS:000349710000001
PM 25651794
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Venneker, S
   van Eenige, R
   Kruisselbrink, AB
   Palubeckaite, I
   Taliento, AE
   Briaire de Bruijn, IH
   Hogendoorn, PCW
   van de Sande, MAJ
   Gelderblom, H
   Mei, HL
   Bovée, JVMG
   Szuhai, K
AF Venneker, Sanne
   van Eenige, Robin
   Kruisselbrink, Alwine B.
   Palubeckaite, Ieva
   Taliento, Alice E.
   Briaire de Bruijn, Inge H.
   Hogendoorn, Pancras C. W.
   van de Sande, Michiel A. J.
   Gelderblom, Hans
   Mei, Hailiang
   Bovee, Judith V. M. G.
   Szuhai, Karoly
TI Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate
   Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone
SO CANCERS
LA English
DT Article
DE bone neoplasm; giant cell tumor of bone; histone H3; 3 variants;
   epigenetics; histone deacetylase; romidepsin; panobinostat
ID EXPRESSION; MUTATIONS; H3F3A; PHARMACOKINETICS; GROWTH
AB Simple Summary Giant cell tumor of bone (GCTB) is an intermediate bone neoplasm which consists of several cell populations, including the neoplastic "stromal" cells. These cells harbor a mutation in one of the histone H3.3 genes (H3F3A), and are therefore considered as the driving component of GCTB. This mutation causes changes in the epigenetic landscape, leading to aberrant gene expression patterns that may drive tumor growth. Surgery is currently the only curative treatment option because contemporary systemic therapies cannot remove the neoplastic cells from GCTB lesions, leading to re outgrowth of the tumor when the treatment is discontinued. Therefore, the aim of this study was to explore whether therapeutic targeting of the epigenome can eliminate the neoplastic cells from GCTB lesions. The findings from this study indicate that histone deacetylase (HDAC) inhibitors may represent such a treatment strategy, which could improve the quality of life of GCTB patients who currently require life long treatment. The neoplastic "stromal" cells in giant cell tumor of bone (GCTB) harbor a mutation in the H3F3A gene, which causes alterations in the epigenome. Current systemic targeted therapies, such as denosumab, do not affect the neoplastic cells, resulting in relapse upon treatment discontinuation. Therefore, this study examined whether targeting the epigenome could eliminate the neoplastic cells from GCTB. We established four novel cell lines of neoplastic "stromal" cells that expressed the H3F3A p.G34W mutation. These cell lines were used to perform an epigenetics compound screen (n = 128), which identified histone deacetylase (HDAC) inhibitors as key epigenetic regulators in the neoplastic cells. Transcriptome analysis revealed that the neoplastic cells expressed all HDAC isoforms, except for HDAC4. Therefore, five HDAC inhibitors targeting different HDAC subtypes were selected for further studies. All GCTB cell lines were very sensitive to HDAC inhibition in both 2D and 3D in vitro models, and inductions in histone acetylation, as well as apoptosis, were observed. Thus, HDAC inhibition may represent a promising therapeutic strategy to eliminate the neoplastic cells from GCTB lesions, which remains the paramount objective for GCTB patients who require life long treatment with denosumab.
C1 [Venneker, Sanne; Kruisselbrink, Alwine B.; Palubeckaite, Ieva; Taliento, Alice E.; Briaire de Bruijn, Inge H.; Hogendoorn, Pancras C. W.; Bovee, Judith V. M. G.] Leiden Univ, Dept Pathol, Med Ctr, NL 2333 ZA Leiden, Netherlands.
   [van Eenige, Robin; Szuhai, Karoly] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, NL 2333 ZC Leiden, Netherlands.
   [van de Sande, Michiel A. J.] Leiden Univ, Dept Orthoped Surg, Med Ctr, NL 2333 ZA Leiden, Netherlands.
   [Gelderblom, Hans] Leiden Univ, Dept Med Oncol, Med Ctr, NL 2333 ZA Leiden, Netherlands.
   [Mei, Hailiang] Leiden Univ, Sequencing Anal Support Core SASC, Med Ctr, NL 2333 ZC Leiden, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University; Leiden University Medical
   Center (LUMC); Leiden University   Excl LUMC; Leiden University   Excl
   LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University; Leiden University Medical Center
   (LUMC); Leiden University   Excl LUMC
RP Szuhai, K (通讯作者)，Leiden Univ, Dept Cell & Chem Biol, Med Ctr, NL 2333 ZC Leiden, Netherlands.
EM k.szuhai@lumc.nl
RI ; van de Sande, Michiel/K 4611 2017; van de Sande, Michiel/N 9607 2019;
   Hogendoorn, Pancras/H 5859 2015; Palubeckaite, Ieva/Y 3033 2018;
   Hogendoorn, Pancras C W/H 5859 2015; Szuhai, Karoly/A 1100 2008; Bovee,
   Judith/AFM 4294 2022; Venneker, Sanne/V 8537 2018
OI Gelderblom, Hans/0000 0001 9270 8636; Mei, Hailiang/0000 0003 1781 5508;
   van de Sande, Michiel/0000 0002 9156 7656; Bovee,
   Judith/0000 0003 1155 0481; Taliento, Alice Emma/0000 0003 0900 9047;
   Palubeckaite, Ieva/0000 0002 2961 5469; Hogendoorn, Pancras C
   W/0000 0002 1513 8104; Szuhai, Karoly/0000 0002 1228 4245; van Eenige,
   Robin/0000 0003 2637 3801; Venneker, Sanne/0000 0002 4067 9818
FU EuroSarc (EU project FP7HEALTH 2011 two stage) [278742]; EIT Health
   (Rare Cancer Programme) [17527]
FX Establishment of the cell lines was financially supported by EuroSarc
   (EU project FP7HEALTH 2011 two stage, Project ID 278742) and RNA
   sequencing was financially supported by EIT Health (Rare Cancer
   Programme, Project ID 17527).
CR Balke M, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 241
   Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   De Vita A, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020372
   Fellenberg J, 2019, CANCER LETT, V448, P61, DOI 10.1016/j.canlet.2019.02.001
   Flanagan A.M., 2020, cell tumour of bone. WHO classification of tumours of soft tissue and bone, V5th ed., P440
   Forsyth RG, 2021, CANCERS, V13, DOI 10.3390/cancers13205119
   Forsyth RG, 2009, J BONE MINER RES, V24, P70, DOI [10.1359/jbmr.080905, 10.1359/JBMR.080905]
   Franceschini N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126273
   Gaspar N, 2021, LANCET ONCOL, V22, P1312, DOI 10.1016/S1470 2045(21)00387 9
   Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]
   Hemingway F, 2012, VIRCHOWS ARCH, V460, P525, DOI 10.1007/s00428 012 1235 x
   Jain SU, 2020, P NATL ACAD SCI USA, V117, P27354, DOI 10.1073/pnas.2006076117
   Jiang YF, 2021, J ORTHOP TRANSL, V29, P106, DOI 10.1016/j.jot.2021.04.004
   Khazaei S, 2020, CANCER DISCOV, V10, P1968, DOI 10.1158/2159 8290.CD 20 0461
   Kumta SM, 2003, LIFE SCI, V73, P1427, DOI 10.1016/S0024 3205(03)00434 X
   Liao TS, 2005, J ORTHOP RES, V23, P203, DOI 10.1016/j.orthres.2004.06.018
   Lieveld M, 2014, VIRCHOWS ARCH, V465, P703, DOI 10.1007/s00428 014 1666 7
   Lipplaa A, 2019, ONCOLOGIST, V24, P889, DOI 10.1634/theoncologist.2019 0280
   Lübbehüsen C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42611 1
   Lutsik P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18955 y
   Maggiani F, 2011, J CLIN PATHOL, V64, P701, DOI 10.1136/jcp.2011.090852
   Mahdal M, 2021, CANCERS, V13, DOI 10.3390/cancers13143543
   Noguchi R, 2020, HUM CELL, V33, P1321, DOI 10.1007/s13577 020 00415 w
   Obri A, 2014, J CELL BIOL, V205, P771, DOI 10.1083/jcb.201403138
   Ono T, 2022, HUM CELL, V35, P392, DOI 10.1007/s13577 021 00639 4
   Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Shi LL, 2018, J MOL BIOL, V430, P1562, DOI 10.1016/j.jmb.2018.04.014
   Subramanian S, 2010, PHARMACEUTICALS, V3, P2751, DOI 10.3390/ph3092751
   van der Heijden L, 2020, CURR OPIN ONCOL, V32, P332, DOI 10.1097/CCO.0000000000000645
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   Van Veggel M, 2018, CLIN PHARMACOKINET, V57, P21, DOI 10.1007/s40262 017 0565 x
   Venneker S, 2019, CANCERS, V11, DOI 10.3390/cancers11121918
   Woo S, 2009, CLIN CANCER RES, V15, P1496, DOI 10.1158/1078 0432.CCR 08 1215
   Yang L, 2022, ANN DIAGN PATHOL, V57, DOI 10.1016/j.anndiagpath.2021.151882
   Yoshimatsu Y, 2021, HUM CELL, V34, P1899, DOI 10.1007/s13577 021 00579 z
NR 39
TC 7
Z9 7
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD OCT
PY 2022
VL 14
IS 19
AR 4708
DI 10.3390/cancers14194708
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 5G0LA
UT WOS:000866698500001
PM 36230631
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Da Ros, F
   Kowal, K
   Vicinanza, C
   Lombardi, E
   Agostini, F
   Ciancia, R
   Rupolo, M
   Durante, C
   Michieli, M
   Mazzucato, M
AF Da Ros, Francesco
   Kowal, Kinga
   Vicinanza, Carla
   Lombardi, Elisabetta
   Agostini, Francesco
   Ciancia, Rosanna
   Rupolo, Maurizio
   Durante, Cristina
   Michieli, Mariagrazia
   Mazzucato, Mario
TI IRE1a Induced FilaminA Phosphorylation Enhances Migration of Mesenchymal
   Stem Cells Derived from Multiple Myeloma Patients
SO CELLS
LA English
DT Article
DE multiple myeloma; mesenchymal stem cells; IRE1a; migration
ID BONE MARROW MICROENVIRONMENT; STROMAL CELLS; DRUG RESISTANCE; EXOSOMES;
   CONTRIBUTOR; ADHESION; BLOCKADE; GROWTH; XBP1S
AB Multiple myeloma (MM) is an aggressive malignancy that shapes, during its progression, a pro tumor microenvironment characterized by altered protein secretion and the gene expression of mesenchymal stem cells (MSCs). In turn, MSCs from MM patients can exert an high pro tumor activity and play a strong immunosuppressive role. Here, we show, for the first time, greater cell mobility paralleled by the activation of FilaminA (FLNA) in MM derived MSCs, when compared to healthy donor (HD) derived MSCs. Moreover, we suggest the possible involvement of the IRE1a FLNA axis in the control of the MSC migration process. In this way, IRE1a can be considered as a good target candidate for MM therapy, considering its pro survival, pro osteoclast and chemoresistance role in the MM microenvironment. Our results suggest that IRE1a downregulation could also interfere with the response of MSCs to MM stimuli, possibly preventing cell cell adhesion mediated drug resistance. In addition, further investigations harnessing IRE1a FLNA interaction could improve the homing efficiency of MSC as cell product for advanced therapy applications.
C1 [Da Ros, Francesco; Vicinanza, Carla; Lombardi, Elisabetta; Agostini, Francesco; Durante, Cristina; Mazzucato, Mario] NCI, IRCCS, CRO Aviano, Dept Res & Adv Canc Diagnost,Stem Cell Unit, Aviano, Italy.
   [Kowal, Kinga] Univ Trieste, Dept Life Sci, I 34151 Trieste, Italy.
   [Ciancia, Rosanna; Rupolo, Maurizio; Michieli, Mariagrazia] NCI, IRCCS, CRO Aviano, Dept Med Oncol,Oncohematol & Cell Therapy Unit, Aviano, Italy.
C3 IRCCS Aviano (CRO); University of Trieste; IRCCS Aviano (CRO)
RP Mazzucato, M (通讯作者)，NCI, IRCCS, CRO Aviano, Dept Res & Adv Canc Diagnost,Stem Cell Unit, Aviano, Italy.
EM francesco.daros@cro.it; mmazzucato@cro.it
RI Rupolo, Maurizio/ABE 7008 2020; Agostini, Francesco/U 2488 2019;
   Lombardi, Elisabetta/AAC 2396 2020; DURANTE, CRISTINA/ABE 1806 2020; Da
   Ros, Francesco/AAC 2012 2022; Mazzucato, Mario/ABF 5472 2020
OI Rupolo, Maurizio/0000 0001 7932 2827; Agostini,
   Francesco/0000 0002 2808 9348; Lombardi, Elisabetta/0000 0002 3688 9281;
   Da Ros, Francesco/0000 0002 9869 077X; Mazzucato,
   Mario/0000 0001 8319 053X
FU "Fincheci siete voi ci sono anche io" Associazione ONLUS
   [j31I17000440007]; Alleanza Contro il Cancro [j34I20000600001];
   Associazione Italiana Contro Leucemie Linfomi e Mieloma (AIL), SEED
   grant [j35F21000650007]; Ottone Zanolin e Elena Dametto" Associazione
   ONLUS; Italian Ministry of Health Ricerca Corrente
FX The project was supported by "Finche ci siete voi ci sono anche io"
   Associazione ONLUS (grant # j31I17000440007), Alleanza Contro il Cancro
   (grant # j34I20000600001), Associazione Italiana Contro Leucemie Linfomi
   e Mieloma (AIL), SEED grant (grant # j35F21000650007), "Ottone Zanolin e
   Elena Dametto" Associazione ONLUS and Italian Ministry of Health Ricerca
   Corrente. The authors declare no competing financial interest.
CR Adamik J, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10183
   Alameda D, 2020, HAEMATOLOGICA, V105, pE470, DOI 10.3324/haematol.2019.235135
   André T, 2015, CANCER IMMUNOL IMMUN, V64, P213, DOI 10.1007/s00262 014 1623 y
   Bagratuni T, 2010, BLOOD, V116, P250, DOI 10.1182/blood 2010 01 263236
   D'Souza S, 2012, BLOOD, V119, P1888, DOI 10.1182/blood 2011 11 393348
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73
   Fernando RC, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 38314 8
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Goldsmith SR, 2019, BLOOD, V134, DOI 10.1182/blood 2019 131135
   Harnoss JM, 2019, P NATL ACAD SCI USA, V116, P16420, DOI 10.1073/pnas.1906999116
   Li LZ, 2015, ONCOTARGET, V6, P12009, DOI 10.18632/oncotarget.3617
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood 2011 07 366633
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Nakamura F, 2011, CELL ADHES MIGR, V5, P160, DOI 10.4161/cam.5.2.14401
   Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood 2010 08 303099
   Raimondi L, 2020, CANCERS, V12, DOI 10.3390/cancers12082167
   Raimondi L, 2015, ONCOTARGET, V6, P13772, DOI 10.18632/oncotarget.3830
   Raimondo S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 018 0689 y
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Siwecka N, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020156
   Szeto SGY, 2015, EXP CELL RES, V330, P248, DOI 10.1016/j.yexcr.2014.10.024
   Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200
   Tsukamoto S, 2018, LEUKEMIA, V32, P1739, DOI 10.1038/s41375 018 0161 6
   Urra H, 2018, NAT CELL BIOL, V20, P942, DOI 10.1038/s41556 018 0141 0
   van de Donk NWCJ, 2021, LANCET, V397, P410, DOI 10.1016/S0140 6736(21)00135 5
   Vicinanza C, 2022, WORLD J STEM CELLS, V14, P54, DOI 10.4252/wjsc.v14.i1.54
   Wang JH, 2016, J PATHOL, V239, P162, DOI 10.1002/path.4712
   Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood 2014 03 562439
   Xu GS, 2012, BLOOD, V119, P4205, DOI 10.1182/blood 2011 05 353300
   Xu S, 2012, LEUKEMIA, V26, P2546, DOI 10.1038/leu.2012.126
   Xu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079752
   Yamashita Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176314
   Yue JY, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 7
NR 36
TC 3
Z9 3
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD AUG
PY 2023
VL 12
IS 15
AR 1935
DI 10.3390/cells12151935
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA O8EW4
UT WOS:001046094300001
PM 37566015
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sui, BD
   Hu, CH
   Zhang, XY
   Zhao, P
   He, T
   Zhou, CH
   Qiu, XY
   Chen, N
   Zhao, XY
   Jin, Y
AF Sui, Bingdong
   Hu, Chenghu
   Zhang, Xinyi
   Zhao, Pan
   He, Tao
   Zhou, Cuihong
   Qiu, Xinyu
   Chen, Nan
   Zhao, Xinyi
   Jin, Yan
TI Allogeneic Mesenchymal Stem Cell Therapy Promotes Osteoblastogenesis and
   Prevents Glucocorticoid Induced Osteoporosis
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Mesenchymal stem cell therapy; Cell
   homing; Bone remodeling; Osteoblastogenesis
ID BONE MARROW; SYSTEMIC INFUSION; NONHUMAN PRIMATES; TRANSPLANTATION;
   MICE; CXCR4; UPDATE
AB Gene modified mesenchymal stem cell (MSC) like cells with enhanced bone marrow homing and osteogenesis have been used in treating glucocorticoid induced murine osteoporosis (GIOP). Recent preclinical studies have further demonstrated the immunomodulatory and anticatabolic potential of allogeneic MSCs in treating osteoporosis under inflammatory and autoimmune conditions. In this study, we investigated whether systemic infusion of allogeneic MSCs without genetic manipulation could prevent GIOP, whether anabolic and anticatabolic effects existed, and whether homing or immunomodulation underlay the putative therapeutic effects. Allogeneic bone marrow derived MSCs (BMMSCs) were isolated, identified, and systemically infused into mice treated with excessive dexamethasone. We revealed that allogeneic MSC transplantation prevented the reduction of bone mass and strength in GIOP. Bone histomorphometric analyses of bone remodeling demonstrated the maintenance of bone formation and osteoblast survival after MSC therapy. Using green fluorescent protein (GFP) labeled BMMSCs, we showed that donor BMMSCsGFP homed and inhabited recipient bone marrow for at least 4 weeks and prevented recipient bone marrow cell apoptosis, as shown by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling. Furthermore, donor BMMSCsGFP committed to Osterix (Osx)(+) osteoblast progenitors and induced recipient osteoblastogenesis, as exhibited by GFP Osx double labeling immunofluorescence analysis. No anticatabolic effects or systemic immunomodulatory effects of infused BMMSCs were detected. These findings demonstrated that allogeneic MSC therapy prevented GIOP by inhabiting and functioning in recipient bone marrow, which promoted osteoblastogenesis, which in turn maintained bone formation. Our findings provide important information regarding cell based anabolic therapy for GIOP and uncover MSC behaviors following the homing event.
   SIGNIFICANCE
   This study revealed the therapeutic potential of systemically infused, genetically unmodified allogeneic MSCs in glucocorticoid induced osteoporosis. The donor MSCs inhabited recipient bone marrow and promoted osteoblastogenesis. The therapeutic effects were based on maintenance of bone formation. These results provide important information regarding cell based anabolic therapy for glucocorticoid induced osteoporosis and uncover previously unrecognized mesenchymal stem cell behaviors following a homing event. The current study also indicates that minimizing the time of cell culture confers an advantage for increasing transplanted mesenchymal stem cells to the targeted organ to promote therapeutic effects.
C1 [Sui, Bingdong; Hu, Chenghu; Zhang, Xinyi; Zhao, Pan; He, Tao; Zhou, Cuihong; Qiu, Xinyu; Chen, Nan; Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, Ctr Tissue Engn, State Key Lab Mil Stomatol, Xian, Shaanxi, Peoples R China.
   [Sui, Bingdong; Hu, Chenghu; Zhang, Xinyi; Zhao, Pan; He, Tao; Zhou, Cuihong; Qiu, Xinyu; Chen, Nan; Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, Res & Dev Ctr Tissue Engn, Xian, Shaanxi, Peoples R China.
   [Sui, Bingdong; Zhao, Xinyi] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Dept Dent Mat, Xian, Shaanxi, Peoples R China.
   [Sui, Bingdong; Zhao, Xinyi] Fourth Mil Med Univ, Sch Stomatol, Dept Dent Mat, 145 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University
RP Zhao, XY (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Dent Mat, 145 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.; Jin, Y (通讯作者)，Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, 145 West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM zhaoxinyi@fmmu.edu.cn; yanjin@fmmu.edu.cn
RI Hu, Cheng Hu/I 4210 2013; 周, 翠红/ACA 7979 2022; Sui,
   Bingdong/HKN 5071 2023; Jin, Yan/I 4204 2013; Zhang, Xinyi/AAJ 4858 2021
OI Hu, Cheng Hu/0000 0003 2443 6485; Sui, Bingdong/0000 0002 7282 0935; 
FU National Natural Science Foundation of China [31301062, 81570937,
   81470710]; National Basic Research Program (973 Program) of China
   [2011CB964700]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31301062, 81570937, and 81470710) and the National
   Basic Research Program (973 Program) of China (2011CB964700).
CR Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cho SW, 2009, MOL THER, V17, P1979, DOI 10.1038/mt.2009.153
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301 472X(00)00635 4
   Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood 2002 06 1830
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Ezquer F, 2012, STEM CELLS, V30, P1664, DOI 10.1002/stem.1132
   Gao LN, 2013, BIOMATERIALS, V34, P9937, DOI 10.1016/j.biomaterials.2013.09.017
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Lapidot T, 2002, LEUKEMIA, V16, P1992, DOI 10.1038/sj.leu.2402684
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Liu SY, 2015, CELL METAB, V22, P606, DOI 10.1016/j.cmet.2015.08.018
   Liu Y, 2014, J DENT RES, V93, P1124, DOI 10.1177/0022034514552675
   Ma L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0091 4
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Oberhaus Stephanie M, 2003, Methods Mol Biol, V218, P85
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763
   Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Zhang C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026504
   Zhang XS, 2004, J GENE MED, V6, P4, DOI 10.1002/jgm.477
NR 29
TC 66
Z9 81
U1 0
U2 28
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701 2884 USA
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD SEP
PY 2016
VL 5
IS 9
BP 1238
EP 1246
DI 10.5966/sctm.2015 0347
PG 9
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DU7UQ
UT WOS:000382420500014
PM 27365487
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lavanya, K
   Balagangadharan, K
   Chandran, SV
   Selvamurugan, N
AF Lavanya, K.
   Balagangadharan, K.
   Chandran, S. Viji
   Selvamurugan, N.
TI Chitosan coated and thymol loaded polymeric semi interpenetrating
   hydrogels: An effective platform for bioactive molecule delivery and
   bone regeneration in vivo
SO BIOMATERIALS ADVANCES
LA English
DT Article
DE Thymol; Osteogenesis; Chitosan; Sodium alginate; Poly
   (2 ethyl 2 oxazoline); RUNX2
ID GROWTH FACTOR DELIVERY; COLLAGENASE 3 EXPRESSION; SCAFFOLDS;
   MINERALIZATION; VITRO; GELATIN; RELEASE; CULTURE; REPAIR; CELLS
AB Thymol (2 isopropyl 5 methylphenol; Thy) is a monoterpene phenolic phytocompound with medicinal proper ties; however, its impact on osteogenesis is yet to be thoroughly investigated. Its distribution is often hampered because of its intricate hydrophobic structure, which reduces its bioavailability. In this study, we synthesized a drug delivery vehicle using semi interpenetrating polymer network (SIPN) hydrogels containing sodium alginate and poly(2 ethyl 2 oxazoline) (SA/Pox) loaded with Thy at varying concentrations (100, 150, and 200 mu M). Subsequently, they were coated with chitosan (CS) to increase bioactivity and for sustained and prolonged release of Thy. Thy loaded CS coated SIPN hydrogels (SA/Pox/CS Thy) were developed using ionic gelation and polyelectrolyte complexation techniques. The addition of CS to hydrogels enhanced their physicochemical and material properties. These hydrogels were cytofriendly toward mouse mesenchymal stem cells (mMSCs). When mMSCs were cultured on hydrogels, Thy stimulated osteoblastic differentiation, as evidenced by calcium deposits at the cellular level. The expression of RUNX2, a key bone transcriptional factor, and other differentiation biomarkers was significantly enhanced in mMSCs cultured on SA/Pox/CS Thy hydrogels. Notably, Thy in the SA/ Pox/CS hydrogels significantly activated the TGF beta/BMP signaling pathway, which is involved in osteogenesis. A rat tibial bone defect model system revealed that the incorporation of Thy into SA/Pox/CS hydrogels augmented bone regeneration. Thus, sustained and prolonged release of Thy from the SA/Pox/CS hydrogels promoted osteoblast differentiation in vitro and bone formation in vivo. These findings shed light on the effect of Thy bioavailability in fostering osteoblast differentiation and its prospective application in bone rejuvenation.
C1 [Lavanya, K.; Balagangadharan, K.; Chandran, S. Viji; Selvamurugan, N.] SRM Inst Sci & Technol, Coll Engn & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Coll Engn & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamun@srmist.edu.in
RI Selvamurugan, Nagarajan/P 7894 2016
FU Department of Science and Technol ogy, India [DST/INSPIRE
   Fellowship/2018/IF180184]
FX Acknowledgement The authors acknowledge the Department of Science and
   Technol ogy, India, for providing financial support (DST/INSPIRE
   Fellowship/2018/IF180184 to K. L.) .
CR Abbah SA, 2015, ADV HEALTHC MATER, V4, P2488, DOI 10.1002/adhm.201500004
   Abhinandan R, 2021, COLLOID SURFACE B, V203, DOI 10.1016/j.colsurfb.2021.111771
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Annabi N, 2010, TISSUE ENG PART B RE, V16, P371, DOI [10.1089/ten.teb.2009.0639, 10.1089/ten.TEB.2009.0639]
   Ashwin B, 2020, INT J BIOL MACROMOL, V162, P523, DOI 10.1016/j.ijbiomac.2020.06.157
   Badita CR, 2020, ROM J PHYS, V65
   Balagangadharan K, 2019, CARBOHYD POLYM, V216, P1, DOI 10.1016/j.carbpol.2019.04.002
   Boraschi Diaz I, 2017, FRONT PHYS LAUSANNE, V5, DOI 10.3389/fphy.2017.00012
   Brown J., 2019, Biomaterials Science: An Introduction to Materials in Medicine (Fourth Edi), DOI [DOI 10.1016/B978 0 12 816137 1.00085 4, 10.1016/B978 0 12 816137 1.00085 4]
   Chandran SV, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48429 1
   Craelius W., 2022, Prosthetic Designs for Restoring Human Limb Function, P133
   Cross LM, 2016, ACTA BIOMATER, V42, P2, DOI 10.1016/j.actbio.2016.06.023
   de la Rosa Victor R, 2014, J Mater Sci Mater Med, V25, P1211, DOI 10.1007/s10856 013 5034 y
   De Witte TM, 2018, REGEN BIOMATER, V5, P197, DOI 10.1093/rb/rby013
   Devi GVY, 2021, J DRUG DELIV SCI TEC, V64, DOI 10.1016/j.jddst.2021.102624
   Dhivya S, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12408
   Dhivya S, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0099 z
   Dinoro J, 2019, BIOMATERIALS, V214, DOI 10.1016/j.biomaterials.2019.05.025
   Fael H, 2018, J PHARM SCI US, V107, P2428, DOI 10.1016/j.xphs.2018.05.015
   GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017, Lancet, V390, P1211, DOI 10.1016/S0140 6736(17)32154 2
   Gkioni K, 2010, TISSUE ENG PART B RE, V16, P577, DOI 10.1089/ten.TEB.2010.0462
   Greenblatt Matthew B, 2022, J Bone Metab, V29, P1, DOI 10.11005/jbm.2022.29.1.1
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gresham RCH, 2021, BIOACT MATER, V6, P1945, DOI 10.1016/j.bioactmat.2020.12.012
   Helmiyati, 2017, IOP CONF SER MAT SCI, V188, DOI 10.1088/1757 899X/188/1/012019
   Hu Y, 2018, J POLYM RES, V25, DOI 10.1007/s10965 018 1546 y
   Ioelovich M., 2014, J. Chem, V3, P7
   Jing Z, 2022, PROCESS BIOCHEM, V118, P252, DOI 10.1016/j.procbio.2022.04.033
   JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146
   Kazi GAS, 2019, J ELECTROCHEM SOC, V166, pB3025, DOI 10.1149/2.0051909jes
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kowalczewski CJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00513
   Kumari S, 2021, CARBOHYD POLYM, V255, DOI 10.1016/j.carbpol.2020.117487
   Lavanya K, 2020, MAT SCI ENG C MATER, V111, DOI 10.1016/j.msec.2020.110862
   Lavikainen J., POLYM ADVAN TECHNOL, V32
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Luxenhofer R, 2011, J CONTROL RELEASE, V153, P73, DOI 10.1016/j.jconrel.2011.04.010
   Marchese A, 2016, FOOD CHEM, V210, P402, DOI 10.1016/j.foodchem.2016.04.111
   Meeran MFN, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00380
   Menon AH, 2018, CARBOHYD POLYM, V195, P356, DOI 10.1016/j.carbpol.2018.04.115
   Nga NK, 2020, RSC ADV, V10, P43045, DOI 10.1039/d0ra09432c
   Pan M., 2021, MATER CHEM PHY, V275
   Park J., 2021, THESIS QUEENSLAND U
   Peter M, 2010, CARBOHYD POLYM, V80, P687, DOI 10.1016/j.carbpol.2009.11.050
   Piattelli A, 1996, BIOMATERIALS, V17, P1443, DOI 10.1016/0142 9612(96)87288 7
   Podevyn A., 2021, FUNCTIONALIZATION M
   Saravanan S, 2017, INT J BIOL MACROMOL, V104, P1975, DOI 10.1016/j.ijbiomac.2017.01.034
   Schafer S, 2021, IN VIVO, V35, P2035, DOI 10.21873/invivo.12472
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Shadamarshan RP, 2018, COLLOID SURFACE B, V171, P698, DOI 10.1016/j.colsurfb.2018.08.005
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Skaalure SC, 2014, ACTA BIOMATER, V10, P3409, DOI 10.1016/j.actbio.2014.04.013
   Song J, 2003, J AM CHEM SOC, V125, P1236, DOI 10.1021/ja028559h
   Sowjanya JA, 2013, COLLOID SURFACE B, V109, P294, DOI 10.1016/j.colsurfb.2013.04.006
   Sruthi R, 2020, COLLOID SURFACE B, V193, DOI 10.1016/j.colsurfb.2020.111110
   Suhail M, 2021, GELS BASEL, V7, DOI 10.3390/gels7020068
   Tian BM, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00195 z
   Tomihata K, 1997, BIOMATERIALS, V18, P567, DOI 10.1016/S0142 9612(96)00167 6
   Trivedi MK., 2015, Molecular Pharmaceutics Organic Process Research, V3, P1000127, DOI [10.4172/2329 9053.1000127, DOI 10.4172/2329 9053.1000127]
   Vaidhyanathan B, 2021, PROCESS BIOCHEM, V100, P178, DOI 10.1016/j.procbio.2020.10.008
   Valentino A, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11115122
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Yang CL, 2020, LAB INVEST, V100, P1494, DOI 10.1038/s41374 020 0451 2
   Zamani Z, 2015, IRAN J PHARM RES, V14, P1031
   Zhang Y, 2021, J MATER SCI, V56, P17221, DOI 10.1007/s10853 021 06382 3
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 68
TC 26
Z9 26
U1 5
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD MAR
PY 2023
VL 146
AR 213305
DI 10.1016/j.bioadv.2023.213305
EA JAN 2023
PG 20
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA G6HP1
UT WOS:000990147500001
PM 36709630
DA 2025 08 17
ER

PT J
AU Chistiakov, DA
   Sobenin, IA
   Orekhov, AN
   Bobryshev, YV
AF Chistiakov, Dimitry A.
   Sobenin, Igor A.
   Orekhov, Alexander N.
   Bobryshev, Yuri V.
TI Mechanisms of Medial Arterial Calcification in Diabetes
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Medial arterial calcification; diabetes; atherosclerosis; vascular
   smooth mucle cell; osteogenic transdifferentiation; mineralizing matrix
   vesicles
ID SMOOTH MUSCLE CELLS; GLYCATION END PRODUCTS; ENDOTHELIAL PROGENITOR
   CELLS; BONE MORPHOGENETIC PROTEIN 2; NECROSIS FACTOR ALPHA; STAGE
   RENAL DISEASE; KAPPA B LIGAND; ACCELERATED VASCULAR CALCIFICATION;
   ABDOMINAL AORTIC CALCIFICATION; GLYCOGEN SYNTHASE KINASE 3
AB Medial artery calcification (MAC) is a characteristic feature of diabetes. MAC represents a concentric calcification that proceeds via matrix vesicle nucleated mineralization accompanied with apatitic calcium phosphate deposits in the arterial tunica media in the absence of atheroma and neointima. Multiple factors contribute to the induction and progression of diabetic MAC including inflammation, oxidative stress, adiposity, insulin resistance, advanced glycation end products, and hyperphosphatemia. Osteoblast like cells form in the vessel wall from vascular smooth muscle cells and multipotent vascular mesenchymal progenitors. These mineralizing cells as well as the recruitment of undifferentiated progenitors to the osteochondrocyte lineage play a critical role in the calcification process. Important transcription factors such as Msx 2, Osterix, and RUNX2 are crucial in the programming of osteogenesis. Currently, no therapy is available to reverse vascular calcification. Available therapies can only reduce and slow the progression of vascular calcification. Targeting regulatory proteins and enzymes directly involved in osteochondrogenesis and hydroxyapatite accumulation in the vascular wall may be beneficial for generating new efficient anti calcific drugs.
C1 [Chistiakov, Dimitry A.] Pirogov Russian State Med Univ, Dept Med Nanobiotechnol, Moscow 117997, Russia.
   [Sobenin, Igor A.] Russian Cardiol Res & Prod Complex, Med Genet Lab, Moscow 121552, Russia.
   [Orekhov, Alexander N.] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Lab Cellular Mech Atherogenesis, Moscow 125315, Russia.
   [Orekhov, Alexander N.] Skolkovo Innovat Ctr, Atherosclerosis Res Inst, Moscow 143025, Russia.
   [Bobryshev, Yuri V.] Univ New S Wales, Sch Med Sci, Fac Med, Kensington, NSW 2052, Australia.
C3 Pirogov Russian National Research Medical University; National Medical
   Research Center of Cardiology; Russian Academy of Medical Sciences;
   Institute of General Pathology & Pathophysiology, RAMS; University of
   New South Wales Sydney
RP Bobryshev, YV (通讯作者)，Univ New S Wales, Fac Med, Sch Med Sci, Sydney, NSW 2052, Australia.
EM y.bobryshev@unsw.edu.au
RI Sobenin, Igor/J 4282 2013; Bobryshev, Yuri/J 2838 2013
OI Sobenin, Igor/0000 0003 0978 6444; 
FU Ministry of Education and Science of the Russian Federation; School of
   Medical Sciences, University of New south Wales, and Sydney, Australia
FX This study was supported by the Ministry of Education and Science of the
   Russian Federation, and by School of Medical Sciences, University of New
   south Wales, and Sydney, Australia.
CR Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42
   Al Aly Z, 2008, TRANSL RES, V151, P233, DOI 10.1016/j.trsl.2007.12.005
   Al Aly Z, 2007, ARTERIOSCL THROM VAS, V27, P2589, DOI 10.1161/ATVBAHA.107.153668
   Alcocer L, 2010, AM J CARDIOVASC DRUG, V10, P143, DOI 10.2165/11536120 000000000 00000
   Alman AC, 2013, DIABETES CARE, V36, P1967, DOI 10.2337/dc12 1874
   Anuurad E, 2006, CLIN LAB MED, V26, P751, DOI 10.1016/j.cll.2006.07.002
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Ayala López W, 2010, J NUCL MED, V51, P768, DOI 10.2967/jnumed.109.071324
   Barascuk N, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471 2261 11 75
   Basalyga DM, 2004, CIRCULATION, V110, P3480, DOI 10.1161/01.CIR.0000148367.08413.E9
   Bear M, 2008, J CELL BIOCHEM, V105, P185, DOI 10.1002/jcb.21812
   Behre CJ, 2007, SCAND J CLIN LAB INV, V67, P449, DOI 10.1080/00365510601158717
   Bhambri Avani, 2008, J Clin Aesthet Dermatol, V1, P38
   Blacher J, 1998, ARTERIOSCL THROM VAS, V18, P535, DOI 10.1161/01.ATV.18.4.535
   Bostom AG, 2011, J CLIN LIPIDOL, V5, P281, DOI 10.1016/j.jacl.2011.03.455
   Boström KI, 2011, CIRC RES, V109, P564, DOI 10.1161/CIRCRESAHA.110.234278
   Bowman MAH, 2011, ARTERIOSCL THROM VAS, V31, P337, DOI 10.1161/ATVBAHA.110.217745
   Brown RJ, 2007, CURR DRUG TARGETS, V8, P1307, DOI 10.2174/138945007783220614
   Bruining N, 2009, CORONARY ARTERY DIS, V20, P409, DOI 10.1097/MCA.0b013e32832fa9b8
   Budoff MJ, 2005, AM HEART J, V149, P695, DOI 10.1016/j.ahj.2004.07.034
   Bunton TE, 2001, CIRC RES, V88, P37, DOI 10.1161/01.RES.88.1.37
   Byers BA, 2004, TISSUE ENG, V10, P1623, DOI 10.1089/ten.2004.10.1623
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Byon CH, 2011, ARTERIOSCL THROM VAS, V31, P1387, DOI 10.1161/ATVBAHA.110.222547
   Chang L, 2011, BIOORG MED CHEM LETT, V21, P2297, DOI 10.1016/j.bmcl.2011.02.089
   Chen H, 2013, DIABETES RES CLIN PR, V100, P272, DOI 10.1016/j.diabres.2013.03.007
   Chen NX, 2010, KIDNEY INT, V77, P436, DOI 10.1038/ki.2009.481
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Chistiakov DA, 2013, CARDIOL REV, V21, P270, DOI 10.1097/CRD.0b013e31828c5ced
   Chiu YW, 2010, KIDNEY INT, V77, P1107, DOI 10.1038/ki.2010.70
   Côté N, 2011, EUR J CLIN INVEST, V41, P1172, DOI 10.1111/j.1365 2362.2011.02522.x
   Csiszar A, 2005, CIRCULATION, V111, P2364, DOI 10.1161/01.CIR.0000164201.40634.1D
   Delomenède M, 2009, ACTA BIOCHIM POL, V56, P301
   Deuell KA, 2012, J VASC RES, V49, P510, DOI 10.1159/000341216
   DOUCET C, 1995, ATHEROSCLEROSIS, V118, P135, DOI 10.1016/0021 9150(95)05600 2
   Fadini GP, 2012, EXP DIABETES RES, DOI 10.1155/2012/921685
   Fadini GP, 2011, CIRC RES, V108, P1112, DOI 10.1161/CIRCRESAHA.110.234088
   Fadini GP, 2010, ATHEROSCLEROSIS, V211, P32, DOI 10.1016/j.atherosclerosis.2010.03.025
   Farrington Rock C, 2004, CIRCULATION, V110, P2226, DOI 10.1161/01.CIR.0000144457.55518.E5
   Flammer AJ, 2012, J CLIN ENDOCR METAB, V97, P4761, DOI 10.1210/jc.2012 2642
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Foley RN, 2009, J AM SOC NEPHROL, V20, P397, DOI 10.1681/ASN.2008020141
   Frazao JM, 2012, NEPHRON CLIN PRACT, V120, pC108, DOI 10.1159/000337087
   Gaillard V, 2005, HYPERTENSION, V46, P372, DOI 10.1161/01.HYP.0000171472.24422.33
   Galassi A, 2006, NEPHROL DIAL TRANSPL, V21, P3215, DOI 10.1093/ndt/gfl395
   Ge L, 2010, J BIOMECH ENG T ASME, V132, DOI 10.1115/1.4000162
   Giachelli CM, 2005, CIRC RES, V96, P717, DOI 10.1161/01.RES.0000161997.24797.c0
   Gilmanov D, 2010, INTERACT CARDIOV TH, V11, P297, DOI 10.1510/icvts.2009.230920
   Gössl M, 2008, J AM COLL CARDIOL, V52, P1314, DOI 10.1016/j.jacc.2008.07.019
   Golub EE, 2011, SEMIN IMMUNOPATHOL, V33, P409, DOI 10.1007/s00281 010 0230 z
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Goustin AS, 2013, CELL SIGNAL, V25, P981, DOI 10.1016/j.cellsig.2012.12.011
   Goustin AS, 2011, CELL SIGNAL, V23, P980, DOI 10.1016/j.cellsig.2010.11.003
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Haffner SM, 2000, CIRCULATION, V101, P975, DOI 10.1161/01.CIR.101.9.975
   Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002 9440(10)63208 7
   Hayden MR, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475 2840 4 4
   Hayden MR, 2004, CARDIOVASC DIABETOL, V3, DOI 10.1186/1475 2840 3 1
   Haynes WG, 2005, EXP PHYSIOL, V90, P683, DOI 10.1113/expphysiol.2005.031237
   He Z, 2003, EUR HEART J SUPPL, V5, pB51, DOI 10.1016/S1520 765X(03)90041 1
   Heiss A, 2008, J BIOL CHEM, V283, P14815, DOI 10.1074/jbc.M709938200
   HEISTAD DD, 1978, J CLIN INVEST, V62, P133, DOI 10.1172/JCI109097
   Helas S, 2009, AM J PATHOL, V175, P473, DOI 10.2353/ajpath.2009.080957
   Helske S, 2004, J AM COLL CARDIOL, V44, P1859, DOI 10.1016/j.jacc.2004.07.054
   Henriksen EJ, 2006, CURR DRUG TARGETS, V7, P1435, DOI 10.2174/1389450110607011435
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Houston B, 2004, BONE, V34, P629, DOI 10.1016/j.bone.2003.12.023
   Howson KM, 2005, AM J PHYSIOL CELL PH, V289, pC1396, DOI 10.1152/ajpcell.00168.2005
   Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628
   Huesa C, 2011, BONE, V48, P1066, DOI 10.1016/j.bone.2011.01.010
   Iijima Katsuya, 2010, Clin Calcium, V20, P1719, DOI CliCa101117191728
   Inaba S, 2009, AM J HYPERTENS, V22, P145, DOI 10.1038/ajh.2008.344
   Ishimura E, 2002, DIABETOLOGIA, V45, P1446, DOI 10.1007/s00125 002 0920 8
   Iwamoto I, 2004, GYNECOL ENDOCRINOL, V19, P97, DOI 10.1080/09513590412331284389
   Ix JH, 2012, CLIN CHEM, V58, P887, DOI 10.1373/clinchem.2011.177725
   Ix JH, 2009, CLIN J AM SOC NEPHRO, V4, P609, DOI 10.2215/CJN.04100808
   Izutani H, 1997, TRANSPL P, V29, P861, DOI 10.1016/S0041 1345(96)00170 4
   Janzen J, 2001, Z Kardiol, V90 Suppl 3, P6
   Jensen MK, 2013, DIABETES CARE, V36, P1222, DOI 10.2337/dc12 1591
   Jensky NE, 2010, HYPERTENSION, V55, P990, DOI 10.1161/HYPERTENSIONAHA.109.147520
   Jia GH, 2012, AM J PHYSIOL HEART C, V303, pH523, DOI 10.1152/ajpheart.00826.2011
   Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kalia NK, 2006, ATHEROSCLEROSIS, V185, P394, DOI 10.1016/j.atherosclerosis.2005.06.018
   Kanazawa I, 2009, CALCIFIED TISSUE INT, V85, P228, DOI 10.1007/s00223 009 9272 4
   Kapustin AN, 2011, CIRC RES, V109, pE1, DOI 10.1161/CIRCRESAHA.110.238808
   Kiffer Moreira T, 2013, J BONE MINER RES, V28, P81, DOI 10.1002/jbmr.1733
   KIM KM, 1976, FED PROC, V35, P156
   Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307
   Kozaki Koichi, 2006, Clin Calcium, V16, P31
   Krauss Ronald M., 1994, Current Opinion in Lipidology, V5, P339, DOI 10.1097/00041433 199410000 00005
   Kuller LH, 1999, ARTERIOSCL THROM VAS, V19, P2189, DOI 10.1161/01.ATV.19.9.2189
   Lai CF, 2012, ENDOCRINOLOGY, V153, P3897, DOI 10.1210/en.2012 1216
   Laird DF, 2006, J COLLOID INTERF SCI, V295, P348, DOI 10.1016/j.jcis.2005.09.013
   Lapolla A, 2005, CLIN CHIM ACTA, V357, P236, DOI 10.1016/j.cccn.2005.03.032
   Laughlin GA, 2012, J AM COLL CARDIOL, V59, P1688, DOI 10.1016/j.jacc.2012.01.038
   Lee HL, 2010, BIOCHEM BIOPH RES CO, V391, P1087, DOI 10.1016/j.bbrc.2009.12.027
   Lee JS, 2006, AM J PATHOL, V168, P490, DOI 10.2353/ajpath.2006.050338
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   Lencel P, 2011, LAB INVEST, V91, P1434, DOI 10.1038/labinvest.2011.83
   Li F, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395 012 0306 0
   Li FY, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532 429X 12 37
   Li GH, 2005, J BONE MINER RES, V20, P1611, DOI 10.1359/JBMR.050513
   Li XW, 2008, ATHEROSCLEROSIS, V199, P271, DOI 10.1016/j.atherosclerosis.2007.11.031
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Li ZY, 2011, CLIN EXP PHARMACOL P, V38, P888, DOI 10.1111/j.1440 1681.2011.05602.x
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   Loomans CJM, 2009, MOL MED, V15, P152, DOI 10.2119/molmed.2009.00032
   Lorant DP, 2011, DIABETES CARE, V34, P156, DOI 10.2337/dc10 0788
   Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Mansfield K, 2003, CALCIFIED TISSUE INT, V73, P161, DOI 10.1007/s00223 002 1056 z
   Martin SS, 2009, DIABETES, V58, P1887, DOI 10.2337/db08 1794
   Massy ZA, 2008, DIABETES METAB, V34, pS16, DOI 10.1016/S1262 3636(08)70098 3
   MAXWELL DB, 1986, J AM COLL NUTR, V5, P55
   Medina RJ, 2011, MOL MED, V17, P1045, DOI 10.2119/molmed.2011.00129
   Mehta NN, 2011, AM J CARDIOL, V107, P406, DOI 10.1016/j.amjcard.2010.09.035
   Mizobuchi M, 2007, KIDNEY INT, V72, P709, DOI 10.1038/sj.ki.5002406
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Mori K, 2012, ADV CLIN CHEM, V56, P175, DOI 10.1016/B978 0 12 394317 0.00010 8
   Mori K, 2010, ANGIOLOGY, V61, P86, DOI 10.1177/0003319708330525
   Movahed A, 2012, J BONE MINER METAB, V30, P683, DOI 10.1007/s00774 012 0367 z
   Mozar A, 2008, J CELL PHYSIOL, V215, P47, DOI 10.1002/jcp.21283
   Mudd JO, 2007, J AM COLL CARDIOL, V50, P1735, DOI 10.1016/j.jacc.2007.07.045
   Nadir MA, 2011, J AM COLL CARDIOL, V58, P570, DOI 10.1016/j.jacc.2011.01.063
   Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097 0177(199703)208:3<432::AID AJA13>3.0.CO;2 1
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   Nellemann B, 2007, DIABETES CARE, V30, P3122, DOI 10.2337/dc07 0919
   New SEP, 2011, CIRC J, V75, P1305, DOI 10.1253/circj.CJ 11 0395
   Nezami N, 2010, CLIN BIOCHEM, V43, P1294, DOI 10.1016/j.clinbiochem.2010.08.012
   Ng K, 2012, J HYPERTENS, V30, P1782, DOI 10.1097/HJH.0b013e3283562e35
   Nguyen N, 2013, CARDIOVASC PATHOL, V22, P167, DOI 10.1016/j.carpath.2012.06.007
   Nicholls SJ, 2007, J AM COLL CARDIOL, V49, P263, DOI 10.1016/j.jacc.2006.10.038
   Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263
   Ninomiya K, 2006, HYPERTENS RES, V29, P269, DOI 10.1291/hypres.29.269
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296
   OUCHI Y, 1993, ANN NY ACAD SCI, V676, P297, DOI 10.1111/j.1749 6632.1993.tb38743.x
   Pageau SC, 2009, MABS AUSTIN, V1, P210, DOI 10.4161/mabs.1.3.8592
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Parhami F, 2002, CIRC RES, V91, P570, DOI 10.1161/01.RES.0000036607.05037.DA
   Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097 218
   Pignolo RJ, 2011, J BONE MINER RES, V26, P1685, DOI 10.1002/jbmr.370
   Pirillo A, 2012, BIOCHEM BIOPH RES CO, V428, P230, DOI 10.1016/j.bbrc.2012.10.020
   Pirro M, 2010, OSTEOPOROSIS INT, V21, P297, DOI 10.1007/s00198 009 0968 0
   Price PA, 2002, CALCIFIED TISSUE INT, V71, P356, DOI 10.1007/s00223 002 1006 9
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Prosdocimo DA, 2010, AM J PHYSIOL CELL PH, V298, pC702, DOI 10.1152/ajpcell.00419.2009
   Proudfoot D, 2002, CIRCULATION, V106, P3044, DOI 10.1161/01.CIR.0000041429.83465.41
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Qasim A, 2008, J AM COLL CARDIOL, V52, P231, DOI 10.1016/j.jacc.2008.04.016
   Qasim AN, 2011, INT J CARDIOL, V150, P17, DOI 10.1016/j.ijcard.2010.02.021
   Rabbani N, 2010, DIABETES, V59, P1038, DOI 10.2337/db09 1455
   Radcliff K, 2005, CIRC RES, V96, P398, DOI 10.1161/01.RES.0000157671.47477.71
   Raggi P, 2010, CLIN J AM SOC NEPHRO, V5, pS31, DOI 10.2215/CJN.05880809
   Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007
   Rajamannan NM, 2005, CIRCULATION, V112, pI229, DOI 10.1161/01.CIRCULATIONAHA.104.524306
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Raymond CB, 2008, AM J HEALTH SYST PH, V65, P1419, DOI 10.2146/ajhp070546
   Reaven PD, 2005, DIABETOLOGIA, V48, P379, DOI 10.1007/s00125 004 1640 z
   Reilly MP, 2004, J CLIN ENDOCR METAB, V89, P3872, DOI 10.1210/jc.2003 031676
   Ren X, 2012, J ENDOCRINOL INVEST, V35, P497, DOI 10.3275/7865
   Ren X, 2009, J INT MED RES, V37, P847, DOI 10.1177/147323000903700329
   Reynolds JL, 2005, J AM SOC NEPHROL, V16, P2920, DOI 10.1681/ASN.2004100895
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Rohde E, 2006, STEM CELLS, V24, P357, DOI 10.1634/stemcells.2005 0072
   Rossi A, 2012, DIABETES CARE, V35, P1781, DOI 10.2337/dc12 0134
   Salas MJ, 2012, J CARDIOVASC PHARM T, V17, P133, DOI 10.1177/1074248411416504
   Santos LL, 2012, CLIN MED INSIGHTS EN, V5, P47, DOI 10.4137/CMED.S10007
   Saremi A, 2012, DIABETES CARE, V35, P2390, DOI 10.2337/dc12 0464
   Sarkar PD, 2012, ARCH PHYSIOL BIOCHEM, V118, P260, DOI 10.3109/13813455.2012.715651
   Savoia C, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001815
   Schernthaner G, 2009, INT J CLIN PRACT, V63, P912, DOI 10.1111/j.1742 1241.2009.02025.x
   Schindler TH, 2009, EUR HEART J, V30, P3064, DOI 10.1093/eurheartj/ehp482
   Sealand R, 2013, CURR DIABETES REP, V13, P411, DOI 10.1007/s11892 013 0376 x
   Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Shimizu T, 2012, INT HEART J, V53, P331, DOI 10.1536/ihj.53.331
   Shimizu T, 2011, J BIOL CHEM, V286, P19138, DOI 10.1074/jbc.M110.175786
   Shoji T, 2001, J AM SOC NEPHROL, V12, P2117, DOI 10.1681/ASN.V12102117
   Siasos G, 2012, CURR MED CHEM, V19, P1193, DOI 10.2174/092986712799320583
   Sniderman AD, 2001, ANN INTERN MED, V135, P447, DOI 10.7326/0003 4819 135 6 200109180 00014
   Son BK, 2006, CIRC RES, V98, P1024, DOI 10.1161/01.RES.0000218859.90970.8d
   Sorescu GP, 2003, J BIOL CHEM, V278, P31128, DOI 10.1074/jbc.M300703200
   Sowers KM, 2010, OXID MED CELL LONGEV, V3, P109, DOI 10.4161/oxim.3.2.11354
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Stewart AJ, 2003, PROTEIN ENG, V16, P889, DOI 10.1093/protein/gzg126
   Suga T, 2011, J ATHEROSCLER THROMB, V18, P670, DOI 10.5551/jat.7120
   Sugitani Hideki, 2002, J Atheroscler Thromb, V9, P292
   Sui YB, 2013, PEPTIDES, V42, P25, DOI 10.1016/j.peptides.2012.12.023
   Sun Y, 2012, CIRC RES, V111, P543, DOI 10.1161/CIRCRESAHA.112.267237
   Tada Y, 2013, HORM METAB RES, V45, P267, DOI 10.1055/s 0032 1329965
   Tanikawa T, 2009, J VASC RES, V46, P572, DOI 10.1159/000226225
   TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261
   Taniwaki H, 2005, NEPHROL DIAL TRANSPL, V20, P2472, DOI 10.1093/ndt/gfi039
   Taylor J, 2011, J CELL BIOCHEM, V112, P581, DOI 10.1002/jcb.22948
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Thomsen SB, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475 2840 9 86
   Tintut Y, 2003, CIRCULATION, V108, P2505, DOI 10.1161/01.CIR.0000096485.64373.C5
   Tison GH, 2011, ATHEROSCLEROSIS, V218, P507, DOI 10.1016/j.atherosclerosis.2011.06.047
   Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427
   Towler DA, 2011, ARTERIOSCL THROM VAS, V31, P237, DOI 10.1161/ATVBAHA.110.220038
   Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Van Campenhout A, 2009, ATHEROSCLEROSIS, V204, P321, DOI 10.1016/j.atherosclerosis.2008.09.033
   Vijan Suresh G, 2009, J Indian Med Assoc, V107, P178
   Vogt MT, 1997, J AM GERIATR SOC, V45, P140, DOI 10.1111/j.1532 5415.1997.tb04498.x
   Wang NN, 2010, NEPHRON EXP NEPHROL, V115, pE60, DOI 10.1159/000313831
   Wang ZQ, 2012, ATHEROSCLEROSIS, V221, P387, DOI 10.1016/j.atherosclerosis.2012.01.019
   WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205
   Wei Q, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471 2261 13 13
   Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805
   Westenfeld R, 2007, NEPHROL DIAL TRANSPL, V22, P1537, DOI 10.1093/ndt/gfm094
   Westenfeld R, 2009, J AM SOC NEPHROL, V20, P1264, DOI 10.1681/ASN.2008060572
   Woldt E, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2087
   Wright E, 2006, INT J CLIN PRACT, V60, P308, DOI 10.1111/j.1368 5031.2006.00825.x
   Wu B, 2005, ARTERIOSCL THROM VAS, V25, P592, DOI 10.1161/01.ATV.0000154278.01871.64
   Wu SY, 2012, EXP BIOL MED, V237, P31, DOI 10.1258/ebm.2011.011175
   Yamagishi S, 2007, MED HYPOTHESES, V68, P1096, DOI 10.1016/j.mehy.2006.07.059
   Yamagishi S, 2004, DRUG EXP CLIN RES, V30, P169
   Yamagishi S, 2011, EXP GERONTOL, V46, P217, DOI 10.1016/j.exger.2010.11.007
   YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167 4781(92)90522 2
   Yang H, 2004, KIDNEY INT, V66, P2293, DOI 10.1111/j.1523 1755.2004.66015.x
   Yeh ETH, 2003, CIRCULATION, V108, P2070, DOI 10.1161/01.CIR.0000099501.52718.70
   Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636
   YLITALO R, 1994, J LAB CLIN MED, V123, P769
   Zeadin MG, 2012, BIOCHEM BIOPH RES CO, V425, P924, DOI 10.1016/j.bbrc.2012.08.011
   Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925 4773(01)00428 2
   Zhang LF, 2003, CIRCULATION, V108, P472, DOI 10.1161/01.CIR.0000080378.96063.23
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620
   Zhou YB, 2012, EXP BIOL MED, V237, P50, DOI 10.1258/ebm.2011.011252
NR 237
TC 33
Z9 37
U1 0
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 37
BP 5870
EP 5883
DI 10.2174/1381612820666140212210451
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3YZ
UT WOS:000342015200010
PM 24533933
DA 2025 08 17
ER

PT J
AU Yao, ZQ
   Li, P
   Zhang, Q
   Schwarz, EM
   Keng, P
   Arbini, A
   Boyce, BF
   Xing, LP
AF Yao, ZQ
   Li, P
   Zhang, Q
   Schwarz, EM
   Keng, P
   Arbini, A
   Boyce, BF
   Xing, LP
TI Tumor necrosis factor α increases circulating osteoclast precursor
   numbers by promoting their proliferation and differentiation in the bone
   marrow through up regulation of c Fms expression
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TNF ALPHA; IN VIVO; RHEUMATOID ARTHRITIS; RECEPTOR ACTIVATOR; JOINT
   DESTRUCTION; TRANSGENIC MICE; PROGENITOR; CELLS; LIGAND; TRANSCRIPTION
AB Osteoclasts are essential cells for bone erosion in inflammatory arthritis and are derived from cells in the myeloid lineage. Recently, we reported that tumor necrosis factor alpha (TNF alpha) increases the blood osteoclast precursor (OCP) numbers in arthritic patients and animals, which are reduced by anti TNF therapy, implying that circulating OCPs may have an important role in the pathogenesis of erosive arthritis. The aim of this study is to investigate the mechanism by which TNF alpha induces this increase in OCP frequency. We found that TNF alpha stimulated cell division and conversion of CD11b(+)/Gr 1( /lo)/c Fms( ) to CD11b(+)/Gr 1( /lo)/c Fms( ) cells, which was not blocked by neutralizing macrophage colony stimulating factor (M CSF) antibody. Ex vivo analysis of monocytes demonstrated the following: (i) blood CD11b(+)/Gr 1( /lo) but not CD11b( )/Gr 1( ) cells give rise to osteoclasts when they were cultured with receptor activator NF kappa B ligand and M CSF; and (ii) TNF transgenic mice have a significant increase in blood CD11b(+)/Gr 1( /lo) cells and bone marrow proliferating CD11b(+)/Gr 1( /lo) cells. Administration of TNF alpha to wild type mice induced bone marrow CD11b(+)/Gr 1( /lo) cell proliferation, which was associated with an increase in CD11b(+)/Gr 1( /lo) OCPs in the circulation. Thus, TNF alpha directly stimulates bone marrow OCP genesis by enhancing c Fms expression. This results in progenitor cell proliferation and differentiation in response to M CSF, leading to an enlargement of the marrow OCP pool. Increased marrow OCPs subsequently egress to the circulation, forming a basis for elevated OCP frequency. Therefore, the first step of TNF induced osteoclastogenesis is at the level of OCP genesis in the bone marrow, which represents another layer of regulation to control erosive disease.
C1 Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA.
   Univ Rochester, Med Ctr, Dept Orthoped, Rochester, NY 14642 USA.
   Univ Rochester, Med Ctr, Canc Res Ctr, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM Lianping_xing@urmc.rochester.edu
OI Arbini, Arnaldo/0000 0003 0345 4174; Yao, Zhenqiang/0000 0002 4664 3648
FU NIAMS NIH HHS [AR43510, AR48697] Funding Source: Medline
CR Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599
   Alford PB, 1997, BIOCHEM BIOPH RES CO, V240, P442, DOI 10.1006/bbrc.1997.7670
   Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Fan X, 1997, J BONE MINER RES, V12, P1387, DOI 10.1359/jbmr.1997.12.9.1387
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074 7613(03)00174 2
   Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223 002 1049 y
   Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327
   Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393
   Huang W, 2003, ARTHRITIS RES THER, V5, pR49, DOI 10.1186/ar612
   Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461
   Kaplan DL, 1996, J CELL PHYSIOL, V168, P199
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lam J, 2002, ANN RHEUM DIS, V61, P82
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Quinones MP, 2004, J CLIN INVEST, V113, P856, DOI 10.1172/JCI200420126
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Xing LP, 2005, CURR RHEUMATOL REV, V1, P21, DOI 10.2174/1573397052954127
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
NR 33
TC 168
Z9 215
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 28
PY 2006
VL 281
IS 17
BP 11846
EP 11855
DI 10.1074/jbc.M512624200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 035GH
UT WOS:000236988100051
PM 16461346
OA hybrid
DA 2025 08 17
ER

PT J
AU Baloun, J
   Pekacova, A
   Wenchich, L
   Hruskova, H
   Senolt, L
   Svec, X
   Pavelka, K
   Stepan, JJ
AF Baloun, Jiri
   Pekacova, Aneta
   Wenchich, Laszlo
   Hruskova, Hana
   Senolt, Ladislav
   Svec, Xiao
   Pavelka, Karel
   Stepan, Jan J.
TI Menopausal Transition: Prospective Study of Estrogen Status, Circulating
   MicroRNAs, and Biomarkers of Bone Metabolism
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE estrogen; circulating miRNA; bone remodeling; oophorectomy; osteoporosis
   prevention and control
ID MESENCHYMAL STEM CELLS; POSTMENOPAUSAL WOMEN; SCLEROSTIN LEVELS; SERUM
   SCLEROSTIN; OSTEOGENIC DIFFERENTIATION; PARATHYROID HORMONE; VITAMIN D;
   MECHANISM; MIRNAS; OSTEOPROTEGERIN
AB ObjectiveOsteoporosis is associated with an impaired balance between bone resorption and formation, which in turn leads to bone loss and fractures. Many recent studies have underlined the regulatory role of microRNAs (miRNAs) in bone remodeling processes and their potential as biomarkers of osteoporosis. The purpose of this study was to prospectively examine the association of circulating miRNAs and bone biomarkers with estrogen status in women before and after oophorectomy, as well as in oophorectomized women on estrogen therapy. MethodsIn this prospective study, we included 11 women before oophorectomy and hysterectomy and at 201 +/  24 days after the surgery. Another 11 women were evaluated 508 +/  127 days after oophorectomy and hysterectomy and after an additional 203 +/  71 days of estradiol treatment. Serum miRNAs were profiled by sequencing. Estrogen status and biomarkers of bone metabolism were quantified. Bone mineral density was assessed in the lumbar spine. ResultsOur analysis revealed 17 miRNAs associated with estrogen levels. Of those miRNAs that were upregulated with estrogen deficiency and downregulated after estrogen therapy, miR 422a correlated with serum beta carboxy terminal type I collagen crosslinks (beta CTX) and procollagen 1 N terminal propeptide (P1NP); and miR 1278 correlated with serum beta CTX, P1NP, osteocalcin, sclerostin, and Dickkopf 1(Dkk1). In contrast, we found an inverse association of miR 24 1 5p with estrogen status and a negative correlation with serum beta CTX, P1NP, osteoprotegerin, and sclerostin levels. ConclusionThe reported miRNAs associated with estrogen status and bone metabolism could be potential biomarkers of bone pathophysiology and would facilitate studies on the prevention of postmenopausal osteoporosis. Our findings require validation in an extended cohort.
C1 [Baloun, Jiri; Pekacova, Aneta; Wenchich, Laszlo; Senolt, Ladislav; Svec, Xiao; Pavelka, Karel; Stepan, Jan J.] Inst Rheumatol, Prague, Czech Republic.
   [Baloun, Jiri; Pekacova, Aneta; Senolt, Ladislav; Pavelka, Karel; Stepan, Jan J.] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic.
   [Hruskova, Hana] Charles Univ Prague, Fac Med 1, Dept Obstet & Gynecol, Prague, Czech Republic.
   [Hruskova, Hana] Gen Univ Hosp Prague, Prague, Czech Republic.
C3 Institute of Rheumatology; Charles University Prague; Charles University
   Prague; General University Hospital Prague
RP Stepan, JJ (通讯作者)，Inst Rheumatol, Prague, Czech Republic.; Stepan, JJ (通讯作者)，Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic.
EM stepan@revma.cz
RI Baloun, Jiri/B 4043 2018; Pavelka, Karel/E 6578 2017; Šenolt,
   Ladislav/IVH 7444 2023; Prokopcová, Aneta/ABV 6519 2022; Stepan,
   Jan/A 7280 2013
OI Baloun, Jiri/0000 0001 7029 1550; Prokopcova, Aneta/0000 0002 8947 5955;
   Svec, Xiao/0000 0001 5700 9055
FU Ministry of Health of the Czech Republic [NV18 05 00394]; Institute of
   Rheumatology [RVO 00023728]; Charles University project [SVV 260~523]
FX This research was funded by the Ministry of Health of the Czech Republic
   under grant NV18 05 00394 and by RVO 00023728 (Institute of
   Rheumatology), Charles University project SVV 260~523.
CR Acibucu F, 2017, EXP CLIN ENDOCR DIAB, V125, P634, DOI 10.1055/s 0035 1559790
   Adeel S, 2013, J INVEST MED, V61, P1178, DOI 10.2310/JIM.0000000000000016
   Ahmed SF, 2013, J OSTEOPOROS, V2013, DOI 10.1155/2013/460210
   An JH, 2014, J BONE MINER RES, V29, P644, DOI 10.1002/jbmr.2060
   Anastasilakis AD, 2022, BONE, V158, DOI 10.1016/j.bone.2022.116354
   Anastasilakis AD, 2018, J CLIN ENDOCR METAB, V103, P1206, DOI 10.1210/jc.2017 02406
   Andrews S., 1973, Soil, DOI DOI 10.1016/0038 0717(73)90093 X
   [Anonymous], 2000, JAMA, V284, P3043
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Brooks ME, 2017, R J, V9, P378, DOI 10.32614/RJ 2017 066
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Cauley JA, 2007, J BONE MINER RES, V22, P1088, DOI 10.1359/JBMR.070409
   Chen ZJ, 2019, BONE, V120, P271, DOI 10.1016/j.bone.2018.11.001
   Cheng VKF, 2019, JBMR PLUS, V3, P2, DOI 10.1002/jbm4.10115
   Chung YE, 2012, OSTEOPOROSIS INT, V23, P1235, DOI 10.1007/s00198 011 1675 1
   Condrat CE, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020276
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Dawson Hughes B, 2014, EUR J ENDOCRINOL, V170, P645, DOI 10.1530/EJE 13 0862
   Edmonston D, 2020, NAT REV NEPHROL, V16, P7, DOI 10.1038/s41581 019 0189 5
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Faubion L, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14535
   Feurer E, 2019, J BONE MINER RES, V34, P1074, DOI 10.1002/jbmr.3685
   Fontana A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82286 1
   Fujita K, 2014, J CLIN ENDOCR METAB, V99, pE81, DOI 10.1210/jc.2013 3249
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grillari J, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115787
   Han KO, 2005, CLIN ENDOCRINOL, V62, P349, DOI 10.1111/j.1365 2265.2005.02221.x
   Hannon R, 1998, J BONE MINER RES, V13, P1124, DOI 10.1359/jbmr.1998.13.7.1124
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Huai Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.516213
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Jones TL, 2021, BONE, V152, DOI 10.1016/j.bone.2021.116068
   Kerschan Schindl K, 2021, CALCIFIED TISSUE INT, V108, P725, DOI 10.1007/s00223 020 00802 3
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kudlacek S, 2003, BONE, V32, P681, DOI 10.1016/S8756 3282(03)00090 5
   Lehmann J, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102224
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003 4819 150 9 200905050 00006
   Lisse TS, 2013, J BONE MINER RES, V28, P1478, DOI 10.1002/jbmr.1882
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   Panach L, 2015, CALCIFIED TISSUE INT, V97, P495, DOI 10.1007/s00223 015 0036 z
   Randolph JF, 2004, J CLIN ENDOCR METAB, V89, P1555, DOI 10.1210/jc.2003 031183
   Roth MJ, 2021, BMC DEV BIOL, V21, DOI 10.1186/s12861 021 00243 7
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Stepan JJ, 2019, CURR OSTEOPOROS REP, V17, P465, DOI 10.1007/s11914 019 00549 3
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007 0001
   Sun MG, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1652417
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   Team R.C., 2022, R: A Language and Environment for Statistical Computing
   Tian J, 2015, J HUAZHONG U SCI MED, V35, P212, DOI 10.1007/s11596 015 1413 6
   Vitsios DM, 2015, BIOINFORMATICS, V31, P3365, DOI 10.1093/bioinformatics/btv380
   Weilner S, 2015, BONE, V79, P43, DOI 10.1016/j.bone.2015.05.027
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
   Yavropoulou MP, 2018, J MUSCULOSKEL NEURON, V18, P18
   Yavropoulou MP, 2017, EUR J ENDOCRINOL, V176, P169, DOI 10.1530/EJE 16 0583
   You L, 2016, CELL PHYSIOL BIOCHEM, V39, P253, DOI 10.1159/000445621
   Zeng Y, 2012, FEBS LETT, V586, P2375, DOI 10.1016/j.febslet.2012.05.049
   Zhao WH, 2018, J CELL PHYSIOL, V233, P9191, DOI 10.1002/jcp.26939
NR 67
TC 7
Z9 9
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 13
PY 2022
VL 13
AR 864299
DI 10.3389/fendo.2022.864299
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1P1DK
UT WOS:000801758200001
PM 35634507
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, J
   Miszuk, JM
   Stein, KM
   Sun, HL
AF Hu, Jue
   Miszuk, Jacob M.
   Stein, Kyle M.
   Sun, Hongli
TI Nanoclay promotes mouse cranial bone regeneration mainly through
   modulating drug binding and sustained release
SO APPLIED MATERIALS TODAY
LA English
DT Article
DE Nanoclays; Sustained drug release; Cranial bone regeneration; 3D
   nanofibrous scaffolds; BMPs; Bone tissue engineering
ID NANOFIBROUS SCAFFOLDS; OSTEOGENIC DIFFERENTIATION; HYDROGELS; LAPONITE;
   WNT
AB Nanoclay (Nanosilicates, NS) is appearing as an intriguing 2D nanomaterial for bone tissue engineering with multiple proposed functions, e.g., intrinsic osteoinductivity, improving mechanical properties, and drug release capacity. However, the mechanism of NS for in vivo bone regeneration has been hardly defined so far. This knowledge gap will significantly affect the design/application of NS based biomaterials. To determine the role of NS in osteoblastic differentiation and bone formation, we used mouse calvarial derived pre osteoblasts (MC3T3 E1) and a clinically relevant mouse cranial bone defect model. Instead of a hydrogel, we prepared biomimetic 3D gelatin nanofibrous scaffolds (GF) and NS blended composite scaffolds (GF/NS) to determine the essential role of NS in critical low dose (0.5 mu g per scaffold) of BMP2 induced cranial bone regeneration. In contrast to "osteoinductivity", our data indicated that NS could enable single dose of BMP2, promoting significant osteoblastic differentiation while multiple dose of BMP2 (without NS) was required to achieve similar efficacy. Moreover, our release study revealed that direct binding to NS in GF scaffolds provided stronger protection to BMP2 and sustained release compared to GF/NS composite scaffolds. Consistently, our in vivo data indicated that only BMP2/NS direct binding treatment was able to repair the large mouse cranial bone defects after 6 weeks of transplantation while neither BMP2, NS alone, nor BMP2 released from GF/NS scaffolds was sufficient to induce significant cranial bone defect repair. Therefore, we concluded that direct nanoclay drug binding enabled sustained release is the most critical contribution to the significantly improved bone regeneration compared to other possible mechanisms based on our study. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hu, Jue; Miszuk, Jacob M.; Stein, Kyle M.; Sun, Hongli] Univ Iowa, Coll Dent, Dept Oral & Maxillofacial Surg, Iowa City, IA 52242 USA.
   [Hu, Jue; Miszuk, Jacob M.; Sun, Hongli] Univ Iowa, Coll Dent, Iowa Inst Oral Hlth Res, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Sun, HL (通讯作者)，Univ Iowa, Coll Dent, Dept Oral & Maxillofacial Surg, Iowa City, IA 52242 USA.; Sun, HL (通讯作者)，Univ Iowa, Coll Dent, Iowa Inst Oral Hlth Res, Iowa City, IA 52242 USA.
EM hongli sun@uiowa.edu
RI Sun, Hongli/GYV 2770 2022
FU Department of Oral and Maxillofacial Surgery at the University of Iowa;
   National Institute of Dental & Craniofacial Research of the National
   Institutes of Health [R03DE027491, RO1DE029159, T90DE023520]
FX This work was supported by the startup funds from the Department of Oral
   and Maxillofacial Surgery at the University of Iowa, the National
   Institute of Dental & Craniofacial Research of the National Institutes
   of Health under Award Numbers R03DE027491, RO1DE029159, and T90DE023520.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health. The authors also would like to thank Dr. Brad A. Amendt and the
   members of his lab for their support in microscope usage.
CR Aguzzi C, 2007, APPL CLAY SCI, V36, P22, DOI 10.1016/j.clay.2006.06.015
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Angelini R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5049
   Ao Q, 2020, ACS APPL MATER INTER, V12, P13400, DOI 10.1021/acsami.0c01371
   Basu S, 2018, ACS NANO, V12, P9866, DOI 10.1021/acsnano.8b02434
   Cancedda R, 2007, BIOMATERIALS, V28, P4240, DOI 10.1016/j.biomaterials.2007.06.023
   Carrow JK, 2018, P NATL ACAD SCI USA, V115, pE3905, DOI 10.1073/pnas.1716164115
   Chaudhuri O, 2016, NAT MATER, V15, P326, DOI [10.1038/NMAT4489, 10.1038/nmat4489]
   Chen LJ, 2018, NANOMEDICINE UK, V13, P1939, DOI 10.2217/nnm 2018 0076
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Costa Pinto Ana, 2016, TESTING NATURAL BIOM, P571, DOI [10.1002/9781119126218.ch30, DOI 10.1002/9781119126218.CH30]
   Cross LM, 2019, ACS APPL MATER INTER, V11, P6741, DOI 10.1021/acsami.8b17733
   Delhorme M, 2012, SOFT MATTER, V8, P9691, DOI 10.1039/c2sm25731a
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Gaharwar AK, 2013, ADV MATER, V25, P3329, DOI 10.1002/adma.201300584
   García Vázquez R, 2020, APPL CLAY SCI, V189, DOI 10.1016/j.clay.2020.105541
   Gibbs DMR, 2016, BIOMATERIALS, V99, P16, DOI 10.1016/j.biomaterials.2016.05.010
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P98, DOI 10.2106/00004623 200100022 00007
   Han PP, 2013, BIOMATER SCI UK, V1, P379, DOI 10.1039/c2bm00108j
   Hou Y, 2018, ACTA BIOMATER, V77, P28, DOI 10.1016/j.actbio.2018.07.003
   Jaiswal MK, 2016, ACS NANO, V10, P246, DOI 10.1021/acsnano.5b03918
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Kim S, 2018, ACTA BIOMATER, V72, P45, DOI 10.1016/j.actbio.2018.03.034
   Kim YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15152 9
   Koshy ST, 2018, ACTA BIOMATER, V65, P36, DOI 10.1016/j.actbio.2017.11.024
   Lad SP, 2013, NEUROSURGERY, V73, P440, DOI 10.1227/NEU.0000000000000018
   Li K, 2014, ACS APPL MATER INTER, V6, P12328, DOI 10.1021/am502094a
   Lin H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1350 6
   Liu YX, 2020, J TISSUE ENG REGEN M, V14, P464, DOI 10.1002/term.3007
   Miszuk JM, 2018, APPL MATER TODAY, V10, P194, DOI 10.1016/j.apmt.2017.12.004
   Ng MH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/345910
   Perikamana SKM, 2015, ACS APPL MATER INTER, V7, P8798, DOI 10.1021/acsami.5b01340
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Rahmany MB, 2013, ACTA BIOMATER, V9, P5431, DOI 10.1016/j.actbio.2012.11.019
   Razafiarison T, 2018, P NATL ACAD SCI USA, V115, P4631, DOI 10.1073/pnas.1704543115
   Sheehy EJ, 2019, MATER TODAY BIO, V3, DOI 10.1016/j.mtbio.2019.100009
   Shuang Y, 2016, BMC ORAL HEALTH, V17, DOI 10.1186/s12903 016 0263 3
   Sun HL, 2014, BIOMATERIALS, V35, P1176, DOI 10.1016/j.biomaterials.2013.10.054
   Sun HL, 2012, TISSUE ENG PT A, V18, P2095, DOI [10.1089/ten.tea.2011.0742, 10.1089/ten.TEA.2011.0742]
   THOMPSON DW, 1992, J COLLOID INTERF SCI, V151, P236, DOI 10.1016/0021 9797(92)90254 J
   Xavier JR, 2015, ACS NANO, V9, P3109, DOI 10.1021/nn507488s
   Yao QQ, 2020, J MATER CHEM B, V8, P3842, DOI 10.1039/c9tb02814e
   Yao QQ, 2018, J CONTROL RELEASE, V279, P69, DOI 10.1016/j.jconrel.2018.04.011
   Yao QQ, 2017, J MATER CHEM B, V5, P5196, DOI [10.1039/C7TB00744B, 10.1039/c7tb00744b]
   Yao QQ, 2017, BIOMATERIALS, V115, P115, DOI 10.1016/j.biomaterials.2016.11.018
   Yao QQ, 2016, ACS APPL MATER INTER, V8, P32450, DOI 10.1021/acsami.6b10538
   Yoshizawa S, 2014, ACTA BIOMATER, V10, P2834, DOI 10.1016/j.actbio.2014.02.002
   Zhang YH, 2020, BIOMATER SCI UK, V8, P682, DOI 10.1039/c9bm01455a
   Zhou Q, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700641
NR 50
TC 19
Z9 20
U1 0
U2 66
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 9407
J9 APPL MATER TODAY
JI Appl. Mater. Today
PD DEC
PY 2020
VL 21
AR 100860
DI 10.1016/j.apmt.2020.100860
PG 10
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA PG6ED
UT WOS:000599825600010
PM 33225042
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mehaney, DA
   Eissa, M
   Anwar, S
   El Din, SF
AF Mehaney, D. A.
   Eissa, M.
   Anwar, S.
   El Din, Fakhr S.
TI Serum sclerostin level among Egyptian rheumatoid arthritis patients:
   relation to disease activity, bone mineral density and radiological
   grading
SO ACTA REUMATOLOGICA PORTUGUESA
LA English
DT Article
DE Sclerostin; Bone loss; Rheumatoid arthritis
ID INFLAMMATORY ARTHRITIS; MECHANISMS; WNT; METHOTREXATE; DICKKOPF 1;
   FRACTURES; DIAGNOSIS; CRITERIA; THERAPY; MASS
AB Introduction: Bone loss in rheumatoid arthritis is caused by increased bone resorption without an increment in bone formation. The Wnt pathway is important in the control of bone formation through the regulation of osteoblast activity Sclerostin is an important regulator of the Wnt pathway by blocking Wnt binding to its receptor and thereby inhibiting bone formation.
   Aim: This study aimed to assess the serum sclerostin level in a group of Egyptian rheumatoid arthritis patients and to correlate its level with bone mineral density, disease activity and radiological grading.
   Methods: Forty rheumatoid arthritis patients (mean age 48.9 +/  11.6 years, disease duration 8 +/  6.4 years) and 40 age and sex matched apparently healthy subjects were included. Serum sclerostin level was measured using enzyme linked immunosorbent assay Plain radiographs of hands and feet and dual energy x ray absorptiometry test were done for all patients.
   Results: No significant difference was found between rheumatoid arthritis patients and healthy controls regarding the mean value of sclerostin level. Postmenopausal healthy women had higher levels of sclerostin than premenopausal healthy women. Serum sclerostin had significantly positive correlations with the age of onset and weight of rheumatoid arthritis patients and negative correlation with erythrocyte sedimentation rate. No correlation was encountered between sclerostin level and bone mineral density, disease activity or radiographic grading.
   Conclusion: For better clarification of the role of sclerostin on bone mass in rheumatoid arthritis, larger sample size is needed. More studies on serum sclerostin levels among different grades of RA activity are encouraged.
C1 [Mehaney, D. A.] Cairo Univ, Fac Med, Clin & Chem Pathol Dept, Cairo, Egypt.
   [Eissa, M.; Anwar, S.; El Din, Fakhr S.] Cairo Univ, Fac Med, Rheumatol & Rehabil Dept, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank
   (EKB); Cairo University
RP Mehaney, DA (通讯作者)，Cairo Univ, Fac Med, Clincial & Chemcial Pathol Dept, Cairo, Egypt.
EM drdinamehaney@kasralainy.edu.eg
RI ; Eissa, Mervat/J 3616 2019
OI Fakhreldin, Sahar/0000 0001 7476 5944; Eissa,
   Mervat/0000 0001 7999 3401; 
FU Cairo University
FX This study is supported by Cairo University research funds.
CR Abdelhadi M, 2002, TRANSPLANT INT, V15, P180, DOI 10.1007/s00147 002 0413 1
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   Alonso Bartolomé P, 1999, SEMIN ARTHRITIS RHEU, V28, P413, DOI 10.1016/S0049 0172(99)80007 9
   Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   [Anonymous], 2007, WHO scientific group on the assessment of osteoporosis at primary care level
   Ardawi MSM, 2012, J BONE MINER RES, V27, P2592, DOI 10.1002/jbmr.1718
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   EGGELMEIJER F, 1993, BRIT J RHEUMATOL, V32, P387
   Garnero P, 2013, OSTEOPOROSIS INT, V24, P489, DOI 10.1007/s00198 012 1978 x
   Gennari L, 2012, J CLIN ENDOCR METAB, V97, P1737, DOI 10.1210/jc.2011 2958
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Güler Yüksel M, 2009, ANN RHEUM DIS, V68, P330, DOI 10.1136/ard.2007.086348
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   Jolles BM, 2002, J RHEUMATOL, V29, P1814
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Minaur NJ, 2002, RHEUMATOLOGY, V41, P741, DOI 10.1093/rheumatology/41.7.741
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   PINCUS T, 1983, ARTHRITIS RHEUM US, V26, P1346, DOI 10.1002/art.1780261107
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   PRESTON SJ, 1993, ANN RHEUM DIS, V52, P582, DOI 10.1136/ard.52.8.582
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Sheng ZF, 2012, CLIN ENDOCRINOL, V76, P797, DOI 10.1111/j.1365 2265.2011.04315.x
   Szulc P, 2013, J BONE MINER RES, V28, P169, DOI 10.1002/jbmr.1726
   Urano T, 2012, J CLIN ENDOCR METAB, V97, pE1473, DOI 10.1210/jc.2012 1218
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   van der Heijde D, 1999, J RHEUMATOL, V26, P743
   Vis M, 2011, ARTHRITIS RHEUM US, V63, pS703
   Vrijhoef HJM, 2003, ANN RHEUM DIS, V62, P419, DOI 10.1136/ard.62.5.419
   Walsh NC, 2004, CURR OPIN RHEUMATOL, V16, P419, DOI 10.1097/01.bor.0000127824.42507.68
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Weidauer SE, 2009, BIOCHEM BIOPH RES CO, V380, P160, DOI 10.1016/j.bbrc.2009.01.062
NR 34
TC 14
Z9 14
U1 0
U2 1
PU PUBLISAUDE EDICOES MEDICAS LDA
PI ALGES
PA ALAMEDA ANTONIO SERGIO 22, 4 B EDIF AMADEO SOUZA CARDOSO, ALGES,
   1495 132, PORTUGAL
SN 0303 464X
J9 ACTA REUMATOL PORT
JI Acta Reumatol. Port.
PD JUL SEP
PY 2015
VL 40
IS 3
BP 268
EP 274
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CX1KT
UT WOS:000365455800008
PM 26535777
DA 2025 08 17
ER

PT J
AU Hamano, T
AF Hamano, Takayuki
TI Mineral and bone disorders in conventional hemodialysis: Challenges and
   solutions
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID CORONARY ARTERY CALCIFICATION; CINACALCET HCL THERAPY; VASCULAR
   CALCIFICATION; CARDIOVASCULAR DISEASE; PHOSPHATE BINDERS; DIALYSIS
   PATIENTS; RECEIVING HEMODIALYSIS; FERRIC CARBOXYMALTOSE; ANEMIA
   MANAGEMENT; HEART FAILURE
AB Despite the advent of cinacalcet and noncalcium containing phosphate binders, controlling the progression of vascular calcification (VC) is still challenging. Recent reports demonstrate that carbamylation driven by high urea concentration aggravates VC, suggesting the importance of adequate dialysis in retarding its progression. Theoretically, other promising measures include the use of iron based phosphate binders, vitamin K, and magnesium supplements, which should be investigated in future randomized controlled trials (RCTs), ideally with hard outcomes. While incidence of hip fracture in patients on dialysis is decreasing in the United States and Japan (possibly owing to better control of PTH levels by cinacalcet) it remains much higher than that in the general population. Many drugs used in the treatment of osteoporosis, including bisphosphonate, raloxifene, denosumab, and teriparatide can, under specific conditions, increase bone mineral density (BMD), which is associated with a lower fracture rate. However, the efficacy of these drugs in reducing the fracture rate remains to be proven in hemodialysis (HD) patients, given their adverse effects such as severe hypocalcemia and resultant worsening of secondary hyperparathyroidism. Some clinical studies have shown that cinacalcet, lanthanum carbonate, and sevelamer reduce mortality in elderly patients on HD, suggesting the benefits of reducing PTH and serum phosphate levels. However, the target ranges of PTH and phosphate levels are based solely on observational studies. This is also the case when treating low PTH levels by decreasing vitamin D or calcium load. RCTs with hard clinical endpoints comparing different targets are necessary in the future.
C1 [Hamano, Takayuki] Osaka Univ, Dept Interorgan Commun Res Kidney Dis, Grad Sch Med, Osaka, Japan.
C3 University of Osaka
RP Hamano, T (通讯作者)，Osaka Univ, Dept Interorgan Commun Res Kidney Dis, Grad Sch Med, Osaka, Japan.
EM hamatea@kid.med.osaka u.ac.jp
RI Hamano, TAKAYUKI/AAZ 4837 2021
CR Akizawa T, 2016, SCI REP UK, V6, DOI 10.1038/srep19612
   Anker SD, 2009, NEW ENGL J MED, V361, P2436, DOI 10.1056/NEJMoa0908355
   Arneson TJ, 2013, AM J KIDNEY DIS, V62, P747, DOI 10.1053/j.ajkd.2013.02.368
   Benson T, 2016, OSTEOPOROSIS INT, V27, P1817, DOI 10.1007/s00198 015 3460 z
   Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167
   Cejka D, 2010, KIDNEY BLOOD PRESS R, V33, P221, DOI 10.1159/000316708
   Chen CL, 2015, J CLIN ENDOCR METAB, V100, P2784, DOI 10.1210/jc.2015 1259
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Ciceri P, 2016, ATHEROSCLEROSIS, V254, P93, DOI 10.1016/j.atherosclerosis.2016.09.071
   Cosman F, 1997, J BONE MINER RES, V12, P958, DOI 10.1359/jbmr.1997.12.6.958
   Covic AC, 2017, NEPHROL DIAL TRANSPL, V32, P1363, DOI 10.1093/ndt/gfw242
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Di Iorio B, 2013, AM J KIDNEY DIS, V62, P771, DOI 10.1053/j.ajkd.2013.03.023
   Eriguchi R, 2009, CLIN NEPHROL, V72, P423
   Hamano T, 2010, J AM SOC NEPHROL, V21, P1998, DOI 10.1681/ASN.2009090944
   Hamano T, 2009, BONE, V45, pS19, DOI 10.1016/j.bone.2009.03.663
   Hanafusa N, 2014, NEPHROL DIAL TRANSPL, V29, P2316, DOI 10.1093/ndt/gfu272
   Hernández E, 2003, KIDNEY INT, V63, P2269, DOI 10.1046/j.1523 1755.2003.00005.x
   Hiramatsu R, 2015, AM J KIDNEY DIS, V66, P175, DOI 10.1053/j.ajkd.2015.03.012
   Isaka Y, 2018, CLIN EXP NEPHROL, V22, P967, DOI 10.1007/s10157 018 1547 5
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Louvet L, 2013, NEPHROL DIAL TRANSPL, V28, P869, DOI 10.1093/ndt/gfs520
   McCabe KM, 2013, KIDNEY INT, V83, P835, DOI 10.1038/ki.2012.477
   Miskulin DC, 2018, J AM SOC NEPHROL, V29, P307, DOI 10.1681/ASN.2017020135
   Mitsopoulos E, 2012, AM J NEPHROL, V36, P238, DOI 10.1159/000341864
   Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876
   Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414
   Mokas S, 2016, KIDNEY INT, V90, P598, DOI 10.1016/j.kint.2016.05.020
   de Oca AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089525
   Mori D, 2018, KIDNEY INT, V94, P72, DOI 10.1016/j.kint.2018.01.033
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nickolas TL, 2013, J BONE MINER RES, V28, P1811, DOI 10.1002/jbmr.1916
   Ochiai M, 2011, NEPHRON CLIN PRACT, V117, pC15, DOI 10.1159/000319642
   Ohtake T, 2013, J CARDIOVASC PHARM T, V18, P439, DOI 10.1177/1074248413486355
   Palcu P, 2015, AM J KIDNEY DIS, V65, P933, DOI 10.1053/j.ajkd.2015.01.025
   Parfrey PS, 2015, CLIN J AM SOC NEPHRO, V10, P791, DOI 10.2215/CJN.07730814
   Pisoni RL, 2004, AM J KIDNEY DIS, V44, P94, DOI 10.1053/j.ajkd.2004.03.023
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Ponikowski P, 2015, EUR HEART J, V36, P657, DOI 10.1093/eurheartj/ehu385
   Raggi P, 2005, J BONE MINER RES, V20, P764, DOI 10.1359/JBMR.041221
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Rix M, 2004, NEPHROL DIAL TRANSPL, V19, P870, DOI 10.1093/ndt/gfg595
   Rodby R, 2015, EXPERT REV PHARM OUT, V15, P545, DOI 10.1586/14737167.2015.995169
   Sakaguchi Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163673
   Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327
   Sawaya BP, 2003, KIDNEY INT, V64, P737, DOI 10.1046/j.1523 1755.2003.00129.x
   Seto T, 2014, J NEPHROL, V27, P135, DOI 10.1007/s40620 014 0046 3
   Spiegel DM, 2009, HEMODIAL INT, V13, P453, DOI 10.1111/j.1542 4758.2009.00364.x
   Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466
   Sumida K, 2016, OSTEOPOROSIS INT, V27, P1441, DOI 10.1007/s00198 015 3377 6
   Tzanakis IP, 2014, INT UROL NEPHROL, V46, P2199, DOI 10.1007/s11255 014 0751 9
   Ueki K, 2015, INTERNAL MED, V54, P2637, DOI 10.2169/internalmedicine.54.4946
   Wakasugi M, 2018, AM J KIDNEY DIS, V71, P173, DOI 10.1053/j.ajkd.2017.07.017
   Wetmore JB, 2005, NEPHROLOGY, V10, P393, DOI 10.1111/j.1440 1797.2005.00436.x
   Wilson R, 2009, CURR MED RES OPIN, V25, P3021, DOI 10.1185/03007990903399398
   Yamamichi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088277
   Zaragatski E, 2016, KIDNEY INT, V89, P601, DOI 10.1038/ki.2015.298
NR 62
TC 9
Z9 11
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0894 0959
EI 1525 139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD NOV DEC
PY 2018
VL 31
IS 6
SI SI
BP 592
EP 598
DI 10.1111/sdi.12729
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA GZ8PT
UT WOS:000449755500010
PM 29900589
DA 2025 08 17
ER

PT J
AU Liu, SM
   Chen, JC
   Huang, SM
   Lin, SH
   Chen, WC
AF Liu, Shih Ming
   Chen, Jian Chih
   Huang, Ssu Meng
   Lin, Shang Hong
   Chen, Wen Cheng
TI Enhanced Cell Osteogenic Differentiation in Alendronate Acid and
   Flufenamic Acid Drug Impregnated Nanoparticles of Mesoporous Bioactive
   Glass Composite Calcium Phosphate Bone Cement In Vitro
SO PHARMACEUTICALS
LA English
DT Article
DE nanoparticles; mesoporous bioactive glass; calcium phosphate bone
   cement; composites; controlled release; drug delivery; in vitro
ID MECHANISMS; RELEASE
AB This study aims to compare the anti osteoporotic drugs alendronic acid (ALN) and flufenamic acid (FA) alone impregnate into nanoparticles of mesoporous bioactive glass (nMBG), which further composites calcium phosphate cement (CPC) and investigates their in vitro performance. The drug release, physicochemical properties, and biocompatibility of nMBG@CPC composite bone cement are tested, and the effect of the composites on improving the proliferation and differentiation efficiency of mouse precursor osteoblasts (D1 cells) is also investigated. Drug release shows that FA impregnates nMBG@CPC composite, a large amount of FA is released rapidly within 8 h, gradually reaching a stable release within 12 h, followed by a slow and sustained release within 14 days, and then reaches a plateau within 21 days. The release phenomenon confirms that the drug impregnated nBMG@CPC composite bone cement effectively achieves slow drug delivery. The working time and setting time of each composite are within 4 10 min and 10 20 min, respectively, meeting the operational requirements of clinical applications. The addition of nMBG nanoparticles in the CPC matrix did not prevent the aggregation phenomenon under microstructural observation, thus resulting in a decrease in the strength of the nMBG@CPC composite. However, after 24 h of immersed reaction, the strength of each 5 wt.% nMBG impregnated with different concentrations of FA and ALN is still greater than 30 MPa, which is higher than the general trabecular bone strength. The drug impregnated nMBG@CPC composites did not hinder the product formation and exhibit biocompatibility. Based on the proliferation and mineralization of D1 cells, the combination of nMBG with abundant FA and ALN in CPC is not conducive to the proliferation of D1 cells. However, when D1 cells are contact cultured for 21 days, alkaline phosphatase (ALP) enzyme activity shows higher ALP secretion from drug impregnated nMBG@CPC composites than drug free composites. Accordingly, this study confirms that nMBG can effectively impregnate the anti osteoporosis drugs FA and ALN, and enhance the mineralization ability of osteoblasts. Furthermore, drug impregnated nMBG applications can be used alone or in combination with CPC as a new option for osteoporotic bone filling surgery.
C1 [Liu, Shih Ming; Chen, Jian Chih; Huang, Ssu Meng; Lin, Shang Hong; Chen, Wen Cheng] Feng Chia Univ, Dept Fiber & Composite Mat, Adv Med Devices & Composites Lab, Taichung, Taiwan.
   [Chen, Jian Chih] Kaohsiung Med Univ, Coll Med, Fac Med Sch, Dept Orthoped, Kaohsiung 807, Taiwan.
   [Chen, Jian Chih] Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung 807, Taiwan.
   [Chen, Wen Cheng] Kaohsiung Med Univ, Coll Pharm, Dept Fragrance & Cosmet Sci, Kaohsiung 807, Taiwan.
   [Chen, Wen Cheng] Kaohsiung Med Univ, Coll Dent Med, Dent Med Devices & Mat Res Ctr, Kaohsiung 807, Taiwan.
C3 Feng Chia University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University
RP Chen, WC (通讯作者)，Feng Chia Univ, Dept Fiber & Composite Mat, Adv Med Devices & Composites Lab, Taichung, Taiwan.; Chen, WC (通讯作者)，Kaohsiung Med Univ, Coll Pharm, Dept Fragrance & Cosmet Sci, Kaohsiung 807, Taiwan.; Chen, WC (通讯作者)，Kaohsiung Med Univ, Coll Dent Med, Dent Med Devices & Mat Res Ctr, Kaohsiung 807, Taiwan.
EM 203home@gmail.com; 830191@yahoo.com.tw; dream161619192020@gmail.com;
   nel3581@gmail.com; wencchen@mail.fcu.edu.tw
RI ; Chen, Wen Cheng/P 4496 2018; HUANG, SSUMENG/KJM 4510 2024; Chen,
   Wen Cheng/C 8774 2009
OI Chen, Jian Chih/0000 0002 9582 6029; Chen,
   Wen Cheng/0000 0002 5581 9991; 
FU National Science and Technology Council, Taiwan [NSTC
   111 2314 B 035 002 MY3, 110 2221 E 035 013, 109 2314 B 037 043,
   109 2622 E 035 014 CC2]
FX This work is supported by the National Science and Technology Council,
   Taiwan [grant numbers NSTC 111 2314 B 035 002 MY3, 110 2221 E 035 013,
   109 2314 B 037 043 and 109 2622 E 035 014 CC2.
CR Brinker CJ, 2013, SOL GEL SCI PHYS CHE, DOI 10.1016/C2009 0 22386 5
   Brown W.E., 1986, NEW CALCIUM PHOSPHAT
   Chen FP, 2018, BIOMED J, V41, P202, DOI [10.1016/j.bj.2018.08.001, 10.1016/j.bj.2018.04.001]
   CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603
   Demir Oguz Ö, 2023, BIOACT MATER, V19, P217, DOI 10.1016/j.bioactmat.2022.04.007
   Dolci LS, 2019, INT J PHARMACEUT, V554, P245, DOI 10.1016/j.ijpharm.2018.11.023
   Fernández D, 2003, ACTA CRYSTALLOGR C, V59, pM543, DOI 10.1107/S0108270103025599
   Fosca M, 2022, BIOACT MATER, V7, P341, DOI 10.1016/j.bioactmat.2021.05.032
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Halim NAA, 2021, INT J NANOMED, V16, P6477, DOI 10.2147/IJN.S298936
   Hasanzadeh A., 2017, ADV BIOL EARTH SCI, V2, P5
   He J, 2021, CARBOHYD POLYM, V253, DOI 10.1016/j.carbpol.2020.117198
   Hu MH, 2022, BIOMIMETICS BASEL, V7, DOI 10.3390/biomimetics7030121
   Aghmiouni DK, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15041214
   Khezri K, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/1520052
   Kim Y, 2021, CERAM INT, V47, P1882, DOI 10.1016/j.ceramint.2020.09.017
   Ko CL, 2014, MAT SCI ENG C MATER, V39, P40, DOI 10.1016/j.msec.2014.02.033
   Komath M, 2003, B MATER SCI, V26, P415, DOI 10.1007/BF02711186
   KORSMEYER RW, 1983, INT J PHARMACEUT, V15, P25, DOI 10.1016/0378 5173(83)90064 9
   Liu XN, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1321 y
   Lodoso Torrecilla I, 2021, ACTA BIOMATER, V119, P1, DOI 10.1016/j.actbio.2020.10.013
   Lodoso Torrecilla I, 2020, MATER TODAY COMMUN, V23, DOI 10.1016/j.mtcomm.2020.100901
   Marinozzi F, 2011, J BIOMECH, V44, P988, DOI 10.1016/j.jbiomech.2010.11.030
   Miladi K, 2013, INT J PHARMACEUT, V445, P181, DOI 10.1016/j.ijpharm.2013.01.031
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Phull SS, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100345
   Pope R, 2021, PHYS ASSIST CLIN, V6, P111, DOI 10.1016/j.cpha.2020.09.009
   Predoi D, 2023, ANTIBIOTICS BASEL, V12, DOI 10.3390/antibiotics12010074
   Predoi D, 2018, COATINGS, V8, DOI 10.3390/coatings8080276
   Pylostomou A, 2023, BIOMATER ADV, V148, DOI 10.1016/j.bioadv.2023.213367
   Ramazanli V. N., 2022, Advances in Biology & Earth Sciences, V6, P238
   Richter RF, 2019, MATERIALS, V12, DOI 10.3390/ma12122022
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seidenstuecker M, 2017, ACTA BIOMATER, V51, P433, DOI 10.1016/j.actbio.2017.01.045
   Sodeman WA, 2005, INSTRUCTIONS GERIATR, P133
   Sun HS, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13122124
   Tan T, 2022, MATERIALS, V15, DOI 10.3390/ma15227898
   Thu HE, 2019, J AYURVEDA INTEGR ME, V10, P102, DOI 10.1016/j.jaim.2017.07.014
   Vallet Regí M, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122636
   Valtanen RS, 2021, INJURY, V52, pS72, DOI 10.1016/j.injury.2020.07.040
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wang SB, 2009, MICROPOR MESOPOR MAT, V117, P1, DOI 10.1016/j.micromeso.2008.07.002
   Wu Y, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111077
   Xia W, 2006, J CONTROL RELEASE, V110, P522, DOI 10.1016/j.jconrel.2005.11.002
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Zaroog O.S., 2019, BIOMATERIALS BONE RE
   Zhang ST, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106014
   Zhou H, 2019, MATER TODAY, V28, P81, DOI 10.1016/j.mattod.2019.04.020
   Zhu H, 2022, ENGINEERING PRC, V13, P197, DOI 10.1016/j.eng.2021.01.010
NR 49
TC 10
Z9 10
U1 3
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD MAY 1
PY 2023
VL 16
IS 5
AR 680
DI 10.3390/ph16050680
PG 21
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA H7CX0
UT WOS:000997510800001
PM 37242463
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Murayama, T
   Kawasoe, Y
   Yamashita, Y
   Ueno, Y
   Minami, S
   Yokouchi, M
   Komiya, S
AF Murayama, Takashi
   Kawasoe, Yasuomi
   Yamashita, Yoshitaka
   Ueno, Yoshinori
   Minami, Syusaku
   Yokouchi, Masahiro
   Komiya, Setsuro
TI Efficacy of the third generation bisphosphonate risedronate alone and in
   combination with anticancer drugs against osteosarcoma cell lines
SO ANTICANCER RESEARCH
LA English
DT Article
DE bisphosphonate; osteosarcoma; apoptosis; synergism
ID ZOLEDRONIC ACID; IN VITRO; INDUCE APOPTOSIS; BONE; GROWTH; INHIBITION;
   PAMIDRONATE; HYPERCALCEMIA; CHEMOTHERAPY; IBANDRONATE
AB Background: Bisphosphonates (BPs) are currently the most important class of inhibitors of osteoclast mediated bone resorption and are widely used in the treatment of osteoporosis and other osteoclast mediated bone diseases. Recently, there has been increasing evidence that BPs also exhibit direct anti tumor activity against several cancer cell lines. However, the efficacies of BPs against osteosarcoma have not yet been fully elucidated, and the anti osteosarcoma activity of the potent new generation BP risedronate, which is widely used clinically, has not been determined. Materials and Methods: The anti proliferative effects of the nitrogen containing BP risedronate on seven osteosarcoma cell lines (LM8, SaOS2, U2OS, HOS, KHOS, MG63 and OST) were studied. The cell viability was determined by MTT assay. Prenylation of Rap1A and Ras and phosphorylation of Erk1 and 2 were examined by Western blot analysis. Genomic DNA fragmentation and TUNEL staining assay were performed to determine whether risedronate induced apoptosis of the osteosarcoma cells. The anti tumor activities of risedronate in combination with carboplatin, doxorubicin, vincristine or etoposide were assayed with CalcuSyn (Biosoft). Results: Risedronate inhibited both prenylation of Rap1A and Ras and phosphorylation of Erk 1 and 2 at a dose of 50 mu M for 48 h. Treatment with risedronate induced significant time  and dose dependent cytotoxicity in the LM8 cell line. Risedronate treatment also increased intranucleosomal genomic DNA fragmentation. The TUNEL assay showed that 10 mu M and 50 mu M risedronate clearly induced apoptosis of osteosarcoma cells. Risedronate also clearly inhibited LM8, SaOS2 and KHOS cell growth in a time  and dose dependent fashion, but only weakly inhibited that of MG63 and U2OS cells. Risedronate augmented the effects of carboplatin, doxorubicin, vincristine and etoposide synergistically across a wide range of fractions affected (Fa) values. Conclusion: The nitrogen containing bisphosphonate risedronate induces apoptosis and inhibits the growth of osteogenic sarcoma through a mechanism involving the down regulation of protein prenylation and may be a candidate for combined use with carboplatin, doxorubicin, vincristine or etoposide.
C1 [Murayama, Takashi; Kawasoe, Yasuomi; Yamashita, Yoshitaka; Ueno, Yoshinori; Minami, Syusaku; Yokouchi, Masahiro; Komiya, Setsuro] Kagoshima Grad Sch Med & Dent Sci, Dept Orthopaed Surg, Kagoshima, Japan.
RP Yokouchi, M (通讯作者)，8 35 1 Sakuragaoka, Kagoshima 8908520, Japan.
EM masahiro@m3.kufm.kagoshima u.ac.jp
CR Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bramwell VHC, 1997, SEMIN ONCOL, V24, P561
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Coukell AJ, 1998, DRUG AGING, V12, P149, DOI 10.2165/00002512 199812020 00007
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097 0142(19950101)75:1+<203::AID CNCR2820751308>3.0.CO;2 V
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   Ferrari S, 1997, ANN ONCOL, V8, P765, DOI 10.1023/A:1008221713505
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hiraga T, 2001, CANCER RES, V61, P4418
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   JAFFE N, 1995, HEMATOL ONCOL CLIN N, V9, P825, DOI 10.1016/S0889 8588(18)30074 1
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Kubo T, 2006, J ORTHOP RES, V24, P1138, DOI 10.1002/jor.20177
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Lee MV, 2001, CANCER RES, V61, P2602
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756 3282(96)00318 3
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1998, CANCER RES, V58, P5294
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
   Whelan JS, 1997, EUR J CANCER, V33, P1611, DOI 10.1016/S0959 8049(97)00251 7
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 38
TC 30
Z9 30
U1 0
U2 5
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL AUG
PY 2008
VL 28
IS 4B
BP 2147
EP 2154
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 333KK
UT WOS:000258151200020
PM 18751388
DA 2025 08 17
ER

PT J
AU von Kroge, S
   Büyükyilmaz, Z
   Alimy, AR
   Hubert, J
   Citak, M
   Amling, M
   Beil, FT
   Ohlmeier, M
   Rolvien, T
AF von Kroge, Simon
   Bueyuekyilmaz, Zekihan
   Alimy, Assil Ramin
   Hubert, Jan
   Citak, Mustafa
   Amling, Michael
   Beil, Frank Timo
   Ohlmeier, Malte
   Rolvien, Tim
TI Do Clinical Parameters Reflect Local Bone Metabolism in Heterotopic
   Ossification After Septic or Aseptic THA?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID TOTAL HIP ARTHROPLASTY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   PROPHYLAXIS; TISSUE; RISK
AB Background Heterotopic ossification (HO) is a common complication after THA. Although current research primarily focuses on treatment and prevention, little is known about the local bone metabolism of HO and clinical contributing factors.
   Questions/purposes We aimed to assess bone remodeling processes in HO using histomorphometry, focusing on the effects of inflammation and prior NSAID treatment. Specifically, we asked: (1) Are HO specimens taken from patients with periprosthetic joint infection (PJI) more likely to exhibit active bone modeling and remodeling than specimens taken at the time of revision from patients without infection? (2) Do clinical or inflammatory serum and synovial parameters reflect the microstructure of and remodeling in both HO entities? (3) Is NSAID treatment before revision surgery associated with altered local bone mineralization or remodeling properties?
   Methods Between June 2021 and May 2022, we screened 395 patients undergoing revision THA at two tertiary centers in Germany. Of those, we considered all patients with radiographic HO as potentially eligible. Based on that, 21% (83 of 395) were eligible; a further 43 were excluded because of an inability to remove the implant intraoperatively (16 patients), insufficient material (11), comorbidities with a major effect on bone metabolism (10), or bone specific drugs (six), leaving 10% (40) for analysis in this retrospective, comparative study. HO specimens were collected during aseptic (25 patients: 18 male, seven female, mean age 70 11 years, mean BMI 29 4 kg/m(2)) and septic (15 patients: 11 male, four female, mean age 69 9 years, mean BMI 32 +/  9 kg/m(2)) revision THA at a mean of 6 +/  7 years after primary implantation and a mean age of 70 +/  9 years at revision. Septic origin (PJI) was diagnosed based on the 2018 International Consensus Meeting criteria, through a preoperative assessment of serum and synovial parameters. To specify the local bone microstructure, ossification, and cellular bone turnover, we analyzed HO specimens using micro CT and histomorphometry on undecalcified sections. Data were compared with those of controls, taken from femoral neck trabecular bone (10 patients: five female, five male, mean age 75 +/  6 years, mean BMI 28 +/  4 kg/m(2)) and osteophytes (10 patients: five female, five male, mean age 70 +/  10 years, mean BMI 29 +/  7 kg/m(2)). The time between primary implantation and revision (time in situ), HO severity based on the Brooker classification, and serum and synovial markers were correlated with HO microstructure and parameters of cellular bone turnover. In a subgroup of specimens of patients with NSAID treatment before revision, osteoid and bone turnover indices were evaluated and compared a matched cohort of specimens from patients without prior NSAID treatment.
   Results Patients with aseptic and septic HO presented with a higher bone volume (BV/TV; aseptic: 0.41 +/  0.15, mean difference 0.20 [95% CI 0.07 to 0.32]; septic: 0.43 +/  0.15, mean difference 0.22 [95% CI 0.08 to 0.36]; femoral neck: 0.21 +/  0.04; both p < 0.001), lower bone mineral density (aseptic: 809 +/  66 mg HA/cm(3), mean difference  91 mg HA/cm(3) [95% CI  144 to  38]; septic: 789 +/  44 mg HA/cm(3), mean difference  111 mg HA/cm(3) [95% CI  169 to  53]; femoral neck: 899 +/  20 mg HA/cm(3); both p < 0.001), and ongoing bone modeling with endochondral ossification and a higher proportion of woven, immature bone (aseptic: 25% +/  17%, mean difference 25% [95% CI 9% to 41%]; septic: 37% +/  23%, mean difference 36% [95% CI 19% to 54%]; femoral neck: 0.4% +/  0.5%; both p < 0.001) compared with femoral neck specimens. Moreover, bone surfaces were characterized by increased osteoblast and osteoclast indices in both aseptic and septic HO, although a higher density of osteocytes was detected exclusively in septic HO (aseptic: 158 +/  56 1/mm(2) versus septic: 272 +/  48 1/mm(2), mean difference 114 1/mm(2) [95% CI 65 to 162]; p < 0.001). Compared with osteophytes, microstructure and turnover indices were largely similar in HO. The Brooker class was not associated with any local bone metabolism parameters. The time in situ was negatively associated with bone turnover in aseptic HO specimens (osteoblast surface per bone surface: r =  0.46; p = 0.01; osteoclast surface per bone surface: r =  0.56; p = 0.003). Serum or synovial inflammatory markers were not correlated with local bone turnover in septic HO. Specimens of patients with NSAID treatment before revision surgery had a higher osteoid thickness (10.1 +/  2.1 mu m versus 5.5 +/  2.6 mu m, mean difference  4.7 mu m [95% CI  7.4 to  2.0]; p = 0.001), but there was no difference in other osteoid, structural, or cellular parameters.
   Conclusion Aseptic and septic HO share phenotypic characteristics in terms of the sustained increase in bone metabolism, although differences in osteocyte and adipocyte numbers suggest distinct homeostatic mechanisms. These results suggest persistent bone modeling or remodeling, with osteoblast and osteoclast indices showing a moderate decline with the time in situ in aseptic HO. Future studies should use longitudinal study designs to correlate our findings with clinical outcomes (such as HO growth or recurrence). In addition, the molecular mechanisms of bone cell involvement during HO formation and growth should be further investigated, which may allow specific therapeutic and preventive interventions.
   Clinical Relevance To our knowledge, our study is the first to systematically investigate histomorphometric bone metabolism parameters in patients with HO after THA, providing a clinical reference for evaluating modeling and remodeling activity. Routine clinical, serum, and synovial markers are not useful for inferring local bone metabolism.
C1 [von Kroge, Simon; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
   [von Kroge, Simon; Alimy, Assil Ramin; Hubert, Jan; Beil, Frank Timo; Rolvien, Tim] Univ Med Ctr Hamburg Eppendorf, Div Orthopaed, Dept Trauma & Orthopaed Surg, Martinistr 52, D 20246 Hamburg, Germany.
   [Bueyuekyilmaz, Zekihan; Citak, Mustafa; Ohlmeier, Malte] Helios ENDO Klin, Dept Joint Surg, Hamburg, Germany.
   [Ohlmeier, Malte] UKM Marienhosp, Dept Orthopaed & Trauma Surg, Steinfurt, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Rolvien, T (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Div Orthopaed, Dept Trauma & Orthopaed Surg, Martinistr 52, D 20246 Hamburg, Germany.
EM s.von kroge@uke.de; Zekihan.Bueyuekyilmaz@helios gesundheit.de;
   assilramin@icloud.com; j.hubert@uke.de;
   mustafa.citak@helios gesundheit.de; amling@uke.de; ft.beil@uke.de;
   malte.ohlmeier@gmail.com; t.rolvien@uke.de
RI Citak, Mustafa/AAE 6859 2021; Ohlmeier, Malte/GOJ 9542 2022; Hubert,
   Jan/HHZ 9619 2022; Beil, Frank Timo/JBI 9771 2023
OI Alimy, Assil Ramin/0000 0002 2013 4212; von Kroge,
   Simon/0000 0002 2898 5732
FU Damp foundation [2022 09]; Else Kroner Fresenius foundation
   [2021_EKEA.23]
FX The institution of one or more of the authors has received, during the
   study period, funding from the Damp foundation under grant no. 2022 09
   (SvK, TR) and the Else Kroner Fresenius foundation under grant no.
   2021_EKEA.23 (TR).
CR Amar E, 2015, J HIP PRESERV SURG, V2, P355, DOI 10.1093/jhps/hnv052
   Baird Evan O, 2009, J Orthop Surg Res, V4, P12, DOI 10.1186/1749 799X 4 12
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623 197355080 00006
   Croes M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132781
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Epsley S, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.511799
   Fang F, 2022, MATRIX BIOL, V105, P87, DOI 10.1016/j.matbio.2021.12.001
   Foley KP, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100440
   GRECO F, 1991, INT ORTHOP, V15, P35, DOI 10.1007/BF00210531
   HAHN M, 1991, VIRCHOWS ARCH A, V418, P1, DOI 10.1007/BF01600238
   Hu ZH, 2021, MED DOSIM, V46, P65, DOI 10.1016/j.meddos.2020.07.010
   Hug KT, 2015, CLIN ORTHOP RELAT R, V473, P2154, DOI 10.1007/s11999 014 4076 x
   Jandl NM, 2023, BONE JOINT J, V105B, P373, DOI [10.1302/0301 620X.105B4.BJJ 2022 0628.R1, 10.1302/0301 620X.105B4.BJJ 2022 0628]
   Joice M, 2018, BONE JOINT J, V100B, P915, DOI 10.1302/0301 620X.100B7.BJJ 2017 1467.R1
   Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635 200403000 00007
   Li ZR, 2022, ELIFE, V11, DOI 10.7554/eLife.78496
   Li ZR, 2019, J CLIN INVEST, V129, P2404, DOI 10.1172/JCI126173
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   MAKLEY JT, 1982, LANCET, V2, P42
   Manrique J, 2018, ARCH BONE JT SURG AB, V6, P486
   Metzger CE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00285
   Meyers C, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10172
   Migliorini F, 2021, CALCIFIED TISSUE INT, V108, P196, DOI 10.1007/s00223 020 00763 7
   Mirsaidi A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02650 y
   NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559
   Neal B, 2002, ANZ J SURG, V72, P808, DOI 10.1046/j.1445 2197.2002.02549.x
   Negri S, 2022, STEM CELL TRANSL MED, V11, P876, DOI 10.1093/stcltm/szac042
   Ohlmeier M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54986 2
   Ormsby RT, 2021, EUR CELLS MATER, V42, P264, DOI 10.22203/eCM.v042a19
   Parvizi J, 2018, J ARTHROPLASTY, V33, P1309, DOI 10.1016/j.arth.2018.02.078
   Rabelo GD, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57303 z
   Ranganathan K, 2015, J BONE JOINT SURG AM, V97A, P1101, DOI 10.2106/JBJS.N.01056
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628
   Xu YL, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.770931
   Zhou M, 2019, CURR OSTEOPOROS REP, V17, P97, DOI 10.1007/s11914 019 00507 z
   Zhu YB, 2015, ARCH ORTHOP TRAUM SU, V135, P1307, DOI 10.1007/s00402 015 2277 8
NR 40
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD OCT
PY 2023
VL 481
IS 10
BP 2029
EP 2041
DI 10.1097/CORR.0000000000002758
PG 13
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA HX2I0
UT WOS:001162738800029
PM 37462509
OA Green Published
DA 2025 08 17
ER

PT J
AU Lee, KH
   Kim, SH
   Kim, CH
   Min, BJ
   Kim, GJ
   Lim, Y
   Kim, HS
   Ahn, KM
   Kim, JH
AF Lee, Kye Hwa
   Kim, Su Hwan
   Kim, Chang Hyen
   Min, Byung Joo
   Kim, Grace Juyun
   Lim, Younggyun
   Kim, Hun Sung
   Ahn, Kang Min
   Kim, Ju Han
TI Identifying genetic variants underlying medication induced osteonecrosis
   of the jaw in cancer and osteoporosis: a case control study
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Osteoporosis; Angiogenesis; Pharmacogenomics; Bioinformatics; Cancer
   biology
ID BISPHOSPHONATE RELATED OSTEONECROSIS; ENDOTHELIAL GROWTH FACTOR;
   MULTIPLE MYELOMA; POLYMORPHISM; ASSOCIATION; PHARMACOGENETICS; CYP2C8;
   RISK; BETA
AB Background Bisphosphonate induced osteonecrosis of the jaw (BRONJ) presents with a typical pattern of jaw necrosis in patients who have been prescribed bisphosphonates (BPs) and other antiangiogenetic drugs to treat osteoporosis or bone related complications of cancer. Methods This study divided 38 patients with BRONJ into two groups according to the prescribing causes: cancer (n = 13) and osteoporosis (n = 25), and underwent whole exome sequencing and compared them with normal controls (n = 90). To identify candidate genes and variants, we conducted three analyses: a traditional genetic model, gene wise variant score burden, and rare variant analysis methods. Results The stop gain mutation (rs117889746) of the PZP gene in the BRONJ cancer group was significantly identified in the additive trend model analysis. In the cancer group, ARIDS, HEBP1, LTBP1, and PLVAP were identified as candidate genes. In the osteoporosis group, VEGFA, DFFA, and FAM193A genes showed a significant association. No significant genes were identified in the rare variant analysis pipeline. Biologically accountable functions related to BRONJ occurrence angiogenesis related signaling (VEGFA and PLVAP genes), TGF beta signaling (LTBP1 and PZP genes), heme toxicity (HEBP1) and osteoblast maturation (ARIDS) were shown in candidate genes. Conclusion This study showed that the candidate causative genes contributing to the development of BRONJ differ according to the BP dose and background disease.
C1 [Lee, Kye Hwa; Kim, Ju Han] Seoul Natl Univ Hosp, Ctr Precis Med, Seoul 03082, South Korea.
   [Kim, Su Hwan] Asan Med Ctr, Dept Periodont, Seoul 05505, South Korea.
   [Kim, Su Hwan] Univ Ulsan, Dept Dent, Coll Med, Seoul 05505, South Korea.
   [Kim, Chang Hyen] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Oral & Maxillofacial Surg, Seoul 06591, South Korea.
   [Min, Byung Joo; Kim, Grace Juyun; Lim, Younggyun; Kim, Ju Han] Seoul Natl Univ, SNUBI, Div Biomed Informat, Coll Med, Seoul 03080, South Korea.
   [Min, Byung Joo; Kim, Grace Juyun; Lim, Younggyun; Kim, Ju Han] Seoul Natl Univ, Syst Biomed Informat Res Ctr, Coll Med, Seoul 03080, South Korea.
   [Kim, Hun Sung] Catholic Univ Korea, Coll Med, Dept Med Informat, Seoul 06591, South Korea.
   [Ahn, Kang Min] Univ Ulsan, Dept Oral & Maxillofacial Surg, Coll Med, Seoul 05505, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   University of Ulsan; Asan Medical Center; University of Ulsan; Catholic
   University of Korea; Seoul St. Mary's Hospital; Seoul National
   University (SNU); Seoul National University (SNU); Catholic University
   of Korea; University of Ulsan
RP Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Ctr Precis Med, Seoul 03082, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, SNUBI, Div Biomed Informat, Coll Med, Seoul 03080, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Syst Biomed Informat Res Ctr, Coll Med, Seoul 03080, South Korea.; Ahn, KM (通讯作者)，Univ Ulsan, Dept Oral & Maxillofacial Surg, Coll Med, Seoul 05505, South Korea.
EM ahnkangmin@ulsan.ac.kr; juhan@snu.ac.kr
RI Lee, Jong Mok/KVY 9550 2024; kim, juhee/HKV 6163 2023; Kim,
   Ju/E 5983 2012
OI Kim, Su Hwan/0000 0002 3431 453X; Lee, Kye Hwa/0000 0002 7593 7020; 
FU Education and Research Encouragement Fund of Seoul National University
   Hospital; National Research Foundation of Korea (NRF)   Ministry of
   Education [NRF 2018R1D1A1A02086109]
FX This work was supported by the Education and Research Encouragement Fund
   of Seoul National University Hospital and the National Research
   Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF 2018R1D1A1A02086109). There are no conflicts of interest to
   declare.
CR [Anonymous], 2015, Nature
   [Anonymous], REGULATORY MECHANISM
   Arduino PG, 2011, J ORAL PATHOL MED, V40, P510, DOI 10.1111/j.1600 0714.2010.01004.x
   Assael LA, 2009, J ORAL MAXIL SURG, V67, P35, DOI 10.1016/j.joms.2009.01.003
   Balla B, 2012, ORAL DIS, V18, P580, DOI 10.1111/j.1601 0825.2012.01912.x
   Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Choi H, 2015, ORAL DIS, V21, P866, DOI 10.1111/odi.12355
   Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035
   Di Martino MT, 2011, BRIT J HAEMATOL, V154, P529, DOI 10.1111/j.1365 2141.2011.08622.x
   English BC, 2010, THER CLIN RISK MANAG, V6, P579, DOI 10.2147/TCRM.S14303
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Fung PL, 2015, ORAL MAXIL SURG CLIN, V27, P537, DOI 10.1016/j.coms.2015.06.005
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 9 r183
   Ikebe T, 2013, ORAL SCI INT, V10, P1, DOI 10.1016/S1348 8643(12)00045 6
   Immenschuh S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00146
   Kastritis E, 2017, LEUKEMIA LYMPHOMA, V58, P2304, DOI 10.1080/10428194.2017.1300889
   Katz J, 2011, INT J ORAL MAX SURG, V40, P605, DOI 10.1016/j.ijom.2011.02.002
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Khan AA, 2011, J RHEUMATOL, V38, P1396, DOI 10.3899/jrheum.100221
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118084
   La Ferla F, 2012, BIOMARK MED, V6, P201, DOI [10.2217/BMM.12.14, 10.2217/bmm.12.14]
   Lee KH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213860
   Lee KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162135
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Marini Francesca, 2011, Front Biosci (Elite Ed), V3, P364, DOI 10.2741/e251
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Nicoletti P, 2012, ONCOLOGIST, V17, P279, DOI 10.1634/theoncologist.2011 0202
   PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647
   PHILIP A, 1994, EUR J BIOCHEM, V221, P687, DOI 10.1111/j.1432 1033.1994.tb18781.x
   R Core Team, R: A language and environment for statistical computing
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016
   Rugani P, 2014, CLIN ORAL INVEST, V18, P401, DOI 10.1007/s00784 013 1012 5
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Seo H, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920 018 0323 4
   Stockmann P, 2013, J CRANIO MAXILL SURG, V41, P71, DOI 10.1016/j.jcms.2012.10.018
   Strickland LA, 2005, J PATHOL, V206, P466, DOI 10.1002/path.1805
   Such E, 2011, HAEMATOL HEMATOL J, V96, P1557, DOI 10.3324/haematol.2011.042572
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Wysowski DK, 2013, BONE, V57, P423, DOI 10.1016/j.bone.2013.09.008
   Yang G, 2019, BONE, V124, P75, DOI 10.1016/j.bone.2019.04.010
   Yang G, 2018, J BONE MINER RES, V33, P91, DOI 10.1002/jbmr.3285
NR 46
TC 28
Z9 30
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 20
PY 2019
VL 17
IS 1
AR 381
DI 10.1186/s12967 019 2129 3
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JQ1HM
UT WOS:000498704300002
PM 31747953
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zeng, HH
   Li, M
   Wang, ZR
   Wang, TQ
   Zhang, ZQ
   Wu, XX
AF Zeng, Huahui
   Li, Man
   Wang, Zhirong
   Wang, Tianqi
   Zhang, Zhenqiang
   Wu, Xiangxiang
TI Disulfide bond based oxidation responsive triptolide loaded nanodrug for
   inflammation targeted treatment of collagen induced arthritis
SO APPLIED MATERIALS TODAY
LA English
DT Article
DE Rheumatoid arthritis; Macrophage polarization; Drug delivery system;
   Oxidation responsive; Triptolide
ID RHEUMATOID ARTHRITIS; MACROPHAGES; OSTEOCLASTS; THERAPY
AB M1 macrophages play a crucial role in the development of rheumatoid arthritis (RA), which can produce various inflammation cytokines, and reactive oxygen species (ROS). Disulfide bonds as reduction responsive linkages have been extensively employed in the drug delivery systems. However, disulfide bonds are rarely reported in the development of the oxidation responsive drug carriers. Herein, we designed and synthetized novel oxidationresponsive drug carriers based on disulfide bonds, and further developed nanoparticles (FA TP@NPs) by selfassembly for the RA treatment. FA TP@NPs was decorated with folic acid and loaded with triptolide (TP), a potent anti inflammation Chinese medicine, to target and enter M1 macrophages through the folate receptor on the cytomembrane for simultaneous repolarization of the M2 macrophage and elimination of the M1 macrophage. As expected, FA TP@NPs exhibited an oxidation responsive TP release via disulfide bond oxidation and ester bond hydrolysis in the presence of intracellular ROS, which accumulated preferentially in inflamed joints. FA TP@NPs exerted a potent anti arthritic effect with high biosafety in CIA mice, as evidenced by repolarizing M2 macrophages, inducing M1 macrophage apoptosis, and reducing TNF alpha, IL 6, and IL 1(3 expression. This work shows that FA TP@NPs give a deep insight into disulfide bond based oxidation responsive drug delivery systems, and provide a potential platform for RA treatment.
C1 [Zeng, Huahui; Li, Man; Wang, Zhirong; Wang, Tianqi; Zhang, Zhenqiang; Wu, Xiangxiang] Acad Chinese Med Sci, Zhengzhou 450046, Peoples R China.
   [Zeng, Huahui; Li, Man; Wang, Zhirong; Wang, Tianqi; Zhang, Zhenqiang; Wu, Xiangxiang] Henan Univ Chinese Med, Sch Basic Med, Zhengzhou 450046, Peoples R China.
   [Zeng, Huahui; Wu, Xiangxiang] Collaborat Innovat Ctr Res & Dev Whole Ind Chain Y, Zhengzhou 450046, Henan, Peoples R China.
C3 Henan University of Traditional Chinese Medicine
RP Zeng, HH; Zhang, ZQ; Wu, XX (通讯作者)，Henan Univ Chinese Med, 156 Jinshuidong Rd, Zhengzhou 450046, Peoples R China.
EM hhzeng@hactcm.edu.cn; zhang_zhenqiang@126.com; wuxx 415@hactcm.edu.cn
RI Wang, Tianqi/KIC 1831 2024
OI Wu, Xiangxiang/0000 0003 3623 1161
FU National Natural Science Foundation of China [82274612]; Henan
   Provincial Science and Technology Research and Development Plan Joint
   Fund [222301420060]
FX This work was supported by National Natural Science Foundation of China
   (82274612) , Henan Provincial Science and Technology Research and
   Development Plan Joint Fund (222301420060) . The authors appreciated the
   TEM technical support of Ning Sun from Henan University of Chinese
   Medicine.
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   An LM, 2020, NANO LETT, V20, P7728, DOI 10.1021/acs.nanolett.0c03279
   Chandrupatla DMSH, 2019, DRUG DELIV TRANSL RE, V9, P366, DOI 10.1007/s13346 018 0589 2
   Cush JJ, 2021, MED CLIN N AM, V105, P355, DOI 10.1016/j.mcna.2020.10.006
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Kikyo N, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241512307
   Kurowska Stolarska M, 2022, NAT REV RHEUMATOL, V18, P384, DOI 10.1038/s41584 022 00790 8
   Li H, 2022, J CONTROL RELEASE, V341, P16, DOI 10.1016/j.jconrel.2021.11.019
   Li JX, 2023, INT J PHARMACEUT, V632, DOI 10.1016/j.ijpharm.2022.122572
   Li M, 2022, DRUG DELIV, V29, P2751, DOI 10.1080/10717544.2022.2115162
   Li P, 2020, J CONTROL RELEASE, V319, P87, DOI 10.1016/j.jconrel.2019.12.025
   Li YF, 2022, ACTA BIOMATER, V152, P406, DOI 10.1016/j.actbio.2022.08.054
   Lin YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040880
   Lu T, 2012, J MOL GRAPH MODEL, V38, P314, DOI 10.1016/j.jmgm.2012.07.004
   Lu T, 2012, J COMPUT CHEM, V33, P580, DOI 10.1002/jcc.22885
   Sun BJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11193 x
   Sun BJ, 2018, NANO LETT, V18, P3643, DOI 10.1021/acs.nanolett.8b00737
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Tu JJ, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/1583647
   Wang XL, 2022, MOLECULES, V27, DOI 10.3390/molecules27123686
   Weyand CM, 2020, IMMUNOL REV, V294, P177, DOI 10.1111/imr.12838
   Weyand CM, 2017, NAT REV RHEUMATOL, V13, P1, DOI 10.1038/nrrheum.2017.49
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   You DG, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe0083
   Zhang B, 2023, J AUTOIMMUN, V141, DOI 10.1016/j.jaut.2023.103047
   Zhang L, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030202
   Zhang L, 2018, INT J NANOMED, V13, P2051, DOI 10.2147/IJN.S151233
NR 27
TC 3
Z9 3
U1 13
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 9407
J9 APPL MATER TODAY
JI Appl. Mater. Today
PD OCT
PY 2024
VL 40
AR 102350
DI 10.1016/j.apmt.2024.102350
EA AUG 2024
PG 13
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA C3V7Y
UT WOS:001288679000001
DA 2025 08 17
ER

PT J
AU van Hellemond, IEG
   Smorenburg, CH
   Peer, PGM
   Swinkels, ACP
   Seynaeve, CM
   van der Sangen, MJC
   Kroep, JR
   de Graaf, H
   Honkoop, AH
   Erdkamp, FLG
   van den Berkmortel, FWPJ
   de Roos, WK
   Linn, SC
   Imholz, ALT
   de Boer, M
   Tjan Heijnen, VCG
AF van Hellemond, Irene E. G.
   Smorenburg, Carolien H.
   Peer, Petronella G. M.
   Swinkels, Astrid C. P.
   Seynaeve, Caroline M.
   van der Sangen, Maurice J. C.
   Kroep, Judith R.
   de Graaf, Hiltje
   Honkoop, Aafke H.
   Erdkamp, Frans L. G.
   van den Berkmortel, Franchette W. P. J.
   de Roos, Wilfred K.
   Linn, Sabine C.
   Imholz, Alexander L. T.
   de Boer, Maaike
   Tjan Heijnen, Vivianne C. G.
CA Dutch Breast Canc Res Grp BOOG
TI Breast cancer outcome in relation to bone mineral density and
   bisphosphonate use: a sub study of the DATA trial
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Tamoxifen; Aromatase inhibitor; Bone health;
   Osteoporosis; Bisphosphonates; Survival; Bone metastases; Distant
   recurrence free survival
ID ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; IN VITRO; THERAPY; CELLS; RISK;
   CHEMOTHERAPY; METASTASIS; MECHANISMS; CLODRONATE
AB Purpose The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2 3 years of tamoxifen in postmenopausal breast cancer patients. This pre planned side study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence free survival (DRFS), and evaluated the effect of bisphosphonates on DRFS. Methods We selected all patients with a BMD measurement within 3 years after randomisation (landmark) without any DRFS events. Kaplan Meier methods and Cox proportional hazards models were used for analyses. Results Of 1860 eligible patients, 1142 had a DEXA scan before the landmark. The BMD was normal in 436 (38.2%) and showed osteopenia in 565 (49.5%) and osteoporosis in 141 (12.3%) patients. After a median follow up of 5.0 years from the landmark, neither osteopenia nor osteoporosis (compared with normal BMD) were associated with DRFS in both the 6 year [osteopenia HR 0.82 (95% CI 0.45 1.49), osteoporosis HR 1.10 (95% CI 0.26 4.67)] and the 3 year arm [osteopenia HR 0.75 (95% CI 0.40 1.42), osteoporosis HR 1.86 (95% CI 0.43 8.01)]. Moreover, bisphosphonate use did not impact DRFS. Conclusion No association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS.
C1 [van Hellemond, Irene E. G.; de Boer, Maaike; Tjan Heijnen, Vivianne C. G.] Maastricht Univ, Med Ctr, Dept Med Oncol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
   [Smorenburg, Carolien H.] Med Ctr Alkmaar, Dept Internal Med, Alkmaar, Netherlands.
   [Peer, Petronella G. M.] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Biostat, Med Ctr, Nijmegen, Netherlands.
   [Swinkels, Astrid C. P.] Netherlands Comprehens Canc Org IKNL, Dept Clin Res, Utrecht, Netherlands.
   [Seynaeve, Caroline M.] Erasmus MC, Dept Med Oncol, Inst Canc, Rotterdam, Netherlands.
   [van der Sangen, Maurice J. C.] Catharina Hosp, Dept Radiat Oncol, Eindhoven, Netherlands.
   [Kroep, Judith R.] Leiden Univ, Dept Med Oncol, Med Ctr, Leiden, Netherlands.
   [de Graaf, Hiltje] Med Ctr Leeuwarden, Dept Med Oncol, Leeuwarden, Netherlands.
   [Honkoop, Aafke H.] Isala Clin, Dept Med Oncol, Zwolle, Netherlands.
   [Erdkamp, Frans L. G.] Zuyderland Med Ctr, Dept Med Oncol, Sittard, Netherlands.
   [van den Berkmortel, Franchette W. P. J.] Zuyderland Med Ctr, Dept Med Oncol, Heerlen, Netherlands.
   [de Roos, Wilfred K.] Gelderse Vallei Hosp, Dept Surg, Ede, Netherlands.
   [Linn, Sabine C.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.
   [Imholz, Alexander L. T.] Deventer Hosp, Dept Med Oncol, Deventer, Netherlands.
   [Tjan Heijnen, Vivianne C. G.] Maastricht Univ, Med Ctr, Div Med Oncol, Dept Internal Med, POB 5800, NL 6202 AZ Maastricht, Netherlands.
C3 Maastricht University; Medical Center Of Alkmaar; Radboud University
   Nijmegen; Erasmus University Rotterdam; Erasmus MC; Catharina Hospital;
   Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC; Medical Center Leeuwarden; Isala Clinics;
   Zuyderland Medical Center; Gelderse Vallei Hospital; Netherlands Cancer
   Institute; Deventer Hospital; Maastricht University
RP Tjan Heijnen, VCG (通讯作者)，Maastricht Univ, Med Ctr, Div Med Oncol, Dept Internal Med, POB 5800, NL 6202 AZ Maastricht, Netherlands.
EM vcg.tjan.heijnen@mumc.nll
RI ; van der Hoeven, Koos/S 3281 2017; van den Berkmortel,
   Franchette/AAB 6784 2022
OI Kroep, Judith/0000 0003 2671 1903; van der Sangen,
   Maurice/0000 0003 1866 7367
FU AstraZeneca NL
FX This study was funded by AstraZeneca NL, ClinicalTrials. gov number,
   NCT00301457.
CR Agarwal P, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818789355
   Bouvard B, 2018, EUR J CANCER, V101, P87, DOI 10.1016/j.ejca.2018.06.028
   Brown J, 2018, JNCI J NATL CANCER I, V110, P871, DOI 10.1093/jnci/djx280
   Brufsky AM, 2012, CANCER AM CANCER SOC, V118, P1192, DOI 10.1002/cncr.26313
   Chen HM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0429
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman RE, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.501
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   KREMER R, 2014, J NATL CANC I
   Kroep JR, 2016, EUR J CANCER, V54, P57, DOI 10.1016/j.ejca.2015.10.011
   Lipton A, 2017, CANCER AM CANCER SOC, V123, P2444, DOI 10.1002/cncr.30682
   Lipton A, 2011, J CLIN ONCOL, V29, P3605, DOI 10.1200/JCO.2010.31.5069
   *MED HEALTHC PROD, 2018, DRUG SAF UPDATE, V11
   Neville Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Rennert G, 2017, CLIN CANCER RES, V23, P1684, DOI 10.1158/1078 0432.CCR 16 0547
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rouach V, 2018, J BONE ONCOL, V12, P91, DOI 10.1016/j.jbo.2018.07.011
   Solomayer EF, 2012, ANN ONCOL, V23, P2271, DOI 10.1093/annonc/mdr612
   Tjan Heijnen VCG, 2017, LANCET ONCOL, V18, P1502, DOI 10.1016/S1470 2045(17)30600 9
   van Hellemond IEG, 2019, INT J CANCER, V145, P1325, DOI 10.1002/ijc.32205
   *WHO SCI GROUP ASS, 2007, SUMM M REP
   Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903
   Zmuda JM, 2001, J NATL CANCER I, V93, P930, DOI 10.1093/jnci/93.12.930
NR 33
TC 5
Z9 5
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2020
VL 180
IS 3
BP 675
EP 685
DI 10.1007/s10549 020 05567 9
EA MAR 2020
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KX6FE
UT WOS:000517710500002
PM 32124136
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Iwayama, T
   Bhongsatiern, P
   Takedachi, M
   Murakami, S
AF Iwayama, T.
   Bhongsatiern, P.
   Takedachi, M.
   Murakami, S.
TI Matrix Vesicle Mediated Mineralization and Potential Applications
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE extracellular vesicles; biomineralization; calcium phosphates;
   lysosomes; mitochondria; regeneration
ID INTRACELLULAR CALCIUM PHOSPHATE; FINE STRUCTURE; GROWTH PLATE; BONE
   MINERALIZATION; IN VITRO; OSTEOBLASTS; BIOGENESIS; CARTILAGE;
   ULTRASTRUCTURE; MITOCHONDRIA
AB Hard tissues, including the bones and teeth, are a fundamental part of the body, and their formation and homeostasis are critically regulated by matrix vesicle mediated mineralization. Matrix vesicles have been studied for 50 y since they were first observed using electron microscopy. However, research progress has been hampered by various technical barriers. Recently, there have been great advancements in our understanding of the intracellular biosynthesis of matrix vesicles. Mitochondria and lysosomes are now considered key players in matrix vesicle formation. The involvement of mitophagy, mitochondrial derived vesicles, and mitochondria lysosome interaction have been suggested as potential detailed mechanisms of the intracellular pathway of matrix vesicles. Their main secretion pathway may be exocytosis, in addition to the traditionally understood mechanism of budding from the outer plasma membrane. This basic knowledge of matrix vesicles should be strengthened by novel nano level microscopic technologies, together with basic cell biologies, such as autophagy and interorganelle interactions. In the field of tissue regeneration, extracellular vesicles such as exosomes are gaining interest as promising tools in cell free bone and periodontal regenerative therapy. Matrix vesicles, which are recognized as a special type of extracellular vesicles, could be another potential alternative. In this review, we outline the recent significant progress in the process of matrix vesicle mediated mineralization and the potential clinical applications of matrix vesicles for tissue regeneration.
C1 [Iwayama, T.; Bhongsatiern, P.; Takedachi, M.; Murakami, S.] Osaka Univ, Dept Periodontol, Grad Sch Dent, 1 8 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 University of Osaka
RP Iwayama, T; Murakami, S (通讯作者)，Osaka Univ, Dept Periodontol, Grad Sch Dent, 1 8 Yamadaoka, Suita, Osaka 5650871, Japan.
EM iwayama.tomoaki.dent@osaka u.ac.jp; murakami.shinya.dent@osaka u.ac.jp
RI Takedachi, Masahide/GVS 6539 2022; Iwayama, Tomoaki/H 5921 2019
OI Iwayama, Tomoaki/0000 0002 3405 5822
FU Japan Society for Promotion of Science (JSPS) KAKENHI [JP20K20476,
   JP19K22713]; JST CREST [JPMJCR19H2]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: Figure
   illustrations were created with Biorender.com. This work was supported
   by the Japan Society for Promotion of Science (JSPS) KAKENHI grant
   numbers JP20K20476 and JP19K22713, as well as JST CREST grant number
   JPMJCR19H2.
CR AKISAKA T, 1988, CALCIFIED TISSUE INT, V42, P383, DOI 10.1007/BF02556357
   ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81
   ANDERSON HC, 1973, DEV BIOL, V34, P211, DOI 10.1016/0012 1606(73)90351 5
   Ao M, 2017, BONE, V105, P134, DOI 10.1016/j.bone.2017.08.027
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   BONUCCI E, 1978, CALC TISS RES, V25, P179, DOI 10.1007/BF02010766
   BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022 5320(67)80034 0
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Boskey AL, 1997, CALCIFIED TISSUE INT, V60, P309, DOI 10.1007/s002239900234
   Bottini M, 2018, BBA GEN SUBJECTS, V1862, P532, DOI 10.1016/j.bbagen.2017.11.005
   BRIGHTON CT, 1978, J BONE JOINT SURG AM, V60, P630, DOI 10.2106/00004623 197860050 00007
   BRIGHTON CT, 1976, FED PROC, V35, P143
   Buratta S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072576
   Claudia G, 2022, CARDIOVASC RES, V118, P84, DOI 10.1093/cvr/cvaa299
   Cui L, 2016, BONE, V87, P147, DOI 10.1016/j.bone.2016.04.007
   Dillon S, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10202
   Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796
   Foster BL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038393
   Gholami L, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578 020 00527 8
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   GOULET F, 1992, BIOCHEM BIOPH RES CO, V188, P554, DOI 10.1016/0006 291X(92)91091 4
   Hasegawa T, 2018, HISTOCHEM CELL BIOL, V149, P289, DOI 10.1007/s00418 018 1646 0
   Hasegawa T, 2017, JPN DENT SCI REV, V53, P34, DOI 10.1016/j.jdsr.2016.09.002
   Iwayama T, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax0672
   Johnson J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.705676
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149
   Kugeratski FG, 2021, NAT CELL BIOL, V23, P631, DOI 10.1038/s41556 021 00693 y
   Kunitomi Y, 2019, J BIOMED MATER RES A, V107, P1021, DOI 10.1002/jbm.a.36618
   LANDIS WJ, 1993, J STRUCT BIOL, V110, P39, DOI 10.1006/jsbi.1993.1003
   Lei C, 2022, J DENT RES, V101, P505, DOI 10.1177/00220345211053814
   Liu M, 2018, J DENT RES, V97, P859, DOI 10.1177/0022034518764411
   Mahamid J, 2008, P NATL ACAD SCI USA, V105, P12748, DOI 10.1073/pnas.0803354105
   Mahamid J, 2011, J STRUCT BIOL, V174, P527, DOI 10.1016/j.jsb.2011.03.014
   Nik AB, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00078
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nudelman F, 2010, NAT MATER, V9, P1004, DOI 10.1038/NMAT2875
   Okada T, 2016, SCI REP UK, V6, DOI 10.1038/srep29169
   Pei DD, 2018, ADV SCI, V5, DOI 10.1002/advs.201800873
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   PLACHOT JJ, 1986, BONE MINER, V1, P157
   Rohde M, 2007, CALCIFIED TISSUE INT, V80, P323, DOI 10.1007/s00223 007 9013 5
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Shapiro IM, 2015, BONE, V79, P29, DOI 10.1016/j.bone.2015.05.013
   Sugiura A, 2014, EMBO J, V33, P2142, DOI 10.15252/embj.201488104
   Tang CZ, 2020, ADV SCI, V7, DOI 10.1002/advs.201902536
   Thouverey C, 2011, J PROTEOMICS, V74, P1123, DOI 10.1016/j.jprot.2011.04.005
   Thumbigere Math V, 2018, J DENT RES, V97, P432, DOI 10.1177/0022034517744773
   van den Bos T, 2005, J DENT RES, V84, P1021, DOI 10.1177/154405910508401110
   Wang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10761 5
   Wei Y, 2019, BIOCHEM BIOPH RES CO, V514, P252, DOI 10.1016/j.bbrc.2019.04.029
   Wong YC, 2019, TRENDS CELL BIOL, V29, P500, DOI 10.1016/j.tcb.2019.02.004
   Wu LG, 2014, ANNU REV PHYSIOL, V76, P301, DOI 10.1146/annurev physiol 021113 170305
   Wuthier RE, 2011, FRONT BIOSCI LANDMRK, V16, P2812, DOI 10.2741/3887
   Yang BW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705611
   Yi GZ, 2021, STEM CELLS DEV, V30, P165, DOI 10.1089/scd.2020.0155
   Yuan FL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00628
   Zhao N, 2016, J DENT RES, V95, P734, DOI 10.1177/0022034516641898
   Zweifler LE, 2016, J DENT RES, V95, P742, DOI 10.1177/0022034516640246
NR 60
TC 28
Z9 30
U1 12
U2 70
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD DEC
PY 2022
VL 101
IS 13
BP 1554
EP 1562
AR 00220345221103145
DI 10.1177/00220345221103145
EA JUN 2022
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 6M4RT
UT WOS:000814322300001
PM 35722955
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Navarro, M
   Pu, FR
   Hunt, JA
AF Navarro, Melba
   Pu, Fanrong
   Hunt, John A.
TI The significance of the host inflammatory response on the therapeutic
   efficacy of cell therapies utilising human adult stem cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Inflammation; Mesenchymal stem cells; Co culture; Osteoblasts; Monocytes
ID HUMAN BONE MARROW; OSTEOBLAST DIFFERENTIATION; STROMAL CELLS;
   EXPRESSION; BIOMATERIALS; MONOCYTES; TISSUE; MSCS; SOX2
AB Controlling the fate of implanted hMSCs is one of the major drawbacks to be overcome to realize tissue engineering strategies. In particular, the effect of the inflammatory environment on hMSCs behaviour is poorly understood. Studying and mimicking the inflammatory process in vitro is a very complex and challenging task that involves multiple variables. This research addressed the questions using in vitro co cultures of primary derived hMSCs together with human peripheral blood mononucleated cells (PBMCs); the latter are key agents in the inflammatory process. This work explored the in vitro phenotypic changes of hMSCs in co culture direct contact with monocytes and lymphocytes isolated from blood using both basal and osteogenic medium. Our findings indicated that hMSCs maintained their undifferentiated phenotype and pluripotency despite the contact with PBMCs. Moreover, hMSCs demonstrated increased proliferation and were able to differentiate specifically down the osteogenic lineage pathway. Providing significant crucial evidence to support the hypothesis that inflammation and host defence mechanisms could be utilised rather than avoided and combated to provide for the successful therapeutic application of stem cell therapies. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Navarro, Melba] Inst Bioengn Catalonia IBEC, Biomat Regenerat Therapies Grp, Barcelona 08028, Spain.
   [Navarro, Melba; Pu, Fanrong; Hunt, John A.] Univ Liverpool, Inst Ageing & Chron Dis, UKCTE, Liverpool L69 3GA, Merseyside, England.
C3 Barcelona Institute of Science & Technology; Institut de Bioenginyeria
   de Catalunya; University of Barcelona; University of Liverpool
RP Navarro, M (通讯作者)，Inst Bioengn Catalonia IBEC, Biomat Regenerat Therapies Grp, C Baldiri Reixac 4 6, Barcelona 08028, Spain.
EM mnavarro@ibecbarcelona.eu
RI Hunt, John/S 2347 2019; Hunt, John/G 6366 2012; Navarro,
   Melba/D 1293 2015
OI Hunt, John/0000 0002 5168 4778; Navarro, Melba/0000 0002 2638 5784
FU European Commission; Medical Research Council [MC_qA137917] Funding
   Source: researchfish; MRC [MC_qA137917] Funding Source: UKRI
FX Authors acknowledge the European Commission for supporting M. Navarro
   with an Intra European Marie Curie fellowship.
CR Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   [Anonymous], 2000, Nat Biotechnol, V18 Suppl, pIT56
   Aubin J.E., 2002, PEDIAT BONE, P43
   Aubin JE, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P85, DOI 10.1016/B978 0 12 373884 4.00026 4
   Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Chaikof EL, 2002, ANN NY ACAD SCI, V961, P96, DOI 10.1111/j.1749 6632.2002.tb03057.x
   Chen SL, 2010, BIOMATERIALS, V31, P3479, DOI 10.1016/j.biomaterials.2010.01.074
   Chen Y, 2008, INT J BIOCHEM CELL B, V40, P815, DOI 10.1016/j.biocel.2008.01.007
   Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763
   DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Hutmacher DW, 2007, J TISSUE ENG REGEN M, V1, P245, DOI 10.1002/term.24
   Jones E, 2008, RHEUMATOLOGY, V47, P126, DOI 10.1093/rheumatology/kem206
   Jones EA, 2002, ARTHRITIS RHEUM US, V46, P3349, DOI 10.1002/art.10696
   Kafienah W, 2006, STEM CELLS, V24, P1113, DOI 10.1634/stemcells.2005 0416
   Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756 3282(99)00111 8
   Kemp KC, 2005, LEUKEMIA LYMPHOMA, V46, P1531, DOI 10.1080/10428190500215076
   Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097 4652(199807)176:1<57::AID JCP7>3.0.CO;2 7
   Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589
   Mooney JE, 2006, CYTOM PART A, V69A, P421
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Okumura Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Sheng HM, 2008, CELL RES, V18, P846, DOI 10.1038/cr.2008.80
   Soskolne WA, 2002, CLIN ORAL IMPLAN RES, V13, P86, DOI 10.1034/j.1600 0501.2002.130111.x
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wu YJ, 2007, WOUND REPAIR REGEN, V15, pS18, DOI 10.1111/j.1524 475X.2007.00221.x
NR 36
TC 4
Z9 5
U1 0
U2 20
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD FEB 15
PY 2012
VL 318
IS 4
BP 361
EP 370
DI 10.1016/j.yexcr.2011.12.006
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 893CP
UT WOS:000300333500006
PM 22198088
DA 2025 08 17
ER

PT J
AU Ganesan, S
   Awan Toor, S
   Guidez, F
   Maslah, N
   Rahimy, R
   Aoun, C
   Gou, PH
   Guiguen, C
   Soret, J
   Ravdan, O
   Bisio, V
   Dulphy, N
   Lobry, C
   Schlageter, MH
   Souyri, M
   Giraudier, S
   Kiladjian, JJ
   Chomienne, C
   Cassinat, B
AF Ganesan, Saravanan
   Awan Toor, Sarah
   Guidez, Fabien
   Maslah, Nabih
   Rahimy, Rifkath
   Aoun, Celine
   Gou, Panhong
   Guiguen, Chloe
   Soret, Juliette
   Ravdan, Odonchimeg
   Bisio, Valeria
   Dulphy, Nicolas
   Lobry, Camille
   Schlageter, Marie Helene
   Souyri, Michele
   Giraudier, Stephane
   Kiladjian, Jean Jacques
   Chomienne, Christine
   Cassinat, Bruno
TI Comprehensive analysis of mesenchymal cells reveals a dysregulated
   TGF β/WNT/ HOXB7 axis in patients with myelofibrosis
SO JCI INSIGHT
LA English
DT Article
ID BONE MARROW FIBROSIS; POLYCYTHEMIA VERA; OSTEOBLAST DIFFERENTIATION;
   STROMAL CELLS; PATHOGENESIS; CONTRIBUTES; SURVIVAL; CATENIN; GENES;
   MODEL
AB Despite the advances in the understanding and treatment of myeloproliferative neoplasm (MPN), the disease remains incurable with the risk of evolution to acute myeloid leukemia or myelofibrosis (MF). Unfortunately, the evolution of the disease to MF remains poorly understood, impeding preventive and therapeutic options. Recent studies in solid tumor microenvironment and organ fibrosis have shed instrumental insights on their respective pathogenesis and drug resistance, yet such precise data are lacking in MPN. In this study, through a patient sample driven transcriptomic and epigenetic description of the MF microenvironment landscape and cell based analyses, we identify homeobox B7 (HOXB7) overexpression and more precisely a potentially novel TGF (3/ WNT/HOXB7 pathway as associated to a pro fibrotic and pro osteoblastic biased differentiation of mesenchymal stromal cells (MSCs). Using gene based and chemical inhibition of this pathway, we reversed the abnormal phenotype of MSCs from patients with MF, providing the MPN field a potentially novel target to prevent and manage evolution to MF.
C1 [Ganesan, Saravanan; Awan Toor, Sarah; Guidez, Fabien; Maslah, Nabih; Aoun, Celine; Gou, Panhong; Guiguen, Chloe; Souyri, Michele; Giraudier, Stephane; Kiladjian, Jean Jacques; Chomienne, Christine; Cassinat, Bruno] Univ Paris Cite, Inst Rech St Louis, INSERM, UMRS 1131, Paris, France.
   [Guidez, Fabien] Univ Bourgogne Franche Comte, Team Epi2THM, INSERM U1232, LNC, Dijon, France.
   [Maslah, Nabih; Ravdan, Odonchimeg; Schlageter, Marie Helene; Giraudier, Stephane; Cassinat, Bruno] Hop St Louis, Serv Serv Biol Cellulaire 3, AP HP, Paris, France.
   [Rahimy, Rifkath] Inst Goncalo Moniz, Lab Rech Genet Hematol Translationnelle, Salvador, BA, Brazil.
   [Soret, Juliette; Kiladjian, Jean Jacques] Univ Paris Cite, Hop St Louis, Ctr Invest Clin, INSERM C 1427,AP HP, Paris, France.
   [Bisio, Valeria; Dulphy, Nicolas] Univ Paris Cite, Inst Rech St Louis, INSERM, UMRS 1160, Paris, France.
   [Dulphy, Nicolas] Hop St Louis, AP HP, Lab Immunol & dHistocompatibil, Paris, France.
   [Lobry, Camille] Univ Paris Cite, Inst Rech St Louis, INSERM U944, CNRS UMR7212, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Universite Bourgogne Europe; Institut Agro;
   AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Paris Cite; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Saint Louis   APHP; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Saint Louis   APHP; Universite Paris Cite; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Saint Louis   APHP;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB); Universite Paris Cite
RP Cassinat, B (通讯作者)，HOP ST LOUIS, Lab Biol Cellulaire, PARIS, France.
EM bruno.cassinat@aphp.fr
RI ; Maslah, Nabih/AAJ 7667 2021; lobry, camille/A 6188 2015; ganesan,
   saravanan/AAA 3775 2019; Guidez, Fabien/B 3750 2009; CASSINAT,
   BRUNO/N 2752 2017; Kiladjian, Jean Jacques/K 5345 2019
OI Ganesan, Saravanan/0000 0002 5773 1715; lobry,
   camille/0000 0003 0550 4921; 
FU Fondation de France
FX This work was supported by Fondation de France (00088498/2019 20) . S
   Ganesan was supported by an early career award from Fondation de France.
   We thank Romuald Peux for technical help in cytokine measurements.
CR Abou Zahr A, 2016, HAEMATOLOGICA, V101, P660, DOI 10.3324/haematol.2015.141283
   Aprile M, 2014, PPAR RES, V2014, DOI 10.1155/2014/537865
   Arranz L, 2014, NATURE, V512, P78, DOI 10.1038/nature13383
   Barbui T, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0054 y
   Bock O, 2006, AM J PATHOL, V169, P471, DOI 10.2353/ajpath.2006.060110
   Cerquozzi S, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.95
   Drexler B, 2019, HAEMATOLOGICA, V104, P710, DOI 10.3324/haematol.2018.200014
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Gao RT, 2015, INT J CLIN EXP MED, V8, P10459
   Gastinne T, 2007, EXP HEMATOL, V35, P64, DOI 10.1016/j.exphem.2006.08.016
   Hayashi Y, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110805
   Hodeib H, 2022, GENES BASEL, V13, DOI 10.3390/genes13030492
   Hoermann G, 2012, FASEB J, V26, P894, DOI 10.1096/fj.11 193078
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Jafary F, 2017, INT J TRANSPLANT MED, V8, P195
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kim JH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073500
   Kobayashi Y, 2008, JPN DENT SCI REV, V44, P76, DOI 10.1016/j.jdsr.2007.11.002
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Leimkühler NB, 2021, CELL STEM CELL, V28, P637, DOI 10.1016/j.stem.2020.11.004
   Lin HT, 2019, INT J MOL MED, V43, P1085, DOI 10.3892/ijmm.2018.4001
   Lu M, 2015, BLOOD, V126, P972, DOI 10.1182/blood 2014 12 618595
   Lucijanic M, 2016, CL LYMPH MYELOM LEUK, V16, P523, DOI 10.1016/j.clml.2016.06.004
   Luther J, 2014, CELL DEATH DIFFER, V21, P655, DOI 10.1038/cdd.2013.198
   Lv HJ, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.940248
   Martinaud C, 2015, CANCER RES, V75, P4753, DOI 10.1158/0008 5472.CAN 14 3696
   Melo Cardenas J, 2022, BLOOD, V140, P2805, DOI 10.1182/blood.2022017326
   Mughal TI, 2014, INT J GEN MED, V7, P89, DOI 10.2147/IJGM.S51800
   Nielsen HM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07057 3
   Passamonti F, 2017, LEUKEMIA, V31, P2726, DOI 10.1038/leu.2017.169
   Pourcelot E, 2014, EXP HEMATOL, V42, P360, DOI 10.1016/j.exphem.2014.01.006
   Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702
   Rux DR, 2017, DEV DYNAM, V246, P310, DOI 10.1002/dvdy.24482
   Saito H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08778 x
   Schneider RK, 2017, CELL STEM CELL, V20, P785, DOI 10.1016/j.stem.2017.03.008
   Seifert A, 2015, WORLD J STEM CELLS, V7, P583, DOI 10.4252/wjsc.v7.i3.583
   Shammo JM, 2016, HEMATOL AM SOC HEMAT, P552, DOI 10.1182/asheducation 2016.1.552
   Steens J, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1002909
   Tefferi A, 2011, J CLIN ONCOL, V29, P1356, DOI 10.1200/JCO.2010.32.9490
   Vaidya R, 2012, AM J HEMATOL, V87, P1003, DOI 10.1002/ajh.23295
   Vlashi R, 2023, GENES DIS, V10, P1291, DOI 10.1016/j.gendis.2022.07.011
   Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701
   Yue LZ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90932
   Zhang WX, 2018, J BIOL CHEM, V293, P17119, DOI 10.1074/jbc.RA118.003608
NR 44
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD DEC 6
PY 2024
VL 9
IS 23
AR e173665
DI 10.1172/jci.insight.173665
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA O8L9W
UT WOS:001373588200001
PM 39470742
OA gold
DA 2025 08 17
ER

PT J
AU Iafisco, M
   Palazzo, B
   Martra, G
   Margiotta, N
   Piccinonna, S
   Natile, G
   Gandin, V
   Marzano, C
   Roveri, N
AF Iafisco, Michele
   Palazzo, Barbara
   Martra, Gianmario
   Margiotta, Nicola
   Piccinonna, Sara
   Natile, Giovanni
   Gandin, Valentina
   Marzano, Cristina
   Roveri, Norberto
TI Nanocrystalline carbonate apatites: role of Ca/P ratio on the upload and
   release of anticancer platinum bisphosphonates
SO NANOSCALE
LA English
DT Article
ID DRUG DELIVERY; BIOMIMETIC HYDROXYAPATITE; AGENTS; BONE; CANCER;
   BIOMATERIALS; MECHANISMS; ADSORPTION; EFFICACY; THERAPY
AB In the present study two nanocrystalline apatites have been investigated as bone specific drug delivery devices to be used for treatment of bone tumors either by local implantation or by injection. In order to assess how the Ca/P ratio can influence the adsorption and release of anticancer platinum bisphosphonate complexes, two kinds of apatite nanocrystals having different Ca/P ratios but similar morphologies, degree of crystallinity, and surface areas have been synthesized and characterized. The two platinum bisphosphonate complexes considered were the bis {ethylenediamineplatinum(II)} 2 amino 1 hydroxyethane 1,1 diyl bisphosphonate and the bis {ethylenediamineplatinum(II)} medronate. The Ca/P ratio plays an important role in the adsorption as well as in the release of the two drugs. In fact, the apatite with a higher Ca/P ratio showed greater affinity for both platinum complexes. Also the chemical structure of the two Pt complexes appreciably affects their affinity towards as well as their release from the two kinds of apatites. In particular, the platinum complex whose bisphosphonate contains a free aminic group showed greater upload and smaller release. The cytotoxicity of the Pt complexes released from the apatite was tested against human cervical, colon, and lung cancer cells as well as against osteosarcoma cells. In agreement with previous work, the Pt complexes released were found to be more cytotoxic than the unmodified complexes.
C1 [Iafisco, Michele; Palazzo, Barbara; Roveri, Norberto] Univ Bologna, Dipartimento Chim G Ciamician, I 40126 Bologna, Italy.
   [Iafisco, Michele] Univ Piemonte Orientale, Dipartimento Sci Med, I 28100 Novara, Italy.
   [Martra, Gianmario] Univ Turin, Dipartimento Chim IFM, I 10125 Turin, Italy.
   [Martra, Gianmario] Univ Turin, Centro Interdipartimentale Eccellenza, NIS, I 10125 Turin, Italy.
   [Margiotta, Nicola; Piccinonna, Sara; Natile, Giovanni] Univ Bari A Moro, Dipartimento Farmacochim, I 70125 Bari, Italy.
   [Gandin, Valentina; Marzano, Cristina; Roveri, Norberto] Univ Padua, Dipartimento Sci Farmaceut, I 35131 Padua, Italy.
C3 University of Bologna; University of Eastern Piedmont Amedeo Avogadro;
   University of Turin; University of Turin; Universita degli Studi di Bari
   Aldo Moro; University of Padua
RP Iafisco, M (通讯作者)，Univ Bologna, Dipartimento Chim G Ciamician, Via Selmi 2, I 40126 Bologna, Italy.
EM michele.iafisco@unibo.it
RI ; Margiotta, Nicola/AAE 3975 2021; Iafisco, Michele/ABF 7752 2020;
   Iafisco, Michele/B 4597 2010
OI Palazzo, Barbara/0000 0001 5645 3779; Natile,
   Giovanni/0000 0002 1790 6365; GANDIN, VALENTINA/0000 0003 0442 0670;
   Martra, Gianmario/0000 0002 8012 5342; Margiotta,
   Nicola/0000 0003 4034 875X; Iafisco, Michele/0000 0002 7813 8347
FU Regione Piemonte (Progetto Ricerca Sanitaria Finalizzata)
   [30258/DB2001]; Inter University Consortium for Research on Chemistry of
   Metals in Biological Systems; University of Bari, Bologna; University of
   Piemonte Orientale, Padova; University of Torino; Italian Ministero
   dell'Istruzione, Universita a e Ricerca (MIUR); Regione Piemonte
FX We thank the Universities of Bari, Bologna, Piemonte Orientale, Padova,
   and Torino (funds for selected research topics), the Italian Ministero
   dell'Istruzione, Universita a e Ricerca (MIUR), the research project
   "Nanoparticelle multifunzionali per la terapia dei carcinomi: studi in
   vitro e in vivo in modelli sperimentali" funded by Regione Piemonte
   (Progetto Ricerca Sanitaria Finalizzata 2009, Grant no: 30258/DB2001)
   and the Inter University Consortium for Research on Chemistry of Metals
   in Biological Systems (C. I. R. C. M. S. B). M. I. is recipient of a
   fellowship from Regione Piemonte. Dr Luca Bertinetti (ex University of
   Torino) is kindly acknowledged for TEM images of CDHA.
CR Adair JH, 2010, ACS NANO, V4, P4967, DOI 10.1021/nn102324e
   ALLEY MC, 1988, CANCER RES, V48, P589
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Bertinetti L, 2007, J PHYS CHEM C, V111, P4027, DOI 10.1021/jp066040s
   Bildstein L, 2011, ADV DRUG DELIVER REV, V63, P3, DOI 10.1016/j.addr.2010.12.005
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078 0432.CCR 07 1441
   DAUGAARD G, 1989, CANCER CHEMOTH PHARM, V25, P1, DOI 10.1007/BF00694330
   Epple M, 2010, J MATER CHEM, V20, P18, DOI 10.1039/b910885h
   ERRASSIF F, 2010, ADV BIOCERAMICS BIOT, V218
   Freundlich H, 1906, Z PHYS CHEM STOCH VE, V57, P385
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018 009 0053 z
   Iafisco M, 2011, DALTON T, V40, P820, DOI 10.1039/c0dt00714e
   Iafisco M, 2010, INT J ARTIF ORGANS, V33, P765
   Iafisco M, 2010, ADV ENG MATER, V12, pB218, DOI 10.1002/adem.201080003
   Iafisco M, 2009, J MATER CHEM, V19, P8385, DOI 10.1039/b914379c
   Jäger C, 2006, MAGN RESON CHEM, V44, P573, DOI 10.1002/mrc.1774
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Leucuta SE, 2010, CURR CLIN PHARMACOL, V5, P257, DOI 10.2174/157488410793352003
   Liou SC, 2004, BIOMATERIALS, V25, P189, DOI 10.1016/S0142 9612(03)00479 4
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   O'Dwyer P J., 1999, Cisplatin: chemistry and biochemistry of a leading anticancer drug, P29, DOI [DOI 10.1002/9783906390420.CH2, 10.1002/9783906390420.ch2]
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pietronave S, 2009, J APPL BIOMATER BIOM, V7, P77
   Rey C, 2007, MAT SCI ENG C BIO S, V27, P198, DOI 10.1016/j.msec.2006.05.015
   REY C, 1989, CALCIFIED TISSUE INT, V45, P157, DOI 10.1007/BF02556059
   Rill C, 2009, LANGMUIR, V25, P2294, DOI 10.1021/la803562e
   Roveri N, 2008, EXPERT OPIN DRUG DEL, V5, P861, DOI 10.1517/17425247.5.8.861 
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell Jones G, 2004, J INORG BIOCHEM, V98, P1625, DOI 10.1016/j.jinorgbio.2004.07.009
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   Sokolova V, 2011, NANOSCALE, V3, P1957, DOI 10.1039/c1nr00002k
   Stigter M, 2004, J CONTROL RELEASE, V99, P127, DOI 10.1016/j.jconrel.2004.06.011
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v
   Zhang MZ, 2009, NANO TODAY, V4, P508, DOI 10.1016/j.nantod.2009.10.009
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 39
TC 72
Z9 73
U1 0
U2 68
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PY 2012
VL 4
IS 1
BP 206
EP 217
DI 10.1039/c1nr11147g
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 859BG
UT WOS:000297848500028
PM 22075933
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Choi, YS
   Kang, EH
   Lee, EY
   Gong, HS
   Kang, HS
   Shin, K
   Lee, EB
   Song, YW
   Lee, YJ
AF Choi, Yong Seok
   Kang, Eun Ha
   Lee, Eun Young
   Gong, Hyun Sik
   Kang, Heun Soo
   Shin, Kichul
   Lee, Eun Bong
   Song, Yeong Wook
   Lee, Yun Jong
TI Joint protective effects of compound K, a major ginsenoside metabolite,
   in rheumatoid arthritis: in vitro evidence
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Ginsenosides; Compound K; Rheumatoid arthritis; Matrix
   metalloproteinase; Osteoclast; Osteoclastogenesis
ID COLLAGEN INDUCED ARTHRITIS; KAPPA B; PANAX NOTOGINSENG; BONE
   DESTRUCTION; CELLS; OSTEOCLASTOGENESIS; SAPONINS; RB1; SYNOVIOCYTES;
   FIBROBLASTS
AB Regulatory expression of matrix metalloproteinases (MMPs) and osteoclastogenesis is implicated in the process of joint destruction in rheumatoid arthritis (RA). Although several reports suggested the anti arthritic effects of ginseng saponins, it has not been investigated whether the most absorbable ginsenoside, compound K (CK), has a joint protective action. We here investigated the effect of CK (0 5 mu M) on TNF alpha induced MMP 1, MMP 3, and MMP 13 and TIMP 1 production from RA fibroblast like synoviocytes (FLS) and determined the inhibitory effect of CK on osteoclastogenesis from RAW264.7 cells co cultured with RA FLS and from human CD14+ monocytes. The effect of CK on NF kappa B, nuclear factor of activated T cells c1 (NFATc1), and mitogen activated protein kinases pathways were evaluated using immunoblotting or specific inhibitors. CK significantly inhibited MMP 1 and MMP 3 productions from RA FLS in a concentration dependent manner through suppressing the JNK and ERK pathways. In the co culture system of TNF alpha stimulated RA FLS and RAW264.7 cells, CK dose dependently reduced receptor activator of NF kappa B ligand (RANKL) expression in the RA FLS and inhibited the formation of tartrate resistant acid phosphatase (TRAP) positive osteoclast like cells. Furthermore, CK significantly inhibited soluble RANKL induced osteoclastogenesis or osteoclast activity in RAW264.7 cells and human CD14+ monocytes through inhibition of RANKL induced I kappa B alpha degradation and NFATc1 expression. In conclusion, our results increase the understanding of the molecular mechanisms of the joint protective effects of CK in RA. The characteristic actions of CK provide in vitro evidence for its potential utility in RA therapy.
C1 [Choi, Yong Seok; Kang, Eun Ha; Lee, Yun Jong] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam 463707, Gyeonggi Do, South Korea.
   [Lee, Eun Young; Lee, Eun Bong; Song, Yeong Wook] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   [Lee, Eun Young; Lee, Eun Bong; Lee, Yun Jong] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
   [Gong, Hyun Sik] Seoul Natl Univ, Bundang Hosp, Dept Orthoped Surg, Songnam 463707, Gyeonggi Do, South Korea.
   [Kang, Heun Soo] Seoul Natl Univ, Coll Med, Canc Res Inst, Metabolab Inc, Seoul, South Korea.
   [Shin, Kichul] Seoul Natl Univ, Dept Internal Med, Borame Med Ctr, Seoul, South Korea.
   [Song, Yeong Wook] Seoul Natl Univ, Coll Med, WCU Dept Mol Med & Biopharmaceut Sci, Med Res Inst, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU)
RP Lee, YJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Internal Med, 166 Gumi Ro, Songnam 463707, Gyeonggi Do, South Korea.
EM yn35@snu.ac.kr
RI ; Lee, Eun/J 5594 2012; Gong, Hyun/J 5371 2012
OI Lee, Eun Young/0000 0001 6975 8627; 
FU Korea Health technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [A090933]
FX This study was supported by a grant of the Korea Health technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea. (A090933).
CR Aletaha D, 2011, ANN RHEUM DIS, V70, P733, DOI 10.1136/ard.2010.138693
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chang SH, 2007, CLIN NUTR, V26, P785, DOI 10.1016/j.clnu.2007.07.008
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Choo MK, 2008, ONCOL REP, V19, P595
   Cunnane G, 2001, ARTHRITIS RHEUM, V44, P2263, DOI 10.1002/1529 0131(200110)44:10<2263::AID ART389>3.3.CO;2 T
   Hasegawa H, 2004, J PHARMACOL SCI, V95, P153, DOI 10.1254/jphs.FMJ04001X4
   He DW, 2011, J FORMOS MED ASSOC, V110, P153, DOI 10.1016/S0929 6646(11)60025 9
   Jung SH, 2006, INT J CANCER, V118, P490, DOI 10.1002/ijc.21356
   Keystone EC, 2009, J RHEUMATOL, V36, P11, DOI 10.3899/jrheum.090125
   Kim HA, 2007, INT IMMUNOPHARMACOL, V7, P1286, DOI 10.1016/j.intimp.2007.05.006
   Kim KR, 2010, BIOL PHARM BULL, V33, P604, DOI 10.1248/bpb.33.604
   Konttinen YT, 1999, MATRIX BIOL, V18, P401, DOI 10.1016/S0945 053X(99)00030 X
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243
   Moore BA, 2000, BBA MOL BASIS DIS, V1502, P307, DOI 10.1016/S0925 4439(00)00056 9
   ODANI T, 1983, CHEM PHARM BULL, V31, P1059
   Papagoras C, 2010, AUTOIMMUN REV, V9, P574, DOI 10.1016/j.autrev.2010.04.002
   Park JS, 2009, J NEUROIMMUNOL, V209, P40, DOI 10.1016/j.jneuroim.2009.01.020
   Pucino F, 2006, AM J HEALTH SYST PH, V63, pS19, DOI 10.2146/ajhp060365
   Rannou FO, 2006, JOINT BONE SPINE, V73, P29, DOI 10.1016/j.jbspin.2004.12.013
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   van den Berg WB, 2005, ARTHRITIS RHEUM US, V52, P995, DOI 10.1002/art.20981
   van den Berg WB, 2008, NAT CLIN PRACT RHEUM, V4, P58, DOI 10.1038/ncprheum0683
   Wakabayashi C, 1997, ONCOL RES, V9, P411
   Xu QF, 2003, J ETHNOPHARMACOL, V84, P187, DOI 10.1016/S0378 8741(02)00317 3
   Yamanaka H, 2000, ARTHRITIS RHEUM, V43, P852, DOI 10.1002/1529 0131(200004)43:4<852::AID ANR16>3.0.CO;2 7
   Young Min S, 2007, ARTHRITIS RHEUM US, V56, P3236, DOI 10.1002/art.22923
   Zhang Jia hong, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P589
NR 31
TC 28
Z9 30
U1 0
U2 38
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD AUG
PY 2013
VL 33
IS 8
BP 1981
EP 1990
DI 10.1007/s00296 013 2664 9
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 187LM
UT WOS:000322120400010
PM 23370854
DA 2025 08 17
ER

PT J
AU Molina Vila, P
   Pérez, PS
   Almerich, EG
   Domingo, AP
AF Molina Vila, Pablo
   Sanchez Perez, Pilar
   Garrigos Almerich, Enrique
   Peris Domingo, Ana
TI Marked improvement in bone metabolism parameters after increasing the
   dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic
   hemodialysis patients
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article
DE bone metabolism; dialysate calcium; hemodialysis; secondary
   hyperparathyroidism
ID SECONDARY HYPERPARATHYROIDISM; MINERAL METABOLISM; BLOOD PRESSURE;
   MANAGEMENT; CARBONATE; HEMODIAFILTRATION; GUIDELINES
AB The optimal dialysate calcium (Ca) concentration for hemodialysis (HD) patients is set at 2.5 mEq/L according to Kidney Disease Outcomes Quality Initiative (K DOQI) guidelines. This recommendation is opinion based and could negatively affect secondary hyperparathyroidism. Studies have suggested that a dialysate Ca of 3.0 mEq/L is a compromise between bone protection and cardiovascular risk. The aim of our study was to investigate the effect on bone metabolism parameters after increasing the dialysate Ca concentration from 2.5 to 3.0 mEq/L. The dialysate Ca concentration in our patients was increased from 2.5 to 3.0 mEq/L. Patients with hypercalcemia, normal high Ca levels with a high Ca Phosphorus product (Ca x P), excessively suppressed parathyroid hormone (PTH), or a past medical history of calciphylaxis were excluded. Twenty two patients were studied over 20 weeks. Parathyroid hormone levels decreased significantly (442 +/  254 vs. 255 +/  226 pg/mL; p=0.000), without significant changes in serum Ca, P, and Ca x P levels at any sampling point. Better control of secondary hyperparathyroidism allowed us to decrease the paracalcitol dosage in 6 of the 12 patients who had been treated with this drug at the beginning of the study. Other potential factors involved in PTH secretion were not modified. A significant improvement in the rate of patients with 3 or more K DOQI parameters within the target ranges (8 [36%] vs. 12 [55%]; p=0.026) was observed. In the absence of hypercalcemia or excessively suppressed PTH, an increase from 2.5mEq to 3.0 mEq/L in dialysate Ca concentration resulted in better control of secondary hyperparathyroidism without affecting Ca, P, and Ca x P levels, thus enabling us to reduce the dosage of vitamin D metabolites.
C1 [Molina Vila, Pablo; Sanchez Perez, Pilar; Garrigos Almerich, Enrique; Peris Domingo, Ana] Hosp Francesc de Borja, Div Nephrol, Valencia 46700, Spain.
RP Molina Vila, P (通讯作者)，Hosp Francesc de Borja, Div Nephrol, Passeig Germanies 76, Valencia 46700, Spain.
EM molina_pab@gva.es
RI Molina, Pablo/ABD 1424 2021
OI Molina, Pablo/0000 0002 8311 6214
CR Al Aly Z, 2004, AM J NEPHROL, V24, P422, DOI 10.1159/000080087
   [Anonymous], J NEPHROL
   Arenas MD, 2006, NEPHROL DIAL TRANSPL, V21, P1663, DOI 10.1093/ndt/gfl006
   Argiles A, 1998, NEPHROL DIAL TRANSPL, V13, P62, DOI 10.1093/ndt/13.suppl_3.62
   ARGILES A, 1993, KIDNEY INT, V43, P630, DOI 10.1038/ki.1993.92
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   CANNATA JB, 2000, NEPHROL DIAL TRAN S5, V18, P39
   CISCART AAI, 1995, NEPHROL DIAL TRANSPL, V10, P451, DOI 10.1093/ndt/10.4.451
   Cunningham J, 2000, NEPHROL DIAL TRANSPL, V15, P34, DOI 10.1093/ndt/15.suppl_5.34
   FERNANDEZ E, 1995, J AM SOC NEPHROL, V6, P132
   Izumi M, 2005, THER APHER DIAL, V9, P24, DOI 10.1111/j.1774 9987.2005.00210.x
   Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P785, DOI 10.1093/ndt/gfh102
   Lorenzo V, 2006, NEPHROL DIAL TRANSPL, V21, P459, DOI 10.1093/ndt/gfi213
   Maduell F, 2005, J NEPHROL, V18, P739
   Malberti F, 2003, NEPHROL DIAL TRANSPL, V18, P37, DOI 10.1093/ndt/gfg1077
   MARTIN KJ, 2006, CLIN GUIDE BONE MINE, P45
   Näppi SE, 2000, KIDNEY INT, V57, P2117, DOI 10.1046/j.1523 1755.2000.00062.x
   *NAT KIDN FDN KIDN, 2003, AM J KIDNEY DIS S, V4, pS99
   Pedrini LA, 2002, CONTRIB NEPHROL, V137, P344
   SAWYER N, 1989, NEPHROL DIAL TRANSPL, V4, P105
   SLATOPOLSKY E, 1986, NEW ENGL J MED, V315, P157, DOI 10.1056/NEJM198607173150304
   SLATOPOLSKY E, 1989, KIDNEY INT, V36, P897, DOI 10.1038/ki.1989.277
   TORREGROSA JV, SPANISH SOC NEPHROLO
   Toussaint Nigel, 2006, Hemodial Int, V10, P326, DOI 10.1111/j.1542 4758.2006.00125.x
   van der Sande FM, 1998, AM J KIDNEY DIS, V32, P125, DOI 10.1053/ajkd.1998.v32.pm9669433
   VANDERMERWE WM, 1990, NEPHROL DIAL TRANSPL, V5, P874, DOI 10.1093/ndt/5.10.874
   vanKuijk WHM, 1997, CLIN NEPHROL, V47, P190
NR 27
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1492 7535
EI 1542 4758
J9 HEMODIAL INT
JI Hemodial. Int.
PD JAN
PY 2008
VL 12
IS 1
BP 73
EP 79
DI 10.1111/j.1542 4758.2008.00244.x
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 306TU
UT WOS:000256271500013
PM 18271845
DA 2025 08 17
ER

PT J
AU Hiraoka, K
   Zenmyo, M
   Watari, K
   Iguchi, H
   Fotovati, A
   Kimura, YN
   Hosoi, F
   Shoda, T
   Nagata, K
   Osada, H
   Ono, M
   Kuwano, M
AF Hiraoka, Koji
   Zenmyo, Michihisa
   Watari, Kousuke
   Iguchi, Haruo
   Fotovati, Abbas
   Kimura, Yusuke N.
   Hosoi, Fumihito
   Shoda, Takanori
   Nagata, Kensei
   Osada, Hiroyuki
   Ono, Mayumi
   Kuwano, Michihiko
TI Inhibition of bone and muscle metastases of lung cancer cells by a
   decrease in the number of monocytes/macrophages
SO CANCER SCIENCE
LA English
DT Article
ID TUMOR ASSOCIATED MACROPHAGES; HORMONE RELATED PROTEIN; REVEROMYCIN A;
   GROWTH; INFILTRATION; ANGIOGENESIS; INFLAMMATION; MIGRATION
AB Attention has recently focused on the critical role of inflammatory responses in the tumor stroma that provide favorable conditions for cancer cell growth and invasion/metastasis. In particular, macrophages recruited into the tumor stroma and activated, known as tumor associated macrophages, are suggested to promote tumorigenesis. In this study, we examined the effect of a decrease in the number of monocytes/macrophages in peripheral blood and the tumor stroma on the development of bone and muscle metastases by lung cancer cells. Treatment with clodronate encapsulated by liposomes (Cl2MDP LIP) has been developed for the depletion of monocytes/macrophages in an animal model. Subcutaneous administration of Cl2MDP LIP markedly reduced the number of monocytes in peripheral blood, resulting in efficient suppression of both bone metastasis and muscle metastasis when lung cancer HARA B cells were injected into the left cardiac ventricle of mice. Treatment with Cl2MDP LIP significantly reduced the number of macrophages in tumors and the number of osteoclasts in bone marrow, as well as peripheral monocytes in mice harboring lung cancer cells. In contrast, treatment with an osteoclast targeting antibiotic, reveromycin A, inhibited bone metastasis by lung cancer cells, but not muscle metastasis. The survival of human macrophages in culture was found to be specifically blocked by Cl2MDP LIP, but not by reveromycin A. Cl2MDP LIP thus exerted antimetastatic effects in both bone and muscle whereas reveromycin A did so only in bone. Liposome encapsulated bisphosphonate may modulate metastasis through decreasing the number of monocytes/macrophages in both peripheral blood and the tumor stroma, suggesting that tumor associated macrophages might be suitable targets for antimetastatic therapy. (Cancer Sci 2008; 99: 1595 1602)
C1 [Hiraoka, Koji; Zenmyo, Michihisa; Shoda, Takanori; Nagata, Kensei] Kurume Univ, Sch Med, Dept Orthoped Surg, Kurume, Fukuoka 8300011, Japan.
   [Hiraoka, Koji; Zenmyo, Michihisa; Fotovati, Abbas; Kimura, Yusuke N.; Hosoi, Fumihito; Shoda, Takanori; Nagata, Kensei; Kuwano, Michihiko] Kurume Univ, Sch Med, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 8300011, Japan.
   [Watari, Kousuke] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut Oncol, Fukuoka 8128582, Japan.
   [Iguchi, Haruo] Shikoku Canc Ctr, Clin Res Inst, Matsuyama, Ehime 7910280, Japan.
   [Osada, Hiroyuki] RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan.
   [Ono, Mayumi; Kuwano, Michihiko] Kyushu Univ, Innovat Ctr Med Redox Navigat, Fukuoka 8128582, Japan.
C3 Kurume University; Kurume University; Kyushu University; RIKEN; Kyushu
   University
RP Hiraoka, K (通讯作者)，Kurume Univ, Sch Med, Dept Orthoped Surg, Kurume, Fukuoka 8300011, Japan.
EM khiraoka@med.kurume u.ac.jp
RI ; Osada, Hiroyuki/AAY 6254 2020
OI Watari, Kosuke/0000 0003 0260 2323; 
FU COE Program for Medical Science; Ministry of Health, Welfare; Innovation
   Center for Medical Redox Navigation, Kyushu University
FX We thank Kazuhiro Yoshida, Hiromi Kuboyama, and Hitomi Wakita for
   technical assistance. This study was partly supported by the 21st
   Century COE Program for Medical Science; a grant in aid for the 3rd term
   comprehensive 10 year strategy for cancer control from the Ministry of
   Health, Welfare ( M. K.), and Labor of Japan; and the Innovation Center
   for Medical Redox Navigation, Kyushu University (M.O., M. K.).
CR Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140 6736(00)04046 0
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166
   Fleisch H., 1988, HDB EXPT PHARM, V83, P441
   Gallwitz WE, 2002, J CLIN INVEST, V110, P1559, DOI 10.1172/JCI200211936
   Gardner CR, 2007, CELL BIOL INT, V31, P672, DOI 10.1016/j.cellbi.2006.12.008
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Iguchi H, 1996, CANCER RES, V56, P4040
   Iguchi H, 2000, INT J ONCOL, V17, P329
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kimura YN, 2007, CANCER SCI, V98, P2009, DOI 10.1111/j.1349 7006.2007.00633.x
   Koshkina NV, 2005, INT J CANCER, V116, P458, DOI 10.1002/ijc.21011
   Kuwano M, 2005, NEW ANGIOGENESIS RESEACH, P157
   Leek RD, 1996, CANCER RES, V56, P4625
   Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648
   Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016
   Muguruma H, 2005, CLIN CANCER RES, V11, P8822, DOI 10.1158/1078 0432.CCR 05 1335
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   ONO M, 2008, CANC SCI IN PRESS
   OSADA H, 1991, J ANTIBIOT, V44, P259, DOI 10.7164/antibiotics.44.259
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0
   Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097 0215(20000115)85:2<182::AID IJC6>3.3.CO;2 D
   VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022 1759(89)90178 6
   Woo JT, 2006, P NATL ACAD SCI USA, V103, P4729, DOI 10.1073/pnas.0505663103
   Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008 5472.CAN 04 1449
   Yano S, 2005, CLIN CANCER RES, V11, P8789, DOI 10.1158/1078 0432.CCR 05 0674
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
NR 34
TC 110
Z9 129
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD AUG
PY 2008
VL 99
IS 8
BP 1595
EP 1602
DI 10.1111/j.1349 7006.2008.00880.x
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 337MQ
UT WOS:000258440600014
PM 18754872
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yokoyama, K
   Shimazaki, R
   Fukagawa, M
   Akizawa, T
   Maeda, Y
   Ueki, K
   Fujii, T
   Miyazaki, R
   Azekura, H
   Kasuga, H
   Tomiyoshi, Y
   Shinzato, T
   Iwashita, R
   Takada, K
   Suda, A
   Nagaoka, T
   Yoshimoto, M
   Taniguchi, M
   Ogawa, H
AF Yokoyama, Keitaro
   Shimazaki, Ryutaro
   Fukagawa, Masafumi
   Akizawa, Tadao
   Maeda, Yoshitaka
   Ueki, Kazue
   Fujii, Takayuki
   Miyazaki, Ryoichi
   Azekura, Hisanori
   Kasuga, Hirotake
   Tomiyoshi, Yoshiyuki
   Shinzato, Takeaki
   Iwashita, Ryuji
   Takada, Kenji
   Suda, Akio
   Nagaoka, Takashi
   Yoshimoto, Mitsuru
   Taniguchi, Masatomo
   Ogawa, Hiroshi
CA Evocalcet Study Grp
TI Long Term Efficacy and Safety of Evocalcet in Japanese Patients with
   Secondary Hyperparathyroidism Receiving Hemodialysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ETELCALCETIDE ONO 5163/AMG 416; SERUM PARATHYROID HORMONE; CINACALCET;
   MANAGEMENT; PLACEBO
AB Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic consequences, termed CKD mineral and bone disorder. Currently, cinacalcet is indicated for the treatment of SHPT; however, cinacalcet is associated with upper gastrointestinal adverse events. Evocalcet has been developed to address these issues, but the long term safety and efficacy of evocalcet need to be evaluated. To more accurately reflect clinical practice, this phase 3, multicenter, open label study was specifically designed without a cinacalcet washout period, and focused on those patients who switched from cinacalcet to evocalcet. A total of 137 SHPT patients undergoing hemodialysis were enrolled, of whom 113 switched from cinacalcet to evocalcet. The most frequent type of adverse drug reaction was decreased adjusted calcium. The incidence of gastrointestinal related adverse events did not increase in a dose dependent manner as the dose of evocalcet was increased. The percentage of patients achieving the target intact parathyroid hormone concentration increased from 40.9% to 72.3% with 52 week treatment. The corrected serum calcium and phosphorus levels remained largely unchanged throughout the study. The long term safety and efficacy of evocalcet was confirmed using a clinically relevant intra subject dose adjustment strategy in SHPT patients undergoing hemodialysis.
C1 [Yokoyama, Keitaro] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens,Minato Ku, 3 25 8 Nishi Shimbashi, Tokyo 1058461, Japan.
   [Shimazaki, Ryutaro] Kyowa Hakko Kirin Co Ltd, R&D Div, Chiyoda Ku, 1 9 2 Otemachi, Tokyo 1000004, Japan.
   [Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Dept Internal Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
   [Akizawa, Tadao] Showa Univ, Sch Med, Div Nephrol, Dept Med,Minato Ku, Namics 301,4 24 51 Takanawa, Tokyo 1080074, Japan.
   [Maeda, Yoshitaka] JA Toride Med Ctr, Dept Nephrol, Ibaraki, Japan.
   [Ueki, Kazue] Sanshikai Toho Hosp, Dialysis Ctr, Gunma, Japan.
   [Fujii, Takayuki] Seirei Sakura Citizen Hosp, Dept Nephrol, Chiba, Japan.
   [Miyazaki, Ryoichi] Fujita Mem Hosp, Dept Internal Med, Fukui, Japan.
   [Azekura, Hisanori] Sanaru Sun Clin, Dept Nephrol, Shizuoka, Japan.
   [Kasuga, Hirotake] Kaikoukai Cent Clin, Dept Internal Med, Nagoya, Aichi, Japan.
   [Tomiyoshi, Yoshiyuki] Takagi Hosp, Dept Nephrol, Fukuoka, Fukuoka, Japan.
   [Shinzato, Takeaki] Shinzato Clin Urakami, Dept Nephrol, Nagasaki, Japan.
   [Iwashita, Ryuji] Ueyama Hosp, Dept Nephrol, Kagoshima, Japan.
   [Takada, Kenji] Tsukuba Gakuen Hosp, Dept Nephrol, Ibaraki, Japan.
   [Suda, Akio] Suda Clin, Dept Internal Med, Tokyo, Japan.
   [Nagaoka, Takashi] Sagamihara Clin, Dept Hematol, Sagamihara, Kanagawa, Japan.
   [Yoshimoto, Mitsuru] Ohno Mem Hosp, Dept Urol, Osaka, Japan.
   [Taniguchi, Masatomo] Fukuoka Renal Clin, Dept Internal Med, Fukuoka, Fukuoka, Japan.
   [Ogawa, Hiroshi] Shinseikai Daiichi Hosp, Dept Internal Med, Nagoya, Aichi, Japan.
C3 Jikei University; Kyowa Kirin Ltd; Tokai University; Showa University
RP Yokoyama, K (通讯作者)，Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens,Minato Ku, 3 25 8 Nishi Shimbashi, Tokyo 1058461, Japan.
EM keitaro@jikei.ac.jp
RI TAKADA, Kenji/L 7719 2015
CR Akizawa T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204896
   Akizawa T, 2016, SCI REP UK, V6, DOI 10.1038/srep19612
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Cozzolino M, 2017, THER CLIN RISK MANAG, V13, P679, DOI 10.2147/TCRM.S108490
   Cunningham J, 2005, THER APHER DIAL, V9, pS35, DOI 10.1111/j.1744 9987.2005.00310.x
   Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
   Fukagawa M, 2018, KIDNEY INT, V94, P818, DOI 10.1016/j.kint.2018.05.013
   Fukagawa M, 2017, NEPHROL DIAL TRANSPL, V32, P1723, DOI 10.1093/ndt/gfw408
   Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744 9987.2008.00648.x
   Hamano N, 2017, EXPERT OPIN PHARMACO, V18, P529, DOI 10.1080/14656566.2017.1303482
   Hamano Naoto, 2017, Clin Calcium, V27, P567, DOI CliCa1704567572
   International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, 1994, EXT POP EXP ASS CLIN
   Japanese Society for Dialysis Therapy, 2007, THER APHER DIAL, V11, P411
   Kawata T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195316
   Komaba H, 2015, KIDNEY INT, V88, P350, DOI 10.1038/ki.2015.72
   Ogata H, 2006, THER APHER DIAL, V10, P355, DOI 10.1111/j.1744 9987.2006.00389.x
   Rodríguez M, 2015, SEMIN DIALYSIS, V28, P497, DOI 10.1111/sdi.12357
   Shigematsu T, 2009, AM J NEPHROL, V29, P230, DOI 10.1159/000156717
   Shigematsu T, 2018, CLIN PHARMACOL ADV A, V10, P101, DOI 10.2147/CPAA.S171044
   Shigematsu T, 2019, CLIN EXP NEPHROL, V23, P258, DOI 10.1007/s10157 018 1635 6
   Yokoyama K, 2017, CLIN NEPHROL, V88, P68, DOI 10.5414/CN108974
NR 23
TC 15
Z9 16
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 23
PY 2019
VL 9
AR 6410
DI 10.1038/s41598 019 42017 z
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HU4AK
UT WOS:000465216200004
PM 31015494
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jiang, XQ
   Chen, JG
   Gittens, S
   Chen, CJ
   Zhang, XL
   Zhang, ZY
AF Jiang, XQ
   Chen, JG
   Gittens, S
   Chen, CJ
   Zhang, XL
   Zhang, ZY
TI The ectopic study of tissue engineered bone with hBMP 4 gene modified
   bone marrow stromal cells in rabbits
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE tissue engineering; bone morphogenetic protein; bone marrow stromal
   cells; gene therapy
ID MORPHOGENETIC PROTEINS; STEM CELLS; THERAPY; DEFECTS; ENHANCEMENT;
   REPAIR
AB Background Tissue engineering techniques combined with gene therapy have been recently reported to improve osteogenesis. In this study, tissue engineered bone constructed by human Bone Morphogenetic Protein 4 (hBMP 4) gene modified bone marrow stromal cells (bMSCs) was explored in an ectopic bone formation model in rabbits.
   Methods A pEGFP hBMP 4 mammalian plasmid ( EGFP: Enhanced Green Fluorescent Protein) was constructed by subcloning techniques. bMSCs obtained from rabbits were cultured and transfected with either pEGFP hBMP 4, pEGFP or left uninfected in vitro. Transfer efficiency was detected through the expression of EGFP. Transcription of the target gene was detected by RT PCR. Alkaline phosphatase (ALP) and Von Kossa tests were also conducted to explore the phenotypes of osteoblasts. The autologous bMSCs of the 3 groups were then combined with Natural Non organic Bone (NNB), a porous hydroxyapatite implant with a dimension of 6 mm x 6 mm x 3 mm, at a concentration of 5 x 10(7) cells/ml. They were subsequently implanted into 6 rabbits subcutaneously using NNB alone as a blank control (6 implants per group). Four weeks after surgery, the implants were evaluated with histological staining and computerized analysis of new bone formation.
   Results pEGFP hBMP 4 expression plasmid was constructed. Under optimal conditions, gene transfer efficiency reached more than 30%. Target gene transfer could strengthen the transcription of BMP 4, and increase the expression of ALP as well as the number of calcium nodules. In the ectopic animal model, NNB alone could not induce new bone formation. The new bone area formed in the bMSCs group was ( 17.2 +/  7.1) %, and pEGFP group was ( 14.7 +/  6.1) %, while pEGFP hBMP 4 group was (29.5 +/  8.2) %, which was the highest among the groups ( F = 7.295, P < 0.01).
   Conclusions The mammalian hBMP 4 expression plasmid was successfully constructed and a comparatively high transfer efficiency was achieved. The gene transfer technique enhanced the expression of BMP 4 and promoted differentiation from bMSCs to osteoblasts. These in vivo results suggested that transfection of bMSCs with hBMP 4 might be a suitable method to enhance their inherent osteogenic capacity for bone tissue engineering applications.
C1 Shanghai Med Univ 2, Peoples Hosp 9, Shanghai Key Lab Stomatol, Dept Oral & Maxillofacial Surg, Shanghai 200011, Peoples R China.
   Peking Univ, Life Sci Ctr, Beijing 100871, Peoples R China.
   Univ Alberta, Fac Med, Dept Biomed Engn, Edmonton, AB T6G 2M7, Canada.
C3 Shanghai Jiao Tong University; Peking University; University of Alberta
RP Shanghai Med Univ 2, Peoples Hosp 9, Shanghai Key Lab Stomatol, Dept Oral & Maxillofacial Surg, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM hosp9th@public3.sta.net.cn
RI Zhang, Xiaoling/J 1666 2016
CR Alden TD, 2002, SPINE, V27, pS87, DOI 10.1097/00007632 200208151 00016
   Bauer TW., 2000, CLIN ORTHOP RELAT R, V371, P10
   Chang SCN, 2003, GENE THER, V10, P2013, DOI 10.1038/sj.gt.3302106
   Gysin R, 2002, GENE THER, V9, P991, DOI 10.1038/sj.gt.3301772
   Hidaka C, 2003, SPINE, V28, P2049, DOI 10.1097/01.BRS.0000091661.11228.C3
   KANG R, 2000, CLIN ORTHOP RELAT R, V375, P324
   Krebsbach PH, 1998, TRANSPLANTATION, V66, P1272, DOI 10.1097/00007890 199811270 00002
   Li JZ, 2003, J GENE MED, V5, P748, DOI 10.1002/jgm.412
   Li JZ, 2003, GENE THER, V10, P1735, DOI 10.1038/sj.gt.3302075
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   MA G, 1996, CHIN J REPAR RECONST, V10, P35
   Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291
   Park J, 2003, GENE THER, V10, P1089, DOI 10.1038/sj.gt.3301960
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623 200100001 00001
   Scaduto AA, 1999, ORTHOP CLIN N AM, V30, P625, DOI 10.1016/S0030 5898(05)70115 2
   Tsuda H, 2003, MOL THER, V7, P354, DOI 10.1016/S1525 0016(02)00062 X
   VACANTI CA, 1999, CLIN ORTHOP S, V367, pS375
   Yaoita H, 2000, J BONE MINER METAB, V18, P63, DOI 10.1007/s007740050013
   Zhang XS, 2004, J GENE MED, V6, P4, DOI 10.1002/jgm.477
NR 22
TC 29
Z9 34
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366 6999
EI 2542 5641
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD FEB 20
PY 2005
VL 118
IS 4
BP 281
EP 288
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 904QA
UT WOS:000227511600003
PM 15740665
DA 2025 08 17
ER

PT J
AU Chen, Y
   Zhou, X
   Shi, XH
   Chen, X
   Xia, X
   Zhang, YM
   Fan, DL
AF Chen, Yao
   Zhou, Xin
   Shi, Xiaohua
   Chen, Xin
   Xia, Xin
   Zhang, Yiming
   Fan, Dongli
TI The Effects of Ion Implanted Silicone Rubber on the Differentiation of
   Rat Bone Marrow Mesenchymal Stem Cells
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Silicone Rubber; Ion Implantation; BMSC; Nanotopography; Differentiation
ID SURFACES; GROWTH; OSTEOBLASTS; SCAFFOLDS; EXPANSION; CULTURE; FATE
AB Recent studies have demonstrated that bone marrow mesenchymal stem cells (BMSCs) with extracellular matrix interactions can regulate stem cell signaling pathways and significantly affect the fate of stem cells and their function. Topographical surface modification of a biomaterial may be an efficient tool for inducing stem cell differentiation and may replace the use of biochemical stimuli. In this study, we used three types of ions implanted into the surface of silicone rubber (SR) to prepare carbon ion implanted silicone rubber, silver ion implanted silicone rubber and nitrogen ion implanted silicone rubber. After the materials were characterized, the effects of different ion implanted silicone rubbers on the differentiation of rBMSCs were investigated. The results indicated that ion implantation changed the nanotopography, which significantly increased the surface roughness and decreased the water contact angle of the SR. Furthermore, ion implantation significantly enhanced the expression of Runx2, which regulates osteogenic differentiation in rBMMSCs, especially on N SR. In conclusion, ion implantation affects the differentiation of stem cells and has the potential for application in stem cell bioprocessing or regenerative medicine.
C1 [Chen, Yao; Zhou, Xin; Shi, Xiaohua; Chen, Xin; Xia, Xin; Zhang, Yiming; Fan, Dongli] Third Mil Med Univ, Xinqiao Hosp, Dept Plast & Cosmet Surg, Chongqing 400037, Peoples R China.
C3 Army Medical University
RP Fan, DL (通讯作者)，Third Mil Med Univ, Xinqiao Hosp, Dept Plast & Cosmet Surg, Chongqing 400037, Peoples R China.
RI ; shi, Xiaohua/H 8366 2016
OI Zhou, Xin/0000 0002 9324 4308; 
FU Third Military Medical University [2012XZH05]; National Natural Science
   Foundation of China [81571918]
FX This work was funded by grants from the National Natural Science
   Foundation of China (grant numbers 81571918), a grant for Transformation
   of Scientific and Technological Achievements from the Third Military
   Medical University (grant numbers 2012XZH05). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albrektsson T, 2004, INT J PROSTHODONT, V17, P536
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Bjerre L, 2008, BIOMATERIALS, V29, P2616, DOI 10.1016/j.biomaterials.2008.03.003
   Boregowda SV, 2012, STEM CELLS, V30, P975, DOI 10.1002/stem.1069
   Chandler KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018540
   Culver JC, 2010, MICROCIRCULATION, V17, P164, DOI 10.1111/j.1549 8719.2010.00025.x
   Even Ram S, 2006, CELL, V126, P645, DOI 10.1016/j.cell.2006.08.008
   Fan VH, 2007, STEM CELLS, V25, P1241, DOI 10.1634/stemcells.2006 0320
   Ghanian MH, 2015, J BIOMED MATER RES A, V103, P3539, DOI 10.1002/jbm.a.35483
   Gugala Z, 2006, J BIOMED MATER RES A, V76A, P288, DOI 10.1002/jbm.a.30462
   Hou Y, 2016, J BIOMATER TISS ENG, V6, P473, DOI 10.1166/jbt.2016.1470
   Iwai R, 2013, BIOMATERIALS, V34, P9096, DOI 10.1016/j.biomaterials.2013.08.027
   Jiang JJ, 2013, ADV HEALTHC MATER, V2, P25, DOI 10.1002/adhm.201200169
   Mackova A, 2013, APPL SURF SCI, V275, P311, DOI 10.1016/j.apsusc.2012.12.071
   MacQueen L, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0179
   Midha S, 2016, BIOMATERIALS, V97, P133, DOI 10.1016/j.biomaterials.2016.04.020
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosa AL, 2014, J CELL BIOCHEM, V115, P540, DOI 10.1002/jcb.24688
   Variola F, 2009, SMALL, V5, P996, DOI 10.1002/smll.200801186
   Wang SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098320
   Wang YJ, 2016, J BIOMATER TISS ENG, V6, P563, DOI 10.1166/jbt.2016.1491
   Zhang D, 2013, BIOMATERIALS, V34, P3962, DOI 10.1016/j.biomaterials.2013.02.029
   Zhang GL, 2017, J BIOMATER TISS ENG, V7, P59, DOI 10.1166/jbt.2017.1534
   Zhao LZ, 2012, BIOMATERIALS, V33, P2629, DOI 10.1016/j.biomaterials.2011.12.024
NR 25
TC 1
Z9 1
U1 1
U2 8
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD NOV
PY 2017
VL 7
IS 11
BP 1184
EP 1189
DI 10.1166/jbt.2017.1682
PG 6
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FQ6CO
UT WOS:000418451400015
DA 2025 08 17
ER

PT J
AU Piccoli, GB
   Trabace, T
   Chatrenet, A
   de La Torre, CAC
   Gendrot, L
   Nielsen, L
   Fois, A
   Santagati, G
   Saulnier, P
   Panocchia, N
AF Piccoli, Giorgina Barbara
   Trabace, Tiziana
   Chatrenet, Antoine
   de La Torre, Carlos Alberto Carranza
   Gendrot, Lurlinys
   Nielsen, Louise
   Fois, Antioco
   Santagati, Giulia
   Saulnier, Patrick
   Panocchia, Nicola
TI New Intravenous Calcimimetic Agents: New Options, New Problems. An
   Example on How Clinical, Economical and Ethical Considerations Affect
   Choice of Treatment
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE principlist ethics; drug choice; hemodialysis; calcimimetic agents;
   non compliance; economic aspects of drug choice
ID CHRONIC KIDNEY DISEASE; SERUM PARATHYROID HORMONE; PATIENTS RECEIVING
   HEMODIALYSIS; ETELCALCETIDE ONO 5163/AMG 416; SECONDARY
   HYPERPARATHYROIDISM; BONE DISORDER; DIALYSIS PATIENTS; PRECISION
   MEDICINE; PAYMENT REFORM; UNITED STATES
AB Background. Dialysis treatment is improving, but several long term problems remain unsolved, including metabolic bone disease linked to chronic kidney disease (CKD MBD). The availability of new, efficacious but expensive drugs (intravenous calcimimetic agents) poses ethical problems, especially in the setting of budget limitations. Methods. Reasons of choice, side effects, biochemical trends were discussed in a cohort of 15 patients (13% of the dialysis population) who stared treatment with intravenous calcimimetics in a single center. All patients had previously been treated with oral calcimimetic agents; dialysis efficacy was at target in 14/15; hemodiafiltration was employed in 10/15. Median Charlson Comorbidity Index was 8. The indications were discussed according to the principlist ethics (beneficience, non maleficience, justice and autonomy). Biochemical results were analyzed to support the clinical ethical choices. Results. In the context of a strict clinical and biochemical surveillance, the lack of side effects ensured "non maleficence"; efficacy was at least similar to oral calcimimetic agents, but tolerance was better. Autonomy was respected through a shared decision making model; all patients appreciated the reduction of the drug burden, and most acknowledged better control of their biochemical data. The ethical conflict resides in the balance between the clinical "beneficience, non maleficience" advantage and "justice" (economic impact of treatment, potentially in attrition with other resources, since the drug is expensive and included in the dialysis bundle). The dilemma is more relevant when a patient's life expectancy is short (economic impact without clear clinical advantages), or when non compliance is an issue (unclear advantage if the whole treatment is not correctly taken). Conclusions. In a context of person centered medicine, autonomy, beneficence and non maleficence should weight more than economic justice. While ethical discussions are not aimed at finding "the right answer" but asking "the right questions", this example can raise awareness of the importance of including an ethical analysis in the choice of "economically relevant" drugs.
C1 [Piccoli, Giorgina Barbara] Univ Torino, Dept Clin & Biol Sci, I 10124 Turin, Italy.
   [Piccoli, Giorgina Barbara; Trabace, Tiziana; Chatrenet, Antoine; de La Torre, Carlos Alberto Carranza; Gendrot, Lurlinys; Nielsen, Louise; Fois, Antioco; Santagati, Giulia] Ctr Hosp Le Mans, Nephrol, F 72037 Le Mans, France.
   [Saulnier, Patrick] Univ Angers, Stat Lab, F 49035 Angers, France.
   [Panocchia, Nicola] Fdn Policlin Univ A Gemelli, IRCCS, Nephrol Dept, I 00168 Rome, Italy.
C3 University of Turin; Centre Hospitalier Le Mans; Universite d'Angers;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Piccoli, GB (通讯作者)，Univ Torino, Dept Clin & Biol Sci, I 10124 Turin, Italy.; Piccoli, GB (通讯作者)，Ctr Hosp Le Mans, Nephrol, F 72037 Le Mans, France.
EM gbpiccoli@yahoo.it; tizi.trb87@gmail.com; antoine.chatrenet@gmail.com;
   just752@hotmail.com; lgendrot@ch lemans.fr; lnielsen@ch lemans.fr;
   afois@ch lemans.fr; giulia.santagati@hotmail.it;
   patrick.saulnier@chu angers.fr; nicola.panocchia@policlinicogemelli.it
RI SAULNIER, Patrick/K 4271 2015; Chatrenet, Antoine/ABG 2386 2021;
   Panocchia, Nicola/AAW 2192 2020
OI Chatrenet, Antoine/0000 0002 4853 180X; piccoli,
   giorgina/0000 0002 2632 4009; Panocchia, Nicola/0000 0003 0381 765X;
   Saulnier, Patrick/0000 0002 6408 3533; 
FU Centre Hospitalier Le Mans
FX Funding none. The Centre Hospitalier Le Mans supports language
   correction and publication fees.
CR Altay H, 2019, ENDOCR METAB IMMUNE, V19, P1134, DOI 10.2174/1871530319666190215150410
   [Anonymous], 1995, Lancet, V345, P1125
   [Anonymous], 2017, Sci. Rep., V7, P1
   Avram MM, 2001, AM J KIDNEY DIS, V38, P1351, DOI 10.1053/ajkd.2001.29254
   Baker Danial E, 2017, Hosp Pharm, V52, P669, DOI 10.1177/0018578717733478
   Bellasi A, 2020, J NEPHROL, V33, P211, DOI 10.1007/s40620 019 00677 0
   Blair HA, 2016, DRUGS, V76, P1787, DOI 10.1007/s40265 016 0671 3
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P2132, DOI 10.1001/jama.2017.4746
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Butler CR, 2016, CLIN J AM SOC NEPHRO, V11, P704, DOI 10.2215/CJN.04780515
   Çermik TF, 2007, NEURORADIOLOGY, V49, P379, DOI 10.1007/s00234 006 0198 5
   Chen P, 2016, CPT PHARMACOMET SYST, V5, P484, DOI 10.1002/psp4.12106
   Chen P, 2018, CLIN PHARMACOKINET, V57, P71, DOI 10.1007/s40262 017 0550 4
   Chou FF, 2008, SURGERY, V143, P526, DOI 10.1016/j.surg.2007.11.019
   Conly S, 2016, THEOR MED BIOETH, V37, P307, DOI 10.1007/s11017 016 9374 8
   Cozzolino M, 2017, THER CLIN RISK MANAG, V13, P679, DOI 10.2147/TCRM.S108490
   Cozzolino M, 2014, NEPHROL DIAL TRANSPL, V29, P1815, DOI 10.1093/ndt/gft514
   Cupisti A, 2018, J NEPHROL, V31, P457, DOI 10.1007/s40620 018 0497 z
   Dobbels F, 2012, PEDIATR TRANSPLANT, V16, P4, DOI 10.1111/j.1399 3046.2011.01633.x
   Dunn TB, 2009, AM J TRANSPLANT, V9, P1337, DOI 10.1111/j.1600 6143.2009.02625.x
   Edson KZ, 2016, KIDNEY INT REP, V1, P24, DOI 10.1016/j.ekir.2016.04.002
   Eidman KE, 2018, SEMIN DIALYSIS, V31, P440, DOI 10.1111/sdi.12734
   Eidman KE, 2018, INT J NEPHROL RENOV, V11, P69, DOI 10.2147/IJNRD.S128252
   Etelcalcetide for Treating Secondary, 2017, TA448 NAT I HLTH CAR
   Friedl C, 2018, DRUG DES DEV THER, V12, P1589, DOI 10.2147/DDDT.S134103
   Fukagawa M, 2017, NEPHROL DIAL TRANSPL, V32, P1723, DOI 10.1093/ndt/gfw408
   Fuller DS, 2019, CLIN J AM SOC NEPHRO, V14, P241, DOI 10.2215/CJN.09550818
   GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184
   GOLDSTEIN DA, 1978, J CLIN INVEST, V62, P88, DOI 10.1172/JCI109118
   Grubbs V, 2014, CLIN J AM SOC NEPHRO, V9, P2203, DOI 10.2215/CJN.00650114
   Hai MTT, 2017, JAMA J AM MED ASSOC, V317, P2132, DOI 10.1001/jama.2017.4743
   Hall YN, 2017, CLIN J AM SOC NEPHRO, V12, P346, DOI 10.2215/CJN.09310916
   Hamano N, 2017, EXPERT OPIN PHARMACO, V18, P529, DOI 10.1080/14656566.2017.1303482
   Harada K, 2019, EUR J PHARMACOL, V842, P139, DOI 10.1016/j.ejphar.2018.10.021
   Harada Kazutsune, 2017, Folia Pharmacologica Japonica, V150, P98, DOI 10.1254/fpj.150.98
   Harris SAC, 1998, NEPHROL DIAL TRANSPL, V13, P1226, DOI 10.1093/ndt/13.5.1226
   Heaf J, 2012, CLIN KIDNEY J, V5, P168, DOI 10.1093/ckj/sfs011
   Hofmann B, 2010, AM J BIOETHICS, V10, P3, DOI 10.1080/15265161.2010.528509
   Huesch MD, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472 6939 13 11
   Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019
   Jovanovich A, 2018, SEMIN NEPHROL, V38, P397, DOI 10.1016/j.semnephrol.2018.05.009
   Karaboyas A, 2015, CLIN J AM SOC NEPHRO, V10, P1814, DOI 10.2215/CJN.02600315
   Ketteler M, 2018, ANN INTERN MED, V168, P422, DOI 10.7326/M17 2640
   Kimata Naoki, 2007, Hemodial Int, V11, P340, DOI 10.1111/j.1542 4758.2007.00190.x
   Komaba H, 2018, THER APHER DIAL, V22, P246, DOI 10.1111/1744 9987.12683
   Li XD, 2017, BONE, V105, P163, DOI 10.1016/j.bone.2017.08.026
   Lin E, 2019, AM J KIDNEY DIS, V73, P385, DOI 10.1053/j.ajkd.2018.11.007
   Lourida I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127574
   Lunyera J, 2018, SEMIN NEPHROL, V38, P542, DOI 10.1016/j.semnephrol.2018.08.001
   MASSRY SG, 1985, KIDNEY INT, pS5
   McCarthy J, 2003, Med Humanit, V29, P65, DOI 10.1136/mh.29.2.65
   Mima A, 2018, J INT MED RES, V46, P4578, DOI 10.1177/0300060518786913
   Morrow Thomas, 2017, Manag Care, V26, P33
   Nemeth EF, 2018, PROGR MED CHEM, V57, P1, DOI 10.1016/bs.pmch.2017.12.001
   Otsubo S, 2007, THER APHER DIAL, V11, P274, DOI 10.1111/j.1744 9987.2007.00490.x
   Otsubo S, 2009, NEPHROL DIAL TRANSPL, V24, P1593, DOI 10.1093/ndt/gfn706
   Papageorgiou SG, 2008, CLIN NEUROL NEUROSUR, V110, P1038, DOI 10.1016/j.clineuro.2008.06.004
   Paris JJ, 2011, AM J BIOETHICS, V11, P16, DOI 10.1080/15265161.2011.581736
   Park JH, 2013, INT UROL NEPHROL, V45, P587, DOI 10.1007/s11255 011 0111 y
   Patel Jena, 2018, P T, V43, P396
   Pereira L, 2018, CLIN KIDNEY J, V11, P80, DOI 10.1093/ckj/sfx125
   Piccoli GB, 2002, NEPHROL DIAL TRANSPL, V17, P1440, DOI 10.1093/ndt/17.8.1440
   Piccoli GB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020276
   Piccoli GB, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100331
   Piccoli GB, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882 018 0948 8
   RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304
   Reiss AB, 2018, ATHEROSCLEROSIS, V278, P49, DOI 10.1016/j.atherosclerosis.2018.08.046
   Rose M, 2018, PHARMACOECONOMICS, V36, P1299, DOI 10.1007/s40273 018 0661 2
   Saab G, 2014, SEMIN DIALYSIS, V27, P562, DOI 10.1111/sdi.12275
   Shigematsu T, 2018, CLIN THER, V40, P2099, DOI 10.1016/j.clinthera.2018.10.016
   Shigematsu T, 2018, CLIN EXP NEPHROL, V22, P426, DOI 10.1007/s10157 017 1442 5
   Societe Francophone de Nephrologie Dialyse et Transplantation (SFNDT), 2016, REP CHRON DIAL FRANC
   Sofronie AC, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882 018 0900 y
   Spoendlin J, 2018, AM J KIDNEY DIS, V72, P178, DOI 10.1053/j.ajkd.2018.03.027
   Stollenwerk B, 2017, J MED ECON, V20, P1110, DOI 10.1080/13696998.2017.1360309
   Stollenwerk B, 2018, PHARMACOECONOMICS, V36, P603, DOI 10.1007/s40273 017 0605 2
   Subramanian R, 2017, CLIN PHARMACOKINET, V56, P179, DOI 10.1007/s40262 016 0433 0
   Swaminathan S, 2015, HEALTH SERV RES, V50, P790, DOI 10.1111/1475 6773.12252
   Tanaka M, 2018, THER APHER DIAL, V22, P242, DOI 10.1111/1744 9987.12685
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213
   Torres PAU, 2017, DRUG TODAY, V53, P489, DOI 10.1358/dot.2017.53.9.2711938
   Turenne M, 2018, HEALTH SERV RES, V53, P1430, DOI 10.1111/1475 6773.12713
   UBEL PA, 1993, JAMA J AM MED ASSOC, V270, P2469, DOI 10.1001/jama.270.20.2469
   Ochoa PV, 2018, NEFROLOGIA, V38, P677, DOI 10.1016/j.nefro.2018.02.003
   Wu B, 2018, J CLIN PHARMACOL, V58, P717, DOI 10.1002/jcph.1090
   Xipell M, 2019, BLOOD PURIFICAT, V48, P106, DOI 10.1159/000496562
   Yamamoto S, 2008, CLIN NEPHROL, V70, P496
   Yamamoto S, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882 018 1056 5
   Ye JZ, 2018, DRUG DES DEV THER, V12, P901, DOI 10.2147/DDDT.S160223
   Yokoyama K, 2017, KIDNEY INT REP, V2, P634, DOI 10.1016/j.ekir.2017.01.016
   Yokoyama K, 2017, CLIN NEPHROL, V88, P68, DOI 10.5414/CN108974
   Yoshimura K, 2018, THER APHER DIAL, V22, P553, DOI 10.1111/1744 9987.12701
   Yu LC, 2017, CALCIFIED TISSUE INT, V101, P641, DOI 10.1007/s00223 017 0319 7
   Zhang Y, 2018, CLIN CHIM ACTA, V482, P40, DOI 10.1016/j.cca.2018.03.028
NR 96
TC 2
Z9 2
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD FEB
PY 2020
VL 17
IS 4
AR 1238
DI 10.3390/ijerph17041238
PG 21
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA KY2GF
UT WOS:000522388500114
PM 32075103
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Martín Merino, E
   Huerta Alvarez, C
   Prieto Alhambra, D
   Montero Corominas, D
AF Martin Merino, Elisa
   Huerta Alvarez, Consuelo
   Prieto Alhambra, Daniel
   Montero Corominas, Dolores
TI Cessation rate of anti osteoporosis treatments and risk factors in
   Spanish primary care settings: a population based cohort analysis
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Anti osteoporosis medication; Cessation; Risk factors; Primary care
ID POSTMENOPAUSAL OSTEOPOROSIS; STRONTIUM RANELATE; VERTEBRAL FRACTURE;
   WOMEN; RISEDRONATE; PERSISTENCE; ALENDRONATE; THERAPY; RALOXIFENE;
   REDUCTION
AB Among 95,057 patients >= 50 years with new antiosteoporosis medications (AOM) (2001 2013) in primary care, 1 year cessation was 51% (28% 68%), higher in men, smokers, patients with missing lifestyle data, and out normal BMI, and lower in those aged 60 79, with recent fractures or other anti osteoporotics, suggesting non severe osteoporosis and less risk awareness.
   Purpose Low compliance to anti osteoporosis medications (AOM) has been previously reported. We aimed to estimate 1 year cessation rates of different AOMs as used in Spanish healthcare settings, and to identify associated risk factors.
   Methods A cohort study was performed using primary care records data (BIFAP). Patients entered the cohort when aged 50 years in 2001 2013, with >= 1 year of data available, and identified as incident users of AOM (1 year washout). Participants were divided into six cohorts: alendronate, other oral bisphosphonates, selective oestrogen receptor modulators, strontium ranelate, teriparatide, and denosumab. Patients were followed from therapy initiation to the earliest of cessation (90 day refill gap), switching (to alternative AOM), loss to follow up, death, or end of 2013. One year therapy cessation was estimated using life tables. Hazard ratios (of cessation) according to age, sex, lifestyle factors, morbidity, and co medication were estimated after stepwise backwards selection.
   Results A total of 95,057 AOM users were identified (91% women; mean age 68). One year cessation was 51% overall, highest for strontium ranelate (68%), and lowest for denosumab (28%). Cessation probability was higher in men (14% to 2.1 fold), smokers (> 6%), and patients with missing BMI (19 28%) or smoking (6 20%) data, and overweight/obese/underweight (7% to 2.6 fold increase compared to normal weight). Patients aged 60 79 years, with a recent fracture or other drugs used for osteoporosis, had better persistence.
   Conclusions Over half of the patients initiating AOM stopped therapy within the first year after initiation. The described risk factors for cessation could be proxies for non severe osteoporosis, and/or disease/risk awareness, which could inform the targeting of high risk patients for monitoring and/or interventions aimed at improving persistence.
C1 [Martin Merino, Elisa; Huerta Alvarez, Consuelo; Montero Corominas, Dolores] Spanish Agcy Med & Med Devices AEMPS, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain.
   [Prieto Alhambra, Daniel] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.
   [Prieto Alhambra, Daniel] Univ Autonoma Barcelona, GREMPAL Res Grp, IDIAP Jordi Gol Primary Care Res Inst, Barcelona, Spain.
   [Prieto Alhambra, Daniel] Univ Autonoma Barcelona, CIBERFES, Barcelona, Spain.
   [Prieto Alhambra, Daniel] Univ Autonoma Barcelona, Inst Salud Carlos III, Barcelona, Spain.
C3 University of Oxford; Autonomous University of Barcelona; CIBER   Centro
   de Investigacion Biomedica en Red; CIBERFES; Autonomous University of
   Barcelona; Instituto de Salud Carlos III; Autonomous University of
   Barcelona
RP Martín Merino, E (通讯作者)，Spanish Agcy Med & Med Devices AEMPS, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain.
EM emartin_fcsai@bifap.aemps.es
RI Martin Merino, Elisa/AFE 6696 2022; Huerta, Consuelo/KLD 9670 2024
OI Martin Merino, Elisa/0000 0002 3576 8605; Huerta,
   Consuelo/0000 0003 4012 7826; Prieto Alhambra,
   Daniel/0000 0002 3950 6346; 
CR Agencia Espanola de Medicamentos y Productos Sanitarios, 2007, RAN ESTR PSS PROT RI
   Agencia Espanola de Medicamentos y Productos Sanitarios, RAN ESTR OSS PROT RE
   Agencia Espanola de Medicamentos y Productos Sanitarios, 2014, DEN PROL XGEV RIESG
   Agencia Espanola de Medicamentos y Productos Sanitarios, 2009, REC PREV OST MAX AS
   Agencia Espanola de Medicamentos y Productos Sanitarios, RAN ESTR OSS PROT CA
   Agencia Espanola de Medicamentos y Productos Sanitarios, 2005, BISF ADM PAR OST MAX
   Agencia Espanola de Medicamentos y Productos Sanitarios   La AEMPS Informa   Notas informativas   Medicamentos de Uso Humano, 2012, NUEV CONTR US
   Aizpurua I, 2015, CONSENSO OSTEOPOROSI
   Amaya MC, SEMERGEN MED FAM, P121
   [Anonymous], 2008, Knowl. Inf. Systeme., DOI DOI 10.1002/14651858.CD001155.PUB2
   BIFAP, 2015, BAS DAT INV FARM AT
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Blanch J, 2016, REV OSTEOPOR METAB M, V8, P15, DOI 10.4321/S1889 836X2016000100003
   Boonen S, 2009, J BONE MINER RES, V24, P719, DOI [10.1359/jbmr.081214, 10.1359/JBMR.081214]
   Cantudo Cuenca MR, 2016, ATEN PRIM, V48, P49, DOI 10.1016/j.aprim.2015.01.012
   Carbonell AC, 2011, REV OSTEOPOR METAB M, V3, P73
   Carbonell Abella C, 2015, CALCIF TISSUE INT, V23
   de Felipe R, 2010, ATEN PRIM, V42, P559, DOI 10.1016/j.aprim.2009.10.022
   Salgueiro ME, 2013, MATURITAS, V74, P74, DOI 10.1016/j.maturitas.2012.10.002
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   European Medicines Agency, 2013, EMAPRAC1366562013
   Gardarsdottir H, 2010, J CLIN EPIDEMIOL, V63, P422, DOI 10.1016/j.jclinepi.2009.07.001
   Gifre L, 2015, REV OSTEOPOROS METAB
   Harrington JT, 2004, CALCIFIED TISSUE INT, V74, P129, DOI 10.1007/s00223 003 0042 4
   Imaz I, 2010, OSTEOPOROSIS INT, V21, P1943, DOI 10.1007/s00198 009 1134 4
   Imaz I, 2010, ANALISIS COSTE UTILI
   Kearney DM, 2006, ANN ALLERG ASTHMA IM, V96, P769, DOI 10.1016/S1081 1206(10)61338 5
   Klop C, 2015, OSTEOPOROSIS INT, V26, P1831, DOI 10.1007/s00198 015 3084 3
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Penning van Beest FJA, 2006, CLIN THER, V28, P236, DOI 10.1016/j.clinthera.2006.01.002
   Reyes C, 2016, CALCIF TISSUE INT
   Roerholt C, 2009, OSTEOPOROSIS INT, V20, P299, DOI 10.1007/s00198 008 0651 x
   Roux C, 2004, CURR MED RES OPIN, V20, P433, DOI 10.1185/030079903125003125
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Tosteson ANA, 2003, AM J MED, V115, P209, DOI 10.1016/S0002 9343(03)00362 0
   Turbi C, 2004, CLIN THER, V26, P245, DOI 10.1016/S0149 2918(04)90023 9
   Molinero AV, 2011, ATEN PRIM, V43, P95, DOI 10.1016/j.aprim.2010.04.008
   White HJ, 2010, FAM PRACT, V27, P593, DOI 10.1093/fampra/cmq060
   *WORLD ORG NAT COL, 1998, INT CLASS PRIM CAR
NR 43
TC 13
Z9 14
U1 0
U2 90
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD DEC
PY 2017
VL 12
IS 1
AR 39
DI 10.1007/s11657 017 0331 6
PG 12
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA ER8LI
UT WOS:000399070600007
PM 28401495
DA 2025 08 17
ER

PT J
AU Hu, HM
   Mao, MH
   Hu, YH
   Zhou, XC
   Li, S
   Chen, CF
   Li, CN
   Yuan, QL
   Li, W
AF Hu, Hong Mei
   Mao, Mu Hua
   Hu, Yu Hui
   Zhou, Xing Chen
   Li, Sheng
   Chen, Cai Fen
   Li, Chun Nan
   Yuan, Qiong Lan
   Li, Wei
TI Artemisinin protects DPSC from hypoxia and TNF α mediated osteogenesis
   impairments through CA9 and Wnt signaling pathway
SO LIFE SCIENCES
LA English
DT Article
DE Dental pulp stem cells (DPSCs); Osteogenic differentiation; Hypoxia;
   Inflammation; Artemisinin; Carbonic anhydrase 9 (CA9); Wnt/beta catenin
   signaling
ID HUMAN DENTAL PULP; NF KAPPA B; MESENCHYMAL STEM CELLS; DIFFERENTIATION
   CAPACITY; IN VITRO; CHEMORESISTANCE; ACTIVATION
AB Dental pulp stem cells (DPSCs) possess the ability of multi lineage differentiation, and are excellent sources of tissue engineering and regenerative medicine. Oxygen concentration and inflammation are two critical environmental factors that affect the osteogenic differentiation of DPSCs. We aimed to study the role of the antimalarial drug artemisinin on the osteogenic differentiation of human DPSCs under the hypoxia and inflammation conditions. We demonstrated that hypoxia (5% O2) and inflammation (20 ng/mL TNF alpha), alone or in combination, significantly diminished in vitro cell survival and increased apoptotic rates. Notably, hypoxia and TNF alpha exerted accumulative effect in suppressing the osteogenic differentiation of DPSCs, as evidenced by reduced expression levels of osteogenesis associated genes including ALP, RUNX2 and OCN in osteogenic condition, as well as reduced mineral nodules formation as indicated by alizarin red staining. Artemisinin at the dose of 40 mu M markedly reversed the suppression in cell survival caused by hypoxia or inflammation, and reduced apoptotic rates and the expressions of pro apoptotic proteins. Additionally, artemisinin restored osteogenic differentiation of DPSCs under the hypoxia or/and inflammation conditions. Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9 mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis. Furthermore, while hypoxia or/and inflammation significantly inactivated the Wnt/beta catenin signaling in DPSCs, additional exposure to artemisinin reactivated this pathway to promote osteogenic differentiation of DPSCs. Our results provide novel insight on the link between artemisinin and DPSC osteogenesis, and suggest promising artemisinin based strategies for better dentin/pulp tissue engineering.
C1 [Hu, Hong Mei; Yuan, Qiong Lan] TongJi Univ, Sch Med, Shanghai 200092, Peoples R China.
   [Hu, Hong Mei; Mao, Mu Hua; Hu, Yu Hui; Zhou, Xing Chen; Li, Sheng; Chen, Cai Fen; Li, Chun Nan; Li, Wei] JingGangShan Univ, Sch Med, Jian 343000, Jiangxi, Peoples R China.
C3 Tongji University; Jinggangshan University
RP Yuan, QL (通讯作者)，TongJi Univ, Sch Med, Shanghai 200092, Peoples R China.; Li, W (通讯作者)，JingGangShan Univ, Sch Med, Jian 343000, Jiangxi, Peoples R China.
EM 416865286@qq.com; liweihuhongmei1218@126.com
RI zhou, xingchen/IAO 5544 2023
FU National Natural Science Foundation of China [81660188]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81660188).
CR Ahmed NEB, 2016, SCI REP UK, V6, DOI 10.1038/srep35476
   Alraies A, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860 017 0128 x
   Aranha AMF, 2010, J ENDODONT, V36, P1633, DOI 10.1016/j.joen.2010.05.013
   Bryniarska N, 2019, ACTA BIOCHIM POL, V66, P491, DOI 10.18388/abp.2019_2893
   Costa AD, 2008, J CRANIOFAC SURG, V19, P204, DOI 10.1097/scs.0b013e31815c8a54
   Crespo Ortiz MP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/247597
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Efferth T, 2007, PLANTA MED, V73, P299, DOI 10.1055/s 2007 967138
   Estrela Carlos, 2011, Braz. Dent. J., V22, P91
   Fehrer C, 2007, AGING CELL, V6, P745, DOI 10.1111/j.1474 9726.2007.00336.x
   Feng GJ, 2015, DEV GROWTH DIFFER, V57, P497, DOI 10.1111/dgd.12233
   Feng XM, 2013, CELL BIOL INT, V37, P1267, DOI 10.1002/cbin.10141
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Goto N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8035759
   Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hahn CL, 2007, J ENDODONT, V33, P643, DOI 10.1016/j.joen.2007.01.001
   He XY, 2017, SCI REP UK, V7, DOI 10.1038/srep40681
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Hou LF, 2016, PHARMACOL THERAPEUT, V166, P123, DOI 10.1016/j.pharmthera.2016.07.002
   Huang XJ, 2007, J PHARM PHARMACOL, V59, P849, DOI 10.1211/jpp.59.6.0011
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jian J, 2018, AM J TRANSL RES, V10, P936
   Jiang WK, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/8907570
   Kim WS, 2015, KOREAN J PHYSIOL PHA, V19, P21, DOI 10.4196/kjpp.2015.19.1.21
   Kockar F, 2012, WORLD J CLIN ONCOL, V3, P82, DOI 10.5306/wjco.v3.i6.82
   Konkimalla VB, 2008, NITRIC OXIDE BIOL CH, V19, P184, DOI 10.1016/j.niox.2008.04.008
   Kwon SY, 2017, TISSUE ENG REGEN MED, V14, P595, DOI 10.1007/s13770 017 0068 8
   Li P, 2017, SCI REP UK, V7, P1
   Li Z, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101297
   Lian M., 2018, CELL REPROGRAM, V20
   Liu HT, 2004, J IMMUNOL, V172, P1907, DOI 10.4049/jimmunol.172.3.1907
   Ma T, 2009, BIOTECHNOL PROGR, V25, P32, DOI 10.1002/btpr.128
   Mohyeldin A., 2008, J CRANIOFAC SURG, V19, P204
   Monti DM, 2017, J ENZYM INHIB MED CH, V32, P5, DOI 10.1080/14756366.2016.1225046
   Mortada I, 2018, CYTOTECHNOLOGY, V70, P1479, DOI 10.1007/s10616 018 0225 5
   Mortada I, 2018, ADV EXP MED BIOL, V1083, P63, DOI 10.1007/5584_2017_71
   Ni LC, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3456719
   Osathanon T, 2011, J CELL BIOCHEM, V112, P1807, DOI 10.1002/jcb.23097
   Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229
   Senzui S., 2010, ORAL MED PATHOL, V14, P107, DOI 10.3353/omp.14.107
   Shi S, 2001, BONE, V29, P532, DOI 10.1016/S8756 3282(01)00612 3
   Tabatabaei FS, 2017, CELL TISSUE BANK, V18, P239, DOI 10.1007/s10561 017 9620 y
   Tsutsui TW, 2020, STEM CELLS CLONING, V13, P33, DOI 10.2147/SCCAA.S166759
   Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036
   Wang Y, 2014, ORAL DIS, V20, P650, DOI 10.1111/odi.12183
   Yamada Y, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01683 x
   Yoshida S, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9070160
   Yu CY, 2002, ARCH ORAL BIOL, V47, P529, DOI 10.1016/S0003 9969(02)00036 5
   Zhang FG, 2016, GENES DIS, V3, P263, DOI 10.1016/j.gendis.2016.09.004
   Zhang YQ, 2018, NAT PRODUCT BIOPROSP, V8, P303, DOI 10.1007/s13659 018 0162 1
   Zheng GP, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0357 6
   Zheng L, 2018, CURR CANCER DRUG TAR, V18, P988, DOI 10.2174/1568009618666180425142653
   Zhong Gang, 2018, Cell Physiol Biochem, V51, P2575, DOI 10.1159/000495926
NR 55
TC 21
Z9 23
U1 0
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JUL 15
PY 2021
VL 277
AR 119471
DI 10.1016/j.lfs.2021.119471
EA APR 2021
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA SU8UT
UT WOS:000663407500005
PM 33811898
DA 2025 08 17
ER

PT J
AU Kubo, T
   Shimose, S
   Matsuo, T
   Sakai, A
   Ochi, M
AF Kubo, Tadahiko
   Shimose, Shoji
   Matsuo, Toshihiro
   Sakai, Akira
   Ochi, Mitsuo
TI Efficacy of a nitrogen containing bisphosphonate, minodronate, in
   conjunction with a p38 mitogen activated protein kinase inhibitor or
   doxorubicin against malignant bone tumor cells
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE bisphosphonates; osteosarcoma; Ewing's sarcoma; doxorubicin; p38 mitogen
   activated protein kinase
ID CANCER CELLS; ZOLEDRONIC ACID; BREAST CANCER; CYCLE ARREST; GROWTH;
   PHARMACOKINETICS; ADRIAMYCIN; PATHWAY; PROLIFERATION; METASTASES
AB Purpose We recently reported the sarcoma selective antitumor effects of a newly developed nitrogen containing bisphosphonate, minodronate (MIN), on malignant bone tumors. The aim of this study was to develop efficient combination MIN therapy in malignant bone tumors.
   Methods We examined downstream molecular events of MIN in osteosarcoma and Ewing's sarcoma cells to search for a partner to combine with MIN. Furthermore, we evaluated the combined effects of MIN and clinically available Doxorubicin (DOX).
   Results We found that MIN inhibited Rap 1A prenylation, and extracellular signal regulated kinase (ERK) or Akt phosphorylation in osteosarcoma (Saos 2) and Ewing's sarcoma (SK ES 1) cells. Interestingly, MIN activated p38 mitogen activated protein kinase (MAPK) only in SK ES 1 cells and a p38 MAPK inhibitor augmented MIN induced growth inhibition in SK ES 1 cells. Doxorubicin (DOX) exerted synergistic effects on Saos 2 and SK ES 1 cell lines. Daily injection of MIN enhanced the growth inhibition of SK ES 1 xenograft sarcoma treated by DOX in nude mice.
   Conclusions These findings suggest that the inhibition of the p38 MAPK pathway may be attractive in overcoming cellular resistance against MIN. In the light of clinical settings, MIN may have a beneficial adjuvant role in the DOX treatment.
C1 [Kubo, Tadahiko; Shimose, Shoji; Matsuo, Toshihiro; Ochi, Mitsuo] Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthopaed Surg, Minami Ku, Hiroshima 7348551, Japan.
   [Sakai, Akira] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Minami Ku, Hiroshima 7348551, Japan.
C3 Hiroshima University; Hiroshima University
RP Kubo, T (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthopaed Surg, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348551, Japan.
EM kubot@hiroshima u.ac.jp
RI Sakai, Akira/B 3186 2008
OI Shimose, Shoji/0009 0002 6048 8805
CR Barancík M, 2001, EUR J PHARM SCI, V14, P29, DOI 10.1016/S0928 0987(01)00139 7
   BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Boissier S, 2000, CANCER RES, V60, P2949
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Dominguez C, 2005, CURR OPIN DRUG DISC, V8, P421
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   GREENE RF, 1983, CANCER RES, V43, P3417
   Héron Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Kubo T, 2006, J ORTHOP RES, V24, P1138, DOI 10.1002/jor.20177
   Lee MV, 2001, CANCER RES, V61, P2602
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Mizutani Y, 1999, CLIN CANCER RES, V5, P2605
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877
   ROBERT J, 1982, EUR J CANCER CLIN ON, V18, P739, DOI 10.1016/0277 5379(82)90072 4
   Rodriguez Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200
   Ural AU, 2005, BIOCHEM BIOPH RES CO, V336, P373, DOI 10.1016/j.bbrc.2005.07.120
   Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543 4552.2000
NR 23
TC 22
Z9 25
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0344 5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD JUN
PY 2008
VL 62
IS 1
BP 111
EP 116
DI 10.1007/s00280 007 0580 y
PG 6
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 287ZP
UT WOS:000254956300012
PM 17874104
DA 2025 08 17
ER

PT J
AU Bosman, MCJ
   Reis, CR
   Schuringa, JJ
   Vellenga, E
   Quax, WJ
AF Bosman, Matthieu C. J.
   Reis, Carlos R.
   Schuringa, Jan J.
   Vellenga, Edo
   Quax, Wim J.
TI Decreased Affinity of Recombinant Human Tumor Necrosis Factor related
   Apoptosis inducing Ligand (rhTRAIL) D269H/E195R to Osteoprotegerin (OPG)
   Overcomes TRAIL Resistance Mediated by the Bone Microenvironment
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MULTIPLE MYELOMA; DECOY RECEPTOR; DRUG RESISTANCE; DEATH RECEPTORS;
   STEM CELLS; CANCER; VARIANTS; DR5; APO2L/TRAIL; DISEASE
AB The bone marrow microenvironment provides important signals for the survival and proliferation of hematopoietic and malignant cells. In multiple myeloma, plasma cells are surrounded by stromal cells including osteoblasts. These stromal cells protect multiple myeloma cells from apoptosis induced by chemotherapeutic agents. Osteoprotegerin (OPG), a soluble receptor of the cytokine TNF related apoptosis inducing ligand (TRAIL), is secreted by osteoblasts and has been implicated in the prevention of cell death induced by TRAIL in malignant cells. Previously, we have designed death receptor specific TRAIL variants that induce apoptosis exclusively via one of its death receptors. Here, we have studied in detail the interaction between recombinant human (rhTRAIL) variants and OPG. We show that a DR5 specific variant (rhTRAIL D269H/E195R) displays a significantly decreased affinity to OPG. Furthermore, this rhTRAIL variant shows a much higher activity when compared with rhTRAIL WT and retains its effectiveness in inducing cell death in multiple myeloma cell lines, in the presence of OPG secreted by stromal cells. We also demonstrate that stromal cells are largely insensitive to high concentrations of this rhTRAIL variant. In conclusion, rhTRAIL D269H/E195R is a potential therapy for multiple myeloma due to its high effectiveness and diminished binding to OPG.
C1 [Bosman, Matthieu C. J.; Reis, Carlos R.; Quax, Wim J.] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmaceut Biol, NL 9713 AV Groningen, Netherlands.
   [Bosman, Matthieu C. J.; Schuringa, Jan J.; Vellenga, Edo] Univ Groningen, Univ Med Ctr Groningen, Dept Expt Hematol, NL 9700 RB Groningen, Netherlands.
C3 University of Groningen; University of Groningen
RP Quax, WJ (通讯作者)，Antonius Deusinglaan 1, NL 9713 AV Groningen, Netherlands.
EM w.j.quax@rug.nl
RI Quax, Wim/K 2802 2012; Reis, Carlos/KDO 7919 2024; Quax, Wim/O 2875 2019
OI Quax, Wim/0000 0002 5162 9947; 
FU University of Groningen; Technology Foundation STW; EFRO Drug Targeting
   Project; SNN; TI Pharma Project [T3 112]; Top Institute Pharma; 
   [STW 11056]
FX Supported by an Ubbo Emmius grant from the University of
   Groningen.Supported by Grant STW 11056 funded by the Technology
   Foundation STW, the EFRO Drug Targeting Project funded by SNN, and TI
   Pharma Project T3 112 funded by the Top Institute Pharma. Present
   address: Dept. of Cell Biology, UT Southwestern Medical Center, Dallas,
   TX 75390 9039.
CR Donnenberg VS, 2005, J CLIN PHARMACOL, V45, P872, DOI 10.1177/0091270005276905
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Gasparian ME, 2009, APOPTOSIS, V14, P778, DOI 10.1007/s10495 009 0349 3
   Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501
   Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221
   Holen I, 2006, CLIN SCI, V110, P279, DOI 10.1042/CS20050175
   Huff CA, 2008, J CLIN ONCOL, V26, P2895, DOI 10.1200/JCO.2007.15.8428
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251
   Locklin RM, 2007, LEUKEMIA, V21, P805, DOI 10.1038/sj.leu.2404518
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Matsui W, 2011, NATURE, V480, pS58, DOI 10.1038/480S58a
   Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Picarda G, 2012, AM J CANCER RES, V2, P45
   Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61
   Reis CR, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002808
   Reis CR, 2009, BIOCHEMISTRY US, V48, P2180, DOI 10.1021/bi801927x
   Shipman CM, 2003, CANCER RES, V63, P912
   Silvestris F, 2003, BRIT J HAEMATOL, V122, P39, DOI 10.1046/j.1365 2141.2003.04374.x
   Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199
   Tur V, 2008, J BIOL CHEM, V283, P20560, DOI 10.1074/jbc.M800457200
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103
   Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200
   Vitovski S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035830
   Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001
   Yones RJ, 2008, BIOL BLOOD MARROW TR, V14, P12, DOI 10.1016/j.bbmt.2007.10.012
   Zinonos I, 2011, J BONE MINER RES, V26, P630, DOI 10.1002/jbmr.244
NR 30
TC 15
Z9 17
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 10
PY 2014
VL 289
IS 2
BP 1071
EP 1078
DI 10.1074/jbc.M113.491589
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 301OH
UT WOS:000330541200039
PM 24280212
OA Green Published
DA 2025 08 17
ER

PT J
AU Dinescu, S
   Ionita, M
   Ignat, SR
   Costache, M
   Hermenean, A
AF Dinescu, Sorina
   Ionita, Mariana
   Ignat, Simona Rebeca
   Costache, Marieta
   Hermenean, Anca
TI Graphene Oxide Enhances Chitosan Based 3D Scaffold Properties for Bone
   Tissue Engineering
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE graphene oxide; biocompatibility; bone tissue engineering; human
   adipose derived stem cells; osteogenesis
ID OSTEOGENIC DIFFERENTIATION; STEM CELLS; IN VITRO; ADIPOSE; OSTEOBLASTS;
   COMPOSITES; ADHESION
AB The main goal of bone tissue engineering (BTE) is to refine and repair major bone defects based on bioactive biomaterials with distinct properties that can induce and support bone tissue formation. Graphene and its derivatives, such as graphene oxide (GO), display optimal properties for BTE, being able to support cell growth and proliferation, cell attachment, and cytoskeleton development as well as the activation of osteogenesis and bone development pathways. Conversely, the presence of GO within a polymer matrix produces favorable changes to scaffold morphologies that facilitate cell attachment and migration i.e., more ordered morphologies, greater surface area, and higher total porosity. Therefore, there is a need to explore the potential of GO for tissue engineering applications and regenerative medicine. Here, we aim to promote one novel scaffold based on a natural compound of chitosan, improved with 3 wt.% GO, for BTE approaches, considering its good biocompatibility, remarkable 3D characteristics, and ability to support stem cell differentiation processes towards the bone lineage.
C1 [Dinescu, Sorina; Ignat, Simona Rebeca; Costache, Marieta] Univ Bucharest, Dept Biochem & Mol Biol, Splaiul Independentei 91 95, Bucharest 050095, Romania.
   [Ionita, Mariana] Univ Politehn Bucuresti, Adv Polymer Mat Grp, Gh Polizu 1 7, Bucharest 011061, Romania.
   [Hermenean, Anca] Vasile Goldis Western Univ Arad, Inst Life Sci, 86 Rebreanu, Arad 310414, Romania.
C3 University of Bucharest; National University of Science & Technology
   POLITEHNICA Bucharest; Vasile Goldis Western University of Arad
RP Costache, M (通讯作者)，Univ Bucharest, Dept Biochem & Mol Biol, Splaiul Independentei 91 95, Bucharest 050095, Romania.
EM sorina.dinescu@bio.unibuc.ro; mariana.ionita@polimi.it;
   simona.ignat@unibuc.ro; marieta.costache@bio.unibuc.ro;
   anca.hermenean@gmail.com
RI Costache, Marieta/F 2806 2016; Ionita, Mariana/C 5664 2012; Dinescu,
   Sorina/H 1410 2016; Hermenean, Anca/G 5360 2010; Ignat,
   Simona/AAG 6760 2020; Nazarie, Simona Rebeca/A 9507 2019
OI Costache, Marieta/0000 0002 8103 3693; Dinescu,
   Sorina/0000 0001 7196 1712; Nazarie, Simona Rebeca/0000 0002 9752 6927;
   Hermenean, Anca/0000 0001 8510 6653
FU Romanian Ministry of Research and Innovation, CCCDI UEFISCDI
   [PNIII P1.1.2 PCCDI 2017 0782/REGMED]; Ministry of Research and
   Innovation, Operational Program Competitiveness Axis 1, Section E;
   European Regional Development Fund [154/25.11.2016, P_37_221/2015,
   108117]
FX This research was funded by the Romanian Ministry of Research and
   Innovation, CCCDI UEFISCDI, grant number
   PNIII P1.1.2 PCCDI 2017 0782/REGMED. Material synthesis and
   characterization was supported by a grant from the Ministry of Research
   and Innovation, Operational Program Competitiveness Axis 1, Section E,
   and a program co financed by the European Regional Development Fund
   under the project number 154/25.11.2016, P_37_221/2015, SMIS code
   108117, "A novel graphene biosensor testing osteogenic potency;
   capturing best stem cell performance for regenerative medicine"
   (GRABTOP).
CR Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131
   Cai X, 2012, CHEM ASIAN J, V7, P1664, DOI 10.1002/asia.201200045
   Ciuffi S, 2017, CLIN CASES MINER BON, V14, P217, DOI 10.11138/ccmbm/2017.14.1.217
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Dai R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6737345
   Dawson E, 2008, ADV DRUG DELIVER REV, V60, P215, DOI 10.1016/j.addr.2007.08.037
   Depan D, 2013, ACTA BIOMATER, V9, P6084, DOI 10.1016/j.actbio.2012.12.019
   Dinescu S, 2014, BIO MED MATER ENG, V24, P2249, DOI 10.3233/BME 141037
   Fu C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188352
   Gomathysankar S, 2016, J STEM CELLS REGEN, V12, pP79
   Gu M, 2014, TISSUE ENG PART B RE, V20, P477, DOI [10.1089/ten.TEB.2013.0638, 10.1089/ten.teb.2013.0638]
   Hermenean A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16599 5
   Hoekstra A, 1998, BIOMATERIALS, V19, P1467, DOI 10.1016/S0142 9612(98)00060 X
   Hong BJ, 2012, ACS NANO, V6, P63, DOI 10.1021/nn202355p
   Ignat SR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163868
   Ionita M, 2016, J MATER CHEM B, V4, P282, DOI 10.1039/c5tb02132d
   Jeong JT, 2016, SCI REP UK, V6, DOI 10.1038/srep33835
   Kalbacova M, 2010, CARBON, V48, P4323, DOI 10.1016/j.carbon.2010.07.045
   Kang ES, 2018, COLLOID SURFACE B, V169, P20, DOI 10.1016/j.colsurfb.2018.04.053
   Kenry, 2018, BIOMATERIALS, V155, P236, DOI 10.1016/j.biomaterials.2017.10.004
   Kim J, 2013, J BIOMED MATER RES A, V101, P3520, DOI 10.1002/jbm.a.34659
   Kim J, 2013, J MATER CHEM B, V1, P933, DOI 10.1039/c2tb00274d
   La WG, 2014, CARBON, V78, P428, DOI 10.1016/j.carbon.2014.07.023
   La WG, 2013, SMALL, V9, DOI 10.1002/smll.201300571
   Lee JH, 2015, SCI REP UK, V5, DOI 10.1038/srep18833
   Lendeckel S, 2004, J CRANIO MAXILL SURG, V32, P370, DOI 10.1016/j.jcms.2004.06.002
   Li KW, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19742 y
   Lu JY, 2013, ADV FUNCT MATER, V23, P3494, DOI 10.1002/adfm.201203637
   Lyu CQ, 2015, ACS APPL MATER INTER, V7, P20245, DOI 10.1021/acsami.5b05802
   Malafaya PB, 2005, J MATER SCI MATER M, V16, P1077, DOI 10.1007/s10856 005 4709 4
   Mesimäki K, 2009, INT J ORAL MAX SURG, V38, P201, DOI 10.1016/j.ijom.2009.01.001
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Noh M, 2017, RSC ADV, V7, P20779, DOI 10.1039/c7ra02410j
   Pandele AM, 2014, CARBOHYD POLYM, V102, P813, DOI 10.1016/j.carbpol.2013.10.085
   Prasadh S, 2018, MATERIALS, V11, DOI 10.3390/ma11081430
   Reimer P.D. L., 1998, Scanning Electron Microscopy: Physics of Image Formation & Microanalysis, P13, DOI [10.1007/978 3 540 38967 52, DOI 10.1007/978 3 540 38967 52]
   Ruan J, 2016, ADV FUNCT MATER, V26, P1085, DOI 10.1002/adfm.201504141
   Sahu A, 2012, CHEM COMMUN, V48, P5820, DOI 10.1039/c2cc31862h
   Shen H, 2012, THERANOSTICS, V2, P283, DOI 10.7150/thno.3642
   Some S, 2012, ACS NANO, V6, P7151, DOI 10.1021/nn302215y
   Wang YF, 2017, J MATER CHEM B, V5, P511, DOI 10.1039/c6tb02333a
   Xie H, 2015, CARBON, V93, P266, DOI 10.1016/j.carbon.2015.05.071
   Xie YT, 2015, INT J NANOMED, V10, P3855, DOI 10.2147/IJN.S77919
NR 43
TC 70
Z9 72
U1 0
U2 37
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT 2
PY 2019
VL 20
IS 20
AR 5077
DI 10.3390/ijms20205077
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JQ3AZ
UT WOS:000498822800109
PM 31614903
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Köller, M
   Hayer, S
   Redlich, K
   Ricci, R
   David, JP
   Steiner, G
   Smolen, JS
   Wagner, EF
   Schett, G
AF Köller, M
   Hayer, S
   Redlich, K
   Ricci, R
   David, JP
   Steiner, G
   Smolen, JS
   Wagner, EF
   Schett, G
TI JNK1 is not essential for TNF mediated joint disease
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE arthritis; JNK1; TNF alpha transgenic
ID TUMOR NECROSIS FACTOR; ACTIVATED PROTEIN KINASE; N TERMINAL KINASE;
   RHEUMATOID ARTHRITIS; FACTOR ALPHA; FACTOR RECEPTORS; SYNOVIAL TISSUE;
   JUN; EXPRESSION; APOPTOSIS
AB Tumour necrosis factor (TNF) signalling molecules are considered as promising therapeutic targets of antirheumatic therapy. Among them, mitogen activated protein kinases are thought to be of central importance. Herein, we investigate the role in vivo of TNF alpha signalling through c Jun N terminal kinase (JNK) 1 in destructive arthritis. Human TNF transgenic (hTNFtg) mice, which develop inflammatory arthritis, were intercrossed with JNK1 deficient (JNK1( / )) mice. Animals ( n = 35) of all four genotypes (wild type, JNK1( / ), hTNFtg, JNK1( / ) hTNFtg) were assessed for clinical and histological signs of arthritis. Clinical features of arthritis ( swelling and decreased grip strength) developed equally in hTNFtg and JNK1( / ) hTNFtg mice. Histological analyses revealed no differences in the quantity of synovial inflammation and bone erosions or in the cellular composition of the synovial infiltrate. Bone destruction and osteoclast formation were observed to a similar degree in hTNFtg and JNK1( / ) hTNFtg animals. Moreover, cartilage damage, as indicated by proteoglycan loss in the articular cartilage, was comparable in the two strains. Intact phosphorylation of JNK and c Jun as well as expression of JNK2 in the synovial tissue of JNK1( / ) hTNFtg mice suggests that signalling through JNK2 may compensate for the deficiency in JNK1. Thus, JNK1 activation does not seem to be essential for TNF mediated arthritis.
C1 Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Vienna, Austria.
   Austrian Acad Sci, Ctr Mol Med, CeMM, A 1010 Vienna, Austria.
   Res Inst Mol Pathol, A 1030 Vienna, Austria.
C3 Medical University of Vienna; Austrian Academy of Sciences; CeMM
   Research Center for Molecular Medicine of the Austrian Academy of
   Sciences; Vienna Biocenter (VBC); Research Institute of Molecular
   Pathology (IMP)
RP Schett, G (通讯作者)，Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Vienna, Austria.
EM Georg.Schett@meduniwien.ac.at
RI ; Smolen, Josef/ADI 7087 2022; Ricci, Romeo/K 3009 2013
OI Hayer, Silvia/0000 0003 1334 5668; Steiner, Guenter/0000 0002 5089 7405;
   Wagner, Erwin F/0000 0001 7872 0196; Ricci, Romeo/0000 0002 9766 4369
CR Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   BRENNAN FM, 1989, J AUTOIMMUN, V2, P177, DOI 10.1016/0896 8411(89)90129 7
   BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0
   Casanova E, 1996, NEUROREPORT, V7, P1320, DOI 10.1097/00001756 199605170 00021
   COPE AP, 1992, ARTHRITIS RHEUM, V35, P1160, DOI 10.1002/art.1780351008
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   DELEURAN BW, 1992, ARTHRITIS RHEUM, V35, P1170, DOI 10.1002/art.1780351009
   Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140 6736(94)90628 9
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Hammaker D, 2003, ANN RHEUM DIS, V62, P86
   Hammaker DR, 2004, J IMMUNOL, V172, P1612, DOI 10.4049/jimmunol.172.3.1612
   Han ZN, 1999, J PHARMACOL EXP THER, V291, P124
   Han ZN, 2002, ARTHRITIS RHEUM, V46, P818, DOI 10.1002/art.10104
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   HANAZAWA S, 1993, J BIOL CHEM, V268, P9526
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Joosten LAB, 1999, ARTHRITIS RES, V1, P81, DOI 10.1186/ar14
   KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945 053X(02)00007 0
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028
   Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317
   Schett G, 2003, CELL DEATH DIFFER, V10, P1126, DOI 10.1038/sj.cdd.4401276
   Schett G, 2000, ARTHRITIS RHEUM, V43, P2501, DOI 10.1002/1529 0131(200011)43:11<2501::AID ANR18>3.0.CO;2 K
   Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092 8674(04)00166 7
NR 28
TC 26
Z9 30
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2005
VL 7
IS 1
BP R166
EP R173
DI 10.1186/ar1473
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 878DM
UT WOS:000225626700023
PM 15642137
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Palumbo, C
   Baldini, A
   Cavani, F
   Sena, P
   Benincasa, M
   Ferretti, M
   Zaffe, D
AF Palumbo, Carla
   Baldini, Andrea
   Cavani, Francesco
   Sena, Paola
   Benincasa, Marta
   Ferretti, Marzia
   Zaffe, Davide
TI Immunocytochemical and structural comparative study of committed
   versus multipotent stem cells cultured with different
   biomaterials
SO MICRON
LA English
DT Article
DE Osteoblast cells; Stem cells; Bone cell differentiation; Biomaterials;
   Titanium; 3D Scaffold
ID DENTAL PULP; TITANIUM; OSTEOBLASTS
AB The aim of this work was the comparison of the behavior of committed (human osteoblast cells   hOB   from bone biopsies) versus multipotent (human dental pulp stem cells   hDPSC   from extracted teeth) cells, cultured on shot peened titanium surfaces, since the kind of cell model considered has been shown to be relevant in techniques widely used in studies on composition/morphology of biomaterial surfaces. The titanium surface morphology, with different roughness, and the behavior of cells were analyzed by confocal microscope (CM), scanning electron microscope (SEM) and X ray microanalysis. The best results, in terms of hOB adhesion/distribution, were highlighted by both CM and SEM in cultured plates having 20 mu m depth cavities. On the contrary, CM and SEM results highlighted the hDPSC growth regardless the different surface morphology, arranged in overlapped layers due to their high proliferation rate, showing their unfitness in biomaterial surface test. Nevertheless, hDPSC cultured inside 3D matrices reproduced an osteocyte like three dimensional network, potentially useful in the repair of critical size bone defects. The behavior of the two cell models suggests a different use in biomaterial cell cultures: committed osteoblast cells could be appropriate in selecting the best surfaces to improve osseointegration, while multipotent cells could be suitable to obtain in vitro osteocyte like network for regenerative medicine. The originality of the present work consists in studying for the first time two different cell models (committed versus multipotent) compared in parallel different biomaterial cultures, thus suggesting distinct targets for each cellular model. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Palumbo, Carla; Cavani, Francesco; Sena, Paola; Benincasa, Marta; Ferretti, Marzia; Zaffe, Davide] Univ Modena & Reggio Emilia, Sect Human Morphol, Dept Biomed Sci, Modena, Italy.
   [Baldini, Andrea] Univ Modena & Reggio Emilia, Dept Mech & Civil Engn, Modena, Italy.
C3 Universita di Modena e Reggio Emilia; Universita di Modena e Reggio
   Emilia
RP Zaffe, D (通讯作者)，Dipartimento Sci Biomed, Sez Morfol Umana, Via Pozzo 71, I 41124 Modena, Italy.
EM davide.zaffe@unimore.it
RI Zaffe, Davide/G 1181 2016; Palumbo, Carla/E 5802 2012; Cavani,
   Francesco/B 2907 2016; Baldini, Andrea/N 3635 2015; Ferretti,
   Marzia/F 1153 2016; Sena, Paola/JCO 2014 2023; Sena, Paola/G 9394 2016
OI Zaffe, Davide/0000 0003 1241 385X; Palumbo, Carla/0000 0003 0587 0112;
   Cavani, Francesco/0000 0002 9084 3997; Baldini,
   Andrea/0000 0002 2427 2663; Ferretti, Marzia/0000 0003 0280 3598; Sena,
   Paola/0000 0003 4724 8786
FU Fondazione di Vignola, Modena, Italy; Banca Popolare dell'Emilia
   Romagna, Modena, Italy
FX The study was supported by funds of "Fondazione di Vignola, Modena,
   Italy" and "Banca Popolare dell'Emilia Romagna, Modena, Italy".
CR Agrawal AA, 2010, BIOMATERIALS, V31, P5408, DOI 10.1016/j.biomaterials.2010.03.041
   Apostolou E, 2011, NATURE, V474, P165, DOI 10.1038/474165a
   Barclay A N, 1988, Adv Exp Med Biol, V237, P3
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chen WH, 2009, ARTHRITIS RHEUM US, V60, P450, DOI 10.1002/art.24265
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   d'Aquino R, 2009, EUR CELLS MATER, V18, P75, DOI 10.22203/eCM.v018a07
   Docheva D, 2010, EUR CELLS MATER, V19, P228, DOI 10.22203/eCM.v019a22
   Gittens RA, 2011, BIOMATERIALS, V32, P3395, DOI 10.1016/j.biomaterials.2011.01.029
   GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164
   Higuchi A, 2011, CHEM REV, V111, P3021, DOI 10.1021/cr1003612
   Koob S, 2011, TISSUE ENG PT A, V17, P311, DOI [10.1089/ten.tea.2010.0338, 10.1089/ten.TEA.2010.0338]
   Laino G, 2006, J CELL PHYSIOL, V206, P693, DOI 10.1002/jcp.20526
   Lavenus S, 2011, ACTA BIOMATER, V7, P1525, DOI 10.1016/j.actbio.2010.12.033
   Mangano C, 2010, BIOMATERIALS, V31, P3543, DOI 10.1016/j.biomaterials.2010.01.056
   Maraldi T, 2009, MOL HUM REPROD, V15, P499, DOI 10.1093/molehr/gap048
   Marotti G, 1996, Ital J Anat Embryol, V101, P25
   Marotti G., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P133
   Necula BS, 2011, ACTA BIOMATER, V7, P2751, DOI 10.1016/j.actbio.2011.02.037
   Okada S, 2011, ACTA BIOMATER, V7, P1290, DOI 10.1016/j.actbio.2010.10.010
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2728, DOI 10.1016/j.biomaterials.2009.12.029
   Paino F, 2010, EUR CELLS MATER, V20, P295
   PALUMBO C, 1990, BONE, V11, P401, DOI 10.1016/8756 3282(90)90134 K
   Palumbo C., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P327
   Palumbo C., 2007, EUR J HISTOCHEM S2, V51, P31
   Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667
   Riccio M, 2010, EUR J HISTOCHEM, V54, P213, DOI 10.4081/ejh.2010.e46
   Riccio M, 2011, OPT LASER TECHNOL, V43, P317, DOI 10.1016/j.optlastec.2009.06.002
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   Rubinacci A, 1998, CALCIFIED TISSUE INT, V63, P331, DOI 10.1007/s002239900536
   Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601 6343.2005.00331.x
   SIMMONS PJ, 1991, BLOOD, V78, P2848
   Song J, 2009, J BIOMED MATER RES A, V89A, P1098, DOI 10.1002/jbm.a.32110
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Wang K, 2010, BIOMACROMOLECULES, V11, P2748, DOI 10.1021/bm1008102
   Ward J, 2010, BIOMACROMOLECULES, V11, P3093, DOI 10.1021/bm100898p
   World Medical Association, 2002, J Postgrad Med, V48, P206
   Xu JW, 2009, J ORTHOP RES, V27, P1306, DOI 10.1002/jor.20890
   Xu WJ, 2010, ACTA BIOMATER, V6, P1992, DOI 10.1016/j.actbio.2009.12.003
   Yukawa H, 2011, BIOMATERIALS, V32, P3729, DOI 10.1016/j.biomaterials.2011.01.013
NR 40
TC 8
Z9 8
U1 0
U2 15
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 4328
J9 MICRON
JI Micron
PD APR
PY 2013
VL 47
BP 1
EP 9
DI 10.1016/j.micron.2012.02.017
PG 9
WC Microscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microscopy
GA 115RZ
UT WOS:000316830900001
PM 22440134
DA 2025 08 17
ER

PT J
AU Mikkelsen, UR
   Paulsen, G
   Schjerling, P
   Helmark, IC
   Langberg, H
   Kjær, M
   Heinemeier, KM
AF Mikkelsen, U. R.
   Paulsen, G.
   Schjerling, P.
   Helmark, I. C.
   Langberg, H.
   Kjaer, M.
   Heinemeier, K. M.
TI The heat shock protein response following eccentric exercise in human
   skeletal muscle is unaffected by local NSAID infusion
SO EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE HSP; Non steroidal anti inflammatory drugs; Muscle damage; Force
   recovery; mRNA; RT PCR; Immunohistochemistry
ID HSP70 RESPONSE; HEAT SHOCK PROTEIN 27 INDUCTION; ANTIINFLAMMATORY
   MEDICATION; LENGTHENING CONTRACTIONS; COX 2 PATHWAY; SINGLE BOUT;
   EXPRESSION; CELLS; HSP27; PROSTAGLANDINS
AB Non steroidal anti inflammatory drugs (NSAIDs) are widely consumed in relation to pain and injuries in skeletal muscle, but may adversely affect muscle adaptation probably via inhibition of prostaglandin synthesis. Induction of heat shock proteins (HSP) represents an important adaptive response in muscle subjected to stress, and in several cell types including cardiac myocytes prostaglandins are important in induction of the HSP response. This study aimed to determine the influence of NSAIDs on the HSP response to eccentric exercise in human skeletal muscle. Healthy males performed 200 maximal eccentric contractions with each leg with intramuscular infusion of the NSAID indomethacin or placebo. Biopsies were obtained from m. vastus lateralis before and after (5, 28 hrs and 8 days) the exercise bout from both legs (NSAID vs unblocked leg) and analysed for expression of the HSPs HSP70, HSP27 and alpha B crystallin (mRNA and protein). NSAID did not affect the mRNA expression of any of the HSPs. Compared to pre values, the mRNA expression of all HSPs was increased; alpha B crystallin, 3.6  and 5.4 fold; HSP70, 26  and 3.4 fold; and HSP27: 4.8  and 6.5 fold at 5 and 28 hrs post exercise, respectively (all p < 0.008). Immunohistochemical stainings for alpha B crystallin and HSP70 revealed increased staining in some samples but with no differences between legs. Changes in force generating capacity correlated with both alpha B crystallin and HSP70 mRNA and immunohistochemisty data. Increased expression of HSPs was observed on mRNA and protein level following eccentric exercise; however, this response was unaffected by local intramuscular infusion of NSAIDs.
C1 [Mikkelsen, U. R.; Schjerling, P.; Helmark, I. C.; Langberg, H.; Kjaer, M.; Heinemeier, K. M.] Univ Copenhagen, Inst Sports Med, Dept Orthoped Surg M, Bispebjerg Hosp, Copenhagen, Denmark.
   [Mikkelsen, U. R.; Schjerling, P.; Helmark, I. C.; Langberg, H.; Kjaer, M.; Heinemeier, K. M.] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Hlth Aging, Copenhagen, Denmark.
   [Mikkelsen, U. R.; Schjerling, P.; Helmark, I. C.; Langberg, H.; Kjaer, M.; Heinemeier, K. M.] Bispebjerg Hosp, Inst Sports Med, DK 2400 Copenhagen NV, Denmark.
   [Paulsen, G.] Norwegian Sch Sport Sci, Dept Phys Performance, Oslo, Norway.
   [Langberg, H.] Univ Copenhagen, CopenRehab, Sect Social Med, Dept Publ Hlth,Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital; Bispebjerg
   Hospital; University of Copenhagen; University of Copenhagen; Copenhagen
   University Hospital; Bispebjerg Hospital; Norwegian School of Sport
   Sciences; University of Copenhagen
RP Mikkelsen, UR (通讯作者)，Bispebjerg Hosp, Inst Sports Med, Bldg 8,Bispebjerg Bakke 23, DK 2400 Copenhagen NV, Denmark.
EM ullaramer@hotmail.com
RI ; Paulsen, Goran/ABG 6995 2020; Schjerling, Peter/F 6194 2011; Kjaer,
   Michael/W 6842 2019
OI Langberg, Henning/0000 0001 8454 6534; Kjaer,
   Michael/0000 0002 4582 8755; Schjerling, Peter/0000 0001 7138 3211; 
FU Danish Medical Research Council [10 094021, 271 07 0742]; H:S Research
   Foundation (Copenhagen University Hospitals); Nordea Foundation;
   Lundbeck Foundation; Danish Rheumatism Association [R38 A328 B166,
   R54 A619 B270]; Team Denmark [33241979 06]
FX The study was supported by grants from The Danish Medical Research
   Council (no. 10 094021 and 271 07 0742), H:S Research Foundation
   (Copenhagen University Hospitals), The Nordea Foundation, The Lundbeck
   Foundation, The Danish Rheumatism Association (R38 A328 B166 and
   R54 A619 B270), and Team Denmark: 33241979 06.
CR ABERNETHY PJ, 1994, SPORTS MED, V17, P22, DOI 10.2165/00007256 199417010 00003
   ALMEKINDERS LC, 1986, AM J SPORT MED, V14, P303, DOI 10.1177/036354658601400411
   BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Cornelussen RNM, 2001, J MOL CELL CARDIOL, V33, P1447, DOI 10.1006/jmcc.2001.1406
   Crameri RM, 2007, J PHYSIOL LONDON, V583, P365, DOI 10.1113/jphysiol.2007.128827
   Flück M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254 002 0004 7
   Folkesson M, 2008, ACTA PHYSL OXF
   Hamel L, 2000, CELL STRESS CHAPERON, V5, P121, DOI 10.1379/1466 1268(2000)005<0121:IOHSPB>2.0.CO;2
   Iguchi G, 2009, CANCER LETT, V282, P152, DOI 10.1016/j.canlet.2009.03.006
   Ito H, 1997, J CELL PHYSIOL, V170, P255, DOI 10.1002/(SICI)1097 4652(199703)170:3<255::AID JCP6>3.0.CO;2 N
   Koh TJ, 2004, AM J PHYSIOL CELL PH, V286, pC713, DOI 10.1152/ajpcell.00341.2003
   Koh TJ, 2001, AM J PHYSIOL REG I, V281, pR155, DOI 10.1152/ajpregu.2001.281.1.R155
   Kozawa O, 2001, CELL SIGNAL, V13, P535, DOI 10.1016/S0898 6568(01)00180 2
   Liu Y, 2000, INT J SPORTS MED, V21, P351, DOI 10.1055/s 2000 3784
   Liu YF, 1999, J APPL PHYSIOL, V86, P101, DOI 10.1152/jappl.1999.86.1.101
   Liu YF, 2001, FRONT BIOSCI LANDMRK, V6, pD12, DOI 10.2741/Liu
   Liu YF, 2006, FRONT BIOSCI LANDMRK, V11, P2802, DOI 10.2741/2011
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Madden LA, 2007, AMINO ACIDS
   McHugh MP, 2003, SCAND J MED SCI SPOR, V13, P88, DOI 10.1034/j.1600 0838.2003.02477.x
   Merwald H, 2006, CELL STRESS CHAPERON, V11, P81, DOI 10.1379/CSC 89R.1
   Mikkelsen UR, 2011, SCAND J MED SCI SPOR, V21, P630, DOI 10.1111/j.1600 0838.2010.01170.x
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   Mikkelsen UR, 2008, J APPL PHYSIOL, V104, P534, DOI 10.1152/japplphysiol.01016.2007
   Monda M, 2009, J MUSCLE RES CELL M, V30, P139, DOI 10.1007/s10974 009 9182 0
   Morton JP, 2006, J APPL PHYSIOL, V101, P176, DOI 10.1152/japplphysiol.00046.2006
   Neuhofer W, 2004, KIDNEY INT, V65, P431, DOI 10.1111/j.1523 1755.2004.00387.x
   Neuhofer W, 2007, J PHYSIOL LONDON, V583, P287, DOI 10.1113/jphysiol.2007.135178
   Nishizawa J, 1999, CIRCULATION, V99, P934, DOI 10.1161/01.CIR.99.7.934
   Noble EG, 2008, APPL PHYSIOL NUTR ME, V33, P1050, DOI 10.1139/H08 069
   Novak ML, 2009, AM J PHYSIOL REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009
   Paulsen G, 2012, EUR J APPL PHYSIOL, V112, P1773, DOI 10.1007/s00421 011 2132 8
   Paulsen G, 2009, J APPL PHYSIOL, V107, P570, DOI 10.1152/japplphysiol.00209.2009
   PAULSEN G, 2009, SCAND J MED SCI SPOR
   Paulsen G, 2007, AM J PHYSIOL REG I, V293, pR844, DOI 10.1152/ajpregu.00677.2006
   SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407
   Shen W, 2005, AM J PATHOL, V167, P1105, DOI 10.1016/S0002 9440(10)61199 6
   Shen W, 2006, J APPL PHYSIOL, V101, P1215, DOI 10.1152/japplphysiol.01331.2005
   Soltow QA, 2006, MED SCI SPORT EXER, V38, P840, DOI 10.1249/01.mss.0000218142.98704.66
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01 0390rev
   Thompson HS, 2003, ACTA PHYSIOL SCAND, V178, P61, DOI 10.1046/j.1365 201X.2003.01112.x
   Thompson HS, 2001, ACTA PHYSIOL SCAND, V171, P187, DOI 10.1046/j.1365 201x.2001.00795.x
   Tokuda H, 2002, J ENDOCRINOL, V172, P271, DOI 10.1677/joe.0.1720271
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Tupling AR, 2007, J APPL PHYSIOL, V103, P2105, DOI 10.1152/japplphysiol.00771.2007
   Vissing K, 2009, ACTA PHYSIOL, V196, P283, DOI 10.1111/j.1748 1716.2008.01940.x
   Warren GL, 1999, SPORTS MED, V27, P43, DOI 10.2165/00007256 199927010 00004
   Xu XH, 2006, BRAIN RES, V1102, P154, DOI 10.1016/j.brainres.2006.04.111
NR 51
TC 13
Z9 15
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1439 6319
EI 1439 6327
J9 EUR J APPL PHYSIOL
JI Eur. J. Appl. Physiol.
PD JUL
PY 2013
VL 113
IS 7
BP 1883
EP 1893
DI 10.1007/s00421 013 2606 y
PG 11
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 163BZ
UT WOS:000320311800024
PM 23467900
DA 2025 08 17
ER

PT J
AU Carothers, AM
   Rizvi, H
   Hasson, RM
   Heit, YI
   Davids, JS
   Bertagnolli, MM
   Cho, NL
AF Carothers, Adelaide M.
   Rizvi, Hira
   Hasson, Rian M.
   Heit, Yvonne I.
   Davids, Jennifer S.
   Bertagnolli, Monica M.
   Cho, Nancy L.
TI Mesenchymal Stromal Cell Mutations and Wound Healing Contribute to the
   Etiology of Desmoid Tumors
SO CANCER RESEARCH
LA English
DT Article
ID FAMILIAL ADENOMATOUS POLYPOSIS; MARROW DERIVED CELLS; STEM CELLS;
   AGGRESSIVE FIBROMATOSIS; EXPRESSION; FIBROCYTES; THERAPY; ANGIOGENESIS;
   DIFFERENTIATION; PROGENITOR
AB Desmoid tumors are nonmalignant neoplasms of mesenchymal origin that mainly contain fibroblast lineage cells. These tumors often occur in patients with familial adenomatous polyposis (FAP) coli who have germ line mutations in the APC gene. Given emerging data that has implicated multipotent mesencyhmal stromal cells (MSC) in the origin of mesenchymal tumors, we hypothesized that desmoid tumors may arise in patients with FAP after MSCs acquire somatic mutations during the proliferative phase of wound healing. To test this idea, we examined 16 desmoid tumors from FAP associated and sporadic cases, finding that all 16 of 16 tumors expressed stem cell markers, whereas matching normal stromal tissues were uniformly negative. Desmoid tumors also contained a subclass of fibrocytes linked to wound healing, angiogenesis, and fibrosis. Using an MSC cell line derived from an FAP associated desmoid tumor, we confirmed an expected loss in the expression of adenomatous polyposis coli (APC) and the transcriptional repressor BMI 1 while documenting the coexpression of markers for chondrocytes, adipocytes, and osteocytes. Together, our findings argue that desmoid tumors result from the growth of MSCs in a wound healing setting that is associated with deregulated Wnt signaling due to APC loss. The differentiation potential of these MSCs combined with expression of BMI 1, a transcriptional repressor downstream of Hedgehog and Notch signaling, suggests that desmoid tumors may respond to therapies targeting these pathways. Cancer Res; 72(1); 346 055. (C) 2011 AACR.
C1 [Carothers, Adelaide M.; Rizvi, Hira; Hasson, Rian M.; Heit, Yvonne I.; Davids, Jennifer S.; Bertagnolli, Monica M.; Cho, Nancy L.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital
RP Cho, NL (通讯作者)，Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
EM nlcho@partners.org
FU Department of Surgery at Brigham and Women's Hospital [K05 CA131504]
FX This work was supported by The Eleanor and Miles Shore/Robert T. Osteen
   Junior Faculty Research Grant from the Department of Surgery at Brigham
   and Women's Hospital awarded to N.L. Cho, and K05 CA131504 awarded to
   M.M. Bertagnolli.
CR Akino K, 2008, INT J DERMATOL, V47, P1112, DOI 10.1111/j.1365 4632.2008.03380.x
   Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Bacac M, 2006, J PATHOL, V208, P543, DOI 10.1002/path.1915
   Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654
   Bertagnolli MM, 2008, EUR J CANCER, V44, P2404, DOI 10.1016/j.ejca.2008.06.038
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Cho NL, 2010, J SURG RES      1126
   Cunha SI, 2011, BLOOD, V117, P6999, DOI 10.1182/blood 2011 01 330142
   Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005 0370
   Denys H, 2004, BRIT J CANCER, V90, P1443, DOI 10.1038/sj.bjc.6601661
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22 5 812
   Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417
   Hansmann A, 2004, CANCER AM CANCER SOC, V100, P612, DOI 10.1002/cncr.11937
   Hartlapp I, 2001, FASEB J, V15, P2215, DOI 10.1096/fj.01 0049com
   Hoos A, 2001, CANCER RES, V61, P3171
   KLEMMER S, 1987, AM J MED GENET, V28, P385, DOI 10.1002/ajmg.1320280217
   Latchford A, 2007, HUM MOL GENET, V16, P78, DOI 10.1093/hmg/ddl442
   Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475
   Li MM, 1996, HUM PATHOL, V27, P939, DOI 10.1016/S0046 8177(96)90221 X
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Mace J, 2002, CANCER AM CANCER SOC, V95, P2373, DOI 10.1002/cncr.11029
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Metz CN, 2003, CELL MOL LIFE SCI, V60, P1342, DOI 10.1007/s00018 003 2328 0
   Middleton SB, 2000, BRIT J CANCER, V82, P827, DOI 10.1054/bjoc.1999.1007
   Mills BG, 2000, J ORTHOPAED RES, V18, P655, DOI 10.1002/jor.1100180419
   Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535 7163.MCT 09 0650
   Moioli EK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003922
   Moon JH, 2008, STEM CELLS DEV, V17, P713, DOI 10.1089/scd.2007.0210
   Nik SA, 2007, EXP CELL RES, V313, P2887, DOI 10.1016/j.yexcr.2007.05.024
   Opalenik SR, 2005, FASEB J, V19, P1561, DOI 10.1096/fj.04 2978fje
   Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997
   Renström J, 2009, CELL STEM CELL, V5, P157, DOI 10.1016/j.stem.2009.05.020
   Robinson SN, 2006, BONE MARROW TRANSPL, V37, P359, DOI 10.1038/sj.bmt.1705258
   RODRIGUEZBIGAS MA, 1994, CANCER, V74, P1270, DOI 10.1002/1097 0142(19940815)74:4<1270::AID CNCR2820740415>3.0.CO;2 7
   Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097 0177(199708)209:4<418::AID AJA9>3.0.CO;2 L
   Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989 5999.2002
   Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703
   Salas S, 2010, GENE CHROMOSOME CANC, V49, P560, DOI 10.1002/gcc.20766
   Styner M, 2010, J CELL BIOCHEM, V111, P1042, DOI 10.1002/jcb.22793
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041
   Vazin T, 2010, TRENDS BIOTECHNOL, V28, P117, DOI 10.1016/j.tibtech.2009.11.008
   Wang GS, 2005, P NATL ACAD SCI USA, V102, P186, DOI 10.1073/pnas.0406266102
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002 9440(10)65297 2
   Wu C, 2010, CANCER RES, V70, P7690, DOI 10.1158/0008 5472.CAN 10 1656
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Wu YJ, 2010, STEM CELLS, V28, P905, DOI 10.1002/stem.420
   Yang LJ, 2005, WOUND REPAIR REGEN, V13, P398, DOI 10.1111/j.1067 1927.2005.130407.x
NR 49
TC 54
Z9 63
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2012
VL 72
IS 1
BP 346
EP 355
DI 10.1158/0008 5472.CAN 11 2819
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 871RO
UT WOS:000298755600034
PM 22094874
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Hofmann, E
   Eggers, B
   Heim, N
   Kramer, FJ
   Nokhbehsaim, M
   Götz, W
AF Hofmann, Elena
   Eggers, Benedikt
   Heim, Nils
   Kramer, Franz Josef
   Nokhbehsaim, Marjan
   Goetz, Werner
TI Bevacizumab and sunitinib mediate osteogenic and pro inflammatory
   molecular changes in primary human alveolar osteoblasts in vitro
SO ODONTOLOGY
LA English
DT Article
DE MRONJ; Alveolar osteoblasts; Bevacizumab; Sunitinib
ID BISPHOSPHONATE RELATED OSTEONECROSIS; ENDOTHELIAL GROWTH FACTOR;
   SURGEONS POSITION PAPER; MARROW STROMAL CELLS; ZOLEDRONIC ACID; MATRIX
   METALLOPROTEINASES; AMERICAN ASSOCIATION; MULTIPLE MYELOMA; FACTOR
   RECEPTORS; GENE EXPRESSION
AB Antiangiogenic medications target the de novo blood vessel formation in tumorigenesis. However, these novel drugs have been linked to the onset of medication related osteonecrosis of the jaw (MRONJ). The aim of this in vitro study was to examine the effects of the vascular endothelial growth factor A (VEGFA) antibody bevacizumab (BEV) and the receptor tyrosine kinase inhibitor (RTKI) sunitinib (SUN) on primary human osteoblasts derived from the alveolar bone. Primary human alveolar osteoblasts (HAOBs) were treated with BEV or SUN for 48 h. Cellular metabolic activity was examined by XTT assay. Differentially regulated genes were identified by screening of 22 selected osteogenic and angiogenic markers by quantitative real time reverse transcriptase polymerase chain reaction (qRT(2) PCR). Protein levels of alkaline phosphatase (ALP), collagen type 1, alpha 1 (COL1A1) and secreted protein acidic and cysteine rich (SPARC) were examined by enzyme linked immunoassay (ELISA). Treatment with BEV and SUN did not exhibit direct cytotoxic effects in HAOBs as confirmed by XTT assay. Of the 22 genes examined by qRT(2) PCR, four genes were significantly regulated after BEV treatment and eight genes in the SUN group as compared to the control group. Gene expression levels of ALPL, COL1A1 and SPARC were significantly downregulated by both drugs. Further analysis by ELISA indicated the downregulation of protein levels of ALP, COL1A1 and SPARC in the BEV and SUN groups. The effects of BEV and SUN in HAOBs may be mediated by alterations to osteogenic and catabolic markers. Therapeutic or preventive strategies in MRONJ may address drug induced depression of osteoblast differentiation.
C1 [Hofmann, Elena; Eggers, Benedikt; Heim, Nils; Kramer, Franz Josef] Univ Hosp Bonn, Dept Oral Maxillofacial & Plast Surg, Welschnonnenstr 17, D 53111 Bonn, Germany.
   [Hofmann, Elena] Charite Univ Med Berlin, Dept Oral & Maxillofacial Surg, Augustenburger Pl 1, D 13353 Berlin, Germany.
   [Hofmann, Elena] Free Univ Berlin, Augustenburger Pl 1, D 13353 Berlin, Germany.
   [Hofmann, Elena] Humboldt Univ, Augustenburger Pl 1, D 13353 Berlin, Germany.
   [Hofmann, Elena] Berlin Inst Hlth, Augustenburger Pl 1, D 13353 Berlin, Germany.
   [Nokhbehsaim, Marjan] Univ Hosp Bonn, Sect Expt Dentomaxillofacial Med, D 53111 Bonn, Germany.
   [Goetz, Werner] Univ Hosp Bonn, Dept Orthodont, D 53111 Bonn, Germany.
C3 University of Bonn; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin;
   Humboldt University of Berlin; Humboldt University of Berlin; Free
   University of Berlin; Charite Universitatsmedizin Berlin; Berlin
   Institute of Health; University of Bonn; University of Bonn
RP Hofmann, E (通讯作者)，Univ Hosp Bonn, Dept Oral Maxillofacial & Plast Surg, Welschnonnenstr 17, D 53111 Bonn, Germany.; Hofmann, E (通讯作者)，Charite Univ Med Berlin, Dept Oral & Maxillofacial Surg, Augustenburger Pl 1, D 13353 Berlin, Germany.; Hofmann, E (通讯作者)，Free Univ Berlin, Augustenburger Pl 1, D 13353 Berlin, Germany.; Hofmann, E (通讯作者)，Humboldt Univ, Augustenburger Pl 1, D 13353 Berlin, Germany.; Hofmann, E (通讯作者)，Berlin Inst Hlth, Augustenburger Pl 1, D 13353 Berlin, Germany.
EM Elena.hofmann@uni bonn.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. No funds,
   grants, or other support was received for conducting this study.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Adamcic U, 2012, NEOPLASIA, V14, P612, DOI 10.1593/neo.11948
   Akintoye SO, 2018, ORAL DIS, V24, P49, DOI 10.1111/odi.12761
   Akintoye SO, 2006, BONE, V38, P758, DOI 10.1016/j.bone.2005.10.027
   Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   Alge CS, 2006, J PROTEOME RES, V5, P862, DOI 10.1021/pr050420t
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Attar Schneider O, 2012, LAB INVEST, V92, P178, DOI 10.1038/labinvest.2011.162
   Bagan J, 2013, J ORAL PATHOL MED, V42, P405, DOI 10.1111/jop.12021
   Basi DL, 2010, MOL MED REP, V3, P399, DOI 10.3892/mmr_00000271
   Biasotto M, 2010, J ORAL PATHOL MED, V39, P390, DOI 10.1111/j.1600 0714.2009.00878.x
   Brown LC, 2020, BIODRUGS, V34, P733, DOI 10.1007/s40259 020 00449 4
   Carneiro A, 2009, ACTA OPHTHALMOL, V87, P517, DOI 10.1111/j.1755 3768.2008.01257.x
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chang J, 2018, CURR OSTEOPOROS REP, V16, P584, DOI 10.1007/s11914 018 0474 4
   Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12 3 356
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Silva PGD, 2017, J ORAL PATHOL MED, V46, P1046, DOI 10.1111/jop.12640
   Ding A, 2020, MOL MED REP, V21, P1581, DOI 10.3892/mmr.2020.10965
   Eguia A, 2020, MED ORAL PATOL ORAL, V25, pE71, DOI 10.4317/medoral.23191
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Gao SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179248
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gong X, 2017, SCI REP UK, V7, DOI 10.1038/srep36129
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008 5472.CAN 09 3722
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kroschwald LM, 2019, ONCOL LETT, V18, P2102, DOI 10.3892/ol.2019.10518
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lee H, 2017, BIOMED REP, V7, P291, DOI 10.3892/br.2017.961
   Lee JT, 2015, CLIN ORAL INVEST, V19, P1223, DOI 10.1007/s00784 014 1353 8
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Lim SS, 2017, OR SURG OR MED OR PA, V123, P8, DOI 10.1016/j.oooo.2016.08.009
   Jornet PL, 2015, J ORAL PATHOL MED, V44, P103, DOI 10.1111/jop.12205
   Lorenzo M, 2008, J Anim Sci, V86, pE94
   Marolt D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092969
   Marolt D, 2012, J ORAL MAXIL SURG, V70, P1081, DOI 10.1016/j.joms.2011.05.002
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McLaughlin KI, 2020, AUST DENT J, V65, P196, DOI 10.1111/adj.12752
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Moraschini V, 2021, J ORAL PATHOL MED, V50, P10, DOI 10.1111/jop.13083
   Morkmued S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71749 6
   Mukherjee A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020455
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Norton KA, 2014, ONCOTARGETS THER, V7, P1571, DOI 10.2147/OTT.S65055
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   Pal S, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115305
   Pathak JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131041
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Rock EP, 2007, ONCOLOGIST, V12, P107, DOI 10.1634/theoncologist.12 1 107
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Saracino S, 2012, J ORAL PATHOL MED, V41, P788, DOI 10.1111/j.1600 0714.2012.01173.x
   Segerström L, 2006, PEDIATR RES, V60, P576, DOI 10.1203/01.pdr.0000242494.94000.52
   Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017 014 8324 8
   Sipos G, 2008, ANAT REC, V291, P1140, DOI 10.1002/ar.20737
   Stefanik D, 2008, ORAL DIS, V14, P465, DOI 10.1111/j.1601 0825.2007.01402.x
   Steinbrech DS, 2000, AM J PHYSIOL CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853
   Su JS, 2015, J ORAL PATHOL MED, V44, P638, DOI 10.1111/jop.12281
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456 014 9420 y
   Videira PA, 2011, UROL INT, V86, P95, DOI 10.1159/000321905
   Wang EP, 2007, J ORAL MAXIL SURG, V65, P1328, DOI 10.1016/j.joms.2007.03.006
   Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645
   Wehrhan F, 2015, CLIN ORAL INVEST, V19, P1289, DOI 10.1007/s00784 014 1354 7
   Zafar S, 2016, CLIN ORAL INVEST, V20, P2023, DOI 10.1007/s00784 015 1706 y
NR 79
TC 5
Z9 6
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1618 1247
EI 1618 1255
J9 ODONTOLOGY
JI Odontology
PD OCT
PY 2022
VL 110
IS 4
BP 634
EP 647
DI 10.1007/s10266 022 00691 y
EA FEB 2022
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 4L1ZR
UT WOS:000756289900001
PM 35171372
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sanghani Kerai, A
   Coathup, M
   Samazideh, S
   Kalia, P
   Di Silvio, L
   Idowu, B
   Blunn, G
AF Sanghani Kerai, A.
   Coathup, M.
   Samazideh, S.
   Kalia, P.
   Di Silvio, L.
   Idowu, B.
   Blunn, G.
TI Osteoporosis and ageing affects the migration of stem cells and this is
   ameliorated by transfection with CXCR4
SO BONE & JOINT RESEARCH
LA English
DT Article
DE Osteoporosis; Bone; Mesenchymal
ID MARROW STROMAL CELLS; BONE MARROW; OSTEOGENIC DIFFERENTIATION; DEPENDENT
   ACTIVATION; HEMATOPOIETIC STEM; SIGNALING PATHWAY; THERAPY; INJURY;
   MICE; TRANSPLANTATION
AB Objectives
   Cellular movement and relocalisation are important for many physiologic properties. Local mesenchymal stem cells (MSCs) from injured tissues and circulating MSCs aid in fracture healing. Cytokines and chemokines such as Stromal cell derived factor 1(SDF 1) and its receptor chemokine receptor type 4 (CXCR4) play important roles in maintaining mobilisation, trafficking and homing of stem cells from bone marrow to the site of injury. We investigated the differences in migration of MSCs from the femurs of young, adult and ovariectomised (OVX) rats and the effect of CXCR4 over expression on their migration.
   Methods
   MSCs from young, adult and OVX rats were put in a Boyden chamber to establish their migration towards SDF 1. This was compared with MSCs transfected with CXCR4, as well as MSCs differentiated to osteoblasts.
   Results
   MSCs from OVX rats migrate significantly (p < 0.05) less towards SDF 1 (9%, SD 5%) compared with MSCs from adult (15%, SD 3%) and young rats (25%, SD 4%). Cells transfected with CXCR4 migrated significantly more towards SDF 1 compared with non transfected cells, irrespective of whether these cells were from OVX (26.5%, SD 4%), young (47%, SD 17%) or adult (21%, SD 4%) rats. Transfected MSCs differentiated to osteoblasts express CXCR4 but do not migrate towards SDF 1.
   Conclusions
   MSC migration is impaired by age and osteoporosis in rats, and this may be associated with a significant reduction in bone formation in osteoporotic patients. The migration of stem cells can be ameliorated by upregulating CXCR4 levels which could possibly enhance fracture healing in osteoporotic patients.
C1 [Sanghani Kerai, A.; Samazideh, S.; Kalia, P.; Di Silvio, L.; Idowu, B.] Univ Coll London, Stanmore HA7 4LP, Middx, England.
   [Coathup, M.] Univ Coll London, Inst Orthopaed & Musculoskeletal Sci, Stanmore HA7 4LP, Middx, England.
   [Blunn, G.] Univ Coll London, John Scales Ctr Biomed Engn, Inst Orthopaed & Musculoskeletal Sci, Div Surg & Intervent Sci,Bioengn, Stanmore HA7 4LP, Middx, England.
   [Kalia, P.; Di Silvio, L.; Idowu, B.] Guys Hosp, Dept Tissue Engn & Biophoton, London SE1 9RT, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; Guy's & St Thomas' NHS Foundation Trust
RP Sanghani Kerai, A (通讯作者)，Univ Coll London, Stanmore HA7 4LP, Middx, England.
EM a.sanghani.12@ucl.ac.uk
OI Idowu, Bernadine/0000 0002 5491 9413; Blunn, Gordon/0000 0003 2141 7385
CR Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Batouli S, 2003, J DENT RES, V82, P976, DOI 10.1177/154405910308201208
   Bhukhai K, 2012, J BIOL CHEM, V287, P36168, DOI 10.1074/jbc.M112.344747
   Cho SW, 2009, MOL THER, V17, P1979, DOI 10.1038/mt.2009.153
   Dar A, 2006, EXP HEMATOL, V34, P967, DOI 10.1016/j.exphem.2006.04.002
   Fan JZ, 2014, MOL CELL BIOCHEM, V392, P85, DOI 10.1007/s11010 014 2021 7
   Haasters F, 2014, BIOCHEM BIOPH RES CO, V452, P118, DOI 10.1016/j.bbrc.2014.08.055
   Ho CY, 2015, TISSUE ENG PT A, V21, P594, DOI [10.1089/ten.tea.2013.0762, 10.1089/ten.TEA.2013.0762]
   Hong L, 2006, TISSUE ENG, V12, P2747, DOI 10.1089/ten.2006.12.2747
   Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102
   Isaacs JD, 2010, CLIN ORTHOP RELAT R, V468, P3384, DOI 10.1007/s11999 010 1535 x
   Ito H, 2011, MOD RHEUMATOL, V21, P113, DOI 10.1007/s10165 010 0357 8
   Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22 3 415
   Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Liang X, 2010, INT J RADIAT BIOL, V86, P230, DOI 10.3109/09553000903422555
   Liang Y, 2005, BLOOD, V106, P1479, DOI 10.1182/blood 2004 11 4282
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Liu C, 2013, INT J MED SCI, V10, P1181, DOI 10.7150/ijms.6657
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Mannello F, 2006, STEM CELLS, V24, P475, DOI 10.1634/stemcells.2005 0333
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Shao HW, 2011, J CELL MOL MED, V15, P2046, DOI 10.1111/j.1582 4934.2010.01231.x
   Shyu WC, 2006, FRONT BIOSCI LANDMRK, V11, P899, DOI 10.2741/1846
   Stich S, 2009, CELL TISSUE RES, V336, P225, DOI 10.1007/s00441 009 0768 z
   Ugarte F, 2009, EXP HEMATOL, V37, P867, DOI 10.1016/j.exphem.2009.03.007
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood 2004 02 0526
NR 31
TC 35
Z9 39
U1 1
U2 12
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD JUN
PY 2017
VL 6
IS 6
BP 358
EP 365
DI 10.1302/2046 3758.66.BJR 2016 0259.R1
PG 8
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA EY8RX
UT WOS:000404265300001
PM 28576885
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Kang, WS
   Nguyen, K
   McKenna, CE
   Sewell, WF
   McKenna, MJ
   Jung, DH
AF Kang, Woo Seok
   Nguyen, Kim
   McKenna, Charles E.
   Sewell, William F.
   McKenna, Michael J.
   Jung, David H.
TI Measurement of Ototoxicity Following Intracochlear Bisphosphonate
   Delivery
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Bisphosphonates; Fluorescence imaging; Inner ear drug delivery;
   Otosclerosis; Ototoxicity
ID DRUG DELIVERY; GUINEA PIGS; OTOSCLEROSIS; BONE; MECHANISMS; PERILYMPH;
   COCHLEA
AB Hypothesis: Assessing the maximum safe dose for local bisphosphonate delivery to the cochlea enables efficient delivery without ototoxicity.
   Background: Otosclerosis is a disease of abnormal bone metabolism affecting the otic capsule, which can cause conductive hearing loss. Larger otosclerotic lesions involving the cochlear endosteum and spiral ligament can result in sensorineural hearing loss. Bisphosphonates are used to treat patients with metabolic bone diseases, including otosclerosis. Local delivery is the most efficient way of delivery to the cochlea while avoiding systemic side effects. To attain intracochlear bisphosphonate delivery without ototoxicity, the maximum safe dose of bisphosphonates requires definition. In the present study, we tested increasing concentrations of zoledronate, a third generation bisphosphonate in an intracochlear delivery system. We measured ototoxicity by monitoring distortion product otoacoustic emissions and compound action potentials.
   Methods: Artificial perilymph and increasing molar concentrations of zoledronate were administered to the cochlea in guinea pigs via a cochleostomy. Hearing was measured at multiple time points. A fluorescently labeled zoledronate derivative (6 FAM ZOL) was coadministered as an internal control for drug delivery. Specimens embedded in the resin blocks were ground to a mid modiolar section and fluorescent photomicrographs were taken.
   Results: No significant shift in hearing was observed in animals treated either with artificial perilymph or with 4% of the human systemic zoledronate dose. However, compound action potentials thresholds increased during infusion of 8% of the human systemic zoledronate dose, improved 4 hours later, and then increased again 4 weeks later. Using fluorescent photomicrography, intracochlear bisphosphonate delivery up to the apical cochlear turn was confirmed by visualizing 6 FAM ZOL.
   Conclusion: These findings provide reference values for intracochlear bisphosphonate delivery in the treatment of cochlear otosclerosis and describe a useful method for tracking cochlear drug delivery.
C1 [Kang, Woo Seok] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea.
   [Kang, Woo Seok; McKenna, Michael J.; Jung, David H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
   [Kang, Woo Seok; Sewell, William F.; McKenna, Michael J.; Jung, David H.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
   [Kang, Woo Seok; Sewell, William F.; McKenna, Michael J.; Jung, David H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
   [Nguyen, Kim; McKenna, Charles E.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA.
C3 University of Ulsan; Asan Medical Center; Harvard University; Harvard
   University Medical Affiliates; Massachusetts Eye & Ear Infirmary;
   Harvard University; Harvard University Medical Affiliates; Massachusetts
   Eye & Ear Infirmary; Harvard University; Harvard Medical School;
   University of Southern California
RP Jung, DH (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM david_jung@meei.harvard.edu
RI Nguyen, Kim/JWP 3649 2024
FU NIDCD [R01 DC009837]
FX This work was primarily supported by NIDCD grant R01 DC009837.
CR Blakley BW, 2008, J OTOLARYNGOL HEAD N, V37, P700, DOI 10.2310/7070.2008.070174
   Ceriani F, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478 811X 10 20
   Doherty JK, 2004, OTOL NEUROTOL, V25, P457, DOI 10.1097/00129492 200407000 00010
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Hahn H, 2012, OTOL NEUROTOL, V33, P660, DOI 10.1097/MAO.0b013e318254501b
   HAN DY, 1994, ORL J OTO RHINO LARY, V56, P125, DOI 10.1159/000276626
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Kang WS, 2016, OTOL NEUROTOL, V37, P218, DOI 10.1097/MAO.0000000000000964
   Kang WS, 2015, OTOL NEUROTOL, V36, P953, DOI 10.1097/MAO.0000000000000786
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   McWilliams ML, 2000, TOXICOL SCI, V56, P124, DOI 10.1093/toxsci/56.1.124
   Mikulec AA, 2009, OTOL NEUROTOL, V30, P131, DOI 10.1097/MAO.0b013e318191bff8
   Poirrier AL, 2010, TOXICOL LETT, V193, P41, DOI 10.1016/j.toxlet.2009.12.003
   Quesnel AM, 2012, OTOL NEUROTOL, V33, P1308, DOI 10.1097/MAO.0b013e318268d1b3
   Rama López J, 2006, OTOL NEUROTOL, V27, P153, DOI 10.1097/01.mao.0000197387.29534.26
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sockalingam R, 2000, AM J OTOL, V21, P521
   Sun ST, 2011, PHOSPHORUS SULFUR, V186, P970, DOI 10.1080/10426507.2010.526674
   US Food and Drug Administration, FULL PRESCR INF RECL
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
NR 21
TC 5
Z9 6
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1531 7129
EI 1537 4505
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD JUL
PY 2016
VL 37
IS 6
BP 621
EP 626
PG 6
WC Clinical Neurology; Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Otorhinolaryngology
GA DO8VX
UT WOS:000378064500006
PM 27153329
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ming, LG
   Zhou, J
   Cheng, GZ
   Ma, HP
   Chen, KM
AF Ming, Lei Guo
   Zhou, Jian
   Cheng, Guo Zheng
   Ma, Hui Ping
   Chen, Ke Ming
TI Osthol, a Coumarin Isolated from Common Cnidium Fruit, Enhances the
   Differentiation and Maturation of Osteoblasts in vitro
SO PHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Osthol; Cell proliferation; Cell differentiation; Bone
   mineralization; Osteoblasts
ID BONE MORPHOGENETIC PROTEIN 2; GENE EXPRESSION; GROWTH; OSTEOPOROSIS;
   PHENOTYPE; RUNX2
AB The effect of osthol on osteoblasts was investigated in primary osteoblastic cells isolated from newborn Wistar rats. Osthol was supplemented into cultured medium at 10( 7), 10( 6), 10( 5) and 10( 4) mol/l, respectively. No stimulating effect was found on cell proliferation, but 10( 5) mol/l osthol caused a significant increase in alkaline phosphatase (ALP) activity. Osteogenic differentiation markers were examined over a period of time at this concentration, and compared with control cells that were not supplemented with osthol. The results showed that the ALP activity, osteocalcin secretion and calcium deposition level in cells treated with osthol were 1.52, 2.74 and 2.0 times higher, respectively, than in the control cells. Results of ALP histochemical staining and mineralized bone nodule assays both showed that the number and area achieved in osthol treated cells were 1.53 fold higher than in control cells. The gene expression of the growth and transcription factors basic fibroblast growth factor, insulin like growth factor I, bone morphogenetic protein 2 (BMP 2), runt related gene 2 (Runx 2) and osterix, which are associated with bone development, were also investigated. The increase in mRNA expression was 1.94, 1.74, 1.68, 1.83 and 2.31 times, respectively, higher compared to the control. Furthermore, osthol increased the protein expression of p38 mitogen activated protein kinase (MAPK) and type I collagen. p38MAPK protein and collagen in osthol treated cells were 1.42 and 1.58 times higher in osthol treated cells compared to the control. The results of these studies support the conclusion that osthol significantly enhances the osteogenic differentiation of cultured osteoblasts. The results also indicated that osthol could stimulate the osteoblastic differentiation of rat calvarial osteoblast cultures by the BMP 2/p38MAPK/Runx 2/osterix pathway and that osthol may be used as an important compound in the development of new antiosteoporosis drugs. Copyright (C) 2011 S. Karger AG, Basel
C1 [Ming, Lei Guo; Zhou, Jian; Cheng, Guo Zheng; Chen, Ke Ming] Lanzhou Command CPLA, Lanzhou Gen Hosp, Inst Orthopaed, Lanzhou 730050, Peoples R China.
   [Ma, Hui Ping] Lanzhou Command CPLA, Lanzhou Gen Hosp, Dept Pharm, Lanzhou 730050, Peoples R China.
RP Chen, KM (通讯作者)，Lanzhou Command CPLA, Lanzhou Gen Hosp, Inst Orthopaed, Lanzhou 730050, Peoples R China.
EM chkeming@yahoo.com.cn
FU Gansu Provincial Science and Technology Department, People's Republic of
   China [092NKDA025]
FX This project was supported by grant 092NKDA025 from Gansu Provincial
   Science and Technology Department, People's Republic of China.
CR Adachi JD, 2003, OSTEOPOROSIS INT, V14, P895, DOI 10.1007/s00198 003 1483 3
   Boyle P, 2001, J Epidemiol Biostat, V6, P185, DOI 10.1080/135952201753172944
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen KM, 2005, PHARMAZIE, V60, P939
   Chen KM, 2004, PHARMAZIE, V59, P61
   CHRISTIANSEN C, 1991, AM J MED, V90, P107
   Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065 6995(03)00018 0
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Effenberger KE, 2005, J STEROID BIOCHEM, V96, P387, DOI 10.1016/j.jsbmb.2005.04.038
   Fisher MC, 2005, BONE, V37, P741, DOI 10.1016/j.bone.2005.07.024
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Hassel S, 2003, J BONE JOINT SURG AM, V85A, P44, DOI 10.2106/00004623 200300003 00009
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Hümpel M, 2005, J STEROID BIOCHEM, V97, P299, DOI 10.1016/j.jsbmb.2005.05.009
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   KURZER MS, 1999, ANNU REV NUTR, V17, P358
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Mahavni V, 2001, CURR OPIN ONCOL, V13, P384, DOI 10.1097/00001622 200109000 00012
   Melton LJ III, 1997, SPINE, V22, p2S, DOI 10.1097/00007632 199712151 00002
   MICHITAKA N, 2004, BIOCHEM BIOPH RES CO, V324, P655
   Milligan S, 2002, REPRODUCTION, V123, P235, DOI 10.1530/rep.0.1230235
   Mundy GR, 1996, CLIN ORTHOP RELAT R, P24, DOI 10.1097/00003086 199603000 00004
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960 0760(00)00113 8
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Stabnov L, 2002, BONE, V30, P909, DOI 10.1016/S8756 3282(02)00738 X
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wada Y, 1998, BONE, V22, P479, DOI 10.1016/S8756 3282(98)00039 8
   *WHO, 1994, TECHN REP SER WHO
NR 33
TC 54
Z9 69
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0031 7012
EI 1423 0313
J9 PHARMACOLOGY
JI Pharmacology
PY 2011
VL 88
IS 1 2
BP 33
EP 43
DI 10.1159/000328776
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 811NW
UT WOS:000294219200005
PM 21734431
DA 2025 08 17
ER

PT J
AU Hu, FL
   Liu, HJ
   Liu, X
   Zhang, X
   Xu, LL
   Zhu, HQ
   Li, YN
   Shi, LJ
   Ren, LM
   Zhang, J
   Li, ZG
   Jia, Y
AF Hu, Fanlei
   Liu, Hongjiang
   Liu, Xu
   Zhang, Xia
   Xu, Liling
   Zhu, Huaqun
   Li, Yingni
   Shi, Lianjie
   Ren, Limin
   Zhang, Jian
   Li, Zhanguo
   Jia, Yuan
TI Pathogenic conversion of regulatory B10 cells into osteoclast priming
   cells in rheumatoid arthritis
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Rheumatoid arthritis; Regulatory B10 cells; Osteoclasts; RANKL
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; DIFFERENTIATION FACTOR; SUBSET;
   RANKL; EXPRESSION; CYTOKINE; HYPOXIA; EROSION
AB Regulatory B10 cells were functionally impaired in rheumatoid arthritis (RA), yet the mechanisms were unclear. B cells are recently recognized as important participants in osteoclastogenesis by producing RANKL. In this study, we investigated whether regulatory B10 cells could convert into RANKL producing cells, thus impairing their immunosuppressive functions in RA and exacerbating the disease progression. Our results showed that human regulatory B10 cells could ectopically express RANKL. Under RA circumstance, RANKL producing B10 cells expanded dramatically, partially induced by TNF a. The frequencies of these cells were positively correlated with RA patient disease activities and tender joint counts, but negatively correlated with the frequencies of regulatory B10 cells. Strikingly, RANKLproducing B10 cells from RA patients, but not healthy individuals significantly promoted osteoclast differentiation and bone erosion in a paracrine and cell cell contact dependent manner. Moreover, these pathogenic RANKL producing B10 cells declined while regulatory IL 10 producing B10 cells increased in RA patients with disease remission after therapy. Collectively, these results showed that in RA, regulatory B10 cells demonstrated the potential of converting into RANKL producing cells, thus exacerbating osteoclast formation, bone destruction and disease progression. Modulating the status of B10 cells might provide novel therapeutic strategies for RA. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Hu, Fanlei; Liu, Xu; Zhang, Xia; Xu, Liling; Zhu, Huaqun; Li, Yingni; Ren, Limin; Zhang, Jian; Li, Zhanguo; Jia, Yuan] Peking Univ, Peoples Hosp, Beijing Key Lab Rheumatism Mech & Immune Diag BZ0, Dept Rheumatol & Immunol, Beijing, Peoples R China.
   [Liu, Hongjiang] China Three Gorges Univ, Dept Rheumatol & Immunol, Peoples Hosp Yichang 1, Yichang, Peoples R China.
   [Shi, Lianjie] Peking Univ, Int Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China.
C3 Peking University; China Three Gorges University; Peking University
RP Li, ZG; Jia, Y (通讯作者)，Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM li99@bjmu.edu.cn; jiayuan1023@sina.com
RI Li, Li/T 4353 2017; Li, Feifei/JTT 8011 2023
FU Natural Science Foundation of China [81671604, 81302554, 31530020,
   31470039, 81401341, 81501396]; Asia Pacific League of Associations for
   Rheumatology [2013 Q 04]
FX This work was supported by grants from the Natural Science Foundation of
   China (81671604 and 81302554 to Dr. F. Hu, 31530020 to Dr. Z. Li,
   31470039 to Dr. X. Liu, 81401341 to Dr. Y. Li, and 81501396 to Dr. L
   Shi), and the Asia Pacific League of Associations for Rheumatology
   (2013 Q 04 to Dr. F. Hu).
CR Adlard NJ, 2014, ANN RHEUM DIS, V73, pA28, DOI 10.1136/annrheumdis 2013 205124.65
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Audo R, 2014, ARTHRITIS RHEUMATOL, V66, pS168, DOI 10.1002/art.38666
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Carter NA, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3736
   Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868
   Han XZ, 2006, J IMMUNOL, V176, P625, DOI 10.4049/jimmunol.176.1.625
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Hu FL, 2016, EUR J IMMUNOL, V46, P742, DOI 10.1002/eji.201545784
   Hu FL, 2014, ANN RHEUM DIS, V73, P928, DOI 10.1136/annrheumdis 2012 202444
   Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood 2010 07 294249
   Jin L, 2013, INT J RHEUM DIS, V16, P698, DOI 10.1111/1756 185X.12229
   Keystone E, 2009, ANN RHEUM DIS, V68, P216, DOI 10.1136/ard.2007.085787
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625
   MASUZAWA T, 1994, J CLIN INVEST, V94, P1090, DOI 10.1172/JCI117424
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Pugliese LS, 2012, IMMUNOBIOLOGY, V217, P336, DOI 10.1016/j.imbio.2011.07.014
   Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497
   Yang M, 2012, AM J PATHOL, V180, P2375, DOI 10.1016/j.ajpath.2012.03.010
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
   Zha BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049835
NR 29
TC 28
Z9 28
U1 0
U2 29
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896 8411
EI 1095 9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD JAN
PY 2017
VL 76
BP 53
EP 62
DI 10.1016/j.jaut.2016.09.002
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA EI7MT
UT WOS:000392682900005
PM 27640100
DA 2025 08 17
ER

PT J
AU Bambini, F
   Santarelli, A
   Putignano, A
   Procaccini, M
   Orsini, G
   Memé, L
   Sartini, D
   Emanuelli, M
   Lo Muzio, L
AF Bambini, F.
   Santarelli, A.
   Putignano, A.
   Procaccini, M.
   Orsini, G.
   Meme, L.
   Sartini, D.
   Emanuelli, M.
   Lo Muzio, L.
TI USE OF SUPERCHARGED COVER SCREW AS STATIC MAGNETIC FIELD GENERATOR FOR
   BONE HEALING, 1st PART: IN VITRO ENHANCEMENT OF OSTEOBLAST LIKE
   CELL DIFFERENTIATION
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE static magnetic fields; MG63; osseointegration; dental implant; cover
   screw; permanent magnets
ID PULSED ELECTROMAGNETIC FIELDS; STIMULATION
AB Since 1979, Pulsed electromagnetic fields (PEMFs) have been approved by the Food and Drug Administration as an effective method in the treatment of non unions. As well as PEMFs, also static magnetic fields (SMFs) have been widely investigated in orthopaedic studies. Even if the exact mechanism of action is not well understood, a large number of studies showed specific effects both at cellular and tissue levels. As bone fracture healing and osseointegration share the same biological events, the application of magnetic field stimulation in order to facilitate the osseointegration process has been suggested. In this study we investigated the proliferation rate and gene expression profile of MG63 osteoblastic like cells after a 24, 48 and 72  hour SMF stimulation, generated by a small, customized cover screw shaped neodymium iron bore magnet placed in the inner cavity of a dental implant. As a result, we found that the application of a SMF to osteoblastic like cells does slightly decrease cell proliferation rate while enhancing the expression of those genes correlated to differentiation and mineralization. Our findings represent, to our knowledge, the first clinical ready technique for dental implants showing the ability of SMF to promote the osteogenesis process in vitro.
C1 [Bambini, F.; Santarelli, A.; Putignano, A.; Procaccini, M.; Orsini, G.; Meme, L.; Sartini, D.; Emanuelli, M.] Marche Polytech Univ, Dept Clin Specialist & Stomatol Sci, Ancona, Italy.
   [Lo Muzio, L.] Foggia Univ, Dept Dept Clin & Expt Med, Foggia, Italy.
C3 Marche Polytechnic University; University of Foggia
RP Lo Muzio, L (通讯作者)，Clin Odontoiatr, Via Rovelli 50, I 71122 Foggia, Italy.
EM lorenzo.lomuzio@unifg.it
RI ; Muzio, Lorenzo/C 8533 2011; Meme', Lucia/HGC 8816 2022; Santarelli,
   Andrea/P 6310 2014; Orsini, Giovanna/B 5470 2016; MEME',
   LUCIA/HGC 8816 2022
OI SARTINI, Davide/0000 0003 3879 8647; PUTIGNANO,
   Angelo/0000 0001 6205 2613; Santarelli, Andrea/0000 0003 4218 3354;
   MEME', LUCIA/0000 0002 0441 3596
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000118698.46535.83
   Chiu KH, 2007, ANN BIOMED ENG, V35, P1932, DOI 10.1007/s10439 007 9370 2
   De Mattei M, 2005, BIOELECTROMAGNETICS, V26, P207, DOI 10.1002/bem.20068
   Fujii Y, 2003, FEBS LETT, V539, P45, DOI 10.1016/S0014 5793(03)00182 0
   Huang HM, 2006, CLIN ORTHOP RELAT R, P201, DOI 10.1097/01.blo.0000203464.35561.be
   Kim HJ, 2005, CLIN ORAL IMPLAN RES, V16, P557, DOI 10.1111/j.1600 0501.2005.01164.x
   Li JKJ, 2007, ELECTROMAGN BIOL MED, V26, P153, DOI 10.1080/15368370701572837
   MAMMI GI, 1993, CLIN ORTHOP RELAT R, P246
   Matsumoto H, 2000, CLIN ORAL IMPLAN RES, V11, P354, DOI 10.1034/j.1600 0501.2000.011004354.x
   SHIMIZU T, 1988, J ORTHOP RES, V6, P248, DOI 10.1002/jor.1100060212
   SOBALLE K, 1993, ACTA ORTHOP SCAND, V64, pR1
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zhang XJ, 2007, ELECTROMAGN BIOL MED, V26, P167, DOI 10.1080/15368370701580756
NR 13
TC 12
Z9 13
U1 0
U2 5
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD JAN MAR
PY 2017
VL 31
IS 1
BP 215
EP 220
PG 6
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA EW6MM
UT WOS:000402624700032
PM 28337895
DA 2025 08 17
ER

PT J
AU Xu, W
   Li, JL
   Li, L
   Hou, TH
   Cai, XP
   Liu, TL
   Yang, XH
   Wei, HF
   Jiang, C
   Xiao, JR
AF Xu, Wei
   Li, Jialin
   Li, Lei
   Hou, Tianhui
   Cai, Xiaopan
   Liu, Tielong
   Yang, Xinghai
   Wei, Haifeng
   Jiang, Cong
   Xiao, Jianru
TI FOXD3 Suppresses Tumor Initiating Features in Lung Cancer via
   Transcriptional Repression of WDR5
SO STEM CELLS
LA English
DT Article
DE Tumor initiating cells; FOXD3; WDR5; Lung cancer; Metastasis
ID STEM CELL; METASTASIS; MIGRATION; GROWTH; ANGIOGENESIS; PROGRESSION;
   CARCINOMA; INVASION
AB The tumor initiating cells (TICs) are a cell population that can initiate tumor occurrence, mediate drug resistance, and give rise to metastasis. FOXD3 is a forkhead box (Fox) transcription factor family that regulates the pluripotency of embryonic stem cell and tumorigenicity. However, it is unclear whether FOXD3 plays any role in TIC and tumor metastasis. The functional analysis of FOXD3 was performed by oncospheres formation and redifferentiation, drug resistance assay, and cell migration. Global genomic RNA Seq and ChIP Seq analysis were used to identify the direct target of FOXD3 in lung cancer. We demonstrated that downregulation of FOXD3 in TICs was positively correlated with higher histologic grades and positive lymph node metastasis. FOXD3 repressed TIC expansion and cell migration, drug resistance, and osteoclasts in vitro and in vivo. Mechanically, we found that FOXD3 represses WDR5, which regulates TIC related signaling pathway. Moreover, WDR5 were positively correlated with the TIC abundance and tumor progression. Besides, patients with high expression of WDR5 presented a poorer overall survival. FOXD3 may suppress TIC accumulation by repressing the expression of WDR5 in lung cancer.
C1 [Xu, Wei; Li, Jialin; Hou, Tianhui; Cai, Xiaopan; Liu, Tielong; Yang, Xinghai; Wei, Haifeng; Jiang, Cong; Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
   [Li, Lei] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China.
   [Li, Lei] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China.
   [Hou, Tianhui] East China Normal Univ, Sch Sports & Hlth, Shanghai, Peoples R China.
C3 Naval Medical University; East China Normal University; East China
   Normal University; East China Normal University
RP Jiang, C; Xiao, JR (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM wen125xiu@126.com; jianruxiao83@163.com
RI ; xin, baoquan/ISB 5957 2023; xu, wei/HHD 2891 2022
OI xiao, jianru/0000 0003 1547 851X; 
FU National Key Research and Development Project of China [2016YFC0902100];
   National Natural Science Foundation of China [81702888]; Shanghai
   Technology Innovation Action Plan [17411950300]; Shanghai Excellent
   Young Medical Talents Program [2018YQ56]; Shanghai Youth Doctor
   Assistance Program
FX We appreciate Prof. Ping Wang (Tongji University, Shanghai, People's
   Republic of China) for providing valuable suggestions for this study.
   This study was supported by the National Key Research and Development
   Project of China (2016YFC0902100), National Natural Science Foundation
   of China (81702888), Shanghai Technology Innovation Action Plan
   (17411950300), Shanghai Excellent Young Medical Talents Program
   (2018YQ56), and Shanghai Youth Doctor Assistance Program (W.X.).
CR Abel EV, 2010, CANCER RES, V70, P2891, DOI 10.1158/0008 5472.CAN 09 3139
   Ali SA, 2016, CANCER CELL, V29, P367, DOI 10.1016/j.ccell.2016.02.012
   Cai XP, 2015, ONCOTARGET, V6, P22905, DOI 10.18632/oncotarget.4416
   Cheng AS, 2013, GASTROENTEROLOGY, V144
   Cheng YY, 2017, ACTA POLYM SIN, P1234, DOI 10.11777/j.issn1000 3304.2017.17095
   Chu TL, 2014, BIOCHEM BIOPH RES CO, V446, P580, DOI 10.1016/j.bbrc.2014.03.019
   Chung CY, 2016, CELL REP, V16, P472, DOI 10.1016/j.celrep.2016.06.002
   Du W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127976
   Fairchild CL, 2014, MECH DEVELOP, V132, P1, DOI 10.1016/j.mod.2014.02.004
   Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672
   Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523
   Hassan KA, 2013, CLIN CANCER RES, V19, P1972, DOI 10.1158/1078 0432.CCR 12 0370
   He GY, 2015, EXP MOL PATHOL, V99, P374, DOI 10.1016/j.yexmp.2015.06.017
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Katiyar P, 2011, MOL CANCER RES, V9, P545, DOI 10.1158/1541 7786.MCR 10 0454
   Krishnakumar R, 2016, CELL STEM CELL, V18, P104, DOI 10.1016/j.stem.2015.10.003
   Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579
   Liu LL, 2014, ONCOTARGET, V5, P5113, DOI 10.18632/oncotarget.2089
   Morise M, 2015, J CANCER RES CLIN, V141, P2121, DOI 10.1007/s00432 015 1985 3
   Respuela P, 2016, CELL STEM CELL, V18, P118, DOI 10.1016/j.stem.2015.09.010
   Schmid CA, 2013, GASTROENTEROLOGY, V144, P22, DOI 10.1053/j.gastro.2012.11.014
   Schunter JA, 2015, J CLIN ENDOCR METAB, V100, pE1335, DOI 10.1210/jc.2015 2126
   Siegel RL., 2019, J Clin, V69, P7, DOI DOI 10.3322/CAAC.21772
   Su M, 2016, ONCOTARGET, V7, P19018, DOI 10.18632/oncotarget.7968
   Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008 5472.CAN 10 0881
   Thomas AJ, 2009, DEVELOPMENT, V136, P1849, DOI 10.1242/dev.031989
   Weiss MB, 2014, MOL CANCER RES, V12, P1314, DOI 10.1158/1541 7786.MCR 14 0170
   Yaklichkin S, 2007, J BIOL CHEM, V282, P2548, DOI 10.1074/jbc.M607412200
   Yan JH, 2015, BIOCHEM BIOPH RES CO, V466, P111, DOI 10.1016/j.bbrc.2015.08.116
   Zakaria N, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1086 3
   Zhu LL, 2014, EMBO REP, V15, P1286, DOI 10.15252/embr.201438643
NR 31
TC 14
Z9 17
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD MAY
PY 2019
VL 37
IS 5
BP 582
EP 592
DI 10.1002/stem.2984
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA HW8PP
UT WOS:000466952000006
PM 30703266
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhao, Y
   Lu, SM
   Zhong, B
   Wang, GC
   Jia, RP
   Wang, Q
   Long, JH
AF Zhao, Yan
   Lu, Sheng Ming
   Zhong, Bing
   Wang, Gong Cheng
   Jia, Rui Peng
   Wang, Qian
   Long, Jian Hua
TI Parathyroid hormone related protein (PTHrP) in tissues with poor
   prognosis in prostate cancer patients
SO MEDICINE
LA English
DT Article
DE e cadherin; immunohistochemical; parathyroid hormone related peptide;
   prostate cancer; PTHrP; survival analysis; vimentin
ID EPITHELIAL MESENCHYMAL TRANSITION; RENAL CELL CARCINOMA; PROMOTER
   METHYLATION; BONE METASTASIS; EXPRESSION; GROWTH; PROGRESSION;
   BIOMARKER; THERAPY; PEPTIDE
AB Background:Parathyroid hormone related peptide (PTHrP) is known to have a pivotal role in the progression of various solid tumors, among which prostate cancer stands out. However, the extent of PTHrP expression and its clinical implications in prostate cancer patients remain shrouded in obscurity. The primary objective of this research endeavor was to shed light on the relevance of PTHrP in the context of prostate cancer patients and to uncover the potential underlying mechanisms.Methods:The expression of PTHrP, E cadherin, and vimentin in tumor tissues of 88 prostate cancer patients was evaluated by immunohistochemical technique. Subsequently, the associations between PTHrP and clinicopathological parameters and prognosis of patients with prostate cancer were analyzed.Results:Immunohistochemical analysis showed that the expression rates of PTHrP, E cadherin, and vimentin in prostate cancer tissues were 95.5%, 88.6%, and 84.1%, respectively. Patients with a high level of PTHrP had a decreased expression of E cadherin (P = .013) and an increased expression of vimentin (P = .010) compared with patients with a low level of PTHrP. Besides, the high expression of PTHrP was significantly correlated with a higher level of initial prostate specific antigen (P = .026), positive lymph node metastasis (P = .010), osseous metastasis (P = .004), and Gleason score (P = .026). Moreover, patients with a high level of PTHrP had shorter progression free survival (P = .002) than patients with a low level of PTHrP.Conclusion:The present study indicates that PTHrP is associated with risk factors of poor outcomes in prostate cancer, while epithelial mesenchymal transition may be involved in this process.
C1 [Zhao, Yan; Wang, Qian] Jiangsu Univ, Xuzhou Canc Hosp, Dept Urol, Affiliated Hosp, Xuzhou 221000, Jiangsu, Peoples R China.
   [Zhao, Yan] Xuzhou New Hlth Geriatr Dis Hosp, Dept Urol, Xuzhou, Jiangsu, Peoples R China.
   [Zhao, Yan] Soochow Univ, Affiliated Hosp 1, Dept Urol, Suzhou, Jiangsu, Peoples R China.
   [Lu, Sheng Ming] Subei Peoples Hosp, Dept Urol, Yangzhou, Jiangsu, Peoples R China.
   [Zhong, Bing; Wang, Gong Cheng] Nanjing Med Univ, Peoples Hosp Huaian 1, Dept Urol, Huaian, Jiangsu, Peoples R China.
   [Jia, Rui Peng] Nanjing Med Univ, Nanjing Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China.
   [Long, Jian Hua] Univ South China, Affiliated Hosp 2, Dept Urol, Hengyang, Hunan, Peoples R China.
C3 Jiangsu University; Soochow University   China; Nanjing Medical
   University; Nanjing Medical University; University of South China
RP Wang, Q (通讯作者)，Jiangsu Univ, Xuzhou Canc Hosp, Dept Urol, Affiliated Hosp, Xuzhou 221000, Jiangsu, Peoples R China.
EM 529735655@qq.com; huanghuang8992@sina.com; 806118662@qq.com;
   601127797@qq.com; weitgbeif94@163.com; 529735655@qq.com;
   20224132064@stu.suda.edu.cn
RI yan, zhao/KBA 2157 2024
OI Zhao, Yan/0000 0001 9673 0494
FU National Natural Science Foundation of China [81673511]; Jiangsu Key
   Research and Development Plan [BE2017613]; Xuzhou City Health Commission
   Science and Technology Project [XWKYHT20230003]
FX This study received funding from the National Natural Science Foundation
   of China (Grant No. 81673511), the Jiangsu Key Research and Development
   Plan (Grant No. BE2017613), and the Xuzhou City Health Commission
   Science and Technology Project (XWKYHT20230003).
CR Bhatia V, 2009, MOL CANCER THER, V8, P1787, DOI 10.1158/1535 7163.MCT 09 0064
   Bryden AAG, 2002, BRIT J CANCER, V86, P322, DOI 10.1038/sj/bjc/6600115
   Chen JJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/901578
   Conant JL, 2011, J CLIN PATHOL, V64, P1088, DOI 10.1136/jclinpath 2011 200216
   Deftos LJ, 2005, BIOCHEM BIOPH RES CO, V327, P468, DOI 10.1016/j.bbrc.2004.11.162
   Dhanapala L, 2022, ANAL CHEM, DOI 10.1021/acs.analchem.2c02648
   Downs TM, 2011, CANCER LETT, V306, P52, DOI 10.1016/j.canlet.2011.02.027
   Filella X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111784
   Harada K, 2012, BJU INT, V110, pE1131, DOI 10.1111/j.1464 410X.2012.11297.x
   He SY, 2018, AM J PATHOL, V188, P1374, DOI 10.1016/j.ajpath.2018.03.003
   Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078 0432.CCR 07 1042
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Irshad S., 2013, Sci Transl Med, V5, p202ra
   Jones AL, 2021, ANAL CHEM, V93, P1059, DOI 10.1021/acs.analchem.0c04034
   Lee CRH, 2020, CELL BIOL TOXICOL, V36, P115, DOI 10.1007/s10565 019 09483 7
   Li JR, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10587
   Li JR, 2011, J CLIN INVEST, V121, P4655, DOI 10.1172/JCI46134
   Lin YL, 2017, MED SCI MONITOR, V23, P4895, DOI 10.12659/MSM.904366
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   Nguyen Nielsen M, 2016, SEMIN NUCL MED, V46, P484, DOI 10.1053/j.semnuclmed.2016.07.002
   Ongkeko WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085803
   Perera M, 2016, NAT REV UROL, V13, P641, DOI 10.1038/nrurol.2016.177
   Pitarresi JR, 2021, CANCER DISCOV, V11, P1774, DOI 10.1158/2159 8290.CD 20 1098
   Rabbani SA, 1999, INT J CANCER, V80, P257, DOI 10.1002/(SICI)1097 0215(19990118)80:2<257::AID IJC15>3.0.CO;2 3
   Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167 0115(02)00007 1
   Tsaur I, 2016, CENT EUR J UROL, V69, P247, DOI 10.5173/ceju.2016.820
   Wan XC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0308 0
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
   Zhang Y, 2014, BBA MOL BASIS DIS, V1842, P1350, DOI 10.1016/j.bbadis.2014.04.018
NR 29
TC 0
Z9 0
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR 26
PY 2024
VL 103
IS 17
AR e37934
DI 10.1097/MD.0000000000037934
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA OP9R6
UT WOS:001208602100075
PM 38669432
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kir, S
   White, JP
   Kleiner, S
   Kazak, L
   Cohen, P
   Baracos, VE
   Spiegelman, BM
AF Kir, Serkan
   White, James P.
   Kleiner, Sandra
   Kazak, Lawrence
   Cohen, Paul
   Baracos, Vickie E.
   Spiegelman, Bruce M.
TI Tumour derived PTH related protein triggers adipose tissue browning and
   cancer cachexia
SO NATURE
LA English
DT Article
ID HORMONE RELATED PROTEIN; SKELETAL MUSCLE; MONOCLONAL ANTIBODY;
   NUDE MICE; MECHANISMS; CELL; THERMOGENESIS; ACTIVATION; SURVIVAL
AB Cachexia is a wasting disorder of adipose and skeletal muscle tissues that leads to profound weight loss and frailty. About half of all cancer patients suffer from cachexia, which impairs quality of life, limits cancer therapy and decreases survival. One key characteristic of cachexia is higher resting energy expenditure levels than in healthy individuals, which has been linked to greater thermogenesis by brown fat(1 6). How tumours induce brown fat activity is unknown. Here, using a Lewis lung carcinoma model of cancer cachexia, we show that tumour derived parathyroid hormone related protein (PTHrP) has an important role in wasting, through driving the expression of genes involved in thermogenesis in adipose tissues. Neutralization of PTHrP in tumour bearing mice blocked adipose tissue browning and the loss of muscle mass and strength. Our results demonstrate that PTHrP mediates energy wasting in fat tissues and contributes to the broader aspects of cancer cachexia. Thus, neutralization of PTHrP might hold promise for ameliorating cancer cachexia and improving patient survival.
C1 [Kir, Serkan; White, James P.; Kleiner, Sandra; Kazak, Lawrence; Cohen, Paul; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   [Baracos, Vickie E.] Univ Alberta, Div Palliat Care Med, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard Medical School; University of Alberta
RP Spiegelman, BM (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
EM bruce_spiegelman@dfci.harvard.edu
RI KIR, SERKAN/IWU 5583 2023
OI Baracos, Vickie/0000 0002 9609 1001; KIR, SERKAN/0000 0001 8722 9913
FU American Cancer Society [PF 13 385 01 TBE]; National Institutes of
   Health [DK31405]
FX We thank M. Mourtzakis and C. Prado for their help with the human study.
   S. Kir is a Robert Black Fellow of the Damon Runyon Cancer Research
   Foundation (DRG 2153 13), and J.P.W. is supported by a postdoctoral
   fellowship from the American Cancer Society (PF 13 385 01 TBE). This
   work was supported by National Institutes of Health grant DK31405 to
   B.M.S.
CR BIANCHI A, 1989, HORM METAB RES, V21, P640, DOI 10.1055/s 2007 1009308
   Bing C, 2000, CANCER RES, V60, P2405
   BROOKS SL, 1981, BIOSCIENCE REP, V1, P509, DOI 10.1007/BF01121584
   Cohen P, 2014, CELL, V156, P304, DOI 10.1016/j.cell.2013.12.021
   Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973
   Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209
   Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011
   Iguchi H, 2006, J BONE MINER METAB, V24, P16, DOI 10.1007/s00774 005 0640 5
   Iguchi H, 2001, INT J CANCER, V94, P24, DOI 10.1002/ijc.1425
   Lieffers JR, 2009, AM J CLIN NUTR, V89, P1173, DOI 10.3945/ajcn.2008.27273
   Mourtzakis M, 2008, APPL PHYSIOL NUTR ME, V33, P997, DOI 10.1139/H08 075
   Mundy GR, 2008, J AM SOC NEPHROL, V19, P672, DOI 10.1681/ASN.2007090981
   OVESEN L, 1993, J CLIN ONCOL, V11, P2043, DOI 10.1200/JCO.1993.11.10.2043
   Penna F, 2010, EXPERT OPIN BIOL TH, V10, P1241, DOI 10.1517/14712598.2010.503773
   Prado Carla M M, 2012, Can J Diet Pract Res, V73, pe298, DOI 10.3148/73.4.2012.e298
   Roe S, 1996, METABOLISM, V45, P645, DOI 10.1016/S0026 0495(96)90037 2
   Ruas JL, 2012, CELL, V151, P1319, DOI 10.1016/j.cell.2012.10.050
   SATO K, 1993, J BONE MINER RES, V8, P849
   SHELLOCK FG, 1986, J CANCER RES CLIN, V111, P82, DOI 10.1007/BF00402783
   Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008
   Tsoli M, 2012, CANCER RES, V72, P4372, DOI 10.1158/0008 5472.CAN 11 3536
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   White JP, 2013, MOL CELL ENDOCRINOL, V365, P174, DOI 10.1016/j.mce.2012.10.019
   Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016
NR 24
TC 507
Z9 552
U1 5
U2 106
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD SEP 4
PY 2014
VL 513
IS 7516
BP 100
EP +
DI 10.1038/nature13528
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AO2SD
UT WOS:000341174800038
PM 25043053
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, JB
   Li, HX
   Bi, SQ
   Sun, Y
   Gu, F
   Yu, TC
AF Li, Jiangbi
   Li, Haixia
   Bi, Songqi
   Sun, Yang
   Gu, Feng
   Yu, Tiecheng
TI Shock wave assisted intracellular delivery of antibiotics against bone
   infection with Staphylococcus aureus via P2X7 receptors
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Chronic osteomyelitis; Shock wave; Cell membrane permeability;
   Osteoblasts
ID CHRONIC OSTEOMYELITIS; STEM CELLS; IN VITRO; EXPRESSION; IMPLANTS;
   THERAPY; RELEASE; MODEL
AB Background: Treatment of chronic osteomyelitis (bone infection) remains a clinical challenge; in particular, it requires enhanced delivery of antibiotic drugs for the treatment of intracellular Staphylococcus aureus (S. aureus), which prevents infection recurrence and resistance. Previous studies have found that noninvasive shock waves used to treat musculoskeletal diseases can alter cell permeability, however, it is unclear whether shock waves alter cell membrane permeability in chronic osteomyelitis. Furthermore, it remains unknown whether such changes in permeability promote the entry of antibiotics into osteoblasts to exert antibacterial effects. Methods: In our study, trypan blue staining was used to determine the shock wave parameters that had no obvious damage to the osteoblast model; the effect of shocks waves on the cell membrane permeability of osteoblast model was detected by BODIPY (R) FL vancomycin; high performance liquid chromatography mass spectrometry (HLPC MS) was used to detect the effect of shock wave on the entry of antibiotics into the osteoblast model; plate colony counting method was used to detect the clearance effect of shock wave assisted antibiotics on S. aureus in the osteoblast model. To explore the mechanism, the effect of different pulses of shock waves on S. aureus was examined by plate colony counting method, besides, P2X7 receptor in osteoblast was detected by immunofluorescence and the extracellular ATP levels was detected. Furthermore, the effect of P2X7 receptor antagonists KN  62 or A740003 on the intracellular antibacterial activity of shock assisted antibiotics was observed. Then, we used S. aureus to establish a rat model of chronic tibial osteomyelitis and investigated the efficacy and safety of shock wave assisted antibiotics in the treatment of chronic osteomyelitis in rats. Results: The viability of the osteoblast models of intracellular S. aureus infection was not significantly affected by the application of up to 400 shock wave pulses at 0.21 mJ/mm2. Surprisingly, the delivery of BODIPY (R) FL vancomycin to osteoblast model cells was markedly enhanced by this shock wave treatment. Furthermore, the shock wave therapy increased the delivery of hydrophilic antibiotics (vancomycin and cefuroxime sodium), but not lipophilic antibiotics (rifampicin and levofloxacin), which improved the intracellular antibacterial effect. Afterwards, we discovered that shock wave treatment increased the extracellular concentration of ATP (the P2X7 receptor activator), while KN  62 or A740003, a P2X7 receptor inhibitor, decreased intracellular antibacterial activity. We then found that 0.1 mL of 1 x 1011 CFU/mL ATCC25923 S. aureus was suitable for modeling chronic osteomyelitis in rats. Besides, the shock wave assisted vancomycin treatment with the strongest antibacterial and osteogenic effects among the tested treatments was confirmed in vivo by imaging examination, microbiological cultures, and histopathology, with favorable safety. Conclusions: Our results suggest that shock waves can promote the entry of antibiotics into osteoblasts for antibacteria by changing the cell membrane permeability in a P2X7 receptor  dependent manner. Besides, considering antibacterial and osteogenic efficiency and a high degree of safety in rat osteomyelitis model, shock wave  assisted vancomycin treatment may thus represent a possible adjuvant therapy for chronic osteomyelitis.
C1 [Li, Jiangbi; Bi, Songqi; Sun, Yang; Yu, Tiecheng] First Hosp Jilin Univ, Orthopaed Ctr, Dept Orthoped, Changchun, Jilin, Peoples R China.
   [Li, Jiangbi] Kunming Med Univ, Yunnan Canc Hosp, Dept Orthopaed, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China.
   [Li, Haixia] Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Dept Neurol, Kunming, Yunnan, Peoples R China.
   [Gu, Feng] Second Hosp Jilin Univ, Dept Orthoped, Changchun, Jilin, Peoples R China.
   [Yu, Tiecheng] 1 Xinmin St, Changchun, Jilin, Peoples R China.
C3 Jilin University; Kunming Medical University; Kunming University of
   Science & Technology; Jilin University
RP Yu, TC (通讯作者)，First Hosp Jilin Univ, Orthopaed Ctr, Dept Orthoped, Changchun, Jilin, Peoples R China.
EM lijb312@163.com; haixiali6677@163.com; bisq7018@163.com;
   sunyang.rocket@outlook.com; gufengjlu@163.com; yutc@jlu.edu.cn
OI Sun, Yang/0009 0007 6297 9831; Gu, Feng/0000 0001 6638 6565
FU National Natural Science Founda  tion of China [31970090]
FX This study was supported by the National Natural Science Founda  tion of
   China (Grant No. 31970090) .
CR Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001
   Al Nawas B, 1998, INFECTION, V26, P165, DOI 10.1007/BF02771843
   Alexander EH, 2001, INFECT IMMUN, V69, P1581, DOI 10.1128/IAI.69.3.1581 1586.2001
   Carryn S, 2003, INFECT DIS CLIN N AM, V17, P615, DOI 10.1016/S0891 5520(03)00066 7
   CHAUSSY C, 1980, LANCET, V2, P1265
   Cheng JH, 2015, INT J SURG, V24, P143, DOI 10.1016/j.ijsu.2015.06.059
   d'Agostino MC, 2015, INT J SURG, V24, P147, DOI 10.1016/j.ijsu.2015.11.030
   Fraunholz M, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00043
   GAMBIHLER S, 1992, BRIT J CANCER, V66, P69, DOI 10.1038/bjc.1992.218
   Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   Hamza T, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866 014 0207 5
   Josse J, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00085
   Kaur S, 2014, APPL MICROBIOL BIOT, V98, P4653, DOI 10.1007/s00253 014 5643 5
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006 3495(00)76432 0
   Kremers HM, 2015, J BONE JOINT SURG AM, V97A, P837, DOI 10.2106/JBJS.N.01350
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Li JH, 2017, ACS APPL MATER INTER, V9, P27475, DOI 10.1021/acsami.7b06867
   Li Y, 2016, BIOMATERIALS, V106, P250, DOI 10.1016/j.biomaterials.2016.08.031
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579 022 00686 0
   Moya D, 2018, J BONE JOINT SURG AM, V100, P251, DOI 10.2106/JBJS.17.00661
   Noore J, 2013, ANTIMICROB AGENTS CH, V57, P1283, DOI 10.1128/AAC.01650 12
   North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   PETTY W, 1985, J BONE JOINT SURG AM, V67A, P1236, DOI 10.2106/00004623 198567080 00015
   PRAT F, 1994, GASTROENTEROLOGY, V106, P937, DOI 10.1016/0016 5085(94)90752 8
   Pumerantz A, 2011, INT J ANTIMICROB AG, V37, P140, DOI 10.1016/j.ijantimicag.2010.10.011
   Ren WJ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010232
   RENARD C, 1987, ANTIMICROB AGENTS CH, V31, P410, DOI 10.1128/AAC.31.3.410
   RISSING JP, 1985, INFECT IMMUN, V47, P581, DOI 10.1128/IAI.47.3.581 586.1985
   Schroeder AN, 2021, CURR SPORT MED REP, V20, P298, DOI 10.1249/JSR.0000000000000851
   Smeltzer MS, 1997, J ORTHOPAED RES, V15, P414, DOI 10.1002/jor.1100150314
   Spellberg B, 2012, CLIN INFECT DIS, V54, P393, DOI 10.1093/cid/cir842
   Sun DH, 2013, STEM CELLS, V31, P1170, DOI 10.1002/stem.1356
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Tschoep K, 2001, J MOL MED JMM, V79, P306, DOI 10.1007/s001090100204
   Tuchscherr L, 2011, EMBO MOL MED, V3, P129, DOI 10.1002/emmm.201000115
   Türk C, 2016, EUR UROL, V69, P475, DOI 10.1016/j.eururo.2015.07.041
   TULKENS PM, 1991, EUR J CLIN MICROBIOL, V10, P100, DOI 10.1007/BF01964420
   Valour F, 2015, ANTIMICROB AGENTS CH, V59, P2029, DOI 10.1128/AAC.04359 14
   Xu XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1253 y
   Yu Y, 2021, ACS NANO, V15, P10628, DOI 10.1021/acsnano.1c03424
   Zhang YC, 2019, INT J CANCER, V145, P1068, DOI 10.1002/ijc.32207
   Zhou KX, 2018, INT J NANOMED, V13, P7333, DOI 10.2147/IJN.S169935
   Zhou SY, 2020, EUR J MED CHEM, V197, DOI 10.1016/j.ejmech.2020.112313
NR 46
TC 4
Z9 4
U1 2
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD MAR
PY 2024
VL 45
BP 10
EP 23
DI 10.1016/j.jot.2023.10.006
EA FEB 2024
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA NG3W8
UT WOS:001199270600001
PM 38434180
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Aziz, SGG
   Fathi, E
   Rahmati Yamchi, M
   Akbarzadeh, A
   Fardyazar, Z
   Pashaiasl, M
AF Aziz, Shiva Gholizadeh Ghaleh
   Fathi, Ezzatollah
   Rahmati Yamchi, Mohammad
   Akbarzadeh, Abolfazl
   Fardyazar, Zahra
   Pashaiasl, Maryam
TI An update clinical application of amniotic fluid derived stem cells
   (AFSCs) in cancer cell therapy and tissue engineering
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Human amniotic fluid stem (hAFS) cells; cell based therapies; cancer
   cells targeting; cancer therapy
ID EXPRESSING CYTOSINE DEAMINASE; MESENCHYMAL STROMAL CELLS; BONE MARROW;
   REGENERATIVE MEDICINE; ADIPOSE TISSUE; IN VITRO; FETAL; DIFFERENTIATION;
   TRANSPLANTATION; MEMBRANE
AB Recent studies have elucidated that cell based therapies are promising for cancer treatments. The human amniotic fluid stem (AFS) cells are advantageous cells for such therapeutic schemes that can be innately changed to express therapeutic proteins. HAFSCs display a natural tropism to cancer cells in vivo. They can be useful in cancer cells targeting. Moreover, they are easily available from surplus diagnostic samples during pregnancy and less ethical and legal concern are associated with the collection and application than other putative cells are subjected. This review will designate representatives of amniotic fluid and stem cell derived from amniotic fluid. For this propose, we collect state of human AFS cells data applicable in cancer therapy by dividing this approach into two main classes (nonengineered and engineered based approaches). Our study shows the advantage of AFS cells over other putative cells types in terms differentiation ability to a wide range of cells by potential and effective use in preclinical studies for a variety of diseases. This study has shown the elasticity of human AFS cells and their favorable potential as a multipotent cell source for regenerative stem cell therapy and capable of giving rise to multiple lineages including such as osteoblasts and adipocyte.
C1 [Aziz, Shiva Gholizadeh Ghaleh; Fardyazar, Zahra; Pashaiasl, Maryam] Tabriz Univ Med Sci, Womens Reprod Hlth Res Ctr, Tabriz, Iran.
   [Aziz, Shiva Gholizadeh Ghaleh; Fardyazar, Zahra] Tabriz Univ Med Sci, Sch Adv Med Sci, Dept Mol Med, Tabriz, Iran.
   [Aziz, Shiva Gholizadeh Ghaleh] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Fathi, Ezzatollah] Univ Tabriz, Dept Clin Sci, Fac Vet Med, Tabriz, Iran.
   [Rahmati Yamchi, Mohammad] Tabriz Univ Med Sci, Dept Clin Biochem, Tabriz, Iran.
   [Akbarzadeh, Abolfazl; Pashaiasl, Maryam] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Pashaiasl, Maryam] Tabriz Univ Med Sci, Fac Med, Dept Anat Sci, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; University of Tabriz;
   Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science
RP Pashaiasl, M (通讯作者)，Tabriz Univ Med Sci, Fac Med, Dept Anat Sci, Tabriz, Iran.
EM pashaim@tbzmed.ac.ir
RI Fardiazar, Zahra/M 5603 2017; Gholizadeh Ghaleh Aziz, Shiva/G 8254 2017;
   Fathi, Ezzatollah/H 1923 2017; pashaiasl, maryam/M 4676 2017; Pashaiasl,
   Maryam/M 4676 2017
OI Gholizadeh Ghaleh Aziz, Shiva/0000 0003 1949 4381; Fathi,
   Ezzatollah/0000 0003 0806 2735; Pashaiasl, Maryam/0000 0002 4490 6627
FU Department of Molecular Medicine, Faculty of Advanced Medical Sciences,
   Tabriz University of Medical Science; Women's Reproductive Health
   Research Center Al Zahra Hospital, Tabriz University of Medical Sciences
   [93/4 10/2]
FX The authors thank the Department of Molecular Medicine, Faculty of
   Advanced Medical Sciences, Tabriz University of Medical Science and
   Women's Reproductive Health Research Center Al Zahra Hospital, Tabriz
   University of Medical Sciences for all support provided (Study ID:
   93/4 10/2).
CR Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370
   Anderson LM, 2000, CANCER GENE THER, V7, P845, DOI 10.1038/sj.cgt.7700191
   Bitsika V, 2012, STEM CELLS DEV, V21, P1097, DOI 10.1089/scd.2011.0151
   Bollini S, 2011, STEM CELLS DEV, V20, P1985, DOI 10.1089/scd.2010.0424
   Bollini S, 2011, STEM CELL REV REP, V7, P364, DOI 10.1007/s12015 010 9200 z
   Bossolasco P, 2006, CELL RES, V16, P329, DOI 10.1038/sj.cr.7310043
   BRACE RA, 1986, SEMIN PERINATOL, V10, P103
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473 3099(16)00095 5
   Carlsson PO, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892 015 0616 3
   Chiavegato A, 2007, J MOL CELL CARDIOL, V42, P746, DOI 10.1016/j.yjmcc.2006.12.008
   Chung SS, 2013, IN VITRO CELL DEV AN, V49, P746, DOI 10.1007/s11626 013 9662 9
   Cipriani S, 2007, CELL BIOL INT, V31, P845, DOI 10.1016/j.cellbi.2007.01.037
   Da Sacco S, 2010, J UROLOGY, V183, P1193, DOI 10.1016/j.juro.2009.11.006
   De Coppi P, 2007, J UROLOGY, V177, P369, DOI 10.1016/j.juro.2006.09.103
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Dobreva MP, 2010, INT J DEV BIOL, V54, P761, DOI 10.1387/ijdb.092935md
   DUENHOELTER JH, 1976, AM J OBSTET GYNECOL, V125, P306, DOI 10.1016/0002 9378(76)90564 0
   Eberli D, 2006, METHOD ENZYMOL, V420, P287, DOI 10.1016/S0076 6879(06)20013 2
   Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001
   Gholizadeh Ghalehaziz S, 2015, INT J STEM CELLS, V8, P115, DOI 10.15283/ijsc.2015.8.2.115
   GOSDEN CM, 1983, BRIT MED BULL, V39, P348, DOI 10.1093/oxfordjournals.bmb.a071847
   Graham CD, 2007, CURR PROTOC STEM CEL
   Granero Molto F, 2008, EXPERT OPIN BIOL TH, V8, P255, DOI 10.1517/14712598.8.3.255 
   Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577
   Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456 006 9040 2
   Han YF, 2012, EUR REV MED PHARMACO, V16, P1873
   Hauser PV, 2010, AM J PATHOL, V177, P2011, DOI 10.2353/ajpath.2010.091245
   Heldring N, 2015, HUM GENE THER, V26, P506, DOI 10.1089/hum.2015.072
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   HOEHN H, 1982, METHOD CELL BIOL, V26, P11
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood 2003 04 1291
   Jiao HL, 2012, MOL BIOL REP, V39, P467, DOI 10.1007/s11033 011 0760 z
   Joo S, 2012, ARCH PHARM RES, V35, P271, DOI 10.1007/s12272 012 0207 7
   Kang NH, 2012, CANCER GENE THER, V19, P517, DOI 10.1038/cgt.2012.30
   Kang NH, 2012, CANCER GENE THER, V19, P412, DOI 10.1038/cgt.2012.15
   Kaviani A, 2001, J PEDIATR SURG, V36, P1662, DOI 10.1053/jpsu.2001.27945
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim J, 2007, CELL PROLIFERAT, V40, P75
   Kim KY, 2010, CANCER SCI, V101, P955, DOI 10.1111/j.1349 7006.2009.01485.x
   Kim SU, 2011, ANTICANCER RES, V31, P1249
   Kobayashi M, 2008, CELL TRANSPLANT, V17, P291, DOI 10.3727/096368908784153904
   Kolambkar YM, 2007, J MOL HISTOL, V38, P405, DOI 10.1007/s10735 007 9118 1
   Kovach TK, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/752510
   La Marca Ghaemmaghami P, 2015, PSYCHOSOM MED, V77, P41, DOI 10.1097/PSY.0000000000000130
   Lai E., 2010, DTIC DOCUMENT
   Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471
   Li L, 2016, GENE THER, V23, P214, DOI 10.1038/gt.2015.90
   Li LR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123350
   Lloyd Griffith C, 2015, J ANAT, V227, P767, DOI 10.1111/joa.12283
   Loukogeorgakis SP, 2016, BEST PRACT RES CL OB, V31, P45, DOI 10.1016/j.bpobgyn.2015.08.009
   Luo Hongwu, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P144
   Manuelpillai U, 2010, CELL TRANSPLANT, V19, P1157, DOI 10.3727/096368910X504496
   Maraldi T, 2014, CELL TISSUE RES, V357, P1, DOI 10.1007/s00441 014 1840 x
   Marongiu F, 2011, HEPATOLOGY, V53, P1719, DOI 10.1002/hep.24255
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   MINEI LJ, 1976, OBSTET GYNECOL, V48, P177
   Moorefield EC, 2010, STEM CELLS LAB CLIN, P113
   Murakami M, 2015, CELL TRANSPLANT, V24, P1753, DOI 10.3727/096368914X683502
   Nazari Shafti TZ, 2015, METHODS MOL BIOL, V1235, P131, DOI 10.1007/978 1 4939 1785 3_12
   Parolini O, 2009, REGEN MED, V4, P275, DOI 10.2217/17460751.4.2.275
   Pashaiasl M, 2016, GENE, V578, P194, DOI 10.1016/j.gene.2015.12.023
   Perin L, 2008, METHOD CELL BIOL, V86, P85, DOI 10.1016/S0091 679X(08)00005 8
   Perin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009357
   Phermthai T, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 79
   Pipino C, 2015, WORLD J STEM CELLS, V7, P681, DOI 10.4252/wjsc.v7.i4.681
   Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105
   Prentice DA, 2006, J INVEST MED, V54, P33, DOI 10.2310/6650.2005.05043
   PRIEST RE, 1978, LAB INVEST, V39, P106
   Prusa Andrea Romana, 2002, Med Sci Monit, V8, pRA253
   Prusa AR, 2004, AM J OBSTET GYNECOL, V191, P309, DOI 10.1016/j.ajog.2003.12.014
   Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279
   Rezania A., 2015, US Patent, Patent No. [20,150,191,700, 20150191700]
   Rosser AE, 2007, CURR OPIN NEUROL, V20, P688, DOI 10.1097/WCO.0b013e3282f132fc
   Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036
   Sessarego N, 2008, HAEMATOLOGICA, V93, P339, DOI 10.3324/haematol.11869
   Shaw SWS, 2011, CURR OPIN OBSTET GYN, V23, P109, DOI 10.1097/GCO.0b013e32834457b1
   Shinagawa K, 2015, CANCER RES, V75, DOI 10.1158/1538 7445.AM2015 5068
   Skardal A, 2012, STEM CELL TRANSL MED, V1, P792, DOI 10.5966/sctm.2012 0088
   Spinelli V, 2013, ORGANOGENESIS, V9, P101, DOI 10.4161/org.25197
   Steigman Shaun A, 2007, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01e02s1
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Toda A, 2007, J PHARMACOL SCI, V105, P215, DOI 10.1254/jphs.CR0070034
   Todorov P, 2015, CR ACAD BULG SCI, V68, P65
   Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448
   Toselli M, 2008, NAT BIOTECHNOL, V26, P269, DOI 10.1038/nbt0308 269
   Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279
   Underwood Mark A, 2005, J Perinatol, V25, P341, DOI 10.1038/sj.jp.7211290
   Vallier L, 2007, STEM CELLS, V25, P1490, DOI 10.1634/stemcells.2006 0825
   Wolbank S, 2007, TISSUE ENG, V13, P1173, DOI 10.1089/ten.2006.0313
   Xu B, 2015, TOXICOLOGY, V328, P160, DOI 10.1016/j.tox.2014.12.010
   Yi BR, 2011, INT J ONCOL, V39, P833, DOI 10.3892/ijo.2011.1126
   Zani A, 2014, GUT, V63, P300, DOI 10.1136/gutjnl 2012 303735
   Zhang DY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021397
   Zhou J, 2014, ARCH GYNECOL OBSTET, V290, P223, DOI 10.1007/s00404 014 3231 7
NR 95
TC 34
Z9 36
U1 1
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD JUN
PY 2017
VL 45
IS 4
BP 765
EP 774
DI 10.1080/21691401.2016.1216857
PG 10
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA ES4FS
UT WOS:000399487000013
PM 27684534
OA Bronze
DA 2025 08 17
ER

PT J
AU Freeze, R
   Hughes, P
   Haystead, T
   Scarneo, S
AF Freeze, Robert
   Hughes, Philip
   Haystead, Timothy
   Scarneo, Scott
TI Transforming Growth Factor β Activated Kinase 1 (TAK1) Alleviates
   Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis
   Preclinical Models
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE TAK1; joint pain; inflammation; kinase; analgesics
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROINFLAMMATORY CYTOKINES;
   SELECTIVE INHIBITOR; AMERICAN COLLEGE; MECHANISMS; NSAIDS; KNEE;
   MANAGEMENT; GUIDELINE; NETWORK
AB Purpose: Joint pain is one of the most commonly reported pain types in the United States. In the case of patients suffering from inflammatory diseases such as osteoarthritis (OA) and gout, persistent inflammation due to long term overexpression of several key cytokines has been linked to neuronal hypersensitivity and damage within the joints. Ultimately, a subset of patients develop chronic pain. Pharmacologic treatment of joint pain involves the use of analgesics such as acetaminophen, non steroidal anti inflammatory drugs (NSAIDs), opioids, antidepressants, as well as intra articular injections of corticosteroids and hyaluronic acid. However, NSAIDs are short acting and fail to alleviate severe pain, opioids are generally ineffective at managing chronic pain, and all therapeutic options involve increased risks of serious side effects. Methods: We explored the therapeutic and analgesic effects of transforming growth factor beta activated kinase 1 (TAK1) inhibition in both the monoiodoacetate (MIA) and monosodium urate (MSU) models of joint pain as an innovative strategy for alleviating chronic inflammatory pain. Mechanical allodynia (Von Frey), weight bearing and histological changes were measured in separate groups of rats receiving either the selective TAK1 inhibitor, HS 276, gabapentin or vehicle. Results: Our data support that TAK1 inhibition effectively prevented the development of mechanical allodynia and differential weight bearing in the MIA model. In the MSU model of gouty arthritis, treatment with HS 276 significantly reduced mechanical allodynia and knee edema in female rats, but not male rats. Histological evaluation of effected joints in both models showed that HS276 treatment significantly reduced disease induced degradation of the joint. Conclusion: Our results support that TAK1 is a critical signaling node in inflammatory joint diseases such as OA and gouty arthritis. Selective pharmacological inhibition significantly attenuated several aspects of the disease, including joint degeneration and mechanical pain. Thus, TAK1 is a novel therapeutic target for the treatment of painful inflammatory joint diseases. Perspective: This article reports on the therapeutic potential of TAK1 in the treatment of chronic inflammatory joint diseases such as OA and gout. Using the selective TAK1 inhibitor, HS 276, we show the therapeutic and analgesic effects of TAK1 inhibition in two preclinical murine models of inflammatory joint pain.
C1 [Freeze, Robert; Hughes, Philip; Haystead, Timothy; Scarneo, Scott] Eydisbio Inc, Durham, NC 27701 USA.
   [Hughes, Philip; Haystead, Timothy] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA.
C3 Duke University
RP Scarneo, S (通讯作者)，Eydisbio Inc, Durham, NC 27701 USA.
EM scott.scarneo@eydisbio.com
RI Hughes, Philip/AAB 2902 2019
FU National Institutes of Health's (NIH) National Institute of Neurological
   Disorders and Stroke (NINDS) [R43NS119087 01A1]
FX This work was funded by the National Institutes of Health's (NIH)
   National Institute of Neurological Disorders and Stroke (NINDS) grant
   R43NS119087 01A1 to S.S and T.H.
CR [Anonymous], 2009, ILARIS® (canakinumab) injection
   Aoyagi K, 2022, OSTEOARTHR CARTILAGE, V30, P545, DOI 10.1016/j.joca.2021.10.014
   Arra M, 2023, OSTEOARTHR CARTILAGE, V31, P1012, DOI 10.1016/j.joca.2023.04.003
   Bale S, 2023, JCI INSIGHT, V8, DOI 10.1172/jci.insight.165358
   Bennell KL, 2022, ANN INTERN MED, V175, P198, DOI 10.7326/M21 2388
   Biancuzzi H, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph191811754
   Burian M, 2005, PHARMACOL THERAPEUT, V107, P139, DOI 10.1016/j.pharmthera.2005.02.004
   Christiansen CL, 2010, ARCH PHYS MED REHAB, V91, P1524, DOI 10.1016/j.apmr.2010.07.009
   Crofford LJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4174
   da Costa BR, 2021, BMJ BRIT MED J, V375, DOI 10.1136/bmj.n2321
   de Lange Brokaar BJE, 2012, OSTEOARTHR CARTILAGE, V20, P1484, DOI 10.1016/j.joca.2012.08.027
   FitzGerald JD, 2020, ARTHRIT CARE RES, V72, P744, DOI 10.1002/acr.24180
   Freeze R, 2023, PHARMACOL RES PERSPE, V11, DOI 10.1002/prp2.1124
   Gallelli L, 2013, OSTEOARTHR CARTILAGE, V21, P1400, DOI 10.1016/j.joca.2013.06.026
   Garsden LR, 1999, CLIN REHABIL, V13, P148, DOI 10.1191/026921599674996411
   Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531
   Helmerhorst GTT, 2017, BONE JOINT J, V99B, P856, DOI 10.1302/0301 620X.99B7.BJJ 2016 1350.R1
   Holden MA, 2023, OSTEOARTHR CARTILAGE, V31, P386, DOI 10.1016/j.joca.2022.10.009
   Jang Y, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974 020 1703 1
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Katsura H, 2008, GLIA, V56, P723, DOI 10.1002/glia.20648
   Koh HK, 2017, JAMA J AM MED ASSOC, V318, P993, DOI 10.1001/jama.2017.13767
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Konttinen YT, 2012, ARTHRITIS RHEUM US, V64, P613, DOI 10.1002/art.33451
   Liu P, 2011, NEUROSCI LETT, V493, P72, DOI 10.1016/j.neulet.2011.01.027
   Lopes EBP, 2017, CURR OSTEOPOROS REP, V15, P593, DOI 10.1007/s11914 017 0411 y
   Machado GC, 2021, BMJ BRIT MED J, V372, DOI 10.1136/bmj.n104
   Matsuda M, 2019, J ANESTH, V33, P131, DOI 10.1007/s00540 018 2579 4
   Nadeau SE, 2021, FRONT PAIN RES, V2, DOI 10.3389/fpain.2021.721357
   Obata K, 2004, LIFE SCI, V74, P2643, DOI 10.1016/j.lfs.2004.01.007
   Pitcher T, 2016, JOVE J VIS EXP, DOI 10.3791/53746
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Romsing J, 2004, ACTA ANAESTH SCAND, V48, P525, DOI 10.1111/j.0001 5172.2004.00379.x
   Scarneo Scott, 2023, J Pain, V24, P1633, DOI 10.1016/j.jpain.2023.04.011
   Scarneo S, 2022, ACS CHEM BIOL, V17, P536, DOI 10.1021/acschembio.1c00788
   Scarneo SA, 2020, J BIOL CHEM, V295, P1565, DOI 10.1074/jbc.RA119.011857
   Scarneo SA, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2073 x
   Scarneo SA, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 35189 7
   Schieker M, 2020, ANN INTERN MED, V173, P509, DOI 10.7326/M20 0527
   Schlesinger N, 2012, SEMIN ARTHRITIS RHEU, V42, P155, DOI 10.1016/j.semarthrit.2012.03.010
   Shi ML, 2023, RMD OPEN, V9, DOI 10.1136/rmdopen 2023 003586
   Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007
   Soto Díaz K, 2020, J NEUROCHEM, V152, P697, DOI 10.1111/jnc.14930
   Totzke J, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200099
   Totzke J, 2017, CELL CHEM BIOL, V24, P1029, DOI 10.1016/j.chembiol.2017.07.011
   vanden Driest JJ, 2020, RHEUMATOLOGY, V59, P2462, DOI 10.1093/rheumatology/kez646
   Vanderwall AG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03009
   Wieseler Frank J, 2005, NEUROSIGNALS, V14, P166, DOI 10.1159/000087655
   Yoshioka NK, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13062 y
   Zheng SC, 2020, OPEN LIFE SCI, V15, P971, DOI 10.1515/biol 2020 0105
NR 50
TC 0
Z9 0
U1 0
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 7090
J9 J PAIN RES
JI J. Pain Res.
PY 2024
VL 17
BP 2287
EP 2298
DI 10.2147/JPR.S451409
PG 12
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA WW3J4
UT WOS:001257866000001
PM 38952995
OA gold
DA 2025 08 17
ER

PT J
AU Lan, XY
   Ma, HP
   Xiong, YP
   Zou, LF
   Yuan, Z
   Xiao, YH
AF Lan, Xiaoyong
   Ma, Haiping
   Xiong, Yipin
   Zou, Lingfeng
   Yuan, Zhen
   Xiao, Yuhong
TI Bone marrow mesenchymal stem cells derived exosomes mediate nuclear
   receptor coactivator 3 expression in osteoblasts by delivering
   miR 532 5p to influence osteonecrosis of the femoral head development
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE bone marrow mesenchymal stem cells; exosomes; microRNA 532 5p; nuclear
   receptor coactivator 3; osteonecrosis of the femoral head
ID ANGIOGENESIS; THERAPY; NCOA3
AB Exosomes (Exo) originated from bone marrow mesenchymal stem cells (BMSCs) have therapeutic impacts on osteonecrosis of the femoral head (ONFH), and microRNA (miR) 532 5p has been confirmed to participate in ONFH progression. In the research, it was figured out whether BMSCs Exo could relieve ONFH by delivering miR 532 5p. MG 63 cells were treated with DEX to construct an ONFH cell model in vitro. The effects of Exo and miR 532 5p on the cell viability, lactate dehydrogenase (LDH) content, and apoptosis of BMSCs were detected. The ONFH rat model was established, and the effect of BMSCs Exo delivering miR 532 5p on the pathological damage of ONFH rats was evaluated. Changes in nuclear receptor coactivator 3 (NCOA3) and apoptotic proteins were assessed by western blot. The relationship between miR 532 5p and NCOA3 was verified by dual luciferase reporter experiments. miR 532 5p was elevated in vivo and in vitro ONFH models, while NCOA3 expression was reduced. Overexpression of miR 532 5p aggravated DEX toxicity in osteoblasts, decreased cell viability, and promoted apoptosis. Knockdown of miR 532 5p made Exo further attenuate the toxic effect of DEX on osteoblasts and inhibited apoptosis. The protective effect of miR 532 5p delivering Exo on osteoblasts was reversed by NCOA3 silencing. In addition, in vivo experiments also confirmed that knockdown of miR 532 5p enhanced the therapeutic effect of Exo on ONFH rats. This study demonstrates that miR 532 5p delivering BMSCs Exo inhibits osteoblast viability and promote apoptosis by targeting NCOA3, thereby aggravating ONFH development.
C1 [Lan, Xiaoyong; Zou, Lingfeng; Yuan, Zhen; Xiao, Yuhong] Nanchang Univ, Dept Rehabil Med, Affiliated Hosp 2, 1 Minde Rd, Nanchang 330008, Jiangxi, Peoples R China.
   [Ma, Haiping] Nanchang Univ, Dept Nursing, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.
   [Xiong, Yipin] Nanchang Univ, Dept Ultrasound Musculoskeletal Ultrasound, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University
RP Lan, XY (通讯作者)，Nanchang Univ, Dept Rehabil Med, Affiliated Hosp 2, 1 Minde Rd, Nanchang 330008, Jiangxi, Peoples R China.
EM lanxybet@outlook.com
RI Ma, Haiping/AFR 4411 2022; , 镜海真人（袁振）/ABG 2380 2020
CR Chen L, 2019, BRIEF BIOINFORM, V20, P1836, DOI 10.1093/bib/bby054
   Chen SH, 2018, BONE, V106, P52, DOI 10.1016/j.bone.2017.09.011
   Cui Y, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974 021 02231 x
   Duan DY, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119548
   Fang SH, 2019, EUR REV MED PHARMACO, V23, P9761, DOI 10.26355/eurrev_201911_19539
   Feng B., 2020, FRONT CELL DEV BIOL, V8, DOI [10.3389/fcell.2020.568304, DOI 10.3389/FCELL]
   Gao RZ, 2020, AM J TRANSL RES, V12, P1070
   Guo XY, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03317 y
   Hao YQ, 2021, CLIN INTERV AGING, V16, P187, DOI 10.2147/CIA.S289479
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Lebouvier A, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0036 y
   Li C, 2021, DIAGN PATHOL, V16, DOI 10.1186/s13000 021 01153 9
   Li L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01991 2
   Li YJ, 2022, ENDOCRINE, V75, P149, DOI 10.1007/s12020 021 02819 6
   Li Z, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12405
   Lu GD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.608521
   Mao SY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 02138 8
   Mohanakrishnan V, 2018, J CELL BIOCHEM, V119, P6181, DOI 10.1002/jcb.26827
   Mou CL, 2014, ACTA BIOCH BIOPH SIN, V46, P1066, DOI 10.1093/abbs/gmu096
   Nan K, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02390 x
   Nan K, 2021, ANN NY ACAD SCI, V1503, P23, DOI 10.1111/nyas.14555
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Peng Zhi, 2023, Bioengineered, V14, P1996015, DOI 10.1080/21655979.2021.1996015
   Ross M, 2021, J DAIRY SCI, V104, P2499, DOI 10.3168/jds.2020 18405
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486
   Suetsugu H, 2022, HUM MOL GENET, V31, P1082, DOI 10.1093/hmg/ddab306
   Wang TT, 2022, PUBLIC HEALTH GENOM, V25, P61, DOI 10.1159/000519577
   Wang XL, 2020, MOL MED, V26, DOI 10.1186/s10020 020 00248 1
   Wang Z, 2019, INT J SURG, V69, P23, DOI 10.1016/j.ijsu.2019.06.016
   Wu PP, 2018, CYTOTHERAPY, V20, P291, DOI 10.1016/j.jcyt.2017.11.002
   Xu HX, 2021, STEM CELL TRANSL MED, V10, P781, DOI 10.1002/sctm.20 0346
   Xu L, 2019, CURR MOL MED, V19, P387, DOI 10.2174/1566524019666190429144310
   Yang W, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02438 y
   Zhang B, 2018, CELL PHYSIOL BIOCHEM, V49, P2396, DOI 10.1159/000493839
   Zhang JX, 2018, ONCOGENE, V37, P2660, DOI 10.1038/s41388 018 0162 y
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang QK, 2018, J INT MED RES, V46, P2141, DOI 10.1177/0300060517700299
   Zhang Y, 2020, INT J NANOMED, V15, P6917, DOI 10.2147/IJN.S264498
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhao HY, 2021, AM J MED SCI, V362, P78, DOI 10.1016/j.amjms.2021.03.005
   Zhou ML, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02249 1
   Zhu GD, 2020, EXP CELL RES, V393, DOI 10.1016/j.yexcr.2020.112109
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
   Zuo RT, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1426 3
NR 44
TC 4
Z9 6
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD DEC
PY 2022
VL 46
IS 12
BP 2185
EP 2197
DI 10.1002/cbin.11902
EA SEP 2022
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 6F1HV
UT WOS:000854873400001
PM 36116109
DA 2025 08 17
ER

PT J
AU Tanriverdi, HA
   Barut, A
   Sarikaya, S
AF Tanriverdi, HA
   Barut, A
   Sarikaya, S
TI Statins have additive effects to vertebral bone mineral density in
   combination with risedronate in hypercholesterolemic postmenopausal
   women
SO EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE atorvastatin; bone mineral density; hypercholesterolaemia; risedronate;
   postmenopause; osteoporosis
ID COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIAL; MEVALONATE
   PATHWAY; OSTEOPOROSIS; RISK; FRACTURE; CHOLESTEROL; SIMVASTATIN;
   ALENDRONATE; PRAVASTATIN
AB Background: Recent data suggest that statins used in the treatment of hypercholesterolaemia decrease fracture risk. In this study, we aimed to investigate prospectively whether statins have an additive effect to bisphosphonates (risedronate) according to the primary hypothesis that the addition of atorvastatin to risedronate would produce an increase, from baseline, in lumbar vertebrae and total hip BMD that was greater than that observed with risedronate alone.
   Methods: A total of 120 hypercholesterolaemic postmenopausal women with osteoporosis or osteopenia were randomized to receive risedronate (5 mg/day) or risedronate (5 mg/day) plus atorvastatin (20 mg/day). Changes in bone mineral density in the lumbar spine and hip, and serum lipid and glucose metabolism changes were assessed.
   Results: Compared with risedronate alone, at 6 months, risedronate plus atorvastatin produced significantly greater increases in the bore mineral density of the lumbar spine (1.58% versus 0.75%, p < 0.05). We found no difference after therapy in BMD of the total hip ( 1.2% versus 1.1%). Risedronate plus atorvastatin therapy had favorable effects on the serum lipid profile: LDL and total cholesterol. Serum fasting glucose and HbA1c levels were not affected during the treatments.
   Conclusion: Statins have modest additive effects to bisphosphonates in improving lumbar spine bone mineral density in hypercholesterolaemic postmenopausal women with established osteoporosis osteopenia. A long term study with adequate sample size is necessary to assess the effects of statins   in combination or alone   on the bones and prevention of fractures. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
C1 Karaelmas Univ, Sch Med, Menopause Clin, Dept Obstet & Gynecol, TR 67600 Kozlu, Zonguldak, Turkey.
   Karaelmas Univ, Sch Med, Dept Phys Med & Rehabil, TR 67600 Kozlu, Zonguldak, Turkey.
C3 Zonguldak Bulent Ecevit University; Zonguldak Bulent Ecevit University
RP Tanriverdi, HA (通讯作者)，Karaelmas Univ, Sch Med, Menopause Clin, Dept Obstet & Gynecol, TR 67600 Kozlu, Zonguldak, Turkey.
EM tanriverdi@artemisonline.net
CR [Anonymous], 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P380, DOI 10.1007/s001980170106
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Drake WM, 2001, CLIN THER, V23, P620, DOI 10.1016/S0149 2918(01)80065 5
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   Galloway P, 2002, EUR J OBSTET GYN R B, V101, P4, DOI 10.1016/S0301 2115(01)00472 9
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heaney RP, 2002, OSTEOPOROSIS INT, V13, P501, DOI 10.1007/s001980200061
   Kukla C, 2002, INJURY, V33, P427, DOI 10.1016/S0020 1383(02)00076 1
   LIEBERMAN UA, 1995, NEW ENGL J MED, V333, P1437
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lindsay R, 1999, J CLIN ENDOCR METAB, V84, P3076, DOI 10.1210/jc.84.9.3076
   López FJ, 2000, CURR OPIN CHEM BIOL, V4, P383
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Melton LJ, 2002, BONE, V31, P119, DOI 10.1016/S8756 3282(02)00788 3
   Meunier PJ, 2001, JOINT BONE SPINE, V68, P576, DOI 10.1016/S1297 319X(01)00329 3
   Moghadasian MH, 2001, CAN MED ASSOC J, V164, P803
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537
   Pines A, 2003, MATURITAS, V44, P287, DOI 10.1016/S0378 5122(03)00041 0
   Poli A, 2003, OBSTET GYNECOL, V102, P922, DOI 10.1016/j.obstetgynecol.2003.07.004
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140 6736(00)04042 3
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Stein EA, 2001, NUTR METAB CARDIOVAS, V11, P84
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Szulc P, 2000, BONE, V27, P841, DOI 10.1016/S8756 3282(00)00398 7
   Tankó LB, 2003, BONE, V32, P8, DOI 10.1016/S8756 3282(02)00918 3
   van Staa TP, 2001, JAMA J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
NR 38
TC 33
Z9 37
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0301 2115
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD MAY 1
PY 2005
VL 120
IS 1
BP 63
EP 68
DI 10.1016/j.ejogrb.2004.08.007
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 928MW
UT WOS:000229276900010
PM 15866088
DA 2025 08 17
ER

PT J
AU Stagner, AM
   Sajed, DP
   Nielsen, GP
   Ebb, DH
   Paquin, WC
   Chebib, I
   Rivera, MN
   Ting, DT
   Resnick, CM
   Peacock, ZS
   Kaban, LB
   Deshpande, V
AF Stagner, Anna M.
   Sajed, Dipti P.
   Nielsen, G. Petur
   Ebb, David H.
   Paquin, William C.
   Chebib, Ivan
   Rivera, Miguel N.
   Ting, David T.
   Resnick, Cory M.
   Peacock, Zachary S.
   Kaban, Leonard B.
   Deshpande, Vikrarn
TI Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In
   Situ Hybridization Regardless of Histologic Pattern
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE giant cell tumor; central giant cell lesion; RANKL; in situ
   hybridization
ID GRANULOMA; DENOSUMAB; JAWS; TUMOR; MANAGEMENT; THERAPY; ALBUMIN; LIGAND;
   BONE
AB Maxillofacial central giant cell lesions (CGCLs) are often locally aggressive tumors in young patients that may be histologically very similar to or quite distinct when compared with giant cell tumors (GCTs) of long bones. It has been well established that GCTs express high levels of receptor activator of nuclear factor kappa B ligand (RANKL) and are amenable to treatment with denosumab. To assess the predictive value of morphology, we evaluated CGCLs with GCT like or non GCT like histology for RANKL expression by RNA in situ hybridization. Tumors were classified by clinical and radiographic criteria as aggressive or nonaggressive and histopathologically as resembling GCT or non GCT like. RNA in situ hybridization for RANKL mRNA was performed and scored semiquantitatively based on the magnification at which the signal was first detected. There were 17 patients (M:F=8:9) with a median age of 15 years. Nine patients were children under 18 years of age. In 10 patients, tumors were characterized as GCT like and in 7, non GCT like; 6 occurred in the setting of a known associated syndrome. Of the sporadic tumors, 9/11 (82%) were classified as aggressive. Fifteen of 17 (88%) tumors strongly expressed RANKL (8/9 aggressive, 2/2 nonaggressive; 10/10 GCT like and 5/7 non GCT like). Two patients with clinically aggressive CGCL, GCT like histology and high tumor RANKL expression were identified as candidates for a trial of denosumab with notable clinical response. CGCLs demonstrate strong and diffuse RANKL mRNA expression in mononuclear stromal cells, regardless of histology or presence of an associated syndrome. Denosumab may be clinically beneficial in aggressive CGCLs.
C1 [Stagner, Anna M.; Sajed, Dipti P.; Nielsen, G. Petur; Paquin, William C.; Chebib, Ivan; Rivera, Miguel N.; Deshpande, Vikrarn] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.
   [Ebb, David H.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
   [Peacock, Zachary S.; Kaban, Leonard B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
   [Ting, David T.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA.
   [Resnick, Cory M.] Boston Childrens Hosp, Dept Plast & Oral Surg, Boston, MA USA.
   [Sajed, Dipti P.] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Harvard University; Harvard University Medical Affiliates;
   Boston Children's Hospital; University of California System; University
   of California Los Angeles
RP Stagner, AM (通讯作者)，Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.
EM astagner@mgh.harvard.edu
RI Ting, David/F 4389 2017; Peacock, Zachary/AAF 9942 2019
OI Ting, David/0000 0002 3261 2322; Stagner, Anna/0000 0001 5585 9056
FU Affymetrix, CA
FX The work was partially funded by a sponsored research agreement between
   the authors' institution and Affymetrix, CA.
CR Arora K, 2016, CANCER CYTOPATHOL, V124, P203, DOI 10.1002/cncy.21629
   Bataineh AB, 2002, J ORAL MAXIL SURG, V60, P756, DOI 10.1053/joms.2002.33241
   BERTONI F, 1992, CANCER, V70, P1124, DOI 10.1002/1097 0142(19920901)70:5<1124::AID CNCR2820700517>3.0.CO;2 P
   Bredell M, 2018, J ORAL MAXIL SURG, V76, P775, DOI 10.1016/j.joms.2017.09.013
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   CHUONG R, 1986, J ORAL MAXIL SURG, V44, P708, DOI 10.1016/0278 2391(86)90040 6
   da Silva NG, 2012, HEAD FACE MED, V8, DOI 10.1186/1746 160X 8 23
   de Lange J, 2004, HEAD NECK J SCI SPEC, V26, P792, DOI 10.1002/hed.20069
   De Lange J, 2007, ORAL SURG ORAL MED O, V104, P603, DOI 10.1016/j.tripleo.2007.04.003
   Fanourakis G, 2010, J ORAL PATHOL MED, V39, P687, DOI 10.1111/j.1600 0714.2010.00924.x
   Ferrone CR, 2016, ANN SURG ONCOL, V23, P290, DOI 10.1245/s10434 014 4247 8
   Gomes CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06690 4
   Gomes CC, 2014, OR SURG OR MED OR PA, V118, P583, DOI 10.1016/j.oooo.2014.07.011
   Gupta B, 2015, J CRANIO MAXILL SURG, V43, P1127, DOI 10.1016/j.jcms.2015.04.011
   Itonaga I, 2003, J ORAL PATHOL MED, V32, P224, DOI 10.1034/j.1600 0714.2003.00069.x
   JAFFE HL, 1953, ORAL SURG ORAL MED O, V6, P159, DOI 10.1016/0030 4220(53)90151 0
   Kruse Lösler B, 2006, ORAL SURG ORAL MED O, V101, P346, DOI 10.1016/j.tripleo.2005.02.060
   Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600 0714.2003.00126.x
   Naidu A, 2014, J ORAL MAXIL SURG, V72, P2469, DOI 10.1016/j.joms.2014.06.456
   Peacock ZS, 2017, J ORAL MAXIL SURG, V75, P298, DOI 10.1016/j.joms.2016.07.014
   Peacock ZS, 2012, J ORAL MAXIL SURG, V70, P2573, DOI 10.1016/j.joms.2011.12.005
   Peacock ZS, 2012, J ORAL MAXIL SURG, V70, P1860, DOI 10.1016/j.joms.2011.08.020
   Resnick CM, 2010, J ORAL MAXIL SURG, V68, P130, DOI 10.1016/j.joms.2009.04.106
   Saw S, 2009, PATHOL ONCOL RES, V15, P291, DOI 10.1007/s12253 008 9124 y
   Saylor PJ, 2017, CLIN CANCER RES, V23, P363, DOI 10.1158/1078 0432.CCR 16 0237
   Schreuder WH, 2014, J ORAL MAXIL SURG, V72, P1301, DOI 10.1016/j.joms.2014.02.017
   Shahid M, 2015, AM J SURG PATHOL, V39, P25, DOI 10.1097/PAS.0000000000000343
   Taylor CR, 2017, APPL IMMUNOHISTO M M, V25, P299, DOI 10.1097/PAI.0000000000000503
   Thomas DM, 2012, CURR OPIN ONCOL, V24, P397, DOI 10.1097/CCO.0b013e328354c129
NR 29
TC 6
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0147 5185
EI 1532 0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD JUN
PY 2019
VL 43
IS 6
BP 819
EP 826
DI 10.1097/PAS.0000000000001257
PG 8
WC Pathology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Surgery
GA HY7JH
UT WOS:000468310500011
PM 30998511
DA 2025 08 17
ER

PT J
AU Saad, M
   Alip, A
   Lim, J
   Abdullah, MM
   Chong, FLT
   Chua, CB
   Ismail, F
   Khong, RKT
   Lim, CS
   Loh, CS
   Malek, R
   Ghani, KAM
   Noor, IM
   Yusoff, NAM
   Nasuha, NA
   Razack, A
   Hoo, HFS
   Sundram, M
   Tan, HM
   Thiagarajan, M
   Teh, GC
   Voon, PJ
   Ong, TA
AF Saad, Marniza
   Alip, Adlinda
   Lim, Jasmine
   Abdullah, Matin Mellor
   Chong, Flora Li Tze
   Chua, Chong Beng
   Ismail, Fuad
   Khong, Rachael Kit Tsan
   Lim, Chun Sen
   Loh, Chit Sin
   Malek, Rohan
   Ghani, Khairul Asri Mohd
   Noor, Ibtisam Md
   Yusoff, Noor Ashani Md
   Nasuha, Noor Azam
   Razack, Azad
   Hoo, Hwoei Fen Soo
   Sundram, Murali
   Tan, Hui Meng
   Thiagarajan, Muthukkumaran
   Teh, Guan Chou
   Voon, Pei Jye
   Ong, Teng Aik
TI Management of advanced prostate cancer in a middle income country:
   real world consideration of the Advanced Prostate Cancer Consensus
   Conference 2017
SO BJU INTERNATIONAL
LA English
DT Article
DE castration resistant prostate cancer; castration naive prostate cancer;
   oligometastatic prostate cancer; high risk localized prostate cancer;
   cost and access to treatment; low middle income countries;
   #ProstateCancer; #pcsm
ID ANDROGEN DEPRIVATION THERAPY; BONE METASTASES; INCREASED SURVIVAL;
   ZOLEDRONIC ACID; SKELETAL EVENTS; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE;
   PREDNISONE; RADIOTHERAPY
AB Objective To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle income country. Methods Six key sections were chosen: (1) high risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration naive prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. Results Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high cost drugs in castration naive or castration resistant metastatic prostate cancer in real world settings. All panellists recommended using generic drugs when available. Conclusions The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle income country in a real world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.
C1 [Saad, Marniza; Alip, Adlinda; Ong, Teng Aik] Univ Malaya, Fac Med, Med Ctr, Dept Clin Oncol, Kuala Lumpur, Malaysia.
   [Lim, Jasmine; Razack, Azad; Tan, Hui Meng] Univ Malaya, Dept Surg, Fac Med, Kuala Lumpur, Malaysia.
   [Abdullah, Matin Mellor] Subang Jaya Med Ctr, Subang Jaya, Selangor, Malaysia.
   [Chong, Flora Li Tze] Sabah Women & Children Hosp, Dept Radiotherapy & Oncol, Kota Kinabalu, Sabah, Malaysia.
   [Chua, Chong Beng; Khong, Rachael Kit Tsan; Loh, Chit Sin] Gleneagles Intan Med Ctr, Kuala Lumpur, Malaysia.
   [Ismail, Fuad] Natl Univ Malaysia, Dept Radiotherapy & Oncol, Kuala Lumpur, Malaysia.
   [Lim, Chun Sen; Nasuha, Noor Azam] Sultan Ismail Hosp, Dept Radiotherapy & Oncol, Johor Baharu, Malaysia.
   [Malek, Rohan] Selayang Hosp, Dept Urol, Selangor, Malaysia.
   [Ghani, Khairul Asri Mohd] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Surg, Serdang, Malaysia.
   [Noor, Ibtisam Md; Thiagarajan, Muthukkumaran] Kuala Lumpur Hosp, Dept Radiotherapy & Oncol, Kuala Lumpur, Malaysia.
   [Yusoff, Noor Ashani Md; Sundram, Murali] Kuala Lumpur Hosp, Dept Urol, Kuala Lumpur, Malaysia.
   [Nasuha, Noor Azam] Raja Perempuan Zainab II Hosp, Dept Surg, Kota Baharu, Kelantan, Malaysia.
   [Hoo, Hwoei Fen Soo] Penang Hosp, Dept Radiotherapy & Oncol, George Town, Malaysia.
   [Teh, Guan Chou] Sarawak Gen Hosp, Dept Urol, Sarawak, Malaysia.
   [Voon, Pei Jye] Sarawak Gen Hosp, Dept Radiotherapy Oncol & Palliat Care, Sarawak, Malaysia.
C3 Universiti Malaya; Universiti Malaya; Universiti Kebangsaan Malaysia;
   Universiti Putra Malaysia
RP Ong, TA (通讯作者)，Univ Malaya, Dept Surg, Fac Med, Level 2, Kuala Lumpur 50603, Malaysia.
EM ongta@ummc.edu.my
RI tan, hui/KYP 1763 2024; JASMINE, LIM/F 7404 2015; Razack,
   Azad/B 8152 2009; Ong, Teng/B 5321 2010; Alip, Adlinda/E 7836 2016;
   SAAD, MARNIZA/B 8947 2010; Noor, I.M./R 8359 2019; alip,
   adlinda/HJI 4729 2023
OI lim, jasmine/0000 0002 7501 1834; alip, adlinda/0000 0003 4744 4533
CR [Anonymous], 2018, EAU ANN C COP
   [Anonymous], 2018, NCCN CLIN GUIDELINES
   Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078 0432.CCR 12 3791
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Bhoo Pathy N, 2017, EUR J CANCER, V74, P26, DOI 10.1016/j.ejca.2016.12.014
   Chiong E, 2019, BJU INT, V123, P22, DOI 10.1111/bju.14489
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257
   Gillessen S, 2018, EUR UROL, V73, P178, DOI 10.1016/j.eururo.2017.06.002
   Hager S, 2016, ANN ONCOL, V27, P975, DOI 10.1093/annonc/mdw156
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536
   James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900
   James ND, 2016, JAMA ONCOL, V2, P493, DOI 10.1001/jamaoncol.2015.5570
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kellokumpu Lehtinen PL, 2013, LANCET ONCOL, V14, P117, DOI 10.1016/S1470 2045(12)70537 5
   Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657
   Loeb S, 2010, UROLOGY, V76, P710, DOI 10.1016/j.urology.2009.09.014
   Mason MD, 2015, J CLIN ONCOL, V33, P2143, DOI 10.1200/JCO.2014.57.7510
   Ong WL, 2017, BJU INT, V120, P35, DOI 10.1111/bju.13969
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Romero Victoriano, 2010, Rev Urol, V12, pe86
   Rutledge AB, 2018, BJU INT, V121, P22, DOI 10.1111/bju.14144
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Saad Fred, 2002, Clin Prostate Cancer, V1, P145, DOI 10.3816/CGC.2002.n.016
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Sydes MR, 2018, ANN ONCOL, V29, P1235, DOI 10.1093/annonc/mdy072
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tosoian JJ, 2017, NAT REV UROL, V14, P15, DOI 10.1038/nrurol.2016.175
   Ward JF, 2005, BJU INT, V95, P751, DOI 10.1111/j.1464 410X.2005.05394.x
   Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140 6736(11)61095 7
   Williams S, 2013, LANCET ONCOL, V14, pE524, DOI 10.1016/S1470 2045(13)70451 0
NR 42
TC 13
Z9 13
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1464 4096
EI 1464 410X
J9 BJU INT
JI BJU Int.
PD SEP
PY 2019
VL 124
IS 3
BP 373
EP 382
DI 10.1111/bju.14807
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA IS9FA
UT WOS:000482452800009
PM 31077523
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Silva, KL
   Vasconcellos, DV
   Castro, EDDP
   Vasconcelos, FD
   Bigni, R
   Maia, RC
AF Silva, Karina Lani
   Vasconcellos, Deborah Vidal
   de Paula Castro, Eric Delfraro
   Vasconcelos, Flavia da Cunha
   Bigni, Ricardo
   Maia, Raquel Ciuvalschi
TI Bisphosphonates induce apoptosis in CLL cells independently of MDR
   phenotype
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE pamidronate; zoledronic acid; apoptosis; CLL; MDR
ID CHRONIC LYMPHOCYTIC LEUKEMIA; ZOLEDRONIC ACID; P GLYCOPROTEIN;
   3RD GENERATION BISPHOSPHONATE; RESISTANCE; EXPRESSION; BONE; MRP;
   ALENDRONATE; MECHANISMS
AB Purpose The anti tumoral activity of bisphosphonates (BPs) has been reported in leukemia. In this study, we attempted to evaluate the apoptotic effects of the BPs pamidronate (PAM) and zoledronic acid (ZOL) in chronic lymphocytic leukemia (CLL) samples, and to correlate it with clinical parameters and multidrug resistance (MDR) phenotype (P glycoprotein and multidrug resistance related protein expression and/or their functional activity).
   Results Both BPs were able to induce apoptosis significantly. No correlation was observed between BP induced apoptosis and clinical parameters or MDR phenotype.
   Conclusion Our data suggest that concurrent or sequential administration of BPs with conventional chemotherapeutic drugs may have significant therapeutic potential for CLL patients.
C1 [Silva, Karina Lani; Vasconcellos, Deborah Vidal; de Paula Castro, Eric Delfraro; Vasconcelos, Flavia da Cunha; Bigni, Ricardo; Maia, Raquel Ciuvalschi] Hosp Canc 1, Serv Hematol, Lab Hematol Celular & Mol, Inst Nacl Canc, BR 20230130 Rio De Janeiro, Brazil.
   [Silva, Karina Lani; Vasconcellos, Deborah Vidal] Univ Fed Rio de Janeiro, Inst Ciencias Biol, Programa Posgrad Ciencias Morfol, Rio De Janeiro, Brazil.
   [Silva, Karina Lani] Inst Nacl Canc, Program Posgrad Oncol, Rio De Janeiro, Brazil.
C3 National Cancer Institute (Inca); Universidade Federal do Rio de
   Janeiro; National Cancer Institute (Inca)
RP Maia, RC (通讯作者)，Hosp Canc 1, Serv Hematol, Lab Hematol Celular & Mol, Inst Nacl Canc, Praca Cruz Vermelha 23,6 Andar, BR 20230130 Rio De Janeiro, Brazil.
EM rcmaia@inca.gov.br
RI maia, raquel/L 4869 2015; Ciuvalschi Maia, Raquel/L 4869 2015;
   Vasconcelos, Flavia/C 7625 2017
OI Ciuvalschi Maia, Raquel/0000 0003 0225 471X; Vasconcelos,
   Flavia/0000 0002 0042 2954
CR Abbott BL, 2006, ONCOLOGIST, V11, P21, DOI 10.1634/theoncologist.11 1 21
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   BERENSON J, 2000, P ASCO, pA209
   Borges João Lindolfo C., 2006, Arq Bras Endocrinol Metab, V50, P755, DOI 10.1590/S0004 27302006000400020
   Cheson BD, 2001, CHRONIC LYMPHOID LEU, P231
   ChinYee I, 1996, CLIN LAB HAEMATOL, V18, P99, DOI 10.1046/j.1365 2257.1996.00146.x
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Consoli U, 2002, BRIT J HAEMATOL, V116, P774, DOI 10.1046/j.0007 1048.2002.03344.x
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Donnenberg VS, 2005, J CLIN PHARMACOL, V45, P872, DOI 10.1177/0091270005276905
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hejdova M, 2005, PHARM WORLD SCI, V27, P149, DOI 10.1007/s11096 005 0014 z
   Hosking D, 2006, BONE, V38, P3, DOI 10.1016/j.bone.2005.11.011
   Hu XF, 1999, BLOOD, V93, P4086, DOI 10.1182/blood.V93.12.4086.412k43_4086_4095
   Juszczynski P, 2002, LEUKEMIA LYMPHOMA, V43, P153, DOI 10.1080/10428190290000329
   Kimura S, 2004, INT J HEMATOL, V79, P37, DOI 10.1007/BF02983531
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Matthews C, 2006, LEUKEMIA LYMPHOMA, V47, P2308, DOI 10.1080/10428190600881421
   Mauro FR, 1999, BLOOD, V94, P448, DOI 10.1182/blood.V94.2.448.414k13_448_454
   Montserrat E, 2006, BLOOD, V107, P1276, DOI 10.1182/blood 2005 02 0819
   Moulin M, 2007, CANCER LETT, V250, P117, DOI 10.1016/j.canlet.2006.10.019
   Nishida S, 2003, BIOL PHARM BULL, V26, P96, DOI 10.1248/bpb.26.96
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Silva KL, 2006, APOPTOSIS, V11, P277, DOI 10.1007/s10495 006 3560 5
   Silva KL, 2003, LEUKEMIA RES, V27, P243, DOI 10.1016/S0145 2126(02)00094 2
   Svoboda Beusan I, 2000, HAEMATOLOGICA, V85, P1261
   TWENTYMAN PR, 1994, EUR J CANCER, V30A, P1360, DOI 10.1016/0959 8049(94)90187 2
   Ural AU, 2003, INT J HEMATOL, V78, P443, DOI 10.1007/BF02983818
   Vasconcelos FC, 2007, LEUKEMIA RES, V31, P445, DOI 10.1016/j.leukres.2006.07.016
   Wall DMP, 1997, BRIT J HAEMATOL, V96, P697, DOI 10.1046/j.1365 2141.1997.d01 2090.x
   Webb M, 1998, BRIT J HAEMATOL, V102, P710
   Yildiz M, 2006, CELL BIOL INT, V30, P278, DOI 10.1016/j.cellbi.2005.11.008
NR 36
TC 3
Z9 4
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0344 5704
EI 1432 0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD JUN
PY 2008
VL 62
IS 1
BP 165
EP 171
DI 10.1007/s00280 008 0710 1
PG 7
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 287ZP
UT WOS:000254956300018
PM 18335218
DA 2025 08 17
ER

PT J
AU Xie, F
   Li, F
   Li, R
   Liu, ZT
   Shi, JW
   Zhang, C
   Dong, NG
AF Xie, Fei
   Li, Fei
   Li, Rui
   Liu, Zongtao
   Shi, Jiawei
   Zhang, Chao
   Dong, Nianguo
TI Inhibition of PP2A enhances the osteogenic differentiation of human
   aortic valvular interstitial cells via ERK and p38 MAPK pathways
SO LIFE SCIENCES
LA English
DT Article
DE PP2A; Osteogenic differentiation; ERK/p38 MAPKs
ID PROTEIN PHOSPHATASE 2A; OSTEOBLAST DIFFERENTIATION; REGULATORY SUBUNIT;
   KINASE PATHWAYS; VALVE STENOSIS; PROMOTES; EXPRESSION; CANCER; ACID;
   HYPERPHOSPHORYLATION
AB Aims: To investigate the role of PP2A in calcified aortic valve disease (CAVD).
   Materials and methods: The expressions of PP2A subunits were detected by real time polymerase chain reaction (RT PCR) and western blot in aortic valves from patients with CAVD and normal controls, the activities of PP2A were analyzed by commercial assay kit at the same time. Aortic valve calcification of mice was evaluated through histological and echocardiographic analysis. ApoE( / ) mice and ApoE( / ) mice injected intraperitoneally with PP2A inhibitor LB100 were fed a high cholesterol diet for 24 weeks. Immunofluorescent staining was used to locate the cell type in which PP2A activity was decreased, the PP2A activity of valvular interstitial cells (VICs) treated with osteogenic induction medium was assessed by western blot and commercial assay kit. After changing the activity of VICs through pharmacologic and genetic intervention, the osteoblast differentiation and mineralization were assessed by western blot and Alizarin Red staining. Finally, the mechanism was clarified by using several specific inhibitors.
   Key findings: PP2A activity was decreased both in calcified aortic valves and human VICs under osteogenic induction. The PP2A inhibitor LB100 aggravated the aortic valve calcification of mice. Furthermore, PPP2CA overexpression inhibited osteogenic differentiation of VICs, whereas PPP2CA knockdown promoted the process. Further study revealed that the ERK/p38 MAPKs signaling pathways mediated the osteogenic differentiation of VICs induced by PP2A inactivation.
   Significance: This study demonstrated that PP2A plays an important role in CAVD pathophysiology, PP2A activation may provide a novel strategy for the pharmacological treatment of CAVD.
C1 [Xie, Fei; Li, Fei; Li, Rui; Liu, Zongtao; Shi, Jiawei; Zhang, Chao; Dong, Nianguo] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiovasc Surg, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Zhang, C; Dong, NG (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiovasc Surg, Wuhan 430022, Peoples R China.
EM cz195@hust.edu.cn; 1986XH0694@hust.edu.cn
RI Shi, Jiawei/KDU 6911 2024; fei, xie/HLH 4893 2023; Li,
   Feifei/JTT 8011 2023
FU National Key Research and Development Program of China [2016YFA0101103];
   National Natural Science Foundation of China [81930052, 81600345]
FX This work was supported by the National Key Research and Development
   Program of China [2016YFA0101103]; and National Natural Science
   Foundation of China [81930052, 81600345].
CR Alam I, 2009, GENOMICS, V94, P257, DOI 10.1016/j.ygeno.2009.05.008
   Ao LH, 2009, AM J PHYSIOL HEART C, V297, pH21, DOI 10.1152/ajpheart.00292.2009
   Arora DK, 2014, ENDOCRINOLOGY, V155, P380, DOI 10.1210/en.2013 1773
   Barancik M, 1999, J CARDIOVASC PHARM, V34, P182, DOI 10.1097/00005344 199908000 00002
   Baskaran R, 2018, LIFE SCI, V210, P40, DOI 10.1016/j.lfs.2018.08.063
   Beg M, 2016, MOL CELL ENDOCRINOL, V437, P97, DOI 10.1016/j.mce.2016.08.016
   Bengtsson L, 2009, J CELL SCI, V122, P1248, DOI 10.1242/jcs.039552
   Braunwald E, 2018, CIRCULATION, V137, P2099, DOI 10.1161/CIRCULATIONAHA.118.033408
   Brewis N, 2000, AM J PHYSIOL HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Cheek JD, 2012, J MOL CELL CARDIOL, V52, P689, DOI 10.1016/j.yjmcc.2011.12.013
   Coté N, 2013, INFLAMMATION, V36, P573, DOI 10.1007/s10753 012 9579 6
   Cristóbal I, 2014, BBA MOL BASIS DIS, V1842, P1823, DOI 10.1016/j.bbadis.2014.06.032
   Feng X, 2012, AMINO ACIDS, V43, P1697, DOI 10.1007/s00726 012 1253 7
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Gergs U, 2004, J BIOL CHEM, V279, P40827, DOI 10.1074/jbc.M405770200
   Goody PR, 2020, ARTERIOSCL THROM VAS, V40, P885, DOI 10.1161/ATVBAHA.119.313067
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Gu XX, 2009, AM J PHYSIOL HEART C, V296, pH1748, DOI 10.1152/ajpheart.00099.2009
   Guo BB, 2020, EMBO J, V39, DOI 10.15252/embj.2019102190
   Huang CX, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/804260
   Huang YM, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109985
   Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004
   Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264 6021:3530417
   Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004
   Jin NN, 2017, FEBS LETT, V591, P1053, DOI 10.1002/1873 3468.12617
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06 7859rev
   Lambrecht C, 2013, METHODS MOL BIOL, V1053, P283, DOI 10.1007/978 1 62703 562 0_17
   Li C, 2013, CARDIOVASC PATHOL, V22, P1, DOI 10.1016/j.carpath.2012.06.005
   Li F, 2015, CARDIOLOGY, V130, P55, DOI 10.1159/000369126
   Li L, 2016, AM J TRANSL RES, V8, P1769
   Lindman BR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.6
   Lindman BR, 2013, CIRC RES, V113, P223, DOI 10.1161/CIRCRESAHA.111.300084
   Liu R, 2008, J CELL MOL MED, V12, P241, DOI 10.1111/j.1582 4934.2008.00249.x
   Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106
   Lubbers ER, 2016, J MOL CELL CARDIOL, V101, P127, DOI 10.1016/j.yjmcc.2016.11.003
   Meng XZ, 2008, AM J PHYSIOL CELL PH, V294, pC29, DOI 10.1152/ajpcell.00137.2007
   Nsaibia MJ, 2017, CARDIOVASC RES, V113, P1351, DOI 10.1093/cvr/cvx089
   O'Connor CM, 2018, INT J BIOCHEM CELL B, V96, P182, DOI 10.1016/j.biocel.2017.10.008
   Okamura H, 2013, J CELL PHYSIOL, V228, P1031, DOI 10.1002/jcp.24250
   Okamura H, 2011, BONE, V49, P368, DOI 10.1016/j.bone.2011.06.004
   Rosa M, 2017, ACTA DIABETOL, V54, P551, DOI 10.1007/s00592 017 0980 3
   Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279
   Rutkovskiy A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006339
   Schoen FJ, 1999, J BIOMED MATER RES, V47, P439, DOI 10.1002/(SICI)1097 4636(19991215)47:4<439::AID JBM1>3.0.CO;2 O
   Sents W, 2017, CANCER RES, V77, P6825, DOI 10.1158/0008 5472.CAN 16 2911
   Serguienko A, 2017, STEM CELLS DEV, V26, P1375, DOI 10.1089/scd.2017.0129
   Terentyev D, 2009, CIRC RES, V104, P514, DOI 10.1161/CIRCRESAHA.108.181651
   Towler DA, 2013, CIRC RES, V113, P198, DOI 10.1161/CIRCRESAHA.113.300155
   Tsuchiya Y, 2017, FEBS LETT, V591, P4083, DOI 10.1002/1873 3468.12912
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955 0674(99)00074 5
   Wang YX, 2015, NEUROBIOL AGING, V36, P188, DOI 10.1016/j.neurobiolaging.2014.07.035
   Ward MP, 2017, BRIT J PHARMACOL, V174, P1116, DOI 10.1111/bph.13759
   Watt LF, 2017, BREAST CANCER RES TR, V166, P117, DOI 10.1007/s10549 017 4403 5
   Weinbrenner C, 1998, CIRCULATION, V98, P899, DOI 10.1161/01.CIR.98.9.899
   Wlodarchak N, 2016, CRIT REV BIOCHEM MOL, V51, P162, DOI 10.3109/10409238.2016.1143913
   Xion Y, 2019, APOPTOSIS, V24, P921, DOI 10.1007/s10495 019 01570 8
   Yu UY, 2014, KOREAN J PHYSIOL PHA, V18, P155, DOI 10.4196/kjpp.2014.18.2.155
   Zhiduleva EV, 2018, B EXP BIOL MED+, V164, P371, DOI 10.1007/s10517 018 3992 2
   Zhou TW, 2020, PHYTOTHER RES, V34, P2074, DOI 10.1002/ptr.6674
NR 63
TC 19
Z9 19
U1 3
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2020
VL 257
AR 118086
DI 10.1016/j.lfs.2020.118086
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NN3UD
UT WOS:000568715400006
PM 32679147
DA 2025 08 17
ER

PT J
AU Tang, SA
   Xie, ZY
   Wang, P
   Li, JT
   Wang, S
   Liu, WJ
   Li, M
   Wu, XH
   Su, HJ
   Cen, SZ
   Ye, GW
   Zheng, G
   Wu, YF
   Shen, HY
AF Tang, Su'an
   Xie, Zhongyu
   Wang, Peng
   Li, Jinteng
   Wang, Shan
   Liu, Wenjie
   Li, Ming
   Wu, Xiaohua
   Su, Hongjun
   Cen, Shuizhong
   Ye, Guiwen
   Zheng, Guan
   Wu, Yanfeng
   Shen, Huiyong
TI LncRNA OG Promotes the Osteogenic Differentiation of Bone Marrow Derived
   Mesenchymal Stem Cells Under the Regulation of hnRNPK
SO STEM CELLS
LA English
DT Article
DE Long noncoding RNA; Mesenchymal stem cells; Osteogenic differentiation;
   Heterogeneous nuclear ribonucleoprotein K
ID LONG NONCODING RNA; MESSENGER RNA; STROMAL CELLS; EXPRESSION; INTERACTS;
   CONTRIBUTES; METHYLATION; REPRESSION; GROWTH
AB Bone marrow derived mesenchymal stem cells (BM MSCs) are the main source of osteoblasts in vivo and are widely used in stem cell therapy. Previously, we analyzed long noncoding RNA (lncRNA) expression profiles during BM MSC osteogenesis, and further investigation is needed to elucidate how lncRNAs regulate BM MSC osteogenesis. Herein, we used customized microarrays to determine lncRNA expression profiles in BM MSCs on days 0 and 10 of osteogenic differentiation. In addition, we identified a novel osteogenesis associated lncRNA (lncRNA OG) that is upregulated during this process. Functional assays showed that lncRNA OG significantly promotes BM MSC osteogenesis. Mechanistically, lncRNA OG interacts with heterogeneous nuclear ribonucleoprotein K (hnRNPK) protein to regulate bone morphogenetic protein signaling pathway activation. Surprisingly, hnRNPK positively regulates lncRNA OG transcriptional activity by promoting H3K27 acetylation of the lncRNA OG promoter. Therefore, our study revealed a novel lncRNA with a positive function on BM MSC osteogenic differentiation and proposed a new interaction between hnRNPK and lncRNA. Stem Cells 2018 Stem Cells 2019;37:270 283
C1 [Tang, Su'an; Xie, Zhongyu; Wang, Peng; Shen, Huiyong] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, 3025 Shen Nan Rd, Shenzhen 518033, Guangdong, Peoples R China.
   [Tang, Su'an] Southern Med Univ, Zhujiang Hosp, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Xie, Zhongyu; Wang, Peng; Li, Jinteng; Wang, Shan; Liu, Wenjie; Li, Ming; Cen, Shuizhong; Ye, Guiwen; Zheng, Guan; Shen, Huiyong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Wu, Xiaohua; Su, Hongjun; Wu, Yanfeng] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Ctr Biotherapy, 107 Yan Jiang Rd West, Guangzhou 510120, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Southern Medical University   China; Sun Yat Sen
   University; Sun Yat Sen University
RP Shen, HY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, 3025 Shen Nan Rd, Shenzhen 518033, Guangdong, Peoples R China.; Wu, YF (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Ctr Biotherapy, 107 Yan Jiang Rd West, Guangzhou 510120, Guangdong, Peoples R China.
EM wuyf@mail.sysu.edu.cn; shenhuiy@mail.sysu.edu.cn
RI Xie, Zhongyu/V 6518 2019; Su, Hongjun/E 4859 2013; Liu,
   Wenji/ADU 1214 2022; zheng, guan/JAC 9450 2023
FU National Natural Science Foundation of China [81672097, 81702120];
   Industrial Technology Research and Development Funding Project of
   Guangdong Province [20160911]; Clinical Medicine Research and
   Transformation Project of Guangzhou City [201604020004]
FX This study was supported by the National Natural Science Foundation of
   China (81672097, 81702120), the Industrial Technology Research and
   Development Funding Project of Guangdong Province (20160911) and the
   Clinical Medicine Research and Transformation Project of Guangzhou City
   (201604020004).
CR Bao XC, 2015, CELL RES, V25, P80, DOI 10.1038/cr.2014.165
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048
   Carlson HL, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005680
   Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008
   Chu C, 2015, CELL, V161, P404, DOI 10.1016/j.cell.2015.03.025
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Hadji F, 2016, CIRCULATION, V134, P1848, DOI 10.1161/CIRCULATIONAHA.116.023116
   Hämmerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Jin CY, 2016, STEM CELLS, V34, P2707, DOI 10.1002/stem.2439
   Kim K, 2008, J BIOL CHEM, V283, P9113, DOI 10.1074/jbc.M708205200
   Klimek Tomczak K, 2004, J MOL BIOL, V342, P1131, DOI 10.1016/j.jmb.2004.07.099
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097 4644(20001201)79:3<395::AID JCB50>3.0.CO;2 M
   Li D, 2018, CANCER RES, V78, P1169, DOI 10.1158/0008 5472.CAN 17 2295
   Li ZH, 2014, P NATL ACAD SCI USA, V111, P1002, DOI 10.1073/pnas.1313768111
   Lian WS, 2017, J MOL MED, V95, P1327, DOI 10.1007/s00109 017 1583 8
   Liu XZ, 2017, EUR J PHARMACOL, V810, P156, DOI 10.1016/j.ejphar.2017.07.013
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436 6453.2005
   Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ramos AD, 2015, CELL STEM CELL, V16, P439, DOI 10.1016/j.stem.2015.02.007
   Ritchie SA, 2003, NUCLEIC ACIDS RES, V31, P1502, DOI 10.1093/nar/gkg246
   Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.44
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003
   Xiao TF, 2015, STEM CELL REP, V5, P856, DOI 10.1016/j.stemcr.2015.09.007
   Xie JJ, 2018, GASTROENTEROLOGY, V154
   Xie ZY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0766 0
   Xie ZY, 2017, J MOL MED, V95, P143, DOI 10.1007/s00109 016 1489 x
   Xie ZY, 2016, J RHEUMATOL, V43, P1523, DOI 10.3899/jrheum.151181
   Xie ZY, 2016, ARTHRITIS RHEUMATOL, V68, P430, DOI 10.1002/art.39433
   Yang F, 2013, FEBS LETT, V587, P3175, DOI 10.1016/j.febslet.2013.07.048
   Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010
   Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247
   Zhang JW, 2018, HEPATOLOGY, V67, P171, DOI 10.1002/hep.29405
   Zhang ZY, 2016, CANCER LETT, V376, P62, DOI 10.1016/j.canlet.2016.03.022
   Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989
NR 45
TC 75
Z9 86
U1 1
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2019
VL 37
IS 2
BP 270
EP 283
DI 10.1002/stem.2937
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA HK9TN
UT WOS:000458334900011
PM 30372559
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Saleh, SR
   Saleh, OM
   El Bessoumy, AA
   Sheta, E
   Ghareeb, DA
   Eweda, SM
AF Saleh, Samar R.
   Saleh, Omnia M.
   El Bessoumy, Ashraf A.
   Sheta, Eman
   Ghareeb, Doaa A.
   Eweda, Saber M.
TI The Therapeutic Potential of Two Egyptian Plant Extracts for Mitigating
   Dexamethasone Induced Osteoporosis in Rats: Nrf2/HO 1 and RANK/RANKL/OPG
   Signals
SO ANTIOXIDANTS
LA English
DT Article
DE purslane (Portulaca oleracea L.); chicory (Cichorium intybus L.);
   natural medicine; bone resorption; alendronate; NFATc1; glucocorticoids;
   antioxidant; inflammation
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; PORTULACA OLERACEA L.; BONE MINERAL
   DENSITY; OXIDATIVE STRESS; IN VITRO; OSTEOCLAST DIFFERENTIATION;
   ANTIOXIDANT PROPERTIES; NRF2 ACTIVATION; KAPPA B; ALENDRONATE
AB The prolonged use of exogenous glucocorticoids, such as dexamethasone (Dex), is the most prevalent secondary cause of osteoporosis, known as glucocorticoid induced osteoporosis (GIO). The current study examined the preventative and synergistic effect of aqueous chicory extract (ACE) and ethanolic purslane extract (EPE) on GIO compared with Alendronate (ALN). The phytochemical contents, elemental analysis, antioxidant scavenging activity, and ACE and EPE combination index were evaluated. Rats were randomly divided into control, ACE, EPE, and ACE/EPE MIX groups (100 mg/kg orally), Dex group (received 1.5 mg Dex/kg, Sc), and four treated groups received ACE, EPE, ACE/EPE MIX, and ALN with Dex. The bone mineral density and content, bone index, growth, turnover, and oxidative stress were measured. The molecular analysis of RANK/RANKL/OPG and Nrf2/HO 1 pathways were also evaluated. Dex causes osteoporosis by increasing oxidative stress, decreasing antioxidant markers, reducing bone growth markers (OPG and OCN), and increasing bone turnover and resorption markers (NFATc1, RANKL, ACP, ALP, IL 6, and TNF alpha). In contrast, ACE, EPE, and ACE/EPE MIX showed a prophylactic effect against Dex induced osteoporosis by modulating the measured parameters and the histopathological architecture. In conclusion, ACE/EPE MIX exerts a powerful synergistic effect against GIO by a mode of action different from ALN.
C1 [Saleh, Samar R.; Saleh, Omnia M.; El Bessoumy, Ashraf A.; Ghareeb, Doaa A.; Eweda, Saber M.] Alexandria Univ, Fac Sci, Biochem Dept, Alexandria 21515, Egypt.
   [Saleh, Samar R.; Saleh, Omnia M.; Ghareeb, Doaa A.] Alexandria Univ, Fac Sci, Biochem Dept, Bioscreening & Preclin Trial Lab, Alexandria 21515, Egypt.
   [Sheta, Eman] Alexandria Univ, Fac Med, Pathol Dept, Alexandria 21515, Egypt.
   [Eweda, Saber M.] Taibah Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Madinah 42353, Saudi Arabia.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB);
   Alexandria University; Taibah University
RP Saleh, SR (通讯作者)，Alexandria Univ, Fac Sci, Biochem Dept, Alexandria 21515, Egypt.; Saleh, SR (通讯作者)，Alexandria Univ, Fac Sci, Biochem Dept, Bioscreening & Preclin Trial Lab, Alexandria 21515, Egypt.
EM samar.saleh@alexu.edu.eg; omnia.mohamed_pg@alexu.edu.eg;
   ashraf.elbasomy@alexu.edu.eg; iman.sheta@alexmed.edu.eg;
   d.ghareeb@alexu.edu.eg; seweda@taibahu.edu.sa
RI ; Ghareeb, Doaa/R 6914 2016; Sheta, Eman/KHT 8932 2024; Eweda,
   Saber/AAT 5681 2020
OI Eweda, Saber/0000 0002 5151 0137; Ghareeb, Doaa/0000 0003 3327 4377;
   Sheta Elsawy, Eman/0000 0001 9018 5229; 
CR Abbas ZK, 2015, SAUDI J BIOL SCI, V22, P322, DOI 10.1016/j.sjbs.2014.11.015
   Abdelfattah MA, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 29070 5
   Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   [Anonymous], 1994, Method 200.7: Determination of Metals and Trace Elements in Water and Wastes by Inductively Coupled Plasma Atomic Emission Spectrometry
   Bayazid A, 2020, FOOD AGR IMMUNOL, V31, P513, DOI 10.1080/09540105.2020.1742667
   Birsa ML, 2023, NUTRIENTS, V15, DOI 10.3390/nu15061322
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bull H, 2002, J CLIN PATHOL MOL PA, V55, P65
   Canalis E, 2001, J CLIN ENDOCR METAB, V86, P5681, DOI 10.1210/jc.86.12.5681
   Castiglioni S, 2013, NUTRIENTS, V5, P3022, DOI 10.3390/nu5083022
   Chakraborty K, 2021, INT J BIOL MACROMOL, V190, P739, DOI 10.1016/j.ijbiomac.2021.09.020
   Che JM, 2023, BIOMED PHARMACOTHER, V168, DOI 10.1016/j.biopha.2023.115748
   Che JM, 2021, EUR J PHARMACOL, V906, DOI 10.1016/j.ejphar.2021.174219
   Chen L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9102012
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   CHIU DTY, 1976, BIOCHIM BIOPHYS ACTA, V445, P558, DOI 10.1016/0005 2744(76)90110 8
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Ciosek Z, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040506
   Dhakal K.S., 2010, Age, V51, P12
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Elshal MF, 2013, AFR J TRADIT COMPLEM, V10, P267, DOI 10.4314/ajtcam.v10i5.8
   Eslami B, 2011, CALCIFIED TISSUE INT, V88, P272, DOI 10.1007/s00223 011 9473 5
   Farley JR, 2001, CALCIFIED TISSUE INT, V68, P43, DOI 10.1007/BF02685002
   Florczyk Soluch U, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29122 1
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Govindarajan P, 2013, INT J EXP PATHOL, V94, P387, DOI 10.1111/iep.12038
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Han DY, 2015, INT J CLIN EXP MED, V8, P1411
   Han J, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.813057
   Hermoso M, 2003, IUBMB LIFE, V55, P497, DOI 10.1080/15216540310001642072
   Hildebrandt S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26300 z
   Hou TT, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109205
   Hozayen WG, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1140 y
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Ionescu AA, 2003, EUR RESPIR J, V22, p64S, DOI [10.1183/09031936.03.00004609, 10.4137/CCRPM.S22803]
   Iqbal Y, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060932
   Janda K, 2021, MOLECULES, V26, DOI 10.3390/molecules26061814
   Kashef R., 2018, Curr. Sci. Int, V7, P616
   Kim JY, 2015, BIOL PHARM BULL, V38, P66, DOI 10.1248/bpb.b14 00567
   Kim Min Ju, 2011, International Journal of Oral Biology, V36, P37
   Kobayashi Y, 2018, J ORAL BIOSCI, V60, P31, DOI 10.1016/j.job.2018.03.001
   Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414
   Kuntic V, 2007, J PHARMACEUT BIOMED, V43, P718, DOI 10.1016/j.jpba.2006.07.019
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Lim YY, 2007, FOOD CHEM, V103, P734, DOI 10.1016/j.foodchem.2006.09.025
   Lin BF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1014173
   Lin YL, 1996, J AGR FOOD CHEM, V44, P1387, DOI 10.1021/jf950652k
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lysiuk R., 2017, Int. J. Trends Food Nutr., V1, pe102
   MAITRA I, 1995, BIOCHEM PHARMACOL, V49, P1649, DOI 10.1016/0006 2952(95)00089 I
   Manzocco L, 1998, FOOD SCI TECHNOL LEB, V31, P694, DOI 10.1006/fstl.1998.0491
   Marcadet L, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.903657
   MARCOCCI L, 1994, BIOCHEM BIOPH RES CO, V201, P748, DOI 10.1006/bbrc.1994.1764
   MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432 1033.1974.tb03714.x
   Marques Carvalho A, 2023, BONE REP, V19, DOI 10.1016/j.bonr.2023.101664
   Miao LC, 2019, FOOD CHEM, V290, P239, DOI 10.1016/j.foodchem.2019.04.005
   Moraes De Souza RA, 2008, CIENC TECNOL ALIMENT, V6, P41, DOI 10.1080/11358120809487626
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Nandagopal S., 2007, Advanced in Biological Research, V1, P17
   NASKAR S., 2009, Journal of scientific research, V2, P144, DOI DOI 10.3329/JSR.V2I1.2643
   Nemzer B, 2020, FOOD CHEM, V320, DOI 10.1016/j.foodchem.2020.126621
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Okafor I.A., 2014, Global Journal of Biology, Agriculture and Health Sciences, V3, P132
   Orsolic N, 2014, EUR J NUTR, V53, P1217, DOI 10.1007/s00394 013 0622 7
   Ostjen CA, 2019, EXP MOL PATHOL, V106, P52, DOI 10.1016/j.yexmp.2018.12.001
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Papadaki HA, 2004, J BONE MINER METAB, V22, P577, DOI 10.1007/s00774 004 0526 y
   Perovic J, 2021, FOOD CHEM, V336, DOI 10.1016/j.foodchem.2020.127676
   Petkova N., 2015, Journal of BioScience and Biotechnology, V4, P101
   Priddy C, 2021, BONE REP, V15, DOI 10.1016/j.bonr.2021.101149
   Qi SS, 2018, BIOL TRACE ELEM RES, V183, P288, DOI 10.1007/s12011 017 1134 8
   Rahimi VB, 2019, MOLECULES, V24, DOI 10.3390/molecules24010139
   Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363
   Roberfroid MB, 2002, J NUTR, V132, P3599, DOI 10.1093/jn/132.12.3599
   Sahan Y, 2017, FOOD CHEM, V217, P483, DOI 10.1016/j.foodchem.2016.08.108
   Saleh SR, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11071272
   Saleh SR, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11030508
   Saleh SR, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94058 y
   Samir D., 2022, Pharmacol. Res. Mod. Chin. Med, V4, DOI [10.1016/j.prmcm.2022.100101, DOI 10.1016/J.PRMCM.2022.100101]
   Shaban NZ, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 03056 6
   Sharma Madan Mohan, 2011, International Journal of Botany, V7, P103, DOI 10.3923/ijb.2011.103.107
   Sheng HF, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3120458
   Sipos RS, 2015, OPEN LIFE SCI, V10, P379, DOI 10.1515/biol 2015 0039
   SMITH OLK, 1990, METABOLISM, V39, P641, DOI 10.1016/0026 0495(90)90033 9
   Soni A., 2013, J PHARMACOGN PHYTOCH, V2, P22
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Szentmihalyi K, 1998, PHYTOTHER RES, V12, P163, DOI 10.1002/(SICI)1099 1573(199805)12:3<163::AID PTR217>3.0.CO;2 Y
   TAPPEL A. L., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P326, DOI 10.1016/0003 9861(59)90258 9
   Tariq S, 2019, PAK J MED SCI, V35, P749, DOI 10.12669/pjms.35.3.188
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Uddin MK, 2012, INT J MOL SCI, V13, P10257, DOI 10.3390/ijms130810257
   United States Environmental Protection Agency (USEPA), 2001, 2007 USEPA
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Vrahnas C, 2018, CALCIFIED TISSUE INT, V103, P625, DOI 10.1007/s00223 018 0455 8
   Wang H, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.932488
   Wang Y, 2017, BIOMED PHARMACOTHER, V96, P993, DOI 10.1016/j.biopha.2017.11.136
   Ward LM, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00576
   Wei D., 2015, Med. J. Chin. People's Lib. Army, V40, P778
   Wolonciej M, 2016, POSTEP HIG MED DOSW, V70, P1483, DOI 10.5604/17322693.1229074
   Xiao HH, 2014, J STEROID BIOCHEM, V144, P382, DOI 10.1016/j.jsbmb.2014.08.002
   Xu YE, 2019, LIFE SCI, V224, P58, DOI 10.1016/j.lfs.2019.03.051
   Yang L, 2019, J ENDOCRINOL INVEST, V42, P1125, DOI 10.1007/s40618 019 01034 5
   Yin YK, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57185 1
   Zhao JR, 2019, J BONE MINER METAB, V37, P805, DOI 10.1007/s00774 019 00989 y
   Zhou JR, 2007, AM J CLIN NUTR, V86, p882S, DOI 10.1093/ajcn/86.3.882S
   Zhou XM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.791585
   Zhu HB, 2010, FOOD ANAL METHOD, V3, P90, DOI 10.1007/s12161 009 9091 2
   Zych M, 2009, ACTA BIOCHIM POL, V56, P503
NR 111
TC 9
Z9 9
U1 5
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD JAN
PY 2024
VL 13
IS 1
AR 66
DI 10.3390/antiox13010066
PG 29
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA GH9S8
UT WOS:001151902200001
PM 38247490
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kuroyanagi, G
   Tokuda, H
   Fujita, K
   Kawabata, T
   Sakai, G
   Kim, W
   Hioki, T
   Tachi, J
   Matsushima Nishiwaki, R
   Otsuka, T
   Iida, H
   Kozawa, O
AF Kuroyanagi, Gen
   Tokuda, Haruhiko
   Fujita, Kazuhiko
   Kawabata, Tetsu
   Sakai, Go
   Kim, Woo
   Hioki, Tomoyuki
   Tachi, Junko
   Matsushima Nishiwaki, Rie
   Otsuka, Takanobu
   Iida, Hiroki
   Kozawa, Osamu
TI Upregulation of TGF β induced HSP27 by HSP90 inhibitors in osteoblasts
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Heat shock protein; HSP90; HSP90 inhibitor; HSP27; TGF beta; SAPK/JNK;
   Osteoblast
ID SHOCK PROTEIN 27; BONE FORMATION; IN VITRO; CANCER; EXPRESSION;
   INDUCTION; PATHWAYS; THERAPY
AB Background: Heat shock protein (HSP) 90 functions as a molecular chaperone and is constitutively expressed and induced in response to stress in many cell types. We have previously demonstrated that transforming growth factor beta (TGF beta), the most abundant cytokine in bone cells, induces the expression of HSP27 through Smad2, p44/p42 mitogen activated protein kinase (MAPK), p38 MAPK, and stress activated protein kinase/c Jun N terminal kinase (SAPK/JNK) in mouse osteoblastic MC3T3 E1 cells. This study investigated the effects of HSP90 on the TGF beta induced HSP27 expression and the underlying mechanism in mouse osteoblastic MC3T3 E1 cells.
   Methods: Clonal osteoblastic MC3T3 E1 cells were treated with the HSP90 inhibitors and then stimulated with TGF beta. HSP27 expression and the phosphorylation of Smad2, p44/p42 MAPK, p38 MAPK, and SAPK/JNK were evaluated by western blot analysis.
   Result: HSP90 inhibitors 17 dimethylaminoethylamino 17 demethoxy geldanamycin (17 DMAG) and onalespib significantly enhanced the TGF beta induced HSP27 expression. TGF beta inhibitor SB431542 reduced the enhancement by 17 DMAG or onalespib of the TGF beta induced HSP27 expression levels. HSP90 inhibitors, geldanamycin, onalespib, and 17 DMAG did not affect the TGF beta stimulated phosphorylation of Smad2. Geldanamycin did not affect the TGF beta stimulated phosphorylation of p44/p42 MAPK or p38 MAPK but significantly enhanced the TGF beta stimulated phosphorylation of SAPK/JNK. Onalespib also increased the TGF beta stimulated phosphorylation of SAPK/JNK. Furthermore, SP600125, a specific inhibitor for SAPK/JNK, significantly suppressed onalespib or geldanamycin's enhancing effect of the TGF beta induced HSP27 expression levels.
   Conclusion: Our results strongly suggest that HSP90 inhibitors upregulated the TGF beta induced HSP27 expression and that these effects of HSP90 inhibitors were mediated through SAPK/JNK pathway in osteoblasts.
C1 [Kuroyanagi, Gen; Fujita, Kazuhiko; Kawabata, Tetsu; Sakai, Go; Otsuka, Takanobu] Nagoya City Univ, Dept Orthoped Surg, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.
   [Kuroyanagi, Gen] Nagoya City Univ, Dept Rehabil Med, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Kuroyanagi, Gen; Tokuda, Haruhiko; Fujita, Kazuhiko; Kawabata, Tetsu; Sakai, Go; Kim, Woo; Hioki, Tomoyuki; Tachi, Junko; Matsushima Nishiwaki, Rie; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Clin Lab, Med Genome Ctr Biobank, Obu, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Metab Res, Obu, Japan.
   [Kim, Woo; Tachi, Junko; Iida, Hiroki] Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Gifu, Japan.
   [Hioki, Tomoyuki] Kizawa Mem Hosp, Dept Dermatol, Minokamo, Japan.
C3 Nagoya City University; Nagoya City University; Gifu University;
   National Center for Geriatrics & Gerontology; National Center for
   Geriatrics & Gerontology; Gifu University
RP Kuroyanagi, G (通讯作者)，Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu, Japan.
EM kokuryugen@yahoo.co.jp
OI Matsushima Nishiwaki, Rie/0009 0003 7496 737X
FU Ministry of Education, Culture, Science, Sports and Technology of Japan
   [15K10487, 17 K11002, 19K18471]; National Center for Geriatrics and
   Gerontology, Japan [28 9, 29 12]; Grants in Aid for Scientific Research
   [19K18471] Funding Source: KAKEN
FX This study was supported by Grants in Aid for Scientific Research
   (15K10487, 17 K11002 and 19K18471) from the Ministry of Education,
   Culture, Science, Sports and Technology of Japan, and Research Funding
   for Longevity Sciences (28 9 and 29 12) from the National Center for
   Geriatrics and Gerontology, Japan.
CR Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Chen HX, 2017, J STEROID BIOCHEM, V171, P236, DOI 10.1016/j.jsbmb.2017.04.004
   Egorin MJ, 2002, CANCER CHEMOTH PHARM, V49, P7, DOI 10.1007/s00280 001 0380 8
   Fuhrmann Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00314 z
   Fujita K, 2018, INT J MOL MED, V42, P2185, DOI 10.3892/ijmm.2018.3785
   Fujita K, 2018, MOL MED REP, V17, P8542, DOI 10.3892/mmr.2018.8878
   Hang K, 2018, CELL STRESS CHAPERON, V23, P1153, DOI 10.1007/s12192 018 0932 z
   Haque A, 2016, CURR PHARM DESIGN, V22, P2947, DOI 10.2174/1381612822666160325152200
   Hatakeyama D, 2002, BBA MOL CELL RES, V1589, P15, DOI 10.1016/S0167 4889(01)00183 5
   Hayashi K, 2008, LIFE SCI, V82, P1012, DOI 10.1016/j.lfs.2008.02.017
   Kainuma S, 2017, INT J MOL MED, V40, P1057, DOI 10.3892/ijmm.2017.3119
   Kampinga HH, 2009, CELL STRESS CHAPERON, V14, P105, DOI 10.1007/s12192 008 0068 7
   Kato K, 2011, ENDOCRINOLOGY, V152, P1872, DOI 10.1210/en.2010 1062
   Kim W, 2019, PROSTAG OTH LIPID M, V143, DOI 10.1016/j.prostaglandins.2019.03.002
   KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014 4827(92)90158 5
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Mellatyar H, 2018, BIOMED PHARMACOTHER, V102, P608, DOI 10.1016/j.biopha.2018.03.102
   Miyasaka M, 2015, TISSUE ENG PT A, V21, P2829, DOI [10.1089/ten.tea.2015.0234, 10.1089/ten.TEA.2015.0234]
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466 1268(2001)006<0105:GTPOAC>2.0.CO;2
   Romanello M, 2006, BONE, V39, P739, DOI 10.1016/j.bone.2006.03.011
   Rong BX, 2018, INT J ONCOL, V52, P321, DOI 10.3892/ijo.2017.4214
   Samadi AK, 2011, CANCER LETT, V312, P158, DOI 10.1016/j.canlet.2011.07.031
   Sims NA, 1996, CALCIFIED TISSUE INT, V59, P121, DOI 10.1007/s002239900098
   Smith V, 2005, CANCER CHEMOTH PHARM, V56, P126, DOI 10.1007/s00280 004 0947 2
   Sreedhar AS, 2004, FEBS LETT, V562, P11
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Woodhead AJ, 2010, J MED CHEM, V53, P5956, DOI 10.1021/jm100060b
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078 0432.CCR 06 2966
   Yamamoto N, 2015, MOL CELL ENDOCRINOL, V405, P35, DOI 10.1016/j.mce.2015.02.002
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
NR 35
TC 2
Z9 2
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 26
PY 2022
VL 23
IS 1
AR 495
DI 10.1186/s12891 022 05419 1
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 1N3LW
UT WOS:000800561700003
PM 35619094
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, IS
   Cho, TH
   Kim, K
   Weber, FE
   Hwang, SJ
AF Kim, In Sook
   Cho, Tae Hyung
   Kim, Kwansik
   Weber, Franz E.
   Hwang, Soon Jung
TI High Power Pulsed Nd:YAG Laser as a New Stimulus to Induce BMP 2
   Expression in MC3T3 E1 Osteoblasts
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE bone, BMP 2, high power laser; Nd:YAG; osteoblast differentiation
ID BONE NODULE FORMATION; RAT CALVARIAL CELLS; IN VITRO; ND YAG;
   IRRADIATION; PROLIFERATION; DIFFERENTIATION; CULTURES; THERAPY;
   STIMULATION
AB Background and Objective: High power laser has recently become a physical stimulus for bone regeneration. Little is known about how high power laser irradiation affects osteoblast differentiation This study investigated osteoblast responses to high power laser and combined irradiation with BMP 2 treatment.
   Study Design/Materials and Methods: MC3T3 E1 preosteoblasts were exposed to laser irradiation, 100 ng/ml BMP 2 or both. Cells were irradiated with a Q switched, pulsed neodymium doped yttrium aluminum garnet (Nd:YAG) laser, with a 1,064 nm wavelength and 0.75W output power under 1.5, 3, or 5 J/cm(2) energy densities. Cell proliferation was evaluated using tetrazolium salt, WST 8 To determine the effect of these treatments on in vitro osteogenesis, we examined alkaline phosphatase (ALP) activity, mineral deposition, and expression of genes associated with osteogenesis Quantitative real time PCR or ELISA was used to examine cytokine expression In each experiment, either non irradiated or BMP 2 (100 ng/m1) treated cells were used as controls.
   Results: High power, low level, Nd:YAG laser irradiation significantly increased ALP activity, when combined with BMP 2 or not Cell proliferation declined in the irradiation and combined irradiation/BMP 2 groups. Interestingly, Nd YAG laser stimulation resulted in significant induction of endogenous BMP 2 protein and gene expression The increased expression of upstream regulators cbfal by Nd YAG laser alone was comparable to exogenous BMP 2 treatment (100 ng/ml) Combined laser/BMP 2 treatment was synergistic in the expression of some genes (IGF 1, cbfal) and ALP activity, compared to both BMP 2 treatment and laser irradiation alone. In vitro matrix mineralization was significantly accelerated by laser stimulation compared to that of the control, more so than with the combined laser/BMP 2 treatment.
   Conclusions: The present in vitro findings demonstrate that high power, low level Nd:YAG laser increased osteoblast activity, very efficiently accelerating mineral deposition. Osteoinductive effect of laser is likely mediated by activation of BMP 2 related signaling pathway. Lasers Surg Med 42:510 518, 2010 (C) 2010 Wiley Liss, Inc.
C1 [Kim, In Sook; Cho, Tae Hyung; Hwang, Soon Jung] Seoul Natl Univ, Dent Res Inst, Seoul 110749, South Korea.
   [Kim, Kwansik] New York Seoul Dent Hosp, Seoul 157871, South Korea.
   [Weber, Franz E.] Univ Zurich Hosp, Lab Osteol, Dept Craniomaxillofacial Surg, CH 8091 Zurich, Switzerland.
   [Hwang, Soon Jung] Seoul Natl Univ, Dept Maxillofacial Cell & Dev Biol, Sch Dent, Program Craniomaxillofacial Life Sci 2, Seoul 110768, South Korea.
C3 Seoul National University (SNU); University of Zurich; University Zurich
   Hospital; Seoul National University (SNU)
RP Hwang, SJ (通讯作者)，Seoul Natl Univ, Dept Oral & Maxillofacial Surg, Sch Dent, 275 1 Yeongun Dong, Seoul 110768, South Korea.
RI Weber, Franz/I 7831 2019
OI Weber, Franz/0000 0003 1670 2296
FU Ministry of Health and Welfare, Republic of Korea [A084359]
FX Contract grant sponsor Ministry of Health and Welfare, Republic of
   Korea, Contract grant number A084359
CR Almeida Lopes L, 2001, LASER SURG MED, V29, P179, DOI 10.1002/lsm.1107
   Arisu HD, 2006, LASER MED SCI, V21, P175, DOI 10.1007/s10103 006 0398 6
   ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006 8993(89)91240 7
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Cleary S. F., 1977, Laser applications in medicine and biology vol.3, P175
   Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600 051X.1996.tb00580.x
   Eduardo FD, 2008, LASER SURG MED, V40, P433, DOI 10.1002/lsm.20646
   FRIEDMANN H, 1991, J PHOTOCH PHOTOBIO B, V11, P87, DOI 10.1016/1011 1344(91)80271 I
   Fujihara NA, 2006, LASER SURG MED, V38, P332, DOI 10.1002/lsm.20298
   Fukuhara E, 2006, CALCIFIED TISSUE INT, V79, P443, DOI 10.1007/s00223 006 0072 9
   Gan JC, 2006, EUR SPINE J, V15, P1301, DOI 10.1007/s00586 006 0087 y
   GUSH RJ, 1991, MED BIOL ENG COMPUT, V29, P387, DOI 10.1007/BF02441659
   Hofmann A, 2008, J TRAUMA, V65, P1402, DOI 10.1097/TA.0b013e318173e7c2
   Hughes Fulford Millie, 2004, Sci STKE, V2004, pRE12
   In De Braekt MM, 1991, J DENT RES, V70, P1467, DOI 10.1177/00220345910700111501
   KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032 198905000 00015
   Kim IS, 2008, DEV GROWTH DIFFER, V50, P553, DOI 10.1111/j.1440 169X.2008.01052.x
   Luger EJ, 1998, LASER SURG MED, V22, P97, DOI 10.1002/(SICI)1096 9101(1998)22:2<97::AID LSM5>3.3.CO;2 E
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102
   Matsui Satoshi, 2008, J Oral Sci, V50, P75, DOI 10.2334/josnusd.50.75
   Moritz A, 1999, J CLIN LASER MED SUR, V17, P161, DOI 10.1089/clm.1999.17.161
   Ninomiya T, 2003, J BONE MINER METAB, V21, P67, DOI 10.1007/s007740300011
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   Sato S, 2001, LASER SURG MED, V29, P464, DOI 10.1002/lsm.10002.abs
   Schindl A, 2000, J INVEST MED, V48, P312
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   VANBREUGEL HHFI, 1992, LASER SURG MED, V12, P528, DOI 10.1002/lsm.1900120512
   Walsh LJ, 1997, AUST DENT J, V42, P247, DOI 10.1111/j.1834 7819.1997.tb00129.x
   Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756 3282(03)00029 2
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   WEISS N, 1992, ANAT EMBRYOL, V186, P497
   Weyts FAA, 2003, CALCIFIED TISSUE INT, V72, P505, DOI 10.1007/s00223 002 2027 0
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 36
TC 20
Z9 24
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0196 8092
EI 1096 9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD AUG
PY 2010
VL 42
IS 6
BP 510
EP 518
DI 10.1002/lsm.20870
PG 9
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Surgery
GA 639XC
UT WOS:000281009400009
PM 20127830
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cai, YL
   Liu, XC
   Ma, L
   Lv, WX
   Wang, WG
   Zhang, XC
AF Cai, Yuli
   Liu, Xiaochen
   Ma, Liang
   Lv, Wenxue
   Wang, Weiguo
   Zhang, Xingcai
TI JIAN PI YI SHEN DRUG CONTAINING SERUM PROMOTES PROLIFERATION AND
   ACTIVITY OF MOUSE OSTEOBLASTS
SO BIOSCIENCE JOURNAL
LA English
DT Article
DE Alkaline Phosphatase; Nitric Oxide; Osteoblasts; Osteoporosis
ID NITRIC OXIDE; OSTEOPOROSIS
AB Jian Pi Yi Shen (JPYS) decoction is a traditional Chinese herbal formula. The present study aimed to investigate the effect of JPYS drug containing serum on the proliferation and activity of mouse osteoblasts. Sprague.Dawley rats were fed JPYS decoction, calcium supplement, or normal saline for 6 weeks, and the serum was collected. Mouse osteoblasts were treated with JPYS drug containing serum, calcium supplement serum, or blank control serum. Cell proliferation was assayed using thiazolyl blue tetrazolium bromide. Levels of alkaline phosphatase, nitric oxide, and nitric oxide synthase in the culture medium were measured. The JPYS drug containing serum significantly improved the proliferation of osteoblasts compared to the blank control serum and the calcium supplement serum. It also significantly increased the levels of alkaline phosphatase in the culture medium compared to the blank control serum and the calcium supplement serum. Treatment with JPYS drug containing serum for 48 h and 72 h significantly increased the nitric oxide (NO) concentration in the culture medium compared to the blank control serum. The NOS activity of the osteoblasts was significantly increased by JPYS drug containing serum compared to blank control serum and calcium supplement serum. All these results were enhanced that the JPYS decoction promotes the proliferation and activity of mouse osteoblasts. These effects may be the underlying mechanisms of JPYS decoction in treating osteoporosis.
C1 [Cai, Yuli; Liu, Xiaochen; Ma, Liang; Lv, Wenxue] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Joint Surg, Jinan, Peoples R China.
   [Wang, Weiguo] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthoped, Jinan, Peoples R China.
   [Zhang, Xingcai] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Resp Med, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine; Shandong University of Traditional
   Chinese Medicine
RP Zhang, XC (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Resp Med, Jinan, Peoples R China.
EM zhangxc_1974@163.com
RI zhang, xingcai/AAK 8496 2021
OI Zhang, Xingcai/0000 0002 8084 8508
CR Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Becerril S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092129
   Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549 018 4697 y
   Deng X, 2019, PHYTOMEDICINE, V65, DOI 10.1016/j.phymed.2019.153103
   Gao Z, 2013, CHIN J INTEGR MED, V19, P862, DOI 10.1007/s11655 013 1328 z
   Guizoni DM, 2020, NITRIC OXIDE BIOL CH, V94, P48, DOI 10.1016/j.niox.2019.10.008
   He JB, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 016 0301 4
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Muhammad RN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71531 8
   Sasaki S, 2018, KIDNEY BLOOD PRESS R, V43, P1409, DOI 10.1159/000493379
   Shu B, 2015, CHIN J INTEGR MED, V21, P656, DOI 10.1007/s11655 015 2306 z
   Siller AF, 2018, J BONE MINER RES, V33, P362, DOI 10.1002/jbmr.3225
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Xu H, 2005, AM J CHINESE MED, V33, P299, DOI 10.1142/S0192415X05002916
   Yan Guang li, 2015, Zhongguo Zhong Yao Za Zhi, V40, P3406
   Zhao YZ, 2015, J PHARMACOL SCI, V129, P83, DOI 10.1016/j.jphs.2015.09.002
NR 22
TC 0
Z9 0
U1 2
U2 8
PU UNIV FEDERAL UBERLANDIA
PI UBERLANDIA
PA AV PARA, 1720 CAMPUS UMUARAMA, UBERLANDIA, 38400 902, BRAZIL
SN 1981 3163
J9 BIOSCI J
JI Biosci. J.
PY 2023
VL 39
AR e39083
DI 10.14393/BJ v39n0a2023 64818
PG 9
WC Agriculture, Multidisciplinary; Agronomy; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Life Sciences & Biomedicine   Other Topics
GA Z8SP9
UT WOS:001114722200003
OA gold
DA 2025 08 17
ER

PT J
AU Rellick, SL
   Hu, GQ
   Piktel, D
   Martin, KH
   Geldenhuys, WJ
   Nair, RR
   Gibson, LF
AF Rellick, Stephanie L.
   Hu, Gangqing
   Piktel, Debra
   Martin, Karen H.
   Geldenhuys, Werner J.
   Nair, Rajesh R.
   Gibson, Laura F.
TI Co culture model of B cell acute lymphoblastic leukemia recapitulates a
   transcription signature of chemotherapy refractory minimal residual
   disease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BONE MARROW MICROENVIRONMENT; THERAPY; SURVIVAL
AB B cell acute lymphoblastic leukemia (ALL) is characterized by accumulation of immature hematopoietic cells in the bone marrow, a well established sanctuary site for leukemic cell survival during treatment. While standard of care treatment results in remission in most patients, a small population of patients will relapse, due to the presence of minimal residual disease (MRD) consisting of dormant, chemotherapy resistant tumor cells. To interrogate this clinically relevant population of treatment refractory cells, we developed an in vitro cell model in which human ALL cells are grown in co culture with human derived bone marrow stromal cells or osteoblasts. Within this co culture, tumor cells are found in suspension, lightly attached to the top of the adherent cells, or buried under the adherent cells in a population that is phase dim (PD) by light microscopy. PD cells are dormant and chemotherapy resistant, consistent with the population of cells that underlies MRD. In the current study, we characterized the transcriptional signature of PD cells by RNA Seq, and these data were compared to a published expression data set derived from human MRD B cell ALL patients. Our comparative analyses revealed that the PD cell population is markedly similar to the MRD expression patterns from the primary cells isolated from patients. We further identified genes and key signaling pathways that are common between the PD tumor cells from co culture and patient derived MRD cells as potential therapeutic targets for future studies.
C1 [Rellick, Stephanie L.; Hu, Gangqing; Piktel, Debra; Martin, Karen H.; Nair, Rajesh R.; Gibson, Laura F.] West Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, 1 Med Ctr Dr, Morgantown, WV 26506 USA.
   [Geldenhuys, Werner J.] West Virginia Univ, Sch Pharm, Dept Pharmaceut Sci, Morgantown, WV 26506 USA.
   [Rellick, Stephanie L.; Piktel, Debra; Martin, Karen H.; Nair, Rajesh R.; Gibson, Laura F.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA.
   [Hu, Gangqing] West Virginia Univ, Bioinformat Core, Morgantown, WV 26506 USA.
   [Hu, Gangqing] West Virginia Clin & Translat Sci Inst, Morgantown, WV 26506 USA.
C3 West Virginia University; West Virginia University; West Virginia
   University; West Virginia University
RP Gibson, LF (通讯作者)，West Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, 1 Med Ctr Dr, Morgantown, WV 26506 USA.; Gibson, LF (通讯作者)，West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA.
EM lgibson@hsc.wvu.edu
RI Hu, Gangqing/ABA 3507 2020
OI Piktel, Debra/0000 0001 6706 5923
FU Alexander B. Osborn Hematopoietic Malignancy and Transplantation Endowed
   Professorship; NIH [1U54GM104942 04, P30GM103488, P30GM121322,
   P20GM103434, P20 GM109098]
FX This work was supported by the Alexander B. Osborn Hematopoietic
   Malignancy and Transplantation Endowed Professorship, NIH Grants
   1U54GM104942 04, P30GM103488, P30GM121322, P20GM103434, and P20
   GM109098. Next Generation Sequencing was completed using the Marshall
   University Genomic and Bioinformatics Core.
CR Abou Dalle I, 2020, THER ADV HEMATOL, V11, DOI 10.1177/2040620720910023
   Adams OJ, 2018, GLYCOBIOLOGY, V28, P640, DOI 10.1093/glycob/cwx108
   Aldawood A M, 2015, Ann Hematol Oncol, V2
   Barwe SP, 2017, SEMIN ONCOL, V44, P101, DOI 10.1053/j.seminoncol.2017.06.005
   Beesley AH, 2005, BRIT J HAEMATOL, V131, P447, DOI 10.1111/j.1365 2141.2005.05785.x
   Berry DA, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.0580
   Bruce A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140506
   Chen Z, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.586820
   Chiarini F, 2016, BBA MOL CELL RES, V1863, P449, DOI 10.1016/j.bbamcr.2015.08.015
   Ciudad J, 1998, J CLIN ONCOL, V16, P3774, DOI 10.1200/JCO.1998.16.12.3774
   Cortez MAA, 2009, PEDIATR BLOOD CANCER, V53, P996, DOI 10.1002/pbc.22220
   Della Starza I, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00726
   Ebinger S, 2016, CANCER CELL, V30, P849, DOI 10.1016/j.ccell.2016.11.002
   Franquiz MJ, 2020, BIOL TARGETS THER, V14, P23, DOI 10.2147/BTT.S202746
   Gibson LF, 2002, LEUKEMIA LYMPHOMA, V43, P19, DOI 10.1080/10428190210188
   Hall BM, 2004, LEUKEMIA LYMPHOMA, V45, P35, DOI 10.1080/1042819031000139620
   Hellmich C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00230
   Howe EA, 2011, BIOINFORMATICS, V27, P3209, DOI 10.1093/bioinformatics/btr490
   Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Lutz C, 2013, LEUKEMIA, V27, P1204, DOI 10.1038/leu.2012.306
   Ma ZL, 2020, STEM CELLS, V38, P756, DOI 10.1002/stem.3169
   Martin K.H., 2015, TRANSL BIOMED, V6, P14, DOI [10.21767/2172 0479.100014, DOI 10.21767/2172 0479.100014]
   Monaghan KL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02779
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Moses BS, 2016, EXP HEMATOL, V44, P50, DOI 10.1016/j.exphem.2015.09.003
   Nair RR, 2020, PHARM RES DORDR, V37, DOI 10.1007/s11095 020 2767 4
   Nair RR, 2018, LEUKEMIA RES, V72, P59, DOI 10.1016/j.leukres.2018.08.002
   Qin Q, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 1934 6
   Riganti C, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv046
   Sang YW, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.608722
   Sekiya Y, 2017, BRIT J HAEMATOL, V176, P248, DOI 10.1111/bjh.14420
   Shishido S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00099
   Slone WL, 2016, JOVE J VIS EXP, DOI 10.3791/53645
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Talarico C, 2016, CELL PHYSIOL BIOCHEM, V39, P1863, DOI 10.1159/000447885
   Usmani S, 2019, ONCOL LETT, V17, P5039, DOI 10.3892/ol.2019.10188
   Williams MS, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2019.1705730
NR 38
TC 17
Z9 17
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 4
PY 2021
VL 11
IS 1
AR 15840
DI 10.1038/s41598 021 95039 x
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA UA0CA
UT WOS:000684832300002
PM 34349149
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kalyan, S
   Wang, J
   Quabius, ES
   Huck, J
   Wiltfang, J
   Baines, JF
   Kabelitz, D
AF Kalyan, Shirin
   Wang, Jun
   Quabius, Elgar Susanne
   Huck, Joern
   Wiltfang, Joerg
   Baines, John F.
   Kabelitz, Dieter
TI Systemic immunity shapes the oral microbiome and susceptibility to
   bisphosphonate associated osteonecrosis of the jaw
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Adverse drug effects; Bisphosphonates; Immune function; Oral microbiome;
   Osteonecrosis of the jaw
ID DELTA T CELLS; FIBROBLAST GROWTH FACTOR 9; ISOPENTENYL PYROPHOSPHATE;
   MULTIPLE MYELOMA; GENE EXPRESSION; THERAPY; BONE; STIMULATION;
   LYMPHOCYTES; ACTIVATION
AB Background: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug effect linked to long term and/or high dose exposure to nitrogen bisphosphonates (N BP), the standard of care for the treatment of bone fragility disorders. The mechanism leading to bisphosphonate associated ONJ (BAONJ) is unclear and optimal treatment strategies are lacking. Recent evidence suggests that BAONJ may be linked to drug induced immune dysfunction, possibly associated with increased susceptibility to infections in the oral cavity. The objective of this investigation was to comprehensively assess the relationship linking immune function, N BP exposure, the oral microbiome and ONJ susceptibility.
   Methods: Leukocyte gene expression of factors important for immunity, wound healing and barrier function were assessed by real time quantitative PCR and the oral microbiome was characterized by 454 pyrosequencing of the 16S rRNA gene in 93 subjects stratified by N BP exposure and a history of ONJ.
   Results: There were marked differences in the systemic expression of genes regulating immune and barrier functions including RANK (p = 0.007), aryl hydrocarbon receptor (AHR, p < 0.001), and FGF9 (p < 0.001), which were collectively up regulated in individuals exposed to N BP without ONJ relative to treatment controls. In contrast, the expression levels of these same genes were significantly down regulated in those who had experienced BAONJ. Surprisingly, the oral microbiome composition was not directly linked to either BAONJ or N BP exposure, rather the systemic leukocyte expression levels of RANK, TNFA and AHR each explained 9% (p = 0.04), 12% (p = 0.01), and 7% (p = 0.03) of the oral bacterial beta diversity.
   Conclusions: The oral microbiome is unlikely causative of ONJ, rather individuals with BAONJ lacked immune resiliency which impaired their capacity to respond adequately to the immunological stress of N BP treatment. This may be the common factor linking N BP and anti RANK agents to ONJ in at risk individuals. Preventive and/or therapeutic strategies should target the wound healing deficits present in those with ONJ.
C1 [Kalyan, Shirin; Quabius, Elgar Susanne; Kabelitz, Dieter] Univ Kiel, Inst Immunol, D 24105 Kiel, Germany.
   [Wang, Jun; Baines, John F.] Max Planck Inst Evolutionary Biol, D 24306 Plon, Germany.
   [Wang, Jun; Baines, John F.] Univ Kiel, Inst Expt Med, D 24105 Kiel, Germany.
   [Quabius, Elgar Susanne] Univ Kiel, Dept Otorhinolaryngol Head & Neck Surg, D 24105 Kiel, Germany.
   [Huck, Joern; Wiltfang, Joerg] Univ Kiel, Dept Oral & Maxillofacial Surg, D 24105 Kiel, Germany.
C3 University of Kiel; Max Planck Society; University of Kiel; University
   of Kiel; University of Kiel
RP Kabelitz, D (通讯作者)，Univ Kiel, Inst Immunol, Arnold Heller Str 3,Bldg 17, D 24105 Kiel, Germany.
EM dietrich.kabelitz@uksh.de
RI Baines, John/B 3580 2010; Wang, Jun/LXV 0504 2024; Kabelitz,
   Dieter/AAB 4199 2021; Kalyan, Shirin/E 2130 2011
OI Wang, Jun/0000 0002 8859 7707; Kalyan, Shirin/0000 0002 7332 2225
FU Alexander von Humboldt Foundation of Germany; Faculty of Medicine Grant
   from Christian Albrechts University of Kiel; Deutsche
   Forschungsgemeinschaft ("Inflammation at Interfaces" Cluster of
   Excellence)
FX This work was completed thanks to the assistance of Professor Heiner
   Monig, Dr. Martin Mrugalla and the network of physicians in Kiel who
   assisted in informing potential participants about the study and their
   subsequent aid in sample collection. We would also like to thank Hilke
   Clasen for technical assistance with the RNA extractions and Professor
   Philip Rosenstiel for critical review of the manuscript. The sequencing
   group of the Institute of Clinical Molecular Biology, University Kiel,
   is acknowledged for performing 16S rRNA gene sequencing. SK was
   supported by a Fellowship from the Alexander von Humboldt Foundation of
   Germany and a Faculty of Medicine Grant from Christian Albrechts
   University of Kiel. DK and JB acknowledge grant support from the
   Deutsche Forschungsgemeinschaft ("Inflammation at Interfaces" Cluster of
   Excellence).
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Anderson MJ, 2003, ECOLOGY, V84, P511, DOI 10.1890/0012 9658(2003)084[0511:CAOPCA]2.0.CO;2
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Boff RC, 2014, ARCH ORAL BIOL, V59, P790, DOI 10.1016/j.archoralbio.2014.05.002
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Deetz CO, 2006, INFECT IMMUN, V74, P4505, DOI 10.1128/IAI.00088 06
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Edwards BJ, 2008, LANCET ONCOL, V9, P1166, DOI 10.1016/S1470 2045(08)70305 X
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Gatti D, 1999, DRUG AGING, V15, P285, DOI 10.2165/00002512 199915040 00004
   Hamady M, 2009, GENOME RES, V19, P1141, DOI 10.1101/gr.085464.108
   Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025
   Ji X, 2012, ORAL DIS, V18, P85, DOI 10.1111/j.1601 0825.2011.01848.x
   Kalyan S, 2014, CELL MOL LIFE SCI, V71, P2335, DOI 10.1007/s00018 013 1495 x
   Kalyan S, 2014, J CLIN ENDOCR METAB, V99, P1307, DOI 10.1210/jc.2013 3648
   Kalyan S, 2014, EUR J IMMUNOL, V44, P627, DOI 10.1002/eji.201344195
   Kalyan S, 2013, J BONE MINER RES, V28, P728, DOI 10.1002/jbmr.1769
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kress E, 2006, MOL IMMUNOL, V43, P2002, DOI 10.1016/j.molimm.2005.11.011
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Linnenbrink M, 2013, MOL ECOL, V22, P1904, DOI 10.1111/mec.12206
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lukens JR, 2012, J IMMUNOL, V188, P3107, DOI 10.4049/jimmunol.1103308
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mawardi H, 2011, J DENT RES, V90, P1339, DOI 10.1177/0022034511420430
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Oksanen J., 2018, Package 'vegan'
   Palaska PK, 2009, ONCOLOGIST, V14, P1154, DOI 10.1634/theoncologist.2009 0115
   Pfeilschifter J, 2006, EXP CLIN ENDOCR DIAB, V114, P611
   Pushalkar S, 2014, INT J ORAL SCI, V6, P219, DOI 10.1038/ijos.2014.46
   Quarto N, 2009, CELLS TISSUES ORGANS, V190, P158, DOI 10.1159/000202789
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Roberts NA, 2012, IMMUNITY, V36, P427, DOI 10.1016/j.immuni.2012.01.016
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Sabbione F, 2014, EUR J IMMUNOL, V44, P819, DOI 10.1002/eji.201343664
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541 09
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vogel CFA, 2013, IMMUNOL CELL BIOL, V91, P568, DOI 10.1038/icb.2013.43
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang CK, 2009, INT J CANCER, V125, P807, DOI 10.1002/ijc.24348
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062 07
   Wei X, 2012, ORAL DIS, V18, P602, DOI 10.1111/j.1601 0825.2012.01916.x
   Wimalawansa SJ, 2008, EXPERT OPIN DRUG SAF, V7, P491, DOI 10.1517/14740338.7.4.491 
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Workalemahu G, 2006, J CELL PHYSIOL, V207, P67, DOI 10.1002/jcp.20541
   Workalemahu G, 2004, J LEUKOCYTE BIOL, V75, P657, DOI 10.1189/jlb.0902471
   Workalemahu G, 2003, J IMMUNOL, V170, P153, DOI 10.4049/jimmunol.170.1.153
NR 52
TC 37
Z9 42
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUL 4
PY 2015
VL 13
AR 212
DI 10.1186/s12967 015 0568 z
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CM0KS
UT WOS:000357367400001
PM 26141514
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Novince, CM
   Ward, BB
   McCauley, LK
AF Novince, Chad M.
   Ward, Brent B.
   McCauley, Laurie K.
TI Osteonecrosis of the Jaw: An Update and Review of Recommendations
SO CELLS TISSUES ORGANS
LA English
DT Article; Proceedings Paper
CT 9th International Conference on the Chemistry and Biology of Mineralized
   Tissues
CY NOV 04 08, 2007
CL Lakeland, TX
DE Osteonecrosis; Maxilla; Mandible; Bisphosphonates; Oral health
ID BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; AUTOSOMAL DOMINANT
   OSTEOPETROSIS; RISK FACTORS; PREVENTION
AB Bisphosphonates have had a very positive impact as therapeutic agents for cancer and osteoporosis, but have also been associated with osteonecrosis of the jaw (ONJ) which has emerged as an idiosyncratic oral complication. Bisphosphonate associated ONJ has generated wide attention despite its considerably rare occurrence. Many speculations exist as to why bisphosphonates may increase the incidence of ONJ. The American Society for Bone and Mineral Research established a task force on bisphosphonate associated ONJ and recently released a summary report of their findings. A case definition delineated a confirmed case of ONJ as 'an area of exposed bone in the maxillofacial region that did not heal within 8 weeks after identification by a health care provider, in a patient who was receiving or had been exposed to a bisphosphonate and had not had radiation therapy to the craniofacial region'. Treatment recommendations have been developed by the American Dental Association, the American Association of Oral and Maxillofacial Surgeons and the American Society for Bone and Mineral Research. Considering the scientific evidence, little is known about the true incidence and pathophysiology, and many questions persist. New epidemiologic studies are surfacing and attempts to ameliorate the condition may shed light on the likely complex etiology. The bones of the oral cavity provide a unique environment relative to blood flow, oral microbiota, bone structure and function. Although little is known of the mechanisms and course of ONJ, even less is known about the spectrum of issues of altered healing that could fall short of defined ONJ. Copyright (C) 2008 S. Karger AG, Basel
C1 [Novince, Chad M.; McCauley, Laurie K.] Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Ward, Brent B.] Univ Michigan, Dept Oral & Maxillofacial Surg, Sch Dent, Ann Arbor, MI 48109 USA.
   [McCauley, Laurie K.] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP McCauley, LK (通讯作者)，Univ Michigan, Dept Periodont & Oral Med, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM mccauley@umich.edu
RI McCauley, Laurie/G 4041 2012
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Alonci A, 2007, LEUKEMIA LYMPHOMA, V48, P1852, DOI 10.1080/10428190701509806
   *AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144
   Bedogni A, 2007, BONE, V41, P942, DOI 10.1016/j.bone.2007.08.025
   Conte P, 2004, SEMIN ONCOL, V31, P59, DOI 10.1053/j.seminoncol.2004.07.024
   D'Silva NJ, 2006, J AM DENT ASSOC, V137, P1667, DOI 10.14219/jada.archive.2006.0112
   Hansen T, 2007, VIRCHOWS ARCH, V451, P1009, DOI 10.1007/s00428 007 0516 2
   Huja SS, 2006, ANAT REC PART A, V288A, P1243, DOI 10.1002/ar.a.20396
   Junquera L, 2005, AM J OTOLARYNG, V26, P275, DOI 10.1016/j.amjoto.2005.01.007
   KELLER EE, 1987, J AM DENT ASSOC, V115, P697, DOI 10.14219/jada.archive.1987.0302
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   LAMBERTENGHIDELILIERS G, 1988, ORAL SURG ORAL MED O, V65, P533, DOI 10.1016/0030 4220(88)90135 1
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   McDonald MM, 2007, IBMS BONEKEY, V4, P236
   MIGLIORATI CA, 2007, J AM DENT ASSOC, V136, P1658
   Polizzotto MN, 2006, BRIT J HAEMATOL, V132, P114, DOI 10.1111/j.1365 2141.2005.05833.x
   RAVANELLI A, 2006, PRIMER METABOLIC BON, P466
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Rubegni P, 2006, NEW ENGL J MED, V355, pE25, DOI 10.1056/NEJMicm054413
   Waguespack SG, 2007, J CLIN ENDOCR METAB, V92, P771, DOI 10.1210/jc.2006 1986
   Wilkinson GS, 2007, JNCI J NATL CANCER I, V99, P1016, DOI 10.1093/jnci/djm025
NR 22
TC 31
Z9 34
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2009
VL 189
IS 1 4
BP 275
EP 283
DI 10.1159/000152915
PG 9
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 384VJ
UT WOS:000261772000048
PM 18765930
DA 2025 08 17
ER

PT J
AU Guan, YZ
   Sun, C
   Zou, F
   Wang, HL
   Lu, FZ
   Song, J
   Liu, SY
   Xia, XL
   Jiang, JY
   Ma, XS
AF Guan, Yunzhi
   Sun, Chi
   Zou, Fei
   Wang, Hongli
   Lu, Feizhou
   Song, Jian
   Liu, Siyang
   Xia, Xinlei
   Jiang, Jianyuan
   Ma, Xiaosheng
TI Carbohydrate sulfotransferase 3 (CHST3) overexpression promotes
   cartilage endplate derived stem cells (CESCs) to regulate molecular
   mechanisms related to repair of intervertebral disc degeneration by rat
   nucleus pulposus
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE carbohydrate sulfotransferase 3; cartilage endplate&#8208; derived stem
   cells; intervertebral disc degeneration; migration; nucleus pulposus
ID GENOME WIDE ANALYSIS; OSTEOGENIC DIFFERENTIATION; PROGENITOR CELLS;
   GENE EXPRESSION; APOPTOSIS; THERAPY; HYPOXIA
AB To investigate the regulatory effect of carbohydrate sulfotransferase 3 (CHST3) in cartilage endplate derived stem cells (CESCs) on the molecular mechanism of intervertebral disc degeneration after nucleus pulposus repair in rats. We performed GO and KEGG analysis of GSE15227 database to select the differential genes CHST3 and CSPG4 in grade II, and F intervertebral disc degeneration, IHC and WB to detect the protein profile of CHST3 and CSPG4, Co IP for the interaction between CHST3 and CSPG4. Then, immunofluorescence was applied to measure the level of CD90 and CD105, and flow cytometry indicated the level of CD73, CD90 and CD105 in CESCs. Next, Alizarin red staining, Alcian blue staining and TEM were performed to evaluate the effects of CESCs into osteoblasts and chondroblasts, respectively, CCK8 for the cell proliferation of osteoblasts and chondroblasts after induction for different times; cell cycle of osteoblasts or chondroblasts was measured by flow cytometry after induction, and WB for the measurement of specific biomarkers of OC and RUNX in osteoblasts and aggrecan, collagen II in chondroblasts. Finally, colony formation was applied to measure the cell proliferation of CESCs transfected with ov CHST3 or sh CHST3 when cocultured with bone marrow cells, WB for the protein expression of CHST3, CSPG4 and ELAVL1 in CSECs, transwell assay for the migration of CESCs to bone marrow cells, TEM image for the cellular characteristics of bone marrow cells, and WB for the protein profile of VCAN, VASP, NCAN and OFD1 in bone marrow cells. CHST3 and CSPG4 were differentially expressed and interacted in grade II, and intervertebral disc degeneration; CD73, CD90 and CD105 were lowly expressed in CESCs, osteogenic or chondroblastic induction changed the characteristics, proliferation, cell cycle and specific biomarkers of osteoblasts and chondroblasts after 14 or 21 days,; CHST3 affected the cell proliferation, protein profile, migration and cellular features of cocultured CESCs or bone marrow cells. CHST3 overexpression promoted CESCs to regulate bone marrow cells through interaction with CSPG4 to repair the grade II, and intervertebral disc degeneration.
C1 [Guan, Yunzhi; Sun, Chi; Zou, Fei; Wang, Hongli; Lu, Feizhou; Song, Jian; Liu, Siyang; Xia, Xinlei; Jiang, Jianyuan; Ma, Xiaosheng] Fudan Univ, Huashan Hosp, Dept Orthoped, 12 Wulumuqi Middle Rd, Shanghai 200040, Peoples R China.
C3 Fudan University
RP Jiang, JY; Ma, XS (通讯作者)，Fudan Univ, Huashan Hosp, Dept Orthoped, 12 Wulumuqi Middle Rd, Shanghai 200040, Peoples R China.
EM jjy@fudanspine.com; mxs893@sina.com
RI xinlei, xia/AAH 7826 2020; Wang, Hong Li/AAT 7264 2021; Liu,
   Si Yang/HNI 0818 2023
FU National Natural Science Foundation [82072488]
FX National Natural Science Foundation (No. 82072488).
CR Albuz B, 2020, CLIN DYSMORPHOL, V29, P61, DOI 10.1097/MCD.0000000000000295
   Ashinsky BG, 2020, J BONE MINER RES, V35, P1572, DOI 10.1002/jbmr.4009
   Biteau B, 2011, CELL STEM CELL, V9, P402, DOI 10.1016/j.stem.2011.10.004
   Deyo RA, 2016, NEW ENGL J MED, V374, P1763, DOI 10.1056/NEJMcp1512658
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ferrone S, 2020, HNO, V68, P100, DOI 10.1007/s00106 019 00811 1
   He ZL, 2017, ACTA BIOCH BIOPH SIN, V49, P25, DOI 10.1093/abbs/gmw111
   Huang B, 2012, EUR SPINE J, V21, P613, DOI 10.1007/s00586 011 2039 4
   Huang ZN, 2017, MED HYPOTHESES, V101, P65, DOI 10.1016/j.mehy.2017.02.014
   Ji ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07360 1
   Jiang C, 2019, EBIOMEDICINE, V48, P619, DOI 10.1016/j.ebiom.2019.10.006
   Liang L, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007178
   Liu LT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026285
   Lykov AP, 2020, B EXP BIOL MED+, V168, P578, DOI 10.1007/s10517 020 04756 2
   Riccardo F, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919855491
   Ruan DK, 2007, LANCET, V369, P993, DOI 10.1016/S0140 6736(07)60496 6
   Sakai D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2226
   Sheng B, 2018, INT J CLIN EXP PATHO, V11, P1660
   Sloan SR, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay2380
   Sun C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1440 5
   Sun Z, 2019, MED HYPOTHESES, V125, P5, DOI 10.1016/j.mehy.2019.02.003
   Wang H, 2016, EUR SPINE J, V25, P2691, DOI 10.1007/s00586 016 4522 4
   Wang H, 2014, TISSUE ENG PT A, V20, P908, DOI [10.1089/ten.tea.2012.0703, 10.1089/ten.TEA.2012.0703]
   Yao Y, 2017, MOL MED REP, V16, P3001, DOI 10.3892/mmr.2017.6907
   Yao Y, 2017, MOL MED REP, V16, P1991, DOI 10.3892/mmr.2017.6846
   Yuan C, 2018, EXP THER MED, V15, P235, DOI 10.3892/etm.2017.5372
   Yurube T, 2019, EUR SPINE J, V28, P993, DOI 10.1007/s00586 019 05910 9
   Zhou ZG, 2021, CONNECT TISSUE RES, V62, P359, DOI 10.1080/03008207.2020.1743697
   Zuo R, 2019, STEM CELLS, V37, P828, DOI 10.1002/stem.2999
NR 29
TC 9
Z9 9
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2021
VL 25
IS 13
BP 6006
EP 6017
DI 10.1111/jcmm.16440
EA MAY 2021
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA TD7RR
UT WOS:000650836100001
PM 33993645
OA Green Published
DA 2025 08 17
ER

PT J
AU Lyu, HC
   Yoshida, K
   Zhao, SS
   Wei, J
   Zeng, C
   Tedeschi, SK
   Leder, BZ
   Lei, GH
   Tang, PF
   Solomon, DH
AF Lyu, Houchen
   Yoshida, Kazuki
   Zhao, Sizheng S.
   Wei, Jie
   Zeng, Chao
   Tedeschi, Sara K.
   Leder, Benjamin Z.
   Lei, Guanghua
   Tang, Peifu
   Solomon, Daniel H.
TI Delayed Denosumab Injections and Fracture Risk Among Patients With
   Osteoporosis A Population Based Cohort Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID VERTEBRAL FRACTURES; POSTMENOPAUSAL WOMEN; TARGET TRIAL;
   COLORECTAL CANCER; DISCONTINUATION; DATABASE; THERAPY; METAANALYSIS;
   VALIDATION; PREVENTION
AB Background: Denosumab is effective for osteoporosis, but discontinuation leads to rapid reversal of its therapeutic effect.
   Objective: To estimate the risk for fracture among users of denosumab who delayed subsequent doses compared with users who received doses on time.
   Design: Population based cohort study.
   Setting: The Health Improvement Network U.K. primary care database, 2010 to 2019.
   Patients: Persons aged 45 years or older who initiated denosumab therapy for osteoporosis.
   Measurements: Observational data were used to emulate an analysis of a hypothetical trial with 3 dosing intervals: subsequent denosumab injection given within 4 weeks after the recommended date ("on time"), delay by 4 to 16 weeks ("short delay"), and delay by more than 16 weeks ("long delay"). The primary outcome was a composite of all fracture types at 6 months after the recommended date. Secondary outcomes were major osteoporotic fracture, vertebral fracture, hip fracture, and nonvertebral fracture.
   Results: Investigators identified 2594 patients initiating denosumab therapy. The risk for composite fracture over 6 months was 27.3 in 1000 for on time dosing, 32.2 in 1000 for short delay, and 42.4 in 1000 for long delay. Compared with on time injections, short delay had a hazard ratio (HR) for composite fracture of 1.03 (95% CI, 0.63 to 1.69) and long delay an HR of 1.44 (CI, 0.96 to 2.17) (P for trend = 0.093). For vertebral fractures, short delay had an HR of 1.48 (CI, 0.58 to 3.79) and long delay an HR of 3.91 (CI, 1.62 to 9.45).
   Limitation: Dosing schedules were not randomly assigned.
   Conclusion: Although delayed administration of subsequent denosumab doses by more than 16 weeks is associated with increased risk for vertebral fracture compared with on time dosing, evidence is insufficient to conclude that fracture risk is increased at other anatomical sites with long delay.
C1 [Lyu, Houchen; Tang, Peifu] Gen Hosp Chinese PLA, Natl Clin Res Ctr Orthoped Sports Med & Rehabil, 28 Fuxing Rd, Beijing 100853, Peoples R China.
   [Yoshida, Kazuki; Tedeschi, Sara K.; Solomon, Daniel H.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 60 Fenwood Rd, Boston, MA 02115 USA.
   [Zhao, Sizheng S.] Univ Liverpool, Inst Life Course & Med Sci, 3rd Floor Clin Sci Ctr, Liverpool L7 8TX, Merseyside, England.
   [Wei, Jie] Cent South Univ, Xiangya Hosp, Hlth Management Ctr, 87 Xiangya Rd, Changsha 410008, Peoples R China.
   [Zeng, Chao; Lei, Guanghua] Cent South Univ, Xiangya Hosp, Dept Orthopaed, 87 Xiangya Rd, Changsha 410008, Peoples R China.
   [Leder, Benjamin Z.] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, 50 Blossom St,THR 1051, Boston, MA 02114 USA.
   [Leder, Benjamin Z.] Harvard Med Sch, 50 Blossom St,THR 1051, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; University of Liverpool; Central South University;
   Central South University; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   Medical School
RP Lei, GH (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthopaed, 87 Xiangya Rd, Changsha 410008, Peoples R China.; Solomon, DH (通讯作者)，Brigham & Womens Hosp, Div Rheumatol, 60 Fenwood Rd, Boston, MA 02115 USA.; Tang, PF (通讯作者)，Gen Hosp Chinese PLA, Natl Clin Resh Ctr Orthoped Sports Med & Rehabil, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM lei_guanghua@csu.edu.cn; pftang301@126.com; dsolomon@bwh.harvard.edu
RI Yoshida, Kazuki/W 2032 2018; Solomon, Daniel/HTO 5518 2023; Zhao,
   Sizheng/L 2878 2019; Lyu, Houchen/AAW 3614 2020; Wei, Jie/ACR 8087 2022
OI Lyu, Houchen/0000 0002 0128 0062; Wei, Jie/0000 0003 3510 8241; Zhao,
   Sizheng Steven/0000 0002 3558 7353; Yoshida, Kazuki/0000 0002 2030 3549;
   
FU National Institutes of Health [NIH P30 AR072577]
FX By grant NIH P30 AR072577 from the National Institutes of Health and by
   internal resources from the National Clinical Research Center for
   Orthopedics, Sports Medicine & Rehabilitation (Beijing) and Xiangya
   Hospital, Central South University.
CR Anastasilakis AD, 2016, OSTEOPOROSIS INT, V27, P1929, DOI 10.1007/s00198 015 3459 5
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Aubry Rozier B, 2016, OSTEOPOROSIS INT, V27, P1923, DOI 10.1007/s00198 015 3380 y
   Baker R, 2016, INJURY PREV, V22, P59, DOI 10.1136/injuryprev 2015 041561
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003 4819 154 8 201104190 00001
   Cain LE, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557 4679.1212
   Cooper C, 2010, OSTEOPOROSIS INT, V21, P569, DOI 10.1007/s00198 009 1003 1
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Danaei G, 2018, J CLIN EPIDEMIOL, V96, P12, DOI 10.1016/j.jclinepi.2017.11.021
   Dickerman BA, 2019, NAT MED, V25, P1601, DOI 10.1038/s41591 019 0597 x
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Emilsson L, 2018, JAMA ONCOL, V4, P63, DOI 10.1001/jamaoncol.2017.2752
   Fahrleitner Pammer A, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0351 2
   García Albéniz X, 2017, EUR J EPIDEMIOL, V32, P495, DOI 10.1007/s10654 017 0287 2
   García Albeníz X, 2017, ANN INTERN MED, V166, P18, DOI 10.7326/M16 0758
   Hadji P, 2015, OSTEOPOROSIS INT, V26, P2479, DOI 10.1007/s00198 015 3164 4
   Hernán MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648 200009000 00012
   Hernán MA, 2018, BMJ BRIT MED J, V360, DOI 10.1136/bmj.k182
   Hernán MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385
   Hernán MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254
   Hippisley Cox J, 2012, BMJ BRIT MED J, V344, DOI 10.1136/bmj.e3427
   Khalid S, 2018, CLIN EPIDEMIOL, V10, P1417, DOI 10.2147/CLEP.S164112
   Khan NF, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471 2296 11 1
   Labrecque JA, 2017, EUR J EPIDEMIOL, V32, P473, DOI 10.1007/s10654 017 0293 4
   Lewis JD, 2007, PHARMACOEPIDEM DR S, V16, P393, DOI 10.1002/pds.1335
   Lyu HC, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz321
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Ogdie A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210441
   Orellana L, 2010, MAIN CONTENT INT J 1, V6, P8, DOI DOI 10.2202/1557 4679.1200
   Orellana L, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557 4679.1242
   Popp AW, 2016, OSTEOPOROSIS INT, V27, P1917, DOI 10.1007/s00198 015 3458 6
   Prieto Alhambra D, 2011, ARTHRITIS RHEUM US, V63, P992, DOI 10.1002/art.30214
   Schlienger RG, 2004, JAMA J AM MED ASSOC, V292, P1326, DOI 10.1001/jama.292.11.1326
   Schneeweiss S, 2019, ANN INTERN MED, V170, P398, DOI 10.7326/M18 3079
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Torgerson DJ, 1998, ANN RHEUM DIS, V57, P378, DOI 10.1136/ard.57.6.378
   Tripto Shkolnik L, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115150
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Van Staa TP, 2000, PHARMACOEPIDEM DR S, V9, P359, DOI 10.1002/1099 1557(200009/10)9:5<359::AID PDS507>3.0.CO;2 E
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16 2607
   Zhang Yi, 2014, Med Care, V52 Suppl 3, pS132, DOI 10.1097/MLR.0b013e3182a53ca8
NR 45
TC 76
Z9 84
U1 2
U2 32
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106 1572 USA
SN 0003 4819
EI 1539 3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 6
PY 2020
VL 173
IS 7
BP 516
EP +
DI 10.7326/M20 0882
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA NX4GS
UT WOS:000575671400007
PM 32716706
DA 2025 08 17
ER

PT J
AU Doherty, AL
   Battaglino, RA
   Donovan, J
   Gagnon, D
   Lazzari, AA
   Garshick, E
   Zafonte, R
   Morse, LR
AF Doherty, Ashley L.
   Battaglino, Ricardo A.
   Donovan, Jayne
   Gagnon, David
   Lazzari, Antonio A.
   Garshick, Eric
   Zafonte, Ross
   Morse, Leslie R.
TI Adiponectin Is a Candidate Biomarker of Lower Extremity Bone Density in
   Men With Chronic Spinal Cord Injury
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; ADIPONECTIN; BIOMARKER; SPINAL CORD INJURY; REHABILITATION
   MEDICINE
ID SYMPATHETIC NERVOUS SYSTEM; RESTING METABOLIC RATE; BODY MASS INDEX;
   MINERAL DENSITY; SERUM LEPTIN; POSTMENOPAUSAL WOMEN; PLASMA LEPTIN;
   ELDERLY MEN; FAT MASS; OSTEOBLAST DIFFERENTIATION
AB Adipose tissue is a major regulator of bone metabolism and in the general population obesity is associated with greater bone mineral density (BMD). However, bone fat interactions are multifactorial, and may involve pathways that influence both bone formation and resorption with competing effects on the skeleton. One such pathway involves adipocyte production of adipokines that regulate bone metabolism. In this study we determined the association between BMD, walking status, and circulating adipokines (adiponectin and leptin) in 149 men with chronic spinal cord injury (SCI). Although adipokine levels did not vary significantly based on walking status, there was a significant inverse association between adiponectin and BMD in wheelchair users independent of body composition. We found no association between adiponectin and BMD in the walkers and no association between leptin and BMD in either group. These findings suggest that for subjects with chronic SCI, walking may mitigate the effect of adiponectin mediated bone loss. For wheelchair users, adipose derived adiponectin may contribute to SCI induced osteoporosis because the osteoprotective benefits of obesity appear to require mechanical loading during ambulation. (c) 2014 American Society for Bone and Mineral Research.
C1 [Doherty, Ashley L.; Donovan, Jayne; Zafonte, Ross; Morse, Leslie R.] Spaulding Rehabil Hosp, Spaulding Harvard Spinal Cord Injury SCI Model Sy, Boston, MA USA.
   [Battaglino, Ricardo A.; Morse, Leslie R.] Forsyth Inst, Cambridge, MA USA.
   [Battaglino, Ricardo A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Gagnon, David] Boston Univ, Sch Publ Hlth, Dept Biostat, VA Cooperat Studies Program,VA Boston Healthcare, Boston, MA USA.
   [Lazzari, Antonio A.] VA Boston Healthcare Syst, Primary Care Sect, Boston, MA USA.
   [Lazzari, Antonio A.] VA Boston Healthcare Syst, Rheumatol Sect, Boston, MA USA.
   [Lazzari, Antonio A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Garshick, Eric] VA Boston Healthcare Syst, Med Serv, Pulm & Crit Care Med Sect, Boston, MA USA.
   [Garshick, Eric] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
   [Zafonte, Ross; Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Spaulding Rehabilitation Hospital; Harvard University;
   Harvard University Medical Affiliates; Forsyth Institute; Harvard
   University; Harvard School of Dental Medicine; Boston University;
   Harvard University; Harvard University Medical Affiliates; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); VA Boston
   Healthcare System; Harvard University; Harvard University Medical
   Affiliates; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Boston Healthcare System; Harvard University;
   Harvard University Medical Affiliates; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Boston Healthcare
   System; Boston University; Harvard University; Harvard University
   Medical Affiliates; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Boston Healthcare System; Harvard University;
   Harvard University Medical Affiliates; Brigham & Women's Hospital;
   Harvard Medical School; Harvard University; Harvard Medical School
RP Morse, LR (通讯作者)，Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Spaulding Harvard SCI Model Syst,Dept PMR, 300 1st Ave, Charlestown, MA 02129 USA.
EM lmorse4@partners.org
RI ; Morse, Leslie/AAU 5608 2020; Garshick, Eric/Y 6509 2019; battaglino,
   ricardo/D 2892 2015
OI Lazzari, Antonio/0000 0003 0256 4742; 
FU National Institute of Child Health and Human Development [R21HD057030,
   R21HD057030 02S1]; National Institute of Arthritis and Musculoskeletal
   and Skin Diseases [1R01AR059270 01]; Department of Education, NIDRR
   [H133N110010]; Office of Research and Development, Rehabilitation
   Research and Development (Merit Review Grant) [B6618R]; Massachusetts
   Veterans Epidemiology Research and Information Center, Cooperative
   Studies Program, Department of Veterans Affairs
FX This work was supported by the National Institute of Child Health and
   Human Development (R21HD057030 and R21HD057030 02S1), the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   (1R01AR059270 01), the Department of Education, NIDRR (H133N110010), the
   Office of Research and Development, Rehabilitation Research and
   Development (Merit Review Grant B6618R), and the Massachusetts Veterans
   Epidemiology Research and Information Center, Cooperative Studies
   Program, Department of Veterans Affairs. We thank Sam Davis, clinical
   research coordinator and technician, Boston VA Healthcare System, for
   assisting with bone density scans; and Rachael Burns and Kara Loo,
   research assistants, Boston VA Healthcare System, for collection of
   anthropometric data.
CR Agbaht K, 2009, ENDOCRINE, V35, P371, DOI 10.1007/s12020 009 9158 2
   [Anonymous], 2008, EXP BIOL MED, V233, pvi
   Araneta MRG, 2009, J BONE MINER RES, V24, P2016, DOI [10.1359/JBMR.090519, 10.1359/jbmr.090519]
   Barbour KE, 2011, J BONE MINER RES, V26, P1568, DOI 10.1002/jbmr.361
   Basurto L, 2009, EUR J ENDOCRINOL, V160, P289, DOI 10.1530/EJE 08 0569
   Battaglino RA, 2012, BONE, V51, P600, DOI 10.1016/j.bone.2012.04.019
   Bauman WA, 1996, HORM METAB RES, V28, P732, DOI 10.1055/s 2007 979889
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Dennison EM, 2004, CALCIFIED TISSUE INT, V74, P401, DOI 10.1007/s00223 002 0017 x
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Ealey KN, 2008, EXP BIOL MED, V233, P1546, DOI 10.3181/0806 RM 192
   Enjuanes A, 2002, J BONE MINER RES, V17, P1135, DOI 10.1359/jbmr.2002.17.6.1135
   FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507
   Gater DR, 2005, TOP SPINAL CORD INJ, V11, P36
   Gezici AR, 2009, J SPINAL CORD MED, V32, P416, DOI 10.1080/10790268.2009.11753205
   Guo Li juan, 2008, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V33, P731
   Hinoi E, 2009, ANN NY ACAD SCI, V1173, pE20, DOI 10.1111/j.1749 6632.2009.05061.x
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Huang KC, 2004, CLIN ENDOCRINOL, V61, P204, DOI 10.1111/j.1365 2265.2004.02081.x
   Huang TS, 2000, ARCH PHYS MED REHAB, V81, P1582, DOI 10.1053/apmr.2000.9173
   Iacobellis G, 2011, J ENDOCRINOL INVEST, V34, pE12, DOI [10.1007/BF03346703, 10.3275/7170]
   Jen KLC, 2005, J LAB CLIN MED, V146, P18, DOI 10.1016/j.lab.2005.02.014
   Jeon JY, 2003, J CLIN ENDOCR METAB, V88, P402, DOI 10.1210/jc.2002 020939
   Johansson H, 2012, J BONE MINER RES, V27, P1390, DOI 10.1002/jbmr.1591
   Jürimäe J, 2009, EUR J ENDOCRINOL, V160, P381, DOI 10.1530/EJE 08 0673
   Jürimäe J, 2008, J BONE MINER METAB, V26, P618, DOI 10.1007/s00774 008 0861 5
   Kanazawa I, 2009, EUR J ENDOCRINOL, V160, P265, DOI 10.1530/EJE 08 0642
   Kaufman BA, 2002, J CLIN ENDOCR METAB, V87, P2777, DOI 10.1210/jc.87.6.2777
   Khosla S, 2002, ENDOCRINOLOGY, V143, P4161, DOI 10.1210/en.2002 220843
   Lee HW, 2009, STEM CELLS, V27, P2254, DOI 10.1002/stem.144
   Lee WY, 2006, CLIN ENDOCRINOL, V65, P631, DOI 10.1111/j.1365 2265.2006.02641.x
   Lenchik L, 2003, BONE, V33, P646, DOI 10.1016/S8756 3282(03)00237 0
   Maïmoun L, 2004, METABOLISM, V53, P989, DOI 10.1016/j.metabol.2004.03.005
   Maruyama Y, 2008, SPINAL CORD, V46, P494, DOI 10.1038/sj.sc.3102171
   Morse LR, 2012, J BONE MINER RES, V27, P352, DOI 10.1002/jbmr.546
   Morse LR, 2009, ARCH PHYS MED REHAB, V90, P827, DOI 10.1016/j.apmr.2008.12.004
   Muñoz MT, 2004, EUR J ENDOCRINOL, V151, P491, DOI 10.1530/eje.0.1510491
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Papadopoulou F, 2004, ARCH ANDROLOGY, V50, P97, DOI 10.1080/01485010490269515
   Peng MA, 2010, BIOCHEM CELL BIOL, V88, P683, DOI 10.1139/O10 007
   Petit MA, 2008, J BONE MINER RES, V23, P180, DOI [10.1359/jbmr.071018, 10.1359/JBMR.071018]
   Raska I Jr, 2005, Prague Med Rep, V106, P137
   Reid IR, 2002, BONE, V31, P547, DOI 10.1016/S8756 3282(02)00864 5
   Richards JB, 2007, J CLIN ENDOCR METAB, V92, P1517, DOI 10.1210/jc.2006 2097
   Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Sööt T, 2007, J SPORT MED PHYS FIT, V47, P65
   Spungen AM, 2003, J APPL PHYSIOL, V95, P2398, DOI 10.1152/japplphysiol.00729.2002
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thomas T, 2003, JOINT BONE SPINE, V70, P18, DOI 10.1016/S1297 319X(02)00005 2
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   Ushiroyama T, 2003, GYNECOL ENDOCRINOL, V17, P31, DOI 10.1080/713603183
   Wang YH, 2005, ARCH PHYS MED REHAB, V86, P1964, DOI 10.1016/j.apmr.2005.04.017
   Yokota T, 2002, J CLIN INVEST, V109, P1303, DOI 10.1172/JCI200214506
   Zeadin MG, 2012, BIOCHEM BIOPH RES CO, V425, P924, DOI 10.1016/j.bbrc.2012.08.011
   Zhang YJ, 2012, BIOCHEM CELL BIOL, V90, P613, DOI [10.1139/o2012 022, 10.1139/O2012 022]
   Zoico E, 2008, J ENDOCRINOL INVEST, V31, P297, DOI 10.1007/BF03346361
NR 59
TC 26
Z9 26
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2014
VL 29
IS 1
BP 251
EP 259
DI 10.1002/jbmr.2020
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 274HS
UT WOS:000328598000025
PM 23787489
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Dimmen, S
   Nordsletten, L
   Engebretsen, L
   Steen, H
   Madsen, JE
AF Dimmen, Sigbjorn
   Nordsletten, Lars
   Engebretsen, Lars
   Steen, Harald
   Madsen, Jan Erik
TI Negative effect of parecoxib on bone mineral during fracture healing in
   rats
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE 2 INHIBITOR;
   DIFFERENTIAL INHIBITION; SELECTIVE INHIBITOR; COX 2 INHIBITORS;
   INDOMETHACIN; SODIUM; CELECOXIB; ACETAMINOPHEN; METABOLISM
AB Background and purpose Non steroidal anti inflammatory drugs (NSAIDs) are conventional cyclooxygen ase (cox) inhibitors commonly used in musculoskeletal trauma to reduce the inflammatory response and pain, but they also seem to affect bone metabolism. Parecoxib is a cox inhibitor that selectively inhibits cox 2. Through their selective mechanism of action, these newer drugs are supposed to reduce the gastrointestinal side effects of conventional cox inhibitors. The effects on bone metabolism and healing have, however, not been fully elucidated. Thus, there are reasons for concern regarding the potential negative effects of these drugs on bone metabolism and bone repair. We investigated the effects of short term administration of parecoxib on bone mineral formation and bone healing in rats.
   Animals and methods 26 female Wistar rats were given parecoxib intraperitoneally for 7 days after a closed tibial fracture that was stabilized with an intra medullary nail, and 26 animals were given saline. At 2, 3, and 6 weeks after surgery bone mineral density (BMD) at the fracture site was measured using dualenergy X ray absorptiometry (DEXA). 6 weeks after the fracture, 14 rats from the parecoxib group and 16 rats from the placebo group were killed for mechanical testing, and the rest of the animals were killed for tissue analysis. The healing fractures and the intact contralateral tibias were mechanically tested by three point cantilever bending.
   Results The BMD at the fracture site was calculated as the average of the results after 2,3, and 6 weeks. Mean BMD was lower in the parecoxib group, 0.23 (SD 0.06) g/ \cm(2), than in the control group, 0.27 (SD 0.05) g/cm(2) (p = 0.01). There were no statistically significant differences in mechanical properties of the healing fractures after 6 weeks. However, the study may have lacked sufficient statistical power to determine whether a negative effect on healing had occurred.
   Interpretation No mechanical differences were detected between the control and treatment groups after 6 weeks, but they may have been present earlier in the fracture healing process. Our findings do, however, indicate that parecoxib given postoperatively for a week has a negative effect on mineralization during the early phase of fracture healing.
C1 [Dimmen, Sigbjorn; Nordsletten, Lars; Engebretsen, Lars; Madsen, Jan Erik] Ullevaal Univ Hosp, Orthoped Ctr, Oslo, Norway.
   [Dimmen, Sigbjorn; Nordsletten, Lars; Engebretsen, Lars; Madsen, Jan Erik] Fac Med, Oslo, Norway.
   [Dimmen, Sigbjorn; Nordsletten, Lars; Steen, Harald; Madsen, Jan Erik] Univ Oslo, Inst Surg Res, N 0316 Oslo, Norway.
   [Steen, Harald] Univ Oslo, Biomech Lab, Dept Orthoped, Radiumhosp Med Ctr,Rikshosp, N 0316 Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; National
   Hospital Norway
RP Dimmen, S (通讯作者)，Ullevaal Univ Hosp, Orthoped Ctr, Oslo, Norway.
EM sidimmen@online.no
CR Aspenberg P, 2004, J ORTHOPAED RES, V22, P684, DOI 10.1016/j.orthres.2004.01.002
   Aspenberg P, 2002, ACTA ORTHOP SCAND, V73, P489, DOI 10.1080/000164702321022730
   Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402 003 0537 5
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Dahl V, 2004, EUR J ANAESTH, V21, P471, DOI 10.1017/S026502150400609X
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   Desjardins PJ, 2001, ANESTH ANALG, V93, P721, DOI 10.1097/00000539 200109000 00036
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Einhorn TA, 2002, J BONE MINER RES, V17, P977, DOI 10.1359/jbmr.2002.17.6.977
   EKELAND A, 1981, ACTA ORTHOP SCAND, V52, P605, DOI 10.3109/17453678108992155
   Endo K, 2005, ACTA ORTHOP, V76, P470, DOI 10.1080/17453670510041439
   ENGESAETER LB, 1992, ACTA ORTHOP SCAND, V63, P330, DOI 10.3109/17453679209154794
   FOGARTY DJ, 1995, ACTA ANAESTH SCAND, V39, P191, DOI 10.1111/j.1399 6576.1995.tb04041.x
   Gan TJ, 2004, ANESTH ANALG, V98, P1665, DOI 10.1213/01.ANE.0000117001.44280.F3
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   GILLIES GWA, 1987, ANAESTHESIA, V42, P727, DOI 10.1111/j.1365 2044.1987.tb05317.x
   Halpin RA, 2000, DRUG METAB DISPOS, V28, P1244
   HOGEVOLD HE, 1992, ACTA ORTHOP SCAND, V63, P607
   Hubbard RC, 2003, BRIT J ANAESTH, V90, P166, DOI 10.1093/bja/aeg038
   Huntjens DRH, 2005, RHEUMATOLOGY, V44, P846, DOI 10.1093/rheumatology/keh627
   KELLER J, 1989, ACTA ORTHOP SCAND, V60, P119, DOI 10.3109/17453678909150109
   Kranke P, 2004, ANESTH ANALG, V99, P797, DOI 10.1213/01.ANE.0000133139.68208.92
   Leese PT, 2000, J CLIN PHARMACOL, V40, P124, DOI 10.1177/00912700022008766
   Madsen JE, 1998, CLIN ORTHOP RELAT R, P230
   Malan TP, 2003, ANESTHESIOLOGY, V98, P950, DOI 10.1097/00000542 200304000 00023
   MCLOUGHLIN C, 1990, BRIT J ANAESTH, V65, P620, DOI 10.1093/bja/65.5.620
   Meunier A, 2006, ARCH ORTHOP TRAUM SU, V126, P433, DOI 10.1007/s00402 006 0160 3
   Mullis BH, 2006, INJURY, V37, P827, DOI 10.1016/j.injury.2005.12.018
   NORDSLETTEN L, 1994, ACTA ORTHOP SCAND, V65, P191, DOI 10.3109/17453679408995432
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P514
   Rasmussen G Lynn, 2002, Am J Orthop (Belle Mead NJ), V31, P336
   RO J, 1976, ACTA ORTHOP SCAND, V47, P588, DOI 10.3109/17453677608988744
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Stichtenoth DO, 2003, DRUGS, V63, P33, DOI 10.2165/00003495 200363010 00003
   SUDMANN E, 1979, EUR J CLIN INVEST, V9, P333, DOI 10.1111/j.1365 2362.1979.tb00893.x
   Talley JJ, 2000, J MED CHEM, V43, P1661, DOI 10.1021/jm000069h
   Weber EWG, 2003, EUR J ANAESTH, V20, P963, DOI 10.1097/00003643 200312000 00005
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 43
TC 29
Z9 38
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1745 3674
EI 1745 3682
J9 ACTA ORTHOP
JI Acta Orthop.
PY 2008
VL 79
IS 3
BP 438
EP 444
DI 10.1080/17453670710015373
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 325MO
UT WOS:000257593200020
PM 18626809
DA 2025 08 17
ER

PT J
AU Nolan, CR
AF Nolan, CR
TI Phosphate binder therapy for attainment of K/DOQI™ bone metabolism
   guidelines
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE calcium acetate; sevelamer hydrochloride; hypercalcemia; metabolic
   acidosis; cardiovascular calcification
ID CORONARY ARTERY CALCIFICATION; VASCULAR CALCIFICATION;
   HEMODIALYSIS PATIENTS; PARATHYROID HORMONE; SERUM PHOSPHORUS; MORTALITY
   RISK; PROGRESSION; ACIDOSIS; CALCIUM; HYPERPHOSPHATEMIA
AB Hyperphosphatemia in patients with chronic kidney disease leads to secondary hyperparathyroidism and renal osteodystrophy, and it is independently associated with mortality risk. The exact mechanism by which hyperphosphatemia increases mortality risk is unknown, but it may relate to enhanced cardiovascular calcification. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI (TM)) Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommends maintenance of serum phosphorus below 5.5 mg/dL, calcium phosphorus (Ca x P) product less than 55 mg(2)/dL(2), intact parathyroid hormone (iPTH) 150 pg/mL to 300 pg/mL, and bicarbonate (HCO3) greater than 22 mEq/L. Although calcium based phosphate binders (CBPB) are cost effective, there are long term safety concerns pertaining to their postulated role in the progression of cardiovascular calcification. Sevelamer hydrochloride has been recommended as an alternative noncalcium phosphate binder. Results from the Calcium Acetate Renagel Evaluation (CARE) study indicate that calcium acetate is more effective than sevelamer hydrochloride in controlling serum phosphorous, Ca x P product, and HCO3 in hemodialysis patients. In the Treat to Goal study, dialysis patients treated with sevelamer hydrochloride had slower progression of coronary and aortic calcification than patients treated with CBPB. The mechanism underlying the beneficial effect of sevelamer hydrochloride is unknown but may relate to decreased calcium loading, or to dramatic reductions in low density lipoprotein (LDL) cholesterol in sevelamer hydrochloride treated patients. At present, evidence incriminating CBPB in the progression of cardiovascular calcification in end stage renal disease (ESRD) remains largely circumstantial. As calcium acetate is more efficacious and cost effective than sevelamer hydrochloride, it remains an accepted first line phosphate binder. This review examines these issues and provides rational guidelines for the use of CBPB in patients on maintenance hemodialysis.
C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM nolan@uthscsa.edu
CR Achenbach S, 2002, CIRCULATION, V106, P1077, DOI 10.1161/01.CIR.0000027567.49283.FF
   [Anonymous], AM J KIDNEY DIS S2, DOI DOI 10.1053/KD.2000.6671
   Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566
   BALLMER PE, 1995, J CLIN INVEST, V95, P39, DOI 10.1172/JCI117668
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Brezina B, 2004, KIDNEY INT, V66, pS39, DOI 10.1111/j.1523 1755.2004.09007.x
   Bushinsky DA, 2000, CURR OPIN NEPHROL HY, V9, P369, DOI 10.1097/00041552 200007000 00008
   Bushinsky DA, 1995, AM J PHYSIOL CELL PH, V269, pC1364, DOI 10.1152/ajpcell.1995.269.6.C1364
   BUSHINSKY DA, 1989, AM J PHYSIOL, V256, pF836, DOI 10.1152/ajprenal.1989.256.5.F836
   Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703
   Chertow GM, 2004, NEPHROL DIAL TRANSPL, V19, P1489, DOI 10.1093/ndt/gfh125
   Chertow GM, 1997, AM J KIDNEY DIS, V29, P66, DOI 10.1016/S0272 6386(97)90009 3
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Davies MR, 2003, J AM SOC NEPHROL, V14, P1559, DOI 10.1097/01.ASN.0000068404.57780.DD
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Guérin AP, 2000, NEPHROL DIAL TRANSPL, V15, P1014, DOI 10.1093/ndt/15.7.1014
   HURST PE, 1963, CLIN SCI, V24, P187
   Manns B, 2004, KIDNEY INT, V66, P1239, DOI 10.1111/j.1523 1755.2004.00877.x
   Nitta K, 2004, NEPHROL DIAL TRANSPL, V19, P2156, DOI 10.1093/ndt/gfh338
   Qunibi WY, 2004, KIDNEY INT, V65, P1914, DOI 10.1111/j.1523 1755.2004.00590.x
   QUNIBI WY, 2002, KIDNEY INT S, V82, P73
   RUBINSTEIN R, 1969, CLIN SCI, V37, P549
   Silver J, 2002, ADV RENAL REPLACE TH, V9, P159, DOI 10.1053/jarr.2002.34846
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   Slatopolsky EA, 1999, KIDNEY INT, V55, P299, DOI 10.1046/j.1523 1755.1999.00240.x
NR 27
TC 7
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2005
VL 68
SU 96
BP S7
EP S14
DI 10.1016/S0085 2538(15)51227 1
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 934BG
UT WOS:000229681000003
PM 15954948
OA Bronze
DA 2025 08 17
ER

PT J
AU Mackey, AL
   Rasmussen, LK
   Kadi, F
   Schjerling, P
   Helmark, IC
   Ponsot, E
   Aagaard, P
   Durigan, JLQ
   Kjaer, M
AF Mackey, Abigail L.
   Rasmussen, Lotte K.
   Kadi, Fawzi
   Schjerling, Peter
   Helmark, Ida C.
   Ponsot, Elodie
   Aagaard, Per
   Durigan, Joao Luiz Q.
   Kjaer, Michael
TI Activation of satellite cells and the regeneration of human skeletal
   muscle are expedited by ingestion of nonsteroidal anti inflammatory
   medication
SO FASEB JOURNAL
LA English
DT Article
DE Pax7; electrical stimulation; telomere length; extracellular matrix;
   Notch signaling pathway
ID TELOMERE LENGTH; STEM CELLS; EXERCISE; NOTCH; INJURY; PROLIFERATION;
   HYPERTROPHY; MYOGENESIS; DAMAGE; DRUGS
AB With this study we investigated the role of nonsteroidal anti inflammatory drugs (NSAIDs) in human skeletal muscle regeneration. Young men ingested NSAID [1200 mg/d ibuprofen (IBU)] or placebo (PLA) daily for 2 wk before and 4 wk after an electrical stimulation induced injury to the leg extensor muscles of one leg. Muscle biopsies were collected from the vastus lateralis muscles before and after stimulation (2.5 h and 2, 7, and 30 d) and were assessed for satellite cells and regeneration by immunohistochemistry and real time RT PCR, and we also measured telomere length. After injury, and compared with PLA, IBU was found to augment the proportion of ActiveNotch1(+) satellite cells at 2 d [IBU, 29 +/  3% vs. PLA, 19 +/  2% (means +/  sem)], satellite cell content at 7 d [IBU, 0.16 +/  0.01 vs. PLA, 0.12 +/  0.01 (Pax7(+) cells/fiber)], and to expedite muscle repair at 30 d. The PLA group displayed a greater proportion of embryonic myosin(+) fibers and a residual approximate to 2 fold increase in mRNA levels of matrix proteins (all P < 0.05). Endomysial collagen was also elevated with PLA at 30 d. Minimum telomere length shortening was not observed. In conclusion, ingestion of NSAID has a potentiating effect on Notch activation of satellite cells and muscle remodeling during large scale regeneration of injured human skeletal muscle.Mackey, A. L., Rasmussen, L. K., Kadi, F., Schjerling, P., Helmark, I. C., Ponsot, E., Aagaard, P., Durigan, J. L. Q., Kjaer, M. Activation of satellite cells and the regeneration of human skeletal muscle are expedited by ingestion of nonsteroidal anti inflammatory medication.
C1 [Mackey, Abigail L.; Rasmussen, Lotte K.; Schjerling, Peter; Helmark, Ida C.; Kjaer, Michael] Bispebjerg Hosp, Inst Sports Med Copenhagen, Dept Orthopaed Surg M, DK 2400 Copenhagen NV, Denmark.
   [Mackey, Abigail L.; Kjaer, Michael] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Ctr Hlth Aging, Copenhagen, Denmark.
   [Kadi, Fawzi; Ponsot, Elodie] Univ Orebro, Sch Hlth & Med Sci, SE 70182 Orebro, Sweden.
   [Aagaard, Per] Univ Southern Denmark, Dept Sports Sci & Clin Biomech, Muscle Res Cluster, Odense, Denmark.
   [Durigan, Joao Luiz Q.] Univ Brasilia, Div Phys Therapy, Brasilia, DF, Brazil.
C3 University of Copenhagen; Copenhagen University Hospital; Bispebjerg
   Hospital; University of Copenhagen; Orebro University; University of
   Southern Denmark; Universidade de Brasilia
RP Mackey, AL (通讯作者)，Bispebjerg Hosp, Inst Sports Med M81, Bldg 8,Level 1,Bispebjerg Bakke 23, DK 2400 Copenhagen NV, Denmark.
EM abigailmac@sund.ku.dk
RI Ponsot, Elodie/E 2899 2015; Durigan, Joao/D 1110 2012; Kjaer,
   Michael/W 6842 2019; Schjerling, Peter/F 6194 2011; Kadi,
   Fawzi/LDV 8063 2024; Durigan, João Luiz/D 1110 2012; Mackey,
   Abigail/D 1060 2009; Aagaard, Per/IQW 6548 2023
OI Durigan, Joao/0000 0002 7511 5289; Aagaard, Per/0000 0002 9773 7361;
   Kjaer, Michael/0000 0002 4582 8755; Schjerling,
   Peter/0000 0001 7138 3211; Mackey, Abigail/0000 0002 2017 4580; kadi,
   fawzi/0000 0002 9831 0896
FU U.S. National Institutes of Health, Eunice Kennedy Shriver National
   Institute of Child Health and Human Development; Nordea Foundation
   [223576]; European Commission; Danish Rheumatism Association; Team
   Danmark; Anti Doping Danmark; Oster Jorgensen og Romhild Andersen
   Fonden; King Christian IX and Queen Louise's Anniversary grant (Kong
   Christian IX og Dronning Louises Jubilaeumslegat); Danish Agency for
   Science Technology and Innovation (Medical Research Council); Lundbeck
   Foundation; Lundbeck Foundation [R198 2015 207] Funding Source:
   researchfish; Novo Nordisk Fonden [NNF14OC0012491] Funding Source:
   researchfish
FX The authors thank Camilla Hansen (Institute of Sports Medicine
   Copenhagen, Bispebjerg Hospital) for excellent technical assistance in
   taking the blood samples and preparing the muscle biopsies and Anja
   Jokipii (Institute of Sports Medicine Copenhagen, Bispebjerg Hospital)
   for the mRNA analysis. The authors also thank Mathias Ekstrand (School
   of Health and Medical Sciences, Orebro University) for excellent
   technical assistance with the telomere analysis. The F1.652 and A4.951
   antibodies developed by Helen M. Blau were obtained from the
   Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA,
   USA), developed under the auspices of the U.S. National Institutes of
   Health, Eunice Kennedy Shriver National Institute of Child Health and
   Human Development and maintained by the Department of Biological
   Sciences, University of Iowa. This work was supported by the Nordea
   Foundation (Healthy Aging grant), MYOAGE (# 223576), which is funded by
   the European Commission under FP7, the Danish Rheumatism Association,
   Team Danmark, Anti Doping Danmark, Oster Jorgensen og Romhild Andersen
   Fonden, King Christian IX and Queen Louise's Anniversary grant (Kong
   Christian IX og Dronning Louises Jubilaeumslegat), the Danish Agency for
   Science Technology and Innovation (Medical Research Council), and the
   Lundbeck Foundation.
CR Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002
   Acharjee S, 2014, J CELL SCI, V127, P599, DOI 10.1242/jcs.136648
   Bjornson CRR, 2012, STEM CELLS, V30, P232, DOI 10.1002/stem.773
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Carlson ME, 2009, EMBO MOL MED, V1, P381, DOI 10.1002/emmm.200900045
   Chiquet M, 2014, INT J BIOCHEM CELL B, V53, P51, DOI 10.1016/j.biocel.2014.04.020
   Collins M, 2003, MED SCI SPORT EXER, V35, P1524, DOI 10.1249/01.MSS.0000084522.14168.49
   Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534 5807(02)00254 X
   Crameri RM, 2007, J PHYSIOL LONDON, V583, P365, DOI 10.1113/jphysiol.2007.128827
   Decary S, 1997, HUM GENE THER, V8, P1429, DOI 10.1089/hum.1997.8.12 1429
   Fry CS, 2014, FASEB J, V28, P1654, DOI 10.1096/fj.13 239426
   Grounds MD, 2014, INT J BIOCHEM CELL B, V56, P56, DOI 10.1016/j.biocel.2014.09.010
   Jarvinen Tero Ah, 2013, Muscles Ligaments Tendons J, V3, P337
   Kadi F, 2008, MED SCI SPORT EXER, V40, P82, DOI 10.1249/mss.0b013e3181596695
   Lemos DR, 2015, NAT MED, V21, P786, DOI 10.1038/nm.3869
   Mackey AL, 2012, SCAND J MED SCI SPOR, V22, pE8, DOI 10.1111/j.1600 0838.2012.01463.x
   Mackey AL, 2008, J APPL PHYSIOL, V105, P1620, DOI 10.1152/japplphysiol.90952.2008
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mackey AL, 2011, FASEB J, V25, P1943, DOI 10.1096/fj.10 176487
   Mackey AL, 2010, J APPL PHYSIOL, V109, P1920, DOI 10.1152/japplphysiol.00789.2010
   McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   Mourikis P, 2012, STEM CELLS, V30, P243, DOI 10.1002/stem.775
   Ponsot E, 2008, ELECTROPHORESIS, V29, P542, DOI 10.1002/elps.200700290
   Ponsot E, 2012, EXP PHYSIOL, V97, P774, DOI 10.1113/expphysiol.2011.063818
   Rae DE, 2010, EUR J APPL PHYSIOL, V109, P323, DOI 10.1007/s00421 010 1353 6
   Redmond EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084122
   Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088
   Rocheteau P, 2012, CELL, V148, P112, DOI 10.1016/j.cell.2011.11.049
   Saclier M, 2013, STEM CELLS, V31, P384, DOI 10.1002/stem.1288
   Shavlakadze T, 2010, BIOGERONTOLOGY, V11, P363, DOI 10.1007/s10522 009 9260 0
   Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013
   Urso ML, 2013, J APPL PHYSIOL, V115, P920, DOI 10.1152/japplphysiol.00036.2013
   Zeng QJ, 2014, POULTRY SCI, V93, P138, DOI 10.3382/ps.2013 03300
NR 34
TC 75
Z9 80
U1 1
U2 25
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2016
VL 30
IS 6
BP 2266
EP 2281
DI 10.1096/fj.201500198R
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA DN2FA
UT WOS:000376878300018
PM 26936358
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, C
   Li, GQ
   Liu, M
   Zhou, TT
   Zhou, HB
AF Li, Cheng
   Li, Guoqiang
   Liu, Meng
   Zhou, Tiantian
   Zhou, Haibin
TI Paracrine effect of inflammatory cytokine activated bone marrow
   mesenchymal stem cells and its role in osteoblast function
SO JOURNAL OF BIOSCIENCE AND BIOENGINEERING
LA English
DT Article
DE Bone marrow mesenchymal stem cells; Inflammatory cytokine; Osteogenesis;
   Paracrine; Bone regeneration
ID STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; PROGENITOR CELLS;
   GROWTH FACTOR; LYMPHOCYTE PROLIFERATION; THERAPY; INHIBIT;
   IMMUNOSUPPRESSION; ANGIOGENESIS; REPAIR
AB Mesenchymal stem cells (MSCs) have a crucial function in bone regeneration. Inflammation is a well documented component of the osteogenic microenvironment. In the present study, we investigated whether stimulation of MSCs with inflammatory cytokines promotes osteogenesis through a paracrine mediator. MSCs were pre stimulated with the inflammatory factors IFN gamma and TNF alpha. After pre stimulation, the MSC secretion levels of IL 6, HGF, VEGF, and TGF beta were significantly elevated (p < 0.01); however, the production of IL 2, IL 4, and IL 10 was not changed (p > 0.05). MG63, an osteoblast like cell line, was cultured in different MSC conditioned media. After treatment with conditioned media collected from MSCs pre treated with cytokines, the proliferation and migration of MG63 cells were significantly improved, and the expression levels of the osteoblast differentiation markers ALP, COLT, OCN and OPN were significantly increased as revealed by a quantitative PCR analysis (p < 0.05). Furthermore, an immunofluorescence staining assay showed that more MG63 cells were OPN positive, while an Alizarin red staining indicated the increased formation of calcium nodules in the IFN gamma and TNF alpha combined pretreatment group. The results indicated that conditioned medium from inflammatory cytokine activated MSCs can significantly promote osteoblast proliferation, migration, differentiation, and mineralization and ultimately enhance osteogenesis through paracrine mechanisms. These findings present a new direction for the clinical application of MSCs in the repair of bone defects. (C) 2015, The Society for Biotechnology, Japan. All rights reserved.
C1 [Li, Cheng; Li, Guoqiang; Zhou, Haibin] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215004, Peoples R China.
   [Li, Cheng; Li, Guoqiang; Liu, Meng; Zhou, Tiantian] Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Zhou, HB (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215004, Peoples R China.
EM 13913133393@163.com
RI zhou, tiantian/KBB 3092 2024; zhou, haibin/N 4597 2014
FU National Natural Science Foundation of China [81301844]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions of
   China
FX We thank Qingyu Wu for the helpful suggestions. This work was supported
   in part by grants from the National Natural Science Foundation of China
   (81301844) and the Priority Academic Program Development of Jiangsu
   Higher Education Institutions of China.
CR Augello A, 2005, EUR J IMMUNOL, V35, P1482, DOI 10.1002/eji.200425405
   Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501
   Burlacu A, 2013, STEM CELLS DEV, V22, P643, DOI 10.1089/scd.2012.0273
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen KT, 2011, BONE, V49, P1194, DOI 10.1016/j.bone.2011.08.023
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56
   Frank O, 2002, J CELL BIOCHEM, V85, P737, DOI 10.1002/jcb.10174
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008 0818]
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood 2002 07 2104
   Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001
   Liu Y, 2011, J BIOL CHEM, V286, P25007, DOI 10.1074/jbc.M110.213108
   Liu YW, 2011, ATHEROSCLEROSIS, V219, P440, DOI 10.1016/j.atherosclerosis.2011.08.033
   Lu ZF, 2012, STEM CELLS DEV, V21, P2420, DOI 10.1089/scd.2011.0589
   Matsumoto T, 2009, ARTHRITIS RHEUM US, V60, P1390, DOI 10.1002/art.24443
   MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240
   Murphy JM, 2003, ARTHRITIS RHEUM US, V48, P3464, DOI 10.1002/art.11365
   Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080
   Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Ringdén O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Rosová I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007 1104
   Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581
   Scheller J, 2011, BBA MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
   Tsai SW, 2008, ACTA BIOMATER, V4, P1332, DOI 10.1016/j.actbio.2008.03.015
   Tsai SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031200
   Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416
   van den Beucken JJJP, 2006, J CONTROL RELEASE, V113, P63, DOI 10.1016/j.jconrel.2006.03.016
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008 0333
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06 6558com
   Zhao LM, 2010, TISSUE ENG PT A, V16, P725, DOI 10.1089/ten.TEA.2009.0495
NR 42
TC 84
Z9 94
U1 0
U2 42
PU SOC BIOSCIENCE BIOENGINEERING JAPAN
PI OSAKA
PA OSAKA UNIV, FACULTY ENGINEERING, 2 1 YAMADAOKA, SUITA, OSAKA, 565 0871,
   JAPAN
SN 1389 1723
EI 1347 4421
J9 J BIOSCI BIOENG
JI J. Biosci. Bioeng.
PD FEB
PY 2016
VL 121
IS 2
BP 213
EP 219
DI 10.1016/j.jbiosc.2015.05.017
PG 7
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA DE8LK
UT WOS:000370887300014
PM 26315505
DA 2025 08 17
ER

PT J
AU Pascual, J
   Torrealba, J
   Myers, J
   Tome, S
   Samaniego, M
   Musat, A
   Djamali, A
AF Pascual, J.
   Torrealba, J.
   Myers, J.
   Tome, S.
   Samaniego, M.
   Musat, A.
   Djamali, A.
TI Collapsing focal segmental glomerulosclerosis in a liver transplant
   recipient on alendronate
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE alendronate; bisphosphonate; chronic kidney disease; nephrotic syndrome;
   osteopenia
ID BONE LOSS; DOSE PAMIDRONATE; GLOMERULOPATHY; CALCITRIOL; FRACTURES;
   PREVENTS; PATIENT; DISEASE; HIV
AB We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia. In view of the increasing incidence of chronic kidney disease in long term liver transplant patients, bisphosphonates need to be used with caution in these patients. The usefulness of bisphosphonates for the prevention of early bone loss after liver transplantation is increasingly reported. However, there is little information on the safety and efficacy of these drugs when used in the later stages of liver transplant, particularly in the presence of chronic kidney disease. Bisphosphonates are excreted unchanged via the kidneys after reaching the systemic circulation. Some cases of severe kidney injury, in particular collapsing focal segmental glomerulosclerosis, have been described that are associated with the use of pamidronate. Alendronate, a widely used bisphosphonate in transplant patients, has not been related to kidney toxicity. We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient soon after the initiation of alendronate for osteopenia. Possible pathogenetic mechanisms are discussed. In view of the increasing incidence of chronic kidney disease in long term liver transplant patients, bisphosphonate need to be used with caution in patients with a low glomerular filtration rate.
C1 Univ Wisconsin Hosp, Clin H4 733 CSC, Dept Surg, Div Transplantat, Madison, WI 53706 USA.
   Univ Wisconsin, Sch Publ Hlth & Med, Dept Surg, Madison, WI 53706 USA.
   Univ Wisconsin, Sch Publ Hlth & Med, Dept Pathol & Lab Med, Madison, WI 53706 USA.
   Univ Wisconsin, Sch Publ Hlth & Med, Dept Med, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University Wisconsin Madison Hospital; University of Wisconsin System;
   University of Wisconsin Madison; University of Wisconsin System;
   University of Wisconsin Madison; University of Wisconsin System;
   University of Wisconsin Madison
RP Pascual, J (通讯作者)，Univ Wisconsin Hosp, Clin H4 733 CSC, Dept Surg, Div Transplantat, 600 Highland Ave, Madison, WI 53706 USA.
EM julpascual@gmail.com
FU NIDDK NIH HHS [KO8 DK067981] Funding Source: Medline
CR Barisoni L, 1999, J AM SOC NEPHROL, V10, P51
   Barri YM, 2004, KIDNEY INT, V65, P634, DOI 10.1111/j.1523 1755.2004.00426.x
   BOUNAMEAUX HM, 1983, LANCET, V1, P471
   Dodidou P, 2003, OSTEOPOROSIS INT, V14, P82, DOI 10.1007/s00198 002 1315 x
   DUMON JC, 1991, BONE MINER, V15, P257, DOI 10.1016/0169 6009(91)90131 I
   Giannini S, 2001, J BONE MINER RES, V16, P2111, DOI 10.1359/jbmr.2001.16.11.2111
   HAAGSMA EB, 1988, J HEPATOL, V6, P94, DOI 10.1016/S0168 8278(88)80467 7
   Jeffery JR, 2003, TRANSPLANTATION, V76, P1498, DOI 10.1097/01.TP.0000092523.30277.13
   Kunin M, 2004, NEPHROL DIAL TRANSPL, V19, P723, DOI 10.1093/ndt/gfg567
   Laurinavicius A, 1999, KIDNEY INT, V56, P2203, DOI 10.1046/j.1523 1755.1999.00769.x
   Leidig Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140 6736(00)03641 2
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Markowitz GS, 2002, AM J KIDNEY DIS, V39, P1118, DOI 10.1053/ajkd.2002.32797
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
   MEYS E, 1994, AM J MED, V97, P445, DOI 10.1016/0002 9343(94)90324 7
   Millonig G, 2005, LIVER TRANSPLANT, V11, P960, DOI 10.1002/lt.20466
   Pillebout E, 2005, AM J TRANSPLANT, V5, P1120, DOI 10.1111/j.1600 6143.2005.00852.x
   Sauter M, 2006, AM J KIDNEY DIS, V47, P1075, DOI 10.1053/j.ajkd.2006.02.189
   Shane E, 2004, NEW ENGL J MED, V350, P767, DOI 10.1056/NEJMoa035617
   YATES AJP, 1985, LANCET, V1, P1474
NR 20
TC 22
Z9 23
U1 0
U2 1
PU SPRINGER LONDON LTD
PI ARTINGTON
PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP,
   GUILDFORD, ENGLAND
SN 0937 941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD OCT
PY 2007
VL 18
IS 10
BP 1435
EP 1438
DI 10.1007/s00198 007 0361 9
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 209SB
UT WOS:000249407200016
PM 17404782
DA 2025 08 17
ER

PT J
AU Liu, Y
   Yang, J
   Jiang, B
   Zheng, GZ
   Wang, Y
AF Liu, Yuan
   Yang, Juan
   Jiang, Bing
   Zheng, Genzi
   Wang, Yao
TI Low energy LED red light inhibits the NF κB pathway and promotes hPDLSCs
   proliferation and osteogenesis in a TNF α environment in vitro
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE hPDLSCs; LED red light; TNF alpha; Proliferation; Osteogenic
   differentiation; NF kappa B
ID MESENCHYMAL STEM CELLS; LASER; DIFFERENTIATION; THERAPY; MECHANISMS
AB There are few studies on the effect of low energy LED red light on periodontal tissue regeneration in an inflammatory environment. In this study, Cell Counting Kit 8 (CCK 8) assays were used to detect the effects of TNF alpha at three different concentrations (0, 10 ng/ml, and 20 ng/ml) on the proliferation of human periodontal ligament stem cells (hPDLSCs), and 10 ng/ml was selected as the subsequent experimental stimulation concentration. CCK 8 assays were used to detect the effect of LED red light with energy density of 1 J/ cm(2), 3 J/ cm(2), and 5 J/cm(2) on the proliferation of hPDLSCs. The promotion effect of energy density of 5 J/cm(2) on the proliferation of hPDLSCS was the most obvious (p < 0.05). Set CON group, ODM group, ODM + 10 ng/ml TNF alpha group, and ODM + 10 ng/ml TNF alpha + 5 J/ cm(2) LED red light group. Alkaline phosphatase staining and activity detection, alizarin red staining and calcium nodules quantitative detection of osteoblast differentiation products, real time fluorescence quantitative PCR detection of osteoblast gene expression (Runx2, Col I, OPN, OCN). The results showed that ODM showed the strongest osteoblast ability, followed by ODM + 10 ng/ml TNF alpha + 5 J/ cm(2) LED red light group. The osteoblast ability of ODM + 10 ng/ml TNF alpha was decreased, but was not found in CON group. Western blot was used to detect the expression of NF kappa B pathway protein and osteoblast related proteins (Runx2, Col I, OPN, OCN) after addition of PDTC inhibitor. The results showed that the expression of p I kappa B alpha was increased and the expression of I kappa B alpha was decreased (p < 0.05). The expression of osteoblast protein increased after the addition of inhibitor (p < 0.05). Therefore, in an inflammatory environment constructed by 10 ng/ml TNF alpha, 5 J/cm(2) LED red light can upregulate the proliferation and osteogenesis of hPDLSCs by inhibiting NF kappa B signaling pathway.
C1 [Liu, Yuan; Wang, Yao] Southwest Med Univ, Inst Stomatol, Luzhou 646000, Peoples R China.
   [Liu, Yuan] Third Hosp Mianyang, Dept Stomatol, Mianyang 621000, Peoples R China.
   [Liu, Yuan] Sichuan Mental Hlth Ctr, Mianyang 621000, Peoples R China.
   [Yang, Juan; Jiang, Bing; Zheng, Genzi; Wang, Yao] Oral & Maxillofacial Reconstruct & Regenerat Luzho, Luzhou 646000, Peoples R China.
   [Yang, Juan] Chenjiaqiao Hosp Shapingba Dist Chongqing, Chongqing 400000, Peoples R China.
   [Jiang, Bing] Dazhou Hosp Integrated TCM & Western Med Hosp, Dazhou 635000, Peoples R China.
   [Zheng, Genzi] Third Hosp Yibin, Dept Stomatol, Yibin 644000, Peoples R China.
   [Wang, Yao] Southwest Med Univ, Affiliated Stomatol Hosp, Luzhou 646000, Peoples R China.
C3 Southwest Medical University; Southwest Medical University
RP Wang, Y (通讯作者)，Southwest Med Univ, Inst Stomatol, Luzhou 646000, Peoples R China.; Wang, Y (通讯作者)，Oral & Maxillofacial Reconstruct & Regenerat Luzho, Luzhou 646000, Peoples R China.; Wang, Y (通讯作者)，Southwest Med Univ, Affiliated Stomatol Hosp, Luzhou 646000, Peoples R China.
EM 516617861@qq.com; 1179222346@qq.com; 499156596@qq.com; 919426575@qq.com;
   438730587@qq.com
FU Sichuan science and technology plan joint innovation special task
   project [2022YFS0634]; Sichuan Province Medical Research Project
   [S21015]; University level scientific research project of Southwest
   Medical University [2021ZKMS013]
FX This work was supported by the Sichuan science and technology plan joint
   innovation special task project (2022YFS0634); Sichuan Province Medical
   Research Project (S21015) and University level scientific research
   project of Southwest Medical University (2021ZKMS013).
CR Agnihotri P, 2023, J BIOMOL STRUCT DYN, V41, P13815, DOI 10.1080/07391102.2023.2196692
   Barnabei L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.716469
   Barolet D, 2009, J INVEST DERMATOL, V129, P2751, DOI 10.1038/jid.2009.186
   Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008 5472.CAN 07 1576
   De Oliveira MF, 2022, EUR J PHYS REHAB MED, V58, P282, DOI 10.23736/S1973 9087.21.07236 1
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Ferino A, 2020, J PHOTOCH PHOTOBIO B, V202, DOI [10.1016/j.photobiol.2019.111672, 10.1016/j.jphotobiol.2019.111672]
   Guimaraes DM, 2021, SUPPORT CARE CANCER, V29, P6441, DOI 10.1007/s00520 021 06206 9
   Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864
   Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337
   Hu CX, 2018, J CELL MOL MED, V22, P1428, DOI 10.1111/jcmm.13492
   Huang TY, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13142245
   Kömerik N, 2003, ANTIMICROB AGENTS CH, V47, P932, DOI 10.1128/AAC.47.3.932 940.2003
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Lee KTD, 2019, LASER MED SCI, V34, P913, DOI 10.1007/s10103 018 2675 6
   Lesniewski A, 2022, PHOTOBIOMOD PHOTOMED, V40, P522, DOI 10.1089/photob.2021.0171
   Li XY, 2020, ORAL DIS, V26, P360, DOI 10.1111/odi.13235
   Li YF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243108
   Liu N, 2022, LASER MED SCI, V37, P849, DOI 10.1007/s10103 021 03322 0
   Ma Yu, 2018, Hua Xi Kou Qiang Yi Xue Za Zhi, V36, P184, DOI 10.7518/hxkq.2018.02.013
   Martignago CCS, 2020, LASER MED SCI, V35, P157, DOI 10.1007/s10103 019 02812 6
   Meng TT, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7961962
   Rahmati A, 2022, BMC ORAL HEALTH, V22, DOI 10.1186/s12903 022 02574 8
   Ren C, 2020, LASER MED SCI, V35, P729, DOI 10.1007/s10103 019 02923 0
   Rosa CB, 2014, LASER MED SCI, V29, P859, DOI 10.1007/s10103 013 1284 7
   Sabino VG, 2020, J TISSUE ENG REGEN M, V14, P1792, DOI 10.1002/term.3134
   Sacono NT, 2008, LASER SURG MED, V40, P625, DOI 10.1002/lsm.20677
   Sakamoto FH, 2012, BRIT J DERMATOL, V166, P413, DOI 10.1111/j.1365 2133.2011.10576.x
   Shu CX, 2022, LASER MED SCI, V37, P2259, DOI 10.1007/s10103 021 03492 x
   Si DW, 2022, LASER MED SCI, V37, P3509, DOI 10.1007/s10103 022 03624 x
   Silveira PCL, 2016, INFLAMMATION, V39, P1395, DOI 10.1007/s10753 016 0371 x
   Song SL, 2017, PHYTOMEDICINE, V34, P115, DOI 10.1016/j.phymed.2017.08.010
   Tan J, 2016, J PERIODONTOL, V87, pE159, DOI 10.1902/jop.2016.150718
   Varfolomeev E, 2018, CYTOKINE, V101, P26, DOI 10.1016/j.cyto.2016.08.035
   Wang LY, 2022, LASER MED SCI, V37, P3591, DOI 10.1007/s10103 022 03638 5
   Wang MH, 2020, DIFFERENTIATION, V111, P1, DOI 10.1016/j.diff.2019.10.003
   Wu Y, 2021, LASER MED SCI, V36, P1535, DOI 10.1007/s10103 021 03278 1
   Yan WH, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12691
   Yang YY, 2020, LASER MED SCI, V35, P1981, DOI 10.1007/s10103 020 02995 3
   Zein R, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.12.120901
   Zhang J, 2014, DIFFERENTIATION, V88, P97, DOI 10.1016/j.diff.2014.10.001
   Zhu TT, 2019, LASER MED SCI, V34, P1473, DOI 10.1007/s10103 019 02750 3
   Zhu WJ, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/4910767
   Zhu WJ, 2013, ARCH ORAL BIOL, V58, P1791, DOI 10.1016/j.archoralbio.2013.09.012
NR 44
TC 1
Z9 1
U1 0
U2 7
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD OCT 18
PY 2023
VL 38
IS 1
AR 240
DI 10.1007/s10103 023 03880 5
PG 12
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA U6WG5
UT WOS:001086182900003
PM 37851127
DA 2025 08 17
ER

PT J
AU Fukushima, E
   Monoi, N
   Mikoshiba, S
   Hirayama, Y
   Serizawa, T
   Adachi, K
   Koide, M
   Ohdera, M
   Murakoshi, M
   Kato, H
AF Fukushima, Eriko
   Monoi, Noriyuki
   Mikoshiba, Shigeo
   Hirayama, Yutaka
   Serizawa, Tetsushi
   Adachi, Kiyo
   Koide, Misao
   Ohdera, Motoyasu
   Murakoshi, Michiaki
   Kato, Hisanori
TI Protective Effects of Acetaminophen on Ibuprofen Induced Gastric Mucosal
   Damage in Rats with Associated Suppression of Matrix Metalloproteinase
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OXIDATIVE STRESS; GENE EXPRESSION;
   INDOMETHACIN; PARACETAMOL; PATHOGENESIS; INHIBITION; ASPIRIN; LESIONS;
   INJURY
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are known to cause gastric mucosal damage as a side effect. Acetaminophen, widely used as an analgesic and antipyretic drug, has gastroprotective effects against gastric lesions induced by absolute ethanol and certain NSAIDs. However, the mechanisms that underlie the gastroprotective effects of acetaminophen have not yet been clarified. In the present study, we examined the role and protective mechanism of acetaminophen on ibuprofen induced gastric damage in rats. Ibuprofen and acetaminophen were administered orally, and the gastric mucosa was macroscopically examined 4 hours later. Acetaminophen decreased ibuprofen induced gastric damage in a dose dependent manner. To investigate the mechanisms involved, transcriptome analyses of the ibuprofen damaged gastric mucosa were performed in the presence and absence of acetaminophen. Ingenuity pathway analysis (IPA) software revealed that acetaminophen suppressed the pathways related to cellular assembly and inflammation, whereas they were highly activated by ibuprofen. On the basis of gene classifications from the IPA Knowledge Base, we identified the following five genes that were related to gastric damage and showed significant changes in gene expression: interleukin 1 beta (IL 1 beta), chemokine (C C motif) ligand 2 (CCL2), matrix metalloproteinase 10 (MMP 10), MMP 13, and FBJ osteosarcoma oncogene (FOS). Expression of these salient genes was confirmed using real time polymerase chain reaction. The expression of MMP 13 was the most reactive to the treatments, showing strong induction by ibuprofen and suppression by acetaminophen. Moreover, MMP 13 inhibitors decreased ibuprofen induced gastric damage. In conclusion, these results suggest that acetaminophen decreases ibuprofen induced gastric mucosal damage and that the suppression of MMP 13 may play an important role in the gastroprotective effects of acetaminophen.
C1 [Fukushima, Eriko; Monoi, Noriyuki; Mikoshiba, Shigeo; Hirayama, Yutaka; Serizawa, Tetsushi; Adachi, Kiyo; Koide, Misao; Ohdera, Motoyasu; Murakoshi, Michiaki] Lion Corp, Res & Dev Headquarters, Odawara, Kanagawa 2560811, Japan.
   [Kato, Hisanori] Univ Tokyo, Org Interdisciplinary Res Projects, Tokyo, Japan.
C3 Lion Corporation; University of Tokyo
RP Fukushima, E (通讯作者)，Lion Corp, Res & Dev Headquarters, 100 Tajima, Odawara, Kanagawa 2560811, Japan.
EM eriko f@lion.co.jp
RI Kimura, Eriko/V 8418 2019
CR Anderson BJ, 2008, PEDIATR ANESTH, V18, P915, DOI 10.1111/j.1460 9592.2008.02764.x
   Barksby HE, 2006, ARTHRITIS RHEUM US, V54, P3244, DOI 10.1002/art.22167
   Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196
   Chen JM, 2000, J AM CHEM SOC, V122, P9648, DOI 10.1021/ja001547g
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Fanjul Fernández M, 2010, BBA MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004
   Funatsu T, 2007, EUR J PHARMACOL, V554, P53, DOI 10.1016/j.ejphar.2006.10.023
   Hernández Díaz S, 2002, J CLIN EPIDEMIOL, V55, P157, DOI 10.1016/S0895 4356(01)00461 9
   Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523 1747.2000.00068.x
   KONTUREK SJ, 1982, GUT, V23, P536, DOI 10.1136/gut.23.6.536
   Kwiecien S, 2012, J PHYSIOL PHARMACOL, V63, P143
   Lanza FL, 1998, AM J GASTROENTEROL, V93, P1051
   Lempinen M, 2000, EUR SURG RES, V32, P169, DOI 10.1159/000008759
   Naito Y, 2007, J CLIN BIOCHEM NUTR, V41, P202, DOI 10.3164/jcbn.2007029
   Naito Y, 2006, REDOX REP, V11, P243, DOI 10.1179/135100006X155021
   OKADA M, 1989, DIGEST DIS SCI, V34, P694, DOI 10.1007/BF01540340
   ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014 5793(93)80263 T
   Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020
   Seegers A J, 1980, Adv Prostaglandin Thromboxane Res, V8, P1547
   Sengupta N, 2007, PHYSIOLOGY, V22, P401, DOI 10.1152/physiol.00027.2007
   Shahin M, 2001, MICROSC RES TECHNIQ, V53, P396, DOI 10.1002/jemt.1108
   Shiozawa S, 2009, CELL CYCLE, V8, P1539, DOI 10.4161/cc.8.10.8411
   Singh LP, 2011, J PINEAL RES, V51, P61, DOI 10.1111/j.1600 079X.2010.00845.x
   STERN AI, 1984, GASTROENTEROLOGY, V86, P728
   Swarnakar S, 2005, J BIOL CHEM, V280, P9409, DOI 10.1074/jbc.M413398200
   Takeuchi K, 2012, WORLD J GASTROENTERO, V18, P2147, DOI 10.3748/wjg.v18.i18.2147
   Takeuchi K, 2011, J PHARMACOL EXP THER, V338, P850, DOI 10.1124/jpet.111.183293
   Tanaka A, 2001, J PHYSIOLOGY PARIS, V95, P21, DOI 10.1016/S0928 4257(01)00005 5
   VANKOLFSCHOTEN AA, 1983, TOXICOL APPL PHARM, V69, P37, DOI 10.1016/0041 008X(83)90116 3
   VANKOLFSCHOTEN AA, 1981, J PHARM PHARMACOL, V33, P462
   WALLACE JL, 1993, AM J PHYSIOL, V265, pG993, DOI 10.1152/ajpgi.1993.265.5.G993
   Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510
   Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948
   Yoon YJ, 2012, KOREAN J FAM MED, V33, P262, DOI 10.4082/kjfm.2012.33.5.262
NR 35
TC 7
Z9 7
U1 0
U2 10
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD APR
PY 2014
VL 349
IS 1
BP 165
EP 173
DI 10.1124/jpet.113.210021
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AD3XN
UT WOS:000333179900018
PM 24496494
DA 2025 08 17
ER

PT J
AU Zeng, YP
   Yang, C
   Li, Y
   Fan, Y
   Yang, HJ
   Liu, B
   Sang, HX
AF Zeng, Yan Ping
   Yang, Chao
   Li, Yuan
   Fan, Yong
   Yang, Hong Jun
   Liu, Bin
   Sang, Hong Xun
TI Aspirin inhibits osteoclastogenesis by suppressing the activation of
   NF B and MAPKs in RANKL induced RAW264.7 cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteoporosis; osteoclast; NF B; MAPK
ID MICROPHTHALMIA TRANSCRIPTION FACTOR; KAPPA B; RECEPTOR ACTIVATOR;
   PHOSPHATIDYLINOSITOL 3 KINASE; C FOS; EXPRESSION; DIFFERENTIATION;
   PATHWAYS; GENE; P38
AB Aspirin is a commonly used medicine as an effective antipyretic, analgesic and anti inflammatory drug. Previous studies have demonstrated its potential effects of anti postmenopausal osteoporosis, while the molecular mechanisms remain unclear. The effects of aspirin on receptor activator of nuclear factor B (NF B) ligand (RANKL) induced osteoclasts were investigated in RAW264.7 cells in the current study. Using tartrate resistant acid phosphatase (TRAP) staining, it was observed that aspirin inhibited the differentiation of RANKL induced RAW264.7 cells. The mRNA expression of osteoclastic marker genes, including cathepsin K, TRAP, matrix metalloproteinase 9 and calcitonin receptor, were suppressed by aspirin as identified using reverse transcription quantitative polymerase chain reaction analysis. The immunofluorescence assay indicated that aspirin markedly inhibited NF B p65 translocation to the nucleus in RANKL induced RAW264.7 cells. In addition, aspirin also suppressed the phosphorylation of mitogen activated protein kinases (MAPKs), observed by western blot analysis. Taken together, these data identified that aspirin inhibits osteoclastogenesis by suppressing the activation of NF B and MAPKs in RANKL induced RAW264.7 cells, implying that aspirin may possess therapeutic potential for use in the prevention and treatment of osteoporosis.
C1 [Zeng, Yan Ping; Yang, Chao; Li, Yuan; Fan, Yong; Yang, Hong Jun; Liu, Bin; Sang, Hong Xun] Fourth Mil Med Univ, Inst Orthoped, Xijing Hosp, Dept Orthoped Surg, 169 Changle Western Rd, Xian 830054, Shaanxi, Peoples R China.
C3 Air Force Medical University
RP Sang, HX (通讯作者)，Fourth Mil Med Univ, Inst Orthoped, Xijing Hosp, Dept Orthoped Surg, 169 Changle Western Rd, Xian 830054, Shaanxi, Peoples R China.
EM sanghongxun_l@163.com
OI Sang, Hongxun/0000 0001 6534 0231
CR Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Baltas C. S., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P388
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen Zhi wen, 2011, Zhonghua Yi Xue Za Zhi, V91, P925
   Choi HJ, 2010, EUR J PHARMACOL, V636, P28, DOI 10.1016/j.ejphar.2010.03.023
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li LY, 2011, J AGR FOOD CHEM, V59, P7708, DOI 10.1021/jf2011613
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mohamed SGK, 2007, BONE, V41, P592, DOI 10.1016/j.bone.2007.05.016
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Valverde P, 2008, CURR MED CHEM, V15, P284, DOI 10.2174/092986708783497274
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
NR 25
TC 26
Z9 28
U1 0
U2 27
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2016
VL 14
IS 3
BP 1957
EP 1962
DI 10.3892/mmr.2016.5456
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DU8EF
UT WOS:000382445400012
PM 27430169
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, QX
   Yang, J
   Wang, YW
   Liu, HX
   Feng, Y
   Qiu, L
   Chen, Y
AF Wang, Qixin
   Yang, Jian
   Wang, Yingwei
   Liu, Hanxiang
   Feng, Yue
   Qiu, Lin
   Chen, Yue
TI Lutetium177 Labeled DOTA Ibandronate: A Novel Radiopharmaceutical for
   Targeted Treatment of Bone Metastases
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE bone metastasis; radionuclide therapy; 177Lu DOTA IBA; ibandronate
ID BREAST CANCER; ZOLEDRONIC ACID; BISPHOSPHONATES; THERAPY
AB Bone metastases of malignant tumors significantly threaten the patient survival and quality of life. We designed and synthesized a novel bisphosphonate radiopharmaceutical [68Ga  or targeted diagnosis and treatment of bone metastases. This study explored the basic biological characteristics of Lu 177 DOTA IBA, guiding clinical translation and providing evidence for future clinical applications. The control variable method was used to optimize the optimal labeling conditions. The in vitro properties, biological distribution, and toxicity of Lu 177 DOTA IBA were studied. Normal mice and tumor bearing mice were imaged using micro SPECT/CT. With Ethics Committee approval, five volunteers were recruited for a preliminary clinical translation study. Lu 177 DOTA IBA has a radiochemical purity of more than 98%, with good biological properties and safety. Blood clearance is fast and soft tissue uptake is low. Tracers are excreted mainly through the urinary system, targeting and continuously concentrating in the bones. Three patients experienced significant pain relief within 3 days after Lu 177 DOTA IBA treatment (740 1110 MBq), lasting more than 2 months, with no toxic side effects. Lu 177 DOTA IBA is easy to prepare and exhibits good pharmacokinetic characteristics. Low dose Lu 177 DOTA IBA is effective, well tolerated, and was associated with no significant adverse reactions. It is a promising radiopharmaceutical for the targeted treatment of bone metastases, controlling the progress of bone metastasis and improving survival and quality of life of patients with advanced bone metastasis.
C1 [Wang, Qixin; Liu, Hanxiang; Feng, Yue; Qiu, Lin; Chen, Yue] Southwest Med Univ, Affiliated Hosp, Dept Nucl Med, Luzhou 646000, Sichuan, Peoples R China.
   [Wang, Qixin; Yang, Jian; Liu, Hanxiang; Feng, Yue; Qiu, Lin; Chen, Yue] Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China.
   [Wang, Qixin; Yang, Jian; Liu, Hanxiang; Feng, Yue; Qiu, Lin; Chen, Yue] Academician Expert Workstat Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China.
   [Wang, Yingwei] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Nucl Med, Chengdu 610054, Sichuan, Peoples R China.
C3 Southwest Medical University; University of Electronic Science &
   Technology of China
RP Qiu, L; Chen, Y (通讯作者)，Southwest Med Univ, Affiliated Hosp, Dept Nucl Med, Luzhou 646000, Sichuan, Peoples R China.; Qiu, L; Chen, Y (通讯作者)，Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China.; Qiu, L; Chen, Y (通讯作者)，Academician Expert Workstat Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China.
EM quilin17111210041@163.com; chenyue5523@126.com
RI Wang, Qixin/A 9372 2008
FU Department of Nuclear Medicine
FX ACKNOWLEDGMENTS The authors are grateful to the members of Department of
   Nuclear Medicine, The Affiliated Hospital, Southwest Medical University
   and Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan
   Province for their technical guidance, cooperation, and assistance in
   completing this case.
CR Barrett Lee P, 2014, LANCET ONCOL, V15, P114, DOI 10.1016/S1470 2045(13)70539 4
   Bodei L, 2022, NAT REV CLIN ONCOL, V19, P534, DOI 10.1038/s41571 022 00652 y
   Burkett BJ, 2021, RADIOLOGY, V298, P261, DOI 10.1148/radiol.2020201745
   Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5 6 463
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Eisen A, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.21.02647
   Fernández R, 2021, J NUCL MED, V62, P1126, DOI 10.2967/jnumed.120.255851
   Gralow JR, 2020, JNCI J NATL CANCER I, V112, P698, DOI 10.1093/jnci/djz215
   Han JH, 2018, PAK J PHARM SCI, V31, P1683
   He YF, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI157917
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Ihle CL, 2022, PHARMACOL THERAPEUT, V239, DOI 10.1016/j.pharmthera.2022.108280
   Lv X, 2022, CELL METAB, V34, P1914, DOI 10.1016/j.cmet.2022.09.025
   Manafi Farid R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082622
   Mhaskar R, 2018, JAMA J AM MED ASSOC, V320, P1483, DOI 10.1001/jama.2018.13773
   Pandit Taskar N, 2014, J NUCL MED, V55, P268, DOI 10.2967/jnumed.112.112482
   Satcher RL, 2022, NAT REV CANCER, V22, P85, DOI 10.1038/s41568 021 00406 5
   Siegel R. L., 2022, CA CANCER J CLIN, V70, P730
   Ueda M, 2020, NEW ENGL J MED, V383, P2188, DOI 10.1056/NEJMc2029828
   Xu Q, 2019, J LABELLED COMPD RAD, V62, P43, DOI 10.1002/jlcr.3694
   Zakaly HMH, 2020, INT J RADIAT BIOL, V96, P779, DOI 10.1080/09553002.2020.1729441
   Zhu MY, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2019.100219
   Zlatev HP, 2016, EUR J PHARM SCI, V86, P58, DOI 10.1016/j.ejps.2016.02.016
NR 23
TC 26
Z9 26
U1 1
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
EI 1543 8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAR 6
PY 2023
VL 20
IS 3
BP 1788
EP 1795
DI 10.1021/acs.molpharmaceut.2c00978
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 9S5YM
UT WOS:000946415000001
PM 36802692
DA 2025 08 17
ER

PT J
AU Jia, TT
   Wang, YN
   Zhang, JJ
   Hao, XY
   Zhang, DJ
   Xu, X
AF Jia, Tingting
   Wang, Ya nan
   Zhang, Jiajia
   Hao, Xinyu
   Zhang, Dongjiao
   Xu, Xin
TI Cinaciguat in combination with insulin induces a favorable effect on
   implant osseointegration in type 2 diabetic rats
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Type 2 diabetes mellitus; Cinaciguat; Cyclic guanosine monophosphate
   (cGMP); Protein kinase G II (PKG II); Insulin; Osseointegration
ID SOLUBLE GUANYLATE CYCLASE; THERAPEUTIC TARGET; BONE REGENERATION;
   TITANIUM IMPLANT; MELLITUS; OSTEOBLAST; ACTIVATION; MASS
AB The osseointegration process of implant is seriously impaired in type 2 diabetes mellitus (T2DM) that causes high failure rate, and insufficiency exists in current insulin therapy, creating a demand for new bone synergistic agent. Cinaciguat, a novel type of soluble guanylate cyclase (sGC) activator, plays a vital role in glucose metabolism, inflammation control and bone regeneration. We hypothesized that the combined application of cinaciguat and insulin could reverse poor implant osseointegration in diabetes. To test this hypothesis, streptozotocin induced diabetic rats were placed implants in the femur, and divided into five groups: control, T2DM, cinaciguat treated T2DM (7 mu g/kg), insulin treated T2DM (12 IU/kg), cinaciguat plus insulin combination treated T2DM (7 mu g/kg and 12 IU/kg respectively), according to different treatment received. The weight and glucose levels of rats were evaluated at fixed times, and plasma level of cyclic guanosine monophosphate (cGMP) was determined before euthanasia. Three months after therapy, the femurs were isolated for pull out test, environmental scanning electron microscope observation, microscopic computerized tomography evaluation and various histology analysis. Results revealed that diabetic rats showed the highest blood glucose level and lowest cGMP content, which led to the worst structural damage and least osseointegration. Combined treatment could attenuate the diabetes induced hyperglycemia to be normal, restore the cGMP content, protein kinase G II (PKG II) expression, phosphodiesterase 5 (PDE5) activity and ameliorate the mechanical strength, the impaired bone microarchitecture and osseointegration to the highest level. Meanwhile, monotreatment (insulin or cinaciguat) also showed restorative effect, but less. Our findings demonstrated that the cGMP/PKG II signaling pathway activated by cinaciguat mediated the favorable effects of the combined application on improving implant fixation under T2DM condition.
C1 [Jia, Tingting; Wang, Ya nan; Zhang, Jiajia; Hao, Xinyu; Zhang, Dongjiao; Xu, Xin] Shandong Univ, Sch Stomatol, Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
   [Jia, Tingting; Wang, Ya nan; Zhang, Jiajia; Zhang, Dongjiao; Xu, Xin] Shandong Univ, Sch Stomatol, Dept Implantol, Jinan, Shandong, Peoples R China.
   [Hao, Xinyu] Shandong Univ, Sch Stomatol, Dept Pediat Dent, Jinan, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Zhang, DJ; Xu, X (通讯作者)，44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
EM djzhang1109@163.com; xinxu@sdu.edu.cn
RI Hao, Xinyu/LMM 9634 2024; zhang, jiajia/GOJ 9805 2022
FU Fundamental Research Funds of Shandong University [2018GN024];
   Construction Engineering Special Fund of Taishan Scholars [TS201511106]
FX This work was supported by the Fundamental Research Funds of Shandong
   University [grant numbers 2018GN024]; and the Construction Engineering
   Special Fund of Taishan Scholars [grant numbers TS201511106].
CR Annibali S, 2016, IMPLANT DENT, V25, P663, DOI 10.1097/ID.0000000000000478
   [Anonymous], 2018, SCI REP
   Campbell JC, 2016, J BIOL CHEM, V291, P5623, DOI 10.1074/jbc.M115.691303
   CRAVEN PA, 1994, J CLIN INVEST, V93, P311, DOI 10.1172/JCI116961
   Czirok S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10125 3
   Dang YG, 2016, INT J NANOMED, V11, P1003, DOI 10.2147/IJN.S102552
   Dasgupta A, 2015, CLIN PHARMACOL THER, V97, P88, DOI 10.1002/cpt.10
   Evgenov OV, 2006, NAT REV DRUG DISCOV, V5, P755, DOI 10.1038/nrd2038
   Fiorellini JP, 1999, CLIN ORAL IMPLAN RES, V10, P362, DOI 10.1111/j.1600 0501.1999.tb00011.x
   Gómez Moreno G, 2015, CLIN ORAL IMPLAN RES, V26, P1031, DOI 10.1111/clr.12391
   Hamann C, 2011, AM J PHYSIOL ENDOC M, V301, pE1220, DOI 10.1152/ajpendo.00378.2011
   Hu ZA, 2018, ACS APPL MATER INTER, V10, P2377, DOI 10.1021/acsami.7b18458
   Huynh K, 2014, PHARMACOL THERAPEUT, V142, P375, DOI 10.1016/j.pharmthera.2014.01.003
   Jia TT, 2018, ENDOCR CONNECT, V7, P1186, DOI 10.1530/EC 18 0241
   Jimenez M, 2012, DIABETES RES CLIN PR, V98, P494, DOI 10.1016/j.diabres.2012.09.039
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Kalk P, 2006, BRIT J PHARMACOL, V148, P853, DOI 10.1038/sj.bjp.0706792
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Khader YS, 2006, J DIABETES COMPLICAT, V20, P59, DOI 10.1016/j.jdiacomp.2005.05.006
   Liu XW, 2017, INT J NANOMED, V12, P7089, DOI 10.2147/IJN.S124584
   Lu L., 2015, EVID BASED COMPL ALT
   Margonar Rogerio, 2003, Implant Dent, V12, P333, DOI 10.1097/01.ID.0000086482.65273.B7
   Mátyás C, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933 015 0309 x
   de Morais JAND, 2009, CLIN ORAL IMPLAN RES, V20, P796, DOI 10.1111/j.1600 0501.2009.01716.x
   Németh BT, 2016, SCI REP UK, V6, DOI 10.1038/srep37166
   Nosti Palacios R, 2014, INT J TOXICOL, V33, P325, DOI 10.1177/1091581814540480
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rubin MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.1
   Salloum FN, 2012, AM J PHYSIOL HEART C, V302, pH1347, DOI 10.1152/ajpheart.00544.2011
   Sawabe T, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.463
   Silver B, 2018, DIABETES THER, V9, P449, DOI 10.1007/s13300 018 0384 6
   Siqueira Jose T, 2003, Implant Dent, V12, P242
   Voss Fels K, 2015, PLANT GENOME US, V8, DOI 10.3835/plantgenome2015.03.0013
   Wang BG, 2011, BRIT J ORAL MAX SURG, V49, P225, DOI 10.1016/j.bjoms.2010.03.006
   Wang L, 2011, NEUROSCIENCE, V193, P399, DOI 10.1016/j.neuroscience.2011.07.039
   Wu YY, 2013, BONE, V52, P1, DOI 10.1016/j.bone.2012.09.005
NR 37
TC 14
Z9 15
U1 0
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2019
VL 118
AR 109216
DI 10.1016/j.biopha.2019.109216
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IY4WZ
UT WOS:000486395000047
PM 31319371
OA gold
DA 2025 08 17
ER

PT J
AU Niedermair, T
   Lukas, C
   Li, SS
   Stöckl, S
   Craiovan, B
   Brochhausen, C
   Federlin, M
   Herrmann, M
   Grässel, S
AF Niedermair, Tanja
   Lukas, Christoph
   Li, Shushan
   Stoeckl, Sabine
   Craiovan, Benjamin
   Brochhausen, Christoph
   Federlin, Marianne
   Herrmann, Marietta
   Graessel, Susanne
TI Influence of Extracellular Vesicles Isolated From Osteoblasts of
   Patients With Cox Arthrosis and/or Osteoporosis on Metabolism and
   Osteogenic Differentiation of BMSCs
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE extracellular vesicles; mesenchymal stem cells; osteoblasts;
   osteoarthritis; osteoporosis; EVs; osteogenic differentiation
ID MESENCHYMAL STEM CELLS; ESTROGEN DEFICIENCY; EXOSOMES; OSTEOARTHRITIS;
   PROLIFERATION; EPIDEMIOLOGY; APOPTOSIS; CULTURE; REPAIR; RNA
AB Background: Studies with extracellular vesicles (EVs), including exosomes, isolated from mesenchymal stem cells (MSC) indicate benefits for the treatment of musculoskeletal pathologies as osteoarthritis (OA) and osteoporosis (OP). However, little is known about intercellular effects of EVs derived from pathologically altered cells that might influence the outcome by counteracting effects from "healthy" MSC derived EVs. We hypothesize, that EVs isolated from osteoblasts of patients with hip OA (coxarthrosis/CA), osteoporosis (OP), or a combination of both (CA/OP) might negatively affect metabolism and osteogenic differentiation of bone marrow derived (B)MSCs.
   Methods: Osteoblasts, isolated from bone explants of CA, OP, and CA/OP patients, were compared regarding growth, viability, and osteogenic differentiation capacity. Structural features of bone explants were analyzed via mu CT. EVs were isolated from supernatant of naive BMSCs and CA, OP, and CA/OP osteoblasts (osteogenic culture for 35 days). BMSC cultures were stimulated with EVs and subsequently, cell metabolism, osteogenic marker gene expression, and osteogenic differentiation were analyzed.
   Results: Trabecular bone structure was different between the three groups with lowest number and highest separation in the CA/OP group. Viability and Alizarin red staining increased over culture time in CA/OP osteoblasts whereas growth of osteoblasts was comparable. Alizarin red staining was by trend higher in CA compared to OP osteoblasts after 35 days and ALP activity was higher after 28 and 35 days. Stimulation of BMSC cultures with CA, OP, and CA/OP EVs did not affect proliferation but increased caspase 3/7 activity compared to unstimulated BMSCs. BMSC viability was reduced after stimulation with CA and CA/OP EVs compared to unstimulated BMSCs or stimulation with OP EVs. ALP gene expression and activity were reduced in BMSCs after stimulation with CA, OP, and CA/OP EVs. Stimulation of BMSCs with CA EVs reduced Alizarin Red staining by trend.
   Conclusion: Stimulation of BMSCs with EVs isolated from CA, OP, and CA/OP osteoblasts had mostly catabolic effects on cell metabolism and osteogenic differentiation irrespective of donor pathology and reflect the impact of tissue microenvironment on cell metabolism. These catabolic effects are important for understanding differences in effects of EVs on target tissues/cells when harnessing them as therapeutic drugs.
C1 [Niedermair, Tanja; Brochhausen, Christoph] Univ Regensburg, Inst Pathol, Regensburg, Germany.
   [Lukas, Christoph; Li, Shushan; Stoeckl, Sabine; Graessel, Susanne] Univ Regensburg, Dept Orthopaed Surg, Expt Orthopaed, Ctr Med Biotechnol ZMB Biopk 1, Regensburg, Germany.
   [Craiovan, Benjamin] Univ Hosp Giessen, Ctr Orthopaed & Trauma Surg, Chair Arthroplasty, Marburg, Germany.
   [Craiovan, Benjamin] Marburg GmbH, Marburg, Germany.
   [Federlin, Marianne] Univ Med Ctr Regensburg, Dept Conservat Dent & Periodontol, Regensburg, Germany.
   [Herrmann, Marietta] Univ Wurzburg, Univ Hosp Wuerzburg, Grp Tissue Regenerat Musculoskeletal Dis, IInterdisciplinary Ctr Clin Res IZKF, Wurzburg, Germany.
   [Herrmann, Marietta] Univ Wurzburg, Bernhard Heine Ctr Locomot Res, Wurzburg, Germany.
C3 University of Regensburg; University of Regensburg; University Hospital
   of Giessen & Marburg; University of Regensburg; University of Wurzburg;
   University of Wurzburg
RP Grässel, S (通讯作者)，Univ Regensburg, Dept Orthopaed Surg, Expt Orthopaed, Ctr Med Biotechnol ZMB Biopk 1, Regensburg, Germany.
EM susanne.graessel@ukr.de
RI Herrmann, Marietta/AAS 6253 2020
OI Herrmann, Marietta/0000 0002 2412 7474; LI, Shushan/0009 0000 1779 6242
FU German Society for Orthopedic and Orthopedic Surgery (DGOOC);
   Interdisciplinary Center for Clinical Research (IZKF) at the University
   of Wurzburg [D 361]
FX This research was funded by a grant assigned to SG from the German
   Society for Orthopedic and Orthopedic Surgery (DGOOC). MH was supported
   by the Interdisciplinary Center for Clinical Research (IZKF) at the
   University of Wurzburg (Project D 361).
CR Anderson HC, 2005, FRONT BIOSCI LANDMRK, V10, P822, DOI 10.2741/1576
   Andreu Z, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00442
   Blain H, 2008, BONE, V43, P862, DOI 10.1016/j.bone.2008.07.236
   Brady JV, 2018, TRANSL ONCOL, V11, P1137, DOI 10.1016/j.tranon.2018.07.004
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chen YH, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1047 2
   Conde Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887
   Cosenza S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15376 8
   Davatchi F, 2016, INT J RHEUM DIS, V19, P219, DOI 10.1111/1756 185X.12670
   Dillon JP, 2012, METHODS MOL BIOL, V816, P3, DOI 10.1007/978 1 61779 415 5_1
   Domenis R, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4814987
   Edgar JR, 2016, BMC BIOL, V14, DOI 10.1186/s12915 016 0268 z
   Giner M, 2009, J STEROID BIOCHEM, V113, P46, DOI 10.1016/j.jsbmb.2008.11.005
   Gowen A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00149
   Grässel S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246156
   Grässel S, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 014 0452 5
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guo SC, 2016, INT J BIOL SCI, V12, P1262, DOI 10.7150/ijbs.16150
   Harrell CR, 2019, BIOMED PHARMACOTHER, V109, P2318, DOI 10.1016/j.biopha.2018.11.099
   Huynh N, 2016, J DENT RES, V95, P673, DOI 10.1177/0022034516633189
   Jia YC, 2020, CALCIFIED TISSUE INT, V106, P509, DOI 10.1007/s00223 019 00656 4
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kolhe R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 01905 y
   Lai CP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8029
   Lässer C, 2012, JOVE J VIS EXP, DOI 10.3791/3037
   Leyh M, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0453 9
   Li WY, 2018, ACS APPL MATER INTER, V10, P5240, DOI 10.1021/acsami.7b17620
   Litwic A, 2013, BRIT MED BULL, V105, P185, DOI 10.1093/bmb/lds038
   Lötvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Manolagas SC, 1998, AGING CLIN EXP RES, V10, P182, DOI 10.1007/BF03339652
   Mansell JP, 1997, BRIT J RHEUMATOL, V36, P16
   Masi L, 2008, CLIN CASES MINER BON, V5, P11
   Mathivanan S, 2010, MOL CELL PROTEOMICS, V9, P197, DOI 10.1074/mcp.M900152 MCP200
   Millán JL, 2013, CALCIFIED TISSUE INT, V93, P299, DOI 10.1007/s00223 012 9672 8
   Nakamura Y, 2015, FEBS LETT, V589, P1257, DOI 10.1016/j.febslet.2015.03.031
   Narayanan R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3808674
   Ni ZH, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0100 9
   Niedermair T, 2020, MECH AGEING DEV, V189, DOI 10.1016/j.mad.2020.111265
   Niedermair T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27432 y
   Nojehdehi S, 2018, J CELL BIOCHEM, V119, P9433, DOI 10.1002/jcb.27260
   Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231
   Orozco L, 2013, TRANSPLANTATION, V95, P1535, DOI 10.1097/TP.0b013e318291a2da
   Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev bioeng 070909 105309
   Paspaliaris V, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/1730978
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   POGRUND H, 1982, CLIN ORTHOP RELAT R, P130
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132
   Rubinacci A, 2012, OSTEOPOROSIS INT, V23, P1967, DOI 10.1007/s00198 011 1795 7
   Shabbir A, 2015, STEM CELLS DEV, V24, P1635, DOI 10.1089/scd.2014.0316
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Sokolova V, 2011, COLLOID SURFACE B, V87, P146, DOI 10.1016/j.colsurfb.2011.05.013
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Takeuchi R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225472
   Tan SHS, 2020, MATER TODAY BIO, V7, DOI 10.1016/j.mtbio.2020.100067
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005 2736(81)90512 5
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wakitani S, 2002, OSTEOARTHR CARTILAGE, V10, P199, DOI 10.1053/joca.2001.0504
   Wallace PK, 2008, CYTOM PART A, V73A, P1019, DOI 10.1002/cyto.a.20619
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wessely A, 2019, FASEB J, V33, P11884, DOI 10.1096/fj.201900925R
   Wu YT, 2015, ANALYST, V140, P6631, DOI 10.1039/c5an00688k
   Xie Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12758
   Yang BC, 2020, BIOCHEM BIOPH RES CO, V524, P883, DOI 10.1016/j.bbrc.2020.02.001
   Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1562 9
   Zhang ZM, 2010, OSTEOPOROSIS INT, V21, P1383, DOI 10.1007/s00198 009 1071 2
   Zhu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0510 9
NR 71
TC 30
Z9 34
U1 3
U2 30
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD DEC 23
PY 2020
VL 8
AR 615520
DI 10.3389/fbioe.2020.615520
PG 15
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA PO1QM
UT WOS:000604945300001
PM 33425878
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Feng, RJ
   Feng, L
   Yuan, ZN
   Wang, DC
   Wang, F
   Tan, BY
   Han, SJ
   Li, T
   Li, D
   Han, Y
AF Feng, Rongjie
   Feng, Li
   Yuan, Zenong
   Wang, Dachuan
   Wang, Feng
   Tan, Bingyi
   Han, Shijie
   Li, Tao
   Li, Dong
   Han, Yong
TI Icariin Protects Against Glucocorticoid Induced Osteoporosis In Vitro
   and Prevents Glucocorticoid Induced Osteocyte Apoptosis In Vivo
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Icariin; Glucocorticoid induced osteoporosis; Osteocyte apoptosis
ID BONE LOSS; MECHANICAL STIMULATION; OSTEOBLAST APOPTOSIS; CELLS;
   ESTROGEN; DIFFERENTIATION; EXPRESSION; CALCIUM; OSTEOPROTEGERIN;
   PATHOGENESIS
AB Icariin is the major active ingredient in Herba epimedii which is a commonly used Chinese herbal medicine for the treatment of osteoporosis. The present study aims to evaluate the osteoprotective effect of Icariin in glucocorticoid induced osteoporosis in vivo and investigate the effect of Icariin on glucocorticoid induced osteocyte apoptosis in vitro. A total of 48 female Sprague Dawley rats were used. Glucocorticoid induced osteoporosis was induced by daily injections of dexamethasone (0.1 mg/kg, daily, s.c.) for 60 days, whereas sham animals were injected daily with vehicle. At the end of the osteoporosis development period, osteoporotic rats were randomized to receive: vehicle (n = 8), Icariin (5,125 mg/kg, i.g.; n = 8), or alendronate (0.03 mg/kg, s.c.; n = 8) for 12 weeks. Sham animals were treated with vehicle for 12 weeks. At the beginning and at the end of treatments, animals were examined for bone mineral density. Serum bone alkaline phosphatase and carboxy terminal collagen cross links were measured. Primary osteocytes were isolated, and apoptosis was determined by trypan blue assay. Interaction between Icariin and estrogen receptor and prosurvival signaling pathways activated by Icariin were also investigated. Icariin showed a comparable efficacy with alendronate in increasing bone mass. Icariin significantly increased bone alkaline phosphatase (bone formation marker) and reduced carboxy terminal collagen cross links (bone resorption marker). In vitro studies demonstrated that Icariin significantly prevented GC induced apoptosis in osteocytes by activating ERK signaling via estrogen receptor. Our results suggest that Icariin might exert osteoprotective effect by maintaining osteocyte viability, thereby, regulating bone remodeling. Furthermore, our study provides preclinical evidence for the efficacy of Icariin for management of Glucocorticoid induced osteoporosis.
C1 [Feng, Rongjie; Yuan, Zenong; Wang, Dachuan; Wang, Feng; Tan, Bingyi; Han, Shijie; Li, Tao] Shandong Univ, Shandong Prov Hosp, Prov Hosp, Dept Spine, Jinan 250021, Shandong, Peoples R China.
   [Feng, Li] Shandong Univ, Shandong Prov Hosp, Prov Hosp, Dept Endocrinol, Jinan 250021, Shandong, Peoples R China.
   [Li, Dong] Shandong Univ, Shandong Prov Hosp, Prov Hosp, Dept Bone & Tumor, Jinan 250021, Shandong, Peoples R China.
   [Han, Yong] Shandong Univ, Shandong Prov Hosp, Prov Hosp, Dept Trauma Orthoped, Jinan 250021, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong University; Shandong
   First Medical University & Shandong Academy of Medical Sciences;
   Shandong University; Shandong University; Shandong First Medical
   University & Shandong Academy of Medical Sciences
RP Feng, RJ (通讯作者)，Shandong Univ, Shandong Prov Hosp, Prov Hosp, Dept Spine, 324 Jing 5 Rd, Jinan 250021, Shandong, Peoples R China.
EM sdslyyfrj@163.com
RI Li, Tao/LUY 9198 2024; Wang, Feng/P 3082 2015
FU National Natural Science Foundation of China [81000323]; Natural Science
   Foundation of Shandong Province, China [ZR2009CM067]
FX This study was supported by the grant from the National Natural Science
   Foundation of China (81000323) and the Natural Science Foundation of
   Shandong Province, China (ZR2009CM067).
CR Adachi JD, 1996, J RHEUMATOL, V23, P995
   Basso N, 2006, BONE, V39, P807, DOI 10.1016/j.bone.2006.04.014
   Bhargavan B, 2009, J CELL BIOCHEM, V108, P388, DOI 10.1002/jcb.22264
   Bitto A, 2009, BRIT J PHARMACOL, V156, P1287, DOI 10.1111/j.1476 5381.2008.00100.x
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Boutsen Y, 2001, J BONE MINER RES, V16, P104, DOI 10.1359/jbmr.2001.16.1.104
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chung BH, 2008, BIOCHEM BIOPH RES CO, V376, P404, DOI 10.1016/j.bbrc.2008.09.001
   Crandall C, 2002, ARCH INTERN MED, V162, P2297, DOI 10.1001/archinte.162.20.2297
   Eastell R, 2000, OSTEOPOROSIS INT, V11, P331, DOI 10.1007/s001980070122
   FEHER JJ, 1979, ENDOCRINOLOGY, V104, P547, DOI 10.1210/endo 104 2 547
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Han EH, 2010, TOXICOL SCI, V114, P204, DOI 10.1093/toxsci/kfq013
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Kogianni G, 2008, J BONE MINER RES, V23, P915, DOI 10.1359/JBMR.080207
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Liu J, 2005, PHARMAZIE, V60, P120
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Manolagas SC, 2000, J BONE MINER RES, V15, P1001, DOI 10.1359/jbmr.2000.15.6.1001
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Meng L., 2012, CHINESE MED J, V125, P1784
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Noble BS, 1997, BONE, V20, P273, DOI 10.1016/S8756 3282(96)00365 1
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Ringe JD, 1999, CALCIFIED TISSUE INT, V65, P337, DOI 10.1007/s002239900708
   Robling A. G., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P354
   Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198 010 1194 5
   Sambrook PN, 2007, NEW ENGL J MED, V357, P2084, DOI 10.1056/NEJMe0706770
   Seeman E, 2006, OSTEOPOROSIS INT, V17, P1443, DOI 10.1007/s00198 006 0220 0
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Vance J, 2005, TISSUE ENG, V11, P1832, DOI 10.1089/ten.2005.11.1832
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   Xu DH, 2010, PLANTA MED, V76, P1809, DOI 10.1055/s 0030 1250040
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zand RSR, 2000, BREAST CANCER RES TR, V62, P35, DOI 10.1023/A:1006422302173
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zheng D, 2012, BONE, V51, P85, DOI 10.1016/j.bone.2012.04.006
NR 51
TC 67
Z9 83
U1 1
U2 47
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085 9195
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD SEP
PY 2013
VL 67
IS 1
SI SI
BP 189
EP 197
DI 10.1007/s12013 013 9533 8
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 208FR
UT WOS:000323663300020
PM 23417569
DA 2025 08 17
ER

PT J
AU Jakubowski, M
   Domke, A
   Ratajczak, M
   Szczuka, J
   Buchwald, T
   Voelkel, A
   Sandomierski, M
AF Jakubowski, Marcel
   Domke, Aleksandra
   Ratajczak, Maria
   Szczuka, Joanna
   Buchwald, Tomasz
   Voelkel, Adam
   Sandomierski, Mariusz
TI Chitosan modified with lanthanum ions as implantable hydrogel for local
   delivery of bisphosphonates
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Hydrogel; Bisphosphonates; Zoledronate; Drug delivery; Lanthanum;
   Chitosan
ID BIOLOGICAL ACTIVITY; MECHANISMS; STRONTIUM; FIXATION; RELEASE; ACID
AB Osteoporosis is a disease that affects many people around the world. One group of drugs used to treat it are bisphosphonates. However, they have poor bioavailability and many side effects. Therefore, research around the world is focused on developing bisphosphonate delivery systems. In this paper, we would like to present the design of a hydrogel material with chitosan matrix modified with lanthanum, that could serve as an implantable hydrogel capable of sustained and slow release of Zoledronate. Various research techniques were used to characterize the materials, and the swelling ratio and water solubility were also tested. The conducted research proved that the prepared hydrogel is capable of the long term release of the Zoledronate. Thanks to this, the prepared material can be successfully used as an implantable hydrogel or a coating on titanium implants for the local delivery of drugs.
C1 [Jakubowski, Marcel; Domke, Aleksandra; Voelkel, Adam; Sandomierski, Mariusz] Poznan Univ Tech, Inst Chem Technol & Engn, Ul Berdychowo 4, PL 60965 Poznan, Poland.
   [Ratajczak, Maria] Poznan Univ Tech, Inst Bldg Engn, Ul Piotrowo 5, PL 60965 Poznan, Poland.
   [Szczuka, Joanna; Buchwald, Tomasz] Poznan Univ Tech, Inst Mat Res & Quantum Engn, Piotrowo 3, PL 60965 Poznan, Poland.
C3 Poznan University of Technology; Poznan University of Technology; Poznan
   University of Technology
RP Sandomierski, M (通讯作者)，Poznan Univ Tech, Inst Chem Technol & Engn, Ul Berdychowo 4, PL 60965 Poznan, Poland.
EM mariusz.sandomierski@put.poznan.pl
RI Buchwald, Tomasz/B 3356 2014; Voelkel, Adam/P 2904 2019; Ratajczak,
   Maria/L 6031 2014
OI Sandomierski, Mariusz/0000 0001 8227 8062; Ratajczak,
   Maria/0000 0003 0575 4963; Domke, Aleksandra/0009 0005 6722 4759; 
FU Polish National Science Centre [UMO 2020/39/B/ST5/00320]; Foundation for
   Polish Sci  ences (FNP)
FX This paper was produced with financial support from the Polish National
   Science Centre (grant number UMO 2020/39/B/ST5/00320) . Mariusz
   Sandomierski was supported by the Foundation for Polish Sci  ences (FNP)
   .
CR Abtahi J, 2013, J DENT RES, V92, P279, DOI 10.1177/0022034512472335
   Aderibigbe BA, 2015, INT J BIOL MACROMOL, V73, P115, DOI 10.1016/j.ijbiomac.2014.10.064
   [Anonymous], J BONE MINER RES, DOI [10.1002/jbmr.4049, DOI 10.1002/JBMR.4049]
   [Anonymous], 2007, ANN ONCOL
   Ansari AA, 2018, COLLOID SURFACE B, V163, P133, DOI 10.1016/j.colsurfb.2017.12.026
   Aswathy SH, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03719
   Azari G, 2022, IRAN BIOMED J, V26, P124, DOI 10.52547/ibj.26.2.124
   Barbosa JS, 2021, J MED CHEM, V64, P1260, DOI 10.1021/acs.jmedchem.0c01292
   Bin Yousaf A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22800 0
   Bongaerts JHH, 2008, J APPL PHYS, V104, DOI 10.1063/1.2952054
   Chen SS, 2020, J ORTHOP TRANSL, V22, P2, DOI 10.1016/j.jot.2019.09.007
   Correa S, 2021, CHEM REV, V121, P11385, DOI 10.1021/acs.chemrev.0c01177
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Cui YT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901073
   Gieroba B, 2020, INT J BIOL MACROMOL, V159, P911, DOI 10.1016/j.ijbiomac.2020.05.155
   Guimaraes MB, 2017, INT J ORAL MAX SURG, V46, P1429, DOI 10.1016/j.ijom.2017.04.014
   Harini D, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5378 6
   He AQ, 2013, J SPECTROSC, V2013, DOI 10.1155/2013/593636
   Hu HR, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0411 9
   Hu ST, 2021, APPL PHYS A MATER, V127, DOI 10.1007/s00339 020 04253 3
   Hu WJ, 2022, DENT MATER, V38, P1362, DOI 10.1016/j.dental.2022.06.014
   Hutchison AJ, 2016, NEPHROLOGY, V21, P987, DOI 10.1111/nep.12864
   Juillard A, 2010, BONE, V47, P895, DOI 10.1016/j.bone.2010.07.018
   Jumelle C, 2020, J CONTROL RELEASE, V321, P1, DOI 10.1016/j.jconrel.2020.01.057
   Karthikeyan P, 2019, INT J BIOL MACROMOL, V124, P492, DOI 10.1016/j.ijbiomac.2018.11.127
   Ke CL, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13060904
   Khamis Aya K, 2018, Evid Based Dent, V19, P82, DOI 10.1038/sj.ebd.6401326
   Kumar S, 2012, INT J MOL SCI, V13, P6102, DOI 10.3390/ijms13056102
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   Li M, 2018, ACTA BIOMATER, V77, P365, DOI 10.1016/j.actbio.2018.07.028
   Martau GA, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11111837
   Negm NA, 2020, INT J BIOL MACROMOL, V152, P681, DOI 10.1016/j.ijbiomac.2020.02.196
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Qiao HX, 2018, CERAM INT, V44, P16632, DOI 10.1016/j.ceramint.2018.06.090
   Queiroz MF, 2015, MAR DRUGS, V13, P141, DOI 10.3390/md13010141
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ray S, 2016, RSC ADV, V6, P89467, DOI 10.1039/c6ra13155g
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Soares AP, 2016, ENVIRON TOXICOL PHAR, V42, P212, DOI 10.1016/j.etap.2016.01.015
   Tan P, 2020, COLLOID SURFACE A, V589, DOI 10.1016/j.colsurfa.2020.124417
   Vigata M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121188
   Wan P, 2021, J MATER SCI TECHNOL, V78, P92, DOI 10.1016/j.jmst.2020.10.055
   Wang WJ, 2020, INT J BIOL MACROMOL, V164, P4532, DOI 10.1016/j.ijbiomac.2020.09.042
   Wang WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020487
   Yamaguchi S, 2022, COATINGS, V12, DOI 10.3390/coatings12020139
   Yang HF, 2005, ANAL CHIM ACTA, V548, P159, DOI 10.1016/j.aca.2005.05.061
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yasmeen S., 2016, International Research Journal of Pure and Applied Chemistry, V10, P1
   Zajac A, 2015, SPECTROCHIM ACTA A, V134, P114, DOI 10.1016/j.saa.2014.06.071
   Zhang XJ, 2020, CERAM INT, V46, P13969, DOI 10.1016/j.ceramint.2020.02.195
NR 51
TC 7
Z9 7
U1 2
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAR 1
PY 2023
VL 230
AR 123429
DI 10.1016/j.ijbiomac.2023.123429
EA JAN 2023
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 8P5MA
UT WOS:000926566300001
PM 36708894
DA 2025 08 17
ER

PT J
AU Villagran, MA
   Gutierrez Castro, FA
   Pantoja, DF
   Alarcon, JC
   Fariña, MA
   Amigo, RF
   Muñoz Godoy, NA
   Pinilla, MG
   Peña, EA
   Gonzalez Chavarria, I
   Toledo, JR
   Rivas, CI
   Vera, JC
   McNerney, EM
   Onate, SA
AF Villagran, Marcelo A.
   Gutierrez Castro, Francisco A.
   Pantoja, Diego F.
   Alarcon, Jose C.
   Farina, Macarena A.
   Amigo, Romina F.
   Munoz Godoy, Natalia A.
   Pinilla, Mabel G.
   Pena, Eduardo A.
   Gonzalez Chavarria, Ivan
   Toledo, Jorge R.
   Rivas, Coralia I.
   Vera, Juan C.
   McNerney, Eileen M.
   Onate, Sergio A.
TI Bone stroma derived cells change coregulators recruitment to androgen
   receptor and decrease cell proliferation in androgen sensitive and
   castration resistant prostate cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Androgens; Transcription; Bone stroma; Prostate cancer
ID GROWTH
AB Prostate cancer (Cap) bone metastasis is an early event that remains inactive until later stage progression. Reduced levels of circulating androgens, due to andropause or androgen deprivation therapies, alter androgen receptor (AR) coactivator expression. Coactivators shift the balance towards enhanced AR mediated gene transcription that promotes progression to androgen resistance. Disruptions in coregulators may represent a molecular switch that reactivates latent bone metastasis. Changes in AR mediated transcription in androgen sensitive LNCaP and androgen resistant C4 2 cells were analyzed for AR coregulator recruitment in co culture with Saos 2 and THP 1. The Saos 2 cell line derived from human osteosarcoma and THP 1 cell line representing human monocytes were used to display osteoblast and osteoclast activity. Increased AR activity in androgen resistant C4 2 was due to increased AR expression and SRC1/TIF2 recruitment and decreased SMRT/NCoR expression. AR activity in both cell types was decreased over 90% when co cultured with Saos 2 or THP 1 due to dissociation of AR from the SRC1/TIF2 and SMRT/NCoR coregulators complex, in a ligand dependent and cell type specific manner. In the absence of androgens, Saos 2 decreased while THP 1 increased proliferation of LNCaP cells. In contrast, both Saos 2 and THP 1 decreased proliferation of C4 2 in absence and presence of androgens. Global changes in gene expression from both CaP cell lines identified potential cell cycle and androgen regulated genes as mechanisms for changes in cell proliferation and AR mediated transactivation in the context of bone marrow stroma cells. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Villagran, Marcelo A.; Gutierrez Castro, Francisco A.; Pantoja, Diego F.; Alarcon, Jose C.; Farina, Macarena A.; Amigo, Romina F.; Munoz Godoy, Natalia A.; McNerney, Eileen M.; Onate, Sergio A.] Univ Concepcion, Mol Endocrinol & Oncol Lab, Concepcion, Chile.
   [Pinilla, Mabel G.; Onate, Sergio A.] Univ Concepcion, Dept Med Specialties, Sch Med, Concepcion, Chile.
   [Pena, Eduardo A.; Gonzalez Chavarria, Ivan; Toledo, Jorge R.; Rivas, Coralia I.; Vera, Juan C.] Univ Concepcion, Dept Physiopathol, Sch Biol Sci, Concepcion, Chile.
   [Onate, Sergio A.] SUNY Buffalo, Dept Urol, Buffalo, NY 14260 USA.
C3 Universidad de Concepcion; Universidad de Concepcion; Universidad de
   Concepcion; State University of New York (SUNY) System; University at
   Buffalo, SUNY
RP Onate, SA (通讯作者)，Univ Concepcion, Dept Med Specialties, Concepcion, Chile.
EM sergio.onate@udec.cl
RI ; Villagran, Marcelo/AAP 1171 2020
OI Pena, Eduardo/0000 0001 7227 659X; Gonzalez Chavarria,
   Ivan/0000 0003 0544 4463; Villagran, Marcelo/0000 0003 3645 5659;
   Toledo, Jorge/0000 0002 9879 7710
FU Fondecyt Regular Program [1120696, 1080261, 1140429, 1121159, 1130842];
   ACS [RGS 012301]; InnovaChile [12IDL2 16267]
FX This study was supported in part by Fondecyt Regular Program to: Sergio
   A. Onate (1120696 and 1080261); Coralia Rivas (1140429); Jorge Roberto
   Toledo (1121159); Juan Carlos Vera (1130842); and ACS (RGS 012301) and
   InnovaChile (12IDL2 16267) to Sergio A. Onate.
CR Cano P, 2007, CANCER RES, V67, P511, DOI 10.1158/0008 5472.CAN 06 1478
   Esposito M, 2014, PHARMACOL THERAPEUT, V141, P222, DOI 10.1016/j.pharmthera.2013.10.006
   Godoy AS, 2012, BIOCHEM BIOPH RES CO, V423, P564, DOI 10.1016/j.bbrc.2012.06.005
   Green SM, 2012, MOL CELL ENDOCRINOL, V360, P3, DOI 10.1016/j.mce.2011.09.046
   Hagglof Christina, 2012, Cancers (Basel), V4, P531, DOI 10.3390/cancers4020531
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Kumagai J, 2013, PROSTATE, V73, P1636, DOI 10.1002/pros.22655
   Lonergan P. E., 2011, J CARCINOG, V10, P1, DOI [10.4103/1477  3163.75458, DOI 10.4103/1477 3163.75458]
   Millard CJ, 2013, J MOL ENDOCRINOL, V51, pT23, DOI 10.1530/JME 13 0227
   Murray NP, 2012, BONE MARROW RES, DOI 10.1155/2012/259351
   Nieto CM, 2014, ENDOCR RELAT CANCER, V21, pT147, DOI 10.1530/ERC 14 0138
   Nishimori H, 2012, J BIOL CHEM, V287, P20037, DOI 10.1074/jbc.M112.353094
   O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008 5472.CAN 09 2223
   Perner S., 2015, ONCOTARGET
   Soe AM, 2014, J GASTRIC CANCER, V14, P271, DOI 10.5230/jgc.2014.14.4.271
   Suzman DL, 2014, CANCER METAST REV, V33, P619, DOI 10.1007/s10555 013 9480 2
   Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041
   Zhu ML, 2008, ENDOCR RELAT CANCER, V15, P841, DOI 10.1677/ERC 08 0084
NR 18
TC 3
Z9 4
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 27
PY 2015
VL 467
IS 4
BP 1039
EP 1045
DI 10.1016/j.bbrc.2015.10.009
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CW6YV
UT WOS:000365145300067
PM 26494300
DA 2025 08 17
ER

PT J
AU Blau, JE
   Bauman, V
   Conway, EM
   Piaggi, P
   Walter, MF
   Wright, EC
   Bernstein, S
   Courville, AB
   Collins, MT
   Rother, KI
   Taylor, SI
AF Blau, Jenny E.
   Bauman, Viviana
   Conway, Ellen M.
   Piaggi, Paolo
   Walter, Mary F.
   Wright, Elizabeth C.
   Bernstein, Shanna
   Courville, Amber B.
   Collins, Michael T.
   Rother, Kristina I.
   Taylor, Simeon I.
TI Canagliflozin triggers the FGF23/1,25 dihydroxyvitamin D/PTH axis in
   healthy volunteers in a randomized crossover study
SO JCI INSIGHT
LA English
DT Article
ID PHOSPHATE; DIETARY; METABOLISM; EXCRETION; CALCIUM; GLUCOSE; SODIUM;
   INTACT; FGF 23; FGF23
AB BACKGROUND. Sodium glucose cotransporter 2 (SGLT2) inhibitors are the most recently approved class of drugs for type 2 diabetes and provide both glycemic efficacy and cardiovascular risk reduction. A number of safety issues have been identified, including treatment emergent bone fractures. To understand the overall clinical profile, these safety issues must be balanced against an attractive efficacy profile. Our study was designed to investigate pathophysiological mechanisms mediating treatment emergent adverse effects on bone health.
   METHODS. We conducted a single blind randomized crossover study in hospitalized healthy adults (n = 25) receiving either canagliflozin (300 mg/d) or placebo for 5 days. The primary end point was the drug induced change in AUC for plasma intact fibroblast growth factor 23 (FGF23) immunoactivity between 24 and 72 hours.
   RESULTS. Canagliflozin administration increased placebo subtracted mean levels of serum phosphorus (+16%), plasma FGF23 (+20%), and plasma parathyroid hormone (PTH) (+25%), while decreasing the level of 1,25 dihydroxyvitamin D ( 10%). There was substantial interindividual variation in the magnitude of each of these pharmacodynamic responses. The increase in plasma FGF23 was correlated with the increase in serum phosphorus, and the decrease in plasma 1,25 dihydroxyvitamin D was correlated with the increase in plasma FGF23.
   CONCLUSIONS. Canagliflozin induced a prompt increase in serum phosphorus, which triggers downstream changes in FGF23, 1,25 dihydroxyvitamin D, and PTH, with potential to exert adverse effects on bone health. These pharmacodynamic data provide a foundation for future research to elucidate pathophysiological mechanisms of adverse effects on bone health, with the objective of devising therapeutic strategies to mitigate the drug associated fracture risk.
C1 [Blau, Jenny E.; Bauman, Viviana; Conway, Ellen M.; Walter, Mary F.; Wright, Elizabeth C.; Rother, Kristina I.; Taylor, Simeon I.] NIDDK, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD USA.
   [Blau, Jenny E.] NICHHD, Off Clin Director, NICHD, NIH, Bethesda, MD 20892 USA.
   [Piaggi, Paolo] NIDDK, Obes & Diabet Clin Res Sect, NIH, Phoenix, AZ USA.
   [Bernstein, Shanna; Courville, Amber B.] NIDCR, Nutr Dept, Hatfield Clin Res Ctr, NIH, Bethesda, MD USA.
   [Collins, Michael T.] NIDCR, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.
   [Taylor, Simeon I.] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of
   Health (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD); National Institutes of Health
   (NIH)   USA; NIH National Institute of Diabetes & Digestive & Kidney
   Diseases (NIDDK); National Institutes of Health (NIH)   USA; NIH
   National Institute of Dental & Craniofacial Research (NIDCR); National
   Institutes of Health (NIH)   USA; NIH National Institute of Dental &
   Craniofacial Research (NIDCR); University System of Maryland; University
   of Maryland Baltimore
RP Blau, JE (通讯作者)，NIH, 10 Ctr Dr,2 5132, Bethesda, MD 20892 USA.; Taylor, SI (通讯作者)，Univ Maryland, Sch Med, MSTF 357 B,655 West Baltimore St, Baltimore, MD 21201 USA.
EM jenny.blau@nih.gov; staylor2@som.umaryland.edu
RI ; Piaggi, Paolo/E 2539 2011; Blau, Jenny/AAE 2980 2019; Wright Jin,
   Elizabeth/N 1111 2019
OI Piaggi, Paolo/0000 0003 2774 9161; Bauman, Viviana/0000 0003 2397 3756; 
FU Intramural Program of NIDDK
FX Supported by the Intramural Program of NIDDK.
CR [Anonymous], 2016, BRIEF DOC END MET DR
   [Anonymous], 2015, FDA DRUGS SAF COMM F
   [Anonymous], Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older
   [Anonymous], 2016, FDA DRUG SAF COMM IN
   [Anonymous], INV INV CAN DRUG SAF
   [Anonymous], 2021, What we eat in America
   Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006 0021
   Becker GJ, 2009, NEPHROL DIAL TRANSPL, V24, P2321, DOI 10.1093/ndt/gfp220
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P43, DOI 10.1210/jc.2015 1860
   Blau JE BV, ACUTE EFFECTS CANAGL
   Blau JE, 2017, DIABETES METAB RES, V33, DOI 10.1002/dmrr.2924
   Brenza HL, 1998, P NATL ACAD SCI USA, V95, P1387, DOI 10.1073/pnas.95.4.1387
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   de Jong MA, EFFECTS SGLT2 INHIBI
   DENNIS VW, 1978, J CLIN INVEST, V62, P387, DOI 10.1172/JCI109140
   El Hajj Fuleihan G, 1997, J CLIN ENDOCR METAB, V82, P281, DOI 10.1210/jc.82.1.281
   Ferrannini E, 2017, CELL METAB, V26, P27, DOI 10.1016/j.cmet.2017.04.011
   GREEN J, 1991, KIDNEY INT, V39, P9, DOI 10.1038/ki.1991.2
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P1603, DOI 10.1210/jc.2002 020773
   Ito N, 2007, J BONE MINER METAB, V25, P419, DOI 10.1007/s00774 007 0779 3
   Kohan DE, 2014, KIDNEY INT, V85, P962, DOI 10.1038/ki.2013.356
   Kwon H, FDA END MET DRUGS AD
   Lee JW, 2015, J AM SOC NEPHROL, V26, P2669, DOI 10.1681/ASN.2014111067
   MIFFLIN MD, 1990, AM J CLIN NUTR, V51, P241, DOI 10.1093/ajcn/51.2.241
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Muskiet MHA, 2015, LANCET DIABETES ENDO, V3, P928, DOI 10.1016/S2213 8587(15)00424 6
   Nauck MA, 2014, DRUG DES DEV THER, V8, P1335, DOI 10.2147/DDDT.S50773
   Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925
   Perwad F, 2005, ENDOCRINOLOGY, V146, P5358, DOI 10.1210/en.2005 0777
   Polidori D, 2018, DIABETES OBES METAB, V20, P1321, DOI 10.1111/dom.13224
   Sha S, 2015, DIABETES OBES METAB, V17, P188, DOI 10.1111/dom.12418
   SHEIKH MS, 1990, MINER ELECTROL METAB, V16, P130
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   SKEITH MD, 1970, AM J PHYSIOL, V219, P1080, DOI 10.1152/ajplegacy.1970.219.4.1080
   Smith ER, 2012, J CLIN ENDOCR METAB, V97, P3357, DOI 10.1210/jc.2012 1811
   Taylor SI, 2015, LANCET DIABETES ENDO, V3, P8, DOI 10.1016/S2213 8587(14)70227 X
   Watts NB, 2016, J CLIN ENDOCR METAB, V101, P156, DOI 10.1210/jc.2015 3167
   Weir MR, 2014, CURR MED RES OPIN, V30, P1759, DOI 10.1185/03007995.2014.919907
   Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720
NR 40
TC 120
Z9 129
U1 0
U2 12
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD APR 19
PY 2018
VL 3
IS 8
AR e99123
DI 10.1172/jci.insight.99123
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GD3KH
UT WOS:000430402300014
PM 29669938
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhao, L
   Wang, Y
   Wang, ZJ
   Xu, Z
   Zhang, QY
   Yin, M
AF Zhao, Lu
   Wang, Yin
   Wang, Zejian
   Xu, Zheng
   Zhang, Qiaoyan
   Yin, Ming
TI Effects of dietary resveratrol on excess iron induced bone loss via
   antioxidative character
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Osteoporosis; Iron overload; Resveratrol; Antioxidant effect; Sirt 1
ID OXIDATIVE STRESS; ALPHA; DIFFERENTIATION; OVEREXPRESSION; OSTEOPOROSIS;
   OSTEOBLASTS; RESORPTION; OSTEOPENIA; OVERLOAD; ESTROGEN
AB Estrogen deficiency has been considered to be a major cause of osteoporosis, but recent epidemiological evidence and mechanistic studies have indicated that aging and the associated increase in reactive oxygen species (ROS) are the proximal pathogenic factors. Through ROS mediated reactions, iron can induce disequilibrium of oxidation and antioxidation and can cause bone loss in mice. Therefore, we investigated the effects of resveratrol (RES) on bone mineral density, bone microstructure and the osteoblast functions under iron overload conditions. Excess iron disrupted the antioxidant/prooxidant equilibrium of the mice and induced the defect and the lesion of the bone trabecula as well as disequilibrium between bone formation and bone resorption in iron overload mice. Oral administration of RES significantly prevented bone loss in the osteoporotic mice. RES reversed the reduction of Runx2, OCN and type I collagen from excess iron; up regulated the level of FOXO1; and maintained the antioxidant/prooxidant equilibrium in the mice. RES also reduced the ratio of OPG/RANKL in MC3T3 E1 cells and in mice and significantly inhibited subsequent osteoclastogenesis. These results provide new insights into the antiosteoporosis mechanisms of RES through antioxidative effects, suggesting that RES can be considered a potential natural resource for developing medicines or dietary supplements to prevent and treat osteoporosis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Zhao, Lu; Wang, Zejian; Yin, Ming] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China.
   [Wang, Yin] Peoples Liberat Army 455 Hosp, Shanghai 200050, Peoples R China.
   [Xu, Zheng] Changzheng Hosp, Shanghai 200003, Peoples R China.
   [Zhang, Qiaoyan] Second Milittny Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
C3 Shanghai Jiao Tong University; Naval Medical University
RP Zhang, QY (通讯作者)，Second Milittny Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
EM zqy1965@163.com; myin@sjtu.edu.cn
FU National Natural Science Foundation of China [81274152]; Natural Science
   Foundation of Shanghai Science and Technology Commission, China
   [13ZR1449600]; Shanghai City Health Planning Commission, China [2013299]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81274152), the Natural Science Foundation
   of Shanghai Science and Technology Commission, China (Grant No.
   13ZR1449600) and the Scientific Research Fund of Shanghai City Health
   Planning Commission, China (Grant No. 2013299).
CR Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Artsi H, 2014, ENDOCRINOLOGY, V155, P3508, DOI 10.1210/en.2014 1334
   Beaumont C, 2009, SEMIN HEMATOL, V46, P328, DOI 10.1053/j.seminhematol.2009.06.004
   Cao Q, 2014, BIOMATERIALS, V35, P8273, DOI 10.1016/j.biomaterials.2014.06.020
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Dumont M, 2009, FASEB J, V23, P2459, DOI 10.1096/fj.09 132928
   Durbin SM, 2014, J BONE MINER METAB, V32, P38, DOI 10.1007/s00774 013 0469 2
   Fernández Mar MI, 2012, FOOD CHEM, V130, P797, DOI 10.1016/j.foodchem.2011.08.023
   Gertz M, 2013, P NATL ACAD SCI USA, V110, pE2772, DOI 10.1073/pnas.1303628110
   Hori YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073875
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Huang W, 2012, ACTA PHARMACOL SIN, V33, P668, DOI 10.1038/aps.2011.189
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004 1058
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jian JL, 2009, ANTIOXID REDOX SIGN, V11, P2939, DOI [10.1089/ars.2009.2576, 10.1089/ARS.2009.2576]
   JOHNSON MA, 1994, FASEB J, V8, P609, DOI 10.1096/fasebj.8.9.8005389
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Kudo H, 2008, TOXICOLOGY, V246, P143, DOI 10.1016/j.tox.2008.01.004
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee S, 2012, HORM METAB RES, V44, P699, DOI 10.1055/s 0032 1311606
   Lee YS, 2014, J MED FOOD, V17, P414, DOI 10.1089/jmf.2013.2841
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Li KC, 2014, ARCH ORAL BIOL, V59, P921, DOI 10.1016/j.archoralbio.2014.05.015
   Liu G, 2008, HEMOGLOBIN, V32, P181, DOI 10.1080/03630260701726707
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Moriwaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097177
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306
   RUIZLARREA MB, 1994, STEROIDS, V59, P383
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shen GS, 2014, CALCIFIED TISSUE INT, V94, P632, DOI 10.1007/s00223 014 9845 8
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Vijayan V, 2013, FREE RADICAL BIO MED, V61, P72, DOI 10.1016/j.freeradbiomed.2013.03.004
   Wang B, 2014, J CELL MOL MED, V18, P1599, DOI 10.1111/jcmm.12312
   Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wenzel E, 2005, MOL NUTR FOOD RES, V49, P472, DOI 10.1002/mnfr.200500010
   Yamasaki K, 2009, TOXICOL LETT, V191, P211, DOI 10.1016/j.toxlet.2009.08.023
   Yang Q, 2011, J BONE MINER RES, V26, P1188, DOI 10.1002/jbmr.337
   Yun JM, 2012, J NUTR BIOCHEM, V23, P699, DOI 10.1016/j.jnutbio.2011.03.012
   Zarjou A, 2010, J BONE MINER RES, V25, P164, DOI 10.1359/jbmr.091002
   Zhao HF, 2014, BRIT J NUTR, V111, P836, DOI 10.1017/S0007114513003115
NR 46
TC 58
Z9 71
U1 0
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0955 2863
EI 1873 4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD NOV
PY 2015
VL 26
IS 11
BP 1174
EP 1182
DI 10.1016/j.jnutbio.2015.05.009
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA CW4RK
UT WOS:000364979600008
PM 26239832
DA 2025 08 17
ER

PT J
AU Dempster, DW
   Roschger, P
   Misof, BM
   Zhou, H
   Paschalis, EP
   Alam, J
   Ruff, VA
   Klaushofer, K
   Taylor, KA
AF Dempster, David W.
   Roschger, Paul
   Misof, Barbara M.
   Zhou, Hua
   Paschalis, Eleftherios P.
   Alam, Jahangir
   Ruff, Valerie A.
   Klaushofer, Klaus
   Taylor, Kathleen A.
TI Differential Effects of Teriparatide and Zoledronic Acid on Bone
   Mineralization Density Distribution at 6 and 24 Months in the SHOTZ
   Study
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANABOLICS; ANTIRESPORPTIVES; CLINICAL TRIALS; OSTEOPOROSIS; MATRIX
   MINERALIZATION
ID PARATHYROID HORMONE 1 34; ILIAC CREST BIOPSIES; CANCELLOUS BONE;
   POSTMENOPAUSAL OSTEOPOROSIS; WOMEN; FRACTURE; QUALITY; RISEDRONATE;
   ALENDRONATE; TRIAL
AB The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone remodeling and material properties in postmenopausal women with osteoporosis. Previously, we reported that biochemical and histomorphometric bone formation indices were significantly higher in patients receiving TPTD versus ZOL. Here we report bone mineralization density distribution (BMDD) results based on quantitative backscattered electron imaging (qBEI). The 12 month primary study was randomized and double blind until the month 6 biopsy, then open label. Patients (TPTD, n = 28; ZOL, n = 31) were then eligible to enter a 12 month open label extension with their original treatment: TPTD 20 mu g/d (subcutaneous injection) or ZOL 5 mg/yr (intravenous infusion). A second biopsy was collected from the contralateral side at month 24 (TPTD, n = 10; ZOL, n = 10). In cancellous bone, ZOL treatment was associated at 6 and 24 months with significantly higher average degree of mineralization (Ca MEAN, +2.2%, p = 0.018; +3.9%, p = 0.009, respectively) and with lower percentage of low mineralized areas (Ca LOW,  34.6%, p = 0.029;  33.7%, p = 0.025, respectively) and heterogeneity of mineralization Ca WIDTH ( 12.3%, p = 0.003;  9.9%, p = 0.012, respectively), indicating higher mineralization density and more homogeneous mineral content versus TPTD. Within the ZOL group, significant changes were found in all parameters from month 6 to 24, indicating a progressive increase in mineralization density. In sharp contrast, mineralization density did not increase over time with TPTD, reflecting ongoing deposition of new bone. Similar results were observed in cortical bone. In this study, TPTD stimulated new bone formation, producing a mineralized bone matrix that remained relatively heterogeneous with a stable mean mineral content. ZOL slowed bone turnover and prolonged secondary mineralization, producing a progressively more homogeneous and highly mineralized bone matrix. Although both TPTD and ZOL increase clinical measures of bone mineral density (BMD), this study shows that the underlying mechanisms of the BMD increases are fundamentally different. (C) 2016 American Society for Bone and Mineral Research.
C1 [Dempster, David W.; Zhou, Hua] Helen Hayes Hosp, Reg Bone Ctr, Route 9W, W Haverstraw, NY 10993 USA.
   [Dempster, David W.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY USA.
   [Roschger, Paul; Misof, Barbara M.; Paschalis, Eleftherios P.; Klaushofer, Klaus] Hanusch Hosp WGKK, Ludwig Boltzmann Inst Osteol, Vienna, Austria.
   [Roschger, Paul; Misof, Barbara M.; Paschalis, Eleftherios P.; Klaushofer, Klaus] Hanusch Hosp, AUVA Trauma Ctr Meidling, Med Dept 1, Vienna, Austria.
   [Alam, Jahangir; Ruff, Valerie A.; Taylor, Kathleen A.] Lilly USA LLC, Indianapolis, IN USA.
C3 Columbia University; WGKK   Hanusch Hospital; Ludwig Boltzmann
   Institute; Ludwig Boltzmann Institute for Osteology; WGKK   Hanusch
   Hospital; Lilly USA LLC
RP Dempster, DW (通讯作者)，Helen Hayes Hosp, Reg Bone Ctr, Route 9W, W Haverstraw, NY 10993 USA.
EM ddempster9@aol.com
RI ; Alam, Jahangir/JND 9306 2023; Misof, Barbara/AAG 5051 2020
OI Misof, Barbara/0000 0001 9923 4920; Paschalis,
   Eleftherios/0000 0002 2079 435X; 
FU Lilly USA, LLC.
FX The authors thank Daniela Gabriel, Petra Keplinger, Sonja Lueger, and
   Phaedra Messmer for sample preparation and quantitative backscatter
   electron imaging measurements at the Bone Material Laboratory of the
   Ludwig Boltzmann Institute of Osteology, Vienna, Austria, and Fangqui
   Zhang, formerly of inVentiv Health Clinical, Toronto, Canada, for
   statistical support. Thomas Melby of inVentiv Health Clinical, Cary, NC,
   USA, provided support in preparing the manuscript. This work was
   sponsored by Lilly USA, LLC.
CR Bala Y, 2011, EUR J ENDOCRINOL, V165, P647, DOI 10.1530/EJE 11 0333
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Boivin G., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P538
   Borah B, 2006, BONE, V39, P345, DOI 10.1016/j.bone.2006.01.161
   Dempster DW, 2016, J BONE MINER RES, V31, P1429, DOI 10.1002/jbmr.2804
   Dempster DW, 2012, J CLIN ENDOCR METAB, V97, P2799, DOI 10.1210/jc.2012 1262
   Eriksen EF, 2014, BONE, V67, P246, DOI 10.1016/j.bone.2014.07.014
   Faulkner KG, 2000, J BONE MINER RES, V15, P183, DOI 10.1359/jbmr.2000.15.2.183
   Fratzl P, 2004, J MATER CHEM, V14, P2115, DOI 10.1039/b402005g
   Fratzl P, 2007, CALCIFIED TISSUE INT, V81, P73, DOI 10.1007/s00223 007 9039 8
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Misof BM, 2014, CALCIFIED TISSUE INT, V95, P332, DOI 10.1007/s00223 014 9901 4
   Misof BM, 2013, J BONE MINER RES, V28, P442, DOI 10.1002/jbmr.1780
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Kulak CAM, 2010, ARQ BRAS ENDOCRINOL, V54, P87, DOI 10.1590/S0004 27302010000200002
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Papapoulos SE, 2011, ANN NY ACAD SCI, V1218, P15, DOI 10.1111/j.1749 6632.2010.05767.x
   Paschalis EP, 2005, J CLIN ENDOCR METAB, V90, P4644, DOI 10.1210/jc.2004 2489
   Peterlik H, 2006, NAT MATER, V5, P52, DOI 10.1038/nmat1545
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   Roschger P, 2003, BONE, V32, P316, DOI 10.1016/S8756 3282(02)00973 0
   Roschger P, 2010, J BONE MINER RES, V25, P48, DOI 10.1359/jbmr.090702
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Roschger P, 2007, J BONE MINER RES, V22, P717, DOI 10.1359/JBMR.070120
   Roschger P, 2014, CURR OSTEOPOROS REP, V12, P338, DOI 10.1007/s11914 014 0218 z
   Ruffoni D, 2008, J BONE MINER RES, V23, P1905, DOI 10.1359/JBMR.080711
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Veenland JF, 1997, CALCIFIED TISSUE INT, V61, P474, DOI 10.1007/s002239900370
   Zoehrer R, 2006, J BONE MINER RES, V21, P1106, DOI 10.1359/JBMR.060401
NR 29
TC 36
Z9 38
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2016
VL 31
IS 8
BP 1527
EP 1535
DI 10.1002/jbmr.2825
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DW5WC
UT WOS:000383717200008
PM 26931279
OA hybrid
DA 2025 08 17
ER

PT J
AU Koyani, CN
   Kitz, K
   Rossmann, C
   Bernhart, E
   Huber, E
   Trummer, C
   Windischhofer, W
   Sattler, W
   Malle, E
AF Koyani, Chintan N.
   Kitz, Kerstin
   Rossmann, Christine
   Bernhart, Eva
   Huber, Evelyn
   Trummer, Christopher
   Windischhofer, Werner
   Sattler, Wolfgang
   Malle, Ernst
TI Activation of the MAPK/Akt/Nrf2 Egr1/HO 1 GCLc axis protects MG 63
   osteosarcoma cells against 15d PGJ2 mediated cell death
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE 15d PGJ(2); Chemotherapy; PI3K/Akt axis; Peroxisome
   proliferator activated receptor gamma; Pro survival signalling; ROS;
   Tumour protein p53
ID D 2 INDUCES APOPTOSIS; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J(2); HEME
   OXYGENASE 1; PPAR GAMMA; HUMAN OSTEOCLASTS; INTERLEUKIN 6 SYNTHESIS;
   GLUTATHIONE SYNTHESIS; OSTEOBLASTIC CELLS; SIGNALING PATHWAYS; CRTH2
   RECEPTORS
AB Despite considerable efforts to improve treatment modalities for osteosarcoma (OS), patient survival remains poor mainly due to pro survival pathways in OS cells. Among others, prostaglandins (PGs) are the potent regulators of bone homoeostasis and OS pathophysiology. Therefore, the present study aimed to elucidate the impact of 15 deoxy Delta(12,14) PGJ(2) (15d PGJ(2), a stable PGD(2) degradation product) on cell death/cell survival pathways in p53 deficient MG 63 OS cells. Our findings show that 15d PGJ(2) induces generation of reactive oxygen species that promote p38 MAPK activation and subsequent Akt phosphorylation. This pathway induced nuclear expression of Nrf2 and Egr1, and increased transcription of haem oxygenase 1 (HO 1) and the catalytic subunit of glutamate cysteine ligase (GCLc), catalysing the first step in GSH synthesis. Silencing of Nrf2, Egr1 and HO 1 significantly elevated 15d PGJ(2) mediated reduction of cellular metabolic activity. Activation of cell survival genes including HO 1 and GCLc inhibited 15d PGJ(2) induced cleavage of pro caspase 3 and PARP. Annexin V/propidium iodide staining showed an increase in early/late apoptotic cells in response to 15d PGJ(2). The observed 15d PGJ(2) mediated signalling events are independent of PGD(2) receptors (DP1 and DP2) and PPAR gamma. In addition, the electrophilic carbon atom C9 is a prerequisite for the observed activity of 15d PGJ(2). The present data show that the intracellular redox imbalance acted as a node and triggered both death and survival pathways in response to 15d PGJ(2). Pharmacological or genetic interference of the pro survival pathway, the p38 MAPK/Akt/Nrf2 Egr1/HO 1 GCLc axis, sensitizes MG 63 cells towards 15d PGJ(2) mediated apoptosis. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Koyani, Chintan N.; Kitz, Kerstin; Rossmann, Christine; Bernhart, Eva; Trummer, Christopher; Sattler, Wolfgang; Malle, Ernst] Med Univ Graz, Inst Mol Biol & Biochem, Harrachgasse 21, A 8010 Graz, Austria.
   [Kitz, Kerstin; Huber, Evelyn; Windischhofer, Werner] Med Univ Graz, Res Unit Osteol Res & Analyt Mass Spectrometry, Dept Pediat & Adolescence Med, A 8010 Graz, Austria.
   [Kitz, Kerstin] Fresenius Kabi Austria GmbH, Graz, Austria.
   [Rossmann, Christine] Med Univ Graz, Inst Physiol Chem, A 8010 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz
RP Malle, E (通讯作者)，Med Univ Graz, Inst Mol Biol & Biochem, Harrachgasse 21, A 8010 Graz, Austria.
EM ernst.malle@medunigraz.at
RI Malle, Ernst/D 3071 2013; Koyani, Chintan/A 7702 2013
OI Rossmann, Christine/0000 0002 1791 1981
FU Austrian Science Fund (FWF) within the "Doctoral College Metabolic and
   Cardiovascular Disease" [W1226 B18]; Ph.D. Program "Molecular Medicine"
   at the Medical University of Graz; FWF [W1241]; Austrian Science Fund
   (FWF) [W 1226] Funding Source: researchfish
FX C.K. was funded by the Austrian Science Fund (FWF, W1226 B18) within the
   "Doctoral College Metabolic and Cardiovascular Disease". K.K. was funded
   by the Ph.D. Program "Molecular Medicine" at the Medical University of
   Graz. This work further received support from FWF, W1241 ("Doctoral
   College   MOLIN"). We thank L. Frank for technical assistance.
CR Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078 0432.CCR 04 2159
   Bernhart E, 2015, BIOCHEM PHARMACOL, V96, P119, DOI 10.1016/j.bcp.2015.05.007
   Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387 2656(05)11004 7
   Bishop Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042
   Chang SY, 2012, J CELL BIOCHEM, V113, P1559, DOI 10.1002/jcb.24024
   Chen HQ, 2010, BIOCHEM BIOPH RES CO, V396, P388, DOI 10.1016/j.bbrc.2010.04.102
   Chen SY, 2014, CHINESE MED J PEKING, V127, P1310, DOI 10.3760/cma.j.issn.0366 6999.20133214
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chen ZH, 2006, J BIOL CHEM, V281, P14440, DOI 10.1074/jbc.M600260200
   de Jong E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025192
   DREW R, 1984, BIOCHEM PHARMACOL, V33, P2989, DOI 10.1016/0006 2952(84)90598 7
   Durand M, 2008, J BONE MINER RES, V23, P1097, DOI 10.1359/JBMR.080228
   During A, 2015, PROG LIPID RES, V59, P126, DOI 10.1016/j.plipres.2015.06.002
   Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211
   Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014 5793(02)03270 2
   Hellwinkel OJC, 2005, J GENE MED, V7, P407, DOI 10.1002/jgm.684
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Ho TC, 2008, J BIOL CHEM, V283, P30273, DOI 10.1074/jbc.M804196200
   Je EM, 2012, TUMORI, V98, P510, DOI 10.1700/1146.12647
   Ji LL, 2011, MOL CARCINOGEN, V50, P580, DOI 10.1002/mc.20741
   Jin S, 2007, APOPTOSIS, V12, P1317, DOI 10.1007/s10495 007 0062 z
   Jin S, 2007, CANCER BIOL THER, V6, P261, DOI 10.4161/cbt.6.2.3621
   Kansanen E, 2009, FREE RADICAL BIO MED, V47, P1310, DOI 10.1016/j.freeradbiomed.2009.06.030
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kato K, 2010, EXP THER MED, V1, P579, DOI 10.3892/etm_00000091
   Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652
   Kitz K, 2011, FREE RADICAL BIO MED, V50, P854, DOI 10.1016/j.freeradbiomed.2010.12.039
   Komiya S, 1998, J ORTHOP RES, V16, P15, DOI 10.1002/jor.1100160104
   Kongpetch S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034994
   KOSHIHARA Y, 1989, BIOCHEM BIOPH RES CO, V159, P1206, DOI 10.1016/0006 291X(89)92238 9
   Koyani CN, 2014, INT J CARDIOL, V173, P472, DOI 10.1016/j.ijcard.2014.03.086
   Kozawa O, 2001, CELL SIGNAL, V13, P535, DOI 10.1016/S0898 6568(01)00180 2
   Kuroyanagi G, 2014, PROSTAG LEUKOTR ESS, V91, P73, DOI 10.1016/j.plefa.2014.04.003
   Lee SJ, 2008, TOXICOLOGY, V248, P121, DOI 10.1016/j.tox.2008.03.014
   Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488
   Li LY, 2001, J BIOL CHEM, V276, P38152
   Lin TH, 2010, J CELL PHYSIOL, V222, P757, DOI 10.1002/jcp.22008
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Lu SC, 2013, BBA GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008
   Mathurin K, 2011, J BIOL CHEM, V286, P2696, DOI 10.1074/jbc.M110.178277
   Miwa S, 2011, INT J ONCOL, V39, P465, DOI 10.3892/ijo.2011.1051
   Na HK, 2014, FREE RADICAL BIO MED, V67, P353, DOI 10.1016/j.freeradbiomed.2013.10.819
   Napimoga MH, 2013, INT IMMUNOPHARMACOL, V16, P131, DOI 10.1016/j.intimp.2013.03.035
   Okano H, 2003, LAB INVEST, V83, P1529, DOI 10.1097/01.LAB.0000092233.50246.F7
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   Powell WS, 2003, J CLIN INVEST, V112, P828, DOI 10.1172/JCI200319796
   Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104
   Rauh A, 2008, BRIT J PHARMACOL, V154, P13, DOI 10.1038/bjp.2008.92
   Rawlinson SCF, 1998, BONE, V23, P433, DOI 10.1016/S8756 3282(98)00125 2
   Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068
   Sakaba Y, 2014, PROSTAG OTH LIPID M, V109, P1, DOI 10.1016/j.prostaglandins.2014.02.001
   Schuligoi R, 2007, BIOCHEM PHARMACOL, V74, P107, DOI 10.1016/j.bcp.2007.03.023
   Semlitsch M, 2011, DNA REPAIR, V10, P848, DOI 10.1016/j.dnarep.2011.05.004
   Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200
   Shibata T, 2015, BIOSCI BIOTECH BIOCH, V79, P1044, DOI 10.1080/09168451.2015.1012149
   Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs
   Tokuda H, 1999, PROSTAG LEUKOTR ESS, V61, P189, DOI 10.1054/plef.1999.0089
   Tokuda H, 2008, PROSTAG LEUKOTR ESS, V79, P41, DOI 10.1016/j.plefa.2008.07.004
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Uchida K, 2008, CHEM RES TOXICOL, V21, P138, DOI 10.1021/tx700177j
   Wall SB, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00369
   Windischhofer W, 2012, BIOCHIMIE, V94, P1997, DOI 10.1016/j.biochi.2012.05.023
   Wu HZ, 2013, J SURG RES, V181, P204, DOI 10.1016/j.jss.2012.07.031
   Xiang ZM, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742 2094 4 18
   Yang HP, 2005, MOL CELL BIOL, V25, P5933, DOI 10.1128/MCB.25.14.5933 5946.2005
   Yen CC, 2014, ONCOTARGET, V5, P716, DOI 10.18632/oncotarget.1704
   Yue L, 2014, BONE, V60, P112, DOI 10.1016/j.bone.2013.12.011
   Yue L, 2012, BONE, V51, P338, DOI 10.1016/j.bone.2012.06.003
   Zhang HQ, 2012, SEMIN CELL DEV BIOL, V23, P722, DOI 10.1016/j.semcdb.2012.03.017
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
NR 72
TC 36
Z9 37
U1 0
U2 19
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2016
VL 104
BP 29
EP 41
DI 10.1016/j.bcp.2016.01.011
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DG3EP
UT WOS:000371952600004
PM 26801686
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Sepulveda, H
   Aguilar, R
   Prieto, CP
   Bustos, F
   Aedo, S
   Lattus, J
   Van Zundert, B
   Palma, V
   Montecino, M
AF Sepulveda, Hugo
   Aguilar, Rodrigo
   Prieto, Catalina P.
   Bustos, Francisco
   Aedo, Socrates
   Lattus, Jose
   Van Zundert, Brigitte
   Palma, Veronica
   Montecino, Martin
TI Epigenetic Signatures at the RUNX2 P1 and Sp7 Gene Promoters Control
   Osteogenic Lineage Commitment of Umbilical Cord Derived Mesenchymal Stem
   Cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BONE FORMATION; OSTEOBLAST DIFFERENTIATION; HISTONE MODIFICATIONS; DNA
   METHYLATION; REGENERATION; EXPRESSION; OSTERIX; TISSUE; DISTINCT;
   READERS
AB Wharton's Jelly mesenchymal stem cells (WJ MSCs) are an attractive potential source of multipotent stem cells for bone tissue replacement therapies. However, the molecular mechanisms involved in their osteogenic conversion are poorly understood. Particularly, epigenetic control operating at the promoter regions of the two master regulators of the osteogenic program, RUNX2/P57 and SP7 has not yet been described in WJ MSCs. Via quantitative PCR profiling and chromatin immunoprecipitation (ChIP) studies, here we analyze the ability of WJ MSCs to engage osteoblast lineage. In undifferentiated WJ MSCs, RUNX2/P57 P1, and SP7 promoters are found deprived of significant levels of the histone post translational marks that are normally associated with transcriptionally active genes (H3ac, H3K27ac, and H3K4me3). Moreover, the RUNX2 P1 promoter lacks two relevant histone repressive marks (H3K9me3 and H3K27me3). Importantly, RUNX2 P1 promoter is found highly enriched in the H3K4me1 mark, which has been shown recently to mediate gene repression of key regulatory genes. Upon induction of WJ MSCs osteogenic differentiation, we found that RUNX2/P57, but not SP7 gene expression is strongly activated, in a process that is accompanied by enrichment of activating histone marks (H3K4me3, H3ac, and H3K27ac) at the P1 promoter region. Histone mark analysis showed that SP7 gene promoter is robustly enriched in epigenetic repressive marks that may explain its poor transcriptional response to osteoblast differentiating media. Together, these results point to critical regulatory steps during epigenetic control of WJ MSCs osteogenic lineage commitment that are relevant for future applications in regenerative medicine. (C) 2016 Wiley Periodicals, Inc.
C1 [Sepulveda, Hugo; Aguilar, Rodrigo; Van Zundert, Brigitte; Montecino, Martin] Univ Andres Bello, Ctr Biomed Res, Ave Republ 239, Santiago, Chile.
   [Sepulveda, Hugo; Aguilar, Rodrigo; Bustos, Francisco; Montecino, Martin] FONDAP Ctr Genome Regulat, Santiago, Chile.
   [Prieto, Catalina P.; Bustos, Francisco; Palma, Veronica] Fac Sci, Lab Stem Cells & Dev Biol, Santiago, Chile.
   [Aedo, Socrates; Lattus, Jose] Univ Chile, Dept Obstet & Gynecol, Fac Med, Campus Oriente, Santiago, Chile.
C3 Universidad Andres Bello; Universidad de Chile
RP Montecino, M (通讯作者)，Univ Andres Bello, Ctr Biomed Res, Ave Republ 239, Santiago, Chile.; Palma, V (通讯作者)，Univ Chile, Fac Ciencias, Dept Biol, Ave Las Palmeras 3425, Santiago, Chile.
EM vpalma@uchile.cl; mmontecino@unab.cl
RI Aguilar, Rodrigo/AAG 6178 2019; Prieto, Catalina/MSZ 1936 2025
OI Aguilar, Rodrigo/0000 0003 0410 5478; Palma,
   Veronica/0000 0002 4320 7525; van Zundert, Brigitte/0000 0002 4129 9972;
   Montecino, Martin/0000 0002 6025 0023; BUSTOS,
   FRANCISCO/0000 0001 5457 4956; 
FU FONDAP [15090007]; CONICYT DRI [2013 0030]; FONDECYT [1130706, 1140301,
   3140368]; FONDEF [D09I1047]; CONICYT, Chile
FX Contract grant sponsor: FONDAP;Contract grant number: 15090007.Contract
   grant sponsor: CONICYT DRI;Contract grant number: 2013 0030.Contract
   grant sponsor: FONDECYT;Contract grant numbers: 1130706, 1140301,
   3140368.Contract grant sponsor: FONDEF;Contract grant number:
   D09I1047.Contract grant sponsor: CONICYT, Chile.
CR Aguilar R, 2016, BBA GENE REGUL MECH, V1859, P1043, DOI 10.1016/j.bbagrm.2016.05.009
   Amable PR, 2014, BMC CELL BIOL, V15, DOI 10.1186/s12860 014 0046 0
   Bieback Karen, 2007, Curr Stem Cell Res Ther, V2, P310, DOI 10.2174/157488807782793763
   Boland MJ, 2014, CIRC RES, V115, P311, DOI 10.1161/CIRCRESAHA.115.301517
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cheng J, 2014, MOL CELL, V53, P979, DOI 10.1016/j.molcel.2014.02.032
   Cruzat F, 2009, BIOCHEMISTRY US, V48, P7287, DOI 10.1021/bi9004792
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Edwards SS, 2014, ANGIOGENESIS, V17, P851, DOI 10.1007/s10456 014 9432 7
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Fernandez Moure JS, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0193 z
   Fong CY, 2016, J CELL BIOCHEM, V117, P815, DOI 10.1002/jcb.25375
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Grandy R, 2011, MOL CELL BIOL, V31, P2997, DOI 10.1128/MCB.05096 11
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Kouroupis D, 2013, REGEN MED, V8, P569, DOI 10.2217/rme.13.47
   La Rocca G, 2013, CURR STEM CELL RES T, V8, P2, DOI 10.2174/1574888X11308010002
   La Rocca G, 2009, HISTOCHEM CELL BIOL, V131, P267, DOI 10.1007/s00418 008 0519 3
   Lee JS, 2011, BIOMATERIALS, V32, P760, DOI 10.1016/j.biomaterials.2010.09.042
   Lee JY, 2006, MOL CELLS, V22, P182
   Lee S, 2014, BMC CELL BIOL, V15, DOI 10.1186/s12860 014 0042 4
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960 9822(03)00432 9
   Leite C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111059
   Loebel C, 2015, TISSUE ENG PT A, V21, P115, DOI [10.1089/ten.tea.2014.0096, 10.1089/ten.TEA.2014.0096]
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Mitsui N, 2006, LIFE SCI, V78, P2697, DOI 10.1016/j.lfs.2005.10.024
   Montecino M, 2015, BONE, V81, P733, DOI 10.1016/j.bone.2015.03.013
   Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140
   Murray IR, 2015, BMC BIOL, V13, DOI 10.1186/s12915 015 0212 7
   Murray IR, 2014, CELL MOL LIFE SCI, V71, P1353, DOI 10.1007/s00018 013 1462 6
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nekanti U, 2010, INT J BIOL SCI, V6, P499
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Penolazzi L, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477 7827 7 106
   Rojas A, 2015, J BIOL CHEM, V290, P28329, DOI 10.1074/jbc.M115.657825
   Sheng GJ, 2015, BMC DEV BIOL, V15, DOI 10.1186/s12861 015 0094 5
   Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356
   Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V286, P74, DOI 10.1006/bbrc.2001.5363
   Sun Y, 2006, CRIT REV EUKAR GENE, V16, P211, DOI 10.1615/CritRevEukarGeneExpr.v16.i3.20
   Tai PWL, 2014, GENE, V550, P1, DOI 10.1016/j.gene.2014.05.044
   Todeschi MR, 2015, STEM CELLS DEV, V24, P1570, DOI 10.1089/scd.2014.0490
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Wang B, 2013, OR SURG OR MED OR PA, V116, pE221, DOI 10.1016/j.oooo.2011.12.024
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007 1028
   Yang D, 2013, J BIOL CHEM, V288, P33530, DOI 10.1074/jbc.M113.497040
   Yun MY, 2011, CELL RES, V21, P564, DOI 10.1038/cr.2011.42
   Zhang YX, 2015, J BIOCHEM, V158, P445, DOI 10.1093/jb/mvv059
NR 51
TC 26
Z9 27
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2017
VL 232
IS 9
BP 2519
EP 2527
DI 10.1002/jcp.25627
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA EZ1CI
UT WOS:000404445700027
PM 27689934
DA 2025 08 17
ER

PT J
AU Kolmas, J
   Pajor, K
   Pajchel, L
   Przekora, A
   Ginalska, G
   Oledzka, E
   Sobczak, M
AF Kolmas, Joanna
   Pajor, Kamil
   Pajchel, Lukasz
   Przekora, Agata
   Ginalska, Grazyna
   Oledzka, Ewa
   Sobczak, Marcin
TI Fabrication and physicochemical characterization of porous composite
   microgranules with selenium oxyanions and risedronate sodium for
   potential applications in bone tumors
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE composites; nanocrystalline hydroxyapatite; drug release; cytotoxicity;
   antitumor activity; ionic substitutions; biomaterials; bisphosphonates
ID NMR INVESTIGATIONS; BISPHOSPHONATES; HYDROXYAPATITE; BIOMATERIALS;
   ADSORPTION; MECHANISM
AB Nanocrystalline hydroxyapatite containing selenite ions (SeHA; 9.6 wt.% of selenium) was synthesized using wet method and subject to careful physicochemical analysis by powder X ray diffraction, Fourier transform infrared spectroscopy, transmission electron microscopy, solid state nuclear magnetic resonance, wavelength dispersive X ray fluorescence, and inductively coupled plasma optical emission spectrometry. SeHA was then used to develop the seleniumcontaining hydroxyapatite/alginate (SeHA/ALG) composite granules. Risedronate sodium (RIS) was introduced to the obtained spherical microgranules of a size of about 1.1 1.5 mm in 2 ways: during the granules' preparation (RIS solution added to a suspension of ALG and SeHA), and as a result of SeHA/ALG granules soaking in aqueous RIS solution. The analysis made using C 13 and P 31 cross polarization magic angle spinning nuclear magnetic resonance confirmed the presence of RIS and its interaction with calcium ions. Then, the release of selenium (inductively coupled plasma optical emission spectrometry) and RIS (high performance liquid chromatography) from microgranules was examined. Moreover, cytotoxicity of fabricated granules was assessed by MTT test. Selenium release was biphasic: the first stage was short and ascribed to a "burst release" probably from a hydrated surface layer of SeHA crystals, while the next stage was significantly longer and ascribed to a sustained release of selenium from the crystals' interior. The study showed that the method of obtaining microgranules containing RIS significantly affects its release profile. Performed cytotoxicity test revealed that fabricated granules had high antitumor activity against osteosarcoma cells. However, because of the "burst release" of selenium during the first 10 h, the granules significantly reduced viability of normal osteoblasts as well.
C1 [Kolmas, Joanna; Pajor, Kamil; Pajchel, Lukasz] Med Univ Warsaw, Fac Pharm, Lab Med Div, Dept Inorgan & Analyt Chem, Ul Banacha 1, PL 02097 Warsaw, Poland.
   [Przekora, Agata; Ginalska, Grazyna] Med Univ Lublin, Dept Biochem & Biotechnol, Fac Pharm, Med Analyt Div, Lublin, Poland.
   [Oledzka, Ewa; Sobczak, Marcin] Univ Warsaw, Dept Biomat Chem, Fac Pharm, Lab Med Div, Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Lublin; University
   of Warsaw
RP Kolmas, J (通讯作者)，Med Univ Warsaw, Fac Pharm, Lab Med Div, Dept Inorgan & Analyt Chem, Ul Banacha 1, PL 02097 Warsaw, Poland.
EM joanna.kolmas@wum.edu.pl
RI Oledzka, Ewa/U 8888 2018; Przekora, Agata/H 8422 2019; Pajchel,
   Lukasz/N 7754 2018; Ginalska, Grazyna/MDT 1080 2025; Kolmas,
   Joanna/U 9980 2018; Sobczak, Marcin/V 6248 2018
OI Oledzka, Ewa/0000 0003 0660 3315; Ginalska, Grazyna/0000 0002 9961 4226;
   Pajchel, Lukasz/0000 0003 1985 0876; Przekora Kusmierz,
   Agata/0000 0002 6076 1309; Kolmas, Joanna/0000 0002 4417 5836; Sobczak,
   Marcin/0000 0002 7362 8881
FU National Science Center, Poland [NCN DEC 2011/03/D/ST5/05793]; Ministry
   of Science and Higher Education in Poland within the DS2 project of the
   Medical University of Lublin
FX This work was supported by the research grant (Project NCN
   DEC 2011/03/D/ST5/05793) of the National Science Center, Poland.
   Financial assistance was partially provided by the Ministry of Science
   and Higher Education in Poland within the DS2 project of the Medical
   University of Lublin. The paper was partially developed using the
   equipment purchased within the agreement No POPW.01.03.00 06 010/09 00
   Operational Programme Development of Eastern Poland 2007 2013, Priority
   Axis I, Modern Economy, Operations 1.3. Innovations Promotion.
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   [Anonymous], 2009, In Vitro Methods, V3 Ed, P42
   Augst AD, 2006, MACROMOL BIOSCI, V6, P623, DOI 10.1002/mabi.200600069
   Bao P, 2015, J PROTEOME RES, V14, P1127, DOI 10.1021/pr501086e
   Cai XL, 2016, SCI REP UK, V6, DOI 10.1038/srep19213
   Cernik RJ, 1997, ANGEW CHEM, V138, P1417
   Dalheim MO, 2016, BIOMATERIALS, V80, P146, DOI 10.1016/j.biomaterials.2015.11.043
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Drosse I, 2008, INJURY, V39, pS9, DOI 10.1016/S0020 1383(08)70011 1
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Fishero BA, 2015, CRANIOMAX TRAUM REC, V8, P23, DOI 10.1055/s 0034 1393724
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Iafisco M, 2016, BIO INSPIRED REGENERATIVE MEDICINE: MATERIALS, PROCESSES, AND CLINICAL APPLICATIONS, P47
   Kolmas J, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671 015 0989 x
   Kolmas J, 2016, CERAM INT, V42, P2472, DOI 10.1016/j.ceramint.2015.10.048
   Kolmas J, 2015, INT J MOL SCI, V16, P11452, DOI 10.3390/ijms160511452
   Kolmas J, 2014, MAT SCI ENG C MATER, V39, P134, DOI 10.1016/j.msec.2014.02.018
   Kolmas J, 2010, J MOL STRUCT, V966, P113, DOI 10.1016/j.molstruc.2009.12.023
   Kyriakides D, 2007, ANAL CHIM ACTA, V584, P153, DOI 10.1016/j.aca.2006.11.012
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Liao WZ, 2016, INT J NANOMED, V11, P1305, DOI 10.2147/IJN.S92257
   Maiyo F, 2017, NANOMEDICINE UK, V12, P1075, DOI 10.2217/nnm 2017 0024
   Mouriño V, 2013, EXPERT OPIN DRUG DEL, V10, P1353, DOI 10.1517/17425247.2013.808183
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Pascaud P, 2014, J MATER SCI MATER M, V25, P2373, DOI 10.1007/s10856 014 5218 0
   Ramakrishna S, 2010, OVERVIEW BIOMATERIAL
   Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sonju Clasen A B, 1997, Adv Dent Res, V11, P523
   Sun JC, 2013, MATERIALS, V6, P1285, DOI 10.3390/ma6041285
   Supova M, 2015, CERAM INT, V41, P9203, DOI 10.1016/j.ceramint.2015.03.316
   Sutter B, 2002, SOIL SCI SOC AM J, V66, P455, DOI 10.2136/sssaj2002.0455
   Thian ES, 2013, J MATER SCI MATER M, V24, P437, DOI 10.1007/s10856 012 4817 x
   Tran PA, 2010, INT J NANOMED, V5, P351
   Wang P, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.17
   Woodruff MA, 2012, MATER TODAY, V15, P430, DOI 10.1016/S1369 7021(12)70194 3
   Xin ZF, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756 9966 28 105
   Zeng HW, 2013, NUTRIENTS, V5, P97, DOI 10.3390/nu5010097
NR 38
TC 22
Z9 25
U1 1
U2 25
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2017
VL 12
BP 5633
EP 5642
DI 10.2147/IJN.S140935
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA FC8RN
UT WOS:000407108700002
PM 28848343
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Holecki, M
   Zahorska Markiewicz, B
   Janowska, J
   Nieszporek, T
   Wojaczynska Stanek, K
   Zak Golab, A
   Wiecek, A
AF Holecki, Michal
   Zahorska Markiewicz, Barbara
   Janowska, Joanna
   Nieszporek, Teresa
   Wojaczynska Stanek, Katarzyna
   Zak Golab, Agnieszka
   Wiecek, Andrzej
TI The influence of weight loss on serum osteoprotegerin concentration in
   obese Perimenopausal women
SO OBESITY
LA English
DT Article
DE weight loss
ID OSTEOPROTEGERIN/OSTEOCLASTOGENESIS INHIBITORY FACTOR;
   PARATHYROID HORMONE; MESSENGER RNA; BONE; EXPRESSION; LIGAND;
   MECHANISMS; BINDING
AB Objective: To assess the influence of weight reduction therapy on serum osteoprotegerin (OPG) concentration in obese patients and compare these results with normal weight controls.
   Research Methods and Procedures: Forty three obese women (BMI, 36.7 +/  4.1 kg/m(2); mean age, 50.1 +/  4.5 years) were studied. The control group consisted of 19 normal weight women (BMI, 24.2 +/  2.1 kg/m(2); mean age, 53.8 +/  5.2 years). In all patients, serum concentrations of OPG, C telopeptide of type I collagen containing the cross linking site (CTX), osteocalcin, parathormone, 25 (OH) D 3 (vitamin D), and total calcium and phosphorus were assessed before and after a 3 month weight reduction therapy.
   Results: In obese subjects, serum concentrations of OPG, 25 (OH) D3. osteocalcin, total calcium, and phosphorus were significantly lower, and serum concentration of parathormone was significantly higher, before weight reduction therapy in comparison with normal weight controls. After weight reduction, a significantly higher serum concentration of 25 (OH) D3 and CTX and significantly lower concentration of OPG were found.
   Discussion: Serum concentration of OPG was significantly lower in obese patients in comparison with normal weight controls. Weight reduction therapy resulted in further decrease in OPG serum concentrations. Therefore, OPG cannot be treated as a protective factor from bone loss in obese patients.
C1 Med Univ Silesia, Dept Pathophysiol, PL 40752 Katowice, Poland.
   Med Univ Silesia, Dept Nephrol Endocrinol & Mat Dis, Katowice, Poland.
   Med Univ Silesia, Dept Pediat & Child Neurol, Katowice, Poland.
C3 Medical University of Silesia; Medical University of Silesia; Medical
   University of Silesia
RP Holecki, M (通讯作者)，Med Univ Silesia, Dept Pathophysiol, Ul Medykow 18, PL 40752 Katowice, Poland.
EM holamed@poczta.onet.pl
OI Zak Golab, Agnieszka/0000 0002 7763 1770; Teresa,
   Nieszporek/0000 0001 6249 7153; Janowska, Joanna/0000 0002 8994 8636;
   Holecki, Michal/0000 0002 3289 1050
CR ANDERSEN T, 1986, METABOLISM, V35, P147, DOI 10.1016/0026 0495(86)90116 2
   Arrighi H, 2000, J BONE MINER RES, V15, pS538
   ARRIGHI HM, 1998, BONE S1, V23, pT411
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V247, P338, DOI 10.1006/bbrc.1998.8783
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   GLASS AR, 1989, MED CLIN N AM, V73, P139, DOI 10.1016/S0025 7125(16)30696 4
   HAFFNER SM, 1989, INT J OBESITY, V13, P1
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   HOLECKI M, 2007, ENDOKRYNOL POL, V1, P7
   KOKOT F, 2006, NEFRON NADCISNIENI T, V3, P8
   LIEL Y, 1988, CALCIFIED TISSUE INT, V43, P199, DOI 10.1007/BF02555135
   Makiishi Shimobayashi C, 2001, BIOCHEM BIOPH RES CO, V281, P361, DOI 10.1006/bbrc.2001.4380
   MOSEKILDE L, 1980, GUT, V21, P624, DOI 10.1136/gut.21.7.624
   Onyia JE, 2000, J BONE MINER RES, V15, P863, DOI 10.1359/jbmr.2000.15.5.863
   Ostrowska, 1998, Endocr Regul, V32, P177
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Seck T, 2001, EUR J ENDOCRINOL, V145, P199, DOI 10.1530/eje.0.1450199
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stepan J J, 2000, Osteoporos Int, V11 Suppl 6, pS45, DOI 10.1007/s001980070005
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   TREMOLLIERES FA, 1993, J CLIN ENDOCR METAB, V77, P683, DOI 10.1210/jc.77.3.683
   Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
NR 25
TC 55
Z9 56
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1930 7381
EI 1930 739X
J9 OBESITY
JI Obesity
PD AUG
PY 2007
VL 15
IS 8
BP 1925
EP 1929
DI 10.1038/oby.2007.229
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 203VJ
UT WOS:000249001800005
PM 17712108
OA Bronze
DA 2025 08 17
ER

PT J
AU Renno, ACM
   Mcdonnell, PA
   Parizotto, NA
   Laakso, EL
AF Renno, A. C. M.
   Mcdonnell, P. A.
   Parizotto, N. A.
   Laakso, E L.
TI The effects of laser irradiation on osteoblast and osteosarcoma cell
   proliferation and differentiation in vitro
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
ID LOW ENERGY LASER; BONE; LIGHT; RADIATION; THERAPY; CULTURE; BLOOD
AB Objective: The aim of this study was to investigate the effects of 670 nm, 780 nm, and 830 nm laser irradiation on cell proliferation of normal primary osteoblast ( MC3T3) and malignant osteosarcoma ( MG63) cell lines in vitro. Background: Some studies have shown that laser phototherapy is able to stimulate the osteogenesis of bone tissue, increasing osteoblast proliferation and accelerating fracture consolidation. It has been suggested that laser light may have a biostimulatory effect on tumor cells. However, the mechanism by which the laser acts on cells is not fully understood. Materials and Methods: Neonatal, murine, calvarial, osteoblastic, and human osteosarcoma cell lines were studied. A single laser irradiation was performed at three different wavelengths, at the energies of 0.5, 1, 5, and 10 J/cm(2). Twenty four hours after laser irradiation, cell proliferation and alkaline phosphatase assays were assessed. Results: Osteoblast proliferation increased significantly after 830 nm laser irradiation ( at 10 J/cm(2)) but decreased after 780 nm laser irradiation ( at 1, 5, and 10 J/cm(2)). Osteosarcoma cell proliferation increased significantly after 670 nm ( at 5 J/cm(2)) and 780 nm laser irradiation ( at 1, 5, and 10 J/cm(2)), but not after 830 nm laser irradiation. Alkaline phosphatase ( ALP) activity in the osteoblast line was increased after 830 nm laser irradiation at 10 J/cm(2), whereas ALP activity in the osteosarcoma line was not altered, regardless of laser wavelength or intensity. Conclusion: Based on the conditions of this study, we conclude that each cell line responds differently to specific wavelength and dose combinations. Further investigations are required to investigate the physiological mechanisms responsible for the contrasting outcomes obtained when using laser irradiation on cultured normal and malignant bone cells.
C1 Univ Fed Sao Carlos, Dept Physiotherapy, BR 13565905 Sao Carlos, SP, Brazil.
   Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia.
   Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast, Qld, Australia.
C3 Universidade Federal de Sao Carlos; Griffith University; Griffith
   University; Griffith University   Gold Coast Campus
RP Renno, ACM (通讯作者)，Univ Fed Sao Carlos, Dept Physiotherapy, BR 13565905 Sao Carlos, SP, Brazil.
EM a.renno@unifesp.br
RI PARIZOTTO, NIVALDO ANTONIO/D 5347 2014; Renno, Ana/C 1266 2015;
   Parizotto, Nivaldo/D 5347 2014
OI PARIZOTTO, NIVALDO ANTONIO/0000 0003 1774 9053; Laakso,
   E Liisa/0000 0003 4820 1090; Renno, Ana/0000 0003 2358 0514; 
CR Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143
   Coombe A R, 2001, Clin Orthod Res, V4, P3, DOI 10.1034/j.1600 0544.2001.040102.x
   Dörtbudak O, 2000, CLIN ORAL IMPLAN RES, V11, P540, DOI 10.1034/j.1600 0501.2000.011006540.x
   Fujihara NA, 2006, LASER SURG MED, V38, P332, DOI 10.1002/lsm.20298
   Hamajima S, 2003, LASER MED SCI, V18, P78, DOI 10.1007/s10103 003 0255 9
   Karu T. I., 1988, Lasers in the Life Sciences, V2, P53
   KARU TI, 1990, PHOTOCHEM PHOTOBIOL, V52, P1089, DOI 10.1111/j.1751 1097.1990.tb08450.x
   KARU TI, 2000, P SPIE
   Khadra M, 2005, J BIOMED MATER RES A, V73A, P55, DOI 10.1002/jbm.a.30270
   Kim W, 1996, KOREAN J DEF ANAL, V8, P223
   Kreisler M, 2003, CLIN ORAL IMPLAN RES, V14, P91, DOI 10.1034/j.1600 0501.2003.140112.x
   Kujawa J, 2004, J CLIN LASER MED SUR, V22, P111, DOI 10.1089/104454704774076163
   Luger EJ, 1998, LASER SURG MED, V22, P97, DOI 10.1002/(SICI)1096 9101(1998)22:2<97::AID LSM5>3.3.CO;2 E
   Marcus R., 2001, Osteoporosis
   Mognato M, 2004, PHOTOMED LASER SURG, V22, P523, DOI 10.1089/pho.2004.22.523
   Moore P, 2005, LASER SURG MED, V36, P8, DOI 10.1002/lsm.20117
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pinheiro ALB, 2002, J CLIN LASER MED SUR, V20, P23, DOI 10.1089/104454702753474977
   PINHEIRO ALB, 2001, LASER THER, V13, P73
   Schaffer M, 1997, J PHOTOCH PHOTOBIO B, V40, P253, DOI 10.1016/S1011 1344(97)00065 1
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood 2004 06 2480
   TAKEDA Y, 1988, INT J ORAL MAX SURG, V17, P388, DOI 10.1016/S0901 5027(88)80070 5
   Tamura Kazutoshi, 1998, Laser Therapy, V10, P25
   TRELLES MA, 1987, LASER SURG MED, V7, P36, DOI 10.1002/lsm.1900070107
   Viñals F, 2004, J BIOL CHEM, V279, P45766, DOI 10.1074/jbc.M408059200
   Werneck CE, 2005, PHOTOMED LASER SURG, V23, P300, DOI 10.1089/pho.2005.23.300
   ZIPORI D, 1985, EXP HEMATOL, V13, P603
NR 28
TC 140
Z9 151
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549 5418
EI 1557 8550
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD AUG
PY 2007
VL 25
IS 4
BP 275
EP 280
DI 10.1089/pho.2007.2055
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 207GO
UT WOS:000249239800007
PM 17803384
DA 2025 08 17
ER

PT J
AU Xiang, MX
   Xu, Z
   Su, HW
   Hu, JY
   Yan, YJ
AF Xiang, Mei Xian
   Xu, Zong
   Su, Han Wen
   Hu, Jinyue
   Yan, Yun Jun
TI Emodin 8 O β D Glucoside from Polygonum Amplexicaule D.
   Don var. Sinense Forb. Promotes Proliferation and
   Differentiation of Osteoblastic MC3T3 E1 Cells
SO MOLECULES
LA English
DT Article
DE emodin 8 O beta D glucoside; Polygonum amplexicaule D. Don var. sinense
   Forb. (Polygonaceae); proliferation; differentiation; osteoblastic
   MC3T3 E1 cell
ID BONE MORPHOGENETIC PROTEIN 2; ALKALINE PHOSPHATASE; I COLLAGEN;
   MINERALIZATION; INCREASES; APOPTOSIS; EXTRACT
AB Polygonum amplexicaule D. Don var. sinense Forb. (Polygonaceae) (PAF) is a famous traditional herb used to treat fractures, rheumatoid arthritis, muscle injury and pain. The present study was designed to investigate a PAF derived chemical compound emodin 8 O beta D glucoside (EG) on the proliferation and differentiation of osteoblastic MC3T3 E1 cell in vitro. A compound was isolated from PAF extract by HPLC and identified as emodin 8 O beta D glucoside (EG) by spectroscopic methods. EG significantly promoted cell proliferation at 0.1 100 ng/mL, and increased the cell proportion in S phase from 16.34% to 32.16%. Moreover, EG increased alkaline phosphatase (ALP) expression in MC3T3 E1 cells at the concentration from 0.1 to 100 ng/mL and inhibited PGE(2) production induced by TNF alpha in osteoblasts at the concentrations ranging from 10 100 ng/mL, suggesting that cell differentiation was induced in MC3T3 E1 osteoblasts. Taken together, these results indicated compound EG directly stimulated cell proliferation and differentiation of osteoblasts, therefore this study preliminarily explored the pharmacological mechanism of PAF to promote the healing of bone rheumatism and various fractures.
C1 [Xiang, Mei Xian; Yan, Yun Jun] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Peoples R China.
   [Xiang, Mei Xian; Xu, Zong] S Cent Univ Nationalities, Coll Pharm, Wuhan 430075, Peoples R China.
   [Su, Han Wen; Hu, Jinyue] Wuhan Univ, Renmin Hosp, Wuhan 430060, Peoples R China.
C3 Huazhong University of Science & Technology; South Central Minzu
   University; Wuhan University
RP Yan, YJ (通讯作者)，Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Peoples R China.
EM jinyuehu@whu.edu.cn; yanyunjun@tom.com
RI Su, Hanwen/LGY 9195 2024
FU natural science foundation of Wuhan City [SZY09005]; Ministry of
   Education, China [NCET 07 0336]; Natural Science Foundation of SCUEC
   [CZY10015]
FX This work was supported by the Fund of natural science foundation of
   Wuhan City (SZY09005), Fund for New Century Excellent Talents from
   Ministry of Education, China (NCET 07 0336) and Fund for the Natural
   Science Foundation of SCUEC (CZY10015). The authors are thankful to
   Professor Dingrong Wan in the Pharmacognosy, the College of Pharmacy,
   South Central University for Nationalities for authenticating the herb
   PAF. The authors are thankful to Dr. Guangzhong Yang for instructing
   isolation and identification of chemicals.
CR AMOS AF, 2008, EUR J PHARMACOL, V587, P35
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Chan BY, 2008, BONE, V43, P567, DOI 10.1016/j.bone.2008.04.018
   Chen Y, 1999, J AGR FOOD CHEM, V47, P2226, DOI 10.1021/jf990092f
   Choi EM, 2005, BIOCHEM PHARMACOL, V70, P363, DOI 10.1016/j.bcp.2005.04.019
   Choi EM, 2001, PHYTOCHEMISTRY, V56, P733, DOI 10.1016/S0031 9422(00)00484 2
   Hu YM, 2008, PHYTOCHEMISTRY, V69, P2367, DOI 10.1016/j.phytochem.2008.05.023
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Kajii T, 1999, ARCH ORAL BIOL, V44, P233, DOI 10.1016/S0003 9969(98)00120 4
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang SK, 2006, IN VITRO CELL DEV AN, V42, P225, DOI 10.1290/0510068.1
   KIM HS, 2010, PLOS ONE, V10
   Kim KW, 2008, J ETHNOPHARMACOL, V115, P42, DOI 10.1016/j.jep.2007.09.003
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Pozharski E, 2010, METHODS MOL BIOL, V606, P385, DOI 10.1007/978 1 60761 447 0_26
   QUARLERS JD, 1999, J BONE MINER RES, V27, P683
   Son YO, 2006, EUR J PHARMACOL, V529, P24, DOI 10.1016/j.ejphar.2005.10.041
   Suh KS, 2003, PHYTOCHEMISTRY, V63, P209, DOI 10.1016/S0031 9422(03)00101 8
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tsutsumi R, 2009, J BONE MINER RES, V24, P1753, DOI [10.1359/JBMR.090412, 10.1359/jbmr.090412]
   Wang CY, 2007, EUR J PHARMACOL, V577, P58, DOI 10.1016/j.ejphar.2007.08.033
   Yamaguchi M, 1998, BIOCHEM PHARMACOL, V55, P71, DOI 10.1016/S0006 2952(97)00402 4
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 26
TC 27
Z9 34
U1 0
U2 20
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2011
VL 16
IS 1
BP 728
EP 737
DI 10.3390/molecules16010728
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 711MT
UT WOS:000286596400052
PM 21245807
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Siddiqi, MH
   Siddiqi, MZ
   Ahn, S
   Kang, S
   Kim, YJ
   Veerappan, K
   Yang, DU
   Yang, DC
AF Siddiqi, Muhammad Hanif
   Siddiqi, Muhammad Zubair
   Ahn, Sungeun
   Kang, Sera
   Kim, Yeon Ju
   Veerappan, Karpagam
   Yang, Dong Uk
   Yang, Deok Chun
TI Stimulative Effect of Ginsenosides Rg5:Rk1 on Murine Osteoblastic
   MC3T3 E1 Cells
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE Panax ginseng; ginsenosides; osteoblast; bone formation; alkaline
   phosphatase; mineralization
ID BONE MORPHOGENETIC PROTEIN 2/P38; ALKALINE PHOSPHATASE ACTIVITY; MARROW
   STROMAL CELLS; IN VITRO; COLLAGEN SYNTHESIS; DIFFERENTIATION;
   MINERALIZATION; PROLIFERATION; ACTIVATION; EXPRESSION
AB Panax ginseng C.A. Meyer (P.ginseng), hereafter referred to as P. ginseng, is known to exert a wide range of pharmacological effects both in vitro and in vivo; however, few studies have investigated the effects of ginseng on bone metabolism. We therefore investigated the potential antiosteoporotic properties of ginseng on the growth and differentiation of murine MC3T3 E1 cells. Rg5:Rk1 is a mixture of protopanaxadiol type ginsenosides, isolated from fresh P.ginseng root, via a repetitive steaming and drying process. In this study, we examined the stimulatory effects of Rg5:Rk1 on the differentiation and mineralization of MC3T3 E1 cells. Undifferentiated cells were treated with a range of concentrations of Rg5:Rk1 (1 50 mu g/mL), and cell viability was measured with the 3 (4,5 dimethyl thiazol 2yl) 2,5 diphenyl tetrazolium bromide (MTT) assay. Treatment with Rg5:Rk1 significantly increased cell viability in a dose dependent manner. To investigate the possible mechanisms by which Rg5:Rk1 affects the early differentiation phase of MC3T3 E1 cells, the cells were treated with Rg5:Rk1 for 14 24days before assessing the levels of multiple osteoblastic markers. The markers examined included alkaline phosphatase (ALP) activity type I collagen content (Coll I), calcium deposition (by Alizarin Red S staining), extracellular mRNA expression of bone morphogenetic protein 2 (BMP 2), and the level of Runt related transcription factor 2 (Runx2). Rg5:Rk1 treatment also increased the activities of proteins associated with osteoblast growth and differentiation in a dose dependent manner. Overall, we found that the Rg5:Rk1 mixture of ginsenosides improved the osteoblastic function of MC3T3 E1 cells by increasing their proliferative capacity. This improvement is due to the action of Rg5:Rk1 on BMP 2, which is mediated by Runx2 dependent pathways. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Siddiqi, Muhammad Hanif; Siddiqi, Muhammad Zubair; Ahn, Sungeun; Kang, Sera; Kim, Yeon Ju; Veerappan, Karpagam; Yang, Dong Uk; Yang, Deok Chun] Kyung Hee Univ, Grad Sch Biotechnol, Coll Life Sci, Ginseng Genet Resource Bank, Suwon 449701, South Korea.
C3 Kyung Hee University
RP Yang, DC (通讯作者)，Kyung Hee Univ, Korean Ginseng Ctr Most Valuable Prod, Yongin 449701, South Korea.
EM dcyang@khu.ac.kr
OI Veerappan, Karpagam/0000 0002 9910 6715
FU Korea Institute of Planning & Evaluation for Technology in Food,
   Agriculture, Forestry Fisheries [KIPET 313038 03 1 SB010]
FX This study was fully supported by the Korea Institute of Planning &
   Evaluation for Technology in Food, Agriculture, Forestry & Fisheries
   (KIPET 313038 03 1 SB010). The ginseng sample used in this study was
   provided by Ginseng Bank Kyung Hee University.
CR Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Bao HY, 2005, ARCH PHARM RES, V28, P335, DOI 10.1007/BF02977802
   Baron R., 2003, GEN PRINCIPLES BONE, P1
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Brewer L, 2011, EUR J CLIN PHARMACOL, V67, P321, DOI 10.1007/s00228 011 0999 2
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chiou WF, 2011, LIFE SCI, V88, P335, DOI 10.1016/j.lfs.2010.12.009
   Domon S, 2001, EUR J ORTHODONT, V23, P339, DOI 10.1093/ejo/23.4.339
   DUNCAN R, 1989, FEBS LETT, V251, P17, DOI 10.1016/0014 5793(89)81420 6
   Globus RK, 1998, J CELL SCI, V111, P1385
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022 1759(84)90190 X
   Han YH, 2009, LUNG CANCER, V65, P150, DOI 10.1016/j.lungcan.2008.11.005
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Hwang JT, 2007, BIOCHEM BIOPH RES CO, V364, P1002, DOI 10.1016/j.bbrc.2007.10.125
   Jezek P, 2005, INT J BIOCHEM CELL B, V37, P2478, DOI 10.1016/j.biocel.2005.05.013
   Johnson K, 2001, ARTHRITIS RHEUM, V44, P1071, DOI 10.1002/1529 0131(200105)44:5<1071::AID ANR187>3.0.CO;2 3
   김염, 2012, [Korean Journal of Plant Reources., 한국자원식물학회지], V25, P473, DOI 10.7732/kjpr.2012.25.4.473
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kim KW, 2008, J ETHNOPHARMACOL, V115, P42, DOI 10.1016/j.jep.2007.09.003
   Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149
   Kogianni Giolanta, 2007, Curr Osteoporos Rep, V5, P81
   Kojima H, 2004, J BIOCHEM, V136, P377, DOI 10.1093/jb/mvh136
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li XD, 2010, CELL PHYSIOL BIOCHEM, V26, P1081, DOI 10.1159/000323986
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Lu XZ, 2008, ACTA PHARMACOL SIN, V29, P1209, DOI 10.1111/j.1745 7254.2008.00874.x
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo 124 1 301
   Merck, 2011, FOS AL SOD TABL OR S
   Ning J, 2000, TOXICOL IN VITRO, V14, P329, DOI 10.1016/S0887 2333(00)00024 2
   Nishikawa T, 2007, ANTIOXID REDOX SIGN, V9, P343, DOI 10.1089/ars.2006.1458
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   PETERSON WJ, 1987, J IMMUNOL METHODS, V96, P171, DOI 10.1016/0022 1759(87)90311 5
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Polan ML, 2004, J WOMENS HEALTH, V13, P427, DOI 10.1089/154099904323087114
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Quan LH, 2010, J GINSENG RES, V34, P288, DOI 10.5142/jgr.2010.34.4.288
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756 3282(09)80003 3
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Shin HY, 2006, INDIAN J MED RES, V124, P199
   Shin YW, 2006, ARCH PHARM RES, V29, P685, DOI 10.1007/BF02968253
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TIETZ NW, 1983, CLIN CHEM, V29, P751
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Wang W, 2007, CANCER CHEMOTH PHARM, V59, P589, DOI 10.1007/s00280 006 0300 z
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yun AJ, 2004, MED HYPOTHESES, V63, P532, DOI 10.1016/S0306 9877(03)00326 8
NR 56
TC 32
Z9 37
U1 1
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD OCT
PY 2014
VL 28
IS 10
BP 1447
EP 1455
DI 10.1002/ptr.5146
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AQ4VP
UT WOS:000342798700002
PM 24643957
OA Bronze
DA 2025 08 17
ER

PT J
AU Frascoli, M
   Proietti, M
   Grassi, F
AF Frascoli, Michela
   Proietti, Michele
   Grassi, Fabio
TI Phenotypic Analysis and Isolation of Murine Hematopoietic Stem Cells and
   Lineage committed Progenitors
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Stem Cell Biology; Issue 65; Molecular Biology; Medicine; Hematopoiesis;
   hematopoietic stem cell; hematopoietic progenitors; bone marrow; flow
   cytometry
ID RECEPTORS; NICHE; ATP
AB The bone marrow is the principal site where HSCs and more mature blood cells lineage progenitors reside and differentiate in an adult organism. HSCs constitute a minute cell population of pluripotent cells capable of generating all blood cell lineages for a life time(1). The molecular dissection of HSCs homeostasis in the bone marrow has important implications in hematopoiesis, oncology and regenerative medicine. We describe the labeling protocol with fluorescent antibodies and the electronic gating procedure in flow cytometry to score hematopoietic progenitor subsets and HSCs distribution in individual mice (Fig. 1). In addition, we describe a method to extensively enrich hematopoietic progenitors as well as long term (LT) and short term (ST) reconstituting HSCs from pooled bone marrow cell suspensions by magnetic enrichment of cells expressing c Kit. The resulting cell preparation can be used to sort selected subsets for in vitro and in vivo functional studies (Fig. 2).
   Both trabecular osteoblasts(2,3) and sinusoidal endothelium(4) constitute functional niches supporting HSCs in the bone marrow. Several mechanisms in the osteoblastic niche, including a subset of N cadherin(+) osteoblasts(3) and interaction of the receptor tyrosine kinase Tie2 expressed in HSCs with its ligand angiopoietin 1(5) concur in determining HSCs quiescence. "Hibernation" in the bone marrow is crucial to protect HSCs from replication and eventual exhaustion upon excessive cycling activity(6). Exogenous stimuli acting on cells of the innate immune system such as Toll like receptor ligands(7) and interferon alpha(6) can also induce proliferation and differentiation of HSCs into lineage committed progenitors. Recently, a population of dormant mouse HSCs within the lin( ) c Kit(+) Sca 1(+) CD150(+) CD48( ) CD34( ) population has been described(8). Sorting of cells based on CD34 expression from the hematopoietic progenitors enriched cell suspension as described here allows the isolation of both quiescent self renewing LT HSCs and ST HSCs9. A similar procedure based on depletion of lineage positive cells and sorting of LT HSC with CD48 and Flk2 antibodies has been previously described(10). In the present report we provide a protocol for the phenotypic characterization and ex vivo cell cycle analysis of hematopoietic progenitors, which can be useful for monitoring hematopoiesis in different physiological and pathological conditions. Moreover, we describe a FACS sorting procedure for HSCs, which can be used to define factors and mechanisms regulating their self renewal, expansion and differentiation in cell biology and signal transduction assays as well as for transplantation.
C1 [Frascoli, Michela; Proietti, Michele; Grassi, Fabio] Inst Res Biomed, Bellinzona, Switzerland.
   [Grassi, Fabio] Univ Milan, Dipartimento Biol & Genet Sci Med, I 20122 Milan, Italy.
C3 Universita della Svizzera Italiana; University of Milan
RP Grassi, F (通讯作者)，Inst Res Biomed, Bellinzona, Switzerland.
EM fabio.grassi@irb.unisi.ch
OI GRASSI, FABIO/0000 0003 3348 1712
FU Swiss National Science Foundation; Swiss Cancer League; Fondazione
   Ticinese per la RIcerca sul Cancro
FX We thank Nobuyuki Onai, Hitoshi Takizawa and Markus Manz for precious
   advice. This work was funded by Swiss National Science Foundation, Swiss
   Cancer League and Fondazione Ticinese per la RIcerca sul Cancro.
CR Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Casati A, 2011, CELL DEATH DIFFER, V18, P396, DOI 10.1038/cdd.2010.107
   Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Lo Celso Cristina, 2007, J Vis Exp, P157, DOI 10.3791/157
   Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008
   Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242
   Romanello M, 2005, BIOCHEM BIOPH RES CO, V331, P1429, DOI 10.1016/j.bbrc.2005.03.246
   Takizawa H, 2011, J EXP MED, V208, P273, DOI 10.1084/jem.20101643
   Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092 8674(00)81692 X
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 14
TC 15
Z9 19
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2012
IS 65
AR e3736
DI 10.3791/3736
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA V36PJ
UT WOS:000209223200010
PM 22805770
OA Green Published
DA 2025 08 17
ER

PT J
AU Post, S
   Abdallah, BM
   Bentzon, JF
   Kassem, M
AF Post, S.
   Abdallah, B. M.
   Bentzon, J. F.
   Kassem, M.
TI Demonstration of the presence of independent pre osteoblastic and
   pre adipocytic cell populations in bone marrow derived mesenchymal stem
   cells
SO BONE
LA English
DT Article
DE mesenchymal stem cells; osteoblast differentiation; adipocyte
   differentiation, stem cells, bone formation, mouse
ID IN VITRO; PROGENITOR CELLS; ADIPOSE TISSUE; DIFFERENTIATION; STRAINS;
   VOLUME; VIVO
AB Mesenchymal stem cells (MSC) are defined as plastic adherent, clonal cells that are common progenitors for osteoblasts and adipocytes. An inverse relationship between bone and fat has been observed in several clinical conditions and has been suggested to be caused by re directing MSC differentiation into one particular lineage. However, this inverse relationship between bone and fat is not consistent and under certain in vivo conditions, bone and fat can change independently suggesting separate precursor cell populations. In order to test for this hypothesis, we extensively characterized two plastic adherent clonal MSC lines (mMSC1 and mMSC2) derived from murine bone marrow. The two cell lines grew readily in culture and have undergone more than 100 population doublings with no apparent differences in their growth rates. Both cell lines were positive for the murine MSC marker Sca 1 and mMSC1 was also positive for CD13. Both cell lines were exposed to in vitro culture induction of osteogenesis and adipogenesis. mMSC1 and not mMSC2 were only able to differentiate to adipocytes evidenced by the expression of adipocyte markers (aP2, adiponectin, adipsin, PPAR gamma 2 and C/EBPa) and the presence of mature adipocytes visualized by Oil Red 0 staining. On the other hand, mMSC2 and not mMSC1 differentiated to osteoblast lineage as demonstrated by up regulation of osteoblastic makers (CBFA1/RUNX2, Osterix, alkaline phosphatase, bone sialoprotein and osteopontin) and formation of alizarin red stained mineralized matrix in vitro. Consistent with the in vitro results, mMSC2 and not mMSC1, were able to form bone in vivo after subcutaneous implantation in immune deficient (NOD/SCID) mice. Our data suggest that contrary to the current belief, bone marrow contains clonal subpopulations of cells that are committed to either osteoblast or adipocyte lineage. These cell populations may undergo independent changes during aging and in bone diseases and thus represent important targets for therapy. (C) 2008 Published by Elsevier Inc.
C1 [Post, S.; Abdallah, B. M.; Kassem, M.] Odense Univ Hosp, Mol Endocrinol Lab KMEB, Dept Endocrinol & Metab, DK 5000 Odense C, Denmark.
   [Bentzon, J. F.] Skejby Univ Hosp, Dept Cardiol, Res Unit, Inst Clin, Aarhus, Denmark.
C3 University of Southern Denmark; Odense University Hospital; Aarhus
   University
RP Kassem, M (通讯作者)，Odense Univ Hosp, Mol Endocrinol Lab KMEB, Dept Endocrinol & Metab, Winslowparken 25, DK 5000 Odense C, Denmark.
EM mkassem@health.sdu.dk
RI Bentzon, Jacob Fog/B 5302 2016; Bentzon, Jacob/B 5302 2016; Kassem,
   Moustapha/J 7688 2013; Abdallah, Basem/G 5667 2017
OI Bentzon, Jacob Fog/0000 0002 3020 5002; Kassem,
   Moustapha/0000 0003 1557 0869; Abdallah, Basem/0000 0003 0324 8055
CR Anjos Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   BENAYAHU D, 1989, J CELL PHYSIOL, V140, P1, DOI 10.1002/jcp.1041400102
   BENNETT JH, 1991, J CELL SCI, V99, P131
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Cassiede P, 1996, J BONE MINER RES, V11, P1264
   CHAILAKHYAN RK, 1978, B EXP BIOL MED+, V86, P1633
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Hachisuka H, 2007, J ORTHOP SCI, V12, P161, DOI 10.1007/s00776 006 1098 6
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Justesen J, 2002, CALCIFIED TISSUE INT, V71, P36, DOI 10.1007/s00223 001 2059 x
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335
   Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365 2141.2003.04669.x
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Orkin SH, 2002, NATURE, V418, P25, DOI 10.1038/418025a
   OWEN M, 1988, CIBA F SYMP, V136, P42
   OWEN ME, 1987, J CELL SCI, V87, P731
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Rickard DJ, 1996, J BONE MINER RES, V11, P312
   Rosenzweig A, 2006, NEW ENGL J MED, V355, P1274, DOI 10.1056/NEJMe068172
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Satomura K, 2000, J CELL BIOCHEM, V78, P391
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Tornvig L, 2001, CALCIFIED TISSUE INT, V69, P46, DOI 10.1007/s002230020018
   Wang XL, 2006, STEM CELLS, V24, P482, DOI 10.1634/stemcells.2005 0219
NR 32
TC 114
Z9 136
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2008
VL 43
IS 1
BP 32
EP 39
DI 10.1016/j.bone.2008.03.011
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 319GC
UT WOS:000257151100005
PM 18456590
DA 2025 08 17
ER

PT J
AU Mo, J
   Yang, RH
   Li, F
   He, B
   Zhang, XC
   Zhao, YQ
   Shen, ZQ
   Chen, P
AF Mo, Jiao
   Yang, Renhua
   Li, Fan
   He, Bo
   Zhang, Xiaochao
   Zhao, Yuqin
   Shen, Zhiqiang
   Chen, Peng
TI Geraniin promotes osteogenic differentiation of bone marrow mesenchymal
   stem cells (BMSCs) via activating  catenin: a comparative study between
   BMSCs from normal and osteoporotic rats
SO JOURNAL OF NATURAL MEDICINES
LA English
DT Article
DE Osteoporosis; Geraniin; Mesenchymal stem cells;  Catenin; Osteogenesis
ID STROMAL CELLS; MOUSE MODEL; PROLIFERATION; OSTEOSARCOMA; TERIPARATIDE;
   PREVENTION; IMPROVES; UPDATE; LRP5
AB Abnormal osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) has been correlated with the pathogenesis of osteoporosis. Geraniin, a polyphenolic compound isolated from Phyllanthus amarus, is effective in preventing osteoporosis, but the mechanisms of action of geraniin and the impact of osteoporotic condition on drug action are not known. In this study we compared the proliferation and osteoblastic differentiation potential of BMSCs from normal rats with that from osteoporotic rats, and examined the responses of both BMSCs to geraniin in parallel. BMSCs of rats subjected to ovariectomy or sham operation were isolated and treated with geraniin. Cell proliferation was measured by CCK 8 assay. Osteoblastic differentiation was quantified by Alizarin Red S staining and alkaline phosphatase assay. Nuclear translocation of  catenin was monitored by immunofluorescent staining. Expression of  catenin was determined by Western blot and quantitative real time polymerase chain reaction. Results showed that the proliferation and osteoblast formation of osteoporotic BMSCs decreased in comparison to that of normal BMSCs. Geraniin enhanced proliferation and osteoblastic differentiation of both BMSCs, but the responses of osteoporotic BMSCs to geraniin were less than those of normal BMSCs. Expression and nuclear accumulation of  catenin in osteoporotic BMSCs were found to be diminished. Geraniin increased nuclear translocation and expression of  catenin in both BMSCs. This study associated the osteogenic effect of geraniin to activation of Wnt/ catenin signaling, and provided rationale for pharmacological investigation of geraniin in osteoporosis prevention and treatment.
C1 [Mo, Jiao; Yang, Renhua; Li, Fan; He, Bo; Zhang, Xiaochao; Zhao, Yuqin; Shen, Zhiqiang; Chen, Peng] Kunming Med Univ, Sch Pharmaceut Sci, 1168 Chunrongxi Rd, Kunming 650500, Yunnan, Peoples R China.
   [Mo, Jiao; Yang, Renhua; Li, Fan; He, Bo; Zhang, Xiaochao; Zhao, Yuqin; Shen, Zhiqiang; Chen, Peng] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, 1168 Chunrongxi Rd, Kunming 650500, Yunnan, Peoples R China.
C3 Kunming Medical University; Kunming Medical University
RP Shen, ZQ; Chen, P (通讯作者)，Kunming Med Univ, Sch Pharmaceut Sci, 1168 Chunrongxi Rd, Kunming 650500, Yunnan, Peoples R China.; Shen, ZQ; Chen, P (通讯作者)，Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, 1168 Chunrongxi Rd, Kunming 650500, Yunnan, Peoples R China.
EM shenzhiqiang@kmmu.edu.cn; chenpeng@kmmu.edu.cn
OI HE, BO/0000 0002 4029 5435; chen, peng/0000 0002 3390 508X
FU National Natural Science Foundation of China [81660613, 81260493];
   Natural Science Foundation of Yunnan Province, P.R. China [2015FA021]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers 81660613, 81260493] and the Natural Science
   Foundation of Yunnan Province, P.R. China [number 2015FA021].
CR Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bhukhai K, 2012, J BIOL CHEM, V287, P36168, DOI 10.1074/jbc.M112.344747
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fan JZ, 2014, MOL CELL BIOCHEM, V392, P85, DOI 10.1007/s11010 014 2021 7
   Futami I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045517
   Gao B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099137
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   He B, 2013, BIOORG MED CHEM LETT, V23, P630, DOI 10.1016/j.bmcl.2012.12.005
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Jin CY, 2017, J BONE MINER RES, V32, P508, DOI 10.1002/jbmr.3009
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Li F, 2007, STEM CELLS, V25, P3183, DOI 10.1634/stemcells.2007 0466
   Li F, 2010, BONE, V47, P546, DOI 10.1016/j.bone.2010.05.040
   Li KJ, 2018, BIOMED PHARMACOTHER, V99, P319, DOI 10.1016/j.biopha.2018.01.040
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Lu YQ, 2015, BIOORG MED CHEM LETT, V25, P673, DOI 10.1016/j.bmcl.2014.11.081
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Patel JR, 2011, J ETHNOPHARMACOL, V138, P286, DOI 10.1016/j.jep.2011.09.040
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Saeed H, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0254 3
   Shoback D, 2007, J CLIN ENDOCR METAB, V92, P747, DOI 10.1210/jc.2007 0042
   Thompson RN, 2012, J BONE JOINT SURG BR, V94B, P385, DOI 10.1302/0301 620X.94B3.27999
   Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238
   Wang C, 2016, THERANOSTICS, V6, P1205, DOI 10.7150/thno.15083
   Wang DW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7532798
   Wang Z, 2006, TISSUE ENG, V12, P1753, DOI 10.1089/ten.2006.12.1753
   Watanabe A, 2012, J TOXICOL SCI, V37, P617
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786
NR 39
TC 12
Z9 14
U1 1
U2 28
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 1340 3443
EI 1861 0293
J9 J NAT MED TOKYO
JI J. Nat. Med.
PD JAN
PY 2019
VL 73
IS 1
BP 262
EP 272
DI 10.1007/s11418 018 1242 6
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HG8QQ
UT WOS:000455268900029
PM 30194656
DA 2025 08 17
ER

PT J
AU Perez, EA
AF Perez, Edith A.
TI New treatment strategies in the management of breast cancer
SO EJC SUPPLEMENTS
LA English
DT Article
DE Adjuvant; Breast cancer; Breast neoplasms; Chemotherapy; DNA repair;
   Eribulin; HER2; Lapatinib; Neoadjuvant; Poly(ADP ribose) polymerases;
   Trastuzumab
ID ADJUVANT CHEMOTHERAPY; OPEN LABEL; TRASTUZUMAB; ESTROGEN; THERAPY;
   AMPLIFICATION; EXPRESSION; METASTASES; DIAGNOSIS; FEATURES
AB Growing understanding of the molecular characteristics of breast cancer is raising the possibility of ultimately delivering therapies that are tailored to the tumour biology of the individual patient. Agents that are currently being evaluated in metastatic breast cancer, irrespective of specific markers such as human epidermal growth factor receptor 2 (HER2) or oestrogen receptor, include the novel microtubule inhibitor eribulin mesylate, and a monoclonal antibody directed against vascular endothelial growth factor A, bevacizumab. Denosumab, a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, has recently been demonstrated to improve bone related metastases in patients with breast cancer, irrespective of biological phenotype. Targeted therapies directed against DNA repair mechanisms such as poly(ADP ribose) polymerase (PARP) may prove particularly useful in the treatment of triple negative breast cancer. Turning to the adjuvant setting in patients with HER2 positive breast cancer, recent studies have shown that concomitant treatment with taxanes and trastuzumab improves survival, and data with novel anti HER2 agents are emerging. Current adjuvant and metastatic studies are evaluating novel targeted treatments aimed at HER2 and other targets. Molecular profiling of tumours is providing and will further provide the needed answers related to therapeutic optimisation. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Mayo Clin, Ctr Canc, Div Hematol Oncol, Jacksonville, FL 32224 USA.
C3 Mayo Clinic
RP Perez, EA (通讯作者)，Mayo Clin, Ctr Canc, Div Hematol Oncol, Jacksonville, FL 32224 USA.
EM perez.edith@mayo.edu
RI Perez, Edith/ACA 8756 2022
FU Genentech; Roche; Glaxo; sanofi oncology; Novartis; Breast Cancer
   Research Foundation; Donna Foundation
FX Dr Perez has received research grants for her studies at Mayo Clinic
   from Genentech, Roche, Glaxo, sanofi oncology and Novartis, and also the
   Breast Cancer Research Foundation and the 26.2 with Donna Foundation.
CR Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006
   Arpino G, 2004, CLIN CANCER RES, V10, P5670, DOI 10.1158/1078 0432.CCR 04 0110
   Asmann YW, 2011, NUCL ACIDS RES  0527
   Baselga J, 2010, 33 ANN SAN ANT BREAS
   Bevers TB, 2009, J NATL COMPR CANC NE, V7, P1060, DOI 10.6004/jnccn.2009.0070
   Brufsky AM, 2010, SEMIN ONCOL, V37, pS12, DOI 10.1053/j.seminoncol.2010.06.002
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Cortes J, 2011, LANCET, V377, P914, DOI 10.1016/S0140 6736(11)60070 6
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078 0432.CCR 06 3045
   Fang L, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13231
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Gianni L, 2009, BREAST, V18, pS11, DOI 10.1016/S0960 9776(09)70033 5
   Gianni L, 2010, 33 ANN SAN ANT BREAS
   Gianni L, 2010, J CLIN ONCOL, V28, P1131, DOI 10.1200/JCO.2009.24.1661
   Goss PE, 2011, J CLIN ONCOL S, V29
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342
   Hines SL, 2008, ANN ONCOL, V19, P1561, DOI 10.1093/annonc/mdn283
   Jimeno A, 2009, CLIN CANCER RES, V15, P3903, DOI 10.1158/1078 0432.CCR 09 1023
   Junttila TT, 2011, BREAST CANCER RES TR, V128, P347, DOI 10.1007/s10549 010 1090 x
   Kurzrock R, 2009, P AM ASS CANC RES
   Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9
   Morris PG, 2010, J CLIN ONCOL, V28, P3407, DOI 10.1200/JCO.2009.26.0125
   National Institutes of Health, NCT011105312 NIH CLI
   National Institutes of Health, NCT01091454 NIH CLIN
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078 0432.CCR 04 0220
   O'Shaughnessy J, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.1005
   O'Shaughnessy J, 2009, J CLIN ONCOL, V27
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418
   Perez EA, 2010, CANCER RES, V70, DOI 10.1158/0008 5472.SABCS10 PD10 02
   Perez EA, 2002, MAYO CLIN PROC, V77, P148
   Perez EA, 2011, J CLIN ONCO IN PRESS
   Perez EA, 2010, ANN ONCOL S8, V21
   Perez EA, 2010, J CLIN ONCOL, V28, P4307, DOI 10.1200/JCO.2009.26.2154
   Piccart Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   Jimenez MAP, 2011, J CLIN ONCOL, V29
   Reinholz MM, 2011, J CLIN ONCOL S, V29
   Russell SD, 2010, J CLIN ONCOL, V28, P3416, DOI 10.1200/JCO.2009.23.6950
   Santana Davila R, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756 8722 3 42
   Slamon D, 2009, CANC RES S3, V69
   Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140 6736(07)60028 2
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008 5472.CAN 10 1040
   Tomasello G, 2008, EXPERT REV ANTICANC, V8, P1883, DOI 10.1586/14737140.8.12.1883
   Trastuzumab Prescribing Information, 2009, TRASTUZUMAB PRESCRIB
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Yang SX, 2009, EXPERT REV ANTICANC, V9, P1715, DOI [10.1586/era.09.153, 10.1586/ERA.09.153]
   Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026
NR 50
TC 3
Z9 5
U1 0
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359 6349
EI 1878 1217
J9 EJC SUPPL
JI EJC Suppl.
PD OCT
PY 2011
VL 9
IS 2
BP 22
EP 29
DI 10.1016/S1359 6349(11)70006 4
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 852EY
UT WOS:000297337200005
OA Bronze
DA 2025 08 17
ER

PT J
AU Tiede Lewis, LM
   Xie, YX
   Hulbert, MA
   Campos, R
   Dallas, MR
   Dusevich, V
   Bonewald, LF
   Dallas, SL
AF Tiede Lewis, LeAnn M.
   Xie, Yixia
   Hulbert, Molly A.
   Campos, Richard
   Dallas, Mark R.
   Dusevich, Vladimir
   Bonewald, Lynda F.
   Dallas, Sarah L.
TI Degeneration of the osteocyte network in the C57BL/6 mouse model of
   aging
SO AGING US
LA English
DT Article
DE aging; osteocytes; osteoporosis; dendrite degeneration; bone fragility
ID MICRO COMPUTED TOMOGRAPHY; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   OSTEOCLAST FORMATION; SCLEROSTIN ANTIBODY; OXIDATIVE STRESS; LACUNAR
   DENSITY; DOUBLE BLIND; AGE; OSTEOPOROSIS
AB Age related bone loss and associated fracture risk are major problems in musculoskeletal health. Osteocytes have emerged as key regulators of bone mass and as a therapeutic target for preventing bone loss. As aging is associated with changes in the osteocyte lacunocanalicular system, we focused on the responsible cellular mechanisms in osteocytes. Bone phenotypic analysis was performed in young (5mo) and aged (22mo) C57BL/6 mice and changes in bone structure/geometry correlated with alterations in osteocyte parameters determined using novel multiplexed 3D confocal imaging techniques. Age related bone changes analogous to those in humans were observed, including increased cortical diameter, decreased cortical thickness, reduced trabecular BV/TV and cortical porosities. This was associated with a dramatic reduction in osteocyte dendrite number and cell density, particularly in females, where osteocyte dendricity decreased linearly from 5, 12, 18 to 22mo and correlated significantly with cortical bone parameters. Reduced dendricity preceded decreased osteocyte number, suggesting dendrite loss may trigger loss of viability. Age related degeneration of osteocyte networks may impair bone anabolic responses to loading and gender differences in osteocyte cell body and lacunar fluid volumes we observed in aged mice may lead to gender related differences in mechanosensitivity. Therapies to preserve osteocyte dendricity and viability may be beneficial for bone health in aging.
C1 [Tiede Lewis, LeAnn M.; Xie, Yixia; Hulbert, Molly A.; Campos, Richard; Dallas, Mark R.; Dusevich, Vladimir; Bonewald, Lynda F.; Dallas, Sarah L.] Univ Missouri Kansas City, Dept Oral & Craniofacial Sci, Sch Dent, Kansas City, MO 64108 USA.
   [Bonewald, Lynda F.] Indiana Univ, Dept Anat & Cell Biol, Sch Med, Indianapolis, IN 46202 USA.
   [Bonewald, Lynda F.] Indiana Univ, Dept Orthopaed Surg, Sch Med, Indianapolis, IN 46202 USA.
C3 University of Missouri System; University of Missouri Kansas City;
   Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis
RP Dallas, SL (通讯作者)，Univ Missouri Kansas City, Dept Oral & Craniofacial Sci, Sch Dent, Kansas City, MO 64108 USA.
EM dallass@umkc.edu
RI Bonewald, Lynda/Q 3638 2019
FU NIH [PO1AG039355, R21AR054449]
FX The work was supported by NIH grants PO1AG039355 and R21AR054449.
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Bilezikian JP, 1999, TRENDS ENDOCRIN MET, V10, P244, DOI 10.1016/S1043 2760(99)00154 X
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bolte S, 2006, J MICROSC OXFORD, V224, P213, DOI 10.1111/j.1365 2818.2006.01706.x
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Burra Sirisha, 2011, Commun Integr Biol, V4, P48, DOI 10.4161/cib.4.1.13646
   Burra S, 2010, P NATL ACAD SCI USA, V107, P13648, DOI 10.1073/pnas.1009382107
   Busse B, 2010, AGING CELL, V9, P1065, DOI 10.1111/j.1474 9726.2010.00633.x
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Gabet Yankel, 2011, Curr Osteoporos Rep, V9, P177, DOI 10.1007/s11914 011 0072 1
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350
   Harvey N., 2013, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P348
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581
   Jähn K, 2017, J BONE MINER RES, V32, P1761, DOI 10.1002/jbmr.3167
   Javaheri B, 2014, J BONE MINER RES, V29, P705, DOI 10.1002/jbmr.2064
   Jilka RL, 2016, CURR OSTEOPOROS REP, V14, P16, DOI 10.1007/s11914 016 0297 0
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13 237578
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Kamel ElSayed SA, 2015, BONE, V76, P129, DOI 10.1016/j.bone.2015.02.011
   Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756 3282(00)00421 X
   Kerschnitzki M, 2013, J BONE MINER RES, V28, P1837, DOI 10.1002/jbmr.1927
   Kobayashi K, 2015, SCI REP UK, V5, DOI 10.1038/srep09148
   Koleske AJ, 2013, NAT REV NEUROSCI, V14, P536, DOI 10.1038/nrn3486
   Kulkarni RN, 2012, BIOCHEM BIOPH RES CO, V420, P11, DOI 10.1016/j.bbrc.2012.02.099
   Lai XH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.9
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006 8993(88)90124 2
   Milovanovic P, 2013, ACS NANO, V7, P7542, DOI 10.1021/nn401360u
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Okada S, 2002, MICROSC MICROANAL, V8, P104, DOI 10.1017/S1431927601020037
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Qiu S, 2002, BONE, V31, P709, DOI 10.1016/S8756 3282(02)00907 9
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Schneider P, 2009, MICROSC RES TECHNIQ, V72, P690, DOI 10.1002/jemt.20720
   Seeman E, 2013, J GERONTOL A BIOL, V68, P1218, DOI 10.1093/gerona/glt071
   Tang GM, 2014, NEURON, V83, P1131, DOI 10.1016/j.neuron.2014.07.040
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Vashishth D, 2000, BONE, V26, P375, DOI 10.1016/S8756 3282(00)00236 2
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yagi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142786
   Yang Y, 2013, TRENDS NEUROSCI, V36, P418, DOI 10.1016/j.tins.2013.04.001
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 56
TC 120
Z9 137
U1 1
U2 25
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD OCT
PY 2017
VL 9
IS 10
BP 2187
EP +
DI 10.18632/aging.101308
PG 19
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA FL4ED
UT WOS:000414179600017
PM 29074822
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Wen, ZK
   Lin, SP
   Li, CC
   Ouyang, ZJ
   Chen, Z
   Li, SX
   Huang, YX
   Luo, WQ
   Zheng, ZC
   Guo, PD
   Kuang, MY
   Ding, Y
AF Wen, Zhenkang
   Lin, Sipeng
   Li, Changchuan
   Ouyang, Zhuji
   Chen, Zhong
   Li, Shixun
   Huang, Yuxi
   Luo, Wenqiang
   Zheng, Zhongcan
   Guo, Peidong
   Kuang, Manyuan
   Ding, Yue
TI MiR 92a/KLF4/p110δ regulates titanium particles induced macrophages
   inflammation and osteolysis
SO CELL DEATH DISCOVERY
LA English
DT Article
ID NECROSIS FACTOR ALPHA; PHOSPHOINOSITIDE 3 KINASE; CELLULAR RESPONSE;
   TRAFFICKING; SECRETION; DELTA; KLF4
AB As total joint replacement is widely applied for severe arthropathy, peri prosthetic aseptic loosening as one of the main causes of implant failure has drawn wide attention. Wear particles such as titanium particles (TiPs) derived from prosthesis can initiate macrophages inflammation and sequentially activate osteoclasts, which results in bone resorption and osteolysis for long term. Therefore, inhibiting wear particles induced macrophages inflammation is considered as a promising therapy for AL. In this research, we found that the inhibition of p110 delta, a member of class IA PI3Ks family, could significantly dampen the TiPs induced secretion of TNF alpha and IL 6. By the transfection of siRNA targeting p110 delta, we confirmed that p110 delta was responsible for TNF alpha and IL 6 trafficking out of Golgi complex without affecting their expression in TiPs treated macrophages. As the upstream transcription repressor of p110 delta, Kruppel like factor 4 (KLF4), targeted by miR 92a, could also attenuate TiPs induced inflammation by mediating NF kappa B pathway and M1/M2 polarization. To further ascertain the roles of KLF4/p110 delta, TiPs induced mice cranial osteolysis model was established and vivo experiments validated that KLF4 knockdown could exacerbate TiPs induced osteolysis, which was strikingly ameliorated by knockdown of p110 delta. In summary, our study suggests the key role of miR 92a/KLF4/p110 delta signal in TiPs induced macrophages inflammation and osteolysis.
C1 [Wen, Zhenkang; Lin, Sipeng; Li, Changchuan; Ouyang, Zhuji; Chen, Zhong; Li, Shixun; Huang, Yuxi; Luo, Wenqiang; Zheng, Zhongcan; Guo, Peidong; Kuang, Manyuan; Ding, Yue] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped Surg, Guangzhou, Peoples R China.
C3 Sun Yat Sen University
RP Ding, Y (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped Surg, Guangzhou, Peoples R China.
EM dingyue@mail.sysu.edu.cn
RI Huang, Yu Xi/AGE 2663 2022; Li, Changchuan/GPX 7405 2022
OI Lin, Sipeng/0000 0001 8395 8561; 
FU National Natural Science Foundation of China [82072453]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No.: 82072453).
CR Budi EH, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa9432
   Chang SF, 2019, J CELL PHYSIOL, V234, P958, DOI 10.1002/jcp.26924
   Chang YJ, 2019, ARTERIOSCL THROM VAS, V39, P2492, DOI 10.1161/ATVBAHA.119.312707
   Chen YCE, 2020, LEUKEMIA, V34, P451, DOI 10.1038/s41375 019 0556 z
   Ding Y, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/4/045019
   Feng F, 2019, J CELL BIOCHEM, V120, P17228, DOI 10.1002/jcb.28984
   Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Halvorsen V, 2019, ACTA ORTHOP, V90, P331, DOI 10.1080/17453674.2019.1615263
   Han S, 2018, CIRC RES, V123, pE5, DOI 10.1161/CIRCRESAHA.118.312871
   Huang JB, 2013, INFLAMMATION, V36, P1041, DOI 10.1007/s10753 013 9636 9
   Huang JB, 2013, ARTIF ORGANS, V37, P298, DOI 10.1111/j.1525 1594.2012.01568.x
   Huang YJ, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.617654
   Jiang FJ, 2020, J HEPATOL, V72, P156, DOI 10.1016/j.jhep.2019.09.014
   Jin LW, 2020, J CELL MOL MED, V24, P1200, DOI 10.1111/jcmm.14628
   Kahlenberg CA, 2019, J ARTHROPLASTY, V34, P1435, DOI 10.1016/j.arth.2019.03.014
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Li SX, 2019, BIOMATER SCI UK, V7, P2702, DOI 10.1039/c9bm00306a
   Li T, 2020, CLIN SCI, V134, P2353, DOI 10.1042/CS20191241
   Li ZZ, 2018, CELL PHYSIOL BIOCHEM, V47, P2278, DOI 10.1159/000491538
   Liao XD, 2011, J CLIN INVEST, V121, P2736, DOI 10.1172/JCI45444
   Lin SP, 2022, ACTA BIOMATER, V142, P345, DOI 10.1016/j.actbio.2022.02.007
   Low PC, 2010, J CELL BIOL, V190, P1053, DOI 10.1083/jcb.201001028
   Manderson AP, 2007, J CELL BIOL, V178, P57, DOI 10.1083/jcb.200612131
   Mercurio L, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.665647
   Merecz Sadowska A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249605
   Nich C, 2013, J BIOMED MATER RES A, V101, P3033, DOI 10.1002/jbm.a.34599
   Niu N, 2019, TRENDS PHARMACOL SCI, V40, P253, DOI 10.1016/j.tips.2019.02.004
   Norman MU, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.655499
   Pajarinen J, 2017, TISSUE ENG PART C ME, V23, P1003, DOI [10.1089/ten.tec.2017.0166, 10.1089/ten.TEC.2017.0166]
   Pan Y, 2019, J CLIN INVEST, V129, P834, DOI 10.1172/JCI123069
   Qin CQ, 2011, ARTIF ORGANS, V35, P706, DOI 10.1111/j.1525 1594.2010.01175.x
   Qiu JX, 2020, BIOMATER SCI UK, V8, P3147, DOI 10.1039/d0bm00147c
   Revelo NH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.234781
   Rommel C, 2010, CURR TOP MICROBIOL, V346, P279, DOI 10.1007/82_2010_79
   Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379
   Sommermann TG, 2011, CANCER RES, V71, P7291, DOI 10.1158/0008 5472.CAN 11 1715
   Taracha Wisniewska A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228843
   Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330
   Vanhaesebroeck B, 2016, J MOL MED, V94, P5, DOI 10.1007/s00109 015 1352 5
   Verboogen DRJ, 2018, FEBS LETT, V592, P1535, DOI 10.1002/1873 3468.13036
   Werner JH, 2018, EXPERT REV CLIN IMMU, V14, P695, DOI 10.1080/1744666X.2018.1511428
   Xia WZ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02778 2
   Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200
   Yu CH, 2015, J IMMUNOL, V195, P3890, DOI 10.4049/jimmunol.1500017
   Zhang H, 2020, OSTEOARTHR CARTILAGE, V28, P555, DOI 10.1016/j.joca.2020.01.007
   Zhang L, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0270 x
NR 47
TC 12
Z9 13
U1 0
U2 14
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058 7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD APR 13
PY 2022
VL 8
IS 1
AR 197
DI 10.1038/s41420 022 00999 2
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 0M9DB
UT WOS:000782446700003
PM 35418181
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Masiá, M
   Padilla, S
   Robledano, C
   López, N
   Ramos, JM
   Gutiérrez, F
AF Masia, Mar
   Padilla, Sergio
   Robledano, Catalina
   Lopez, Natividad
   Manuel Ramos, Jose
   Gutierrez, Felix
TI Short Communication: Early Changes in Parathyroid Hormone Concentrations
   in HIV Infected Patients Initiating Antiretroviral Therapy with
   Tenofovir
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID VITAMIN D DEFICIENCY; HIGH PREVALENCE; DENSITY; COHORT
AB Initiation of combined antiretroviral therapy (cART) is associated with bone loss, which may be more intense with regimens including tenofovir. The underlying mechanisms are not well understood. Cross sectional data have linked tenofovir with higher parathyroid hormone (PTH) concentrations in patients with vitamin D deficiency. We performed a longitudinal study with a 48 week follow up to evaluate sequential changes in PTH and 25 hydroxyvitamin D [25(OH) D] levels in patients starting cART with either tenofovir/emtricitabine or abacavir/lamivudine. Fifty seven patients were included, 31 initiating tenofovir/emtricitabine and 26 initiating abacavir/lamivudine. Median PTH levels turned out to be significantly higher among tenofovir/emtricitabine users at week 4 (p = 0.01), week 24 (p = 0.008), and week 36 (p = 0.02), and were above the upper limits of normal values (ULN) at weeks 24, 36, and 48 only in patients receiving tenofovir/emtricitabine. 25(OH) D, serum and urine calcium and phosphate, and renal tubular maximum reabsorption of phosphate to the glomerular filtration rate (TmP/GFR) levels did not differ between the two treatment arms over the study period. Among tenofovir/emtricitabine users, median (interquartile range) PTH concentrations were significantly higher in patients with suboptimal 25(OH) D levels (< 30 mu g/liter) at week 24 [63 (57.8 82.4) ng/liter vs. 54.3 (34.4 63.067.5) ng/liter, p = 0.05] and week 48 [67.5 (59.6 86.0) ng/liter vs. 41.9 (37.3 68.8) ng/liter, p = 0.03]. A multivariable logistic regression model showed that tenofovir/emtricitabine use was an independent predictor of high PTH levels (>= 53 ng/liter). Starting cART with tenofovir regimens is associated with an elevation in PTH plasma concentrations soon after introducing the drug. Suboptimal baseline 25(OH) D levels increase the risk of developing secondary hyperparathyroidism among tenofovir users.
C1 [Masia, Mar; Padilla, Sergio; Robledano, Catalina; Manuel Ramos, Jose; Gutierrez, Felix] Hosp Gen Univ Elche, Infect Dis Unit, Alicante, Spain.
   [Lopez, Natividad] Hosp Gen Univ Elche, Biochem Sect, Alicante, Spain.
   [Gutierrez, Felix] Univ Miguel Hernandez, Dept Clin Med, Alicante, Spain.
C3 Universidad Miguel Hernandez de Elche
RP Masiá, M (通讯作者)，Hosp Gen Univ Elche Dept, Unidad Enfermedades Infecciosas, Cami Almazara 11, Elche 03203, Spain.
EM marmasia@ya.com
RI Gutierrez, Felix/Q 7880 2018; Ramos, Jose/B 6420 2018; Masiá,
   Mar/U 7510 2017; Padilla, Sergio/U 7682 2017; Iribarren,
   José/AAK 5528 2021; López, Natividad/ABH 1323 2020; Masia,
   Mar/U 7510 2017; Ramos Rincon, Jose Manuel/B 6420 2018
OI Gutierrez, Felix/0000 0002 9485 6867; Lopez,
   Natividad/0000 0003 0423 4616; Padilla, Sergio/0000 0002 8420 7310;
   Masia, Mar/0000 0001 9878 2458; Ramos Rincon, Jose
   Manuel/0000 0002 6501 9867
FU FIBELX [05/05, 07/20, 10/11, 10/12, 10/13]; FIS [PI081893]; Generalitat
   Valenciana [PI051338, 083/05, AP 091/07, AP 087/10]; FIPSE [12655/07];
   IS CIII RETIC [RD06/0027]; Gilead; Bristol Myers Squibb;
   GlaxoSmithKline; Viiv Healthcare; Abbot; Janssen Cilag Laboratories
FX Supported in part by FIBELX (05/05, 07/20, 10/11, 10/12, 10/13), FIS
   (PI081893), Generalitat Valenciana (PI051338, 083/05, AP 091/07,
   AP 087/10), FIPSE (12655/07), and IS CIII RETIC RD06/0027 Red Tematica
   Cooperativa de Investigacion en SIDA. Mar Masia Sergio Padilla and Felix
   Gutierrez have served as scientific advisers to or have spoken at events
   sponsored by Gilead, Bristol Myers Squibb, GlaxoSmithKline and Viiv
   Healthcare, Abbot, and Janssen Cilag Laboratories.
CR Bonjoch A, 2010, AIDS, V24, P2827, DOI 10.1097/QAD.0b013e328340a28d
   Childs KE, 2010, AIDS RES HUM RETROV, V26, P855, DOI 10.1089/aid.2009.0308
   Fux CA, 2008, ANTIVIR THER, V13, P1077
   Gupta SK, 2008, AIDS PATIENT CARE ST, V22, P99, DOI 10.1089/apc.2007.0052
   Gutiérrez F, 2011, AIDS REV, V13, P109
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Martin A, 2009, CLIN INFECT DIS, V49, P1591, DOI 10.1086/644769
   Mueller NJ, 2010, AIDS, V24, P1127, DOI 10.1097/QAD.0b013e328337b161
   Peyrière H, 2004, JAIDS J ACQ IMM DEF, V35, P269, DOI 10.1097/00126334 200403010 00007
   Rosenvinge MM, 2010, JAIDS J ACQ IMM DEF, V54, P496, DOI 10.1097/QAI.0b013e3181caebaa
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468 1293.2009.00716.x
NR 12
TC 54
Z9 57
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889 2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAR
PY 2012
VL 28
IS 3
BP 242
EP 246
DI 10.1089/aid.2011.0052
PG 5
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA 904VK
UT WOS:000301226100003
PM 21639815
DA 2025 08 17
ER

PT J
AU Ha, CM
   Park, S
   Choi, YK
   Jeong, JY
   Oh, CJ
   Bae, KH
   Lee, SJ
   Kim, JH
   Park, KG
   Jun, DY
   Lee, IK
AF Ha, Chae Myeong
   Park, Sungmi
   Choi, Young Keun
   Jeong, Ji Yun
   Oh, Chang Joo
   Bae, Kwi Hyun
   Lee, Sun Joo
   Kim, Ji Hyun
   Park, Keun Gyu
   Jun, Do Youn
   Lee, In Kyu
TI Activation of Nrf2 by dimethyl fumarate improves vascular calcification
SO VASCULAR PHARMACOLOGY
LA English
DT Article
DE Dimethyl fumarate; NF E2 related factor 2; Hyperphosphatemia;
   Osteoblast; Vascular calcification
ID SMOOTH MUSCLE CELLS; PLACEBO CONTROLLED PHASE 3; CHRONIC KIDNEY DISEASE;
   CHRONIC RENAL FAILURE; OXIDATIVE STRESS; OSTEOBLAST DIFFERENTIATION;
   MULTIPLE SCLEROSIS; ANTIOXIDANT PATHWAY; BONE FORMATION; EMERGING ROLE
AB Dimethyl fumarate (DMF) has several pharmacological benefits including immunomodulation and prevention of fibrosis, which are dependent on the NF E2 related factor 2 (Nrf2) antioxidant pathways. Therefore, we hypothesized that DMF could attenuate vascular calcification via Nrf2 activation. Vascular calcification induced by hyperphosphataemia was significantly inhibited by DMF in vascular smooth muscle cells (VSMCs) in a dose dependent manner. DMF mediated Nrf2 upregulation was accompanied by the reduced expressions of genes related with osteoblast like phenotype based on promoter activity, mRNA and protein expression, and von Kossa staining. Likewise, Nrf2 overexpression significantly decreased the formation of calcium deposit similar to the level of osteogenic staining in VSMCs, and DMF with Nrf2 knockdown failed to attenuate hyperphosphatemia induced vascular calcification. Furthermore, DMF significantly attenuated the calcification of ex vivo ring culture from both rat common carotid artery and mouse thoracic aorta as well as in vivo mouse model of Vitamin D 3 induced calcification consistent with the increased Nrf2 protein levels in early stage of calcification by DMF. In conclusion, our data support that DMF stimulates Nrf2 activity to attenuate hyperphosphatamia in vitro or Vitamin D 3 induced in vivo vascular calcification, which would be a beneficial effect on vascular diseases induced by oxidative stress such as vascular calcification. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Ha, Chae Myeong; Lee, Sun Joo; Kim, Ji Hyun] Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Taegu 702210, South Korea.
   [Ha, Chae Myeong; Lee, In Kyu] Kyungpook Natl Univ, Plus KNU Biomed Convergence Program BK21, Taegu 702210, South Korea.
   [Park, Sungmi; Park, Keun Gyu; Jun, Do Youn; Lee, In Kyu] Kyungpook Natl Univ, Leading Edge Res Ctr Drug Discovery & Dev Diabet, Taegu 702210, South Korea.
   [Choi, Young Keun; Oh, Chang Joo; Lee, In Kyu] Kyungpook Natl Univ, Res Inst Aging & Metab, Taegu 702210, South Korea.
   [Jeong, Ji Yun; Bae, Kwi Hyun; Park, Keun Gyu; Lee, In Kyu] Kyungpook Natl Univ, Dept Internal Med, Sch Med, Taegu 700721, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Kyungpook National
   University (KNU); Kyungpook National University (KNU)
RP Jun, DY (通讯作者)，Kyungpook Natl Univ, Leading Edge Res Ctr Drug Discovery & Dev Diabet, 807 Hoguk Ro, Taegu 702210, South Korea.
EM dyjun@knu.ac.kr; leei@knu.ac.kr
RI Kim, Ji Hyun/IQV 8302 2023; Lee, In Kyu/AAR 6374 2021
FU National Research Foundation of Korea [NRF 2012R1A2A1A03670452]; Korea
   Health Technology R&D Project, Ministry of Health & Welfare, Republic of
   Korea [A111345]
FX This work was supported in part by grants from the National Research
   Foundation of Korea (grant number: NRF 2012R1A2A1A03670452) and the
   Korea Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea (grant number: A111345). We thank Prof. Robert A.
   Harris at University of Indiana (Indianapolis, IN, USA) for reviewing
   the manuscript and Dr. Kyung ah Seo at Daegu Gyeongbuk Medical
   Innovation Foundation for sharing her expertise regarding DMF
   pharmacokinetics.
CR Ashrafian H, 2012, CELL METAB, V15, P361, DOI 10.1016/j.cmet.2012.01.017
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen NX, 2006, KIDNEY INT, V70, P1046, DOI 10.1038/sj.ki.5001663
   Copple IM, 2012, ADV PHARMACOL, V63, P43, DOI 10.1016/B978 0 12 398339 8.00002 1
   Cross SA, 2011, J IMMUNOL, V187, P5015, DOI 10.4049/jimmunol.1101868
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Dreger H, 2010, CARDIOVASC RES, V85, P395, DOI 10.1093/cvr/cvp279
   Fadini GP, 2011, CIRC RES, V108, P1112, DOI 10.1161/CIRCRESAHA.110.234088
   Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328
   Galle J, 2001, NEPHROL DIAL TRANSPL, V16, P2135, DOI 10.1093/ndt/16.11.2135
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Giachelli CM, 2004, J AM SOC NEPHROL, V15, P2959, DOI 10.1097/01.ASN.0000145894.57533.C4
   Gold R, 2012, CLIN IMMUNOL, V142, P44, DOI 10.1016/j.clim.2011.02.017
   Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287
   Han MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083584
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Hayden MR, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475 2840 4 4
   Hinoi E, 2007, BONE, V40, P337, DOI 10.1016/j.bone.2006.08.016
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097 0177(199904)214:4<279::AID AJA1>3.0.CO;2 W
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kim HJ, 2009, ARTERIOSCL THROM VAS, V29, P1558, DOI 10.1161/ATVBAHA.109.190058
   Kim H, 2012, J CELL MOL MED, V16, P273, DOI 10.1111/j.1582 4934.2011.01294.x
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Leik CE, 2004, HYPERTENSION, V43, P837, DOI 10.1161/01.HYP.0000119191.33112.9c
   Levonen AL, 2007, ARTERIOSCL THROM VAS, V27, P741, DOI 10.1161/01.ATV.0000258868.80079.4d
   Li XW, 2008, ATHEROSCLEROSIS, V199, P271, DOI 10.1016/j.atherosclerosis.2007.11.031
   Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386
   Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68
   Mann Giovanni E., 2007, Shengli Xuebao, V59, P117
   Meili Butz S, 2008, EUR J PHARMACOL, V586, P251, DOI 10.1016/j.ejphar.2008.02.038
   Moharregh Khiabani D, 2009, CURR NEUROPHARMACOL, V7, P60, DOI 10.2174/157015909787602788
   Neven E, 2011, CIRC RES, V108, P249, DOI 10.1161/CIRCRESAHA.110.225904
   Oh CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045870
   Price PA, 2006, ARTERIOSCL THROM VAS, V26, P1079, DOI 10.1161/01.ATV.0000216406.44762.7c
   Reaven PD, 2005, DIABETOLOGIA, V48, P379, DOI 10.1007/s00125 004 1640 z
   Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132
   Schwarz U, 2000, NEPHROL DIAL TRANSPL, V15, P218, DOI 10.1093/ndt/15.2.218
   Seidel P, 2010, RESP RES, V11, DOI 10.1186/1465 9921 11 145
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Speer MY, 2010, J CELL BIOCHEM, V110, P935, DOI 10.1002/jcb.22607
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Takaya K, 2012, FREE RADICAL BIO MED, V53, P817, DOI 10.1016/j.freeradbiomed.2012.06.023
   Tanaka T, 2008, MOL CELL BIOL, V28, P1147, DOI 10.1128/MCB.01771 07
   Wiesner D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076670
NR 47
TC 61
Z9 64
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1537 1891
EI 1879 3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD OCT
PY 2014
VL 63
IS 1
BP 29
EP 36
DI 10.1016/j.vph.2014.06.007
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AR1LT
UT WOS:000343347400005
PM 25135648
DA 2025 08 17
ER

PT J
AU von Knoch, F
   Heckelei, A
   Wedemeyer, C
   Saxler, G
   Hilken, G
   Brankamp, J
   Sterner, T
   Landgraeber, S
   Henschke, F
   Löer, F
   von Knoch, M
AF von Knoch, F
   Heckelei, A
   Wedemeyer, C
   Saxler, G
   Hilken, G
   Brankamp, J
   Sterner, T
   Landgraeber, S
   Henschke, F
   Löer, F
   von Knoch, M
TI Suppression of polyethylene particle induced osteolysis by exogenous
   osteoprotegerin
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE osteoprotegerin; polyethylene particles; osteoclastogenesis; osteolysis;
   calvarial model
ID MOLECULAR WEIGHT POLYETHYLENE; DEBRIS INDUCED OSTEOLYSIS; ANTITUMOR
   NECROSIS FACTOR; TOTAL HIP REPLACEMENTS; GENE THERAPY; OSTEOCLAST
   DIFFERENTIATION; WEAR PARTICLES; CROSS LINKING; BONE LOSS; IN VIVO
AB Alterations of the key regulators of osteoclastogenesis, receptor activator of NF kappaB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) have been implicated in wear particle induced osteolysis, the most common cause for implant failure in total joint replacements. This study investigated the effect of exogenous OPG on ultra high molecular weight polyethylene (UHMWPE) particle induced osteolysis. The murine calvarial osteolysis model was utilized in 28 C57BL/6J mice randomized to four groups. Group I underwent sham surgery only, group II received UHMWPE particles, and group III and IV particles and subcutaneous OPG starting from day 0 (group III) or day 5 (group IV) until sacrifice. After 2 weeks, calvaria were prepared for histology and histomorphometry. Bone resorption was measured within the midline suture using Giemsa staining and osteoclast numbers were determined using TRAP staining. UHMWPE particle implantation resulted in grossly pronounced osteoclastogenesis and bone resorption. Both immediate and delayed treatment with OPG counteracted these particle induced effects significantly, suppressing osteoclast formation and bone resorption (p < 0.001 and p < 0.001, respectively). In conclusion, exogenous OPG markedly suppressed UHMWPE particle induced osteolysis in a murine calvarial model. This important finding underscores the crucial significance of the OPG RANKLRANK signaling in wear particle induced osteolysis. Exogenous OPG may prove an effective treatment modality for wear debris mediated periprosthetic osteolysis after total joint arthroplasty. (c) 2005 Wiley Periodicals, Inc.
C1 Kantonsspital Chur, Dept Orthopaed Surg, CH 7000 Chur, Switzerland.
   Univ Duisburg Essen, Dept Orthopaed Surg, D 45239 Essen, Germany.
   Univ Duisburg Essen, Cent Anim Lab, D 45122 Essen, Germany.
   Pathol Inst Am Johannisstift, D 33102 Paderborn, Germany.
C3 University of Duisburg Essen; University of Duisburg Essen
RP von Knoch, F (通讯作者)，Kantonsspital Chur, Dept Orthopaed Surg, Loestr 170, CH 7000 Chur, Switzerland.
EM fabianvonknoch@yahoo.com
RI Sterner, Thomas/AGZ 2537 2022
CR Baumann B, 2004, ACTA ORTHOP SCAND, V75, P295, DOI 10.1080/00016470410001222
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Clohisy JC, 2003, J ORTHOPAED RES, V21, P202, DOI 10.1016/S0736 0266(02)00133 X
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623 198365050 00001
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   JONES LC, 1987, CLIN ORTHOP RELAT R, P192
   Kim KS, 2000, IPAP CONFERENCE SER, V1, P393
   Kurtz SM, 1999, BIOMATERIALS, V20, P1659, DOI 10.1016/S0142 9612(99)00053 8
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LIU CC, 1987, J HISTOCHEM CYTOCHEM, V35, P1355, DOI 10.1177/35.12.3680930
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   McKellop H, 1999, J ORTHOP RES, V17, P157, DOI 10.1002/jor.1100170203
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Morony S, 1999, J BONE MINER RES, V14, P1478, DOI 10.1359/jbmr.1999.14.9.1478
   Muratoglu OK, 2001, J ARTHROPLASTY, V16, P149, DOI 10.1054/arth.2001.20540
   Premnath V, 1999, POLYMER, V40, P2215, DOI 10.1016/S0032 3861(98)00438 8
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sinha RK, 1998, AAOS INSTR COURS LEC, V47, P307
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   von Knoch F, 2005, BIOMATERIALS, V26, P3549, DOI 10.1016/j.biomaterials.2004.09.043
   von Knoch M, 2005, BIOMATERIALS, V26, P1803, DOI 10.1016/j.biomaterials.2004.06.010
   von Knoch M, 2004, Z ORTHOP GRENZGEB, V142, P366, DOI 10.1055/s 2004 822589
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   WILLERT HG, 1990, CLIN ORTHOP RELAT R, P95
   WILLERT HG, 1977, J BIOMED MATER RES, V11, P157, DOI 10.1002/jbm.820110202
   Yang SY, 2002, ARTHRITIS RHEUM, V46, P2514, DOI 10.1002/art.10527
NR 34
TC 34
Z9 36
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV 1
PY 2005
VL 75A
IS 2
BP 288
EP 294
DI 10.1002/jbm.a.30441
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 974GE
UT WOS:000232578500006
PM 16088891
DA 2025 08 17
ER

PT J
AU Aguila, HL
AF Aguila, Hector Leonardo
TI Regulation of hematopoietic niches by sympathetic innervation
SO BIOESSAYS
LA English
DT Article
ID COLONY STIMULATING FACTOR; ENDOCHONDRAL BONE FORMATION; STEM CELL
   MOBILIZATION; NERVOUS SYSTEM; PROGENITOR CELLS; STROMAL CELLS; MARROW;
   MICE; OSTEOBLASTS; GALACTOCEREBROSIDE
AB Once hematopoiesis is established in the bone marrow, a continuous egress of hematopoietic stem cells (HSCs) to the periphery occurs at a low frequency. It has been proposed that this phenomenon is part of a regenerative homeostatic mechanism that ensures the maintenance of hematopoiesis through the life of the individual. The administration of certain cytotoxic drugs or cytokines can enhance the mobilization of hematopoietic progenitors to the periphery. During the past 15 years, granulocyte colony stimulating factor (G CSF) has been used as a standard cytokine for mobilization protocols in experimental models and in humans. Despite extensive efforts by multiple groups, a definitive mechanism explaining its role in mobilization has not been provided. In a recent paper, Katayama et al.,((1)) through a series of clever associations supported by well defined experimental systems, proposed that signals through the sympathetic nervous system modify the activity of the hematopoietic niche, acting as regulators of the mobilization of hematopoietic progenitors. This surprising finding adds a new level of complexity to the cellular milieu responsible for generation and maintenance of the hematopoietic niche.
C1 Univ Connecticut, Ctr Hlth, Dept Immunol, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Aguila, HL (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Immunol, 263 Farmington Ave, Farmington, CT 06030 USA.
EM aguila@nso1.uchc.edu
CR Abkowitz JL, 2003, BLOOD, V102, P1249, DOI 10.1182/blood 2003 01 0318
   Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CALVO W, 1968, AM J ANAT, V123, P315, DOI 10.1002/aja.1001230206
   Carlevaro MF, 2000, J CELL SCI, V113, P59
   Chen J, 2006, BLOOD, V107, P3764, DOI 10.1182/blood 2005 09 3593
   Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006
   Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092 8674(00)80093 8
   Deguchi K, 1999, BIOCHEM BIOPH RES CO, V255, P352, DOI 10.1006/bbrc.1999.0163
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Frenette PS, 2000, BLOOD, V96, P2460, DOI 10.1182/blood.V96.7.2460.h8002460_2460_2468
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   Jacenko O, 2002, AM J PATHOL, V160, P2019, DOI 10.1016/S0002 9440(10)61152 2
   Katayama Y, 2003, IMMUNITY, V18, P789, DOI 10.1016/S1074 7613(03)00150 X
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.immunol.7.1.111
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301 472X(02)00883 4
   Levesque JP, 2004, BLOOD, V104, P65, DOI 10.1182/blood 2003 05 1589
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031
   MOLINEUX G, 1990, BLOOD, V75, P563
   MOLINEUX G, 1990, BLOOD, V76, P2153
   Nelissen JMDT, 2000, EXP HEMATOL, V28, P422, DOI 10.1016/S0301 472X(00)00127 2
   Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313
   SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788
   Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677
   Taichman RS, 1997, BONE, V21, P353, DOI 10.1016/S8756 3282(97)00166 X
   Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thomas J, 2002, CURR OPIN HEMATOL, V9, P183, DOI 10.1097/00062752 200205000 00002
   THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Winkler IG, 2005, J EXP MED, V201, P1077, DOI 10.1084/jem.20042299
   YAMAZAKI K, 1990, AM J ANAT, V187, P261, DOI 10.1002/aja.1001870306
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 47
TC 12
Z9 12
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0265 9247
J9 BIOESSAYS
JI Bioessays
PD JUL
PY 2006
VL 28
IS 7
BP 687
EP 691
DI 10.1002/bies.20427
PG 5
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA 067SM
UT WOS:000239322900002
PM 16850400
DA 2025 08 17
ER

PT J
AU Lv, B
   Gao, GY
   Guo, YH
   Zhang, ZP
   Liu, RF
   Dai, ZZ
   Ju, C
   Liang, YP
   Tang, XF
   Tang, M
   Lv, XB
AF Lv, Bin
   Gao, Guangyu
   Guo, Yuhong
   Zhang, Zhiping
   Liu, Renfeng
   Dai, Zhengzai
   Ju, Cheng
   Liang, Yiping
   Tang, Xiaofeng
   Tang, Min
   Lv, Xiao Bin
TI Serglycin promotes proliferation, migration, and invasion via the
   JAK/STAT signaling pathway in osteosarcoma
SO AGING US
LA English
DT Article
DE SRGN; osteosarcoma; GEO; bioinformatics analysis; JAK; STAT
ID COLORECTAL CANCER; PROTEOGLYCAN; THERAPY
AB Background: Osteosarcoma (OS) is a common disease in the world, and its pathogenesis is still unclear. This study aims to identify the key genes that promote the proliferation, invasion, and metastasis of osteosarcoma cells. Method: GSE124768 and GSE126209 were downloaded from the Gene Expression Omnibus (GEO) database. The gene ontology and enrichment pathway were analyzed by FunRich software. qPCR and Western blot were used to detect the gene expression. After gene knockdown, Transwell and wound healing assays were conducted on osteosarcoma cells to detect whether the genes were defined before enhancing the invasion of osteosarcoma. Results: Totally, 341 mRNAs were found to be regulated differentially in osteosarcoma cells compared to osteoblasts. In addition, the expression level of Serglycin (SRGN) in osteosarcoma cells was higher than that in human osteoblasts. The invasion and proliferation ability of osteosarcoma cells with upregulated Serglycin was significantly increased, and on the contrary, decreased after Serglycin knockdown. Moreover, we preliminarily found that Serglycin may associate with the JAK/STAT signaling pathway. Conclusions: By using microarray and bioinformatics analyses, differently expressed mRNAs were identified and a complete gene network was constructed. To our knowledge, we describe for the first time Serglycin as a
C1 [Lv, Bin; Guo, Yuhong; Zhang, Zhiping; Liu, Renfeng; Dai, Zhengzai; Liang, Yiping; Tang, Xiaofeng; Lv, Xiao Bin] Nanchang Univ, Affiliated Hosp 3, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Nanchang, Jiangxi, Peoples R China.
   [Lv, Bin; Guo, Yuhong; Zhang, Zhiping; Liu, Renfeng; Dai, Zhengzai] Nanchang Univ, Affiliated Hosp 3, Dept Orthoped, Nanchang 330008, Jiangxi, Peoples R China.
   [Lv, Bin; Guo, Yuhong; Zhang, Zhiping; Liu, Renfeng; Dai, Zhengzai] Nanchang Univ, Affiliated Hosp 3, Nanchang Key Lab Orthopaed, Nanchang, Jiangxi, Peoples R China.
   [Lv, Bin; Guo, Yuhong; Liu, Renfeng; Dai, Zhengzai] Nanchang Univ, Med Dept, Grad Sch, Nanchang 330006, Jiangxi, Peoples R China.
   [Gao, Guangyu] Soochow Univ, Affiliated Hosp 2, Dept Oncol, Suzhou 215004, Jiangsu, Peoples R China.
   [Ju, Cheng] Fourth Mil Med Univ, Beijing Orthopaed Hosp, Xian, Shanxi, Peoples R China.
   [Tang, Min] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Radiotherapy & Oncol, Kunshan, Jiangsu, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University; Soochow University   China; Air Force Medical University;
   Jiangsu University
RP Lv, XB (通讯作者)，Nanchang Univ, Affiliated Hosp 3, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Nanchang, Jiangxi, Peoples R China.; Tang, M (通讯作者)，Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Radiotherapy & Oncol, Kunshan, Jiangsu, Peoples R China.
EM drtangmin@126.com; nclvxiaobin@sina.cn
RI Tang, Min/KOC 3090 2024; lv, bin/MBH 2664 2025; Zhang,
   Zhengdong/AAK 8555 2021; tang, xiaofeng/JUF 8623 2023; Lv,
   Xiao Bin/T 7607 2019; Ju, Cheng/O 8988 2019; liang, yiping/JAC 6695 2023
FU Special Fund for Postgraduate Innovation in Jiangxi Province
   [YC2020 S141]
FX This work was supported by grants from Special Fund for Postgraduate
   Innovation in Jiangxi Province (Grant No. YC2020 S141).
CR Bouris P, 2018, MATRIX BIOL, V74, P35, DOI 10.1016/j.matbio.2018.05.011
   Chu QQ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.287
   Djamgoz MBA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0092
   Guo JY, 2017, ONCOGENE, V36, P2457, DOI 10.1038/onc.2016.404
   Hakomori S, 2001, ADV EXP MED BIOL, V491, P369
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kolset SO, 2008, CELL MOL LIFE SCI, V65, P1073, DOI 10.1007/s00018 007 7455 6
   Korpetinou A, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00327
   Li XJ, 2011, CANCER RES, V71, P3162, DOI 10.1158/0008 5472.CAN 10 3557
   Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078 0432.CCR 15 0198
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Niemann CU, 2007, LEUKEMIA, V21, P2406, DOI 10.1038/sj.leu.2404975
   Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001
   Premkumar LS, 2013, LIFE SCI, V92, P415, DOI 10.1016/j.lfs.2012.08.010
   Roy A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156151
   Subramaniam D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2335 1
   Sun W, 2016, INT J MOL MED, V38, P466, DOI 10.3892/ijmm.2016.2657
   Tominaga O, 1997, JPN J CANCER RES, V88, P855, DOI 10.1111/j.1349 7006.1997.tb00461.x
   TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437
   Wang ZW, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4628962
   Xu Y, 2018, CELL PHYSIOL BIOCHEM, V48, P2429, DOI 10.1159/000492657
   Yue TT, 2009, MOL CELL PROTEOMICS, V8, P1697, DOI 10.1074/mcp.M900135 MCP200
   Zernichow L, 2006, J BIOL CHEM, V281, P26792, DOI 10.1074/jbc.M512889200
   Zhang BT, 2018, BIOMED PHARMACOTHER, V107, P270, DOI 10.1016/j.biopha.2018.07.119
   Zhang Z, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.53
NR 27
TC 7
Z9 9
U1 1
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD SEP 15
PY 2021
VL 13
IS 17
BP 21142
EP 21154
DI 10.18632/aging.203392
PG 13
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA WC6VV
UT WOS:000704394600017
PM 34493692
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hughes, FJ
   Ghuman, M
   Talal, A
AF Hughes, F. J.
   Ghuman, M.
   Talal, A.
TI Periodontal regeneration: a challenge for the tissue engineer?
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H JOURNAL OF
   ENGINEERING IN MEDICINE
LA English
DT Article
DE periodontal; regeneration; tissue engineering; stem cells; growth
   factors
ID BONE MORPHOGENETIC PROTEINS; CONTROLLED CLINICAL TRIAL; HUMAN INTRABONY
   DEFECTS; BABOON PAPIO URSINUS; GROWTH FACTOR; HISTOLOGIC EVALUATION;
   GENE THERAPY; STEM CELLS; GROWTH/DIFFERENTIATION FACTOR 5; OSTEOBLAST
   DIFFERENTIATION
AB Periodontitis affects around 15 per cent of human adult populations. While periodontal treatment aimed at removing the bacterial cause of the disease is generally very successful, the ability predictably to regenerate the damaged tissues remains a major unmet objective for new treatment strategies. Existing treatments include the use of space maintaining barrier membranes (guided tissue regeneration), use of graft materials, and application of bioactive molecules to induce regeneration, but their overall effects are relatively modest and restricted in application. The periodontal ligament is rich in mesenchymal stem cells, and the understanding of the signalling molecules that may regulate their differentation has increased enormously in recent years. Applying these principles for the development of new tissue engineering strategies for periodontal regeneration will require further work to determine the efficacy of current experimental preclinical treatments, including pharmacological application of growth factors such as bone morphogenetic proteins (BMPs) or Wnts, use of autologous stem cell reimplantation strategies, and development of improved biomaterial scaffolds. This article describes the background to this problem, addresses the current status of periodontal regeneration, including the background biology, and discusses the potential for some of these experimental therapies to achieve the goal of clinically predictable periodontal regeneration.
C1 [Hughes, F. J.; Ghuman, M.] Kings Coll London, Inst Dent, Dept Periodontol, London SE1 9RT, England.
   [Talal, A.] Natl Univ Sci & Technol, Army Med Coll, Dept Dent, Islamabad, Pakistan.
C3 University of London; King's College London; National University of
   Sciences & Technology   Pakistan
RP Hughes, FJ (通讯作者)，Kings Coll London, Guys Hosp, Dept Periodontol, Floor 21,Tower Wing, London SE1 9RT, England.
EM francis.hughes@kcl.ac.uk
RI Talal, A/A 4289 2015
OI Ghuman, Mandeep/0000 0001 8927 0741; Hughes,
   Francis/0000 0001 9073 8962; Talal, Ahmed/0009 0005 7574 1262
FU Medical Research Council [G0601408] Funding Source: Medline; Medical
   Research Council [G0601408] Funding Source: researchfish; MRC [G0601408]
   Funding Source: UKRI
CR Aichelmann Reidy M E, 1998, Dent Clin North Am, V42, P491
   ARCEO N, 1991, J PERIODONTOL, V62, P499, DOI 10.1902/jop.1991.62.8.499
   Aspriello SD, 2011, CLIN ORAL INVEST, V15, P225, DOI 10.1007/s00784 009 0369 y
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bosshardt DD, 2008, J CLIN PERIODONTOL, V35, P87, DOI 10.1111/j.1600 051X.2008.01264.x
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Carnes DL, 1997, J PERIODONTOL, V68, P701, DOI 10.1902/jop.1997.68.7.701
   CHEN TL, 1991, J BONE MINER RES, V6, P1387
   Chen YL, 2008, GENE THER, V15, P1469, DOI 10.1038/gt.2008.131
   Cortellini P, 1996, J PERIODONTOL, V67, P217, DOI 10.1902/jop.1996.67.3.217
   Cortellini P, 2004, J PERIODONTOL, V75, P672, DOI 10.1902/jop.2004.75.5.672
   Cortellini P, 1998, J CLIN PERIODONTOL, V25, P981, DOI 10.1111/j.1600 051X.1998.tb02402.x
   Döri F, 2008, J CLIN PERIODONTOL, V35, P44, DOI 10.1111/j.1600 051X.2007.01161.x
   Esposito M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003878.pub4
   Giannobile William V, 2003, Ann Periodontol, V8, P193, DOI 10.1902/annals.2003.8.1.193
   GOTTLOW J, 1984, J CLIN PERIODONTOL, V11, P494, DOI 10.1111/j.1600 051X.1984.tb00901.x
   GOTTLOW J, 1986, J CLIN PERIODONTOL, V13, P604, DOI 10.1111/j.1600 051X.1986.tb00854.x
   Harris RJ, 1999, INT J PERIODONT REST, V19, P225
   Herberg S, 2008, J CLIN PERIODONTOL, V35, P976, DOI 10.1111/j.1600 051X.2008.01323.x
   Hosoya A, 2008, BONE, V42, P350, DOI 10.1016/j.bone.2007.09.054
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671
   Ivanovski S, 2001, J PERIODONTAL RES, V36, P131, DOI 10.1034/j.1600 0765.2001.360301.x
   Jin QM, 2004, MOL THER, V9, P519, DOI 10.1016/j.ymthe.2004.01.016
   Jin QM, 2003, J PERIODONTOL, V74, P202, DOI 10.1902/jop.2003.74.2.202
   Kémoun P, 2007, CELL TISSUE RES, V329, P283, DOI 10.1007/s00441 007 0397 3
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim JY, 2007, CELL TISSUE RES, V330, P123, DOI 10.1007/s00441 007 0434 2
   Kim TG, 2009, J CLIN PERIODONTOL, V36, P589, DOI 10.1111/j.1600 051X.2009.01420.x
   King GN, 1997, J DENT RES, V76, P1460, DOI 10.1177/00220345970760080801
   King GN, 1999, J PERIODONTOL, V70, P1125, DOI 10.1902/jop.1999.70.10.1125
   Kirker Head CA, 2000, ADV DRUG DELIVER REV, V43, P65, DOI 10.1016/S0169 409X(00)00078 8
   Kobayashi M, 1999, J DENT RES, V78, P1624, DOI 10.1177/00220345990780100701
   Leboy PS, 2006, ANN NY ACAD SCI, V1068, P14, DOI 10.1196/annals.1346.003
   Leucht P, 2008, DEVELOPMENT, V135, P2845, DOI 10.1242/dev.023788
   Lin NH, 2009, PERIODONTOL 2000, V51, P239, DOI 10.1111/j.1600 0757.2009.00303.x
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Luan X, 2009, J DENT RES, V88, P781, DOI 10.1177/0022034509340641
   LYNCH SE, 1991, J PERIODONTOL, V62, P458, DOI 10.1902/jop.1991.62.7.458
   McAllister BS, 2007, J PERIODONTOL, V78, P377, DOI 10.1902/jop.2007.060048
   MCCULLOCH CAG, 1987, ANAT RECORD, V219, P233, DOI 10.1002/ar.1092190304
   Moore YR, 2010, J CLIN PERIODONTOL, V37, P288, DOI 10.1111/j.1600 051X.2009.01527.x
   Mouri Y, 2003, CELL BIOL INT, V27, P519, DOI 10.1016/S1065 6995(03)00075 1
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282
   Park YJ, 1998, J CONTROL RELEASE, V51, P201, DOI 10.1016/S0168 3659(97)00169 7
   Parkar MH, 1999, ARCH ORAL BIOL, V44, P823, DOI 10.1016/S0003 9969(99)00077 1
   Rai Balwant, 2008, J Oral Sci, V50, P53, DOI 10.2334/josnusd.50.53
   Rawlinson SCF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008358
   Reynolds MA, 1996, J PERIODONTOL, V67, P150, DOI 10.1902/jop.1996.67.2.150
   Reynolds Mark A, 2003, Ann Periodontol, V8, P227, DOI 10.1902/annals.2003.8.1.227
   Richardson CR, 1999, J CLIN PERIODONTOL, V26, P421, DOI 10.1034/j.1600 051X.1999.260702.x
   Ripamonti U, 1996, ARCH ORAL BIOL, V41, P121, DOI 10.1016/0003 9969(95)00110 7
   Ripamonti U, 2005, CYTOKINE GROWTH F R, V16, P357, DOI 10.1016/j.cytogfr.2005.02.006
   RIPAMONTI U, 1994, J PERIODONTAL RES, V29, P439, DOI 10.1111/j.1600 0765.1994.tb01246.x
   RUTHERFORD RB, 1993, J CLIN PERIODONTOL, V20, P537, DOI 10.1111/j.1600 051X.1993.tb00403.x
   Sculean A, 2008, J PERIODONTOL, V79, P1991, DOI [10.1902/jop.2008.080009, 10.1902/jop.2008.080009 ]
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sigurdsson TJ, 1996, INT J PERIODONT REST, V16, P525
   SIGURDSSON TJ, 1995, J PERIODONTOL, V66, P131, DOI 10.1902/jop.1995.66.2.131
   Stavropoulos Andreas, 2004, Clin Oral Investig, V8, P226, DOI 10.1007/s00784 004 0277 0
   Stavropoulos A, 2010, J PERIODONTOL, V81, P325, DOI 10.1902/jop.2009.090386
   Takayama S, 2001, J DENT RES, V80, P2075, DOI 10.1177/00220345010800121001
   Talal A, 2009, J DENT, V37, P820, DOI 10.1016/j.jdent.2009.06.014
   Talwar R, 2001, J CLIN PERIODONTOL, V28, P340, DOI 10.1034/j.1600 051x.2001.028004340.x
   Tan Z, 2009, CYTOTHERAPY, V11, P317, DOI 10.1080/14653240902824757
   Tashiro T, 2006, J ORTHOP RES, V24, P71, DOI 10.1002/jor.20002
   Tonetti MS, 1998, J PERIODONTOL, V69, P1183, DOI 10.1902/jop.1998.69.11.1183
   Tonetti MS, 1996, J CLIN PERIODONTOL, V23, P548, DOI 10.1111/j.1600 051X.1996.tb01823.x
   Trombelli L, 2008, J CLIN PERIODONTOL, V35, P117, DOI 10.1111/j.1600 051X.2008.01265.x
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   WESSELINK PR, 1994, J CLIN PERIODONTOL, V21, P472, DOI 10.1111/j.1600 051X.1994.tb00410.x
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wu XW, 2007, ANN NY ACAD SCI, V1116, P29, DOI 10.1196/annals.1402.053
   Yukna RA, 2000, J PERIODONTOL, V71, P1671, DOI 10.1902/jop.2000.71.11.1671
NR 77
TC 49
Z9 60
U1 0
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954 4119
EI 2041 3033
J9 P I MECH ENG H
JI Proc. Inst. Mech. Eng. Part H J. Eng. Med.
PY 2010
VL 224
IS H12
SI SI
BP 1345
EP 1358
DI 10.1243/09544119JEIM820
PG 14
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 687CS
UT WOS:000284752600003
PM 21287824
DA 2025 08 17
ER

PT J
AU Hapidin, H
   Hashim, NM
   Kasiram, MZ
   Abdullah, H
AF Hapidin, Hermizi
   Hashim, Nor Munira
   Kasiram, Mohamad Zahid
   Abdullah, Hasmah
TI The Effects of Polyphenol, Tannic Acid, or Tannic Acid in Combination
   with Pamidronate on Human Osteoblast Cell Line Metabolism
SO MOLECULES
LA English
DT Article
DE bone sialoprotein; osteoblast; osterix; pamidronate; synergism; tannic
   acid
ID OXIDATIVE STRESS; HUMAN HEALTH; BONE; QUANTIFICATION; EXPRESSION;
   CALCIUM; DIFFERENTIATION; MECHANISMS; PHOSPHATE; CULTURE
AB Background: This study investigates the effect of tannic acid (TA) combined with pamidronate (PAM) on a human osteoblast cell line. Methods: EC50 for TA, PAM, and different combination ratios of TA and PAM (25:75, 50:50, 75:25) were measured by 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyl 2H tetrazolium bromide (MTT) assay. The combination index value was utilized to analyze the degree of drug interaction, while trypan blue assay was applied to analyze the cells proliferation effect. The mineralization and detection of bone BSP and Osx genes were determined via histochemical staining and PCR test, respectively. Results: The EC50 of osteoblasts treated with TA and a 75:25 ratio of TA and PAM were more potent with lower EC50 at 0.56 mu g/mL and 0.48 mu g/mL, respectively. The combination of TA and PAM (75:25) was shown to have synergistic interaction. On Day 7, both TA and PAM groups showed significantly increased proliferation compared with control and combination groups. On Day 7, both the TA and combination treated groups demonstrated a higher production of calcium deposits than the control and PAM treated groups. Moreover, on Day 7, the combination treated group showed a significantly higher expression of BSP and Osx genes than both the TA and PAM groups. Conclusion: Combination treatment of TA and PAM at 75:25 ameliorated the highest enhancement of osteoblast proliferation and mineralization as well as caused a high expression of BSP and Osx genes.
C1 [Hapidin, Hermizi; Hashim, Nor Munira; Kasiram, Mohamad Zahid; Abdullah, Hasmah] Univ Sains Malaysia, Sch Hlth Sci, Biomed Programme, Hlth Campus, Kubang Kerian 16150, Malaysia.
C3 Universiti Sains Malaysia
RP Hapidin, H (通讯作者)，Univ Sains Malaysia, Sch Hlth Sci, Biomed Programme, Hlth Campus, Kubang Kerian 16150, Malaysia.
EM hermizi@usm.my; normunira94@gmail.com; zahidkasiram@gmail.com;
   hasmahab@usm.my
RI Hapidin, Hermizi/E 1692 2012; Abdullah, Hasmah/B 2604 2018; abdullah,
   hasmah/B 2604 2018
OI Hapidin, Hermizi/0000 0002 9427 1332; Abdullah,
   Hasmah/0000 0003 2550 0354; Hashim, Nor Munira/0000 0002 5793 9567;
   Kasiram, Mohamad Zahid/0000 0003 2033 676X
FU Ministry of Higher Education Malaysia under Fundamental Fundamental
   Research Grant Scheme [FRGS/1/2020/STG01/USM/02/16]
FX This research was funded by Ministry of Higher Education Malaysia under
   Fundamental Fundamental Research Grant Scheme
   (FRGS/1/2020/STG01/USM/02/16).
CR Abdullah AR, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/5319528
   Bleve G, 2003, APPL ENVIRON MICROB, V69, P4116, DOI 10.1128/AEM.69.7.4116 4122.2003
   Bonjour JP, 2011, J AM COLL NUTR, V30, p438S, DOI 10.1080/07315724.2011.10719988
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Brauer A, 2016, BIOTECH HISTOCHEM, V91, P161, DOI 10.3109/10520295.2015.1110254
   Chang CY, 2016, RADIOGRAPHICS, V36, P1871, DOI 10.1148/rg.2016160004
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008 5472.CAN 09 1947
   Chung KT, 1998, CRIT REV FOOD SCI, V38, P421, DOI 10.1080/10408699891274273
   Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71
   Cosan DT, 2015, CYTOTECHNOLOGY, V67, P97, DOI 10.1007/s10616 013 9661 4
   Daroszewska A., 2015, OBSTET GYNAECOL REPR, V25, P181, DOI [10.1016/j.ogrm.2015.04.001, DOI 10.1016/J.OGRM.2015.04.001]
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   García Martínez O, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150045
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hapidin H, 2019, MICROSC RES TECHNIQ, V82, P1928, DOI 10.1002/jemt.23361
   Hassan MA, 2015, J TEKNOL, V77
   Horcajada Marie Noelle, 2012, Curr Mol Pharmacol, V5, P205
   Hubert PA, 2014, ANTIOXIDANTS BASEL, V3, P144, DOI 10.3390/antiox3010144
   HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175
   Jahanian E., 2016, J Parathyr Disease, V4, P60
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Ko Chun Hay, 2012, Evid Based Complement Alternat Med, V2012, P203732, DOI 10.1155/2012/203732
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Lee JH, 2015, SCI REP UK, V5, DOI 10.1038/srep18833
   Leiper KA, 2009, BEER: A QUALITY PERSPECTIVE: A VOLUME OF THE HANDBOOK OF ALCOHOLIC BEVERAGES SERIES, P111, DOI 10.1016/B978 0 12 669201 3.00004 X
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973 7847.70902
   Manzano Moreno FJ, 2015, IMPLANT DENT, V24, P565, DOI 10.1097/ID.0000000000000308
   Nidhi S., 2012, IRJP, V3, P120
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Pazianas M, 2013, THER CLIN RISK MANAG, V9, P395, DOI 10.2147/TCRM.S52291
   Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809
   Peng YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056451
   Ponader S, 2008, COLLOID SURFACE B, V64, P275, DOI 10.1016/j.colsurfb.2008.02.002
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Raudhah AA, 2018, ASIAN PAC J TROP BIO, V8, P261, DOI 10.4103/2221 1691.233007
   Rebouças ED, 2013, BRAZ ARCH BIOL TECHN, V56, P143
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Sato C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43608 6
   Sharma K, 2021, TOXIN REV, V40, P432, DOI 10.1080/15569543.2019.1662813
   Shen CL, 2012, NUTR RES, V32, P897, DOI 10.1016/j.nutres.2012.09.018
   Sooi LK, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/438139
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tian XG, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420968030
   Tomaszewska E, 2017, EXP TOXICOL PATHOL, V69, P131, DOI 10.1016/j.etp.2016.12.003
   Tong Wilbur, 2007, J Stem Cells, V2, P139
   Torre E, 2017, PHYTOCHEM REV, V16, P1183, DOI 10.1007/s11101 017 9529 x
   Trzeciakiewicz A, 2009, NUTR RES REV, V22, P68, DOI 10.1017/S095442240926402X
   Wang C, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.896742
   Wang S, 2011, GENE, V476, P46, DOI 10.1016/j.gene.2011.01.016
   Yang Y, 2016, BIOCHEM BIOPH RES CO, V476, P574, DOI 10.1016/j.bbrc.2016.05.164
   Zhang C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026504
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 57
TC 6
Z9 6
U1 1
U2 19
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2022
VL 27
IS 2
AR 451
DI 10.3390/molecules27020451
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YM8SG
UT WOS:000746838400001
PM 35056766
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Inoue, Y
   Mitsunaga, K
   Yamamoto, T
   Chiba, K
   Yamaide, F
   Nakano, T
   Morita, Y
   Yamaide, A
   Suzuki, S
   Arima, T
   Yamaguchi, K
   Tomiita, M
   Shimojo, N
   Kohno, Y
AF Inoue, Yuzaburo
   Mitsunaga, Kanako
   Yamamoto, Takeshi
   Chiba, Koki
   Yamaide, Fumiya
   Nakano, Taiji
   Morita, Yoshinori
   Yamaide, Akiko
   Suzuki, Shuichi
   Arima, Takayasu
   Yamaguchi, Ken ichi
   Tomiita, Minako
   Shimojo, Naoki
   Kohno, Yoichi
TI Early use of alendronate as a protective factor against the development
   of glucocorticoid induced bone loss in childhood onset rheumatic
   diseases: a cross sectional study
SO PEDIATRIC RHEUMATOLOGY
LA English
DT Article
DE Osteoporosis; Bone loss; Alendronate; Glucocorticoid; Childhood onset
   rheumatic disease
ID INDUCED OSTEOPOROSIS; CHILDREN; PREVENTION; MECHANISMS; FRACTURES
AB Background: Bisphosphonates are recommended for use as first line therapy for the prevention and treatment of glucocorticoid induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid induced osteoporosis in children remains unclear.
   Methods: We performed a cross sectional study to clarify the factors associated with the development of glucocorticoid induced bone loss and osteoporosis in patients with childhood onset rheumatic disease and to investigate the impact of the early use of alendronate. We recruited 39 patients with childhood onset rheumatic disease who were evaluated to detect bone loss or osteoporosis at 3 months to 1.5 years after the initiation of treatment. The primary outcome of the study was the presence of bone loss or osteoporosis at the initial evaluation of the bone mineral density after at least 3 months of glucocorticoid therapy.
   Results: Bone loss and a history of fracture were found in 56 and 18% of the participants, respectively. Weekly oral alendronate therapy (median, 25.4 mg/m(2)) had been started by the time of the evaluation of osteoporosis in 46% of the participants and within 3 months after the start of glucocorticoid in 31% of the participants. There were no significant differences between the participants with bone loss (wBL group) and without bone loss (w/oBL group) in terms of gender, primary disease, or the age at the onset of primary disease. In terms of glucocorticoid use, there was no significant difference in the age at the start of glucocorticoid therapy, the length of glucocorticoid use, or the dose of glucocorticoids. The proportion of patients in the w/oBL group who received alendronate within 3 months after the start of glucocorticoid therapy was significantly greater than that in the wBL group. In the logistic regression analysis, only "alendronate therapy within 3 months after the start of glucocorticoid therapy" had a statistically significant effect on the development of bone loss (OR, 0.08; 95% CI, 0.02 0.43). The analysis did not reveal any factors associated with the development of osteoporosis.
   Conclusions: The early use of alendronate may have a preventive effect against the development of bone loss in glucocorticoid treated patients with childhood onset rheumatic disease.
C1 [Inoue, Yuzaburo] Eastern Chiba Med Ctr, Dept Pediat, 3 6 2 Okayamadai, Togane, Chiba 2838686, Japan.
   [Inoue, Yuzaburo] Chiba Univ, Grad Sch Med, Dept Gen Med Sci, Chiba, Chiba, Japan.
   [Mitsunaga, Kanako] Chiba Kaihin Municipal Hosp, Dept Pediat, Chiba, Chiba, Japan.
   [Yamamoto, Takeshi; Yamaide, Akiko; Tomiita, Minako] Chiba Childrens Hosp, Dept Allergy & Rheumatol, Chiba, Chiba, Japan.
   [Chiba, Koki] Toho Univ, Omori Med Ctr, Dept Tradit Med, Ota Ku, Tokyo, Japan.
   [Yamaide, Fumiya; Nakano, Taiji; Shimojo, Naoki] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Chiba, Japan.
   [Morita, Yoshinori] IMS Mem Hosp, Dept Pediat, Itabashi Ku, Tokyo, Japan.
   [Suzuki, Shuichi] Shimoshizu Natl Hosp, Dept Pediat, Chiba, Japan.
   [Arima, Takayasu] Kimitsu Chuo Hosp, Dept Pediat, Kisarazu, Chiba, Japan.
   [Yamaguchi, Ken ichi] St Lukes Int Hosp, Immunorheumatol Ctr, Chuou Ku, Tokyo, Japan.
   [Kohno, Yoichi] Chiba Rosai Hosp, Ichihara, Chiba, Japan.
C3 Chiba University; Chiba Children's Hospital; Chiba University; St.
   Luke's International Hospital
RP Inoue, Y (通讯作者)，Eastern Chiba Med Ctr, Dept Pediat, 3 6 2 Okayamadai, Togane, Chiba 2838686, Japan.; Inoue, Y (通讯作者)，Chiba Univ, Grad Sch Med, Dept Gen Med Sci, Chiba, Chiba, Japan.
EM yuzaburo@chiba u.jp
RI Suzuki, Shuichi/ABC 7790 2020; Inoue, Yuzaburo/E 3262 2019; Yamaide,
   Fumiya/GLU 2426 2022
OI Inoue, Yuzaburo/0000 0001 5904 687X; Nakano, Taiji/0000 0001 7499 1204;
   YAMAIDE, FUMIYA/0000 0002 2916 9710
CR Bishop N, 2014, J CLIN DENSITOM, V17, P275, DOI 10.1016/j.jocd.2014.01.004
   Bonjour JP, 2009, SALUD PUBLICA MEXICO, V51, pS5
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   Haugeberg G, 2004, ANN RHEUM DIS, V63, P940, DOI 10.1136/ard.2003.011734
   Inoue Y, 2008, CLIN RHEUMATOL, V27, P909, DOI 10.1007/s10067 008 0864 6
   LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003 4819 119 10 199311150 00001
   Nakagi Yoshihiko, 2010, Environmental Health and Preventive Medicine, V15, P222, DOI 10.1007/s12199 009 0131 8
   Nishiyama S, 2001, CLIN PEDIAT ENDOCRIN, V10, P113
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodd C, 2012, ARTHRIT CARE RES, V64, P122, DOI 10.1002/acr.20589
   Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913
   von Scheven E, 2014, CURR OSTEOPOROS REP, V12, P289, DOI 10.1007/s11914 014 0228 x
NR 15
TC 9
Z9 10
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1546 0096
J9 PEDIATR RHEUMATOL
JI Pediatr. Rheumatol.
PD JUN 18
PY 2018
VL 16
AR 36
DI 10.1186/s12969 018 0258 5
PG 9
WC Pediatrics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Rheumatology
GA GK1NW
UT WOS:000435886300001
PM 29914510
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kimura, K
   Terasaka, T
   Iwata, N
   Katsuyama, T
   Komatsubara, M
   Nagao, R
   Inagaki, K
   Otsuka, F
AF Kimura, Kosuke
   Terasaka, Tomohiro
   Iwata, Nahoko
   Katsuyama, Takayuki
   Komatsubara, Motoshi
   Nagao, Ryota
   Inagaki, Kenichi
   Otsuka, Fumio
TI Combined Effects of Androgen and Growth Hormone on Osteoblast Marker
   Expression in Mouse C2C12 and MC3T3 E1 Cells Induced by Bone
   Morphogenetic Protein
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE androgen; bone morphogenetic protein (BMP); dihydrotestosteone (DHT);
   growth hormone (GH); osteoblasts
ID NECROSIS FACTOR ALPHA; IGF I; REPLACEMENT THERAPY; DIFFERENTIATION;
   MUSCLE; TESTOSTERONE; ESTROGEN; RECEPTOR; MICE; DEFICIENCY
AB Osteoblasts undergo differentiation in response to various factors, including growth factors and steroids. Bone mass is diminished in androgen  and/or growth hormone (GH) deficient patients. However the functional relationship between androgen and GH, and their combined effects on bone metabolism, remains unclear. Here we investigated the mutual effects of androgen and GH on osteoblastic marker expression using mouse myoblastic C2C12 and osteoblast like MC3T3 E1 cells. Combined treatment with dihydrotestosterone (DHT) and GH enhanced BMP 2 induced expression of Runx2, ALP, and osteocalcin mRNA, compared with the individual treatments in C2C12 cells. Co treatment with DHT and GH activated Smad1/5/8 phosphorylation, Id 1 transcription, and ALP activity induced by BMP 2 in C2C12 cells but not in MC3T3 E1 cells. The insulin like growth factor (IGF I) mRNA level was amplified by GH and BMP 2 treatment and was restored by co treatment with DHT in C2C12 cells. The mRNA level of the IGF I receptor was not significantly altered by GH or DHT, while it was increased by IGF I. In addition, IGF I treatment increased collagen 1 mRNA expression, whereas blockage of endogenous IGF I activity using an anti IGF I antibody failed to suppress the effect of GH and DHT on BMP 2 induced Runx2 expression in C2C12 cells, suggesting that endogenous IGF I was not substantially involved in the underlying GH actions. On the other hand, androgen receptor and GH receptor mRNA expression was suppressed by BMP 2 in both cell lines, implying the existence of a feedback action. Collectively the results showed that the combined effects of androgen and GH facilitated BMP 2 induced osteoblast differentiation at an early stage by upregulating BMP receptor signaling.
C1 [Kimura, Kosuke; Terasaka, Tomohiro; Iwata, Nahoko; Nagao, Ryota; Otsuka, Fumio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Med, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
   [Terasaka, Tomohiro; Katsuyama, Takayuki; Komatsubara, Motoshi; Inagaki, Kenichi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med & Clin Sci, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
C3 Okayama University; Okayama University
RP Otsuka, F (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Med, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
EM k_kimura14@yahoo.co.jp; teras t@cc.okayama u.ac.jp;
   nao53mayflower@gmail.com; takayukikatsuyama@gmail.com;
   swe_etfish@yahoo.co.jp; p4le6611@s.okayama u.ac.jp;
   kenina@md.okayama u.ac.jp; fumiotsu@md.okayama u.ac.jp
FU Japan Rheumatism Foundation; Novo Nordisk Research Grant; Foundation for
   Growth Science; Japan Foundation for Applied Enzymology (Japan);
   Kawasaki Foundation for Medical Science & Medical Welfare; Uehara
   Memorial Foundation;  [24591364];  [15K09434]
FX This work was supported in part by Grants in Aid for Scientific Research
   (No. 24591364 and 15K09434), the Japan Rheumatism Foundation, the Novo
   Nordisk Research Grant, the Foundation for Growth Science, the Japan
   Foundation for Applied Enzymology (Japan), the Kawasaki Foundation for
   Medical Science & Medical Welfare, and The Uehara Memorial Foundation.
CR Al Mukaddam M, 2014, J CLIN ENDOCR METAB, V99, P1236, DOI 10.1210/jc.2013 3665
   Bex M, 2002, J BONE MINER RES, V17, P1081, DOI 10.1359/jbmr.2002.17.6.1081
   Bikle D, 2001, J BONE MINER RES, V16, P2320, DOI 10.1359/jbmr.2001.16.12.2320
   Blackman MB, 2002, JAMA J AM MED ASSOC, V288, P2282, DOI 10.1001/jama.288.18.2282
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Chen Y, 2008, J ENDOCRINOL INVEST, V31, P910, DOI 10.1007/BF03346441
   Diel P, 2008, J MOL ENDOCRINOL, V40, P231, DOI 10.1677/JME 07 0175
   Frost RA, 2002, ENDOCRINOLOGY, V143, P492, DOI 10.1210/en.143.2.492
   Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001 0044
   Hansen M, 2013, SCAND J MED SCI SPOR, V23, P614, DOI 10.1111/j.1600 0838.2011.01431.x
   Iglesias Gato D, 2014, CARCINOGENESIS, V35, P24, DOI 10.1093/carcin/bgt304
   Kanno Y, 2013, BIOL PHARM BULL, V36, P1460
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Katsuyama T, 2015, PEPTIDES, V73, P88, DOI 10.1016/j.peptides.2015.09.007
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1443, DOI 10.1210/jc.87.4.1443
   Klover P, 2009, FASEB J, V23, P3140, DOI 10.1096/fj.08 128215
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Matsumoto Y, 2010, MOL CELL ENDOCRINOL, V325, P118, DOI 10.1016/j.mce.2010.05.004
   Mauras N, 2003, METABOLISM, V52, P964, DOI 10.1016/S0026 0495(03)00163 X
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Nakamura E, 2012, ENDOCRINOLOGY, V153, P469, DOI 10.1210/en.2011 1646
   Olson LE, 2011, CALCIFIED TISSUE INT, V88, P1, DOI 10.1007/s00223 010 9436 2
   Otsuka F, 2010, ENDOCR J, V57, P3, DOI 10.1507/endocrj.K09E 310
   Sadowski CL, 2001, ENDOCRINOLOGY, V142, P3890, DOI 10.1210/en.142.9.3890
   Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003 0007
   Singhal V, 2013, BONE RES, V1, DOI 10.4248/BR201301006
   Sinnesael M, 2013, CURR OPIN ENDOCRINOL, V20, P240, DOI 10.1097/MED.0b013e32835f7d04
   Snyder PJ, 2007, J BONE MINER RES, V22, P762, DOI 10.1359/JBMR.070205
   Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   Takano M, 2012, MOL CELL ENDOCRINOL, V348, P224, DOI 10.1016/j.mce.2011.08.027
   Tritos NA, 2011, J CLIN ENDOCR METAB, V96, P1516, DOI 10.1210/jc.2010 2662
   Venken K, 2007, J BONE MINER RES, V22, P72, DOI 10.1359/JBMR.060911
   Wüster C, 2001, J BONE MINER RES, V16, P398, DOI 10.1359/jbmr.2001.16.2.398
   Xin XP, 2004, AM J PHYSIOL GASTR L, V286, pG777, DOI 10.1152/ajpgi.00293.2003
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
NR 36
TC 4
Z9 6
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2077 0383
J9 J CLIN MED
JI J. Clin. Med.
PD JAN
PY 2017
VL 6
IS 1
AR 6
DI 10.3390/jcm6010006
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EO2NK
UT WOS:000396533000006
PM 28067796
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Kusec, V
AF Kusec, Vesna
TI The skeleton in diabetes   involvement and interaction
SO PERIODICUM BIOLOGORUM
LA English
DT Article
DE diabetes; bone; insulin; osteocalcin
ID VITAMIN D; INSULIN RESISTANCE; GLYCEMIC CONTROL; FAT MASS;
   UNDERCARBOXYLATED OSTEOCALCIN; POSTMENOPAUSAL WOMEN; SERUM OSTEOCALCIN;
   PLASMA GLUCOSE; BONE TURNOVER; FRACTURE RISK
AB Diabetes mellitus (DM) is characterized by high blood glucose; impairment of the skeleton is among its other deleterious effects. Adverse effect upon the bone tissue is primarily altered bone quality and consequently increased bone fragility. In DM 1, bone mass may be low and in DM2 normal or even increased. Therapy for DM2 also affects bone metabolism as thiazolidine diones cause differentiation shift of mesenchyme precursors from osteoblasts into adipocytes. Association of bone with glucose metabolism was discovered in the last decade indicating that insulin is necessary for synthesis of undercarboxylated osteocalcin which acts in a hormonal fashion to promote insulin secretion in the pancreas, adiponectin in adipocytes, and increases insulin sensitivity in target tissues. Undercarboxylated osteocalcin is also secreted from resorbed bone. Thus insulin is required for normal bone metabolism and bone acts as an endocrine organ. Additional role of osteocalcin is in promoting testosterone secretion in testes.
C1 Univ Hosp Ctr Zagreb, Dept Lab Diagnost, Zagreb 10000, Croatia.
C3 University of Zagreb; UNIVERSITY ZAGREB HOSPITAL
RP Kusec, V (通讯作者)，Univ Hosp Ctr Zagreb, Dept Lab Diagnost, Kispaticeva 12, Zagreb 10000, Croatia.
EM vkusec@kbc zagreb.hr
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   BENER A, 2008, ACTA DIABETOL
   Borkar VV, 2010, PEDIATR DIABETES, V11, P345, DOI 10.1111/j.1399 5448.2009.00589.x
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   de Paula FJA, 2010, DIABETES METAB RES, V26, P622, DOI 10.1002/dmrr.1135
   Dobnig H, 2006, J CLIN ENDOCR METAB, V91, P3355, DOI 10.1210/jc.2006 0460
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   George PS, 2012, DIABETIC MED, V29, pE142, DOI 10.1111/j.1464 5491.2012.03672.x
   Hein G, 2006, ANN RHEUM DIS, V65, P101, DOI 10.1136/ard.2004.034348
   Holick MF, 2008, AM J CLIN NUTR, V87, p1080S
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Kanazawa I, 2011, OSTEOPOROSIS INT, V22, P187, DOI 10.1007/s00198 010 1184 7
   Kanazawa I, 2011, BONE, V48, P720, DOI 10.1016/j.bone.2010.12.020
   Kanazawa I, 2009, J CLIN ENDOCR METAB, V94, P45, DOI 10.1210/jc.2008 1455
   Khazai NB, 2009, CURR OPIN ENDOCRINOL, V16, P435, DOI 10.1097/MED.0b013e328331c7eb
   Kindblom JM, 2009, J BONE MINER RES, V24, P785, DOI 10.1359/JBMR.081234
   Kirmani S, 2011, J BONE MINER RES, V26, P2212, DOI 10.1002/jbmr.421
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P178, DOI 10.1007/s11914 010 0027 y
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Levinger I, 2011, OSTEOPOROSIS INT, V22, P1621, DOI 10.1007/s00198 010 1370 7
   Littorin B, 2006, DIABETOLOGIA, V49, P2847, DOI 10.1007/s00125 006 0426 x
   Madar AA, 2014, BMJ OPEN DIAB RES CA, V2, DOI 10.1136/bmjdrc 2014 000026
   Fernández Real JM, 2009, J CLIN ENDOCR METAB, V94, P237, DOI 10.1210/jc.2008 0270
   Mathieu C, 2005, TRENDS ENDOCRIN MET, V16, P261, DOI 10.1016/j.tem.2005.06.004
   Motyl KJ, 2010, ARCH BIOCHEM BIOPHYS, V503, P2, DOI 10.1016/j.abb.2010.07.030
   Muszkat P, 2010, ARQ BRAS ENDOCRINOL, V54, P110, DOI 10.1590/S0004 27302010000200005
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Parker J, 2010, MATURITAS, V65, P225, DOI 10.1016/j.maturitas.2009.12.013
   Pittas AG, 2009, J CLIN ENDOCR METAB, V94, P827, DOI 10.1210/jc.2008 1422
   Prats Puig A, 2010, DIABETES CARE, V33, P661, DOI 10.2337/dc09 1837
   Reinehr T, 2010, INT J OBESITY, V34, P852, DOI 10.1038/ijo.2009.282
   Rosato MT, 1998, CALCIFIED TISSUE INT, V63, P107, DOI 10.1007/s002239900498
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Schwartz AV, 2008, DIABETES CARE, V31, P391, DOI 10.2337/dc07 1152
   Schwetz V, 2012, EUR J ENDOCRINOL, V166, P959, DOI 10.1530/EJE 12 0030
   Shea MK, 2009, AM J CLIN NUTR, V90, P1230, DOI 10.3945/ajcn.2009.28151
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Sosa M, 2009, AGING CLIN EXP RES, V21, P27, DOI 10.1007/BF03324895
   Takiishi T, 2010, ENDOCRIN METAB CLIN, V39, P419, DOI 10.1016/j.ecl.2010.02.013
   Targher G, 2006, CLIN ENDOCRINOL, V65, P593, DOI 10.1111/j.1365 2265.2006.02633.x
   Thrailkill KM, 2012, OSTEOPOROSIS INT, V23, P1799, DOI 10.1007/s00198 011 1807 7
   Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756 3282(00)00434 8
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Yamaguchi T, 2011, ENDOCR J, V58, P613, DOI 10.1507/endocrj.EJ11 0063
NR 46
TC 1
Z9 1
U1 0
U2 1
PU PERIODICUM BIOLOGORUM
PI ZAGREB
PA HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA
SN 0031 5362
J9 PERIOD BIOL
JI Period. Biol.
PD MAR
PY 2015
VL 117
IS 1
BP 87
EP 93
PG 7
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA CJ5XQ
UT WOS:000355567400013
DA 2025 08 17
ER

PT J
AU Koca, I
   Özgür, A
   Er, M
   Gümüs, M
   Coskun, KA
   Tutar, Y
AF Koca, Irfan
   Ozgur, Aykut
   Er, Muhammet
   Gumus, Mehmet
   Coskun, Kubra Acikalin
   Tutar, Yusuf
TI Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90
   inhibitors in invasive ductal breast cancer and its bone metastasis
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Pyrimidine; Thiourea Breast cancer; Bone cancer; Hsp90; Client proteins
ID CARCINOMA IN SITU; DERIVATIVES; GELDANAMYCIN; DENOSUMAB; KINASES;
   COMPLEX; TARGETS; DCIS
AB Invasive ductal carcinoma is the most common breast malignancies tumors and has tendency to bone metastases. Many oncogenic client proteins involved in formation of metastatic pathways. Stabilization, regulation, and maintenance of these oncogenic client proteins are provided with Heat Shock Protein 90 (Hsp90). Hsp90 perform these processes through its ATP binding and subsequent hydrolysis energy. Therefore, designing Hsp90 inhibitors is a novel cancer treatment method. However, many Hsp90 inhibitors have solubility problems and showed adverse effects in clinical trials. Thus, we designed and synthesized novel pyrimidinyl acyl thiourea derivatives to selectively inhibit Hsp90 alpha in human invasive ductal breast (MCF 7) and human bone osteosarcoma (Saos 2) cell lines. In vitro experiments showed that the compounds inhibited cell proliferation, ATP hydrolysis, and exhibited cytotoxic effect on these cancer cell lines. Further, gene expression was analyzed by microarray studies on MCF 7 cell lines. Several genes that play vital roles in breast cancer pathogenesis displayed altered gene expression in the presence of a selected pyrimidinyl acyl thiourea compound. Molecular docking studies were also performed to determine interaction between Hsp90 ATPase domain and pyrimidinyl acyl thiourea derivatives. The results indicated that the compounds are able to interact with Hsp90 ATP binding pocket and inhibit ATPase function. The designed compounds powerfully inhibit Hsp90 by an average of 1 mu M inhibition constant. And further, the compounds perturb Hsp90 N terminal domain proper orientation and ATP may not provide required conformational change for Hsp90 function as evidenced by in silico experiments. Therefore, the designed compounds effectively inhibited both invasive ductal breast carcinoma and bone metastasis. Pyrimidinyl acyl thiourea derivatives may provide a drug template for effective treatment of invasive ductal breast carcinoma and its bone metastasis as well as new therapeutic perspective for drug design. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Koca, Irfan; Er, Muhammet; Gumus, Mehmet] Bozok Univ, Fac Arts & Sci, Dept Chem, Yozgat, Turkey.
   [Ozgur, Aykut; Coskun, Kubra Acikalin] Gaziosmanpasa Univ, Fac Nat Sci & Engn, Dept Bioengn, Tokat, Turkey.
   [Tutar, Yusuf] Cumhuriyet Univ, Div Biochem, Dept Basic Sci, Fac Pharm, Sivas, Turkey.
C3 Bozok University; Tokat Gaziosmanpasa University; Cumhuriyet University
RP Koca, I (通讯作者)，Bozok Univ, Fac Arts & Sci, Dept Chem, Yozgat, Turkey.; Tutar, Y (通讯作者)，Cumhuriyet Univ, Div Biochem, Dept Basic Sci, Fac Pharm, Sivas, Turkey.
EM i_koca@yahoo.com; ytutar@cumhuriyet.edu.tr
RI ; TUTAR, Yusuf/JUV 7385 2023; KOCA, İrfan/AAT 9013 2021; Tutar,
   Yusuf/JUV 7385 2023; Özgür, Aykut/AAE 4823 2022; Gümüş,
   Mehmet/Y 7359 2018
OI Gumus, Mehmet/0000 0001 9262 7940; TUTAR, Yusuf/0000 0003 2613 9644;
   Gumus, Mehmet/0000 0003 3643 5703; KOCA, IRFAN/0000 0001 7873 159X
FU Bozok University [FBE/T127]; Scientific and Technological Research
   Council of Turkey [TUBITAK 114Z365]
FX This work was funded through a seed grand from Bozok University (Project
   No:FBE/T127) and through The Scientific and Technological Research
   Council of Turkey (TUBITAK 114Z365).
CR Agrawal R, 2012, MINI REV MED CHEM, V12, P87, DOI 10.2174/138955712798995048
   Bartsch R, 2009, EXPERT OPIN BIOL TH, V9, P1225, DOI 10.1517/14712590903146877
   Body J J, 1995, Can J Oncol, V5 Suppl 1, P16
   Carter NJ, 2010, AM J CARDIOVASC DRUG, V10, P383, DOI 10.2165/11204600 000000000 00000
   Cheng Shinta, 2003, Cancer Treat Res, V115, P293
   Coskun KA, 2013, PROTEIN PEPTIDE LETT, V20, P1294
   Czaykowski P M, 1997, Clin Oncol (R Coll Radiol), V9, P181, DOI 10.1016/S0936 6555(97)80077 5
   Diaz Moralli S, 2013, PHARMACOL THERAPEUT, V138, P255, DOI 10.1016/j.pharmthera.2013.01.011
   Dürr HR, 2002, CLIN ORTHOP RELAT R, P191
   El Serag HB, 2001, AM J GASTROENTEROL, V96, P979
   Esteves Souza A, 2006, BIOORGAN MED CHEM, V14, P492, DOI 10.1016/j.bmc.2005.08.031
   Fukuyo Y, 2010, CANCER LETT, V290, P24, DOI 10.1016/j.canlet.2009.07.010
   Holla BS, 2006, BIOORGAN MED CHEM, V14, P2040, DOI 10.1016/j.bmc.2005.10.053
   Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746
   KAYMAKCIOGLU KOCYGGGT., 2003, Current Topics Gn Medicinal Chemistry, V3, P121
   Koca I, 2015, ANTI CANCER AGENT ME, V15, P916
   Koca I, 2013, BIOORGAN MED CHEM, V21, P3859, DOI 10.1016/j.bmc.2013.04.021
   Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147 007 0726 2
   Li ZY, 2014, EUR J MED CHEM, V87, P346, DOI 10.1016/j.ejmech.2014.09.078
   Liu RY, 2012, ANESTH ANALG, V114, P947, DOI 10.1213/ANE.0b013e31824c4def
   Lok ASF, 2003, GASTROENTEROLOGY, V125, P1714, DOI 10.1053/j.gastro.2003.09.033
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu YX, 2012, EXPERT OPIN DRUG DIS, V7, P375, DOI 10.1517/17460441.2012.678829
   Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622 200311000 00003
   Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466 1268(2001)006<0105:GTPOAC>2.0.CO;2
   Ozgur A., 2015, ANTI CANCER AGENT ME, V15, P1
   Özgür A, 2015, LETT DRUG DES DISCOV, V12, P180
   Özgür A, 2014, CURR PROTEOMICS, V11, P2, DOI 10.2174/1570164611666140415224635
   Petrut B, 2008, CURR ONCOL, V15, pS50, DOI 10.3747/co.2008.176
   Rodig SJ, 2010, CURR OPIN INVEST DR, V11, P1477
   Sakorafas GH, 2008, CANCER TREAT REV, V34, P483, DOI 10.1016/j.ctrv.2008.03.001
   Sakorafas GH, 2000, CANCER TREAT REV, V26, P103, DOI 10.1053/ctrv.1999.0149
   Sandler Alan, 2003, Oncology (Williston Park), V17, P17
   Sener A, 2004, TURK J CHEM, V28, P659
   Sohn W, 2014, BRIT J CLIN PHARMACO, V78, P477, DOI 10.1111/bcp.12355
   Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092 8674(00)80203 2
   Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656
   Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/eott.7.2.215.23784
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Tutar L, 2010, CURR PHARM BIOTECHNO, V11, P216, DOI 10.2174/138920110790909632
   Virnig BA, 2010, J NATL CANCER I, V102, P170, DOI 10.1093/jnci/djp482
   Zagouri F, 2013, BREAST, V22, P569, DOI 10.1016/j.breast.2013.06.003
   Zhao HP, 2015, EUR J MED CHEM, V89, P442, DOI 10.1016/j.ejmech.2014.10.034
   Zhou WQ, 2005, J MOL STRUC THEOCHEM, V730, P133, DOI 10.1016/j.theochem.2005.06.012
NR 44
TC 38
Z9 41
U1 0
U2 55
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD OCT 21
PY 2016
VL 122
BP 280
EP 290
DI 10.1016/j.ejmech.2016.06.032
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DV5XL
UT WOS:000383003900024
PM 27376491
DA 2025 08 17
ER

PT J
AU Vargas Becerril, N
   Patiño Carachure, C
   Rodriguez Lorenzo, LM
   Téllez Jurado, L
AF Vargas Becerril, Nancy
   Patino Carachure, Cristobal
   Rodriguez Lorenzo, Luis M.
   Tellez Jurado, Lucia
TI Synthesis of hybrid compounds apatite alendronate by reactive milling
   and effects on the structure and morphology of the apatite phase
SO CERAMICS INTERNATIONAL
LA English
DT Article
DE Apatite; Alendronate; Hybrids; Reactive milling
ID HYDROXYAPATITE NANOPARTICLES; CALCIUM PHOSPHATE; BISPHOSPHONATES; BONE;
   DELIVERY; NANOCRYSTALS; MECHANISMS; SYSTEMS; IONS; ACID
AB The preparation of apatite alendronate hybrid materials by reactive milling is proposed in this work. Calcium phosphate compounds of various compositions have been associated to bisphosphonates and found suitable for local application with release kinetics of the drug compatible with the inhibition of bone resorption. Hybrid compounds have been obtained by reactive milling. The compositions used were: AP(X 100), Alendronate(X) where X=7 and X=15. An interaction between the hydroxyl group of the apatite and the amine group of alendronate can be identified with FTIR and enables to confirm the formation of the hybrids. The incorporation of the alendronate hinders the growing of the apatite crystals resulting in smaller coherent domains of diffraction for the apatite phase. (C) 2012 Elsevier Ltd and Techna Group S.r.l. All rights reserved.
C1 [Vargas Becerril, Nancy; Tellez Jurado, Lucia] Natl Politecn Inst, ESIQIE Zacatenco, Mexico City 07738, DF, Mexico.
   [Patino Carachure, Cristobal] UNACAR, Ciudad Del Carmen 24115, Campeche, Mexico.
   [Rodriguez Lorenzo, Luis M.] ICTP CSIC, Biomat Grp, Madrid 28006 3, Spain.
C3 Universidad Autonoma del Carmen; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC   Instituto de Ciencia & Tecnologia de
   Polimeros (ICTP)
RP Vargas Becerril, N (通讯作者)，Natl Politecn Inst, ESIQIE Zacatenco, Mexico City 07738, DF, Mexico.
EM lennon_nancy@hotmail.com
RI Patiño Carachure, Cristobal/AGZ 9935 2022; Téllez Jurado,
   Lucia/R 5387 2018; Rodriguez Lorenzo, Luis/A 1090 2008; Tellez Jurado,
   Lucia/R 5387 2018
OI Rodriguez Lorenzo, Luis M./0000 0002 4816 1087; Tellez Jurado,
   Lucia/0000 0002 5172 0134; Patino Carachure,
   Cristobal/0000 0002 1436 1259
FU CONACyT; National Politecnic Institute IPN, Mexico City; Science and
   Technology Institute of Polymers ITCP, Madrid Spain; CICYT
   [MAT2010 18155]
FX The authors thank the financial support from CONACyT, the National
   Politecnic Institute IPN, Mexico City, and the Science and Technology
   Institute of Polymers ITCP, Madrid Spain, for their support and for
   providing the necessary tools to do this work through CICYT project
   MAT2010 18155.
CR Agougui H., APPL SURFACE SCI, V257, P1377
   Al Ali F, 2005, J COLLOID INTERF SCI, V289, P504, DOI 10.1016/j.jcis.2005.03.095
   [Anonymous], 1994, Structure and Chemistry of the Apatites and Other Calcium Orthophosphates
   Balamurugan A, 2006, CERAM SILIKATY, V50, P27
   Balasundaram G, 2006, BIOMATERIALS, V27, P2798, DOI 10.1016/j.biomaterials.2005.12.008
   Bayle MA, 2008, DENT MATER, V24, P386, DOI 10.1016/j.dental.2007.06.007
   Boanini E, 2007, ADV MATER, V19, P2499, DOI 10.1002/adma.200602497
   Chakraborty S, 2006, J APPL CRYSTALLOGR, V39, P385, DOI 10.1107/S0021889806010351
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   de Campos M, 2007, J MATER SCI MATER M, V18, P669, DOI 10.1007/s10856 006 0006 0
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Gafni G, 1999, J CRYST GROWTH, V205, P618, DOI 10.1016/S0022 0248(99)00282 1
   Sillero MAG, 2006, FEBS LETT, V580, P5723, DOI 10.1016/j.febslet.2006.09.026
   Han YC, 2009, J NANOPART RES, V11, P1235, DOI 10.1007/s11051 008 9507 8
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Juillard A, 2010, BONE, V47, P895, DOI 10.1016/j.bone.2010.07.018
   Koch CC, 2003, REV ADV MATER SCI, V5, P91
   Lazic S, 2001, THERMOCHIM ACTA, V374, P13, DOI 10.1016/S0040 6031(01)00453 1
   Mahabole MP, 2005, B MATER SCI, V28, P535, DOI 10.1007/BF02706339
   Maltezou E., 2010, BIOINORG CHEM APPL, P1
   Martin TJ., 2000, Aust Prescriber, V23, P130
   Martinez Valencia A., 2011, INT J PHYS SCI, V6, P2731, DOI [10.5897/IJPS11.313, DOI 10.5897/IJPS11.313]
   Martins MA, 2008, J COLLOID INTERF SCI, V318, P210, DOI 10.1016/j.jcis.2007.10.008
   Mathew M, 2001, J RES NATL INST STAN, V106, P1035, DOI 10.6028/jres.106.054
   Okada M, 2006, J MATER SCI, V41, P6134, DOI 10.1007/s10853 006 0444 6
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Patashnik S, 1997, J DRUG TARGET, V4, P371, DOI 10.3109/10611869709017894
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Paul W, 1999, J MATER SCI MATER M, V10, P383, DOI 10.1023/A:1008918412198
   Rehman I, 1997, J MATER SCI MATER M, V8, P1, DOI 10.1023/A:1018570213546
   Rodriguez Lorenzo L.M., 2007, J BIOMEDICAL MAT R B, P596
   Rodríguez Lorenzo LM, 2005, KEY ENG MAT, V284 286, P357, DOI 10.4028/www.scientific.net/KEM.284 286.357
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sadat Shojai M, 2009, J IRAN CHEM SOC, V6, P386, DOI 10.1007/BF03245848
   Silva CC, 2003, SOLID STATE SCI, V5, P553, DOI 10.1016/S1293 2558(03)00035 9
   Sridhar TM, 1997, J MATER SCI LETT, V16, P1964, DOI 10.1023/A:1018511406374
   Tamai M, 2007, J ARTIF ORGANS, V10, P22, DOI 10.1007/s10047 006 0363 y
   Wright JEI, 2004, ADV EXP MED BIOL, V553, P139
   Xiao XF, 2008, MATER SCI TECH LOND, V24, P1199, DOI 10.1179/174328407X161088
   Zhu SH, 2004, J NANOPART RES, V6, P307, DOI 10.1023/B:NANO.0000034721.06473.23
   Zhu XD, 2012, J BIOMED MATER RES B, V100B, P516, DOI 10.1002/jbm.b.31978
NR 42
TC 8
Z9 8
U1 0
U2 34
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272 8842
J9 CERAM INT
JI Ceram. Int.
PD MAY
PY 2013
VL 39
IS 4
BP 3921
EP 3929
DI 10.1016/j.ceramint.2012.10.239
PG 9
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 133HI
UT WOS:000318129100060
DA 2025 08 17
ER

PT J
AU Liu, YL
   Cao, R
   Wang, Y
   Oldfield, E
AF Liu, Yi Liang
   Cao, Rong
   Wang, Yang
   Oldfield, Eric
TI Farnesyl Diphosphate Synthase Inhibitors With Unique Ligand Binding
   Geometries
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Farnesyl diphosphate synthase; inhibitor; T. brucei; diamidine
ID NITROGEN CONTAINING BISPHOSPHONATES; ISOPRENOID BIOSYNTHESIS; STRUCTURAL
   BASIS; IN VIVO; PAMIDRONATE; MECHANISM; DISCOVERY; ANALOGS; DRUGS
AB Farnesyl diphosphate synthase (FPPS) is an important drug target for bone resorption, cancer, and some infectious diseases. Here, we report five new structures including two having unique bound ligand geometries. The diamidine inhibitor 7 binds to human FPPS close to the homoallylic (S2) and allosteric (S3) sites and extends into a new site, here called S4. With the bisphosphonate inhibitor 8, two molecules bind to Trypanosoma brucei FPPS, one molecule in the allylic site (Si) and the other close to S2, the first observation of two bisphosphonate molecules bound to FPPS. We also report the structures of apo FPPS from T brucei, together with two more bisphosphonate bound structures (2,9), for purposes of comparison. The diamidine structure is of particular interest because 7 could represent a new lead for lipophilic FPPS inhibitors, while 8 has low micromolar activity against T. brucei, the causative agent of human African trypanosomiasis.
C1 [Liu, Yi Liang; Cao, Rong; Wang, Yang; Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign
RP Oldfield, E (通讯作者)，Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
EM eoldfiel@illinois.edu
RI Cao, Rong/A 7943 2010; Liu, Yiliang/O 8412 2018
OI Cao, Rong/0000 0002 2398 399X
FU United States Public Health Service (NIH) [CA158191]; Harriet A Harlin
   Professorship; University of Illinois Foundation/Oldfield Research Fund;
   U.S. DOE [DE AC02 06CH11357]; Michigan Technology Tri Corridor
   [085P1000817]
FX This work was supported by grants from the United States Public Health
   Service (NIH grant CA158191), a Harriet A Harlin Professorship (E.O.),
   and the University of Illinois Foundation/Oldfield Research Fund. Use of
   the Advanced Photon Source, an Office of Science User Facility operated
   for the U.S. Department of Energy (DOE) Office of Science by Argonne
   National Laboratory, was supported by the U.S. DOE under Contract No.
   DE AC02 06CH11357. Use of the LS CAT Sector 21 was supported by the
   Michigan Economic Development Corporation and the Michigan Technology
   Tri Corridor (Grant 085P1000817).
CR Aaron JA, 2010, PURE APPL CHEM, V82, P1585, DOI 10.1351/PAC CON 09 09 37
   Amstutz R., 2009, U.S. Patent Application, Patent No. 2009052314
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Boissier S, 2000, CANCER RES, V60, P2949
   Chemical Computing Group Inc, 2014, MOL OP ENV MOE 2013
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Lindert S, 2013, CHEM BIOL DRUG DES, V81, P742, DOI 10.1111/cbdd.12121
   Liu CI, 2008, SCIENCE, V319, P1391, DOI 10.1126/science.1153018
   Liu YL, 2014, P NATL ACAD SCI USA, V111, pE2530, DOI 10.1073/pnas.1409061111
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   No JH, 2012, P NATL ACAD SCI USA, V109, P4058, DOI 10.1073/pnas.1118215109
   Oldfield E, 2012, ANGEW CHEM INT EDIT, V51, P1124, DOI 10.1002/anie.201103110
   Oldfield E, 2010, ACCOUNTS CHEM RES, V43, P1216, DOI 10.1021/ar100026v
   POULTER CD, 1977, BIOCHEMISTRY US, V16, P5470, DOI 10.1021/bi00644a012
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Swiezewska E, 2005, PROG LIPID RES, V44, P235, DOI 10.1016/j.plipres.2005.05.002
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Tsagozis P, 2008, CANCER IMMUNOL IMMUN, V57, P1451, DOI 10.1007/s00262 008 0482 9
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
NR 27
TC 20
Z9 21
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948 5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD MAR
PY 2015
VL 6
IS 3
BP 349
EP 354
DI 10.1021/ml500528x
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CD6IP
UT WOS:000351193100024
PM 25815158
OA Green Published
DA 2025 08 17
ER

PT J
AU Hoey, DA
   Tormey, S
   Ramcharan, S
   O'Brien, FJ
   Jacobs, CR
AF Hoey, David A.
   Tormey, Shane
   Ramcharan, Stacy
   O'Brien, Fergal J.
   Jacobs, Christopher R.
TI Primary Cilia Mediated Mechanotransduction in Human Mesenchymal Stem
   Cells
SO STEM CELLS
LA English
DT Article
DE Human mesenchymal stem cell; Primary cilium; Mechanotransduction; Fluid
   flow; Osteogenic Differentiation; Proliferation
ID MARROW STROMAL CELLS; FLOW PERFUSION CULTURE; FLUID SHEAR STRESS;
   BONE MARROW; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION;
   INDUCED PROLIFERATION; NITRIC OXIDE; IN VIVO; INDUCTION
AB Physical loading is a potent stimulus required to maintain bone homeostasis, partly through the renewal and osteogenic differentiation of mesenchymal stem cells (MSCs). However, the mechanism by which MSCs sense a biophysical force and translate that into a biochemical bone forming response (mechanotransduction) remains poorly understood. The primary cilium is a single sensory cellular extension, which has recently been shown to demonstrate a role in cellular mechanotransduction and MSC lineage commitment. In this study, we present evidence that short periods of mechanical stimulation in the form of oscillatory fluid flow (OFF) is sufficient to enhance osteogenic gene expression and proliferation of human MSCs (hMSCs). Furthermore, we demonstrate that the cilium mediates fluid flow mechanotransduction in hMSCs by maintaining OFF induced increases in osteogenic gene expression and, surprisingly, to limit OFF induced increases in proliferation. These data therefore demonstrate a pro osteogenic mechanosensory role for the primary cilium, establishing a novel mechanotransduction mechanism in hMSCs. Based on these findings, the application of OFF may be a beneficial component of bioreactor based strategies to form bone like tissues suitable for regenerative medicine and also highlights the cilium as a potential therapeutic target for efforts to mimic loading with the aim of preventing bone loss during diseases such as osteoporosis. Furthermore, this study demonstrates a role for the cilium in controlling mechanically mediated increases in the proliferation of hMSCs, which parallels proposed models of polycystic kidney disease. Unraveling the mechanisms leading to rapid proliferation of mechanically stimulated MSCs with defective cilia could provide significant insights regarding ciliopathies and cystic diseases. STEM CELLS2012;30:25612570
C1 [Hoey, David A.] Univ Limerick, Dept Mech Aeronaut & Biomed Engn, Ctr Appl Biomed Engn Res, Mat & Surface Sci Inst, Limerick, Ireland.
   [Hoey, David A.; Tormey, Shane; Ramcharan, Stacy; Jacobs, Christopher R.] Columbia Univ City New York, Dept Biomed Engn, New York, NY USA.
   [Hoey, David A.; O'Brien, Fergal J.] Royal Coll Surgeons Ireland, Dept Anat, Dublin 2, Ireland.
   [O'Brien, Fergal J.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin, Ireland.
C3 University of Limerick; Columbia University; Royal College of Surgeons  
   Ireland; Trinity College Dublin
RP Hoey, DA (通讯作者)，Univ Limerick, Dept Mech Aeronaut & Biomed Engn, Ctr Appl Biomed Engn Res, Mat & Surface Sci Inst, Limerick, Ireland.
EM david.hoey@ul.ie
RI Hoey, David/G 3301 2013; Hoey, David/X 9231 2019; O'Brien,
   Fergal/F 9485 2011
OI Hoey, David/0000 0001 5898 0409; O'Brien, Fergal/0000 0003 2030 8005
FU IRCSET Marie Curie International Mobility Fellowship in Science,
   Engineering and Technology; New York State Stem Cell Grant [N089 210];
   NIH [AR45989, AR54156, AR62177]
FX This study was supported by an IRCSET Marie Curie International Mobility
   Fellowship in Science, Engineering and Technology, New York State Stem
   Cell Grant (N089 210) and NIH Grants (AR45989, AR54156, and AR62177).
CR Abdul Majeed S, 2012, CELL MOL LIFE SCI, V69, P165, DOI 10.1007/s00018 011 0744 0
   Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599
   Barou O, 1998, AM J PHYSIOL ENDOC M, V274, pE108, DOI 10.1152/ajpendo.1998.274.1.E108
   Berbari NF, 2009, CURR BIOL, V19, pR526, DOI 10.1016/j.cub.2009.05.025
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bjerre L, 2008, BIOMATERIALS, V29, P2616, DOI 10.1016/j.biomaterials.2008.03.003
   Bjerre L, 2011, J BIOMED MATER RES A, V97A, P251, DOI 10.1002/jbm.a.33051
   Boehlke C, 2010, NAT CELL BIOL, V12, P1115, DOI 10.1038/ncb2117
   Castillo Alesha B, 2010, Curr Osteoporos Rep, V8, P98, DOI 10.1007/s11914 010 0015 2
   Clement CA, 2009, J CELL SCI, V122, P3070, DOI 10.1242/jcs.049676
   Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835
   Cullen DM, 2001, J APPL PHYSIOL, V91, P1971, DOI 10.1152/jappl.2001.91.5.1971
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   Ecker A., 1844, ARCH ANAT PHYSIOL, P520
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Gerasimovskaya EV, 2005, J BIOL CHEM, V280, P1838, DOI 10.1074/jbc.M409466200
   Gurkan UA, 2008, ANN BIOMED ENG, V36, P1978, DOI 10.1007/s10439 008 9577 x
   Hildebrandt F, 2011, NEW ENGL J MED, V364, P1533, DOI 10.1056/NEJMra1010172
   Hoey DA, 2012, J BIOMECH, V45, P17, DOI 10.1016/j.jbiomech.2011.08.008
   Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   James AW, 2010, TISSUE ENG PT A, V16, P2605, DOI [10.1089/ten.tea.2010.0048, 10.1089/ten.TEA.2010.0048]
   Kelly DJ, 2010, BIRTH DEFECTS RES C, V90, P75, DOI 10.1002/bdrc.20173
   Keogh MB, 2011, BIOTECHNOL BIOENG, V108, P1203, DOI 10.1002/bit.23032
   Khan KM, 2009, BRIT J SPORT MED, V43, P247, DOI 10.1136/bjsm.2008.054239
   Kiprilov EN, 2008, J CELL BIOL, V180, P897, DOI 10.1083/jcb.200706028
   Knippenberg M, 2005, TISSUE ENG, V11, P1780, DOI 10.1089/ten.2005.11.1780
   Kreke MR, 2005, BONE, V36, P1047, DOI 10.1016/j.bone.2005.03.008
   Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09 148007
   Lee DY, 2010, J BIOL CHEM, V285, P30, DOI 10.1074/jbc.M109.010512
   Lee HW, 2009, STEM CELLS, V27, P2254, DOI 10.1002/stem.144
   Lee KL, 2010, CLIN REV BONE MINER, V8, P201, DOI 10.1007/s12018 010 9078 y
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   Litzenberger JB, 2010, CALCIFIED TISSUE INT, V86, P325, DOI 10.1007/s00223 010 9343 6
   Liu LY, 2010, BIOMECH MODEL MECHAN, V9, P659, DOI 10.1007/s10237 010 0206 x
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Masyuk AI, 2008, AM J PHYSIOL GASTR L, V295, pG725, DOI 10.1152/ajpgi.90265.2008
   Masyuk AI, 2006, GASTROENTEROLOGY, V131, P911, DOI 10.1053/j.gastro.2006.07.003
   McCoy RJ, 2010, TISSUE ENG PART B RE, V16, P587, DOI [10.1089/ten.teb.2010.0370, 10.1089/ten.TEB.2010.0370]
   McGarry JG, 2005, BIOCHEM BIOPH RES CO, V330, P341, DOI 10.1016/j.bbrc.2005.02.175
   McGlashan SR, 2006, J HISTOCHEM CYTOCHEM, V54, P1005, DOI 10.1369/jhc.5A6866.2006
   Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710 6718.2004
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076
   Nowlan NC, 2010, BIRTH DEFECTS RES C, V90, P203, DOI 10.1002/bdrc.20184
   Plaisant M, 2009, STEM CELLS, V27, P703, DOI 10.1634/stemcells.2008 0888
   Potier E, 2010, J BIOMECH, V43, P807, DOI 10.1016/j.jbiomech.2009.11.019
   Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232 001 0075 4
   Praetorius HA, 2005, ANNU REV PHYSIOL, V67, P515, DOI 10.1146/annurev.physiol.67.040403.101353
   Praetorius HA, 2002, J AM SOC NEPHROL, V13, p739A
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   Riddle RC, 2007, J BONE MINER RES, V22, P589, DOI 10.1359/JBMR.070113
   Rubin CT, 2007, P NATL ACAD SCI USA, V104, P17879, DOI 10.1073/pnas.0708467104
   Scaglione S, 2008, J BIOMED MATER RES A, V86A, P411, DOI 10.1002/jbm.a.31607
   Shao YY, 2012, BONE, V50, P79, DOI 10.1016/j.bone.2011.08.033
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103
   Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534
   Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589
   Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368
   Tjabringa GS, 2006, STEM CELLS, V24, P2262, DOI 10.1634/stemcells.2005 0625
   Tummala P, 2010, CELL MOL BIOENG, V3, P207, DOI 10.1007/s12195 010 0127 x
   Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756 3282(98)00041 6
   Weimbs T, 2007, AM J PHYSIOL RENAL, V293, pF1423, DOI 10.1152/ajprenal.00275.2007
   Whitfield JF, 2009, CELL SIGNAL, V21, P1351, DOI 10.1016/j.cellsig.2009.02.013
   WRONSKI TJ, 1987, AM J PHYSIOL, V252, pR252, DOI 10.1152/ajpregu.1987.252.2.R252
   Xiao ZS, 2010, ANN NY ACAD SCI, V1192, P410, DOI 10.1111/j.1749 6632.2009.05239.x
   Xiao ZS, 2010, J BIOL CHEM, V285, P1177, DOI 10.1074/jbc.M109.050906
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhao F, 2007, BIOTECHNOL BIOENG, V96, P584, DOI 10.1002/bit.21184
   Zimmermann K. W., 1898, Archiv fuer Mikroskopische Anatomie, Vlii, P552
NR 73
TC 137
Z9 157
U1 1
U2 59
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD NOV
PY 2012
VL 30
IS 11
BP 2561
EP 2570
DI 10.1002/stem.1235
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 023ZP
UT WOS:000310077000019
PM 22969057
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wu, CT
   Fan, W
   Zhu, YF
   Gelinsky, M
   Chang, J
   Cuniberti, G
   Albrecht, V
   Friis, T
   Xiao, Y
AF Wu, Chengtie
   Fan, Wei
   Zhu, Yufang
   Gelinsky, Michael
   Chang, Jiang
   Cuniberti, Gianaurelio
   Albrecht, Victoria
   Friis, Thor
   Xiao, Yin
TI Multifunctional magnetic mesoporous bioactive glass scaffolds with a
   hierarchical pore structure
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Magnetic scaffolds; Mesoporous bioactive glasses; Drug delivery;
   Hyperthermia; Bone tumors
ID IN VITRO; BONE; HYPERTHERMIA; BIOCOMPATIBILITY; OSTEOBLASTS; CERAMICS;
   SPHERES
AB Hyperthermia and local drug delivery have been proposed as potential therapeutic approaches for bone defects resulting from malignant bone tumors. The development of bioactive materials with magnetic and drug delivery properties may potentially meet this target. The aim of this study was to develop a multifunctional mesoporous bioactive glass (MEG) scaffold system for both hyperthermic and local drug delivery applications. To this end iron (Fe) containing MBG (Fe MBG) scaffolds with a hierarchical large pores structure (300 500 mu m) and fingerprint like mesopores (4.5 nm) have been prepared. The effects of Fe on the mesopore structure and physiochemical, magnetic, drug delivery and biological properties of MBG scaffolds have been systematically investigated. The results show that the morphology of the mesopores varied from straight channels to curved fingerprint like channels after incorporation of Fe into MBG scaffolds. The magnetism of MEG scaffolds can be tailored by controlling the Fe content. Furthermore, the incorporation of Fe into mesoporous MBG glass scaffolds enhanced the mitochondrial activity and the expression of bone related genes (ALP and OCN) in human bone marrow mesenchymal stem cells (BMSC) attached to the scaffolds. The Fe MBG scaffolds obtained also possessed high specific surface areas and demonstrated sustained drug delivery. Thus Fe MBG scaffolds are magnetic, degradable and bioactive. The multifunctionality of Fe MBG scaffolds suggests that there is great potential for their use in the treatment and regeneration of large bone defects caused by malignant bone tumors through a combination of hyperthermia, local drug delivery and osteoconductivity. (C) 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Wu, Chengtie; Fan, Wei; Friis, Thor; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Wu, Chengtie; Chang, Jiang] Chinese Acad Sci, Shanghai Inst Ceram, Shanghai 200050, Peoples R China.
   [Zhu, Yufang] Univ Shanghai Sci & Technol, Sch Mat Sci & Engn, Shanghai 200093, Peoples R China.
   [Gelinsky, Michael] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Med Fac & Hosp, D 01307 Dresden, Germany.
   [Cuniberti, Gianaurelio] Tech Univ Dresden, Inst Mat Sci, D 01069 Dresden, Germany.
   [Cuniberti, Gianaurelio] Tech Univ Dresden, Max Bergmann Ctr Biomat, D 01069 Dresden, Germany.
   [Albrecht, Victoria] Leibniz Inst Polymer Res Dresden, D 01069 Dresden, Germany.
C3 Queensland University of Technology (QUT); Chinese Academy of Sciences;
   Shanghai Institute of Ceramics, CAS; University of Shanghai for Science
   & Technology; Technische Universitat Dresden; Technische Universitat
   Dresden; Technische Universitat Dresden; Leibniz Institut fur
   Polymerforschung Dresden
RP Wu, CT (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
EM chengtie.wu@qut.edu.au; Yin.Xiao@qut.edu.au
RI Xiao, Yin/AAM 4033 2020; Fan, Wei/W 3408 2018; Cuniberti,
   Gianaurelio/B 7192 2008; Friis, Thor/HTN 2970 2023; Gelinsky,
   Michael/A 9680 2012; Cuniberti, Gianaurelio (Giovanni)/B 7192 2008
OI Xiao, Yin/0000 0003 1785 3491; Gelinsky, Michael/0000 0001 9075 5121;
   Cuniberti, Gianaurelio (Giovanni)/0000 0002 6574 7848
FU Queensland University of Technology; Alexander von Humboldt Foundation,
   Germany
FX The authors thank the Vice chancellor Research Fellowship of Queensland
   University of Technology and the Alexander von Humboldt Foundation,
   Germany, for providing a research grant for this study. We also thank
   Dr. Cheng Song and Dr. Paul Simon for help with the material
   characterization.
CR Alcaide M, 2010, ACTA BIOMATER, V6, P892, DOI 10.1016/j.actbio.2009.09.008
   Andronescu E, 2010, J MATER SCI MATER M, V21, P2237, DOI 10.1007/s10856 010 4076 7
   Arcos D, 2010, ACTA BIOMATER, V6, P2874, DOI 10.1016/j.actbio.2010.02.012
   Bock N, 2010, ACTA BIOMATER, V6, P786, DOI 10.1016/j.actbio.2009.09.017
   Chen QZZ, 2006, BIOMATERIALS, V27, P2414, DOI 10.1016/j.biomaterials.2005.11.025
   Chou YF, 2005, BIOMATERIALS, V26, P285, DOI 10.1016/j.biomaterials.2004.02.030
   ElGhannam A, 1997, BIOMATERIALS, V18, P295, DOI 10.1016/S0142 9612(96)00059 2
   Gong XQ, 2009, ADV FUNCT MATER, V19, P292, DOI 10.1002/adfm.200801315
   Hou CH, 2009, BIOMATERIALS, V30, P3956, DOI 10.1016/j.biomaterials.2009.04.020
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Le Renard PE, 2010, BIOMATERIALS, V31, P691, DOI 10.1016/j.biomaterials.2009.09.091
   Li GD, 2010, MAT SCI ENG C MATER, V30, P148, DOI 10.1016/j.msec.2009.09.011
   Martín Saavedra FM, 2010, ACTA BIOMATER, V6, P4522, DOI 10.1016/j.actbio.2010.06.030
   Meng J, 2010, NANOSCALE, V2, P2565, DOI 10.1039/c0nr00178c
   Miguel BS, 2010, J BIOMED MATER RES A, V94A, P1023, DOI 10.1002/jbm.a.32773
   Parsons AJ, 2004, J BIOMED MATER RES A, V71A, P283, DOI 10.1002/jbm.a.30161
   Schulze T, 2006, INT J HYPERTHER, V22, P301, DOI 10.1080/02656730600665504
   Serrano MC, 2004, BIOMATERIALS, V25, P5603, DOI 10.1016/j.biomaterials.2004.01.037
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   Singh RK, 2009, J MATER SCI MATER M, V20, P147, DOI 10.1007/s10856 008 3497 z
   Tang S., 2010, ADV FUNCT MATER, V20, P1
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Wang TW, 2007, J BIOMED MATER RES A, V83A, P828, DOI 10.1002/jbm.a.31411
   Wu CT, 2007, BIOMATERIALS, V28, P3171, DOI 10.1016/j.biomaterials.2007.04.002
   Wu CT, 2007, J MATER SCI MATER M, V18, P857, DOI [10.1007/s10856 006 0083 0, 10.1007/S10856 006 0083 0]
   Wu CT, 2011, ACTA BIOMATER, V7, P2644, DOI 10.1016/j.actbio.2011.03.009
   Wu CT, 2011, ACTA BIOMATER, V7, P2229, DOI 10.1016/j.actbio.2010.12.019
   Wu CT, 2011, ACTA BIOMATER, V7, P1797, DOI 10.1016/j.actbio.2010.12.018
   Wu CT, 2010, ACTA BIOMATER, V6, P2237, DOI 10.1016/j.actbio.2009.12.022
   Wu CT, 2010, BIOMATERIALS, V31, P3429, DOI 10.1016/j.biomaterials.2010.01.061
   Wu C, 2009, BIOMATERIALS, V30, P2199, DOI 10.1016/j.biomaterials.2009.01.029
   Wu HC, 2010, ADV FUNCT MATER, V20, P67, DOI 10.1002/adfm.200901108
   Xu S, 2008, BIOMATERIALS, V29, P2588, DOI 10.1016/j.biomaterials.2008.03.013
   Yamasaki K, 2009, TOXICOL LETT, V191, P211, DOI 10.1016/j.toxlet.2009.08.023
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Zhu YF, 2008, MICROPOR MESOPOR MAT, V112, P494, DOI 10.1016/j.micromeso.2007.10.029
   Zhu YF, 2010, SMALL, V6, P471, DOI 10.1002/smll.200901403
NR 38
TC 184
Z9 193
U1 3
U2 197
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD OCT
PY 2011
VL 7
IS 10
BP 3563
EP 3572
DI 10.1016/j.actbio.2011.06.028
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 825RZ
UT WOS:000295301100004
PM 21745610
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Zuo, CQ
   Pan, YQ
   Leng, D
   Chen, XJ
   Dong, FH
   Lin, ZY
   Dai, Z
   Wang, ZG
AF Zuo, Changqing
   Pan, Yaqiong
   Leng, Dan
   Chen, Xiuju
   Dong, Fanghongniu
   Lin, Zhanying
   Dai, Zhong
   Wang, Zonggui
TI Transcriptome analysis of long non coding RNAs reveals NR_015556 lncRNA
   is a novel regulator for adipocyte differentiation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE NR_015556; Adipocyte differentiation; Wnt10b; &beta;  catenin
ID ADIPOGENIC DIFFERENTIATION; CELL; OSTEOBLASTOGENESIS; INHIBITION;
   INSIGHTS; BROWN; ALPHA
AB Long non coding RNAs (lncRNAs) have gained extensive attentions due to their significant roles in diverse biological process. However, the potential functions of lncRNAs participation in adipocyte differentiation have not been fully explored. In the present study, we globally profiled lncRNA expression using lncRNA microarray and identified 1745 lncRNA probes with differential expression on day 0 and day 4 post induction in both C3H10T1/2 mesenchymal stem cells and 3T3 L1 preadipocytes. Furthermore, we showed that stable shRNA knockdown (KD) of NR_015556, a novel lncRNA that was signifi cantly down regulated in adipocyte differentiation, promoted adipocyte differentiation by increasing the number of lipid droplets and adipocyte markers such as Fabp4, Adipsin and Fasn. Mechanistically, NR_015556 KD attenuated the expression of Wnt signaling components Wnt10b and non phospho (active) b catenin, and elevated adipocyte master factors Ppar g and C/EBPa levels. Conversely, pharmacological activation of Wnt10b b catenin signaling by LiCl suppressed NR_015556 KD induced enhancement of adipocyte differentiation and Ppar g and C/EBPa expression levels. Taken together, these results indicate that down regulation of NR_015556 promotes adipocyte differentiation through inhibiting Wnt10b b catenin signaling pathway and then elevating Ppar g and C/EBPa triggered transcriptional cascades.(c) 2022 Elsevier Inc. All rights reserved.
C1 [Zuo, Changqing; Pan, Yaqiong; Leng, Dan; Chen, Xiuju; Dong, Fanghongniu; Lin, Zhanying; Dai, Zhong] Guangdong Med Univ, Guangdong Prov Key Lab Res & Dev Nat Drugs, Dongguan 523808, Peoples R China.
   [Zuo, Changqing; Pan, Yaqiong; Leng, Dan; Chen, Xiuju; Dong, Fanghongniu; Lin, Zhanying; Dai, Zhong] Guangdong Med Univ, Sch Pharm, Dongguan 523808, Peoples R China.
   [Zuo, Changqing; Dai, Zhong] Guangdong Med Univ, Key Lab Tradit Chinese Med & New Pharm Dev, Dongguan 523808, Peoples R China.
   [Pan, Yaqiong] Guangdong Med Univ, Dongguan Liaobu Hosp, Dept Pharm, Dongguan 523400, Peoples R China.
   [Wang, Zonggui] Guangdong Med Univ, Dept Biochem & Mol Biol, Guangdong Prov Key Lab Med Mol Diagnost, Dongguan 523808, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University; Guangdong
   Medical University; Guangdong Medical University; Guangdong Medical
   University
RP Dai, Z (通讯作者)，Guangdong Med Univ, Guangdong Prov Key Lab Res & Dev Nat Drugs, Dongguan 523808, Peoples R China.; Dai, Z (通讯作者)，Guangdong Med Univ, Sch Pharm, Dongguan 523808, Peoples R China.; Wang, ZG (通讯作者)，Guangdong Med Univ, Dept Biochem & Mol Biol, 1 Xincheng Ave,Songshan Lake Ind & Tech Pk, Dongguan 523808, Peoples R China.
EM daizhong.gdmu@163.com; wangzonggui@gdmu.edu.cn
FU Guangdong Provincial Natural Science Foundation, China
   [2018A0303130203]; Key Project of Guangdong Medical University
   [GDMUZ201802]; Discipline Construction Project of Guangdong Medical
   University [4SG21002G]; National Innovation Training Program for College
   Students, China [202010571025, 202010571029]
FX This work was supported by Guangdong Provincial Natural Science
   Foundation, China (No. 2018A0303130203), Key Project of Guangdong
   Medical University (No. GDMUZ201802), Discipline Construction Project of
   Guangdong Medical University (No. 4SG21002G), and National Innovation
   Training Program for College Students, China (No. 202010571025,
   202010571029).
CR Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen C, 2018, CELL SIGNAL, V51, P47, DOI 10.1016/j.cellsig.2018.07.012
   Chen J, 2017, INT J OBESITY, V41, P299, DOI 10.1038/ijo.2016.189
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   de Winter TJJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.627429
   Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/s0140 6736(16)30054 x
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580 018 0093 z
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140 6736(05)67483 1
   Hu WQ, 2012, EMBO REP, V13, P971, DOI 10.1038/embor.2012.145
   Jeon M, 2016, BIOCHEM BIOPH RES CO, V479, P22, DOI 10.1016/j.bbrc.2016.08.178
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kang YJ, 2017, NUCLEIC ACIDS RES, V45, pW12, DOI 10.1093/nar/gkx428
   Lai SJ, 2020, DIABET METAB SYND OB, V13, P3193, DOI 10.2147/DMSO.S264830
   Li HX, 2008, MOL CELL ENDOCRINOL, V291, P116, DOI 10.1016/j.mce.2008.05.005
   Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898
   Liu YT, 2018, STEM CELL RES, V32, P35, DOI 10.1016/j.scr.2018.08.016
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Rey F, 2021, OBES REV, V22, DOI 10.1111/obr.13203
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Squillaro T, 2020, ELIFE, V9, DOI 10.7554/eLife.59053
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Wang ZG, 2017, BIOCHEM BIOPH RES CO, V492, P419, DOI 10.1016/j.bbrc.2017.08.083
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Xiao TF, 2015, STEM CELL REP, V5, P856, DOI 10.1016/j.stemcr.2015.09.007
   Zhu ED, 2019, FASEB J, V33, P2396, DOI 10.1096/fj.201800739RRR
NR 30
TC 1
Z9 2
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 23
PY 2022
VL 601
BP 79
EP 85
DI 10.1016/j.bbrc.2022.02.069
EA FEB 2022
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 1I6IX
UT WOS:000797332800012
PM 35231655
DA 2025 08 17
ER

PT J
AU Tsujimoto, M
   Uenaka, K
   Iwata, A
   Higashiuchi, Y
   Sowa, H
AF Tsujimoto, Mika
   Uenaka, Kazunori
   Iwata, Atsuko
   Higashiuchi, Yoshihiro
   Sowa, Hideaki
TI Effects of teriparatide in Japanese and non Japanese populations:
   bridging findings on pharmacokinetics and efficacy
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE ICH E5 guideline; Bridging; Ethnic comparison; Teriparatide; Japan
ID BONE MINERAL DENSITY; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   PARATHYROID HORMONE 1 34; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS;
   ALENDRONATE; BMD; THERAPY; DRUGS; IMPROVEMENTS
AB Teriparatide is an anabolic therapy for osteoporosis approved in the United States since 2002 and European Union since 2003; however, approval in Japan lagged significantly. This report describes analyses based on International Conference on Harmonisation (ICH) E 5 guidelines that support bridging between Japanese studies and the large Fracture Prevention Trial (FPT). We analyzed data from single teriparatide doses in healthy Japanese and Caucasian postmenopausal women (J PK) and from studies of 6 months [Phase 2, dose ranging (J Ph2)] and 12 months [Phase 3, efficacy and safety (J Ph3)] of randomized, placebo controlled, once daily treatment in Japanese subjects with osteoporosis. In J PK, apparent teriparatide area under the curve (AUC) and peak concentration (C max) were up to 40% higher in Japanese versus Caucasian women; however, body weight adjusted values were comparable between populations; these findings were supported by population pharmacokinetic analyses. Between the FPT and Japanese studies, baseline demographic characteristics were similar but bone mineral density (BMD) at lumbar spine (L1 L4) and body weight were lower for Japanese subjects. With teriparatide 20 mu g/day, significant increases in BMD were observed compared to placebo at 12 months in both the FPT and J Ph3 study, and percent change and actual change in BMD were comparable between studies. Dose response at 6 months was also comparable across populations. No novel safety signals were identified in Japanese subjects. These analyses show that teriparatide clinical data met ICH E 5 criteria for bridging. Findings from foreign trials such as the FPT can thus be extrapolated to Japanese subjects treated with teriparatide 20 mu g/day.
C1 [Tsujimoto, Mika; Iwata, Atsuko] Eli Lilly Japan KK, Lilly Res Labs, Dev Ctr Excellence Asia Pacific, Chuo Ku, Kobe, Hyogo 6510086, Japan.
   [Uenaka, Kazunori; Higashiuchi, Yoshihiro; Sowa, Hideaki] Eli Lilly Japan KK, Lilly Res Labs, Dev Ctr Excellence Japan, Kobe, Hyogo 6510086, Japan.
C3 Eli Lilly; Lilly Research Laboratories; Eli Lilly; Lilly Research
   Laboratories
RP Tsujimoto, M (通讯作者)，Eli Lilly Japan KK, Lilly Res Labs, Dev Ctr Excellence Asia Pacific, Chuo Ku, Sannomiya Plaza Bldg,7 1 5 Isogamidori, Kobe, Hyogo 6510086, Japan.
EM Tsujimoto_mika@lilly.com
FU Eli Lilly and Company
FX The studies described in this work were funded by Eli Lilly and Company.
   The authors would like to thank Thomas Melby of i3 Statprobe and Miho
   Hatano of Eli Lilly Japan K. K. for assistance in the preparation of the
   manuscript.
CR [Anonymous], 1998, ETHNIC FACTORS ACCEP
   Boonen S, 2006, J AM GERIATR SOC, V54, P782, DOI 10.1111/j.1532 5415.2006.00695.x
   Chen PQ, 2007, J BONE MINER RES, V22, P1173, DOI 10.1359/JBMR.070413
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Delmas PD, 2002, OSTEOPOROSIS INT, V13, P1, DOI 10.1007/s198 002 8331 3
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Hirai Y, 2010, CLIN PHARMACOL THER, V87, P212, DOI 10.1038/clpt.2009.215
   Iki M, 2001, OSTEOPOROSIS INT, V12, P529, DOI 10.1007/s001980170073
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miyauchi A, 2008, J BONE MINER METAB, V26, P624, DOI 10.1007/s00774 008 0871 3
   Miyauchi A, 2010, BONE, V47, P493, DOI 10.1016/j.bone.2010.05.022
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Orimo H, 1998, J BONE MINER METAB, V16, P139, DOI 10.1007/s007740050038
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Recker RR, 2009, J BONE MINER RES, V24, P1358, DOI [10.1359/jbmr.090315, 10.1359/JBMR.090315]
   Reginster JY, 2006, OSTEOPOROSIS INT, V17, P1, DOI 10.1007/s00198 005 1984 3
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Uusi Rasi K, 2005, BONE, V36, P948, DOI 10.1016/j.bone.2005.03.003
   Uyama Y, 2005, CLIN PHARMACOL THER, V78, P102, DOI 10.1016/j.clpt.2005.04.001
NR 25
TC 19
Z9 21
U1 0
U2 4
PU SPRINGER TOKYO
PI TOKYO
PA 1 11 11 KUDAN KITA, CHIYODA KU, TOKYO, 102 0073, JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2012
VL 30
IS 3
BP 326
EP 337
DI 10.1007/s00774 011 0314 4
PG 12
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 952WL
UT WOS:000304825300008
PM 21938381
DA 2025 08 17
ER

PT J
AU Chen, RX
   Ren, L
   Cai, QW
   Zou, Y
   Fuo, Q
   Ma, YY
AF Chen, Ruixin
   Ren, Lin
   Cai, Qingwei
   Zou, Yang
   Fuo, Qiang
   Ma, Yuanyuan
TI The role of epigenetic modifications in the osteogenic differentiation
   of adipose derived stem cells
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Epigenetic; DNA methylation; histone modification; RNAi; adipose derived
   stem cells; osteogenic differentiation
ID HISTONE DEACETYLASE INHIBITOR; LONG NONCODING RNAS; PROMOTES OSTEOBLAST
   DIFFERENTIATION; DNA METHYLATION; BONE MARROW; ADIPOCYTE
   DIFFERENTIATION; MICRORNA EXPRESSION; STROMAL CELLS; CANCER CELLS;
   TISSUE
AB Over the last decade, stem cells have drawn extensive attention from scientists due to their full potential in tissue engineering, gene therapy, and cell therapy. Adipose derived stem cells (ADSCs), which represent one type of mesenchymal stem cell (MSC), hold great promise in bone tissue engineering due to their painless collection procedure, their ability to self renew and their multi lineage differentiation properties. Major epigenetic mechanisms, which involve DNA methylation, histone modifications and RNA interference (RNAi), are known to represent one of the determining factors of ADSC fate and differentiation. Understanding the epigenetic modifications of ADSCs may provide a clue for improving stem cell therapy in bone repair and regeneration. The aim of this review is to present the recent advances in understanding the epigenetic mechanisms that facilitate ADSC differentiation into an osteogenic lineage, in addition to the characteristics of the main epigenetic modifications.
C1 [Chen, Ruixin; Ren, Lin; Cai, Qingwei; Zou, Yang; Fuo, Qiang; Ma, Yuanyuan] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Prosthodont, Guangzhou, Guangdong, Peoples R China.
   [Chen, Ruixin; Ren, Lin; Cai, Qingwei; Zou, Yang; Fuo, Qiang; Ma, Yuanyuan] Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Ma, YY (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
EM Mayy5@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81300856,81570955];
   Natural Science Foundation of Guangdong Province [2018A030313153]
FX This work was supported by the National Natural Science Foundation of
   China [81300856,81570955], and the Natural Science Foundation of
   Guangdong Province [2018A030313153].
CR Baer PC, 2013, STEM CELLS DEV, V22, P330, DOI 10.1089/scd.2012.0346
   Bánfai B, 2012, GENOME RES, V22, P1646, DOI 10.1101/gr.134767.111
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Berdasco M, 2012, AM J PATHOL, V181, P2079, DOI 10.1016/j.ajpath.2012.08.016
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bloushtain Qimron N, 2009, CELL CYCLE, V8, P809, DOI 10.4161/cc.8.6.7938
   Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev biochem 052610 091920
   Chen JR, 2012, FASEB J, V26, P1131, DOI 10.1096/fj.11 197822
   Chen J, 2014, CURR STEM CELL RES T, V9, P268, DOI 10.2174/1574888X09666140213203309
   Chen S, 2017, STEM CELL REP, V8, P773, DOI 10.1016/j.stemcr.2017.01.028
   Cheng XD, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018747
   Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0426 x
   Delgado Calle J, 2011, BONE, V49, P830, DOI 10.1016/j.bone.2011.06.006
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Eslaminejad MB, 2013, CELL J, V15, P1
   Fan C, 2016, STEM CELL REP, V7, P236, DOI 10.1016/j.stemcr.2016.06.010
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   Freitas CS, 2006, CELL TISSUE RES, V325, P403, DOI 10.1007/s00441 006 0172 x
   Gao Y, 2018, J CELL BIOCHEM, V119, P6986, DOI 10.1002/jcb.26907
   Ge WS, 2014, BIOMATERIALS, V35, P6015, DOI 10.1016/j.biomaterials.2014.04.055
   Gimble JM, 2012, REGEN MED, V7, P225, DOI [10.2217/RME.11.119, 10.2217/rme.11.119]
   Gudas LJ, 2013, SEMIN CELL DEV BIOL, V24, P701, DOI 10.1016/j.semcdb.2013.08.002
   Hao J, 2015, ACTA BIOMATER, V20, P1, DOI 10.1016/j.actbio.2015.04.008
   Heilmeier U, 2016, J BONE MINER RES, V31, P2173, DOI 10.1002/jbmr.2897
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Heo JB, 2011, SCIENCE, V331, P76, DOI 10.1126/science.1197349
   Hodges WM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122597
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Hu XQ, 2014, DEV GROWTH DIFFER, V56, P206, DOI 10.1111/dgd.12119
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang B, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0018 0
   Huang GX, 2017, CELL PHYSIOL BIOCHEM, V42, P1037, DOI 10.1159/000478751
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Ibrahim AEK, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl551
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jin CY, 2017, CELL BIOL INT, V41, P33, DOI 10.1002/cbin.10697
   Jin CY, 2016, STEM CELLS, V34, P2707, DOI 10.1002/stem.2439
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lagarkova MA, 2006, CELL CYCLE, V5, P416, DOI 10.4161/cc.5.4.2440
   Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004
   Lande Diner L, 2007, J BIOL CHEM, V282, P12194, DOI 10.1074/jbc.M607838200
   Lee HS, 2015, NUTRIENTS, V7, P9492, DOI 10.3390/nu7115467
   Leppert S, 2014, CURR PHARM DESIGN, V20, P1812, DOI 10.2174/13816128113199990534
   Leto BA, 2013, BIOMED RES INT, V2013
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Li G, 2013, CELL PROLIFERAT, V46, P586, DOI 10.1111/cpr.12053
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li J, 2015, BONE, V78, P130, DOI 10.1016/j.bone.2015.05.003
   Li SS, 2016, CALCIFIED TISSUE INT, V99, P174, DOI 10.1007/s00223 016 0137 3
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Liao YH, 2014, BIOMATERIALS, V35, P4901, DOI 10.1016/j.biomaterials.2014.02.055
   Liu L, 2011, J CELL BIOL, V193, P257, DOI 10.1083/jcb.201010131
   Liu SX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101770
   Liu YS, 2016, J BIOMED NANOTECHNOL, V12, P1270, DOI 10.1166/jbn.2016.2254
   Lu CH, 2013, BIOTECHNOL ADV, V31, P1695, DOI 10.1016/j.biotechadv.2013.08.015
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Luzi E, 2012, NUCLEIC ACID THER, V22, P103, DOI 10.1089/nat.2012.0344
   Lv LW, 2015, BIOMATERIALS, V39, P193, DOI 10.1016/j.biomaterials.2014.11.002
   Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604
   Maroni P, 2012, BIOCHEM BIOPH RES CO, V428, P271, DOI 10.1016/j.bbrc.2012.10.044
   Maunakea AK, 2010, CIRC RES, V107, P327, DOI 10.1161/CIRCRESAHA.110.222463
   McCauley BS, 2014, BBA GENE REGUL MECH, V1839, P1454, DOI 10.1016/j.bbagrm.2014.05.008
   Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076
   Nagy C, 2015, EPIGENOMICS UK, V7, P781, DOI 10.2217/epi.15.46
   Nakatsuka R, 2010, ARCH ORAL BIOL, V55, P350, DOI 10.1016/j.archoralbio.2010.03.003
   Huynh NCN, 2017, BONE, V95, P76, DOI 10.1016/j.bone.2016.11.017
   Nie SB, 2016, BIOCHEM BIOPH RES CO, V470, P61, DOI 10.1016/j.bbrc.2015.12.115
   Noer A, 2006, MOL BIOL CELL, V17, P3543, DOI 10.1091/mbc.E06 04 0322
   Ohbo Kazuyuki, 2015, BioMolecular Concepts, V6, P1, DOI 10.1515/bmc 2014 0036
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qureshi AT, 2015, ACTA BIOMATER, V12, P166, DOI 10.1016/j.actbio.2014.10.010
   Ravid Orly, 2014, Stem Cell Res Ther, V5, P139, DOI 10.1186/scrt529
   Rivera C, 2014, BBA GENE REGUL MECH, V1839, P1433, DOI 10.1016/j.bbagrm.2014.03.009
   Rosenbluth EM, 2013, FERTIL STERIL, V99, P855, DOI 10.1016/j.fertnstert.2012.11.001
   Sachs PC, 2012, CELL TISSUE RES, V349, P505, DOI 10.1007/s00441 012 1423 7
   Saldanha SN, 2015, INT J MOL MED, V17, P1, DOI DOI 10.3390/ijms17010016
   Samsonraj RM, 2018, STEM CELL TRANSL MED, V7, P197, DOI 10.1002/sctm.17 0086
   Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018 016 2174 5
   Senarath Yapa K, 2014, INT J MOL SCI, V15, P9314, DOI 10.3390/ijms15069314
   Shen Y, 2016, J CELL MOL MED, V20, P537, DOI 10.1111/jcmm.12755
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Strauss S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051264
   Su GH, 2000, CANCER RES, V60, P3137
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Teven CM, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/201371
   Tian YL, 2015, J SURG RES, V198, P127, DOI 10.1016/j.jss.2015.04.071
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Vincent A, 2009, DIFFERENTIATION, V78, P99, DOI 10.1016/j.diff.2009.07.002
   Vivek K, 2014, INDIAN J PLAST SURG, V47, P386, DOI 10.4103/0970 0358.146604
   Vlaikou AM, 2017, BBA MOL CELL RES, V1864, P1371, DOI 10.1016/j.bbamcr.2017.05.005
   Wang CD, 2017, EXP CELL RES, V352, P346, DOI 10.1016/j.yexcr.2017.02.021
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Xie Q, 2017, SCI REP UK, V7, DOI 10.1038/srep42840
   Xie Q, 2016, BIOMATERIALS, V75, P279, DOI 10.1016/j.biomaterials.2015.10.042
   Xu LL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0716 x
   Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846
   Yang XM, 2010, ARCH MED SCI, V6, P152, DOI 10.5114/aoms.2010.13886
   Yi JY, 2019, CELL TISSUE RES, V376, P113, DOI 10.1007/s00441 018 2963 2
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zeng Y, 2012, FEBS LETT, V586, P2375, DOI 10.1016/j.febslet.2012.05.049
   Zhang RP, 2011, J BIOL CHEM, V286, P41083, DOI 10.1074/jbc.M111.258715
   Zhang WB, 2014, BONE, V58, P59, DOI 10.1016/j.bone.2013.09.015
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhang YF, 2018, GENE, V650, P41, DOI 10.1016/j.gene.2018.01.054
   Zhou GS, 2009, CYTOTECHNOLOGY, V60, P11, DOI 10.1007/s10616 009 9203 2
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
   Zych J, 2013, BRAZ J MED BIOL RES, V46, P405, DOI 10.1590/1414 431X20132893
NR 119
TC 9
Z9 9
U1 1
U2 27
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD NOV 2
PY 2019
VL 60
IS 6
BP 507
EP 520
DI 10.1080/03008207.2019.1593395
EA JUN 2019
PG 14
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA IS8VA
UT WOS:000478131100001
PM 31203665
DA 2025 08 17
ER

PT J
AU Govindarajan, P
   Khassawna, T
   Kampschulte, M
   Böcker, W
   Huerter, B
   Dürselen, L
   Faulenbach, M
   Heiss, C
AF Govindarajan, Parameswari
   Khassawna, Thaqif
   Kampschulte, Marian
   Boecker, Wolfgang
   Huerter, Britta
   Duerselen, Lutz
   Faulenbach, Miriam
   Heiss, Christian
TI Implications of combined ovariectomy and glucocorticoid (dexamethasone)
   treatment on mineral, microarchitectural, biomechanical and matrix
   properties of rat bone
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE animal model; dexamethasone; extracellular matrix; the micro CT;
   OVX Steroid; rats
ID INDUCED OSTEOPOROSIS; TRABECULAR BONE; CORTICAL BONE; ANIMAL MODEL;
   PREDNISOLONE; MECHANISMS; EXPRESSION; RESORPTION; OSTEOPENIA; FRACTURE
AB Osteoporosis is one of the deleterious side effects of long term glucocorticoid therapy. Since the condition is particularly aggressive in postmenopausal women who are on steroid therapy, in this study we have attempted to analyse the combined effect of glucocorticoid (dexamethasone) treatment and cessation of oestrogen on rat bone. The dual aim was to generate osteoporotic bone status in a short time scale and to characterise the combination of glucocorticoid postmenopausal osteoporotic conditions. Sprague Dawley rats (N=42) were grouped randomly into three groups: untreated control, sham operated and ovariectomized steroid (OVX Steroid) rats. Control animals were euthanized with no treatment [Month 0 (M0)], while sham and OVX Steroid rats were monitored up to 1month (M1) and 3months (M3) post laparotomy/post OVX Steroid treatment. Histology, dual energy X ray absorptiometry (DXA), micro computed tomography (micro CT), and biomechanical and mRNA expression analysis of collagenous, non collagenous matrix proteins and osteoclast markers were examined. The study indicated enhanced osteoclastogenesis and significantly lower bone mineral density (BMD) in the OVX Steroid rats with Z scores below  2.5, reduced torsional strength, reduced bone volume (BV/TV%), significantly enhanced trabecular separation (Tb.S), and less trabecular number (Tb.N) compared with sham rats. Osteoclast markers, cathepsin K and MMP 9 were upregulated along with Col11 and biglycan with no significant expression variation in fibronectin, MMP 14, LRP 5, Car II and TNC. These results show higher bone turnover with enhanced bone resorption accompanied with reduced torsional strength in OVX Steroid rats; and these changes were attained within a short timeframe. This could be a useful model which mimics human postmenopausal osteoporosis that is associated with steroid therapy and could prove of value both in disease diagnosis and for testing generating and testing biological agents which could be used in treatment.
C1 [Govindarajan, Parameswari; Khassawna, Thaqif; Huerter, Britta; Heiss, Christian] Univ Giessen, Lab Expt Trauma Surg, D 35390 Giessen, Germany.
   [Kampschulte, Marian; Faulenbach, Miriam] Univ Hosp Giessen Marburg, Dept Radiol, D 35385 Giessen, Germany.
   [Boecker, Wolfgang; Heiss, Christian] Univ Hosp Giessen Marburg, Dept Trauma Surg, D 35385 Giessen, Germany.
   [Duerselen, Lutz] Univ Ulm, Ctr Musculoskeletal Res Ulm, Inst Orthoped Res & Biomech, D 89069 Ulm, Germany.
C3 Justus Liebig University Giessen; University Hospital of Giessen &
   Marburg; University Hospital of Giessen & Marburg; Ulm University
RP Heiss, C (通讯作者)，Univ Hosp Giessen Marburg, Dept Trauma Surg, Rudolf Buchheim Str 7, D 35385 Giessen, Germany.
EM christian.heiss@chiru.med.uni giessen.de
RI khassawna, Thaqif/J 9748 2013; Durselen, Lutz/B 9447 2012; El khassawna,
   Thaqif/J 9748 2013; Dürselen, Lutz/B 9447 2012
OI Durselen, Lutz/0000 0002 5470 5423; El khassawna,
   Thaqif/0000 0002 1187 8578; 
FU Deutsche Forschungsgemeinschaft (DFG) [SFB/TRR 79, T1]
FX This study was solely funded by the Deutsche Forschungsgemeinschaft
   (DFG) (SFB/TRR 79, T1).
CR Aris RM, 1996, CHEST, V109, P1176, DOI 10.1378/chest.109.5.1176
   Blake GM, 2007, POSTGRAD MED J, V83, P509, DOI 10.1136/pgmj.2007.057505
   Butler JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 210
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Canto M, 1993, INT J ANTHR, V8, P205
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   COATES TD, 1983, BLOOD, V62, P1070
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Dallas S. L., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P370
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Francisco JI, 2011, J ORTHOP RES, V29, P189, DOI 10.1002/jor.21217
   Fraser LA, 2009, THER ADV MUSCULOSKEL, V1, P71, DOI 10.1177/1759720X09343729
   French DL, 2008, PHYTOMEDICINE, V15, P1069, DOI 10.1016/j.phymed.2008.06.007
   GEUSENS P, 1990, CALCIFIED TISSUE INT, V47, P243, DOI 10.1007/BF02555926
   GOULDING A, 1988, ENDOCRINOLOGY, V122, P482, DOI 10.1210/endo 122 2 482
   Hao YJ, 2007, BONE, V41, P631, DOI 10.1016/j.bone.2007.06.006
   Heiss C, 2012, MED SCI MONITOR, V18, pBR199, DOI 10.12659/MSM.882895
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Iwamoto J, 2006, EXP ANIM TOKYO, V55, P349, DOI 10.1538/expanim.55.349
   Jagtap VR, 2011, INDIAN J CLIN BIOCHE, V26, P70, DOI 10.1007/s12291 010 0074 2
   Kalpakcioglu BB, 2011, BONE, V48, P1221, DOI 10.1016/j.bone.2011.02.005
   Kim MH, 2009, LIFE SCI, V85, P146, DOI 10.1016/j.lfs.2009.05.013
   Kwok L. K., 2008, RHEUM DIS, V8, P12
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Lill CA, 2002, OSTEOPOROSIS INT, V13, P407, DOI 10.1007/s001980200047
   Liu XL, 2012, MED ENG PHYS, V34, P2, DOI 10.1016/j.medengphy.2011.06.010
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   Lu L, 2012, CELL BIOL TOXICOL, V28, P279, DOI 10.1007/s10565 012 9222 1
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756 3282(02)00737 8
   Nielsen KL, 2003, J BONE MINER RES, V18, P2152, DOI 10.1359/jbmr.2003.18.12.2152
   Ogoshi T, 2008, MOD RHEUMATOL, V18, P552, DOI 10.1007/s10165 008 0096 2
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Shefrin AE, 2009, CAN FAM PHYSICIAN, V55, P704
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914 012 0103 6
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   van Brussel MS, 2009, EXPERT OPIN PHARMACO, V10, P997, DOI [10.1517/14656560902868225 , 10.1517/14656560902868225]
   Vashishth Deepak, 2007, Curr Osteoporos Rep, V5, P62
   Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220
   Waddington R. J., 2003, European Cells & Materials, V6, P12
   WEILER HA, 1995, AM J CLIN NUTR, V61, P805, DOI 10.1093/ajcn/61.4.805
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   YAMAUCHI H, 1995, J BONE MINER RES, V10, P1033
   Yeh JK, 1996, BONE, V18, P443, DOI 10.1016/8756 3282(96)00045 2
   Young MF, 2003, OSTEOPOROSIS INT, V14, pS35, DOI 10.1007/s00198 002 1342 7
   Zarrinkalam MR, 2009, EUR SPINE J, V18, P244, DOI 10.1007/s00586 008 0813 8
   Zhao H, 1997, J Tongji Med Univ, V17, P28
NR 50
TC 34
Z9 38
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0959 9673
EI 1365 2613
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD DEC
PY 2013
VL 94
IS 6
BP 387
EP 398
DI 10.1111/iep.12038
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 295QK
UT WOS:000330130400004
PM 23998329
OA Green Published
DA 2025 08 17
ER

PT J
AU Henney, NC
   Li, B
   Elford, C
   Reviriego, P
   Campbell, AK
   Wann, KT
   Evans, BAJ
AF Henney, Neil C.
   Li, Bo
   Elford, Carole
   Reviriego, Pablo
   Campbell, Anthony K.
   Wann, Kenneth T.
   Evans, Bronwen A. J.
TI A large conductance (BK) potassium channel subtype affects both growth
   and mineralization of human osteoblasts
SO AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY
LA English
DT Article
DE MG63 cells; bone; potassium current; tetrandrine
ID CA2+ ACTIVATED K+ CHANNELS; MESENCHYMAL STEM CELLS; ION CHANNELS;
   GLUTAMATE RECEPTORS; RAT OSTEOBLASTS; EXPRESSION; KINASE; PROLIFERATION;
   TETRANDRINE; ACTIVATION
AB Henney NC, Li B, Elford C, Reviriego P, Campbell AK, Wann KT, Evans BA. A large conductance (BK) potassium channel subtype affects both growth and mineralization of human osteoblasts. Am J Physiol Cell Physiol 297: C1397 C1408, 2009. First published September 23, 2009; doi:10.1152/ajpcell.00311.2009. The pharmacology of the large conductance K+ (BK) channel in human osteoblasts is not well defined, and its role in bone is speculative. Here we assess BK channel properties in MG63 cells and primary human osteoblasts and determine whether pharmacological modulation affects cell function. We used RT PCR and patch clamp methods to determine the expression of BK channel subunits and cell number assays in the absence and presence of BK channel modulators. RT PCR showed the presence of KCNMA1, KCNMB1, KCNMB2, KCNMB3, and KCNMB4 subunits. The BK channel was voltage dependent, with a mean unitary conductance of 228.8 pS (n = 10) in cell attached patches (140 mM K+/140 mM K+) and a conductance of 142.5 pS (n = 16) in excised outside out and 155 pS (n = 6) in inside out patches in 3 mM K+/140 mM K+. The selectivity ratio (ratio of K+ to Na+ permeability) was 15:1. The channel was blocked by tetraethylammonium (TEA, 0.3 mM), iberiotoxin (5 60 nM), tetrandrine (5 30 mu M), and paxilline (10 mu M) and activated by isopimaric acid (20 mu M). BK channel modulators affected MG63 cell numbers: TEA and tetrandrine significantly increased cell numbers at low concentrations (3 mM and 3 mu M, respectively) and reduced cell numbers at higher concentrations (>10 mM and >10 mu M, respectively). Neither iberiotoxin (20   300 nM) nor slotoxin (300 nM) affected cell numbers. The increase in cell numbers by TEA was blocked by isopimaric acid. TEA (0.1 3.0 mM) significantly increased mineralization in primary osteoblasts. In conclusion, the BK channel has a distinctive pharmacology and is thus a target for therapeutic strategies aimed at modulating osteoblast proliferation and function.
C1 [Henney, Neil C.; Li, Bo; Reviriego, Pablo; Wann, Kenneth T.] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales.
   [Elford, Carole; Evans, Bronwen A. J.] Cardiff Univ, Dept Child Hlth, Sch Med, Cardiff CF10 3NB, S Glam, Wales.
   [Campbell, Anthony K.] Cardiff Univ, Dept Med Biochem & Immunol, Sch Med, Cardiff CF10 3NB, S Glam, Wales.
C3 Cardiff University; Cardiff University; Cardiff University
RP Wann, KT (通讯作者)，Cardiff Univ, Welsh Sch Pharm, Redwood Bldg,King Edward VII Ave, Cardiff CF10 3NB, S Glam, Wales.
EM wann@cardiff.ac.uk
RI Wann, Kenneth/M 8153 2014; Campbell, Anthony/N 5855 2014
OI Wann, Kenneth/0000 0002 7235 7610; Campbell,
   Anthony/0000 0002 2506 5500; 
FU Welsh School of Pharmacy; Welsh Development Agency Engineering and
   Physical Sciences Research Council; Overseas Research Student Award
FX N. C. Henney was supported by a Welsh School of Pharmacy studentship and
   P. Reviriego by a Welsh Development Agency Engineering and Physical
   Sciences Research Council studentship. B. Li is supported by an Overseas
   Research Student Award.
CR Burg ED, 2006, J MEMBRANE BIOL, V209, P3, DOI 10.1007/s00232 005 0838 4
   CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006 3495(92)81630 2
   Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010
   Chapman H, 2007, BRAIN RES, V1129, P15, DOI 10.1016/j.brainres.2006.10.060
   Davies JH, 2002, BONE, V31, P319, DOI 10.1016/S8756 3282(02)00822 0
   Deng XL, 2007, CELL PROLIFERAT, V40, P656, DOI 10.1111/j.1365 2184.2007.00458.x
   DUNCAN RL, 1994, AM J PHYSIOL RENAL, V267, pF909, DOI 10.1152/ajprenal.1994.267.6.F909
   Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021
   Gu Y, 2002, CALCIFIED TISSUE INT, V70, P194, DOI 10.1007/s00223 001 2004 z
   Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200
   Harbour ME, 2000, PEDIATR RES, V48, P163, DOI 10.1203/00006450 200008000 00008
   Hattori T, 2001, CELL CALCIUM, V30, P67, DOI 10.1054/ceca.2001.0214
   Hirukawa K, 2008, CALCIFIED TISSUE INT, V83, P222, DOI 10.1007/s00223 008 9167 9
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   Hughes S, 2006, J CELL PHYSIOL, V206, P738, DOI 10.1002/jcp.20536
   Imaizumi Y, 2002, MOL PHARMACOL, V62, P836, DOI 10.1124/mol.62.4.836
   Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024
   Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232 005 0781 4
   Lehenkari P, 2003, J BONE MINER RES, V18, P473, DOI 10.1359/jbmr.2003.18.3.473
   LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094
   Li GR, 2005, STEM CELLS, V23, P371, DOI 10.1634/stemcells.2004 0213
   Li GR, 2006, STEM CELLS, V24, P1519, DOI 10.1634/stemcells.2005 0307
   Lippiat JD, 2003, J MEMBRANE BIOL, V192, P141, DOI 10.1007/s00232 002 1070 0
   Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597
   Moreau R, 1996, J MEMBRANE BIOL, V150, P175, DOI 10.1007/s002329900042
   Moreau R, 1997, J BONE MINER RES, V12, P1984, DOI 10.1359/jbmr.1997.12.12.1984
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   RAVESLOOT JH, 1990, J BONE MINER RES, V5, P1201
   REINHART PH, 1991, J NEUROSCI, V11, P1627
   REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896 6273(89)90227 4
   Rezzonico R, 2003, J BONE MINER RES, V18, P1863, DOI 10.1359/jbmr.2003.18.10.1863
   Rezzonico R, 2002, J BONE MINER RES, V17, P869, DOI 10.1359/jbmr.2002.17.5.869
   RICHTER C, 1991, BONE MINER, V15, P57, DOI 10.1016/0169 6009(91)90110 L
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Steinert M, 1997, J PHYSIOL LONDON, V500, P653, DOI 10.1113/jphysiol.1997.sp022050
   TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896 6273(94)90418 9
   WANG G, 1992, PFLUG ARCH EUR J PHY, V421, P558, DOI 10.1007/BF00375051
   WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460 9568.1994.tb00305.x
   Wann KT, 2004, J BONE MINER RES, V19, P1051
   WANN KT, 2004, J PHYSL P, V555, pPC59
   Weskamp M, 2000, J MEMBRANE BIOL, V178, P11, DOI 10.1007/s002320010010
   Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135
   Wu SN, 2003, CURR MED CHEM, V10, P649, DOI 10.2174/0929867033457863
   Wu SN, 1997, EUR J PHARMACOL, V327, P233, DOI 10.1016/S0014 2999(97)89666 5
   Yellowley CE, 1998, CALCIFIED TISSUE INT, V62, P122, DOI 10.1007/s002239900405
   Zanello LP, 2006, STEROIDS, V71, P291, DOI 10.1016/j.steroids.2005.09.012
NR 46
TC 45
Z9 49
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363 6143
EI 1522 1563
J9 AM J PHYSIOL CELL PH
JI Am. J. Physiol. Cell Physiol.
PD DEC
PY 2009
VL 297
IS 6
BP C1397
EP C1408
DI 10.1152/ajpcell.00311.2009
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 524PV
UT WOS:000272156100010
PM 19776394
OA Green Published
DA 2025 08 17
ER

PT J
AU Fahmy Garcia, S
   Farrell, E
   Witte Bouma, J
   Robbesom van den Berge, I
   Suarez, M
   Mumcuoglu, D
   Wailes, H
   Kluijtmans, SGJM
   van der Eerden, BCJ
   van Osch, GJVM
   van Leeuwen, JPTM
   van Driel, M
AF Fahmy Garcia, Shorouk
   Farrell, Eric
   Witte Bouma, Janneke
   Robbesom van den Berge, Iris
   Suarez, Melva
   Mumcuoglu, Didem
   Wailes, Heike
   Kluijtmans, Sebastiaan G. J. M.
   van der Eerden, Bram C. J.
   van Osch, Gerjo J. V. M.
   van Leeuwen, Johannes P. T. M.
   van Driel, Marjolein
TI Follistatin Effects in Migration, Vascularization, and Osteogenesis
   in vitro and Bone Repair in vivo
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE follistatin 315 (FST315); follistatin 288 (FST288); migration;
   vascularization; osteogenesis; injectable in situ gelling slow release
   system; bone tissue engineering; regenerative medicine
ID ACTIVIN BINDING PROTEIN; TGF BETA; ENDOTHELIAL CELLS; POTENT REGULATOR;
   RECEPTOR; MYOSTATIN; MUSCLE; OSTEOBLAST; ISOFORMS; COMPLEX
AB The use of biomaterials and signaling molecules to induce bone formation is a promising approach in the field of bone tissue engineering. Follistatin (FST) is a glycoprotein able to bind irreversibly to activin A, a protein that has been reported to inhibit bone formation. We investigated the effect of FST in critical processes for bone repair, such as cell recruitment, osteogenesis and vascularization, and ultimately its use for bone tissue engineering. In vitro, FST promoted mesenchymal stem cell (MSC) and endothelial cell (EC) migration as well as essential steps in the formation and expansion of the vasculature such as EC tube formation and sprouting. FST did not enhance osteogenic differentiation of MSCs, but increased committed osteoblast mineralization. In vivo, FST was loaded in an in situ gelling formulation made by alginate and recombinant collagen based peptide microspheres and implanted in a rat calvarial defect model. Two FST variants (FST288 and FST315) with major differences in their affinity to cell surface proteoglycans, which may influence their effect upon in vivo bone repair, were tested. In vitro, most of the loaded FST315 was released over 4 weeks, contrary to FST288, which was mostly retained in the biomaterial. However, none of the FST variants improved in vivo bone healing compared to control. These results demonstrate that FST enhances crucial processes needed for bone repair. Further studies need to investigate the optimal FST carrier for bone regeneration.
C1 [Fahmy Garcia, Shorouk; Mumcuoglu, Didem; van Osch, Gerjo J. V. M.] Univ Med Ctr, Erasmus MC, Dept Orthoped, Rotterdam, Netherlands.
   [Fahmy Garcia, Shorouk; Robbesom van den Berge, Iris; van der Eerden, Bram C. J.; van Leeuwen, Johannes P. T. M.; van Driel, Marjolein] Univ Med Ctr, Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Farrell, Eric; Witte Bouma, Janneke] Univ Med Ctr, Erasmus MC, Dept Oral & Maxillofacial Surg, Rotterdam, Netherlands.
   [Suarez, Melva; Wailes, Heike] Julius Maximillians Univ Wurzburg, Inst Tissue Engn & Regenerat Med, Wurzburg, Germany.
   [Mumcuoglu, Didem; Kluijtmans, Sebastiaan G. J. M.] Fujifilm Mfg Europe BV, Tilburg, Netherlands.
   [van Osch, Gerjo J. V. M.] Univ Med Ctr, Erasmus MC, Dept Otorhinolaryngol Head & Neck Surg, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of
   Wurzburg; Fujifilm Corporation; Erasmus University Rotterdam; Erasmus MC
RP Farrell, E (通讯作者)，Univ Med Ctr, Erasmus MC, Dept Oral & Maxillofacial Surg, Rotterdam, Netherlands.
EM e.farrell@erasmusmc.nl
RI ; Farrell, Eric/J 9379 2012; van Leeuwen, Johannes/D 5015 2014; van der
   Eerden, Bram/I 7496 2012
OI Mumcuoglu, Didem/0000 0002 3920 7514; Witte Bouma,
   Janneke/0000 0002 1833 1321; Farrell, Eric/0000 0001 6886 6693; van
   Leeuwen, Johannes/0000 0002 2282 4006; van der Eerden,
   Bram/0000 0003 4403 6497
FU European Union [607051]
FX The research leading to these results has received funding from the
   European Union Seventh Framework Programme FP7 PEOPLE 2013 ITN under
   grant agreement no 607051.
CR Abe Y, 2004, J BONE MINER RES, V19, P1302, DOI 10.1359/JBMR.040408
   Abe Y, 2004, GROWTH FACTORS, V22, P105, DOI 10.1080/08977190410001704688
   Alves RDAM, 2013, MOL CELL PROTEOMICS, V12, P2890, DOI 10.1074/mcp.M112.024927
   Barakat B, 2008, REPRODUCTION, V136, P345, DOI 10.1530/REP 08 0140
   Bialek P, 2014, BONE, V60, P162, DOI 10.1016/j.bone.2013.12.002
   Bowser M, 2013, EXP GERONTOL, V48, P290, DOI 10.1016/j.exger.2012.11.004
   Cash JN, 2012, MOL ENDOCRINOL, V26, P1167, DOI 10.1210/me.2012 1061
   CHIBA H, 1993, JPN J CANCER RES, V84, P290, DOI 10.1111/j.1349 7006.1993.tb02869.x
   Datta Mannan A, 2013, J PHARMACOL EXP THER, V344, P616, DOI 10.1124/jpet.112.201491
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Endo D, 2004, J HEPATOL, V40, P399, DOI 10.1016/j.jhep.2003.11.019
   Fahmy Garcia S, 2018, TISSUE ENG PT A, V24, P207, DOI [10.1089/ten.tea.2016.0537, 10.1089/ten.TEA.2016.0537]
   Fajardo RJ, 2010, BONE, V46, P64, DOI 10.1016/j.bone.2009.09.018
   Funaba M, 1996, ENDOCRINOLOGY, V137, P4250, DOI 10.1210/en.137.10.4250
   Gajos Michniewicz A, 2010, BIOMARKERS, V15, P563, DOI 10.3109/1354750X.2010.495786
   Gajos Michniewicz A, 2012, J BONE MINER METAB, V30, P426, DOI 10.1007/s00774 011 0347 8
   Gao XW, 2007, FEBS LETT, V581, P5505, DOI 10.1016/j.febslet.2007.10.059
   Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432 1327.2000.01325.x
   Glister C, 2004, REPRODUCTION, V127, P239, DOI 10.1530/rep.1.00090
   GRUBER HE, 1992, BIOTECH HISTOCHEM, V67, P30, DOI 10.3109/10520299209110002
   Hashimoto O, 2000, CELL SIGNAL, V12, P565, DOI 10.1016/S0898 6568(00)00099 1
   Hedger MP, 2011, VITAM HORM, V85, P255, DOI 10.1016/B978 0 12 385961 7.00013 5
   Hinck AP, 2013, STRUCTURE, V21, P1269, DOI 10.1016/j.str.2013.07.015
   INOUE S, 1994, CALCIFIED TISSUE INT, V55, P395, DOI 10.1007/BF00299321
   Kawao N, 2018, J CELL PHYSIOL, V233, P1191, DOI 10.1002/jcp.25986
   Kirsch T, 2000, FEBS LETT, V468, P215, DOI 10.1016/S0014 5793(00)01214 X
   Kleinhans C, 2013, BIOTECHNOL J, V8, P327, DOI 10.1002/biot.201200210
   Koseki T, 2002, CELL SIGNAL, V14, P31, DOI 10.1016/S0898 6568(01)00221 2
   Kozian DH, 1997, LAB INVEST, V76, P267
   KOZIAN DH, 1995, BIOCHEM BIOPH RES CO, V209, P1068, DOI 10.1006/bbrc.1995.1606
   Kretlow JD, 2009, ADV MATER, V21, P3368, DOI 10.1002/adma.200802009
   Krneta J, 2006, CANCER RES, V66, P5686, DOI 10.1158/0008 5472.CAN 05 3821
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   Maeshima A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/376191
   Maeshima K, 2004, ENDOCRINOLOGY, V145, P3739, DOI 10.1210/en.2004 0213
   MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0
   Mumcuoglu D, 2018, EUR CELLS MATER, V35, P242, DOI 10.22203/eCM.v035a17
   Mumcuoglu D, 2018, MAT SCI ENG C MATER, V84, P271, DOI 10.1016/j.msec.2017.11.031
   Nagamine T, 1998, J ORTHOPAED RES, V16, P314, DOI 10.1002/jor.1100160307
   NAKAMURA T, 1991, J BIOL CHEM, V266, P19432
   Ogino H, 2008, CLIN CANCER RES, V14, P660, DOI 10.1158/1078 0432.CCR 07 1221
   Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357 2725(98)00064 8
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169
   Poon B, 2016, J PHARM PHARMACOL, V68, P139, DOI 10.1111/jphp.12506
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   SAKAI R, 1993, BIOCHEM BIOPH RES CO, V195, P39, DOI 10.1006/bbrc.1993.2006
   Schneyer A, 2003, ENDOCRINOLOGY, V144, P1671, DOI 10.1210/en.2002 0203
   Schneyer AL, 2004, J CLIN ENDOCR METAB, V89, P5067, DOI 10.1210/jc.2004 0162
   Sidis Y, 2001, J BIOL CHEM, V276, P17718, DOI 10.1074/jbc.M100736200
   Sidis Y, 2006, ENDOCRINOLOGY, V147, P3586, DOI 10.1210/en.2006 0089
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008
   Venkatesan J, 2015, INT J BIOL MACROMOL, V72, P269, DOI 10.1016/j.ijbiomac.2014.07.008
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yaden BC, 2014, J PHARMACOL EXP THER, V349, P355, DOI 10.1124/jpet.113.211169
   Zhu JH, 2011, AM J PATHOL, V179, P915, DOI 10.1016/j.ajpath.2011.04.008
NR 59
TC 19
Z9 23
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAR 1
PY 2019
VL 7
AR 38
DI 10.3389/fbioe.2019.00038
PG 14
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA HN3TR
UT WOS:000460107700001
PM 30881954
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, Y
   Li, HJ
   Luo, XC
   Liu, HH
   Zhong, YM
   Wu, X
   Liu, XG
AF Chen, Yang
   Li, Haijun
   Luo, Xiaochao
   Liu, Huahui
   Zhong, Yumei
   Wu, Xiao
   Liu, Xuguang
TI Moxibustion of Zusanli (ST36) and Shenshu (BL23) Alleviates Cartilage
   Degradation through RANKL/OPG Signaling in a Rabbit Model of Rheumatoid
   Arthritis
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID BONE EROSION; OSTEOPROTEGERIN; DISEASE; DIFFERENTIATION; INFLAMMATION
AB Rheumatoid arthritis (RA) is a systemic and chronic autoimmune inflammatory disease characterized by severe synovial hyperplasia associated with progressive cartilage degradation. Due to the severe pain and disability caused by RA, effective therapeutic strategies that could simultaneously alleviate the inflammatory response and delay the disease progression are urgently needed. As a major alternative therapy in traditional Chinese medicine, moxibustion has been demonstrated that it could reduce the chronic inflammatory responses of a series of musculoskeletal diseases; however, whether moxibustion has protective effects on RA is still unclear. To investigate the effects of moxibustion on RA, moxibustion was applied to Zusanli (ST36) and Shenshu (BL23) acupoints in a RA rabbit model. HE staining of articular cartilage showed that moxibustion alleviated the cartilage degradation and bone destruction. In addition, moxibustion decreased the osteoclast number in RA rabbits. Real time PCR revealed that moxibustion decreased the expression of RANKL mRNA while increased the expression of OPG mRNA, indicating a restoration of the balance between osteogenesis and osteoclastogenesis. Taken together, our results indicated that moxibustion had promising antiarthritic effects and could be an useful alternative method in RA therapeutics.
C1 [Chen, Yang; Luo, Xiaochao; Liu, Huahui; Zhong, Yumei; Liu, Xuguang] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Sichuan, Peoples R China.
   [Li, Haijun] Peoples Hosp Qingbaijiang Dist Chengdu City, Chengdu 610300, Sichuan, Peoples R China.
   [Wu, Xiao] Southwest Med Univ, Chinese Med Hosp, Luzhou 646000, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Southwest Medical
   University
RP Liu, XG (通讯作者)，Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Sichuan, Peoples R China.
EM m18782948954@163.com; lihaijun109@163.com; lxclxc6089@yahoo.com;
   Ferrari2@163.com; zhongyumei1205@163.com; 29434230@qq.com;
   lxg@cdutcm.edu.cn
FU National Natural Science Foundation of China [81674068]
FX This work was supported by grants from the National Natural Science
   Foundation of China (no. 81674068).
CR Alamanos Y, 2006, SEMIN ARTHRITIS RHEU, V36, P182, DOI 10.1016/j.semarthrit.2006.08.006
   Baum R, 2014, CURR OSTEOPOROS REP, V12, P9, DOI 10.1007/s11914 013 0183 y
   Bolon B, 2015, VET PATHOL, V52, P873, DOI 10.1177/0300985815586221
   Cheng Cisong, 2015, Zhongguo Zhen Jiu, V35, P397
   Deng HY, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/379291
   Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727
   Finckh A, 2006, ANN RHEUM DIS, V65, P746, DOI 10.1136/ard.2005.045062
   Gaffo A, 2006, AM J HEALTH SYST PH, V63, P2451, DOI 10.2146/ajhp050514
   Haynes D, 2008, ARTHRIT RHEUM ARTHR, V59, P911, DOI 10.1002/art.23818
   Ideguchi H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1943
   Josef S., 1909, BRIT MED J, V1, P1120
   Kim TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101973
   Klemp M., 2010, BIOL EARLY RHEUMATOI
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee HY, 2006, ARTHRITIS RHEUM US, V54, P1747, DOI 10.1002/art.21873
   Li Z., 2003, Experimental acupuncture., P314
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Megeff C E, 2000, J Fam Pract, V49, P108
   Neog MK, 2017, BIOFACTORS, V43, P698, DOI 10.1002/biof.1377
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott DL, 2000, RHEUMATOLOGY, V39, P122, DOI 10.1093/rheumatology/39.2.122
   Silman AJ, 2002, ARTHRITIS RES THER, V4, pS265, DOI 10.1186/ar578
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   van Tuyl LHD, 2010, ANN RHEUM DIS, V69, P1623, DOI 10.1136/ard.2009.121764
   Venkatesha SH, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/986797
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wei Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/214683
   Xu Shu Jun, 2012, Zhongguo Zhen Jiu, V32, P769
   Yang Han Qi, 2013, Zhen Ci Yan Jiu, V38, P134
   Yi T, 2016, NEURAL REGEN RES, V11, P610, DOI 10.4103/1673 5374.180746
   Zhao Yingxia, 2002, J Tradit Chin Med, V22, P67
NR 32
TC 23
Z9 30
U1 0
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2019
VL 2019
AR 6436420
DI 10.1155/2019/6436420
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA HH5IE
UT WOS:000455758900001
PM 30719064
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Nowak, WN
   Taha, H
   Kachamakova Trojanowska, N
   Stepniewski, J
   Markiewicz, JA
   Kusienicka, A
   Szade, K
   Szade, A
   Bukowska Strakova, K
   Hajduk, K
   Klóska, D
   Kopacz, A
   Grochot Przeczek, A
   Barthenheier, K
   Cauvin, C
   Dulak, J
   Józkowicz, A
AF Nowak, Witold Norbert
   Taha, Hevidar
   Kachamakova Trojanowska, Neli
   Stepniewski, Jacek
   Markiewicz, Joanna Agata
   Kusienicka, Anna
   Szade, Krzysztof
   Szade, Agata
   Bukowska Strakova, Karolina
   Hajduk, Karolina
   Kloska, Damian
   Kopacz, Aleksandra
   Grochot Przeczek, Anna
   Barthenheier, Kathrin
   Cauvin, Camille
   Dulak, Jozef
   Jozkowicz, Alicja
TI Murine Bone Marrow Mesenchymal Stromal Cells Respond Efficiently to
   Oxidative Stress Despite the Low Level of Heme Oxygenases 1 and 2
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
DE stem cells; antioxidant gene response; heme; mesenchymal stem cell
ID PLURIPOTENT STEM CELLS; ENDOTHELIAL CELLS; CARBON MONOXIDE;
   GROWTH FACTOR; UP REGULATION; NITRIC OXIDE; DIFFERENTIATION;
   ANTIOXIDANT; EXPRESSION; BACH1
AB Aims: Mesenchymal stromal cells (MSCs) are heterogeneous cells from adult tissues that are able to differentiate in vitro into adipocytes, osteoblasts, or chondrocytes. Such cells are widely studied in regenerative medicine. However, the success of cellular therapy depends on the cell survival. Heme oxygenase 1 (HO 1, encoded by the Hmox1 gene), an enzyme converting heme to biliverdin, carbon monoxide, and Fe2+, is cytoprotective and can affect stem cell performance. Therefore, our study aimed at assessing whether Hmox1 is critical for survival and functions of murine bone marrow MSCs.
   Results: Both MSC Hmox1(+/+) and Hmox1( / ) showed similar phenotype, differentiation capacities, and production of cytokines or growth factors. Hmox1(+/+) and Hmox1( / ) cells showed similar survival in response to 50 mu mol/L hemin even in increased glucose concentration, conditions that were unfavorable for Hmox1( / ) bone marrow derived proangiogenic cells (BDMC). Hmox1(+/+) MSCs but not fibroblasts retained low ROS levels even after prolonged incubation with 50mol/L hemin, although both cell types have a comparable Hmox1 expression and similarly increase its levels in response to hemin. MSCs Hmox1( / ) treated with hemin efficiently induced expression of a vast panel of antioxidant genes, especially enzymes of the glutathione pathway.
   Innovation and Conclusion: Hmox1 overexpression is a popular strategy to enhance viability and performance of MSCs after the transplantation. However, murine MSCs Hmox1( / ) do not differ from wild type MSCs in phenotype and functions. MSC Hmox1( / ) show better resistance to hemin than fibroblasts and BDMCs and rapidly react to the stress by upregulation of quintessential genes in antioxidant response. Antioxid. Redox Signal. 00, 000 000.
C1 [Nowak, Witold Norbert; Taha, Hevidar; Kachamakova Trojanowska, Neli; Stepniewski, Jacek; Markiewicz, Joanna Agata; Kusienicka, Anna; Szade, Krzysztof; Szade, Agata; Bukowska Strakova, Karolina; Hajduk, Karolina; Kloska, Damian; Kopacz, Aleksandra; Grochot Przeczek, Anna; Barthenheier, Kathrin; Cauvin, Camille; Dulak, Jozef; Jozkowicz, Alicja] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Med Biotechnol, Ul Gronostajowa 7, PL 30387 Krakow, Poland.
   [Taha, Hevidar] Univ Duhok, Dept Anim Prod, Coll Agr, Duhok, Iraq.
   [Bukowska Strakova, Karolina] Jagiellonian Univ, Inst Pediat, Dept Clin Immunol, Med Coll, Krakow, Poland.
   [Dulak, Jozef] Kardiomed Silesia, Zabrze, Poland.
C3 Jagiellonian University; University of Duhok; Jagiellonian University;
   Collegium Medicum Jagiellonian University
RP Józkowicz, A (通讯作者)，Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Med Biotechnol, Ul Gronostajowa 7, PL 30387 Krakow, Poland.
EM alicja.jozkowicz@uj.edu.pl
RI Szade, Krzysztof/AIF 3657 2022; Szade, Agata/E 7328 2018;
   Kachamakova Trojanowska, Neli/K 3776 2019; Bukowska Strakova,
   Karolina/HGF 0752 2022; Kopacz, Aleksandra/AAZ 1889 2020; Kusienicka,
   Anna/GYU 6079 2022
OI Szade, Krzysztof/0000 0002 7227 4276; Kachamakova Trojanowska,
   Neli/0000 0002 3226 0726; Kusienicka, Anna/0000 0003 0933 2610; Nowak,
   Witold/0000 0002 1526 3511; Grochot Przeczek, Anna/0000 0003 0533 7254;
   Kloska, Damian/0000 0003 3206 5493; Kopacz,
   Aleksandra/0000 0003 0335 8238; Szade, Agata/0000 0002 0575 4659;
   Markiewicz Mizera, Joanna/0000 0002 4168 9049
FU Polish National Science Centre [2013/11/N/NZ3/00958,
   2013/11/N/NZ1/02399, 2015/18/NZ3/00387]; European Union under the
   European Regional Development Fund Operational Programme Innovative
   Economy [POIG 01.02.01 109/09]; National Centre for Research and
   Development (STRATEGMED) [2/269415/11/NCBR/2015]; Foundation for Polish
   Science (FNP); Ministry of Science and Higher Education
FX This work was supported by the Polish National Science Centre (grants
   2013/11/N/NZ3/00958, 2013/11/N/NZ1/02399, 2015/18/NZ3/00387), the
   European Union under the European Regional Development Fund Operational
   Programme Innovative Economy 2007 2013 (POIG 01.02.01 109/09), and the
   grant from the National Centre for Research and Development (STRATEGMED
   (2/269415/11/NCBR/2015). WNN was supported by the Foundation for Polish
   Science (FNP). The Faculty of Biochemistry, Biophysics and Biotechnology
   of Jagiellonian University is a partner of the Leading National Research
   Center (KNOW) that is supported by the Ministry of Science and Higher
   Education. Servier Medical Art image bank was used to prepare Figure 5A.
CR Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Benzie IFF, 1999, METHOD ENZYMOL, V299, P15
   Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev cellbio 100913 013132
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chabannes D, 2007, BLOOD, V110, P3691, DOI 10.1182/blood 2007 02 075481
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dulak J, 2008, CIRCULATION, V117, P231, DOI 10.1161/CIRCULATIONAHA.107.698316
   Eggenhofer E, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00297
   Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015
   Fisher AB, 2011, ANTIOXID REDOX SIGN, V15, P831, DOI 10.1089/ars.2010.3412
   Florczyk U, 2014, ANTIOXID REDOX SIGN, V20, P1693, DOI 10.1089/ars.2013.5219
   Foresti R, 2003, BIOCHEM J, V372, P381, DOI 10.1042/BJ20021516
   Grochot Przeczek A, 2014, ANTIOXID REDOX SIGN, V20, P1677, DOI 10.1089/ars.2013.5426
   Grundemar L, 1997, TRENDS PHARMACOL SCI, V18, P193, DOI 10.1016/S0165 6147(97)90622 2
   Hamedi Asl P, 2012, CELL STRESS CHAPERON, V17, P181, DOI 10.1007/s12192 011 0298 y
   Ho PJ, 2013, ANTIOXID REDOX SIGN, V18, P1895, DOI 10.1089/ars.2012.4692
   Hou CL, 2013, BIOMATERIALS, V34, P112, DOI 10.1016/j.biomaterials.2012.09.022
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jaishankar A, 2009, STEM CELLS DEV, V18, P793, DOI 10.1089/scd.2008.0156
   Józkowicz A, 2003, ACTA BIOCHIM POL, V50, P69, DOI 10.18388/abp.2003_3715
   Kasper G, 2009, STEM CELLS, V27, P1288, DOI 10.1002/stem.49
   Kim KB, 2014, ANIM CELLS SYST, V18, P318, DOI 10.1080/19768354.2014.950605
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Kozakowska M, 2012, ANTIOXID REDOX SIGN, V16, P113, DOI 10.1089/ars.2011.3964
   Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004
   Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003
   Lee CH, 2010, J CLIN INVEST, V120, P3340, DOI 10.1172/JCI43230
   Lin CY, 2012, STEM CELLS DEV, V21, P1675, DOI 10.1089/scd.2011.0304
   Lin TH, 2010, J CELL PHYSIOL, V222, P757, DOI 10.1002/jcp.22008
   Mabuchi Y, 2013, STEM CELL REP, V1, P152, DOI 10.1016/j.stemcr.2013.06.001
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008 5472.CAN 08 0943
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Mougiakakos D, 2011, BLOOD, V117, P4826, DOI 10.1182/blood 2010 12 324038
   Munakata H, 2004, J BIOCHEM, V136, P233, DOI 10.1093/jb/mvh112
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Nowak WN, 2014, J DIABETES INVEST, V5, P99, DOI 10.1111/jdi.12131
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Puri N, 2012, J CELL BIOCHEM, V113, P1926, DOI 10.1002/jcb.24061
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Schmid I, 2007, NAT PROTOC, V2, P187, DOI 10.1038/nprot.2006.458
   Sedlak TW, 2009, P NATL ACAD SCI USA, V106, P5171, DOI 10.1073/pnas.0813132106
   Stachurska A, 2013, MOL NUTR FOOD RES, V57, P504, DOI 10.1002/mnfr.201200456
   Starzyski RR, 2012, BIOCHEM J, V449, P69
   Stepniewski J, 2015, SCI REP UK, V5, DOI 10.1038/srep08597
   STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864
   Su J, 2014, CELL DEATH DIFFER, V21, P388, DOI 10.1038/cdd.2013.149
   Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516
   Taha H, 2010, ARTERIOSCL THROM VAS, V30, P1634, DOI 10.1161/ATVBAHA.110.207316
   Tsubokawa T, 2010, AM J PHYSIOL HEART C, V298, pH1320, DOI 10.1152/ajpheart.01330.2008
   Valle Prieto A, 2010, STEM CELLS DEV, V19, P1885, DOI 10.1089/scd.2010.0093
   Vanella L, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt176
   Vanella L, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/890671
   Vanella L, 2011, PROSTAG OTH LIPID M, V96, P54, DOI 10.1016/j.prostaglandins.2011.07.005
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wagner W, 2006, EXP HEMATOL, V34, P536, DOI 10.1016/j.exphem.2006.01.002
   Warnatz HJ, 2011, J BIOL CHEM, V286, P23521, DOI 10.1074/jbc.M111.220178
   Was H, 2011, FREE RADICAL BIO MED, V51, P1717, DOI 10.1016/j.freeradbiomed.2011.07.025
   Wojakowski W, 2012, THROMB HAEMOSTASIS, V108, P464, DOI 10.1160/TH12 05 0303
   Zarjou A, 2011, AM J PHYSIOL RENAL, V300, pF254, DOI 10.1152/ajprenal.00594.2010
   Zarjou A, 2009, J AM SOC NEPHROL, V20, P1254, DOI 10.1681/ASN.2008070788
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou HL, 2006, STEM CELLS DEV, V15, P79, DOI 10.1089/scd.2006.15.79
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 68
TC 17
Z9 18
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523 0864
EI 1557 7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUL
PY 2018
VL 29
IS 2
BP 111
EP 127
DI 10.1089/ars.2017.7097
EA JAN 2018
PG 17
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GJ2QJ
UT WOS:000419356500001
PM 29065700
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Scariano, JK
   Emery Cohen, AJ
   Pickett, GG
   Morgan, M
   Simons, PC
   Alba, F
AF Scariano, John K.
   Emery Cohen, Alexandra J.
   Pickett, Gavin G.
   Morgan, Marilee
   Simons, Peter C.
   Alba, Frances
TI Estrogen receptors alpha (ESR1) and beta (ESR2) are expressed in
   circulating human lymphocytes
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE estrogen; estrogen receptor; estrogen receptor beta; lymphocytes
ID BONE LOSS; THERAPY
AB Bone marrow thymocytes in part mediate the bone preserving effects of estrogen by decreasing their production of osteoclast growth factors such as interleukin 1 and  6 and tumor necrosis factor alpha in the presence of physiological amounts of estradiol. Although several in vitro studies implicate the T lymphocyte as a candidate mediator of estrogen signaling in the skeleton, whether these cells or any lymphocytes ordinarily express one or both nuclear estrogen receptors was previously unresolved. The purpose of our investigation was therefore to ascertain, by using real time PCR, immmunoblotting, and cytometric techniques, if any of the nuclear estrogen receptors could be detected in normal peripheral blood mononuclear cells (PBMNC) collected from healthy volunteers. The results of immunoblotting experiments revealed that both estrogen receptor alpha (ESR1) and beta (ESR2) proteins are expressed in nuclei, but not in the cytoplasm of PBMNC harvested from all of the 15 healthy male and female volunteers (aged 23 50 years) we tested. PBMNCs contained mRNA coding for the two major full length isoforms of ESR2 and the expression of ESR2 protein was localized within a lymphocyte sub population by cytometric analysis. Our data provide further evidence that lymphocytes and monocytes are responsive to estrogen and underscore its importance in modulating the immune response, as well as the vascular and skeletal health of men and women.
C1 [Scariano, John K.] Univ New Mexico, Dept Internal Med, Med Lab Sci, Albuquerque, NM 87131 USA.
   [Scariano, John K.; Emery Cohen, Alexandra J.; Simons, Peter C.] Univ New Mexico, Dept Pathol, Sch Med, Albuquerque, NM 87131 USA.
   [Pickett, Gavin G.; Morgan, Marilee] Univ New Mexico, Keck UNM Genom Resource, Sch Med, Albuquerque, NM 87131 USA.
   [Scariano, John K.] Univ New Mexico, Dept Pathol, Med Lab Sci, Albuquerque, NM 87131 USA.
   [Alba, Frances] Univ New Mexico, Sch Med, Dept Surg, Albuquerque, NM 87131 USA.
   [Alba, Frances] Univ New Mexico, Sch Med, Dept Urol, Albuquerque, NM 87131 USA.
C3 University of New Mexico; University of New Mexico; University of New
   Mexico; University of New Mexico; University of New Mexico; University
   of New Mexico
RP Scariano, JK (通讯作者)，1 Univ New Mexico, Dept Pathol, Med Lab Sci, MSC09 5250, Albuquerque, NM 87131 USA.
EM Jscariano@salud.unm.edu
CR Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873
   Imamov O, 2005, BIOL REPROD, V73, P866, DOI 10.1095/biolreprod.105.043497
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1443, DOI 10.1210/jc.87.4.1443
   Lakoski SG, 2005, CLIMACTERIC, V8, P317, DOI 10.1080/13697130500345109
   Leung YK, 2006, P NATL ACAD SCI USA, V103, P13162, DOI 10.1073/pnas.0605676103
   Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062
   Miller AP, 2003, HYPERTENSION, V42, P657, DOI 10.1161/01.HYP.0000085560.02979.0C
   Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738
   Mor G, 2003, J IMMUNOL, V170, P114, DOI 10.4049/jimmunol.170.1.114
   Nancy P, 2005, ENDOCRINOLOGY, V146, P2345, DOI 10.1210/en.2004 1003
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Shim GJ, 2006, J PATHOL, V208, P408, DOI 10.1002/path.1883
   Shim GJ, 2003, P NATL ACAD SCI USA, V100, P6694, DOI 10.1073/pnas.0731830100
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Stirone C, 2003, AM J PHYSIOL ENDOC M, V284, pE184, DOI 10.1152/ajpendo.00165.2002
   Takao T, 2005, J ENDOCRINOL, V184, P191, DOI 10.1677/joe.1.05914
   ZAFAR N, 2004, MOL ENDOCRINOL, V18, P493
NR 20
TC 31
Z9 38
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1079 9893
EI 1532 4281
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PY 2008
VL 28
IS 3
BP 285
EP 293
DI 10.1080/10799890802084614
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 314WK
UT WOS:000256839700007
PM 18569528
DA 2025 08 17
ER

PT J
AU Abney, KK
   Galipeau, J
AF Abney, Kristopher K.
   Galipeau, Jacques
TI Aryl hydrocarbon receptor in mesenchymal stromal cells: new frontiers in
   AhR biology
SO FEBS JOURNAL
LA English
DT Article
DE aryl hydrocarbon receptor; cell therapy; mesenchymal stromal cells
ID REGULATORY T CELLS; STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   INTERNATIONAL SOCIETY; IFN GAMMA; WILD TYPE; ACTIVATION; TRANSCRIPTION;
   LIGAND; PROTEIN
AB Mesenchymal stromal cells (MSCs) are nonhematopoietic cells that have been clinically explored as investigational cellular therapeutics for tissue injury regeneration and immune mediated diseases. Their pharmaceutical properties arise from activation of endogenous receptors and transcription factors leading to a paracrine effect which mirror the biology of progenitors from which they arise. The aryl hydrocarbon receptor (AhR) is a transcription factor that has been extensively studied as an environmental sensor for xenobiotics, but recent findings suggest it can modulate immunological functions. Both genetic and pharmacological investigations revealed that MSCs express AhR and that it plays roles in inflammation, immunomodulation, and mesodermal plasticity of endogenous MSCs. Further, AhR has been shown to interact with key signaling cascades associated with these conditions. Therefore, AhR has potential to be an attractive target in both endogenous and culture adapted MSCs for novel therapeutics to treat inflammation and other age related disorders.
C1 [Abney, Kristopher K.; Galipeau, Jacques] Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
   [Abney, Kristopher K.; Galipeau, Jacques] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Galipeau, J (通讯作者)，Univ Wisconsin, Dept Med, Madison, WI 53705 USA.; Galipeau, J (通讯作者)，Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA.
EM jgalipeau@wisc.edu
RI Galipeau, Jacques/R 9909 2019
OI Galipeau, Jacques/0000 0002 9374 1996
FU National Institutes of Health, National Institute of Diabetes and
   Digestive and Kidney Diseases award [R01DK109508]
FX This work was supported by National Institutes of Health, National
   Institute of Diabetes and Digestive and Kidney Diseases award
   R01DK109508 to JG.
CR A Ghezi ZZ, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02349
   Apetoh L, 2010, NAT IMMUNOL, V11, P854, DOI 10.1038/ni.1912
   Bara JJ, 2014, STEM CELLS, V32, P1713, DOI 10.1002/stem.1649
   Bilezikian JP, 1998, NEW ENGL J MED, V339, P599, DOI 10.1056/NEJM199808273390905
   Bravo Ferrer I, 2019, FASEB J, V33, P12644, DOI 10.1096/fj.201901333R
   BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185
   Cox MB, 2004, CELL STRESS CHAPERON, V9, P4, DOI 10.1379/1466 1268(2004)009<0004:COHSPA>2.0.CO;2
   Cui Z, 2020, J IMMUNOTOXICOL, V17, P21, DOI 10.1080/1547691X.2019.1706671
   da Silva ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932
   Denison MS, 2002, CHEM BIOL INTERACT, V141, P3, DOI 10.1016/S0009 2797(02)00063 7
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   DiNatale BC, 2010, TOXICOL SCI, V115, P89, DOI 10.1093/toxsci/kfq024
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   El Refaey M, 2017, J BONE MINER RES, V32, P2182, DOI 10.1002/jbmr.3224
   EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006 291X(92)91185 S
   Fader KA, 2018, TOXICOL APPL PHARM, V348, P85, DOI 10.1016/j.taap.2018.04.013
   Farahani RM, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/362753
   Farmahin R, 2016, BIOCHEM PHARMACOL, V115, P134, DOI 10.1016/j.bcp.2016.06.005
   FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381
   FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609
   FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Goncalves K, 2019, NEUROLOGY, V92
   Harstad EB, 2006, MOL PHARMACOL, V69, P1534, DOI 10.1124/mol.105.020107
   Hinden L, 2015, STEM CELLS, V33, P2256, DOI 10.1002/stem.2026
   Hogan CJ, 1997, BLOOD, V90, P85
   Hoque MM, 2019, BLOOD RES, V54, P253, DOI 10.5045/br.2019.54.4.253
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Ichihara S, 2019, ARCH TOXICOL, V93, P1543, DOI 10.1007/s00204 019 02446 1
   ISRAEL DI, 1983, J BIOL CHEM, V258, P390
   ISRAEL DI, 1984, J BIOL CHEM, V259, P5400
   Izawa T, 2016, J IMMUNOL, V197, P4639, DOI 10.4049/jimmunol.1600822
   Kabat M, 2020, STEM CELL TRANSL MED, V9, P17, DOI 10.1002/sctm.19 0202
   Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519
   Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594 2607.2001
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Khan S, 2006, MOL ENDOCRINOL, V20, P2199, DOI 10.1210/me.2006 0100
   Kim DS, 2018, EBIOMEDICINE, V28, P261, DOI 10.1016/j.ebiom.2018.01.002
   Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945
   Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004
   Kimura A, 2014, INT IMMUNOL, V26, P209, DOI 10.1093/intimm/dxt067
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kondrikov D, 2020, EXP GERONTOL, V130, DOI 10.1016/j.exger.2019.110805
   Korkalainen M, 2009, BONE, V44, P1134, DOI 10.1016/j.bone.2009.02.019
   Lewis HC, 2017, ONCOTARGET, V8, P91914, DOI 10.18632/oncotarget.20166
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li XM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150551
   Liu XZ, 2020, TOXICOLOGY, V431, DOI 10.1016/j.tox.2019.152353
   Ma Q, 1997, J BIOL CHEM, V272, P8878
   Mabuchi Y, 2016, INT J HEMATOL, V103, P138, DOI 10.1007/s12185 015 1921 y
   Matthews Jason, 2006, Nucl Recept Signal, V4, pe016
   Mellor AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01360
   Memari B, 2015, J IMMUNOL, V195, P4479, DOI 10.4049/jimmunol.1501141
   Mendicino M, 2014, CELL STEM CELL, V14, P141, DOI 10.1016/j.stem.2014.01.013
   Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978
   Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670
   Miettinen HM, 2005, TOXICOL SCI, V85, P1003, DOI 10.1093/toxsci/kfi136
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nagy SR, 2002, TOXICOL SCI, V65, P200, DOI 10.1093/toxsci/65.2.200
   Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006 2952(99)00310 X
   Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Pedrazza L, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0734 8
   Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129
   Pollenz RS, 2000, MOL CELL BIOL, V20, P6095, DOI 10.1128/MCB.20.16.6095 6104.2000
   PROBST MR, 1993, MOL PHARMACOL, V44, P511
   Procházková J, 2011, TOXICOL SCI, V122, P349, DOI 10.1093/toxsci/kfr129
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671
   Rodríguez Sosa M, 2005, FEBS LETT, V579, P6403, DOI 10.1016/j.febslet.2005.10.023
   Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731
   Sekine H, 2009, MOL CELL BIOL, V29, P6391, DOI 10.1128/MCB.00337 09
   Shi C, 2011, IMMUNITY, V34, P590, DOI 10.1016/j.immuni.2011.02.016
   Singh NP, 2016, J IMMUNOL, V196, P1108, DOI 10.4049/jimmunol.1501727
   Smith KJ, 2011, J PHARMACOL EXP THER, V338, P318, DOI 10.1124/jpet.110.178392
   Thackaberry E A, 2002, Cardiovasc Toxicol, V2, P263, DOI 10.1385/CT:2:4:263
   Thurmond TS, 2000, TOXICOL APPL PHARM, V165, P227, DOI 10.1006/taap.2000.8942
   Tong YL, 2017, EXP CELL RES, V350, P349, DOI 10.1016/j.yexcr.2016.12.009
   Vaidyanathan B, 2017, J EXP MED, V214, P197, DOI 10.1084/jem.20160789
   Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881
   Vogel CFA, 2013, IMMUNOL CELL BIOL, V91, P568, DOI 10.1038/icb.2013.43
   Walker MK, 2000, COMP BIOCHEM PHYS C, V126, P305, DOI 10.1016/S0742 8413(00)00119 5
   Wang G, 2018, CELL DEATH DIFFER, V25, P1209, DOI 10.1038/s41418 017 0006 2
   Watson ATD, 2019, TOXICOL SCI, V167, P145, DOI 10.1093/toxsci/kfy225
   Wejheden C, 2010, TOXICOL SCI, V114, P48, DOI 10.1093/toxsci/kfp284
   Wisniewski HG, 1996, J IMMUNOL, V156, P1609
   Xu T, 2015, J IMMUNOL, V195, P5539, DOI 10.4049/jimmunol.1501198
   Yan YP, 2010, J IMMUNOL, V185, P5953, DOI 10.4049/jimmunol.1001628
   Zhou YQ, 2017, SCI TOTAL ENVIRON, V587, P305, DOI 10.1016/j.scitotenv.2017.02.152
NR 92
TC 6
Z9 6
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 464X
EI 1742 4658
J9 FEBS J
JI FEBS J.
PD JUL
PY 2021
VL 288
IS 13
BP 3962
EP 3972
DI 10.1111/febs.15599
EA NOV 2020
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA TE4PT
UT WOS:000583189900001
PM 33064873
OA Bronze
DA 2025 08 17
ER

PT J
AU Settino, M
   Maurotti, S
   Tirinato, L
   Greco, S
   Coppoletta, AR
   Cardamone, A
   Musolino, V
   Montalcini, T
   Pujia, A
   Mare, R
AF Settino, Mariagiovanna
   Maurotti, Samantha
   Tirinato, Luca
   Greco, Simona
   Coppoletta, Anna Rita
   Cardamone, Antonio
   Musolino, Vincenzo
   Montalcini, Tiziana
   Pujia, Arturo
   Mare, Rosario
TI Zibibbo Grape Seeds' Polyphenolic Profile: Effects on Bone Turnover and
   Metabolism
SO PHARMACEUTICALS
LA English
DT Article
DE grape seeds; polyphenols; flavonoids; osteoporosis; bone health
ID ANTIOXIDANT ACTIVITY; CONSUMPTION; HEALTH
AB Background: The consumption of seeds as food has become increasingly common due to their numerous health benefits. Among these, the seeds of the Zibibbo grape from Pantelleria, a native species of southern Italy, remain largely unexplored and are usually considered waste material from viticulture. Nevertheless, Zibibbo grape seeds may offer health benefits, particularly for the elderly and people with metabolic disorders, due to their potential content of beneficial compounds such as polyphenols. Methods: The Zibibbo grape seeds extract (ZSE) was characterized using UV visible spectrophotometry and HPLC chromatography. The antioxidant activity of ZSE was measured by different colorimetric assays and Electronic Paramagnetic Resonance (EPR). Additionally, specific in vitro tests were conducted on human osteoblast cell lines (Saos 2 and MG63) aiming to evaluate the ZSE's effects on bone turnover and metabolism. Western blotting was used to assess the impact on specific proteins and pathways related to bone health. Results: The ZSE contained almost similar to 3 mg/mL of carbohydrates and phenolic compounds, including rutin (similar to 6.4 ppm) and hesperidin (similar to 44.6 ppm). The extracts exhibited an antioxidant activity greater than 90% across all tests performed. Moreover, the Zibibbo seed extracts exerted a significant proliferative effect on the Saos 2 cell human osteoblast like cell line, also modulating the phosphorylation of specific kinases involved in cell health and metabolism. Conclusions: Zibibbo grape seeds are rich in phenolic compounds, especially flavonoids with strong antioxidant and free radical scavenging properties. ZSE demonstrated beneficial effects on bone metabolism and osteoblast proliferation, suggesting potential for counteracting osteodegenerative conditions like osteoporosis. If confirmed through further studies, Zibibbo grape seed phenolic compounds could serve as an adjunctive therapy for osteoporosis, helping to slow aging and bone degeneration.
C1 [Settino, Mariagiovanna; Maurotti, Samantha; Montalcini, Tiziana] Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, I 88100 Catanzaro, Italy.
   [Tirinato, Luca; Greco, Simona; Pujia, Arturo; Mare, Rosario] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, I 88100 Catanzaro, Italy.
   [Coppoletta, Anna Rita; Cardamone, Antonio] Magna Graecia Univ Catanzaro, Inst Res Food Safety & Hlth IRC FSH, Dept Hlth Sci, Pharmacol Lab, I 88100 Catanzaro, Italy.
   [Musolino, Vincenzo] Magna Graecia Univ Catanzaro, Inst Res Food Safety & Hlth IRC FSH, Dept Hlth Sci, Lab Pharmaceut Biol, I 88100 Catanzaro, Italy.
   [Montalcini, Tiziana; Pujia, Arturo] Magna Graecia Univ Catanzaro, Res Ctr Prevent & Treatment Metab Dis, I 88100 Catanzaro, Italy.
C3 Magna Graecia University of Catanzaro; Magna Graecia University of
   Catanzaro; Magna Graecia University of Catanzaro; Magna Graecia
   University of Catanzaro; Magna Graecia University of Catanzaro
RP Pujia, A; Mare, R (通讯作者)，Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, I 88100 Catanzaro, Italy.; Pujia, A (通讯作者)，Magna Graecia Univ Catanzaro, Res Ctr Prevent & Treatment Metab Dis, I 88100 Catanzaro, Italy.
EM margiov.settino@gmail.com; smaurotti@unicz.it; tirinato@unicz.it;
   simona.greco001@studenti.unicz.it; annarita.coppoletta1@gmail.com;
   tony.c@outlook.it; v.musolino@unicz.it; tmontalcini@unicz.it;
   pujia@unicz.it; mare@unicz.it
RI Musolino, Vincenzo/AAD 2678 2019; Tirinato, Luca/K 8192 2016;
   Montalcini, Tiziana/AGV 1479 2022; Cardamone, Antonio/HGA 5612 2022;
   Coppoletta, Annarita/LSK 7367 2024; Greco, Simona/J 5374 2016; Maurotti,
   Samantha/AGX 8571 2022
OI Tirinato, Luca/0000 0001 9826 2129; Greco, Simona/0009 0006 9257 1995;
   MONTALCINI, Tiziana/0000 0001 7048 5830; Mare,
   Rosario/0000 0003 0881 4036; Maurotti, Samantha/0000 0001 7644 1337;
   Cardamone, Antonio/0000 0002 9091 1806; Musolino,
   Vincenzo/0000 0002 4763 2211
CR Addepalli V, 2018, BIOMED PHARMACOTHER, V108, P1517, DOI 10.1016/j.biopha.2018.09.179
   Alasalvar C, 2021, COMPR REV FOOD SCI F, V20, P2382, DOI 10.1111/1541 4337.12730
   Astorino S., 2003, Enologo Milano, V39, P99
   Balakrishna R, 2022, ADV NUTR, V13, P2136, DOI 10.1093/advances/nmac077
   Boccellino M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165642
   Choi NR, 2022, INT J MED SCI, V19, P941, DOI 10.7150/ijms.72529
   Corona G., 2007, Il Ruolo Del Settore Vitivinicolo Nei Processi Di Sviluppo Sostenibile, P372
   Cotelle Nicole, 2001, Current Topics in Medicinal Chemistry, V1, P569, DOI 10.2174/1568026013394750
   DAgostino S., 2002, Ind. Delle Bevande
   Di Lorenzo R., 2006, P 1 C INT VIT MONT F, P89
   Du J, 2024, CHEM BIOL TECHNOL AG, V11, DOI 10.1186/s40538 024 00631 8
   Dussert S, 2013, PLANT PHYSIOL, V162, P1337, DOI 10.1104/pp.113.220525
   Feringa HHH, 2011, J AM DIET ASSOC, V111, P1173, DOI 10.1016/j.jada.2011.05.015
   Fitzpatrick DF, 2002, ANN NY ACAD SCI, V957, P78, DOI 10.1111/j.1749 6632.2002.tb02907.x
   Gerber M, 2015, BRIT J NUTR, V113, pS4, DOI 10.1017/S0007114514003912
   Iannone M, 2017, INT J BIOL MACROMOL, V104, P1039, DOI 10.1016/j.ijbiomac.2017.07.022
   Ispiryan A, 2024, PLANTS BASEL, V13, DOI 10.3390/plants13040504
   Karagecili H, 2023, LIFE BASEL, V13, DOI 10.3390/life13030735
   Maiuolo J, 2021, NUTRIENTS, V13, DOI 10.3390/nu13072476
   Mandic AI, 2008, INT J FOOD PROP, V11, P713, DOI 10.1080/10942910701584260
   Mare R, 2023, PLANTS BASEL, V12, DOI 10.3390/plants12234046
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Masuoka N, 2012, FOOD CHEM, V131, P541, DOI 10.1016/j.foodchem.2011.09.020
   Maurotti S, 2021, NUTRIENTS, V13, DOI 10.3390/nu13124330
   Micek A, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12020272
   Novita N., 2024, Indones. J. Orthod. (InJO), V1, P1
   Patitucci F, 2024, PHARMACEUTICS, V16, DOI 10.3390/pharmaceutics16010099
   Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509
   Prasad C, 2019, AM J LIFESTYLE MED, V13, P384, DOI 10.1177/1559827617708991
   Pujia A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091305
   Quek YY, 2023, NUTR REV, V82, P1187, DOI 10.1093/nutrit/nuad121
   Spigno G, 2007, J FOOD ENG, V81, P200, DOI 10.1016/j.jfoodeng.2006.10.021
   Tonietto J, 2004, AGR FOREST METEOROL, V124, P81, DOI 10.1016/j.agrformet.2003.06.001
   Vaisman N, 2015, INT J FOOD SCI NUTR, V66, P342, DOI 10.3109/09637486.2014.1000840
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Xiao JB, 2014, BIOTECHNOL ADV, V32, P1145, DOI 10.1016/j.biotechadv.2014.04.006
   Zarev Y, 2023, PLANTS BASEL, V12, DOI 10.3390/plants12152795
NR 37
TC 1
Z9 1
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD NOV
PY 2024
VL 17
IS 11
AR 1418
DI 10.3390/ph17111418
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA N8Z1R
UT WOS:001367138400001
PM 39598330
OA gold
DA 2025 08 17
ER

PT J
AU Blackburn, G
   Scott, TG
   Bayer, IS
   Ghosh, A
   Biris, AS
   Biswas, A
AF Blackburn, Gary
   Scott, Timothy G.
   Bayer, Ilker S.
   Ghosh, Anindya
   Biris, Alexandru S.
   Biswas, Abhijit
TI Bionanomaterials for bone tumor engineering and tumor destruction
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID ANTIMICROBIAL ACTIVITY; MECHANICAL PROPERTIES; PROTEIN FUNCTION;
   LOCAL DELIVERY; DRUG DELIVERY; BREAST CANCER; SCAFFOLDS; CHITOSAN;
   NANOPARTICLES; HYPERTHERMIA
AB Recent advances have led to the development of multifunctional bionanomaterials that can target a bone tumor and deliver therapeutic drugs or genes. Bionanomaterial based bone cancer treatment offers hope for treating bone cancer and provides many exciting possibilities to enable important new therapeutic outcomes. Physicists, chemists, engineers, biologists, and clinicians will continue to address research questions at the level of fundamental biology and science to develop novel biomaterials and systems, particularly enabling cost effective and large scale production of multifunctional nanomaterial systems. This review provides a comprehensive reflection of the recent advancements in bionanomaterials for use in bone cancer treatment. The review examines in detail different bionanomaterials (hydroxyapatite nanocrystals and nanometals, nanoscale conjugated copolymer, selenium and liposome) that have been researched and developed over the last six years for bone tissue engineering. It also discusses an important area of research  the use of engineered bone scaffolds in cancer treatment. Recently, bone scaffolds have been identified as potential targets for metastatic spread as well as a means by which escape from tumor dormancy can be studied. This review also includes discussions of a highly potent new class of anticancer compounds, e.g., geminal bisphosphonates, that has been shown to have strong affinity towards various hydroxyapatite based bone scaffolds with controlled adsorption and release for anticancer activity. Finally, perspectives on future directions in nanotechnology enabled bone tumor treatment are presented.
C1 [Blackburn, Gary; Scott, Timothy G.; Biswas, Abhijit] Univ Notre Dame, Dept Elect Engn, Ctr Nano Sci & Technol, Notre Dame, IN 46556 USA.
   [Blackburn, Gary] Trinity Coll Dublin, Coll Green, Dept Mech Engn, Dublin 2, Ireland.
   [Scott, Timothy G.] Univ Notre Dame, Dept Aerosp & Mech Engn, Notre Dame, IN 46556 USA.
   [Bayer, Ilker S.] Ist Italiano Tecnol, I 16163 Genoa, Italy.
   [Ghosh, Anindya] Univ Arkansas, Dept Chem, Little Rock, AR 72204 USA.
   [Biris, Alexandru S.] Univ Arkansas, Ctr Integrat Nanotechnol Sci, Little Rock, AR 72204 USA.
C3 University of Notre Dame; Trinity College Dublin; University of Notre
   Dame; Istituto Italiano di Tecnologia   IIT; University of Arkansas
   System; University of Arkansas Little Rock; University of Arkansas
   Fayetteville; University of Arkansas System; University of Arkansas
   Fayetteville; University of Arkansas Little Rock
RP Blackburn, G (通讯作者)，Univ Notre Dame, Dept Elect Engn, Ctr Nano Sci & Technol, Notre Dame, IN 46556 USA.
EM ilker.bayer@iit.it; abiswas@nd.edu
RI Biris, Alexandru/A 8507 2010; Ghosh, Anindya/IAR 8274 2023
OI Bayer, Ilker S./0000 0002 7951 8851; 
FU Naughton Fellowship
FX Gary Blackburn is most indebted to the Naughton Fellowship program that
   has enabled him pursue his interest in bionanomaterials and to the Notre
   Dame Center for Nano Science and Technology (NDnano) for hosting him to
   do research under Prof. Abhijit Biswas. He would also like to express
   his gratitude to the lecturers of the Mechanical Engineering Department
   in Trinity College Dublin, most notably Dr Gareth Bennett who encouraged
   him and other undergraduates to pursue this fellowship. The authors
   greatly appreciate Dr Marinelle Ringer for her assistance with the
   editing.
CR Alatorre Meda M, 2011, COLLOID SURFACE B, V82, P54, DOI 10.1016/j.colsurfb.2010.08.013
   Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903
   [Anonymous], 2008, Cancer Facts Figures 2008
   Arcos D, 2003, J BIOMED MATER RES A, V65A, P71, DOI 10.1002/jbm.a.10445
   Bhargava P, 1999, CLIN CANCER RES, V5, P1989
   Biswas A, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3607283
   Branco MC, 2009, ACTA BIOMATER, V5, P817, DOI 10.1016/j.actbio.2008.09.018
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096 9101(2000)27:5<451::AID LSM1006>3.0.CO;2 1
   Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535 6108(04)00079 0
   Cai YR, 2007, J MATER CHEM, V17, P3780, DOI 10.1039/b705129h
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078 0432.CCR 07 1441
   Ciofani G, 2010, EXPERT OPIN DRUG DEL, V7, P889, DOI 10.1517/17425247.2010.499897
   Dhule SS, 2012, NANOMED NANOTECHNOL, V8, P440, DOI 10.1016/j.nano.2011.07.011
   Di Nunzio S, 2004, J EUR CERAM SOC, V24, P2935, DOI 10.1016/j.jeurceramsoc.2003.11.010
   Dougherty TJ, 1998, JNCI J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   DuBois S, 2007, CANCER AM CANCER SOC, V109, P813, DOI 10.1002/cncr.22455
   Egerton N, 2010, CANCER CHEMOTH PHARM, V66, P1005, DOI 10.1007/s00280 010 1467 x
   Fan QY, 1996, BIOELECTROMAGNETICS, V17, P218, DOI 10.1002/(SICI)1521 186X(1996)17:3<218::AID BEM7>3.0.CO;2 6
   Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004
   Gopi D, 2012, SPECTROCHIM ACTA A, V93, P131, DOI 10.1016/j.saa.2012.02.033
   Groenemeyer DHW, 2002, ACAD RADIOL, V9, P467, DOI 10.1016/S1076 6332(03)80194 0
   Gross K., 2002, EUR CELLS MATER, V3, P114
   Gu RL, 2010, BIOMATERIALS, V31, P1270, DOI 10.1016/j.biomaterials.2009.10.023
   Hansen M. F., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P554
   Harisinghani MG, 2005, UROLOGY, V66, P1066, DOI 10.1016/j.urology.2005.05.049
   Hasan T., 2003, Holland Frei Cancer Med
   He JQ, 2012, APPL SURF SCI, V258, P6823, DOI 10.1016/j.apsusc.2012.03.109
   HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151 2916.1991.tb07132.x
   Hou CH, 2009, BIOMATERIALS, V30, P3956, DOI 10.1016/j.biomaterials.2009.04.020
   Howlader N., 2011, SEER cancer statistics review, 1975 2008
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iafisco M, 2012, J INORG BIOCHEM, V117, P237, DOI 10.1016/j.jinorgbio.2012.06.004
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Itokazu M, 1998, J BIOMED MATER RES, V39, P536, DOI 10.1002/(SICI)1097 4636(19980315)39:4<536::AID JBM5>3.0.CO;2 K
   JARCHO M, 1976, J MATER SCI, V11, P2027, DOI 10.1007/BF02403350
   JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454
   Jiang M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.224107
   Jo JH, 2009, J BIOMED MATER RES B, V91B, P213, DOI 10.1002/jbm.b.31392
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Khanna R., 2010, INT J POLYM SCI, V10, P12
   Khanna R, 2009, J ENG MECH, V135, P468, DOI 10.1061/(ASCE)EM.1943 7889.0000002
   Khor E, 2003, BIOMATERIALS, V24, P2339, DOI 10.1016/S0142 9612(03)00026 7
   Lapotko D, 2006, CANCER LETT, V239, P36, DOI 10.1016/j.canlet.2005.07.031
   Lapotko DO, 2006, LASER SURG MED, V38, P631, DOI 10.1002/lsm.20359
   Li XR, 2009, NANO LETT, V9, P2763, DOI 10.1021/nl901582f
   Lim PY, 2006, CHEM PHYS LETT, V420, P304, DOI 10.1016/j.cplett.2005.12.075
   Lin CP, 1999, IEEE J SEL TOP QUANT, V5, P963, DOI 10.1109/2944.796318
   Lin RZ, 2011, J CELL PHYSIOL, V226, P1750, DOI 10.1002/jcp.22504
   Liu HS, 1997, CERAM INT, V23, P19, DOI 10.1016/0272 8842(95)00135 2
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065 2571(00)00013 3
   Mahmood M, 2011, J CELL MOL MED, V15, P2297, DOI 10.1111/j.1582 4934.2010.01234.x
   Malawer M. M., 2004, CANC PRINCIPLES PRAC, V2
   Masuda Y., 1990, J CERAM SOC JPN, V99, P1255
   Matsumine A, 2007, CLIN EXP METASTAS, V24, P191, DOI 10.1007/s10585 007 9068 8
   Matsumine A, 2011, INT J CLIN ONCOL, V16, P101, DOI 10.1007/s10147 011 0217 3
   Miele E, 2009, INT J NANOMED, V4, P99
   Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585 007 9098 2
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mishra A., 2011, J NANOSCI NANOTECHNO, V11, P204
   Moreau JE, 2007, CANCER RES, V67, P10304, DOI 10.1158/0008 5472.CAN 07 2483
   National Cancer Institute, BEN TREATM CLIN OUTC
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nikpour MR, 2012, COMPOS PART B ENG, V43, P1881, DOI 10.1016/j.compositesb.2012.01.056
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   Oldenburg SJ, 1998, CHEM PHYS LETT, V288, P243, DOI 10.1016/S0009 2614(98)00277 2
   Oraevsky AA, 2001, PROC SPIE, V4434, P60, DOI 10.1117/12.446693
   Park JH, 2010, ADV DRUG DELIVER REV, V62, P28, DOI 10.1016/j.addr.2009.10.003
   Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165 4608(01)00575 1
   Pathia S., 2011, J BIOMATER APPL, V32, P5112
   Peket Y., 2009, BIOMATERIALS, V30, P822
   Peter M, 2010, CARBOHYD POLYM, V79, P284, DOI 10.1016/j.carbpol.2009.08.001
   Pitsillides CM, 2003, BIOPHYS J, V84, P4023, DOI 10.1016/S0006 3495(03)75128 5
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Ragetly G, 2010, ACTA BIOMATER, V6, P3988, DOI 10.1016/j.actbio.2010.05.016
   Ranganathan SI, 2010, ACTA BIOMATER, V6, P3448, DOI 10.1016/j.actbio.2010.03.029
   Ribeiro R, 2007, J MATER RES, V22, P1632, DOI 10.1557/JMR.2007.0204
   Roegener J, 2000, P SOC PHOTO OPT INS, V3902, P35, DOI 10.1117/12.379339
   Rogel MR, 2008, J MATER CHEM, V18, P4233, DOI 10.1039/b804692a
   Ruppel ME, 2008, OSTEOPOROSIS INT, V19, P1251, DOI 10.1007/s00198 008 0579 1
   Safra T, 2000, ANN ONCOL, V11, P1029, DOI 10.1023/A:1008365716693
   Sahithi K, 2010, J BIOMED NANOTECHNOL, V6, P333, DOI 10.1166/jbn.2010.1138
   Saranya N, 2011, J BIOMED NANOTECHNOL, V7, P238, DOI 10.1166/jbn.2011.1283
   Saravanan S, 2011, INT J BIOL MACROMOL, V49, P188, DOI 10.1016/j.ijbiomac.2011.04.010
   Sarvestani AS, 2006, BIOMACROMOLECULES, V7, P1573, DOI 10.1021/bm050958s
   Satchi Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007
   Satchi Fainaro R, 2004, NAT MED, V10, P255, DOI 10.1038/nm1002
   Satchi Fainaro R, 2008, ANGIOGENESIS INTEGRA, P387
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Sentürk SB, 2011, CARBOHYD POLYM, V84, P141, DOI 10.1016/j.carbpol.2010.11.015
   Shih HA, 2005, INT J RADIAT ONCOL, V63, P1262, DOI 10.1016/j.ijrobp.2005.07.952
   Sprenger C., 2012, CANC RES, V72, DOI 1538 7445.AM2012 5239
   Tampieri A, 2012, ACTA BIOMATER, V8, P843, DOI 10.1016/j.actbio.2011.09.032
   Thein Han WW, 2009, ACTA BIOMATER, V5, P1182, DOI 10.1016/j.actbio.2008.11.025
   Tran PA, 2010, MATER SCI FORUM, V638 642, P718, DOI 10.4028/www.scientific.net/MSF.638 642.718
   Vogl TJ, 2001, CARDIOVASC INTER RAD, V24, P432, DOI 10.1007/s00270 001 0037 3
   Wang FS, 1996, TRENDS CELL BIOL, V6, P442, DOI 10.1016/S0962 8924(96)40005 8
   Wang M, 2003, BIOMATERIALS, V24, P2133, DOI 10.1016/S0142 9612(03)00037 1
   West JL, 2003, ANNU REV BIOMED ENG, V5, P285, DOI 10.1146/annurev.bioeng.5.011303.120723
   Wong AL, 2009, ANN ONCOL, V20, P1605, DOI 10.1093/annonc/mdp368
   Wu H. C., 2009, ADV FUNCT MATER, V19, P1
   Wu HC, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/16/165601
   YAZAWA Y, 1990, CLIN ORTHOP RELAT R, P213
   Yu YY, 1997, J PHYS CHEM B, V101, P6661, DOI 10.1021/jp971656q
   Zhongli S., 2010, J BIOMATER APPL, V25, P19
   Zhou CJ, 2011, COLLOID SURFACE B, V84, P155, DOI 10.1016/j.colsurfb.2010.12.030
NR 107
TC 33
Z9 34
U1 1
U2 100
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2013
VL 1
IS 11
BP 1519
EP 1534
DI 10.1039/c3tb00536d
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 093CJ
UT WOS:000315169000001
PM 32260715
DA 2025 08 17
ER

PT J
AU Yao, ZQ
   Lei, W
   Duan, R
   Li, YY
   Luo, L
   Boyce, BF
AF Yao, Zhenqiang
   Lei, Wei
   Duan, Rong
   Li, Yanyun
   Luo, Lu
   Boyce, Brendan F.
TI RANKL cytokine enhances TNF induced osteoclastogenesis independently of
   TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast
   precursors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; NF KAPPA B; GROWTH FACTOR BETA; BONE RESORPTION;
   TGF BETA; DEFECTIVE INTERLEUKIN 1; RHEUMATOID ARTHRITIS; T CELLS; C FOS;
   ACTIVATION
AB Cytokines, including receptor activator of nuclear factor kappa B ligand (RANKL) and TNF, induce increased osteoclast (OC) formation and bone loss in postmenopausal osteoporosis and inflammatory arthritides. RANKL and TNF can independently induce OC formation in vitro from WT OC precursors via TNF receptor associated factor (TRAF) adaptor proteins, which bind to their receptors. Of these, only TRAF6 is required for RANKL induced osteoclastogenesis in vitro. However, the molecular mechanisms involved remain incompletely understood. Here we report that RANKL induced the formation of bone resorbing OCs from TRAF6( / ) OC precursors when cultured on bone slices but not on plastic. The mechanisms involved increased TNF production by TRAF6( / ) OC precursors resulting from their interaction with bone matrix and release of active TGF beta from the resorbed bone, coupled with RANKL induced autophagolysosomal degradation of TRAF3, a known inhibitor of OC formation. Consistent with these findings, RANKL enhanced TNF induced OC formation from TRAF6( / ) OC precursors. Moreover, TNF induced significantly more OCs from mice with TRAF3 conditionally deleted in myeloid lineage cells, and it did not inhibit RANKL induced OC formation from these cells. TRAF6( / ) OC precursors that overexpressed TRAF3 or were treated with the autophagolysosome inhibitor chloroquine formed significantly fewer OCs in response to TNF alone or in combination with RANKL. We conclude that RANKL can enhance TNF induced OC formation independently of TRAF6 by degrading TRAF3. These findings suggest that preventing TRAF3 degradation with drugs like chloroquine could reduce excessive OC formation in diseases in which bone resorption is increased in response to elevated production of these cytokines.
C1 [Yao, Zhenqiang; Lei, Wei; Duan, Rong; Li, Yanyun; Luo, Lu; Boyce, Brendan F.] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   [Yao, Zhenqiang; Boyce, Brendan F.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Lei, Wei] Henan Univ, Affiliated Hosp 1, Dept Med Imaging, 357 Ximen St, Kaifeng 475001, Henan, Peoples R China.
C3 University of Rochester; University of Rochester; Henan University
RP Yao, ZQ; Boyce, BF (通讯作者)，Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM zhenqiang_yao@urmc.rochester.edu; Brendan_Boyce@urmc.rochester.edu
OI Luo, Lu/0000 0002 6749 6616; Yao, Zhenqiang/0000 0002 4664 3648
FU NIAMS, National Institutes of Health [R01AR43510, P30 AR069655,
   1S10RR027340]; NIA, National Institutes of Health [R01AG049994]
FX This work was supported by NIAMS, National Institutes of Health Grant
   R01AR43510 (to B. F. B.) and NIA, National Institutes of Health Grant
   R01AG049994 (to B. F. B. and Z. Y.). This work was also supported by
   NIAMS Grants P30 AR069655 and 1S10RR027340 (to. B. F. B) from the
   National Institutes of Health. The authors declare that they have no
   conflicts of interest with the contents of this article. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413
   Agbanoma G, 2012, J IMMUNOL, V188, P1307, DOI 10.4049/jimmunol.1100625
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678
   Bertrand MJM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022356
   Besse A, 2007, J BIOL CHEM, V282, P3918, DOI 10.1074/jbc.M608867200
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Funakoshi Tago M, 2009, CYTOKINE, V45, P72, DOI 10.1016/j.cyto.2008.10.010
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727
   Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014 5793(98)01731 1
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074 7613(03)00230 9
   Kullberg MC, 2005, EUR J IMMUNOL, V35, P2886, DOI 10.1002/eji.200526106
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340
   Mease PJ, 2002, ANN RHEUM DIS, V61, P298, DOI 10.1136/ard.61.4.298
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460 2075.1991.tb08049.x
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakhaei P, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000650
   Ninomiya Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006 291X(89)92795 2
   OURSLER MJ, 1994, J BONE MINER RES, V9, P443
   Pihusch V, 2005, THROMB RES, V116, P233, DOI 10.1016/j.thromres.2004.12.010
   Ruocco MG, 2007, ADV EXP MED BIOL, V602, P125
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Salmon CR, 2013, J PROTEOMICS, V91, P544, DOI 10.1016/j.jprot.2013.08.016
   Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152
   Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Toossi Z, 1996, J IMMUNOL, V156, P3461
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xiao YC, 2013, NAT MED, V19, P595, DOI 10.1038/nm.3111
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015383
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao ZJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135728
NR 65
TC 58
Z9 71
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 16
PY 2017
VL 292
IS 24
BP 10169
EP 10179
DI 10.1074/jbc.M116.771816
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA EX9LW
UT WOS:000403580600027
PM 28438834
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Qu, ZG
   Li, SL
AF Qu, Zhigang
   Li, Shenglong
TI Long noncoding RNA LINC01278 favors the progression of osteosarcoma via
   modulating miR 133a 3p/PTHR1 signaling
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE ceRNA; lncRNA; miR 133a 3p; osteosarcoma; PTHR1
ID IN SITU HYBRIDIZATION; CELL PROLIFERATION; CANCER PROGRESSION; TYPE 1
   RECEPTOR; ENDOGENOUS RNA; EXPRESSION; MICRORNAS; INVASION; GROWTH;
   PHENOTYPE
AB As one of the most aggressive malignancies, osteosarcoma has high risks of death. Although long noncoding RNAs (lncRNAs) may promote the osteosarcoma progression as verified, the potential molecular mechanism of lncRNAs in osteosarcoma remains unknown. Herein, we analyzed lncRNA microarray of osteosarcoma and selected LINC01278 as the study object. Then, we found that the expression of LINC01278 tested by quantitative reverse transcription polymerase chain reaction was enhanced in tumor tissues compared with the para carcinoma tissues and related to clinical stage, distant metastasis in osteosarcoma. In addition, the clinical outcomes were poor in osteosarcoma patients with high LINC01278 level. Moreover, LINC01278 promoted proliferation and restrained apoptosis in osteosarcoma cells. Afterward, mechanistic studies turned out that LINC01278 was a competing endogenous RNA of parathyroid hormone type 1 receptor (PTHR1) in osteosarcoma by sponging miR 133a 3p, which was considered as a tumor inhibitor in osteosarcoma. Furthermore, PTHR1 downregulation restored the impacts of inhibited miR 133a 3p on the processes in osteosarcoma cells. Our findings clarified that the carcinogenic effect of LINC01278 in osteosarcoma was mediated through miR 133a 3p/PTHR1 signaling, creating a novel insight into good targets for the therapy and prognosis of osteosarcoma.
C1 [Qu, Zhigang] First Hosp Jilin Univ, Dept Spine Surg, Changchun, Jilin, Peoples R China.
   [Li, Shenglong] Liaoning Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor Surg, Shenyang 110042, Liaoning, Peoples R China.
C3 Jilin University
RP Li, SL (通讯作者)，Liaoning Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor Surg, Shenyang 110042, Liaoning, Peoples R China.
EM lishenglong@cancerhosp ln cmu.com
RI ; Li, Shenglong/W 4929 2019
OI Li, Shenglong/0000 0003 2244 1184; 
FU Liaoning Cancer Hospital Institute; First Hospital of Jilin University
   (Changchun)
FX We thank the generous support by Liaoning Cancer Hospital & Institute
   (Shenyang) and The First Hospital of Jilin University (Changchun).
CR Angulo P, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 016 0373 z
   Cao YL, 2017, CELL BIOCHEM FUNCT, V35, P296, DOI 10.1002/cbf.3276
   Cui CH, 2018, CANCER RES TREAT, V50, P992, DOI 10.4143/crt.2017.226
   Faisham WI, 2017, ASIA PAC J CLIN ONCO, V13, pE104, DOI 10.1111/ajco.12346
   Guo JB, 2019, J CELL BIOCHEM, V120, P17975, DOI 10.1002/jcb.29064
   Guo XQ, 2017, J CANCER RES CLIN, V143, P555, DOI 10.1007/s00432 016 2268 3
   Han G, 2016, WORLD J SURG, V40, P2016, DOI 10.1007/s00268 016 3500 7
   He BX, 2018, J CELL BIOCHEM, V119, P338, DOI 10.1002/jcb.26182
   He M, 2019, AGING US, V11, P5744, DOI 10.18632/aging.102157
   Ho PWM, 2015, ONCOGENE, V34, P2922, DOI 10.1038/onc.2014.217
   Huang XY, 2016, ONCOTARGET, V7, P57379, DOI 10.18632/oncotarget.10545
   Huo XQ, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0734 4
   Jarroux J, 2017, ADV EXP MED BIOL, V1008, P1, DOI 10.1007/978 981 10 5203 3_1
   Jathar S, 2017, ADV EXP MED BIOL, V1008, P283, DOI 10.1007/978 981 10 5203 3_10
   Javidi MA, 2014, MED ONCOL, V31, DOI 10.1007/s12032 014 0295 y
   Kadmiel M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181597
   Kager L, 2017, FUTURE ONCOL, V13, P357, DOI 10.2217/fon 2016 0261
   Kumari R, 2006, INT J CANCER, V119, P49, DOI 10.1002/ijc.21802
   Li DG, 2017, CANCER BIOL THER, V18, P927, DOI 10.1080/15384047.2017.1385682
   Li HH, 2019, MED SCI MONITOR, V25, P656, DOI 10.12659/MSM.912813
   Li JP, 2013, BIOCHEM BIOPH RES CO, V433, P200, DOI 10.1016/j.bbrc.2013.02.083
   Li Z, 2016, TUMOR BIOL, V37, P2811, DOI 10.1007/s13277 015 4749 4
   Liao SA, 2019, CANCER CHEMOTH PHARM, V83, P1065, DOI 10.1007/s00280 019 03822 5
   Liz J, 2016, BBA GENE REGUL MECH, V1859, P169, DOI 10.1016/j.bbagrm.2015.06.015
   Ma YX, 2018, CANCER LETT, V419, P27, DOI 10.1016/j.canlet.2018.01.008
   Mao Y, 2017, CANCER GENE THER, V24, P267, DOI 10.1038/cgt.2017.14
   Miyashita H, 2008, MOL MED REP, V1, P821, DOI 10.3892/mmr_00000034
   Moreno F, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26533
   Muskhelishvili L, 2003, J HISTOCHEM CYTOCHEM, V51, P1681, DOI 10.1177/002215540305101212
   Qiu XL, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5045827
   Querido E, 2017, METHODS, V126, P149, DOI 10.1016/j.ymeth.2017.07.005
   Sakurai K, 2015, MOL CANCER RES, V13, P828, DOI 10.1158/1541 7786.MCR 15 0016 T
   Seriwatanachai D, 2011, FASEB J, V25, P3057, DOI 10.1096/fj.11 183277
   Su Y, 2018, CELL CYCLE, V17, P459, DOI 10.1080/15384101.2017.1403688
   Tang YJ, 2017, ONCOL REP, V38, P941, DOI 10.3892/or.2017.5751
   Terashima M, 2018, J BIOL CHEM, V293, P18016, DOI 10.1074/jbc.RA118.004006
   Wang GY, 2017, FREE RADICAL BIO MED, V106, P24, DOI 10.1016/j.freeradbiomed.2017.02.015
   Wang JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P581, DOI 10.1159/000485093
   Wang YC, 2019, CELL BIOL INT, V43, P1453, DOI 10.1002/cbin.11194
   Wu SK, 2020, J CELL PHYSIOL, V235, P339, DOI 10.1002/jcp.28973
   Xu JN, 2020, J CELL BIOCHEM, V121, P344, DOI 10.1002/jcb.29181
   Xu YX, 2019, MED SCI MONITOR, V25, P1140, DOI 10.12659/MSM.912450
   Yang R, 2007, INT J CANCER, V121, P943, DOI 10.1002/ijc.22749
   Yang ZZ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.272
   Yin YW, 2019, J CELL PHYSIOL, V234, P12757, DOI 10.1002/jcp.27896
   Zhang EQ, 2019, J CELL BIOCHEM, V120, P16575, DOI 10.1002/jcb.28917
   Zhang J, 2015, CLIN CHIM ACTA, V444, P9, DOI 10.1016/j.cca.2015.01.025
   Zhang JW, 2018, HEPATOLOGY, V67, P171, DOI 10.1002/hep.29405
   Zhou GX, 2013, J INT MED RES, V41, P1, DOI 10.1177/0300060513475959
   Zhou GQ, 2018, ONCOL RES, V26, P795, DOI 10.3727/096504017X15004613574679
   Zöllner H, 2014, METHODS MOL BIOL, V1095, P121, DOI 10.1007/978 1 62703 703 7_10
NR 51
TC 30
Z9 30
U1 2
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2024
VL 239
IS 12
AR e29582
DI 10.1002/jcp.29582
EA JAN 2020
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA P7F8X
UT WOS:000509771100001
PM 31994731
DA 2025 08 17
ER

PT J
AU Roato, I
   Pavone, L
   Pedraza, R
   Bosso, I
   Baima, G
   Erovigni, F
   Mussano, F
AF Roato, Ilaria
   Pavone, Lorenzo
   Pedraza, Riccardo
   Bosso, Ilaria
   Baima, Giacomo
   Erovigni, Francesco
   Mussano, Federico
TI Denosumab and Zoledronic Acid Differently Affect Circulating Immune
   Subsets: A Possible Role in the Onset of MRONJ
SO CELLS
LA English
DT Article
DE anti resorptive drugs; denosumab; osteonecrosis; T cells; zoledronate
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MEDICATION RELATED OSTEONECROSIS;
   DELTA T CELLS; SPONTANEOUS OSTEOCLASTOGENESIS; JAW; PATHOGENESIS;
   MECHANISMS; NECROSIS; DISEASE; UPDATE
AB This work investigated whether the anti resorptive drugs (ARDs) zoledronic acid (Zol) and denosumab (Dmab) affect differently the levels of circulating immune cell subsets, possibly predicting the risk of developing medication related ONJ (MRONJ) during the first 18 months of treatment. Blood samples were collected from 10 bone metastatic breast cancer patients receiving cyclin inhibitors at 0, 6, 12, and 18 months from the beginning of Dmab or Zol treatment. Eight breast cancer patients already diagnosed with MRONJ and treated with cyclin inhibitors and ARDs were in the control group. PBMCs were isolated; the trend of circulating immune subsets during the ARD treatment was monitored, and 12 pro inflammatory cytokines were analyzed in sera using flow cytometry. In Dmab treated patients, activated T cells were stable or increased, as were the levels of IL 12, TNF alpha, GM CSF, IL 5, and IL 10, sustaining them. In Zol treated patients, CD8+T cells decreased, and the level of IFN gamma was undetectable. gamma delta T cells were not altered in Dmab treated patients, while they dramatically decreased in Zol treated patients. In the MRONJ control group, Zol ONJ patients showed a reduction in activated T cells and gamma delta T cells compared to Dmab ONJ patients. Dmab was less immunosuppressive than Zol, not affecting gamma delta T cells and increasing activated T cells.
C1 [Roato, Ilaria; Pavone, Lorenzo; Pedraza, Riccardo; Baima, Giacomo; Mussano, Federico] Univ Turin, CIR Dent Sch, Dept Surg Sci, Bone & Dent Bioengn Lab, Via Nizza 230, I 10126 Turin, Italy.
   [Pedraza, Riccardo] Natl Council Res, Inst Sci & Technol Sustainable Energy & Mobil, I 10135 Turin, Italy.
   [Pedraza, Riccardo; Baima, Giacomo] Politecn Torino, DIMEAS, I 10129 Turin, Italy.
   [Bosso, Ilaria; Erovigni, Francesco] Citta Sci & Salute, CIR Dent Sch, I 10126 Turin, Italy.
C3 A.O.U. Citta della Salute e della Scienza di Torino; University of
   Turin; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze e
   Tecnologie per l'Energia e la Mobilita Sostenibili (STEMS CNR);
   Polytechnic University of Turin; A.O.U. Citta della Salute e della
   Scienza di Torino
RP Roato, I (通讯作者)，Univ Turin, CIR Dent Sch, Dept Surg Sci, Bone & Dent Bioengn Lab, Via Nizza 230, I 10126 Turin, Italy.
EM ilaria.roato@unito.it; lorenzo.pavone@edu.unito.it;
   riccardo.pedraza@unito.it; ilaria.bosso@unito.it;
   giacomo.baima@unito.it; francesco.erovigni@unito.it;
   federico.mussano@unito.it
RI ; Baima, Giacomo/AAY 3609 2021; Roato, Ilaria/ACF 6827 2022
OI Roato, Ilaria/0000 0003 3029 4743; Pavone, Lorenzo/0009 0009 3885 7142;
   Mussano, Federico/0000 0001 5800 0749; Pedraza,
   Riccardo/0009 0009 2955 4246; Baima, Giacomo/0000 0002 9395 4967; Bosso,
   Ilaria/0000 0003 2572 6564
FU CRT Foundations [CRT2020]; Fondazione Ricerca Molinette ONLUS; PRIN
   (CONCERTO) [2020BN5ZW9]
FX This research was funded by CRT Foundations (CRT2020), Fondazione
   Ricerca Molinette ONLUS, and PRIN (CONCERTO) Prot. 2020BN5ZW9.
CR Abiko Y, 2007, MED MOL MORPHOL, V40, P179, DOI 10.1007/s00795 007 0381 8
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Dai JL, 2010, CANCER RES, V70, P5014, DOI 10.1158/0008 5472.CAN 10 0100
   Du W, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00166 4
   Eguia A, 2020, MED ORAL PATOL ORAL, V25, pE71, DOI 10.4317/medoral.23191
   Elsayed R, 2020, FASEB J, V34, P2595, DOI 10.1096/fj.201901819RR
   Ewald F, 2021, CLIN ORAL INVEST, V25, P2801, DOI 10.1007/s00784 020 03595 9
   Francisconi CF, 2018, J DENT RES, V97, P917, DOI 10.1177/0022034518759302
   Fusco V, 2016, EXPERT OPIN DRUG SAF, V15, P925, DOI 10.1080/14740338.2016.1177021
   Gan YH, 2001, J BIOL REG HOMEOS AG, V15, P277
   Gkouveris I, 2022, CANCERS, V14, DOI 10.3390/cancers14020330
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015
   Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600 065X.2003.00051.x
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Huja SS, 2006, ANAT REC PART A, V288A, P1243, DOI 10.1002/ar.a.20396
   Idrees ASM, 2013, CANCER SCI, V104, P536, DOI 10.1111/cas.12124
   Kalyan S, 2016, J BONE MINER RES, V31, P1997, DOI 10.1002/jbmr.2875
   Kalyan S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0568 z
   Kalyan S, 2013, CELL MOL IMMUNOL, V10, P21, DOI 10.1038/cmi.2012.44
   Kaur K, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1111627
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kimura MY, 2019, SEMIN IMMUNOPATHOL, V41, P349, DOI 10.1007/s00281 019 00734 7
   Koyama Nasu R, 2022, INT IMMUNOL, V34, P555, DOI 10.1093/intimm/dxac024
   Maleki KT, 2016, CLIN IMMUNOL, V163, P52, DOI 10.1016/j.clim.2015.12.012
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Meghji S, 1998, BRIT J RHEUMATOL, V37, P1095
   Messer JG, 2018, BONE, V108, P79, DOI 10.1016/j.bone.2017.12.025
   Movila A, 2016, BIOCHEM BIOPH RES CO, V480, P42, DOI 10.1016/j.bbrc.2016.10.012
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Panebianco C, 2018, MICROBIOME, V6, DOI 10.1186/s40168 018 0483 7
   Papadopoulou E, 2022, DENT J BASEL, V10, DOI 10.3390/dj10120232
   Pappalardo A, 2015, BONE, V71, P180, DOI 10.1016/j.bone.2014.10.019
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   Peng J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1017391
   Prager I, 2019, J LEUKOCYTE BIOL, V105, P1319, DOI 10.1002/JLB.MR0718 269R
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Roato I, 2008, LUNG CANCER, V61, P109, DOI 10.1016/j.lungcan.2007.10.016
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Roato I, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24097948
   Roberts NA, 2012, IMMUNITY, V36, P427, DOI 10.1016/j.immuni.2012.01.016
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P395, DOI 10.1007/s00223 012 9647 9
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Salesi N, 2006, ANTICANCER RES, V26, P3111
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Soma T, 2022, SCI REP UK, V12, DOI 10.1038/s41598 021 03966 6
   Soma T, 2021, J BONE MINER METAB, V39, P372, DOI 10.1007/s00774 020 01174 2
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   Ullrich KAM, 2020, EXCLI J, V19, P1563, DOI 10.17179/excli2020 3104
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh M, 2016, LEUKEMIA LYMPHOMA, V57, P977, DOI 10.3109/10428194.2015.1088653
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhu WW, 2019, FASEB J, V33, P5208, DOI 10.1096/fj.201801791RR
NR 57
TC 5
Z9 5
U1 5
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD OCT
PY 2023
VL 12
IS 20
AR 2430
DI 10.3390/cells12202430
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA W8OP2
UT WOS:001094169300001
PM 37887274
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Damment, SJP
   Shen, V
AF Damment, SJP
   Shen, V
TI Assessment of effects of lanthanum carbonate with and without phosphate
   supplementation on bone mineralization in uremic rats
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE lanthanum carbonate; bone mineralization; chronic renal failure;
   phosphorus; osteomalacia
ID CHRONIC RENAL FAILURE; VITAMIN D RECEPTOR; HEMODIALYSIS PATIENTS;
   SECONDARY HYPERPARATHYROIDISM; INDUCED OSTEOMALACIA; DIETARY PHOSPHORUS;
   UP REGULATION; ALUMINUM; CALCIUM; DISEASE
AB Aims: Previous studies have indicated that impaired bone mineralization in 5/6(th) nephrectomized rats given high doses of lanthanum carbonate is due to phosphorus depletion caused by excessive binding to, and reduced absorption of, dietary phosphate. This study aimed to test this hypothesis by: 1) directly comparing the effects of a supra therapeutic dose of lanthanum carbonate or dietary phosphorus restriction on bone mineralization in a rodent model of chronic renal failure (CRF); and 2) investigating whether phosphorus supplementation would prevent the bone mineralization defect associated with lanthanum carbonate treatment. Methods and materials: Male Sprague Dawley rats were subjected to sham surgery or a two step 5/6th nephrectomy to induce CRF and randomized across five treatment groups: sham, CRF, CRF + dietary phosphorus deficiency, CRF + lanthanum carbonate (1000 mg/kg/day), and CRF + lanthanum carbonate + parenteral phosphorus repletion. Results: Rats with 5/6(th) nephrectomy had elevated serum creatinine, blood urea concentration, and urine volume and protein, consistent with impaired renal function, and increased urinary phosphorus and serum parathyroid hormone, consistent with hyperparathyroidism. Lanthanum carbonate and dietary phosphate insufficiency induced parallel changes in serum and urine markers of phosphate homeostasis and increased osteoid formation. These changes induced by lanthanum carbonate were normalized by systemic phosphate supplementation. Conclusions: These findings provide further support for the concept that supratherapeutic doses of lanthanum carbonate induce effects on bone mineralization in uremic rats via an indirect pharmacological mechanism (phosphate depletion) and not via direct bone toxicity.
C1 Shire Pharmaceut Dev Ltd, Dept Biosci, Basingstoke RG24 8EP, Hants, England.
   SkeleTech Inc, Seattle, WA USA.
C3 Shire Pharmaceuticals Limited
RP Shire Pharmaceut Dev Ltd, Dept Biosci, Hampshire Int Business Pk, Basingstoke RG24 8EP, Hants, England.
CR Behets Geert J., 2001, Journal of the American Society of Nephrology, V12, p740A
   Behets GJ, 2004, J AM SOC NEPHROL, V15, P2219, DOI 10.1097/01.ASN.0000133022.32912.95
   Block GA, 2000, CLIN NEPHROL, V54, P318
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Boutsen Y, 1996, CLIN RHEUMATOL, V15, P75, DOI 10.1007/BF02231691
   Burke SK, 1997, NEPHROL DIAL TRANSPL, V12, P1640, DOI 10.1093/ndt/12.8.1640
   Chertow GM, 1997, AM J KIDNEY DIS, V29, P66, DOI 10.1016/S0272 6386(97)90009 3
   Chertow GM, 1999, NEPHROL DIAL TRANSPL, V14, P2907, DOI 10.1093/ndt/14.12.2907
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   CLEMENTS MR, 1987, CLIN SCI, V73, P659, DOI 10.1042/cs0730659
   CONDON JR, 1971, ARCH DIS CHILD, V46, P269, DOI 10.1136/adc.46.247.269
   CORNELL CN, 1995, CURR OPIN ORTHOP, V6, P14
   D'Haese P C, 1987, Adv Exp Med Biol, V223, P89
   D'Haese PC, 2003, KIDNEY INT, V63, pS73, DOI 10.1046/j.1523 1755.63.s85.18.x
   DAMMENT SJP, 2003, AM SOC NEPHR ANN M S
   FOLDES J, 1991, BONE, V12, P67, DOI 10.1016/8756 3282(91)90002 Z
   GOODMAN WG, 1985, AM J KIDNEY DIS, V6, P330, DOI 10.1016/S0272 6386(85)80089 5
   GOODMAN WG, 1991, MINER ELECTROL METAB, V17, P221
   GOODMAN WG, 1984, J LAB CLIN MED, V103, P749
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   GOODMAN WG, 1986, KIDNEY INT, pS32
   Hergesell O, 2002, NEPHROL DIAL TRANSPL, V17, P14, DOI 10.1093/ndt/17.1.14
   HUTCHISON AJ, 1998, PERITON DIALYSIS INT, V18, pS38
   JABLONSKI G, 1993, BIOSCIENCE REP, V13, P275, DOI 10.1007/BF01137964
   Joy MS, 2003, AM J KIDNEY DIS, V42, P96, DOI 10.1016/S0272 6386(03)00554 7
   KOYAMA H, 1992, AM J PHSYL 2, V266, pF706
   LIEUALLEN WG, 1990, BONE, V11, P267, DOI 10.1016/8756 3282(90)90079 E
   LIEUALLEN WG, 1990, BONE, V11, P41, DOI 10.1016/8756 3282(90)90070 F
   Malluche HH, 2004, J AM SOC NEPHROL, V15, p270A
   Maluche HH, 2000, CLIN NEPHROL, V54, P309
   Martin KJ, 2001, AM J KIDNEY DIS, V38, P1430, DOI 10.1053/ajkd.2001.29283
   MCCLURE J, 1987, J CLIN PATHOL, V40, P446, DOI 10.1136/jcp.40.4.446
   Moscovici A, 1996, NEPHROL DIAL TRANSPL, V11, P146
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   RADER JI, 1979, AM J PHYSIOL, V236, pE118, DOI 10.1152/ajpendo.1979.236.2.E118
   ROBERTSON JA, 1983, KIDNEY INT, V23, P327, DOI 10.1038/ki.1983.23
   RODRIGUEZ M, 1990, J BONE MINER RES, V5, P59, DOI 10.1002/jbmr.5650050110
   Rufino M, 1998, NEPHROL DIAL TRANSPL, V13, P65, DOI 10.1093/ndt/13.suppl_3.65
   Silver J, 2002, ADV RENAL REPLACE TH, V9, P159, DOI 10.1053/jarr.2002.34846
   Slatopolsky E, 1999, AM J MED SCI, V317, P370, DOI 10.1097/00000441 199906000 00004
   SLATOPOLSKY E, 1986, NEW ENGL J MED, V315, P157, DOI 10.1056/NEJM198607173150304
   SLATOPOLSKY E, 1994, AM J KIDNEY DIS, V23, P229, DOI 10.1016/S0272 6386(12)80977 2
   SRIUSSADAPORN S, 1995, J BONE MINER RES, V10, P271
   Zabetakis PM, 2000, AM J KIDNEY DIS, V36, pS31, DOI 10.1053/ajkd.2000.19929
NR 45
TC 20
Z9 20
U1 0
U2 1
PU DUSTRI VERLAG DR KARL FEISTLE
PI DEISENHOFEN MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D 82032 DEISENHOFEN MUENCHEN, GERMANY
SN 0301 0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD FEB
PY 2005
VL 63
IS 2
BP 127
EP 137
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 894QA
UT WOS:000226805500011
PM 15730055
DA 2025 08 17
ER

PT J
AU Chen, TY
   Lin, NY
   Wen, CH
   Lin, CA
   Venkatesan, P
   Wijerathna, P
   Lin, CY
   Lai, PS
AF Chen, Tzu Yang
   Lin, Neng Yu
   Wen, Chih Hao
   Lin, Chih An
   Venkatesan, Parthiban
   Wijerathna, Prasanna
   Lin, Chung Yu
   Lai, Ping Shan
TI Development of triamcinolone acetonide hyaluronic acid conjugates with
   selective targeting and less osteoporosis effect for rheumatoid
   arthritis treatments
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Hyaluronic acid; Poorly water soluble corticosteroid; Rheumatoid
   arthritis
ID BASIS SETS; NANOPARTICLES; DELIVERY; RECOMMENDATIONS; NANOCARRIER;
   SOLUBILITY; PREDNISONE; MANAGEMENT; MICELLES; THERAPY
AB Rheumatoid arthritis (RA) is a common systemic autoimmune disease in developed countries. In clinical treat ment, steroids have been used as bridging and adjunctive therapy after disease modifying anti rheumatic drug administration. However, the severe side effects caused by the nonspecific targeting of organs followed by long term administration have limited their usage in RA. In this study, poorly water soluble triamcinolone acetonide (TA), a highly potent corticosteroid for intra articular injection, is conjugated on hyaluronic acid (HA) for intravenous purposes with increased specific drug accumulation in inflamed parts for RA. Our results demon strate that the designed HA/TA coupling reaction reveals >98 % conjugation efficiency in the dimethyl sulf oxide/water system, and the resulting HA TA conjugates show lower osteoblastic apoptosis compared with that in free TA treated osteoblast like NIH3T3 cells. Furthermore, in a collagen antibody induced arthritis animal study, HA TA conjugates enhanced the initiative targeting ability to inflame tissue and reduce the histopatho logical arthritic changes (score = 0). Additionally, the level of bone formation marker P1NP in HA TA treated ovariectomized mice (303.6 +/  40.6 pg/mL) is significantly higher than that in the free TA treated group (143.1 +/  3.9 pg/mL), indicating the potential for osteoporotic reduction using an efficient HA conjugation strategy for the long term administration of steroids against RA.
C1 [Chen, Tzu Yang; Wen, Chih Hao; Lin, Chih An; Venkatesan, Parthiban; Wijerathna, Prasanna; Lin, Chung Yu; Lai, Ping Shan] Natl Chung Hsing Univ, Dept Chem, Taichung 40227, Taiwan.
   [Chen, Tzu Yang] Holy Stone Healthcare Co Ltd, Basic Res Div, Taipei 114, Taiwan.
   [Lin, Neng Yu] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.
   [Lai, Ping Shan] Natl Chung Hsing Univ, Program Tissue Engn & Regenerat Med, Taichung 40227, Taiwan.
C3 National Chung Hsing University; National Taiwan University; National
   Chung Hsing University
RP Lai, PS (通讯作者)，Natl Chung Hsing Univ, Dept Chem, Taichung 40227, Taiwan.
EM cypanjimmy@gmail.com; nylin@ntu.edu.tw; pslai@email.nchu.edu.tw
RI ; Lai, Ping Shan/HOA 6819 2023; Venkatesan, Parthiban/GPF 5428 2022
OI Chen, Tzu Yang/0000 0002 3918 0710; Lai, Ping Shan/0000 0001 8589 184X
FU National Science and Technology Council of Taiwan
   [110 2113 M 005 021 MY3, 110 2124 M 001 MY3]; Ministry of Education of
   Taiwan [109RA112]
FX This research was funded by the National Science and Technology Council
   of Taiwan (110 2113 M 005 021 MY3, 110 2124 M 001 MY3 to P. S.L.) and
   the Ministry of Education of Taiwan (109RA112 to P. S. L.).
CR Abdallah BM, 2006, CELL MOL BIOL LETT, V11, P461, DOI 10.2478/s11658 006 0038 y
   Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Badraoui R, 2017, EUR J PHARM SCI, V105, P41, DOI 10.1016/j.ejps.2017.04.023
   Balkrishna A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44485 9
   Bardwell WA, 2002, RHEUMATOLOGY, V41, P38, DOI 10.1093/rheumatology/41.1.38
   Becker LC, 2009, INT J TOXICOL, V28, P5, DOI 10.1177/1091581809337738
   BINKLEY JS, 1980, J AM CHEM SOC, V102, P939, DOI 10.1021/ja00523a008
   BLOCK LH, 1973, J PHARM SCI, V62, P617, DOI 10.1002/jps.2600620416
   Campoccia D, 1998, BIOMATERIALS, V19, P2101, DOI 10.1016/S0142 9612(98)00042 8
   Caplan A, 2017, J AM ACAD DERMATOL, V76, P1, DOI 10.1016/j.jaad.2016.01.062
   Chen TY, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091366
   Combe B, 2007, BEST PRACT RES CL RH, V21, P27, DOI 10.1016/j.berh.2006.08.011
   Daley Yates PT, 2015, BRIT J CLIN PHARMACO, V80, P372, DOI 10.1111/bcp.12637
   Dobson AW, 2002, AM J PHYSIOL LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001
   Fieber W, 2007, MACROMOLECULES, V40, P5372, DOI 10.1021/ma070222i
   Fraenkel L, 2021, ARTHRIT CARE RES, V73, P924, DOI 10.1002/acr.24596
   Grishko V, 2009, J BIOL CHEM, V284, P9132, DOI 10.1074/jbc.M804178200
   Hoes JN, 2007, ANN RHEUM DIS, V66, P1560, DOI 10.1136/ard.2007.072157
   Hua C, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen 2017 000536
   Huerta Angeles G, 2018, CARBOHYD POLYM, V193, P383, DOI 10.1016/j.carbpol.2018.04.021
   Hyung W, 2008, BIOTECHNOL BIOENG, V99, P442, DOI 10.1002/bit.21578
   Jafari S, 2016, EUR J PHARM SCI, V91, P225, DOI 10.1016/j.ejps.2016.05.014
   Jensen F, 2001, J CHEM PHYS, V115, P9113, DOI 10.1063/1.1413524
   Jeon J, 2016, J NANOSCI NANOTECHNO, V16, P11849, DOI 10.1166/jnn.2016.13606
   Jian YS, 2017, INT J NANOMED, V12, P2315, DOI 10.2147/IJN.S120847
   Kang LJ, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120967
   Kompel AJ, 2019, RADIOLOGY, V293, P656, DOI 10.1148/radiol.2019190341
   Krasselt M, 2014, EXPERT REV CLIN IMMU, V10, P557, DOI 10.1586/1744666X.2014.904746
   Kumar P, 2013, CLIN MED INSIGHTS AR, V6, P35, DOI 10.4137/CMAMD.S5558
   KUO JW, 1991, BIOCONJUGATE CHEM, V2, P232, DOI 10.1021/bc00010a007
   Lee F, 2009, J CONTROL RELEASE, V134, P186, DOI 10.1016/j.jconrel.2008.11.028
   Li M, 2022, CARBOHYD POLYM, V288, DOI 10.1016/j.carbpol.2022.119402
   Liao JH, 2018, INT J BIOL MACROMOL, V113, P737, DOI 10.1016/j.ijbiomac.2018.03.004
   Lin CA, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101569
   Lühder F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091836
   Manju S, 2011, J COLLOID INTERF SCI, V359, P318, DOI 10.1016/j.jcis.2011.03.071
   Mauri E, 2020, EUR J PHARM BIOPHARM, V146, P143, DOI 10.1016/j.ejpb.2019.11.002
   Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201
   Moura MD, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012658
   Nahar M, 2009, PHARM RES DORDR, V26, P2588, DOI 10.1007/s11095 009 9973 4
   Naor D, 2003, ARTHRITIS RES THER, V5, P105, DOI 10.1186/ar746
   Oh EJ, 2010, J CONTROL RELEASE, V141, P2, DOI 10.1016/j.jconrel.2009.09.010
   Otón T, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.101477
   Ou HL, 2018, ACTA BIOMATER, V65, P339, DOI 10.1016/j.actbio.2017.10.034
   Quiñones JP, 2017, CARBOHYD POLYM, V173, P157, DOI 10.1016/j.carbpol.2017.05.048
   Radu AF, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112857
   Ren K, 2014, J CONTROL RELEASE, V175, P1, DOI 10.1016/j.jconrel.2013.11.024
   Romanou V, 2021, J PERS MED, V11, DOI 10.3390/jpm11060556
   Salt AN, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00347
   Schett G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05800 6
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Schoenmakers RG, 2004, J CONTROL RELEASE, V95, P291, DOI 10.1016/j.jconrel.2003.12.009
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Strehl C, 2017, EXPERT OPIN INV DRUG, V26, P187, DOI 10.1080/13543784.2017.1276562
   Svanovsky E, 2008, EUR J DRUG METAB PH, V33, P149
   Szulc P, 2017, OSTEOPOROSIS INT, V28, P2541, DOI 10.1007/s00198 017 4082 4
   Taz M, 2019, MAT SCI ENG C MATER, V99, P1058, DOI 10.1016/j.msec.2019.02.051
   Timmermans S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01545
   Tit DM, 2017, IRAN J PUBLIC HEALTH, V46, P1528
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   Vanniasinghe AS, 2014, CLIN IMMUNOL, V151, P43, DOI 10.1016/j.clim.2014.01.005
   Vogus DR, 2017, J CONTROL RELEASE, V267, P191, DOI 10.1016/j.jconrel.2017.08.016
   Wang Q, 2021, ACTA PHARM SIN B, V11, P1158, DOI 10.1016/j.apsb.2021.03.013
   Wang Q, 2016, J CONTROL RELEASE, V230, P64, DOI 10.1016/j.jconrel.2016.03.035
   Wang ZY, 2020, DRUG DES DEV THER, V14, P1095, DOI 10.2147/DDDT.S230306
   Weikum ER, 2017, MOL PHARMACOL, V92, P12, DOI 10.1124/mol.117.108506
   Wilson LA, 2020, J ARTHROPLASTY, V35, P1979, DOI 10.1016/j.arth.2020.04.012
   Wu GJ, 2007, J CELL BIOCHEM, V101, P1520, DOI 10.1002/jcb.21268
   Yalkowsky S.H., 1992, AQUASOL DATABASE AQU
   You DG, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe0083
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhai PS, 2020, INT J BIOL MACROMOL, V151, P1224, DOI 10.1016/j.ijbiomac.2019.10.169
   Zhao NB, 2016, J BIOMED MATER RES A, V104, P1560, DOI 10.1002/jbm.a.35681
   Zhong YN, 2016, BIOMATERIALS, V84, P250, DOI 10.1016/j.biomaterials.2016.01.049
   Zhou ML, 2018, DRUG DELIV, V25, P716, DOI 10.1080/10717544.2018.1447050
NR 75
TC 5
Z9 5
U1 2
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAY 15
PY 2023
VL 237
AR 124047
DI 10.1016/j.ijbiomac.2023.124047
EA MAR 2023
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA C1JC7
UT WOS:000959555800001
PM 36933598
DA 2025 08 17
ER

PT J
AU Li, CC
   Liu, YC
   Deng, MX
   Li, J
   Li, SQ
   Li, XY
   Zuo, YL
   Shen, CY
   Wang, YC
AF Li, Chuncai
   Liu, Yincong
   Deng, Mingxing
   Li, Jun
   Li, Shengqi
   Li, Xiaoyu
   Zuo, Yuling
   Shen, Chongyang
   Wang, Yichao
TI Comparison of the therapeutic effects of mesenchymal stem cells derived
   from human dental pulp (DP), adipose tissue (AD), placental amniotic
   membrane (PM), and umbilical cord (UC) on postmenopausal osteoporosis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoporosis; mesenchymal stem cells; Th17/Treg; macrophage
   polarization; immunoregulatory activity
ID BONE MARROW; OSTEOGENIC DIFFERENTIATION; PATHOGENESIS; METABOLISM;
   ACTIVATION; OSTEOLYSIS; HEALTH; IL 17
AB Background: Osteoporosis is a systemic bone disease characterized by bone loss and microstructural degeneration. Recent preclinical and clinical trials have further demonstrated that the transplantation of mesenchymal stem cells (MSCs) derived from human adipose tissue (AD), dental pulp (DP), placental amniotic membrane (AM), and umbilical cord (UC) tissues can serve as an effective form of cell therapy for osteoporosis. However, MSC mediated osteoimmunology and the ability of these cells to regulate osteoclast osteoblast differentiation varies markedly among different types of MSCs.Methods: In this study, we investigated whether transplanted allogeneic MSCs derived from AD, DP, AM, and UC tissues were able to prevent osteoporosis in an ovariectomy (OVX) induced mouse model of osteoporosis. The homing and immunomodulatory ability of these cells as well as their effects on osteoblastogenesis and the maintenance of bone formation were compared for four types of MSCs to determine the ideal source of MSCs for the cell therapy based treatment of OVX induced osteoporosis. The bone formation and bone resorption ability of these four types of MSCs were analyzed using micro computed tomography analyses and histological staining. In addition, cytokine array based analyses of serological markers and bioluminescence imaging assays were employed to evaluate cell survival and homing efficiency. Immune regulation was determined by flow cytometer assay to reflect the mechanisms of osteoporosis treatment.Conclusion: These analyses demonstrated that MSCs isolated from different tissues have the capacity to treat osteoporosis when transplanted in vivo. Importantly, DP MSCs infusion was able to maintain trabecular bone mass more efficiently with corresponding improvements in trabecular bone volume, mineral density, number, and separation. Among the tested MSC types, DP MSCs were also found to exhibit greater immunoregulatory capabilities, regulating the Th17/Treg and M1/M2 ratios. These data thus suggest that DP MSCs may represent an effective tool for the treatment of osteoporosis.
C1 [Li, Chuncai; Liu, Yincong; Deng, Mingxing; Li, Xiaoyu; Zuo, Yuling; Shen, Chongyang] Chengdu Univ Tradit Chinese Med, Stem Cells Res Ctr, Chengdu, Peoples R China.
   [Li, Chuncai; Zuo, Yuling] Chengdu Univ Tradit Chinese Med, TCM Hosp Sichuan Prov, Chengdu, Peoples R China.
   [Li, Jun; Li, Shengqi] Sichuan Prov Cells Tissue Bank, Chengdu, Peoples R China.
   [Wang, Yichao] Sichuan Univ, West China Hosp, Dept Thyroid Surg, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Sichuan University
RP Zuo, YL; Shen, CY (通讯作者)，Chengdu Univ Tradit Chinese Med, Stem Cells Res Ctr, Chengdu, Peoples R China.; Zuo, YL (通讯作者)，Chengdu Univ Tradit Chinese Med, TCM Hosp Sichuan Prov, Chengdu, Peoples R China.; Wang, YC (通讯作者)，Sichuan Univ, West China Hosp, Dept Thyroid Surg, Chengdu, Peoples R China.
EM zuoyl@cdutcm.edu.cn; scylc@163.com; xiaohonghuman@163.com
RI Li, Xiaoyu/R 4413 2016
FU National Natural Science Foundation of China [82174226]; Xinglin talent
   Foundation of Chengdu University of TCM [XSGG2020002]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   by the National Natural Science Foundation of China (No. 82174226),
   Xinglin talent Foundation of Chengdu University of TCM (XSGG2020002).
CR Ahmadi H, 2020, IRAN J PUBLIC HEALTH, V49, P1769, DOI 10.18502/ijph.v49i9.4098
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471 4906(00)01812 3
   Avioli L V, 1976, Adv Intern Med, V21, P391
   Barlow S, 2008, STEM CELLS DEV, V17, P1095, DOI 10.1089/scd.2007.0154
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Cao XC, 2020, THERANOSTICS, V10, P7697, DOI 10.7150/thno.45434
   Chen TN, 2021, BIOL RES, V54, DOI 10.1186/s40659 021 00366 y
   Damani JJ, 2022, ADV NUTR, V13, P1476, DOI 10.1093/advances/nmab162
   de Witte SFH, 2018, STEM CELLS, V36, P602, DOI 10.1002/stem.2779
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   Feng SY, 2020, J ORAL REHABIL, V47, P1150, DOI 10.1111/joor.13041
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Govey PM, 2014, J BIOMECH, V47, P1838, DOI 10.1016/j.jbiomech.2014.03.022
   Hardaway AL, 2015, CLIN EXP METASTAS, V32, P353, DOI 10.1007/s10585 015 9714 5
   Heo JS, 2016, INT J MOL MED, V37, P115, DOI 10.3892/ijmm.2015.2413
   Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007
   Hu YQ, 2020, MOL MED REP, V22, P4716, DOI 10.3892/mmr.2020.11543
   Hu Y, 2020, THERANOSTICS, V10, P2293, DOI 10.7150/thno.39238
   Hua Q, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02990 1
   Hurley DL, 1997, MAYO CLIN PROC, V72, P943
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Kong FX, 2018, HUM GENE THER, V29, P271, DOI 10.1089/hum.2017.091
   Korbecki J, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084205
   Kumar A, 2018, BIOCHIMIE, V155, P129, DOI 10.1016/j.biochi.2018.10.014
   Lechner J, 2018, CLIN COSMET INVESTIG, V10, P251, DOI 10.2147/CCIDE.S184498
   Lee K, 2011, J CELL MOL MED, V15, P2082, DOI 10.1111/j.1582 4934.2010.01230.x
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li KL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 021 01236 1
   Li XY, 2014, INT J MOL MED, V34, P695, DOI 10.3892/ijmm.2014.1821
   Lin WL, 2020, AM J CHINESE MED, V48, P1749, DOI 10.1142/S0192415X20500871
   LINDSAY R, 1993, BAILLIERE CLIN RHEUM, V7, P499, DOI 10.1016/S0950 3579(05)80075 5
   Maeda A, 2022, EXP THER MED, V23, DOI 10.3892/etm.2022.11228
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Molnár I, 2014, OSTEOPOROSIS INT, V25, P783, DOI 10.1007/s00198 013 2548 6
   Mulholland BS, 2019, CURR OSTEOPOROS REP, V17, P538, DOI 10.1007/s11914 019 00545 7
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sanvoranart T, 2014, BIOCHEM BIOPH RES CO, V447, P580, DOI 10.1016/j.bbrc.2014.04.044
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Shi HF, 2018, CANCER SCI, V109, P3826, DOI 10.1111/cas.13809
   Sonoda S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01818 0
   Sophocleous A, 2019, METHODS MOL BIOL, V1914, P261, DOI 10.1007/978 1 4939 8997 3_13
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Tang MJ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.625034
   Tian J, 2023, BIOACT MATER, V22, P326, DOI 10.1016/j.bioactmat.2022.10.001
   Tsubaki M, 2010, J CELL BIOCHEM, V111, P1661, DOI 10.1002/jcb.22907
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Wang XY, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107370
   Yang CY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02270 4
   Yang XS, 2021, BIOACT MATER, V6, P3150, DOI 10.1016/j.bioactmat.2021.02.034
   Ye XH, 2014, CYTOTHERAPY, V16, P1643, DOI 10.1016/j.jcyt.2014.07.009
   Yin Y, 2022, J TISSUE ENG REGEN M, V16, P538, DOI 10.1002/term.3300
   YOO ZB, 1995, J IMMUNOL, V155, P5483
   Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441 017 2598 8
   Zhang Y, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00150 4
   Zhao RQ, 2016, ANN NUTR METAB, V68, P113, DOI 10.1159/000443531
   Zhu L, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979 020 00202 z
NR 59
TC 6
Z9 7
U1 3
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 27
PY 2024
VL 15
AR 1349199
DI 10.3389/fphar.2024.1349199
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NE8L2
UT WOS:001198867300001
PM 38601464
OA gold
DA 2025 08 17
ER

PT J
AU Chanda, D
   Isayeva, T
   Kumar, S
   Siegal, GP
   Szafran, AA
   Zinn, KR
   Reddy, VVB
   Ponnazhagan, S
AF Chanda, Diptiman
   Isayeva, Tatyana
   Kumar, Sanjay
   Siegal, Gene P.
   Szafran, April A.
   Zinn, Kurt R.
   Reddy, Vishnu V. B.
   Ponnazhagan, Selvarangan
TI Systemic osteoprotegerin gene therapy restores tumor induced bone loss
   in a therapeutic model of breast cancer bone metastasis
SO MOLECULAR THERAPY
LA English
DT Article
ID PROSTATE CANCER; MURINE MODEL; HUMORAL HYPERCALCEMIA; CELLS; OPG;
   MECHANISMS; OSTEOLYSIS; GROWTH; RANKL; INHIBITION
AB Enhanced production of receptor activator of nuclear factor kappa B ligand ( RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis. Osteoprotegerin ( OPG) is a decoy receptor that prevents RANKL RANK interaction. This study determined the effects of sustained expression of OPG using a recombinant adeno associated viral (rAAV) vector in mouse model of osteolytic breast cancer. Bone metastasis was established by intracardiac injection of the human breast cancer cell line MDA MB435. Following this, mice were administered a one time intramuscular injection of rAAV encoding either OPG. Fc (OPG) or green fluorescent protein (GFP). Mice were killed 1 month later and the effects of therapy on tumor growth and bone remodeling were evaluated. Bioluminescence imaging showed significant reduction of tumor growth in bone of OPG. Fc treated mice. Micro computed tomography (mu CT) analysis and histomorphometry of the tibia indicated significant protection of trabecular and cortical bones after OPG. Fc therapy. Despite the prevention of bone loss and tumor growth in bone, OPG. Fc therapy failed to provide long term survival. OPG. Fc treated mice developed more bone than age matched normal mice, indicating a requirement for regulated transgene expression. Results of this study indicate the potential of rAAV OPG therapy for reducing morbidity and mortality in breast cancer patients with osteolytic bone damage.
C1 [Chanda, Diptiman; Isayeva, Tatyana; Kumar, Sanjay; Siegal, Gene P.; Szafran, April A.; Reddy, Vishnu V. B.; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Zinn, Kurt R.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, Dept Pathol, 701 19th St S,LHRB 513, Birmingham, AL 35294 USA.
EM pons@uab.edu
RI ; Siegal, Gene/A 8653 2009; kumar, Sanjay/ITT 3680 2023
OI Zinn, Kurt/0000 0001 7463 4741; Reddy, Vishnu/0000 0001 5474 3289; 
FU NCI NIH HHS [R01CA98817, 5P30CA013148] Funding Source: Medline; NIAMS
   NIH HHS [R01AR50251] Funding Source: Medline
CR Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Capparelli C, 2000, CANCER RES, V60, P783
   Collaco RF, 1999, GENE, V238, P397, DOI 10.1016/S0378 1119(99)00347 9
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Fisher JL, 2006, CANCER RES, V66, P3620, DOI 10.1158/0008 5472.CAN 05 3119
   Holen I, 2006, CLIN SCI, V110, P279, DOI 10.1042/CS20050175
   Holen I, 2005, BREAST CANCER RES TR, V92, P207, DOI 10.1007/s10549 005 2419 8
   Isayeva T, 2005, CLIN CANCER RES, V11, P1342
   Isayeva T, 2007, CANCER RES, V67, P5789, DOI 10.1158/0008 5472.CAN 06 3637
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   KINGSTON RE, 2001, CURRENT PROTOCOLS MO, V2, P1
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Li CW, 2005, CANCER GENE THER, V12, P913, DOI 10.1038/sj.cgt.7700876
   Mastro AM, 2004, J CELL BIOCHEM, V91, P265, DOI 10.1002/jcb.10746
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Morony S, 2001, CANCER RES, V61, P4432
   Onyia JE, 2004, J PHARMACOL EXP THER, V309, P369, DOI 10.1124/jpet.103.057893
   Ponnazhagan S, 1997, HUM GENE THER, V8, P275, DOI 10.1089/hum.1997.8.3 275
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Tannehill Gregg SH, 2006, CLIN EXP METASTAS, V23, P19, DOI 10.1007/s10585 006 9008 z
   Ulrich Vinther M, 2005, BONE, V37, P751, DOI 10.1016/j.bone.2005.07.021
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Wang CY, 1997, ANTICANCER RES, V17, P2471
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Yang SY, 2002, ARTHRITIS RHEUM, V46, P2514, DOI 10.1002/art.10527
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 36
TC 26
Z9 31
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD MAY
PY 2008
VL 16
IS 5
BP 871
EP 878
DI 10.1038/mt.2008.48
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 296AT
UT WOS:000255516600014
PM 18388919
OA hybrid
DA 2025 08 17
ER

PT J
AU Song, HM
   Wei, YC
   Li, N
   Wu, B
   Xie, N
   Wang, HM
AF Song, Hongmei
   Wei, Yingchen
   Li, Nan
   Wu, Bin
   Xie, Na
   Wang, Heming
TI WENYANGBUSHEN INDUCED EXPRESSION OF VEGF, OPG, RANK, AND RANKL IN
   RABBITS WITH STEROID INDUCED FEMORAL HEAD AVASCULAR NECROSIS
SO GENETIKA BELGRADE
LA English
DT Article
DE Steroid induced avascular Necrosis of the Femoral Head; Wenyangbushen
   Formula; VEGF; OPG RANK RANKLSignaling pathways
ID ENDOTHELIAL GROWTH FACTOR; RECEPTOR ACTIVATOR; GENE EXPRESSION;
   OSTEONECROSIS; OSTEOPROTEGERIN; BONE; HIP; SYSTEM; LIGAND
AB This study was aimed to investigate the effects of Wenyangbushen formula on the mRNA and protein expression of VEGF, OPG, RANK, and RANKL in the steroidinduced avascular necrosis of the rabbit femoral head (SANFH) and to further explore the potential mechanism of this formula on the treatment of SANFH. One hundred and thirty six New Zealand rabbits were randomly divided into 5 groups (n = 24 rabbits in each group): normal group, model group, Traditional Chinese Medicine (TCM) Wenyangbushen decoction at low, moderate and high dose group. The normal group and positive control group were intragastrically (i.g.) administered with saline. The TCM group was treated with Wenyangbushen decoction at the indicated dosage. After treated for eight weeks, the mRNA and protein expression of VEGF, OPG, RANK, and RANKL in the femoral head tissues was determined by RT PCR and Western blotting, respectively. Wenyangbushen decoction treatment can effectively promote bone cells, osteoblasts and chondrocytes growth, as well as prevent the cell apoptosis in SANFH. The mRNA and protein expression of OPG and VEGF was increased while the levels of RANK and RANKL were reduced in the necrotic tissue of model group compared with those in the normal rabbits. And Wenyangbushen treatment prevented those changes, as manifested by up regulation of VEGF and OPG, while down regulation of RANK and RANKL levels in a dose dependent manner. Wenyangbushen Formula treatment can alleviate necrosis of femoral head induced by steroid. It can promote bone cells, osteoblasts and chondrocytes growth, as well as prevent the cell apoptosis. Meanwhile, it up regulates OPG and VEGF while inhibits RANK and RANKL expression. This may be one of the mechanisms for the effective treatment of SANFH.
C1 [Song, Hongmei; Wu, Bin] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 2, Internal Med Dept Dept, Fuzhou, Fujian, Peoples R China.
   [Song, Hongmei; Wei, Yingchen; Li, Nan; Wang, Heming] Fujian Univ Tradit Chinese Med, Fuzhou, Fujian, Peoples R China.
   [Xie, Na] Halison Int Peace Hosp, Hengshui, Hebei, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine
RP Wang, HM (通讯作者)，Fujian Univ Tradit Chinese Med, Fuzhou, Fujian, Peoples R China.
EM hemingwangfj@gmail.com
FU National Natural Science Foundation of China [81173283]; Project of
   Fujian Province Educational Department [JA13156]
FX This work was supported by the Project about treatment of
   steroid induced necrosis of femoral head by wenyangbushen prescription
   through regulating RANKL/OPG/RANK signaling pathways expression
   supported by National Natural Science Foundation of China (No. 81173283)
   and Project of Fujian Province Educational Department (No. JA13156)
CR Beckmann R, 2014, SCI WORLD J, DOI 10.1155/2014/347813
   Bekler Halil, 2007, Acta Orthop Traumatol Turc, V41, P58
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Chen Wei Heng, 2011, Zhongguo Gu Shang, V24, P352
   Hofstaetter JG, 2009, OSTEOARTHR CARTILAGE, V17, P362, DOI 10.1016/j.joca.2008.07.013
   Kim HKW, 2006, J BONE MINER RES, V21, P1946, DOI 10.1359/JBMR.060905
   Lee YJ, 2012, J ORTHOP RES, V30, P21, DOI 10.1002/jor.21492
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Sheng H, 2013, INT J CLIN EXP PATHO, V6, P1046
   Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steffen RT, 2010, J BONE JOINT SURG BR, V92B, P787, DOI 10.1302/0301 620X.92B6.23377
   Tong PJ, 2011, CALCIFIED TISSUE INT, V89, P271, DOI 10.1007/s00223 011 9516 y
   Varoga D, 2009, CLIN ORTHOP RELAT R, V467, P3273, DOI 10.1007/s11999 009 1076 3
   Wang G, 2010, J INT MED RES, V38, P1060, DOI 10.1177/147323001003800333
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Yeh LCC, 1999, MOL CELL ENDOCRINOL, V153, P113, DOI 10.1016/S0303 7207(99)00076 3
NR 17
TC 1
Z9 2
U1 0
U2 12
PU SERBIAN GENETICS SOC
PI BELGRADE
PA SLOBODANA BAJICA 1, BELGRADE, ZEMUN 11185, SERBIA
SN 0534 0012
EI 1820 6069
J9 GENETIKA BELGRADE
JI Genetika Belgrade
PY 2015
VL 47
IS 2
BP 477
EP 488
DI 10.2298/GENSR1502477S
PG 12
WC Agronomy; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Genetics & Heredity
GA CT8HL
UT WOS:000363055800010
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kolenda, C
   Josse, J
   Medina, M
   Fevre, C
   Lustig, S
   Ferry, T
   Laurent, F
AF Kolenda, Camille
   Josse, Jerome
   Medina, Mathieu
   Fevre, Cindy
   Lustig, Sebastien
   Ferry, Tristan
   Laurent, Frederic
TI Evaluation of the Activity of a Combination of Three Bacteriophages
   Alone or in Association with Antibiotics on Staphylococcus aureus
   Embedded in Biofilm or Internalized in Osteoblasts
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE Staphylococcus aureus; antibiotic; bacteriophages; biofilm;
   intracellular; osteoblasts
ID PHAGE THERAPY
AB Staphylococcus aureus is responsible for difficult to treat bone and joint infections (BJIs). This is related to its ability to form biofilm and to be internalized and persist inside osteoblasts. Recently, bacteriophage therapy has emerged as a promising option to improve treatment of such infections, but data on its activity against the specific bacterial lifestyles presented above remain scarce. We evaluated the activity of a combination of three bacteriophages, recently used for compassionate treatment in France, against S. aureus HG001 in a model of staphylococcal biofilm and a model of osteoblasts infection, alone or in association with vancomycin or rifampin. The activity of bacteriophages against biofilm embedded S. aureus was dose dependent. In addition, synergistic effects were observed when bacteriophages were combined with antibiotics used at the lowest concentrations. Phage penetration into osteoblasts was observed only when the cells were infected, suggesting a S. aureus dependent Trojan horse mechanism for internalization. The intracellular bacterial count of bacteria in infected osteoblasts treated with bacteriophages as well as with vancomycin was significantly higher than in cells treated with lysostaphin, used as a control condition, owing to the absence of intracellular activity and the rapid killing of bacteria released after the death of infected cells. These results suggest that bacteriophages are both inactive in the intracellular compartment after being internalized in infected osteoblasts and present a delayed killing effect on bacteria released after cell lysis into the extracellular compartment, which avoids preventing them from infecting other osteoblasts. The combination of bacteriophages tested was highly active against S. aureus embedded in biofilm but showed no activity against intracellular bacteria in the cell model used.
C1 [Kolenda, Camille; Josse, Jerome; Ferry, Tristan; Laurent, Frederic] Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon, UMR5308, CNRS,CIRI,Inserm U1111, Lyon, France.
   [Kolenda, Camille; Laurent, Frederic] Hosp Civils Lyon, Inst Agents Infect, Lab Bacteriol, Lyon, France.
   [Medina, Mathieu; Fevre, Cindy] Pherecydes Pharma, Romainville, France.
   [Lustig, Sebastien] Hosp Civils Lyon, Hop Croix Rousse, Serv Chirurg Orthoped & Traurnatol, Lyon, France.
   [Ferry, Tristan] Hosp Civils Lyon, Hop Croix Rousse, Serv Malad Infect & Trop, Lyon, France.
   [Kolenda, Camille; Josse, Jerome; Lustig, Sebastien; Ferry, Tristan; Laurent, Frederic] Hosp Civils Lyon, Ctr Interreg Reference Infect Osteoarticulaires C, Lyon, France.
   [Laurent, Frederic] Hosp Civils Lyon, Inst Agents Infect, Ctr Natl Reference Staphylocoques, Lyon, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de
   LYON); Universite Claude Bernard Lyon 1; Institut National de la Sante
   et de la Recherche Medicale (Inserm); CHU Lyon; CHU Lyon; CHU Lyon; CHU
   Lyon; CHU Lyon
RP Kolenda, C (通讯作者)，Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon, UMR5308, CNRS,CIRI,Inserm U1111, Lyon, France.; Kolenda, C (通讯作者)，Hosp Civils Lyon, Inst Agents Infect, Lab Bacteriol, Lyon, France.; Kolenda, C (通讯作者)，Hosp Civils Lyon, Ctr Interreg Reference Infect Osteoarticulaires C, Lyon, France.
EM camille.kolenda@chu lyon.fr
RI Kolenda, Camille/AAE 2592 2022; Lustig, Sébastien/E 3375 2013; LAURENT,
   Frederic/AGM 0706 2022
OI Kolenda, Camille/0000 0002 3716 0521; 
CR Akanda ZZ, 2018, J ORTHOP RES, V36, P1051, DOI 10.1002/jor.23755
   Alisky J, 1998, J INFECTION, V36, P5, DOI 10.1016/S0163 4453(98)92874 2
   Chaudhry WN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168615
   Doern CD, 2014, J CLIN MICROBIOL, V52, P4124, DOI 10.1128/JCM.01121 14
   Dupieux C, 2017, J ANTIMICROB CHEMOTH, V72, P3353, DOI 10.1093/jac/dkx314
   Ferry Tristan, 2005, Curr Infect Dis Rep, V7, P420, DOI 10.1007/s11908 005 0043 8
   Ferry T, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy269
   Ferry T, 2018, J ANTIMICROB CHEMOTH, V73, P2901, DOI 10.1093/jac/dky263
   Fischetti VA, 2010, INT J MED MICROBIOL, V300, P357, DOI 10.1016/j.ijmm.2010.04.002
   Green SI, 2017, SCI REP UK, V7, DOI 10.1038/srep46151
   Herbert S, 2010, INFECT IMMUN, V78, P2877, DOI 10.1128/IAI.00088 10
   Jonczyk E, 2011, FOLIA MICROBIOL, V56, P191, DOI 10.1007/s12223 011 0039 8
   Josse J, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00085
   Kapadia BH, 2016, LANCET, V387, P386, DOI 10.1016/S0140 6736(14)61798 0
   Kaur S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157626
   Kaur S, 2014, APPL MICROBIOL BIOT, V98, P4653, DOI 10.1007/s00253 014 5643 5
   Kim JH, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00119 19
   Kishor C, 2016, INDIAN J MED RES, V143, P87, DOI 10.4103/0971 5916.178615
   Kumaran D, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00127
   Kutateladze M, 2008, MED MALADIES INFECT, V38, P426, DOI 10.1016/j.medmal.2008.06.023
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   MAURIN M, 1992, J INFECT DIS, V166, P1097, DOI 10.1093/infdis/166.5.1097
   McConoughey SJ, 2014, FUTURE MICROBIOL, V9, P987, DOI [10.2217/fmb.14.64, 10.2217/FMB.14.64]
   Patey O, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11010018
   Rahman M, 2011, BIOFOULING, V27, P1087, DOI 10.1080/08927014.2011.631169
   Rollin G, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01354
   Saginur R, 2006, ANTIMICROB AGENTS CH, V50, P55, DOI 10.1128/AAC.50.1.55 61.2006
   Sanchez CJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471 2334 13 47
   Summers WC, 2001, ANNU REV MICROBIOL, V55, P437, DOI 10.1146/annurev.micro.55.1.437
   Tkhilaishvili T, 2018, INT J ANTIMICROB AG, V52, P842, DOI 10.1016/j.ijantimicag.2018.09.006
   Valour F, 2015, ANTIMICROB AGENTS CH, V59, P2029, DOI 10.1128/AAC.04359 14
   Yilmaz C, 2013, J BONE JOINT SURG AM, V95A, P117, DOI 10.2106/JBJS.K.01135
   Zhang LL, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01990 16
NR 33
TC 47
Z9 49
U1 1
U2 29
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
EI 1098 6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2020
VL 64
IS 3
AR e02231 19
DI 10.1128/AAC.02231 19
PG 9
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA KQ2MQ
UT WOS:000516763200070
PM 31871084
OA Green Published
DA 2025 08 17
ER

PT J
AU Han, SJ
   Zhu, Y
   Wu, ZH
   Zhang, JG
   Qiu, GX
AF Han, Shijie
   Zhu, Yong
   Wu, Zhihong
   Zhang, Jianguo
   Qiu, Guixing
TI The differently expressed proteins in MSCs of degenerative scoliosis
SO JOURNAL OF ORTHOPAEDIC SCIENCE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ANDROGEN INSENSITIVITY SYNDROME; BONE MINERAL
   DENSITY; OSTEOBLAST DIFFERENTIATION; RECEPTOR; TRANSCRIPTION; PROTEOMES;
   THERAPY; OSTERIX
AB Purpose Degenerative scoliosis (DS) is an important degenerative lumbar disease causing spinal dysfunction. The true reason or pathogenesis of DS is still unknown. Bone marrow derived mesenchymal stem cells (BM MSCs) are the stem/progenitor cells of the osteoblasts. The diseases associated with osteogenesis could be caused by abnormality of the MSCs. The purpose of this study was to find the differential proteins expressed in MSCs of patients with DS.
   Methods We collected and cultured the MSCs from 12 DS patients and 12 age and gender matched patients with lumbar spinal stenosis. Then the MSC samples were analyzed with 2D DIGE and MALDI TOF MS to find the differential proteins which were further validated by Western blot.
   Results We found 115 spots that were differently expressed in the MSC of DS patients with 2D DIGE, and 44 proteins were identified from samples of DS and control using MALDI TOF MS. Of these proteins, PIAS2, NDUFA2, and TRIM 68, which were up regulated in DS more than 4 times were validated by Western blot.
   Conclusions The information obtained with this proteomics analysis will be useful in understanding the pathophysiology of DS. Further investigations on the functioning pathway, the specificity and the mechanism of these proteins will be carried out.
C1 [Han, Shijie] Shandong Univ, Dept Orthopaed, Prov Hosp, Jinan 250100, Peoples R China.
   [Zhu, Yong] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed, Chongqing, Peoples R China.
   [Wu, Zhihong; Zhang, Jianguo; Qiu, Guixing] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Orthoped Surg, Beijing 100730, Peoples R China.
   [Wu, Zhihong; Zhang, Jianguo; Qiu, Guixing] Peking Union Med Coll, Beijing 100730, Peoples R China.
C3 Shandong University; Chongqing Medical University; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Peking Union Medical
   College Hospital; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Peking Union Medical College
RP Qiu, GX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Orthoped Surg, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
EM 86774570@qq.com
OI Qiu, Guixing/0000 0002 4597 9350
FU National Natural Science Foundation of China [30772191]
FX This work was supported by National Natural Science Foundation of China
   grants (no. 30772191).
CR Ali MM, 2007, J CELL SCI, V120, P2565, DOI 10.1242/jcs.005090
   Bertelloni S, 1998, HORM RES, V50, P309, DOI 10.1159/000023296
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Cooper SC, 2001, AM J MED GENET, V104, P1, DOI 10.1002/ajmg.10024
   Daffner Scott D, 2003, Am J Orthop (Belle Mead NJ), V32, P77
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Faldini C, 2006, J ORTHOP TRAUMATOL, V7, P67, DOI 10.1007/s10195 006 0123 z
   Huber DM, 2001, ENDOCRINOLOGY, V142, P3800, DOI 10.1210/en.142.9.3800
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Miyajima N, 2008, CANCER RES, V68, P3486, DOI 10.1158/0008 5472.CAN 07 6059
   MUNOZTORRES M, 1995, CALCIFIED TISSUE INT, V57, P94, DOI 10.1007/BF00298426
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884
   Pappou IP, 2006, SPINE, V31, P1614, DOI 10.1097/01.brs.0000222030.32171.5f
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ramagli LS, 1999, METH MOL B, V112, P99
   Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140
   Rosas Acosta G, 2005, VIROLOGY, V331, P190, DOI 10.1016/j.virol.2004.10.025
   Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018 003 3129 1
   Shirley D, 2005, J ORTHOP RES, V23, P1013, DOI 10.1016/j.orthres.2005.01.013
   Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667
   Tribus Clifford B, 2003, J Am Acad Orthop Surg, V11, P174
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Wagner W, 2006, EXP HEMATOL, V34, P536, DOI 10.1016/j.exphem.2006.01.002
   Yang ZY, 2009, SPINE, V34, pE115, DOI 10.1097/BRS.0b013e3181895aca
   Zhang W, 2004, STEM CELLS DEV, V13, P263, DOI 10.1089/154732804323099190
   Zhou H, 2010, BIOL BLOOD MARROW TR, V16, P403, DOI 10.1016/j.bbmt.2009.11.006
   Zhu Y, 2011, J ORTHOP RES, V29, P1896, DOI 10.1002/jor.21466
NR 30
TC 12
Z9 12
U1 0
U2 9
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0949 2658
EI 1436 2023
J9 J ORTHOP SCI
JI J. Orthop. Sci.
PD NOV
PY 2013
VL 18
IS 6
BP 885
EP 892
DI 10.1007/s00776 013 0444 8
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 269TR
UT WOS:000328265300003
PM 23934146
DA 2025 08 17
ER

PT J
AU Clyburn, RD
   Reid, P
   Evans, CA
   Lefley, DV
   Holen, I
AF Clyburn, Rhys D.
   Reid, Penny
   Evans, Catherine A.
   Lefley, Diane V.
   Holen, Ingunn
TI Increased anti tumour effects of doxorubicin and zoledronic acid in
   prostate cancer cells in vitro: supporting the benefits of combination
   therapy
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Prostate cancer; Chemotherapy; Combination therapy; Bisphosphonates
ID NITROGEN CONTAINING BISPHOSPHONATES; BREAST TUMOR CELLS; C MYC
   EXPRESSION; MEVALONATE PATHWAY; INDUCE APOPTOSIS; DECREASED OSTEOLYSIS;
   BONE METASTASIS; GROWTH ARREST; LUNG CANCER; MOUSE MODEL
AB Combination treatment using the chemotherapy drug doxorubicin and the anti resorptive agent zoledronic acid has shown to be very effective in inducing apoptosis in breast cancer cells, and also to eradicate breast tumour growth in vivo. Here, we investigated whether apoptotic cell death is increased when zoledronic acid and doxorubicin are given in sequence or in combination in prostate cancer cells in vitro.
   PC3, DU145 and LNCaP prostate cancer cells were treated with zoledronic acid or doxorubicin alone, in sequence or in combination, and apoptosis was measured by evaluation of nuclear morphology following staining with Hoechst and PI. The involvement of the mevalonate pathway in the induction of apoptosis was assessed through the addition of the mevalonate pathway intermediate geranylgeraniol.
   Both agents induced PC3 cell death, with 5 mu M zoledronic acid inducing 1.73% apoptosis and 50 nM doxorubicin 3.60% apoptosis following 24 h of exposure. In contrast, sequential exposure (doxorubicin followed by zoledronic acid) caused 8.87% apoptosis. Doxorubicin followed by zoledronic acid induced 4.77% apoptosis in LNCaP cells, compared to 1.53% caused by zol alone, 2.23% by dox alone and 2.5% following the reverse sequence (P < 0.001 in all cases). In DU145 cells doxorubicin followed by zoledronic acid induced 5.73% apoptosis, compared to 1.8% following zol alone, 2.93% by dox alone, and 3.20% following the reverse sequence (P < 0.001 in all cases).
   This is the first detailed study to show that an increased anti tumour effect is generated when doxorubicin and zoledronic acid are given in sequence in both hormone sensitive and insensitive prostate cancer cells in vitro. Our results suggest that combined treatment with these agents is superior to single agent therapy, and should be explored in a tumour model of prostate cancer.
C1 [Holen, Ingunn] Univ Sheffield, DU Sch Med & Biomed Sci 39, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Clyburn, Rhys D.; Reid, Penny; Evans, Catherine A.; Lefley, Diane V.] Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield
RP Holen, I (通讯作者)，Univ Sheffield, DU Sch Med & Biomed Sci 39, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM I.Holen@shef.ac.uk
OI Holen, Ingunn/0000 0002 8759 6913
FU Weston Park Hospital Cancer Charity, Sheffield, UK
FX R. D. Clyburn was sponsored by bursary by Yorkshire Cancer Research, UK.
   P. Reid is funded by a grant from Weston Park Hospital Cancer Charity,
   Sheffield, UK.
CR Boissier S, 2000, CANCER RES, V60, P2949
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   Budman DR, 2006, ONCOLOGY BASEL, V70, P147, DOI 10.1159/000093006
   Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10
   CLINES GA, 2008, EXPERT REV MOL MED, V6, pE7
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   FORNARI FA, 1994, CELL GROWTH DIFFER, V5, P723
   FORNARI FA, 1994, MOL PHARMACOL, V45, P649
   Fornari FA, 1996, BIOCHEM PHARMACOL, V51, P931, DOI 10.1016/0006 2952(96)00050 0
   FOURNIER P, 2002, CANCER RES, V62, P6238
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   GOLDENBERG GJ, 1986, CANCER RES, V46, P2978
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kröger N, 1999, CANCER TREAT REV, V25, P279, DOI 10.1053/ctrv.1999.0137
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Mike S, 2006, COCHRANE DB SYST REV, V18
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Pandha H, 2006, J UROLOGY, V176, P2255, DOI 10.1016/j.juro.2006.07.053
   Petrioli R, 2008, CANCER TREAT REV, V34, P710, DOI 10.1016/j.ctrv.2008.05.004
   Potter AJ, 2002, CARCINOGENESIS, V23, P389, DOI 10.1093/carcin/23.3.389
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Saad F, 2005, WORLD J UROL, V23, P14, DOI 10.1007/s00345 004 0472 2
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   SUNJIN K, 2005, CANCER RES, V65, P3707
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249
   Thudi NK, 2008, PROSTATE, V68, P1116, DOI 10.1002/pros.20776
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   VANBEEK ER, 2008, BREAST CANC RES TREA
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Ye L, 2007, INT J MOL MED, V20, P103
NR 44
TC 26
Z9 30
U1 1
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344 5704
EI 1432 0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD APR
PY 2010
VL 65
IS 5
BP 969
EP 978
DI 10.1007/s00280 009 1106 6
PG 10
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 557FR
UT WOS:000274655500018
PM 19730863
DA 2025 08 17
ER

PT S
AU Schwarz, EM
   Proulx, ST
   Ritchlin, CT
   Boyce, BF
   Xing, LP
AF Schwarz, Edward M.
   Proulx, Steven T.
   Ritchlin, Christopher T.
   Boyce, Brendan F.
   Xing, Lianping
BE Choi, Y
TI The Role of Bone Marrow Edema and Lymphangiogenesis in
   Inflammatory Erosive Arthritis
SO OSTEOIMMUNOLOGY: INTERACTIONS OF THE IMMUNE AND SKELETAL SYSTEMS II
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Proceedings Paper
CT 2nd International Conference on Osteoimmunology
CY JUN 08 13, 2008
CL Rhodes, GREECE
DE Inflammatory arthritis; Lymphangiogenesis; In vivo imaging; 3D MRI
ID TUMOR NECROSIS FACTOR; CELL DERIVED FACTOR 1; RHEUMATOID ARTHRITIS;
   OSTEOCLAST PRECURSORS; TRANSGENIC MICE; ANKYLOSING SPONDYLITIS;
   PSORIATIC ARTHRITIS; COMPUTED TOMOGRAPHY; JOINT DAMAGE; LYMPH NODE
AB A common feature of autoimmune diseases is the perpetual production of macrophage, dendritic and/or osteoclast effector cells, which mediate parenchymal tissue destruction in end organs. In support of this, we have demonstrated previously that patients and mice with inflammatory erosive arthritis have a marked increase in circulating CD11b+ precursor cells, which are primed for osteoclastogenesis, and that this increase in osteoclast precursors (OCPs) is due to systemically increased TNF production. From these data, we proposed a unifying hypothesis to explain these osteoimmunologic findings during the pathogenesis of inflammatory erosive arthritis, which has three postulates: (1) myelopoiesis chronically induced by TNF has profound effects on the bone marrow and joint tissues that should be evident from a longitudinal MRI; (2) TNF alters the chemokine/chemokine receptor axis in the bone marrow to stimulate OCP release into the blood, and (3) OCP mediated lymphangiogenesis occurs in the end organ as a compensatory mechanism to drain the inflammation and remove by products of joint catabolism. Here, we describe our recent experimental findings that support these hypotheses and speculate on how this information can be used as diagnostic biomarkers and tools to discover novel therapies to treat patients with inflammatory erosive arthritis.
C1 [Schwarz, Edward M.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
C3 University of Rochester
RP Schwarz, EM (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
EM edward_schwarz@urmc.rochester.edu; steven.proulx@pharma.ethz.ch;
   christopher_ritchlin@urmc.rochester.edu;
   brendan_boyce@urmc.rochester.edu; lianping_xing@urmc.rochester.edu
OI Proulx, Steven/0000 0003 2154 8502; ritchlin,
   christopher/0000 0002 2602 1219
FU NIAMS NIH HHS [R01 AR048697, R01 AR056702] Funding Source: Medline
CR Anandarajah AP, 2008, ANN RHEUM DIS, V67, P296, DOI 10.1136/ard.2007.076091
   Appel H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2035
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P1805, DOI 10.1002/art.21907
   Benton N, 2004, ANN RHEUM DIS, V63, P555, DOI 10.1136/ard.2003.011544
   Boyce BF, 2006, CURR OPIN RHEUMATOL, V18, P427, DOI 10.1097/01.bor.0000231913.32364.32
   Bradfield PF, 2003, ARTHRITIS RHEUM, V48, P2472, DOI 10.1002/art.11219
   Conaghan PG, 2005, J RHEUMATOL, V32, P2465
   Dohn UM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1995
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Haavardsholm EA, 2005, ARTHRITIS RHEUM US, V52, P3860, DOI 10.1002/art.21493
   Jimenez Boj E, 2005, J IMMUNOL, V175, P2579, DOI 10.4049/jimmunol.175.4.2579
   Jimenez Boj E, 2007, ARTHRITIS RHEUM US, V56, P1118, DOI 10.1002/art.22496
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kirkham BW, 2006, ARTHRITIS RHEUM, V54, P1122, DOI 10.1002/art.21749
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kuek A, 2007, POSTGRAD MED J, V83, P251, DOI 10.1136/pgmj.2006.052688
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Martínez Martínez MU, 2007, ANN RHEUM DIS, V66, P134, DOI 10.1136/ard.2006.056432
   Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018
   McGonagle D, 1999, ARTHRITIS RHEUM, V42, P1706, DOI 10.1002/1529 0131(199908)42:8<1706::AID ANR20>3.0.CO;2 Z
   McQueen FM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2075
   McQueen FM, 2000, RHEUMATOLOGY, V39, P700, DOI 10.1093/rheumatology/39.7.700
   Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002
   Ostergaard M, 1999, ARTHRITIS RHEUM, V42, P918, DOI 10.1002/1529 0131(199905)42:5<918::AID ANR10>3.0.CO;2 2
   Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147
   Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329
   Proulx ST, 2008, ARTHRITIS RHEUM US, V58, P2019, DOI 10.1002/art.23546
   Proulx ST, 2007, ANN NY ACAD SCI, V1117, P106, DOI 10.1196/annals.1402.016
   Proulx ST, 2007, ARTHRITIS RHEUM US, V56, P4024, DOI 10.1002/art.23128
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002 9440(10)65550 2
   Schwarz EM, 2006, ANN NY ACAD SCI, V1068, P275, DOI 10.1196/annals.1346.031
   Shealy DJ, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar430
   Su JL, 2007, BRIT J CANCER, V96, P541, DOI 10.1038/sj.bjc.6603487
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Zhang Q, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2326
   Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200
   Zhang Q, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2391
NR 41
TC 6
Z9 7
U1 0
U2 2
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
BN 978 1 4419 1049 3
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2010
VL 658
BP 1
EP 10
DI 10.1007/978 1 4419 1050 9_1
PG 10
WC Immunology; Medicine, Research & Experimental
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA BOD91
UT WOS:000276344400001
PM 19950010
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cifola, I
   Lionetti, M
   Pinatel, E
   Todoerti, K
   Mangano, E
   Pietrelli, A
   Fabris, S
   Mosca, L
   Simeon, V
   Petrucci, MT
   Morabito, F
   Offidani, M
   Di Raimondo, F
   Falcone, A
   Caravita, T
   Battaglia, C
   De Bellis, G
   Palumbo, A
   Musto, P
   Neri, A
AF Cifola, Ingrid
   Lionetti, Marta
   Pinatel, Eva
   Todoerti, Katia
   Mangano, Eleonora
   Pietrelli, Alessandro
   Fabris, Sonia
   Mosca, Laura
   Simeon, Vittorio
   Petrucci, Maria Teresa
   Morabito, Fortunato
   Offidani, Massimo
   Di Raimondo, Francesco
   Falcone, Antonietta
   Caravita, Tommaso
   Battaglia, Cristina
   De Bellis, Gianluca
   Palumbo, Antonio
   Musto, Pellegrino
   Neri, Antonino
TI Whole exome sequencing of primary plasma cell leukemia discloses
   heterogeneous mutational patterns
SO ONCOTARGET
LA English
DT Article
DE whole exome sequencing; plasma cell leukemia; multiple myeloma;
   mutations
ID IN SITU HYBRIDIZATION; MYELOMA WORKING GROUP; MULTIPLE MYELOMA;
   DRUG RESISTANCE; HUMAN CANCER; INTRACLONAL HETEROGENEITY;
   EXTRACELLULAR MATRIX; MOLECULAR MECHANISMS; GENETIC ABERRATIONS;
   BONE MARROW
AB Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell dyscrasia and may represent a valid model for high risk multiple myeloma (MM). To provide novel information concerning the mutational profile of this disease, we performed the whole exome sequencing of a prospective series of 12 pPCL cases included in a Phase II multicenter clinical trial and previously characterized at clinical and molecular levels. We identified 1, 928 coding somatic non silent variants on 1, 643 genes, with a mean of 166 variants per sample, and only few variants and genes recurrent in two or more samples. An excess of C > T transitions and the presence of two main mutational signatures (related to APOBEC over activity and aging) occurring in different translocation groups were observed. We identified 14 candidate cancer driver genes, mainly involved in cell matrix adhesion, cell cycle, genome stability, RNA metabolism and protein folding. Furthermore, integration of mutation data with copy number alteration profiles evidenced biallelically disrupted genes with potential tumor suppressor functions. Globally, cadherin/Wnt signaling, extracellular matrix and cell cycle checkpoint resulted the most affected functional pathways. Sequencing results were finally combined with gene expression data to better elucidate the biological relevance of mutated genes. This study represents the first whole exome sequencing screen of pPCL and evidenced a remarkable genetic heterogeneity of mutational patterns. This may provide a contribution to the comprehension of the pathogenetic mechanisms associated with this aggressive form of PC dyscrasia and potentially with high risk MM.
C1 [Cifola, Ingrid; Pinatel, Eva; Mangano, Eleonora; Pietrelli, Alessandro; Battaglia, Cristina; De Bellis, Gianluca] CNR, Inst Biomed Technol, I 20133 Milan, Italy.
   [Lionetti, Marta; Fabris, Sonia; Mosca, Laura; Neri, Antonino] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Lionetti, Marta; Fabris, Sonia; Mosca, Laura; Neri, Antonino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol, Milan, Italy.
   [Todoerti, Katia; Simeon, Vittorio] Referral Canc Ctr Basilicata, IRCCS CROB, Lab Preclin & Translat Res, Rionero In Vulture, PZ, Italy.
   [Petrucci, Maria Teresa] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Hematol, Rome, Italy.
   [Morabito, Fortunato] Azienda Osped Cosenza, Hematol Unit, Cosenza, Italy.
   [Offidani, Massimo] Azienda Osped Univ Osped Riuniti Ancona, Hematol Clin, Ancona, Italy.
   [Di Raimondo, Francesco] Univ Catania, Osped Ferrarotto, Div Hematol, Dept Biomed Sci, Catania, Italy.
   [Falcone, Antonietta] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy.
   [Caravita, Tommaso] Univ Roma Tor Vergata, Osped S Eugenio, Dept Hematol, Rome, Italy.
   [Battaglia, Cristina] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy.
   [Palumbo, Antonio] Univ Turin, AOU San Giovanni Battista, Div Hematol, Turin, Italy.
   [Musto, Pellegrino] Referral Canc Ctr Basilicata, IRCCS CROB, Sci Direct, Rionero In Vulture, PZ, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie
   Biomediche (ITB CNR); University of Milan; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; IRCCS CROB; Sapienza University Rome; Azienda
   Ospedaliera di Cosenza; University of Catania; IRCCS Casa Sollievo Della
   Sofferenza; University of Rome Tor Vergata; Sant'Eugenio Hospital;
   University of Milan; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista Molinette; IRCCS CROB
RP Neri, A (通讯作者)，Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
EM ingrid.cifola@itb.cnr.it; antonino.neri@unimi.it
RI Falcone, Antonietta/AAA 7407 2021; Di Raimondo, Francesco/K 7965 2016;
   Pinatel, Eva/AAC 1365 2019; Pietrelli, Alessandro/J 4389 2016; Simeon,
   Vittorio/K 6373 2016; Battaglia, Cristina/E 5166 2017; Palumbo,
   Antonio/ACP 1575 2022; De Bellis, Gianluca/H 9725 2013; Mangano,
   Eleonora/P 7028 2018; MANGANO, Eleonora/P 7028 2018; Cifola,
   Ingrid/IUQ 2311 2023; Caravita, Tommaso/O 8929 2019; Neri,
   Antonino/I 9690 2014
OI Di Raimondo, Francesco/0000 0002 7749 0293; Offidani,
   Massimo/0000 0003 2749 7347; Pietrelli, Alessandro/0000 0003 0241 8542;
   Simeon, Vittorio/0000 0003 2387 4125; , Antonietta
   Pia/0000 0003 1070 8873; Battaglia, Cristina/0000 0003 3025 9657;
   Todoerti, Katia/0000 0001 6687 6871; Fabris, Sonia/0000 0003 1341 0503;
   De Bellis, Gianluca/0000 0002 1622 4477; PINATEL, Eva
   Maria/0000 0002 2544 4594; CIFOLA, INGRID/0000 0003 2819 1171; MANGANO,
   Eleonora/0000 0002 4040 4654; Musto, Pellegrino/0000 0003 3277 6594;
   Neri, Antonino/0000 0001 9047 5912
FU Associazione Italiana Ricerca sul Cancro [IG 10136]; Italian Ministry of
   Health Finalized Research for Young Researchers [E66110000230001,
   GR 2011 02352026]; MIUR FIRB [RBFR10OS4G]
FX This work was supported by grants from the Associazione Italiana Ricerca
   sul Cancro (IG 10136) (A.N.), the Italian Ministry of Health Finalized
   Research for Young Researchers (CUP project E66110000230001) (K.T., P.M.
   and A.N.) (GR 2011 02352026) (I.C.) and the MIUR FIRB for Young
   Researchers (RBFR10OS4G) (I.C.).
CR Abdi J, 2013, ONCOTARGET, V4, P2186, DOI 10.18632/oncotarget.1497
   Albarracin F, 2011, BLOOD REV, V25, P107, DOI 10.1016/j.blre.2011.01.005
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008
   Avet Loiseau H, 2012, LEUKEMIA, V26, P158, DOI 10.1038/leu.2011.176
   Avet Loiseau H, 2001, BLOOD, V97, P822, DOI 10.1182/blood.V97.3.822
   Bladé J, 1999, HEMATOL ONCOL CLIN N, V13, P1259, DOI 10.1016/S0889 8588(05)70125 8
   Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997
   Bommert K, 2006, EUR J CANCER, V42, P1574, DOI 10.1016/j.ejca.2005.12.026
   Chang H, 2005, CANCER GENET CYTOGEN, V156, P150, DOI 10.1016/j.cancergencyto.2004.05.004
   Chang H, 2009, LEUKEMIA RES, V33, P259, DOI 10.1016/j.leukres.2008.06.027
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chiecchio L, 2009, GENE CHROMOSOME CANC, V48, P624, DOI 10.1002/gcc.20670
   Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097 0177(200006)218:2<213::AID DVDY1>3.0.CO;2 R
   Cristóbal I, 2013, HAEMATOLOGICA, V98, pE103, DOI [10.3324/haematol.2013.084731, 10.3324/haematol.2043.084731]
   Datta S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 397
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood 2012 01 405977
   Fei M, 2013, INT J HEMATOL, V98, P446, DOI 10.1007/s12185 013 1435 4
   de Larrea CF, 2013, LEUKEMIA, V27, P780, DOI 10.1038/leu.2012.336
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008 5472.CAN 05 4437
   Jossé R, 2014, CANCER RES, V74, P6968, DOI 10.1158/0008 5472.CAN 13 3369
   Kassambara A, 2014, ONCOTARGET, V5, P2487, DOI 10.18632/oncotarget.1740
   KYLE RA, 1974, ARCH INTERN MED, V133, P813, DOI 10.1001/archinte.133.5.813
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Lionetti M, 2013, CLIN CANCER RES, V19, P3130, DOI 10.1158/1078 0432.CCR 12 2043
   Lodé L, 2010, HAEMATOL HEMATOL J, V95, P1973, DOI 10.3324/haematol.2010.023697
   Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015
   Magi A, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 10 r120
   Mattioli M, 2005, ONCOGENE, V24, P2461, DOI 10.1038/sj.onc.1208447
   Melloni GEM, 2014, GENOME MED, V6, DOI 10.1186/gm563
   Messina M, 2014, BLOOD, V123, P2378, DOI 10.1182/blood 2013 10 534271
   Morris LGT, 2013, CELL CYCLE, V12, P1011, DOI 10.4161/cc.24305
   Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538
   Mosca L, 2013, AM J HEMATOL, V88, P16, DOI 10.1002/ajh.23339
   Musto P, 2014, LEUKEMIA, V28, P222, DOI 10.1038/leu.2013.241
   NERI A, 1993, BLOOD, V81, P128
   Ocio EM, 2014, LEUKEMIA, V28, P525, DOI 10.1038/leu.2013.350
   Schambony A, 2004, DIFFERENTIATION, V72, P307, DOI 10.1111/j.1432 0436.2004.07207002.x
   Slany A, 2014, J PROTEOME RES, V13, P844, DOI 10.1021/pr400881p
   Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597
   Tiedemann RE, 2008, LEUKEMIA, V22, P1044, DOI 10.1038/leu.2008.4
   Todoerti K, 2013, CLIN CANCER RES, V19, P3247, DOI 10.1158/1078 0432.CCR 12 3461
   Tomecki R, 2014, NUCLEIC ACIDS RES, V42, P1270, DOI 10.1093/nar/gkt930
   Vacca A, 2000, Dev Immunol, V7, P77, DOI 10.1155/2000/74372
   Vincent T, 2005, LEUKEMIA LYMPHOMA, V46, P803, DOI 10.1080/10428190500051448
   Walker BA, 2014, LEUKEMIA, V28, P384, DOI 10.1038/leu.2013.199
   Walker BA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7997
   Walker BA, 2012, BLOOD, V120, P1077, DOI 10.1182/blood 2012 03 412981
   Wang F, 2013, CELL MOL LIFE SCI, V70, P3989, DOI 10.1007/s00018 012 1254 4
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092 8674(00)80789 8
NR 54
TC 50
Z9 54
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 10
PY 2015
VL 6
IS 19
BP 17543
EP 17558
DI 10.18632/oncotarget.4028
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CO2VB
UT WOS:000359013600075
PM 26046463
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Liao, NS
   Huang, YM
   Ye, JX
   Chen, WL
   Li, ZF
   Lin, RH
   Li, XH
   Zheng, LP
   Liu, XX
AF Liao, Naishun
   Huang, Yunmei
   Ye, Jinxia
   Chen, Wenlie
   Li, Zuan Fang
   Lin, Ruhui
   Li, Xihai
   Zheng, Liangpu
   Liu, Xianxiang
TI Protective effects of Tougu Xiaotong capsule on tumor necrosis
   factor α injured UMR 106 cells
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE osteoblast; proliferation; differentiation; tumor necrosis factor alpha;
   Tougu Xiaotong capsule
ID OSTEOARTHRITIC SUBCHONDRAL BONE; TNF ALPHA; OSTEOBLAST DIFFERENTIATION;
   IN VITRO; CARTILAGE; EXPRESSION; APOPTOSIS; CYTOKINES; DISEASE; MODELS
AB Tumor necrosis factor alpha (TNF alpha) plays an important role in the abnormal metabolism of osteoblasts (OBs), which leads to subchondral bone (SB) alterations in osteoarthritis. In the present study, Tougu Xiaotong capsule (TXC), a traditional Chinese medicine, was used to treat TNF alpha injured OB like cells. The cellular viability, mortality and ultramicroscopic morphology were evaluated. Thereafter, the activity of alkaline phosphatase (ALP), secretion of osteocalcin (OCN) and mineralization of nodules were analyzed. The results showed that TXC treatment significantly promoted cell proliferation, reduced cellular mortality and improved cellular ultrastructure, particularly that of the endoplasmic reticulum and nucleus. These data indicate that TXC is able to promote cell growth, as well as prevent inflammation in OB like cells. Furthermore, the activity of ALP, secretion of OCN and mineralization of nodules were accelerated, and the calcium content of the TNF alpha injured OB like cells was promoted by TXC treatment. These results indicate that TXC protected the OB like cells from TNF alpha induced injuries. This may be a potential mechanism through which TXC regulates SB remodeling in the clinical treatment of osteoarthritis.
C1 [Liao, Naishun; Huang, Yunmei; Ye, Jinxia; Chen, Wenlie; Li, Zuan Fang; Lin, Ruhui; Li, Xihai; Zheng, Liangpu; Liu, Xianxiang] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China.
   [Huang, Yunmei; Ye, Jinxia; Chen, Wenlie; Li, Zuan Fang; Lin, Ruhui; Zheng, Liangpu; Liu, Xianxiang] Fujian Univ Tradit Chinese Med, Fujian Key Lab Integrat Med Geriatr, Fujian 350122, Peoples R China.
   [Huang, Yunmei; Chen, Wenlie; Li, Zuan Fang; Lin, Ruhui] Fujian Acad Integrat Med, Natl Lab Tradit Chinese Med Pharmacol Cell Struct, Fuzhou 350122, Fujian, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine
RP Chen, WL (通讯作者)，Fujian Univ Tradit Chinese Med, Acad Integrat Med, 1 Qiuyang Rd, Fuzhou 350122, Fujian, Peoples R China.
EM chen.wl@163.com; liuxianxiang@163.com
RI Li, Xihai/NUQ 4105 2025; liao, naishun/AAU 2618 2020
OI Liao, Naishun/0000 0002 2781 4229
FU Fujian Province Department of Science and Technology [2012Y4006];
   Natural Science Foundation of Fujian Province [2014J01356]; National
   Natural Science Foundation of China [81202836]; Chen Keji Development
   Fund for Integrative Medicine [CKJ2011004]
FX This study was supported by the Key Project of Fujian Province
   Department of Science and Technology (Grant no. 2012Y4006), the Natural
   Science Foundation of Fujian Province (Grant no. 2014J01356), the
   National Natural Science Foundation of China (Grant no. 81202836) and
   the Chen Keji Development Fund for Integrative Medicine (Grant no.
   CKJ2011004).
CR Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Chae HJ, 2000, ENDOCRINOLOGY, V141, P2904, DOI 10.1210/en.141.8.2904
   Cunningham CC, 2012, CLIN IMMUNOL, V144, P228, DOI 10.1016/j.clim.2012.06.007
   dela Cruz A, 2014, BONE, V59, P211, DOI 10.1016/j.bone.2013.11.021
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Huang W, 2012, ACTA PHARMACOL SIN, V33, P668, DOI 10.1038/aps.2011.189
   Huang YM, 2011, ZHONGGUO ZHONG YI GU, V19, P1
   Hulejová H, 2007, CYTOKINE, V38, P151, DOI 10.1016/j.cyto.2007.06.001
   Imhof H, 2000, INVEST RADIOL, V35, P581, DOI 10.1097/00004424 200010000 00004
   Joung YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047477
   Kuroki K, 2011, OSTEOARTHR CARTILAGE, V19, P1142, DOI 10.1016/j.joca.2011.06.007
   [李民 Li Min], 2012, [中国组织工程研究, Chinese Journal of Tissue Engineering Research], V16, P2669
   Li XH, 2011, CHIN J INTEGR MED, V17, P436, DOI 10.1007/s11655 011 0751 x
   Li XH, 2014, INT J MOL MED, V34, P545, DOI 10.3892/ijmm.2014.1794
   Lin MN, 2005, FUJIAN J TRADIT CHIN, V36, P15
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167 010 1054 z
   Minamitani C, 2010, MOL CELL ENDOCRINOL, V315, P195, DOI 10.1016/j.mce.2009.10.005
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Muraoka T, 2007, ARTHRITIS RHEUM US, V56, P3366, DOI 10.1002/art.22921
   Pon On W, 2013, MAT SCI ENG C MATER, V33, P1423, DOI 10.1016/j.msec.2012.12.046
   Stannus O, 2010, OSTEOARTHR CARTILAGE, V18, P1441, DOI 10.1016/j.joca.2010.08.016
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   Tat SK, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2325
   Tat SK, 2011, BONE, V49, P559, DOI 10.1016/j.bone.2011.06.005
   Tsukasaki M, 2011, BIOCHEM BIOPH RES CO, V410, P766, DOI 10.1016/j.bbrc.2011.06.048
   Xue Li wei, 2009, Hua Xi Kou Qiang Yi Xue Za Zhi, V27, P378
   Zheng CS, 2009, CHIN J INTEGR MED, V15, P371, DOI 10.1007/s11655 009 0371 x
NR 28
TC 4
Z9 4
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD NOV
PY 2015
VL 10
IS 5
BP 1908
EP 1914
DI 10.3892/etm.2015.2739
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CW3JW
UT WOS:000364889600045
PM 26640571
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Etschmaier, V
   Glänzer, D
   Eck, N
   Schäfer, U
   Leithner, A
   Georg, D
   Lohberger, B
AF Etschmaier, Vanessa
   Glaenzer, Dietmar
   Eck, Nicole
   Schaefer, Ute
   Leithner, Andreas
   Georg, Dietmar
   Lohberger, Birgit
TI Proton and Carbon Ion Irradiation Changes the Process of Endochondral
   Ossification in an Ex Vivo Femur Organotypic Culture Model
SO CELLS
LA English
DT Article
DE organotypic bone slides; particle therapy; proton irradiation; carbon
   ion irradiation; bone biology
ID HYPERTROPHIC CARTILAGE; BONE LOSS; GROWTH; RADIATION; RADIOTHERAPY;
   OSTEOBLAST; COMPONENT; COLLAGEN; TARGET; MATRIX
AB Particle therapy (PT) that utilizes protons and carbon ions offers a promising way to reduce the side effects of radiation oncology, especially in pediatric patients. To investigate the influence of PT on growing bone, we exposed an organotypic rat ex vivo femur culture model to PT. After irradiation, histological staining, immunohistochemical staining, and gene expression analysis were conducted following 1 or 14 days of in vitro culture (DIV). Our data indicated a significant loss of proliferating chondrocytes at 1 DIV, which was followed by regeneration attempts through chondrocytic cluster formation at 14 DIV. Accelerated levels of mineralization were observed, which correlated with increased proteoglycan production and secretion into the pericellular matrix. Col2 alpha 1 expression, which increased during the cultivation period, was significantly inhibited by PT. Additionally, the decrease in ColX expression over time was more pronounced compared to the non IR control. The chondrogenic markers BMP2, RUNX2, OPG, and the osteogenic marker ALPL, showed a significant reduction in the increase in expression after 14 DIV due to PT treatment. It was noted that carbon ions had a stronger influence than protons. Our bone model demonstrated the occurrence of pathological and regenerative processes induced by PT, thus building on the current understanding of the biological mechanisms of bone.
C1 [Etschmaier, Vanessa; Glaenzer, Dietmar; Eck, Nicole; Leithner, Andreas; Lohberger, Birgit] Med Univ Graz, Dept Orthopaed & Trauma, A 8036 Graz, Austria.
   [Schaefer, Ute] Med Univ Graz, Dept Neurosurg, Res Unit Expt Neurotraumatol, A 8036 Graz, Austria.
   [Georg, Dietmar] Med Univ Vienna, Dept Radiat Oncol, A 1090 Vienna, Austria.
   [Georg, Dietmar] MedAustron Ion Therapy Ctr, A 2700 Wiener Neustadt, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Vienna
RP Lohberger, B (通讯作者)，Med Univ Graz, Dept Orthopaed & Trauma, A 8036 Graz, Austria.
EM vanessa.mair@medunigraz.at; dietmar.glaenzer@medunigraz.at;
   nicole.eck@medunigraz.at; ute.schaefer@medunigraz.at;
   andreas.leithner@medunigraz.at; dietmar.georg@meduniwien.ac.at;
   birgit.lohberger@medunigraz.at
RI ; Georg, Dietmar/F 2783 2011; Leithner, Andreas/JBI 9805 2023
OI Leithner, Andreas/0000 0002 2598 2325; Lohberger,
   Birgit/0000 0002 3156 7902; Georg, Dietmar/0000 0002 8327 3877; 
FU The authors thank Katharina Stasny, Anna Falkner, and Sandra Barna for
   technical support during the irradiation shifts. Furthermore, we thank
   our native speaker colleague James Smith for proofreading our
   manuscript. Open Access Funding by the Austrian Scie; Austrian Science
   Fund (FWF)
FX The authors thank Katharina Stasny, Anna Falkner, and Sandra Barna for
   technical support during the irradiation shifts. Furthermore, we thank
   our native speaker colleague James Smith for proofreading our
   manuscript. Open Access Funding by the Austrian Science Fund (FWF).
CR Aigner T, 2003, ADV DRUG DELIVER REV, V55, P1569, DOI 10.1016/j.addr.2003.08.009
   Alvarez J, 2001, J BONE MINER RES, V16, P511, DOI 10.1359/jbmr.2001.16.3.511
   Chandra A, 2015, J BIOL CHEM, V290, P157, DOI 10.1074/jbc.M114.608158
   Chandra A, 2014, BONE, V67, P33, DOI 10.1016/j.bone.2014.06.030
   Chen HY, 2014, J BONE MINER RES, V29, P2653, DOI 10.1002/jbmr.2287
   Chen H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.664168
   Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623 200307000 00017
   Damron TA, 2008, RADIAT RES, V170, P284, DOI 10.1667/RR1254.1
   Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176377
   Durante M, 2018, SEMIN RADIAT ONCOL, V28, P160, DOI 10.1016/j.semradonc.2017.11.004
   Emerzian SR, 2023, J BONE MINER RES, V38, P1032, DOI 10.1002/jbmr.4828
   Garrison P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176752
   Grau C, 2020, MOL ONCOL, V14, P1492, DOI 10.1002/1878 0261.12677
   Guan XY, 2019, RADIAT ONCOL, V14, DOI 10.1186/s13014 019 1407 9
   Guo CJ, 2016, SCI REP UK, V6, DOI 10.1038/srep31318
   Hallett SA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236009
   Hartley KA, 2008, INT J RADIAT ONCOL, V70, P1343, DOI 10.1016/j.ijrobp.2007.08.085
   Hayden PJ, 2021, IN VITRO CELL DEV AN, V57, P95, DOI 10.1007/s11626 020 00500 2
   Horton JA, 2006, J ORTHOP RES, V24, P1945, DOI 10.1002/jor.20251
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Keller B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016421
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Krasin MJ, 2010, SEMIN RADIAT ONCOL, V20, P21, DOI 10.1016/j.semradonc.2009.09.001
   Kuess P, 2017, PHYS MED BIOL, V62, P9189, DOI 10.1088/1361 6560/aa955e
   LINSENMAYER TF, 1988, PATHOL IMMUNOPATH R, V7, P14, DOI 10.1159/000157085
   Lohberger B, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032315
   Majeed H, 2023, Adverse effects of radiation therapyM
   Margulies BS, 2006, CALCIFIED TISSUE INT, V78, P302, DOI 10.1007/s00223 005 0135 3
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Mitchell MJ, 1998, RADIOGRAPHICS, V18, P1125, DOI 10.1148/radiographics.18.5.9747611
   Mizumoto M, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28617
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Nilsson O, 2007, J ENDOCRINOL, V193, P75, DOI 10.1677/joe.1.07099
   Pacheco R, 2013, CURR OSTEOPOROS REP, V11, P299, DOI 10.1007/s11914 013 0174 z
   Park SH, 2011, RADIAT ONCOL J, V29, P135, DOI 10.3857/roj.2011.29.3.135
   Paulino AC, 2004, INT J RADIAT ONCOL, V60, P265, DOI 10.1016/j.ijrobp.2004.02.001
   Roebuck DJ, 1999, RADIOGRAPHICS, V19, P873, DOI 10.1148/radiographics.19.4.g99jl01873
   Ruangchan S, 2020, PHYS MEDICA, V76, P182, DOI 10.1016/j.ejmp.2020.07.010
   Srinivasaiah S, 2019, TISSUE ENG PART C ME, V25, P197, DOI [10.1089/ten.tec.2018.0368, 10.1089/ten.TEC.2018.0368]
   Stock M, 2018, Z MED PHYS, V28, P196, DOI 10.1016/j.zemedi.2017.09.007
   Sun Y, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9100488
   Wang BL, 2015, SCI REP UK, V5, DOI 10.1038/srep13667
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 43
TC 1
Z9 1
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD SEP
PY 2023
VL 12
IS 18
AR 2301
DI 10.3390/cells12182301
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA T1UX5
UT WOS:001075915700001
PM 37759523
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, JJ
   Li, J
   Hu, YM
   Dai, KR
   Gan, YK
   Zhao, JY
   Huang, MJ
   Zhang, XL
AF Xu, Jiajia
   Li, Jiao
   Hu, Yiming
   Dai, Kerong
   Gan, Yaokai
   Zhao, Jingyu
   Huang, Mingjian
   Zhang, Xiaoling
TI IL 23, but not IL 12, plays a critical role in inflammation mediated
   bone disorders
SO THERANOSTICS
LA English
DT Article
DE IL 12; IL 23; BMMSCs; bone formation/resorption; bone regeneration
ID MESENCHYMAL STEM CELLS; OSTEOCLAST FORMATION; EXTRACELLULAR VESICLES;
   IFN GAMMA; RHEUMATOID ARTHRITIS; RECEPTOR ACTIVATOR; IL 23/IL 17 AXIS;
   GENE EXPRESSION; MARROW CELLS; T CELLS
AB Interleukin 12 (IL 12) and IL 23 are thought to have central roles in inflammation and are critical to pathologies associated with inflammation induced bone disorders. The deletion of IL 12p40 (a common subunit of IL 12 and IL 23) can improve bone regeneration. However, the relative roles of IL 12 and IL 23 in bone disorders are largely unknown.
   Methods: Ectopic bone formation and skull defect models were established to evaluate the relative roles of IL 12 and IL 23 in inflammatory bone disorders. Differences in bone mass among WT, IL 12p35( / ), and IL 12p40( / ) mice (young and elderly) were detected by micro CT. Osteogenic and osteoclastic activities were explored using ELISA, qRT PCR, and histological analysis. Moreover, the mechanisms by which IL 12 and IL 23 regulated the differentiation of BMMSCs and RAW264.7 cells were explored using Alizarin Red and tartrate resistant acid phosphatase staining in vitro. Apilimod was used to inhibit IL 12 and IL 23 production in vivo.
   Results: Mice deficient in IL 12p40 promoted bone formation and protected against aging related bone loss. By contrast, bone loss was aggravated in IL 12( / ) mice, suggesting that IL 23 may play a dominant role in inflammation related bone disorders. Mechanistically, IL 12 and IL 23 coupled osteogenesis and osteoclastic activities to regulate bone homeostasis and repair. IL 23 deficiency increased bone formation and inhibited bone resorption. Finally, apilimod treatment significantly improved bone regeneration and calvarial defect repair.
   Conclusion: These data collectively uncover a previously unrecognized role of IL 23 in skeletal tissue engineering. Thus, IL 23 can act as a biomarker to predict diseases and treatment efficacy, and apilimod can be used as an effective therapeutic drug to combat inflammatory bone disorders
C1 [Xu, Jiajia; Li, Jiao; Zhao, Jingyu; Huang, Mingjian; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Orthoped Surg, Shanghai 200092, Peoples R China.
   [Xu, Jiajia; Hu, Yiming; Dai, Kerong; Zhang, Xiaoling] Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Chinese Acad Sci, Shanghai 200031, Peoples R China.
   [Dai, Kerong; Gan, Yaokai] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed, Shanghai Key Lab Orthopaed Implant,Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; University
   of Chinese Academy of Sciences, CAS; Shanghai Jiao Tong University
RP Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Orthoped Surg, Shanghai 200092, Peoples R China.; Zhang, XL (通讯作者)，Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Chinese Acad Sci, Shanghai 200031, Peoples R China.
EM xlzhang@shsmu.edu.cn
RI Zhang, Xiaoling/J 1666 2016; Hu, Yiming/HCH 0648 2022; huang,
   mingjian/IVH 6647 2023; xu, jiajia/AAL 9885 2020
OI Xu, Jiajia/0000 0002 6084 2029; Zhao, Jingyu/0000 0001 5744 3097; Huang,
   Mingjian/0000 0002 1921 4397; Zhang, Xiaoling/0000 0002 0134 1347; 
FU National Natural Science Foundation of China [81830078, 81772347,
   81572123]; Science and Technology Commission of Shanghai Municipality
   [19XD1434100, 16430723500]; Shanghai Municipal Education Commission Gao
   feng Clinical Medicine Grant Support [20161314]; Shanghai Jiao Tong
   University The Chinese University of Hong Kong Joint Research
   Collaboration Fund
FX This work was supported by grants from National Natural Science
   Foundation of China (No. 81830078, 81772347, 81572123), Science and
   Technology Commission of Shanghai Municipality (No.19XD1434100,
   16430723500), Shanghai Municipal Education Commission Gao feng Clinical
   Medicine Grant Support (No.20161314) and Shanghai Jiao Tong
   University The Chinese University of Hong Kong Joint Research
   Collaboration Fund.
CR Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Amcheslavsky A, 2006, J CELL PHYSIOL, V207, P244, DOI 10.1002/jcp.20563
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chen L, 2008, EUR J IMMUNOL, V38, P2845, DOI 10.1002/eji.200838192
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Croxford AL, 2014, CYTOKINE GROWTH F R, V25, P415, DOI 10.1016/j.cytogfr.2014.07.017
   Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   Curtis MM, 2009, J IMMUNOL, V183, P381, DOI 10.4049/jimmunol.0900939
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Gan YK, 2008, BIOMATERIALS, V29, P3973, DOI 10.1016/j.biomaterials.2008.06.026
   Gao MJ, 2017, THERANOSTICS, V7, P3690, DOI 10.7150/thno.18345
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood 2016 09 736892
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508
   Josephson AM, 2019, P NATL ACAD SCI USA, V116, P6995, DOI 10.1073/pnas.1810692116
   Ju JH, 2008, J IMMUNOL, V181, P1507, DOI 10.4049/jimmunol.181.2.1507
   Kamolmatyakul S, 2001, J DENT RES, V80, P351, DOI 10.1177/00220345010800011001
   Keino H, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2530
   Kim HO, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 113
   Kim N, 2013, KOREAN J INTERN MED, V28, P387, DOI 10.3904/kjim.2013.28.4.387
   Kitami S, 2010, BIOCHIMIE, V92, P398, DOI 10.1016/j.biochi.2009.12.011
   Kitaura H, 2002, J IMMUNOL, V169, P4732, DOI 10.4049/jimmunol.169.9.4732
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105 2896.2004.00214.x
   Lin H, 2019, BIOMATERIALS, V203, P96, DOI 10.1016/j.biomaterials.2018.06.026
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lubberts E, 2015, NAT REV RHEUMATOL, V11, P415, DOI 10.1038/nrrheum.2015.53
   McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003
   Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   Nagata N, 2003, BONE, V33, P721, DOI 10.1016/S8756 3282(03)00213 8
   Nguyen CT, 2018, CLIN IMMUNOL
   Paradowska Gorycka A, 2010, SCAND J IMMUNOL, V71, P134, DOI 10.1111/j.1365 3083.2009.02361.x
   Peters F, 2004, MATERIALWISS WERKST, V35, P203, DOI 10.1002/mawe.200400735
   Pope RM, 2013, NAT REV RHEUMATOL, V9, P252, DOI 10.1038/nrrheum.2012.170
   Rea IM, 2000, CYTOKINE, V12, P156, DOI 10.1006/cyto.1999.0537
   Sakkas LI, 1998, CELL IMMUNOL, V188, P105, DOI 10.1006/cimm.1998.1363
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Shanmugarajan S, 2009, J CELL BIOCHEM, V107, P104, DOI 10.1002/jcb.22104
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Suzuki E, 2014, AUTOIMMUN REV, V13, P496, DOI 10.1016/j.autrev.2014.01.050
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Tang CL, 2012, IMMUNOLOGY, V135, P112, DOI 10.1111/j.1365 2567.2011.03522.x
   Teng MWL, 2015, NAT MED, V21, P719, DOI 10.1038/nm.3895
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   Vernal R, 2008, ARCH ORAL BIOL, V53, P910, DOI 10.1016/j.archoralbio.2008.04.004
   Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366
   Vonk LA, 2018, THERANOSTICS, V8, P906, DOI 10.7150/thno.20746
   Wada Y, 2007, BLOOD, V109, P1156, DOI 10.1182/blood 2006 04 019398
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Xu JJ, 2020, J BONE MINER RES, V35, P167, DOI 10.1002/jbmr.3871
   Xu JJ, 2016, CELL DEATH DIFFER, V23, P1941, DOI 10.1038/cdd.2016.72
   Yin H, 2019, THERANOSTICS, V9, P2678, DOI 10.7150/thno.31884
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zaky DSE, 2016, INT IMMUNOPHARMACOL, V31, P105, DOI 10.1016/j.intimp.2015.12.011
   Zhang JR, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5950395
   Zhang LM, 2019, THERANOSTICS, V9, P196, DOI 10.7150/thno.27550
   Zheng ZW, 2018, THERANOSTICS, V8, P5482, DOI 10.7150/thno.28315
NR 61
TC 15
Z9 16
U1 2
U2 24
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 9
BP 3925
EP 3938
DI 10.7150/thno.41378
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA KT1LO
UT WOS:000518773300006
PM 32226529
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, RJ
   Ginn, SL
   Lek, M
   North, KN
   Alexander, IE
   Little, DG
   Schindeler, A
AF Liu, Renjing
   Ginn, Samantha L.
   Lek, Monkol
   North, Kathryn N.
   Alexander, Ian E.
   Little, David G.
   Schindeler, Aaron
TI Myoblast sensitivity and fibroblast insensitivity to osteogenic
   conversion by BMP 2 correlates with the expression of Bmpr 1a
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; MUSCLE DERIVED CELLS; HUMAN
   SKELETAL MUSCLE; VIVO GENE THERAPY; HETEROTOPIC OSSIFICATION;
   STEM CELLS; OSTEOPROGENITOR CELLS; C2C12 MYOBLASTS; IN VITRO; OSTEOBLAST
   DIFFERENTIATION
AB Background: Osteoblasts are considered to primarily arise from osseous progenitors within the periosteum or bone marrow. We have speculated that cells from local soft tissues may also take on an osteogenic phenotype. Myoblasts are known to adopt a bone gene program upon treatment with the osteogenic bone morphogenetic proteins (BMP 2, 4, 6, 7, 9), but their osteogenic capacity relative to other progenitor types is unclear. We further hypothesized that the sensitivity of cells to BMP 2 would correlate with BMP receptor expression.
   Methods: We directly compared the BMP 2 sensitivity of myoblastic murine cell lines and primary cells with osteoprogenitors from osseous tissues and fibroblasts. Fibroblasts forced to undergo myogenic conversion by transduction with a MyoD expressing lentiviral vector (LV MyoD) were also examined. Outcome measures included alkaline phosphatase expression, matrix mineralization, and expression of osteogenic genes (alkaline phosphatase, osteocalcin and bone morphogenetic protein receptor 1A) as measured by quantitative PCR.
   Results: BMP 2 induced a rapid and robust osteogenic response in myoblasts and osteoprogenitors, but not in fibroblasts. Myoblasts and osteoprogenitors grown in osteogenic media rapidly upregulated Bmpr 1a expression. Chronic BMP 2 treatment resulted in peak Bmpr 1a expression at day 6 before declining, suggestive of a negative feedback mechanism. In contrast, fibroblasts expressed low levels of Bmpr 1a that was only weakly up regulated by BMP 2 treatment. Bioinformatics analysis confirmed the presence of myogenic responsive elements in the proximal promoter region of human and murine BMPR 1A/Bmpr 1a. Forced myogenic gene expression in fibroblasts was associated with a significant increase in Bmpr 1a expression and a synergistic increase in the osteogenic response to BMP 2.
   Conclusion: These data demonstrate the osteogenic sensitivity of muscle progenitors and provide a mechanistic insight into the variable response of different cell lineages to BMP 2.
C1 [Liu, Renjing; Little, David G.; Schindeler, Aaron] Childrens Hosp Westmead, Orthopaed Res & Biotechnol Unit, Sydney, NSW, Australia.
   [Liu, Renjing; Lek, Monkol; North, Kathryn N.; Alexander, Ian E.; Little, David G.; Schindeler, Aaron] Univ Sydney, Fac Med, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia.
   [Ginn, Samantha L.; Alexander, Ian E.] Childrens Med Res Inst, Gene Therapy Res Unit, Sydney, NSW, Australia.
   [Lek, Monkol; North, Kathryn N.] Childrens Hosp Westmead, Inst Neuromuscular Res, Sydney, NSW, Australia.
C3 NSW Health; The Children's Hospital at Westmead; University of Sydney;
   University of Sydney; Children's Medical Research Institute   Australia;
   University of Sydney; University of Sydney; NSW Health; The Children's
   Hospital at Westmead
RP Liu, RJ (通讯作者)，Childrens Hosp Westmead, Orthopaed Res & Biotechnol Unit, Sydney, NSW, Australia.
EM renjingl@chw.edu.au; sginn@cmri.com.au; MonkolL@chw.edu.au;
   Kathryn@chw.edu.au; IanA@chw.edu.au; DavidL3@chw.edu.au;
   aarons@chw.edu.au
RI ; North, Kathryn/K 6476 2012
OI Alexander, Ian E/0000 0002 6213 5627; Liu, Renjing/0000 0001 9099 0076;
   Schindeler, Aaron/0000 0002 7757 6281; North,
   Kathryn/0000 0003 0841 8009
FU Australian Orthopaedic Research Foundation (AORF); National Health &
   Medical Research Council [457245]
FX We like to thank Professor Inder Verma (Salk Institute, San Diego) for
   providing the lentiviral constructs. This work was supported by grants
   from the Australian Orthopaedic Research Foundation (AORF) and from the
   National Health & Medical Research Council (NH& MRC, grant # 457245).
   Samantha L. Ginn is the recipient of a fellowship honouring the memory
   of Noel Dowling.
CR Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680
   Bosch P, 2000, J ORTHOP RES, V18, P933, DOI 10.1002/jor.1100180613
   Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Cossu G, 2003, CURR OPIN GENET DEV, V13, P537, DOI 10.1016/j.gde.2003.08.001
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Hewitt J, 2008, ENDOCRINOLOGY, V149, P3698, DOI 10.1210/en.2007 1556
   Jortikka L, 1998, LIFE SCI, V62, P2359, DOI 10.1016/S0024 3205(98)00218 5
   Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756 3282(99)00111 8
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359 6101(97)00036 1
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Khouri RK, 1996, PLAST RECONSTR SURG, V98, P103, DOI 10.1097/00006534 199607000 00017
   Kizana E, 2005, CIRCULATION, V111, P394, DOI 10.1161/01.CIR.0000153812.64956.EF
   KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961
   Komaki M, 2004, J CELL SCI, V117, P1457, DOI 10.1242/jcs.00965
   Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Lee JY, 2001, J BONE JOINT SURG AM, V83A, P1032, DOI 10.2106/00004623 200107000 00008
   Lee JY, 2002, HUM GENE THER, V13, P1201, DOI 10.1089/104303402320138989
   Levy MM, 2001, BONE, V29, P317, DOI 10.1016/S8756 3282(01)00585 3
   Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Musgrave DS, 2001, BONE, V28, P499, DOI 10.1016/S8756 3282(01)00413 6
   Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290
   Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046
   Otsuru S, 2007, BIOCHEM BIOPH RES CO, V354, P453, DOI 10.1016/j.bbrc.2006.12.226
   Pakos EE, 2004, INT J RADIAT ONCOL, V60, P888, DOI 10.1016/j.ijrobp.2003.11.015
   Péault B, 2007, MOL THER, V15, P867, DOI 10.1038/mt.sj.6300145
   Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257
   Rasko JEJ, 2003, PATHOLOGY, V35, P5, DOI 10.1080/0031302021000062253
   Rumi MN, 2005, J ORTHOP RES, V23, P34, DOI 10.1016/j.orthres.2004.05.003
   Schindeler A, 2009, DIFFERENTIATION, V77, P12, DOI 10.1016/j.diff.2008.09.007
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   TENDIJKE P, 1994, J BIOL CHEM, V269, P16985
   Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628
   Wright VJ, 2002, MOL THER, V6, P169, DOI 10.1006/mthe.2002.0654
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
NR 44
TC 28
Z9 32
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 15
PY 2009
VL 10
AR 51
DI 10.1186/1471 2474 10 51
PG 12
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 456AL
UT WOS:000266810200001
PM 19442313
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, S
   Karsdal, MA
   Bay Jensen, AC
   Sorensen, MG
   Zheng, Q
   Dziegiel, MH
   Maksymowych, WP
   Henriksen, K
AF Sun, S.
   Karsdal, M. A.
   Bay Jensen, A. C.
   Sorensen, M. G.
   Zheng, Q.
   Dziegiel, M. H.
   Maksymowych, W. P.
   Henriksen, K.
TI The development and characterization of an ELISA specifically detecting
   the active form of cathepsin K
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Cathepsin K; Active form; Bone resorption; Serum
ID POSTMENOPAUSAL OSTEOPOROSIS; HUMAN OSTEOCLASTS; ANKYLOSING SPONDYLITIS;
   MATRIX DEGRADATION; BONE RESORPTION; SERUM LEVELS; I COLLAGEN; WOMEN;
   OSTEOPETROSIS; PYCNODYSOSTOSIS
AB Objective: Cathepsin K plays essential roles in bone resorption and is intensely investigated as a therapeutic target for the treatment of osteoporosis. Hence an assessment of the active form of cathepsin K may provide important biological information in metabolic bone diseases, such as osteoporosis or ankylosing spondylitis.
   Methods: Presently there are no robust assays for the assessment of active cathepsin K in serum, and therefore an ELISA specifically detecting the N terminal of the active form of cathepsin K was developed.
   Results: The assay was technically robust, with a lowest limit of detection (LOD) of 0.085 ng/ml.. The average intra  and inter assay CV% were 6.60% and 8.56% respectively. The dilution recovery and spike recovery tests in human serum were within 100 +/  20% within the range of the assay. A comparison of latent and active cathepsin K confirmed specificity towards the active form. Quantification of the levels of active cathepsin K in supernatants of purified human osteoclasts compared to corresponding macrophages showed a 30 fold induction (p < 0.001). In contrast, in serum samples from osteoporotic women on estrogen or bisphosphonate therapy and from ankylosing spondylitis patients no clinically relevant differences were observed.
   Conclusion: In summary, we have developed a robust and sensitive assay specifically detecting the active form of cathepsin K; however, while it monitors osteoclasts with high specificity in vitro, it appears that circulating levels of active cathepsin K do not reflect bone changes under these circumstances. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Sun, S.; Karsdal, M. A.; Bay Jensen, A. C.; Sorensen, M. G.; Henriksen, K.] Nord Biosci Biomarkers & Res, Herlev, Denmark.
   [Zheng, Q.] Nord Biosci Biomarkers & Res, Beijing, Peoples R China.
   [Dziegiel, M. H.] Rigshosp, Rigshosp Blodbank, Denmark Dept Med, DK 2100 Copenhagen, Denmark.
   [Maksymowych, W. P.] Univ Alberta, Edmonton, AB, Canada.
C3 Nordic Bioscience; University of Copenhagen; Copenhagen University
   Hospital; Rigshospitalet; University of Alberta
RP Sun, S (通讯作者)，Nord Biosci AS, Hovedgade 207, DK 2730 Herlev, Denmark.
EM ssu@nordicbioscience.com
RI ; Bay Jensen, Anne Christine/AEQ 7281 2022; Bay Jensen, Anne
   C/G 6759 2013
OI Dziegiel, Morten Hanefeld/0000 0001 8034 1523; Karsdal,
   Morten/0000 0001 5026 8740; Sun, Shu/0000 0002 2477 8904; Bay Jensen,
   Anne C/0000 0001 7952 9297; Maksymowych, Walter/0000 0002 1291 1755
CR Adolf D, 2012, MATURITAS, V71, P169, DOI 10.1016/j.maturitas.2011.11.024
   Barascuk N, 2010, CLIN BIOCHEM, V43, P899, DOI 10.1016/j.clinbiochem.2010.03.012
   Barry ZT, 2012, J BIOL CHEM, V287, P27723, DOI 10.1074/jbc.M111.332684
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Bromme D, 1996, BIOCHEMISTRY US, V35, P3970, DOI 10.1021/bi9523015
   Dodds RA, 2001, J BONE MINER RES, V16, P478, DOI 10.1359/jbmr.2001.16.3.478
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818
   Gelb BD, 1996, BIOCHEM MOL MED, V59, P200, DOI 10.1006/bmme.1996.0088
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Henriksen K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027482
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Kerschan Schindl K, 2005, EXP GERONTOL, V40, P532, DOI 10.1016/j.exger.2005.04.001
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Leeming DJ, 2010, CLIN BIOCHEM, V43, P1249, DOI 10.1016/j.clinbiochem.2010.07.025
   LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756 3282(96)00351 1
   Maksymowych WP, 2007, ARTHRITIS RHEUM US, V56, P1846, DOI 10.1002/art.22589
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955
   Meier C, 2006, CLIN LAB, V52, P1
   Muñoz Torres M, 2009, MATURITAS, V64, P188, DOI 10.1016/j.maturitas.2009.09.011
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   Nishi Y, 1999, J BONE MINER RES, V14, P1902, DOI 10.1359/jbmr.1999.14.11.1902
   Prezelj J, 2008, MENOPAUSE, V15, P369, DOI 10.1097/gme.0b013e3181271873
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sassi ML, 2000, BONE, V26, P367, DOI 10.1016/S8756 3282(00)00235 0
   Skoumal M, 2005, ARTHRITIS RES THER, V7, pR65, DOI 10.1186/ar1461
   Sorensen MG, 2007, BIOMARKERS, V12, P266, DOI 10.1080/13547500601070842
   Warming L, 2004, CLIMACTERIC, V7, P103, DOI 10.1080/13697130310001651535
   Wendling D, 2008, JOINT BONE SPINE, V75, P559, DOI 10.1016/j.jbspin.2008.01.026
NR 35
TC 10
Z9 11
U1 1
U2 12
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009 9120
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD OCT
PY 2013
VL 46
IS 15
BP 1601
EP 1606
DI 10.1016/j.clinbiochem.2013.04.012
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA 226SM
UT WOS:000325056300047
PM 23623829
DA 2025 08 17
ER

PT J
AU Lu, OY
   Qiufang, ZF
   Ruan, XZ
   Feng, YB
   Wang, XB
AF Lu Ouyang
   Qiufang Zhang
   Ruan, Xuzhi
   Feng, Yibin
   Wang, Xuanbin
TI Treatment effect of Bushen Huayu extract on postmenopausal
   osteoporosis in vivo
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE traditional Chinese medicine; nilestriol; interleukin 6; alkaline
   phosphatase; estradiol
ID BONE TURNOVER; HEALTH; WOMEN
AB Bushen Huayu extract (BSHY), a traditional Chinese medicine, has been demonstrated to treat postmenopausal osteoporosis, however, the underlying mechanism remains to be fully elucidated. The aim of the present study was to investigate the therapeutic effect of BSHY and the mechanisms underlying this effect in an in vivo postmenopausal osteoporosis animal model. A total of 1 g BSHY containing 7.12 mu g icariin was prepared. Low dose BSHY (BSHY L; 11.1 g/kg), medium dose BSHY (BSHY M; 22.2 g/kg) and high dose BSHY (BSHY H; 44.4 g/kg) was administered to oophorectomized rats using intragastric infusion: Estradiol (E2), interleukin 6 (IL 6) and serum alkaline phosphatase (ALP) levels, as well as bone density, were determined. It was found that the levels of serum ALP in the BSHY L, BSHY M and BSHY H groups (197.75 +/  41.74, 166.63 +/  44.83 and 165.63 +/  44.90 IU/l, respectively) were significantly decreased compared with the model group (299.13 +/  45.79 IU/l; P<0.05), whilst the levels of E2 (16.89 +/  1.71, 17.95 +/  1.40 and 18.34 +/  1.43 pg/ml, respectively) increased compared with the model group (14.54 +/  1.61; P<0.05). In addition, the levels of IL 6 decreased in the BSHY L, BSHY M and BSHY H groups (91.85 +/  14.81,82.99 +/  15.65 and 80.54 +/  14.61 pg/ml, respectively) compared with the model group (105.93 +/  16.50 pg/ml; P<0.05). Furthermore, it was demonstrated that BSHY increased the bone density in the BSHY L, BSHY M and BSHY H groups (0.20 +/  0.014, 0.22 +/  0.016 and 0.22 +/  0.017 g/cm(2), respectively) compared with the model group (0.19 +/  0.011 g/cm(2); P<0.05). BSHY was also found to increase the number of osteoblasts in the BSHY L, BSHY M and BSHY H groups (25.38 +/  2.17, 29.25 +/  2.12 and 30.00 +/  2.39, respectively), compared with in the model group (14.75 +/  2.38; P<0.05), and decrease the number of osteoclasts in the BSHY L, BSHY M and BSHY H groups (4.00 +/  1.85, 4.25 +/  1.39 and 5.75 +/  1.49, respectively) compared with 9.50 +/  1.60 observed in the model group (P<0.05). These results suggest that BSHY is a potential therapeutic drug for the treatment of osteoporosis in vivo. Furthermore, these results suggest that the mechanism by which BSHY decreases the serum levels of IL 6 may be by regulating E2.
C1 [Lu Ouyang; Qiufang Zhang; Wang, Xuanbin] Hubei Univ Med, Renmin Hosp, Lab Chinese Herbal Pharmacol, Shiyan 442000, Hubei, Peoples R China.
   [Lu Ouyang; Qiufang Zhang; Wang, Xuanbin] Hubei Univ Med, Sch Pharm, Shiyan 442000, Hubei, Peoples R China.
   [Qiufang Zhang; Ruan, Xuzhi] Hubei Univ Med, Basic Sch Med, Shiyan 442000, Hubei, Peoples R China.
   [Feng, Yibin] Univ Hong Kong, LKS Fac, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
C3 Hubei University of Medicine; Hubei University of Medicine; Hubei
   University of Medicine; University of Hong Kong
RP Wang, XB (通讯作者)，Hubei Univ Med, Renmin Hosp, Lab Chinese Herbal Pharmacol, 39 Chaoyang Midrd, Shiyan 442000, Hubei, Peoples R China.
EM xbwang2013@163.com
RI Wang, Xuanbin/AHE 9819 2022; Feng, Yibin/I 5245 2012
OI Wang, Xuanbin/0000 0003 0769 2874; 
FU Education Department of Hubei Province, China [B20082412]; Public Health
   Project of Shiyan City [2011057]
FX This study was supported by the Class B Funding of the Education
   Department of Hubei Province, China (Code no. B20082412), The Public
   Health Project of Shiyan City (grant no. 2011057) and Hubei 2011
   Research Project Funding (grant no. 4). The authors would like to thank
   Mr. Hongliang Li, Mrs. Ming Liu and Mrs. Hongli Guo for their technical
   support.
CR Cavalli L, 2011, Int J Clin Rheumatol, V6, P359
   Craft CS, 2012, J CELL BIOCHEM, V113, P93, DOI 10.1002/jcb.23331
   Eastell R, 2012, BONE, V50, P1135, DOI 10.1016/j.bone.2012.02.004
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Joo MK, 2013, MOL MED REP, V7, P1267, DOI 10.3892/mmr.2013.1327
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   Lindsay R, 2004, ENDOCRINE, V24, P223, DOI 10.1385/ENDO:24:3:223
   McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134
   Mingyue Wang, 2005, J Tradit Chin Med, V25, P132
   Mysliwiec J, 2011, ENDOKRYNOL POL, V62, P299
   Ouyang L, 2010, ZHONG GUO YAO SHI, V13, P13
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sanders S, 2013, SOUTH MED J, V106, P698, DOI 10.1097/SMJ.0b013e3182a0df8b
   Song Y, 2012, JUN YI JIN XIU XUE Y, V33, P400
   Wang Y, 2011, MOL CELL ENDOCRINOL, V337, P43, DOI 10.1016/j.mce.2011.01.018
   Yang LJ, 2013, J ETHNOPHARMACOL, V145, P715, DOI 10.1016/j.jep.2012.11.031
   Yoldemir T, 2012, GYNECOL ENDOCRINOL, V28, P884, DOI 10.3109/09513590.2012.683066
   Zhang Shangshang, 2012, Zhongguo Zhong Yao Za Zhi, V37, P658
NR 18
TC 3
Z9 3
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUN
PY 2014
VL 7
IS 6
BP 1687
EP 1690
DI 10.3892/etm.2014.1661
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AI0QX
UT WOS:000336555100044
PM 24926367
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Terao, Y
   Satomi Kobayashi, S
   Hirata, K
   Rikitake, Y
AF Terao, Yuya
   Satomi Kobayashi, Seimi
   Hirata, Ken ichi
   Rikitake, Yoshiyuki
TI Involvement of Rho associated protein kinase (ROCK) and bone
   morphogenetic protein binding endothelial cell precursor derived
   regulator (BMPER) in high glucose increased alkaline phosphatase
   expression and activity in human coronary artery smooth muscle cells
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
DE ALP; BMPER; High glucose; ROCK; Statin; Vascular smooth muscle cells
ID COA REDUCTASE INHIBITORS; LIPID LOWERING THERAPY; UP REGULATION;
   IN VITRO; CALCIFICATION; STATINS; ATORVASTATIN; PATHWAY; PROGRESSION;
   CALCIUM
AB Background: Vascular calcification is an independent risk factor for cardiovascular disease. Diabetes mellitus increases the incidence of vascular calcification; however, detailed molecular mechanisms of vascular calcification in diabetes mellitus remain unknown. We recently reported that bone morphogenetic protein binding endothelial cell precursor derived regulator (BMPER) regulates osteoblast like trans differentiation of human coronary artery smooth muscle cells (HCASMCs).
   Methods: We investigated the effect of a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin), commonly used in patients with atherosclerotic diseases and diabetes mellitus, on alkaline phosphatase (ALP) mRNA expression in aortas of streptozotocin induced diabetic mice. We also investigated the effects of the statin, Rho associated protein kinase (ROCK) inhibitors and BMPER knockdown on ALP mRNA expression and activity in HCASMCs cultured in high glucose containing media.
   Results: Alkaline phosphatase mRNA expression was increased in aortas of streptozotocin induced diabetic mice, and the increase was inhibited by rosuvastatin. ALP mRNA expression and activity were increased in HCASMCs cultured in high glucose containing media, and the increases were suppressed by rosuvastatin. This suppression was reversed by the addition of mevalonate or geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate. High glucose increased ALP mRNA expression and activity were suppressed by ROCK inhibitors. Moreover, BMPER mRNA expression was increased in diabetic mouse aortas and in HCASMCs cultured in high glucose containing media, but was not inhibited by rosuvastatin or ROCK inhibitors. Knockdown of BMPER suppressed high glucose increased ALP activity, but not ROCK activity in HCASMCs.
   Conclusions: There are at least two independent pathways in high glucose induced ALP activation in HCASMCs: the Rho ROCK signaling pathway and the BMPER dependent pathway.
C1 [Terao, Yuya; Satomi Kobayashi, Seimi; Hirata, Ken ichi; Rikitake, Yoshiyuki] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Rikitake, Yoshiyuki] Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Signal Transduct,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Kobe University
RP Rikitake, Y (通讯作者)，Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Signal Transduct,Chuo Ku, 7 5 1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM rikitake@med.kobe u.ac.jp
RI Rikitake, Yoshiyuki/HRC 9413 2023
FU Japan Society for the Promotion of Science; Global Center of Excellence;
   Takeda Science Foundation; Mochida Memorial Foundation for Medical and
   Pharmaceutical Research; AstraZeneca; Grants in Aid for Scientific
   Research [25461128] Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research from
   Japan Society for the Promotion of Science (to Y.R.), and grants from
   the Global Center of Excellence (to K.H. and Y.R.), Takeda Science
   Foundation, the Mochida Memorial Foundation for Medical and
   Pharmaceutical Research, and from AstraZeneca (to Y.R.).
CR Achenbach S, 2002, CIRCULATION, V106, P1077, DOI 10.1161/01.CIR.0000027567.49283.FF
   Arad Y, 2005, J AM COLL CARDIOL, V46, P166, DOI 10.1016/j.jacc.2005.02.089
   Blanco Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021 9150(01)00613 X
   Budoff MJ, 2000, AM J CARDIOL, V86, P8, DOI 10.1016/S0002 9149(00)00820 1
   Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703
   Chen NX, 2006, NEPHROL DIAL TRANSPL, V21, P3435, DOI 10.1093/ndt/gfl429
   Chen Neal X, 2003, Curr Diab Rep, V3, P28, DOI 10.1007/s11892 003 0049 2
   Cicek FA, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475 2840 12 51
   Cormack Aboud FC, 2009, NEPHROL DIAL TRANSPL, V24, P404, DOI 10.1093/ndt/gfn528
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Helbing T, 2010, ARTERIOSCL THROM VAS, V30, P554, DOI 10.1161/ATVBAHA.109.201087
   Houslay ES, 2006, HEART, V92, P1207, DOI 10.1136/hrt.2005.080929
   Katsiki N, 2010, ATHEROSCLEROSIS, V211, P9, DOI 10.1016/j.atherosclerosis.2009.12.028
   Kawamura H, 2004, ARTERIOSCL THROM VAS, V24, P276, DOI 10.1161/01.ATV.0000112012.33770.2a
   Kizu A, 2004, J CELL BIOCHEM, V93, P1011, DOI 10.1002/jcb.20207
   Knapp AC, 2000, ATHEROSCLEROSIS, V152, P217, DOI 10.1016/S0021 9150(99)00462 1
   Kovarnik T, 2012, CIRC J, V76, P176, DOI 10.1253/circj.CJ 11 0730
   Li HA, 2010, BASIC CLIN PHARMACOL, V107, P798, DOI 10.1111/j.1742 7843.2010.00580.x
   Liu DM, 2014, CELL PHYSIOL BIOCHEM, V33, P129, DOI 10.1159/000356656
   Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664 5679.2003
   Pearson JT, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475 2840 12 111
   Piconi L, 2008, J DIABETES COMPLICAT, V22, P38, DOI 10.1016/j.jdiacomp.2007.03.004
   Puri R, 2015, J AM COLL CARDIOL, V65, P1273, DOI 10.1016/j.jacc.2015.01.036
   Raggi P, 2005, CIRCULATION, V112, P563, DOI 10.1161/CIRCULATIONAHA.104.512681
   Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23
   Rikitake Y, 2005, CIRCULATION, V111, P3261, DOI 10.1161/CIRCULATIONAHA.105.534024
   Satomi Kobayashi S, 2012, J BIOL CHEM, V287, P30336, DOI 10.1074/jbc.M111.329110
   Serpe M, 2008, DEV CELL, V14, P940, DOI 10.1016/j.devcel.2008.03.023
   Shimokawa H, 2015, ARTERIOSCL THROM VAS, V35, P1756, DOI 10.1161/ATVBAHA.115.305353
   Sindermann JR, 2000, ATHEROSCLEROSIS, V150, P331, DOI 10.1016/S0021 9150(99)00393 7
   Sinha A, 2013, DIABETES VASC DIS RE, V10, P410, DOI 10.1177/1479164113485101
   Son BK, 2006, CIRC RES, V98, P1024, DOI 10.1161/01.RES.0000218859.90970.8d
   Tawa H, 2010, CIRC RES, V106, P1731, DOI 10.1161/CIRCRESAHA.110.216747
   Trion A, 2008, MOL CELL BIOCHEM, V308, P25, DOI 10.1007/s11010 007 9608 1
   VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295
   Vilahur G, 2009, ATHEROSCLEROSIS, V206, P95, DOI 10.1016/j.atherosclerosis.2009.02.009
   Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs
   Wang CY, 2008, TRENDS MOL MED, V14, P37, DOI 10.1016/j.molmed.2007.11.004
   Wei Q, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471 2261 13 13
   Widyantoro B, 2010, CIRCULATION, V121, P2407, DOI 10.1161/CIRCULATIONAHA.110.938217
   Zhou Q, 2010, CIRC J, V74, P818, DOI 10.1253/circj.CJ 10 0110
NR 41
TC 18
Z9 20
U1 0
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475 2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD AUG 12
PY 2015
VL 14
AR 104
DI 10.1186/s12933 015 0271 7
PG 10
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA CO6RZ
UT WOS:000359285200001
PM 26264461
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Cao, H
   Ke, Y
   Zhang, Y
   Zhang, CJ
   Qian, W
   Zhang, GL
AF Cao, Hong
   Ke, Yong
   Zhang, Ying
   Zhang, Chang Jun
   Qian, Wei
   Zhang, Gong Li
TI Icariin stimulates MC3T3 E1 cell proliferation and differentiation
   through up regulation of bone morphogenetic protein 2
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE osteoporosis; bone morphogenetic protein 2; icariin; MC3T3 E1 cells
ID MARROW STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; IN VITRO;
   POSTMENOPAUSAL WOMEN; MINERAL DENSITY; OSTEOPOROSIS; OSTEOBLASTS;
   EXPRESSION; MANNER; BMP 2
AB Previous studies suggest that icariin has anabolic effects on bone, but the mechanisms are unknown. We aimed to investigate the osteogenic effects of icariin in an undifferentiated osteoblast cell line by detecting cell morphology, viability, cell cycling and bone morphogenetic protein 2 (BMP 2) expression. We treated pre osteoblastic MC3T3 E1 cells with different concentrations of icariin [0 (as a control), 10, 20 and 40 ng/ml] for 48, 72 and 96 h. Cell morphology, viability and the cell cycle were examined and measured using microscopy, the MTT assay or flow cytometry, respectively. BMP 2 positive cells and BMP 2 protein expression levels in icariin treated MC3T3 E1 cells were examined using immunohistochemistry staining with fluorescence optical density analysis and Western blotting. MC3T3 E1 cells showed typical characteristics of osteoblasts in response to treatment with icariin. Cells treated with all concentrations of icariin had increased percentages of S phase cells and decreased percentages of G1 phase cells, especially in the 10 and 20 ng/ml icariin groups. The number of BMP 2 positive cells and BMP 2 protein expression levels in the 10 and 20 ng/ml icariin treatment groups were greater compared to the 0 and 40 ng/ml groups. Treatment of icariin promotes osteoblast MC3T3 E1 proliferation and differentiation in vitro, potentially owing to its role in increasing BMP 2 protein expression. Icariin potentially can be used as a drug in clinical settings to treat osteoporosis.
C1 [Zhang, Ying; Zhang, Chang Jun] Hubei Univ Med, Renmin Hosp, Reprod Med Ctr, Shiyan 442000, Hubei, Peoples R China.
   [Cao, Hong; Ke, Yong; Qian, Wei; Zhang, Gong Li] Hubei Univ Med, Renmin Hosp, Dept Orthoped Surg, Shiyan 442000, Hubei, Peoples R China.
C3 Hubei University of Medicine; Hubei University of Medicine
RP Zhang, Y (通讯作者)，Hubei Univ Med, Renmin Hosp, Reprod Med Ctr, Shiyan 442000, Hubei, Peoples R China.
EM 33556511@qq.com
RI Zhang, Xiaoping/AFW 5367 2022
CR Abe E, 2006, ANN NY ACAD SCI, V1068, P41, DOI 10.1196/annals.1346.007
   Ahn KH, 2010, AUST NZ J OBSTET GYN, V50, P371, DOI 10.1111/j.1479 828X.2010.01183.x
   Allali Fadoua, 2009, BMC Womens Health, V9, P31, DOI 10.1186/1472 6874 9 31
   Bardyn T, 2009, INT J ORAL MAX IMPL, V24, P1006
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Chen KM, 2005, PHARMAZIE, V60, P939
   Compston J, 2010, RADIOL CLIN N AM, V48, P477, DOI 10.1016/j.rcl.2010.02.010
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hiligsmann M, 2010, EXPERT REV PHARM OUT, V10, P359, DOI [10.1586/erp.10.53, 10.1586/ERP.10.53]
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Ohba S, 2007, BIOCHEM BIOPH RES CO, V357, P854, DOI 10.1016/j.bbrc.2007.03.173
   Peng SL, 2009, BONE, V45, P534, DOI 10.1016/j.bone.2009.05.022
   Samelson Elizabeth J, 2006, Curr Rheumatol Rep, V8, P76, DOI 10.1007/s11926 006 0030 6
   Santiago RC, 2009, AM J ORTHOD DENTOFAC, V136, P243, DOI 10.1016/j.ajodo.2007.08.031
   Sumanasinghe RD, 2006, TISSUE ENG, V12, P3459, DOI 10.1089/ten.2006.12.3459
   Tsurko VV, 2009, TERAPEVT ARKH, V81, P92
   Yang XB, 2003, J BONE MINER RES, V18, P47, DOI 10.1359/jbmr.2003.18.1.47
   Yin YX, 2007, CHINESE MED J PEKING, V120, P204, DOI 10.1097/00029330 200702010 00006
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 26
TC 65
Z9 74
U1 0
U2 29
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2012
VL 29
IS 3
BP 435
EP 439
DI 10.3892/ijmm.2011.845
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 889ZV
UT WOS:000300115800015
PM 22109711
OA Bronze
DA 2025 08 17
ER

PT J
AU Kuchuk, I
   Simos, D
   Addison, CL
   Clemons, M
AF Kuchuk, I.
   Simos, D.
   Addison, C. L.
   Clemons, M.
TI A national portfolio of bone oncology trials The Canadian experience in
   2012
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bone; Bone metastasis; Bone treatment; Bisphosphonates; Cancer
AB Background: The impact of both cancer and its treatment on bone is an essential component of oncological practice. Bone oncology not only affects patients with both early stage and metastatic disease but also covers the entire spectrum of tumour types. We therefore decided to review and summarise bone oncology related trials that are currently being conducted in Canada. Method: We assessed ongoing and recently completed trials in Canada. We used available North American and Canadian cancer trial websites and also contacted known investigators in this field for their input. Results: Twenty seven clinical trials were identified. Seven pertained to local treatment of bone metastasis from any solid tumour type. Seven were systemic treatment trials, five focused on bone biology and predictive factors, three evaluated safety of bone targeted agents, three were adjuvant trials and two trials investigated impact of cancer therapy on bone health. The majority of trials were related to systemic treatment and bone biology in breast cancer. Most were small, single centre, grant funded studies. Not surprisingly the larger safety and adjuvant studies were pharmaceutical company driven. Discussion: Despite the widespread interest in bone targeted therapies our survey would suggest that most studies are single centre and breast cancer focused. If major advances in bone oncology are to be made then collaborative strategies are needed to not only increase current sample sizes but to also expand these studies into non breast cancer populations. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Kuchuk, I.; Simos, D.; Clemons, M.] Univ Ottawa, Canc Ctr, Div Med Oncol, Ottawa Hosp, Ottawa, ON, Canada.
   [Kuchuk, I.; Simos, D.; Clemons, M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
   [Addison, C. L.] Ottawa Hosp, Res Inst, Canc Therapeut Program, Ottawa, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Ottawa; Ottawa Hospital Research Institute
RP Clemons, M (通讯作者)，Ottawa Hosp, Canc Ctr, Div Med Oncol, 501 Smyth Rd, Ottawa, ON, Canada.
EM mclemons@toh.on.ca
CR Bouganim N, 2010, CURRENT ONCOLOGY, V17, P113
   Cawthorn TR, 2009, CLIN EXP METASTAS, V26, P935, DOI 10.1007/s10585 009 9284 5
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Cowan Robert W, 2012, Front Endocrinol (Lausanne), V3, P89, DOI 10.3389/fendo.2012.00089
   Fathers KE, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3183
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Hilton JF, 2011, BREAST CANCER RES TR, V129, P761, DOI 10.1007/s10549 010 1264 6
   Hojjat SP, 2012, J BIOMECHANICS
   Howe GA, 2012, CELL ADHES MIGR, V6, P71, DOI 10.4161/cam.20077
   Li JR, 2011, J CLIN INVEST, V121, P4655, DOI 10.1172/JCI46134
   Lo VCK, 2012, BREAST CANCER RES TR, V135, P391, DOI 10.1007/s10549 012 2146 x
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Quellet V, 2011, AM J PATHOL, V178, P2377
   Seidlitz EP, 2011, BONE, V48, pS32, DOI 10.1016/j.bone.2010.10.087
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
NR 17
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1366
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD DEC
PY 2012
VL 1
IS 3
BP 95
EP 100
DI 10.1016/j.jbo.2012.09.001
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V37LL
UT WOS:000209277200006
PM 26909263
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kajiwara, H
   Yamaza, T
   Yoshinari, M
   Goto, T
   Iyama, S
   Atsuta, I
   Kido, MA
   Tanaka, T
AF Kajiwara, H
   Yamaza, T
   Yoshinari, M
   Goto, T
   Iyama, S
   Atsuta, I
   Kido, MA
   Tanaka, T
TI The bisphosphonate pamidronate on the surface of titanium stimulates
   bone formation around tibial implants in rats
SO BIOMATERIALS
LA English
DT Article
DE bisphosphonate; titanium; implant; bone formation
ID MEVALONATE PATHWAY; OSTEOCLAST FORMATION; ALENDRONATE; CELLS;
   DIFFERENTIATION; OSTEOPROTEGERIN; RESORPTION; INHIBITION; EXPRESSION;
   GERANYLGERANIOL
AB Many materials with differing surfaces have been developed for clinical implant therapy in dentistry and orthopedics. We analyzed the quantity of new bone formed in vivo around caleium immobilized titanium implants with surfaces modified using pamidronate (PAM), a nitrogen containing bisphosphonate (N BP), implants of pure titanium, and titanium implants immobilized with calcium ions. New bone formation was visualized using fluorescent labeling (calcein blue and alizarin complexone) with intravenous injection at 1 and 3 weeks after implantation. After 4 weeks, undecalcified sections were prepared, and new bone formation around the implants was examined by morphometry using confocal laser scanning microscopy images. After 1 week, more new bone formed around the PAM immobilized implant than around the calcium immobilized and pure titanium implants. This was also seen with the new bone formation after 3 weeks. After 4 weeks, significantly more new bones were formed around the BP immobilized implant than around the calcium ion implanted and pure titanium implants. The new N BP modified titanium surface stimulates new bone formation around the implant, which might contribute to the success of implant therapy. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Kyushu Univ, Grad Sch Dent Sci, Dept Oral Anat & Cell Biol, Fukuoka 8128582, Japan.
   Tokyo Dent Coll, Oral Hlth Sci Ctr, Chiba 2618502, Japan.
   Tokyo Dent Coll, Dept Dent Mat Sci, Chiba 2618502, Japan.
   Kyushu Dent Coll, Dept Oral Anat, Kitakyushu, Fukuoka 8038580, Japan.
   Kyushu Univ, Grad Sch Dent Sci, Dept Removable Prosthodont, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Dent Sci, Dept Fixed Prosthodont, Fukuoka 8128582, Japan.
C3 Kyushu University; Tokyo Dental College; Tokyo Dental College; Kyushu
   Dental University; Kyushu University; Kyushu University
RP Kyushu Univ, Grad Sch Dent Sci, Dept Oral Anat & Cell Biol, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
EM tanaka@dent.kyushu u.ac.jp
OI Yamaza, Takayoshi/0000 0001 7055 3370; Kido, Mizuho/0000 0002 9348 0706
CR ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   AMIN D, 1992, J LIPID RES, V33, P1657
   Ayukawa Y, 1998, J BIOMED MATER RES, V41, P111
   BAB I, 1986, J CELL SCI, V84, P139
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   DOUGLAS DL, 1980, LANCET, V1, P1043
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1999, P NATL ACAD SCI USA, V96, P133
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Fujita T, 2001, JPN J PHARMACOL, V86, P86, DOI 10.1254/jjp.86.86
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Goto T, 2003, BIOMATERIALS, V24, P3885, DOI 10.1016/S0142 9612(03)00258 8
   Hanawa T, 1997, J BIOMED MATER RES, V36, P131, DOI 10.1002/(SICI)1097 4636(199707)36:1<131::AID JBM16>3.0.CO;2 L
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Iyama S, 1997, J PERIODONTOL, V68, P1169, DOI 10.1902/jop.1997.68.12.1169
   JANSEN JA, 1991, J BIOMED MATER RES, V25, P973, DOI 10.1002/jbm.820250805
   KADOYA Y, 1994, BONE MINER, V27, P85, DOI 10.1016/S0169 6009(08)80211 5
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   LUK SC, 1974, J ULTRA MOL STRUCT R, V46, P165, DOI 10.1016/S0022 5320(74)80054 7
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reinholz GG, 2000, CANCER RES, V60, P6001
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Sanders JL, 1998, J BONE MINER RES, V13, P786, DOI 10.1359/jbmr.1998.13.5.786
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   TSUCHIMOTO M, 1994, JPN J PHARMACOL, V66, P25, DOI 10.1254/jjp.66.25
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Yoshinari M, 2002, BIOMATERIALS, V23, P2879, DOI 10.1016/S0142 9612(01)00415 X
   Yoshinari M, 2001, BIOMATERIALS, V22, P709, DOI 10.1016/S0142 9612(00)00234 9
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 46
TC 106
Z9 123
U1 0
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2005
VL 26
IS 6
BP 581
EP 587
DI 10.1016/j.biomaterials.2004.02.072
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 857RK
UT WOS:000224135800001
PM 15282136
DA 2025 08 17
ER

PT J
AU Wang, Z
   Fu, J
   Zhang, X
   Sun, Y
   Ge, X
AF Wang, Z.
   Fu, J. X.
   Zhang, X. H.
   Sun, Y.
   Ge, X. P.
TI CONNEXIN 43 GAP JUNCTION AFFECTS SURVIVAL AND DRUG RESISTANCE OF
   MULTIPLE MYELOMA SIDE POPULATION CELLS
SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE multiple myeloma; bone marrow stromal cells; connexin 43; gap junction
   intercellular communication; side population cells; apoptosis;
   tumorigenicity; drug resistance
ID MESENCHYMAL STEM CELLS; BONE MARROW; GROWTH FACTOR; UP REGULATION;
   EXPRESSION; PROLIFERATION; COMMUNICATION; OSTEOBLASTS; MIGRATION;
   ADHESION
AB Drug resistance remains a major challenge for multiple myeloma (MM) treatment, and side population (SP) cells may play a key role in this resistance. The function of connexin 43 (Cx43) mediated gap junction intercellular communication (GJ IC) in MM cells is poorly understood. Bone marrow mesenchymal stem cells (BMSCs) from different sources were isolated and cultured. SP cells of MM cell line RPMI 8266 were separated by flow cytometry. Real time reverse transcriptase polymerase chain reaction and Western blot were used to detect Cx43 mRNA and protein expression in BMSCs, RPMI 8266 and SP cells from different sources. The effects of BMSCs from different sources on SP cell cycle, in vitro colony formation ability, stem cell related gene expression and drug resistance, and the addition of 18a glycyrrhetinic acid (18aGA) as a pathway inhibitor were observed. Here, we demonstrate that MM cells expressed Cx43 and contained a high percentage of SP cells. We observed an increase in the survival and proliferative capacity of SP cells compared with RPMI 8226 cells, but treatment with 18aGA decreased SP cell survival and proliferation (all P<0.05). MM cells were sensitive to dexamethasone and bortezomib induced apoptosis; however, this sensitivity was significantly decreased when MM cells were co cultured with BMSCs, and 18aGA partly recovered this cytotoxicity (all P<0.05). Collectively, our data suggest that GJ IC between BMSCs and MM cells is one of the important regulatory mechanisms underlying MM cells survival, proliferation, and drug sensitivity.
C1 [Wang, Z.; Fu, J. X.; Zhang, X. H.; Sun, Y.; Ge, X. P.] Soochow Univ, Affiliated Hosp 2, Dept Hematol, 1055 Sanxiang Rd, Suzhou 215000, Jiangsu, Peoples R China.
C3 Soochow University   China
RP Fu, J (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Hematol, 1055 Sanxiang Rd, Suzhou 215000, Jiangsu, Peoples R China.
EM fujinxiang@gzhmu edu.cn
RI ge, xueping/KIJ 3282 2024
FU National Nature Science Foundation of China (NFSC) [80171934, 81272631]
FX Funding : This study was supported by grants from the National Nature
   Science Foundation of China (NFSC, Grant Nos. 80171934 and 81272631) .
   The authors thank Zhang H for his technical assistance.
CR Agarwal A, 2013, CLIN CANCER RES, V19, P985, DOI 10.1158/1078 0432.CCR 12 2922
   Anderson KC, 2008, LEUKEMIA, V22, P231, DOI 10.1038/sj.leu.2405016
   Anderson KC, 2015, J NATL COMPR CANC NE, V13, P1398, DOI 10.6004/jnccn.2015.0167
   Anguiano A, 2009, J CLIN ONCOL, V27, P4197, DOI 10.1200/JCO.2008.19.1916
   Bladé J, 2011, CL LYMPH MYELOM LEUK, V11, P44, DOI 10.3816/CLML.2011.n.005
   Cancelas JA, 2000, BLOOD, V96, P498
   Ciovacco WA, 2009, BONE, V44, P80, DOI 10.1016/j.bone.2008.08.117
   Ciurea ME, 2014, INT J MOL SCI, V15, P8169, DOI 10.3390/ijms15058169
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Fowler JA, 2011, BONE, V48, P121, DOI 10.1016/j.bone.2010.06.029
   Fu JX, 2010, ARCH MED SCI, V6, P496, DOI 10.5114/aoms.2010.14459
   Garcia Gomez A, 2014, ONCOTARGET, V5, P8284, DOI 10.18632/oncotarget.2058
   Garcia Gomez Antonio, 2014, World J Stem Cells, V6, P322, DOI 10.4252/wjsc.v6.i3.322
   Goodell Margaret A, 2005, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0918s34
   Gu ZJ, 1996, BLOOD, V88, P3972, DOI 10.1182/blood.V88.10.3972.bloodjournal88103972
   Hecht M, 2007, BRIT J HAEMATOL, V138, P446, DOI 10.1111/j.1365 2141.2007.06665.x
   Krenacs T, 1998, AM J PATHOL, V152, P993
   Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470 2045(16)30206 6
   Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922
   Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22 11 04302.2002
   Luczkowska K, 2018, J PHYSIOL PHARMACOL, V69, DOI 10.26402/jpp.2018.2.02
   McLachlan E, 2007, J MEMBRANE BIOL, V218, P107, DOI 10.1007/s00232 007 9052 x
   Mesnil M, 2005, BBA BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004
   Nara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056954
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Presley CA, 2005, CELL COMMUN ADHES, V12, P307, DOI 10.1080/15419060500514200
   Rugowska A, 2019, J PHYSIOL PHARMACOL, V70, P917, DOI 10.26402/jpp.2019.6.10
   Siegel R, 2014, CA CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Strale PO, 2012, MOL CARCINOGEN, V51, P845, DOI 10.1002/mc.20853
   Takeda T, 2020, J PHYSIOL PHARMACOL, V71, P467, DOI 10.26402/jpp.2020.4.02
   Westhoff MA, 2008, ONCOGENE, V27, P5169, DOI 10.1038/onc.2008.148
   Wong RCB, 2008, STEM CELL REV, V4, P283, DOI 10.1007/s12015 008 9038 9
   Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048
   Yi ZC, 2007, ORAL ONCOL, V43, P898, DOI 10.1016/j.oraloncology.2006.11.004
   Yu SC, 2012, STEM CELLS, V30, P108, DOI 10.1002/stem.1685
   Zhang XH, 2015, LEUKEMIA LYMPHOMA, V56, P211, DOI 10.3109/10428194.2014.913289
NR 38
TC 2
Z9 2
U1 1
U2 2
PU POLISH PHYSIOLOGICAL SOC
PI GRZEGORZECKA
PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31 531 KRAKOW, 16
   GRZEGORZECKA, POLAND
SN 0867 5910
J9 J PHYSIOL PHARMACOL
JI J. Physiol. Pharmacol.
PD JUN
PY 2023
VL 74
IS 3
BP 355
EP 365
DI 10.26402/jpp.2023.3.10
PG 11
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA W9RE1
UT WOS:001094922200010
PM 37661187
DA 2025 08 17
ER

PT J
AU Sun, LN
   Liu, XL
AF Sun, Li na
   Liu, Xiao li
TI Functions of adiponectin signaling in regulating neural plasticity and
   its application as the therapeutic target to neurological and
   psychiatric diseases
SO REVIEWS IN THE NEUROSCIENCES
LA English
DT Article
DE adiponectin; metabolism; neural plasticity; neurodegeneration;
   psychiatric disorders
ID HIPPOCAMPAL SYNAPTIC PLASTICITY; STREPTOZOTOCIN DIABETIC RATS; MILD
   COGNITIVE IMPAIRMENT; ACTIVATED PROTEIN KINASE; ADULT NEUROGENESIS;
   ALZHEIMERS DISEASE; ENERGY METABOLISM; HUMAN OSTEOBLASTS; MAJOR
   DEPRESSION; SPATIAL MEMORY
AB Convergent lines of evidence indicate the critical roles of adiponectin in regulating neural functions on different levels. Because of the importance in maintaining neural plasticity including adult neurogenesis and synaptic plasticity, adiponectin has the potential to serve as the treatment targets in therapies of neurological and psychiatric disorders. Hence, systematic review is needed to summarize how adiponectin works in the brain, and how the adiponectin pathway is employed as the treatment method needs to be determined. Moreover, the benefits of adiponectin as the regulator for neural plasticity such as synaptic plasticity and neurogenesis have been supported by many literatures. In the current article, we reviewed the functions of adiponectin in different types of neural plasticity. We also demonstrated the potential value of adiponectin as the treatment target for different types of neurodegenerative and psychiatric disorders. Taken together, this review offers a new insight about adiponectin as the ideal target to develop the new treatment methods against neurodegeneration or psychiatric diseases.
C1 [Sun, Li na; Liu, Xiao li] Beijing Normal Univ, Sch PE & Sport, Beijing 100875, Peoples R China.
C3 Beijing Normal University
RP Liu, XL (通讯作者)，Beijing Normal Univ, Sch PE & Sport, Beijing 100875, Peoples R China.
EM xiaolil@bnu.edu.cn
RI Liu, Xiaoli/AAB 5964 2022
FU National Natural Science Foundation of China [31571221]; China
   Postdoctoral Science Fund [2014M560198]; Fundamental Research Funds for
   the Central Universities [2018NTSS30]
FX This study was supported by National Natural Science Foundation of China
   (31571221), the China Postdoctoral Science Fund (2014M560198) and
   Fundamental Research Funds for the Central Universities (2018NTSS30).
CR Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014
   Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747
   Bauche IB, 2007, ENDOCRINOLOGY, V148, P1539, DOI 10.1210/en.2006 0838
   Bayer TA, 2001, BRAIN PATHOL, V11, P1
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Biessels GJ, 1998, BRAIN RES, V800, P125, DOI 10.1016/S0006 8993(98)00510 1
   Biessels GJ, 1996, DIABETES, V45, P1259, DOI 10.2337/diabetes.45.9.1259
   BRINDLEY DN, 1989, CLIN SCI, V77, P453, DOI 10.1042/cs0770453
   Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Chan KH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052354
   Chen J, 2006, DIABETOLOGIA, V49, P1292, DOI 10.1007/s00125 006 0194 7
   Chung MM, 2015, BBA MOL BASIS DIS, V1852, P720, DOI 10.1016/j.bbadis.2015.01.006
   Civitarese AE, 2006, CELL METAB, V4, P75, DOI 10.1016/j.cmet.2006.05.002
   Craggs L, 2011, NEUROREPORT, V22, P1, DOI 10.1097/WNR.0b013e328342741c
   De Roo M, 2008, CEREB CORTEX, V18, P151, DOI 10.1093/cercor/bhm041
   Detopoulou P, 2010, EUR J CLIN NUTR, V64, P161, DOI 10.1038/ejcn.2009.130
   Deuschle M, 2013, CURR OPIN PSYCHIATR, V26, P60, DOI 10.1097/YCO.0b013e32835a4206
   Dhar M, 2014, MOL ENDOCRINOL, V28, P1073, DOI 10.1210/me.2013 1332
   Díez JJ, 2003, EUR J ENDOCRINOL, V148, P293, DOI 10.1530/eje.0.1480293
   Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460 9568.2006.05026.x
   Duman RS, 2016, NAT MED, V22, P238, DOI 10.1038/nm.4050
   Duman RS, 2001, NEUROPSYCHOPHARMACOL, V25, P836, DOI 10.1016/S0893 133X(01)00358 X
   Efstathiou SP, 2005, STROKE, V36, P1915, DOI 10.1161/01.STR.0000177874.29849.f0
   Eisch AJ, 2002, PROG BRAIN RES, V138, P315, DOI 10.1016/S0079 6123(02)38085 3
   Erion JR, 2014, J NEUROSCI, V34, P2618, DOI 10.1523/JNEUROSCI.4200 13.2014
   Fasshauer M, 2004, BIOCHIMIE, V86, P779, DOI 10.1016/j.biochi.2004.09.016
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22 03 00612.2002
   Gao C, 2018, MOL NEUROBIOL, V55, P9334, DOI 10.1007/s12035 018 1042 8
   Gao C, 2018, MOL NEUROBIOL, V55, P5537, DOI 10.1007/s12035 017 0785 y
   Gao C, 2017, NEUROCHEM INT, V106, P24, DOI 10.1016/j.neuint.2017.02.001
   Gao C, 2014, BRAIN PATHOL, V24, P261, DOI 10.1111/bpa.12116
   Gault VA, 2018, PEPTIDES, V100, P101, DOI 10.1016/j.peptides.2017.11.017
   Hajszan T, 2005, EUR J NEUROSCI, V21, P1299, DOI 10.1111/j.1460 9568.2005.03968.x
   Harvey J, 2007, CURR OPIN PHARMACOL, V7, P643, DOI 10.1016/j.coph.2007.10.006
   Huang CY, 2016, CLIN SCI, V130, P1523, DOI 10.1042/CS20160117
   Huot RL, 2002, BRAIN RES, V950, P52, DOI 10.1016/S0006 8993(02)02985 2
   Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096 9861(19971020)387:2<167::AID CNE1>3.0.CO;2 Z
   Hwang LL, 2010, OBESITY, V18, P463, DOI 10.1038/oby.2009.273
   Ibi D, 2008, J NEUROCHEM, V105, P921, DOI 10.1111/j.1471 4159.2007.05207.x
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jenwitheesuk A, 2014, INT J MOL SCI, V15, P16848, DOI 10.3390/ijms150916848
   Jung Yong Su, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P171, DOI 10.7461/jcen.2013.15.3.171
   Kamal A, 2000, DIABETOLOGIA, V43, P500, DOI 10.1007/s001250051335
   Kiebish MA, 2012, J LIPID RES, V53, P273, DOI 10.1194/jlr.M020628
   Kiefer F, 2005, J PSYCHIATR RES, V39, P545, DOI 10.1016/j.jpsychires.2004.11.005
   Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klampfl S, 2013, J NEUROSCI, V33, P11515, DOI 10.1523/JNEUROSCI.5044 12.2013
   Leo R, 2006, NEUROSCI LETT, V407, P211, DOI 10.1016/j.neulet.2006.08.043
   Li D, 2016, J ALZHEIMERS DIS, V54, P89, DOI 10.3233/JAD 150979
   Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702
   Liu J, 2012, P NATL ACAD SCI USA, V109, P12248, DOI 10.1073/pnas.1202835109
   Liu LH, 2014, J ASIAN NAT PROD RES, V16, P1074, DOI 10.1080/10286020.2014.939071
   Lou YB, 2018, J BIOL REG HOMEOS AG, V32, P75
   Lu XY, 2007, CURR OPIN PHARMACOL, V7, P648, DOI 10.1016/j.coph.2007.10.010
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094
   Majumdar D, 2011, MOL CELL NEUROSCI, V46, P633, DOI 10.1016/j.mcn.2011.01.003
   Martínez Tellez R, 2005, BRAIN RES, V1048, P108, DOI 10.1016/j.brainres.2005.04.048
   Mazer C, 1997, BRAIN RES, V760, P68, DOI 10.1016/S0006 8993(97)00297 7
   Moon HS, 2013, DIABETOLOGIA, V56, P627, DOI 10.1007/s00125 012 2799 3
   Nabavi S, 2014, NATURE, V511, P348, DOI 10.1038/nature13294
   Narita K, 2006, PROG NEURO PSYCHOPH, V30, P1159, DOI 10.1016/j.pnpbp.2006.03.030
   Ng RCL, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024 016 0136 x
   Nicolas S, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398 018 0210 y
   Nicolas S, 2015, PSYCHONEUROENDOCRINO, V57, P72, DOI 10.1016/j.psyneuen.2015.03.017
   O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20 22 08435.2000
   Okuyama S, 2018, BIOSCI BIOTECH BIOCH, V82, P1384, DOI 10.1080/09168451.2018.1469396
   Ormerod BK, 2013, BRAIN BEHAV IMMUN, V29, P28, DOI 10.1016/j.bbi.2012.10.017
   Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200
   Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474 4422(09)70236 4
   Pousti F, 2018, NEUROSCI LETT, V662, P227, DOI 10.1016/j.neulet.2017.10.042
   Qiu G, 2011, AGE, V33, P155, DOI 10.1007/s11357 010 9173 5
   Ruan H, 2016, J MOL CELL BIOL, V8, P101, DOI 10.1093/jmcb/mjw014
   Saravi SSS, 2017, BIOMED PHARMACOTHER, V90, P724, DOI 10.1016/j.biopha.2017.04.038
   Sarlak G, 2013, J PHARMACOL SCI, V123, P9, DOI 10.1254/jphs.13R01SR
   Scheff S, 2003, NEUROCHEM RES, V28, P1625, DOI 10.1023/A:1026048619220
   SCHULZ PE, 1994, J NEUROSCI, V14, P5325
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960 9822(98)70133 2
   Shi LJ, 2017, BEHAV BRAIN RES, V327, P65, DOI 10.1016/j.bbr.2017.03.032
   Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287
   Song J, 2014, BIOMED RES INT UK, V2014, DOI 10.1155/2014/261672
   Spielman LJ, 2014, J NEUROIMMUNOL, V273, P8, DOI 10.1016/j.jneuroim.2014.06.004
   Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470
   Sugiyama M, 2009, INT J ONCOL, V34, P339, DOI 10.3892/ijo_00000156
   Takeuchi Satoru, 2013, Acta Neurochir Suppl, V118, P111, DOI 10.1007/978 3 7091 1434 6_19
   Tanaka K, 2014, CIRC HEART FAIL, V7, P976, DOI 10.1161/CIRCHEARTFAILURE.114.001279
   Teixeira AL, 2013, NEUROMOL MED, V15, P115, DOI 10.1007/s12017 012 8201 2
   Une K, 2011, EUR J NEUROL, V18, P1006, DOI 10.1111/j.1468 1331.2010.03194.x
   Vafaei Nezhad S, 2016, NEUROSCIENCE, V318, P122, DOI 10.1016/j.neuroscience.2016.01.025
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   Wang CH, 2007, J BIOL CHEM, V282, P7991, DOI 10.1074/jbc.M700098200
   Wang CH, 2009, J BIOL CHEM, V284, P31608, DOI 10.1074/jbc.M109.010355
   Wang SH, 2009, MOL CELL ENDOCRINOL, V307, P176, DOI 10.1016/j.mce.2009.02.012
   Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200
   Weisz F, 2017, APPL NUMER HARMON AN, P71, DOI 10.1007/978 3 319 56814 0_2
   Whitehead JP, 2006, DIABETES OBES METAB, V8, P264, DOI 10.1111/j.1463 1326.2005.00510.x
   Wosiski Kuhn M, 2014, PSYCHONEUROENDOCRINO, V42, P165, DOI 10.1016/j.psyneuen.2014.01.020
   Xie LF, 2018, ULTRASOUND MED BIOL, V44, P1233, DOI 10.1016/j.ultrasmedbio.2018.01.020
   Xu NB, 2018, NEUROPHARMACOLOGY, V133, P415, DOI 10.1016/j.neuropharm.2018.02.024
   Yamada KA, 1998, NEUROBIOL DIS, V5, P67, DOI 10.1006/nbdi.1998.0190
   Yau SY, 2014, P NATL ACAD SCI USA, V111, P15810, DOI 10.1073/pnas.1415219111
   Ye JP, 2007, AM J PHYSIOL ENDOC M, V293, pE1118, DOI 10.1152/ajpendo.00435.2007
   Yoon G, 2018, MOL NEUROBIOL, V55, P6673, DOI 10.1007/s12035 017 0847 1
   Yuan TF, 2014, PROG NEURO PSYCHOPH, V54, P26, DOI 10.1016/j.pnpbp.2014.05.013
   Zhang D, 2016, ENDOCRINOLOGY, V157, P2853, DOI 10.1210/en.2015 2078
   Zhang D, 2011, J BIOL CHEM, V286, P44913, DOI 10.1074/jbc.M111.310052
   Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033
   ZUBENKO GS, 1988, ARCH NEUROL CHICAGO, V45, P1182, DOI 10.1001/archneur.1988.00520350020008
   Zunszain PA, 2013, MOL PSYCHIATR, V18, P1236, DOI 10.1038/mp.2013.87
NR 114
TC 5
Z9 6
U1 0
U2 12
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D 10785 BERLIN, GERMANY
SN 0334 1763
EI 1607 8470
J9 REV NEUROSCIENCE
JI Rev. Neurosci.
PD JUL
PY 2019
VL 30
IS 5
BP 485
EP 495
DI 10.1515/revneuro 2018 0062
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA IG0PH
UT WOS:000473492100004
PM 30864396
DA 2025 08 17
ER

PT S
AU Mendez Ferrer, S
   Frenette, PS
AF Mendez Ferrer, Simon
   Frenette, Paul S.
BE Zaidi, M
TI Hematopoietic stem cell trafficking   Regulated adhesion and attraction
   to bone marrow microenvironment
SO SKELETAL BIOLOGY AND MEDICINE, PT A: ASPECTS OF BONE MORPHOGENESIS AND
   REMODELING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 2nd Conference on Skeletal Biology and Medicine
CY APR 25 28, 2007
CL New York, NY
SP Mt Sinai Sch Med, New York Acad Sci
DE hematopoietic stem and progenitor cells; adhesion; homing; mobilization;
   sympathetic nervous system; stem cell niche
ID COLONY STIMULATING FACTOR; E SELECTIN LIGAND;
   SYMPATHETIC NERVOUS SYSTEM; LATE ANTIGEN (VLA) 4; PROGENITOR CELLS;
   G CSF; P SELECTIN; C KIT; PERIPHERAL BLOOD; STROMAL CELLS
AB Hematopoiesis takes place preferentially within bone cavities, suggesting that bone derived factors contribute to blood formation. Hematopoietic stem and progenitor cells (HSPCs) can be mobilized from the bone marrow parenchyma to the circulation by various agonists whose common downstream action leads to alteration in the expression or function of the chemokine CXCL12 and adhesion molecules mediating migration. Granulocyte colony stimulating factor (G CSF), the most prevalent drug used to mobilize HSPCs, dramatically suppresses osteoblast function. Recent studies suggest that G CSF mediated suppression requires signals from the sympathetic nervous system (SNS). This review summarizes emerging concepts thought to contribute to stem cell migration.
C1 [Frenette, Paul S.] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY 10029 USA.
   [Mendez Ferrer, Simon; Frenette, Paul S.] Mt Sinai Sch Med, Dept Gene & Cell Med, Inst Immunol, New York, NY 10029 USA.
   Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai
RP Frenette, PS (通讯作者)，Mt Sinai Sch Med, Dept Med, Inst Immunol, 1 Gustave L Levy Pl,Box 1079, New York, NY 10029 USA.
EM simon.mendez ferrer@mssm.edu; paul.frenette@mssm.edu
RI /R 4916 2019; Mendez Ferrer, Simon/L 8088 2014; Méndez Ferrer,
   Simón/L 8088 2014
OI Mendez Ferrer, Simon/0000 0002 9805 9988; 
FU NHGRI NIH HHS [HG003950] Funding Source: Medline; NHLBI NIH HHS
   [HL69438] Funding Source: Medline; NIAID NIH HHS [AI069402] Funding
   Source: Medline; NIDDK NIH HHS [R01 DK056638] Funding Source: Medline
CR Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Arroyo AG, 2000, J IMMUNOL, V165, P4667, DOI 10.4049/jimmunol.165.8.4667
   ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092 8674(90)90694 A
   ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092 8674(91)90570 O
   Auffray I, 1996, BLOOD, V88, P1608, DOI 10.1182/blood.V88.5.1608.bloodjournal8851608
   Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood 2003 10 3611
   BARR JS, 1950, J BONE JOINT SURG AM, V32 A, P793, DOI 10.2106/00004623 195032040 00007
   BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600
   Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280
   BRECHER G, 1951, P SOC EXP BIOL MED, V77, P292
   Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CALVO W, 1968, AM J ANAT, V123, P315, DOI 10.1002/aja.1001230206
   Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006
   Christ O, 2001, EXP HEMATOL, V29, P380, DOI 10.1016/S0301 472X(00)00674 3
   Christopherson KW, 2003, EXP HEMATOL, V31, P1126, DOI 10.1016/j.exphem.2003.07.002
   Christopherson KW, 2003, BLOOD, V101, P4680, DOI 10.1182/blood 2002 12 3893
   Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092 8674(00)80093 8
   Cui L, 1997, J IMMUNOL, V159, P1961
   CYNSHI O, 1991, LEUKEMIA, V5, P75
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092 8674(00)81812 7
   DEHAAS M, 1994, BLOOD, V84, P3885, DOI 10.1182/blood.V84.11.3885.bloodjournal84113885
   Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521 4141(200103)31:3<699::AID IMMU699>3.0.CO;2 6
   DERCKSEN MW, 1995, BLOOD, V85, P3313, DOI 10.1182/blood.V85.11.3313.bloodjournal85113313
   Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Emambokus NR, 2003, IMMUNITY, V19, P33, DOI 10.1016/S1074 7613(03)00173 0
   Eto T, 2005, EXP HEMATOL, V33, P232, DOI 10.1016/j.exphem.2004.10.018
   Falanga A, 1999, BLOOD, V93, P2506, DOI 10.1182/blood.V93.8.2506.408k31_2506_2514
   FELDMAN RD, 1987, J IMMUNOL, V139, P3355
   Ferkowicz MJ, 2003, DEVELOPMENT, V130, P4393, DOI 10.1242/dev.00632
   FREEHAFER AA, 1965, J BONE JOINT SURG AM, VA 47, P683, DOI 10.2106/00004623 196547040 00003
   Frenette PS, 2000, BLOOD, V96, P2460, DOI 10.1182/blood.V96.7.2460.h8002460_2460_2468
   Frenette PS, 1998, P NATL ACAD SCI USA, V95, P14423, DOI 10.1073/pnas.95.24.14423
   Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092 8674(00)81032 6
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   GILLESPIE JA, 1954, J BONE JOINT SURG BR, V36, P464, DOI 10.1302/0301 620X.36B3.464
   Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010
   GUNJI Y, 1992, BLOOD, V80, P429
   HARDY AG, 1963, J BONE JOINT SURG BR, V45, P76, DOI 10.1302/0301 620X.45B1.76
   Haylock DN, 2006, BRIT J HAEMATOL, V134, P467, DOI 10.1111/j.1365 2141.2006.06218.x
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092 8674(02)00754 7
   Hidalgo A, 2005, BLOOD, V105, P567, DOI 10.1182/blood 2004 03 1026
   Hidalgo A, 2004, BLOOD, V104, P993, DOI 10.1182/blood 2003 10 3702
   Hidalgo A, 2002, J CLIN INVEST, V110, P559, DOI 10.1172/JCI200214047
   Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301 472X(00)00668 8
   Hidalgo A, 2007, IMMUNITY, V26, P477, DOI 10.1016/j.immuni.2007.03.011
   Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074 7613(01)00166 2
   Hsu HC, 2000, BLOOD, V96, P3757, DOI 10.1182/blood.V96.12.3757.h8003757_3757_3762
   Hunt P., 2003, Health and Human Rights, V7, P1, DOI DOI 10.2307/4065415
   HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Ihara H, 2001, J BIOL CHEM, V276, P13065, DOI 10.1074/jbc.M010938200
   IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225
   IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045
   Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014
   Katayama Y, 2004, BLOOD, V104, P2020, DOI 10.1182/blood 2003 12 4157
   Katayama Y, 2003, BLOOD, V102, P2060, DOI 10.1182/blood 2003 04 1212
   Katayama Y, 2003, IMMUNITY, V18, P789, DOI 10.1016/S1074 7613(03)00150 X
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kiel MJ, 2007, CELL STEM CELL, V1, P204, DOI 10.1016/j.stem.2007.06.001
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kim I, 2005, BLOOD, V106, P903, DOI 10.1182/blood 2004 12 4960
   KINASHI T, 1994, BLOOD, V83, P1033
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   Lai CF, 2006, J BONE MINER RES, V21, P1897, DOI 10.1359/JBMR.060906
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301 472X(02)00883 4
   Legras S, 1997, BLOOD, V89, P1905, DOI 10.1182/blood.V89.6.1905
   LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805
   Levesque JP, 2004, BLOOD, V104, P65, DOI 10.1182/blood 2003 05 1589
   Lévesque JP, 2002, EXP HEMATOL, V30, P440, DOI 10.1016/S0301 472X(02)00788 9
   Lévesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289
   Lévesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074 7613(00)80112 0
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   Lévesque JP, 2003, EXP HEMATOL, V31, P109, DOI 10.1016/S0301 472X(02)01028 7
   Levesque JP, 1996, BLOOD, V88, P1168, DOI 10.1182/blood.V88.4.1168.bloodjournal8841168
   Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471 4914(03)00071 6
   Li ZX, 2006, TRENDS BIOCHEM SCI, V31, P589, DOI 10.1016/j.tibs.2006.08.001
   Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031
   Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074 7613(00)80504 X
   LORD BI, 1975, BLOOD, V46, P65
   Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600 065X.2002.18603.x
   MAESTRONI GJM, 1994, EXP HEMATOL, V22, P313
   Maestroni GJM, 1997, EXP HEMATOL, V25, P491
   Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092 8674(00)80137 3
   Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465
   Mazzali M, 2002, QJM INT J MED, V95, P3, DOI 10.1093/qjmed/95.1.3
   McEver RP, 2004, E SCHERING RES FDN W, V44, P137
   McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200
   MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477
   Möhle R, 2007, SEMIN HEMATOL, V44, P193, DOI 10.1053/j.seminhematol.2007.04.006
   Mohle R, 1995, EXP HEMATOL, V23, P1535
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Nakamura Y, 2004, EXP HEMATOL, V32, P390, DOI 10.1016/j.exphem.2004.01.004
   Nervi B, 2006, J CELL BIOCHEM, V99, P690, DOI 10.1002/jcb.21043
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Okumura N, 1996, BLOOD, V87, P4100, DOI 10.1182/blood.V87.10.4100.bloodjournal87104100
   Oostendorp RAJ, 2000, BONE MARROW TRANSPL, V26, P559, DOI 10.1038/sj.bmt.1702536
   Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239
   Papayannopoulou T, 2003, BLOOD, V101, P4739, DOI 10.1182/blood 2002 09 2741
   PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647
   Papayannopoulou T, 2001, BLOOD, V97, P1282, DOI 10.1182/blood.V97.5.1282
   Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296
   Pelus LM, 2004, BLOOD, V103, P110, DOI 10.1182/blood 2003 04 1115
   Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813
   Pruijt JFM, 1999, P NATL ACAD SCI USA, V96, P10863, DOI 10.1073/pnas.96.19.10863
   Pruijt JFM, 2002, P NATL ACAD SCI USA, V99, P6228, DOI 10.1073/pnas.092112999
   Puri MC, 2003, P NATL ACAD SCI USA, V100, P12753, DOI 10.1073/pnas.2133552100
   Qian H, 2006, BLOOD, V107, P3503, DOI 10.1182/blood 2005 10 3932
   Rameshwar P, 1996, BLOOD, V88, P98
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   ROBERTS DD, 1986, J BIOL CHEM, V261, P6872
   RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179
   Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965
   Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   Schmitz H, 1997, PHILOS RUNDSCH, V44, P90
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   SCHWARTZMAN RJ, 1987, ARCH NEUROL CHICAGO, V44, P555, DOI 10.1001/archneur.1987.00520170081028
   Scott LM, 2003, MOL CELL BIOL, V23, P9349, DOI 10.1128/MCB.23.24.9349 9360.2003
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Sharma S, 2006, STEM CELLS DEV, V15, P755, DOI 10.1089/scd.2006.15.755
   Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703
   SKINNER MP, 1991, J BIOL CHEM, V266, P5371
   Snapp KR, 1997, BLOOD, V89, P896, DOI 10.1182/blood.V89.3.896
   Solanilla A, 2003, BRIT J HAEMATOL, V120, P782, DOI 10.1046/j.1365 2141.2003.04155.x
   SPENGLER RN, 1990, J IMMUNOL, V145, P1430
   Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523
   Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880
   Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011
   STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Suda T, 2005, TRENDS IMMUNOL, V26, P426, DOI 10.1016/j.it.2005.06.006
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Sweeney EA, 2000, P NATL ACAD SCI USA, V97, P6544, DOI 10.1073/pnas.97.12.6544
   Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074 7613(00)80665 2
   Takamatsu Y, 1998, BLOOD, V92, P3465, DOI 10.1182/blood.V92.9.3465.421k35_3465_3473
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   TRENTIN JJ, 1968, PROLIFERATION SPREAD, V3, P713
   Umemoto T, 2006, J IMMUNOL, V177, P7733, DOI 10.4049/jimmunol.177.11.7733
   Valenzuela Fernández A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200
   van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687
   Velders GA, 2002, BLOOD, V100, P327, DOI 10.1182/blood.V100.1.327
   VERFAILLIE CM, 1994, BLOOD, V84, P1802
   Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403
   WARREN S, 1960, LAB INVEST, V9, P191
   Weimar IS, 1998, EXP HEMATOL, V26, P885
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
   Winkler IG, 2005, J EXP MED, V201, P1077, DOI 10.1084/jem.20042299
   Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081
   Wright N, 2002, J IMMUNOL, V168, P5268, DOI 10.4049/jimmunol.168.10.5268
   Xia LJ, 2004, BLOOD, V104, P3091, DOI 10.1182/blood 2004 02 0650
   YAMAZAKI K, 1990, AM J ANAT, V187, P261, DOI 10.1002/aja.1001870306
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   Zanjani ED, 1999, BLOOD, V94, P2515, DOI 10.1182/blood.V94.7.2515.419k15_2515_2522
   ZANNETTINO ACW, 1995, BLOOD, V85, P3466, DOI 10.1182/blood.V85.12.3466.bloodjournal85123466
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 167
TC 59
Z9 70
U1 0
U2 8
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 684 2
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1116
BP 392
EP 413
DI 10.1196/annals.1402.086
PG 22
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Orthopedics
GA BHA44
UT WOS:000251898900036
PM 18083941
OA Bronze
DA 2025 08 17
ER

PT J
AU Mancim Imbriani, MJ
   Duarte, JL
   Di Filippo, LD
   Durao, LPL
   Chorilli, M
   Spolidorio, DMP
   Maquera Huacho, PM
AF Mancim Imbriani, Maria Julia
   Duarte, Jonatas Lobato
   Di Filippo, Leonardo Delello
   Durao, Leticia Pereira Lima
   Chorilli, Marlus
   Spolidorio, Denise Madalena Palomari
   Maquera Huacho, Patricia Milagros
TI Formulation of a Novel Hesperetin Loaded Nanoemulsion and Its Promising
   Effect on Osteogenesis
SO PHARMACEUTICS
LA English
DT Article
DE nanoparticles; flavonoids; materials testing; cytotoxicity tests; bone
   regeneration; hesperetin
ID DRUG DELIVERY SYSTEMS; SPONTANEOUS EMULSIFICATION; BONE;
   DIFFERENTIATION; MINERALIZATION; NANOPARTICLES; ENHANCEMENT; HESPERIDIN
AB Alternative therapies associating natural products and nanobiotechnology show new perspectives on controlled drug release. In this context, nanoemulsions (NEs) present promising results for their structural design and properties. Hesperetin (HT), a flavonoid mainly found in citrus fruits, presents highlighted bone benefits. In this context, we developed a hesperetin loaded nanoemulsion (HT NE) by sonication method and characterized it by dynamic light scattering, analyzing its encapsulation efficiency, and cumulative release. The biocompatibility in human osteoblasts Saos 2 like was evaluated by the cytotoxicity assay and IC50. Then, the effects of the HT NE on osteogenesis were evaluated by the cellular proliferation, calcium nodule formation, bone regulators gene expression, collagen quantification, and alkaline phosphatase activity. The results showed that the formulation presented ideal values of droplet size, polydispersity index, and zeta potential, and the encapsulation efficiency was 74.07 +/  5.33%, showing a gradual and controlled release. Finally, HT NE was shown to be biocompatible and increased cellular proliferation, and calcium nodule formation, regulated the expression of Runx2, ALPL, and TGF beta genes, and increased the collagen formation and alkaline phosphatase activity. Therefore, the formulation of this NE encapsulated the HT appropriately, allowing the increasing of its effects on mechanisms to improve or accelerate the osteogenesis process.
C1 [Mancim Imbriani, Maria Julia; Durao, Leticia Pereira Lima; Maquera Huacho, Patricia Milagros] Sao Paulo State Univ UNESP, Sch Dent, Dept Diag & Surg, BR 14801385 Araraquara, SP, Brazil.
   [Mancim Imbriani, Maria Julia; Durao, Leticia Pereira Lima; Spolidorio, Denise Madalena Palomari; Maquera Huacho, Patricia Milagros] Sao Paulo State Univ UNESP, Sch Dent, Dept Physiol & Pathol, BR 14801385 Araraquara, SP, Brazil.
   [Duarte, Jonatas Lobato; Di Filippo, Leonardo Delello; Chorilli, Marlus] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Drugs & Med, BR 14800903 Araraquara, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista;
   Universidade Estadual Paulista
RP Maquera Huacho, PM (通讯作者)，Sao Paulo State Univ UNESP, Sch Dent, Dept Diag & Surg, BR 14801385 Araraquara, SP, Brazil.; Maquera Huacho, PM (通讯作者)，Sao Paulo State Univ UNESP, Sch Dent, Dept Physiol & Pathol, BR 14801385 Araraquara, SP, Brazil.
EM maria.mancim@unesp.br; jl.duarte@unesp.br; leonardo.filippo@unesp.br;
   leticia.durao@unesp.br; marlus.chorilli@unesp.br;
   denise.mp.spolidorio@unesp.br; patricia.maquera@unesp.br
RI Lobato Duarte, Jonatas/M 4442 2017; Huacho, Patricia/AAG 2458 2020;
   Chorilli, Marlus/D 9238 2012; Spolidorio, Denise/P 3530 2016; Duarte,
   Jonatas/M 4442 2017; Maquera Huacho, Patricia Milagros/IAN 3318 2023; Di
   Filippo, Leonardo/AAZ 3151 2020
OI Lobato Duarte, Jonatas/0000 0002 7276 3686; Chorilli,
   Marlus/0000 0002 6698 0545; Mancim Imbriani, Maria
   Julia/0000 0002 3600 0307; Maquera Huacho, Patricia
   Milagros/0000 0002 2193 9979; Delello Di Filippo,
   Leonardo/0000 0001 6365 8756
FU Sao Paulo Research Foundation (FAPESP) [2020/14155 0, 2021/05881 1,
   2018/16540 8, 2021/15178 6]; Swedish Research Council [2021 05881]
   Funding Source: Swedish Research Council
FX This research was funded by grant #2020/14155 0, Sao Paulo Research
   Foundation (FAPESP);grant #2021/05881 1, Sao Paulo Research Foundation
   (FAPESP); grant #2018/16540 8, Sao Paulo Research Foundation (FAPESP)
   and grant #2021/15178 6, Sao Paulo Research Foundation (FAPESP).
CR Ahmad S, 2016, MOL CELL BIOCHEM, V423, P115, DOI 10.1007/s11010 016 2830 y
   Algahtani MS, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9080384
   Ali M, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/7669255
   Alipour M, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 28267 y
   Ambroszkiewicz J, 2023, NUTRIENTS, V15, DOI 10.3390/nu15061376
   Bagherpour I, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1073435
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Bonifácio BV, 2024, CHEM PAP, V78, P973, DOI 10.1007/s11696 023 03134 2
   Bonifácio BV, 2014, INT J NANOMED, V9, P1, DOI 10.2147/IJN.S52634
   Bosly HAE, 2022, SAUDI J BIOL SCI, V29, DOI 10.1016/j.sjbs.2022.103455
   Bouchemal K, 2004, INT J PHARM, V280, P241, DOI 10.1016/j.ijpharm.2004.05.016
   Cassidy A, 2017, AM J CLIN NUTR, V105, P10, DOI 10.3945/ajcn.116.136051
   Chen LH, 2020, ADV SCI, V7, DOI 10.1002/advs.202001677
   Clogston JD, 2011, METHODS MOL BIOL, V697, P63, DOI 10.1007/978 1 60327 198 1_6
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Diedrich C, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15061592
   Ramos MAD, 2020, INT J PHARMACEUT, V589, DOI 10.1016/j.ijpharm.2020.119780
   Duarte JL, 2024, BEILSTEIN J NANOTECH, V15, P104, DOI 10.3762/bjnano.15.10
   Duarte JL, 2020, ENVIRON SCI POLLUT R, V27, P28737, DOI 10.1007/s11356 020 09278 y
   Duranoglu D, 2018, NANOTECHNOLOGY, V29, DOI 10.1088/1361 6528/aad111
   García Melero J, 2022, MATERIALS, V15, DOI 10.3390/ma15134572
   Geiser AG, 2005, ENDOCRINOLOGY, V146, P4524, DOI 10.1210/en.2005 0024
   Gu SF, 2019, J ZHEJIANG UNIV SC B, V20, P273, DOI 10.1631/jzus.B1800346
   Gupta A, 2016, SOFT MATTER, V12, P2826, DOI 10.1039/c5sm02958a
   Huacho Patricia Milagros Maquera, 2017, Braz. Dent. J., V28, P317, DOI 10.1590/0103 6440201601136
   Huang Y, 2017, MAT SCI ENG C MATER, V75, P1034, DOI 10.1016/j.msec.2017.02.174
   Hvattum E, 2012, J PHARMACEUT BIOMED, V62, P7, DOI 10.1016/j.jpba.2011.12.009
   Izzotti A, 2013, J Prev Med Hyg, V54, P138
   Kara S, 2014, SCI WORLD J, DOI 10.1155/2014/797824
   Karaguzel G, 2010, REV ENDOCR METAB DIS, V11, P237, DOI 10.1007/s11154 010 9154 0
   Kelmann RG, 2007, INT J PHARMACEUT, V342, P231, DOI 10.1016/j.ijpharm.2007.05.004
   Kim SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067504
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Kozuch B, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15092332
   Kushwaha AC, 2022, ACS BIOMATER SCI ENG, V8, P3810, DOI 10.1021/acsbiomaterials.2c00165
   Laxmi M, 2015, ARTIF CELL NANOMED B, V43, P334, DOI 10.3109/21691401.2014.887018
   Lin ZP, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115013
   Ling JKU, 2022, J FOOD SCI TECH MYS, V59, P1677, DOI 10.1007/s13197 021 05128 y
   Liu L, 2021, MED MOL MORPHOL, V54, P1, DOI 10.1007/s00795 020 00251 9
   Liu WJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0029 4
   Lotfipour F, 2014, Drug Res (Stuttg), V64, P348, DOI 10.1055/s 0033 1358747
   Lu JH, 2004, ENVIRON SCI TECHNOL, V38, P4603, DOI 10.1021/es049575c
   Marwa A, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e15457
   McClements DJ, 2021, PROG LIPID RES, V81, DOI 10.1016/j.plipres.2020.101081
   Meng SY, 2011, J BONE MINER METAB, V29, P535, DOI 10.1007/s00774 010 0257 1
   Meyer MB, 2014, J BIOL CHEM, V289, P16016, DOI 10.1074/jbc.M114.552216
   Miastkowska M, 2020, MOLECULES, V25, DOI 10.3390/molecules25122747
   Muhammad T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030648
   Narawi MM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00214
   Nobakht M, 2017, PLANTS BASEL, V6, DOI 10.3390/plants6030039
   Nones J, 2011, NEUROCHEM RES, V36, P1776, DOI 10.1007/s11064 011 0493 3
   Ortiz AD, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12050626
   Pandey P, 2020, RECENT PAT NANOTECH, V14, P276, DOI 10.2174/1872210514666200604145755
   Rashed MMA, 2023, FOODS, V12, DOI 10.3390/foods12010057
   de Souza ALR, 2012, CURR NANOSCI, V8, P512
   Rothwell JA, 2017, CURR OPIN CLIN NUTR, V20, P512, DOI 10.1097/MCO.0000000000000424
   Santamaría E, 2024, MOLECULES, V29, DOI 10.3390/molecules29010158
   Sato MR, 2015, CURR TOP MED CHEM, V15, P287, DOI 10.2174/1568026615666150108145614
   Tanomaru M, 2017, INT ENDOD J, V50, pE31, DOI 10.1111/iej.12780
   Trzeciakiewicz A, 2010, J NUTR BIOCHEM, V21, P424, DOI 10.1016/j.jnutbio.2009.01.017
   Trzeciakiewicz A, 2010, J AGR FOOD CHEM, V58, P668, DOI 10.1021/jf902680n
   Vaz G, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14010194
   Wolfram J, 2016, CURR DRUG DELIV, V13, P711, DOI 10.2174/1567201812666151027142412
   Xue DT, 2017, ONCOTARGET, V8, P21031, DOI 10.18632/oncotarget.15473
   Yao H, 2020, INT J MED SCI, V17, P1692, DOI 10.7150/ijms.45786
   Yu B, 2022, PERIODONTOL 2000, V89, P99, DOI 10.1111/prd.12422
NR 66
TC 2
Z9 3
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JUN
PY 2024
VL 16
IS 6
AR 698
DI 10.3390/pharmaceutics16060698
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WQ1T9
UT WOS:001256254500001
PM 38931821
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Unger, RE
   Sartoris, A
   Peters, K
   Motta, A
   Migliaresi, C
   Kunkel, M
   Bulnheim, U
   Rychly, J
   Kirkpatrick, CJ
AF Unger, Ronald E.
   Sartoris, Anne
   Peters, Kirsten
   Motta, Antonella
   Migliaresi, Claudio
   Kunkel, Martin
   Bulnheim, Ulrike
   Rychly, Joachim
   Kirkpatrick, C. James
TI Tissue like self assembly in cocultures of endothelial cells and
   osteoblasts and the formation of microcapillary like structures on
   three dimensional porous biomaterials
SO BIOMATERIALS
LA English
DT Article
DE coculture; angiogenesis; tissue self assembly; bone tissue engineering;
   osteoblast; endothelial
ID FIBROBLAST GROWTH FACTOR; HOLLOW FIBER MEMBRANES; IN VITRO ANGIOGENESIS;
   MARROW STROMAL CELLS; SILK FIBROIN NET; GENE EXPRESSION; MESSENGER RNA;
   BONE; DIFFERENTIATION; VASCULARIZATION
AB The survival and functioning of a bone biomaterial requires a rapid and stable vascularization after implantation. However, the mechanisms involved in the context of the complex healing microenvironment are poorly understood. To evaluate the vascularization potential of bone biomaterials, angiogenic stimuli were added to human dermal microvascular endothelial cells (HDMEC) growing on three dimensional (3 D) bone biomaterials consisting of porous hydroxyapatite, porous calcium phosphate, porous nickel titanium, successfully being used in humans, and also silk fibroin nets. HDMEC did not migrate to form microcapillary like structures as they did on cell culture plastic. In cocultures of HDMEC and primary human osteoblast cells (HOS) or the human osteoblast like cell line MG 63 on these biomaterials, a tissue like self assembly of cells occurred with time, with endothelial cells forming microcapillary like structures containing a lumen and giving a strong PECAM 1 expression at cell interfaces. These microcapillary like structures were intertwined between cell layers of osteoblasts and did not form when exogenous angiogenic stimuli were added to these cocultures. The life span of HDMEC was also significantly enhanced by coculture; with HDMEC being present for up to at least 42 days, compared to the monoculture where cells began to die rapidly after I week without passage. This coculture system may be applicable to a prevascularization strategy for biomaterials prior to implantation. Irrespective of this, the coculture model holds promise for studies to deepen our understanding of bone regeneration on 3 D substrates. Most importantly, these data raise important questions concerning the exact nature of pro angiogenic drug  or gene delivery systems to be incorporated into scaffolds. Our results underline the necessity to take into account the in situ production of growth factors by invading mesenchymal cells in the regenerative niche. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Mainz, Inst Pathol, REPAIR Lab, D 55101 Mainz, Germany.
   Univ Mainz, Clin Maxillofacial Surg, D 55101 Mainz, Germany.
   Univ Rostock, Dept Cell Biol, D 18055 Rostock, Germany.
   Univ Trent, Dept Mat Engn & Ind Technol, I 38050 Trento, Italy.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; University of Rostock; University of Trento
RP Unger, RE (通讯作者)，Univ Mainz, Inst Pathol, REPAIR Lab, D 55101 Mainz, Germany.
EM runger@uni mainz.de
RI ; Peters, Kirsten/S 3484 2016; Motta, Antonella/E 2554 2014
OI Kirkpatrick, Charles James/0000 0002 0088 418X; Peters,
   Kirsten/0000 0003 0254 176X; Motta, Antonella/0000 0003 4893 6863
CR Annaz B, 2004, J MICROSC OXFORD, V216, P97, DOI 10.1111/j.0022 2720.2004.01403.x
   Botelho CM, 2006, J BIOMED MATER RES A, V79A, P723, DOI 10.1002/jbm.a.30806
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chennazhy KP, 2005, BIOMATERIALS, V26, P5658, DOI 10.1016/j.biomaterials.2005.02.024
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289
   Dziubla TD, 2004, J BIOMED MATER RES A, V68A, P603, DOI 10.1002/jbm.a.20023
   FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745
   Furumatsu T, 2003, J BIOCHEM, V133, P633, DOI 10.1093/jb/mvg081
   Gao Y, 2006, J MATER SCI MATER M, V17, P815, DOI 10.1007/s10856 006 9840 3
   Hirschi KK, 2002, ANN NY ACAD SCI, V961, P223, DOI 10.1111/j.1749 6632.2002.tb03090.x
   Kaigler D, 2003, TISSUE ENG, V9, P95, DOI 10.1089/107632703762687573
   Kim BS, 1998, BIOTECHNOL BIOENG, V57, P46
   Ma ZW, 2005, TISSUE ENG, V11, P1149, DOI 10.1089/ten.2005.11.1149
   McLucas E, 2006, ENDOTHELIUM J ENDOTH, V13, P35, DOI 10.1080/10623320600660185
   Oliveira JM, 2006, BIOMATERIALS, V27, P6123, DOI 10.1016/j.biomaterials.2006.07.034
   Patrick CW, 1999, TISSUE ENG, V5, P139, DOI 10.1089/ten.1999.5.139
   Perets A, 2003, J BIOMED MATER RES A, V65A, P489, DOI 10.1002/jbm.a.10542
   Peters K, 2003, CARDIOVASC RES, V60, P49, DOI 10.1016/S0008 6363(03)00397 3
   Peters K, 2005, MOL CELL BIOCHEM, V270, P157, DOI 10.1007/s11010 005 4504 z
   Peters K, 2002, MICROVASC RES, V64, P334, DOI 10.1006/mvre.2002.2438
   Peters K, 2002, BIOMATERIALS, V23, P3413, DOI 10.1016/S0142 9612(02)00042 X
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   Rouwkema J, 2006, TISSUE ENG, V12, P2685, DOI 10.1089/ten.2006.12.2685
   Santos MI, 2007, BIOMATERIALS, V28, P240, DOI 10.1016/j.biomaterials.2006.08.006
   SIDDAPPA R, 2007, J ORTHOP RES
   Stahl A, 2005, FEBS LETT, V579, P5338, DOI 10.1016/j.febslet.2005.09.005
   Stahl A, 2004, BIOCHEM BIOPH RES CO, V322, P684, DOI 10.1016/j.bbrc.2004.07.175
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Tabata Y, 1999, J BIOMAT SCI POLYM E, V10, P957, DOI 10.1163/156856299X00559
   Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434
   Unger RE, 2005, BIOMATERIALS, V26, P1877, DOI 10.1016/j.biomaterials.2004.05.032
   Unger RE, 2005, BIOMATERIALS, V26, P3461, DOI 10.1016/j.biomaterials.2004.09.047
   Unger RE, 2004, BIOMATERIALS, V25, P5137, DOI 10.1016/j.biomaterials.2003.12.040
   Unger RE, 2004, BIOMATERIALS, V25, P1069, DOI [10.1016/S0142 9612(03)00619 7, 10.1016/S0142 9612(03)00630 6]
   Villars F, 2000, J CELL BIOCHEM, V79, P672, DOI 10.1002/1097 4644(20001215)79:4<672::AID JCB150>3.0.CO;2 2
   von Schroeder HP, 2003, BONE, V33, P673, DOI 10.1016/S8756 3282(03)00215 1
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wenger A, 2004, TISSUE ENG, V10, P1536, DOI 10.1089/ten.2004.10.1536
   Zhu YB, 2004, J MATER SCI MATER M, V15, P283, DOI 10.1023/B:JMSM.0000015489.27261.f0
NR 42
TC 332
Z9 381
U1 1
U2 171
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2007
VL 28
IS 27
BP 3965
EP 3976
DI 10.1016/j.biomaterials.2007.05.032
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 202JO
UT WOS:000248898000009
PM 17582491
DA 2025 08 17
ER

PT J
AU Zhang, ZW
   Fu, XW
   Xu, L
   Hu, XL
   Deng, F
   Yang, ZQ
   Jiang, L
   Fu, TW
   Zhou, PF
   Song, JL
   Ji, P
   Huang, J
   Wu, XM
AF Zhang, Zhiwei
   Fu, Xuewei
   Xu, Ling
   Hu, Xiaolei
   Deng, Feng
   Yang, Zhiqiang
   Jiang, Lin
   Fu, Tiwei
   Zhou, Pengfei
   Song, Jinlin
   Ji, Ping
   Huang, Jiao
   Wu, Xiaomian
TI Nanosized Alumina Particle and Proteasome Inhibitor Bortezomib Prevented
   inflammation and Osteolysis Induced by Titanium Particle via Autophagy
   and NF κB Signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
ID WEAR DEBRIS; HUMAN OSTEOBLASTS; OSTEOCLASTOGENESIS; SUPPRESSION;
   EXPRESSION; DEGRADATION; IMPLANTS; NANOPARTICLES; MACROPHAGES; EXPOSURE
AB Autophagy and NF kappa B signaling are involving in the process of Particle Disease, which was caused by the particles released from friction interface of artificial joint, implant materials of particle reinforced composite, scaffolds for tissue engineering, or material for drug delivery. However, the biological interaction of different material particles and the mechanism of proteasome inhibitor, Bortezomib (BTZ), against Titanium (Ti) particle induced Particle Disease remain unclear. In this study, we evaluated effect of nanosized Alumina (Al) particles and BTZ on reducing and treating the Ti particle induced inflammatory reaction in MG 63 cells and mouse calvarial osteolysis model. We found that Al particles and BTZ could block apoptosis and NF  kappa B activation in osteoblasts in vitro and in a mouse model of calvarial resorption induced by Ti particles. We found that Al particles and BTZ attenuated the expression of inflammatory cytokines (IL 1 beta, IL 6, TNF alpha). And Al prevented the IL 1 beta expression induced by Ti via attenuating the NF  kappa B activation beta  TRCP and reducing the expression of Casepase 3. Expressions of autophagy marker LC3 was activated in Ti group, and reduced by Al and/not BTZ. Furthermore, the expressions of OPG were also higher in these groups than the Ti treated group. Collectively, nanosized Al could prevent autophagy and reduce the apoptosis, inflammatory and osteolysis induced by Ti particles. Our data offered a basic data for implant design when it was inevitable to use Ti as biomaterials, considering the outstanding mechanical propertie of Ti. What's more, proteasome inhibitor BTZ could be a potential therapy for wear particle induced inflammation and osteogenic activity via regulating the activity of NF  kappa B signaling pathway.
C1 [Zhang, Zhiwei; Fu, Xuewei; Xu, Ling; Deng, Feng; Yang, Zhiqiang; Jiang, Lin; Fu, Tiwei; Zhou, Pengfei; Song, Jinlin; Ji, Ping; Huang, Jiao; Wu, Xiaomian] Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing 401147, Peoples R China.
   [Zhang, Zhiwei; Fu, Xuewei; Xu, Ling; Deng, Feng; Yang, Zhiqiang; Jiang, Lin; Fu, Tiwei; Zhou, Pengfei; Song, Jinlin; Ji, Ping; Huang, Jiao; Wu, Xiaomian] Chongqing Med Univ, Coll Stomatol, Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing 401147, Peoples R China.
   [Deng, Feng; Song, Jinlin; Wu, Xiaomian] Chongqing Med Univ, Coll Stomatol, Dept Orthodont, Chongqing 40015, Peoples R China.
   [Zhang, Zhiwei; Huang, Jiao] Chongqing Med Univ, Coll Stomatol, Dept Periodontol, Chongqing 40015, Peoples R China.
   [Fu, Xuewei; Xu, Ling] Chongqing Med Univ, Coll Stomatol, Dept Prosthodont, Chongqing 40015, Peoples R China.
   [Hu, Xiaolei] Chongqing Med Univ, Coll Lab Med, Key Lab Clin Lab Sci, Minist Educ, Chongqing 40016, Peoples R China.
   [Yang, Zhiqiang; Ji, Ping] Chongqing Med Univ, Coll Stomatol, Dept Oral & Maxillofacial Surg, Chongqing 401147, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University; Chongqing Medical
   University; Chongqing Medical University; Chongqing Medical University
RP Huang, J; Wu, XM (通讯作者)，Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing 401147, Peoples R China.; Huang, J; Wu, XM (通讯作者)，Chongqing Med Univ, Coll Stomatol, Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing 401147, Peoples R China.; Wu, XM (通讯作者)，Chongqing Med Univ, Coll Stomatol, Dept Orthodont, Chongqing 40015, Peoples R China.; Huang, J (通讯作者)，Chongqing Med Univ, Coll Stomatol, Dept Periodontol, Chongqing 40015, Peoples R China.
EM huangjiao@hospital.cqmu.edu.cn; wuxiaomian@hospital.cqmu.edu.cn
RI zhang, zhiwie/HPH 8504 2023; Wu, Xiaomian/W 3131 2019; Fu,
   Xuewei/W 1108 2018
FU National Natural Science Foundation of China [31400808, 81570979,
   21402018, 31871464]; Overseas Returnees Innovation and Entrepreneurship
   Support Program of Chongqing [cx2019095]; Natural Science Foundation
   Project of Chongqing, China [CSTS2015JCYJA10039]; Science and Technology
   Research Project of Chongqing Municipal Education Commission of China
   [KJ1600226]; Program for Innovation Team Building at Institutions of
   Higher Education in Chongqing in 2016 [CXTDG201602006]
FX Our study was supported by the National Natural Science Foundation of
   China to Xiaomian Wu (31400808), Feng Deng (81570979), Xiaolei Hu
   (21402018) and Ping Ji (31871464). It is also supported by the Overseas
   Returnees Innovation and Entrepreneurship Support Program of Chongqing
   (cx2019095) to Xiaomian Wu, Natural Science Foundation Project of
   Chongqing, China (CSTS2015JCYJA10039), Science and Technology Research
   Project of Chongqing Municipal Education Commission of China
   (KJ1600226), and Program for Innovation Team Building at Institutions of
   Higher Education in Chongqing in 2016 (CXTDG201602006).
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Bitar D, 2015, WORLD J ORTHOP, V6, P172, DOI 10.5312/wjo.v6.i2.172
   Bressan E, 2019, MATERIALS, V12, DOI 10.3390/ma12122036
   Buciumeanu M, 2018, TRIBOL INT, V119, P381, DOI 10.1016/j.triboint.2017.11.032
   Chen Y, 2016, J ORTHOP RES, V34, P845, DOI 10.1002/jor.23080
   Córdova LA, 2015, ACTA BIOMATER, V13, P150, DOI 10.1016/j.actbio.2014.10.042
   de Chambrun GP, 2014, MUCOSAL IMMUNOL, V7, P589, DOI 10.1038/mi.2013.78
   Deng ZT, 2017, INT J NANOMED, V12, P3617, DOI 10.2147/IJN.S124661
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Ekstrand Hammarström B, 2015, BIOMATERIALS, V51, P58, DOI 10.1016/j.biomaterials.2015.01.031
   Goodman SB, 2006, BIOMATERIALS, V27, P6096, DOI 10.1016/j.biomaterials.2006.08.023
   Green JM, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0325 3
   Han SH, 2015, YONSEI MED J, V56, P112, DOI 10.3349/ymj.2015.56.1.112
   Hashimoto M, 2016, J BIOMED MATER RES B, V104, P241, DOI 10.1002/jbm.b.33377
   He ZJ, 2017, FOOD CHEM TOXICOL, V101, P55, DOI 10.1016/j.fct.2017.01.002
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Hu LH, 2017, MOL MED REP, V15, P4093, DOI 10.3892/mmr.2017.6524
   Hu W, 2014, CANCER LETT, V343, P239, DOI 10.1016/j.canlet.2013.09.035
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Huang MT, 2019, MAT SCI ENG C MATER, V97, P412, DOI 10.1016/j.msec.2018.11.075
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71
   Jiang L, 2017, J PERIODONTOL, V88, P473, DOI 10.1902/jop.2016.160396
   Jing XG, 2018, EXP CELL RES, V368, P174, DOI 10.1016/j.yexcr.2018.04.026
   Jonitz Heincke A, 2016, MOL MED REP, V14, P1491, DOI 10.3892/mmr.2016.5415
   Kanarek N, 2012, IMMUNOL REV, V246, P77, DOI 10.1111/j.1600 065X.2012.01098.x
   Kang CR, 2017, INT J NANOMED, V12, P4323, DOI 10.2147/IJN.S136281
   Knight Stephen Richard, 2011, Orthop Rev (Pavia), V3, pe16, DOI 10.4081/or.2011.e16
   Lochner K, 2011, INT J MOL MED, V28, P1055, DOI 10.3892/ijmm.2011.778
   Lohmann CH, 2000, BIOMATERIALS, V21, P551, DOI 10.1016/S0142 9612(99)00211 2
   Ma MX, 2019, BIOMATER SCI UK, V7, P1437, DOI 10.1039/c8bm01539b
   Mao X, 2012, INFLAMMATION, V35, P1411, DOI 10.1007/s10753 012 9454 5
   Mao X, 2012, INFLAMMATION, V35, P905, DOI 10.1007/s10753 011 9392 7
   Meiners S, 2008, MED RES REV, V28, P309, DOI 10.1002/med.20111
   Nandy A, 2018, CELL REP, V25, P2110, DOI 10.1016/j.celrep.2018.10.076
   Nich C, 2013, J BIOMED MATER RES A, V101, P3033, DOI 10.1002/jbm.a.34599
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Okafor CC, 2006, J ORTHOP RES, V24, P461, DOI 10.1002/jor.20075
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Riediker M, 2019, PART FIBRE TOXICOL, V16, DOI 10.1186/s12989 019 0302 8
   SALVATI EA, 1993, CLIN ORTHOP RELAT R, P160
   Shah FA, 2016, MAT SCI ENG C MATER, V62, P960, DOI 10.1016/j.msec.2016.01.032
   Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750
   Soto Alvaredo J, 2014, METALLOMICS, V6, P1702, DOI 10.1039/c4mt00133h
   Terkawi MA, 2018, ACTA BIOMATER, V65, P417, DOI 10.1016/j.actbio.2017.11.001
   Thounaojam MC, 2015, ONCOTARGET, V6, P32439, DOI 10.18632/oncotarget.5857
   Thrivikraman G, 2014, RSC ADV, V4, P12763, DOI 10.1039/c3ra44483j
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Wu XM, 2014, ONCOTARGET, V5, P4211, DOI 10.18632/oncotarget.1971
   Wu XM, 2012, INT J NANOMED, V7, P1215, DOI 10.2147/IJN.S28101
   Yan Y, 2009, WEAR, V267, P683, DOI 10.1016/j.wear.2008.12.110
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Zaveri TD, 2017, BIOMATERIALS, V115, P128, DOI 10.1016/j.biomaterials.2016.10.038
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhao YP, 2016, SCI REP UK, V6, DOI 10.1038/srep20909
   Zhu SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep36251
   Zhu W, 2015, INT J NANOMED, V10, P7385, DOI 10.2147/IJN.S92733
NR 60
TC 16
Z9 17
U1 0
U2 16
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 27
PY 2020
VL 10
IS 1
AR 5562
DI 10.1038/s41598 020 62254 x
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NB3HW
UT WOS:000560406800010
PM 32221318
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lo, KWH
   Kan, HM
   Gagnon, KA
   Laurencin, CT
AF Lo, Kevin W.  H.
   Kan, Ho Man
   Gagnon, Keith A.
   Laurencin, Cato T.
TI One day treatment of small molecule 8 bromo cyclic AMP analogue induces
   cell based VEGF production for in vitro angiogenesis and
   osteoblastic differentiation
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE angiogenesis; osteoblastic differentiation; regenerative engineering;
   bone regeneration; small molecules; cAMP; morphogenesis
ID MESENCHYMAL STROMAL CELLS; CYCLIC AMP; BONE FORMATION; PATHWAY; TISSUE;
   DELIVERY; KINASE; EPAC; VIVO; CHONDROGENESIS
AB Small molecule based regenerative engineering is emerging as a promising strategy for regenerating bone tissue. Small molecule cAMP analogues have been proposed as novel biofactors for bone repair and regeneration and, while promising, the effect that these small molecules have on angiogenesis, a critical requirement for successful bone regeneration, is still unclear. Our previous research demonstrated that the small molecule cAMP analogue 8 bromoadenosine 3', 5' cyclic monophosphate (8 Br cAMP) was able to promote initial osteoblast adhesion on a polymeric scaffold via cAMP signalling cascades. Here, we report that 8 Br cAMP is capable of inducing in vitro cell based VEGF production for angiogenesis promotion. We first demonstrated that treating osteoblast like MC3T3 E1 cells with 8 Br cAMP for 1 day significantly increased VEGF production and secretion. We then demonstrated that 8 Br cAMP induced cell secreted VEGF is biologically active and may promote angiogenesis, as evidenced by increased human umbilical vein endothelial cells (HUVECs) migration and tubule formation. In addition, treatment of MC3T3 E1 cells with 8 Br cAMP for as short as a single day resulted in enhanced ALP activity as well as matrix mineralization, demonstrating in vitro osteoblastic differentiation. A short term 8 Br cAMP treatment also addresses the concern of non specific cytotoxicity, as our data indicate that a 1 day 8 Br cAMP treatment scheme supports cellular proliferation of MC3T3 E1 cells as well as HUVECs. While the major concern associated with small molecule drugs is the risk of nonspecific cytotoxicity, the short exposure treatment outlined in this paper provides a very promising strategy to mitigate the risk associated with small molecules. Copyright (C) 2013 John Wiley & Sons, Ltd.
C1 [Lo, Kevin W.  H.; Kan, Ho Man; Gagnon, Keith A.; Laurencin, Cato T.] Univ Connecticut, Ctr Hlth, Sch Med, Inst Regenerat Engn, Farmington, CT 06030 USA.
   [Lo, Kevin W.  H.; Kan, Ho Man; Laurencin, Cato T.] Univ Connecticut, Ctr Hlth, Sch Med, Raymond & Beverly Sackler Ctr Biomed Biol Phys &, Farmington, CT 06030 USA.
   [Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Sch Med, Dept Med,Div Endocrinolog, Farmington, CT 06030 USA.
   [Lo, Kevin W.  H.; Laurencin, Cato T.] Univ Connecticut, Sch Engn, Dept Biomed Engn, Storrs, CT USA.
   [Kan, Ho Man; Laurencin, Cato T.] Univ Connecticut, Ctr Hlth, Sch Med, Dept Orthoped Surg, Farmington, CT 06030 USA.
   [Laurencin, Cato T.] Univ Connecticut, Sch Engn, Dept Chem Mat & Biomol Engn, Storrs, CT USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut; University of Connecticut;
   University of Connecticut
RP Lo, KWH; Laurencin, CT (通讯作者)，Univ Connecticut, Ctr Hlth, Sch Med, Inst Regenerat Engn, Farmington, CT 06030 USA.
EM wlo@uchc.edu; laurencin@uchc.edu
FU National Institutes of Health (NIH) [R21AR060480]; Raymond and Beverly
   Sackler Center for Biomedical, Biological, Physical and Engineering
   Sciences; Presidential Award for Excellence in Science, Mathematics, and
   Engineering Mentorship
FX We would like to thank Dr Bret D. Ulery for his comments. The authors
   gratefully acknowledge funding from the National Institutes of Health
   (NIH; Grant No. R21AR060480) and the Raymond and Beverly Sackler Center
   for Biomedical, Biological, Physical and Engineering Sciences. Dr
   Laurencin was the recipient of the Presidential Faculty Fellowship Award
   from President William Clinton and the Presidential Award for Excellence
   in Science, Mathematics, and Engineering Mentorship from President
   Barack Obama.
CR Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Brouwers L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022187
   Chen JZ, 2004, J CARDIOVASC PHARM, V43, P347, DOI 10.1097/00005344 200403000 00004
   Chiu LLY, 2011, J TISSUE ENG REGEN M, V5, P69, DOI 10.1002/term.292
   Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200
   Cui QJ, 2013, CURR PHARM DESIGN, V19, P3374, DOI 10.2174/1381612811319190004
   Doorn J, 2012, TISSUE ENG PT A, V18, P558, DOI [10.1089/ten.tea.2011.0312, 10.1089/ten.TEA.2011.0312]
   Doorn J, 2013, BIOMATERIALS, V34, P3053, DOI 10.1016/j.biomaterials.2012.12.037
   Doorn J, 2012, TISSUE ENG PT A, V18, P1431, DOI [10.1089/ten.tea.2011.0484, 10.1089/ten.TEA.2011.0484]
   Egusa H, 2010, J ORAL BIOSCI, V52, P107, DOI 10.2330/joralbiosci.52.107
   Ennett AB, 2006, J BIOMED MATER RES A, V79A, P176, DOI 10.1002/jbm.a.30771
   FOLKMAN J, 1980, T OPHTHAL SOC UK, V100, P346
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   He J, 2013, TOXICOL SCI, V134, P26, DOI 10.1093/toxsci/kft101
   HO WC, 1982, J EXP ZOOL, V224, P321, DOI 10.1002/jez.1402240305
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim J, 2012, J TISSUE ENG REGEN M, V6, P404, DOI 10.1002/term.442
   KOSHER RA, 1980, J EMBRYOL EXP MORPH, V56, P91
   Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e
   Lamb D, 2002, J CELL PHYSIOL, V192, P216, DOI 10.1002/jcp.10131
   Laurencin CT, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004467
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Lo Kevin W. H., 2011, Recent Patents on Biomedical Engineering, V4, P153, DOI 10.2174/1874764711104030153
   Lo KWH, 2012, ADV DRUG DELIVER REV, V64, P1277, DOI 10.1016/j.addr.2012.03.014
   Lo KWH, 2012, J TISSUE ENG REGEN M, V6, P40, DOI 10.1002/term.395
   Lo KWH, 2011, J ORTHOP RES, V29, P602, DOI 10.1002/jor.21276
   Lo KWH, 2014, J TISSUE ENG REGEN M, V8, P728, DOI 10.1002/term.1573
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Lo KWH, 2013, J TISSUE ENG REGEN M, V19, P3374
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300 483X(97)00151 0
   Masuya K, 2010, EXPERT OPIN THER PAT, V20, P563, DOI 10.1517/13543771003604729
   Namkoong S, 2009, CELL SIGNAL, V21, P906, DOI 10.1016/j.cellsig.2009.01.038
   Osusky Katherine L., 2004, Angiogenesis, V7, P225, DOI 10.1007/s10456 004 3149 y
   Ozdemir T, 2013, CURR PHARM DESIGN, V19, P3446, DOI 10.2174/1381612811319190010
   Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105
   Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163 7258(00)00051 6
   Sefcik Lauren S, 2008, Organogenesis, V4, P215
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   SOLURSH M, 1979, DIFFERENTIATION, V15, P183, DOI 10.1111/j.1432 0436.1979.tb01049.x
   SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021 9150(90)90150 H
   STARZEC AB, 1994, J CELL PHYSIOL, V161, P31, DOI 10.1002/jcp.1041610105
   Sun JZ, 2004, CANCER RES, V64, P3586, DOI 10.1158/0008 5472.CAN 03 2673
   Tischer T, 2010, TISSUE ENG PT A, V16, P1031, DOI 10.1089/ten.TEA.2009.0043
   Wieghaus KA, 2006, TISSUE ENG, V12, P1903, DOI 10.1089/ten.2006.12.1903
NR 46
TC 22
Z9 23
U1 0
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD OCT
PY 2016
VL 10
IS 10
BP 867
EP 875
DI 10.1002/term.1839
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA EC0JI
UT WOS:000387786200006
PM 24493289
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Craft, AM
   Ahmed, N
   Rockel, JS
   Baht, GS
   Alman, BA
   Kandel, RA
   Grigoriadis, AE
   Keller, GM
AF Craft, April M.
   Ahmed, Nazish
   Rockel, Jason S.
   Baht, Gurpreet S.
   Alman, Benjamin A.
   Kandel, Rita A.
   Grigoriadis, Agamemnon E.
   Keller, Gordon M.
TI Specification of chondrocytes and cartilage tissues from embryonic stem
   cells
SO DEVELOPMENT
LA English
DT Article
DE Cartilage; Chondrocyte; Embryonic stem cell; Induced pluripotent stem
   cell; Paraxial; Somite
ID IN VITRO; CHONDROGENIC DIFFERENTIATION; PRIMITIVE STREAK; SOMITE
   FORMATION; SYNOVIAL JOINT; MOUSE; EXPRESSION; INDUCTION; BMP; ACTIVATION
AB Osteoarthritis primarily affects the articular cartilage of synovial joints. Cell and/or cartilage replacement is a promising therapy, provided there is access to appropriate tissue and sufficient numbers of articular chondrocytes. Embryonic stem cells (ESCs) represent a potentially unlimited source of chondrocytes and tissues as they can generate a broad spectrum of cell types under appropriate conditions in vitro. Here, we demonstrate that mouse ESC derived chondrogenic mesoderm arises from a Flk 1( )/Pdgfr alpha(+) (F P+) population that emerges in a defined temporal pattern following the development of an early cardiogenic F P+ population. Specification of the late arising F P+ population with BMP4 generated a highly enriched population of chondrocytes expressing genes associated with growth plate hypertrophic chondrocytes. By contrast, specification with Gdf5, together with inhibition of hedgehog and BMP signaling pathways, generated a population of non hypertrophic chondrocytes that displayed properties of articular chondrocytes. The two chondrocyte populations retained their hypertrophic and non hypertrophic properties when induced to generate spatially organized proteoglycan rich cartilage like tissue in vitro. Transplantation of either type of chondrocyte, or tissue generated from them, into immunodeficient recipients resulted in the development of cartilage tissue and bone within an 8 week period. Significant ossification was not observed when the tissue was transplanted into osteoblast depleted mice or into diffusion chambers that prevent vascularization. Thus, through stage specific manipulation of appropriate signaling pathways it is possible to efficiently and reproducibly derive hypertrophic and non hypertrophic chondrocyte populations from mouse ESCs that are able to generate distinct cartilage like tissue in vitro and maintain a cartilage tissue phenotype within an avascular and/or osteoblast free niche in vivo.
C1 [Craft, April M.; Keller, Gordon M.] Univ Hlth Network, McEwen Ctr Regenerat Med, Toronto, ON M5G 1L7, Canada.
   [Ahmed, Nazish; Kandel, Rita A.] Univ Toronto, Mt Sinai Hosp, CIHR BioEngn Skeletal Tissues Team, Toronto, ON M5G 1X5, Canada.
   [Rockel, Jason S.; Baht, Gurpreet S.; Alman, Benjamin A.] Hosp Sick Children, Toronto, ON M5G 1L7, Canada.
   [Grigoriadis, Agamemnon E.] Kings Coll London, Guys Hosp, Dept Craniofacial Dev & Stem Cell Biol, London SE1 9RT, England.
C3 University of Toronto; University Health Network Toronto; University of
   Toronto; Sinai Health System Toronto; University of Toronto; Hospital
   for Sick Children (SickKids); Guy's & St Thomas' NHS Foundation Trust;
   University of London; King's College London
RP Keller, GM (通讯作者)，Univ Hlth Network, McEwen Ctr Regenerat Med, Toronto, ON M5G 1L7, Canada.
EM gkeller@uhnresearch.ca
RI Kandel, Rita/E 2149 2017
OI Keller, Gordon/0000 0001 9309 9297
FU Canadian Institutes of Health Research (CIHR) [MOP 219710]
FX This work was supported by a grant from the Canadian Institutes of
   Health Research (CIHR) [MOP 219710] to B.A.A. and G.M.K.
CR Ahmed N, 2009, TISSUE ENG PT A, V15, P665, DOI 10.1089/ten.tea.2008.0004
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Archer Charles W., 2003, Birth Defects Research, V69, P144, DOI 10.1002/bdrc.10015
   Blumer MJF, 2007, DEV DYNAM, V236, P2077, DOI 10.1002/dvdy.21228
   Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455
   Burgess R, 1996, NATURE, V384, P570, DOI 10.1038/384570a0
   Bussen M, 2004, GENE DEV, V18, P1209, DOI 10.1101/gad.300104
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Colnot C, 2005, J CELL BIOCHEM, V95, P688, DOI 10.1002/jcb.20449
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Dao DY, 2012, J BONE MINER RES, V27, P1680, DOI 10.1002/jbmr.1639
   Darabi R, 2008, NAT MED, V14, P134, DOI 10.1038/nm1705
   Fehling HJ, 2003, DEVELOPMENT, V130, P4217, DOI 10.1242/dev.00589
   Fletcher RB, 2008, DEV DYNAM, V237, P1243, DOI 10.1002/dvdy.21517
   Gadue P, 2006, P NATL ACAD SCI USA, V103, P16806, DOI 10.1073/pnas.0603916103
   Gouon Evans V, 2006, NAT BIOTECHNOL, V24, P1402, DOI 10.1038/nbt1258
   Guo SZ, 2010, CELL MOL BIOL LETT, V15, P153, DOI 10.2478/s11658 009 0040 2
   Hatakeyama Y, 2004, J CELL BIOCHEM, V91, P1204, DOI 10.1002/jcb.20019
   Hirsinger E, 2000, INT REV CYTOL, V198, P1
   Hwang NS, 2006, STEM CELLS, V24, P284, DOI 10.1634/stemcells.2005 0024
   Hwang YS, 2008, STEM CELLS DEV, V17, P971, DOI 10.1089/scd.2007.0229
   Jukes JM, 2008, P NATL ACAD SCI USA, V105, P6840, DOI 10.1073/pnas.0711662105
   Kattman SJ, 2011, CELL STEM CELL, V8, P228, DOI 10.1016/j.stem.2010.12.008
   Kinder SJ, 1999, DEVELOPMENT, V126, P4691
   Knosp WM, 2007, J BIOL CHEM, V282, P6843, DOI 10.1074/jbc.M610775200
   Koyama E, 2008, DEV BIOL, V316, P62, DOI 10.1016/j.ydbio.2008.01.012
   Kramer J, 2000, MECH DEVELOP, V92, P193, DOI 10.1016/S0925 4773(99)00339 1
   Kulesa PM, 2002, SCIENCE, V298, P991, DOI 10.1126/science.1075544
   LaPrade RF, 2008, AM J SPORT MED, V36, P360, DOI 10.1177/0363546507308359
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   LAWSON KA, 1991, DEVELOPMENT, V113, P891
   Lin AC, 2009, NAT MED, V15, P1421, DOI 10.1038/nm.2055
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Luche H, 2007, EUR J IMMUNOL, V37, P43, DOI 10.1002/eji.200636745
   Mankoo BS, 2003, DEVELOPMENT, V130, P4655, DOI 10.1242/dev.00687
   Minina E, 2001, DEVELOPMENT, V128, P4523
   Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104
   Nakayama N, 2003, J CELL SCI, V116, P2015, DOI 10.1242/jcs.00417
   Ng A., 2011, J BONE MINER RES S1
   Nostro MC, 2008, CELL STEM CELL, V2, P60, DOI 10.1016/j.stem.2007.10.011
   Ormestad M, 2004, DEV DYNAM, V229, P328, DOI 10.1002/dvdy.10426
   Pacifici M, 2006, ANN NY ACAD SCI, V1068, P74, DOI 10.1196/annals.1346.010
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Pelttari K, 2008, INJURY, V39, pS58, DOI 10.1016/j.injury.2008.01.038
   Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355
   Singh MK, 2005, MECH DEVELOP, V122, P131, DOI 10.1016/j.mod.2004.10.011
   Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001
   Steinert AF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2195
   Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008
   Takakura N, 1997, J HISTOCHEM CYTOCHEM, V45, P883, DOI 10.1177/002215549704500613
   TAM PPL, 1992, DEVELOPMENT, V115, P703
   Tanaka M, 2009, STEM CELL RES, V3, P126, DOI 10.1016/j.scr.2009.07.001
   Tardif G, 2006, ANN RHEUM DIS, V65, P261, DOI 10.1136/ard.2005.037523
   Tins BJ, 2005, RADIOLOGY, V234, P501, DOI 10.1148/radiol.2342031970
   Tsumaki N, 2002, J BONE MINER RES, V17, P898, DOI 10.1359/jbmr.2002.17.5.898
   Visnjic D, 2001, J BONE MINER RES, V16, P2222, DOI 10.1359/jbmr.2001.16.12.2222
   Yamashita A, 2009, CELL DEATH DIFFER, V16, P278, DOI 10.1038/cdd.2008.149
   Yasuhara R, 2011, LAB INVEST, V91, P1739, DOI 10.1038/labinvest.2011.144
   Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092 8674(03)00847 X
   Yoon BS, 2006, DEVELOPMENT, V133, P4667, DOI 10.1242/dev.02680
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhang QY, 2011, GENESIS, V49, P75, DOI 10.1002/dvg.20702
   Zhang Y, 2007, BIOCHEM BIOPH RES CO, V363, P694, DOI 10.1016/j.bbrc.2007.09.030
   zur Nieden NI, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471 213X 5 1
NR 64
TC 87
Z9 110
U1 0
U2 51
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0950 1991
EI 1477 9129
J9 DEVELOPMENT
JI Development
PD JUN 15
PY 2013
VL 140
IS 12
BP 2597
EP 2610
DI 10.1242/dev.087890
PG 14
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA 154EY
UT WOS:000319655800018
PM 23715552
DA 2025 08 17
ER

PT J
AU Xiao, YS
   Ren, Q
   Zheng, YZ
   Zhang, SS
   Ouyang, J
   Jiao, LH
   Tang, CF
   Li, LF
   Shi, WM
   Wang, MF
   Zhang, SN
   Zhang, D
   Zhong, B
   Peng, F
   Chen, ZX
   Wu, LH
AF Xiao, Yaosheng
   Ren, Qun
   Zheng, Yizhou
   Zhang, Shanshan
   Ouyang, Jing
   Jiao, Linhui
   Tang, Chunfang
   Li, Linfu
   Shi, Weimei
   Wang, Miaofei
   Zhang, Sainan
   Zhang, Di
   Zhong, Bin
   Peng, Fang
   Chen, Zhixi
   Wu, Longhuo
TI Geniposide ameliorated dexamethasone induced endoplasmic reticulum
   stress and mitochondrial apoptosis in osteoblasts
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Glucocorticoid; Osteoporosis; Geniposide; ER stress; Osteoblasts
ID INDUCED OSTEOPOROSIS; RECEPTOR PLAYS; CELLS; ER
AB Ethnopharmacological relevance: Eucommia ulmoides Oliver has been traditionally used for treatment of various diseases, including osteoporosis, knee pain, and paralysis. The extract of Eucommia ulmoides has been reported to stimulate the bone formation and suppress the bone resorption, leading to protection against osteoporosis (OP). Geniposide (GEN) has been considered as one of the effective compounds responsible for the therapeutic efficacy of Eucommia ulmoides against OP. Aim of the study: To explore whether GEN protected against dexamethasone (DEX) induced osteoporosis (OP) by activating NRF2 expression and inhibiting endoplasmic reticulum (ER) stress. Materials and methods: The DEX induced rat OP models were duplicated. The pathological changes were examined by histological/immunohistochemical evaluation and micro computed tomography (micro CT) assessment. Apoptosis was detected by a flow cytometer. Mitochondrial Ca2+ concentrations and mitochondrial membrane potential were detected. Western blot assays were used to detect the protein expression. Results: GEN effectively reversed DEX induced pathological changes of trabecular bone in rats. In addition, the DEX increased expression of ATF4/CHOP was also ameliorated. In MC3T3 E1 cells, DEX promoted endoplasmic reticulum (ER) stress and mitochondrial apoptosis. Inhibition of ER stress abolished the induction of apoptosis by DEX. Similarly, GEN significantly ameliorated DEX induced mitochondrial apoptosis. The possible underlying mechanism might be associated with the pharmacological effects of GEN on activating the expression of NRF2 and alleviating ER stress in DEX treated MC3T3 E1 cells. Conclusion: GEN ameliorated DEX induced ER stress and mitochondrial apoptosis in osteoblasts.
C1 [Xiao, Yaosheng; Tang, Chunfang; Zhong, Bin] Gannan Med Univ, Affiliated Hosp 1, Dept Orthopaed, Ganzhou 341000, Peoples R China.
   [Ren, Qun; Zheng, Yizhou; Zhang, Shanshan; Jiao, Linhui; Li, Linfu; Shi, Weimei; Wang, Miaofei; Zhang, Sainan; Chen, Zhixi; Wu, Longhuo] Gannan Med Univ, Coll Pharm, Ganzhou 341000, Peoples R China.
   [Ouyang, Jing] Gannan Med Univ, Coll Rehabil, Ganzhou 341000, Peoples R China.
   [Zhang, Di] Gannan Med Univ, Affiliated Hosp 1, Dept Med Imaging, Ganzhou 341000, Peoples R China.
   [Peng, Fang] Ganzhou Peoples Hosp, Dept Pathol, Ganzhou 341000, Peoples R China.
C3 Gannan Medical University; Gannan Medical University; Gannan Medical
   University; Gannan Medical University
RP Wu, LH (通讯作者)，Gannan Med Univ, Coll Pharm, Ganzhou 341000, Peoples R China.
EM longhwu@hotmail.com
RI Yizhou, Zheng/AAP 6728 2020; Zhang, shanshan/HLP 6320 2023; xiao,
   yaosheng/MIU 3357 2025
OI Shi, weimei/0000 0002 5409 8969; Chen, Zhixi/0000 0003 2487 707X; Zheng,
   Yizhou/0000 0002 8246 5009; 
FU National Natural Science Foundation of China [82060407, 81860261,
   81860388, 81960883]; Jiangxi Provincial Natural Science
   [20212ACB206002]; Scientific Research Fund of Jiangxi Provincial
   Education Department [GJJ211503, GJJ211505, GJJ211520, GJJ211521]
FX Funding statement This study was financially supported by National
   Natural Science Foundation of China (82060407, 81860261, 81860388, and
   81960883) , Jiangxi Provincial Natural Science (20212ACB206002) ,
   Scientific Research Fund of Jiangxi Provincial Education Department
   (GJJ211503, GJJ211505, GJJ211520, and GJJ211521) .
CR Balsa E, 2019, MOL CELL, V74, P877, DOI 10.1016/j.molcel.2019.03.031
   Bevinakoppamath S., 2021, FRONT PHARMACOL, V12
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Burkewitz K, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108125
   Carreras Sureda A, 2019, NAT CELL BIOL, V21, P755, DOI 10.1038/s41556 019 0329 y
   Che JM, 2021, CELL SIGNAL, V84, DOI 10.1016/j.cellsig.2021.110024
   Chen J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0217 y
   Chen L, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106121
   Chipurupalli S, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.758311
   Dusabimana T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041651
   Eun SY, 2021, NUTRIENTS, V13, DOI 10.3390/nu13113904
   Guan GP, 2019, N S ARCH PHARMACOL, V392, P715, DOI 10.1007/s00210 019 01625 2
   Guan MQ, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/3641317
   Guido G, 2009, CLIN CASES MINER BON, V6, P114
   Guo LX, 2012, ACTA PHARMACOL SIN, V33, P237, DOI 10.1038/aps.2011.146
   Guo Y., MOL BIOL REP, V48, P7841
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Jia W, 2019, CURR RES TRANSL MED, V67, P35, DOI 10.1016/j.retram.2019.03.002
   Jiang YQ, 2016, CELL PHYSIOL BIOCHEM, V39, P407, DOI 10.1159/000445634
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Kobza AO, 2021, OPEN ACCESS RHEUMATO, V13, P177, DOI 10.2147/OARRR.S282606
   Kokkinopoulou I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116054
   Lee HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081349
   Li JC, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 7040
   Li N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00854
   Liu WL, 2018, INT J MOL MED, V41, P2028, DOI 10.3892/ijmm.2018.3412
   Liu W, 2018, TOXICOLOGY, V406, P70, DOI 10.1016/j.tox.2018.06.002
   Malaise O, 2021, J CLIN MED, V10, DOI 10.3390/jcm10225331
   Pan YL, 2014, AM J CHINESE MED, V42, P143, DOI 10.1142/S0192415X14500104
   Peng CH, 2021, TZU CHI MED J, V33, P212, DOI 10.4103/tcmj.tcmj_233_20
   Proulx J, 2021, FRONT NEUROSCI SWITZ, V15, DOI 10.3389/fnins.2021.715945
   Psarra AMG, 2003, GLIA, V41, P38, DOI 10.1002/glia.10130
   Qi SS, 2019, BIOL TRACE ELEM RES, V187, P172, DOI 10.1007/s12011 018 1362 6
   Saag KG, 2016, ARTHRITIS RHEUMATOL, V68, P2122, DOI 10.1002/art.39726
   Shakeri A, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104335
   Shen BY, 2020, J CELL MOL MED, V24, P5097, DOI 10.1111/jcmm.15139
   Sunanda T, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111669
   Suzuki R, 2020, J BONE MINER RES, V35, P1992, DOI 10.1002/jbmr.4053
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wang LF, 2019, J CELL PHYSIOL, V234, P3207, DOI 10.1002/jcp.27335
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Xie BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00411
   Xin X, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6615881
   Xiong JL, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114735
   Yan TB, 2018, FREE RADICAL RES, V52, P223, DOI 10.1080/10715762.2017.1423070
   Yang HJ, 2020, ANN PALLIAT MED, V9, P2826, DOI 10.21037/apm 20 279
   Yang JH, 2017, J BONE MINER METAB, V35, P366, DOI 10.1007/s00774 016 0778 3
   Yang LY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6623464
   Yin F, 2010, ACTA PHARMACOL SIN, V31, P540, DOI 10.1038/aps.2010.28
   Yuan XL, 2017, CURR PHARM DESIGN, V23, P1693, DOI 10.2174/1381612822666161025152423
   Yuan XL, 2017, BIOMED PHARMACOTHER, V89, P1262, DOI 10.1016/j.biopha.2017.03.028
   Zhao X, 2020, FOOD SCI NUTR, V8, P4897, DOI 10.1002/fsn3.1779
   Zhou RY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.602307
   Zhou YH, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02797 5
   Zou TY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.553728
NR 56
TC 21
Z9 22
U1 3
U2 48
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 12
PY 2022
VL 291
AR 115154
DI 10.1016/j.jep.2022.115154
EA MAR 2022
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1W2RW
UT WOS:000806625700002
PM 35240241
DA 2025 08 17
ER

PT J
AU Kagy, VD
   Muniz, LTB
   Michels, AC
   Luiz, ST
   Alanis, LRA
   Brancher, JA
   Grégio, AMT
   Ignácio, SA
   Camargo, ES
   Machado, MAN
   Johann, ACBR
AF Kagy, Viviane da Silva
   Bittencourt Muniz, Luciana Trevisan
   Michels, Arieli Carini
   Luiz, Suelen Teixeira
   Azevedo Alanis, Luciana Reis
   Brancher, Joao Armando
   Trindade Gregio, Ana Maria
   Ignacio, Sergio Aparecido
   Camargo, Elisa Souza
   Naval Machado, Maria Angela
   Batista Rodrigues Johann, Aline Cristina
TI Effect of the Chronic Use of Lithium Carbonate on Induced Tooth Movement
   in Wistar Rats
SO PLOS ONE
LA English
DT Article
ID ROOT RESORPTION; ALVEOLAR BONE; THERAPY; DISORDERS; TOXICITY;
   ACTIVATION; MECHANISM; TISSUE; ERRORS; DRUGS
AB Patients who seek dental treatment may have bipolar disorder, and lithium carbonate (LC) is the drug of choice used in the treatment of this disorder. Taking into consideration the controversial results found in the literature, and the possible influence of LC on induced tooth movement, the objective was to evaluate tooth movement induced in rats after administration of lithium carbonate. One hundred and ninety two rats were divided into 3 groups. In the L group, the animals received daily 60mg/kg of LC, they were not subjected to orthodontic movement, and they were euthanized after 33, 37, 44 or 51 days. In the LM group, the LC was administered for 30 days and during the subsequent 3, 7, 14 and 21 days, corresponding to the period of induced tooth movement, and they received a spring that produced a 30cN force. In the SM group, saline solution was applied. Measurements were made of tooth displacement, the numbers of osteoclasts and serum lithium phosphate (PO4), alkaline phosphatase (ALP) and creatinine levels. The tooth displacement was lower in the LM group compared to the SM group at 44 days. A tendency toward reduction in the number of osteoclasts was observed in the LM group compared to the SM group at 44 days. The average lithium were higher in the L and LM groups compared to the SM group. The opposite was observed for the PO4 group. A higher value for the ALP was found in the L group. The average creatinine level was lower in the LM group. LC inhibited tooth movement for 14 days, possibly due to the reduction in the number of osteoclasts.
C1 [Kagy, Viviane da Silva; Bittencourt Muniz, Luciana Trevisan; Michels, Arieli Carini; Luiz, Suelen Teixeira; Azevedo Alanis, Luciana Reis; Brancher, Joao Armando; Trindade Gregio, Ana Maria; Ignacio, Sergio Aparecido; Camargo, Elisa Souza; Batista Rodrigues Johann, Aline Cristina] Pontificia Univ Catolica Parana, Dept Sch Hlth & Biosci, Curitiba, PR, Brazil.
   [Naval Machado, Maria Angela] Univ Fed Parana, Sch Dent, Dept Stomatol, Curitiba, PR, Brazil.
C3 Pontificia Universidade Catolica do Parana; Universidade Federal do
   Parana
RP Johann, ACBR (通讯作者)，Pontificia Univ Catolica Parana, Dept Sch Hlth & Biosci, Curitiba, PR, Brazil.
EM alinecristinabatista@yahoo.com.br
RI Machado, Maria/ABH 7992 2020; Muniz, Luciana/Y 2102 2019; Brancher, Joao
   Armando/C 7758 2014; Camargo, Elisa/P 7077 2016; Azevedo Alanis,
   Luciana/G 9150 2012; Souza Camargo, Elisa/P 7077 2016; IGNACIO,
   SERGIO/NZO 0408 2025; Batista Rodrigues Johann, Aline
   Cristina/G 7190 2012; Johann, Aline/G 7190 2012; Brancher,
   João/AAQ 4858 2020
OI Azevedo Alanis, Luciana/0000 0001 8809 3579; Brancher, Joao
   Armando/0000 0002 8914 702X; Teixeira Luiz, Suelen/0000 0001 5675 8134;
   Michels, Arieli Carini/0000 0001 9099 0893; Souza Camargo,
   Elisa/0000 0002 7382 1526; Gregio Hardy, Ana Maria/0000 0003 0445 8206;
   Batista Rodrigues Johann, Aline Cristina/0000 0002 1678 9363; Machado,
   Maria Angela Naval/0000 0002 2752 1979; 
CR Allagui MS, 2005, CR BIOL, V328, P900, DOI 10.1016/j.crvi.2005.08.005
   ALTAMURA AC, 1977, EUR J CLIN PHARMACOL, V12, P59, DOI 10.1007/BF00561406
   ANDERSSON KE, 1986, ACTA PHARMACOL TOX, V59, P27
   [Anonymous], ORTHODONTICS CURRENT
   [Anonymous], DISEASES OF THE WIST
   Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   Baloul SS, 2011, AM J ORTHOD DENTOFAC, V139, pS83, DOI 10.1016/j.ajodo.2010.09.026
   BARAN DT, 1978, J CLIN INVEST, V61, P1691, DOI 10.1172/JCI109090
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Close H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090169
   Cohen O, 1998, HORM METAB RES, V30, P594, DOI 10.1055/s 2007 978939
   DAVIES NL, 1991, J S AFR VET ASSOC, V62, P140
   Dibart S, 2014, EUR J ORTHODONT, V36, P457, DOI 10.1093/ejo/cjt079
   Diravidamani K, 2012, J PHARM BIOALLIED SC, V4, pS299, DOI 10.4103/0975 7406.100278
   Ekizer A, 2015, LASER MED SCI, V30, P779, DOI 10.1007/s10103 013 1405 3
   Frigotto GCF, 2015, AM J ORTHOD DENTOFAC, V148, P450, DOI 10.1016/j.ajodo.2015.04.031
   Galvao MJ, 2011, EUR J HISTOCHEM, V55, P1, DOI 10.4081/ejh.2011.e1
   Giglio JA, 2010, QUINTESSENCE INT, V41, P433
   Gonzales C, 2009, ANGLE ORTHOD, V79, P715, DOI 10.2319/072108 381.1
   Grande I, 2016, LANCET, V387, P1561, DOI 10.1016/S0140 6736(15)00241 X
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   Hillert M, 2012, NEUROSCI LETT, V521, P62, DOI 10.1016/j.neulet.2012.05.060
   HOUSTON WJB, 1983, AM J ORTHOD DENTOFAC, V83, P382, DOI 10.1016/0002 9416(83)90322 6
   Jensen HV, 1996, J AFFECT DISORDERS, V36, P89, DOI 10.1016/0165 0327(95)00052 6
   KEELING SD, 1993, AM J ORTHOD DENTOFAC, V103, P320, DOI 10.1016/0889 5406(93)70012 D
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lepkifker E, 2007, DEPRESS ANXIETY, V24, P571, DOI 10.1002/da.20273
   Lewicki M, 2006, EXP TOXICOL PATHOL, V58, P197, DOI 10.1016/j.etp.2006.06.003
   Mak TWL, 1998, J CLIN ENDOCR METAB, V83, P3857, DOI 10.1210/jc.83.11.3857
   Marquezan M, 2010, PHOTOMED LASER SURG, V28, P757, DOI 10.1089/pho.2009.2694
   McCormack SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102387
   McKnight RF, 2012, LANCET, V379, P721, DOI 10.1016/S0140 6736(11)61516 X
   Meikle MC, 2006, EUR J ORTHODONT, V28, P221, DOI 10.1093/ejo/cj1001
   MIDTGARD J, 1974, ANGLE ORTHOD, V44, P56
   Milne TJ, 2009, EUR J ORTHODONT, V31, P221, DOI 10.1093/ejo/cjp032
   Moe SM, 2008, PRIMARY CARE, V35, P215, DOI 10.1016/j.pop.2008.01.007
   Ng F, 2009, BIPOLAR DISORD, V11, P559, DOI 10.1111/j.1399 5618.2009.00737.x
   Patel BD, 2013, PSYCHIAT QUART, V84, P407, DOI 10.1007/s11126 013 9253 7
   Paton C, 2013, BIPOLAR DISORD, V15, P865, DOI 10.1111/bdi.12128
   Pearson GS, 2012, J CHILD ADOL PS NURS, V25, P232, DOI 10.1111/jcap.12008
   Prigent A, 2008, SEMIN NUCL MED, V38, P32, DOI 10.1053/j.semnuclmed.2007.09.003
   Retamoso LB, 2009, MICRON, V40, P827, DOI 10.1016/j.micron.2009.07.003
   Ribeiro Jucienne Salgado, 2013, Braz. Dent. J., V24, P503, DOI 10.1590/0103 6440201302286
   Sharma SD, 2005, BIOL PHARM BULL, V28, P834, DOI 10.1248/bpb.28.834
   Shoji S, 2010, CALCIFIED TISSUE INT, V87, P181, DOI 10.1007/s00223 010 9384 x
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tamura M, 2011, INT J BIOCHEM CELL B, V43, P760, DOI 10.1016/j.biocel.2011.01.021
   Tang GH, 2011, J DENT RES, V90, P336, DOI 10.1177/0022034510389180
   Teng GYY, 2014, J ORAL MAXIL SURG, V72, P19, DOI 10.1016/j.joms.2013.09.012
   Wang Y, 2014, EXP THER MED, V7, P468, DOI 10.3892/etm.2013.1410
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zhang MY, 2009, CELL SIGNAL, V21, P559, DOI 10.1016/j.cellsig.2008.12.010
NR 52
TC 8
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 3
PY 2016
VL 11
IS 8
AR e0160400
DI 10.1371/journal.pone.0160400
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DT3GA
UT WOS:000381367800075
PM 27487121
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Lipinski, RJA
   Thillier, Y
   Morisseau, C
   Sebastiano, CS
   Smith, BC
   Hall, CD
   Katritzky, AR
AF Jones Lipinski, Rachel A.
   Thillier, Yann
   Morisseau, Christophe
   Sebastiano, Christopher S., Jr.
   Smith, Brian C.
   Hall, C. Dennis
   Katritzky, Alan R.
TI Molecular docking guided synthesis of NSAID glucosamine bioconjugates
   and their evaluation as COX 1/COX 2 inhibitors with potentially reduced
   gastric toxicity
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE COX 1/COX 2; glucosamine bioconjugates; molecular docking; NSAIDs
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHONDROITIN SULFATE; ACCURATE
   DOCKING; CYCLOOXYGENASE 2; IBUPROFEN; KNEE; SELECTIVITY; CELECOXIB;
   NAPROXEN; PROTEIN
AB Non steroidal anti inflammatory drugs (NSAIDs) are a powerful class of inhibitors targeting two isoforms of the family of cyclooxygenase enzymes (COX 1 and COX2). While NSAIDs are widely used in the management of pain, in particular as a treatment for osteo  and rheumatoid arthritis, their long term use has been associated with numerous on  and off target effects. As the carboxylic acid moiety present in common NSAIDs is responsible for some of their adverse effects, but is not required for their anti inflammatory activity, we sought to mask this group through direct coupling to glucosamine, which is thought to prevent cartilage degradation. We report herein the conjugation of commonly prescribed NSAIDs to glucosamine hydrochloride and the use of molecular docking to show that addition of the carbohydrate moiety to the parent NSAID can enhance binding in the active site of COX 2. In a preliminary, in vitro screening assay, the diclofenac glucosamine bioconjugate exhibited 10 fold greater activity toward COX 2, making it an ideal candidate for future in vivo studies. Furthermore, in an intriguing result, we observed that the mefenamic acid glucosamine bioconjugate displayed enhanced activity toward COX 1 rather than COX 2.
C1 [Jones Lipinski, Rachel A.; Thillier, Yann; Sebastiano, Christopher S., Jr.; Hall, C. Dennis; Katritzky, Alan R.] Univ Florida, Dept Chem, Ctr Heterocycl Cpds, Gainesville, FL 32611 USA.
   [Jones Lipinski, Rachel A.; Smith, Brian C.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
   [Jones Lipinski, Rachel A.; Smith, Brian C.] Med Coll Wisconsin, Program Chem Biol, Milwaukee, WI 53226 USA.
   [Morisseau, Christophe] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Dept Entomol & Nematol, Davis, CA 95616 USA.
   [Katritzky, Alan R.] King Adbulaziz Univ, Fac Sci, Chem Dept, Jeddah, Saudi Arabia.
   [Thillier, Yann] Univ Massachusetts, Med Sch, RNA Therapeut Inst, Worcester, MA 01605 USA.
C3 State University System of Florida; University of Florida; Medical
   College of Wisconsin; Medical College of Wisconsin; University of
   California System; University of California Davis; King Abdulaziz
   University; University of Massachusetts System; University of
   Massachusetts Worcester
RP Lipinski, RJA (通讯作者)，Univ Florida, Dept Chem, Ctr Heterocycl Cpds, Gainesville, FL 32611 USA.
EM racjones@mcw.edu
RI Jones, Rachel/J 2103 2014; Jones Lipinski, Rachel/J 2103 2014; Smith,
   Brian/D 9949 2013; Thillier, Yann/KBC 8688 2024
OI Morisseau, Christophe/0000 0002 5672 6631; Jones Lipinski,
   Rachel/0000 0003 4586 0445; 
FU King Abdulaziz University [D 006/431]; National Institute of
   Environmental Health Sciences (NIEHS) [R35ES030443]; National Institute
   of General Medical Sciences [R35GM128840]; National Institute of General
   Medical Sciences [R35GM128840] Funding Source: NIH RePORTER
FX King Abdulaziz University, Grant/Award Number: D 006/431; National
   Institute of Environmental Health Sciences (NIEHS), Grant/Award Number:
   R35ES030443; National Institute of General Medical Sciences, Grant/Award
   Number: R35GM128840
CR Abdu Allah HHM, 2020, BIOORG CHEM, V94, DOI 10.1016/j.bioorg.2019.103378
   Altman RD, 2005, OSTEOARTHR CARTILAGE, V13, P13, DOI 10.1016/j.joca.2004.10.012
   Aly MRE, 2005, EUR J ORG CHEM, V2005, P4382, DOI 10.1002/ejoc.200500107
   Bajaj K, 2012, CHEM BIOL DRUG DES, V80, P17, DOI 10.1111/j.1747 0285.2012.01364.x
   BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P734, DOI 10.1039/c39760000734
   Carroux CJ, 2013, J MED CHEM, V56, P9623, DOI 10.1021/jm401163e
   Chen F, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111612
   Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771
   Cryer B, 1998, AM J MED, V104, P413, DOI 10.1016/S0002 9343(98)00091 6
   Dahmer S, 2008, AM FAM PHYSICIAN, V78, P471
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   HART FD, 1984, DRUGS, V27, P232, DOI 10.2165/00003495 198427030 00004
   Hawkey C, 2000, ARTHRITIS RHEUM US, V43, P370, DOI 10.1002/1529 0131(200002)43:2<370::AID ANR17>3.0.CO;2 D
   Huskisson EC, 2008, J INT MED RES, V36, P1161, DOI 10.1177/147323000803600602
   Jang BC, 2007, J BIOL CHEM, V282, P27622, DOI 10.1074/jbc.M610778200
   Jones MB, 2004, BIOTECHNOL BIOENG, V85, P394, DOI 10.1002/bit.10901
   Jones RA, 2014, ORG BIOMOL CHEM, V12, P8325, DOI 10.1039/c4ob01681e
   Kang YH, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 015 0176 7
   Katritzky AR, 2008, BIOCONJUGATE CHEM, V19, P1471, DOI 10.1021/bc8001369
   Katritzky AR, 2008, J ORG CHEM, V73, P511, DOI 10.1021/jo7018637
   Katritzky AR, 2007, BIOCONJUGATE CHEM, V18, P994, DOI 10.1021/bc0603687
   Katritzky AR, 2009, SYNLETT, P2392, DOI 10.1055/s 0029 1217827
   Katritzky AR, 2009, CHEM BIOL DRUG DES, V73, P618, DOI 10.1111/j.1747 0285.2009.00811.x
   Kourounakis PN, 2000, TOXICOLOGY, V144, P205, DOI 10.1016/S0300 483X(99)00208 5
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022 2836(88)90471 8
   LIEFLAND.M, 1967, H S Z PHYSIOL CHEM, V348, P477, DOI 10.1515/bchm2.1967.348.1.477
   LIEFLANDER M, 1967, H S Z PHYSIOL CHEM, V348, P363, DOI 10.1515/bchm2.1967.348.1.363
   MacDonald TM, 2017, EUR HEART J, V38, P1843, DOI 10.1093/eurheartj/ehw387
   MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693
   Mitchell Jane A, 2019, Br J Pharmacol, V176, P1038, DOI 10.1111/bph.14167
   MOSER P, 1990, J MED CHEM, V33, P2358, DOI 10.1021/jm00171a008
   Murphy LB, 2018, ARTHRIT CARE RES, V70, P869, DOI 10.1002/acr.23425
   Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI 10.1056/NEJMoa1611593
   Perrone MG, 2010, CURR MED CHEM, V17, P3769
   Sahu S, 2013, SYNTHESIS STUTTGART, V45, P3369, DOI 10.1055/s 0033 1339920
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Savjani JK, 2017, EUR J PHARMACOL, V801, P28, DOI 10.1016/j.ejphar.2017.02.051
   Scheiman JM, 2010, CLIN THER, V32, P667, DOI 10.1016/j.clinthera.2010.04.009
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822 007 9133 z
   Silva DJ, 1999, J ORG CHEM, V64, P5926, DOI 10.1021/jo9903499
   Tiwari AD, 2014, ORG BIOMOL CHEM, V12, P7238, DOI 10.1039/c4ob01281j
   Ullah N, 2016, J ENZYM INHIB MED CH, V31, P1018, DOI 10.3109/14756366.2015.1088840
   Vangsness CT, 2009, ARTHROSCOPY, V25, P86, DOI 10.1016/j.arthro.2008.07.020
   Wang JL, 2010, BIOORG MED CHEM LETT, V20, P7155, DOI 10.1016/j.bmcl.2010.07.053
   Zhang W, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00431
   Zhang ZY, 1999, J AM CHEM SOC, V121, P734, DOI 10.1021/ja982232s
NR 48
TC 11
Z9 11
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1747 0277
EI 1747 0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD JUL
PY 2021
VL 98
IS 1
BP 102
EP 113
DI 10.1111/cbdd.13855
EA MAY 2021
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA SV3GQ
UT WOS:000655531900001
PM 33955172
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Bradford, EM
   Ryu, SH
   Singh, AP
   Lee, G
   Goretsky, T
   Sinh, P
   Williams, DB
   Cloud, AL
   Gounaris, E
   Patel, V
   Lamping, OF
   Lynch, EB
   Moyer, MP
   De Plaen, IG
   Shealy, DJ
   Yang, GY
   Barrett, TA
AF Bradford, Emily M.
   Ryu, Stacy H.
   Singh, Ajay Pal
   Lee, Goo
   Goretsky, Tatiana
   Sinh, Preetika
   Williams, David B.
   Cloud, Amber L.
   Gounaris, Elias
   Patel, Vihang
   Lamping, Olivia F.
   Lynch, Evan B.
   Moyer, Mary Pat
   De Plaen, Isabelle G.
   Shealy, David J.
   Yang, Guang Yu
   Barrett, Terrence A.
TI Epithelial TNF Receptor Signaling Promotes Mucosal Repair in
   Inflammatory Bowel Disease
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; STEM CELLS; NEGATIVE REGULATOR; WNT/BETA CATENIN;
   PROGENITOR CELLS; CROHNS DISEASE; IN VITRO; SURVIVIN; HOMEOSTASIS;
   ACTIVATION
AB TNF plays an integral role in inflammatory bowel disease (IBD), as evidenced by the dramatic therapeutic responses in Crohn's disease (CD) patients induced by chimeric anti TNF mAbs. However, treatment of CD patients with etanercept, a decoy receptor that binds soluble TNF, fails to improve disease. To explore this discrepancy, we investigated the role of TNF signaling in Wnt/beta catenin mediated intestinal stem cell and progenitor cell expansion in CD patients, human cells, and preclinical mouse models. We hypothesized that TNF exerts beneficial effects on intestinal epithelial cell (IEC) responses to injury. In CD patients, intestinal stem cell and progenitor cell Wnt/beta catenin signaling correlates with inflammation status. TNF deficient (Tnf( / )) mice exhibited increased apoptosis, less IEC proliferation, and less Wnt signaling when stimulated with anti CD3 mAb. Bone marrow (BM) chimera mice revealed that mucosal repair depended on TNF production by BM derived cells and TNFR expression by radioresistant IECs. Wild type  > Tnfr1/2( / ) BM chimera mice with chronic dextran sodium sulfate colitis exhibited delayed ulcer healing, more mucosal inflammation, and impaired Wnt/beta catenin signaling, consistent with the hypothesis that epithelial TNFR signaling participates in mucosal healing. The direct effect of TNF on stem cells was demonstrated by studies of TNF induced Wnt/beta catenin target gene expression in murine enteroids and colonoid cultures and TNF induced beta catenin activation in non transformed human NCM460 cells (TOPFlash) and mice (TOP GAL). Together, these data support the hypothesis that TNF plays a beneficial role in enhancing Wnt/beta catenin signaling during ulcer healing in IBD. These novel findings will inform clinicians and therapeutic chemists alike as they strive to develop novel therapies for IBD patients.
C1 [Bradford, Emily M.; Ryu, Stacy H.; Singh, Ajay Pal; Lee, Goo; Goretsky, Tatiana; Sinh, Preetika; Williams, David B.; Gounaris, Elias; Barrett, Terrence A.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Internal Med, Chicago, IL 60611 USA.
   [Bradford, Emily M.; Goretsky, Tatiana; Cloud, Amber L.; Patel, Vihang; Lamping, Olivia F.; Lynch, Evan B.; Barrett, Terrence A.] Univ Kentucky, Div Gastroenterol, 800 Rose St,MN 649, Lexington, KY 40536 USA.
   [Ryu, Stacy H.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Driskill Grad Program Life Sci, Chicago, IL 60611 USA.
   [Moyer, Mary Pat] INCELL Corp, San Antonio, TX 78249 USA.
   [De Plaen, Isabelle G.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Chicago, IL 60611 USA.
   [Shealy, David J.] Janssen Res & Dev, Radnor, PA 19087 USA.
   [Yang, Guang Yu] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol, Chicago, IL 60611 USA.
C3 Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern
   University; Feinberg School of Medicine; University of Kentucky; Ann &
   Robert H. Lurie Children's Hospital of Chicago; Northwestern University;
   Feinberg School of Medicine; Incell Corporation LLC; Ann & Robert H.
   Lurie Children's Hospital of Chicago; Northwestern University; Feinberg
   School of Medicine; Northwestern University; Feinberg School of
   Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago
RP Bradford, EM (通讯作者)，Univ Kentucky, Div Gastroenterol, 800 Rose St,MN 649, Lexington, KY 40536 USA.
EM emily.bradford@uky.edu
RI Singh, Ashutosh/F 9731 2012; Gounaris, Elias/B 3184 2011; Lynch,
   Evan/ABG 7724 2020
OI Ryu, Stacy Hyunji/0000 0002 5448 339X; Bradford,
   Emily/0000 0002 4711 5628; De Plaen, Isabelle G/0000 0002 1742 2926;
   Barrett, Terrence/0000 0001 6428 3271; Gounaris,
   Elias/0000 0001 8679 9711
FU Veterans Affairs Merit Award [I01CX001353 0141]; National Institutes of
   Health [R01AI061701, R01DK 095662]; Training Program in Oncogenesis and
   Developmental Biology through the National Cancer Institute [T32
   CA080621]; Institutional Development Award from the National Institute
   of General Medical Sciences, National Institutes of Health [8
   P20GM103527 05]; National Cancer Institute Cancer Center Support Grant
   [P30 CA060553]
FX This work was supported by a Veterans Affairs Merit Award
   (I01CX001353 0141 to T.A.B.), the National Institutes of Health (Grants
   R01AI061701 and R01DK 095662 to T.A.B.), the Training Program in
   Oncogenesis and Developmental Biology through the National Cancer
   Institute (T32 CA080621, to support E.M.B.), and an Institutional
   Development Award from the National Institute of General Medical
   Sciences, National Institutes of Health (8 P20GM103527 05, to support
   tissue processing). Imaging work was also performed at the Northwestern
   Cell Imaging Facility, supported by National Cancer Institute Cancer
   Center Support Grant P30 CA060553 awarded to the Robert H. Lurie
   Comprehensive Cancer Center.
CR Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Barrett TA, 2012, SCIENCE, V338, P51, DOI 10.1126/science.1229414
   BEUTLER B, 1993, CRIT CARE MED, V21, pS423
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Bressenot AM, 2016, ALIMENT PHARM THER, V43, P439, DOI 10.1111/apt.13489
   Church DN, 2012, CURR ONCOL REP, V14, P120, DOI 10.1007/s11912 012 0215 2
   Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970
   Cohran V, 2016, AM J PATHOL, V186, P1837, DOI 10.1016/j.ajpath.2016.03.008
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034 07
   Flavin P, 2011, FEBS LETT, V585, P2537, DOI 10.1016/j.febslet.2011.07.005
   Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65
   Fuss IJ, 1996, J IMMUNOL, V157, P1261
   Goretsky T, 2012, AM J PATHOL, V181, P1306, DOI 10.1016/j.ajpath.2012.06.016
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928
   Koch S, 2011, GASTROENTEROLOGY, V141, P259, DOI 10.1053/j.gastro.2011.03.043
   Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037
   Leppkes M, 2014, INT IMMUNOL, V26, P509, DOI 10.1093/intimm/dxu051
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   Martini E, 2016, CELL CYCLE, V15, P2875, DOI 10.1080/15384101.2016.1231286
   Martini E, 2016, CELL REP, V14, P1062, DOI 10.1016/j.celrep.2016.01.010
   Merger M, 2002, GUT, V51, P155, DOI 10.1136/gut.51.2.155
   Miura N, 2005, INT IMMUNOL, V17, P513, DOI 10.1093/intimm/dxh231
   Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153
   Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821
   Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001
   Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219
   Rogler G, 1998, WORLD J SURG, V22, P382, DOI 10.1007/s002689900401
   Sandborn WJ, 2001, GASTROENTEROLOGY, V121, P1088, DOI 10.1053/gast.2001.28674
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012
   Tang YM, 2010, AM J PATHOL, V176, P158, DOI 10.2353/ajpath.2010.090548
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031
   Waetzig GH, 2004, FASEB J, V18, P91, DOI 10.1096/fj.04 2073fje
   Zganiacz A, 2004, J CLIN INVEST, V113, P401, DOI 10.1172/JCI200418991
NR 40
TC 112
Z9 129
U1 0
U2 21
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD SEP 1
PY 2017
VL 199
IS 5
BP 1886
EP 1897
DI 10.4049/jimmunol.1601066
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA FE1VH
UT WOS:000408005200036
PM 28747340
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lu, MT
   Guo, SY
   Hong, FL
   Zhang, YX
   Yuan, LC
   Ma, CY
   Ma, JQ
AF Lu, Mengting
   Guo, Shuyu
   Hong, Fangling
   Zhang, Yuxin
   Yuan, Lichan
   Ma, Changyan
   Ma, Junqing
TI Pax2 is essential for proliferation and osteogenic differentiation of
   mouse mesenchymal stem cells via Runx2
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Paired box 2; Proliferation; Osteogenic differentiation; Runx2;
   Mitogen activated protein kinases; Compact bone derived mouse
   mesenchymal stem cells
ID COMPACT BONE; EXPRESSION; APOPTOSIS; PROMOTES; PHOSPHORYLATION;
   OSTEOBLASTS; PHENOTYPE; PATHWAYS; DISEASE; PROTEIN
AB Mesenchymal stem cells (MSCs) have been widely studied in the field of regenerative medicine with the potential to solve osteoporosis. Paired box 2 (Pax2), as a transcription factor, is the master regulator of embryogenesis and oncogenesis. However, the function of Pax2 in osteogenesis is unknown. Here, we reported for the first time that the expression of Pax2 gradually increased during osteogenic differentiation of mouse MSCs, and osteoprogenitor cells. However, detected in osteoblastic cells of mouse tibia, the expression of Pax2 in the embryonic stage was higher than that in adulthood. In C3H/10/T1/2 cells and compact bone derived mouse MSCs (mMSCs), Pax2 knock down inhibited the proliferation of these cells, down regulated the expression of osteogenic marker genes, as well as repressed the ALP activity and mineralization. In addition, Pax2 enhanced the transcriptional activity of Runx2, and activated the MAPK pathway genes (ERK, JNK and p38). Furthermore, knock down of Pax2 repressed the mMSCs mediated bone regeneration in an ectopic bone formation model. In conclusion, Pax2 promotes osteogenesis of mouse MSCs, suggesting that Pax2 has a role in the pathophysiology of bone related diseases, and has potential application in bone tissue regeneration.
C1 [Lu, Mengting; Guo, Shuyu; Zhang, Yuxin; Yuan, Lichan; Ma, Junqing] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Hong, Fangling; Ma, Changyan] Nanjing Med Univ, Dept Med Genet, Longmian Rd 101, Nanjing 211166, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Ma, JQ (通讯作者)，Nanjing Med Univ, Jiangsu Key Lab Oral Dis, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM jma@njmu.edu.cn
RI ; guo, shuyu/LBH 1222 2024
OI Ma, Junqing/0000 0001 7703 5373; 
FU National Natural Science Foundation of China [81771029]; Priority
   Academic Program Development of Jiangsu Higher Education Institution
   [2014 037]
FX This research was funded by the National Natural Science Foundation of
   China (81771029), Project Funding by the Priority Academic Program
   Development of Jiangsu Higher Education Institution (2014 037).
CR Abu Elghanam G, 2017, METHODS MOL BIOL, V1553, P25, DOI 10.1007/978 1 4939 6756 8_3
   Arva NC, 2018, APPL IMMUNOHISTO M M, V26, P721, DOI 10.1097/PAI.0000000000000520
   Blashki D, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416661196
   Buttiglieri S, 2004, J BIOL CHEM, V279, P4136, DOI 10.1074/jbc.M306824200
   Cai Y, 2003, EMBO J, V22, P5522, DOI 10.1093/emboj/cdg536
   Cai Y, 2002, J BIOL CHEM, V277, P1217, DOI 10.1074/jbc.M109663200
   Cao YN, 2015, J CLIN INVEST, V125, P1679, DOI 10.1172/JCI73780
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   DRESSLER GR, 1990, DEVELOPMENT, V109, P787
   Eimori K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156991
   Fabian P, 2015, FRONT GENET, V6, DOI [10.3382/fgene.2015.00228, 10.3389/fgene.2015.00228]
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Grimley E, 2018, KIDNEY INT, V94, P259, DOI 10.1016/j.kint.2018.01.025
   Guo SY, 2018, CELL DEATH DIFFER, V25, P1996, DOI 10.1038/s41418 018 0083 x
   Guo ZK, 2006, STEM CELLS, V24, P992, DOI 10.1634/stemcells.2005 0224
   Hinoi E, 2012, J BONE MINER RES, V27, P2526, DOI 10.1002/jbmr.1708
   Hueber PA, 2006, KIDNEY INT, V69, P1139, DOI 10.1038/sj.ki.5000136
   Jahangiri R, 2018, TISSUE CELL, V52, P135, DOI 10.1016/j.tice.2018.05.005
   Kavaler J, 1999, DEVELOPMENT, V126, P2261
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Liu JW, 2018, GENE, V641, P74, DOI 10.1016/j.gene.2017.10.050
   Liu PF, 2015, CELL PHYSIOL BIOCHEM, V35, P740, DOI 10.1159/000369734
   McCarroll MN, 2012, DEVELOPMENT, V139, P2740, DOI 10.1242/dev.076075
   Modi DA, 2017, ONCOGENE, V36, P3015, DOI 10.1038/onc.2016.455
   Paixao Côrtes VR, 2015, SEMIN CELL DEV BIOL, V44, P64, DOI 10.1016/j.semcdb.2015.08.014
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Shan ZF, 2017, J GEN VIROL, V98, P2615, DOI 10.1099/jgv.0.000907
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tai LW, 2018, NEUROSCIENCE, V384, P139, DOI 10.1016/j.neuroscience.2018.05.024
   Tang Y, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12369
   Thompson JA, 2011, PROG NEUROBIOL, V95, P334, DOI 10.1016/j.pneurobio.2011.08.012
   Torres M, 1995, DEVELOPMENT, V121, P4057
   Wang HF, 2017, INT IMMUNOPHARMACOL, V42, P67, DOI 10.1016/j.intimp.2016.11.012
   Washausen S, 2017, BRAIN STRUCT FUNCT, V222, P2671, DOI 10.1007/s00429 016 1364 0
   Xiang LN, 2014, STEM CELL RES THER, V5, DOI [10.1186/scrt473, 10.1186/scrt525]
   Zha X, 2016, J NAT MED TOKYO, V70, P634, DOI 10.1007/s11418 016 0993 1
   Zhang C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10601 w
   Zhang HS, 2012, J BIOL CHEM, V287, P44164, DOI 10.1074/jbc.M112.401521
   Zhou TT, 2017, J MOL HISTOL, V48, P187, DOI 10.1007/s10735 017 9719 2
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 40
TC 9
Z9 10
U1 0
U2 11
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 15
PY 2018
VL 371
IS 2
BP 342
EP 352
DI 10.1016/j.yexcr.2018.08.026
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA GV3DS
UT WOS:000445975100005
PM 30144446
DA 2025 08 17
ER

PT J
AU Chen, SJ
   van Tok, MN
   Knaup, VL
   Kraal, L
   Pots, D
   Bartels, L
   Gravallese, EM
   Taurog, JD
   van de Sande, M
   van Duivenvoorde, LM
   Baeten, DL
AF Chen, Sijia
   van Tok, Melissa N.
   Knaup, Veronique L.
   Kraal, Lianne
   Pots, Desiree
   Bartels, Lina
   Gravallese, Ellen M.
   Taurog, Joel D.
   van de Sande, Marleen
   van Duivenvoorde, Leonie M.
   Baeten, Dominique L.
TI mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation
   and New Bone Formation in vitro and in vivo
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE spondyloarthtritis; mTOR; rapamycin; IL 17A; fibroblast like
   synoviocytes; small molecule treatment; animal models; HLA B27 tg rats
ID MAMMALIAN TARGET; OSTEOCLAST DIFFERENTIATION; CLASSIFICATION CRITERIA;
   RHEUMATOID ARTHRITIS; SECUKINUMAB; SPONDYLITIS; ACTIVATION; EXPRESSION;
   CELLS; MASS
AB Introduction: Spondyloarthritis (SpA) is characterized by inflammation, articular bone erosions and pathologic new bone formation. Targeting TNF alpha or IL 17A with current available therapies reduces inflammation in SpA, however, treatment of the bone pathology in SpA remains an unmet clinical need. Activation of the mammalian target Of rapamycin (mTOR) promotes IL 17A expression and osteogenesis. Therefore, the inhibition of mTOR (with rapamycin) could be a promising therapeutic avenue in SpA.
   Objectives: To investigate the effect of blocking mTOR on inflammation, bone erosions and new bone formation in SpA.
   Methods: Peripheral blood mononuclear cells (PBMCs) from patients with SpA were stimulated with anti CD3/CD28 in the presence or absence of rapamycin and the resulting cytokine expression was assessed. Fibroblast like synoviocytes (FLS) from SpA patients were assessed for osteogenic differentiation potential in conditions with TNF alpha, IL 17A, or TNF alpha plus IL 17A, in the presence or absence of rapamycin. HLA B27/Hu beta 2m transgenic rats were immunized with low dose heat inactivated Mycobacterium tuberculosis (M. tub), treated with 1.5 mg/kg rapamycin prophylactically or therapeutically and monitored for arthritis and spondylitis. Histology and mRNA analysis were performed after 5 weeks of treatment to assess inflammation and bone pathology.
   Results: In vitro TNF alpha and IL 17A protein production by SpA PBMCs was inhibited in the presence of rapamycin. Rapamycin also inhibited osteogenic differentiation of human SpA FLS. Ex vivo analysis of SpA synovial biopsies indicated activation of the mTOR pathway in the synovial tissue of SpA patients. In vivo, prophylactic treatment of HLA B27/Hu beta 2m transgenic rats with rapamycin significantly inhibited the development and severity of inflammation in peripheral joints and spine (arthritis and spondylitis), with histological evidence of reduced bone erosions and new bone formation around peripheral joints. In addition, therapeutic treatment with rapamycin significantly decreased severity of arthritis and spondylitis, with peripheral joint histology showing reduced inflammation, bone erosions and new bone formation. IL 17A mRNA expression was decreased in the metacarpophalangeal joints after rapamycin treatment.
   Conclusion: mTOR blockade inhibits IL 17A and TNF alpha production by PBMCs, and osteogenic differentiation of FLS from patients with SpA in vitro. In the HLA B27 transgenic rat model of SpA, rapamycin inhibits arthritis and spondylitis development and severity, reduces articular bone erosions, decreases pathologic new bone formation and suppresses IL 17A expression. These results may support efforts to evaluate the efficacy of targeting the mTOR pathway in SpA patients.
C1 [Chen, Sijia; van Tok, Melissa N.; Knaup, Veronique L.; Kraal, Lianne; Pots, Desiree; Bartels, Lina; van de Sande, Marleen; van Duivenvoorde, Leonie M.; Baeten, Dominique L.] Univ Amsterdam, Acad Med Ctr, Amsterdam Univ Med Ctr, Dept Expt Immunol,Infect & Immun Inst, Amsterdam, Netherlands.
   [Chen, Sijia; van Tok, Melissa N.; Kraal, Lianne; Pots, Desiree; van de Sande, Marleen; van Duivenvoorde, Leonie M.; Baeten, Dominique L.] Univ Amsterdam, Acad Med Ctr, Amsterdam Univ Med Ctr, Dept Clin Immunol & Rheumatol,Amsterdam Rheumatol, Amsterdam, Netherlands.
   [Chen, Sijia; Gravallese, Ellen M.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA.
   [Chen, Sijia; Gravallese, Ellen M.] Harvard Med Sch, Boston, MA 02115 USA.
   [Taurog, Joel D.] UT Southwestern Med Ctr, Internal Med, Rheumat Dis Div, Dallas, TX USA.
   [Baeten, Dominique L.] UCB Pharma, Slough, Berks, England.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; Harvard University;
   Harvard University Medical Affiliates; Brigham & Women's Hospital;
   Harvard University; Harvard Medical School; University of Texas System;
   University of Texas Southwestern Medical Center; UCB Pharma SA
RP Baeten, DL (通讯作者)，Univ Amsterdam, Acad Med Ctr, Amsterdam Univ Med Ctr, Dept Expt Immunol,Infect & Immun Inst, Amsterdam, Netherlands.; Baeten, DL (通讯作者)，Univ Amsterdam, Acad Med Ctr, Amsterdam Univ Med Ctr, Dept Clin Immunol & Rheumatol,Amsterdam Rheumatol, Amsterdam, Netherlands.; Baeten, DL (通讯作者)，UCB Pharma, Slough, Berks, England.
EM d.l.baeten@amsterdamumc.nl
RI ; van Duivenvoorde, Leonie/HKW 4001 2023; Chen, Sijia/AAP 2259 2020
OI van Duivenvoorde, Leonie/0000 0002 7035 4715; Chen, Jia
   (Sijia)/0000 0001 8966 3422; 
FU Dutch Arthritis Foundation; VICI grant from the Netherlands Organization
   for Scientific Research (NWO); European Research Council (ERC)
FX This work was supported by a grant from the Dutch Arthritis Foundation,
   by a VICI grant from the Netherlands Organization for Scientific
   Research (NWO) and by the Consolidator Grant from the European Research
   Council (ERC).
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Baeten D, 2000, ANN RHEUM DIS, V59, P945, DOI 10.1136/ard.59.12.945
   Baeten D, 1999, CLIN RHEUMATOL, V18, P434, DOI 10.1007/s100670050134
   Baeten D, 2015, NEW ENGL J MED, V373, P2534, DOI 10.1056/NEJMoa1505066
   Baraliakos X, 2018, CLIN EXP RHEUMATOL, V36, P50
   Baum R, 2016, CLIN REV ALLERG IMMU, V51, P1, DOI 10.1007/s12016 015 8515 6
   Braun J, 2017, ANN RHEUM DIS, V76, P1070, DOI 10.1136/annrheumdis 2016 209730
   Buerger C, 2017, ACTA DERM VENEREOL, V97, P1087, DOI 10.2340/00015555 2724
   CAFFREY MFP, 1973, NATURE, V242, P121, DOI 10.1038/242121a0
   Cejka D, 2010, ARTHRITIS RHEUM US, V62, P2294, DOI 10.1002/art.27504
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Colbert RA, 2014, MOL IMMUNOL, V57, P44, DOI 10.1016/j.molimm.2013.07.013
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   Delay ML, 2009, ARTHRITIS RHEUM US, V60, P2633, DOI 10.1002/art.24763
   Dougados M, 2011, LANCET, V377, P2127, DOI 10.1016/S0140 6736(11)60071 8
   Eriksson P, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00082
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Finzel S, 2013, ANN RHEUM DIS, V72, P1176, DOI 10.1136/annrheumdis 2012 201580
   Galluzzi L, 2012, METHODS MOL BIOL, V821, P125, DOI 10.1007/978 1 61779 430 8_9
   Glatigny S, 2012, ARTHRITIS RHEUM US, V64, P110, DOI 10.1002/art.33321
   Glatt S, 2017, BRIT J CLIN PHARMACO, V83, P991, DOI 10.1111/bcp.13185
   Gorman JD, 2019, RMD OPEN, P5, DOI [10.1136/rmdopen 2019 001005, DOI 10.1136/RMDOPEN 2019 001005]
   Gravallese EM, 2018, NAT REV RHEUMATOL, V14, P631, DOI 10.1038/s41584 018 0091 8
   Hu SR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159758
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Liu DM, 2016, BONE, V90, P50, DOI 10.1016/j.bone.2016.05.010
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lories RJU, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2642
   Martin SK, 2015, STEM CELLS, V33, P1359, DOI 10.1002/stem.1931
   Navid F, 2018, ARTHRITIS RHEUMATOL, V70, P746, DOI 10.1002/art.40414
   Nguyen LS, 2019, DRUG SAFETY, V42, P813, DOI 10.1007/s40264 019 00810 9
   Osta B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00151
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Qureshi AT, 2017, AM J PATHOL, V187, P2536, DOI 10.1016/j.ajpath.2017.07.010
   Ren WK, 2016, EUR J IMMUNOL, V46, P291, DOI 10.1002/eji.201545886
   Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sen B, 2014, J BONE MINER RES, V29, P78, DOI 10.1002/jbmr.2031
   Shi Y, 2015, P NATL ACAD SCI USA, V112, P4678, DOI 10.1073/pnas.1502301112
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Smith MD, 2006, ANN RHEUM DIS, V65, P93, DOI 10.1136/ard.2005.036905
   Taurog JD, 2012, ARTHRITIS RHEUM US, V64, P2518, DOI 10.1002/art.34480
   Tran TM, 2006, ARTHRITIS RHEUM US, V54, P1317, DOI 10.1002/art.21740
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van Duivenvoorde LM, 2012, ARTHRITIS RHEUM US, V64, P3210, DOI 10.1002/art.34600
   van Mens LJJ, 2018, ARTHRITIS RHEUMATOL, V70, P1994, DOI 10.1002/art.40581
   van Tok MN, 2019, ARTHRITIS RHEUMATOL, V71, P612, DOI 10.1002/art.40770
   Van Tok MN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01550
   van Tok MN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00920
   Vieira Sousa E, 2015, ARTHRITIS RHEUMATOL, V67, P2813, DOI 10.1002/art.39282
   Wade SM, 2019, ANN RHEUM DIS, V78, P350, DOI 10.1136/annrheumdis 2018 214138
   Webster A, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004756
   Weichhart T, 2012, METHODS MOL BIOL, V821, P1, DOI 10.1007/978 1 61779 430 8_1
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
   Yin H, 2013, IMMUNOLOGY, V139, P494, DOI 10.1111/imm.12096
   Zhang JR, 2016, JOINT BONE SPINE, V83, P257, DOI 10.1016/j.jbspin.2015.06.013
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
NR 65
TC 25
Z9 27
U1 1
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 27
PY 2020
VL 10
AR 2344
DI 10.3389/fimmu.2019.02344
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA LB5ZP
UT WOS:000524714400001
PM 32194539
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Leite, DM
   Sousa, DM
   Lamghari, M
   Pêgo, AP
AF Leite, Diana M.
   Sousa, Daniela M.
   Lamghari, Meriem
   Pego, Ana Paula
TI Exploring Poly(Ethylene Glycol) Poly(Trimethylene Carbonate)
   Nanoparticles as Carriers of Hydrophobic Drugs to Modulate Osteoblastic
   Activity
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE nanomedicine; nanoparticles; polymeric drug delivery systems;
   biodegradable polymers; poorly water soluble drug; polyglycolic acid
   (PLGA)
ID LOADED PLGA NANOPARTICLES; IN VITRO; POLY(TRIMETHYLENE CARBONATE);
   POLYMERIC NANOPARTICLES; CONTROLLED RELEASE; BONE FORMATION;
   DEXAMETHASONE; BMP 2; BEHAVIOR; VIVO
AB Current treatment options for bone related disorders rely on a systemic administration of therapeutic agents that possess low solubility and intracellular bioavailability, as well as a high pharmacokinetic variability, which in turn lead to major off target side effects. Hence, there is an unmet need of developing drug delivery systems that can improve the clinical efficacy of such therapeutic agents. Nanoparticle delivery systems might serve as promising carriers of hydrophobic molecules. Here, we propose 2 nanoparticle based delivery systems based on monomethoxy poly(ethylene glycol) poly(trimethyl carbonate) (mPEG PTMC) and poly(lactide co glycolide) for the intracellular controlled release of a small hydrophobic drug (dexamethasone) to osteoblast cells in vitro. mPEG PTMC self assembles into stable nanoparticles in the absence of surfactant and shows a greater entrapment capacity of dexamethasone, while assuring bioactivity in MC3T3 E1 and bone marrow stromal cells cultured under apoptotic and osteogenic conditions, respectively. The mPEG PTMC nanoparticles represent a potential vector for the intracellular delivery of hydrophobic drugs in the framework of bone related diseases. (C) 2020 American Pharmacists Association (R) Published by Elsevier Inc. All rights reserved.
C1 [Leite, Diana M.; Sousa, Daniela M.; Lamghari, Meriem; Pego, Ana Paula] Univ Porto, I3S, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.
   [Leite, Diana M.; Sousa, Daniela M.; Lamghari, Meriem; Pego, Ana Paula] Univ Porto, INEB Inst Engn Biomed, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.
   [Leite, Diana M.; Pego, Ana Paula] Univ Porto, Fac Engn, R Dr Roberto Frias S N, P 4200465 Porto, Portugal.
   [Lamghari, Meriem; Pego, Ana Paula] Univ Porto, ICBAS, R Jorge Viterbo Ferreira 228, P 4050313 Porto, Portugal.
   [Leite, Diana M.] UCL, Dept Chem, 20 Gordon St,Christopher Ingold Bldg, London WC1H 0AJ, England.
C3 Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; Universidade do Porto; University of London; University College
   London
RP Pêgo, AP (通讯作者)，Univ Porto, I3S, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.; Pêgo, AP (通讯作者)，Univ Porto, INEB Inst Engn Biomed, Rua Alfredo Allen 208, P 4200135 Porto, Portugal.; Pêgo, AP (通讯作者)，Univ Porto, Fac Engn, R Dr Roberto Frias S N, P 4200465 Porto, Portugal.; Pêgo, AP (通讯作者)，Univ Porto, ICBAS, R Jorge Viterbo Ferreira 228, P 4050313 Porto, Portugal.
EM apego@i3s.up.pt
RI ; Pêgo, Ana/C 6942 2012; Leite, Diana/Z 1844 2018; Lamghari,
   Meriem/K 2159 2013; Leite, Diana Moreira/Z 1844 2018; Sousa,
   Daniela/C 1485 2014
OI Moubarrad, Meriem/0009 0006 8440 912X; Leite, Diana
   Moreira/0000 0002 6017 6433; Sousa, Daniela/0000 0001 8498 0664
FU FEDER funds through the Programa Operacional Factores de Competitividade
     COMPETE; Portuguese funds through the Fundacao para a Ciencia e a
   Tecnologia FCT (Portugal) [PEst C/SAU/LA0002/2013,
   PTDC/BIM MED/1047/2012]; Norte Portugal Regional Operational Programme
   (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the
   European Regional Development Fund (ERDF) [NORTE 01 0145 FEDER 000008,
   NORTE 01 0145FEDER 000012]; FEDER funds through the COMPETE 2020  
   Operational Programme for Competitiveness and Internationalisation
   (POCI), Portugal 2020; FCT [SFRH/BPD/115341/2016]; Fundação para a
   Ciência e a Tecnologia [PEst C/SAU/LA0002/2013, PTDC/BIM MED/1047/2012,
   SFRH/BPD/115341/2016] Funding Source: FCT
FX The authors would like to acknowledge Centro de Materiais da
   Universidade do Porto (CEMUP) for the 1H NMR analysis. Confocal
   microscopy was conducted at the Bioimaging i3S Scientific Platform,
   member of the PPBI (PPBI POCI 01 0145 FEDER 022122), with the assistance
   of Maria L ~azaro and nanoparticle size and zeta potential determination
   was conducted at the Biointerfaces and Nanotechnology Scientific
   Platform of i3S, with the assistance of Ricardo Vidal. This work was
   financed by FEDER funds through the Programa Operacional Factores de
   Competitividade   COMPETE and by Portuguese funds through the Fundacao
   para a Ciencia e a Tecnologia FCT (Portugal) in the framework of the
   financed projects PEst C/SAU/LA0002/2013 and PTDC/BIM MED/1047/2012; and
   projects NORTE 01 0145 FEDER 000008 and NORTE 01 0145FEDER 000012,
   supported by Norte Portugal Regional Operational Programme (NORTE 2020),
   under the PORTUGAL 2020 Partnership Agreement, through the European
   Regional Development Fund (ERDF) and FEDER funds through the COMPETE
   2020   Operational Programme for Competitiveness and
   Internationalisation (POCI), Portugal 2020. DMS acknowledges FCT for her
   Post doctoral fellowship (SFRH/BPD/115341/2016).
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Ali H, 2013, INT J PHARMACEUT, V454, P149, DOI 10.1016/j.ijpharm.2013.07.010
   Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998
   Bertrand N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00600 w
   Bhatt P, 2018, INT J PHARMACEUT, V536, P95, DOI 10.1016/j.ijpharm.2017.11.048
   Bibbo C, 2015, CLIN PODIATR MED SUR, V32, P35, DOI 10.1016/j.cpm.2014.09.005
   Budhian A, 2007, INT J PHARM, V336, P367, DOI 10.1016/j.ijpharm.2006.11.061
   Carpenter JF, 1997, PHARMACEUT RES, V14, P969, DOI 10.1023/A:1012180707283
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Chung YI, 2007, J CONTROL RELEASE, V121, P91, DOI 10.1016/j.jconrel.2007.05.029
   Espina B, 2008, J CELL PHYSIOL, V215, P488, DOI 10.1002/jcp.21335
   Francis M. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P2
   Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640
   Gómez Graete C, 2007, INT J PHARMACEUT, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Jäger M, 2008, J ORTHOP RES, V26, P1440, DOI 10.1002/jor.20565
   Jiang XY, 2011, INT J PHARMACEUT, V420, P385, DOI 10.1016/j.ijpharm.2011.08.052
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Konan YN, 2003, EUR J PHARM BIOPHARM, V55, P115, DOI 10.1016/S0939 6411(02)00128 5
   Konan YN, 2002, INT J PHARM, V233, P239, DOI 10.1016/S0378 5173(01)00944 9
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306
   Liu M, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.14
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Matsuo T, 2003, J BIOMED MATER RES A, V66A, P747, DOI 10.1002/jbm.a.10002
   Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Ogston N, 2002, STEROIDS, V67, P895, DOI 10.1016/S0039 128X(02)00054 5
   Oliveira JM, 2009, BIOMATERIALS, V30, P804, DOI 10.1016/j.biomaterials.2008.10.024
   Pathak Y, 2007, DRUGS PHARM SCI, P185
   Pego AP, 2003, J BIOMED MATER RES A, V67A, P1044, DOI 10.1002/jbm.a.10121
   Pillai RR, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/3/034114
   Reis CP, 2006, NANOMED NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   Song IH, 2009, J ORTHOP RES, V27, P916, DOI 10.1002/jor.20838
   Tahara K, 2011, EUR J PHARM BIOPHARM, V77, P84, DOI 10.1016/j.ejpb.2010.11.002
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Teixeira L, 2009, J CELL BIOCHEM, V107, P908, DOI 10.1002/jcb.22194
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u
   Urbanska J, 2014, LIFE SCI, V96, P1, DOI 10.1016/j.lfs.2013.12.020
   Vauthier C, 2009, PHARM RES DORDR, V26, P1025, DOI 10.1007/s11095 008 9800 3
   Wang GL, 2008, PHARM RES DORDR, V25, P2896, DOI 10.1007/s11095 008 9692 2
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xie GP, 2010, J MATER SCI MATER M, V21, P1875, DOI 10.1007/s10856 010 4038 0
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zhang SF, 2008, BIOTECHNOL PROGR, V24, P945, DOI 10.1002/btpr.12
   Zhang Z, 2006, J CONTROL RELEASE, V111, P263, DOI 10.1016/j.jconrel.2005.12.001
   Zhang Z, 2006, BIOMATERIALS, V27, P1741, DOI 10.1016/j.biomaterials.2005.09.017
   Zhao H, 2017, J BIOMED NANOTECHNOL, V13, P427, DOI 10.1166/jbn.2017.2357
NR 52
TC 6
Z9 7
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD APR
PY 2020
VL 109
IS 4
BP 1594
EP 1604
DI 10.1016/j.xphs.2020.01.007
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA KY8VW
UT WOS:000522855200019
PM 31935391
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Huang, L
   Wu, H
   Wu, Y
   Song, F
   Zhang, L
   Li, Z
   Sun, H
   Huang, C
AF Huang, L.
   Wu, H.
   Wu, Y.
   Song, F.
   Zhang, L.
   Li, Z.
   Sun, H.
   Huang, C.
TI Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via
   LDLR
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE bone loss; osteoclast; inflammation; cell differentiation; gene therapy;
   infectious disease
ID INFLAMMATORY RESPONSE; OSTEOCLAST FORMATION; MICE; INOS
AB Apical periodontitis (AP), an inflammatory lesion around the apex of tooth roots, is mostly caused by dental pulp infection. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a vital role in regulating cholesterol homeostasis by targeting low density lipoprotein receptor (LDLR) and participates in bacterium induced chronic periodontitis. However, the roles of PCSK9 in AP are unknown. Here, we investigated its role in AP by using Pcsk9( / ) mice. Micro computed tomography scanning and histological staining revealed that the periapical bone loss of Pcsk9( / ) mice was greater than that of wild type (WT) mice, and increased expression of inflammation related factors tumor necrosis factor alpha (TNF alpha) and interleukin (IL) 6 was also observed. Immunofluorescence staining and quantitative real time polymerase chain reaction showed PCSK9 expression in bone marrow macrophages (BMMs) was increased after treatment with lipopolysaccharide (LPS). This finding was consistent with the in vivo results that the expression level of PCSK9 in exposed WT mice increased compared with that in unexposed WT mice. After LPS challenge, the expression levels of TNF alpha, IL 1 beta, and IL 6 in BMMs were increased, and Pcsk9 knockout aggravated the expression of these inflammatory factors. The number of osteoclasts positive for tartrate resistant acid phosphatase staining around the apical lesion in Pcsk9( / ) mice was higher than that in WT mice. Then BMMs underwent the osteoclast differentiation. Pcsk9 knockout BMMs induced increased and larger osteoclasts. While this effect of Pcsk9 knockout was abolished by the addition of Ldlr small interfering RNA, revealing that Pcsk9 knockout increased osteoclastogenesis was dependent on the LDLR. Immunohistochemistry staining showed increased expression level of LDLR in exposed Pcsk9( / ) periapical areas. In vitro experiments showed that LPS promoted the expression level of LDLR in Pcsk9( / ) BMMs and increased osteoclast formation ability, indicating that LPS promoted the elevation of osteoclasteogenesis caused by the Pcsk9 knockout. In conclusion, Pcsk9 deficiency aggravated the inflammatory response and promoted the osteoclastogenesis in an LDLR dependent manner in AP experimental mice.
C1 [Huang, L.; Wu, H.; Wu, Y.; Song, F.; Zhang, L.; Li, Z.; Sun, H.; Huang, C.] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol Hu, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
   [Huang, L.; Wu, H.; Wu, Y.; Song, F.; Zhang, L.; Li, Z.; Sun, H.; Huang, C.] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University
RP Sun, H; Huang, C (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol Hu, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.; Sun, H; Huang, C (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
EM sunhualing@163.com; Huangcui@whu.edu.cn
FU National Natural Science Foundation of China [81970918]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Natural Science Foundation of China (No.
   81970918).
CR Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161
   Azuma MM, 2014, INT ENDOD J, V47, P615, DOI 10.1111/iej.12196
   Belibasakis GN, 2013, INT ENDOD J, V46, P99, DOI 10.1111/j.1365 2591.2012.02105.x
   Brown J, 2011, J DENT RES, V90, P417, DOI 10.1177/0022034510381264
   Buonavoglia A, 2013, ODONTOLOGY, V101, P84, DOI 10.1007/s10266 011 0053 y
   Chapman KE, 2013, J STEROID BIOCHEM, V137, P82, DOI 10.1016/j.jsbmb.2013.02.002
   Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305 328c
   Cotti E, 2014, J ENDODONT, V40, P1902, DOI 10.1016/j.joen.2014.08.013
   Fukada SY, 2008, J DENT RES, V87, P1155, DOI 10.1177/154405910808701207
   Lambert G, 2009, ATHEROSCLEROSIS, V203, P1, DOI 10.1016/j.atherosclerosis.2008.06.010
   Li LC, 2013, AM J PHYSIOL HEART C, V304, pH874, DOI 10.1152/ajpheart.00096.2012
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   Maxwell KN, 2005, CURR OPIN LIPIDOL, V16, P167, DOI 10.1097/01.mol.0000162321.31925.a3
   Mehrazarin Shebli, 2017, Dent Clin North Am, V61, P17, DOI 10.1016/j.cden.2016.08.003
   Metzger Z, 2000, ENDOD DENT TRAUMATOL, V16, P1
   Nair PNR, 2004, CRIT REV ORAL BIOL M, V15, P348, DOI 10.1177/154411130401500604
   Netea MG, 1996, J CLIN INVEST, V97, P1366, DOI 10.1172/JCI118556
   Okayasu M, 2012, J BIOL CHEM, V287, P19229, DOI 10.1074/jbc.M111.323600
   Pongratz G, 2013, NAT REV RHEUMATOL, V9, P117, DOI 10.1038/nrrheum.2012.181
   Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102
   Ricci C, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20425 x
   Ruscica M, 2018, ATHEROSCLEROSIS, V268, P235, DOI 10.1016/j.atherosclerosis.2017.10.022
   Sahebkar A, 2016, BRIT J CLIN PHARMACO, V81, P1175, DOI 10.1111/bcp.12905
   Silva MJB, 2011, J DENT RES, V90, P495, DOI 10.1177/0022034510391792
   Siqueira JF, 2009, J DENT RES, V88, P969, DOI 10.1177/0022034509346549
   Sun HL, 2018, J INFECT DIS, V217, P667, DOI 10.1093/infdis/jix574
   Tang ZH, 2012, INT J MOL MED, V30, P931, DOI 10.3892/ijmm.2012.1072
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teramachi J, 2017, ORAL DIS, V23, P181, DOI 10.1111/odi.12592
   Topchiy E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155030
   Wu Y, 2018, J DENT RES, V97, P442, DOI 10.1177/0022034517741261
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
   Yang T, 2017, PHYSIOL REV, V97, P1211, DOI 10.1152/physrev.00013.2016
NR 33
TC 9
Z9 10
U1 1
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JAN
PY 2022
VL 101
IS 1
BP 83
EP 92
AR 00220345211015128
DI 10.1177/00220345211015128
EA MAY 2021
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA XV5ON
UT WOS:000681106100001
PM 34036816
DA 2025 08 17
ER

PT J
AU Xie, WD
   Yang, H
   Guo, C
   Xie, R
   Yu, GL
   Li, YF
AF Xie, Wendong
   Yang, Hua
   Guo, Chun
   Xie, Rui
   Yu, Guoliang
   Li, Yifu
TI Integrated Network Pharmacology and Experimental Validation Approach to
   Investigate the Mechanisms of Stigmasterol in the Treatment of
   Rheumatoid Arthritis
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE rheumatoid arthritis; Sinomenium acutum; stigmasterol; network
   pharmacology; osteoclasts
ID RANKL; TARGET; RISK
AB Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints associated with systemic comorbidities. Sinomenium acutum is regarded as an effective traditional Chinese medicine (TCM) for the treatment of RA.Materials and Methods: Based on network pharmacology and Gene Expression Omnibus (GEO) database, 33 RA related differentially expressed genes (DEGs) targeting active compounds of Sinomenium acutum were initially screened in our investigation.Results: Gene Ontology (GO) and Kyoto encyclopaedia of genes and genome (KEGG) analyses found the important involvement of these DEGs in osteoclast differentiation, and finally 5 core DEGs, including NCF4, NFKB1, CYBA, IL 113 and NCF1 were determined through protein protein interaction (PPI) network. We also identified the related active component of Sinomenium acutum include Stigmasterol. Finally, in order to experimentally verify these results, a rat model of collagen induced arthritis (CIA) was established, and subsequently treated with Stigmasterol solution.Conclusion: Similar to the healing effect of Indomethacin, Stigmasterol was observed to reduce the levels of inflammatory factors (IL 6 and IL 113) and osteoclast differentiation related factors (RANKL, ACP5 and Cathepsin K), which can also reduce the arthritis index score and alleviate the degree of pathological injury of rat ankle joints. The predictions and experimental data uncover the involvement of Stigmasterol, an active component of Sinomenium acutum, in regulation of osteoclast differentiation, exerting great medicinal potential in the treatment of RA.
C1 [Xie, Wendong; Yang, Hua; Xie, Rui; Yu, Guoliang; Li, Yifu] Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha, Peoples R China.
   [Guo, Chun] Hunan Univ Tradit Chinese Med, Hosp 1, Med Innovat Expt Ctr, Changsha, Peoples R China.
C3 Hunan Agricultural University; Hunan University of Chinese Medicine
RP Yang, H (通讯作者)，Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha, Peoples R China.
EM yhua7710@126.com
RI XIE, rui/JXR 6421 2024
FU Hunan Natural Science Foundation [2020JJ4043]; Hunan Provincial
   Traditional Chinese Medicine Administration Scientific Research Project
   [2021212]
FX Funding This study was supported by Hunan Natural Science Foundation
   (No.2020JJ4043) and Hunan Provincial Traditional Chinese Medicine
   Administration Scientific Research Project (No.2021212) .
CR Athanassiou Panagiotis, 2020, Mediterr J Rheumatol, V31, P319, DOI 10.31138/mjr.31.3.319
   Auréal M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010048
   Azizov V, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041324
   Berardicurti O, 2020, EXPERT REV CLIN PHAR, V13, P593, DOI 10.1080/17512433.2020.1772055
   Bergström U, 2013, SCAND J RHEUMATOL, V42, P123, DOI 10.3109/03009742.2012.723744
   Braverman G, 2022, CURR OPIN COLLOID IN, V61, DOI 10.1016/j.coph.2022.102308
   Caporali R, 2013, DRUGS, V73, P31, DOI 10.1007/s40265 013 0008 4
   Chen WP, 2012, ACTA BIOCHIM POL, V59, P537
   Cush JJ, 2022, RHEUM DIS CLIN N AM, V48, P537, DOI 10.1016/j.rdc.2022.02.010
   Dias IRDR, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105696
   Finckh A, 2022, NAT REV RHEUMATOL, V18, P591, DOI 10.1038/s41584 022 00827 y
   Girman C, 2022, ADV THER, V39, P3072, DOI 10.1007/s12325 022 02176 4
   Gruber HE, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3454
   Gunasekera WM, 2016, BMJ Clin Evid, V2016, P1
   Guo B, 2022, PHARMACOL RES, V175, DOI 10.1016/j.phrs.2021.106000
   Guo X, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106201
   Hu T, 2021, BRIT J BIOMED SCI, V78, P67, DOI 10.1080/09674845.2020.1810400
   Ilchovska D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102741
   Khan MA, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106642
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Li R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041244
   Liu JQ, 2021, DRUG DES DEV THER, V15, P3255, DOI 10.2147/DDDT.S319786
   Liu L, 2021, J CHROMATOGR SCI, V59, P606, DOI 10.1093/chromsci/bmab048
   Liu WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02228
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Padyukov L, 2022, SEMIN IMMUNOPATHOL, V44, P47, DOI 10.1007/s00281 022 00912 0
   Pohl S, 2018, J BONE MINER RES, V33, P2186, DOI 10.1002/jbmr.3563
   Portal Núñez S, 2017, TRENDS ENDOCRIN MET, V28, P695, DOI 10.1016/j.tem.2017.06.003
   Prodinger B, 2022, ARTHRIT CARE RES, V74, P579, DOI 10.1002/acr.24503
   Riley TR, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2020 001235
   Rooney CM, 2021, RHEUMATOLOGY, V60, P3380, DOI 10.1093/rheumatology/keaa792
   Sampath SJP, 2021, INFLAMMOPHARMACOLOGY, V29, P1701, DOI 10.1007/s10787 021 00874 z
   Sano T, 2010, J NAT MED TOKYO, V64, P257, DOI 10.1007/s11418 010 0397 6
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Shi YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.561962
   Smolen JS, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102425
   Sun D, 2016, BIOMED CHROMATOGR, V30, P1843, DOI 10.1002/bmc.3761
   Tanaka S, 2021, J BONE MINER METAB, V39, P106, DOI 10.1007/s00774 020 01159 1
   Tanaka S, 2018, MOD RHEUMATOL, V28, P9, DOI 10.1080/14397595.2017.1369491
   Thakur S, 2018, BIOMED PHARMACOTHER, V106, P1011, DOI 10.1016/j.biopha.2018.07.027
   Venetsanopoulou AI, 2022, EXPERT REV CLIN IMMU, V18, P923, DOI 10.1080/1744666X.2022.2106970
   Wang X, 2021, CHIN J NAT MEDICINES, V19, P1, DOI 10.1016/S1875 5364(21)60001 8
   Wang Y, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114368
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   Zhang GB, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/621423
NR 47
TC 10
Z9 11
U1 1
U2 17
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2023
VL 17
BP 691
EP 706
DI 10.2147/DDDT.S387570
PG 16
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 9U0TZ
UT WOS:000947436000001
PM 36915642
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yamamoto, K
   Hojo, H
   Koshima, I
   Chung, U
   Ohba, S
AF Yamamoto, Kenichi
   Hojo, Hironori
   Koshima, Isao
   Chung, Ung il
   Ohba, Shinsuke
TI Famotidine suppresses osteogenic differentiation of tendon cells in
   vitro and pathological calcification of tendon in vivo
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE tendon calcification; H2 blocker; osteogenic differentiation
ID HETEROTOPIC OSSIFICATION; OSTEOBLASTS; CIMETIDINE; BONE; OSTEOCLASTS
AB Heterotopic ossification or calcification follows any type of musculoskeletal trauma and is known to occur after arthroplasties of hip, knee, shoulder, or elbow; fractures; joint dislocations; or tendon ruptures. Histamine receptor H2 (Hrh2) has been shown to be effective for reducing pain and decreasing calcification in patients with calcifying tendinitis, which suggested that H2 blockers were effective for the treatment of tendon ossification or calcification. However, the detailed mechanisms of its action on tendon remain to be clarified. We investigated the mechanisms underlying H2 blocker mediated suppression of tendon calcification, with a focus on the direct action of the drug on tendon cells. Famotidine treatment suppressed the mRNA expressions of Col10a1 and osteocalcin, ossification markers, in a tendon derived cell line TT D6, as well as a preosteoblastic one MC3T3 E1. Both of the cell lines expressed Hrh2; histamine treatment induced osteocalcin expression in these cells. Famotidine administration suppressed calcification in the Achilles tendon of ttw mice, a mouse model of ectopic ossification. These data suggest that famotidine inhibits osteogenic differentiation of tendon cells in vitro, and this inhibition may underlie the anti calcification effects of the drug in vivo. This study points to the use of H2 blockers as a promising strategy for treating heterotopic ossification or calcification in tendon, and provides evidence in support of the clinical use of famotidine. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:19581962, 2012
C1 [Yamamoto, Kenichi; Hojo, Hironori; Chung, Ung il; Ohba, Shinsuke] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Div Clin Biotechnol,Bunkyo Ku, Tokyo 1130033, Japan.
   [Yamamoto, Kenichi; Koshima, Isao] Univ Tokyo, Grad Sch Med, Dept Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Chung, Ung il] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Bunkyo Ku, Tokyo 1138656, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo
RP Ohba, S (通讯作者)，Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Div Clin Biotechnol,Bunkyo Ku, 7 3 1 Hongo, Tokyo 1130033, Japan.
EM soba@bmw.t.u tokyo.ac.jp
OI Hojo, Hironori/0000 0003 2245 6853; Ohba, Shinsuke/0000 0002 6874 8539
FU Japan Society for the Promotion of Science (JSPS); Center for Medical
   System Innovation (CMSI); Ministry of Education, Culture, Sports,
   Science and Technology through the Center for NanoBio Integration
   (CNBI); Grants in Aid for Scientific Research [23592159, 11J04835]
   Funding Source: KAKEN
FX We thank CLEA Japan Inc., K. Morii, Y. Hasegawa, M. Zenibayashi, K.
   Date, S. Ogura, and H. Kobayashi for technical assistance. We also
   appreciate the helpful discussions with members of the Chung Lab at the
   University of Tokyo. This work was supported by a grant from the Japan
   Society for the Promotion of Science (JSPS) through the "Funding Program
   for World Leading Innovative R&D on Science and Technology (FIRST
   Program)" initiated by the Council for Science and Technology Policy
   (CSTP); by funding from the Center for Medical System Innovation (CMSI
   program); and by Grants in Aid for Scientific Research. This work was
   also supported by the Ministry of Education, Culture, Sports, Science
   and Technology through the Center for NanoBio Integration (CNBI
   program).
CR Aboshi H, 2010, FORENSIC SCI INT, V200, P35, DOI 10.1016/j.forsciint.2010.03.024
   Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053
   BERARDI RR, 1988, CLIN PHARMACY, V7, P271
   Biosse Duplan M, 2009, AM J PATHOL, V174, P1426, DOI 10.2353/ajpath.2009.080871
   Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706
   DelValle J, 1997, AM J PHYSIOL GASTR L, V273, pG987, DOI 10.1152/ajpgi.1997.273.5.G987
   Ikawa Yoshiko, 2007, Journal of Toxicological Sciences, V32, P555, DOI 10.2131/jts.32.555
   JACOB AI, 1980, NEW ENGL J MED, V302, P671, DOI 10.1056/NEJM198003203021207
   Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004
   Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200
   LIAN JB, 1988, CLIN ORTHOP RELAT R, P267
   Naraghi FF, 1996, ORTHOPEDICS, V19, P145
   Ogata N, 2007, J BIOL CHEM, V282, P35757, DOI 10.1074/jbc.M611902200
   Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956
   Saito T, 2007, EMBO REP, V8, P504, DOI 10.1038/sj.embor.7400934
   Sakamoto A, 2005, J BIOL CHEM, V280, P21369, DOI 10.1074/jbc.M500346200
   Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014 4827(03)00107 1
   SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120
   SCHMID TM, 1990, ANN NY ACAD SCI, V580, P64, DOI 10.1111/j.1749 6632.1990.tb17918.x
   Shehab D, 2002, J NUCL MED, V43, P346
   SHERWOOD J, 1979, NEW ENGL J MED, V300, P200
   Yokoyama M, 2003, REGION ANESTH PAIN M, V28, P248, DOI 10.1053/rapm.2003.50048
NR 22
TC 11
Z9 12
U1 2
U2 20
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD DEC
PY 2012
VL 30
IS 12
BP 1958
EP 1962
DI 10.1002/jor.22146
PG 5
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 027XO
UT WOS:000310387600013
PM 22592911
OA Bronze
DA 2025 08 17
ER

PT J
AU Frantellizzi, V
   Monari, F
   Mascia, M
   Costa, R
   Rubini, G
   Spanu, A
   Farcomeni, A
   Rizzini, EL
   Cindolo, L
   Licari, M
   Lavelli, V
   Nuvoli, S
   Ricci, M
   Dionisi, V
   Nappi, AG
   De Vincentis, G
AF Frantellizzi, Viviana
   Monari, Fabio
   Mascia, Manlio
   Costa, Renato
   Rubini, Giuseppe
   Spanu, Angela
   Farcomeni, Alessio
   Rizzini, Elisa Lodi
   Cindolo, Luca
   Licari, Maria
   Lavelli, Valentina
   Nuvoli, Susanna
   Ricci, Maria
   Dionisi, Valeria
   Nappi, Anna Giulia
   De Vincentis, Giuseppe
TI Overall survival in mCPRC patients treated with Radium 223 in
   association with bone health agents: a national multicenter study
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article
DE Radium 223 dichloride; prostate cancer; overall survival; bone health
   agents; mCRPC
ID RESISTANT PROSTATE CANCER
AB Purpose
   Radium 223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium 223 in combination with BHA.
   Materials and methods
   430 consecutive patients treated with Radium 223 alone or in combination with BHA, affected by mCRPC, from January 2015 to July 2019 in six Italian Nuclear Medicine Units, were included. Furthermore, data were collected at baseline, after every Radium 223 administration, and during follow up, at 3 and 6 months and 1 year after the 6th cycle. Clinical data have been evaluated before starting treatment with Radium 223 and at the end of treatment and/or at progression. Patients who received target bone therapy with BHA before Radium 223 treatment together with patients who did not receive this therapy at all (NO BHA GROUP), were compared to patients treated with concomitant Radium 223 and BHA (BHA GROUP).
   Results
   In univariate models (p < .05) several clinical aspects have an impact on OS: concomitant BHA (p = .018), BMI (p .001), ECOG PS (p = .000), Baseline Hb (p = .000), Baseline PSA (p = .000), Baseline tALP (p = .000), Baseline LDH (p = .000), and Baseline neutrophils (p = .009). Baseline Hb, Baseline tALP, and Baseline LDH have been confirmed as statistically significant parameters in multivariate models. Indeed, concomitant BHA has not a significant impact on OS (p = .244) in multivariate models.
   Conclusions
   At univariate analysis, our data showed that NO BHA GROUP and BHA GROUP differ in OS by 7 months (95%CI: (1 16.4), p = .02). This is not confirmed at multivariate analysis where after adjusting for other baseline factors, BHA is not significant anymore. This is clearly explained as bias by indication: patients with the same levels of tALP, Hb, and LDH receiving or not receiving BHA are expected to have a similar survival. Our results support and confirm the role of Radium 223 therapy on OS and, furthermore, appear to confirm that BHA treatment has not a survival benefit.
C1 [Frantellizzi, Viviana] Sapienza Univ Rome, Dept Mol Med, Rome, Italy.
   [Monari, Fabio; Dionisi, Valeria] St Orsola Marcello Malpighi Hosp, Radiat Oncol Ctr, Bologna, Italy.
   [Mascia, Manlio] Spirito Santo Hosp, Unit Nucl Med, Pescara, Italy.
   [Costa, Renato; Licari, Maria] Univ Palermo, Biomed Dept Internal & Specialist Med, Unit Nucl Med, Palermo, Italy.
   [Rubini, Giuseppe; Lavelli, Valentina; Nappi, Anna Giulia] Univ Bari Aldo Moro, Nucl Med Dept, Bari, Italy.
   [Spanu, Angela; Nuvoli, Susanna] Univ Sassari, Dept Med Surg & Expt Sci, Unit Nucl Med, Sassari, Italy.
   [Farcomeni, Alessio] Univ Roma Tor Vergata, Dept Econ & Finance, Rome, Italy.
   [Rizzini, Elisa Lodi] St Orsola Marcello Malpighi Hosp, Nucl Med Unit, Bologna, Italy.
   [Cindolo, Luca] Villa Stuart Private Hosp, Dept Urol, Rome, Italy.
   [Ricci, Maria; De Vincentis, Giuseppe] Sapienza Univ Rome, Dept Radiol Sci Oncol & Anat Pathol, Rome, Italy.
C3 Sapienza University Rome; IRCCS Azienda Ospedaliero Universitaria di
   Bologna; University of Palermo; Universita degli Studi di Bari Aldo
   Moro; University of Sassari; University of Rome Tor Vergata; IRCCS
   Azienda Ospedaliero Universitaria di Bologna; Sapienza University Rome
RP Frantellizzi, V (通讯作者)，Sapienza Univ Rome, Dept Mol Med, Rome, Italy.
EM viviana.frantellizzi@uniroma1.it
RI ; Farcomeni, Alessio/K 8719 2016; Cindolo, Luca/Q 8342 2016; MONARI,
   FABIO/AAD 3223 2021; De Vincentis, Giuseppe            /U 1130 2017;
   Dionisi, Valeria/HNC 1826 2023; De Vincentis, Giuseppe/U 1130 2017;
   Frantellizzi, Viviana/U 1129 2017; ricci, maria/MSV 8034 2025; Nuvoli,
   Susanna/M 9745 2019; Lodi Rizzini, Elisa/HLH 7067 2023
OI Rubini, Giuseppe/0000 0003 1972 3308; Farcomeni,
   Alessio/0000 0002 7104 5826; Lodi Rizzini, Elisa/0000 0002 2412 5807; De
   Vincentis, Giuseppe/0000 0003 4690 1528; Frantellizzi,
   Viviana/0000 0003 3497 4236; ricci, maria/0000 0002 9277 6337; Nappi,
   Anna Giulia/0000 0002 9046 6378; Costa, Renato
   Patrizio/0000 0001 5181 2242; MASCIA, Manlio/0000 0002 5009 9112;
   NUVOLI, Susanna Maria F./0000 0002 7194 985X; 
CR Baldari S, 2017, CRIT REV ONCOL HEMAT, V113, P43, DOI 10.1016/j.critrevonc.2017.03.001
   Basch E, 2014, J CLIN ONCOL, V32, P3436, DOI 10.1200/JCO.2013.54.8404
   De Vincentis G, 2019, ANN ONCOL OFF J EUR, V30
   De Vincentis G, 2019, EUR J CANCER CARE, V28, DOI 10.1111/ecc.13112
   De Vincentis G, 2018, FUTURE ONCOL, V14, P2821, DOI 10.2217/fon 2018 0318
   De Vincentis G, 2018, AGING CLIN EXP RES, V30, P677, DOI 10.1007/s40520 017 0826 4
   De Vincentis G, 2016, CLIN GENITOURIN CANC, V14, pE529, DOI 10.1016/j.clgc.2016.04.014
   Dorff TB, 2018, ASIAN J ANDROL, V20, P215, DOI 10.4103/aja.aja_12_18
   Du Y, 2017, EUR J NUCL MED MOL I, V44, P1671, DOI 10.1007/s00259 017 3756 7
   Frantellizzi V, 2018, ANN NUCL MED, V32, P142, DOI 10.1007/s12149 017 1228 6
   Heinrich D, 2018, FUTURE ONCOL, V14, P2543, DOI 10.2217/fon 2018 0087
   James ND, 2016, JAMA ONCOL, V2, P493, DOI 10.1001/jamaoncol.2015.5570
   Logothetis C, 2018, CANCER METAST REV, V37, P189, DOI 10.1007/s10555 017 9719 4
   Miller K, 2018, PROSTATE CANCER P D, V21, P461, DOI 10.1038/s41391 018 0060 y
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Prelaj A, 2019, ONCOL LETT, V17, P1467, DOI 10.3892/ol.2018.9785
   Ricci M, 2019, INT J RADIAT BIOL, V95, P554, DOI 10.1080/09553002.2019.1558301
   Saad F, 2019, CLIN GENITOURIN CANC, V17, P348, DOI 10.1016/j.clgc.2019.05.012
   Saad F, 2018, CANCER TREAT REV, V68, P25, DOI 10.1016/j.ctrv.2018.04.014
   Sabbatini P, 1999, J CLIN ONCOL, V17, P948, DOI 10.1200/JCO.1999.17.3.948
   Sartor O, 2017, ANN ONCOL, V28, P1090, DOI 10.1093/annonc/mdx044
   Sartor O, 2018, ONCOLOGIST, V23, P1, DOI 10.1634/theoncologist.2017 0437
   Sciarra A, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015608
   Sciarra A, 2018, UROL ONCOL SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.03.022
   Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470 2045(18)30860 X
   van der Doelen MJ, 2019, CLIN GENITOURIN CANC, V17, P79, DOI 10.1016/j.clgc.2018.11.008
   Wong WW, 2017, CLIN GENITOURIN CANC, V15, pE969, DOI 10.1016/j.clgc.2017.04.016
   Zeng L, 2012, INT J RADIAT ONCOL, V84, pE337, DOI 10.1016/j.ijrobp.2012.05.028
NR 28
TC 7
Z9 7
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955 3002
EI 1362 3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD DEC 1
PY 2020
VL 96
IS 12
BP 1608
EP 1613
DI 10.1080/09553002.2020.1838655
EA NOV 2020
PG 6
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA OZ8HY
UT WOS:000584714000001
PM 33074066
DA 2025 08 17
ER

PT J
AU Kung, AWC
   Pasion, EG
   Sofiyan, M
   Lau, EMC
   Tay, BK
   Lam, KS
   Wilawan, K
   Ongphiphadhanakul, B
   Thiebaud, D
AF Kung, A. W. C.
   Pasion, E. G.
   Sofiyan, M.
   Lau, E. M. C.
   Tay, B. K.
   Lam, K. S.
   Wilawan, K.
   Ongphiphadhanakul, B.
   Thiebaud, D.
TI A comparison of teriparatide and calcitonin therapy in postmenopausal
   Asian women with osteoporosis: a 6 month study
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Asia; bone mineral density; calcitonin; osteoporosis; teriparatide
ID BONE MINERAL DENSITY; FRACTURE RISK REDUCTION; PARATHYROID HORMONE;
   SALMON CALCITONIN; ESTABLISHED OSTEOPOROSIS; DOSE RESPONSE; MASS; BMD;
   ALENDRONATE; TRIAL
AB Objective: The number of hip fractures is expected to double in the next 20 years, with current estimates that Asia will account for 37% of these cases. As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
   Methodology: A total of 104 patients (n = 47 teriparatide [20 mu g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand. Calcium (500 mg/day) and vitamin D (200 400 IU/day) supplements were taken throughout the 6 month controlled, randomized study.
   Results: Teriparatide was associated with a 5.03 +/  4.77% increase in lumbar spine BMD (p < 0.0001, mean +/  SD change from baseline), whereas changes in lumbar spine BMD for patients on calcitonin were not statistically significant (mean change of 0.36 +/  4.12%, p = 0.16). Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001). No statistically significant changes were observed for total hip or femoral neck BMD. Serum bone specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, p = 0.24); osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin ( 15.25%, p = 0.03). Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups ( teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively). There were no clinically relevant changes observed in laboratory parameters.
   Conclusions: Both treatments were similarly tolerated, however teriparatide was associated with greater increases in lumbar spine BMD and bone formation markers, demonstrating the unique mechanism of action and safety of this treatment for osteoporosis in these Asian women.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.
   Our Lady Lourdes Hosp, Manila, Philippines.
   Hosp Kuala Lumpur, Inst Orthopaed & Traumatol, Kuala Lumpur, Malaysia.
   Hong Kong Orthopaed & Osteoporosis Ctr, Hong Kong, Peoples R China.
   Singapore Gen Hosp, Dept Orthopaed Surg, Singapore 0316, Singapore.
   Changi Gen Hosp, Singapore, Singapore.
   Mahidol Univ, Ramathibodi Hosp, Dept Med, Bangkok 10700, Thailand.
   Eli Lilly & Co, Indianapolis, IN 46285 USA.
C3 University of Hong Kong; Singapore General Hospital; Changi General
   Hospital; Mahidol University; Eli Lilly
RP Thiebaud, D (通讯作者)，Eli Lilly Australia Pty Ltd, 112 Wharf Rd, W Ryde, NSW 2114, Australia.
EM thiebaud_daniel@lilly.com
RI Kung, Annie/C 4294 2009; Lam, Karen/C 4315 2009
CR Chen P, 2005, J BONE MINER RES, V20, pS56
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Crandall C, 2002, ARCH INTERN MED, V162, P2297, DOI 10.1001/archinte.162.20.2297
   Cummings SR, 2000, AM J MED, V109, P330, DOI 10.1016/S0002 9343(00)00539 8
   Divittorio G, 2006, PHARMACOTHERAPY, V26, P104, DOI 10.1592/phco.2006.26.1.104
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   GENNARI C, 1985, CURR THER RES CLIN E, V38, P455
   Greenblatt D, 2005, PHARMACOTHERAPY, V25, P574, DOI 10.1592/phco.25.4.574.61031
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Heaney Robert P, 2003, Clin Med Res, V1, P93
   Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620
   Hwang JS, 2006, OSTEOPOROSIS INT, V17, P373, DOI 10.1007/s00198 005 2002 5
   KANIS JA, 2006, OSTEOPOROSIS INT, V10, P1
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   ODOHERTY DP, 1990, CLIN SCI, V78, P215, DOI 10.1042/cs0780215
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   OVERGAARD K, 1991, J CLIN ENDOCR METAB, V72, P344, DOI 10.1210/jcem 72 2 344
   OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Seeman E, 2001, TRENDS ENDOCRIN MET, V12, P281, DOI 10.1016/S1043 2760(01)00460 X
   THAMSBORG G, 1991, CALCIFIED TISSUE INT, V48, P302, DOI 10.1007/BF02556148
NR 24
TC 24
Z9 29
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD MAY
PY 2006
VL 22
IS 5
BP 929
EP 937
DI 10.1185/030079906X104768
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 055JX
UT WOS:000238447700012
PM 16709314
DA 2025 08 17
ER

PT J
AU Hou, CY
   Zhang, YJ
   Lv, ZY
   Luan, YR
   Li, J
   Meng, CX
   Liu, K
   Luo, X
   Chen, LY
   Liu, FZ
AF Hou, Caiyao
   Zhang, Yujue
   Lv, Zhaoyong
   Luan, Yurun
   Li, Jun
   Meng, Chunxiu
   Liu, Kun
   Luo, Xin
   Chen, Liyu
   Liu, Fengzhen
TI Macrophage exosomes modified by miR 365 2 5p promoted osteoblast
   osteogenic differentiation by targeting OLFML1
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE macrophage; exosomes; osteogenesis; osteoimmunology
ID DELIVERY; CELLS
AB In the bone immune microenvironment, immune cells can regulate osteoblasts through a complex communication network. Macrophages play a central role in mediating immune osteogenesis, exosomes derived from them have osteogenic regulation and can be used as carriers in bone tissue engineering. However, there are problems with exosomal therapy alone, such as poor targeting, and the content of loaded molecules cannot reach the therapeutic concentration. In this study, macrophage derived exosomes modified with miR 365 2 5p were developed to accelerate bone healing. MC3T3 E1 cells were incubated with the culture supernatants of M0, M1 and M2 macrophages, and it was found that the culture medium of M2 macrophages had the most significant effects in contributing to osteogenesis. High throughput sequencing identified that miR 365 2 5p was significantly expressed in exosomes derived from M2 macrophages. We incubated MC3T3 E1 with exosomes overexpressing or knocking down miR 365 2 5p to examine the biological function of exosome miR 365 2 5p on MC3T3 E1 differentiation. These findings suggested that miR 365 2 5p secreted by exosomes increased the osteogenesis of MC3T3 E1. Moreover, miR 365 2 5p had a direct influence over osteogenesis for MC3T3 E1. Sequencing analysis combined with dual luciferase detection indicated that miR 365 2 5p binded to the 3' UTR of OLFML1. In summary, exosomes secreted by M2 macrophages targeted OLFML1 through miR 365 2 5p to facilitate osteogenesis.
C1 [Hou, Caiyao; Liu, Fengzhen] Liaocheng Univ, Dept Mat Sci & Engn, Liaocheng 252000, Peoples R China.
   [Zhang, Yujue; Lv, Zhaoyong; Luan, Yurun; Li, Jun; Meng, Chunxiu; Liu, Kun; Luo, Xin; Liu, Fengzhen] Shandong First Med Univ, Liaocheng Peoples Hosp, Liaocheng Hosp, Liaocheng 252000, Peoples R China.
   [Chen, Liyu] Shandong Univ, Hosp 2, Cheeloo Coll Med, Jinan 250023, Peoples R China.
C3 Liaocheng University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong University
RP Liu, FZ (通讯作者)，Liaocheng Univ, Dept Mat Sci & Engn, Liaocheng 252000, Peoples R China.; Luo, X; Liu, FZ (通讯作者)，Shandong First Med Univ, Liaocheng Peoples Hosp, Liaocheng Hosp, Liaocheng 252000, Peoples R China.; Chen, LY (通讯作者)，Shandong Univ, Hosp 2, Cheeloo Coll Med, Jinan 250023, Peoples R China.
EM 459700038@qq.com; menghuo1006@126.com; LDCLLFZ@163.com
RI luo, xin/A 9404 2017; Zhang, Xiaoyun/ABI 1084 2022; Zhang,
   yueling/HZH 7176 2023; Liu, Kun/JYQ 6291 2024; Chen, LiYu/KIG 3529 2024
OI Liu, Fengzhen/0000 0002 1192 8002; 
FU Science Foundation of Shandong Province of China [ZR2021MH026,
   ZR2022MH075, ZR2020MH100]; Shandong Province Medical and Health Science
   and Technology Development Plan [2018WS426]; Liaocheng Key Research and
   Development Plan of Shandong Province of China [2022YDSF16, 2022YDSF21,
   2023YD28, 2023YD34]
FX This work was financed by the Science Foundation of Shandong Province of
   China (Grant Nos ZR2021MH026, ZR2022MH075, ZR2020MH100), Shandong
   Province Medical and Health Science and Technology Development Plan
   (2018WS426), Liaocheng Key Research and Development Plan of Shandong
   Province of China (Grant Nos 2022YDSF16, 2022YDSF21, 2023YD28,
   2023YD34).
CR Chen S, 2023, BIOACT MATER, V25, P176, DOI 10.1016/j.bioactmat.2023.01.022
   Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090
   Hu LC, 2022, EXP MOL MED, V54, P961, DOI 10.1038/s12276 022 00799 9
   Hu YK, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6324912
   Huang EE, 2022, J ORTHOP TRANSL, V36, P64, DOI 10.1016/j.jot.2022.05.010
   Huang Y, 2021, EXP MOL MED, V53, P973, DOI 10.1038/s12276 021 00631 w
   Iaquinta MR, 2021, THERANOSTICS, V11, P6573, DOI 10.7150/thno.55664
   Isaac R, 2021, CELL METAB, V33, P1744, DOI 10.1016/j.cmet.2021.08.006
   Letarouilly JG, 2019, GENOMICS, V111, P793, DOI 10.1016/j.ygeno.2018.05.001
   Li QL, 2017, Int J Nurs Sci, V4, P12, DOI [10.3390/ijms18050977, 10.1016/j.ijnss.2016.12.001]
   Li ZY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.680328
   Liu K, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.801432
   Locati M, 2020, ANNU REV PATHOL MECH, V15, P123, DOI 10.1146/annurev pathmechdis 012418 012718
   Louiselle AE, 2021, TRANSL RES, V236, P109, DOI 10.1016/j.trsl.2021.05.006
   Luo X, 2023, REGEN BIOMATER, V10, DOI 10.1093/rb/rbad075
   Meng CX, 2021, J BIOMED MATER RES A, V109, P1328, DOI 10.1002/jbm.a.37124
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Murakami K, 2018, BIOCHEM BIOPH RES CO, V505, P419, DOI 10.1016/j.bbrc.2018.09.112
   Nagashima D, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15010060
   Rahimian Neda, 2023, Methods Mol Biol, V2595, P13, DOI 10.1007/978 1 0716 2823 2_2
   Salazar Puerta AI, 2023, ADV MATER, V35, DOI 10.1002/adma.202210579
   Shao JT, 2020, INT J NANOMED, V15, P9355, DOI 10.2147/IJN.S281890
   Suh JS, 2013, BIOMATERIALS, V34, P4347, DOI 10.1016/j.biomaterials.2013.02.039
   Tsai YC, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964 022 00997 y
   Wang D, 2023, INT J NANOMED, V18, P1063, DOI 10.2147/IJN.S398446
   Wang JQ, 2021, BIOCHEM GENET, V59, P1146, DOI 10.1007/s10528 021 10048 9
   Wolf SJ, 2021, SEMIN CELL DEV BIOL, V119, P111, DOI 10.1016/j.semcdb.2021.06.013
   Wu P, 2023, MILITARY MED RES, V10, DOI 10.1186/s40779 023 00469 5
   Xiong Y, 2022, SMALL, V18, DOI 10.1002/smll.202104229
   Zeng KR, 2023, ORAL DIS, V29, P2107, DOI 10.1111/odi.14195
   Zhang Cheng, 2022, Sichuan Da Xue Xue Bao Yi Xue Ban, V53, P63, DOI 10.12182/20220160207
   Zhang F, 2024, BIOACT MATER, V31, P231, DOI 10.1016/j.bioactmat.2023.08.008
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhao XB, 2022, CELL MOL IMMUNOL, V19, P540, DOI 10.1038/s41423 022 00841 w
   Zhou YK, 2024, BIOACT MATER, V31, P192, DOI 10.1016/j.bioactmat.2023.08.006
   Zhu QH, 2023, PHARMACOL RES, V192, DOI 10.1016/j.phrs.2023.106798
   Zhu Y, 2022, J ORTHOP RES, V40, P1563, DOI 10.1002/jor.25189
NR 37
TC 7
Z9 7
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD JAN 2
PY 2024
VL 11
AR rbae018
DI 10.1093/rb/rbae018
EA MAR 2024
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LD3P7
UT WOS:001184805700001
PM 38487712
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yokoyama, T
   Ostermann, A
   Mizuguchi, M
   Niimura, N
   Schrader, TE
   Tanaka, I
AF Yokoyama, Takeshi
   Ostermann, Andreas
   Mizuguchi, Mineyuki
   Niimura, Nobuo
   Schrader, Tobias E.
   Tanaka, Ichiro
TI Crystallization and preliminary neutron diffraction experiment of human
   farnesyl pyrophosphate synthase complexed with risedronate
SO ACTA CRYSTALLOGRAPHICA SECTION F STRUCTURAL BIOLOGY COMMUNICATIONS
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; PROTEIN CRYSTALLOGRAPHY;
   DIPHOSPHATE SYNTHASE; TRYPANOSOMA CRUZI; ZOLEDRONIC ACID; DRUG DESIGN;
   CANCER; CELLS; APOPTOSIS; MECHANISM
AB Nitrogen containing bisphosphonates (N BPs), such as risedronate and zoledronate, are currently used as a clinical drug for bone resorption diseases and are potent inhibitors of farnesyl pyrophosphate synthase (FPPS). X ray crystallographic analyses of FPPS with N BPs have revealed that N BPs bind to FPPS with three magnesium ions and several water molecules. To understand the structural characteristics of N BPs bound to FPPS, including H atoms and hydration by water, neutron diffraction studies were initiated using BIODIFF at the Heinz Maier Leibnitz Zentrum (MLZ). FPPS risedronate complex crystals of approximate dimensions 2.8 x 2.5 x 1.5 mm (similar to 3.5 mm(3)) were obtained by repeated macro seeding. Monochromatic neutron diffraction data were collected to 2.4 angstrom resolution with 98.4% overall completeness. Here, the first successful neutron data collection from FPPS in complex with N BPs is reported.
C1 [Yokoyama, Takeshi; Mizuguchi, Mineyuki] Toyama Univ, Fac Pharmaceut Sci, Toyama 9300914, Japan.
   [Ostermann, Andreas] Tech Univ Munich, Heinz Maier Leibnitz Zentrum MLZ, D 85748 Garching, Germany.
   [Niimura, Nobuo; Tanaka, Ichiro] Ibaraki Univ, Frontier Res Ctr Appl Atom Sci, Tokai, Ibaraki 3191106, Japan.
   [Schrader, Tobias E.] MLZ, Forschungszentrum Julich GmbH Outstn, JCNS, D 85747 Garching, Germany.
   [Tanaka, Ichiro] Ibaraki Univ, Coll Engn, Hitachi, Ibaraki 3168511, Japan.
C3 University of Toyama; Technical University of Munich; Ibaraki
   University; Helmholtz Association; Research Center Julich; Ibaraki
   University
RP Yokoyama, T (通讯作者)，Toyama Univ, Fac Pharmaceut Sci, 2630 Sugitani, Toyama 9300914, Japan.
EM tyokoya3@pha.u toyama.ac.jp
RI ; Mineyuki, Mizuguchi/IUM 3999 2023; Schrader, Tobias/LKJ 0868 2024
OI Yokoyama, Takeshi/0000 0002 5362 8606; Schrader, Tobias
   Erich/0000 0001 5159 0846
FU [25860022]; Grants in Aid for Scientific Research [25860022] Funding
   Source: KAKEN
FX We acknowledge funding from a Grant in Aid for Young Scientists (B)
   (project No. 25860022).
CR Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Chen JCH, 2012, P NATL ACAD SCI USA, V109, P15301, DOI 10.1073/pnas.1208341109
   de Beer SBA, 2010, CURR TOP MED CHEM, V10, P55, DOI 10.2174/156802610790232288
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968 0004(90)90213 U
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Mitrofan LM, 2010, J BIOL CHEM, V285, P1967, DOI 10.1074/jbc.M109.038935
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Naoe M, 2010, ONCOL RES, V18, P493, DOI 10.3727/096504010X12671222663638
   Niimura N, 2008, ACTA CRYSTALLOGR A, V64, P12, DOI 10.1107/S0108767307043498
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45
   Yokoyama T, 2012, J STRUCT BIOL, V177, P283, DOI 10.1016/j.jsb.2011.12.022
NR 20
TC 7
Z9 8
U1 0
U2 13
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
EI 2053 230X
J9 ACTA CRYSTALLOGR F
JI Acta Crystallogr. F Struct. Biol. Commun.
PD APR
PY 2014
VL 70
BP 470
EP 472
DI 10.1107/S2053230X14004087
PN 4
PG 3
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA AE1VB
UT WOS:000333757800014
PM 24699741
OA Green Published
DA 2025 08 17
ER

PT J
AU Cui, Y
   Bhandary, B
   Marahatta, A
   Lee, GH
   Li, B
   Kim, DS
   Chae, SW
   Kim, HR
   Chae, HJ
AF Cui, Yan
   Bhandary, Bidur
   Marahatta, Anu
   Lee, Geum Hwa
   Li, Bo
   Kim, Do Sung
   Chae, Soo Wan
   Kim, Hyung Ryong
   Chae, Han Jung
TI Characterization of Salvia Miltiorrhiza ethanol extract as an
   anti osteoporotic agent
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Salvia miltiorrhiza; OVX; BMD; morphometry; oxidative stress
ID BONE MINERAL CONTENT; PHOSPHATASE; RESORPTION; CHEMISTRY; DENSITY;
   INJURY; RATS
AB Background: Salvia miltiorrhiza (SM) has long been used as a traditional oriental medicine for cardiovascular disease. Accumulating evidence also indicates that SM has anti osteoporotic effects. This study was conducted to examine the SM induced anti osteoporotic effect and its possible mechanisms with various doses of SM.
   Methods: We studied Sprague Dawley female rats aged 12 weeks, divided into six groups: sham operated control (SHAM), OVX rats supplemented with SM (1, 3, 10 and 30 mg/kg) orally for 8 weeks. At the end of the experiment, blood samples were collected and biochemistry analysis was performed. Specimens from both tibia and liver were processed for light microscopic examination. DEXA and mu CT analyses of the tibia were also performed.
   Results: SM treatment significantly ameliorated the decrease in BMD and trabecular bone mass according to DEXA and trabecular bone architecture analysis of trabecular bone structural parameters by mu CT scanning. In serum biochemical analysis, SM decreased the released TRAP 5b, an osteoclast activation marker and oxidative stress parameters including MDA and NO induced by OVX.
   Conclusions: The preventive effect of SM was presumably due to its anti oxidative stress partly via modulation of osteoclast maturation and number. In current study, SM appears to be a promising osteoporosis therapeutic natural product.
C1 [Lee, Geum Hwa; Kim, Hyung Ryong] Wonkwang Univ, Dept Dent Pharmacol, Sch Dent, Iksan, Chonbuk, South Korea.
   [Lee, Geum Hwa; Kim, Hyung Ryong] Wonkwang Univ, Wonkwang Dent Res Inst, Sch Dent, Iksan, Chonbuk, South Korea.
   [Cui, Yan; Bhandary, Bidur; Marahatta, Anu; Li, Bo; Kim, Do Sung; Chae, Soo Wan; Chae, Han Jung] Chonbuk Natl Univ, Dept Pharmacol, Sch Med, Jeonju, Chonbuk, South Korea.
   [Cui, Yan; Bhandary, Bidur; Marahatta, Anu; Li, Bo; Kim, Do Sung; Chae, Soo Wan; Chae, Han Jung] Chonbuk Natl Univ, Inst Cardiovasc Res, Sch Med, Jeonju, Chonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Jeonbuk National University;
   Jeonbuk National University
RP Kim, HR (通讯作者)，Wonkwang Univ, Dept Dent Pharmacol, Sch Dent, Iksan, Chonbuk, South Korea.
EM hrkimdp@wonkwang.ac.kr; hjchae@jbnu.ac.kr
RI ; Kim, Cheorl Ho/T 6753 2019
OI Chae, Han Jung/0000 0003 4190 9889; Kim,
   Hyung Ryong/0000 0002 6710 6964; 
FU National Research Foundation [2010 0029477, 2009 0087202]; Korea
   Research Foundation [KRF 2008 313 E00540]; Korea Science and Engineering
   Foundation [R01 2007 000 20275 0]
FX This work was supported by the National Research Foundation Grants
   (2010 0029477, 2009 0087202) and was partly supported by Korea Research
   Foundation (KRF 2008 313 E00540) and by Korea Science and Engineering
   Foundation Grants (R01 2007 000 20275 0). We appreciate YJ Chang for
   technical assistance about mu CT (Basic Research Institute, Jeonju,
   Korea).
CR BORIES PN, 1995, CLIN CHEM, V41, P904
   Brouwers JEM, 2008, CALCIFIED TISSUE INT, V82, P202, DOI 10.1007/s00223 007 9084 3
   Chae HJ, 2004, IMMUNOPHARM IMMUNOT, V26, P135, DOI 10.1081/IPH 120029951
   Cremers S, 2006, DRUGS, V66, P2031, DOI 10.2165/00003495 200666160 00001
   Ding Y, 1995, J Osaka Univ Dent Sch, V35, P21
   DRAPER HH, 1990, METHOD ENZYMOL, V186, P421
   FARLEY JR, 1981, CLIN CHEM, V27, P2002
   Göthe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329
   Halleen JM, 2006, CLIN LAB, V52, P499
   Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008
   Järvinen TLN, 1998, BONE, V22, P551, DOI 10.1016/S8756 3282(98)00025 8
   Jiang SD, 2007, OSTEOPOROSIS INT, V18, P743, DOI 10.1007/s00198 006 0299 3
   Kannus P, 1996, J BONE MINER RES, V11, P1339
   Kastl S, 2002, BONE, V30, P243, DOI 10.1016/S8756 3282(01)00641 X
   Kim DS, 2009, KOR J CLIN PHARM, V19, P75
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kireev RA, 2010, BIOGERONTOLOGY, V11, P229, DOI 10.1007/s10522 009 9242 2
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koh JM, 2006, J BONE MINER RES, V21, P1003, DOI 10.1359/JBMR.060406
   Lay IS, 2003, PLANTA MED, V69, P26, DOI 10.1055/s 2003 37034
   Madsen JE, 1996, BONE, V18, P411, DOI 10.1016/8756 3282(96)00027 0
   MOSEKILDE L, 1977, ACTA ENDOCRINOL COP, V85, P515, DOI 10.1530/acta.0.0850515
   MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889 8529(18)30338 4
   NILAS L, 1988, EUR J CLIN INVEST, V18, P529, DOI 10.1111/j.1365 2362.1988.tb01052.x
   Sánchez Rodríguez MA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 124
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Vassilopoulou Sellin R, 2003, ANN NY ACAD SCI, V997, P341, DOI 10.1196/annals.1290.037
   Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077
   Wong RWK, 2008, J BIOMED MATER RES A, V85A, P506, DOI 10.1002/jbm.a.31577
   Zhang Y, 2004, PLANTA MED, V70, P138, DOI 10.1055/s 2004 815490
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
   Zhu YZ, 2004, NAT PROD REP, V21, P478, DOI 10.1039/b304821g
NR 32
TC 21
Z9 23
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD NOV 28
PY 2011
VL 11
AR 120
DI 10.1186/1472 6882 11 120
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 907OP
UT WOS:000301427500001
PM 22118263
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Herrero, AB
   García Gómez, A
   Garayoa, M
   Corchete, LA
   Hernández, JM
   Miguel, JS
   Gutierrez, NC
AF Herrero, Ana B.
   Garcia Gomez, Antonio
   Garayoa, Mercedes
   Corchete, Luis A.
   Hernandez, Jose M.
   Miguel, Jesus San
   Gutierrez, Norma C.
TI Effects of IL 8 Up Regulation on Cell Survival and Osteoclastogenesis in
   Multiple Myeloma
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID NF KAPPA B; ENDOTHELIAL GROWTH FACTOR; MARROW STROMAL CELLS; AUTOCRINE
   GROWTH; CANCER CELLS; CXC CHEMOKINES; INTERLEUKIN 8; EXPRESSION;
   APOPTOSIS; ACTIVATION
AB IL 8 promotes cancer cell growth, survival, angiogenesis, and metastasis in several tumors. Herein, we investigated the sources of IL 8 production in multiple myeloma (MM) and its potential roles in MM pathogenesis. We found that bone marrow cells from patients with MM secreted higher amounts of IL 8 than healthy donors. IL 8 production was detected in cultures of CD138+ plasma cells and CD138( ) cells isolated from bone marrows of MM patients, and in three of seven human myeloma cell lines (HMCLs) analyzed. Interactions between MM and stromal cells increased IL 8 secretion by stromal cells through cell cell adhesion and soluble factors. Interestingly, 1L8 expression also increased in HMCLs, stromal cells, and osteoclasts after treatment with the antimyeloma drugs melphalan and bortezomib. In fact, the effect of bortezomib on IL 8 production was higher than that exerted by stromal MM cell interactions. Addition of exogenous IL 8 did not affect growth of HMCLs, although it protected cells from death induced by serum starvation through a caspase independent mechanism. Furthermore, IL 8 induced by stromal MM cell interactions strongly contributed to osteoclast formation in vitro, because osteoclastogenesis was markedly reduced by IL 8 specific neutralizing antibodies. In conclusion, our results implicate IL 8 in myeloma bone disease and point to the potential utility of an anti IL 8 therapy to prevent unwanted effects of IL 8 up regulation on survival, angiogenesis, and osteolysis in MM.
C1 [Herrero, Ana B.; Garayoa, Mercedes; Corchete, Luis A.; Gutierrez, Norma C.] Univ Hosp Salamanca, Biomed Res Inst Salamanca, Dept Hematol, Salamanca, Spain.
   [Herrero, Ana B.; Garayoa, Mercedes; Corchete, Luis A.; Gutierrez, Norma C.] Univ Salamanca, Canc Res Ctr, Salamanca, Spain.
   [Garcia Gomez, Antonio] Bellvitge Biomed Res Inst, Barcelona, Spain.
   [Hernandez, Jose M.] Gen Hosp Segovia, Dept Hematol, Segovia, Spain.
   [Miguel, Jesus San] Univ Navarra Clin, Navarra Inst Hlth Res, Ctr Appl Med Res, Pamplona, Spain.
C3 University of Salamanca; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC   Centro de Investigacion del Cancer (CIC); Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Navarra
RP Gutierrez, NC (通讯作者)，Univ Hosp Salamanca, Paseo San Vicente 58 182, Salamanca 37007, Spain.
EM normagu@usal.es
RI ; Corchete Sánchez, Luis Antonio/D 1336 2018; Garayoa,
   Mercedes/O 6039 2017; Hernández, José/JKI 8418 2023; SAN MIGUEL,
   JESUS/V 8977 2018; Corchete Sanchez, Luis Antonio/D 1336 2018; Herrero,
   Ana/AAF 1694 2021; San Miguel, Jesús/V 8977 2018
OI Gutierrez, Norma/0000 0001 5834 9510; Garcia,
   Antonio/0000 0003 0527 7351; Garayoa, Mercedes/0000 0003 2194 2841;
   Herrero, Ana/0000 0002 1414 6532; SAN MIGUEL, JESUS/0000 0002 9183 4857;
   Corchete Sanchez, Luis Antonio/0000 0003 4577 8599; 
FU Spanish Myeloma Network Program [RD12/0036/0058]; Spanish Association
   for Cancer Research [GCB120981SAN]; INNOCAMPUS Program [CEI10 1 0010];
   Spanish MINECO ISCIII [PI12/02591]; FEDER; Consejeria de Educacion from
   Junta Castilla y Leon [FIC335U14]; Centers for Regenerative Medicine and
   Cellular Therapy from Castilla y Leon
FX Supported in part by the Spanish Myeloma Network Program
   (RD12/0036/0058), Spanish Association for Cancer Research
   (GCB120981SAN), the INNOCAMPUS Program (CEI10 1 0010), Spanish
   MINECO ISCIII (PI12/02591) and FEDER, Consejeria de Educacion from Junta
   Castilla y Leon (FIC335U14) and the Centers for Regenerative Medicine
   and Cellular Therapy from Castilla y Leon.
CR Anderson IC, 2000, CANCER RES, V60, P269
   Baumann P, 2008, LEUKEMIA RES, V32, P1144, DOI 10.1016/j.leukres.2007.11.015
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bendre MS, 2002, CANCER RES, V62, P5571
   Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Collins TS, 2000, CANCER IMMUNOL IMMUN, V49, P78, DOI 10.1007/s002620050605
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Frassanito MA, 1998, CLIN EXP IMMUNOL, V114, P179
   Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092 8674(00)81731 6
   Garcia Gomez A, 2014, CLIN CANCER RES, V20, P1542, DOI 10.1158/1078 0432.CCR 13 1657
   Gasparian AV, 2009, CELL CYCLE, V8, P1559, DOI 10.4161/cc.8.10.8415
   Ghobrial IM, 2012, BLOOD, V120, P20, DOI 10.1182/blood 2012 01 379024
   Gomez Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949
   Green AR, 1997, INT J CANCER, V72, P937
   Grigorieva I, 1998, EXP HEMATOL, V26, P597
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Hamabe W, 2000, MOL BRAIN RES, V78, P186, DOI 10.1016/S0169 328X(00)00074 7
   HARDIN J, 1994, BLOOD, V84, P3063
   Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Hideshima T, 2009, BLOOD, V114, P1046, DOI 10.1182/blood 2009 01 199604
   Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847
   Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004
   Karadag A, 2000, BRIT J HAEMATOL, V108, P383
   Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124
   Kitadai Y, 1998, AM J PATHOL, V152, P93
   KLEIN B, 1989, BLOOD, V73, P517
   Kline M, 2007, LEUKEMIA RES, V31, P591, DOI 10.1016/j.leukres.2006.06.012
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Li Aihua, 2005, Angiogenesis, V8, P63, DOI 10.1007/s10456 005 5208 4
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327
   LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076
   López Corral L, 2014, HAEMATOLOGICA, V99, P1365, DOI 10.3324/haematol.2013.087809
   Mahindra A, 2010, BLOOD REV, V24, pS5, DOI 10.1016/S0268 960X(10)70003 5
   Maïga S, 2013, BRIT J CANCER, V108, P1801, DOI 10.1038/bjc.2013.186
   MERICO F, 1993, CLIN EXP IMMUNOL, V92, P27
   Metzner B, 1999, ONCOL REP, V6, P1405
   Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365 2141.2003.04217.x
   Miyamoto M, 1998, CANCER IMMUNOL IMMUN, V47, P47, DOI 10.1007/s002620050503
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood 2002 01 0151
   Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood 2003 02 0402
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Pappa CA, 2011, CYTOKINE, V56, P616, DOI 10.1016/j.cyto.2011.08.034
   Pellegrino A, 2005, BRIT J HAEMATOL, V129, P248, DOI 10.1111/j.1365 2141.2005.05443.x
   Podar K, 2008, ONCOGENE, V27, P721, DOI 10.1038/sj.onc.1210679
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470 2045(14)70442 5
   San Miguel JF, 2006, EUR J CANCER, V42, P1510, DOI 10.1016/j.ejca.2005.11.039
   Sanacora S, 2015, BIOCHEM BIOPH RES CO, V460, P375, DOI 10.1016/j.bbrc.2015.03.041
   Singh S, 2010, FUTURE ONCOL, V6, P111, DOI [10.2217/fon.09.128, 10.2217/FON.09.128]
   Singha B, 2014, J BIOL CHEM, V289, P2687, DOI 10.1074/jbc.M113.502641
   Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676 200007000 00051
   Tsirakis G, 2011, EUR J HISTOCHEM, V55, P113, DOI 10.4081/ejh.2011.e21
   Wang TH, 2006, ONCOGENE, V25, P4857, DOI 10.1038/sj.onc.1209498
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078 0432.CCR 07 4843
   Yoneda J, 1998, JNCI J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447
   YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233
   Yuan A, 2005, FRONT BIOSCI LANDMRK, V10, P853, DOI 10.2741/1579
NR 59
TC 38
Z9 39
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2016
VL 186
IS 8
BP 2171
EP 2182
DI 10.1016/j.ajpath.2016.04.003
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA DS2ON
UT WOS:000380623500017
PM 27301357
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cardeira, J
   Gavaia, PJ
   Fernández, I
   Cengiz, IF
   Moreira Silva, J
   Oliveira, JM
   Reis, RL
   Cancela, ML
   Laizé, V
AF Cardeira, Joao
   Gavaia, Paulo J.
   Fernandez, Ignacio
   Cengiz, Ibrahim Fatih
   Moreira Silva, Joana
   Oliveira, Joaquim Miguel
   Reis, Rui L.
   Leonor Cancela, M.
   Laize, Vincent
TI Quantitative assessment of the regenerative and mineralogenic
   performances of the zebrafish caudal fin
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ALIZARIN RED S; VITAMIN K; RETINOIC ACID; TAIL FIN; SONIC HEDGEHOG;
   DIFFERENTIATION; MINERALIZATION; PROLIFERATION; OSTEOBLAST; BLASTEMA
AB The ability of zebrafish to fully regenerate its caudal fin has been explored to better understand the mechanisms underlying de novo bone formation and to develop screening methods towards the discovery of compounds with therapeutic potential. Quantifying caudal fin regeneration largely depends on successfully measuring new tissue formation through methods that require optimization and standardization. Here, we present an improved methodology to characterize and analyse overall caudal fin and bone regeneration in adult zebrafish. First, regenerated and mineralized areas are evaluated through broad, rapid and specific chronological and morphometric analysis in alizarin red stained fins. Then, following a more refined strategy, the intensity of the staining within a 2D longitudinal plane is determined through pixel intensity analysis, as an indicator of density or thickness/volume. The applicability of this methodology on live specimens, to reduce animal experimentation and provide a tool for in vivo tracking of the regenerative process, was successfully demonstrated. Finally, the methodology was validated on retinoic acid and warfarin treated specimens, and further confirmed by micro computed tomography. Because it is easily implementable, accurate and does not require sophisticated equipment, the present methodology will certainly provide valuable technical standardization for research in tissue engineering, regenerative medicine and skeletal biology.
C1 [Cardeira, Joao] Univ Algarve, Dept Biomed Sci & Med, ProRegeM PhD Programme, Campus Gambelas, Faro, Portugal.
   [Cardeira, Joao; Gavaia, Paulo J.; Fernandez, Ignacio; Leonor Cancela, M.; Laize, Vincent] Univ Algarve, Ctr Marine Sci CCMAR, Campus Gambelas, Faro, Portugal.
   [Gavaia, Paulo J.; Leonor Cancela, M.] Univ Algarve, Dept Biomed Sci & Med, Campus Gambelas, Faro, Portugal.
   [Cengiz, Ibrahim Fatih; Oliveira, Joaquim Miguel; Reis, Rui L.] Univ Minho, Headquarters European Inst Excellence Tissue Engn, Res Grp Biomat Biodegradables & Biomimet 3Bs, Zona Ind Gandra, Avepk,Parque Ciencia & Tecnol, P 4805017 Barco, Gmr, Portugal.
   [Cengiz, Ibrahim Fatih; Moreira Silva, Joana; Oliveira, Joaquim Miguel; Reis, Rui L.] PT Govt Associated Lab, ICVS 3Bs, Barco, Portugal.
C3 Universidade do Algarve; Universidade do Algarve; Universidade do
   Algarve; Universidade do Minho; Laboratorio Associado ICVS 3B's
RP Laizé, V (通讯作者)，Univ Algarve, Ctr Marine Sci CCMAR, Campus Gambelas, Faro, Portugal.
RI Cardeira, Joao/AAM 1926 2020; Cengiz, Ibrahim Fatih/AAB 6439 2020;
   Laizé, Vincent/B 4463 2008; Reis, Rui/A 8938 2008; Fernandez Monzon,
   Ignacio Valentin/B 1527 2017; Cengiz, Ibrahim Fatih/J 3360 2013; Laize,
   Vincent/B 4463 2008; Reis, Rui L./A 8938 2008; Oliveira,
   Joaquim/H 8636 2012; Oliveira, Joaquim Miguel/H 8636 2012; Cancela,
   M./F 4665 2012; Fernández Monzón, Ignacio Valentín/B 1527 2017; Gavaia,
   Paulo/A 6470 2011
OI Fernandez Monzon, Ignacio Valentin/0000 0002 8088 7902; Cengiz, Ibrahim
   Fatih/0000 0003 0886 632X; Laize, Vincent/0000 0001 9565 9198; Reis, Rui
   L./0000 0002 4295 6129; Cancela, M. Leonor/0000 0003 3114 6662;
   Oliveira, Joaquim Miguel/0000 0001 7052 8837; Cardeira da Silva,
   Joao/0000 0003 3722 8810; Gavaia, Paulo/0000 0002 9582 1957
FU Portuguese Foundation for Science and Technology (FCT)
   [PD/BD/52425/2013, PD/00117/2012, SFRH/BDP/82049/2011,
   SFRH/BD/99555/2014]; FCT [IF/00423/2012, SFRH/BPD/70230/2010,
   PTDC/MAR/112992/2009, UID/Multi/04326/2013]; European Commission
   (ERDF COMPETE) [PEst C/MAR/LA0015/2011]; Fundação para a Ciência e a
   Tecnologia [SFRH/BPD/70230/2010, PTDC/MAR/112992/2009, PD/BD/52425/2013,
   UID/Multi/04326/2013, SFRH/BD/99555/2014] Funding Source: FCT
FX J.C., I.F. and I.F.C. acknowledge the financial support from the
   Portuguese Foundation for Science and Technology (FCT) through the
   doctoral grant PD/BD/52425/2013 within the ProRegeM PhD Programme
   (PD/00117/2012), the post doctoral grant SFRH/BDP/82049/2011, and the
   doctoral grant SFRH/BD/99555/2014, respectively. J.M.O. also thanks FCT
   for the funds provided under the program Investigador FCT 2012
   (IF/00423/2012) and through the post doctoral grant SFRH/BPD/70230/2010.
   This work was financed by the FCT through research project
   PTDC/MAR/112992/2009 (AQUATOX) and project UID/Multi/04326/2013, and
   co financed by the FCT and the European Commission (ERDF COMPETE)
   through PEst C/MAR/LA0015/2011 project. The help of Gil Martins, Luis
   Granadeiro and Pedro Catela in fish maintenance is gratefully
   acknowledged.
CR Akimenko MA, 2003, DEV DYNAM, V226, P190, DOI 10.1002/dvdy.10248
   Atkins GJ, 2009, AM J PHYSIOL CELL PH, V297, pC1358, DOI 10.1152/ajpcell.00216.2009
   Azevedo AS, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 24
   BECERRA J, 1983, CELL TISSUE RES, V230, P127
   Bensimon Brito A, 2016, BMC DEV BIOL, V16, DOI 10.1186/s12861 016 0102 4
   Bensimon Brito A, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 28
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   Blum N, 2015, DEVELOPMENT, V142, P2894, DOI 10.1242/dev.120204
   Blum N, 2015, DEVELOPMENT, V142, P2888, DOI 10.1242/dev.120212
   Blum N, 2012, DEVELOPMENT, V139, P107, DOI 10.1242/dev.065391
   Boominathan VP, 2012, ZEBRAFISH, V9, P207, DOI 10.1089/zeb.2012.0741
   Brenner B, 2009, SEMIN THROMB HEMOST, V35, P439, DOI 10.1055/s 0029 1225766
   Brown AM, 2009, DEV DYNAM, V238, P2922, DOI 10.1002/dvdy.22114
   Connolly MH, 2010, J APPL ICHTHYOL, V26, P274, DOI 10.1111/j.1439 0426.2010.01419.x
   Danziger J, 2008, CLIN J AM SOC NEPHRO, V3, P1504, DOI 10.2215/CJN.00770208
   Fernández I, 2014, ENVIRON POLLUT, V194, P86, DOI 10.1016/j.envpol.2014.07.015
   Fernández I, 2014, J STEROID BIOCHEM, V140, P34, DOI 10.1016/j.jsbmb.2013.11.012
   Gemberling M, 2013, TRENDS GENET, V29, P611, DOI 10.1016/j.tig.2013.07.003
   GERAUDIE J, 1995, INT J DEV BIOL, V39, P373
   Grotek B, 2013, DEVELOPMENT, V140, P1412, DOI 10.1242/dev.087452
   Haga Y, 2009, TRANSGENIC RES, V18, P669, DOI 10.1007/s11248 009 9259 y
   Hall B K., 2015, Bones and Cartilage, V2nd
   Jeong HM, 2011, ARCH PHARM RES, V34, P1381, DOI 10.1007/s12272 011 0819 3
   JOHNSON SL, 1995, GENETICS, V141, P1583
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Laforest L, 1998, DEVELOPMENT, V125, P4175
   Laize Vincent., 2014, Drug Discovery Today: Disease Models, V13, P29
   Mackay EW, 2015, DEVELOPMENT, V142, P1095, DOI 10.1242/dev.113811
   MONTES GS, 1982, HISTOCHEMISTRY, V75, P363, DOI 10.1007/BF00496739
   Münch J, 2013, DEVELOPMENT, V140, P1402, DOI 10.1242/dev.087346
   Neacsu CD, 2011, MATRIX BIOL, V30, P369, DOI 10.1016/j.matbio.2011.07.002
   Nechiporuk A, 2002, DEVELOPMENT, V129, P2607
   Oppedal D, 2010, ZEBRAFISH, V7, P53, DOI 10.1089/zeb.2009.0633
   Pearson DA, 2007, NUTR CLIN PRACT, V22, P517, DOI 10.1177/0115426507022005517
   Petrie TA, 2014, DEVELOPMENT, V141, P2581, DOI 10.1242/dev.098459
   Pfefferli C, 2015, REGENERATION, V2, P72, DOI 10.1002/reg2.33
   Poss KD, 2003, DEV DYNAM, V226, P202, DOI 10.1002/dvdy.10220
   Poss KD, 2007, SEMIN CELL DEV BIOL, V18, P36, DOI 10.1016/j.semcdb.2006.11.009
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Quint E, 2002, P NATL ACAD SCI USA, V99, P8713, DOI 10.1073/pnas.122571799
   Recidoro AM, 2014, J BONE MINER RES, V29, P2346, DOI 10.1002/jbmr.2274
   RUSSELL W. M. S., 1959
   Simoes MG, 2014, BMC DEV BIOL, V14, DOI 10.1186/s12861 014 0049 2
   Simon A, 2013, WIRES DEV BIOL, V2, P291, DOI 10.1002/wdev.73
   Sîrbulescu RF, 2011, BRAIN RES REV, V67, P73, DOI 10.1016/j.brainresrev.2010.11.001
   Smith A, 2006, DEV BIOL, V299, P438, DOI 10.1016/j.ydbio.2006.08.016
   Sousa S, 2011, DEVELOPMENT, V138, P3897, DOI 10.1242/dev.064717
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   Stewart S, 2014, CELL REP, V6, P482, DOI 10.1016/j.celrep.2014.01.010
   Stewart S, 2012, DEV BIOL, V365, P339, DOI 10.1016/j.ydbio.2012.02.031
   Tu S, 2011, DEV CELL, V20, P725, DOI 10.1016/j.devcel.2011.04.013
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Wang XQ, 2007, INT J THERM SCI, V46, P1, DOI 10.1016/j.ijthermalsci.2006.06.010
   Watanabe N, 2009, DEV GROWTH DIFFER, V51, P135, DOI 10.1111/j.1440 169X.2009.01090.x
   Watson CJ, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.114
   Wehner D, 2015, TRENDS GENET, V31, P336, DOI 10.1016/j.tig.2015.03.012
   Wehner D, 2014, CELL REP, V6, P467, DOI 10.1016/j.celrep.2013.12.036
   Winsor L., 1994, Laboratory histopathology, V4, P1
   Xiao SM, 2012, HUM MOL GENET, V21, P1648, DOI 10.1093/hmg/ddr586
   Yamaguchi M, 2011, INT J MOL MED, V27, P3, DOI 10.3892/ijmm.2010.562
   Yokoyama H, 2008, DEV GROWTH DIFFER, V50, P13, DOI 10.1111/j.1440 169x.2007.00973.x
NR 61
TC 34
Z9 38
U1 0
U2 24
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 19
PY 2016
VL 6
AR 39191
DI 10.1038/srep39191
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EF3MY
UT WOS:000390229800001
PM 27991522
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shi, XQ
   Wu, P
   Jie, LS
   Zhang, L
   Mao, J
   Yin, SJ
AF Shi, Xiaoqing
   Wu, Peng
   Jie, Lishi
   Zhang, Li
   Mao, Jun
   Yin, Songjiang
TI Integrated Serum Metabolomics and Network Pharmacology to Reveal the
   Interventional Effects of Quzhi Decoction against Osteoarthritis Pain
SO INTERNATIONAL JOURNAL OF ANALYTICAL CHEMISTRY
LA English
DT Article
ID GENES; MECHANISMS; SAFETY; NSAIDS
AB Objectives. Chronic pain, the main symptom of knee osteoarthritis (OA), remains the primary reason for decreased functional capacity. Quzhi decoction, a TCM prescription, is effective in treating chronic pain in OA, but the potential mechanisms require further exploration. Methods. An anterior cruciate ligament transection (ACLT) rat model was established, and pain like behavior was evaluated. Metabolomics analysis of serum samples was performed to identify differential metabolites, and network pharmacology was used to identify potential targets of Quzhi decoction for the treatment of OA. Finally, we constructed a comprehensive network of serum metabolomics and network pharmacology. At the same time, the obtained key targets were verified by molecular docking. Results. Quzhi decoction was shown to attenuate pain like behavior and joint inflammation in OA rats. Through serum metabolomics, thirty potentially significant metabolites were found to be involved in the therapeutic effects of Quzhi decoction against OA pain. According to network pharmacology, 107 active drug components were matched with 115 disease targets, which was partly consistent with the metabolomics findings. Further analysis focused on 6 key targets, including CYP3A4, PLA2G4A, PTGS1, PTGS2, TYR, and ALOX5, and their associated core metabolites and pathways. Molecular docking results showed that the related targets had high affinity with the active pharmaceutical ingredients in Quzhi decoction. Conclusion. The effect of Quzhi decoction on OA pain may be related to the inhibition of joint inflammation, mainly through disturbing arachidonic acid metabolism, tyrosine metabolism, and leukotriene metabolism. Further systematic molecular biology experiments are needed to verify the accurate mechanism.
C1 [Shi, Xiaoqing; Wu, Peng; Jie, Lishi; Zhang, Li; Mao, Jun; Yin, Songjiang] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210029, Peoples R China.
   [Shi, Xiaoqing; Wu, Peng; Jie, Lishi; Zhang, Li; Mao, Jun; Yin, Songjiang] Jiangsu Prov Hosp Chinese Med, Nanjing 210029, Peoples R China.
   [Mao, Jun; Yin, Songjiang] Nanjing Univ Chinese Med, Coll Clin Med 1, Dept Tradit Chinese Osteopathy & Traumatol, Nanjing 210023, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Yin, SJ (通讯作者)，Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210029, Peoples R China.; Yin, SJ (通讯作者)，Jiangsu Prov Hosp Chinese Med, Nanjing 210029, Peoples R China.; Yin, SJ (通讯作者)，Nanjing Univ Chinese Med, Coll Clin Med 1, Dept Tradit Chinese Osteopathy & Traumatol, Nanjing 210023, Peoples R China.
EM shixiaoqing_2016@163.com; drwupengwr@163.com; 707636022@qq.com;
   183718670@qq.com; junmao1978@hotmail.com; 260303@njucm.edu.cn
FU National Natural Science Foundation of China [81873329]; Natural Science
   Foundation of Jiangsu province [SBK2020041404]; Third Batch of Peak
   Academic Talents Project of Jiangsu Hospital of Traditional Chinese
   Medicine [y2021rc20]; Natural Science Foundation of Nanjing University
   of Chinese Medicine [XZR2020013]; Universities Natural Science Research
   Project of Jiangsu Province [20KJB360003]
FX The authors wish to express their gratitude to all staff in the medical
   research center of first college of clinical medicine, the Nanjing
   University of Chinese Medicine, Nanjing, China. This research was
   supported by the National Natural Science Foundation of China
   (81873329), The Natural Science Foundation of Jiangsu province
   (SBK2020041404), The Third Batch of Peak Academic Talents Project of
   Jiangsu Hospital of Traditional Chinese Medicine (y2021rc20), Natural
   Science Foundation of Nanjing University of Chinese Medicine
   (XZR2020013), and Universities Natural Science Research Project of
   Jiangsu Province (20KJB360003).
CR Agúndez JAG, 2015, PHARMACOGENOMICS, V16, P501, DOI [10.2217/pgs.15.6, 10.2217/PGS.15.6]
   Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   Ansari MY, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110452
   Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Chen B, 2016, AM J CHINESE MED, V44, P677, DOI 10.1142/S0192415X16500373
   Courties A, 2019, JOINT BONE SPINE, V86, P725, DOI 10.1016/j.jbspin.2018.12.005
   Harte AL, 2010, J INFLAMM LOND, V7, DOI 10.1186/1476 9255 7 15
   Huang ZY, 2016, OSTEOARTHR CARTILAGE, V24, P1769, DOI 10.1016/j.joca.2016.05.008
   Huang ZY, 2016, NAT REV RHEUMATOL, V12, P123, DOI 10.1038/nrrheum.2015.158
   Jian GH, 2020, BIODATA MIN, V13, DOI 10.1186/s13040 020 00221 y
   Li ZY, 2018, BIOMED RES INT UK, V2018, DOI 10.1155/2018/9482726
   Lo PC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015964
   Luo Y, 2020, AM J CHINESE MED, V48, P1, DOI 10.1142/S0192415X20500019
   Ostojic M, 2019, PSYCHIAT DANUB, V31, P126
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Pepine CJ, 2017, CLIN CARDIOL, V40, P1352, DOI 10.1002/clc.22814
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Qu ZA, 2020, EUR REV MED PHARMACO, V24, P2855, DOI 10.26355/eurrev_202003_20649
   Schaible HG, 2018, CURR OPIN SUPPORT PA, V12, P148, DOI 10.1097/SPC.0000000000000334
   Shi X.Q., 2021, J BASIC CHINESE MED, V27, P325
   Shi YY, 2020, COMPUT BIOL CHEM, V89, DOI 10.1016/j.compbiolchem.2020.107397
   Shu CC, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2117 2
   Srivastava S, 2016, INFLAMMOPHARMACOLOGY, V24, P377, DOI 10.1007/s10787 016 0289 9
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Tilg H, 2014, GUT, V63, P1513, DOI 10.1136/gutjnl 2014 306928
   Wang L, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/5712187
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu P, 2020, CHIN MED UK, V15, DOI 10.1186/s13020 020 0290 5
   Wu R, 2017, EXP THER MED, V14, P2721, DOI 10.3892/etm.2017.4819
   Xiao P, 2021, HUM CELL, V34, P60, DOI 10.1007/s13577 020 00433 8
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Zhang X, 2018, BONE JOINT RES, V7, P298, DOI 10.1302/2046 3758.74.BJR 2017 0245.R1
   Zhu NQ, 2019, MED SCI MONITOR, V25, P6051, DOI 10.12659/MSM.915821
NR 34
TC 5
Z9 5
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1687 8760
EI 1687 8779
J9 INT J ANAL CHEM
JI Int. J. Anal. Chem.
PD AUG 12
PY 2022
VL 2022
AR 9116175
DI 10.1155/2022/9116175
PG 11
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 3X8GB
UT WOS:000843272000002
PM 35992559
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yan, MM
   Duan, X
   Cai, L
   Zhang, WL
   Silva, MJ
   Brophy, RH
   Rai, MF
AF Yan, Mingming
   Duan, Xin
   Cai, Lei
   Zhang, Weili
   Silva, Matthew J.
   Brophy, Robert H.
   Rai, Muhammad Farooq
TI KIF26B Silencing Prevents Osseous Transdifferentiation of
   Progenitor/Stem Cells and Attenuates Ectopic Calcification in a Murine
   Model
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE KIF26B; ECTOPIC CALCIFICATION; Wnt/beta CATENIN SIGNALING; CELL
   PROLIFERATION; CELL APOPTOIS
ID HETEROTOPIC OSSIFICATION; CHONDROCYTE DIFFERENTIATION; STEM CELLS;
   MOUSE; CARTILAGE; TRAUMA; INHIBITION; OSTEOBLAST; THERAPY; PROTEIN
AB Ectopic calcification is an osteogenic process that leads to the formation of inappropriate bone within intra articular soft tissues, often in response to injury or surgery. The molecular mechanisms governing this phenotype have yet to be determined. Using a population genetics approach, we identified an association of the kinesin superfamily member 26b (Kif26b) with injury induced ectopic calcification through quantitative trait locus analysis of recombinant inbred mouse strains, consistent with a genomewide association study that identified KIF26B as a severity locus for ectopic calcification in patients with hip osteoarthritis. Despite these associations of KIF26B with ectopic calcification, its mechanistic role and functional implications have not yet been fully elucidated. Here, we aim to decipher the functional role of KIF26B in osseous and chondrogenic transdifferentiation of human and murine progenitor/stem cells and in a murine model of non invasive injury induced intra articular ectopic calcification. We found that KIF26B ablation via lentivirus mediated shRNA significantly arrested osteogenesis of progenitor/stem cells and suppressed the expression of typical osteogenic marker genes. Conversely, KIF26B loss of function increased chondrogenesis as demonstrated by enhanced Safranin O staining and by the elevated expression of chondrogenic marker genes. Furthermore, cell function analysis revealed that KIF26B knockdown significantly decreased cell viability and proliferation and induced cellular apoptosis. Mechanistically, loss of osteogenesis was reverted by the addition of a Wnt agonist, SKL2001, demonstrating a role of KIF26B in canonical Wnt/beta catenin signaling. Finally, intra articular delivery of Kif26b shRNA in B6 129SF2/J mice significantly hampered the development of intra articular ectopic calcification at 8 weeks after injury compared with mice treated with non target scrambled shRNA. In summary, these observations highlight that KIF26B plays a crucial role in ectopic bone formation by repressing osteogenesis, but not chondrogenesis, potentially via modulating Wnt/beta catenin signaling. These findings establish KIF26B as a critical determinant of the osteogenic process in pathologic endochondral bone formation and an actionable target for pharmacotherapy to mitigate ectopic calcification (and heterotopic ossification). (C) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Yan, Mingming; Duan, Xin; Cai, Lei; Zhang, Weili; Silva, Matthew J.; Brophy, Robert H.; Rai, Muhammad Farooq] Washington Univ, Musculoskeletal Res Ctr, Dept Orthoped Surg, Sch Med, St Louis, MO 63110 USA.
   [Yan, Mingming] Cent South Univ, Xiangya Hosp 2, Dept Orthoped Surg, Changsha, Peoples R China.
   [Rai, Muhammad Farooq] Washington Univ, Dept Cell Biol & Physiol, Sch Med, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Central South University; Washington
   University (WUSTL)
RP Rai, MF (通讯作者)，Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthoped Surg,Musculoskeletal Res Ctr, Campus Box 8233 004 11,425 South Euclid Ave, St Louis, MO 63110 USA.
EM rai.m@wustl.edu
RI ; Brophy, Robert/AAX 8562 2021; Jiao, Zheng/H 7596 2014; Rai,
   Muhammad/AFQ 0568 2022
OI Brophy, Robert/0000 0002 2912 8265; Duan, Xin/0000 0002 5775 9670; 
FU NIAMS, NIH [AR 074992]; Department of Orthopedic Surgery; China
   Scholarship Council [201906375034]
FX The mu CT work was partly supported by a P30 Core Center award to the
   Washington University Musculoskeletal Research Center from NIAMS, NIH
   (AR 074992). This study was supported by research funding by the
   Department of Orthopedic Surgery. MY's postdoctoral fellowship was
   supported by the China Scholarship Council (award no. 201906375034), a
   non profit institution affiliated with the Ministry of Education of the
   P.R. China. The content of this publication is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the Department of Orthopedic Surgery, Washington University, or the
   China
CR Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   Bensaid S, 2019, J PHYSIOL BIOCHEM, V75, P367, DOI 10.1007/s13105 019 00687 3
   BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846
   Cai L, 2019, FASEB J, V33, P8386, DOI 10.1096/fj.201802281R
   Chinzei N, 2019, ARTHRITIS RHEUMATOL, V71, P370, DOI 10.1002/art.40730
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Descamps B, 2012, CIRC RES, V110, P47, DOI 10.1161/CIRCRESAHA.111.250936
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duan X, 2017, J ORTHOP RES, V35, P524, DOI 10.1002/jor.23413
   Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792
   Gwak J, 2012, CELL RES, V22, P237, DOI 10.1038/cr.2011.127
   Hashimoto K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61825 2
   Hashimoto S, 2012, OSTEOARTHR CARTILAGE, V20, P562, DOI 10.1016/j.joca.2012.01.022
   Hatzikotoulas K., 2019, BIORXIV2019845958, DOI [10.1101/845958, DOI 10.1101/845958]
   Huang YF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0509 1
   Huynh NPT, 2019, FASEB J, V33, P358, DOI 10.1096/fj.201800534R
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kraft CT, 2016, J TRAUMA ACUTE CARE, V80, P156, DOI 10.1097/TA.0000000000000883
   Marikawa Y, 2004, DEV GENES EVOL, V214, P64, DOI 10.1007/s00427 003 0377 x
   Meyers CA, 2018, ADV EXP MED BIOL, V1109, P21, DOI 10.1007/978 3 030 02601 1_3
   Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398
   Mundy C, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abd0536
   Nalesso G, 2017, ANN RHEUM DIS, V76, P218, DOI 10.1136/annrheumdis 2015 208577
   Pacifici M, 2018, CURR OPIN PHARMACOL, V40, P51, DOI 10.1016/j.coph.2018.03.007
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Rai MF, 2017, SCI REP UK, V7, DOI 10.1038/srep45223
   Rai MF, 2015, J ORTHOP RES, V33, P1412, DOI 10.1002/jor.22944
   Rai MF, 2013, G3 GENES GENOM GENET, V3, P1881, DOI 10.1534/g3.113.007302
   Rai MF, 2012, ARTHRITIS RHEUM US, V64, P2300, DOI 10.1002/art.34396
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   Shehab D, 2002, J NUCL MED, V43, P346
   Sinha S, 2016, BONE, V90, P59, DOI 10.1016/j.bone.2016.02.008
   Sorkin M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14172 4
   Steinert AF, 2011, TISSUE ENG PT A, V17, P1375, DOI [10.1089/ten.tea.2010.0413, 10.1089/ten.TEA.2010.0413]
   Sugita D, 2013, SPINE, V38, pE1388, DOI 10.1097/BRS.0b013e3182a40489
   Susman MW, 2017, ELIFE, V6, DOI 10.7554/eLife.26509
   Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101
   van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309
   Wang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02988 5
   Wu CL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20598 y
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
   Yan H, 2016, P NATL ACAD SCI USA, V113, pE6199, DOI 10.1073/pnas.1608245113
   Zhang Q, 2020, J CELL MOL MED, V24, P5428, DOI 10.1111/jcmm.15240
NR 45
TC 9
Z9 9
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2022
VL 37
IS 2
BP 349
EP 368
DI 10.1002/jbmr.4473
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YV6WQ
UT WOS:000752868600021
PM 34787331
OA Bronze
DA 2025 08 17
ER

PT J
AU Aghaloo, TL
   Amantea, CM
   Cowan, CM
   Richardson, JA
   Wu, BM
   Parhami, F
   Tetradis, S
AF Aghaloo, Tara L.
   Amantea, Christopher M.
   Cowan, Catherine M.
   Richardson, Jennifer A.
   Wu, Ben M.
   Parhami, Farhad
   Tetradis, Sotirios
TI Oxysterols enhance osteoblast differentiation in vitro and bone healing
   in vivo
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE oxysterol; bone; osteoblast; healing
ID MARROW STROMAL CELLS; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA 1;
   CHOLESTEROL BIOSYNTHETIC PATHWAY; GROWTH FACTOR BB; MORPHOGENETIC
   PROTEIN 2; GENE THERAPY; HEPATIC METABOLISM; CALVARIAL DEFECTS; COLLAGEN
   SPONGES; STEM CELLS
AB Oxysterols, naturally occurring cholesterol oxidation products, can induce osteoblast differentiation. Here, we investigated short term 22(S) hydroxycholesterol + 20(S) hydroxycholesterol (SS) exposure on osteoblastic differentiation of marrow stromal cells. We further explored oxysterol ability to promote bone healing in vivo. Osteogenic differentiation was assessed by alkaline phosphatase (ALP) activity, osteocalcin (OCN) mRNA expression, mineralization, and Runx2 DNA binding activity. To explore the effects of osteogenic oxysterols in vivo, we utilized the critical sized rat calvarial defect model. Poly(lactic co glycolic acid) (PLGA) scaffolds alone or coated with 140 ng (low dose) or 1400 ng (high dose) oxysterol cocktail were implanted into the defects. Rats were sacrificed at 6 weeks and examined by three dimensional (3D) microcomputed tomography (MicroCT). Bone volume (BV), total volume (TV), and BV/TV ratio were measured. Culture exposure to SS for 10 min significantly increased ALP activity after 4 days, while 2 h exposure significantly increased mineralization after 14 days. Four hour SS treatment increased OCN mRNA measured after 8 days and nuclear protein binding to an OSE2 site measured after 4 days. The calvarial defects showed slight bone healing in the control group. However, scaffolds adsorbed with low or high dose oxysterol cocktail significantly enhanced bone formation. Histologic examination confirmed bone formation in the defect sites grafted with oxysterol adsorbed scaffolds, compared to mostly fibrous tissue in control sites. Our results suggest that brief exposure to osteogenic oxysterols triggered events leading to osteoblastic cell differentiation and function in vitro and bone formation in vivo. These results identify oxysterols as potential agents in local and systemic enhancement of bone formation. (C) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
C1 Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Gaffen Sch Med, Div Cardiol, Dept Med, Los Angeles, CA USA.
   Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles
RP Tetradis, S (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Room 53 068 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM tetradis@ucla.edu
RI ; Cowan, Catherine/F 4181 2010; Wu, Benjamin/JFK 5518 2023
OI Wu, Benjamin/0000 0001 5236 8534; Dwyer, Jennifer/0000 0002 5893 6026
FU NIAMS NIH HHS [R01 AR050426] Funding Source: Medline; NIDCR NIH HHS [R01
   DE013316, K08 DE015800] Funding Source: Medline
CR Aghaloo T, 2005, J BONE MINER RES, V20, pS361
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   BJORKHEM I, 1987, J LIPID RES, V28, P889
   Björkhem I, 2002, ARTERIOSCL THROM VAS, V22, P734, DOI 10.1161/01.ATV.0000013312.32196.49
   Blom EJ, 2001, CLIN ORAL IMPLAN RES, V12, P609, DOI 10.1034/j.1600 0501.2001.120609.x
   Bodin K, 2002, J BIOL CHEM, V277, P31534, DOI 10.1074/jbc.M201712200
   Bosch C, 1996, J CRANIOFAC SURG, V7, P300, DOI 10.1097/00001665 199607000 00011
   Bretillon L, 2000, J LIPID RES, V41, P840
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Cowan CM, 2005, CURR TOP DEV BIOL, V66, P239, DOI 10.1016/S0070 2153(05)66008 5
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   FRAZZA E J, 1971, Journal of Biomedical Materials Research Biomedical Materials Symposium, V1, P43
   Friess W, 1999, INT J PHARM, V187, P91, DOI 10.1016/S0378 5173(99)00174 X
   Giannobile WV, 1996, J PERIODONTAL RES, V31, P301, DOI 10.1111/j.1600 0765.1996.tb00497.x
   Goodman SB, 2003, J BIOMED MATER RES A, V65A, P454, DOI 10.1002/jbm.a.3000
   Govender Preneshlin V, 2002, Neurosurg Focus, V13, pe4
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Gysin R, 2002, GENE THER, V9, P991, DOI 10.1038/sj.gt.3301772
   Hartman EHM, 2002, J INVEST SURG, V15, P185, DOI 10.1080/08941930290085967
   Hicok KC, 1998, J BONE MINER RES, V13, P205, DOI 10.1359/jbmr.1998.13.2.205
   Hyun SJ, 2005, J PERIODONTOL, V76, P1667, DOI 10.1902/jop.2005.76.10.1667
   Ishaug SL, 1997, J BIOMED MATER RES, V36, P17
   Johnson EE, 2000, CLIN ORTHOP RELAT R, P61, DOI 10.1097/00003086 200002000 00008
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Lee JY, 2001, J BONE JOINT SURG AM, V83A, P1032, DOI 10.2106/00004623 200107000 00008
   Lee YM, 2000, J PERIODONTOL, V71, P418, DOI 10.1902/jop.2000.71.3.418
   Li IWS, 1996, J CELL PHYSIOL, V169, P115, DOI 10.1002/(SICI)1097 4652(199610)169:1<115::AID JCP12>3.0.CO;2 C
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Lyons MA, 1999, J LIPID RES, V40, P1846
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410
   Meaney S, 2001, J LIPID RES, V42, P70
   Mehrara BJ, 2002, PLAST RECONSTR SURG, V110, P506, DOI 10.1097/00006534 200208000 00022
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   MIKI T, 1994, J ORAL MAXIL SURG, V52, P387, DOI 10.1016/0278 2391(94)90443 X
   Minamide A, 2005, SPINE, V30, P1134, DOI 10.1097/01.brs.0000162394.75425.04
   Nussenbaum B, 2005, LARYNGOSCOPE, V115, P1170, DOI 10.1097/01.MLG.0000166513.74247.CC
   Oldham JB, 2000, J BIOMECH ENG T ASME, V122, P289, DOI 10.1115/1.429662
   OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336
   Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Parhami F, 2002, J BONE MINER RES, V17, P1997, DOI 10.1359/jbmr.2002.17.11.1997
   Park YJ, 1998, J CONTROL RELEASE, V51, P201, DOI 10.1016/S0168 3659(97)00169 7
   REDDI AH, 1995, CLIN ORTHOP RELAT R, P115
   Ripamonti U, 1997, J BONE MINER RES, V12, P1584, DOI 10.1359/jbmr.1997.12.10.1584
   ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168 9525(92)90197 C
   Ruhe PQ, 2003, J BONE JOINT SURG AM, V85A, P75
   Russell DW, 2000, BBA MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388 1981(00)00142 6
   Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504
   Schroepfer GJ Jr, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Tang Ting ting, 2005, Chin J Traumatol, V8, P3
   Uludag H, 1999, ANN NY ACAD SCI, V875, P369, DOI 10.1111/j.1749 6632.1999.tb08519.x
   van den Bergh JPA, 2000, J CLIN PERIODONTOL, V27, P627, DOI 10.1034/j.1600 051x.2000.027009627.x
   Winn SR, 2000, ADV DRUG DELIVER REV, V42, P121, DOI 10.1016/S0169 409X(00)00057 0
   Woo BH, 2001, PHARMACEUT RES, V18, P1747, DOI 10.1023/A:1013382832091
   Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375
NR 64
TC 59
Z9 68
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD NOV
PY 2007
VL 25
IS 11
BP 1488
EP 1497
DI 10.1002/jor.20437
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 228NX
UT WOS:000250737700011
PM 17568450
OA Bronze
DA 2025 08 17
ER

PT J
AU Suh, JS
   Lee, JY
   Lee, G
   Chung, CP
   Park, YJ
AF Suh, Jin Sook
   Lee, Jue Yeon
   Lee, Gene
   Chung, Chong Pyoung
   Park, Yoon Jeong
TI Simultaneous imaging and restoration of cell function using cell
   permeable peptide probe
SO BIOMATERIALS
LA English
DT Article
DE Cell penetrating peptide probe; Stem cell monitoring;
   Ubiquitin proteasomal system; Theranosis; Osteogenesis
ID GROWTH FACTOR; IN VIVO; INDUCED ARTHRITIS; RAT OSTEOBLAST; UBIQUITIN;
   PROTEIN; DOMAIN; ACTIVATION; PROMOTES; CANCER
AB Targeting tissues/cells using probing materials to detect diseases such as cancer and inflammatory disease has been attempted with some success. Most of the molecular targets used in diagnosis and therapy were identified through the discovery of intracellular signaling pathways. Among intracellular signaling processes, the ubiquitination of proteins, and thereby their proteasomal degradation, is important because it plays a role in most diseases involving alterations to a component of the ubiquitination system, particularly E3 ligases, which have selective target binding affinity and are key to the success of regulating the disorder. The regulation and monitoring of E3 ligases can be achieved using peptides containing protein protein binding motifs. We generated a human protein derived peptide that could target Smurf1, a member of the E3 ligase family, by competitively binding to osteo Smads. To effectively deliver it into cells, the peptide was further modified with a cell penetrating peptide. The peptide contains two fluorescent dyes: fluorescein isothiocyanate (FITC; absorbance/emission wavelengths: 495/519 nm) as a fluorophore and black hole quencher 1 (BHQ 1) as a fluorescence quencher. When the target Smurf1 combined with complementary sequences in the peptide probe, the distance between the fluorophore and BHQ 1 increased via a conformational change, resulting in the recovery of the fluorescence signal. Simultaneously, the degradation of Smad1/5/8 was blocked by the binding of the peptide probe to Smurf1, leading to the potentiation of the osteogenic pathway, which was reflected by an increase in the expression of osteoinductive genes, such as alkaline phosphatase and osteocalcin. Possible future applications of the peptide probe include its integration into imaging tools for the diagnosis of Smurfl overexpressing diseases. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Suh, Jin Sook; Lee, Gene; Park, Yoon Jeong] Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul, South Korea.
   [Lee, Jue Yeon; Chung, Chong Pyoung; Park, Yoon Jeong] NIBEC, Cent Res Inst, Seoul, South Korea.
C3 Seoul National University (SNU)
RP Park, YJ (通讯作者)，Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul, South Korea.
EM parkyj@snu.ac.kr
RI Lee, Sang Jin/S 4056 2019
FU Bio & Medical Technology Development Program [2012049727];
   Oromaxillofacial Dysfunction Research Center for the Elderly at Seoul
   National University in Korea of the National Research Foundation (NRF)  
   Ministry of Science, ICT, and Future Planning [2012000912]
FX None of the authors have a conflict of interest. This work was supported
   in part by the Bio & Medical Technology Development Program
   (#2012049727) and in part by the Oromaxillofacial Dysfunction Research
   Center for the Elderly at Seoul National University in Korea
   (#2012000912) of the National Research Foundation (NRF) funded by the
   Ministry of Science, ICT, and Future Planning.
CR Ahmed AS, 2010, ARTHRITIS RHEUM US, V62, P2160, DOI 10.1002/art.27492
   Akhatib B, 2013, J BIOL CHEM, V288, P19280, DOI 10.1074/jbc.M112.443010
   Amiable N, 2009, BONE, V44, P1143, DOI 10.1016/j.bone.2009.02.015
   Blanco Mezquita T, 2013, INVEST OPHTH VIS SCI, V54, P3880, DOI 10.1167/iovs.12 10816
   Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125
   Campbell RE, 2009, ANAL CHEM, V81, P5972, DOI 10.1021/ac802613w
   Cao J, 2012, CONTRAST MEDIA MOL I, V7, P390, DOI 10.1002/cmmi.1464
   Choi YJ, 2010, BIOMATERIALS, V31, P7226, DOI 10.1016/j.biomaterials.2010.05.022
   Choi YS, 2010, BIOMATERIALS, V31, P1429, DOI 10.1016/j.biomaterials.2009.11.001
   Czernin J, 2006, ANNU REV MED, V57, P99, DOI 10.1146/annurev.med.57.080904.190431
   Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001
   Ehrlich A, 2013, BIOCHEM PHARMACOL, V86, P1263, DOI 10.1016/j.bcp.2013.08.019
   Gompels LL, 2011, ARTHRITIS RHEUM US, V63, P107, DOI 10.1002/art.30082
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023
   Hung CF, 2006, BIOCHEM BIOPH RES CO, V346, P707, DOI 10.1016/j.bbrc.2006.05.164
   Ito Y, 2002, DEV DYNAM, V224, P69, DOI 10.1002/dvdy.10088
   Kim EM, 2009, NUCL MED BIOL, V36, P371, DOI 10.1016/j.nucmedbio.2009.01.005
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Liao EY, 2004, J ENDOCRINOL INVEST, V27, P1
   Marquez BV, 2012, BIOCONJUGATE CHEM, V23, P1080, DOI 10.1021/bc300114d
   Niki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037447
   Oh JY, 2009, CYTOKINE, V46, P100, DOI 10.1016/j.cyto.2008.12.011
   Pan WW, 2013, J BIOL CHEM, V288, P29680, DOI 10.1074/jbc.M113.495069
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04 2322fje
   PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205
   Ryu JH, 2011, ARTHRITIS RHEUM US, V63, P3824, DOI 10.1002/art.30628
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Sangadala S, 2007, PROTEINS, V68, P690, DOI 10.1002/prot.21429
   Sangadala S, 2006, J BIOL CHEM, V281, P17212, DOI 10.1074/jbc.M511013200
   Schnetzke U, 2013, LEUKEMIA RES, V37, P1557, DOI 10.1016/j.leukres.2013.08.004
   Schulman BA, 2009, NAT REV MOL CELL BIO, V10, P319, DOI 10.1038/nrm2673
   Suh JS, 2009, BIOCHEM BIOPH RES CO, V379, P669, DOI 10.1016/j.bbrc.2008.12.041
   Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502
   Tian MM, 2013, J INTEGR PLANT BIOL, V55, P54, DOI 10.1111/jipb.12007
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968 0896(02)00248 1
   Van Der Horst G, 2002, BONE, V31, P661, DOI 10.1016/S8756 3282(02)00903 1
   Wang ZH, 2013, NEOPLASIA, V15, P1028, DOI 10.1593/neo.13678
   Wunder A, 2004, ARTHRITIS RHEUM US, V50, P2459, DOI 10.1002/art.20379
   Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780
   Zhou Q, 2013, CLIN EXP IMMUNOL, V173, P131, DOI 10.1111/cei.12095
NR 41
TC 9
Z9 10
U1 0
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2014
VL 35
IS 24
BP 6287
EP 6298
DI 10.1016/j.biomaterials.2014.04.045
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AL0GD
UT WOS:000338804500014
PM 24831974
DA 2025 08 17
ER

PT J
AU Bornstein, S
   Moschetta, M
   Kawano, Y
   Sacco, A
   Huynh, D
   Brooks, D
   Manier, S
   Fairfield, H
   Falank, C
   Roccaro, AM
   Nagano, K
   Baron, R
   Bouxein, M
   Vary, C
   Ghobrial, IM
   Rosen, CJ
   Reagan, MR
AF Bornstein, Sheila
   Moschetta, Michele
   Kawano, Yawara
   Sacco, Antonio
   Huynh, Daisy
   Brooks, Daniel
   Manier, Salomon
   Fairfield, Heather
   Falank, Carolyne
   Roccaro, Aldo M.
   Nagano, Kenichi
   Baron, Roland
   Bouxein, Mary
   Vary, Calvin
   Ghobrial, Irene M.
   Rosen, Clifford J.
   Reagan, Michaela R.
TI Metformin Affects Cortical Bone Mass and Marrow Adiposity in
   Diet Induced Obesity in Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID MINERAL DENSITY; INSULIN RESISTANCE; IN VIVO; TISSUE; WOMEN; WEIGHT;
   MICROARCHITECTURE; MICROSTRUCTURE; STRENGTH; MYELOMA
AB Obesity during maturation can affect the growing skeleton directly and indirectly, although these effects and the mechanisms behind them are not fully understood. Our objective was to determine how a high fat diet with or without metformin treatment affects skeletal development. We also sought to characterize changes that occur in white adipose tissue, circulating metabolites, lipids, and gut microbiota. A diet induced obesity C57BL/6J mouse model was used to test the effects of obesity and metformin on bone using bone histomorphometry and microcomputed tomography. Bone marrow adipose tissue was quantified with osmium tetroxide microcomputed tomography and histology. Dual energy x ray absorptiometry was used to analyze body composition. Hematoxylin and eosin staining was used to assess changes in white adipose depots, mass spectrometry was used for circulating lipids and protein metabolite analysis, and ribosomal RNA sequencing was used for gut microbiome analysis. Mice fed a high fat diet since wean displayed increased medullary areas and decreased osteoblast numbers in the long bones; this phenotype was partially normalized by metformin. Marrow and inguinal adipose expansion was also noted in obese mice, and this was partially normalized by metformin. A drug by diet interaction was noted for circulating lipid molecules, protein metabolites, and gut microbiome taxonomical units. Obesity was not detrimental to trabecular bone in growing mice, but bone marrow medullary expansion was observed, likely resulting from inhibition of osteoblastogenesis, and this was partially reversed by metformin treatment.
C1 [Bornstein, Sheila; Fairfield, Heather; Falank, Carolyne; Vary, Calvin; Rosen, Clifford J.; Reagan, Michaela R.] Maine Med Ctr, Res Inst, 81 Res Dr, Scarborough, ME 04074 USA.
   [Moschetta, Michele; Kawano, Yawara; Sacco, Antonio; Huynh, Daisy; Manier, Salomon; Roccaro, Aldo M.; Reagan, Michaela R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Sacco, Antonio; Roccaro, Aldo M.] Azienda Socio Sanitaria Territoriale Spedali Civi, Progettaz Ric Clin & Studi Fase 1, Lab Ctr Ric OncoEmatol AIL, Brescia, BS, Italy.
   [Brooks, Daniel; Bouxein, Mary] Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Brooks, Daniel; Bouxein, Mary] Massachusetts Gen Hosp, Skeletal Res Ctr, Boston, MA 02114 USA.
   [Fairfield, Heather; Falank, Carolyne; Vary, Calvin; Rosen, Clifford J.; Reagan, Michaela R.] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA.
   [Fairfield, Heather; Falank, Carolyne; Vary, Calvin; Rosen, Clifford J.; Reagan, Michaela R.] Tufts Univ, Sch Med, Boston, MA 02215 USA.
   [Nagano, Kenichi; Baron, Roland] Harvard Med Sch, Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
C3 Maine Medical Center; Harvard University; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   University Medical Affiliates; Beth Israel Deaconess Medical Center;
   Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; University of Maine System; University of Maine Orono;
   Tufts University; Harvard University; Harvard School of Dental Medicine;
   Harvard Medical School
RP Reagan, MR (通讯作者)，Maine Med Ctr, Res Inst, 81 Res Dr, Scarborough, ME 04074 USA.
EM Mreagan@mmc.org
RI ; Sacco, Antonio/AFL 7734 2022; Sacco, Antonio/K 4681 2016; Manier,
   Salomon/N 5976 2017; Kawano, Yawara/AAH 8714 2020; Reagan,
   Michaela/E 3549 2017; rosen, clifford/JOZ 3228 2023; Nagano,
   Kenichi/AAH 3246 2019; Roccaro, Aldo/J 9252 2014
OI Reagan, Michaela/0000 0003 2884 6481; Sacco,
   Antonio/0000 0003 2945 9416; Kawano, Yawara/0000 0002 8269 440X;
   Ghobrial, Irene/0000 0001 7361 3092; 
FU Center for Skeletal Research Core [National Institutes of Health (NIH)]
   [P30 AR066261]; National Institute of General Medical Sciences
   (NIGMS)/NIH [P30 GM106391]; Histopathology Core of NIH Grants NIGMS [P30
   GM103392, P30GM106391]; Maine Medical Center Research Institute;
   NIH/National Institute of Diabetes and Digestive and Kidney Diseases
   [R24 DK092759 01]; American Cancer Society [IRG 16 191 33]
FX This work was supported by funding from the Center for Skeletal Research
   Core [National Institutes of Health (NIH) Grant P30 AR066261], the
   National Institute of General Medical Sciences (NIGMS)/NIH Grant P30
   GM106391, the Histopathology Core of NIH Grants NIGMS P30 GM103392 (R.
   Friesel, principal investigator) and P30GM106391 (D. Wojchowski,
   principal investigator), startup funds from the Maine Medical Center
   Research Institute, the NIH/National Institute of Diabetes and Digestive
   and Kidney Diseases (Grant R24 DK092759 01), and the American Cancer
   Society (Research Grant IRG 16 191 33).
CR Barbato DL, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.404
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bredella MA, 2012, J CLIN ENDOCR METAB, V97, P4115, DOI 10.1210/jc.2012 2246
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   Chandel NS, 2016, CELL METAB, V23, P569, DOI 10.1016/j.cmet.2016.03.010
   Chandran M, 2017, CALCIFIED TISSUE INT, V100, P133, DOI 10.1007/s00223 016 0203 x
   Chen X, 2016, BONE, V93, P104, DOI 10.1016/j.bone.2016.09.016
   Delahunty KM, 2006, ENDOCRINOLOGY, V147, P3915, DOI 10.1210/en.2006 0277
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Doucette CR, 2015, J CELL PHYSIOL, V230, P2032, DOI 10.1002/jcp.24954
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Evans AL, 2015, J BONE MINER RES, V30, P920, DOI 10.1002/jbmr.2407
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Fu R, 2016, ANN HEMATOL, V95, P1099, DOI 10.1007/s00277 016 2657 3
   Hu CC, 2004, OBES RES, V12, P1264, DOI 10.1038/oby.2004.160
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Kim E.K., 2016, Mediators of inflammation, V5813030, P1, DOI [10.1155/2016/5813030, DOI 10.1155/2016/5813030]
   Liaw L, 2016, J CELL BIOCHEM, V117, P2182, DOI 10.1002/jcb.25522
   Luo B, 2007, J CHROMATOGR A, V1147, P153, DOI 10.1016/j.chroma.2007.02.034
   Luo T, 2016, DIABETES, V65, P2295, DOI 10.2337/db15 1122
   Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010
   Lutz TA, 2012, CURR PROTOC PHARM, V61, P1
   Fernández JM, 2013, EUR J PHARMACOL, V706, P41, DOI 10.1016/j.ejphar.2013.02.042
   Mao Y, 2013, CHINESE MED J PEKING, V126, P3717, DOI 10.3760/cma.j.issn.0366 6999.20122806
   McCreight LJ, 2016, DIABETOLOGIA, V59, P426, DOI 10.1007/s00125 015 3844 9
   Morin S, 2009, OSTEOPOROSIS INT, V20, P363, DOI 10.1007/s00198 008 0688 x
   Neglia C, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111067
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Ramos ES, 2017, J BONE MINER RES, V32, P974, DOI 10.1002/jbmr.3072
   Risérus U, 2009, PROG LIPID RES, V48, P44, DOI 10.1016/j.plipres.2008.10.002
   Samelson EJ, 2004, BONE, V34, P557, DOI 10.1016/j.bone.2003.11.024
   Scheller EL, 2014, METHOD ENZYMOL, V537, P123, DOI 10.1016/B978 0 12 411619 1.00007 0
   Shu L, 2015, CALCIFIED TISSUE INT, V96, P313, DOI 10.1007/s00223 015 9954 z
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Simons B, 2012, METABOLITES, V2, P195, DOI 10.3390/metabo2010195
   Solomon Daniel H, 2005, Am J Med, V118, P1414, DOI 10.1016/j.amjmed.2005.07.031
   Sornay Rendu E, 2013, J BONE MINER RES, V28, P1679, DOI 10.1002/jbmr.1880
   Souza Mello V, 2010, CLIN SCI, V119, P239, DOI 10.1042/CS20100061
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Wang FN, 2010, BIOCHEM J, V425, P71, DOI 10.1042/BJ20090928
   Wanninger J, 2008, BBA MOL CELL BIOL L, V1781, P321, DOI 10.1016/j.bbalip.2008.04.012
   Woo SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091111
   Yu EW, 2017, BONE, V97, P38, DOI 10.1016/j.bone.2016.12.018
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhao JX, 2010, BIOCHEM BIOPH RES CO, V395, P146, DOI 10.1016/j.bbrc.2010.03.161
NR 45
TC 50
Z9 50
U1 1
U2 20
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT
PY 2017
VL 158
IS 10
BP 3369
EP 3385
DI 10.1210/en.2017 00299
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FI9BO
UT WOS:000412298700028
PM 28977604
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Bundred, NJ
AF Bundred, Nigel J.
TI Aromatase inhibitors and bone health
SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
LA English
DT Article
DE aromatase inhibitors; bone mineral density; fractures; osteopaenia;
   osteoporosis
ID BREAST CANCER; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; TAMOXIFEN;
   PREVENTION; TRIAL; RISK; OSTEOPOROSIS; METAANALYSIS; MANAGEMENT
AB Purpose of review
   Aromatase inhibitors improve survival in breast cancer patients but adversely affect bone health.
   Recent findings
   Hormone receptor positive breast cancer is increasingly targeted with chemotherapy, ovarian suppression and the use of aromatase inhibitors. Aromatase inhibitors block oestrogen production in peripheral tissues and the three third generation aromatase inhibitors (anastrozole, letrozole and exemestane) reduce circulating oestrogen levels, leading to accelerated bone loss and an increased risk of fracture. The majority of fractures occur in osteopaenic women prescribed aromatase inhibitors. Current guidelines advocate bone mineral density (BMD) measurement in all patients on aromatase inhibitors with selective use of antiresorptive therapy in osteoporotic (T score >  2.5) women. Risk factors for premature bone loss and fracture include a low BMI, family history or personal history of fragility fracture after the age of 50, oral corticosteroid use more than 6 months and cigarette smoking. Emerging evidence supports concomitant use of bisphosphonates in all women on aromatase inhibitors to prevent fracture and breast cancer recurrence.
   Summary
   The increasing use of aromatase inhibitors requires selection of patients for antiresorptive therapy and careful bone health management to reduce bone loss and prevent fragility fractures.
C1 Univ S Manchester Hosp, Educ & Res Ctr, Manchester M23 9LT, Lancs, England.
C3 Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital
RP Bundred, NJ (通讯作者)，Univ S Manchester Hosp, Educ & Res Ctr, 2nd Floor,Southmoor Rd, Manchester M23 9LT, Lancs, England.
EM bundredn@manchester.ac.uk
CR Brufsky A, 2008, ONCOLOGIST, V13, P503, DOI 10.1634/theoncologist.2007 0206
   Chen Z, 2005, ARCH INTERN MED, V165, P552, DOI 10.1001/archinte.165.5.552
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140 6736(07)60200 1
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Cuzick J, 2008, EXPERT REV ANTICANC, V8, P1377, DOI 10.1586/14737140.8.9.1377
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Eastell R, 2007, J BONE MINER RES, V22, pS113
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   ELLIS G, 2007, 30 ANN SAN ANT BREAS
   Ellis GK, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.546
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Gnant MFX, 2007, J CLIN ONCOL, V25, P820, DOI 10.1200/JCO.2005.02.7102
   Hadji P, 2008, ANN ONCOL, V19, P1407, DOI 10.1093/annonc/mdn164
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140 6736(04)17666 6
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Reid DM, 2008, CANCER TREAT REV, V34, pS3, DOI 10.1016/j.ctrv.2008.03.007
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Siris ES, 2004, J BONE MINER RES, V19, P1215, DOI 10.1359/JBMR.040508
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
NR 23
TC 24
Z9 30
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040 872X
EI 1473 656X
J9 CURR OPIN OBSTET GYN
JI Curr. Opin. Obstet. Gynecol.
PD FEB
PY 2009
VL 21
IS 1
BP 60
EP 67
DI 10.1097/GCO.0b013e32831da80e
PG 8
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 403QA
UT WOS:000263095900011
PM 19125005
DA 2025 08 17
ER

PT J
AU Jann, J
   Drevelle, O
   Lauzon, MA
   Faucheux, N
AF Jann, J.
   Drevelle, O.
   Lauzon, M A
   Faucheux, N.
TI Adhesion, intracellular signalling and osteogenic differentiation of
   mesenchymal progenitor cells and preosteoblasts on poly(epsilon)
   caprolactone films functionalized by peptides derived from fibronectin
   and/or BMP 9
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Bone morphogenetic proteins; IGF 2; RGD; Smad; FAK; RUNX2; Alkaline
   phosphatase
ID BONE MORPHOGENETIC PROTEINS; STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   CLINICAL APPLICATIONS; ADIPOSE TISSUE; INTEGRIN; RGD; MARROW;
   PERSPECTIVES; MIMICKING
AB Biomaterials that can control the behaviour of stem cells play a major role in regenerative medicine and tissue engineering. We previously showed that poly(epsilon)caprolactone (PCL) films functionalized with adhesive peptides containing sequences of both cell binding domain (RGD) and synergistic site (PHSRN) of the fibronectin (pFibro) enhanced the osteoblastic commitment of C3H10T1/2 mesenchymal progenitor cells (C3H10T1/2 cells) induced by soluble BMP 9 or its derived peptide SpBMP 9. Here, the effect of PCL films functionalized with pFibro and/or SpBMP 9 or its negative peptide NSpBMP 9 on adhesion and intracellular signalling of C3H10T1/2 cells was determined. The differentiation of adherent C3H10T1/2 cells and MC3T3 E1 preosteoblasts into osteoblasts was also analysed with or without IGF 2, since this growth factor can favour the osteoblastic differentiation induced by BMP 9. We found that pFibro and SpBMP 9 co functionalization on PCL films promoted the adhesion of C3H10T1/2 cells with well organized focal adhesion points and FAK activation. In these mesenchymal progenitor cells, PCL SpBMP 9 and PCL pFibro/SpBMP 9 induced the activation and nuclear translocation of Smad 1/5 after 4 h, and enhanced the protein expression of RUNX2 (3 d) and alkaline phosphatase (ALP) activity (7 d), two markers of osteoblast differentiation. No PPAR gamma, a marker of adipogenic differentiation, was detected. C3H10T1/2 cells attached to PCL SpBMP 9 also contained more SOX9, a marker of chondroblastic lineage, compared with other experimental conditions. The use of inactive peptides NSpBMP 9 confirmed the specificity and effectiveness of SpBMP 9 on cell adhesion, intracellular signalling and osteoblastic differentiation. Adding IGF 2 only significantly improved the differentiation of MC3T3 E1 preosteoblasts into osteoblasts as shown by the increase in gene expression encoding Osterix (mRNA Sp7) and ALP (mRNA Alpl), probably because of the lack of serum in the medium. Therefore, material surface co functionalized with pFibro and SpBMP 9 could be most useful for developing scaffolds with both osseointegrative and osteoinductive properties for bone application and tissue engineering strategy when combined with IGF 2 in serum free medium.
C1 [Jann, J.; Faucheux, N.] Univ Sherbrooke, Dept Chem & Biotechnol Engn, Cell Biomat Biohybrid Syst, 2500 Boul Univ, Sherbrooke, PQ J1K 2R1, Canada.
   [Drevelle, O.] Univ Sherbrooke, Dept Chem & Biotechnol Engn, Thermal Plasma & Nanomat Synth Lab, 2500 Boul Univ, Sherbrooke, PQ J1K 2R1, Canada.
   [Lauzon, M A] Univ Sherbrooke, Dept Chem & Biotechnol Engn, 3D Cell Culture Syst Lab, 2500 Boul Univ, Sherbrooke, PQ J1K 2R1, Canada.
   [Faucheux, N.] Ctr Hosp Univ Sherbrooke, Clin Res Ctr, 12e Ave N, Sherbrooke, PQ J1H 5N4, Canada.
C3 University of Sherbrooke; University of Sherbrooke; University of
   Sherbrooke; University of Sherbrooke
RP Faucheux, N (通讯作者)，Univ Sherbrooke, Dept Chem & Biotechnol Engn, Cell Biomat Biohybrid Syst, 2500 Boul Univ, Sherbrooke, PQ J1K 2R1, Canada.
EM Jessica.Jann@usherbrooke.ca; Olivier.Drevelle@usherbrooke.ca;
   Marc Antoine.Lauzon@usherbrooke.ca; Nathalie.Faucheux@usherbrooke.ca
FU Natural Sciences and Engineering Research Council of Canada program
   [298359, 33062]
FX We thank Dr. Owen Parkes for editing the English text and Pamela Menard
   for technical assistance on supplementary data using MC3T3 E1 cells.
   This research was supported through a Natural Sciences and Engineering
   Research Council of Canada program (grant number 298359 and 33062).
CR Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102
   Beauvais S, 2016, ACTA BIOMATER, V31, P241, DOI 10.1016/j.actbio.2015.12.005
   Bergeron E, 2007, J MATER SCI MATER M, V18, P255, DOI 10.1007/s10856 006 0687 4
   Bergeron E, 2012, TISSUE ENG PT A, V18, P342, DOI [10.1089/ten.tea.2011.0008, 10.1089/ten.TEA.2011.0008]
   Bergeron E, 2009, TISSUE ENG PT A, V15, P3341, DOI [10.1089/ten.tea.2009.0189, 10.1089/ten.TEA.2009.0189]
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bilem I, 2018, J BIOMED MATER RES A, V106, P959, DOI 10.1002/jbm.a.36296
   Bilem I, 2016, ACTA BIOMATER, V36, P132, DOI 10.1016/j.actbio.2016.03.032
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Boda SK, 2019, ACTA BIOMATER, V85, P282, DOI 10.1016/j.actbio.2018.12.051
   Brinkerhoff CJ, 2005, TISSUE ENG, V11, P865, DOI 10.1089/ten.2005.11.865
   Burkus JK, 2004, ORTHOPEDICS, V27, P723
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Comisar WA, 2011, J THEOR BIOL, V274, P120, DOI 10.1016/j.jtbi.2011.01.007
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Downey J, 2015, BONE, V71, P164, DOI 10.1016/j.bone.2014.10.020
   Drevelle Olivier, 2013, Front Biosci (Schol Ed), V5, P369
   Drevelle O, 2013, BIOMATERIALS, V34, P1051, DOI 10.1016/j.biomaterials.2012.10.066
   Drevelle O, 2010, BIOMATERIALS, V31, P6468, DOI 10.1016/j.biomaterials.2010.05.010
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Federal Interagency Forum on Aging Related Statistics, 2016, OLD AM 2016 KEY IND
   Fraioli R, 2015, COLLOID SURFACE B, V128, P191, DOI 10.1016/j.colsurfb.2014.12.057
   Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Greenblatt MB, 2010, ANN NY ACAD SCI, V1192, P385, DOI 10.1111/j.1749 6632.2009.05222.x
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   He XZ, 2008, LANGMUIR, V24, P12508, DOI 10.1021/la802447v
   He XZ, 2012, LANGMUIR, V28, P5387, DOI 10.1021/la205005h
   Huntley R, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100207
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kao WJ, 2001, J BIOMED MATER RES, V55, P79, DOI 10.1002/1097 4636(200104)55:1<79::AID JBM110>3.0.CO;2 Z
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lauzon MA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04835 x
   Lauzon MA, 2016, TISSUE ENG PT A, V22, P1075, DOI [10.1089/ten.TEA.2016.0151, 10.1089/ten.tea.2016.0151]
   Lauzon MA, 2014, TISSUE ENG PT A, V20, P2524, DOI [10.1089/ten.tea.2014.0091, 10.1089/ten.TEA.2014.0091]
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Luo JJ, 2018, COLLOID SURFACE B, V163, P369, DOI 10.1016/j.colsurfb.2017.12.043
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Ma YR, 2016, BIOMACROMOLECULES, V17, P1486, DOI 10.1021/acs.biomac.6b00088
   Madl CM, 2014, BIOMACROMOLECULES, V15, P445, DOI 10.1021/bm401726u
   Marquis ME, 2008, BIOMATERIALS, V29, P1005, DOI 10.1016/j.biomaterials.2007.10.047
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   McPhee JS, 2016, BIOGERONTOLOGY, V17, P567, DOI 10.1007/s10522 016 9641 0
   Mobasseri R, 2018, MAT SCI ENG C MATER, V84, P80, DOI 10.1016/j.msec.2017.11.017
   Moon JS, 2014, J BONE MINER RES, V29, P1586, DOI 10.1002/jbmr.2197
   Moore NM, 2011, ACTA BIOMATER, V7, P2091, DOI 10.1016/j.actbio.2011.01.019
   Nagae M, 2012, J CELL BIOL, V197, P131, DOI 10.1083/jcb.201111077
   Carreira ACO, 2015, VITAM HORM, V99, P293, DOI 10.1016/bs.vh.2015.06.002
   Pryor LS, 2009, CRANIOMAX TRAUM REC, V2, P151, DOI 10.1055/s 0029 1224777
   Ren XY, 2016, ADV HEALTHC MATER, V5, P1821, DOI 10.1002/adhm.201600187
   Ren Y, 2020, MAT SCI ENG C MATER, V108, DOI 10.1016/j.msec.2019.110276
   Rezania A, 2000, J BIOMED MATER RES, V52, P595, DOI 10.1002/1097 4636(20001215)52:4<595::AID JBM3>3.3.CO;2 V
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   Saito A, 2004, J BIOMED MATER RES A, V70A, P115, DOI 10.1002/jbm.a.30071
   Saito A, 2003, BBA PROTEINS PROTEOM, V1651, P60, DOI 10.1016/S1570 9639(03)00235 8
   SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955 0674(94)90097 3
   Schmidmaier G, 2008, INJURY, V39, pS37, DOI 10.1016/S0020 1383(08)70014 7
   Shekaran A, 2014, BIOMATERIALS, V35, P5453, DOI 10.1016/j.biomaterials.2014.03.055
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Song DZ, 2017, J CELL MOL MED, V21, P2782, DOI 10.1111/jcmm.13193
   Sreekumar V, 2017, ARCH TOXICOL, V91, P1353, DOI 10.1007/s00204 016 1796 6
   Süloglu AK, 2019, J BIOMATER APPL, V34, P375, DOI 10.1177/0885328219853421
   Tian HY, 2012, EMBO J, V31, P3885, DOI 10.1038/emboj.2012.246
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Watabe H, 2011, EXP CELL RES, V317, P2642, DOI 10.1016/j.yexcr.2011.07.015
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yang Y, 2018, BIOPOLYMERS, V109, DOI 10.1002/bip.23223
   Yoon ST, 2002, CLIN ORTHOP RELAT R, P33
   Zaidel Bar R, 2010, J CELL SCI, V123, P1385, DOI 10.1242/jcs.066183
   Zhang PB, 2011, BIOMACROMOLECULES, V12, P2667, DOI 10.1021/bm2004725
   Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097 0177(199708)209:4<377::AID AJA5>3.0.CO;2 F
   Zouani OF, 2010, BIOMATERIALS, V31, P8245, DOI 10.1016/j.biomaterials.2010.07.042
NR 83
TC 7
Z9 7
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP
PY 2020
VL 114
AR 111088
DI 10.1016/j.msec.2020.111088
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA OD1ZY
UT WOS:000579654700028
PM 32994028
DA 2025 08 17
ER

PT J
AU Alaseem, AM
   Madiraju, P
   Aldebeyan, SA
   Noorwali, H
   Antoniou, J
   Mwale, F
AF Alaseem, Abdulrahman M.
   Madiraju, Padma
   Aldebeyan, Sultan A.
   Noorwali, Hussain
   Antoniou, John
   Mwale, Fackson
TI Naproxen Induces Type X Collagen Expression in Human Bone Marrow Derived
   Mesenchymal Stem Cells Through the Upregulation of 5 Lipoxygenase
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   GLOW DISCHARGE PLASMA; OSTEOARTHRITIC CHONDROCYTES;
   SELECTIVE INHIBITION; GENE EXPRESSION; LEUKOTRIENE B 4; IN VIVO;
   CARTILAGE; DIFFERENTIATION
AB Several studies have shown that type X collagen (COL X), a marker of late stage chondrocyte hypertrophy, is expressed in mesenchymal stem cells (MSCs) from osteoarthritis (OA) patients. We recently found that Naproxen, but not other nonsteroidal anti inflammatory drugs (NSAIDs) (Ibuprofen, Celebrex, Diclofenac), can induce type X collagen gene (COL10A1) expression in bone marrow derived MSCs from healthy and OA donors. In this study we determined the effect of Naproxen on COL X protein expression and investigated the intracellular signaling pathways that mediate Naproxen induced COL10A1 expression in normal and OA hMSCs. MSCs of OA patients were isolated from aspirates from the intramedullary canal of donors (50 80 years of age) undergoing hip replacement surgery for OA and were treated with or without Naproxen (100 mu g/mL). Protein expression and phosphorylation were determined by immunoblotting using specific antibodies (COL X, p38 mitogen activated protein kinase [p38], phosphorylated p38, c Jun N terminal kinase [JNK], phosphorylated JNK, extracellular signal regulated kinase [ERK], and phosphorylated ERK). Real time reverse transcription polymerase chain reaction (RT PCR) was performed to determine the expression of COL10A1 and Runt related transcription factor 2 gene (Runx2). Our results show that Naproxen significantly stimulated COL X protein expression after 72 h of exposure both in normal and OA hMSCs. The basal phosphorylation of mitogen activated protein kinases (MAPKs) (ERK, JNK, and p38) in OA hMSCs was significantly higher than in normal. Naproxen significantly increased the MAPK phosphorylation in normal and OA hMSCs. NSAID cellular effects include cyclooxygenase, 5 lipoxygenase, and p38 MAPK signaling pathways. To investigate the involvement of these pathways in the Naproxen induced COL10A1 expression, we incubated normal and OA hMSCs with Naproxen with and without inhibitors of ERK (U0126), JNK (BI 78D3), p38 (SB203580), and 5 lipoxygenase (MK 886). Our results showed that increased basal COL10A1 expression in OA hMSCs was significantly suppressed in the presence of JNK and p38 inhibitors, whereas Naproxen induced COL10A1 expression was suppressed by 5 lipoxygenase inhibitor. This study shows that Naproxen induces COL X both at transcriptional and translational levels in normal and OA hMSCs. Elevated basal COL10A1 expression in OA hMSCs is probably through the activation of MAPK pathway and Naproxen induced COL10A1 expression is through the increased 5 lipoxygenase signaling.
C1 [Alaseem, Abdulrahman M.; Aldebeyan, Sultan A.; Noorwali, Hussain; Antoniou, John; Mwale, Fackson] McGill Univ, Div Orthopaed Surg, Montreal, PQ, Canada.
   [Alaseem, Abdulrahman M.; Madiraju, Padma; Aldebeyan, Sultan A.; Noorwali, Hussain; Antoniou, John; Mwale, Fackson] SMBD Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Alaseem, Abdulrahman M.] King Saud Univ, Coll Med, Dept Orthoped, Riyadh 11461, Saudi Arabia.
   [Aldebeyan, Sultan A.] King Fahad Med City, Dept Orthopaed Surg, Riyadh, Saudi Arabia.
   [Noorwali, Hussain] King Abdulaziz Univ, Dept Orthoped, Jeddah 21413, Saudi Arabia.
C3 McGill University; Jewish General Hospital   Montreal; Lady Davis
   Institute; King Saud University; King Fahad Medical City; King Abdulaziz
   University
RP Mwale, F (通讯作者)，SMBD Jewish Gen Hosp, Lady Davis Inst Med Res, Room F 602,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.
EM fmwale@ldi.jgh.mcgill.ca
RI Noorwali, Hussain/LCD 5685 2024; Alaseem, Abdulrahman/HIZ 7146 2022
OI Alaseem, Abdulrahman/0000 0001 6034 9739
FU Canadian Institutes of Health Research (CIHR)
FX This study was supported by the Canadian Institutes of Health Research
   (CIHR).
CR Almaawi A, 2013, TISSUE ENG PT A, V19, P1039, DOI [10.1089/ten.TEA.2012.0129, 10.1089/ten.tea.2012.0129]
   Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007
   Bobick Brent E., 2008, Birth Defects Research, V84, P131, DOI 10.1002/bdrc.20126
   Brown KK, 2008, J INFLAMM LOND, V5, DOI 10.1186/1476 9255 5 22
   Capone ML, 2007, J PHARMACOL EXP THER, V322, P453, DOI 10.1124/jpet.107.122283
   Celotti F, 2003, PROSTAG OTH LIPID M, V71, P147, DOI 10.1016/S1098 8823(03)00039 X
   Chen SH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2926
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Ding L, 2010, OSTEOARTHR CARTILAGE, V18, P1509, DOI 10.1016/j.joca.2010.08.014
   Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161
   Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200
   Gaudreault E, 2009, J IMMUNOL, V183, P2650, DOI 10.4049/jimmunol.0804135
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   KONSTAN MW, 1990, AM REV RESPIR DIS, V141, P186, DOI 10.1164/ajrccm/141.1.186
   Kudo C, 2003, BIOCHEM PHARMACOL, V66, P289, DOI 10.1016/S0006 2952(03)00235 1
   Lee SJ, 2010, TOXICOL APPL PHARM, V242, P191, DOI 10.1016/j.taap.2009.10.007
   Litwic A, 2013, BRIT MED BULL, V105, P185, DOI 10.1093/bmb/lds038
   Loeser RF, 2008, CURR OPIN RHEUMATOL, V20, P581, DOI 10.1097/BOR.0b013e3283090463
   Lützner J, 2009, NAT REV RHEUMATOL, V5, P309, DOI 10.1038/nrrheum.2009.88
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Maier TJ, 2008, BIOCHEM PHARMACOL, V76, P862, DOI 10.1016/j.bcp.2008.07.009
   Malemud CJ, 2004, CLIN ORTHOP RELAT R, pS145, DOI 10.1097/01.blo.0000143802.41885.50
   Markworth JF, 2013, AM J PHYSIOL REG I, V305, pR1281, DOI 10.1152/ajpregu.00128.2013
   Martel Pelletier J, 2004, ARTHRITIS RHEUM US, V50, P3925, DOI 10.1002/art.20632
   Mobasheri A, 2009, HISTOL HISTOPATHOL, V24, P347, DOI 10.14670/HH 24.347
   Mwale F, 2006, BIOMATERIALS, V27, P2258, DOI 10.1016/j.biomaterials.2005.11.006
   Mwale F, 2006, TISSUE ENG, V12, P2639, DOI 10.1089/ten.2006.12.2639
   Mwale F, 2006, J ORTHOP RES, V24, P1791, DOI 10.1002/jor.20200
   Mwale F, 2010, TISSUE ENG PT A, V16, P3449, DOI [10.1089/ten.tea.2010.0091, 10.1089/ten.TEA.2010.0091]
   Nelea V, 2005, J BIOMED MATER RES A, V75A, P216, DOI 10.1002/jbm.a.30402
   Pelletier JP, 2003, ARTHRITIS RHEUM US, V48, P1582, DOI 10.1002/art.11014
   Pelletier JP, 1999, OSTEOARTHR CARTILAGE, V7, P374, DOI 10.1053/joca.1998.0215
   Pelletier JP, 2001, J RHEUMATOL, V28, P2509
   Qi YY, 2012, MOL BIOL REP, V39, P5683, DOI 10.1007/s11033 011 1376 z
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Raynauld JP, 2009, ANN RHEUM DIS, V68, P938, DOI 10.1136/ard.2008.088732
   Raynauld JP, 2011, ANN RHEUM DIS, V70, P1382, DOI 10.1136/ard.2010.146407
   SEVELIUS H, 1980, BRIT J CLIN PHARMACO, V10, P259, DOI 10.1111/j.1365 2125.1980.tb01753.x
   Shen G, 2005, Orthod Craniofac Res, V8, P11, DOI 10.1111/j.1601 6343.2004.00308.x
   Steinhilber D, 2014, BASIC CLIN PHARMACOL, V114, P70, DOI 10.1111/bcpt.12114
   Suri P, 2012, PM&R, V4, pS10, DOI 10.1016/j.pmrj.2012.01.007
   Tchetina E, 2003, J BONE MINER RES, V18, P844, DOI 10.1359/jbmr.2003.18.5.844
   Tsatsanis C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI 10.1016/j.biocel.2006.03.021
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Ulbrich H, 2005, BIOCHEM PHARMACOL, V70, P30, DOI 10.1016/j.bcp.2005.03.031
   VANDERHOEK JY, 1984, J BIOL CHEM, V259, P6752
   VONDERMARK K, 1992, ARTHRITIS RHEUM US, V35, P806, DOI 10.1002/art.1780350715
   Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089
NR 48
TC 9
Z9 10
U1 1
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JAN 1
PY 2015
VL 21
IS 1 2
BP 234
EP 245
DI 10.1089/ten.tea.2014.0148
PG 12
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA CA1YQ
UT WOS:000348706100005
PM 25091567
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhao, YH
   Gibb, SL
   Zhao, J
   Moore, AN
   Hylin, MJ
   Menge, T
   Xue, HS
   Baimukanova, G
   Potter, D
   Johnson, EM
   Holcomb, JB
   Cox, CS
   Dash, PK
   Pati, S
AF Zhao, Yuhai
   Gibb, Stuart L.
   Zhao, Jing
   Moore, Anthony N.
   Hylin, Michael J.
   Menge, Tyler
   Xue, Hasen
   Baimukanova, Gyulnar
   Potter, Daniel
   Johnson, Evan M.
   Holcomb, John B.
   Cox, Charles S., Jr.
   Dash, Pramod K.
   Pati, Shibani
TI Wnt3a, a Protein Secreted by Mesenchymal Stem Cells Is Neuroprotective
   and Promotes Neurocognitive Recovery Following Traumatic Brain Injury
SO STEM CELLS
LA English
DT Article
DE Mesenchymal stem cells; Wnt3a; Traumatic brain injury; Neuroprotection;
   Neurogenesis
ID ADULT HIPPOCAMPAL NEUROGENESIS; PATTERN SEPARATION; DENTATE GYRUS;
   OBJECT RECOGNITION; NEURONS; MICE; TRANSPLANTATION; ACTIVATION; MEMORY;
   TSG 6
AB Intravenous administration of bone marrow derived mesenchymal stem cells (MSCs) has been shown to reduce blood brain barrier compromise and improve neurocognition following traumatic brain injury (TBI). These effects occur in the absence of engraftment and differentiation of these cells in the injured brain. Recent studies have shown that soluble factors produced by MSCs mediate a number of the therapeutic effects. In this study, we sought to determine if intravenous administration of MSCs (IV MSCs) could enhance hippocampal neurogenesis following TBI. Our results demonstrate that IV MSC treatment attenuates loss of neural stem cells and promotes hippocampal neurogenesis in TBI injured mice. As Wnt signaling has been implicated in neurogenesis, we measured circulating Wnt3a levels in serum following IV MSC administration and found a significant increase in Wnt3a. Concurrent with this increase, we detected increased activation of the Wnt/beta catenin signaling pathway in hippocampal neurons. Furthermore, IV recombinant Wnt3a treatment provided neuroprotection, promoted neurogenesis, and improved neurocognitive function in TBI injured mice. Taken together, our results demonstrate a role for Wnt3a in the therapeutic potential of MSCs and identify Wnt3a as a potential stand alone therapy or as part of a combination therapeutic strategy for the treatment of TBI.
C1 [Zhao, Yuhai] Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA USA.
   [Gibb, Stuart L.; Menge, Tyler; Baimukanova, Gyulnar; Potter, Daniel; Dash, Pramod K.] Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
   [Gibb, Stuart L.; Baimukanova, Gyulnar; Potter, Daniel] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Zhao, Jing; Moore, Anthony N.; Hylin, Michael J.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA.
   [Xue, Hasen; Johnson, Evan M.; Holcomb, John B.; Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA.
   [Xue, Hasen; Johnson, Evan M.; Holcomb, John B.; Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA.
   [Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA.
   [Hylin, Michael J.; Pati, Shibani] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Vitalant; Vitalant Research Institute;
   University of California System; University of California San Francisco;
   University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston; University of Texas System; University of Texas Health
   Science Center Houston; University of Texas System; University of Texas
   Health Science Center Houston; Southern Illinois University System;
   Southern Illinois University
RP Pati, S (通讯作者)，Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
EM SPati@bloodsystems.org
RI Dash, Paban/E 9935 2013; Hylin, Michael/U 2878 2019; ZHAO,
   YUHAI/A 1167 2010
OI holcomb, john/0000 0001 8312 9157; Dash, Pramod
   Kumar/0000 0001 6746 1002
FU Blood Systems Research Institute
FX We thank Scott Holmes for graphic work and Dr. Peng, Zhanglong for
   assistance in imaging data analysis. TIRR Foundation Mission Connect and
   intramural grant funding from Blood Systems Research Institute supported
   this work.
CR Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003
   Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014
   Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063
   Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013 0100
   Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205
   Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078
   Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265 10.2011
   Burke SN, 2010, BEHAV NEUROSCI, V124, P559, DOI 10.1037/a0020893
   Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215
   Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822
   Dhamdhere GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083650
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735 7044.112.4.863
   Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677
   Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189
   Goldring CEP, 2011, CELL STEM CELL, V8, P618, DOI 10.1016/j.stem.2011.05.012
   Grigorian AS, 2011, B EXP BIOL MED+, V150, P551, DOI 10.1007/s10517 011 1187 1
   Hylin MJ, 2013, LEARN MEMORY, V20, P267, DOI 10.1101/lm.030197.112
   Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609
   Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72
   Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921
   Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008 0818]
   Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360
   Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111
   Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50
   Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922
   Maltman DJ, 2011, NEUROCHEM INT, V59, P347, DOI 10.1016/j.neuint.2011.06.008
   Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1
   Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660
   Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041
   Oh SH, 2015, CELL TRANSPLANT, V24, P1097, DOI 10.3727/096368914X679237
   Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013
   Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589
   Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042
   Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837
   Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708
   Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817
   Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051
   Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857
   Tfilin M, 2010, MOL PSYCHIATR, V15, P1164, DOI 10.1038/mp.2009.110
   Varela Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100
   Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005
   Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198
   Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017
   Yan YF, 2014, NEURAL REGEN RES, V9, P798, DOI 10.4103/1673 5374.131596
   Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006
   Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629 08.2008
   Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033
NR 50
TC 54
Z9 64
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD MAY
PY 2016
VL 34
IS 5
BP 1263
EP 1272
DI 10.1002/stem.2310
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA DL8MU
UT WOS:000375896900012
PM 26840479
OA Bronze
DA 2025 08 17
ER

PT J
AU Shinji, S
   Umezawa, K
   Nihashi, Y
   Nakamura, S
   Shimosato, T
   Takaya, T
AF Shinji, Sayaka
   Umezawa, Koji
   Nihashi, Yuma
   Nakamura, Shunichi
   Shimosato, Takeshi
   Takaya, Tomohide
TI Identification of the Myogenetic Oligodeoxynucleotides (myoDNs) That
   Promote Differentiation of Skeletal Muscle Myoblasts by Targeting
   Nucleolin
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE oligodeoxynucleotide (ODN); berberine (CID; 12457); nucleolin (NCL);
   skeletal muscle myoblast; myogenic differentiation
ID RIBOSOMAL PROTEIN L26; IN VITRO; TRANSLATIONAL CONTROL;
   CELL PROLIFERATION; GENE EXPRESSION; BACTERIAL DNA; CPG MOTIF; P53;
   ACTIVATION; OSTEOBLASTS
AB Herein we report that the 18 base telomeric oligodeoxynucleotides (ODNs) designed from the Lactobacillus rhamnosus GG genome promote differentiation of skeletal muscle myoblasts which are myogenic precursor cells. We termed these myogenetic ODNs (myoDNs). The activity of one of the myoDNs, iSN04, was independent of Toll like receptors, but dependent on its conformational state. Molecular simulation and iSN04 mutants revealed stacking of the 13 15th guanines as a core structure for iSN04. The alkaloid berberine bound to the guanine stack and enhanced iSN04 activity, probably by stabilizing and optimizing iSN04 conformation. We further identified nucleolin as an iSN04 binding protein. Results showed that iSN04 antagonizes nucleolin, increases the levels of p53 protein translationally suppressed by nucleolin, and eventually induces myotube formation by modulating the expression of genes involved in myogenic differentiation and cell cycle arrest. This study shows that bacterial derived myoDNs serve as aptamers and are potential nucleic acid drugs directly targeting myoblasts.
C1 [Shinji, Sayaka; Nakamura, Shunichi; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, Nagano, Japan.
   [Umezawa, Koji; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Fac Agr, Dept Agr & Life Sci, Nagano, Japan.
   [Umezawa, Koji; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, Nagano, Japan.
   [Nihashi, Yuma; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Grad Sch Med Sci & Technol, Dept Sci & Technol, Nagano, Japan.
C3 Shinshu University; Shinshu University; Shinshu University; Shinshu
   University
RP Takaya, T (通讯作者)，Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, Nagano, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Fac Agr, Dept Agr & Life Sci, Nagano, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, Nagano, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Grad Sch Med Sci & Technol, Dept Sci & Technol, Nagano, Japan.
EM ttakaya@shinshu u.ac.jp
RI Shimosato, Takeshi/ABA 1499 2020; Takaya, Tomohide/D 6372 2012
OI Nihashi, Yuma/0000 0002 5689 116X; Takaya, Tomohide/0000 0002 3610 0906
FU Japan Society for the Promotion of Science [16K19397, 19K05948]; TOBE
   MAKI Scholarship Foundation [17 JA503]; Skylark Food Science Institute;
   Takano Science Foundation; Japan Society for Bioscience, Biotechnology,
   and Agrochemistry; Fund of Nagano Prefecture to Promote Scientific
   Activity [H30 3 3]; Grants in Aid for Scientific Research [16K19397,
   19K05948] Funding Source: KAKEN
FX This study was supported in part by Grants in Aid from the Japan Society
   for the Promotion of Science (16K19397 and 19K05948), the TOBE MAKI
   Scholarship Foundation (17 JA503), the Skylark Food Science Institute,
   the Takano Science Foundation, and the Japan Society for Bioscience,
   Biotechnology, and Agrochemistry to TT, and a Grant in Aid from the Fund
   of Nagano Prefecture to Promote Scientific Activity (H30 3 3) to SS.
CR Amcheslavsky A, 2005, J BONE MINER RES, V20, P1692, DOI 10.1359/JBMR.050515
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140 6736(96)07015 8
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   Barel M, 2001, J IMMUNOL, V166, P3167, DOI 10.4049/jimmunol.166.5.3167
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498
   Bazzicalupi C, 2013, NUCLEIC ACIDS RES, V41, P632, DOI 10.1093/nar/gks1001
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Carrero JJ, 2008, CLIN NUTR, V27, P557, DOI 10.1016/j.clnu.2008.04.007
   Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676
   Chang JH, 2009, BIOCHEM BIOPH RES CO, V389, P28, DOI 10.1016/j.bbrc.2009.08.080
   Chen J, 2012, J BIOL CHEM, V287, P16467, DOI 10.1074/jbc.M112.349274
   Chen QH, 2011, ANAL BIOANAL CHEM, V399, P2877, DOI 10.1007/s00216 011 4651 x
   Cheng Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167094
   Cui W, 2019, TOXICOL APPL PHARM, V378, DOI 10.1016/j.taap.2019.114625
   Dailey MM, 2010, NUCLEIC ACIDS RES, V38, P4877, DOI 10.1093/nar/gkq166
   Dumont NA, 2015, COMPR PHYSIOL, V5, P1027, DOI 10.1002/cphy.c140068
   Fähling M, 2006, J BIOL CHEM, V281, P26089, DOI 10.1074/jbc.M604939200
   Feng ZY, 2011, INT J MOL SCI, V12, P2543, DOI 10.3390/ijms12042543
   Fukada S, 2018, J BIOCHEM, V163, P353, DOI 10.1093/jb/mvy019
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535 7163.MCT 05 0361
   GU W, 1993, CELL, V72, P309, DOI 10.1016/0092 8674(93)90110 C
   Guo YQ, 2015, SPECTROCHIM ACTA A, V136, P1635, DOI 10.1016/j.saa.2014.10.058
   Harford TJ, 2017, APOPTOSIS, V22, P1532, DOI 10.1007/s10495 017 1423 x
   Harford TJ, 2010, APOPTOSIS, V15, P71, DOI 10.1007/s10495 009 0428 5
   Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534 5807(04)00107 8
   Ikebe J, 2011, J COMPUT CHEM, V32, P1286, DOI 10.1002/jcc.21710
   Imenshahidi M, 2019, PHYTOTHER RES, V33, P504, DOI 10.1002/ptr.6252
   Jia WY, 2017, LIFE SCI, V186, P1, DOI 10.1016/j.lfs.2017.07.025
   Juliano RL, 2018, NUCLEIC ACID THER, V28, P166, DOI 10.1089/nat.2018.0727
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kim M, 2015, INT J MOL MED, V35, P755, DOI 10.3892/ijmm.2014.2046
   Klinman D, 2008, J LEUKOCYTE BIOL, V84, P958, DOI 10.1189/jlb.1107775
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Li N, 2012, J CHROMATOGR SCI, V50, P885, DOI 10.1093/chromsci/bms086
   Litchfield LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038278
   Losfeld ME, 2009, EXP CELL RES, V315, P357, DOI 10.1016/j.yexcr.2008.10.039
   Macke TJ, 1998, ACS SYM SER, V682, P379
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Marchildon F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145583
   McCormick R, 2018, BIOGERONTOLOGY, V19, P519, DOI 10.1007/s10522 018 9775 3
   Nigar S, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865 017 0227 7
   Nihashi Y, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52946 4
   Nihashi Y, 2019, DEV COMP IMMUNOL, V91, P115, DOI 10.1016/j.dci.2018.10.013
   Norgaard NN, 2010, J IMMUNOL, V185, P3131, DOI 10.4049/jimmunol.0903605
   Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441
   Ou TM, 2008, CHEMMEDCHEM, V3, P690, DOI 10.1002/cmdc.200700300
   Pohar J, 2015, J IMMUNOL, V195, P4396, DOI 10.4049/jimmunol.1500600
   Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295
   Quemener AM, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1594
   Ramos KS, 2020, J CANCER, V11, P733, DOI 10.7150/jca.37776
   Reyes Reyes EM, 2015, MOL ONCOL, V9, P1392, DOI 10.1016/j.molonc.2015.03.012
   Rubin H, 2003, P NATL ACAD SCI USA, V100, P5384, DOI 10.1073/pnas.0931260100
   Ruijtenberg S, 2016, CELL CYCLE, V15, P196, DOI 10.1080/15384101.2015.1120925
   Sackesen C, 2013, ALLERGY, V68, P593, DOI 10.1111/all.12133
   Shaltouki A, 2007, APOPTOSIS, V12, P2143, DOI 10.1007/s10495 007 0135 z
   Shen YQ, 2012, INT J MOL SCI, V13, P2877, DOI 10.3390/ijms13032877
   Shinji S., 2020, IDENTIFICATION MYOGE, DOI [10.1101/2020.10.07.330472, DOI 10.1101/2020.10.07.330472]
   Shinji S, 2020, BIOSCI BIOTECH BIOCH, V84, P63, DOI 10.1080/09168451.2019.1659714
   Siddiqui Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034
   Takaya T, 2017, ANIM SCI J, V88, P1880, DOI 10.1111/asj.12884
   Tang ZX, 2017, J CELL BIOCHEM, V118, P4285, DOI 10.1002/jcb.26079
   Teng Y, 2007, CANCER RES, V67, P10491, DOI 10.1158/0008 5472.CAN 06 4206
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097 0282(2000)56:4<275::AID BIP10024>3.0.CO;2 E
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   Wang H, 2015, DIABETES, V64, P2442, DOI 10.2337/db14 0528
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang T, 2019, BIOTECHNOL ADV, V37, P28, DOI 10.1016/j.biotechadv.2018.11.001
   Wang YQ, 2015, MOL THER, V23, P297, DOI 10.1038/mt.2014.239
   Yamamoto Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01049
   Yang GA, 2010, IMMUNOLOGY, V131, P501, DOI 10.1111/j.1365 2567.2010.03322.x
   Yazdian Robati R, 2020, INT J BIOL MACROMOL, V155, P1420, DOI 10.1016/j.ijbiomac.2019.11.118
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e
   Zhang LP, 2010, J AM SOC NEPHROL, V21, P419, DOI 10.1681/ASN.2009060571
   Zou W, 2003, J BIOL CHEM, V278, P16732, DOI 10.1074/jbc.M212473200
NR 82
TC 12
Z9 12
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JAN 11
PY 2021
VL 8
AR 616706
DI 10.3389/fcell.2020.616706
PG 16
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA PW9WO
UT WOS:000611017900001
PM 33585451
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Nakamura, K
   Koide, M
   Kobayashi, Y
   Yamashita, T
   Matsushita, M
   Yasuda, H
   Ishihara, Y
   Yoshinari, N
   Udagawa, N
AF Nakamura, Keigo
   Koide, Masanori
   Kobayashi, Yasuhiro
   Yamashita, Teruhito
   Matsushita, Mai
   Yasuda, Hisataka
   Ishihara, Yuichi
   Yoshinari, Nobuo
   Udagawa, Nobuyuki
TI Sclerostin deficiency effectively promotes bone morphogenetic
   protein 2 induced ectopic bone formation
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE BMP 2; ectopic bone; osteocyte; osterix; sclerostin
ID ANTIBODY; WNT; SOST; MASS; PROTEIN; GENE; DKK1; REGENERATION;
   ROMOSOZUMAB; OSTEOBLASTS
AB Background and ObjectiveSevere periodontitis causes alveolar bone resorption, resulting in tooth loss. Developments of tissue regeneration therapy that can restore alveolar bone mass are desired for periodontal disease. The application of bone morphogenetic protein 2 (BMP 2) has been attempted for bone fractures and severe alveolar bone loss. BMP 2 reportedly induces sclerostin expression, an inhibitor of Wnt signals, that attenuates bone acquisition. However, the effect of sclerostin deficiency on BMP 2 induced bone regeneration has not been fully elucidated. We investigated BMP 2 induced ectopic bones in Sost knockout (KO) mice. MethodsrhBMP 2 were implanted into the thighs of C57BL/6 (WT) and Sost KO male mice at 8 weeks of age. The BMP 2 induced ectopic bones in these mice were examined on days 14 and 28 after implantation. ResultsImmunohistochemical and quantitative RT PCR analyses showed that BMP 2 induced ectopic bones expressed sclerostin in osteocytes on days 14 and 28 after implantation in Sost Green reporter mice. Micro computed tomography analysis revealed that BMP 2 induced ectopic bones in Sost KO mice showed a significant increased relative bone volume and bone mineral density (WT = 468 mg/cm(3), Sost KO = 602 mg/cm(3)) compared with those in WT mice on day 14 after implantation. BMP 2 induced ectopic bones in Sost KO mice showed an increased horizontal cross sectional bone area on day 28 after implantation. Immunohistochemical staining showed that BMP 2 induced ectopic bones in Sost KO mice had an increased number of osteoblasts with osterix positive nuclei compared with those in WT mice on days 14 and 28 after implantation. ConclusionSclerostin deficiency increased bone mineral density in BMP 2 induced ectopic bones.
C1 [Nakamura, Keigo; Yoshinari, Nobuo] Matsumoto Dent Univ, Dept Operat Dent Endodontol & Periodontol, Shiojiri, Nagano, Japan.
   [Koide, Masanori; Kobayashi, Yasuhiro; Yamashita, Teruhito; Matsushita, Mai; Udagawa, Nobuyuki] Matsumoto Dent Univ, Inst Oral Sci, Div Hard Tissue Res, Shiojiri, Nagano, Japan.
   [Yasuda, Hisataka] Oriental Yeast Co Ltd, Bioind Div, Tokyo, Japan.
   [Ishihara, Yuichi] Lion Fdn Dent Hlth, Tokyo, Japan.
   [Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Shiojiri, Nagano, Japan.
   [Koide, Masanori] Matsumoto Dent Univ, Inst Oral Sci, Div Hard Tissue Res, 1780 Gobara,Hiro Oka, Shiojiri, Nagano 3990781, Japan.
C3 Matsumoto Dental University; Matsumoto Dental University; Oriental Yeast
   Co., Ltd.; Lion Corporation; Matsumoto Dental University; Matsumoto
   Dental University
RP Koide, M (通讯作者)，Matsumoto Dent Univ, Inst Oral Sci, Div Hard Tissue Res, 1780 Gobara,Hiro Oka, Shiojiri, Nagano 3990781, Japan.
EM masanori.koide@mdu.ac.jp
RI ; Yoshinari, Nobuo/AAI 4494 2020; Koide, Masanori/ABE 9670 2020
OI Ishihara, Yuichi/0009 0000 6896 9676; Koide,
   Masanori/0000 0002 6511 9999; 
FU JSPS KAKENHI [JP22K19638, JP21H03125, JP22K18402, JP20K21689]; JSPS
   KAKENHI; Grants in Aid for Scientific Research [23K21488, 22K10282,
   22K18402, 22K19638, 21K09863] Funding Source: KAKEN
FX Grant numbers JP22K19638 (MK), JP21H03125 (NU), JP22K18402 (YK), and
   JP20K21689 (NU); JSPS KAKENHI
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bordukalo Niksic T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.869422
   Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130
   Broers DLM, 2022, INT DENT J, V72, P52, DOI 10.1016/j.identj.2021.01.011
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Chen H, 2015, BONE, V76, P141, DOI 10.1016/j.bone.2015.04.002
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Garrett S, 1996, Ann Periodontol, V1, P621, DOI 10.1902/annals.1996.1.1.621
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Hajishengallis G, 2021, PERIODONTOL 2000, V86, P210, DOI 10.1111/prd.12371
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Jäger A, 2010, J PERIODONTAL RES, V45, P246, DOI 10.1111/j.1600 0765.2009.01227.x
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kim HKW, 2013, BONE, V54, P141, DOI 10.1016/j.bone.2013.01.031
   Kim J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19155 4
   Kitamura M, 2016, J BONE MINER RES, V31, P806, DOI 10.1002/jbmr.2738
   Koide M, 2022, BONE, V160, DOI 10.1016/j.bone.2022.116401
   Koide M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70817 1
   Kucher U, 2014, INT J ORAL SCI, V6, P70, DOI 10.1038/ijos.2014.12
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li FF, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44368 z
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Liu M, 2018, J DENT RES, V97, P1031, DOI 10.1177/0022034518766874
   Maurel DB, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0037 4
   Morse A, 2017, CALCIFIED TISSUE INT, V101, P217, DOI 10.1007/s00223 017 0275 2
   Mosey H, 2017, FRONT MATER, V4, DOI 10.3389/fmats.2017.00027
   Nelson AL, 2022, J TISSUE ENG REGEN M, V16, P961, DOI 10.1002/term.3349
   NYMAN S, 1982, J CLIN PERIODONTOL, V9, P290, DOI 10.1111/j.1600 051X.1982.tb02095.x
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ozden FO, 2022, J PERIODONTAL RES, V57, P849, DOI 10.1111/jre.13023
   Qin WP, 2015, J BONE MINER RES, V30, P1994, DOI 10.1002/jbmr.2549
   REDDI AH, 1981, COLLAGEN REL RES, V1, P209
   Reynolds Mark A, 2010, Dent Clin North Am, V54, P55, DOI 10.1016/j.cden.2009.09.003
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Tan JL, 2019, ACS NANO, V13, P5616, DOI 10.1021/acsnano.9b00788
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   URIST MR, 1984, P NATL ACAD SCI BIOL, V81, P371, DOI 10.1073/pnas.81.2.371
   van Bezooijen RL, 2007, DEV DYNAM, V236, P606, DOI 10.1002/dvdy.21054
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
   Yao Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73026 y
NR 52
TC 6
Z9 6
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD AUG
PY 2023
VL 58
IS 4
BP 769
EP 779
DI 10.1111/jre.13134
EA MAY 2023
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA L0KJ7
UT WOS:000982829200001
PM 37154419
DA 2025 08 17
ER

PT J
AU Bolomsky, A
   Schlangen, K
   Schreiner, W
   Zojer, N
   Ludwig, H
AF Bolomsky, Arnold
   Schlangen, Karin
   Schreiner, Wolfgang
   Zojer, Niklas
   Ludwig, Heinz
TI Targeting of BMI 1 with PTC 209 shows potent anti myeloma activity and
   impairs the tumour microenvironment
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Multiple myeloma; BMI 1; PTC 209; Microenvironment
ID BONE MARROW MICROENVIRONMENT; POOR PROGNOSIS; MOLECULAR MARKER; SIDE
   POPULATION; PROTEIN BMI 1; EXPRESSION; CELLS; INHIBITOR; NOXA; WNT
AB Background: The polycomb complex protein BMI 1 (BMI 1) is a putative oncogene reported to be overexpressed in multiple myeloma (MM). Silencing of BMI 1 was shown to impair the growth and survival of MM cells. However, therapeutic agents specifically targeting BMI 1 were not available so far. Here, we investigated PTC 209, a novel small molecule inhibitor of BMI 1, for its activity in MM.
   Methods: BMI 1 expression was analysed in human MM cell lines and primary MM cells by using publically available gene expression profiling (GEP) data. The anti MM activity of PTC 209 was investigated by viability testing, cell cycle analysis, annexin V and 7 AAD staining, quantification of cleaved poly(ADP ribose) polymerase (PARP), JC 1 as well as colony formation assays. Deregulation of central myeloma growth and survival genes was studied by quantitative PCR and flow cytometry, respectively. In addition, the impact of PTC 209 on in vitro osteoclast, osteoblast and tube formation was analysed.
   Results: We confirmed overexpression of BMI 1 in MM patients by using publically available GEP datasets. Of note, BMI 1 expression was further increased at relapse which translated into significantly shorter overall survival in relapsed/refractory patients treated with bortezomib or dexamethasone.
   Treatment with PTC 209 significantly decreased viable cell numbers in human MM cell lines, induced a G1 cell cycle arrest, promoted apoptosis and demonstrated synergistic activity with pomalidomide and carfilzomib. The anti MM activity of PTC 209 was accompanied by a significant decrease of cyclin D1 (CCND1) and v myc avian myelocytomatosis viral oncogene homolog (MYC) expression as well as upregulation of cyclin dependent kinase inhibitor 1A (CDKN1A) and cyclin dependent kinase inhibitor 1B (CDKN1B). We also observed upregulation of NOXA (up to 3.6 +/  1.2 fold induction, P = 0.009) and subsequent downregulation of myeloid cell leukemia 1 (MCL 1) protein levels, which likely mediates the apoptotic effects of PTC 209. Importantly, the anti MM activity was upheld in the presence of stromal support or myeloma growth factors insulin like growth factor 1 (IGF 1) and interleukin 6 (IL 6).
   In the MM microenvironment, PTC 209 impaired tube formation, impaired osteoclast development and decreased osteoblast formation in a dose dependent manner (P < 0.01 at 1 mu M, respectively). The latter might be attributed to an induction of DKK1 and was reversed by concurrent anti DKK1 antibody treatment.
   Conclusions: We confirmed overexpression of BMI 1 in MM highlighting its role as an attractive drug target and reveal therapeutic targeting of BMI 1 by PTC 209 as a promising novel therapeutic intervention for MM.
C1 [Bolomsky, Arnold; Zojer, Niklas; Ludwig, Heinz] Wilhelminenspital Stadt Wien, Dept Med 1, Wilhelminen Canc Res Inst, Montleartstr 37, A 1160 Vienna, Austria.
   [Schlangen, Karin; Schreiner, Wolfgang] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Wilhelminenspital; Medical University of Vienna
RP Ludwig, H (通讯作者)，Wilhelminenspital Stadt Wien, Dept Med 1, Wilhelminen Canc Res Inst, Montleartstr 37, A 1160 Vienna, Austria.
EM heinz.ludwig@wienkav.at
OI , Arnold/0000 0002 1585 5429
FU Austrian Forum against Cancer
FX This study was supported by the Austrian Forum against Cancer. The
   authors would like to thank Lisa Holzer and Waltraud Scherbler for
   excellent technical assistance.
CR Aikawa T, 2010, FEBS LETT, V584, P681, DOI 10.1016/j.febslet.2010.01.026
   Bjorklund CC, 2011, J BIOL CHEM, V286, P11009, DOI 10.1074/jbc.M110.180208
   Bolomsky A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 014 0105 1
   Bolomsky A, 2014, EXP HEMATOL, V42, P516, DOI 10.1016/j.exphem.2014.03.005
   BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0
   Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0224 3
   Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Chen F, 2015, ANTICANCER AGENTS ME
   Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008 5472.CAN 07 5882
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Chowdhury M, 2007, LEUKEMIA, V21, P1116, DOI 10.1038/sj.leu.2404623
   De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868
   Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 10
   Han J, 2007, J BIOL CHEM, V282, P16223, DOI 10.1074/jbc.M611186200
   HAUPT Y, 1993, ONCOGENE, V8, P3161
   HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092 8674(91)90383 A
   Hernández Muñoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047 11058.2005
   Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760
   Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008 5472.CAN 09 4229
   Jiang LL, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 406
   Jiang L, 2013, GENOME ANNOUNCEMENTS, V1, DOI 10.1128/genomeA.00308 13
   Kang MK, 2007, BRIT J CANCER, V96, P126, DOI 10.1038/sj.bjc.6603529
   Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233
   Kim K, 2010, BRIT J HAEMATOL, V149, P537, DOI 10.1111/j.1365 2141.2010.08127.x
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Mathur R, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0161 1
   Mayr C, 2016, ONCOTARGET, V7, P745, DOI 10.18632/oncotarget.6378
   Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood 2005 06 2393
   Mourgues L, 2015, LEUKEMIA, V29, P1993, DOI 10.1038/leu.2015.112
   Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood 2006 09 044974
   Nishida Y, 2015, CANCER SCI, V106, P1705, DOI 10.1111/cas.12833
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008 5472.CAN 06 0094
   Spencer A, 2014, BLOOD, V124, P2190, DOI 10.1182/blood 2014 03 559963
   Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood 2011 12 396853
   Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808
   Teshima K, 2014, ONCOGENE, V33, P2191, DOI 10.1038/onc.2013.177
   Tong YQ, 2012, ASIA PAC J CLIN ONCO, V8, pE55, DOI 10.1111/j.1743 7563.2012.01564.x
   Wang H, 2008, J CANCER RES CLIN, V134, P535, DOI 10.1007/s00432 007 0316 8
   Wang Y, 2012, MOL VIS, V18, P803
   Wu SQ, 2014, INT J MOL MED, V34, P616, DOI 10.3892/ijmm.2014.1798
   Wu ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014648
   Xie CF, 2015, SCI REP UK, V5, DOI 10.1038/srep13975
   Xu CR, 2009, MOL CANCER RES, V7, P1937, DOI 10.1158/1541 7786.MCR 09 0333
   Yadirgi G, 2011, STEM CELLS, V29, P700, DOI 10.1002/stem.614
   Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000
   Yang DD, 2011, CELL BIOCHEM BIOPHYS, V61, P703, DOI 10.1007/s12013 011 9229 x
   Yao H, 2011, Blood Cancer J, V1, pe43, DOI 10.1038/bcj.2011.41
   Yuan J, 2011, LEUKEMIA, V25, P1335, DOI 10.1038/leu.2011.85
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zheng XY, 2014, NUCLEIC ACID THER, V24, P210, DOI 10.1089/nat.2013.0459
NR 54
TC 43
Z9 46
U1 1
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756 8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD MAR 2
PY 2016
VL 9
AR 17
DI 10.1186/s13045 016 0247 4
PG 13
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA DF1VC
UT WOS:000371126300002
PM 26935956
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Prié, D
   Torres, PU
   Friedlander, G
AF Prie, D.
   Torres, P. U.
   Friedlander, G.
TI Fibroblast growth factor 23 Klotho: A new axis of phosphate balance
   control
SO MEDECINE NUCLEAIRE IMAGERIE FONCTIONNELLE ET METABOLIQUE
LA English
DT Article
DE Fibroblast growth factor; Klotho; Phosphate; Calcitriol; Kidney
ID HOMOZYGOUS MISSENSE MUTATION; CHRONIC KIDNEY DISEASE; KLOTHO GENE;
   HYPOPHOSPHATEMIC RICKETS; 1 ALPHA,25 DIHYDROXYVITAMIN D 3; ONCOGENIC
   OSTEOMALACIA; PARATHYROID HORMONE; TUMORAL CALCINOSIS; FUNCTIONAL
   VARIANT; CALCITRIOL THERAPY
AB The kidney is a key player of phosphate balance, it determines serum phosphate levels by Coupling phosphate reabsorption in the renal proximal tubule, calcitriol synthesis and consequently intestinal phosphate absorption. The identification of fibroblast growth factor 23 (FGF23) as a hormone regulating phosphate and calcitriol metabolism has unveiled the mechanisms that coordinate these renal proximal tubule functions. A bone kidney axis has emerged that controls bone mineralization. Animal model studies have improved our understanding of phosphate homeostasis and revealed the role of the protein Klotho, which is mandatory to FGF23 action. In this review we detail FGF23 and Klotho implications in physiology and in genetic or acquired disorders. Phosphate ion is involved in vascular and soft tissue calcification and is important for cell proliferation. Disorders of FGF23 Klotho axis alter life span and the survival in some cancers. (c) 2008 Elsevier Masson SAS. All rights reserved.
C1 [Prie, D.] Hop Necker Enfants Malad, AP HP, Serv Explorat Fonct, F 75743 Paris 15, France.
   [Prie, D.; Friedlander, G.] Univ Paris 05, Fac Med, INSERM, Ctr Rech Croissance & Signalisat,U845, Paris, France.
   [Torres, P. U.] Clin Landy, Serv Nephrol & Dialyse, St Ouen, France.
   [Friedlander, G.] Hop Europeen Georges Pompidou, AP HP, Serv Physiol & Radio Isotopes, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Europeen Georges Pompidou   APHP
RP Prié, D (通讯作者)，Hop Necker Enfants Malad, AP HP, Serv Explorat Fonct, Batiment Sevres 8E Etage,149 Rue Sevres, F 75743 Paris 15, France.
EM dominique.prie@inserm.fr
RI Torres, Pablo/LBH 6671 2024
CR Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006 0021
   Araya K, 2005, J CLIN ENDOCR METAB, V90, P5523, DOI 10.1210/jc.2005 0301
   Arking DE, 2005, CIRC RES, V96, P412, DOI 10.1161/01.RES.0000157171.04054.30
   Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035
   Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299
   Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004 0233
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Beret Pagès A, 2004, BONE, V35, P455, DOI 10.1016/j.bone.2004.04.002
   Berndt TJ, 2007, PFLUG ARCH EUR J PHY, V454, P615, DOI 10.1007/s00424 007 0231 5
   Bhan I, 2006, KIDNEY INT, V70, P1486, DOI 10.1038/sj.ki.5001788
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245
   Chefetz I, 2005, HUM GENET, V118, P261, DOI 10.1007/s00439 005 0026 8
   Dupond JL, 2005, REV MED INTERNE, V26, P238, DOI 10.1016/j.revmed.2004.11.013
   Dupond JL, 2005, BONE, V36, P375, DOI 10.1016/j.bone.2005.01.001
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004 1039
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   Frishberg Y, 2007, J BONE MINER RES, V22, P235, DOI 10.1359/JBMR.061105
   Garringer HJ, 2006, J CLIN ENDOCR METAB, V91, P4037, DOI 10.1210/jc.2006 0305
   Gupta A, 2004, J CLIN ENDOCR METAB, V89, P4489, DOI 10.1210/jc.2004 0724
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Ichikawa S, 2005, J CLIN ENDOCR METAB, V90, P2420, DOI 10.1210/jc.2004 2302
   ICHIKAWA S, 2007, J CLIN ENDOCRINOL ME
   ICHIKAWA S, 2005, J CLIN ENDOCRINOL ME
   Ichikawa S, 2007, J CLIN INVEST, V117, P2684, DOI 10.1172/JCI31330
   Inoue Y, 2005, BIOCHEM J, V390, P325, DOI 10.1042/BJ20041799
   Kawano KI, 2002, J BONE MINER RES, V17, P1744, DOI 10.1359/jbmr.2002.17.10.1744
   Kazama JJ, 2005, KIDNEY INT, V67, P1120, DOI 10.1111/j.1523 1755.2005.00178.x
   Koh N, 2001, BIOCHEM BIOPH RES CO, V280, P1015, DOI 10.1006/bbrc.2000.4226
   Kolek OI, 2005, AM J PHYSIOL GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Krajisnik T, 2007, J ENDOCRINOL, V195, P125, DOI 10.1677/JOE 07 0267
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004 2238
   Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003 1768
   Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523 1755.2003.00328.x
   Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91
   Liu S., 2008, J Am Soc Nephrol
   Liu SG, 2006, J AM SOC NEPHROL, V17, P1305, DOI 10.1681/ASN.2005111185
   Liu X, 2006, DRUG METAB REV, V38, P49
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   Lu L, 2008, CANCER INVEST, V26, P185, DOI 10.1080/07357900701638343
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Nagano N, 2006, KIDNEY INT, V69, P531, DOI 10.1038/sj.ki.5000020
   Nakanishi S, 2005, KIDNEY INT, V67, P1171, DOI 10.1111/j.1523 1755.2005.00184.x
   Nishi H, 2005, NEPHRON CLIN PRACT, V101, pC94, DOI 10.1159/000086347
   Ogata N, 2002, BONE, V31, P37, DOI 10.1016/S8756 3282(02)00786 X
   Prié D, 2005, CURR OPIN NEPHROL HY, V14, P318, DOI 10.1097/01.mnh.0000172716.41853.1e
   Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05 5432fje
   Riancho JA, 2007, BIOGERONTOLOGY, V8, P121, DOI 10.1007/s10522 006 9039 5
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200
   Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200
   Seufert J, 2001, NEW ENGL J MED, V345, P1883, DOI 10.1056/NEJMoa010839
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Sitara D, 2006, AM J PATHOL, V169, P2161, DOI 10.2353/ajpath.2006.060329
   Stubbs JR, 2007, J AM SOC NEPHROL, V18, P2116, DOI 10.1681/ASN.2006121385
   Takeuchi Y, 2004, J CLIN ENDOCR METAB, V89, P3979, DOI 10.1210/jc.2004 0406
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
   Torres PU, 2008, KIDNEY INT, V73, P102, DOI 10.1038/sj.ki.5002622
   Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003 0048
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Ward LM, 2004, BONE, V34, P905, DOI 10.1016/j.bone.2003.12.025
   Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227
   White KE, 2005, AM J HUM GENET, V76, P361, DOI 10.1086/427956
   White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497
   White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664
   Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
   Yamazaki Y, 2008, J BONE MINER RES, V23, P1509, DOI 10.1359/JBMR.080417
NR 78
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0928 1258
EI 1878 6820
J9 MED NUCL
JI Med. Nucl. Imag. Fonct. Metab.
PD JAN
PY 2009
VL 33
IS 1
BP 62
EP 67
DI 10.1016/j.mednuc.2008.10.008
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 407EG
UT WOS:000263345800010
DA 2025 08 17
ER

PT J
AU An, HQ
   Chu, C
   Zhang, Z
   Zhang, YH
   Wei, R
   Wang, B
   Xu, K
   Li, LH
   Liu, YL
   Li, G
   Li, X
AF An, Hongqiang
   Chu, Chu
   Zhang, Zhen
   Zhang, Yunhong
   Wei, Ran
   Wang, Bin
   Xu, Ke
   Li, Lihua
   Liu, Yonglin
   Li, Gang
   Li, Xia
TI Hyperoside alleviates postmenopausal osteoporosis via regulating
   miR 19a 5p/IL 17A axis
SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
DE Hyperoside; IL 17A; miRNA 19a 5p; postmenopausal osteoporosis
ID DEFICIENCY; RECEPTOR; CELLS
AB ProblemPostmenopausal osteoporosis (PMO) is a common osteoporosis. Hyperoside (Hyp), a natural flavonoid compound, has anti osteoporotic effects, but the underlying mechanisms remain poorly understood. Inflammatory cytokine IL 17A is upregulated in PMO and plays vital roles in bone loss, but the upstream regulatory factors and mechanisms are still unknown. Method of studyTwenty PMO patients and 20 healthy control subjects were included to analyze IL 17A expression changes and screen dys regulated miRNAs in the peripheral blood of PMO patients. miR 19a 5p mimics and inhibitor were transfected into RAW264.7 osteoclasts, and injected into bilateral ovariectomized (OVX) mice to explore the regulatory effect of miR 19a 5p on IL 17A. OVX mice were randomly grouped and treated with different doses of Hyp to uncover the effective targets for the medicine in PMO disease. ResultsMiR 19a 5p was downregulated in PMO patients and the expression level was negatively correlated with that of IL 17A. miR 19a 5p could directly bind to the 3 ' UTR of IL 17A and regulate its expression. Both in vitro and in vivo studies demonstrated that miR 19a 5p mimics decreased the expression of IL 17A, RANK and Cathepsin K, while miR 19a 5p inhibitor significantly increased the expression of IL 17A, RANK, and Cathepsin K. Importantly, the Hyp could improve bone structure of OVX mice by enhancing miR 19a 5p mediated IL 17A downregulation. ConclusionOverall, these data demonstrated that miR 19a 5p/IL 17A axis might serve as novel therapeutic candidate for PMO. Hyp could relieve bone resorption by targeting the miR 19a 5p/IL 17A axis in OVX mice and exhibited prospective for the treatment of PMO.
C1 [An, Hongqiang; Chu, Chu; Zhang, Zhen; Zhang, Yunhong; Wei, Ran; Xu, Ke; Li, Lihua; Liu, Yonglin; Li, Xia] Shandong Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, Jinan, Peoples R China.
   [An, Hongqiang; Wang, Bin; Li, Gang] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan, Peoples R China.
   [An, Hongqiang] Peoples Hosp Xintai, Tai An, Peoples R China.
   [Zhang, Zhen; Wei, Ran; Xu, Ke; Li, Lihua] Shandong First Med Univ & Shandong Acad Med Sci, Sch Clin & Basic Med Sci, Jinan, Peoples R China.
   [Li, Gang] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan 250014, Peoples R China.
   [Li, Xia] Shandong Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, Jinan 250355, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong University of Traditional
   Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan 250014, Peoples R China.; Li, X (通讯作者)，Shandong Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, Jinan 250355, Peoples R China.
EM doctorlee808@163.com; 60230033@sdutcm.edu.cn
RI Xu, Ke/I 6079 2018; Zhang, Yun Hong/I 5155 2019
FU Natural Science Foundation of China [82274575, 81873337]; Natural
   Science Foundation of Shandong Province [ZR2019MH039, ZR2020KH012];
   Shandong Province key RD Plan [2021CXGC010501]; Central Government
   Guides Local Science and Technology Development Fund Projects of
   Shandong Province [YDZX20203700001407]; Research Leader Studio Project
   of Jinan Science and Technology Bureau [2020GXRC050]; Taishan Scholars
   [Tsqn201812125]
FX the Natural Science Foundation of China, Grant/Award Numbers: 82274575,
   81873337; Natural Science Foundation of Shandong Province, Grant/Award
   Numbers: ZR2019MH039, ZR2020KH012; Shandong Province key R&D Plan,
   Grant/Award Number: 2021CXGC010501; Central Government Guides Local
   Science and Technology Development Fund Projects of Shandong Province,
   Grant/Award Number: YDZX20203700001407; Research Leader Studio Project
   of Jinan Science and Technology Bureau, Grant/Award Number: 2020GXRC050;
   Taishan Scholars, Grant/Award Number: Tsqn201812125
CR Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Chen Y., 2016, EUR J IMMUNOL, V46, P1162
   Chen YQ, 2018, BIOMED PHARMACOTHER, V107, P1175, DOI 10.1016/j.biopha.2018.08.069
   DeSelm CJ, 2012, J CELL BIOCHEM, V113, P2895, DOI 10.1002/jcb.24165
   Fan HH, 2017, INT IMMUNOPHARMACOL, V50, P14, DOI 10.1016/j.intimp.2017.06.004
   Fang H, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23016
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao Y, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105561
   He YH, 2021, CLIN INTERV AGING, V16, P1357, DOI 10.2147/CIA.S289613
   Hensley AP, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115760
   Jia XB, 2020, ONCOTARGETS THER, V13, P6987, DOI 10.2147/OTT.S261033
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Li R, 2021, J PHARMACOL SCI, V145, P69, DOI 10.1016/j.jphs.2020.11.004
   Li Y., 2019, PROTEIN CELL, V49, P694
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Liu YQ, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0625 8
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   Molnár I, 2014, MENOPAUSE, V21, P749, DOI [10.1097/gme.0000000000000125, 10.1097/GME.0000000000000125]
   Nie XW, 2019, CLIN CHIM ACTA, V495, P646, DOI 10.1016/j.cca.2018.05.004
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Ren SY, 2019, CANCER SCI, V110, P1621, DOI 10.1111/cas.14002
   Shen F, 2008, CYTOKINE, V41, P92, DOI 10.1016/j.cyto.2007.11.013
   Song L, 2019, MOL MED REP, V19, P4743, DOI 10.3892/mmr.2019.10155
   Sun K, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153387
   Sun YX, 2017, EXP THER MED, V14, P1647, DOI 10.3892/etm.2017.4641
   Tang MJ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.625034
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Tyagi AM, 2014, J BONE MINER RES, V29, P1981, DOI 10.1002/jbmr.2228
   Wang YH, 2018, GENE, V670, P166, DOI 10.1016/j.gene.2018.05.063
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Zhang J, 2015, GYNECOL ENDOCRINOL, V31, P183, DOI 10.3109/09513590.2014.975683
   Zhang Q, 2019, MOL MED REP, V19, P41, DOI 10.3892/mmr.2018.9622
   Zhong H, 2021, GENOMICS, V113, P2392, DOI 10.1016/j.ygeno.2021.05.016
NR 34
TC 5
Z9 6
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1046 7408
EI 1600 0897
J9 AM J REPROD IMMUNOL
JI Am. J. Reprod. Immunol.
PD JUL
PY 2023
VL 90
IS 1
DI 10.1111/aji.13709
EA MAY 2023
PG 11
WC Immunology; Reproductive Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Reproductive Biology
GA L1XN5
UT WOS:000985036500001
PM 37157916
OA hybrid
DA 2025 08 17
ER

PT J
AU Iskender, MF
   Çina, M
   Çamli, ST
   Çiris, IM
   Yüceer, RO
AF Iskender, Muhsin Firat
   Cina, Muge
   Camli, Sevket Tolga
   Ciris, Ibrahim Metin
   Yuceer, Ramazan Oguz
TI Evaluation of the Effects of Locally Applied Resveratrol and Cigarette
   Smoking on Bone Healing
SO APPLIED SCIENCES BASEL
LA English
DT Article
DE resveratrol; controlled drug delivery systems; cigarette smoking; bone
   healing
ID MESENCHYMAL STEM CELLS; GENE EXPRESSION; OSTEOBLASTIC DIFFERENTIATION;
   TOBACCO; BIOAVAILABILITY; PROLIFERATION; ANGIOGENESIS; HYDROGELS; REPAIR
AB Background: Bone healing is a complex process controlled by various mechanisms. It is known that cigarette smoking (CS) negatively affects bone healing by disrupting many of these mechanisms. In an effort to find ways to eliminate these negative effects caused by CS, studies have been conducted on various vitamins, antioxidants, and medications. Since high doses and repeated injections are required to increase the therapeutic effect of conventional drug applications, controlled drug delivery systems have been developed to avoid such problems. This study aimed to investigate the effects of resveratrol (RES), which has been made into a controlled drug delivery system, on bone healing in rats that were experimentally exposed to cigarette smoke to create a chronic smoking model. Methods: After establishing a chronic CS model by exposing the subjects to cigarette smoke of six cigarettes/day for four weeks, monocortical critical size defects of 3 mm (SD +/  0.02 mm) in diameter were created in the femur using a trephine bur. During the operation, the defects in RES groups were filled locally with a gel formed solution of RES (50 mu M) and Pluronic F 127 (14 mu L). CS exposure was continued during the bone healing period after surgery. All groups were sacrificed one month after the operation, and femur samples were taken. Results: The obtained samples were examined by histomorphometric and immunohistochemical techniques; osteoblast count, new bone area, macroscopic filling score, vascularization, and proliferation were evaluated. Conclusion: The results of this study indicate that CS negatively affects bone healing and that local application of RES reduces this effect.
C1 [Iskender, Muhsin Firat; Cina, Muge] Suleyman Demirel Univ, Fac Dent, Dept Oral & Maxillofacial Surg, TR 32260 Isparta, Turkiye.
   [Camli, Sevket Tolga] Silika Chem Co Ltd, TR 42050 Konya, Turkiye.
   [Ciris, Ibrahim Metin] Suleyman Demirel Univ, Fac Med, Dept Med Pathol, TR 32260 Isparta, Turkiye.
   [Yuceer, Ramazan Oguz] Sivas Cumhuriyet Univ, Fac Med, Dept Med Pathol, TR 58140 Sivas, Turkiye.
C3 Suleyman Demirel University; Suleyman Demirel University; Cumhuriyet
   University
RP Çina, M (通讯作者)，Suleyman Demirel Univ, Fac Dent, Dept Oral & Maxillofacial Surg, TR 32260 Isparta, Turkiye.
EM m.firatiskender@hotmail.com; mugecina@hotmail.com; tolgacamli@gmail.com;
   ibrahimciris@sdu.edu.tr; r.yuceer66@hotmail.com
RI ; çiriş, ibrahim/ABE 7921 2020; Çına, Müge/B 4733 2017
OI ciris, metin/0000 0002 5619 4989; iskender, Muhsin
   Firat/0000 0002 5154 0272; Cina, Muge/0000 0003 2005 3153
FU Department of Scientific Research Projects, Suleyman Demirel University
   [TDH 2021 8455]
FX The present study was funded by the Department of Scientific Research
   Projects, Suleyman Demirel University (Grant/Award Number:
   TDH 2021 8455).
CR Adhikari N, 2021, J PERIODONTAL RES, V56, P735, DOI 10.1111/jre.12870
   Al Bashaireh AM, 2018, J OSTEOPOROS, V2018, DOI 10.1155/2018/1206235
   Amri A, 2012, J CONTROL RELEASE, V158, P182, DOI 10.1016/j.jconrel.2011.09.083
   Arakkunakorn W, 2023, METHODSX, V11, DOI 10.1016/j.mex.2023.102457
   Bergström J, 2004, J CLIN PERIODONTOL, V31, P260, DOI 10.1111/j.1600 051X.2004.00475.x
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Casarin RC, 2014, INT J ORAL MAX SURG, V43, P900, DOI 10.1016/j.ijom.2014.01.009
   Casati MZ, 2013, J PERIODONTOL, V84, pE58, DOI 10.1902/jop.2013.120746
   Chang CJ, 2020, BONE JOINT RES, V9, P99, DOI 10.1302/2046 3758.93.BJR 2019 0089.R1
   Cottart CH, 2010, MOL NUTR FOOD RES, V54, P7, DOI 10.1002/mnfr.200900437
   Cusano NE, 2015, CURR OSTEOPOROS REP, V13, P302, DOI 10.1007/s11914 015 0278 8
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   DePhillipo NN, 2018, ORTHOP J SPORTS MED, V6, DOI 10.1177/2325967118804544
   Diniz IMA, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5493 4
   Dumortier G, 2006, PHARM RES DORDR, V23, P2709, DOI 10.1007/s11095 006 9104 4
   Franck FC, 2018, INT J ORAL MAX SURG, V47, P541, DOI 10.1016/j.ijom.2017.08.004
   Heikkinen J, 2024, TOB INDUC DIS, V22, DOI 10.18332/tid/185281
   Hernigou J, 2019, BONE JOINT RES, V8, P255, DOI 10.1302/2046 3758.86.BJR 2018 0344.R1
   Hugo Almeida M. H. A., 2012, J APPL PHARM SCI, V2, P01
   Kaga S, 2005, J MOL CELL CARDIOL, V39, P813, DOI 10.1016/j.yjmcc.2005.08.003
   Kolkesen Sahin Ö, 2016, TURK J MED SCI, V46, P1203, DOI 10.3906/sag 1501 109
   Kost J, 2001, ADV DRUG DELIVER REV, V46, P125, DOI 10.1016/S0169 409X(00)00136 8
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   Li JY, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.71
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Ma L, 2010, J BONE MINER RES, V25, P1305, DOI 10.1002/jbmr.19
   Min KK, 2020, J PERIODONTAL RES, V55, P247, DOI 10.1111/jre.12710
   Moghaddam A, 2011, INJURY, V42, P1435, DOI 10.1016/j.injury.2011.05.011
   Ozcan Kucuk A, 2018, J ORAL MAXIL SURG, V76, P1404, DOI 10.1016/j.joms.2018.02.030
   Ozkan A, 2014, J CRANIOFAC SURG, V25, pE397, DOI 10.1097/SCS.0b013e31829ae609
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Riccitiello F, 2018, EUR POLYM J, V99, P289, DOI 10.1016/j.eurpolymj.2017.12.035
   Rothem DE, 2009, J BONE MINER METAB, V27, P555, DOI 10.1007/s00774 009 0075 5
   Saldanha JB, 2006, J ORAL MAXIL SURG, V64, P1359, DOI 10.1016/j.joms.2006.05.021
   Salla M, 2024, PHARMACEUTICS, V16, DOI 10.3390/pharmaceutics16040569
   Sánchez Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Scolaro JA, 2014, J BONE JOINT SURG AM, V96A, P674, DOI 10.2106/JBJS.M.00081
   Song LH, 2006, TOXICOL IN VITRO, V20, P915, DOI 10.1016/j.tiv.2006.01.016
   Sorensen LT, 2010, SURGERY, V148, P982, DOI 10.1016/j.surg.2010.02.005
   Tang TH, 2009, J CLIN PERIODONTOL, V36, P713, DOI 10.1111/j.1600 051X.2009.01444.x
   Uysal T, 2011, ORTHOD CRANIOFAC RES, V14, P80, DOI 10.1111/j.1601 6343.2011.01511.x
   Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445
   Wang W, 2020, NUTR METAB, V17, DOI 10.1186/s12986 020 00449 9
   Ward KD, 2001, CALCIFIED TISSUE INT, V68, P259, DOI 10.1007/BF02390832
   Wong SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061453
   Yoon V, 2012, OSTEOPOROSIS INT, V23, P2081, DOI 10.1007/s00198 012 1940 y
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Zhang W, 2024, FOODS, V13, DOI 10.3390/foods13081246
NR 49
TC 0
Z9 0
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3417
J9 APPL SCI BASEL
JI Appl. Sci. Basel
PD AUG
PY 2024
VL 14
IS 15
AR 6411
DI 10.3390/app14156411
PG 11
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA C1G5B
UT WOS:001286915900001
OA gold
DA 2025 08 17
ER

PT J
AU Mitchell, EA
   Chaffey, BT
   McCaskie, AW
   Lakey, JH
   Birch, MA
AF Mitchell, Elizabeth A.
   Chaffey, Benjamin T.
   McCaskie, Andrew W.
   Lakey, Jeremy H.
   Birch, Mark A.
TI Controlled spatial and conformational display of immobilised bone
   morphogenetic protein 2 and osteopontin signalling motifs regulates
   osteoblast adhesion and differentiation in vitro
SO BMC BIOLOGY
LA English
DT Article
ID ENDOTHELIAL CELL PROLIFERATION; GENE EXPRESSION; PEPTIDE SVVYGLR; BMP
   RECEPTOR; STEM CELLS; INTEGRIN; SURFACE; GROWTH; ACTIVATION; KINASE
AB Background: The interfacial molecular mechanisms that regulate mammalian cell growth and differentiation have important implications for biotechnology (production of cells and cell products) and medicine (tissue engineering, prosthetic implants, cancer and developmental biology). We demonstrate here that engineered protein motifs can be robustly displayed to mammalian cells in vitro in a highly controlled manner using a soluble protein scaffold designed to self assemble on a gold surface.
   Results: A protein was engineered to contain a C terminal cysteine that would allow chemisorption to gold, followed by 12 amino acids that form a water soluble coil that could switch to a hydrophobic helix in the presence of alkane thiols. Bioactive motifs from either bone morphogenetic protein 2 or osteopontin were added to this scaffold protein and when assembled on a gold surface assessed for their ability to influence cell function. Data demonstrate that osteoblast adhesion and short term responsiveness to bone morphogenetic protein 2 is dependent on the surface density of a cell adhesive motif derived from osteopontin. Furthermore an immobilised cell interaction motif from bone morphogenetic protein supported bone formation in vitro over 28 days (in the complete absence of other osteogenic supplements). In addition, two dimensional patterning of this ligand using a soft lithography approach resulted in the spatial control of osteogenesis.
   Conclusion: These data describe an approach that allows the influence of immobilised protein ligands on cell behaviour to be dissected at the molecular level. This approach presents a durable surface that allows both short (hours or days) and long term (weeks) effects on cell activity to be assessed. This widely applicable approach can provide mechanistic insight into the contribution of immobilised ligands in the control of cell activity.
C1 [Mitchell, Elizabeth A.; McCaskie, Andrew W.; Birch, Mark A.] Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Mitchell, Elizabeth A.; Chaffey, Benjamin T.; Lakey, Jeremy H.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University   UK; Newcastle University   UK
RP Birch, MA (通讯作者)，Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM m.a.birch@ncl.ac.uk
RI ; Birch, Mark/B 7051 2009
OI Birch, Mark/0009 0004 2625 2537; McCaskie, Andrew/0000 0001 6476 0832
FU BBSRC [13/E19051]; Biotechnology and Biological Sciences Research
   Council [E19051] Funding Source: researchfish
FX The authors are grateful to the BBSRC for the support of BTC (Grant
   13/E19051) and EAM.
CR Anderluh G, 2003, PROTEIN EXPRES PURIF, V28, P173, DOI 10.1016/S1046 5928(02)00681 2
   Arnold M, 2004, CHEMPHYSCHEM, V5, P383, DOI 10.1002/cphc.200301014
   Bokhari MA, 2005, BIOMATERIALS, V26, P5198, DOI 10.1016/j.biomaterials.2005.01.040
   Chaffey BT, 2008, INT J NANOMED, V3, P287
   Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064
   Ehrbar M, 2005, J CONTROL RELEASE, V101, P93, DOI 10.1016/j.jconrel.2004.07.018
   Falconnet D, 2006, BIOMATERIALS, V27, P3044, DOI 10.1016/j.biomaterials.2005.12.024
   Garamszegi N, 2009, MOL CANCER RES, V7, P319, DOI 10.1158/1541 7786.MCR 08 0227
   Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023
   Hamada Y, 2004, DENT MATER J, V23, P650, DOI 10.4012/dmj.23.650
   Hamada Y, 2003, BIOCHEM BIOPH RES CO, V310, P153, DOI 10.1016/j.bbrc.2003.09.001
   Hamada Y, 2007, DENT MATER J, V26, P487, DOI 10.4012/dmj.26.487
   Hartung A, 2006, MOL CELL BIOL, V26, P7791, DOI 10.1128/MCB.00022 06
   HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866
   Irvine DJ, 2001, BIOMACROMOLECULES, V2, P545, DOI 10.1021/bm015510f
   Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075
   Kirmizidis G, 2009, TISSUE ENG PT A, V15, P1427, DOI 10.1089/ten.tea.2008.0137
   Koo LY, 2002, J CELL SCI, V115, P1423
   Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lallier TE, 2001, J DENT RES, V80, P1748, DOI 10.1177/00220345010800081301
   Lim TY, 2009, J MATER SCI MATER M, V20, P1, DOI 10.1007/s10856 008 3528 9
   Marquis ME, 2008, BIOMATERIALS, V29, P1005, DOI 10.1016/j.biomaterials.2007.10.047
   Matsuzaka K, 2004, BIOMED RES TOKYO, V25, P263, DOI 10.2220/biomedres.25.263
   Nohe A, 2003, J CELL SCI, V116, P3277, DOI 10.1242/jcs.00519
   Pallu S, 2003, PEPTIDES, V24, P1349, DOI 10.1016/j.peptides.2003.09.003
   Phillippi JA, 2008, STEM CELLS, V26, P127, DOI 10.1634/stemcells.2007 0520
   PIERSCHBACHER MD, 1984, P NATL ACAD SCI BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]
   Rao HW, 2006, J BONE MINER RES, V21, P1657, DOI 10.1359/JBMR.060718
   Sahni A, 1999, J BIOL CHEM, V274, P14936, DOI 10.1074/jbc.274.21.14936
   Sahni A, 2004, BLOOD, V104, P409, DOI 10.1182/blood 2004 01 0126
   Saito A, 2003, BBA PROTEINS PROTEOM, V1651, P60, DOI 10.1016/S1570 9639(03)00235 8
   Saito A, 2006, J BIOMED MATER RES A, V77A, P700, DOI 10.1002/jbm.a.30662
   Shah DS, 2007, BIOCHEM SOC T, V35, P522, DOI 10.1042/BST0350522
   Singhatanadgit W, 2008, INT J BIOCHEM CELL B, V40, P2854, DOI 10.1016/j.biocel.2008.06.005
   Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772
   Tsujigiwa H, 2006, J BIOMED MATER RES A, V77A, P507, DOI 10.1002/jbm.a.30661
   Wiemann M, 2002, J BIOMED MATER RES, V62, P119, DOI 10.1002/jbm.10251
   Winkler L, 2006, J BIOMED MATER RES A, V79A, P895, DOI 10.1002/jbm.a.30822
   Yamachika E, 2009, J BIOMED MATER RES A, V88A, P599, DOI 10.1002/jbm.a.31833
   Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328
NR 44
TC 26
Z9 29
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1741 7007
J9 BMC BIOL
JI BMC Biol.
PD MAY 10
PY 2010
VL 8
AR 57
DI 10.1186/1741 7007 8 57
PG 12
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 623XK
UT WOS:000279780500001
PM 20459712
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, S
   Mun, S
   Shin, W
   Han, K
   Kim, MY
AF Kim, Songmi
   Mun, Seyoung
   Shin, Wonseok
   Han, Kyudong
   Kim, Moon Young
TI Identification of Potentially Pathogenic Variants Associated with
   Recurrence in Medication Related Osteonecrosis of the Jaw (MRONJ)
   Patients Using Whole Exome Sequencing
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE bisphosphonates; medication related osteonecrosis of the jaws;
   osteonecrosis of the jaw; single nucleotide polymorphism; whole exome
   sequencing
ID WHITE SPONGE NEVUS; BISPHOSPHONATES; PHOSPHORYLATION; REORGANIZATION;
   MUTATIONS; KERATIN 8; DISEASE; GENOME; FAMILY; FAS
AB Background: Bisphosphonates are antiresorptive and antiangiogenic drugs that prevent and treat bone loss and mineralization in women with postmenopausal osteoporosis and cancer patients. Medication related osteonecrosis of the jaw (MRONJ) is commonly caused by tooth extraction and dental trauma. Although genetic and pathological studies about MRONJ have been conducted, the pathogenesis of MRONJ still remains unclear. Methods: We aimed to identify genetic variants associated with MRONJ, using whole exome sequencing (WES). Ten MRONJ patients prescribed bisphosphonates were recruited for WES, and jawbone tissue and blood samples were collected from the patients. Results: The analysis of the WES data found a total of 1866 SNP and 40 InDel variants which are specific to MRONJ. The functional classification assay using Gene Ontology and pathway analysis discovered that genes bearing the MRONJ variants are significantly enriched for keratinization and calcium ion transport. Some of the variants are potential pathogenic variants (24 missense mutations and seven frameshift mutations) with MAF < 0.01. Conclusions: The variants are located in eight different genes (KRT18, MUC5AC, NBPF9, PABPC3, MST1L, ASPN, ATN1, and SLAIN1). Nine deleterious SNPs significantly associated with MRONJ were found in the KRT18 and PABPC3 genes. It suggests that KRT18 and PABPC3 could be MRONJ related key genes.
C1 [Kim, Songmi; Mun, Seyoung; Han, Kyudong] Dankook Univ, Ctr Bio Med Engn, Core Facil, Cheonan 31116, South Korea.
   [Kim, Songmi; Mun, Seyoung; Han, Kyudong] Dankook Univ, Dept Microbiol, Cheonan 31116, South Korea.
   [Shin, Wonseok] Dankook Univ Hosp, NGS Clin Lab, Cheonan 31116, South Korea.
   [Kim, Moon Young] Dankook Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Cheonan 31116, South Korea.
C3 Dankook University; Dankook University; Dankook University; Dankook
   University Hospital; Dankook University
RP Han, K (通讯作者)，Dankook Univ, Ctr Bio Med Engn, Core Facil, Cheonan 31116, South Korea.; Han, K (通讯作者)，Dankook Univ, Dept Microbiol, Cheonan 31116, South Korea.; Kim, MY (通讯作者)，Dankook Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Cheonan 31116, South Korea.
EM songmik66@gmail.com; munseyoung@gmail.com; w.shin86@gmail.com;
   kyudong.han@gmail.com; kmyomfs@dankook.ac.kr
RI ; kim, nayoung/IWV 4038 2023; Han, Kyudong/AAF 1788 2019; Mun,
   Seyoung/IAN 5306 2023
OI Kim, Moon Young/0000 0001 9596 7481; kim, songmi/0000 0002 5497 1174;
   Shin, Wonseok/0000 0001 5964 1425; Han, Kyudong/0000 0001 6791 2408;
   Mun, Seyoung/0000 0002 9669 4494
FU National Research Foundation of Korea (NRF)   Ministry of Science and
   ICT [2021R1C1C1008843]; Priority Research Center Program by the Ministry
   of Education [2019R1A6A1A11034536]; Medical Research Center Program NRF
   [2021R1A5A2022318]
FX M. Y.K. was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Ministry of Science and ICT (2021R1C1C1008843),
   Priority Research Center Program provided by the Ministry of Education
   (2019R1A6A1A11034536) and Medical Research Center Program NRF
   (2021R1A5A2022318).
CR Aki T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199734
   Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   Anastasio N, 2010, AM J HUM GENET, V87, P553, DOI 10.1016/j.ajhg.2010.09.005
   Arduino PG, 2011, J ORAL PATHOL MED, V40, P510, DOI 10.1111/j.1600 0714.2010.01004.x
   Beaumont S, 2021, CANCERS, V13, DOI 10.3390/cancers13174479
   Busch T, 2012, J CELL SCI, V125, P2148, DOI 10.1242/jcs.080127
   Cai WP, 2014, META GENE, V2, P374, DOI 10.1016/j.mgene.2014.04.008
   Camuzard O, 2016, ONCOTARGET, V7, P66416, DOI 10.18632/oncotarget.12013
   Chang J, 2018, CURR OSTEOPOROS REP, V16, P584, DOI 10.1007/s11914 018 0474 4
   Cheng J, 2019, ANIMALS BASEL, V9, DOI 10.3390/ani9050273
   da Silva JSP, 2019, INT J ORAL MAX SURG, V48, P1289, DOI 10.1016/j.ijom.2019.04.014
   Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357 2725(01)00046 2
   Fortunato L, 2018, J STOMATOL ORAL MAXI, V119, P389, DOI 10.1016/j.jormas.2018.04.006
   Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456
   George Estee L, 2018, Bone Rep, V8, P104, DOI 10.1016/j.bonr.2018.03.003
   Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   He LN, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 020 00093 2
   Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586 021 03819 2
   Kalamajski S, 2009, BIOCHEM J, V423, P53, DOI 10.1042/BJ20090542
   Katz J, 2011, INT J ORAL MAX SURG, V40, P605, DOI 10.1016/j.ijom.2011.02.002
   Kiel DP, 2007, BMC MED GENET, V8, DOI 10.1186/1471 2350 8 S1 S14
   Kim JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118084
   Kim Kyoung Min, 2015, J Bone Metab, V22, P151, DOI 10.11005/jbm.2015.22.4.151
   Kimura M, 2013, INT J ORAL MAX SURG, V42, P615, DOI 10.1016/j.ijom.2012.10.030
   Kos M, 2015, J CRANIO MAXILL SURG, V43, P863, DOI 10.1016/j.jcms.2015.04.018
   Kovacic N, 2010, EXPERT OPIN THER TAR, V14, P1121, DOI 10.1517/14728222.2010.522347
   Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee KH, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 2129 3
   Lee S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04642 4
   Maggi L, 2021, CELLS BASEL, V10, DOI 10.3390/cells10061521
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Mzoughi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17064 0
   Nicoletti P, 2012, ONCOLOGIST, V17, P279, DOI 10.1634/theoncologist.2011 0202
   Otto S, 2020, J BONE MINER RES, V35, P2179, DOI 10.1002/jbmr.4119
   Paninka RM, 2016, MOL GENET GENOMICS, V291, P1535, DOI 10.1007/s00438 016 1185 0
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Rodrigues CHM, 2021, PROTEIN SCI, V30, P60, DOI 10.1002/pro.3942
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P61, DOI 10.14219/jada.archive.2009.0019
   Sharma D, 2013, VASC CELL, V5, DOI 10.1186/2045 824X 5 1
   Soufi M, 2018, NEUROL GENET, V4, DOI 10.1212/NXG.0000000000000274
   Tao GZ, 2009, J CELL SCI, V122, P3851, DOI 10.1242/jcs.051862
   Tatsuda Y, 2010, EUR J PHARMACOL, V627, P348, DOI 10.1016/j.ejphar.2009.10.067
   Thumbigere Math V, 2014, J PERIODONTOL, V85, P226, DOI 10.1902/jop.2013.130017
   Toivola DA, 2004, HEPATOLOGY, V40, P459, DOI 10.1002/hep.20277
   Toivola DM, 2015, CURR OPIN CELL BIOL, V32, P73, DOI 10.1016/j.ceb.2014.12.008
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 56
TC 6
Z9 6
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2077 0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 8
AR 2145
DI 10.3390/jcm11082145
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 0Q6IN
UT WOS:000785020000001
PM 35456240
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU McClung, MR
   Ebetino, FH
AF McClung, Michael R.
   Ebetino, Frank H.
TI History of risedronate
SO BONE
LA English
DT Article
DE Bisphosphonates; Pyridyl; Risedronate; Osteoporosis; Fractures; Paget's
   disease
ID BONE MINERAL DENSITY; NITROGEN CONTAINING BISPHOSPHONATES; ONCE WEEKLY
   RISEDRONATE; DOUBLE BLIND; POSTMENOPAUSAL OSTEOPOROSIS; PAGETS DISEASE;
   VERTEBRAL FRACTURE; 35 MG; TRABECULAR ARCHITECTURE; DIPHOSPHONATE
   TREATMENT
AB Herein we review the discovery, development, commercial history and legacy of risedronate or NE 58095, a potent N containing bisphosphonate developed by scientists at the Cincinnati Miami Valley Laboratories and the Norwich Eaton Laboratories of Procter and Gamble. It is characterized by a hydroxyl substituent (R 1) and a pyridyl methylene substituent (R 2) at the carbon bridging two phosphonate moieties. It was shown to have greater potency than alendronate in cell based systems while binding affinity to bone matrix was lower than alendronate, accounting for the relatively rapid offset of bone turnover inhibition when therapy is discontinued. Risedronate was shown to significantly reduce serum alkaline phosphatase and clinical features in patients with Paget's disease and was approved for this indication, at a dose of 30 mg daily for 2 months, in 1998. Formal dose response testing for treatment of osteoporosis was not performed. In large Phase 3 studies, 5 mg risedronate daily increased bone mineral density more than did the 2.5 mg dose. As a result, the 2.5 mg dose was dropped from most of the Phase 3 studies after 12 months. The 5 mg daily dose was approved for treating and preventing postmenopausal osteoporosis and glucocorticoid induced osteoporosis in 2000. The drug was subsequently approved for treating men with osteoporosis. Following the leads of other companies, weekly and monthly preparations were developed and approved, based on non inferiority BMD studies vs the 5 mg daily oral dose as was a unique dosing regimen of 75 mg given on 2 consecutive days each month. Finally, to overcome the effect of food on limiting the already poor gastrointestinal absorption of the drug, a once weekly oral preparation containing the chelating agent EDTA and with an enteric coating delaying dissolution until the tablet was in the small intestine was approved in 2010 to be administered after breakfast.
   The Alliance for Better Bone Health, a collaboration between Procter & Gamble Pharmaceuticals and sanofiaventis U.S. was formed to market risedronate as Actonel (R) and, subsequently, Aconel EC (R) or Aelvia (R). These drugs are still marketed by sanofi aventis in some countries. The sale of the pharmaceutical division of Procter & Gamble to Warner Chilcott (US) was based, in large part, on the perceived value and marketability of the risedronate drugs. When marketing targets of Warner Chilcott were not met, the rights of risedronate were sold to Allergan USA, Inc. which never actively promoted the drug. Generic forms of risedronate were introduced into the United States in 2015 but are rarely used, although several generic forms are actively marketed in other countries.
C1 [McClung, Michael R.] Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA.
   [McClung, Michael R.] Australian Catholic Univ, Mary MacKillop Ctr Hlth Res, Melbourne, Vic, Australia.
   [Ebetino, Frank H.] Univ Rochester, Chem Dept, Rochester, NY USA.
   [Ebetino, Frank H.] BioVinc, Pasadena, CA USA.
C3 Oregon Osteoporosis Center; Australian Catholic University; University
   of Rochester
RP McClung, MR (通讯作者)，Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA.
EM mmcclung.ooc@gmail.com
RI ; McClung, Michael/ABA 4100 2021
OI McClung, Michael/0000 0002 7827 0778; 
CR Bekker PJ, 1997, J BONE MINER RES, V12, pS474
   Benedict J J., 1982, Symposium CEMO (Centre dEtude des Maladies Osteoarticulaires de Geneve) IV. Diphosphonates and bone, P1
   BENEDICT JJ, 1986, CALCIFIED TISSUE INT, V38, pS31
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boises E., 1985, US Pat, Patent No. 4666895
   Boonen S, 2004, J AM GERIATR SOC, V52, P1832, DOI 10.1111/j.1532 5415.2004.52506.x
   Boonen S, 2009, J BONE MINER RES, V24, P719, DOI [10.1359/jbmr.081214, 10.1359/JBMR.081214]
   Borah B, 2002, J BONE MINER RES, V17, P1139, DOI 10.1359/jbmr.2002.17.7.1139
   Borah B, 2006, BONE, V39, P345, DOI 10.1016/j.bone.2006.01.161
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Borah B, 2010, J BONE MINER RES, V25, P41, DOI 10.1359/jbmr.090711
   Boyce RW, 1996, J BONE MINER RES, V11, P600
   BOYCE RW, 1995, J BONE MINER RES, V10, P211
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Brown JP, 1999, CALCIFIED TISSUE INT, V64, P93, DOI 10.1007/s002239900584
   BROWN JP, 1994, SEMIN ARTHRITIS RHEU, V23, P272, DOI 10.1016/0049 0172(94)90060 4
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002 9343(99)80134 X
   Clemmesen B, 1997, OSTEOPOROSIS INT, V7, P488, DOI 10.1007/PL00004152
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   Delmas PD, 2008, OSTEOPOROSIS INT, V19, P1039, DOI 10.1007/s00198 007 0531 9
   Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955
   Delmas PD, 2008, BONE, V42, P36, DOI 10.1016/j.bone.2007.09.001
   Dufresne TE, 2003, CALCIFIED TISSUE INT, V73, P423, DOI 10.1007/s00223 002 2104 4
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Eastell R.P.J., 2000, OSTEOPOROSIS INT, V11, P152
   Eastell R, 2011, J CLIN ENDOCR METAB, V96, P3367, DOI 10.1210/jc.2011 0412
   Ebetino F.H., 1990, OSTEOPOROSIS 1990, P1344
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino FH, 1999, PHOSPHORUS SULFUR, V144, P9, DOI 10.1080/10426509908546169
   Ebetino FH, 2008, U.S. Pat. Appl. Publ., Patent No. [WO/2008/076417, WO2008076417]
   Ebetino FH, 2010, U.S. Pat., Patent No. [7,781,481, 7781481]
   Ebetino FH., 1995, Bisphosphonate on Bones, P139
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ejersted C, 1998, CALCIFIED TISSUE INT, V62, P316, DOI 10.1007/s002239900438
   Epstein S, 2009, CURR MED RES OPIN, V25, P2951, DOI 10.1185/03007990903361307
   FAULKNER KG, 1995, OSTEOPOROSIS INT, V5, P218, DOI 10.1007/BF01774010
   Faulkner KG, 1996, OSTEOPOROSIS INT, V6, P432, DOI 10.1007/BF01629574
   Fogelman I, 2000, J CLIN ENDOCR METAB, V85, P1895, DOI 10.1210/jc.85.5.1895
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Geddes A D., 1994, Bone and Mineral Research, P265
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Gold DT, 2006, CURR MED RES OPIN, V22, P2383, DOI 10.1185/030079906X154042
   Harris S, 2000, J BONE MINER RES, V15, pS226
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khan SA, 1997, BONE, V20, P263, DOI 10.1016/S8756 3282(96)00364 X
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lawson MA, 2017, J BONE MINER RES, V32, P1860, DOI 10.1002/jbmr.3138
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   LIN BY, 1994, BONE, V15, P489, DOI 10.1016/8756 3282(94)90272 0
   LOOKER AC, 1995, J BONE MINER RES, V10, P796
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Lundy MW, 2007, J BONE MINER RES, V22, pS443
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P293, DOI 10.1007/s00198 012 2056 0
   McClung MR, 2012, OSTEOPOROSIS INT, V23, P267, DOI 10.1007/s00198 011 1791 y
   McClung Michael R, 2003, Clin Cornerstone, VSuppl 2, pS22
   McClung MR, 2013, CALCIFIED TISSUE INT, V92, P59, DOI 10.1007/s00223 012 9668 4
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mellström DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223 004 0286 7
   Miller PD, 1999, AM J MED, V106, P513, DOI 10.1016/S0002 9343(99)00062 5
   Mitchell DY, 1999, BRIT J CLIN PHARMACO, V48, P536, DOI 10.1046/j.1365 2125.1999.00035.x
   Mitchell DY, 2000, J CLIN PHARMACOL, V40, P258, DOI 10.1177/00912700022008928
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Mortensen L, 1998, J CLIN ENDOCR METAB, V83, P396, DOI 10.1210/jc.83.2.396
   Naylor KE, 2016, OSTEOPOROSIS INT, V27, P21, DOI 10.1007/s00198 015 3145 7
   Paggiosi MA, 2014, OSTEOPOROSIS INT, V25, P2729, DOI 10.1007/s00198 014 2817 z
   REASNER CA, 1993, J CLIN ENDOCR METAB, V77, P1067, DOI 10.1210/jc.77.4.1067
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006
   Reid DM, 2006, CLIN DRUG INVEST, V26, P63, DOI 10.2165/00044011 200626020 00002
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   ROUX C, 1994, BONE, V15, P41, DOI 10.1016/8756 3282(94)90890 7
   Rubin KH, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115296
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schott AM, 1998, OSTEOPOROSIS INT, V8, P247, DOI 10.1007/s001980050061
   Sebba AI, 2004, CURR MED RES OPIN, V20, P2031, DOI 10.1185/030079904X16768
   Shiraki M, 2003, OSTEOPOROSIS INT, V14, P225, DOI 10.1007/s00198 002 1369 9
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Siris ES, 1998, J BONE MINER RES, V13, P1032, DOI 10.1359/jbmr.1998.13.6.1032
   Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002 9343(97)00130 7
   TAKEUCHI M, 1993, CHEM PHARM BULL, V41, P688
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Wasnich Richard D, 2004, Menopause, V11, P622
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Watts NB, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115222
   WRONSKI TJ, 1993, CALCIFIED TISSUE INT, V53, P210, DOI 10.1007/BF01321840
   WRONSKI TJ, 1989, ENDOCRINOLOGY, V125, P810, DOI 10.1210/endo 125 2 810
   WRONSKI TJ, 1991, J BONE MINER RES, V6, P387
NR 99
TC 18
Z9 21
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2020
VL 137
AR 115407
DI 10.1016/j.bone.2020.115407
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MH8XS
UT WOS:000547005800025
PM 32387834
DA 2025 08 17
ER

PT J
AU vom Scheidt, A
   Hemmatian, H
   Püschel, K
   Krause, M
   Amling, M
   Busse, B
AF vom Scheidt, Annika
   Hemmatian, Haniyeh
   Pueschel, Klaus
   Krause, Matthias
   Amling, Michael
   Busse, Bjoern
TI Bisphosphonate treatment changes regional distribution of trabecular
   microstructure in human lumbar vertebrae
SO BONE
LA English
DT Article
DE Bisphosphonates; Fracture risk; Vertebrae; Regional heterogeneity;
   Osteoporosis treatment
ID DISC DEGENERATION; OSTEOPOROSIS; BONE; FRACTURES; AGE; PREVENTION;
   PARAMETERS; IMPACT; BODY; CT
AB Background: In osteoporosis patients, antiresorptive treatments such as alendronate reduce the resorption of trabecular bone and thus minimize vertebral fracture risk. However, fracture risk reduction efficacy of antiresorptive drugs varies between skeletal sites and is highest for vertebral bone. In human vertebrae, cancellous bone is distributed heterogeneously between regions. This microstructural heterogeneity is changing with patient age and is likely to play a major role in vertebral failure mechanisms and fracture susceptibility. Whether antiresorptive treatment affects the heterogeneity of vertebral microstructure in osteoporosis has not been unraveled.
   Methods: Our aim was to assess whether antiresorptive treatment would have a region dependent influence on vertebral trabecular bone. Therefore, we used high resolution peripheral quantitative computed tomography (HR pQCT), microcomputed tomography (microCT) and uniaxial compression testing to determine the structure and mechanical properties of trabecular bone cores from anterior and posterior regions of 22 lumbar vertebrae from elderly osteoporotic women. We analyzed age matched ex vivo bone samples from bisphosphonate treated female osteoporosis patients (age: 82 +/  7y, bisphosphonate treatment period: 4 +/  2 years) along treatment naive female controls (82 +/  7y).
   Results: MicroCT analysis showed a significantly lower bone volume fraction (p = 0.006) and lower trabecular number (p = 0.003) for the anterior bone cores compared to posterior bone cores in the treatment naive group. The bisphosphonate treated group had a more homogeneous bone volume distribution and did not show significant regional differences in bone volume, it however also displayed significantly different trabecular numbers (p = 0.016). In bone cores of the bisphosphonate treated group, trabeculae were thicker in comparison to treatment naive controls (p = 0.011). Differences in bone volume further resulted in different maximum forces during compression testing between the samples. In addition, the percental difference between BV/TV mu CT in anterior and posterior bone cores was lower in bisphosphonate treated vertebrae when vertebrae with directly adjacent fractures (n = 3) were excluded.
   Conclusion: In conclusion, regional trabecular bone microstructure in lumbar vertebrae of bisphosphonate treated women was more homogeneous compared to treatment naive controls. Bisphosphonate treatment, which specifically targets resorption surfaces common in anterior vertebral bone, might have resulted in a region specific preservation of vertebral microstructure and loading capacity. This could have positive implications for the reduction of wedge fracture risk and add to the explanation of the higher efficacy of fracture risk reduction in vertebrae in comparison to other fracture regions.
C1 [vom Scheidt, Annika; Hemmatian, Haniyeh; Amling, Michael; Busse, Bjoern] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Lottestr 55A, D 22529 Hamburg, Germany.
   [Pueschel, Klaus] Univ Med Ctr Hamburg Eppendorf, Dept Forens Med, Butenfeld 34, D 22529 Hamburg, Germany.
   [Krause, Matthias] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, D 20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Busse, B (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Lottestr 55A, D 22529 Hamburg, Germany.
EM a.vom scheidt@uke.de; h.hemmatian@uke.de; pueschel@uke.de;
   m.krause@uke.de; amling@uke.de; b.busse@uke.uni hamburg.de
RI ; Busse, Björn/AAC 4033 2020; Scheidt, Annika/AAH 4263 2020
OI Hemmatian, Haniyeh/0000 0001 6314 1765; Busse,
   Bjorn/0000 0002 3099 8073; vom Scheidt, Annika/0000 0002 3756 8770; 
FU German Research Foundation [DFG BU 2562/2 1/3 1]; Federal Ministry of
   Education and Research (BMBF) [BioAsset 01EC1005D]
FX This study was supported by research grants from the German Research
   Foundation (DFG BU 2562/2 1/3 1) and the Federal Ministry of Education
   and Research (BMBF, BioAsset 01EC1005D). The authors would like to
   acknowledge the support and expertise of Dr. Michael Hahn regarding
   specimen preparation.
CR Abelson A, 2010, OSTEOPOROSIS INT, V21, P1021, DOI 10.1007/s00198 009 1046 3
   Been E, 2014, SPINE J, V14, P87, DOI 10.1016/j.spinee.2013.07.464
   Byun Ji Hye, 2017, J Bone Metab, V24, P37
   Chen H, 2008, OSTEOPOROSIS INT, V19, P1473, DOI 10.1007/s00198 008 0593 3
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   El Miedany Y, 2014, CURR RHEUMATOL REV, V10, P99, DOI 10.2174/1573397110666150120103340
   Fleurence RL, 2007, PHARMACOECONOMICS, V25, P913, DOI 10.2165/00019053 200725110 00003
   Giambini H, 2013, CLIN BIOMECH, V28, P10, DOI 10.1016/j.clinbiomech.2012.10.005
   Gong H, 2005, J BONE MINER METAB, V23, P174, DOI 10.1007/s00774 004 0557 4
   Hulme PA, 2007, BONE, V41, P946, DOI 10.1016/j.bone.2007.08.019
   ITOI E, 1990, CALCIFIED TISSUE INT, V47, P202, DOI 10.1007/BF02555920
   Jansen JP, 2009, CURR MED RES OPIN, V25, P1861, DOI 10.1185/03007990903035281
   Keaveny TM, 1997, J ORTHOPAED RES, V15, P101, DOI 10.1002/jor.1100150115
   Kilincer C, 2013, TURK NEUROSURG, V23, P476, DOI 10.5137/1019 5149.JTN.7442 12.0
   Krause M, 2014, OSTEOPOROSIS INT, V25, P1595, DOI 10.1007/s00198 014 2650 4
   Krause M, 2013, OSTEOPOROSIS INT, V24, P1859, DOI 10.1007/s00198 012 2156 x
   Lewiecki EM, 2017, CURR OSTEOPOROS REP, V15, P103, DOI 10.1007/s11914 017 0350 7
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   Murrie VL, 2003, CLIN ANAT, V16, P144, DOI 10.1002/ca.10114
   Onyemaechi NOC, 2016, PATIENT PREFER ADHER, V10, P291, DOI 10.2147/PPA.S90967
   Pollintine P, 2004, SPINE, V29, P774, DOI 10.1097/01.BRS.0000119401.23006.D2
   Pollintine P, 2004, J BIOMECH, V37, P197, DOI 10.1016/S0021 9290(03)00308 7
   Reid IR, 2013, EUR J INTERN MED, V24, P691, DOI 10.1016/j.ejim.2013.03.012
   Rincón Kohli L, 2009, BIOMECH MODEL MECHAN, V8, P195, DOI 10.1007/s10237 008 0128 z
   Ritzel H, 1997, J BONE MINER RES, V12, P89, DOI 10.1359/jbmr.1997.12.1.89
   Romero Vargas S, 2013, EUR SPINE J, V22, P878, DOI 10.1007/s00586 012 2560 0
   Sambrook PN, 2010, MED J AUSTRALIA, V193, P154, DOI 10.5694/j.1326 5377.2010.tb03835.x
   SANDOR T, 1991, J CLIN ENDOCR METAB, V72, P1157, DOI 10.1210/jcem 72 5 1157
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Seeman E, 2013, J GERONTOL A BIOL, V68, P1218, DOI 10.1093/gerona/glt071
   Tower RJ, 2015, BONE, V74, P171, DOI 10.1016/j.bone.2015.01.009
   Wang Y, 2013, BONE, V56, P249, DOI 10.1016/j.bone.2013.06.022
   Waterloo S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 3
   Wegrzyn J, 2010, J BONE MINER RES, V25, P2324, DOI 10.1002/jbmr.164
NR 34
TC 7
Z9 7
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2019
VL 127
BP 482
EP 487
DI 10.1016/j.bone.2019.07.003
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IU2ZR
UT WOS:000483449000055
PM 31280018
DA 2025 08 17
ER

PT J
AU Xu, L
   Wang, H
   Yu, QQ
   Ge, JR
   Zhang, XZ
   Mei, D
   Liang, FQ
   Cai, XY
   Zhu, Y
   Shu, JL
   Tai, Y
   Wei, W
   Zhang, LL
AF Xu, Li
   Wang, Han
   Yu, Qian qian
   Ge, Jin ru
   Zhang, Xian zheng
   Mei, Dan
   Liang, Fa qin
   Cai, Xiao yu
   Zhu, Yue
   Shu, Jin ling
   Tai, Yu
   Wei, Wei
   Zhang, Ling ling
TI The monomer derivative of paeoniflorin inhibits macrophage pyroptosis
   via regulating TLR4/NLRP3/GSDMD signaling pathway in adjuvant arthritis
   rats
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Rheumatoid arthritis; Macrophage pyroptosis; Adjuvant arthritis; Monomer
   derivative of paeoniflorin; TLR4; NLRP3; GSDMD signaling pathway
ID RHEUMATOID ARTHRITIS; TACI IG; INFLAMMASOMES; LYMPHOCYTES; MANAGEMENT;
   RECEPTOR; NSAIDS; DRUGS
AB Objective: This study was aimed to investigate the effect of monomer derivative of paeoniflorin (MDP) on macrophage pyroptosis mediated by TLR4/NLRP3/GSDMD signaling pathway in adjuvant arthritis (AA) rats. Method: Wistar rats were divided into normal group, AA model group, MDP (50 mg/kg) group and MTX (0.5 mg/ kg) group. The expression of TLR4, NLRP3 and GSDMD in macrophage were detected by immunofluorescence assay. The expression of TLR4 and the ratio of macrophage pyroptosis were analyzed by flow cytometry. Cell morphology was observed by scanning electron microscopy. The cytokine levels of IL 18 and IL 1I3 were detected by ELISA. The expressions of proteins related to macrophage pyroptosis were detected by western blot. Results: MDP has a therapeutic effect on rats AA by reducing the secondary inflammation and improving pathological changes. The results of X ray imaging and ultrasound images showed that MDP could inhibit bone erosion, soft tissue swelling, and joint space narrowing. Macrophage pyroptosis was found in secondary inflammation of AA rats. The expressions of TLR4, MyD88, NLRP3, Caspase 1, ASC, and GSDMD N in macrophage were increased, the levels of IL 18 and IL 1I3 were enhanced, and the morphology of pyroptosis could be observed. MDP could inhibit macrophage polarization and macrophage pyroptosis, and down regulated the cytokine levels of IL 18 and IL 1I3 in AA rats. MDP could regulate the M1/M2 ratio, decreased the ratio of macrophage pyroptosis and down regulated the expressions of TLR4, MyD88, NLRP3, Caspase 1, ASC, and GSDMD N in vivo and in vitro. Conclusion: Abnormal activation of TLR4/NLRP3/GSDMD signaling pathway may be involved in macrophage pyroptosis in AA rats. The therapeutic effect of MDP on AA rats is related to the inhibition of macrophage pyroptosis by regulating the TLR4/NLRP3/GSDMD signaling pathway.
C1 [Xu, Li; Wang, Han; Yu, Qian qian; Ge, Jin ru; Zhang, Xian zheng; Mei, Dan; Liang, Fa qin; Cai, Xiao yu; Zhu, Yue; Shu, Jin ling; Tai, Yu; Wei, Wei; Zhang, Ling ling] Anhui Med Univ, Anhui Collaborat Innovat Ctr Antiinflammatory & I, Key Lab Antiinflammatory & Immune Med, Inst Clin Pharmacol,Minist Educ,Ctr Rheumatoid Ar, Hefei 230032, Peoples R China.
C3 Anhui Medical University
RP Wei, W; Zhang, LL (通讯作者)，Anhui Med Univ, Anhui Collaborat Innovat Ctr Antiinflammatory & I, Key Lab Antiinflammatory & Immune Med, Inst Clin Pharmacol,Minist Educ,Ctr Rheumatoid Ar, Hefei 230032, Peoples R China.
EM wwei@ahmu.edu.cn; ll zhang@hotmail.com
RI wei, wei/HHR 8613 2022; Cai, Xiaoyu/H 9984 2019; zhang,
   lingling/HDM 2189 2022
FU National Natural Science Foundation of China [U1803129, 81973332,
   81803538]; Popu lation Health Special Project of Key Research and
   Development Plan of Anhui Province [202104j07020032]
FX The study was supported by the National Natural Science Foundation of
   China (grant numbers U1803129, 81973332, 81803538) , The Popu lation
   Health Special Project of Key Research and Development Plan of Anhui
   Province in 2021 (Number: 202104j07020032) .
CR Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Chang Y, 2011, RHEUMATOLOGY, V50, P862, DOI 10.1093/rheumatology/keq404
   Chatzidionysiou K, 2017, ANN RHEUM DIS, V76, P1102, DOI [10.1136/annrheumdis 2016 210711, 10.1136/annrheumdis 2016 210713]
   Culemann S, 2019, ADV IMMUNOL, V143, P75, DOI 10.1016/bs.ai.2019.08.006
   Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020
   Dong WJ, 2019, CHEM RES TOXICOL, V32, P1051, DOI 10.1021/acs.chemrestox.8b00376
   Fei F, 2019, INFLAMMOPHARMACOLOGY, V27, P1193, DOI 10.1007/s10787 019 00615 3
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Jie FM, 2021, J ETHNOPHARMACOL, V264, DOI 10.1016/j.jep.2020.113243
   Kang R, 2018, CELL HOST MICROBE, V24, P97, DOI 10.1016/j.chom.2018.05.009
   Kong FQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00369
   Li DD, 2018, MOL MED REP, V18, P4399, DOI 10.3892/mmr.2018.9427
   Li YY, 2019, CELL METAB, V30, P477, DOI 10.1016/j.cmet.2019.06.016
   Li ZY, 2019, AGING US, V11, P1226, DOI 10.18632/aging.101831
   Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev immunol 051116 052406
   Liu BL, 2018, EXP THER MED, V16, P5009, DOI 10.3892/etm.2018.6852
   Liu WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02228
   Liu YJ, 2011, EUR J PHARMACOL, V654, P304, DOI 10.1016/j.ejphar.2011.01.002
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   McInnes IB, 2010, ANN RHEUM DIS, V69, P1898, DOI 10.1136/ard.2010.134684
   McKenzie BA, 2019, P NATL ACAD SCI USA, V116, P13145, DOI 10.1073/pnas.1909025116
   Orning P, 2019, J EXP MED, V216, P2453, DOI 10.1084/jem.20190545
   Plóciennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018 014 1762 5
   Qiu CC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02608
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Roubille C, 2014, SEMIN ARTHRITIS RHEU, V43, P613, DOI 10.1016/j.semarthrit.2013.09.005
   Schwaneck EC, 2018, ARTHRITIS RHEUMATOL, V70, P1914, DOI 10.1002/art.40654
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shu JL, 2019, ACTA PHARMACOL SIN, V40, P801, DOI 10.1038/s41401 018 0169 5
   Sparks JA, 2019, ANN INTERN MED, V170, pITC1, DOI 10.7326/AITC201901010
   Thakur S, 2018, BIOMED PHARMACOTHER, V106, P1011, DOI 10.1016/j.biopha.2018.07.027
   Udalova IA, 2016, NAT REV RHEUMATOL, V12, P472, DOI 10.1038/nrrheum.2016.91
   Wang D, 2011, CLIN EXP IMMUNOL, V163, P225, DOI 10.1111/j.1365 2249.2010.04293.x
   Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027
   Wu H, 2007, INT IMMUNOPHARMACOL, V7, P662, DOI 10.1016/j.intimp.2007.01.019
   Wu XY, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102336
   Yang M, 2017, CURR MED RES OPIN, V33, P973, DOI 10.1080/03007995.2017.1281110
   Yi YS, 2018, KOREAN J PHYSIOL PHA, V22, P1, DOI 10.4196/kjpp.2018.22.1.1
   Zhang H, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0911 z
   Zhang J, 2015, J PHARMACOL SCI, V128, P8, DOI 10.1016/j.jphs.2015.02.011
   Zhang LL, 2008, INFLAMM RES, V57, P388, DOI 10.1007/s00011 007 7240 x
   Zhang LL, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107452
   Zhou RX, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1651 9
   Zu SQ, 2020, CELL BIOL INT, V44, P2140, DOI 10.1002/cbin.11422
NR 45
TC 34
Z9 43
U1 3
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2021
VL 101
AR 108169
DI 10.1016/j.intimp.2021.108169
EA OCT 2021
PN A
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA WE4GK
UT WOS:000705586000002
PM 34607227
DA 2025 08 17
ER

PT J
AU Akizawa, T
   Kido, R
   Fukagawa, M
   Onishi, Y
   Yamaguchi, T
   Hasegawa, T
   Fukuhara, S
   Kurokawa, K
AF Akizawa, Tadao
   Kido, Ryo
   Fukagawa, Masafumi
   Onishi, Yoshihiro
   Yamaguchi, Takuhiro
   Hasegawa, Takeshi
   Fukuhara, Shunichi
   Kurokawa, Kiyoshi
TI Decreases in PTH in Japanese Hemodialysis Patients with Secondary
   Hyperparathyroidism: Associations with Changing Practice Patterns
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID DIALYSIS OUTCOMES; SERUM CALCIUM; VITAMIN D; PARATHYROID HORMONE;
   MINERAL METABOLISM; BONE METABOLISM; KIDNEY DISEASE; MORTALITY RISK;
   CINACALCET; PHOSPHORUS
AB Background and objectives Control of serum concentrations of calcium (Ca), phosphorus (P), and parathyroid hormone (PTH) is essential for management of secondary hyperparathyroidism (SHPT).
   Design, setting, participants, & measurements This is a planned interim analysis of a longitudinal cohort study. The settings are dialysis facilities in Japan. Eligible patients comprise all those who were receiving hemodialysis at one of 86 participating facilities and who have SHPT. Using data from a random sample (n = 3276) of the participants from January 2008 through June 2009, we measured changes in the percentages of patients who were within the national guideline specified target ranges of Ca (8.4 to 10 mg/di), P (3.5 to 6.0 mg/dl), and intact PTH (iPTH) (60 to 180 pg/ml), and changes in prescriptions of drugs targeting SHPT. We used regression models to identify factors affecting the achievement of the guideline specified targets.
   Results There were no notable changes in the percentage of patients who were within the guideline for Ca, P, or both. The percentage who were within the iPTH guideline increased from 14.5% to 43.3% (P < 0.001). There were no remarkable changes in the percentage of patients receiving vitamin D or phosphate binders. The percentage who received cinacalcet increased from 0% to 29%. Prescription of cinacalcet was associated with improvement or target achievement for iPTH and for Ca by 16.8 percentage points (95% CI: 8.1 to 17.0) and by 12.6 percentage points (13.7 to 19.9), respectively.
   Conclusions In the routine care of hemodialysis patients, increasing use of cinacalcet was associated with better control of SHPT. Clin J Am Soc Nephrol 6: 2280 2288, 2011. doi:10.2215/CJN.11501210
C1 [Onishi, Yoshihiro] Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Nakagyo Ku, Kyoto 6040847, Japan.
   [Akizawa, Tadao] Showa Univ, Sch Med, Div Nephrol, Dept Med, Tokyo 142, Japan.
   [Kido, Ryo; Fukuhara, Shunichi] Kyoto Univ, Dept Epidemiol & Healthcare Res, Grad Sch Med & Publ Hlth, Kyoto, Japan.
   [Fukagawa, Masafumi] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa 25911, Japan.
   [Yamaguchi, Takuhiro] Tohoku Univ, Div Biostat, Grad Sch Med, Sendai, Miyagi 980, Japan.
   [Hasegawa, Takeshi] Showa Univ, Fujigaoka Hosp, Div Nephrol, Dept Internal Med, Yokohama, Kanagawa 227, Japan.
   [Kurokawa, Kiyoshi] Natl Grad Inst Policy Studies, Tokyo, Japan.
C3 Showa University; Kyoto University; Tokai University; Tohoku University;
   Showa University; National Graduate Institute for Policy Studies
RP Onishi, Y (通讯作者)，Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Nakagyo Ku, Akinono Cho 513,Kyoto Daiichiseimei Izumiya Bldg, Kyoto 6040847, Japan.
EM onishi@i hope.jp
OI Fukagawa, Masafumi/0000 0002 7832 2339; Hasegawa,
   Takeshi/0000 0003 0420 5583
FU Kyowa Hakko Kirin
FX The MBD 5D is supported by research grants from Kyowa Hakko Kirin
   (manufacturer of intravenous calcitriol, cinacalcet hydrochloride, and
   sevelamer hydrochloride), without restrictions on publications. T.A. has
   acted as a consultant for Kyowa Hakko Kirin, has received grants
   (research support) from Kyowa Hakko Kirin, and is a member of speakers'
   bureau of Kyowa Hakko Kirin. S.F. has acted as a scientific advisor for
   Kyowa Hakko Kirin and has received grants (research support) from Kyowa
   Hakko Kirin. M.F. has acted as a consultant for Kyowa Hakko Kirin, has
   received honoraria from Kyowa Hakko Kirin, and has received grants
   (research support) from Kyowa Hakko Kirin. Y.O., T.Y., T.H., R.K., and
   K.K. have no such potential competing interests to declare.
CR Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167
   Cannata Andia JB, 2008, J NEPHROL, V21, P290
   Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206
   Danese MD, 2008, CLIN J AM SOC NEPHRO, V3, P1423, DOI 10.2215/CJN.01060308
   Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fishbane S, 2008, CLIN J AM SOC NEPHRO, V3, P1718, DOI 10.2215/CJN.01040308
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   Fukagawa M, 2011, AM J NEPHROL, V33, P427, DOI 10.1159/000327654
   Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744 9987.2008.00648.x
   Fukuhara S, 2011, THER APHER DIAL, V15, P169, DOI 10.1111/j.1744 9987.2010.00906.x
   Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57
   Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523 1755.2000.00819.x
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kimata Naoki, 2007, Hemodial Int, V11, P340, DOI 10.1111/j.1542 4758.2007.00190.x
   Komaba H, 2008, THER APHER DIAL, V12, pS44, DOI 10.1111/j.1744 9987.2008.00631.x
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Nakai S, 2009, THER APHER DIAL, V13, P457, DOI 10.1111/j.1744 9987.2009.00789.x
   Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013
   Palmer SC, 2007, ANN INTERN MED, V147, P840, DOI 10.7326/0003 4819 147 12 200712180 00004
   PAYNE RB, 1973, BMJ BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643
   Peter WLS, 2009, CLIN J AM SOC NEPHRO, V4, P354, DOI 10.2215/CJN.05241008
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY, P146, DOI [10.1016/S0169 7161(07)27003 8, DOI 10.1016/S0169 7161(07)27003 8]
   Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Wetmore JB, 2009, NAT CLIN PRACT NEPHR, V5, P24, DOI 10.1038/ncpneph0977
NR 33
TC 25
Z9 25
U1 0
U2 11
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555 9041
EI 1555 905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2011
VL 6
IS 9
BP 2280
EP 2288
DI 10.2215/CJN.11501210
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 817EN
UT WOS:000294654200025
PM 21836149
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Chen, SL
   Pan, YL
   Guo, Y
   Sun, XX
   Bai, X
   Liu, MM
   Wang, LN
   Xiao, J
   Chen, C
   Ma, Y
AF Chen, Shuangliu
   Pan, Yalan
   Guo, Yang
   Sun, Xiaoxian
   Bai, Xue
   Liu, Mengmin
   Wang, Lining
   Xiao, Jirimutu
   Chen, Cheng
   Ma, Yong
TI Integrative bioinformatics and experimental analysis of curcumin's role
   in regulating ferroptosis to combat osteoporosis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoporosis; Ferroptosis; Iron overload; Curcumin; BMSC
AB This study utilized bioinformatics and data mining techniques to explore the molecular mechanism of curcumin in treating osteoporosis (OP) through the lens of ferroptosis, thereby identifying novel therapeutic targets. The datasets GSE35958, GSE35956, GSE7429, and GSE7158 were obtained from the Gene Expression Omnibus (GEO) database. GSE35958 and GSE35956 were employed as training sets for data integration, while GSE7429 and GSE7158 served as independent validation sets. Through retrieval from the FerrDb database, iron deathrelated genes (FRGs) were identified, and the differentially expressed genes (DEGs) were intersected to obtain differentially expressed FRGs (DEFRGs). Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted, followed by the construction of a Protein Protein Interaction (PPI) network to identify Hub genes. The DGIdb database was utilized to predict candidate drugs associated with the Hub genes, and molecular docking and in vitro experiments confirmed that curcumin targets the Hub genes EGFR and PTGS2.Through in vitro testing of curcumin on BMSC cells, researchers examined cell vitality, iron death, osteogenic differentiation, mineralization, and the impact on EGFR and PTGS2 levels. The analysis yielded 2212 DEGs, 484 FRGs, with 45 FDEGs at the intersection. GO analysis revealed involvement in regulating mitochondrial proteins, amino acid transport across plasma membranes, and protein ubiquitination. KEGG pathway analysis indicated associations with iron death, FoxO signaling, mTOR signaling, cell aging, osteoclast differentiation, and GSH metabolism. Utilizing the MCC algorithm, five Hub genes were identified: MAPK3, PTGS2, TGFB1, CYBB, and EGFR, showing diagnostic potential for iron death. Curcumin displayed affinity for EGFR and PTGS2, mitigating iron induced effects on BMSCs such as increased reactive oxygen species, Fe3+ levels, and decreased mitochondrial membrane potential. Furthermore, curcumin reversed these effects, suggesting EGFR and PTGS2 as targets for curcumin to inhibit BMSC ferroptosis and potentially delay osteoporosis development. Maintaining iron homeostasis and targeting BMSC ferroptosis could offer therapeutic avenues for iron overload induced osteoporosis.
C1 [Chen, Shuangliu] Nanjing Univ Chinese Med, Sch Chinese Med, Nanjing, Peoples R China.
   [Pan, Yalan; Guo, Yang; Bai, Xue; Liu, Mengmin; Wang, Lining; Ma, Yong] Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, Nanjing, Peoples R China.
   [Chen, Shuangliu; Pan, Yalan; Guo, Yang; Sun, Xiaoxian; Bai, Xue; Liu, Mengmin; Wang, Lining; Ma, Yong] Nanjing Univ Chinese Med, Lab New Tech Restorat & Reconstruct Orthoped & Tra, Nanjing 210023, Jiangsu, Peoples R China.
   [Ma, Yong] Nanjing Univ Chinese Med, Yancheng TCM Hosp, Yancheng, Peoples R China.
   [Xiao, Jirimutu] Inner Mongolia Med Univ, Coll Mongolian Med, Hohhot, Inner Mongolia, Peoples R China.
   [Chen, Cheng] Nanjing Univ Chinese Med, Jiangyan Hosp, Jiangyan, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing University of
   Chinese Medicine; Inner Mongolia Medical University; Nanjing University
   of Chinese Medicine
RP Ma, Y (通讯作者)，Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, Nanjing, Peoples R China.; Chen, C (通讯作者)，Nanjing Univ Chinese Med, Jiangyan Hosp, Jiangyan, Peoples R China.
EM gj20040814@163.com; mayong@njucm.edu.cn
RI ; PAN, Misty/JRX 0528 2023
OI PAN, Yalan/0000 0003 0604 9852; 
FU Jiangsu Provincial Clinical Medicine Innovation Center for Degenerative
   Osteoarthropathy of Traditional Chinese Medicine (Science and Education
   of Traditional Chinese Medicine in Suzhou) [BK20221351]; State
   Administration of Traditional Chinese Medicine [85]; Postgraduates'
   Research Innovation Program of Jiangsu Province;  [KYCX24_2197]
FX General Program of National Natural Science Foundation of China
   (82074458, 82174411) ;Regional projects of the National Natural Science
   Foundation of China (82260981) ;General Project of Natural Science
   Foundation of Jiangsu Province (BK20221351) ;Funded by Jiangsu
   Provincial Clinical Medicine Innovation Center for Degenerative
   Osteoarthropathy of Traditional Chinese Medicine (Science and Education
   of Traditional Chinese Medicine in Suzhou [2021] No.4) ;Funded by the
   State Administration of Traditional Chinese Medicine (Chinese Medicine
   Teaching Letter [2023] No. 85) ; Postgraduates' Research Innovation
   Program of Jiangsu Province in 2024 (KYCX24_2197) .
CR Abd El Hack ME, 2021, J SCI FOOD AGR, V101, P5747, DOI 10.1002/jsfa.11372
   Chengxiang M.A., 2024, Rheumatism and Arthritis, V13, P71
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Fan DS, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/4974343
   He Q, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.113915
   Inchingolo AD, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173519
   Jiang ZX, 2022, IUBMB LIFE, V74, P1052, DOI 10.1002/iub.2656
   Lan DM, 2022, J MOL ENDOCRINOL, V69, P401, DOI 10.1530/JME 22 0086
   Li GW, 2015, INT J CLIN EXP PATHO, V8, P15684
   Liang Y, 2021, FOOD FUNCT, V12, P10667, DOI [10.1039/D1FO02002A, 10.1039/d1fo02002a]
   Liu F, 2023, PHARMACOL RES, V192, DOI 10.1016/j.phrs.2023.106788
   Liu WJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1448 x
   Mandrekar JN, 2010, J THORAC ONCOL, V5, P1315, DOI 10.1097/JTO.0b013e3181ec173d
   Mohan M, 2021, EUR J PHARM SCI, V160, DOI 10.1016/j.ejps.2021.105743
   Ning KT, 2022, MOL METAB, V58, DOI 10.1016/j.molmet.2022.101450
   Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422 020 00441 1
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xue CC, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1234563
   Yan CL, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.910675
   Yang C, 2020, J CELL MOL MED, V24, P1553, DOI 10.1111/jcmm.14842
   Yang C, 2021, INT J NANOMED, V16, P8049, DOI 10.2147/IJN.S334965
   Zhang YW, 2024, AGEING RES REV, V94, DOI 10.1016/j.arr.2024.102196
   Zhang YW, 2024, GUT MICROBES, V16, DOI 10.1080/19490976.2023.2295432
NR 25
TC 2
Z9 2
U1 2
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 20
PY 2024
VL 739
AR 150949
DI 10.1016/j.bbrc.2024.150949
EA NOV 2024
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA M4V3I
UT WOS:001357528900001
PM 39541922
DA 2025 08 17
ER

PT J
AU Chen, YJ
   He, YH
   Lo, YH
   Yang, HS
   Abomughaid, MM
   Kumar, KJS
   Lin, WT
AF Chen, Yi Ju
   He, Yen Hua
   Lo, Yun Hsin
   Yang, Hong Siang
   Abomughaid, Mosleh Mohammad
   Kumar, K. J. Senthil
   Lin, Wan Teng
TI Potato protein hydrolysate inhibits RANKL induced osteoclast development
   by inhibiting osteoclastogenic genes via the NF κB/MAPKs signaling
   pathways
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article; Early Access
DE anti osteoclast; HO 1; MAPK; NF kappa B; osteoclast; peptides; potato
   protein hydrolysate; RANKL
ID DIFFERENTIATION; OSTEOPOROSIS; PEPTIDE
AB In recent times, there has been growing attention towards exploring the nutritional and functional aspects of potato protein, along with its diverse applications. In the present study, we examined the anti osteoclast properties of potato protein hydrolysate (PP902) in vitro. Murine macrophages (RAW264.7) were differentiated into osteoclasts by receptor activator of nuclear factor kappa B ligand (RANKL), and PP902 was examined for its inhibitory effect. Initially, treatment with PP902 was found to significantly prevent RANKL induced morphological changes in macrophage cells, as determined by tartrate resistant acid phosphatase (TRAP) staining analysis. This notion was further supported by F actin analysis using a confocal microscope. Furthermore, PP902 treatment effectively and dose dependently down regulated the expression of RANKL induced osteoclastogenic marker genes, including TRAP, CTR, RANK, NFATc1, OC STAMP, and c Fos. These inhibitory effects were associated with suppressing NF kappa B transcriptional activation and subsequent reduced nuclear translocation. The decrease in NF kappa B activity resulted from reduced activation of its upstream kinases, including I kappa B alpha and IKK alpha. Moreover, PP902 significantly inhibited RANKL induced p38MAPK and ERK1/2 activities. Nevertheless, PP902 treatment prevents RANKL induced intracellular reactive oxygen species generation via increased HO 1 activity. The combined antioxidant and anti inflammatory effects of PP902 resulted in significant suppression of osteoclastogenesis, suggesting its potential as an adjuvant therapy for osteoclast related diseases.
C1 [Chen, Yi Ju] Taichung Vet Gen Hosp, Dept Surg, Taichung, Taiwan.
   [Chen, Yi Ju] Tunghai Univ, Coll Agr & Hlth, Dept Anim Sci & Biotechnol, Taichung, Taiwan.
   [He, Yen Hua; Lo, Yun Hsin] Tunghai Univ, Coll Agr & Hlth, Dept Food Sci, Taichung, Taiwan.
   [Yang, Hong Siang; Lin, Wan Teng] Tunghai Univ, Coll Agr & Hlth, Dept Hospitality Management, Taichung, Taiwan.
   [Abomughaid, Mosleh Mohammad] Univ Bisha, Coll Appl Med Sci, Dept Med Lab Sci, Bisha, Saudi Arabia.
   [Kumar, K. J. Senthil] Natl Chung Hsing Univ, Bachelor Program Biotechnol, Taichung, Taiwan.
   [Kumar, K. J. Senthil] Natl Chung Hsing Univ, Ctr Gen Educ, Taichung, Taiwan.
   [Lin, Wan Teng] Utopia Holiday Hotel Corp, Res & Dev Div, Taichung, Taiwan.
C3 Taichung Veterans General Hospital; Tunghai University; Tunghai
   University; Tunghai University; University of Bisha; National Chung
   Hsing University; National Chung Hsing University
RP Lin, WT (通讯作者)，Tunghai Univ, Coll Agr & Hlth, Dept Hospitality Management, Taichung, Taiwan.; Kumar, KJS (通讯作者)，Natl Chung Hsing Univ, Bachelor Program Biotechnol, Taichung, Taiwan.; Kumar, KJS (通讯作者)，Natl Chung Hsing Univ, Ctr Gen Educ, Taichung, Taiwan.
EM zenkumar@dragon.nchu.edu.tw; 040770@thu.edu.tw
RI Wu, Jia Ping/E 3513 2013; K.J., Senthil/F 5309 2011; Abomughaid,
   Mosleh/AAI 8872 2021; Abomughiad, Mosleh/AAI 8872 2021
OI Abomughaid, Mosleh/0000 0001 9663 8874; 
FU Tunghai University, Taiwan
FX No Statement Availabler No Statement Availabler No Statement Available
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Arora H, 2020, FOOD FUNCT, V11, P7197, DOI [10.1039/d0fo00497a, 10.1039/D0FO00497A]
   Asokan SM, 2020, AGING US, V12, P7334, DOI 10.18632/aging.103081
   Asokan SM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040779
   Bartova V., 2018, Res Agric Eng, V54, P170, DOI [10.17221/703RAE, DOI 10.17221/703]
   Beals KA, 2019, AM J POTATO RES, V96, P102, DOI 10.1007/s12230 018 09705 4
   Milian Linares MC, 2018, J FUNCT FOODS, V47, P299, DOI 10.1016/j.jff.2018.05.069
   Chakrabarti S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111738
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Chen YJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26216577
   Chuang HL, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13525
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Duvigneau JC, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8100475
   El Desoky AHH, 2022, J NAT MED TOKYO, V76, P575, DOI 10.1007/s11418 022 01622 5
   Fu Y, 2020, INT J FOOD SCI TECH, V55, P2314, DOI 10.1111/ijfs.14343
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Huang CY, 2015, J FUNCT FOODS, V12, P389, DOI 10.1016/j.jff.2014.11.027
   Jeong DH, 2020, J NAT PROD, V83, P1174, DOI 10.1021/acs.jnatprod.9b01212
   Ji HY, 2024, HELIYON, V10, DOI 10.1016/j.heliyon.2024.e25601
   Jung SY, 2022, EXP CELL RES, V418, DOI 10.1016/j.yexcr.2022.113252
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim MJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040431
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Kowalczewski PL, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071523
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Long WL, 2020, MOL MED REP, V22, P97, DOI 10.3892/mmr.2020.11119
   Mei LW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.734774
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Okeke EB, 2022, MOLECULES, V27, DOI 10.3390/molecules27123869
   Park OJ, 2017, J MOL MED, V95, P1315, DOI 10.1007/s00109 017 1589 2
   Qu ZC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1043975
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Shen GY, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101767
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Sun Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778078
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   To TT, 2012, DEVELOPMENT, V139, P141, DOI 10.1242/dev.071035
   Wang YW, 2012, ADV DRUG DELIVER REV, V64, P1341, DOI 10.1016/j.addr.2011.09.002
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2022.114101
   Yang ML, 2022, FOOD FUNCT, V13, P1975, DOI [10.1039/D1FO03696C, 10.1039/d1fo03696c]
   Zaky AA, 2022, FRONT NUTR, V8, DOI 10.3389/fnut.2021.815640
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zhang H, 2017, J INTEGR AGR, V16, P2924, DOI 10.1016/S2095 3119(17)61736 2
NR 47
TC 1
Z9 1
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD 2024 APR 12
PY 2024
DI 10.1002/tox.24251
EA APR 2024
PG 13
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA NO5C0
UT WOS:001201394200001
PM 38606910
DA 2025 08 17
ER

PT J
AU McKay, RR
   Zukotynski, KA
   Werner, L
   Voznesensky, O
   Wu, JS
   Smith, SE
   Jiang, Z
   Melnick, K
   Yuan, X
   Kantoff, PW
   Montgomery, B
   Balk, SP
   Taplin, ME
AF McKay, R. R.
   Zukotynski, K. A.
   Werner, L.
   Voznesensky, O.
   Wu, J. S.
   Smith, S. E.
   Jiang, Z.
   Melnick, K.
   Yuan, X.
   Kantoff, P. W.
   Montgomery, B.
   Balk, S. P.
   Taplin, M E
TI Imaging, procedural and clinical variables associated with tumor yield
   on bone biopsy in metastatic castration resistant prostate cancer
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
ID MARROW BIOPSY; VERTEBRAL BIOPSY; GUIDED BIOPSY; CARCINOMA; SPINE
AB BACKGROUND: Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has historically been a challenge. In this exploratory analysis, we evaluated imaging, procedural and clinical variables associated with tumor yield on image guided bone biopsy in men with mCRPC.
   METHODS: Clinical data were collected prospectively from men with mCRPC enrolled on a phase II trial with serial metastasis biopsies performed according to standard clinical protocol. Imaging was retrospectively reviewed. We evaluated the percent positive biopsy cores (PPC), calculated as the number of positive cores divided by the total number of cores collected per biopsy.
   RESULTS: Twenty nine men had 39 bone biopsies. Seventy seven percent of bone biopsies had at least one positive biopsy core. We determined that lesion size and distance from the skin to the lesion edge correlated with tumor yield on biopsy (median PPC 75% versus 42% for lesions > 8.8 cm(3) versus <= 8.8 cm(3), respectively, P = 0.05; median PPC 33% versus 71% for distance >= 6.1 versus < 6.1 cm, respectively, P = 0.02). There was a trend towards increased tumor yield in patients with increased uptake on radionuclide bone scan, higher calcium levels and shorter duration of osteoclast targeting therapy, although this was not statistically significant. Ten men had 14 soft tissue biopsies. All soft tissue biopsies had at least one positive biopsy core.
   CONCLUSIONS: This exploratory analysis suggests that there are imaging, procedural and clinical variables that have an impact on image guided bone biopsy yield. In order to maximize harvest of prostate cancer tissue, we have incorporated a prospective analysis of the metrics described here as part of a multi institutional project aiming to use the molecular characterization of mCRPC tumors to direct individual therapy.
C1 [McKay, R. R.; Werner, L.; Smith, S. E.; Jiang, Z.; Melnick, K.; Kantoff, P. W.; Taplin, M E] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
   [Zukotynski, K. A.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
   [Zukotynski, K. A.; Smith, S. E.; Yuan, X.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Voznesensky, O.; Wu, J. S.; Balk, S. P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Montgomery, B.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; University of Toronto; Sunnybrook Research Institute;
   Sunnybrook Health Science Center; Harvard University; Harvard University
   Medical Affiliates; Brigham & Women's Hospital; Harvard University;
   Harvard University Medical Affiliates; Beth Israel Deaconess Medical
   Center; Fred Hutchinson Cancer Center; University of Washington;
   University of Washington Seattle
RP Taplin, ME (通讯作者)，Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 450 Brookline Ave, Boston, MA 02115 USA.
EM mtaplin@partners.org
RI Smith, stacy/HNS 1781 2023; Wu, JIm/AAQ 3416 2021
OI Kantoff, Philip/0000 0001 7275 0597; 
FU Janssen; Fairweather Family Fund; Prostate Cancer Foundation Challenge
   Award
FX The clinical trial described in this manuscript was funded by Janssen.
   GlaxoSmithKline provided dutasteride for this trial. The cost of the
   tumor biopsies was funded through the Fairweather Family Fund and the
   Prostate Cancer Foundation Challenge Award.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRUGIERES P, 1991, J NEURORADIOLOGY, V18, P351
   CHUA DT, 1969, J UROLOGY, V102, P602, DOI 10.1016/S0022 5347(17)62209 2
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   GHELMAN B, 1991, SPINE, V16, P736, DOI 10.1097/00007632 199107000 00008
   Lis E, 2004, AM J NEURORADIOL, V25, P1583
   MEHAN DJ, 1966, J UROLOGY, V95, P241, DOI 10.1016/S0022 5347(17)63440 2
   Ross RW, 2005, CLIN CANCER RES, V11, P8109, DOI 10.1158/1078 0432.CCR 05 1250
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Siegel R, 2013, CA CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   SPIERS ASD, 1982, J MED, V13, P303
   Spritzer CE, 2013, RADIOLOGY, V269, P816, DOI 10.1148/radiol.13121782
   STOKER DJ, 1985, CLIN RADIOL, V36, P569, DOI 10.1016/S0009 9260(85)80235 X
   Sy F A, 1973, Urology, V2, P125, DOI 10.1016/0090 4295(73)90243 4
   Wu JS, 2008, RADIOLOGY, V248, P962, DOI 10.1148/radiol.2483071742
NR 15
TC 30
Z9 30
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365 7852
EI 1476 5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD DEC
PY 2014
VL 17
IS 4
BP 325
EP 331
DI 10.1038/pcan.2014.28
PG 7
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA AT3LC
UT WOS:000344835400005
PM 25091040
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Magallanes, J
   Liu, NQ
   Zhang, JK
   Ouyang, YX
   Mkaratigwa, T
   Bian, FZ
   Van Handel, B
   Skorka, T
   Petrigliano, FA
   Evseenko, D
AF Magallanes, Jenny
   Liu, Nancy Q.
   Zhang, Jiankang
   Ouyang, Yuxin
   Mkaratigwa, Tadiwanashe
   Bian, Fangzhou
   Van Handel, Ben
   Skorka, Tautis
   Petrigliano, Frank A.
   Evseenko, Denis
TI A new mouse model of post traumatic joint injury allows to identify the
   contribution of Gli1+mesenchymal progenitors in arthrofibrosis and
   acquired heterotopic endochondral ossification
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE fication; mesenchymal progenitors; joint injury; differentiation
ID RADIATION THERAPY; RABBIT MODEL; STEM CELLS; CONTRACTURE; CAPSULE; NICHE
AB Complex injury and open reconstructive surgeries of the knee often lead to joint dysfunction that may alter the normal biomechanics of the joint. Two major complications that often arise are excessive deposition of fibrotic tissue and acquired heterotopic endochondral ossification. Knee arthrofibrosis is a fibrotic joint disorder where aberrant buildup of scar tissue and adhesions develop around the joint. Heterotopic ossification is ectopic bone formation around the periarticular tissues. Even though arthrofibrosis and heterotopic ossification pose an immense clinical problem, limited studies focus on their cellular and molecular mechanisms. Effective cell targeted therapeutics are needed, but the cellular origin of both knee disorders remains elusive. Moreover, all the current animal models of knee arthrofibrosis and stiffness are developed in rats and rabbits, limiting genetic experiments that would allow us to explore the contribution of specific cellular targets to these knee pathologies. Here, we present a novel mouse model where surgically induced injury and hyperextension of the knee lead to excessive deposition of disorganized collagen in the meniscus, synovium, and joint capsule in addition to formation of extra skeletal bone in muscle and soft tissues within the joint capsule. As a functional outcome, arthrofibrosis and acquired heterotopic endochondral ossification coupled with a significant increase in total joint stiffness were observed. By employing this injury model and genetic lineage tracing, we also demonstrate that Gli1+ mesenchymal progenitors proliferate after joint injury and contribute to the pool of fibrotic cells in the synovium and ectopic osteoblasts within the joint capsule. These findings demonstrate that Gli1+ cells are a major cellular contributor to knee arthrofibrosis and acquired heterotopic ossification that manifest after knee injury. Our data demonstrate that genetic manipulation of Gli1+ cells in mice may offer a platform for identification of novel therapeutic targets to prevent knee joint dysfunction after chronic injury.
C1 [Magallanes, Jenny; Liu, Nancy Q.; Zhang, Jiankang; Ouyang, Yuxin; Mkaratigwa, Tadiwanashe; Bian, Fangzhou; Van Handel, Ben; Petrigliano, Frank A.; Evseenko, Denis] Univ Southern Calif USC, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90007 USA.
   [Magallanes, Jenny; Mkaratigwa, Tadiwanashe; Bian, Fangzhou; Evseenko, Denis] USC, Keck Sch Med, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90007 USA.
   [Zhang, Jiankang] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Skorka, Tautis] USC, Keck Sch Med, Dept Radiol, Los Angeles, CA USA.
C3 University of Southern California; University of Southern California
   Keck Hospital; Sichuan University; University of Southern California;
   University of Southern California Keck Hospital
RP Evseenko, D (通讯作者)，Univ Southern Calif USC, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90007 USA.; Evseenko, D (通讯作者)，USC, Keck Sch Med, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90007 USA.
EM evseenko@usc.edu
RI Bian, Fangzhou/LSL 5787 2024
OI Magallanes, Jenny/0000 0001 7388 3359; Mkaratigwa, Tadiwanashe
   Blessing/0009 0003 6914 9719
FU National Institutes of Health; California Institute of Regenerative
   Medicine [R01AR071734, R01AG058624, W81XWH 13 1 0465]; USC Epstein
   Center for Sport Medicine [TRAN1 09288]; National Institute of Arthritis
   and Musculoskeletal and Skin Diseases [R01AR071734] Funding Source: NIH
   RePORTER; National Institute on Aging [R01AG058624] Funding Source: NIH
   RePORTER
FX Research reported in this publication was supported by the following
   funding sources: National Institutes of Health grant R01AR071734 (DE),
   National Institutes of Health grant R01AG058624 (DE), Department of
   Defense grant W81XWH 13 1 0465 (DE), California Institute of
   Regenerative Medicine grant TRAN1 09288 (DE), and research pilot grant
   from the USC Epstein Center for Sport Medicine (DE).
CR Abdel MP, 2012, J ORTHOP RES, V30, P713, DOI 10.1002/jor.21588
   Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023
   Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102
   Baranowski A, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0894 y
   Cheuy VA, 2017, J ARTHROPLASTY, V32, P2604, DOI 10.1016/j.arth.2017.02.005
   Eltawil NM, 2009, OSTEOARTHR CARTILAGE, V17, P695, DOI 10.1016/j.joca.2008.11.003
   Hazlewood D, 2018, J ORTHOP RES, V36, P2687, DOI 10.1002/jor.24038
   Hildebrand KA, 2004, J ORTHOP RES, V22, P313, DOI 10.1016/j.orthres.2003.08.012
   Huang YF, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00178 4
   Julien A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22842 5
   Kan C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1107 7
   Kan C, 2018, BONE, V109, P71, DOI 10.1016/j.bone.2017.06.014
   Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287
   Kaneguchi A, 2021, CONNECT TISSUE RES, V62, P263, DOI 10.1080/03008207.2019.1693548
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Lake SP, 2016, J ORTHOP RES, V34, P354, DOI 10.1002/jor.22981
   Lee CH, 2016, ANN REHABIL MED ARM, V40, P1135, DOI 10.5535/arm.2016.40.6.1135
   Li FF, 2013, INT J MOL SCI, V14, P20833, DOI 10.3390/ijms141020833
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Markolf KL, 2016, J BIOMECH ENG T ASME, V138, DOI 10.1115/1.4032693
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256 005 0958 z
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mishra MV, 2011, J MED IMAG RADIAT ON, V55, P333, DOI 10.1111/j.1754 9485.2011.02275.x
   Monument MJ, 2013, J ORTHOP SCI, V18, P869, DOI 10.1007/s00776 013 0447 5
   Mundy C, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abd0536
   Pagani CA, 2021, STEM CELL REP, V16, P626, DOI 10.1016/j.stemcr.2021.01.011
   Pavey GJ, 2015, CLIN ORTHOP RELAT R, V473, P2814, DOI 10.1007/s11999 015 4266 1
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Sono T, 2020, AM J PATHOL, V190, P1909, DOI 10.1016/j.ajpath.2020.05.017
   Steplewski A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257147
   Sun YB, 2016, EXP THER MED, V11, P547, DOI 10.3892/etm.2015.2948
   Tokuda K, 2022, CONNECT TISSUE RES, V63, P169, DOI 10.1080/03008207.2021.1892088
   Usher KM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0047 x
   Whelan DS, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59174 1
   Zhang L, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.684389
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
   Zhao H, 2014, CELL STEM CELL, V14, P160, DOI 10.1016/j.stem.2013.12.013
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 40
TC 2
Z9 3
U1 1
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 24
PY 2022
VL 10
AR 939296
DI 10.3389/fcell.2022.954028
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 5Q7SS
UT WOS:000874027100001
PM 36092701
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gao, HX
   Wang, MB
   Li, SJ
   Niu, J
   Xue, J
   Li, J
   Li, XX
AF Gao, Hai xia
   Wang, Meng bo
   Li, Si jing
   Niu, Jing
   Xue, Jing
   Li, Jun
   Li, Xin xia
TI Identification of Hub Genes and Key Pathways Associated with Peripheral
   T cell Lymphoma
SO CURRENT MEDICAL SCIENCE
LA English
DT Article
DE peripheral T cell lymphomas; bioinformatic analysis; protein protein
   interaction; hub genes; pathways
ID P AKT EXPRESSION; CLINICAL FEATURES; KINASE; INHIBITION; SURVIVAL;
   IMPACT; TNF; BIOMARKERS; APOPTOSIS; THERAPY
AB Peripheral T cell lymphoma (PTCL) is a very aggressive and heterogeneous hematological malignancy and has no effective targeted therapy. The molecular pathogenesis of PTCL remains unknown. In this study, we chose the gene expression profile of GSE6338 from the Gene Expression Omnibus (GEO) database to identify hub genes and key pathways and explore possible molecular pathogenesis of PTCL by bioinformatic analysis. Differentially expressed genes (DEGs) between PTCL and normal T cells were selected using GEO2R tool. Gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis were performed using Database for Annotation, Visualization and Integrated Discovery (DAVID). Moreover, the Search Tool for the Retrieval of Interacting Genes (STRING) and Molecular Complex Detection (MCODE) were utilized to construct protein protein interaction (PPI) network and perform module analysis of these DEGs. A total of 518 DEGs were identified, including 413 down regulated and 105 up regulated genes. The down regulated genes were enriched in osteoclast differentiation, Chagas disease and mitogen activated protein kinase (MAPK) signaling pathway. The up regulated genes were mainly associated with extracellular matrix (ECM) receptor interaction, focal adhesion and pertussis. Four important modules were detected from the PPI network by using MCODE software. Fifteen hub genes with a high degree of connectivity were selected. Our study identified DEGs, hub genes and pathways associated with PTCL by bioinformatic analysis. Results provide a basis for further study on the pathogenesis of PTCL.
C1 [Gao, Hai xia; Li, Si jing; Niu, Jing; Xue, Jing; Li, Xin xia] Xinjiang Med Univ, Dept Pathol, Affiliated Hosp 1, Urumqi 830054, Peoples R China.
   [Gao, Hai xia; Li, Si jing; Niu, Jing; Xue, Jing] Xinjiang Med Univ, Urumqi 830011, Peoples R China.
   [Gao, Hai xia] Shihezi Univ, Affiliated Hosp 1, Dept Pathol, Sch Med, Shihezi 832002, Peoples R China.
   [Gao, Hai xia] Shihezi Univ, Affiliated Hosp 1, Key Lab Xinjiang Endem & Ethn Dis, Sch Med, Shihezi 832002, Peoples R China.
   [Wang, Meng bo; Li, Jun] Shihezi Univ, Affiliated Hosp 1, Dept Ultrasound, Sch Med, Shihezi 832002, Peoples R China.
C3 Xinjiang Medical University; Xinjiang Medical University; Shihezi
   University; Shihezi University; Shihezi University
RP Li, XX (通讯作者)，Xinjiang Med Univ, Dept Pathol, Affiliated Hosp 1, Urumqi 830054, Peoples R China.
EM 69839721@qq.com; 58946915@qq.com; lxx patho@163.com
OI Gao, Hai Xia/0000 0001 9719 8313; li, jun/0000 0002 9125 7754
FU National Natural Science Foundation of China [81660036]; Project of the
   Bingtuan Science and Technology [2019DB012]
FX The study was supported by grants from the National Natural Science
   Foundation of China (No. 81660036) and the Project of the Bingtuan
   Science and Technology (No. 2019DB012).
CR Armitage JO, 2012, AM J HEMATOL, V87, P512, DOI 10.1002/ajh.23144
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319
   Barreca A, 2011, J MOL ENDOCRINOL, V47, pR11, DOI 10.1530/JME 11 0004
   Boi M, 2016, ONCOTARGET, V7, P79623, DOI 10.18632/oncotarget.12876
   Bosch R, 2014, HISTOPATHOLOGY, V65, P119, DOI 10.1111/his.12381
   Brandt S, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162 3619 2 27
   Chow C, 2005, HAEMATOLOGICA, V90, P274
   de Leval L, 2009, CRIT REV ONCOL HEMAT, V72, P125, DOI 10.1016/j.critrevonc.2009.01.002
   Dlouhy I, 2017, LEUKEMIA RES, V59, P20, DOI 10.1016/j.leukres.2017.05.014
   Dunleavy K, 2010, CLIN CANCER RES, V16, P5608, DOI 10.1158/1078 0432.CCR 09 1995
   Foss FM, 2011, BLOOD, V117, P6756, DOI 10.1182/blood 2010 05 231548
   Gambacorti Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056/NEJMc1013224
   Garcia V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008173
   Goto N, 2014, J CLIN EXP HEMATOP, V54, P117, DOI 10.3960/jslrt.54.117
   Guo X, 2017, ONCOGENE, V36, P4224, DOI 10.1038/onc.2017.90
   Hasselblom S, 2010, BRIT J HAEMATOL, V149, P560, DOI 10.1111/j.1365 2141.2010.08123.x
   Hong JY, 2014, ANN ONCOL, V25, P182, DOI 10.1093/annonc/mdt530
   Hong JY, 2015, ANTICANCER RES, V35, P2465
   Horwitz SM, 2014, BLOOD, V123, P3095, DOI 10.1182/blood 2013 12 542142
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang WS, 2015, J LEUKOCYTE BIOL, V97, P477, DOI 10.1189/jlb.1RI0614 293R
   Huang YL, 2010, BLOOD, V115, P1226, DOI 10.1182/blood 2009 05 221275
   Intlekofer AM, 2014, INT J HEMATOL, V99, P249, DOI 10.1007/s12185 014 1521 2
   Islam S, 2017, MOL CANCER THER, V16, P2083, DOI 10.1158/1535 7163.MCT 17 0089
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   KATO H, 1994, LEUKEMIA LYMPHOMA, V16, P125, DOI 10.3109/10428199409114149
   Li S, 2017, ONCOL LETT, V14, P3967, DOI 10.3892/ol.2017.6707
   Li Y, 2016, TUMOR BIOL, V37, P1
   Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520
   Louissaint A, 2016, BLOOD, V128, P1093, DOI 10.1182/blood 2015 12 682591
   MacDonald I, 1996, BLOOD, V87, P1147, DOI 10.1182/blood.V87.3.1147.bloodjournal8731147
   Malumbres R, 2008, BLOOD, V111, P5509, DOI 10.1182/blood 2008 02 136374
   Martín Sánchez E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112148
   Martínez Delgado B, 2005, LEUKEMIA, V19, P2254, DOI 10.1038/sj.leu.2403960
   Morachis JM, 2010, GENE DEV, V24, P135, DOI 10.1101/gad.1856710
   Moskowitz AJ, 2014, BLOOD, V123, P2636, DOI 10.1182/blood 2013 12 516245
   Nakamura N, 2013, EUR J HAEMATOL, V91, P322, DOI 10.1111/ejh.12139
   Nakayama S, 2014, AM J SURG PATHOL, V38, P228, DOI 10.1097/PAS.0000000000000094
   Ning X, 2017, ONCOTARGETS THER, V10, P1673, DOI 10.2147/OTT.S131386
   Nocturne G, 2017, J AUTOIMMUN, V80, P56, DOI 10.1016/j.jaut.2017.02.001
   O'Leary H, 2009, CURR OPIN HEMATOL, V16, P292, DOI 10.1097/MOH.0b013e32832b89a9
   Ono K, 2015, F1000RES, V4
   Ott GR, 2016, J MED CHEM, V59, P7478, DOI 10.1021/acs.jmedchem.6b00487
   Paluch EK, 2016, ANNU REV CELL DEV BI, V32, P469, DOI 10.1146/annurev cellbio 111315 125341
   Pearson J.D., 2012, Journal of signal transduction, V2012, P123253
   Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833
   Piccaluga PP, 2014, INT J HEMATOL, V99, P219, DOI 10.1007/s12185 014 1522 1
   Ramezani S, 2017, MED MICROBIOL IMMUN, V206, P327, DOI 10.1007/s00430 017 0506 1
   Rassidakis GZ, 2005, BLOOD, V105, P827, DOI 10.1182/blood 2004 06 2125
   RUCO LP, 1990, AM J PATHOL, V137, P1163
   Scarisbrick JJ, 2014, BRIT J DERMATOL, V170, P1226, DOI 10.1111/bjd.12909
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Sebestyén A, 2007, EXP CELL RES, V313, P3167, DOI 10.1016/j.yexcr.2007.05.028
   Slupianek A, 2001, CANCER RES, V61, P2194
   Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood 2016 01 643569
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood 2006 04 016907
   Wang C, 2015, BLOOD, V126, P1741, DOI 10.1182/blood 2015 05 644591
   Wang YJ, 2017, ONCOTARGET, V8, P72182, DOI 10.18632/oncotarget.20053
   Xiang LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035378
   Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood 2009 06 222794
   Zamani Ahmadmahmudi M, 2017, BMC VET RES, V13, DOI 10.1186/s12917 016 0919 x
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011
   Zhang HW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0132 y
   Zhang JX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34199 9
   Zhu JJ, 2014, ANIMAL, V8, P1469, DOI 10.1017/S1751731114001323
NR 69
TC 4
Z9 5
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2096 5230
EI 2523 899X
J9 CURR MED SCI
JI Curr. Med. Sci.
PD OCT
PY 2020
VL 40
IS 5
BP 885
EP 899
DI 10.1007/s11596 020 2250 9
EA SEP 2020
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OH9KB
UT WOS:000573199000006
PM 32980897
DA 2025 08 17
ER

PT J
AU Casarin, S
   Dondossola, E
AF Casarin, Stefano
   Dondossola, Eleonora
TI An agent based model of prostate Cancer bone metastasis progression and
   response to Radium223
SO BMC CANCER
LA English
DT Article
DE In silico model; Radium 223; Prostate cancer bone metastasis; Tumor
   growth; Therapy response; Therapy optimization
ID RADIUM 223 DICHLORIDE; VASCULAR ADAPTATION; SURVIVAL; MICROENVIRONMENT;
   EVENTS
AB BackgroundBone metastasis is the most frequent complication in prostate cancer patients and associated outcome remains fatal. Radium223 (Rad223), a bone targeting radioisotope improves overall survival in patients (3.6months vs. placebo). However, clinical response is often followed by relapse and disease progression, and associated mechanisms of efficacy and resistance are poorly understood.Research efforts to overcome this gap require a substantial investment of time and resources. Computational models, integrated with experimental data, can overcome this limitation and drive research in a more effective fashion.MethodsAccordingly, we developed a predictive agent based model of prostate cancer bone metastasis progression and response to Rad223 as an agile platform to maximize its efficacy. The driving coefficients were calibrated on ad hoc experimental observations retrieved from intravital microscopy and the outcome further validated, in vivo.ResultsIn this work we offered a detailed description of our data integrated computational infrastructure, tested its accuracy and robustness, quantified the uncertainty of its driving coefficients, and showed the role of tumor size and distance from bone on Rad223 efficacy. In silico tumor growth, which is strongly driven by its mitotic character as identified by sensitivity analysis, matched in vivo trend with 98.3% confidence. Tumor size determined efficacy of Rad223, with larger lesions insensitive to therapy, while medium  and micro sized tumors displayed up to 5.02 and 152.28 fold size decrease compared to control treated tumors, respectively. Eradication events occurred in 652% of cases in micro tumors only. In addition, Rad223 lost any therapeutic effect, also on micro tumors, for distances bigger than 400 mu m from the bone interface.Conclusions p id=Par This model has the potential to be further developed to test additional bone targeting agents such as other radiopharmaceuticals or bisphosphonates.
C1 [Casarin, Stefano] Houston Methodist Res Inst, Ctr Computat Surg, Houston, TX 77030 USA.
   [Casarin, Stefano] Houston Methodist Hosp, Dept Surg, Houston, TX 77030 USA.
   [Casarin, Stefano] Houston Methodist Acad Inst, Houston, TX 77030 USA.
   [Dondossola, Eleonora] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.
C3 Houston Methodist; Houston Methodist; Houston Methodist; University of
   Texas System; UTMD Anderson Cancer Center
RP Casarin, S (通讯作者)，Houston Methodist Res Inst, Ctr Computat Surg, Houston, TX 77030 USA.; Casarin, S (通讯作者)，Houston Methodist Hosp, Dept Surg, Houston, TX 77030 USA.; Casarin, S (通讯作者)，Houston Methodist Acad Inst, Houston, TX 77030 USA.
EM scasarin@houstonmethodist.org
OI Casarin, Stefano/0000 0002 7416 2366
FU AACR Bayer Innovation and Discovery Grant; MD Anderson Cancer Center
   Prostate Cancer SPORE [P50 CA140388 09]; Bayer HealthCare
   Pharmaceuticals [57440]; NIH/NCI [P30 CA016672]; John F. Jr. and Carolyn
   Bookout Presidential Distinguished Chair fund
FX Dr. Casarin is supported by the John F. Jr. and Carolyn Bookout
   Presidential Distinguished Chair fund. Dr. Dondossola is supported by
   the AACR Bayer Innovation and Discovery Grant, the MD Anderson Cancer
   Center Prostate Cancer SPORE (P50 CA140388 09) and Bayer HealthCare
   Pharmaceuticals (57440). The Genitourinary Cancers Program of the Cancer
   Center Support Grant (CCSG) shared resources at MD Anderson Cancer
   Center is supported by NIH/NCI award number P30 CA016672. The funders
   did not have any influence on any aspects of the study, including
   design, data collection, analyses, interpretation, or writing the
   manuscript.
CR Araujo A, 2018, B MATH BIOL, V80, P1046, DOI 10.1007/s11538 018 0416 4
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Casarin S, 2018, J COMPUT SCI NETH, V29, P59, DOI 10.1016/j.jocs.2018.09.013
   Cook LM, 2016, SCI REP UK, V6, DOI 10.1038/srep29384
   Corti A, 2020, COMPUT BIOL MED, V118, DOI 10.1016/j.compbiomed.2020.103623
   Deshayes E, 2017, DRUG DES DEV THER, V11, P2643, DOI 10.2147/DDDT.S122417
   Dondossola E, 2019, J NATL CANC I
   Gandaglia G, 2014, PROSTATE, V74, P210, DOI 10.1002/pros.22742
   Garbey M, 2017, J THEOR BIOL, V429, P149, DOI 10.1016/j.jtbi.2017.06.013
   Jemal A, 2010, CA CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
   Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008 5472.CAN 15 1215
   Logothetis C, 2018, CANCER METAST REV, V37, P189, DOI 10.1007/s10555 017 9719 4
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Roodman GD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.122
   Santini D, 2010, CANCER TREAT REV, V36, pS6, DOI 10.1016/S0305 7372(10)70013 X
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Steele CB, 2017, CANCER AM CANCER SOC, V123, P5160, DOI 10.1002/cncr.31026
   Suominen MI, 2017, CLIN CANCER RES, V23, P4335, DOI 10.1158/1078 0432.CCR 16 2955
   Suominen MI, 2013, JNCI J NATL CANCER I, V105, P908, DOI 10.1093/jnci/djt116
   Suzman DL, 2014, CANCER METAST REV, V33, P619, DOI 10.1007/s10555 013 9480 2
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Winslow RL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003528
NR 24
TC 13
Z9 16
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 29
PY 2020
VL 20
IS 1
DI 10.1186/s12885 020 07084 w
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA MG7ME
UT WOS:000546212500006
PM 32600282
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tachi, J
   Tokuda, H
   Onuma, T
   Yamaguchi, S
   Kim, W
   Hioki, T
   Matsushima Nishiwaki, R
   Tanabe, K
   Kozawa, O
   Iida, H
AF Tachi, Junko
   Tokuda, Haruhiko
   Onuma, Takashi
   Yamaguchi, Shinobu
   Kim, Woo
   Hioki, Tomoyuki
   Matsushima Nishiwaki, Rie
   Tanabe, Kumiko
   Kozawa, Osamu
   Iida, Hiroki
TI Duloxetine strengthens osteoblast activation by prostaglandin
   E1 : Upregulation of p38 MAP kinase
SO PROSTAGLANDINS & OTHER LIPID MEDIATORS
LA English
DT Article
DE Duloxetine; PGE1; OPG; IL 6; Osteoblast
ID OSTEOPROTEGERIN SYNTHESIS; BONE; INHIBITOR; SEROTONIN; DIFFERENTIATION
AB Duloxetine, a serotonin norepinephrine reuptake inhibitor, is currently recommended as a useful medicine to chronic pain including low back pain. However, as the analogy of classical selective serotonin reuptake in hibitors, there is a concern to deteriorate osteoporosis with remaining to clarify the exact mechanism of duloxetine in bone metabolism. We have previously reported that prostaglandin E 1 (PGE(1)) induces the synthesis of both osteoprotegerin (OPG) and interleukin 6 (IL 6), essential regulators of bone metabolism, in osteoblastlike MC3T3 E1 cells. Based upon them, we herein investigated the mechanism whereby the effect of duloxetine on the synthesis of OPG and IL 6 induced by PGE(1) in these cells. Duloxetine enhanced the release from MC3T3 E1 cells of both OPG and IL 6 stimulated by PGE(1). However, reboxetine, a selective and specific inhibitor of norepinephrine reuptake, failed to affect the PGE(1) induced release of OPG or IL 6. Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE(1) stimulated release of both OPG and IL 6. Duloxetine amplified the expression of OPG mRNA and IL 6 mRNA stimulated by PGE(1). Duloxetine strengthened the PGE(1) induced p38 MAP kinase phosphorylation, which was amplified by fluvoxamine as well. SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE(1) stimulated release of OPG and IL 6. These results strongly suggest that duloxetine could strengthen osteoblast activation by PGE(1) through the upregulation of p38 MAP kinase, leading to increasing the synthesis of OPG and IL 6.
C1 [Tachi, Junko; Onuma, Takashi; Yamaguchi, Shinobu; Kim, Woo; Tanabe, Kumiko; Iida, Hiroki] Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, 1 1 Yanagido, Gifu 5011194, Japan.
   [Tachi, Junko; Tokuda, Haruhiko; Kim, Woo; Hioki, Tomoyuki; Matsushima Nishiwaki, Rie; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Med Genome Ctr Biobank, Dept Clin Lab, Obu, Japan.
   [Hioki, Tomoyuki] Kizawa Mem Hosp, Dept Dermatol, Minokamo, Japan.
C3 Gifu University; Gifu University; National Center for Geriatrics &
   Gerontology
RP Iida, H (通讯作者)，Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, 1 1 Yanagido, Gifu 5011194, Japan.
EM iida@gifu u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [26462289, 15K10487]; National Center for Geriatrics and Gerontology,
   Japan [29 12]; Grants in Aid for Scientific Research [26462289,
   15K10487] Funding Source: KAKEN
FX This study was supported in part by Grant in Aid for Scientific Research
   (26462289, 15K10487) from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan and the Research Funding for Longevity
   Sciences (29 12) from National Center for Geriatrics and Gerontology,
   Japan.
CR Agas D, 2013, J CELL PHYSIOL, V228, P25, DOI 10.1002/jcp.24117
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bradaschia Correa V, 2017, J BONE MINER RES, V32, P821, DOI 10.1002/jbmr.3045
   CLAASSEN V, 1977, BRIT J PHARMACOL, V60, P505, DOI 10.1111/j.1476 5381.1977.tb07528.x
   CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014 5793(95)00357 F
   Dhaliwal J.S., 2020, STATPERLS
   Fekete S, 2015, EUR J PHARMACOL, V761, P65, DOI 10.1016/j.ejphar.2015.04.029
   Ferroni L, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108853
   Fujii T, 2013, EUR SPINE J, V22, P432, DOI 10.1007/s00586 012 2439 0
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Haney EM, 2010, BONE, V46, P13, DOI 10.1016/j.bone.2009.07.083
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Hirai T, 2010, BIOCHEM BIOPH RES CO, V396, P278, DOI 10.1016/j.bbrc.2010.04.078
   HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kawabata T, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59392 7
   KOE BK, 1983, J PHARMACOL EXP THER, V226, P686
   Konno S, 2016, SPINE, V41, P1709, DOI 10.1097/BRS.0000000000001707
   Koura SM, 2019, MOL MED REP, V19, P2611, DOI 10.3892/mmr.2019.9924
   KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014 4827(92)90158 5
   Kuroyanagi G, 2017, MOL MED REP, V15, P1847, DOI 10.3892/mmr.2017.6177
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Larsson B, 2018, CALCIFIED TISSUE INT, V103, P278, DOI 10.1007/s00223 018 0427 z
   Ma Y, 2013, J BIOL CHEM, V288, P30105, DOI 10.1074/jbc.M113.481309
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Prystaz K, 2018, AM J PATHOL, V188, P474, DOI 10.1016/j.ajpath.2017.10.011
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16 2367
   Rabenda V, 2013, OSTEOPOROSIS INT, V24, P121, DOI 10.1007/s00198 012 2015 9
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003
   Strauss DH, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 025002
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   WatanabeTomita Y, 1997, CELL SIGNAL, V9, P105, DOI 10.1016/S0898 6568(96)00114 3
   Wong EHF, 2000, BIOL PSYCHIAT, V47, P818, DOI 10.1016/S0006 3223(99)00291 7
   Yamamoto N, 2015, PROSTAG OTH LIPID M, V116, P57, DOI 10.1016/j.prostaglandins.2015.01.003
NR 36
TC 7
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1098 8823
EI 2212 196X
J9 PROSTAG OTH LIPID M
JI Prostaglandins Other Lipid Mediat.
PD DEC
PY 2020
VL 151
AR 106481
DI 10.1016/j.prostaglandins.2020.106481
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA OU9XK
UT WOS:000591876000004
PM 33002595
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Ma, J
   Wang, Z
   Zhao, JQ
   Miao, WJ
   Ye, TW
   Chen, AM
AF Ma, Jun
   Wang, Zhu
   Zhao, Jianquan
   Miao, Wujun
   Ye, TianWen
   Chen, Aimin
TI Resveratrol Attenuates Lipopolysaccharides (LPS) Induced Inhibition of
   Osteoblast Differentiation in MC3T3 E1 Cells
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Cell Differentiation; Lipopolysaccharides; Osteoblasts
ID OSTEOGENIC DIFFERENTIATION; MITOCHONDRIAL FUNCTION;
   MOLECULAR MECHANISMS; OXIDATIVE STRESS; NITRIC OXIDE; RECEPTOR;
   CONTRIBUTES; INJURY; LPS; DYSFUNCTION
AB Background: LPS inhibited osteoblastic differentiation plays an important role in the pathogenesis of osteomyelitis. Thus, searching for drugs that affect LPS mediated osteoblastic differentiation may be crucial in developing therapies for osteomyelitis. The purpose of this study was to investigate the role and mechanisms of resveratrol, a natural polyphenol present in red wine, on LPS inhibited osteoblastic differentiation.
   Material/Methods: Cell viability was measured by MMT assay. Mitochondrial ATP levels, membrane potential, and superoxide production were measured to evaluate the effects of LPS and resveratrol on mitochondrial functions in osteoblast like MC3T3 E1 cells. Osteoblast related genes, including ALP, OCN, OPN, and RUNX2, were measured by ELISA analysis and RT PCR in differentiated osteoblast cells treated with LPS and resveratrol. Cellular Sirt1 and PCG 1 alpha levels were measured by Western blot to probe the impact of resveratrol treatment in LPS stimulated MC3T3 E1 osteoblasts.
   Results: The results showed that LPS caused significant mitochondrial dysfunctions of MC3T3 E1 cells in a dose dependent manner, which were attenuated by resveratrol. Furthermore, LPS markedly decreased the expression of ALP, OCN, OPN, and RUNX2 in MC3T3 E1 cells cultivated in osteoblast differentiation medium, suggesting that LPS inhibited the osteoblastic differentiation of MC3T3 E1 cells. However, resveratrol obviously alleviated the suppressive impact of LPS on osteoblast differentiation. In addition, resveratrol increased expression of Sirt1 and PGC 1 alpha in MC3T3 E1 cells treated with LPS.
   Conclusions: Taken together, these results show that resveratrol alleviated the suppression of LPS on osteoblast differentiation by improving, at least in part, mitochondrial function.
C1 [Ma, Jun; Wang, Zhu; Zhao, Jianquan; Miao, Wujun; Ye, TianWen; Chen, Aimin] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Trauma Surg, Shanghai, Peoples R China.
C3 Naval Medical University
RP Ye, TW; Chen, AM (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Trauma Surg, Shanghai, Peoples R China.
EM yetianwen@hotmail.com; Aiminchen1964@163.com
OI Ma, Jun/0000 0002 1796 8283
FU National Natural Science Foundation of China [81472129, 81672202];
   Science and Technology Commission of Shanghai Municipality [17411971900,
   15411950900]; "Shuguang Program"   Shanghai Education Development
   Foundation [14SG34]; "Shuguang Program"   Shanghai Municipal Education
   Commission [14SG34]; "Outstanding Young Scholar Program"   Second
   Military Medical University; "Research Clinician Program"   Shanghai
   Changzheng Hospital
FX This study was sponsored by the National Natural Science Foundation of
   China (No. 81472129 and No. 81672202), the Science and Technology
   Commission of Shanghai Municipality (No. 17411971900 and No.
   15411950900), the "Shuguang Program" supported by the Shanghai Education
   Development Foundation and Shanghai Municipal Education Commission (No.
   14SG34), the "Outstanding Young Scholar Program" supported by Second
   Military Medical University, and the "Research Clinician Program"
   supported by Shanghai Changzheng Hospital
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Cantó C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018 010 0454 z
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Du JK, 2016, FREE RADICAL BIO MED, V96, P406, DOI 10.1016/j.freeradbiomed.2016.05.006
   Durbin SM, 2014, J BONE MINER METAB, V32, P38, DOI 10.1007/s00774 013 0469 2
   Fu CL, 2017, MOL MED REP, V15, P131, DOI 10.3892/mmr.2016.6012
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Han X, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7809581
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hunter R, 2017, NEUROSCI RES, V114, P62, DOI 10.1016/j.neures.2016.09.007
   Ikeda Kyoji, 2011, Nihon Rinsho, V69, P1203
   Kadono H, 1999, INFECT IMMUN, V67, P2841, DOI 10.1128/IAI.67.6.2841 2846.1999
   Kwon IK, 2015, BBA MOL CELL RES, V1853, P561, DOI 10.1016/j.bbamcr.2014.12.011
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Li TJ, 2016, SCI REP UK, V6, DOI 10.1038/srep19049
   Lin SK, 2003, J BONE MINER RES, V18, P39, DOI 10.1359/jbmr.2003.18.1.39
   Liu HZ, 2016, J TOXICOL SCI, V41, P185, DOI 10.2131/jts.41.185
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Nagao M., 2017, J. Cell. Physiol
   Ornstrup MJ, 2016, CALCIFIED TISSUE INT, V99, P155, DOI 10.1007/s00223 016 0130 x
   Pietilä M, 2010, TISSUE ENG PART C ME, V16, P435, DOI 10.1089/ten.tec.2009.0247
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sun M, 2017, SCI REP UK, V7, DOI 10.1038/srep44352
   Tennen RI, 2012, CELL, V148, P387, DOI 10.1016/j.cell.2012.01.032
   Tsai PH, 2015, STEM CELLS DEV, V24, P2561, DOI 10.1089/scd.2015.0066
   Vincent AM, 2009, ANTIOXID REDOX SIGN, V11, P425, DOI 10.1089/ars.2008.2235
   Wang CN, 2015, FREE RADICAL BIO MED, V83, P31, DOI 10.1016/j.freeradbiomed.2015.02.024
   Wang MN, 2011, ANN NY ACAD SCI, V1240, P61, DOI 10.1111/j.1749 6632.2011.06258.x
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 38
TC 62
Z9 74
U1 2
U2 59
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD APR 6
PY 2018
VL 24
BP 2045
EP 2052
DI 10.12659/MSM.905703
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GC4WW
UT WOS:000429786900003
PM 29624568
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Tan, F
   Al Rubeai, M
AF Tan, Fei
   Al Rubeai, Mohamed
TI A multifunctional dexamethasone delivery implant fabricated using
   atmospheric plasma and its effects on apoptosis, osteogenesis and
   inflammation
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article
DE Atmospheric plasma; Dexamethasone; Implant; Drug delivery; Apoptosis;
   Osteogenesis; Inflammation; Osteoblast; Macrophage; Otorhinolaryngology;
   Head and neck surgery
ID MESENCHYMAL STEM CELLS; IN VITRO; CELLULAR MECHANISMS; GENE EXPRESSION;
   DRUG DELIVERY; DIFFERENTIATION; TITANIUM; WETTABILITY; RECEPTOR; OSTERIX
AB Implant based local drug delivery is a unique surgical therapy with many clinical advantages. Atmospheric pressure plasma is a novel non thermal surface biotechnology that has only recently been applied in enhancing a surgical implant. We are the first to use this technology to successfully create a dexamethasone delivery metallic implant. Irrespective of the loaded medication, the surface of this novel implant possesses advantageous material features including homogeneity, hydrophilicity, and optimal roughness. UV vis spectroscopy revealed much more sustainable drug release compared to the implants produced using simple drug attachment. In addition, our drug releasing implant was found to have multiple biological benefits. As proven by the ELISA data, this multi layer drug complex provides differential regulation on the cell apoptosis, as well as pro osteogenic and anti inflammatory effects on the peri implant tissue. Furthermore, using the pathway specific PCR array, our study discovered 28 and 26 upregulated and downregulated genes during osteogenesis and inflammation on our newly fabricated drug delivery implant, respectively. The medication induced change in molecular profile serves as a promising clue for designing future implant based therapy. Collectively, we present atmospheric pressure plasma as a potent tool for creating a surgical implant based drug delivery system, which renders multiple therapeutic potentials.
C1 [Tan, Fei] Tongji Univ, Shanghai East Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Shanghai, Peoples R China.
   [Tan, Fei] Tongji Univ, Sch Med, Shanghai, Peoples R China.
   [Tan, Fei] Univ Coll Dublin Natl Univ Ireland, Sch Chem & Bioproc Engn, Dublin, Ireland.
   [Tan, Fei] Univ Coll Dublin Natl Univ Ireland, Conway Inst Biomol & Biomed Res, Dublin, Ireland.
   [Tan, Fei] Royal Coll Surgeons England, London, England.
   [Al Rubeai, Mohamed] Cihan Univ Erbil, Dept Biol, Erbil, Iraq.
C3 Tongji University; Tongji University; University College Dublin; Royal
   College of Surgeons of England; Cihan University Erbil
RP Tan, F (通讯作者)，Tongji Univ, Shanghai East Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Shanghai, Peoples R China.; Tan, F (通讯作者)，Tongji Univ, Sch Med, Shanghai, Peoples R China.; Tan, F (通讯作者)，Univ Coll Dublin Natl Univ Ireland, Sch Chem & Bioproc Engn, Dublin, Ireland.; Tan, F (通讯作者)，Univ Coll Dublin Natl Univ Ireland, Conway Inst Biomol & Biomed Res, Dublin, Ireland.; Tan, F (通讯作者)，Royal Coll Surgeons England, London, England.
EM iatrologist@163.com
RI tan, fei/KOD 4737 2024
OI Tan, Fei/0000 0003 1010 0163
FU Shanghai Pujiang Program [19PJ1408800]
FX This work was sponsored by the Shanghai Pujiang Program (project no.
   19PJ1408800). It was initiated by Science Foundation Ireland and
   Shanghai East Hospital.
CR Achuthan A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0332 4
   Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282
   Araujo JV, 2008, J BIOMAT SCI POLYM E, V19, P1261, DOI 10.1163/156856208786052335
   Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4
   Barry JN, 2014, J BIOMED MATER RES A, V102, P871, DOI 10.1002/jbm.a.34755
   Benzon HT, 2007, ANESTHESIOLOGY, V106, P331, DOI 10.1097/00000542 200702000 00022
   Bhatt S, 2013, POLYMER, V54, P4820, DOI 10.1016/j.polymer.2013.06.054
   Breathnach R, 2018, BIOINTERPHASES, V13, DOI 10.1116/1.5046489
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Campos PP, 2006, HISTOL HISTOPATHOL, V21, P1263, DOI 10.14670/HH 21.1263
   Chen JH, 2011, J MATER SCI MATER M, V22, P547, DOI 10.1007/s10856 011 4232 8
   Chrysis D, 2005, ENDOCRINOLOGY, V146, P1391, DOI 10.1210/en.2004 1152
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   Dapunt U, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728619
   Dimitriadis PA, 2016, BMC EAR NOSE THROAT, V16, DOI 10.1186/s12901 016 0033 5
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Dowling DP, 2016, J PHYS D APPL PHYS, V49, DOI 10.1088/0022 3727/49/36/364005
   Dowling DP, 2014, IEEE T PLASMA SCI, V42, P2426, DOI 10.1109/TPS.2014.2326962
   Dowling DP, 2009, PLASMA PROCESS POLYM, V6, pS483, DOI 10.1002/ppap.200931110
   Duarte PM, 2016, J PERIODONTAL RES, V51, P689, DOI 10.1111/jre.12354
   Duske K, 2012, J CLIN PERIODONTOL, V39, P400, DOI 10.1111/j.1600 051X.2012.01853.x
   Faia Torres AB, 2015, ACTA BIOMATER, V28, P64, DOI 10.1016/j.actbio.2015.09.028
   Forouzandeh A, 2014, CERAM INT, V40, P1081, DOI 10.1016/j.ceramint.2013.06.107
   Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917
   Gittens RA, 2014, ACTA BIOMATER, V10, P2907, DOI 10.1016/j.actbio.2014.03.032
   Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357 2725(98)00058 2
   Gross KL, 2011, MOL ENDOCRINOL, V25, P1087, DOI 10.1210/me.2010 0051
   Gruver Yates Amanda L, 2013, Cells, V2, P202, DOI 10.3390/cells2020202
   Hallab NJ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00005
   Hata K, 2007, J BIOMED MATER RES A, V81A, P446, DOI 10.1002/jbm.a.31086
   Heinlin J, 2011, J EUR ACAD DERMATOL, V25, P1, DOI 10.1111/j.1468 3083.2010.03702.x
   Jia H, 2013, ANN OTO RHINOL LARYN, V122, P33, DOI 10.1177/000348941312200107
   Kesavan K, 2013, THER DELIV, V4, P1385, DOI [10.4155/tde.13.106, 10.4155/TDE.13.106]
   KOKUBO T, 1991, BIOMATERIALS, V12, P155, DOI 10.1016/0142 9612(91)90194 F
   Kzhyshkowska J, 2015, J LEUKOCYTE BIOL, V98, P953, DOI 10.1189/jlb.5VMR0415 166R
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McHugh Jessica, 2018, Nat Rev Rheumatol, V14, P622, DOI 10.1038/s41584 018 0104 7
   Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359 6101(02)00045 X
   Metcalfe C, 2017, EUR ARCH OTO RHINO L, V274, P2637, DOI 10.1007/s00405 017 4529 4
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Na Young, 2009, J Adv Prosthodont, V1, P91, DOI 10.4047/jap.2009.1.2.91
   Parithimarkalaignan S, 2013, J Indian Prosthodont Soc, V13, P2, DOI 10.1007/s13191 013 0252 z
   Park JB, 2012, J SURG RES, V173, P99, DOI 10.1016/j.jss.2010.09.010
   Petlin DG, 2017, J CONTROL RELEASE, V266, P57, DOI 10.1016/j.jconrel.2017.09.023
   Phillips JE, 2006, J CELL SCI, V119, P581, DOI 10.1242/jcs.02758
   Ponsonnet L, 2003, MAT SCI ENG C BIO S, V23, P551, DOI 10.1016/S0928 4931(03)00033 X
   Prasad BR, 2010, COLLOID SURFACE B, V78, P237, DOI 10.1016/j.colsurfb.2010.03.006
   Rashid H, 2014, CONNECT TISSUE RES, V55, P83, DOI 10.3109/03008207.2014.923872
   Ren RQ, 2012, ENDOCRINOLOGY, V153, P5346, DOI 10.1210/en.2012 1563
   Saliba JB, 2016, INVEST OPHTH VIS SCI, V57, P1671, DOI 10.1167/iovs.15 18127
   Santos A, 2014, J MATER CHEM B, V2, P6157, DOI 10.1039/c4tb00548a
   Sarrette JP, 2006, PLASMA PROCESS POLYM, V3, P120, DOI [10.1002/ppap.200500113, 10.1002/ppap.200500t13]
   Schierano G, 2003, J DENT RES, V82, P428, DOI 10.1177/154405910308200605
   Schinke T, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P109, DOI 10.1016/B978 0 12 373884 4.00027 6
   Schneider GB, 2004, J BIOMED MATER RES A, V69A, P462, DOI 10.1002/jbm.a.30016
   Schneider H, 2014, TISSUE ENG PT A, V20, P335, DOI [10.1089/ten.tea.2012.0563, 10.1089/ten.TEA.2012.0563]
   Setzer B, 2009, BIOMATERIALS, V30, P979, DOI 10.1016/j.biomaterials.2008.10.054
   Shapiro S, 2018, OTOL NEUROTOL, V39, P865, DOI 10.1097/MAO.0000000000001877
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Smith LK, 2010, PROG BRAIN RES, V182, P1, DOI 10.1016/S0079 6123(10)82001 1
   Song IH, 2009, J ORTHOP RES, V27, P916, DOI 10.1002/jor.20838
   Spano A, 2013, CELL PROLIFERAT, V46, P328, DOI 10.1111/cpr.12030
   Spriano S, 2018, ACTA BIOMATER, V79, P1, DOI 10.1016/j.actbio.2018.08.013
   Stallard CP, 2013, PLASMA PROCESS POLYM, V10, P888, DOI 10.1002/ppap.201300056
   Stea S, 2000, BIOMATERIALS, V21, P1393, DOI 10.1016/S0142 9612(00)00041 7
   Strnad G, 2016, PROC TECH, V22, P946, DOI 10.1016/j.protcy.2016.01.094
   Tan F, 2013, TRENDS BIOTECHNOL, V31, P678, DOI 10.1016/j.tibtech.2013.09.001
   Tan F, 2012, ACTA BIOMATER, V8, P1627, DOI 10.1016/j.actbio.2011.12.014
   Tan F, 2012, BIOTECHNOL ADV, V30, P352, DOI 10.1016/j.biotechadv.2011.07.008
   Tan F, 2011, BIOTECHNOL BIOENG, V108, P454, DOI 10.1002/bit.22955
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Trajkovski B, 2012, ADV DRUG DELIVER REV, V64, P1142, DOI 10.1016/j.addr.2012.05.016
   Tu Q, 2007, TISSUE ENG, V13, P2431, DOI 10.1089/ten.2006.0406
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   Tynan J, 2009, PLASMA PROCESS POLYM, V6, pS51, DOI 10.1002/ppap.200930310
   Varma TK, 2001, INFECT IMMUN, V69, P5249, DOI 10.1128/IAI.69.9.5249 5263.2001
   von Woedtke T, 2013, PHYS REP, V530, P291, DOI 10.1016/j.physrep.2013.05.005
   Wang Q, 2010, BIOMATERIALS, V31, P4980, DOI 10.1016/j.biomaterials.2010.02.052
   Wen LP, 1997, AM J PHYSIOL LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921
   Werner S B, 1996, J Oral Implantol, V22, P216
   Xuereb M, 2015, INT J PROSTHODONT, V28, P51, DOI 10.11607/ijp.4124
   Yang DH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081695
   Yang JH, 2011, J BIOMED MATER RES B, V99B, P150, DOI 10.1002/jbm.b.31882
   Yoshida S, 2013, SURF COAT TECH, V233, P99, DOI 10.1016/j.surfcoat.2013.02.042
   Zeng S, 2017, DRUG DES DEV THER, V11, P3097, DOI 10.2147/DDDT.S147014
   Zhang C, 2011, PROSTATE, V71, P157, DOI 10.1002/pros.21231
   Zhong Y, 2005, I IEEE EMBS C NEUR E, P522
NR 88
TC 9
Z9 9
U1 0
U2 24
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 2190 393X
EI 2190 3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD FEB
PY 2021
VL 11
IS 1
BP 86
EP 102
DI 10.1007/s13346 019 00700 8
EA JAN 2020
PG 17
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA PT2VE
UT WOS:000505324300001
PM 31898081
DA 2025 08 17
ER

PT J
AU Guo, LH
   Luo, T
   Fang, Y
   Yang, L
   Wang, LP
   Liu, JW
   Shi, B
AF Guo, Lvhua
   Luo, Tao
   Fang, Ying
   Yang, Lan
   Wang, Liping
   Liu, Jingwen
   Shi, Bin
TI Effects of erythropoietin on osteoblast proliferation and function
SO CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Erythropoietin; Osteoblast cells; ALP activity; Osteocalcin secretion;
   Jak2/Stat3 pathway
ID BONE FORMATION; MARKERS; TISSUE; EPO
AB The purposes of this study were to investigate the effects of erythropoietin (EPO) on the proliferation and function of human osteoblast cells (hFOB 1.19) cultured in vitro and to explore the underlying molecular mechanisms to provide a theoretical foundation for clinical applications of EPO in oral implant and restoration therapies. Cultured hFOB 1.19 cells were treated with high and low doses of EPO. Changes in cell viability after 24 and 48 h of treatment were evaluated with the Mosmann tetrazolium assay. Changes in cell proliferation after 48 h of EPO treatment were measured by bromodeoxyuridine (BrdU) labeling, and changes in alkaline phosphatase (ALP) activity were determined by a specific assay. The effects of EPO on osteocalcin secretion were determined with the enzyme linked immunosorbent assay, and changes in the protein expression of osteoprotegerin (OPG), osteopontin (OPN) and receptor activator of NF kappa B ligand (RANKL) were assayed by western blot. The effects of EPO treatment on the levels of the EPO receptor (EPOR), phosphorylated Jak2 (P Jak2) and phosphorylated Stat3 (P Stat3) in hFOB 1.19 cells were evaluated in conjunction with a Jak2/Stat3 inhibitor. After 24 h of EPO treatment, hFOB 1.19 cells showed increased cell viability compared with the blank control group (p < 0.05). After 48 h, cell viability and growth were further improved relative to controls, with a significant increase observed for viability (p < 0.05). A significant increase in the proportion of BrdU labeled proliferating cells was observed in the high dose EPO group (p < 0.05), and EPO treated cells also showed enhanced ALP activity (p < 0.05). There were no statistically significant differences in osteocalcin secretion between groups after 48 h of EPO treatment (p > 0.05); however, increased secretion was observed in EPO treated cells after 96 h of treatment (p < 0.05). EPO treatment significantly promoted OPG and OPN expression (p < 0.05) while significantly inhibiting RANKL expression (p < 0.01). EPO treatment also significantly upregulated the levels of EPOR, P Jak2 and P Stat3 in hFOB 1.19 cells (p < 0.01); these effects were abrogated by co treatment with a Jak2/Stat3 inhibitor (AG490) (p < 0.01). EPO significantly stimulated osteoblast proliferation and differentiation. The underlying molecular mechanism is associated with the ability of EPO to promote ALP activity, osteocalcin secretion and OPG and OPN expression and to inhibit RANKL expression in osteoblasts. This mechanism appears to be mediated by the Jak2/Stat3 pathway.
C1 [Guo, Lvhua; Shi, Bin] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Peoples R China.
   [Guo, Lvhua; Shi, Bin] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan 430079, Peoples R China.
   [Guo, Lvhua; Luo, Tao; Fang, Ying; Yang, Lan; Wang, Liping; Liu, Jingwen] Guangzhou Med Univ, Hosp Stomatol, Guangzhou 510140, Guangdong, Peoples R China.
C3 Wuhan University; Wuhan University; Guangzhou Medical University
RP Shi, B (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol Hu, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
EM shibwh@163.com
RI Liu, Jingwen/J 5058 2019; Wang, Liping/B 2827 2012; Shi, Bin/B 3461 2019
FU Administration of Traditional Chinese Medicine of Guangdong Province
   [20111264]; Research Foundation of Science & Technology Bureau of Liwan
   District of Guangzhou city [20111213053]
FX This work was supported by Administration of Traditional Chinese
   Medicine of Guangdong Province (20111264) and Research Foundation of
   Science & Technology Bureau of Liwan District of Guangzhou city
   (20111213053). The authors are grateful to Dr Aaron L for editing the
   manuscript.
CR Aapro M, 2012, BRIT J CANCER, V106, P1249, DOI 10.1038/bjc.2012.42
   Al Omiri MK, 2011, INT J ORAL MAX IMPL, V26, P877
   Anchieta RB, 2012, DENT TRAUMATOL, V28, P166, DOI 10.1111/j.1600 9657.2011.01048.x
   Annunziata M, 2011, J DENT, V39, P720, DOI 10.1016/j.jdent.2011.08.003
   Bajek A, 2011, POSTEP HIG MED DOSW, V65, P124, DOI 10.5604/17322693.933878
   Boykin C, 2012, BRIT J CANCER, V106, P1248, DOI 10.1038/bjc.2012.77
   Carpentier B, 2011, INT J ARTIF ORGANS, V34, P259, DOI 10.5301/IJAO.2011.6333
   Chateauvieux S, 2011, BIOCHEM PHARMACOL, V82, P1291, DOI 10.1016/j.bcp.2011.06.045
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chiba T, 2009, EXPERT OPIN THER TAR, V13, P1155, DOI 10.1517/14728220903213426
   Cho HJ, 2009, CURR ATHEROSCLER REP, V11, P206, DOI 10.1007/s11883 009 0032 8
   Dong SW, 2012, BIOCHEM BIOPH RES CO, V418, P587, DOI 10.1016/j.bbrc.2012.01.075
   Duan WX, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395 012 0263 7
   El Haj AJ, 2010, P I MECH ENG H, V224, P1523, DOI 10.1243/09544119JEIM802
   Gundberg CM, 2000, CLIN LAB MED, V20, P489
   Holstein JH, 2011, BONE, V49, P1037, DOI 10.1016/j.bone.2011.08.004
   Holstein JH, 2007, LIFE SCI, V80, P893, DOI 10.1016/j.lfs.2006.11.023
   Horvai AE, 2011, SEMIN DIAGN PATHOL, V28, P13, DOI 10.1053/j.semdp.2011.02.004
   Iwamoto J, 2011, NUTR REV, V69, P162, DOI 10.1111/j.1753 4887.2011.00380.x
   Jelkmann W, 2007, METHOD ENZYMOL, V435, P179, DOI 10.1016/S0076 6879(07)35010 6
   Kermanac'h NS, 2002, EUR CYTOKINE NETW, V13, P144
   Kim J, 2012, J CELL BIOCHEM, V113, P220, DOI 10.1002/jcb.23347
   Li Minqi, 2006, Clin Calcium, V16, P591
   Marolt D, 2012, J ORAL MAXIL SURG, V70, P1081, DOI 10.1016/j.joms.2011.05.002
   Mcgee SJ, 2012, GROWTH FACTORS, V30, P22, DOI 10.3109/08977194.2011.637034
   Moore E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110 5820 1 3
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Orsini G, 2011, INT J PERIODONT REST, V31, P535
   Pivodova V, 2011, BIOMED PAP, V155, P109, DOI 10.5507/bp.2011.021
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Villafán Bernal JR, 2011, INT J MOL MED, V28, P283, DOI 10.3892/ijmm.2011.706
   Rathod DB, 2011, J INVEST MED, V59, P1083, DOI 10.2310/JIM.0b013e31822cf86e
   Reichel C, 2011, ANAL BIOANAL CHEM, V401, P463, DOI 10.1007/s00216 011 5116 y
   Reyes Garcia Rebeca, 2011, Endocrinol Nutr, V58, P353, DOI 10.1016/j.endonu.2011.05.004
   Seong WJ, 2011, INT J ORAL MAX IMPL, V26, P826
   Shiozawa Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010853
   Sorg H, 2013, MED RES REV, V33, P637, DOI 10.1002/med.21259
   Stein SH, 2011, J TENN DENT ASS, V91, P34
   Stein Sidney H, 2011, J Tenn Dent Assoc, V91, P30
NR 39
TC 28
Z9 28
U1 0
U2 15
PU SPRINGER VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1591 8890
EI 1591 9528
J9 CLIN EXP MED
JI Clin. Exper. Med.
PD FEB
PY 2014
VL 14
IS 1
BP 69
EP 76
DI 10.1007/s10238 012 0220 7
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AA4NW
UT WOS:000331073800008
PM 23135151
DA 2025 08 17
ER

PT J
AU Wang, Y
   Wang, SG
   Li, YM
   Jiang, JM
   Zhou, C
   Li, CX
   Li, D
   Lu, LQ
   Liu, PQ
   Huang, M
   Shen, XY
AF Wang, Ying
   Wang, Shaogui
   Li, Yanmei
   Jiang, Jianmin
   Zhou, Chun
   Li, Cuixian
   Li, Dong
   Lu, Liang
   Liu, Peiqing
   Huang, Min
   Shen, Xiaoyan
TI Therapeutic effect of Cryptotanshinone on collagen induced
   arthritis in rats via inhibiting nuclear factor kappa B signaling
   pathway
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID NECROSIS FACTOR ALPHA; RHEUMATOID ARTHRITIS; MATRIX METALLOPROTEINASES;
   ADJUVANT ARTHRITIS; BONE DESTRUCTION; GELATINASE B; SYNOVIOCYTES;
   INFLAMMATION; ACTIVATION; CYTOKINES
AB The discovery of new therapeutic drugs with the ability of preventing inflammation and joint destruction with less adverse effects is extremely urgent for rheumatoid arthritis (RA). Cryptotanshinone (CTS), an active component isolated from the root of Salvia miltiorrhiza Bunge, has been reported to have antibacterial and antitumor effects. However, its effects on RA have not been clearly elucidated. Here, we investigated the therapeutic effect of CTS on type II collagen induced arthritis (CIA) in rats and explored the underlying mechanisms. Our results revealed that CTS treatment efficaciously ameliorated inflammation and joint destruction of rats with CIA. Both in vivo and in vitro studies showed that CTS suppressed the production of proinflammatory cytokines including interleukin 1 beta, tumor necrosis factor alpha, and interleukin 17 alpha production and downregulated the production and activity of matrix metalloproteinase 9. By receptor activator of nuclear factor kappa B (NF kappa B) ligand induced bone marrow macrophages, we observed that CTS could inhibit osteoclast differentiation, which is critic for joint destruction. Further studies on inflammatory signaling revealed that CTS could inhibit the degradation of inhibitor of NF kappa B (I kappa B) alpha in vivo and in vitro, prevent the nuclear translocation of NF kappa B p65 induced by lipopolysaccharide in a time  and dose dependent manner. By electrophoretic mobility shift assay and luciferase reporter assay, we found that CTS distinctively inhibited the NF kappa B DNA binding activity and NF kappa B dependent luciferase activity. These results indicate that the therapeutic effect of CTS on CIA is accomplished mainly through the inhibition of NF kappa B signaling. Our findings provide the evidence to develop CTS as a potential therapeutic agent for patients with RA.
C1 Sun Yat Sen Univ, Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Guangzhou 510275, Guangdong, Peoples R China.
   [Shen, Xiaoyan] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 201203, Peoples R China.
C3 Sun Yat Sen University; Fudan University
RP Shen, XY (通讯作者)，Fudan Univ, Sch Pharm, Dept Pharmacol, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.
EM 1247380682@qq.com
RI ; Wang, Ying/T 9438 2018; Zhou, Chun/AGK 7203 2022
OI Zhou, Chun/0000 0001 7395 5842; , Xiaoyan/0000 0003 4828 3268; Wang,
   Ying/0000 0002 1407 2668; 
FU National Natural Science Foundation of China [81173056, 81371923,
   81460619]; Projects of International Cooperation and Exchanges, Science
   and Technology Planning Project of Guangdong Province, China
   [1011420600004]
FX This study was supported by the National Natural Science Foundation of
   China (no. 81173056, 81371923, and 81460619); Projects of International
   Cooperation and Exchanges, Science and Technology Planning Project of
   Guangdong Province, China (no. 1011420600004).
CR Aupperle KR, 1999, J IMMUNOL, V163, P427
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Giannelli G, 2004, CLIN EXP RHEUMATOL, V22, P335
   Granet C, 2004, ARTHRITIS RES THER, V6, pR190, DOI 10.1186/ar1159
   Gruber BL, 1996, CLIN IMMUNOL IMMUNOP, V78, P161, DOI 10.1006/clin.1996.0025
   Ha MK, 2011, BIOL PHARM BULL, V34, P1432, DOI 10.1248/bpb.34.1432
   Habermann B, 2007, ACTA ORTHOP, V78, P221, DOI 10.1080/17453670710013717
   Han ZN, 1998, AUTOIMMUNITY, V28, P197, DOI 10.3109/08916939808995367
   He C, 1996, CANCER LETT, V106, P185, DOI 10.1016/0304 3835(96)04318 2
   Isomäki P, 1997, ANN MED, V29, P499, DOI 10.3109/07853899709007474
   Joosten LAB, 1997, ARTHRITIS RHEUM, V40, P249, DOI 10.1002/art.1780400209
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691
   Lee DS, 1999, BIOSCI BIOTECH BIOCH, V63, P2236, DOI 10.1271/bbb.63.2236
   Lee HS, 2013, ARTHRITIS RHEUM US, V65, P1776, DOI 10.1002/art.37963
   Lee YR, 2011, BRIT J PHARMACOL, V164, P794, DOI 10.1111/j.1476 5381.2011.01441.x
   Li YM, 2013, TRANSL RES, V161, P89, DOI 10.1016/j.trsl.2012.06.001
   Mizuno M, 2001, ARTHRITIS RHEUM US, V44, P2425, DOI 10.1002/1529 0131(200110)44:10<2425::AID ART407>3.0.CO;2 4
   Okamoto H, 2007, FEBS J, V274, P4588, DOI 10.1111/j.1742 4658.2007.05987.x
   Paramalingam SS, 2007, ANN ACAD MED SINGAP, V36, P96
   Roman Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Schett G, 2001, ARTHRITIS RHEUM, V44, P2888, DOI 10.1002/1529 0131(200112)44:12<2888::AID ART477>3.0.CO;2 3
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tsai CY, 2007, ARTHRITIS RHEUM US, V56, P544, DOI 10.1002/art.22401
   Wang XD, 2013, BONE, V52, P111, DOI 10.1016/j.bone.2012.09.018
   Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003
   Yong VW, 1998, TRENDS NEUROSCI, V21, P75
   Zheng FL, 2011, CHINESE MED J PEKING, V124, P4293, DOI 10.3760/cma.j.issn.0366 6999.2011.24.030
   Zheng FL, 2009, CHINESE MED J PEKING, V122, P3039, DOI 10.3760/cma.j.issn.0366 6999.2009.24.024
NR 37
TC 28
Z9 32
U1 1
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1931 5244
EI 1878 1810
J9 TRANSL RES
JI Transl. Res.
PD JUN
PY 2015
VL 165
IS 6
BP 704
EP 716
DI 10.1016/j.trsl.2014.12.004
PG 13
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA CI6ZL
UT WOS:000354912600008
PM 25605261
DA 2025 08 17
ER

PT J
AU Li, XH
   Yan, Y
   Wang, Z
   Hou, JY
   Meng, YH
   Cui, DD
   Long, Y
   Li, M
   Yang, R
AF Li, Xinhao
   Yan, Yan
   Wang, Zhuo
   Hou, Jingyi
   Meng, Yuhan
   Cui, Dedong
   Long, Yi
   Li, Ming
   Yang, Rui
TI The link between osteoporosis and frozen shoulder: exploring the
   therapeutic effect of TAK715 on reversing fibrosis and protecting
   against osteoporosis via the p38 MAPK signaling pathway
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Osteoporosis (OP); Frozen Shoulder (FS); P38 MAPK; TAK715
ID ADHESIVE CAPSULITIS; MACROPHAGE POLARIZATION; TNF ALPHA; DIAGNOSIS;
   KINASE
AB Background The global incidence of frozen shoulder (FS) (2% similar to 5%) and osteoporosis (OP) is high (9.1% 12.1%). Clinically, postmenopausal women are particularly at risk for both diseases. The main objective of this current research is to investigate the pathogenesis mechanism of FS and explore the connection between FS and OP.
   Methods We obtained FS and OP datasets from GEO and identified crosstalk genes. Following KEGG and GO enrich analysis, the p38 MAPK signaling pathway was focused and the specific p38 alpha inhibitor TAK715 was screened out. We conducted flow cytometry, western blot, and PCR analyses to assess the treatment effect of TAK715 on FS synovium fibroblasts at different concentrations. Additionally, we employed SD rats to validate the treatment effects of TAK715 in vivo.
   Results TAK715 was useful in reversing fibrosis at the concentration of 1 mu M, 5 mu M and 10 mu M. The unbalanced apoptosis process in frozen shoulder cell and the activation of osteoclast were inhibited at the concentration of 5 mu M by TAK715. Then we successfully established a FS and OP rat model, with the FS with OP rat displaying less range of motion (ROM) and thicker shoulder capsule. In FS rat that was treated with TAK715, the frozen shoulder side was corrected in ROM and bone loss.
   Conclusions The frozen shoulder with osteoporosis may exhibit more severe symptoms, and TAK715 is effective in protecting fibrosis and osteoporosis both in vitro and vivo. The therapy to correct FS and OP simultaneously by TAK715 provides novel approach in FS treatment and study.
C1 [Li, Xinhao; Yan, Yan; Wang, Zhuo; Hou, Jingyi; Meng, Yuhan; Cui, Dedong; Long, Yi; Li, Ming; Yang, Rui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [Li, Xinhao; Yan, Yan; Wang, Zhuo; Hou, Jingyi; Meng, Yuhan; Cui, Dedong; Long, Yi; Li, Ming; Yang, Rui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Sports Med, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [Yan, Yan] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, 17 Lujiang Rd, Hefei, Anhui, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of
   Sciences; University of Science & Technology of China, CAS
RP Long, Y; Li, M; Yang, R (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.; Long, Y; Li, M; Yang, R (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Sports Med, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM longy68@mail.sysu.edu.cn; liming76@mail.sysu.edu.cn;
   yangr@mail.sysu.edu.cn
RI meng, yuhan/LBI 0707 2024
FU Sun Yat sen Memorial Hospital of Sun Yat sen University
FX We gratefully acknowledge Weike Zeng and Huijun Hu from the Department
   of Radiology, the Sun Yat sen Memorial Hospital of Sun Yat sen
   University, Qingqiang Tu and Min Zhou from Sun Yat sen University for
   providing guidance on X ray and CT imaging.
CR Akbar M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2102715118
   Akbar M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215301
   Brun SP, 2019, AUST J GEN PRACT, V48, P757, DOI 10.31128/AJGP 07 19 4992
   Cho CH, 2020, CLIN ORTHOP SURG, V12, P60, DOI 10.4055/cios.2020.12.1.60
   Cho CH, 2020, BREAST J, V26, P825, DOI 10.1111/tbj.13610
   Cho CH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7274517
   Coulthard LR, 2009, TRENDS MOL MED, V15, P369, DOI 10.1016/j.molmed.2009.06.005
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Deng YX, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.815245
   Dias R, 2005, BMJ BRIT MED J, V331, P1453, DOI 10.1136/bmj.331.7530.1453
   du Sert NP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000411
   Dyer BP, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen 2022 062377
   Falck D, 2013, J MASS SPECTROM, V48, P718, DOI 10.1002/jms.3219
   Falck D, 2010, ANAL BIOANAL CHEM, V398, P1771, DOI 10.1007/s00216 010 4087 8
   Gundtoft PH, 2020, DAN MED J, V67
   Herrmann FE, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.838449
   Hu YX, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.986384
   Itoi E, 2016, ARTHROSCOPY, V32, P1402, DOI 10.1016/j.arthro.2016.03.024
   Jang HY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242417358
   Jing F, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.805432
   Kamal N, 2020, J ORTHOP RES, V38, P2280, DOI 10.1002/jor.24686
   Karbowiak M, 2022, Frozen shoulder. Bmj., V377
   Kisseleva T, 2021, NAT REV GASTRO HEPAT, V18, P151, DOI 10.1038/s41575 020 00372 7
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Koorevaar RCT, 2017, ARCH ORTHOP TRAUM SU, V137, P293, DOI 10.1007/s00402 016 2589 3
   Leppälä J, 1998, BONE, V22, P691, DOI 10.1016/S8756 3282(98)00049 0
   Li FQ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1359 x
   Millar NL, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572 022 00386 2
   Millar NL, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 020 00234 1
   Miwatashi S, 2005, J MED CHEM, V48, P5966, DOI 10.1021/jm050165o
   Okamura K, 1999, ARCH ORTHOP TRAUM SU, V119, P363, DOI 10.1007/s004020050430
   Poston L, 2016, LANCET DIABETES ENDO, V4, P1025, DOI 10.1016/S2213 8587(16)30217 0
   Ramirez J, 2019, AM FAM PHYSICIAN, V99, P297
   RILEY D, 1989, J NEUROL NEUROSUR PS, V52, P63, DOI 10.1136/jnnp.52.1.63
   Rodeo SA, 1997, J ORTHOPAED RES, V15, P427, DOI 10.1002/jor.1100150316
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Ryan V, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1190 9
   Safran O, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117716450
   Struyf F, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19106228
   Sun YY, 2021, J INFLAMM RES, V14, P1055, DOI 10.2147/JIR.S304555
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang JP, 2007, INT ORTHOP, V31, P333, DOI 10.1007/s00264 006 0195 7
   Wang YH, 2024, BIOCHEM BIOPH RES CO, V703, DOI 10.1016/j.bbrc.2024.149665
   Weiskirchen R, 2019, MOL ASPECTS MED, V65, P2, DOI 10.1016/j.mam.2018.06.003
   Wen Y, 2020, AM J PHYSIOL RENAL, V318, pF107, DOI 10.1152/ajprenal.00347.2019
   Wolf MT, 2014, BIOMATERIALS, V35, P6838, DOI 10.1016/j.biomaterials.2014.04.115
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Yan Y, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1230174
   Yang CG, 2019, MOL MED REP, V19, P1065, DOI 10.3892/mmr.2018.9752
   Yang R, 2022, MOL IMMUNOL, V150, P29, DOI 10.1016/j.molimm.2022.07.007
   Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490
   Yu B, 2022, PERIODONTOL 2000, V89, P99, DOI 10.1111/prd.12422
   Yue JC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072346
   Zhao HK, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111700
NR 56
TC 2
Z9 2
U1 8
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD NOV 21
PY 2024
VL 25
IS 1
AR 942
DI 10.1186/s12891 024 08068 8
PG 22
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA N0V0T
UT WOS:001361597500004
PM 39574076
OA gold
DA 2025 08 17
ER

PT J
AU Fan, MK
   Zhang, GC
   Xie, MF
   Liu, XB
   Zhang, Q
   Wang, L
AF Fan, Mengke
   Zhang, Guochuan
   Xie, Mingfang
   Liu, Xinbo
   Zhang, Qi
   Wang, Ling
TI Siglec 15 as a New Perspective Therapy Target in Human Giant Cell Tumor
   of Bone
SO CURRENT ONCOLOGY
LA English
DT Article
DE giant cell tumor of bone; Siglec 15; CXCL8; functional assays; KEGG
   analysis; GO analysis
ID PROMOTES; RECURRENCE; EXPRESSION; DENOSUMAB; ADORA1; MICROENVIRONMENT;
   PROGRESSION; PROGNOSIS; SYSTEM; GROWTH
AB The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients. Although the treatment methods for a GCTB, such as scraping and resection, effectively inhibit the disease, the tendency toward malignant transformation remains. Therefore, it is important to identify new treatment methods for a GCTB. In this study, we first found high Siglec 15 expression in GCTB tissues, which was significantly associated with Campanacci staging and tumor recurrence. In Spearman's analysis, Siglec 15 expression was significantly correlated with Ki 67 levels in tumor tissues. In vitro, the mRNA and protein levels of Siglec 15 were high in GCTB stromal cells (Hs737. T), and Siglec 15 knockdown inhibited the biological characteristics of GCTB stromal cells. The RNA sequencing results enabled a prediction of the downstream genes by using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and MCODE analyses, and the findings showed that CXCL8 was significantly regulated by Siglec 15 and might be a promising downstream target gene of Siglec 15. Therefore, Siglec 15 may be a potential immunotherapy target for a GCTB.
C1 [Fan, Mengke; Zhang, Qi; Wang, Ling] Hebei Med Univ, Dept Orthoped Res Ctr, Hosp 3, Shijiazhuang 050051, Hebei, Peoples R China.
   [Fan, Mengke; Zhang, Guochuan; Xie, Mingfang; Wang, Ling] Hebei Med Univ, Dept Orthoped Oncol, Hosp 3, Shijiazhuang 050051, Hebei, Peoples R China.
   [Liu, Xinbo] Hebei Med Univ, Dept Thorac Surg, Hosp 4, Shijiazhuang 050010, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; Hebei Medical
   University
RP Zhang, Q; Wang, L (通讯作者)，Hebei Med Univ, Dept Orthoped Res Ctr, Hosp 3, Shijiazhuang 050051, Hebei, Peoples R China.; Wang, L (通讯作者)，Hebei Med Univ, Dept Orthoped Oncol, Hosp 3, Shijiazhuang 050051, Hebei, Peoples R China.
EM wangj_heb3y@163.com; wangling2016uw@126.com
RI ; 刘, 新博/KFB 1096 2024
OI wang, ling/0000 0002 2463 5487; 
FU National Natural Science Foundation of China [82173210]; Hebei Natural
   Science Foundation [H2021206176]; outstanding medical talents project by
   Hebei Province
FX This work was supported by several grants from National Natural Science
   Foundation of China (82173210), Hebei Natural Science Foundation
   (H2021206176) and outstanding medical talents project supported by Hebei
   Province in 2022.
CR Ajona D, 2018, AM J RESP CRIT CARE, V197, P1164, DOI 10.1164/rccm.201703 0660OC
   Ajona D, 2017, CANCER DISCOV, V7, P694, DOI 10.1158/2159 8290.CD 16 1184
   Amanatullah DF, 2014, ORTHOPEDICS, V37, P112, DOI 10.3928/01477447 20140124 08
   Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200
   Baci D, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1461 z
   Brondani LA, 2019, CURR EYE RES, V44, P994, DOI 10.1080/02713683.2019.1610178
   Chai KX, 1996, GENOMICS, V31, P51, DOI 10.1006/geno.1996.0008
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chang YC, 2020, ADV EXP MED BIOL, V1204, P197, DOI 10.1007/978 981 15 1580 4_8
   Chao CC, 2020, CANCERS, V12, DOI 10.3390/cancers12020459
   Chen MC, 2019, J CELL PHYSIOL, V234, P11822, DOI 10.1002/jcp.27891
   Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056
   Doron H, 2019, CELL REP, V28, P1785, DOI 10.1016/j.celrep.2019.07.033
   Edderkaoui B, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00039
   Fan MK, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.710689
   Frankel T, 2017, ADV EXP MED BIOL, V1036, P51, DOI 10.1007/978 3 319 67577 0_4
   Gao Q, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0511 6
   Gao Y, 2015, INT J ONCOL, V47, P690, DOI 10.3892/ijo.2015.3041
   Gao YJ, 2018, ONCOTARGETS THER, V11, P7333, DOI 10.2147/OTT.S167872
   Griciuc A, 2019, NEURON, V103, P820, DOI 10.1016/j.neuron.2019.06.010
   Gui SL, 2016, INT UROL NEPHROL, V48, P701, DOI 10.1007/s11255 016 1222 2
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Hanada R, 2001, BIOCHEM BIOPH RES CO, V289, P225, DOI 10.1006/bbrc.2001.5945
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   He YF, 2017, RADIOL MED, V122, P505, DOI 10.1007/s11547 017 0746 6
   Herr I, 2017, CANCER LETT, V409, P49, DOI 10.1016/j.canlet.2017.08.029
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Huang J, 2016, NEUROCHEM RES, V41, P1774, DOI 10.1007/s11064 016 1893 1
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Humphrey MB, 2016, CLIN REV ALLERG IMMU, V51, P48, DOI 10.1007/s12016 015 8521 8
   Hwang HJ, 2020, CANCER LETT, V490, P100, DOI 10.1016/j.canlet.2020.06.019
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Kang FB, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104728
   Kuruoglu D, 2022, J SURG ONCOL, V126, P798, DOI 10.1002/jso.26967
   Läubli H, 2020, CELL MOL LIFE SCI, V77, P593, DOI 10.1007/s00018 019 03288 x
   Lau CPY, 2020, J ORTHOP RES, V38, P297, DOI 10.1002/jor.24456
   Li CX, 2016, J HEPATOL, V65, P944, DOI 10.1016/j.jhep.2016.05.032
   Li L, 2017, NEOPLASMA, V64, P778, DOI 10.4149/neo_2017_517
   Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008
   Lin P, 2018, ORTHOP SURG, V10, P107, DOI 10.1111/os.12375
   Lin TY, 2016, ONCOTARGET, V7, P10228, DOI 10.18632/oncotarget.7169
   Liu H, 2020, CANCER CELL, V37, P324, DOI 10.1016/j.ccell.2020.02.006
   Liu Q, 2016, CYTOKINE GROWTH F R, V31, P61, DOI 10.1016/j.cytogfr.2016.08.002
   Liu S, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11947
   Liu WF, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100334
   López Pousa A, 2015, CLIN TRANSL ONCOL, V17, P419, DOI 10.1007/s12094 014 1268 5
   Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737
   Mandelli GE, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020291
   Mao ZY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389 020 00249 z
   Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655
   Mohaidat ZM, 2019, RARE TUMORS, V11, DOI 10.1177/2036361319878894
   Montgomery C, 2019, J KNEE SURG, V32, P331, DOI 10.1055/s 0038 1675815
   Teixeira LEM, 2014, ACTA ORTHOP TRAUMATO, V48, P136, DOI 10.3944/AOTT.2014.2714
   Muheremu A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 261
   Nabizadeh JA, 2019, FASEB J, V33, P11060, DOI 10.1096/fj.201800980RR
   Natsume M, 2020, BRIT J CANCER, V123, P459, DOI 10.1038/s41416 020 0898 3
   Ni S, 2020, ONCOTARGETS THER, V13, P12409, DOI 10.2147/OTT.S272621
   Ogawa R, 2019, CLIN CANCER RES, V25, P2887, DOI 10.1158/1078 0432.CCR 18 3684
   Palmerini E, 2017, EUR J CANCER, V76, P118, DOI 10.1016/j.ejca.2017.01.028
   Qi YL, 2020, J CELL PHYSIOL, V235, P4756, DOI 10.1002/jcp.29353
   Quattrini I, 2015, J ORTHOP RES, V33, P1205, DOI 10.1002/jor.22873
   Ruffini PA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00040
   See ALP, 2014, CURR CANCER DRUG TAR, V14, P294, DOI 10.2174/1568009614666140305222328
   Skubitz KM, 2014, CURR TREAT OPTION ON, V15, P507, DOI 10.1007/s11864 014 0289 1
   Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303
   Sun DP, 2020, CANCERS, V12, DOI 10.3390/cancers12030667
   Taki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03966 7
   Uday S, 2018, J CLIN ENDOCR METAB, V103, P596, DOI 10.1210/jc.2017 02025
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
   Vilgelm AE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00333
   Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591 019 0374 x
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
   Wu PF, 2015, TUMOR BIOL, V36, P495, DOI 10.1007/s13277 015 3094 y
   Wülling M, 2001, J CANCER RES CLIN, V127, P467, DOI 10.1007/s004320100234
   Xiao WY, 2019, ORTHOP SURG, V11, P126, DOI 10.1111/os.12414
   Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871
   Yin SS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01324
   Yoo W, 2019, CANCERS, V11, DOI 10.3390/cancers11101477
   Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367
   Zhou ZH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0361 z
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074 7613(00)80165 X
NR 81
TC 8
Z9 9
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1198 0052
EI 1718 7729
J9 CURR ONCOL
JI Curr. Oncol.
PD OCT
PY 2022
VL 29
IS 10
BP 7655
EP 7671
DI 10.3390/curroncol29100605
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 5O4PO
UT WOS:000872457600001
PM 36290882
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bachl, N
   Ruoff, G
   Wessner, B
   Tschan, H
AF Bachl, Norbert
   Ruoff, Gerhard
   Wessner, Barbara
   Tschan, Harald
TI Electromagnetic interventions in musculoskeletal disorders
SO CLINICS IN SPORTS MEDICINE
LA English
DT Article
ID COMBINED MAGNETIC FIELDS; OSTEOBLAST LIKE CELLS; DOUBLE BLIND TRIAL;
   IN VITRO; STRESS RESPONSE; MESSENGER RNA; THERAPY; BONE; EXPRESSION;
   INCREASE
AB Electromagnetic interventions in general and those considering the musculoskeletal system in particular hold many obscurities. Several studies revealing positive effects of electromagnetic fields oppose those showing no beneficial effects. After a historical review and a discussion of basic details on electromagnetic signals, this article provides information on the effects of electromagnetic fields on a cellular level and gives an account of preclinical and clinical studies focused on electromagnetic interventions by means of weak pulsed electromagnetic fields on musculoskeletal disorders.
C1 [Bachl, Norbert; Ruoff, Gerhard; Wessner, Barbara; Tschan, Harald] Univ Vienna, Inst Sports Sci, Dept Sports & Exercise Physiol, A 1150 Vienna, Austria.
   [Bachl, Norbert] Int Olymp Comm Med Commiss, Lausanne, Switzerland.
C3 University of Vienna
RP Bachl, N (通讯作者)，Univ Vienna, Inst Sports Sci, Dept Sports & Exercise Physiol, Auf Schmelz 6A, A 1150 Vienna, Austria.
EM norbert.bachl@univie.ac.at
RI Wessner, Barbara/J 8244 2012
OI Wessner, Barbara/0000 0002 9061 7914
CR Aaron RK, 1996, J ORTHOP RES, V14, P582, DOI 10.1002/jor.1100140412
   Aaron RK, 2004, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000118699.26862.41
   Aaron RK, 1999, BIOELECTROMAGNETICS, V20, P453, DOI 10.1002/(SICI)1521 186X(199910)20:7<453::AID BEM7>3.0.CO;2 H
   Aaron RK, 2002, J ORTHOP RES, V20, P233, DOI 10.1016/S0736 0266(01)00084 5
   Ahmadian S, 2006, BIOTECHNOL APPL BIOC, V43, P71, DOI 10.1042/BA20050086
   Alfieri RR, 2006, RADIAT RES, V165, P95, DOI 10.1667/RR3487.1
   BARKER AT, 1984, LANCET, V1, P994
   BERNATZKY G, 2006, INT FEDERATION SPORT, P55
   Blank M, 2004, J CELL PHYSIOL, V199, P359, DOI 10.1002/jcp.20004
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   CHANG KT, 2002, THESIS CHUNG YUAN CH
   Di Carlo A, 2002, J CELL BIOCHEM, V84, P447, DOI 10.1002/jcb.10036
   Fioravanti A, 2002, ANN RHEUM DIS, V61, P1032, DOI 10.1136/ard.61.11.1032
   FITZSIMMONS RJ, 1992, J CELL PHYSIOL, V150, P84, DOI 10.1002/jcp.1041500112
   FITZSIMMONS RJ, 1995, ENDOCRINOLOGY, V136, P3100, DOI 10.1210/en.136.7.3100
   FITZSIMMONS RJ, 1995, J BONE MINER RES, V10, P812
   FOLEYNOLAN D, 1990, ORTHOPEDICS, V13, P445
   FOLEYNOLAN D, 1992, SCAND J REHABIL MED, V24, P51
   Funk RHW, 2006, CELLS TISSUES ORGANS, V182, P59, DOI 10.1159/000093061
   Gartzke J, 2002, AM J PHYSIOL CELL PH, V283, pC1333, DOI 10.1152/ajpcell.00167.2002
   Goodman R, 1998, CELL STRESS CHAPERON, V3, P79, DOI 10.1379/1466 1268(1998)003<0079:MFSIEO>2.3.CO;2
   Goodman R, 2002, J CELL PHYSIOL, V192, P16, DOI 10.1002/jcp.10098
   Green S, 2003, Cochrane Database Syst Rev, pCD004258
   Guerkov HH, 2001, CLIN ORTHOP RELAT R, P265
   Ito Hiromoto, 2001, Journal of Nippon Medical School, V68, P149, DOI 10.1272/jnms.68.149
   Junkersdorf B, 2000, BIOELECTROMAGNETICS, V21, P100, DOI 10.1002/(SICI)1521 186X(200002)21:2<100::AID BEM4>3.0.CO;2 U
   Kafka WA, 2005, ORTHOPADISCHE PRAXIS, V41, P23
   KLOPP R, 2006, HEILPRAKTIKER VOLKSH, V10, P49
   Kroeling P, 2005, SPINE, V30, pE641, DOI 10.1097/01.brs.0000184302.34509.48
   Lee PB, 2006, J INT MED RES, V34, P160, DOI 10.1177/147323000603400205
   Liboff A.R., 2004, BIOELECTROMAGNETIC M, P17
   Lin H, 1997, J CELL BIOCHEM, V66, P482, DOI 10.1002/(SICI)1097 4644(19970915)66:4<482::AID JCB7>3.0.CO;2 H
   Lin H, 2001, J CELL BIOCHEM, V81, P143, DOI 10.1002/1097 4644(20010401)81:1<143::AID JCB1030>3.0.CO;2 4
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   Lohmann CH, 2003, J ORTHOP RES, V21, P326, DOI 10.1016/S0736 0266(02)00137 7
   Manni V, 2004, BIOELECTROMAGNETICS, V25, P118, DOI 10.1002/bem.10158
   Manni V, 2002, BIOELECTROMAGNETICS, V23, P298, DOI 10.1002/bem.10023
   Markov MS, 2004, BIOELECTROMAGNETIC M, P251
   McCarthy CJ, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 51
   MOONEY V, 1990, SPINE, V15, P708, DOI 10.1097/00007632 199007000 00016
   NAGAI M, 1994, J DENT RES, V73, P1601, DOI 10.1177/00220345940730100401
   Otter MW, 1998, CLIN ORTHOP RELAT R, pS90
   Patterson TE, 2006, BIOELECTROMAGNETICS, V27, P535, DOI 10.1002/bem.20244
   Pezzetti F, 1999, CALCIFIED TISSUE INT, V65, P396, DOI 10.1007/s002239900720
   PILLA AA, HDB BIOL EFFECTS ELE
   Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00 0294rev
   Quittan M, 2000, ACTA MED AUST, V27, P61
   RUOFF GW, 2006, OSTERREICHISCHES J S, V36, P32
   Schmidt Rohlfing B, 2000, Z ORTHOP GRENZGEB, V138, P379, DOI 10.1055/s 2000 10165
   Schuhfried O, 2005, INT J SPORTS MED, V26, P886, DOI 10.1055/s 2005 837451
   SHARRARD WJW, 1990, J BONE JOINT SURG BR, V72, P347, DOI 10.1302/0301 620X.72B3.2187877
   SIBLEY LM, 2001, PULSED SIGNAL THERAP
   Smith TL, 2004, J ORTHOPAED RES, V22, P80, DOI 10.1016/S0736 0266(03)00157 8
   Spadaro JA, 2002, CALCIFIED TISSUE INT, V70, P496, DOI 10.1007/s00223 001 1001 6
   Tepper OM, 2004, FASEB J, V18, P1231, DOI 10.1096/fj.03 0847fje
   Tokalov SV, 2004, ENVIRON RES, V94, P145, DOI 10.1016/S0013 9351(03)00088 4
   TROCK DH, 1994, J RHEUMATOL, V21, P1903
   Wenzel F, 2005, BIOMED TECH, V50, P14, DOI 10.1515/BMT.2005.003
   Zhuang HM, 1997, BIOCHEM BIOPH RES CO, V237, P225, DOI 10.1006/bbrc.1997.7118
NR 59
TC 30
Z9 33
U1 0
U2 9
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 5919
EI 1556 228X
J9 CLIN SPORT MED
JI Clin. Sports Med.
PD JAN
PY 2008
VL 27
IS 1
BP 87
EP +
DI 10.1016/j.csm.2007.10.006
PG 20
WC Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Sport Sciences
GA 265YP
UT WOS:000253398200007
PM 18206570
DA 2025 08 17
ER

PT J
AU Cooles, FAH
   Isaacs, JD
   Anderson, AE
AF Cooles, Faye A. H.
   Isaacs, John D.
   Anderson, Amy E.
TI Treg Cells in Rheumatoid Arthritis: An Update
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Rheumatoid arthritis; Tregs; Regulatory T cell; Tolerance defects;
   Cellular cross talk; TNF alpha; Th17 cell; Novel therapies; Monocytes;
   Osteoclasts; Fibroblast like synoviocytes
ID REGULATORY T CELLS; COLLAGEN INDUCED ARTHRITIS;
   VASOACTIVE INTESTINAL PEPTIDE; ANTIGEN SPECIFIC SUPPRESSION;
   SYNOVIAL FLUID; TH17 CELLS; MEDIATED SUPPRESSION; PERIPHERAL BLOOD;
   DENDRITIC CELLS; CUTTING EDGE
AB Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease arising from a breakdown in immunological self tolerance, which leads to aberrant immune responses to autoantigens. Regulatory CD4(+) T cells (Tregs) underpin one of the key mechanisms of self tolerance and are a major focus of study in RA and other autoimmune diseases. In order to design new and improved therapies to reinstate self tolerance, and perhaps cure disease, we need to understand the complex mechanism of action of Tregs. This review addresses recent findings in the field of Tregs in RA, with particular focus on identification of potential defects in Treg mediated self tolerance mechanisms present in RA patients, as well as how Tregs interact with other cells in the inflamed joints. As antigen specific Tregs are a potential route for the reinstatement of immune tolerance, we also discuss new strategies currently being investigated which expand or induce de novo generation of Tregs.
C1 [Cooles, Faye A. H.; Isaacs, John D.; Anderson, Amy E.] Newcastle upon Tyne Hosp NHS Fdn Trust, Newcastle NIHR Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Cooles, Faye A. H.; Isaacs, John D.; Anderson, Amy E.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University
     UK
RP Isaacs, JD (通讯作者)，Newcastle upon Tyne Hosp NHS Fdn Trust, Newcastle NIHR Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
EM faye.cooles@ncl.ac.uk; john.isaacs@ncl.ac.uk; amy.anderson@ncl.ac.uk
RI ; Anderson, Amy/AFL 4916 2022
OI Isaacs, John/0000 0002 6103 7056; Cooles, Faye/0000 0002 8529 3337;
   Anderson, Amy/0000 0003 0532 623X; 
FU Arthritis Research UK [18155] Funding Source: Medline; National
   Institute for Health Research [ACF 2011 01 001] Funding Source:
   researchfish; Versus Arthritis [18155] Funding Source: researchfish
CR Alvarez Quiroga C, 2011, J CLIN IMMUNOL, V31, P588, DOI 10.1007/s10875 011 9527 5
   Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Aravena O, 2011, IMMUNOBIOLOGY, V216, P1256, DOI 10.1016/j.imbio.2011.07.006
   Arce F, 2011, ARTHRITIS RHEUM US, V63, P84, DOI 10.1002/art.30099
   Benito Miguel M, 2009, J IMMUNOL, V183, P8268, DOI 10.4049/jimmunol.0900007
   Beriou G, 2009, BLOOD, V113, P4240, DOI 10.1182/blood 2008 10 183251
   Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev immunol 020711 075043
   Biton J, 2011, J IMMUNOL, V186, P3899, DOI 10.4049/jimmunol.1003372
   Blache C, 2011, RHEUMATOLOGY, V50, P1814, DOI 10.1093/rheumatology/ker183
   Cao TH, 2010, CLIN IMMUNOL, V136, P329, DOI 10.1016/j.clim.2010.04.014
   Capini C, 2009, J IMMUNOL, V182, P3556, DOI 10.4049/jimmunol.0802972
   Carranza F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040356
   Chen G, 2008, SCAND J IMMUNOL, V68, P572, DOI 10.1111/j.1365 3083.2008.02178.x
   Chistiakov DA, 2007, HUM IMMUNOL, V68, P375, DOI 10.1016/j.humimm.2007.01.013
   Darrasse Jèze G, 2009, J EXP MED, V206, P1853, DOI 10.1084/jem.20090746
   Dehlin M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003633
   Deknuydt F, 2009, CLIN IMMUNOL, V131, P298, DOI 10.1016/j.clim.2008.12.008
   Dominguez MD, 2011, AUTOIMMUNITY, V44, P471, DOI 10.3109/08916934.2010.550590
   Deng SH, 2010, CELL IMMUNOL, V265, P105, DOI 10.1016/j.cellimm.2010.07.010
   Duarte J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010558
   E XQ, 2012, SCAND J RHEUMATOL, V41, P413, DOI 10.3109/03009742.2012.696135
   Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165
   Ellis GI, 2012, J VIS EXP, V62
   Feuchtenberger Martin, 2008, Open Rheumatol J, V2, P81, DOI 10.2174/1874312900802010081
   Flores Borja F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005407
   Flores Borja F, 2008, P NATL ACAD SCI USA, V105, P19396, DOI 10.1073/pnas.0806855105
   Furuzawa Carballeda J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/618608
   Gonzalez Rey E, 2010, ANN RHEUM DIS, V69, P241, DOI 10.1136/ard.2008.101881
   Hamel KM, 2011, J IMMUNOL, V187, P4900, DOI 10.4049/jimmunol.1101844
   Haque R, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2983
   Haufe S, 2011, ARTHRITIS RHEUM US, V63, P3153, DOI 10.1002/art.30503
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Huang L, 2012, J IMMUNOL, V188, P4913, DOI 10.4049/jimmunol.1103668
   Kelchtermans H, 2009, ANN RHEUM DIS, V68, P744, DOI 10.1136/ard.2007.086066
   Kim Sung Hoon, 2012, Immune Netw, V12, P217, DOI 10.4110/in.2012.12.5.217
   Kleijwegt FS, 2010, J IMMUNOL, V185, P1412, DOI 10.4049/jimmunol.1000560
   Ko HJ, 2010, J AUTOIMMUN, V34, P111, DOI 10.1016/j.jaut.2009.07.006
   Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood 2008 01 133967
   Kong N, 2012, ANN RHEUM DIS, V71, P1567, DOI 10.1136/annrheumdis 2011 201052
   Lawson CA, 2006, RHEUMATOLOGY, V45, P1210, DOI 10.1093/rheumatology/kel089
   Liu MF, 2005, SCAND J IMMUNOL, V62, P312, DOI 10.1111/j.1365 3083.2005.01656.x
   Maddur MS, 2012, AM J PATHOL, V181, P8, DOI 10.1016/j.ajpath.2012.03.044
   McGovern JL, 2012, ARTHRITIS RHEUM US, V64, P3129, DOI 10.1002/art.34565
   Miranda Carús ME, 2004, J IMMUNOL, V173, P1463, DOI 10.4049/jimmunol.173.2.1463
   Möttönen M, 2005, CLIN EXP IMMUNOL, V140, P360, DOI 10.1111/j.1365 2249.2005.02754.x
   Nadkarni S, 2007, J EXP MED, V204, P33, DOI 10.1084/jem.20061531
   Nagar M, 2010, J IMMUNOL, V184, P3570, DOI 10.4049/jimmunol.0902070
   Nagata S, 2009, J IMMUNOL, V182, P7518, DOI 10.4049/jimmunol.0802230
   Niu Q, 2012, RHEUMATOL INT, V32, P2731, DOI 10.1007/s00296 011 1984 x
   Notley CA, 2010, ARTHRITIS RHEUM US, V62, P171, DOI 10.1002/art.25058
   Oh JS, 2013, RHEUMATOL INT, V33, P381, DOI 10.1007/s00296 012 2365 9
   Park MJ, 2011, ARTHRITIS RHEUM US, V63, P1668, DOI 10.1002/art.30326
   Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   Pesce B, 2013, CLIN EXP IMMUNOL, V171, P237, DOI 10.1111/cei.12017
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Samson M, 2012, ARTHRITIS RHEUM US, V64, P2499, DOI 10.1002/art.34477
   Saouaf SJ, 2009, EXP MOL PATHOL, V87, P99, DOI 10.1016/j.yexmp.2009.06.003
   Solt LA, 2012, ACS CHEM BIOL, V7, P1515, DOI 10.1021/cb3002649
   Song XQ, 2010, BIOMED PHARMACOTHER, V64, P463, DOI 10.1016/j.biopha.2010.01.007
   Srivastava RK, 2011, J IMMUNOL, V186, P2262, DOI 10.4049/jimmunol.1002691
   Sun J, 2012, ARTHRITIS RHEUM US, V64, P2158, DOI 10.1002/art.34372
   Svensson MND, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054884
   Swainson LA, 2010, J IMMUNOL, V184, P3639, DOI 10.4049/jimmunol.0903943
   Tang TT, 2011, J LIPID RES, V52, P1023, DOI 10.1194/jlr.M010876
   Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028
   Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood 2005 11 4567
   Valmori D, 2010, P NATL ACAD SCI USA, V107, P19402, DOI 10.1073/pnas.1008247107
   van Amelsfort JMR, 2004, ARTHRITIS RHEUM, V50, P2775, DOI 10.1002/art.20499
   van Amelsfort JMR, 2007, ARTHRITIS RHEUM, V56, P732, DOI 10.1002/art.22414
   Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106
   Walter GJ, 2013, ARTHRITIS RHEUM US, V65, P627, DOI 10.1002/art.37832
   Wang TY, 2010, CAN J PHYSIOL PHARM, V88, P45, DOI 10.1139/Y09 094
   Wang WH, 2012, RHEUMATOL INT, V32, P887, DOI 10.1007/s00296 010 1710 0
   Wehrens EJ, 2011, BLOOD, V118, P3538, DOI 10.1182/blood 2010 12 328187
   Weng L, 2010, ANN RHEUM DIS, V69, P1519, DOI 10.1136/ard.2009.121111
   Wright GP, 2009, P NATL ACAD SCI USA, V106, P19078, DOI 10.1073/pnas.0907396106
   Xiao H, 2011, J CLIN IMMUNOL, V31, P1112, DOI 10.1007/s10875 011 9559 x
   Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725
   Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007
   Yoshida H, 2010, EUR J PHARMACOL, V634, P178, DOI 10.1016/j.ejphar.2010.02.026
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zaiss MM, 2010, J IMMUNOL, V184, P7238, DOI 10.4049/jimmunol.0903841
   Zanin Zhorov A, 2012, P NATL ACAD SCI USA, V109, P1625, DOI 10.1073/pnas.1110120109
   Zanin Zhorov A, 2010, SCIENCE, V328, P372, DOI 10.1126/science.1186068
   Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112
NR 85
TC 85
Z9 99
U1 0
U2 46
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD SEP
PY 2013
VL 15
IS 9
AR 352
DI 10.1007/s11926 013 0352 0
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 228HB
UT WOS:000325175500002
PM 23888361
DA 2025 08 17
ER

PT J
AU Gonçalves, CF
   Desiderá, AD
   do Nascimento, GC
   Issa, JPM
   Leite Panissi, CRA
AF Goncalves, Carolina Ferreira
   Desidera, Amanda de Carvalho
   do Nascimento, Glauce Crivelaro
   Mardegan Issa, Joo Paulo
   Andrade Leite Panissi, Christie Ramos
TI Experimental tooth movement and photobiomodulation on bone remodeling in
   rats
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Tooth movement; Low intensity laser therapy; Bone cells and collagen
   fibers
ID LEVEL LASER THERAPY; ALVEOLAR BONE; ORTHODONTIC MOVEMENT; IRRADIATION;
   ACTIVATION; RODENTS; RELAPSE; LIGHT
AB Photobiomodulation (PBM) is a therapy induced by a specific type of laser that affects biologic systems through non thermal ways. The study of its basic mechanism has gained interest since little is known about the causes of the different effects of this treatment. In the present study, we investigated the action of the PBM application rate changes in the peri implant tissues in rats subjected to tooth movement in different periods. Wistar rats (+/  250 g) received an apparatus in the region of the central incisors superiors tightly (70 g) or not, and they were also subjected to one or three PBM sessions. After 7 or 14 days, the rats were subjected to euthanasia and the jaws were dissected and processed for histology. For analysis, serial sections were made that were stained by Picrosirius Red for analysis of collagen fibers, Masson's trichrome for newly formed bone scan, and Hematoxylin Eosin for quantification of osteoblasts. PBM applied in one or three sessions increased the population of osteoblasts. Still, the application of three sessions of PBM increased the density of collagen fibers and new bone formation compared to the controls. An increase was observed in the interincisal distance in irradiated groups with three PBM sessions and the application of force for both 7 or 14 days. These findings suggest that PBM can contribute positively to the orthodontic movement. So the laser therapy can be used as an adjunct procedure to be performed concurrently for orthodontic treatment in the dental clinic.
C1 [Goncalves, Carolina Ferreira; Desidera, Amanda de Carvalho; do Nascimento, Glauce Crivelaro; Mardegan Issa, Joo Paulo; Andrade Leite Panissi, Christie Ramos] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Morphol Physiol & Basic Pathol, BR 14040904 Sao Paulo, Brazil.
   [Andrade Leite Panissi, Christie Ramos] Univ Sao Paulo, Sch Philosophy Sci & Literature Ribeirao Preto, Psychobiol Grad Program, BR 14040901 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Leite Panissi, CRA (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Morphol Physiol & Basic Pathol, BR 14040904 Sao Paulo, Brazil.; Leite Panissi, CRA (通讯作者)，Univ Sao Paulo, Sch Philosophy Sci & Literature Ribeirao Preto, Psychobiol Grad Program, BR 14040901 Sao Paulo, Brazil.
EM christie@forp.usp.br
RI Leite Panissi, Christie/A 2011 2013; Crivelaro Nascimento,
   Glauce/G 2307 2014; Nascimento, Glauce/G 2307 2014; Leite Panissi,
   Christie R A/A 2011 2013; Issa, João/A 2505 2011
OI Crivelaro Nascimento, Glauce/0000 0001 5116 2200; Leite Panissi,
   Christie R A/0000 0003 1762 2730; 
FU CAPES; CNPq; FAPESP
FX This work was supported by CAPES, CNPq, and FAPESP.
CR Altan BA, 2012, LASER MED SCI, V27, P131, DOI 10.1007/s10103 010 0853 2
   Amat A, 2005, J PHOTOCH PHOTOBIO B, V81, P26, DOI 10.1016/j.jphotobiol.2005.05.012
   Amirov NB, 2003, EKSP KLIN GASTROENTE, V5, P45
   Aras MH, 2015, NIGER J CLIN PRACT, V18, P607, DOI 10.4103/1119 3077.154218
   Bicakci AA, 2012, PHOTOMED LASER SURG, V30, P460, DOI 10.1089/pho.2012.3245
   Bonafe Oliveira L, 2003, EUR J ORAL SCI, V111, P410, DOI 10.1034/j.1600 0722.2003.00067.x
   Cho KW, 2007, ORAL DIS, V13, P314, DOI 10.1111/j.1601 0825.2006.01286.x
   Cruz DR, 2004, LASER SURG MED, V35, P117, DOI 10.1002/lsm.20076
   de Carvalho FB, 2015, LASER MED SCI, V30, P389, DOI 10.1007/s10103 014 1680 7
   Desiderá AC, 2015, ORAL DIS, V21, P652, DOI 10.1111/odi.12330
   Farivar S, 2014, J LASERS MED SCI, V5, P58
   Fekrazad R, 2015, J PHOTOCH PHOTOBIO B, V151, P180, DOI 10.1016/j.jphotobiol.2015.08.002
   Fekrazad R, 2012, J LASERS MED SCI, V3, P135
   Gama SKC, 2010, PHOTOMED LASER SURG, V28, DOI 10.1089/pho.2009.2618
   Genc G, 2013, LASER MED SCI, V28, P41, DOI 10.1007/s10103 012 1059 6
   Habib FAL, 2010, PHOTOMED LASER SURG, V28, P823, DOI 10.1089/pho.2009.2732
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Kale S, 2004, AM J ORTHOD DENTOFAC, V125, P607, DOI 10.1016/j.ajodo.2003.06.002
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Kim SJ, 2013, LASER MED SCI, V28, P325, DOI 10.1007/s10103 012 1146 8
   Lin F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 16
   Madan MS, 2007, AM J ORTHOD DENTOFAC, V131, DOI 10.1016/j.ajodo.2006.06.014
   Magdalena CM, 2004, J DENT RES, V83, P50, DOI 10.1177/154405910408300110
   Maia LGM, 2014, J PHOTOCH PHOTOBIO B, V135, P65, DOI 10.1016/j.jphotobiol.2014.03.023
   Mermut S, 2007, ANGLE ORTHOD, V77, P135, DOI 10.2319/122105 451R.1
   Misawa Kageyama Y, 2007, EUR J ORAL SCI, V115, P124, DOI 10.1111/j.1600 0722.2007.00428.x
   Nishimura M, 2008, AM J ORTHOD DENTOFAC, V133, P572, DOI 10.1016/j.ajodo.2006.01.046
   Novaes APR, 2014, WORLD J NEUROSCI, V4, P183
   Pinheiro ALB, 2006, PHOTOMED LASER SURG, V24, P169, DOI 10.1089/pho.2006.24.169
   Novaes APR, 2010, ANGLE ORTHOD, V80, P111, DOI 10.2319/100708 522.1
   Salehi P, 2015, AM J ORTHOD DENTOFAC, V147, P578, DOI 10.1016/j.ajodo.2014.12.024
   STARK TM, 1987, AM J ORTHOD DENTOFAC, V91, P91, DOI 10.1016/0889 5406(87)90465 3
   Ten Cate AR, 1991, ORAL HISTOLOGY DEV S
   Tortamano A, 2009, AM J ORTHOD DENTOFAC, V136, P662, DOI 10.1016/j.ajodo.2008.06.028
   Youssef M, 2008, LASER MED SCI, V23, P27, DOI 10.1007/s10103 007 0449 7
NR 35
TC 9
Z9 11
U1 0
U2 16
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD DEC
PY 2016
VL 31
IS 9
BP 1883
EP 1890
DI 10.1007/s10103 016 2064 y
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA ED1YC
UT WOS:000388639800018
PM 27576737
DA 2025 08 17
ER

PT J
AU Efstathiadou, ZA
   Kostoulas, C
   Polyzos, SA
   Adamidou, F
   Georgiou, I
   Kita, M
AF Efstathiadou, Zoe A.
   Kostoulas, Charilaos
   Polyzos, Stergios A.
   Adamidou, Fotini
   Georgiou, Ioannis
   Kita, Marina
TI A mutation inNOTCH2gene first associated with Hajdu Cheney
   syndrome in a Greek family: diversity in phenotype and response to
   treatment
SO ENDOCRINE
LA English
DT Article
DE Hajdu Cheney Syndrome; NOTCH; Osteoporosis; fractures; Acroosteolysis;
   Crohn's disease
ID ANABOLIC THERAPY; NOTCH2; OSTEOPOROSIS; PATIENT
AB Introduction Hajdu Cheney Syndrome (HCS) is a rare genetic autosomal dominant disorder, characterized by distinctive facial features, acroosteolysis, and severe osteoporosis. Very rarely HCS is associated with polycystic kidney disease, splenomegaly or Crohn's disease (CD). It is caused by gain of function mutations inNOTCH2gene. Treatment with bisphosphonates or denosumab is reported to result in BMD increase. Objective We report a mutation in exon 34 ofNOTCH2gene, in a Greek pedigree, with diverse phenotypes among members. Description of the pedigree The 48 year old mother had a history of a T12 vertebral fracture, postpartum at the age of 21 and two subsequent uneventful full term pregnancies and never received treatment. Her 29 year old son, presented with severe osteoporosis and multiple morphological vertebral fractures. Her 21 year old daughter had recurrent vertebral fractures starting at 10 years of age. At 17 years, she developed severe CD, resistant to treatment with biologic agents, and functional hypothalamic hypogonadism. One male pedigree died of cystic fibrosis. All subjects bore the typical facial characteristics and acroosteolysis, while none had splenomegaly or renal defects. Zoledronate infusion led to BMD increase. Genetic testing Mutation in c.6758 G > A (NM_008163.1), leading to a Trp2253Ter replacement. This mutation has been reported as possibly pathogenic (SCV000620308), but not in association with HCS. Conclusions Bone involvement can present with diverse severity in the same pedigree, ranging from low BMD to multiple fragility fractures. Antiresorptive therapy improves BMD, but its anti fracture efficacy remains to be shown. The presence of CD might indicate the significant role of NOTCH2 signaling in different tissues.
C1 [Efstathiadou, Zoe A.; Adamidou, Fotini; Kita, Marina] Hippokrat Gen Hosp Thessaloniki, Dept Endocrinol, Thessaloniki, Greece.
   [Kostoulas, Charilaos; Georgiou, Ioannis] Univ Ioannina, Fac Med, Lab Med Genet Clin Practice, Ioannina, Greece.
   [Polyzos, Stergios A.] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol 1, Thessaloniki, Greece.
C3 University of Ioannina; Aristotle University of Thessaloniki
RP Efstathiadou, ZA (通讯作者)，Hippokrat Gen Hosp Thessaloniki, Dept Endocrinol, Thessaloniki, Greece.
EM zefsta@endo.gr
RI ; Efstathiadou, Zoe/AAI 4427 2021; Polyzos, Stergios/H 2844 2019
OI Efstathiadou, Zoe/0000 0002 7345 7912; Georgiou,
   Ioannis/0000 0002 0308 5703; 
CR Adami G, 2016, BONE, V92, P150, DOI 10.1016/j.bone.2016.08.025
   Canalis E, 2018, METABOLISM, V80, P48, DOI 10.1016/j.metabol.2017.08.002
   Canalis E, 2017, ENDOCRINOLOGY, V158, P730, DOI 10.1210/en.2016 1787
   Canalis E, 2016, CURR OSTEOPOROS REP, V14, P126, DOI 10.1007/s11914 016 0311 6
   Chacko J, 2018, ANN CLIN PATHOL, V6, P1140
   Descartes M, 2014, CLIN DYSMORPHOL, V23, P88, DOI 10.1097/MCD.0000000000000034
   Drake WM, 2003, J BONE MINER RES, V18, P131, DOI 10.1359/jbmr.2003.18.1.131
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   Galli Tsinopoulou A, 2012, MINERVA ENDOCRINOL, V32, P283
   Graversen L, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2019.04.007
   Gray MJ, 2012, EUR J HUM GENET, V20, P122, DOI 10.1038/ejhg.2011.125
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hwang S, 2011, YONSEI MED J, V52, P543, DOI 10.3349/ymj.2011.52.3.543
   Jastrzebski S, 2019, J IMMUNOL, V203, P105, DOI 10.4049/jimmunol.1801032
   Jirekova J, 2018, MED REP, V119, P156, DOI [10.14712/23362936.2019.3, DOI 10.14712/23362936.2019.3]
   Lee SY, 2018, J CLIN INVEST, V128, P5573, DOI 10.1172/JCI96221
   McKiernan FE, 2008, OSTEOPOROSIS INT, V19, P379, DOI 10.1007/s00198 007 0461 6
   McKiernan FE, 2007, OSTEOPOROSIS INT, V18, P245, DOI 10.1007/s00198 006 0221 z
   Narumi Y, 2013, AM J MED GENET A, V161A, P518, DOI 10.1002/ajmg.a.35772
   National Center for Biotechnology Information, 2019, CLINVAR
   Ortiz Masiá D, 2016, J CROHNS COLITIS, V10, P582, DOI 10.1093/ecco jcc/jjw009
   Pittaway JFH, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023 018 0795 5
   Reichrath J, 2020, ADV EXP MED BIOL, V1218, P159, DOI 10.1007/978 3 030 34436 8_9
   Sakka S, 2017, J CLIN ENDOCR METAB, V102, P4163, DOI 10.1210/jc.2017 01102
   Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023
   Yu J, 2019, J BIOL CHEM, V294, P14203, DOI 10.1074/jbc.RA119.009824
NR 26
TC 5
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD JAN
PY 2021
VL 71
IS 1
BP 208
EP 215
DI 10.1007/s12020 020 02446 7
EA AUG 2020
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PX7OZ
UT WOS:000557752000001
PM 32772338
DA 2025 08 17
ER

PT J
AU Zheng, Y
   Wang, PP
   Fu, Y
   Chen, YY
   Ding, ZY
AF Zheng, Yue
   Wang, Pei pei
   Fu, Yang
   Chen, Yue yun
   Ding, Zhen Yu
TI Zoledronic acid enhances the efficacy of immunotherapy in non small cell
   lung cancer
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Immune checkpoint inhibitors; Zoledronic acid; Non small cell lung
   cancer; Immunotherapy; Bone metastasis
ID DELTA T CELLS; SKELETAL METASTASES; SOLID TUMORS; DOUBLE BLIND;
   PHASE III; BISPHOSPHONATES; CARCINOMA; INTERLEUKIN 18; COMBINATION;
   PROGRESSION
AB Background: Only a minority of patients benefit from immune checkpoint inhibitors (ICIs) therapy, although they have become the standard of care for patients of non small cell lung cancer (NSCLC) without driver mutations. Zoledronic acid (ZA) enhances the antitumor efficacy of endocrine therapy, chemotherapy and targeted therapy. However, little is known about the effect of ZA on the clinical outcomes of ICIs, or its possible mechanisms. Methods: Patients with advanced NSCLC treated with ICIs alone or in combination with ZA were recruited. The clinical efficacy was compared between the two cohorts. We used an LL2 mouse model to confirm the combined effects of ZA with ICIs. Immune cell populations and cytokines in the tumor microenvironment and circulation were assayed and analyzed. Results: The median PFS for the patients treated with and without ZA was 5.4 months and 2.8 months, respec tively. The combination group showed a higher rate of disease control. In the mouse LL2 lung cancer model, tumor growth was significantly inhibited in mice treated with the combination treatment. More CD8 + IFN gamma + T cells and gamma 6 T cells, and fewer CD11b cells were found in the circulation and TILs in the combination group. Anti tumor cytokines INF gamma and IL 18 were elevated in the sera after combination therapy. Conclusion: Our study provides preclinical and clinical evidence to show that ZA could improve the therapeutic effects of ICIs. This effect was likely related to the activation of immune cells and elevated cytokines, which provided a new way to improve the effect of ICIs therapy, and is worth exploring further.
C1 [Zheng, Yue; Wang, Pei pei; Fu, Yang; Chen, Yue yun; Ding, Zhen Yu] Sichuan Univ, West China Hosp, Canc Ctr, West China Med Sch,Dept Biotherapy, Chengdu, Sichuan Provinc, Peoples R China.
   [Ding, Zhen Yu] Sichuan Univ, West China Hosp, Canc Ctr, West China Med Sch,Dept Biotherapy,State Key Lab B, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Ding, ZY (通讯作者)，Sichuan Univ, West China Hosp, Canc Ctr, West China Med Sch,Dept Biotherapy,State Key Lab B, Chengdu 610041, Peoples R China.
EM dingzhenyu@scu.edu.cn
RI chen, yueyun/LCD 7409 2024; Wang, Peipei/JVP 1674 2024
FU CAMS Clinical and Translational Research Foundation [JH2021038]
FX This article is founded by CAMS Clinical and Translational Research
   Foundation JH2021038.
CR Albini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00527
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Chang JWC, 2009, CANCER LETT, V278, P17, DOI 10.1016/j.canlet.2008.12.019
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Girardi M, 2003, J EXP MED, V198, P747, DOI 10.1084/jem.20021282
   Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916
   Godfrey DI, 2018, IMMUNITY, V48, P453, DOI 10.1016/j.immuni.2018.03.009
   Gonzalez Villasana V, 2015, CLIN CANCER RES, V21, P2127, DOI 10.1158/1078 0432.CCR 14 2279
   Hopkins AM, 2017, BRIT J CANCER, V117, P913, DOI 10.1038/bjc.2017.274
   Iwasaki M, 2011, EUR J IMMUNOL, V41, P345, DOI 10.1002/eji.201040959
   Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434
   Kato Y, 2001, J IMMUNOL, V167, P5092, DOI 10.4049/jimmunol.167.9.5092
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328
   Li Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4412 8
   Muinelo Romay L, 2013, ANTICANCER RES, V33, P5295
   Murakami H, 2014, CANCER SCI, V105, P989, DOI 10.1111/cas.12448
   Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Ottewell PD, 2012, BREAST CANCER RES TR, V133, P523, DOI 10.1007/s10549 011 1782 x
   Ou W, 2018, J CONTROL RELEASE, V281, P84, DOI 10.1016/j.jconrel.2018.05.018
   Pandya KJ, 2010, LUNG CANCER, V67, P330, DOI 10.1016/j.lungcan.2009.04.020
   Raskov H, 2021, BRIT J CANCER, V124, P359, DOI 10.1038/s41416 020 01048 4
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Sato K, 2006, BRIT J CANCER, V95, P1354, DOI 10.1038/sj.bjc.6603423
   Scagliotti GV, 2012, ANN ONCOL, V23, P2082, DOI 10.1093/annonc/mds128
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Silva Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568 019 0153 5
   Silva Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904
   Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928
   Srivastava S, 2010, CURR MED CHEM, V17, P3353, DOI 10.2174/092986710793176348
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Tanaka Y, 2020, IMMUNOL REV, V298, P237, DOI 10.1111/imr.12917
   Terme M, 2012, CANCER RES, V72, P2757, DOI 10.1158/0008 5472.CAN 11 3379
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568 019 0235 4
   Vidal Vanaclocha F, 2006, CANCER METAST REV, V25, P417, DOI 10.1007/s10555 006 9013 3
NR 42
TC 11
Z9 11
U1 1
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD SEP
PY 2022
VL 110
AR 109030
DI 10.1016/j.intimp.2022.109030
EA JUL 2022
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 3S1QN
UT WOS:000839377600002
PM 35978519
OA hybrid
DA 2025 08 17
ER

PT J
AU Kulak, CAM
   Baz Hecht, M
   Nieves, J
   Shen, V
   Lindsay, R
   Cosman, F
AF Kulak, Carolina A. M.
   Baz Hecht, Merav
   Nieves, Jeri
   Shen, Victor
   Lindsay, Robert
   Cosman, Felicia
TI Responses of Urinary N Telopeptide and Renal Calcium Handling to PTH
   Infusion after Treatment with Estrogen, Raloxifene, and Tamoxifen
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Interleukin; PTH infusion; Renal calcium absorption; Estrogen; Estrogen
   agonist/antagonist
ID HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL; HEALTHY
   POSTMENOPAUSAL WOMEN; BONE TURNOVER MARKERS; PARATHYROID HORMONE;
   RECEPTOR MODULATORS; IN VITRO; SEX STEROIDS; OSTEOPOROSIS;
   OSTEOPROTEGERIN
AB This prospective, randomized, placebo controlled study investigated whether estrogen, tamoxifen, and raloxifene protect the skeleton from the acute catabolic effects of continuous PTH(1 34) infusion. It was infused over 24 h in 25 postmenopausal women both before and while on medication for 16 20 weeks (estrogen n = 7, raloxifene n = 5, tamoxifen n = 7, placebo n = 6). Blood and urine samples were collected at baseline and every 4 h during the PTH(1 34) infusion and analyzed for calcium homeostasis, bone remodeling, and specific cytokines. Data for the premedication PTH(1 34) infusions were pooled. During the premedication PTH(1 34) infusions, serum calcium and urine phosphorus increased, while serum phosphorus and urine calcium declined. Osteocalcin decreased (mean 18%), while urine NTX increased (mean 315%). Serum IL 6 increased 260%, but there were no other cytokine changes as a result of the PTH(1 34) infusion. On medication, the mean peak change in NTX with PTH(1 34) infusion was less (77, 59, and 31 nM/mM with raloxifene, tamoxifen, and estrogen, respectively). The reduction in urine calcium excretion was prolonged with each agent but only significantly with estrogen. There was no reduction in the IL 6 elevation induced by PTH(1 34) with any medication. The differential skeletal resorption response to PTH(1 34) infusion after the treatments may reflect different potencies of these agents or variability in interaction with the estrogen receptor. Renal calcium conservation and the blunted response of bone resorption to PTH(1 34) infusion may be mechanisms by which estrogen and estrogen agonist/antagonist agents preserve bone mass.
C1 [Kulak, Carolina A. M.] Univ Fed Parana, Hosp Clin, Div Endocrinol SEMPR, BR 80030110 Curitiba, PR, Brazil.
   [Kulak, Carolina A. M.; Baz Hecht, Merav; Nieves, Jeri; Shen, Victor; Lindsay, Robert; Cosman, Felicia] Helen Hayes Hosp, Clin Res Reg Bone Ctr, W Haverstraw, NY 10993 USA.
   [Kulak, Carolina A. M.; Lindsay, Robert; Cosman, Felicia] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
   [Kulak, Carolina A. M.] Univ Fed Parana, Hosp Clin, Dept Med, BR 80030110 Curitiba, PR, Brazil.
   [Nieves, Jeri] Columbia Univ Coll Phys & Surg, Dept Epidemiol, New York, NY 10032 USA.
C3 Universidade Federal do Parana; Columbia University; Universidade
   Federal do Parana; Columbia University
RP Kulak, CAM (通讯作者)，Univ Fed Parana, Hosp Clin, Div Endocrinol SEMPR, Rua Agostinho Leao Jr 285, BR 80030110 Curitiba, PR, Brazil.
EM kulakjc@gmail.com
OI Nieves, Jeri/0000 0001 8593 343X
FU NIDDK [46381]
FX This work was supported by NIDDK 46381.
CR AITKEN JM, 1973, BRIT MED J, V2, P325, DOI 10.1136/bmj.2.5862.325
   Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Boros S, 2009, PFLUG ARCH EUR J PHY, V458, P99, DOI 10.1007/s00424 008 0602 6
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   CHRISTIANSEN C, 1980, Ugeskrift for Laeger, V142, P2896
   CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338
   COSMAN F, 1993, ANN INTERN MED, V118, P337, DOI 10.7326/0003 4819 118 5 199303010 00003
   COSMAN F, 1991, J CLIN ENDOCR METAB, V73, P1345, DOI 10.1210/jcem 73 6 1345
   Cosman F, 2003, CLIN GERIATR MED, V19, P371, DOI 10.1016/S0749 0690(02)00114 3
   COSMAN F, 1994, J CLIN ENDOCR METAB, V78, P939, DOI 10.1210/jc.78.4.939
   Cranney A, 2002, ENDOCR REV, V23, P524, DOI 10.1210/er.2001 4002
   Delmas PD, 2000, BONE, V26, P553, DOI 10.1016/S8756 3282(00)00271 4
   DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478
   Fernández García D, 2008, J ENDOCRINOL INVEST, V31, P416, DOI 10.1007/BF03346385
   JOBORN C, 1991, CLIN ENDOCRINOL, V34, P335, DOI 10.1111/j.1365 2265.1991.tb00302.x
   Kumru S, 2008, ARCH GYNECOL OBSTET, V277, P489, DOI 10.1007/s00404 007 0521 3
   LINDSAY R, 1980, LANCET, V2, P1151
   MARCUS R, 1992, J CLIN ENDOCR METAB, V74, P413, DOI 10.1210/jc.74.2.413
   Masiukiewicz US, 2002, J CLIN ENDOCR METAB, V87, P2892, DOI 10.1210/jc.87.6.2892
   Masiukiewicz US, 2000, ENDOCRINOLOGY, V141, P2526, DOI 10.1210/en.141.7.2526
   MCKANE WR, 1995, J CLIN ENDOCR METAB, V80, P3458, DOI 10.1210/jc.80.12.3458
   Méndez Dávila C, 2004, J ENDOCRINOL INVEST, V27, P904, DOI 10.1007/BF03347531
   Michael H, 2007, BRIT J PHARMACOL, V151, P384, DOI 10.1038/sj.bjp.0707232
   Özmen B, 2007, EUR CYTOKINE NETW, V18, P148
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Prestwood KM, 2000, J CLIN ENDOCR METAB, V85, P2197, DOI 10.1210/jc.85.6.2197
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rogers A, 2007, BONE, V40, P105, DOI 10.1016/j.bone.2006.07.011
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Siris E, 2002, OSTEOPOROSIS INT, V13, P907, DOI 10.1007/s001980200125
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756 3282(89)90126 9
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vural P, 2006, PHARMACOL RES, V54, P298, DOI 10.1016/j.phrs.2006.06.006
NR 39
TC 10
Z9 10
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2012
VL 90
IS 4
BP 263
EP 271
DI 10.1007/s00223 012 9572 y
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 912JU
UT WOS:000301795000002
PM 22311517
DA 2025 08 17
ER

PT J
AU Wang, HY
   Bao, Q
   Yi, H
   Xia, Q
AF Wang, Hongyang
   Bao, Qian
   Yi, Hua
   Xia, Quan
TI The evaluation of embryotoxicity of Ligusticum chuanxiong on mice and
   embryonic stem cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Ligusticum chuanxiong; Embryotoxicity; Skeleton deformity; Mice; Mouse
   embryonic stem cell test
ID CHINESE HERBAL MEDICINE; PREGNANCY
AB Ethnopharmacological relevance: Chuanxiong (Chuanxiong Rhizoma, CR), the dried rhizome of Ligusticum chuanxiong Hort, has been used during pregnancy for more than 2000 years. However, the embryotoxicity of CR was not evaluated so far. The purpose of this study was to examine the safety and rational use of CR during pregnancy on mice and mouse embryonic stem cell (ES), and to explore the mechanism of embryotoxicity.
   Aim of the study: This study was carried out to evaluate embryotoxicity of CR decoction in vivo and in vitro, and to explore the mechanism of embryotoxicity from the perspective of bone metabolism.
   Materials and methods: In animal experiments, pregnant mice were randomly assigned into 5 groups, i.e. mice were orally treated with CR decoction at dosages of 0 (distilled water, as negative controls), 2, 8, 32 g/kg/d (low, medium and high dose group), and vitamin A (as positive controls), respectively. Maternal and embryo fetal parameters were registered after cesarean section. The fetal skeletal development was further assessed with the alizarin red S and Hematoxylin Eosin staining (H&E staining) and fluorescent imaging. Meanwhile, the mouse embryonic stem cell test model (EST model) was established to objectively evaluate the toxicity of CR on the embryo development. The median inhibitory proliferation values (IC50) for both the mouse embryonic stem cell D3 (ES) and mouse embryonic fibroblast 3T3 (3T3) were detected with MTT assays. After removal of inhibiting factor (LIF), mouse embryonic stem cells spontaneously differentiated into cardiomyocytes, the expression of specific myosin heavy chain gene (beta MHC) contained in cardiomyocytes were detected by q PCR quantitative analysis, and median inhibitory differentiation concentration (ID50) of ES was obtained. The development toxicity calculation formula was used to determine the embryotoxicity grade of CR decoction. finally, based on the successful induction of osteoblasts, the molecular mechanism of CR embryotoxicity was preliminarily studied based on BMP Smads signal pathway.
   Results: Compared with the negative control group, high, medium, and low doses of CR decoction had no significant effect on the maternal body weight and uterine weight (P > 0.05), as well as on the maternal liver, heart, and kidneys. The observation results showed that high dose of CR decoction significantly increase the number of absorbed fetuses (P < 0.05). The EST model was successfully established, the IC50 3T3, IC50 ES and ID50 ES of CR were 9.39 mg/mL, 18.78 mg/mL, and 10.20 mg/mL, respectively. CR was classified as weak embryonic development toxicity by the EST linear discriminant formula. Meanwhile, osteoblasts were successfully induced in vitro, the relative expression levels of BMP2, BMPR2, Smad1, and Smad5 were down regulated in varying degrees after 3, 6, and 9 days of treatment with different concentration gradients of CR decoction.
   Conclusions: Combining in vivo and in vitro experiments, CR showed a potential embryotoxicity. The mechanism of embryotoxicity may be related to inhibiting the expression of key genes in the BMP SMADs signaling pathway. In the clinical application, the normal dosage of CR is safe to a certain extent. However, when the dosage is too high (160 g/60 kg/d), there may be a risk of embryotoxicity.
C1 [Wang, Hongyang; Xia, Quan] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
   [Bao, Qian] Jiangxi Med Sch, Nanchang 330000, Jiangxi, Peoples R China.
   [Yi, Hua] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou 510006, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine
RP Xia, Q (通讯作者)，Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
EM xia@gzucm.edu.cn
FU Guangdong Provincial Natural Science Foundation of China
   [2014A030313414]; Science Program for Overseas School of Guangzhou
   University of Chinese Medicine [XH20140110]
FX This work was supported financially by the Guangdong Provincial Natural
   Science Foundation of China (No.2014A030313414) and Science Program for
   Overseas School of Guangzhou University of Chinese Medicine (No.
   XH20140110).
CR Abolaji AO, 2013, PHYTOTHER RES, V27, P647, DOI 10.1002/ptr.4760
   [Anonymous], 2001, OECD guideline for testing of chemicals, P1, DOI DOI 10.1787/9789264070943 EN
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   *ECVAM, 2002, EMBR STEM CELL TEST, P1
   Jagt Kvan der., 2004, Alternative approaches can reduce the use of test animals under REACH
   Kong D, 2013, FOOD CHEM TOXICOL, V60, P497, DOI 10.1016/j.fct.2013.08.006
   Li LY, 2015, MOL MED REP, V12, P2348, DOI 10.3892/mmr.2015.3598
   Ong CO, 2005, ACTA OBSTET GYN SCAN, V84, P699, DOI 10.1111/j.0001 6349.2005.00659.x
   Ou SY, 2004, J SCI FOOD AGR, V84, P1261, DOI 10.1002/jsfa.1873
   Pharmacopeoia C. O. C, 2015, PHARM PEOPL REP CHIN, P40
   Piao L, 2015, PLACENTA, V36, P559, DOI 10.1016/j.placenta.2015.02.006
   Retting KN, 2009, DEVELOPMENT, V136, P1093, DOI 10.1242/dev.029926
   Rezvanfar MA, 2016, LIFE SCI, V158, P137, DOI 10.1016/j.lfs.2016.05.027
   Seiler AEM, 2011, NAT PROTOC, V6, P961, DOI 10.1038/nprot.2011.348
   Srinivasan M., 2007, RECENT ADV INDIAN HE, P92
   Standardization I O. F., 2015, 18644 IOF ISO
   Wang CC, 2012, HUM REPROD, V27, P2448, DOI 10.1093/humrep/des180
   Wiebrecht A, 2014, COMPLEMENT THER MED, V22, P954, DOI 10.1016/j.ctim.2014.08.005
   Xiao TT, 2014, J ETHNOPHARMACOL, V151, P114, DOI 10.1016/j.jep.2013.10.001
   Xu M, 2012, BIRTH DEFECTS RES B, V95, P386, DOI 10.1002/bdrb.21028
   Zhang W, 2013, TIANJIN J TRADIT CHI, V30, P431
   zur Nieden NI, 2010, TOXICOL APPL PHARM, V247, P91, DOI 10.1016/j.taap.2010.05.010
NR 23
TC 14
Z9 15
U1 0
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 15
PY 2019
VL 239
AR 111895
DI 10.1016/j.jep.2019.111895
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA IE1CS
UT WOS:000472124100006
PM 31014960
DA 2025 08 17
ER

PT J
AU Huang, JS
   Lin, CW
   Fang, JT
   Li, XX
   Wang, J
   Deng, SH
   Zhang, S
   Su, WH
   Feng, XR
   Chen, B
   Cheng, D
   Shuai, XT
AF Huang, Jinsheng
   Lin, Chaowen
   Fang, Jintao
   Li, Xiaoxia
   Wang, Jin
   Deng, Shaohui
   Zhang, Sheng
   Su, Wanhan
   Feng, Xiaoreng
   Chen, Bin
   Cheng, Du
   Shuai, Xintao
TI pH Sensitive Nanocarrier Mediated Codelivery of Simvastatin and Noggin
   siRNA for Synergistic Enhancement of Osteogenesis
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE codelivery of simvastatin and siRNA; osteogenesis; BMP 2; noggin;
   pH sensitive nanocarrier
ID BONE MORPHOGENETIC PROTEIN 2; INTRACELLULAR DRUG RELEASE; MESENCHYMAL
   STEM CELLS; IN VIVO; OSTEOBLAST DIFFERENTIATION; DELIVERY; SCAFFOLDS;
   NANOPARTICLES; DEFECTS; MICELLE
AB The inexpensive hypolipidemic drug simvastatin (SIM), which promotes bone regeneration by enhancing bone morphogenetic protein 2 (BMP 2) expression, has been regarded as an ideal alternative to BMP 2 therapy. However, SIM has low bioavailability and may induce the upregulation of the BMP 2 antagonistic noggin protein, which greatly limits the osteogenic effect. Here, a pH sensitive copolymer, monomethoxy poly(ethylene glycol) b branched polyethyleneimine b poly(N (N',N' diisopropylaminoethyl) co benzylamino)aspartamide (mPEG bPEI PAsp(DIP BzA)) (PBP), was synthesized and self assembled into a cationic micelle. SIM and siRNA targeting the noggin gene (N siRNA) were loaded into the PAsp(DIP BzA) core and the cationic bPEI interlayer of the micelle via hydrophobic and electrostatic interactions, respectively. The SIM loaded micelle effectively delivered SIM into preosteoblast MC3T3 E1 cells and rapidly released it inside the acidic lysosome, resulting in the elevated expression of BMP 2. Meanwhile, the codelivered N siRNA effectively suppressed the expression of noggin. Consequently, SIM and N siRNA synergistically increased the BMP 2/noggin ratio and resulted in an obviously higher osteogenetic effect than did simvastatin or N siRNA alone, both in vitro and in vivo.
C1 [Huang, Jinsheng; Li, Xiaoxia; Deng, Shaohui; Cheng, Du; Shuai, Xintao] Sun Yat Sen Univ, Sch Mat Sci & Engn, PCFM Lab Minist Educ, Guangzhou 510275, Guangdong, Peoples R China.
   [Lin, Chaowen; Zhang, Sheng; Feng, Xiaoreng; Chen, Bin] Southern Med Univ, Nanfang Hosp, Dept Orthopaed & Traumatol, Guangzhou 510515, Guangdong, Peoples R China.
   [Fang, Jintao] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Microsurg & Orthoped Trauma, Guangzhou 510080, Guangdong, Peoples R China.
   [Wang, Jin; Shuai, Xintao] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China.
   [Su, Wanhan] Fujian Med Univ, Longyan Hosp 1, Dept Spinal Surg, Longyan 364000, Fujian, Peoples R China.
C3 Sun Yat Sen University; Southern Medical University   China; Sun Yat Sen
   University; Sun Yat Sen University; Fujian Medical University
RP Cheng, D; Shuai, XT (通讯作者)，Sun Yat Sen Univ, Sch Mat Sci & Engn, PCFM Lab Minist Educ, Guangzhou 510275, Guangdong, Peoples R China.; Chen, B (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthopaed & Traumatol, Guangzhou 510515, Guangdong, Peoples R China.; Shuai, XT (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China.
EM chb@smu.edu.cn; chengdu@mail.sysu.edu.cn; shuaixt@mail.sysu.edu.cn
RI ; Shuai, Xintao/C 5819 2008; li, xiaomin/ABC 3188 2020; Huang,
   Jinsheng/AAY 6908 2020; cheng, du/GPK 2264 2022
OI Shuai, Xintao/0000 0003 4271 0310; Deng, Shaohui/0000 0001 9883 8570;
   Huang, Jinsheng/0000 0002 6371 4532; 
FU National Basic Research Program of China [2015CB755500]; National
   Natural Science Foundation of China [U1401242, 51373203, U1501243,
   31530023, 81271562]; National Key R&D Program of China [2016YFE0117100];
   Natural Science Foundation of the Guangdong Province [2014A030312018,
   2016A030313554, 2015A030313283]; Guangdong Innovative and
   Entrepreneurial Research Team Program [2013S086]; Guangdong Hongkong
   Joint Innovation Project [2016A050503026]; Project on the Integration of
   Industry, Education and Research of Guangdong Province [2013B090500094];
   Major Project on the Integration of Industry, Education and Research of
   Guangzhou City [201704030123]; Fundamental Research Funds for the
   Central Universities [16lgjc59, 20162900031650004]
FX This work was supported by National Basic Research Program of China
   (2015CB755500), the National Natural Science Foundation of China
   (U1401242, 51373203, U1501243, 31530023, and 81271562), National Key R&D
   Program of China (2016YFE0117100), Natural Science Foundation of the
   Guangdong Province (2014A030312018, 2016A030313554, and 2015A030313283),
   the Guangdong Innovative and Entrepreneurial Research Team Program
   (2013S086), the Guangdong Hongkong Joint Innovation Project
   (2016A050503026), Project on the Integration of Industry, Education and
   Research of Guangdong Province (2013B090500094), the Major Project on
   the Integration of Industry, Education and Research of Guangzhou City
   (201704030123), and the Fundamental Research Funds for the Central
   Universities (16lgjc59 and 20162900031650004).
CR Ahmed TAE, 2007, TISSUE ENG, V13, P1469, DOI 10.1089/ten.2006.0354
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Berner A, 2012, CELL TISSUE RES, V347, P501, DOI 10.1007/s00441 011 1184 8
   Brazil DP, 2015, TRENDS CELL BIOL, V25, P249, DOI 10.1016/j.tcb.2014.12.004
   Brown KV, 2011, TISSUE ENG PT A, V17, P1735, DOI [10.1089/ten.TEA.2010.0446, 10.1089/ten.tea.2010.0446]
   Calori GM, 2011, INJURY, V42, pS56, DOI 10.1016/j.injury.2011.06.011
   Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen WC, 2014, SMALL, V10, P2678, DOI 10.1002/smll.201303951
   Ciapetti G, 2003, BIOMATERIALS, V24, P3815, DOI 10.1016/S0142 9612(03)00263 1
   Cui ZK, 2017, ACTA BIOMATER, V58, P214, DOI 10.1016/j.actbio.2017.05.057
   Cui ZK, 2015, J CONTROL RELEASE, V217, P42, DOI 10.1016/j.jconrel.2015.08.031
   Dai J, 2011, ANGEW CHEM INT EDIT, V50, P9404, DOI 10.1002/anie.201103806
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632 200208151 00004
   Fan JB, 2016, STEM CELL TRANSL MED, V5, P539, DOI 10.5966/sctm.2015 0249
   Garrett IR, 2007, J ORTHOP RES, V25, P1351, DOI 10.1002/jor.20391
   Garrett MP, 2010, NEUROSURGERY, V66, P1044, DOI 10.1227/01.NEU.0000369517.21018.F2
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1825, DOI 10.1007/s10529 009 0100 8
   Kim S, 2008, BIOMATERIALS, V29, P1043, DOI 10.1016/j.biomaterials.2007.11.005
   Kowalczewski CJ, 2015, ACTA BIOMATER, V25, P109, DOI 10.1016/j.actbio.2015.07.045
   Kretlow JD, 2010, TISSUE ENG PT A, V16, P3555, DOI [10.1089/ten.tea.2010.0471, 10.1089/ten.TEA.2010.0471]
   Liu XN, 2013, COLLOID SURFACE B, V102, P420, DOI 10.1016/j.colsurfb.2012.06.037
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   MAURO VF, 1993, CLIN PHARMACOKINET, V24, P195, DOI 10.2165/00003088 199324030 00002
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nabar GM, 2018, INT J NANOMED, V13, P351, DOI 10.2147/IJN.S142079
   Nakanishi M, 2007, REACT FUNCT POLYM, V67, P1361, DOI 10.1016/j.reactfunctpolym.2007.08.009
   Neu M, 2005, J GENE MED, V7, P992, DOI 10.1002/jgm.773
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Saul JM, 2007, BIOMATERIALS, V28, P4705, DOI 10.1016/j.biomaterials.2007.07.026
   Sawyer AA, 2009, BIOMATERIALS, V30, P2479, DOI 10.1016/j.biomaterials.2008.12.055
   Schneider H, 2014, TISSUE ENG PT A, V20, P335, DOI [10.1089/ten.tea.2012.0563, 10.1089/ten.TEA.2012.0563]
   Shah SR, 2015, NATL SCI REV, V2, P85, DOI 10.1093/nsr/nwu028
   Shuai XT, 2004, J CONTROL RELEASE, V98, P415, DOI 10.1016/j.jconrel.2004.06.003
   Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Tiwari R, 2011, INT J PHARMACEUT, V415, P232, DOI 10.1016/j.ijpharm.2011.05.044
   Tu JW, 2009, BIOMATERIALS, V30, P4369, DOI 10.1016/j.biomaterials.2009.04.054
   Wadagaki R, 2011, ANN BIOMED ENG, V39, P1872, DOI 10.1007/s10439 011 0327 0
   Wang L, 2016, BIOMATERIALS, V78, P40, DOI 10.1016/j.biomaterials.2015.11.024
   Wang WW, 2012, ADV MATER, V24, P115, DOI 10.1002/adma.201104066
   Yuan X, 2016, TISSUE ENG PT A, V22, P928, DOI [10.1089/ten.tea.2016.0052, 10.1089/ten.TEA.2016.0052]
   Zhang YZ, 2011, INT J PHARMACEUT, V410, P118, DOI 10.1016/j.ijpharm.2010.07.040
NR 44
TC 37
Z9 38
U1 0
U2 115
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 29
PY 2018
VL 10
IS 34
BP 28471
EP 28482
DI 10.1021/acsami.8b10521
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA GS4WC
UT WOS:000443654600024
PM 30067011
DA 2025 08 17
ER

PT J
AU Cai, Z
   Feng, Y
   Li, CT
   Yang, KD
   Sun, TH
   Xu, L
   Chen, Y
   Yan, CH
   Lu, WW
   Chiu, KY
AF Cai, Zhe
   Feng, Yu
   Li, Chentian
   Yang, Kedi
   Sun, Tianhao
   Xu, Lei
   Chen, Yan
   Yan, Chun Hoi
   Lu, William Weijia
   Chiu, Kwong Yuen
TI Magnoflorine with hyaluronic acid gel promotes subchondral bone
   regeneration and attenuates cartilage degeneration in early
   osteoarthritis
SO BONE
LA English
DT Article
DE Magnoflorine; Osteoarthritis; Articular cartilage; Subchondral
   trabecular bone; Hyaluronic acid gel; Osteoclast
ID MIAO SAN SUPPLEMENTATION; NF KAPPA B; MESENCHYMAL STEM CELLS; LINE
   DRAWING ATLAS; RHEUMATOID ARTHRITIS; KNEE OSTEOARTHRITIS; HISTOLOGICAL
   ASSESSMENTS; GUINEA PIGS; HISTOPATHOLOGY; PROGRESSION
AB Objective: To investigate efficacy of Chinese medicine magnoflorine combined with hyaluronic acid (HA) gel in promoting subchondral bone (SCB) regeneration and attenuating cartilage degeneration in early osteoarthritis (OA).
   Methods: MC3T3 E1 under magnoflorine treatment was assayed by XTT to determine cell viability. Cell proliferation was reflected through cell cycle. Osteoblast mineralization was stained by Alizarin Red. Standardized bone canal of 1 mm in diameter and 4 mm in depth was made on tibial medial plateau of 4 month old Dunkin Hartley spontaneous knee OA guinea pigs. Guinea pigs (n = 5/group) were treated once intra bone canal injection of 2 p1 HA gel, 2 1 HA gel +50 ng magnoflorine and null (Defect) respectively, except sham group. The left hind limbs were harvested for uCT scan and histopathological staining 2 month post surgery.
   Results: 25 g/m1 magnoflorine treatment significantly increased cell viability, S phase and mineralization of MC3T3 E1 cells. In vivo, HA gel + magnoflorine treatment significantly altered SCB microstructure; changes included increase in bone volume fraction (BV/TV), trabecular number (Tb.N), connectivity density (Conn.Dn), and decrease in degree of anisotropy (DA), which implied trabecular bone regeneration. Treatment also resulted in a decrease in modified Mankin's scores, and an increase in volume ratio of hyaline cartilage (HC)/calcified cartilage (CC) and fractal dimension (FD, roughness indicator of osteochondral conjunction), compared to Defect and HA groups. Furthermore, FD was positively associated with volume ratio of HC/CC and negatively associated with modified Mankin's scores. Finally, histological results showed that due to a faster regeneration of SCB with the HA gel + magnoflorine treatment, the reduction of cartilage matrix and the decreased expression of chondrogenic signals were attenuated.
   Conclusion: Our study elucidated the potential benefits of HA gel + magnoflorine in promoting SCB regeneration and revealed a protective effect of stimulating recovery of the SCB integrity on attenuating cartilage degradation to prevent OA progression.
C1 [Cai, Zhe; Li, Chentian; Yang, Kedi; Sun, Tianhao; Xu, Lei; Yan, Chun Hoi; Lu, William Weijia; Chiu, Kwong Yuen] Univ Hong Kong, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Feng, Yu] Ningxia Med Univ, Gen Hosp, Dept Traumatol, Yinchuan, Ningxia Hui Aut, Peoples R China.
   [Chen, Yan] Guangxi Med Univ, Affiliated Hosp 1, Dept Bone & Joint Surg, Nanning, Guangxi, Peoples R China.
   [Lu, William Weijia] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
C3 University of Hong Kong; Ningxia Medical University; Guangxi Medical
   University; Chinese Academy of Sciences; Shenzhen Institute of Advanced
   Technology, CAS
RP Lu, WW (通讯作者)，Univ Hong Kong, Dept Orthopaed & Traumatol, Room 904, Hong Kong, Hong Kong, Peoples R China.; Chiu, KY (通讯作者)，Queen Mary Hosp, Room 216,New Clin Bldg, Pokfulam, Hong Kong, Peoples R China.
EM wwlu@hku.hk; pkychiu@hku.hk
RI Chen, Yan/MDS 5942 2025; Chiu, Peter/C 4246 2009; yan, ch/JCE 8484 2023;
   CAI, Zhe/AAC 1132 2020; Li, Chentian/GZN 1242 2022
OI Chiu, Kwong Yuen/0000 0001 9284 5817; 
FU Research Grant Council (RGC) Theme based Research Scheme (TRS)
   [HKUT13 402/17 N]; Research Grant Council of Hong Kong [RGC GRF
   HKU17206916]
FX This work was supported by The Research Grant Council (RGC) Theme based
   Research Scheme (TRS) funding (HKUT13 402/17 N) and the Research Grant
   Council of Hong Kong (RGC GRF HKU17206916).
CR Akkiraju H, 2015, J DEV BIOL, V3, P177, DOI 10.3390/jdb3040177
   Ayhan E, 2014, WORLD J ORTHOP, V5, P351, DOI 10.5312/wjo.v5.i3.351
   Bailey AJ, 1997, GERONTOLOGY, V43, P296
   Bao YX, 2006, IMMUNOPHARM IMMUNOT, V28, P197, DOI 10.1080/08923970600815097
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Cai Z, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0093 x
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chen DP, 2011, J ETHNOPHARMACOL, V137, P457, DOI 10.1016/j.jep.2011.05.048
   Chen Y, 2015, OSTEOARTHR CARTILAGE, V23, P2174, DOI 10.1016/j.joca.2015.07.012
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Dawson J, 1998, J BONE JOINT SURG BR, V80B, P63, DOI 10.1302/0301 620X.80B1.7859
   Day JS, 2001, J ORTHOPAED RES, V19, P914, DOI 10.1016/S0736 0266(01)00012 2
   Ding M, 2003, J BONE JOINT SURG BR, V85B, P906, DOI 10.1302/0301 620X.85B6.12595
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Karpouzas G A, 1999, Curr Rheumatol Rep, V1, P121, DOI 10.1007/s11926 999 0008 2
   Kon E, 2010, KNEE SURG SPORT TR A, V18, P472, DOI 10.1007/s00167 009 0940 8
   Kraus VB, 2010, OSTEOARTHR CARTILAGE, V18, pS35, DOI 10.1016/j.joca.2010.04.015
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Lam FFY, 2008, J ETHNOPHARMACOL, V120, P44, DOI 10.1016/j.jep.2008.07.028
   Li Chunmei, 2014, [Korean Journal of Plant Reources., 한국자원식물학회지], V27, P223, DOI 10.7732/kjpr.2014.27.3.223
   Li EK, 2007, ARTHRIT RHEUM ARTHR, V57, P1143, DOI 10.1002/art.22994
   Li TF, 2005, FRONT BIOSCI LANDMRK, V10, P681, DOI 10.2741/1563
   Li XH, 2010, INT J MOL MED, V26, P77, DOI 10.3892/ijmm_00000437
   Li X, 2009, ARTHRITIS RHEUM US, V60, P513, DOI 10.1002/art.24258
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Losina E, 2013, ARTHRIT CARE RES, V65, P703, DOI 10.1002/acr.21898
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Muraoka T, 2007, ARTHRITIS RHEUM US, V56, P3366, DOI 10.1002/art.22921
   Nagaosa Y, 2000, ANN RHEUM DIS, V59, P587, DOI 10.1136/ard.59.8.587
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Racková L, 2004, BIOORGAN MED CHEM, V12, P4709, DOI 10.1016/j.bmc.2004.06.035
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Roman Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Sun D, 2016, BIOMED CHROMATOGR, V30, P1843, DOI 10.1002/bmc.3761
   Taruc Uy RL, 2013, PRIMARY CARE, V40, P821, DOI 10.1016/j.pop.2013.08.003
   van der Kraan PM, 2012, OSTEOARTHR CARTILAGE, V20, P223, DOI 10.1016/j.joca.2011.12.003
   van der Kraan PM, 2009, OSTEOARTHR CARTILAGE, V17, P1539, DOI 10.1016/j.joca.2009.06.008
   Walsh DA, 2007, OSTEOARTHR CARTILAGE, V15, P743, DOI 10.1016/j.joca.2007.01.020
   Wang T, 2013, OSTEOARTHR CARTILAGE, V21, P574, DOI 10.1016/j.joca.2013.01.002
   Wilkinson CE, 2005, ANN RHEUM DIS, V64, P1467, DOI 10.1136/ard.2004.033282
   Yue RC, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/439690
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhao WW, 2016, J ORTHOP RES, V34, P763, DOI 10.1002/jor.23079
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 50
TC 29
Z9 33
U1 1
U2 53
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2018
VL 116
BP 266
EP 278
DI 10.1016/j.bone.2018.08.015
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GW8ME
UT WOS:000447232100032
PM 30149068
DA 2025 08 17
ER

PT J
AU Narasimhan, A
   Shahda, S
   Kays, JK
   Perkins, SM
   Cheng, LJ
   Schloss, KNH
   Schloss, DEI
   Koniaris, LG
   Zimmers, TA
AF Narasimhan, Ashok
   Shahda, Safi
   Kays, Joshua K.
   Perkins, Susan M.
   Cheng, Lijun
   Schloss, Katheryn N. H.
   Schloss, Daniel E., I
   Koniaris, Leonidas G.
   Zimmers, Teresa A.
TI Identification of Potential Serum Protein Biomarkers and Pathways for
   Pancreatic Cancer Cachexia Using an Aptamer Based Discovery Platform
SO CANCERS
LA English
DT Article
DE pancreatic adenocarcinoma; cachexia; biomarkers; humans; neoplasms;
   proteome; weight loss; paracrine communication
ID SKELETAL MUSCLE; WEIGHT LOSS; INTERLEUKIN 6; OBESITY; GROWTH; SURVIVAL;
   AXIS; IL 6; INHIBITION; EXPRESSION
AB Simple Summary
   Patients with pancreatic cancer and other advanced cancers suffer from progressive weight loss that reduces treatment response and quality of life and increases treatment toxicity and mortality. Effective interventions to prevent such weight loss, known as cachexia, require molecular markers to diagnose, stage, and monitor cachexia. No such markers are currently validated or in clinical use. This study used a discovery platform to measure changes in plasma proteins in patients with pancreatic cancer compared with normal controls. We found proteins specific to pancreatic cancer and cancer stage, as well as proteins that correlate with cachexia. These include some previously known proteins along with novel ones and implicates both well known and new molecular mechanisms. Thus, this study provides novel insights into the molecular processes underpinning cancer and cachexia and affords a basis for future validation studies in larger numbers of patients with pancreatic cancer and cachexia.
   Patients with pancreatic ductal adenocarcinoma (PDAC) suffer debilitating and deadly weight loss, known as cachexia. Development of therapies requires biomarkers to diagnose, and monitor cachexia; however, no such markers are in use. Via Somascan, we measured similar to 1300 plasma proteins in 30 patients with PDAC vs. 11 controls. We found 60 proteins specific to local PDAC, 46 to metastatic, and 67 to presence of >5% cancer weight loss (FC >= |1.5|, p <= 0.05). Six were common for cancer stage (Up: GDF15, TIMP1, IL1RL1; Down: CCL22, APP, CLEC1B). Four were common for local/cachexia (C1R, PRKCG, ELANE, SOST: all oppositely regulated) and four for metastatic/cachexia (SERPINA6, PDGFRA, PRSS2, PRSS1: all consistently changed), suggesting that stage and cachexia status might be molecularly separable. We found 71 proteins that correlated with cachexia severity via weight loss grade, weight loss, skeletal muscle index and radiodensity (r >= |0.50|, p <= 0.05), including some known cachexia mediators/markers (LEP, MSTN, ALB) as well as novel proteins (e.g., LYVE1, C7, F2). Pathway, correlation, and upstream regulator analyses identified known (e.g., IL6, proteosome, mitochondrial dysfunction) and novel (e.g., Wnt signaling, NK cells) mechanisms. Overall, this study affords a basis for validation and provides insights into the processes underpinning cancer cachexia.
C1 [Narasimhan, Ashok; Kays, Joshua K.; Schloss, Katheryn N. H.; Schloss, Daniel E., I; Koniaris, Leonidas G.; Zimmers, Teresa A.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Shahda, Safi] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Shahda, Safi; Perkins, Susan M.; Zimmers, Teresa A.] Indiana Univ, Simon & Bren Comprehens Canc Ctr, Indianapolis, IN 46202 USA.
   [Perkins, Susan M.; Cheng, Lijun] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA.
   [Koniaris, Leonidas G.; Zimmers, Teresa A.] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Zimmers, Teresa A.] Indiana Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN 46202 USA.
   [Zimmers, Teresa A.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Zimmers, Teresa A.] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.
   [Shahda, Safi] Eli Lilly Co, Indianapolis, IN 46225 USA.
   [Cheng, Lijun] Ohio State Univ, Dept Biomed Informat, Coll Med, Columbus, OH 43210 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Indianapolis; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Richard L. Roudebush VA Medical Center; Eli Lilly;
   University System of Ohio; Ohio State University
RP Zimmers, TA (通讯作者)，Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.; Zimmers, TA (通讯作者)，Indiana Univ, Simon & Bren Comprehens Canc Ctr, Indianapolis, IN 46202 USA.; Zimmers, TA (通讯作者)，Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.; Zimmers, TA (通讯作者)，Indiana Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN 46202 USA.; Zimmers, TA (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Zimmers, TA (通讯作者)，Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA.
EM ashnaras@iu.edu; safishanda@lilly.com; joshkays@iupui.edu;
   sperkin1@iupui.edu; Lijun.Cheng@osumc.edu; schlosskn@upmc.edu;
   schlossde@upmc.edu; lkoniari@iu.edu; zimmerst@iu.edu
RI ; Zimmers, Teresa/AAD 5461 2019
OI Zimmers, Teresa/0000 0001 7872 0540; Koniaris,
   Leonidas/0000 0003 4864 6380; Narasimhan, Ashok/0000 0003 2065 0580;
   Kays, Joshua/0000 0003 4260 9386; 
FU Heroes Foundation; National Institutes of Health [R01 CA122596,
   R01 CA194593]; Lustgarten Foundation; IUPUI Signature Center for
   Pancreatic Cancer Research; NIH [R01 DK096167]; Lilly Endowment, Inc.;
   National Cancer Institute [P30 CA082709]
FX This work was funded in part by grants to S.S. from the Heroes
   Foundation, to T.A.Z. from the National Institutes of Health (grants
   R01 CA122596 and R01 CA194593), the Lustgarten Foundation, and the IUPUI
   Signature Center for Pancreatic Cancer Research, and to L.G.K. from NIH
   (R01 DK096167) and the Lilly Endowment, Inc. This work also used the
   Biostatistics & Data Management Core of the IU Simon Cancer Center,
   supported by the National Cancer Institute (P30 CA082709).
CR Argilés JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829
   Argiles Josep M, 2009, Curr Opin Support Palliat Care, V3, P263, DOI 10.1097/SPC.0b013e3283311d09
   Attaix D, 2005, ESSAYS BIOCHEM, V41, P173, DOI 10.1042/EB0410173
   Au ED, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00682
   Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105
   Bieliuniene E, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55100649
   Blyuss O, 2020, BRIT J CANCER, V122, P692, DOI 10.1038/s41416 019 0694 0
   Bonetto A, 2016, JOVE J VIS EXP, DOI 10.3791/54893
   Bonetto A, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00679
   Bonetto A, 2012, AM J PHYSIOL ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012
   Brown JL, 2017, J CACHEXIA SARCOPENI, V8, P926, DOI 10.1002/jcsm.12232
   Burfeind KG, 2020, ELIFE, V9, DOI 10.7554/eLife.54095
   Carson JA, 2010, EXERC SPORT SCI REV, V38, P168, DOI 10.1097/JES.0b013e3181f44f11
   Castiglioni A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128094
   Costamagna D, 2020, J CACHEXIA SARCOPENI, V11, P783, DOI 10.1002/jcsm.12539
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161 5890(02)00210 9
   Esfandiari N, 2014, J FRALITY AGING, V3, P3, DOI 10.14283/jfa.2014.1
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470 2045(10)70218 7
   Fujiwara Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113259
   Golan T, 2018, J CACHEXIA SARCOPENI, V9, P871, DOI 10.1002/jcsm.12331
   Gonzalez Freire M, 2017, J CACHEXIA SARCOPENI, V8, P5, DOI 10.1002/jcsm.12121
   Griffin OM, 2019, PANCREATOLOGY, V19, P850, DOI 10.1016/j.pan.2019.07.039
   Hansel DE, 2003, CANCER RES, V63, P7032
   Hendifar AE, 2018, J GASTROINTEST ONCOL, V9, P17, DOI 10.21037/jgo.2017.11.10
   Hu K, 2018, TRANSL ONCOL, V11, P552, DOI 10.1016/j.tranon.2018.02.010
   Huot JR, 2020, J CACHEXIA SARCOPENI, V11, P1779, DOI 10.1002/jcsm.12642
   Kandarian SC, 2018, J CACHEXIA SARCOPENI, V9, P1109, DOI 10.1002/jcsm.12346
   Kaur H, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01306
   Kays JK, 2018, J CACHEXIA SARCOPENI, V9, P673, DOI 10.1002/jcsm.12307
   Keller A, 2011, RNA BIOL, V8, P506, DOI 10.4161/rna.8.3.14994
   Kemik O, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477 7819 8 85
   Kieler M, 2019, MED ONCOL, V36, DOI 10.1007/s12032 018 1223 3
   Kim EY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161125
   Klimek MEB, 2010, BIOCHEM BIOPH RES CO, V391, P1548, DOI 10.1016/j.bbrc.2009.12.123
   Kuroda K, 2007, UROLOGY, V69, P113, DOI 10.1016/j.urology.2006.09.039
   Lehallier B, 2019, NAT MED, V25, P1843, DOI 10.1038/s41591 019 0673 2
   Lerner L, 2016, J CACHEXIA SARCOPENI, V7, P467, DOI 10.1002/jcsm.12077
   Lerner L, 2015, J CACHEXIA SARCOPENI, V6, P317, DOI 10.1002/jcsm.12033
   Li C, 2016, ONCOTARGET, V7, P860, DOI 10.18632/oncotarget.6205
   Loumaye A, 2015, J CLIN ENDOCR METAB, V100, P2030, DOI 10.1210/jc.2014 4318
   Martin L, 2015, J CLIN ONCOL, V33, P90, DOI 10.1200/JCO.2014.56.1894
   Martin L, 2013, J CLIN ONCOL, V31, P1539, DOI 10.1200/JCO.2012.45.2722
   Mattila N, 2018, CLIN APPL THROMB HEM, V24, P1267, DOI 10.1177/1076029618779133
   Michaelis KA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12657 w
   Miller A, 2017, ONCOGENE, V36, P3059, DOI 10.1038/onc.2016.437
   Miller J, 2019, CURR OPIN CLIN NUTR, V22, P196, DOI 10.1097/MCO.0000000000000555
   Moran AL, 2007, J APPL PHYSIOL, V102, P1387, DOI 10.1152/japplphysiol.01305.2006
   Nakanishi T, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01441 2020
   Narsale AA, 2014, CURR OPIN SUPPORT PA, V8, P321, DOI 10.1097/SPC.0000000000000091
   Naumann P, 2019, CANCERS, V11, DOI 10.3390/cancers11111655
   Naumann P, 2019, CANCERS, V11, DOI 10.3390/cancers11050709
   Nemer L, 2017, PANCREAS, V46, P1152, DOI 10.1097/MPA.0000000000000898
   Okada K, 2015, CIRC HEART FAIL, V8, P799, DOI 10.1161/CIRCHEARTFAILURE.114.001958
   Parenté A, 2020, FASEB J, V34, P4026, DOI 10.1096/fj.201901220R
   Park HK, 2015, METABOLISM, V64, P24, DOI 10.1016/j.metabol.2014.08.004
   Penafuerte CA, 2016, BRIT J CANCER, V114, P680, DOI 10.1038/bjc.2016.3
   Peng H, 2020, CANCERS, V12, DOI 10.3390/cancers12061534
   Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI 10.1016/S1470 2045(08)70153 0
   Prokopchuk O, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4055 9
   Qi Q, 2016, CANCER AM CANCER SOC, V122, P2158, DOI 10.1002/cncr.30057
   Reddel CJ, 2017, J THROMB HAEMOST, V15, P477, DOI 10.1111/jth.13612
   Roeland EJ, 2020, J CLIN ONCOL, V38, P2438, DOI 10.1200/JCO.20.00611
   Rohloff JC, 2014, MOL THER NUCL ACIDS, V3, DOI 10.1038/mtna.2014.49
   Sarkar RR, 2019, J NATL COMPR CANC NE, V17, P432, DOI 10.6004/jnccn.2018.7111
   Schwarz S, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3116 9
   Sciorati C, 2016, CELL DEATH DIFFER, V23, P927, DOI 10.1038/cdd.2015.171
   Sheen YY, 2013, BIOMOL THER, V21, P323, DOI 10.4062/biomolther.2013.072
   Shukla SK, 2020, CANCER LETT, V484, P29, DOI 10.1016/j.canlet.2020.04.017
   Shum Angie M Y, 2018, Oncotarget, V9, P22001, DOI 10.18632/oncotarget.25146
   Sierzega M, 2017, BRIT J CANCER, V117, P266, DOI 10.1038/bjc.2017.190
   Sikdar N, 2018, CURR GENOMICS, V19, P444, DOI 10.2174/1389202919666180221160753
   Skipworth RJE, 2007, CLIN NUTR, V26, P667, DOI 10.1016/j.clnu.2007.03.011
   Soreide K, 2020, J PANCREATIC CANCER, V6, P12, DOI 10.1089/pancan.2019.0014
   Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME D 12 00156.1
   Suriben R, 2020, NAT MED, V26, P1264, DOI 10.1038/s41591 020 0945 x
   Takenaga K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232230
   Talbert EE, 2019, CELL REP, V28, P1612, DOI 10.1016/j.celrep.2019.07.016
   Tanaka T, 2018, AGING CELL, V17, DOI 10.1111/acel.12799
   Tidball JG, 2017, NAT REV IMMUNOL, V17, P165, DOI 10.1038/nri.2016.150
   Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110
   Yablonka Reuveni Z, 1999, J HISTOCHEM CYTOCHEM, V47, P23, DOI 10.1177/002215549904700104
   Yi Q, 2016, TUMOR BIOL, V37, P5805, DOI 10.1007/s13277 015 3982 1
   Yuen EYN, 2020, SUPPORT CARE CANCER, V28, P329, DOI 10.1007/s00520 019 04797 y
   Zhong XL, 2019, J CACHEXIA SARCOPENI, V10, P1083, DOI 10.1002/jcsm.12461
   Zimmers TA, 2016, SEMIN CELL DEV BIOL, V54, P28, DOI 10.1016/j.semcdb.2016.02.009
NR 85
TC 31
Z9 36
U1 3
U2 27
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD DEC
PY 2020
VL 12
IS 12
AR 3787
DI 10.3390/cancers12123787
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA PJ3DX
UT WOS:000601654100001
PM 33334063
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ogata, K
   Katagiri, W
   Osugi, M
   Kawai, T
   Sugimura, Y
   Hibi, H
   Nakamura, S
   Ueda, M
AF Ogata, Kenichi
   Katagiri, Wataru
   Osugi, Masashi
   Kawai, Takamasa
   Sugimura, Yukiko
   Hibi, Hideharu
   Nakamura, Seiji
   Ueda, Minoru
TI Evaluation of the therapeutic effects of conditioned media from
   mesenchymal stem cells in a rat bisphosphonate related osteonecrosis of
   the jaw like model
SO BONE
LA English
DT Article
DE Bisphosphonate related osteonecrosis; Conditioned media; Paracrine
   effects; Secretome; Osteoclasts; Osteogenesis
ID MARROW STROMAL CELLS; ZOLEDRONIC ACID; MULTIPLE MYELOMA;
   ENDOTHELIAL CELLS; IN VITRO; BONE; PAMIDRONATE; CANCER; GROWTH;
   REGENERATION
AB Bisphosphonate related osteonecrosis of the jaw (BRONJ) is defined as an exposed necrotic bone in the oral cavity that does not heal after appropriate intervention for >8 weeks with present or previous bisphosphonate treatment in the absence of radiotherapy. Until now, although several risk factors, including invasive dental procedures, infection, mechanical trauma to the jawbone, and concomitant use of immunosuppressive and chemotherapy drugs have been implicated in the etiology of BRONJ, its underlying mechanisms and treatments remain largely unknown. A study recently showed that intravenous administration of mesenchymal stem cells (MSCs) improved BRONJ, and it was hypothesized that paracrine effects by secretomes from MSCs are the main constituent. Here we used rat BRONJ models to examine the therapeutic effects with serum free conditioned media from human MSCs (MSC CM), including various secretomes. We showed that MSC CM has protected rat MSCs and rat osteoclasts. MSC CM enhanced the expression of osteogenic related genes and neovascularization related genes by real time reverse transcriptase polymerase chain reaction analysis in in vitro study. In in vivo study, 5 week old Wistar/ST male rats received zoledronate (35 mu g/kg/week) and dexamethasone (1 mg/kg/day) subcutaneously for 2 weeks. Unilateral maxillary molars were then extracted. Two weeks later, rats were divided into non treatment, serum free Dulbecco's modified Eagle's medium, and MSC CM groups. In the MSC CM group, the open alveolar sockets in 63% of the rats with BRONJ healed with complete soft tissue coverage and socket bones, whereas the exposed necrotic bone with inflamed soft tissue remained in the other groups. Histological analysis showed new bone formation and the appearance of osteoclasts in the MSC CM group. Osteoclasts were significantly reduced in the non treatment group. Thus, we concluded that the antiapoptotic and antiinflammatory effects of MSC CM dramatically regulated the turnover of local bone and indicated therapeutic effects on BRONJ. (c) 2015 Elsevier Inc. All rights reserved.
C1 [Ogata, Kenichi; Nakamura, Seiji] Kyushu Univ, Sect Oral & Maxillofacial Oncol, Div Maxillofacial Diagnost & Surg Sci, Fac Dent Sci,Higashi Ku, Fukuoka 8128582, Japan.
   [Ogata, Kenichi; Katagiri, Wataru; Osugi, Masashi; Kawai, Takamasa; Sugimura, Yukiko; Hibi, Hideharu; Ueda, Minoru] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Kyushu University; Nagoya University
RP Katagiri, W (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM k.ogata@dent.kyushu u.ac.jp; w kat@med.nagoya u.ac.jp;
   masashi@med.nagoya u.ac.jp; takamasa@med.nagoya u.ac.jp;
   sugimuray@med.nagoya u.ac.jp; hibihi@med.nagoya u.ac.jp;
   seiji@dent.kyushu u.ac.jp; mueda@med.nagoya u.ac.jp
RI KATAGIRI, Wataru/E 4447 2015; Hibi, Hideharu/E 4443 2015
OI Hibi, Hideharu/0000 0003 0248 7476
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [21791985, 23592883]; Grants in Aid for Scientific Research [21791985,
   23592883, 25293408] Funding Source: KAKEN
FX We thank the members of the Department of Oral and Maxillofacial
   Surgery, Nagoya University, for their encouragement to complete this
   study as well as Prof. Tatsushi Kawai of the Graduate School of
   Dentistry, Aichi Gakuin University. We also thank the Division of
   Experimental Animals and Medical Research,Engineering, Nagoya University
   Graduate School of Medicine, for housing the rats. This work was
   supported in part by Grants in Aid for Scientific Research (Nos.
   21791985 and 23592883) from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan.
CR Ando Y, 2014, BONE, V61, P82, DOI 10.1016/j.bone.2013.12.029
   Atsuta I, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt322
   Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908
   Bagan J, 2009, ORAL ONCOL, V45, P551, DOI 10.1016/j.oraloncology.2009.01.002
   Basso FG, 2013, ARCH ORAL BIOL, V58, P467, DOI 10.1016/j.archoralbio.2012.09.016
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Cella L, 2011, HEAD FACE MED, V7, DOI 10.1186/1746 160X 7 16
   Cetiner S, 2009, J BONE MINER METAB, V27, P435, DOI 10.1007/s00774 009 0047 9
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Fournier P, 2002, CANCER RES, V62, P6538
   Fujita H, 2011, BASIC CLIN PHARMACOL, V109, P78, DOI 10.1111/j.1742 7843.2011.00685.x
   Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23
   Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006 0686
   Ide C, 2010, BRAIN RES, V1332, P32, DOI 10.1016/j.brainres.2010.03.043
   Inukai T, 2013, BIOCHEM BIOPH RES CO, V430, P763, DOI 10.1016/j.bbrc.2012.11.074
   Kaigler D, 2003, TISSUE ENG, V9, P95, DOI 10.1089/107632703762687573
   Katagiri W, 2013, INT J ORAL MAX IMPL, V28, P1009, DOI 10.11607/jomi.3036
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Kuehn BM, 2006, JAMA J AM MED ASSOC, V295, P2833, DOI 10.1001/jama.295.24.2833
   Li X, 2012, J BONE MINER RES, V27, P1635, DOI 10.1002/jbmr.1620
   Li Y, 2007, BIOCHEM BIOPH RES CO, V356, P780, DOI 10.1016/j.bbrc.2007.03.049
   Lipton A, 2005, EXPERT OPIN BIOL TH, V5, P817, DOI 10.1517/14712598.5.6.817
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   López Jornet P, 2010, J ORAL PATHOL MED, V39, P697, DOI 10.1111/j.1600 0714.2010.00927.x
   Mandel K, 2013, STEM CELLS DEV, V22, P3114, DOI 10.1089/scd.2013.0249
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Oskowitz A, 2011, STEM CELL RES, V6, P215, DOI 10.1016/j.scr.2011.01.004
   Osugi M, 2012, TISSUE ENG PT A, V18, P1479, DOI [10.1089/ten.tea.2011.0325, 10.1089/ten.TEA.2011.0325]
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Rosland GV, 2009, CANCER RES, V69, P5331, DOI 10.1158/0008 5472.CAN 08 4630
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senel FC, 2010, ORAL SURG ORAL MED O, V109, P385, DOI 10.1016/j.tripleo.2009.10.011
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Wilkinson GS, 2007, JNCI J NATL CANCER I, V99, P1016, DOI 10.1093/jnci/djm025
   Wimalawansa SJ, 2008, EXPERT OPIN DRUG SAF, V7, P491, DOI 10.1517/14740338.7.4.491 
   Wislet Gendebien S, 2003, J CELL SCI, V116, P3295, DOI 10.1242/jcs.00639
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yamamoto Silva FP, 2013, MICROSC RES TECHNIQ, V76, P633, DOI 10.1002/jemt.22210
NR 54
TC 80
Z9 83
U1 1
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2015
VL 74
BP 95
EP 105
DI 10.1016/j.bone.2015.01.011
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CD6HE
UT WOS:000351189400011
PM 25613174
DA 2025 08 17
ER

PT J
AU Shehata, AS
   Amer, MG
   Abd El Haleem, MR
   Karam, RA
AF Shehata, Azza Saad
   Amer, Mona Gomah
   Abd El Haleem, Manal Reda
   Karam, Rehab Ahmed
TI The ability of hesperidin compared to that of insulin for preventing
   osteoporosis induced by type I diabetes in young male albino rats: A
   histological and biochemical study
SO EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE Diabetes mellitus; Hesperidin; Osteoporosis; TNF alpha; NF kappa B
ID OXIDATIVE STRESS; BONE LOSS; METABOLISM; INHIBITION; FLAVONOIDS;
   GLUCOSE; MARKERS; EXPRESSION; FRACTURES; MECHANISM
AB Background: Patients with type I diabetes are at increased risk of osteoporosis even after insulin therapy in adult stage. This study was conducted to compare the efficacy of hesperidin (hesp) therapy versus that of insulin alone in the alleviation of osteoporosis arising from type I diabetes mellitus (T1DM) in young rats.
   Materials and methods: Hesperidin was administered orally to STZ induced diabetes. The animals were evaluated morphologically and biochemically and compared with that received daily SC injections of long acting insulin.
   Results: Histologically, we observed the degeneration of osteoblasts and osteocytes, decreased collagen fibers, and disturbed bone turn over markers in untreated DM rats. Hesperidin+ insulin supplementation to diabetic rats caused significant improvement of most of the bone histological and morphometric parameters compared with the insulin treated group. Furthermore, hesp treatment significantly reduced pro inflammatory mediators TNF alpha and NF kappa B and increased serum biochemical markers of bone turnover, including osteopontin (OPN), osteocalcin (OC) and decreased serum alkaline phosphatase (ALP).
   Conclusion: These data demonstrated that hesp could be considered to be a beneficial drug for preventing diabetic osteoporosis in growing age. (C) 2017 Elsevier GmbH. All rights reserved.
C1 [Shehata, Azza Saad; Amer, Mona Gomah; Abd El Haleem, Manal Reda] Zagazig Univ, Fac Med, Histol & Cell Biol, Zagazig, Egypt.
   [Karam, Rehab Ahmed] Zagazig Univ, Fac Med, Med Biochem, Zagazig, Egypt.
C3 Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian Knowledge
   Bank (EKB); Zagazig University
RP Amer, MG (通讯作者)，Zagazig Univ, Fac Med, Histol & Cell Biol, Zagazig, Egypt.
EM mona_amer@rocketmail.com
RI Ahmed Karam, Rehab/T 3604 2019; Karam, Rehab/T 3604 2019; amer,
   mona/AAE 6801 2020; Sobhy, Ayman/MGT 0719 2025
OI Ahmed Karam, Rehab/0000 0001 9750 3218; , mona/0000 0002 7594 4423
FU Zagazig University Projects, Zagazig University Post Graduate & Research
   Affairs
FX This study was funded with the support of academic research in Zagazig
   University Projects, Zagazig University Post Graduate & Research
   Affairs.
CR Akiyama S, 2010, J CLIN BIOCHEM NUTR, V46, P87, DOI 10.3164/jcbn.09 82
   Ashafaq M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/249031
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   BANCROFT JD, 2002, THEORY PRACTICE HIST
   Bayat F, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251 6581 12 45
   Birdee G.S., 2010, Clinical Diabetes, V28, P147, DOI [DOI 10.2337/DIACLIN.28.4.147, 10.2337/diaclin.28.4.147]
   Cao H, 2007, J AGR FOOD CHEM, V55, P6372, DOI 10.1021/jf070695o
   Chiba H, 2003, J NUTR, V133, P1892, DOI 10.1093/jn/133.6.1892
   Choi EM, 2008, CELL BIOL TOXICOL, V24, P225, DOI 10.1007/s10565 007 9031 0
   Coleman R, 2008, CANCER TREAT REV, V34, P629, DOI 10.1016/j.ctrv.2008.05.001
   Comalada M, 2006, BIOCHEM PHARMACOL, V72, P1010, DOI 10.1016/j.bcp.2006.07.016
   Confavreux CB, 2009, MOL CELL ENDOCRINOL, V310, P21, DOI 10.1016/j.mce.2009.04.004
   Czernik BL, 2015, DIABETIC BONE DIS BA, P8
   Erdal N, 2012, DIABETES RES CLIN PR, V97, P461, DOI 10.1016/j.diabres.2012.03.005
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Fröde TS, 2008, J ETHNOPHARMACOL, V115, P173, DOI 10.1016/j.jep.2007.10.038
   Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166 2236(00)01656 8
   Glauret A, 1998, PHYSIOLOGIC SPECIMEN, V17
   Gordi DA, 2010, B TRANSILV U BRASOV, V3, pVI
   Gumieniczek A, 2003, LIFE SCI, V74, P553, DOI 10.1016/j.lfs.2003.03.004
   Heap J, 2004, J PEDIATR US, V144, P56, DOI 10.1016/j.jpeds.2003.10.066
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Horcajada MN, 2008, J APPL PHYSIOL, V104, P648, DOI 10.1152/japplphysiol.00441.2007
   Institute of Laboratory Animal Resources, 1996, GUID CAR US LAB AM I
   Jagtap AG, 2010, FOOD CHEM TOXICOL, V48, P2030, DOI 10.1016/j.fct.2010.04.048
   Jakus V, 2012, EXP DIABETES RES, DOI 10.1155/2012/510902
   Jr Cohen, 2006, AM J MED GENET A, V140, P2646
   Jung UJ, 2006, INT J BIOCHEM CELL B, V38, P1134, DOI 10.1016/j.biocel.2005.12.002
   Kalaitzoglou E, 2016, CURR OSTEOPOROS REP, V14, P310, DOI 10.1007/s11914 016 0329 9
   Kim SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067504
   Kohzaki K, 2008, INVEST OPHTH VIS SCI, V49, P3595, DOI 10.1167/iovs.08 1679
   Lee JS, 2006, LIFE SCI, V79, P1578, DOI 10.1016/j.lfs.2006.06.030
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lister CE, 2007, CURR TOP NUTRACEUT R, V5, P67
   Mahmoud AM, 2012, J DIABETES COMPLICAT, V26, P483, DOI 10.1016/j.jdiacomp.2012.06.001
   Mann CJ, 2010, CURR PHARM DESIGN, V16, P1002, DOI 10.2174/138161210790883435
   Mao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092686
   Marcu F, 2011, ROM J MORPHOL EMBRYO, V52, P321
   Martin B, 2016, J CLIN ENDOCRINOL ME, V101, P3
   Neumann T, 2016, BONE, V82, P50, DOI 10.1016/j.bone.2015.04.017
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Partridge CR, 2008, MATRIX BIOL, V27, P462, DOI 10.1016/j.matbio.2008.01.009
   Publishing S., 2012, ADV BIOSCI BIOTECHNO, V3, P712, DOI DOI 10.4236/ABB.2012.326092
   Rathee Permender, 2009, Inflammation & Allergy Drug Targets, V8, P229
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Shapses SA, 2003, CALCIFIED TISSUE INT, V73, P86, DOI 10.1007/s00223 002 1090 x
   Sharma B, 2008, FOOD CHEM TOXICOL, V46, P2376, DOI 10.1016/j.fct.2008.03.020
   Shi XP, 2012, MOLECULES, V17, P12868, DOI 10.3390/molecules171112868
   Starup Linde J, 2016, BONE, V82, P69, DOI 10.1016/j.bone.2015.02.019
   Trzeciakiewicz A, 2010, J AGR FOOD CHEM, V58, P668, DOI 10.1021/jf902680n
   Vincent AM, 2002, ANN NY ACAD SCI, V959, P368, DOI 10.1111/j.1749 6632.2002.tb02108.x
   Wang KX, 2008, CYTOKINE GROWTH F R, V19, P333, DOI 10.1016/j.cytogfr.2008.08.001
   Watts NB, 1999, CLIN CHEM, V45, P1359
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Wilmsen PK, 2005, J AGR FOOD CHEM, V53, P4757, DOI 10.1021/jf0502000
   Yamamoto M, 2009, J BONE MINER RES, V24, P702, DOI 10.1359/JBMR.081207
   Yuce HB, 2014, ACTA ODONTOL SCAND, V72, P729, DOI 10.3109/00016357.2014.898789
   Zhang SQ, 2007, J BONE MINER METAB, V25, P293, DOI 10.1007/s00774 007 0759 7
   Zhukouskaya VV., 2014, Adv Endocrinol, V2014, P1
NR 59
TC 13
Z9 14
U1 0
U2 13
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0940 2993
EI 1618 1433
J9 EXP TOXICOL PATHOL
JI Exp. Toxicol. Pathol.
PD APR
PY 2017
VL 69
IS 4
BP 203
EP 212
DI 10.1016/j.etp.2017.01.008
PG 10
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Toxicology
GA ES4RD
UT WOS:000399521500005
PM 28132802
DA 2025 08 17
ER

PT J
AU Chang, B
AF Chang, Bo
TI Study on the application of nanotube combined exercise rehabilitation
   therapy in the treatment of knee arthritis patients
SO INTERNATIONAL JOURNAL OF NANOTECHNOLOGY
LA English
DT Article
DE titanium nanotubes; osteoarthritis; cell growth; knee; exercise therapy;
   stem cells; joint
ID OSTEOARTHRITIS
AB Knee osteoarthritis (KOA) is a common chronic joint disease in clinical practice, and there is currently no effective cure. Among the many non surgical therapies for KOA, exercise therapy as a safe and effective treatment has been accepted by more and more people. At present, more clinically applied and researched exercise therapies include strength training, aerobic training, neuromuscular training, proprioceptive neuromuscular promotion method, whole body vibration training, and its therapeutic effects include alleviating knee pain, enhancing lower limb muscle strength and stability to improve knee function. The current research has explored the action mechanism of exercise therapy for KOA from the perspective of molecular biology and physiology, but the specific action mechanisms of various kinds of exercise therapy and the intensity, time and frequency in clinical application need to be further studied. In this paper, titanium dioxide nanotube coatings were prepared by electrochemical anodisation, and the structure characterisation and electron microscope observation were performed. Materials with different nanotube pore sizes were prepared under different preparation conditions and their structural characteristics were compared. Then, bone marrow mesenchymal stem cells were cultured on the surface of titanium nanotubes, and their activities of adhesion, growth and differentiation were observed. The effects of nanotube structure on osteoblasts were compared on different nanostructure surfaces. Finally, it was found that the surface of the titanium nanotube material is suitable for bone marrow mesenchymal stem cells to adhere, grow, and promote their differentiation into osteoblasts. The surface of titanium nanotube materials with different pore sizes has different effects on bone marrow mesenchymal stem cells. When d = 30 nm, stem cells tend to adhere and have less morphology. As the pore diameter increases to 100 nm, the ability to adhere to cells decreases, and the morphology of the cells becomes longer and the osteogenesis ability is enhanced.
C1 [Chang, Bo] Huainan United Univ, Students Affairs Div, Huainan 232038, Anhui, Peoples R China.
RP Chang, B (通讯作者)，Huainan United Univ, Students Affairs Div, Huainan 232038, Anhui, Peoples R China.
EM changbo0813@163.com
CR Allah NN, 2019, J BACK MUSCULOSKELET, V32, P487, DOI 10.3233/BMR 181156
   Broeckx SY, 2019, STEM CELLS DEV, V28, P410, DOI 10.1089/scd.2018.0061
   Fellows CR, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00213
   Golovach I.Y., 2019, TRAUMA, V20, P23
   Hochberg MC, 2016, ANN RHEUM DIS, V75, P37, DOI 10.1136/annrheumdis 2014 206792
   Honvo G, 2019, DRUG AGING, V36, P101, DOI 10.1007/s40266 019 00657 w
   Inan OT, 2018, J APPL PHYSIOL, V124, P537, DOI 10.1152/japplphysiol.00366.2017
   Iturriaga L, 2018, EXPERT OPIN BIOL TH, V18, P883, DOI 10.1080/14712598.2018.1502266
   Jevsevar DS, 2018, J AM ACAD ORTHOP SUR, V26, P325, DOI 10.5435/JAAOS D 17 00318
   Kielly J, 2017, CAN PHARM J, V150, P156, DOI 10.1177/1715163517702168
   Kolodziejska Justyna, 2018, Reumatologia (Warsaw), V56, P174, DOI 10.5114/reum.2018.76816
   Kwiatkowska B., 2018, REUMATOLOGIA, V55, P290
   Miloro M, 2018, J ORAL MAXIL SURG, V76, P2669, DOI 10.1016/j.joms.2018.06.001
   Moriya M, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018 016 0504 9
   Pang G., 2018, IEEE REV BIOMED ENG, V12, P34
   Pereira H, 2019, EFORT OPEN REV, V4, P279, DOI 10.1302/2058 5241.4.180103
   Schwan Josianna, 2019, Anesthesiol Clin, V37, P547, DOI 10.1016/j.anclin.2019.04.012
   Shewale AR, 2017, J ARTHROPLASTY, V32, P2952, DOI 10.1016/j.arth.2017.04.041
   Tavares D.R.B., 2018, JMIR RES PROTOC, V7, P11
NR 19
TC 2
Z9 2
U1 0
U2 23
PU INDERSCIENCE ENTERPRISES LTD
PI GENEVA
PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE BOIS, CASE POSTALE 856, CH 1215
   GENEVA, SWITZERLAND
SN 1475 7435
EI 1741 8151
J9 INT J NANOTECHNOL
JI Int. J. Nanotechnol.
PY 2020
VL 17
IS 2 6
SI SI
BP 393
EP 410
DI 10.1504/IJNT.2020.110725
PG 18
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA OP9DS
UT WOS:000588391000019
DA 2025 08 17
ER

PT J
AU Margiotta, N
   Capitelli, F
   Ostuni, R
   Natile, G
AF Margiotta, Nicola
   Capitelli, Francesco
   Ostuni, Rosa
   Natile, Giovanni
TI A new dinuclear platinum complex with a nitrogen containing geminal
   bisphosphonate as potential anticancer compound specifically targeted to
   bone tissues
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Platinum complexes; Geminal bisphosphonates; Bone tumors; X ray
   diffraction; Sol gel crystallization; NMR spectroscopy
ID CRYSTAL STRUCTURE; NMR SPECTROSCOPY; LIGANDS; AGENTS; DERIVATIVES;
   RESORPTION; CHEMISTRY; DRUGS
AB The paper describes the synthesis and characterization of a new platinum dinuclear complex (2) bearing a nitrogen containing geminal bisphosphonate (NBP, 1), structurally related to the commercial drug risedronate. NBPs themselves have shown in quite a few cases to be endowed with anticancer activity, therefore the new platinum complex has two potential antitumor moieties (the NBP ligand and the platinum residue) and could have high affinity for bone tumors or metastases (due to the presence of NBP). The free bisphosphonate (1) has been crystallized by a sol gel method and characterized by X ray diffraction analysis. The platinum complex (2) has been found to have a dinuclear structure with the bisphosphonate bridging two platinum moieties in a W conformation. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Margiotta, Nicola; Ostuni, Rosa; Natile, Giovanni] Univ Bari, Dipartimento Farmacochim, I 70125 Bari, Italy.
   [Capitelli, Francesco] CNR, Ist Cristallog, I 70126 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle
   Ricerche (CNR); Istituto Di Cristallografia (IC CNR)
RP Margiotta, N (通讯作者)，Univ Bari, Dipartimento Farmacochim, Via Orabona 4, I 70125 Bari, Italy.
EM nmargiotta@farmchim.uniba.it
RI ; Margiotta, Nicola/AAE 3975 2021; Capitelli, Francesco/AAY 2822 2020
OI Natile, Giovanni/0000 0002 1790 6365; Margiotta,
   Nicola/0000 0003 4034 875X; Capitelli, Francesco/0000 0001 7721 8049; 
FU University of Bar; Italian "Ministero dell'Universita e della Ricerca
   (MUR)"; EC [D39/0004/06]; Interuniversity Consortium for Research on the
   Chemistry of Metal
FX The authors are very grateful to Prof. Concetta Pacifico (Dipartimento
   Farmaco Chimico, Universita degli Studi di Bari) for helpful discussion
   on single crystal X ray diffraction and to Ms. Aurelia Falcicchio for
   the help in the syntheses of the compounds. The authors thank the
   University of Bari, the Italian "Ministero dell'Universita e della
   Ricerca (MUR)", and the EC (COST Chemistry project D39/0004/06), and the
   Interuniversity Consortium for Research on the Chemistry of Metal tons
   in Biological Systems (C.I.R.C.M.S.B.) for support.
CR *ADV CHEM DEV INC, 2002, ACD PKA DB 7 00 REL
   Altomare A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717
   [Anonymous], KALEIDAGRAPH 3 5
   [Anonymous], 2007, INORGANIC CRYSTAL ST
   APPLETON TG, 1986, INORG CHEM, V25, P726, DOI 10.1021/ic00226a005
   BernersPrice SJ, 1996, COORDIN CHEM REV, V151, P1
   Choi MG, 2000, ACTA CRYSTALLOGR C, V56, P808, DOI 10.1107/S0108270100006168
   Duisenberg AJM, 2003, J APPL CRYSTALLOGR, V36, P220, DOI 10.1107/S0021889802022628
   Durif A., 1995, CRYSTAL CHEM CONDENS
   FELTHAM RD, 1964, J CHEM SOC, P4587, DOI 10.1039/jr9640004587
   GORENSTEIN DG, 1983, PROG NUCL MAG RES SP, V16, P1
   Gossman WL, 2003, ACTA CRYSTALLOGR C, V59, pM33, DOI 10.1107/S0108270102021996
   KLENNER T, 1990, J CANCER RES CLIN, V116, P341, DOI 10.1007/BF01612916
   KLENNER T, 1990, J CANCER RES CLIN, V116, P453, DOI 10.1007/BF01612993
   Kobashi D, 1997, ACTA CRYSTALLOGR C, V53, P1523, DOI 10.1107/S0108270197006689
   Kontturi M, 2005, INORG CHEM, V44, P2400, DOI 10.1021/ic048329z
   Kontturi M., 2005, Polyhedron, V24, P305, DOI DOI 10.1016/J.P0LY.2004.11.006
   Kotsikorou E, 2003, J MED CHEM, V46, P2932, DOI 10.1021/jm030054u
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Lee YA, 1997, J INORG BIOCHEM, V68, P289, DOI 10.1016/S0162 0134(97)00109 8
   LIBSON K, 1980, J AM CHEM SOC, V102, P2476, DOI 10.1021/ja00527a066
   LIPPERT B, 1999, CISPLATIN CHEM BIOCH
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   PASINI A, 1993, SYN REACT INORG MET, V23, P1021, DOI 10.1080/15533179308016879
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Rochon FD, 2005, INORG CHIM ACTA, V358, P2040, DOI 10.1016/j.ica.2004.12.030
   Rochon FD, 2000, INORG CHIM ACTA, V306, P193, DOI 10.1016/S0020 1693(00)00171 7
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551
   Sheldrick G.M., 1996, SADABS ABSORPTION CO
   Sheldrick G.M., 1993, PROGRAM CRYSTAL STRU
   Stahl K, 2005, ACTA CRYSTALLOGR E, V61, pM132, DOI 10.1107/S1600536804032568
   UCHTMAN VA, 1976, ACTA CRYSTALLOGR B, V32, P488, DOI 10.1107/S0567740876003294
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v
   Zhang Y, 2006, J MED CHEM, V49, P5804, DOI 10.1021/jm060280e
NR 38
TC 33
Z9 37
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0162 0134
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD DEC
PY 2008
VL 102
IS 12
SI SI
BP 2078
EP 2086
DI 10.1016/j.jinorgbio.2008.07.008
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 379XL
UT WOS:000261429700008
PM 18760482
DA 2025 08 17
ER

PT J
AU Grad Akrish, S
   Rachmiel, A
   Ben Izhak, O
AF Grad Akrish, Sharon
   Rachmiel, Adi
   Ben Izhak, Ofer
TI SATB2 is not a reliable diagnostic marker for distinguishing between
   oral osteosarcoma and fibro osseous lesions of the jaws
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID FIBROUS DYSPLASIA; MALIGNANT TRANSFORMATION; BONE; EXPRESSION; SURVIVAL;
   TUMORS; DIFFERENTIATION; PERIOSTEAL
AB Objective. Special AT rich binding protein 2 (SATB2) is an immunohistochemical marker for osteoblast differentiation. Our aim was to investigate SATB2 expression in oral osteosarcoma and other bone producing oral tumors/reactive lesions to evaluate its usefulness as a diagnostic marker.
   Study Design. A total of 74 intraosseous and soft tissue bone producing surgical samples and 10 samples of reactive bone tissue were stained with SATB2, including osteosarcoma/chondrosarcoma (n = 16), fibro osseous lesions (n = 42), central giant cell granuloma (n = 6), osteoblastoma (n = 1), and gingival lesions (n = 9). Nuclear labeling of the stromal spindle cells and intensity of staining was scored and analyzed.
   Results. The intraosseous (n = 65/65) and soft tissue samples (n = 9/9) diffusely expressed SATB2. The strongest expression was observed in juvenile aggressive ossifying fibroma (n = 2/2). Weak SATB2 expression was observed in the stromal spindle cells adjacent to reactive bone tissue (periosteal bone reaction).
   Conclusions. Our results indicate that SATB2 is not a reliable diagnostic marker for oral osteosarcoma but has practical use in detecting cells with osteoblast differentiation in histologic samples with scant bone production or in differentiating between a periosteal bone reaction and neoplastic bone induced by the tumor mesenchymal cells. Targeting SATB2 as an alternative therapy in oral osteosarcoma, fibro osseous lesions, and central giant cell granuloma should be further investigated.
C1 [Grad Akrish, Sharon; Ben Izhak, Ofer] Rambam Med Ctr, Dept Pathol, Haifa, Israel.
   [Grad Akrish, Sharon; Rachmiel, Adi] Rambam Med Ctr, Dept Oral & Maxillofacial Surg, Haifa, Israel.
   [Grad Akrish, Sharon; Rachmiel, Adi; Ben Izhak, Ofer] Ruth & Bruce Rappaport Fac Med, Haifa, Israel.
C3 Rambam Health Care Campus; Rambam Health Care Campus; Technion Israel
   Institute of Technology; Rappaport Faculty of Medicine
RP Grad Akrish, S (通讯作者)，Rambam Med Ctr, Oral & Maxillofacial Surg, POB 9602, IL 3109601 Haifa, Israel.
EM Sjakrish@gmail.com
OI akrish, sharon/0000 0002 9092 7699
CR Bennett JH, 2000, ORAL SURG ORAL MED O, V90, P323, DOI 10.1067/moe.2000.108274
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   BERTONI F, 1993, CANCER, V71, P338, DOI 10.1002/1097 0142(19930115)71:2<338::AID CNCR2820710212>3.0.CO;2 H
   Byun BH, 2013, CLIN NUCL MED, V38, P482, DOI 10.1097/RLU.0b013e31828da632
   Chen QY, 2019, CARCINOGENESIS, V40, P393, DOI 10.1093/carcin/bgz020
   Chindia ML, 2001, ORAL ONCOL, V37, P545, DOI 10.1016/S1368 8375(00)00129 9
   Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138
   DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU
   Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34
   Falconieri G, 2016, AM J DERMATOPATH, V38, P824, DOI 10.1097/DAD.0000000000000555
   Fernandes R, 2007, J ORAL MAXIL SURG, V65, P1286, DOI 10.1016/j.joms.2006.10.030
   Franceschini N, 2020, VIRCHOWS ARCH, V476, P147, DOI 10.1007/s00428 019 02683 w
   GARRINGTON GE, 1967, CANCER AM CANCER SOC, V20, P377, DOI 10.1002/1097 0142(1967)20:3<377::AID CNCR2820200306>3.0.CO;2 T
   Gupta Shruti, 2019, J Oral Maxillofac Res, V10, pe5, DOI 10.5037/jomr.2019.10205
   Hornick J., 2014, MODERN PATHOL, V27, P547
   Horvai A, 2006, J ORTHOP SCI, V11, P412, DOI 10.1007/s00776 006 1037 6
   Horvai AE, 2012, MODERN PATHOL, V25, P1452, DOI 10.1038/modpathol.2012.110
   Ida M, 1997, DENTOMAXILLOFAC RAD, V26, P169, DOI 10.1038/sj.dmfr.4600234
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jones AC, 2006, ORAL SURG ORAL MED O, V102, P639, DOI 10.1016/j.tripleo.2005.09.004
   Kaplan Ilana, 2007, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V103, pe35, DOI 10.1016/j.tripleo.2006.03.017
   KURT AM, 1990, CANCER AM CANCER SOC, V65, P1418, DOI 10.1002/1097 0142(19900315)65:6<1418::AID CNCR2820650629>3.0.CO;2 Q
   Li M, 2016, Zhonghua Bing Li Xue Za Zhi, V45, P631, DOI 10.3760/cma.j.issn.0529 5807.2016.09.009
   Liang LZ, 2019, HEAD NECK J SCI SPEC, V41, P2016, DOI 10.1002/hed.25668
   Lin F, 2014, ARCH PATHOL LAB MED, V138, P1015, DOI 10.5858/arpa.2013 0452 OA
   Ma YN, 2018, CLIN EXP MED, V18, P37, DOI 10.1007/s10238 017 0464 3
   Machado I, 2016, PATHOL RES PRACT, V212, P811, DOI 10.1016/j.prp.2016.06.012
   Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae
   Mardinger O, 2001, ORAL SURG ORAL MED O, V91, P445, DOI 10.1067/moe.2001.112330
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mohammadi A, 2012, INT J SURG CASE REP, V3, P296, DOI 10.1016/j.ijscr.2012.02.009
   Neville BW, 2013, ORAL MAXILLOFACIAL P
   Prapayasatok S, 2000, DENTOMAXILLOFAC RAD, V29, P245, DOI 10.1038/sj.dmfr.4600528
   Regezi JA, 2002, MODERN PATHOL, V15, P331, DOI 10.1038/modpathol.3880527
   RUGGIERI P, 1994, CANCER, V73, P1411, DOI 10.1002/1097 0142(19940301)73:5<1411::AID CNCR2820730516>3.0.CO;2 T
   Sangoi AR, 2017, INT J GYNECOL PATHOL, V36, P140, DOI 10.1097/PGP.0000000000000301
   SCHWARTZ DT, 1964, AM J MED SCI, V247, P1, DOI 10.1097/00000441 196401000 00001
   Seong BKA, 2015, ONCOGENE, V34, P3582, DOI 10.1038/onc.2014.289
   SLOOTWEG PJ, 1994, J ORAL PATHOL MED, V23, P385, DOI 10.1111/j.1600 0714.1994.tb00081.x
   Slootweg PJ, 1996, SEMIN DIAGN PATHOL, V13, P104
   SLOOTWEG PJ, 1985, J MAXILLOFAC SURG, V13, P158, DOI 10.1016/S0301 0503(85)80040 0
   Smeland S, 2019, EUR J CANCER, V109, P36, DOI 10.1016/j.ejca.2018.11.027
   Speight PM, 2018, VIRCHOWS ARCH, V472, P331, DOI 10.1007/s00428 017 2182 3
   Turan S, 2015, CURR OSTEOPOROS REP, V13, P146, DOI 10.1007/s11914 015 0268 x
   van den Berg H., 2013, Sarcoma, V2013, P316123, DOI 10.1155/2013/316123
   Widhe B, 2000, J BONE JOINT SURG AM, V82A, P667, DOI 10.2106/00004623 200005000 00007
   YABUT SM, 1988, CLIN ORTHOP RELAT R, P281
   YAMASHIRO M, 1987, INT J ORAL MAX SURG, V16, P112, DOI 10.1016/S0901 5027(87)80040 1
   Yildiz FR, 2014, INT J CLIN EXP PATHO, V7, P2800
   Zhang J, 2011, TISSUE ENG PT A, V17, P1767, DOI 10.1089/ten.tea.2010.0503
NR 52
TC 6
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2212 4403
EI 2212 4411
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD MAY
PY 2021
VL 131
IS 5
BP 572
EP 581
DI 10.1016/j.oooo.2020.10.025
EA APR 2021
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA RR0PH
UT WOS:000642810600015
PM 33309262
DA 2025 08 17
ER

PT J
AU Zhang, SL
   Zhuang, Y
   Jin, SB
   Wang, KL
AF Zhang, Shengling
   Zhuang, Yan
   Jin, Shaobin
   Wang, Kelai
TI Preparation of Nanoscale Graphene Oxide and Its Application on β Catenin
   Expression in Pediatric Osteosarcoma Cells Combine with Probiotics
SO SCIENCE OF ADVANCED MATERIALS
LA English
DT Article
DE Probiotics; Nanoscale Graphene Oxide; beta ChainProtein; Wnt Signaling
   Pathway; Bifidobacterium
ID PHOTODYNAMIC THERAPY; NANO GRAPHENE; INHIBITOR; NANOPARTICLES;
   DOXORUBICIN; APOPTOSIS; DELIVERY
AB This work aimed to study the effect of nanoscale graphene oxide (NGO) and probiotics on the expression of beta catenin (chain protein) in pediatric osteosarcoma (OSA) cells. Ninety pediatric patients with OSA were taken as the research object, who were classified into control group, GO (NGO) group, and probiotics group. Their tumor tissues were collected and cultured. NGO materials were prepared by adding N, N dimethylformamide solvent into graphite powder. The control group was interfered with normal saline, the GO group was treated with NGO, and the probiotics group was interfered with mixed bacterial solution. The results showed that the expression of beta catenin mRNA in GO group and probiotics group was considerably inferior to control group (P < 0.05). Expression of beta catenin protein in control group increased, while that in GO group and probiotics group decreased. The OSA cell counts of GO group and probiotics group were evidently lower relative to control group (P < 0.05). In short, NGO and probiotics can reduce the expression of beta catenin protein in pediatric OSA cells, and inhibition of signaling pathway that involved beta catenin can suppress the proliferation of OSA cells.
C1 [Zhang, Shengling; Zhuang, Yan; Jin, Shaobin; Wang, Kelai] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pediat Surg, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University
RP Wang, KL (通讯作者)，Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pediat Surg, Jinan 250012, Shandong, Peoples R China.
EM kelaiwang@yeah.net
CR Burnett M, 2020, J CANCER, V11, P5007, DOI 10.7150/jca.46464
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Dalgic AD, 2018, J BIOMATER APPL, V32, P1392, DOI 10.1177/0885328218763665
   Gao T, 2020, CANCER BIOL MED, V17, P371, DOI 10.20892/j.issn.2095 3941.2019.0452
   Ghosh S, 2020, J NANOSCI NANOTECHNO, V20, P3994, DOI 10.1166/jnn.2020.17689
   Gulzar A, 2018, DALTON T, V47, P3931, DOI 10.1039/c7dt04141a
   Haghiralsadat F, 2018, INT J NANOMED, V13, P3853, DOI 10.2147/IJN.S150017
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Huang X, 2020, ACTA BIOMATER, V109, P229, DOI 10.1016/j.actbio.2020.04.009
   Katoh M, 2018, INT J MOL MED, V42, P713, DOI 10.3892/ijmm.2018.3689
   Li L, 2018, NANOMED NANOTECHNOL, V14, P581, DOI 10.1016/j.nano.2017.11.001
   Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004
   Galdeano CM, 2019, ANN NUTR METAB, V74, P115, DOI 10.1159/000496426
   Nomura M, 2019, JNCI J NATL CANCER I, V111, P1216, DOI 10.1093/jnci/djz026
   Ou LL, 2020, INT J NANOMED, V15, P5131, DOI 10.2147/IJN.S257084
   Paz E, 2017, MAT SCI ENG C MATER, V77, P1003, DOI 10.1016/j.msec.2017.03.269
   Rahman M, 2015, CURR DRUG METAB, V16, P397, DOI 10.2174/1389200215666141125120633
   Tang ZB, 2018, INT J NANOMED, V13, P2907, DOI 10.2147/IJN.S159388
   Yang K, 2016, ADV DRUG DELIVER REV, V105, P228, DOI 10.1016/j.addr.2016.05.015
   Yu W, 2019, BIOMATERIALS, V192, P128, DOI 10.1016/j.biomaterials.2018.11.019
NR 20
TC 1
Z9 1
U1 0
U2 5
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1947 2935
EI 1947 2943
J9 SCI ADV MATER
JI Sci. Adv. Mater.
PD NOV
PY 2021
VL 13
IS 11
BP 2131
EP 2137
DI 10.1166/sam.2021.4140
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science; Physics
GA YU2SG
UT WOS:000751896800004
DA 2025 08 17
ER

PT J
AU Wang, WJ
   Itaka, K
   Ohba, S
   Nishiyama, N
   Chung, UI
   Yamasaki, Y
   Kataoka, K
AF Wang, Wenjie
   Itaka, Keiji
   Ohba, Shinsuke
   Nishiyama, Nobuhiro
   Chung, Ung il
   Yamasaki, Yuichi
   Kataoka, Kazunori
TI 3D spheroid culture system on micropatterned substrates for improved
   differentiation efficiency of multipotent mesenchymal stem cells
SO BIOMATERIALS
LA English
DT Article
DE Mesenchymal stem cell; Micropatterning; Three dimension cell culture;
   Spheroid; Differentiation efficiency
ID GENE EXPRESSION; BONE MARROW; STROMAL CELLS; 3 DIMENSIONAL CULTURE;
   IN VIVO; ENVIRONMENT; DIAMETER; COLLAGEN; NICHE; MOUSE
AB Multipotent mesenchymal stem cells (MSCs) are one of the most powerful tools in regeneration medicine. Their low differentiation efficiency, however, limits further application of MSCs in clinical therapy. Here we report that a much higher multipotent differentiation efficiency of MSCs to adult cells can be achieved using a 3D spheroid culture method based on photolithography and micropatterning techniques. MSC spheroid of precise dimension and uniform quality cultured on the microdomain substrates was prepared first, and then was induced into adipocytes and osteoblasts. Both gene expression results from RT PCR and morphology observation results revealed that the 3D spheroid culture method could greatly improve differentiation efficiency. Gene expression profiles obtained from gene microarray analysis confirmed the high differentiation efficiency and revealed that MSCs induced in 3D spheroid culture system regulated gene expression not only by increasing the expression levels of genes related to adipogenesis and osteogenesis, but also by down regulating the gene maintaining MSCs' self renewal phenotypes. We conclude that our 3D spheroid culture system contributes to an optimization for efficient differentiation of MSCs, offers insight into the mechanism of efficient differentiation of engineered 3D culture system, and has promise for wide applications in regeneration medicine and drug discovery fields. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Wang, Wenjie; Yamasaki, Yuichi; Kataoka, Kazunori] Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, Tokyo 1138656, Japan.
   [Itaka, Keiji; Nishiyama, Nobuhiro; Chung, Ung il; Kataoka, Kazunori] Univ Tokyo, Ctr NanoBio Integrat, Bunkyo Ku, Tokyo 1138656, Japan.
   [Itaka, Keiji; Ohba, Shinsuke; Nishiyama, Nobuhiro; Chung, Ung il; Kataoka, Kazunori] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Div Clin Biotechnol,Bunkyo Ku, Tokyo 1130033, Japan.
   [Ohba, Shinsuke] Univ Tokyo, Grad Sch Med, Dept Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Chung, Ung il] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1138654, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo;
   University of Tokyo; University of Tokyo
RP Kataoka, K (通讯作者)，Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138656, Japan.
EM kataoka@bmw.t.u tokyo.ac.jp
RI Yamasaki, Yuichi/JCN 6094 2023; Itaka, Keiji/KXQ 4687 2024; Nishiyama,
   Nobuhiro/F 1867 2014; Kataoka, Kazunori/K 7108 2012; wu,
   wenjie/HKM 3623 2023
OI Nishiyama, Nobuhiro/0000 0002 6886 9357; Kataoka,
   Kazunori/0000 0002 8591 413X; Ohba, Shinsuke/0000 0002 6874 8539; 
FU Japan Science and Technology Agency (JST); Ministry of Health, Labor and
   Welfare (MHLW), Japan
FX The authors would like to acknowledge Professor Hans Marcus Textor, ETH
   Zurich, for his helpful comments about our manuscript. The authors Would
   also like to express thanks to Dr. Satoshi Kondou, Toray Industries
   Inc., for providing technical advice on the DNA microarray. This work
   was financially supported by the Core Research for Evolutional Science
   and Technology (CREST) from the Japan Science and Technology Agency
   (JST), and the Health and Labor Sciences Research Grants in Research on
   Advanced Medical Technology in Nanomedicine Area from the Ministry of
   Health, Labor and Welfare (MHLW), Japan.
CR Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a
   Allen LT, 2003, P NATL ACAD SCI USA, V100, P6331, DOI 10.1073/pnas.1031426100
   Anderson DG, 2004, NAT BIOTECHNOL, V22, P863, DOI 10.1038/nbt981
   ANDREWS HC, 1995, GENOMICS, V27, P155
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Barry Frank P., 2003, Birth Defects Research, V69, P250, DOI 10.1002/bdrc.10021
   Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040 8428(00)00077 9
   Battista S, 2005, BIOMATERIALS, V26, P6194, DOI 10.1016/j.biomaterials.2005.04.003
   Borene ML, 2004, ANN BIOMED ENG, V32, P274, DOI 10.1023/B:ABME.0000012747.97620.3a
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Chen CS, 2005, MRS BULL, V30, P194, DOI 10.1557/mrs2005.52
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955 0674(02)00364 2
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   EBBESEN P, 2004, STEM CELLS, V22, P1346
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166
   Gerecht Nir S, 2004, BIOTECHNOL BIOENG, V86, P493, DOI 10.1002/bit.20045
   Gerecht Nir S, 2004, BIOTECHNOL BIOENG, V88, P313, DOI 10.1002/bit.20248
   Gerstenfeld LC, 2003, CONNECT TISSUE RES, V44, P85, DOI 10.1080/03008200390152142
   GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965
   Groebe K, 1996, INT J RADIAT ONCOL, V34, P395, DOI 10.1016/0360 3016(95)02065 9
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   Hwang NS, 2006, STEM CELLS, V24, P284, DOI 10.1634/stemcells.2005 0024
   INSOO H, 2007, CELL STEM CELL, V1, P367
   Ito T, 2007, ONCOLOGY BASEL, V73, P366, DOI 10.1159/000136156
   Janderová L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Kunz Schughart LA, 1999, CELL BIOL INT, V23, P157, DOI 10.1006/cbir.1999.0384
   Layer PG, 2002, TRENDS NEUROSCI, V25, P131, DOI 10.1016/S0166 2236(00)02036 1
   Leven RM, 2004, J BIOMED MATER RES A, V70A, P391, DOI 10.1002/jbm.a.30082
   Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100
   Li Nianzhen, 2003, Crit Rev Biomed Eng, V31, P423, DOI 10.1615/CritRevBiomedEng.v31.i56.20
   Liu H, 2005, TISSUE ENG, V11, P319, DOI 10.1089/ten.2005.11.319
   Liu H, 2006, BIOMATERIALS, V27, P5978, DOI 10.1016/j.biomaterials.2006.05.053
   Liu TM, 2007, STEM CELLS, V25, P750, DOI 10.1634/stemcells.2006 0394
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Michelini M, 2006, CELL PROLIFERAT, V39, P217, DOI 10.1111/j.1365 2184.2006.00381.x
   Muguruma Y, 2003, EXP HEMATOL, V31, P1323, DOI 10.1016/j.exphem.2003.09.003
   Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487
   Nur E Kamal A, 2006, STEM CELLS, V24, P426, DOI 10.1634/stemcells.2005 0170
   Nyström K, 2004, J VIROL METHODS, V118, P83, DOI 10.1016/j.jviromet.2004.01.019
   Otsuka H, 2004, CHEMBIOCHEM, V5, P850, DOI 10.1002/cbic.200300822
   OWEN M, 1988, CIBA F SYMP, V136, P42
   Park TH, 2003, BIOTECHNOL PROGR, V19, P243, DOI 10.1021/bp020143k
   Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Raty S, 2004, LAB CHIP, V4, P186, DOI 10.1039/b316437c
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sakai Y, 2007, ACTA BIOMATER, V3, P1033, DOI 10.1016/j.actbio.2007.06.004
   Schwartz MA, 2005, J BIOMED MATER RES A, V73A, P30, DOI 10.1002/jbm.a.30228
   SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tondreau T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 166
   Viravaidya K, 2004, BIOTECHNOL PROGR, V20, P590, DOI 10.1021/bp034238d
   Walker GM, 2004, LAB CHIP, V4, P91, DOI 10.1039/b311214d
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343 5349.2000
NR 61
TC 285
Z9 330
U1 3
U2 91
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2009
VL 30
IS 14
BP 2705
EP 2715
DI 10.1016/j.biomaterials.2009.01.030
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 429XR
UT WOS:000264953900006
PM 19215979
DA 2025 08 17
ER

PT J
AU Patel, P
   Hardy, R
   Sumathi, V
   Bartle, G
   Kindblom, LG
   Grimer, R
   Bujalska, I
   Stewart, PM
   Rabbitt, E
   Gittoes, NJL
   Cooper, MS
AF Patel, Pushpa
   Hardy, Rowan
   Sumathi, Vaiyapuri
   Bartle, Gillian
   Kindblom, Lars Gunnar
   Grimer, Robert
   Bujalska, Iwona
   Stewart, Paul M.
   Rabbitt, Elizabeth
   Gittoes, Neil J. L.
   Cooper, Mark S.
TI Expression of 11β hydroxysteroid dehydrogenase enzymes in human
   osteosarcoma: potential role in pathogenesis and as targets for
   treatments
SO ENDOCRINE RELATED CANCER
LA English
DT Article
ID CELL PROLIFERATION; IN VIVO; BONE; GLUCOCORTICOIDS; DETERMINANT; TYPE 1;
   DEXAMETHASONE; OSTEOBLASTS; ISOZYMES
AB Osteosarcoma (OS) is a primary malignant tumour of bone occurring predominantly in children and young adults. Despite chemotherapy, relapse is common and mortality remains high. Non transformed osteoblasts are highly sensitive to glucocorticoids, which reduce proliferation and induce apoptosis. Previously, we observed that OS cells, but not normal osteoblasts, express 11 beta hydroxysteroid dehydrogenase type 2 (11 beta HSD2). This enzyme inactivates cortisol (active) to cortisone (inactive) and expression of 11 beta HSD2 renders OS cells resistant to glucocorticoids. By contrast, the related enzyme 11 beta HSD1 converts cortisone to cortisol and reduces OS cell proliferation in vitro. Some synthetic glucocorticoids (e.g. dehydrodexamethasone (DHD), inactive counterpart of dexamethasone (DEX)) have been reported to be activated by 11 beta HSD2. We therefore investigated expression and enzymatic activity of 11 beta HSD isozymes in human OS tissue, determined whether 11 beta HSD expression has prognostic value in the response to therapy, and evaluated the potential use of synthetic glucocorticoids to selectively target OS cells. OS samples expressed both 11 beta HSD1 and 11 beta HSD2. 11 beta HSD1 expression in pretreatment biopsy specimens positively correlated with primary tumour size. Expression and activity of 11 beta HSD1 in post treatment biopsies were unrelated to the degree of tumour necrosis following chemotherapy. However, high 11 beta HSD2 expression in post treatment biopsies correlated with a poor response to therapy. OS cells that expressed 11 beta HSD2 inactivated endogenous glucocorticoids; but these cells were also able to generate DEX from DHD. These results suggest that OS treatment response is related to 11 beta HSD2 enzyme expression. Furthermore, OS cells expressing this enzyme could be targeted by treatment with synthetic glucocorticoids that are selectively reactivated by the enzyme. Endocrine Related Cancer (2012) 19 589 598
C1 [Patel, Pushpa; Hardy, Rowan; Bujalska, Iwona; Stewart, Paul M.; Rabbitt, Elizabeth; Gittoes, Neil J. L.; Cooper, Mark S.] Univ Birmingham, Inst Biomed Res, Sch Clin & Expt Med, Birmingham B15 2TH, W Midlands, England.
   [Sumathi, Vaiyapuri; Bartle, Gillian; Kindblom, Lars Gunnar] Queen Elizabeth Hosp, Royal Orthopaed Hosp NHS Fdn Trust, Dept Musculoskeletal Pathol, Birmingham B15 2TT, W Midlands, England.
   [Grimer, Robert] Royal Orthopaed Hosp NHS Fdn Trust, Dept Oncol, Birmingham B31 2AP, W Midlands, England.
C3 University of Birmingham; Royal Orthopaedic Hospital; University of
   Birmingham; Royal Orthopaedic Hospital
RP Cooper, MS (通讯作者)，Univ Birmingham, Queen Elizabeth Hosp, MS Cooper Ctr Endocrinol Diabet & Metab, Birmingham B15 2TH, W Midlands, England.
EM m.s.cooper@bham.ac.uk
RI ; Hardy, Rowan/N 9185 2018; Cooper, Mark/C 9529 2012
OI Cooper, Mark/0000 0003 3112 7728; Hardy, Rowan/0000 0001 6938 6739; 
FU University Hospital Birmingham Charities; National Institute for Health
   Research [NF SI 0508 10356] Funding Source: researchfish
FX This study was funded by a grant from the University Hospital Birmingham
   Charities.
CR Best R, 1997, J ENDOCRINOL, V153, P41, DOI 10.1677/joe.0.1530041
   Bland R, 1999, J ENDOCRINOL, V161, P455, DOI 10.1677/joe.0.1610455
   Bramer JAM, 2005, EUR J CANCER, V41, P2846, DOI 10.1016/j.ejca.2005.07.024
   Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012
   Cooper M, 1998, QJM MON J ASSOC PHYS, V91, P453, DOI 10.1093/qjmed/91.7.453
   Cooper MS, 2009, J CLIN ENDOCR METAB, V94, P4645, DOI 10.1210/jc.2009 1412
   Cooper MS, 2001, J BONE MINER RES, V16, P1037, DOI 10.1359/jbmr.2001.16.6.1037
   Cooper MS, 2004, CLIN SCI, V107, P111, DOI 10.1042/CS20040070
   Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979
   Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756 3282(00)00344 6
   Coulter CL, 1998, ENDOCR RES, V24, P875, DOI 10.3109/07435809809032701
   Diederich S, 2002, J CLIN ENDOCR METAB, V87, P5695, DOI 10.1210/jc.2002 020970
   Eyre LJ, 2001, J CELL BIOCHEM, V81, P453, DOI 10.1002/1097 4644(20010601)81:3<453::AID JCB1059>3.0.CO;2 Z
   Hardy R, 2008, ANN RHEUM DIS, V67, P1204, DOI 10.1136/ard.2008.090662
   Kudawara I, 2001, EUR J CANCER, V37, P1703, DOI 10.1016/S0959 8049(01)00185 X
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Rabbitt E, 2003, ONCOGENE, V22, P1663, DOI 10.1038/sj.onc.1206293
   Rabbitt EH, 2002, FASEB J, V16, P36, DOI 10.1096/fj.01 0582com
   Raymond A., 2002, WHO CLASSIFICATION T, P264
   Sai S, 2011, LEUKEMIA RES, V35, P1644, DOI 10.1016/j.leukres.2011.07.002
   Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003 0031
   Wafa H, 2006, EXPERT REV ANTICANC, V6, P239, DOI 10.1586/14737140.6.2.239
NR 23
TC 11
Z9 12
U1 0
U2 6
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1351 0088
J9 ENDOCR RELAT CANCER
JI Endocr. Relat. Cancer
PD AUG
PY 2012
VL 19
IS 4
BP 589
EP 598
DI 10.1530/ERC 12 0079
PG 10
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA 035BY
UT WOS:000310918400009
PM 22719058
OA Bronze
DA 2025 08 17
ER

PT J
AU Wong, KC
   Lee, KS
   Luk, HK
   Wan, HY
   Ho, CK
   Zhang, Y
   Wong, MS
AF Wong, Ka Chun
   Lee, Kin Shing
   Luk, Hon Kit
   Wan, Hoi Ying
   Ho, Chui Kwan
   Zhang, Yan
   Wong, Man Sau
TI Er Xian Decoction Exerts Estrogen Like Osteoprotective Effects In
   Vivo and In Vitro
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Osteoporosis; Er Xian Decoction; Ovariectomized Rats; Estrogen Receptor;
   Rat Osteoblast like UMR 106 Cells
ID CHINESE HERBAL FORMULA; CURCULIGO ORCHIOIDES; OVARIECTOMIZED RATS;
   MENOPAUSAL SYMPTOMS; ANGELICA SINENSIS; TRABECULAR BONE; RECEPTOR;
   EXTRACT; PROLIFERATION; OSTEOPOROSIS
AB Er xian Decoction (EXD), containing Herba epimedii Maxim (HEP) and Curculigo orchioides Gaertn (XM) as principal drugs, is a traditional Chinese medicine (TCM) formula prescribed for the treatment of postmenopausal osteoporosis. In the present study, the in vivo anti osteoporosis effects of EXD, HEP and XM on four month old ovariectomized (OVX) Sprague Dawley rats were investigated. Micro computed tomography analysis showed that EXD could significantly improve the micro architectural parameters (BMD, BV/TV, Tb.N, Tb.Th, and Tb.Sp) of trabecular bone in the distal femur and proximal tibia in OVX rats (p < 0.05). The biomechanical parameters of the distal femur in rats treated with EXD were also improved significantly (p < 0.05 vs. OVX group). The in vivo efficacy of EXD was found to be superior to HEP or XM alone in improving the bone properties of OVX rats. Treatment of rat osteoblastic like UMR 106 cells with EXD, HEP, and XM significantly promoted the cell proliferation rate (p < 0.05) with the most promising effects observed in cells treated with EXD (p < 0.001). The proliferative effect in UMR 106 cells induced by EXD, HEP, and XM were abolished in the presence of the estrogen antagonist, ICI182780, suggesting that their effects were mediated by estrogen receptor (ER). Additionally, EXD could activate ER alpha and ER beta mediated estrogen response element (ERE) dependent luciferase activity as well as phosphorylate ER alpha at serine 118 in UMR 106 cells. Taken together, EXD offered better osteoprotective effects than its single principal herb, and the beneficial effects of EXD in preventing bone deteriorations are, at least partially, through the ER signaling pathway.
C1 [Wong, Ka Chun; Lee, Kin Shing; Luk, Hon Kit; Wan, Hoi Ying; Ho, Chui Kwan; Zhang, Yan; Wong, Man Sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
   [Ho, Chui Kwan; Zhang, Yan; Wong, Man Sau] State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen, Peoples R China.
C3 Hong Kong Polytechnic University
RP Wong, MS (通讯作者)，Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Room Y806,Lee Shau Kei Bldg, Kowloon, Hong Kong, Peoples R China.
EM yzhang@polyu.edu.hk; man sau.wong@polyu.edu.hk
RI Wong, Man Sau/F 2059 2015; Wong, Ka Chun/L 7160 2019
OI Wong, Man Sau/0000 0002 0729 8618; 
FU Hong Kong Polytechnic University [I BB8N]; National Key Basic Research
   Development Plan (973 plan) [2012CB723506]; National Natural Science
   Foundation of China [81202894]; Shenzhen Key Laboratory Advancement
   Program [CXB201104220020A]; State Key Laboratory of Chinese Medicine and
   Molecular Pharmacology (Incubation), Shenzhen
FX We thank the State Key Laboratory of Chinese Medicine and Molecular
   Pharmacology (Incubation), Shenzhen for its support. This work was
   supported by the Niche Area Fund from the Hong Kong Polytechnic
   University (I BB8N), the National Key Basic Research Development Plan
   (973 plan, 2012CB723506) the National Natural Science Foundation of
   China (81202894) as well as Shenzhen Key Laboratory Advancement Program
   (CXB201104220020A).
CR An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200
   An SJ, 2000, CHIN J OSTEOPOROSIS, V6, P55
   Bagi CM, 2006, BONE, V38, P136, DOI 10.1016/j.bone.2005.07.028
   Bao LL, 2011, CHEM BIOL INTERACT, V194, P97, DOI 10.1016/j.cbi.2011.08.013
   Carr BR, 1996, EUR J OBSTET GYN R B, V64, pS17, DOI 10.1016/0301 2115(95)02351 8
   Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420
   Chen HY, 2008, AM J CHINESE MED, V36, P233, DOI 10.1142/S0192415X08005746
   Chen WF, 2011, BRIT J NUTR, V105, P180, DOI 10.1017/S0007114510003247
   Circosta C, 2006, PHYTOTHER RES, V20, P665, DOI 10.1002/ptr.1928
   ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002 9378(92)91653 R
   Glasier A, 2006, WOMENS HLTH MED, V3, P15
   Hormminga J., 2002, BONE, V30, P759
   JI H, 2001, CHIN J OSTEOPOROSIS, V7, P4
   Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317
   Judex S, 2003, ANN BIOMED ENG, V31, P12, DOI 10.1114/1.1535414
   Kanis JA, 2002, OSTEOPOROSIS INT, V13, P527, DOI 10.1007/s001980200069
   Kim CH, 2007, J BIOMECH ENG T ASME, V129, P481, DOI 10.1115/1.2746368
   Kim JH, 2011, J ETHNOPHARMACOL, V134, P234, DOI 10.1016/j.jep.2010.12.005
   Li CM, 2013, AM J CHINESE MED, V41, P831, DOI 10.1142/S0192415X13500560
   Li FM, 2001, PHARM BIOL, V39, P351, DOI 10.1076/phbi.39.5.351.5901
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142 9612(97)00073 2
   Scheid V, 2007, COMPLEMENT THER MED, V15, P54, DOI 10.1016/j.ctim.2005.12.002
   Sze SCW, 2009, J ETHNOPHARMACOL, V123, P27, DOI 10.1016/j.jep.2009.02.034
   Sze SCW, 2012, EUR J INTEGR MED, V4, pE187, DOI 10.1016/j.eujim.2012.01.006
   van der Woude H, 2005, MOL NUTR FOOD RES, V49, P763, DOI 10.1002/mnfr.200500036
   Vijayanarayana K, 2007, J ETHNOPHARMACOL, V114, P241, DOI 10.1016/j.jep.2007.08.009
   Wang X.J., 2012, HDB ANTHROPOMETRY, P2243
   Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014
   Wong M.S., 2013, HDB NUTR DIET MENOPA, P427
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Wong SP, 2009, J PHARMACEUT BIOMED, V50, P216, DOI 10.1016/j.jpba.2009.04.022
   Wu CS, 2011, J PHARMACEUT BIOMED, V54, P186, DOI 10.1016/j.jpba.2010.07.010
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   Xue LM, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/241416
   Xue LM, 2011, INT J MOL SCI, V12, P7635, DOI 10.3390/ijms12117635
   Xutian S, 2012, AM J CHINESE MED, V40, P231, DOI 10.1142/S0192415X12500188
   Yang Q, 2002, CLIN CHIM ACTA, V324, P89, DOI 10.1016/S0009 8981(02)00210 3
   Yap SP, 2007, J ETHNOPHARMACOL, V113, P218, DOI 10.1016/j.jep.2007.05.029
   Zhong LLD, 2013, MENOPAUSE, V20, P767, DOI [10.1097/gme.0b013e31827cd3dd, 10.1097/GME.0b013e31827cd3dd]
   Zhu Z, 2010, MOLECULES, V15, P4695, DOI 10.3390/molecules15074695
NR 45
TC 31
Z9 36
U1 0
U2 31
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2014
VL 42
IS 2
BP 409
EP 426
DI 10.1142/S0192415X1450027X
PG 18
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA AD2UR
UT WOS:000333091500011
PM 24707871
DA 2025 08 17
ER

PT J
AU Shen, XK
   Gu, H
   Ma, PP
   Luo, Z
   Li, MH
   Hu, Y
   Cai, KY
AF Shen, Xinkun
   Gu, Hao
   Ma, Pingping
   Luo, Zhong
   Li, Menghuan
   Hu, Yan
   Cai, Kaiyong
TI Minocycline incorporated multilayers on titanium substrates for
   simultaneous regulation of MSCs and macrophages
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Titanium; Minocycline; Macrophages; Osteogenesis
ID BONE FORMATION; DIFFERENTIATION; EXPRESSION; OSTEOBLASTS; METABOLISM;
   PATHWAY; IMMUNE; MODEL
AB Minocycline (Mino) is a well established antibiotic, which also has osseointegration and anti inflammatory functions. In this study, we fabricated a multilayered structure with potential osteoinduction capability on titanium via a spin assisted layer by layer (LBL) assembly technique. Mino was used as the intercalated material, while gelatin and chitosan were used as the polycation and polyanion, respectively. The successful fabrication of the multilayers was validated by scanning electronic microscopy (SEM), atomic force microscopy (AFM) and water contact angle measurements. The release result shows that the sustained release of Mino might be attributed to the synergistic effect of drug diffusion and multilayer degradation. The evaluations of alkaline phosphatase (ALP), mineralization, and osteogenic gene expression consistently demonstrate that the Mino modified samples (Ti/LBL/Mino) significantly improved the osteogenic differentiation of MSCs compared with the control group (Ti). More importantly, the results of flow cytometry, quantitative real time polymerase chain reaction (qRT PCR), and western blot confirm that Ti/LBL/Mino substrates could indirectly promote osteogenesis through macrophage regulation, such as phenotype transformation from M1 to M2 and regulation of inflammatory/osteogenic genes. The aforementioned properties make Ti/LBL/Mino substrate highly suitable for orthopedic applications.
C1 [Shen, Xinkun; Gu, Hao; Ma, Pingping; Hu, Yan; Cai, Kaiyong] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
   [Shen, Xinkun; Luo, Zhong; Li, Menghuan] Chongqing Univ, Sch Life Sci, Chongqing 400044, Peoples R China.
C3 Chongqing University; Chongqing University
RP Hu, Y; Cai, KY (通讯作者)，Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
EM huyan303@cqu.edu.cn; kaiyong_cai@cqu.edu.cn
RI ; Cai, Kaiyong/G 1233 2011; Luo, Zhong/AAU 2225 2020
OI Luo, Zhong/0000 0002 9019 3314; Cai, Kaiyong/0000 0001 9029 680X
FU State Key Project of Research and Development [2016YFC1100300,
   2017YFB0702603]; National Natural Science Foundation of China [51673032,
   31700827, 51773023]; Natural Science Foundation of Chongqing Municipal
   Government [CXTDX201601002, cstc2018jcyjAX0368]; China Postdoctoral
   Science Foundation [2018T110946]; Fundamental Research Funds for the
   Central Universities [2018CDPTCG0001/21]
FX This work was financially supported by State Key Project of Research and
   Development (Grant No. 2016YFC1100300 & 2017YFB0702603), National
   Natural Science Foundation of China (51673032, 31700827 and 51773023),
   Natural Science Foundation of Chongqing Municipal Government
   (CXTDX201601002 & cstc2018jcyjAX0368), China Postdoctoral Science
   Foundation funded project (2018T110946) and Fundamental Research Funds
   for the Central Universities (2018CDPTCG0001/21).
CR Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   Barwacz CA, 2015, CLIN ORAL IMPLAN RES, V26, pe35, DOI 10.1111/clr.12326
   Cao YX, 2016, J LEUKOCYTE BIOL, V100, P513, DOI 10.1189/jlb.1A1215 543R
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035 014 8790 x
   Dong L, 2017, MOL IMMUNOL, V83, P46, DOI 10.1016/j.molimm.2017.01.007
   Dou XC, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/2/025002
   El Khassawna T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00562
   Farghadan M, 2016, IRAN J ALLERGY ASTHM, V15, P515
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   Garrido Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139
   Ge J, 2015, J CHEM THERMODYN, V80, P1, DOI 10.1016/j.jct.2014.08.008
   Ge Q, 2017, SCI REP UK, V7, DOI 10.1038/srep40253
   Graham C, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1154 3
   Hasan J, 2017, SCI REP UK, V7, DOI 10.1038/srep41118
   Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742 2094 5 15
   HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793
   Huang L, 2016, J BIOMED MATER RES A, V104, P1437, DOI 10.1002/jbm.a.35667
   Klopfleisch R, 2016, ACTA BIOMATER, V43, P3, DOI 10.1016/j.actbio.2016.07.003
   Lee CH, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/8/085101
   Lee Jung Hyuk, 2018, Oral Biology Research, V42, P187, DOI 10.21851/obr.42.04.201812.187
   Li GL, 2016, ACS APPL MATER INTER, V8, P3840, DOI 10.1021/acsami.5b10633
   Lv HB, 2014, J DENT, V42, P1464, DOI 10.1016/j.jdent.2014.06.003
   Magatti M, 2017, J TISSUE ENG REGEN M, V11, P2895, DOI 10.1002/term.2193
   Martinez FO, 2008, FRONT BIOSCI LANDMRK, V13, P453, DOI 10.2741/2692
   Mulder R, 2014, IMMUNOBIOLOGY, V219, P737, DOI 10.1016/j.imbio.2014.05.005
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Nover AB, 2015, ACTA BIOMATER, V27, P286, DOI 10.1016/j.actbio.2015.08.045
   Park JB, 2012, J SURG RES, V178, P737, DOI 10.1016/j.jss.2012.03.072
   Park OJ, 2015, J ENDODONT, V41, P658, DOI 10.1016/j.joen.2014.12.015
   Pearl JI, 2011, BIOMATERIALS, V32, P5535, DOI 10.1016/j.biomaterials.2011.04.046
   Qiao YQ, 2014, BIOMATERIALS, V35, P6882, DOI 10.1016/j.biomaterials.2014.04.101
   Ranran Fu, 2017, Key Engineering Materials, V730, P127, DOI 10.4028/www.scientific.net/KEM.730.127
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Shen XK, 2016, J MATER CHEM B, V4, P7101, DOI 10.1039/c6tb01779g
   Shen XK, 2016, J MATER CHEM B, V4, P1423, DOI 10.1039/c5tb01956g
   Shen XK, 2014, ACS APPL MATER INTER, V6, P16426, DOI 10.1021/am5049338
   Shin HJ, 2013, INT IMMUNOPHARMACOL, V15, P38, DOI 10.1016/j.intimp.2012.11.005
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Sun JL, 2017, BIOMATERIALS, V113, P203, DOI 10.1016/j.biomaterials.2016.10.050
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tham AY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081222
   Tu MG, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5607 z
   Wang FL, 2017, CELL PHYSIOL BIOCHEM, V41, P1725, DOI 10.1159/000471865
   Wang Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02311 0
   Williams S, 1998, Adv Dent Res, V12, P71
   Williams S, 1996, BONE, V19, P637, DOI 10.1016/S8756 3282(96)00302 X
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Xu BB, 2016, ACS APPL MATER INTER, V8, P6685, DOI 10.1021/acsami.5b12820
   Yildirim C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124347
   Zankovych S, 2013, ACTA BIOMATER, V9, P4926, DOI 10.1016/j.actbio.2012.08.013
   Zhou JH, 2016, ACTA BIOMATER, V43, P358, DOI 10.1016/j.actbio.2016.07.045
NR 53
TC 9
Z9 9
U1 2
U2 74
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP
PY 2019
VL 102
BP 696
EP 707
DI 10.1016/j.msec.2019.04.074
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IE2VE
UT WOS:000472241700067
PM 31147042
DA 2025 08 17
ER

PT J
AU Zhu, BJ
   Wu, JX
   Li, T
   Liu, ST
   Guo, JH
   Yu, YJ
   Qiu, XY
   Zhao, Y
   Peng, HR
   Zhang, JL
   Miao, LY
   Wei, H
AF Zhu, Bijun
   Wu, Jiangjiexing
   Li, Tong
   Liu, Songtao
   Guo, Junheng
   Yu, Yijun
   Qiu, Xinyi
   Zhao, Yue
   Peng, Haoran
   Zhang, Jinli
   Miao, Leiying
   Wei, Hui
TI A Glutathione Peroxidase Mimicking Nanozyme Precisely Alleviates
   Reactive Oxygen Species and Promotes Periodontal Bone Regeneration
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE nanozymes; oxidative stress; periodontal regeneration; periodontitis;
   reactive oxygen species
ID HYDROGEN PEROXIDE; OSTEOCLAST DIFFERENTIATION; ALVEOLAR MACROPHAGES;
   VANADIUM; DISEASE; COMPLEX; POLARIZATION; INFLAMMATION; CHEMISTRY
AB The use of oxidoreductase nanozymes to regulate reactive oxygen species (ROS) has gradually emerged in periodontology treatments. However, current nanozymes for treating periodontitis eliminate ROS extensively and non specifically, ignoring the physiological functions of ROS under normal conditions, which may result in uncontrolled side effects. Herein, using the MIL 47(V) F (MVF) nanozyme, which mimics the function of glutathione peroxidase (GPx), it is proposed that ROS can be properly regulated by specifically eliminating H2O2, the most prominent ROS. Through H2O2 elimination, MVF contributes to limiting inflammation, regulating immune microenvironment, and promoting periodontal regeneration. Moreover, MVF stimulates osteogenic differentiation of periodontal stem cells directly, further promoting regeneration due to the vanadium in MVF. Mechanistically, MVF regulates ROS by activating the nuclear factor erythroid 2 related factor 2/heme oxygenase 1 (Nrf2/HO 1) pathway and promotes osteogenic differentiation directly through the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) pathway. A promising periodontitis therapy strategy is presented using GPx mimicking nanozymes through their triple effects of antioxidation, immunomodulation, and bone remodeling regulation, making nanozymes an excellent tool for developing precision medicine.
   A GPx mimicking nanozyme, MVF, is developed and its selective clearance of H2O2 is demonstrated. The experimental findings elucidate the triple functionality of MVF in regulating ROS, macrophage polarization, and the balance between osteogenesis and osteoclastogenesis, ultimately leading to the repair and regeneration of periodontal bone tissue.image
C1 [Zhu, Bijun; Yu, Yijun; Qiu, Xinyi; Zhao, Yue; Peng, Haoran; Miao, Leiying] Nanjing Univ, Nanjing Stomatol Hosp, Dept Cariol & Endodont, Med Sch, Nanjing 210008, Jiangsu, Peoples R China.
   [Wu, Jiangjiexing] Tianjin Univ, Sch Marine Sci & Technol, Tianjin 300072, Peoples R China.
   [Li, Tong; Wei, Hui] Nanjing Univ, Coll Engn & Appl Sci, Nanjing Natl Lab Microstruct, Jiangsu Key Lab Artificial Funct Mat, Nanjing 210023, Jiangsu, Peoples R China.
   [Liu, Songtao; Guo, Junheng; Zhang, Jinli] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Wei, Hui] Nanjing Univ, Chem & Biomed Innovat Ctr ChemBIC, Sch Chem & Chem Engn, State Key Lab Analyt Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University; Tianjin University; Nanjing University; Tianjin
   University; Nanjing University
RP Miao, LY (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Dept Cariol & Endodont, Med Sch, Nanjing 210008, Jiangsu, Peoples R China.; Wu, JX (通讯作者)，Tianjin Univ, Sch Marine Sci & Technol, Tianjin 300072, Peoples R China.; Wei, H (通讯作者)，Nanjing Univ, Coll Engn & Appl Sci, Nanjing Natl Lab Microstruct, Jiangsu Key Lab Artificial Funct Mat, Nanjing 210023, Jiangsu, Peoples R China.; Zhang, JL (通讯作者)，Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM wjjx1987@tju.edu.cn; zhangjinli@tju.edu.cn; miaoleiying80@163.com;
   weihui@nju.edu.cn
RI Wu, Jiangjiexing/JXM 8280 2024; Zhu, Bijun/KFT 0402 2024; Peng,
   haoran/JQV 9583 2023; Wei, Hui/E 6799 2011; Li, Tong/IWU 5179 2023
FU This work was supported by the Project of Invigorating Healthcare
   through Science, Technology and Education, Jiangsu Provincial Medical
   Youth Talent under award No. QNRC2016120 (to L.M.), National Natural
   Science Foundation of China grant No. 22104054 (to [QNRC2016120];
   Project of Invigorating Healthcare through Science, Technology and
   Education, Jiangsu Provincial Medical Youth Talent [22104054]; National
   Natural Science Foundation of China [BK20221177]; Natural Science
   Foundation of Jiangsu Province [0223A203]; Cultivation Program for
   Reserve Talents for Academic Leaders of Nanjing Stomatological School,
   Medical School of Nanjing University [2019060009]; Nanjing Clinical
   Research Center for Oral Diseases [YKK20153]; Medical Science and
   Technology Development Foundation, Nanjing Department of Health
FX This work was supported by the Project of Invigorating Healthcare
   through Science, Technology and Education, Jiangsu Provincial Medical
   Youth Talent under award No. QNRC2016120 (to L.M.), National Natural
   Science Foundation of China grant No. 22104054 (to J.W.), the Natural
   Science Foundation of Jiangsu Province under award No. BK20221177 (to
   L.M.), "2015" Cultivation Program for Reserve Talents for Academic
   Leaders of Nanjing Stomatological School, Medical School of Nanjing
   University under award No. 0223A203 (to L.M.), Nanjing Clinical Research
   Center for Oral Diseases under award No. 2019060009 (to L.M.), General
   Project supported by Medical Science and Technology Development
   Foundation, Nanjing Department of Health under Grant under award No.
   YKK20153 (to Y.Y.).
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Barrio DA, 2006, CAN J PHYSIOL PHARM, V84, P677, DOI 10.1139/Y06 022
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   Barthelet K, 2002, ANGEW CHEM INT EDIT, V41, P281, DOI 10.1002/1521 3773(20020118)41:2<281::AID ANIE281>3.0.CO;2 Y
   BAUGHMAN RP, 1986, J LAB CLIN MED, V107, P233
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Boya P, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146506
   Brüne B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785
   Buccitelli C, 2020, NAT REV GENET, V21, P630, DOI 10.1038/s41576 020 0258 4
   Sczepanik FSC, 2020, PERIODONTOL 2000, V84, P45, DOI 10.1111/prd.12342
   Casas AI, 2020, PHARMACOL REV, V72, P801, DOI 10.1124/pr.120.019422
   Centrone A, 2010, SMALL, V6, P1598, DOI 10.1002/smll.201000773
   Chen Y, 2024, ADV MATER, V36, DOI 10.1002/adma.202206421
   Chen ZT, 2017, ACS NANO, V11, P4494, DOI 10.1021/acsnano.6b07808
   Cortizo AM, 2006, INT J BIOCHEM CELL B, V38, P1171, DOI 10.1016/j.biocel.2005.12.007
   Crans DC, 2004, CHEM REV, V104, P849, DOI 10.1021/cr020607t
   Dommisch H, 2018, PERIODONTOL 2000, V78, P129, DOI 10.1111/prd.12233
   Dong HJ, 2019, BIOCONJUGATE CHEM, V30, P1273, DOI 10.1021/acs.bioconjchem.9b00171
   Fedeli S, 2021, CHEM SOC REV, V50, P13467, DOI 10.1039/d0cs00659a
   GREENWALD RA, 1990, FREE RADICAL BIO MED, V8, P201, DOI 10.1016/0891 5849(90)90092 W
   Griess B, 2020, FREE RADICAL BIO MED, V147, P48, DOI 10.1016/j.freeradbiomed.2019.12.018
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Guo JX, 2018, ARTIF CELL NANOMED B, V46, P58, DOI 10.1080/21691401.2018.1452020
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Huang L, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav5490
   Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672
   Im J, 2016, CHEM MATER, V28, P5336, DOI 10.1021/acs.chemmater.6b01148
   Ji SF, 2021, NAT CATAL, V4, P407, DOI 10.1038/s41929 021 00609 x
   Jiao J, 2021, J CLIN PERIODONTOL, V48, P168, DOI 10.1111/jcpe.13396
   Kang T, 2020, COORDIN CHEM REV, V403, DOI 10.1016/j.ccr.2019.213092
   Kianoush F, 2017, J BIOMED MATER RES A, V105, P2499, DOI 10.1002/jbm.a.36107
   Korschelt K, 2018, CHEM EUR J, V24, P9703, DOI 10.1002/chem.201800384
   Lai YF, 2023, BIOMATER SCI UK, V11, P2292, DOI 10.1039/d2bm01915a
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Li FY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 35022 w
   Li JF, 2021, J MATER CHEM B, V9, P7848, DOI 10.1039/d1tb01479j
   Lin YH, 2022, BIOMATER ADV, V133, DOI 10.1016/j.msec.2022.112660
   Ling L, 2010, J BIOL CHEM, V285, P26233, DOI 10.1074/jbc.M110.122069
   Liu R., 2020, BIOL MED PARIS, V161, P339
   Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014
   Marie PJ, 2012, CURR OSTEOPOROS REP, V10, P190, DOI 10.1007/s11914 012 0109 0
   Mittler R, 2017, TRENDS PLANT SCI, V22, P11, DOI 10.1016/j.tplants.2016.08.002
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mu XY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abk1210
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Pal RP, 2018, BIOL TRACE ELEM RES, V182, P248, DOI 10.1007/s12011 017 1095 y
   Pereira DD, 2022, BIOACT MATER, V8, P241, DOI 10.1016/j.bioactmat.2021.06.036
   Petelin M, 2000, J CLIN PERIODONTOL, V27, P918, DOI 10.1034/j.1600 051x.2000.027012918.x
   Rendra E, 2019, IMMUNOBIOLOGY, V224, P242, DOI 10.1016/j.imbio.2018.11.010
   Renvert S, 2016, PERIODONTOL 2000, V72, P108, DOI 10.1111/prd.12130
   Sanchez Gonzalez C, 2017, METALLOMICS, V9, P258, DOI 10.1039/c6mt00272b
   Seong JB, 2021, FREE RADICAL BIO MED, V176, P322, DOI 10.1016/j.freeradbiomed.2021.10.010
   Shamsabadi A, 2024, ADV MATER, V36, DOI 10.1002/adma.202300184
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Singh S, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013314
   Sun MZ, 2018, NAT CHEM, V10, P821, DOI 10.1038/s41557 018 0083 y
   Tang MS, 2022, DRUG DES DEV THER, V16, P2043, DOI 10.2147/DDDT.S364759
   Vernekar AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6301
   Wang LW, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202217448
   Wang S, 2015, CELL MOL LIFE SCI, V72, P1699, DOI 10.1007/s00018 014 1829 3
   Wang Y, 2021, SMALL, V17, DOI 10.1002/smll.202101505
   Wei F, 2023, BIOACT MATER, V21, P547, DOI 10.1016/j.bioactmat.2022.09.011
   Weng YT, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101849
   Wilhelm J, 2003, PHYSIOL RES, V52, P327, DOI 10.33549/physiolres.930211
   Wu JJX, 2021, ANGEW CHEM INT EDIT, V60, P1227, DOI 10.1002/anie.202010714
   Wu JJX, 2019, CHEM SOC REV, V48, P1004, DOI 10.1039/c8cs00457a
   Wu YX, 2016, BIOMED PHARMACOTHER, V82, P399, DOI 10.1016/j.biopha.2016.05.008
   Yang BW, 2019, ADV MATER, V31, DOI 10.1002/adma.201901778
   Ye CY, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200787
   Yu T, 2016, J PERIODONTOL, V87, P1092, DOI 10.1902/jop.2016.160081
   Yu YJ, 2022, NANOSCALE, V14, P2628, DOI 10.1039/d1nr06043k
   Zandieh M, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202212013
   Zhang DC, 2020, RSC ADV, V10, P8685, DOI 10.1039/c9ra10262k
   Zhang RF, 2021, ACCOUNTS MATER RES, V2, P534, DOI 10.1021/accountsmr.1c00074
   Zhang XD, 2022, NANO MICRO LETT, V14, DOI 10.1007/s40820 022 00828 2
   Zhang Y, 2013, CELL RES, V23, P898, DOI 10.1038/cr.2013.75
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
   Zhu B., 2022, CHEMBIOCHEM
NR 79
TC 22
Z9 22
U1 23
U2 148
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD FEB
PY 2024
VL 13
IS 4
DI 10.1002/adhm.202302485
EA NOV 2023
PG 16
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA HI2E9
UT WOS:001102493400001
PM 37902093
DA 2025 08 17
ER

PT J
AU Zhang, X
   Zhao, Q
   Zhou, N
   Liu, Y
   Qin, K
   Buhl, EM
   Wang, XH
   Hildebrand, F
   Balmayor, ER
   Greven, J
AF Zhang, Xing
   Zhao, Qun
   Zhou, Nan
   Liu, Yu
   Qin, Kang
   Buhl, Eva Miriam
   Wang, Xinhong
   Hildebrand, Frank
   Balmayor, Elizabeth R.
   Greven, Johannes
TI Osteoblast derived extracellular vesicles induced by dexamethasone: A
   novel biomimetic tool for enhancing osteogenesis in vitro
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE extracellular vesicles; dexamethasone stimulation; intercellular
   crosstalk; osteoblastic differentiation; osteogenesis; bone regeneration
ID STEM CELLS; BONE; SCAFFOLDS; DIFFERENTIATION; MOLECULES; EXOSOMES; VIVO
AB Extracellular vesicles (EVs) are newly appreciated communicators involved in intercellular crosstalk, and have emerged as a promising biomimetic tool for bone tissue regeneration, overcoming many of the limitations associated with cell based therapies. However, the significance of osteoblast derived extracellular vesicles on osteogenesis has not been fully established. In this present study, we aim to investigate the therapeutic potential of extracellular vesicles secreted from consecutive 14 days of dexamethasone stimulated osteoblasts (OB EVDex) to act as a biomimetic tool for regulating osteogenesis, and to elucidate the underlying mechanisms. OB EVdex treated groups are compared to the clinically used osteo inductor of BMP 2 as control. Our findings revealed that OB EVDex have a typical bilayer membrane nanostructure of, with an average diameter of 178 +/  21 nm, and that fluorescently labeled OB EVDex were engulfed by osteoblasts in a time dependent manner. The proliferation, attachment, and viability capacities of OB EVDex treated osteoblasts were significantly improved when compared to untreated cells, with the highest proliferative rate observed in the OB EVDex + BMP 2 group. Notably, combinations of OB EVDex and BMP 2 markedly promoted osteogenic differentiation by positively upregulating osteogenesis related gene expression levels of RUNX2, BGLAP, SPP1, SPARC, Col 1A1, and ALPL relative to BMP 2 or OB EVDex treatment alone. Mineralization assays also showed greater pro osteogenic potency after combined applications of OB EVDex and BMP 2, as evidenced by a notable increase in mineralized nodules (calcium deposition) revealed by Alkaline Phosphatase (ALP), Alizarin Red Alizarin Red staining (ARS), and von Kossa staining. Therefore, our findings shed light on the potential of OB EVDex as a new therapeutic option for enhancing osteogenesis.
C1 [Zhang, Xing; Zhao, Qun; Zhou, Nan; Liu, Yu; Qin, Kang; Hildebrand, Frank; Balmayor, Elizabeth R.; Greven, Johannes] Univ Hosp RWTH Aachen, Dept Orthoped Trauma & Reconstruct Surg, Aachen, Germany.
   [Buhl, Eva Miriam] Univ Hosp RWTH Aachen, Inst Pathol, Electron Microscopy Facil, Aachen, Germany.
   [Buhl, Eva Miriam] Univ Hosp RWTH Aachen, Med Clin 2, Aachen, Germany.
   [Wang, Xinhong] Xuzhou Med Univ, Huaian Peoples Hosp 2, Dept Orthoped, Affliated Huaian Hosp, Huaian, Jiangsu, Peoples R China.
C3 RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen
   University; RWTH Aachen University Hospital; RWTH Aachen University;
   RWTH Aachen University Hospital; Xuzhou Medical University
RP Zhang, X; Zhao, Q (通讯作者)，Univ Hosp RWTH Aachen, Dept Orthoped Trauma & Reconstruct Surg, Aachen, Germany.; Wang, XH (通讯作者)，Xuzhou Med Univ, Huaian Peoples Hosp 2, Dept Orthoped, Affliated Huaian Hosp, Huaian, Jiangsu, Peoples R China.
EM xinzhang@ukaachen.de; qzhao@ukaachen.de; xinhonghot@126.com
RI ; Zhang, Xing/IWE 2002 2023; Balmayor, E./N 9283 2015
OI Zhao, Qun/0000 0002 5039 9385; Zhou, Nan/0000 0003 0526 3494
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
   [429837092]; China Scholarship Council (CSC) [202008080053]
FX The project was partially funded by the Deutsche Forschungsgemeinschaft
   (DFG, German Research Foundation) Project Number 429837092. The author,
   XZ, is finically funded and supervised by China Scholarship Council
   (CSC) under Grant 202008080053.
CR Alqurashi H, 2021, TISSUE ENG PART B RE, V27, P530, DOI [10.1089/ten.teb.2020.0222, 10.1089/ten.TEB.2020.0222]
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Buzhor E, 2014, REGEN MED, V9, P649, DOI [10.2217/RME.14.35, 10.2217/rme.14.35]
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Chen DS, 2021, BIOMATERIALS, V274, DOI 10.1016/j.biomaterials.2021.120812
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev cellbio 101512 122326
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   Davies OG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13027 6
   Davies OG, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00092
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Hade MD, 2021, CELLS BASEL, V10, DOI 10.3390/cells10081959
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Hu HX, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1778883
   Huang C, 2017, CELL TISSUE RES, V368, P229, DOI 10.1007/s00441 016 2462 2
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Kwon JS, 2014, BIOMATERIALS, V35, P5337, DOI 10.1016/j.biomaterials.2014.03.045
   Li Q, 2021, ACTA BIOMATER, V125, P253, DOI 10.1016/j.actbio.2021.02.039
   Lin Z, 2022, BIOACT MATER, V13, P300, DOI 10.1016/j.bioactmat.2021.10.042
   Liu H, 2022, BIOACT MATER, V14, P169, DOI 10.1016/j.bioactmat.2021.12.006
   Lu GD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.608521
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   Ma T, 2019, J CELL BIOCHEM, V120, P10847, DOI 10.1002/jcb.28376
   Man K, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.829969
   Man K, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12118
   Martins A, 2010, BIOMATERIALS, V31, P5875, DOI 10.1016/j.biomaterials.2010.04.010
   Matta C, 2019, DIFFERENTIATION, V107, P24, DOI 10.1016/j.diff.2019.05.002
   Monaco E, 2011, THERIOGENOLOGY, V75, P1381, DOI 10.1016/j.theriogenology.2010.11.020
   Narayanan R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3808674
   Ng J, 2017, TISSUE ENG PART B RE, V23, P480, DOI [10.1089/ten.teb.2016.0289, 10.1089/ten.TEB.2016.0289]
   Perpétuo IP, 2019, METHODS MOL BIOL, V1914, P21, DOI 10.1007/978 1 4939 8997 3_2
   Pizzicannella J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133256
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Théry C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   van Niel G, 2022, NAT REV MOL CELL BIO, V23, P369, DOI 10.1038/s41580 022 00460 3
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Walmsley GG, 2016, STEM CELL REV REP, V12, P524, DOI 10.1007/s12015 016 9665 5
   Yan YF, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801043
   Yom Tov O, 2014, J BIOMED MATER RES A, V102, P4371, DOI 10.1002/jbm.a.35134
   Zhang X, 2019, ACS BIOMATER SCI ENG, V5, P294, DOI 10.1021/acsbiomaterials.8b00908
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
NR 46
TC 6
Z9 6
U1 2
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAR 10
PY 2023
VL 11
AR 1160703
DI 10.3389/fbioe.2023.1160703
PG 13
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA C5RH1
UT WOS:000962480100001
PM 37020508
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ma, YG
   Chai, Z
   Ren, LL
   Hu, QL
AF Ma, Yonggang
   Chai, Zhen
   Ren, Longlong
   Hu, Qiaolong
TI Bazedoxifene effects on osteoprotegerin, insulin like growth factor,
   tumor necrosis factor and bone mineral density
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Estrogen; Bazedoxifene Osteoporosis; Clinical effect
ID OSTEOCLAST DIFFERENTIATION; OSTEOPOROSIS; FRACTURE; LIGAND; ALPHA
AB To observe the clinical effect of estrogenic drugs (Bazedoxifene) on bone targeting in the treatment of osteoporosis and explore its mechanism. Methods:112 patients with postmenopausal osteoporosis who received Bazedoxifene drugs in our hospital from January to December 2018 were collected as a study group, and 56 patients treated with calcium alone were collected as a control group. the risk of adverse events such as bone mineral density, osteoprotegerin (OPG), insulin like growth factor (IGF), tumor necrosis factor (TNF alpha), and fracture after treatment were analyzed before and after treatment. Results: There was no significant difference in the mean lumbar positive position (L2 4) and right femoral neck bone density and OPG, IGF, TNF alpha level between the two groups before treatment (P>0.05). The total effective rate of clinical treatment in the study group was 88.39%, the control group was 23.21%, the difference between the two groups was statistically significant (P?0.05). After treatment, the mean lumbar positive position (L2 4) and the right femoral neck bone density and OPG, IGF in the study group were higher than those in the control group, lower than those in the control group (P<0.05). the occurrence of adverse events such as fracture, spinal deformation and fatigue in the study group after 12 months of treatment was significantly lower than that in the control group (P<0.05), but there was no significant difference in the occurrence of hot flashes and venous thromboembolism between the two groups (P>0.05). Conclusion: Bazedoxifene is an effective drug for the treatment of postmenopausal osteoporosis. It can not only prevent the rapid loss of bone mass, effectively relieve the symptoms of menopause, but also improve bone density and reduce the risk of fracture.
C1 [Ma, Yonggang; Chai, Zhen; Ren, Longlong; Hu, Qiaolong] Second Hosp Yulin, Dept Orthopaed, Yulin 719000, Peoples R China.
RP Chai, Z (通讯作者)，Second Hosp Yulin, Dept Orthopaed, Yulin 719000, Peoples R China.
EM raguilar43@student.cccs.edu
CR Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Duursma S A, 1992, Obstet Gynecol Surv, V47, P38, DOI 10.1097/00006254 199201000 00015
   Ferretti C, 2014, TISSUE ENG PART A, V2017, P2473
   Figliomeni A, 2018, CLIN EXP RHEUMATOL, V36, P948
   Hofbauer LC, 1997, EUR J ENDOCRINOL, V137, P345, DOI 10.1530/eje.0.1370345
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Jehle Peter M., 2003, Eur J Intern Med, V14, P32, DOI 10.1016/S0953 6205(02)00183 8
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li ZN, 2019, BIOCHEM PHARMACOL, V163, P279, DOI 10.1016/j.bcp.2019.02.002
   Mano H, 2001, CYTOTECHNOLOGY, V35, P17, DOI 10.1023/A:1008188120766
   Mesalic L, 2008, BOSNIAN J BASIC MED, V8, P188, DOI 10.17305/bjbms.2008.2980
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Sang CL, 2016, BONE, V84, P78, DOI 10.1016/j.bone.2015.12.012
   Schnitzer Thomas J, 2003, Curr Rheumatol Rep, V5, P43, DOI 10.1007/s11926 003 0082 9
   Sun MQ, 2016, CYTOKINE, V80, P35, DOI 10.1016/j.cyto.2016.01.011
   Xiang D, 2018, EUR REV MED PHARMACO, V22, P8084, DOI 10.26355/eurrev_201812_16498
   Xiong Q, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/596789
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 20
TC 1
Z9 3
U1 1
U2 5
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145 5680
EI 1165 158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2020
VL 66
IS 3
BP 109
EP 112
DI 10.14715/cmb/2020.66.3.16
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA LY3EW
UT WOS:000540410000016
PM 32538755
OA hybrid
DA 2025 08 17
ER

PT J
AU Shao, LT
   Luo, L
   Qiu, JH
   Deng, DYB
AF Shao, Li tao
   Luo, Liang
   Qiu, Jie hong
   Deng, David Y. B.
TI PTH (1 34) enhances the therapeutic effect of bone marrow mesenchymal
   stem cell derived exosomes by inhibiting proinflammatory cytokines
   expression on OA chondrocyte repair in vitro
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Osteoarthritis; Parathyroid hormone; Exosome; Chondrocyte
ID CARTILAGE; OSTEOARTHRITIS; INFLAMMATION
AB Background The effects of bone marrow mesenchymal stem cells (BMSCs) during the treatment of cartilage damage have been proven to be attributed to paracrine mechanisms, particularly the effect of exosomes. Exosomes from different batches are inhomogeneous, and different treatment effects are observed between samples. The purpose of this research was to find more effective and homogeneous exosomes for the repair of chondrocytes in osteoarthritis (OA). We observed the potential effects and possible mechanisms of exosomes derived from parathyroid hormone (PTH) (1 34) preconditioned BMSCs (Exo(PTH)) in the alleviation of OA. Materials and methods Exosomes derived from BMSCs (Exo(BMSC)) and Exo(PTH) were isolated by differential centrifugation. Primary rat chondrocytes were used to establish the OA model by interleukin 1 beta (IL 1 beta) in vitro. The effects of these two types of exosomes on OA chondrocyte proliferation, migration, apoptosis, and extracellular matrix formation were measured and compared. We observed changes in IL 2, TNF alpha, and IL 6 levels via Western blotting (WB), and quantitative real time PCR (qRT PCR). Results We successfully extracted Exo(BMSC) and Exo(PTH) and established an IL 1 beta induced OA model in primary chondrocytes from rats. Our study showed that IL 2, TNF alpha, and IL 6 levels increased significantly in OA chondrocytes; however, both Exo(BMSC) and Exo(PTH) reduced the levels of IL 2, TNF alpha, and IL 6. In addition, Exo(PTH) exhibited stronger anti inflammatory effects. Exo(PTH) had a more marked effect on proliferation, migration, and production of the extracellular matrix (Col II) in OA chondrocytes than Exo(BMSC) at 24 h. Conclusion Exo(PTH) increased the migration, proliferation, and chondral matrix formation of OA chondrocytes in vitro. In OA chondrocyte therapy, the potential mechanism of Exo(PTH) might involve the inhibition of production of proinflammatory cytokines. Although the two types of exosomes had some similar effects, most effects of Exo(PTH) were better than those of Exo(BMSC), so Exo(PTH) may have a better ability to alleviate OA.
C1 [Shao, Li tao; Deng, David Y. B.] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Sci Res Ctr, Shenzhen, Peoples R China.
   [Luo, Liang] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Crit Care Med, Shenzhen, Peoples R China.
   [Qiu, Jie hong] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Obstet & Gynecol, Shenzhen, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Deng, DYB (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 7, Dept Sci Res Ctr, Shenzhen, Peoples R China.
EM dengyub@mail.sysu.edu.cn
RI Deng, Davy/AGZ 4210 2022
FU National Natural Science Foundation of China (NSFC)
   [JCYJ20210324123001003]; Postdoctoral start up fund [ZSQYRSFPD0037]
FX The study was supported by the National Natural Science Foundation of
   China (NSFC JCYJ20210324123001003) and the Postdoctoral start up fund
   (ZSQYRSFPD0037).
CR Alquraini A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1301 5
   Bari E, 2019, NANOMEDICINE UK, V14, P753, DOI 10.2217/nnm 2018 0240
   Bocelli Tyndall C, 2009, ANN RHEUM DIS, V68, P1352, DOI 10.1136/ard.2008.094003
   Buhrmann C, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4393
   Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166
   Chapuis J, 2009, MOL PSYCHIATR, V14, P1004, DOI 10.1038/mp.2009.10
   Chen X, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02325 6
   Chen YS, 2016, MED SCI MONIT BASIC, V22, P132, DOI 10.12659/MSMBR.900242
   Dokic J, 2012, J CLIN PERIODONTOL, V39, P807, DOI 10.1111/j.1600 051X.2012.01917.x
   Fei JL, 2019, BIOMED PHARMACOTHER, V109, P1586, DOI 10.1016/j.biopha.2018.09.161
   Feng XR, 2020, NANOMEDICINE UK, V15, P1585, DOI 10.2217/nnm 2020 0102
   Feng XR, 2019, ADV SCI, V6, DOI 10.1002/advs.201900101
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   He L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01781 w
   Hu HX, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1778883
   Kovács B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184653
   Le HX, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420943839
   Li R, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2146 x
   Liang LL, 2020, J ASSIST REPROD GEN, V37, P395, DOI 10.1007/s10815 019 01687 4
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Liang YZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0410 z
   Liang YJ, 2020, ACS APPL MATER INTER, V12, P36938, DOI 10.1021/acsami.0c10458
   Liu C, 2020, NANOMEDICINE UK, V15, P273, DOI 10.2217/nnm 2019 0208
   Liu QB, 2019, GENE, V712, DOI 10.1016/j.gene.2019.143959
   Liu XC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1529 7
   Liu YB, 2018, BIOCHEM J, V475, P3629, DOI 10.1042/BCJ20180675
   Lu JS, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02512 z
   Pagliari M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01288
   Qi H, 2019, IN VITRO CELL DEV AN, V55, P203, DOI 10.1007/s11626 019 00330 x
   Qiao L, 2019, J CLIN INVEST, V129, P2237, DOI 10.1172/JCI123135
   Reichenbach S, 2020, JAMA J AM MED ASSOC, V323, P1802, DOI 10.1001/jama.2020.3565
   Shao L, 2020, BONE JOINT RES, V9, P675, DOI 10.1302/2046 3758.910.BJR 2020 0018.R1
   Su TQ, 2022, J CONTROL RELEASE, V343, P152, DOI 10.1016/j.jconrel.2021.12.036
   Sun K, 2021, AUTOPHAGY, V17, P2082, DOI 10.1080/15548627.2020.1822097
   Wang JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074255
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Wang XH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.644380
   Xu F, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1196 y
   Zhang R, 2019, AM J TRANSL RES, V11, P6275
   Zhang SP, 2019, BIOMATERIALS, V200, P35, DOI 10.1016/j.biomaterials.2019.02.006
   Zhang S, 2019, THERANOSTICS, V9, P7108, DOI 10.7150/thno.38182
   Zhao W, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01845 x
   Zhou XH, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 00374 z
   Zhu XB, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02457 3
   Zwerina J, 2007, P NATL ACAD SCI USA, V104, P11742, DOI 10.1073/pnas.0610812104
NR 46
TC 29
Z9 29
U1 1
U2 29
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD APR 29
PY 2022
VL 24
IS 1
AR 96
DI 10.1186/s13075 022 02778 x
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 0W3FK
UT WOS:000788916900008
PM 35488245
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, AR
   Kim, JH
   Kim, A
   Sohn, Y
   Cha, JH
   Bak, EJ
   Yoo, YJ
AF Kim, Ae Ri
   Kim, Ji Hye
   Kim, Aeryun
   Sohn, Yongsung
   Cha, Jeong Heon
   Bak, Eun Jung
   Yoo, Yun Jung
TI Simvastatin attenuates tibial bone loss in rats with type 1 diabetes and
   periodontitis
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Diabetes; Periodontitis; Bone loss; Sclerostin; Simvastatin
ID SUBGINGIVALLY DELIVERED SIMVASTATIN; ALVEOLAR BONE; THERAPY;
   STREPTOZOTOCIN; MECHANISMS; MELLITUS; EFFICACY; DEFECTS; PROTEIN
AB BackgroundDiabetes induces long bone loss and aggravation of periodontitis induced alveolar bone loss. Simvastatin (SIM), which is a lipid lowering agent is known to have an anabolic effect on bone. Therefore, we investigated effect of SIM on tibial and alveolar bone loss in type 1 diabetic rats with periodontitis.MethodsRats were divided into control (C), diabetes with periodontitis (DP), and diabetes with periodontitis treated with SIM (DPS) groups. DP and DPS groups were intravenously injected with streptozotocin (50mg/kg), and C group was injected with citrate buffer. Seven days later (day 0), periodontitis was induced by ligatures of mandibular first molars. DP and DPS groups were orally administered vehicle or SIM (30mg/kg) from day 0 to days 3, 10, or 20. Alveolar and tibial bone loss was measured using histological and m CT analysis alone or in combination. Osteoclast number and sclerostin positive osteocytes in tibiae were evaluated by tartrate resistant acid phosphatase and immunohistochemical staining, respectively. Glucose, triglyceride (TG), cholesterol (CHO), and low density lipoprotein (LDL) were evaluated.ResultsConsistent with diabetes induction, the DP group showed higher glucose and TG levels at all timepoints and higher CHO levels on day 20 than C group. Compared to the DP group, the DPS group exhibited reduced levels of glucose (day 3), TG (days 10 and 20), CHO, and LDL levels (day 20). Bone loss analysis revealed that the DP group had lower bone volume fraction, bone mineral density, bone surface density, and trabecular number in tibiae than C group at all timepoints. Interestingly, the DPS group exhibited elevation of these indices at early stages compared to the DP group. The DPS group showed reduction of osteoclasts (day 3) and sclerostin positive osteocytes (days 3 and 20) compared with the DP group. There was no difference in alveolar bone loss between DP and DPS groups.ConclusionsThese results suggest that SIM attenuates tibial, but not alveolar bone loss in type 1 diabetic rats with periodontitis. Moreover, attenuation of tibial bone loss by SIM may be related to inhibition of osteoclast formation and reduction of sclerostin expression.
C1 [Kim, Ae Ri; Cha, Jeong Heon; Bak, Eun Jung; Yoo, Yun Jung] Yonsei Univ, Coll Dent, Dept Oral Biol, 134 Sinchon Dong, Seoul 120752, South Korea.
   [Kim, Ae Ri; Kim, Aeryun; Cha, Jeong Heon; Yoo, Yun Jung] Yonsei Univ, Grad Sch, Dept Appl Life Sci, Seoul, South Korea.
   [Kim, Ae Ri; Cha, Jeong Heon] Yonsei Univ, Coll Dent, PLUS Project BK21, Seoul, South Korea.
   [Kim, Ji Hye] Jeonju Kijeon Coll, Dept Dent Hyg, Jeonju, South Korea.
   [Sohn, Yongsung] DONG A Pharm, Yongin, Gyeonggi Do, South Korea.
   [Cha, Jeong Heon] Guangzhou Med Univ, Stomatol Hosp, Guangzhou Inst Oral Dis, Microbiol & Mol Biol,Key Lab Oral Med, Guangzhou, Guangdong, Peoples R China.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University; Yonsei University Health System; Guangzhou Medical
   University
RP Bak, EJ; Yoo, YJ (通讯作者)，Yonsei Univ, Coll Dent, Dept Oral Biol, 134 Sinchon Dong, Seoul 120752, South Korea.
EM missbak@hanmail.net; yu618@yuhs.ac
RI ; Yoo, Yun Jung/HDN 0946 2022; Kim, Ji Hye/JDC 9347 2023
OI Cha, Jeong Heon/0000 0002 9385 2653; Yoo, Yun Jung/0000 0002 0045 9597;
   Kim, Ae Ri/0000 0002 5661 9596; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Science, ICT and Future Planning
   [NRF 2014R1A2A1A11049412]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT and Future Planning (NRF 2014R1A2A1A11049412).
CR Bertl K, 2018, J PERIODONTAL RES, V53, P267, DOI 10.1111/jre.12514
   Bertl K, 2017, J DENT, V67, P18, DOI 10.1016/j.jdent.2017.08.011
   Bradley AD, 2016, J PERIODONTOL, V87, P577, DOI 10.1902/jop.2016.150599
   Dalcico R, 2013, J PERIODONTOL, V84, P1145, DOI 10.1902/jop.2012.120114
   Ezirganli S, 2014, CLIN ORAL IMPLAN RES, V25, P969, DOI 10.1111/clr.12177
   Furman Brian L, 2015, Curr Protoc Pharmacol, V70, DOI 10.1002/0471141755.ph0547s70
   Jin J, 2014, J PERIODONTAL RES, V49, P518, DOI 10.1111/jre.12132
   Jin J, 2014, J DENT RES, V93, P294, DOI 10.1177/0022034513516980
   Jindal Ankita, 2015, J Int Oral Health, V7, P17
   Kim JH, 2015, J PERIODONTOL, V86, P1005, DOI 10.1902/jop.2015.150083
   KJAER K, 1992, ACTA ENDOCRINOL COP, V126, P229
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   Moshiri A, 2016, CLIN EXP PHARMACOL P, V43, P659, DOI 10.1111/1440 1681.12577
   Motyl K, 2009, BIOL PROCED ONLINE, V11, P296, DOI 10.1007/s12575 009 9000 5
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nassar PO, 2009, J PERIODONTAL RES, V44, P479, DOI 10.1111/j.1600 0765.2008.01143.x
   Polak D, 2018, J CLIN PERIODONTOL, V45, P150, DOI 10.1111/jcpe.12803
   Pradeep AR, 2013, J PERIODONTOL, V84, P24, DOI 10.1902/jop.2012.110721
   Pradeep AR, 2012, J PERIODONTOL, V83, P1472, DOI 10.1902/jop.2012.110716
   Pradeep AR, 2010, J PERIODONTOL, V81, P214, DOI 10.1902/jop.2009.090429
   Rao NS, 2013, AUST DENT J, V58, P156, DOI 10.1111/adj.12042
   ten Dijke P, 2008, J BONE JOINT SURG AM, V90A, P31, DOI 10.2106/JBJS.G.01183
   Tulbah AS, 2016, EXPERT OPIN DRUG DEL, V13, P1407, DOI 10.1080/17425247.2016.1193150
   Uysal Ali Riza, 2007, Endocr Pract, V13, P114
   Valderrabano Rodrigo J, 2018, Clin Diabetes Endocrinol, V4, P9, DOI 10.1186/s40842 018 0060 9
   Xu XC, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0284 0
   Yee CS, 2016, BONE, V82, P122, DOI 10.1016/j.bone.2015.04.048
   Yu SG, 2015, INT J CLIN EXP PATHO, V8, P3681
   Zhang Y, 2016, MOLECULES, V21, DOI 10.3390/molecules21010007
NR 29
TC 13
Z9 16
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 9
PY 2018
VL 16
AR 306
DI 10.1186/s12967 018 1681 6
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GZ9LI
UT WOS:000449820500001
PM 30413166
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Almeida, LA Jr
   de Carvalho, MS
   Almeida, LKY
   Silva Sousa, AC
   Sousa Neto, MD
   Silva, RAB
   Silva, LAB
   Paula Silva, FWG
AF Almeida Junior, Luciano Aparecido
   de Carvalho, Marcio Santos
   Almeida, Lana Kei Yamamoto
   Silva Sousa, Alice Correa
   Sousa Neto, Manoel Damiao
   Silva, Raquel Assed Bezerra
   Silva, Lea Assed Bezerra
   Paula Silva, Francisco Wanderley Garcia
TI TNF a TNFR1 Signaling Mediates Inflammation and Bone Resorption in
   Apical Periodontitis
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Apical periodontitis; bone resorption; inflammation; TNFR1; tumor
   necrosis factor a
ID TNF ALPHA; INDUCED OSTEOCLASTOGENESIS; DIFFERENTIATION; THERAPY; MATRIX;
   TEETH
AB Introduction: The aim of this study was to investigate the role of the proinflammatory axis TNF a TNFR1 in experimentally induced periapical inflammation and bone resorption in mice. Methods: After receiving Ethics Committee Approval (2019.1.139.58.0), experimental apical periodontitis was induced by means of inoculating oral microorganisms into the root canals of molars of mice. Genetically deficient tumor necrosis factor  a receptor 1 mice (TNFR1( / ); n = 50) response was compared with that of C57Bl6 wild type mice (wild type; n = 50) after 7, 14, 28, and 42 days. The analyses performed were micro computed tomographic, his topathologic, histomicrobiological, and histometric evaluation, tartrate resistant acid phos phatase staining, immunohistochemistry, and quantitative reverse transcriptase polymerase chain reaction. Data were analyzed by using one way analysis of variance, followed by Tukey or Bonferroni tests (a = 5%). Results: TNFR1( / )mice exhibited lower recruitment of neutrophils at 14, 28, and 42 days (P < .05), which resulted in reduced area and volume of apical periodontitis at 42 days (P < .05). The number of osteoclasts was also lower in TNFR1( / )animals at 14 and 42 days (P < .01), along with reduced synthesis of CTSK, MMP 9, and COX 2. Expression of RANKL, but not OPG, was reduced at 14 and 42 days (P < .001). The highest RANKL expression over OPG (ratio > 1) was found in wild type animals at 7 (P < .0001) and 42 days (P < .001). Conclusions: Periapical inflammation and bone resorption were exacerbated in wild type animals compared with TNFR1( / )mice, demon strating that the TNF a TNFR1 signaling pathway mediated catabolic events in bone after root canal contamination. (J Endod 2023;49:1319 1328.)
C1 [Almeida Junior, Luciano Aparecido; de Carvalho, Marcio Santos; Almeida, Lana Kei Yamamoto; Silva, Raquel Assed Bezerra; Paula Silva, Francisco Wanderley Garcia] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Dent, Sao Paulo, Brazil.
   [Silva Sousa, Alice Correa; Sousa Neto, Manoel Damiao] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Restorat Dent, Sao Paulo, Brazil.
   [Paula Silva, Francisco Wanderley Garcia] Univ Sao Paulo, Sch Dent Ribeirao Preto, Ave Cafe s n, Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de
   Sao Paulo
RP Paula Silva, FWG (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Ave Cafe s n, Ribeirao Preto, SP, Brazil.
EM franciscogarcia@forp.usp.br
RI Silva Sousa, Alice/T 7527 2017; Silva, Lea/B 3953 2016; da Silva,
   Raquel/M 8655 2016; Silva, Lea/AAG 6401 2019; Sousa Neto,
   Manoel/E 6539 2013; Paula Silva, Francisco Wanderley/D 1712 2012;
   Almeida Junior, Luciano Aparecido/GPX 2407 2022
OI Silva, Lea/0000 0001 7118 6859; ALMEIDA, LANA KEI/0000 0002 6308 0613;
   Paula Silva, Francisco Wanderley/0000 0001 8559 532X; 
FU Sao Paulo Research Foundation (FAPESP) [2019/00204 1, 2019/02432 1];
   CAPES [001]
FX This study was supported by grants from the Sao Paulo Research
   Foundation (FAPESP) grant 2019/00204 1 to FWGPS and fellowship
   2019/02432 1 to LAAJ. MSC and ACSS received fellowships from CAPES
   (financial code: 001).
CR AlQranei MS, 2020, J ORAL BIOSCI, V62, P123, DOI 10.1016/j.job.2020.02.002
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   da Silva RAB, 2012, J ENDODONT, V38, P803, DOI 10.1016/j.joen.2012.03.017
   Bloom BJ, 2000, ARTHRITIS RHEUM, V43, P2606, DOI 10.1002/1529 0131(200011)43:11<2606::AID ANR31>3.0.CO;2 X
   Braz Silva PH, 2019, ACTA ODONTOL SCAND, V77, P173, DOI 10.1080/00016357.2018.1521005
   Chen CP, 1999, AM J PATHOL, V155, P2145, DOI 10.1016/S0002 9440(10)65532 0
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   de Carvalho MS, 2022, J ENDODONT, V48, P1400, DOI 10.1016/j.joen.2022.08.003
   De Rossi A, 2008, J ENDODONT, V34, P31, DOI 10.1016/j.joen.2007.09.021
   ENGBAEK K, 1979, J CLIN PATHOL, V32, P187, DOI 10.1136/jcp.32.2.187
   Falcai MJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/507848
   Galler KM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031480
   Gamrot Z, 2021, ENDOKRYNOL POL, V72, P625, DOI 10.5603/EP.a2021.0082
   de Paula Silva FWG, 2009, ORAL SURG ORAL MED O, V108, P796, DOI 10.1016/j.tripleo.2009.06.016
   de Paula Silva FWG, 2009, J ENDODONT, V35, P1009, DOI 10.1016/j.joen.2009.04.006
   Paula Silva FWG, 2021, CLIN ORAL INVEST, V25, P4699, DOI 10.1007/s00784 021 03784 0
   Paula Silva FWG, 2020, J APPL ORAL SCI, V28, DOI 10.1590/1678 7757 2019 0699
   Paula Silva FWG, 2016, J ENDODONT, V42, P447, DOI 10.1016/j.joen.2015.12.003
   Paula Silva FWG, 2010, J ENDODONT, V36, P231, DOI 10.1016/j.joen.2009.10.030
   Goldman E, 2021, CELLS BASEL, V10, DOI 10.3390/cells10030671
   Goldman E, 2019, JOVE J VIS EXP, DOI 10.3791/59521
   Hirsch V, 2017, ARCH ORAL BIOL, V82, P38, DOI 10.1016/j.archoralbio.2017.05.008
   Holbrook Jonathan, 2019, F1000Res, V8, DOI 10.12688/f1000research.17023.1
   Jang DI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052719
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031481
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756 3282(01)00420 3
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Landini G, 2021, BIOINFORMATICS, V37, P1485, DOI 10.1093/bioinformatics/btaa847
   Maretti Mira AC, 2011, CLIN EXP IMMUNOL, V163, P207, DOI 10.1111/j.1365 2249.2010.04285.x
   Márton IJ, 2014, J ENDODONT, V40, P155, DOI 10.1016/j.joen.2013.10.036
   Medler J, 2019, EXPERT OPIN THER TAR, V23, P295, DOI 10.1080/14728222.2019.1586886
   Nikolic N, 2019, J ENDODONT, V45, P123, DOI 10.1016/j.joen.2018.10.015
   Novinec M, 2013, BIOL CHEM, V394, P1163, DOI 10.1515/hsz 2013 0134
   Pagliari D, 2015, ANAL CELL PATHOL, V2015, P1, DOI 10.1155/2015/434389
   Petean IBF, 2021, INT ENDOD J, V54, P1289, DOI 10.1111/iej.13472
   de Castro GAP, 2023, INT ENDOD J, V56, P17, DOI 10.1111/iej.13841
   Prso IB, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/38210
   Romualdo PC, 2018, J ENDODONT, V44, P780, DOI 10.1016/j.joen.2018.01.010
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   SAFAVI KE, 1991, J ENDODONT, V17, P12, DOI 10.1016/S0099 2399(07)80154 3
   Salles Alessandro Guimarães, 2017, Braz. Dent. J., V28, P535, DOI 10.1590/0103 6440201701491
   Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852
   Tack CJ, 2009, DIABETOLOGIA, V52, P1442, DOI 10.1007/s00125 009 1381 0
   Xu K, 2018, CELL REPROGRAM, V20, P107, DOI 10.1089/cell.2017.0042
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Zhang N, 2020, CYTOKINE GROWTH F R, V55, P80, DOI 10.1016/j.cytogfr.2020.03.002
NR 48
TC 14
Z9 16
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0099 2399
EI 1878 3554
J9 J ENDODONT
JI J. Endod.
PD OCT
PY 2023
VL 49
IS 10
BP 1319
EP +
DI 10.1016/j.joen.2023.07.013
EA SEP 2023
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA W6ND4
UT WOS:001092764900001
PM 37499863
DA 2025 08 17
ER

PT J
AU Moe, SM
   Chen, NX
AF Moe, Sharon M.
   Chen, Neal X.
TI Mechanisms of vascular calcification in chronic kidney disease
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CARDIOVASCULAR MORTALITY; HEMODIALYSIS PATIENTS; COMPUTED TOMOGRAPHY;
   DIALYSIS PATIENTS; ALL CAUSE; CALCIUM
AB Vascular calcification is common in chronic kidney disease and associated with increased morbidity and mortality. Its mechanism is multifactorial and incompletely understood. Patients with chronic kidney disease are at risk for vascular calcification because of multiple risk factors that induce vascular smooth muscle cells to change into a chondrocyte or osteoblast like cell; high total body burden of calcium and phosphorus due to abnormal bone metabolism; low levels of circulating and locally produced inhibitors; impaired renal excretion; and current therapies. Together these factors increase risk and complicate the management of vascular calcification.
C1 [Moe, Sharon M.; Chen, Neal X.] Indiana Univ, Dept Med, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis
RP Moe, SM (通讯作者)，Indiana Univ, Dept Med, 1001 W 10th St,OPW 526, Indianapolis, IN 46202 USA.
EM smoe@iupui.edu
FU NIDDK NIH HHS [K01 DK64766, K24 DK002775] Funding Source: Medline
CR Bellasi A, 2006, KIDNEY INT, V70, P1623, DOI 10.1038/sj.ki.5001820
   Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059
   Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272 6386(96)90363 7
   El Abbadi M, 2007, ADV CHRONIC KIDNEY D, V14, P54, DOI 10.1053/j.ackd.2006.10.007
   IBELS LS, 1979, AM J MED, V66, P790, DOI 10.1016/0002 9343(79)91118 5
   Ketteler M, 2005, CURR OPIN NEPHROL HY, V14, P337, DOI 10.1097/01.mnh.0000172719.26606.6f
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Moe SM, 2006, EUR J CLIN INVEST, V36, P51, DOI 10.1111/j.1365 2362.2006.01665.x
   Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98
   Murphy WA, 2003, RADIOLOGY, V226, P614, DOI 10.1148/radiol.2263020338
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   O'Neill WC, 2007, KIDNEY INT, V72, P792, DOI 10.1038/sj.ki.5002412
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Schmermund Axel, 2003, Cardiology Clinics, V21, P521, DOI 10.1016/S0733 8651(03)00088 2
   Wang AYM, 2003, J AM SOC NEPHROL, V14, P159, DOI 10.1097/01.ASN.0000038685.95946.83
NR 16
TC 396
Z9 432
U1 0
U2 17
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046 6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD FEB
PY 2008
VL 19
IS 2
BP 213
EP 216
DI 10.1681/ASN.2007080854
PG 4
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 265DW
UT WOS:000253340300007
PM 18094365
OA Bronze
DA 2025 08 17
ER

PT J
AU Bonadonna, S
   Burattin, A
   Nuzzo, M
   Bugari, G
   Rosei, EA
   Valle, D
   Iori, N
   Bilezikian, JP
   Veldhuis, JD
   Giustina, A
AF Bonadonna, S
   Burattin, A
   Nuzzo, M
   Bugari, G
   Rosei, EA
   Valle, D
   Iori, N
   Bilezikian, JP
   Veldhuis, JD
   Giustina, A
TI Chronic glucocorticoid treatment alters spontaneous pulsatile
   parathyroid hormone secretory dynamics in human subjects
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID GROWTH HORMONE; POSTMENOPAUSAL WOMEN; FREQUENCY MODULATION; INDUCED
   OSTEOPOROSIS; PULSE AMPLITUDE; DOWN REGULATION; BONE; MECHANISMS;
   THERAPY; CALCIUM
AB Objective: Spontaneous parathyroid hormone (PTH) secretory dynamics include tonic and pulsatile components. It is not known how glucocorticoids might alter these secretory dynamics.
   Design: The aim of our study was to evaluate spontaneous fluctuations in serum PTH levels in six adult male patients (aged 31   64 years) receiving chronic ( > 6 months) therapy with glucocorticoids (daily dosage > 7.5 mg of prednisone or dose equivalent of other corticosteroid) as compared with a control group of 10 age  and sex matched normal subjects.
   Methods: Peripheral venous blood. sampling was performed every 3 min for 6 h from 0900 to 1500 h. Plasma PTH release profiles were subjected to deconvolution analysis, a method that resolves measured hormone concentrations into secretion and clearance components, and to an approximate entropy (ApEn) estimate, that in turn provides an integrated measure of the serial regularity or orderliness of the release process.
   Results: In the glucocorticoid treated group, the PTH tonic secretory rate was reduced (4.3+/ 0.74 vs 8.8 +/  1.4 pg/ml per min in controls, P = 0.017). There was, however, an increase in the fractional pulsatile PTH secretion (42+/ 8.2 vs 18.3 +/  3.9 pg/ml per min, P = 0.006) in glucocorticoid treated vs normal subjects. Mean overall PTH concentration, as well as mean integrated area, was similar among normal and glucocorticoid treated subjects.
   Conclusions: These results demonstrate, for the first time, that chronic glucocorticoid treatment induces a redistribution of spontaneous PTH secretory dynamics by reducing the amount released in tonic fashion and increasing the amount released as pulses.
C1 Univ Brescia, Dept Med Sci, Brescia, Italy.
   Spedali Civil Brescia, Lab 3, Brescia, Italy.
   Eli Lilly & Co, Div Med, Florence, Italy.
   Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA.
   Mayo Clin, Rochester, MN USA.
C3 University of Brescia; Hospital Spedali Civili Brescia; Eli Lilly;
   Columbia University; Mayo Clinic
RP Med Spedali Civili 2A, Endocrine Sect, I 25215 Brescia, Italy.
EM a.giustina@libero.it
RI bonadonna, stefania/JBR 5703 2023; Giustina, Andrea/AAN 5938 2020
OI bonadonna, stefania/0000 0001 7325 7542
CR CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69, DOI 10.1210/jcem 72 1 69
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Canalis E, 2001, J CLIN ENDOCR METAB, V86, P5681, DOI 10.1210/jc.86.12.5681
   COSMAN F, 1994, J BONE MINER RES, V9, P1097
   Diamond T, 1997, BRIT J HAEMATOL, V97, P641, DOI 10.1046/j.1365 2141.1997.1042920.x
   GENNARI C, 1993, BRIT J RHEUMATOL, V32, P11
   GIUSTINA A, 1991, CLIN ENDOCRINOL, V35, P491, DOI 10.1111/j.1365 2265.1991.tb00933.x
   GIUSTINA A, 1992, J CLIN ENDOCR METAB, V74, P1301, DOI 10.1210/jc.74.6.1301
   Giustina A, 1997, J CLIN ENDOCR METAB, V82, P1210, DOI 10.1210/jc.82.4.1210
   Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717
   GIUSTINA A, 1995, TRENDS ENDOCRIN MET, V3, P306
   Gram J, 1998, BONE, V23, P297, DOI 10.1016/S8756 3282(98)00097 0
   HARMS HM, 1989, J CLIN ENDOCR METAB, V69, P843, DOI 10.1210/jcem 69 4 843
   HARMS HM, 1994, J CLIN ENDOCR METAB, V78, P48, DOI 10.1210/jc.78.1.48
   HATTERSLEY AT, 1994, CALCIFIED TISSUE INT, V54, P198, DOI 10.1007/BF00301678
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   IRANMANESH A, 1990, J CLIN ENDOCR METAB, V71, P1276, DOI 10.1210/jcem 71 5 1276
   KITAMURA N, 1990, J CLIN ENDOCR METAB, V70, P252, DOI 10.1210/jcem 70 1 252
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   LAW WM, 1983, J CLIN INVEST, V72, P1106, DOI 10.1172/JCI111035
   LEBOFF MS, 1991, J RHEUMATOL, V18, P339
   Locklin RM, 2001, BONE, V28, pS80
   LUKERT BP, 1992, J BONE MINER RES, V7, P1063
   MAHONEY CA, 1983, J CLIN INVEST, V72, P411, DOI 10.1172/JCI110989
   Manelli F, 2000, TRENDS ENDOCRIN MET, V11, P79, DOI 10.1016/S1043 2760(00)00234 4
   Manolagas SC, 1998, LANCET, V352, P1940, DOI 10.1016/S0140 6736(05)60443 6
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55
   PAZPACHECO E, 1995, J BONE MINER RES, V10, P1713
   PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo 112 3 1000
   Reid IR, 1996, ARCH INTERN MED, V156, P1173, DOI 10.1001/archinte.156.11.1173
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002 012101
   SAMUELS MH, 1990, J CLIN ENDOCR METAB, V71, P425, DOI 10.1210/jcem 71 2 425
   SAMUELS MH, 1993, J CLIN ENDOCR METAB, V77, P399, DOI 10.1210/jc.77.2.399
   Samuels MH, 1997, J BONE MINER RES, V12, P616, DOI 10.1359/jbmr.1997.12.4.616
   Schmitt CP, 1996, J CLIN ENDOCR METAB, V81, P4236, DOI 10.1210/jc.81.12.4236
   SLOVIK DM, 1980, CLIN ENDOCRINOL, V12, P243, DOI 10.1111/j.1365 2265.1980.tb02706.x
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   TEITELBAUM AP, 1986, ENDOCRINOLOGY, V118, P595, DOI 10.1210/endo 118 2 595
   Wehrenberg WB, 2000, NEUROENDOCRINOLOGY IN PHYSIOLOGY AND MEDICINE, P181
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 43
TC 63
Z9 66
U1 0
U2 1
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804 4643
EI 1479 683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD FEB
PY 2005
VL 152
IS 2
BP 199
EP 205
DI 10.1530/eje.1.01841
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 901LI
UT WOS:000227283600006
PM 15745926
DA 2025 08 17
ER

PT J
AU Mundy, GR
AF Mundy, Gregory R.
TI Osteoporosis and inflammation
SO NUTRITION REVIEWS
LA English
DT Article; Proceedings Paper
CT Conference on Living Well to 100   Is Inflammation Central to Aging
CY NOV, 2006
CL Tufts Univ, Boston, MA
HO Tufts Univ
DE osteoporosis; inflammation; cytokines; osteoclast activating factor;
   postmenopausal; RANKL; RANK; osteoprotegerin; bone resorption
ID TUMOR NECROSIS FACTOR; OSTEOCLASTOGENESIS INHIBITORY FACTOR;
   BONE RESORPTION; POSTMENOPAUSAL WOMEN; RHEUMATOID ARTHRITIS; MICE
   LACKING; OSTEOPROTEGERIN LIGAND; INTERLEUKIN 1 RECEPTOR; DIFFERENTIATION
   FACTOR; EQUINE ESTROGEN
AB Osteoporosis represents a major healthcare burden, affecting approximately 10 million people aged over 50 years in the United States and with another 30 million or more at risk. One of the major contributing factors to osteoporosis is withdrawal of estrogen during menopause in women. Human and animal experiments have implicated pro inflammatory cytokines as primary mediators of the accelerated bone loss tit menopause including interleukin 1, tumor necrosis factor alpha, and interleukin 6. Increased production of pro inflammatory cytokines is associated with osteoclastic bone resorption in a number of disease states including rheumatoid arthritis, periodontitis, and multiple myeloma; estrogen withdrawal is associated with increased production of pro inflammatory cytokines, and exposure of bone cultures to supernatants from activated leukocytes is associated with increased bone resorption. A major advance has been the discovery of RANKL, its receptor RANK, and the endogenous inhibitor osteoprotegerin. The binding of RANKL to RANK is essential for the differentiation and activation of osteoclasts and mediates the actions of essentially all known stimulators of osteoclastic bone resorption. RANKL expression is heightened in post  compared with pre menopausal women, and this effect is attenuated by estrogen replacement therapy. RANKL is also a therapeutic target; a human antibody with high specificity and affinity to RANKL is currently under clinical evaluation for the treatment of osteoporosis in post menopausal women and of metastatic bone disease in cancer patients with bone metastasis. Early data are promising.
C1 [Mundy, Gregory R.] Vanderbilt Univ, Ctr Med, Ctr Bone Biol, Nashville, TN 37232 USA.
C3 Vanderbilt University
RP Mundy, GR (通讯作者)，Vanderbilt Univ, Ctr Med, Ctr Bone Biol, 1235 Med Res Bldg 4,2215B Garland Ave, Nashville, TN 37232 USA.
EM gregory.r.mundy@vanderbilt.edu
CR Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Anderson Kenneth C, 2002, Hematology Am Soc Hematol Educ Program, P214
   Bartold PM, 2005, J PERIODONTOL, V76, P2066, DOI 10.1902/jop.2005.76.11 S.2066
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   *BON HLTH OST, 2004, REP SURG GEN ROCKV
   BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo 125 3 1142
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   CAPUTO CB, 1976, ENDOCRINOLOGY, V98, P1065, DOI 10.1210/endo 98 4 1065
   Chen HM, 2006, HUM MOL GENET, V15, P519, DOI 10.1093/hmg/ddi469
   Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772
   DEWHIRST FE, 1985, J IMMUNOL, V135, P2562
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gass M, 2006, AM J MED, V119, p3S, DOI 10.1016/j.amjmed.2005.12.017
   GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130
   Goldring SR, 2002, CURR OPIN RHEUMATOL, V14, P406, DOI 10.1097/00002281 200207000 00013
   GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0
   Hill PA, 1998, ENDOCRINOLOGY, V139, P1564, DOI 10.1210/en.139.4.1564
   HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   KONIG A, 1988, J BONE MINER RES, V3, P621
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022
   MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   MUNDY GR, 1974, NEW ENGL J MED, V291, P1041, DOI 10.1056/NEJM197411142912001
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303
   Ogata Y, 1999, J IMMUNOL, V162, P2754
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.10
   Roux S, 2000, ARTHRITIS RES, V2, P451, DOI 10.1186/ar127
   Shumaker SA, 2004, JAMA J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   THOMSON BM, 1987, J IMMUNOL, V138, P775
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596
   Wong AHC, 2005, HUM MOL GENET, V14, pR11, DOI 10.1093/hmg/ddi116
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yeh HS, 2006, CLIN CANCER RES, V12, p6279S, DOI 10.1158/1078 0432.CCR 06 0681
NR 54
TC 497
Z9 556
U1 1
U2 50
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029 6643
EI 1753 4887
J9 NUTR REV
JI Nutr. Rev.
PD DEC
PY 2007
VL 65
IS 12
BP S147
EP S151
DI 10.1301/nr.2007.dec.S147 S151
PN 2
PG 5
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Nutrition & Dietetics
GA 245FL
UT WOS:000251920400003
PM 18240539
DA 2025 08 17
ER

PT J
AU Yang, SC
   Wu, CH
   Tu, YK
   Huang, SY
   Chou, PC
AF Yang, Shih Chieh
   Wu, Chin Hsien
   Tu, Yuan Kun
   Huang, Shin Yu
   Chou, Pai Chien
TI Exposure to 2,3,7,8 tetrachlorodibenzo p dioxin increases the activation
   of aryl hydrocarbon receptor and is associated with the aggressiveness
   of osteosarcoma MG 63 osteoblast like cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE osteoblast; osteosarcoma; 2; 3; 7; 8 tetrachlorodibenzo p dioxin; aryl
   hydrocarbon receptor; receptor activator of nuclear factor B ligand
ID DIOXIN; TCDD; EXPRESSION; PATHWAY; CANCER; DIFFERENTIATION; MECHANISM;
   LINES; AHR
AB The aryl hydrocarbon receptor (AhR) is a ligand dependent transcription factor whose activity is modulated by xenobiotics and physiological ligands. Activation of the AhR by environmental xenobiotics may induce a conformational change in AhR and has been implicated in a variety of cellular processes, including inflammation and tumorigenesis. It is unknown whether the activation of AhR serves a role in modulating the progression of osteosarcoma. The osteosarcoma cell line MG 63, was treated with AhR ligand, 2,3,7,8 tetrachlorodibenzo p dioxin (TCDD). TCDD treatment degrades AhR expression through activation of the AhR signaling pathway, however there were no survival differences observed in MG 63 cells. There were concomitant elevations of cyclooxygenase 2 and receptor activator of nuclear factor B ligand secretion from MG 63 cells upon TCDD treatment on a protein and mRNA level at 24 and 72 h. In addition, TCDD treatment also increases the production of prostaglandin E2 on MG 63 cells, and induces the expression of chemokine receptor CXCR4. However, CXCL12 production was not altered in MG 63 cells when stimulated with TCDD. The AhR antagonist CH 223191, blocks the effects on TCDD induced RANKL, COX 2, PGE2 and CXCR4 changes. In conclusion, these findings suggest that AhR signal therapy should be further explored as a therapeutic option for the treatment of osteosarcoma.
C1 [Yang, Shih Chieh; Wu, Chin Hsien; Tu, Yuan Kun] I Shou Univ, E Da Hosp, Dept Orthoped Surg, Kaohsiung 82445, Taiwan.
   [Chou, Pai Chien] St Pauls Hosp, Dept Thorac Med, Taoyuan 33069, Taiwan.
   [Huang, Shin Yu; Chou, Pai Chien] Chang Gung Univ, Dept Thorac Med, Chang Gung Med Fdn, Coll Med, 5 Fushin St, Taoyuan 33305, Taiwan.
C3 E Da Hospital; I Shou University; Chang Gung University; Chang Gung
   Memorial Hospital
RP Chou, PC (通讯作者)，Chang Gung Univ, Dept Thorac Med, Chang Gung Med Fdn, Coll Med, 5 Fushin St, Taoyuan 33305, Taiwan.
EM baechainchou@gmail.com
FU E Da Hospital; I Shou University [EDAHP 103025]; Chang Gung Memorial
   Hospital [CMRPG3E0731]
FX The present study was supported by grants from the E Da Hospital and
   I Shou University (grant no. EDAHP 103025) and the Chang Gung Memorial
   Hospital (grant no. CMRPG3E0731).
CR Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046
   Benayahu D, 2002, J CELL BIOCHEM, V84, P108, DOI 10.1002/jcb.1270
   Bilbe G, 1996, BONE, V19, P437, DOI 10.1016/S8756 3282(96)00254 2
   Branstetter D, 2015, J BONE ONCOL, V4, P59, DOI 10.1016/j.jbo.2015.06.002
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Chang YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103038
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   Clohisy JC, 2003, J ORTHOPAED RES, V21, P202, DOI 10.1016/S0736 0266(02)00133 X
   Dalla Torre Cristiane Arruda, 2007, J Orthop Res, V25, P958, DOI 10.1002/jor.20371
   Denison MS, 2011, TOXICOL SCI, V124, P1, DOI 10.1093/toxsci/kfr218
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   Eskenazi B, 2014, ENVIRON HEALTH PERSP, V122, P51, DOI 10.1289/ehp.1306788
   Garcia Moure M, 2017, J BONE ONCOL, V9, P41, DOI 10.1016/j.jbo.2016.12.001
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harvey WA, 2016, TOXICOLOGY, V344, P26, DOI 10.1016/j.tox.2016.02.001
   Herlin M, 2013, TOXICOL APPL PHARM, V273, P219, DOI 10.1016/j.taap.2013.09.002
   Hsu EL, 2007, TOXICOL SCI, V98, P436, DOI 10.1093/toxsci/kfm125
   HUFF J, 1994, ANNU REV PHARMACOL, V34, P343
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Korkalainen M, 2009, BONE, V44, P1134, DOI 10.1016/j.bone.2009.02.019
   Le Vu B, 1998, INT J CANCER, V77, P370, DOI 10.1002/(SICI)1097 0215(19980729)77:3<370::AID IJC11>3.0.CO;2 C
   Liu C, 2015, INT J HYG ENVIR HEAL, V218, P58, DOI 10.1016/j.ijheh.2014.07.006
   Lu Y, 2015, ONCOL LETT, V10, P2123, DOI 10.3892/ol.2015.3535
   Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432
   Miki Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102159
   Mimura J, 2003, BBA GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304 4165(02)00485 3
   Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008 5472.CAN 11 2449
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Qu LY, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935 015 0220 2
   Ray S, 2009, BIOCHEM PHARMACOL, V77, P681, DOI 10.1016/j.bcp.2008.11.022
   Rezzonico R, 2002, J BONE MINER RES, V17, P869, DOI 10.1359/jbmr.2002.17.5.869
   Schwarz M, 2005, REGUL TOXICOL PHARM, V43, P19, DOI 10.1016/j.yrtph.2005.05.008
   Shahnazari M, 2013, FASEB J, V27, P3505, DOI 10.1096/fj.12 225763
   Svec David, 2015, Biomol Detect Quantif, V3, P9, DOI 10.1016/j.bdq.2015.01.005
   Trieb K, 2015, ONCOL LETT, V10, P1813, DOI 10.3892/ol.2015.3489
   Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881
   Walker NJ, 2007, TOXICOL SCI, V95, P297, DOI 10.1093/toxsci/kfl170
   Yellowley Clare, 2013, Bonekey Rep, V2, P300, DOI 10.1038/bonekey.2013.34
   Yu Y, 2017, J CELL MOL MED, V21, P3540, DOI 10.1111/jcmm.13265
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010225
NR 42
TC 14
Z9 15
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2018
VL 16
IS 3
BP 3849
EP 3857
DI 10.3892/ol.2018.9098
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GQ7TE
UT WOS:000441948400139
PM 30127998
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU H'ng, CH
   Amarasinghe, SL
   Zhang, BY
   Chang, HJ
   Qu, XL
   Powell, DR
   Rosello Diez, A
AF H'ng, Chee Ho
   Amarasinghe, Shanika L.
   Zhang, Boya
   Chang, Hojin
   Qu, Xinli
   Powell, David R.
   Rosello Diez, Alberto
TI Compensatory growth and recovery of cartilage cytoarchitecture after
   transient cell death in fetal mouse limbs
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CATCH UP GROWTH; HYPERTROPHIC CHONDROCYTES; PLATE CHONDROCYTES;
   BONE GROWTH; SIGNALING CONTROLS; BETA CATENIN; OSTEOBLASTS; SENESCENCE;
   MTOR; TRANSITION
AB A major question in developmental and regenerative biology is how organ size and architecture are controlled by progenitor cells. While limb bones exhibit catch up growth (recovery of a normal growth trajectory after transient developmental perturbation), it is unclear how this emerges from the behaviour of chondroprogenitors, the cells sustaining the cartilage anlagen that are progressively replaced by bone. Here we show that transient sparse cell death in the mouse fetal cartilage is repaired postnatally, via a two step process. During injury, progression of chondroprogenitors towards more differentiated states is delayed, leading to altered cartilage cytoarchitecture and impaired bone growth. Then, once cell death is over, chondroprogenitor differentiation is accelerated and cartilage structure recovered, including partial rescue of bone growth. At the molecular level, ectopic activation of mTORC1 correlates with, and is necessary for, part of the recovery, revealing a specific candidate to be explored during normal growth and in future therapies.
   How growing organs recover from transient injuries is unclear. Here, authors used mouse models of transient cell death in the limb cartilage to identify cellular and molecular mechanisms (e.g. mTORC1) involved in cartilage repair and catch up growth.
C1 [H'ng, Chee Ho; Amarasinghe, Shanika L.; Zhang, Boya; Chang, Hojin; Qu, Xinli; Rosello Diez, Alberto] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3800, Australia.
   [Amarasinghe, Shanika L.; Powell, David R.] Monash Univ, Monash Genom & Bioinformat Platform, Bioinformat Node, Clayton, Vic 3800, Australia.
   [Rosello Diez, Alberto] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England.
   [Chang, Hojin] Univ Melbourne, Fac Med Dent & Hlth Sci, Biol Opt Microscopy Platform, Parkville, Vic 3010, Australia.
C3 Australian Regenerative Medicine Institute; Monash University; Monash
   University; University of Cambridge; University of Melbourne
RP Rosello Diez, A (通讯作者)，Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3800, Australia.; Rosello Diez, A (通讯作者)，Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England.
EM alberto.rosellodiez@monash.edu
RI Powell, David/K 2404 2019; Roselló Díez, Alberto/K 7295 2016
OI Zhang, Boya/0009 0000 4662 6509; Powell, David
   Richard/0000 0002 6639 6250; Chang, Hojin/0009 0002 1343 7415; H'ng,
   Chee Ho/0000 0002 4649 0645; 
FU Human Frontier Science Program (HFSP) [CDA00021/2019 C]; Monash
   Bioinformatics Platform   HFSP [2002084]; NHMRC; State Government of
   Victoria; Australian Government
FX We thank Jonathan Gleadle, Vincent Wong and Darling Rojas Canales for
   inspiring discussions about mTORC1 and the balance between proliferation
   and cell size in compensatory responses. We also acknowledge the Monash
   Bioinformatics Platform (especially Kirill Tsyganov), and Trevor Wilson,
   at the Medical Genomics Facility, Monash Health Translation Precinct,
   for their excellent technical help. This study is funded by HFSP
   CDA00021/2019 C (to A.R D.) and NHMRC Ideas grant 2002084 (to C.H.H. and
   A.R D.). The Australian Regenerative Medicine Institute is supported by
   grants from the State Government of Victoria and the Australian
   Government.
CR Ahmadzadeh E, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.186650
   Andrews S, 2010, FASTQC QUALITY CONTR
   BARON J, 1994, ENDOCRINOLOGY, V135, P1367, DOI 10.1210/en.135.4.1367
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bushnell B., 2014, 9 ANN GEN EN ENV M
   Chen JQ, 2014, DEVELOPMENT, V141, P2848, DOI 10.1242/dev.108811
   Cooper KL, 2019, INTEGR COMP BIOL, V59, P1356, DOI 10.1093/icb/icz082
   Cooper KL, 2013, NATURE, V495, P375, DOI 10.1038/nature11940
   Diaz SB, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.736574
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Emons JAM, 2005, J PEDIATR US, V147, P843, DOI 10.1016/j.jpeds.2005.07.033
   Farnum CE, 1998, SKELETAL GROWTH AND DEVELOPMENT: CLINICAL ISSUES AND BASIC SCIENCE ADVANCES, P517
   FARNUM CE, 1993, CALCIFIED TISSUE INT, V52, P110, DOI 10.1007/BF00308319
   Gafni RI, 2001, PEDIATR RES, V50, P618, DOI 10.1203/00006450 200111000 00014
   Golovchenko S, 2013, BONE, V55, P102, DOI 10.1016/j.bone.2013.03.019
   Guan YJ, 2014, FASEB J, V28, P4470, DOI 10.1096/fj.14 252783
   H'ng CH, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1153473
   Houben A, 2016, DEVELOPMENT, V143, P3826, DOI 10.1242/dev.137489
   Jing Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10048 z
   KEMBER NF, 1973, CLIN ORTHOP RELAT R, P288
   Kolde R., 2019, pheatmap: Pretty Heatmaps
   Kozhemyakina E, 2015, DEVELOPMENT, V142, P817, DOI 10.1242/dev.105536
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lai LP, 2013, P NATL ACAD SCI USA, V110, P19450, DOI 10.1073/pnas.1309001110
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 2 r29
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Lui JC, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005263
   Lui JLC, 2011, ENDOCR DEV, V21, P23, DOI 10.1159/000328117
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Marino R, 2008, ENDOCRINOLOGY, V149, P1820, DOI 10.1210/en.2007 0993
   Martin M., 2011, EMBnet.Journal, V17, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Muruganandan S, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30247 1
   Newton PT, 2019, NATURE, V567, P234, DOI 10.1038/s41586 019 0989 6
   Ohba S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186665
   Oichi T, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00258 9
   Park J, 2015, BIOL OPEN, V4, P608, DOI 10.1242/bio.201411031
   Payzin Dogru D, 2024, bioRxiv, DOI [10.1101/2021.12.29.474455, 10.1101/2021.12.29.474455, DOI 10.1101/2021.12.29.474455]
   Phornphutkul C, 2008, DEV DYNAM, V237, P702, DOI 10.1002/dvdy.21464
   Posey KL, 2009, AM J PATHOL, V175, P1555, DOI 10.2353/ajpath.2009.090184
   Powell David, 2019, Zenodo
   Redd MJ, 2004, PHILOS T R SOC B, V359, P777, DOI 10.1098/rstb.2004.1466
   Repudi SR, 2013, J CELL SCI, V126, P1650, DOI 10.1242/jcs.119859
   Ring NAR, 2023, DEV CELL, V58, P981, DOI 10.1016/j.devcel.2023.04.001
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   ROACH HI, 1992, BONE MINER, V19, P1, DOI 10.1016/0169 6009(92)90840 A
   Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255
   Rolian C, 2020, WIRES DEV BIOL, V9, DOI 10.1002/wdev.373
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Roselló Díez A, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005086
   Roselló Díez A, 2015, ENDOCR REV, V36, P646, DOI 10.1210/er.2015 1048
   Shiratori H, 2006, DEVELOPMENT, V133, P3015, DOI 10.1242/dev.02470
   Sjögren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088
   Smith T, 2017, GENOME RES, V27, P491, DOI 10.1101/gr.209601.116
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Srinivas V, 2009, CELLS TISSUES ORGANS, V189, P88, DOI 10.1159/000151428
   Usami Y, 2019, J BONE MINER RES, V34, P964, DOI 10.1002/jbmr.3658
   Wang J, 1999, FASEB J, V13, P1985, DOI 10.1096/fasebj.13.14.1985
   Wang LJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12767 9
   Wang YM, 2011, J BONE MINER RES, V26, P1437, DOI 10.1002/jbmr.359
   Wickham H, 2009, USE R, P1, DOI 10.1007/978 0 387 98141 3
   Wilsman NJ, 1996, J ORTHOP RES, V14, P927, DOI 10.1002/jor.1100140613
   Wit JM, 2002, J PEDIATR ENDOCR MET, V15, P1229
   Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401
   Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324
   Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 72
TC 0
Z9 0
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR 5
PY 2024
VL 15
IS 1
AR 2940
DI 10.1038/s41467 024 47311 7
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NB1M7
UT WOS:001197889600017
PM 38580631
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Guma, A
   Akhtar, S
   Najafzadeh, M
   Isreb, M
   Baumgartner, A
   Anderson, D
AF Guma, Azeza
   Akhtar, Shabana
   Najafzadeh, Mojgan
   Isreb, Mohammad
   Baumgartner, Adolf
   Anderson, Diana
TI Ex vivo/in vitro effects of aspirin and ibuprofen, bulk and nano
   forms, in peripheral lymphocytes of prostate cancer patients and healthy
   individuals
SO MUTATION RESEARCH GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
LA English
DT Article
DE Comet assay; Micronucleus assay; Prostate cancer; Healthy individuals;
   Ibuprofen and aspirin; Bulk and nano forms
ID BONE MARROW CELLS; COMET ASSAY; INDUCED GENOTOXICITY; OXIDATIVE STRESS;
   IN VITRO; INFLAMMATION; MECHANISMS; INSTABILITY
AB Inhibiting inflammatory processes or eliminating inflammation represents a logical role in the suppression and treatment strategy of cancer. Several studies have shown that anti inflammatory drugs (NSAIDs) act as anticancer agents while reducing metastases and mortality rate. NSAIDs are seriously limited by their side effects and toxicity, which can become cumulative with their long term administration for chemoprevention. In the current ex vivo / in vitro study, the genotoxicity mechanisms of NSAIDS in bulk and nanoparticle forms allowed a strategy to prevent and minimise the damage in human lymphocytes. When compared to their bulk forms, acetylsalicylic acid (Aspirin) nano and ibuprofen nano (IBU N), both NSAIDs in 500 mu g/mL concentration significantly decreased DNA damage measured by alkaline comet assay. Micronuclei (MNi) frequency also decreased after ASP N (500 mu g/mL), ASP B (500 mu g/mL) and IBU N (200 mu g/mL) in prostate cancer patients and healthy individuals, however, the ibuprofen bulk (200 mu g/mL) showed a significant increase in MNi formation in lymphocytes from healthy and prostate cancer patients when compared to the respective untreated lymphocytes. These findings suggest that a reduction in particle size had an impact on the reactivity of the drug, further emphasising the potential of nanoparticles to improve the current treatment options.
C1 [Guma, Azeza; Akhtar, Shabana; Najafzadeh, Mojgan; Isreb, Mohammad; Anderson, Diana] Univ Bradford, Bradford, W Yorkshire, England.
   [Baumgartner, Adolf] York St John Univ, York, N Yorkshire, England.
C3 University of Bradford; York Saint John University
RP Anderson, D (通讯作者)，Univ Bradford, Bradford, W Yorkshire, England.
EM d.anderson1@bradford.ac.uk
RI Akhtar, Shabana/AAJ 6364 2021
FU Libyan Embassy
FX This study was kindly funded by the Libyan Embassy.
CR Afzal M, 2017, ARCH BIOCHEM BIOPHYS, V623, P58, DOI 10.1016/j.abb.2017.05.006
   Akhtar S., 2020, ARCH TOXICOL
   Akhtar S, 2020, TOXICOL LETT, V327, P33, DOI 10.1016/j.toxlet.2020.03.012
   Anderson D, 2014, FASEB J, V28, P4563, DOI 10.1096/fj.14 254748
   Antonio N, 2015, EMBO J, V34, P2219, DOI 10.15252/embj.201490147
   Azqueta A, 2013, ARCH TOXICOL, V87, P949, DOI 10.1007/s00204 013 1070 0
   Ben Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006
   Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140 6736(11)61049 0
   Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249
   Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105
   Dandah O, 2018, MUTAT RES GEN TOX EN, V826, P41, DOI 10.1016/j.mrgentox.2017.12.001
   Day RO, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f3195
   Doat S, 2017, CANCER MED US, V6, P2461, DOI 10.1002/cam4.1186
   DUNN TL, 1987, MUTAT RES, V189, P299, DOI 10.1016/0165 1218(87)90061 9
   Eiró N, 2012, WORLD J GASTRO SURG, V4, P62, DOI 10.4240/wjgs.v4.i3.62
   El Zein RA, 2006, CANCER RES, V66, P6449, DOI 10.1158/0008 5472.CAN 06 0326
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Faust F, 2004, MUTAT RES REV MUTAT, V566, P209, DOI 10.1016/j.mrrev.2003.09.007
   Fenech M, 2002, DRUG DISCOV TODAY, V7, P1128, DOI 10.1016/S1359 6446(02)02502 3
   Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77
   Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498
   Garaj Vrhovac V, 2009, CELL BIOL TOXICOL, V25, P33, DOI 10.1007/s10565 008 9060 3
   Ghosh M, 2010, TOXICOL IND HEALTH, V26, P417, DOI 10.1177/0748233710369125
   Giri AK, 1996, MUTAT RES GENET TOX, V370, P1, DOI 10.1016/S0165 1218(96)90121 4
   Gopalan RC, 2011, TOXICOL LETT, V207, P322, DOI 10.1016/j.toxlet.2011.09.010
   Antunes LMG, 2007, MUTAT RES GEN TOX EN, V626, P155, DOI 10.1016/j.mrgentox.2006.09.009
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Hiroi T, 2017, JOVE J VIS EXP, DOI 10.3791/54885
   Karbaschi M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236072
   Karlsson HL, 2015, ENVIRON MOL MUTAGEN, V56, P82, DOI 10.1002/em.21933
   Lou JL, 2007, MUTAT RES FUND MOL M, V617, P104, DOI 10.1016/j.mrfmmm.2007.01.004
   Magdolenova Z, 2014, NANOTOXICOLOGY, V8, P233, DOI 10.3109/17435390.2013.773464
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Najafzadeh M, 2016, FRONT MOL BIOSCI, V3, DOI 10.3389/fmolb.2016.00050
   Niikawa M, 2006, DRUG CHEM TOXICOL, V29, P379, DOI 10.1080/01480540600820528
   Niikawa M, 2008, ASIAN PAC J CANCER P, V9, P279
   ObrechtPflumio S, 1996, ARCH TOXICOL, V70, P244, DOI 10.1007/s002040050267
   OECD, 2016, OECDTEST NO 487 IN V
   OECD, 2016, OECDTEST NO 489 IN V
   Park JH, 2014, CANCER TREAT REV, V40, P68, DOI 10.1016/j.ctrv.2013.05.006
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Sfanos KS, 2014, ADV EXP MED BIOL, V816, P153, DOI 10.1007/978 3 0348 0837 8_7
   Sfanos KS, 2012, HISTOPATHOLOGY, V60, P199, DOI 10.1111/j.1365 2559.2011.04033.x
   Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098 2280(2000)35:3<206::AID EM8>3.0.CO;2 J
   Tripathi R, 2012, DRUG CHEM TOXICOL, V35, P389, DOI 10.3109/01480545.2011.630670
   Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
NR 47
TC 9
Z9 9
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1383 5718
EI 1879 3592
J9 MUTAT RES GEN TOX EN
JI Mutat. Res. Genet. Toxicol. Environ. Mutagen.
PD JAN FEB
PY 2021
VL 861
AR 503306
DI 10.1016/j.mrgentox.2020.503306
EA FEB 2021
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA QL6PZ
UT WOS:000621207800012
PM 33551100
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, JY
   Wang, YH
   Wang, GJ
   Ho, ML
   Wang, CZ
   Yeh, ML
   Chen, CH
AF Wu, Jyun Yi
   Wang, Yan Hsiung
   Wang, Gwo Jaw
   Ho, Mei Ling
   Wang, Chau Zen
   Yeh, Ming Long
   Chen, Chia Hsin
TI Low Power GaAlAs Laser Irradiation Promotes the Proliferation and
   Osteogenic Differentiation of Stem Cells via IGF1 and BMP2
SO PLOS ONE
LA English
DT Article
ID RAT CALVARIAL CELLS; BONE MARROW; IN VITRO; GENE EXPRESSION; THERAPY;
   OSTEOBLASTS; OSTEOPOROSIS; TGF BETA 1; CULTURE; ARREST
AB Low power laser irradiation (LPLI) has been found to induce various biological effects and cellular processes. Also, LPLI has been shown to promote fracture repair. Until now, it has been unclear how LPLI promotes bone formation and fracture healing. The aim of this study was to investigate the potential mechanism of LPLI mediated enhancement of bone formation using mouse bone marrow mesenchymal stem cells (D1 cells). D1 cells were irradiated daily with a gallium aluminum arsenide (GaAlAs) laser at dose of 0, 1, 2, or 4 J/cm(2). The lactate dehydrogenase (LDH) assay showed no cytotoxic effects of LPLI on D1 cells, and instead, LPLI at 4 J/cm(2) significantly promoted D1 cell proliferation. LPLI also enhanced osteogenic differentiation in a dose dependent manner and moderately increased expression of osteogenic markers. The neutralization experiments indicated that LPLI regulated insulin like growth factor 1 (IGF1) and bone morphogenetic protein 2 (BMP2) signaling to promote cell proliferation and/or osteogenic differentiation. In conclusion, our study suggests that LPLI may induce IGF1 expression to promote both the proliferation and osteogenic differentiation of D1 cells, whereas it may induce BMP2 expression primarily to enhance osteogenic differentiation.
C1 [Wu, Jyun Yi; Yeh, Ming Long] Natl Cheng Kung Univ, Inst Biomed Engn, Tainan 70101, Taiwan.
   [Wang, Yan Hsiung] Kaohsiung Med Univ, Sch Dent, Coll Dent Med, Kaohsiung, Taiwan.
   [Wang, Yan Hsiung; Wang, Gwo Jaw; Ho, Mei Ling; Wang, Chau Zen] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan.
   [Wang, Gwo Jaw] Kaohsiung Med Univ, Dept Orthopaed, Coll Med, Kaohsiung, Taiwan.
   [Wang, Gwo Jaw] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung, Taiwan.
   [Wang, Gwo Jaw] Univ Virginia, Dept Orthopaed Surg, Charlottesville, VA USA.
   [Ho, Mei Ling; Wang, Chau Zen] Kaohsiung Med Univ, Dept Physiol, Coll Med, Kaohsiung, Taiwan.
   [Ho, Mei Ling; Wang, Chau Zen] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.
   [Chen, Chia Hsin] Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan.
   [Chen, Chia Hsin] Kaohsiung Med Univ, Dept Phys Med & Rehabil, Coll Med, Fac Med, Kaohsiung, Taiwan.
   [Chen, Chia Hsin] Kaohsiung Municipal Tatung Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan.
C3 National Cheng Kung University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; University of
   Virginia; Kaohsiung Medical University; Kaohsiung Medical University;
   Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Municipal Ta Tung Hospital
RP Wu, JY (通讯作者)，Natl Cheng Kung Univ, Inst Biomed Engn, Tainan 70101, Taiwan.
EM mlyeh@mail.ncku.edu.tw; chchen@kmu.edu.tw
RI Ho, Mei Ling/D 5515 2009; Zhu, Zhi/D 3721 2011; Wang,
   Chau Zen/D 4868 2009; yang, chaoyong/F 9741 2010; Wang,
   Yan Hsiung/ABD 4004 2020; Chen, Chia Hsin/C 7884 2009
OI Zhu, Zhi/0000 0002 3287 4920; Wang, Yan Hsiung/0000 0001 8161 7472; Ho,
   Mei Ling/0000 0001 8064 8488; Chen, Chia Hsin/0000 0002 6557 9848; yang,
   chaoyong/0000 0002 2374 5342; 
FU National Science Council [NSC 96 2221 E 006 259, NSC 96 2314 B 037 059];
   National Health Research Institutes, Taiwan [NHRI EX97 9615EP]
FX This study was supported by two grants from the National Science Council
   (NSC 96 2221 E 006 259, NSC 96 2314 B 037 059) and a grant from the
   National Health Research Institutes (NHRI EX97 9615EP) of Taiwan. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arany PR, 2007, WOUND REPAIR REGEN, V15, P866, DOI 10.1111/j.1524 475X.2007.00306.x
   Arisu HD, 2006, LASER MED SCI, V21, P175, DOI 10.1007/s10103 006 0398 6
   Baron W, 2000, MOL CELL NEUROSCI, V15, P314, DOI 10.1006/mcne.1999.0827
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Cen Shiqiang, 2008, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V22, P84
   Chen CH, 2005, OSTEOPOROSIS INT, V16, P2039, DOI 10.1007/s00198 005 1995 0
   Coombe A R, 2001, Clin Orthod Res, V4, P3, DOI 10.1034/j.1600 0544.2001.040102.x
   Dahir GA, 2000, CLIN ORTHOP RELAT R, pS134
   DIDUCH DR, 1993, J BONE JOINT SURG AM, V75A, P92, DOI 10.2106/00004623 199301000 00012
   Eduardo FD, 2008, LASER SURG MED, V40, P433, DOI 10.1002/lsm.20646
   Fukuhara E, 2006, CALCIFIED TISSUE INT, V79, P443, DOI 10.1007/s00223 006 0072 9
   Gál P, 2009, LASER MED SCI, V24, P539, DOI 10.1007/s10103 008 0604 9
   Hamajima S, 2003, LASER MED SCI, V18, P78, DOI 10.1007/s10103 003 0255 9
   Horvát Karajz K, 2009, LASER SURG MED, V41, P463, DOI 10.1002/lsm.20791
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Huang XM, 2003, FRONT BIOSCI LANDMRK, V8, pS740, DOI 10.2741/1093
   IIJIMA K, 1989, CLIN J PAIN, V5, P271
   Jin Dong mei, 2006, Zhejiang Da Xue Xue Bao Yi Xue Ban, V35, P55
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Khadra M, 2004, CLIN ORAL IMPLAN RES, V15, P325, DOI 10.1111/j.1600 0501.2004.00994.x
   Mehler PS, 2009, INT J EAT DISORDER, V42, P195, DOI 10.1002/eat.20593
   Moore NM, 2011, ACTA BIOMATER, V7, P2091, DOI 10.1016/j.actbio.2011.01.019
   Mvula B, 2008, LASER MED SCI, V23, P277, DOI 10.1007/s10103 007 0479 1
   Ninomiya T, 2003, J BONE MINER METAB, V21, P67, DOI 10.1007/s007740300011
   Oliveira DAAP, 2008, PHOTOMED LASER SURG, V26, P401, DOI 10.1089/pho.2007.2101
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Pretel H, 2007, LASER SURG MED, V39, P788, DOI 10.1002/lsm.20585
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Sakurai Y, 2000, EUR J ORAL SCI, V108, P29, DOI 10.1034/j.1600 0722.2000.00783.x
   Schindl A, 2003, BRIT J DERMATOL, V148, P334, DOI 10.1046/j.1365 2133.2003.05070.x
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Taniguchi D, 2009, LASER SURG MED, V41, P232, DOI 10.1002/lsm.20750
   Totosy de Zepetnek JO, 2009, J REHABIL RES DEV, V46, P529, DOI 10.1682/JRRD.2008.09.0136
   Tuby H, 2007, LASER SURG MED, V39, P373, DOI 10.1002/lsm.20492
   Wang YH, 2009, MOL THER, V17, P302, DOI 10.1038/mt.2008.267
   Wildemann B, 2003, J BIOMED MATER RES B, V65B, P150, DOI 10.1002/jbm.b.10512
   Xu M, 2009, PHOTOMED LASER SURG, V27, P309, DOI 10.1089/pho.2008.2283
NR 41
TC 82
Z9 99
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2012
VL 7
IS 9
AR e44027
DI 10.1371/journal.pone.0044027
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 002ZJ
UT WOS:000308577600024
PM 23029506
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, WX
   Yang, NL
   Shi, XM
AF Zhang, Weixi
   Yang, Nianlan
   Shi, Xing Ming
TI Regulation of mesenchymal stem cell osteogenic differentiation by
   glucocorticoid induced leucine zipper (GILZ)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MARROW STROMAL CELLS; INHIBITION; ADIPOGENESIS; PROTEIN; GENE; LINE;
   CORTICOSTEROIDS; DEXAMETHASONE; OSTEOPOROSIS; OSF2/CBFA1
AB Mesenchymal stem cells (MSCs) can differentiate into multiple cell lineages, including osteoblasts and adipocytes. We reported previously that glucocorticoid induced leucine zipper (GILZ) inhibits peroxisome proliferator activated receptor gamma 2 (Ppar gamma 2) expression and blocks adipocyte differentiation. Here we show that overexpression of GILZ in mouse MSCs, but not MC3T3 E1 osteoblasts, increases alkaline phosphatase activity and enhances mineralized bone nodule formation, whereas knockdown of Gilz reduces MSC osteogenic differentiation capacity. Consistent with these observations, real time reverse transcription PCR analysis showed that both basal and differentiation induced transcripts of the lineage commitment gene Runx2/Cbfa1, as well as osteoblast differentiation marker genes including alkaline phosphatase, type I collagen, and osteocalcin, were all increased in GILZ expressing cells. In contrast, the mRNA levels of adipogenic Ppar gamma 2 and C/ebp alpha were significantly reduced in GILZ expressing cells under both osteogenic and adipogenic conditions. Together, our results demonstrate that GILZ functions as a modulator of MSCs and that overexpression of GILZ shifts the balance between osteogenic and adipogenic differentiation of MSCs toward the osteogenic pathway. These data suggest that GILZ may have therapeutic value for stem cell based therapies of metabolic bone diseases, such as fracture repair.
C1 [Shi, Xing Ming] Med Coll Georgia, Inst Mol Med & Genet, Dept Pathol, Augusta, GA 30912 USA.
   [Zhang, Weixi; Yang, Nianlan; Shi, Xing Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Mol Med & Genet, Guangzhou, Peoples R China.
   [Zhang, Weixi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou, Peoples R China.
   [Yang, Nianlan] Wuhan Univ, Renmin Hosp, Dept Hematol, Wuhan 430072, Peoples R China.
C3 University System of Georgia; Augusta University; Sun Yat Sen
   University; Sun Yat Sen University; Wuhan University
RP Shi, XM (通讯作者)，Med Coll Georgia, Inst Mol Med & Genet, Dept Pathol, 1120 15th St,CB 2803, Augusta, GA 30912 USA.
EM xshi@mcg.edu
RI , 张维溪/AHC 3024 2022
CR Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097 4644(20010401)81:1<23::AID JCB1021>3.0.CO;2 H
   Altose MD, 2000, NEW ENGL J MED, V343, P1902
   Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929 7941.2002
   Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743
   Barnes PJ, 2005, IMMUNOL ALLERGY CLIN, V25, P451, DOI 10.1016/j.iac.2005.05.003
   Bazzy Asaad A, 2001, CURR OPIN PEDIATR, V13, P523, DOI 10.1097/00008480 200112000 00005
   BERESFORD JN, 1994, ARCH ORAL BIOL, V39, P941, DOI 10.1016/0003 9969(94)90077 9
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Clowes JA, 2001, CURR OPIN RHEUMATOL, V13, P326, DOI 10.1097/00002281 200107000 00015
   Conn DL, 2001, ARTHRIT RHEUM ARTHR, V45, P462, DOI 10.1002/1529 0131(200110)45:5<462::AID ART366>3.0.CO;2 V
   Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P405, DOI 10.1016/S1081 1206(10)62922 5
   CRUESS RL, 1975, CLIN ORTHOP RELAT R, V113, P178
   Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623 199707000 00012
   D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074 7613(00)80398 2
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Gimble JM, 1996, MOL PHARMACOL, V50, P1087
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   HARRIS ED, 1983, HOSP PRACT, V18, P137
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804
   Kirwan JR, 2000, Z RHEUMATOL, V59, P85
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200
   Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400
   Park SJ, 2001, J HEART LUNG TRANSPL, V20, P304, DOI 10.1016/S1053 2498(00)00316 8
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Reichardt HM, 2000, Z RHEUMATOL, V59, P1
   Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805
   SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Tichopad A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng122
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Tynan SH, 2004, J STEROID BIOCHEM, V91, P225, DOI 10.1016/j.jsbmb.2004.05.002
   Walsh LJ, 2001, THORAX, V56, P279, DOI 10.1136/thorax.56.4.279
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   YANG N, 2007, IN PRESS J CELL BIOC
NR 47
TC 123
Z9 137
U1 0
U2 23
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 22
PY 2008
VL 283
IS 8
BP 4723
EP 4729
DI 10.1074/jbc.M704147200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 266IA
UT WOS:000253426500030
PM 18084007
OA hybrid
DA 2025 08 17
ER

PT J
AU Duan, WP
   Wang, Q
   Li, F
   Xiang, C
   Zhou, L
   Xu, JK
   Feng, HT
   Wei, XC
AF Duan Wangping
   Wang Qing
   Li Fang
   Xiang Chuan
   Zhou Lin
   Xu Jiake
   Feng Haotian
   Wei Xiaochun
TI Anti catabolic effect of caffeic acid phenethyl ester, an active
   component of honeybee propolis on bone loss in ovariectomized mice: a
   micro computed tomography study and histological analysis
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE caffeic acid phenethyl ester; osteoporosis; bone loss; micro computed
   tomography
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; PAGETS DISEASE; ACTIVATION;
   RESORPTION; LIGAND; INHIBITION; PATHWAYS; CELLS; RATS
AB Background Osteoporosis (OP) is a common bone disease, which adversely affects life quality. Effective treatments are necessary to combat both the loss and fracture of bone. Recent studies indicated that caffeic acid phenethyl ester (CAPE) is a natural chemical compound from honeybee propolis which is capable of attenuating osteoclastogenesis and bone resorption. Therefore, this study aimed to investigate the effect of CAPE on bone loss in OP mice using micro computed tomography (CT) and histology.
   Methods Eighteen mice were prepared and evenly divided into three groups. The six mice in the sham+PBS group did not undergo ovariectomy and were intraperitoneally injected with PBS during the curing period. Twelve mice were ovariectomized (OVX) to induce OP. Six of them in the OVX+CAPE group were intraperitoneally injected with 0.5 mg/kg CAPE twice per week for 4 weeks after ovariectomy. The other six OVX mice in OVX+PBS group were treated with PBS. All the mice were sacrificed 4 weeks after ovariectomy. The tibias were bilaterally excised for micro CT scan and histological analysis. The Mann Whitney U test was used to test the statistical differences among groups.
   Results Bone loss occurred in OVX mice. Compared with the sham+PBS group, mice in the OVX+PBS group exhibited a significant decrease in bone mineral density (BMD, P <0.05), bone volume fraction (BV/TV, P <0.01), trabecular thickness (Tb.Th, P <0.05), and trabecular number (Tb.N, P <0.01), as well as a non insignificant increase in the number of osteoclasts (N.Oc/B.Pm). With CAPE treatment, the microarchitecture of the tibial metaphyses was significantly improved with a reduction of osteoclast formation. Compared with the OVX+PBS group, BV/TV in the OVX+CAPE group was significantly increased by 33.9% (P <0.05).
   Conclusion CAPE therapy results in the protection of bone loss induced by OVX.
C1 [Duan Wangping; Xiang Chuan; Wei Xiaochun] Shanxi Med Univ, Dept Orthopaed, Hosp 2, Shanxi Key Lab Bone & Soft Tissue Injury Repair, Taiyuan 030001, Shanxi, Peoples R China.
   [Wang Qing] Southern Med Univ, Inst Med Informat, Sch Biomed Engn, Guangzhou 510515, Guangdong, Peoples R China.
   [Li Fang; Zhou Lin; Xu Jiake] Univ Western Australia, Sch Med & Pathol, Perth, WA 6009, Australia.
   [Feng Haotian] Nestle R&D China Ltd, Program Nutr & Bone & Joint Hlth, Beijing 100095, Peoples R China.
C3 Shanxi Medical University; Southern Medical University   China;
   University of Western Australia
RP Wei, XC (通讯作者)，Shanxi Med Univ, Dept Orthopaed, Hosp 2, Taiyuan 030001, Shanxi, Peoples R China.
EM weixiaochun06@163.com
OI Xu, Jiake/0000 0003 2021 8309; xiang, chuan/0000 0002 1121 6443
FU Endeavour Research Fellowship Award; National Natural Science Foundation
   of China [31340010, 31271033]; Science Foundation of Ministry of
   Education of China [20121417120004]; Natural Science Foundation of
   Shanxi Province [2013021036 3]; Special Funds for Talent Introduction in
   Guang Dong Universities
FX This study was partially supported by an Endeavour Research Fellowship
   Award awarded to Dr. Wang Qing, and grants from National Natural Science
   Foundation of China (No. 31340010 and No. 31271033), Science Foundation
   of Ministry of Education of China (No. 20121417120004), Natural Science
   Foundation of Shanxi Province (No. 2013021036 3), and Special Funds for
   Talent Introduction in Guang Dong Universities.
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Ang ESM, 2009, J CELL PHYSIOL, V221, P642, DOI 10.1002/jcp.21898
   Campbell GM, 2011, OSTEOPOROSIS INT, V22, P931, DOI 10.1007/s00198 010 1283 5
   Cheng T, 2009, MOL ENDOCRINOL, V23, P35, DOI 10.1210/me.2007 0465
   Geary N, 2001, AM J PHYSIOL REG I, V281, pR1290, DOI 10.1152/ajpregu.2001.281.4.R1290
   Ha J, 2009, INT IMMUNOPHARMACOL, V9, P774, DOI 10.1016/j.intimp.2009.03.001
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lewiecki EM, 2010, EXPERT OPIN BIOL TH, V10, P467, DOI 10.1517/14712591003604708
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Rea SL, 2006, J BONE MINER RES, V21, P1136, DOI 10.1359/JBMR.060405
   Rea SL, 2013, ENDOCR REV, V34, P501, DOI 10.1210/er.2012 1034
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
NR 22
TC 9
Z9 10
U1 0
U2 15
PU CHINESE MEDICAL ASSOC
PI BEIJING
PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA
SN 0366 6999
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD NOV 20
PY 2014
VL 127
IS 22
BP 3932
EP 3936
DI 10.3760/cma.j.issn.0366 6999.20141399
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AW5QQ
UT WOS:000346329600018
PM 25421193
OA gold
DA 2025 08 17
ER

PT J
AU Xiao, JG
   Wu, Y
   Chen, RL
   Lin, YF
   Wu, L
   Tian, WD
   Liu, L
AF Xiao, Jingang
   Wu, Yao
   Chen, Runliang
   Lin, Yunfeng
   Wu, Ling
   Tian, Weidong
   Liu, Lei
TI Expression of Pcp4 gene during osteogenic differentiation of bone marrow
   mesenchymal stem cells in vitro
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone marrow mesenchymal stem cells; osteogenic differentiation; gene
   chip; real time quantitative PCR
ID POLYMERASE CHAIN REACTION; TIME QUANTITATIVE PCR; OSTEOBLAST
   DIFFERENTIATION; MORPHOGENETIC PROTEINS; PEP 19; CHONDROCYTES;
   MICROARRAY; PCP4/PEP19; ACTIVATOR; THERAPY
AB In this study, we established an in vitro model of osteogenic inductive differentiation of rat bone marrow mesenchymal stem cells (BMSCs) to determine the mechanisms and relative gene function underlying BMSCs osteogenesis. Osteoplastic differentiation of the third generation BMSCs was induced with the alpha minimal essential medium containing beta glyceraldehyde 3 phosphate, L ascorbic acid, dexamethasone and 1,25 2(OH)(2) vitamin D 3 prior to applying gene chip technology (also called microarray technology) for global gene expression screening. Real time quantitative PCR (Real time PCR) was used to determine the temporal profile of mRNA expression of regulated genes during osteogenic differentiation of BMSCs. A bioinformatic analysis was utilized to determine the functional significance of the identified osteogenic related genes. Purkinje cell protein 4 (Pcp4) mRNA expression was identified by the gene chip screening as being up regulated during osteoplastic differentiation of BMSCs. Real time PCR analysis confirmed the increased expression of Pcp4 mRNA expression during osteoplastic differentiation of BMSCs with an upward trend that peaked at day 14. The bioinformatic analysis identified Pcp4 as a gene involved in the deposition of calcium and the modulation of CaM dependent protein kinase. Thus, we hypothesize that Pcp4 osteoplastic differentiation of BMSCs is mediated in part via Pcp4 induced calcium deposition to form mineral nodules and modulation of certain signal transduction pathways of BMPs.
C1 [Xiao, Jingang; Wu, Yao; Wu, Ling; Tian, Weidong] State Key Lab Stomatol, Chengdu 610044, Peoples R China.
   [Xiao, Jingang; Lin, Yunfeng; Liu, Lei] Sichuan Univ, W China Coll Stomatol, Dept Oral & Maxillofacial Surg, Chengdu 610041, Peoples R China.
   [Chen, Runliang] Tianjin First People Hosp, Tianjin 300192, Peoples R China.
C3 Sichuan University
RP Tian, WD (通讯作者)，State Key Lab Stomatol, Chengdu 610044, Peoples R China.
EM drtwd@sina.com; drliulei@163.com
RI Lin, Yunfeng/H 3393 2011; zhang, Weihua/JJD 6447 2023; Wu,
   Ling/G 9563 2011; liu, lei/B 2263 2012
OI Lin, Yunfeng/0000 0003 1224 6561; Tian, Weidong/0000 0003 0175 1132
CR Abe A, 1999, J CLIN MICROBIOL, V37, P2899, DOI 10.1128/JCM.37.9.2899 2903.1999
   Apple FS, 2002, AM HEART J, V144, P981, DOI 10.1067/mhj.2002.124048
   Bergwitz C, 2001, J INHERIT METAB DIS, V24, P648, DOI 10.1023/A:1012758925617
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Caplan AI, 2000, TISSUE ENG, V6, P1, DOI 10.1089/107632700320838
   Chen HM, 1996, HUM GENET, V98, P672, DOI 10.1007/s004390050282
   *COUNC INT ORG MED, 1985, INT GUID PRINC AN RE
   Dickerson JB, 2006, BRAIN RES, V1092, P16, DOI 10.1016/j.brainres.2006.03.048
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Girard BM, 2002, REGUL PEPTIDES, V109, P89, DOI 10.1016/S0167 0115(02)00191 X
   Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261
   Grove JE, 2004, STEM CELLS, V22, P487, DOI 10.1634/stemcells.22 4 487
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hu ZM, 2005, J CRANIOFAC SURG, V16, P1006, DOI 10.1097/01.scs.0000170449.72040.ee
   Iwamoto K, 2004, NEUROSCI RES, V49, P379, DOI 10.1016/j.neures.2004.04.002
   Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742 7843.2004.pto950502.x
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   Krex D, 2001, ACTA NEUROCHIR, V143, P429
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li MZ, 2006, DEV BIOL, V292, P555, DOI 10.1016/j.ydbio.2006.01.033
   Lin YF, 2006, MOL CELL BIOCHEM, V291, P1, DOI 10.1007/s11010 006 9188 5
   Liu Lei, 2005, Hua Xi Kou Qiang Yi Xue Za Zhi, V23, P60
   Liu WH, 2002, ANAL BIOCHEM, V302, P52, DOI 10.1006/abio.2001.5530
   Murray KD, 2007, P NATL ACAD SCI USA, V104, P1989, DOI 10.1073/pnas.0610742104
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Pola E, 2004, GENE THER, V11, P683, DOI 10.1038/sj.gt.3302207
   Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904 810
   Putkey JA, 2003, J BIOL CHEM, V278, P49667, DOI 10.1074/jbc.C300372200
   Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032
   Rabie ABM, 2004, ARCH ORAL BIOL, V49, P109, DOI 10.1016/j.archoralbio.2003.09.006
   Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266
   Sala A, 2007, INT J MOL MED, V19, P501
   Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141
   Simpson D, 2000, MOL VIS, V6, P178
   Slemmon JR, 2000, MOL NEUROBIOL, V22, P99, DOI 10.1385/MN:22:1 3:099
   Takamoto M, 2003, J ENDOCRINOL, V177, P413, DOI 10.1677/joe.0.1770413
   Thompson KH, 1997, REV PORT QUIM, V4, P3
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   VAN LS, 2005, FRONT BIOSCI, V10, P2966
   Viemann D, 2004, BLOOD, V103, P3365, DOI 10.1182/blood 2003 09 3296
   Wu L, 2007, MOL CELL BIOCHEM, V301, P83, DOI 10.1007/s11010 006 9399 9
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   YOO JU, 2000, CURR OPIN ORTHOP, V11, P391
   Yue B, 2005, CALCIFIED TISSUE INT, V77, P395, DOI 10.1007/s00223 005 0180 y
NR 46
TC 19
Z9 22
U1 1
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2008
VL 309
IS 1 2
BP 143
EP 150
DI 10.1007/s11010 007 9652 x
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 255DW
UT WOS:000252638200016
PM 18008138
DA 2025 08 17
ER

PT J
AU Tanaka, Y
AF Tanaka, Y.
TI Human mesenchymal stem cells as a tool for joint repair in rheumatoid
   arthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE rheumatoid arthritis; joint; mesenchymal stem cell; regeneration;
   inflammation
ID BONE MARROW; ARTICULAR CARTILAGE; DIFFERENTIATION; THERAPY;
   NANOTECHNOLOGY; INDUCTION; PATHWAY; LINEAGE; GROWTH
AB Rheumatoid arthritis (RA) is characterised with chronic inflammatory synovitis and progressive joint. Because damaged and/or deformed joints cannot be repaired, a novel treatment strategy aimed at both anti inflammation and bone regeneration is a prerequisite Mesenchymal stem cells (MSCs) can be easily isolated from various organs and possess multipotent capacity and exhibit immunoregulatory properties. Using human MSC derived from bone marrow and adipose tissue, we have clarified the following novel findings in vitro. 1) MSCs differentiated into osteoblasts or osteocytes under osteoblast conditioned medium including the inflammatory stimuli such as IL 1. 2) The combination of IL 6 and soluble IL 6 receptor induced differentiation of MSCs to chondrocyte. 3) MSCs produced osteoprotegerin and inhibited osteoclasto genesis. Furthermore, we developed a local delivery system of MSCs by using nano fibre scaffold. MSCs seeded on nano fibre scaffold suppressed arthritis and joint destruction by inhibiting systemic inflammatory reaction and immune response through the induction of regulatory T cells and subsequent reduction in the production of anti type II collagen antibody in vivo. Thus, our data may serve as a new strategy for MSC based therapy in inflammatory diseases and an alternative delivery method for the treatment of damaged joints in RA.
C1 Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan.
C3 University of Occupational & Environmental Health   Japan
RP Tanaka, Y (通讯作者)，Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM tanaka@med.uoeh u.ac.jp
FU Ministry of Health, Labor and Welfare of Japan; Ministry of Education,
   Culture, Sports, Science and Technology of Japan; University of
   Occupational and Environmental Health, Japan, through UOEH Grant for
   Advanced Research
FX this work was supported in part by a Grant In Aid for Scientific
   Research from the Ministry of Health, Labor and Welfare of Japan, the
   Ministry of Education, Culture, Sports, Science and Technology of Japan,
   and the University of Occupational and Environmental Health, Japan,
   through UOEH Grant for Advanced Research.
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Alsalameh S, 2004, ARTHRITIS RHEUM US, V50, P1522, DOI 10.1002/art.20269
   Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Burmester GR, 2015, ANN RHEUM DIS, V74, P1037, DOI 10.1136/annrheumdis 2013 204769
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Djouad F, 2009, NAT REV RHEUMATOL, V5, P392, DOI 10.1038/nrrheum.2009.104
   Dowthwaite GP, 2004, J CELL SCI, V117, P889, DOI 10.1242/jcs.00912
   Fukuyo S, 2014, RHEUMATOLOGY, V53, P1282, DOI 10.1093/rheumatology/ket496
   Furst DE, 2014, RHEUMATOLOGY, V53, P1560, DOI 10.1093/rheumatology/ket414
   González MA, 2009, ARTHRITIS RHEUM US, V60, P1006, DOI 10.1002/art.24405
   Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664
   Guo CA, 2007, J BIOSCI BIOENG, V103, P547, DOI 10.1263/jbb.103.547
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Kondo M, 2015, ARTHRITIS RHEUMATOL, V67, P1250, DOI 10.1002/art.39036
   Kondo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079463
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lü JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2728, DOI 10.1016/j.biomaterials.2009.12.029
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Pretzel D, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3320
   Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763
   Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488
   Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919
   Sonomoto K, 2012, ARTHRITIS RHEUM US, V64, P3355, DOI 10.1002/art.34555
   Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68
   Urbán VS, 2008, STEM CELLS, V26, P244, DOI 10.1634/stemcells.2007 0267
   Zhang XM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114621
NR 30
TC 35
Z9 40
U1 0
U2 13
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD JUL AUG
PY 2015
VL 33
IS 4
SU 92
BP S58
EP S62
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CV6BX
UT WOS:000364356800014
PM 26457506
DA 2025 08 17
ER

PT J
AU Mönkkönen, H
   Kuokkanen, J
   Holen, I
   Evans, A
   Lefley, DV
   Jauhiainen, M
   Auriola, S
   Mönkkönen, J
AF Monkkonen, Hannu
   Kuokkanen, Johanna
   Holen, Ingunn
   Evans, Alyson
   Lefley, Diane V.
   Jauhiainen, Marjo
   Auriola, Seppo
   Monkkonen, Jukka
TI Bisphosphonate induced ATP analog formation and its effect on inhibition
   of cancer cell growth
SO ANTI CANCER DRUGS
LA English
DT Article
DE ATP analog; clodronate; metabolism; mevalonate pathway; zoledronic acid
ID ZOLEDRONIC ACID; BONE; BREAST; CLODRONATE; APOPTOSIS; TRANSLOCASE;
   METABOLITES; PRENYLATION; ACTIVATION
AB Bisphosphonates (Bps) are effective inhibitors of tumor induced bone resorption. Recent studies have demonstrated that Bps inhibit growth, attachment and invasion of cancer cells in culture and promote apoptosis. The mechanisms responsible for the observed anti tumor effects of Bps are beginning to be elucidated. Recently, we reported that nitrogen containing bisphosphonates (N BPs) induce formation of a novel ATP analog (Apppl) as a consequence of the inhibition of farnesyl diphosphate synthase in the mevalonate pathway. Similar to AppCp type metabolites of non N BPs, Apppl is able to induce apoptosis. This study investigated BP incluced ATP analog formation and its effect on cancer cell growth. To evaluate zoledronic acid (a N BP) induced Apppl accumulation, inhibition of protein prenylation and clodronate (a non N BP) metabolism to ApPCCl(2)p, MCF 7 and MDA MB 436 breast cancer cells, MCF 10A nonmalignant breast cells, PC 3 prostate cancer cells, MG 63 osteosarcoma cells, RPMI 8226, and NCI H929 myeloma cells were treated with 25 mu mol/l zoledronic acid or 500 mu mol/l clodronate for 24 h. The inhibition of cell growth by zoledronic acid and clodronate was studied in MCF 7, MDA MB 436, and RPMI 8226 cells by exposing cells with 1 100 mu mol/l zoledronic acid or 10 2000 mu mol/l clodronate for 72 h. Marked differences in zoledronic acid induced Apppl formation and clodronate metabolism between the cancer cell lines were observed. The production of cytotoxic ATP analogs in tumor cells after BP treatment is likely to depend on the activity of enzymes, such as farnesyl diphosphate synthase or aminoacyl tRNA synthetases, responsible for ATP analog formation. Additionally, the potency of clodronate to inhibit cancer cell growth corresponds to ATP analog formation. Anti Cancer Drugs 19:391 399 (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Monkkonen, Hannu; Kuokkanen, Johanna; Holen, Ingunn; Evans, Alyson; Lefley, Diane V.; Jauhiainen, Marjo; Auriola, Seppo; Monkkonen, Jukka] Univ Kuopio, Dept Pharmaceut, FIN 70211 Kuopio, Finland.
C3 University of Eastern Finland
RP Mönkkönen, H (通讯作者)，Univ Kuopio, Dept Pharmaceut, POB 1627, FIN 70211 Kuopio, Finland.
EM hannu.monkkonen@uku.fi
OI Holen, Ingunn/0000 0002 8759 6913
CR AMIN D, 1992, J LIPID RES, V33, P1657
   Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Boissier S, 2000, CANCER RES, V60, P2949
   Coleman RE, 2004, BREAST, V13, pS19, DOI 10.1016/j.breast.2004.09.004
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2000, J CHROMATOGR B, V738, P395, DOI 10.1016/S0378 4347(99)00559 9
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
NR 28
TC 63
Z9 69
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959 4973
EI 1473 5741
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD APR
PY 2008
VL 19
IS 4
BP 391
EP 399
PG 9
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 277XC
UT WOS:000254247000007
PM 18454049
DA 2025 08 17
ER

PT J
AU Mi, L
   Li, JC
   Hii, ARK
   Zuo, ZH
   Tang, Y
   Zhou, W
   Wu, ZH
   Qi, XL
AF Mi, Li
   Li, Jiachen
   Hii, Adric Ru Khiing
   Zuo, Zhenhao
   Tang, Ya
   Zhou, Wei
   Wu, Zhenghong
   Qi, Xiaole
TI Dental cementum anchored microspheres embedded in a self healing
   hydrogel for the antibacterial, anti inflammation, osteogenic, and
   anti osteoclastic management of periodontitis disease
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID THERMOSENSITIVE HYDROGELS; TETRACYCLINES; THERAPY
AB Periodontitis, a prevalent chronic oral disease, poses a significant threat to periodontal tissues, often resulting in substantial attachment loss and tooth shedding. Leveraging the principles of bone affinity and the mechanism underlying tetracycline pigmentation of teeth, this study strategically employed tetracycline (TC) as a bone affinity group. We modified TC on the surface of polylactic co glycolic acid copolymer (PLGA) microspheres (MSs) through covalent binding, and then loaded berberine (BBR) MSs into a thermosensitive self healing hydrogel delivery system (BBR/TC MS). It was verified that the BBR/TC MS gel rapidly formed an in situ reservoir in the periodontal pocket upon injection, and the chelation between TC and cementum in the periodontal pocket enhanced the anchoring effect of the TC modified microspheres on cementum, preventing their loss through gingival crevicular fluid. Subsequently, we proved in vitro and in vivo that the BBR/TC MS gel has excellent bacteriostatic effects against the periodontal pathogenic bacteria Fusobacterium necrophorum (Fn), anti inflammation property in periodontal and gingival tissues, and osteogenic effect by regulating the RANKL RANK OPG pathway to diminish osteoclast activity, thus continuously exerting antibacterial, anti inflammatory, osteogenic, and anti osteoclastic effects. This innovative approach holds promise as a targeted and effective strategy for combating multifaceted challenges posed by periodontitis.
   Periodontitis, a prevalent chronic oral disease, poses a significant threat to periodontal tissues, often resulting in substantial attachment loss and tooth shedding.
C1 [Mi, Li; Li, Jiachen; Hii, Adric Ru Khiing; Zuo, Zhenhao; Wu, Zhenghong; Qi, Xiaole] China Pharmaceut Univ, Nanjing 210009, Peoples R China.
   [Tang, Ya] Nanjing Univ, Outpatient Dept 2, Nanjing Stomatol Hosp, Affiliated Hosp,Med Sch,Inst Stomatol, Nanjing, Peoples R China.
   [Qi, Xiaole] China Pharmaceut Univ, Hangzhou Innovat Inst Pharmaceut, Hangzhou 310018, Peoples R China.
   [Zhou, Wei] Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp, Dept Periodont,Inst Stomatol,Med Sch, Nanjing, Peoples R China.
C3 China Pharmaceutical University; Nanjing University; China
   Pharmaceutical University; Nanjing University
RP Wu, ZH; Qi, XL (通讯作者)，China Pharmaceut Univ, Nanjing 210009, Peoples R China.; Zhou, W (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp, Dept Periodont,Inst Stomatol,Med Sch, Nanjing, Peoples R China.
EM 83705@163.com; zhenghongwu66@cpu.edu.cn; qixiaole523@cpu.edu.cn
RI Li, Jiachen/AAC 5526 2019
OI Qi, Xiaole/0000 0002 5799 8604
FU National Natural Science Foundation of China [82373810]
FX This work was supported by the National Natural Science Foundation of
   China (no. 82373810).
CR Cheng C, 2017, CASE REP ENDOCRINOL, V2017, DOI 10.1155/2017/2608392
   Cobb CM, 2021, J PERIODONTOL, V92, P1370, DOI 10.1002/JPER.20 0839
   Eke PI, 2020, PERIODONTOL 2000, V82, P257, DOI 10.1111/prd.12323
   Gittens SA, 2003, PHARMACEUT RES, V20, P978, DOI 10.1023/A:1024445903306
   GREENSTEIN G, 1995, J PERIODONTOL, V66, P925, DOI 10.1902/jop.1995.66.11.925
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Han X, 2018, MAT SCI ENG C MATER, V93, P1064, DOI 10.1016/j.msec.2018.08.064
   Huang HQ, 2019, SAUDI PHARM J, V27, P990, DOI 10.1016/j.jsps.2019.08.001
   Huang WC, 2008, CHINESE CHEM LETT, V19, P19, DOI 10.1016/j.cclet.2007.10.048
   Huang YQ, 2015, WORLD J GASTROENTERO, V21, P4225, DOI 10.3748/wjg.v21.i14.4225
   Jiang YC, 2016, CARBOHYD POLYM, V144, P245, DOI 10.1016/j.carbpol.2016.02.059
   Jin H, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.724525
   JOHNSON RH, 1966, J DENT RES, V45, P86, DOI 10.1177/00220345660450013601
   Katsumi H, 2020, CHEM PHARM BULL, V68, P560, DOI 10.1248/cpb.c20 00017
   Ke CL, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13060904
   Könönen E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081135
   Liang QZ, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1207520
   McKenna AM, 2021, J PERIODONTOL, V92, pE76, DOI 10.1002/JPER.20 0657
   Mesa F, 2019, BBA MOL BASIS DIS, V1865, P476, DOI 10.1016/j.bbadis.2018.12.001
   Nakajima M, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121069
   Niu YT, 2022, NANO TODAY, V45, DOI 10.1016/j.nantod.2022.101529
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Que YD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.993095
   R R. H., 2019, J CONTROL RELEASE, V307, P393
   Ramseier CA, 2017, J CLIN PERIODONTOL, V44, P1182, DOI 10.1111/jcpe.12782
   Sanz M, 2018, J CLIN PERIODONTOL, V45, P138, DOI 10.1111/jcpe.12808
   Shen ZS, 2020, BIOACT MATER, V5, P1113, DOI 10.1016/j.bioactmat.2020.07.002
   Shi NX, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115219
   Wang C, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076364
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Yuan H., 2015, INT J NANOMED, V10, P5671
   Yuan S, 2021, MILITARY MED RES, V8, DOI 10.1186/s40779 021 00344 1
   Zeng J, 2023, ASIAN J PHARM SCI, V18, DOI 10.1016/j.ajps.2023.100799
   Zeng J, 2021, EUR POLYM J, V160, DOI 10.1016/j.eurpolymj.2021.110808
   Zhang WJ, 2018, BIOMATERIALS, V181, P378, DOI 10.1016/j.biomaterials.2018.07.051
   Zhang YB, 2019, BIOMACROMOLECULES, V20, P1478, DOI 10.1021/acs.biomac.9b00043
   Zheng HY, 2023, J MATER CHEM B, V11, P7321, DOI 10.1039/d3tb00835e
NR 38
TC 2
Z9 2
U1 8
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD OCT 9
PY 2024
VL 12
IS 39
BP 9947
EP 9962
DI 10.1039/d4tb00579a
EA JUL 2024
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA I2T5T
UT WOS:001279947500001
PM 39072701
DA 2025 08 17
ER

PT J
AU Souza, L
   Ferreira, FV
   Lopes, JH
   Camilli, JA
   Martin, RA
AF Souza, Lucas
   V. Ferreira, Filipe
   Lopes, Joao H.
   Camilli, Jose Angelo
   Martin, Richard A. .
TI Cancer Inhibition and In Vivo Osteointegration and Compatibility of
   Gallium Doped Bioactive Glasses for Osteosarcoma Applications
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Early Access
DE bioglass; gallium; biocompatibility; in vivo regeneration; in vitro
   toxicity; bone cancer
ID STRUCTURAL CHARACTERIZATION; PERFORMANCE; IRON
AB Traditional osteosarcoma therapies tend to focus solely on eradicating residual cancer cells and often fail to promote local bone regeneration and even inhibit it due to lack of precise control over target cells, i.e., the treatment affects both normal and cancer cells. Typically, multistep procedures are required for optimal efficacy. Here, we found that a silica based bioactive material containing 3 mol % gallium oxide selectively kills human osteosarcoma cells and presents excellent in vivo osteointegration, while showing no local or systemic toxicity. Cell culture media conditioned with the proposed material was able to kill 41% of osteosarcoma cells, and no significant deleterious effect on normal human osteoblasts was observed. In addition, rats treated with the gallium doped material showed excellent material bone integration with no sign of local toxicity or implant rejection. Systemic biocompatibility investigation did not indicate any sign of toxicity, with no presence of fibrosis or cellular infiltrate in the histological microstructure of the liver and kidneys after 56 days of observation. Taken together, these results show that synergistic bone regeneration and targeted cancer therapy can be combined, paving the way toward new bone cancer treatment approaches.
C1 [V. Ferreira, Filipe] Embrapa Instrumentat, Nanotechnol Natl Lab Agr, BR 13560970 Sao Carlos, Brazil.
   [Lopes, Joao H.] Aeronaut Inst Technol, Dept Chem, BR 12228900 Sao Paulo, Brazil.
   [Camilli, Jose Angelo] Univ Estadual Campinas, Dept Funct & Struct Biol, BR 13083970 Campinas, Brazil.
   [Souza, Lucas; Martin, Richard A. .] Aston Univ, Engn Hlth Res Ctr, Coll Engn & Phys Sci, Birmingham B4 7ET, England.
C3 Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade
   Estadual de Campinas; Aston University
RP Souza, L; Martin, RA (通讯作者)，Aston Univ, Engn Hlth Res Ctr, Coll Engn & Phys Sci, Birmingham B4 7ET, England.
EM souzal@aston.ac.uk; r.a.martin@aston.ac.uk
RI Camilli, José Angelo/GZG 3550 2022; Ferreira, Fernanda/F 8377 2015;
   Martin, Richard/AAG 9489 2020
OI Pereira Lopes de Souza, Lucas/0000 0002 0188 5168; Martin,
   Richard/0000 0002 6013 2334; Camilli, Jose Angelo/0000 0002 8519 3926; 
FU Brazilian National Council for Scientific and Technological
   Development CNPq; Brazilian Nanotechnology National Laboratory (LNNano)
   , part of the Brazilian Centre for Research in Energy and Materials
   (CNPEM); Brazilian Ministry for Science, Technology, and Innovations
   (MCTI); Sao Paulo Research Foundation (FAPESP);  [436164/2018 3]; 
   [2020/07956 6]
FX The authors are grateful for the financial support provided by the
   Brazilian National Council for Scientific and Technological
   Development CNPq (Grant 436164/2018 3) and from the Sao Paulo Research
   Foundation (FAPESP; Grant 2020/07956 6) . This research used facilities
   of the Brazilian Nanotechnology National Laboratory (LNNano) , part of
   the Brazilian Centre for Research in Energy and Materials (CNPEM) , a
   private nonprofit organization under the supervision of the Brazilian
   Ministry for Science, Technology, and Innovations (MCTI) . The AFM, XPS,
   ? CT, and SEM staff is acknowledged for the assistance during the
   experiments (AFM 24109, 20220394, and SEM 23261) . In addition, the
CR Aguiar H, 2009, J NON CRYST SOLIDS, V355, P475, DOI 10.1016/j.jnoncrysol.2009.01.010
   Bishop MW, 2016, CURR OPIN PEDIATR, V28, P26, DOI 10.1097/MOP.0000000000000298
   Bosch Rué E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.614545
   Boyd A, 2020, FRONTLINE GASTROENTE, V11, P40, DOI 10.1136/flgastro 2018 101139
   Cerruti M, 2005, J PHYS CHEM B, V109, P14496, DOI 10.1021/jp050705t
   Cerruti M, 2005, BIOMATERIALS, V26, P1665, DOI 10.1016/j.biomaterials.2004.07.009
   Chitambar CR, 2017, PHARMACOL RES, V115, P56, DOI 10.1016/j.phrs.2016.11.009
   Chitambar CR, 2016, BBA MOL CELL RES, V1863, P2044, DOI 10.1016/j.bbamcr.2016.04.027
   Chitambar CR, 2010, INT J ENV RES PUB HE, V7, P2337, DOI 10.3390/ijerph7052337
   Christodoulou I, 2005, J BIOMED MATER RES B, V74B, P529, DOI 10.1002/jbm.b.30249
   Collery P, 1996, ANTICANCER RES, V16, P687
   Collery P, 2002, CRIT REV ONCOL HEMAT, V42, P283, DOI 10.1016/S1040 8428(01)00225 6
   de Souza UPL, 2020, J BIOMED MATER RES A, V108, P446, DOI 10.1002/jbm.a.36826
   Ferreira FV, 2021, MAT SCI ENG C MATER, V123, DOI 10.1016/j.msec.2020.111853
   Ferreira FV, 2019, NANOSCALE, V11, P19842, DOI 10.1039/c9nr05383b
   Gómez Cerezo N, 2018, ACTA BIOMATER, V76, P333, DOI 10.1016/j.actbio.2018.06.036
   Gupta S, 2021, J CONTROL RELEASE, V335, P481, DOI 10.1016/j.jconrel.2021.05.043
   Heidari R., 2021, SCI REP UK, V11, P1
   Hench LL, 2006, J MATER SCI MATER M, V17, P967, DOI 10.1007/s10856 006 0432 z
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Keenan TJ, 2016, CARBOHYD POLYM, V153, P482, DOI 10.1016/j.carbpol.2016.07.100
   Koenig G, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/818570
   Kolahdoozan Shadi, 2020, Middle East J Dig Dis, V12, P194, DOI 10.34172/mejdd.2020.182
   Koudrine AV, 1998, J TRACE ELEM MED BIO, V12, P65, DOI 10.1016/S0946 672X(98)80028 X
   Kurtuldu F, 2021, MAT SCI ENG C MATER, V124, DOI 10.1016/j.msec.2021.112050
   Lopes JH, 2020, J BIOMED MATER RES B, V108, P1372, DOI 10.1002/jbm.b.34486
   Michels WM, 2010, CLIN J AM SOC NEPHRO, V5, P1003, DOI 10.2215/CJN.06870909
   Nesbitt HW, 2011, J NON CRYST SOLIDS, V357, P170, DOI 10.1016/j.jnoncrysol.2010.09.031
   Perardi A, 2005, STUD SURF SCI CATAL, V155, P461
   Pourshahrestani S, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aa9b3e
   Pourshahrestani S, 2017, ACS APPL MATER INTER, V9, P31381, DOI 10.1021/acsami.7b07769
   Pourshahrestani S, 2016, J MATER CHEM B, V4, P71, DOI 10.1039/c5tb02062j
   Prudowsky ZD, 2021, CANCERS, V13, DOI 10.3390/cancers13010083
   Raja FNS, 2022, ACS BIOMATER SCI ENG, V8, P1193, DOI 10.1021/acsbiomaterials.1c00876
   Rana KS, 2017, ACS BIOMATER SCI ENG, V3, P3425, DOI 10.1021/acsbiomaterials.7b00283
   Robles Diaz M, 2015, LIVER INT, V35, P2474, DOI 10.1111/liv.12834
   Souza L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31114 0
   Strazic Geljic I, 2016, BIOCHEM PHARMACOL, V116, P11, DOI 10.1016/j.bcp.2016.06.020
   Takemura K, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10040549
   Tilocca A, 2010, LANGMUIR, V26, P545, DOI 10.1021/la902548f
   Wajda A, 2018, CERAM INT, V44, P22698, DOI 10.1016/j.ceramint.2018.09.051
   Wang MQ, 2021, J MATER CHEM B, V9, P4735, DOI 10.1039/d1tb00387a
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Yazdi AR, 2018, J BIOMED MATER RES B, V106, P1186, DOI 10.1002/jbm.b.33930
   Zareidoost A, 2012, J MATER SCI MATER M, V23, P1479, DOI 10.1007/s10856 012 4611 9
   Zhao YY, 2008, J RAMAN SPECTROSC, V39, P1494, DOI 10.1002/jrs.2028
   Zivojevic K, 2021, J CONTROL RELEASE, V337, P193, DOI 10.1016/j.jconrel.2021.07.029
   Zuo YG, 2008, ANAL SCI, V24, P1589, DOI 10.2116/analsci.24.1589
NR 49
TC 22
Z9 22
U1 2
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD 2022 SEP 28
PY 2022
DI 10.1021/acsami.2c12102
EA SEP 2022
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA 5B6EM
UT WOS:000863660800001
PM 36170227
OA Green Published, hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, SY
   Ma, JY
   Liu, J
   Liu, C
   Ni, S
   Dai, T
   Wang, Y
   Weng, YP
   Zhao, HB
   Zhou, D
   Zhao, XB
AF Wu, Siyu
   Ma, Jiayi
   Liu, Jun
   Liu, Chun
   Ni, Su
   Dai, Ting
   Wang, Yan
   Weng, Yiping
   Zhao, Hongbin
   Zhou, Dong
   Zhao, Xiubo
TI Immunomodulation of Telmisartan Loaded PCL/PVP Scaffolds on Macrophages
   Promotes Endogenous Bone Regeneration
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE telmisartan; electrospinning immunomodulation; macrophage polarization;
   osteogenesis
ID MESENCHYMAL STEM CELLS; TISSUE ENGINEERING APPLICATIONS;
   CONTROLLED RELEASE; IN VIVO; OSTEOBLAST DIFFERENTIATION; DRUG DELIVERY;
   PCL SCAFFOLDS; TNF ALPHA; OSTEOGENESIS; POLARIZATION
AB Biomaterial immune system interactions play an important role in postimplantation osseointegration to retain the functionality of healthy and intact bones. Therefore, appropriate osteoimmunomodulation of implants has been considered and validated as an efficient strategy to alleviate inflammation and enhance new bone formation. Here, we fabricated a nanostructured PCL/PVP (polycaprolactone/polyvinylpyrrolidone) electrospinning scaffold for cell adhesion, tissue ingrowth, and bone defect padding. In addition, telmisartan, an angiotensin 2 receptor blocker with distinct immune bioactivity, was doped into PCL /PVP electrospun scaffolds at different proportions [1% (TPP 1), 5% (TPP 5), and 10% (TPP 10)] to investigate its immunomodulatory effects and osteoinductivity/conductivity. Telmisartan loaded scaffolds displayed in vitro anti inflammatory bioactivity on lipopolysaccharide induced M1 macrophages by polarizing them to an M2 like phenotype and exhibited pro osteogenic properties on bone marrow derived mesenchymal stem cells (BMSCs). Histological analysis and micro CT results of a rat skull defect model also showed that the telmisartan loaded scaffolds induced a higher M2/M1 ratio, less inflammatory infiltration, and better bone regenerative patterns. Furthermore, activation of the BMP2 (bone morphogenetic protein 2) Smad signaling pathway was found to be dominant in telmisartan loaded scaffold mediated macrophage BMSC interactions. These findings indicate that telmisartan incorporation with PCL/PVP nanofibrous scaffolds is a potential therapeutic strategy for promoting bone healing by modulating M1 macrophages to a more M2 phenotype at early stages of postimplantation.
C1 [Wu, Siyu; Ma, Jiayi; Liu, Jun; Liu, Chun; Ni, Su; Dai, Ting; Wang, Yan; Weng, Yiping; Zhao, Hongbin; Zhou, Dong] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Changzhou 213164, Peoples R China.
   [Zhao, Xiubo] Changzhou Univ, Sch Pharm, Changzhou 213164, Peoples R China.
   [Zhao, Xiubo] Univ Sheffield, Dept Chem & Biol Engn, Sheffield S1 3JD, S Yorkshire, England.
C3 Nanjing Medical University; Changzhou University; University of
   Sheffield
RP Zhao, HB; Zhou, D (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Changzhou 213164, Peoples R China.; Zhao, XB (通讯作者)，Changzhou Univ, Sch Pharm, Changzhou 213164, Peoples R China.; Zhao, XB (通讯作者)，Univ Sheffield, Dept Chem & Biol Engn, Sheffield S1 3JD, S Yorkshire, England.
EM zhao761032@163.com; zhoudong1012@163.com; xiubo.zhao@sheffield.ac.uk
RI Wu, Siyu/JHU 8376 2023; Zhao, Xiubo/AAZ 9058 2021; Zhao,
   Hongbin/A 4166 2019; Ni, Su/KOX 1297 2024
OI chun, liu/0000 0001 9875 0544; Zhao, Xiubo/0000 0002 4620 2893; 
FU Key Project of Science and Technology of Jiangsu Province [BE2018644];
   Science and Technology Support Plan of Changzhou city (Social
   Development) [CE20185047]; Changzhou SciTech Program [CJ20210102]; EPSRC
   [EP/N007174/1, EP/N023579/1]; Jiangsu, a specially appointed professor
   program; EPSRC [EP/N023579/1, EP/N007174/1] Funding Source: UKRI;
   Engineering and Physical Sciences Research Council [EP/N023579/1,
   EP/N007174/1] Funding Source: researchfish
FX The authors would like to thank the Key Project of Science and
   Technology of Jiangsu Province (BE2018644), the Science and Technology
   Support Plan of Changzhou city (Social Development) (CE20185047), the
   Changzhou Sci&Tech Program (CJ20210102), the EPSRC (EP/N007174/1 and
   EP/N023579/1), and Jiangsu, a specially appointed professor program for
   support.
CR Abalymov AA, 2021, ADV MATER INTERFACES, V8, DOI 10.1002/admi.202002202
   Abedalwafa M, 2013, REV ADV MATER SCI, V34, P123
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Ardeshirylajimi A, 2015, CELL PROLIFERAT, V48, P455, DOI 10.1111/cpr.12198
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Azi ML, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1312 4
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Barth KA, 2013, J BIOMED MATER RES A, V101, P2679, DOI 10.1002/jbm.a.34562
   Brown BN, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00510
   Brown BN, 2012, BIOMATERIALS, V33, P3792, DOI 10.1016/j.biomaterials.2012.02.034
   Brown BN, 2012, ACTA BIOMATER, V8, P978, DOI 10.1016/j.actbio.2011.11.031
   Chan LW, 2003, CHEM PHARM BULL, V51, P107, DOI 10.1248/cpb.51.107
   Chu CY, 2020, J BIOMED MATER RES A, V108, P127, DOI 10.1002/jbm.a.36798
   Chung CC, 2020, LAB INVEST, V100, P285, DOI 10.1038/s41374 019 0341 7
   Coates BA, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115737
   Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064
   Di Filippo C, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/972761
   Dinescu S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205077
   Duan J, 2018, REPROD BIOMED ONLINE, V37, P254, DOI 10.1016/j.rbmo.2018.05.017
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Fernandes TL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00111
   Fichtner Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Gautam S, 2013, MAT SCI ENG C MATER, V33, P1228, DOI 10.1016/j.msec.2012.12.015
   Gong L, 2016, ANN CLIN LAB SCI, V46, P65
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Hotchkiss KM, 2016, ACTA BIOMATER, V31, P425, DOI 10.1016/j.actbio.2015.12.003
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Jain N, 2019, ANNU REV BIOMED ENG, V21, P267, DOI 10.1146/annurev bioeng 062117 121224
   Jeon EJ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 38399 1
   Jetten N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102994
   Ji HZ, 2021, ACTA BIOMATER, V135, P274, DOI 10.1016/j.actbio.2021.08.050
   Kempny T, 2019, MICROSURG, V39, P476, DOI 10.1002/micr.30441
   Klopfleisch R, 2016, ACTA BIOMATER, V43, P3, DOI 10.1016/j.actbio.2016.07.003
   Knipper JA, 2015, IMMUNITY, V43, P803, DOI 10.1016/j.immuni.2015.09.005
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Lee J, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801106
   Lee J, 2012, BIOMATERIALS, V33, P6709, DOI 10.1016/j.biomaterials.2012.06.017
   Li MT, 2020, MAT SCI ENG C MATER, V109, DOI 10.1016/j.msec.2019.110508
   Li RT, 2018, J BIOMED NANOTECHNOL, V14, P321, DOI 10.1166/jbn.2018.2485
   Lian CJ, 2016, J PINEAL RES, V61, P317, DOI 10.1111/jpi.12349
   Luo Y, 2021, AAPS PHARMSCITECH, V22, DOI 10.1208/s12249 020 01909 4
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Marins NH, 2019, COLLOID SURFACE B, V182, DOI 10.1016/j.colsurfb.2019.110386
   Matsumura T, 2011, ARTERIOSCL THROM VAS, V31, P1268, DOI 10.1161/ATVBAHA.110.222067
   McGovern JA, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033084
   Michalski MN, 2017, PHARMACOL THERAPEUT, V174, P43, DOI 10.1016/j.pharmthera.2017.02.017
   Miron RJ, 2016, BIOMATERIALS, V82, P1, DOI 10.1016/j.biomaterials.2015.12.017
   Miroshnichenko S, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9040637
   Mokarram N, 2012, BIOMATERIALS, V33, P8793, DOI 10.1016/j.biomaterials.2012.08.050
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev physiol 022516 034339
   Nawaz A, 2019, J DIABETES INVEST, V10, P1394, DOI 10.1111/jdi.13114
   Nematollahi E, 2021, INT J BIOL MACROMOL, V183, P600, DOI 10.1016/j.ijbiomac.2021.04.160
   Oh SH, 2007, BIOMATERIALS, V28, P1664, DOI 10.1016/j.biomaterials.2006.11.024
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Philipp D, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1039 2
   Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017
   Ranganathan S, 2019, INT J BIOL MACROMOL, V133, P354, DOI 10.1016/j.ijbiomac.2019.04.115
   Reeves ARD, 2015, BIOMATERIALS, V73, P272, DOI 10.1016/j.biomaterials.2015.09.027
   Reynolds JJ, 2016, SPINE, V41, pS199, DOI 10.1097/BRS.0000000000001834
   Ribba L, 2014, J BIOMED NANOTECHNOL, V10, P3508, DOI 10.1166/jbn.2014.2046
   Roffi A, 2017, INT ORTHOP, V41, P221, DOI 10.1007/s00264 016 3342 9
   Rosario BH, 2008, EXPERT OPIN DRUG MET, V4, P485, DOI 10.1517/17425255.4.4.485 
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Sharpe M, 2001, DRUGS, V61, P1501, DOI 10.2165/00003495 200161100 00009
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Siddiqui N, 2018, MOL BIOTECHNOL, V60, P506, DOI 10.1007/s12033 018 0084 5
   Sigrist B, 2020, AM J SPORT MED, V48, P1857, DOI 10.1177/0363546520919958
   Sohn JM, 2018, J ARTHROPLASTY, V33, P2465, DOI 10.1016/j.arth.2018.02.082
   Sok MCP, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120475
   Sousa I, 2013, PROCEDIA ENGINEER, V59, P279, DOI 10.1016/j.proeng.2013.05.122
   Spiller KL, 2015, BIOMATERIALS, V37, P194, DOI 10.1016/j.biomaterials.2014.10.017
   Spiller KL, 2014, BIOMATERIALS, V35, P4477, DOI 10.1016/j.biomaterials.2014.02.012
   Sun K, 2011, EXPRESS POLYM LETT, V5, P342, DOI 10.3144/expresspolymlett.2011.34
   Teodorescu M, 2019, BIOTECHNOL ADV, V37, P109, DOI 10.1016/j.biotechadv.2018.11.008
   Truong T, 2018, J BIOMED MATER RES A, V106, P2424, DOI 10.1002/jbm.a.36436
   Wang CY, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109833
   Wang JJ, 2018, INT J NANOMED, V13, P4029, DOI 10.2147/IJN.S163956
   Wang Q, 2015, J CONTROL RELEASE, V206, P232, DOI 10.1016/j.jconrel.2015.03.019
   Xiao L, 2012, FRONT BIOSCI LANDMRK, V17, P2667, DOI 10.2741/4077
   Xu ZK, 2018, CARBOHYD POLYM, V197, P237, DOI 10.1016/j.carbpol.2018.06.004
   Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158
   Yu XR, 2018, EXP CELL RES, V372, P178, DOI 10.1016/j.yexcr.2018.09.024
   Zha Y, 2021, THERANOSTICS, V11, P397, DOI 10.7150/thno.50741
   Zhang CY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7404038
   Zhang JK, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12907
   Zhao DW, 2021, MAT SCI ENG C MATER, V118, DOI 10.1016/j.msec.2020.111512
   Zheng ZW, 2018, THERANOSTICS, V8, P5482, DOI 10.7150/thno.28315
   Zhu WM, 2016, ARTIF CELL NANOMED B, V44, P1122, DOI 10.3109/21691401.2015.1011804
NR 91
TC 26
Z9 30
U1 4
U2 83
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD APR 13
PY 2022
VL 14
IS 14
BP 15942
EP 15955
DI 10.1021/acsami.1c24748
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA 1N3AY
UT WOS:000800533100007
PM 35353482
DA 2025 08 17
ER

PT J
AU Pineda, B
   Hermenegildo, C
   Tarín, JJ
   Cano, A
   García Pérez, MA
AF Pineda, Begona
   Hermenegildo, Carlos
   Tarin, Juan J.
   Cano, Antonio
   Angel Garcia Perez, Miguel
TI Effects of administration of hormone therapy or raloxifene on the immune
   system and on biochemical markers of bone remodeling
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Antiresorptive therapies; Immune system; Postmenopausal women;
   Raloxifene; Hormone therapy
ID TUMOR NECROSIS FACTOR; POSTMENOPAUSAL WOMEN; T CELLS; OSTEOCLAST
   DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; ESTROGEN REPLACEMENT; SURGICAL
   MENOPAUSE; IN VITRO; RECEPTOR; TURNOVER
AB Objective: Over the last few years, conclusive evidence of the involvement of the immune system in the regulation of bone metabolism has been identified. Consequently, one question that should be formulated concerns the possible effects of antiresorptive therapies on the immune system. Therefore, the purpose of the present work was to evaluate both the functionality of the immune system and bone turnover in women receiving antiresorptive therapies, such as hormone therapy (HT; n = 33) and raloxifene (RLX; n = 66), acting through estrogen receptors.
   Methods: To that end, this study analyzed bone turnover markers in a population of postmenopausal women before and after beginning therapy and compared these with data of women not treated (NT; n = 102). In a subgroup of participants (NT = 33, RLX = 24, and HT = 26), we analyzed the effects of treatments on immune system parameters such as serum levels of interleukin (IL) 6, tumor necrosis factor alpha, and IL 1 beta; lymphocyte sub populations; cell proliferation by peripheral blood mononuclear cells (PBMCs); in vitro production of IL 1 beta by PBMCs; and the expression of receptor activator of nuclear factor kappa B ligand, transforming growth factor beta, and IL 4 genes by PBMCs.
   Results: The results showed that bone resorption was inhibited strongly in women in the RLX and HT groups when compared with women in the NT group. Interestingly, the administration of RLX inhibited the production of the Wnt/beta catenin signaling pathway inhibitor Dickkopf Homolog 1 (P < 0.05) and tended to increase the levels of the osteoclastogenesis inhibitor osteoprotegerin at month 6 (P = 0.059). With regard to the immune system, the different treatments did not markedly perturb the parameters analyzed, with the exception of the increase in serum IL 1 beta detected in the HT group at month 6 (P < 0.05).
   Conclusions: The main conclusions of the present work were that HT or RLX do not disturb the immune system and that both treatments have a similar antiresorptive power.
C1 [Angel Garcia Perez, Miguel] Univ Valencia, Dept Genet, E 46100 Valencia, Spain.
   [Hermenegildo, Carlos] Univ Valencia, Dept Physiol, E 46100 Valencia, Spain.
   [Tarin, Juan J.] Univ Valencia, Dept Funct Biol & Phys Anthropol, E 46100 Valencia, Spain.
   [Cano, Antonio] Univ Valencia, Dept Pediat Obstet & Gynecol, E 46100 Valencia, Spain.
   [Pineda, Begona; Angel Garcia Perez, Miguel] INCLIVA, Hosp Clin Univ, Res Fdn, Valencia, Spain.
C3 University of Valencia; University of Valencia; University of Valencia;
   University of Valencia
RP García Pérez, MA (通讯作者)，Univ Valencia, Dept Genet, C Dr Moliner 50, E 46100 Valencia, Spain.
EM migarpe@uv.es
RI Hermenegildo, Carlos/C 5995 2008; Garcia Perez, Miguel
   Angel/S 8090 2018; Fernández Cano, Antonio/B 7376 2008
OI Garcia Perez, Miguel Angel/0000 0002 0626 7502; Hermenegildo,
   Carlos/0000 0002 4015 2645; Tarin, Juan J./0000 0002 4436 5162
FU Conselleria d'Empresa [GV05/141]; Universitat i Ciencia (Generalitat
   Valenciana) [EVES 045 2007]; Instituto Carlos III (Ministerio de Ciencia
   e Innovacion, Madrid, Spain) [PS09/00184, PS09/01687]; Eli Lilly; Fondo
   de Investigacion Sanitaria Conselleria de Sanitat (Generalitat
   Valenciana)
FX This work was supported by grants GV05/141 from Conselleria d'Empresa,
   Universitat i Ciencia (Generalitat Valenciana), EVES 045 2007, and
   PS09/00184 and PS09/01687 from Instituto Carlos III (Ministerio de
   Ciencia e Innovacion, Madrid, Spain). Dr. Cano reports having received
   lecture fees from Eli Lilly. Dr. Garcia Perez was a recipient of a
   research contract from Fondo de Investigacion Sanitaria Conselleria de
   Sanitat (Generalitat Valenciana) during the performance of this work.
   All the other authors have nothing to declare.
CR Abrahamsen B, 1997, BONE, V20, P251, DOI 10.1016/S8756 3282(96)00384 5
   Alnaeeli M, 2007, J BONE MINER RES, V22, P775, DOI 10.1359/JBMR.070314
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Breuil V, 2010, OSTEOPOROSIS INT, V21, P805, DOI 10.1007/s00198 009 1018 7
   Brooks Asplund EM, 2002, CYTOKINE, V19, P193, DOI 10.1006/cyto.2002.1963
   Chaki O, 2000, J BONE MINER RES, V15, P1537, DOI 10.1359/jbmr.2000.15.8.1537
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   DEWHIRST FE, 1985, J IMMUNOL, V135, P2562
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Effros RB, 2003, CRIT REV IMMUNOL, V23, P45, DOI 10.1615/CritRevImmunol.v23.i12.30
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   García Pérez MA, 2006, INT J IMMUNOPATH PH, V19, P807, DOI 10.1177/039463200601900410
   García Pérez MA, 2006, HUM REPROD, V21, P880, DOI 10.1093/humrep/dei413
   García Pérez MA, 2004, CALCIFIED TISSUE INT, V74, P143, DOI 10.1007/s00223 003 0054 0
   Gianni W, 2004, J CLIN ENDOCR METAB, V89, P6097, DOI 10.1210/jc.2004 0795
   Grubeck Loebenstein B, 2002, ADV IMMUNOL, V80, P243, DOI 10.1016/S0065 2776(02)80017 7
   Heaney RP, 1997, J CLIN ENDOCR METAB, V82, P3425, DOI 10.1210/jc.82.10.3425
   HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   John V, 1996, ENDOCRINOLOGY, V137, P2457, DOI 10.1210/en.137.6.2457
   Kim JG, 2008, MENOPAUSE, V15, P357, DOI 10.1097/gme.0b013e318133a153
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Ku Lowell T, 2009, Immun Ageing, V6, P1, DOI 10.1186/1742 4933 6 1
   Kumru S, 2004, J REPROD IMMUNOL, V63, P31, DOI 10.1016/j.jri.2004.02.001
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Liu PY, 2005, J CLIN ENDOCR METAB, V90, P1953, DOI 10.1210/jc.2004 1583
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lufkin EG, 1998, J BONE MINER RES, V13, P1747, DOI 10.1359/jbmr.1998.13.11.1747
   Messalli EM, 2007, MATURITAS, V56, P38, DOI 10.1016/j.maturitas.2006.05.007
   Onoe Y, 2000, J BONE MINER RES, V15, P541, DOI 10.1359/jbmr.2000.15.3.541
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pineda B, 2011, OSTEOPOROSIS INT, V22, P1451, DOI 10.1007/s00198 010 1324 0
   Prestwood KM, 2000, J CLIN ENDOCR METAB, V85, P2197, DOI 10.1210/jc.85.6.2197
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rogers A, 2007, BONE, V40, P105, DOI 10.1016/j.bone.2006.07.011
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Uebelhart B, 2004, J BONE MINER RES, V19, P1518, DOI 10.1359/JBMR.040503
   Weinstein RS, 2003, OSTEOPOROSIS INT, V14, P814, DOI 10.1007/s00198 003 1434 z
   Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068
   Yasui T, 2009, ATHEROSCLEROSIS, V204, P471, DOI 10.1016/j.atherosclerosis.2008.09.014
   Yun TJ, 2001, J IMMUNOL, V166, P1482, DOI 10.4049/jimmunol.166.3.1482
NR 45
TC 7
Z9 9
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1072 3714
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD MAR
PY 2012
VL 19
IS 3
BP 319
EP 327
DI 10.1097/gme.0b013e3182310a98
PG 9
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 899ZA
UT WOS:000300854000013
PM 22067277
DA 2025 08 17
ER

PT J
AU Zhao, M
   Zhao, Z
   Koh, JT
   Jin, TC
   Franceschi, RT
AF Zhao, M
   Zhao, Z
   Koh, JT
   Jin, TC
   Franceschi, RT
TI Combinatorial gene therapy for bone regeneration: Cooperative
   interactions between adenovirus vectors expressing bone morphogenetic
   proteins 2, 4, and 7
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BNAP; bone regeneration
ID FACTOR BETA SUPERFAMILY; IN VIVO; OSTEOGENIC PROTEIN 1; CELL LINE;
   OSTEOBLASTIC DIFFERENTIATION; SIGNAL TRANSDUCTION; C2C12 MYOBLASTS;
   FRACTURE REPAIR; BMP 2 GENE; RECEPTORS
AB Bone morphogenetic proteins (BMPs) have demonstrated effectiveness as bone regeneration agents whether delivered as recombinant proteins or via gene therapy. Current gene therapy approaches use vectors expressing single BMPs. In contrast, multiple BMPs are coordinately expressed during bone development and fracture healing. Furthermore, BMPs likely exist in vivo as heterodimeric molecules having enhanced biological activity. In the present study, we test the hypothesis that gene therapy based bone regeneration can be enhanced by expressing combinations of BMPs. For in vitro Studies, mesenchymal cell lines were transduced with individual adenoviruses containing BMP2, 4, or 7 cDNA undercontrol of a CMV promoter (AdBMP2, 4, 7) or virus combinations. Significantly, combined transduction with AdBMP2 plus AdBMP7 or AdBMP4 plus AdBMP7 resulted in a synergistic stimulation of osteoblast differentiation. This synergy is best explained by formation of BMP2/7 and 4/7 heterodimers. To test in vivo biological activity, fibroblasts were transduced with specific virus combinations and implanted into C57BL6 mice. Consistent with in vitro results, strong synergy was observed using combined AdBMP2/BMP7 treatment, which induced twofold to threefold more bone than would be predicted based on the activity of individual AdBMPs. These studies show that dramatic enhancement of osteogenesis can be achieved using gene therapy to express specific combinations of interacting regenerative molecules. (c) 2005 Wiley Liss, Inc.
C1 Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA.
   Univ Michigan, Ctr Craniofacial Regenerat, Ann Arbor, MI USA.
   Chonnam Natl Univ, Kwangju, South Korea.
   Univ Michigan, Sch Dent, Mol Biol Core Lab, Ann Arbor, MI USA.
   Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Chonnam National University;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM rennyf@umich.edu
RI Jin, Taicheng/JJF 1088 2023
FU NCI NIH HHS [R24 CA83099] Funding Source: Medline; NIAMS NIH HHS
   [P30 AR46024] Funding Source: Medline; NIDCR NIH HHS [DE11723, DE13386,
   DE12211] Funding Source: Medline
CR Aoki H, 2001, J CELL SCI, V114, P1483
   AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712
   Baltzer AWA, 2000, GENE THER, V7, P734, DOI 10.1038/sj.gt.3301166
   Baltzer AWA, 2000, CLIN ORTHOP RELAT R, pS120
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Cochran DI, 2000, J PERIODONTOL, V71, P1241, DOI 10.1902/jop.2000.71.8.1241
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Franceschi RT, 2004, CELLS TISSUES ORGANS, V176, P95, DOI 10.1159/000075031
   Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097 4644(20000901)78:3<476::AID JCB12>3.0.CO;2 5
   Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301 620X.81B4.9311
   Giannobile WV, 1998, J PERIODONTOL, V69, P129, DOI 10.1902/jop.1998.69.2.129
   Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245
   Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842 1849.1997
   HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578
   HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003 2697(81)90082 8
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006 291X(05)80208 6
   KATAGIRI T, 1995, J CELL BIOL, V128, P713
   King GN, 1997, J DENT RES, V76, P1460, DOI 10.1177/00220345970760080801
   Kirker Head CA, 2000, ADV DRUG DELIVER REV, V43, P65, DOI 10.1016/S0169 409X(00)00078 8
   Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925 4773(94)00326 I
   MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115
   Mason JM, 1998, GENE THER, V5, P1098, DOI 10.1038/sj.gt.3300703
   Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290
   Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046
   Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925 4773(98)00070 7
   Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   Otsuka E, 1999, AM J PHYSIOL CELL PH, V277, pC132, DOI 10.1152/ajpcell.1999.277.1.C132
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Riew KD, 1998, CALCIFIED TISSUE INT, V63, P357, DOI 10.1007/s002239900540
   Rutherford RB, 2002, TISSUE ENG, V8, P441, DOI 10.1089/107632702760184709
   SAMPATH TK, 1990, J BIOL CHEM, V265, P13198
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092 8674(79)90317 9
   TENDIJKE P, 1994, J BIOL CHEM, V269, P16985
   Winn SR, 2000, ADV DRUG DELIVER REV, V42, P121, DOI 10.1016/S0169 409X(00)00057 0
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
   YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Zhou SH, 2004, J BONE MINER RES, V19, P1732, DOI 10.1359/JBMR.040702
   Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821
NR 53
TC 102
Z9 120
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY 1
PY 2005
VL 95
IS 1
BP 1
EP 16
DI 10.1002/jcb.20411
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 921DI
UT WOS:000228744000001
PM 15759283
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Deev, RV
   Drobyshev, AY
   Bozo, IY
   Isaev, AA
AF Deev, R. V.
   Drobyshev, A. Y.
   Bozo, I. Y.
   Isaev, A. A.
TI Ordinary and Activated Bone Grafts: Applied Classification and the Main
   Features
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; MESENCHYMAL STEM CELLS; ANGIOGENESIS
   IN VITRO; MARROW STROMAL CELLS; GENE THERAPY; MORPHOGENETIC PROTEIN 2;
   OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; BETA TCP;
   TRANSFORMING GROWTH FACTOR BETA 1
AB Bone grafts are medical devices that are in high demand in clinical practice for substitution of bone defects and recovery of atrophic bone regions. Based on the analysis of the modern groups of bone grafts, the particularities of their composition, the mechanisms of their biological effects, and their therapeutic indications, applicable classification was proposed that separates the bone substitutes into "ordinary" and "activated." The main differential criterion is the presence of biologically active components in the material that are standardized by qualitative and quantitative parameters: growth factors, cells, or gene constructions encoding growth factors. The pronounced osteoinductive and (or) osteogenic properties of activated osteoplastic materials allow drawing upon their efficacy in the substitution of large bone defects.
C1 [Deev, R. V.; Bozo, I. Y.; Isaev, A. A.] Human Stem Cells Inst, Moscow 199333, Russia.
   [Deev, R. V.] Kazan Volga Reg Fed Univ, Dept Morphol & Gen Pathol, Kazan 420008, Russia.
   [Drobyshev, A. Y.; Bozo, I. Y.] AI Evdokimov Moscow State Univ Med & Dent, Dept Maxillofacial & Plast Surg, Moscow 127473, Russia.
   [Bozo, I. Y.] AI Burnasyan Fed Med Biophys Ctr, Dept Maxillofacial Surg, Moscow 123098, Russia.
C3 Kazan Federal University; Moscow State University of Medicine &
   Dentistry; Burnazyan Federal Medical Biophysical Center
RP Bozo, IY (通讯作者)，Human Stem Cells Inst, Moscow 199333, Russia.
EM bozo.ilya@gmail.com
RI ; Bozo, Ilia/P 6288 2017; Isaev, Artur/AAA 1754 2022; Drobyshev,
   Alexey/C 6146 2016; Deev, Roman/L 1658 2015
OI Drobyshev, Aleksey/0000 0002 1710 6923; Bozo, Ilia/0000 0002 0138 5614;
   Isaev, Artur/0000 0001 5848 5117; Deev, Roman/0000 0001 8389 3841
CR Abdelaal MM, 2004, J CRANIOFAC SURG, V15, P736, DOI 10.1097/00001665 200409000 00007
   Aenlle KK, 2014, MOL ENDOCRINOL, V28, P722, DOI 10.1210/me.2013 1286
   Akiyama I, 2014, REPROD SCI, V21, P477, DOI 10.1177/1933719113503411
   Alekseev I. S., 2012, CELLULAR TRANSPLANTA, V7, P97
   Amable PR, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt442
   Anitua E, 2012, J CONTROL RELEASE, V157, P29, DOI 10.1016/j.jconrel.2011.07.004
   Arutyunyan IV, 2013, CELL TRANSPLANT TISS, V8, P12
   Baboo S, 2014, NUCLEUS PHILA, V5, P281, DOI 10.4161/nucl.29577
   Bai Y, 2014, CELL TISSUE RES, V356, P109, DOI 10.1007/s00441 013 1781 9
   Baltzer AWA, 2000, GENE THER, V7, P734, DOI 10.1038/sj.gt.3301166
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Beckmann R, 2014, ORTHOPADE, V43, P298, DOI 10.1007/s00132 013 2160 7
   Berendsen AD, 2014, J HISTOCHEM CYTOCHEM, V62, P103, DOI 10.1369/0022155413516347
   Bertone AL, 2004, J ORTHOP RES, V22, P1261, DOI 10.1016/j.orthres.2004.03.014
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Betz VM, 2007, HUM GENE THER, V18, P907, DOI 10.1089/hum.2007.077
   Bhatt RA, 2012, HAND CLIN, V28, P457, DOI 10.1016/j.hcl.2012.08.001
   Bhattacharya R, 2009, J CELL SCI, V122, P1025, DOI 10.1242/jcs.041913
   Bhattarai G, 2013, J DENT RES, V92, P840, DOI 10.1177/0022034513497753
   Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632 200212010 00005
   Breitbart AS, 1999, ANN PLAS SURG, V42, P488, DOI 10.1097/00000637 199905000 00005
   Bright C, 2006, SPINE, V31, P2163, DOI 10.1097/01.brs.0000232721.59901.45
   Brown ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099656
   Buemi Michele, 2010, Recenti Progressi in Medicina, V101, P253
   Burgazli KM, 2013, EUR REV MED PHARMACO, V17, P2874
   Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337, DOI 10.1097/00024720 200210000 00001
   Cao L, 2012, J BIOMED MATER RES B, V100B, P1229, DOI 10.1002/jbm.b.32687
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chang PC, 2013, BIOMATERIALS, V34, P9990, DOI 10.1016/j.biomaterials.2013.09.030
   Chekanov AV, 2012, CELLULAR TRANSPLANT, V7, P75
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JC, 2007, PLAST RECONSTR SURG, V120, P1503, DOI 10.1097/01.prs.0000282029.99225.b5
   Chen X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.14
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Chiapasco M, 2009, INT J ORAL MAX IMPL, V24, P237
   Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood 2008 10 184754
   Ciurea Alexandru Vlad, 2009, J Med Life, V2, P5
   Cohen MM, 2013, J CRANIOFAC SURG, V24, P130, DOI 10.1097/SCS.0b013e3182636b7e
   Cokic BBB, 2014, MICROVASC RES, V92, P34, DOI 10.1016/j.mvr.2014.01.009
   Colciago Alessandra, 2009, Int J Biomed Sci, V5, P380
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   Cucchiarini M, 2013, J MOL MED, V91, P625, DOI 10.1007/s00109 012 0978 9
   D'Alimonte I, 2011, J BIOL REG HOMEOS AG, V25, P57
   De Francesco F., 2015, TISSUE ENG B
   Deev R, 2014, J TISSUE ENG REGEN M, V8, P64
   Deev R. V., 2012, EVEV BON GRAFTS 5 RU
   Deev R. V., 2013, CELLULAR TRANSPLANTA, V8, P78
   Deev RV, 2015, J CARDIOVASC PHARM T, V20, P473, DOI 10.1177/1074248415574336
   Deev RV, 2008, Traumatol Orthop Russia, V47, P65
   Deng Y, 2014, TISSUE ENG PT A, V20, P2019, DOI [10.1089/ten.tea.2013.0604, 10.1089/ten.TEA.2013.0604]
   Die Xiaohong, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1273
   Dimar JR, 2009, J BONE JOINT SURG AM, V91A, P1377, DOI 10.2106/JBJS.H.00200
   Drobyshev AY, 2011, B EXP CLIN SURG, VIV, P764
   Elangovan S, 2014, BIOMATERIALS, V35, P737, DOI 10.1016/j.biomaterials.2013.10.021
   Evans CH, 2012, ADV DRUG DELIVER REV, V64, P1331, DOI 10.1016/j.addr.2012.03.013
   Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Feichtinger GA, 2014, HUM GENE THER METHOD, V25, P57, DOI 10.1089/hgtb.2013.113
   Finkenzeller G, 2012, MICROVASC RES, V84, P81, DOI 10.1016/j.mvr.2012.03.010
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719
   Gao XW, 2008, ACTA BIOCH BIOPH SIN, V40, P619, DOI 10.1111/j.1745 7270.2008.00442.x
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Glassman SD, 2008, SPINE, V33, P2843, DOI 10.1097/BRS.0b013e318190705d
   Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432 1327.2000.01325.x
   Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627
   Goldman H. M., 1958, J PERIODONTOL, V29, P272
   Gololobov VG, 2006, MORPHOFUNCTIONAL ORG
   Gololobov VG, 2011, GUIDELINES HISTOLOGY, V2, P238
   Grigorian AS, 2011, CELL TRANSPLANT TISS, V6, P24
   Guo X, 2006, BIOMED MATER, V1, P93, DOI 10.1088/1748 6041/1/3/001
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Herzog DPE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/320123
   Hollawell SM, 2012, J FOOT ANKLE SURG, V51, P222, DOI 10.1053/j.jfas.2011.10.001
   Holloway JL, 2014, J CONTROL RELEASE, V191, P63, DOI 10.1016/j.jconrel.2014.05.053
   Illich DJ, 2011, STEM CELLS, V29, P555, DOI 10.1002/stem.611
   Itaka K, 2007, MOL THER, V15, P1655, DOI 10.1038/sj.mt.6300218
   Ito H, 2005, NAT MED, V11, P291, DOI 10.1038/nm1190
   Jin QM, 2004, MOL THER, V9, P519, DOI 10.1016/j.ymthe.2004.01.016
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kan I, 2005, CURR DRUG TARGETS, V6, P31, DOI 10.2174/1389450053344902
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kasten P, 2010, BIOMATERIALS, V31, P3878, DOI 10.1016/j.biomaterials.2010.01.109
   Kayal RA, 2007, J BONE MINER RES, V22, P560, DOI 10.1359/JBMR.070115
   Keeney M, 2010, BIOMATERIALS, V31, P2893, DOI 10.1016/j.biomaterials.2009.12.041
   Kerr Eubulus J 3rd, 2011, J Surg Orthop Adv, V20, P193
   Khurana S, 2014, STEM CELLS, V32, P3012, DOI 10.1002/stem.1794
   Kim BS, 2013, J BIOMED MATER RES A, V101, P2661, DOI 10.1002/jbm.a.34567
   Kim MJ, 2011, STEM CELLS DEV, V20, P1349, DOI 10.1089/scd.2010.0311
   Kimelman Bleich N, 2011, MOL THER, V19, P53, DOI 10.1038/mt.2010.190
   Kleinschmidt K, 2013, BIOMATERIALS, V34, P5926, DOI 10.1016/j.biomaterials.2013.04.029
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906
   Komlev VS, 2014, ACS APPL MATER INTER, V6, P16610, DOI 10.1021/am502583p
   Kuroda S, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/891049
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lanao RPF, 2013, TISSUE ENG PART B RE, V19, P380, DOI [10.1089/ten.TEB.2012.0443, 10.1089/ten.teb.2012.0443]
   Larsson S, 2014, ARCH ORTHOP TRAUM SU, V134, P291, DOI 10.1007/s00402 012 1558 8
   Lattanzi W, 2008, GENE THER, V15, P1330, DOI 10.1038/gt.2008.116
   Lauzon MA, 2012, J CONTROL RELEASE, V162, P502, DOI 10.1016/j.jconrel.2012.07.041
   Lekishvili M. V., 2007, N PRIOROV J TRAUMATO, V3, P80
   Levi B, 2010, PLAST RECONSTR SURG, V126, P41, DOI 10.1097/PRS.0b013e3181da8858
   Li BY, 2015, J INTERF CYTOK RES, V35, P23, DOI 10.1089/jir.2014.0004
   Li C, 2014, CELL BIOCHEM BIOPHYS, V70, P1199, DOI 10.1007/s12013 014 0042 1
   Li JJ, 2012, J SURG RES, V176, pE13, DOI 10.1016/j.jss.2011.12.011
   Li JZ, 2006, TISSUE ENG, V12, P209, DOI 10.1089/ten.2006.12.209
   Li Xiaojing, 2014, Zhonghua Kou Qiang Yi Xue Za Zhi, V49, P204
   Liu Ji zhong, 2003, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V17, P1
   Liu JS, 2011, MED HYPOTHESES, V76, P173, DOI 10.1016/j.mehy.2010.09.009
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu XH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/854917
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Lu Yu ming, 2013, Zhonghua Yi Xue Za Zhi, V93, P1335
   Lutz R, 2008, CLIN ORAL IMPLAN RES, V19, P590, DOI 10.1111/j.1600 0501.2007.01526.x
   Ma Xing Na, 2013, Zhongguo Dang Dai Er Ke Za Zhi, V15, P800
   Marini M, 2012, HISTOL HISTOPATHOL, V27, P1579, DOI 10.14670/HH 27.1579
   Marquez Curtis LA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/561098
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   McMahon MS, 2012, ORTHOPEDICS, V35, P920, DOI 10.3928/01477447 20121023 02
   Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397
   Menendez MI, 2011, OSTEOARTHR CARTILAGE, V19, P1066, DOI 10.1016/j.joca.2011.05.007
   Merlo GR, 2000, INT J DEV BIOL, V44, P619
   Miller Sallyann, 2014, Emerg Nurse, V22, P28, DOI 10.7748/en.22.4.28.e1219
   Muraev AA., 2012, CURR TECHNOL MED, V1, P21
   Nakamura T, 2010, P JPN ACAD B PHYS, V86, P588, DOI 10.2183/pjab.86.588
   Neman J, 2013, SPINE J, V13, P162, DOI 10.1016/j.spinee.2012.11.017
   Neve A, 2013, REGUL PEPTIDES, V184, P81, DOI 10.1016/j.regpep.2013.03.014
   Niederberger E, 2013, EXPERT REV PROTEOMIC, V10, P189, DOI [10.1586/EPR.13.5, 10.1586/epr.13.5]
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Omelyanenko N. P., 2013, CONNECTIVE TISSUE HI
   Osepyan IA, 1988, VESTN KHIR GREK, V5, P56
   Osepyan IA, 1982, ORTOP TRAVMATOL PROT, V9, P59
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Palioto DB, 2011, HEAD FACE MED, V7, DOI 10.1186/1746 160X 7 13
   Pan HT, 2014, J BIOMED MATER RES A, V102, P2864, DOI 10.1002/jbm.a.34961
   Park JB, 2014, ADV CLIN EXP MED, V23, P463, DOI 10.17219/acem/37146
   Pelegrine AA, 2014, CLIN ORAL IMPLAN RES, V25, P567, DOI 10.1111/clr.12117
   Peshavariya HM, 2014, J CELL MOL MED, V18, P1172, DOI 10.1111/jcmm.12263
   Phillips JE, 2006, J CELL SCI, V119, P581, DOI 10.1242/jcs.02758
   Reichert JC, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt316
   Rivera JC, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00125
   Roberts T, 2013, OR SURG OR MED OR PA, V115, P46, DOI 10.1016/j.oooo.2012.07.435
   Rose T, 2005, UNFALLCHIRURG, V108, P25, DOI 10.1007/s00113 004 0888 6
   Rundle CH, 2008, J GENE MED, V10, P229, DOI 10.1002/jgm.1148
   Sai Y, 2014, BIOL PHARM BULL, V37, P688, DOI 10.1248/bpb.b13 00841
   Samee M, 2008, J PHARMACOL SCI, V108, P18, DOI 10.1254/jphs.08036FP
   Savaridas T, 2013, BONE JOINT J, V95B, P1263, DOI 10.1302/0301 620X.95B9.31562
   Schek RM, 2004, MOL THER, V9, P130, DOI 10.1016/j.ymthe.2003.10.002
   Seamon J, 2013, BONE MARROW RES, DOI 10.1155/2013/737580
   Shaw RJ, 2009, MICROSURG, V29, P299, DOI 10.1002/micr.20623
   [Щепкина Е.А. Shchepkina E.A.], 2007, [Клеточная трансплантология и тканевая инженерия, Cellular Transplantaition and Tissue Engineering, Kletochnaya transplantologiya i tkanevaya inzheneriya], V2, P67
   Shen FH, 2002, J ORTHOP TRAUMA, V16, P651, DOI 10.1097/00005131 200210000 00007
   Sheng Matilda H C, 2014, J Bone Metab, V21, P41, DOI 10.11005/jbm.2014.21.1.41
   Sheyn D, 2011, MOL PHARMACEUT, V8, P1592, DOI 10.1021/mp200226c
   Shim JB, 2014, BIOMED MATER, V9, DOI 10.1088/1748 6041/9/4/045015
   Shiozawa Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010853
   Shu B, 2011, J CELL SCI, V124, P3428, DOI 10.1242/jcs.083659
   Sloan A, 2010, SURG J R COLL SURG E, V8, P111, DOI 10.1016/j.surge.2009.10.014
   Song K, 2008, J HUAZHONG U SCI MED, V28, P17, DOI 10.1007/s11596 008 0105 x
   Srouji S, 2012, HUM GENE THER, V23, P167, DOI 10.1089/hum.2011.059
   Stine KC, 2014, J ORTHOP RES, V32, P464, DOI 10.1002/jor.22527
   Strohbach CA, 2008, CALCIFIED TISSUE INT, V83, P202, DOI 10.1007/s00223 008 9163 0
   Subramanian IV, 2009, J CARDIOVASC TRANSL, V2, P81, DOI 10.1007/s12265 008 9063 8
   Suzuki Y, 2010, J CELL SCI, V123, P1684, DOI 10.1242/jcs.061556
   Takahashi T, 2011, CALCIFIED TISSUE INT, V88, P336, DOI 10.1007/s00223 011 9461 9
   Tarkka T, 2003, J GENE MED, V5, P560, DOI 10.1002/jgm.392
   TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023
   Tombran Tink J, 2004, BIOCHEM BIOPH RES CO, V316, P573, DOI 10.1016/j.bbrc.2004.02.076
   Tsuji K, 2008, J BONE JOINT SURG AM, V90A, P14, DOI 10.2106/JBJS.G.01109
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Tu Q, 2007, TISSUE ENG, V13, P2431, DOI 10.1089/ten.2006.0406
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Virk MS, 2008, BONE, V42, P921, DOI 10.1016/j.bone.2007.12.216
   Wallmichrath J, 2009, J CELL MOL MED, V13, P2593, DOI 10.1111/j.1582 4934.2008.00600.x
   Wan L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102010
   Wang SF, 2014, BONE, V67, P292, DOI 10.1016/j.bone.2014.07.025
   Wang Z, 2013, MAT SCI ENG C MATER, V33, P1894, DOI 10.1016/j.msec.2012.12.041
   Ward SG, 2006, TRENDS IMMUNOL, V27, P80, DOI 10.1016/j.it.2005.12.004
   Wegman F, 2011, EUR CELLS MATER, V21, P230, DOI 10.22203/eCM.v021a18
   Wehrhan F, 2013, CLIN ORAL IMPLAN RES, V24, P910, DOI 10.1111/j.1600 0501.2012.02489.x
   Wen Q, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 114
   Wong VW, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/190486
   Woo EJ, 2012, J ORAL MAXIL SURG, V70, P765, DOI 10.1016/j.joms.2011.09.008
   Woodward J, 2010, CELL ADHES MIGR, V4, P4, DOI 10.4161/cam.4.1.10106
   Wu Y, 2013, J PERIODONTAL RES, V48, P52, DOI 10.1111/j.1600 0765.2012.01503.x
   Xue DT, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 45
   Yang L, 2010, J PERIODONTAL RES, V45, P532, DOI 10.1111/j.1600 0765.2009.01268.x
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Yun YR, 2012, REGEN MED, V7, P369, DOI [10.2217/RME.12.1, 10.2217/rme.12.1]
   Zakaria SM, 2013, TISSUE ENG PART B RE, V19, P431, DOI [10.1089/ten.teb.2012.0624, 10.1089/ten.TEB.2012.0624]
   Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06 6558com
   Zhang WJ, 2014, EUR CELLS MATER, V27, P1
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhao Z, 2007, J DENT RES, V86, P1207, DOI 10.1177/154405910708601213
   Zhou Z, 2010, DEV CELL, V19, P90, DOI 10.1016/j.devcel.2010.06.016
   Zhu FC, 2012, J CELL PHYSIOL, V227, P2677, DOI 10.1002/jcp.23010
   Zorin VL, 2014, BIOMED MATER, V9, DOI 10.1088/1748 6041/9/5/055005
   Zou DH, 2012, BIOMATERIALS, V33, P2097, DOI 10.1016/j.biomaterials.2011.11.053
NR 208
TC 27
Z9 31
U1 0
U2 25
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 365050
DI 10.1155/2015/365050
PG 19
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CX2TE
UT WOS:000365548900001
PM 26649300
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Namini, MS
   Bayat, N
   Tajerian, R
   Ebrahimi Barough, S
   Azami, M
   Irani, S
   Jangjoo, S
   Shirian, S
   Ai, J
AF Namini, Mojdeh Salehi
   Bayat, Neda
   Tajerian, Roxana
   Ebrahimi Barough, Somayeh
   Azami, Mahmoud
   Irani, Shiva
   Jangjoo, Saranaz
   Shirian, Sadegh
   Ai, Jafar
TI A comparison study on the behavior of human endometrial stem
   cell derived osteoblast cells on PLGA/HA nanocomposite scaffolds
   fabricated by electrospinning and freeze drying methods
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Bone tissue engineering; Endometrial stem cells; PLGA/HA scaffolds;
   Freeze drying; Electrospinning
ID COMPOSITE SCAFFOLDS; CALCIUM PHOSPHATE; DRUG DELIVERY; IN VIVO; BONE;
   DIFFERENTIATION; HYDROXYAPATITE; NANOFIBERS; REPAIR; DEFECT
AB Background: An engineered tissue structure is an artificial scaffold combined with cells and signaling factors. Among various polymers, the polylactide co glycolide/hydroxyapatite (PLGA/HA) has attracted much attention due to their optimal properties. The aim of this study was to study the behavior of human endometrial stem cell (hEnSC) derived osteoblast cells cultured on PLGA/HA nanocomposite scaffolds.
   Methods: hEnSCs were isolated and exposed to osteogenic media for 21 days. Differentiated cells were cultured on PLGA/HA synthetic scaffolds. The PLGA/HA based nanocomposite scaffolds were fabricated using either electrospinning or freeze drying methods. Behavior of the cells was evaluated a week after seeding hEnSC derived osteoblast like cells on these scaffolds. Osteogenesis was investigated in terms of alkaline phosphatase activity, gene expression, immunocytochemistry (ICC), proliferation, and scanning electron microscopy (SEM). Moreover, scaffold properties, such as pore size and morphology of the cells, onto the scaffolds were evaluated using SEM. Furthermore, biocompatibility of these scaffolds was confirmed by 3 (4,5 dimethylthiazoyl 2 yl) 2,5 diphenyltetrazolium bromide (MTT) assay.
   Results: The matrix mineralization was proved by alizarin red staining, and the osteogenic media treated cultures positively expressed osteocalcin and osteopontin markers. Moreover, qRT PCR results confirmed the positive gene expression of osteopontin and osteonectin in the differentiated osteoblast like cells. The results of behavior assessment of the cultured cells on electrospinning and freeze dried scaffolds showed that the behavior of the cultured cells on the freeze dried PLGA/HA scaffolds was significantly better than the electrospinning PLGA/HA scaffolds.
   Conclusion: It has been shown that the freeze dried PLGA/HA nanocomposite scaffolds can appropriately support the attachment and proliferation of the differentiated osteoblast cells and are a suitable candidate for bone tissue engineering.
C1 [Namini, Mojdeh Salehi; Irani, Shiva] Islamic Azad Univ, Dept Biol, Sci & Res Branch, Tehran, Iran.
   [Bayat, Neda; Tajerian, Roxana; Ebrahimi Barough, Somayeh; Azami, Mahmoud; Ai, Jafar] Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
   [Bayat, Neda; Ai, Jafar] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran.
   [Jangjoo, Saranaz] Shiraz Univ Med Sci, Sch Med, Shiraz, Iran.
   [Shirian, Sadegh] Shahrekord Univ, Sch Vet Med, Dept Pathol, Shahr E Kord, Iran.
   [Shirian, Sadegh] Shiraz Mol Pathol Res Ctr, Dr Daneshbod Lab Pathol, Shiraz, Iran.
C3 Islamic Azad University; Tehran University of Medical Sciences; Tehran
   University of Medical Sciences; Shiraz University of Medical Science;
   Shahrekord University
RP Ai, J (通讯作者)，Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.; Ai, J (通讯作者)，Univ Tehran Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran.
EM jafar_ai@tums.ac.ir
RI ; Azami, Mahmoud/ABD 4046 2020; Irani, shiva/AAE 8167 2020; Shirian,
   Sadegh/ABA 6006 2021
OI Irani, Shiva/0000 0002 4202 9931; Azami, Mahmoud/0000 0003 4209 0668;
   ebrahimibarough, somayeh/0000 0002 5234 4791
CR Agarwal S, 2008, POLYMER, V49, P5603, DOI 10.1016/j.polymer.2008.09.014
   Azami M, 2013, TISSUE CELL, V45, P328, DOI 10.1016/j.tice.2013.05.002
   Bahrami N, 2017, ARTIF CELL NANOMED B, V45, P1343, DOI 10.1080/21691401.2016.1236804
   Biondi M, 2008, ADV DRUG DELIVER REV, V60, P229, DOI 10.1016/j.addr.2007.08.038
   Chen GP, 2002, MACROMOL BIOSCI, V2, P67, DOI 10.1002/1616 5195(20020201)2:2<67::AID MABI67>3.0.CO;2 F
   Chuenjitkuntaworn B, 2016, J BIOMED MATER RES A, V104, P264, DOI 10.1002/jbm.a.35558
   Ciapetti G, 2017, ACTA BIOMATER, V50, P102, DOI 10.1016/j.actbio.2016.12.013
   Cordonnier T, 2011, ADV ENG MATER, V13, pB135, DOI 10.1002/adem.201080098
   Ebrahimi Barough S, 2015, MOL NEUROBIOL, V52, P1704, DOI 10.1007/s12035 014 8931 2
   Ebrahimi Barough S, 2013, J MOL NEUROSCI, V51, P265, DOI 10.1007/s12031 013 9957 z
   Gargett CE, 2010, MOL HUM REPROD, V16, P818, DOI 10.1093/molehr/gaq061
   Gillette BM, 2011, BIOMATERIALS, V32, P8067, DOI 10.1016/j.biomaterials.2011.05.043
   Haider A, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556 276X 9 314
   Huang YC, 2005, GENE THER, V12, P418, DOI 10.1038/sj.gt.3302439
   Jaiswal AK, 2013, APPL SURF SCI, V268, P477, DOI 10.1016/j.apsusc.2012.12.152
   Jiang J, 2013, BIOTECHNOL LETT, V35, P657, DOI 10.1007/s10529 012 1121 2
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Joshy MIA, 2013, MAT SCI ENG C MATER, V33, P466, DOI 10.1016/j.msec.2012.09.016
   Kim Hyeongseok, 2013, International Journal of Stem Cells, V6, P67
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Lao LH, 2011, J MATER SCI MATER M, V22, P1873, DOI 10.1007/s10856 011 4374 8
   Laurencin CT, 2001, BIOMATERIALS, V22, P1271, DOI 10.1016/S0142 9612(00)00279 9
   Li CM, 2006, BIOMATERIALS, V27, P3115, DOI 10.1016/j.biomaterials.2006.01.022
   Li L, 2015, BIOMATERIALS, V37, P218, DOI 10.1016/j.biomaterials.2014.10.015
   Li XY, 2012, INT J BIOL MACROMOL, V50, P43, DOI 10.1016/j.ijbiomac.2011.09.021
   Li Y, 2017, CURR STEM C IN PRESS
   Liu L, 2012, J BIOMED MATER RES B, V100B, P956, DOI 10.1002/jbm.b.32658
   Marolt D, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt10
   Moutos FT, 2008, BIORHEOLOGY, V45, P501, DOI 10.3233/BIR 2008 0491
   Murphy CM, 2010, BIOMATERIALS, V31, P461, DOI 10.1016/j.biomaterials.2009.09.063
   Nazarpak MH, 2012, ASIAN BIOMED, V6, P753, DOI 10.5372/1905 7415.0605.117
   Neshati Z, 2012, CYTOTECHNOLOGY, V64, P485, DOI 10.1007/s10616 012 9426 5
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Pallela R, 2012, J BIOMED MATER RES A, V100A, P486, DOI 10.1002/jbm.a.33292
   Patel AN, 2008, CELL TRANSPLANT, V17, P303, DOI 10.3727/096368908784153922
   Schneider RK, 2010, BIOMATERIALS, V31, P467, DOI 10.1016/j.biomaterials.2009.09.059
   Sharif S, 2017, J BIOMED B IN PRESS
   Shirian S, 2016, MOL NEUROBIOL, V53, P5278, DOI 10.1007/s12035 015 9442 5
   Smith IO, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014102
   Sun F, 2011, ACTA BIOMATER, V7, P3813, DOI 10.1016/j.actbio.2011.07.002
   Taherian M. Z., 2012, CELL BIOL INT REP, V19, P10
   Tavakol S, 2014, J NANOPART RES, V14, P1265
   Vlasea M, 2015, ADDIT MANUF, V6, P30, DOI 10.1016/j.addma.2015.03.001
   Wu Q, 2013, CERAM INT, V39, P2389, DOI 10.1016/j.ceramint.2012.08.091
   Xu Y, 2011, CHINESE J POLYM SCI, V29, P215, DOI 10.1007/s10118 010 1015 5
   Yousefi AM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6180487
   Yu XH, 2012, J MATER CHEM, V22, P9721, DOI 10.1039/c2jm30332a
   Zhang H, 2015, COLLOID SURFACE B, V136, P27, DOI 10.1016/j.colsurfb.2015.08.015
   Zhang Y, 2012, J POROUS MAT, V19, P251, DOI 10.1007/s10934 011 9467 8
NR 49
TC 28
Z9 29
U1 0
U2 48
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD MAR 27
PY 2018
VL 13
AR 63
DI 10.1186/s13018 018 0754 9
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA GA8EK
UT WOS:000428570800002
PM 29587806
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Godfrey, TC
   Wildman, BJ
   Javed, A
   Lengner, CJ
   Hassan, MQ
AF Godfrey, Tanner C.
   Wildman, Benjamin J.
   Javed, Amjad
   Lengner, Christopher J.
   Hassan, Mohammad Quamarul
TI Epigenetic remodeling and modification to preserve skeletogenesis in
   vivo
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE BAF; osteoblast differentiation; miR 23a cluster; chromtin remodeling;
   chromatin modification; PRC2
AB Current studies offer little insight on how epigenetic remodeling of bone specific chromatin maintains bone mass in vivo. Understanding this gap and precise mechanism is pivotal for future therapeutic innovation to prevent bone loss. Recently, we found that low bone mass is associated with decreased H3K27 acetylation (activating histone modification) of bone specific gene promoters. Here, we aim to elucidate the epigenetic mechanisms by which a miRNA cluster controls bone synthesis and homeostasis by regulating chromatin accessibility and H3K27 acetylation. In order to decipher the epigenetic axis that regulates osteogenesis, we studied a drug inducible anti miR 23a cluster (miR 23a Cl ZIP) knockdown mouse model. MiR 23a cluster knockdown (heterozygous) mice developed high bone mass. These mice displayed increased expression of Runx2 and Baf45a, essential factors for skeletogenesis; and decreased expression of Ezh2, a chromatin repressor indispensable for skeletogenesis. ChIP assays using miR 23a Cl knockdown calvarial cells revealed a BAF45A EZH2 epigenetic antagonistic mechanism that maintains bone formation. Together, our findings support that the miR 23a Cl connection with tissue specific RUNX2 BAF45A EZH2 function is a novel molecular epigenetic axis through which a miRNA cluster orchestrates chromatin modification to elicit major effects on osteogenesis in vivo.
C1 [Godfrey, Tanner C.; Wildman, Benjamin J.; Javed, Amjad; Hassan, Mohammad Quamarul] Univ Alabama Birmingham, Sch Dent, RNA Biol & Epigenet Lab, Dept Oral & Maxillofacial Surg,IOHR, Birmingham, AL 35294 USA.
   [Lengner, Christopher J.] Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA.
   [Lengner, Christopher J.] Univ Penn, Inst Regenerat Med, Philadelphia, PA 19104 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Pennsylvania; University of Pennsylvania
RP Hassan, MQ (通讯作者)，Univ Alabama Birmingham, Sch Dent, RNA Biol & Epigenet Lab, Dept Oral & Maxillofacial Surg,IOHR, Birmingham, AL 35294 USA.
EM hassank@uab.edu
RI Hassan, Mohammad/GZA 7507 2022
FU NIAMS [R01 (1R01AR069578 01A1)]; DART [T90 (NIDCR 4T90DE022736 05)];
   Medical Research Council [MR/J000094/1, MC_UP_A620_1017] Funding Source:
   researchfish; MRC [MC_UP_A620_1017, MR/J000094/1] Funding Source: UKRI
FX NIAMS R01 (1R01AR069578 01A1), DART T90 (NIDCR 4T90DE022736 05)
CR Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180
   Gordon JAR, 2014, CURR OSTEOPOROS REP, V12, P496, DOI 10.1007/s11914 014 0240 1
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Kadoch C, 2016, BIOCHEMISTRY US, V55, P1600, DOI 10.1021/acs.biochem.5b01191
   Montecino M, 2015, BONE, V81, P733, DOI 10.1016/j.bone.2015.03.013
NR 5
TC 5
Z9 6
U1 0
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PY 2018
VL 59
SU 1
BP 52
EP 54
DI 10.1080/03008207.2017.1408599
PG 3
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA GF7MO
UT WOS:000432152500009
PM 29745807
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Higuchi, J
   Klimek, K
   Wojnarowicz, J
   Opalinska, A
   Chodara, A
   Szalaj, U
   Dabrowska, S
   Fudala, D
   Ginalska, G
AF Higuchi, Julia
   Klimek, Katarzyna
   Wojnarowicz, Jacek
   Opalinska, Agnieszka
   Chodara, Agnieszka
   Szalaj, Urszula
   Dabrowska, Sylwia
   Fudala, Damian
   Ginalska, Grazyna
TI Electrospun Membrane Surface Modification by Sonocoating with HA and
   ZnO:Ag Nanoparticles Characterization and Evaluation of Osteoblasts and
   Bacterial Cell Behavior In Vitro
SO CELLS
LA English
DT Article
DE regenerative medicine; bone regeneration; electrospinning; sonocoating;
   nanohydroxyapatite; bimetallic nanocomposites; cellular responses
ID ZINC OXIDE NANOPARTICLES; GUIDED TISSUE REGENERATION;
   DRUG DELIVERY SYSTEMS; ANTIBACTERIAL ACTIVITY; SILVER NANOPARTICLES;
   BONE; MECHANISM; MATRIX; NANOCOMPOSITES; BIOMATERIALS
AB Guided tissue regeneration and guided bone regeneration membranes are some of the most common products used for bone regeneration in periodontal dentistry. The main disadvantage of commercially available membranes is their lack of bone cell stimulation and easy bacterial colonization. The aim of this work was to design and fabricate a new membrane construct composed of electrospun poly (D,L lactic acid)/poly (lactic co glycolic acid) fibers sonocoated with layers of nanoparticles with specific properties, i.e., hydroxyapatite and bimetallic nanocomposite of zinc oxide silver. Thus, within this study, four different variants of biomaterials were evaluated, namely: poly (D,L lactic acid)/poly (lactic co glycolic acid) biomaterial, poly(D,L lactic acid)/poly (lactic co glycolic acid)/nano hydroxyapatite biomaterial, poly (D,L lactic acid)/poly (lactic co glycolic acid)/nano zinc oxide silver biomaterial, and poly (D,L lactic acid)/poly (lactic co glycolic acid)/nano hydroxyapatite/nano zinc oxide silver biomaterial. First, it was demonstrated that the wettability of biomaterials a prerequisite property important for ensuring desired biological response was highly increased after the sonocoating process. Moreover, it was indicated that biomaterials composed of poly (D,L lactic acid)/poly (lactic co glycolic acid) with or without a nano hydroxyapatite layer allowed proper osteoblast growth and proliferation, but did not have antibacterial properties. Addition of a nano zinc oxide silver layer to the biomaterial inhibited growth of bacterial cells around the membrane, but at the same time induced very high cytotoxicity towards osteoblasts. Most importantly, enrichment of this biomaterial with a supplementary underlayer of nano hydroxyapatite allowed for the preservation of antibacterial properties and also a decrease in the cytotoxicity towards bone cells, associated with the presence of a nano zinc oxide silver layer. Thus, the final structure of the composite poly (D,L lactic acid)/poly (lactic co glycolic acid)/nano hydroxyapatite/nano zinc oxide silver seems to be a promising construct for tissue engineering products, especially guided tissue regeneration/guided bone regeneration membranes. Nevertheless, additional research is needed in order to improve the developed construct, which will simultaneously protect the biomaterial from bacterial colonization and enhance the bone regeneration properties.
C1 [Higuchi, Julia; Wojnarowicz, Jacek; Opalinska, Agnieszka; Chodara, Agnieszka; Szalaj, Urszula; Dabrowska, Sylwia; Fudala, Damian] Polish Acad Sci, Inst High Pressure Phys, Lab Nanostruct, PL 01142 Warsaw, Poland.
   [Klimek, Katarzyna; Ginalska, Grazyna] Med Univ Lublin, Fac Pharm, Chair & Dept Biochem & Biotechnol, PL 20093 Lublin, Poland.
   [Szalaj, Urszula; Dabrowska, Sylwia] Warsaw Univ Technol, Fac Mat Sci & Engn, PL 02507 Warsaw, Poland.
C3 Polish Academy of Sciences; Institute of High Pressure Physics of the
   Polish Academy of Sciences; Medical University of Lublin; Warsaw
   University of Technology
RP Higuchi, J (通讯作者)，Polish Acad Sci, Inst High Pressure Phys, Lab Nanostruct, PL 01142 Warsaw, Poland.
EM j.higuchi@labnano.pl; katarzyna.klimek@umlub.pl;
   jacek.wojnarowicz@tlen.pl; a.opalinska@labnano.pl; achodara@leyton.com;
   u.szalaj@labnano.pl; sdabrowska@leyton.com; d.fudala@labnano.pl;
   g.ginalska@umlub.pl
RI Szalaj, Urszula/NES 2704 2025; Wojnarowicz, Jacek/O 4096 2016;
   Dąbrowska, Sylwia/AAG 5716 2019; Higuchi, Julia/AAF 2975 2019; Ginalska,
   Grazyna/MDT 1080 2025
OI Klimek, Katarzyna/0000 0003 4236 9087; Wojnarowicz,
   Jacek/0000 0002 6106 5188; Ginalska, Grazyna/0000 0002 9961 4226;
   Szalaj, Urszula/0000 0003 2304 1481; Higuchi, Julia/0000 0001 9528 5982;
   Opalinska, Agnieszka/0000 0002 5210 9257; Dabrowska,
   Sylwia/0000 0002 0175 4635
FU Center for Preclinical Research and Technology CePT II from the Regional
   Operational Programme of the Mazowieckie Voivodeship 2014 2020
   [RPMA.01.01.00 14 8476/17 04]; DS2 projects of Medical University of
   Lublin, Poland; Operational Program Development of Eastern Poland
   2007 2013, Priority Axis I, Modern Economy, Operations 1.3. Innovations
   Promotion [POPW.01.03.00 06 010/09 00]
FX The research studies were conducted using equipment funded by the Center
   for Preclinical Research and Technology CePT II
   (RPMA.01.01.00 14 8476/17 04) from the Regional Operational Programme of
   the Mazowieckie Voivodeship 2014 2020. This research was partially
   funded by the DS2 projects of Medical University of Lublin, Poland. This
   paper was developed using the equipment purchased with agreement No.
   POPW.01.03.00 06 010/09 00 Operational Program Development of Eastern
   Poland 2007 2013, Priority Axis I, Modern Economy, Operations 1.3.
   Innovations Promotion.
CR Abdelaziz D, 2021, J ADV RES, V28, P51, DOI 10.1016/j.jare.2020.06.014
   Agarwal S, 2008, POLYMER, V49, P5603, DOI 10.1016/j.polymer.2008.09.014
   Ali SM, 2020, GLOB POWER SHIFT, P1, DOI [10.1007/978 3 030 36244 7_1, 10.1080/10408347.2020.1743964]
   Almoudi MM, 2018, SAUDI DENT J, V30, P283, DOI 10.1016/j.sdentj.2018.06.003
   Bandzerewicz A, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050914
   Banoee M, 2010, J BIOMED MATER RES B, V93B, P557, DOI 10.1002/jbm.b.31615
   Behera A., 2020, Multifunctional Hybrid Nanomaterials for Sustainable Agri food and Ecosystems, P639, DOI [DOI 10.1016/B978 0 12 821354 4.00025 X, 10.1016/B978 0 12 821354 4.00025 X]
   Binamé F, 2010, MOL BIOSYST, V6, P648, DOI 10.1039/b915591k
   Bostan HB, 2016, LIFE SCI, V165, P91, DOI 10.1016/j.lfs.2016.09.017
   Braghirolli DI, 2014, DRUG DISCOV TODAY, V19, P743, DOI 10.1016/j.drudis.2014.03.024
   Burlibasa L, 2020, ARAB J CHEM, V13, P4180, DOI 10.1016/j.arabjc.2019.06.015
   Cerovic A, 2007, BIOL TRACE ELEM RES, V116, P61, DOI 10.1007/BF02685919
   Chauhan A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64419 0
   Chen XB, 2019, BIOCHEM BIOPH RES CO, V516, P1085, DOI 10.1016/j.bbrc.2019.06.163
   Cheng CF, 2009, J PERIODONTOL, V80, P1471, DOI 10.1902/jop.2009.090044
   Cierech M, 2016, INT J PHARMACEUT, V510, P323, DOI 10.1016/j.ijpharm.2016.06.052
   Colon G, 2006, J BIOMED MATER RES A, V78A, P595, DOI 10.1002/jbm.a.30789
   da Silva BL, 2019, INT J NANOMED, V14, P9395, DOI 10.2147/IJN.S216204
   Das B, 2016, SCI REP UK, V6, DOI 10.1038/srep36403
   Deo Priya Nimish, 2019, J Oral Maxillofac Pathol, V23, P122, DOI 10.4103/jomfp.JOMFP_304_18
   Donkor Eric S, 2020, Infect Dis (Auckl), V13, p1178633720976581, DOI 10.1177/1178633720976581
   Emami Karvani Z, 2011, AFR J MICROBIOL RES, V5, P1368
   Feng K, 2010, J CONTROL RELEASE, V146, P363, DOI 10.1016/j.jconrel.2010.05.035
   Ginebra MP, 2018, EFORT OPEN REV, V3, P173, DOI 10.1302/2058 5241.3.170056
   Gnaneshwar PV, 2019, MAT SCI ENG C MATER, V96, P337, DOI 10.1016/j.msec.2018.11.033
   Higuchi J, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9111625
   Huang TL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041236
   Iqbal N, 2014, CERAM INT, V40, P4507, DOI 10.1016/j.ceramint.2013.08.125
   Ivanovski S, 2009, AUST DENT J, V54, pS118, DOI 10.1111/j.1834 7819.2009.01150.x
   Jaffat HS, 2017, RES J PHARM BIOL CHE, V8, P1911
   Jaworski S, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671 018 2533 2
   Jiang T, 2015, PROG POLYM SCI, V46, P1, DOI 10.1016/j.progpolymsci.2014.12.001
   Kaviya S, 2011, J NANOTECHNOL, V2011, DOI 10.1155/2011/152970
   Kazimierczak P, 2019, INT J NANOMED, V14, P6615, DOI 10.2147/IJN.S217245
   Kikuchi M, 2004, BIOMATERIALS, V25, P5979, DOI 10.1016/j.biomaterials.2004.02.001
   Klimek K, 2022, CELLS BASEL, V11, DOI 10.3390/cells11020282
   Kolodziejczak Radzimska A, 2014, MATERIALS, V7, P2833, DOI 10.3390/ma7042833
   Korsch M, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01439 w
   Król A, 2017, ADV COLLOID INTERFAC, V249, P37, DOI 10.1016/j.cis.2017.07.033
   Kusnieruk S, 2016, BEILSTEIN J NANOTECH, V7, P1586, DOI 10.3762/bjnano.7.153
   Laudenslager M.J., 2012, ENCY NANOTECHNOLOGY, P769
   Liang YX, 2020, BIOACT MATER, V5, P297, DOI 10.1016/j.bioactmat.2020.02.012
   Liu XZ, 2020, ACTA BIOMATER, V108, P207, DOI 10.1016/j.actbio.2020.03.044
   Liu Y, 2019, ASIAN J PHARM SCI, V14, P130, DOI 10.1016/j.ajps.2018.04.004
   Lu WW, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/44/445711
   Maimaiti B, 2020, COLLOID SURFACE B, V186, DOI 10.1016/j.colsurfb.2019.110731
   McShan D, 2014, J FOOD DRUG ANAL, V22, P116, DOI 10.1016/j.jfda.2014.01.010
   Mohamed EM, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010007
   Nanditha S, 2011, J Indian Soc Periodontol, V15, P156, DOI 10.4103/0972 124X.84386
   Nurzynska A, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12091893
   O'Connor JP, 2020, MATERIALS, V13, DOI 10.3390/ma13102211
   Pande KC, 2015, ORTHOP RES REV, V7, P71, DOI 10.2147/ORR.S50753
   Paul O, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.609614
   Pearson JJ, 2020, J BIOMED MATER RES B, V108, P1157, DOI 10.1002/jbm.b.34466
   Pokrowiecki R, 2022, INT J NANOMED, V17, P1679, DOI 10.2147/IJN.S333720
   Pokrowiecki R, 2019, INT J NANOMED, V14, P9235, DOI 10.2147/IJN.S221608
   Porrelli D, 2021, ACS APPL MATER INTER, V13, P17255, DOI 10.1021/acsami.1c01016
   Predoi D, 2020, COATINGS, V10, DOI 10.3390/coatings10090905
   Przekora A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020435
   Rani Santoshi, 2015, J Int Acad Periodontol, V17, P66
   Rogowska Tylman J.W.B., 2017, U.S. Patent, Patent No. [9,675,459, 9675459]
   Rogowska Tylman J, 2019, MAT SCI ENG C MATER, V99, P669, DOI 10.1016/j.msec.2019.01.084
   Rojas MA, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0766 9
   Roy T.S., 2020, Materials Sciences and Applications, V11, P601, DOI [DOI 10.4236/MSA.2020.119040, 10.4236/msa.2020.119040]
   Shaikh S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102468
   Shemtov Yona K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253283
   Shi C, 2016, ANN JOINT, V1, DOI 10.21037/aoj.2016.11.02
   Shi R, 2019, MAT SCI ENG C MATER, V100, P523, DOI 10.1016/j.msec.2019.03.039
   Shitole AA, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6255 5
   Singh S, 2019, TOXICOL MECH METHOD, V29, P300, DOI 10.1080/15376516.2018.1553221
   Sirelkhatim A, 2015, NANO MICRO LETT, V7, P219, DOI 10.1007/s40820 015 0040 x
   Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259
   Sun YJ, 2019, ACS APPL MATER INTER, V11, P36449, DOI 10.1021/acsami.9b14572
   Szalaj U, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9071005
   Yazdi MET, 2021, RES CHEM INTERMEDIAT, V47, P1285, DOI 10.1007/s11164 020 04355 w
   Ul Hassan S, 2021, CHEM BIOL DRUG DES, V98, P1007, DOI 10.1111/cbdd.13959
   Wang DY, 2020, J PHOTOCH PHOTOBIO B, V202, DOI 10.1016/j.jphotobiol.2019.111652
   Wang HL, 2002, J PERIODONTAL RES, V37, P340, DOI 10.1034/j.1600 0765.2002.01625.x
   Wojnarowicz J, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10061086
   Wozniak B, 2019, MATER LETT, V249, P155, DOI 10.1016/j.matlet.2019.04.078
   Wu T, 2021, CARBOHYD POLYM, V269, DOI 10.1016/j.carbpol.2021.118276
   Yavari Hamidreza, 2017, J Clin Exp Dent, V9, pe1109, DOI 10.4317/jced.54069
   Zanichelli V, 2018, J ANTIMICROB CHEMOTH, V73, P17, DOI 10.1093/jac/dky115
   Zhang ES, 2016, MAT SCI ENG C MATER, V58, P278, DOI 10.1016/j.msec.2015.08.032
   Zhang YZ, 2018, ACS APPL MATER INTER, V10, P1266, DOI 10.1021/acsami.7b17351
NR 85
TC 24
Z9 25
U1 2
U2 37
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAY
PY 2022
VL 11
IS 9
AR 1582
DI 10.3390/cells11091582
PG 22
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 1E9AP
UT WOS:000794772200001
PM 35563888
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Heo, JS
   Lee, SG
   Kim, HO
AF Heo, June Seok
   Lee, Seung Gwan
   Kim, Hyun Ok
TI Distal less homeobox 5 is a master regulator of the osteogenesis of
   human mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE distal less homeobox 5; mesenchymal stem cells; osteogenesis; tanshinone
   IIA
ID OSTEOBLAST DIFFERENTIATION; TANSHINONE IIA; RUNX2 EXPRESSION;
   BONE FORMATION; DLX5; GENE; TRANSCRIPTION; INVOLVEMENT; INDUCTION;
   PROTEINS
AB Mesenchymal stem cells (MSCs) differentiate into multiple lineages and are a promising source of cells for clinical use. Previously, we found that the gene distal less homeobox 5 (DLX5) is specifically expressed in MSCs with osteogenic potential. Understanding the mechanism of osteogenesis is necessary for successful bone regeneration using MSCs. The aim of this study was to examine the function of the DLX5 gene in MSCs during osteogenesis (bone development). We analyzed the possible association between DLX5 expression and osteogenesis , chondrogenesis and adipogenesis related gene expression in different cells isolated from bone marrow and cord blood. Differentiation capacity was assessed by observing morphological changes, monitoring gene expression patterns, and staining with Von Kossa, safranin O, and Oil Red O. Suppression of DLX5 expression by means of a small interfering RNA (siRNA) downregulated osteogenic markers and reduced the signs of calcium mineralization. Tanshinone IIA is a known small molecule activator of bone morphogenetic protein (BMP) signaling. Here, we report that induction of DLX5 by tanshinone IIA in MSCs enhanced osteogenic differentiation. In addition, we showed that tanshinone IIA (as a mediator of BMP2 signaling) activates runt related transcription factor 2 (RUNX2) in MSCs and initiates calcium mineralization during osteogenesis. Taken together, these findings indicate that, in MSCs, DLX5 is a master regulator of osteogenesis. Furthermore, tanshinone IIA may be valuable for stem cell based therapies of certain bone diseases.
C1 [Heo, June Seok] Korea Univ, Dept Integrated Biomed & Life Sci, Coll Hlth Sci, Seoul 02841, South Korea.
   [Heo, June Seok; Kim, Hyun Ok] Severance Hosp, Cell Therapy Ctr, Seoul 03722, South Korea.
   [Lee, Seung Gwan] Korea Univ, Dept Hlth & Environm Sci, Coll Hlth Sci, Anam Campus,145 Anam Ro, Seoul 02841, South Korea.
   [Kim, Hyun Ok] Yonsei Univ, Dept Lab Med, Coll Med, 250 Seongsan Ro, Seoul 03722, South Korea.
C3 Korea University; Yonsei University; Yonsei University Health System;
   Korea University; Yonsei University; Yonsei University Health System
RP Lee, SG (通讯作者)，Korea Univ, Dept Hlth & Environm Sci, Coll Hlth Sci, Anam Campus,145 Anam Ro, Seoul 02841, South Korea.; Kim, HO (通讯作者)，Yonsei Univ, Dept Lab Med, Coll Med, 250 Seongsan Ro, Seoul 03722, South Korea.
EM seunggwan@korea.ac.kr; hyunok1019@yuhs.ac
RI Kim, Hyongbum/D 5804 2019
OI Kim, Hyun Ok/0000 0002 4964 1963
FU Korea Health Technology R&D Project through Korea Health Industry
   Development Institute (KHIDI) [HI15C0942]; Ministry of Health and
   Welfare, Republic of Korea
FX The present study was supported by Grant HI15C0942 from the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health and Welfare,
   Republic of Korea.
CR Acampora D, 1999, DEVELOPMENT, V126, P3795
   Chen XW, 1996, ANN NY ACAD SCI, V785, P38, DOI 10.1111/j.1749 6632.1996.tb56242.x
   Depew MJ, 2002, SCIENCE, V298, P381, DOI 10.1126/science.1075703
   Depew MJ, 1999, DEVELOPMENT, V126, P3831
   Erceg I, 2003, CROAT MED J, V44, P407
   FERRARI D, 1995, MECH DEVELOP, V52, P257, DOI 10.1016/0925 4773(95)98113 O
   Heo JS, 2016, INT J MOL MED, V37, P115, DOI 10.3892/ijmm.2015.2413
   Holleville N, 2003, DEV BIOL, V257, P177, DOI 10.1016/S0012 1606(03)00059 9
   Jang SI, 2003, PLANTA MED, V69, P1057, DOI 10.1055/s 2003 45157
   Kim HJ, 2010, AMINO ACIDS, V39, P1217, DOI 10.1007/s00726 010 0557 8
   Koç ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Lee SY, 2005, ARCH PHARM RES, V28, P909, DOI 10.1007/BF02973876
   Maeno T, 2011, BONE, V49, P673, DOI 10.1016/j.bone.2011.07.023
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Ménard C, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt214
   Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197
   Newberry EP, 1998, BIOCHEMISTRY US, V37, P16360, DOI 10.1021/bi981878u
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681
   SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250
   Sohn HS, 2013, CYTOTHERAPY, V15, P460, DOI 10.1016/j.jcyt.2012.10.015
   Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wang XJ, 2005, INT J CANCER, V116, P799, DOI 10.1002/ijc.20880
   Weiss KM, 1995, CONNECT TISSUE RES, V32, P35, DOI 10.3109/03008209509013703
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zhang ZY, 2003, MECH DEVELOP, V120, P1469, DOI 10.1016/j.mod.2003.09.002
NR 32
TC 32
Z9 32
U1 2
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD NOV
PY 2017
VL 40
IS 5
BP 1486
EP 1494
DI 10.3892/ijmm.2017.3142
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FK3PS
UT WOS:000413398800019
PM 28949384
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Song, B
   Fu, HJ
   Liu, JW
   Ren, K
   Weir, MD
   Schneider, A
   Wang, P
   Song, Y
   Zhao, L
   Xu, HK
AF Song, Bing
   Fu, Haijun
   Liu, Jianwei
   Ren, Ke
   Weir, Michael D.
   Schneider, Abraham
   Wang, Ping
   Song, Yang
   Zhao, Liang
   Xu, Huakun
TI Bioactive small molecules in calcium phosphate scaffold enhanced
   osteogenic differentiation of human induced pluripotent stem cells
SO DENTAL MATERIALS JOURNAL
LA English
DT Article
DE Bone tissue engineering; Calcium phosphate cement; Induced pluripotent
   stem cells; Small molecule SB431542; Osteogenic differentiation
ID GROWTH FACTOR BETA; UMBILICAL CORD; TGF BETA; BONE REGENERATION;
   CRANIOFACIAL BONE; CEMENT SCAFFOLDS; REINFORCEMENT; REPRESSION;
   GENERATION; DERIVATION
AB Human induced pluripotent stem cells (hiPSCs) are exciting for regenerative medicine due to their multi potent differentiation. SB431542 bioactive molecule can activate bone morphogenetic protein signalling in osteoblasts. The objectives were to: (1) develop a novel injectable calcium phosphate cement (CPC) SB431542 scaffold for dental/craniofacial bone engineering; and (2) investigate cell proliferation and osteo differentiation of hiPSC derived mesenchymal stem cells (hiPSC MSCs) on CPC SB431542 scaffold. Three groups were tested: CPC control; CPC with SB431542 inside CPC (CPCSM); CPC with SB431542 in osteogenic medium (CPC+SMM). SB431542 in CPC promoted stem cell proliferation and viability. hiPSC MSCs differentiated into osteogenic lineage and synthesized bone minerals. CPC with SB431542 showed much greater osteo expressions and more bone minerals than those without SB431542. In conclusion, hiPSC MSCs on CPC scaffold containing SB431542 showed excellent osteo differentiation and bone mineral synthesis for the first time. CPC was a suitable scaffold for delivering stem cells and SB431542 to promote bone regeneration in dental/craniofacial applications.
C1 [Song, Bing; Zhao, Liang] Southern Med Univ, Dept Orthoped Surg, Shunde Hosp, Shunde 528300, Guangdong, Peoples R China.
   [Song, Bing; Weir, Michael D.; Wang, Ping; Song, Yang; Zhao, Liang; Xu, Huakun] Univ Maryland, Dept Adv Oral Sci & Therapeut, Sch Dent, Baltimore, MD 21201 USA.
   [Fu, Haijun; Liu, Jianwei] Sun Yat Sen Univ, Guanghua Sch Stomatol, Dept Operat Dent & Endodont, Guangzhou 510055, Guangdong, Peoples R China.
   [Fu, Haijun; Liu, Jianwei] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Ren, Ke] Univ Maryland, Dept Neural & Pain Sci, Sch Dent, Baltimore, MD 21201 USA.
   [Schneider, Abraham] Univ Maryland, Dept Oncol & Diagnost Sci, Sch Dent, Baltimore, MD 21201 USA.
   [Song, Yang] Sun Yat Sen Univ, Guanghua Sch Stomatol, Dept Prosthodont, Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Xu, Huakun] Univ Maryland, Ctr Stem Cell Biol & Regenerat Med, Sch Med, Baltimore, MD 21201 USA.
   [Xu, Huakun] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA.
C3 Southern Medical University   China; University System of Maryland;
   University of Maryland Baltimore; Sun Yat Sen University; University
   System of Maryland; University of Maryland Baltimore; University System
   of Maryland; University of Maryland Baltimore; Sun Yat Sen University;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Zhao, L (通讯作者)，Southern Med Univ, Dept Orthoped Surg, Shunde Hosp, Shunde 528300, Guangdong, Peoples R China.; Zhao, L (通讯作者)，Univ Maryland, Dept Adv Oral Sci & Therapeut, Sch Dent, Baltimore, MD 21201 USA.
EM lzhaonf@126.com
RI ; Weir, Michael/M 7729 2013; Zhao, Liang/T 9147 2019; Schneider,
   Abraham/AAR 5941 2021
OI Fu, Haijun/0000 0001 6651 108X; 
FU National Natural Science Foundation of China [3171051]; Guangzhou
   Science and Technology Planning Project [201803010114]; University of
   Maryland School of Dentistry bridge fund; University of Maryland
   Baltimore Seed Grant
FX Authors would like to thank Dr. Linzhao Cheng for providing the hiPSC
   BC1 cells. This study was supported by the National Natural Science
   Foundation of China No. 3171051, Guangzhou Science and Technology
   Planning Project (201803010114), University of Maryland School of
   Dentistry bridge fund, and University of Maryland Baltimore Seed Grant.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Ambard Alberto J, 2006, J Prosthodont, V15, P321, DOI 10.1111/j.1532 849X.2006.00129.x
   Bendinelli P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102520
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Chen G, 2015, J CLIN INVEST, V125, P3226, DOI 10.1172/JCI80883
   Chen WC, 2014, DENT MATER, V30, P535, DOI 10.1016/j.dental.2014.02.007
   Chen WC, 2013, BIOMATERIALS, V34, P9917, DOI 10.1016/j.biomaterials.2013.09.002
   Chen WC, 2012, ACTA BIOMATER, V8, P2297, DOI 10.1016/j.actbio.2012.02.021
   Chen YS, 2012, STEM CELL TRANSL MED, V1, P83, DOI 10.5966/sctm.2011 0022
   Cheng LZ, 2012, CELL STEM CELL, V10, P337, DOI 10.1016/j.stem.2012.01.005
   Costa Pinto AR, 2011, TISSUE ENG PART B RE, V17, P331, DOI 10.1089/ten.teb.2010.0704
   de Gorter DJJ, 2011, J BONE MINER RES, V26, P1178, DOI 10.1002/jbmr.313
   Frankenburg EP, 1998, J BONE JOINT SURG AM, V80A, P1112, DOI 10.2106/00004623 199808000 00004
   Han QQ, 2013, FUTURE MED CHEM, V5, P1671, DOI 10.4155/fmc.13.133
   Hu QB, 2016, CARBOHYD POLYM, V151, P624, DOI 10.1016/j.carbpol.2016.05.109
   IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092 8674(87)90146 2
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kanke K, 2014, STEM CELL REP, V2, P751, DOI 10.1016/j.stemcr.2014.04.016
   Kawahara T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125590
   Li F, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471 2121 13 35
   Li RG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/873251
   Li WL, 2009, STEM CELLS, V27, P2992, DOI 10.1002/stem.240
   Liu J, 2014, ACTA BIOMATER, V10, P5128, DOI 10.1016/j.actbio.2014.08.016
   Liu J, 2013, BIOMATERIALS, V34, P7862, DOI 10.1016/j.biomaterials.2013.07.029
   Loh YH, 2009, BLOOD, V113, P5476, DOI 10.1182/blood 2009 02 204800
   Luzzani CD, 2017, STEM CELL REV REP, V13, P68, DOI 10.1007/s12015 016 9695 z
   Mahmood A, 2010, J BONE MINER RES, V25, P1216, DOI 10.1002/jbmr.34
   Mali P, 2008, STEM CELLS, V26, P1998, DOI 10.1634/stemcells.2008 0346
   Ono N, 2016, CURR OPIN GENET DEV, V40, P103, DOI 10.1016/j.gde.2016.06.012
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457
   Sagi I, 2016, NATURE, V532, P107, DOI 10.1038/nature17408
   Schindeler A, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 105
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Shi AY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1281 2
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi K, 2013, DEVELOPMENT, V140, P2457, DOI 10.1242/dev.092551
   Tang M, 2012, ACTA BIOMATER, V8, P3436, DOI 10.1016/j.actbio.2012.05.016
   Tang MH, 2014, TISSUE ENG PT A, V20, P1295, DOI [10.1089/ten.tea.2013.0211, 10.1089/ten.TEA.2013.0211]
   Tang MH, 2012, J TISSUE ENG REGEN M, V6, P214, DOI 10.1002/term.419
   Teng SS, 2014, TISSUE ENG PART B RE, V20, P328, DOI [10.1089/ten.teb.2013.0301, 10.1089/ten.TEB.2013.0301]
   Thein Han W, 2012, DENT MATER, V28, P1059, DOI 10.1016/j.dental.2012.06.009
   TheinHan WW, 2013, BONE RES, V1, P371, DOI 10.4248/BR201304008
   Villa Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084
   Wang L, 2015, J CLIN INVEST, V125, P796, DOI 10.1172/JCI79220
   Wang L, 2016, MAT SCI ENG C MATER, V69, P1125, DOI 10.1016/j.msec.2016.08.019
   Wang P, 2014, J DENT RES, V93, P618, DOI 10.1177/0022034514534689
   Wang P, 2018, J TISSUE ENG REGEN M, V12, P437, DOI 10.1002/term.2470
   Wang P, 2015, ACTA BIOMATER, V18, P236, DOI 10.1016/j.actbio.2015.02.011
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Weir MD, 2010, ACTA BIOMATER, V6, P4118, DOI 10.1016/j.actbio.2010.04.029
   Weir MD, 2010, J BIOMED MATER RES B, V93B, P93, DOI 10.1002/jbm.b.31563
   Xu HHK, 2004, BIOMATERIALS, V25, P1029, DOI 10.1016/S0142 9612(03)00608 2
   Xu HHK, 2002, BIOMATERIALS, V23, P193, DOI 10.1016/S0142 9612(01)00095 3
   Xu HHK, 2008, DENT MATER, V24, P1212, DOI 10.1016/j.dental.2008.02.001
   Xu HHK, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.56
   Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang YL, 2019, THERANOSTICS, V9, P1387, DOI 10.7150/thno.29761
   Zhao HJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0230 1
   Zhao LA, 2010, BIOMATERIALS, V31, P6502, DOI 10.1016/j.biomaterials.2010.05.017
NR 62
TC 3
Z9 3
U1 0
U2 15
PU JAPANESE SOC DENTAL MATERIALS DEVICES
PI TOKYO
PA C/O KOKU HOKEN KYOKAI, 1 43 9 KOMAGOME TS BDG, KOMAGOME, TOSHIMA KU,
   TOKYO, 170 0003, JAPAN
SN 0287 4547
J9 DENT MATER J
JI Dent. Mater. J.
PD JUN
PY 2021
VL 40
IS 3
BP 615
EP 624
DI 10.4012/dmj.2019 263
PG 10
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 0A5HZ
UT WOS:000773986900008
PM 33814531
OA gold
DA 2025 08 17
ER

PT J
AU Newcomb, PA
   Trentham Dietz, A
   Hampton, JM
AF Newcomb, P. A.
   Trentham Dietz, A.
   Hampton, J. M.
TI Bisphosphonates for osteoporosis treatment are associated with reduced
   breast cancer risk
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE bisphosphonates; osteoporosis; breast cancer; case control
ID NITROGEN CONTAINING BISPHOSPHONATES; ANTIDEPRESSANT MEDICATION USE;
   ZOLEDRONIC ACID; ANTITUMOR ACTIVITY; OLDER WOMEN; IN VITRO; APOPTOSIS;
   PAMIDRONATE; INHIBITION; MECHANISMS
AB BACKGROUND: Bisphosphanates are used primarily for the prevention and treatment of osteoporosis, and are also indicated for osseous complications of malignancy. In addition to their bone resorption properties, the most commonly used nitrogen containing bisphosphonate compounds also inhibit protein prenylation, and thus may exert anti tumour properties.
   METHODS: To evaluate whether the use of these drugs may be associated with cancer, specifically breast cancer, we conducted a population based case control study in Wisconsin from 2003 to 2006. Participants included 2936 incident invasive breast cancer cases and 2975 population controls aged <70 years. Bisphosphonate use and potential confounders were assessed by interview.
   RESULTS: Using multivariable logistic regression, the odds ratio for breast cancer in current bisphosphonate users compared with non users was 0.67 (95% confidence interval 0.51 0.89). Increasing duration of use was associated with a greater reduction in risk (P trend = 0.01). Risk reduction was observed in women who were not obese (P interaction = 0.005).
   CONCLUSION: These results are suggestive of an additional benefit of the common use of bisphosphonates, in this instance, the reduction in breast cancer risk. British Journal of Cancer (2010) 102, 799 802. doi: 10.1038/sj.bjc.6605555 www.bjcancer.com Published online 16 February 2010 (C) 2010 Cancer Research UK
C1 [Newcomb, P. A.; Trentham Dietz, A.; Hampton, J. M.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53726 USA.
   [Newcomb, P. A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Fred
   Hutchinson Cancer Center
RP Newcomb, PA (通讯作者)，Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, 610 Walnut St, Madison, WI 53726 USA.
EM pnewcomb@fhcrc.org
FU National Cancer Institute at the National Institutes of Health [R01
   CA47147]
FX This work was supported by the National Cancer Institute at the National
   Institutes of Health (R01 CA47147). The authors are grateful to Drs
   Henry Anderson, Patrick L Remington, Meir J Stampfer, Walter C Willett,
   John A Baron, Kathleen Egan, Linda Titus Ernstoff, John A Baron, E
   Robert Greenberg, and Richard R Love for their contributions in planning
   and conduct at various stages of this study; Laura Stephenson and the
   Wisconsin Cancer Reporting System, and the Women's Health Study staff,
   especially Julie McGregor, for generous assistance with study
   management.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Bedard PL, 2009, J CLIN ONCOL, V27, P4043, DOI 10.1200/JCO.2008.21.4908
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Boudreau DM, 2005, PHARMACOEPIDEM DR S, V14, P877, DOI 10.1002/pds.1119
   Boudreau DM, 2004, AM J EPIDEMIOL, V159, P308, DOI 10.1093/aje/kwh038
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Cauley JA, 1996, JAMA J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hankinson SE, 2004, BREAST CANCER RES, V6, P213, DOI 10.1186/bcr921
   Hiraga T, 2001, CANCER RES, V61, P4418
   Lipworth L, 2001, INT J EPIDEMIOL, V30, P303, DOI 10.1093/ije/30.2.303
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Newcomb PA, 2001, AM J EPIDEMIOL, V153, P1071, DOI 10.1093/aje/153.11.1071
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saad F, 2008, J CLIN ONCOL, V26, P5465, DOI 10.1200/JCO.2008.18.4184
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Silverman SL, 2004, J AM GERIATR SOC, V52, P1543, DOI 10.1111/j.1532 5415.2004.52420.x
   Sprague BL, 2008, AM J EPIDEMIOL, V168, P404, DOI 10.1093/aje/kwn143
   Wernli KJ, 2009, PHARMACOEPIDEM DR S, V18, P284, DOI 10.1002/pds.1719
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 28
TC 100
Z9 105
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAR 2
PY 2010
VL 102
IS 5
BP 799
EP 802
DI 10.1038/sj.bjc.6605555
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 563XH
UT WOS:000275170300003
PM 20160722
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Zeng, Y
   Deng, JJ
   Jiang, QL
   Wang, CL
   Zhang, L
   Li, T
   Jiang, J
AF Zeng, Yang
   Deng, Ji Jun
   Jiang, Qi Lan
   Wang, Chun Lian
   Zhang, Li
   Li, Tao
   Jiang, Jun
TI Thyrotropin inhibits osteogenic differentiation of human periodontal
   ligament stem cells
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE osteogenic differentiation; periodontal ligament stem cells (PDLSCs);
   subclinical hypothyroidism; thyrotropin
ID THYROID STIMULATING HORMONE; NECROSIS FACTOR ALPHA; NF KAPPA B;
   TNF ALPHA; CARTILAGE REGENERATION; TSH LEVELS; OSTEOCLASTOGENESIS;
   EXPRESSION; PROTEINS; PROLIFERATION
AB Background and ObjectivePeriodontal ligament stem cells (PDLSCs) are derived from the periodontal ligament and have the characteristics of pluripotent differentiation, including osteogenesis, and are one of the important seed cells in oral tissue engineering. Thyrotropin (TSH) has been shown to regulate bone metabolism independently of thyroid hormone, including the fate of osteoblasts and osteoclasts, but whether it affects osteogenic differentiation of PDLSCs is unknown. Materials and MethodsPDLSCs were isolated and cultured from human periodontal ligament and grown in osteogenic medium (containing sodium beta glycerophosphate, ascorbic acid, and dexamethasone). Recombinant human TSH was added to the culture medium. Osteogenic differentiation of PDLSCs was assessed after 14 days by staining with alkaline phosphatase and alizarin red and by detection of osteogenic differentiation genes. Differentially expressed genes (DEGs) in PDLSCs under TSH were detected by high throughput sequencing. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyzed the biological functions and signaling pathways involved in DEGs. ResultsWe found that osteogenic differentiation of PDLSCs was significantly inhibited in the presence of TSH: including decreased calcium nodule formation, decreased alkaline phosphatase levels, and decreased collagen synthesis. Using high throughput sequencing, we found changes in the expression of some osteogenesis related genes, which may be the reason that TSH inhibits osteogenic differentiation of PDLSCs. ConclusionUnless TSH is >= 10 mU/L, patients with subclinical hypothyroidism usually do not undergo thyroxine supplementation therapy. However, in this work, we found that elevated TSH inhibited the osteogenic differentiation of PDLSCs. Therefore, correction of TSH levels in patients with subclinical hypothyroidism may be beneficial to improve orthodontic, implant, and periodontitis outcomes in these patients.
C1 [Zeng, Yang; Zhang, Li] Southwest Med Univ, Affiliated Stomatol Hosp, Dept Orthodont, Luzhou Key Lab Oral & Maxillofacial Reconstruct &, Luzhou, Sichuan, Peoples R China.
   [Deng, Ji Jun; Wang, Chun Lian; Jiang, Jun] Southwest Med Univ, Affiliated Hosp, Dept Gen Surg Thyroid Surg, Luzhou, Sichuan, Peoples R China.
   [Jiang, Qi Lan] Southwest Med Univ, Affiliated Hosp, Dept Clin Nutr, Luzhou, Sichuan, Peoples R China.
   [Li, Tao] Southwest Med Univ, Inst Cardiovasc Res, Collaborat Innovat Ctr Prevent & Treatment Cardiov, Key Lab Med Electrophysiol Minist Educ, Luzhou, Sichuan, Peoples R China.
C3 Southwest Medical University; Southwest Medical University; Southwest
   Medical University; Southwest Medical University
RP Jiang, J (通讯作者)，Southwest Med Univ, Affiliated Hosp, Dept Gen Surg Thyroid Surg, Luzhou, Sichuan, Peoples R China.; Li, T (通讯作者)，Southwest Med Univ, Inst Cardiovasc Res, Collaborat Innovat Ctr Prevent & Treatment Cardiov, Key Lab Med Electrophysiol Minist Educ, Luzhou, Sichuan, Peoples R China.
EM leta49@swmu.edu.cn; jiangjun@swmu.edu.cn
RI Li, Tao/KQU 9516 2024; Jiang, Jun/AGB 9967 2022
OI Li, Tao/0000 0003 2255 1885; 
FU National Natural Science Foundation of China [82070288, 31900813];
   Sichuan Science and Technology Program [2022YFS0627]; Health Commission
   of Sichuan Province [21PJ100]; Office of Science & Technology and Talent
   Work of Luzhou [2022 JYJ 131]
FX National Natural Science Foundation of China, Grant/Award Number:
   82070288 and 31900813; Sichuan Science and Technology Program,
   Grant/Award Number: 2022YFS0627; Health Commission of Sichuan Province,
   Grant/Award Number: 21PJ100; Office of Science & Technology and Talent
   Work of Luzhou, Grant/Award Number: 2022 JYJ 131; Sichuan Science and
   Technology Program, Grant/Award Number: 2022YFS0627
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Baliram R, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00252
   Baliram R, 2011, P NATL ACAD SCI USA, V108, P16277, DOI 10.1073/pnas.1110286108
   Biondi B, 2019, JAMA J AM MED ASSOC, V322, P153, DOI 10.1001/jama.2019.9052
   Boutin A, 2014, FASEB J, V28, P3446, DOI 10.1096/fj.14 251124
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Cappola AR, 2019, CIRCULATION, V139, P2892, DOI [10.1161/CIRCULATIONAHA.118.036859, 10.1089/thy.2018.0416]
   Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982
   El Rashidy AA, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13172950
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Feng XM, 2013, CELL BIOL INT, V37, P1267, DOI 10.1002/cbin.10141
   Floriani C, 2018, EUR HEART J, V39, P503, DOI 10.1093/eurheartj/ehx050
   Gao H, 2015, INT J NANOMED, V10, P4009, DOI 10.2147/IJN.S83357
   Garber JR, 2012, THYROID, V22, P1200, DOI 10.1089/thy.2012.0205
   Hase H, 2006, P NATL ACAD SCI USA, V103, P12849, DOI 10.1073/pnas.0600427103
   Heo YY, 2011, ORAL DIS, V17, P320, DOI 10.1111/j.1601 0825.2010.01728.x
   Huang H, 2011, CELL PROLIFERAT, V44, P420, DOI 10.1111/j.1365 2184.2011.00769.x
   Hwang JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135519
   Inoue Kosuke, 2020, JAMA Netw Open, V3, pe1920745, DOI 10.1001/jamanetworkopen.2019.20745
   Ivanovski S, 2006, ORAL DIS, V12, P358, DOI 10.1111/j.1601 0825.2006.01253.x
   Jehan F, 2022, FASEB BIOADV, V4, P524, DOI 10.1096/fba.2021 00092
   Jeong DH, 2020, J NAT PROD, V83, P1174, DOI 10.1021/acs.jnatprod.9b01212
   Kim Eun Heui, 2019, J Bone Metab, V26, P31, DOI 10.11005/jbm.2019.26.1.31
   Kim SM, 2021, J CLIN ENDOCR METAB, V106, pE4809, DOI 10.1210/clinem/dgab548
   Kim SH, 2009, J PERIODONTOL, V80, P1815, DOI 10.1902/jop.2009.090249
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Krstic J, 2021, WORLD J STEM CELLS, V13, P1696, DOI 10.4252/wjsc.v13.i11.1696
   Lappin DF, 2011, J CLIN PERIODONTOL, V38, P887, DOI 10.1111/j.1600 051X.2011.01757.x
   Lee SH, 2016, BIOCHEM BIOPH RES CO, V473, P1309, DOI 10.1016/j.bbrc.2016.04.068
   Li JS, 2019, ENDOCR CONNECT, V8, P1288, DOI 10.1530/EC 19 0316
   Liao CS, 2020, J CELL PHYSIOL, V235, P4466, DOI 10.1002/jcp.29323
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu WJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1448 x
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Ma RS, 2011, THYROID, V21, P897, DOI 10.1089/thy.2010.0457
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Marconi GD, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10090931
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   Peeters RP, 2017, NEW ENGL J MED, V376, P2556, DOI 10.1056/NEJMcp1611144
   Ramajayam G, 2012, MOL CELL BIOCHEM, V368, P77, DOI 10.1007/s11010 012 1345 4
   Rath Deschner B, 2021, ANN ANAT, V234, DOI 10.1016/j.aanat.2020.151648
   Rohde M, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00422
   Ruddy MJ, 2004, J LEUKOCYTE BIOL, V76, P135, DOI 10.1189/jlb.0204065
   Sampath TK, 2007, J BONE MINER RES, V22, P849, DOI 10.1359/JBMR.070302
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   Sun L, 2013, P NATL ACAD SCI USA, V110, P9891, DOI 10.1073/pnas.1308336110
   Sun MY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0798 0
   Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001
   Taylor PN, 2014, J CLIN ENDOCR METAB, V99, P3895, DOI 10.1210/jc.2014 1954
   Toh WS, 2016, CURR STEM CELL RES T, V11, P618, DOI 10.2174/1574888X10666150723150525
   Trubiani O, 2019, STEM CELLS DEV, V28, P995, DOI 10.1089/scd.2019.0025
   Wan JT, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.663978
   Williams GR, 2011, ANN ENDOCRINOL PARIS, V72, P68, DOI 10.1016/j.ando.2011.03.006
   Wu Z, 2017, ONCOTARGETS THER, V10, P5329, DOI 10.2147/OTT.S149905
   Wu Z, 2016, MOL MED REP, V13, P497, DOI 10.3892/mmr.2015.4541
   Xu XY, 2019, STEM CELL TRANSL MED, V8, P392, DOI 10.1002/sctm.18 0181
   Yamoah K, 2008, MOL ENDOCRINOL, V22, P1141, DOI 10.1210/me.2007 0460
   Yin HY, 2016, ACTA BIOMATER, V33, P96, DOI 10.1016/j.actbio.2016.01.024
   Zhang L, 2021, BIOCHEM BIOPH RES CO, V534, P337, DOI 10.1016/j.bbrc.2020.11.081
   Zhang N, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10486
   Zhang WW, 2014, J BIOMECH, V47, P1307, DOI 10.1016/j.jbiomech.2014.02.015
   Zhou Q, 2016, SCI REP UK, V6, DOI 10.1038/srep19343
   Zhu DJ, 2018, J CELL BIOCHEM, V119, P4184, DOI 10.1002/jcb.26635
   Zhu WJ, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/972313
   Zouali M, 2017, AUTOIMMUNITY, V50, P61, DOI 10.1080/08916934.2016.1261841
NR 68
TC 6
Z9 6
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2023
VL 58
IS 3
BP 668
EP 678
DI 10.1111/jre.13109
EA FEB 2023
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AS6R9
UT WOS:000935465100001
PM 36807238
DA 2025 08 17
ER

PT J
AU Chen, SJ
   Bai, Y
   Li, Z
   Jia, KH
   Jin, YY
   He, B
   Qiu, WW
   Du, CS
   Siwko, S
   Chen, HQ
   Liu, MY
   Luo, J
AF Chen, Shijie
   Bai, Yang
   Li, Zhen
   Jia, Kunhang
   Jin, Yunyun
   He, Bei
   Qiu, Wen Wei
   Du, Changsheng
   Siwko, Stefan
   Chen, Huaqing
   Liu, Mingyao
   Luo, Jian
TI A betulinic acid derivative SH479 inhibits collagen induced arthritis by
   modulating T cell differentiation and cytokine balance
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Betulinic acid; SH479; Collagen induced arthritis; Th17 cell
   differentiation; STAT3 signaling
ID RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; JOINT INFLAMMATION;
   KAPPA B; OSTEOPROTEGERIN LIGAND; BONE RESORPTION; DOUBLE BLIND;
   DESTRUCTION; MECHANISMS; CARTILAGE
AB The ideal therapeutic drug for rheumatoid arthritis (RA) should not only inhibit inflammation, but also prevent articular joint damage and particularly inhibit osteoclastogenesis. Betulinic acid (BA) is a natural pentacyclic triterpene that has displayed moderate anti inflammatory and anti osteoclastogenesis activities in various experimental systems, suggesting that BA or its derivatives could have an inhibitory effect on RA. In this study, we screened BA derivatives and found a heterocyclic ring fused BA derivative, SH479, which had greater inhibitory effect than BA on Th17 differentiation. Moreover, we investigated the immune regulatory activity and potential therapeutic effects of SH479 in an experimental model of rheumatoid arthritis, the collagen induced arthritis (CIA) mouse model. SH479 significantly inhibited Th1 and Th17 polarization, antigen specific T cell proliferation and splenic lymphocyte induced osteoclastogenesis. Furthermore, it diminished arthritis scores as well as bone destruction and cartilage depletion in the CIA mouse model. The protective effect of SH479 was accompanied by decreased levels of pro inflammatory cytokines IL 17 and IFN gamma, together with enhanced anti inflammatory cytokine expression including IL 10 and IL 4, as well as elevated CD4(+) Foxp3(+) cell number. At the molecular level, our results indicated that SH479 alleviated CIA through regulation of CD4(+) T cell subtypes by JAK STAT pathways. In conclusion, this study demonstrates that SH479 has therapeutic potential for rheumatoid arthritis through an anti inflammatory effect by shifting a pathogenic Th17/Th1 response to a Th2/Treg phenotype, and also through an additional articular bone protection effect. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Chen, Shijie; Bai, Yang; Li, Zhen; Jia, Kunhang; Jin, Yunyun; He, Bei; Chen, Huaqing; Liu, Mingyao; Luo, Jian] East China Normal Univ, Shanghai Fengxian Dist Cent Hosp, Shanghai 200241, Peoples R China.
   [Chen, Shijie; Bai, Yang; Li, Zhen; Jia, Kunhang; Jin, Yunyun; He, Bei; Chen, Huaqing; Liu, Mingyao; Luo, Jian] East China Normal Univ, Joint Ctr Translat Med, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
   [Chen, Shijie; Bai, Yang; Li, Zhen; Jia, Kunhang; Jin, Yunyun; He, Bei; Chen, Huaqing; Liu, Mingyao; Luo, Jian] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Chen, Shijie] Cent S Univ, Xiangya Hosp 3, Dept Orthopaed, Changsha 410013, Hunan, Peoples R China.
   [Qiu, Wen Wei] East China Normal Univ, Sch Chem & Mol Engn, Dept Chem, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
   [Du, Changsheng] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Lab Receptor Based Biomed, Shanghai 200092, Peoples R China.
   [Siwko, Stefan; Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Dept Mol & Cellular Med, Houston, TX USA.
C3 East China Normal University; East China Normal University; East China
   Normal University; Central South University; East China Normal
   University; Tongji University; Texas A&M University System; Texas A&M
   University College Station; Texas A&M Health Science Center; University
   of Texas System; University of Texas Health Science Center Houston
RP Chen, HQ; Liu, MY; Luo, J (通讯作者)，East China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
EM hqchen@bio.ecnu.edu.cn; myliu@bio.ecnu.edu.cn; jluo@bio.ecnu.edu.cn
RI jin, yun/GQZ 6618 2022; Luo, Jian/H 3362 2016; Bai, Yang/MNO 4555 2025;
   Du, Changsheng/E 1552 2011
OI Luo, Jian/0000 0003 3583 0154; Siwko, Stefan/0000 0003 4260 2985
FU National Key Research and Development Program of China [2016YFC0902102];
   National Natural Science Foundation of China [81472048, 81272911,
   81330049, 31200678, 31271468]; Innovation Program of Shanghai Municipal
   Education Commission [14ZZ051]; Science and Technology Commission of
   Shanghai Municipality [12ZR1447900]
FX This work is supported by grants from the National Key Research and
   Development Program of China (2016YFC0902102), the National Natural
   Science Foundation of China (81472048, 81272911, 81330049, 31200678,
   31271468), Innovation Program of Shanghai Municipal Education Commission
   (14ZZ051), and the Science and Technology Commission of Shanghai
   Municipality (12ZR1447900).
CR Agarwal SK, 2011, J MANAGE CARE PHARM, V17, pS14, DOI 10.18553/jmcp.2011.17.s9 b.S14
   Agarwal S, 2009, RHEUMATOL INT, V29, P907, DOI 10.1007/s00296 008 0805 3
   Aragoneses Fenoll L, 2016, BIOCHEM PHARMACOL, V106, P56, DOI 10.1016/j.bcp.2016.02.005
   Arai MA, 2008, BIOORGAN MED CHEM, V16, P9420, DOI 10.1016/j.bmc.2008.09.053
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407 345
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Breedveld FC, 2006, ARTHRITIS RHEUM US, V54, P26, DOI 10.1002/art.21519
   Chabaud M, 1998, J IMMUNOL, V161, P409
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Cohen SB, 2004, ANN RHEUM DIS, V63, P1062, DOI 10.1136/ard.2003.016014
   Culshaw S, 2011, J CLIN PERIODONTOL, V38, P106, DOI 10.1111/j.1600 051X.2010.01669.x
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fulda S, 2009, MOL NUTR FOOD RES, V53, P140, DOI 10.1002/mnfr.200700491
   Glatigny S, 2010, EUR J IMMUNOL, V40, P460, DOI 10.1002/eji.200939566
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 2000, ARTHRITIS RHEUM US, V43, P2143, DOI 10.1002/1529 0131(200010)43:10<2143::AID ANR1>3.3.CO;2 J
   Huh JE, 2009, INT IMMUNOPHARMACOL, V9, P230, DOI 10.1016/j.intimp.2008.11.016
   Ivashkiv LB, 2004, ARTHRITIS RES THER, V6, P159, DOI 10.1186/ar1197
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Kashiwada Y, 1996, J MED CHEM, V39, P1016, DOI 10.1021/jm950922q
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140 6736(01)06075 5
   Lubberts E, 2000, ARTHRITIS RHEUM US, V43, P1300, DOI 10.1002/1529 0131(200006)43:6<1300::AID ANR12>3.0.CO;2 D
   Lubberts E, 2004, ARTHRITIS RHEUM US, V50, P650, DOI 10.1002/art.20001
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Martel Pelletier J, 1999, ARTHRITIS RHEUM US, V42, P2399, DOI 10.1002/1529 0131(199911)42:11<2399::AID ANR19>3.0.CO;2 Y
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Mori H, 2002, HISTOCHEM CELL BIOL, V117, P283, DOI 10.1007/s00418 001 0376 9
   Mukherjee PK, 1997, PLANTA MED, V63, P367, DOI 10.1055/s 2006 957705
   Mukherjee R, 2004, BIOORG MED CHEM LETT, V14, P2181, DOI 10.1016/j.bmcl.2004.02.044
   Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954
   Romagnani P, 2000, EUR CYTOKINE NETW, V11, P510
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tran Chinh N, 2005, Pathophysiology, V12, P183, DOI 10.1016/j.pathophys.2005.07.005
   Wang JB, 2015, INT IMMUNOPHARMACOL, V29, P687, DOI 10.1016/j.intimp.2015.09.009
   Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167 5699(97)01053 0
   Williams R O, 1989, Autoimmunity, V4, P237, DOI 10.3109/08916938909014700
   Xie F, 2005, BIOL PHARM BULL, V28, P1879, DOI 10.1248/bpb.28.1879
   Xin WY, 2014, BRIT J PHARMACOL, V171, P3526, DOI 10.1111/bph.12715
   Xu J, 2012, J MED CHEM, V55, P3122, DOI 10.1021/jm201540h
   Yazawa K, 2011, J NUTR SCI VITAMINOL, V57, P104, DOI 10.3177/jnsv.57.104
   Yoon JJ, 2010, J CELL BIOCHEM, V111, P1501, DOI 10.1002/jcb.22880
NR 49
TC 17
Z9 23
U1 0
U2 33
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD FEB 15
PY 2017
VL 126
BP 69
EP 78
DI 10.1016/j.bcp.2016.12.006
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EK8TC
UT WOS:000394196500006
PM 27965071
DA 2025 08 17
ER

PT J
AU Elsafadi, M
   Manikandan, M
   Alajez, NM
   Hamama, R
   Abu Dawud, R
   Aldahmash, A
   Iqbal, Z
   Alfayez, M
   Kassem, M
   Mahmood, A
AF Elsafadi, Mona
   Manikandan, Muthurangan
   Alajez, Nehad M.
   Hamama, Rimi
   Abu Dawud, Raed
   Aldahmash, Abdullah
   Iqbal, Zafar
   Alfayez, Musaad
   Kassem, Moustapha
   Mahmood, Amer
TI MicroRNA 4739 regulates osteogenic and adipocytic differentiation of
   immortalized human bone marrow stromal cells via targeting LRP3
SO STEM CELL RESEARCH
LA English
DT Article
ID RECEPTOR RELATED PROTEIN; MESENCHYMAL STEM CELLS; GENE FAMILY; IN VITRO;
   EXPRESSION; ACTIVATION; MECHANISM; TISSUE; FAT; ADIPOGENESIS
AB Understanding the regulatory networks underlying lineage differentiation and fate determination of human bone marrow stromal cells (hBMSC) is a prerequisite for their therapeutic use. The goal of the current study was to unravel the novel role of the low density lipoprotein receptor related protein 3 (LRP3) in regulating the osteogenic and adipogenic differentiation of immortalized hBMSCs. Gene expression profiling revealed significantly higher LRP3 levels in the highly osteogenic hBMSC clone imCL1 than in the less osteogenic clone imCL2, as well as a significant upregulation of LRP3 during the osteogenic induction of the imCL1 clone. Data from functional and gene expression assays demonstrated the role of LRP3 as a molecular switch promoting hBMSC lineage differentiation into osteoblasts and inhibiting differentiation into adipocytes. Interestingly, microRNA (miRNA) expression profiling identified miR 4739 as the most under represented miRNA ( 36.11 fold) in imCL1 compared to imCL2. The TargetScan prediction algorithm, combined with functional and biochemical assays, identified LRP3 mRNA as a novel target of miR 4739, with a single potential binding site for miR 4739 located in the LRP3 3'UTR. Regulation of LRP3 expression by miR 4739 was subsequently confirmed by qRT PCR, western blotting, and luciferase assays. Over expression of miR 4739 mimicked the effects of LRP3 knockdown on promoting adipogenic and suppressing osteogenic differentiation of hBMSCs. Hence, we report for the first time a novel biological role for the LRP3/hsa miR 4739 axis in balancing osteogenic and adipocytic differentiation of hBMSCs. Our data support the potential utilization of miRNA based therapies in regenerative medicine. (C) 2017 The Authors. Published by Elsevier B.V.
C1 [Elsafadi, Mona; Manikandan, Muthurangan; Alajez, Nehad M.; Hamama, Rimi; Aldahmash, Abdullah; Alfayez, Musaad; Kassem, Moustapha; Mahmood, Amer] King Saud Univ, Stem Cell Unit, Dept Anat, Coll Med, Riyadh 11461, Saudi Arabia.
   [Abu Dawud, Raed] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh 12713, Saudi Arabia.
   [Elsafadi, Mona; Kassem, Moustapha] Univ Southern Denmark, Univ Hosp Odense, Dept Endocrinol, KMEB, Winslowspk 25 1, DK 5000 Odense C, Denmark.
   [Aldahmash, Abdullah] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh 11461, Saudi Arabia.
   [Iqbal, Zafar] King Saud Bin Abdulaziz Univ Hlth Sci KSAU HS, Dept Basic Sci, Coll Appl Med Sci, Natl Guard Hlth Affairs, Al Hasa, Saudi Arabia.
C3 King Saud University; King Faisal Specialist Hospital & Research Center;
   University of Southern Denmark; Odense University Hospital; King Saud
   University; King Saud Bin Abdulaziz University for Health Sciences;
   Ministry of National Guard   Health Affairs; National Guard Health
   Affairs   Saudi Arabia
RP Mahmood, A (通讯作者)，POB 2925,28, Riyadh 11461, Saudi Arabia.
EM melsafadi@ksu.edu.sa; nalajez@ksu.edu.sa; dahmash@ksu.edu.sa;
   alfayez@ksu.edu.sa; mkassem@health.sdu.dk; ammahmood@ksu.edu.sa
RI ; Iqbal, Dr. Zafar/S 9011 2018; Aldahmash, Abdullah/D 4693 2015;
   Mahmood, Amer/A 9514 2011; muthurangan, manikandan/GVU 5356 2022;
   Kassem, Moustapha/J 7688 2013
OI Mahmood, Amer/0000 0002 9199 0120; muthurangan,
   manikandan/0000 0003 3057 1851; Alajez, Nehad/0000 0002 1546 1091;
   Iqbal, Zafar/0000 0002 1334 6372; Elsafadi, Mona/0000 0002 7096 998X;
   Kassem, Moustapha/0000 0003 1557 0869
FU Deanship of Scientific Research at King Saud University [RGP 1438 032];
   Novo Nordisk Fonden [NNF15OC0016284] Funding Source: researchfish
FX The authors would like to extend their sincere appreciation to the
   Deanship of Scientific Research at King Saud University for its funding
   of this research through the Research Group Project no RGP 1438 032.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008 5472.CAN 10 2754
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Anaraki PK, 2014, STEM CELLS DEV, V23, P352, DOI 10.1089/scd.2013.0318
   [Anonymous], CIBA F SYMP
   [Anonymous], BIOMED RES INT
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco Paolo, 2015, Development, V142, P1023, DOI 10.1242/dev.102210
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Cattaneo M, 2015, J CELL PHYSIOL, V230, P1770, DOI 10.1002/jcp.24876
   Chen LY, 2015, CELL PHYSIOL BIOCHEM, V37, P2101, DOI 10.1159/000438568
   Chiba T, 2003, ARTERIOSCL THROM VAS, V23, P1423, DOI 10.1161/01.ATV.0000085040.58340.36
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Croy JE, 2003, BIOCHEMISTRY US, V42, P13049, DOI 10.1021/bi034752s
   Dong L, 2015, TUMOR BIOL, V36, P6973, DOI 10.1007/s13277 015 3415 1
   Dong SW, 2012, BIOCHEM BIOPH RES CO, V418, P587, DOI 10.1016/j.bbrc.2012.01.075
   Driller K, 2007, MOL CELL BIOL, V27, P3855, DOI 10.1128/MCB.02293 06
   Elsafadi M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9378081
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Ferguson BS, 2016, J CELL PHYSIOL, V231, P1562, DOI 10.1002/jcp.25248
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074 7696(08)60092 3
   FRIEDENSTEIN AY, 1968, CLIN ORTHOP RELAT R, P21
   FromentalRamain C, 1996, DEVELOPMENT, V122, P461
   Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458
   Geneviève D, 2008, NAT GENET, V40, P284, DOI 10.1038/ng.2007.66
   Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756 3282(96)00258 X
   Gimble JM, 2004, ENDOCRINE, V23, P183, DOI 10.1385/ENDO:23:2 3:183
   Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381
   Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Huang Y, 2011, J PHYSIOL BIOCHEM, V67, P129, DOI 10.1007/s13105 010 0050 6
   Huebner AK, 2008, ARCH BIOCHEM BIOPHYS, V473, P210, DOI 10.1016/j.abb.2008.02.013
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Ishii H, 1998, GENOMICS, V51, P132, DOI 10.1006/geno.1998.5339
   Jang MK, 2014, BIOCHEM BIOPH RES CO, V454, P58, DOI 10.1016/j.bbrc.2014.10.028
   Jeong YH, 2010, BIOCHEM BIOPH RES CO, V391, P1110, DOI 10.1016/j.bbrc.2009.12.033
   Jernås M, 2009, BIOCHEM BIOPH RES CO, V383, P63, DOI 10.1016/j.bbrc.2009.03.120
   Jia SJ, 2014, DISCOV MED, V18, P237
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kim JY, 2007, ARCH BIOCHEM BIOPHYS, V464, P100, DOI 10.1016/j.abb.2007.04.018
   Kim K, 2010, J IMMUNOL, V185, P7460, DOI 10.4049/jimmunol.1000885
   Kim SY, 2010, BIOCHEM BIOPH RES CO, V392, P323, DOI 10.1016/j.bbrc.2010.01.012
   Kim S, 2016, MOL CELL BIOCHEM, V413, P145, DOI 10.1007/s11010 015 2648 z
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Laine SK, 2012, GENE, V497, P1, DOI 10.1016/j.gene.2012.01.045
   Laine SK, 2012, J CELL BIOCHEM, V113, P2687, DOI 10.1002/jcb.24144
   Li YH, 2001, MOL NEUROBIOL, V23, P53
   Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Ling HY, 2011, CLIN EXP PHARMACOL P, V38, P239, DOI 10.1111/j.1440 1681.2011.05493.x
   Masson O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007422
   Min SY, 2013, INT J OBESITY, V37, P584, DOI 10.1038/ijo.2012.85
   Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006
   Nykjaer A, 2002, TRENDS CELL BIOL, V12, P273, DOI 10.1016/S0962 8924(02)02282 1
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Pi CX, 2015, FRONT BIOSCI LANDMRK, V20, P119, DOI 10.2741/4301
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Quarto N, 2015, STEM CELLS, V33, P833, DOI 10.1002/stem.1907
   Sato T, 2011, J BIOL CHEM, V286, P5803, DOI 10.1074/jbc.M110.159244
   Serra Rosa, 2003, Birth Defects Research, V69, P333, DOI 10.1002/bdrc.10023
   Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092608
   Skårn M, 2012, STEM CELLS DEV, V21, P873, DOI 10.1089/scd.2010.0503
   STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268 9499(94)90718 8
   Tétreault N, 2013, CLIN BIOCHEM, V46, P842, DOI 10.1016/j.clinbiochem.2013.02.009
   Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092 8674(00)80782 5
   Tsai CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119511
   Ueda M, 2016, ARCH ORAL BIOL, V62, P86, DOI 10.1016/j.archoralbio.2015.11.010
   Vishnubalaji R, 2016, ONCOTARGET, V7, P35789, DOI 10.18632/oncotarget.8937
   Wakabayashi S, 2002, J BONE MINER RES, V17, P249, DOI 10.1359/jbmr.2002.17.2.249
   Wang CY, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3357
   Wang Chen, 2015, Zhonghua Bing Li Xue Za Zhi, V44, P565
   Wang YC, 2010, J NUTR BIOCHEM, V21, P317, DOI 10.1016/j.jnutbio.2009.01.004
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Wolski H, 2015, GINEKOL POL, V86, P311
   Yanagitai M, 2012, BIOCHEM BIOPH RES CO, V417, P294, DOI 10.1016/j.bbrc.2011.11.103
   Yokota T, 2003, J IMMUNOL, V171, P5091, DOI 10.4049/jimmunol.171.10.5091
   Yokota T, 2002, J CLIN INVEST, V109, P1303, DOI 10.1172/JCI200214506
NR 86
TC 35
Z9 36
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873 5061
EI 1876 7753
J9 STEM CELL RES
JI Stem Cell Res.
PD APR
PY 2017
VL 20
BP 94
EP 104
DI 10.1016/j.scr.2017.03.001
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA EW4MD
UT WOS:000402474700019
PM 28340487
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hou, R
   Wang, YW
   Liang, HF
   Zhang, ZG
   Liu, ZM
   Zhang, BH
   Zhang, BX
   Chen, XP
AF Hou, Rui
   Wang, Yu wei
   Liang, Hui fang
   Zhang, Zhan guo
   Liu, Zhi min
   Zhang, Bin hao
   Zhang, Bi xiang
   Chen, Xiao ping
TI Animal and cellular models of hepatocellular carcinoma bone metastasis:
   establishment and characterisation
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Animal model; Bone metastasis; Cell line; CTGF; Hepatocellular
   carcinoma; MMP 1; Osteoclasts; PTHrP
ID BREAST CANCER METASTASIS; ALPHA FETOPROTEIN; TUMOR GROWTH
AB An increasingly high occurrence of bone metastases in hepatocellular carcinoma (HCC) patients highlights the importance of fundamental research on HCC bone metastasis, which has been limited in its success due to the lack of a model system.
   Establishment of animal and cellular models of HCC bone metastasis and discovery of HCC bone metastasis related genes.
   Luciferase transfected HCC cell lines HCCLM3, MHCC97H, and SMMC 7721 were used to inoculate nude mice intracardially. Formation of bone metastases was examined by bioluminescence imaging, SPECT, and pathology study. Metastatic cells in bone were isolated and subcultured. Differences between bone metastatic cells and their parental cells were studied by in vitro/in vivo assays.
   Mouse model of HCC bone metastasis was successfully established. Injected tumour cells formed metastases in the skull, the spine, the hind limbs, and the sternum, causing osteolytic lesions via act of MMP 1 and recruitment of osteoclasts. Four bone metastatic cell lines were extracted from HCCLM3 inoculated mice and were demonstrated to exhibit a much stronger ability to form bone metastases as well as other phenotypes, including enhanced in vitro migration/invasion and colony formation. Moreover, the expression of PTHrP, MMP 1, and CTGF was significantly elevated in bone metastatic cells compared to parental HCC cells.
   The nude mouse model and bone metastatic cell lines together provide an effective simulation of HCC bone metastasis. This model system will become powerful tool with which to explore the mechanisms and therapies of HCC bone metastasis. Additionally, PTHrP, MMP 1, and CTGF are candidate genes related to HCC bone metastasis.
C1 [Hou, Rui] Chinese Acad Med Sci, Dept Surg, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Wang, Yu wei; Liang, Hui fang; Zhang, Zhan guo; Zhang, Bin hao; Zhang, Bi xiang; Chen, Xiao ping] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Peoples R China.
   [Liu, Zhi min] Sixth Subsidiary Sun Yat Sen Univ Hosp, Dept Surg, Guangzhou, Guangdong, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Huazhong University of Science &
   Technology
RP Zhang, BX (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
EM bixiangzhang@yahoo.com.cn; chen_xiaoping52@163.com
RI Zhang, Biao/A 8662 2013; HOU, RUI/LVR 3058 2024
FU State Key Project on Infectious Diseases of China [2012ZX10002016 004,
   2012ZX10002010 001 004]; Chinese Ministry of Public Health for Key
   Clinical Projects [439]; National Nature Science Foundation of China
   [30973498, 81072001]; National Training Programs of Innovation and
   Entrepreneurship for Undergraduates [1210487144]
FX We thank Ph.D. Qing qing Mo for technical support in bioluminescence
   imaging and Dr Yan xia Shen, Yun feng Han, and Jin ling Tian for
   technical support in SPECT scanning. This work is supported by the State
   Key Project on Infectious Diseases of China (Grant Nos.
   2012ZX10002016 004 and 2012ZX10002010 001 004), the Chinese Ministry of
   Public Health for Key Clinical Projects (No. 439, 2010) to Prof
   Xiao ping Chen, the National Nature Science Foundation of China (Nos.
   30973498 and 81072001) to Prof Bixiang Zhang, and the National Training
   Programs of Innovation and Entrepreneurship for Undergraduates (No.
   1210487144) to Rui Hou.
CR Allen M, 2011, J PATHOL, V223, P162, DOI 10.1002/path.2803
   Canosa MA, 2011, CIR ESPAN, V89, P223, DOI 10.1016/j.ciresp.2010.12.002
   Bäuerle T, 2005, INT J CANCER, V115, P177, DOI 10.1002/ijc.20840
   Casimiro S, 2012, CLIN EXP METASTAS, V29, P155, DOI 10.1007/s10585 011 9438 0
   Deryugina EI, 1997, ANTICANCER RES, V17, P3201
   Dong R, 1980, J 2 MILITARY MED U S, V1, P5
   Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585 006 9011 4
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Fukutomi M, 2001, EUR J GASTROEN HEPAT, V13, P1083, DOI 10.1097/00042737 200109000 00015
   Giannini EG, 2012, HEPATOLOGY, V56, P1371, DOI 10.1002/hep.25814
   Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018
   Harms JF, 2003, CLIN EXP METASTAS, V20, P327, DOI 10.1023/A:1024062911144
   Ho CL, 2011, RADIOLOGY, V258, P515, DOI 10.1148/radiol.10100672
   Huo TI, 2004, ONCOL REP, V11, P543
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Katyal S, 2000, RADIOLOGY, V216, P698, DOI 10.1148/radiology.216.3.r00se24698
   Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Li M, 2012, ONCOL LETT, V3, P802, DOI 10.3892/ol.2012.586
   Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602
   Liu Nan nan, 2010, Zhonghua Zhong Liu Za Zhi, V32, P203
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Neeff H, 2009, ZBL CHIR, V134, P127, DOI 10.1055/s 0028 1098881
   Notting IC, 2005, INVEST OPHTH VIS SCI, V46, P1581, DOI 10.1167/iovs.04 0245
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Power CA, 2009, PROSTATE, V69, P1613, DOI 10.1002/pros.21010
   Quinn JMW, 1998, J PATHOL, V184, P31, DOI 10.1002/(SICI)1096 9896(199801)184:1<31::AID PATH962>3.0.CO;2 V
   Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416
   Siegel RL., 2019, J Clin, V69, P7, DOI DOI 10.3322/CAAC.21772
   Strube A, 2010, CLIN EXP METASTAS, V27, P319, DOI 10.1007/s10585 010 9329 9
   Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432 003 0511 1
   Xiang ZL, 2011, ONCOLOGIST, V16, P1028, DOI 10.1634/theoncologist.2010 0358
   Xiao Y, 2004, RADIOL PRACT, V19, P682
   [张菁 Zhang Jing], 2012, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V32, P636
NR 34
TC 11
Z9 11
U1 3
U2 46
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 5216
EI 1432 1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD NOV
PY 2015
VL 141
IS 11
BP 1931
EP 1943
DI 10.1007/s00432 015 1958 6
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CR7TK
UT WOS:000361553800005
PM 25820528
DA 2025 08 17
ER

PT J
AU Lee, JH
   Choi, HK
   Yang, L
   Chueng, STD
   Choi, JW
   Lee, KB
AF Lee, Jin Ho
   Choi, Hye Kyu
   Yang, Letao
   Chueng, Sy Tsong Dean
   Choi, Jeong Woo
   Lee, Ki Bum
TI Nondestructive Real Time Monitoring of Enhanced Stem Cell
   Differentiation Using a Graphene Au Hybrid Nanoelectrode Array
SO ADVANCED MATERIALS
LA English
DT Article
DE biosensing; graphene Au hybrid nanoelectrode arrays; nondestructive
   real time detection; osteogenesis from stem cells; stem cell
   differentiation
ID ALKALINE PHOSPHATASE; SKELETAL MUSCLE; REGENERATIVE MEDICINE; OXIDE;
   FATE; TUMORIGENICITY; OSTEOGENESIS; BONE; HETEROGENEITY; OSTEOBLASTS
AB Stem cells have attracted increasing research interest in the field of regenerative medicine because of their unique ability to differentiate into multiple cell lineages. However, controlling stem cell differentiation efficiently and improving the current destructive characterization methods for monitoring stem cell differentiation are the critical issues. To this end, multifunctional graphene gold (Au) hybrid nanoelectrode arrays (NEAs) to: (i) investigate the effects of combinatorial physicochemical cues on stem cell differentiation, (ii) enhance stem cell differentiation efficiency through biophysical cues, and (iii) characterize stem cell differentiation in a nondestructive real time manner are developed. Through the synergistic effects of physiochemical properties of graphene and biophysical cues from nanoarrays, the graphene Au hybrid NEAs facilitate highly enhanced cell adhesion and spreading behaviors. In addition, by varying the dimensions of the graphene Au hybrid NEAs, improved stem cell differentiation efficiency, resulting from the increased focal adhesion signal, is shown. Furthermore, graphene Au hybrid NEAs are utilized to monitor osteogenic differentiation of stem cells electrochemically in a nondestructive real time manner. Collectively, it is believed the unique multifunctional graphene Au hybrid NEAs can significantly advance stem cell based biomedical applications.
C1 [Lee, Jin Ho; Yang, Letao; Chueng, Sy Tsong Dean; Lee, Ki Bum] Rutgers State Univ, Dept Chem & Chem Biol, IAMDN, Piscataway, NJ 08854 USA.
   [Lee, Jin Ho; Choi, Hye Kyu; Choi, Jeong Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 04107, South Korea.
   [Lee, Ki Bum] Kyung Hee Univ, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Rutgers University System; Rutgers University New Brunswick; Sogang
   University; Kyung Hee University
RP Lee, KB (通讯作者)，Rutgers State Univ, Dept Chem & Chem Biol, IAMDN, Piscataway, NJ 08854 USA.; Choi, JW (通讯作者)，Sogang Univ, Dept Chem & Biomol Engn, Seoul 04107, South Korea.; Lee, KB (通讯作者)，Kyung Hee Univ, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM jwchoi@sogang.ac.kr; kblee@rutgers.edu
RI ; Lee, Jin Ho/AEE 5544 2022; LEE, Ki Bum/JDC 3477 2023; Yang,
   Letao/X 6193 2019
OI LEE, Ki Bum/0000 0002 8164 0047; Choi, Hye Kyu/0000 0002 3111 2422;
   Chueng, Sy Tsong/0000 0002 1447 5491; Yang, Letao/0000 0002 0572 9787;
   Lee, Jin Ho/0000 0002 5877 0222; 
FU NIH R21 [1R21AR071101 01]; NSF [CHE 1429062]; New Jersey Commission on
   Spinal Cord [CSCR16ERG019]; NRF   MSIP of Korea [2013K1A4A3055268,
   2016R1A6A1A03012845]; ME of Korea; National Research Foundation of Korea
   [22A20150013275] Funding Source: Korea Institute of Science & Technology
   Information (KISTI), National Science & Technology Information Service
   (NTIS)
FX K.B.L. acknowledges the partial financial support from the NIH R21
   (1R21AR071101 01), the NSF (CHE 1429062), and New Jersey Commission on
   Spinal Cord (CSCR16ERG019). J.W.C. acknowledges partial financial
   support from the NRF (2013K1A4A3055268) and (2016R1A6A1A03012845) funded
   by MSIP and the ME of Korea. The authors are also grateful to Thanapat
   Pongkulapa and Dr. Tae Hyung Kim for their kind support and valuable
   discussion.
CR Ambrosi A, 2014, CHEM REV, V114, P7150, DOI 10.1021/cr500023c
   Balis N, 2016, MATER TODAY, V19, P580, DOI 10.1016/j.mattod.2016.03.018
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Ben David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Cahan P, 2013, NAT REV MOL CELL BIO, V14, P357, DOI 10.1038/nrm3584
   Chen D, 2012, CHEM REV, V112, P6027, DOI 10.1021/cr300115g
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen WQ, 2014, NANO TODAY, V9, P759, DOI 10.1016/j.nantod.2014.12.002
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Eigler S, 2012, CARBON, V50, P3666, DOI 10.1016/j.carbon.2012.03.039
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fu YS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.256601
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955 0674(00)00255 6
   Goodwin HS, 2001, BIOL BLOOD MARROW TR, V7, P581, DOI 10.1053/bbmt.2001.v7.pm11760145
   Iskratsch T, 2014, NAT REV MOL CELL BIO, V15, P825, DOI 10.1038/nrm3903
   Jiao HP, 2014, ACS APPL MATER INTER, V6, P1979, DOI 10.1021/am405020b
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim KS, 2010, ADV FUNCT MATER, V20, P3055, DOI 10.1002/adfm.201000613
   Kim TH, 2015, ADV MATER, V27, P6356, DOI 10.1002/adma.201502489
   Kim TH, 2015, ACS NANO, V9, P3780, DOI 10.1021/nn5066028
   Knoepfler PS, 2015, ADV DRUG DELIVER REV, V82 83, P192, DOI 10.1016/j.addr.2014.12.001
   Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Lee JH, 2013, BIOSENS BIOELECTRON, V49, P531, DOI 10.1016/j.bios.2013.06.010
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Li XH, 2014, ADV FUNCT MATER, V24, P3114, DOI 10.1002/adfm.201303384
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Muller Sieburg CE, 2012, BLOOD, V119, P3900, DOI 10.1182/blood 2011 12 376749
   Murphy WL, 2014, NAT MATER, V13, P547, DOI [10.1038/NMAT3937, 10.1038/nmat3937]
   Narsinh KH, 2011, J CLIN INVEST, V121, P1217, DOI 10.1172/JCI44635
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   SAFADI A, 1991, J HISTOCHEM CYTOCHEM, V39, P199, DOI 10.1177/39.2.1987264
   Selhuber Unkel C, 2008, BIOPHYS J, V95, P5424, DOI 10.1529/biophysj.108.139584
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Sterneckert JL, 2014, NAT REV GENET, V15, P625, DOI 10.1038/nrg3764
   Tsimbouri PM, 2017, NAT BIOMED ENG, V1, P758, DOI 10.1038/s41551 017 0127 4
   Tsui JH, 2017, ACS NANO, V11, P11954, DOI 10.1021/acsnano.7b00186
   Wang J, 2005, ELECTROANAL, V17, P7, DOI 10.1002/elan.200403113
   Wang X, 2015, NANO LETT, V15, P1457, DOI 10.1021/nl5049862
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
   Yeo JS, 2015, NANO ENERGY, V12, P96, DOI 10.1016/j.nanoen.2014.12.022
   Yi NB, 2016, SCI REP UK, V6, DOI 10.1038/srep25134
   You MH, 2010, BIOMACROMOLECULES, V11, P1856, DOI 10.1021/bm100374n
   Yu AM, 2003, NANO LETT, V3, P1203, DOI 10.1021/nl034363j
   Zhou M, 2009, ANAL CHEM, V81, P5603, DOI 10.1021/ac900136z
   Zhu CZ, 2015, ANAL CHEM, V87, P230, DOI 10.1021/ac5039863
NR 53
TC 49
Z9 58
U1 2
U2 128
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD SEP 26
PY 2018
VL 30
IS 39
AR 1802762
DI 10.1002/adma.201802762
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA GU5LR
UT WOS:000445327500013
PM 30073706
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Pinheiro, ALB
   Gerbi, MEMM
AF Pinheiro, ALB
   Gerbi, MEMM
TI Photoengineering of bone repair processes
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
ID LOW POWER LASER; RAT CALVARIAL CELLS; HE NE IRRADIATION; IN VITRO;
   NODULE FORMATION; BOVINE BONE; THERAPY; LIGHT; STIMULATION; MEMBRANE
AB Objective: This paper aims to report the state of the art with respect to photoengineering of bone repair using laser therapy. Background Data: Laser therapy has been reported as an important tool to positively stimulate bone both in vivo and in vitro. These results indicate that photophysical and photochemical properties of some wavelengths are primarily responsible for the tissue responses. The use of correct and appropriate parameters has been shown to be effective in the promotion of a positive biomodulative effect in healing bone. Methods: A series of papers reporting the effects of laser therapy on bone cells and tissue are presented, and new and promising protocols developed by our group are presented. Results: The results of our studies and others indicate that bone irradiated mostly with infrared (IR) wavelengths shows increased osteoblastic proliferation, collagen deposition, and bone neorformation when compared to nonirradiated bone. Further, the effect of laser therapy is more effective if the treatment is carried out at early stages when high cellular proliferation occurs. Vascular responses to laser therapy were also suggested as one of the possible mechanisms responsible for the positive clinical results observed following laser therapy. It still remains uncertain if bone stimulation by laser light is a general effect or if the isolate stimulation of osteoblasts is possible. Conclusion: It is possible that the laser therapy effect on bone regeneration depends not only on the total dose of irradiation, but also on the irradiation time and the irradiation mode. The threshold parameter energy density and intensity are biologically independent of one another. This independence accounts for the success and the failure of laser therapy achieved at low energy density levels.
C1 Univ Fed Bahia, Fac Odontol, Ctr Laser,Sch dent, Dept Propedeut & Clin Integrada, BR 40140110 Salvador, BA, Brazil.
   Univ Vale Paraiba, Inst Res & Dev, Sao Jose Dos Campos, SP, Brazil.
   Univ Fed Pernambuco, Ctr Ciencias Saude, Dept Protese & Cirurgia Buco Facial, Recife, PE, Brazil.
C3 Universidade Federal da Bahia; Universidade do Vale do Paraiba;
   Universidade Federal de Pernambuco
RP Pinheiro, ALB (通讯作者)，Univ Fed Bahia, Fac Odontol, Ctr Laser,Sch dent, Dept Propedeut & Clin Integrada, Av Araujo Pinho 62, BR 40140110 Salvador, BA, Brazil.
EM albp@ufba.br
RI Pinheiro, Antonio/A 1962 2008; BARBOSA PINHEIRO, ANTONIO
   LUIZ/A 1962 2008
OI BARBOSA PINHEIRO, ANTONIO LUIZ/0000 0002 5805 0321
CR BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Dörtbudak O, 2000, CLIN ORAL IMPLAN RES, V11, P540, DOI 10.1034/j.1600 0501.2000.011006540.x
   Freitas IGF, 2000, APPL SURF SCI, V154, P548, DOI 10.1016/S0169 4332(99)00431 6
   Garavello I, 2004, HISTOL HISTOPATHOL, V19, P43, DOI 10.14670/HH 19.43
   Gerbi MEM, 2005, PHOTOMED LASER SURG, V23, P382, DOI 10.1089/pho.2005.23.382
   GERBI MEM, 2004, THESIS U FEDERAL BAH
   Guzzardella GA, 2003, CLIN ORAL IMPLAN RES, V14, P226, DOI 10.1034/j.1600 0501.2003.00872.x
   Guzzardella GA, 2002, LASER MED SCI, V17, P216, DOI 10.1007/s101030200031
   Horowitz I., 1996, LASER THER, V8, P29
   Kandra M., 2005, BIOMATERIALS, V26, P3503
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Limeira Jr FA, 2004, THESIS U FEDERAL BAH
   Lopes CB, 2005, PHOTOMED LASER SURG, V23, P27, DOI 10.1089/pho.2005.23.27
   LUBART R, 1992, J PHOTOCH PHOTOBIO B, V12, P305, DOI 10.1016/1011 1344(92)85032 P
   MAS JR, 1998, LASERS ODONTOLOGIA M, P68
   Nicolau RA, 2003, LASER MED SCI, V18, P89, DOI 10.1007/s10103 003 0260 z
   OZAWA Y, 1995, P SOC PHOTO OPT INS, V1984, P281, DOI 10.1117/12.207040
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pinheiro AL, 2001, REV FOUFBA, V22, P12
   Pinheiro ALB, 2003, J CLIN LASER MED SUR, V21, P383, DOI 10.1089/104454703322650202
   PINHEIRO ALB, 2002, J CLIN LASER MED SUR, V20, P22
   Pinheiro Antonio Luiz Barbosa, 2003, Braz. Dent. J., V14, P177, DOI 10.1590/S0103 64402003000300007
   Rochkind S, 2004, PHOTOMED LASER SURG, V22, P249, DOI 10.1089/1549541041438579
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889 5406(97)70152 5
   Silva AN, 2002, J CLIN LASER MED SUR, V20, P83, DOI 10.1089/104454702753768061
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   TRELLES MA, 1987, LASER SURG MED, V7, P36, DOI 10.1002/lsm.1900070107
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
   VALCANAIA TC, 1999, THESIS PONTIFICIA U
   WEBER JBB, 2003, THESIS PONTIFICIA U
   Yaakobi T, 1996, CALCIFIED TISSUE INT, V59, P297, DOI 10.1007/s002239900126
   YAMADA K, 1991, Journal of the Japanese Orthopaedic Association, V65, P787
NR 33
TC 205
Z9 215
U1 1
U2 7
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549 5418
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD APR
PY 2006
VL 24
IS 2
BP 169
EP 178
DI 10.1089/pho.2006.24.169
PG 10
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 047EN
UT WOS:000237862700008
PM 16706695
OA Green Published
DA 2025 08 17
ER

PT J
AU Simfia, I
   Schiavi, J
   McNamara, LM
AF Simfia, Irene
   Schiavi, Jessica
   McNamara, Laoise M.
TI ROCK II inhibition suppresses impaired mechanobiological responses in
   early estrogen deficient osteoblasts
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Mechanobiology; Osteoporosis; Estrogen; Rho associated coiled kinase
   (ROCK)
ID FLUID SHEAR STRESS; HORMONE REPLACEMENT THERAPY; ILIAC CREST BIOPSIES;
   BONE CELLS; POSTMENOPAUSAL OSTEOPOROSIS; MECHANICAL STRESS;
   PROSTAGLANDIN E 2; NITRIC OXIDE; SIGNAL TRANSDUCTION; SP1 POLYMORPHISM
AB Mechanobiological responses by osteoblasts are governed by downstream Rho ROCK signalling through actin cytoskeleton re arrangements but whether these responses are influenced by estrogen deficiency during osteoporosis remains unknown. The objective of this study was to determine alterations in the mechanobiological responses of estrogen deficient osteoblasts and investigate whether an inhibitor of the Rho ROCK signalling can revert these changes. MC3T3 E1 cells were pre treated with 10 nM 17 p estradiol for 7 days and further cultured with or without estradiol for next 2 days. These cells were treated with or without ROCK II inhibitor, Y 27632, and oscillatory fluid flow (OFF, 1Pa, 0.5 Hz, 1 h) was applied. Here, we report that Prostaglandin E2 release, Runt related transcription factor 2 and Osteopontin gene expression were significantly enhanced in response to OFF in estrogen deficient cells than in cells with estrogen (3.73 vs 1.63 pg/ng DNA; 13.5 vs 2.6 fold, 2.1 vs 0.4 fold respectively). Upon ROCK II inhibition, these enhanced effects of estrogen deficiency were downregulated. OFF increased the fibril anisotropy in cells pre treated with estrogen and this increase was suppressed upon ROCK II inhibition. This study is the first to demonstrate altered mechanobiological responses by osteoblasts during early estrogen deficiency and that these responses to OFF can be suppressed upon ROCK inhibition.
C1 [Simfia, Irene; Schiavi, Jessica; McNamara, Laoise M.] Natl Univ Ireland Galway, Coll Engn & Informat, Mechanobiol & Med Device Res Grp, Biomech Res Ctr,Biomed Engn, Galway, Ireland.
C3 Ollscoil na Gaillimhe University of Galway
RP McNamara, LM (通讯作者)，Natl Univ Ireland Galway, Coll Engn & Informat, Biomed Engn, Galway, Ireland.
EM laoise.mcnamara@nuigalway.ie
RI SCHIAVI TRITZ, Jessica/J 1261 2019
OI Schiavi Tritz, Jessica/0000 0003 2872 2067
FU Irish Research Council (IRC) under the EMBARK program; European Research
   Council [ERC 2010 StG, 258,992 BONEMECHBIO]; Science Foundation Ireland
   Investigators Grant under the European Regional Development fund
   [14/IA/2884]
FX This study was funded by Irish Research Council (IRC) under the EMBARK
   program, the European Research Council Grant ERC 2010 StG Grant 258,992
   BONEMECHBIO and the Science Foundation Ireland Investigators Grant
   co funded under the European Regional Development fund (14/IA/2884).
CR Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002
   Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bailey AJ, 1999, EXP GERONTOL, V34, P337, DOI 10.1016/S0531 5565(99)00016 9
   BAILEY AJ, 1993, CONNECT TISSUE RES, V29, P119, DOI 10.3109/03008209309014239
   Bakker AD, 2005, OSTEOPOROSIS INT, V16, P983, DOI 10.1007/s00198 004 1785 0
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   BATGE B, 1992, EUR J CLIN INVEST, V22, P805, DOI 10.1111/j.1365 2362.1992.tb01450.x
   Batra NN, 2005, J BIOMECH, V38, P1909, DOI 10.1016/j.jbiomech.2004.08.009
   BAUD CA, 1988, BONE, V9, P361, DOI 10.1016/8756 3282(88)90117 2
   Bell K. L., 1996, Bone (New York), V19, p131S, DOI 10.1016/8756 3282(96)89264 7
   Birkenhaeger Frenkel D., 1987, INT S OST NORH DENM, P443
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Boudaoud A, 2014, NAT PROTOC, V9, P457, DOI 10.1038/nprot.2014.024
   Boyde A, 1998, BONE, V22, P241, DOI 10.1016/S8756 3282(97)00275 5
   Brennan MA, 2014, HORM METAB RES, V46, P537, DOI 10.1055/s 0033 1363265
   Brennan M A, 2011, Eur Cell Mater, V21, P396
   Brennan M. A., 2012, IMPACT SHEAR STRESS
   Brennan O, 2012, HORM METAB RES, V44, P47, DOI 10.1055/s 0031 1291358
   Brennan O, 2012, CALCIFIED TISSUE INT, V91, P440, DOI 10.1007/s00223 012 9657 7
   Buxboim A, 2010, J PHYS CONDENS MAT, V22, DOI 10.1088/0953 8984/22/19/194116
   Cheng MZ, 2002, J BONE MINER RES, V17, P593, DOI 10.1359/jbmr.2002.17.4.593
   Christiansen C, 1996, MATURITAS, V23, pS71
   Ciarelli TE, 2003, BONE, V32, P311, DOI 10.1016/S8756 3282(02)00975 4
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Damien E, 1998, J BONE MINER RES, V13, P1275, DOI 10.1359/jbmr.1998.13.8.1275
   Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169
   Deepak V, 2017, FASEB J, V31, P3027, DOI 10.1096/fj.201601280R
   DICKENSON RP, 1981, J BONE JOINT SURG BR, V63, P233, DOI 10.1302/0301 620X.63B2.7217148
   Donahue TLH, 2003, J BIOMECH, V36, P1363, DOI 10.1016/S0021 9290(03)00118 0
   Efstathiadou Z, 2001, J BONE MINER RES, V16, P1586, DOI 10.1359/jbmr.2001.16.9.1586
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Evans ND, 2009, EUR CELLS MATER, V18, P1
   FEYEN JHM, 1987, ENDOCRINOLOGY, V121, P819, DOI 10.1210/endo 121 2 819
   Gadeleta SJ, 2000, BONE, V27, P541, DOI 10.1016/S8756 3282(00)00362 8
   Gardinier J, 2014, AM J PHYSIOL CELL PH, V306, pC1058, DOI 10.1152/ajpcell.00254.2013
   Geoghegan IP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41095 3
   Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096 203
   GRYNPAS MD, 1994, BONE, V15, P505, DOI 10.1016/8756 3282(94)90274 7
   Hamamura K, 2012, CONNECT TISSUE RES, V53, P398, DOI 10.3109/03008207.2012.671398
   Harris SS, 2000, CALCIFIED TISSUE INT, V66, P268, DOI 10.1007/PL00005842
   Haugh MG, 2015, J MECH BEHAV BIOMED, V42, P67, DOI 10.1016/j.jmbbm.2014.11.001
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Hoey David A, 2012, Front Endocrinol (Lausanne), V3, P75, DOI 10.3389/fendo.2012.00075
   Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072
   Hu WX, 2015, CELL STEM CELL, V17, P204, DOI 10.1016/j.stem.2015.07.006
   Ikeda T, 1996, J BONE MINER RES, V11, P780
   Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349 7006.2000.tb01018.x
   Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333
   Jaasma MJ, 2006, ANN BIOMED ENG, V34, P759, DOI 10.1007/s10439 005 9052 x
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Joldersma M, 2001, AM J PHYSIOL ENDOC M, V280, pE436, DOI 10.1152/ajpendo.2001.280.3.E436
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Klein Nulend J, 2012, EUR CELLS MATER, V24, P278, DOI 10.22203/eCM.v024a20
   KleinNulend J, 1996, J CELL PHYSIOL, V168, P1, DOI 10.1002/(SICI)1097 4652(199607)168:1<1::AID JCP1>3.0.CO;2 T
   Kowitz J, 1997, CALCIFIED TISSUE INT, V60, P501, DOI 10.1007/s002239900271
   Lee KL, 2014, FASEB J, V28, P1157, DOI 10.1096/fj.13 240432
   Li CJ, 2011, BONE, V48, P286, DOI 10.1016/j.bone.2010.09.020
   Li J, 2012, J BIOMECH, V45, P247, DOI 10.1016/j.jbiomech.2011.10.037
   Liedert A, 2010, BIOCHEM BIOPH RES CO, V394, P755, DOI 10.1016/j.bbrc.2010.03.065
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Litzenberger JB, 2010, CALCIFIED TISSUE INT, V86, P325, DOI 10.1007/s00223 010 9343 6
   MAJESKA RJ, 1994, J BONE JOINT SURG AM, V76A, P713, DOI 10.2106/00004623 199405000 00013
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Mansell JP, 2003, INT J BIOCHEM CELL B, V35, P522, DOI 10.1016/S1357 2725(02)00312 6
   McAllister TN, 2000, BIOCHEM BIOPH RES CO, V270, P643, DOI 10.1006/bbrc.2000.2467
   McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   McCreadie BR, 2006, BONE, V39, P1190, DOI 10.1016/j.bone.2006.06.008
   McGarry JG, 2004, FASEB J, V18, P482, DOI 10.1096/fj.04 2210fje
   McNamara LM, 2006, BONE, V39, P392, DOI 10.1016/j.bone.2006.02.070
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   MIKUNITAKAGAKI Y, 1995, J BONE MINER RES, V10, P231, DOI 10.1002/jbmr.5650100209
   Moreno Cuevas JE, 2000, IN VITRO CELL DEV AN, V36, P447, DOI 10.1290/1071 2690(2000)036<0447:EMAIIP>2.0.CO;2
   Muthukumaran P, 2012, BIOCHEM BIOPH RES CO, V423, P503, DOI 10.1016/j.bbrc.2012.05.149
   Naqvi SM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00601
   Nauman EA, 2001, J APPL PHYSIOL, V90, P1849, DOI 10.1152/jappl.2001.90.5.1849
   NeidlingerWilke C, 1995, J BIOMECH, V28, P1411, DOI 10.1016/0021 9290(95)00089 5
   Norvell SM, 2004, J APPL PHYSIOL, V96, P957, DOI 10.1152/japplphysiol.00869.2003
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Oxlund H, 1996, BONE, V19, P479, DOI 10.1016/S8756 3282(96)00283 9
   Paschalis EP, 1997, CALCIFIED TISSUE INT, V61, P487, DOI 10.1007/s002239900372
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ponik SM, 2007, J CELL BIOCHEM, V100, P794, DOI 10.1002/jcb.21089
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Randell KM, 2002, J BONE MINER RES, V17, P528, DOI 10.1359/jbmr.2002.17.3.528
   Reilly GC, 2003, BIORHEOLOGY, V40, P591
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Rosen CJ, 2000, BEST PRACT RES CL EN, V14, P181, DOI 10.1053/beem.2000.0068
   Rowlands AS, 2008, AM J PHYSIOL CELL PH, V295, pC1037, DOI 10.1152/ajpcell.67.2008
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   SPOTILA LD, 1991, P NATL ACAD SCI USA, V88, P5423, DOI 10.1073/pnas.88.12.5423
   Sterck JGH, 1998, AM J PHYSIOL ENDOC M, V274, pE1113, DOI 10.1152/ajpendo.1998.274.6.E1113
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Verbruggen SW, 2015, BIOPHYS J, V108, P1587, DOI 10.1016/j.bpj.2015.02.031
   Voisin M., 2015, ANAT REC
   Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006 291X(02)02124 1
   Wang Y., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P332
   Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104
   Waters KM, 2001, J CELL BIOCHEM, V83, P448, DOI 10.1002/jcb.1242
   Wittkowske C, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00087
   Xi Guangjun, 2013, Genomics Proteomics & Bioinformatics, V11, P312, DOI 10.1016/j.gpb.2013.09.003
   Yang Q, 2011, J BONE MINER RES, V26, P1188, DOI 10.1002/jbmr.337
   Yeh CR, 2010, J BONE MINER RES, V25, P627, DOI 10.1359/jbmr.091008
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Zhu XH, 2008, TRANSL RES, V152, P18, DOI 10.1016/j.trsl.2008.05.003
   Ziambaras K, 1998, J BONE MINER RES, V13, P218, DOI 10.1359/jbmr.1998.13.2.218
NR 113
TC 6
Z9 7
U1 0
U2 7
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD NOV 1
PY 2020
VL 396
IS 1
AR 112264
DI 10.1016/j.yexcr.2020.112264
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA OF9AO
UT WOS:000581491000031
PM 32898551
OA Green Published
DA 2025 08 17
ER

PT J
AU Snoeks, TJA
   Mol, IM
   Que, I
   Kaijzel, EL
   Löwik, CWGM
AF Snoeks, Thomas J. A.
   Mol, Isabel M.
   Que, Ivo
   Kaijzel, Eric L.
   Loewik, Clemens W. G. M.
TI 2 Methoxyestradiol Analogue ENMD 1198 Reduces Breast Cancer Induced
   Osteolysis and Tumor Burden Both In Vitro and In Vivo
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID REGULATORY T CELLS; BONE METASTASES; CYCLOPHOSPHAMIDE; GROWTH;
   BISPHOSPHONATES; ANGIOGENESIS; MECHANISM; MODEL; INHIBITION; RESORPTION
AB It has been estimated that 70% of advanced breast cancer patients will face the complication of bone metastases. Three processes are pivotal during bone metastatic growth of breast cancer, namely, tumor cell proliferation, angiogenesis, and osteolysis. During tumor induced osteolysis, a number of cytokines and growth factors are released from the degraded bone matrix. These factors stimulate further tumor growth, tumor angiogenesis, and tumor induced osteolysis. New therapies should target all relevant processes to halt this powerful feedback loop. Here, we characterized the new 2 methoxyestradiol analogue ENMD 1198 and showed that it is cytotoxic to tumor cells. Moreover, ENMD 1198 showed both antiangiogenic and vascular disruptive properties and was capable of protecting the bone against tumor induced osteolysis. We confirmed the in vitro data with a series of in vivo experiments showing the beneficial effects of ENMD 1198 and ENMD 1198 based combination treatments of metastatic breast cancer in bone both on tumor progression and on survival with long term ENMD 1198 treatment. We confirmed the in vivo relevance of the ENMD 1198 protective effect on bone both with X ray radiographs and microcomputed tomography. In addition, we combined ENMD 1198 treatment with low dose metronomic cyclophosphamide and the bisphosphonate risedronic acid, leading to a mild increase in treatment efficacy. Mol Cancer Ther; 10(5); 874 82. (C) 2011 AACR.
C1 [Snoeks, Thomas J. A.; Mol, Isabel M.; Que, Ivo; Kaijzel, Eric L.; Loewik, Clemens W. G. M.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC
RP Snoeks, TJA (通讯作者)，Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, Bldg 1,C4 R67,Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM t.j.a.snoeks@lumc.nl; c.w.g.m.lowik@lumc.nl
RI ; Snoeks, Thomas/E 9742 2010; Kaijzel, Eric/GZN 2333 2022
OI Snoeks, Thomas/0000 0003 3866 346X; Kaijzel, Eric/0000 0003 3118 9910
FU Dutch Cancer Society Koningin Wilhelmina Fonds [UL2007 3801]; EU
   [LSHC CT 2004 503569, LSBH CT 2005 512146]
FX This work has been supported by the Dutch Cancer Society Koningin
   Wilhelmina Fonds (UL2007 3801; T.J.A. Snoeks) and the sixth FP EU grants
   EMIL (LSHC CT 2004 503569; I. M. Mol, C. W. G. M. Lowik) and DiMI
   (LSBH CT 2005 512146; I. Que, E. L. Kaijzel, C.W.G.M. Lowik).
CR Agoston GE, 2009, BIOORG MED CHEM LETT, V19, P6241, DOI 10.1016/j.bmcl.2009.08.020
   Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014 5793(03)00131 5
   Benedikt MB, 2010, J CELL BIOCHEM, V109, P950, DOI 10.1002/jcb.22473
   Bocci G, 2002, CANCER RES, V62, P6938
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Buijs JT, 2009, BONE, V44, P380, DOI 10.1016/j.bone.2008.10.047
   Cicek M, 2007, CANCER RES, V67, P10106, DOI 10.1158/0008 5472.CAN 07 1362
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Deckers M, 2001, LAB INVEST, V81, P5, DOI 10.1038/labinvest.3780207
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunn LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006896
   Emmenegger U, 2007, MOL CANCER THER, V6, P2280, DOI 10.1158/1535 7163.MCT 07 0181
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262 006 0225 8
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   LaVallee TM, 2008, MOL CANCER THER, V7, P1472, DOI 10.1158/1535 7163.MCT 08 0107
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418 008 0530 8
   Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood 2004 06 2410
   Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535 6108(03)00077 1
   Man S, 2002, CANCER RES, V62, P2731
   Maran A, 2006, J CELL BIOCHEM, V99, P425, DOI 10.1002/jcb.20924
   Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001
   Mooberry Susan L., 2003, Current Opinion in Oncology, V15, P425, DOI 10.1097/00001622 200311000 00004
   Moser C, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 206
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pasquier E, 2010, MOL CANCER THER, V9, P1408, DOI 10.1158/1535 7163.MCT 09 0894
   PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   van Wijngaarden J, 2010, BIOCHEM BIOPH RES CO, V391, P1161, DOI 10.1016/j.bbrc.2009.11.097
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Virk MS, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2169
   Voorzanger Rousselot N, 2006, BRIT J CANCER, V95, P506, DOI 10.1038/sj.bjc.6603285
   Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002 9440(10)64934 6
   Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008 5472.CAN 10 0283
   Zhou Q, 2011, INVEST NEW DRUG, V29, P340, DOI 10.1007/s10637 009 9383 9
NR 41
TC 14
Z9 16
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2011
VL 10
IS 5
BP 874
EP 882
DI 10.1158/1535 7163.MCT 10 0997
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 774ZY
UT WOS:000291427000016
PM 21422268
DA 2025 08 17
ER

PT J
AU Tian, S
   Guo, L
   Song, YG
   Miao, JX
   Peng, MF
   Fang, XY
   Bai, M
   Miao, MS
AF Tian, Shuo
   Guo, Lin
   Song, Yagang
   Miao, Jinxin
   Peng, Mengfan
   Fang, Xiaoyan
   Bai, Ming
   Miao, Mingsan
TI Transcriptomic analysis the mechanisms of anti osteoporosis of
   desert living Cistanche herb in ovariectomized rats of postmenopausal
   osteoporosis
SO FUNCTIONAL & INTEGRATIVE GENOMICS
LA English
DT Article
DE Desert living Cistanche herb; Transcriptomic analysis;
   Anti osteoporosis; Differential expressed genes
ID LIGHT CHAIN; MYOSIN; MUSCLE; EXPRESSION; GENE; CARDIOMYOPATHY;
   EVOLUTION; HEART; MUTATIONS; LINKAGE
AB Desert living Cistanche herb (DC), as a traditional Chinese medicine for tonifying kidney yang, is often used to treat postmenopausal osteoporosis (PMOP). Total phenylethanoid glycosides are instruction ingredients for discrimination and assay according to the China pharmacopoeia for DC. This research aimed to reveal the anti osteoporosis mechanism of total phenylethanoid glycosides of DC (PGC) by transcriptomic analysis of ovariectomized rats. Serum levels of BGP were evaluated by ELISA, the bone weight was measured, and transmission electron microscopy was used to examine the ultrastructure of osteoblasts in rats. In addition, micro CT was used to detect the bone volume (Tb.BS/BV), bone mineral density (Tb.BMD), and bone mineral content (Tb.BMC) in trabecular bone, and the ratio of cortical bone area to total area (Ct.ar/Tt.ar), and the level of bone mineral content (Ct.BMC) in cortical bone. Differential expressed genes (DEGs) after PGC treatment were analyzed by transcriptomics. Then, a bioinformatics analysis of DEGs was carried out through GO enrichment, KEGG enrichment, and selection of the nucleus gene through the protein protein interaction network. Through qRT PCR analysis, the DEGs were verified. The analysis results indicated that PGC increased the secretion of osteogenic markers, and ultrastructural characterization of osteoblasts and bone morphology were improved in ovariectomized rats. A total of 269 genes were differentially expressed, including 201 genes that were downregulated and 68 genes that were upregulated between the model group and the PGC group. Bioinformation analysis results prompt the conclusion that PGC could promote the bone metabolism by muscle cell development, myofibril assembly, etc. In addition, our study also found that PGC has a good effect on osteoporosis complicated with cardiomyopathy, and it also provided evidence for the correlation between sarcopenia and osteoporosis.
C1 [Tian, Shuo; Song, Yagang; Miao, Jinxin; Bai, Ming; Miao, Mingsan] Henan Univ Chinese Med, Acad Tradit Chinese Med, Zhengzhou 450046, Peoples R China.
   [Tian, Shuo] Henan Univ Chinese Med, Henan Collaborat Innovat Ctr Res & Dev Whole Ind C, Zhengzhou 450046, Peoples R China.
   [Guo, Lin; Peng, Mengfan; Fang, Xiaoyan] Henan Univ Chinese Med, Dept Pharmacol, Zhengzhou 450046, Peoples R China.
C3 Henan University of Traditional Chinese Medicine; Henan University of
   Traditional Chinese Medicine; Henan University of Traditional Chinese
   Medicine
RP Miao, MS (通讯作者)，Henan Univ Chinese Med, Acad Tradit Chinese Med, Zhengzhou 450046, Peoples R China.
EM miaomingsan@163.com
RI Miao, Jinxin/K 4607 2019
FU Science and technology project of Henan Province [212102310351]; Henan
   Province Youth Talent Promotion Project [2021HYTP055]; Postdoctoral
   Research project of Henan Province [202001053]; National Natural Science
   Project of China [81274154]
FX This work was supported by the Science and technology project of Henan
   Province (212102310351), Henan Province Youth Talent Promotion Project
   (2021HYTP055), Postdoctoral Research project of Henan Province
   (202001053), and the National Natural Science Project of China
   (81274154).
CR Ahmadi N, 2018, OSTEOPOROSIS INT, V29, P1609, DOI 10.1007/s00198 018 4524 7
   Andersen PS, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/685108
   Andruchov O, 2006, J PHYSIOL LONDON, V571, P231, DOI 10.1113/jphysiol.2005.099770
   ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092 8674(94)90192 9
   Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092 8674(00)81878 4
   BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249
   Beckwée D, 2019, J NUTR HEALTH AGING, V23, P494, DOI 10.1007/s12603 019 1196 8
   Binkley N, 2009, J CLIN DENSITOM, V12, P413, DOI 10.1016/j.jocd.2009.06.004
   Blümel JE, 2020, CLIMACTERIC, V23, P184, DOI 10.1080/13697137.2019.1656186
   Bu XY., 2021, PROG PHYSL SCI, V52, P431
   Buyandelger B, 2011, PFLUG ARCH EUR J PHY, V462, P135, DOI 10.1007/s00424 011 0961 2
   王昌, 2022, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V44, P285
   Cervellati R, 2002, J AGR FOOD CHEM, V50, P7504, DOI 10.1021/jf020578n
   Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252
   Colegrave M, 2014, ANAT REC, V297, P1670, DOI 10.1002/ar.22973
   Crandall C., 2004, ACP J CLUB, V140, P46, DOI [10.7326/ACPJC 2004 140 2 046, DOI 10.7326/ACPJC 2004 140 2 046]
   Di Monaco M, 2022, EUR J PHYS REHAB MED, V58, P638, DOI 10.23736/S1973 9087.22.07215 X
   Fan Qiong ling, 2020, Chinese Pharmacological Bulletin, V36, P583, DOI 10.3969/j.issn.1001 1978.2020.04.024
   Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002
   Foth BJ, 2006, P NATL ACAD SCI USA, V103, P3681, DOI 10.1073/pnas.0506307103
   Gao LH, 2018, GYNECOL ENDOCRINOL, V34, P332, DOI 10.1080/09513590.2017.1405929
   Garofolini A, 2019, HUM MOVEMENT SCI, V64, P75, DOI 10.1016/j.humov.2019.01.006
   Ghatpande S, 2001, BIOL RES, V34, P1
   Gómez J, 2014, CIRC J, V78, P2963, DOI 10.1253/circj.CJ 14 0628
   Gosset A, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101551
   Hagiwara K, 2011, EUR J PHARMACOL, V662, P78, DOI 10.1016/j.ejphar.2011.04.023
   HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095
   He H, 2014, GENE, V535, P17, DOI 10.1016/j.gene.2013.11.014
   He Yi Min, 2017, Yi Chuan, V39, P877, DOI 10.16288/j.yczz.17 090
   Hernández Martínez P, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01146 1
   Hu GL, 2022, FOOD CHEM, V376, DOI 10.1016/j.foodchem.2021.131923
   [胡扬 Hu Yang], 2021, [中成药, Chinese Traditional Patent Medicine], V43, P1988
   Jagelaviciene E, 2016, MEDICINA LITHUANIA, V52, P125, DOI 10.1016/j.medici.2016.02.005
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jay A, 2013, CARDIOLOGY, V124, P248, DOI 10.1159/000347138
   Jiang P, 2002, DEV BIOL, V243, P281, DOI 10.1006/dbio.2002.0574
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kemmler W, 2020, J BONE MINER RES, V35, P1634, DOI 10.1002/jbmr.4027
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Komurcu Bayrak E, 2012, MOL BIOL REP, V39, P8065, DOI 10.1007/s11033 012 1653 5
   Kumar K, 2022, FUNCT INTEGR GENOMIC, V22, P905, DOI 10.1007/s10142 022 00869 1
   Lan TW, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/8219296
   [李福春 Li Fuchun], 2012, [中国组织工程研究, Chinese Journal of Tissue Engineering Research], V16, P8361
   Li J, 2022, CLIMACTERIC, V25, P562, DOI 10.1080/13697137.2022.2102894
   Li JL., 2016, CHINA PHARM, V27, P2849
   [李野 Li Ye], 2021, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V27, P123
   Liang Z, 2020, J MATER CHEM B, V8, P6378, DOI 10.1039/d0tb00422g
   Liu RR, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.775512
   [刘晓青 LIU Xiaoqing], 2009, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V15, P153
   Locquet M, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2752 4
   Miao KT., 2020, CHIN MED HERALD, V17, P104
   Motojima H, 2013, J NAT MED TOKYO, V67, P790, DOI 10.1007/s11418 013 0753 4
   Mukherjee K, 2016, BIOCHEM PHARMACOL, V117, P10, DOI 10.1016/j.bcp.2016.04.010
   Nie HT, 2021, FUNCT INTEGR GENOMIC, V21, P341, DOI 10.1007/s10142 021 00780 1
   North KN, 1999, NAT GENET, V21, P353, DOI 10.1038/7675
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Papalouka V, 2009, MOL CELL BIOL, V29, P6046, DOI 10.1128/MCB.00654 09
   Pasco JA, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0586 2
   Pathak P, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 01864 1
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Reiss J, 2019, Z GERONTOL GERIATR, V52, P688, DOI 10.1007/s00391 019 01553 z
   Rozenberg S, 2020, OSTEOPOROSIS INT, V31, P2271, DOI 10.1007/s00198 020 05497 8
   Ruggiero A, 2013, CARDIOVASC RES, V97, P44, DOI 10.1093/cvr/cvs294
   Rushforth AM, 1998, GENETICS, V150, P1067
   Si JY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919159
   Stefancsik R, 2003, COMP FUNCT GENOM, V4, P609, DOI 10.1002/cfg.343
   Swoap SJ, 2000, AM J PHYSIOL CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915
   Tajsharghi H, 2013, ACTA NEUROPATHOL, V125, P3, DOI 10.1007/s00401 012 1024 2
   Tanaka K, 2012, J BIOL CHEM, V287, P11616, DOI 10.1074/jbc.M111.292193
   Tian S, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111884
   Timson DJ, 2003, BIOCHIMIE, V85, P639, DOI 10.1016/S0300 9084(03)00131 7
   [中华中医药学会中药实验药理专业委员会 Traditional Chinese Medicine Experimental Pharmacology Professional Committee of China Association of Chinese Medicine], 2018, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V33, P996
   Vihola A, 2010, ACTA NEUROPATHOL, V119, P465, DOI 10.1007/s00401 010 0637 6
   Wang FJ, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113899
   [王高祥 Wang Gaoxiang], 2022, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V28, P766
   Wang H., 2021, S CHINA J PREV MED, V47, P1031
   Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356
   [王琳琳 Wang Linlin], 2015, [天然产物研究与开发, Natural Product Research and Development], V27, P377
   Wei B, 2016, GENE, V582, P1, DOI 10.1016/j.gene.2016.01.006
   Wei ZZ., 2013, J TRADIT CHIN MED, V28, P1688, DOI [10.16368/j.issn.1674 8999.2013.11.050, DOI 10.16368/J.ISSN.1674 8999.2013.11.050]
   Wu Yi Qi, 2021, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V37, P380, DOI 10.13865/j.cnki.cjbmb.2021.02.1685
   Ying XX, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00252
   Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 2 r14
   Yu Q, 2016, ANN VASC SURG, V34, P234, DOI 10.1016/j.avsg.2016.04.002
   Yuan WJ, 2022, FUNCT INTEGR GENOMIC, V22, P731, DOI 10.1007/s10142 022 00887 z
   Zhang B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01412
   Zhang CL, 2016, GENE, V577, P209, DOI 10.1016/j.gene.2015.11.041
   Zhao XY., 2019, PROG ANAT SCI, V25, P497, DOI [10.16695/j.cnki.1006 2947.2019.05.001, DOI 10.16695/J.CNKI.1006 2947.2019.05.001]
   Zhao Y, 2022, FUNCT INTEGR GENOMIC, V22, P435, DOI 10.1007/s10142 022 00839 7
   Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092
NR 91
TC 5
Z9 6
U1 2
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1438 793X
EI 1438 7948
J9 FUNCT INTEGR GENOMIC
JI Funct. Integr. Genomics
PD SEP
PY 2023
VL 23
IS 3
AR 237
DI 10.1007/s10142 023 01154 5
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA M4OF4
UT WOS:001030011800001
PM 37439895
DA 2025 08 17
ER

PT J
AU Park, HJ
   Drevelle, O
   Daviau, A
   Senta, H
   Bergeron, E
   Faucheux, N
AF Park, Hyunjin
   Drevelle, Olivier
   Daviau, Alex
   Senta, Helena
   Bergeron, Eric
   Faucheux, Nathalie
TI Preventing MEK1 activation influences the responses of human
   osteosarcoma cells to bone morphogenetic proteins 2 and 9
SO ANTI CANCER DRUGS
LA English
DT Article
DE extracellular signal regulated kinase 1/2; MG 63; osterix; p38; peptides
   derived from bone morphogenetic proteins; proliferation; SaOS 2; Smad
ID OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; TRANSCRIPTION FACTOR;
   OSTERIX EXPRESSION; QUANTITATIVE PCR; STEM CELLS; IN VIVO; KINASE;
   BMP 2; LINE
AB It was recently suggested that bone morphogenetic protein (BMP) 2 may be useful for treating osteosarcoma cells. BMP 9, which has been patented to treat breast and prostate cancers, has a higher osteoinductive potential than BMP 2. Peptides derived from the knuckle epitope of BMPs (pBMPs) also induced osteogenic differentiation. However, the effect of BMP 9 and pBMPs on osteosarcoma cells is unclear. We analyzed the effects of BMP 2, BMP 9, pBMP 2, and pBMP 9 on the behavior of human MG 63 and SaOS 2 osteosarcoma cells. An inhibitor of MEK1 activation (PD98059) that prevents downstream extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation and a specific inhibitor of p38 were also used as mitogen activated protein kinase targeting therapy is being investigated as a treatment modality for osteosarcoma. BMP 2 and BMP 9 (1.92 nmol/l) induced the phosphorylation of Smad1/5/8 in both osteosarcoma cells within 1 h but had different effects on mitogen activated protein kinase pathways. Whereas BMP 2 mainly activated ERK1/2, BMP 9 phosphorylated p38 within 1 h. pBMP 2 did not activate either the Smad or ERK/p38, whereas pBMP 9, like BMP 9, induced both Smad1/5/8 and p38 phosphorylation. p38 activation by BMP 9 or pBMP 9 was also enhanced by PD98059. However, BMP 2 or BMP 9 increased the amounts of distal less homeobox 5 and Osterix mRNAs in SaOS 2 cells within 6 h, whereas pBMP 9 had no effect. PD98059 promoted the highest level of Osterix mRNA in SaOS 2 cells incubated with BMP 2 or BMP 9, whereas p38 inhibitor had no effect. Furthermore, PD98059 induced the lowest proliferation of MG 63 cells incubated with BMP 2, whereas p38 inhibitor did not affect the proliferation of either osteosarcoma cell line. Therefore a combination of BMP 2 or BMP 9 and an inhibitor of MEK1 may be a promising tool for regulating osteosarcoma cell behavior. Anti Cancer Drugs 24:278 290 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Park, Hyunjin; Drevelle, Olivier; Daviau, Alex; Senta, Helena; Bergeron, Eric; Faucheux, Nathalie] Univ Sherbrooke, Dept Chem Engn & Biotechnol Engn, Lab Cell Biomat Biohybrid Syst, Sherbrooke, PQ J1K 2R1, Canada.
   [Senta, Helena; Faucheux, Nathalie] Sherbrooke Univ Hosp Ctr CHUS, Etienne LeBel Clin Res Ctr, Sherbrooke, PQ, Canada.
   [Bergeron, Eric] Ecole Polytech, Dept Engn Phys, Lab Laser Proc & Plasmon, Montreal, PQ H3C 3A7, Canada.
C3 University of Sherbrooke; Universite de Montreal; Polytechnique Montreal
RP Faucheux, N (通讯作者)，Univ Sherbrooke, Dept Chem Engn & Biotechnol Engn, Lab Cell Biomat Biohybrid Syst, 2500 Blvd Univ, Sherbrooke, PQ J1K 2R1, Canada.
EM nathalie.faucheux@usherbrooke.ca
RI Bergeron, Eric/G 6544 2011; Park, Hyun Jin/HSG 6465 2023
OI Drevelle, Olivier/0000 0002 3759 6931
FU Natural Sciences and Engineering Research Council of Canada; Research
   Chair of Canada (Laboratory of Cell, Biomaterials Biohybrid Systems)
FX We thank Dr Owen Parkes for editing the English text. This research was
   supported through a Research Chair of Canada (Laboratory of Cell,
   Biomaterials Biohybrid Systems) and a Natural Sciences and Engineering
   Research Council of Canada program.
CR ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Bergeron E, 2012, TISSUE ENG PT A, V18, P342, DOI [10.1089/ten.tea.2011.0008, 10.1089/ten.TEA.2011.0008]
   Bergeron E, 2009, TISSUE ENG PT A, V15, P3341, DOI [10.1089/ten.tea.2009.0189, 10.1089/ten.TEA.2009.0189]
   Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200
   Buijs JT, 2012, ONCOGENE, V31, P2164, DOI 10.1038/onc.2011.400
   Burkus JK, 2004, ORTHOPEDICS, V27, P723
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood 2006 07 034124
   de Laszlo SE, 1998, BIOORG MED CHEM LETT, V8, P2689, DOI 10.1016/S0960 894X(98)00495 8
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   FRANCESCHI RT, 1985, J CELL PHYSIOL, V123, P401, DOI 10.1002/jcp.1041230316
   Gobbi G, 2002, INT J ONCOL, V20, P143
   Gorlick R, 2010, J BONE MINER RES, V25, P683, DOI 10.1002/jbmr.77
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Huang WB, 2002, EXP CELL RES, V274, P226, DOI 10.1006/excr.2002.5483
   JIANG WG, 2008, Patent No. 2008015383
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Karlen Y, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 131
   Kawano M, 2011, BIOCHEM BIOPH RES CO, V405, P575, DOI 10.1016/j.bbrc.2011.01.071
   Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314
   Kloesch B., 2007, EUR CELLS MATER, V14, P70
   Krattinger N, 2011, EUR CELLS MATER, V21, P46, DOI 10.22203/eCM.v021a04
   Kugimiya F, 2006, J BONE MINER METAB, V24, P95, DOI 10.1007/s00774 005 0653 0
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Liu LF, 2012, J PINEAL RES, V53, P60, DOI 10.1111/j.1600 079X.2011.00971.x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lord E, 2010, GROWTH FACTORS, V28, P149, DOI 10.3109/08977190903512610
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Noh K, 2011, J BONE JOINT SURG AM, V93A, P723, DOI 10.2106/JBJS.J.00302
   Park H, 2010, BIOCHEM BIOPH RES CO, V399, P446, DOI 10.1016/j.bbrc.2010.07.114
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Robitaille K, 2008, CELL DEATH DIFFER, V15, P1522, DOI 10.1038/cdd.2008.77
   RODAN SB, 1987, CANCER RES, V47, P4961
   Saito A, 2003, BBA PROTEINS PROTEOM, V1651, P60, DOI 10.1016/S1570 9639(03)00235 8
   Shapira L, 2009, CLIN ORAL IMPLAN RES, V20, P50, DOI 10.1111/j.1600 0501.2008.01594.x
   Shimo T, 2007, J CELL COMMUN SIGNAL, V1, P103, DOI 10.1007/s12079 007 0010 2
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Suzuki Y, 2000, J BIOMED MATER RES, V50, P405, DOI 10.1002/(SICI)1097 4636(20000605)50:3<405::AID JBM15>3.0.CO;2 Z
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wang L, 2011, CANCER BIOL THER, V11, P457, DOI 10.4161/cbt.11.5.14372
   Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192
   Ye L, 2008, MOL CANCER RES, V6, P1594, DOI 10.1158/1541 7786.MCR 08 0171
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 85
   Zhang Y, 2007, CELL MOL LIFE SCI, V64, P2771, DOI 10.1007/s00018 007 7012 3
NR 52
TC 10
Z9 14
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0959 4973
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD MAR
PY 2013
VL 24
IS 3
BP 278
EP 290
DI 10.1097/CAD.0b013e32835cbde7
PG 13
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 078MX
UT WOS:000314104300007
PM 23262982
DA 2025 08 17
ER

PT J
AU Park, JY
   Kwon, YW
   Kim, SA
   Park, SD
   Kim, CH
   Kim, JH
   Lee, JH
AF Park, Ju Yeon
   Kwon, Young Won
   Kim, Sun Ah
   Park, Sun Dong
   Kim, Chang Hyun
   Kim, Jin Hee
   Lee, Ju Hee
TI Polyherbal formula SC E3 inhibits rheumatoid arthritis activity in a
   mouse model of type II collagen induced arthritis
SO JOURNAL OF INTEGRATIVE MEDICINE JIM
LA English
DT Article
DE Herbal formula; Anti inflammatory; Rheumatoid arthritis;
   Collagen induced arthritis; Osteoclastogenesis
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OSTEOCLAST DIFFERENTIATION; CHRONIC
   INFLAMMATION; NECROSIS FACTOR; BONE EROSION; MECHANISMS; MICE;
   GENIPOSIDE; FLAVONOIDS; CYTOKINES
AB Objective: SC E3 is a polyherbal formula that contains five medicinal herbs used frequently in traditional herbal medicine. In our previous study, we demonstrated the antioxidant and anti inflammatory effects of SC E3. The present study examined the effects of SC E3 in a mouse model of type II collagen induced arthritis (CIA). Methods: In vivo, male DBA/1J mice were immunized by intradermal injection of bovine type II collagen and complete or incomplete Freund's adjuvant, to induce arthritis. SC E3 was orally administered daily for 23 days. In vitro, bone marrow derived macrophages (BMMs) were treated with macrophage colony stimulating factor (M CSF) and receptor activator of nuclear factor kappa B ligand (RANKL) in the absence or presence of SC E3. Results: Administrations of SC E3 were found to have anti arthritic effects in the joints of CIA mice, as evidenced by reduced paw swelling, bone erosion and deformation, inflammatory cell infiltration, and inflammation in synovial membrane. SC E3 also reduced serum levels of tumor necrosis factor a, interleukin 1b, aspartate aminotransferase and alanine aminotransferase. Furthermore, tartrateresistant acid phosphatase positive osteoclast numbers in the joints were significantly lower in SC E3treated CIA mice than in CIA mice. In addition, the differentiations of BMMs to multinucleated osteoclasts induced by M CSF and RANKL stimulation were dose dependently reduced by SC E3. Conclusion: These results suggest that SC E3 possesses substantial anti arthritic activity because it inhibits pro inflammatory cytokines and osteoclastogenesis, and that SC E3 has potential therapeutic use for the treatment of rheumatoid arthritis. Please cite this article as: Park JY, Kwon YW, Kim SA, Park SD, Kim CH, Kim JH, Lee JH. Polyherbal formula SC E3 inhibits rheumatoid arthritis activity in a mouse model of type II collagen induced arthritis. (C) 2020 Shanghai Changhai Hospital. Published by ELSEVIER B.V. All rights reserved.
C1 [Park, Ju Yeon; Kwon, Young Won; Kim, Sun Ah; Park, Sun Dong; Lee, Ju Hee] Dongguk Univ, Coll Korean Med, Goyang 10326, South Korea.
   [Kim, Chang Hyun] Dongguk Univ, Dept Med, Coll Med, Goyang 10326, South Korea.
   [Kim, Jin Hee] Cheongju Univ, Dept Biomed Lab Sci, Coll Hlth Sci, Cheongju 28503, South Korea.
C3 Dongguk University; Dongguk University; Cheongju University
RP Lee, JH (通讯作者)，Dongguk Univ, Coll Korean Med, Goyang 10326, South Korea.; Kim, JH (通讯作者)，Cheongju Univ, Dept Biomed Lab Sci, Coll Hlth Sci, Cheongju 28503, South Korea.
EM jinheekim@snu.ac.kr; jh1548@dongguk.ac.kr
RI Lee, Sang Jin/S 4056 2019; Park, Ju Yeon/MYR 6366 2025; Kim,
   Jin/AAS 5810 2021
OI Lee, Ju Hee/0000 0003 4147 9794; 
FU National Research Foundation of Korea   Korea government
   [2019R1F1A1062998]
FX This work was supported by the National Research Foundation of Korea
   grant funded by the Korea government (No. 2019R1F1A1062998) . The
   funding source was not involved in study design, data collection,
   analysis and interpretation of data, writing the report or in the
   decision of submitting the article for publication.
CR Alamgeer, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1879 9
   Araki Y, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6290682
   Asquith DL, 2009, EUR J IMMUNOL, V39, P2040, DOI 10.1002/eji.200939578
   BABER N, 1979, ANN RHEUM DIS, V38, P128, DOI 10.1136/ard.38.2.128
   Bessone F, 2010, WORLD J GASTROENTERO, V16, P5651, DOI 10.3748/wjg.v16.i45.5651
   Bharate SB, 2019, J INTEGR MED JIM, V17, P192, DOI 10.1016/j.joim.2019.03.001
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Chen L, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1739 7
   Choudhary M, 2015, J INTERCULT ETHNOPHA, V4, P147, DOI 10.5455/jice.20150313021918
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crofford LJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4174
   Dai MM, 2014, INT IMMUNOPHARMACOL, V20, P46, DOI 10.1016/j.intimp.2014.02.021
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gallotti FCM, 2020, RECENT PATENTS INFLA, V14, P95, DOI 10.2174/1872213X14666200228103001
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524
   Heidari B, 2011, CASP J INTERN MED, V2, P161
   Hughes SD, 2017, CRIT REV FOOD SCI, V57, P3601, DOI 10.1080/10408398.2016.1246413
   Jeoung BR, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 47
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kinne RW, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2333
   Kozlowska A., 2014, Rocz Panstw Zakl Hig, V65, P79
   Kumar P, 2013, CLIN MED INSIGHTS AR, V6, P35, DOI 10.4137/CMAMD.S5558
   Kumar V, 2020, J ETHNOPHARMACOL, V254, DOI 10.1016/j.jep.2020.112758
   LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091 6749(93)90078 T
   Lee JM, 2012, MANUAL BOOK SASANG C
   Lee SC, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/1725246
   Lee WS, 2018, CELL BIOL INT, V42, P393, DOI 10.1002/cbin.10861
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710 1492 9 30
   Lubberts E, 2003, ADV EXP MED BIOL, V520, P194
   Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098
   Murdoch JR, 2010, MUTAT RES FUND MOL M, V690, P24, DOI 10.1016/j.mrfmmm.2009.09.005
   Park JY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1874 1
   Pérez Cano FJ, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100659
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Rosengren S, 2003, CLIN DIAGN LAB IMMUN, V10, P1002, DOI 10.1128/CDLI.10.6.1002 1010.2003
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Sostres C, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4175
   Townsend HB, 2004, CLIN EXP RHEUMATOL, V22, pS77
   TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857
   Tsai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051351
   Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431
   Wang CX, 2016, MOL MED REP, V14, P1365, DOI 10.3892/mmr.2016.5357
   Wang R, 2017, PHYTOTHER RES, V31, P631, DOI 10.1002/ptr.5775
   WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762
   Wong SH, 2004, ARCH IMMUNOL THER EX, V52, P379
   Xiao C, 2011, EUR J PHARMACOL, V666, P242, DOI 10.1016/j.ejphar.2011.05.061
   Zhang LS, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01684
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
NR 54
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095 4964
J9 J INTEGR MED JIM
JI J. Integr. Med. JIM
PD MAY
PY 2021
VL 19
IS 3
BP 265
EP 273
DI 10.1016/j.joim.2020.12.001
EA MAY 2021
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA RZ5ZR
UT WOS:000648676000010
PM 33349609
DA 2025 08 17
ER

PT J
AU Deng, XY
   He, GC
   Levine, A
   Ca, Y
   Mullins, C
AF Deng, Xiyun
   He, Guangchun
   Levine, Andrea
   Ca, Ya
   Mullins, Chad
TI Adenovirus mediated expression of TIMP 1 and TIMP 2 in bone inhibits
   osteolytic degradation by human prostate cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; matrix metalloproteinases; tissue inhibitors of
   metalloproteinases; recombinant adenovirus; bone metastasis; SCID hu
   mouse model
ID MATRIX METALLOPROTEINASE INHIBITORS; CARCINOMA CELL LINE; TISSUE
   INHIBITOR; TUMOR GROWTH; PROLONGS SURVIVAL; GENE THERAPY; METASTASIS;
   MODEL; OVEREXPRESSION; ANGIOGENESIS
AB Matrix metalloproteinases (MMPs) are proteolytic enzymes that play critical roles in the pathogenesis of human cancers. Clinical trials using synthetic small molecule MMP inhibitors have been carried out but with little success. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors that block the extracellular matrix degrading activity of MMPs. Here, we investigated the possibilities of genetically modifying human bones with TIMPs to create a high TIMP bone microenvironment, which is hostile to metastatic prostate cancer cells using adenovirus mediated gene transfer technology and SCID hu end organ colonization mouse model. Two strategies were used to achieve bone specific TIMP expression: (i) ex vivo bone adenoviral infection followed by in vivo bone implantation; and (ii) ex vivo BMS cell infection followed by injection into in vivo implanted human fetal bones. PC 3 prostate cancer cells were injected into human fetal bones 4 weeks after implantation in SCID mice. In vitro, adenovirus mediated expression of TIMP 1 or TIMP 2 in bone fragments inhibited MMP 2 activity, bone turnover and prostate cancer cell induced proteolytic degradation as determined by gelatin zymography, calcium measurement and DQ protein quenched fluorescence assay, respectively. In vivo, immunohistochemistry confirmed TIMP 2 expression in AdTIMP 2 infected bone implants 4 weeks after implantation in SCID mice. Mice receiving AdTIMP treated bone fragments showed significantly reduced PC 3 induced osteolysis, osteoclast recruitment and bone turnover in the implanted bones. We propose that adenoviral gene transfer of TIMP 1 and TIMP 2 can prevent the proteolytic activity of prostate cancer cells in bone and that enhancing antiproteolytic defense mechanisms in target organs represents a promising form of prostate cancer gene therapy. (C) 2007 Wiley Liss, Inc.
C1 Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA.
   Cent S Univ, Xiangya Sch Med, Canc Res Inst, Changsha 410083, Hunan, Peoples R China.
   Guangdong Med Coll, China Amer Canc Res Inst, Dongguan, Guangdong, Peoples R China.
   Guangdong Med Coll, Dept Pathophysiol, Dongguan, Guangdong, Peoples R China.
C3 University System of Ohio; Ohio State University; Central South
   University; Guangdong Medical University; Guangdong Medical University
RP Deng, XY (通讯作者)，Ohio State Univ, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.
EM deng_xiyun@yahoo.com
RI Cao, Ya/C 6801 2008
OI Deng, Xiyun/0000 0003 2203 970X
CR ALLEN TD, 1984, EXP HEMATOL, V12, P517
   Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594
   Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063
   BLAVIER L, 1995, J CELL SCI, V108, P3649
   Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645
   Brand K, 2000, CANCER RES, V60, P5723
   Brand Karsten, 2002, Current Gene Therapy, V2, P255, DOI 10.2174/1566523024605564
   Brehmer B, 2003, PROSTATE CANCER P D, V6, P217, DOI 10.1038/sj.pcan.4500657
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Deng XY, 2002, BIOCHEM BIOPH RES CO, V296, P792, DOI 10.1016/S0006 291X(02)00948 8
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555 006 7886 9
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002 9440(10)62337 1
   Eder IE, 2005, CURR GENE THER, V5, P1
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Elezkurtaj S, 2004, J GENE MED, V6, P1228, DOI 10.1002/jgm.637
   Fingleton B, 2006, FRONT BIOSCI LANDMRK, V11, P479, DOI 10.2741/1811
   Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   Hart CA, 2002, BRIT J CANCER, V86, P1136, DOI 10.1038/sj/bjc/6600207
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053
   Hsieh CL, 2004, CANCER GENE THER, V11, P148, DOI 10.1038/sj.cgt.7700665
   Jemal A, 2005, CA CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jodele S, 2006, CANCER METAST REV, V25, P35, DOI 10.1007/s10555 006 7887 8
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kanoh Y, 2002, ANTICANCER RES, V22, P1813
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lein M, 2002, ONCOGENE, V21, P2089, DOI 10.1038/sj.onc.1205267
   Leto G, 2006, ANTICANCER RES, V26, P23
   Li H, 2001, HUM GENE THER, V12, P515, DOI 10.1089/104303401300042429
   Lokeshwar BL, 2002, INT J CANCER, V98, P297, DOI 10.1002/ijc.10168
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Mazhar D, 2004, BJU INT, V93, P465, DOI 10.1111/j.1464 410X.2003.04652.x
   MONTGOMERY AMP, 1994, CANCER RES, V54, P5467
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869
   Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305
   Pinski J, 2005, EUR J CANCER, V41, P932, DOI 10.1016/j.ejca.2004.12.026
   Rabbani SA, 2000, INT J CANCER, V87, P276, DOI 10.1002/1097 0215(20000715)87:2<276::AID IJC20>3.0.CO;2 L
   Ramnath Nithya, 2004, Curr Oncol Rep, V6, P96, DOI 10.1007/s11912 004 0020 7
   Rouis M, 1999, CIRCULATION, V100, P533, DOI 10.1161/01.CIR.100.5.533
   Sameni M, 2001, BIOL CHEM, V382, P785, DOI 10.1515/BC.2001.094
   Sanchez Sweatman Otto H., 1998, Invasion and Metastasis, V18, P297, DOI 10.1159/000024522
   SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0
   Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59
   SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661
   Singh AS, 2006, ONCOL REP, V15, P519
   Stearns M, 1996, ONCOL RES, V8, P69
   STEARNS ME, 1993, CANCER RES, V53, P878
   STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   van der Poel HG, 2006, UROL INT, V77, P50, DOI 10.1159/000092935
   Vergani V, 2001, INT J CANCER, V91, P241, DOI 10.1002/1097 0215(200002)9999:9999<::AID IJC1035>3.3.CO;2 G
   WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167 4838(91)90132 J
   WILSON WD, 2001, BIACORE J, V1, P15
   Zacchigna S, 2004, CANCER GENE THER, V11, P73, DOI 10.1038/sj.cgt.7700657
NR 59
TC 31
Z9 34
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 1
PY 2008
VL 122
IS 1
BP 209
EP 218
DI 10.1002/ijc.23053
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 234WA
UT WOS:000251193700028
PM 17847032
OA Bronze
DA 2025 08 17
ER

PT J
AU Wu, SZ
   Yang, SJ
   Chen, HM
   Peng, FF
   Yu, H
   Krepinsky, JC
   Zhang, BF
AF Wu, Su Zhen
   Yang, Si Jun
   Chen, Hong Min
   Peng, Fang Fang
   Yu, Hong
   Krepinsky, Joan C.
   Zhang, Bai Fang
TI Dual roles of parathyroid hormone related protein in TGF β1 signaling
   and fibronectin up regulation in mesangial cells
SO BIOSCIENCE REPORTS
LA English
DT Article
ID EXTRACELLULAR MATRIX PROTEINS; TGF BETA; DIABETIC NEPHROPATHY;
   TRANSFORMING GROWTH FACTOR BETA 1; POSTMENOPAUSAL OSTEOPOROSIS;
   PTH/PTHRP RECEPTOR; PTHRP; HYPERTROPHY; ACTIVATION; EXPRESSION
AB Little is known about the cross talk between parathyroid hormone (PTH) related protein (PTHrP) and TGF beta 1 in mesangial cells (MCs). Our results showed that PTHrP treatment (<= 3 h) induced internalization of PTH1R (PTH/PTHrP receptor) T beta RII (TGF beta type 2 receptor) complex and suppressed TGF beta 1 mediated Smad2/3 activation and fibronectin (FN) up regulation. However, prolonged PTHrP treatment (12 48 h) failed to induce PTH1R T beta RII association and internalization. Total protein levels of PTH1R and T beta RII were unaffected by PTHrP treatment. These results suggest that internalization of PTH1R and T beta RII after short PTHrP treatment might not lead to their proteolytic destruction, allowing the receptors to be recycled back to the plasma membrane during prolonged PTHrP exposure. Receptor re expression at the cell surface allows PTHrP to switch from its initial inhibitory effect to promote induction of FN. Our study thus demonstrates the dual roles of PTHrP on TGF beta 1 signaling and FN up regulation for the first time in glomerular MCs. These data also provided new insights to guide development of therapy for diabetic kidney disease (DKD).
C1 [Wu, Su Zhen; Chen, Hong Min; Peng, Fang Fang; Yu, Hong; Zhang, Bai Fang] Wuhan Univ, Dept Biochem, Sch Basic Med Sci, Wuhan, Hubei, Peoples R China.
   [Wu, Su Zhen; Chen, Hong Min; Peng, Fang Fang; Yu, Hong; Zhang, Bai Fang] Wuhan Univ, Hubei Prov Key Lab Dev Originated Dis, Sch Basic Med Sci, Wuhan, Hubei, Peoples R China.
   [Wu, Su Zhen] Gannan Med Univ, Biochem Dept, Ganzhou, Peoples R China.
   [Yang, Si Jun] Wuhan Univ, Sch Med, ABSL Lab 3, Ctr Expt Anim, Wuhan, Hubei, Peoples R China.
   [Yang, Si Jun] Wuhan Univ, Sch Med, State Key Lab Virol, Wuhan, Hubei, Peoples R China.
   [Krepinsky, Joan C.] McMaster Univ, Div Nephrol, Hamilton, ON, Canada.
C3 Wuhan University; Wuhan University; Gannan Medical University; Wuhan
   University; Wuhan University; McMaster University
RP Zhang, BF (通讯作者)，Wuhan Univ, Dept Biochem, Sch Basic Med Sci, Wuhan, Hubei, Peoples R China.; Zhang, BF (通讯作者)，Wuhan Univ, Hubei Prov Key Lab Dev Originated Dis, Sch Basic Med Sci, Wuhan, Hubei, Peoples R China.
EM zbfwq@whu.edu.cn
RI ; Wu, Suzhen/AEM 0170 2022
OI wu, suzhen/0000 0002 0980 3091; yang, sijun/0000 0003 4358 4002
FU National Natural Science Foundation of China [81370819, 81070643]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers 81370819, 81070643].
CR Bosch RJ, 1999, AM J PHYSIOL ENDOC M, V277, pE990, DOI 10.1152/ajpendo.1999.277.6.E990
   Böttinger EP, 2007, SEMIN NEPHROL, V27, P309, DOI 10.1016/j.semnephrol.2007.02.009
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Esbrit P, 2001, AM J NEPHROL, V21, P179, DOI 10.1159/000046244
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Fujinaka Y, 2004, DIABETES, V53, P3120, DOI 10.2337/diabetes.53.12.3120
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Hirai T, 2011, P NATL ACAD SCI USA, V108, P191, DOI 10.1073/pnas.1005011108
   Hochane M, 2013, ENDOCRINOLOGY, V154, P853, DOI 10.1210/en.2012 1802
   Horwitz MJ, 2010, J CLIN ENDOCR METAB, V95, P1279, DOI 10.1210/jc.2009 0233
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Hu C, 2015, CURR MED CHEM, V22, P2858, DOI 10.2174/0929867322666150625095407
   Ikushima H, 2012, CELL TISSUE RES, V347, P37, DOI 10.1007/s00441 011 1179 5
   Izquierdo A, 2006, KIDNEY INT, V69, P2171, DOI 10.1038/sj.ki.5000195
   Kolm V, 1996, AM J PHYSIOL RENAL, V270, pF812, DOI 10.1152/ajprenal.1996.270.5.F812
   Krepinsky JC, 2003, J AM SOC NEPHROL, V14, P2790, DOI 10.1097/01.ASN.0000094085.04161.A7
   Largo R, 1999, KIDNEY INT, V55, P82, DOI 10.1046/j.1523 1755.1999.00241.x
   López Hernández FJ, 2012, CELL TISSUE RES, V347, P141, DOI 10.1007/s00441 011 1275 6
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Massfelder T, 1996, BRIT J PHARMACOL, V118, P1995, DOI 10.1111/j.1476 5381.1996.tb15635.x
   Maycas M, 2017, J BONE MINER RES, V32, P486, DOI 10.1002/jbmr.3007
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   MCKAY NG, 1993, EXP MOL PATHOL, V59, P211, DOI 10.1006/exmp.1993.1040
   Mozar A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158414
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Ortega A, 2012, J CELL PHYSIOL, V227, P1980, DOI 10.1002/jcp.22926
   Peng FF, 2016, BIOCHEM BIOPH RES CO, V478, P1093, DOI 10.1016/j.bbrc.2016.08.073
   Peng FF, 2007, J AM SOC NEPHROL, V18, P189, DOI 10.1681/ASN.2006050498
   Poncelet AC, 1998, AM J PHYSIOL RENAL, V275, pF458
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Romero M, 2010, NEPHROL DIAL TRANSPL, V25, P2447, DOI 10.1093/ndt/gfq104
   Santos S, 2001, KIDNEY INT, V60, P982, DOI 10.1046/j.1523 1755.2001.060003982.x
   Sutariya B, 2016, IMMUNOPHARM IMMUNOT, V38, P39, DOI 10.3109/08923973.2015.1127382
   SUZUKI S, 1993, EXP NEPHROL, V1, P229
   Tawfeek HAW, 2004, AM J PHYSIOL ENDOC M, V286, pE704, DOI 10.1152/ajpendo.00404.2003
   Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165 6147(00)01620 5
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200
   Williams K, 2011, DIABETOLOGIA, V54, P2867, DOI 10.1007/s00125 011 2260 z
   Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523 1755.1999.00590.x
   Wu DC, 2009, J AM SOC NEPHROL, V20, P554, DOI 10.1681/ASN.2008040445
   Wu TT, 2013, AM J PHYSIOL RENAL, V304, pF820, DOI 10.1152/ajprenal.00294.2012
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
NR 44
TC 6
Z9 6
U1 1
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144 8463
EI 1573 4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD OCT 31
PY 2017
VL 37
AR BSR20171061
DI 10.1042/BSR20171061
PN 5
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FU0XA
UT WOS:000423572500023
PM 28954822
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Tseng, PC
   Hou, SM
   Chen, RJ
   Peng, HW
   Hsieh, CF
   Kuo, ML
   Yen, ML
AF Tseng, Pei Chi
   Hou, Sheng Mou
   Chen, Ruey Jien
   Peng, Hsiao Wen
   Hsieh, Chi Fen
   Kuo, Min Liang
   Yen, Men Luh
TI Resveratrol Promotes Osteogenesis of Human Mesenchymal Stem Cells by
   Upregulating RUNX2 Gene Expression via the SIRT1/FOXO3A Axis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE RESVERATROL; SIRT1; FOXO3A; RUNX2; OSTEOGENESIS; MESENCHYMAL STEM CELLS
ID FOXO TRANSCRIPTION FACTORS; SMALL MOLECULE ACTIVATORS; FORKHEAD BOX O;
   OXIDATIVE STRESS; OSTEOBLAST DIFFERENTIATION; BETA CATENIN; SIRT1; BONE;
   PROLIFERATION; ADIPOCYTES
AB Reports of the bone protective effects of resveratrol, a naturally occurring phytoestrogen and agonist for the longevity gene SIRT1, have highlighted this compound as a candidate for therapy of osteoporosis. Moreover, SIRT1 antagonism enhances adipogenesis. There has been speculation that resveratrol can promote osteogenesis through SIRT1, but the mechanism remains unclear. In this study we investigated the molecular mechanism of how resveratrol can modulate the lineage commitment of human mesenchymal stem cells to osteogenesis other than adipogenesis. We found that resveratrol promoted spontaneous osteogenesis but prevented adipogenesis in human embryonic stem cell derived mesenchymal progenitors. Resveratrol upregulated the expression of osteo lineage genes RUNX2 and osteocalcin while suppressing adipo lineage genes PPAR gamma 2 and LEPTIN in adipogenic medium. Furthermore, we found that the osteogenic effect of resveratrol was mediated mainly through SIRT1/FOXO3A with a smaller contribution from the estrogenic pathway. Resveratrol activated SIRT1 activity and enhanced FOXO3A protein expression, a known target of SIRT1, in an independent manner. As a result, resveratrol increased the amount of the SIRT1 FOXO3A complex and enhanced FOXO3A dependent transcriptional activity. Ectopic overexpression or silencing of SIRT1/FOXO3A expression regulated RUNX2 promoter activity, suggesting an important role for SIRT1 FOXO3A complex in regulating resveratrol induced RUNX2 gene transcription. Further mutational RUNX2 promoter analysis and chromatin immunoprecipitation assay revealed that resveratrol induced SIRT1 FOXO3A complex bound to a distal FOXO response element ( 1269/ 1263), an action that transactivated RUNX2 promoter activity in vivo. Taken together, our results describe a novel mechanism of resveratrol in promoting osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. (C) 2011 American Society for Bone and Mineral Research.
C1 [Tseng, Pei Chi; Peng, Hsiao Wen; Hsieh, Chi Fen; Yen, Men Luh] Natl Taiwan Univ, Coll Med, Dept Primary Care Med, Taipei 10051, Taiwan.
   [Chen, Ruey Jien; Yen, Men Luh] Natl Taiwan Univ, Coll Med, Dept Obstet Gynecol, Taipei 10051, Taiwan.
   [Kuo, Min Liang] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10051, Taiwan.
   [Tseng, Pei Chi; Hou, Sheng Mou] Shin Kong Wo Ho Su Mem Hosp, Dept Orthoped Surg, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan
   University; Shin Kong Wu Ho Su Memorial Hospital
RP Yen, ML (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Primary Care Med, 1 Jen Ai Rd,Sect 1, Taipei 10051, Taiwan.
EM pctseng@ntu.edu.tw; mlyen@ntu.edu.tw
RI ; Kuo, Min Liang/C 4872 2009; Chen, Renjie/KIA 2659 2024
OI KUO, MIN LIANG/0000 0002 7139 0144; CHEN, RUEY JIEN/0000 0003 0291 006X;
   YEN, MEN LUH/0000 0003 3800 3664
FU Taiwan National Science Council [NSC 99 3111 B 002 005, NSC
   97 2314 B 002 060 MY3]
FX We acknowledge Dr ME Greenberg for providing expression plasmids to
   Addgene, including flag SIRT1, flag SIRT1 H363Y, HA FOXO3A, and
   HA FOXO3A DBM (H212R). This work was supported in part by NSC
   99 3111 B 002 005 and NSC 97 2314 B 002 060 MY3 from the Taiwan National
   Science Council.
CR Abeyta MJ, 2004, HUM MOL GENET, V13, P601, DOI 10.1093/hmg/ddh068
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Bäckesjö CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Cao ZX, 2004, EUR J PHARMACOL, V489, P39, DOI 10.1016/j.ejphar.2004.02.031
   Couzin J, 2003, SCIENCE, V302, P1136, DOI 10.1126/science.302.5648.1136
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Escande C, 2010, J CLIN INVEST, V120, P545, DOI 10.1172/JCI39319
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim MJ, 2009, FEBS LETT, V583, P1183, DOI 10.1016/j.febslet.2009.03.007
   Knutson MD, 2008, NUTR REV, V66, P591, DOI 10.1111/j.1753 4887.2008.00109.x
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lian QZ, 2007, STEM CELLS, V25, P425, DOI 10.1634/stemcells.2006 0420
   Libert S, 2008, NAT CELL BIOL, V10, P373, DOI 10.1038/ncb0408 373
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092 8674(01)00524 4
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78
   Olivier EN, 2006, STEM CELLS, V24, P1914, DOI 10.1634/stemcells.2005 0648
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Rahman I, 2008, NUTR REV, V66, pS42, DOI 10.1111/j.1753 4887.2008.00067.x
   Rosen CJ, 2008, CELL METAB, V7, P7, DOI 10.1016/j.cmet.2007.12.004
   Sakamoto T, 2010, J NUTR BIOCHEM, V21, P856, DOI 10.1016/j.jnutbio.2009.06.010
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Song LH, 2006, TOXICOL IN VITRO, V20, P915, DOI 10.1016/j.tiv.2006.01.016
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303 7207(03)00151 5
   Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712
   van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092 8674(01)00527 X
   Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796
   Yen BL, 2009, STEM CELLS, V27, P451, DOI 10.1634/stemcells.2008 0390
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Zhou HB, 2009, EXP CELL RES, V315, P2953, DOI 10.1016/j.yexcr.2009.07.030
NR 47
TC 253
Z9 282
U1 3
U2 68
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2011
VL 26
IS 10
BP 2552
EP 2563
DI 10.1002/jbmr.460
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 824ZQ
UT WOS:000295241100022
PM 21713995
OA Bronze
DA 2025 08 17
ER

PT J
AU Lin, HB
   Chen, Z
   Guo, QQ
   Zhang, PP
   Tian, Y
   Chen, HS
   Zhao, HP
   Shen, YQ
AF Lin, Hongbing
   Chen, Zhen
   Guo, Qianqian
   Zhang, Peipei
   Tian, Yue
   Chen, Huishan
   Zhao, Haiping
   Shen, Yuqin
TI Deer Antler Reserve Mesenchyme Cell Conditioned Medium Reduces the
   Destruction of Periodontitis in Mice
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE reserve mesenchyme cells; conditioned medium; periodontitis; osteoclast;
   macrophage
ID STEM CELLS; REGENERATION; POLARIZATION; THERAPY
AB Reserve mesenchyme cells (RMCs) are a type of antler stem cells (ASCs) that contribute to the rapid growth of deer antlers, the only known mammalian organ that can fully regenerate annually. Based on the prior evidence, ASC conditioned medium could improve regenerative cutaneous healing in rats. The purpose of the study was to evaluate the therapeutic effects of RMC conditioned medium (RMC CM) on reducing the destruction in the mice periodontitis (PD) model and the underlying mechanisms. The lipopolysaccharide (LPS) stimulated RAW264.7 cells were used in vitro to verify the effects of RMC CM. The results revealed that RMC CM could significantly reduce bone resorption and osteoclast activation, upregulate anti inflammatory macrophages (M2) related interleukin (IL) 10 and CD206, and downregulate pro inflammatory macrophages (M1) related tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase in vivo. In vitro, RMC CM could significantly promote LPS stimulated RAW264.7 cells migration, reduce osteoclast differentiation, downregulate the expression of TNF alpha, IL 6, and IL 1 beta, and upregulate the expression of IL 10 and arginase 1. According to the results, we concluded that RMC CM could significantly reduce alveolar bone resorption and inhibit inflammation in gingival tissue by decreasing the activation of osteoclasts and inducing macrophage polarization toward the M2 phenotype. This study may serve as the experimental foundation for RMC CM in the treatment of PD.
C1 [Lin, Hongbing; Zhang, Peipei; Tian, Yue; Chen, Huishan; Shen, Yuqin] Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun, Peoples R China.
   [Chen, Zhen; Shen, Yuqin] Guangzhou Med Univ, Affiliated Stomatol Hosp, Dept Periodont, Guangzhou Key Lab Basic & Appl Res Oral Regenerat, Guangzhou, Peoples R China.
   [Guo, Qianqian] Chinese Acad Agr Sci CAAS, Inst Special Anim & Plant Sci, Changchun, Peoples R China.
   [Zhao, Haiping] Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao, Peoples R China.
   [Guo, Qianqian] Changchun Scitech Univ, Inst Antler Sci & Prod Technol, Changchun, Peoples R China.
   [Shen, Yuqin] Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Jilin, Peoples R China.
   [Zhao, Haiping] Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao 266109, Shandong, Peoples R China.
C3 Jilin University; Guangzhou Medical University; Chinese Academy of
   Agricultural Sciences; Institute of Special Animal & Plant Sciences,
   CAAS; Qingdao Agricultural University; Jilin University; Qingdao
   Agricultural University
RP Shen, YQ (通讯作者)，Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun, Peoples R China.; Shen, YQ (通讯作者)，Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Jilin, Peoples R China.; Zhao, HP (通讯作者)，Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao 266109, Shandong, Peoples R China.
EM zhperic@163.com; 2020686041@gzhmu.edu.cn
RI zhao, haiping/GVR 9191 2022; 赵, 海平/GVR 9191 2022
OI zhao, haiping/0000 0002 5153 4681; 
CR Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Bashir S, 2016, INFLAMM RES, V65, P1, DOI 10.1007/s00011 015 0874 1
   Bernhardt A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052451
   Bian YF, 2019, IUBMB LIFE, V71, P1048, DOI 10.1002/iub.2074
   Bosshardt DD, 2009, PERIODONTOL 2000, V51, P208, DOI 10.1111/j.1600 0757.2009.00317.x
   Chew JRJ, 2019, ACTA BIOMATER, V89, P252, DOI 10.1016/j.actbio.2019.03.021
   Cidonio G, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab19fd
   Gaggi G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186589
   Galván Peña S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420
   Gan L, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8864572
   Garaicoa Pazmino C, 2019, J CLIN PERIODONTOL, V46, P830, DOI 10.1111/jcpe.13156
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Jiao YZ, 2013, CELL HOST MICROBE, V13, P595, DOI 10.1016/j.chom.2013.04.005
   Katagiri W, 2017, IMPLANT DENT, V26, P607, DOI 10.1097/ID.0000000000000618
   Katagiri W, 2016, HEAD FACE MED, V12, DOI 10.1186/s13005 016 0101 5
   Ker DFE, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1027 6
   Kumar LP, 2019, CYTOKINE GROWTH F R, V46, P1, DOI 10.1016/j.cytogfr.2019.04.002
   Lei H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582772
   Lei JH, 2022, PROTEIN CELL, V13, P220, DOI 10.1007/s13238 021 00860 9
   Li C, 2008, J EXP ZOOL PART B, V310B, P267, DOI 10.1002/jez.b.21210
   Li CY, 2014, INT J BIOCHEM CELL B, V56, P111, DOI 10.1016/j.biocel.2014.07.007
   Liu JY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1409 4
   Liu J, 2019, CELLS BASEL, V8, DOI 10.3390/cells8060537
   Liu LL, 2020, BMC IMMUNOL, V21, DOI 10.1186/s12865 020 00355 y
   Madrigal M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0260 8
   Marchesan J, 2018, NAT PROTOC, V13, P2247, DOI 10.1038/s41596 018 0035 4
   Nagata M, 2017, TISSUE ENG PT A, V23, P367, DOI [10.1089/ten.tea.2016.0274, 10.1089/ten.TEA.2016.0274]
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Panta W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123016
   Parisi L, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8917804
   Qiu JL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 019 1546 9
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Rong XL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1457 9
   Rong XL, 2020, CELL TISSUE RES, V379, P195, DOI 10.1007/s00441 019 03081 z
   Shen ZS, 2020, BIOACT MATER, V5, P1113, DOI 10.1016/j.bioactmat.2020.07.002
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Song L, 2019, MOL MED REP, V19, P4743, DOI 10.3892/mmr.2019.10155
   Sui ZG, 2020, J CHROMATOGR A, V1609, DOI 10.1016/j.chroma.2019.460496
   Tsukasaki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03147 6
   von Bahr L, 2012, STEM CELLS, V30, P1575, DOI 10.1002/stem.1118
   Wang DT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1686 y
   Wang LX, 2019, J LEUKOCYTE BIOL, V106, P345, DOI 10.1002/JLB.3RU1018 378RR
   Xu XY, 2019, STEM CELL TRANSL MED, V8, P392, DOI 10.1002/sctm.18 0181
   Yamamoto M, 2021, PERIODONTOL 2000, V86, P142, DOI 10.1111/prd.12367
   Yang JM, 2018, ARCH ORAL BIOL, V96, P234, DOI 10.1016/j.archoralbio.2017.03.006
   Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050 7771 2 1
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
NR 52
TC 3
Z9 5
U1 0
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD DEC 1
PY 2022
VL 31
IS 23 24
BP 766
EP 776
DI 10.1089/scd.2022.0110
EA OCT 2022
PG 11
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 6S5JU
UT WOS:000872971600001
PM 36114617
DA 2025 08 17
ER

PT J
AU Sayed, NFE
   El Hussieny, M
   Mansour, ST
   Fouad, MA
   Saad, MA
   Ewies, EF
AF Sayed, Naglaa F. El 
   El Hussieny, Marwa
   Mansour, Shaimaa T.
   Fouad, Marwa A.
   Saad, Muhammed A.
   Ewies, Ewies F.
TI Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis
   efficacy in ovariectomized rats: A mixed binding approach beyond
   bisphosphonates
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Antiosteoporosis; Farnesyl pyrophosphate synthase inhibitor;
   Non bisphosphonate; Ovariectomized rats; Vanillin; Zoledronate
ID OSTEOCLASTOGENESIS; DIFFERENTIATION; BEHAVIOR; CELLS
AB The primary focus of bisphosphonate medications is on targeting human farnesyl pyrophosphate synthase (hFPPS), an essential regulator of mammalian isoprenoids. Yet, these drugs encounter limitations due to their restricted "druglike" properties and their effectiveness primarily in treating skeletal disorders. In this study, we synthesized novel non bisphosphonate compounds, using 4,4 ' (ethane 1,2 diylbis(oxy))bis(3 methox  ybenzaldehyde) ( 1 ) as a starting compound, with the aim of targeting hFPPS through a mixed binding approach. Among the various compounds tested, compounds 4a and 4b exhibited significant inhibition of hFPPS activity, with IC 50 values of 1.108 and 1.24 mu M, respectively. Docking studies further revealed that both compounds bound within the allylic binding site and near the isopentenyl diphosphate (IPP) site within the hFPPS pocket. Molecular dynamic simulations were performed on the best docking pose of the most potent compound 4a to confirm the formation of a stable complex with hFPPS. In an in vivo study conducted on ovariectomized rats, various biochemical markers including osteocalcin, estradiol, osteoprotegerin, bone mineral content, and density were negatively impacted, while levels of bone specific alkaline phosphatase, receptor activator of nuclear factor kappa  & Vcy; ligand, serum/urinary calcium, and phosphate increased. Notably, compound 4a exhibited antiresorptive properties similar to zoledronate, effectively restoring most of the perturbed biochemical estimations. These findings suggest the potential of compound 4a , a non bisphosphonate compound, as alternative therapeutic agents for combating osteoporosis.
C1 [Sayed, Naglaa F. El ; El Hussieny, Marwa; Mansour, Shaimaa T.; Ewies, Ewies F.] Natl Res Ctr, Organometall & Organometalloid Chem Dept, 33 ElBohouth St, Giza 12622, Egypt.
   [Fouad, Marwa A.] Cairo Univ, Fac Pharm, Pharmaceut Chem Dept, Kasr El Aini St, Cairo 11562, Egypt.
   [Fouad, Marwa A.] Newgiza Univ, Sch Pharm, Pharmaceut Chem Dept, Km 22 Cairo Alexandria Desert Rd, Cairo, Egypt.
   [Saad, Muhammed A.] Gulf Med Univ, Coll Pharm, Dept Pharmaceut Sci, POB 4184, Ajman, U Arab Emirates.
   [Saad, Muhammed A.] Cairo Univ, Fac Pharm, Pharmacol & Toxicol Dept, Cairo, Egypt.
   [Fouad, Marwa A.] Cairo Univ, Newgiza Univ, Fac Pharm,Pharm Chem Dept, Sch Pharm, Km 22 Cairo Alexandria Desert Rd, Cairo 11562, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian
   Knowledge Bank (EKB); Cairo University; Newgiza University (NGU);
   Egyptian Knowledge Bank (EKB); Cairo University; Newgiza University
   (NGU); Egyptian Knowledge Bank (EKB); Cairo University
RP Ewies, EF (通讯作者)，Natl Res Ctr, Organometall & Organometalloid Chem Dept, 33 ElBohouth St, Giza 12622, Egypt.; Fouad, MA (通讯作者)，Cairo Univ, Fac Pharm, Pharmaceut Chem Dept, Kasr El Aini St, Cairo 11562, Egypt.; Fouad, MA (通讯作者)，Newgiza Univ, Sch Pharm, Pharmaceut Chem Dept, Km 22 Cairo Alexandria Desert Rd, Cairo, Egypt.; Fouad, MA (通讯作者)，Cairo Univ, Newgiza Univ, Fac Pharm,Pharm Chem Dept, Sch Pharm, Km 22 Cairo Alexandria Desert Rd, Cairo 11562, Egypt.
EM marwa.fouad@pharma.cu.edu.eg
RI Ewies, Ewies F./E 4356 2017; El Hussieny, Marwa/ABF 1052 2020; ElSayed,
   Naglaa/ABE 9782 2020; Ewies, Ewies/E 4356 2017; Fouad, Marwa/C 6908 2017
OI Ewies, Ewies F./0000 0002 4832 5766; F. El Sayed,
   Naglaa/0000 0002 3226 9093; Fouad, Marwa/0000 0003 3227 8683
FU National Research Centre
FX The authors thank the National Research Centre for the financial
   support, and NewGiza University for licence of software.
CR Abd El Maksoud M.A., Research Journal of Pharmaceutical, Biological and Chemical Sciences
   Abo Elenin MHH, 2024, CLIN TRANSL METAB, V22, DOI 10.1007/s12018 024 09291 6
   Ali A., 2017, Inorg. Chem. Ind. J., V12, P111
   [Anonymous], 1965, ANGEW CHEM, V77, P850
   Baud'huin M, 2007, EXPERT REV ANTICANC, V7, P221, DOI 10.1586/14737140.7.2.221
   Beard R.L., 2010, Indole 3  carboxylic Acid Amide, Ester, Thioamide and Thiol Ester Compounds Bearing Aryl or Heteroaryl Groups Having Sphingosine 1 Phosphate(S1P) Receptor Antagonist Biological Activity
   Bekheit MS, 2024, DRUG DEVELOP RES, V85, DOI 10.1002/ddr.22135
   Boldarine VT, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47152 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cadogan J.L.G., 1979, ORGANOPHOSPHORUS REA
   Chen YQ, 2018, LIFE SCI, V208, P305, DOI 10.1016/j.lfs.2018.07.048
   Cheon Songhee, 2017, Osong Public Health Res Perspect, V8, P227, DOI 10.24171/j.phrp.2017.8.3.10
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   El Hussieny M, 2015, PHOSPHORUS SULFUR, V190, P1845, DOI 10.1080/10426507.2015.1025904
   El Hussieny M, 2020, BIOORG CHEM, V95, DOI 10.1016/j.bioorg.2019.103521
   El Sayed NF, 2020, BIOORG CHEM, V95, DOI 10.1016/j.bioorg.2019.103499
   Ewies EF, 2019, EUR J MED CHEM, V180, P310, DOI 10.1016/j.ejmech.2019.07.029
   Gao JB, 2010, CHEM COMMUN, V46, P5340, DOI 10.1039/c0cc00992j
   Gayen KS, 2020, ASIAN J ORG CHEM, V9, P508, DOI 10.1002/ajoc.202000032
   Hafez T.S., 2007, Egypt. J. Chem., V50, P45
   Halder M, 2024, BIOMACROMOLECULES, V25, P2286, DOI 10.1021/acs.biomac.3c01148
   Ibrahim NM, 2006, PHOSPHORUS SULFUR, V181, P1773, DOI 10.1080/10426500500536523
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Johnson A.W., 2012, Ylid Chemistry
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kim T. H., 2024, In Vivo and Clinical Studies
   KIRBY GW, 1993, PHOSPHORUS SULFUR, V74, P17, DOI 10.1080/10426509308038098
   Mahran MRH, 1998, PHOSPHORUS SULFUR, V139, P13, DOI 10.1080/10426509808035674
   Maigali SS, 2014, J CHEM RES, P754, DOI 10.3184/174751914X14179446629855
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   MCGREGOR WM, 1993, CHEM SOC REV, V22, P199, DOI 10.1039/cs9932200199
   Merino P, 2017, RSC ADV, V7, P10947, DOI 10.1039/c6ra28316k
   MUSTAFA A, 1968, LIEBIGS ANN CHEM, V712, P116
   Park J, 2021, FRONT CHEM, V8, DOI 10.3389/fchem.2020.612728
   Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14132
   Peled A, 2012, EXPERT OPIN INV DRUG, V21, P341, DOI 10.1517/13543784.2012.656197
   Pizzino G, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00558
   RAMIREZ F, 1966, J ORG CHEM, V31, P4105, DOI 10.1021/jo01350a055
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsourdi E., 2020, PRINCIPLES BONE BIOL, P1689
   Uçar RA, 2024, BIOTECHNOL BIOPROC E, V29, P69, DOI 10.1007/s12257 024 00006 8
   Wang P, 2016, P NATL ACAD SCI USA, V113, pE4726, DOI 10.1073/pnas.1609198113
   Wang XX, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1333993
NR 49
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD OCT 5
PY 2024
VL 276
AR 116679
DI 10.1016/j.ejmech.2024.116679
EA JUL 2024
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA ZB8G7
UT WOS:001272916200001
PM 39018923
DA 2025 08 17
ER

PT J
AU Saji, VS
   Kumeria, T
   Gulati, K
   Prideaux, M
   Rahman, S
   Alsawat, M
   Santos, A
   Atkins, GJ
   Losic, D
AF Saji, Viswanathan S.
   Kumeria, Tushar
   Gulati, Karan
   Prideaux, Matthew
   Rahman, Shafiur
   Alsawat, Mohammed
   Santos, Abel
   Atkins, Gerald J.
   Losic, Dusan
TI Localized drug delivery of selenium (Se) using nanoporous anodic
   aluminium oxide for bone implants
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID PROSTATE CANCER; CELLULAR UPTAKE; NANOPARTICLES; ANTICANCER;
   ANTIOXIDANT; MEMBRANES; RELEASE; OSTEOSARCOMA; OSTEOBLASTS; NANOSPHERES
AB Electrochemically engineered nanoporous anodized aluminium oxide (AAO) prepared on aluminium (Al) foil by anodization process was employed as a platform for loading different forms of selenium (Se) in order to investigate their release behaviour and potential application for localized drug delivery targeting bone cancer. Several forms of Se including inorganic Se (H2SeO3), organic Se ((C6H5)(2)Se 2), metallic Se, their chitosan composites, electrodeposited (ED) and chemical vapour deposited (CVD) Se were explored and combined with another model drug (indomethacin). Structural, drug loading and in vitro drug releasing characteristics of prepared Se based drug delivery carriers were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA) and UV visible spectroscopy (UV Vis), respectively. Sustained and controlled release of Se was demonstrated through chitosan composites of inorganic, organic or metallic forms of Se loaded into nanoporous AAO carriers. Cell viability studies showed decreasing toxicity to cancer cells in the order: inorganic Se > ED Se > CVD Se > metallic Se > organic Se. The study suggests new alternatives for localized drug treatment based on low cost nano engineered carriers loaded with Se having anti cancer properties.
C1 [Saji, Viswanathan S.; Kumeria, Tushar; Gulati, Karan; Rahman, Shafiur; Alsawat, Mohammed; Santos, Abel; Losic, Dusan] Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia.
   [Prideaux, Matthew; Atkins, Gerald J.] Univ Adelaide, Discipline Orthopaed & Trauma, Adelaide, SA 5005, Australia.
C3 University of Adelaide; University of Adelaide
RP Saji, VS (通讯作者)，Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia.
EM vssaji@hotmail.com; dusan.losic@adelaide.edu.au
RI ; Losic, Dusan/B 2436 2009; Rahman, Shafiur/LFV 5206 2024; Santos,
   Abel/U 7181 2017
OI Saji, Viswanathan S./0000 0003 1724 0011; Losic,
   Dusan/0000 0002 1930 072X; /0000 0003 3351 7148; Gulati,
   Karan/0000 0002 0927 8362; Prideaux, Matt/0000 0001 9211 9698; Atkins,
   Gerald/0000 0002 3123 9861; Santos, Abel/0000 0002 5081 5684
FU Australian Department of Education; Australian Research Council [FT
   FT110100711, DP120101680]
FX The authors acknowledge Endeavour Research Fellowship from the
   Australian Department of Education to support VSS. The financial support
   from Australian Research Council (FT FT110100711 and DP120101680) is
   also acknowledged. We thank members of the Losic Nano research group,
   School of Chemical Engineering, The University of Adelaide for their
   help during this study. The support from the technical staff from the
   Adelaide Microscopy, University of Adelaide, for providing SEM imaging
   facilities is also acknowledged.
CR Akhmetov H. C., 1973, INORG CHEM, P298
   Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756 3282(02)00858 X
   Aw MS, 2014, BIOMATER SCI UK, V2, P10, DOI 10.1039/c3bm60196j
   Bleiman N, 2010, J HAZARD MATER, V183, P590, DOI 10.1016/j.jhazmat.2010.07.065
   Brandao R, 2009, J APPL TOXICOL, V29, P612, DOI 10.1002/jat.1449
   Chen XY, 2013, COLLOID SURFACE B, V103, P149, DOI 10.1016/j.colsurfb.2012.10.022
   Dhanjal S, 2010, MICROB CELL FACT, V9, DOI 10.1186/1475 2859 9 52
   Donnenberg VS, 2010, TISSUE ENG PART B RE, V16, P567, DOI [10.1089/ten.teb.2010.0352, 10.1089/ten.TEB.2010.0352]
   Drake EN, 2006, MED HYPOTHESES, V67, P318, DOI 10.1016/j.mehy.2006.01.058
   Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960
   Dwivedi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057404
   Ferrari S, 2005, J CLIN ONCOL, V23, P8845, DOI 10.1200/JCO.2004.00.5785
   Flohe L., 2011, SELENIUM TELLURIUM C, P285
   Huang YY, 2013, BIOMATERIALS, V34, P7106, DOI 10.1016/j.biomaterials.2013.04.067
   Jani AMM, 2013, PROG MATER SCI, V58, P636, DOI 10.1016/j.pmatsci.2013.01.002
   Jeon G, 2012, J MATER CHEM, V22, P14814, DOI 10.1039/c2jm32430j
   Kang HJ, 2007, THIN SOLID FILMS, V515, P5184, DOI 10.1016/j.tsf.2006.10.029
   Kohara S, 1998, CHEM PHYS LETT, V287, P282, DOI 10.1016/S0009 2614(98)00184 5
   Kumeria T, 2014, ACS APPL MATER INTER, V6, P12971, DOI 10.1021/am502882d
   La Flamme KE, 2007, BIOMATERIALS, V28, P2638, DOI 10.1016/j.biomaterials.2007.02.010
   Lin ZH, 2005, MATER CHEM PHYS, V92, P591, DOI 10.1016/j.matchemphys.2005.02.023
   Liu W, 2012, ACS NANO, V6, P6578, DOI 10.1021/nn202452c
   Marshall J. R., 2007, ENCY CANC SOC, P785
   MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466
   Oremland RS, 2004, APPL ENVIRON MICROB, V70, P52, DOI 10.1128/AEM.70.1.52 60.2004
   Plano D, 2010, MOLECULES, V15, P7292, DOI 10.3390/molecules15107292
   Ramos JF, 2012, INT J NANOMED, V7, P3907, DOI 10.2147/IJN.S33767
   Reid ME, 2008, NUTR CANCER, V60, P155, DOI 10.1080/01635580701684856
   Roman M, 2014, METALLOMICS, V6, P25, DOI 10.1039/c3mt00185g
   Rosa RM, 2007, MUTAT RES GEN TOX EN, V631, P44, DOI 10.1016/j.mrgentox.2007.04.005
   Saji VS, 2013, RSC ADV, V3, P10058, DOI 10.1039/c3ra40678d
   Santos A, 2014, J MATER CHEM B, V2, P6157, DOI 10.1039/c4tb00548a
   Seng HL, 2012, APPL ORGANOMET CHEM, V26, P655, DOI 10.1002/aoc.2928
   Shah CP, 2010, MATER RES BULL, V45, P1213, DOI 10.1016/j.materresbull.2010.05.013
   SHAMBERGER RJ, 1976, ARCH ENVIRON HEALTH, V31, P231, DOI 10.1080/00039896.1976.10667225
   Siepmann J, 1999, J CONTROL RELEASE, V60, P379, DOI 10.1016/S0168 3659(99)00093 0
   Steinbrenner H, 2009, BBA GEN SUBJECTS, V1790, P1478, DOI 10.1016/j.bbagen.2009.02.014
   Swan EEL, 2005, J BIOMED MATER RES A, V72A, P288, DOI 10.1002/jbm.a.30223
   Ta HT, 2009, BIOMATERIALS, V30, P3605, DOI 10.1016/j.biomaterials.2009.03.022
   Tran P, 2008, INT J NANOMED, V3, P391
   van den Brandt PA, 2003, CANCER EPIDEM BIOMAR, V12, P866
   Wang Y, 2014, BIOMATERIALS, V35, P5517, DOI 10.1016/j.biomaterials.2014.03.059
   Waters DJ, 2005, CARCINOGENESIS, V26, P1256, DOI 10.1093/carcin/bgi077
   Weekley CM, 2011, J AM CHEM SOC, V133, P18272, DOI 10.1021/ja206203c
   Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015
   Yang F, 2012, INT J NANOMED, V7, P835, DOI 10.2147/IJN.S28278
   Yang JY, 2006, ARCH PHARM RES, V29, P859, DOI 10.1007/BF02973906
   Yu B, 2014, J MATER CHEM B, V2, P5409, DOI 10.1039/c4tb00399c
   Zare B, 2013, NANOMED J, V1, P13, DOI 10.7508/NMJ.2013.01.002
   Zhang YB, 2013, NANOMED NANOTECHNOL, V9, P74, DOI 10.1016/j.nano.2012.04.002
NR 51
TC 23
Z9 26
U1 1
U2 56
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2015
VL 3
IS 35
BP 7090
EP 7098
DI 10.1039/c5tb00125k
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CQ2QO
UT WOS:000360446400012
PM 32262711
DA 2025 08 17
ER

PT J
AU Han, SJ
   Liu, Q
   Wang, F
   Yuan, ZN
AF Han, Shijie
   Liu, Qian
   Wang, Feng
   Yuan, Zenong
TI Targeting the SH3 domain of human osteoclast stimulating factor with
   rationally designed peptoid inhibitors
SO JOURNAL OF PEPTIDE SCIENCE
LA English
DT Article
DE osteoclast stimulating factor; peptide; peptoid; SH3 domain;
   N substituted amino acid; bone
ID PROLINE RECOGNITION; SPECIFICITY; PREDICTION; REVEALS
AB Human osteoclast stimulating factor (hOSF) is an intracellular protein produced by osteoclasts that induces osteoclast formation and bone resorption. The protein contains a modular Src homology 3 (SH3) domain that mediates the intermolecular recognition and interaction of hOSF with its biological partners. Here, we proposed targeting the hOSF SH3 domain to disrupt hOSF partner interactions for bone disease therapy by using SH3 inhibitors. In the procedure, the primary sequences of three known hOSF interacting proteins (c Src, SMN and Sam68) were parsed, from which totally 31 octapeptide segments that contain the core SH3 bindingmotif PXXP were extracted, and their binding behavior to hOSF SH3 domain was investigated at structural level using a biomolecular modeling protocol. Several SH3 binding candidates were identified theoretically and then determined to have high or moderate affinity for the domain using fluorescence spectroscopy assays. One potent peptide (425)APPARPVK(432) (K d= 3.2 mu M), which corresponds to the residues 425 432 of Sam68 protein, was used as template to derive N substitution of peptides (peptoids). Considering that proline is the only endogenous N substituted amino acid that plays a critical role in SH3 peptide binding, the substitution was addressed at the two key proline residues (Pro427 and Pro430) of the template peptide with nine N substituted amino acid types. By systematically evaluating the structural and energetic effects of different N substituted amino acids presenting at the two proline sites on peptide binding, we rationally designed five peptoid inhibitors and then determined in vitro their binding affinity to hOSF SH3 domain. Consequently, two designed peptoids APPAR(N Clp) VK and APPAR(N Ffa) VK with Pro430 replaced by N Clp and N Ffa were confirmed to have increased (K d= 0.87 mu M) and comparable (K d= 2.9 mu M) affinities relative to the template, respectively. In addition, we also found that the Pro427 residue plays an essential role in restricting peptide/peptoid conformations to polyproline II (PPII) helix as the basic requirement of SH3 binding so that the residue cannot be modified. Copyright (C) 2016 European Peptide Society and John Wiley & Sons, Ltd.
C1 [Han, Shijie; Wang, Feng; Yuan, Zenong] Shandong Prov Hosp, Dept Orthoped, 324 Seven Five Wei Rd, Jinan 250021, Peoples R China.
   [Liu, Qian] Shandong Univ, Qilu Hosp, Dept Pain Management, Jinan 250012, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University
RP Han, SJ (通讯作者)，Shandong Prov Hosp, Dept Orthoped, 324 Seven Five Wei Rd, Jinan 250021, Peoples R China.
EM shijie_han@sina.cn
CR Adzhubei AA, 2013, J MOL BIOL, V425, P2100, DOI 10.1016/j.jmb.2013.03.018
   Apweiler R, 2011, NUCLEIC ACIDS RES, V39, pD214, DOI 10.1093/nar/gkq1020
   Asbach B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038540
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Combs SA, 2013, NAT PROTOC, V8, P1277, DOI 10.1038/nprot.2013.074
   FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465
   Gfeller D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.18
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Kurihara N, 2001, J BIOL CHEM, V276, P41035, DOI 10.1074/jbc.M100233200
   Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411
   Nagata K, 2012, PROTEINS, V80, P142, DOI 10.1002/prot.23170
   Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088
   Pisabarro MT, 1996, BIOCHEMISTRY US, V35, P10634, DOI 10.1021/bi960203t
   Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097 4652(199812)177:4<636::AID JCP14>3.0.CO;2 H
   Rohl CA, 2004, METHOD ENZYMOL, V383, P66
   Sammond DW, 2007, J MOL BIOL, V371, P1392, DOI 10.1016/j.jmb.2007.05.096
   Schmidt H, 2007, J MOL BIOL, V365, P1517, DOI 10.1016/j.jmb.2006.11.013
   Seng CO, 2015, HUM MOL GENET, V24, P2138, DOI 10.1093/hmg/ddu734
   SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367
   Tong SL, 2009, PROTEINS, V75, P245, DOI 10.1002/prot.22333
   Wiebe S H, 1996, Oral Dis, V2, P167
NR 22
TC 14
Z9 17
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1075 2617
EI 1099 1387
J9 J PEPT SCI
JI J. Pept. Sci.
PD AUG
PY 2016
VL 22
IS 8
BP 533
EP 539
DI 10.1002/psc.2901
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DW2IW
UT WOS:000383467100005
PM 27443979
DA 2025 08 17
ER

PT J
AU Hong, W
   Wei, ZY
   Qiu, ZH
   Li, Z
   Fu, CS
   Ye, ZB
   Xu, XY
AF Hong, Wei
   Wei, Zhanying
   Qiu, Zhaohui
   Li, Zheng
   Fu, Chensheng
   Ye, Zhibin
   Xu, Xiaoya
TI Atorvastatin promotes bone formation in aged apoE<SUP> / </SUP> mice
   through the Sirt1 Runx2 axis
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE ApoE ;   mice; Aged; Sirt1; Bone formation; Atorvastatin
ID NITRIC OXIDE SYNTHASE; MINERAL DENSITY; STEM CELLS; STATINS;
   DIFFERENTIATION; OSTEOPOROSIS; SIRT1; EXPRESSION; RUNX2; ATHEROSCLEROSIS
AB BackgroundStatins are the most widely used drugs in elderly patients; the most common clinical application of statins is in aged hyperlipemia patients. There are few studies on the effects and mechanisms of statins on bone in elderly mice with hyperlipemia. The study is to examine the effects of atorvastatin on bone phenotypes and metabolism in aged apolipoprotein E deficient (apoE( / )) mice, and the possible mechanisms involved in these changes.MethodsTwenty four 60 week old apoE( / ) mice were randomly allocated to two groups. Twelve mice were orally gavaged with atorvastatin (10mg/kg body weight/day) for 12weeks; the others served as the control group. Bone mass and skeletal microarchitecture were determined using micro CT. Bone metabolism was assessed by serum analyses, qRT PCR, and Western blot. Bone marrow derived mesenchymal stem cells (BMSCs) from apoE( / ) mice were differentiated into osteoblasts and treated with atorvastatin and silent information regulator 1 (Sirt1) inhibitor EX 527.ResultsThe results showed that long term administration of atorvastatin increases bone mass and improves bone microarchitecture in trabecular bone but not in cortical bone. Furthermore, the serum bone formation marker osteocalcin (OCN) was ameliorated by atorvastatin, whereas the bone resorption marker tartrate resistant acid phosphatase 5b (Trap5b) did not appear obviously changes after the treatment of atorvastatin. The mRNA expression of Sirt1, runt related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and OCN in bone tissue were increased after atorvastatin administration. Western blot showed same trend in Sirt1 and Runx2. The in vitro study showed that when BMSCs from apoE( / ) mice were pretreated with EX527, the higher expression of Runx2, ALP, and OCN activated by atorvastatin decreased significantly or showed no difference compared with the control. The protein expression of Runx2 showed same trend.ConclusionsAccordingly, the current study validates the hypothesis that atorvastatin can increase bone mass and promote osteogenesis in aged apoE( / ) mice by regulating the Sirt1 Runx2 axis.
C1 [Hong, Wei] Fu Dan Univ, Huadong Hosp, Dept Osteoporosis & Bone Metab Dis, Shanghai, Peoples R China.
   [Hong, Wei; Xu, Xiaoya] Fudan Univ, Huadong Hosp, Shanghai Key Lab Clin Geriatr Med, Shanghai, Peoples R China.
   [Wei, Zhanying] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Osteoporosis & Related Bone Dis, Sch Med, Shanghai, Peoples R China.
   [Qiu, Zhaohui] Shanghai Jiao Tong Univ, TongRen Hosp, Dept Cardiol, Sch Med, Shanghai, Peoples R China.
   [Li, Zheng] Fudan Univ, Zhongshan Hosp, Lab Anim Ctr, Shanghai, Peoples R China.
   [Fu, Chensheng; Ye, Zhibin] Fudan Univ, Huadong Hosp, Dept Nephrol, Shanghai, Peoples R China.
   [Xu, Xiaoya] Fudan Univ, Inst Radiat Med, Dept Radiat Biol, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University; Fudan University; Fudan University; Fudan
   University
RP Xu, XY (通讯作者)，Fudan Univ, Huadong Hosp, Shanghai Key Lab Clin Geriatr Med, Shanghai, Peoples R China.; Ye, ZB (通讯作者)，Fudan Univ, Huadong Hosp, Dept Nephrol, Shanghai, Peoples R China.; Xu, XY (通讯作者)，Fudan Univ, Inst Radiat Med, Dept Radiat Biol, Shanghai, Peoples R China.
EM yezb2013@163.com; xiaoyaxu@fudan.edu.cn
RI Wang, Zhengtao/AAH 7360 2019; Xu, Xiaoya/AAF 1426 2020
FU Shanghai Municipal Health Commission [201740028]; National Natural
   Science Foundation of China [81102071]
FX This work was supported by the grants from the Shanghai Municipal Health
   Commission (No. 201740028, Wei Hong) and the National Natural Science
   Foundation of China (No. 81102071, Xiaoya Xu).
CR Ahmadi N, 2018, OSTEOPOROSIS INT, V29, P1609, DOI 10.1007/s00198 018 4524 7
   Almeida M, 2019, BONE, V121, P284, DOI 10.1016/j.bone.2019.01.018
   An T, 2017, OSTEOPOROSIS INT, V28, P47, DOI 10.1007/s00198 016 3844 8
   [Anonymous], 2017, PLOS ONE
   Bäckesjö CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744
   Bartoli Leonard F, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00183
   Bone HG, 2007, J CLIN ENDOCR METAB, V92, P4671, DOI 10.1210/jc.2006 1909
   Caffarelli C, 2017, CLIN INTERV AGING, V12, P1819, DOI 10.2147/CIA.S138002
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen ZG, 2014, ARCH GERONTOL GERIAT, V59, P515, DOI 10.1016/j.archger.2014.07.006
   Demir BÇ, 2013, J OBSTET GYNAECOL RE, V39, P229, DOI 10.1111/j.1447 0756.2012.01969.x
   Dolci GS, 2018, AM J ORTHOD DENTOFAC, V153, P872, DOI 10.1016/j.ajodo.2017.09.021
   Du G, 2014, INT J MOL MED, V34, P177, DOI 10.3892/ijmm.2014.1740
   El Nabarawi N, 2017, DRUG DES DEV THER, V11, P1383, DOI 10.2147/DDDT.S133020
   Fazio S, 2001, FRONT BIOSCI LANDMRK, V6, pD515, DOI 10.2741/Fazio
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Goes Paula, 2010, Braz. Dent. J., V21, P193, DOI 10.1590/S0103 64402010000300003
   Gong X, 2014, EXP GERONTOL, V52, P9, DOI 10.1016/j.exger.2014.01.015
   Guarente L, 2000, GENE DEV, V14, P1021
   Hong W, 2015, ACTA PHARMACOL SIN, V36, P1487, DOI 10.1038/aps.2015.95
   Hu HJ, 2015, INT J CARDIOL, V187, P58, DOI 10.1016/j.ijcard.2015.03.196
   Ibrahim NI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115595
   Kaji H, 2008, HORM METAB RES, V40, P746, DOI 10.1055/s 0028 1082051
   Kilic U, 2015, CLIN EXP PHARMACOL P, V42, P321, DOI 10.1111/1440 1681.12362
   Kitada M, 2016, AGING ALBANY NY, V810, P2290
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Lange V, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/3946569
   Lee WS, 2018, KOREAN J INTERN MED, V33, P397, DOI 10.3904/kjim.2015.244
   Li X, 2011, J BONE MINER METAB, V29, P396, DOI 10.1007/s00774 010 0231 y
   Issa JPM, 2015, GROWTH FACTORS, V33, P139, DOI 10.3109/08977194.2015.1011270
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Oka S, 2013, TISSUE ENG PT A, V19, P1233, DOI [10.1089/ten.tea.2012.0325, 10.1089/ten.TEA.2012.0325]
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Ota H, 2010, ARTERIOSCL THROM VAS, V30, P2205, DOI 10.1161/ATVBAHA.110.210500
   Qadir F, 2016, JCPSP J COLL PHYSICI, V26, P41, DOI 01.2016/JCPSP.4145
   Qian LF, 2017, VASC PHARMACOL, V89, P49, DOI 10.1016/j.vph.2016.12.003
   Qiao LJ, 2011, MOL CELLS, V32, P437, DOI 10.1007/s10059 011 0107 6
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Sato AYS, 2014, ATHEROSCLEROSIS, V235, P45, DOI 10.1016/j.atherosclerosis.2014.03.030
   Szekanecz Z, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 018 1805 7
   Tasic I, 2015, SRP ARK CELOK LEK, V143, P28, DOI 10.2298/SARH1502028T
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Uyar Y, 2009, MATURITAS, V63, P261, DOI 10.1016/j.maturitas.2009.03.018
   van Staa TP, 2001, JAMA J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   von Stechow D, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471 2474 4 8
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   Yang XF, 2017, ONCOTARGET, V8, P51447, DOI 10.18632/oncotarget.17691
   Yao W., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P277
   Ye CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154740
   Zainabadi K, 2019, PHARMACOL RES, V143, P97, DOI 10.1016/j.phrs.2019.03.007
   Zhou H, 2017, J BONE MINER METAB, V35, P245, DOI 10.1007/s00774 016 0750 2
NR 54
TC 15
Z9 15
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD AUG 6
PY 2020
VL 15
IS 1
AR 303
DI 10.1186/s13018 020 01841 0
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA NC3MA
UT WOS:000561117900006
PM 32762716
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Nogués, X
   Prieto Alhambra, D
   Güerri Fernández, R
   Garcia Giralt, N
   Rodriguez Morera, J
   Cos, L
   Mellibovsky, L
   Pérez, AD
AF Nogues, Xavier
   Prieto Alhambra, Daniel
   Gueerri Fernandez, Roberto
   Garcia Giralt, Natalia
   Rodriguez Morera, Jaime
   Cos, Lourdes
   Mellibovsky, Leonardo
   Diez Perez, Adolfo
TI Fracture during oral bisphosphonate therapy is associated with
   deteriorated bone material strength index
SO BONE
LA English
DT Article
DE Bisphosphonates; Fracture; BMSi; Microindentation; BMD
ID REFERENCE POINT INDENTATION; MINERAL DENSITY; IN VIVO; POSTMENOPAUSAL
   WOMEN; OSTEOPOROSIS
AB Background: Some patients experience fractures while receiving oral bisphosphonates (BPs) treatment. Clinical risk factors, advanced bone density loss, and microarchitecture deterioration have been associated with such fractures but bone tissue properties other than bone mineral density (BMD) have not been assessed.
   Methods: In a cross sectional study of postmenopausal women on bisphosphonates for at least 4 years with good adherence to treatment, 21 patients with incident fractures were compared with 18 treated patients without new fractures. Demographic and clinical variables, BMD, laboratory tests, and bone material strength index (BMSi) assessed by impact microindentation at the tibial diaphysis were recorded for all participants.
   Results: Clinical and laboratory results did not differ between patients taking BPs with incident fractures and those without new fractures. However, BMSi was significantly lower (mean +/  SD) in those who fractured (73.76 +/  6.49) than in no fracture patients (81.64 +/  6.26; p = 0.001). Lumbar spine (LS) BMD was also lower in fractured patients (p = 0.03). Adjusted models including age, body mass index, years on BP treatment, and LS BMD confirmed an increase in fracture risk per BMSi standard deviation decrease: adjusted OR 23.5 [95% CI 2.16 to 255.66], p = 0.01. ROC analyses showed an area under the curve of 0.82 (95% CI 0.68 to 0.95) for BMSi, higher than that for BMD at any location, which ranged from 0.64 (95% CI 0.47 to 0.82) for femoral neck (FN) BMD to 0.71 (95% CI 0.55 to 0.87) for LS BMD.
   Conclusions: Patients who fracture while receiving BPs treatment have worse BMSi scores than BP treated patients without fractures. The potential for BMSi to provide an additional osteoporosis treatment target should be explored. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Nogues, Xavier; Prieto Alhambra, Daniel; Gueerri Fernandez, Roberto; Garcia Giralt, Natalia; Rodriguez Morera, Jaime; Cos, Lourdes; Mellibovsky, Leonardo; Diez Perez, Adolfo] CIBERFES, Hosp Mar Res Inst, IMIM, Barcelona, Spain.
   [Nogues, Xavier; Gueerri Fernandez, Roberto; Rodriguez Morera, Jaime; Cos, Lourdes; Mellibovsky, Leonardo; Diez Perez, Adolfo] Univ Autonoma Barcelona, Hosp del Mar, Internal Med Dept, Barcelona, Spain.
   [Prieto Alhambra, Daniel] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford NIHR Musculoskeletal Biomed Res Unit, Oxford, England.
   [Prieto Alhambra, Daniel] Autonomous Univ Barcelona, Idiap Jordi Gol Primary Care Res Inst, GREMPAL, Barcelona, Spain.
C3 CIBER   Centro de Investigacion Biomedica en Red; CIBERFES; Hospital del
   Mar Research Institute; Hospital del Mar; Hospital del Mar Research
   Institute; Hospital del Mar; Autonomous University of Barcelona;
   University of Oxford; Autonomous University of Barcelona
RP Pérez, AD (通讯作者)，Hosp del Mar, IMIM, C Dr Aiguader 88, Barcelona 08003, Spain.
EM adiez@parcdesalutmar.cat
RI Mellibovsky, Leonardo/IRG 7294 2023; Guerri Fernandez,
   Robert/I 1306 2013; Garcia Giralt, Natalia/AAA 7588 2021
OI Nogues, Xavier/0000 0001 8201 9933; Nogues, Xavier/0000 0002 5537 1859;
   Garcia Giralt, Natalia/0000 0001 6507 0147; Mellibovsky,
   Leonardo/0009 0001 7921 8840; Prieto Alhambra,
   Daniel/0000 0002 3950 6346; Cos Esquius, Maria
   Lourdes/0000 0001 9389 9059; Guerri Fernandez,
   Robert/0000 0002 9794 9161; 
FU Red Tematica de Investigacion Cooperativa en Envejecimiento y Fragilidad
   (RETICEF) [RD12/0043/0022]; Centro de Investigacion Biomedica en Red de
   Fragilidad y Envejecimiento Saludable (CIBERFES) [CB16/10/00245]; FIS
   [P113/00444]; FEDER funds
FX This work was supported by the Red Tematica de Investigacion Cooperativa
   en Envejecimiento y Fragilidad (RETICEF; RD12/0043/0022), Centro de
   Investigacion Biomedica en Red de Fragilidad y Envejecimiento Saludable
   (CIBERFES; CB16/10/00245), FIS P113/00444 and FEDER funds.
CR Allen MR, 2015, J BONE MINER RES, V30, P1539, DOI 10.1002/jbmr.2603
   [Anonymous], 2013, ARCH OSTEOPOROS
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bridges D, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3693085
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Diez Perez A, 2016, Bone Rep, V5, P181
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Díez Pérez A, 2012, J BONE MINER RES, V27, P817, DOI 10.1002/jbmr.1496
   Farr JN, 2014, J BONE MINER RES, V29, P787, DOI 10.1002/jbmr.2106
   Gallant MA, 2013, BONE, V53, P301, DOI 10.1016/j.bone.2012.12.015
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   González Macías J, 2015, REV CLIN ESP, V215, P515, DOI 10.1016/j.rce.2015.08.003
   Güerri Fernández R, 2016, JAIDS J ACQ IMM DEF, V72, P314, DOI 10.1097/QAI.0000000000000965
   Jenkins T, 2016, J BONE MINER RES, V31, P196, DOI 10.1002/jbmr.2605
   Kanis JA, 2014, OSTEOPOROSIS INT, V25, P2533, DOI 10.1007/s00198 014 2787 1
   Karim L., 2015, Bone
   Kopperdahl DL, 2014, J BONE MINER RES, V29, P570, DOI 10.1002/jbmr.2069
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   Malgo F, 2015, J CLIN ENDOCR METAB, V100, P2039, DOI 10.1210/jc.2014 4346
   Mellibovsky L, 2015, J BONE MINER RES, V30, P1651, DOI 10.1002/jbmr.2497
   Prieto Alhambra D, 2014, J BONE MINER RES, V29, P268, DOI 10.1002/jbmr.2011
   Rudäng R, 2016, OSTEOPOROSIS INT, V27, P1585, DOI 10.1007/s00198 015 3419 0
   Sosa DD, 2015, J BONE MINER RES, V30, P1784, DOI 10.1002/jbmr.2537
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
NR 25
TC 16
Z9 16
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2017
VL 103
BP 64
EP 69
DI 10.1016/j.bone.2017.06.018
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF0NY
UT WOS:000408599600008
PM 28655603
DA 2025 08 17
ER

PT J
AU Moses, BS
   Slone, WL
   Thomas, P
   Evans, R
   Piktel, D
   Angel, PM
   Walsh, CM
   Cantrell, PS
   Rellick, SL
   Martin, KH
   Simpkins, JW
   Gibson, LE
AF Moses, Blake S.
   Slone, William L.
   Thomas, Patrick
   Evans, Rebecca
   Piktel, Debbie
   Angel, Peggi M.
   Walsh, Callee M.
   Cantrell, Pamela S.
   Rellick, Stephanie L.
   Martin, Karen H.
   Simpkins, James W.
   Gibson, Laura E.
TI Bone marrow microenvironment modulation of acute lymphoblastic leukemia
   phenotype
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID MESENCHYMAL STROMAL CELLS; HEMATOPOIETIC STEM CELLS; PROGENITOR CELLS;
   NICHE; THERAPY; SURVIVAL; PHARMACOKINETICS; PHOSPHORYLATION;
   PROLIFERATION; RESISTANCE
AB Acute lymphoblastic leukemia (ALL) treatment regimens have dramatically improved the survival of ALL patients. However, chemoresistant minimal residual disease that persists following cessation of therapy contributes to aggressive relapse. The bone marrow microenvironment (BMM) is an established "site of sanctuary" for ALL, as well as myeloid lineage hematopoietic disease, with signals in this unique anatomic location contributing to drug resistance. Several models have been developed to recapitulate the interactions between the BMM and ALL cells. However, many in vitro models fail to accurately reflect the level of protection afforded to the most resistant subset of leukemic cells during coculture with BMM elements. Preclinical in vivo models have advantages, but can be costly, and are often not fully informed by optimal in vitro studies. We describe an innovative extension of 2 D coculture wherein ALL cells uniquely interact with bone marrow derived stromal cells. Tumor cells in this model bury beneath primary human bone marrow derived stromal cells or osteoblasts, termed "phase dim" ALL, and exhibit a unique phenotype characterized by altered metabolism, distinct protein expression profiles, increased quiescence, and pronounced chemotherapy resistance. Investigation focused on the phase dim subpopulation may more efficiently inform preclinical design and investigation of the minimal residual disease and relapse that arise from BMM supported leukemic tumor cells. Copyright (C) 2016 ISEH   International Society for Experimental Hematology. Published by Elsevier Inc.
C1 [Moses, Blake S.; Slone, William L.; Thomas, Patrick; Evans, Rebecca; Piktel, Debbie; Martin, Karen H.; Gibson, Laura E.] W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr,Robert C Byrd Hlth Sc, Alexander B Osbonz Hematopoiet Malignancy & Trans, Morgantown, WV 26506 USA.
   [Angel, Peggi M.; Walsh, Callee M.; Cantrell, Pamela S.] Protea Biosci, Morgantown, WV USA.
   [Rellick, Stephanie L.; Simpkins, James W.] W Virginia Univ, Sch Med, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA.
   [Martin, Karen H.] W Virginia Univ, Sch Med, Dept Neurobiol & Anat, Morgantown, WV 26506 USA.
   [Simpkins, James W.] W Virginia Univ, Sch Med, Ctr Basic & Translat Stroke Res, Morgantown, WV 26506 USA.
   [Simpkins, James W.] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA.
   [Gibson, Laura E.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.
C3 West Virginia University; West Virginia University; West Virginia
   University; West Virginia University; West Virginia University; West
   Virginia University
RP Gibson, LE (通讯作者)，W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Off Res & Grad Educ, Morgantown, WV 26506 USA.
EM lgibson@hsc.wvu.edu
OI Martin, Karen/0000 0001 8916 4092; Gibson, Laura/0000 0002 7291 9046;
   Walsh, Callee/0000 0002 3368 9209; Moses, Blake/0000 0001 8045 3066;
   Thomas, Patrick/0000 0002 5907 1327; Piktel, Debra/0000 0001 6706 5923
FU National Institutes of Health (NIH) [S10 OD016165]; Institutional
   Development Award (IDeA) from the NIH Institute of General Medical
   Sciences [CoBRE P30GM103488, INBRE P20GM103434]; Mary Babb Randolph
   Cancer Center; NIH [P20 RR016440, P30 GM103488, P20 GM103434]; NIH NHLBI
   [R01 HL056888]; NIH NCI [P30 GM103488, R01 CA134573NIH]; West Virginia
   CTR IDEA NIH [1U54 GM104942]; Alexander B. Osborn Hematopoietic
   Malignancy and Transplantation Program; WV Research Trust Fund
FX The authors thank Dr. Michael Craig for his assistance in acquiring
   primary patient ALL samples and Ian Hare for manuscript editing. We are
   grateful for the support of Dr. Kathy Brundage and the West Virginia
   University Flow Cytometry Core Facility, supported by National
   Institutes of Health (NIH) Grant S10 OD016165 and the Institutional
   Development Award (IDeA) from the NIH Institute of General Medical
   Sciences (CoBRE P30GM103488 and INBRE P20GM103434). Imaging experiments
   were performed in the West Virginia University Microscope Imaging
   Facility, supported by the Mary Babb Randolph Cancer Center and NIH
   Grants P20 RR016440, P30 GM103488 and P20 GM103434.NIH NHLBI Grant R01
   HL056888 (LFG), NIH NCI Grant R01 CA134573NIH (LFG), Grant P30 GM103488
   (LFG), West Virginia CTR IDEA NIH 1U54 GM104942, Alexander B. Osborn
   Hematopoietic Malignancy and Transplantation Program, and WV Research
   Trust Fund.
CR Ayala F, 2009, LEUKEMIA, V23, P2233, DOI 10.1038/leu.2009.175
   Barcellos de Souza P, 2013, BBA REV CANCER, V1836, P321, DOI 10.1016/j.bbcan.2013.10.004
   Bemiakovich I, 2013, INT J MOL SCI, V14, P2119
   Bhojwani D, 2014, J CLIN ONCOL, V32, P949, DOI 10.1200/JCO.2013.53.0808
   Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood 2012 12 475483
   Bradstock K, 1996, LEUKEMIA, V10, P813
   Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006 3495(01)75733 5
   Clutter SD, 2005, EXP HEMATOL, V33, P1192, DOI 10.1016/j.exphem.2005.06.022
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Duan CW, 2014, CANCER CELL, V25, P778, DOI 10.1016/j.ccr.2014.04.015
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Gibson L F, 1997, Biol Blood Marrow Transplant, V3, P122
   Hathcock KS, 2001, CURRENT PROTOCOLS IM
   Holzwarth C, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 11
   Jacoby E, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00095
   Jing DH, 2010, HAEMATOL HEMATOL J, V95, P542, DOI 10.3324/haematol.2009.010736
   Joannon P, 2004, PEDIATR BLOOD CANCER, V43, P17, DOI 10.1002/pbc.20032
   Krause DS, 2013, CYTOM PART B CLIN CY, V84B, P7, DOI 10.1002/cyto.b.21066
   Krauss S, 2001, IMMUNITY, V15, P497, DOI 10.1016/S1074 7613(01)00205 9
   Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514
   Li L, 2011, CLIN CANCER RES, V17, P4936, DOI 10.1158/1078 0432.CCR 10 1499
   Liedtke M, 2014, LEUKEMIA RES, V38, P1441, DOI 10.1016/j.leukres.2014.09.018
   Liem NLM, 2004, BLOOD, V103, P3905, DOI 10.1182/blood 2003 08 2911
   MANABE A, 1994, BLOOD, V83, P758
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647
   Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932
   O'Leary H, 2010, CANCER MICROENVIRON, V3, P67, DOI 10.1007/s12307 010 0035 6
   Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607
   Samuels AL, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.52
   Shen Hongmei, 2008, V430, P77, DOI 10.1007/978 1 59745 182 6_5
   Slone WS, J VIS EXP IN PRESS
   Szczepanek J, 2011, ARCH IMMUNOL THER EX, V59, P61, DOI 10.1007/s00005 010 0110 1
   Tesfai Y, 2012, LEUKEMIA RES, V36, P299, DOI 10.1016/j.leukres.2011.08.001
   VANDENBERG HW, 1982, CANCER CHEMOTH PHARM, V8, P215, DOI 10.1007/BF00255487
   Wang L, 2005, STEM CELLS, V23, P1122, DOI 10.1634/stemcells.2004 0354
   Wang L, 2005, LEUKEMIA, V19, P1486, DOI 10.1038/sj.leu.2403837
   Wang L, 2005, LEUKEMIA, V19, P344, DOI 10.1038/sj.leu.2403643
   WEINSTEIN HJ, 1982, BLOOD, V59, P1351
NR 41
TC 29
Z9 33
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 472X
EI 1873 2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD JAN
PY 2016
VL 44
IS 1
BP 50
EP 59
DI 10.1016/j.exphem.2015.09.003
PG 10
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Research & Experimental Medicine
GA CZ0HJ
UT WOS:000366785400006
PM 26407636
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Marcuccilli, M
   Chonchol, M
   Jovanovich, A
AF Marcuccilli, Morgan
   Chonchol, Michel
   Jovanovich, Anna
TI Phosphate Binders and Targets Over Decades: Do We have it Right Now?
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; LEFT VENTRICULAR
   HYPERTROPHY; CARDIOVASCULAR DISEASE; HEMODIALYSIS PATIENTS; LANTHANUM
   CARBONATE; PARATHYROID HORMONE; MINERAL METABOLISM; SERUM PHOSPHORUS;
   MORTALITY RISK
AB In advanced renal disease, the kidney is unable to maintain phosphate balance due to decreased urinary excretion as well as the imbalance of the bone metabolic axis. It is well established that hyperphosphatemia is associated with increased cardiovascular events and mortality in patients with chronic kidney disease (CKD). However, there are no randomized controlled trials that demonstrate a clear benefit on hard outcomes in lowering serum phosphate levels to recommended targets in the CKD or dialysis population. In addition, while calcium based phosphate binders have traditionally been the standard of care in the treatment of hyperphosphatemia, data regarding the increased risk of vascular mineralization continues to emerge. Clinicians continue to search for new phosphate lowering therapies as well as investigate novel nutritional perspectives. The Kidney Disease: Improving Global Outcomes is currently revising the guidelines on phosphate goals in CKD. This review will outline the history of phosphate targets and phosphate binders, and explore innovative phosphate lowering therapies. Based on current data, clinicians moving forward should continue to treat end stage renal disease patients with hyperphosphatemia based on individual risk factors for vascular mineralization.
C1 [Marcuccilli, Morgan; Chonchol, Michel; Jovanovich, Anna] Hypertens Univ Colorado, Div Renal Dis, Denver, CO USA.
   [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Veterans Affairs Medical Center   Denver
RP Chonchol, M (通讯作者)，Div Renal Dis & Hypertens, 12700,East 19th Ave C281, Aurora, CO 80045 USA.
EM michel.chonchol@ucdenver.edu
CR [Anonymous], CHANG NUTR FACTS LAB
   Barreto DV, 2008, NEPHRON CLIN PRACT, V110, pC273, DOI 10.1159/000170783
   Barreto FC, 2011, EXPERT OPIN PHARMACO, V12, P2627, DOI 10.1517/14656566.2011.626768
   Blaine J, 2015, CLIN J AM SOC NEPHRO, V10, P1257, DOI 10.2215/CJN.09750913
   Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223
   Chang AR, 2014, AM J CLIN NUTR, V99, P320, DOI 10.3945/ajcn.113.073148
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Chonchol M, 2009, AM J MED, V122, P380, DOI 10.1016/j.amjmed.2008.09.039
   Culleton BF, 2007, JAMA J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   Di Marco GS, 2014, NEPHROL DIAL TRANSPL, V29, P2028, DOI 10.1093/ndt/gfu190
   Drüeke TB, 2007, SEMIN DIALYSIS, V20, P329, DOI 10.1111/j.1525 139X.2007.00299.x
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Floege J, 2014, KIDNEY INT, V86, P638, DOI 10.1038/ki.2014.58
   Foley RN, 2008, AM HEART J, V156, P556, DOI 10.1016/j.ahj.2008.05.016
   Freemont AJ, 2005, CLIN NEPHROL, V64, P428
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Gonzalez Parra E, 2011, NEPHROL DIAL TRANSPL, V26, P2567, DOI 10.1093/ndt/gfr144
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Hutchison AJ, 2009, KIDNEY INT, V75, P906, DOI 10.1038/ki.2009.60
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   KDIGO Panel (under public review), 2016, KDIGO 2016 CLIN PRAC
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2012, KIDNEY INT S, V2013, P19
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Labonté ED, 2015, J AM SOC NEPHROL, V26, P1138, DOI 10.1681/ASN.2014030317
   Levin A, 2003, SEMIN DIALYSIS, V16, P101, DOI 10.1046/j.1525 139X.2003.16025.x
   LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203
   Lewis JB, 2015, J AM SOC NEPHROL, V26, P493, DOI 10.1681/ASN.2014020212
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Negri AL, 2015, CLIN KIDNEY J, V8, P161, DOI 10.1093/ckj/sfu139
   Mathew S, 2008, J AM SOC NEPHROL, V19, P1092, DOI 10.1681/ASN.2007070760
   Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756 3282(00)00346 X
   Moe SM, 2011, CLIN J AM SOC NEPHRO, V6, P257, DOI 10.2215/CJN.05040610
   Moe SM, 2009, KIDNEY INT, V75, P176, DOI 10.1038/ki.2008.456
   Oliveira RB, 2010, CLIN J AM SOC NEPHRO, V5, P286, DOI 10.2215/CJN.05420709
   Pai AB, 2009, PHARMACOTHERAPY, V29, P554, DOI 10.1592/phco.29.5.554
   Qunibi W, 2008, AM J KIDNEY DIS, V51, P952, DOI 10.1053/j.ajkd.2008.02.298
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192
   SLATOPOLSKY E, 1986, SEMIN NEPHROL, V6, P35
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275
   Sprague S, 2015, CLIN INVESTIG, V5, P1
   Strózecki P, 2001, RENAL FAILURE, V23, P115, DOI 10.1081/JDI 100001291
   Stubbs J, 2007, SEMIN DIALYSIS, V20, P302, DOI 10.1111/j.1525 139X.2007.00308.x
   Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
   Turgut F, 2008, INT UROL NEPHROL, V40, P1075, DOI 10.1007/s11255 008 9410 3
   Voormolen N, 2007, NEPHROL DIAL TRANSPL, V22, P2909, DOI 10.1093/ndt/gfm286
   Weisinger JR, 1998, LANCET, V352, P391, DOI 10.1016/S0140 6736(97)10535 9
   WILZ DR, 1979, AM J CLIN NUTR, V32, P2052, DOI 10.1093/ajcn/32.10.2052
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 60
TC 9
Z9 9
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0894 0959
EI 1525 139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAR APR
PY 2017
VL 30
IS 2
SI SI
BP 134
EP 141
DI 10.1111/sdi.12568
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA EM5HK
UT WOS:000395342400008
PM 28064444
DA 2025 08 17
ER

PT J
AU Li, JJ
   Chen, WL
   Wang, JY
   Hu, QW
   Sun, ZP
   Zhang, S
   Liu, S
   Han, XH
AF Li, Jia jia
   Chen, Wei ling
   Wang, Jian yi
   Hu, Qian wen
   Sun, Zhen ping
   Zhang, Shuai
   Liu, Sheng
   Han, Xiang hui
TI Wenshen Zhuanggu formula effectively suppresses breast cancer bone
   metastases in a mouse xenograft model
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE breast cancer; bone metastases; traditional Chinese medicine; Wenshen
   Zhuanggu formula; zoledronic acid; bone marrow derived mesenchymal stem
   cells; CCL5/CCR5; IL 17B/IL 17BR
ID MESENCHYMAL STEM CELLS; CD8(+) T CELLS; NF KAPPA B; IN VIVO; EXPRESSION;
   CCL5; DIFFERENTIATION; PROLIFERATION; PROGRESSION; MECHANISMS
AB Wenshen Zhuanggu formula (WSZG) is a traditional Chinese medicine used as an adjuvant for the prevention of bone metastases in breast cancer patients. In this study we investigated the efficacy of WSZG in preventing bone metastases and the potential mechanisms in a mouse xenograft model of breast cancer bone metastases. This model was established by injection of human MDA MB 231BO Luc breast cancer cells alone or a mixture of the cancer cells with bone marrow derived mesenchymal stem cells (BMSCs) into left ventricle of the heart in female nude mice. Then the mice were treated with WSZG (3.25, 6.5 or 13.0 mg.kg( 1).d( 1), ig) for four weeks, whereas zoledronic acid (100 mu g/kg per week, ig) was used as a positive control. The occurrence and development of bone metastases were monitored via bioluminescent imaging, and bone lesions were assessed using micro CT. Intracardiac injection of the mixture of MDA MB 231BO Luc breast cancer cells with BMSCs significantly facilitated the bone metastatic capacity of the breast cancer cells, and aggravated bone lesions in the mouse xenograft model of breast cancer bone metastases. Administration of WSZG dose dependently inhibited the incidence and intensity of bone metastases and protected against bone lesions by suppressing osteoclast formation and tumor cell infiltration. Furthermore, administration of WSZG caused a marked reduction in the expression of CCL5/CCR5 and IL 17B/IL 17BR in bone metastatic tissues. The results demonstrate that WSZG exerts potential therapeutic effects in a mouse xenograft model of breast cancer bone metastases, which are partially mediated by weakening the interaction between BMSCs and breast cancer cells in the tumor microenvironment.
C1 [Li, Jia jia; Chen, Wei ling; Hu, Qian wen; Sun, Zhen ping; Zhang, Shuai; Liu, Sheng; Han, Xiang hui] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Chinese Tradit Surg, Shanghai 200032, Peoples R China.
   [Wang, Jian yi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Liver Dis, Shanghai 201203, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Liu, S; Han, XH (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Chinese Tradit Surg, Shanghai 200032, Peoples R China.
EM lshtcm@163.com; hanxianghui1106@163.com
RI j, z/JPX 2698 2023; Li, Tsung Ju/LKO 0126 2024; Weiling,
   Chen/JAA 9972 2023
FU National Natural Science Foundation of China [81102598, 81573973,
   81603629]; Program for Longhua Medical Research Team [LYTD 17]
FX This work was supported by the National Natural Science Foundation of
   China (No 81102598, 81573973, 81603629) and the Program for Longhua
   Medical Research Team (No LYTD 17).
CR Bermejo DA, 2013, NAT IMMUNOL, V14, P514, DOI 10.1038/ni.2569
   Cambien B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028842
   Chang LY, 2012, CANCER RES, V72, P1092, DOI 10.1158/0008 5472.CAN 11 2493
   Chiovaro F, 2015, INT J CANCER, V137, P1842, DOI 10.1002/ijc.29565
   Cook J, 2013, CURR OPIN PHARMACOL, V13, P595, DOI 10.1016/j.coph.2013.05.017
   Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800
   Dragulescu Andrasi A, 2009, BIOCONJUGATE CHEM, V20, P1660, DOI 10.1021/bc9002508
   Dunn L, 2009, MOL DIAGN THER, V13, P73, DOI 10.2165/01250444 200913020 00002
   Furuta S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001374
   Goldstein RH, 2010, CANCER RES, V70, P10044, DOI 10.1158/0008 5472.CAN 10 1254
   Han XH, 2015, J ETHNOPHARMACOL, V162, P39, DOI 10.1016/j.jep.2014.12.036
   Huang CK, 2014, ONCOGENE, V33, P2968, DOI 10.1038/onc.2013.268
   Huang H, 2009, CELL DEATH DIFFER, V16, P1332, DOI 10.1038/cdd.2009.74
   Huber M, 2013, J CLIN INVEST, V123, P247, DOI 10.1172/JCI63681
   Jung MY, 2009, ONCOL REP, V22, P1141, DOI 10.3892/or_00000547
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kershaw MH, 2013, NAT REV CANCER, V13, P525, DOI 10.1038/nrc3565
   Lee WH, 2015, ONCOTARGET, V6, P18244, DOI 10.18632/oncotarget.4892
   Li M, 2016, ONCOL REP, V36, P936, DOI 10.3892/or.2016.4853
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meleshina AV, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0003 7
   Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009
   Normanno N, 2005, ENDOCR RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311
   Sun Zh, 2010, THESIS
   Suva LJ, 2009, ENDOCR RELAT CANCER, V16, P703, DOI 10.1677/ERC 09 0012
   Swamydas M, 2013, CELL ADHES MIGR, V7, P315, DOI 10.4161/cam.25138
   Tu QS, 2009, J CELL PHYSIOL, V218, P135, DOI 10.1002/jcp.21576
   Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002 9440(10)61180 7
   Wu HH, 2015, J EXP MED, V212, P333, DOI 10.1084/jem.20141702
   Yang RL, 2013, CELL RES, V23, P107, DOI 10.1038/cr.2012.179
   Yang X, 2016, STEM CELLS DEV, V25, P1629, DOI 10.1089/scd.2016.0217
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   [张小慧 Zhang Xiaohui], 2014, [中成药, Chinese Traditional Patent Medicine], V36, P1569
   Zhang YM, 2014, ONCOL REP, V32, P2769, DOI 10.3892/or.2014.3479
   Zhang YM, 2009, ONCOL REP, V21, P1113, DOI 10.3892/or_00000331
   Zhu LB, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/9469276
NR 39
TC 18
Z9 21
U1 2
U2 15
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD OCT
PY 2017
VL 38
IS 10
BP 1369
EP 1380
DI 10.1038/aps.2017.13
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA FI6SC
UT WOS:000412125600005
PM 28414206
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kempfle, JS
   Nguyen, K
   Hamadani, C
   Koen, N
   Edge, AS
   Kashemirov, BA
   Jung, DH
   McKenna, CE
AF Kempfle, Judith S.
   Nguyen, Kim
   Hamadani, Christine
   Koen, Nicholas
   Edge, Albert S.
   Kashemirov, Boris A.
   Jung, David H.
   McKenna, Charles E.
TI Bisphosphonate Linked TrkB Agonist: Cochlea Targeted Delivery of a
   Neurotrophic Agent as a Strategy for the Treatment of Hearing Loss
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID SPIRAL GANGLION NEURONS; INNER EAR; DRUG DELIVERY; NERVE DEGENERATION;
   IN VIVO; RECEPTOR; KINASE; MICE; 7,8 DIHYDROXYFLAVONE; SYNAPTOPATHY
AB Hearing loss affects more than two thirds of the elderly population, and more than 17% of all adults in the U.S. Sensorineural hearing loss related to noise exposure or aging is associated with loss of inner ear sensory hair cells (HCs), cochlear spiral ganglion neurons (SGNs), and ribbon synapses between HCs and SGNs, stimulating intense interest in therapies to regenerate synaptic function. 7,8 Dihydroxyflavone (DHF) is a selective and potent agonist of tropomyosin receptor kinase B (TrkB) and protects the neuron from apoptosis. Despite evidence that TrkB agonists can promote survival of SGNs, local delivery of drugs such as DHF to the inner ear remains a challenge. We previously demonstrated in an animal model that a fluorescently labeled bisphosphonate, 6 FAM Zol, administered to the round window membrane penetrated the membrane and diffused throughout the cochlea. Given their affinity for bone mineral, including cochlear bone, bisphosphonates offer an intriguing modality for targeted delivery of neurotrophic agents to the SGNs to promote survival, neurite outgrowth, and, potentially, regeneration of synapses between HCs and SGNs. The design and synthesis of a bisphosphonate conjugate of DHF (Ris DHF) is presented, with a preliminary evaluation of its neurotrophic activity. Ris DHF increases neurite outgrowth in vitro, maintains this ability after binding to hydroxyapatite, and regenerates synapses in kainic acid damaged cochlear organ of Corti explants dissected in vitro with attached SGNs. The results suggest that bisphosphonate TrkB agonist conjugates have promise as a novel approach to targeted delivery of drugs to treat sensorineural hearing loss.
C1 [Kempfle, Judith S.; Hamadani, Christine; Koen, Nicholas; Edge, Albert S.; Jung, David H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
   [Kempfle, Judith S.; Hamadani, Christine; Koen, Nicholas; Edge, Albert S.; Jung, David H.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
   [Kempfle, Judith S.; Hamadani, Christine; Koen, Nicholas; Edge, Albert S.; Jung, David H.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02114 USA.
   [Kempfle, Judith S.] Univ Tubingen, Dept Otolaryngol, Med Ctr, D 72076 Tubingen, Germany.
   [Nguyen, Kim; Kashemirov, Boris A.; McKenna, Charles E.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90089 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   Eye & Ear Infirmary; Harvard University; Harvard University Medical
   Affiliates; Massachusetts Eye & Ear Infirmary; Harvard University;
   Harvard Medical School; Eberhard Karls University of Tubingen;
   University of Southern California
RP Jung, DH (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.; Jung, DH (通讯作者)，Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.; Jung, DH (通讯作者)，Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02114 USA.; McKenna, CE (通讯作者)，Univ Southern Calif, Dept Chem, Los Angeles, CA 90089 USA.
EM david_jung@meei.harvard.edu; mckenna@usc.edu
RI Edge, Albert/Q 5448 2019; Nguyen, Kim/JWP 3649 2024; Hamadani,
   Christine/AAW 8883 2021
FU American Academy of Otolaryngology Head and Neck Surgery Herbert
   Silverstein Otology and Neurotology Research Award; American Otological
   Society Research Grant; National Institute of Deafness and other
   Communicative Disorders [R01 DC007174]
FX We thank Ms. Inah Kang for her invaluable assistance in the preparation
   of this manuscript and Prof. M. Charles Liberman for initial guidance in
   3 D imaging of synapses. This work was supported by the American Academy
   of Otolaryngology Head and Neck Surgery Herbert Silverstein Otology and
   Neurotology Research Award, the American Otological Society Research
   Grant, and by a grant from the National Institute of Deafness and other
   Communicative Disorders, R01 DC007174.
CR Bertrand T, 2012, J MOL BIOL, V423, P439, DOI 10.1016/j.jmb.2012.08.002
   Bharadwaj HM, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00026
   Budenz CL, 2015, SCI REP UK, V5, DOI 10.1038/srep08619
   Cazorla M, 2011, J CLIN INVEST, V121, P1846, DOI 10.1172/JCI43992
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ernfors P, 1995, INT J DEV BIOL, V39, P799
   Evans AJ, 2009, J BIOMED MATER RES A, V91A, P241, DOI 10.1002/jbm.a.32228
   Goycoolea MV, 2001, ACTA OTO LARYNGOL, V121, P437, DOI 10.1080/000164801300366552
   Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107
   Kang WS, 2015, OTOL NEUROTOL, V36, P953, DOI 10.1097/MAO.0000000000000786
   Kao SY, 2013, NEUROBIOL DIS, V56, P25, DOI 10.1016/j.nbd.2013.04.008
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092 8674(91)90628 C
   Kujawa SG, 2006, J NEUROSCI, V26, P2115, DOI 10.1523/JNEUROSCI.4985 05.2006
   Kujawa SG, 2015, HEARING RES, V330, P191, DOI 10.1016/j.heares.2015.02.009
   Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845 09.2009
   Lin FR, 2011, J GERONTOL A BIOL, V66, P582, DOI 10.1093/gerona/glr002
   Liu X, 2014, J BIOL CHEM, V289, P27571, DOI 10.1074/jbc.M114.562561
   Müller U, 2015, NAT REV DRUG DISCOV, V14, P346, DOI 10.1038/nrd4533
   Nadol JB, 1997, OTOLARYNG HEAD NECK, V117, P220, DOI 10.1016/S0194 5998(97)70178 5
   Nguyen K, 2016, 2016 WORLD MOL IM C
   Nguyen K, 2017, EXPERT OPIN THER PAT, V27, P191, DOI 10.1080/13543776.2017.1252751
   Parker M, 2010, JOVE J VIS EXP, P1685
   Plontke SK, 2014, OTOL NEUROTOL, V35, P1168, DOI 10.1097/MAO.0000000000000434
   Quesnel AM, 2012, OTOL NEUROTOL, V33, P1308, DOI 10.1097/MAO.0b013e318268d1b3
   Ramekers D, 2015, J NEUROSCI, V35, P12331, DOI 10.1523/JNEUROSCI.0096 15.2015
   Ramekers D, 2012, HEARING RES, V288, P19, DOI 10.1016/j.heares.2012.03.002
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Salt AN, 2009, AUDIOL NEURO OTOL, V14, P350, DOI 10.1159/000241892
   SCHUKNECHT HF, 1993, ANN OTO RHINOL LARYN, V102, P1
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Sergeyenko Y, 2013, J NEUROSCI, V33, P13686, DOI 10.1523/JNEUROSCI.1783 13.2013
   Shibata SB, 2010, EXP NEUROL, V223, P464, DOI 10.1016/j.expneurol.2010.01.011
   Sly DJ, 2016, OTOL NEUROTOL, V37, P1223, DOI 10.1097/MAO.0000000000001191
   SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092 8674(91)90396 G
   Stankovic K, 2004, J NEUROSCI, V24, P8651, DOI 10.1523/JNEUROSCI.0733 04.2004
   Sun HP, 2012, EUR J MED CHEM, V51, P110, DOI 10.1016/j.ejmech.2012.02.029
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Suzuki J, 2016, SCI REP UK, V6, DOI 10.1038/srep24907
   Swan EEL, 2008, ADV DRUG DELIVER REV, V60, P1583, DOI 10.1016/j.addr.2008.08.001
   Takada Y, 2014, HEARING RES, V309, P124, DOI 10.1016/j.heares.2013.11.009
   Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469 7580.1999.19410001.x
   Tong M., 2014, ANN M ASS RES OT SAN
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Viana LM, 2015, HEARING RES, V327, P78, DOI 10.1016/j.heares.2015.04.014
   Wan GQ, 2014, ELIFE, V3, DOI 10.7554/eLife.03564
   Wang Q, 2011, J NEUROSCI, V31, P7938, DOI 10.1523/JNEUROSCI.1434 10.2011
   Yu Q, 2013, J NEUROSCI, V33, P13042, DOI 10.1523/JNEUROSCI.0854 13.2013
NR 49
TC 20
Z9 22
U1 0
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2018
VL 29
IS 4
BP 1240
EP 1250
DI 10.1021/acs.bioconjchem.8b00022
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GD6TQ
UT WOS:000430641700045
PM 29485861
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Murahari, S
   Jalkanen, AL
   Kulp, SK
   Chen, CS
   Modiano, JF
   London, CA
   Kisseberth, WC
AF Murahari, Sridhar
   Jalkanen, Aimee L.
   Kulp, Samuel K.
   Chen, Ching Shih
   Modiano, Jaime F.
   London, Cheryl A.
   Kisseberth, William C.
TI Sensitivity of osteosarcoma cells to HDAC inhibitor AR 42 mediated
   apoptosis
SO BMC CANCER
LA English
DT Article
DE Apoptosis; AR 42; Dog; Histone deacetylase inhibitor; Osteosarcoma
ID HISTONE DEACETYLASE INHIBITOR; HEPATOCELLULAR CARCINOMA; SURVIVIN
   EXPRESSION; PROSTATE CANCER; DOWN REGULATION; ACETYLATION; PROGRESSION;
   PATHWAY; MODELS; DRUGS
AB Background: Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with chemotherapy has been the mainstay of treatment for OS. Many patients are not cured with current therapies, presenting a real need for developing new treatments. Histone deacetylase (HDAC) inhibitors are a promising new class of anticancer agents. In this study, we investigated the activity of the novel HDAC inhibitor AR 42 in a panel of human and canine OS cell lines.
   Methods: The effect of AR 42 and suberoylanilide hydroxamic acid (SAHA) alone or in combination with doxorubicin on OS cell viability was assessed. Induction of histone acetylation after HDAC inhibitor treatment was confirmed by Western blotting. Drug induced apoptosis was analyzed by FACS. Apoptosis was assessed further by measuring caspase 3/7 enzymatic activity, nucleosome fragmentation, and caspase cleavage. Effects on Akt signaling were demonstrated by assessing phosphorylation of Akt and downstream signaling molecules.
   Results: AR 42 was a potent inhibitor of cell viability and induced a greater apoptotic response compared to SAHA when used at the same concentrations. Normal osteoblasts were much less sensitive. The combination of AR 42 with doxorubicin resulted in a potent inhibition of cell viability and apparent synergistic effect. Furthermore, we showed that AR 42 and SAHA induced cell death via the activation of the intrinsic mitochondrial pathway through activation of caspase 3/7. This potent apoptotic activity was associated with the greater ability of AR 42 to downregulate survival signaling through Akt.
   Conclusions: These results confirm that AR 42 is a potent inhibitor of HDAC activity and demonstrates its ability to significantly inhibit cell survival through its pleiotropic effects in both canine and human OS cells and suggests that spontaneous OS in pet dogs may be a useful large animal model for preclinical evaluation of HDAC inhibitors. HDAC inhibition in combination with standard doxorubicin treatment offers promising potential for chemotherapeutic intervention in both canine and human OS.
C1 [Murahari, Sridhar; Jalkanen, Aimee L.; London, Cheryl A.; Kisseberth, William C.] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA.
   [London, Cheryl A.] Ohio State Univ, Dept Vet Biosci, Coll Vet Med, Columbus, OH 43210 USA.
   [Kulp, Samuel K.; Chen, Ching Shih] Ohio State Univ, Div Med Chem & Pharmacognosy, Coll Pharm, Columbus, OH 43210 USA.
   [Modiano, Jaime F.] Univ Minnesota, Dept Vet Clin Sci, Coll Vet Med, St Paul, MN 55108 USA.
   [Modiano, Jaime F.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   [Jalkanen, Aimee L.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University; University of Minnesota System; University of Minnesota Twin
   Cities; University of Minnesota System; University of Minnesota Twin
   Cities; Colorado State University System; Colorado State University Fort
   Collins
RP Kisseberth, WC (通讯作者)，Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA.
EM kisseberth.2@osu.edu
RI MODIANO, JAIME/K 3583 2019; Kisseberth, William/A 2587 2013; London,
   Cheryl/E 6561 2012
OI Modiano, Jaime/0000 0001 6398 7648
FU Ohio State University College of Veterinary Medicine Canine Grants funds
FX This work was supported by The Ohio State University College of
   Veterinary Medicine Canine Grants funds.
CR Alvarez FJ, 2007, VET COMP ONCOL, V5, P47, DOI 10.1111/j.1476 5829.2006.00117.x
   Barneda Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Bolden JE, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.9
   Bose P, 2014, PHARMACOL THERAPEUT, V143, P323, DOI 10.1016/j.pharmthera.2014.04.004
   Chalhoub N, 2009, ANNU REV PATHOL MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chen CS, 2007, CANCER RES, V67, P5318, DOI 10.1158/0008 5472.CAN 06 3996
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Fenger JM, 2014, ILAR J, V55, P69, DOI 10.1093/ilar/ilu009
   Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042
   Guha M, 2015, NAT REV DRUG DISCOV, V14, P226, DOI 10.1038/nrd4583
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Khanna C, 2014, CLIN CANCER RES, V20, P4200, DOI 10.1158/1078 0432.CCR 13 2574
   Kisseberth WC, 2008, AM J VET RES, V69, P938, DOI 10.2460/ajvr.69.7.938
   Kulp SK, 2006, CLIN CANCER RES, V12, P5199, DOI 10.1158/1078 0432.CCR 06 0429
   Lin TY, 2010, BLOOD, V115, P4217, DOI 10.1182/blood 2009 07 231985
   Lu Q, 2005, J MED CHEM, V48, P5530, DOI 10.1021/jm0503749
   Lu YS, 2007, HEPATOLOGY, V46, P1119, DOI 10.1002/hep.21804
   Lu YS, 2012, INT J RADIAT ONCOL, V83, pE181, DOI 10.1016/j.ijrobp.2011.12.022
   Lucas DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010941
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Osaka E, 2007, J ORTHOP RES, V25, P116, DOI 10.1002/jor.20291
   Paoloni M, 2008, NAT REV CANCER, V8, P147, DOI 10.1038/nrc2273
   Rao Bindal K, 2013, CURR CANCER DRUG TAR, V13, P411, DOI 10.2174/1568009611313040005
   Roh MS, 2004, APOPTOSIS, V9, P583, DOI 10.1023/B:APPT.0000038037.68908.6e
   Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004
   Sargeant AM, 2008, CANCER RES, V68, P3999, DOI 10.1158/0008 5472.CAN 08 0203
   Scott MC, 2015, J BIOL CHEM, V290, P28070, DOI 10.1074/jbc.M115.679696
   Seo SK, 2008, MOL PHARMACOL, V73, P1005, DOI 10.1124/mol.107.041293
   Thayanithy V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043720
   Trieb K, 2003, EUR J SURG ONCOL, V29, P379, DOI 10.1053/ejso.2002.1415
   Wang WJ, 2006, J SURG ONCOL, V93, P578, DOI 10.1002/jso.20507
   Watanabe K, 2005, CELL DEATH DIFFER, V12, P10, DOI 10.1038/sj.cdd.4401507
   Wittenburg LA, 2010, CLIN CANCER RES, V16, P4832, DOI 10.1158/1078 0432.CCR 10 1238
   Wittenburg LA, 2011, CANCER CHEMOTH PHARM, V67, P83, DOI 10.1007/s00280 010 1287 z
   Yang YT, 2009, NEOPLASIA, V11, P552, DOI 10.1593/neo.09204
   Zhang SH, 2011, INT J CANCER, V129, P204, DOI 10.1002/ijc.25660
   Zhao P, 2010, BIOCHEM BIOPH RES CO, V395, P219, DOI 10.1016/j.bbrc.2010.03.165
NR 40
TC 37
Z9 41
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 21
PY 2017
VL 17
AR 67
DI 10.1186/s12885 017 3046 6
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EI2TV
UT WOS:000392342200001
PM 28109246
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Montaño, AM
   Oikawa, H
   Tomatsu, S
   Nishioka, T
   Vogler, C
   Gutierrez, MA
   Oguma, T
   Tan, Y
   Grubb, JH
   Dung, VC
   Ohashi, A
   Miyamoto, K
   Orii, T
   Yoneda, Y
   Sly, WS
AF Montano, Adriana M.
   Oikawa, Hirotaka
   Tomatsu, Shunji
   Nishioka, Tatsuo
   Vogler, Carole
   Gutierrez, Monica A.
   Oguma, Toshihiro
   Tan, Yuri
   Grubb, Jeffrey H.
   Dung, Vu Chi
   Ohashi, Amiko
   Miyamoto, Ken ichi
   Orii, Tadao
   Yoneda, Yukio
   Sly, William S.
TI Acidic amino acid tag enhances response to enzyme replacement in
   mucopolysaccharidosis type VII mice
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE beta glucuronidase; enzyme replacement therapy; lysosomal storage
   disease; acidic oligopeptide; drug delivery system
ID TANDEM MASS SPECTROMETRY; HUMAN BETA GLUCURONIDASE; ALPHA L IDURONIDASE;
   SULFATE OLIGOSACCHARIDES; LYSOSOMAL ENZYME; GAUCHER DISEASE;
   CHONDROITIN/DERMATAN SULFATE; RETICULOENDOTHELIAL CELLS; COMPOSITIONAL
   ANALYSIS; HUMAN FIBROBLASTS
AB We have tested an acidic oligopeptide based targeting system for delivery of enzymes to tissues, especially bone and brain, in a murine mucopolysaccharidosis type VII (NIPS VII) model. This strategy is based upon tagging a short peptide consisting of acidic amino acids (AAA) to N terminus of human P glucuronidase (GUS). The pharmacokinetics, biodistribution, and the pathological effect on MPS VII mouse after 12 weekly infusions were determined for recombinant human untagged and tagged GUS.
   The tagged GUS was taken up by NIPS VII fibroblasts in a mannose 6 phosphate receptor dependent manner. Intravenously injected AAA tagged enzyme had five times more prolonged blood clearance compared with the untagged enzyme. The tagged enzyme was delivered effectively to bone, bone marrow, and brain in NIPS VII mice and was effective in reversing the storage pathology. The storage in osteoblasts was cleared similarly with both enzyme types. However, cartilage showed a little response to any of the enzymes. The tagged enzyme reduced storage in cortical neurons, hippocampus, and glia cells. A highly sensitive method of tandem mass spectrometry on serum indicated that the concentration of serum dermatan sulfate and heparan sulfate in mice treated with the tagged enzyme decreased more than the untagged enzyme.
   These preclinical studies suggest that this AAA based targeting system may enhance enzyme replacement therapy. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Montano, Adriana M.; Oikawa, Hirotaka; Tomatsu, Shunji; Nishioka, Tatsuo; Gutierrez, Monica A.; Dung, Vu Chi; Ohashi, Amiko] St Louis Univ, Dept Pediat, St Louis, MO 63104 USA.
   [Vogler, Carole] St Louis Univ, Dept Pathol, St Louis, MO 63104 USA.
   [Oguma, Toshihiro] Daiichi Sankyo Pharmaceut CO, Tokyo, Japan.
   [Tan, Yuri; Grubb, Jeffrey H.; Sly, William S.] St Louis Univ, Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
   [Miyamoto, Ken ichi] Kanazawa Univ, Dept Hosp Pharm, Kanazawa, Ishikawa, Japan.
   [Orii, Tadao] Gifu Univ, Dept Pediat, Gifu, Japan.
   [Oikawa, Hirotaka; Yoneda, Yukio] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.
C3 Saint Louis University; Saint Louis University; Daiichi Sankyo Company
   Limited; Saint Louis University; Kanazawa University; Gifu University;
   Kanazawa University
RP Tomatsu, S (通讯作者)，St Louis Univ, Dept Pediat, 1100 S Grand Blvd, St Louis, MO 63104 USA.
EM tomatsus@slu.edu
RI Yoneda, Yukio/ABI 1864 2020; Montano, Adriana/AHE 8741 2022; Oikawa,
   Hirotaka/D 6657 2018; Tomatsu, Shunji/AAA 4360 2022
OI Yoneda, Yukio/0000 0002 4624 177X; Vu, Dung Chi/0009 0007 0418 2613;
   Tomatsu, Shunji/0000 0002 0673 2160; Oikawa,
   Hirotaka/0000 0002 2050 4957; Montano, Adriana M./0000 0002 3971 5789; 
CR ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092 8674(78)90102 2
   Barranger JA, 2001, J INHERIT METAB DIS, V24, P89, DOI 10.1023/A:1012440428282
   BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104
   BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913
   Charrow J, 2007, CLIN GENET, V71, P205, DOI 10.1111/j.1399 0004.2007.00769.x
   DACOL R, 1993, J CHROMATOGR, V647, P289, DOI 10.1016/0021 9673(93)83409 L
   Dahl SV, 2006, CURR MED RES OPIN, V22, P1045, DOI 10.1185/030079906X104623
   Desnick RJ, 2002, NAT REV GENET, V3, P954, DOI 10.1038/nrg963
   DIETRICH CP, 1976, BIOCHEM BIOPH RES CO, V71, P1, DOI 10.1016/0006 291X(76)90241 2
   Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361
   Fuller M, 2004, GLYCOBIOLOGY, V14, P443, DOI 10.1093/glycob/cwh049
   FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304 4165(81)90474 8
   GLASER JH, 1973, J LAB CLIN MED, V82, P969
   Grabowski GA, 2003, ANNU REV GENOM HUM G, V4, P403, DOI 10.1146/annurev.genom.4.070802.110415
   Green I, 2003, TRENDS PHARMACOL SCI, V24, P213, DOI 10.1016/S0165 6147(03)00076 2
   Harmatz P, 2005, PEDIATRICS, V115, pE681, DOI 10.1542/peds.2004 1023
   ISLAM MR, 1993, J BIOL CHEM, V268, P22627
   Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304
   KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026
   Karlsson NG, 2005, J CHROMATOGR B, V824, P139, DOI 10.1016/j.jchromb.2005.07.014
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367
   LeBowitz JH, 2004, P NATL ACAD SCI USA, V101, P3083, DOI 10.1073/pnas.0308728100
   Lee SY, 2003, J MICROBIOL BIOTECHN, V13, P313
   Mason KE, 2006, ANAL CHEM, V78, P4534, DOI 10.1021/ac052083d
   Muenzer J, 2006, GENET MED, V8, P465, DOI 10.1097/01.gim.0000232477.37660.fb
   MURRAY GJ, 1987, METHOD ENZYMOL, V149, P25
   Nishioka T, 2006, MOL GENET METAB, V88, P244, DOI 10.1016/j.ymgme.2006.02.012
   Oguma T, 2001, ANAL BIOCHEM, V290, P68, DOI 10.1006/abio.2000.4940
   Oguma T, 2001, BIOMED CHROMATOGR, V15, P356, DOI 10.1002/bmc.74
   Oguma T, 2001, J CHROMATOGR B, V754, P153, DOI 10.1016/S0378 4347(00)00601 0
   Oguma T, 2007, BIOMED CHROMATOGR, V21, P356, DOI 10.1002/bmc.760
   Orii KO, 2005, MOL THER, V12, P345, DOI 10.1016/j.ymthe.2005.02.031
   Pope RM, 2001, GLYCOBIOLOGY, V11, P505, DOI 10.1093/glycob/11.6.505
   Prince WS, 2004, J BIOL CHEM, V279, P35037, DOI 10.1074/jbc.M402630200
   Roces DP, 2004, HUM MOL GENET, V13, P1979, DOI 10.1093/hmg/ddh220
   Saad OM, 2005, GLYCOBIOLOGY, V15, P818, DOI 10.1093/glycob/cwi064
   Saad OM, 2003, ANAL CHEM, V75, P2985, DOI 10.1021/ac0340455
   SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092 8674(77)90262 8
   Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200
   SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193
   SILVESTRO L, 1992, J CHROMATOGR, V591, P225, DOI 10.1016/0021 9673(92)80241 L
   Sly WS, 2006, P NATL ACAD SCI USA, V103, P15172, DOI 10.1073/pnas.0607053103
   Sly WS, 2001, P NATL ACAD SCI USA, V98, P2205, DOI 10.1073/pnas.051623698
   STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399
   TOLEDO OMS, 1977, BIOCHIM BIOPHYS ACTA, V498, P114, DOI 10.1016/0304 4165(77)90092 7
   Türeci Ö, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608
   Ulmasov B, 2000, P NATL ACAD SCI USA, V97, P14212, DOI 10.1073/pnas.97.26.14212
   Vogler C, 2005, P NATL ACAD SCI USA, V102, P14777, DOI 10.1073/pnas.0506892102
   Wenstrup RJ, 2007, J BONE MINER RES, V22, P119, DOI 10.1359/JBMR.061004
   Wraith J E, 2002, Semin Neonatol, V7, P75, DOI 10.1053/siny.2001.0088
   Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Zaia J, 2001, ANAL CHEM, V73, P233, DOI 10.1021/ac000777a
   Zamfir A, 2003, GLYCOBIOLOGY, V13, P733, DOI 10.1093/glycob/cwg086
   Zhang Y, 2005, ANAL CHEM, V77, P902, DOI 10.1021/ac040074j
   Zhang YT, 2005, INVEST OPHTH VIS SCI, V46, P1604, DOI 10.1167/iovs.04 1453
NR 57
TC 39
Z9 43
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1096 7192
EI 1096 7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JUN
PY 2008
VL 94
IS 2
BP 178
EP 189
DI 10.1016/j.ymgme.2008.01.007
PG 12
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 308EU
UT WOS:000256371900008
PM 18359257
DA 2025 08 17
ER

PT J
AU Huang, LJ
   Zhang, J
   Deng, YL
   Wang, H
   Zhao, P
   Zhao, GZ
   Zeng, W
   Wang, YH
   Chen, CN
   Wagstaff, W
   Haydon, RC
   Reid, RR
   He, TC
   Shen, L
   Luu, HH
   Zhao, L
AF Huang, Linjuan
   Zhang, Jing
   Deng, Youling
   Wang, Hao
   Zhao, Piao
   Zhao, Guozhi
   Zeng, Wei
   Wang, Yonghui
   Chen, Connie
   Wagstaff, William
   Haydon, Rex C.
   Reid, Russell R.
   He, Tong Chuan
   Shen, Le
   Luu, Hue H.
   Zhao, Ling
TI Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
SO GENES & DISEASES
LA English
DT Article
DE Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide;
   Ovarian cancer
ID MESENCHYMAL STEM CELLS; BMP9 INDUCED OSTEOGENIC DIFFERENTIATION;
   SUPPRESSES TUMOR GROWTH; WNT/BETA CATENIN; ANTIHELMINTHIC NICLOSAMIDE;
   OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; INHIBITION; PATHWAY;
   PROLIFERATION
AB Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag nosis. The standard treatment for OC includes a combination of debulking surgery and platinum taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu tic agents to overcome the chemoresistance of OC. The anti parasite agent niclosamide (NA) has been repurposed as an anti cancer agent and exerts potent anti cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
C1 [Huang, Linjuan; Zhang, Jing; Deng, Youling; Zhao, Piao; Zhao, Guozhi; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China.
   [Huang, Linjuan; Zhang, Jing; Deng, Youling; Zhao, Piao; Zhao, Guozhi; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China.
   [Huang, Linjuan; Zhang, Jing; Deng, Youling; Zhao, Piao; Zhao, Guozhi; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China.
   [Huang, Linjuan; Zhang, Jing; Deng, Youling; Wang, Hao; Zhao, Piao; Zhao, Guozhi; Zeng, Wei; Wang, Yonghui; Chen, Connie; Wagstaff, William; Haydon, Rex C.; Reid, Russell R.; He, Tong Chuan; Shen, Le; Luu, Hue H.; Zhao, Ling] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Wang, Hao] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China.
   [Wang, Hao] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China.
   [Zeng, Wei] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China.
   [Wang, Yonghui] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China.
   [Reid, Russell R.] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA.
   [He, Tong Chuan; Shen, Le] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; University of Chicago; University of Chicago Medical
   Center; Chongqing Medical University; Chongqing Medical University;
   Jianghan University; Shanghai Jiao Tong University; University of
   Chicago; University of Chicago Medical Center; University of Chicago;
   University of Chicago Medical Center
RP Zhao, L (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China.
EM zl203047@hospital cqmu.com
RI Reid, Russell/LIF 6227 2024; Chang, Liu/JTU 3058 2023
FU National Institutes of Health [CA226303, DE030480]; Medical Scientist
   Training Program of the National Institutes of Health (USA) [T32
   GM007281]; University of Chicago Cancer Center Support Grant
   [P30CA014599]; National Center for Advancing Translational Sciences of
   the National Institutes of Health (USA) [UL1 TR000430]; Mabel Green
   Myers Research Endowment Fund; University of Chicago Orthopaedics Alumni
   Fund
FX The reported work was supported in part by research grants from the
   National Institutes of Health (No. CA226303 to TCH, and No. DE030480 to
   RRR). WW was supported by the Medical Scientist Training Program of the
   National Institutes of Health (USA) (No. T32 GM007281). This project was
   also supported in part by The University of Chicago Cancer Center
   Support Grant (No. P30CA014599) and the National Center for Advancing
   Translational Sciences of the National Institutes of Health (USA) (No.
   UL1 TR000430). TCH was also supported by the Mabel Green Myers Research
   Endowment Fund and The University of Chicago Orthopaedics Alumni Fund.&
   nbsp;<STRONG>Funding & nbsp;</STRONG>sources were not involved in the
   study design, collection, analysis & interpretation of data, writing of
   the report, and the decision to submit the paper for publication.
CR Amable L, 2016, PHARMACOL RES, V106, P27, DOI 10.1016/j.phrs.2016.01.001
   An LQ, 2021, GENES DIS, V8, P531, DOI 10.1016/j.gendis.2020.11.004
   Arend RC, 2014, GYNECOL ONCOL, V134, P112, DOI 10.1016/j.ygyno.2014.04.005
   Barbosa EJ, 2019, EUR J PHARM BIOPHARM, V141, P58, DOI 10.1016/j.ejpb.2019.05.004
   Burock S, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4197 9
   Cao DG, 2020, AM J CANCER RES, V10, P3248
   Chen B, 2017, GASTROENTEROLOGY, V152, P2022, DOI 10.1053/j.gastro.2017.02.039
   Cui JJ, 2021, GENES DIS, V8, P509, DOI 10.1016/j.gendis.2019.12.012
   Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797
   Deng YL, 2015, SCI REP UK, V5, DOI 10.1038/srep17523
   Fan JM, 2020, CANCER GENE THER, V27, P424, DOI 10.1038/s41417 019 0113 y
   Fan JM, 2017, ONCOTARGET, V8, P27105, DOI 10.18632/oncotarget.15637
   Gao JL, 2013, ONCOL REP, V30, P292, DOI 10.3892/or.2013.2438
   Goode LL, 2010, NAT GENET, V42, P874, DOI 10.1038/ng.668
   Gou YN, 2022, BIOENG TRANSL MED, V7, DOI 10.1002/btm2.10306
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He F, 2022, NUCLEIC ACIDS RES, V50, DOI 10.1093/nar/gkab1153
   He F, 2020, MOL THER NUCL ACIDS, V22, P885, DOI 10.1016/j.omtn.2020.10.007
   Hu X, 2017, ONCOTARGET, V8, P111847, DOI 10.18632/oncotarget.22915
   Huang B, 2020, GENES DIS, V7, P225, DOI 10.1016/j.gendis.2019.04.005
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang LJ, 2021, AGING US, V13, P17407, DOI 10.18632/aging.203232
   Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008 5472.CAN 09 3950
   Judson PL, 1999, CANCER RES, V59, P2425
   King ML, 2015, ONCOGENE, V34, P3452, DOI 10.1038/onc.2014.277
   Kurnit KC, 2021, OBSTET GYNECOL, V137, P108, DOI 10.1097/AOG.0000000000004173
   Kuroki L, 2020, BMJ BRIT MED J, V371, DOI 10.1136/bmj.m3773
   LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006 2952(88)90325 5
   Lheureux S, 2019, CA CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559
   Li R, 2013, MOL CANCER THER, V12, P2200, DOI 10.1158/1535 7163.MCT 13 0095
   Li YH, 2014, CANCER LETT, V349, P8, DOI 10.1016/j.canlet.2014.04.003
   Li Z, 2017, AM J TRANSL RES, V9, P3776
   Liao J, 2017, GENE THER, V24, P333, DOI 10.1038/gt.2017.24
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078 0432.CCR 13 3296
   Liu QQ, 2022, GENES DIS, V9, P1624, DOI 10.1016/j.gendis.2021.12.020
   Liu W, 2020, GENES DIS, V7, P235, DOI 10.1016/j.gendis.2019.08.003
   Londoño Joshi AI, 2014, MOL CANCER THER, V13, P800, DOI 10.1158/1535 7163.MCT 13 0555
   Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388 018 0340 y
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther GA, 2013, CANCER LETT, V336, P222, DOI 10.1016/j.canlet.2013.05.002
   Lynch HT, 2009, MOL ONCOL, V3, P97, DOI 10.1016/j.molonc.2009.02.004
   Makovec T, 2019, RADIOL ONCOL, V53, P148, DOI 10.2478/raon 2019 0018
   Mao YK, 2021, GENES DIS, V8, P918, DOI 10.1016/j.gendis.2021.04.004
   Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61
   Ni N, 2021, MOL THER ONCOLYTICS, V23, P602, DOI 10.1016/j.omto.2021.11.011
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Pantziarka P, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.790952
   PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080
   Perego P, 1998, ANN ONCOL, V9, P423, DOI 10.1023/A:1008265012435
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Reid BM, 2017, CANCER BIOL MED, V14, P9, DOI 10.20892/j.issn.2095 3941.2016.0084
   Sack U, 2011, JNCI J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190
   Schcolnik Cabrera A, 2021, CURR MED CHEM, V28, P2085, DOI 10.2174/0929867327666200831141337
   Schweizer MT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198389
   Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637
   Shu Y, 2020, CANCER RES, V80, P988, DOI 10.1158/0008 5472.CAN 19 1471
   Shu Y, 2018, MOL THER NUCL ACIDS, V13, P556, DOI 10.1016/j.omtn.2018.09.025
   Shu Y, 2018, J CELL BIOCHEM, V119, P8872, DOI 10.1002/jcb.27140
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Sleire L, 2017, PHARMACOL RES, V124, P74, DOI 10.1016/j.phrs.2017.07.013
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Tran AA, 2020, LANCET ONCOL, V21, P1134, DOI 10.1016/S1470 2045(20)30424 1
   Wang LH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30692 3
   Wang X, 2021, GENES DIS, V8, P298, DOI 10.1016/j.gendis.2020.04.013
   Wang X, 2019, ACS SYNTH BIOL, V8, P2092, DOI 10.1021/acssynbio.9b00203
   Wang X, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 36214 5
   Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078 0432.CCR 12 2895
   Wu XX, 2021, GENES DIS, V8, P814, DOI 10.1016/j.gendis.2021.01.004
   YAO KS, 1995, CANCER RES, V55, P4367
   Yo YT, 2012, MOL CANCER THER, V11, P1703, DOI 10.1158/1535 7163.MCT 12 0002
   You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535 7163.MCT 13 0608
   Yu XY, 2018, GENES DIS, V5, P137, DOI 10.1016/j.gendis.2018.04.003
   Yu XY, 2018, CELL PHYSIOL BIOCHEM, V47, P957, DOI 10.1159/000490140
   Zeng ZY, 2020, J ADV RES, V24, P239, DOI 10.1016/j.jare.2019.12.005
   Zeng Zongyue, 2018, Genes Dis, V5, P62, DOI 10.1016/j.gendis.2018.02.001
   Zhang B, 2020, STEM CELLS DEV, V29, P498, DOI 10.1089/scd.2019.0292
   Zhang P, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 224
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhao C, 2019, ACS APPL MATER INTER, V11, P8749, DOI 10.1021/acsami.8b19094
   Zhao L, 2020, AM J TRANSL RES, V12, P8084
   Zhao X, 2021, AM J TRANSL RES, V13, P4233
   ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689
   Zhong JM, 2022, BIOACT MATER, V9, P523, DOI 10.1016/j.bioactmat.2021.07.022
   Zhong JM, 2021, AM J CANCER RES, V11, P793
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304 3835(03)00013 2
   Zou YL, 2017, ACS APPL MATER INTER, V9, P15922, DOI 10.1021/acsami.7b00272
NR 91
TC 8
Z9 11
U1 0
U2 5
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
SN 2352 4820
EI 2352 3042
J9 GENES DIS
JI Genes Dis.
PD JUL
PY 2023
VL 10
IS 4
BP 1687
EP 1701
DI 10.1016/j.gendis.2022.12.005
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA K6KW6
UT WOS:001017520200001
PM 37397523
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dalla Bona, DA
   Tanaka, E
   Oka, H
   Yamano, E
   Kawai, N
   Miyauchi, M
   Takata, T
   Tanne, K
AF Araujo Dalla Bona, Diego
   Tanaka, Eiji
   Oka, Hiroko
   Yamano, Eizo
   Kawai, Nobuhiko
   Miyauchi, Mutsumi
   Takata, Takashi
   Tanne, Kazuo
TI Effects of ultrasound on cementoblast metabolism in vitro
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE ultrasound; cementoblast; root resorption; bone metabolism
ID GENE EXPRESSION; PROGRESSIVE DEVELOPMENT; PERIODONTAL LIGAMENT; BONE
   SIALOPROTEIN; OSTEOPONTIN; OSTEOBLAST; CELLS; ROOT; DIFFERENTIATION;
   RESORPTION
AB Ultrasound (US) has been shown to alter cell/tissue functions. However the effects of US on cementoblasts are not known. The aim of the present study was to evaluate the effect of US exposure on proliferation and metabolism of cementoblast (murine cementoblastic cell line [OCCM 30]) in vitro. Cultured cementoblasts received US exposure (frequency = 1 MHz; pulsed 1:4; spatial average intensities (I SA) = 100, 150 or 400mW/ cm 2) or sham exposure for 15 min per d for 4 d. They were then assayed for calcium content and cell proliferation. Furthermore, expression levels of osteocalcin, bone sialoprotein, alkaline phosphatase and osteopontin were analyzed by real time polymerase chain reaction. Calcium content was statistically increased (P < 0.05) after US exposure at 100 or 150 mW/cm(2). Alkaline phosphatase mRNA levels were (p < 0.05) increased significantly by US stimulation with 150 mW/cm(2). These results demonstrate that US affects cementoblasts by regulation of some genes related protein in vitro and, although more studies are necessary, it may be important to consider in designing in vivo US therapies targeted at the oral cavity. (c) 2006 World Federation for Ultrasound in Medicine & Biology.
C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, Hiroshima 7348553, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral Maxillofacial Pathobiol, Hiroshima, Japan.
C3 Hiroshima University; Hiroshima University
RP Dalla Bona, DA (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
EM diego@hiroshima u.ac.jp
RI Tanaka, Eiji/E 7105 2015
OI Tanaka, Eiji/0000 0002 2707 1613
CR AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   ANDERSON HC, 1989, LAB INVEST, V60, P320
   ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203
   Bosshardt DD, 1998, ANAT REC, V250, P13, DOI 10.1002/(SICI)1097 0185(199801)250:1<13::AID AR3>3.0.CO;2 F
   BOSSHARDT DD, 2000, J PERIODONTOL, V13, P41
   BUCKLEY MJ, 1988, BONE MINER, V4, P225
   D'Errico JA, 2000, J PERIODONTOL, V71, P63, DOI 10.1902/jop.2000.71.1.63
   Denhardt DT, 2001, BIOCHEM BIOPH RES CO, V288, P448, DOI 10.1006/bbrc.2001.5780
   DErrico JA, 1997, BONE, V20, P117, DOI 10.1016/S8756 3282(96)00348 1
   Dyson M., 1985, Biological effects of ultrasound, P121
   El Bialy T, 2004, AM J ORTHOD DENTOFAC, V126, P186, DOI 10.1016/j.ajodo.2004.02.010
   El Bialy TH, 2003, AM J ORTHOD DENTOFAC, V124, P427, DOI 10.1016/S0889 5406(03)00408 6
   El Bialy TH, 2002, ANN BIOMED ENG, V30, P1251, DOI 10.1114/1.1529196
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   Grzesik WJ, 2002, CRIT REV ORAL BIOL M, V13, P474, DOI 10.1177/154411130201300605
   Harle J, 2001, ULTRASOUND MED BIOL, V27, P579, DOI 10.1016/S0301 5629(00)00326 4
   Lekic P, 1996, ANAT RECORD, V244, P50
   Liang H, 2003, DENTOMAXILLOFAC RAD, V32, P150, DOI 10.1259/dmfr/12925020
   LUKINMAA PL, 1991, J DENT RES, V70, P19, DOI 10.1177/00220345910700010201
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Ne RF, 1999, QUINTESSENCE INT, V30, P9
   Nociti FH, 2004, J DENT RES, V83, P602, DOI 10.1177/154405910408300804
   Ouyang H, 2000, J BONE MINER RES, V15, P2140, DOI 10.1359/jbmr.2000.15.11.2140
   Ouyang HJ, 2000, ENDOCRINOLOGY, V141, P4671, DOI 10.1210/en.141.12.4671
   SOMERMAN MJ, 1993, CARIOLOGY 1990S, P155
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   TENORIO D, 1993, J PERIODONTAL RES, V28, P411, DOI 10.1111/jre.1993.28.6.411
   Tokiyasu Y, 2000, J PERIODONTOL, V71, P1829, DOI 10.1902/jop.2000.71.12.1829
   VANDIJK S, 1993, J BONE MINER RES, V8, P1499
   Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154
   Wolff J, 1986, LAW BONE REMODEL
   Zhao M, 2003, J DENT RES, V82, P23, DOI 10.1177/154405910308200106
NR 32
TC 39
Z9 45
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD JUN
PY 2006
VL 32
IS 6
BP 943
EP 948
DI 10.1016/j.ultrasmedbio.2006.01.015
PG 6
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 056XG
UT WOS:000238557800016
PM 16785015
DA 2025 08 17
ER

PT J
AU Weng, YM
   Ke, CR
   Kong, JZ
   Chen, H
   Hong, JJ
   Zhou, DS
AF Weng, Y.  M.
   Ke, C.  R.
   Kong, J.  Z.
   Chen, H.
   Hong, J.  J.
   Zhou, D.  S.
TI The significant role of ATG5 in the maintenance of normal functions of
   Mc3T3 E1 osteoblast
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoporosis; ATG5; Autophagy; Proliferation; Apoptosis; Differentiation
ID MESENCHYMAL STEM CELLS; BONE HOMEOSTASIS; AUTOPHAGY; DIFFERENTIATION;
   PATHWAY; MINERALIZATION; MACROPHAGES; FRACTURES; TARGET; RUNX2
AB OBJECTIVE: To observe the effects of autophagy related gene 5 (ATG5) on the proliferation, differentiation, and apoptosis of Mc3T3 E1 osteoblast as well as the effects of ATG5 on apoptosis of osteoblasts under the conditions of non oxidative stress and oxidative stress.
   MATERIALS AND METHODS: ATG5 overexpressing and silencing cell lines were established in this experiment with lentiviral vector and transcription activator like effect or nuclease (Talen) technique, respectively, using Mc3T3 E1 cells. Cell counting kit 8 (CCK 8) was used to detect the proliferation rate of osteoblasts, and flow cytometry was applied to detect the impacts of overexpressed and silenced ATG5 on the cell cycle. Alizarin red staining was used to detect the mineralization capacity of osteoblasts after 4 week osteoinduction differentiation. Quantitative Real time polymerase chain reaction (qRT PCR) and Western blot methods were adopted to detect the levels of gene and protein expressions of runt related transcription factor 2 (Runx2), osteocalcin (OCN) and collagen I (COL I) correlated with osteoblast differentiation after 48 h of osteoinduction differentiation. The staining with Annexin V phycoerythrin/7 amino actinomycin D (Annexin V PE/7AAD) and flow cytometry were performed to detect the influence of ATG5 on osteoblast apoptosis.
   RESULTS: Stable ATG5 overexpressing and silencing Mc3T3 E1 cell lines were established successfully. CCK 8 test results showed that ATG5 silence inhibited cell proliferation, but the overexpression of ATG5 did not result in an obvious change in cell proliferation. Cell cycle did not change when ATG5 was overexpressed, while was stagnated in S phase when silenced. The number of mineralized nodules of cells was reduced notably when ATG5 was silenced, while the overexpression of ATG5 did not have an impact on mineralization capacity of the cell after 4 week of osteoinduction differentiation. The test results of qRT PCR and Western blotting suggested that ATG5 silence inhibited the gene and protein expressions of Runx2, OCN, and COL I, while the influence of overexpressed ATG5 on the expressions of genes related to osteoblastic differentiation was not obvious after 48 h of osteoinduction differentiation. ATG5 silence made the cells easier to be damaged by hydrogen peroxide, which resulted in the rise of apoptosis rate of osteoblasts, while the overexpressed ATG5 inhibited osteoblast apoptosis after treatment with hydrogen peroxide for 12 h.
   CONCLUSIONS: ATG5 silence can lead to inhibition of osteoblast proliferation and differentiation. Moreover, it makes the cells easier to be damaged by oxidative stress, and it causes an increase in apoptosis. However, the overexpression of ATG5 strengthens the anti oxidative capacity of osteoblasts and reduces apoptosis. ATG5 may be an effective target of anti oxidative therapy for osteoporosis, which brings a new direction for the treatment of osteoporosis.
C1 [Weng, Y.  M.; Zhou, D.  S.] Shandong Univ, Shandong Prov Hosp, Dept Traumat Orthoped, Jinan, Shandong, Peoples R China.
   [Weng, Y.  M.; Ke, C.  R.; Kong, J.  Z.; Chen, H.; Hong, J.  J.] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.
   [Weng, Y.  M.; Ke, C.  R.; Kong, J.  Z.; Chen, H.; Hong, J.  J.] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Wenzhou Medical University; Wenzhou
   Medical University
RP Weng, YM (通讯作者)，Shandong Univ, Shandong Prov Hosp, Dept Traumat Orthoped, Jinan, Shandong, Peoples R China.; Weng, YM (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.; Weng, YM (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
RI Chen, Haiyan/HGB 6216 2022
FU Wenzhou Science and Technology Bureau Foundation [Y20140714]
FX This work was supported by Wenzhou Science and Technology Bureau
   Foundation (No. Y20140714).
CR Chen XY, 2017, AUTOPHAGY, V13, P955, DOI 10.1080/15548627.2017.1287652
   Corrado A, 2017, POSTGRAD MED, V129, P858, DOI 10.1080/00325481.2017.1362312
   Dong QQ, 2016, AM J CHINESE MED, V44, P1393, DOI 10.1142/S0192415X16500786
   Dong ZW, 2016, BLOOD REV, V30, P369, DOI 10.1016/j.blre.2016.04.005
   Fu WM, 2016, EUR REV MED PHARMACO, V20, P3490
   Hwang HS, 2015, INT J MOL SCI, V16, P29265, DOI 10.3390/ijms161226164
   Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1223 7
   Koch FP, 2011, J CRANIO MAXILL SURG, V39, P562, DOI 10.1016/j.jcms.2010.10.007
   Kumar S, 2017, ALIMENT PHARM THER, V46, P1094, DOI 10.1111/apt.14345
   Li C, 2018, ACTA PHARMACOL SIN, V39, P345, DOI 10.1038/aps.2017.120
   Li YQ, 2018, CELL BIOL INT, V42, P205, DOI 10.1002/cbin.10888
   Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Sigurdsson G, 2017, LAEKNABLADID, V103, P423, DOI [10.17992/lbl.2017.10.154, 10.17992/Ib1.2017.10.154]
   Simon D, 2017, BONE, V105, P35, DOI 10.1016/j.bone.2017.08.013
   Su LY, 2017, AUTOPHAGY, V13, P1496, DOI 10.1080/15548627.2017.1332549
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Tao J, 2016, EXP CELL RES, V349, P221, DOI 10.1016/j.yexcr.2016.09.013
   Thiagarajan L, 2017, STEM CELL TRANSL MED, V6, P2146, DOI 10.1002/sctm.17 0137
   Wang CY, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0385 5
   Wang JL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 01174 9
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu LY, 2017, MOL MED REP, V16, P8699, DOI 10.3892/mmr.2017.7720
   Zhang L, 2017, ONCOTARGET, V8, P77360, DOI 10.18632/oncotarget.20483
NR 26
TC 13
Z9 21
U1 0
U2 8
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2018
VL 22
IS 5
BP 1224
EP 1232
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GA4JN
UT WOS:000428296000011
PM 29565478
DA 2025 08 17
ER

PT J
AU Fong, CY
   Kong, AN
   Noordin, M
   Poh, BK
   Ong, LC
   Ng, CC
AF Fong, Choong Yi
   Kong, Ann Nie
   Noordin, Mazidah
   Poh, Bee Koon
   Ong, Lai Choo
   Ng, Ching Ching
TI Determinants of low bone mineral density in children with epilepsy
SO EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
LA English
DT Article
DE Epilepsy; Antiepileptic drug; Bone mineral density; Lifestyle; Genetic
ID GENOME WIDE ASSOCIATION; VITAMIN D DEFICIENCY; ANTIEPILEPTIC DRUGS;
   AMBULATORY PATIENTS; MALAYSIAN CHILDREN; FRACTURE RISK; D RECEPTOR;
   OSTEOPOROSIS; ADOLESCENTS; HEALTH
AB Introduction: Children with epilepsy on long term antiepileptic drugs (AEDs) are at risk of low bone mineral density (BMD). The aims of our study were to evaluate the prevalence and determinants of low BMD among Malaysian children with epilepsy.
   Method: Cross sectional study of ambulant children with epilepsy on long term AEDs for >1 year seen in a tertiary hospital in Malaysia from 2014 to 2015. Detailed assessment of anthropometric measurements; environmental lifestyle risk factors; serum vitamin D, calcium and parathyroid hormone levels; genotyping of single nucleotide polymorphisms of genes in vitamin D and calcium metabolism; and lumbar spine BMD were obtained. Low BMD was defined as BMD Z score <=   2.0 SD.
   Results: Eighty seven children with mean age of 11.9 years (56 males) participated in the study. The prevalence of low lumbar BMD was 21.8% (19 patients). Multivariate logistic regression analysis identified polytherapy >2 AEDs (OR: 7.86; 95% CI 1.03 59.96), small frame size with wrist breadth of <15th centile (OR 14.73; 95% CI 2.21 98.40), and body mass index Z score <  2.0 (OR 8.73, 95% CI 1.17 65.19) as significant risk factors for low BMD.
   Conclusion: One fifth of Malaysian children with epilepsy on long term AEDs had low BMD. Targeted BMD should be performed for those who are on >2 AEDs, underweight or with small frame size as they are at higher risk of having low BMD. (C) 2017 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
C1 [Fong, Choong Yi; Kong, Ann Nie; Noordin, Mazidah; Ong, Lai Choo] Univ Malaya, Fac Med, Dept Paediat, Div Paediat Neurol, Kuala Lumpur 50603, Malaysia.
   [Noordin, Mazidah] UiTM Med Fac, Univ Inst Teknol MARA, Dept Paediat, Sungai Buloh, Selangor, Malaysia.
   [Poh, Bee Koon] Univ Kebangsaan Malaysia, Fac Hlth Sci, Nutr Sci Programme, Kuala Lumpur, Malaysia.
   [Ng, Ching Ching] Univ Malaya, Fac Sci, Inst Biol Sci, Genet & Mol Biol, Kuala Lumpur, Malaysia.
C3 Universiti Malaya; Universiti Kebangsaan Malaysia; Universiti Malaya
RP Fong, CY (通讯作者)，Univ Malaya, Fac Med, Dept Paediat, Div Paediat Neurol, Kuala Lumpur 50603, Malaysia.
EM cyfong@ummc.edu.my
RI Fong, Choong/A 4584 2015; Poh, Bee Koon/LLL 3691 2024; Ong,
   Lai/G 6439 2011; NG, CHING/B 9221 2010
OI Poh, Bee Koon/0000 0003 0713 5197
FU University of Malaya [UMRG 532 13HTM, PG166 2015A]
FX This study has received funds from the University of Malaya research
   grant (UMRG 532 13HTM and PG166 2015A).
CR Ahn J, 2010, HUM MOL GENET, V19, P2739, DOI 10.1093/hmg/ddq155
   Aini JN, 2013, PEDIATR INT, V55, P223, DOI 10.1111/ped.12035
   Albaghdadi O, 2016, CLIN NEUROL NEUROSUR, V146, P52, DOI 10.1016/j.clineuro.2016.04.019
   [Anonymous], WHO GROWTH REF DAT 5
   Bachrach LK, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016 2398
   Barger Lux MJ, 2002, J CLIN ENDOCR METAB, V87, P4952, DOI 10.1210/jc.2002 020636
   BONJOUR JP, 1994, OSTEOPOROSIS INT, V4, P7
   Chan P. J., 2014, International Journal of Osteoporosis & Metabolic Disorders, V7, P1
   Chumlea WC, 2002, AM J CLIN NUTR, V75, P1012, DOI 10.1093/ajcn/75.6.1012
   Coppola G, 2009, EPILEPSIA, V50, P2140, DOI 10.1111/j.1528 1167.2009.02082.x
   Crabtree NJ, 2014, J CLIN DENSITOM, V17, P225, DOI 10.1016/j.jocd.2014.01.003
   El Hajj Fuleihan G, 2008, BONE, V43, P149, DOI 10.1016/j.bone.2008.03.002
   Farhat G, 2002, NEUROLOGY, V58, P1348, DOI 10.1212/WNL.58.9.1348
   FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869
   Fong CY, 2016, EPILEPSIA, V57, P1271, DOI 10.1111/epi.13443
   Fong CY, 2011, EUR J PAEDIATR NEURO, V15, P417, DOI 10.1016/j.ejpn.2011.04.002
   Frisancho A.Roberto., 2008, Anthropometric Standards: An Interactive Nutritional Reference of Body Size and Body Composition for Children and Adults
   Gennari L, 2009, PHARMACOGENOMICS, V10, P417, DOI 10.2217/14622416.10.3.417
   Gniatkowska Nowakowska A, 2010, SEIZURE EUR J EPILEP, V19, P324, DOI 10.1016/j.seizure.2010.04.013
   Henderson RC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e5
   JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   KRALL EA, 1993, J BONE MINER RES, V8, P1
   Kuan YC, 2012, ANN THORAC MED, V7, P69, DOI 10.4103/1817 1737.94522
   McClung JP, 2010, NUTR REV, V68, P365, DOI 10.1111/j.1753 4887.2010.00295.x
   Misra M, 2008, PEDIATRICS, V122, P398, DOI 10.1542/peds.2007 1894
   Poh BK, 2011, INT J PEDIATR OBES, V6, P229, DOI 10.3109/17477166.2011.583658
   Samaniego Edgar A, 2007, Semin Pediatr Neurol, V14, P196, DOI 10.1016/j.spen.2007.08.006
   Shellhaas RA, 2010, PEDIATR NEUROL, V42, P385, DOI 10.1016/j.pediatrneurol.2009.12.005
   Sheth RD, 2008, NEUROLOGY, V70, P170, DOI 10.1212/01.wnl.0000284595.45880.93
   Siong T. E., 1997, Nutrient composition of Malaysian foods, V4th
   Souverein PC, 2005, EPILEPSIA, V112, P2777
   Tandon N, 2012, OSTEOPOROSIS INT, V23, P2447, DOI 10.1007/s00198 011 1857 x
   Vestergaard P, 2005, ACTA NEUROL SCAND, V112, P277, DOI 10.1111/j.1600 0404.2005.00474.x
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140 6736(10)60588 0
   WELTEN DC, 1994, J BONE MINER RES, V9, P1089, DOI 10.1002/jbmr.5650090717
   WHO, 2006, WHO child growth standards: length/height for age, weight for age, weight for length, weight for height and body mass index for age, methods and development
   Yee Y. S. S., 2013, Malaysian Journal of Nutrition, V19, P293
NR 40
TC 14
Z9 16
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090 3798
EI 1532 2130
J9 EUR J PAEDIATR NEURO
JI Eur. J. Paediatr. Neurol.
PD JAN
PY 2018
VL 22
IS 1
BP 155
EP 163
DI 10.1016/j.ejpn.2017.10.007
PG 9
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA FV8SW
UT WOS:000424858100021
PM 29122496
DA 2025 08 17
ER

PT J
AU Ginnetti, AT
   Paone, D
   Nanda, KK
   Li, J
   Busuek, M
   Johnson, SA
   Lu, J
   Soisson, SM
   Robinson, R
   Fisher, J
   Webber, A
   Wesolowski, G
   Ma, B
   Duong, L
   Carroll, S
   Burgey, CS
   Stachel, SJ
AF Ginnetti, Anthony T.
   Paone, Daniel, V
   Nanda, Kausik K.
   Li, Jing
   Busuek, Marina
   Johnson, Scott A.
   Lu, Jun
   Soisson, Stephen M.
   Robinson, Ronald
   Fisher, John
   Webber, Andrea
   Wesolowski, Gregg
   Ma, Bennett
   Le Duong
   Carroll, Steven
   Burgey, Christopher S.
   Stachel, Shawn J.
TI Lead optimization of cathepsin K inhibitors for the treatment of
   Osteoarthritis
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Cathepsin K; Cathepsin F; Osteoarthritis; Protease inhibitor; Free drug
   hypothesis; Lead Optimization
ID MODEL
AB Cathepsin K (Cat K) is a cysteine protease involved in bone remodeling. In addition to its role in bone biology, Cat K is upregulated in osteoclasts, chondrocytes and synoviocytes in osteoarthritic (OA) disease states making it a potential therapeutic target for disease modifying OA. Starting from a prior preclinical compound, MK 1256, lead optimization efforts were carried out in the search for potent Cat K inhibitors with improved selectivity profiles with an emphasis on cathepsin F. Herein, we report the SAR studies which led to the discovery of the highly selective oxazole compound 23, which was subsequently shown to inhibit cathepsin K in vivo as measured by reduced levels of urinary C telopeptide of collagen type I in dog.
C1 [Ginnetti, Anthony T.; Paone, Daniel, V; Nanda, Kausik K.; Busuek, Marina; Burgey, Christopher S.; Stachel, Shawn J.] Merck & Co Inc, MRL, Discovery Chem, POB 4, West Point, PA 19486 USA.
   [Li, Jing] Merck & Co Inc, MRL, Discovery Proc Chem, POB 4, West Point, PA 19486 USA.
   [Johnson, Scott A.; Lu, Jun; Soisson, Stephen M.] Merck & Co Inc, MRL, Struct Chem, POB 4, West Point, PA 19486 USA.
   [Robinson, Ronald; Carroll, Steven] Merck & Co Inc, MRL, In Vitro Pharmacol, POB 4, West Point, PA 19486 USA.
   [Fisher, John; Wesolowski, Gregg; Le Duong] Merck & Co Inc, MRL, Bone Biol, POB 4, West Point, PA 19486 USA.
   [Webber, Andrea] Merck & Co Inc, MRL, Mol Biomarkers, POB 4, West Point, PA 19486 USA.
   [Ma, Bennett] Merck & Co Inc, MRL, Pharmacokinet Pharmacodynam & Drug Metab, POB 4, West Point, PA 19486 USA.
C3 Merck & Company; Merck & Company USA; Merck & Company; Merck & Company
   USA; Merck & Company; Merck & Company USA; Merck & Company; Merck &
   Company USA; Merck & Company; Merck & Company USA; Merck & Company;
   Merck & Company USA; Merck & Company; Merck & Company USA
RP Ginnetti, AT (通讯作者)，Merck & Co Inc, MRL, Discovery Chem, POB 4, West Point, PA 19486 USA.
EM anthony_ginnetti@merck.com
CR Connor JR, 2009, OSTEOARTHR CARTILAGE, V17, P1236, DOI 10.1016/j.joca.2009.03.015
   Crane SN, 2006, J MED CHEM, V49, P1066, DOI 10.1021/jm051059p
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Lemaire PA, 2014, J BIOL CHEM, V289, P21562, DOI 10.1074/jbc.M114.559898
   Ma B, 2019, J CIRC BIOMARK, V8
   Ma B, 2017, N S ARCH PHARMACOL, V390, P435, DOI 10.1007/s00210 017 1356 5
   Morko JP, 2004, ANN RHEUM DIS, V63, P649, DOI 10.1136/ard.2002.004671
   Robichaud J, 2008, J MED CHEM, V51, P6410, DOI 10.1021/jm800610j
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Tang CH, 2006, MOL CELL BIOL, V26, P2309, DOI 10.1128/MCB.26.6.2309 2316.2006
   Wang Q, 2008, PHARM RES DORDR, V25, P1641, DOI 10.1007/s11095 008 9557 8
NR 12
TC 5
Z9 5
U1 1
U2 6
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 894X
EI 1464 3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD OCT 15
PY 2022
VL 74
AR 128927
DI 10.1016/j.bmcl.2022.128927
EA AUG 2022
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy; Chemistry
GA 4H5WY
UT WOS:000849949800011
PM 35944849
DA 2025 08 17
ER

PT J
AU Qiu, J
   Huang, G
   Na, N
   Chen, LZ
AF Qiu, Jiang
   Huang, Gang
   Na, Ning
   Chen, Lizhong
TI MicroRNA 214 5p/TGF β/Smad2 signaling alters adipogenic differentiation
   of bone marrow stem cells in postmenopausal osteoporosis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE microRNA 214 5p; adipogenic differentiation; bone marrow stem cells;
   transforming growth factor beta; Smad2
ID GENE EXPRESSION PROFILES; NF KAPPA B; OSTEOBLAST DIFFERENTIATION;
   SERUM LEVELS; IN VITRO; WOMEN; ASSOCIATION; SCLEROSTIN; TRIAL;
   POLYMORPHISMS
AB Postmenopausal osteoporosis (OPM) is a common type of osteoporosis in females. It is a systemic, chronic bone disease that presents as microstructure degradation of osseous tissue, decreased bone mineral density and increased osteopsathyrosis caused by hypoovarianism and reduced estrogen levels in the body following menopause. In the present study, the role of microRNA (miR) 214 5p in the regulation of the expression of bone marrow stem cells (BMSCs) was investigated, and its molecular mechanism of osteogenic induction in vitro was assessed. When dexamethasone induced adipogenic differentiation was performed, miR 214 5p expression was increased compared with the control group, as determined by RT qPCR. Furthermore, oil red O staining, RT qPCR and western blot analysis demonstrated that overexpression of miR 214 5p promoted adipogenic differentiation, inhibited alkaline phosphatase (ALP), runt related transcription factor 2 (Runx2), osteocalcin (OC) and collagen 1 (I) chain (COL1A1) mRNA expression, and suppressed transforming growth factor (TGF) beta, phosphorylated (p) Smad2 and collagen type IV 1 chain (COL4A1) protein expression in BMSCs. Additionally, downregulation of miR 214 5p increased the ALP, Runx2, OC and COL1 mRNA expression and increased TGF beta, Smad2 and COL4A1 protein expression in BMSCs. Furthermore, a TGF beta inhibitor was employed to inhibit TGF beta expression in BMSCs following miR 214 5p downregulation, which led to reduced Smad2, TGF beta and COL4A1 protein expression, and ALP, Runx2, OC and COL1 mRNA expression was also reduced, compared with the miR 214 5p downregulation only group. It was demonstrated that miR 214 5p may weaken osteogenic differentiation of BMSCs through regulating COL4A1. In conclusion, the results of the present study indicated that miR 214 5p may promote the adipogenic differentiation of BMSCs through regulation of the TGF beta/Smad2/COL4A1 signaling pathway, and potentially may be used to develop a novel drug for postmenopausal osteoporosis.
C1 [Qiu, Jiang; Huang, Gang; Chen, Lizhong] Sun Yat Sen Univ, Div Organ Transplantat, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Na, Ning] Sun Yat Sen Univ, Div Organ Transplantat, Affiliated Hosp 3, 600 Tian He Rd, Guangzhou 510630, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Na, N (通讯作者)，Sun Yat Sen Univ, Div Organ Transplantat, Affiliated Hosp 3, 600 Tian He Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM ningna9740@163.com
OI Na, Ning/0000 0001 8623 9837
FU Nature Scientific Foundation of Guangdong Province, China
   [2016A030313190]; National Nature Scientific Foundation of China
   [81470977, 81270835]; Science and Technology Planning Project of
   Guangdong Province, China [2013B021800077, 2014A020212121]; Basic
   Service Charge Young Teachers Cultivation Project of Sun Yat sen
   University [13ykpy35]
FX The present study was supported by the Nature Scientific Foundation of
   Guangdong Province, China (grant no. 2016A030313190), the National
   Nature Scientific Foundation of China (grant nos. 81470977 and
   81270835), the Science and Technology Planning Project of Guangdong
   Province, China (grant nos. 2013B021800077 and 2014A020212121) and the
   Basic Service Charge Young Teachers Cultivation Project of Sun Yat sen
   University (grant no. 13ykpy35).
CR Bi D, 2016, CLIN GENET, V90, P149, DOI 10.1111/cge.12723
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Catalano A, 2013, J CLIN ENDOCR METAB, V98, P1911, DOI 10.1210/jc.2012 4039
   Cheng Q, 2016, CLIN CHIM ACTA, V455, P87, DOI 10.1016/j.cca.2016.01.025
   Donoso O, 2015, J CELL BIOCHEM, V116, P1267, DOI 10.1002/jcb.25082
   Filip R, 2015, J NUTR HEALTH AGING, V19, P77, DOI 10.1007/s12603 014 0480 x
   Gale DP, 2016, NEPHROL DIAL TRANSPL, V31, P1908, DOI 10.1093/ndt/gfw051
   Gu JM, 2015, ACTA PHARMACOL SIN, V36, P841, DOI 10.1038/aps.2015.30
   Heilmeier U, 2016, J BONE MINER RES, V31, P2173, DOI 10.1002/jbmr.2897
   Hooshmand S, 2014, BRIT J NUTR, V112, P55, DOI 10.1017/S0007114514000671
   Hopwood B, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2301
   Huang C, 2016, J BIOL REG HOMEOS AG, V30, P565
   Iizuka M, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755 1536 5 12
   Itabashi A, 2015, J BONE MINER METAB, V33, P61, DOI 10.1007/s00774 013 0554 6
   Kessous R, 2014, TAIWAN J OBSTET GYNE, V53, P206, DOI 10.1016/j.tjog.2014.04.015
   Komatsu Y, 2016, INT J MOL MED, V38, P139, DOI 10.3892/ijmm.2016.2582
   Li Baojie, 2008, Endocrine Metabolic & Immune Disorders Drug Targets, V8, P208, DOI 10.2174/187153008785700127
   Li F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149400
   Li QS, 2017, BONE JOINT RES, V6, P464, DOI 10.1302/2046 3758.68.BJR 2016 0208.R2
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Liu XD, 2015, BIOL CHEM, V396, P339, DOI 10.1515/hsz 2014 0268
   Liu YQ, 2015, MOL MED REP, V12, P6584, DOI 10.3892/mmr.2015.4283
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martin PJ, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0057 5
   Matsumoto T, 2015, J MED ULTRASON, V42, P445, DOI 10.1007/s10396 015 0610 z
   Pawlowski JW, 2015, AM J CLIN NUTR, V102, P695, DOI 10.3945/ajcn.114.093906
   Pfeifer M, 2011, AM J PHYS MED REHAB, V90, P805, DOI 10.1097/PHM.0b013e31821f6df3
   Plaisier E., 1993, GENEREVIEWS
   Saad MN, 2015, GENE, V568, P124, DOI 10.1016/j.gene.2015.05.037
   Saeed H, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0116 4
   Sun JJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000461
   Sun XD, 2016, CHEM BIOL INTERACT, V244, P9, DOI 10.1016/j.cbi.2015.11.027
   Tomotaki S, 2016, PEDIATR NEONATOL, V57, P522, DOI 10.1016/j.pedneo.2014.04.001
   Utennam D, 2012, GENET MOL RES, V11, P87, DOI 10.4238/2012.January.13.2
   Wen Y, 2016, OSTEOPOROSIS INT, V27, P1041, DOI 10.1007/s00198 015 3364 y
   Zavrski I, 2003, J CANCER RES CLIN, V129, P383, DOI 10.1007/s00432 003 0454 6
NR 36
TC 50
Z9 52
U1 0
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2018
VL 17
IS 5
BP 6301
EP 6310
DI 10.3892/mmr.2018.8713
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GD5OR
UT WOS:000430556800011
PM 29532880
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Chanda, D
   Isayeva, T
   Kumar, S
   Hensel, JA
   Sawant, A
   Ramaswamy, G
   Siegal, GP
   Beatty, MS
   Ponnazhagan, S
AF Chanda, Diptiman
   Isayeva, Tatyana
   Kumar, Sanjay
   Hensel, Jonathan A.
   Sawant, Anandi
   Ramaswamy, Girish
   Siegal, Gene P.
   Beatty, Matthew S.
   Ponnazhagan, Selvarangan
TI Therapeutic Potential of Adult Bone Marrow Derived Mesenchymal Stem
   Cells in Prostate Cancer Bone Metastasis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MURINE MODEL; OSTEOPROTEGERIN OPG; TUMOR BURDEN; MECHANISMS; PREVENTS;
   SURVIVAL; RANK
AB Purpose: Current evidence indicates that an osteoblast lesion in prostate cancer is preceded by osteolysis. Thus, prevention of osteolysis would reduce complications of bone metastasis. Bone marrow derived mesenchymal stem cells have the ability to differentiate into osteoblast and produce osteoprotegerin, a decoy receptor for the receptor activator for nuclear factor k B ligand, naturally. The present study examined the potential of unmodified mesenchymal stem cells to prevent osteolytic bone lesions in a preclinical mouse model of prostate cancer.
   Experimental Design: The human prostate cancer cell line PC3 was implanted in tibiae of severe combined immunodeficient mice. After establishment of the tumor, either unmodified or genetically engineered mesenchymal stem cells overexpressing osteoprotegerin was injected at the site of tumor growth. The effects of therapy were monitored by bioluminescence imaging, micro computed tomography, immunohistochemistry, and histomorphometry.
   Results: Data indicated significant (P < 0.001) inhibition of tumor growth and restoration of bone in mice treated with unmodified and modified mesenchymal stem cells. Detailed analysis suggested that the donor mesenchymal stem cell inhibited tumor progression by producing woven bone around the growing tumor cells in the tibiae and by preventing osteoclastogenesis.
   Conclusions: Overcoming the limitation of the number of mesenchymal stem cells available in the bone can provide significant amelioration for osteolytic damage without further modification. (Clin Cancer Res 2009;15(23):7175 85)
C1 [Chanda, Diptiman; Isayeva, Tatyana; Kumar, Sanjay; Hensel, Jonathan A.; Sawant, Anandi; Siegal, Gene P.; Beatty, Matthew S.; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Ramaswamy, Girish] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, Dept Pathol, 701,19th St S,LHRB 513, Birmingham, AL 35294 USA.
EM pons@uab.edu
RI kumar, Sanjay/ITT 3680 2023; Siegal, Gene/A 8653 2009
OI Beatty, Matthew/0000 0001 5734 1322
FU NIH [R01CA98817, R01AR50251, R01CA108585, P30AR046031]; U.S. Army
   Department of Defense [BC044440, PC050949]
FX NIH grants R01CA98817, R01AR50251, R01CA108585, and P30AR046031, and the
   U.S. Army Department of Defense grants BC044440 and PC050949.
CR Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Capparelli C, 2000, CANCER RES, V60, P783
   Chanda D, 2008, MOL THER, V16, P871, DOI 10.1038/mt.2008.48
   Choueiri MB, 2006, CANCER METAST REV, V25, P601, DOI 10.1007/s10555 006 9034 y
   Dotan ZA, 2008, NAT CLIN PRACT UROL, V5, P434, DOI 10.1038/ncpuro1190
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Fritz V, 2008, STEM CELLS, V26, P2981, DOI 10.1634/stemcells.2008 0139
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Holen I, 2002, CANCER RES, V62, P1619
   Holen I, 2006, CLIN SCI, V110, P279, DOI 10.1042/CS20050175
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kumar S, 2008, GENE THER, V15, P711, DOI 10.1038/gt.2008.35
   Kumar S, 2007, FASEB J, V21, P3917, DOI 10.1096/fj.07 8275com
   Morony S, 2001, CANCER RES, V61, P4432
   Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276
   Nyambo R, 2004, J BONE MINER RES, V19, P1712, DOI 10.1359/JBMR.040703
   Onyia JE, 2004, J PHARMACOL EXP THER, V309, P369, DOI 10.1124/jpet.103.057893
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Whang PG, 2005, J ORTHOP RES, V23, P1475, DOI 10.1016/j.orthres.2005.05.004
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Ye L, 2007, INT J MOL MED, V20, P103
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 29
TC 45
Z9 53
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 1
PY 2009
VL 15
IS 23
BP 7175
EP 7185
DI 10.1158/1078 0432.CCR 09 1938
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 527JQ
UT WOS:000272363700012
PM 19920103
OA Bronze, Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Pan, XH
   Zhang, JX
   Yu, XW
   Qin, L
   Kang, LG
   Zhang, P
AF Pan, Xiao Hua
   Zhang, Jianxin
   Yu, Xiaowei
   Qin, Ling
   Kang, Ligeng
   Zhang, Peng
TI New Therapeutic Approaches for the Treatment of Rheumatoid Arthritis may
   Rise from the Cholinergic Anti Inflammatory Pathway and Antinociceptive
   Pathway
SO THESCIENTIFICWORLDJOURNAL
LA English
DT Article
DE rheumatoid arthritis; anti inflammatory pathway; antinociceptive
   pathway; nicotinic acetylcholine receptor
ID NICOTINIC ACETYLCHOLINE RECEPTOR; COLLAGEN INDUCED ARTHRITIS;
   POSTOPERATIVE PAIN; MOUSE MODEL; STIMULATION; AGONISTS; INFLAMMATION;
   EXPRESSION; RATS; OSTEOCLASTOGENESIS
AB Due to the complex etiology of rheumatoid arthritis (RA), it is difficult to be completely cured at the current stage although many approaches have been applied in clinics, especially the wide application of nonsteroidal anti inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs (DMARDs). New drug discovery and development via the recently discovered cholinergic anti inflammatory and antinociceptive pathways should be promising. Based on the above, the nicotinic acetylcholine receptor agonists maintain the potential for the treatment of RA. Therefore, new therapeutic approaches may rise from these two newly discovered pathways. More preclinical experiments and clinical trials are required to confirm our viewpoint.
C1 [Qin, Ling; Zhang, Peng] Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen, Guangdong, Peoples R China.
   [Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Kang, Ligeng] Taian Hosp Tradit Chinese Med, Dept Orthopaed, Tai An, Shandong, Peoples R China.
   [Yu, Xiaowei] Nanjing Med Univ, Affiliated Hosp 2, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Jianxin] Shandong Univ Tradit Chinese Med, Dept Orthopaed, Jinan, Shandong, Peoples R China.
   [Pan, Xiao Hua] Jinan Univ, Clin Med Coll 2, Dept Orthopaed, Shenzhen, Guangdong, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese University of Hong Kong; Nanjing Medical University;
   Shandong University of Traditional Chinese Medicine; Jinan University
RP Zhang, P (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen, Guangdong, Peoples R China.
EM superzhangpeng@163.com
RI qin, ling/KIB 1029 2024; Qin, Ling/J 9047 2018; Zhang,
   Peng/NDT 6282 2025
OI Qin, Ling/0000 0001 6173 6167; 
FU National Natural Science Foundation of China [81000786]
FX This research was supported by the National Natural Science Foundation
   of China. Support number: 81000786.
CR ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Blaschke S, 2001, J RHEUMATOL, V28, P12
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   Bruchfeld A, 2010, J INTERN MED, V268, P94, DOI 10.1111/j.1365 2796.2010.02226.x
   Damaj MI, 2000, NEUROPHARMACOLOGY, V39, P2785, DOI 10.1016/S0028 3908(00)00139 8
   de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229
   Goldstein RS, 2007, MOL MED, V13, P210, DOI 10.2119/2006 00108.Goldstein
   Haibel H, 2009, CLIN EXP RHEUMATOL, V27, pS159
   Hosur V, 2009, J NEUROCHEM, V111, P848, DOI 10.1111/j.1471 4159.2009.06373.x
   IWAMOTO ET, 1993, J PHARMACOL EXP THER, V266, P329
   IWAMOTO ET, 1989, J PHARMACOL EXP THER, V251, P412
   Jessop DS, 2010, ANN NY ACAD SCI, V1193, P117, DOI 10.1111/j.1749 6632.2009.05294.x
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kooloos WM, 2010, CURR PHARM DESIGN, V16, P164, DOI 10.2174/138161210790112764
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   MATTILA MJ, 1968, ANN MED EXP BIOL FEN, V46, P78
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McInnes IB, 2005, NAT CLIN PRACT RHEUM, V1, P31, DOI 10.1038/ncprheum0020
   McIntosh JM, 2009, BIOCHEM PHARMACOL, V78, P693, DOI 10.1016/j.bcp.2009.05.020
   Morita Y, 2010, CALCIFIED TISSUE INT, V86, P242, DOI 10.1007/s00223 010 9335 6
   Morris VH, 1997, PAIN, V71, P179, DOI 10.1016/S0304 3959(97)03361 7
   Nizri E, 2009, J IMMUNOL, V183, P6681, DOI 10.4049/jimmunol.0902212
   Pullerits R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2445
   QUAYLE JA, 1995, ANN RHEUM DIS, V54, P930, DOI 10.1136/ard.54.11.930
   Rewatkar PV, 2010, MINI REV MED CHEM, V10, P98
   Ritchlin C, 2000, ARTHRITIS RES, V2, P356, DOI 10.1186/ar112
   Rowley TJ, 2010, BRIT J ANAESTH, V105, P201, DOI 10.1093/bja/aeq113
   Rowley TJ, 2008, ANESTH ANALG, V107, P1052, DOI 10.1213/ane.0b013e318165e0c0
   SCHAIBLE HG, 1993, PAIN, V55, P5, DOI 10.1016/0304 3959(93)90183 P
   SCHAIBLE HG, 1988, J NEUROPHYSIOL, V60, P2180, DOI 10.1152/jn.1988.60.6.2180
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Smolen JS, 2005, CLIN REV ALLERG IMMU, V28, P239, DOI 10.1385/CRIAI:28:3:239
   Straub RH, 2008, ARTHRITIS RHEUM US, V58, P456, DOI 10.1002/art.23206
   Tegeder I, 2004, PHARMACOL REV, V56, P351, DOI 10.1124/pr.56.3.2
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   van Maanen MA, 2009, NAT REV RHEUMATOL, V5, P229, DOI 10.1038/nrrheum.2009.31
   van Maanen MA, 2009, ARTHRITIS RHEUM US, V60, P1272, DOI 10.1002/art.24470
   van Maanen MA, 2009, ARTHRITIS RHEUM US, V60, P114, DOI 10.1002/art.24177
   Walker JG, 2005, J RHEUMATOL, V32, P1650
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   Westman M, 2009, SCAND J IMMUNOL, V70, P136, DOI 10.1111/j.1365 3083.2009.02266.x
   Wiens A, 2010, PHARMACOTHERAPY, V30, P339, DOI 10.1592/phco.30.4.339
   Yoshimatsu M, 2009, BONE, V45, P1010, DOI 10.1016/j.bone.2009.07.079
   Zhang P, 2008, INFLAMM RES, V57, P322, DOI 10.1007/s00011 008 8070 1
   Zhang P, 2010, INFLAMM RES, V59, P415, DOI 10.1007/s00011 010 0160 1
   Zhang P, 2010, RHEUMATOL INT, V30, P713, DOI 10.1007/s00296 010 1370 0
NR 47
TC 10
Z9 10
U1 2
U2 19
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537 744X
J9 THESCIENTIFICWORLDJO
JI TheScientificWorldJOURNAL
PY 2010
VL 10
BP 2247
EP 2253
DI 10.1100/tsw.2010.207
PG 6
WC Environmental Sciences; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Science & Technology   Other Topics
GA 682VS
UT WOS:000284431700004
PM 21103793
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Valdes, AM
   Richards, JB
   Gardner, JP
   Swaminathan, R
   Kimura, M
   Xiaobin, L
   Aviv, A
   Spector, TD
AF Valdes, A. M.
   Richards, J. B.
   Gardner, J. P.
   Swaminathan, R.
   Kimura, M.
   Xiaobin, L.
   Aviv, A.
   Spector, T. D.
TI Telomere length in leukocytes correlates with bone mineral density and
   is shorter in women with osteoporosis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE aging; bone mineral density; C reactive protein; inflammation;
   osteoporosis; telomere
ID REPLICATIVE SENESCENCE; DISEASE; CELLS; OSTEOBLASTS; MECHANISMS;
   PREVENTS; TISSUES; TNF
AB Telomere length decreases with age and is associated with osteoblast senescence. In 2,150 unselected women, leukocyte telomere length was significantly correlated with bone mineral density. Clinical osteoporosis was associated with shorter telomeres, suggesting that telomere length can be used as a marker of bone aging.
   Introduction The length of telomeres in proliferative cells diminishes with age. Telomere shortening and telomerase activity have been linked to in vitro osteoblast senescence and to increased secretion of pro inflammatory cytokines. We explored whether bone mineral density correlates with telomere length in leukocytes.
   Materials and methods The relationship between leukocyte telomere length, bone mineral density (BMD) and osteoporosis ( as defined by the World Health Organization) was examined in a cohort of 2,150 women from a population based twin cohort aged 18 79.
   Results After adjusting for age, body mass index, menopausal status, smoking, hormone replacement therapy status, telomere length was positively correlated with BMD of the spine (p < 0.005), forearm (p < 0.013), but not the femoral neck (p < 0.06). Longer telomeres were associated with reduced the risk of clinical OP at two or more sites ( odds ratio= 0.594 95% CI 0.42 0.84 p < 0.003) and in women over the age of 50, clinical osteoporosis was associated with 117 bp shorter telomere length (p < 0.02) equivalent to 5.2 years of telomeric aging.
   Conclusions Shortened leukocyte telomere length is independently associated with a decrease in BMD and the presence of osteoporosis in women. Our data provide evidence that leukocyte telomere length could be a marker of biological aging of bone.
C1 Kings Coll London, Twin Res & Genet Epidemiol Unit, London SE1 7EH, England.
   Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Human Dev & Aging, Newark, NJ 07103 USA.
   St Thomas Hosp, Dept Chem Pathol, London SE1, England.
C3 University of London; King's College London; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences
RP Spector, TD (通讯作者)，Kings Coll London, Twin Res & Genet Epidemiol Unit, St Thomas Hosp Campus, London SE1 7EH, England.
EM ana.valdes@kcl.ac.uk; brent.richards@kcl.ac.uk; gardner@umdnj.edu;
   swaminathan@kcl.ac.uk; kimurama@umdnj.edu; luxi@umdnj.edu;
   avivab@umdnj.edu; tim.spector@kcl.ac.uk
RI Valdes, Ana/AFK 8052 2022; Gardner, Jonathan/M 3224 2016; Richards,
   J/AAF 4225 2019
OI Valdes, Ana M./0000 0003 1141 4471; 
FU NIA NIH HHS [AG020132, AG021593] Funding Source: Medline; Wellcome Trust
   Funding Source: Medline
CR Andrew T, 2001, Twin Res, V4, P464, DOI 10.1375/1369052012803
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   AVIV A, 2006, INT J EPIDEMIOL  OCT
   Bekaert S, 2005, MECH AGEING DEV, V126, P1115, DOI 10.1016/j.mad.2005.04.007
   Benetos A, 2004, HYPERTENSION, V43, P182, DOI 10.1161/01.HYP.0000113081.42868.f4
   Benetos A, 2001, HYPERTENSION, V37, P381, DOI 10.1161/01.HYP.37.2.381
   Beyne Rauzy O, 2004, ONCOGENE, V23, P7507, DOI 10.1038/sj.onc.1208024
   Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500
   Brouilette S, 2003, ARTERIOSCL THROM VAS, V23, P842, DOI 10.1161/01.ATV.0000067426.96344.32
   Browner WS, 2004, AM J MED, V117, P851, DOI 10.1016/j.amjmed.2004.06.033
   Butler MG, 1998, CANCER GENET CYTOGEN, V105, P138, DOI 10.1016/S0165 4608(98)00029 6
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Effros RB, 2004, EXP GERONTOL, V39, P517, DOI 10.1016/j.exger.2003.09.024
   Erdmann J, 1999, MECH AGEING DEV, V110, P73, DOI 10.1016/S0047 6374(99)00043 3
   Etherington J, 1996, J BONE MINER RES, V11, P1333
   Friedrich U, 2000, MECH AGEING DEV, V119, P89, DOI 10.1016/S0047 6374(00)00173 1
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Garcia Moreno C, 2004, BONE, V35, P170, DOI 10.1016/j.bone.2004.02.021
   GINALDI L, 2005, IMMUN AGEING, V4, P14
   Hunter DJ, 2001, OSTEOPOROSIS INT, V12, P406, DOI 10.1007/s001980170110
   Inoue K, 1997, J BONE MINER RES, V12, P989, DOI 10.1359/jbmr.1997.12.6.989
   Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935
   Kveiborg M, 1999, MECH AGEING DEV, V106, P261, DOI 10.1016/S0047 6374(98)00114 6
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Pietschmann P, 2001, EXP GERONTOL, V36, P1749, DOI 10.1016/S0531 5565(01)00125 5
   PRATT DA, 1992, ANAL BIOCHEM, V207, P168, DOI 10.1016/0003 2697(92)90519 D
   Rodan Gideon A., 1996, P979
   Samani NJ, 2001, LANCET, V358, P472, DOI 10.1016/S0140 6736(01)05633 1
   Saretzki G, 2002, ANN NY ACAD SCI, V959, P24, DOI 10.1111/j.1749 6632.2002.tb02079.x
   Schnabl B, 2003, HEPATOLOGY, V37, P653, DOI 10.1053/jhep.2003.50097
   Sivas F, 2006, RHEUMATOL INT, V26, P896, DOI 10.1007/s00296 006 0104 9
   SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140 6736(05)66630 5
   Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453
NR 38
TC 130
Z9 139
U1 0
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD SEP
PY 2007
VL 18
IS 9
BP 1203
EP 1210
DI 10.1007/s00198 007 0357 5
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 216ST
UT WOS:000249900000007
PM 17347788
DA 2025 08 17
ER

PT J
AU Piccinonna, S
   Margiotta, N
   Pacifico, C
   Lopalco, A
   Denora, N
   Fedi, S
   Corsini, M
   Natile, G
AF Piccinonna, Sara
   Margiotta, Nicola
   Pacifico, Concetta
   Lopalco, Antonio
   Denora, Nunzio
   Fedi, Serena
   Corsini, Maddalena
   Natile, Giovanni
TI Dinuclear Pt(II) bisphosphonate complexes: a scaffold for multinuclear
   or different oxidation state platinum drugs
SO DALTON TRANSACTIONS
LA English
DT Article
ID CRYSTAL STRUCTURE; BISPHOSPHONATES; REDUCTION; DELIVERY; RELEASE;
   DIAMINE; CANCER
AB Geminal bisphosphonates (BPs), used in the clinic for the treatment of hypercalcaemia and skeletal metastases, have been also exploited for promoting the specific accumulation of platinum antitumor drugs in bone tissue. In this work, the platinum dinuclear complex [{Pt(en)}(2)(mu AHBP H 2)](+) (1) (the carbon atom bridging the two phosphorous atoms carrying a 2 ammonioethyl and a hydroxyl group, AHBP H 2) has been used as scaffold for the synthesis of a Pt(II) trinuclear complex, [{Pt(en)}(3)(mu AHBP)](+) (2), and a Pt(IV) adamantane shaped dinuclear complex featuring an oxo bridge, [{Pt IV(en)Cl}(2)(mu O)(mu AHBP H 2)](+) (3) (X ray structure). Compound 2 undergoes a reversible, pH dependent, rearrangement with a neat switch point around pH = 5.4. Compound 3 undergoes a one step electrochemical reduction at E pc =  0.84 Vaffording compound 1. Such a potential is far lower than that of glutathione ( 0.24 V), nevertheless compound 3 can undergo chemical reduction to 1 by GSH, most probably through a different (inner sphere) mechanism. In vitro cytotoxicity of the new compounds, tested against murine glioma (C6) and human cervix ( HeLa) and hepatoma (HepG2) cell lines, has shown that, while the Pt IV dimer 3 is inactive up to a concentration of 50 mu M, the two Pt II polynuclear compounds 1 and 2 have a cytotoxicity comparable to that of cisplatin with the trinuclear complex 2 generally more active than the dinuclear complex 1.
C1 [Margiotta, Nicola; Lopalco, Antonio; Denora, Nunzio] Univ Bari, Dipartimento Farmacochim, Div Tecnol Farmaceut, I 70125 Bari, Italy.
   [Fedi, Serena; Corsini, Maddalena] Univ Siena, Dipartimento Chim, I 53100 Siena, Italy.
C3 Universita degli Studi di Bari Aldo Moro; University of Siena
RP Margiotta, N (通讯作者)，Univ Bari, Dipartimento Farmacochim, Div Tecnol Farmaceut, Via E Orabona 4, I 70125 Bari, Italy.
EM nmargiotta@farmchim.uniba.it; natile@farmchim.uniba.it
RI DENORA, Nunzio/J 6881 2018; Margiotta, Nicola/AAE 3975 2021; Lopalco,
   Antonio/Y 7524 2018; Corsini, Maddalena/JCE 7948 2023
OI DENORA, Nunzio/0000 0002 7756 7828; Lopalco,
   Antonio/0000 0003 2124 9211; Natile, Giovanni/0000 0002 1790 6365;
   Iacobazzi, Rosa Maria/0000 0002 0737 6591; Pacifico,
   Concetta/0000 0001 6642 8083; Margiotta, Nicola/0000 0003 4034 875X;
   Corsini, Maddalena/0000 0002 5920 5436; 
CR ALBAKER S, 1986, J AM CHEM SOC, V108, P5643, DOI 10.1021/ja00278a056
   [Anonymous], ACTA CRYSTALLOGR A
   [Anonymous], BRUK COSMO APEX2 BIS
   [Anonymous], KALEIDAGRAPH 3 5
   [Anonymous], UNPUB
   Barnes CL, 1997, J APPL CRYSTALLOGR, V30, P568, DOI 10.1107/S0021889897006638
   BAU R, 1988, J AM CHEM SOC, V110, P7546, DOI 10.1021/ja00230a050
   Berners Price SJ, 2006, PROG NUCL MAG RES SP, V49, P65, DOI 10.1016/j.pnmrs.2006.05.002
   Burla M. C., 2003, Journal of Applied Crystallography, V36, DOI 10.1107/S0021889803012585
   Choi S, 1998, INORG CHEM, V37, P2500, DOI 10.1021/ic971047x
   FARRUGIA LJ, 1999, J APPL CRYSTALLOGR, V32, DOI [DOI 10.1107/S0021889899006020, 10.1107/S0021889812029111, DOI 10.1107/S0021889812029111]
   FELTHAM RD, 1964, J CHEM SOC, P4587, DOI 10.1039/jr9640004587
   Hall MD, 2002, COORDIN CHEM REV, V232, P49, DOI 10.1016/S0010 8545(02)00026 7
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022 1759(89)90397 9
   Iafisco M, 2012, NANOSCALE, V4, P206, DOI 10.1039/c1nr11147g
   Iafisco M, 2009, J MATER CHEM, V19, P8385, DOI 10.1039/b914379c
   Jakupec MA, 2008, DALTON T, P183, DOI 10.1039/b712656p
   Junicke H, 1999, Z ANORG ALLG CHEM, V625, P2149, DOI 10.1002/(SICI)1521 3749(199912)625:12<2149::AID ZAAC2149>3.0.CO;2 6
   Kalayda GV, 2003, EUR J INORG CHEM, P4347, DOI 10.1002/ejic.200300315
   Kartalou M, 2001, MUTAT RES FUND MOL M, V478, P23, DOI 10.1016/S0027 5107(01)00141 5
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kotsikorou E, 2003, J MED CHEM, V46, P2932, DOI 10.1021/jm030054u
   Krakoff I.H., 1988, PLATINUM OTHER METAL, P351
   Lee YA, 1997, J INORG BIOCHEM, V68, P289, DOI 10.1016/S0162 0134(97)00109 8
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIPPERT B, 1999, CISPLATIN CHEM BIOCH
   LOEHRER PJ, 1988, J NATL CANCER I, V80, P1373, DOI 10.1093/jnci/80.17.1373
   LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003 4819 100 5 704
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Margiotta N, 2011, J INORG BIOCHEM, V105, P548, DOI 10.1016/j.jinorgbio.2010.12.011
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   MILLIS KK, 1993, J ORG CHEM, V58, P4144, DOI 10.1021/jo00067a060
   NARDELLI M, 1983, COMPUT CHEM, V7, P95, DOI 10.1016/0097 8485(83)85001 3
   NARDELLI M, 1995, J APPL CRYSTALLOGR, V28, P659, DOI [DOI 10.1107/S0021889895007138, 10.1107/S0021889895007138]
   Pacifico C, 2010, BIOINORG CHEM APPL, V2010, DOI 10.1155/2010/102863
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   PASINI A, 1993, SYN REACT INORG MET, V23, P1021, DOI 10.1080/15533179308016879
   Reedijk J, 2009, EUR J INORG CHEM, P1303, DOI 10.1002/ejic.200900054
   Reithofer MR, 2011, J INORG BIOCHEM, V105, P46, DOI 10.1016/j.jinorgbio.2010.09.006
   Rochon FD, 2005, INORG CHIM ACTA, V358, P2040, DOI 10.1016/j.ica.2004.12.030
   Rochon FD, 2000, INORG CHIM ACTA, V306, P193, DOI 10.1016/S0020 1693(00)00171 7
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   Sheldrick G. M., 1996, SADABS: Program for Scaling and Correction of Area Detector Data
   Shi Y, 2012, J INORG BIOCHEM, V107, P6, DOI 10.1016/j.jinorgbio.2011.10.012
   Singh A, 2008, DALTON T, P2314, DOI 10.1039/b715663d
   Teletchéa S, 2006, CHEM EUR J, V12, P3741, DOI 10.1002/chem.200500923
   Todd RC, 2009, METALLOMICS, V1, P280, DOI 10.1039/b907567d
   VONHOFF DD, 1979, CANCER TREAT REP, V63, P1527
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v
   Zhang FB, 2007, CHEM COMMUN, P1496, DOI 10.1039/b617341a
NR 52
TC 29
Z9 30
U1 1
U2 44
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477 9226
EI 1477 9234
J9 DALTON T
JI Dalton Trans.
PY 2012
VL 41
IS 32
BP 9689
EP 9699
DI 10.1039/c2dt30712j
PG 11
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 978NJ
UT WOS:000306749100021
PM 22782180
DA 2025 08 17
ER

PT J
AU Huang, YH
   Lin, Y
   Rong, MD
   Liu, WZ
   He, JB
   Zhou, L
AF Huang, Yinghe
   Lin, Yao
   Rong, Mingdeng
   Liu, Weizhen
   He, Junbing
   Zhou, Lei
TI 20(S) hydroxycholesterol and simvastatin synergistically enhance
   osteogenic differentiation of marrow stromal cells and bone regeneration
   by initiation of Raf/MEK/ERK signaling
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; GENE EXPRESSION; IN VITRO; OSTEOBLAST
   DIFFERENTIATION; MORPHOGENETIC PROTEINS; OXYSTEROLS; PATHWAYS; STRESS;
   GROWTH; REPAIR
AB Previous studies have demonstrated the significant roles of simvastatin (SVA) and oxysterols in the osteogenesis process. In this study, we evaluate the effect of a combination of SVA and 20(S) hydroxycholesterol (20(S)OHC) on the cell viability and osteogenic differentiation of bone marrow stromal cells (BMSCs). After treatment with a control vehicle, SVA (0.025, 0.10, 0.25 or 1.0 mu M), 20(S)OHC (5 mu M), or a combination of both (0.25 mu M SVA + 5 mu M 20(S)OHC), the proliferation, apoptosis, ALP activity, mineralization, osteogenesis related gene expression and Raf/MEK/ERK signaling activity in BMSCs were measured. Our results showed that high concentrations of SVA (0.25 and 1.0 mu M) enhanced osteogenesis related genes expression while attenuating cell viability. The addition of 5 mu M 20(S)OHC induced significantly higher proliferative activity, which neutralized the inhibitory effect of SVA on the viability of BMSCs. Moreover, compared to supplementation with only one of the additives, combined supplementation with both SVA and 20(S)OHC induced significantly enhanced ALP activity, calcium sedimentation, osteogenesis related genes (ALP, OCN and BMP 2) expression and Raf/MEK/ERK signaling activity in BMSCs; these enhancements were attenuated by treatment with the inhibitor U0126, indicating a significant role of Raf/MEK/ERK signaling in mediating the synergistically enhanced osteogenic differentiation of BMSCs by combined SVA and 20(S)OHC treatment. Additionally, histological examination confirmed a synergistic effect of SVA and 20(S)OHC on enhancing bone regeneration in a rabbit calvarial defect model. This newly developed SVA/20(S)OHC formulation may be used as an osteoinductive drug to enhance bone healing.
C1 [Huang, Yinghe; Rong, Mingdeng; Liu, Weizhen; Zhou, Lei] Southern Med Univ, Stomatol Hosp, Ctr Oral Implantol, 366 South Jiangnan Rd, Guangzhou 510280, Guangdong, Peoples R China.
   [Huang, Yinghe] Guangdong Med Univ, Dept Stomatol, Taishan Peoples Hosp, Taishan, Guangdong, Peoples R China.
   [Lin, Yao; He, Junbing] SunYat Sen Univ, Dept Stomatol, Jieyang Affiliated Hosp, Jieyang, Guangdong, Peoples R China.
C3 Southern Medical University   China; Guangdong Medical University
RP Zhou, L (通讯作者)，Southern Med Univ, Stomatol Hosp, Ctr Oral Implantol, 366 South Jiangnan Rd, Guangzhou 510280, Guangdong, Peoples R China.
EM zho668@263.net
RI rong, mingdeng/GRJ 8507 2022; He, Junbing/MNQ 7014 2025
FU National Nature Science Foundation of China [81170998]; Science and
   Technology Plan Projects funds of Taishan City [201634611]
FX This work was supported by the National Nature Science Foundation of
   China under Grant (81170998); and the Science and Technology Plan
   Projects funds of Taishan City under Grant (201634611).
CR Aghaloo TL, 2007, J ORTHOP RES, V25, P1488, DOI 10.1002/jor.20437
   Allon I, 2014, J ORAL IMPLANTOL, V40, P251, DOI 10.1563/AAID JOI D 11 00222
   Amantea CM, 2008, J CELL BIOCHEM, V105, P424, DOI 10.1002/jcb.21840
   Amerongen GPV, 2000, CIRCULATION, V102, P2803
   Baek KH, 2005, J KOREAN MED SCI, V20, P438, DOI 10.3346/jkms.2005.20.3.438
   Bardsley K, 2017, BIOMATERIALS, V112, P313, DOI 10.1016/j.biomaterials.2016.10.014
   Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   During A, 2015, PROG LIPID RES, V59, P126, DOI 10.1016/j.plipres.2015.06.002
   Fowlkes JL, 2006, J BONE MINER RES, V21, P1359, DOI 10.1359/JBMR.060618
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Johnson JS, 2011, J CELL BIOCHEM, V112, P1673, DOI 10.1002/jcb.23082
   Kaji H, 2005, HORM METAB RES, V37, P589, DOI 10.1055/s 2005 870538
   Kaji H, 2008, HORM METAB RES, V40, P746, DOI 10.1055/s 0028 1082051
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Katz S, 2006, INT J BIOCHEM CELL B, V38, P2082, DOI 10.1016/j.biocel.2006.05.018
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Kim WK, 2007, J BONE MINER RES, V22, P1711, DOI 10.1359/JBMR.070710
   Kim WK, 2010, J BONE MINER RES, V25, P782, DOI 10.1359/jbmr.091024
   Kwon IK, 2015, BBA MOL CELL RES, V1853, P561, DOI 10.1016/j.bbamcr.2014.12.011
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Mannheim D, 2011, ATHEROSCLEROSIS, V216, P283, DOI 10.1016/j.atherosclerosis.2011.02.036
   Montazerolghaem M, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5639 4
   Montero Javier, 2014, J Clin Exp Dent, V6, pe286, DOI 10.4317/jced.51415
   Moshiri A, 2016, CLIN EXP PHARMACOL P, V43, P659, DOI 10.1111/1440 1681.12577
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002
   Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
   Osuga Jun ichi, 2004, Clin Calcium, V14, P235
   Qiao LJ, 2011, MOL CELLS, V32, P437, DOI 10.1007/s10059 011 0107 6
   Richardson JA, 2007, J CELL BIOCHEM, V100, P1131, DOI 10.1002/jcb.21112
   Ruiz Gaspa S, 2007, J CELL BIOCHEM, V101, P1430, DOI 10.1002/jcb.21259
   Shah SR, 2015, NATL SCI REV, V2, P85, DOI 10.1093/nsr/nwu028
   Shouhed D, 2005, J CELL BIOCHEM, V95, P1276, DOI 10.1002/jcb.20497
   Simmonds MC, 2013, ANN INTERN MED, V158, P877, DOI 10.7326/0003 4819 158 12 201306180 00005
   Stappenbeck F, 2012, BIOORG MED CHEM LETT, V22, P5893, DOI 10.1016/j.bmcl.2012.07.073
   Tai IC, 2013, INT J NANOMED, V8, P3895, DOI 10.2147/IJN.S48694
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Weivoda MM, 2011, J CELL BIOCHEM, V112, P1506, DOI 10.1002/jcb.23087
   Winn SR, 2000, ADV DRUG DELIVER REV, V42, P121, DOI 10.1016/S0169 409X(00)00057 0
   Wöltje M, 2015, IN VIVO, V29, P247
   Wong RWK, 2003, BRIT J ORAL MAX SURG, V41, P244, DOI 10.1016/S0266 4356(03)00081 0
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yalom A, 2014, PLAST RECONSTR SURG, V134, P960, DOI 10.1097/PRS.0000000000000601
   Yue XX, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/11/115708
   Zhang T, 2016, NANOSCI NANOTECH LET, V8, P211, DOI 10.1166/nnl.2016.2142
   Zhang YJ, 2014, PHARMACOL RES, V88, P53, DOI 10.1016/j.phrs.2013.12.009
   Zhang YQ, 2012, MOL BIOL REP, V39, P285, DOI 10.1007/s11033 011 0737 y
NR 52
TC 28
Z9 31
U1 1
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD AUG
PY 2019
VL 30
IS 8
AR 87
DI 10.1007/s10856 019 6284 0
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA IK4FN
UT WOS:000476542600001
PM 31325047
DA 2025 08 17
ER

PT J
AU Perez Aso, M
   Montesinos, MC
   Mediero, A
   Wilder, T
   Schafer, PH
   Cronstein, B
AF Perez Aso, Miguel
   Montesinos, M. Carmen
   Mediero, Aranzazu
   Wilder, Tuere
   Schafer, Peter H.
   Cronstein, Bruce
TI Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates
   inflammation through multiple cAMP downstream effectors
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID NECROSIS FACTOR ALPHA; RHEUMATOID ARTHRITIS; CYCLIC AMP; OSTEOCLAST
   FORMATION; ADENOSINE RECEPTORS; METHOTREXATE; MACROPHAGES;
   IDENTIFICATION; CELLS; INTERLEUKIN 6
AB Introduction: This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A(2A) receptors (A(2A)R).
   Methods: After apremilast and LPS incubation, intracellular cAMP, TNF alpha, IL 10, IL 6 and IL 1 alpha were measured in the Raw264.7 monocytic murine cell line. PKA, Epac1/2 (signaling intermediates for cAMP) and A(2A)R knockdowns were performed by shRNA transfection and interactions with A(2A)R and A(2B)R, as well as with methotrexate were tested in vitro and in the murine air pouch model. Statistical differences were determined using one or two way ANOVA or Student's t test. The alpha nominal level was set at 0.05 in all cases. A P value of < 0.05 was considered significant.
   Results: In vitro, apremilast increased intracellular cAMP and inhibited TNF alpha release (IC50= 104nM) and the specific A(2A)R alpha gonist CGS21680 (1 mu M) increased apremilast potency (IC50 = 25nM). In this cell line, apremilast increased IL 10 production. PKA, Epac1 and Epac2 knockdowns prevented TNF alpha inhibition and IL 10 stimulation by apremilast. In the murine air pouch model, both apremilast and MTX significantly inhibited leukocyte infiltration, while apremilast, but not MTX, significantly inhibited TNF alpha release. The addition of MTX (1 mg/kg) to apremilast (5 mg/kg) yielded no more inhibition of leukocyte infiltration or TNF alpha release than with apremilast alone.
   Conclusions: The immunoregulatory effects of apremilast appear to be mediated by cAMP through the downstream effectors PKA, Epac1, and Epac2. A(2A)R agonism potentiated TNF alpha inhibition by apremilast, consistent with the cAMP elevating effects of that receptor. Because the A(2A)R is also involved in the anti inflammatory effects of MTX, the mechanism of action of both drugs involves cAMP dependent pathways and is therefore partially overlapping in nature.
C1 [Perez Aso, Miguel; Mediero, Aranzazu; Wilder, Tuere; Cronstein, Bruce] NYU, Sch Med, Dept Med, New York, NY 10016 USA.
   [Montesinos, M. Carmen] Univ Valencia, Fac Farm, Dept Farmacol, E 46100 Burjassot, Spain.
   [Schafer, Peter H.] Celgene Corp, Dept Translat Dev, Summit, NJ USA.
   [Cronstein, Bruce] NYU, Sch Med, Dept Med, Div Translat Med, New York, NY 10016 USA.
C3 New York University; University of Valencia; Bristol Myers Squibb;
   Celgene Corporation; New York University
RP Cronstein, B (通讯作者)，NYU, Sch Med, Dept Med, 550 First Ave, New York, NY 10016 USA.
EM Bruce.Cronstein@nyumc.org
RI ; Cronstein, Bruce/JTD 2507 2023; Montesinos, M. Carmen/G 8852 2015;
   Mediero, Aranzazu/AAA 8362 2020
OI Cronstein, Bruce/0000 0002 4295 7383; Perez Aso,
   Miguel/0000 0002 4703 4182; Mediero, Aranzazu/0000 0002 5368 574X;
   Pintor, Jesus/0000 0002 9191 7679; Montesinos, M.
   Carmen/0000 0003 1801 311X; 
FU Celgene; National Institutes of Health [AR56672, AR54897]; NYU HHC
   (Health and Hospitals Corporation) Clinical and Translational Science
   Institute [UL1TR000038]; Laura and Isaac Perlmutter Cancer Center the
   Cancer Center Support Grant [P30CA016087]; NIH/ORIP [S10OD01058]
FX This work was supported by grants from Celgene and the National
   Institutes of Health (AR56672 and AR54897), NYU HHC (Health and
   Hospitals Corporation) Clinical and Translational Science Institute
   (UL1TR000038), the Laura and Isaac Perlmutter Cancer Center the Cancer
   Center Support Grant (P30CA016087) and NIH/ORIP S10OD01058.
CR BARRERA P, 1995, BRIT J RHEUMATOL, V34, P747
   Borchers AT, 2004, SEMIN ARTHRITIS RHEU, V34, P465, DOI 10.1016/j.semarthrit.2003.12.003
   Bryn T, 2006, J IMMUNOL, V176, P7361, DOI 10.4049/jimmunol.176.12.7361
   Cheng XD, 2008, ACTA BIOCH BIOPH SIN, V40, P651, DOI 10.1111/j.1745 7270.2008.00438.x
   Cooper DMF, 2014, BIOCHEM J, V462, P199, DOI 10.1042/BJ20140560
   CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441
   de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884
   Dietsch GN, 2006, TOXICOL PATHOL, V34, P39, DOI 10.1080/01926230500385549
   Dyke HJ, 2002, EXPERT OPIN INV DRUG, V11, P1
   Eigler A, 1998, J LEUKOCYTE BIOL, V63, P101, DOI 10.1002/jlb.63.1.101
   Essayan DM, 1999, BIOCHEM PHARMACOL, V57, P965, DOI 10.1016/S0006 2952(98)00331 1
   Fischmeister R, 2006, CIRC RES, V99, P816, DOI 10.1161/01.RES.0000246118.98832.04
   Georg S, 2011, ARTHRITIS RHEUM, V63, P10
   Gerards AH, 2003, RHEUMATOLOGY, V42, P1189, DOI 10.1093/rheumatology/keg323
   Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495 200059020 00004
   Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476 5381.1996.tb15629.x
   Gottlieb AB, 2008, CURR MED RES OPIN, V24, P1529, DOI 10.1185/030079908X301866 
   Haskó G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00085
   Haskó G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003
   HENNEY CS, 1971, J IMMUNOL, V107, P610
   Hertz AL, 2009, P NATL ACAD SCI USA, V106, P21978, DOI 10.1073/pnas.0911684106
   Hidi R, 2000, EUR RESPIR J, V15, P342, DOI 10.1034/j.1399 3003.2000.15b21.x
   Jin S L Catherine, 2012, Chang Gung Med J, V35, P197
   Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09 147447
   Kavanaugh A, 2014, ANN RHEUM DIS, V73, P1020, DOI 10.1136/annrheumdis 2013 205056
   Kumar N, 2013, BMC MED, V11, DOI 10.1186/1741 7015 11 96
   Man HW, 2009, J MED CHEM, V52, P1522, DOI 10.1021/jm900210d
   Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911
   McCann FE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3041
   McConnachie G, 2006, TRENDS MOL MED, V12, P317, DOI 10.1016/j.molmed.2006.05.008
   Mediero A, 2014, FASEB J, V28, P4901, DOI 10.1096/fj.14 255703
   Momtazi M, 2013, WOUND REPAIR REGEN, V21, P77, DOI 10.1111/j.1524 475X.2012.00856.x
   Montesinos MC, 2007, ARTHRITIS RHEUM US, V56, P1440, DOI 10.1002/art.22643
   Muller GW, 1998, BIOORG MED CHEM LETT, V8, P2669, DOI 10.1016/S0960 894X(98)00475 2
   Németh ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260
   Niu MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082360
   Olsen NJ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4444
   Perez Aso M, 2013, PURINERG SIGNAL, V9, P573, DOI 10.1007/s11302 013 9368 1
   Pessler F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2435
   Pinhal Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002 9440(10)63698 X
   Rich TC, 2007, AM J PHYSIOL CELL PH, V292, pC319, DOI 10.1152/ajpcell.00121.2006
   Schafer P, 2014, ANN EUR C RHEUM
   Schafer PH, 2014, CELL SIGNAL, V26, P2016, DOI 10.1016/j.cellsig.2014.05.014
   Schafer PH, 2010, BRIT J PHARMACOL, V159, P842, DOI 10.1111/j.1476 5381.2009.00559.x
   Schett G, 2010, THER ADV MUSCULOSKEL, V2, P271, DOI 10.1177/1759720X10381432
   Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898 6568(03)00058 5
   Spadaro A, 1997, REV RHUM, V64, P89
   Spina D, 2008, BRIT J PHARMACOL, V155, P308, DOI 10.1038/bjp.2008.307
   Sung JY, 2000, IMMUNOPHARMACOLOGY, V47, P35, DOI 10.1016/S0162 3109(99)00185 X
   Taskén K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003
   Tokuda H, 2003, J ENDOCRINOL, V177, P101, DOI 10.1677/joe.0.1770101
   Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829
   Zaccolo M, 2007, CIRC RES, V100, P1569, DOI 10.1161/CIRCRESAHA.106.144501
NR 53
TC 64
Z9 69
U1 1
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD SEP 15
PY 2015
VL 17
AR 249
DI 10.1186/s13075 015 0771 6
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CR1PL
UT WOS:000361097200001
PM 26370839
OA Green Published
DA 2025 08 17
ER

PT J
AU Di Tomo, P
   Pipino, C
   Lanuti, P
   Morabito, C
   Pierdomenico, L
   Sirolli, V
   Bonomini, M
   Miscia, S
   Mariggio, MA
   Marchisio, M
   Barboni, B
   Pandolfi, A
AF Di Tomo, Pamela
   Pipino, Caterina
   Lanuti, Paola
   Morabito, Caterina
   Pierdomenico, Laura
   Sirolli, Vittorio
   Bonomini, Mario
   Miscia, Sebastiano
   Mariggio, Maria Addolorata
   Marchisio, Marco
   Barboni, Barbara
   Pandolfi, Assunta
TI Calcium Sensing Receptor Expression in Ovine Amniotic Fluid Mesenchymal
   Stem Cells and the Potential Role of R 568 during Osteogenic
   Differentiation
SO PLOS ONE
LA English
DT Article
ID FUNCTIONAL EXPRESSION; BONE; OSTEOBLASTS; CLONING; ZETA; CAR
AB Amniotic fluid derived stem (AFS) cells have been identified as a promising source for cell therapy applications in bone traumatic and degenerative damage. Calcium Sensing Receptor (CaSR), a G protein coupled receptor able to bind calcium ions, plays a physiological role in regulating bone metabolism. It is expressed in different kinds of cells, as well as in some stem cells. The bone CaSR could potentially be targeted by allosteric modulators, in particular by agonists such as calcimimetic R 568, which may potentially be helpful for the treatment of bone disease. The aim of our study was first to investigate the presence of CaSR in ovine Amniotic Fluid Mesenchymal Stem Cells (oAFMSCs) and then the potential role of calcimimetics in in vitro osteogenesis. oAFMSCs were isolated, characterized and analyzed to examine the possible presence of CaSR by western blotting and flow cytometry analysis. Once we had demonstrated CaSR expression, we worked out that 1 mu M R 568 was the optimal and effective concentration by cell viability test (MTT), cell number, Alkaline Phosphatase (ALP) and Alizarin Red S (ARS) assays. Interestingly, we observed that basal diffuse CaSR expression in oAFMSCs increased at the membrane when cells were treated with R 568 (1 mu M), potentially resulting in activation of the receptor. This was associated with significantly increased cell mineralization (ALP and ARS staining) and augmented intracellular calcium and Inositol trisphosphate (IP3) levels, thus demonstrating a potential role for calcimimetics during osteogenic differentiation. Calhex 231, a CaSR allosteric inhibitor, totally reversed R 568 induced mineralization. Taken together, our results demonstrate for the first time that CaSR is expressed in oAFMSCs and that calcimimetic R 568, possibly through CaSR activation, can significantly improve the osteogenic process. Hence, our study may provide useful information on the mechanisms regulating osteogenesis in oAFMSCs, perhaps prompting the use of calcimimetics in bone regenerative medicine.
C1 [Di Tomo, Pamela; Pipino, Caterina; Pandolfi, Assunta] Univ G dAnnunzio, Dept Expt & Clin Sci, Chieti, Italy.
   [Di Tomo, Pamela; Pipino, Caterina; Lanuti, Paola; Morabito, Caterina; Pierdomenico, Laura; Miscia, Sebastiano; Mariggio, Maria Addolorata; Marchisio, Marco; Pandolfi, Assunta] Univ G dAnnunzio, Univ G dAnnunzio Fdn Chieti, Aging Res Ctr, Ce SI, Chieti, Italy.
   [Di Tomo, Pamela; Pipino, Caterina; Lanuti, Paola; Morabito, Caterina; Pierdomenico, Laura; Miscia, Sebastiano; Mariggio, Maria Addolorata; Marchisio, Marco; Barboni, Barbara; Pandolfi, Assunta] Univ G dAnnunzio, StemTeCh Grp Chieti, Chieti, Italy.
   [Lanuti, Paola; Morabito, Caterina; Pierdomenico, Laura; Sirolli, Vittorio; Bonomini, Mario; Miscia, Sebastiano; Marchisio, Marco] Univ G dAnnunzio, Dept Med & Aging Sci, Chieti, Italy.
   [Morabito, Caterina; Mariggio, Maria Addolorata] Univ G dAnnunzio, Dept Neurosci & Imaging, Chieti, Italy.
   [Barboni, Barbara] Univ Teramo, Dept Comparat Biomed Sci, Teramo, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; G d'Annunzio University of Chieti Pescara; G d'Annunzio
   University of Chieti Pescara; G d'Annunzio University of Chieti Pescara;
   University of Teramo
RP Pandolfi, A (通讯作者)，Univ G dAnnunzio, Dept Expt & Clin Sci, Chieti, Italy.
EM pandolfi@unich.it
RI PANDOLFI, Assunta/K 4595 2016; Sirolli, Vittorio/AAB 2290 2019;
   Mariggiò, Maria/T 9047 2017; pandolfi, assunta/K 4595 2016; Mariggio,
   Maria Addolorata/T 9047 2017; Pipino, Caterina/N 2078 2019
OI PANDOLFI, Assunta/0000 0003 4135 7631; Mariggio, Maria
   Addolorata/0000 0002 3508 8706; Morabito, Caterina/0000 0002 5144 2584;
   Marchisio, Marco/0000 0003 3058 3422; PIPINO,
   CATERINA/0000 0002 4350 8686; Mariggio, Maria
   Addolorata/0000 0001 5306 7143; 
FU CariChieti Foundation; ERA Amgen [2010547324]; Era Amgen, USA
FX This study was supported by CariChieti Foundation and ERA Amgen
   (Contract#2010547324). The authors received funding from a commercial
   source (Era Amgen, USA), this does not alter the authors' adherence to
   all the PLOS ONE policies on sharing data and materials. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Antonucci I, 2011, CELL TRANSPLANT, V20, P789, DOI 10.3727/096368910X539074
   Antonucci I, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472 6750 9 9
   Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Berardinelli P, 2013, CLIN ORAL INVEST, V17, P1661, DOI 10.1007/s00784 012 0857 3
   Bollini S, 2011, STEM CELLS DEV, V20, P1985, DOI 10.1089/scd.2010.0424
   Bonomini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030682
   Brown E. M., 2007, V45, P139
   Brown E. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P412
   Chang W, 2013, SCI SIGNAL, V1, P1
   Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003 1127
   Colosimo A, 2013, CELL TRANSPLANT, V22, P99, DOI 10.3727/096368912X638883
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Drüeke TB, 2009, CLIN J AM SOC NEPHRO, V4, P234, DOI 10.2215/CJN.04520908
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919
   Gray FL, 2012, J PEDIATR SURG, V47, P1072, DOI 10.1016/j.jpedsurg.2012.03.006
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gutwald R, 2010, BRIT J ORAL MAX SURG, V48, P285, DOI 10.1016/j.bjoms.2009.06.226
   Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015
   House MG, 1997, J BONE MINER RES, V12, P1959, DOI 10.1359/jbmr.1997.12.12.1959
   Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448
   Kanatani N, 1999, BIOCHEM BIOPH RES CO, V261, P144, DOI 10.1006/bbrc.1999.0932
   Lam BS, 2011, BLOOD, V117, P1167, DOI 10.1182/blood 2010 05 286294
   Lanuti P, 2006, J IMMUNOL METHODS, V315, P37, DOI 10.1016/j.jim.2006.06.015
   Lanuti P, 2012, J IMMUNOL METHODS, V380, P16, DOI 10.1016/j.jim.2012.03.007
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Martino NA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017714
   Mauro A, 2010, VET RES COMMUN, V34, pS25, DOI 10.1007/s11259 010 9393 2
   Miller S, 1999, CELLS, V140, P1911
   Miscia S, 2009, NEUROBIOL AGING, V30, P394, DOI 10.1016/j.neurobiolaging.2007.07.011
   Orciani M, 2011, J BIOL REG HOMEOS AG, V25, P115
   Parolini O, 2009, REGEN MED, V4, P275, DOI 10.2217/17460751.4.2.275
   Piccoli M, 2012, STEM CELLS, V30, P1675, DOI 10.1002/stem.1134
   Pipino C, 2013, BRIT MED BULL, V105, P43, DOI 10.1093/bmb/lds033
   RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131
   Sedrakyan S, 2012, CURR UROL REP, V13, P47, DOI 10.1007/s11934 011 0230 0
   Shaw SWS, 2011, CELL TRANSPLANT, V20, P1015, DOI 10.3727/096368910X543402
   Song IH, 2009, J ORTHOP RES, V27, P916, DOI 10.1002/jor.20838
   Turner CG, 2011, J PEDIATR SURG, V46, P57, DOI 10.1016/j.jpedsurg.2010.09.063
   Yamaguchi T, 2001, AM J PHYSIOL CELL PH, V280, pC382, DOI 10.1152/ajpcell.2001.280.2.C382
   Yamaguchi T, 2008, J BONE MINER METAB, V26, P301, DOI 10.1007/s00774 008 0843 7
   Yamauchi M, 2005, AM J PHYSIOL ENDOC M, V288, pE608, DOI 10.1152/ajpendo.00229.2004
NR 45
TC 20
Z9 20
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2013
VL 8
IS 9
AR e73816
DI 10.1371/journal.pone.0073816
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 244QV
UT WOS:000326405300133
PM 24040082
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, CY
   Huang, TJ
   Wu, MH
   Li, YY
   Lee, KD
AF Lee, Ching Yu
   Huang, Tsung Jen
   Wu, Meng Huang
   Li, Yen Yao
   Lee, Kuan Der
TI High Expression of Acid Sensing Ion Channel 2 (ASIC2) in Bone Cells in
   Osteoporotic Vertebral Fractures
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID IN VITRO; CHONDROCYTES; INHIBITION; ACTIVATION; APOPTOSIS; DIAGNOSIS;
   PAIN; 1A
AB Little is known about the function of acid sensing ion channels (ASICs) in bone cells or osteoporotic vertebral fractures (OVF). This study delineated ASICs expression in adult human bone marrow mesenchymal stem cells  (BM MSC ) derived osteoblasts and in OVF bone cells. Adult BM MSC derived osteoblasts were isolated and cultured in different pH values. Osteogenic markers as alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OC) mRNA were assessed. Western blots method was applied to analyze ASICs protein expression in different pH values. Amiloride was added into the osteogenic media to analyze the Na+/K+ ATPase change. We harvested the vertebral cancellous bone through a bone biopsy needle in 26 OVF patients when performing percutaneous vertebroplasty. Six vertebral bone specimens obtained from 4 patients with high energy vertebral fractures were used as the control. The reverse transcription polymerase chain reaction was performed to analyze the quantitative mRNA expression of ASICs. Osteogenic markers as ALP, OPN, and OC mRNA were higher expressed in increasing pH values throughout osteoblastogenesis. ASIC proteins were higher expressed in lower pH media, especially ASIC3, and ASIC4. The highest protein expression at days 7, 14, and 21 was ASIC2, ASIC4, and ASIC3, respectively. Expression of Na+/K+ ATPase was significantly decreased in cultured osteoblasts by addition of amiloride into the pH 6.9 osteogenic media. ASIC2 mRNA was most highly expressed with a 65.93 fold increase in the biopsied vertebral bone cells in OVF compared with the control. In conclusion, we found osteoblastogenesis was reduced in an acidic environment, and ASIC2, ASIC3, and ASIC4 were most highly expressed in turn during osteoblastogenesis within acidic media. ASIC2 was the most abundantly expressed gene in human bone cells in OVF compared with the control. ASIC2 could be crucial in the pathogenesis of osteoporosis and could serve as a therapeutic target for antiosteoporotic therapies.
C1 [Lee, Ching Yu; Huang, Tsung Jen; Wu, Meng Huang] Taipei Med Univ Hosp, Dept Orthoped, Taipei, Taiwan.
   [Lee, Ching Yu; Huang, Tsung Jen; Wu, Meng Huang] Taipei Med Univ, Sch Med, Dept Orthopaed, Coll Med, Taipei, Taiwan.
   [Lee, Ching Yu; Wu, Meng Huang] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan.
   [Li, Yen Yao] Chang Gung Mem Hosp, Dept Orthoped Surg, Chiayi, Taiwan.
   [Lee, Kuan Der] Taipei Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taipei, Taiwan.
   [Lee, Kuan Der] Taipei Med Univ, Sch Med, Dept Internal Med, Coll Med, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Taipei
   Medical University; Chang Gung University; Chang Gung Memorial Hospital;
   Taipei Medical University; Taipei Medical University Hospital; Taipei
   Medical University
RP Huang, TJ (通讯作者)，Taipei Med Univ Hosp, Dept Orthoped, Taipei, Taiwan.; Huang, TJ (通讯作者)，Taipei Med Univ, Sch Med, Dept Orthopaed, Coll Med, Taipei, Taiwan.
EM tjdhuang@tmu.edu.tw
RI ; Lee, ChunYing/KWT 9099 2024; Wu, Meng huang/AAH 2195 2020
OI Huang, Tsung Jen/0000 0002 3640 3018; Lee, Ching Yu/0000 0001 6118 1667;
   Wu, Meng huang/0000 0003 1606 2444
FU Chang Gung Memorial Hospital, Chia Yi, Taiwan [CMRPG 670151 2,
   CMRPG670151]; Ministry of Science and Technology, Taiwan
   [107 2314 B 038 067 ]
FX The authors thank the grants from the Chang Gung Memorial Hospital,
   Chia Yi, Taiwan, for financially supporting this research under the
   contract of CMRPG 670151 2 and CMRPG670151, and the Ministry of Science
   and Technology, Taiwan (107 2314 B 038 067 ). They also thank Miss
   Yi Fang Tsai for her assistance regarding statistical analysis.
CR Ahn H, 2012, BIOCHEM BIOPH RES CO, V418, P144, DOI 10.1016/j.bbrc.2011.12.149
   Arnett TR, 2008, J NUTR, V138, p415S, DOI 10.1093/jn/138.2.415S
   Brandao Burch A, 2005, CALCIFIED TISSUE INT, V77, P167, DOI 10.1007/s00223 004 0285 8
   Cheng YR, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0448 y
   Cuesta A, 2014, CONNECT TISSUE RES, V55, P197, DOI 10.3109/03008207.2014.884083
   Francis MJO, 2002, INT J BIOCHEM CELL B, V34, P459, DOI 10.1016/S1357 2725(01)00142 X
   Frassetto L, 1996, J GERONTOL A BIOL, V51, pB91, DOI 10.1093/gerona/51A.1.B91
   Gannon KP, 2008, AM J PHYSIOL HEART C, V294, pH1793, DOI 10.1152/ajpheart.01380.2007
   Hanukoglu I, 2017, FEBS J, V284, P525, DOI 10.1111/febs.13840
   Holzer P, 2003, CURR OPIN PHARMACOL, V3, P618, DOI 10.1016/j.coph.2003.06.008
   Jahr H, 2005, BIOCHEM BIOPH RES CO, V337, P349, DOI 10.1016/j.bbrc.2005.09.054
   Jones NG, 2004, J NEUROSCI, V24, P10974, DOI 10.1523/JNEUROSCI.2619 04.2004
   Kanaya K, 2016, J ORTHOP RES, V34, P566, DOI 10.1002/jor.23047
   Kanis JA, 2015, J BONE MINER RES, V30, P1747, DOI 10.1002/jbmr.2531
   Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Li X, 2014, EXPERT OPIN THER TAR, V18, P1, DOI 10.1517/14728222.2014.859248
   Li X, 2013, FEBS LETT, V587, P3236, DOI 10.1016/j.febslet.2013.08.017
   Lu YJ, 2009, NEURON, V64, P885, DOI 10.1016/j.neuron.2009.11.007
   Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113
   Montaño JA, 2009, NEUROSCI LETT, V463, P114, DOI 10.1016/j.neulet.2009.07.073
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Rong C, 2012, CELL BIOL INT, V36, P635, DOI 10.1042/CBI20110432
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Soicher MA, 2011, BONE, V48, P663, DOI 10.1016/j.bone.2010.11.009
   Su XF, 2006, J BIOL CHEM, V281, P36960, DOI 10.1074/jbc.M608002200
   Tong J, 2011, J IMMUNOL, V186, P3686, DOI 10.4049/jimmunol.1001346
   Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709
   Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433
   Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0
   Wu FR, 2014, MOL CELL BIOCHEM, V395, P199, DOI 10.1007/s11010 014 2125 0
   Yoder N, 2018, NATURE, V555, P397, DOI 10.1038/nature25782
   Yuan FL, 2010, INFLAMM RES, V59, P939, DOI 10.1007/s00011 010 0206 4
   Zhang Z, 2017, SCI REP UK, V7, DOI [10.1038/s41598 017 02144 x, 10.1038/srep46161]
NR 36
TC 7
Z9 7
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD AUG 19
PY 2019
VL 2019
AR 4714279
DI 10.1155/2019/4714279
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA IW1QD
UT WOS:000484743400001
PM 31531354
OA Green Published
DA 2025 08 17
ER

PT J
AU Todenhöfer, T
   Hennenlotter, J
   Schmiedel, BJ
   Hohneder, A
   Grimm, S
   Kühs, U
   Salih, HR
   Bühring, HJ
   Fehm, T
   Gakis, G
   Blumenstock, G
   Aufderklamm, S
   Schilling, D
   Stenzl, A
   Schwentner, C
AF Todenhoefer, Tilman
   Hennenlotter, Joerg
   Schmiedel, Benjamin Joachim
   Hohneder, Andrea
   Grimm, Sabrina
   Kuehs, Ursula
   Salih, Helmut Rainer
   Buehring, Hans Joerg
   Fehm, Tanja
   Gakis, Georgios
   Blumenstock, Gunnar
   Aufderklamm, Stefan
   Schilling, David
   Stenzl, Arnulf
   Schwentner, Christian
TI Alterations of the RANKL pathway in blood and bone marrow samples of
   prostate cancer patients without bone metastases
SO PROSTATE
LA English
DT Article
DE prostate cancer; bone metastases; receptor activator of NF kB (RANKL);
   osteoprotegerin (OPG); denosumab
ID ANDROGEN DEPRIVATION THERAPY; HORMONE RELATED PROTEIN; RECEPTOR
   ACTIVATOR; POSTMENOPAUSAL WOMEN; LIGAND EXPRESSION; TURNOVER MARKERS;
   SERUM LEVELS; TUMOR CELLS; OSTEOPROTEGERIN; CARCINOMA
AB OBJECTIVES The receptor activator of the NF kB ligand (RANKL) pathway is a key mediator of prostate cancer (PC) induced bone disease. However, little is known about this pathway in patients with non metastatic PC. We aimed to investigate whether changes of RANKL, its inhibitor osteoprotegerin (OPG) and bone marrow mesenchymal stromal cells (BM MSCs) occur in PC patients without manifest bone metastases.
   PATIENTS AND METHODS We determined OPG and soluble RANKL (sRANKL) in serum and corresponding bone marrow (BM) samples of 140 patients before radical prostatectomy by enzyme linked immunosorbent assay (ELISA). As control serum samples of 50 patients with benign prostate hyperplasia were analyzed. BM mononuclear cells (BMNCs) of 16 PC patients were analyzed for expression of RANKL and CD271 (as marker for MSCs) by flow cytometry.
   RESULTS PC patients had significantly lower serum levels of OPG compared to BPH patients (P?=?0.007), whereas no differences were observed for serum sRANKL (P?=?0.74). Both OPG and sRANKL concentrations of serum and corresponding BM samples correlated significantly (P?<?0.0001 each). Interestingly, in PC patients, lower serum and BM OPG levels were associated with a higher proportion of BM MSCs (P?=?0.04 and 0.0016, respectively). No correlations were observed for sRANKL, OPG, BM MSCs, and established risk parameters of PC.
   DISCUSSION The results of the study indicate that localized PC is associated with early specific changes of the RANKL pathway in serum and bone marrow (BM). These changes might be part of the pre metastatic niche of PC and implicate a potential benefit of RANKL inhibition in patients with localized PC. Prostate 73: 162168, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Todenhoefer, Tilman; Hennenlotter, Joerg; Hohneder, Andrea; Kuehs, Ursula; Gakis, Georgios; Aufderklamm, Stefan; Schilling, David; Stenzl, Arnulf; Schwentner, Christian] Univ Tubingen Hosp, Dept Urol, Tubingen, Germany.
   [Schmiedel, Benjamin Joachim; Grimm, Sabrina; Salih, Helmut Rainer; Buehring, Hans Joerg] Univ Tubingen Hosp, Dept Med, Tubingen, Germany.
   [Fehm, Tanja] Univ Tubingen Hosp, Dept Gynecol & Obstet, Tubingen, Germany.
   [Blumenstock, Gunnar] Univ Tubingen, Dept Med Biometry, D 72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital
RP Schwentner, C (通讯作者)，Univ Tubingen, Dept Urol, Hoppe Seyler Str 3, D 72076 Tubingen, Germany.
EM christian.schwentner@med.uni tuebingen.de
OI Fehm, Tanja/0000 0002 4926 0108; Schmiedel, Benjamin
   J/0000 0002 9103 9378
CR Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   D'Amico AV, 2003, J CLIN ONCOL, V21, P2163, DOI 10.1200/JCO.2003.01.075
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Fehm T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2349
   Fei QM, 2010, ACTA BIOCH BIOPH SIN, V42, P801, DOI 10.1093/abbs/gmq086
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Freedland SJ, 2009, PROSTATE CANCER P D, V12, P333, DOI 10.1038/pcan.2009.35
   Gannagé Yared MH, 2006, CLIN ENDOCRINOL, V64, P652, DOI 10.1111/j.1365 2265.2006.02522.x
   Groot MT, 2003, EUR UROL, V43, P226, DOI 10.1016/S0302 2838(03)00007 1
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hussain SA, 2003, BJU INT, V92, P690, DOI 10.1046/j.1464 410X.2003.04471.x
   Jung K, 2004, INT J CANCER, V111, P783, DOI 10.1002/ijc.20314
   Kamiya N, 2011, INT J CLIN ONCOL, V16, P366, DOI 10.1007/s10147 011 0193 7
   Kraj M, 2005, ARCH IMMUNOL THER EX, V53, P454
   Leeming DJ, 2006, CANCER EPIDEM BIOMAR, V15, P32, DOI 10.1158/1055 9965.EPI 05 0492
   Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133
   Menschikowski M, 2012, INFLAMMATION, V35, P1113, DOI 10.1007/s10753 011 9418 1
   Morrissey C, 2010, PROSTATE, V70, P412, DOI 10.1002/pros.21075
   Mountzios G, 2010, TRANSL RES, V155, P247, DOI 10.1016/j.trsl.2010.01.002
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Noort WA, 2012, J CELL MOL MED, V16, P1827, DOI 10.1111/j.1582 4934.2011.01455.x
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Palvolgyi R, 2011, UROLOGY, V77, P1330, DOI 10.1016/j.urology.2010.12.083
   Park SI, 2011, CANCER MICROENVIRON, V4, P237, DOI 10.1007/s12307 011 0081 8
   Pérez Martínez FC, 2008, HISTOL HISTOPATHOL, V23, P709, DOI 10.14670/HH 23.709
   Pérez Martínez FC, 2007, J CLIN PATHOL, V60, P290, DOI 10.1136/jcp.2006.037853
   Rogers A, 2002, J CLIN ENDOCR METAB, V87, P4470, DOI 10.1210/jc.2002 020396
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Shahnazari M, 2012, BONE, V50, P628, DOI 10.1016/j.bone.2011.11.010
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P3162, DOI 10.1210/jc.86.7.3162
   Todenhoefer T., 2011, Clinical Investigation, V1, P265, DOI 10.4155/cli.10.25
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 38
TC 7
Z9 8
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD JAN
PY 2013
VL 73
IS 2
BP 162
EP 168
DI 10.1002/pros.22551
PG 7
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 060XE
UT WOS:000312810900006
PM 22715006
OA Bronze
DA 2025 08 17
ER

PT J
AU Beane, OS
   Darling, LEO
   Fonseca, VC
   Darling, EM
AF Beane, Olivia S.
   Darling, Louise E. O.
   Fonseca, Vera C.
   Darling, Eric M.
TI Disparate Response to Methotrexate in Stem Versus Non Stem Cells
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Cancer; Chemotherapy; Mesenchymal stem cell; Methotrexate; Regenerative
   medicine
ID HIGH DOSE METHOTREXATE; DIFFERENTIATION IN VITRO;
   CHEMOTHERAPEUTIC AGENTS; BREAST CANCER; FOLINIC ACID; BONE MARROW;
   RHEUMATOID ARTHRITIS; THYMIDINE; RESCUE; VIVO
AB Methotrexate (MTX) is a commonly used chemotherapeutic agent that kills cancer cells by binding dihydrofolate reductase (DHFR) as a competitive inhibitor. Due to its non selectivity, MTX also impairs normal (non cancerous) cell function and causes long term damage to healthy tissue. These consequences have been investigated extensively in bone derived cells due to their sensitivity to the drug. While DHFR likely plays a role in normal cell response to MTX, research in this area is limited. Moreover, how MTX sensitivity differs among cell types responsible for maintaining connective tissues is unknown. The goal of this study was to investigate the role of DHFR and subsequent nucleotide synthesis in normal cell response to MTX. We also sought to compare adverse effects of MTX among normal cell types to identify sensitive populations and resistant cell sources for regenerative procedures targeting patients undergoing chemotherapy. DHFR overexpression or exogenous amino acid + nucleoside delivery rescued normal cells from adverse MTX effects. Conversely, DHFR knockdown impaired MTX treated adipose derived stem cell (ASC) osteogenesis. Proliferation of ASCs and bone marrow stem cells was more resistant to MTX than that of terminally differentiated osteoblasts. However, stem cells became susceptible to the drug after beginning differentiation. These results suggest that the ability of stem cells to survive and to maintain their surrounding tissues likely depends on whether they are in a "stem" state when exposed to MTX. Therapeutic strategies that delay the differentiation of stem cells until clearance of the drug may produce more favorable outcomes in the long term health of treated tissues.
C1 [Beane, Olivia S.; Darling, Eric M.] Brown Univ, Ctr Biomed Engn, Providence, RI 02912 USA.
   [Darling, Louise E. O.] Wellesley Coll, Dept Biol Sci, Wellesley, MA 02181 USA.
   [Fonseca, Vera C.; Darling, Eric M.] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.
   [Darling, Eric M.] Brown Univ, Sch Engn, Providence, RI 02912 USA.
   [Darling, Eric M.] Brown Univ, Dept Orthopaed, Providence, RI 02912 USA.
C3 Brown University; Wellesley College; Brown University; Brown University;
   Brown University
RP Darling, EM (通讯作者)，Brown Univ, Ctr Biomed Engn, Providence, RI 02912 USA.; Darling, EM (通讯作者)，Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.; Darling, EM (通讯作者)，Brown Univ, Sch Engn, Providence, RI 02912 USA.; Darling, EM (通讯作者)，Brown Univ, Dept Orthopaed, Providence, RI 02912 USA.
EM eric_darling@brown.edu
RI Darling, Eric/K 2529 2013
OI Darling, Louise/0000 0002 7798 8024; Darling, Eric/0000 0002 3932 8623
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01AR063642]; National Science Foundation [CBET1253189]; Staley Small
   Grant from Wellesley College
FX The authors would like to thank Jason Machan for advice on statistical
   analyses, Paul Liu and Mikki Ciombor for providing lipoaspirate samples,
   and Mark Dooner and the COBRE Flow Cytometry Core at Rhode Island
   Hospital for their assistance with FACS experiments. This work was
   supported by awards from the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (R01AR063642; EMD), National Science
   Foundation (CAREER Award, CBET1253189; EMD), and a Staley Small Grant
   from Wellesley College (LEOD). The content of this article is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health or National Science
   Foundation.
CR Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140 6736(11)61625 5
   Arnoldo A, 2014, GENOME MED, V6, DOI 10.1186/gm549
   Baum B J, 1985, Spec Care Dentist, V5, P274, DOI 10.1111/j.1754 4505.1985.tb00593.x
   Beane OS, 2014, EXP CELL RES, V327, P222, DOI 10.1016/j.yexcr.2014.06.015
   Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518
   BIANCHI PA, 1962, BIOCHIM BIOPHYS ACTA, V55, P547
   CAYLEY PJ, 1981, BIOCHEMISTRY US, V20, P874, DOI 10.1021/bi00507a034
   CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088
   Chan ESL, 2002, ARTHRITIS RES, V4, P266, DOI 10.1186/ar419
   Chen L, 2014, SCI REP UK, V4, DOI 10.1038/srep03819
   Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140 6736(02)08213 2
   Cohen IJ, 2014, PEDIATR BLOOD CANCER, V61, P7, DOI 10.1002/pbc.24770
   Colak S., 2014, CELL CYCLE
   Davies JH, 2003, J CLIN ENDOCR METAB, V88, P6088, DOI 10.1210/jc.2003 030712
   Deep G, 2008, CURR OPIN INVEST DR, V9, P591
   DeOliveira CC, 2012, MOL CELL ENDOCRINOL, V361, P92, DOI 10.1016/j.mce.2012.03.016
   DUBBS DR, 1964, EXP CELL RES, V33, P19, DOI 10.1016/S0014 4827(64)81006 5
   Estes BT, 2008, BIOTECHNOL BIOENG, V99, P986, DOI 10.1002/bit.21662
   Estes BT, 2010, NAT PROTOC, V5, P1294, DOI 10.1038/nprot.2010.81
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Georgiou KR, 2012, J CELL PHYSIOL, V227, P909, DOI 10.1002/jcp.22807
   Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Guilak F, 2006, J CELL PHYSIOL, V206, P229, DOI 10.1002/jcp.20463
   HOWELL SB, 1978, CANCER RES, V38, P325
   JOLIVET J, 1982, J CLIN INVEST, V70, P351, DOI 10.1172/JCI110624
   KENNEDY DG, 1983, BIOCHEM PHARMACOL, V32, P41, DOI 10.1016/0006 2952(83)90649 4
   Kim TK, 2010, ANAL BIOANAL CHEM, V397, P3173, DOI 10.1007/s00216 010 3821 6
   Kimura E, 2004, INT J BIOCHEM CELL B, V36, P814, DOI 10.1016/j.biocel.2003.09.002
   Labriola NR, 2015, J BIOMECH, V48, P1058, DOI 10.1016/j.jbiomech.2015.01.033
   Li J, 2004, BRIT J HAEMATOL, V127, P326, DOI 10.1111/j.1365 2141.2004.05200.x
   May KP, 1996, ARTHRITIS RHEUM, V39, P489, DOI 10.1002/art.1780390317
   Minaur NJ, 2002, RHEUMATOLOGY, V41, P735, DOI 10.1093/rheumatology/41.7.735
   PINEDO HM, 1976, CANCER RES, V36, P4418
   PIPER A A, 1983, Cancer Research, V43, P5101
   Prochazka E, 2010, INT ORTHOP, V34, P137, DOI 10.1007/s00264 008 0717 6
   Qi Z, 2012, CELL BIOL INT, V36, P857, DOI 10.1042/CBI20110637
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140 6736(91)90733 6
   ROSENBLATT DS, 1982, MOL PHARMACOL, V21, P718
   Saltz, 1996, Oncologist, V1, P22
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   SCHWARTZ PM, 1992, P NATL ACAD SCI USA, V89, P594, DOI 10.1073/pnas.89.2.594
   Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902
   Suga H, 2014, ANN PLAS SURG, V72, P234, DOI 10.1097/SAP.0b013e318264fd6a
   Uchiyama H, 2010, CANCER SCI, V101, P728, DOI 10.1111/j.1349 7006.2009.01449.x
   Uehara R, 2001, J RHEUMATOL, V28, P251
   VanderVeen MJ, 1996, BRIT J RHEUMATOL, V35, P342
   Wisnivesky JP, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4013
   WOLFROM C, 1990, EUR J CLIN PHARMACOL, V39, P377, DOI 10.1007/BF00315414
   Youssef J, 2011, P NATL ACAD SCI USA, V108, P6993, DOI 10.1073/pnas.1102559108
   Costa HJZR, 2013, BRAIN RES, V1510, P10, DOI 10.1016/j.brainres.2013.03.025
   Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539
   Zheng B, 2006, TISSUE ENG, V12, P1891, DOI 10.1089/ten.2006.12.1891
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 55
TC 9
Z9 10
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD JUN
PY 2016
VL 12
IS 3
BP 340
EP 351
DI 10.1007/s12015 016 9645 9
PG 12
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA DM9IQ
UT WOS:000376679300008
PM 26815725
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Blaszczak Swiatkiewicz, K
AF Blaszczak Swiatkiewicz, Katarzyna
TI New Selective Progesterone Receptor Modulators and Their Impact on the
   RANK/RANKL Complex Activity
SO MOLECULES
LA English
DT Article
DE RANK RANKL complex; antiprogestins; mesoprogestins; osteoporosis; breast
   cancer
ID NF KAPPA B; SIGNALING COMPLEX; BREAST; KINASE; TRAF6; RANK;
   PROLIFERATION; INTERLEUKIN 1; INTEGRATION; ACTIVATION
AB Breast cancer depends on women's age. Its chemotherapy and hormone therapy lead to the loss of bone density and disruption of the skeleton. The proteins RANK and RANKL play a pivotal role in the formation of osteoclasts. It is also well established that the same proteins (RANK and RANKL) are the main molecules that play an important role in mammary stem cell biology. Mammary stem cells guarantee differentiation of the epithelial mammary cells, the growth of which is regulated by the progesterone induced RANKL signaling pathway. The crosstalk between progesterone receptor, stimulated by progesterone and its analogues results in RANKL to RANK binding and activation of cell proliferation and subsequently unlimited expansion of the breast cancer cells. Therefore downstream regulation of this signaling pathway is desirable. To meet this need, a new class of selective estrogen receptor modulators (SPRMs) with anti  and mesoprogestin function were tested as potential anti RANK agents. To establish the new feature of SPRMs, the impact of tested SPRMs on RANK RANKL proteins interaction was tested. Furthermore, the cells proliferation upon RANKL stimulation, as well as NFkB and cyclin D1 expression, induced by tested SPRMs were analyzed. Conducted experiments proved NFkB expression inhibition as well as cyclin D1 expression limitation under asoprisnil and ulipristal treatment. The established paracrine anti proliferative activity of antiprogestins together with competitive interaction with RANK make this class of compounds attractive for further study in order to deliver more evidence of their anti RANK activity and potential application in the breast cancer therapy together with its accompanied osteoporosis.
C1 [Blaszczak Swiatkiewicz, Katarzyna] Med Univ Lodz, Dept Appl Pharm, Muszynskiego 1, Lodz 90151, Poland.
C3 Medical University Lodz
RP Blaszczak Swiatkiewicz, K (通讯作者)，Med Univ Lodz, Dept Appl Pharm, Muszynskiego 1, Lodz 90151, Poland.
EM katarzyna.blaszczak swiatkiewicz@umed.lodz.pl
RI ; Blaszczak Swiatkiewicz, Katarzyna/S 9938 2016
OI BLASZCZAK SWIATKIEWICZ, KATARZYNA/0000 0002 7322 0712; 
FU Medical University of Lodz, Poland
FX Research was funded by the Medical University of Lodz, Poland.
CR Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Blaszczak Swiatkiewicz K, 2019, MOLECULES, V24, DOI 10.3390/molecules24213902
   Boonyaratanakornkit V, 2007, MOL ENDOCRINOL, V21, P359, DOI 10.1210/me.2006 0337
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Christian F, 2016, CELLS BASEL, V5, DOI 10.3390/cells5010012
   Chwalisz K, 2005, ENDOCR REV, V26, P423, DOI 10.1210/er.2005 0001
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Duheron V, 2011, P NATL ACAD SCI USA, V108, P5342, DOI 10.1073/pnas.1013054108
   Faivre E, 2005, STEROIDS, V70, P418, DOI 10.1016/j.steroids.2005.02.012
   Fernandez Valdivia R, 2012, MOL CELL ENDOCRINOL, V357, P91, DOI 10.1016/j.mce.2011.09.030
   Husejko J., 2019, J ED HLTH SPORT, V8, P412, DOI [10.5281/zenodo.3379055, DOI 10.5281/ZENODO.3379055]
   Israël A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000158
   Jassem J., 2015, ONKOLOGIA PRAKTYCE K, V11, P24
   Kobayashi S, 2010, MOL ENDOCRINOL, V24, P2292, DOI 10.1210/me.2010 0289
   Lange CA, 2008, J STEROID BIOCHEM, V108, P203, DOI 10.1016/j.jsbmb.2007.09.019
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nair HB, 2016, ONCOTARGET, V7, P10857, DOI 10.18632/oncotarget.7516
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Sigl V, 2014, CYTOKINE GROWTH F R, V25, P205, DOI 10.1016/j.cytogfr.2014.01.002
   Singhal Hari, 2018, Oncotarget, V9, P4282, DOI 10.18632/oncotarget.21378
   Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475 2484.2001
   VanderWalde A, 2011, CA CANCER J CLIN, V61, P139, DOI 10.3322/caac.20103
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
NR 24
TC 7
Z9 8
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD MAR 2
PY 2020
VL 25
IS 6
AR 1321
DI 10.3390/molecules25061321
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LJ6BO
UT WOS:000530248700064
PM 32183159
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nasr, M
   Awad, GAS
   Mansour, S
   Taha, I
   Al Shamy, A
   Mortada, ND
AF Nasr, Maha
   Awad, Gehanne A. S.
   Mansour, Samar
   Taha, Ismail
   Al Shamy, Abdelhamid
   Mortada, Nahed D.
TI Different modalities of NaCl osmogen in biodegradable microspheres for
   bone deposition of risedronate sodium by alveolar targeting
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Risedronate; Surface engineer; Microspheres; Pulmonary; Osmogen
ID LARGE POROUS PARTICLES; IN VITRO EVALUATION; DRUG RELEASE;
   SUSTAINED RELEASE; ACID MICROSPHERES; DELIVERY; BISPHOSPHONATES;
   FORMULATION; ALENDRONATE; MODEL
AB Risedronate sodium was formulated into polylactide co glycolic acid microspheres for pulmonary delivery using the w/o/w double emulsion technique. Sodium chloride was used as osmogen in either the internal or external aqueous phase to surface engineer the particles to achieve favorable properties. The prepared microspheres were characterized for the surface morphology, entrapment efficiency, in vitro release behavior, particle size, surface area, aerodynamic as well as powder flow properties. Furthermore, the safety of the drug and the selected formula were assessed by MTT viability test performed on Calu 3 cell line as well as histopathological lung tissue examination. A novel in vivo approach based on the radiolabeling of risedronate sodium with I 125 was developed in order to assess its deposition in the bones of male albino rats. The majority of the prepared microspheres exhibited high entrapment efficiency, sustained release profile up to 15 days, suitable geometric and aerodynamic particle sizes as well as good flow properties. The safety of the drug and the selected formula were proven by the high cell viability percentage of Calu 3 cells as well as the normal lung histology after intra tracheal administration. The in vivo study showed high bone deposition for risedronate sodium following the pulmonary route, suggesting that it could be utilized as an alternative route of administration for delivery of bisphosphonates. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Nasr, Maha; Awad, Gehanne A. S.; Mansour, Samar; Al Shamy, Abdelhamid; Mortada, Nahed D.] Ain Shams Univ, Fac Pharm, Dept Pharmaceut, Cairo, Egypt.
   [Taha, Ismail] Atom Energy Author, Hot Lab Ctr, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge
   Bank (EKB); Egyptian Atomic Energy Authority (EAEA)
RP Nasr, M (通讯作者)，Ain Shams Univ, Fac Pharm, Dept Pharmaceut, Monazamet El Wehda El Afrikia St, Cairo, Egypt.
EM maha2929@gmail.com
RI ; Taha, Ismail/AAD 1108 2021
OI Mansour, Samar/0000 0002 3033 164X; Awad, Gehanne A/0000 0003 0357 3114;
   Nasr, Maha/0000 0002 0912 7011; Mortada, Nahed/0000 0003 2017 4676
CR Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Allen MR, 2008, EXPERT OPIN DRUG MET, V4, P1371, DOI 10.1517/17425255.4.11.1371 
   Amin AM, 2010, J LABELLED COMPD RAD, V53, P1, DOI 10.1002/jlcr.1698
   Arifin DY, 2006, ADV DRUG DELIVER REV, V58, P1274, DOI 10.1016/j.addr.2006.09.007
   Bahl Y, 2000, AAPS PharmSciTech, V1, pE5, DOI 10.1208/pt010105
   Bittner B, 1998, EUR J PHARM BIOPHARM, V45, P295, DOI 10.1016/S0939 6411(98)00012 5
   Blank MA, 2000, ALIMENT PHARM THER, V14, P1215
   Blank MA, 1997, DIGEST DIS SCI, V42, P281, DOI 10.1023/A:1018849415297
   Blumentals WA, 2009, ANN PHARMACOTHER, V43, P577, DOI 10.1345/aph.1L555
   Chan HK, 2003, ADV DRUG DELIVER REV, V55, P793, DOI 10.1016/S0169 409X(03)00078 4
   Cook RO, 2005, J CONTROL RELEASE, V104, P79, DOI 10.1016/j.jconrel.2005.01.003
   Cui F, 2005, J CONTROL RELEASE, V107, P310, DOI 10.1016/j.jconrel.2005.07.001
   E Sherbiny IM, 2010, INT J PHARMACEUT, V395, P132, DOI 10.1016/j.ijpharm.2010.05.032
   Edwards DA, 1998, J APPL PHYSIOL, V85, P379, DOI 10.1152/jappl.1998.85.2.379
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   El Ghany EA, 2005, J RADIOANAL NUCL CH, V266, P117, DOI 10.1007/s10967 005 0879 2
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Faisant N, 2002, EUR J PHARM SCI, V15, P355, DOI 10.1016/S0928 0987(02)00023 4
   FLORENCE AT, 1982, INT J PHARM, V11, P277, DOI 10.1016/0378 5173(82)90080 1
   Healy AM, 2008, EUR J PHARM BIOPHARM, V69, P1182, DOI 10.1016/j.ejpb.2008.04.020
   Jones CF, 2009, ADV DRUG DELIVER REV, V61, P438, DOI 10.1016/j.addr.2009.03.005
   Katsumi H, 2010, INT J PHARMACEUT, V400, P124, DOI 10.1016/j.ijpharm.2010.08.041
   Lee J, 2010, J CONTROL RELEASE, V146, P61, DOI 10.1016/j.jconrel.2010.05.026
   MADDALENA DJ, 1983, TISCON BASIC COMPUTE
   Milner RJ, 2004, J VET INTERN MED, V18, P597, DOI 10.1892/0891 6640(2004)18<597:BAC>2.0.CO;2
   Mohamed F, 2006, INT J PHARMACEUT, V311, P97, DOI 10.1016/j.ijpharm.2005.12.016
   Nasr M, 2011, J PHARM SCI US, V100, P612, DOI 10.1002/jps.22297
   Nolan LM, 2009, EUR J PHARM SCI, V37, P593, DOI 10.1016/j.ejps.2009.05.007
   PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110
   Perugini P, 2001, AAPS PharmSciTech, V2, pE10
   Peter CP, 1998, DIGEST DIS SCI, V43, P1998, DOI 10.1023/A:1018894827961
   Pistel KF, 2000, J MICROENCAPSUL, V17, P467
   Rawat A, 2008, J CONTROL RELEASE, V128, P224, DOI 10.1016/j.jconrel.2008.03.013
   Samdancioglu S, 2006, DRUG DEV IND PHARM, V32, P473, DOI 10.1080/03639040500528871
   Sebti T, 2006, EUR J PHARM BIOPHARM, V63, P51, DOI 10.1016/j.ejpb.2005.11.003
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169 409X(01)00116 8
   Sivadas N, 2008, INT J PHARMACEUT, V358, P159, DOI 10.1016/j.ijpharm.2008.03.024
   Taki M, 2010, INT J PHARMACEUT, V388, P40, DOI 10.1016/j.ijpharm.2009.12.031
   Tewes F, 2008, J CONTROL RELEASE, V129, P93, DOI 10.1016/j.jconrel.2008.04.007
   Uchida T, 1996, J MICROENCAPSUL, V13, P219, DOI 10.3109/02652049609052909
   Ungaro F, 2006, EUR J PHARM SCI, V28, P423, DOI 10.1016/j.ejps.2006.05.005
   Ungaro F, 2010, EUR J PHARM SCI, V41, P60, DOI 10.1016/j.ejps.2010.05.011
   Ungaro F, 2009, J CONTROL RELEASE, V135, P25, DOI 10.1016/j.jconrel.2008.12.011
   Vay K, 2010, INT J PHARMACEUT, V402, P20, DOI 10.1016/j.ijpharm.2010.09.014
   Weidenauer U, 2004, J MICROENCAPSUL, V21, P137, DOI 10.1080/02652040310001637857
   Yoshizawa H, 2005, INT J PHARMACEUT, V296, P112, DOI 10.1016/j.ijpharm.2005.02.010
NR 46
TC 42
Z9 42
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939 6411
EI 1873 3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD NOV
PY 2011
VL 79
IS 3
BP 601
EP 611
DI 10.1016/j.ejpb.2011.07.010
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 846UX
UT WOS:000296929800016
PM 21827854
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Wang, N
   Ma, J
   Chen, XC
   Li, Z
   Zhao, W
AF Zhang, Y.
   Wang, N.
   Ma, J.
   Chen, X. C.
   Li, Z.
   Zhao, W.
TI Expression profile analysis of new candidate genes for the therapy of
   primary osteoporosis
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Primary osteoporosis; Genes; Enrichment analysis; Protein protein
   interaction network; Sub network
ID OSTEOBLAST DIFFERENTIATION; CELL ADHESION; BONE; PATHOGENESIS;
   MINIREVIEW; SURVIVAL; KINASE; AKT1
AB OBJECTIVE: Primary osteoporosis is a progressive bone disease that is characterized by a decrease in bone mass and density which can lead to an increased risk of fracture. Most of present treatments are effective for osteoporosis, but have limitations and side effects. With the aging of the world population is increasing, the incidence of osteoporosis is rising. Therefore, the purpose of this study was to identify new candidate genes used as the therapeutic targets of primary osteoporosis.
   MATERIALS AND METHODS: In this study, microarray data GSE35958 were downloaded from Gene Expression Omnibus, then the differentially expressed genes (DEGs) were identified by limma package. Gene Ontology (GO) and KEGG pathway enrichment analyses were performed for both up and down regulated DEGs using DAVID. In addition, the transcription factor analysis was conducted for DEGs. The protein protein interaction (PPI) network was constructed by STRING and Cytoscape. Finally, CFinder was used to analyze the PPI sub network.
   RESULTS: Totally, 327 up regulated DEGs and 396 down regulated DEGs were identified. The DEGs such as EGFR and AKT1 were mainly enriched in the pathway of focal adhesion. EGFR was also involved in cell adhesion based on GO enrichment analysis. Functional analysis of DEGs indicated that 26 transcription factors were screened. Moreover, EGFR, AKT1 and transcription factor CTNNB1 were the key nodes with high degrees according to PPI network and sub network.
   CONCLUSIONS: The literature suggested that AKT1, EGFR and CTNNB1 were closely related to osteoblastic differentiation and osteoclastogenesis. Some crucial DEGs such as EGFR, AKT1 and CTNNB1 might be connected with primary osteoporosis and could be used as therapeutic targets of osteoporosis.
C1 [Zhang, Y.; Wang, N.; Ma, J.; Chen, X. C.; Li, Z.; Zhao, W.] Shenyang Med Coll, Cent Hosp, Dept Orthoped, Shenyang, Province Liaoni, Peoples R China.
C3 Shenyang Medical College
RP Zhao, W (通讯作者)，Shenyang Med Coll, Cent Hosp, Dept Orthoped, Shenyang, Province Liaoni, Peoples R China.
EM weizhaowwz@163.com
CR Adamcsek B, 2006, BIOINFORMATICS, V22, P1021, DOI 10.1093/bioinformatics/btl039
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   De Luca A, 2011, J CELL PHYSIOL, V226, P2131, DOI 10.1002/jcp.22548
   Diboun I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 252
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Hidalgo Bastida LA, 2010, TISSUE ENG PART B RE, V16, P405, DOI [10.1089/ten.teb.2009.0714, 10.1089/ten.TEB.2009.0714]
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lo KWH, 2011, J ORTHOP RES, V29, P602, DOI 10.1002/jor.21276
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108
   Melton LJ, 2003, ENDOCRIN METAB CLIN, V32, P1, DOI 10.1016/S0889 8529(02)00061 0
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480
   Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755
   Perinpanayagam H, 2001, J ORTHOPAED RES, V19, P993, DOI 10.1016/S0736 0266(01)00045 6
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schneider MR, 2009, TRENDS ENDOCRIN MET, V20, P517, DOI 10.1016/j.tem.2009.06.008
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Valtieri M, 2008, J CELL PHYSIOL, V217, P296, DOI 10.1002/jcp.21521
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Zhou SH, 2011, J CELL BIOCHEM, V112, P1651, DOI 10.1002/jcb.23079
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
NR 42
TC 26
Z9 28
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD FEB
PY 2016
VL 20
IS 3
BP 433
EP 440
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DF5IX
UT WOS:000371386300008
PM 26914116
DA 2025 08 17
ER

PT J
AU Renders, GAP
   Vermeer, JAF
   Leung, PM
   Reynaert, F
   Prins, C
   Langenbach, GEJ
   Everts, V
AF Renders, Greetje A. P.
   Vermeer, Jenny A. F.
   Leung, Pui Ming
   Reynaert, Freya
   Prins, Carla
   Langenbach, Geerling E. J.
   Everts, Vincent
TI Implications of High Dosage Bisphosphonate Treatment on Bone Tissue in
   the Jaw and Knee Joint
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Zoledronic acid; Mandibular condyle; MicroCT; Mouse model
ID MICRO COMPUTED TOMOGRAPHY; BEAGLE DOGS; MICROCOMPUTED TOMOGRAPHY;
   CORTICAL BONE; MINERALIZATION; OSTEOARTHRITIS; CARTILAGE; OSTEONECROSIS;
   ACCURACY; NECROSIS
AB Bisphosphonates are bone antiresorptive agents traditionally used on a relatively large scale for treatment of bone metabolic diseases and on a smaller scale for bone metastasis treatment. A study on the effects of bisphosphonate treatment on healthy instead of diseased animals will give more insight into the basic mechanisms of bisphosphonates and their effects on different bone sites. We aimed to assess the effect of BP on the mouse knee and jaw joint. Three month old female C57BL/6 mice were used (twenty four and eighteen control and experimental group, respectively). At baseline and after treatment with zoledronic acid (ZA) for one, three or six months, we combined bone assessment via A mu CT and additional histology. Our results showed that, in the knee joint, ZA treatment increased TMD, bone volume, trabecular thickness but did not influence cortical thickness. In both control and ZA group, a higher trabecular TMD compared to cortical TMD was seen. Unseen in the knee joint, ZA treatment in the jaw joint resulted in bone site specific changes in mineralization; a significant time dependent higher TMD was evident in the subchondral bone compared to the most distal region of the condyle. MicroCT images revealed the presence of mineral in this region and histology showed that this region did not contain mature bone tissue but cartilage like tissue. Our data indicate the possibility of site specific negative side effects, i.e., disturbing normal mandibular development under the influence of bisphosphonate therapy.
C1 [Renders, Greetje A. P.; Vermeer, Jenny A. F.; Leung, Pui Ming; Reynaert, Freya; Langenbach, Geerling E. J.; Everts, Vincent] Univ Amsterdam, Dept Oral Cell Biol & Funct Anat, Acad Ctr Dent Amsterdam ACTA, MOVE Res Inst Amsterdam, NL 1081 LA Amsterdam, Netherlands.
   [Renders, Greetje A. P.; Vermeer, Jenny A. F.; Leung, Pui Ming; Reynaert, Freya; Langenbach, Geerling E. J.; Everts, Vincent] Vrije Univ Amsterdam, NL 1081 LA Amsterdam, Netherlands.
   [Prins, Carla] Vrije Univ Amsterdam Med Ctr, Ctr Anim Facil, Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam;
   University of Amsterdam; Vrije Universiteit Amsterdam; Vrije
   Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER
RP Renders, GAP (通讯作者)，Univ Amsterdam, Dept Oral Cell Biol & Funct Anat, Acad Ctr Dent Amsterdam ACTA, MOVE Res Inst Amsterdam, Gustav Mahlerlaan 3004, NL 1081 LA Amsterdam, Netherlands.
EM greetjerenders@gmail.com
OI Vermeer, Jenny A.F./0000 0001 6772 9144
FU Dutch Organization for Scientific Research (NWO [021.001.050]
FX This project was funded by the Dutch Organization for Scientific
   Research (NWO; Grant Number: 021.001.050). The authors thank Rika van
   der Laan (Center for Animal Facilities VU Medical Center, Amsterdam);
   Jolanda Hogervorst, Marion van Duin, Hans Korfage (Oral Cell Biology and
   Functional Anatomy, ACTA, Amsterdam), and Jan Stap (LCAM AMC, Amsterdam)
   for their technical assistance. Appreciation goes to Lars Mulder for
   editorial advice.
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   Allen MR, 2010, J BONE MINER RES, V25, P98, DOI 10.1359/jbmr.090713
   Bab I.A., 2007, MICROTOMOGRAPHIC ATL
   Bala Y, 2010, BONE, V46, P1204, DOI 10.1016/j.bone.2009.11.032
   Boivin G, 2002, CONNECT TISSUE RES, V43, P535, DOI 10.1080/03008200290000934
   Boivin G, 2009, OSTEOPOROSIS INT, V20, P1023, DOI 10.1007/s00198 009 0861 x
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bradaschia Correa V, 2012, Eur J Histochem, V56, pe24, DOI 10.4081/ejh.2012.24
   BRIGHTON CT, 1978, CLIN ORTHOP RELAT R, P22
   BROOKS RA, 1976, PHYS MED BIOL, V21, P390, DOI 10.1088/0031 9155/21/3/004
   Burghardt AJ, 2008, CALCIFIED TISSUE INT, V83, P129, DOI 10.1007/s00223 008 9158 x
   Burr DB, 2009, ORTHOD CRANIOFAC RES, V12, P221, DOI 10.1111/j.1601 6343.2009.01456.x
   De Rossi A, 2007, J ORAL PATHOL MED, V36, P377, DOI 10.1111/j.1600 0714.2007.00542.x
   Delatte M, 2004, EUR J ORAL SCI, V112, P156, DOI 10.1111/j.0909 8836.2004.00108.x
   Deuerling JM, 2010, MED PHYS, V37, P5138, DOI 10.1118/1.3480507
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fuchs RK, 2011, BONE, V49, P701, DOI 10.1016/j.bone.2011.05.009
   FURSTMAN L, 1963, AM J ORTHOD DENTOFAC, V49, P672, DOI 10.1016/0002 9416(63)90038 1
   GONG JK, 1964, ANAT RECORD, V149, P325, DOI 10.1002/ar.1091490303
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   HODGSKINSON R, 1989, J ORTHOP RES, V7, P754, DOI 10.1002/jor.1100070518
   Huja SS, 2008, ANAT REC, V291, P1, DOI 10.1002/ar.20619
   Kazakia GJ, 2008, MED PHYS, V35, P3170, DOI 10.1118/1.2924210
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Mulder L, 2004, ACTA RADIOL, V45, P769, DOI 10.1080/02841850410008171
   Nuzzo S, 2002, MED PHYS, V29, P2672, DOI 10.1118/1.1513161
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Qvist P, 2008, PHARMACOL RES, V58, P1, DOI 10.1016/j.phrs.2008.06.001
   Renders GAP, 2014, DENTOMAXILLOFAC RAD, V43, DOI 10.1259/dmfr.20130098
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Sebestyen JF, 2012, CLIN PEDIATR, V51, P1011, DOI 10.1177/0009922812452118
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
NR 37
TC 9
Z9 10
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD NOV
PY 2014
VL 95
IS 5
BP 436
EP 445
DI 10.1007/s00223 014 9912 1
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AQ8OW
UT WOS:000343088500007
PM 25183284
DA 2025 08 17
ER

PT J
AU Ruderman, I
   Holt, SG
   Kirkland, GS
   Maslen, S
   Hawley, CM
   Oliver, V
   Krishnasamy, R
   Gray, NA
   Talaulikar, GS
   Nelson, CL
   Rajaram, Y
   Gock, H
   Au, E
   Elder, GJ
   Mainra, R
   Toussaint, ND
AF Ruderman, Irene
   Holt, Stephen G.
   Kirkland, Geoffrey S.
   Maslen, Sophie
   Hawley, Carmel M.
   Oliver, Veronica
   Krishnasamy, Rathika
   Gray, Nicholas A.
   Talaulikar, Girish S.
   Nelson, Craig L.
   Rajaram, Yogeshwar
   Gock, Hilton
   Au, Eric
   Elder, Grahame J.
   Mainra, Rahul
   Toussaint, Nigel D.
TI Outcomes of cinacalcet withdrawal in Australian dialysis patients
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE end stage kidney disease; secondary hyperparathyroidism; dialysis;
   parathyroid hormone; cinacalcet
ID PATIENTS RECEIVING HEMODIALYSIS; QUALITY OF LIFE; SECONDARY
   HYPERPARATHYROIDISM; PARATHYROID HORMONE; CARDIOVASCULAR DISEASE;
   CALCIMIMETIC AMG 073; EVENTS; HCL; CALCIFICATION; METABOLISM
AB BackgroundSecondary hyperparathyroidism (SHPT) in chronic kidney disease is associated with cardiovascular and bone pathology. Measures to achieve parathyroid hormone (PTH) target values and control biochemical abnormalities associated with SHPT require complex therapies, and severe SHPT often requires parathyroidectomy or the calcimimetic cinacalcet. In Australia, cinacalcet was publicly funded for dialysis patients from 2009 to 2015 when funding was withdrawn following publication of the EVOLVE study, which resulted in most patients on cinacalcet ceasing therapy. We examined the clinical and biochemical outcomes associated with this change at Australian renal centres.
   AimTo assess changes to biochemical and clinical outcomes in dialysis patients following cessation of cinacalcet.
   MethodsWe conducted a retrospective study of dialysis patients who ceased cinacalcet after August 2015 in 11 Australian units. Clinical outcomes and changes in biochemical parameters were assessed over a 24  and 12 month period, respectively, from cessation of cinacalcet.
   ResultsA total of 228 patients was included (17.7% of all dialysis patients from the units). Patients were aged 63 15 years with 182 patients on haemodialysis and 46 on peritoneal dialysis. Over 24 months following cessation of cinacalcet, we observed 26 parathyroidectomies, 3 episodes of calciphylaxis, 8 fractures and 50 deaths. Eight patients recommenced cinacalcet, meeting criteria under a special access scheme. Biochemical changes from baseline to 12 months after cessation included increased levels of serum PTH from 54 (interquartile range 27 90) pmol/L to 85 (interquartile range 41 139) pmol/L (P < 0.0001), serum calcium from 2.3 +/  0.2 mmol/L to 2.5 +/  0.1 mmol/L (P < 0.0001) and alkaline phosphatase from 123 (92 176) IU/L to 143 (102 197) IU/L (P < 0.0001).
   ConclusionSignificant increases in serum PTH, calcium and alkaline phosphatase occurred over a 12 month period following withdrawal of cinacalcet. Longer term follow up will determine if these biochemical and therapeutic changes are associated with altered rates of parathyroidectomies and cardiovascular mortality and morbidity.
C1 [Ruderman, Irene; Holt, Stephen G.; Toussaint, Nigel D.] Royal Melbourne Hosp, Dept Nephrol, Melbourne, Vic, Australia.
   [Ruderman, Irene; Holt, Stephen G.; Toussaint, Nigel D.] Univ Melbourne, Dept Med RMH, Melbourne, Vic, Australia.
   [Nelson, Craig L.] Western Hlth, Dept Nephrol, Melbourne, Vic, Australia.
   [Nelson, Craig L.] Western Hlth, Dept Med, Melbourne, Vic, Australia.
   [Nelson, Craig L.] St Vincents Hlth, Western Hlth Chron Dis Alliance, Melbourne, Vic, Australia.
   [Rajaram, Yogeshwar; Gock, Hilton] St Vincents Hlth, Dept Nephrol, Melbourne, Vic, Australia.
   [Kirkland, Geoffrey S.; Maslen, Sophie] Royal Hobart Hosp, Dept Nephrol, Hobart, Tas, Australia.
   [Hawley, Carmel M.; Oliver, Veronica] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia.
   [Krishnasamy, Rathika; Gray, Nicholas A.] Sunshine Coast Hosp Univ Hosp, Dept Nephrol, Sunshine Coast, Qld, Australia.
   [Talaulikar, Girish S.] Canberra Hosp, Dept Nephrol, Canberra, ACT, Australia.
   [Au, Eric; Elder, Grahame J.] Westmead Hosp, Dept Nephrol, Sydney, NSW, Australia.
   [Elder, Grahame J.] Garvan Inst Med Res, Osteoporosis & Bone Biol Div, Sydney, NSW, Australia.
   [Mainra, Rahul] Sir Charles Gairdner Hosp, Dept Nephrol, Perth, WA, Australia.
C3 Melbourne Health; Royal Melbourne Hospital; University of Melbourne;
   Western Health; Western Health; St Vincent's Health; St Vincent's
   Health; Royal Hobart Hospital; Princess Alexandra Hospital; Australian
   National University; Canberra Hospital; University of Sydney; NSW
   Health; Westmead Hospital; Garvan Institute of Medical Research;
   University of Western Australia; Sir Charles Gairdner Hospital
RP Ruderman, I (通讯作者)，Royal Melbourne Hosp, Dept Nephrol, 300 Grattan St, Parkville, Vic 3050, Australia.
EM irene.ruderman@mh.org.au
RI Au, Eric/I 9582 2019; Hawley, Carmel/C 4905 2011; Gray,
   Nicholas/O 4300 2019; Gray, Nicholas/D 8340 2011; Holt,
   Stephen/AAU 7808 2020
OI Krishnasamy, Rathika/0000 0001 6974 7880; Gray,
   Nicholas/0000 0001 9112 0304; Au, Eric/0000 0002 6089 5913; Nelson,
   Craig/0000 0003 3548 4167
CR Agha A, 2012, EUR ARCH OTO RHINO L, V269, P1519, DOI 10.1007/s00405 011 1776 7
   AKMAL M, 1990, KIDNEY INT, V37, P854, DOI 10.1038/ki.1990.58
   ANZDATA Registry, 2017, MORT END STAG KIDN D
   AVRAM MM, 1978, NEW ENGL J MED, V298, P1000, DOI 10.1056/NEJM197805042981805
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Eandi M, 2010, PHARMACOECONOMICS, V28, P1041, DOI 10.2165/11538600 000000000 00000
   Eddington H, 2014, ANN CLIN BIOCHEM, V51, P228, DOI 10.1177/0004563213491236
   Floege J, 2015, CLIN J AM SOC NEPHRO, V10, P800, DOI 10.2215/CJN.10221014
   Ishani A, 2015, CLIN J AM SOC NEPHRO, V10, P90, DOI 10.2215/CJN.03520414
   Kestenbaum B, 2004, KIDNEY INT, V66, P2010, DOI 10.1111/j.1523 1755.2004.00972.x
   Ketteler M, 2005, KIDNEY INT, V67, pS120, DOI 10.1111/j.1523 1755.2005.09428.x
   Komaba H, 2012, AM J KIDNEY DIS, V60, P262, DOI 10.1053/j.ajkd.2011.12.034
   Lafrance JP, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 100
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523 1755.2003.00720.x
   LONDON GM, 1987, KIDNEY INT, V32, P900, DOI 10.1038/ki.1987.293
   Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414
   Moldovan D, 2015, INT UROL NEPHROL, V47, P1871, DOI 10.1007/s11255 015 1106 x
   Parfrey PS, 2015, CLIN J AM SOC NEPHRO, V10, P791, DOI 10.2215/CJN.07730814
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Rodriguez M, 2009, SEMIN DIALYSIS, V22, P363, DOI 10.1111/j.1525 139X.2009.00581.x
   van der Plas WY, 2017, NEPHROL DIAL TRANSPL, V32, P1902, DOI 10.1093/ndt/gfx044
   Yuan F, 2018, BLOOD PURIFICAT, V45, P73, DOI 10.1159/000484435
NR 26
TC 9
Z9 9
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1444 0903
EI 1445 5994
J9 INTERN MED J
JI Intern. Med. J.
PD JAN
PY 2019
VL 49
IS 1
BP 48
EP 54
DI 10.1111/imj.14036
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA HL6BY
UT WOS:000458820000007
PM 29992701
OA Green Published
DA 2025 08 17
ER

PT J
AU Xu, AH
   Yang, Y
   Shao, Y
   Wu, M
   Sun, YX
AF Xu, Aihua
   Yang, Yang
   Shao, Yang
   Wu, Meng
   Sun, Yongxin
TI Inhibiting effect of microRNA 187 3p on osteogenic differentiation of
   osteoblast precursor cells by suppressing cannabinoid receptor type 2
SO DIFFERENTIATION
LA English
DT Article
DE miR 187 3p; Cannabinoid receptor type 2; Osteoblast; Cell proliferation;
   Osteogenic differentiation
ID BONE; OVEREXPRESSION; PROLIFERATION; OSTEOPOROSIS; ACTIVATION;
   EXPRESSION; APOPTOSIS; MIR 187; CB2
AB Induction of osteoblast differentiation is an effective approach in promoting osteoblastogenesis and bone formation. MicroRNA (miR) is a kind of small regulatory RNA molecules that control both physiological and pathological processes. The purpose of this research was to explore the function of miR 187 3p in proliferation and osteogenic differentiation in human osteoblastic precursor cells (hFOB 1.19). Our results showed a significant promotion of cell proliferation by miR 187 3p in hFOB 1.19 cell accompanied by increased proliferating cell nuclear antigen (PCNA) and Ki67 expression, whereas miR 187 3p knockdown led to an inhibition of cell proliferation. Moreover, our data revealed that miR 187 3p was decreased in hFOB 1.19 cells undergoing osteoblastic differentiation. Silencing of miR 187 3p dramatically accelerated hFOB 1.19 osteoblastic differentiation, as evidenced by the increase of alkaline phosphatase (ALP) activity and calcium deposition, as well as elevated osteopontin (OPN), collagen type I alpha 1 (COL1A1), and bone sialoprotein (BSP) gene expression, whereas overexpression of miR 187 3p suppressed osteoblastic differentiation. Furthermore, we demonstrated that miR 187 3p could inhibit cannabinoid receptor type 2 (CNR2) expression by targeting its 3' untranslated region (UTR). Upregulation of CNR2 inversed the inhibiting influence of miR 187 3p on hFOB 1.19 osteogenic differentiation. Collectively, our results showed a pivotal role of miR 187 3p/CNR2 axis in osteoblastic differentiation, indicating that miR 187 3p may serve as a promising target in the therapy of osteoporosis.
C1 [Xu, Aihua; Yang, Yang; Shao, Yang; Wu, Meng; Sun, Yongxin] China Med Univ, Dept Rehabil Med, Affiliated Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University
RP Sun, YX (通讯作者)，China Med Univ, Dept Rehabil Med, Affiliated Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
EM sunyongxin@cmu.edu.cn
FU National Natural Science Foundation of China [81572221]; Science and
   Technology Project of Liaoning Province [LK201655]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81572221) and the Science and Technology
   Project of Liaoning Province (No. LK201655).
CR Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Alsharafi WA, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00466
   Baum R, 2014, CURR OSTEOPOROS REP, V12, P9, DOI 10.1007/s11914 013 0183 y
   Corrado A, 2017, POSTGRAD MED, V129, P858, DOI 10.1080/00325481.2017.1362312
   Dou CW, 2016, CANCER LETT, V381, P380, DOI 10.1016/j.canlet.2016.08.011
   Fei D, 2016, AM J CANCER RES, V6, P2859
   Garmilla Ezquerra P, 2015, CALCIFIED TISSUE INT, V96, P30, DOI 10.1007/s00223 014 9935 7
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gui H, 2015, IMMUNOBIOLOGY, V220, P817, DOI 10.1016/j.imbio.2014.12.012
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Ignatius A, 2005, BIOMATERIALS, V26, P311, DOI 10.1016/j.biomaterials.2004.02.045
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Li ZW, 2018, BIOMED PHARMACOTHER, V105, P461, DOI 10.1016/j.biopha.2018.05.122
   Locke JM, 2014, DIABETOLOGIA, V57, P122, DOI 10.1007/s00125 013 3089 4
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Mulrane L, 2012, CLIN CANCER RES, V18, P6702, DOI 10.1158/1078 0432.CCR 12 1420
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Palmieri Annalisa, 2008, J Oral Implantol, V34, P190, DOI 10.1563/0.869.1
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Saeedi P, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9020031
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Shao BZ, 2014, CNS NEUROSCI THER, V20, P1021, DOI 10.1111/cns.12349
   Sophocleous A, 2017, AGING CELL, V16, P1051, DOI 10.1111/acel.12638
   Stiehler M, 2009, J BIOMED MATER RES A, V89A, P96, DOI 10.1002/jbm.a.31967
   SUN YX, 2015, BIOMED RES INT, V15, DOI DOI 10.1142/S0219265915400046
   Wang BJ, 2018, EXP THER MED, V15, P357, DOI 10.3892/etm.2017.5369
   Yan ZX, 2014, LEUKEMIA, V28, P880, DOI 10.1038/leu.2013.291
NR 31
TC 16
Z9 16
U1 1
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD SEP OCT
PY 2019
VL 109
BP 9
EP 15
DI 10.1016/j.diff.2019.07.002
PG 7
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA JG8FG
UT WOS:000492313000002
PM 31352121
DA 2025 08 17
ER

PT J
AU Sun, QL
   Choudhary, S
   Mannion, C
   Kissin, Y
   Zilberberg, J
   Lee, WY
AF Sun, Qiaoling
   Choudhary, Saba
   Mannion, Ciaran
   Kissin, Yair
   Zilberberg, Jenny
   Lee, Woo Y.
TI Ex vivo construction of human primary 3D networked osteocytes
SO BONE
LA English
DT Article
DE Human bone tissue model; Human primary osteocytes; Human primary
   osteoblasts; 3D culture; Microfluidic; Sclerostin; SOST; FGF23
ID MYELOMA BONE DISEASE; MULTIPLE MYELOMA; CHEMORESPONSE ASSAY; PERFUSION
   CULTURE; ANIMAL MODELS; CELL LINES; CANCER; SCLEROSTIN; ESTABLISHMENT;
   INHIBITION
AB A human bone tissue model was developed by constructing ex vivo the 3D network of osteocytes via the biomimetic assembly of primary human osteoblastic cells with 20 25 mu m microbeads and subsequent microfluidic perfusion culture. The biomimetic assembly: (1) enabled 3D constructed cells to form cellular network via processes with an average cell to cell distance of 20 25 pm, and (2) inhibited cell proliferation within the interstitial confine between the microbeads while the confined cells produced extracellular matrix (ECM) to form a mechanically integrated structure. The mature osteocytic expressions of SOST and FGF23 genes became significantly higher, especially for SOST by 250 folds during 3D culture. The results validate that the bone tissue model: (1) consists of 3D cellular network of primary human osteocytes, (2) mitigates the osteoblastic differentiation and proliferation of primary osteoblast like cells encountered in 2D culture, and (3) therefore reproduces ex vivo the phenotype of human 3D networked osteocytes. The 3D tissue construction approach is expected to provide a clinically relevant and high throughput means for evaluating drugs and treatments that target bone diseases with in vitro convenience. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Sun, Qiaoling; Lee, Woo Y.] Stevens Inst Technol, Dept Mat Sci & Chem Engn, Hoboken, NJ 07030 USA.
   [Choudhary, Saba] Stevens Inst Technol, Dept Biomed Engn Chem & Biol Sci, Hoboken, NJ 07030 USA.
   [Zilberberg, Jenny] Hackensack Univ, Med Ctr, Res Dept, Hackensack, NJ 07601 USA.
   [Mannion, Ciaran] Hackensack Univ, Med Ctr, Dept Pathol, Hackensack, NJ USA.
   [Kissin, Yair] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
C3 Stevens Institute of Technology; Stevens Institute of Technology;
   Hackensack University Medical Center; Hackensack University Medical
   Center; Hackensack University Medical Center
RP Lee, WY (通讯作者)，Stevens Inst Technol, Dept Mat Sci & Chem Engn, Hoboken, NJ 07030 USA.; Zilberberg, J (通讯作者)，Hackensack Univ, Med Ctr, Res Dept, Hackensack, NJ 07601 USA.
EM Jenny.Zilberberg@hackensackmeridian.org; wlee@stevens.edu
OI Zilberberg, Jenny/0000 0002 4139 2616
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [1R21AR065032]; National Science
   Foundation [DMR 1409779]; Division Of Materials Research; Direct For
   Mathematical & Physical Scien [1409779] Funding Source: National Science
   Foundation
FX Research in this publication was supported by grants from: (1) the
   National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health under Award Number 1R21AR065032 to WYL
   and JZ and (2) the National Science Foundation (DMR 1409779) to WYL and
   JZ. The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health and the National Science Foundation. We would like to thank
   Professor Lynda Bonewald at Indiana University, Indianapolis for kindly
   providing us with the MLO A5 cells. We thank Luke Fritzky at the
   Histology Core Facility at Rutgers New Jersey Medical School for
   paraffin embedding and sectioning.
CR Appelman Dijkstra NM, 2016, CALCIFIED TISSUE INT, V98, P370, DOI 10.1007/s00223 016 0126 6
   Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Bodine PVN, 1996, ENDOCRINOLOGY, V137, P4592, DOI 10.1210/en.137.11.4592
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Couzin Frankel J, 2014, SCIENCE, V346, P28, DOI 10.1126/science.346.6205.28
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Delgado Calle J, 2014, CURR OPIN SUPPORT PA, V8, P407, DOI 10.1097/SPC.0000000000000090
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Gillet J., 2013, J NATL CANC I, V105
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Gu YX, 2015, J MATER CHEM B, V3, P3625, DOI 10.1039/c5tb00421g
   Hartung T., 2008, PARKINSONISM RELAT D, V14, P581
   Holzapfel BM, 2013, CANCER METAST REV, V32, P129, DOI 10.1007/s10555 013 9437 5
   Holzapfel Boris Michael, 2013, Sarcoma, V2013, P153640, DOI 10.1155/2013/153640
   Hutmacher DW, 2009, J CELL MOL MED, V13, P1417, DOI 10.1111/j.1582 4934.2009.00853.x
   Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224
   Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622
   Kurata K, 2006, J BONE MINER RES, V21, P616, DOI 10.1359/JBMR.060106
   Larson SR, 2013, PROSTATE, V73, P932, DOI 10.1002/pros.22639
   Lee JH, 2011, TISSUE ENG PART C ME, V17, P39, DOI 10.1089/ten.TEC.2010.0285
   Li AG, 2008, MOL CANCER RES, V6, P21, DOI 10.1158/1541 7786.MCR 07 0280
   Loiselle AE, 2013, BONE, V54, P205, DOI 10.1016/j.bone.2012.08.132
   Mi ZB, 2008, ANTICANCER RES, V28, P1733
   Mulcahy LE, 2011, BONE, V48, P182, DOI 10.1016/j.bone.2010.09.014
   Pajevic PaolaDivieti., 2014, Curr Biotechnol, V2, P179, DOI DOI 10.2174/22115501113029990017.OSTEOCYTE
   Prideaux M, 2016, BONE, V88, P64, DOI 10.1016/j.bone.2016.04.017
   Rhrissorrakrai K, 2015, BIOINFORMATICS, V31, P471, DOI 10.1093/bioinformatics/btu611
   Rosser J, 2012, METHODS MOL BIOL, V816, P67, DOI 10.1007/978 1 61779 415 5_6
   Rutherford T, 2013, GYNECOL ONCOL, V131, P362, DOI 10.1016/j.ygyno.2013.08.009
   Sandberg R., 2005, PNAS
   Sottnik JL, 2015, CANCER RES, V75, P2151, DOI 10.1158/0008 5472.CAN 14 2493
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Sun QL, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.26
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Thomas R, 2004, CANC TREAT RES, V118, P47
   Torreggiani E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075204
   Vazquez M, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00208
   Walker RE, 2014, BRIT MED BULL, V111, P117, DOI 10.1093/bmb/ldu016
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Zhang W, 2015, LAB CHIP, V15, P2854, DOI 10.1039/c5lc00341e
NR 45
TC 26
Z9 28
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2017
VL 105
BP 245
EP 252
DI 10.1016/j.bone.2017.09.012
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FL1SK
UT WOS:000413994500029
PM 28942121
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Soriano Souza, C
   Valiense, H
   Mavropoulos, E
   Martinez Zelaya, V
   Costa, AM
   Alves, AT
   Longuinho, M
   Resende, R
   Mourao, C
   Granjeiro, J
   Rocha Leao, MH
   Rossi, A
   Calasans Maia, M
AF Soriano Souza, Carlos
   Valiense, Helder
   Mavropoulos, Elena
   Martinez Zelaya, Victor
   Costa, Andrea Machado
   Alves, Adriana T.
   Longuinho, Mariana
   Resende, Rodrigo
   Mourao, Carlos
   Granjeiro, Jose
   Rocha Leao, Maria H.
   Rossi, Alexandre
   Calasans Maia, Monica
TI Doxycycline containing hydroxyapatite ceramic microspheres as a
   bone targeting drug delivery system
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE biocompatibility; cytotoxicity; doxycycline; drug delivery;
   hydroxyapatite
ID IN VITRO; ANIMAL RESEARCH; NANOPARTICLES; TETRACYCLINES; MINOCYCLINE;
   RELEASE; SURFACE; CHLORHEXIDINE; HYCLATE; ZINC
AB Drug delivery technology is a promising way to enhance the therapeutic efficacy of drugs. The purpose of this study is to evaluate the physical and chemical properties of hydroxyapatite ceramic microspheres loaded with doxycycline (HADOX), their effects on in vitro osteoblast viability, and their antimicrobial activity, and to determine the effects of DOX on the healing of rat sockets after tooth extraction. The internal microsphere porosity was sensitive to the treatment used to adsorb DOX onto microsphere surface; HA microspheres without DOX presented 26% of pores, whereas HADOX0.15 microspheres presented 52.0%. An initial drug release of 49.15 mu g/ml was observed in the first 24 hr. The minimal inhibitory concentration (MIC) tested against Enterococcus faecalis demonstrated that bacterial growth was inhibited for up to 7 days. Results of cell viability and cell proliferation did not indicate statistical differences in the metabolic activity of HADOX samples relative to HA without DOX microspheres (p > .05). After 1 week, a discreet inflammation reaction was observed in the control group, and after 6 weeks, newly formed bone was observed in the HADOX0.15 (p < .05). The HADOX did not interfere in the bone repair and controlled the early inflammatory response. HADOX could be a promising biomaterial to promote bone repair in infected sites.
C1 [Soriano Souza, Carlos; Longuinho, Mariana; Rossi, Alexandre] Brazilian Ctr Phys Res, Dept Appl Phys, Rio De Janeiro, Brazil.
   [Valiense, Helder] Fed Fluminense Univ, Dent Sch, Rio De Janeiro, Brazil.
   [Mavropoulos, Elena] Brazilian Ctr Phys Res, LABIOMAT, Rio De Janeiro, Brazil.
   [Martinez Zelaya, Victor] Brazilian Ctr Phys Res, Dept Phys, Rio De Janeiro, Brazil.
   [Costa, Andrea Machado] CBPF, COMAN, Rio De Janeiro, Brazil.
   [Alves, Adriana T.] Fed Fluminense Univ, Dept Oral Pathol, Rio De Janeiro, Brazil.
   [Resende, Rodrigo] Fluminense Fed Univ, Oral Surg Dept, Rio De Janeiro, Brazil.
   [Mourao, Carlos] Univ Fed Fluminense, Unidade Pesquisa Clin, Rio De Janeiro, Brazil.
   [Granjeiro, Jose] Natl Inst Metrol Standardizat & Ind Qual, Dept Bioengn, Rio De Janeiro, Brazil.
   [Rocha Leao, Maria H.] Fed Univ Rio Janeiro, Chem Sch, Rio De Janeiro, Brazil.
   [Calasans Maia, Monica] Fluminense Fed Univ, Oral Surg Dept, Dent Sch, Rio De Janeiro, Brazil.
C3 Centro Brasileiro de Pesquisas Fisicas; Universidade Federal Fluminense;
   Centro Brasileiro de Pesquisas Fisicas; Centro Brasileiro de Pesquisas
   Fisicas; Centro Brasileiro de Pesquisas Fisicas; Universidade Federal
   Fluminense; Universidade Federal Fluminense; Universidade Federal
   Fluminense; Instituto Nacional de Metrologia, Qualidade e Tecnologia
   (INMETRO); Universidade Federal do Rio de Janeiro; Universidade Federal
   Fluminense
RP Calasans Maia, M (通讯作者)，Fluminense Fed Univ, Oral Surg Dept, Dent Sch, Rio De Janeiro, Brazil.
EM monicacalasansmaia@gmail.com
RI Calasans Maia, Monica/G 6203 2013; Granjeiro, Jose/D 8289 2012; Costa,
   Andrea/N 9864 2015; Mourão, Carlos Fernando/N 8805 2018; Mourao, Carlos
   Fernando/N 8805 2018
OI Calasans Maia, Monica/0000 0001 5759 7926; Granjeiro,
   Jose/0000 0002 8027 8293; Longuinho, Mariana/0000 0002 7817 2115;
   Martinez Zelaya, Victor/0000 0001 5256 2919; Mourao, Carlos
   Fernando/0000 0001 5775 0222
CR Adibkia K., 2014, J MOL PHARM ORG PROC, V03, DOI DOI 10.4172/2329 9053.1000E118
   Almazin SM, 2009, J PERIODONTOL, V80, P999, DOI 10.1902/jop.2009.080574
   Balduino A, 2005, CELL TISSUE RES, V319, P255, DOI 10.1007/s00441 004 1006 3
   Boonsongrit Y, 2008, MATER SCI ENG B ADV, V148, P162, DOI 10.1016/j.mseb.2007.09.006
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Bouillaguet S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02374
   BRION M, 1981, INORG CHIM A BIOINOR, V55, P47, DOI 10.1016/S0020 1693(00)90781 3
   BROOKS RA, 1976, PHYS MED BIOL, V21, P390, DOI 10.1088/0031 9155/21/3/004
   Calasans Maia M, 2014, MAT SCI ENG C MATER, V41, P309, DOI 10.1016/j.msec.2014.04.054
   Chang CY, 2000, J PERIODONTOL, V71, P1086, DOI 10.1902/jop.2000.71.7.1086
   Clinical and Laboratory Standards Institute, 2013, M100S23 CLIN LAB STA
   Ding L, 2018, DENT MATER J, V37, P130, DOI 10.4012/dmj.2017 007
   Eduardo X. M., 2014, J PHYS C SERIES, V490
   El Fiqi A, 2017, ACTA BIOMATER, V60, P38, DOI 10.1016/j.actbio.2017.07.036
   Golub LM, 2001, J CLIN PERIODONTOL, V28, P146, DOI 10.1034/j.1600 051x.2001.028002146.x
   Golub LM, 2016, INT DENT J, V66, P127, DOI 10.1111/idj.12221
   Granjeiro J. M., 2012, BIOMATERIAIS ODONTOL, V1, P57
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Alkhraisat MH, 2010, ACTA BIOMATER, V6, P1522, DOI 10.1016/j.actbio.2009.10.043
   Injac R, 2007, J CHROMATOGR SCI, V45, P623, DOI 10.1093/chromsci/45.9.623
   ISO, 2009, ISO 10993 5:2009(E)
   Janito Filho V. F., 2017, ARXIV170408364
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Kinugawa S, 2012, J IMMUNOL, V188, P1772, DOI 10.4049/jimmunol.1101174
   Martin V, 2019, MAT SCI ENG C MATER, V101, P15, DOI 10.1016/j.msec.2019.03.056
   Martinez Zelaya VR, 2019, INT J NANOMED, V14, P3471, DOI 10.2147/IJN.S197157
   Mauffrey C, 2015, J AM ACAD ORTHOP SUR, V23, P143, DOI 10.5435/JAAOS D 14 00018
   Miqueles EX, 2016, PROGR IND MATH ECMI, P243, DOI DOI 10.1007/978 3 319 23413 7_32
   Narasaraju TSB, 1996, J MATER SCI, V31, P1, DOI 10.1007/BF00355120
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Ramírez Agudelo R, 2018, MAT SCI ENG C MATER, V83, P25, DOI 10.1016/j.msec.2017.08.012
   Schmitt MO, 2000, PHYSCHEMCOMM, DOI 10.1039/b005722n
   Sheikh Zeeshan, 2017, Biomater Res, V21, P9
   Smith AJ, 2018, LAB ANIM UK, V52, P135, DOI 10.1177/0023677217724823
   de Souza CAS, 2011, COLLOID SURFACE B, V87, P310, DOI 10.1016/j.colsurfb.2011.05.035
   Soriano Souza CA, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5505 4
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Thomas SC, 2015, CURR PHARM DESIGN, V21, P6165, DOI 10.2174/1381612821666151027153246
   Trajano VCC, 2016, MAT SCI ENG C MATER, V64, P370, DOI 10.1016/j.msec.2016.03.103
   Walter MS, 2014, DENT MATER, V30, P463, DOI 10.1016/j.dental.2014.01.015
   Wang SN, 2010, ADV POWDER TECHNOL, V21, P268, DOI 10.1016/j.apt.2009.12.001
   Wang SG, 2011, INT J NANOMED, V6, P3449, DOI 10.2147/IJN.S27166
   Wang XY, 2012, MATER SCI ENG B ADV, V177, P367, DOI 10.1016/j.mseb.2011.12.030
NR 44
TC 22
Z9 23
U1 3
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD MAY
PY 2020
VL 108
IS 4
BP 1351
EP 1362
DI 10.1002/jbm.b.34484
EA SEP 2019
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA LB9IE
UT WOS:000485546200001
PM 31496111
DA 2025 08 17
ER

PT J
AU Zhu, Z
   Liu, ZH
   Liu, JY
   Bi, M
   Yang, TY
   Wang, JY
AF Zhu, Zhen
   Liu, Zhihui
   Liu, Jingyue
   Bi, Ming
   Yang, Taoyuan
   Wang, Jingyun
TI Proteomic profiling of human placenta derived mesenchymal stem cells
   upon transforming LIM mineralization protein 1 stimulation
SO CYTOTECHNOLOGY
LA English
DT Article
DE Proteomics; LMP 1; hPDMSCs; Mass spectrometry
ID IN VITRO DIFFERENTIATION; GENE EXPRESSION; OSTEOBLAST DIFFERENTIATION;
   MULTIPOTENT CELLS; NUCLEAR ANTIGEN; MOUSE PLACENTA; BONE; LMP 1;
   IDENTIFICATION; IDENTITY
AB Human placenta derived mesenchymal stem cells (hPDMSCs) can differentiate into different types of cells and thus have tremendous potential for cell therapy and tissue engineering. LIM mineralization protein 1 (LMP 1) plays an important role in osteoblast differentiation, maturation and bone formation. To determine a global effect of LMP 1 on hPDMSCs, we designed a study using a proteomic approach combined with adenovirus mediated gene transfer of LMP 1 to identify LMP 1 induced changes in hPDMSCs on proteome level. We have generated proteome maps of undifferentiated hPDMSCs and LMP 1 induced hPDMSCs. Two dimensional gel electrophoresis revealed 22 spots with at least 2.0 fold changes in expression and 15 differently expressed proteins were successfully identified by MALDI TOF MS. The proteins regulated by LMP 1 included cytoskeletal proteins, cadmium binding proteins, and metabolic proteins, etc. The expression of some identified proteins was confirmed by further Western blot analyses. Our results will play an important role in better elucidating the underlying molecular mechanism in LMP 1 included hPDMSCs differentiation into osteoblasts.
C1 [Zhu, Zhen; Liu, Zhihui; Bi, Ming; Yang, Taoyuan; Wang, Jingyun] Jilin Univ, Stomatol Hosp, Changchun 130021, Peoples R China.
   [Liu, Jingyue] Stomatol Hosp Zhenjiang, Zhenjiang 212002, Peoples R China.
C3 Jilin University
RP Wang, JY (通讯作者)，Jilin Univ, Stomatol Hosp, Changchun 130021, Peoples R China.
EM jlccjingyun@sina.com
RI 志辉, 刘/HRC 8063 2023
FU 10th Science and Technology Supporting Program project from Zhenjiang
   city [SH2010043]; Natural Science Foundation of Jilin Province
   [20130101017jc]
FX This work was supported by the 10th Science and Technology Supporting
   Program project from Zhenjiang city (SH2010043) and Natural Science
   Foundation of Jilin Province (20130101017jc).
CR Alvarez Silva M, 2003, DEVELOPMENT, V130, P5437, DOI 10.1242/dev.00755
   Annunen Rasila J, 2007, PROTEOMICS, V7, P2189, DOI 10.1002/pmic.200601031
   [Anonymous], COLD SPRING HARB PER
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125
   Bünger MH, 2003, CALCIFIED TISSUE INT, V73, P446, DOI 10.1007/s00223 002 2109 z
   Chien CC, 2006, STEM CELLS, V24, P1759, DOI 10.1634/stemcells.2005 0521
   Conget PA, 2000, EXP HEMATOL, V28, P382, DOI 10.1016/S0301 472X(00)00134 X
   Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955 0674(99)00062 9
   Dirim A, 2008, INT UROL NEPHROL, V40, P861, DOI 10.1007/s11255 008 9362 7
   Dyballa Nadine, 2009, J Vis Exp, DOI 10.3791/1431
   Faça VM, 2012, EXPERT REV PROTEOMIC, V9, P217, DOI [10.1586/EPR.12.9, 10.1586/epr.12.9]
   Fei QM, 2007, ACTA BIOCH BIOPH SIN, V39, P693, DOI 10.1111/j.1745 7270.2007.00333.x
   Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22 5 649
   Gillette JM, 2004, J CELL SCI, V117, P441, DOI 10.1242/jcs.00909
   Guido RVC, 2009, CURR TOP MED CHEM, V9, P824, DOI 10.2174/156802609789207064
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Huang Hsing I, 2007, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01e01s1
   Hughes CS, 2011, PROTEOMICS, V11, P3983, DOI 10.1002/pmic.201100030
   Hughes CS, 2011, PROTEOMICS, V11, P675, DOI 10.1002/pmic.201000407
   Kelleher MT, 2009, TARGET ONCOL, V4, P235, DOI 10.1007/s11523 009 0116 y
   Kim HS, 2003, SPINE, V28, P219, DOI 10.1097/00007632 200302010 00004
   Kim SH, 2005, BIOCHEM BIOPH RES CO, V330, P423, DOI 10.1016/j.bbrc.2005.02.173
   Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149
   Kitching R, 2002, J BONE MINER METAB, V20, P269, DOI 10.1007/s007740200039
   Kurpinski K, 2009, CELL MOL BIOENG, V2, P606, DOI 10.1007/s12195 009 0090 6
   Lee SK, 2009, PROTEOMICS, V9, P4389, DOI 10.1002/pmic.200900165
   Liang P, 1997, J CELL SCI, V110, P1431
   Margaritescu Cl, 2005, Rom J Morphol Embryol, V46, P211
   MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0
   Matikainen Tiina, 2005, Toxicol Appl Pharmacol, V207, P544, DOI 10.1016/j.taap.2005.01.039
   Miao ZN, 2006, CELL BIOL INT, V30, P681, DOI 10.1016/j.cellbi.2006.03.009
   Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623 200306000 00007
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Morsczeck C, 2005, CELL BIOL INT, V29, P567, DOI 10.1016/j.cellbi.2005.03.020
   Nelson KJ, 2011, PROTEINS, V79, P947, DOI 10.1002/prot.22936
   NYGARD O, 1990, J BIOL CHEM, V265, P6030
   Panepucci RA, 2004, STEM CELLS, V22, P1263, DOI 10.1634/stemcells.2004 0024
   Park HW, 2007, PROTEOMICS, V7, P2881, DOI 10.1002/pmic.200700089
   Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007 0594
   Portmann Lanz CB, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.10.893
   PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0
   Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748
   RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014 5793(91)80798 8
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Strakova Z, 2008, CELL TISSUE RES, V332, P479, DOI 10.1007/s00441 008 0604 x
   Strohbach CA, 2008, CALCIFIED TISSUE INT, V83, P202, DOI 10.1007/s00223 008 9163 0
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Walker CA, 1999, J THORAC CARDIOV SUR, V118, P375, DOI 10.1016/S0022 5223(99)70233 3
   Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014
   Wang XL, 2011, GROWTH FACTORS, V29, P36, DOI 10.3109/08977194.2010.544656
   Wei B, 2008, BIOL RES, V41, P261, DOI /S0716 97602008000300003
   WILLIAM F, 1988, J CELL PHYSIOL, V137, P402, DOI 10.1002/jcp.1041370303
   Ye NS, 2006, STEM CELLS DEV, V15, P665, DOI 10.1089/scd.2006.15.665
   Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004 0098
   Yi B, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 98
   Yoon ST, 2002, CLIN ORTHOP RELAT R, P33
   Yoon ST, 2004, SPINE, V29, P2603, DOI 10.1097/01.brs.0000146103.94600.85
   Zhang AX, 2007, MOL CELL BIOCHEM, V304, P167, DOI 10.1007/s11010 007 9497 3
   Zhang XH, 2006, BIOCHEM BIOPH RES CO, V340, P944, DOI 10.1016/j.bbrc.2005.12.091
   Zhang Y, 2004, CHINESE MED J PEKING, V117, P882
NR 61
TC 1
Z9 1
U1 0
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920 9069
EI 1573 0778
J9 CYTOTECHNOLOGY
JI Cytotechnology
PD MAR
PY 2015
VL 67
IS 2
BP 285
EP 297
DI 10.1007/s10616 013 9684 x
PG 13
WC Biotechnology & Applied Microbiology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Cell Biology
GA CB6WW
UT WOS:000349768500011
PM 24468833
OA Green Published
DA 2025 08 17
ER

PT J
AU Kosikowska, P
   Bochno, M
   Macegoniuk, K
   Forlani, G
   Kafarski, P
   Berlicki, L
AF Kosikowska, Paulina
   Bochno, Marta
   Macegoniuk, Katarzyna
   Forlani, Giuseppe
   Kafarski, Pawel
   Berlicki, Lukasz
TI Bisphosphonic acids as effective inhibitors of Mycobacterium
   tuberculosis glutamine synthetase
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE Bisphosphonates; enzyme inhibitors; nitrogen metabolism;
   organophosphorus compounds; tuberculosis
ID DERIVATIVES; EVOLUTION; GROWTH; GENE; DRUG
AB Inhibition of glutamine synthetase (GS) is one of the most promising strategies for the discovery of novel drugs against tuberculosis. Forty three bisphosphonic and bis H phosphinic acids of various scaffolds, bearing aromatic substituents, were screened against recombinant GS from Mycobacterium tuberculosis. Most of the studied compounds exhibited activities in micromolar range, with N (3,5 dichlorophenyl) 2 aminoethylidenebisphoshonic acid, N (3,5difluorophenyl) 2 aminoethylidene bisphoshonic acid and N (3,4 dichlorophenyl) 1 hydroxy1,1 ethanebisphosphonic acid showing the highest potency with kinetic parameters similar to the reference compound   L methionine S sulfoximine. Moreover, these inhibitors were found to be much more effective against pathogen enzyme than against the human ortholog. Thus, with the bone targeting properties of the bisphosphonate compounds in mind, this activity/selectivity profile makes these compounds attractive agents for the treatment of bone tuberculosis.
C1 [Kosikowska, Paulina; Bochno, Marta; Macegoniuk, Katarzyna; Kafarski, Pawel; Berlicki, Lukasz] Wroclaw Univ Technol, Fac Chem, Dept Bioorgan Chem, Wroclaw, Poland.
   [Forlani, Giuseppe] Univ Ferrara, Dept Life Sci & Biotechnol, Ferrara, Italy.
C3 Wroclaw University of Science & Technology; University of Ferrara
RP Berlicki, L (通讯作者)，Wroclaw Univ Technol, Fac Chem, Dept Bioorgan Chem, Wroclaw, Poland.
EM lukasz.berlicki@pwr.edu.pl
RI Kafarski, Paweł/AAA 9112 2019; Forlani, Giuseppe/B 7869 2009; Berlicki,
   Lukasz/AAB 2140 2019
OI Berlicki, Lukasz/0000 0003 0318 4944; Forlani,
   Giuseppe/0000 0003 2598 5718; Kosikowska Adamus,
   Paulina/0000 0002 4737 2771
FU Polish Ministry of Science and Higher Education [N N302 159937]; Wroclaw
   Centre of Biotechnology, programme The Leading National Research Centre
   (KNOW)
FX L. B. acknowledges the financial support from the Polish Ministry of
   Science and Higher Education (grant N N302 159937). The project was
   supported by Wroclaw Centre of Biotechnology, programme The Leading
   National Research Centre (KNOW) for years 2014 2018. The authors report
   no declarations of interest.
CR ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0
   Berlicki L, 2008, MINI REV MED CHEM, V8, P869, DOI 10.2174/138955708785132800
   Berlicki L, 2006, BIOORGAN MED CHEM, V14, P4578, DOI 10.1016/j.bmc.2006.02.022
   Bochno M, 2014, TETRAHEDRON LETT, V55, P219, DOI 10.1016/j.tetlet.2013.10.153
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Dabrowska E, 2009, J ORGANOMET CHEM, V694, P3806, DOI 10.1016/j.jorganchem.2009.07.025
   Eisenberg D, 2000, BBA PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167 4838(99)00270 8
   Forlani G, 2013, J AGR FOOD CHEM, V61, P6792, DOI 10.1021/jf401234s
   Gising J, 2012, J MED CHEM, V55, P2894, DOI 10.1021/jm201212h
   GROSS H, 1976, J PRAKT CHEM, V318, P116, DOI 10.1002/prac.19763180113
   Harth G, 1999, J EXP MED, V189, P1425, DOI 10.1084/jem.189.9.1425
   Harth G, 2003, INFECT IMMUN, V71, P456, DOI 10.1128/IAI.71.1.456 464.2003
   HUTCHINSON DW, 1988, J ORGANOMET CHEM, V346, P341, DOI 10.1016/0022 328X(88)80134 7
   Krajewski WW, 2008, J MOL BIOL, V375, P217, DOI 10.1016/j.jmb.2007.10.029
   Krajewski WW, 2005, P NATL ACAD SCI USA, V102, P10499, DOI 10.1073/pnas.0502248102
   KUMADA Y, 1993, P NATL ACAD SCI USA, V90, P3009, DOI 10.1073/pnas.90.7.3009
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Llorca O, 2006, J STRUCT BIOL, V156, P469, DOI 10.1016/j.jsb.2006.06.003
   Nilsson MT, 2009, J MOL BIOL, V393, P504, DOI 10.1016/j.jmb.2009.08.028
   Obojska A, 2004, J AGR FOOD CHEM, V52, P3337, DOI 10.1021/jf049843q
   Occhipinti A, 2010, PEST MANAG SCI, V66, P51, DOI 10.1002/ps.1830
   PESOLE G, 1995, MOL BIOL EVOL, V12, P189
   RONZIO RA, 1968, P NATL ACAD SCI USA, V59, P164, DOI 10.1073/pnas.59.1.164
   Stadtman ER, 2001, J BIOL CHEM, V276, P44357, DOI 10.1074/jbc.R100055200
   Suarez Garcia I, 2002, INT J INF DIS, V16, pe774
   Tullius MV, 2003, INFECT IMMUN, V71, P3927, DOI 10.1128/IAI.71.7.3927 3936.2003
   van Rooyen JM, 2011, STRUCTURE, V19, P471, DOI 10.1016/j.str.2011.02.001
   YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681
NR 28
TC 18
Z9 20
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1475 6366
EI 1475 6374
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PY 2016
VL 31
IS 6
BP 931
EP 938
DI 10.3109/14756366.2015.1070846
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DY6WR
UT WOS:000385270300010
PM 26235917
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Gardner, TA
   Lee, SJ
   Lee, SD
   Li, X
   Shirakawa, T
   Kwon, DD
   Park, RY
   Ahn, KY
   Jung, C
AF Gardner, Thomas A.
   Lee, Sang Jin
   Lee, Sang Don
   Li, Xiong
   Shirakawa, Toshihiro
   Kwon, Dong Deuk
   Park, Ra Young
   Ahn, Kyu Youn
   Jung, Chaeyong
TI Differential expression of osteocalcin during the metastatic progression
   of prostate cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE osteocalcin; prostate cancer; metastasis
ID GROWTH FACTOR CONTRIBUTES; MATRIX GLA PROTEIN; BONE METASTASIS;
   OSTEOBLAST DIFFERENTIATION; GENE THERAPY; OSTEOMIMETIC PROPERTIES; SERUM
   OSTEOCALCIN; CLINICAL TRIAL; CHROMATIN; CELLS
AB Osteocalcin expression is restricted to osteoblasts and serum osteocalcin level is elevated in metastatic bone tumors including prostate tumours, which predominantly metastasizes to the bone and causes typical osteoblastic lesions. Previously, we have reported that osteocalcin RNA is widely expressed but incompletely spliced in the prostate including prostate tumors. Considering that many studies using osteocalcin driven gene therapy have been conducted to treat hormone refractory metastatic tumors, detailed mechanisms controlling osteocalcin expression needs to be clarified. We aim to learn how osteocalcin expression is regulated during the metastatic process of prostate cancer. We applied assays of immunohistochemistry and RNA in situ hybridization in prostate tumors acquired from prostate (15) and metastatic sites, 13 from lymph node and 14 from bone. RT PCR analysis in various cultured prostate cells was also performed. As predicted, osteocalcin RNA was highly expressed in most prostate epithelial cells of tumors, regardless of metastatic status of the tumor. However, osteocalcin protein was undetectable in tumors acquired from the primary site or lymph nodes whereas protein was highly expressed in the majority of bone metastasized prostate tumors. RT PCR analysis demonstrated that there was more completely spliced form of osteocalcin RNA present in bone derived prostate cancer cells. Our data suggest that osteocalcin RNA was expressed but not completely spliced in non bone environment, ultimately resulting in improper production of osteocalcin protein. This study explains why serum osteocalcin level is increased in patients with bone metastasized prostate cancers. Yet, it remains to be clarified what regulates bone specific osteocalcin RNA splicing in prostate tumors.
C1 [Park, Ra Young; Ahn, Kyu Youn; Jung, Chaeyong] Chonnam Natl Univ, Sch Med, Dept Anat, Kwangju, South Korea.
   [Gardner, Thomas A.; Li, Xiong] Indiana Univ, Sch Med, Dept Urol, Indianapolis, IN 46202 USA.
   [Lee, Sang Don] Pusan Natl Univ, Sch Med, Pusan 609735, South Korea.
   [Lee, Sang Jin] Natl Canc Ctr, Gyeonggi Do, South Korea.
   [Shirakawa, Toshihiro] Kobe Univ, Sch Med, Int Ctr Med Res & Treatment, Kobe, Hyogo 650, Japan.
   [Kwon, Dong Deuk] Chonnam Natl Univ, Sch Med, Dept Urol, Kwangju, South Korea.
   [Kwon, Dong Deuk; Park, Ra Young; Ahn, Kyu Youn; Jung, Chaeyong] Chonnam Natl Univ, Res Inst Clin Med, Kwangju, South Korea.
C3 Chonnam National University; Indiana University System; Indiana
   University Indianapolis; Pusan National University; Pusan National
   University Hospital; National Cancer Center   Korea (NCC); Kobe
   University; Chonnam National University; Chonnam National University
RP Jung, C (通讯作者)，Chonnam Natl Univ, Sch Med, Dept Anat, Kwangju, South Korea.
EM chjung@jnu.ac.kr
RI ; Jung, Chaeyong/AAD 8357 2021; Park, Kyoung Un/J 5473 2012
OI Gardner, Thomas/0000 0002 0124 4176; 
FU Korea Science & Engineering Foundation [R13 2002 013 04002 0]; Chonnam
   National University Hospital Research Institute of Clinical Medicine
   [CRT07009 1]
FX This work was supported by the Korea Science & Engineering Foundation
   through the Medical Research Center for Gene Regulation
   (R13 2002 013 04002 0) at Chonnam National University, and partly by a
   research grant (CRT07009 1) from the Chonnam National University
   Hospital Research Institute of Clinical Medicine.
CR Andersen H, 2003, J BONE MINER RES, V18, P195, DOI 10.1359/jbmr.2003.18.2.195
   ARAI Y, 1992, PROSTATE, V20, P169, DOI 10.1002/pros.2990200302
   CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460 2075.1986.tb04440.x
   CURATOLO C, 1992, EUR UROL, V21, P105
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   HERRINGTON CS, 1992, CYTOPATHOLOGY, V3, P71, DOI 10.1111/j.1365 2303.1992.tb00028.x
   Huang WC, 2006, CANCER RES, V66, P9108, DOI 10.1158/0008 5472.CAN 06 1996
   Javed A, 1999, MOL CELL BIOL, V19, P7491
   Javed A, 2000, J CELL SCI, V113, P2221
   Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378 1119(01)00513 3
   Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008 5472.CAN 05 1809
   Koeneman KS, 2000, WORLD J UROL, V18, P102, DOI 10.1007/s003450050181
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kubo H, 2003, HUM GENE THER, V14, P227, DOI 10.1089/10430340360535788
   LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406
   Lian JB, 2001, STEROIDS, V66, P159, DOI 10.1016/S0039 128X(00)00160 4
   MARCELLINI M, 1992, EUR UROL, V21, P102
   Matsubara S, 2001, CANCER RES, V61, P6012
   McCarthy HO, 2007, J GENE MED, V9, P511, DOI 10.1002/jgm.1045
   Montecino M, 1996, BIOCHEMISTRY US, V35, P5093, DOI 10.1021/bi952489s
   Nadiminty N, 2006, CLIN CANCER RES, V12, P1420, DOI 10.1158/1078 0432.CCR 05 1849
   Paredes R, 2004, J STEROID BIOCHEM, V89 90, P269, DOI 10.1016/j.jsbmb.2004.03.076
   SHIH WJ, 1990, J NUCL MED, V31, P1486
   Shirakawa T, 2007, HUM GENE THER, V18, P1225, DOI 10.1089/hum.2007.074
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339 3351.2003
   THIEDE MA, 1994, ENDOCRINOLOGY, V135, P929, DOI 10.1210/en.135.3.929
   Valta MP, 2008, INT J CANCER, V123, P22, DOI 10.1002/ijc.23422
   VALTA MP, 2006, ENDOCRINOLOGY
   Villagra A, 2006, J BIOL CHEM, V281, P22695, DOI 10.1074/jbc.M511640200
   Yeung F, 2002, J CELL BIOCHEM, P65, DOI 10.1002/jcb.10044
   Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200
   Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200
NR 36
TC 22
Z9 24
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD APR
PY 2009
VL 21
IS 4
BP 903
EP 908
DI 10.3892/or_00000302
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 426GM
UT WOS:000264696000011
PM 19287987
OA Bronze
DA 2025 08 17
ER

PT J
AU Hashizume, M
   Mihara, M
AF Hashizume, M.
   Mihara, M.
TI Desirable effect of combination therapy with high molecular weight
   hyaluronate and NSAIDs on MMP production
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE High molecular weight hyaluronate; NSAID; Metalloprotease;
   Interleukin 1; Interleukin 6
ID HUMAN ARTICULAR CARTILAGE; MATRIX METALLOPROTEINASES; GENE EXPRESSION;
   PROINFLAMMATORY CYTOKINES; SYNOVIAL FIBROBLASTS; OSTEOARTHRITIS;
   CHONDROCYTES; PROTEOGLYCANS; METABOLISM; ARTHRITIS
AB Objective: We previously reported that nonsteroidal anti inflammatory drugs (NSAIDs) aggravated cartilage degeneration and that hyaluronate (HA) reversed the cartilage destruction accelerated by NSAIDs in a rabbit osteoarthritis (OA) model. In the present study, we analyzed the mechanisms of these effects of NSAIDs and HA.
   Method An experimental rabbit model of OA was induced by partial meniscectomy and treated with NSAIDs, HA and the combination of NSAIDs and HA over 2 weeks. After sacrifice, cartilage degeneration and the levels of matrix metalloproteases (MMP) 1, MMP 3 and MMP 13 in synovial lavage fluid were measured. In an in vitro study, human articular chondrocytes were cultured with NSAIDs and HA in the presence of interleukin (IL) 1 beta or IL 6 + sIL 6 for 24 h. After culture, the production of MMPs, IL 1 beta, and IL 6 was measured.
   Results: The levels of MMP 1, MMP 3 and MMP 13 in synovial fluid from the NSAID treated group were significantly higher than in controls. The increased production of MMPs induced by NSAIDs was counteracted by the concomitant administration of HA. In vitro studies showed that NSAIDs augmented IL 1 beta  and IL 6 induced production of MMPs from human chondrocytes, while completely inhibiting the IL 1 beta  and IL 6/sIL 6R induced production of prostaglandin E 2 (PGE(2)). The addition of PGE2 did not reduce the augmentation of MMP production. HA inhibited the promotion of cytokine induced MMP and cytokine production by NSAIDs.
   Conclusions: Our data clearly showed that HA inhibited NSAID accelerated MMP production which was followed by inflammatory cytokine production from cytokine activated chondrocytes. The results warrant further evaluation of the potential chondroprotective effects of co administration of HA with NSAIDs. (C) 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Hashizume, M.; Mihara, M.] Chugai Pharmaceut Co Ltd, Prod Res Dept, Shizuoka 4128513, Japan.
C3 Roche Holding; Roche Holding Japan; Chugai Pharmaceutical Co., Ltd.
RP Mihara, M (通讯作者)，Chugai Pharmaceut Co Ltd, Prod Res Dept, 1 135 Komakado, Shizuoka 4128513, Japan.
EM mihar amsh@chugai pharm.co.jp
CR BALAZS EA, 1967, ARTHRITIS RHEUM US, V10, P357, DOI 10.1002/art.1780100407
   Blot L, 2000, BRIT J PHARMACOL, V131, P1413, DOI 10.1038/sj.bjp.0703710
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   El Hajjaji H, 2003, J RHEUMATOL, V30, P2444
   Fiedorczyk M, 2006, J RHEUMATOL, V33, P1523
   François M, 2006, ARTHRITIS RHEUM US, V54, P1233, DOI 10.1002/art.21728
   Goldring SR, 2004, CLIN ORTHOP RELAT R, pS27, DOI 10.1097/01.blo.0000144854.66565.8f
   HUSKISSON EC, 1995, J RHEUMATOL, V22, P1941
   Julovi SM, 2004, ARTHRITIS RHEUM US, V50, P516, DOI 10.1002/art.20004
   Julovi SM, 2008, MOD RHEUMATOL, V18, P263, DOI 10.1007/s10165 008 0067 7
   Kaneko S, 2000, CYTOKINES CELL MOL T, V6, P71, DOI 10.1080/13684730050515796
   Legendre F, 2005, J RHEUMATOL, V32, P1307
   MANICOURT DH, 1994, BRIT J PHARMACOL, V113, P1113, DOI 10.1111/j.1476 5381.1994.tb17111.x
   Mihara M, 2007, OSTEOARTHR CARTILAGE, V15, P543, DOI 10.1016/j.joca.2006.11.001
   Mitsui Y, 2008, J ORTHOP RES, V26, P1032, DOI 10.1002/jor.20558
   QUI B, 2005, CHIN J TRAUMATOL, V8, P8
   RASHAD S, 1989, LANCET, V2, P519
   Shimizu M, 2003, J RHEUMATOL, V30, P1164
   Takahashi K, 1999, OSTEOARTHR CARTILAGE, V7, P182, DOI 10.1053/joca.1998.0207
   Tanaka M, 2006, RHEUMATOL INT, V26, P185, DOI 10.1007/s00296 004 0547 9
   Wang CT, 2006, OSTEOARTHR CARTILAGE, V14, P1237, DOI 10.1016/j.joca.2006.05.009
   Yatabe T, 2009, ANN RHEUM DIS, V68, P1051, DOI 10.1136/ard.2007.086884
NR 22
TC 38
Z9 40
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD NOV
PY 2009
VL 17
IS 11
BP 1513
EP 1518
DI 10.1016/j.joca.2009.04.018
PG 6
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 515GP
UT WOS:000271456300017
PM 19447215
OA Bronze
DA 2025 08 17
ER

PT J
AU Machado, NED
   Banci, HA
   da Silva, LD
   Santinoni, CD
   de Oliveira, DL
   Ervolino, E
   do Prado, RL
   Mori, GG
AF Machado, Nathalia Evelyn da Silva
   Banci, Henrique Augusto
   da Silva, Lucas Deszo
   Santinoni, Carolina dos Santos
   de Oliveira, Danilo Louzada
   Ervolino, Edilson
   do Prado, Rosana Leal
   Mori, Graziela Garrido
TI Influence of anti allergic drugs used systemically on the process of
   root resorption during delayed tooth replantation: A study in rats
SO DENTAL TRAUMATOLOGY
LA English
DT Article
DE anti allergic agents; root resorption; tooth replantation
ID BONE RESORPTION; TEETH; QUERCETIN; PROGNOSIS; ATOPY; GLUCOCORTICOIDS;
   OSTEOCLASTS; MANAGEMENT; PATHWAYS; ALVEOLAR
AB Background/Aim Anti allergic drugs can inhibit the hard tissue resorption process, and due to similarities between root resorption and bone mechanisms, it can be inferred that these drugs may also control root resorption. The aim of this study was to analyze the effects of anti allergic drugs used systemically on the process of root resorption following delayed tooth replantation. Materials and Methods Thirty two maxillary right incisors of rats were extracted and subsequently replanted. Rats were divided into four groups according to the anti allergic drug administered: the rats in groups DEX, Q, and MO were treated systemically with dexamethasone phosphate, quercetin, and montelukast, respectively, and no systemic medication was administered to rats in group C. After 60 days, the animals were euthanized, and the specimens were processed for histomorphometric and immunohistochemical analyses. Statistical significance was set at P There were no significant differences between the groups in terms of inflammatory resorption, replacement resorption, or presence of tartrate resistant acid phosphatase. In terms of events occurring in the periodontal ligament space, there was a difference between groups Q and MO due to the presence of dental ankylosis and inflammatory connective tissue (P < .05). A difference in inflammatory cells was also observed through CD45 immunolabeling between the DEX and Q groups when compared to the C group (P < .05). Conclusion The systemic administration of anti allergic drugs did not have an effect on the process of root resorption following delayed tooth replantation.
C1 [Machado, Nathalia Evelyn da Silva; Santinoni, Carolina dos Santos; do Prado, Rosana Leal; Mori, Graziela Garrido] Univ Western Sao Paulo, Grad Program Dent, Rua Jose Bongiovani 700, BR 19050920 Presidente Prudente, SP, Brazil.
   [Machado, Nathalia Evelyn da Silva; Banci, Henrique Augusto] UNESP Univ Estadual Paulista, Aracatuba Dent Sch, Dept Endodont, Aracatuba, Brazil.
   [Banci, Henrique Augusto; da Silva, Lucas Deszo; Santinoni, Carolina dos Santos; de Oliveira, Danilo Louzada; do Prado, Rosana Leal; Mori, Graziela Garrido] Univ Western Sao Paulo, Dent Sch Presidente Prudente, Presidente Prudente, Brazil.
   [Ervolino, Edilson] UNESP Univ Estadual Paulista, Aracatuba Dent Sch, Dept Basic Sci, Aracatuba, Brazil.
C3 Universidade do Oeste Paulista; Universidade Estadual Paulista;
   Universidade do Oeste Paulista; Universidade Estadual Paulista
RP Mori, GG (通讯作者)，Univ Western Sao Paulo, Grad Program Dent, Rua Jose Bongiovani 700, BR 19050920 Presidente Prudente, SP, Brazil.
EM grazielagm@hotmail.com
RI Mori, Graziela/F 7826 2017; Banci, Henrique/X 7502 2018; Banci, Henrique
   Augusto/X 7502 2018; Leal do Prado, Rosana/J 5998 2016; Ervolino,
   Edilson/D 1500 2018; da Silva Machado, Nathalia Evelyn/G 8545 2017;
   Santinoni, Carolina/J 6399 2014; Garrido Mori Panucci,
   Graziela/F 7826 2017
OI Banci, Henrique Augusto/0000 0002 4344 4491; da Silva Machado, Nathalia
   Evelyn/0000 0002 4196 782X; Santinoni, Carolina/0000 0001 5153 2419;
   Garrido Mori Panucci, Graziela/0000 0002 8690 5294
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior  (Brazil)
    CAPES
FX Special Scientific Initiation Program PEIC/University of Western Sao
   Paulo (Protocol 3905). This work was carried out with the support of
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior  (Brazil)
    CAPES.
CR Abbott PV, 2016, AUST DENT J, V61, P82, DOI 10.1111/adj.12400
   Adcock IM, 2017, HANDB EXP PHARMACOL, V237, P171, DOI 10.1007/164_2016_98
   Andersson L, 2012, DENT TRAUMATOL, V28, P88, DOI 10.1111/j.1600 9657.2012.01125.x
   Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476 5381.2010.01199.x
   Bastos JV, 2017, J ENDODONT, V43, P203, DOI 10.1016/j.joen.2016.10.018
   Bouvard B, 2013, JOINT BONE SPINE, V80, P77, DOI 10.1016/j.jbspin.2012.01.009
   Calapai G, 2014, PHARMACOLOGY, V94, P60, DOI 10.1159/000366164
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Hamann A, 2019, BIOTECHNOL BIOENG, V116, P427, DOI 10.1002/bit.26870
   He D, 2015, J DENT RES, V94, P129, DOI 10.1177/0022034514553817
   Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106
   Iglesias Linares A, 2017, J DENT RES, V96, P145, DOI 10.1177/0022034516677539
   Kang JH, 2018, MOL MED REP, V18, P2387, DOI 10.3892/mmr.2018.9179
   Kimata M, 2000, CLIN EXP ALLERGY, V30, P501, DOI 10.1046/j.1365 2222.2000.00768.x
   Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738
   Li YN, 2018, KAOHSIUNG J MED SCI, V34, P207, DOI 10.1016/j.kjms.2018.01.007
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Mori GG, 2013, DENT TRAUMATOL, V29, P34, DOI 10.1111/j.1600 9657.2012.01131.x
   Mori GG, 2010, DENT TRAUMATOL, V26, P80, DOI 10.1111/j.1600 9657.2009.00856.x
   Moura AP, 2014, BONE, V69, P133, DOI 10.1016/j.bone.2014.09.019
   Najeeb S, 2017, DENT TRAUMATOL, V33, P77, DOI 10.1111/edt.12316
   Napimoga MH, 2013, J NAT PROD, V76, P2316, DOI 10.1021/np400691n
   National Centre for the Replacement Refinement & Reduction of Animals in Research, ARRIVE GUID
   Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034
   Panzarini SR, 2013, DENT TRAUMATOL, V29, P15, DOI 10.1111/j.1600 9657.2012.01127.x
   Peters Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Roskamp L, 2017, J ENDODONT, V43, P25, DOI 10.1016/j.joen.2016.09.020
   Roskamp L, 2011, J ENDODONT, V37, P463, DOI 10.1016/j.joen.2010.12.013
   Roskamp L, 2010, J TRAUMA, V69, pE79, DOI 10.1097/TA.0b013e3181ec112b
   Roskamp L, 2009, J PERIODONTOL, V80, P1121, DOI 10.1902/jop.2009.090019
   Rumpler M, 2013, CALCIFIED TISSUE INT, V93, P526, DOI 10.1007/s00223 013 9786 7
   Segeletz S, 2016, PROTEOMICS, V16, P2545, DOI 10.1002/pmic.201500519
   Teitelbaum SL, 2015, CLIN EXP RHEUMATOL, V33, pS37
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Sousa LHT, 2017, ARCH ORAL BIOL, V77, P55, DOI 10.1016/j.archoralbio.2017.01.014
   Tsuji M, 2009, J BONE MINER METAB, V27, P673, DOI 10.1007/s00774 009 0088 0
   Wang W, 2013, CHEST, V143, P146, DOI 10.1378/chest.12 0681
   Wang YY, 2018, J CELL BIOCHEM, V119, P2298, DOI 10.1002/jcb.26392
   Wang Z, 2011, ORAL DIS, V17, P129, DOI 10.1111/j.1601 0825.2010.01718.x
   Weng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033805
   ZHENG C, 2018, ARTIF CELL NANOMED B, V5, P1
NR 42
TC 1
Z9 1
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1600 4469
EI 1600 9657
J9 DENT TRAUMATOL
JI Dent. Traumatol.
PD JUN
PY 2020
VL 36
IS 3
BP 264
EP 271
DI 10.1111/edt.12535
EA JAN 2020
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA LP3KI
UT WOS:000504967200001
PM 31845526
DA 2025 08 17
ER

PT J
AU Phillippi, JA
   Miller, E
   Weiss, L
   Huard, J
   Waggoner, A
   Campbell, P
AF Phillippi, Julie A.
   Miller, Eric
   Weiss, Lee
   Huard, Johnny
   Waggoner, Alan
   Campbell, Phil
TI Microenvironments engineered by inkjet bioprinting spatially direct
   adult stem cells toward muscle  and bone like subpopulations
SO STEM CELLS
LA English
DT Article
DE inkjet printing; bone morphogenetic protein 2; muscle; bone; spatial
   patterning
ID EXTRACELLULAR MATRIX; GROWTH FACTOR; MORPHOGENETIC PROTEIN 2;
   GENE EXPRESSION; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; SOFT
   LITHOGRAPHY; C2C12 MYOBLASTS; IN VITRO; NOGGIN
AB In vivo, growth factors exist both as soluble and as solid phase molecules, immobilized to cell surfaces and within the extracellular matrix. We used this rationale to develop more biologically relevant approaches to study stem cell behaviors. We engineered stem cell microenvironments using inkjet bioprinting technology to create spatially defined patterns of immobilized growth factors. Using this approach, we engineered cell fate toward the osteogenic lineage in register to printed patterns of bone morphogenetic protein (BMP) 2 contained within a population of primary muscle derived stem cells (MDSCs) isolated from adult mice. This patterning approach was conducive to patterning the MDSCs into subpopulations of osteogenic or myogenic cells simultaneously on the same chip. When cells were cultured under myogenic conditions on BMP 2 patterns, cells on pattern differentiated toward the osteogenic lineage, whereas cells off pattern differentiated toward the myogenic lineage. Time lapse microscopy was used to visualize the formation of multinucleated myotubes, and immunocytochemistry was used to demonstrate expression of myosin heavy chain (fast) in cells off BMP 2 pattern. This work provides proof of concept for engineering spatially controlled multilineage differentiation of stem cells using patterns of immobilized growth factors. This approach may be useful for understanding cell behaviors to immobilized biological patterns and could have potential applications for regenerative medicine.
C1 [Campbell, Phil] Carnegie Mellon Univ, Inst Complex Engn Syst, Pittsburgh, PA 15209 USA.
   [Phillippi, Julie A.; Waggoner, Alan] Mol Biosensor & Imaging Ctr, Pittsburgh, PA USA.
   [Phillippi, Julie A.; Huard, Johnny] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA.
   [Miller, Eric] Carnegie Mellon Univ, Dept Biomed Engn, Pittsburgh, PA 15209 USA.
   [Weiss, Lee] Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15209 USA.
C3 Carnegie Mellon University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Carnegie Mellon University;
   Carnegie Mellon University
RP Campbell, P (通讯作者)，Carnegie Mellon Univ, Inst Complex Engn Syst, 5000 Forbes Ave,1213 Hamburg Hall, Pittsburgh, PA 15209 USA.
EM pcampbel@cs.cmu.edu
RI ; Phillippi, Julie/AAW 3205 2021
OI Miller, Eric/0000 0002 4931 3521; 
FU NCRR NIH HHS [1 U54 RR022241 01] Funding Source: Medline; NIBIB NIH HHS
   [EB004343] Funding Source: Medline; NIDCR NIH HHS [DE13420] Funding
   Source: Medline; PHS HHS [1C76 HF 00381 01] Funding Source: Medline
CR Akeson AL, 2003, DEV BIOL, V264, P443, DOI 10.1016/j.ydbio.2003.09.004
   Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805
   Campbell PG, 2005, BIOMATERIALS, V26, P6762, DOI 10.1016/j.biomaterials.2005.04.032
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   Chen GP, 2001, BIOMATERIALS, V22, P2453, DOI 10.1016/S0142 9612(00)00432 4
   Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955 0674(91)90049 5
   Damsky CH, 1997, KIDNEY INT, V51, P1427, DOI 10.1038/ki.1997.195
   Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756 3282(99)00106 4
   Deasy BM, 2004, CURR OPIN BIOTECH, V15, P419, DOI 10.1016/j.copbio.2004.08.004
   Deasy BM, 2005, MOL BIOL CELL, V16, P3323, DOI 10.1091/mbc.E05 02 0169
   Delamarche E, 2002, J AM CHEM SOC, V124, P3834, DOI 10.1021/ja017854j
   Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632 200208151 00004
   Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08
   Falconnet D, 2004, NANO LETT, V4, P1909, DOI 10.1021/nl0489438
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500
   Hannallah D, 2004, J BONE JOINT SURG AM, V86A, P80, DOI 10.2106/00004623 200401000 00013
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Ito Y, 1998, BIOCONJUGATE CHEM, V9, P277, DOI 10.1021/bc970190b
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   JADLOWIEC J, 2005, ENDOCRINOLOGY, V26
   Jadlowiec JA, 2006, J BIOL CHEM, V281, P5341, DOI 10.1074/jbc.M506158200
   Kaji K, 2004, REPRODUCTION, V127, P423, DOI 10.1530/rep.1.00163
   Kalajzic I, 2003, J CELL BIOCHEM, V88, P1168, DOI 10.1002/jcb.10459
   Kane RS, 1999, BIOMATERIALS, V20, P2363, DOI 10.1016/S0142 9612(99)00165 9
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kawasaki K, 1998, BONE, V23, P223, DOI 10.1016/S8756 3282(98)00105 7
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Lee JY, 2001, J BONE JOINT SURG AM, V83A, P1032, DOI 10.2106/00004623 200107000 00008
   Miller ED, 2006, BIOMATERIALS, V27, P2213, DOI 10.1016/j.biomaterials.2005.10.021
   MILLER ER, 2007, IN PRESS COMBINATORI
   Mrksich M, 1996, ANNU REV BIOPH BIOM, V25, P55, DOI 10.1146/annurev.bb.25.060196.000415
   MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Paine Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200
   Patel N, 2000, J BIOMAT SCI POLYM E, V11, P319, DOI 10.1163/156856200743724
   Peng HR, 2005, MOL THER, V12, P239, DOI 10.1016/j.ymthe.2005.02.027
   Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603
   Qu Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150
   Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699 0463.1999.tb01529.x
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432 1033.1996.0295n.x
   Sahni A, 1999, J BIOL CHEM, V274, P14936, DOI 10.1074/jbc.274.21.14936
   Sahni A, 2003, J THROMB HAEMOST, V1, P1304, DOI 10.1046/j.1538 7836.2003.00250.x
   Schmoekel HG, 2005, BIOTECHNOL BIOENG, V89, P253, DOI 10.1002/bit.20168
   Sieron AL, 2002, CYTOKINE, V18, P214, DOI 10.1006/cyto.2002.1035
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Soen Y, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100076
   Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960 9822(00)00378 X
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   Tickle C, 1999, SEMIN CELL DEV BIOL, V10, P345, DOI 10.1006/scdb.1999.0294
   Watanabe K, 2003, ZOOL SCI, V20, P429, DOI 10.2108/zsj.20.429
   Weiss LE, 2005, COMPUT AIDED DESIGN, V37, P1127, DOI 10.1016/j.cad.2005.02.004
   Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335
   Wiemann M, 2002, J BIOMED MATER RES, V62, P119, DOI 10.1002/jbm.10251
   Wolpert L, 1996, TRENDS GENET, V12, P359, DOI 10.1016/S0168 9525(96)80019 9
   Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Xu JT, 2004, BIOMED MICRODEVICES, V6, P117, DOI 10.1023/B:BMMD.0000031748.13353.10
   Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744
   Zaugg FG, 2003, MRS BULL, V28, P837, DOI 10.1557/mrs2003.233
   Zhang SG, 1999, BIOMATERIALS, V20, P1213, DOI 10.1016/S0142 9612(99)00014 9
   Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018
   Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069
NR 68
TC 267
Z9 324
U1 3
U2 99
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PY 2008
VL 26
IS 1
BP 127
EP 134
DI 10.1634/stemcells.2007 0520
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 250LV
UT WOS:000252302500015
PM 17901398
OA Bronze
DA 2025 08 17
ER

PT J
AU Terpos, E
   Christoulas, D
   Katodritou, E
   Bratengeier, C
   Gkotzamanidou, M
   Michalis, E
   Delimpasi, S
   Pouli, A
   Meletis, J
   Kastritis, E
   Zervas, K
   Dimopoulos, MA
AF Terpos, Evangelos
   Christoulas, Dimitrios
   Katodritou, Eirini
   Bratengeier, Cornelia
   Gkotzamanidou, Maria
   Michalis, Eurydiki
   Delimpasi, Sosana
   Pouli, Anastasia
   Meletis, John
   Kastritis, Efstathios
   Zervas, Konstantinos
   Dimopoulos, Meletios A.
TI Elevated circulating sclerostin correlates with advanced disease
   features and abnormal bone remodeling in symptomatic myeloma: Reduction
   post bortezomib monotherapy
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE multiple myeloma; sclerostin; osteoblast; osteocyte; dickkopf 1; bone
   disease; bortezomib
ID RELAPSED MULTIPLE MYELOMA; RECEPTOR ACTIVATOR; DICKKOPF 1
AB Sclerostin is a Wingless and Int 1 inhibitor, which is produced by osteocytes and inhibits osteoblast driven bone formation. Sclerostin is implicated in the pathogenesis of bone loss in metabolic bone disorders but there is no information for its effect on multiple myeloma (MM) related osteolytic disease. We evaluated circulating sclerostin in 157 newly diagnosed patients with symptomatic myeloma, in 25 with relapsed myeloma who received bortezomib monotherapy, in 21 patients with monoclonal gammopathy of undetermined significance (MGUS), and in 21 healthy controls. Patients with active myeloma had elevated circulating sclerostin compared to MGUS patients and controls (p < 0.01). MM patients who presented with fractures at diagnosis (n = 34) had very high levels of circulating sclerostin compared with all others (p < 0.01), whereas sclerostin correlated negatively with bone specific alkaline phosphatase (a bone formation marker; r =  0.541, p < 0.0001) and positively with C telopeptide of collagen type 1 (a bone resorption marker; r = 0.524, p < 0.0001). Patients with International Staging System (ISS) 3 disease had higher circulating sclerostin compared to ISS 1 and ISS 2 MM (p = 0.001). Furthermore, patients with high sclerostin (upper quartile, n = 40) had a median survival of 27 months versus 98 months of all others (p = 0.031). Relapsed MM patients had higher levels of circulating sclerostin even compared to newly diagnosed patients (p < 0.01). Bortezomib monotherapy resulted in a reduction of sclerostin by almost 50% in both responders and non responders. These results suggest that patients with active myeloma have elevated circulating sclerostin, which correlated with advanced disease features including severe bone disease. Our study indicates sclerostin as a possible target for the development of novel therapies to enhance osteoblast function in myeloma.
C1 [Bratengeier, Cornelia] Biomarker Design Forsch GmbH, Vienna, Austria.
RP Terpos, E (通讯作者)，Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece.
EM eterpos@med.uoa.gr
RI Dimopoulos, Meletios/AAD 4130 2019; Kastritis, Efstathios/AAD 3656 2019;
   Terpos, Evangelos/AAD 3667 2019
OI Bratengeier, Cornelia/0000 0001 9302 0710; KATODRITOU,
   EIRINI/0000 0001 9404 807X; Kastritis, Efstathios/0000 0001 8191 5832;
   Terpos, Evangelos/0000 0001 5133 1422; Dimopoulos,
   Meletios/0000 0001 8990 3254; 
CR Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810
   Christoulas D, 2009, EXPERT REV HEMATOL, V2, P385, DOI 10.1586/ehm.09.36
   Colucci S, 2010, BLOOD, V116, P1221
   D'Amelio P, 2011, OSTEOPOROSIS INT, V22, P2869, DOI 10.1007/s00198 010 1496 7
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Giuliani N, 2010, BLOOD, V116, P62
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Politou M, 2004, BRIT J HAEMATOL, V126, P686, DOI 10.1111/j.1365 2141.2004.05092.x
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Polyzos SA, OSTEOPOROS IN PRESS
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Terpos E, 2010, ANN ONCOL, V21, P1561, DOI 10.1093/annonc/mdq259
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van Oers RFM, 2011, BIOMECH MODEL MECHAN, V10, P663, DOI 10.1007/s10237 010 0264 0
   Voskaridou E, 2010, BLOOD, V116, P691
NR 20
TC 128
Z9 135
U1 0
U2 2
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 15
PY 2012
VL 131
IS 6
BP 1466
EP 1471
DI 10.1002/ijc.27342
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 978JD
UT WOS:000306735700047
PM 22052418
OA Bronze
DA 2025 08 17
ER

PT J
AU Xiao, MD
   Hong, SY
   Peng, P
   Cai, SY
   Huang, YT
   Liang, J
   Bai, X
   Bao, QY
   Li, W
   Cheng, GL
   Xiong, Y
   Gu, MC
   Mu, CF
AF Xiao, Mengdi
   Hong, Shiyi
   Peng, Pei
   Cai, Siying
   Huang, Yutian
   Liang, Jing
   Bai, Xue
   Bao, Qiying
   Li, Wei
   Cheng, Guilin
   Xiong, Yang
   Gu, Mancang
   Mu, Chaofeng
TI Co delivery of protopanaxatriol/icariin into niche cells restores bone
   marrow niches to rejuvenate HSCs for chemotherapy induced
   myelosuppression
SO PHYTOMEDICINE
LA English
DT Article
DE Protopanaxatriol; Icariin; Niche directed therapies; Niche cell
   targeting; Bone marrow niche restoration; Hematopoietic stem cell
   rejuvenation
ID HEMATOPOIETIC STEM CELLS; DRUG DELIVERY; GINSENOSIDES
AB Background: Up to 80 % of chemotherapeutic drugs induce myelosuppression in patients. Chemotherapy not only impairs of hematopoietic stem cells (HSCs) but also damages bone marrow niches (vascular and endosteal). Current treatments for myelosuppression overlook these chemotherapy induced damages to bone marrow niches and the critical role of niche restoration on hematopoietic regeneration. Ginsenoside protopanaxatriol (PPT) protects vascular endothelium from injury, while icariin (ICA) promotes osteogenic differentiation. The combination of PPT and ICA aims to restore damaged vascular and endosteal niches, thus rejuvenating HSCs for treating myelosuppression. Purpose: This study aims to develop effective, bone marrow niche directed PPT/ICA therapies for treating chemotherapy induced myelosuppression. Methods: 3D cell spheroids were used to investigate the effects of PPT/ICA on cell cell interactions in vascular niches, osteogenesis, and extracellular matrix (ECM) secretion in endosteal niches. In vitro mimic niche models were designed to access the drug combination's efficacy in rejuvenating and mobilizing in HSCs within bone marrow niches. The delivery capability of PPT/ICA to key niche cell types (mesenchymal stromal cells (MSCs), endothelial cells (ECs), and osteoblasts (OBs)) via nanocarriers has been determined. DSS6 peptide modified nanoparticles (DSS6 NPs) were prepared for specific co delivery of PPT/ICA into key niche cell populations in vivo. . Results: PPT can prevent vascular niche injury by restoring vascular EC cell cell adhesion and the intercellular interactions between ECs and MSCs in 5 fluorouracil (5 FU) damaged cell spheroids. ICA repaired 5 FU damaged endosteal niches by promoting osteogenesis and ECM secretion. The combination of PPT and ICA restores key HSC niche factor gene expressions, normalizing HSC differentiation and mobilization. The in vitro cellular uptake efficiency of nanocarriers in a mimic niche is positively correlated with their in vivo delivery into bone marrow niche cells. DSS6 NPs greatly enhance the delivery of PPT/ICA into MSCs and OBs within bone marrow niches. Co loading of PPT/ICA into DSS6 NPs effectively repairs damaged bone marrow niches and promotes HSC rejuvenation in vivo. . Conclusion: The combination of PPT and ICA effectively prevents injury to the vascular and endosteal niches, thereby promoting hematopoietic regeneration in the bone marrow. This study provides novel niche directed PPT/ICA therapies for managing chemotherapy induced myelosuppression.
C1 [Xiao, Mengdi; Hong, Shiyi; Peng, Pei; Cai, Siying; Huang, Yutian; Bai, Xue; Xiong, Yang; Gu, Mancang; Mu, Chaofeng] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Peoples R China.
   [Liang, Jing] Chinese Acad Sci, Shenzhen Inst Synthet Biol, Shenzhen Inst Adv Technol, Ctr Synthet Biochem, Shenzhen 518055, Peoples R China.
   [Bao, Qiying] Hangzhou Fuyang Hosp TCM Orthoped, Pharm Dept, Hangzhou 311400, Peoples R China.
   [Li, Wei; Cheng, Guilin] Zhejiang Chinese Med Univ, Acad Chinese Med Sci, Hangzhou 310053, Peoples R China.
C3 Zhejiang Chinese Medical University; Chinese Academy of Sciences;
   Shenzhen Institute of Advanced Technology, CAS; Zhejiang Chinese Medical
   University
RP Gu, MC; Mu, CF (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Peoples R China.
EM gmancang@zcmu.edu.cn; cmu2005@126.com
OI Qiying, Bao/0009 0001 2268 869X
FU Natural Science Foundation of Zhejiang Province [LY24H280003,
   LZ23H290001, LZ22H290001]; National Natural Science Foundation of China
   [81703713, 82174095, 82274364]; Scientific Research Project of Zhejiang
   Chinese Medical University [2023FSYYZY38]
FX The authors acknowledge financial support from the Natural Science
   Foundation of Zhejiang Province grants (LY24H280003, LZ23H290001,
   LZ22H290001) , National Natural Science Foundation of China (81703713,
   82174095, 82274364) , and Scientific Research Project of Zhejiang
   Chinese Medical University (2023FSYYZY38) . We appreciate the technical
   support from the Public Platform of Medical Research Center, Academy of
   Chinese Medical Science, Zhejiang Chinese Medical University.
CR Baccin C, 2020, NAT CELL BIOL, V22, P38, DOI 10.1038/s41556 019 0439 6
   Batsivari A, 2020, NAT CELL BIOL, V22, P7, DOI 10.1038/s41556 019 0444 9
   Biechonski S, 2017, CARCINOGENESIS, V38, P367, DOI 10.1093/carcin/bgx002
   Braham MVJ, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801444
   Chen Q, 2019, CELL STEM CELL, V25, P768, DOI 10.1016/j.stem.2019.10.006
   Christodoulou C, 2020, NATURE, V578, P278, DOI 10.1038/s41586 020 1971 z
   Clapes T, 2021, NAT CELL BIOL, V23, P704, DOI 10.1038/s41556 021 00707 9
   Comazzetto S, 2021, DEV CELL, V56, P1848, DOI 10.1016/j.devcel.2021.05.018
   Cordeiro Spinetti E, 2015, J CELL BIOCHEM, V116, P6, DOI 10.1002/jcb.24952
   Fan LH, 2020, INT J PHARMACEUT, V579, DOI 10.1016/j.ijpharm.2020.119179
   Frisch BJ, 2019, BONE, V119, P8, DOI 10.1016/j.bone.2018.05.017
   Gencheva M, 2013, EUR J HAEMATOL, V90, P469, DOI 10.1111/ejh.12109
   Guo PP, 2017, J CLIN INVEST, V127, P4242, DOI 10.1172/JCI92309
   Hassanshahi M, 2019, CRIT REV ONCOL HEMAT, V137, P43, DOI 10.1016/j.critrevonc.2019.01.024
   He SH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3986
   Herault A, 2017, NATURE, V544, P53, DOI 10.1038/nature21693
   Himburg HA, 2018, CELL STEM CELL, V23, P370, DOI 10.1016/j.stem.2018.07.003
   Himburg HA, 2017, NAT MED, V23, P91, DOI 10.1038/nm.4251
   Hofmann J., 2024, Blood
   Hu ZY, 2013, DRUG METAB DISPOS, V41, P1457, DOI 10.1124/dmd.113.051391
   Khan AO, 2023, CANCER DISCOV, V13, P364, DOI 10.1158/2159 8290.CD 22 0199
   Kokkaliaris KD, 2020, BLOOD, V136, P2296, DOI 10.1182/blood.2020006574
   Laurenti E, 2018, NATURE, V553, P418, DOI 10.1038/nature25022
   Liu C, 2022, ACTA PHARM SIN B, V12, P364, DOI 10.1016/j.apsb.2021.06.012
   Luan X, 2016, BIOMATERIALS, V95, P60, DOI 10.1016/j.biomaterials.2016.04.008
   Lyman GH, 2013, ANN ONCOL, V24, P2475, DOI 10.1093/annonc/mdt226
   Méndez Ferrer S, 2020, NAT REV CANCER, V20, P285, DOI 10.1038/s41568 020 0245 2
   Mu CF, 2018, BIOMATERIALS, V155, P191, DOI 10.1016/j.biomaterials.2017.11.029
   Nakamura Ishizu A, 2019, CELL STEM CELL, V24, P355, DOI 10.1016/j.stem.2019.02.007
   Olson TS, 2013, BLOOD, V121, P5238, DOI 10.1182/blood 2012 10 463414
   Owen Woods C, 2022, SEMIN CELL DEV BIOL, V123, P36, DOI 10.1016/j.semcdb.2021.06.025
   Peci F, 2022, BONE MARROW TRANSPL, V57, P1357, DOI 10.1038/s41409 022 01728 0
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   Reagan MR, 2016, NAT REV RHEUMATOL, V12, P154, DOI 10.1038/nrrheum.2015.160
   Sacma M, 2019, NAT CELL BIOL, V21, P1309, DOI 10.1038/s41556 019 0418 y
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Tan AR, 2022, CLIN CANCER RES, V28, P629, DOI 10.1158/1078 0432.CCR 21 2272
   Taylor SJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam8060
   Termini CM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27263 y
   Wang QS, 2016, INT J PHARMACEUT, V515, P176, DOI 10.1016/j.ijpharm.2016.10.002
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Yan R, 2022, ACS NANO, V16, P8399, DOI 10.1021/acsnano.2c02900
   Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang XY, 2023, CELL STEM CELL, V30, P378, DOI 10.1016/j.stem.2023.03.005
   Zhao M, 2019, CELL REP, V26, P652, DOI 10.1016/j.celrep.2018.12.093
   Zhu GX, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105647
NR 47
TC 3
Z9 3
U1 2
U2 19
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD NOV
PY 2024
VL 134
AR 155978
DI 10.1016/j.phymed.2024.155978
EA AUG 2024
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA E3B3I
UT WOS:001301781000001
PM 39186857
DA 2025 08 17
ER

PT J
AU Huang, JM
   Ye, ZY
   Wang, J
   Chen, QC
   Huang, DL
   Liu, HY
AF Huang, Jianming
   Ye, Zhiyang
   Wang, Jun
   Chen, Qichuan
   Huang, Danlei
   Liu, Haoyuan
TI USP13 mediates PTEN to ameliorate osteoarthritis by restraining
   oxidative stress, apoptosis and inflammation via AKT dependent manner
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoarthritis; USP13; PTEN; AKT
ID FIBROBLAST LIKE SYNOVIOCYTES; COLLAGEN INDUCED ARTHRITIS;
   RHEUMATOID ARTHRITIS; PATHWAY
AB Osteoarthritis is a chronic, systemic and inflammatory disease. However, the pathogenesis and understanding of RA are still limited. Ubiquitin specific protease 13 (USP13) belongs to the deubiquitinating enzyme (DUB) superfamily, and has been implicated in various cellular events. Nevertheless, its potential on RA progression has little to be investigated. In the present study, we found that USP13 expression was markedly up regulated in synovial tissue samples from patients with RA, and was down regulated in human fibroblast like synoviocytes (H FLSs) stimulated by interleukin 1 beta (IL 1 beta), tumor necrosis factor alpha (TNF alpha) or lipopolysaccharide (LPS). We then showed that over expressing USP13 markedly suppressed inflammatory response, oxidative stress and apoptosis in H FLSs upon IL 1 beta or TNF alpha challenge, whereas USP13 knockdown exhibited detrimental effects. In addition, USP13 induced protective effects were associated with the improvement of nuclear factor erythroid 2 related factor 2 (Nrf 2) and the repression of Casapse 3. Furthermore, phosphatase and tensin homolog (PTEN) expression was greatly improved by USP13 in H FLSs upon IL 1 beta or TNF alpha treatment, whereas phosphorylated AKT expression was diminished. In response to IL 1 beta or TNF alpha exposure, nuclear transcription factor kappa B (NF kappa B) signaling pathway was activated, whereas being significantly restrained in H FLSs over expressing USP13. Mechanistically, USP13 directly interacted with PTEN. Of note, we found that USP13 regulated cellular processes including inflammation, oxidative stress and apoptotic cell death were partly dependent on AKT activation. Furthermore, USP13 over expression effectively inhibited osteoclastogenesis and osteoclast associated gene expression. The in vivo experiments finally confirmed that USP13 dramatically repressed synovial hyperplasia, inflammatory cell infiltration, cartilage damage and bone loss in collagen induced arthritis (CIA) mice via the same molecular mechanisms detected in vitro. Taken together, these findings suggested that targeting USP13 may provide feasible therapies for RA.
C1 [Huang, Jianming; Ye, Zhiyang; Wang, Jun; Chen, Qichuan; Huang, Danlei; Liu, Haoyuan] Xiamen Univ, Dept Orthoped, Chenggong Hosp, 73th Grp Mil Hosp Peoples Liberat Army, Xiamen 361003, Peoples R China.
C3 Xiamen University
RP Huang, JM; Liu, HY (通讯作者)，Xiamen Univ, Dept Orthoped, Chenggong Hosp, 73th Grp Mil Hosp Peoples Liberat Army, Xiamen 361003, Peoples R China.
EM 8303260@qq.com; liuhaoyuan@medmail.com.cn
RI 刘, 浩源/KGM 0002 2024
FU Xiamen Superior Sub specialty construction project of Arthroscopic
   minimally invasive Orthopedics Department [2018296]; Xiamen Key
   Specialty construction project of Traumatic Orthopedics Department
   [2015347]
FX This work was supported by (1) Xiamen Superior Sub specialty
   construction project of Arthroscopic minimally invasive Orthopedics
   Department (2018296) and (2) Xiamen Key Specialty construction project
   of Traumatic Orthopedics Department (2015347). Thanks to Ms. Lydia for
   her care and help in my work and life.
CR Ahn B, 2018, REDOX BIOL, V17, P47, DOI 10.1016/j.redox.2018.04.004
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Bitar MS, 2010, LIFE SCI, V86, P844, DOI 10.1016/j.lfs.2010.03.019
   Biterge S.B., 2020, LIFE SCI, V258
   Boosani CS, 2019, EXPERT OPIN THER PAT, V29, P881, DOI 10.1080/13543776.2019.1669562
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Britsemmer K, 2011, ANN RHEUM DIS, V70, P1468, DOI 10.1136/ard.2010.148619
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Choi ST, 2009, CLIN RHEUMATOL, V28, P333, DOI 10.1007/s10067 008 1075 x
   Geng J, 2015, RESP RES, V16, DOI 10.1186/s12931 015 0286 3
   Haizhen Z., 2019, J HUNAN U NATURAL SC, V46, P12
   Han DD, 2017, ONCOTARGET, V8, P14680, DOI 10.18632/oncotarget.14747
   Higuchi M, 2016, STEM CELL REP, V7, P1116, DOI 10.1016/j.stemcr.2016.11.003
   Huang TC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040471
   Ijuin T, 2019, SEMIN CANCER BIOL, V59, P50, DOI 10.1016/j.semcancer.2019.03.003
   Ji YX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11267
   Julien O, 2017, CELL DEATH DIFFER, V24, P1380, DOI 10.1038/cdd.2017.44
   Karami J, 2020, IMMUNOL CELL BIOL, V98, P171, DOI 10.1111/imcb.12311
   Khalilzadeh B, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604 018 2980 6
   Li L, 2019, EBIOMEDICINE, V45, P553, DOI 10.1016/j.ebiom.2019.06.011
   Li S, 2017, AM J TRANSL RES, V9, P2065
   Li X, 2020, INFLAMMATION, V43, P1729, DOI 10.1007/s10753 020 01246 5
   Li XF, 2019, ARTIF CELL NANOMED B, V47, P3687, DOI 10.1080/21691401.2019.1661849
   Li Xiao Feng, 2019, Cell Physiol Biochem, V52, P1446, DOI 10.33594/000000101
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Man XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1262 4
   Manganelli V, 2018, RHEUMATOLOGY, V57, P2032, DOI 10.1093/rheumatology/key174
   Mansuri ML, 2014, GENES NUTR, V9, DOI 10.1007/s12263 014 0400 z
   Melagraki G, 2018, CURR TOP MED CHEM, V18, P661, DOI 10.2174/1568026618666180607084430
   Messemaker TC, 2015, J AUTOIMMUN, V64, P74, DOI 10.1016/j.jaut.2015.07.007
   Muschter D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139726
   Myasoedova E, 2020, ANN RHEUM DIS, V79, P440, DOI 10.1136/annrheumdis 2019 216694
   Ni S, 2019, J CELL PHYSIOL, V234, P454, DOI 10.1002/jcp.26580
   Ogawa M, 2013, BRIT J NUTR, V109, P1349, DOI 10.1017/S0007114512003297
   Qu Z, 2019, CANCER MANAG RES, V11, P9175, DOI 10.2147/CMAR.S186829
   Rubbert Roth A, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102398
   Ryu JH, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001881
   Sarzi Puttini P, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102409
   Simmonds RE, 2008, RHEUMATOLOGY, V47, P584, DOI 10.1093/rheumatology/kem298
   Stagakis I, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3874
   Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534
   Tu JJ, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/1583647
   Wang CR, 2008, ARTHRITIS RHEUM US, V58, P1650, DOI 10.1002/art.23517
   Wei YL, 2018, CELL PHYSIOL BIOCHEM, V51, P2309, DOI 10.1159/000495874
   Weyand CM, 2020, IMMUNOL REV, V294, P177, DOI 10.1111/imr.12838
   Wu WJ, 2016, REDOX BIOL, V10, P157, DOI 10.1016/j.redox.2016.08.011
   Xiang SJ, 2015, ONCOL REP, V33, P1342, DOI 10.3892/or.2014.3694
   Yamakawa T, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115494
   Yang L, 2019, CANCER METAST REV, V38, P179, DOI 10.1007/s10555 019 09785 6
   Yang XZ, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12854
   Yu JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152236
   Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874
   Zhang XY, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3214196
   Zhang Y, 2019, ANN NY ACAD SCI, V1457, P166, DOI 10.1111/nyas.14196
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0648 1
   Zhao YP, 2015, ANN RHEUM DIS, V74, P2244, DOI 10.1136/annrheumdis 2014 205779
NR 56
TC 36
Z9 38
U1 0
U2 22
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2021
VL 133
AR 111089
DI 10.1016/j.biopha.2020.111089
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA PN6VC
UT WOS:000604613600005
PM 33378983
OA gold
DA 2025 08 17
ER

PT J
AU Oki, Y
   Ono, H
   Motohashi, T
   Sugiura, N
   Nobusue, H
   Kano, K
AF Oki, Yoshinao
   Ono, Hiromasa
   Motohashi, Takeharu
   Sugiura, Nobuki
   Nobusue, Hiroyuki
   Kano, Koichiro
TI Dedifferentiated follicular granulosa cells derived from pig ovary can
   transdifferentiate into osteoblasts
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE dedifferentiated fat cell (DFAT cell); dedifferentiated follicular
   granulosa (DFOG); differentiation; osteoblast; ovary;
   transdifferentiation
ID IN VITRO; FAT CELLS; LENS REGENERATION; AROMATASE ACTIVITY;
   BONE FORMATION; DIFFERENTIATION; EXPRESSION; SCAFFOLDS; VIVO;
   OSTEOGENESIS
AB Transdifferentiation is the conversion of cells from one differentiated cell type into another. How functionally differentiated cells already committed to a specific cell lineage can transdifferentiate into other cell types is a key question in cell biology and regenerative medicine. In the present study we show that porcine ovarian follicular GCs (granulosa cells) can transdifferentiate into osteoblasts in vitro and in vivo. Pure GCs isolated and cultured in Dulbecco's modified Eagle's medium supplemented with 20% FBS (fetal bovine serum) proliferated and dedifferentiated into fibroblast like cells. We referred to these cells as DFOG (dedifferentiated follicular granulosa) cells. Microarray analysis showed that DFOG cells lost expression of GC specific marker genes, but gained the expression of osteogenic marker genes during dedifferentiation. After osteogenic induction, DFOG cells underwent terminal osteoblast differentiation and matrix mineralization in vitro. Furthermore, when DFOG cells were transplanted subcutaneously into SCID mice, these cells formed ectopic osteoid tissue. These results indicate that DFOG cells derived from GCs can differentiate into osteoblasts in vitro and in vivo. We suggest that GCs provide a useful model for studying the mechanisms of transdifferentiation into other cell lineages in functionally differentiated cells.
C1 [Oki, Yoshinao; Ono, Hiromasa; Motohashi, Takeharu; Sugiura, Nobuki; Nobusue, Hiroyuki; Kano, Koichiro] Nihon Univ, Lab Cell & Tissue Biol, Coll Bioresource Sci, Fujisawa, Kanagawa 2520880, Japan.
C3 Nihon University
RP Kano, K (通讯作者)，Nihon Univ, Lab Cell & Tissue Biol, Coll Bioresource Sci, 1866 Kameino, Fujisawa, Kanagawa 2520880, Japan.
EM kkano@brs.nihon u.ac.jp
RI ; Nobusue, Hiroyuki/J 6047 2013; Ono, Hiromasa/ABA 1412 2021
OI Nobusue, Hiroyuki/0000 0003 1341 0298; Ono,
   Hiromasa/0000 0001 8675 963X; Kano, Koichiro/0000 0001 6190 0780; 
FU Okinawa Research and Industrialization Project for the Forefront Medical
   Care; Ministry of Education, Science, Sports, and Culture of Japan
   [22580340]; Grants in Aid for Scientific Research [22580340] Funding
   Source: KAKEN
FX This work was supported by Okinawa Research and Industrialization
   Project for the Forefront Medical Care. K.K. was also supported by the
   Ministry of Education, Science, Sports, and Culture of Japan [grant
   number 22580340].
CR Araki M, 2007, DEV GROWTH DIFFER, V49, P109, DOI 10.1111/j.1440 169x.2007.00911.x
   BARUA R, 1982, AUST NZ J OBSTET GYN, V22, P183, DOI 10.1111/j.1479 828X.1982.tb01440.x
   Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881
   Carr BR, 1998, CONTRACEPTION, V58, p23S, DOI 10.1016/S0010 7824(98)00079 1
   CHAN WK, 1986, J ENDOCRINOL, V108, P335, DOI 10.1677/joe.0.1080335
   Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28
   FUJIWARA H, 1995, BIOL REPROD, V53, P407, DOI 10.1095/biolreprod53.2.407
   GARZO VG, 1984, AM J OBSTET GYNECOL, V148, P657, DOI 10.1016/0002 9378(84)90769 5
   GERBIE AB, 1958, OBSTET GYNECOL, V11, P573
   Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121
   Grogg MW, 2006, SEMIN CELL DEV BIOL, V17, P753, DOI 10.1016/j.semcdb.2006.10.001
   Henry JJ, 2003, INT REV CYTOL, V228, P195, DOI 10.1016/S0074 7696(03)28005 0
   Kazama T, 2008, BIOCHEM BIOPH RES CO, V377, P780, DOI 10.1016/j.bbrc.2008.10.046
   Kossowska Tomaszczuk K, 2009, STEM CELLS, V27, P210, DOI 10.1634/stemcells.2008 0233
   Lee YM, 2000, J PERIODONTOL, V71, P410, DOI 10.1902/jop.2000.71.3.410
   Li WC, 2005, MECH DEVELOP, V122, P835, DOI 10.1016/j.mod.2005.01.001
   LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501
   MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304
   Mauney JR, 2005, BIOMATERIALS, V26, P3173, DOI 10.1016/j.biomaterials.2004.08.020
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Niswender GD, 2000, PHYSIOL REV, V80, P1, DOI 10.1152/physrev.2000.80.1.1
   Nye HLD, 2003, DEV DYNAM, V226, P280, DOI 10.1002/dvdy.10236
   Ohta Y, 2008, CELL TRANSPLANT, V17, P877, DOI 10.3727/096368908786576516
   Okada T.S., 1991, TRANSDIFFERENTIATION
   Oki Y, 2008, CELL STRUCT FUNCT, V33, P211, DOI 10.1247/csf.08038
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315
   Shen CN, 2003, MECH DEVELOP, V120, P107, DOI 10.1016/S0925 4773(02)00337 4
   Shipton E. A., 1965, AUST NZ J OBSTET GYN, V90, P100
   Sun HC, 2007, BIOMED ENG ONLINE, V6, DOI 10.1186/1475 925X 6 41
   Tsonis PA, 2004, INT J DEV BIOL, V48, P975, DOI 10.1387/ijdb.041867pt
   TURKSEN K, 1991, J CELL BIOL, V114, P373, DOI 10.1083/jcb.114.2.373
   Uemura T, 2003, BIOMATERIALS, V24, P2277, DOI 10.1016/S0142 9612(03)00039 5
   WEAKLEY BS, 1966, J ANAT, V100, P503
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Zahn CM, 2001, MIL MED, V166, P915, DOI 10.1093/milmed/166.10.915
NR 37
TC 25
Z9 29
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264 6021
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 2012
VL 447
BP 239
EP 248
DI 10.1042/BJ20120172
PN 2
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 024HQ
UT WOS:000310100700006
PM 22839299
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Tabti, R
   Lamoureux, F
   Charrier, C
   Ory, B
   Heymann, D
   Bentouhami, E
   Désaubry, L
AF Tabti, Redouane
   Lamoureux, Francois
   Charrier, Celine
   Ory, Benjamin
   Heymann, Dominique
   Bentouhami, Embarek
   Desaubry, Laurent
TI Development of prohibitin ligands against osteoporosis
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Osteoclastogenesis; Prohibitins; SAR; Osteoporosis; STAT3
ID ONE POT SYNTHESIS; FLAVAGLINES; APOPTOSIS; EFFICIENT; CELLS; COLITIS
AB Current therapeutic approaches to osteoporosis display some potential adverse effects and a limited efficacy on non vertebral fracture reduction. Some sulfonylamidines targeting the scaffold proteins prohibitins 1 and 2 (PHB1/2) have been showed to inhibit the formation of osteoclasts in charge of bone resorption. Herein, we report the development of a second generation of anti osteoclastic PHB ligands. The most potent compound, IN45, showed 88% inhibition at the low concentration of 5 mu M, indicates that it might serve as a basis for the development of new antiosteoporotic drugs. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Tabti, Redouane; Desaubry, Laurent] INSERM, CRBS, Lab Regenerat Nanomed RNM, U1260, Rue Eugene Boeckel, F 67000 Strasbourg, France.
   [Tabti, Redouane; Bentouhami, Embarek] Univ Ferhat Abbas, Fac Technol, LCIMN Lab, Setif, Algeria.
   [Lamoureux, Francois; Charrier, Celine; Ory, Benjamin] INSERM, UMR 1238, Nantes, France.
   [Heymann, Dominique] Inst Cancerol Ouest, Site Rene Gauducheau,Blvd Prof Jacques Monod, St Herblain, France.
   [Heymann, Dominique] Univ Nantes, Fac Med, Nantes, France.
   [Heymann, Dominique] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Desaubry, Laurent] Tianjin Univ Sci & Technol, Coll Biotechnol, Sino French Joint Lab Food Nutr Safety & Med Chem, Tianjin, Peoples R China.
   [Lamoureux, Francois; Charrier, Celine; Ory, Benjamin] Univ Nantes, Nantes Atlantique Univ, Lab Sarcome Osseux & Remodelage Tissus Osseux Cal, Fac Med, Nantes, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Ferhat Abbas Setif; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UNICANCER; Institut de
   Cancerologie de l'Ouest (ICO); Nantes Universite; University of
   Sheffield; Tianjin University Science & Technology; Nantes Universite
RP Désaubry, L (通讯作者)，INSERM, CRBS, Lab Regenerat Nanomed RNM, U1260, Rue Eugene Boeckel, F 67000 Strasbourg, France.
EM desaubry@unistra.fr
RI Charrier, Céline/K 9198 2015; Heymann, Dominique/AAC 6014 2019; ory,
   benjamin/K 8231 2015; Lamoureux, Francois/K 8021 2015
OI CHARRIER, Celine/0000 0002 4487 5066; Heymann,
   Dominique/0000 0001 7777 0669; Lamoureux, Francois/0000 0002 2738 0758;
   ory, benjamin/0000 0002 2622 7356; 
FU French Ministry for Foreign Affairs; Algerian Ministry for Foreign
   Affairs
FX The authors are grateful to the French and Algerian Ministries for
   Foreign Affairs for a fellowship to Redouane Tabti via the PHC Tassili
   scientific exchange program.
CR Bae I, 2005, J AM CHEM SOC, V127, P2038, DOI 10.1021/ja0432968
   Basmadjian C, 2013, FUTURE MED CHEM, V5, P2185, DOI 10.4155/fmc.13.177
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Chang SY, 2011, BIOORG MED CHEM LETT, V21, P727, DOI 10.1016/j.bmcl.2010.11.123
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Djehal A, 2018, EUR J MED CHEM, V155, P880, DOI 10.1016/j.ejmech.2018.06.052
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Emhemmed F, 2014, BIOCHEM PHARMACOL, V89, P185, DOI 10.1016/j.bcp.2014.02.020
   Fest C., 1989, PHENYL SULPHONYLISOU
   Han J, 2016, INFLAMM BOWEL DIS, V22, P55, DOI 10.1097/MIB.0000000000000592
   Han J, 2014, CELL SIGNAL, V26, P2086, DOI 10.1016/j.cellsig.2014.06.006
   Hausott B, 2004, INT J CANCER, V109, P933, DOI 10.1002/ijc.20033
   Kathiria AS, 2012, CANCER RES, V72, P5778, DOI 10.1158/0008 5472.CAN 12 0603
   Kim MH, 2011, BIOORG MED CHEM LETT, V21, P4263, DOI 10.1016/j.bmcl.2011.05.058
   KING C, 1960, J ORG CHEM, V25, P352, DOI 10.1021/jo01073a010
   Lange JHM, 2011, TETRAHEDRON LETT, V52, P3198, DOI 10.1016/j.tetlet.2011.04.031
   Lee CH, 2015, BIOCHEM BIOPH RES CO, V463, P1028, DOI 10.1016/j.bbrc.2015.06.053
   Lee MY, 2010, BIOORG MED CHEM LETT, V20, P541, DOI 10.1016/j.bmcl.2009.11.104
   MAGNUS P, 1991, J ORG CHEM, V56, P1529, DOI 10.1021/jo00004a035
   Nebigil CG, 2020, EUR J MED CHEM, V203, DOI 10.1016/j.ejmech.2020.112653
   Park JH, 2017, MOL CELLS, V40, P706
   Poole KES, 2006, BMJ BRIT MED J, V333, P1251, DOI 10.1136/bmj.39050.597350.47
   Proksch P, 2005, J IMMUNOL, V174, P7075, DOI 10.4049/jimmunol.174.11.7075
   Qureshi R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141826
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Wintachai P, 2015, MICROBIOL IMMUNOL, V59, P129, DOI 10.1111/1348 0421.12230
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Zhu JY, 2007, INT J CANCER, V121, P1839, DOI 10.1002/ijc.22883
NR 28
TC 6
Z9 6
U1 0
U2 11
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JAN 15
PY 2021
VL 210
AR 112961
DI 10.1016/j.ejmech.2020.112961
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA PO1AR
UT WOS:000604903800014
PM 33129591
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Zhang, HY
   Majdeddin, M
   Gaublomme, D
   Taminiau, B
   Boone, M
   Elewaut, D
   Daube, G
   Josipovic, I
   Zhang, KY
   Michiels, J
AF Zhang, Huaiyong
   Majdeddin, Maryam
   Gaublomme, Djoere
   Taminiau, Bernard
   Boone, Matthieu
   Elewaut, Dirk
   Daube, George
   Josipovic, Ivan
   Zhang, Keying
   Michiels, Joris
TI 25 hydroxycholecalciferol reverses heat induced alterations in bone
   quality in finisher broilers associated with effects on intestinal
   integrity and inflammation
SO JOURNAL OF ANIMAL SCIENCE AND BIOTECHNOLOGY
LA English
DT Article
DE Bone remodeling; HS; Inflammation; Intestinal barrier; Tibial mass
ID HIGH AMBIENT TEMPERATURE; NF KAPPA B; VITAMIN D; GUT MICROBIOTA;
   RECEPTOR ACTIVATOR; STRESS; GROWTH; PERFORMANCE; SUPPLEMENTATION;
   MECHANISMS
AB Background Alterations in ambient temperature have been associated with multiple detrimental effects on broilers such as intestinal barrier disruption and dysbiosis resulting in systemic inflammation. Inflammation and 25 hydroxycholecalciferol (25 OH D 3) have shown to play a negative and positive role, respectively, in the regulation of bone mass. Hence the potential of 25 OH D 3 in alleviating heat induced bone alterations and its mechanisms was studied. Results Heat stress (HS) directly induced a decrease in tibia material properties and bone mass, as demonstrated by lower mineral content, and HS caused a notable increase in intestinal permeability. Treatment with dietary 25 OH D 3 reversed the HS induced bone loss and barrier leak. Broilers suffering from HS exhibited dysbiosis and increased expression of inflammatory cytokines in the ileum and bone marrow, as well as increased osteoclast number and activity. The changes were prevented by dietary 25 OH D 3 administration. Specifically, dietary 25 OH D 3 addition decreased abundance of B  and T cells in blood, and the expression of inflammatory cytokines, especially TNF alpha, in both the ileum and bone marrow, but did not alter the diversity and population or composition of major bacterial phyla. With regard to bone remodeling, dietary 25 OH D 3 supplementation was linked to a decrease in serum C terminal cross linked telopeptide of type I collagen reflecting bone resorption and a concomitant decrement in osteoclast specific marker genes expression (e.g. cathepsin K), whereas it did not apparently change serum bone formation markers during HS. Conclusions These data underscore the damage of HS to intestinal integrity and bone health, as well as that dietary 25 OH D 3 supplementation was identified as a potential therapy for preventing these adverse effects.
C1 [Zhang, Huaiyong; Majdeddin, Maryam; Michiels, Joris] Univ Ghent, Dept Anim Sci & Aquat Ecol, Lab Anim Nutr & Anim Prod Qual, B 9000 Ghent, Belgium.
   [Zhang, Huaiyong; Zhang, Keying] Sichuan Agr Univ, Inst Anim Nutr, Key Lab Anim Dis Resistant Nutr, Minist Educ, Yaan 611130, Sichuan, Peoples R China.
   [Gaublomme, Djoere; Elewaut, Dirk] Univ Ghent, VIB Ctr Inflammat Res, Unit Mol Immunol & Inflammat, B 9000 Ghent, Belgium.
   [Gaublomme, Djoere; Elewaut, Dirk] Ghent Univ Hosp, Dept Rheumatol, B 9000 Ghent, Belgium.
   [Taminiau, Bernard; Daube, George] Univ Liege, Dept Food Sci Microbiol, B 4000 Liege, Belgium.
   [Boone, Matthieu; Josipovic, Ivan] Univ Ghent, Ghent Univ Ctr Xray Tomog UGCT, B 9000 Ghent, Belgium.
   [Boone, Matthieu] Univ Ghent, Dept Phys & Astron, Radiat Phys Res Grp, B 9000 Ghent, Belgium.
C3 Ghent University; Sichuan Agricultural University; Ghent University;
   Flanders Institute for Biotechnology (VIB); Ghent University; Ghent
   University Hospital; University of Liege; Ghent University; Ghent
   University
RP Michiels, J (通讯作者)，Univ Ghent, Dept Anim Sci & Aquat Ecol, Lab Anim Nutr & Anim Prod Qual, B 9000 Ghent, Belgium.
EM joris.michiels@ugent.be
RI zhang, Huaiyong/AAM 3985 2020; Michiels, Joris/JLL 6258 2023; Boone,
   Matthieu/I 2664 2013; Elewaut, Dirk/K 6831 2014; Taminiau,
   Bernard/E 8008 2017; Zhang, Keying/AAG 5912 2020
OI zhang, Huaiyong/0000 0002 1490 8541; Elewaut, Dirk/0000 0002 7468 974X; 
FU China Scholarship Council (CSC) [[2019]110]; Ghent University Special
   Research Fund [BOF.EXP.2017.0007]
FX This work was supported by the China Scholarship Council (CSC,
   [2019]110) The support by DSM Nutritional Products (Basel, Switzerland)
   for the analysis of vitamin D3 and metabolites is well appreciated. The
   Ghent University Special Research Fund is acknowledged for the financial
   support to the UGCT Centre of Expertise (BOF.EXP.2017.0007).
CR Baxter MFA, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00056
   Bianchi ML, 2010, ARCH BIOCHEM BIOPHYS, V503, P54, DOI 10.1016/j.abb.2010.06.026
   Bruno LDG, 2000, BRIT POULTRY SCI, V41, P389, DOI 10.1080/713654955
   Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   Cardoso EF, 2018, TROP ANIM HEALTH PRO, V50, P317, DOI 10.1007/s11250 017 1434 1
   Castro Montoya J, 2012, ANIM FEED SCI TECH, V176, P47, DOI 10.1016/j.anifeedsci.2012.07.007
   Chen YC, 2017, J CLIN ENDOCR METAB, V102, P3635, DOI 10.1210/jc.2017 00513
   Christakos S, 2011, MOL CELL ENDOCRINOL, V347, P25, DOI 10.1016/j.mce.2011.05.038
   D'Amelio P, 2018, CALCIFIED TISSUE INT, V102, P415, DOI 10.1007/s00223 017 0331 y
   Deeb N, 2002, POULTRY SCI, V81, P293, DOI 10.1093/ps/81.3.293
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Dong SQ, 2018, DIGEST DIS SCI, V63, P92, DOI 10.1007/s10620 017 4738 0
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Grotto D, 2007, J PHARMACEUT BIOMED, V43, P619, DOI 10.1016/j.jpba.2006.07.030
   Guo CX, 2014, ENDOCR METAB IMMUNE, V14, P255, DOI 10.2174/1871530314666140709085159
   Guss JD, 2017, J BONE MINER RES, V32, P1343, DOI 10.1002/jbmr.3114
   Hall DM, 2001, AM J PHYSIOL HEART C, V280, pH509, DOI 10.1152/ajpheart.2001.280.2.H509
   Han JC, 2018, POULTRY SCI, V97, P1263, DOI 10.3382/ps/pex423
   Han JC, 2016, ASIAN AUSTRAL J ANIM, V29, P1145, DOI 10.5713/ajas.15.0553
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hernández P, 2004, MEAT SCI, V66, P525, DOI 10.1016/S0309 1740(03)00155 4
   HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174
   Hosseini Vashan SJ, 2016, INT J BIOMETEOROL, V60, P1183, DOI 10.1007/s00484 015 1112 9
   Irwin R, 2016, AM J PHYSIOL REG I, V311, pR1149, DOI 10.1152/ajpregu.00051.2016
   Jain SK, 2013, BIOCHEM BIOPH RES CO, V437, P7, DOI 10.1016/j.bbrc.2013.06.004
   Jankowski J, 2015, VET REC, V176, DOI 10.1136/vr.102216
   Jiang SQ, 2015, POULTRY SCI, V94, P2210, DOI 10.3382/ps/pev163
   Kamiya Y, 2010, ANIM SCI J, V81, P482, DOI 10.1111/j.1740 0929.2010.00761.x
   Khan SH, 2010, J ANIM PHYSIOL AN N, V94, P584, DOI 10.1111/j.1439 0396.2009.00943.x
   Knowles TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001545
   Koch F, 2019, P NATL ACAD SCI USA, V116, P10333, DOI 10.1073/pnas.1820130116
   KOELKEBECK KW, 1993, POULTRY SCI, V72, P1800, DOI 10.3382/ps.0721800
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lara Lucas J, 2013, Animals (Basel), V3, P356, DOI 10.3390/ani3020356
   Lee C, 2019, PEDIATR SURG INT, V35, P1395, DOI 10.1007/s00383 019 04586 y
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lieben L, 2013, J STEROID BIOCHEM, V136, P102, DOI 10.1016/j.jsbmb.2012.09.019
   Liu LL, 2016, FOOD FUNCT, V7, P1329, DOI [10.1039/C5FO01338K, 10.1039/c5fo01338k]
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Majdeddin M, 2020, POULTRY SCI, V99, P4442, DOI 10.1016/j.psj.2020.05.023
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   Masschaele B, 2013, J PHYS CONF SER, V463, DOI 10.1088/1742 6596/463/1/012012
   Murer H, 2004, PFLUG ARCH EUR J PHY, V447, P763, DOI 10.1007/s00424 003 1072 5
   Nakamichi Y, 2018, J STEROID BIOCHEM, V177, P70, DOI 10.1016/j.jsbmb.2017.11.005
   Nakamichi Y, 2017, J BONE MINER RES, V32, P1297, DOI 10.1002/jbmr.3096
   Ohlsson C, 2017, CELL IMMUNOL, V317, P55, DOI 10.1016/j.cellimm.2017.05.003
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
   Quinteiro WM, 2012, J ANIM SCI, V90, P1986, DOI 10.2527/jas.2011 3949
   Rath NC, 2000, POULTRY SCI, V79, P1024, DOI 10.1093/ps/79.7.1024
   Reiter K, 2009, BERL MUNCH TIERARZTL, V122, P264, DOI 10.2376/0005 9366 122 264
   Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584
   Ruff J, 2020, POULTRY SCI, V99, P1687, DOI 10.1016/j.psj.2019.10.075
   Sahin K, 2006, POULTRY SCI, V85, P486, DOI 10.1093/ps/85.3.486
   Sahin N, 2009, BRIT POULTRY SCI, V50, P709, DOI 10.1080/00071660903261944
   Santiago M., 2016, Open Journal of Animal Sciences, V6, P180, DOI 10.4236/ojas.2016.63023
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Schepper JD, 2019, J BONE MINER RES, V34, P681, DOI 10.1002/jbmr.3635
   Schirmer M, 2018, NAT MICROBIOL, V3, P337, DOI 10.1038/s41564 017 0089 z
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541 09
   Schwarzer M, 2016, SCIENCE, V351, P854, DOI 10.1126/science.aad8588
   Seliger C, 2012, VET IMMUNOL IMMUNOP, V145, P86, DOI 10.1016/j.vetimm.2011.10.010
   Sepidarkish M, 2019, PHARMACOL RES, V139, P141, DOI 10.1016/j.phrs.2018.11.011
   Sharir A, 2008, VET J, V177, P8, DOI 10.1016/j.tvjl.2007.09.012
   Shi DY, 2019, POULTRY SCI, V98, P2405, DOI 10.3382/ps/pez026
   Sjögren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588
   Spranghers T, 2018, ANIM FEED SCI TECH, V235, P33, DOI 10.1016/j.anifeedsci.2017.08.012
   Stanley D, 2013, VET MICROBIOL, V164, P85, DOI 10.1016/j.vetmic.2013.01.030
   Sun ZW, 2013, POULTRY SCI, V92, P3071, DOI 10.3382/ps.2013 03278
   Turner AG, 2014, J STEROID BIOCHEM, V144, P114, DOI 10.1016/j.jsbmb.2013.10.003
   Turner CH, 2006, ANN NY ACAD SCI, V1068, P429, DOI 10.1196/annals.1346.039
   van der Meijden K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110283
   van Driel M, 2017, MOL CELL ENDOCRINOL, V453, P46, DOI 10.1016/j.mce.2017.06.008
   van Nevel CJ, 2003, ARCH ANIM NUTR, V57, P399, DOI 10.1080/0003942032000161054
   Vlassenbroeck J, 2007, NUCL INSTRUM METH A, V580, P442, DOI 10.1016/j.nima.2007.05.073
   Wagner D, 2011, J STEROID BIOCHEM, V126, P72, DOI 10.1016/j.jsbmb.2011.05.003
   Walters JRF, 2004, CURR OPIN GASTROEN, V20, P70, DOI 10.1097/00001574 200403000 00004
   Wang XJ, 2018, POULTRY SCI, V97, P2153, DOI 10.3382/ps/pey032
   Waterhouse M, 2019, EUR J NUTR, V58, P2895, DOI 10.1007/s00394 018 1842 7
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wideman RF, 2015, POULTRY SCI, V94, P1821, DOI 10.3382/ps/pev160
   Wiernusz CJ, 1996, BRIT POULTRY SCI, V37, P677, DOI 10.1080/00071669608417897
   Xing S, 2019, POULTRY SCI, V98, P5257, DOI 10.3382/ps/pez440
   Yamamoto Y, 2006, ENDOCRINOLOGY, V147, P3366, DOI 10.1210/en.2006 0216
   Yan FF, 2019, POULTRY SCI, V98, P1083, DOI 10.3382/ps/pey508
   Yan J, 2018, GUT MICROBES, V9, P84, DOI 10.1080/19490976.2017.1371893
   Yan J, 2017, CURR OSTEOPOROS REP, V15, P376, DOI 10.1007/s11914 017 0382 z
   Yang DQ, 2018, J STEROID BIOCHEM, V177, P83, DOI 10.1016/j.jsbmb.2017.09.005
   Zaiss MM, 2019, J CLIN INVEST, V129, P3018, DOI 10.1172/JCI128521
   Zhang C, 2017, POULTRY SCI, V96, P4325, DOI 10.3382/ps/pex266
   Zhang HY, 2020, POULTRY SCI, V99, P1241, DOI 10.1016/j.psj.2019.10.068
   Zhao Y, 2014, BRIT J NUTR, V112, P381, DOI 10.1017/S000711451400097X
   Zhu LH, 2019, APPL MICROBIOL BIOT, V103, P461, DOI 10.1007/s00253 018 9465 8
NR 94
TC 30
Z9 34
U1 3
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1674 9782
EI 2049 1891
J9 J ANIM SCI BIOTECHNO
JI J. Anim. Sci. Biotechnol.
PD OCT 8
PY 2021
VL 12
IS 1
AR 104
DI 10.1186/s40104 021 00627 6
PG 21
WC Agriculture, Dairy & Animal Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture
GA WD5ID
UT WOS:000704973200001
PM 34620220
OA gold, Green Published
DA 2025 08 17
ER

EF